FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Krzyzewski, RM
   Klis, KM
   Kwinta, BM
   Stachura, K
   Guzik, TJ
   Gasowski, J
AF Krzyzewski, Roger M.
   Klis, Kornelia M.
   Kwinta, Borys M.
   Stachura, Krzysztof
   Guzik, Tomasz J.
   Gasowski, Jerzy
TI High Leukocyte Count and Risk of Poor Outcome After Subarachnoid
   Hemorrhage: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Meta-analysis; Outcome; Subarachnoid hemorrhage; White blood cell count
ID DELAYED CEREBRAL-ISCHEMIA; INFLAMMATORY RESPONSE SYNDROME; CELL
   DISTRIBUTION WIDTH; VASOSPASM; PREDICTION; MORTALITY; ALPHA
AB BACKGROUND: Subarachnoid hemorrhage is (SAH) is a devastating neurologic emergency often associated with systemic inflammatory response. Many reports have demonstrated an association between elevated inflammatory markers and poor outcome. We performed an observational study and a meta-analysis of the impact of high leukocyte count on outcome after SAH.
   METHODS: We initially retrospectively analyzed 147 patients with SAH through assessment of medical records database. Poor outcome was defined as modified Rankin Scale score >3. Then, we performed a systematic literature search of PubMed, EMBASE, and the Cochrane Library. Prospective and retrospective studies were included if they assessed impact of leukocytosis on outcome after aneurysmal SAH in adults. We used a random-effect model and quality-effect model, based on the study quality assessment tool, an adapted version of inventory to assess quality of intervention studies.
   RESULTS: Within our initial observational study, a total of 63 (42.86%) patients had poor treatment outcome. Those patients significantly more often had elevated white blood cell count upon admission (60.32 vs. 40.48%; P = 0.02). A literature search identified 10,119 articles, of which 13 were included into the meta-analysis. Pooled impact of high leukocyte count on outcome was odds ratio 1.42 (95% confidence interval 1.24-1.63) for random-effect model and OR 1.86 (95% confidence interval 1.46-2.36) for the quality-effect model. However, the studies were heterogenous (I = 54%).
   CONCLUSIONS: Elevated white blood cells is a marker of poor outcome after SAH. Despite the fact that it is unlikely to be causative, it may be treated as a useful risk predictor.
C1 [Krzyzewski, Roger M.; Kwinta, Borys M.; Stachura, Krzysztof] Jagiellonian Univ, Dept Neurosurg & Neurotraumatol, Med Coll, Krakow, Poland.
   [Krzyzewski, Roger M.; Klis, Kornelia M.; Kwinta, Borys M.; Gasowski, Jerzy] Jagiellonian Univ, TENSOR Team NeuroSurg Oriented Res, Med Coll, Krakow, Poland.
   [Klis, Kornelia M.] Jagiellonian Univ, Fac Med, Med Coll, Krakow, Poland.
   [Guzik, Tomasz J.] Jagiellonian Univ, Dept Internal & Agr Med, Med Coll, Lab Translat Med, Krakow, Poland.
   [Gasowski, Jerzy] Jagiellonian Univ, Dept Internal Med & Gerontol, Med Coll, Krakow, Poland.
   [Klis, Kornelia M.] AGH Univ Sci & Technol, Fac Comp Sci Elect & Telecommun, Krakow, Poland.
   [Guzik, Tomasz J.] Univ Glasgow, BHF Ctr Res Excellence, Inst Cardiovasc & Med Res, Glasgow, Lanark, Scotland.
RP Krzyzewski, RM (reprint author), Jagiellonian Univ, Dept Neurosurg & Neurotraumatol, Med Coll, Krakow, Poland.; Krzyzewski, RM (reprint author), Jagiellonian Univ, TENSOR Team NeuroSurg Oriented Res, Med Coll, Krakow, Poland.
EM roger.krzyzewski@gmail.com
RI Guzik, Tomasz/AAM-5007-2020; K, Kornelia/AAJ-9526-2020
OI Gasowski, Jerzy/0000-0002-8025-5323
FU National Science Centre-Poland [2014/15/N/NZ4/01062]
FX This study was funded by the National Science Centre-Poland under grant
   number 2014/15/N/NZ4/01062 to Roger M. Krzyzewski. The funder had no
   role in study design, in the collection, analysis and interpretation of
   data, in the writing of the report, and in the decision to submit the
   article for publication.
CR Al-Mufti F, 2019, NEUROSURGERY, V84, P397, DOI 10.1093/neuros/nyy045
   Badjatia N, 2015, NEUROLOGY, V84, P680, DOI 10.1212/WNL.0000000000001259
   Beeftink MMA, 2011, NEUROCRIT CARE, V15, P405, DOI 10.1007/s12028-011-9556-1
   Choi JH, 2007, KOREAN J CEREBROVASC, V9, P135
   Chotai S, 2013, NEUROL MED-CHIR, V53, P157, DOI 10.2176/nmc.53.157
   Chou SHY, 2012, J INVEST MED, V60, P1054, DOI 10.2310/JIM.0b013e3182686932
   Chugh C, 2015, NEUROCRIT CARE, V23, P217, DOI 10.1007/s12028-015-0117-x
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Doi SAR, 2008, EPIDEMIOLOGY, V19, P94, DOI 10.1097/EDE.0b013e31815c24e7
   Dumont AS, 2003, NEUROSURGERY, V53, P123, DOI 10.1227/01.NEU.0000068863.37133.9E
   Da Silva IRF, 2017, J CRIT CARE, V37, P126, DOI 10.1016/j.jcrc.2016.09.011
   Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004
   Holling M, 2009, J NEUROSURG, V110, P487, DOI 10.3171/2008.8.JNS08789
   Kasius KM, 2010, CEREBROVASC DIS, V29, P576, DOI 10.1159/000306645
   Kitamura Y, 2010, NEUROL MED-CHIR, V50, P456, DOI 10.2176/nmc.50.456
   Kreiter KT, 2013, J NEUROL SCI, V335, P64, DOI 10.1016/j.jns.2013.08.024
   KUBOTA T, 1993, STROKE, V24, P1993, DOI 10.1161/01.STR.24.12.1993
   Macdonald RL, 2011, LANCET NEUROL, V10, P618, DOI 10.1016/S1474-4422(11)70108-9
   McGirt MJ, 2003, J NEUROSURG, V98, P1222, DOI 10.3171/jns.2003.98.6.1222
   Miller BA, 2014, BIOMED RES INT, V2014, P654
   Mocco J, 2002, J NEUROSURG, V97, P537, DOI 10.3171/jns.2002.97.3.0537
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Muroi C, 2013, NEUROSURGERY, V72, P367, DOI 10.1227/NEU.0b013e31828048ce
   Naredi S, 2006, INTENS CARE MED, V32, P1955, DOI 10.1007/s00134-006-0408-y
   NEILDWYER G, 1974, BRAIN, V97, P79, DOI 10.1093/brain/97.1.79
   Niikawa Shuji, 1997, Neurologia Medico-Chirurgica, V37, P881, DOI 10.2176/nmc.37.881
   PETERSON JW, 1990, J NEUROSURG, V72, P767, DOI 10.3171/jns.1990.72.5.0767
   Pluta RM, 2009, NEUROL RES, V31, P151, DOI 10.1179/174313209X393564
   Polin RS, 1998, J NEUROSURG, V89, P559, DOI 10.3171/jns.1998.89.4.0559
   Prabhakaran S, 2014, NEUROSURGERY, V75, P500, DOI 10.1227/NEU.0000000000000475
   Provencio JJ, 2013, ACTA NEUROCHIR SUPPL, V115, P233, DOI 10.1007/978-3-7091-1192-5_42
   Provencio JJ, 2005, SEMIN NEUROL, V25, P435, DOI 10.1055/s-2005-923537
   Sadamasa N, 2011, NEUROL MED-CHIR, V51, P745
   Siegler JE, 2017, NEUROCRIT CARE, V26, P26, DOI 10.1007/s12028-016-0306-2
   Szklener S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007795
   Tewari M, 2015, ANN NEUROSCI, V22, P78, DOI 10.5214/ans.0972.7531.220205
   Vrsajkov V, 2015, INDIAN J NEUROSURG, V4
   Wang TZ, 2011, ACTA NEUROCHIR SUPPL, V110, P219, DOI 10.1007/978-3-7091-0353-1_38
   Yepes M, 2006, DRUG NEWS PERSPECT, V19, P589, DOI 10.1358/dnp.2006.19.10.1068005
   Yilmaz G, 2010, NEUROMOL MED, V12, P193, DOI 10.1007/s12017-009-8074-1
   Yoshimoto Y, 2001, STROKE, V32, P1989, DOI 10.1161/hs0901.095646
NR 41
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.056
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600064
PM 31863891
DA 2020-05-12
ER

PT J
AU Kundu, B
   Awad, AW
   Park, MS
   Grandhi, R
   Enniss, T
   Hawryluk, GWJ
AF Kundu, Bornali
   Awad, Al-Wala
   Park, Min S.
   Grandhi, Ramesh
   Enniss, Toby
   Hawryluk, Gregory W. J.
TI Characterization of Focal Brain Tissue Water Measurements in Human
   Traumatic Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Blood flow; Brain injury; Cerebral edema; Hemedex; Neuromonitoring;
   Tissue water
ID CEREBRAL-BLOOD-FLOW; INTRACRANIAL HYPERTENSION; CELLULAR EDEMA;
   TIME-COURSE; AUTOREGULATION; MANAGEMENT
AB BACKGROUND: Cerebral edema is a major cause of morbidity in patients with severe traumatic brain injury (TBI). Intraparenchymal thermal conductivity-based probes that measure local cerebral blood flow can measure percent brain tissue water (%BTW) content, but such measures have been insufficiently characterized in patients with TBI.
   METHODS: We retrospectively reviewed physiologic data from patients with severe TBI treated at our institution (2014-2016) who underwent cerebral blood flow monitoring.
   RESULTS: Sixteen patients underwent focal %BTW measurements at a 15-minute sampling rate. %BTW measurements showed characteristic temporal profiles, with a mean time to peak of 3.7 +/- 1.7 days. The mean minimum and maximum %BTWs were 71.0 +/- 3.9% and 82.7 +/- 7.4%, respectively (overall mean %BTW, 77.0 +/- 2.9%). Intracranial pressure (ICP) values of 22 mm Hg (the current treatment threshold for patients with trauma) corresponded to 75.8 +/- 5.4 %BTW. Repeated measures correlation showed that %BTW is negatively correlated with serum sodium concentration (r = -0.3; P< 0.001) and weakly positively correlated with ICP (r = 0.08; P = 0.01) and regional cerebral blood flow (r = 0.06; P< 0.001). These effects were consistent in a multivariable model including time from injury. In the best model, time was modeled as a quadratic term because the %BTW followed a parabolic trajectory.
   CONCLUSIONS: %BTW may be a clinically useful, real-time measurement of cerebral edema in patients with TBI. It is closely associated with the serum sodium concentration and follows a characteristic temporal course with characteristic trajectory and stability over time.
C1 [Kundu, Bornali; Awad, Al-Wala; Grandhi, Ramesh; Hawryluk, Gregory W. J.] Univ Utah, Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT 84112 USA.
   [Park, Min S.] Univ Virginia, Sch Med, Dept Neurosurg, Charlottesville, VA 22908 USA.
   [Enniss, Toby] Univ Utah, Dept Surg, Salt Lake City, UT USA.
   [Hawryluk, Gregory W. J.] Univ Manitoba, Sect Neurosurg, Winnipeg, MB, Canada.
RP Hawryluk, GWJ (reprint author), Univ Utah, Clin Neurosci Ctr, Dept Neurosurg, Salt Lake City, UT 84112 USA.; Hawryluk, GWJ (reprint author), Univ Manitoba, Sect Neurosurg, Winnipeg, MB, Canada.
EM ghawryluk@hsc.mb.ca
OI Grandhi, Ramesh/0000-0001-9000-6083
CR Adams H, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002353
   Amyot F, 2015, J NEUROTRAUM, V32, P1693, DOI 10.1089/neu.2013.3306
   Bakdash JZ, 2017, FRONT PSYCHOL, V8, DOI 10.3389/fpsyg.2017.00456
   Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839
   Barzo P, 1997, ACT NEUR S, V70, P119
   BLAND JM, 1995, BRIT MED J, V310, P633, DOI 10.1136/bmj.310.6980.633
   Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451
   Ko SB, 2012, ANN NEUROL, V72, P344, DOI 10.1002/ana.23619
   Maegele M, 2015, ACTA RADIOL OPEN, V4, DOI 10.1177/2047981614555142
   Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720
   MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287
   MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503
   MILLER JD, 1974, INJURY, V5, P265, DOI 10.1016/S0020-1383(74)80021-5
   MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289
   MUIZELAAR JP, 1983, J NEUROSURG, V59, P822, DOI 10.3171/jns.1983.59.5.0822
   OBRIEN JS, 1965, J LIPID RES, V6, P537
   Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360
   Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8
   Stocchetti N, 2007, J NEUROTRAUM, V24, P1339, DOI 10.1089/neu.2007.0300
   Stocchetti N, 2017, LANCET NEUROL, V16, P452, DOI 10.1016/S1474-4422(17)30118-7
   Tackla R, 2015, NEUROCRIT CARE, V23, P339, DOI 10.1007/s12028-015-0146-5
   Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265
   Vlodavsky E, 2017, J CEREBR BLOOD F MET, V37, P166, DOI 10.1177/0271678X15621068
   Winkler EA, 2016, NEUROSURG CLIN N AM, V27, P473, DOI 10.1016/j.nec.2016.05.008
NR 24
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.132
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600031
PM 31805402
DA 2020-05-12
ER

PT J
AU Kuwabara, M
   Nakahara, T
   Mitsuhara, T
   Shimonaga, K
   Hosogai, M
   Kurisu, K
   Sakamoto, S
AF Kuwabara, Masashi
   Nakahara, Toshinori
   Mitsuhara, Takafumi
   Shimonaga, Koji
   Hosogai, Masahiro
   Kurisu, Kaoru
   Sakamoto, Shigeyuki
TI Transient Cerebral Vasospasm After Carotid Artery Stenting: A Case
   Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Carotid artery stenting; Cerebral vasospasm; Ischemic complication
ID VASOCONSTRICTION SYNDROME; ENDARTERECTOMY; ENCEPHALOPATHY; ANGIOGRAPHY;
   PERFUSION; RISK
AB BACKGROUND: Cerebral embolism after carotid artery stenting (CAS) is a Well-known complication, but cerebral ischemia owing to cerebral vasospasm after CAS is rare and has seldom been reported. We describe a patient with transient ischemic complications owing to reversible cerebral vasospasm of the middle cerebral artery after CAS.
   CASE DESCRIPTION: A 74-year-old man presented with right hemiparesis caused by acutely scattered brain infarction in the left cerebral hemisphere. Magnetic resonance angiography showed severe stenosis of the left cervical internal carotid artery origin. CAS under a distal filter protection was performed without any intraprocedural complications, but 12 hours later, the patient had aphasia and Gerstmann syndrome. Urgent magnetic resonance imaging revealed no evidence of an intracranial hemorrhage or new cerebral infarction. However, magnetic resonance angiography showed diffuse vasospasm of the left middle cerebral artery. His symptoms and imaging findings improved gradually with conservative treatment. The patient was discharged without new neurologic deficit or recurrent attack 3 weeks after CAS.
   CONCLUSIONS: In a patient with delayed neurologic symptoms after CAS, the possibility of cerebral vasospasm should be kept in mind to select appropriate treatment.
C1 [Kuwabara, Masashi; Mitsuhara, Takafumi; Kurisu, Kaoru; Sakamoto, Shigeyuki] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
   [Nakahara, Toshinori; Shimonaga, Koji; Hosogai, Masahiro] Hiroshima City Asa Hosp, Dept Neurosurg, Hiroshima, Japan.
RP Kuwabara, M (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Neurosurg, Hiroshima, Japan.
EM m214028@gmail.com
OI Hosogai, Masahiro/0000-0001-7217-4446; , KOJI/0000-0002-6652-6393;
   Sakamoto, Shigeyuki/0000-0003-3683-4771
CR Aghaebrahim A, 2014, NEUROLOGY, V83, P570, DOI 10.1212/WNL.0000000000000677
   Arai M, 2013, J NEUROENDOVASC THER, V7, P119, DOI DOI 10.5797/jnet.7.119
   Bartynski WS, 2008, AM J NEURORADIOL, V29, P447, DOI 10.3174/ajnr.A0839
   Bates ER, 2007, J AM COLL CARDIOL, V49, P126, DOI 10.1016/j.jacc.2006.10.021
   BRICK JF, 1990, J NEUROSURG, V73, P151, DOI 10.3171/jns.1990.73.1.0151
   Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Calabrese LH, 2007, ANN INTERN MED, V146, P34, DOI 10.7326/0003-4819-146-1-200701020-00007
   Coutts SB, 2003, NEUROSURGERY, V53, P1053, DOI 10.1227/01.NEU.0000088738.80838.74
   Dagher HN, 2005, CEREBROVASC DIS, V20, P205, DOI 10.1159/000087327
   Ducros A, 2007, BRAIN, V130, P3091, DOI 10.1093/brain/awm256
   Fang HY, 2009, CATHETER CARDIO INTE, V73, P123, DOI 10.1002/ccd.21779
   LopezValdes E, 1997, NEUROLOGY, V49, P303, DOI 10.1212/WNL.49.1.303
   Ohashi T, 2012, JNET, V6, P353
   Qureshi AI, 2000, STROKE, V31, P376, DOI 10.1161/01.STR.31.2.376
   Rosenbloom MH, 2007, AM J NEURORADIOL, V28, P920
   Soltanolkotabi M, 2012, J NEUROINTERV SURG, V4, P49
   Wu TY, 2011, J CLIN NEUROSCI, V18, P1725, DOI 10.1016/j.jocn.2011.03.018
   Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127
NR 18
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.151
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600114
PM 31837494
DA 2020-05-12
ER

PT J
AU Lee, J
   Song, KS
AF Lee, Jeongik
   Song, Kwang-Sup
TI Transpedicular Intravertebral Cage Augmentation in a Patient with
   Neurologic Deficits After Severely Collapsed Kummel Disease: Minimum
   2-Year Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Delayed neurology; Intravertebral cage; Kummel disease; Osteoporosis;
   Posterior approach; Surgical outcome
ID POSTERIOR INSTRUMENTATION; ANTERIOR DECOMPRESSION; VERTEBRAL COLLAPSE;
   SURGICAL-TREATMENT; BURST; RECONSTRUCTION; VERTEBROPLASTY; MANAGEMENT;
   FRACTURES; FUSION
AB OBJECTIVE: We have reported the surgical outcomes of an anterior column support procedure, the intravertebral cage augmentation technique for the osteoporotic spine.
   METHODS: A total of 10 consecutive osteoporotic patients with severely collapsed plana-type vertebrae, causing delayed neurologic deficits, were enrolled in cohort manner. They underwent intravertebral cage augmentation using a single posterior approach. The postoperative follow-up period was >2 years. The patients were divided into 2 groups: group I, fractured index vertebra at the thoracolumbar; and group II, fractured index vertebra at the lower lumbar. The radiographic analysis included the restored ratio of anterior vertebral height, local kyphotic angle, thoracolumbar kyphosis, and lumbar lordosis. The radiographic and clinical results, ambulatory status, and Oswestry disability index were evaluated.
   RESULTS: Compared with preoperatively, the average restored ratio of the anterior vertebral height was 2.98 and 2.35 times greater, and the local kyphotic angle had been corrected from an average of 20.3 degrees and 14.8 degrees to an average of 3.0 degrees and 0.2 degrees at the final follow-up visit in groups I and II, respectively. The thoracolumbar kyphosis in group I had been corrected from an average of 32.9 degrees to 19.7 degrees and the lumbar lordosis in group II had improved from an average of -15.8 degrees to -32.3 degrees at the final follow-up visit. All patients who could not independently ambulate preoperatively became able to walk, except for 2 patients who required a cane. Also, all the patients showed significant improvement in the Oswestry disability index (group I: average, from 38.2 to 12.8; group II, from 37.3 to 19.3).
   CONCLUSIONS: The introduced technique is a valuable surgical option for obtaining anterior column support in osteoporotic patients with severely collapsed Kummel disease who require decompression and stabilization procedures using only a posterior approach.
C1 [Lee, Jeongik; Song, Kwang-Sup] Chung Ang Univ, Chung Ang Univ Hosp, Coll Med, Dept Orthoped Surg, Seoul, South Korea.
RP Song, KS (reprint author), Chung Ang Univ, Chung Ang Univ Hosp, Coll Med, Dept Orthoped Surg, Seoul, South Korea.
EM ksong70@cau.ac.kr
CR Alanay A, 2001, SPINE, V26, P213, DOI 10.1097/00007632-200101150-00017
   Baron EM, 2006, SPINE, V31, pS106, DOI 10.1097/01.brs.0000232713.69342.df
   Birkenmaier C, 2011, SPINE J, V11, P460, DOI 10.1016/j.spinee.2011.03.005
   Chen HH, 2004, SPINE, V29, pE382, DOI 10.1097/01.brs.0000139308.65813.70
   Cho Y, 2017, ASIAN SPINE J, V11, P634, DOI 10.4184/asj.2017.11.4.634
   Choma TJ, 2011, SPINE, V36, P454, DOI 10.1097/BRS.0b013e3181d449ec
   Dodwad SNM, 2013, ORTHOP CLIN N AM, V44, P243, DOI 10.1016/j.ocl.2013.01.008
   Erdem MN, 2017, SPINE J, V17, P328, DOI 10.1016/j.spinee.2016.10.001
   Freedman BA, 2009, J AM BOARD FAM MED, V22, P75, DOI 10.3122/jabfm.2009.01.080100
   Goldstein CL, 2015, NEUROSURGERY, V77, pS98, DOI 10.1227/NEU.0000000000000948
   Kashii M, 2013, EUR SPINE J, V22, P1633, DOI 10.1007/s00586-013-2759-8
   Korovessis P, 2008, SPINE, V33, P658, DOI 10.1097/BRS.0b013e318166e0bb
   Lee GW, 2013, SPINE, V38, pE244, DOI 10.1097/BRS.0b013e31827efef2
   Lehman RA, 2015, J AM ACAD ORTHOP SUR, V23, P253, DOI 10.5435/JAAOS-D-14-00042
   Lin HH, 2018, INT ORTHOP, V42, P1313, DOI 10.1007/s00264-018-3812-3
   Nakamae T, 2013, EUR SPINE J, V22, P1624, DOI 10.1007/s00586-013-2686-8
   Nakashima H, 2015, SPINE, V40, pE120, DOI 10.1097/BRS.0000000000000661
   Ponnusamy KE, 2011, SPINE J, V11, P54, DOI 10.1016/j.spinee.2010.09.024
   Sudo H, 2013, SPINE J, V13, P1726, DOI 10.1016/j.spinee.2013.05.041
   Suzuki T, 2012, ASIAN SPINE J, V6, P123, DOI 10.4184/asj.2012.6.2.123
   Verlaan JJ, 2013, SPINE J, V13, P1733, DOI 10.1016/j.spinee.2013.07.029
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.131
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600122
PM 31790842
DA 2020-05-12
ER

PT J
AU Lee, L
   Loh, D
   King, NKK
AF Lee, Lester
   Loh, Daniel
   King, Nicolas Kon Kam
TI Posterior Fossa Surgery for Stroke: Differences in Outcomes Between
   Cerebellar Hemorrhage and Infarcts
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebellar haemorrhage; Cerebellar infarct; Posterior fossa surgery;
   Stroke; Stroke outcomes
ID SUBOCCIPITAL DECOMPRESSIVE CRANIECTOMY; SPONTANEOUS INTRACEREBRAL
   HEMORRHAGE; HEALTH-CARE PROFESSIONALS; SURGICAL-TREATMENT; MANAGEMENT;
   GUIDELINES; HEMATOMAS; MORTALITY
AB BACKGROUND: Posterior fossa surgery is the established treatment for large cerebellar strokes with brainstem compression. Despite this, there is a paucity of data for long-term outcomes.
   METHODS: A retrospective analysis of patients who underwent posterior fossa surgery for cerebellar hemorrhages and infarcts was performed to compare their difference in 6-month outcomes and to identify factors that affect outcomes. Patients were dichotomized into groups with good outcomes (modified Rankin scale [mRS] score 0-3) or poor outcomes (mRS score 4-6). Sex, age, preoperative Glasgow Coma Scale score, Charleston comorbidity index, time to surgery, intraventricular hemorrhage, surgical complications, length of intensive care unit and hospital stay, shunt dependence, and tracheostomy rates were analyzed.
   RESULTS: In total, 126 patients were recruited: 76 in hemorrhage group and 50 in infarct group. There was a greater mortality in the hemorrhage group (P = 0.0730). At 6 months, more patients in the hemorrhage group had poor outcomes (P = 0.0074, odds ratio 3.04) and greater mortality (P = 0.0730, odds ratio 2.20). More patients in the hemorrhage group required a tracheostomy (P = 0.0245). Factors predictive of poor outcome include older age (P = 0.0108), Glasgow Coma Scale score <= 8 (P = 0.0011), and tracheostomy (P = 0.0269). A total of 69.2% of patients had improvements in mRS scores at 6 months. Shorter length of stay (P = 0.0003) and discharge to a rehabilitation hospital (P = 0.0001) were predictive of functional improvement.
   CONCLUSIONS: Patients who underwent posterior fossa surgery for cerebellar hemorrhage had worse outcomes compared with patients with cerebellar infarcts and were more likely to require a tracheostomy. Rehabilitation helped to improved outcomes.
C1 [Lee, Lester; Loh, Daniel; King, Nicolas Kon Kam] Natl Neurosci Inst, Dept Neurosurg, Singapore, Singapore.
   [Lee, Lester; Loh, Daniel; King, Nicolas Kon Kam] Singapore Gen Hosp, Dept Neurosurg, Singapore, Singapore.
   [Lee, Lester; King, Nicolas Kon Kam] Duke NUS Med Sch, Dept Neurosurg, Singapore, Singapore.
RP Lee, L (reprint author), Natl Neurosci Inst, Dept Neurosurg, Singapore, Singapore.; Lee, L (reprint author), Singapore Gen Hosp, Dept Neurosurg, Singapore, Singapore.; Lee, L (reprint author), Duke NUS Med Sch, Dept Neurosurg, Singapore, Singapore.
EM lester_ch_lee@nni.com.sg
OI Kon Kam King, Nicolas/0000-0002-6009-4411; Lee,
   Lester/0000-0003-1885-8251
CR Amar AP, 2012, NEUROSURG FOCUS, V32, P1
   Arnone GD, 2017, WORLD NEUROSURG, V106, P543, DOI 10.1016/j.wneu.2017.07.041
   Ayling OGS, 2018, WORLD NEUROSURG, V110, P450, DOI 10.1016/j.wneu.2017.10.144
   Broderick J, 2007, CIRCULATION, V116, pE391, DOI 10.1161/CIRCULATIONAHA.107.183689
   CHEN HJ, 1992, STROKE, V23, P957, DOI 10.1161/01.STR.23.7.957
   CUNEO RA, 1979, ARCH NEUROL-CHICAGO, V36, P618, DOI 10.1001/archneur.1979.00500460052006
   Datar S, 2014, NEUROL CLIN, V32, P993, DOI 10.1016/j.ncl.2014.07.006
   DINSDALE HB, 1964, ARCH NEUROL-CHICAGO, V10, P200, DOI 10.1001/archneur.1964.00460140086011
   FAIRBURN B, 1956, BMJ-BRIT MED J, V1, P1335, DOI 10.1136/bmj.1.4979.1335
   Hackenberg KAM, 2017, CLIN NEUROL NEUROSUR, V155, P22, DOI 10.1016/j.clineuro.2017.01.019
   Hemphill JC, 2015, STROKE, V46, P2032, DOI 10.1161/STR.0000000000000069
   HEROS RC, 1982, STROKE, V13, P106, DOI 10.1161/01.STR.13.1.106
   Jauss M, 1999, J NEUROL, V246, P257, DOI 10.1007/s004150050344
   Juttler E, 2009, STROKE, V40, P3060, DOI 10.1161/STROKEAHA.109.550913
   Kim MJ, 2016, STROKE, V47, P2565, DOI 10.1161/STROKEAHA.116.014078
   Kirollos RW, 2001, NEUROSURGERY, V49, P1378, DOI 10.1097/00006123-200112000-00015
   Klingshim H, 2017, J REHABIL MED, V47, P577
   KOBAYASHI S, 1994, NEUROSURGERY, V34, P246, DOI 10.1227/00006123-199402000-00006
   Kudo Hiroshi, 2007, J Stroke Cerebrovasc Dis, V16, P259, DOI 10.1016/j.jstrokecerebrovasdis.2007.09.001
   Lee L, 2018, J CRIT CARE, V48, P269, DOI 10.1016/j.jcrc.2018.09.010
   LINDGREN SO, 1956, J NEUROSURG, V13, P575, DOI 10.3171/jns.1956.13.6.0575
   Luney MS, 2016, NEUROCRIT CARE, V25, P365, DOI 10.1007/s12028-015-0217-7
   MATHEW P, 1995, J NEUROL NEUROSUR PS, V59, P287, DOI 10.1136/jnnp.59.3.287
   Michel P, 2009, INT J STROKE, V4, P218, DOI 10.1111/j.1747-4949.2009.00283.x
   Neugebauer H, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2013.2.FOCUS12363
   Pallesen LP, 2019, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01119
   Pfefferkorn T, 2009, STROKE, V40, P3045, DOI 10.1161/STROKEAHA.109.550871
   Puffer RC, 2016, WORLD NEUROSURG, V92, P166, DOI 10.1016/j.wneu.2016.05.003
   Sykora M, 2010, INT J STROKE, V5, P170, DOI 10.1111/j.1747-4949.2010.00426.x
   Tewari MK, 2015, TURK NEUROSURG, V25, P712, DOI 10.5137/1019-5149.JTN.11011-14.1
   Tsitsopoulos PP, 2011, ACTA NEUROL SCAND, V123, P345, DOI 10.1111/j.1600-0404.2010.01404.x
   Tsitsopoulos PP, 2012, ACTA NEUROCHIR, V154, P1189, DOI 10.1007/s00701-012-1372-7
   Tsitsopoulos PP, 2011, ACTA NEUROCHIR, V153, P2075, DOI 10.1007/s00701-011-1120-4
   Wijdicks EFM, 2014, STROKE, V45, P1222, DOI 10.1161/01.str.0000441965.15164.d6
   Witsch J, 2013, CLIN NEUROL NEUROSUR, V115, P863, DOI 10.1016/j.clineuro.2013.04.009
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.177
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600042
PM 31816455
DA 2020-05-12
ER

PT J
AU Lei, KL
   Wei, S
   Liu, XJ
   Yuan, X
   Pei, LL
   Xu, YM
   Song, B
   Sun, SL
AF Lei, Kunlun
   Wei, Sen
   Liu, Xinjing
   Yuan, Xin
   Pei, Lulu
   Xu, Yuming
   Song, Bo
   Sun, Shilei
TI Combination of Ultraearly Hematoma Growth and Hypodensities for Outcome
   Prediction after Intracerebral Hemorrhage
SO WORLD NEUROSURGERY
LA English
DT Article
DE Hypodensities; Noncontrast computed tomography; Neuroimaging markers;
   Spontaneous intracerebral hemorrhage; Ultraearly hematoma growth
ID ANGIOGRAPHY SPOT SIGN; BLOOD-PRESSURE REDUCTION; BLACK-HOLE SIGN;
   COMPUTED-TOMOGRAPHY; BLEND SIGN; EXPANSION; DENSITY; DETERIORATION;
   ENLARGEMENT; MARKERS
AB BACKGROUND: Noncontrast computed tomography hypodensities (HD) and ultraearly hematoma growth (uHG) are reliable markers for outcome prediction in patients with spontaneous intracerebral hemorrhage (sICH). The present study aimed to assess whether the combination of these 2 markers could improve the prognostic value for sICH.
   METHODS: We recruited 242 patients with sICH who had been admitted within 6 hours from the onset of symptoms. HD was assessed by 2 independent blinded readers, and uHG was calculated as baseline ICH volume/onset-to-imaging time. We divided the study population into 4 groups: uHG(L) HD(-) (uHG <6.16 mL/hour and HD negative), uHG(L) HD( + ) (uHG<6.16 mL/hour and HD positive), uHG(H) HD(-) (uHG >= 6.16 mL/hour and HD negative), and uHG(H) HD( + ) (uHG >= 6.16 mL/h and HD positive). The outcome at 90 days was evaluated by the modified Rankin Scale (mRS) score and was dichotomized as good (mRS score 0-3) and poor (mRS score 4-6). The association between the combined indicators and unfavorable outcome was investigated using multivariable logistic regression models.
   RESULTS: Patients with poor outcomes were more likely to have HD and higher uHG in univariate analysis. In multivariate logistic regression analysis, uHG(H) HD( + ) had a higher risk of unfavorable outcomes compared with uHG(L) HD(-) (odds ratio [OR], 5.710; P< 0.001). In addition, the risk of unfavorable outcomes was increased in uHG(H) HD(-) (OR, 2.957, P = 0.044) and uHG(L) HD( + ) (OR, 1.924; P = 0.232). The proportions of unfavorable prognoses were 32.6% in uHG(L) HD(-), 48.3% in uHG(L) HD( + ), 72.2% in uHG(H) HD(-), and 87.5% in uHG(H) HD( + ) (P< 0.001).
   CONCLUSIONS: The combination of uHG and HD improves the stratification of unfavorable prognoses in patients with sICH.
C1 [Lei, Kunlun; Liu, Xinjing; Yuan, Xin; Pei, Lulu; Xu, Yuming; Song, Bo; Sun, Shilei] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou, Henan, Peoples R China.
   [Wei, Sen] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol Intervent, Zhengzhou, Henan, Peoples R China.
RP Sun, SL (reprint author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou, Henan, Peoples R China.
EM sunshilei18@163.com
FU Medical Science and Technology Research Project of Henan Province, China
   [201701007]
FX This research was supported by the Medical Science and Technology
   Research Project of Henan Province, China (Grant 201701007).
CR An SJ, 2017, J STROKE, V19, P3, DOI 10.5853/jos.2016.00864
   Barras CD, 2009, STROKE, V40, P1325, DOI 10.1161/STROKEAHA.108.536888
   Blacquiere D, 2015, STROKE, V46, P3111, DOI 10.1161/STROKEAHA.115.010566
   Boulouis G, 2016, STROKE, V47, P2511, DOI 10.1161/STROKEAHA.116.014425
   Boulouis G, 2016, JAMA NEUROL, V73, P961, DOI 10.1001/jamaneurol.2016.1218
   BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987
   Cordonnier C, 2018, LANCET, V392, P1257, DOI 10.1016/S0140-6736(18)31878-6
   Delcourt C, 2016, STROKE, V47, P1227, DOI 10.1161/STROKEAHA.116.012921
   Demchuk AM, 2012, LANCET NEUROL, V11, P307, DOI 10.1016/S1474-4422(12)70038-8
   Fujii Y, 1998, STROKE, V29, P1160, DOI 10.1161/01.STR.29.6.1160
   Kazui S, 1996, STROKE, V27, P1783, DOI 10.1161/01.STR.27.10.1783
   Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304
   Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC
   Li Q, 2017, STROKE, V48, P3019, DOI 10.1161/STROKEAHA.117.017985
   Li Q, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183082
   Li Q, 2016, STROKE, V47, P1777, DOI 10.1161/STROKEAHA.116.013186
   Li Q, 2015, STROKE, V46, P2119, DOI 10.1161/STROKEAHA.115.009185
   Morotti A, 2018, STROKE, V49, P2067, DOI 10.1161/STROKEAHA.118.022010
   Morotti A, 2017, NEUROLOGY, V89, P548, DOI 10.1212/WNL.0000000000004210
   Ng D, 2018, AM J NEURORADIOL, V39, P232, DOI 10.3174/ajnr.A5465
   Qureshi AI, 2009, LANCET, V373, P1632, DOI 10.1016/S0140-6736(09)60371-8
   Radmanesh F, 2014, STROKE, V45, P1833, DOI 10.1161/STROKEAHA.114.005276
   Rodriguez-Luna D, 2011, NEUROLOGY, V77, P1599, DOI 10.1212/WNL.0b013e3182343387
   Rodriguez-Luna D, 2016, NEUROLOGY, V87, P357, DOI 10.1212/WNL.0000000000002897
   Sato S, 2014, NEUROLOGY, V83, P2232, DOI 10.1212/WNL.0000000000001076
   Shimoda Y, 2017, CEREBROVASC DIS, V44, P105, DOI 10.1159/000477179
   Sporns PB, 2018, STROKE, V49, P2317, DOI 10.1161/STROKEAHA.118.021625
   Sporns PB, 2017, J STROKE, V19, P333, DOI 10.5853/jos.2016.02061
   Sporns PB, 2017, STROKE, V48, P131, DOI 10.1161/STROKEAHA.116.014068
   van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0
   Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3
   Yu ZY, 2019, WORLD NEUROSURG, V126, pE694, DOI 10.1016/j.wneu.2019.02.125
   Yu ZY, 2017, J NEUROL SCI, V379, P44, DOI 10.1016/j.jns.2017.05.049
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.069
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600072
PM 31870816
DA 2020-05-12
ER

PT J
AU Li, CY
   Chen, CC
   Chen, CT
   Hsieh, PC
   Wang, AYC
   Wu, YM
   Wong, HF
   Yeap, MC
   Chang, CH
AF Li, Cheng-Yu
   Chen, Ching-Chang
   Chen, Chun-Ting
   Hsieh, Po-Chuan
   Wang, Alvin Yi-Chou
   Wu, Yi-Ming
   Wong, Ho-Fai
   Yeap, Mun-Chun
   Chang, Chien-Hung
TI Endovascular Treatment of Ruptured Proximal Segment of the Anterior
   Cerebral Artery Aneurysms: Single-Center Experience and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE A1 aneurysm; Angiography; Endovascular treatment; Ruptured aneurysm
ID MULTIPLE INTRACRANIAL ANEURYSMS; A1 SEGMENT; COIL EMBOLIZATION;
   MANAGEMENT; CLASSIFICATION
AB BACKGROUND: Proximal anterior cerebral artery (A1) aneurysms are rare among all intracranial aneurysms and are regarded as difficult to treat endovascularly. Treatment is even more challenging in patients with ruptured aneurysms and acute subarachnoid hemorrhage owing to the small size and proximity to perforators. Though challenging, endovascular treatment can provide favorable outcomes in such patients. We report our case series of endovascular treatment in ruptured proximal A1 aneurysms.
   METHODS: Between January 2010 and December 2017, 1200 aneurysms were treated endovascularly at our center. There were 15 patients with 15 ruptured proximal A1 aneurysms who presented with subarachnoid hemorrhage. Five patients underwent simple coiling, 9 underwent balloon-assisted coiling, and 1 underwent catheter protective coiling. Medical records and angiographic results were obtained retrospectively.
   RESULTS: All aneurysms were successfully treated with endovascular techniques. Multiplicity rate was 53.3% (n = 8). Initial complete obliteration rate was 93.3% (n = 14), with a 13.3% recurrence rate (n = 2). One patient experienced intraoperative bleeding; this was the only procedure-related complication. Eleven patients (73.3%) had a good clinical outcome. When excluding Hunt and Hess grade 4 patients, the good outcome rate was 81.8%.
   CONCLUSIONS: Ruptured proximal A1 aneurysm is a rare condition and is highly associated with multiple aneurysms. Despite being a more difficult and complicated technique, endovascular coiling performed in high-volume, experienced medical centers is an effective modality with excellent clinical outcomes.
C1 [Li, Cheng-Yu; Chen, Ching-Chang; Chen, Chun-Ting; Hsieh, Po-Chuan; Yeap, Mun-Chun] Chang Gung Univ, Chang Gung Mem Hosp, Linkou Med Ctr, Dept Neurosurg, Taoyuan, Taiwan.
   [Wang, Alvin Yi-Chou] Guangdong Prov Hosp Chinese Med, Dept Neurosurg, Guangzhou, Peoples R China.
   [Wu, Yi-Ming; Wong, Ho-Fai] Linkou Chang Gung Mem Hosp, Dept Radiol, Div Neuroradiol, Taoyuan, Taiwan.
   [Chang, Chien-Hung] Linkou Chang Gung Mem Hosp, Dept Neurol, Taoyuan, Taiwan.
   [Chang, Chien-Hung] Chang Gung Univ, Taoyuan, Taiwan.
RP Chen, CC (reprint author), Chang Gung Univ, Chang Gung Mem Hosp, Linkou Med Ctr, Dept Neurosurg, Taoyuan, Taiwan.
EM jcchen130@gmail.com
FU Chang Gung Memorial HospitalChang Gung Memorial Hospital [CMRPG3H0741]
FX This study is supported by Chang Gung Memorial Hospital (Grant No.
   CMRPG3H0741).
CR Andic C, 2017, J NEUROINTERV SURG, V9, P1069, DOI 10.1136/neurintsurg-2016-012745
   Bhaisora KS, 2014, NEUROL INDIA, V62, P410, DOI 10.4103/0028-3886.141284
   Chalif DJ, 1998, NEUROSURG CLIN N AM, V9, P797, DOI 10.1016/S1042-3680(18)30230-4
   Chang HW, 2011, ACTA NEUROCHIR, V153, P279, DOI 10.1007/s00701-010-0804-5
   Cho YD, 2014, NEURORADIOLOGY, V56, P219, DOI 10.1007/s00234-014-1319-1
   Czepko R, 2005, J Neurosurg Sci, V49, P85
   Dashti R, 2007, SURG NEUROL, V68, P366, DOI 10.1016/j.surneu.2007.07.084
   Ding XM, 2017, WORLD NEUROSURG, V104, P291, DOI 10.1016/j.wneu.2017.04.106
   Gupta R, 2006, J NEUROIMAGING, V16, P117, DOI 10.1111/j.1552-6569.2006.00033.x
   HANDA J, 1984, SURG NEUROL, V22, P486, DOI 10.1016/0090-3019(84)90308-2
   Hino A, 2002, ACTA NEUROCHIR, V144, P1291, DOI 10.1007/s00701-002-1014-6
   Jang CK, 2018, NEUROL SCI, V39, P1735, DOI 10.1007/s10072-018-3492-1
   Jeon P, 2014, AM J NEURORADIOL, V35, P1170, DOI 10.3174/ajnr.A3821
   Kim MK, 2019, WORLD NEUROSURG, V127, pE488, DOI [10.1016/J.WNEU.2019.03.178, 10.1016/j.wneu.2019.03.178]
   Ko JK, 2013, J KOREAN NEUROSURG S, V54, P75, DOI 10.3340/jkns.2013.54.2.75
   Kwon HJ, 2018, AM J NEURORADIOL, V39, P2297, DOI 10.3174/ajnr.A5875
   Lee Ha Young, 2011, Neurointervention, V6, P95, DOI 10.5469/neuroint.2011.6.2.95
   Lee JM, 2010, WORLD NEUROSURG, V74, P478, DOI 10.1016/j.wneu.2010.06.040
   Liu P, 2016, NEUROL INDIA, V64, P694, DOI 10.4103/0028-3886.185405
   Lubicz B, 2009, NEURORADIOLOGY, V51, P99, DOI 10.1007/s00234-008-0474-7
   Maiti TK, 2016, WORLD NEUROSURG, V85, P85, DOI 10.1016/j.wneu.2015.07.022
   McDougall CG, 2012, J NEUROSURG, V116, P135, DOI 10.3171/2011.8.JNS101767
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Moret J, 2000, AM J NEURORADIOL, V21, P262
   Park Hyun-Seok, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P13, DOI 10.7461/jcen.2013.15.1.13
   ROSNER SS, 1984, J NEUROSURG, V61, P468, DOI 10.3171/jns.1984.61.3.0468
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Spetzler RF, 2013, J NEUROSURG, V119, P146, DOI 10.3171/2013.3.JNS12683
   SUZUKI M, 1992, J NEUROSURG, V76, P455, DOI 10.3171/jns.1992.76.3.0455
   WAKABAYASHI T, 1985, SURG NEUROL, V24, P31, DOI 10.1016/0090-3019(85)90059-X
   Wanibuchi M, 2001, SURG NEUROL, V55, P148, DOI 10.1016/S0090-3019(01)00396-2
   Yasargil M. G., 1984, MICRONEUROSURGERY
   Yilmaz M, 2014, BOSNIAN J BASIC MED, V14, P8
   Yu B, 2010, NEUROL INDIA, V58, P446, DOI 10.4103/0028-3886.65538
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.135
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600028
PM 31790836
DA 2020-05-12
ER

PT J
AU Li, NY
   Patel, SA
   Durand, WM
   Ready, LV
   Owens, BD
   Daniels, AH
AF Li, Neill Y.
   Patel, Shyam A.
   Durand, Wesley M.
   Ready, Lauren, V
   Owens, Brett D.
   Daniels, Alan H.
TI Increased Risk of Chronic Opioid Use and Revision After Anterior
   Cervical Diskectomy and Fusion in Patients with Prior Shoulder
   Arthroscopy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical diskectomy and fusion; Narcotics; Opioid; Revision
   anterior cervical diskectomy and fusion; Shoulder arthroscopy
ID ROTATOR CUFF TEARS; QUALITY-OF-LIFE; PAIN; SPINE; IMPACT
AB OBJECTIVE: The purpose of this study was to compare differences in the outcomes of patients who undergo anterior cervical diskectomy and fusion (ACDF) with and without a history of shoulder arthroscopy.
   METHODS: The PeariDiver Patient Records Database (www.peardiverinc.com ) from 2007 to 2017 was used to query patients by Current Procedural Terminology, isolating those who underwent ACDF with and without prior shoulder arthroscopy. Postoperative complications within 30 days of the index procedure, opioid use, and revision procedures were assessed for each cohort using ICD-9/10 and Current Procedural Terminology coding.
   RESULTS: A total of 39,969 ACDF patients were queried, of which 38,859 (97.2%) underwent ACDF alone and 1110 (2.8%) underwent ACDF with prior shoulder arthroscopy. ACDF revision rates were significantly greater in patients with prior shoulder arthroscopy compared with ACDF alone (5.8% vs. 3.6%, aOR = 1.64, P = 0.0002). Patients with prior shoulder arthroscopy were also significantly more likely to fill opioid prescriptions at 3 months (aOR 1.19, P = 0.02), 6 months (aOR 1.22, P = 0.01), and 12 months (aOR 1.18, P = 0.04).
   CONCLUSIONS: Patients who undergo ACDF with a prior shoulder arthroscopy have significantly greater revision rates, respiratory complications, and prolonged opioid use compared with patients without prior shoulder arthroscopy. With efforts to limit narcotic use and the importance of maximizing patient satisfaction, this analysis improves on the surgeon's ability to set expectations and postoperative plans for patients undergoing ACDF who have a history of shoulder arthroscopy.
C1 [Li, Neill Y.; Patel, Shyam A.; Owens, Brett D.; Daniels, Alan H.] Brown Univ, Alpert Med Sch, Dept Orthopaed, Providence, RI 02912 USA.
   [Durand, Wesley M.; Ready, Lauren, V] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
RP Li, NY (reprint author), Brown Univ, Alpert Med Sch, Dept Orthopaed, Providence, RI 02912 USA.
EM li.neillyun@gmail.com
CR [Anonymous], 2018, UND EP DRUG OV CDC I
   Bokshan SL, 2016, AM J MED, V129, P913, DOI 10.1016/j.amjmed.2016.04.023
   Eriks-Hoogland IE, 2014, J SPINAL CORD MED, V37, P288, DOI 10.1179/2045772313Y.0000000168
   Falla D, 2017, CLIN J PAIN, V33, P1006, DOI 10.1097/AJP.0000000000000513
   Florence CS, 2016, MED CARE, V54, P901, DOI 10.1097/MLR.0000000000000625
   Fountas KN, 2007, SPINE, V32, P2310, DOI 10.1097/BRS.0b013e318154c57e
   Garimella V, 2013, CLIN COLON RECT SURG, V26, P191, DOI 10.1055/s-0033-1351138
   Gause Trent M 2nd, 2020, Hand (N Y), V15, P234, DOI 10.1177/1558944718792276
   Gorski JM, 2003, J BONE JOINT SURG AM, V85A, P635, DOI 10.2106/00004623-200304000-00008
   Gutierrez DD, 2007, J SPINAL CORD MED, V30, P251, DOI 10.1080/10790268.2007.11753933
   Hattrup SJ, 2010, J SHOULDER ELB SURG, V19, P937, DOI 10.1016/j.jse.2010.05.007
   HAWKINS RJ, 1990, CLIN ORTHOP RELAT R, P142
   Jo Hyun-Jin, 2012, Korean J Spine, V9, P223, DOI 10.14245/kjs.2012.9.3.223
   Johnson SP, 2016, J HAND SURG-AM, V41, P947, DOI 10.1016/j.jhsa.2016.07.113
   Lee YS, 2015, GLOB SPINE J, V5
   Lucas CE, 2007, J AM COLL SURGEONS, V205, P101, DOI 10.1016/j.jamcollsurg.2007.01.062
   Maharaj Monish M, 2016, J Spine Surg, V2, P105, DOI 10.21037/jss.2016.05.01
   Malige A, 2018, SPINE J, V18, pS188
   Manifold SG, 1999, CLIN ORTHOP RELAT R, P105
   Morone NE, 2013, CLIN THER, V35, P1728, DOI 10.1016/j.clinthera.2013.10.001
   Rubenstein WJ, 2017, ARTHROSCOPY, V33, P49, DOI 10.1016/j.arthro.2016.05.035
   Silvestri J, 2017, DISABIL REHABIL, V39, P82, DOI 10.3109/09638288.2016.1140829
   Soelberg CD, 2017, ANESTH ANALG, V125, P1675, DOI 10.1213/ANE.0000000000002403
   Steiner SRH, 2018, ARTHROSCOPY, V34, P1931, DOI 10.1016/j.arthro.2018.01.052
   Tasiou Anastasia, 2017, J Spine Surg, V3, P444, DOI 10.21037/jss.2017.08.03
   Warrender WJ, 2017, AM J SPORT MED, V45, P1676, DOI 10.1177/0363546516667906
   Wright AR, 2015, MYOPAIN, V23, P34, DOI 10.3109/10582452.2015.1132026
   Yamamoto A, 2015, J SHOULDER ELB SURG, V24, P446, DOI 10.1016/j.jse.2014.07.012
   Zhang AL, 2015, J SPINAL DISORD TECH, V28, pE206, DOI 10.1097/BSD.0000000000000223
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.116
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600024
PM 31786377
DA 2020-05-12
ER

PT J
AU Li, T
   Yang, JS
   Wang, XF
   Meng, CY
   Wei, JM
   Wang, YX
   Zou, P
   Chen, H
   Liu, TJ
   Liu, P
   Hao, DJ
   Chu, L
AF Li, Tao
   Yang, Jun-Song
   Wang, Xiang-Fu
   Meng, Chun-Yang
   Wei, Jian-Min
   Wang, Ye-Xin
   Zou, Peng
   Chen, Hao
   Liu, Tuan-Jiang
   Liu, Peng
   Hao, Ding-Jun
   Chu, Lei
TI Can Zero-Profile Cage Maintain the Cervical Curvature Similar to
   Plate-Cage Construct for Single-Level Anterior Cervical Diskectomy and
   Fusion?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cervical decompression and fusion; Bone mineral density;
   Cervical curvature; Cervical spondylosis; Intervertebral fusion device
ID POLYETHERETHERKETONE PEEK CAGES; INTERBODY FUSION; SPONDYLOTIC
   MYELOPATHY; DYSPHAGIA; AUGMENTATION; SUBSIDENCE; TITANIUM; SPINE
AB OBJECTIVE: We sought to compare the clinical and radiologic outcomes after anterior cervical surgery between zero-profile (Zero-P) cage and plate-cage construct (PCC).
   METHODS: One-hundred and sixteen patients with single-level cervical disk herniation who underwent anterior cervical diskectomy and fusion between May 2015 and March 2017 were enrolled. They were divided into a Zero-P group (61 cases) and a PCC group (55 cases). At 1, 6,12, and 24 months after the operation, routine follow-up evaluation was recommended including visual analog scale score and Japanese Orthopaedic Association score. The lateral x-ray film was performed at 1 and 24 months postoperatively.
   RESULTS: All 116 patients successfully completed the operation and achieved bone fusion. While there was no significant difference in the amount of bleeding between the 2 groups, the operation time of the Zero-P group was significantly shorter than that of the PCC group with statistically difference. The visual analog scale score and Japanese Orthopaedic Association score of the 2 groups at each follow-up interval postoperatively were significantly improved compared with that before operation; the difference was statistically significant (P < 0.05, respectively). While all the C2-7 cervical curvature, segmental Cobb angle, and height of adjacent vertebral body were lost at the 24-month follow-up, the significant difference was observed in the Zero-P group (P < 0.05, respectively).
   CONCLUSIONS: Compared with the Zero-P system, the PCC system provides a comparable clinical outcome. Although it showed the disadvantages in controlling the operation time and surgical bleeding, the radiologic outcome was better at the 2-year follow-up.
C1 [Li, Tao; Yang, Jun-Song; Zou, Peng; Chen, Hao; Liu, Tuan-Jiang; Liu, Peng; Hao, Ding-Jun] Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
   [Wei, Jian-Min] Baoji City Hosp Tradit Chinese Med, Baoji, Shaanxi, Peoples R China.
   [Meng, Chun-Yang; Wang, Ye-Xin] Jining Med Univ, Affiliated Hosp, Jining, Shandong, Peoples R China.
   [Wang, Xiang-Fu] Gansu Prov Hosp Tradit Chinese Med, Spinal Minimally Invas Surg, Lanzhou, Gansu, Peoples R China.
   [Chu, Lei] Chongqing Med Univ, Affiliated Hosp 2, Orthopaed, Chongqing, Peoples R China.
RP Liu, P (reprint author), Xi An Jiao Tong Univ, Honghui Hosp, Dept Spine Surg, Xian, Shaanxi, Peoples R China.
EM 13991814651@163.com
OI liu, peng/0000-0003-3453-2278; chen, hao/0000-0002-7122-9027
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81772357, 81830077]
FX The National Natural Science Foundation of China (81772357 and 81830077
   for Ding-Jun Hao) provided grants.
CR Barsa P, 2007, EUR SPINE J, V16, P1395, DOI 10.1007/s00586-006-0284-8
   Chen Y, 2013, EUR SPINE J, V22, P1539, DOI 10.1007/s00586-013-2772-y
   Guo Long, 2015, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V29, P840
   Kalsi-Ryan S, 2013, NEUROSCIENTIST, V19, P409, DOI 10.1177/1073858412467377
   Kim CH, 2015, J SPINAL DISORD TECH, V28, pE17, DOI 10.1097/BSD.0000000000000137
   Lee CH, 2013, J SPINAL DISORD TECH, V26, P112, DOI 10.1097/BSD.0b013e318274148e
   Lee MJ, 2005, J SPINAL DISORD TECH, V18, P406, DOI 10.1097/01.bsd.0000177211.44960.71
   Lee YS, 2015, SPINE, V40, pE563, DOI 10.1097/BRS.0000000000000864
   Li YB, 2015, J SPINAL DISORD TECH, V28, P398, DOI 10.1097/BSD.0000000000000032
   Nemoto Osamu, 2015, Eur J Orthop Surg Traumatol, V25 Suppl 1, pS127, DOI 10.1007/s00590-014-1547-4
   Oliver JD, 2018, SPINE, V43, pE413, DOI 10.1097/BRS.0000000000002441
   Pitzen TR, 2009, SPINE, V34, P641, DOI 10.1097/BRS.0b013e318198ce10
   Riley LH, 2005, SPINE, V30, P2564, DOI 10.1097/01.brs.0000186317.86379.02
   Schmieder K, 2006, J NEUROSURG-SPINE, V4, P447, DOI 10.3171/spi.2006.4.6.447
   SEVASTIKOGLOU JA, 1969, ACTA ORTHOP SCAND, V40, P608, DOI 10.3109/17453676908989526
   SMITH GW, 1958, J BONE JOINT SURG AM, V40, P607, DOI 10.2106/00004623-195840030-00009
   Song KJ, 2009, SPINE, V34, P2886, DOI 10.1097/BRS.0b013e3181b64f2c
   Vanek P, 2013, SPINE, V38, pE792, DOI 10.1097/BRS.0b013e3182913400
   Yang HS, 2015, ARCH ORTHOP TRAUM SU, V135, P781, DOI 10.1007/s00402-015-2212-z
   Yue WM, 2005, SPINE, V30, P2138, DOI 10.1097/01.brs.0000180479.63092.17
   [朱迪 Zhu Di], 2019, [中华老年医学杂志, Chinese Journal of Geriatrics], V38, P185
NR 21
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.153
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600034
PM 31805404
DA 2020-05-12
ER

PT J
AU Li, ZH
   Wei, F
   Liu, ZJ
   Liu, XG
   Jiang, L
   Yu, M
   Xu, NF
   Wu, FL
   Dang, L
   Zhou, H
   Li, ZH
AF Li, Zhehuang
   Wei, Feng
   Liu, Zhongjun
   Liu, Xiaoguang
   Jiang, Liang
   Yu, Miao
   Xu, Nanfang
   Wu, Fengliang
   Dang, Lei
   Zhou, Hua
   Li, Zihe
TI Risk Factors for Instrumentation Failure After Total En Bloc
   Spondylectomy of Thoracic and Lumbar Spine Tumors Using Titanium Mesh
   Cage for Anterior Reconstruction
SO WORLD NEUROSURGERY
LA English
DT Article
DE Instrumentation failure; Nonfusion; Revision surgery; Risk factors;
   Spinal neoplasms; Total en bloc spondylectomy
ID SURGICAL-TECHNIQUES; RESECTION; RADIOTHERAPY; METASTASES; CONSENSUS;
   PLATE
AB OBJECTIVE: The present study investigated the risk factors for instrumentation failure (IF) after total en bloc spondylectomy (TES) of thoracic and lumbar spine tumors using a titanium mesh cage (TMC) for anterior reconstruction.
   METHODS: The data from patients who had undergone TES for thoracic and lumbar spine tumors in our institution were retrospectively reviewed. Anterior reconstruction was performed using a TMC filled with morcelized aliograft or morcelized autograft. Posterior reconstruction was performed using pedicle fixation. Survival analysis from TES to IF was conducted. The Kaplan-Meier method was used for univariate analysis. Factors of statistical significance were included in the multivariate analysis using Cox regression analysis.
   RESULTS: A total of 30 patients (20 men and 10 women), with a mean age of 37.1 +/- 14.3 years (range, 14-65 years) were included. The mean follow-up period was 41.8 +/- 21.3 months (range, 13-120 months). Bone fusion was achieved in 23 patients (76.7%). IF occurred in 8 patients. The mean interval from TES to the first IF was 31.8 +/- 15.1 months (range, 13-64 months). On univariable analysis, a body mass index >28 kg/m(2), perioperative radiotherapy, and the TMC in an oblique position were associated with IF. On multivariable analysis, these 3 factors were entered into the Cox regression model and were also significant.
   CONCLUSIONS: The use of TES can achieve durable oncological control. However, IF, a not uncommon late complication that leads to reoperation, should be a cause for concern. We found perioperative radiotherapy, a TMC in an oblique position, and a body mass index >28 kg/m(2) were significant predictive factors for IF.
C1 [Li, Zhehuang; Wei, Feng; Liu, Zhongjun; Liu, Xiaoguang; Jiang, Liang; Yu, Miao; Xu, Nanfang; Wu, Fengliang; Dang, Lei; Zhou, Hua; Li, Zihe] Peking Univ, Dept Orthoped, Hosp 3, Beijing, Peoples R China.
RP Liu, ZJ (reprint author), Peking Univ, Dept Orthoped, Hosp 3, Beijing, Peoples R China.
EM zjliu@bjmu.edu.cn
CR Bartlow CM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204928
   Boriani S, 2010, EUR SPINE J, V19, P231, DOI 10.1007/s00586-009-1137-z
   Cloyd JM, 2010, NEUROSURGERY, V67, P435, DOI 10.1227/01.NEU.0000371987.85090.FF
   Colman MW, 2015, SPINE J, V15, P1728, DOI 10.1016/j.spinee.2015.03.042
   Elder BD, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2016.8.FOCUS16112
   Fisher CG, 2010, SPINE, V35, pE1221, DOI 10.1097/BRS.0b013e3181e16ae2
   Girolami M, 2018, EUR SPINE J, V27, P3073, DOI 10.1007/s00586-018-5708-8
   Glennie RA, 2016, SPINE, V41, pS205, DOI 10.1097/BRS.0000000000001835
   Harel R, 2010, WORLD NEUROSURG, V74, P517, DOI 10.1016/j.wneu.2010.06.037
   Hernandez RK, 2015, CLIN EPIDEMIOL, V7, P335, DOI 10.2147/CLEP.S85496
   Hobusch GM, 2016, CLIN ORTHOP RELAT R, V474, P1508, DOI 10.1007/s11999-016-4741-3
   Husain ZA, 2017, J NEUROSURG-SPINE, V27, P295, DOI 10.3171/2017.1.SPINE16684
   Kato S, 2014, ANN SURG ONCOL, V21, P1330, DOI 10.1245/s10434-013-3333-7
   Kawahara N, 2011, SPINE, V36, P74, DOI 10.1097/BRS.0b013e3181cded6c
   Kawahara N, 2009, ORTHOP CLIN N AM, V40, P47, DOI 10.1016/j.ocl.2008.09.004
   Lu T, 2017, MED SCI MONITOR, V23, P2863, DOI 10.12659/MSM.905466
   Luzzati AD, 2015, CLIN ORTHOP RELAT R, V473, P858, DOI 10.1007/s11999-014-3578-x
   Matsumoto M, 2011, J NEUROSURG-SPINE, V15, P320, DOI 10.3171/2011.5.SPINE10813
   Mesfin A, 2015, ORTHOPEDICS, V38, pE995, DOI 10.3928/01477447-20151020-08
   Mohammad-Shahi MH, 2013, J SPINAL DISORD TECH, V26, P268, DOI 10.1097/BSD.0b013e3182425eab
   Park SJ, 2019, SPINE J, V19, P1613, DOI 10.1016/j.spinee.2019.04.018
   Robertson PA, 2004, J SPINAL DISORD TECH, V17, P44, DOI 10.1097/00024720-200402000-00010
   Sciubba DM, 2016, EUR SPINE J, V25, P4080, DOI 10.1007/s00586-016-4641-y
   Shah AA, 2017, J BONE JOINT SURG AM, V99, P1476, DOI 10.2106/JBJS.17.00141
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   TOMITA K, 1994, INT ORTHOP, V18, P291
   Tomita K, 1997, SPINE, V22, P324, DOI 10.1097/00007632-199702010-00018
   van Leeuwen-Segarceanu EM, 2012, INT J RADIAT ONCOL, V82, P612, DOI 10.1016/j.ijrobp.2010.11.064
   Yamazaki T, 2009, SPINE, V34, pS31, DOI 10.1097/BRS.0b013e3181b8b796
   Yanamadala V, 2017, NEUROSURGERY, V81, P156, DOI 10.1093/neuros/nyw057
   Yao Kevin C, 2003, Neurosurg Focus, V15, pE6
   Yoshioka K, 2013, SPINE, V38, pE1511, DOI 10.1097/BRS.0b013e3182a6427a
   Zhang LL, 2015, SCI REP, V5
NR 33
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.057
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600015
PM 31756507
DA 2020-05-12
ER

PT J
AU Li, ZZ
   Xu, RY
   Chen, W
   Wang, HL
   Ding, JK
   Shao, W
   Du, HP
   Gao, WB
   Liu, PF
   Liu, YL
   Li, M
   Li, JM
   Li, ZF
AF Li Zhenzhu
   Xu Ruiyu
   Chen Wei
   Wang Henglu
   Ding Jinke
   Shao Wei
   Du Hongpeng
   Gao Wenbo
   Liu Pengfei
   Liu Yongliang
   Li Meng
   Li Jianmin
   Li Zefu
TI Novel Cost-Effective Tubular Port Based on Glove and Syringe for
   Endoscopic Surgery of Intracerebral Hematomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic surgery; Intracerebral hematoma; Minimally invasive brain
   surgery; Transportal brain surgery; Tubular port
ID EVACUATION; HEMORRHAGE; REMOVAL; LESIONS; SHEATH
AB BACKGROUND: Intracerebral hematomas (ICH) is a common disease in the developing countries, and minimally invasive transportal resection of ICH is a widely accepted surgical technique. Many port systems are available, but most are disposable and expensive. We present a safe and cost-effective glove-syringe substitute for endoscopic hematoma evacuation, suitable for developing countries such as China.
   METHODS: A port substitute of different sizes and lengths was constructed using sterile gloves and syringes, commonly found in a surgical environment.
   RESULTS: We successfully performed endoscopic hematoma removal in 7 patients including 1 cerebellar hemorrhage case and the remaining 6 supratentorial basal ganglia cases (1 patient taking oral aspirin). Bipolar electrocoagulation was used to control bleeding from the ruptured blood vessels. There were no postsurgical complications.
   CONCLUSIONS: The glove-syringe port is a convenient, safe, and cost-effective tubular port system for endoscopic surgery of ICH. Such ports can be used as substitutes when commercial sleeves are unavailable, especially in rural areas and developing countries.
C1 [Li Zhenzhu; Li Zefu] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Peoples R China.
   [Li Zhenzhu; Chen Wei; Wang Henglu; Ding Jinke; Shao Wei; Du Hongpeng; Gao Wenbo; Liu Pengfei; Liu Yongliang; Li Meng; Li Jianmin; Li Zefu] Binzhou Med Univ Hosp, Dept Neurosurg, Binzhou, Shandong, Peoples R China.
   [Xu Ruiyu] Binzhou Med Univ Hosp, Dept Endocrinol, Binzhou, Shandong, Peoples R China.
RP Li, ZF (reprint author), Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Peoples R China.; Li, ZF (reprint author), Binzhou Med Univ Hosp, Dept Neurosurg, Binzhou, Shandong, Peoples R China.
EM lizefu163@163.com
FU Natural Science Foundation of Shandong ProvinceNatural Science
   Foundation of Shandong Province [ZR2018LH007]; Binzhou Medical
   University Project [BY2015KJ28]
FX This study was supported by Natural Science Foundation of Shandong
   Province (ZR2018LH007) and Binzhou Medical University Project
   (BY2015KJ28).
CR Almubarak AO, 2018, WORLD NEUROSURG, V117, P54, DOI 10.1016/j.wneu.2018.05.236
   Bander ED, 2016, J NEUROSURG, V124, P1053, DOI 10.3171/2015.4.JNS142576
   Barnes B, 2014, CURR OPIN CRIT CARE, V20, P148, DOI 10.1097/MCC.0000000000000077
   Dye JA, 2012, J NEUROSURG, V117, P767, DOI 10.3171/2012.7.JNS111567
   Eliyas JK, 2016, WORLD NEUROSURG, V90, P556, DOI 10.1016/j.wneu.2015.12.100
   Fratzoglou M, 2003, NEUROSURG REV, V1, P10
   Gross BA, 2019, JAMA-J AM MED ASSOC, V321, P1295, DOI 10.1001/jama.2019.2413
   Hwang SC, 2016, WORLD NEUROSURG, V90, P268, DOI 10.1016/j.wneu.2016.03.001
   Ishikawa T, 2019, INTERDISCIP NEUROSUR, V15, P53, DOI 10.1016/j.inat.2018.10.001
   Jia WH, 2011, NEUROSCIENCES, V16, P335
   Kim JY, 2017, J STROKE, V19, P28, DOI 10.5853/jos.2016.01935
   Li Y, 2016, WORLD NEUROSURG, V88, P76, DOI 10.1016/j.wneu.2015.12.038
   Longatti P, 2013, WORLD NEUROSURG, V79, DOI 10.1016/j.wneu.2012.02.025
   Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1
   Miller CM, 2008, SURG NEUROL, V69, P441, DOI 10.1016/j.surneu.2007.12.016
   Nishihara T, 2000, J NEUROSURG, V92, P1053, DOI 10.3171/jns.2000.92.6.1053
   Nishihara T, 2007, CHILD NERV SYST, V23, P677, DOI 10.1007/s00381-007-0325-6
   Sharif S, 2019, WORLD NEUROSURG, V131, P339, DOI 10.1016/j.wneu.2019.06.202
   Singh H, 2018, WORLD NEUROSURG, V114, P117, DOI 10.1016/j.wneu.2018.03.019
   Singh L, 2009, ACTA NEUROCHIR, V151, P1493, DOI 10.1007/s00701-009-0256-y
   Thabet AM, 2017, HAND CLINIC, V140, P177, DOI 10.1016/B978-0-444-63600-3.00011-8
   Xu T, 2018, WORLD NEUROSURG, V120, P27, DOI 10.1016/j.wneu.2018.08.136
NR 22
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.097
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600163
PM 31770599
DA 2020-05-12
ER

PT J
AU Lin, CW
   Chang, CC
   Chen, HT
   Chen, YJ
   Lin, CS
   Hsu, HC
   Tsou, HK
AF Lin, Chung-Wei
   Chang, Chien-Chun
   Chen, Hsien-Te
   Chen, Yen-Jen
   Lin, Chih-Sheng
   Hsu, Horng-Chaung
   Tsou, Hsi-Kai
TI 3D Real-Time Image-Guided Navigation Spine Corpectomy with Ultrasonic
   Bone Cutter: Technical Note
SO WORLD NEUROSURGERY
LA English
DT Article
DE Corpectomy; Hemivertebra; Hemivertebrectomy; Navigation; Ultrasonic bone
   cutter
ID PEDICLE SCREW PLACEMENT; HEMIVERTEBRA RESECTION; SCOLIOSIS; OSTEOTOME;
   ACCURACY; OUTCOMES; CURETTE; FUSION; LUMBAR; DEVICE
AB BACKGROUND: Surgical interventions for congenital scoliosis are challenging for spine surgeons. The coordination of 3-dimensional (3D), real-time, image-guided navigation with an ultrasonic bone cutter allows surgeons to localize the affected area of the spine accurately and remove the lesion without damaging soft tissue structures. The goal of this technical paper is to report a previously undescribed method of hemivertebrectomy that combines 3D, real-time, image-guided navigation and an ultrasonic bone cutter. We highlight the feasibility and safety of this method in spinal surgery.
   METHODS: Three patients with congenital scoliosis were treated with this technique. We present three illustrative cases comprising hemivertebrectomies for congenital scoliosis. Intraoperative photos demonstrating the technique are also provided.
   RESULTS: All surgeries were completed without complications. The hemivertebrae were completely removed, and marked correction of congenital scoliosis was noted.
   CONCLUSIONS: We believe that the combination of 3D, real-time image navigation and an ultrasonic bone cutter improves hemivertebrectomy by increasing accuracy and avoiding dura laceration, major organ damage, or potential vessel damage.
C1 [Lin, Chung-Wei; Chang, Chien-Chun; Chen, Hsien-Te; Chen, Yen-Jen; Hsu, Horng-Chaung] China Med Univ, China Med Univ Hosp, Dept Orthoped Surg, Taichung, Taiwan.
   [Chang, Chien-Chun; Lin, Chih-Sheng] Natl Chiao Tung Univ, Dept Biol Sci & Technol, Hsinchu, Taiwan.
   [Chang, Chien-Chun; Lin, Chih-Sheng] Natl Chiao Tung Univ, PhD Degree Program Biomed Sci & Engn, Hsinchu, Taiwan.
   [Chen, Hsien-Te] China Med Univ, Coll Hlth Care, Dept Sports Med, Taichung, Taiwan.
   [Chang, Chien-Chun; Chen, Hsien-Te; Chen, Yen-Jen] China Med Univ, China Med Univ Hosp, Spine Ctr, Taichung, Taiwan.
   [Chen, Yen-Jen; Hsu, Horng-Chaung] China Med Univ, Sch Med, Taichung, Taiwan.
   [Tsou, Hsi-Kai] Taichung Vet Gen Hosp, Neurol Inst, Funct Neurosurg Div, Taichung, Taiwan.
   [Tsou, Hsi-Kai] Jen Teh Jr Coll Med Nursing & Management, Dept Rehabil, Houlong Township, Miaoli County, Taiwan.
RP Chen, HT (reprint author), China Med Univ, China Med Univ Hosp, Dept Orthoped Surg, Taichung, Taiwan.; Chen, HT (reprint author), China Med Univ, Coll Hlth Care, Dept Sports Med, Taichung, Taiwan.; Chen, HT (reprint author), China Med Univ, China Med Univ Hosp, Spine Ctr, Taichung, Taiwan.
EM bonekid1@gmail.com
OI Lin, Chung-Wei/0000-0002-6993-6814
FU China Medical University Hospital [CRS-108-034]
FX The study was sponsored by China Medical University Hospital
   (CRS-108-034).
CR Al-Mahfoudh R, 2014, BRIT J NEUROSURG, V28, P56, DOI 10.3109/02688697.2013.812182
   Ammirati M, 2013, NEUROSURG REV, V36, P157, DOI 10.1007/s10143-012-0421-2
   Aydogan M, 2008, J PEDIATR ORTHOP B, V17, P33, DOI 10.1097/01.bpb.0000218031.75557.f0
   Baaj AA, 2013, CLIN NEUROL NEUROSUR, V115, P342, DOI 10.1016/j.clineuro.2012.05.007
   Brooks A T, 1993, J Arthroplasty, V8, P413, DOI 10.1016/S0883-5403(06)80041-0
   Bydon M, 2014, J PEDIATR ORTHOPED, V34, P780, DOI 10.1097/BPO.0000000000000211
   Chen ZH, 2018, SPINE, V43, P394, DOI 10.1097/BRS.0000000000002325
   Feng Y, 2016, EUR SPINE J, V25, P3274, DOI 10.1007/s00586-016-4556-7
   Hazer DB, 2016, BIOMED RES INT, DOI 10.1155/2016/8428530
   Houten JK, 2012, NEUROSURGERY, V70, P990, DOI 10.1227/NEU.0b013e318237a829
   Hu XB, 2013, EUR SPINE J, V22, P2845, DOI 10.1007/s00586-013-2780-y
   Kim CH, 2015, J KOREAN NEUROSURG S, V58, P571, DOI 10.3340/jkns.2015.58.6.571
   Mroz TE, 2011, J SPINAL DISORD TECH, V24, P264, DOI 10.1097/BSD.0b013e3181eed618
   Nakagawa H, 2005, J NEUROSURG-SPINE, V2, P431, DOI 10.3171/spi.2005.2.4.0431
   Oertel MF, 2011, J NEUROSURG-SPINE, V14, P532, DOI 10.3171/2010.10.SPINE091032
   Parker SL, 2012, OPER NEUROSURG, V73
   Rampersaud YR, 2000, SPINE, V25, P2637, DOI 10.1097/00007632-200010150-00016
   Rivkin MA, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.1.FOCUS13499
   Ruf M, 2009, SPINE, V34, P1791, DOI 10.1097/BRS.0b013e3181ab6290
   Shin BJ, 2012, J NEUROSURG-SPINE, V17, P113, DOI 10.3171/2012.5.SPINE11399
   Siasios Ioannis D, 2017, J Spine Surg, V3, P657, DOI 10.21037/jss.2017.12.05
   Silbermann J, 2011, EUR SPINE J, V20, P875, DOI 10.1007/s00586-010-1683-4
   Srikandarajah N, 2017, SPINE J, V17, pS5
   Van de Kelft E, 2012, SPINE, V37, pE1580, DOI 10.1097/BRS.0b013e318271b1fa
   Xiao R, 2017, J NEUROSURG-SPINE, V26, P628, DOI 10.3171/2016.10.SPINE16373
   Zhang JG, 2011, EUR SPINE J, V20, P1692, DOI 10.1007/s00586-011-1710-0
   Zhu WG, 2017, J NEUROSURG-PEDIATR, V19, P472, DOI 10.3171/2016.11.PEDS16412
NR 27
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.186
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600133
PM 31706972
DA 2020-05-12
ER

PT J
AU Lin, YH
   Lin, HL
   Cho, DY
AF Lin, Yu-Hsiang
   Lin, Hung-Lin
   Cho, Der-Yang
TI Tension Pneumoventricle After Endoscopic Transsphenoidal Surgery for
   Rathke Cleft Cyst
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraventricular air accumulation; Rathke cleft cyst; Tension
   pneumocephalus; Tension pneumoventricle
ID PNEUMOCEPHALUS
AB BACKGROUND: Tension pneumoventricle is an extremely rare, but treatable, neurosurgical emergency. The prompt and accurate diagnosis of tension pneumoventricle requires vigilance for the detection of clinical signs, which should also be corroborated by the imaging findings. We have reported on the pathophysiology of tension pneumoventricle and its management.
   CASE DESCRIPTION: A 66-year-old woman had presented with a Rathke cleft cyst. The patient underwent transsphenoidal surgery (TSS), with no clinical cerebrospinal fluid leakage observed peri- or postoperatively. However, she developed an altered mental status 8 hours after surgery, and a computed tomography scan showed evidence of a tension pneumoventricle. The patient underwent emergent external ventricular drainage insertion and exploratory endoscopic TSS. A 1-way valve was observed during TSS, and the sella floor was packed with a fat graft for 1-way valve obliteration. The patient recovered well without neurologic deficits. No radiologic regrowth was noted at the 48-month follow-up examination.
   CONCLUSIONS: Tension pneumoventricle is an extremely rare, but life-threatening, complication of TSS. The development of tension pneumoventricle should be kept in mind even when the surgery has proceeded very smoothly. Sellar reconstruction will, theoretically, prevent this extremely rare complication but might increase the recurrence rate of Rathke cleft cysts. The related symptoms and signs should be recognized. Prompt recognition and treatment of this condition can be life-saving, and the long-term outcomes have generally been favorable if the condition has been recognized early.
C1 [Lin, Yu-Hsiang; Lin, Hung-Lin; Cho, Der-Yang] China Med Univ Hosp, Div Neurosurg, Taichung, Taiwan.
   [Lin, Yu-Hsiang; Lin, Hung-Lin; Cho, Der-Yang] China Med Univ, Taichung, Taiwan.
RP Lin, HL (reprint author), China Med Univ Hosp, Div Neurosurg, Taichung, Taiwan.; Lin, HL (reprint author), China Med Univ, Taichung, Taiwan.
EM linhunglin0405@yahoo.com.tw
OI Lin, Yu-hsiang/0000-0002-5120-3778
CR Aho CJ, 2005, J NEUROSURG, V102, P189, DOI 10.3171/jns.2005.102.2.0189
   ALTINORS N, 1988, NEUROSURGERY, V23, P516, DOI 10.1227/00006123-198810000-00022
   Benveniste RJ, 2004, J NEUROSURG, V101, P577, DOI 10.3171/jns.2004.101.4.0577
   Frank G, 2005, NEUROSURGERY, V56, P124, DOI 10.1227/01.NEU.0000144824.80046.1F
   Higgins DM, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.5.FOCUS1175
   Iplikcioglu AC, 2003, NEUROSURGERY, V52, P960, DOI 10.1227/01.NEU.0000053027.30314.64
   Kasperbauer JL, 2002, LARYNGOSCOPE, V112, P1836, DOI 10.1097/00005537-200210000-00024
   Kopelovich JC, 2012, J CLIN ANESTH, V24, P415, DOI 10.1016/j.jclinane.2011.12.003
   Kuroiwa M, 2014, NEUROL MED-CHIR, V54, P578, DOI 10.2176/nmc.cr2013-0014
   Mendelson ZS, 2014, J CLIN NEUROSCI, V21, P378, DOI 10.1016/j.jocn.2013.07.008
   Ruiz-Juretschke F, 2007, NEUROCIRUGIA, V18, P134
   Satyarthee GD, 2003, J CLIN NEUROSCI, V10, P495, DOI 10.1016/S0967-5868(03)00087-0
   Sawka AM, 1999, J CLIN ENDOCR METAB, V84, P4731, DOI 10.1210/jc.84.12.4731
   Siow TY, 2018, WORLD NEUROSURG, V117, P11, DOI 10.1016/j.wneu.2018.05.228
   Steno A, 2009, J NEUROSURG, V110, P359, DOI 10.3171/2008.7.JNS08287
   Zada G, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.5.FOCUS1183
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.065
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600139
PM 31863895
DA 2020-05-12
ER

PT J
AU Liu, BL
   Wang, Y
   Zheng, T
   Liu, SJ
   Lv, WH
   Lu, D
   Chen, L
   Chen, L
   Ma, T
   Gao, GD
   Qu, Y
   He, SM
AF Liu, Bolin
   Wang, Yuan
   Zheng, Tao
   Liu, Shujuan
   Lv, Wenhai
   Lu, Dan
   Chen, Lei
   Chen, Long
   Ma, Tao
   Gao, Guodong
   Qu, Yan
   He, Shiming
TI Effect of Intraoperative Lumbar Drainage on Gross Total Resection and
   Cerebrospinal Fluid Leak Rates in Endoscopic Transsphenoidal Surgery of
   Pituitary Macroadenomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebrospinal fluid leak; Endoscopic transsphenoidal approach; Enhanced
   recovery; Gross total resection; Lumbar drainage; Pituitary adenoma
ID ENDONASAL SURGERY; ADENOMAS; COMPLICATIONS; PRESSURE
AB OBJECTIVE: We sought to assess whether controlled, intraoperative lumbar drainage (ID) of cerebrospinal fluid (CSF) could facilitate resection of pituitary macroadenomas and reduce the rate of CSF leak.
   METHODS: A retrospective cohort study from a prospective database was conducted on 189 patients with pituitary macroadenoma who received endoscopic trans-sphenoidal surgery between 2013 and 2017. Patients were classified into 2 groups: 119 patients received an intraoperative LD (LD group) and 70 patients underwent routine endoscopic surgery without LD (control group). In the LD group, lumbar catheters were placed preoperatively and CSF was drained intermittently during tumor resection. The rates of gross total resection (GTR) and CSF leaks were assessed both intraoperatively and postoperatively.
   RESULTS: Intraoperative LD was associated with a higher rate of GTR (92.4% in the LD group vs. 78.6% in the control group, P = 0.006), especially in macroadenomas with suprasellar extension (90.3% vs. 75.0%, P = 0.012). Both intraoperative and postoperative CSF leak rates were significantly decreased in the LD group (intraoperative: 10.1% vs. 31.4%, P < 0.001; postoperative: 3.4% vs. 11.4%, P = 0.035). In functioning adenomas, a better remission rate of excess-hormone secretion was observed in the LD group compared with the controls (89.1% vs. 60.6%, P = 0.001). Patients in the LD group also had an enhanced recovery with a shorter postoperative length of stay (7 days vs. 5 days, P = 0.020).
   CONCLUSIONS: Intraoperative LD may assist surgeons during endoscopic transsphenoidal resection of pituitary macroadenomas by achieving a higher rate of GTR and a lower rate of perioperative CSF leaks. Validation in prospective randomized controlled studies is needed.
C1 [Liu, Bolin; Zheng, Tao; Lu, Dan; Chen, Lei; Ma, Tao; He, Shiming] Fourth Mil Med Univ, Dept Neurosurg, Tangdu Hosp, Xian Int Med Ctr, Xian, Shaanxi, Peoples R China.
   [Liu, Bolin; Wang, Yuan; Zheng, Tao; Lv, Wenhai; Lu, Dan; Chen, Lei; Chen, Long; Ma, Tao; Gao, Guodong; Qu, Yan; He, Shiming] Fourth Mil Med Univ, Dept Neurosurg, Tangdu Hosp, Xian, Shaanxi, Peoples R China.
   [Liu, Shujuan] Fourth Mil Med Univ, Xijing Hosp, Dept Obstet & Gynecol, Xian, Shaanxi, Peoples R China.
RP He, SM (reprint author), Fourth Mil Med Univ, Dept Neurosurg, Tangdu Hosp, Xian Int Med Ctr, Xian, Shaanxi, Peoples R China.; He, SM (reprint author), Fourth Mil Med Univ, Dept Neurosurg, Tangdu Hosp, Xian, Shaanxi, Peoples R China.
EM he-shiming@163.com
CR Aghamohamadi Davood, 2013, Anesth Pain Med, V2, P159, DOI 10.5812/aapm.6510
   BASKIN DS, 1982, J NEUROSURG, V56, P634, DOI 10.3171/jns.1982.56.5.0634
   Buchy M, 2019, PITUITARY, V22, P467, DOI 10.1007/s11102-019-00976-6
   Caggiano C, 2018, WORLD NEUROSURG, V117, pE575, DOI 10.1016/j.wneu.2018.06.090
   Cappabianca P, 2014, WORLD NEUROSURG, V82, pS3, DOI 10.1016/j.wneu.2014.07.019
   Castano-Leon Ana M, 2020, Neurosurgery, V86, P348, DOI 10.1093/neuros/nyz201
   Chamoun R, 2014, J NEUROL SURG PART A, V75, P48, DOI 10.1055/s-0032-1326940
   Cohen S, 2018, OPER NEUROSURG, V14, P66, DOI 10.1093/ons/opx070
   Dehdashti AR, 2008, NEUROSURGERY, V62, P1006, DOI 10.1227/01.neu.0000325862.83961.12
   Dehdashti AR, 2016, J NEUROL SURG PART B, V77, P271, DOI 10.1055/s-0035-1568871
   Ding ZQ, 2019, WORLD J CLIN CASES, V7, P1591, DOI 10.12998/wjcc.v7.i13.1591
   Do H, 2017, WORLD NEUROSURG, V102, P35, DOI 10.1016/j.wneu.2017.02.131
   Gondim JA, 2010, PITUITARY, V13, P68, DOI 10.1007/s11102-009-0195-x
   Grady RE, 1999, ANESTH ANALG, V88, P388
   Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.e4
   Jain AK, 2008, AM J OTOLARYNG, V29, P48, DOI 10.1016/j.amjoto.2007.01.006
   Jonathan GE, 2018, NEUROL INDIA, V66, P133, DOI 10.4103/0028-3886.222823
   KNOSP E, 1993, NEUROSURGERY, V33, P610, DOI 10.1227/00006123-199310000-00008
   Korula G, 2001, J NEUROSURG ANESTH, V13, P255, DOI 10.1097/00008506-200107000-00015
   Lam G, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.4.FOCUS1268
   Magro E, 2016, WORLD NEUROSURG, V89, P442, DOI 10.1016/j.wneu.2016.02.059
   Mehta GU, 2012, J NEUROSURG, V116, P1299, DOI 10.3171/2012.3.JNS112160
   Messerer M, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2011.1.FOCUS10308
   NATH G, 1995, J NEUROSURG ANESTH, V7, P1, DOI 10.1097/00008506-199501000-00001
   Pepper JP, 2011, LARYNGOSCOPE, V121, P468, DOI 10.1002/lary.21409
   Shiley SG, 2003, LARYNGOSCOPE, V113, P1283, DOI 10.1097/00005537-200308000-00003
   Stokken J, 2015, CURR OPIN OTOLARYNGO, V23, P78, DOI 10.1097/MOO.0000000000000119
   Wang FY, 2015, SURG ENDOSC, V29, P1270, DOI 10.1007/s00464-014-3815-0
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.100
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600075
PM 31881340
DA 2020-05-12
ER

PT J
AU Liu, CY
   Shi, XE
   Zhou, ZQ
   Qian, H
   Liu, FJ
   Sun, YM
   Wang, L
AF Liu, Chengyin
   Shi, Xiang'en
   Zhou, Zhongqing
   Qian, Hai
   Liu, Fangjun
   Sun, Yuming
   Wang, Long
TI Microsuturing Technique for the Treatment of Blood Blister Aneurysms: A
   Series of 7 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterior cerebral circulation aneurysm; Blood blister aneurysms;
   Microsurgical suturing technique; Ruptured aneurysm
ID INTERNAL CAROTID-ARTERY; MIDDLE CEREBRAL-ARTERY; INTRACRANIAL ANEURYSMS;
   EMBOLIZATION DEVICE; NONBRANCHING SITES; BYPASS; COMPLICATIONS;
   DIAGNOSIS; CLIP
AB BACKGROUND: A blood blister aneurysm (BBA) is an abnormal bulge at the nonbranching point of a vessel. However, the optimal treatment strategy for this formidable disorder remains unknown. The aim of this study was to evaluate the safety and validity of using a direct microsurgical repair technique in BBAs.
   METHODS: Direct microsuturing of aneurysms was performed with nylon thread in 7 patients from 2014-2018. Postoperative angiography was used to confirm the obliteration of the aneurysms and the absence of stenosis of the parent artery. Neurologic function was assessed by the modified Rankin Scale.
   RESULTS: Two male and 5 female patients with a mean age of 43.7 years (range, 29-62 years) were assessed. Subarachnoid hemorrhage occurred in 6 patients, including 4 patients with Hunt-Hess grade II and 2 patients with grade III. BBAs of the internal carotid artery were observed in 3 patients, BBAs of the middle cerebral artery trunk were observed in 2 patients, and a BBA of the anterior communicating artery was observed in 1 patient. One BBA of the anterior communicating artery in 1 patient was detected incidentally during the resection of a craniopharyngioma. All BBAs were closed with blood-tight sutures via standard frontotemporal craniotomies. Postoperatively, all BBAs were completely eliminated from the circulation without stenosis of the sutured parent vessel.
   CONCLUSIONS: The proposed microsuture technique appears to be a safe, cost-effective, durable treatment for BBAs in the anterior circulation, and should be a part of the arsenal of neurosurgical practitioners who treat anterior circulation BBAs.
C1 [Liu, Chengyin; Shi, Xiang'en] Capital Med Univ, Beijing Fuxing Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Zhou, Zhongqing; Qian, Hai; Liu, Fangjun; Sun, Yuming; Wang, Long] Capital Med Univ, Beijing Sanbo Brain Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Wang, Long] Sapporo Teishinkai Hosp, Stroke Ctr, Dept Neurosurg, Sapporo, Hokkaido, Japan.
RP Shi, XE (reprint author), Capital Med Univ, Beijing Fuxing Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM shixen@sina.com
FU Beijing Municipal Science and Technology CommissionBeijing Municipal
   Science & Technology Commission [7161005]; Capital Foundation of Medical
   Development [Z161100000516019]
FX This work was supported by the Beijing Municipal Science and Technology
   Commission in the form of Natural Science Foundation of Beijing
   Municipality (grant number 7161005, Xiang'en Shi) and Capital Foundation
   of Medical Development (grant number Z161100000516019, Xiang'en Shi)
   grants. The sponsor had no role in the design or conduct of this
   research.
CR Abe M, 1998, J NEUROSURG, V89, P419, DOI 10.3171/jns.1998.89.3.0419
   Andaluz N, 2008, NEUROSURGERY, V62, P807, DOI 10.1227/01.neu.0000318164.44601.09
   ANDREWS BT, 1986, NEUROSURGERY, V18, P204, DOI 10.1227/00006123-198602000-00017
   Brinjikji W, 2013, J NEUROINTERV SURG, V5, P45, DOI 10.1136/neurintsurg-2011-010165
   Britz GW, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.02.017
   Chen FH, 2018, WORLD NEUROSURG, V109, P271, DOI 10.1016/j.wneu.2017.09.203
   Chiu AHY, 2015, AM J NEURORADIOL, V36, P1728, DOI 10.3174/ajnr.A4329
   Cikla U, 2014, ACTA NEUROCHIR, V156, P2071, DOI 10.1007/s00701-014-2212-8
   Cohen JE, 2014, J CLIN NEUROSCI, V21, P1116, DOI 10.1016/j.jocn.2013.11.010
   Curcio A, 2011, CIRC J, V75, P1287, DOI 10.1253/circj.CJ-11-0366
   Darsaut TE, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.09.036
   Darsaut TE, 2012, J NEUROSURG, V117, P37, DOI 10.3171/2012.4.JNS111916
   Fang YB, 2019, WORLD NEUROSURG, V126, pE486, DOI 10.1016/j.wneu.2019.02.076
   Gaughen JR, 2010, AM J NEURORADIOL, V31, P1132, DOI 10.3174/ajnr.A2016
   Guedon A, 2016, J NEUROSURG, V125, P929, DOI 10.3171/2015.10.JNS15703
   Ji TF, 2017, INT J MED SCI, V14, P390, DOI 10.7150/ijms.17979
   Joo SP, 2006, SURG NEUROL, V66, P424, DOI 10.1016/j.surneu.2006.01.024
   Kamijo K, 2010, J NEUROSURG, V113, P781, DOI 10.3171/2009.10.JNS09970
   Kim BM, 2008, NEURORADIOLOGY, V50, P251, DOI 10.1007/s00234-007-0331-0
   Kubo Y, 2015, VASC HEALTH RISK MAN, V11, P297, DOI 10.2147/VHRM.S73779
   Kung DK, 2011, J NEUROSURG, V114, P1021, DOI 10.3171/2010.9.JNS10445
   Lee BH, 2009, J NEUROSURG, V110, P431, DOI 10.3171/2008.7.JNS08257
   Lee JW, 2009, ACTA NEUROCHIR, V151, P125, DOI 10.1007/s00701-008-0165-5
   Pumar JM, 2017, NEUROSURGERY, V81, P595, DOI 10.1093/neuros/nyw123
   Meckel S, 2011, AM J NEURORADIOL, V32, P764, DOI 10.3174/ajnr.A2392
   Meling TR, 2008, J NEUROSURG, V108, P662, DOI 10.3171/JNS/2008/108/4/0662
   Ogawa A, 2000, NEUROSURGERY, V47, P578, DOI 10.1097/00006123-200009000-00008
   Ohara H, 1979, CEREBRAL ANEURYSMS, P673
   Park J, 2013, WORLD NEUROSURG, V80, DOI 10.1016/j.wneu.2013.03.075
   Park J, 2009, J KOREAN NEUROSURG S, V46, P68, DOI 10.3340/jkns.2009.46.1.68
   Peschillo S, 2015, NEUROSURG REV, V38, P197, DOI 10.1007/s10143-014-0581-3
   Ryan RW, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS1757
   Saatci I, 2012, AM J NEURORADIOL, V33, P1436, DOI 10.3174/ajnr.A3246
   Sanai N, 2009, NEUROSURGERY, V65, P670, DOI 10.1227/01.NEU.0000348557.11968.F1
   Satoh A, 1993, SURG CEREB STROKE, V21, P467
   SHIGETA H, 1992, ACTA NEUROCHIR, V119, P42, DOI 10.1007/BF01541780
   Sim SY, 2006, J NEUROSURG, V105, P400, DOI 10.3171/jns.2006.105.3.400
   Strickland B, 2018, WORLD NEUROSURG, V117, pE417, DOI 10.1016/j.wneu.2018.06.046
   Takahashi A, 1988, SURGERY CEREBRAL STR, V16, P72
   Vashu R, 2009, J CLIN NEUROSCI, V16, P960, DOI 10.1016/j.jocn.2008.09.013
   Wang L, 2018, WORLD NEUROSURG, V118, P148, DOI 10.1016/j.wneu.2018.06.195
   Yanaka K, 2002, NEUROSURGERY, V50, P218, DOI 10.1097/00006123-200201000-00037
   Yasargil M., 1984, INTERNAL CAROTID ART
NR 43
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.084
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600004
PM 31655237
DA 2020-05-12
ER

PT J
AU Liu, Z
   Li, WW
   Xu, ZC
   Zhang, YL
   Wu, YQ
   Wang, XY
   Zeng, H
AF Liu, Zheng
   Li, Weiwei
   Xu, Zhengchao
   Zhang, Yilu
   Wu, Yunqi
   Wang, Xiyang
   Zeng, Hao
TI Treatment of Monosegment Spinal Tuberculosis via Posterior Unilateral
   Vertebral Laminar Fenestration Debridement and Bone Grafting Fusion
   Combined with Laminar Reconstruction and Internal Fixation: A
   Retrospective Case-Control Study with a Minimum 5-Year Follow-Up
SO WORLD NEUROSURGERY
LA English
DT Article
DE Laminar reconstruction; Monosegment spinal tuberculosis; Posterior
   unilateral vertebral lamina fenestration debridement
ID LAMINECTOMY MEMBRANE FORMATION; SURGICAL-TREATMENT; LUMBAR;
   INSTRUMENTATION; DECOMPRESSION; ANTERIOR; SURGERY; SPONDYLITIS;
   STENOSIS; REPAIR
AB OBJECTIVE: To investigate the clinical and imaging outcomes of posterior unilateral vertebral lamina fenestration debridement and bone grafting fusion combined with laminar reconstruction and instrumentation compared with the traditional posterior-only method for treating monosegment spinal tuberculosis.
   METHODS: Fifty-four patients underwent posterior unilateral vertebral lamina fenestration debridement and bone grafting fusion combined with laminar reconstruction and internal fixation (group A), and 60 patients underwent 1-stage posterior debridement, laminectomy decompression, bone grafting fusion and instrumentation (group B). The clinical and radiographic outcomes of these groups were analyzed and compared.
   RESULTS: Group A had less intraoperative blood loss, shorter hospitalization, and a shorter fusion time than did group B (P < 0.05). At 3 months postoperatively, group A had a lower mean Oswestry Disability Index than did group B (P< 0.05). At the final follow-up, group A had a lower mean visual analog scale pain score and a lower mean OW than did group B (P < 0.05). Group A had a smaller kyphotic angle loss (1.2 degrees +/- 0.6 degrees) and loss rate (4.8% +/- 2.5%) than did group B (P < 0.05).
   CONCLUSIONS: The procedure of posterior unilateral vertebral lamina fenestration debridement and bone grafting fusion combined with laminar reconstruction and internal fixation is safe and effective in treating monosegment spinal tuberculosis. Compared with the conventional posterior-only approach, this method maximizes the retention and reconstruction of the posterior column and is minimally invasive, achieving faster postoperative recovery with fewer complications.
C1 [Liu, Zheng; Li, Weiwei; Xu, Zhengchao; Wang, Xiyang] Cent South Univ, Xiangya Hosp, Dept Spine Surg, Changsha, Hunan, Peoples R China.
   [Liu, Zheng; Li, Weiwei; Xu, Zhengchao; Zhang, Yilu; Wu, Yunqi; Wang, Xiyang] Cent South Univ, Xiangya Hosp, Hunan Engn Lab Adv Artificial Osteomat, Changsha, Hunan, Peoples R China.
   [Zeng, Hao] Guangxi Med Univ, Dept Spinal Surg, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Zeng, Hao] Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
RP Wang, XY (reprint author), Cent South Univ, Xiangya Hosp, Dept Spine Surg, Changsha, Hunan, Peoples R China.; Wang, XY (reprint author), Cent South Univ, Xiangya Hosp, Hunan Engn Lab Adv Artificial Osteomat, Changsha, Hunan, Peoples R China.
EM 229061878@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81672191]; Clinical Scientific Research Funds of
   Xiangya Hospital [2016L07]; Fundamental Research Funds for the Central
   Universities of Central South University [2019zzts336, 502221902]; Young
   Scientist Fund of Guangxi Medical University [GXMUYSF201701]; Natural
   Science Fund of Guangxi Zhuang Autonomous Region [2018JJB140199]
FX The work was supported by the National Natural Science Foundation of
   China (grant number 81672191), Clinical Scientific Research Funds of
   Xiangya Hospital (grant number 2016L07), the Fundamental Research Funds
   for the Central Universities of Central South University (2019zzts336,
   502221902), Young Scientist Fund of Guangxi Medical University (grant
   number GXMUYSF201701) and Natural Science Fund of Guangxi Zhuang
   Autonomous Region (grant number 2018JJB140199). No benefit in any form
   has been or will be received from a commercial party related directly or
   indirectly to the subject of this article.
CR Aykac B, 2011, ACTA ORTHOP TRAUMATO, V45, P47, DOI [10.3944/AOTT.2011.2387, 10.3944/AOTT.2011.2420]
   Benli IT, 2007, CLIN ORTHOP RELAT R, P108, DOI 10.1097/BLO.0b013e318065b70d
   Bezer M, 2005, J SPINAL DISORD TECH, V18, P425, DOI 10.1097/01.bsd.0000171627.11171.6f
   CASPAR W, 1994, ACTA NEUROCHIR, V131, P130, DOI 10.1007/BF01401463
   Chandler K, 2006, VET J, V172, P1, DOI 10.1016/j.tvjl.2005.04.011
   DENIS F, 1983, SPINE, V8, P817, DOI 10.1097/00007632-198311000-00003
   Dunn R, 2011, SPINE, V36, P469, DOI 10.1097/BRS.0b013e3181d265c0
   Garg B, 2012, INDIAN J ORTHOP, V46, P165, DOI 10.4103/0019-5413.93682
   Hollingworth W, 2011, SPINE, V36, P2076, DOI 10.1097/BRS.0b013e31822a867c
   Hsu WH, 2011, J CLIN NEUROSCI, V18, P1645, DOI 10.1016/j.jocn.2011.03.031
   Jain AK, 2008, J BONE JOINT SURG BR, V90B, P1477, DOI 10.1302/0301-620X.90B11.20972
   Jain AK, 2010, J BONE JOINT SURG BR, V92B, P905, DOI 10.1302/0301-620X.92B7.24668
   Kim CW, 2010, SPINE, V35, pS281, DOI 10.1097/BRS.0b013e3182022d32
   Kramer R, 2002, BIOMED TECH, V47, P159, DOI 10.1515/bmte.2002.47.6.159
   LAWSON KJ, 1991, SPINE, V16, pS222, DOI 10.1097/00007632-199106001-00009
   LEE CK, 1995, SPINE, V20, P356, DOI 10.1097/00007632-199502000-00018
   Liu Z, 2018, INT ORTHOP, V42, P1
   Liu Z, 2019, BIOMED RES INT, V2019, P11
   Liu Z, 2016, CLIN NEUROL NEUROSUR, V141, P111, DOI 10.1016/j.clineuro.2016.01.002
   Lv CL, 2013, SPINE J, V13, P1912, DOI 10.1016/j.spinee.2013.06.055
   Ma YZ, 2012, INT ORTHOP, V36, P299, DOI 10.1007/s00264-011-1390-8
   Moon MS, 2002, CLIN ORTHOP RELAT R, P40
   Muheremu A, 2015, EUR J ORTHOP SURG TR, V25, P69
   Pigrau-Serrallach C, 2013, EUR SPINE J, V22, P556, DOI 10.1007/s00586-012-2331-y
   Pu XB, 2012, INT ORTHOP, V36, P307, DOI 10.1007/s00264-011-1329-0
   Ross JS, 1996, NEUROSURGERY, V38, P855, DOI 10.1227/00006123-199604000-00053
   SONGER MN, 1990, SPINE, V15, P550, DOI 10.1097/00007632-199006000-00022
   Wang LJ, 2017, SPINE, V42, P808, DOI 10.1097/BRS.0000000000001955
   Wang YX, 2016, INT ORTHOP, V40, P1117, DOI 10.1007/s00264-016-3161-z
   Xie JM, 2012, EUR SPINE J, V21, P705, DOI 10.1007/s00586-011-1985-1
   Zeng H, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891-016-1034-7
   Zhang HQ, 2012, ARCH ORTHOP TRAUM SU, V132, P1677, DOI 10.1007/s00402-012-1604-6
   Zhao ZH, 2018, MED SCI MONITOR, V24, P5573, DOI 10.12659/MSM.907958
NR 33
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.036
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600055
PM 31843726
DA 2020-05-12
ER

PT J
AU Lohani, S
   Bhandari, S
   Ranabhat, K
   Agrawal, P
AF Lohani, Subash
   Bhandari, Shreeram
   Ranabhat, Kajan
   Agrawal, Prity
TI Does Diffuse Axonal Injury MRI Grade Really Correlate with Functional
   Outcome?
SO WORLD NEUROSURGERY
LA English
DT Article
DE DAI; GOSE
ID MAGNETIC-RESONANCE; PROGNOSTIC VALUE; CORPUS-CALLOSUM; HEAD-INJURIES;
   BRAIN-INJURY; MODERATE
AB OBJECTIVE: Diffuse axonal injury (DAI) is a common form of primary head injury. This study was done to see the association of DAI grades with extended Glasgow Outcome Scale (GOSE).
   METHODS: We retrospectively reviewed the charts and radiology reports of a cohort of patients discharged with the diagnosis of diffuse axonal injury. We collected data on variables like age, sex, Glasgow Coma Scale (GCS) at admission, grade of DAI, length of hospital stay, and occurrence of post-traumatic seizures. We contacted the patients after 6 months to assess their GOSE. Outcome analysis was done with SPSS version 23.
   RESULTS: For 40 patients, DAI and 6-month GOSE were -tillable for analysis. Mean age was 27.8 years, with male to female ratio of 12:1. There were 8 patients with DAI grade I (20.5%),13 patients with DAI grade II (33.3%), and 18 patients with DAI grade III (46.2%). Nine of 39 patients (23.07%) had post-traumatic seizures. Mean GCS at admission was 9.67- Mean length of hospital stay was 24.12 days. Mean GOSE after 6 months was 6.10. There were 5 mortalities. Patients with low mean GCS portended significant unfavorable outcome. Higher DAI grades were not associated with unfavorable outcome.
   CONCLUSIONS: Mean GCS at presentation is a better predictor of outcome after DAI rather than its grade.
C1 [Lohani, Subash; Bhandari, Shreeram] Upendra Devkota Mem Natl Inst Neurol & Allied Sci, Dept Neurosurg, Kathmandu, Nepal.
   [Ranabhat, Kajan; Agrawal, Prity] Upendra Devkota Mem Natl Inst Neurol & Allied Sci, Dept Radiol, Kathmandu, Nepal.
RP Lohani, S (reprint author), Upendra Devkota Mem Natl Inst Neurol & Allied Sci, Dept Neurosurg, Kathmandu, Nepal.
EM subash.lohani@gmail.com
OI Ranabhat, Kajan/0000-0002-3689-3889
CR Abu Hamdeh S, 2017, J NEUROTRAUM, V34, P341, DOI 10.1089/neu.2016.4426
   ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x
   Vieira RDA, 2018, WORLD NEUROSURG, V109, P140, DOI 10.1016/j.wneu.2017.09.101
   Chelly H, 2011, J TRAUMA, V71, P838, DOI 10.1097/TA.0b013e3182127baa
   Cicuendez M, 2017, ACTA NEUROCHIR, V159, P25, DOI 10.1007/s00701-016-3000-4
   CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261
   de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214
   Ezaki Y, 2006, ACTA RADIOL, V47, P733, DOI 10.1080/02841850600771486
   Firsching R, 2017, DTSCH ARZTEBL INT, V114, P313, DOI 10.3238/arztebl.2017.0313
   GENTRY LR, 1994, RADIOLOGY, V191, P1
   Henninger N, 2018, J TRAUMA ACUTE CARE, V84, P473, DOI 10.1097/TA.0000000000001733
   Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002
   Izzy S, 2017, NEUROCRIT CARE, V27, P199, DOI 10.1007/s12028-017-0399-2
   Lagares A, 2006, NEUROCIRUGIA, V17, P105
   Matsukawa H, 2011, ACTA NEUROCHIR, V153, P1687, DOI 10.1007/s00701-011-1002-9
   Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137
   Moen KG, 2014, J NEUROTRAUM, V31, P1486, DOI 10.1089/neu.2013.3258
   Moenninghoff C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122329
   Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882
   Park SJ, 2009, J KOREAN NEUROSURG S, V46, P205, DOI 10.3340/jkns.2009.46.3.205
   Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016
   Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626
   Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003
   Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123
   Verellen Rebecca M, 2010, Therapy, V7, P527, DOI 10.2217/thy.10.57
   Yates PJ, 2006, J NEUROL NEUROSUR PS, V77, P699, DOI 10.1136/jnnp.2005.081901
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.017
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600049
PM 31843722
DA 2020-05-12
ER

PT J
AU London, NR
   Rooper, LM
   Bishop, JA
   Xu, HY
   Bernhardt, LJ
   Ishii, M
   Hann, CL
   Taube, JM
   Izumchenko, E
   Gaykalova, DA
   Gallia, GL
AF London, Nyall R., Jr.
   Rooper, Lisa M.
   Bishop, Justin A.
   Xu, Haiying
   Bernhardt, Lydia J.
   Ishii, Masaru
   Hann, Christine L.
   Taube, Janis M.
   Izumchenko, Evgeny
   Gaykalova, Daria A.
   Gallia, Gary L.
TI Expression of Programmed Cell Death Ligand 1 and Associated Lymphocyte
   Infiltration in Olfactory Neuroblastoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Esthesioneuroblastoma; Immune checkpoint inhibitors; Immunotherapy;
   Olfactory neuroblastoma; PD-L1
ID PD-L1 EXPRESSION; PROGNOSTIC IMPACT; T-CELLS; CANCER;
   ESTHESIONEUROBLASTOMA; NIVOLUMAB; MPDL3280A; BLOCKADE; MELANOMA;
   SURVIVAL
AB BACKGROUND: Programmed cell death ligand 1 (PD-L1) is a transmembrane glycoprotein that interacts with the receptor programmed cell death 1 (PD-1) to suppress T-cell activation, reduce adjacent tissue damage, and promote tolerance to self-antigens. Tumors may express PD-L1 as a mechanism to evade immune detection. Recent clinical trials have demonstrated the efficacy of PD-L1/PD-1 antagonists through activation of tumor-infiltrated CD8(+) T cells. The aim of this study was to determine the expression pattern of PD-L1 and PD-1 in olfactory neuroblastoma (ONB) tumor cells and to determine the presence of PD-1(+) and CD8(+) lymphocytes in the ONB immune microenvironment.
   METHODS: Immunohistochemistry for expression of PD-L1, PD-1, and CD8 was performed on paraffin-embedded ONB tissue.
   RESULTS: Of the 10 primary site ONB samples, 4 demonstrated positive PD-L1 expression. Of PD-L1(+) tumors, the 2 highest expressing samples were found to contain PD-1(+) tumor cells. Of the 4 available metastatic samples, all of which arose from PD-L1(-) primary site ONB, 3 were positive for PD-L1 and contained PD-1(+) tumor cells. PD-L1(+) primary and metastatic tumors also demonstrated increased PD-1(+) infiltrating lymphocytes in the tumor and stroma (11.6- and 4.62-fold increase) compared with PD-L1(-) samples (P < 0.05 and P = 0.068 respectively). PD-L1(+) specimens demonstrated increased CD8(+) lymphocytes in the tumor and stroma (7.46- and 2.14-fold increase) compared with PD-L1(-) tumors (P < 0.05 for both).
   CONCLUSIONS: These data demonstrate that a proportion of ONB primary and metastatic tumors express PD-L1 and possess an associated tumor and stromal infiltrate of PD-1(+) and CD8(+) lymphocytes.
C1 [London, Nyall R., Jr.; Ishii, Masaru; Izumchenko, Evgeny; Gaykalova, Daria A.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA.
   [Rooper, Lisa M.; Bishop, Justin A.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Xu, Haiying; Taube, Janis M.] Johns Hopkins Univ, Sch Med, Dept Dermatol, Baltimore, MD 21205 USA.
   [Bernhardt, Lydia J.; Gallia, Gary L.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
   [Hann, Christine L.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
   [London, Nyall R., Jr.] Natl Inst Deafness & Other Commun Disorders, Natl Inst Hlth, Bethesda, MD USA.
   [Bishop, Justin A.] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX USA.
RP Gallia, GL (reprint author), Johns Hopkins Univ, Sch Med, Dept Neurosurg, Baltimore, MD 21205 USA.
EM ggallia1@jhmi.edu
FU NIDCR NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Dental &
   Craniofacial Research (NIDCR) [R01 DE027809]
CR Abiko K, 2013, CLIN CANCER RES, V19, P1363, DOI 10.1158/1078-0432.CCR-12-2199
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627
   Classe M, 2019, HISTOPATHOLOGY, V75, P853, DOI 10.1111/his.13954
   Classe M, 2018, CELL REP, V25, P811, DOI 10.1016/j.celrep.2018.09.047
   Darb-Esfahani S, 2016, ONCOTARGET, V7, P1486, DOI 10.18632/oncotarget.6429
   Dulguerov P, 2001, LANCET ONCOL, V2, P683, DOI 10.1016/S1470-2045(01)00558-7
   Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027
   Gadiot J, 2011, CANCER-AM CANCER SOC, V117, P2192, DOI 10.1002/cncr.25747
   Han J, 2017, J PATHOL TRANSL MED, V51, P40, DOI 10.4132/jptm.2016.08.31
   Han SJ, 2016, J NEURO-ONCOL, V130, P543, DOI 10.1007/s11060-016-2256-0
   Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011
   Huang J, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00242
   Jacobs JFM, 2009, NEURO-ONCOLOGY, V11, P394, DOI 10.1215/15228517-2008-104
   Jethanamest D, 2007, ARCH OTOLARYNGOL, V133, P276, DOI 10.1001/archotol.133.3.276
   Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]
   Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362
   Li YQ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0539-x
   Luksik AS, 2017, NEUROTHERAPEUTICS, V14, P1049, DOI 10.1007/s13311-017-0513-3
   Mahoney KM, 2014, ONCOLOGY-NY, V28, P39
   Merelli B, 2014, CRIT REV ONCOL HEMAT, V89, P140, DOI 10.1016/j.critrevonc.2013.08.002
   Mu CY, 2011, MED ONCOL, V28, P682, DOI 10.1007/s12032-010-9515-2
   Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904
   Roxbury CR, 2016, OTOLARYNG CLIN N AM, V49, P153, DOI 10.1016/j.otc.2015.09.010
   Sunshine JC, 2017, CLIN CANCER RES, V23, P4938, DOI 10.1158/1078-0432.CCR-16-1821
   Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271
   Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954
   Velcheti V, 2014, LAB INVEST, V94, P107, DOI 10.1038/labinvest.2013.130
   Wang QQ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006369
   Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862
   Xue S, 2017, ONCOTARGET, V8, P49702, DOI 10.18632/oncotarget.17922
   Zeng J, 2016, ONCOTARGET, V7, P8944, DOI 10.18632/oncotarget.6884
   Zeng J, 2013, INT J RADIAT ONCOL, V86, P343, DOI 10.1016/j.ijrobp.2012.12.025
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.112
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600022
PM 31785431
DA 2020-05-12
ER

PT J
AU LoPresti, MA
   Treiber, JM
   Srinivasan, VM
   Chintalapani, G
   Chen, SR
   Burkhardt, JK
   Johnson, JN
   Lam, S
   Kan, P
AF LoPresti, Melissa A.
   Treiber, Jeffrey M.
   Srinivasan, Visish M.
   Chintalapani, Gouthami
   Chen, Stephen R.
   Burkhardt, Jan-Karl
   Johnson, Jeremiah N.
   Lam, Sandi
   Kan, Peter
TI Utility of Immediate Postprocedural Cone Beam Computed Tomography Scan
   in the Detection of Ischemic and Hemorrhagic Complications in Pediatric
   Neurointerventional Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications; Cone beam computed tomography scan; Intracerebral
   hemorrhage; Neurointerventional surgery; Pediatric angiography; Stroke
ID RADIATION-EXPOSURE; CT
AB BACKGROUND: Cone beam computed tomography (CBCT) imaging is used commonly in neurointerventional surgery for rapid intraprocedural assessment and planning of intracranial interventions. Our goal was to evaluate the ability of immediate postprocedural CBCT scan in assessing potential complications in pediatric patients.
   METHODS: A retrospective review was completed to include all pediatric patients at our hospital with an immediate postprocedural CBCT scan with the Artis Q system. Demographic, clinical, and imaging data were examined. CBCT images were reviewed by 3 independent neuro-interventionalists to assess ventricular system/subarachnoid spaces, gray-white differentiation, and ischemia or hemorrhage if present. Each assessment was rated qualitatively on a 4-point scale and was compared with conventional computed tomography (cCT) scan when available. Interrater reliability was assessed and radiation dose data were reviewed.
   RESULTS: Thirty-five patients were included with an average age of 11.0 +/- 5.1 years (median, 10.9; range, 1.1-18 years). Of the patients, 54.3% were boys; 34.3% were Hispanic and 34.3% were non-Hispanic white. Diagnoses included a variety of vascular pathologies. CBCT scan had a mean score of 2.69 +/- 0.54 out of 3 for ventricular and subarachnoid space assessment with a combined interrater reliability of 0.82, 1.71 +/- 1.38 for hemorrhage with a combined interrater reliability of 1.00, and 0.52 +/- 0.60 for gray-white differentiation with a combined interrater reliability of 0.79.
   CONCLUSIONS: Immediate postprocedural CBCT images were adequate to detect ventricular size/subarachnoid spaces changes and large volume hemorrhage compared with cCT scan in pediatric patients. However, there are limitations using immediate CBCT images to detect small volume hemorrhage and ischemic changes.
C1 [LoPresti, Melissa A.; Treiber, Jeffrey M.; Srinivasan, Visish M.; Burkhardt, Jan-Karl; Johnson, Jeremiah N.; Lam, Sandi; Kan, Peter] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
   [Chen, Stephen R.] Baylor Coll Med, Div Radiol, Houston, TX 77030 USA.
   [LoPresti, Melissa A.; Treiber, Jeffrey M.; Srinivasan, Visish M.; Burkhardt, Jan-Karl; Johnson, Jeremiah N.; Lam, Sandi; Kan, Peter] Texas Childrens Hosp, Div Neurosurg, Houston, TX 77030 USA.
   [Chintalapani, Gouthami] Siemens Med Solut USA Inc, Div Imaging & Therapy Syst, Malvern, PA USA.
RP Kan, P (reprint author), Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.; Kan, P (reprint author), Texas Childrens Hosp, Div Neurosurg, Houston, TX 77030 USA.
EM peter.kan@bcm.edu
OI Chen, Stephen/0000-0002-5580-831X
CR Bauhs JA, 2008, RADIOGRAPHICS, V28, P245, DOI 10.1148/rg.281075024
   Christner JA, 2010, AM J ROENTGENOL, V194, P881, DOI 10.2214/AJR.09.3462
   Delye H, 2015, J NEUROSURG-PEDIATR, V16, P687, DOI 10.3171/2015.4.PEDS1493
   Doelken M, 2008, NEURORADIOLOGY, V50, P517, DOI 10.1007/s00234-008-0372-z
   Doerfler A, 2015, CLIN NEURORADIOL, V25, P291, DOI 10.1007/s00062-015-0423-x
   Eckert M, 2017, CEREBROVASC DIS, V43, P9, DOI 10.1159/000450727
   Gupta N, 2017, INDIAN PEDIATR, V54, P581, DOI 10.1007/s13312-017-1072-8
   Hudson MM, 2010, OBSTET GYNECOL, V116, P1171, DOI 10.1097/AOG.0b013e3181f87c4b
   Kleinerman RA, 2006, PEDIATR RADIOL, V36, P121, DOI 10.1007/s00247-006-0191-5
   Lechuga L, 2016, CUREUS, V8, DOI 10.7759/cureus.778
   Maier IL, 2018, AM J NEURORADIOL, V39, P881, DOI 10.3174/ajnr.A5595
   Miracle AC, 2009, AM J NEURORADIOL, V30, P1088, DOI 10.3174/ajnr.A1653
   RAPPAPORT R, 1989, PEDIATR RES, V25, P561, DOI 10.1203/00006450-198906000-00001
   Reyes D, 2018, INTERV NEUROL, V7, P457, DOI 10.1159/000490577
   von Gottberg P, 2013, NEUROL NEUROCHIR POL, V47, P32, DOI 10.5114/ninp.2013.32996
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.003
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600046
PM 31821910
DA 2020-05-12
ER

PT J
AU Low, SYY
   Lim, EHL
   Loh, LE
   Mok, YH
   Siow, YN
   Ng, LP
   Seow, WT
   Kirollos, RW
   Low, DCY
AF Low, Sharon Y. Y.
   Lim, Evangeline H. L.
   Loh, Lik Eng
   Mok, Yee Hui
   Siow, Yew Nam
   Ng, Lee Ping
   Seow, Wan Tew
   Kirollos, Ramez W.
   Low, David C. Y.
TI Use of an Offsite Intraoperative MRI Operating Theater for Pediatric
   Brain Tumor Surgery: Experience from a Singapore Children's Hospital
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intraoperative MRI; Pediatric brain tumor
ID MAGNETIC-RESONANCE; RESECTION; NEUROSURGERY; FEASIBILITY; MANAGEMENT;
   SYSTEM; IMPACT; GLIOMA
AB BACKGROUND: Intraoperative magnetic resonance imaging (iMRI) has been recognized as a useful adjunct for brain tumor surgery in pediatric patients. There is minimal data on the use of an offsite intraoperative magnetic resonance imaging operating theater (iMRI OT), whereby vehicle transfer of patients is involved. The primary aim of this study is to validate the feasibility of perioperative patient transfer to use an offsite iMRI OT for patients with pediatric brain tumor. Secondary objectives include the assessment of tumor resection efficacy and perioperative outcomes in our patient cohort.
   METHODS: This is a retrospective, single-institution clinical study of prospectively collected data from Singapore's largest children hospital. Variables of interest include issues encountered during interhospital transfer, achievement of surgical aims, length of stay in hospital, and postoperative complications. Our findings were compared with results of related studies published in the literature.
   RESULTS: From January 1, 2009 to December 31, 2018, a total of 35 pediatric operative cases were performed in our offsite iMRI OT. Within this cohort, 24 of these were brain tumor surgery cases. For all the patients in this study, use of the iMRI OT influenced intraoperative decisions. Average ambulance transport time from parent hospital to the iMRI OT was 30.5 minutes, and from iMRI OT back to the parent hospital after surgery was 27.7 minutes. The average length of hospitalization stay was 7.9 days per patient. There were no ferromagnetic accidents during perioperative iMRI scanning and no airway/hemodynamic incidents in patients encountered during interhospital transfer.
   CONCLUSIONS: In our local context, the use of interhospital transfers for access to iMRI OT is a safe and feasible option in ensuring good patient outcomes for a select group of patients with pediatric brain tumors.
C1 [Lim, Evangeline H. L.; Siow, Yew Nam] KK Womens & Childrens Hosp, Dept Paediat Anaesthesia, Singapore, Singapore.
   [Loh, Lik Eng; Mok, Yee Hui] KK Womens & Childrens Hosp, Childrens Intens Care Unit, Singapore, Singapore.
   [Low, Sharon Y. Y.; Ng, Lee Ping; Seow, Wan Tew; Kirollos, Ramez W.; Low, David C. Y.] KK Womens & Childrens Hosp, Neurosurg Serv, Singapore, Singapore.
   [Low, Sharon Y. Y.; Seow, Wan Tew; Kirollos, Ramez W.; Low, David C. Y.] Natl Neurosci Inst, Dept Neurosurg, Singapore, Singapore.
   [Low, Sharon Y. Y.; Seow, Wan Tew; Kirollos, Ramez W.; Low, David C. Y.] SingHlth Duke NUS Neurosci Acad Clin Program, Singapore, Singapore.
RP Low, SYY (reprint author), KK Womens & Childrens Hosp, Neurosurg Serv, Singapore, Singapore.; Low, SYY (reprint author), Natl Neurosci Inst, Dept Neurosurg, Singapore, Singapore.; Low, SYY (reprint author), SingHlth Duke NUS Neurosci Acad Clin Program, Singapore, Singapore.
EM sharon.low.y.y@singhealth.com.sg
CR Abdullah HR, 2010, PROC SINGAP HEALTHC, V19, P349, DOI 10.1177/201010581001900411
   ALBERT FK, 1994, NEUROSURGERY, V34, P45, DOI 10.1097/00006123-199401000-00008
   Black PM, 1999, NEUROSURGERY, V45, P423, DOI 10.1097/00006123-199909000-00001
   Choudhri AF, 2014, AM J NEURORADIOL, V35, P2382, DOI 10.3174/ajnr.A4040
   Foster MT, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00309
   Giordano M, 2017, J NEUROSURG-PEDIATR, V19, P77, DOI 10.3171/2016.8.PEDS15708
   Haji-Michael P, 2005, CRIT CARE, V9, P343, DOI 10.1186/cc3773
   Kaya S, 2012, TURK NEUROSURG, V22, P218, DOI 10.5137/1019-5149.JTN.5615-11.0
   Kremer P, 2006, CHILD NERV SYST, V22, P674, DOI 10.1007/s00381-005-0030-2
   Kremer P, 2002, ACTA NEUROCHIR, V144, P433, DOI 10.1007/s007010200064
   Kubben PL, 2012, CHILD NERV SYST, V28, P1171, DOI 10.1007/s00381-012-1815-8
   Kuhnt D, 2011, NEURO-ONCOLOGY, V13, P1339, DOI 10.1093/neuonc/nor133
   Lam CH, 2001, PEDIATR NEUROSURG, V34, P295, DOI 10.1159/000056041
   Levy R, 2009, J NEUROSURG-PEDIATR, V4, P467, DOI 10.3171/2009.4.PEDS08464
   Liberati A, 2009, ANN INTERN MED, V151, pW65, DOI 10.7326/0003-4819-151-4-200908180-00136
   Lim E, 2013, ANAESTH INTENS CARE, V41, P535, DOI 10.1177/0310057X1304100416
   Low SYY, 2018, CHILD NERV SYST, V34, P19, DOI 10.1007/s00381-017-3627-3
   Makary M, 2011, J MAGN RESON IMAGING, V34, P1022, DOI 10.1002/jmri.22739
   Mislow JMK, 2009, NEUROSURG CLIN N AM, V20, P137, DOI 10.1016/j.nec.2009.04.002
   Pitfield AF, 2012, PEDIATR EMERG CARE, V28, P200, DOI 10.1097/PEC.0b013e318243fb72
   Roder C, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15530
   Sethi D, 2014, SAUDI J ANAESTH, V8, P104, DOI 10.4103/1658-354X.125964
   Shah MN, 2012, J NEUROSURG-PEDIATR, V9, P259, DOI 10.3171/2011.12.PEDS11227
   Singh JM, 2009, CRIT CARE, V13, DOI 10.1186/cc7883
   Spiriev Toma, 2017, Surg Neurol Int, V8, P241, DOI 10.4103/sni.sni_419_16
   Tan TK, 2009, SINGAP MED J, V50, P4
   Tejada S, 2018, CHILD NERV SYST, V34, P617, DOI 10.1007/s00381-018-3751-8
   Yousaf Jawad, 2012, Surg Neurol Int, V3, pS65, DOI 10.4103/2152-7806.95417
NR 28
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.083
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600005
PM 31655229
DA 2020-05-12
ER

PT J
AU Lu, M
   Fu, ZH
   He, XJ
   Lu, JK
   Deng, XQ
   Lin, DL
   Gu, YM
   Fan, YF
   Lai, MY
   Li, J
   Yang, MM
   Chen, ZP
AF Lu, Ming
   Fu, Zheng-hao
   He, Xiao-jun
   Lu, Jian-kan
   Deng, Xin-qing
   Lin, De-liu
   Gu, You-ming
   Fan, Yan-feng
   Lai, Ming-yao
   Li, Juan
   Yang, Ming-ming
   Chen, Zhong-ping
TI T2 Fluid-Attenuated Inversion Recovery Resection for Glioblastoma
   Involving Eloquent Brain Areas Facilitated Through Awake Craniotomy and
   Clinical Outcome
SO WORLD NEUROSURGERY
LA English
DT Article
DE Awake craniotomy; Fluid-attenuated inversion recovery; Glioblastoma;
   Sodium fluorescein
ID FLAIR VOLUME; GLIOMA; SURVIVAL; SURGERY; EXTENT; SAFE
AB BACKGROUND: Despite evidence that a greater extent of resection (EOR) improves survival, the role of extended resection based on magnetic resonance imaging (MRI) fluid-attenuated inversion recovery (FLAIR) in the prognosis of glioblastoma (GBM) remains controversial. This study aims to investigate the role of additional resection of FLAIR-detected abnormalities and its influence on clinical outcomes of patients with GBM.
   METHODS: Forty-six patients with newly diagnosed GBM involving eloquent brain areas were included. Surgeries were performed using awake craniotomy (AC) or AC combined with sodium fluorescein (SF) guidance. Following total removal of the contrast-enhancing tumor area, the EOR of FLAIR abnormalities was dichotomized to identify the best separation threshold for progression-free survival (PFS), overall survival (OS), and 30-day postoperative neurologic function of patients with GBM.
   RESULTS: The threshold for removal of FLAIR abnormalities affecting survival was determined to be 25%. The median OS and PFS were shorter in the group with FLAIR resection <25% compared with the group with FLAIR resection >= 25% (12 months vs. 26 months; P = 0.001 and 6 months vs. 15 months; P = 0.016, respectively). Univariate and multivariate analyses identified tumor location within or near the eloquent brain areas and the 25% threshold for FLAIR EOR as independent factors affecting OS and PFS.
   CONCLUSIONS: Identifying a feasible threshold for the resection of FLAIR abnormalities is valuable in improving the survival of patients with GBM. Extended resection of GBM involving eloquent brain areas was safe when using a combination of AC and SF-guided surgery.
C1 [Lu, Ming; Fu, Zheng-hao; He, Xiao-jun; Lu, Jian-kan; Deng, Xin-qing; Lin, De-liu; Gu, You-ming; Fan, Yan-feng] Guangdong 999 Brain Hosp, Dept Neurosurg, Guangzhou, Peoples R China.
   [Lai, Ming-yao; Li, Juan] Guangdong 999 Brain Hosp, Dept Oncol, Guangzhou, Peoples R China.
   [Yang, Ming-ming] Guangdong 999 Brain Hosp, Dept Anesthesiol, Guangzhou, Peoples R China.
   [Chen, Zhong-ping] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Neurosurg Neuro Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.
RP Chen, ZP (reprint author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Neurosurg Neuro Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China.
EM chenzhp@sysucc.org.cn
FU National Basic Research Program of ChinaNational Basic Research Program
   of China [2015CB755505]; Guangzhou Science Technology and Innovation
   Project [201508020125]; Science and Technology Planning Project of
   Guangdong Province [2016A020213004]; Medical Science and Technology
   Research Fund Project of Guangdong Province [A2018532]
FX This study was supported by grants from National Basic Research Program
   of China (973, No. 2015CB755505), Guangzhou Science Technology and
   Innovation Project (No. 201508020125), Science and Technology Planning
   Project of Guangdong Province (No. 2016A020213004), and Medical Science
   and Technology Research Fund Project of Guangdong Province (A2018532).
CR Acerbi F, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.11.FOCUS13487
   Almeida JP, 2015, CURR NEUROL NEUROSCI, V15, DOI 10.1007/s11910-014-0517-x
   Bowden SG, 2018, NEUROSURGERY, V82, P719, DOI 10.1093/neuros/nyx271
   Brennum J, 2018, ACTA NEUROCHIR, V160, P1043, DOI 10.1007/s00701-018-3521-0
   Buchfelder M, 2018, NEUROSURG REV, V41, P1, DOI 10.1007/s10143-017-0916-y
   Costa E, 2019, J NEUROSURG SCI, V63, P251, DOI 10.23736/S0390-5616.18.04180-2
   D'Amico RS, 2017, WORLD NEUROSURG, V103, P538, DOI 10.1016/j.wneu.2017.04.041
   Duffau H, 2018, NEUROSURG REV, V41, P133, DOI 10.1007/s10143-017-0918-9
   Eseonu CI, 2017, NEUROSURGERY, V81, P481, DOI 10.1093/neuros/nyx023
   Garrett MD, 2017, TOMOGRAPHY, V3, P131, DOI 10.18383/j.tom.2017.00009
   Grabowski MM, 2014, J NEUROSURG, V121, P1115, DOI 10.3171/2014.7.JNS132449
   Grossman R, 2017, ANN SURG ONCOL, V24, P794, DOI 10.1245/s10434-016-5635-z
   Hervey-Jumper SL, 2016, J NEURO-ONCOL, V130, P269, DOI 10.1007/s11060-016-2110-4
   Hervey-Jumper SL, 2015, J NEUROSURG, V123, P325, DOI 10.3171/2014.10.JNS141520
   Jenkinson MD, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012788.pub2
   Khan MB, 2016, NEUROSURGERY, V79, pN12, DOI 10.1227/01.neu.0000508600.08200.c1
   Li YM, 2016, J NEUROSURG, V124, P977, DOI 10.3171/2015.5.JNS142087
   Lu VM, 2018, CLIN NEUROL NEUROSUR, V169, P121, DOI 10.1016/j.clineuro.2018.04.011
   Mampre D, 2018, BRIT J NEUROSURG, V32, P528, DOI 10.1080/02688697.2018.1498450
   Neira JA, 2017, J NEUROSURG, V127, P111, DOI 10.3171/2016.7.JNS16232
   Pallud J, 2017, NEUROCHIRURGIE, V63, P164, DOI 10.1016/j.neuchi.2016.08.009
   Pessina F, 2017, J NEURO-ONCOL, V135, P129, DOI 10.1007/s11060-017-2559-9
   Quan GM, 2018, J NEURO-ONCOL, V137, P631, DOI 10.1007/s11060-018-2758-z
   Rozumenko A, 2018, NEUROSURG REV, V41, P1045, DOI 10.1007/s10143-018-0948-y
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Zhang NN, 2017, BIOMED RES INT, DOI 10.1155/2017/7865747
   Zinn PO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025451
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.130
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600089
PM 31899397
DA 2020-05-12
ER

PT J
AU Luo, PJ
   Tang, YC
   Zhou, TP
   Guo, HZ
   Guo, DQ
   Mo, GY
   Ma, YH
   Liu, PJ
   Zhang, SC
   Liang, D
AF Luo, Pei-jie
   Tang, Yong-chao
   Zhou, Teng-peng
   Guo, Hui-zhi
   Guo, Dan-qing
   Mo, Guo-ye
   Ma, Yan-huai
   Liu, Pan-jie
   Zhang, Shun-cong
   Liang, De
TI Risk Factor Analysis of the Incidence of Subsequent Adjacent Vertebral
   Fracture After Lumbar Spinal Fusion Surgery with Instrumentation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adjacent vertebral compression fracture; Lumbar instrumented spinal
   fusion; Risk factor
ID PROXIMAL JUNCTIONAL FRACTURES; LORDOSIS MISMATCH; INTERBODY FUSION;
   PELVIC INCIDENCE; DEFORMITY SURGERY; SEGMENT DISEASE; DEGENERATION
AB OBJECTIVE: This study aimed to evaluate the risk factors for adjacent vertebral compression fractures after lumbar spinal fusion with instrumentation.
   METHODS: A total of 669 patients who received lumbar instrumented spinal fusion between January 2012 and December 2015 were divided into 2 groups according to whether the adjacent vertebral body was fractured. The covariates recorded were age, sex, bone mineral density, and the number of fixed segments. The anatomic variables were pelvic incidence angle (PI), preoperative lumbar lordosis angle (Pre-LL), postoperative lumbar lordosis angle (Post-LL), Pre-LL minus Post-LL (Loss of LL), postoperative pelvic tilt (Post-PT), postoperative sacral slope, Pre-PI-LL mismatch (Pre-PI minus Pre-LL), and Post-PI-LL mismatch (Post-PI minus Post-LL). A 1-way analysis of variance (ANOVA) was performed with the aforementioned parameters, and binary logistic regression analysis was used to determine the relative risk factors.
   RESULTS: The 669 patients were followed-up for a mean of 2.7 +/- 1.1 years (range, 2-4 years). Twenty-seven patients demonstrated fractures in the adjacent vertebral body after surgery. Analysis by 1-way ANOVA demonstrated that age, PI, Pre-LL, Post-LL, Loss of LL, Post-PI-LL mismatch, Post-PT, and osteoporosis were potential risk factors (all parameters, P < 0.001). Furthermore, binary logistic regression analysis showed that a large Loss of LL, osteoporosis, and old age were also risk factors for adjacent vertebral compression fractures.
   CONCLUSIONS: A greater Loss of LL, osteoporosis, and advanced age may be risk factors for fractures in the adjacent vertebral body of the fixed segment after lumbar fusion fixation.
C1 [Luo, Pei-jie; Zhou, Teng-peng; Guo, Hui-zhi; Mo, Guo-ye; Ma, Yan-huai; Liu, Pan-jie; Zhang, Shun-cong] Guangzhou Univ Chinese Med, Sch Clin Med 1, Baiyun Dist, Guangdong, Peoples R China.
   [Luo, Pei-jie; Tang, Yong-chao; Zhou, Teng-peng; Guo, Hui-zhi; Guo, Dan-qing; Mo, Guo-ye; Ma, Yan-huai; Liu, Pan-jie; Zhang, Shun-cong; Liang, De] Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
RP Zhang, SC (reprint author), Guangzhou Univ Chinese Med, Sch Clin Med 1, Baiyun Dist, Guangdong, Peoples R China.; Zhang, SC (reprint author), Guangzhou Univ Chinese Med, Affiliated Hosp 1, Guangzhou, Peoples R China.
EM dr_luopj@sina.com
OI GUO, HuiZhi/0000-0003-3952-0030
CR Bastian L, 2001, EUR SPINE J, V10, P295, DOI 10.1007/s005860100278
   Bertagnoli R, 2006, J NEUROSURG-SPINE, V4, P91, DOI 10.3171/spi.2006.4.2.91
   BOGDANFFY GM, 1995, SPINE, V20, P1674, DOI 10.1097/00007632-199508000-00005
   Chen W J, 2001, Spine (Phila Pa 1976), V26, pE519, DOI 10.1097/00007632-200111150-00024
   Chiu YC, 2016, MEDICINE, V95, P1
   Chow DHK, 1996, SPINE, V21, P549, DOI 10.1097/00007632-199603010-00004
   COTREL Y, 1988, CLIN ORTHOP RELAT R, P10
   DeWald CJ, 2006, SPINE, V31, pS144, DOI 10.1097/01.brs.0000236893.65878.39
   HU SS, 1992, INVEST RADIOL, V27, P632, DOI 10.1097/00004424-199208000-00015
   Kaito T, 2011, ARCH ORTHOP TRAUM SU, V131, P1499, DOI 10.1007/s00402-011-1343-0
   Kebaish KM, 2013, SPINE J, V13, P1897, DOI 10.1016/j.spinee.2013.06.039
   Li YC, 2015, BONE JOINT J, V97B, P1411, DOI 10.1302/0301-620X.97B10.34927
   Mac-Thiong JM, 2007, EUR SPINE J, V16, P227, DOI 10.1007/s00586-005-0013-8
   Mehta Vivek A, 2015, Neurosurgery, V76 Suppl 1, pS42, DOI 10.1227/01.neu.0000462077.50830.1a
   Park P, 2004, SPINE, V29, P1938, DOI 10.1097/01.brs.0000137069.88904.03
   Rothenfluh DA, 2015, EUR SPINE J, V24, P1251, DOI 10.1007/s00586-014-3454-0
   Sears WR, 2011, SPINE J, V11, P11, DOI 10.1016/j.spinee.2010.09.026
   Senteler M, 2014, EUR SPINE J, V23, P1384, DOI 10.1007/s00586-013-3132-7
   Smith JS, 2013, SPINE, V38, P1663, DOI 10.1097/BRS.0b013e31829ec563
   Tang S, 2012, IRAN RED CRESCENT ME, V14, P139
   Tempel ZJ, 2017, NEUROSURGERY, V80, P880, DOI 10.1093/neuros/nyw073
   Theologis AA, 2015, SPINE, V40, P1516, DOI 10.1097/BRS.0000000000001043
   Umehara S, 2000, SPINE, V25, P1617, DOI 10.1097/00007632-200007010-00004
   Wang JC, 2005, SPINE, V30, pS33, DOI 10.1097/01.brs.0000174559.13749.83
   Watanabe K, 2010, SPINE, V35, P138, DOI 10.1097/BRS.0b013e3181c8f35d
   Wu CH, 2008, J SPINAL DISORD TECH, V21, P310, DOI 10.1097/BSD.0b013e318148b256
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.010
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600012
PM 31715415
DA 2020-05-12
ER

PT J
AU Ma, SC
   Liu, S
   Agazzi, S
   Jia, W
AF Ma, Shun-Chang
   Liu, Shih
   Agazzi, Siviero
   Jia, Wang
TI The Jugular Process: A Key Anatomical Landmark for Approaches to the
   Jugular Foramen
SO WORLD NEUROSURGERY
LA English
DT Article
DE Approach; Jugular foramen; Jugular process; Microsurgical anatomy;
   Morphology
ID MICROSURGICAL ANATOMY; SURGICAL-TREATMENT; LATERAL APPROACH;
   TRANSCONDYLAR; SUPRACONDYLAR; POSTERIOR; TUBERCLE; TUMORS; MAGNUM
AB OBJECTIVE: To describe the morphology and anatomical relationship of the jugular process (JP) and to elucidate its utility as a surgical landmark in the lateral and posterior lateral approaches to the jugular foramen.
   MATERIALS AND METHODS: Eight dry adult skulls and 10 silicon-injected cadaver heads were used for this study. The distances to selected structures and the thickness of the JP at 3 selected sites were measured. We also included the data of 20 thin-sliced 3-dimensional computed tomography scans. The radiology data of these patients were transferred to a workstation for 3-dimensional reconstruction.
   RESULTS: The JP, an irregular trapezoid structure, is an important surgical landmark when approaching the jugular foramen. Laterally the JP is rough with 1 or 2 prominences to which the rectus capitis lateralis is attached. The JP is relatively flat medially. The condylar part of the occipital bone could be conceived as a "3-story building." The JP, hypoglossal canal, and lateral and posterior condylar emissary veins are located on the middle floor. The stylomastoid foramen is found constantly in the triangle formed by the styloid process, JP, and the base of the mastoid process.
   CONCLUSIONS: The JP is an important surgical landmark in the identification of jugular foramen, especially in the lateral and posterior approaches. A better understanding of its morphology and its relationship with the surrounding structures is a prerequisite for accurate surgical planning and intraoperative orientation.
C1 [Ma, Shun-Chang; Jia, Wang] Capital Med Univ, Beijing Neurosurg Inst, Dept Neurot, Beijing, Peoples R China.
   [Ma, Shun-Chang; Jia, Wang] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
   [Liu, Shih; Agazzi, Siviero] Univ S Florida, Tampa Gen Hosp, Dept Neurosurg, Tampa, FL 33620 USA.
RP Jia, W (reprint author), Capital Med Univ, Beijing Neurosurg Inst, Dept Neurot, Beijing, Peoples R China.; Jia, W (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
EM jwttyybni@126.com
OI Agazzi, Siviero/0000-0001-5760-0187
CR Anichini G, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.05.031
   BABU RP, 1994, J NEUROSURG, V81, P49, DOI 10.3171/jns.1994.81.1.0049
   Cohen MA, 2017, J NEUROSURG, V127, P1398, DOI 10.3171/2016.9.JNS16723
   Dallan I, 2010, NEUROSURGERY, V67, P1, DOI 10.1227/01.NEU.0000354351.00684.B9
   FISCH U, 1978, J LARYNGOL OTOL, V92, P949, DOI 10.1017/S0022215100086382
   GEORGE B, 1988, SURG NEUROL, V29, P484, DOI 10.1016/0090-3019(88)90145-0
   Hellstern V, 2019, CLIN NEURORADIOL, V29, P341, DOI 10.1007/s00062-018-0669-1
   Kadri PA, 2007, NEUROSURG FOCUS, V17, pE9
   Katsuta T, 1997, NEUROSURGERY, V41, P149, DOI 10.1097/00006123-199707000-00030
   Komune N, 2019, OPER NEUROSURG, V16, P486, DOI 10.1093/ons/opy198
   Komune N, 2016, HEAD NECK-J SCI SPEC, V38, pE1041, DOI 10.1002/hed.24156
   Liu JK, 2006, NEUROSURGERY, V59, P115, DOI 10.1227/01.NEU.0000220025.81500.8D
   Ma SC, 2019, WORLD NEUROSURG, V128, pE859, DOI 10.1016/j.wneu.2019.05.018
   Matsushima K, 2019, WORLD NEUROSURG, V125, pE984, DOI 10.1016/j.wneu.2019.01.223
   Matsushima K, 2014, J NEUROSURG, V121, P397, DOI 10.3171/2014.3.JNS132419
   Matsushima K, 2014, NEUROSURG REV, V37, P115, DOI 10.1007/s10143-013-0493-7
   Matsushima T, 1998, SKULL BASE SURG, V8, P119, DOI 10.1055/s-2008-1058570
   Matsushima T, 2010, SKULL BASE-INTERD AP, V20, P83, DOI 10.1055/s-0029-1242193
   Mintelis A, 2006, J NEUROSURG, V105, P753, DOI 10.3171/jns.2006.105.5.753
   Nakamizo A, 2013, BRIT J NEUROSURG, V27, P212, DOI 10.3109/02688697.2012.722705
   Perneczky A., 1986, SURG BRAIN STEM 3 VE
   Ramina Ricardo, 2004, Neurosurg Focus, V17, pE5
   Rhoton AL, 2000, NEUROSURGERY, V47, pS29, DOI 10.1097/00006123-200009001-00010
   RHOTON AL, 2000, NEUROSURGERY S3, V47, pS19
   SAMII M, 1995, J NEUROSURG, V82, P711, DOI 10.3171/jns.1995.82.5.0711
   Samii M, 2016, J NEUROSURG, V124, P1061, DOI 10.3171/2015.3.JNS142904
   Samii M, 2015, NEUROSURGERY, V77, P424, DOI 10.1227/NEU.0000000000000831
   SEN CN, 1990, NEUROSURGERY, V27, P197, DOI 10.1227/00006123-199008000-00004
   Tubbs RS, 2007, SURG RADIOL ANAT, V29, P219, DOI 10.1007/s00276-007-0196-2
   Wen HT, 1997, J NEUROSURG, V87, P555, DOI 10.3171/jns.1997.87.4.0555
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.103
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600082
PM 31884127
DA 2020-05-12
ER

PT J
AU Madhavan, AA
   Kim, DK
   Brinjikji, W
   Atkinson, J
   Carr, CM
AF Madhavan, Ajay A.
   Kim, Dong Kun
   Brinjikji, Waleed
   Atkinson, John
   Carr, Carrie M.
TI Diagnosis of a Cerebrospinal Fluid-Venous Fistula Associated with a
   Venous Malformation Using Digital Subtraction and Computed Tomography
   Myelography
SO WORLD NEUROSURGERY
LA English
DT Article
DE CSF-venous fistula; Digital subtraction myelography; Intracranial
   hypotension; Myelography
ID SPONTANEOUS INTRACRANIAL HYPOTENSION; PARASPINAL VEIN SIGN; CSF LEAK
AB BACKGROUND: Spontaneous cerebrospinal fluid (CSF) leaks can be an intractable cause of orthostatic headaches but have several treatable causes. CSF-venous fistulas are an increasingly recognized cause of rapid CSF leaks. Although CSF-venous fistulas have been previously reported in the literature, their imaging appearance, associated anomalies, and treatment are incompletely understood. We present a case of a CSF-venous fistula draining to adjacent venous malformations with symptoms responding to surgical treatment. This is the first such case to our knowledge showing enhancement of venous malformations on computed tomography myelography.
   CASE DESCRIPTION: A 61-year-old woman with known soft tissue venous malformations presented with progressive hearing loss, headaches, and nausea. Brain magnetic resonance imaging performed at an outside institution showed findings of CSF hypotension. Her symptoms were refractory to a single-level blood patch. Digital subtraction and computed tomography myelography performed at our institution showed CSF-venous fistulas arising from thoracic nerve root sleeve diverticula and draining to paraspinal venous malformations. She was treated with surgical ligation of the fistula and associated nerve roots. At 3-month follow-up, she reported improvement in her headaches, and magnetic resonance imaging showed resolution of all brain abnormalities.
   CONCLUSIONS: CSF-venous fistulas are a relatively uncommon cause of spontaneous CSF leaks. Though difficult to diagnose, they can respond to surgical treatment as seen in this case. In our experience, decubitus digital subtraction myelography combined with computed tomography myelography is instrumental in making the diagnosis and fully characterizing any abnormalities associated with the fistula. This case also supports the suggested association between CSF-venous fistulas and venous malformations, which is worthy of continued study.
C1 [Madhavan, Ajay A.; Kim, Dong Kun; Brinjikji, Waleed; Carr, Carrie M.] Mayo Clin, Dept Radiol, Div Neuroradiol, Rochester, MN 55905 USA.
   [Atkinson, John] Mayo Clin, Dept Neurosurg, Rochester, MN USA.
RP Madhavan, AA (reprint author), Mayo Clin, Dept Radiol, Div Neuroradiol, Rochester, MN 55905 USA.
EM madhavan.ajay@mayo.edu
CR Adler F, 2011, AM J NEURORADIOL, V32, pE198, DOI 10.3174/ajnr.A2413
   Clark MS, 2018, DIAGN INTERV RADIOL, V24, P54, DOI 10.5152/dir.2017.17220
   Dobrocky T, 2019, JAMA NEUROL, V76, P580, DOI 10.1001/jamaneurol.2018.4921
   Farb RI, 2019, AM J NEURORADIOL, V40, P745, DOI 10.3174/ajnr.A6016
   Hoxworth JM, 2009, AM J NEURORADIOL, V30, P516, DOI 10.3174/ajnr.A1294
   Kranz PG, 2016, AM J NEURORADIOL, V37, P1379, DOI 10.3174/ajnr.A4682
   Kranz PG, 2017, AM J ROENTGENOL, V209, P1360, DOI 10.2214/AJR.17.18351
   Kumar N, 2016, NEUROLOGY, V86, P2310, DOI 10.1212/WNL.0000000000002776
   LIN PM, 1974, J NEUROSURG, V41, P773, DOI 10.3171/jns.1974.41.6.0773
   Luetmer PH, 2003, AM J NEURORADIOL, V24, P1711
   Mokri B, 2014, HEADACHE, V54, P726, DOI [10.1111/head.12340, 10.1111/head.12262]
   Schievink WI, 2006, JAMA-J AM MED ASSOC, V295, P2286, DOI 10.1001/jama.295.19.2286
   Schievink WI, 2004, NEUROSURGERY, V54, P65, DOI 10.1227/01.NEU.0000097200.18478.7B
   Schievink WI, 2020, J NEUROSURG-SPINE, V32, P305, DOI 10.3171/2019.8.SPINE19716
   Schievink WI, 2014, NEUROLOGY, V83, P472, DOI 10.1212/WNL.0000000000000639
   Thielen KR, 2015, J NEUROSURG-SPINE, V22, P324, DOI 10.3171/2014.10.SPINE14209
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.075
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600147
PM 31870817
DA 2020-05-12
ER

PT J
AU Malik, AT
   Deiparine, S
   Khan, SN
   Kim, J
   Yu, E
AF Malik, Azeem Tariq
   Deiparine, Selina
   Khan, Safdar N.
   Kim, Jeffery
   Yu, Elizabeth
TI Costs Associated With a 90-Day Episode of Care After Single-Level
   Anterior Lumbar Interbody Fusion
SO WORLD NEUROSURGERY
LA English
DT Article
DE ALIF; Anterior lumbar interbody fusion; Bundled payment; Commercial;
   Costs; Humana; Medicare Advantage
ID TOTAL JOINT ARTHROPLASTY; BUNDLED PAYMENTS; HEALTH-CARE
AB BACKGROUND: Anterior lumbar interbody fusion (ALIF) is a commonly performed surgical procedure for the management of degenerative lumbar spine pathologic entities. Despite an increasing number of ALIFs performed nationally, to the best of our knowledge, no study has evaluated the costs associated with the 90-day episode of care postoperatively.
   METHODS: The 2007-2016 Humana Administrative Claims data set, a national database of commercial and Medicare Advantage (MA) beneficiaries, was queried using Current Procedural Terminology code 22558 for patients who had undergone single-level ALIF. The 90-day costs were defined using the following categories: facility, surgeon, anesthesia, other hospitalization costs and services, radiology, office visits, physical therapy/rehabilitation, emergency department visits, and readmissions.
   RESULTS: A total of 365 ALIF procedures (MA, n = 244; commercial, n = 121) were included in the analysis. The average 90-day cost of single-level ALIF was $25,568 and $51,741 for the MA and commercial enrollees, respectively. The major proportion of 90-day costs was attributable to facility reimbursement (74%-76%), followed by surgeon costs (9%-11%). Postacute care (i.e., office visits and physical therapy/rehabilitation) was not a major driver of the 90-day costs, consisting of only 0.7%-1.3% of the total 90-day reimbursement. Of patients who had required readmission, the costs of the readmission increased the average 90-day costs by 65%-66%.
   CONCLUSIONS: Facility costs were the major drivers of a stipulated 90-day reimbursement for patients undergoing single-level ALIF. Health policy makers and providers can use these data to better understand the distribution of costs in a stipulated bundled-payment model for ALIFs and allow them to identify areas in which cost reduction strategies can be performed.
C1 [Malik, Azeem Tariq; Deiparine, Selina; Khan, Safdar N.; Kim, Jeffery; Yu, Elizabeth] Ohio State Univ, Dept Orthopaed, Wexner Med Ctr, Columbus, OH 43210 USA.
RP Yu, E (reprint author), Ohio State Univ, Dept Orthopaed, Wexner Med Ctr, Columbus, OH 43210 USA.
EM Elizabeth.yu@osumc.edu
CR Anderson GF, 2019, HEALTH AFFAIR, V38, P87, DOI 10.1377/hlthaff.2018.05144
   Anderson GF, 1999, HEALTH AFFAIR, V18, P178, DOI 10.1377/hlthaff.18.3.178
   Bozic KJ, 2014, CLIN ORTHOP RELAT R, V472, P188, DOI 10.1007/s11999-013-3034-3
   Cram P, 2015, GERIATR ORTHOP SURG, V6, P3, DOI 10.1177/2151458514559832
   Culler SD, 2016, SPINE, V41, P1613, DOI 10.1097/BRS.0000000000001641
   Deng Hansen, 2019, J Neurosurg Sci, DOI 10.23736/S0390-5616.19.04647-2
   El-Othmani MM, 2019, J ARTHROPLASTY, V34, P2532, DOI 10.1016/j.arth.2019.06.041
   Ellimoottil C, 2017, JAMA SURG, V152, P49, DOI 10.1001/jamasurg.2016.3098
   Friedberg Mark W, 2015, Rand Health Q, V5, P8
   Grace TR, 2018, J ARTHROPLASTY, V33, P1681, DOI 10.1016/j.arth.2018.01.071
   Hussey Peter S, 2012, Evid Rep Technol Assess (Full Rep), P1
   Jain N, 2018, SPINE, V43, P193, DOI 10.1097/BRS.0000000000002283
   Kapoor Deepak A, 2017, Rev Urol, V19, P198, DOI 10.3909/riu193NewsinUro
   Malik AT, 2019, WORLD NEUROSURG, V130, pE535, DOI 10.1016/j.wneu.2019.06.149
   Malik AT, 2019, SPINE J, V19, P1706, DOI 10.1016/j.spinee.2019.06.009
   Malik AT, 2020, SPINE J, V20, P32, DOI 10.1016/j.spinee.2019.04.024
   Nussbaum S, 2018, JAMA-J AM MED ASSOC, V319, P653, DOI 10.1001/jama.2017.20226
   Patel K, 2016, CLIN GASTROENTEROL H, V14, P497, DOI 10.1016/j.cgh.2015.06.025
   Rajaee SS, 2012, SPINE, V37, P67, DOI 10.1097/BRS.0b013e31820cccfb
   Sisko AM, 2019, HEALTH AFFAIR, V38, P491, DOI 10.1377/hlthaff.2018.05499
   Sullivan R, 2017, CURR REV MUSCULOSKE, V10, P218, DOI 10.1007/s12178-017-9405-8
   Ugiliweneza B, 2014, SPINE, V39, P1235, DOI 10.1097/BRS.0000000000000378
   Varshneya Kunal, 2019, Clin Spine Surg, DOI 10.1097/BSD.0000000000000904
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.117
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600086
PM 31899389
DA 2020-05-12
ER

PT J
AU Maragkos, GA
   Penumaka, A
   Ahrendsen, JT
   Salem, MM
   Nelton, EB
   Alterman, RL
AF Maragkos, Georgios A.
   Penumaka, Anirudh
   Ahrendsen, Jared T.
   Salem, Mohamed M.
   Nelton, Emmalin B.
   Alterman, Ron L.
TI Factors Affecting the Diagnostic Yield of Frame-Based Stereotactic
   Intracranial Biopsies
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diagnostic yield; Frame based; Intracranial biopsy; Stereotactic
ID FLUORESCEIN SODIUM FLUORESCENCE; 5-AMINOLEVULINIC ACID; NEEDLE-BIOPSY;
   BRAIN BIOPSY; ACCURACY; LESIONS; TUMOR; EXPERIENCE; MANAGEMENT;
   PRECISION
AB OBJECTIVE: Frame-based stereotactic biopsy (FSB) remains the "gold standard" for obtaining diagnostic samples of intracranial lesions to guide therapy. Nevertheless, diagnostic yield is highly variable. This study aims to provide an analysis of diagnostic yield, surgical complications, and factors associated with obtaining nondiagnostic samples in a contemporary FSB series.
   METHODS: A retrospective cohort study was conducted of all adult patients with imaging-documented lesions undergoing FSB at our institution between 2013 and 2018. Diagnostic accuracy, lesion characteristics associated with nondiagnostic biopsy, and surgical complications were evaluated. A biopsy was considered nondiagnostic if all frozen samples and the final pathology yielded normal brain tissue or nonspecific reactive tissue unless the "reactive" pathology was consistent with radiation injury from prior therapy.
   RESULTS: Our search identified 198 FSB patients. Mean (standard deviation) age was 62 +/- 17 years, and 44.2% were female. Median procedure time was 32 minutes. A definitive histologic diagnosis was established in 187 cases (94.4% diagnostic yield). Mean lesion diameter was 31.9 +/- 16.8 mm. Multivariable logistic regression revealed only lesion diameter to be significantly associated with diagnostic result (odds ratio for nondiagnostic result: 0.94 per mm diameter decrease, 95% confidence interval 0.87-0.99, P = 0.028). On univariable analysis, diagnosis of central nervous system lymphoma appeared to increase the risk of a nondiagnostic biopsy (P = 0.025), but this association disappeared when controlling for lesion size and steroid administration before biopsy. Eight patients (4.0%) developed postoperative hemorrhagic complications, 3 of whom required reoperation, and another expired.
   CONCLUSIONS: This study demonstrates that diagnostic yield from contemporary FSB is high and depends predominantly on lesion size.
C1 [Maragkos, Georgios A.; Penumaka, Anirudh; Ahrendsen, Jared T.; Salem, Mohamed M.; Nelton, Emmalin B.; Alterman, Ron L.] Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02215 USA.
   [Ahrendsen, Jared T.] Beth Israel Deaconess Med Ctr, Neurol Pathol Serv, Boston, MA 02215 USA.
   [Maragkos, Georgios A.; Penumaka, Anirudh; Salem, Mohamed M.; Nelton, Emmalin B.; Alterman, Ron L.] Harvard Med Sch, Dept Neurol Surg, Boston, MA 02115 USA.
RP Alterman, RL (reprint author), Beth Israel Deaconess Med Ctr, Neurosurg Serv, Boston, MA 02215 USA.; Alterman, RL (reprint author), Harvard Med Sch, Dept Neurol Surg, Boston, MA 02115 USA.
EM ralterma@bidmc.harvard.edu
OI Maragkos, Georgios/0000-0003-2156-7391
CR Air EL, 2009, J NEUROSURG, V111, P820, DOI 10.3171/2009.3.JNS081695
   APUZZO MLJ, 1983, NEUROSURGERY, V12, P277, DOI 10.1227/00006123-198303000-00005
   APUZZO MLJ, 1987, NEUROSURGERY, V20, P930, DOI 10.1227/00006123-198706000-00019
   Binnahil M, 2016, CAN J NEUROL SCI, V43, P721, DOI 10.1017/cjn.2016.255
   Bjartmarz H, 2007, STEREOT FUNCT NEUROS, V85, P235, DOI 10.1159/000103262
   BLACK P, 1987, AM J CLIN ONCOL-CANC, V10, P285, DOI 10.1097/00000421-198708000-00004
   Chen CC, 2009, CLIN NEUROL NEUROSUR, V111, P835, DOI 10.1016/j.clineuro.2009.08.013
   da Silva EU, 2009, ARQ NEURO-PSIQUIAT, V67, P1062, DOI 10.1590/S0004-282X2009000600019
   Dammers R, 2010, ACTA NEUROCHIR, V152, P1915, DOI 10.1007/s00701-010-0752-0
   Ersahin M, 2011, TURK NEUROSURG, V21, P582, DOI [10.5137/1019-5149.JTN .4656-11.1, 10.5137/1019-5149.JTN.4656-11.1]
   FEIDEN W, 1991, NEUROSURG REV, V14, P51
   Field P, 2001, J NEUROSURG, V94, P545, DOI 10.3171/jns.2001.94.4.0545
   FRIEDMAN WA, 1989, NEUROSURGERY, V25, P180, DOI 10.1227/00006123-198908000-00005
   GAMETCHU B, 1987, SCIENCE, V236, P456, DOI 10.1126/science.3563523
   Jain D, 2006, BRAIN TUMOR PATHOL, V23, P71, DOI 10.1007/s10014-006-0204-y
   KELLY PJ, 1986, NEUROLOGY, V36, P535, DOI 10.1212/WNL.36.4.535
   Kim SH, 2011, CLIN NEUROPATHOL, V30, P328, DOI 10.5414/NP300404
   LOBATO RD, 1982, APPL NEUROPHYSIOL, V45, P426
   LUNSFORD LD, 1984, SURG NEUROL, V22, P222
   Marbacher S, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.12.FOCUS13464
   Moriuchi S, 2011, J NEUROSURG, V115, P278, DOI 10.3171/2011.4.JNS102137
   Owen CM, 2009, J NEURO-ONCOL, V93, P139, DOI 10.1007/s11060-009-9871-y
   Rey-Dios R, 2014, ACTA NEUROCHIR, V156, P1071, DOI 10.1007/s00701-014-2097-6
   Smith JS, 2005, J NEURO-ONCOL, V73, P173, DOI 10.1007/s11060-004-4208-3
   Thien A, 2018, ACTA NEUROCHIR, V160, P317, DOI 10.1007/s00701-017-3429-0
   Thien A, 2017, ACTA NEUROCHIR, V159, P371, DOI 10.1007/s00701-016-3041-8
   Tilgner J, 2005, NEUROSURGERY, V56, P257, DOI 10.1227/01.neu.0000148899.39020.87
   Ulm AJ, 2001, SURG NEUROL, V56, P366, DOI 10.1016/S0090-3019(01)00602-4
   VAQUERO J, 1984, J NEUROSURG, V60, P174, DOI 10.3171/jns.1984.60.1.0174
   von Campe G, 2012, ACTA NEUROCHIR, V154, P585, DOI 10.1007/s00701-012-1290-8
   Waters J Dawn, 2013, Surg Neurol Int, V4, pS176, DOI 10.4103/2152-7806.110677
   Weller M, 1999, J NEURO-ONCOL, V43, P237, DOI 10.1023/A:1006254518848
   WHITING DM, 1992, CLEV CLIN J MED, V59, P48, DOI 10.3949/ccjm.59.1.48
   Widhalm G, 2012, NEUROSURG REV, V35, P381, DOI 10.1007/s10143-012-0374-5
   Woodworth GF, 2006, J NEUROSURG, V104, P233, DOI 10.3171/jns.2006.104.2.233
   Yamamoto T, 2015, PHOTOCHEM PHOTOBIOL, V91, P1452, DOI 10.1111/php.12510
   Zacest A, 2009, STEREOT FUNCT NEUROS, V87, P168, DOI 10.1159/000215932
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.102
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600083
PM 31883483
DA 2020-05-12
ER

PT J
AU Martinez-Perez, R
   Albonette-Felicio, T
   Zachariah, MA
   Hardesty, DA
   Carrau, RL
   Prevedello, DM
AF Martinez-Perez, Rafael
   Albonette-Felicio, Thiago
   Zachariah, Marcus A.
   Hardesty, Douglas A.
   Carrau, Ricardo L.
   Prevedello, Daniel M.
TI Quantitative Anatomic Study of the Minipterional Craniotomy in the
   Paraclinoid Region: Benefits of Extradural Anterior Clinoidectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid-ophthalmic; Cerebral aneurysms; Craniopharyngioma; Meningioma;
   Minimally invasive; Ophthalmic artery; Tuberculum sellae
ID ANEURYSMS; EXPERIENCE; PREDICTION; NECESSITY
AB BACKGROUND: Extradural anterior clinoidectomy (eAC) via the minipterional craniotomy (MPT) approach (MPT+ eAC) has been recently introduced to the neurosurgical armamentarium to improve access to anterior and middle fossa skull base structures using a minimally invasive approach. However, the effect of extradural clinoidectomy on surgical exposure with the minipterional approach has not been evaluated. Moreover, the effect of eAC on surgical maneuverability has not been established for either traditional pterional or minipterional craniotomy. We sought to illustrate the microsurgical anatomy of the MPT+ eAC and to evaluate the effect of eAC on surgical exposure and maneuverability.
   METHODS: The area of exposure, area of surgical freedom, and maneuverability score for the MPT approach and MPT+ eAC were compared in 5 cadaveric heads.
   RESULTS: Compared with the MPT approach, the MPT+ eAC enlarged the area of exposure approximately twofold (93 cm(2) vs. 184 cm(2) ; P < 0.001). All targets considered in the paraclinoid region, including the posterior communicating artery origin, prechiasmatic region, and ophthalmic artery origin, showed an increase in surgical freedom and maneuverability after performing eAC. Targets remote from the clinoid such as the internal carotid bifurcation were not affected.
   CONCLUSIONS: MPT+ eAC offers a larger area of exposure and greater surgical freedom and maneuverability at the paraclinoid region using this minimally invasive approach.
C1 [Martinez-Perez, Rafael; Albonette-Felicio, Thiago; Zachariah, Marcus A.; Hardesty, Douglas A.; Carrau, Ricardo L.; Prevedello, Daniel M.] Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.
   [Hardesty, Douglas A.; Carrau, Ricardo L.; Prevedello, Daniel M.] Ohio State Univ, Dept Otolaryngol Head & Neck Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
RP Prevedello, DM (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Neurol Surg, Columbus, OH 43210 USA.; Prevedello, DM (reprint author), Ohio State Univ, Dept Otolaryngol Head & Neck Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
EM Daniel.prevedello@osumc.edu
RI Martinez-Perez, Rafael/E-2408-2014
OI Martinez-Perez, Rafael/0000-0002-2896-2346; Albonette Felicio,
   Thiago/0000-0003-2325-8074
CR Ammirati M, 1998, NEUROSURGERY, V43, P1398, DOI 10.1097/00006123-199812000-00081
   Beer-Furlan A, 2014, J CLIN NEUROSCI, V21, P836, DOI 10.1016/j.jocn.2013.10.006
   Caplan JM, 2014, OPER NEUROSURG, V10, P200, DOI 10.1227/NEU.0000000000000348
   Chiarullo M, 2019, WORLD NEUROSURG, V129, pE502, DOI 10.1016/j.wneu.2019.05.196
   Davies JM, 2014, NEUROSURGERY, V74, pS7, DOI 10.1227/NEU.0000000000000193
   Dolenc VV, 1999, ACT NEUR S, V72, P89
   Elhadi AM, 2015, OPER NEUROSURG, V11, P69, DOI 10.1227/NEU.0000000000000601
   Figueiredo EG, 2007, NEUROSURGERY, V61, P256, DOI 10.1227/01.neu.0000303978.11752.45
   Figueiredo EG, 2016, J CLIN NEUROSCI, V27, P34, DOI 10.1016/j.jocn.2015.07.032
   Figueiredo EG, 2014, NEUROSURGERY, V75, pN324, DOI 10.1227/NEU.0000000000000456
   Fukuda H, 2016, NEUROSURGERY, V78, P381, DOI 10.1227/NEU.0000000000001131
   Giammattei L, 2019, WORLD NEUROSURG, V129, pE700, DOI 10.1016/j.wneu.2019.05.253
   GIBO H, 1981, J NEUROSURG, V55, P560, DOI 10.3171/jns.1981.55.4.0560
   Tra H, 2018, WORLD NEUROSURG, V109, P36, DOI 10.1016/j.wneu.2017.09.058
   Iwasaki K, 2018, ACTA NEUROCHIR SUPPL, V129, P39, DOI 10.1007/978-3-319-73739-3_6
   Kamide T, 2018, WORLD NEUROSURG, V109, pE493, DOI 10.1016/j.wneu.2017.10.007
   Kang Ho-Jun, 2013, J Cerebrovasc Endovasc Neurosurg, V15, P5, DOI 10.7461/jcen.2013.15.1.5
   Martinez-Perez R, 2019, ACTA NEUROCHIR, V161, P2577, DOI 10.1007/s00701-019-04064-3
   Martinez-Perez R, 2019, WORLD NEUROSURG, V125, P534, DOI 10.1016/j.wneu.2018.10.240
   Matsukawa H, 2014, J NEUROSURG, V120, P104, DOI 10.3171/2013.9.JNS13921
   Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5
   Noiphithak R, 2019, OPER NEUROSURG, V17, P174, DOI 10.1093/ons/opy309
   OCHIAI C, 1989, ACTA NEUROCHIR, V99, P117, DOI 10.1007/BF01402319
   Otani Naoki, 2018, Asian J Neurosurg, V13, P1165, DOI 10.4103/ajns.AJNS_176_18
   Rychen J, 2019, NEUROL RES, V41, P68, DOI 10.1080/01616412.2018.1531202
   VANLOVEREN HR, 1991, J NEUROSURG, V74, P837, DOI 10.3171/jns.1991.74.5.0837
   Welling LC, 2015, J NEUROSURG, V122, P1012, DOI 10.3171/2014.11.JNS146
   Wicks Robert T, 2019, Neurosurg Focus, V46, pV9, DOI 10.3171/2019.2.FocusVid.18660
   Yagmurlu K, 2017, J NEUROSURG, V127, P646, DOI 10.3171/2016.6.JNS16306
   YANG Y, 2006, NEUROSURGERY S2, V5
   YASARGIL MG, 1987, J NEUROSURG, V67, P463, DOI 10.3171/jns.1987.67.3.0463
NR 31
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.120
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600026
PM 31786378
DA 2020-05-12
ER

PT J
AU Mathew, P
   Chiu, L
   Lee, C
   Carroll, R
   Johnson, MD
AF Mathew, Pawan
   Chiu, Lucinda
   Lee, Christopher
   Carroll, Rona
   Johnson, Mark D.
TI Idiopathic Normal Pressure Hydrocephalus With Stuttering: Report of Two
   Cases and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Normal pressure hydrocephalus; Stuttering; Ventriculoperitoneal shunt;
   Neurological disorders of aging
AB BACKGROUND: Idiopathic normal pressure hydrocephalus (iNPH) is a disorder of aging that is characterized by enlarged cerebral ventricles, gait apraxia, dementia, and urinary incontinence. iNPH is frequently misdiagnosed, in part because the symptoms resemble other neurological disorders, and because other associated symptoms have not been fully characterized. Importantly, iNPH has not previously been associated with stuttering, and shunting has not been shown to alleviate the symptom of stuttering.
   CASE DESCRIPTIONS: Here, we report 2 cases of patients with iNPH presenting with stuttering that resolved after ventriculoperitoneal (VP) shunt placement. Each patient presented with gait difficulty, incontinence, cognitive impairment, and stuttering. Lasting improvements of the symptoms (including stuttering) were seen in both patients after cerebrospinal fluid (CSF) drainage procedures that included lumbar puncture, extended lumbar CSF drainage, placement of a VP shunt, and VP shunt revision.
   CONCLUSIONS: These findings suggest that iNPH can present with stuttering or dysarthria. The significant improvement in stuttering and dysarthria, along with the improvements in gait difficulty, incontinence, and cognitive impairment that occurred after CSF drainage, suggests that the motor apraxia observed in iNPH can affect speech production. Practitioners should be aware that iNPH can present with stuttering, and that CSF drainage can improve stuttering in select circumstances.
C1 [Mathew, Pawan; Chiu, Lucinda; Lee, Christopher; Carroll, Rona; Johnson, Mark D.] Univ Massachusetts, Sch Med, Dept Neurol Surg, Worcester, MA 01655 USA.
   [Carroll, Rona; Johnson, Mark D.] Brigham & Womens Hosp, Adult Hydrocephalus Program, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.
   [Carroll, Rona; Johnson, Mark D.] Harvard Med Sch, Boston, MA 02115 USA.
RP Johnson, MD (reprint author), Univ Massachusetts, Sch Med, Dept Neurol Surg, Worcester, MA 01655 USA.; Johnson, MD (reprint author), Brigham & Womens Hosp, Adult Hydrocephalus Program, Dept Neurosurg, 75 Francis St, Boston, MA 02115 USA.; Johnson, MD (reprint author), Harvard Med Sch, Boston, MA 02115 USA.
EM Mark.Johnson3@umassmemorial.org
CR Boon AJW, 1997, J NEUROSURG, V87, P687, DOI 10.3171/jns.1997.87.5.0687
   Falk S, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.00847
   Hebb AO, 2001, NEUROSURGERY, V49, P1166, DOI 10.1097/00006123-200111000-00028
   Lenfeldt N, 2008, BRAIN, V131, P2904, DOI 10.1093/brain/awn232
   Ludlow CL, 2003, J FLUENCY DISORD, V28, P273, DOI 10.1016/j.jfludis.2003.07.001
   Nass RD, 1996, PEDIATR NEUROL, V15, P166, DOI 10.1016/0887-8994(96)00120-8
   Rusz J, 2015, J NEUROL, V262, P992, DOI 10.1007/s00415-015-7671-1
   Sakakibara R, 2008, J NEURAL TRANSM, V115, P443, DOI 10.1007/s00702-007-0855-9
   Silverberg GD, 2004, BRAIN, V127, P947, DOI 10.1093/brain/awh178
   Toma AK, 2013, ACTA NEUROCHIR, V155, P1977, DOI 10.1007/s00701-013-1835-5
NR 10
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.152
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600128
PM 31805405
DA 2020-05-12
ER

PT J
AU Mendoza-Elias, N
   Dunbar, M
   Ghogawala, Z
   Whitmore, RG
AF Mendoza-Elias, Nasya
   Dunbar, Melissa
   Ghogawala, Zoher
   Whitmore, Robert G.
TI Opioid Use, Risk Factors, and Outcome in Lumbar Fusion Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lumbar fusion; Opioid fusion outcome; Opioid use; Risk factors and
   lumbar fusion outcome; Risk factors for opioid use
ID PAIN; ASSOCIATION; OVERDOSE; BURDEN; USAGE
AB OBJECTIVE: Inappropriate opioid use resulted in 68% of all U.S. drug overdoses in 2017-nearly 75% of all opioid deaths-costing $80 billion per year. It is imperative to understand the impact of opioid use on outcome from surgery for lower back pain disorders.
   METHODS: A retrospective review of lumbar spinal fusion registry data at a single center from 2015-2018 was performed. A novel algorithm was used to extract opioid utilization from the electronic health record. Number of levels fused, fusion type, and minimally invasive surgery status were collected from the registry, as were depres-sion status, European Quality of Life 5 level score, and Oswestry Disability Index at 6 months to 1 year postoperatively.
   RESULTS: We included 294 patients (mean age 62 years, 48% male). Patients younger than 65 years trended toward more opioid use before surgery and significantly higher opioid use after surgery (P < 0.0001). Depression trended toward increasing opioid use after surgery (P = 0.08). Fusions of 4 or more levels were associated with overall greater opioid use after surgery (P = 0.03). Higher rate of opioid use before and after surgery is associated with worse European Quality of Life 5 level scores after surgery (P = 0.01 and P = 0.04) and worse Oswestry Disability Index scores after surgery (P = 0.006 and P = 0.002).
   CONCLUSIONS: This registry finds that younger age and lower functional status scores are associated with higher opioid use before surgery. Opioid use before surgery, younger age, and >4 levels of fusion are associated with higher opioid use after surgery. Overall, opioid use is associated with worse functional outcome and may serve as a marker of disease progression.
C1 [Mendoza-Elias, Nasya; Dunbar, Melissa; Ghogawala, Zoher; Whitmore, Robert G.] Lahey Hosp & Med Ctr, Alan L Jacqueline B Stuart Spine Res Ctr, Dept Neurosurg, Burlington, MA 01805 USA.
   [Mendoza-Elias, Nasya] Univ Chicago, Sect Neurosurg, Chicago, IL 60637 USA.
RP Mendoza-Elias, N (reprint author), Lahey Hosp & Med Ctr, Alan L Jacqueline B Stuart Spine Res Ctr, Dept Neurosurg, Burlington, MA 01805 USA.; Mendoza-Elias, N (reprint author), Univ Chicago, Sect Neurosurg, Chicago, IL 60637 USA.
EM nasya.mendoza-elias@uchospitals.edu
CR Adogwa O, 2011, J SPINAL DISORD TECH, V24, P479, DOI 10.1097/BSD.0b013e3182055cac
   Armaghani SJ, 2014, SPINE, V39, pE1524, DOI 10.1097/BRS.0000000000000622
   Brusko GD, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18692
   Cahill KS, 2019, JAMA-J AM MED ASSOC, V302, P58
   CDC, 2015, LOW BACK PAIN NHIS O
   Centers for Disease Control and Prevention and National Center for Health Statistics (Institution/ Organization), 2017, MULT CAUS DEATH FIL
   Cheng JS, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.5.FOCUS1377
   Corniola MV, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18657
   Davison MA, 2018, WORLD NEUROSURG, V120, pE580, DOI 10.1016/j.wneu.2018.08.131
   Elsarrag M, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18700
   Emami A, 2018, ASIAN SPINE J, V12, P830, DOI 10.31616/asj.2018.12.5.830
   Fineberg SJ, 2013, SPINE, V38, P1304, DOI 10.1097/BRS.0b013e31828f494c
   Florence CS, 2016, MED CARE, V54, P901, DOI 10.1097/MLR.0000000000000625
   Hedegaard H, 2018, NATL VITAL STAT REPO, V67, P9
   Hyer Lee, 2015, J Opioid Manag, V11, P147, DOI 10.5055/jom.2015.0264
   Jain N, 2018, SPINE, V43, P1
   Kalakoti P, 2018, SPINE, V43, P1208, DOI 10.1097/BRS.0000000000002734
   Khor S, 2018, JAMA SURG, V153, P634, DOI 10.1001/jamasurg.2018.0072
   Lee MJ, 2018, J AM ACAD ORTHOP SUR, V26, P124, DOI 10.5435/JAAOS-D-15-00756
   Martell BA, 2007, ANN INTERN MED, V146, P116, DOI 10.7326/0003-4819-146-2-200701160-00006
   Maruenda JI, 2016, EUR SPINE J, V25, P1550, DOI 10.1007/s00586-016-4469-5
   Nielsen RV, 2018, DAN MED J, V65
   Nielsen RV, 2017, PAIN, V158, P463, DOI 10.1097/j.pain.0000000000000782
   O'Connell C, 2018, NEUROSURG FOCUS, V44, DOI 10.3171/2017.10.FOCUS17563
   Ong KL, 2018, AM J MANAG CARE, V24, pE234
   Pacreu S, 2012, ACTA ANAESTH SCAND, V56, P1250, DOI 10.1111/j.1399-6576.2012.02743.x
   Parker SL, 2012, PROF CASE MANAG, V17, P229, DOI 10.1097/NCM.0b013e3182529c05
   Przewlocki R, 2001, EUR J PHARMACOL, V429, P79, DOI 10.1016/S0014-2999(01)01308-5
   Pyati S, 2007, CNS DRUGS, V21, P185, DOI 10.2165/00023210-200721030-00002
   Seth P, 2018, AM J PUBLIC HEALTH, V108, P500, DOI 10.2105/AJPH.2017.304265
   Sharma M, 2018, J NEUROSURG-SPINE, V29, P271, DOI 10.3171/2018.1.SPINE171258
   Sharma Neena K, 2017, Hosp Pharm, V52, P774, DOI 10.1177/0018578717737431
   Sivaganesan A, 2018, NEUROSURGERY, P1
   Soffin EM, 2019, NEUROSURG FOCUS, V46, DOI 10.3171/2019.1.FOCUS18645
   Tank A, 2018, SPINE, V43, P1739, DOI 10.1097/BRS.0000000000002714
   Xu M, 2004, J NEUROSCI, V24, P4576, DOI 10.1523/JNEUROSCI.5552-03.2004
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.073
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600069
PM 31870819
DA 2020-05-12
ER

PT J
AU Michel, P
   Finet, P
   Goffette, P
   Raftopoulos, C
AF Michel, Pauline
   Finet, Patrice
   Goffette, Pierre
   Raftopoulos, Christian
TI Bilateral Fornical Columns Infarction Secondary to an Arteriovenous
   Malformation Embolization
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; Embolization; Fornix; Infarction;
   Subcallosal artery
ID ANTERIOR COMMUNICATING ARTERY; SUBCALLOSAL ARTERY
AB BACKGROUND: Three group of perforation branches are described coming out from the anterior communicating artery (AcoA): the hypothalamic branches, chiasmatic branches, and subcallosal artery (ScA). Bilateral anterior fornix infarction with sudden anterograde amnesia after ScA ischemic stroke has been previously described. Although only a few cases are reported in the literature, ScA occlusion has been well described for both noniatrogenic and iatrogenic causes. Several cases of iatrogenic injuries have been reported after AcoA aneurysm clipping or, less frequently, after embolization.
   CASE DESCRIPTION: A 43-year-old man was admitted for a subarachnoid hemorrhage secondary to the rupture of a right high-flow anterior cerebral artery (ACA) aneurysm related to a right frontobasal arteriovenous malformation (AVM). The aneurysm was treated early by endovascular embolization. At discharge, the patient was Glasgow Outcome Scale score 1. Five months later, the AVM was treated endovascularly in 3 sessions. The last session was performed through a median branch of the right A2 segment of the ACA, allowing an 80% AVM exclusion. However, the patient woke up with anterograde memory impairment and confusion. Magnetic resonance imaging showed infarction of both anterior columns of the fornix. The clinical condition of the patient 3 years after stroke has improved.
   CONCLUSIONS: Bilateral anterior fornix infarction leading to amnestic syndrome is encountered in ScA stroke. We report a rare case of bilateral anterior fornix infarction secondary to an AVM embolization supplied by the ACA, not an anatomic region that provides blood supply of the anterior columns of the fornix.
C1 [Michel, Pauline; Finet, Patrice; Goffette, Pierre; Raftopoulos, Christian] Catholic Univ Louvain, Clin Univ St Luc, Dept Neurosurg, Brussels, Belgium.
   [Goffette, Pierre] Catholic Univ Louvain, Clin Univ St Luc, Dept Intervent Radiol, Brussels, Belgium.
RP Raftopoulos, C (reprint author), Catholic Univ Louvain, Clin Univ St Luc, Dept Neurosurg, Brussels, Belgium.
EM Raftopoulos.christian@hotmail.com
CR Baweja R, 2015, CAN J NEUROL SCI, V42, P205, DOI 10.1017/cjn.2015.27
   GADE A, 1982, SURG NEUROL, V18, P46, DOI 10.1016/0090-3019(82)90013-1
   Kannath SK, 2017, WORLD NEUROSURG, V107, DOI 10.1016/j.wneu.2017.07.052
   Matsushige T, 2016, EUR RADIOL, V26, P2908, DOI 10.1007/s00330-015-4117-1
   Meila D, 2015, NEURORADIOLOGY, V57, P41, DOI 10.1007/s00234-014-1438-8
   Mosimann Pascal John, 2012, Neurol Clin Pract, V2, P260, DOI 10.1212/CPJ.0b013e31826af1cf
   Mugikura S, 2014, AM J NEURORADIOL, V35, P2293, DOI 10.3174/ajnr.A4057
   Najera E, 2019, OPER NEUROSURG, V17, P79, DOI 10.1093/ons/opy276
   Nieuwenhuys R, 2008, HUMAN CENTRAL NERVOU
   Pardina-Vilella L, 2018, NEUROL SCI, V39, P1463, DOI 10.1007/s10072-018-3425-z
   Serizawa T, 1997, NEUROSURGERY, V40, P1211, DOI 10.1097/00006123-199706000-00019
   Turine G, 2016, ACTA NEUROL BELG, V116, P371, DOI 10.1007/s13760-015-0553-6
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.141
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600116
PM 31790837
DA 2020-05-12
ER

PT J
AU Monroe, CL
   Travers, S
   Woldu, HG
   Litofsky, NS
AF Monroe, Courtney L.
   Travers, Sarah
   Woldu, Henok G.
   Litofsky, N. Scott
TI Does Surveillance-Detected Disease Progression Yield Superior Patient
   Outcomes in High-Grade Glioma?
SO WORLD NEUROSURGERY
LA English
DT Article
DE Follow-up care; High-grade glioma; Recurrent glioblastoma; Surveillance
   imaging
ID CENTRAL-NERVOUS-SYSTEM; ADJUVANT TEMOZOLOMIDE; UNITED-STATES;
   HEALTH-CARE; CHILDREN; SURVIVAL; GLIOBLASTOMA; MANAGEMENT; RADIOTHERAPY;
   CONCOMITANT
AB BACKGROUND: Standard follow-up care for patients with high-grade glioma (HGG) involves routine surveillance imaging to detect disease progression, assess treatment response, and monitor clinical symptoms. Although logical in nature, evidence supporting this practice is limited. We hypothesize patients with tumor recurrence detected on routine surveillance imaging will experience superior outcomes relative to symptomatic detection, using measures of survival and postrecurrence neurologic function.
   METHODS: Adult patients receiving treatment for HGG at our institution from 2004 to 2018 were identified, and data including tumor characteristics, imaging results, neurologic status, and survival were extracted from the medical records of patients meeting inclusion criteria. All participants were followed for a minimum of 12 months, or for survival duration. Survival and neurologic function differences were assessed using log rank and 2-sample t tests with 2-sided 0.05 alpha level of significance.
   RESULTS: Of the 74 patients meeting inclusion criteria, 47 (63.5%) had recurrence detected via routine surveillance imaging, and 27 (36.5%) had symptomatic detection outside of the surveillance schedule. Neither median overall survival (14.8 months for surveillance and 15.7 months for symptomatic; P = 0.600) nor postrecurrence neurologic function (assessed by Karnofsky Performance Scale Index and Eastern Cooperative Oncology Group) differed between the surveillance and symptomatic detection groups (P = 0.699 and P = 0.908, respectively).
   CONCLUSIONS: Recurrence detection occurring via routine surveillance imaging did not yield superior patient outcomes relative to symptomatic detection occurring outside of the standard surveillance schedule in patients with HGG. Further evaluation of surveillance imaging and alternative follow-up methods for this patient population may be warranted.
C1 [Monroe, Courtney L.; Travers, Sarah; Litofsky, N. Scott] Univ Missouri, Sch Med, Div Neurol Surg, Columbia, MO 65211 USA.
   [Woldu, Henok G.] Univ Missouri, Sch Med, Biostat & Res Design, Columbia, MO 65211 USA.
RP Litofsky, NS (reprint author), Univ Missouri, Sch Med, Div Neurol Surg, Columbia, MO 65211 USA.
EM litofskyn@health.missouri.edu
FU University of Missouri Research Council Summer Research Fellowship; Head
   for the Cure Foundation
FX This work was supported by the University of Missouri Research Council
   Summer Research Fellowship and a Head for the Cure Foundation
   philanthropic gift.
CR Altwairgi AK, 2017, INT J HEALTH SCI-IJH, V11, P54
   Basch E, 2017, JAMA-J AM MED ASSOC, V318, P197, DOI 10.1001/jama.2017.7156
   Basch E, 2016, J CLIN ONCOL, V34, P557, DOI 10.1200/JCO.2015.63.0830
   Bauml JM, 2016, LUNG CANCER, V100, P110, DOI 10.1016/j.lungcan.2016.08.002
   Bouffet E, 1998, BRIT J CANCER, V77, P1321, DOI 10.1038/bjc.1998.220
   Brat DJ, 2018, ACTA NEUROPATHOL, V136, P805, DOI 10.1007/s00401-018-1913-0
   Catt Susan, 2012, CNS Oncol, V1, P39, DOI 10.2217/cns.12.8
   Ciric IS, 2013, WORLD NEUROSURG, V80, P691, DOI 10.1016/j.wneu.2012.10.021
   Denis F, 2019, JAMA-J AM MED ASSOC, V321, P306, DOI 10.1001/jama.2018.18085
   Dubrow R, 2013, NEURO-ONCOLOGY, V15, P1750, DOI 10.1093/neuonc/not122
   Guo Christina, 2019, Oncotarget, V10, P694, DOI 10.18632/oncotarget.26619
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Huang RY, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00033
   Jayamanne D, 2018, ANZ J SURG, V88, P196, DOI 10.1111/ans.14153
   Kaste Sue C, 2011, Pediatr Radiol, V41 Suppl 2, P505, DOI 10.1007/s00247-011-2108-1
   Keir ST, 2008, PSYCHO-ONCOL, V17, P621, DOI 10.1002/pon.1271
   Keir ST, 2006, SUPPORT CARE CANCER, V14, P1213, DOI 10.1007/s00520-006-0087-9
   Korones DN, 2001, J NEURO-ONCOL, V53, P33, DOI 10.1023/A:1011804404246
   Kotronoulas G, 2014, J CLIN ONCOL, V32, P1480, DOI 10.1200/JCO.2013.53.5948
   Kovanlikaya A, 2003, EUR J RADIOL, V47, P188, DOI 10.1016/S0720-048X(02)00213-9
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Lu VM, 2019, WORLD NEUROSURG, V127, P31, DOI 10.1016/j.wneu.2019.03.250
   Martinez-Garcia M, 2018, CLIN TRANSL ONCOL, V20, P22, DOI 10.1007/s12094-017-1763-6
   Mendel E, 1996, NEUROSURGERY, V38, P692, DOI 10.1227/00006123-199604000-00011
   National Comprehensive Cancer Network, 2011, NCCN CLIN PRACT GUID
   Olson JJ, 2014, J NEURO-ONCOL, V118, P557, DOI 10.1007/s11060-013-1339-4
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087
   Papanicolas I, 2018, JAMA-J AM MED ASSOC, V319, P1024, DOI 10.1001/jama.2018.1150
   Prelaj A, 2019, MOL CLIN ONCOL, V10, P49, DOI 10.3892/mco.2018.1745
   Rowe LS, 2018, J NEURO-ONCOL, V139, P145, DOI 10.1007/s11060-018-2855-z
   RUBLEE DA, 1994, HEALTH AFFAIR, V13, P113, DOI 10.1377/hlthaff.13.4.113
   Shaw DWW, 1997, J CLIN ONCOL, V15, P1811, DOI 10.1200/JCO.1997.15.5.1811
   Steinbok P, 1996, J NEUROSURG, V84, P726, DOI 10.3171/jns.1996.84.5.0726
   Stevens SP, 2018, J NEURO-ONCOL, V139, P507, DOI 10.1007/s11060-018-2901-x
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Thompson CA, 2010, ANN ONCOL, V21, P2262, DOI 10.1093/annonc/mdq215
   TORRES CF, 1994, NEW ENGL J MED, V330, P892, DOI 10.1056/NEJM199403313301303
   Udaka YT, 2013, J NEUROSURG-PEDIATR, V11, P119, DOI 10.3171/2012.10.PEDS12307
   Vassilyadi M, 2009, CAN J NEUROL SCI, V36, P707, DOI 10.1017/S0317167100008313
   Weller M, 2017, LANCET ONCOL, V18, pE315, DOI 10.1016/S1470-2045(17)30194-8
   Yalcin B, 2002, MED PEDIATR ONCOL, V38, P91, DOI 10.1002/mpo.1278.abs
   Zhu P, 2017, ONCOTARGET, V8, P44015, DOI 10.18632/oncotarget.17054
   Zikou A, 2018, CONTRAST MEDIA MOL I, DOI 10.1155/2018/6828396
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.001
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600047
PM 31821913
DA 2020-05-12
ER

PT J
AU Mulcahy, MJ
   Chaganti, J
   Al-Khawaja, D
AF Mulcahy, Michael J.
   Chaganti, Joga
   Al-Khawaja, Darweesh
TI The Case of the Disappearing Colloid Cyst
SO WORLD NEUROSURGERY
LA English
DT Article
DE Central nervous system cysts; Colloid cyst; Magnetic resonance imaging;
   Spontaneous regression; Third ventricle
ID 3RD-VENTRICLE
AB BACKGROUND: The natural history of colloid cysts is imperfectly understood, controversies remain in defining broad management strategies for incidental colloid cysts. The gradual asymptomatic regression of a colloid cyst has not been reported.
   CASE DESCRIPTION: We present a unique case demonstrating the clinically at, gradual regression of a colloid cyst over many years.
   CONCLUSIONS: Gradual regression of a colloid cyst is possible. The philosophical and practical implications of this case on the neurosurgeon's approach to managing patients with colloid cysts are discussed.
C1 [Mulcahy, Michael J.; Al-Khawaja, Darweesh] Nepean Publ Hosp, Dept Neurosurg, Sydney, NSW, Australia.
   [Chaganti, Joga] Nepean Publ Hosp, Dept Radiol, Sydney, NSW, Australia.
RP Mulcahy, MJ (reprint author), Nepean Publ Hosp, Dept Neurosurg, Sydney, NSW, Australia.
EM michael.mulcahy@health.nsw.gov.au
CR Annamalai G, 2008, Br J Radiol, V81, pe20
   Bakhtevari MH, 2015, WORLD NEUROSURG, V84, P1997, DOI 10.1016/j.wneu.2015.06.064
   Gbejuade H, 2011, BRIT J NEUROSURG, V25, P655, DOI 10.3109/02688697.2011.578766
   HO KL, 1992, ACTA NEUROPATHOL, V83, P605, DOI 10.1007/BF00299409
   Jeffree RL, 2001, J CLIN NEUROSCI, V8, P328, DOI 10.1054/jocn.2000.0800
   KONDZIOLKA D, 1989, J NEUROSURG, V71, P91, DOI 10.3171/jns.1989.71.1.0091
   LACH B, 1993, J NEUROSURG, V78, P101, DOI 10.3171/jns.1993.78.1.0101
   Mathiesen T, 1997, J NEUROSURG, V86, P5, DOI 10.3171/jns.1997.86.1.0005
   Motoyama Y, 2002, NEUROL MED-CHIR, V42, P228, DOI 10.2176/nmc.42.228
   O'Neill AH, 2018, J CLIN NEUROSCI, V53, P122, DOI 10.1016/j.jocn.2018.04.061
   Peeters SM, 2016, WORLD NEUROSURG, V90, DOI 10.1016/j.wneu.2016.02.116
   Westwick HJ, 2017, J NEUROSURG, V126, P1779, DOI 10.3171/2016.5.JNS153015
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.013
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600112
PM 31837498
DA 2020-05-12
ER

PT J
AU Nabil, M
   Chater, G
   Correia, P
   Wegener, S
   Baltsavias, G
AF Nabil, Mohamed
   Chater, George
   Correia, Pamela
   Wegener, Susanne
   Baltsavias, Gerasimos
TI Thrombectomy-Related Emboli: Direct Aspiration versus Stent Retriever
   Thrombectomy for Acute Ischemic Stroke: Our Experience and Literature
   Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Acute stroke; Aspiration; Emboli; Stent retrieval; Thrombectomy
ID 1ST PASS TECHNIQUE; INITIAL CLINICAL-EXPERIENCE; BASILAR
   ARTERY-OCCLUSION; BALLOON-GUIDING CATHETER; MECHANICAL THROMBECTOMY;
   ENDOVASCULAR TREATMENT; ADAPT TECHNIQUE; IN-VITRO; REVASCULARIZATION;
   THROMBUS
AB OBJECTIVE: Thrombectomy-related emboli (IRE) represent a potentially dangerous complication of thrombectomy procedures for acute ischemic stroke. The aim of this study was to compare the rate of TRE in aspiration thrombectomy (ASP) and stent retriever thrombectomy techniques.
   METHODS: We retrospectively compared clinical and radiologic outcomes of 2 groups of consecutive patients with stroke, ASP group and SRT group, with TRE rates as the primary study endpoint. Emboli were classified as either affected territory emboli or unaffected territory emboli (uTRE). Relevant literature was also reviewed.
   RESULTS: The ASP group had better rates of successful recanalization (97.1% vs. 77.1%, P = 0.02), mean number of passes per case (2.0 vs. 3.3, P = 0.04), and mean operative time (34.1 minutes vs. 84.8 minutes, P < 0.0001). Thrombectomy technique (ASP vs. SRT) did not appear to predict rates of either affected territory emboli (odds ratio [OR] = 1.24, 95% confidence interval [CI] 0.33-4.63, P = 0.74) or uTRE (OR = 5.67, 95% CI 0.60-53.42, P = 0.13). Longer operative time was linked to higher uTRE rates (OR = 1.03, 95% CI 1.01-1.05, P = 0.02). ASP technique (OR 0.1, 95% CI 0.01-0.88; P = 0.04) and shorter operative time (OR = 0.98, 95% CI 0.97-0.99, P = 0.03) were linked to better rates of successful recanalization.
   CONCLUSIONS: The applied thrombectomy technique (ASP vs. SRT) is not an independent predictor of TRE rates. Operative time tends to affect the rates of uTRE and successful recanalization. The ASP technique offers higher rates of successful recanalization in less operative time.
C1 [Nabil, Mohamed; Chater, George; Correia, Pamela; Baltsavias, Gerasimos] Univ Hosp Zurich, Clin Neurosci Ctr, Dept Neuroradiol, Zurich, Switzerland.
   [Wegener, Susanne] Univ Hosp Zurich, Clin Neurosci Ctr, Dept Neurol, Zurich, Switzerland.
   [Nabil, Mohamed] Menoufia Univ Hosp, Dept Neurosurg, Shebin Elkoum, Egypt.
   [Correia, Pamela] Lausanne Univ Hosp, Dept Neurol, Lausanne, Switzerland.
RP Nabil, M (reprint author), Univ Hosp Zurich, Clin Neurosci Ctr, Dept Neuroradiol, Zurich, Switzerland.; Nabil, M (reprint author), Menoufia Univ Hosp, Dept Neurosurg, Shebin Elkoum, Egypt.
EM mohamed.nabil@med.menofia.edu.eg
CR Almandoz JED, 2016, J NEUROINTERV SURG, V8, P1123, DOI 10.1136/neurintsurg-2015-012122
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Chueh JY, 2017, J NEUROINTERV SURG, V9, P183, DOI 10.1136/neurintsurg-2015-012256
   Comai A, 2015, RADIOL MED, V120, P655, DOI 10.1007/s11547-015-0501-9
   Costalat V, 2012, EUR J RADIOL, V81, P4075, DOI 10.1016/j.ejrad.2012.07.012
   Davalos A, 2012, STROKE, V43, P2699, DOI 10.1161/STROKEAHA.112.663328
   Eom YI, 2014, AM J NEURORADIOL, V35, P2354, DOI 10.3174/ajnr.A4045
   Gascou G, 2014, AM J NEURORADIOL, V35, P734, DOI 10.3174/ajnr.A3746
   Gerber JC, 2017, NEURORADIOLOGY, V59, P297, DOI 10.1007/s00234-017-1802-6
   Gralla J, 2008, AM J NEURORADIOL, V29, P247, DOI 10.3174/ajnr.A0790
   Gratz PP, 2015, AM J NEURORADIOL, V36, P1277, DOI 10.3174/ajnr.A4275
   Higashida RT, 2003, STROKE, V34, pE109, DOI 10.1161/01.STR.0000082721.62796.09
   Humphries W, 2015, J NEUROINTERV SURG, V7, P90, DOI 10.1136/neurintsurg-2013-010986
   Jankowitz B, 2015, J NEUROINTERV SURG, V7, P27, DOI 10.1136/neurintsurg-2013-011024
   Kabbasch C, 2016, INTERV NEURORADIOL, V22, P333, DOI 10.1177/1591019916632370
   Kang DH, 2011, AM J NEURORADIOL, V32, P283, DOI 10.3174/ajnr.A2299
   Kim YS, 2015, INTERV NEURORADIOL, V21, P694, DOI 10.1177/1591019915609167
   Klinger-Gratz PP, 2015, NEURORADIOLOGY, V57, P1045, DOI 10.1007/s00234-015-1583-8
   Kowoll A, 2016, J NEUROINTERV SURG, V8, P230, DOI 10.1136/neurintsurg-2014-011520
   Kurre W, 2013, AM J NEURORADIOL, V34, P1606, DOI 10.3174/ajnr.A3462
   Lapergue B, 2016, AM J NEURORADIOL, V37, P1860, DOI 10.3174/ajnr.A4840
   Lapergue B, 2017, JAMA-J AM MED ASSOC, V318, P443, DOI 10.1001/jama.2017.9644
   Liebig T, 2008, NEURORADIOLOGY, V50, P43, DOI 10.1007/s00234-007-0297-y
   Maegerlein C, 2017, CARDIOVASC INTER RAD, V40, P987, DOI 10.1007/s00270-017-1614-4
   Massari F, 2016, INTERV NEURORADIOL, V22, P325, DOI 10.1177/1591019916632369
   Matsumoto H, 2017, J NEUROINTERV SURG, V9, P1160, DOI 10.1136/neurintsurg-2016-012787
   Maus V, 2018, CLIN NEURORADIOL, V28, P327, DOI 10.1007/s00062-017-0566-z
   Mokin M, 2016, STROKE, V47, P782, DOI 10.1161/STROKEAHA.115.011598
   Mokin M, 2016, J NEUROINTERV SURG, V8, P413, DOI 10.1136/neurintsurg-2014-011617
   Mordasini P, 2012, NEURORADIOL J, V25, P243, DOI 10.1177/197140091202500216
   Nguyen TN, 2014, STROKE, V45, P141, DOI 10.1161/STROKEAHA.113.002407
   Oh JS, 2017, J KOREAN NEUROSURG S, V60, P155, DOI 10.3340/jkns.2016.0809.003
   Pereira VM, 2013, STROKE, V44, P2802, DOI 10.1161/STROKEAHA.113.001232
   Prothmann S, 2018, CLIN NEURORADIOL, V28, P217, DOI 10.1007/s00062-016-0555-7
   Romano DG, 2017, J NEUROINTERV SURG, V9, P6, DOI 10.1136/neurintsurg-2016-012298
   Stampfl S, 2017, J NEUROINTERV SURG, V9, P346, DOI 10.1136/neurintsurg-2015-012208
   Turk AS, 2014, J NEUROINTERV SURG, V6, P231, DOI 10.1136/neurintsurg-2013-010713
   Vargas J, 2017, J NEUROINTERV SURG, V9, P437, DOI 10.1136/neurintsurg-2015-012211
   Yuki I, 2012, AM J NEURORADIOL, V33, P643, DOI 10.3174/ajnr.A2842
NR 40
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.071
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600070
PM 31870820
DA 2020-05-12
ER

PT J
AU Nakahara, M
   Misaki, K
   Tsutsui, T
   Nakajima, R
   Yoshikawa, A
   Miyashita, K
   Uchiyama, N
   Nakada, M
AF Nakahara, Mitsutaka
   Misaki, Kouichi
   Tsutsui, Taishi
   Nakajima, Riho
   Yoshikawa, Akifumi
   Miyashita, Katsuyoshi
   Uchiyama, Naoyuki
   Nakada, Mitsutoshi
TI Effect of Unilateral Carotid Artery Stenting on Cognitive Function in
   Patients with Severe Bilateral Stenosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Acetazolamide; Bilateral carotid artery stenosis; Cerebral vascular
   reactivity; Cognitive function; Dementia; Hyperperfusion; Unilateral
   carotid artery stent
ID ENDARTERECTOMY; HYPERPERFUSION; RISK
AB CASE DESCRIPTION: An 82-year-old man with dementia, gait disturbance, a small cerebral infarction owing to severe bilateral carotid artery stenosis was successfully treated with carotid artery stenting (CAS). Preoperative cerebral vascular reactivity was reduced in the bilateral cerebral hemispheres. We performed CAS to treat right internal carotid artery stenosis. Following CAS, cerebral vascular reactivity showed an increase in the bilateral cerebral hemispheres. Memory, fluency, and attention also showed improvement.
   CONCLUSIONS: This case illustrates the potential benefit of single-stage CAS for cognitive function in severe bilateral carotid artery stenosis without hyperperfusion syndrome.
C1 [Nakahara, Mitsutaka; Misaki, Kouichi; Tsutsui, Taishi; Yoshikawa, Akifumi; Miyashita, Katsuyoshi; Uchiyama, Naoyuki; Nakada, Mitsutoshi] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Hlth Sci, Dept Neurosurg, Kanazawa, Ishikawa, Japan.
   [Nakajima, Riho] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Hlth Sci, Dept Occupat Therapy, Kanazawa, Ishikawa, Japan.
RP Misaki, K (reprint author), Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Hlth Sci, Dept Neurosurg, Kanazawa, Ishikawa, Japan.
EM misaki@med.kanazawa-u.ac.jp
OI Misaki, Kouichi/0000-0002-3752-2406; Miyashita,
   Katsuyoshi/0000-0001-5454-8766
CR Aida Y, 2018, WORLD NEUROSURG, V111, pE850, DOI 10.1016/j.wneu.2017.12.179
   Hosoda K, 2003, STROKE, V34, P1187, DOI 10.1161/01.STR.0000068781.31429.BE
   Hosoda K, 2001, STROKE, V32, P1567, DOI 10.1161/01.STR.32.7.1567
   Ishikawa M, 2016, J NEUROL SCI, V361, P43, DOI 10.1016/j.jns.2015.12.019
   Jackson DC, 2016, ARCH CLIN NEUROPSYCH, V31, P1, DOI 10.1093/arclin/acv082
   Misaki K, 2018, J NEURORADIOLOGY, V45, P362, DOI 10.1016/j.neurad.2018.02.008
   Misaki K, 2016, WORLD NEUROSURG, V90, P397, DOI 10.1016/j.wneu.2016.03.027
   Morgenstern LB, 1997, NEUROLOGY, V48, P911, DOI 10.1212/WNL.48.4.911
   Takaiwa A, 2013, ACTA NEUROCHIR, V155, P627, DOI 10.1007/s00701-013-1625-0
   Uchida K, 2015, NEUROL MED-CHIR, V55, P824, DOI 10.2176/nmc.oa.2015-0102
   Yadav JS, 2004, NEW ENGL J MED, V351, P1493, DOI 10.1056/NEJMoa040127
   Yoshimura S, 2009, NEUROSURGERY, V64, pS122, DOI 10.1227/01.NEU.0000334046.41985.BB
NR 12
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.068
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600131
PM 31863885
DA 2020-05-12
ER

PT J
AU Nassiri, F
   Hachem, LD
   Wang, JZ
   Badhiwala, JH
   Zadeh, G
   Gladstone, D
   Scales, DC
   Pirouzmand, F
AF Nassiri, Farshad
   Hachem, Laureen D.
   Wang, Justin Z.
   Badhiwala, Jetan H.
   Zadeh, Gelareh
   Gladstone, David
   Scales, Damon C.
   Pirouzmand, Farhad
TI Reinitiation of Anticoagulation After Surgical Evacuation of Subdural
   Hematomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Adult; Cerebral; Clinical neurosciences; Clotting platelets; Hemorrhage;
   Neurology; Neurosurgery; Stroke
ID INTRACEREBRAL HEMORRHAGE; ANTITHROMBOTIC AGENTS; ORAL ANTICOAGULATION;
   RESUMPTION; WARFARIN; NEUROSURGEONS; PROPHYLAXIS; MANAGEMENT
AB BACKGROUND: Chronic subdural hematoma (cSDH) is an increasingly common condition due to the growing use of anticoagulation. Currently, there remains a lack of evidence to guide the optimal timing of anticoagulant reinitiation for stroke prevention in atrial fibrillation after cSDH evacuation. We aimed to better understand the perceived risks of hemorrhagic and embolic complications along with current practice patterns on restarting anticoagulation after surgical evacuation of cSDH.
   METHODS: We conducted a survey of Canadian neurosurgeons and stroke neurologists using a novel self-administered questionnaire using clinical cases that included questions on clinical experience, practice setting, practice patterns, and perceptions on stroke/bleeding risk with anticoagulation reinitiation after cSDH evacuation. The instrument was evaluated for clinical sensibility by 5 neurosurgeons, neurologists, and intensivists.
   RESULTS: The response rate after 4 mailings was 49% for neurosurgeons (55/136) and 21% for stroke neurologists (26/122). Almost all participants would restart anticoagulation for stroke prevention in atrial fibrillation after cSDH evacuation (91.8% in low-risk patients, 98.6% in high-risk patients). Time to reinitiation of anticoagulation varied considerably, particularly for high-risk patients where 36% of participants would restart anticoagulation within 1 week of surgery, 44% between 1 and 4 weeks after surgery, and 19% after 4 weeks postoperatively. The perceived risk of stroke and SDH reaccumulation varied considerably among participants and was dependent on timing of anticoagulation reinitiation.
   CONCLUSIONS: There is considerable variation in current practice patterns and perceived risks of embolic and hemorrhagic complications with anticoagulation reinitiation after cSDH evacuation. These results demonstrate clinical equipoise that warrant further targeted investigation in large-scale randomized controlled trials.
C1 [Nassiri, Farshad; Hachem, Laureen D.; Wang, Justin Z.; Badhiwala, Jetan H.; Zadeh, Gelareh; Pirouzmand, Farhad] Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.
   [Zadeh, Gelareh] Toronto Western Hosp, Div Neurosurg, Toronto, ON, Canada.
   [Gladstone, David] Sunnybrook Hlth Sci Ctr, Div Neurol, Toronto, ON, Canada.
   [Scales, Damon C.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Interdept Div Crit Care Med, Toronto, ON, Canada.
   [Pirouzmand, Farhad] Sunnybrook Hlth Sci Ctr, Div Neurosurg, Toronto, ON, Canada.
RP Pirouzmand, F (reprint author), Univ Toronto, Dept Surg, Div Neurosurg, Toronto, ON, Canada.; Pirouzmand, F (reprint author), Sunnybrook Hlth Sci Ctr, Div Neurosurg, Toronto, ON, Canada.
EM Farhad.Pirouzmand@sunnybrook.ca
CR AlKherayf F, 2017, CLIN NEUROL NEUROSUR, V154, P23, DOI 10.1016/j.clineuro.2017.01.006
   Baechli H, 2004, NEUROSURG REV, V27, P263, DOI 10.1007/s10143-004-0337-6
   Balser D, 2015, J NEUROSURG, V123, P1209, DOI 10.3171/2014.9.JNS141550
   Bauer KA, 2013, HEMATOL-AM SOC HEMAT, P464, DOI 10.1182/asheducation-2013.1.464
   Chari A, 2014, BRIT J NEUROSURG, V28, P2, DOI 10.3109/02688697.2013.812184
   Chatterjee S, 2013, JAMA NEUROL, V70, P1486, DOI 10.1001/jamaneurol.2013.4021
   Connolly S, 2006, LANCET, V367, P1903, DOI 10.1016/s0140-6736(06)68845-4
   Cuker A, 2019, AM J HEMATOL, V94, P697, DOI 10.1002/ajh.25475
   Datar M, 2019, AM J HEALTH-SYST PH, V76, P275, DOI 10.1093/ajhp/zxy032
   Ducruet AF, 2012, NEUROSURG REV, V35, P155, DOI 10.1007/s10143-011-0349-y
   Foreman PM, 2018, WORLD NEUROSURG, V116, pE649, DOI 10.1016/j.wneu.2018.05.064
   Frontera JA, 2016, CRIT CARE MED, V44, P2251, DOI 10.1097/CCM.0000000000002057
   Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039
   Guha D, 2016, J NEUROSURG, V124, P750, DOI 10.3171/2015.2.JNS141889
   Hagii J, 2014, STROKE, V45, P2805, DOI 10.1161/STROKEAHA.114.006661
   Hohnloser SH, 2012, EUR HEART J, V33, P1864, DOI 10.1093/eurheartj/ehs032
   Inohara T, 2018, JAMA-J AM MED ASSOC, V319, P463, DOI 10.1001/jama.2017.21917
   Knopman J, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.3737
   Lamb LC, 2018, AM SURGEON, V84, P1010
   Law SWY, 2018, J AM COLL CARDIOL, V72, P271, DOI 10.1016/j.jacc.2018.04.066
   Licci M, 2018, CRIT CARE MED, V46, pE26, DOI 10.1097/CCM.0000000000002804
   McAbee JH, 2015, J NEUROSURG, V123, P161, DOI 10.3171/2014.12.JNS141348
   Mehta V, 2018, J CLIN NEUROSCI, V50, P7, DOI 10.1016/j.jocn.2018.01.050
   Miranda LB, 2011, J NEUROSURG, V114, P72, DOI 10.3171/2010.8.JNS10298
   Nakaguchi H, 2001, J NEUROSURG, V95, P256, DOI 10.3171/jns.2001.95.2.0256
   Nathan S, 2017, NEUROLOGY, V88, P1889, DOI 10.1212/WNL.0000000000003918
   Phan K, 2018, WORLD NEUROSURG, V109, pE792, DOI 10.1016/j.wneu.2017.10.091
   Scales DC, 2009, J CRIT CARE, V24, P176, DOI 10.1016/j.jcrc.2009.03.010
   Scotti Pasquale, 2019, J Neurosurg, P1, DOI 10.3171/2019.4.JNS19252
   Xian Y, 2019, JAMA NEUROL, V76, P1192, DOI 10.1001/jamaneurol.2019.2099
   Yang WY, 2017, NEUROSURG CLIN N AM, V28, P205, DOI 10.1016/j.nec.2016.11.002
   Yeon JY, 2012, J NEUROTRAUM, V29, P1334, DOI 10.1089/neu.2011.2074
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.080
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600073
PM 31874290
DA 2020-05-12
ER

PT J
AU Newman, S
   Boulter, JH
   Malcolm, JG
   Pradilla, I
   Pradilla, G
AF Newman, Sarah
   Boulter, Jason H.
   Malcolm, James G.
   Pradilla, Ivan
   Pradilla, Gustavo
TI Outcomes in Patients with Moyamoya Syndrome and Sickle Cell Disease: A
   Systematic Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Chronic transfusion therapy; Moyamoya syndrome; Revascularization;
   Sickle cell disease; Stroke
ID PEDIATRIC-PATIENTS; REVASCULARIZATION; CHILDREN; ANEMIA
AB BACKGROUND: Moyamoya syndrome, a progressive, idiopathic stenosis of the internal carotid arteries, results in increased risk for both ischemic and hemorrhagic strokes. Revascularization procedures have been shown in small studies to be both safe and efficacious for these patients; however, randomized controlled trials are lacking. The goal of this systematic review is to organize the literature evaluating surgical intervention versus conservative medical management.
   METHODS: A systematic review was performed including studies with 3 or more participants with moyamoya syndrome in the setting of sickle cell disease and a measured outcome after either medical or surgical intervention. Relevant studies were identified using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses criteria and a set of predetermined key words.
   RESULTS: Sixty-one articles were identified with 6 articles ultimately included in this review (N = 122). Of the patients, 73 (59.8%) were revascularized surgically (all indirect procedures), whereas 49 (40.2%) remained on chronic transfusion therapy. Of the patients that underwent indirect revascularization surgery, a total of 1 perioperative (1.4%) and 4 postoperative strokes (5.5%) were reported over 44 months (1 stroke per 53.3 patient-years). In comparison, an average of 46.5% of patients who were receiving chronic transfusions had major events (stroke or transient ischemic attack) while undergoing therapy (1 stroke per 13.65 patient-years, P = 0.00215).
   CONCLUSIONS: We present a large systematic review of the literature regarding outcomes of surgical and medical management for patients with moyamoya syndrome and sickle cell disease. The findings redemonstrate the efficacy and safety of surgical revascularization, and advocate for earlier discussion around surgical intervention.
C1 [Newman, Sarah] Emory Univ, Sch Med, Atlanta, GA 30303 USA.
   [Boulter, Jason H.] Walter Reed Natl Mil Med Ctr, Div Neurosurg, Bethesda, MD USA.
   [Malcolm, James G.; Pradilla, Gustavo] Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA.
   [Pradilla, Ivan] Univ Rosario, Escuela Med & Ciencias Salud, Neurosci Res Grp NeURos, Bogota, DC, Colombia.
RP Newman, S (reprint author), Emory Univ, Sch Med, Atlanta, GA 30303 USA.
EM Sarah.Newman2@Emory.edu
OI Pradilla, Gustavo/0000-0002-3661-3269
CR Bersano A, 2016, CEREBROVASC DIS, V41, P105, DOI 10.1159/000442298
   Dobson SR, 2002, BLOOD, V99, P3144, DOI 10.1182/blood.V99.9.3144
   Fryer RH, 2003, PEDIATR NEUROL, V29, P124, DOI 10.1016/S0887-8994(03)00047-X
   Griessenauer CJ, 2015, J NEUROSURG-PEDIATR, V16, P64, DOI 10.3171/2014.12.PEDS14522
   Hall EM, 2016, PEDIATR BLOOD CANCER, V63, P1431, DOI 10.1002/pbc.26022
   Hankinson TC, 2008, J NEUROSURG-PEDIATR, V1, P211, DOI 10.3171/PED/2008/1/3/211
   Hosoda Y, 1997, CLIN NEUROL NEUROSUR, V99, pS203, DOI 10.1016/s0303-8467(97)00044-9
   Houkin K, 2012, NEUROL MED-CHIR, V52, P267, DOI 10.2176/nmc.52.267
   Hulbert ML, 2011, BLOOD, V117, P772, DOI 10.1182/blood-2010-01-261123
   Kennedy BC, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.10.FOCUS13405
   Kim JM, 2013, NEUROLOGY, V80, P775, DOI 10.1212/WNL.0b013e3182825162
   Kronenburg A, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-013-0423-7
   Smith ER, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.01.FOCUS08307
   Takekawa Y, 2004, NEUROPATHOLOGY, V24, P236, DOI 10.1111/j.1440-1789.2004.00550.x
   Yang WY, 2017, J NEUROSURG-PEDIATR, V20, P232, DOI 10.3171/2017.1.PEDS16576
NR 15
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.137
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600125
PM 31790841
DA 2020-05-12
ER

PT J
AU Nica, DA
   Moisa, HA
   Mohan, A
   Ciurea, AV
AF Nica, Dan Aurel
   Moisa, Horatiu Alexandru
   Mohan, Aurel
   Ciurea, Alexandru Vlad
TI Leonardo Gigli and the Gigli Saw - Gigli Fiedivivus
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gigli saw; History; Leonardo Gigli; Neurosurgery
AB Just like Raymond M. Peardon Donaghy and Gazi Yasargil changed modern neurosurgery by introducing the surgical microscope into the operating room, so did Leonardo Gigli by developing and using for the first time a tool that allowed faster, easier, and safer opening of the skull. The invention of the simple but brilliant Gigli saw represented a game changer for practitioners of neurosurgery worldwide.
   Gigli (1863- 1908) was an Italian surgeon and obstetrician remembered among others for describing his operation-the lateralized version of Severin Pineau's pubiotomy for safe delivery in cases of maternal pelvic deformity-and for designing the Gigli saw, a simple yet brilliant wire saw, versatile enough to be used as both a tool of war and a surgical instrument in the fields of gynecology, orthopedics, surgery, and neurosurgery.
   The authors pay tribute to Gigli and his contribution at 125 years since the first written mention of his innovative instrument.
C1 [Nica, Dan Aurel; Moisa, Horatiu Alexandru] Grigore Alexandrescu Emergency Childrens Hosp, Dept Pediat Neurosurg, Bucharest, Romania.
   [Moisa, Horatiu Alexandru; Ciurea, Alexandru Vlad] Carol Davila Univ, Dept Neurosurg, Sch Med, Bucharest, Romania.
   [Ciurea, Alexandru Vlad] Sanador Med Ctr Hosp, Dept Neurosurg, Bucharest, Romania.
   [Mohan, Aurel] Bihor Cty Emergency Hosp, Oradea, Romania.
RP Moisa, HA (reprint author), Grigore Alexandrescu Emergency Childrens Hosp, Dept Pediat Neurosurg, Bucharest, Romania.
EM horatiumoisa@yahoo.com
CR BRUNORI A, 1995, J NEUROSURG, V82, P1086, DOI 10.3171/jns.1995.82.6.1086
   Chatelin CT, 1918, WOUNDS SKULL BRAIN
   Chipault A., 1894, ETUDES CHIRURG MEDUL
   Fox JL, 1989, PTERIONAL PERSPECTIV, P3
   Gigli L, 1898, CENTRALBL CHIR, V25, P425
   Gigli L, 1897, CENTRALBL CHIR, V24, P785
   Gigli L, 1894, ZENTRALB CHIR, V21, P409
   Greenblatt S, 1997, HIST NEUROSURGERY
   Jandial R, 2011, CORE TECHNIQUES NEUR, P11
   Obalinski A, 1897, ZBL CHIR, V24, P857
   Ozek MM, 2015, POSTERIOR FOSSA TUMO, P45
   Patellani S., 1908, GINECOLOGIA MODERNA, V1, P225
   Restrepo CEN, 2006, NEUR MED GEN SPAN, P44
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.157
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600100
PM 31809893
DA 2020-05-12
ER

PT J
AU Nikoubashman, O
   Tabrizi, CM
   Munstermann, M
   Schubert, GA
   Reich, A
   Wiesmann, M
   Muller, M
AF Nikoubashman, Omid
   Tabrizi, Carolin Molavi
   Muenstermann, Malte
   Schubert, Gerrit Alexander
   Reich, Arno
   Wiesmann, Martin
   Mueller, Marguerite
TI Findings and Prognostic Value of Contrast-Enhanced Early Magnetic
   Resonance Imaging After Coil Embolization of Cerebral Aneurysms
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Coiling; Contrast; MRI; Rupture
ID WALL ENHANCEMENT
AB BACKGROUND: Recent studies imply an association between aneurysm wall enhancement (AWE) on contrast-enhanced magnetic resonance imaging and aneurysm rupture. We investigated the prevalence and clinical significance of AWE and enhancement within the aneurysm (inner enhancement [IE]) in coiled aneurysms.
   METHODS: We assessed the frequency of AWE and IE after coil embolization on postinterventional magnetic resonance imaging (<6 weeks) in 30 consecutive patients with 33 aneurysms and elucidated the association between enhancement and subsequent aneurysm recurrence or hemorrhage.
   RESULTS: AWE and IE occurred in 97% and 36% of cases, respectively. There was no rehemorrhage, and there was no significant association between subsequent reperfusion and AWE (P = 0.200) or IE (P = 0.148) during a median follow-up period of 19 months. The greatest share of IE (8 of 12 aneurysms) was found in incompletely coiled aneurysms with small remnants (P = 0.001).
   CONCLUSIONS: AWE after coil embolization cannot be used for recurrence risk stratification owing to its high prevalence. IE is likely to represent contrast inflow in the coiled aneurysm.
C1 [Nikoubashman, Omid; Tabrizi, Carolin Molavi; Muenstermann, Malte; Wiesmann, Martin; Mueller, Marguerite] Univ Hosp RWTH Aachen, Dept Neuroradiol, Aachen, Germany.
   [Reich, Arno] Univ Hosp RWTH Aachen, Dept Neurol, Aachen, Germany.
   [Schubert, Gerrit Alexander] Univ Hosp RWTH Aachen, Dept Neurosurg, Aachen, Germany.
RP Nikoubashman, O (reprint author), Univ Hosp RWTH Aachen, Dept Neuroradiol, Aachen, Germany.
EM onikoubashman@ukaachen.de
CR Backes D, 2018, NEUROSURGERY, V83, P719, DOI 10.1093/neuros/nyx487
   Edjlali M, 2014, STROKE, V45, P3704, DOI 10.1161/STROKEAHA.114.006626
   Hu P, 2016, NEURORADIOLOGY, V58, P979, DOI 10.1007/s00234-016-1729-3
   Kataoka K, 1999, STROKE, V30, P1396, DOI 10.1161/01.STR.30.7.1396
   Lv N, 2019, NEUROSURGERY, V84, pE385, DOI 10.1093/neuros/nyy310
   Mascitelli JR, 2015, J NEUROINTERV SURG, V7, P496, DOI 10.1136/neurintsurg-2014-011258
   Matouk CC, 2013, NEUROSURGERY, V72, P492, DOI 10.1227/NEU.0b013e31827d1012
   Nagahata S, 2016, CLIN NEURORADIOL, V26, P277, DOI 10.1007/s00062-014-0353-z
   Peschillo S, 2017, OPER NEUROSURG, V13, P492, DOI 10.1093/ons/opx032
   Szikora I, 2006, AM J NEURORADIOL, V27, P283
   Tulamo R, 2010, J NEUROINTERV SURG, V2, P120, DOI 10.1136/jnis.2009.002055
   TURKMANI A, 2015, NEUROL-NEUROIMMUNOL, V2, P102
   Wang GX, 2018, J NEUROINTERV SURG, V10, P566, DOI 10.1136/neurintsurg-2017-013308
NR 13
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.173
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600043
PM 31816454
DA 2020-05-12
ER

PT J
AU Obled, L
   Peciu-Florianu, I
   Perbet, R
   Vannod-Michel, Q
   Reyns, N
AF Obled, Louis
   Peciu-Florianu, Iulia
   Perbet, Romain
   Vannod-Michel, Quentin
   Reyns, Nicolas
TI Rare Case of Giant Supratentorial Dermoid Cyst
SO WORLD NEUROSURGERY
LA English
DT Article
DE Convexity; Dermoid cyst; Supratentorial
AB BACKGROUND: Dermoid cysts are benign, congenital rare lesions, frequently occurring in or near the midline. Rare localizations and variable radiologic findings have been described but remain exceptional.
   CASE DESCRIPTION: The authors present a rare case of a giant tempor-oparietal dermoid cyst in an adult female who was paucisymptomatic. No sign of rupture was identified, with a clinical presentation suggesting a slow-growing lesion. Gross total excision was performed with a favorable clinical and radiologic outcome.
   CONCLUSIONS: Rare localizations previously published in the literature are discussed for dermoid cysts. To our best knowledge, this is the first giant dermoid cyst presenting with this localization.
C1 [Obled, Louis; Peciu-Florianu, Iulia; Reyns, Nicolas] CHU Lille, Serv Neurosurg, Dept Neurosci, Lille, France.
   [Perbet, Romain] CHU Lille, Serv Pathol Anat, Pathol Inst, Lille, France.
   [Vannod-Michel, Quentin] CHU Lille, Serv Neuroradiol, Dept Radiol, Lille, France.
RP Peciu-Florianu, I (reprint author), CHU Lille, Serv Neurosurg, Dept Neurosci, Lille, France.
EM Iuliapeciu_florianu@yahoo.com
CR Anand D, 2014, J CLIN DIAGN RES, V8, pRD01, DOI 10.7860/JCDR/2014/8917.4789
   Chung LK, 2018, J NEUROL SURG PART B, V79, P139, DOI 10.1055/s-0037-1604332
   El-Bahy K, 2006, ACTA NEUROCHIR, V148, P457, DOI 10.1007/s00701-005-0722-0
   Esquenazi Yoshua, 2013, Surg Neurol Int, V4, P80, DOI 10.4103/2152-7806.113357
   Garces J, 2016, WORLD NEUROSURG, V93, DOI 10.1016/j.wneu.2016.05.037
   Jackow J, 2018, POL J RADIOL, V83, pE465, DOI 10.5114/pjr.2018.80206
   Khalid S, 2017, J NEUROSURG-PEDIATR, V20, P30, DOI 10.3171/2017.2.PEDS16701
   Kim IY, 2008, J CLIN NEUROSCI, V15, P469, DOI 10.1016/j.jocn.2006.10.028
   Liu JK, 2008, NEUROSURGERY, V62, P377, DOI 10.1227/01.neu.0000316004.88517.29
   Orakcioglu B, 2008, ACTA NEUROCHIR, V150, P1227, DOI 10.1007/s00701-008-0152-x
   Osborn AG, 2006, RADIOLOGY, V239, P650, DOI 10.1148/radiol.2393050823
   Park SK, 2012, CLIN NEUROL NEUROSUR, V114, P421, DOI 10.1016/j.clineuro.2011.11.006
   Shashidhar A, 2019, J CLIN NEUROSCI, V67, P172, DOI 10.1016/j.jocn.2019.04.025
   Stendel R, 2002, SURG NEUROL, V57, P391, DOI 10.1016/S0090-3019(02)00723-1
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.007
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600107
PM 31821914
DA 2020-05-12
ER

PT J
AU Odeh, K
   Rosinski, A
   Nguyen, J
   Modak, A
   Leasure, J
   Siebert, S
   Kondrashov, D
AF Odeh, Khalid
   Rosinski, Alexander
   Nguyen, Jacqueline
   Modak, Ashin
   Leasure, Jeremi
   Siebert, Scott
   Kondrashov, Dimitriy
TI Anterior Lumbar Interbody Fusion May Provide Superior Decompression of
   the Foraminal Space Compared with Direct Foraminotomy: Biomechanical
   Cadaveric Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Decompression; Extension; Foraminotomy; Lumbar interbody fusion (ALIF);
   Lumbar spine anterior
ID SAGITTAL ALIGNMENT; SPINAL STABILITY; FACETECTOMY; DISTRACTION; FORAMEN
AB OBJECTIVE: The objective of this cadaveric biomechanical study was to compare the area of the foraminal space during motion in the intact condition, after direct decompression via foraminotomy, and after indirect decompression via anterior lumbar interbody spacer insertion.
   METHODS: Eight (8) L5-S1 cadaver specimens were used for testing. Each specimen was tested in the intact state, after posterior foraminotomy, and after standalone anterior lumbar interbody fusion (ALIF). Each specimen was 3-dimensional imaged under neutral loading, flexion, and extension. The 3-dimensional images were analyzed for changes in the foraminal area under each loading scenario. A repeat-measures design was used. Outcome measures from testing included the frequency in which an increase in cross-sectional area was observed, as well as the percent increase of the foraminal area for each surgical group and loading direction.
   RESULTS: Direct foraminotomy and ALIF maintained the foraminal space during initial distraction under no loading with areas 99.7% and 96.5% of the native foraminal area, respectively (P = 0.955 and P = 0.455). Direct foraminotomy increased the foraminal area significantly during flexion to 112.2% of the area before motion (P = 0.008) while ALIF did not. Direct foraminotomy significantly decreased the foraminal area during extension to 89.2% of the area before motion (P = 0.006). ALIF, however, maintained its initial distraction during extension with 98.2% of the area before motion (P = 0.808).
   CONCLUSIONS: ALIF maintains the foraminal area in extension while direct posterior foraminotomy does not.
C1 [Odeh, Khalid; Nguyen, Jacqueline; Siebert, Scott; Kondrashov, Dimitriy] San Francisco Orthopaed Residency Program, San Francisco, CA USA.
   [Rosinski, Alexander; Modak, Ashin; Leasure, Jeremi] Taylor Collaborat, San Francisco, CA 94117 USA.
   [Kondrashov, Dimitriy] St Marys Spine Ctr, San Francisco, CA USA.
RP Leasure, J (reprint author), Taylor Collaborat, San Francisco, CA 94117 USA.
EM jleasure@taylorcollaboration.org
CR ABUMI K, 1990, SPINE, V15, P1142, DOI 10.1097/00007632-199011010-00011
   Afathi M, 2017, ORTHOP TRAUMATOL-SUR, V103, P1245, DOI 10.1016/j.otsr.2017.09.014
   Chang SB, 2006, SPINE, V31, P1163, DOI 10.1097/01.brs.0000216431.69359.91
   CHEN DY, 1995, SPINE, V20, P74, DOI 10.1097/00007632-199501000-00014
   Choi KC, 2011, ACTA NEUROCHIR, V153, P567, DOI 10.1007/s00701-010-0876-2
   CRAWFORD NR, 1995, SPINE, V20, P2097, DOI 10.1097/00007632-199510000-00005
   Fredericson M, 2001, Spine J, V1, P10, DOI 10.1016/S1529-9430(01)00014-6
   Fujiwara A, 2001, SPINE, V26, P876, DOI 10.1097/00007632-200104150-00010
   Hsieh PC, 2007, J NEUROSURG-SPINE, V7, P379, DOI 10.3171/SPI-07/10/379
   Jenis L G, 2001, Am J Orthop (Belle Mead NJ), V30, P205
   Kim SY, 2008, J SPINAL DISORD TECH, V21, P33, DOI 10.1097/BSD.0b013e3180577223
   Kuchta J, 2009, EUR SPINE J, V18, P823, DOI 10.1007/s00586-009-0967-z
   Lee KK, 2004, SPINE, V29, P1624, DOI 10.1097/01.BRS.0000132650.24437.15
   Marawar S, 2014, INT J SPINE SURG, V8, DOI 10.14444/1002
   Nguyen J, 2017, J NEUROSURG-SPINE, P1
   Okawa A, 1996, J SPINAL DISORD, V9, P518
   Oliveira L, 2010, SPINE, V35, pS331, DOI 10.1097/BRS.0b013e3182022db0
   PINTAR FA, 1992, SPINE, V17, P804, DOI 10.1097/00007632-199207000-00013
   Richards JC, 2005, SPINE, V30, P744, DOI 10.1097/01.brs.0000157483.28505.e3
   Rothrock RJ, 2018, WORLD NEUROSURG, V118, P21, DOI 10.1016/j.wneu.2018.06.216
   SCHLEGEL JD, 1994, SPINE, V19, P2041, DOI 10.1097/00007632-199409150-00004
   Schmid MR, 1999, AM J ROENTGENOL, V172, P1095, DOI 10.2214/ajr.172.4.10587155
   Singh V, 2013, SPINE J, V13, P1080, DOI 10.1016/j.spinee.2013.03.041
   Wang M, 2007, SPINE J, V7, P563, DOI 10.1016/j.spinee.2006.10.019
   Watanabe K, 2011, J SPINAL DISORD TECH, V24, P137, DOI 10.1097/BSD.0b013e3181e1cd99
   Watkins RG, 2014, J SPINAL DISORD TECH, V27, P253, DOI 10.1097/BSD.0b013e31828a8447
NR 26
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.139
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600009
PM 31678445
DA 2020-05-12
ER

PT J
AU Ogul, H
AF Ogul, Hayri
TI Double Ophthalmic Arteries Arising from the Internal Carotid Artery and
   the Accessory Meningeal Artery: A Case Report of a New Anatomic
   Variation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Accessory meningeal artery; Magnetic resonance angiography; Ophthalmic
   artery; Variant origin
ID UNUSUAL ORIGIN
AB BACKGROUND: Variant origin of the ophthalmic artery (OA) is uncommon. The majority of variant origins are from the middle meningeal artery and from the infraclinoid segment of the internal carotid artery. An OA arising from the accessory meningeal artery is an extremely rare vascular variation that has not been described previously in the English literature.
   CASE DESCRIPTION: We report the first case of double origin of the OA from the supraclinoid segment of the internal carotid artery and from the accessory meningeal artery branch of the maxillary artery. A 33-year-old woman was referred to our clinic with suspicion of a middle cerebral artery aneurysm. She had nonspecific neurologic symptoms. The patient underwent cerebral magnetic resonance imaging and magnetic resonance angiography.
   CONCLUSIONS: Being aware of variant origin of the OA from the accessory meningeal artery is very important for transarterial chemoembolization in the external carotid artery territory. Reconstructed images from magnetic resonance angiography are very useful to reveal the variant origin of the OA.
C1 [Ogul, Hayri] Ataturk Univ, Med Fac, Dept Radiol, Erzurum, Turkey.
RP Ogul, H (reprint author), Ataturk Univ, Med Fac, Dept Radiol, Erzurum, Turkey.
EM drhogul@gmail.com
OI Ogul, Hayri/0000-0001-5989-3729
CR Hannequin P, 2013, SURG RADIOL ANAT, V35, P269, DOI 10.1007/s00276-012-1028-6
   Hayreh S S, 1962, Br J Ophthalmol, V46, P65, DOI 10.1136/bjo.46.2.65
   Kam CK, 2003, INTERV NEURORADIOL, V9, P383, DOI 10.1177/159101990300900409
   Lasjaunias P, 2001, SURG NEUROANGIOGRAPH, V1, P15
   Liu QL, 2001, NEUROSURGERY, V49, P401, DOI 10.1097/00006123-200108000-00025
   Louw L, 2015, CLIN ANAT, V28, P576, DOI 10.1002/ca.22470
   Morandi X, 1998, SURG RADIOL ANAT, V20, P69, DOI 10.1007/s00276-998-0069-3
   OGAWA T, 1990, NEURORADIOLOGY, V32, P508, DOI 10.1007/BF02426466
   Ogul H, 2016, J CRANIOFAC SURG, V27, pE336, DOI 10.1097/SCS.0000000000002482
   Rivera R, 2015, SURG RADIOL ANAT, V37, P399, DOI 10.1007/s00276-014-1327-1
   Sade B, 2004, AM J NEURORADIOL, V25, P1730
   Tanoue S, 2013, RADIOGRAPHICS, V33, pE209, DOI 10.1148/rg.337125173
   Tsutsumi S, 2012, SURG RADIOL ANAT, V34, P833, DOI 10.1007/s00276-012-0965-4
   Uchino A, 2013, SURG RADIOL ANAT, V35, P775, DOI 10.1007/s00276-013-1085-5
   Uchino A, 2013, SURG RADIOL ANAT, V35, P173, DOI 10.1007/s00276-012-1005-0
   Watanabe A, 1996, NEURORADIOLOGY, V38, P806, DOI 10.1007/s002340050353
   WEINBERG PE, 1981, ARCH NEUROL-CHICAGO, V38, P315, DOI 10.1001/archneur.1981.00510050081016
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.016
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600113
PM 31837499
DA 2020-05-12
ER

PT J
AU Okano, I
   Carlson, BB
   Chiapparelli, E
   Salzmann, SN
   Winter, F
   Shirahata, T
   Miller, CO
   Rentenberge, C
   Shue, J
   Carrino, JA
   Sama, AA
   Cammisa, FP
   Girardi, FP
   Hughes, AP
AF Okano, Ichiro
   Carlson, Brandon B.
   Chiapparelli, Erika
   Salzmann, Stephan N.
   Winter, Fabian
   Shirahata, Toshiyuki
   Miller, Courtney Ortiz
   Rentenberge, Colleen
   Shue, Jennifer
   Carrino, John A.
   Sama, Andrew A.
   Cammisa, Frank P.
   Girardi, Federico P.
   Hughes, Alexander P.
TI Local Mechanical Environment and Spinal Trabecular Volumetric Bone
   Mineral Density Measured by Quantitative Computed Tomography: A Study on
   Lumbar Lordosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Bone mineral density; Deformity; Lumbar lordosis; Quantitative computed
   tomography; Spinopelvic alignment
ID INTERVERTEBRAL DISC DEGENERATION; THORACIC KYPHOSIS; VERTEBRAL BODY;
   ALIGNMENT; OSTEOPOROSIS; TERIPARATIDE; CURVATURE; STRENGTH; FAILURES;
   SURGERY
AB OBJECTIVE: There have been some reports on the association between spinal balance parameters and regional bone mineral density (BMD), but the results are controversial. The purpose of this study is to evaluate the relationship between spinopelvic parameters and regional volumetric BMDs (vBMDs) measured by quantitative computed tomography (QCT) in the lumbosacral region of patients undergoing lumbar fusion surgery.
   METHODS: The data of consecutive patients undergoing posterior lumbar spinal fusion with preoperative computed tomography was reviewed. QCT measurements were conducted in L1-S1 vertebral trabecular bone. The associations between spinopelvic sagittal parameters and vBMDs were evaluated. Multivariate analyses adjusted with age, gender, race, and body mass index were conducted with vBMD as the response variable.
   RESULTS: A total of 144 patients were included in the final analyses. Mean age (+/- standard deviation) was 65.4 +/- 11.8 years. Mean vBMD in L1 (+/- standard deviation) was 118.3 +/- 37.4 mg/cm(3) . After adjusting by cofactors, lumbar lordosis was negatively associated with vBMDs in all levels from L1 to L5 (% regression coefficients and adjusted R-2 values: L1, -0.438, 0.268; L2, -0.556, 0.296; L3, -0.608, 0.362; L4, -0.554, 0.228; L5, -0.424, 0.194), but not in S1. Sacral slope was negatively associated with vBMD only at L4 (% coefficient, -0.588; R-2 , 0.208). Other parameters were not significantly associated with vBMDs at any levels.
   CONCLUSIONS: Higher lumbar lordosis was associated with lower vBMDs in all lumbar spine levels. Our results suggest that BMD is affected not only by metabolic factors but also by the mechanical environment. Further longitudinal studies are needed to elucidate this effect of vBMD on clinical outcomes.
C1 [Okano, Ichiro; Carlson, Brandon B.; Chiapparelli, Erika; Salzmann, Stephan N.; Winter, Fabian; Shirahata, Toshiyuki; Miller, Courtney Ortiz; Rentenberge, Colleen; Shue, Jennifer; Sama, Andrew A.; Cammisa, Frank P.; Girardi, Federico P.; Hughes, Alexander P.] Hosp Special Surg, Spine Care Serv, 535 E 70th St, New York, NY 10021 USA.
   [Carlson, Brandon B.] Univ Kansas, Comprehens Spine Ctr, Kansas City, KS USA.
   [Shirahata, Toshiyuki] Showa Univ, Dept Orthopaed Surg, Sch Med, Tokyo, Japan.
   [Carrino, John A.] Hosp Special Surg, Dept Radiol & Imaging, 535 E 70th St, New York, NY 10021 USA.
RP Hughes, AP (reprint author), Hosp Special Surg, Spine Care Serv, 535 E 70th St, New York, NY 10021 USA.
EM hughesa@hss.edu
OI Winter, Fabian/0000-0003-0695-7877; Okano, Ichiro/0000-0003-1741-5176
CR American College of Radiologists, 2018, ACR SPR SSR PRACT PA
   Bousson V, 2006, OSTEOPOROSIS INT, V17, P855, DOI 10.1007/s00198-006-0074-5
   Chen JH, 2010, J BIOMECH, V43, P108, DOI 10.1016/j.jbiomech.2009.09.016
   Dai J, 2015, EUR SPINE J, V24, P737, DOI 10.1007/s00586-014-3637-8
   EDMONDSTON SJ, 1994, BRIT J RADIOL, V67, P969, DOI 10.1259/0007-1285-67-802-969
   Fujita Nobuyuki, 2019, J Orthop Sci, DOI 10.1016/j.jos.2019.05.011
   Guglielmi G, 2005, ACTA RADIOL, V46, P269, DOI 10.1080/02841850510012661
   Ishikawa Y, 2017, GAIT POSTURE, V53, P98, DOI 10.1016/j.gaitpost.2017.01.011
   Jentzsch T, 2017, CLIN SPINE SURG, V30, P129, DOI 10.1097/BSD.0b013e3182aab266
   Keller TS, 1999, J SPINAL DISORD, V12, P313
   Kleck C, SPINE, DOI [10.1097/brs. 0000000000003290, DOI 10.1097/BRS.0000000000003290,ACCESSEDNOVEMBER1,2019]
   Knutsen AR, 2017, HIP INT, V27, P26, DOI 10.5301/hipint.5000413
   Lafage R, 2015, SPINE J, V15, P2493, DOI 10.1016/j.spinee.2015.08.067
   Lafage V, 2012, EUR SPINE J, V21, P698, DOI 10.1007/s00586-011-1967-3
   Mattei TA, 2013, MED HYPOTHESES, V80, P582, DOI 10.1016/j.mehy.2013.01.030
   Nagamoto Y, 2015, J NEUROSURG-SPINE, V23, P209, DOI 10.3171/2014.12.SPINE14590
   O'Leary PT, 2009, SPINE, V34, P2134, DOI 10.1097/BRS.0b013e3181b2e17e
   Organization WH, 2000, WHO TECHN REP SER
   Papadakis M, 2011, J MUSCULOSKEL NEURON, V11, P46
   Pavlovic A, 2013, OSTEOPOROSIS INT, V24, P2269, DOI 10.1007/s00198-013-2296-7
   Pollintine P, 2004, SPINE, V29, P774, DOI 10.1097/01.BRS.0000119401.23006.D2
   Rand T, 1997, CALCIFIED TISSUE INT, V60, P430, DOI 10.1007/s002239900258
   Salzmann SN, 2019, SPINE J, V19, P695, DOI 10.1016/j.spinee.2018.10.007
   Salzmann SN, 2019, SPINE J, V19, P238, DOI 10.1016/j.spinee.2018.05.021
   Schwab F, 2009, SPINE, V34, P1828, DOI 10.1097/BRS.0b013e3181a13c08
   Seki S, 2017, EUR SPINE J, V26, P2121, DOI 10.1007/s00586-017-4959-0
   Sinaki M, 1996, AM J PHYS MED REHAB, V75, P370, DOI 10.1097/00002060-199609000-00013
   Teichtahl AJ, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0738-7
   Tuli SM, 2005, CLIN ORTHOP RELAT R, P80, DOI 10.1097/01.blo.0000152600.61198.d3
   Wang YXJ, 2011, OSTEOPOROSIS INT, V22, P91, DOI 10.1007/s00198-010-1200-y
   WOLFF J, 1892, GESETZ TRANSFORMATIO
   Yagi M, 2016, OSTEOPOROSIS INT, V27, P3495, DOI 10.1007/s00198-016-3676-6
   Zou LX, 2019, NEUROSURG REV, V42, P671, DOI 10.1007/s10143-018-1004-7
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.139
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600032
PM 31790845
DA 2020-05-12
ER

PT J
AU Omar, AT
   Sandoval, MAS
   Pascual, JLR
   Khu, KJO
AF Omar, Abdelsimar T., II
   Sandoval, Mark Anthony S.
   Pascual, Jose Leonard R., III
   Khu, Kathleen Joy O.
TI Management of Hydrocephalus in Paget's Disease of Bone: Systematic
   Review and Illustrative Case
SO WORLD NEUROSURGERY
LA English
DT Review
DE Hydrocephalus; Paget's disease of the bone; Shunt surgery
ID NEUROLOGIC COMPLICATIONS; DEMENTIA-COMPLEX; SKULL; PARKINSONISM;
   FEATURES
AB OBJECTIVE: Paget's disease of the bone (PDB) is a focal bone disorder characterized by excessive resorption and deposition of pathologic bone. It can involve the skull and cause neurologic dysfunction. Hydrocephalus occurring as a complication has also been reported. However, owing to its rarity, the optimal treatment has not yet been determined.
   METHODS: We report the case of a 60-year-old woman with a diagnosis of PDB who had presented with symptomatic hydrocephalus and was successfully treated with ventriculoperitoneal shunt insertion. We also performed a systematic review of the Scopus and PubMed databases for case reports and series documenting patients with PDB complicated by hydrocephalus and discussed the clinical features and therapeutic strategies used.
   RESULTS: We found 28 cases of PDB complicated by hydrocephalus in reported studies, including the present case. The median age was 67 years (range, 48-85 years; interquartile range, 7 years), with a female sex predilection. The most common neurologic manifestations were cognitive impairment, gait unsteadiness, urinary incontinence, hearing loss, and headache. Surgery had been performed in 73% of the 28 cases. The most common operation was insertion of a ventriculoperitoneal shunt (63.2%). Cerebrospinal fluid diversion resulted in significant or complete neurologic recovery in 78.9% of the 28 patients. Posterior fossa decompression was performed in 15.8% of operative cases but did not significantly alter the clinical course.
   CONCLUSION: Patients with hydrocephalus occurring as a complication of PDB will most commonly present with cognitive impairment, gait unsteadiness, and urinary incontinence. Surgery plays an important role in the treatment, with CSF diversion procedures resulting in significant neurologic recovery in most cases.
C1 [Omar, Abdelsimar T., II; Khu, Kathleen Joy O.] Univ Philippines Manila, Coll Med, Sect Neurosurg, Dept Neurosci, Manila, Philippines.
   [Omar, Abdelsimar T., II; Khu, Kathleen Joy O.] Univ Philippines Manila, Philippine Gen Hosp, Sect Neurosurg, Dept Neurosci, Manila, Philippines.
   [Sandoval, Mark Anthony S.] Univ Philippines Manila, Coll Med, Dept Physiol, Manila, Philippines.
   [Sandoval, Mark Anthony S.] Univ Philippines Manila, Philippine Gen Hosp, Dept Physiol, Manila, Philippines.
   [Sandoval, Mark Anthony S.] Univ Philippines Manila, Coll Med, Sect Endocrinol Diabet & Metab, Dept Med, Manila, Philippines.
   [Sandoval, Mark Anthony S.] Univ Philippines Manila, Sect Endocrinol Diabet & Metab, Dept Med, Philippine Gen Hosp, Manila, Philippines.
   [Pascual, Jose Leonard R., III] Univ Philippines Manila, Coll Med, Dept Neurosci, Sect Adult Neurol, Manila, Philippines.
   [Pascual, Jose Leonard R., III] Univ Philippines Manila, Philippine Gen Hosp, Dept Neurosci, Sect Adult Neurol, Manila, Philippines.
RP Khu, KJO (reprint author), Univ Philippines Manila, Coll Med, Sect Neurosurg, Dept Neurosci, Manila, Philippines.; Khu, KJO (reprint author), Univ Philippines Manila, Philippine Gen Hosp, Sect Neurosurg, Dept Neurosci, Manila, Philippines.
EM kathleen.khu@neurosurgery.ph
RI Khu, Kathleen Joy/AAN-2658-2020; Omar, Abdelsimar Tan/AAF-1608-2019
OI Omar, Abdelsimar Tan/0000-0002-2965-8506; Sandoval, Mark
   Anthony/0000-0003-0622-8287
CR Ackerman L, 1997, SEMIN NUCL MED, V27, P190, DOI 10.1016/S0001-2998(97)80049-9
   ALLISON FG, 1951, CAN MED ASSOC J, V65, P476
   Bandong IS, 2008, PHILIPP J NUCL MED, V3, P37
   Bhadada S, 2006, J Assoc Physicians India, V54, P530
   BOTEZ MI, 1977, CAN J NEUROL SCI, V4, P139, DOI 10.1017/S0317167100120542
   CHAKRAVORTY NK, 1978, GERONTOLOGY, V24, P459, DOI 10.1159/000212286
   Chan YP, 2000, J ROY SOC MED, V93, P595, DOI 10.1177/014107680009301113
   Clegg JL, 1937, LANCET, V2, P128
   CULEBRAS A, 1974, J NEUROL SCI, V23, P307, DOI 10.1016/0022-510X(74)90233-0
   d'Arailh L, 2011, EUR GERIATR MED, V2, P249, DOI 10.1016/j.eurger.2011.05.007
   DOHRMANN PJ, 1982, J NEUROL NEUROSUR PS, V45, P835, DOI 10.1136/jnnp.45.9.835
   Ferraz-de-Souza B, 2013, J BONE MINER METAB, V31, P360, DOI 10.1007/s00774-012-0395-8
   Gennari L, 2018, EXPERT OPIN ORPHAN D, V6, P485, DOI 10.1080/21678707.2018.1500691
   GOLDHAMMER Y, 1979, NEUROLOGY, V29, P513, DOI 10.1212/WNL.29.4.513
   GOODBODY RA, 1950, LANCET, V258, P809
   GOTTSCHALK PG, 1979, NEUROLOGY, V29, P1430, DOI 10.1212/WNL.29.10.1430-a
   GUYER PB, 1978, CLIN RADIOL, V29, P421, DOI 10.1016/S0009-9260(78)80104-4
   Hashimoto J, 2006, J BONE MINER METAB, V24, P186, DOI 10.1007/s00774-005-0670-z
   HAUSSER C, 1984, CAN J NEUROL SCI, V11, P69, DOI 10.1017/S0317167100045352
   HENS L, 1979, CLIN NEUROL NEUROSUR, V81, P255, DOI 10.1016/0303-8467(79)90030-1
   Ikeda K, 1997, MOVEMENT DISORD, V12, P241, DOI 10.1002/mds.870120217
   Jorge-Mora Alberto, 2016, Eur J Orthop Surg Traumatol, V26, P27, DOI 10.1007/s00590-015-1659-5
   LOBATO RD, 1980, ACTA NEUROCHIR, V55, P85, DOI 10.1007/BF01808923
   Maderazo E, 2009, INT J RHEUM DIS, V12, P348, DOI 10.1111/j.1756-185X.2009.01433.x
   MARTIN BJ, 1985, GERONTOLOGY, V31, P397
   Moiyadi AV, 2006, ACTA NEUROCHIR, V148, P1297, DOI 10.1007/s00701-006-1048-2
   Monsell EM, 2004, LARYNGOSCOPE, V114, P598, DOI 10.1097/00005537-200404000-00002
   Morton A, 2005, ANN RHEUM DIS, V64, P1386, DOI 10.1136/ard.2004.031302
   Pandit V, 2008, NEUROL INDIA, V56, P216, DOI 10.4103/0028-3886.42014
   Pinter NK, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0580-x
   Poncelet A, 1999, J BONE MINER RES, V14, P88, DOI 10.1002/jbmr.5650140218
   Ralston SH, 2019, J BONE MINER RES, V34, P579, DOI 10.1002/jbmr.3657
   Raubenheimer PJ, 2002, BRIT J NEUROSURG, V16, P513, DOI 10.1080/026886902320909178
   Roohi F, 2005, CLIN NEUROL NEUROSUR, V107, P325, DOI 10.1016/j.clineuro.2004.07.007
   Rubin DJ, 2009, ENDOCR PRACT, V15, P158, DOI 10.4158/EP.15.2.158
   Singer FR, 2014, J CLIN ENDOCR METAB, V99, P4408, DOI 10.1210/jc.2014-2910
   Van Staa TP, 2002, J BONE MINER RES, V17, P465, DOI 10.1359/jbmr.2002.17.3.465
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.099
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600076
PM 31881339
DA 2020-05-12
ER

PT J
AU Paredes, I
   Munarriz, PM
   Toldos, O
   Castano-Leon, AM
   Panero, I
   Eiriz, C
   Garcia-Perez, D
   Perez-Nunez, A
   Lagares, A
   Alen, JAF
AF Paredes, Igor
   Munarriz, Pablo M.
   Toldos, Oscar
   Maria Castano-Leon, Ana
   Panero, Irene
   Eiriz, Carla
   Garcia-Perez, Daniel
   Perez-Nunez, Angel
   Lagares, Alfonso
   Alen, Jose Antonio F.
TI True Dural Spinal Epidural Cysts: Report of 5 Cases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Compressive myelopathy; Dural communication; Dural tear; Extradural
   spinal arachnoid cyst; True dura cyst
ID EXTRADURAL ARACHNOID CYSTS; CORD COMPRESSION; MRI
AB BACKGROUND: Spinal arachnoid cysts are a rare cause of compressive myelopathy. Spinal extradural arachnoid cysts (SEACs) are even rarer.
   METHODS: We retrospectively reviewed the SEACs operated on in our hospital between 2015 and 2019, according to their clinical and radiologic findings, treatments performed, and outcomes.
   RESULTS: We identified 5 cases (2 males and 3 females), ranging in age from 21 months to 78 years. Except for the pediatric case, all patients presented with pain and 3 had some grade of neurologic impairment. Preoperative magnetic resonance imaging showed multiloculated cyst in 4 cases, and the communication with the dura was properly identified in only 1 case. The patients were operated through a laminectomy or laminoplasty and total removal of the cyst, and the communication with the dura was identified and repaired in all cases. In all cases, the defect was near the exit of a nerve root, and rootlets were seen through it, producing a ball-like valve mechanism. Histology of the cyst wall showed true dura in every case. One patient needed a reoperation for evacuation of a fluid collection (related to the dural sealant). Following Odom's criteria, 3 patients had an excellent outcome and 2 had a fair outcome.
   CONCLUSIONS: Total excision of a symptomatic SEAC through either laminectomy or laminoplasty is a safe and effective treatment option. Although isolated repair of the dural communication without cyst removal may seem appealing, we have found it very difficult to identify the point of communication preoperatively.
C1 [Paredes, Igor; Munarriz, Pablo M.; Maria Castano-Leon, Ana; Panero, Irene; Eiriz, Carla; Garcia-Perez, Daniel; Perez-Nunez, Angel; Lagares, Alfonso; Alen, Jose Antonio F.] Univ Hosp 12 Octubre, Dept Neurosurg, Madrid, Spain.
   [Toldos, Oscar] Univ Hosp 12 Octubre, Dept Pathol, Madrid, Spain.
RP Paredes, I (reprint author), Univ Hosp 12 Octubre, Dept Neurosurg, Madrid, Spain.
EM igorparedes@gmail.com
RI ; Munarriz, Pablo/S-3398-2018
OI Castano-Leon, Ana M/0000-0002-7918-5049; Munarriz,
   Pablo/0000-0002-9888-7046
CR Apel K, 2006, ACTA NEUROCHIR, V148, P221, DOI 10.1007/s00701-005-0697-x
   Bitaraf Mohammad Ali, 2009, Cases J, V2, P7531, DOI 10.1186/1757-1626-2-7531
   BOISSERIELACROIX M, 1990, COMPUT MED IMAG GRAP, V14, P221, DOI 10.1016/0895-6111(90)90065-J
   Chang IC, 2004, PEDIATR NEUROSURG, V40, P70, DOI 10.1159/000078911
   Choi SW, 2013, J KOREAN NEUROSURG S, V54, P355, DOI 10.3340/jkns.2013.54.4.355
   CONGIA S, 1992, NEURORADIOLOGY, V34, P444, DOI 10.1007/BF00596513
   Dev R, 2008, BRIT J NEUROSURG, V22, P585, DOI 10.1080/02688690701819610
   Doita M, 2003, SPINE, V28, pE229, DOI 10.1097/00007632-200306150-00024
   Eroglu U, 2019, WORLD NEUROSURG, V122, pE1146, DOI 10.1016/j.wneu.2018.11.005
   Fam MD, 2018, J NEUROSURG-SPINE, V29, P711, DOI 10.3171/2018.5.SPINE1820
   FORTUNA A, 1977, ACTA NEUROCHIR, V39, P259, DOI 10.1007/BF01406736
   Fukumoto H, 2016, WORLD NEUROSURG, V86, DOI 10.1016/j.wneu.2015.10.027
   Funao H, 2012, NEUROSURGERY, V71, P278, DOI 10.1227/NEU.0b013e318257bf74
   GRAY L, 1988, J COMPUT ASSIST TOMO, V12, P646, DOI 10.1097/00004728-198807000-00023
   Gu K, 2016, KOREAN J RADIOL, V17, P111, DOI 10.3348/kjr.2016.17.1.111
   Ido K, 2002, J CLIN NEUROSCI, V9, P694, DOI 10.1054/jocn.2002.1138
   Ishibe T, 2014, SPINE, V39, pE1394, DOI 10.1097/BRS.0000000000000591
   Kadono Y, 2015, CASE REP ORTHOP, V2015
   Kanetaka M, 2011, J CLIN NEUROSCI, V18, P863, DOI 10.1016/j.jocn.2010.10.013
   Kikuta KI, 2006, J NEUROSURG-SPINE, V4, P251, DOI 10.3171/spi.2006.4.3.251
   KIM KS, 1986, SURG NEUROL, V26, P249, DOI 10.1016/0090-3019(86)90157-6
   Kulkarni AG, 2004, BRIT J NEUROSURG, V18, P484, DOI 10.1080/02688690400012368
   Lee CH, 2012, ACTA NEUROCHIR, V154, P1219, DOI 10.1007/s00701-012-1356-7
   Lee SH, 2014, EUR SPINE J, V23, P1755, DOI 10.1007/s00586-014-3393-9
   Lee SW, 2018, WORLD NEUROSURG, V116, P343, DOI 10.1016/j.wneu.2018.05.199
   Liu James K, 2007, Neurosurg Focus, V22, pE6
   Liu JK, 2005, J NEUROSURG, V103, P266, DOI 10.3171/ped.2005.103.3.0266
   Mishra RK, 2017, J NEUROSURG-SPINE, V27, P185, DOI 10.3171/2017.2.SPINE16637
   Miyamoto M, 2006, NEUROSURGERY, V59, P941, DOI 10.1227/01.NEU.0000232659.56174.28
   Morizane K, 2018, J ORTHOP SCI, V23, P464, DOI 10.1016/j.jos.2018.01.005
   NABORS MW, 1988, J NEUROSURG, V68, P366, DOI 10.3171/jns.1988.68.3.0366
   Nakagawa A, 2004, MINIM INVAS NEUROSUR, V47, P369, DOI 10.1055/s-2004-830129
   Nejat F, 2006, J NEUROSURG, V104, P210, DOI 10.3171/ped.2006.104.3.210
   Neo M, 2004, SPINE, V29, pE426, DOI 10.1097/01.brs.0000141189.41705.70
   ODOM GL, 1958, JAMA-J AM MED ASSOC, V166, P23, DOI 10.1001/jama.1958.02990010025006
   Ogura Y, 2018, J ORTHOP SCI, V23, P455, DOI 10.1016/j.jos.2018.01.010
   Ogura Yoji, 2015, Hum Genome Var, V2, P15032, DOI 10.1038/hgv.2015.32
   Ogura Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142126
   Ogura Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080548
   Oh JK, 2012, ACTA NEUROCHIR, V154, P341, DOI 10.1007/s00701-011-1110-6
   Qi W, 2015, ACTA NEUROCHIR, V157, P539, DOI 10.1007/s00701-014-2278-3
   Quillo-Olvera J, 2017, CIR CIR, V85, P544, DOI 10.1016/j.circir.2016.09.003
   Rimmelin A, 1997, NEURORADIOLOGY, V39, P203, DOI 10.1007/s002340050394
   Tanaka T, 2018, WORLD NEUROSURG, V109, P298, DOI 10.1016/j.wneu.2017.10.003
   Uemura K, 1996, J NEUROSURG, V85, P354, DOI 10.3171/jns.1996.85.2.0354
   Yabuki S, 2007, AM J MED GENET A, V143A, P884, DOI 10.1002/ajmg.a.31669
NR 46
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.010
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600110
PM 31841718
DA 2020-05-12
ER

PT J
AU Passias, PG
   Brown, AE
   Lebovic, J
   Pierce, KE
   Ahmad, W
   Bortz, CA
   Alas, H
   Diebo, BG
   Buckland, AJ
AF Passias, Peter G.
   Brown, Avery E.
   Lebovic, Jordan
   Pierce, Katherine E.
   Ahmad, Waleed
   Bortz, Cole A.
   Alas, Haddy
   Diebo, Bassel G.
   Buckland, Aaron J.
TI Metabolic Syndrome has a Negative Impact on Cost Utility Following Spine
   Surgery
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cervical fusion; Costs per QALY; Lumbar fusion; Metabolic syndrome;
   Obesity; Quality adjusted life years; Spine surgery
ID BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; COMPLICATIONS; OBESITY;
   VALIDATION; MORTALITY; OUTCOMES; FUSION; RISK
AB OBJECTIVE: Investigate the differences in spine surgery cost for metabolic syndrome patients.
   METHODS: Included were patients >= 18 undergoing fusion. Patients were divided into cervical, thoracic, and lumbar groups based on their upper instrumented vertebrae (UIV). Metabolic syndrome patients (MetS) included those with body mass index >30, diabetes mellitus, dyslipidemia, and hypertension. Propensity score matching for invasiveness between non-MetS and MetS used to assess cost differences. Total surgery costs for MetS and non-MetS adult spinal deformity patients were compared. Quality-adjusted life years (QALYs) and cost per QALY for UIV groups were calculated.
   RESULTS: A total of 312 invasiveness matched surgeries met inclusion criteria. Baseline demographics and surgical details included age 57.7 +/- 14.5, 54% female, body mass index 31.1 +/- 6.6, 17% anterior approach, 70% posterior approach, 13% combined approach, and 3.8 +/- 4.1 levels fused. The average costs of surgery between MetS and non-Mets patients was $60,579.30 versus $52,053.23 (P< 0.05). When costs were compared between UIV groups, MetS patients had higher cervical and thoracic surgery costs ($23,203.43 vs. $19,153.43, $75,230.05 vs. $65,746.16, all P < 0.05) and lower lumbar costs ($31,775.64 vs. $42,643.37, P < 0.05). However, the average cost per QALY at 1 year was $639,069.32 for MetS patients and $425,840.30 for non-Mets patients (P < 0.05). At life expectancy, the cost per QALY was $45,456.83 versus $26,026.84 (P < 0.05).
   CONCLUSIONS: When matched by invasiveness, MetS patients had an average 16.4% higher surgery costs, 50% higher costs per QALY at 1 year, and 75% higher cost per QALY at life expectancy. Further research is needed on the possible utility of reducing comorbidities in preoperative patients.
C1 [Passias, Peter G.; Brown, Avery E.; Lebovic, Jordan; Pierce, Katherine E.; Ahmad, Waleed; Bortz, Cole A.; Alas, Haddy; Buckland, Aaron J.] NYU, Med Ctr, NY Spine Inst, Div Spinal Surg,Dept Orthopaed, New York, NY 10003 USA.
   [Passias, Peter G.; Brown, Avery E.; Lebovic, Jordan; Pierce, Katherine E.; Ahmad, Waleed; Bortz, Cole A.; Alas, Haddy; Buckland, Aaron J.] NYU, Med Ctr, NY Spine Inst, Div Spinal Surg,Dept Neurosurg, New York, NY 10003 USA.
   [Diebo, Bassel G.] SUNY Downstate, Dept Orthoped Surg, New York, NY USA.
RP Passias, PG (reprint author), NYU, Med Ctr, NY Spine Inst, Div Spinal Surg,Dept Orthopaed, New York, NY 10003 USA.; Passias, PG (reprint author), NYU, Med Ctr, NY Spine Inst, Div Spinal Surg,Dept Neurosurg, New York, NY 10003 USA.
EM peter.passias@nyumc.org
RI Buckland, Aaron/H-2765-2016
OI Buckland, Aaron/0000-0003-0275-5020
CR Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Azimi P, 2018, ASIAN SPINE J, V12, P1085, DOI [10.31616/asj.2018.6.1085, 10.31616/asj.2018.12.6.1085]
   Bono OJ, 2018, SPINE J, V18, P1204, DOI 10.1016/j.spinee.2017.11.015
   Buerba RA, 2014, SPINE J, V14, P2008, DOI 10.1016/j.spinee.2013.11.047
   Champain S, 2006, EUR SPINE J, V15, P982, DOI 10.1007/s00586-005-0927-1
   Chan Andrew K, 2020, Neurosurgery, V86, P80, DOI 10.1093/neuros/nyy589
   Chung AS, 2018, SPINE, V43, P661, DOI 10.1097/BRS.0000000000002397
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Edejer TT-T, 2003, MAK CHOIC HLTH WHO G
   Edelstein AI, 2017, J ARTHROPLASTY, V32, P362, DOI 10.1016/j.arth.2016.08.007
   Gelalis Ioannis D, 2019, Eur J Orthop Surg Traumatol, V29, P321, DOI 10.1007/s00590-018-2359-8
   Goyal A, 2019, CLIN NEUROL NEUROSUR, V177, P27, DOI 10.1016/j.clineuro.2018.12.012
   Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6
   Horn SR, 2018, WORLD NEUROSURG, V120, pE533, DOI 10.1016/j.wneu.2018.08.123
   Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683
   Jain D, 2019, J AM ACAD ORTHOP SUR, V27, pE499, DOI 10.5435/JAAOS-D-17-00837
   Klineberg EO, 2016, SPINE, V41, pE798, DOI 10.1097/BRS.0000000000001391
   Knutsson B, 2013, SPINE, V38, P435, DOI 10.1097/BRS.0b013e318270b243
   Lakka HM, 2002, JAMA-J AM MED ASSOC, V288, P2709, DOI 10.1001/jama.288.21.2709
   Lovecchio F, 2018, GLOB SPINE J, V8, P683, DOI 10.1177/2192568218765149
   Malik AT, 2019, SPINE, V44, pE282, DOI 10.1097/BRS.0000000000002824
   Memtsoudis SG, 2012, SPINE, V37, P989, DOI 10.1097/BRS.0b013e31823a3a13
   Mirza SK, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471-2474-7-53
   MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429
   O'Brien MF, 2005, SPINAL DEFORMITY STU
   Passias PG, 2018, ACTA NEUROCHIR, V160, P2459, DOI 10.1007/s00701-018-3722-6
   PASSIAS PG, 2018, SPINE J, V17, pS243, DOI DOI 10.1016/J.SPINEE.2017.08.150
   Poorman GW, 2018, SPINE J, V18, P1552, DOI 10.1016/j.spinee.2018.01.016
   Rillardon L, 2003, REV CHIR ORTHOP, V89, P218
   Samson SL, 2014, ENDOCRIN METAB CLIN, V43, P1, DOI 10.1016/j.ecl.2013.09.009
   Sassi F, 2006, HEALTH POLICY PLANN, V21, P402, DOI 10.1093/heapol/czl018
   Soroceanu A, 2015, J NEUROSURG-SPINE, V23, P656, DOI 10.3171/2015.3.SPINE14743
   Wilson PWF, 2005, CIRCULATION, V112, P3066, DOI 10.1161/CIRCULATIONAHA.105.539528
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.053
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600059
PM 31857269
DA 2020-05-12
ER

PT J
AU Pesce, A
   Palmieri, M
   Zancana, G
   Salvati, M
   Santoro, A
   Raco, A
   Frati, A
AF Pesce, Alessandro
   Palmieri, Mauro
   Zancana, Giuseppa
   Salvati, Maurizio
   Santoro, Antonio
   Raco, Antonino
   Frati, Alessandro
TI Radiation-Induced Brain Aneurysms: Institutional Experience and State of
   the Art in the Contemporary Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain aneurysms; Complications; Intracranial aneurysms; Radiation
   therapy; SRS; Vascular lesions
ID INTERNAL CAROTID-ARTERY; DE-NOVO ANEURYSM; GAMMA-KNIFE SURGERY; RUPTURED
   INTRACRANIAL ANEURYSM; VESTIBULAR SCHWANNOMA;
   ARTERIOVENOUS-MALFORMATION; NASOPHARYNGEAL CARCINOMA; SUBARACHNOID
   HEMORRHAGE; METABOLIC SYNDROME; CHILDHOOD-CANCER
AB BACKGROUND: Brain aneurysms (BAs) are the most common intracranial vascular condition, with an overall incidence of 1%-2%. Among the common causes of their initial formation and growth, the role of radiation therapy (RT) has been reported in some studies. The aim of the present study is to report the most relevant features of BA related to a previous cranial RT.
   METHODS: Data deriving from 1 patient treated for RT-induced BA in our institution were added to reports of another 66 BAs retrieved from the literature. The following parameters were evaluated: age, sex, location, primary lesion, clinical presentation, dosage/amount of radiation delivered, type of treatment for the BA, dimension, morphology, chemotherapy, comorbidities, risk factors, and number of BAs.
   RESULTS: The most commonly involved vessel was the internal carotid artery (34%). In general, the anterior circulation showed higher vulnerability compared with the posterior circulation and middle cerebral artery (56.7%). The average latency between RT and the first imaging showing the BA was 9.01 +/- 6.85 years. Vessels coursing in the posterior cranial fossa showed a significant univariate association with lower X-ray dosages (P = 0.014) compared with the other locations. No statistically significant correlation between the continuous variables age, latency of BA appearance, RT delivered dose, and dimension of the BA was shown.
   CONCLUSIONS: The apparent higher fragility of the vascular structures of the posterior cranial fossa was statistically outlined, and the X-ray dosage, the primary condition target of the RT, the age of the patients, and no statistically significant correlation were outlined. Biological factors could play a significant role.
C1 [Pesce, Alessandro; Frati, Alessandro] IRCCS Neuromed, Pozzilli, Isernia, Italy.
   [Palmieri, Mauro; Zancana, Giuseppa; Raco, Antonino] Azienda Osped St Andrea, Rome, Italy.
   [Palmieri, Mauro; Zancana, Giuseppa; Raco, Antonino] Sapienza Univ, NESMOS Dept, Dept Neurosurg, Rome, Italy.
   [Salvati, Maurizio; Santoro, Antonio] Sapienza Univ, Dept Human Neurosci, Neurosurg Div, Rome, Italy.
RP Frati, A (reprint author), IRCCS Neuromed, Pozzilli, Isernia, Italy.
EM Alessandro.frati@uniroma1.it
OI Palmieri, Mauro/0000-0001-5131-1392
CR Aichholzer M, 2001, CHILD NERV SYST, V17, P173, DOI 10.1007/s003810000364
   Akai T, 2015, J NEUROL SURG REP, V76, P105, DOI 10.1055/s-0035-1549223
   Akamatsu Y, 2009, J NEUROSURG, V110, P543, DOI 10.3171/2008.8.JNS08177
   Aoki S, 2002, RADIOLOGY, V223, P683, DOI 10.1148/radiol.2233010822
   BENSON PJ, 1989, J NEUROSURG, V70, P545, DOI 10.3171/jns.1989.70.4.0545
   Brisman JL, 2006, NEW ENGL J MED, V355, P928, DOI 10.1056/NEJMra052760
   Brown RD, 2014, LANCET NEUROL, V13, P393, DOI 10.1016/S1474-4422(14)70015-8
   CASEY ATH, 1993, BRIT J NEUROSURG, V7, P575, DOI 10.3109/02688699308995083
   Chen HC, 2004, OTOLARYNG HEAD NECK, V130, P388, DOI 10.1016/j.otohns.2003.08.010
   Cheng KY, 2008, HEAD NECK-J SCI SPEC, V30, P1132, DOI 10.1002/hed.20753
   Cheng KM, 2001, ACTA NEUROCHIR, V143, P351, DOI 10.1007/s007010170089
   D'Andrea G, 2017, WORLD NEUROSURG, V97, P169, DOI 10.1016/j.wneu.2016.09.054
   D'Andrea G, 2015, CLIN NEUROL NEUROSUR, V133, P34, DOI 10.1016/j.clineuro.2015.03.007
   de Haas EC, 2010, LANCET ONCOL, V11, P193, DOI 10.1016/S1470-2045(09)70287-6
   Dho YS, 2017, STEREOT FUNCT NEUROS, V95, P379, DOI 10.1159/000481666
   Endo H, 2011, NEUROL MED-CHIR, V51, P226, DOI 10.2176/nmc.51.226
   Frati A, 2018, WORLD NEUROSURG, V114, pE565, DOI 10.1016/j.wneu.2018.03.034
   Fujita K, 2014, J NEUROL SURG REP, V75, pE200, DOI 10.1055/s-0034-1383859
   Gabriel CM, 2004, J NEUROL NEUROSUR PS, V75, P1343, DOI 10.1136/jnnp.2003.028662
   GOMORI JM, 1987, ANGIOLOGY, V38, P147, DOI 10.1177/000331978703800209
   Gonzales-Portillo GA, 2006, SURG NEUROL, V65, P391, DOI 10.1016/j.surneu.2005.07.074
   Green DM, 2012, J CLIN ONCOL, V30, P246, DOI 10.1200/JCO.2010.34.4267
   Gulati P, 2014, INDIAN J NEUROSURG, V3, P44, DOI 10.4103/2277-9167.132005
   Holodny AI, 1996, AM J NEURORADIOL, V17, P226
   Huang PP, 2001, AM J NEURORADIOL, V22, P1346
   Hughes JD, 2015, OTOL NEUROTOL, V36, P1428, DOI 10.1097/MAO.0000000000000807
   Huh Won, 2012, J Cerebrovasc Endovasc Neurosurg, V14, P300, DOI 10.7461/jcen.2012.14.4.300
   JAKUBOWSKI J, 1978, J NEUROL NEUROSUR PS, V41, P972, DOI 10.1136/jnnp.41.11.972
   Jensen FK, 1997, ACTA RADIOL, V38, P37, DOI 10.1080/02841859709171239
   JOHN DG, 1993, J LARYNGOL OTOL, V107, P137, DOI 10.1017/S002221510012242X
   JUVELA S, 1993, STROKE, V24, P639, DOI 10.1161/01.STR.24.5.639
   Kamide Tomoya, 2016, Surg Neurol Int, V7, pS880, DOI 10.4103/2152-7806.194501
   Kellner CP, 2015, J NEUROINTERV SURG, V7, pE21, DOI 10.1136/neurintsurg-2014-011206.rep
   Kraft J, 2019, CURR TREAT OPTION NE, V21, DOI 10.1007/s11940-019-0548-3
   Lam HCK, 2001, OTOLARYNG HEAD NECK, V125, P522, DOI 10.1067/mhn.2001.118248
   Lau WYS, 2005, ANN OTO RHINOL LARYN, V114, P939, DOI 10.1177/000348940511401208
   Lawrence YR, 2010, INT J RADIAT ONCOL, V76, pS20, DOI 10.1016/j.ijrobp.2009.02.091
   Liu AK, 2009, PEDIATR BLOOD CANCER, V52, P227, DOI 10.1002/pbc.21787
   Lo AC, 2016, PEDIATR BLOOD CANCER, V63, P786, DOI 10.1002/pbc.25889
   Louis E, 2003, REV NEUROL-FRANCE, V159, P319
   Mak WK, 2000, AUST NZ J SURG, V70, P237, DOI 10.1046/j.1440-1622.2000.01795.x
   Maruyama K, 2000, ACTA NEUROCHIR, V142, P139, DOI 10.1007/s007010050016
   Mascitelli JR, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011736.rep
   Mattei L, 2017, ACTA NEUROCHIR, V159, P2405, DOI 10.1007/s00701-017-3306-x
   McGill HC, 2002, CIRCULATION, V105, P2712, DOI 10.1161/01.CIR.0000018121.67607.CE
   MORIYAMA T, 1992, Neurological Surgery, V20, P487
   Murakami N, 2002, ACT NEUR S, V82, P55
   Nanney AD, 2014, WORLD NEUROSURG, V81, P511, DOI 10.1016/j.wneu.2013.10.044
   Nishi T, 1987, Neurol Med Chir (Tokyo), V27, P224, DOI 10.2176/nmc.27.224
   Parag Sayal, 2016, Surg Neurol Int, V7, pS387, DOI 10.4103/2152-7806.183496
   Park KY, 2009, J NEUROSURG, V110, P540, DOI 10.3171/2008.9.JNS08860
   Partap S, 2012, SEMIN PEDIATR NEUROL, V19, P18, DOI 10.1016/j.spen.2012.02.012
   Pereira P, 2002, NEUROSURGERY, V50, P885, DOI 10.1097/00006123-200204000-00042
   Pesce A, 2018, WORLD NEUROSURG, V120, P190, DOI 10.1016/j.wneu.2018.08.124
   Romano S, 2018, ROUT ADV HEALT, P30
   Salvati M, 2019, WORLD NEUROSURG, V124, pE480, DOI 10.1016/j.wneu.2018.12.118
   Scaringi C, 2018, ANTICANCER RES, V38, P6041, DOI 10.21873/anticanres.12954
   Sciubba DM, 2006, J NEUROSURG, V105, P134, DOI 10.3171/ped.2006.105.2.134
   SCODARY DJ, 1990, ACTA NEUROCHIR, V102, P141, DOI 10.1007/BF01405429
   Sheehan JP, 2014, WORLD NEUROSURG, V81, P487, DOI 10.1016/j.wneu.2013.11.003
   Shiue I, 2012, J NEUROL SCI, V313, P92, DOI 10.1016/j.jns.2011.09.017
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Sunderland G, 2014, BRIT J NEUROSURG, V28, P536, DOI 10.3109/02688697.2013.847168
   Takao T, 2006, ACTA NEUROCHIR, V148, P1317, DOI 10.1007/s00701-006-0912-4
   Tamura M, 2013, J NEUROL SURG REP, V74, P111, DOI 10.1055/s-0033-1358379
   Twitchell S, 2019, J NEUROSURG, V130, P1889, DOI 10.3171/2017.12.JNS172635
   Uchikawa H, 2017, WORLD NEUROSURG, V99, DOI 10.1016/j.wneu.2016.11.069
   Vogel TD, 2011, J NEUROSURG-PEDIATR, V7, P633, DOI 10.3171/2011.3.PEDS10562
   Wong ND, 2012, JACC-CARDIOVASC IMAG, V5, P358, DOI 10.1016/j.jcmg.2011.12.015
   Wooding T, 2018, CLIN NEURORADIOL, V28, P289, DOI 10.1007/s00062-017-0611-y
   Wu H, 2014, J CRANIOFAC SURG, V25, pE380, DOI 10.1097/SCS.0000000000000930
   Wu YH, 2016, CHILD NERV SYST, V32, P1641, DOI 10.1007/s00381-016-3144-9
   Yamaguchi S, 2009, NEUROL MED-CHIR, V49, P202, DOI 10.2176/nmc.49.202
   Yoon WS, 2011, J KOREAN NEUROSURG S, V50, P457, DOI 10.3340/jkns.2011.50.5.457
   Yucesoy K, 2004, SKULL BASE-INTERD AP, V14, P169, DOI 10.1055/s-2004-832263
NR 75
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.09.157
PG 13
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600160
PM 31605840
DA 2020-05-12
ER

PT J
AU Potts, MB
   da Matta, L
   Abdalla, RN
   Shaibani, A
   Ansari, SA
   Jahromi, BS
   Hurley, MC
AF Potts, Matthew B.
   da Matta, Lucas
   Abdalla, Ramez N.
   Shaibani, Ali
   Ansari, Sameer A.
   Jahromi, Babak S.
   Hurley, Michael C.
TI Stenting of Mobile Calcified Emboli After Failed Thrombectomy in Acute
   Ischemic Stroke: Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Calcified emboli; Intracranial stenting; Stroke; Thrombectomy
ID MECHANICAL THROMBECTOMY; INTRACRANIAL STENTS; CEREBRAL EMBOLI; RESCUE;
   THROMBOEMBOLI; SOLITAIRE; HISTOLOGY; FAILURE; PATIENT
AB BACKGROUND: Mobile calcified emboli are a rare cause of large vessel occlusion and acute ischemic stroke and pose unique challenges to standard mechanical thrombectomy techniques. Intracranial stenting has been reported as a rescue maneuver in cases of failed mechanical thrombectomy owing to dissection or calcified atherosclerotic plaques, but its use for calcified emboli is not well described.
   CASE DESCRIPTION: We present 2 cases of acute ischemic stroke caused by calcifies emboli. Standard mechanical thrombectomy techniques using aspiration catheters and stent-retrievers failed to remove these emboli, so intracranial stenting was successfully performed in each case, albeit after overcoming unique challenges associated with the stenting of calcified emboli. We also review the literature on intracranial stenting as a salvage therapy for failed mechanical thrombectomy.
   CONCLUSIONS: Mobile calcified emboli are rare causes of acute ischemic stroke. Intracranial stenting can be used to successfully treat calcified emboli when mechanical thrombectomy has failed.
C1 [Potts, Matthew B.; da Matta, Lucas; Shaibani, Ali; Ansari, Sameer A.; Jahromi, Babak S.; Hurley, Michael C.] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Northwestern Mem Hosp, Chicago, IL 60611 USA.
   [Potts, Matthew B.; Abdalla, Ramez N.; Shaibani, Ali; Ansari, Sameer A.; Jahromi, Babak S.; Hurley, Michael C.] Northwestern Univ, Feinberg Sch Med, Dept Radiol, Northwestern Mem Hosp, Chicago, IL 60611 USA.
RP Potts, MB (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Northwestern Mem Hosp, Chicago, IL 60611 USA.; Potts, MB (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Radiol, Northwestern Mem Hosp, Chicago, IL 60611 USA.
EM matthew.potts@northwestern.edu
CR Acosta FD, 2017, RADIOLOGIA-MADRID, V59, P218, DOI 10.1016/j.rx.2017.01.003
   Argetsinger DS, 2016, J CLIN NEUROSCI, V29, P173, DOI 10.1016/j.jocn.2016.01.016
   Baek JH, 2016, STROKE, V47, P2360, DOI 10.1161/STROKEAHA.116.014073
   Baracchini C, 2017, WORLD NEUROSURG, V103, P57, DOI 10.1016/j.wneu.2017.03.070
   Chang Y, 2018, STROKE, V49, P958, DOI 10.1161/STROKEAHA.117.020072
   Cheang MY, 2014, J CLIN NEUROSCI, V21, P401, DOI 10.1016/j.jocn.2013.05.005
   Chueh JY, 2011, AM J NEURORADIOL, V32, P1237, DOI 10.3174/ajnr.A2485
   Cornelissen SA, 2018, CLIN NEURORADIOL, V372, P1
   Dobrocky T, 2018, J NEUROINTERV SURG, V10, P345, DOI 10.1136/neurintsurg-2017-013226
   Fassa AA, 2014, CIRC-CARDIOVASC INTE, V7, P125, DOI 10.1161/CIRCINTERVENTIONS.113.000995
   Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4
   Goyal M, 2016, LANCET, V387, P1723, DOI 10.1016/S0140-6736(16)00163-X
   Krischek O, 2011, MINIM INVAS NEUROSUR, V54, P21, DOI 10.1055/s-0031-1271681
   Linfante I, 2011, STROKE, V42, P2636, DOI 10.1161/STROKEAHA.111.618389
   Nappini S, 2019, J NEURORADIOLOGY, V46, P141, DOI 10.1016/j.neurad.2018.05.004
   Powers WJ, 2018, STROKE, V49, pE46, DOI 10.1161/STR.0000000000000158
   Raghib MF, 2018, J CLIN NEUROSCI, V47, P56, DOI 10.1016/j.jocn.2017.10.042
   Tsang ACO, 2019, STROKE, V50, P1460, DOI 10.1161/STROKEAHA.119.024889
   Uneda A, 2017, J STROKE CEREBROVASC, V26, pE5, DOI 10.1016/j.jstrokecerebrovasdis.2016.09.029
   Walker BS, 2014, AM J NEURORADIOL, V35, P1515, DOI 10.3174/ajnr.A3892
   Yuki I, 2012, AM J NEURORADIOL, V33, P643, DOI 10.3174/ajnr.A2842
   Zhou TF, 2018, WORLD NEUROSURG, V120, pE181, DOI 10.1016/j.wneu.2018.08.002
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.096
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600143
PM 31881346
DA 2020-05-12
ER

PT J
AU Pressman, E
   Penn, D
   Patel, NJ
AF Pressman, Elliot
   Penn, David
   Patel, Nirav J.
TI Intracranial Hemorrhage from Meningioma: 2 Novel Risk Factors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Estrogen; Hemorrhage; Hormone replacement therapy; Meningioma; Selective
   serotonin reuptake inhibitor; Spontaneous; Subarachnoid hemorrhage
ID SEROTONIN REUPTAKE INHIBITORS; SUBARACHNOID HEMORRHAGE;
   SUBDURAL-HEMATOMA; BRAIN-TUMOR; ANTIDEPRESSANTS; ASSOCIATION; MECHANISM;
   THERAPY
AB BACKGROUND: Meningiomas are the most common benign intracranial tumor. Although meningiomas are slow growing and potentially highly vascularized, hemorrhage of these tumors is rare. We propose 2 novel modifiable risk factors that may provoke intratumoral hemorrhage of a World Health Organization grade I meningioma.
   CASE DESCRIPTION: We outline the clinical presentation of a 56-year-old female with spontaneous subarachnoid hemorrhage with intraventricular extension in a coma from a petroclival meningioma taking escitalopram for depression and high-dose estrogen replacement therapy for menopause. Pathology confirmed the diagnosis of World Health Organization grade I meningioma. Postoperatively, the patient declined neurologically and developed vasospasm of the basilar artery, as well as seizures, fever, and new-onset atrial fibrillation.
   CONCLUSIONS: Spontaneous hemorrhage of meningiomas is a rare event. Known risk factors are age older than 70 or younger than 30; intraventricular or convexity location; malignant, fibrous, or angioblastic histopathology; and presence of hypertension, anticoagulation therapy, and traumatic brain injury. We propose 2 new risk factors to be considered that may predispose to hemorrhage of a meningioma: serotonin-modulating therapy and high-dose estrogen-replacement.
C1 [Pressman, Elliot] Univ S Florida, Dept Neurosurg & Brain Repair, Tampa, FL 33620 USA.
   [Penn, David; Patel, Nirav J.] Harvard Med Sch, Neurosurg, Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Patel, NJ (reprint author), Harvard Med Sch, Neurosurg, Brigham & Womens Hosp, Boston, MA 02115 USA.
EM npatel40@bwh.harvard.edu
OI Pressman, Elliot/0000-0002-5160-802X
CR Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701
   ASKENASY HM, 1960, NEUROLOGY, V10, P484, DOI 10.1212/WNL.10.5.484
   Bambakidis NC, 2008, NEUROSURGERY, V62, P1182, DOI [10.1227/01.NEU.0000280119.36270.BA, 10.1227/01.neu.0000333784.04435.65]
   BLOOMGARDEN GM, 1987, NEUROSURGERY, V20, P24, DOI 10.1227/00006123-198701000-00006
   Bosnjak R, 2005, J NEUROSURG, V103, P473, DOI 10.3171/jns.2005.103.3.0473
   BUDNY JL, 1977, SURG NEUROL, V8, P323
   CHASKIS C, 1992, CLIN NEUROL NEUROSUR, V94, P269, DOI 10.1016/0303-8467(92)90103-A
   Cheng MH, 1997, J FORMOS MED ASSOC, V96, P116
   Cushing H, 1938, MENINGIOMAS THEIR CL
   de Almeida JPC, 2009, J CLIN NEUROSCI, V16, P1246, DOI 10.1016/j.jocn.2008.11.017
   Douros A, 2018, CNS DRUGS, V32, P321, DOI 10.1007/s40263-018-0507-7
   EL-BANHAWY A, 1962, Acta Neurochir (Wien), V10, P194, DOI 10.1007/BF01406544
   EVERETT BA, 1979, SURG NEUROL, V11, P233
   Globus JH, 1942, J AMER MED ASSOC, V120, P348, DOI 10.1001/jama.1942.02830400022006
   GORAN A, 1965, ARCH NEUROL-CHICAGO, V13, P65, DOI 10.1001/archneur.1965.00470010069009
   GRUSZKIEWICZ J, 1969, NEUROCHIRURGIA, V12, P107
   Hackam DG, 2012, NEUROLOGY, V79, P1862, DOI 10.1212/WNL.0b013e318271f848
   Hadidy AM, 2010, NEUROSCIENCES, V15, P11
   Halperin Demian, 2007, Dialogues Clin Neurosci, V9, P47
   Hambra Di Vitantonio, 2014, Surg Neurol Int, V5, pS469, DOI 10.4103/2152-7806.143724
   HAMER J, 1979, NEUROCHIRURGIA, V22, P189
   HELLE TL, 1980, J NEUROL NEUROSUR PS, V43, P725, DOI 10.1136/jnnp.43.8.725
   HOESSLY GF, 1955, J NEUROSURG, V12, P614, DOI 10.3171/jns.1955.12.6.0614
   JONES N R, 1989, British Journal of Neurosurgery, V3, P691, DOI 10.3109/02688698908992693
   Kim DG, 2000, ACTA NEUROCHIR, V142, P165, DOI 10.1007/s007010050019
   KOHLI CM, 1984, NEUROSURGERY, V15, P237, DOI 10.1227/00006123-198408000-00014
   Kouyialis AT, 2004, J CLIN NEUROSCI, V11, P906, DOI 10.1016/j.jocn.2004.02.014
   LANG I, 1995, AM J NEURORADIOL, V16, P1378
   LAZARO RP, 1981, NEUROSURGERY, V8, P96, DOI 10.1227/00006123-198101000-00018
   Lee Heui Seung, 2013, Korean J Spine, V10, P255, DOI 10.14245/kjs.2013.10.4.255
   MARTINEZLAGE JF, 1991, ACTA NEUROCHIR, V110, P129, DOI 10.1007/BF01400680
   Meijer WEE, 2004, ARCH INTERN MED, V164, P2367, DOI 10.1001/archinte.164.21.2367
   Miyazawa Takahito, 2008, J Stroke Cerebrovasc Dis, V17, P325, DOI 10.1016/j.jstrokecerebrovasdis.2008.03.009
   MODESTI LM, 1976, J NEUROSURG, V45, P437, DOI 10.3171/jns.1976.45.4.0437
   Motegi H, 2012, BRAIN TUMOR PATHOL, V29, P240, DOI 10.1007/s10014-012-0088-y
   Movig KLL, 2003, ARCH INTERN MED, V163, P2354, DOI 10.1001/archinte.163.19.2354
   Nakao N, 1991, No To Shinkei, V43, P589
   Niiro M, 2003, ACTA NEUROCHIR, V145, P767, DOI 10.1007/s00701-003-0089-z
   Niwa J, 1989, Neurol Med Chir (Tokyo), V29, P927, DOI 10.2176/nmc.29.927
   Okuno S, 1999, SURG NEUROL, V52, P180, DOI 10.1016/S0090-3019(97)00028-1
   Onesti ST, 1996, ACTA NEUROCHIR, V138, P1250, DOI 10.1007/BF01809756
   PLUCHINO F, 1983, ACTA NEUROCHIR, V68, P45, DOI 10.1007/BF01406201
   Qureshi AI, 2016, J NEUROSURG, V124, P45, DOI 10.3171/2014.12.JNS142329
   Renoux C, 2017, JAMA NEUROL, V74, P173, DOI 10.1001/jamaneurol.2016.4529
   Rim NJ, 2008, KOREAN J RADIOL, V9, pS10, DOI 10.3348/kjr.2008.9.s.s10
   Rossouw JE, 2007, JAMA-J AM MED ASSOC, V297, P1465, DOI 10.1001/jama.297.13.1465
   Shuangshoti S, 1999, NEUROPATHOLOGY, V19, P150
   SPEKTOR S, 1995, ACTA NEUROCHIR, V134, P51, DOI 10.1007/BF01428502
   van Walraven C, 2001, BMJ-BRIT MED J, V323, P655, DOI 10.1136/bmj.323.7314.655
   WAKAI S, 1982, NEUROSURGERY, V10, P437, DOI 10.1227/00006123-198204000-00004
   WANG AM, 1985, J COMPUT ASSIST TOMO, V9, P511, DOI 10.1097/00004728-198505000-00019
   Wang HC, 2016, WORLD NEUROSURG, V94, P319, DOI 10.1016/j.wneu.2016.07.042
   Wassertheil-Smoller S, 2003, JAMA-J AM MED ASSOC, V289, P2673, DOI 10.1001/jama.289.20.2673
NR 53
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.173
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600137
PM 31698125
DA 2020-05-12
ER

PT J
AU Qu, XP
   Qu, Y
   Wang, C
   Liu, B
AF Qu, Xiao-Peng
   Qu, Yan
   Wang, Chao
   Liu, Bei
TI Long-Term Cognitive Improvement After Functional Hemispherectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cognitive improvement; Epilepsy surgery; FSIQ; Functional
   hemispherectomy
ID REFRACTORY EPILEPSY; PRESCHOOL-CHILDREN; PEDIATRIC-PATIENTS; SURGERY;
   HEMISPHEROTOMY; PREDICTORS; POPULATION; OUTCOMES
AB BACKGROUND: To investigate intellectual development after functional hemispherectomy and to evaluate the favorable or unfavorable factors affecting prognosis.
   METHODS: Twenty-three patients from the patient follow-up database of the Epilepsy Center of Neurosurgery were selected for this retrospective study. The inclusion criteria of the patients were functional hemispherectomy surgery, surgical age older than 6 years, patients able to complete the intelligence assessment, follow-up time not less than 2 years, and availability of complete preoperative evaluation and postoperative follow-up data. Full Scale Intelligence Quotients (FSIQ) were calculated preoperatively and at the follow-up times for each patient. Correlations between the preoperative to postoperative changes in FSIQ and risk factors (age at epilepsy onset, duration of preoperative epilepsy, postoperative changes in the electroencephalogram, seizure status after surgery, and followup time) were analyzed. EpiData 3.1 software was used to establish a database and SPSS 22.0 software was used for data collation and analysis, and used the matching sample Wilcoxon symbol rank and test to conduct the analysis.
   RESULTS: The data of 23 patients were analyzed. The final follow-up results showed that 73.9% of the patients (17/23) had a significant increase in FSIQ scores (P = 0.006) after surgery, indicating that their cognitive function improved significantly. Successful surgery, successful postoperative seizure control, normalization of postoperative electroencephalogram, shorter disease duration before surgery, and longer recovery periods after surgery (follow-up time) were all related with good intellectual prognosis.
   CONCLUSIONS: Successful functional hemispherectomy significantly improved the cognitive function of patients. Functional hemispherectomy is a safe and effective treatment for patients with intractable epilepsy caused by hemispheric lesions and can effectively promote intellectual recovery and development.
C1 [Liu, Bei] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian, Peoples R China.
   [Liu, Bei] Fourth Mil Med Univ, Tangdu Hosp, Inst Funct Brain Disorders, Xian, Peoples R China.
RP Liu, B (reprint author), Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian, Peoples R China.; Liu, B (reprint author), Fourth Mil Med Univ, Tangdu Hosp, Inst Funct Brain Disorders, Xian, Peoples R China.
EM lbsjwk@163.com
FU National Science Foundation for Young Scientists of China [81971206]
FX supported by the Project supported by the National Science Foundation
   for Young Scientists of China (Grant No. 81971206).
CR Althausen A, 2013, J NEUROL NEUROSUR PS, V84, P529, DOI 10.1136/jnnp-2012-303811
   Besag F, 2016, EPILEPTIC DISORD, V18, pS49, DOI 10.1684/epd.2016.0816
   CHIRON C, 1991, EPILEPSY RES, V8, P232, DOI 10.1016/0920-1211(91)90069-R
   Cook SW, 2004, J NEUROSURG, V100, P125, DOI 10.3171/ped.2004.100.2.0125
   Curtiss S, 2001, BRAIN LANG, V79, P379, DOI 10.1006/brln.2001.2487
   Delalande O, 2007, NEUROSURGERY, V60, P19, DOI 10.1227/01.NEU.0000249246.48299.12
   Dorfer C, 2013, EPILEPSIA, V54, P1905, DOI 10.1111/epi.12394
   Engel Jr J., 1993, SURG TREATMENT EPILE, P609
   Freitag H, 2005, EPILEPSIA, V46, P561, DOI 10.1111/j.0013-9580.2005.03504.x
   Griessenauer CJ, 2015, J NEUROSURG-PEDIATR, V15, P34, DOI 10.3171/2014.10.PEDS14155
   Groppel G, 2015, SEIZURE-EUR J EPILEP, V30, P70, DOI 10.1016/j.seizure.2015.05.018
   Hu WH, 2016, J NEUROSURG, V124, P952, DOI 10.3171/2015.4.JNS14438
   Puka K, 2017, J NEUROPSYCHOL, V11, P161, DOI 10.1111/jnp.12081
   Puka K, 2015, EPILEPSIA, V56, P873, DOI 10.1111/epi.13004
   SCHRAMM J, 1995, NEUROSURGERY, V36, P509, DOI 10.1227/00006123-199503000-00010
   Shurtleff HA, 2015, J NEUROSURG-PEDIATR, V16, P383, DOI 10.3171/2015.3.PEDS14359
   Skirrow C, 2015, BRAIN, V138, P80, DOI 10.1093/brain/awu313
   Smith ML, 2011, NEUROPSYCHOLOGY CARE, P239
   Traub-Weidinger T, 2016, J NEUROSURG-PEDIATR, V18, P683, DOI 10.3171/2016.5.PEDS1652
   Verdinelli C, 2015, SEIZURE-EUR J EPILEP, V30, P76, DOI 10.1016/j.seizure.2015.05.016
   Wechsler D., 2003, MANUAL WECHSLER INTE
   Wechsler D, 2008, ADM SCORING MANUAL
   Westerveld M, 2000, J NEUROSURG, V92, P24, DOI 10.3171/jns.2000.92.1.0024
   Wieser HG, 2001, EPILEPSIA, V42, P282, DOI 10.1046/j.1528-1157.2001.4220282.x
NR 24
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.058
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600062
PM 31863898
DA 2020-05-12
ER

PT J
AU Ragurajaprakash, K
   Hanakita, J
   Takahashi, T
   Ueno, M
   Minami, M
   Tomita, Y
   Tsujimoto, Y
   Kanematsu, R
AF Ragurajaprakash, Kirubakaran
   Hanakita, Junya
   Takahashi, Toshiyuki
   Ueno, Manabu
   Minami, Manabu
   Tomita, Yosuke
   Tsujimoto, Yoshitaka
   Kanematsu, Ryo
TI Giant Invasive Sacral Schwannoma with Aortic Bifurcation Compression and
   Hydronephrosis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aortic bifurcation; Giant; Hydronephrosis; Invasive; Sacrum; Schwannoma;
   Vascular compression
AB BACKGROUND: Sacral schwannomas are rare tumors arising from nerve sheath Schwann cells. They are classified into 3 types: first type schwannoma arising from the sacrum, second type schwannoma eroding the sacrum, and third type schwannoma extending extensively, involving anterior, posterior, and retroperitoneal space. Among these type 2 sacral tumors, according to Klimo's classification, an eroding sacrum extending all over posteriorly, anteriorly, and laterally is still rarer. Only 38 cases have been reported in literature reviews. Only 6 cases of giant tumors of >10 cm in any 1 dimension have been reported.
   CASE DESCRIPTION: We present such a giant sacral schwannoma, with invasiveness eroding the sacrum; compressing the ureters, aortic bifurcation, bladder, and bowel; and presenting as lower abdominal pain, hydronephrosis, dysuria, and constipation. This is the first case reported in the literature that has described a large retroperitoneal tumor compressing retroperitoneal structures-aortic bifurcation vascular compression and ureter compression causing hydronephrosis.
   CONCLUSIONS: Though complete resection, which caused various severe postoperative complications in the reported cases, is the best option, a less morbid procedure would be appropriate; hence we underwent subtotal excision of the tumor, with complete recovery of our patient's symptoms without neurologic deficit.
C1 [Ragurajaprakash, Kirubakaran] Royal Care Super Specialty Hosp, Dept Neurosurg, Coimbatore, Tamil Nadu, India.
   [Hanakita, Junya; Takahashi, Toshiyuki; Minami, Manabu; Tomita, Yosuke; Tsujimoto, Yoshitaka; Kanematsu, Ryo] Fujieda Heisei Mem Hosp, Spinal Disorders Ctr, Fujieda, Shizuoka, Japan.
   [Ueno, Manabu] Fujieda Heisei Mem Hosp, Dept Urol, Fujieda, Shizuoka, Japan.
RP Ragurajaprakash, K (reprint author), Royal Care Super Specialty Hosp, Dept Neurosurg, Coimbatore, Tamil Nadu, India.
EM ragurajaprakash@yahoo.com
CR Chandhanayingyong Chandhanarat, 2008, Sarcoma, V2008, P845132, DOI 10.1155/2008/845132
   Dominguez J, 1997, ACTA NEUROCHIR, V139, P954, DOI 10.1007/BF01411305
   Fris TL, 2015, BRIT J NEUROSURG, V29, P595, DOI 10.3109/02688697.2015.1019416
   Girgin C, 2003, INT J UROL, V10, P616, DOI 10.1046/j.1442-2042.2003.00702.x
   Hoarau N, 2013, Diagn Interv Imaging, V94, P1133, DOI 10.1016/j.diii.2013.06.002
   Khan UA, 2018, WORLD NEUROSURG, V115, P65, DOI 10.1016/j.wneu.2018.03.203
   Klimo Paul Jr, 2003, Neurosurg Focus, V15, pE12
   Li Q, 2007, ANZ J SURG, V77, P237, DOI 10.1111/j.1445-2197.2007.04025.x
   Pongsthorn C, 2010, UPSALA J MED SCI, V115, P146, DOI 10.3109/03009730903359674
   Rasmussen TB, 1940, ANN SURG, V111, P513, DOI 10.1097/00000658-194004000-00001
   Schellinger KA, 2008, J NEURO-ONCOL, V87, P173, DOI 10.1007/s11060-007-9507-z
   Sridhar K, 2001, J NEUROSURG, V94, P210, DOI 10.3171/spi.2001.94.2.0210
   Stecken J, 1996, NEUROCHIRURGIE, V42, P294
   Togral G, 2014, NEUROSCIENCES, V19, P224
   Whittaker LD, 1938, ANN SURG, V107, P96, DOI 10.1097/00000658-193801000-00011
   Zhou M, 2013, SPINE J, V13, P1154, DOI 10.1016/j.spinee.2013.03.054
   Zou F, 2013, ONCOL LETT, V6, P1646, DOI 10.3892/ol.2013.1634
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.088
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600148
PM 31883482
DA 2020-05-12
ER

PT J
AU Rao, S
   Uppar, AM
   Santosh, V
AF Rao, Shilpa
   Uppar, Alok Mohan
   Santosh, Vani
TI Sonic Hedgehog-Activated Large Cell/Anaplastic Medulloblastoma with
   Myogenic Differentiation
SO WORLD NEUROSURGERY
LA English
DT Article
DE LCA; Medulloblastoma; Myogenic; SHH
ID MEDULLOMYOBLASTOMA
AB BACKGROUND: Medulloblastoma (MB) with myogenic differentiation is a histologic variant.
   CASE DESCRIPTION: We report a case of a 7-year-old female child who presented with a left cerebellar mass. Histopathologic examination showed a cellular neoplasm comprising undifferentiated cells along with foci of bizarre giant cells. Immunohistochemistry revealed that the tumor corresponded to the MB, sonic hedgehog - activated subgroup.
   CONCLUSIONS: The case is being reported to document this rare variant of MB that had myogenic differentiation, Molecular characterization of this variant has been analyzed in few cases so far.
C1 [Rao, Shilpa; Uppar, Alok Mohan; Santosh, Vani] Natl Inst Mental Hlth & Neurosci, Dept Neuropathol & Neurosurg, Bangladore, India.
RP Santosh, V (reprint author), Natl Inst Mental Hlth & Neurosci, Dept Neuropathol & Neurosurg, Bangladore, India.
EM vani.santosh@gmail.com
CR Bergmann M, 1998, ACTA NEUROPATHOL, V95, P205, DOI 10.1007/s004010050788
   Cavalli FMG, 2017, CANCER CELL, V31, P737, DOI 10.1016/j.ccell.2017.05.005
   Ellison DW, 2016, WHO CLASSIFICATION T, P184
   Fathaddin AA, 2014, INDIAN J PATHOL MICR, V57, P294, DOI 10.4103/0377-4929.134722
   Gupta K, 2018, HUM PATHOL, V75, P26, DOI 10.1016/j.humpath.2018.01.014
   Helton KJ, 2004, CANCER-AM CANCER SOC, V101, P1445, DOI 10.1002/cncr.20450
   KALIMO H, 1987, PEDIATR NEUROSCI, V13, P188, DOI 10.1159/000120328
   MANNOJI H, 1981, ACTA NEUROPATHOL, V55, P63, DOI 10.1007/BF00691533
   Nozza P, 2008, PEDIATR BLOOD CANCER, V50, P183, DOI 10.1002/pbc.20817
   Ramaswamy V, 2016, ACTA NEUROPATHOL, V131, P821, DOI 10.1007/s00401-016-1569-6
   Sarkar P, 2017, NEUROL INDIA, V65, P647, DOI 10.4103/neuroindia.NI_181_16
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.161
PG 3
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600096
PM 31809895
DA 2020-05-12
ER

PT J
AU Robinson, D
   Khoury, JC
   Kleindorfer, D
AF Robinson, David
   Khoury, Jane C.
   Kleindorfer, Dawn
TI Regional Variation in the Management of Nontraumatic Subdural Hematomas
   Across the United States
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epidemiology; Subdural hematomas; Surgical decision-making
ID TRAUMATIC BRAIN-INJURY; ASSOCIATION; EVACUATION; MORTALITY; ADMISSION;
   DIAGNOSIS; RATES; SCORE
AB BACKGOUND: Nontraumatic subdural hematomas are a common indication for inpatient hospitalization in the United States, yet there is little high-quality evidence regarding which patients should receive surgical or medical treatment. We sought to assess variation in surgical management and medical treatment with steroids for nontraumatic subdural hematomas across the United States.
   METHODS: Using the Premier database, we analyzed patients with a primary discharge diagnosis of nontraumatic subdural hematoma in 2014. international Classification of Diseases, Ninth Revision, procedure codes were used to identify patients who underwent surgical management, and pharmacy data were used to identify patients treated with dexamethasone. Univariable and multivariable analyses were used to examine the association of age, race, sex, academic versus nonacademic center, and regions of the United States with conservative or surgical management.
   RESULTS: There were 3915 inpatient hospitalizations for nontraumatic subdural hematomas in 2014 in the Premier database, of whom 1860 (47.5%) underwent surgery, and 360 (9.2%) underwent treatment with dexamethasone, either as a primary treatment or as an adjuvant to surgery. Older age, female sex, and being managed outside of the Western U.S. region were associated with a lower likelihood of undergoing surgical management on multivariable analysis; only younger age was associated with a greater likelihood of being treated with dexamethasone.
   CONCLUSIONS: There is considerable variability in surgical management of nontraumatic subdural hematomas across the United States based on age, sex, and region. Future studies should explore the reasons for the variability and attempt to better clarify indications for surgical management of subdural hematomas.
C1 [Robinson, David; Kleindorfer, Dawn] Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH 45221 USA.
   [Khoury, Jane C.] Cincinnati Childrens Med Ctr, Div Biostat & Epidemiol, Cincinnati, OH USA.
   [Khoury, Jane C.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA.
RP Robinson, D (reprint author), Univ Cincinnati, Dept Neurol & Rehabil Med, Cincinnati, OH 45221 USA.
EM robin2dv@ucmail.uc.edu
OI Robinson, David/0000-0003-3221-3599
FU National Institute of Neurological Disorders and StrokeUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS)
   [T32NS047996-13]
FX Funded by National Institute of Neurological Disorders and Stroke
   (T32NS047996-13).
CR Balser D, 2015, J NEUROSURG, V123, P1209, DOI 10.3171/2014.9.JNS141550
   Birkmeyer JD, 2013, LANCET, V382, P1121, DOI 10.1016/S0140-6736(13)61215-5
   Bullock MR, 2006, NEUROSURGERY S, V58, pSi
   Busl KM, 2013, J NEUROSURG, V119, P1296, DOI 10.3171/2013.4.JNS122236
   CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930
   Franko LR, 2018, J NEUROSURG, V129, P1008, DOI 10.3171/2017.6.JNS17188
   Frontera JA, 2011, CRIT CARE MED, V39, P1619, DOI 10.1097/CCM.0b013e3182186ed6
   Gaist D, 2017, JAMA-J AM MED ASSOC, V317, P836, DOI 10.1001/jama.2017.0639
   Gernsback JE, 2018, WORLD NEUROSURG, V120, pE414, DOI 10.1016/j.wneu.2018.08.095
   Glancz LJ, 2019, NEUROSURGERY, V85, P486, DOI 10.1093/neuros/nyy366
   Hotta K, 2017, WORLD NEUROSURG, V105, P47, DOI 10.1016/j.wneu.2017.05.105
   Jiang RC, 2018, JAMA NEUROL, V75, P1338, DOI 10.1001/jamaneurol.2018.2030
   Kalanithi P, 2011, J NEUROSURG, V115, P1013, DOI 10.3171/2011.6.JNS101989
   Karlson EW, 1997, AM J MED, V102, P524
   Kleindorfer D, 2008, STROKE, V39, P924, DOI 10.1161/STROKEAHA.107.490375
   Kocak A, 2009, TURK NEUROSURG, V19, P333
   Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448
   Marion DW, 2006, NEUROSURGERY, V58, P655
   Mehta V, 2018, J CLIN NEUROSCI, V50, P7, DOI 10.1016/j.jocn.2018.01.050
   Miah IP, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2945-4
   Missios S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092057
   Morris NA, 2016, NEUROCRIT CARE, V24, P226, DOI 10.1007/s12028-015-0178-x
   Patel PV, 2009, ARCH NEUROL-CHICAGO, V66, P79, DOI 10.1001/archneur.66.1.79
   Petridis AK, 2009, CENT EUR NEUROSURG, V70, P73, DOI 10.1055/s-0029-1224096
   Poulsen FR, 2016, PHARMACOEPIDEM DR S, V25, P1253, DOI 10.1002/pds.4058
   Reichman J, 2012, NEUROSURGERY, V71, P74, DOI 10.1227/NEU.0b013e3182517938
   Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6
   Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021
   THOMAS TPL, 1984, GERONTOLOGY, V30, P60
   Van Essen TA, 2018, J NEUROTRAUM, V35, pA184
   van Essen TA, 2017, J NEUROTRAUM, V34, P881, DOI 10.1089/neu.2016.4495
   WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412
   Yang WY, 2017, NEUROSURG CLIN N AM, V28, P205, DOI 10.1016/j.nec.2016.11.002
   Yao Z, 2017, ACTA NEUROCHIR, V159, P2037, DOI 10.1007/s00701-017-3309-7
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.011
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600048
PM 31862343
DA 2020-05-12
ER

PT J
AU Romano, DG
   Frauenfelder, G
   Napoletano, R
   Botto, A
   Locatelli, G
   Panza, MP
   Siani, A
   Tartaglione, S
   Visconti, E
   Saponiero, R
AF Romano, Daniele Giuseppe
   Frauenfelder, Giulia
   Napoletano, Rosa
   Botto, Annibale
   Locatelli, Gianpiero
   Panza, Maria Pia
   Siani, Alfredo
   Tartaglione, Salvatore
   Visconti, Emiliano
   Saponiero, Renato
TI ADAPT with New Catalyst 5 Reperfusion Catheter for Distal M2 Ischemic
   Stroke: Preliminary Experience
SO WORLD NEUROSURGERY
LA English
DT Article
DE Angiography; Catheter; Stroke; Thrombectomy
ID MIDDLE CEREBRAL-ARTERY; 1ST PASS TECHNIQUE; MECHANICAL THROMBECTOMY;
   ASPIRATION THROMBECTOMY; STENT RETRIEVER; OCCLUSION; THERAPY; LABEL
AB OBJECTIVE: We sought to assess preliminary technical and clinical outcomes of Catalyst 5 (CAT 5) as front-line aspiration treatment for M2-M3 occlusion in acute ischemic stroke.
   METHODS: Patients with symptomatic stroke and distal M2 or M3 occlusions were enrolled retrospectively. A direct aspiration first-pass technique was used as the first treatment option for absolute contraindication to intravenous fibrinolytic therapy. Time to recanalization, first attempt recanalization, and number of attempts were recorded. Successful recanalization was defined as a modified thrombolysis in cerebral infarction score >= 2b; incidence of procedure-related complications was recorded. National Institutes of Health Stroke Scale at discharge and modified Rankin Scale score at 90 days were evaluated by a dedicated neurologist.
   RESULTS: A total of 11 acute occlusions of distal M2-M3 segment were treated with a direct aspiration first-pass technique using CAT 5 (mean age 69.3 years). Tandem occlusion was present in 2 cases. Intracranial preocclusive mean vessel diameter was 1.9 mm. Overall modified thrombolysis in cerebral infarction score >= 2b was obtained in 72.7% of patients with mean time to recanalization of 36.4 minutes and a mean of 1.9 attempts. First-attempt recanalization with CAT 5 was obtained in 54% of patients with a mean time to recanalization of 29.2 minutes. A stent retriever with proximal aspiration was incorporated as a rescue device in 2 cases. Embolization of new territories was reported after CAT 5 aspiration in 1 patient. No intracranial hemorrhage was detected on follow-up computed tomography. The median National Institutes of Health Stroke Scale score at discharge was 3. At 90 days, a modified Rankin Scale score of 0-2 was achieved in 90.9% of patients.
   CONCLUSIONS: Preliminary experience using CAT 5 in distal occlusions demonstrates that it may be safe and effective in acute stroke treatment.
C1 [Romano, Daniele Giuseppe; Frauenfelder, Giulia; Botto, Annibale; Locatelli, Gianpiero; Panza, Maria Pia; Siani, Alfredo; Tartaglione, Salvatore; Visconti, Emiliano; Saponiero, Renato] AOU San Giovanni Dio & Ruggi Aragona, Dept Neuroradiol, Salerno, Italy.
   [Napoletano, Rosa] AOU San Giovanni Dio & Ruggi Aragona, Stroke Unit, Salerno, Italy.
RP Frauenfelder, G (reprint author), AOU San Giovanni Dio & Ruggi Aragona, Dept Neuroradiol, Salerno, Italy.
EM giulia.frauenfelder@gmail.com
CR Alawieh A, 2019, WORLD NEUROSURG, V128, pE445, DOI 10.1016/j.wneu.2019.04.175
   Altenbernd J, 2018, J NEUROINTERV SURG, V10, P434, DOI 10.1136/neurintsurg-2017-013233
   Baek JH, 2019, STROKE, V50, P1490, DOI 10.1161/STROKEAHA.118.024723
   Brehm A, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1291-9
   Chartrain AG, 2017, J CLIN NEUROSCI, V45, P140, DOI 10.1016/j.jocn.2017.07.026
   Coutinho JM, 2016, AM J NEURORADIOL, V37, P667, DOI 10.3174/ajnr.A4591
   Davalos A, 2004, NEUROLOGY, V62, P2187, DOI 10.1212/01.WNL.0000130570.41127.EA
   European stroke Organisation ( ESO), 2019, EUR STROKE J, V4, P6
   Gory B, 2018, EUR J NEUROL, V25, P284, DOI 10.1111/ene.13490
   Gory B, 2018, STROKE, V49, P461, DOI 10.1161/STROKEAHA.117.019598
   Grieb D, 2019, J NEURORADIOLOGY, V46, P231, DOI 10.1016/j.neurad.2019.01.096
   Hu YC, 2016, J NEUROINTERV SURG, V8, P244, DOI 10.1136/neurintsurg-2014-011563
   Kim YW, 2017, J NEUROINTERV SURG, V9, P626, DOI 10.1136/neurintsurg-2016-012466
   Mokin M, 2017, NEUROSURGERY, V81, P795, DOI 10.1093/neuros/nyx060
   Navia P, 2016, J NEUROINTERV SURG, V8, P787, DOI 10.1136/neurintsurg-2015-011798
   Nikoubashman O, 2017, AM J NEURORADIOL, V38, P2277, DOI 10.3174/ajnr.A5401
   Park JS, 2016, J KOREAN NEUROSURG S, V59, P352, DOI 10.3340/jkns.2016.59.4.352
   Premat K, 2018, CLIN NEURORADIOL, V28, P553, DOI 10.1007/s00062-017-0594-8
   Romano DG, 2019, RADIOL MED, V124, P408, DOI 10.1007/s11547-018-0965-5
   Saber H, 2018, J NEUROINTERV SURG, V10, P620, DOI 10.1136/neurintsurg-2017-013515
   Sarraj A, 2016, JAMA NEUROL, V73, P1291, DOI 10.1001/jamaneurol.2016.2773
   Stampfl S, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011801
   Turk AS, 2019, LANCET, V393, P998, DOI 10.1016/S0140-6736(19)30297-1
   Vargas J, 2017, WORLD NEUROSURG, V99, P31, DOI 10.1016/j.wneu.2016.11.035
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.098
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600077
PM 31881341
DA 2020-05-12
ER

PT J
AU Rosinski, A
   Odeh, K
   Leasure, J
   Kondrashov, D
AF Rosinski, Alexander
   Odeh, Khalid
   Leasure, Jeremi
   Kondrashov, Dimitriy
TI Motion Preservation at All Costs? Multilevel Hinge Nonunion, Plate
   Breakage, and Intradural Plate Migration After Cervical Laminoplasty: A
   Case Report and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cervical spondylotic myelopathy; Laminoplasty; Nonunion
ID OPEN-DOOR LAMINOPLASTY; POSTERIOR LONGITUDINAL LIGAMENT; EXPANSIVE
   LAMINOPLASTY; REVISION SURGERY; CANAL EXPANSION; MYELOPATHY; SPACERS;
   OSSIFICATION; FIXATION; FRACTURE
AB BACKGROUND: Cervical laminoplasty is a motion-preserving procedure that addresses spinal cord compression and avoids postlaminectomy kyphosis associated with cervical laminectomy. The most common complications include C5 nerve palsy, axial neck pain, hinge nonunion, and premature closure. Plating is a relatively newer method of laminoplasty fixation that may provide greater stabilization postoperatively and reduce the risk of laminoplasty closure compared with less rigid (e.g., suture) fixation techniques. Although prior studies have reported low rates of laminar/lateral mass screw back out, plate breakage and migration have not been previously described in the literature. The purpose of this paper is to present a case of multilevel hinge nonunion, plate breakage, and plate fragment migration. Although rare, plate failure may result in a dural tear and spinal cord injury/compression.
   CASE DESCRIPTION: In this case, a 61-year-old man with a history of cervical myelopathy treated with C3-7 laminoplasty 7 years prior presented to our hospital with severe headaches and electrical-type pain through the left upper and lower extremities. Imaging studies revealed several broken laminoplasty plates and intradural migration of a fragment of the C7 plate.
   CONCLUSIONS: We provide recommendations for preventing hinge nonunion because resultant micromotion likely contributed to the plate breakages observed in this patient.
C1 [Rosinski, Alexander; Leasure, Jeremi] Taylor Collaborat, San Francisco, CA 94117 USA.
   [Odeh, Khalid; Leasure, Jeremi; Kondrashov, Dimitriy] St Marys Hosp, San Francisco Orthopaed Residency Program, San Francisco, CA 94117 USA.
RP Leasure, J (reprint author), Taylor Collaborat, San Francisco, CA 94117 USA.; Leasure, J (reprint author), St Marys Hosp, San Francisco Orthopaed Residency Program, San Francisco, CA 94117 USA.
EM jleasure@taylorcollaboration.org
CR Chen H, 2016, CLIN SPINE SURG, V29, pE288, DOI 10.1097/BSD.0000000000000131
   Chiba K, 2006, SPINE, V31, P2998, DOI 10.1097/01.brs.0000250307.78987.6b
   Cho Sung Hoon, 2014, Korean J Spine, V11, P45, DOI 10.14245/kjs.2014.11.2.45
   Dimar John R 2nd, 2009, Am J Orthop (Belle Mead NJ), V38, pE123
   Duetzmann S, 2015, J NEUROSURG-SPINE, V23, P24, DOI 10.3171/2014.11.SPINE14427
   Goto T, 2002, J NEUROSURG, V97, P323, DOI 10.3171/spi.2002.97.3.0323
   HIRABAYASHI K, 1983, SPINE, V8, P693, DOI 10.1097/00007632-198310000-00003
   Hosono N, 2005, J NEUROSURG-SPINE, V3, P29, DOI 10.3171/spi.2005.3.1.0029
   Hur JW, 2016, J KOREAN NEUROSURG S, V59, P368, DOI 10.3340/jkns.2016.59.4.368
   Iwasaki M, 2007, SPINE, V32, P654, DOI 10.1097/01.brs.0000257566.91177.cb
   Jiang LJ, 2012, ORTHOPEDICS, V35, pE225, DOI 10.3928/01477447-20120123-07
   Kaito T, 2009, J NEUROSURG-SPINE, V10, P551, DOI 10.3171/2009.2.17680
   Kanemura A, 2008, J NEUROSURG-SPINE, V8, P121, DOI 10.3171/SPI/2008/8/2/121
   Kawaguchi Y, 1999, J SPINAL DISORD, V12, P392
   Kawaguchi Y, 2001, J BONE JOINT SURG AM, V83A, P1798, DOI 10.2106/00004623-200112000-00005
   Kimura A, 2011, EUR SPINE J, V20, P1560, DOI 10.1007/s00586-011-1724-7
   Komura S, 2011, ARCH ORTHOP TRAUM SU, V131, P1177, DOI 10.1007/s00402-010-1248-3
   Leckie SK, 2016, OPERATIVE TECHNIQUES, P27
   Lee DH, 2017, J CLIN NEUROSCI, V43, P72, DOI 10.1016/j.jocn.2017.04.037
   Lee Jung Hwan, 2018, Korean J Neurotrauma, V14, P118, DOI 10.13004/kjnt.2018.14.2.118
   Lee S, 2015, GLOB SPINE J, V5, P9, DOI 10.1055/s-0034-1394128
   Lehman RA, 2008, J AM ACAD ORTHOP SUR, V16, P47, DOI 10.5435/00124635-200801000-00007
   Liu G, 2015, ASIAN SPINE J, V9, P849, DOI 10.4184/asj.2015.9.6.849
   Liu G, 2009, SPINE, V34, P2760, DOI 10.1097/BRS.0b013e3181b11ee1
   Maeda T, 2002, CLIN ORTHOP RELAT R, P132
   Matsumoto M, 2012, SPINE, V37, P1288, DOI 10.1097/BRS.0b013e3182498434
   Matsumoto M, 2008, J NEUROSURG-SPINE, V9, P530, DOI 10.3171/SPI.2008.4.08176
   Ohara Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204147
   Ono A, 2007, J NEUROSURG-SPINE, V7, P230, DOI 10.3171/SPI-07/08/230
   Onuma H, 2018, J ORTHOP SCI, V23, P923, DOI 10.1016/j.jos.2018.07.018
   Park AE, 2004, J SPINAL DISORD TECH, V17, P265, DOI 10.1097/01.bsd.0000095401.27687.c0
   Park YK, 2014, SPINE J, V14, P1205, DOI 10.1016/j.spinee.2013.08.012
   Ratliff JK, 2003, J NEUROSURG, V98, P230, DOI 10.3171/spi.2003.98.3.0230
   Rhee JM, 2011, SPINE, V36, P9, DOI 10.1097/BRS.0b013e3181fea49c
   Sakaura H, 2011, EUR SPINE J, V20, P928, DOI 10.1007/s00586-011-1690-0
   Satomi K, 2001, Spine J, V1, P26, DOI 10.1016/S1529-9430(01)00008-0
   SATOMI K, 1994, SPINE, V19, P507, DOI 10.1097/00007632-199403000-00003
   Seichi A, 2001, SPINE, V26, P479, DOI 10.1097/00007632-200103010-00010
   Shigematsu H, 2015, SPINE J, V15, pE7, DOI 10.1016/j.spinee.2013.11.048
   Suk KS, 2007, SPINE, V32, pE656, DOI 10.1097/BRS.0b013e318158c573
   Tadepalli Srinivas C, 2011, Iowa Orthop J, V31, P207
   Takahashi Y, 2006, J SPINAL DISORD TECH, V19, P194, DOI 10.1097/01.bsd.0000193821.50146.78
   Tamai K, 2016, SPINE J, V16, P1062, DOI 10.1016/j.spinee.2016.04.018
   Tanaka N, 2008, J SPINAL DISORD TECH, V21, P547, DOI 10.1097/BSD.0b013e31815c85bd
   Tanaka S, 2011, NEUROL MED-CHIR, V51, P673, DOI 10.2176/nmc.51.673
   Thakur NA, 2013, SEMIN SPINE SURG, V25, P209
   Veeravagu A, 2018, J CLIN NEUROSCI, V48, P66, DOI 10.1016/j.jocn.2017.10.089
   Yamazaki A, 1999, SPINE, V24, P32, DOI 10.1097/00007632-199901010-00008
   Yonenobu K, 2003, EUR SPINE J, V12, pS195, DOI 10.1007/s00586-003-0599-7
   Yuan W, 2019, WORLD NEUROSURG, V130, pE90, DOI 10.1016/j.wneu.2019.05.240
NR 50
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.074
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600109
PM 31759152
DA 2020-05-12
ER

PT J
AU Rybkin, I
   Azizkhanian, I
   Gary, J
   Cole, C
   Schmidt, M
   Gandhi, C
   Al-Mufti, F
   Anderson, P
   Santarelli, J
   Bowers, C
AF Rybkin, Ilya
   Azizkhanian, Ida
   Gary, James
   Cole, Chad
   Schmidt, Meic
   Gandhi, Chirag
   Al-Mufti, Fawaz
   Anderson, Patrice
   Santarelli, Justin
   Bowers, Christian
TI Unique Neurosurgical Morbidity and Mortality Conference Characteristics:
   A Comprehensive Literature Review of Neurosurgical Morbidity and
   Mortality Conference Practices with Proposed Recommendations
SO WORLD NEUROSURGERY
LA English
DT Review
DE Adverse event; Complication; Complication grading; Complication scale;
   Frailty; Morbidity and mortality; Surgical complexity
ID CHARLSON COMORBIDITY INDEX; ADVERSE EVENTS; FRAILTY-INDEX; RISK
   STRATIFICATION; SPINE SURGERY; COMPLICATIONS; CLASSIFICATION; OUTCOMES;
   FUSION; ASA
AB OBJECTIVE: The aim of the present study was to review the reported data for neurosurgical complication definitions, report the current scales used to classify these complications, and discuss their limitations.
   METHODS: A systematic review was performed through a PubMed search using predetermined MeSH terms and inclusion criteria. Studies meeting the inclusion criteria were specific to the field of neurosurgery and had presented a unique complication grading scale.
   RESULTS: A total of 2156 PubMed results matched our predetermined MeSH terms. Of those, 7 met our inclusion criteria. These 7 studies were reported from 2001 to 2019. Of the 7 studies, 4 were applicable to general neurosurgery, 2 to spine surgery, and 1 to neuroendovascular surgery. The scales were based on the therapy needed, predictability and avoidability, survey/consensus of expert judgment, and the underlying cause of an adverse event. None of these studies had considered the complexity of the surgery or the frailty of the patient in the final grading score.
   CONCLUSIONS: No current standardized neurosurgical complication grade has been used throughout morbidity and mortality conferences. Although scales have been proposed in reported studies, each with their strengths and limitations, none of these has considered surgery complexity or patient frailty and comorbidities. We believe a comprehensive scale is required that includes a preoperative grading system that factors in baseline surgical complexity and patient frailty.
C1 [Rybkin, Ilya; Azizkhanian, Ida] New York Med Coll, Sch Med, Valhalla, NY 10595 USA.
   [Gary, James] Albert Einstein Coll Med, Sch Med, Bronx, NY 10467 USA.
   [Cole, Chad; Schmidt, Meic; Gandhi, Chirag; Al-Mufti, Fawaz; Santarelli, Justin; Bowers, Christian] New York Med Coll, Westchester Med Ctr, Dept Neurosurg, Valhalla, NY 10595 USA.
   [Anderson, Patrice] New York Med Coll, Westchester Med Ctr, Dept Surg, New York, NY 10595 USA.
RP Rybkin, I (reprint author), New York Med Coll, Sch Med, Valhalla, NY 10595 USA.
EM irybkin@student.nymc.edu
OI Bowers, Christian/0000-0001-6299-503X
CR Ali R, 2016, J NEUROSURG-SPINE, V25, P537, DOI 10.3171/2015.10.SPINE14582
   Antonacci AC, 2008, J SURG RES, V147, P172, DOI 10.1016/j.jss.2008.02.054
   Baron EM, 2006, SPINE, V31, pS106, DOI 10.1097/01.brs.0000232713.69342.df
   Bekelis K, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.8.FOCUS15354
   Bohnen JD, 2016, ANN SURG, V263, P857, DOI 10.1097/SLA.0000000000001508
   Bonsanto MM, 2001, ACT NEUR S, V78, P139
   Bortz CA, 2019, CLIN SPINE SURG, V32, P263, DOI 10.1097/BSD.0000000000000748
   Brock Stefano, 2016, Surg Neurol Int, V7, pS565, DOI 10.4103/2152-7806.188471
   Broggi Morgan, 2018, Surg Neurol Int, V9, P65, DOI 10.4103/sni.sni_424_17
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Clark JC, 2011, WORLD NEUROSURG, V75, P608, DOI 10.1016/j.wneu.2010.12.032
   CLAVIEN PA, 1992, SURGERY, V111, P518
   Dekutoski MB, 2010, SPINE PHILA PA 197 S, V35, pS9
   Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae
   FACISZEWSKI T, 1995, SPINE, V20, P1592, DOI 10.1097/00007632-199507150-00007
   Ferreira KS, 2019, J SURG EDUC, V76, P174, DOI 10.1016/j.jsurg.2018.07.002
   Ferroli P, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.9.FOCUS15339
   Ferroli P, 2015, J NEUROSURG, V122, P983, DOI 10.3171/2014.10.JNS142269
   Ferroli P, 2014, WORLD NEUROSURG, V82, pE576, DOI 10.1016/j.wneu.2014.03.036
   Gozal YM, 2020, J NEUROSURG, V132, P272, DOI 10.3171/2018.9.JNS181004
   Hamilton A., 1999, PREFACE, V1, pxix
   Houkin K, 2009, NEUROSURGERY, V65, P587, DOI 10.1227/01.NEU.0000350860.59902.68
   Jacobs Jeffrey P, 2017, Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu, V20, P43, DOI 10.1053/j.pcsu.2016.09.008
   Lakomkin N, 2019, SPINE, V44, pE782, DOI 10.1097/BRS.0000000000002970
   Ibanez FAL, 2011, WORLD NEUROSURG, V75, P709, DOI 10.1016/j.wneu.2010.11.010
   Lebude B, 2010, J SPINAL DISORD TECH, V23, P493, DOI 10.1097/BSD.0b013e3181c11f89
   Leven DM, 2016, SPINE, V41, pE1394, DOI 10.1097/BRS.0000000000001886
   Mahdy ME, 2019, EGYTPIAN J NEUROL PS, V55, P19
   McGirt MJ, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2012.10.FOCUS12297
   Newman WC, 2016, J NEUROSURG, V125, P713, DOI 10.3171/2015.8.JNS14553
   Ondeck NT, 2018, SPINE J, V18, P44, DOI 10.1016/j.spinee.2017.05.028
   Parker SL, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.9.FOCUS15355
   Patel N, 2007, J NEUROSURG-SPINE, V6, P291, DOI 10.3171/spi.2007.6.4.1
   Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433
   Rampersaud YR, 2006, SPINE, V31, P1503, DOI 10.1097/01.brs.0000220652.39970.c2
   Ravindra VM, 2016, WORLD NEUROSURG, V95, P1, DOI 10.1016/j.wneu.2016.07.089
   Reponen E, 2016, WORLD NEUROSURG, V91, P567, DOI 10.1016/j.wneu.2016.03.102
   Rotman LE, 2018, WORLD NEUROSURG, V115, pE105, DOI 10.1016/j.wneu.2018.03.195
   Saklad M, 1941, ANESTHESIOLOGY, V2, P281, DOI DOI 10.1097/00000542-194105000-00004
   Sarnthein J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163154
   Sawaya R, 1998, NEUROSURGERY, V42, P1044, DOI 10.1097/00006123-199805000-00054
   Schiavolin S, 2015, WORLD NEUROSURG, V84, P36, DOI 10.1016/j.wneu.2015.02.008
   Seely AJE, 2010, ANN THORAC SURG, V90, P936, DOI 10.1016/j.athoracsur.2010.05.014
   Sokol Daniel K, 2008, World J Surg, V32, P942, DOI 10.1007/s00268-008-9471-6
   Steiger HJ, 2010, ACTA NEUROCHIR, V152, P2013, DOI 10.1007/s00701-010-0822-3
   Velanovich V, 2013, J SURG RES, V183, P104, DOI 10.1016/j.jss.2013.01.021
   Youngerman BE, 2018, J NEURO-ONCOL, V136, P197, DOI 10.1007/s11060-017-2644-0
NR 47
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.028
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600103
PM 31733387
DA 2020-05-12
ER

PT J
AU Sadique, SI
   Pandey, P
   Chaudhuri, AK
AF Sadique, Shahid, I
   Pandey, Pranjal
   Chaudhuri, Anup K.
TI Cerebrospinal Fluid Flowmetry in Pediatric Patients with Chiari
   Malformation I with Surgical Implications
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chiari I; Craniocervical decompression; CSF flow velocity; Hindbrain
   anomalies; Peak flow velocity; Posterior fossa decompression
ID FLOW; CSF; EXPERIENCE
AB BACKGROUND: Chiari malformations include a large spectrum of anomalies of hindbrain formation that appear at different stages of development of the central nervous system. Chiari described these malformations as congenital anomalies of the hindbrain characterized by downward elongation of the brain stem and cerebellum into the cervical portion of spinal cord. Much research regarding Chiari malformation I (CMI) has focused on the cerebrospinal fluid (CSF) dynamics rather than the anatomic relationships of the tonsils and brainstem. The aim of the present study was to measure the peak CSF velocity at the foramen magnum and record the changes after foramen magnum decompression in patients with CMI aged <18 years.
   METHODS: A total of 39 patients with CMI were included during a 2-year period and were analyzed for peak CSF flow velocity with respect to surgical intervention using predefined magnetic resonance imaging protocols and surgical technique.
   RESULTS: After foramen magnum decompression, the postoperative mean CSF peak flow velocity showed a statistically significant difference compared with the preoperative value.
   CONCLUSION: Decompression of the foramen magnum was associated with decreased CSF peak velocity in patients with CMI.
C1 [Sadique, Shahid, I; Pandey, Pranjal; Chaudhuri, Anup K.] Inst Post Grad Med Educ & Res, Bangur Inst Neurosci, Dept Neurosurg, Kolkata, India.
RP Pandey, P (reprint author), Inst Post Grad Med Educ & Res, Bangur Inst Neurosci, Dept Neurosurg, Kolkata, India.
EM drpranjalpandey@gmail.com
OI Pandey, Pranjal/0000-0002-2675-6426
CR ARMONDA RA, 1994, NEUROSURGERY, V35, P214, DOI 10.1227/00006123-199408000-00006
   BHADELIA RA, 1995, RADIOLOGY, V196, P195, DOI 10.1148/radiology.196.1.7784567
   Brugieres P, 2000, AM J NEURORADIOL, V21, P1785
   Chern JJ, 2011, J NEUROSURG-PEDIATR, V8, P1, DOI 10.3171/2011.4.PEDS10528
   CHIARI H, 1987, PEDIATR NEUROSCI, V13, P3, DOI 10.1159/000120293
   Dolar MT, 2004, AM J NEURORADIOL, V25, P142
   DYSTE GN, 1989, J NEUROSURG, V71, P159, DOI 10.3171/jns.1989.71.2.0159
   GREITZ D, 1992, NEURORADIOLOGY, V34, P370, DOI 10.1007/BF00596493
   Heiss JD, 1999, J NEUROSURG, V91, P553, DOI 10.3171/jns.1999.91.4.0553
   Hofmann E, 2000, AM J NEURORADIOL, V21, P151
   Iskandar BJ, 1998, J NEUROSURG, V89, P212, DOI 10.3171/jns.1998.89.2.0212
   Quigley MF, 2004, RADIOLOGY, V232, P229, DOI 10.1148/radiol.2321030666
   Tubbs RS, 2011, J NEUROSURG-PEDIATR, V7, P248, DOI 10.3171/2010.12.PEDS10379
   Tubbs RS, 2003, J NEUROSURG, V99, P291, DOI 10.3171/jns.2003.99.2.0291
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.184
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600011
PM 31704358
DA 2020-05-12
ER

PT J
AU Sang, HP
   Cui, W
   Sang, DC
   Guo, Z
   Liu, BG
AF Sang, Hongpeng
   Cui, Wei
   Sang, Dacheng
   Guo, Ze
   Liu, Baoge
TI How Center of Rotation Changes and What Affects These After Cervical
   Arthroplasty: A Systematic Review and Meta-analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Center of rotation; Cervical arthroplasty; Clinical study; In vivo
ID TOTAL DISC REPLACEMENT; IN-VIVO KINEMATICS; TERM-FOLLOW-UP; INTERBODY
   FUSION; SPINE; IMPLANTATION; DISKECTOMY
AB PURPOSE: To determine how center of rotation (COR) changes and what affects changes in COR after cervical arthroplasty.
   METHODS: A systematic literature review of in vivo clinical studies comparing the location of the COR before and after cervical arthroplasty with different artificial prostheses was performed. Meta-analysis was performed using a fixed effects model where appropriate.
   RESULTS: A systematic review of the PubMed, EMBASE, and Cochrane Library databases was conducted. We initially identified 267 studies, of which 14 involved in vivo kinematics studies evaluating COR following cervical arthroplasty. We found that at the last follow-up, the COR location shifted anteriorly in patients from 4 studies including 85 segments, superiorly in patients from 4 studies including 98 segments, anterior-superiorly in patients from 4 studies including 290 segments, and anterior-inferiorly in patients from 1 study including 272 segments after cervical arthroplasty. The COR location showed no significant change in patients from 5 studies including 106 segments after cervical arthroplasty. Changes in COR showed a certain trend after cervical arthroplasty with different types of prostheses.
   CONCLUSIONS: Prosthesis design affects changes in COR after cervical arthroplasty. If a constrained or semiconstrained prosthesis is chosen (2-piece implant, balland-socket, or ball-in-trough design), the COR location tends to shift anteriorly and/or superiorly, whereas if a nonconstrained prosthesis is chosen (3-piece implant, mobile nucleus design), the COR tends to keep the same location as preoperation. In addition, the position of the prosthesis in the intervertebral space also can affect changes in COR after cervical arthroplasty.
C1 [Sang, Hongpeng; Cui, Wei; Sang, Dacheng; Guo, Ze; Liu, Baoge] Capital Med Univ, Beijing Tiantan Hosp, Dept Orthopaed Surg, Beijing, Peoples R China.
   [Sang, Hongpeng; Cui, Wei; Sang, Dacheng; Guo, Ze; Liu, Baoge] China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
RP Liu, BG (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Orthopaed Surg, Beijing, Peoples R China.; Liu, BG (reprint author), China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China.
EM baogeliu@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81772370, 81972084]; Beijing Municipal
   Administration of Hospital Clinical Medicine Development of Special
   Funding Support [XMLX201803]
FX This work was supported by funding from the National Natural Science
   Foundation of China (Grant Nos. 81772370 and 81972084) and the Beijing
   Municipal Administration of Hospital Clinical Medicine Development of
   Special Funding Support (Grant No. XMLX201803).
CR Barrey C, 2012, EUR SPINE J, V21, P1648, DOI 10.1007/s00586-012-2180-8
   BOHLMAN HH, 1993, J BONE JOINT SURG AM, V75A, P1298, DOI 10.2106/00004623-199309000-00005
   Duggal N, 2011, J SPINAL DISORD TECH, V24, P334, DOI 10.1097/BSD.0b013e3181fbf8aa
   DVORAK J, 1991, J ORTHOPAED RES, V9, P828, DOI 10.1002/jor.1100090608
   Galbusera F, 2006, BIOMECH MODEL MECHAN, V5, P253, DOI 10.1007/s10237-006-0015-4
   Goffin J, 2004, J SPINAL DISORD TECH, V17, P79, DOI 10.1097/00024720-200404000-00001
   Ishihara Hirokazu, 2004, Spine J, V4, P624, DOI 10.1016/j.spinee.2004.04.011
   Koller H, 2013, EUR SPINE J, V22, P747, DOI 10.1007/s00586-012-2583-6
   Kowalczyk I, 2013, INT J SPINE SURG, V7, DOI 10.1016/j.ijsp.2013.10.003
   Kowalczyk I, 2011, J NEUROSURG-SPINE, V15, P630, DOI 10.3171/2011.8.SPINE11273
   Lazaro BCR, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2010.3.FOCUS1058
   Liu BG, 2014, EUR SPINE J, V23, P2307, DOI 10.1007/s00586-014-3431-7
   Lou JG, 2016, ACTA ORTHOP TRAUMATO, V50, P339, DOI 10.3944/AOTT.2016.15.0182
   Matsunaga S, 1999, SPINE, V24, P670, DOI 10.1097/00007632-199904010-00011
   Meisel HJ, 2016, J NEUROSURG-SPINE, V25, P556, DOI 10.3171/2016.3.SPINE15810
   Mummaneni PV, 2004, J NEUROSURG-SPINE, V1, P155, DOI 10.3171/spi.2004.1.2.0155
   Park DK, 2011, SPINE, V36, P721, DOI 10.1097/BRS.0b013e3181df10fc
   Patwardhan AG, 2012, EUR SPINE J, V21, pS618, DOI 10.1007/s00586-010-1575-7
   Pickett GE, 2005, SPINE, V30, P1949, DOI 10.1097/01.brs.0000176320.82079.ce
   Powell JW, 2010, J SPINAL DISORD TECH, V23, P89, DOI 10.1097/BSD.0b013e3181991413
   Riina Joseph, 2008, Am J Orthop (Belle Mead NJ), V37, pE71
   Rong X, 2014, SPINE, V39, pB12, DOI 10.1097/BRS.0000000000000634
   Rousseau MA, 2008, SPINE, V33, pE6, DOI 10.1097/BRS.0b013e31815e5dce
   Rousseau MA, 2008, SPINE, V33, pE10, DOI 10.1097/BRS.0b013e31815e62ea
   Ryu WHA, 2013, SPINE J, V13, P628, DOI 10.1016/j.spinee.2013.02.046
   Yue WM, 2005, SPINE, V30, P2138, DOI 10.1097/01.brs.0000180479.63092.17
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.111
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600084
PM 31887466
DA 2020-05-12
ER

PT J
AU Sath, S
   Kalidindi, KKV
   Manghwani, J
   Chhabra, HS
AF Sath, Sulaiman
   Kalidindi, Kalyan Kumar Varma
   Manghwani, Jitesh
   Chhabra, Harvinder Singh
TI Spinal Epidural Hematoma Post Evacuation of Spontaneous Spinal
   Intradural Hematoma
SO WORLD NEUROSURGERY
LA English
DT Article
DE Epidural hematoma after surgical decompression; Intradural hematoma;
   Intradural hematoma presenting as a multiloculated cystic lesion;
   Intradural spinal hematoma; Recurrent spinal hematoma; Spinal hematoma
   after dengue fever with normal platelet counts; Spontaneous spinal
   hematoma post dengue fever
ID SUBDURAL-HEMATOMA
AB BACKGROUND: Spinal hematomas are rarely associated with dengue syndrome and usually occur at the time of active dengue fever. Late presentation after recovery from dengue fever, intradural hematoma, presentation as a multiloculated cystic lesion with longitudinal extensive myelitis, and recurrence after surgery are rarely or not described. Due to the peculiar association of all these findings, we report this case to provide insight into the existence of such a rare presentation.
   CASE DESCRIPTION: A 79-year-old-male developed sudden-onset paraparesis after 1 week of recovery from dengue fever. The blood counts were normal. Magnetic resonance imaging of the thoracic spine was suggestive of intradural hematoma. The patient underwent emergency decompression and drainage of hematoma with recovery in the neurologic status over the next few weeks. lie presented to our emergency department after 5 weeks of the first surgery with deterioration in the neurologic status to complete paraplegia. Repeat magnetic resonance imaging showed a posterior epidural collection bulging anteriorly, causing cord compression. The patient was reoperated on by decompression. There was no neurologic recovery. The patient was managed with multidisciplinary rehabilitation, and he was independent in most of the activities at the time of discharge.
   CONCLUSIONS: Spinal hematoma should be kept in mind in patients who present with neurologic complications after dengue fever. It can have an atypical radiologic presentation and may present with recurrent hemorrhage after surgery. Attention should also be given to delayed presentation of neurologic complications, which may develop even after weeks of recovery from dengue fever.
C1 [Sath, Sulaiman; Kalidindi, Kalyan Kumar Varma; Manghwani, Jitesh; Chhabra, Harvinder Singh] Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
RP Kalidindi, KKV (reprint author), Indian Spinal Injuries Ctr, Dept Spine Serv, New Delhi, India.
EM kalyanvarmambbs@gmail.com
OI Manghwani, Jitesh/0000-0003-1344-9352
CR Baruah S, 2019, WORLD NEUROSURG, V122, P272, DOI 10.1016/j.wneu.2018.10.201
   Fong CY, 2016, EUR J PAEDIATR NEURO, V20, P449, DOI 10.1016/j.ejpn.2016.01.012
   Kaur J, 2017, 2017 INTERNATIONAL CONFERENCE ON NEXT GENERATION COMPUTING AND INFORMATION SYSTEMS (ICNGCIS), P177, DOI 10.1109/ICNGCIS.2017.35
   Kutty Raja Krishnan, 2019, Asian J Neurosurg, V14, P211, DOI 10.4103/ajns.AJNS_318_17
   Maheshwari Vikas, 2019, Asian J Neurosurg, V14, P550, DOI 10.4103/ajns.AJNS_228_18
   Morandi X, 2001, Spine (Phila Pa 1976), V26, pE547, DOI 10.1097/00007632-200112010-00022
   Pancharoen Chitsanu, 2001, Southeast Asian Journal of Tropical Medicine and Public Health, V32, P341
   SCHILLER F, 1948, LANCET, V252, P842, DOI 10.1016/S0140-6736(48)91427-5
   SWANN KW, 1984, J NEUROSURG, V61, P975, DOI 10.3171/jns.1984.61.5.0975
NR 9
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.119
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600124
PM 31786376
DA 2020-05-12
ER

PT J
AU Scala, M
   Fiaschi, P
   Cama, A
   Consales, A
   Piatelli, G
   Giannelli, F
   Barra, S
   Satragno, C
   Pacetti, M
   Secci, F
   Tortora, D
   Garre, ML
   Pavanello, M
AF Scala, Marcello
   Fiaschi, Pietro
   Cama, Armando
   Consales, Alessandro
   Piatelli, Gianluca
   Giannelli, Flavio
   Barra, Salvina
   Satragno, Camilla
   Pacetti, Mattia
   Secci, Francesca
   Tortora, Domenico
   Garre, Maria Luisa
   Pavanello, Marco
TI Radiation-Induced Moyamoya Syndrome in Children with Brain Tumors: Case
   Series and Literature Review
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain tumors; Moyamoya syndrome; Radiation therapy; Revascularization
ID CRANIAL IRRADIATION; CEREBRAL VASCULOPATHY; PEDIATRIC-PATIENTS;
   OCCLUSIVE DISEASE; THERAPY; REVASCULARIZATION; CRANIOPHARYNGIOMA;
   GLIOMA; ABNORMALITIES; RADIOTHERAPY
AB BACKGROUND: Over the last decades, significant advancements have been achieved in the treatment of pediatric brain tumors as a result of radiation therapy (RT). With the increasing diffusion of this treatment, iatrogenic damage to cerebrovascular tissues contouring the radiation target volume has become the subject of debate, especially radiation-induced moyamoya syndrome (RIMS).
   METHODS: A systematic literature search was performed on the association between moyamoya vasculopathy and cranial irradiation in children. Large case series of patients with moyamoya were analyzed and clinicoradiologic data were collected reviewing pediatric patients treated with RT for primary brain tumors at our institution.
   RESULTS: The risk of developing RIMS is higher in younger children, in patients with optic pathway glioma, and in those receiving higher radiation doses. Headache is the most common presenting symptom and cerebral infarction is frequent. The preferred surgical techniques were pial synangiosis and encephaloduroarteriosynangiosis. In our case series, surgical revascularization led to neovascularization, with clinical improvement or stability in all patients. Medical therapy did not significantly affect the clinical course.
   CONCLUSIONS: Pediatric patients receiving involved field RT for the treatment of brain tumors have an increased risk of developing RIMS. Prompt diagnosis and early surgical revascularization play a pivotal role in decreasing the clinical impact of this complication. The use of new techniques, such as the intensity-modulated RT, and the increasing dose saving for the organs at risk, are essential to prevent iatrogenic vasculopathy. The combination of appropriate medical therapy and surgery will improve patient management and clinical outcome.
C1 [Scala, Marcello; Cama, Armando; Consales, Alessandro; Piatelli, Gianluca; Pacetti, Mattia; Secci, Francesca; Pavanello, Marco] IRCCS Ist Giannina Gaslini, Dept Neurosurg, Genoa, Italy.
   [Tortora, Domenico] IRCCS Ist Giannina Gaslini, Neuroradiol Unit, Genoa, Italy.
   [Garre, Maria Luisa] IRCCS Ist Giannina Gaslini, Neuroncol Unit, Genoa, Italy.
   [Scala, Marcello] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
   [Fiaschi, Pietro] Univ Genoa, Dept Neurosci DINOGMI, Div Neurosurg, Osped Policlin San Martino IST, Genoa, Italy.
   [Giannelli, Flavio; Barra, Salvina] Osped Policlin San Martino, Dept Radiat Oncol, Genoa, Italy.
   [Satragno, Camilla] Univ Genoa, Hlth Sci Dept DISSAL & Radiat Oncol, Osped Policlin San Martino, Genoa, Italy.
   [Satragno, Camilla] San Martino Hosp, Genoa, Italy.
RP Scala, M (reprint author), IRCCS Ist Giannina Gaslini, Dept Neurosurg, Genoa, Italy.; Scala, M (reprint author), Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy.
EM marcelloscala87@gmail.com
OI Pacetti, Mattia/0000-0001-6426-6164
CR Alahmari Mohammed, 2019, Surg Neurol Int, V10, P96, DOI 10.25259/SNI-213-2019
   ALAMRO A, 1995, ACTA ONCOL, V34, P261, DOI 10.3109/02841869509093967
   Aoki S, 2002, RADIOLOGY, V223, P683, DOI 10.1148/radiol.2233010822
   BEYER RA, 1986, NEUROLOGY, V36, P1173, DOI 10.1212/WNL.36.9.1173
   BITZER M, 1995, STROKE, V26, P131, DOI 10.1161/01.STR.26.1.131
   Brandicourt P, 2018, NEUROCHIRURGIE, V64, P63, DOI 10.1016/j.neuchi.2017.11.004
   Campen CJ, 2012, STROKE, V43, P3035, DOI 10.1161/STROKEAHA.112.661561
   DARMODY WR, 1967, NEUROLOGY, V17, P1190, DOI 10.1212/WNL.17.12.1190
   DEBRUN G, 1974, NEURORADIOLOGY, V7, P277, DOI 10.1007/BF00344247
   Desai SS, 2006, INT J RADIAT ONCOL, V65, P1222, DOI 10.1016/j.ijrobp.2006.01.038
   Dlamini N, 2019, PEDIATR NEUROL, V91, P11, DOI 10.1016/j.pediatrneurol.2018.10.006
   Duan L, 2012, STROKE, V43, P56, DOI 10.1161/STROKEAHA.111.621300
   EPSTEIN MA, 1992, CANCER, V70, P887
   Feghali James, 2019, J Neurosurg, P1, DOI 10.3171/2019.6.JNS191099
   FLICKINGER JC, 1988, CANCER, V61, P635, DOI 10.1002/1097-0142(19880215)61:4<635::AID-CNCR2820610403>3.0.CO;2-2
   Ghosh PS, 2013, J CHILD NEUROL, V28, P95, DOI 10.1177/0883073812441059
   Goto Yasunobu, 1992, Neurologia Medico-Chirurgica, V32, P883, DOI 10.2176/nmc.32.883
   GRINDAL AB, 1974, STROKE, V5, P603, DOI 10.1161/01.STR.5.5.603
   Guey S, 2015, APPL CLIN GENET, V8, P49, DOI 10.2147/TACG.S42772
   Han JY, 2017, J KOREAN MED SCI, V32, P1896, DOI 10.3346/jkms.2017.32.11.1896
   Hayashi K, 2013, CLIN NEUROL NEUROSUR, V115, P930, DOI 10.1016/j.clineuro.2012.09.020
   HILAL SK, 1971, RADIOLOGY, V99, P71, DOI 10.1148/99.1.71
   HIRATA Y, 1985, ACTA NEUROCHIR, V74, P141, DOI 10.1007/BF01418804
   Horiguchi S, 2011, NEUROL MED-CHIR, V51, P310, DOI 10.2176/nmc.51.310
   Horn P, 2004, CHILD NERV SYST, V20, P382, DOI 10.1007/s00381-004-0960-0
   Hoshino H, 2012, NEUROL MED-CHIR, V52, P295, DOI 10.2176/nmc.52.295
   KARASAWA J, 1978, J NEUROSURG, V49, P679, DOI 10.3171/jns.1978.49.5.0679
   Kato Y, 2019, J STROKE CEREBROVASC, V28, pE46, DOI 10.1016/j.jstrokecerebrovasdis.2019.01.033
   KESTLE JRW, 1993, J NEUROSURG, V79, P32, DOI 10.3171/jns.1993.79.1.0032
   Kim TG, 2011, PEDIATR NEUROSURG, V47, P138, DOI 10.1159/000330541
   KLATTE EC, 1976, SEMIN ROENTGENOL, V11, P17, DOI 10.1016/0037-198X(76)90061-4
   Kraemer M, 2008, STROKE, V39, P3193, DOI 10.1161/STROKEAHA.107.513408
   LAU YL, 1986, J ROY SOC MED, V79, P236, DOI 10.1177/014107688607900414
   Lee HS, 2011, J KOREAN NEUROSURG S, V50, P535, DOI 10.3340/jkns.2011.50.6.535
   LEE KF, 1967, RADIOL CLIN N AM, V5, P363
   Liu AK, 2009, PEDIATR BLOOD CANCER, V52, P227, DOI 10.1002/pbc.21787
   Manion B, 2011, J CLIN NEUROSCI, V18, P1403, DOI 10.1016/j.jocn.2011.01.032
   Maruyama K, 2000, ACTA NEUROCHIR, V142, P139, DOI 10.1007/s007010050016
   MATSUSHIMA T, 1992, NEUROSURGERY, V31, P401, DOI 10.1227/00006123-199209000-00003
   MONTANERA W, 1990, AM J NEURORADIOL, V11, P1153
   MORI K, 1978, J NEUROSURG, V49, P22, DOI 10.3171/jns.1978.49.1.0022
   Murphy ES, 2015, J NEURO-ONCOL, V122, P421, DOI 10.1007/s11060-015-1732-2
   NISHIZAWA S, 1991, Neurologia Medico-Chirurgica, V31, P336, DOI 10.2176/nmc.31.336
   Okuno T, 1985, Pediatr Neurol, V1, P311, DOI 10.1016/0887-8994(85)90036-0
   RAJAKULASINGAM K, 1979, CHILD BRAIN, V5, P467
   Reynolds MR, 2016, PEDIATR NEUROSURG, V51, P297, DOI 10.1159/000446075
   Robert-Boire V, 2017, PEDIATR NEUROL, V75, P55, DOI 10.1016/j.pediatrneurol.2017.06.019
   Robertson RL, 1997, AM J NEURORADIOL, V18, P837
   Rosser TL, 2005, NEUROLOGY, V64, P553, DOI 10.1212/01.WNL.0000150544.00016.69
   Scala M, 2018, CHILD NERV SYST, V34, P1311, DOI 10.1007/s00381-018-3833-7
   Scaringi C, 2018, ANTICANCER RES, V38, P6041, DOI 10.21873/anticanres.12954
   Scott RM, 2009, NEW ENGL J MED, V360, P1226, DOI 10.1056/NEJMra0804622
   Scott RM, 2004, J NEUROSURG, V100, P142, DOI 10.3171/ped.2004.100.2.0142
   Serdaroglu A, 2000, J CHILD NEUROL, V15, P765, DOI 10.1177/088307380001501112
   SERVO A, 1978, J NEUROSURG, V48, P1026, DOI 10.3171/jns.1978.48.6.1026
   Smith ER, 2012, J NEUROSURG-PEDIATR, V9, P353, DOI 10.3171/2011.12.PEDS1172
   SUZUKI J, 1983, STROKE, V14, P104, DOI 10.1161/01.STR.14.1.104
   Twitchell S, 2019, J NEUROSURG, V130, P1889, DOI 10.3171/2017.12.JNS172635
   Uchino K, 2005, NEUROLOGY, V65, P956, DOI 10.1212/01.wnl.0000176066.33797.82
   Ullrich NJ, 2007, NEUROLOGY, V68, P932, DOI 10.1212/01.wnl.0000257095.33125.48
   Ullrich NJ, 2011, J CHILD NEUROL, V26, P228, DOI 10.1177/0883073810379639
   Wang CY, 2014, PEDIATR NEUROL, V50, P549, DOI 10.1016/j.pediatrneurol.2013.09.018
   Wu YH, 2016, CANCER MED-US, V5, P2155, DOI 10.1002/cam4.785
   Zwagerman NT, 2014, PEDIATR BLOOD CANCER, V61, P1490, DOI 10.1002/pbc.24961
NR 64
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.155
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600117
PM 31805403
DA 2020-05-12
ER

PT J
AU Schmidt, BT
   Pun, CD
   Caropreso, B
   Hetzel, SJ
   Lake, W
   Resnick, DK
AF Schmidt, Bradley T.
   Pun, Conrad D.
   Caropreso, Barbara
   Hetzel, Scott J.
   Lake, Wendell
   Resnick, Daniel K.
TI Use of a Laryngeal Mask Airway Decreases Radiation Exposure During
   Computed Tomography-Guided Percutaneous Glycerol Rhizotomy for
   Trigeminal Neuralgia
SO WORLD NEUROSURGERY
LA English
DT Article
DE Foramen ovale; Glycerol; Radiation; Rhizotomy; Trigeminal neuralgia
ID SAFETY
AB BACKGROUND: We have been using computed tomography (CT) guidance for percutaneous glycerol rhizotomy (PGR) for the last 7 years. As a quality improvement exercise, we recently began using general anesthesia (GA) with the use of a laryngeal mask airway (LMA) because of our perception that the procedure went faster and that there was less radiation exposure because of less patient movement. We aim to compare PGR radiation exposure and procedural time between patients receiving local anesthetic with sedation and those receiving GA/LMA.
   METHODS: A single-center historical cohort study was performed using patients treated with PGR between 2017 and 2019. Ninety-two surgeries were conducted during the study period: 64 surgeries had local anesthetic with intravenous sedation, and 28 surgeries had deeper anesthetic with LMA. Data analyzed included the number of CT sequences obtained, needle placement time, and total radiation dose.
   RESULTS: Use of GA/LMA resulted in a 23% decrease in mean radiation dose (565.5 vs. 436.1 mu Gy x cm, P = 0.014), number of CT sequences required (7.4 vs. 5.7, P = 0.003), and needle placement time (12.8 vs. 9.8 minutes, P = 0.006). Additionally, 10 patients underwent multiple glycerol rhizotomies during the collection period with both anesthetic types being used at least once. Seven of 10 patients (70.0%) had a reduction in total radiation dose, number of CT sequences obtained, and needle placement time when GA/LMA was used. There were no procedure- or anesthetic-related complications in this patient cohort.
   CONCLUSIONS: The use of GA/LMA during PGR is associated with decreased radiation exposure without increased anesthetic complications.
C1 [Schmidt, Bradley T.; Lake, Wendell; Resnick, Daniel K.] Univ Wisconsin Hosp & Clin, Dept Neurosurg, Madison, WI 53792 USA.
   [Pun, Conrad D.] Univ Wisconsin Hosp & Clin, Dept Radiol, Madison, WI 53792 USA.
   [Caropreso, Barbara] UnityPoint Hlth Meriter, Madison Anesthesia Consultants, Madison, WI USA.
   [Hetzel, Scott J.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA.
RP Resnick, DK (reprint author), Univ Wisconsin Hosp & Clin, Dept Neurosurg, Madison, WI 53792 USA.
EM resnick@neurosurgery.wisc.edu
FU Clinical and Translational Science Award program, through the NIH
   National Center for Advancing Translational Sciences [UL1TR002373]
FX The project was supported by the Clinical and Translational Science
   Award program, through the NIH National Center for Advancing
   Translational Sciences [UL1TR002373].
CR BECK DW, 1986, J NEUROSURG, V65, P28, DOI 10.3171/jns.1986.65.1.0028
   Cheng JR, 2014, IEEE ANTENNAS PROP, P25, DOI 10.1109/APS.2014.6904344
   Fry DE, 2011, J AM COLL SURGEONS, V212, P779, DOI 10.1016/j.jamcollsurg.2010.12.046
   Harries AM, 2011, BRIT J NEUROSURG, V25, P268, DOI 10.3109/02688697.2011.558946
   Hartel F, 1914, MED KLIN, V10, P582
   KEHLER CH, 1982, NEUROSURGERY, V10, P200, DOI 10.1227/00006123-198202000-00005
   Kim TH, 2006, KOREAN J RADIOL, V7, P125, DOI 10.3348/kjr.2006.7.2.125
   R Core Team, R PROJECT STAT COMPU
   Schmidt BT, 2019, CT GUIDANCE PERCUTAN
   SWERDLOW B, 1988, ANAESTHESIA, V43, P861
   Udupi BP, 2012, NEUROSURGERY, V70, P407, DOI 10.1227/NEU.0b013e318233a85f
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.136
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600027
PM 31790838
DA 2020-05-12
ER

PT J
AU Shah, KA
   Katz, JM
   Dehdashti, AR
AF Shah, Kevin A.
   Katz, Jeffrey M.
   Dehdashti, Amir R.
TI Cerebral Abscess After Onyx Embolization of an Arteriovenous
   Malformation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Arteriovenous malformation; Cerebral abscess; Embolization; Liquid
   embolic; Onyx
ID COMPLICATING EMBOLIZATION; INFECTION
AB BACKGROUND: Endovascular embolization is being increasingly used to treat cerebral arteriovenous malformations. Common complications associated with embolization include intracranial hemorrhage and ischemic stroke; intracranial infections seldomly occur and are even less frequently reported. Although abscess formation after embolization is exceedingly rare, it is a serious condition that warrants immediate attention.
   CASE DESCRIPTION: This 53-year-old male with a ruptured left temporal-occipital arteriovenous malformation. He underwent uncomplicated 2-stage embolization with Onyx and was discharged. Five weeks after embolization, he returned to the hospital with worsening aphasia and contralateral hemiparesis, and a cerebral abscess was detected at the site of embolization. Bacterial cultures were positive for Escherichia coli, and he was treated successfully with surgical excision of the abscess and Onyx material, followed by long-term antibiotics.
   CONCLUSIONS: Although rare, formation of an intracranial abscess after endovascular embolization is a potential complication in the treatment of arteriovenous malformations.
C1 [Shah, Kevin A.; Dehdashti, Amir R.] North Shore Univ Hosp, Dept Neurosurg, Manhasset, NY 11030 USA.
   [Katz, Jeffrey M.] North Shore Univ Hosp, Dept Neurol, Manhasset, NY USA.
RP Shah, KA (reprint author), North Shore Univ Hosp, Dept Neurosurg, Manhasset, NY 11030 USA.
EM kshah8@northwell.edu
CR Brassel F, 2015, CLIN NEURORADIOL, V25, P333, DOI 10.1007/s00062-015-0419-6
   Bruno CA, 2012, INTERV NEUROL, V1, P109, DOI 10.1159/000346927
   Burkhardt JK, 2020, J NEUROSURG, V132, P797, DOI 10.3171/2018.10.JNS182540
   Chagla AS, 2008, J NEUROSURG, V109, P347, DOI 10.3171/JNS/2008/109/8/0347
   Choudhry AJ, 2016, J GASTROINTEST SURG, V20, P656, DOI 10.1007/s11605-015-2875-3
   Cossu G, 2017, ACTA NEUROCHIR, V159, P583, DOI 10.1007/s00701-016-3069-9
   Jabre R, 2019, WORLD NEUROSURG, V132, P29, DOI 10.1016/j.wneu.2019.08.095
   Kelkar PS, 2013, NEUROSURGERY, V72, P327, DOI 10.1227/NEU.0b013e31827d0ff7
   Khoshnevisan A, 2014, IRAN J NEUROL, V13, P181
   Kim BJ, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01336
   Lopes DK, 2016, J NEUROINTERV SURG, V8, DOI 10.1136/neurintsurg-2015-011779
   MOURIER KL, 1993, ACTA NEUROCHIR, V122, P130, DOI 10.1007/BF01447000
   Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407
   Pendarkar H, 2006, J NEURORADIOLOGY, V33, P133, DOI 10.1016/S0150-9861(06)77246-7
   Pierot L, 2013, EUR RADIOL, V23, P2838, DOI 10.1007/s00330-013-2870-6
   Sharma A, 2011, NEUROL INDIA, V59, P131, DOI 10.4103/0028-3886.84351
   Taylor CL, 2004, J NEUROSURG, V100, P810, DOI 10.3171/jns.2004.100.5.0810
   US Food and Drug Administration, PREM APPR PMA
   van Beijnum J, 2011, JAMA-J AM MED ASSOC, V306, P2011, DOI 10.1001/jama.2011.1632
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.009
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600111
PM 31841721
DA 2020-05-12
ER

PT J
AU Shah, V
   Mohyeldin, A
   London, NR
   Fritz, J
   Prevedello, DM
   Carrau, RL
   Hardesty, DA
AF Shah, Varun
   Mohyeldin, Ahmed
   London, Nyall R.
   Fritz, Joel
   Prevedello, Daniel M.
   Carrau, Ricardo L.
   Hardesty, Douglas A.
TI When a Meningioma Isn't: Endoscopic Endonasal Orbital Decompression and
   Biopsy of Skull Base Rosai-Dorfman Disease Treated Previously with
   Empiric Radiation Therapy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Endoscopic skull base surgery; Histiocytsosis; Meningioma; Rosai-Dorfman
   disease
ID INTRACRANIAL SINUS HISTIOCYTOSIS; MASSIVE LYMPHADENOPATHY; COMPLICATIONS
AB BACKGROUND: Rosai-Dorfman disease (RDD) is a rare, benign histiocytosis disorder with only approximately 100 reported central nervous system cases in the literature. Even less common is skull base involvement of RDD, with about 41 reported cases. Radiographically, RDD can appear similar to a meningioma; the true diagnosis is only found with histologic analysis. Although "benign," RDD can lead to significant neurologic morbidity from the disease or unnecessary surgical and nonsurgical treatment. While rare, intracranial RDD has been treated with chemotherapy or radiotherapy, with surgery playing a limited role to relieve mass effect. Surgical approaches to the skull base are invasive and pose risk, especially for a benign and self-limiting disease like RDD.
   CASE DESCRIPTION: Here we present the case of a 63-year-old woman with a presumed spheno-orbital meningioma for which the patient previously underwent radiation therapy. On presentation to our facility, the patient noted pressure headaches and blurry vision, and imaging demonstrated progression of her disease. For these reasons, surgical debulking and biopsy were undertaken.
   CONCLUSIONS: This report demonstrates the role of EEA for tissue biopsy and decompression of the affected cranial nerves and orbit. This paradigm seems to provide a safe and effective way to manage patients with compressive symptoms, while also allowing for tissue sampling.
C1 [Shah, Varun] Ohio State Univ, Coll Med, Columbus, OH 43210 USA.
   [Mohyeldin, Ahmed; Prevedello, Daniel M.; Hardesty, Douglas A.] Ohio State Univ, James Canc Hosp, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
   [London, Nyall R.; Carrau, Ricardo L.] Ohio State Univ, James Canc Hosp, Dept Otolaryngol, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Fritz, Joel] Ohio State Univ, James Canc Hosp, Dept Radiol, Wexner Med Ctr, Columbus, OH 43210 USA.
   [Fritz, Joel] Solove Res Inst, Columbus, OH USA.
RP Hardesty, DA (reprint author), Ohio State Univ, James Canc Hosp, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
EM Douglas.Hardesty@osumc.edu
CR Adeleye AO, 2010, NEUROL RES, V32, P572, DOI 10.1179/016164109X12608733393836
   Andriko JAW, 2001, MODERN PATHOL, V14, P172, DOI 10.1038/modpathol.3880278
   Chivukula S, 2015, J NEUROL SURG PART A, V76, P244, DOI 10.1055/s-0034-1382780
   Deschler DG, 1996, SKULL BASE SURG, V6, P113, DOI 10.1055/s-2008-1058652
   Ghosal N, 2012, J NEURO-ONCOL, V106, P339, DOI 10.1007/s11060-011-0669-3
   Goyal G, 2019, MAYO CLIN PROC, V94, P2054, DOI 10.1016/j.mayocp.2019.02.023
   Hollon T, 2016, WORLD NEUROSURG, V87, DOI 10.1016/j.wneu.2015.08.015
   Kaminsky J, 2005, CLIN NEUROPATHOL, V24, P194
   Karthigeyan M, 2017, WORLD NEUROSURG, V107, DOI 10.1016/j.wneu.2017.08.073
   Nalini A, 2012, J NEUROL SCI, V314, P152, DOI 10.1016/j.jns.2011.10.002
   Petzold A, 2001, J NEUROL NEUROSUR PS, V71, P538, DOI 10.1136/jnnp.71.4.538
   Pulsoni A, 2002, AM J HEMATOL, V69, P67, DOI 10.1002/ajh.10008
   ROSAI J, 1969, ARCH PATHOL, V87, P63
   Sakashita T, 2009, SKULL BASE-INTERD AP, V19, P127, DOI 10.1055/s-0028-1096201
   Scumpia AJ, 2009, J CLIN NEUROSCI, V16, P1108, DOI 10.1016/j.jocn.2008.10.022
   SHAVER EG, 1993, J NEUROSURG, V79, P769, DOI 10.3171/jns.1993.79.5.0769
   Wang FL, 2011, ACTA NEUROCHIR, V153, P859, DOI 10.1007/s00701-010-0895-z
   Woodcock RJ, 1999, RADIOLOGY, V213, P808, DOI 10.1148/radiology.213.3.r99dc30808
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.032
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600121
PM 31843730
DA 2020-05-12
ER

PT J
AU Shah, VS
   Eaton, RG
   Cua, S
   Dornbos, D
   Hoang, N
   Schunemann, V
   Nimjee, S
   Youssef, P
   Powers, CJ
AF Shah, Varun S.
   Eaton, Ryan G.
   Cua, Santino
   Dornbos, David, III
   Nguyen Hoang
   Schunemann, Victoria
   Nimjee, Shahid
   Youssef, Patrick
   Powers, Ciaran J.
TI Scoring of Middle Cerebral Artery Collaterals Predicts RAPID
   CT-Perfusion Analysis and Short-Term Outcomes in Acute Ischemic Stroke
   Patients Undergoing Thrombectomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Ischemic stroke; MCA collateral scoring; RAPID; Thrombectomy
ID AGGRESSIVE DECOMPRESSIVE SURGERY; ENDOVASCULAR THERAPY; SYMPTOM ONSET;
   INFARCTION; CORE
AB OBJECTIVE: The rapid processing of perfusion and diffusion (RAPID) system for automating perfusion and diffusion data from head computed tomography has improved acute ischemic stroke treatment by quickly and accurately identifying those patients who may benefit from thrombectomy. Collateral scoring (CS) of cerebral arteries using computed tomography angiography (CTA) has proven useful in predicting postintervention infarct volumes and functional outcomes in ischemic stroke patients. Here we evaluate the relationship between CS and RAPID software in an effort to augment triage and provide improved predictability of functional outcomes in ischemic stroke patients.
   METHODS: A retrospective review of 77 mechanical thrombectomy patients from January 2017 to October 2018 with large vessel occlusions of the anterior circulation who underwent RAPID and CTA imaging was performed. Baseline characteristics, RAPID data, CS, modified Rankin Scale score, and procedural data were collected. magnetic resonance imaging was used to calculate the postintervention stroke volume.
   RESULTS: CS inversely correlates with the volume of RAPID cerebral blood flow <30% (13 = -18.131, 95% confidence interval [CI] -24.384 to -11.879, P < 0.001), RAPID Tmax >6s (beta = -22.205, 95% CI -39.125 to -5.285, P = 0.011), postintervention stroke volume (beta = -30.637, 95% CI -41.554 to -19.720, P < 0.001), and discharge National Institutes of Health Stroke Scale score (beta = -1.922, 95% CI -3.575 to -0.269, P = 0.023).
   CONCLUSIONS: CS on CTA may be a useful way to identify patients who would benefit from mechanical thrombectomy and predict functional outcomes postintervention. CS may allow the stroke team to optimize the care of patients who may not be able to obtain RAPID analysis.
C1 [Shah, Varun S.; Cua, Santino] Ohio State Univ, Coll Med, Columbus, OH 43210 USA.
   [Eaton, Ryan G.; Dornbos, David, III; Nguyen Hoang; Schunemann, Victoria; Nimjee, Shahid; Youssef, Patrick; Powers, Ciaran J.] Ohio State Univ, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
RP Powers, CJ (reprint author), Ohio State Univ, Dept Neurol Surg, Wexner Med Ctr, Columbus, OH 43210 USA.
EM Ciaran.Powers@osumc.edu
OI Eaton, Ryan/0000-0003-3388-9195
CR Albers GW, 2016, ANN NEUROL, V79, P76, DOI 10.1002/ana.24543
   Arenillas JF, 2018, J CEREBR BLOOD F MET, V38, P1839, DOI 10.1177/0271678X17740293
   Berkhemer OA, 2015, NEW ENGL J MED, V372, P11, DOI 10.1056/NEJMoa1411587
   Boers AMM, 2018, AM J NEURORADIOL, V39, P1074, DOI 10.3174/ajnr.A5623
   Campbell BCV, 2015, NEW ENGL J MED, V372, P1009, DOI 10.1056/NEJMoa1414792
   Dehkharghani S, 2016, AM J NEURORADIOL, V37, P1399, DOI 10.3174/ajnr.A4727
   Elijovich L, 2016, J NEUROINTERV SURG, V8, P559, DOI 10.1136/neurintsurg-2015-011731
   Goyal M, 2015, NEW ENGL J MED, V372, P1019, DOI 10.1056/NEJMoa1414905
   Hand PJ, 2006, NEUROLOGY, V66, P1159, DOI 10.1212/01.wnl.0000202524.43850.81
   Hankey G J, 1987, Clin Exp Neurol, V23, P71
   Jovin TG, 2015, NEW ENGL J MED, V372, P2296, DOI 10.1056/NEJMoa1503780
   Kawano H, 2016, STROKE, V47, P742, DOI 10.1161/STROKEAHA.115.011320
   Marks MP, 2014, STROKE, V45, P1035, DOI 10.1161/STROKEAHA.113.004085
   Mori K, 2001, ACTA NEUROCHIR, V143, P483, DOI 10.1007/s007010170078
   Mori K, 2001, ACTA NEUROCHIR, V143, P491
   Prakkamakul Supada, 2017, Top Magn Reson Imaging, V26, P103, DOI 10.1097/RMR.0000000000000122
   Saver JL, 2015, NEW ENGL J MED, V372, P2285, DOI 10.1056/NEJMoa1415061
   Sims JR, 2009, NEUROLOGY, V72, P2104, DOI 10.1212/WNL.0b013e3181aa5329
   Souza LCS, 2012, AM J NEURORADIOL, V33, P1331, DOI 10.3174/ajnr.A2985
   Straka M, 2010, J MAGN RESON IMAGING, V32, P1024, DOI 10.1002/jmri.22338
   Tan BYQ, 2017, J NEUROIMAGING, V27, P217, DOI 10.1111/jon.12387
   Thomalla G, 2010, ANN NEUROL, V68, P435, DOI 10.1002/ana.22125
   Vagal A, 2016, STROKE, V47, P535, DOI 10.1161/STROKEAHA.115.011461
NR 23
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.033
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600058
PM 31843729
DA 2020-05-12
ER

PT J
AU Shenoy, S
   Shenoy, SN
AF Shenoy, Saraswati
   Shenoy, Satyanarayana N.
TI Progeny in an Inhospitable Milieu-Solitary Intraventricular Metastasis
   From a Triple-Negative Breast Cancer Mimicking Central Neurocytoma: Case
   Report and Review of Diagnostic Pitfalls and Management Strategies
SO WORLD NEUROSURGERY
LA English
DT Review
DE Brain metastases; Choroid plexus metastases; Hydrocephalus;
   Intraventricular metastases; Metaplastic breast carcinoma;
   Triple-negative breast cancer
ID CHOROID-PLEXUS METASTASIS; CARCINOMA; BRAIN; NEOPLASMS
AB BACKGROUND: Triple-negative breast cancer (TNBC) is one of the most invasive subtypes of breast cancer, with high rates of visceral metastases and recurrence. Choroid plexus metastasis from breast cancer is infrequent despite a high incidence of brain parenchymal metastasis.
   METHODS: We report a case of solitary metastasis to the choroid plexus from a TNBC that masqueraded as central neurocytoma, and we review the PubMed database for similar cases focusing on their diagnostic challenges and management strategies.
   RESULTS: A 28-year-old woman with a history of TNBC presented with recurrent seizures, headache, and vomiting. Imaging studies depicted a well-defined lesion in the right anterior lateral ventricle that was attached to the septum pellucidum. After an initial radiological diagnosis of central neurocytoma, she deteriorated rapidly with intraventricular hemorrhage requiring emergency transcallosal microsurgical tumor decompression. Histopathological examination and immunohistochemistry confirmed breast carcinoma as the origin of the intraventricular mass. A review of the PubMed database identified only 2 case reports of choroid plexus metastases from breast cancer reported thus far.
   CONCLUSIONS: Choroid plexus metastases are exceedingly infrequent and can be mistaken for the more common central neurocytoma. The intraventricular milieu is inhospitable suggesting some extracranial carcinomas develop traits that help them to thrive in the acellular cerebrospinal fluid. Intraventricular mass lesions with a history of primary neoplasm should raise suspicion for choroid plexus metastases. A high index of suspicion despite excellent control of the primary tumor and the absence of systemic metastases is indispensable.
C1 [Shenoy, Saraswati] Washington Univ, Brown Sch, St Louis, MO 63110 USA.
   [Shenoy, Satyanarayana N.] Tarun Neuro Clin, Thana, India.
RP Shenoy, S (reprint author), Washington Univ, Brown Sch, St Louis, MO 63110 USA.
EM shenoy22@wustl.edu
CR Al-Anazi A, 2000, J NEUROSURG, V92, P506, DOI 10.3171/jns.2000.92.3.0506
   Boire A, 2017, CELL, V168, P1101, DOI 10.1016/j.cell.2017.02.025
   Della Puppa A, 2010, J NEURO-ONCOL, V97, P123, DOI 10.1007/s11060-009-9988-z
   Farnia B, 2014, J NEUROSURG, V121, P26, DOI 10.3171/2014.8.GKS141354
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Hassaneen W, 2010, J NEUROSURG, V112, P1046, DOI 10.3171/2009.7.JNS09571
   Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01
   JELINEK J, 1990, AM J ROENTGENOL, V155, P365, DOI 10.2214/ajr.155.2.2115270
   KENDALL B, 1983, NEURORADIOLOGY, V25, P11, DOI 10.1007/BF00327474
   Kohno M, 1996, J NEURO-ONCOL, V27, P47, DOI 10.1007/BF00146083
   Miettinen M, 2014, AM J SURG PATHOL, V38, P13, DOI 10.1097/PAS.0b013e3182a0218f
   Sajko T, 2009, ACTA CLIN CROAT, V48, P55
   Shapira Y, 2014, ACTA NEUROCHIR, V156, P1469, DOI 10.1007/s00701-014-2108-7
   Sharifi G, 2015, WORLD NEUROSURG, V84, P1142, DOI 10.1016/j.wneu.2015.05.027
   Shee K, 2019, DIAGN CYTOPATHOL, V47, P912, DOI 10.1002/dc.24210
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Siomin V, 2011, INT J RADIAT ONCOL, V80, P1134, DOI 10.1016/j.ijrobp.2010.03.016
   Smith AB, 2013, RADIOGRAPHICS, V33, P21, DOI 10.1148/rg.331125192
   Spector R, 2015, EXP NEUROL, V267, P78, DOI 10.1016/j.expneurol.2015.02.032
   Sperduto PW, 2012, INT J RADIAT ONCOL, V82, P2111, DOI 10.1016/j.ijrobp.2011.02.027
   Sung WS, 2008, J CLIN NEUROSCI, V15, P594, DOI 10.1016/j.jocn.2007.02.001
   Tseng LM, 2013, NEOPLASMA, V60, P290, DOI 10.4149/neo_2013_038
   Vecil GG, 2003, NEUROSURG CLIN N AM, V14, P593, DOI 10.1016/S1042-3680(03)00056-1
   VIADANA E, 1973, CANCER RES, V33, P179
   Wasita B, 2010, NEUROSURGERY, V66, pE1213, DOI 10.1227/01.NEU.0000369193.03305.00
NR 25
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.066
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600155
PM 31863888
DA 2020-05-12
ER

PT J
AU Sherrod, BA
   Condie, CK
   Brock, AA
   Ledyard, H
   Menacho, ST
   Mazur, MD
AF Sherrod, Brandon A.
   Condie, Chad K.
   Brock, Andrea A.
   Ledyard, Holly
   Menacho, Sarah T.
   Mazur, Marcus D.
TI Emergent Reversal of Direct Oral Anticoagulants Permitting Neurosurgical
   Intervention for Nonhemorrhagic Pathology
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anticoagulation; Direct oral anticoagulants; Neurosurgery;
   Nonhemorrhagic pathology; Reversal agent
ID MANAGEMENT
AB BACKGROUND: Direct oral anticoagulants (DOACs) are becoming the medication of choice for the management of venous thromboembolism and stroke prevention in atrial fibrillation because of simplified dosing, a more predictive pharmacokinetic profile, and better clinical outcomes when compared with traditional vitamin K antagonists. Recently, reversal agents for DOACs have been approved by the U.S. Food and Drug Administration for use in managing life-threatening or uncontrolled bleeding; however, for acute nonhemorrhagic conditions requiring surgical intervention, such as acute hydrocephalus requiring ventriculostomy, there is little evidence to help guide appropriate management for patients on DOACs.
   CASE DESCRIPTION: We report the use of andexanet alfa to counteract rivaroxaban treatment in a 28-year-old woman who developed herniation syndrome and acute hydrocephalus from a cerebellar tumor.
   CONCLUSIONS: We describe how appropriate timing of administration of the DOAC reversal agent may permit urgent neurosurgical intervention.
C1 [Sherrod, Brandon A.; Brock, Andrea A.; Menacho, Sarah T.; Mazur, Marcus D.] Univ Utah, Dept Neurosurg, Clin Neurosci Ctr, Salt Lake City, UT 84112 USA.
   [Ledyard, Holly] Univ Utah, Dept Neurol, Clin Neurosci Ctr, Salt Lake City, UT USA.
   [Condie, Chad K.] Univ Utah, Dept Pharm, Salt Lake City, UT USA.
RP Mazur, MD (reprint author), Univ Utah, Dept Neurosurg, Clin Neurosci Ctr, Salt Lake City, UT 84112 USA.
EM neuropub@hsc.utah.edu
CR Beynon C, 2019, NEUROCRIT CARE, V30, P322, DOI 10.1007/s12028-018-0635-4
   Burnett AE, 2016, J THROMB THROMBOLYS, V41, P206, DOI 10.1007/s11239-015-1310-7
   Connolly SJ, 2019, NEW ENGL J MED, V380, P1326, DOI 10.1056/NEJMoa1814051
   Croci DM, 2017, WORLD NEUROSURG, V105, P841, DOI 10.1016/j.wneu.2017.06.105
   Dias JD, 2019, J TRAUMA ACUTE CARE, V87, P364, DOI 10.1097/TA.0000000000002357
   Ebner M, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009807
   Grottke O, 2014, CRIT CARE, V18, DOI 10.1186/cc13717
   Jacobs V, 2016, AM J CARDIOL, V118, P210, DOI 10.1016/j.amjcard.2016.04.039
   Kuramatsu JB, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2492-8
   Levy JH, 2018, J THROMB HAEMOST, V16, P54, DOI 10.1111/jth.13894
   Levy JH, 2016, AM J EMERG MED, V34, P14, DOI 10.1016/j.ajem.2016.09.048
   Samama MM, 2012, THROMB HAEMOSTASIS, V107, P379, DOI 10.1160/TH11-06-0391
   Siegal DM, 2015, NEW ENGL J MED, V373, P2413, DOI 10.1056/NEJMoa1510991
NR 13
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.162
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600101
PM 31809896
DA 2020-05-12
ER

PT J
AU Shimizu, Y
   Tsuchiya, K
   Fujisawa, H
AF Shimizu, Yu
   Tsuchiya, Katsuhiro
   Fujisawa, Hironori
TI Intracranial Low-Grade Fibromyxoid Sarcoma: Findings on Electron
   Microscopy and Histologic Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Electron microscopy; Histology; LGFMS; Low-grade fibromyxoid sarcoma;
   Radiology
ID SPINDLE-CELL TUMOR; GIANT ROSETTES
AB BACKGROUND: Low-grade fibromyxoid sarcoma is a rare tumor that manifests as a deep soft tissue mass characterized by a benign histology, but with potentially aggressive clinical behavior and a high rate of recurrence; primary intracranial sarcomas are even rarer. We present a case of primary intracranial low-grade fibromyxoid sarcoma, emphasizing its clinical, radiologic, and histologic features.
   CASE DESCRIPTION: A 39-year-old woman presented with a recent history of headache and seizures. A right parietal mass was detected on computed tomography and magnetic resonance imaging, and she was subsequently operated on to remove the intracranial mass. Histologic examination of the resected tumor revealed mildly atypical fibroblastic cells embedded within a myxoid matrix. The diagnosis was confirmed by electron microscopy and cytogenetic analyses.
   CONCLUSIONS: This report describes electron microscopic evaluation of intracranial low-grade fibromyxoid sarcoma, which has an extremely rare occurrence.
C1 [Shimizu, Yu; Tsuchiya, Katsuhiro; Fujisawa, Hironori] Natl Hosp Org Kanazawa Med Ctr, Dept Neurosurg, Kanazawa, Ishikawa, Japan.
RP Shimizu, Y (reprint author), Natl Hosp Org Kanazawa Med Ctr, Dept Neurosurg, Kanazawa, Ishikawa, Japan.
EM bleuler3a@yahoo.co.jp
OI Shimizu, Yu/0000-0003-3036-6321
CR Gomiz EB, 2011, RADIOLOGIA-MADRID, V53, P171, DOI 10.1016/j.rx.2010.04.009
   Chen N, 2015, NEUROPATHOLOGY, V35, P348, DOI 10.1111/neup.12197
   Evans HL, 2011, AM J SURG PATHOL, V35, P1450, DOI 10.1097/PAS.0b013e31822b3687
   EVANS HL, 1987, AM J CLIN PATHOL, V88, P615, DOI 10.1093/ajcp/88.5.615
   Ferlosio Amedeo, 2013, Cardiovasc Pathol, V22, pe15, DOI 10.1016/j.carpath.2012.11.004
   Folpe AL, 2000, AM J SURG PATHOL, V24, P1353, DOI 10.1097/00000478-200010000-00004
   Karthigeyan M, 2019, WORLD NEUROSURG, V122, P500, DOI 10.1016/j.wneu.2018.11.082
   Kim L, 2007, PATHOL INT, V57, P153, DOI 10.1111/j.1440-1827.2006.02073.x
   Matsuyama A, 2006, AM J SURG PATHOL, V30, P1077
   PAULUS W, 1991, HISTOPATHOLOGY, V18, P395, DOI 10.1111/j.1365-2559.1991.tb00869.x
   Rando G, 2005, PEDIATR SURG INT, V21, P311, DOI 10.1007/s00383-005-1400-2
   Reid R, 2003, AM J SURG PATHOL, V27, P1229, DOI 10.1097/00000478-200309000-00006
   Rubinstein JC, 2014, PEDIATR DEVEL PATHOL, V17, P321, DOI 10.2350/14-05-1487-CR.1
   Saito R, 2008, J NEUROSURG, V108, P798, DOI 10.3171/JNS/2008/108/4/0798
   Tang Z, 2010, J ORAL MAXIL SURG, V68, P873, DOI 10.1016/j.joms.2009.04.136
   Tun K, 2008, J CLIN NEUROSCI, V15, P1298, DOI 10.1016/j.jocn.2007.07.085
   White IK, 2015, J NEUROSURG-PEDIATR, V16, P372, DOI 10.3171/2015.3.PEDS14564
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.135
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600152
PM 31899392
DA 2020-05-12
ER

PT J
AU Shingai, Y
   Kimura, N
   Doijiri, R
   Takahashi, K
   Yokosawa, M
   Kanoke, A
   Kikuchi, T
   Sugawara, T
   Tominaga, T
AF Shingai, Yuto
   Kimura, Naoto
   Doijiri, Ryosuke
   Takahashi, Ken
   Yokosawa, Michiko
   Kanoke, Atsushi
   Kikuchi, Takahiko
   Sugawara, Takayuki
   Tominaga, Teiji
TI Effect of Preoperative Administration of Proprotein Convertase
   Subtilisin/Kexin Type 9 Inhibitor on Carotid Artery Stenting
SO WORLD NEUROSURGERY
LA English
DT Article
DE Carotid artery stenosis; Carotid artery stenting; Low-density
   lipoprotein cholesterol; PCSK9i; Proprotein convertase subtilisin/kexin
   type 9 inhibitor; Statin
ID SECONDARY ANALYSIS; RISK; CHOLESTEROL; STROKE; ATORVASTATIN; DISEASE;
   ENDARTERECTOMY; ANGIOPLASTY; EVOLOCUMAB; REDUCTION
AB BACKGROUND: Perioperative embolic stroke is one of the most serious complications during carotid artery stenting (CAS). Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) is a low-density lipoprotein-lowering drug that inhibits proprotein convertase subtilisin/kexin type 9, which normally binds to the low-density lipoprotein cholesterol (LDL-C) receptor. Its combination with statin significantly decreases LDL-C levels. PCSK9i is expected to achieve lower LDL-C levels than single use of statin. This study aimed to investigate whether perioperative PCSK9i administration stabilizes carotid artery plaque and reduces perioperative complications of CAS.
   METHODS: Nine patients with symptomatic stenosis (North American Symptomatic Carotid Endarterectomy Trial [NASCET] 50%) or asymptomatic stenosis (NASCET >= 80%) were included. PCSK9i was administered at least twice (once in 2 weeks) in the outpatient clinic before CAS. Perioperative complications; results from blood tests, magnetic resonance imaging (MRI), magnetic resonance angiography, and carotid ultrasonography (US); and modified Rankin scale score at discharge were assessed.
   RESULTS: High intensity on diffusion-weighted imaging was not observed in 8 patients. Changes in carotid plaque characteristics were found with MRI and/or carotid US in 7 patients. The plaque to muscle ratio decreased in 3 patients. The carotid plaque became hyperechoic in 2 patients, and the fibrous cap was seen more clearly on carotid US. Two patients had findings of stabilized plaque on MRI and carotid US, which indicates that plaque transformation was more stable.
   CONCLUSIONS: Lowering LDL-C level could reduce ischemic complications, and low LDL-C level affects plaque stability and antithrombus formation. PCSK9i can possibly stabilize carotid plaque and reduce perioperative complications of CAS.
C1 [Shingai, Yuto; Kimura, Naoto; Yokosawa, Michiko; Kanoke, Atsushi; Sugawara, Takayuki] Iwate Prefectural Cent Hosp, Dept Neurosurg, Morioka, Iwate, Japan.
   [Doijiri, Ryosuke; Takahashi, Ken; Kikuchi, Takahiko] Iwate Prefectural Cent Hosp, Dept Neurol, Morioka, Iwate, Japan.
   [Tominaga, Teiji] Tohoku Univ, Dept Neurosurg, Grad Sch Med, Sendai, Miyagi, Japan.
RP Shingai, Y (reprint author), Iwate Prefectural Cent Hosp, Dept Neurosurg, Morioka, Iwate, Japan.
EM yutos0123@gmail.com
CR Blauw GJ, 1997, STROKE, V28, P946, DOI 10.1161/01.STR.28.5.946
   BOYSEN G, 1988, STROKE, V19, P1345, DOI 10.1161/01.STR.19.11.1345
   Brott TG, 2010, NEW ENGL J MED, V363, P11, DOI 10.1056/NEJMoa0912321
   Collins R, 2004, LANCET, V363, P757
   Crisby M, 2001, CIRCULATION, V103, P926, DOI 10.1161/01.cir.103.7.926
   Derdeyn CP, 2014, LANCET, V383, P333, DOI 10.1016/S0140-6736(13)62038-3
   Giugliano RP, 2017, LANCET, V390, P1962, DOI 10.1016/S0140-6736(17)32290-0
   Kimura N, 2011, JAPANESE J ENDOVASCU, V12, P10
   Mas JL, 2008, LANCET NEUROL, V7, P885, DOI 10.1016/S1474-4422(08)70195-9
   McDonnell CO, 2006, EUR J VASC ENDOVASC, V32, P46, DOI 10.1016/j.ejvs.2005.12.026
   Nicholls SJ, 2016, JAMA-J AM MED ASSOC, V316, P2373, DOI 10.1001/jama.2016.16951
   OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752
   Pasceri V, 2004, CIRCULATION, V110, P674, DOI 10.1161/01.CIR.0000137828.06205.87
   Roth EM, 2012, NEW ENGL J MED, V367, P1891, DOI 10.1056/NEJMoa1201832
   Sabatine MS, 2017, NEW ENGL J MED, V376, P1713, DOI 10.1056/NEJMoa1615664
   Schwartz GG, 2018, NEW ENGL J MED, V379, P2097, DOI 10.1056/NEJMoa1801174
   Sillesen H, 2008, STROKE, V39, P3297, DOI 10.1161/STROKEAHA.108.516450
   Silver FL, 2011, STROKE, V42, P675, DOI 10.1161/STROKEAHA.110.610212
   Takayama K, 2014, CARDIOVASC INTER RAD, V37, P1436, DOI 10.1007/s00270-013-0813-x
   Teramoto T, 2016, CIRC J, V80, P1980, DOI 10.1253/circj.CJ-16-0387
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.095
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600006
PM 31655235
DA 2020-05-12
ER

PT J
AU Vellutini, EDS
   Gomes, MDT
   Brock, RS
   de Oliveira, MF
   Salomone, R
   Godoy, LFD
   Ruschel, LG
AF Silva Vellutini, Eduardo de Arnaldo
   Teles Gomes, Marcos de Queiroz
   Brock, Roger Schmidt
   de Oliveira, Matheus Fernandes
   Salomone, Raquel
   de Souza Godoy, Luis Filipe
   Ruschel, Leonardo Gilmone
TI Radiologic Features of Spontaneous Regression of Vestibular Schwannomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Conservative management; Natural history; Radiology; Spontaneous
   involution; Vestibular schwannoma
ID NATURAL-HISTORY; CONSERVATIVE MANAGEMENT; TUMOR-GROWTH; RADIOSURGERY;
   SURGERY; HEARING
AB BACKGROUND: Vestibular schwannoma (VS) is the most common benign tumor originating in the cerebellopontine angle. In most cases, tumors tend to grow and deserve proper treatment. Sometimes they stabilize, and rarely they decrease in size spontaneously.
   METHODS: We evaluated retrospectively the images of patients with spontaneous tumor regression. We describe the common neuroimage findings of patients with spontaneous tumoral regression.
   RESULTS: Four patients with diagnosis of VS were folowed with magnetic resonance imaging (MRI). There were some relevant features in MRI: a heterogeneous contrast enhancement in the outer layer of the tumor and presence of a cerebrospinal fluid column between the tumor and the entrance of the internal auditory canal. The percentage of tumor diameter reduction ranged from 20% to 40%.
   CONCLUSIONS: Some MRI features may demonstrate spontaneous involution of VS and may be closely followed in asymptomatic or oligosymptomatic patients.
C1 [Silva Vellutini, Eduardo de Arnaldo; Teles Gomes, Marcos de Queiroz; Brock, Roger Schmidt; de Oliveira, Matheus Fernandes; Ruschel, Leonardo Gilmone] DFV Neuro, Sao Paulo, Brazil.
   [Silva Vellutini, Eduardo de Arnaldo; Teles Gomes, Marcos de Queiroz; Brock, Roger Schmidt; de Oliveira, Matheus Fernandes; Salomone, Raquel; de Souza Godoy, Luis Filipe; Ruschel, Leonardo Gilmone] Hosp Sirio Libanes, Sao Paulo, Brazil.
   [Silva Vellutini, Eduardo de Arnaldo; Teles Gomes, Marcos de Queiroz; Brock, Roger Schmidt; de Oliveira, Matheus Fernandes; Salomone, Raquel; Ruschel, Leonardo Gilmone] Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil.
RP de Oliveira, MF (reprint author), DFV Neuro, Sao Paulo, Brazil.; de Oliveira, MF (reprint author), Hosp Sirio Libanes, Sao Paulo, Brazil.; de Oliveira, MF (reprint author), Hosp Alemao Oswaldo Cruz, Sao Paulo, Brazil.
EM mafernoliv@yahoo.com.br
OI Oliveira, Matheus/0000-0003-1123-7583
CR Amoo Michael, 2019, Br J Neurosurg, P1, DOI 10.1080/02688697.2019.1582749
   BEDERSON JB, 1991, NEUROSURGERY, V28, P646, DOI 10.1227/00006123-199105000-00002
   Berenholz CP, 1992, ANN OTOL RHINOL LARI, V24, P827
   Bussard Jonatan, 2018, Rev Med Suisse, V14, P1739
   Caye-Thomasen P, 2005, OTOL NEUROTOL, V26, P98, DOI 10.1097/00129492-200501000-00017
   Chihara Y, 2007, ACTA OTO-LARYNGOL, V127, P65, DOI 10.1080/03655230701596467
   de Vries M, 2012, VIRCHOWS ARCH, V460, P629, DOI 10.1007/s00428-012-1236-9
   Ferri GG, 2008, LARYNGOSCOPE, V118, P951, DOI 10.1097/MLG.0b013e31816a8955
   Hempel JM, 2006, EUR ARCH OTO-RHINO-L, V263, P714, DOI 10.1007/s00405-006-0054-6
   Huang X, 2013, J LARYNGOL OTOL, V127, P739, DOI 10.1017/S0022215113001266
   Kondziolka D, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS12192
   Koutsimpelas D, 2007, OTOL NEUROTOL, V28, P1094, DOI 10.1097/MAO.0b013e31814b2787
   Lahlou G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217752
   Massick DD, 2000, LARYNGOSCOPE, V110, P1843, DOI 10.1097/00005537-200011000-00015
   Pennings RJE, 2011, NEUROSURGERY, V68, P68, DOI 10.1227/NEU.0b013e3181fc60cb
   Reddy CEE, 2014, J LARYNGOL OTOL, V128, P752, DOI 10.1017/S0022215114001315
   Roche Pierre-Hugues, 2008, Prog Neurol Surg, V21, P200, DOI 10.1159/000156999
   Rogg JM, 2005, NEURORADIOLOGY, V47, P344, DOI 10.1007/s00234-005-1363-y
   Samii M, 2006, J NEUROSURG, V105, P527, DOI 10.3171/jns.2006.105.4.527
   Vellutini EDS, 2017, NEUROSURGERY, V81, pE51, DOI 10.1093/neuros/nyx317
   Stangerup SE, 2006, OTOL NEUROTOL, V27, P547, DOI 10.1097/00129492-200606000-00018
   STRASNICK B, 1994, LARYNGOSCOPE, V104, P1115
   Sughrue ME, 2010, J NEUROSURG, V112, P163, DOI 10.3171/2009.4.JNS08895
   Tschudi DC, 2000, AM J OTOL, V21, P722
   Vellutini EAS, 2014, ARQ NEURO-PSIQUIAT, V72, P925, DOI 10.1590/0004-282X20140152
   WELLING DB, 1990, OTOLARYNG HEAD NECK, V103, P364, DOI 10.1177/019459989010300305
   Yoshimoto Y, 2005, J NEUROSURG, V103, P59, DOI 10.3171/jns.2005.103.1.0059
   Zou Jing, 2017, J Otol, V12, P174, DOI 10.1016/j.joto.2017.08.002
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.034
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600057
PM 31843724
DA 2020-05-12
ER

PT J
AU Singh, T
   Parr, WCH
   Choy, WJ
   Budiono, GR
   Maharaj, M
   Mathis, X
   Phan, K
   Walsh, WR
   Mobbs, RJ
AF Singh, Telvinderjit
   Parr, William Chase Harington
   Choy, Wen Jie
   Budiono, Gideon Richard
   Maharaj, Monish
   Mathis, Xavier
   Phan, Kevin
   Walsh, William Robert
   Mobbs, Ralph Jasper
TI Three-Dimensional Morphometric Analysis of Lumbar Vertebral End Plate
   Anatomy
SO WORLD NEUROSURGERY
LA English
DT Article
DE Age; Concave depth; Gender; Geometric morphometric method; Spinal level;
   Three-dimensional shape; Vertebral end plate
ID GEOMETRIC MORPHOMETRICS; MORPHOLOGY; AREAS; SHAPE; BIOMECHANICS; CAGES;
   SIZE
AB BACKGROUND: Information on the three-dimensional (30) shape of vertebral end plates is lacking. Previous studies have analyzed two-dimensional shape; however, 3D data are important because they may help improve our understanding of how differences in shape are related to age, gender, race, size, and other parameters, which may subsequently help improve device design for interbody prosthesis.
   OBJECTIVE: To study the 3D shape of lumbar vertebral end plates from normal adult lumbar spines and correlate them with age, gender, spinal/end plate level, end plate surface area, concave depth, and size.
   METHODS: An in vivo analysis was undertaken of lumbar vertebral end plate 3D shape. A total of 136 patients' computed tomography scans were used to create 3D models of the lumbar spine for each patient, which were subsequently analyzed.
   RESULTS: The shape of the superior end plates is different compared with inferior end plates. Across the lumbar spine (L1-S1), the shape of inferior end plates is similar; however, the shape of the superior end plate varies between spinal levels significantly. There was no clear relationship between age and principal component (PC) shapes but there was a strong correlation between end plate concave depth and end plate PC shape scores.
   CONCLUSIONS: Future interbody (disc replacement and fusion) device designs could use the findings that inferior end plate shape is similar throughout the length of the lumbar spine, whereas superior end plate shape changes. Further, future implants could be level-specific because the present study shows that end plate shape varies through the length of the lumbar spine.
C1 [Singh, Telvinderjit; Parr, William Chase Harington; Choy, Wen Jie; Budiono, Gideon Richard; Maharaj, Monish; Mathis, Xavier; Phan, Kevin; Walsh, William Robert; Mobbs, Ralph Jasper] Prince Wales Private Hosp, NeuroSpine Surg Res Grp NSURG, Sydney, NSW, Australia.
   [Singh, Telvinderjit; Choy, Wen Jie; Budiono, Gideon Richard; Maharaj, Monish; Phan, Kevin; Mobbs, Ralph Jasper] Prince Wales Private Hosp, Dept Neurosurg, NeuroSpine Clin, Sydney, NSW, Australia.
   [Singh, Telvinderjit; Parr, William Chase Harington; Choy, Wen Jie; Budiono, Gideon Richard; Maharaj, Monish; Phan, Kevin; Walsh, William Robert; Mobbs, Ralph Jasper] UNSW, Fac Med, Sydney, NSW, Australia.
   [Singh, Telvinderjit; Parr, William Chase Harington; Mathis, Xavier; Walsh, William Robert; Mobbs, Ralph Jasper] Univ New South Wales, Prince Wales Clin Sch, Surg & Orthopaed Res Labs, Sydney, NSW, Australia.
   [Parr, William Chase Harington; Mathis, Xavier] 3D Morph Pty Ltd, Sydney, NSW, Australia.
   [Mathis, Xavier] Univ Sydney, Fac Engn, Sydney, NSW, Australia.
RP Singh, T (reprint author), Prince Wales Private Hosp, NeuroSpine Surg Res Grp NSURG, Sydney, NSW, Australia.; Singh, T (reprint author), Prince Wales Private Hosp, Dept Neurosurg, NeuroSpine Clin, Sydney, NSW, Australia.; Singh, T (reprint author), UNSW, Fac Med, Sydney, NSW, Australia.; Singh, T (reprint author), Univ New South Wales, Prince Wales Clin Sch, Surg & Orthopaed Res Labs, Sydney, NSW, Australia.
EM telvinder95@yahoo.com
OI Choy, Wen Jie/0000-0001-8929-8170; Maharaj, Monish/0000-0002-3555-7955
CR Adams DC, 2004, ITAL J ZOOL, V71, P5, DOI 10.1080/11250000409356545
   Assem Y, 2017, ORTHOP SURG, V9, P191, DOI 10.1111/os.12283
   BOOKSTEIN FL, 1989, IEEE T PATTERN ANAL, V11, P567, DOI 10.1109/34.24792
   Brinckmann P, 1989, Clin Biomech (Bristol, Avon), V4 Suppl 2, piii, DOI 10.1016/0268-0033(89)90071-5
   Chen H, 2011, EUR SPINE J, V20, P1814, DOI 10.1007/s00586-011-1787-5
   COLOMBINI D, 1989, SPINE, V14, P51, DOI 10.1097/00007632-198901000-00010
   Ferguson SJ, 2003, EUR SPINE J, V12, pS97, DOI 10.1007/s00586-003-0621-0
   Gangnet N, 2006, SPINE, V31, pE507, DOI 10.1097/01.brs.0000224533.19359.89
   GOWER JC, 1975, PSYCHOMETRIKA, V40, P33, DOI 10.1007/BF02291478
   He X, 2012, SPINE, V37, pE1068, DOI 10.1097/BRS.0b013e31825640eb
   Hotelling H, 1933, J EDUC PSYCHOL, V24, P417, DOI 10.1037/h0071325
   Klingenberg CP, 2016, DEV GENES EVOL, V226, P113, DOI 10.1007/s00427-016-0539-2
   Lakshmanan P, 2012, EUR SPINE J, V21, pS160, DOI 10.1007/s00586-012-2168-4
   Michaela G, 2008, EUR SPINE J, V17, P1470, DOI 10.1007/s00586-008-0780-0
   Mobbs RJ, 2018, WORLD NEUROSURG, V120, P256, DOI 10.1016/j.wneu.2018.08.237
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Parr WCH, 2014, J ANAT, V225, P42, DOI 10.1111/joa.12195
   Parr WCH, 2012, J THEOR BIOL, V301, P1, DOI 10.1016/j.jtbi.2012.01.030
   Parr WCH, 2011, J THEOR BIOL, V272, P64, DOI 10.1016/j.jtbi.2010.11.030
   Parr WCH, 2016, EVOL BIOL, V43, P171, DOI 10.1007/s11692-016-9371-x
   Parr WCH, 2011, J ANAT, V218, P386, DOI 10.1111/j.1469-7580.2011.01347.x
   Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720
   Phan K, 2016, ORTHOP SURG, V8, P270, DOI 10.1111/os.12259
   Rehm J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171258
   ROHLF FJ, 1990, SYST ZOOL, V39, P40, DOI 10.2307/2992207
   ROHLF FJ, 1993, TRENDS ECOL EVOL, V8, P129, DOI 10.1016/0169-5347(93)90024-J
   Seidel H, 2008, INT J IND ERGONOM, V38, P844, DOI 10.1016/j.ergon.2007.10.001
   STOKES IAF, 1994, SPINE, V19, P236, DOI 10.1097/00007632-199401001-00020
   Suh PB, 2017, J AM ACAD ORTHOP SUR, V25, P160, DOI 10.5435/JAAOS-D-16-00390
   Suh PB, 2015, SPINE J, V15, pS178
   Tang R, 2016, EUR SPINE J, V25, P4116, DOI 10.1007/s00586-016-4405-8
   Thompson D., 1917, GROWTH FORM
   TWOMEY LT, 1987, CLIN ORTHOP RELAT R, P97
   van der Houwen EB, 2010, ANN BIOMED ENG, V38, P33, DOI 10.1007/s10439-009-9827-6
   Wang Y, 2012, EUR SPINE J, V21, P2316, DOI 10.1007/s00586-012-2415-8
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.158
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600036
PM 31809892
DA 2020-05-12
ER

PT J
AU Su, YS
   Ali, MS
   Pukenas, BA
   Favilla, CG
   Zanaty, M
   Hasan, DM
   Kung, DK
AF Su, YouRong S.
   Ali, Muhammad S.
   Pukenas, Bryan A.
   Favilla, Christopher G.
   Zanaty, Mario
   Hasan, David M.
   Kung, David K.
TI Novel Treatment of Cerebral Vasospasm Using Solitaire Stent
   Retriever-Assisted Angioplasty: Case Series
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebral vasospasm; Delayed cerebral ischemia; Endovascular treatment;
   Stent-assisted angioplasty; Subarachnoid hemorrhage
ID TRANSLUMINAL BALLOON ANGIOPLASTY; SUBARACHNOID HEMORRHAGE; INTRAARTERIAL
   PAPAVERINE; MANAGEMENT; EFFICACY; SAFETY
AB BACKGROUND: Endovascular procedures such as intraarterial (IA) vasodilator injection and balloon angioplasty are used to treat medically refractory cerebral vasospasm. The effects of IA therapy may be short lived and thus require multiple treatments. Balloon angioplasty also has limitations including transient occlusion of the spastic blood vessel, possible endothelial injury, and limited access to proximal vessels. We aim to demonstrate a novel technique using a stent retriever for the management of medically refractory vasospasm, especially in distal vessels. Compared with balloon angioplasty, stent retrievers provide a passive, self-limiting expansion of blood vessels. Other benefits over balloon angioplasty include 1) ability to simultaneously inject IA vasodilators, 2) limited contact and damage to vessel wall, 3) nonocclusive expansion, and 4) technical ease.
   METHODS: Fourteen blood vessels from 6 patients with symptomatic vasospasm after subarachnoid hemorrhage were identified. We injected 5 mg of IA vasodilator medication into the vasospastic segments without radiographic improvement in vessel diameter and blood flow. The stent retriever was deployed for 2-5 minutes in each vasospastic segment.
   RESULTS: Distal anterior and posterior circulation segments were easily accessible with the stent retriever system. It resulted in improved vessel diameter and blood flow with subsequent improvement in neurologic examination. All patients demonstrated radiographic resolution of vasospasm. No procedural-related complications were noted.
   CONCLUSIONS: We demonstrate the safety and efficacy of a novel technique for the treatment of medically refractory cerebral vasospasm using stent retriever angioplasty in distal vessels. Stent angioplasty can be used as an additional tool in the management of subarachnoid hemorrhage - induced cerebral vasospasm.
C1 [Su, YouRong S.; Kung, David K.] Hosp Univ Penn, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Pukenas, Bryan A.] Hosp Univ Penn, Dept Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Favilla, Christopher G.] Hosp Univ Penn, Dept Neurol, 3400 Spruce St, Philadelphia, PA 19104 USA.
   [Ali, Muhammad S.; Zanaty, Mario; Hasan, David M.] Univ Iowa Hosp & Clin, Dept Neurosurg, Iowa City, IA 52242 USA.
RP Kung, DK (reprint author), Hosp Univ Penn, Dept Neurosurg, 3400 Spruce St, Philadelphia, PA 19104 USA.
EM david.kung@pennmedicine.upenn.edu
CR Abruzzo T, 2012, J NEUROINTERV SURG, V4, P169, DOI 10.1136/neurintsurg-2011-010248
   Adami D, 2019, J NEURORADIOLOGY, V46, P15, DOI 10.1016/j.neurad.2018.04.001
   Bederson JB, 2000, CIRCULATION, V102, P2300
   Bhogal P, 2019, CLIN NEURORADIOL, V29, P763, DOI 10.1007/s00062-019-00776-2
   Bhogal P, 2017, INTERV NEURORADIOL, V23, P330, DOI 10.1177/1591019917694838
   Bhogal P, 2017, J NEUROINTERV SURG, V9, P52, DOI 10.1136/neurintsurg-2016-012546
   Chaudhry NS, 2017, INTERV NEURORADIOL, V23, P372, DOI 10.1177/1591019917699980
   Connolly ES, 2012, STROKE, V43, P1711, DOI 10.1161/STR.0b013e3182587839
   Dabus G, 2013, INTERV NEUROL, V2, P30, DOI 10.1159/000354755
   Eskridge JM, 1998, NEUROSURGERY, V42, P510, DOI 10.1097/00006123-199803000-00016
   Firlik KS, 1999, SURG NEUROL, V51, P66, DOI 10.1016/S0090-3019(97)00370-4
   Hoh BL, 2005, NEUROSURG CLIN N AM, V16, P501, DOI 10.1016/j.nec.2005.04.004
   Johnston SC, 1998, NEUROLOGY, V50, P1413, DOI 10.1212/WNL.50.5.1413
   Kwon HJ, 2019, CLIN NEURORADIOL, V29, P751, DOI 10.1007/s00062-018-0711-3
   Lawton MT, 2017, NEW ENGL J MED, V377, P257, DOI 10.1056/NEJMcp1605827
   Machi P, 2017, J NEUROINTERV SURG, V9, P257, DOI 10.1136/neurintsurg-2015-012213
   Ohkawa M, 1996, RADIOLOGY, V198, P179, DOI 10.1148/radiology.198.1.8539374
   Patel AS, 2017, WORLD NEUROSURG, V98, P189, DOI 10.1016/j.wneu.2016.10.064
   Rasmussen Rune, 2015, Acta Neurochir Suppl, V120, P183, DOI 10.1007/978-3-319-04981-6_31
   Stuart Daniel, 2018, JBI Database System Rev Implement Rep, V16, P2013, DOI 10.11124/JBISRIR-2017-003493
   YAMAMOTO Y, 1992, NEUROSURGERY, V30, P1
   Zhang YP, 2013, J STROKE CEREBROVASC, V22, P1201, DOI 10.1016/j.jstrokecerebrovasdis.2012.04.005
   Zwienenberg-Lee M, 2008, STROKE, V39, P1759, DOI 10.1161/STROKEAHA.107.502666
NR 23
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.097
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600078
PM 31881345
DA 2020-05-12
ER

PT J
AU Sung, KS
   Roh, TH
   Moon, JH
   Kim, EH
   Kang, SG
   Kim, SH
   Chang, JH
AF Sung, Kyoung Su
   Roh, Tae Hoon
   Moon, Ju Hyung
   Kim, Eui Hyun
   Kang, Seok-Gu
   Kim, Se Hoon
   Chang, Jong Hee
TI Treatment Results for Recurrent Glioblastoma and Alteration of
   Programmed Death-Linand 1 Expression After Recurrence
SO WORLD NEUROSURGERY
LA English
DT Article
DE Immune status; Programmed death-ligand 1; Recurrent glioblastoma
ID SURGICAL RESECTION; PROMOTER METHYLATION; ADJUVANT TREATMENT; SURVIVAL;
   SURGERY; IMPACT; EXTENT; TEMOZOLOMIDE; REOPERATION; MULTICENTER
AB OBJECTIVE: This study was designed to analyze the results of recurrent glioblastoma (GBM) treatment, investigate the changes in molecular expression on paired primary and recurrent tumor specimens of GBM, and evaluate the effect of these changes on patient survival.
   METHODS: A total of 170 adult patients were diagnosed with recurrent GBM at a single institution between 2005 and 2015. Patients were divided into the reoperation and nonoperation groups. In addition, we evaluated the expression of immunologic markers of 43 paired surgical specimens from the first and second operations.
   RESULTS: The median overall survival (OS) after recurrence in the reoperation group was significantly longer than that in the nonoperation group (median, 9.1 months vs. 5.6 months; P = 0.024). The groups differed in characteristics such as age, performance scale, and progression-free survival. In the reoperation group, higher performance scale at recurrence, better extent of resection, and adjuvant treatment were related to longer overall survival. Among 43 paired surgical specimens, programmed death-ligand 1 (PD-L1) was positively expressed in 17 (39.5%) and 6 (13.9%) patients after the first and second operations, respectively. PD-L1 expression after recurrence showed an increase, decrease, and no change in 6 (13.9%), 14 (32.5%), and 23 (53.4%) patients, respectively. Changes in PD-L1 expression after recurrence did not affect survival after recurrence during progression.
   CONCLUSIONS: The extent of resection and adjuvant treatment was important for prolonged survival. Reoperation without adjuvant treatment was not effective for prolonged survival. Initial and follow-up PD-L1 expression from both operations did not influence patient survival.
C1 [Sung, Kyoung Su] Dong A Univ, Dept Neurosurg, Dong A Univ Hosp, Coll Med, Busan, South Korea.
   [Roh, Tae Hoon] Ajou Univ, Ajou Univ Hosp, Dept Neurosurg, Coll Med, Suwon, South Korea.
   [Moon, Ju Hyung; Kim, Eui Hyun; Kang, Seok-Gu; Chang, Jong Hee] Yonsei Univ, Severance Hosp, Dept Neurosurg, Coll Med, Seoul, South Korea.
   [Kim, Se Hoon] Yonsei Univ, Severance Hosp, Dept Pathol, Coll Med, Seoul, South Korea.
   [Moon, Ju Hyung; Kim, Eui Hyun; Kang, Seok-Gu; Kim, Se Hoon; Chang, Jong Hee] Yonsei Univ, Coll Med, Train Tumor Ctr, Yonsei Univ Hlth Syst, Seoul, South Korea.
   [Moon, Ju Hyung; Kim, Eui Hyun; Kang, Seok-Gu; Chang, Jong Hee] Yonsei Univ, Brain Res Inst, Yonsei Univ Hlth Syst, Coll Med, Seoul, South Korea.
RP Chang, JH (reprint author), Yonsei Univ, Severance Hosp, Dept Neurosurg, Coll Med, Seoul, South Korea.; Chang, JH (reprint author), Yonsei Univ, Coll Med, Train Tumor Ctr, Yonsei Univ Hlth Syst, Seoul, South Korea.; Chang, JH (reprint author), Yonsei Univ, Brain Res Inst, Yonsei Univ Hlth Syst, Coll Med, Seoul, South Korea.
EM changjh@yuhs.ac
OI Kim, Eui Hyun/0000-0002-2523-7122; Kang, Seok-Gu/0000-0001-5676-2037;
   Chang, Jong Hee/0000-0003-1509-9800; Kim, Se Hoon/0000-0001-7516-7372
FU National Research Foundation of Korea (NRF) - Korean government
   [NRF-2014R1A1A2058058]; Yonsei University College of Medicine
   [6-2018-0061]
FX This study was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korean government (NRF-2014R1A1A2058058) and a
   faculty research grant of Yonsei University College of Medicine
   (6-2018-0061).
CR Berghoff AS, 2015, NEURO-ONCOLOGY, V17, P1064, DOI 10.1093/neuonc/nou307
   Bloch O, 2012, J NEUROSURG, V117, P1032, DOI 10.3171/2012.9.JNS12504
   Clarke JL, 2011, NEURO-ONCOLOGY, V13, P1118, DOI 10.1093/neuonc/nor110
   Ening G, 2015, CLIN NEUROL NEUROSUR, V136, P89, DOI 10.1016/j.clineuro.2015.05.024
   Franceschi E, 2015, ANTICANCER RES, V35, P1743
   Fuller CD, 2007, RADIAT ONCOL, V2, DOI 10.1186/1748-717X-2-26
   Han J, 2017, J PATHOL TRANSL MED, V51, P40, DOI 10.4132/jptm.2016.08.31
   Hodi FS, 2010, J CUTAN PATHOL, V37, P48, DOI 10.1111/j.1600-0560.2010.01506.x
   Jung TY, 2010, ONCOL REP, V23, P1269, DOI 10.3892/or_00000760
   Kim HR, 2015, J CLIN NEUROSCI, V22, P468, DOI 10.1016/j.jocn.2014.09.018
   Lee J, 2018, YONSEI MED J, V59, P194, DOI 10.3349/ymj.2018.59.2.194
   Lee KS, 2018, J NEURO-ONCOL, V136, P453, DOI 10.1007/s11060-017-2675-6
   Lu VM, 2018, WORLD NEUROSURG, V115, P453, DOI 10.1016/j.wneu.2018.04.016
   Miyazaki T, 2017, J NEURO-ONCOL, V133, P277, DOI 10.1007/s11060-017-2451-7
   Montemurro N, 2016, CLIN NEUROL NEUROSUR, V142, P60, DOI 10.1016/j.clineuro.2016.01.010
   Nabors LB, 2017, J NATL COMPR CANC NE, V15, P1331, DOI 10.6004/jnccn.2017.0166
   Nandeesh BN, 2018, J NEUROSCI RURAL PRA, V9, P86, DOI 10.4103/jnrp.jnrp_417_17
   Nava F, 2014, NEURO-ONCOLOGY, V16, P719, DOI 10.1093/neuonc/not316
   Navarria P, 2016, CANCER RES TREAT, V48, P37, DOI 10.4143/crt.2014.259
   Nduom EK, 2016, NEURO-ONCOLOGY, V18, P195, DOI 10.1093/neuonc/nov172
   Oppenlander ME, 2014, J NEUROSURG, V120, P846, DOI 10.3171/2013.12.JNS13184
   Park CK, 2013, NEURO-ONCOLOGY, V15, P1096, DOI 10.1093/neuonc/not069
   Park CK, 2012, TRANSL ONCOL, V5, P393, DOI 10.1593/tlo.12253
   Park HH, 2016, J NEURO-ONCOL, V126, P559, DOI 10.1007/s11060-015-2001-0
   Park JK, 2010, J CLIN ONCOL, V28, P3838, DOI 10.1200/JCO.2010.30.0582
   Pessina F, 2017, J NEURO-ONCOL, V131, P377, DOI 10.1007/s11060-016-2310-y
   Preusser M, 2015, CLIN NEUROPATHOL, V34, P313, DOI 10.5414/NP300922
   Ringel F, 2016, NEURO-ONCOLOGY, V18, P96, DOI 10.1093/neuonc/nov145
   Roh TH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007422
   Seystahl K, 2016, CRIT REV ONCOL HEMAT, V99, P389, DOI 10.1016/j.critrevonc.2016.01.018
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Sughrue ME, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.12.FOCUS14726
   van Linde ME, 2017, J NEURO-ONCOL, V135, P183, DOI 10.1007/s11060-017-2564-z
   Wang QQ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006369
   Wang Z, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1196310
   Wick W, 2009, NEURO-ONCOLOGY, V11, P69, DOI 10.1215/15228517-2008-078
   Wu P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131403
   Yong RL, 2014, J NEUROSURG, V121, P802, DOI 10.3171/2014.6.JNS132038
   Zanovello WG, 2016, ARQ NEURO-PSIQUIAT, V74, P887, DOI [10.1590/0004-282X20160144, 10.1590/0004-282x20160144]
   Zeng J, 2016, ONCOTARGET, V7, P8944, DOI 10.18632/oncotarget.6884
NR 40
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.028
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600054
PM 31843727
DA 2020-05-12
ER

PT J
AU Supreeth, S
   Al Ghafri, KA
   Jayachandra, RK
   Al Balushi, ZY
AF Supreeth, Sam
   Al Ghafri, Khalifa A.
   Jayachandra, Renjit K.
   Al Balushi, Zakariya Y.
TI First Report of Candida auris Spondylodiscitis in Oman: A Rare
   Presentation
SO WORLD NEUROSURGERY
LA English
DT Article
DE Candida auris; Caspofungin; Clade; Oman; Spondylodiscitis
ID MANAGEMENT; EPIDEMIOLOGY; GUIDELINE; DIAGNOSIS
AB BACKGROUND: Candida auris is an emerging superbug which was recently discovered and has spread widely across the world. With a steady rise in incidence involving multisystems, this presents a unique challenge to caregivers.
   CASE DESCRIPTION: A 50-year-old man with sickle cell disease, diabetes mellitus, and multiple surgeries presented with progressive low back pain radiating to bilateral limbs and intact neurology. Radiologic and laboratory investigations suggested spondylodiscitis with epidural collection, which was operated with posterior decompression and stabilization. The tissue analysis was reported as C. auris, which was accordingly treated with caspofungin. Magnetic resonance imaging at 4 months showed resolution of infection with return of inflammatory markers to normal.
   CONCLUSIONS: C. auris appears to be an emerging superbug, which is hospital-acquired. All practitioners must be aware of its existence and presentation. Given the low incidence, high mortality, and no clear guidelines of management so far, formulation of any such strategies is complicated. Further studies and research are needed for this superbug.
C1 [Supreeth, Sam; Al Ghafri, Khalifa A.; Jayachandra, Renjit K.; Al Balushi, Zakariya Y.] Khoula Hosp, Muscat, Oman.
RP Supreeth, S (reprint author), Khoula Hosp, Muscat, Oman.
EM supreethsam13@gmail.com
CR Al-Siyabi T, 2017, J INFECTION, V75, P373, DOI 10.1016/j.jinf.2017.05.016
   Arendrup MC, 2010, CURR OPIN CRIT CARE, V16, P445, DOI 10.1097/MCC.0b013e32833e84d2
   Arendrup MC, 2017, J INFECT DIS, V216, pS445, DOI 10.1093/infdis/jix131
   Bassetti M, 2013, ANN CLIN MICROB ANTI, V12, DOI 10.1186/1476-0711-12-22
   Blizzard DJ, 2015, J CLIN NEUROSCI, V22, P1758, DOI 10.1016/j.jocn.2015.05.021
   Chowdhary A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006290
   Cortegiani A, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-018-0342-4
   Cuenca-Estrella M, 2012, CLIN MICROBIOL INFEC, V18, P9, DOI 10.1111/1469-0691.12038
   Duarte RM, 2013, EUR SPINE J, V22, P2787, DOI 10.1007/s00586-013-2850-1
   Felix C, 2018, MYCOSES, V61, P48
   Heath CH, 2019, EMERG INFECT DIS, V25, P192, DOI 10.3201/eid2501.181321
   Herren C, 2017, DTSCH ARZTEBL INT, V114, P875, DOI 10.3238/arztebl.2017.0875
   Kathuria S, 2015, J CLIN MICROBIOL, V53, P1823, DOI 10.1128/JCM.00367-15
   Kullberg BJ, 2015, NEW ENGL J MED, V373, P1445, DOI 10.1056/NEJMra1315399
   Larkin E, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.02396-16, 10.1128/aac.02396-16]
   Laxminarayan R, 2016, LANCET, V387, P168, DOI 10.1016/S0140-6736(15)00474-2
   Lockhart SR, 2017, CLIN INFECT DIS, V64, P134, DOI 10.1093/cid/ciw691
   Mohsin J, 2017, MYCOSES, V60, P569, DOI 10.1111/myc.12647
   Pappas PG, 2016, CLIN INFECT DIS, V62, P409, DOI 10.1093/cid/civ1194
   Richaud C, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007525
   Roberts SC, 2019, EMERG MICROBES INFEC, V8, P866, DOI 10.1080/22221751.2019.1625287
   Satoh K, 2009, MICROBIOL IMMUNOL, V53, P41, DOI 10.1111/j.1348-0421.2008.00083.x
   Schelenz S, 2016, ANTIMICROB RESIST IN, V5, DOI 10.1186/s13756-016-0132-5
   Sekyere JO, 2018, MICROBIOLOGYOPEN, V7, DOI 10.1002/mbo3.578
   Sherry L, 2017, EMERG INFECT DIS, V23, P328, DOI 10.3201/eid2302.161320
NR 25
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.09.021
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600159
PM 31525477
DA 2020-05-12
ER

PT J
AU Susko, MS
   Garcia, MA
   Ma, LJ
   Nakamura, JL
   Raleigh, DR
   Fogh, S
   Theodosopoulos, P
   McDermott, M
   Sneed, PK
   Braunstein, SE
AF Susko, Matthew S.
   Garcia, Michael A.
   Ma, Lijun
   Nakamura, Jean L.
   Raleigh, David R.
   Fogh, Shannon
   Theodosopoulos, Philip
   McDermott, Michael
   Sneed, Penny K.
   Braunstein, Steve E.
TI Stereotactic Radiosurgery to More Than 10 Brain Metastases: Evidence to
   Support the Role of Radiosurgery for Ideal Hippocampal Sparing in the
   Treatment of Multiple Brain Metastases
SO WORLD NEUROSURGERY
LA English
DT Article
DE Brain metastasis; Hippocampal sparing; SRS
ID CELL LUNG-CANCER; RADIATION-THERAPY; OPEN-LABEL; MANAGEMENT;
   EPIDEMIOLOGY; RADIOTHERAPY; MELANOMA; SURGERY
AB BACKGROUND: Brain metastases are a common occurrence, with literature supporting the treatment of a limited number of brain metastases with stereotactic radiosurgery (SRS), as opposed to whole brain radiotherapy (WBRT). Less well understood is the role of SRS in patients with >= 10 brain metastases.
   METHODS: Patients treated with SRS to >= 10 brain metastases without concurrent WBRT between March 1999 and December 2016 were reviewed. Analysis was performed for overall survival, treated lesion freedom from progression (FFP), freedom from new metastases (FFNMs), and adverse radiation effect. Hippocampal volumes were retrospectively generated in patients treated with up-front SRS for evaluation of dose volume metrics.
   RESULTS: A total of 143 patients were identified with 75 patients having up-front SRS and 68 patients being treated as salvage therapy after prior WBRT. The median number of lesions per patient was 13 (interquartile range [IQR], 11-17). Median total volume of treatment was 4.1 cm(3) (IQR, 2.0-9.9 cm(3)). The median 12-month FFP for up-front and salvage treatment was 96.8% (95% confidence interval [CI], 95.5-98.1) and 83.6% (95% CI, 79.9-87.5), respectively (P < 0.001). Twelve-month FFNMs for up-front and salvage SRS was 18.8% (95% CI, 10.9-32.3) versus 19.2% (95% CI, 9.7-37.8), respectively (P = 0.90). The mean hippocampal dose was 150 cGy (IQR, 100-202 cGy).
   CONCLUSIONS: Excellent rates of local control can be achieved when treating patients with >10 intracranial metastases either in the up-front or salvage setting. Hippocampal sparing is readily achievable with expected high rates of new metastatic lesions in treated patients.
C1 [Susko, Matthew S.; Garcia, Michael A.; Ma, Lijun; Nakamura, Jean L.; Raleigh, David R.; Fogh, Shannon; Sneed, Penny K.; Braunstein, Steve E.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
   [Theodosopoulos, Philip; McDermott, Michael] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
RP Braunstein, SE (reprint author), Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA.
EM Steve.Braunstein@UCSF.edu
OI Susko, Matthew/0000-0002-8522-4585
CR Andrews DW, 2004, LANCET, V363, P1665, DOI 10.1016/S0140-6736(04)16250-8
   Aoyama H, 2006, JAMA-J AM MED ASSOC, V295, P2483, DOI 10.1001/jama.295.21.2483
   BORGELT B, 1980, INT J RADIAT ONCOL, V6, P1, DOI 10.1016/0360-3016(80)90195-9
   Brown PD, 2016, JAMA-J AM MED ASSOC, V316, P401, DOI 10.1001/jama.2016.9839
   Chang EL, 2009, LANCET ONCOL, V10, P1037, DOI 10.1016/S1470-2045(09)70263-3
   Garcia MA, 2018, PRACT RADIAT ONCOL, V8, pE369, DOI 10.1016/j.prro.2018.06.004
   Goldberg SB, 2016, LANCET ONCOL, V17, P976, DOI 10.1016/S1470-2045(16)30053-5
   GONDI V, 2019, J CLIN ONCOL S, V37
   Gondi V, 2018, NEURO-ONCOLOGY, V20, P2, DOI 10.1093/neuonc/nox180
   Gondi V, 2014, J CLIN ONCOL, V32, P3810, DOI 10.1200/JCO.2014.57.2909
   Gondi V, 2010, INT J RADIAT ONCOL, V78, P1244, DOI 10.1016/j.ijrobp.2010.01.039
   Grandhi R, 2012, J NEUROSURG, V117, P237, DOI 10.3171/2012.4.JNS11870
   Heon S, 2012, CLIN CANCER RES, V18, P4406, DOI 10.1158/1078-0432.CCR-12-0357
   Karlsson B, 2009, J NEUROSURG, V111, P449, DOI 10.3171/2008.10.JNS08214
   Kim CH, 2008, J KOREAN NEUROSURG S, V44, P358, DOI 10.3340/jkns.2008.44.6.358
   Kocher M, 2011, J CLIN ONCOL, V29, P134, DOI 10.1200/JCO.2010.30.1655
   LINDQUIST C, 1989, NEUROSURGERY, V25, P802, DOI 10.1227/00006123-198911000-00018
   Magnuson WJ, 2017, J CLIN ONCOL, V35, P1070, DOI 10.1200/JCO.2016.69.7144
   Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674
   Nayak L, 2012, CURR ONCOL REP, V14, P48, DOI 10.1007/s11912-011-0203-y
   Patchell RA, 2003, CANCER TREAT REV, V29, P533, DOI 10.1016/S0305-7372(03)00105-1
   PATCHELL RA, 1990, NEW ENGL J MED, V322, P494, DOI 10.1056/NEJM199002223220802
   Rava P, 2013, J NEUROSURG, V119, P457, DOI 10.3171/2013.4.JNS121751
   Reungwetwattana T, 2018, J CLIN ONCOL, V36, P3290, DOI 10.1200/JCO.2018.78.3118
   Serizawa T, 2010, J NEURO-ONCOL, V98, P163, DOI 10.1007/s11060-010-0169-x
   Sneed PK, 1999, INT J RADIAT ONCOL, V43, P549, DOI 10.1016/S0360-3016(98)00447-7
   Tabouret E, 2012, ANTICANCER RES, V32, P4655
   Tawbi HA, 2018, NEW ENGL J MED, V379, P722, DOI 10.1056/NEJMoa1805453
   Yamamoto M, 2014, LANCET ONCOL, V15, P387, DOI 10.1016/S1470-2045(14)70061-0
   Yang JJ, 2017, LANCET RESP MED, V5, P707, DOI 10.1016/S2213-2600(17)30262-X
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.089
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600020
PM 31785436
DA 2020-05-12
ER

PT J
AU Taher, M
   Gholampour, S
AF Taher, Mehran
   Gholampour, Seifollah
TI Effect of Ambient Temperature Changes on Blood Flow in Anterior Cerebral
   Artery of Patients with Skull Prosthesis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Aneurysm; Cold ambient temperature; Hot ambient temperature; Skull
   prosthesis; Thermal fluid structure interaction (thermal-FSI)
ID NUMERICAL-SIMULATION; HEAT-TRANSFER; TITANIUM
AB BACKGROUND: In many cases, an injury to the head leads to the replacement of a part of the skull with materials such as titanium and polyether ether ketone.
   METHODS: Three-dimensional heads model of 15 healthy individuals and 13 patients were prepared. The models were simulated using thermal fluid structure interaction analysis to evaluate the effects of cold (5 degrees C) and hot (55 degrees C) temperatures of the skull on the conditions of blood flow in the anterior cerebral artery.
   RESULTS: The results showed negligible changes (<3%) in wall shear stress (WSS) vessel and von Mises stress between the healthy individuals and patients both at 25 degrees C and 55 degrees C. However, at 5 degrees C, the values of these 2 parameters in the patients were 2.1 and 2.5 times those in healthy individuals, respectively. The value of WSS in healthy individuals and the patients in cold temperature was 1.2 and 2.9 times those at normal temperature. The corresponding values for von Mises stress were 1.1 and 2.2, respectively. Accordingly, the stress changes between cold and hot ambient temperatures were found to be negligible in all samples.
   CONCLUSIONS: The changes in stress were significant only for the patients when exposed to cold ambient temperature, and only in patients, exposure to a cold ambient temperature significantly increased the risks of vascular aneurysm and damage to the brain tissue surrounding the blood vessels. These risks were found to be negligible for both healthy individuals and patients when exposed to hot ambient temperature and also for healthy individuals exposed to cold ambient temperature.
C1 [Taher, Mehran; Gholampour, Seifollah] Islamic Azad Univ, Dept Biomed Engn, North Tehran Branch, Tehran, Iran.
RP Gholampour, S (reprint author), Islamic Azad Univ, Dept Biomed Engn, North Tehran Branch, Tehran, Iran.
EM s.gholampour@iau-tnb.ac.ir
CR Chou YC, 2008, J CLIN NEUROSCI, V15, P1240, DOI 10.1016/j.jocn.2007.05.016
   Elwassif MM, 2006, J NEURAL ENG, V3, P306, DOI 10.1088/1741-2560/3/4/008
   Finnie JW, 2011, J CLIN NEUROSCI, V18, P947, DOI 10.1016/j.jocn.2010.11.010
   Gholampour S, 2017, J APPL MECH TECH PH+, V58, P386, DOI 10.1134/S0021894417030026
   Gholampour S., 2017, INT CLIN NEUROSCIENC, V4, P4, DOI [10.22037/icnj.v4i1.16691, DOI 10.22037/ICNJ.V4I1.16691]
   Gholampour S, 2014, INT CLIN NEUROSCI J, V1, P1, DOI DOI 10.22037/ICNJ.V1I1.6536
   Gholampour Seifollah, 2019, BMC Res Notes, V12, P338, DOI 10.1186/s13104-019-4381-2
   Gholampour S, 2019, BASIC CLIN NEUROSCI, V10, P185, DOI 10.32598/bcn.9.10.285
   Gholampour S, 2019, BIOMED ENG ONLINE, V18, DOI 10.1186/s12938-019-0686-6
   Gholampour S, 2018, TECHNOL HEALTH CARE, V26, P687, DOI 10.3233/THC-181246
   Gholampour S, 2018, BIOMECH MODEL MECHAN, V17, P1599, DOI 10.1007/s10237-018-1046-3
   Gholampour S, 2018, WORLD NEUROSURG, V116, pE830, DOI 10.1016/j.wneu.2018.05.108
   Gholampour S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196216
   Gholampour S, 2017, J CLIN NEUROSCI, V35, P50, DOI 10.1016/j.jocn.2016.09.012
   Goubergrits L, 2012, J R SOC INTERFACE, V9, P677, DOI 10.1098/rsif.2011.0490
   Hajirayat K, 2017, J APPL MECH TECH PH+, V58, P968, DOI 10.1134/S0021894417060025
   Hajirayat K., 2016, INT CLIN NEUROSCI J, V3, P44, DOI DOI 10.22037/ICNJ.V3I1.12460]
   He Y, 2008, INT J NUMER METHOD H, V18, P932, DOI 10.1108/09615530810899033
   Isoda H, 2010, NEURORADIOLOGY, V52, P913, DOI 10.1007/s00234-009-0634-4
   Kaburcuk F, 2018, APPL COMPUT ELECTROM, V33, P367
   Kandala SK, 2013, ASME 2013 INT MECH E
   Karli R, 2014, OPEN ENG, V4, P39, DOI 10.2478/s13531-013-0140-7
   Lambiase F, 2018, THIN WALL STRUCT, V130, P254, DOI 10.1016/j.tws.2018.05.020
   Linninger AA, 2016, ANNU REV FLUID MECH, V48, P219, DOI 10.1146/annurev-fluid-122414-034321
   Mat D.A.A., 2010, INT J NETWORK MOB TE, V1, P60
   Men-Chi H, 2007, Cardiovasc Eng, V7, P7, DOI 10.1007/s10558-007-9026-8
   Mondal A, 2016, J NANOPART RES, V18, DOI 10.1007/s11051-016-3422-1
   Motherway J., 2009, LEGAL MED, V11, P220
   Nourhashemi M, 2016, NEUROPHOTONICS, V3, DOI 10.1117/1.NPh.3.1.015001
   Vosahlo J, 2014, APPL MECH MAT, V732, P165
   Wessapan T, 2011, J HEAT TRANS-T ASME, V133, DOI 10.1115/1.4003115
   Xue X, 2013, COMPUT BIOL MED, V43, P63, DOI 10.1016/j.compbiomed.2012.10.004
   Yan WY, 2011, COMPUT METHOD BIOMEC, V14, P1049, DOI 10.1080/10255842.2010.506435
   Yang ZJ, 2010, T NONFERR METAL SOC, V20, P1957, DOI 10.1016/S1003-6326(09)60401-5
NR 34
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.171
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600040
PM 31837495
DA 2020-05-12
ER

PT J
AU Thien, A
   Soh, S
   Lock, C
   Han, JLXG
   Chen, MW
   Srivatsava, S
   Rao, JP
   Ang, BT
   Seow, WT
   Keong, NC
AF Thien, Ady
   Soh, Samantha
   Lock, Christine
   Han, Julian Xinguang
   Chen, Min Wei
   Srivatsava, Sunku
   Rao, Jai Prashanth
   Ang, Beng Ti
   Seow, Wan Tew
   Keong, Nicole C.
TI The National Neuroscience Institute External Ventricular Drain Study: A
   Pragmatic Multisite Risk-Stratification Pathway to Reduce
   Ventriculostomy-Related Infection
SO WORLD NEUROSURGERY
LA English
DT Article
DE External ventricular drain; Infection; Pathway; Protocol; Risk
   management; Ventriculitis; Ventriculostomy
ID CATHETERS; PROTOCOL; PREVENTION; PLACEMENT; DURATION; EXCHANGE; RATES
AB OBJECTIVE: Ventriculostomy-related infection (VRI) is associated with potential serious morbidity, extended hospitalization duration, increased health care costs, and mortality. We assessed the effectiveness of a pragmatic risk-stratification pathway for external ventricular drain (EVD) management, allowing for surgical decision making, in reducing the rate of VRIs.
   METHODS: Two studies were performed concurrently. A retrospective audit of EVD infection rates and outcomes in our unit across 3 hospitals was conducted from January to December 2014. The second prospective study compared the same variables during the implementation of the EVD pathway across the 3 sites from January 2015 to December 2016.
   RESULTS: The number of patients requiring EVDs increased from 2014 to 2016 (165 vs. 189 vs. 197 patients, respectively), with a significant increase in patients with intraventricular hemorrhage (P = 0.009). Despite increasing risk, overall EVD infections decreased during the implementation period, from 4.8% (8/165) in 2014 to 3.7% in 2015 (7/189) and 2.0% in 2016 (4/197, P = 0.33). In 2 sites (site 1, 2.0% vs. 2.1% vs. 1.9%, and site 2, 4.7% vs. 5.0% vs. 5.3%), transition to the EVD risk-stratification pathway maintained already low infection rates; in site 3, EVD infections decreased from 6.8% (5/73) to 3.9% (4/102) and 0% (0/86, P = 0.06).
   CONCLUSIONS: The introduction of a pragmatic evidence-based risk-stratification pathway, in which different options for EVD management are incorporated, results in low EVD infection rates across a multisite institutional practice. Our results are comparable to published protocols involving the implementation of standard care bundles and/or antibacterial EVDs alone, in reducing VRIs.
C1 [Thien, Ady; Soh, Samantha; Lock, Christine; Han, Julian Xinguang; Chen, Min Wei; Srivatsava, Sunku; Rao, Jai Prashanth; Ang, Beng Ti; Seow, Wan Tew; Keong, Nicole C.] Natl Neurosci Inst, Dept Neurosurg, Singapore, Singapore.
   [Rao, Jai Prashanth; Ang, Beng Ti; Seow, Wan Tew; Keong, Nicole C.] Duke NUS Med Sch, Singapore, Singapore.
RP Keong, NC (reprint author), Natl Neurosci Inst, Dept Neurosurg, Singapore, Singapore.; Keong, NC (reprint author), Duke NUS Med Sch, Singapore, Singapore.
EM nchkeong@cantab.net
CR Arabi Y, 2005, AM J INFECT CONTROL, V33, P137, DOI 10.1016/j.ajic.2004.11.008
   Beer R, 2008, J NEUROL, V255, P1617, DOI 10.1007/s00415-008-0059-8
   Chi H, 2010, INT J INFECT DIS, V14, pE216, DOI 10.1016/j.ijid.2009.04.006
   Dasic D, 2006, BRIT J NEUROSURG, V20, P296, DOI 10.1080/02688690600999901
   Edwards NC, 2015, J NEUROSURG, V122, P139, DOI 10.3171/2014.9.JNS131277
   Flint AC, 2013, NEUROSURGERY, V72, P993, DOI 10.1227/NEU.0b013e31828e8dfd
   Fried HI, 2016, NEUROCRIT CARE, V24, P61, DOI 10.1007/s12028-015-0224-8
   Harrop JS, 2010, NEUROSURGERY, V67, P187, DOI 10.1227/01.NEU.0000370247.11479.B6
   Hoefnagel D, 2008, ACTA NEUROCHIR, V150, P209, DOI 10.1007/s00701-007-1458-9
   Holloway KL, 1996, J NEUROSURG, V85, P419, DOI 10.3171/jns.1996.85.3.0419
   Kang DH, 2010, NEUROSURGERY, V66, P904, DOI 10.1227/01.NEU.0000368385.74625.96
   Keong NCH, 2012, NEUROSURGERY, V71, P394, DOI 10.1227/NEU.0b013e318257bebb
   Kim JH, 2012, WORLD NEUROSURG, V77, P135, DOI 10.1016/j.wneu.2011.04.017
   Konstantelias AA, 2015, J NEUROSURG, V122, P1096, DOI 10.3171/2014.12.JNS14908
   Korinek AM, 2005, ACTA NEUROCHIR, V147, P39, DOI 10.1007/s00701-004-0416-z
   Kubilay Z, 2013, J NEUROSURG, V118, P514, DOI 10.3171/2012.11.JNS121336
   Lo CH, 2007, J NEUROSURG, V106, P378, DOI 10.3171/jns.2007.106.3.378
   Lozier AP, 2002, NEUROSURGERY, V51, P170, DOI 10.1097/00006123-200207000-00024
   Mallucci CL, 2019, LANCET, V394, P1530, DOI 10.1016/S0140-6736(19)31603-4
   Muttaiyah S, 2008, J MED MICROBIOL, V57, P207, DOI 10.1099/jmm.0.47518-0
   Sussman ES, 2014, J NEUROSURG, V120, P931, DOI 10.3171/2013.12.JNS131685
   van de Beek D, 2010, NEW ENGL J MED, V362, P146, DOI 10.1056/NEJMra0804573
   Weisenberg SH, 2016, J NEUROSURG, V125, P1504, DOI 10.3171/2015.12.JNS151181
   Wong GKC, 2002, J NEUROL NEUROSUR PS, V73, P759, DOI 10.1136/jnnp.73.6.759
   Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725
   Zingale A, 1999, J Neurosurg Sci, V43, P125
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.070
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600017
PM 31756500
DA 2020-05-12
ER

PT J
AU Tiwari, S
   Yadav, T
   Pamnani, J
   Mathew, JM
   Elhence, P
   Praneeth, K
   Vedant, D
   Khera, PS
   Garg, P
   Vyas, V
AF Tiwari, Sarbesh
   Yadav, Taruna
   Pamnani, Jaya
   Mathew, John M.
   Elhence, Poonam
   Praneeth, Kokkula
   Vedant, Deepak
   Khera, Pushpinder Singh
   Garg, Pawan
   Vyas, Varuna
TI Diffuse Leptomeningeal Glioneuronal Tumor: A Unique Leptomeningeal Tumor
   Entity
SO WORLD NEUROSURGERY
LA English
DT Article
DE Diffuse leptomeningeal glioneuronal tumor; Hydrocephalus; Subpial cysts
AB BACKGROUND: Diffuse leptomeningeal glioneuronal tumor (DLGNT) is a recent addition to the World Health Organization classification schema of brain tumors, under the heading of neuronal and mixed neuronal-glial tumors. DLGNTs have a classic imaging appearance. However, it has often been misdiagnosed owing to its rarity, its resemblance to granulomatous/leptomeningeal etiologies, and the clinical presentation.
   CASE DESCRIPTION: We have described the case of a 3-year-old girl who had presented with complaints of nonprojectile vomiting and altered sensorium that had been initially diagnosed and treated as a case of tubercular meningitis at a peripheral health facility. However, the nonresponse to antitubercular medication necessitated a repeat magnetic resonance imaging evaluation at our institute, which had revealed the classic imaging appearance of DLGNT. The diagnosis was further established by meningeal biopsy and the histopathological evaluation findings.
   CONCLUSION: We have described the classic imaging appearance of this rare brain tumor. Radiologists and clinicians should be aware of this entity to avoid misdiagnosis and a delay in management.
C1 [Tiwari, Sarbesh; Yadav, Taruna; Pamnani, Jaya; Khera, Pushpinder Singh; Garg, Pawan] All India Inst Med Sci, Dept Diagnost & Intervent Radiol, Jodhpur, Rajasthan, India.
   [Mathew, John M.] All India Inst Med Sci, Dept Radiotherapy, Jodhpur, Rajasthan, India.
   [Elhence, Poonam; Vedant, Deepak] All India Inst Med Sci, Dept Pathol, Jodhpur, Rajasthan, India.
   [Praneeth, Kokkula] All India Inst Med Sci, Dept Neurosurg, Jodhpur, Rajasthan, India.
   [Vyas, Varuna] All India Inst Med Sci, Dept Pediat, Jodhpur, Rajasthan, India.
RP Yadav, T (reprint author), All India Inst Med Sci, Dept Diagnost & Intervent Radiol, Jodhpur, Rajasthan, India.
EM drtanu.taruna@gmail.com
CR Aguilera D, 2018, CHILD NERV SYST, V34, P329, DOI 10.1007/s00381-017-3584-x
   Carletti F., 2019, CLIN NEURORADIOLOGY
   Deng MY, 2018, ACTA NEUROPATHOL, V136, P239, DOI 10.1007/s00401-018-1865-4
   Fiaschi P, 2018, WORLD NEUROSURG, V114, P53, DOI 10.1016/j.wneu.2018.02.160
   Gardiman MP, 2010, BRAIN PATHOL, V20, P361, DOI 10.1111/j.1750-3639.2009.00285.x
   Kung JH, 2018, J NEUROPATH EXP NEUR, V77, P751, DOI 10.1093/jnen/nly053
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Lyle Megan R, 2015, Child Neurol Open, V2, p2329048X14567531, DOI 10.1177/2329048X14567531
   Rodriguez FJ, 2012, ACTA NEUROPATHOL, V124, P627, DOI 10.1007/s00401-012-1037-x
   Schwetye KE, 2017, HUM PATHOL, V70, P105, DOI 10.1016/j.humpath.2017.06.004
   Tiwari N, 2019, CHILD NERV SYST, V35, P1609, DOI 10.1007/s00381-019-04074-7
   Yamasaki T, 2018, BRAIN TUMOR PATHOL, V35, P209, DOI 10.1007/s10014-018-0326-z
NR 12
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.119
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600151
PM 31899391
DA 2020-05-12
ER

PT J
AU Tonsbeek, AM
   Groen, JL
   Vleggeert-Lankamp, CLAM
AF Tonsbeek, Anthony M.
   Groen, Justus L.
   Vleggeert-Lankamp, Carmen L. A. M.
TI Surgical Interventions for Cervical Radiculopathy Caused by a Vertebral
   Artery Loop: A Case Report and Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cervical radiculopathy; Surgery; Vascular anomaly; Vertebral artery loop
ID MEDIAL-LOOP; INJURY; TORTUOSITY; EROSION; DECOMPRESSION; COMPRESSION;
   SEGMENT; ROOT
AB BACKGROUND: Aberrant vertebral artery loops are a rare clinical condition, with sparse data regarding the optimal treatment guidelines for individual patients. The heterogeneity of treatment options in the literature creates a problem when tailoring treatments to individual patients. In this review of the literature, multiple surgical treatments for cervical vertebral artery loops were analyzed and compared. In addition, this article provides a clinical case of a patient with a vertebral artery loop.
   METHODS: A literature review was conducted to identify studies investigating surgical treatments for a vertebral artery loop. Different surgical techniques were examined and the involved techniques and approaches described. The outcomes were assessed for each study and the effectiveness of the treatment determined.
   RESULTS: Twelve articles met the inclusion criteria for this review. Six types of surgical interventions were found in the literature. Each intervention had similar postoperative results, leading to either a significant improvement or a complete resolution of symptoms.
   CONCLUSIONS: Multiple successful surgical interventions have been described in the medical literature. However, because of the lack of evidence-based studies, no surgical intervention protocol could be determined. Treatment should therefore he tailored to individual patients' characteristics. Because not every radiologically detected vertebral artery loop is the main reason for a patient's symptoms, a thorough multidisciplinary approach is justified and advocated in patients with an atypical presentation, before a neurosurgical intervention takes place. More deliberate clinical decisions can be made once the understanding of the pathogenesis of this rare disease entity has been established and treatment protocols formulated.
C1 [Tonsbeek, Anthony M.; Groen, Justus L.; Vleggeert-Lankamp, Carmen L. A. M.] Leiden Univ, Dept Neurosurg, Med Ctr, Leiden, Netherlands.
RP Tonsbeek, AM (reprint author), Leiden Univ, Dept Neurosurg, Med Ctr, Leiden, Netherlands.
EM m.tonsbeek@lumc.nl
CR Ashkan K, 2002, BRIT J NEUROSURG, V16, P146, DOI 10.1080/02688690220131741
   Bruneau M, 2006, NEUROSURGERY, V59, P20, DOI 10.1227/01.NEU.0000219931.64378.B5
   Capelle HH, 2010, J HEADACHE PAIN, V11, P339, DOI 10.1007/s10194-010-0213-4
   Caridi John M, 2011, HSS J, V7, P265
   Chen JF, 2000, SURG NEUROL, V53, P281, DOI 10.1016/S0090-3019(00)00169-5
   Chibbaro S, 2012, WORLD NEUROSURG, V78, DOI 10.1016/j.wneu.2011.12.002
   COOPER DF, 1980, J NEUROSURG, V53, P106, DOI 10.3171/jns.1980.53.1.0106
   Dandaleh NS, 2010, J CLIN NEUROSCI, V17, P788, DOI 10.1016/j.jocn.2009.10.004
   Deep NL, 2017, LARYNGOSCOPE, V127, P715, DOI 10.1002/lary.26126
   Detwiler PW, 1998, J NEUROSURG, V89, P485, DOI 10.3171/jns.1998.89.3.0485
   Doweidar A, 2014, J RADIOL CASE REP, V8, P35, DOI 10.3941/jrcr.v8i5.1407
   DUTHEL R, 1994, NEUROSURGERY, V35, P140, DOI 10.1227/00006123-199407000-00022
   Eksi MS, 2016, EUR SPINE J, V25, P4171, DOI 10.1007/s00586-016-4691-1
   EPSTEIN NE, 1995, J SPINAL DISORD, V8, P308, DOI 10.1097/00002517-199508040-00008
   Gkekas N, 2013, ACTA NEUROCHIR, V155, P1247, DOI 10.1007/s00701-013-1738-5
   Hage ZA, 2012, J NEUROSURG-SPINE, V17, P337, DOI 10.3171/2012.7.SPINE123
   Ju CI, 2017, WORLD NEUROSURG, V104, DOI 10.1016/j.wneu.2017.05.090
   Khansuheb MZ, 2020, WORLD NEUROSURG, V134, P280, DOI 10.1016/j.wneu.2019.10.068
   Kim HS, 2010, J KOREAN NEUROSURG S, V48, P465, DOI 10.3340/jkns.2010.48.5.465
   Korinth MC, 2007, SURG NEUROL, V67, P172, DOI 10.1016/j.surneu.2006.03.047
   LINDSEY RW, 1985, J BONE JOINT SURG AM, V67A, P806, DOI 10.2106/00004623-198567050-00020
   Molinari RW, 2015, GLOB SPINE J, V5, P528, DOI 10.1055/s-0035-1566225
   Nardin RA, 1999, MUSCLE NERVE, V22, P151, DOI 10.1002/(SICI)1097-4598(199902)22:2<151::AID-MUS2>3.0.CO;2-B
   Oga M, 1996, SPINE, V21, P1085, DOI 10.1097/00007632-199605010-00019
   Ozgen S, 2004, J NEUROSURG-SPINE, V1, P299, DOI 10.3171/spi.2004.1.3.0299
   Paksoy Y, 2003, SPINE, V28, P1183, DOI 10.1097/00007632-200306010-00019
   Park S, 2012, J KOREAN NEUROSURG S, V52, P54
   Saavedra-Pozo FM, 2014, OCHSNER J, V14, P78
   Sakaida H, 2001, J NEUROSURG, V94, P145, DOI 10.3171/spi.2001.94.1.0145
   SHARMA RR, 1993, J NEUROSURG, V78, P669, DOI 10.3171/jns.1993.78.4.0669
   Sivaraju L, 2017, EUR SPINE J, V26, P1028, DOI 10.1007/s00586-016-4580-7
   SLOVER WP, 1965, RADIOLOGY, V84, P112, DOI 10.1148/84.1.112
   Tandon A, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.6.FOCUS1339
   Tumialan LM, 2004, SPINE, V29, pE343, DOI 10.1097/01.BRS.0000134593.98662.D0
   Wakao N, 2016, SPINE, V41, P293, DOI 10.1097/BRS.0000000000001241
   Wang DD, 2017, WORLD NEUROSURG, V101, P289, DOI 10.1016/j.wneu.2017.01.129
   Wood L, 2017, Eur Spine J, DOI 10.1007/s00586-017-5123-6
   ZIMMERMAN HB, 1970, AMER J ROENTGENOL RA, V108, P767, DOI 10.2214/ajr.108.4.767
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.164
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600099
PM 31809894
DA 2020-05-12
ER

PT J
AU Turgut, M
   Turgut, AT
   Dogra, VS
AF Turgut, Mehmet
   Turgut, Ahmet Tuncay
   Dogra, Vikram S.
TI Iatrogenic Ureteral Injury as a Complication of Posterior or Lateral
   Lumbar Spine Surgery: A Systematic Review of the Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Degenerative disc disease; Herniated intervertebral disc; Iatrogenic;
   Lumbar spinal stenosis; Spondylolisthesis; Surgery; Ureteral injury
ID INTERBODY FUSION SURGERY; DISK SURGERY; VISCERAL INJURIES; RARE
   COMPLICATION; ILIAC ARTERY; DISKECTOMY; DIAGNOSIS; AVULSION;
   LAMINECTOMY; MANAGEMENT
AB OBJECTIVE: Iatrogenic ureteral injury associated with lumbar spine surgery is an uncommon but devastating complication with associated medicolegal implications.
   METHODS: We performed a systematic review of the English language literature published between 1954 and 2019, accessed through 4 popular databases. We found 44 articles (28 case reports, 9 case-based reviews, 4 case series, 1 original article, 1 case illustration, and 1 pictorial) containing 46 cases of ureteral injuries after posterior or lateral lumbar spine surgery.
   RESULTS: Except for 5 cases with insufficient data, 24 of the remaining 41 patients were female and 17 were male, with ages ranging from 16 years to 83 years. Excluding 4 cases without enough information, initial diagnoses of lumbar disc herniation (n = 33) or lumbar spinal stenosis (n = 4), spondylolisthesis (n = 3), degenerative disc disease (n = 1), and failed back surgery syndrome (n = 1) were reported from 18 countries; 54% of patients were from the United States, Japan, or Turkey. The interval from spinal surgery to restorative surgery ranged from <24 hours to 1 month to 1 year; in 48% of patients, it was >1 week, and 90% of patients recovered completely. Initial surgery was combined with vascular injury in 15% of patients.
   CONCLUSIONS: Ureteral injury associated with lumbar spine surgery is overreported in developed or developing countries. It should be considered in the differential diagnosis of any patient who presents with symptoms of acute abdomen after lumbar spine surgery, and patients who underwent restorative surgery had a good prognosis.
C1 [Turgut, Mehmet] Adnan Menderes Univ, Dept Neurosurg, Fac Med, Aydin, Turkey.
   [Turgut, Ahmet Tuncay] Yuksek Ihtisas Univ, Dept Radiol, Fac Med, Ankara, Turkey.
   [Dogra, Vikram S.] Univ Rochester, Med Ctr, Sch Med & Dent, Dept Imaging Sci, Rochester, NY 14642 USA.
RP Turgut, AT (reprint author), Yuksek Ihtisas Univ, Dept Radiol, Fac Med, Ankara, Turkey.
EM ahmettuncayturgut@yahoo.com
CR Abboudi H, 2013, NAT REV UROL, V10, P108, DOI 10.1038/nrurol.2012.254
   Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   Akpinar S, 2015, UROL J, V12, P2291
   ALTEBARMAKIAN VK, 1981, UROLOGY, V17, P462, DOI 10.1016/0090-4295(81)90191-6
   Anand N, 2013, J NEUROSURG-SPINE, V18, P18, DOI 10.3171/2012.9.SPINE12659
   [Anonymous], 1995, RADIOGRAPHICS, V15, P216
   Balak N, 2010, J NEUROSURG SCI, V54, P129
   Baser A, 2016, TURK J UROL, V42, P108, DOI 10.5152/tud.2016.70105
   BEC A, 1989, BRIT J UROL, V63, P552, DOI 10.1111/j.1464-410X.1989.tb05961.x
   BORSKI AA, 1960, J NEUROSURG, V17, P925, DOI 10.3171/jns.1960.17.5.0925
   Burks FN, 2014, THER ADV UROL, V6, P115, DOI 10.1177/1756287214526767
   Cho KT, 2008, SURG NEUROL, V69, P135, DOI 10.1016/j.surneu.2007.01.072
   CHOW CC, 1994, AM J ROENTGENOL, V163, P353, DOI 10.2214/ajr.163.2.8037029
   Crobeddu E, 2014, J Neurosurg Sci, V58, P107
   de Quintana-Schmidt C, 2011, NEUROCIRUGIA, V22, P162
   DEFAY P, 1986, BRIT J UROL, V58, P567, DOI 10.1111/j.1464-410X.1986.tb05478.x
   Demirkesen O, 2006, INT UROL NEPHROL, V38, P459, DOI 10.1007/s11255-006-6651-x
   DESAUSSURE RL, 1959, J NEUROSURG, V16, P222, DOI 10.3171/jns.1959.16.2.0222
   Dosoglu M, 2006, CLIN NEUROL NEUROSUR, V108, P174, DOI 10.1016/j.clineuro.2004.11.019
   FAYE R, 1983, J UROLOGIE, V89, P273
   FLAM TA, 1992, J UROLOGY, V148, P1249, DOI 10.1016/S0022-5347(17)36875-1
   Fomekong E, 2018, WORLD NEUROSURG, V111, P28, DOI [10.1016/J.WNEU.2017.11.175, 10.1016/j.wneu.2017.11.175]
   Fruhwirth J, 1996, ACTA NEUROCHIR, V138, P912, DOI 10.1007/BF01411278
   Fujibayashi S, 2017, SPINE, V42, P1478, DOI 10.1097/BRS.0000000000002139
   GANGAI M P, 1976, Urology, V8, P22, DOI 10.1016/0090-4295(76)90046-7
   GANGAI MP, 1972, J NEUROSURG, V36, P90, DOI 10.3171/jns.1972.36.1.0090
   Garg N, 2017, UROL ANNALS, V9, P200, DOI 10.4103/0974-7796.204191
   GAUCHER A, 1982, REV RHUM, V49, P51
   Gayer Gabriela, 2002, Spine (Phila Pa 1976), V27, pE451, DOI 10.1097/00007632-200210150-00024
   Goodkin R, 1998, SURG NEUROL, V49, P358, DOI 10.1016/S0090-3019(97)00372-8
   GRAINGER DA, 1990, OBSTET GYNECOL, V75, P839
   Hajiha Mohammad, 2017, J Endourol Case Rep, V3, P158, DOI 10.1089/cren.2017.0112
   Hekal IA, 2008, J TRAUMA, V64, P1387, DOI 10.1097/TA.0b013e31816bbe4c
   HELLER V, 1986, UROLOGE A, V25, P347
   Hey HWD, 2017, EUR SPINE J, V26, pS36, DOI 10.1007/s00586-016-4678-y
   HIGGINS CC, 1967, J AMER MED ASSOC, V199, P82, DOI 10.1001/jama.199.2.82
   HOLSCHER EC, 1968, J BONE JOINT SURG AM, VA 50, P383, DOI 10.2106/00004623-196850020-00017
   Hung MJ, 2000, ULTRASOUND OBST GYN, V16, P279, DOI 10.1046/j.1469-0705.2000.00219.x
   Kaffenberger Samuel, 2010, Can Urol Assoc J, V4, pE82
   KERN HB, 1969, J UROLOGY, V102, P675, DOI 10.1016/S0022-5347(17)62229-8
   KRONE A, 1985, ACTA NEUROCHIR, V78, P108, DOI 10.1007/BF01808688
   Kubota Go, 2017, BMC Res Notes, V10, P193, DOI 10.1186/s13104-017-2509-9
   Lai CJ, 2019, RES REP UROL, V11, P15, DOI 10.2147/RRU.S189259
   Lee HJ, 2017, WORLD NEUROSURG, V102, DOI 10.1016/j.wneu.2017.04.038
   MCKAY HW, 1954, JAMA-J AM MED ASSOC, V154, P202, DOI 10.1001/jama.1954.02940370014005
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   MOORE CA, 1968, AM J SURG, V115, P574, DOI 10.1016/0002-9610(68)90208-0
   NOYES DT, 1982, UROLOGY, V19, P651, DOI 10.1016/0090-4295(82)90022-X
   Omidi-Kashani F, 2015, SICOT-J, V1, DOI 10.1051/sicotj/2015031
   Onol Y, 1995, TURK J UROL, V21, P14
   Palmer LS, 1999, UROLOGY, V54, P34, DOI 10.1016/S0090-4295(99)00025-4
   PARKER JM, 1971, J UROLOGY, V105, P85, DOI 10.1016/S0022-5347(17)61465-4
   Parpala-Sparman T, 2008, SCAND J UROL NEPHROL, V42, P422, DOI 10.1080/00365590802025857
   Perez-Brayfield MR, 2001, J UROLOGY, V166, P119, DOI 10.1016/S0022-5347(05)66089-2
   Pillai SB, 2013, BMJ CASE REP, V2013
   Rios Gonzalez E, 2002, Actas Urol Esp, V26, P504
   SANDOZ I, 1965, J UROLOGY, V93, P687, DOI 10.1016/S0022-5347(17)63858-8
   Sarikaya S, 1996, ONDOKUZ MAYIS U TIP, V13, P163
   SORGMAN JA, 1992, INT J PANCREATOL, V11, P195
   STEG A, 1974, REV CHIR ORTHOP, V60, P169
   Tainio H, 1999, BJU INT, V84, P369
   Teber D, 2005, UROLOGE, V44, P870, DOI 10.1007/s00120-005-0857-x
   Titton RL, 2003, RADIOGRAPHICS, V23, P1133, DOI 10.1148/rg.235035029
   Trinchieri A, 2001, J UROLOGY, V165, P1210, DOI 10.1016/S0022-5347(05)66480-4
   Tsai PJ, 2013, FORMOS J SURG, V46, P217, DOI 10.1016/j.fjs.2013.10.001
   Turunc T, 2010, CAN J UROL, V17, P5478
   ZINMAN L M, 1978, Urology, V12, P290, DOI 10.1016/0090-4295(78)90394-1
NR 67
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.107
PG 17
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600150
PM 31887462
DA 2020-05-12
ER

PT J
AU Uysal, E
   Reese, J
   Cohen, M
   Curtis, D
   Shelton, C
   Couldwell, WT
AF Uysal, Ece
   Reese, Jared
   Cohen, Michael
   Curtis, David
   Shelton, Clough
   Couldwell, William T.
TI Internal Auditory Canal Lipoma: An Unusual Intracranial Lesion
SO WORLD NEUROSURGERY
LA English
DT Article
DE Cerebellopontine angle; Internal auditory canal; Lipoma
ID CEREBELLOPONTINE ANGLE; TUMORS
AB BACKGROUND: Internal auditory canal (IAC) lipomas are rare intracranial lesions. Consequently, preoperative imaging is essential in differentiating IAC lipomas from more common tumors such as vestibular schwannomas. The hallmark of lipomas on magnetic resonance imaging (MRI) is hyperintensity on T1-weighted images that suppresses on fat-suppressed sequences and does not enhance with gadolinium administration.
   CASE DESCRIPTION: The present case describes a 53-year-old woman who was misdiagnosed with a vestibular schwannoma because of the lack of appropriate MRI sequences.
   CONCLUSIONS: This case demonstrates the importance of ensuring that both fat-suppressed and non-fat-suppressed It-weighted pregadolinium images are obtained in the diagnostic process of IAC lesions. It is therefore recommended that imaging centers ensure that such sequences are included in their MRI protocols.
C1 [Uysal, Ece; Reese, Jared; Cohen, Michael; Couldwell, William T.] Univ Utah, Dept Neurosurg, Salt Lake City, UT 84109 USA.
   [Shelton, Clough] Univ Utah, Dept Otolaryngol, Salt Lake City, UT USA.
   [Curtis, David] Univ Utah, Dept Pathol, Salt Lake City, UT USA.
   [Cohen, Michael] Northern Light Neurosurg & Spine, Bangor, ME USA.
   [Uysal, Ece] Okmeydani Training & Res Hosp, Dept Neurosurg, Istanbul, Turkey.
RP Couldwell, WT (reprint author), Univ Utah, Dept Neurosurg, Salt Lake City, UT 84109 USA.
EM neuropub@hsc.utah.edu
OI Reese, Jared/0000-0001-7942-0435
CR Ajal M, 1998, J LARYNGOL OTOL, V112, P650, DOI 10.1017/S0022215100141350
   Bacciu A, 2014, ANN OTO RHINOL LARYN, V123, P58, DOI 10.1177/0003489414521384
   Bertot B, 2017, CUREUS, V9, DOI 10.7759/cureus.1894
   Brodsky JR, 2006, AM J OTOLARYNG, V27, P271, DOI 10.1016/j.amjoto.2005.11.002
   BUDKA H, 1974, ACTA NEUROPATHOL, V28, P205, DOI 10.1007/BF00719025
   Choi JS, 2012, AURIS NASUS LARYNX, V39, P431, DOI 10.1016/j.anl.2011.10.014
   Friedmann DR, 2015, OTOLARYNG CLIN N AM, V48, P461, DOI 10.1016/j.otc.2015.02.006
   Greinwald JH, 1997, LARYNGOSCOPE, V107, P364, DOI 10.1097/00005537-199703000-00016
   Lakshmi M, 2009, NEUROIMAG CLIN N AM, V19, P393, DOI 10.1016/j.nic.2009.06.004
   SAUNDERS JE, 1991, LARYNGOSCOPE, V101, P1031
   Schuhmann MU, 1997, SKULL BASE SURG, V7, P199, DOI 10.1055/s-2008-1058596
   Tankere F, 2002, NEUROSURGERY, V50, P626, DOI 10.1097/00006123-200203000-00037
   White JR, 2013, LARYNGOSCOPE, V123, P1531, DOI 10.1002/lary.23882
   Wu SS, 2003, ARCH PATHOL LAB MED, V127, P1475
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.037
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600123
PM 31843721
DA 2020-05-12
ER

PT J
AU Vankipuram, S
   Sasane, SV
   Chandra, A
   Ojha, BK
   Singh, SK
   Srivastava, C
   Jaiswal, S
   Bajaj, A
   Jaiswal, M
AF Vankipuram, Siddharth
   Sasane, Sumeet, V
   Chandra, Anil
   Ojha, Bal K.
   Singh, Sunil K.
   Srivastava, Chhitij
   Jaiswal, Somil
   Bajaj, Ankur
   Jaiswal, Manish
TI A Comparative Analysis Between Four-Quadrant Osteoplastic Decompressive
   Craniotomy versus Conventional Decompressive Craniectomy for Traumatic
   Brain Injury
SO WORLD NEUROSURGERY
LA English
DT Article
DE Complications of decompressive craniectomy; Decompressive craniectomy;
   Four-quadrant osteoplastic decompressive craniotomy; ICP monitoring;
   Subdural hematoma; Traumatic brain injury
ID CRANIOPLASTY
AB OBJECTIVE: Primary decompressive craniectomy (DC) is indicated to evacuate the hematoma and reduce intracranial pressure in traumatic brain injury (TBI). However, there are a myriad of complications because of absence of the bone flap. A novel technique, four-quadrant osteoplastic decompressive craniotomy (FoQOsD) retains the bone flap while achieving adequate cerebral decompression.
   METHODS: A single-center randomized controlled trial of 115 patients with TBI needing decompressive surgery was conducted. Of these patients, 59 underwent DC and 56 underwent FoQOsD. The primary outcome determined was functional status at 6 months using the Glasgow Outcome Scale-Extended.
   RESULTS: No significant differences were identified in baseline characteristics between both groups. Mean Glasgow Outcome Scale-Extended score was comparable at 6 months (4.28 in DC vs. 4.38 in FoQOsD; P = 0.856). Further, 22 of 58 patients in the DC group had died (38%) compared with 25 of 55 patients in the FaQOsD group (44.6%) (odds ratio [OR], 1.19; 95% confidence interval [CI], 0.6-2.36; P = 0.6) (1 patient lost to follow-up in each group). A favorable outcome was seen in 56.8% of patients in the DC group versus 54.4% of patients in the FoQOsD group (P = 0.74). Presence of intraventricular hemorrhage and subarachnoid hemorrhage (OR, 7.17; 95% CI, 1.364-37.7; P = 0.020), opposite side contusions (OR, 3.838; 95% CI, 1.614-9.131; P = 0.002) and anisocoria (OR, 3.235; 95% CI, 1.490-7.026; P = 0.003) preoperatively were individual factors that played a significant role in final outcome.
   CONCLUSIONS: FoQOsD is as efficacious as conventional DC with the added benefit of avoiding a second surgery. The procedure is associated with better cosmesis and fewer complications.
C1 [Vankipuram, Siddharth; Sasane, Sumeet, V; Chandra, Anil; Ojha, Bal K.; Singh, Sunil K.; Srivastava, Chhitij; Jaiswal, Somil; Bajaj, Ankur; Jaiswal, Manish] King Georges Med Univ, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
RP Vankipuram, S (reprint author), King Georges Med Univ, Dept Neurosurg, Lucknow, Uttar Pradesh, India.
EM vanki.siddharth@gmail.com
OI Jaiswal, Manish/0000-0002-1300-3716; Jaiswal, Somil/0000-0001-7879-7521
CR Ann DH, 2009, J KOREAN NEUROSURG S, V46, P417, DOI 10.3340/jkns.2009.46.4.417
   Bullock MR, 2011, YOUMANS NEUROLOGICAL, P3267
   Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432
   Erdogan E, 2003, NEUROL INDIA, V51, P479
   Flint AC, 2008, J NEUROTRAUM, V25, P503, DOI 10.1089/neu.2007.0442
   Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215
   Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337
   Kenning TJ, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0960
   Kocher T., 1901, THERAPIE HIRNDRUCKES
   Kolias AG, 2016, BRIT J NEUROSURG, V30, P246, DOI 10.3109/02688697.2016.1159655
   Kolias AG, 2013, NAT REV NEUROL, V9, P405, DOI 10.1038/nrneurol.2013.106
   Kuo JR, 2004, J CLIN NEUROSCI, V11, P486, DOI 10.1016/j.jocn.2003.06.005
   Lu J, 2005, ACT NEUR S, V95, P281
   Park J, 2009, J NEUROSURG, V110, P101, DOI 10.3171/2008.4.17540
   Peethambaran AK, 2015, NEUROL INDIA, V63, P895, DOI 10.4103/0028-3886.170081
   RICHAUD J, 1985, NEUROCHIRURGIE, V31, P183
   Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8
   Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965
   Vankipuram S, 2017, INDIAN J NEUROTRAUM, V14, DOI 10.1055/s-0038-1649329
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.004
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600045
PM 31821915
DA 2020-05-12
ER

PT J
AU Vimala, S
   Arulvelan, A
   Vilanilam, GC
AF Vimala, Smita
   Arulvelan, Appavoo
   Vilanilam, George Chandy
TI Comparison of the Effects of Propofol and Sevoflurane Induced Burst
   Suppression on Cerebral Blood Flow and Oxygenation: A Prospective,
   Randomised, Double-Blinded Study
SO WORLD NEUROSURGERY
LA English
DT Article
DE Burst suppression; Cerebral blood flow velocity; Cerebral oxygenation;
   Propofol; Sevoflurane
ID PERFUSION-PRESSURE; SATURATION; ANESTHESIA; ISOFLURANE;
   HYPERVENTILATION; SURGERY; IMPACT; INDEX; OXIDE
AB OBJECTIVE: Pharmacologically induced electroenceph alogram (EEG) silence increases tolerance of ischemic period by reducing cerebral metabolism. We hypothesized that sevoflurane, a cerebral vasodilator, will maintain cerebral blood flow (CBF) and cerebral metabolic rate of oxygen (CMRO2) better than propofol, a cerebral vasoconstrictor, during EEG silence. To validate this, we compared the effect of sevoflurane and propofol on CBF and CMRO2 during surgical plane of anasthesia (SP) and burst suppression on EEG (BS).
   METHODS: We conducted a prospective, double-blinded trial where patients undergoing neurosurgery were randomized to receive propofol or sevoflurane. Mean velocity (MV) and pulsatility index (PI) of bilateral middle cerebral arteries (MCA) were measured as surrogate of CBF. Jugular venous oxygen saturation (SjvO(2)) and arteriovenous oxygen difference (AjvDO(2)) were obtained to assess CMRO2 . The values were compared between groups using Student t test and within the group with analysis of variance at SP and BS.
   RESULTS: BS decreased MV and increased PI in propofol group (P < 0.001 and P < 0.02 on normal side, P < 0.004 and P < 0.001 on tumor side). There was no significant change in sevoflurane group. BS with sevoflurane increased SjvO(2) (P < 0.001) and decreased AjvDO(2) (P < 0.001). Change in SjvO(2) and AjvDO(2) with propofol at SP and BS was variable.
   CONCLUSIONS: In our study, sevoflurane had a safer profile on cerebral oxygenation during BS while not altering the CBF, suggesting increased availability of oxygen. Propofol, on the other hand, produced cerebral vasoconstriction with BS. The effect of propofol on oxygenation was unpredictable, with low SjvO(2) and high AjvDO(2) even at surgical plane of anesthesia.
C1 [Vimala, Smita; Arulvelan, Appavoo] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Anesthesiol, Div Neuroanesthesiol, Thiruvananthapuram, Kerala, India.
   [Arulvelan, Appavoo] Sree Chitra Tirunal Inst Med Sci & Technol, Dept Neurosurg, Thiruvananthapuram, Kerala, India.
   [Vilanilam, George Chandy] Apollo Hosp, Neuroanesthesiol, Chennai, Tamil Nadu, India.
RP Vimala, S (reprint author), Sree Chitra Tirunal Inst Med Sci & Technol, Dept Anesthesiol, Div Neuroanesthesiol, Thiruvananthapuram, Kerala, India.
EM smita_vimala@yahoo.com
FU Internal Funding of Institute Projects by Sree Chitra Tirunal Institute
   for Medical Sciences and Technology, India [6089]
FX This project was financially supported by a grant from Internal Funding
   of Institute Projects (Project no. 6089) by Sree Chitra Tirunal
   Institute for Medical Sciences and Technology, India. The funding source
   has no involvement in study design, in the collection, analysis and
   interpretation of data, in the writing of the report, or in the decision
   to submit the article for publication.
CR Alexander BS, 2013, ACTA ANAESTH SCAND, V57, P604, DOI 10.1111/aas.12054
   Belfort MA, 1999, AM J OBSTET GYNECOL, V181, P402, DOI 10.1016/S0002-9378(99)70569-7
   Czosnyka M, 1996, J NEUROSURG, V84, P79, DOI 10.3171/jns.1996.84.1.0079
   Dinsmore J, 2007, BRIT J ANAESTH, V99, P68, DOI 10.1093/bja/aem132
   Gentz BA, 2001, DRUGS, V61, P2155, DOI 10.2165/00003495-200161150-00001
   Heath KJ, 1997, ANESTH ANALG, V85, P1284, DOI 10.1097/00000539-199712000-00019
   Hemphill S, 2019, BRIT J ANAESTH, V122, P448, DOI 10.1016/j.bja.2018.12.025
   Hindman BJ, 2010, ANESTHESIOLOGY, V112, P86, DOI 10.1097/ALN.0b013e3181c5e28f
   Iwata M, 2006, ANESTHESIOLOGY, V104, P33, DOI 10.1097/00000542-200601000-00007
   Jansen GFA, 1999, ANESTH ANALG, V89, P358, DOI 10.1097/00000539-199908000-00021
   Jeong H, 2012, ANESTHESIOLOGY, V116, P1047, DOI 10.1097/ALN.0b013e31825154d2
   Mahajan C, 2014, NEUROL INDIA, V62, P262, DOI 10.4103/0028-3886.136908
   Marval PD, 2005, ANESTH ANALG, V100, P835, DOI 10.1213/01.ANE.0000146522.84181.D3
   Matta BF, 1999, ANESTHESIOLOGY, V91, P677, DOI 10.1097/00000542-199909000-00019
   MATTA BF, 1995, ANESTHESIOLOGY, V83, P980, DOI 10.1097/00000542-199511000-00011
   Meng L, 2015, CHINESE MED J-PEKING, V128, P1321, DOI 10.4103/0366-6999.156775
   NEWMAN MF, 1995, ANESTH ANALG, V81, P452, DOI 10.1097/00000539-199509000-00004
   Nunn G, 2008, BJA EDUC, V8, P1, DOI 10.1093/bjaceaccp/mkm052
   Petersen KD, 2003, ANESTHESIOLOGY, V98, P329, DOI 10.1097/00000542-200302000-00010
   Roach GW, 1999, ANESTHESIOLOGY, V90, P1255, DOI 10.1097/00000542-199905000-00006
   Rossetti AO, 2011, NEUROCRIT CARE, V14, P4, DOI 10.1007/s12028-010-9445-z
   Schell RM, 2000, ANESTH ANALG, V90, P559, DOI 10.1097/00000539-200003000-00012
   Sessler DI, 2012, ANESTHESIOLOGY, V116, P1195, DOI 10.1097/ALN.0b013e31825683dc
   Strebel SP, 1998, ANESTHESIOLOGY, V89, P67, DOI 10.1097/00000542-199807000-00012
   Vandesteene A, 1988, Anaesthesia, V43 Suppl, P42, DOI 10.1111/j.1365-2044.1988.tb09067.x
   Warner DS, 2004, ANESTH ANALG, V98, P563, DOI 10.1213/01.ANE.0000111213.71914.54
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.015
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600050
PM 31837497
DA 2020-05-12
ER

PT J
AU Vlasak, AL
   Shin, DH
   Kubilis, PS
   Roper, SN
   Karachi, A
   Hoh, BL
   Rahman, M
AF Vlasak, Alexander L.
   Shin, David H.
   Kubilis, Paul S.
   Roper, Steven N.
   Karachi, Aida
   Hoh, Brian L.
   Rahman, Maryam
TI Comparing Standard Performance and Outcome Measures in Hospitalized
   Pituitary Tumor Patients with Secretory versus Nonsecretory Tumors
SO WORLD NEUROSURGERY
LA English
DT Article
DE Agency for Healthcare Research Quality (AHRQ); Brain tumor;
   Hospital-acquired condition (HAC); National (Nationwide) Inpatient
   Sample; Patient safety indicator (PSI); Pituitary adenoma; Quality
   measures
ID SAFETY INDICATORS; INSURANCE STATUS; ACQUIRED CONDITIONS; PROVIDER
   VOLUME; UNITED-STATES; MORTALITY; BRAIN; RESECTION; COST; PATHOGENESIS
AB BACKGROUND: Patient safety indicators (PSIs) and hospital-acquired conditions (HACs) are reported quality measures. We compared their prevalence in patients with secretory and nonsecretory pituitary adenoma using the National (Nationwide) Inpatient Sample (NIS), Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality.
   METHODS: The NIS was queried for hospitalizations 2002-2014 involving pituitary adenomas. Prevalence of PSI, HAC, and 9 pituitary-related complications was determined using International Classification of Diseases, Ninth Revision codes. Patient risk factors were evaluated through multivariate analysis.
   RESULTS: A total of 20,743 patients with nonsecretory tumor and 3385 patients with secretory tumor were identified. Among patients with nonsecretory tumor, 3.79% experienced any PSI or HAC. Of patients with secretory tumor, 2.54% had any PSI or HAC. Before adjusting for covariation, secretory patients were less likely to have any PSI or HAC (odds ratio [OR], 0.652; P = 0.0002), experience any pituitary-related complication (OR, 0.804; P < 0.0001), have a poor outcome (hazard ratio [HR], 0.435; P < 0.0001), and die during hospitalization (HR, 0.293; P = 0.0015). Secretory patients had significantly shorter mean hospital length of stay (secretory/nonsecretory percent difference, -11.95%; P< 0.0001). However, inverse propensity score-weighted ORs comparing the groups' outcomes showed that there was no significant difference in the prevalence of any PSIs and HACs (OR, 0.963; P = 0.8570), pituitary-related complications (OR, 0.894; P = 0.1321), poor outcomes (HR, 0.990; P = 0.9287), in-hospital death (HR, 0.663; P = 0.2967), and length of stay (percent difference, -2.31%; P = 0.2967) between groups.
   CONCLUSIONS: Lack of significant difference in outcome measures after controlling for covariation is consistent with our finding that patients with nonsecretory tumor have more comorbidities on presentation for treatment. PSIs and HACs have limited ability to measure complications specific to pituitary tumors.
C1 [Vlasak, Alexander L.; Shin, David H.; Kubilis, Paul S.; Roper, Steven N.; Karachi, Aida; Hoh, Brian L.; Rahman, Maryam] Univ Florida, Lillian S Wells Dept Neurosurg, Gainesville, FL 32611 USA.
RP Shin, DH (reprint author), Univ Florida, Lillian S Wells Dept Neurosurg, Gainesville, FL 32611 USA.
EM david.shin@neurosurgery.ufl.edu
CR Ament JD, 2018, WORLD NEUROSURG, V110, pE496, DOI 10.1016/j.wneu.2017.11.046
   ARON DC, 1995, WESTERN J MED, V162, P340
   Asa SL, 2002, NAT REV CANCER, V2, P836, DOI 10.1038/nrc926
   Asa SL, 2009, ANNU REV PATHOL-MECH, V4, P97, DOI 10.1146/annurev.pathol.4.110807.092259
   Austin PC, 2011, MULTIVAR BEHAV RES, V46, P119, DOI 10.1080/00273171.2011.540480
   Bahl V, 2008, MED CARE, V46, P516, DOI 10.1097/MLR.0b013e31815f537f
   Blumenthal D, 2013, J HOSP MED, V8, P271, DOI 10.1002/jhm.2045
   Centers for Medicare & Medicaid Services (CMS) HHS, 2011, Fed Regist, V76, P26490
   Chernov MF, 2004, NEUROSURGERY, V54, P1027, DOI 10.1227/01.NEU.0000117120.32806.22
   Corliss BM, 2015, NEUROSURGERY, V77, P44, DOI 10.1227/NEU.0000000000000734
   Cowan JA, 2003, NEUROSURGERY, V52, P48, DOI 10.1097/00006123-200301000-00005
   Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004
   Fargen KM, 2015, J NEUROSURG, V122, P870, DOI 10.3171/2014.12.JNS14646
   Fargen KM, 2013, J NEUROSURG, V119, P966, DOI 10.3171/2013.5.JNS122378
   Fry DE, 2007, ANN SURG, V246, P875, DOI 10.1097/SLA.0b013e3180cc2e7a
   Giacovelli JK, 2008, J VASC SURG, V48, P905, DOI 10.1016/j.jvs.2008.05.010
   Harrell Jr FE, 2015, SPRINGER SER STAT, DOI DOI 10.1007/978-3-319-19425-7
   Hooten KG, 2015, NEUROSURGERY, V76, P239, DOI 10.1227/NEU.0000000000000594
   Houchens RL, 2008, JT COMM J QUAL PATIE, V34, P154, DOI 10.1016/S1553-7250(08)34018-5
   Ironside JW, 2003, J CLIN PATHOL, V56, P561, DOI 10.1136/jcp.56.8.561
   Kalbfleisch J. D., 2002, STAT ANAL FAILURE TI
   Kelz RR, 2004, CANCER-AM CANCER SOC, V101, P2187, DOI 10.1002/cncr.20624
   Ketelaar NABM, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004538.pub2
   Kohn LT, 2000, ERR IS HUMAN BUILDIN
   Medicare Learning Network, US DEP HLTH HUM SERV
   Miller M R, 2001, Health Serv Res, V36, P110
   Ostrom QT, 2017, NEURO-ONCOLOGY, V19, pV1, DOI 10.1093/neuonc/nox158
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
   Pine M, 2009, MED DECIS MAKING, V29, P69, DOI 10.1177/0272989X08323297
   Podolsky DK, 2014, PLAST RECONSTR SURG, V134, p981E, DOI 10.1097/PRS.0000000000000713
   Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712
   Rahman M, 2013, WORLD NEUROSURG, V80, P699, DOI 10.1016/j.wneu.2013.08.024
   Rahman M, 2013, NEURO-ONCOLOGY, V15, P1580, DOI 10.1093/neuonc/not108
   Rosen AK, 2012, MED CARE, V50, P74, DOI 10.1097/MLR.0b013e3182293edf
   Smith ER, 2004, NEUROSURGERY, V54, P553, DOI 10.1227/01.NEU.0000108421.69822.67
   Squitieri L, 2017, PLAST RECONSTR SURG, V140, P205, DOI 10.1097/PRS.0000000000003431
   Stone ML, 2013, J PEDIATR SURG, V48, P81, DOI 10.1016/j.jpedsurg.2012.10.021
   van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5
   West N, 2015, MED MED RES REV, V4, pii
   Winters BD, 2016, MED CARE, V55, P1105, DOI 10.1097/MLR.0000000000000550
   Zacharia BE, 2014, NEUROSURGERY, V74, P638, DOI 10.1227/NEU.0000000000000342
NR 41
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.059
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600061
PM 31863896
DA 2020-05-12
ER

PT J
AU Wang, F
   He, YJ
   Li, CD
   Wang, YG
   Zhong, LY
AF Wang, Fang
   He, Yanjiao
   Li, Chunde
   Wang, Yonggang
   Zhong, Liyong
TI Malignant Craniopharyngioma: A Report of Seven Cases and Review of the
   Literature
SO WORLD NEUROSURGERY
LA English
DT Review
DE Craniopharyngioma; Hypopituitarism; Malignant transformation; Radiation
   therapy
ID TRANSFORMATION
AB BACKGROUND: Malignant craniopharyngioma is a rare clinical entity; most patients with this disease show transformation from an initially benign craniopharyngioma. The rare prevalence of the disease, nonspecific presenting symptoms, and imaging features that overlap with benign craniopharyngiomas make preoperative identification challenging.
   METHODS: In this study, we retrospectively evaluated the data of 7 patients diagnosed with malignant craniopharyngioma within a 5-year period in a single center. A thorough review of patient records from Beijing Tiantan Hospital, Capital Medical University, between 2013 and 2018 was performed. After identifying these 7 patients with malignant craniopharyngioma, we evaluated their demographic and clinical characteristics, including symptoms at presentation, imaging characteristics, treatment, and outcomes.
   RESULTS: Five patients showed transformation from benign craniopharyngiomas, and 2 had de novo malignancy. Two patients were children at diagnosis of malignancy. Patients' average age was 22 years. Headache was the most common presenting symptom, followed by visual field defects and adenohypophyseal dysfunction. Imaging characteristics showed that all patients had giant mass in the sellar, suprasellar, and/or parasellar regions that had invaded surrounding anatomic structures. Of the 5 patients who showed transformation from benign craniopharyngioma, 3 had undergone radiologic treatment before the diagnosis of malignant transformation.
   CONCLUSIONS: Malignant craniopharyngioma should not be overlooked in patients with a giant sellar mass, especially in young patients who have experienced multiple recurrences of craniopharyngioma and patients who received radiologic therapy.
C1 [Wang, Fang; Zhong, Liyong] Capital Med Univ, Beijing Tiantan Hosp, Dept Endocrinol, Beijing, Peoples R China.
   [He, Yanjiao] Capital Med Univ, Beijing Tiantan Hosp, Beijing Neurosurg Inst, Dept Neuropathol, Beijing, Peoples R China.
   [Li, Chunde; Wang, Yonggang] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing, Peoples R China.
RP Zhong, LY (reprint author), Capital Med Univ, Beijing Tiantan Hosp, Dept Endocrinol, Beijing, Peoples R China.
EM zhongliyong@126.com
FU Beijing Municipal Science & Technology CommissionBeijing Municipal
   Science & Technology Commission [Z181100001718122]
FX This work was supported by a grant from Beijing Municipal Science &
   Technology Commission (grant number Z181100001718122) awarded to Liyong
   Zhong.
CR Beer-Furlan A, 2016, NEUROSURGERY, V79, pE313, DOI 10.1227/NEU.0000000000001292
   Brastianos PK, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv310
   Brastianos PK, 2014, NAT GENET, V46, P161, DOI 10.1038/ng.2868
   Castle-Kirszbaum M, 2018, PITUITARY, V21, P463, DOI 10.1007/s11102-018-0899-x
   Dong L, 2005, CHIN J MOD DRUG APPL, V8, P27
   Heinks K, 2018, ENDOCRINE, V59, P364, DOI 10.1007/s12020-017-1489-9
   Himes BT, 2019, J NEUROSURG, V130, P1299, DOI 10.3171/2017.11.JNS172373
   Jeong TS, 2017, J KOREAN NEUROSURG S, V60, P108, DOI 10.3340/jkns.2015.0707.022
   Liu CH, 2016, WORLD NEUROSURG, V88, DOI 10.1016/j.wneu.2015.11.031
   Liu HL, 2016, INT J CLIN EXP PATHO, V9, P7700
   Lu YT, 2014, CHINESE MED J-PEKING, V127, P3187, DOI 10.3760/cma.j.issn.0366-6999.20140427
   Muller HL, 2014, ENDOCR REV, V35, P513, DOI 10.1210/er.2013-1115
   Narla S, 2017, NEUROL INDIA, V65, P418, DOI 10.4103/neuroindia.NI_528_16
   Negoto Tetsuya, 2015, Surg Neurol Int, V6, P50, DOI 10.4103/2152-7806.154274
   Nomura S, 2018, WORLD NEUROSURG, V117, P332, DOI 10.1016/j.wneu.2018.05.244
   Ordonez-Rubiano EG, 2019, J NEUROSURG, V131, P1163, DOI 10.3171/2018.6.JNS18901
   Rittinger O, 2003, J PEDIATR ENDOCR MET, V16, P97
   SALYER D, 1973, CANCER, V31, P713, DOI 10.1002/1097-0142(197303)31:3<713::AID-CNCR2820310334>3.0.CO;2-S
   Signorelli F, 2015, NEUROSURGERY, V76, pE358, DOI 10.1227/NEU.0000000000000634
   Smith TR, 2016, J NEUROSURG-PEDIATR, V18, P408, DOI 10.3171/2016.4.PEDS16112
   Sofela AA, 2014, NEUROSURGERY, V75, P306, DOI 10.1227/NEU.0000000000000380
   Taguchi T, 2010, J NEURO-ONCOL, V100, P321, DOI 10.1007/s11060-010-0161-5
   Wang W, 2015, NEUROPATHOLOGY, V35, P50, DOI 10.1111/neup.12142
   Yamanaka R, 2018, NEUROSURG REV, V41, P719, DOI 10.1007/s10143-016-0786-8
   Yin F, 2017, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V52, P779, DOI 10.3760/cma.j.issn.1673-0860.2017.10.014
   Zairi F, 2014, BRIT J NEUROSURG, V28, P284, DOI 10.3109/02688697.2013.835381
   Zhang Y, 2019, WORLD NEUROSURG, V122, pE472, DOI 10.1016/j.wneu.2018.10.082
NR 27
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.111
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600023
PM 31785438
DA 2020-05-12
ER

PT J
AU Wilkinson, BM
   Oh, JY
   Swarnkar, AS
   Galgano, M
AF Wilkinson, Brandon M.
   Oh, Justin Y.
   Swarnkar, Amar S.
   Galgano, Michael
TI Dramatic Resolution of Symptomatic Thoracolumbar Traumatic Spinal
   Subdural Hygroma with Lumbar Puncture: A Literature Review and Case
   Illustration
SO WORLD NEUROSURGERY
LA English
DT Review
DE Cauda equina; Lumbar puncture; Subdural hygroma; Thoracolumbar;
   Traumatic
ID FORAMEN MAGNUM DECOMPRESSION; POSTERIOR-FOSSA; MALFORMATION;
   COMPLICATION
AB BACKGROUND: Subdural hygromas are excess fluid accumulations in the subdural compartment, likely occurring via tears in the arachnoid membrane causing cerebrospinal fluid (CSF) leakage into the subdural space. Treatment recommendations for spinal subdural hygromas are lacking.
   CASE DESCRIPTION: We report a case of a 30-year-old man who developed delayed-onset cauda equina syndrome after a motor vehicle accident. Magnetic resonance imaging of the thoracic and lumbar spine revealed a CSF intensity collection involving most of the thoracic spine and extending toward the distal end of the thoracic with ventral displacement of the spinal cord and nerve roots. The patient was successfully treated using interventional radiology-auided lumbar puncture.
   CONCLUSIONS: Posttraumatic spinal subdural hygromas are rare complications, as evidenced by the lack of literature and treatment guidelines. Using lumbar puncture, we demonstrate clinical and radiographic resolution of a traumatic subdural hygroma. This outcome suggests lumbar puncture may be an effective treatment modality for similar patients, and can potentially be used to avoid a more invasive surgical decompression.
C1 [Wilkinson, Brandon M.; Oh, Justin Y.; Galgano, Michael] SUNY Upstate Med Univ, Dept Neurosurg, Syracuse, NY 13210 USA.
   [Swarnkar, Amar S.] SUNY Upstate Med Univ, Dept Neuro Intervent Radiol, Syracuse, NY 13210 USA.
RP Wilkinson, BM (reprint author), SUNY Upstate Med Univ, Dept Neurosurg, Syracuse, NY 13210 USA.
EM wilkinsb@upstate.edu
CR Bahuleyan B, 2011, J NEUROSURG, V114, P510, DOI 10.3171/2010.8.JNS10413
   Darwish HA, 2016, J NEUROSURG-SPINE, V25, P328, DOI 10.3171/2016.2.SPINE151480
   Elder BD, 2017, CUREUS, V9, DOI 10.7759/cureus.1171
   Filis AK, 2009, PEDIATR NEUROSURG, V45, P425, DOI 10.1159/000270159
   Pereira EAC, 2014, BRIT J NEUROSURG, V28, P396, DOI 10.3109/02688697.2013.829558
   Ranjan A, 1996, BRIT J NEUROSURG, V10, P301, DOI 10.1080/02688699650040188
   Singleton WGB, 2012, BRIT J NEUROSURG, V26, P429, DOI 10.3109/02688697.2011.625063
   STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005
   Suzuki F, 2011, NEUROL MED-CHIR, V51, P389, DOI 10.2176/nmc.51.389
   Yi Chong K, 2014, BMJ Case Rep, V2014, DOI 10.1136/bcr-2014-206223
   Zakaria R, 2012, BRIT J NEUROSURG, V26, P476, DOI 10.3109/02688697.2011.650738
NR 11
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.103
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600097
PM 31778836
DA 2020-05-12
ER

PT J
AU Woodhouse, C
   Slobodian, O
   Nebor, I
   Xu, A
   Zhebrykov, D
   Montemagno, K
   Kashyrina, O
   Matern, T
   Hoang, S
   Mendez-Rosito, D
   Cheng, J
   Forbes, J
AF Woodhouse, Cody
   Slobodian, Olesia
   Nebor, Ivanna
   Xu, Alice
   Zhebrykov, Dmytro
   Montemagno, Kora
   Kashyrina, Oleksandra
   Matern, Tyson
   Hoang, Stanley
   Mendez-Rosito, Diego
   Cheng, Joseph
   Forbes, Jonathan
TI Risk of Infection Associated with Transmucosal Placement of
   Instrumentation in Clean-Contaminated Field: Systematic Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Contaminated; Infection; Odontoidectomy; Transnasal; Transoral;
   Trans-mucosal
ID TRANSORAL DECOMPRESSION; CRANIOCERVICAL JUNCTION; SCREW FIXATION;
   FUSION; ODONTOIDECTOMY; RESECTION; SURGERY; PLATE
AB Instability of the craniovertebral junction (CVJ) following odontoidectomy is relatively common. Traditionally, separate stage posterior atlantoaxial +/- occipitocervical fusion is used for treatment. A transmucosal approach using a clean-contaminated route is associated with hypothetical risks of infectious complications. There is a paucity of information in the literature assessing the risk of surgical site infection (SSI) using the transmucosal approach for hardware placement.
   The authors conducted a literature search through PubMed identifying patients with pathology requiring transmucosal (i.e., transnasal or transoral) CVJ fixation. Studies that described 1) cases requiring a transmucosal approach and 2) associated infectious complications were included. Rates of SSIs, device removal, unplanned reoperation, and hardware failures were analyzed. Descriptive statistics and odds ratios (ORs) were used to compare complications.
   Nine studies with a total of 431 patients were identified. There were 4 (0.93%) superficial SSIs and 4 (0.93%) deep SSIs. In total, 1.86% of patients experienced SSI. There were 18 (4.18%) cases of unplanned reoperation, 4 (0.93%) related to SSI. Five (1.16%) patients required removal of their anterior fixation device, 4 (0.93%) related to SSI. ORs comparing our results with Medvedev et al's retrospective National Surgical Quality Improvement Program study assessing the risk associated with posterior cervical fixation showed no statistical difference between postoperative infection rates (OR = 0.72, P = 0.36).
   An extensive review of the literature found no evidence to suggest placement of spinal hardware via transmucosal corridor is associated with an increased risk of SSI.
C1 [Woodhouse, Cody; Slobodian, Olesia; Nebor, Ivanna; Xu, Alice; Zhebrykov, Dmytro; Montemagno, Kora; Kashyrina, Oleksandra; Matern, Tyson; Hoang, Stanley; Cheng, Joseph; Forbes, Jonathan] Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45267 USA.
   [Mendez-Rosito, Diego] Natl Med Ctr, Dept Neurol Surg, ISSSTE, Mexico City, DF, Mexico.
RP Woodhouse, C (reprint author), Univ Cincinnati, Med Ctr, Dept Neurosurg, Cincinnati, OH 45267 USA.
EM cody.j.woodhouse@gmail.com
CR Archavlis E, 2017, J NEUROSURG-SPINE, V26, P190, DOI 10.3171/2016.7.SPINE16244
   Chang PY, 2016, J NEUROSURG-SPINE, V24, P300, DOI 10.3171/2015.5.SPINE141249
   Choi D, 2013, NEUROSURGERY, V73, P296, DOI 10.1227/01.neu.0000430324.24623.10
   DICKMAN CA, 1992, J NEUROSURG, V77, P525, DOI 10.3171/jns.1992.77.4.0525
   DILORENZO N, 1992, ACTA NEUROCHIR, V118, P112, DOI 10.1007/BF01401296
   Dlouhy BJ, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14837
   Fairholm D, 1996, NEUROSURGERY, V38, P38, DOI 10.1097/00006123-199601000-00010
   Fenoy AJ, 2008, J NEUROSURG-SPINE, V8, P22, DOI 10.3171/SPI-08/01/022
   GOEL A, 1994, BRIT J NEUROSURG, V8, P743, DOI 10.3109/02688699409101191
   Iacoangeli M, 2017, WORLD NEUROSURG, V107, P820, DOI 10.1016/j.wneu.2017.08.063
   Kassam AB, 2005, NEUROSURGERY, V57, P213, DOI 10.1227/01.NEU.0000163687.64774.E4
   Kerschbaumer F, 2000, SPINE, V25, P2708, DOI 10.1097/00007632-200010150-00029
   Klekamp J, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14783
   Macki M, 2018, J NEUROSURG-SPINE, V28, P33, DOI 10.3171/2017.5.SPINE161064
   McGirt MJ, 2008, J NEUROSURG-PEDIATR, V1, P337, DOI 10.3171/PED/2008/1/4/337
   Medvedev G, 2016, SPINE, V41, P1477, DOI 10.1097/BRS.0000000000001564
   MENEZES AH, 1988, J NEUROSURG, V69, P895, DOI 10.3171/jns.1988.69.6.0895
   Meyer B, 2001, ACTA NEUROCHIR, V143, P759, DOI 10.1007/s007010170029
   Patel NP, 2002, J NEUROSURG, V96, P190, DOI 10.3171/spi.2002.96.2.0190
   Rossini Z, 2018, WORLD NEUROSURG, V110, P373, DOI 10.1016/j.wneu.2017.11.153
   Shkarubo AN, 2018, WORLD NEUROSURG, V109, pE155, DOI 10.1016/j.wneu.2017.09.124
   Wang JH, 2019, WORLD NEUROSURG, V127, P92, DOI 10.1016/j.wneu.2019.03.249
   Wang X, 2010, EUR SPINE J, V19, pS91, DOI 10.1007/s00586-009-1088-4
   Xu ZW, 2015, EUR SPINE J, V24, P694, DOI 10.1007/s00586-014-3747-3
   Yadav YR, 2017, NEUROL INDIA, V65, P341, DOI 10.4103/neuroindia.NI_1276_16
   Yin QS, 2016, SPINE, V41, pE1151, DOI 10.1097/BRS.0000000000001593
   Zheng Y, 2016, ORTHOPADE, V45, P174, DOI 10.1007/s00132-015-3219-4
   Zhu CR, 2019, J NEUROSURG-PEDIATR, V24, P323, DOI 10.3171/2019.4.PEDS1928
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.168
PG 5
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600158
PM 31811965
DA 2020-05-12
ER

PT J
AU Wu, J
   Wei, W
   Gao, YH
   Liang, FT
   Gao, YL
   Yu, HG
   Huang, QL
   Long, XQ
   Zhou, YF
AF Wu, Jun
   Wei, Wei
   Gao, Yue-hua
   Liang, Fang-te
   Gao, Yun-long
   Yu, Hai-guang
   Huang, Qing-liang
   Long, Xin-quan
   Zhou, Yu-fan
TI Surgical Decompression versus Conservative Treatment in Patients with
   Malignant Infarction of the Middle Cerebral Artery: Direct Comparison of
   Death-Related Complications
SO WORLD NEUROSURGERY
LA English
DT Article
DE Conservative treatment; Decompressive surgery; Malignant infarction of
   the middle cerebral artery; Meta-analysis
ID INTRACRANIAL-PRESSURE; TERRITORY INFARCTION; CONTROLLED-TRIAL; BRAIN
   EDEMA; HEMICRANIECTOMY; STROKE; CRANIECTOMY; DETERIORATION; MULTICENTER;
   SURGERY
AB BACKGROUND: Surgical decompression and conservative treatment are routinely used in the treatment of patients with malignant infarction of the middle cerebral artery (MIMCA). However, efficacy and safety are controversial. The purpose of this study is to systematically compare the clinical outcomes between surgical decompression and conservative treatment in patients with MIMCA.
   METHODS: This study retrieved available academic randomized controlled trials (RCTs) comparing the clinical outcomes between surgical decompression and conservative treatment in patients with MIMCA from the data-bases of ScienceDirect, Cochrane Library, Embase, and PubMed. The references of previous reviews and related clinical studies were manually checked to retrieve potential literature that was not involved in our electronic search results.
   RESULTS: A total of 7 RCTs were included in the study. The overall number of participants in the surgical decompression group was 165, whereas it was 173 in the conservative treatment group. The results revealed that the surgical decompression group was related to a lower incidence of 1-year death (odds ratio [OR] 0.192; 95% confidence interval [CI], 0.119-0.309; P < 0.001), 1-year death in patients >60 years of age (OR, 0.202; 95% CI, 0.097-0.421; P < 0.001), 1-year death in patients <60 years of age (OR, 0.145; 95% CI, 0.069-0.301; P < 0.001), 1-year death in patients treated within 48 hours of stroke onset (OR, 0.159; 95% CI, 0.090-0.282; P < 0.001), and modified Rankin Scale (mRS) score <= 3 (OR, 2.082; 95% CI, 1.185-3.658; P < 0.001).
   CONCLUSIONS: Based on current evidence for patients with MIMCA, decompressive surgery not only is a lifesaving therapy but also reduces the incidence of mortality without increasing the risk of severe disability.
C1 [Wu, Jun; Gao, Yun-long; Yu, Hai-guang; Huang, Qing-liang; Long, Xin-quan; Zhou, Yu-fan] Nanchang Univ, Dept Neurosurg, Affiliated Hosp 5, First Peoples Hosp Fuzhou, Fuzhou, Jiangxi, Peoples R China.
   [Wei, Wei] Mianyang Cent Hosp, Dept Neurol, Mianyang, Sichuan, Peoples R China.
   [Gao, Yue-hua] Tianjin Med Univ Gen Hosp, Dept Gynecol & Obstet, Tianjin, Peoples R China.
   [Liang, Fang-te] Guangxi Med Univ, Dept Anesthesiol, Nanning, Guangxi, Peoples R China.
RP Zhou, YF (reprint author), Nanchang Univ, Dept Neurosurg, Affiliated Hosp 5, First Peoples Hosp Fuzhou, Fuzhou, Jiangxi, Peoples R China.
EM fuzhoushiyiyuan@163.com
CR Arac A, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0958
   BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16
   Cruz-Flores S, 2012, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858
   Dasenbrock HH, 2017, STROKE, V48, P704, DOI 10.1161/STROKEAHA.116.014727
   Frank JI, 2014, STROKE, V45, P781, DOI 10.1161/STROKEAHA.113.003200
   Gupta R, 2004, STROKE, V35, P539, DOI 10.1161/01.STR.0000109772.64650.18
   Hacke W, 1996, ARCH NEUROL-CHICAGO, V53, P309, DOI 10.1001/archneur.1996.00550040037012
   Heinsius T, 1998, NEUROLOGY, V50, P341, DOI 10.1212/WNL.50.2.341
   Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X
   Holtkamp M, 2001, J NEUROL NEUROSUR PS, V70, P226, DOI 10.1136/jnnp.70.2.226
   Juttler E, 2014, NEW ENGL J MED, V370, P1091, DOI 10.1056/NEJMoa1311367
   Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649
   Kasner SE, 2001, STROKE, V32, P2117, DOI 10.1161/hs0901.095719
   Leonhardt G, 2002, J NEUROL, V249, P1433, DOI 10.1007/s00415-002-0875-1
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Maramattom BV, 2004, NEUROLOGY, V63, P2142, DOI 10.1212/01.WNL.0000145626.30318.8A
   Mori K, 2004, SURG NEUROL, V62, P420, DOI 10.1016/j.surneu.2003.12.017
   Qureshi AI, 2003, CRIT CARE MED, V31, P272, DOI 10.1097/00003246-200301000-00043
   RIEKE K, 1995, CRIT CARE MED, V23, P1576, DOI 10.1097/00003246-199509000-00019
   ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017
   Sardar P, 2017, J AM COLL CARDIOL, V69, P2266, DOI 10.1016/j.jacc.2017.02.053
   Schwab S, 1997, NEUROLOGY, V48, P1608, DOI 10.1212/WNL.48.6.1608
   Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888
   Schwarz S, 1998, STROKE, V29, P1550, DOI 10.1161/01.STR.29.8.1550
   Schwarz S, 2002, STROKE, V33, P497, DOI 10.1161/hs0202.102376
   SILVER FL, 1984, STROKE, V15, P492, DOI 10.1161/01.STR.15.3.492
   Slezins J, 2012, MEDICINA-LITHUANIA, V48, P521
   Vahedi K, 2005, J NEUROL NEUROSUR PS, V76, P1181, DOI 10.1136/jnnp.2004.058537
   Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235
   Wartenberg KE, 2012, CURR OPIN CRIT CARE, V18, P152, DOI 10.1097/MCC.0b013e32835075c5
   Zhao JW, 2012, NEUROCRIT CARE, V17, P161, DOI 10.1007/s12028-012-9703-3
NR 31
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.170
PG 9
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600041
PM 31816452
DA 2020-05-12
ER

PT J
AU Xie, TH
   Wang, CY
   Yang, ZQ
   Xiu, P
   Yang, X
   Wang, XD
   Wang, D
   Song, YM
   Zeng, JC
AF Xie, Tianhang
   Wang, Chaoyang
   Yang, Zhiqiang
   Xiu, Peng
   Yang, Xi
   Wang, Xiandi
   Wang, Duan
   Song, Yueming
   Zeng, Jiancheng
TI Minimally Invasive Oblique Lateral Lumbar Interbody Fusion Combined with
   Anterolateral Screw Fixation for Lumbar Degenerative Disc Disease
SO WORLD NEUROSURGERY
LA English
DT Article
DE Anterolateral screw fixation; Degenerative instability; Degenerative
   spondylolisthesis; Lumbar spinal stenosis; OLIF
ID COMPLICATIONS; OUTCOMES; SINGLE; INJURY; RISK; TLIF
AB OBJECTIVE: The purposes of the present study were to introduce an indirect decompression using oblique lateral lumbar interbody fusion combined with anterolateral screw fixation (OLIF-AF) for the treatment of lumbar degenerative disc disease and examine the clinical efficacy and radiographic outcomes.
   METHODS: A total of 65 patients had undergone single-level OLIF-AF at L2-L5 from December 2017 to August 2018. The cross-sectional area of the thecal sac was evaluated using magnetic resonance imaging. The disk height, foraminal height (FH), and degree of upper vertebral slippage were evaluated using computed tomography. The visual analog scale score and Oswestry disability index were recorded pre- and postoperatively.
   RESULTS: The visual analog scale scores and Oswestry disability index had significantly improved after surgery (P < 0.001). At 3 days postoperatively, the cross-sectional area had improved from 93.2 +/- 14.4 mm(2) to 124.2 +/- 7.5 mm(2) (P< 0.001), the disk height had increased from 9.9 +/- 1.7 mm to 12.7 +/- 1.0 mm (P < 0.001), the left FH had increased from 16.6 +/- 2.0 mm to 19.6 +/- 2.0 mm (P < 0.001). In contrast, the right FH had increased from 16.7 +/- 2.1 mm to 19.9 +/- 2.0 mm (P < 0.001), and the degree of upper vertebral vertebral slippage had decreased from 14.2% +/- 3.1% to 4.6% +/- 2.8% (P < 0.001), respectively. At the 12-month follow-up examination, these parameters showed no statistically significant differences compared with the values at 3 days postoperatively (P> 0.05). Adverse events were observed in 15 patients (23.1%) patients and included pain at the iliac bone donor site in 1 (1.5%), left thigh pain/ numbness in 2 (3.1%), quadriceps weakness in 2 (3.1%), psoas weakness in 3 (4.6%), intraoperative endplate injury in 2 (3.1%) and cage subsidence in 5 (7.7%).
   CONCLUSIONS: Our results have shown that OLIF-AF surgery is a relatively safe and effective surgical option for LDDD at L2-L5. Cage subsidence was the most common operative complication.
C1 [Xie, Tianhang; Wang, Chaoyang; Yang, Zhiqiang; Xiu, Peng; Yang, Xi; Wang, Xiandi; Wang, Duan; Song, Yueming; Zeng, Jiancheng] Sichuan Univ, West China Hosp, West China Sch Med, Dept Orthoped, Chengdu, Peoples R China.
RP Zeng, JC (reprint author), Sichuan Univ, West China Hosp, West China Sch Med, Dept Orthoped, Chengdu, Peoples R China.
EM tomzeng5@126.com
CR Abe K, 2017, SPINE, V42, P55, DOI 10.1097/BRS.0000000000001650
   Barbagallo Giuseppe M V, 2014, Evid Based Spine Care J, V5, P28, DOI 10.1055/s-0034-1368670
   Blizzard DJ, 2018, SPINE, V43, P440, DOI 10.1097/BRS.0000000000002330
   Brau Salvador A, 2004, Spine J, V4, P409, DOI 10.1016/j.spinee.2003.12.003
   Chung NS, 2017, EUR SPINE J, V26, P2797, DOI 10.1007/s00586-017-5176-6
   Cummock MD, 2011, J NEUROSURG-SPINE, V15, P11, DOI 10.3171/2011.2.SPINE10374
   Davis TT, 2014, J NEUROSURG-SPINE, V21, P785, DOI 10.3171/2014.7.SPINE13564
   Fricka KB, 2002, SPINE, V27, P702, DOI 10.1097/00007632-200204010-00006
   Fujibayashi S, 2017, SPINE, V42, P1478, DOI 10.1097/BRS.0000000000002139
   Garg J, 2010, J VASC SURG, V51, P946, DOI 10.1016/j.jvs.2009.11.039
   Hey HWD, 2010, INDIAN J ORTHOP, V44, P159, DOI 10.4103/0019-5413.62066
   Jin CZ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0740-2
   Jin D, 2000, CHINESE J SURG, V38, P900
   Jin J, 2018, CLIN SPINE SURG, V31, P31, DOI 10.1097/BSD.0000000000000474
   Jutte PC, 2002, EUR SPINE J, V11, P594, DOI 10.1007/s00586-002-0469-8
   Kunze B, 2011, Z ORTHOP UNFALLCHIR, V149, P312, DOI 10.1055/s-0030-1250689
   Liu JP, 2020, WORLD NEUROSURG, V134, pE944, DOI 10.1016/j.wneu.2019.11.046
   Lowe TG, 2005, SPINE, V30, P311, DOI 10.1097/01.brs.0000152376.09501.ae
   Lykissas MG, 2014, SPINE J, V14, P749, DOI 10.1016/j.spinee.2013.06.066
   Malham GM, 2015, J NEUROSURG-SPINE, V23, P589, DOI 10.3171/2015.1.SPINE14566
   Mayer HM, 1997, SPINE, V22, P691, DOI 10.1097/00007632-199703150-00023
   Oda I, 2000, SPINE, V25, P2303, DOI 10.1097/00007632-200009150-00007
   Orita S, 2017, SPINE, V42, P135, DOI 10.1097/BRS.0000000000001700
   Ozgur BM, 2009, MINIMALLY INVASIVE S, P13
   Pumberger M, 2012, EUR SPINE J, V21, P1192, DOI 10.1007/s00586-011-2087-9
   Sato J, 2017, EUR SPINE J, V26, P671, DOI 10.1007/s00586-015-4170-0
   Schreiber U, 2005, EUR SPINE J, V14, P197, DOI 10.1007/s00586-004-0770-9
   Shunsuke F, 2015, SPINE, V40, P175
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Uribe JS, 2010, J NEUROSURG-SPINE, V13, P260, DOI 10.3171/2010.3.SPINE09766
   Wong AP, 2014, NEUROSURG CLIN N AM, V25, P279, DOI 10.1016/j.nec.2013.12.007
   Woo BG, 1999, SPINE, V24, P1414
   Woods KRM, 2017, SPINE J, V17, P545, DOI 10.1016/j.spinee.2016.10.026
   Xie TH, 2020, EUR SPINE J, V29, P199, DOI 10.1007/s00586-019-06163-2
   Zeng ZY, 2018, ORTHOP SURG, V10, P98, DOI 10.1111/os.12380
NR 35
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.105
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600080
PM 31884124
DA 2020-05-12
ER

PT J
AU Xie, TH
   Xiu, P
   Yang, ZQ
   Wang, D
   Zeng, JC
   Song, YM
AF Xie, Tianhang
   Xiu, Peng
   Yang, Zhiqiang
   Wang, Duan
   Zeng, Jiancheng
   Song, Yueming
TI OLIF Combined with Anterior Fixation for Lumbar Synovial Cysts with
   Instability
SO WORLD NEUROSURGERY
LA English
DT Article
DE Indirect decompression; Lumbar synovial cysts; OLIF
ID INTERBODY-FUSION; SPINAL STENOSIS; COMPLICATION
AB BACKGROUND: The optimal management of lumbar synovial cysts (LSCs) has always been controversial. Open or minimally invasive partial hemilaminotomy as a direct decompression approach has been widely studied, whereas to our knowledge, there has been no report of an indirect decompression method for LSC.
   CASE DESCRIPTION: A 60-year-old male complained of chronic low back for 2 years. He reported that the pain had been getting worse and started radiating to the bilateral posterior thighs and right lateral calf for 6 months. An ovoid lesion with a hyperintense center attached to the medial side of the right facet joint at the L4-5 level, as well as L4-5 dynamic instability, were found with magnetic resonance imaging and lumbar x-ray examinations, respectively. L4-5 oblique lumbar interbody fusion combined with anterior fixation was performed. After surgery, the patient felt distinct pain relief and was discharged on the third day postoperatively. Three months later, lumbar magnetic resonance imaging and 3-dimensional computed tomography were performed again. The L4-5 disk height and foraminal height recovered from 7.1-12.3 mm and 14.8-18.5 mm, respectively. No evidence of a cyst was disclosed. The patient did not complain of any low back pain or radicular pain during the 12-month follow-up.
   CONCLUSIONS: Indirect decompression surgery may be a new option for the management of LSC, especially in those with lumbar instability and that communicate with the facet joint. Further research with a larger and more comprehensive sample population is required.
C1 [Xie, Tianhang; Xiu, Peng; Yang, Zhiqiang; Wang, Duan; Zeng, Jiancheng; Song, Yueming] Sichuan Univ, West China Hosp, Dept Orthoped, West China Sch Med, Chengdu, Peoples R China.
RP Zeng, JC (reprint author), Sichuan Univ, West China Hosp, Dept Orthoped, West China Sch Med, Chengdu, Peoples R China.
EM tomzeng5@126.com
CR Boody BS, 2016, J AM ACAD ORTHOP SUR, V24, P829, DOI 10.5435/JAAOS-D-14-00461
   Bydon A, 2010, SPINE J, V10, P820, DOI 10.1016/j.spinee.2010.04.010
   Calvo-Echenique A, 2019, BIOMED ENG ONLINE, V18, DOI 10.1186/s12938-019-0684-8
   Cambron SC, 2013, AM J NEURORADIOL, V34, P1661, DOI 10.3174/ajnr.A3441
   Epstein NE, 2004, SPINE, V29, P1049, DOI 10.1097/00007632-200405010-00018
   Jin J, 2018, CLIN SPINE SURG, V31, P31, DOI 10.1097/BSD.0000000000000474
   KAO CC, 1968, J NEUROSURG, V29, P168, DOI 10.3171/jns.1968.29.2.0168
   Kusakabe T, 2006, J NEUROSURG-SPINE, V5, P398, DOI 10.3171/spi.2006.5.5.398
   Martha JF, 2009, SPINE J, V9, P899, DOI 10.1016/j.spinee.2009.06.010
   Mehren C, 2016, CLIN ORTHOP RELAT R, V474, P2020, DOI 10.1007/s11999-016-4883-3
   Mobbs Ralph J, 2015, J Spine Surg, V1, P2, DOI 10.3978/j.issn.2414-469X.2015.10.05
   Oertel JM, 2017, WORLD NEUROSURG, V103, P122, DOI 10.1016/j.wneu.2017.02.075
   Park WM, 2013, COMPUT BIOL MED, V43, P1234, DOI 10.1016/j.compbiomed.2013.06.011
   Parlier-Cuau C, 1999, RADIOLOGY, V210, P509, DOI 10.1148/radiology.210.2.r99fe60509
   Rentenberger C, 2020, WORLD NEUROSURG, V134, pE657, DOI 10.1016/j.wneu.2019.10.164
   Shuang F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111695
   Silvestre C, 2012, ASIAN SPINE J, V6, P89, DOI 10.4184/asj.2012.6.2.89
   Weiner Bradley K, 2007, J Orthop Surg Res, V2, P5, DOI 10.1186/1749-799X-2-5
   Wilby MJ, 2009, SPINE, V34, P2518, DOI 10.1097/BRS.0b013e3181b22bd0
   Woods KRM, 2017, SPINE J, V17, P545, DOI 10.1016/j.spinee.2016.10.026
   Wu HH, 2018, WORLD NEUROSURG, V116, P35, DOI 10.1016/j.wneu.2018.05.018
   Xu RS, 2010, SPINE, V35, P1044, DOI 10.1097/BRS.0b013e3181bdafed
   Yamashita T, 1996, SPINE, V21, P538, DOI 10.1097/00007632-199603010-00002
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.094
PG 4
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600108
PM 31765867
DA 2020-05-12
ER

PT J
AU Xie, YL
   Lu, Q
   Lenahan, C
   Yang, SX
   Zhou, DY
   Qi, XC
AF Xie, Yonglin
   Lu, Qin
   Lenahan, Cameron
   Yang, Shuxu
   Zhou, Daoyang
   Qi, Xuchen
TI A Comparison of Subperiosteal or Subgaleal Drainage with Subdural
   Drainage on the Outcomes of Chronic Subdural Hematoma: A Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Article
DE Chronic subdural hematoma; Meta-analysis; Outcome; Subdural drainage;
   Subgaleal drainage; Subperiosteal drainage
ID BURR-HOLE TREPANATION; MANAGEMENT
AB OBJECTIVE: The aim of the present study was to compare the outcomes of patients with chronic subdural hematoma after undergoing burr hole craniotomy with subperiosteal or subgaleal drainage (SPGD) with those of patients who have undergone burr hole craniotomy with subdural drainage.
   METHODS: We searched 4 databases (PubMed, Web of Science, Embase, and Cochrane Library) for relevant re-ports from January 1995 to September 2019. Two reviewers recorded the major outcomes data as follows: recurrence, mortality, postoperative seizures, postoperative bleeding events, surgical infection, pneumocephalus, modified Rankin scale scores, and Glasgow outcome scale scores. The pooled odds ratios (ORs) and 95% confidence intervals (Cls) were calculated.
   RESULTS: A total of 3149 patients from 10 studies were included in our analysis. Compared with the SSD group, the SPGD group had a lower recurrence rate (OR, 0.72; 95% CI, 0.57-0.91) and a smaller risk of postoperative bleeding (OR, 0.41; 95% CI, 0.22-0.78). Also, no significant differences were found in the incidence of mortality (OR, 0.79; 95% CI, 0.54-1.18), postoperative seizures (OR, 0.74; 95% CI, 0.39-1.40), surgical infection (OR, 0.98; 95% CI, 0.55-1.76), pneumocephalus (OR, 0.58; 95% CI, 0.28-1.20), modified Rankin scale score 0-3 (OR, 1.04 at discharge; OR, 1.33 at 6 months), and Glasgow outcome scale score 4-5 (OR, 1.48; 95% CI, 0.82-2.67).
   CONCLUSIONS: Burr hole craniotomy with SPGD can be recommended as an effective and safe surgical therapy for patients with chronic subdural hematoma owing to its lower recurrence rate and reduced incidence of postoperative brain injuries, in addition to no increase in the rate of some postoperative complications. However, more studies are necessary for further confirmation.
C1 [Xie, Yonglin; Zhou, Daoyang] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Emergency, Sch Med, Hangzhou, Peoples R China.
   [Lu, Qin; Yang, Shuxu; Qi, Xuchen] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Neurosurg, Sch Med, Hangzhou, Peoples R China.
   [Lenahan, Cameron] Burrell Coll Osteopath Med, Las Cruces, NM USA.
   [Lenahan, Cameron] Loma Linda Univ, Sch Med, Ctr Neurosci Res, Loma Linda, CA USA.
RP Qi, XC (reprint author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Neurosurg, Sch Med, Hangzhou, Peoples R China.
EM qixuchen@zju.edu.cn
FU National Science Foundation for Young Scientists of China [81702974];
   Hangzhou General Project for Health and Science of China [2018A89]
FX The present analysis was financially supported by the National Science
   Foundation for Young Scientists of China (grant 81702974) and Hangzhou
   General Project for Health and Science of China (grant 2018A89).
CR Alcala-Cerra G, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.012
   Almenawer SA, 2014, ANN SURG, V259, P449, DOI 10.1097/SLA.0000000000000255
   Bellut D, 2012, WORLD NEUROSURG, V77, P111, DOI 10.1016/j.wneu.2011.05.036
   Brennan PM, 2017, J NEUROSURG, V127, P732, DOI 10.3171/2016.8.JNS16134
   Chih ANW, 2017, MALAYS J MED SCI, V24, P21, DOI 10.21315/mjms2017.24.1.3
   Glancz LJ, 2019, NEUROSURGERY, V85, P486, DOI 10.1093/neuros/nyy366
   Han MH, 2017, J NEUROSURG, V127, P1117, DOI 10.3171/2016.8.JNS16867
   Hani Levin, 2019, J Neurosurg, P1, DOI 10.3171/2019.5.JNS19858
   Ishfaq A, 2017, JCPSP-J COLL PHYSICI, V27, P419, DOI 2656
   Kaliaperumal C, 2012, ACTA NEUROCHIR, V154, P2083, DOI 10.1007/s00701-012-1483-1
   Kolias AG, 2014, NAT REV NEUROL, V10, P570, DOI 10.1038/nrneurol.2014.163
   Oral S, 2015, NORTH CLIN ISTANB, V2, P115, DOI 10.14744/nci.2015.06977
   Santarius T, 2009, LANCET, V374, P1067, DOI 10.1016/S0140-6736(09)61115-6
   Sjavik K, 2017, J NEUROSURG, V23, P1, DOI DOI 10.3171/2016.12.JNS161713
   Soleman J, 2019, NEUROSURGERY, V85, pE825, DOI 10.1093/neuros/nyz095
   Weigel R, 2003, J NEUROL NEUROSUR PS, V74, P937, DOI 10.1136/jnnp.74.7.937
   Zhang JJY, 2019, WORLD NEUROSURG, V131, pE392, DOI 10.1016/j.wneu.2019.07.168
   Zumofen D, 2009, NEUROSURGERY, V64, P1116, DOI 10.1227/01.NEU.0000345633.45961.BB
NR 18
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.116
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600087
PM 31899385
DA 2020-05-12
ER

PT J
AU Xin, WQ
   Wang, WH
   Yin, Q
   Xin, QQ
   Cai, SF
   Yang, XY
AF Xin, Wen-qiang
   Wang, Wei-han
   Yin, Qiang
   Xin, Qi-qiang
   Cai, Shi-fei
   Yang, Xin-yu
TI Meta-Analysis of Pterional Versus Supraorbital Keyhole Approach for
   Clipping Intracranial Aneurysms: Direct Comparison of Approach-Related
   Complications
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial aneurysms; Pterional approach; Supraorbital keyhole
   approach
ID EXPERIENCE; SURGERY; TRIAL
AB BACKGROUND: The supraorbital keyhole approach (SKA) and pterional approach (PA) have been recommended for clipping intracranial aneurysms (IAs). We conducted a meta-analysis to systematically and comprehensively compare the clinical outcomes between the 2 approaches.
   METHODS: We retrieved potential academic studies that had compared the clinical outcomes of SKA and PA for clipping IAs from the Cochrane Library, Medline, PubMed, and EMBASE databases. The references of the identified studies were carefully reviewed to ensure that all available documents had been included in the present study. The meta-analysis was conducted in accordance with the acknowledged PRISMA (prioritized reported items for systematic review and meta-analysis) guidelines.
   RESULTS: A total of 8 studies with 1016 participants were included in our study. Of these 1016 patients with IAs, 518 were assigned to the SKA group and 498 to the PA group. Our results showed that the SKA is preferable for clipping IAs compared with the PA because of its shorter operative time (weighted mean difference, -3.163; 95% confidence interval [CI], -5.577 to -0.749; P = 0.01) and length of stay, especially for the patients with unruptured IAs (weighted mean difference, -52.107; 95% CI, -81.597 to -22.618). However, a lower risk of postoperative infection was found in the SKA group (4.6% vs. 8.5%; odds ratio, 0.398; 95% CI, 0.186-0.850; P = 0.017), which seemed to derive from the ruptured IAs (OR, 0.330; 95% CI, 0.136-0.800; P = 0.014). However, no significant difference was found in the incidence of frontal sinus opening, completed occlusion, procedural complications, intraoperative rupture, postoperative hematoma, or cerebral vessel spasm.
   CONCLUSIONS: The SKA was associated with a shorter length of stay and operation time and a lower risk of postoperative infection. Hence, the SKA seems to be equally effective and safe for clipping IAs compared with PA and should be recommended for surgeons who have acquired sufficient experience with this technique owing to its advantages compared with the PA.
C1 [Xin, Wen-qiang; Wang, Wei-han; Cai, Shi-fei; Yang, Xin-yu] Tianjin Med Univ Canc Inst & Hosp, Dept Neurosurg, Tianjin, Peoples R China.
   [Yin, Qiang] Tianjin Med Univ Canc Inst & Hosp, Neurooncol & Neurosurg, Tianjin, Peoples R China.
   [Xin, Qi-qiang] Nanchang Univ, Sch Publ Hlth, Dept Prevent Med, Nanchang, Jiangxi, Peoples R China.
RP Yang, XY (reprint author), Tianjin Med Univ Canc Inst & Hosp, Dept Neurosurg, Tianjin, Peoples R China.
EM tumeduxinyu@yeah.net
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81570507]
FX Our work was supported by funding from the National Natural Science
   Foundation of China (grant 81570507 to X.Y.Y.).
CR Brydon HL, 2008, BRIT J NEUROSURG, V22, P40, DOI 10.1080/02688690701601521
   Chalouhi N, 2013, NEUROSURGERY, V72, P437, DOI 10.1227/NEU.0b013e3182804e9c
   Chen LK, 2009, ACTA NEUROCHIR, V151, P781, DOI 10.1007/s00701-009-0205-9
   Czirjak S, 2001, NEUROSURGERY, V48, P145, DOI 10.1097/00006123-200101000-00025
   Tra H, 2018, WORLD NEUROSURG, V109, P36, DOI 10.1016/j.wneu.2017.09.058
   La Rocca G, 2018, WORLD NEUROSURG, V119, pE192, DOI 10.1016/j.wneu.2018.07.091
   Lan Q, 2006, SURG NEUROL, V66, P2, DOI 10.1016/j.surneu.2006.06.039
   Lan Q, 2017, WORLD NEUROSURG, V102, P350, DOI 10.1016/j.wneu.2017.02.025
   Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700
   Maduri R, 2019, ACTA NEUROCHIR, V161, P781, DOI 10.1007/s00701-019-03837-0
   McDougall CG, 2012, J NEUROSURG, V116, P135, DOI 10.3171/2011.8.JNS101767
   Mitchell P, 2005, SURG NEUROL, V63, P47, DOI 10.1016/j.surneu.2004.02.030
   Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6
   Mone CM, 1998, J PEDIATR ENDOCR MET, V11, P563
   Park J, 2019, J NEUROSURG, V130, P220, DOI 10.3171/2017.8.JNS171167
   Perneczky A, 1998, NEUROSURGERY, V42, P219, DOI 10.1097/00006123-199802000-00001
   Reisch R, 2005, NEUROSURGERY, V57, P242, DOI 10.1227/01.NEU.0000178353.42777.2C
   Shin D, 2012, J KOREAN NEUROSURG S, V52, P306, DOI 10.3340/jkns.2012.52.4.306
   Spetzler RF, 2015, J NEUROSURG, V123, P609, DOI 10.3171/2014.9.JNS141749
   Wardlaw JM, 2000, BRAIN, V123, P205, DOI 10.1093/brain/123.2.205
   Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3
   Wu XH, 2019, WORLD NEUROSURG, V121, pE596, DOI 10.1016/j.wneu.2018.09.174
   Yamahata H, 2014, NEUROSURG REV, V37, P629, DOI 10.1007/s10143-014-0562-6
   Yu Le-Bao, 2020, Neurosurg Rev, V43, P547, DOI 10.1007/s10143-018-1053-y
   Zumofen DW, 2017, WORLD NEUROSURG, V98, P614, DOI 10.1016/j.wneu.2016.10.110
NR 25
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.134
PG 12
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600029
PM 31790840
DA 2020-05-12
ER

PT J
AU Yacoub, A
   Wimmer, W
   Molinari, G
   Alicandri-Ciufelli, M
   Presutti, L
   Caversaccio, M
   Anschuetz, L
AF Yacoub, Abraam
   Wimmer, Wilhelm
   Molinari, Giulia
   Alicandri-Ciufelli, Matteo
   Presutti, Livio
   Caversaccio, Marco
   Anschuetz, Lukas
TI Transcanal Transpromontorial Approach to Lateral Skull Base: Maximal
   Area of Exposure and Surgical Extensions
SO WORLD NEUROSURGERY
LA English
DT Article
DE Area of exposure; Lateral skull base; Minimally invasive surgery;
   Transcanal transpromontorial approach; Vestibular schwannoma
ID QUANTITATIVE-ANALYSIS; CEREBELLOPONTINE ANGLE; ANATOMY; ACCURACY;
   PETROSAL; REMOVAL; FREEDOM
AB OBJECTIVE: To determine the possible surgical extensions and maximal area of exposure (AOE) achievable through the transcanal transpromontorial approach (TTA) to the internal auditory canal (IAC) and cerebellopontine angle. We hypothesize a possible extension of indication for this minimally invasive approach to the lateral skull base.
   METHODS: In this experimental anatomic study, the expanded TTA was first carried out in 4 temporal bones to define the anatomic boundaries of the maximal exposure, from 2 perspectives, the middle ear and the porus of the IAC. Consecutively, these identified boundaries were translated on segmented 3-dimensional (3D) surface models of 32 temporal bone high-resolution computed tomography scans.
   RESULTS: The dissections performed were the basis followed during the determination of the AOE on the 3D surface models. The measurements revealed that the AOE at the middle ear was 152.9 +/- 33.6 mm(2) , whereas it was 151.9 +/- 24.8 mm(2) at the porus of the IAC. The mean superoinferior and anteroposterior extensions at the middle ear were 14.7 +/- 2.5 mm and 16.9 +/- 2.5 mm, respectively. On the other hand, the mean superoinferior and anteroposterior extensions at the IAC porus were 10.3 +/- 1.3 mm and 18.5 +/- 1.9 mm, respectively.
   CONCLUSIONS: Consistent with the minimally invasive approaches, the AOE is limited; however, if compared with traditional approaches, it appears of considerable size. Our results may assist the surgeon in the selection process of the appropriate candidates for the TTA and to tailor the approach to the disease.
C1 [Yacoub, Abraam; Wimmer, Wilhelm; Molinari, Giulia; Caversaccio, Marco; Anschuetz, Lukas] Inselspital Univ Hosp, Dept Otolaryngol Head & Neck Surg, Bern, Switzerland.
   [Yacoub, Abraam; Wimmer, Wilhelm; Molinari, Giulia; Caversaccio, Marco; Anschuetz, Lukas] Univ Bern, Bern, Switzerland.
   [Yacoub, Abraam; Wimmer, Wilhelm; Caversaccio, Marco; Anschuetz, Lukas] Univ Bern, ARTORG Ctr Biomed Engn, Hearing Res Lab, Bern, Switzerland.
   [Yacoub, Abraam] Ain Shams Univ, Fac Med, Dept Otolaryngol Head & Neck Surg, Cairo, Egypt.
   [Molinari, Giulia; Alicandri-Ciufelli, Matteo; Presutti, Livio] Univ Hosp Modena, Dept Otolaryngol Head & Neck Surg, Modena, Italy.
RP Yacoub, A (reprint author), Inselspital Univ Hosp, Dept Otolaryngol Head & Neck Surg, Bern, Switzerland.; Yacoub, A (reprint author), Univ Bern, Bern, Switzerland.; Yacoub, A (reprint author), Univ Bern, ARTORG Ctr Biomed Engn, Hearing Res Lab, Bern, Switzerland.; Yacoub, A (reprint author), Ain Shams Univ, Fac Med, Dept Otolaryngol Head & Neck Surg, Cairo, Egypt.
EM abraam.yacoub@gmail.com
RI Anschuetz, Lukas/X-3595-2019
OI Anschuetz, Lukas/0000-0001-6927-0664; Wimmer,
   Wilhelm/0000-0001-5392-2074
FU Karl Storz SE Co. [2017-01]; Tuttlingen, Germany
FX This study was partially funded by CTU-grant Nr. 2017-01 allocated to L.
   Anschuetz and a matching grant by Karl Storz SE & Co. KG, Tuttlingen,
   Germany. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ansari SF, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.6.FOCUS12163
   Anschuetz L, 2018, OTOL NEUROTOL, V39, P785, DOI 10.1097/MAO.0000000000001827
   Bennett M, 2008, NEUROSURG CLIN N AM, V19, P331, DOI 10.1016/j.nec.2008.02.002
   Bergin M, 2010, OTOL NEUROTOL, V31, P1511, DOI 10.1097/MAO.0b013e3181f6c880
   Hasebe S, 2003, LARYNGOSCOPE, V113, P802, DOI 10.1097/00005537-200305000-00007
   Horgan MA, 2000, J NEUROSURG, V93, P108, DOI 10.3171/jns.2000.93.1.0108
   Hsu FPK, 2004, J NEUROSURG, V100, P695, DOI 10.3171/jns.2004.100.4.0695
   Kempfle J, 2016, OTOLARYNG HEAD NECK, V154, P920, DOI 10.1177/0194599816630979
   Komune N, 2017, J NEUROSURG, V126, P1974, DOI 10.3171/2016.5.JNS16261
   Marchioni D, 2018, OTOLARYNG HEAD NECK, V158, P710, DOI 10.1177/0194599818756592
   Marchioni D, 2018, EUR ARCH OTO-RHINO-L, V275, P1095, DOI 10.1007/s00405-018-4937-0
   Marchioni D, 2018, OTOL NEUROTOL, V39, P242, DOI 10.1097/MAO.0000000000001658
   Marchioni D, 2017, J NEUROSURG, V126, P98, DOI 10.3171/2015.11.JNS15952
   Marchioni D, 2013, EUR ARCH OTO-RHINO-L, V270, P1267, DOI 10.1007/s00405-012-2137-x
   Master A, 2016, J INT ADV OTOL, V12, P298, DOI 10.5152/iao.2016.2998
   Presutti L, 2017, ACTA OTORHINOLARYNGO, V37, P224, DOI 10.14639/0392-100X-1258
   Presutti L, 2017, LARYNGOSCOPE, V127, P2608, DOI 10.1002/lary.26559
   Presutti L, 2013, LARYNGOSCOPE, V123, P2862, DOI 10.1002/lary.24072
   Rathgeb C, 2018, EUR ARCH OTO-RHINO-L, V275, P905, DOI 10.1007/s00405-018-4906-7
   Schneider D, 2018, OTOL NEUROTOL, V39, P1326, DOI 10.1097/MAO.0000000000001993
   Sennaroglu L, 2003, LARYNGOSCOPE, V113, P332, DOI 10.1097/00005537-200302000-00025
   Siwanuwatn R, 2006, J NEUROSURG, V104, P137, DOI 10.3171/jns.2006.104.1.137
   Tang CT, 2013, CLIN NEUROL NEUROSUR, V115, P1058, DOI 10.1016/j.clineuro.2012.10.023
   Zador Z, 2015, J NEUROL SURG PART B, V76, P310, DOI 10.1055/s-0035-1549000
   Zhou CZ, 2016, INT J COMPUT ASS RAD, V11, P2097, DOI 10.1007/s11548-016-1394-3
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.102
PG 6
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600021
PM 31778835
DA 2020-05-12
ER

PT J
AU Yahanda, AT
   Patel, B
   Sutherland, G
   Honeycutt, J
   Jensen, RL
   Smyth, MD
   Limbrick, DD
   Dacey, RG
   Dowling, JL
   Dunn, GP
   Kim, AH
   Leuthardt, EC
   Rich, KM
   Zipfel, GJ
   Leonard, JR
   Cahill, DP
   Shah, MV
   Abram, SR
   Evans, J
   Tao, Y
   Chicoine, MR
AF Yahanda, Alexander T.
   Patel, Bhuvic
   Sutherland, Garnette
   Honeycutt, John
   Jensen, Randy L.
   Smyth, Matthew D.
   Limbrick, David D., Jr.
   Dacey, Ralph G.
   Dowling, Joshua L.
   Dunn, Gavin P.
   Kim, Albert H.
   Leuthardt, Eric C.
   Rich, Keith M.
   Zipfel, Gregory J.
   Leonard, Jeffrey R.
   Cahill, Daniel P.
   Shah, Mitesh, V
   Abram, Steven R.
   Evans, John
   Tao, Yu
   Chicoine, Michael R.
TI A Multi-Institutional Analysis of Factors Influencing Surgical Outcomes
   for Patients with Newly Diagnosed Grade I Gliomas
SO WORLD NEUROSURGERY
LA English
DT Article
DE Clinical research; Grade I glioma; Intraoperative magnetic resonance
   imaging; Neurosurgery; Registry; Treatment outcomes
ID END RESULTS PROGRAM; INTRAOPERATIVE MRI; PILOCYTIC ASTROCYTOMA;
   MALIGNANT-TRANSFORMATION; TUMOR RESECTION; ADULT PATIENTS; SURVIVAL;
   EXTENT; SURGERY; MANAGEMENT
AB OBJECTIVE: To assess the impact of intraoperative magnetic resonance imaging (iMRI), extent of resection (EOR), and other factors on overall survival (OS) and progression-free survival (PFS) for patients with newly diagnosed grade I gliomas.
   METHODS: A multicenter database was queried to identify patients with grade I gliomas. Retrospective analyses assessed the impact of patient, treatment, and tumor characteristics on OS and PFS.
   RESULTS: A total of 284 patients underwent treatment for grade I gliomas, including 248 resections (205 with iMRI, 43 without), 23 biopsies, and 13 laser interstitial thermal therapy treatments. Log-rank analyses of Kaplan-Meier plots showed improved 5-year OS (P = 0.0107) and PFS (P = 0.0009) with increasing EOR, and a trend toward improved 5-year OS for patients with lower American Society of Anesthesiologists score (P = 0.0528). Greater EOR was associated with significantly increased 5-year PFS for pilocytic astrocytoma (P < 0.0001), but not for ganglioglioma (P = 0.10) or dysembryoplastic neuroepithelial tumor (P = 0.57). Temporal tumors (P = 0.04) and location of "other" (P = 0.04) were associated with improved PFS, and occipital/parietal tumors (P = 0.02) were associated with decreased PFS compared with all other locations. Additional tumor resection was performed after iMRI in 49.7% of cases using iMRI, which produced gross total resection in 64% of these additional resection cases.
   CONCLUSIONS: Patients with grade I gliomas have extended OS and PFS, which correlates positively with increasing EOR, especially for patients with pilocytic astrocytoma. iMRI may increase EOR, indicated by the rate of gross total resection after iMRI use but was not independently associated with increased OS or PFS.
C1 [Yahanda, Alexander T.; Patel, Bhuvic; Smyth, Matthew D.; Limbrick, David D., Jr.; Dacey, Ralph G.; Dowling, Joshua L.; Dunn, Gavin P.; Kim, Albert H.; Leuthardt, Eric C.; Rich, Keith M.; Zipfel, Gregory J.; Evans, John; Chicoine, Michael R.] Washington Univ, Dept Neurol Surg, Sch Med St Louis, St Louis, MO 63110 USA.
   [Tao, Yu] Washington Univ, Dept Biostat, Sch Med St Louis, St Louis, MO 63110 USA.
   [Sutherland, Garnette] Univ Calgary, Dept Neurol Surg, Sch Med, Calgary, AB, Canada.
   [Honeycutt, John] Cook Childrens Med Ctr, Dept Neurol Surg, Ft Worth, TX USA.
   [Jensen, Randy L.] Univ Utah, Sch Med, Dept Neurol Surg, Salt Lake City, UT USA.
   [Leonard, Jeffrey R.] Ohio State Univ, Coll Med, Dept Neurol Surg, Columbus, OH 43210 USA.
   [Cahill, Daniel P.] Massachusetts Gen Hosp, Dept Neurol Surg, Boston, MA 02114 USA.
   [Shah, Mitesh, V] Goodman Campbell Brain & Spine, Dept Neurol Surg, Indianapolis, IN USA.
   [Abram, Steven R.] St Thomas Hosp, Dept Neurol Surg, Nashville, TN USA.
RP Yahanda, AT (reprint author), Washington Univ, Dept Neurol Surg, Sch Med St Louis, St Louis, MO 63110 USA.
EM ayahanda@wustl.edu
OI Patel, Bhuvic/0000-0001-8062-7310; Yahanda,
   Alexander/0000-0003-3630-1166
CR Aghi MK, 2015, J NEURO-ONCOL, V125, P503, DOI 10.1007/s11060-015-1867-1
   Bornhorst Miriam, 2016, Handb Clin Neurol, V134, P329, DOI 10.1016/B978-0-12-802997-8.00020-7
   Brown PD, 2004, INT J RADIAT ONCOL, V58, P1153, DOI 10.1016/j.ijrobp.2003.09.020
   Chaichana KL, 2010, J NEUROSURG, V112, P10, DOI 10.3171/2008.10.JNS08608
   Chassoux F, 2013, EPILEPSIA, V54, P129, DOI 10.1111/epi.12457
   Choudhri AF, 2014, AM J NEURORADIOL, V35, P2382, DOI 10.3174/ajnr.A4040
   Claus EB, 2005, CANCER-AM CANCER SOC, V103, P1227, DOI 10.1002/cncr.20867
   Coburger J, 2016, NEUROSURGERY, V78, P775, DOI 10.1227/NEU.0000000000001081
   Collins VP, 2015, ACTA NEUROPATHOL, V129, P775, DOI 10.1007/s00401-015-1410-7
   D'Amico RS, 2017, WORLD NEUROSURG, V103, P538, DOI 10.1016/j.wneu.2017.04.041
   Diwanji TP, 2017, ADOLESC HEALTH MED T, V8, P99, DOI 10.2147/AHMT.S53391
   Ellis JA, 2009, J NEURO-ONCOL, V95, P377, DOI 10.1007/s11060-009-9935-z
   FORSYTH PA, 1993, CANCER-AM CANCER SOC, V72, P1335, DOI 10.1002/1097-0142(19930815)72:4<1335::AID-CNCR2820720431>3.0.CO;2-E
   Gerard CS, 2014, SEMIN ONCOL, V41, P458, DOI 10.1053/j.seminoncol.2014.06.008
   Giordano M, 2016, CHILD NERV SYST, V32, P1915, DOI 10.1007/s00381-016-3177-0
   Nguyen HS, 2017, WORLD NEUROSURG, V103, P380, DOI 10.1016/j.wneu.2017.04.093
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hatiboglu MA, 2009, NEUROSURGERY, V64, P1073, DOI 10.1227/01.NEU.0000345647.58219.07
   Hawasli AH, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14471
   Haydon DH, 2014, NEUROSURGERY, V75, P37, DOI 10.1227/NEU.0000000000000349
   Haydon DH, 2013, NEUROSURGERY, V60, P92, DOI 10.1227/01.neu.0000430321.39870.be
   Hollon T, 2015, SEMIN RADIAT ONCOL, V25, P181, DOI 10.1016/j.semradonc.2015.02.007
   Jenkinson MD, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012788.pub2
   Jiang T, 2011, CHILD NERV SYST, V27, P55, DOI 10.1007/s00381-010-1159-1
   Johannesen TB, 2003, J NEUROSURG, V99, P854, DOI 10.3171/jns.2003.99.5.0854
   Johnson DR, 2012, J NEURO-ONCOL, V108, P187, DOI 10.1007/s11060-012-0829-0
   Kremer P, 2006, CHILD NERV SYST, V22, P674, DOI 10.1007/s00381-005-0030-2
   Kuhnt D, 2011, NEURO-ONCOLOGY, V13, P1339, DOI 10.1093/neuonc/nor133
   Kuhnt D, 2011, NEUROSURGERY, V69, P852, DOI 10.1227/NEU.0b013e318225ea6b
   Leuthardt EC, 2011, NEUROSURGERY, V69, P194, DOI 10.1227/NEU.0b013e31821d0e4c
   Liang D, 2012, SURG NEUROL INT, V3, P320
   Luyken C, 2004, CANCER, V101, P146, DOI 10.1002/cncr.20332
   Maldaun MVC, 2014, J NEUROSURG, V121, P810, DOI 10.3171/2014.6.JNS132285
   McGirt MJ, 2008, NEUROSURGERY, V63, P700, DOI 10.1227/01.NEU.0000325729.41085.73
   Missios S, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.12.FOCUS14762
   Moazzam AA, 2014, NEUROREPORT, V25, P894, DOI 10.1097/WNR.0000000000000184
   Nakamura M, 2000, ONCOLOGY-BASEL, V58, P108, DOI 10.1159/000012087
   Napolitano M, 2014, NEUROCHIRURGIE, V60, P143, DOI 10.1016/j.neuchi.2014.03.010
   Nimsky C, 2004, NEUROSURGERY, V55, P358, DOI 10.1227/01.NEU.0000129694.64671.91
   Nimsky C, 2006, NEUROL RES, V28, P482, DOI 10.1179/016164106X115125
   Ostrom QT, 2016, NEURO-ONCOLOGY, V18, pv1, DOI 10.1093/neuonc/now207
   Reponen E, 2014, ANESTH ANALG, V119, P420, DOI 10.1213/ANE.0000000000000234
   Rezvan A, 2009, ACTA NEUROCHIR, V151, P1359, DOI 10.1007/s00701-009-0435-x
   Roder C, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2015.11.FOCUS15530
   Senft C, 2011, LANCET ONCOL, V12, P997, DOI 10.1016/S1470-2045(11)70196-6
   Senft C, 2010, TECHNOL CANCER RES T, V9, P339, DOI 10.1177/153303461000900404
   Shah MN, 2012, J NEUROSURG-PEDIATR, V9, P259, DOI 10.3171/2011.12.PEDS11227
   Sievert AJ, 2009, J CHILD NEUROL, V24, P1397, DOI 10.1177/0883073809342005
   Smith JS, 2008, J CLIN ONCOL, V26, P1338, DOI 10.1200/JCO.2007.13.9337
   Snyder LA, 2014, J NEUROSURG, V120, P309, DOI 10.3171/2013.10.JNS13368
   Stuer C, 2007, CANCER-AM CANCER SOC, V110, P2799, DOI 10.1002/cncr.23148
   Tomita T, 2016, CHILD NERV SYST, V32, P1839, DOI 10.1007/s00381-016-3140-0
   Tovar-Spinoza Z, 2016, CHILD NERV SYST, V32, P1947, DOI 10.1007/s00381-016-3193-0
   Wisoff JH, 2011, NEUROSURGERY, V68, P1548, DOI 10.1227/NEU.0b013e318214a66e
NR 54
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.156
PG 11
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600091
PM 31901497
DA 2020-05-12
ER

PT J
AU Yu, G
   Wang, XW
   Zhang, X
   Quan, K
   Hua, W
   Yang, ZX
   Li, PL
   Liu, PX
   Song, JP
   Zhu, W
AF Yu, Guo
   Wang, Xiaowen
   Zhang, Xin
   Quan, Kai
   Hua, Wei
   Yang, Zixiao
   Li, Peiliang
   Liu, Peixi
   Song, Jianping
   Zhu, Wei
TI Gravity-Assisted Ipsilateral Paramedian Approach for Parafalcine
   Meningioma Resection
SO WORLD NEUROSURGERY
LA English
DT Article
DE Gravity-assisted surgery; Keyhole; Microsurgery; Parafalcine meningioma
ID FALCINE MENINGIOMAS; SURGICAL-TREATMENT
AB BACKGROUND: In our series, the gravity-assisted ipsilateral paramedian approach was shown to be safe and advantageous for the resection of parafalcine meningioma, because it does not result in contralateral brain impingement and does not require brain retraction. We have reported the technical details of this method and the outcomes of our patients.
   METHODS: From September 2018 to September 2019, 10 consecutive patients with parafalcine meningioma underwent microsurgery using the gravity-assisted ipsilateral paramedian approach. The clinical data, radiological images, and surgical outcomes were collected and analyzed.
   RESULTS: All 10 patients (5 men and 5 women, mean age, 55.8 +/- 12.5 years) underwent safe tumor resection. Of the 10 tumors, 6 were located in the frontal area, 2 in the parietal area, and 2 in frontal and parietal area. The superior sagittal sinus wall had been affected in 6 patients. Obvious perilesional edema was observed in 60% of the patients. During surgery, bridging veins were encountered in 8 patients and were preserved, except for a small branch. Brain retraction or transgression was not required, and gross total resection was achieved in all 10 patients. No major postoperative complications occurred, except for an unexpected subacute subdural hematoma 1 month postoperatively. All 10 patients had achieved a favorable outcome (Glasgow outcome scale, >= 4) at discharge, which remained the same after a mean follow-up of 5.8 +/- 3.7 months.
   CONCLUSIONS: The results from the present case series demons:rated the safety of the gravity-assisted ipsilateral paramedian approach for parafalcine meningioma resection. The approach provides good tumor exposure and clear identification and preservation of bridging veins, does not result in contralateral brain impingement, and does not require excessive brain retraction.
C1 [Yu, Guo; Wang, Xiaowen; Zhang, Xin; Quan, Kai; Hua, Wei; Yang, Zixiao; Li, Peiliang; Liu, Peixi; Song, Jianping; Zhu, Wei] Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
RP Song, JP (reprint author), Fudan Univ, Huashan Hosp, Dept Neurosurg, Shanghai, Peoples R China.
EM neurosurgerysong@foxmail.com
OI Song, Jianping/0000-0003-3411-1457; Zhang, Xin/0000-0002-3915-5873; Hua,
   Wei/0000-0001-6409-5078; Li, Peiliang/0000-0002-7854-9162
FU Outstanding Academic Leaders Program of Shanghai Municipal Commission of
   Health and Family Planning [2017BR006]; Shanghai Rising-Star Program
   [18QA1400900]
FX This study was supported by the Outstanding Academic Leaders Program of
   Shanghai Municipal Commission of Health and Family Planning (grant
   2017BR006 to W.Z.), and the Shanghai Rising-Star Program (grant
   18QA1400900 to J.P.S.).
CR Barkhoudarian G, 2017, OPER NEUROSURG, V13, P528, DOI 10.1093/ons/opx067
   Biroli A, 2012, ACTA NEUROCHIR, V154, P1987, DOI 10.1007/s00701-012-1454-6
   Chung SB, 2007, J KOREAN NEUROSURG S, V42, P276, DOI 10.3340/jkns.2007.42.4.276
   Eichberg DG, 2019, BRIT J NEUROSURG, DOI 10.1080/02688697.2019.1635988
   Karthigeyan M, 2019, ACTA NEUROCHIR, V161, P327, DOI 10.1007/s00701-018-3770-y
   Mukherjee S, 2014, BRIT J NEUROSURG, V28, P699, DOI 10.3109/02688697.2014.887655
   Nowak A, 2014, NEUROL NEUROCHIR POL, V48, P174, DOI 10.1016/j.pjnns.2014.05.003
   Roser F, 2018, ACTA NEUROCHIR, V160, P79, DOI 10.1007/s00701-017-3382-y
   Song J, 2018, J NEUROSURG, V128, P1270, DOI 10.3171/2017.7.JNS171564
NR 9
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.067
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600141
PM 31863889
DA 2020-05-12
ER

PT J
AU Yu, J
   Zhang, JB
   Li, JL
   Zhang, JJ
   Chen, JC
AF Yu, Jin
   Zhang, Jibo
   Li, Jieli
   Zhang, Jianjian
   Chen, Jincao
TI Cerebral Hyperperfusion Syndrome After Revascularization Surgery in
   Patients with Moyamoya Disease: Systematic Review and Meta-Analysis
SO WORLD NEUROSURGERY
LA English
DT Review
DE Bypass surgery; Cerebral hyperperfusion syndrome; Incidence; Moyamoya
   disease
ID SUPERFICIAL TEMPORAL ARTERY; EXTRACRANIAL-INTRACRANIAL BYPASS;
   BLOOD-FLOW; CLINICAL-FEATURES; POSTOPERATIVE HYPERPERFUSION; SURGICAL
   REVASCULARIZATION; NEUROLOGIC DETERIORATION; CT PERFUSION; ACUTE STAGE;
   IVY SIGN
AB BACKGROUND: Cerebral hyperperfusion syndrome (CHS) after bypass surgery is known as a complication of moyamoya disease (MMD). However, the incidence of CHS has not been accurately reported, and there is no consensus on related risk factors.
   OBJECTIVE: To evaluate the incidence and characteristics of CHS in patients with MMD after revascularization surgery via meta-analysis.
   METHODS: Relevant cohort studies were retrieved through a literature search of PubMed, Embase, and Ovid until December 1, 2018. Eligible studies were identified per search criteria. A systematic review and meta-analysis were used to assess the CHS total incidence, incidence in pediatric patients with MMD and adult patients with MMD, incidence for direct and combined bypass surgery, progress rate, and proportion of each symptom (including transient neurologic deficits [TNDs], hemorrhage, and seizure).
   RESULTS: A total of 27 cohort studies with 2225 patients were included in this meta-analysis. The weighted proportions per random-effects model were 16.5% (range, 11.3%-22.3%) for CHS total incidence, 3.8% (range, 0.3%-9.6%) for pediatric patients with MMD, 19.9% (range, 11.7%-29.4%) for adult patients with MMD, 15.4% (range, 5.4%-28.8%) for direct bypass surgery, and 15.2% (range, 8.4%-23.2%) for combined bypass surgery. Progress rate was 39.5% (range, 28.7%-50.8%). The most common CHS-related symptom was TNDs (70.2%; range, 56.3%-82.7%), followed by hemorrhage (15.0%; range, 5.5%-26.9%) and seizure (5.3%; range, 0.6%-12.9%).
   CONCLUSIONS: CHS is a common complication after revascularization surgery in MMD. It is more frequently seen in adult patients. The most common CHS-related symptom was TNDs, followed by hemorrhage and seizure.
C1 [Yu, Jin; Zhang, Jibo; Li, Jieli; Zhang, Jianjian; Chen, Jincao] Wuhan Univ, Dept Neurosurg, Zhongnan Hosp, Wuhan, Peoples R China.
RP Chen, JC (reprint author), Wuhan Univ, Dept Neurosurg, Zhongnan Hosp, Wuhan, Peoples R China.
EM yokinns@163.com
CR Abla AA, 2013, NEUROSURGERY, V73, P430, DOI 10.1227/NEU.0000000000000017
   Cho WS, 2013, CLIN NUCL MED, V38, P44, DOI 10.1097/RLU.0b013e31827083d8
   Fujimura M, 2008, CHILD NERV SYST, V24, P827, DOI 10.1007/s00381-007-0551-y
   Fujimura M, 2007, SURG NEUROL, V67, P273, DOI 10.1016/j.surneu.2006.07.017
   Fujimura M, 2015, NEUROL MED-CHIR, V55, P775, DOI 10.2176/nmc.ra.2015-0063
   Fujimura M, 2015, NEUROL RES, V37, P131, DOI 10.1179/1743132814Y.0000000432
   Fujimura M, 2014, J STROKE, V16, P65, DOI 10.5853/jos.2014.16.2.65
   Fujimura M, 2014, NEUROSURGERY, V74, P163, DOI 10.1227/NEU.0000000000000238
   Fujimura M, 2012, NEUROL MED-CHIR, V52, P327, DOI 10.2176/nmc.52.327
   Fujimura M, 2011, NEUROSURGERY, V68, P957, DOI 10.1227/NEU.0b013e318208f1da
   Fujimura M, 2009, SURG NEUROL, V72, P476, DOI 10.1016/j.surneu.2008.10.009
   Fujimura M, 2009, SURG NEUROL, V71, P442, DOI 10.1016/j.surneu.2008.02.031
   Fujimura M, 2009, SURG NEUROL, V71, P223, DOI 10.1016/j.surneu.2007.07.077
   Goto Yasunobu, 1992, Neurologia Medico-Chirurgica, V32, P883, DOI 10.2176/nmc.32.883
   Guzman R, 2009, J NEUROSURG, V111, P927, DOI 10.3171/2009.4.JNS081649
   Hara S, 2017, AM J NEURORADIOL, V38, P696, DOI 10.3174/ajnr.A5068
   Hayashi K, 2012, WORLD NEUROSURG, V78, P447, DOI 10.1016/j.wneu.2011.10.041
   Horie N, 2014, STROKE, V45, P1488, DOI 10.1161/STROKEAHA.114.004755
   Houkin K, 1997, CLIN NEUROL NEUROSUR, V99, pS142
   Hwang JW, 2013, BRIT J ANAESTH, V110, P773, DOI 10.1093/bja/aes470
   Ishiguro T, 2019, NEUROSURG REV, V42, P559, DOI 10.1007/s10143-018-01059-z
   Ishii Y, 2017, WORLD NEUROSURG, V108, P427, DOI 10.1016/j.wneu.2017.09.001
   Ishikawa T, 2018, WORLD NEUROSURG, V119, pE750, DOI 10.1016/j.wneu.2018.07.258
   Januszewski J, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2013.12.FOCUS13473
   Jin SC, 2011, NEUROSURGERY, V68, P1227, DOI 10.1227/NEU.0b013e31820c045a
   Jung YJ, 2011, J KOREAN NEUROSURG S, V50, P492, DOI 10.3340/jkns.2011.50.6.492
   Kainth D, 2013, NEUROEPIDEMIOLOGY, V40, P282, DOI 10.1159/000345957
   Kaku Y, 2012, J CEREBR BLOOD F MET, V32, P2066, DOI 10.1038/jcbfm.2012.110
   Kamada K, 2014, NEUROL MED-CHIR, V54, P775, DOI 10.2176/nmc.st.2014-0176
   Kashiwazaki D, 2017, NEUROSURGERY, V81, P986, DOI 10.1093/neuros/nyx140
   Kawamata T, 2011, NEUROSURG REV, V34, P355, DOI 10.1007/s10143-011-0331-8
   Kazumata K, 2014, J NEUROSURG, V121, P432, DOI 10.3171/2014.1.JNS13946
   Kim JE, 2008, CEREBROVASC DIS, V25, P580, DOI 10.1159/000132205
   Kim JS, 2016, J STROKE, V18, P2, DOI 10.5853/jos.2015.01627
   Kim SK, 2010, ANN NEUROL, V68, P92, DOI 10.1002/ana.21981
   Kim SK, 2004, NEUROSURGERY, V54, P840, DOI 10.1227/01.NEU.0000114140.41509.14
   Kim T, 2016, J STROKE, V18, P21, DOI 10.5853/jos.2015.01739
   Kohama M, 2008, NEUROSURG REV, V31, P451, DOI 10.1007/s10143-008-0147-3
   Kornblihtt LI, 2005, STROKE, V36, pE71, DOI 10.1161/01.STR.0000174193.89864.55
   Kraemer M, 2018, J NEUROL, V265, P2370, DOI 10.1007/s00415-018-8997-2
   Kuroda S, 2008, LANCET NEUROL, V7, P1056, DOI 10.1016/S1474-4422(08)70240-0
   Lee S, 2018, RADIOLOGY, V288, P565, DOI 10.1148/radiol.2018170509
   Matano F, 2019, TURK NEUROSURG, V29, P598, DOI 10.5137/1019-5149.JTN.19271-16.1
   Mesiwala AH, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/2/E15
   Mukerji N, 2015, J NEUROSURG, V122, P90, DOI 10.3171/2014.8.JNS132413
   Nakagawa A, 2009, J NEUROSURG, V111, P1158, DOI 10.3171/2009.4.JNS08585
   Narisawa A, 2007, NEUROL SURG TOKYO, V35, P467
   Noguchi T, 2015, EUR J RADIOL, V84, P1137, DOI 10.1016/j.ejrad.2015.03.011
   Nomura S, 2018, WORLD NEUROSURG, V118, pE468, DOI 10.1016/j.wneu.2018.06.218
   Ogasawara K, 2005, NEUROSURGERY, V56, P1380, DOI 10.1227/01.NEU.0000159719.47528.2E
   Ogasawara K, 2004, NEUROSURGERY, V55, P1060, DOI 10.1227/01.NEU.0000140838.27450.63
   Qiao PG, 2017, J NEURORADIOLOGY, V44, P273, DOI 10.1016/j.neurad.2016.12.006
   Sasagawa A, 2018, J CLIN NEUROSCI, V47, P183, DOI 10.1016/j.jocn.2017.09.020
   Sato K, 2016, AM J NEURORADIOL, V37, P1244, DOI 10.3174/ajnr.A4715
   Scott R M, 2000, Clin Neurosurg, V47, P378
   Sugino T, 2013, J STROKE CEREBROVASC, V22, P811, DOI 10.1016/j.jstrokecerebrovasdis.2012.05.010
   Suzuki C, 2017, NUCL MED BIOL, V47, P19, DOI 10.1016/j.nucmedbio.2016.12.006
   Uchino H, 2016, STROKE, V47, P1930, DOI 10.1161/STROKEAHA.116.013304
   Uchino H, 2014, ACTA NEUROCHIR, V156, P1753, DOI 10.1007/s00701-014-2161-2
   Uchino H, 2012, STROKE, V43, P2610, DOI 10.1161/STROKEAHA.112.654723
   Uchino K, 2005, NEUROLOGY, V65, P956, DOI 10.1212/01.wnl.0000176066.33797.82
   UEKI K, 1994, MAYO CLIN PROC, V69, P749, DOI 10.1016/S0025-6196(12)61094-5
   Uno M, 1998, NEUROL MED-CHIR, V38, P420, DOI 10.2176/nmc.38.420
   Venkatraghavan L, 2018, J STROKE CEREBROVASC, V27, P301, DOI 10.1016/j.jstrokecerebrovasdis.2017.08.035
   Wang DF, 2015, SCI REP-UK, V5, DOI 10.1038/srep14140
   Wang R, 2014, EUR RADIOL, V24, P1135, DOI 10.1007/s00330-014-3098-9
   Xie AM, 2015, INT J CLIN EXP MED, V8, P21351
   Xu SX, 2018, WORLD NEUROSURG, V114, pE412, DOI 10.1016/j.wneu.2018.02.193
   Yang T, 2018, J NEUROSURG, V128, P1304, DOI 10.3171/2016.11.JNS162403
   Yu JL, 2016, INT J MED SCI, V13, P578, DOI 10.7150/ijms.15390
   Zhang JG, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000012768
   Zhao Hexiang, 2009, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V23, P1097
   Zhao M, 2019, J NEUROSURG, V130, P531, DOI 10.3171/2017.10.JNS171749
   Zhao WG, 2013, BRIT J NEUROSURG, V27, P321, DOI 10.3109/02688697.2012.757294
NR 74
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.065
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600162
PM 31759149
DA 2020-05-12
ER

PT J
AU Zhai, X
   Li, B
   Yang, YL
   Shao, J
   Zhang, Y
   Hu, W
   Chen, K
   Yang, MY
   Zhou, XY
   Wei, XZ
   Chen, ZQ
   Zhao, YC
   Bai, YS
   Li, M
AF Zhai, Xiao
   Li, Bo
   Yang, Yilin
   Shao, Jie
   Zhang, Yi
   Hu, Wen
   Chen, Kai
   Yang, Mingyuan
   Zhou, Xiaoyi
   Wei, Xiaozhao
   Chen, Ziqiang
   Zhao, Yingchuan
   Bai, Yushu
   Li, Ming
TI Reduced Puncture Time and Radiation Exposure of Percutaneous
   Transpedicular Puncture with Electronic Conductivity Device: A
   Randomized Clinical Trial
SO WORLD NEUROSURGERY
LA English
DT Article
DE Electronic conductivity cevice; Percutaneous transpedicular puncture;
   Randomized clinical trial
ID PEDICLE SCREWS; PLACEMENT; RISKS
AB OBJECTIVES: The present study introduced an electronic conductivity device (ECD) to reduce time of percutaneous transpedicular puncture and frequency of patient valid radiation exposure in percutaneous kyphoplasty (PKP) or percutaneous vertebroplasty (PVP).
   METHODS: A randomized self-control clinical study was undertaken. Medical records of patients with vertebral compression fractures (VCFs) for bilateral PKP or PVP were collected, and each side was performed randomly with ECD or conventional trocar.
   RESULTS: We enrolled 61 patients (44 women, 17 men) with 75 vertebras with VCF. Compared with the conventional fluoroscopy group, significant reductions in puncture time (504.33 +/- 152.03 vs. 652.68 +/- 167.60 seconds; P < 0.001) and fluoroscopy frequency (5.11 +/- 1.23 vs. 8.15 +/- 1.83; P < 0.001) for each percutaneous puncture were observed in the ECD group. When compared with the VCFs <= 50% group, the 2 indexes in the VCFs >50% group were significantly increased. And in the ECD group, the learning curve in the VCFs >50% group showed a steeper decreasing trend than that in the VCFs <= 50% group. No complications were observed in any patient.
   CONCLUSIONS: ECD could reduce puncture time of percutaneous transpedicular puncture and exposure of radiation in PVP and PKP. ECD has more benefits in complicated transpedicular puncture in patients with vertebral compression >50%.
C1 [Zhai, Xiao; Li, Bo; Yang, Yilin; Shao, Jie; Zhang, Yi; Hu, Wen; Chen, Kai; Yang, Mingyuan; Zhou, Xiaoyi; Wei, Xiaozhao; Chen, Ziqiang; Zhao, Yingchuan; Bai, Yushu; Li, Ming] Navy Med Univ, Shanghai Changhai Hosp, Dept Orthoped, Shanghai, Peoples R China.
RP Li, M (reprint author), Navy Med Univ, Shanghai Changhai Hosp, Dept Orthoped, Shanghai, Peoples R China.
EM limingchspine@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81701199]; Pilot Project Clinical Collaboration of
   Traditional Chinese Medicine and Western Medicine for Major and
   Difficult Diseases [ZY[2018-2020]-FWTX-2005]; Shanghai Science and
   Technology Commission Fund [17441900500, 16DZ0504000]; Foundation of
   Changhai Hospital [CH201717]
FX This study was supported by National Natural Science Foundation of China
   (81701199); Pilot Project Clinical Collaboration of Traditional Chinese
   Medicine and Western Medicine for Major and Difficult Diseases
   (ZY[2018-2020]-FWTX-2005); Shanghai Science and Technology Commission
   Fund (17441900500, 16DZ0504000); Foundation of Changhai Hospital
   (CH201717). Xiao Zhai, Bo Li, Yilin Yang, and Yushu Bai contributed
   equally to this work, they are considered as co-first authors.
CR Abdelgawaad AS, 2018, SPINE J, V18, P1143, DOI 10.1016/j.spinee.2017.11.001
   Allaoui M, 2018, WORLD NEUROSURG, V120, pE466, DOI 10.1016/j.wneu.2018.08.105
   Auloge Pierre, 2019, Eur Spine J, DOI 10.1007/s00586-019-06054-6
   Bai YS, 2013, J SPINAL DISORD TECH, V26, P316, DOI 10.1097/BSD.0b013e318247f21d
   Brenner DJ, 2004, RADIOLOGY, V232, P735, DOI 10.1148/radiol.2323031095
   Chaput CD, 2012, SPINE, V37, pE1305, DOI 10.1097/BRS.0b013e3182666adc
   Crouser N, 2018, WORLD NEUROSURG, V118, pE483, DOI 10.1016/j.wneu.2018.06.221
   Heo Y, 2019, OPER NEUROSURG, V17, P603, DOI 10.1093/ons/opz070
   Hewson DW, 2018, ANAESTHESIA, V73, P43, DOI 10.1111/anae.14139
   Koller H, 2009, EUR SPINE J, V18, P1300, DOI 10.1007/s00586-009-1054-1
   Lonjon N, 2016, WORLD NEUROSURG, V93, P371, DOI 10.1016/j.wneu.2016.05.070
   Ovadia D, 2011, SPINE, V36, pE1314, DOI 10.1097/BRS.0b013e31822a82ec
   Perdomo-Pantoja A, 2019, WORLD NEUROSURG, V126, P664, DOI 10.1016/j.wneu.2019.02.217
   Perisinakis K, 2004, RADIOLOGY, V232, P701, DOI 10.1148/radiol.2323031412
   Sandhu FA, 2017, EUR SPINE J, V26, P2941, DOI 10.1007/s00586-017-5242-0
   Stewart F. A., 2012, Annals of the ICRP, V41, P37, DOI 10.1016/j.icrp.2012.02.001
   Suess O, 2016, ADV MED, V2016
   Uehara M, 2014, EUR SPINE J, V23, P2189, DOI 10.1007/s00586-014-3502-9
   Zeller R, 2009, J PEDIATR ORTHOPED, V29, P760, DOI 10.1097/BPO.0b013e3181b768c3
   Zhao YZ, 2018, WORLD NEUROSURG, V119, pE997, DOI 10.1016/j.wneu.2018.08.038
NR 20
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.10.129
PG 7
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600007
PM 31678438
DA 2020-05-12
ER

PT J
AU Zhang, HQ
   Wang, YX
   Wu, JH
   Chen, J
AF Zhang, Hong-Qi
   Wang, Yu-Xiang
   Wu, Jian-Huang
   Chen, Jing
TI Debridement and Interbody Graft Using Titanium Mesh Cage, Posterior
   Monosegmental Instrumentation, and Fusion in the Surgical Treatment of
   Monosegmental Lumbar or Lumbosacral Pyogenic Vertebral Osteomyelitis via
   a Posterior-Only Approach
SO WORLD NEUROSURGERY
LA English
DT Article
DE Lumbar; Lumbosacral; Monosegmental; Posterior monosegmental
   instrumentation; Pyogenic vertebral osteomyelitis; Titanium mesh cage
ID STAGE ANTERIOR DEBRIDEMENT; SPINAL TUBERCULOSIS; FOCUS DEBRIDEMENT;
   THORACOLUMBAR SPINE; SPONDYLODISCITIS; RECONSTRUCTION; MANAGEMENT;
   FIXATION; EPIDEMIOLOGY; DISCITIS
AB OBJECTIVE: The main objective of the present study was to analyze the efficacy and feasibility of surgical management for patients with monosegmental lumbar or lumbosacral pyogenic vertebral osteomyelitis (PVO) by using one stage posterior debridement, interbody graft using titanium mesh cage, posterior monosegmental instrumentation, and fusion.
   METHODS: From February 2014 to May 2016, 27 patients with lumbar or lumbosacral PVO were treated by posterior debridement, interbody graft using titanium mesh cage, posterior monosegmental instrumentation, and fusion. The degree of damage to the patients' vertebral bodies was one third to one half height. There were 16 male and 11 female, with a mean age of 43.5 years (range, 32-56 years) at the time of surgery. The mean follow-up time was 35.7 months (range, 26-53 months). The clinical efficacy was evaluated on average operation time, blood loss, visual analog scale, erythrocyte sedimentation rate, C-reactive protein level, and neurologic function recovery.
   RESULTS: PVO was completely cured and the grafted bone was fused in all 27 patients. There was no recurrent vertebral osteomyelitis infection. Erythrocyte sedimentation rate and C-reactive protein level achieved normal limits within 3 months in all patients. The American Spinal Injury Association neurologic classification was improved in all cases. Pain relief was obtained in all patients.
   CONCLUSIONS: Our results showed that one stage posterior debridement, interbody graft using titanium mesh cage, posterior monosegmental instrumentation, and fusion was an effective treatment for patients with one third to one half height of vertebral body damaged in monosegmental lumbar or lumbosacral PVO. The surgical method is characterized as minimum surgical trauma, good pain relief, good neurologic recovery, and good reconstruction of spinal stability.
C1 [Zhang, Hong-Qi; Wang, Yu-Xiang; Wu, Jian-Huang; Chen, Jing] Cent South Univ, Xiangya Spinal Surg Ctr, Dept Spine Surg, Xiangya Hosp, Changsha, Peoples R China.
   [Zhang, Hong-Qi; Wang, Yu-Xiang; Wu, Jian-Huang; Chen, Jing] Cent South Univ, Natl Clin Res Ctr Geriatr Disorder, Xiangya Hosp, Changsha, Peoples R China.
RP Wang, YX (reprint author), Cent South Univ, Xiangya Spinal Surg Ctr, Dept Spine Surg, Xiangya Hosp, Changsha, Peoples R China.; Wang, YX (reprint author), Cent South Univ, Natl Clin Res Ctr Geriatr Disorder, Xiangya Hosp, Changsha, Peoples R China.
EM wangyuxiang201808@163.com
FU Hunan Province Natural Science Foundation of ChinaNatural Science
   Foundation of Hunan Province [2017JJ3489]; Youth Research Fund of
   Xiangya Hospital of Central South University [2017Q16]; Xiangya
   Hospital, China; Key Research and Development Project of Hunan Province
   [2017SK2062]; Department of Science and Technology of Hunan Province,
   China
FX The work was supported by the Hunan Province Natural Science Foundation
   of China (2017JJ3489), Youth Research Fund of Xiangya Hospital of
   Central South University (2017Q16), Xiangya Hospital, China, and Key
   Research and Development Project of Hunan Province (2017SK2062),
   Department of Science and Technology of Hunan Province, China.
CR ABRAMOVITZ JN, 1986, SPINE, V11, P418, DOI 10.1097/00007632-198606000-00003
   Carragee EJ, 1997, J BONE JOINT SURG AM, V79A, P874, DOI 10.2106/00004623-199706000-00011
   Chen WH, 2007, EUR SPINE J, V16, P1307, DOI 10.1007/s00586-006-0251-4
   Chiriano J, 2009, J VASC SURG, V50, P148, DOI 10.1016/j.jvs.2009.01.007
   Cottle L, 2008, J INFECTION, V56, P401, DOI 10.1016/j.jinf.2008.02.005
   D'Agostino C, 2010, INFECTION, V38, P102, DOI 10.1007/s15010-009-9340-8
   Dai LY, 2008, EUR SPINE J, V17, P1027, DOI 10.1007/s00586-008-0661-6
   Defino HL, 2005, INJURY, V36, P90, DOI 10.1016/j.injury.2005.06.019
   Desoutter S, 2015, ANTIMICROB AGENTS CH, V59, P7700, DOI 10.1128/AAC.01516-15
   EMERY SE, 1989, SPINE, V14, P284
   Fayazi Amir H, 2004, Spine J, V4, P388, DOI 10.1016/j.spinee.2004.01.004
   Gasbarrini A, 2012, EUR REV MED PHARMACO, V16, P26
   Gorensek M, 2013, EUR SPINE J, V22, P633, DOI 10.1007/s00586-012-2487-5
   Gouliouris T, 2010, J ANTIMICROB CHEMOTH, V65, piii11, DOI 10.1093/jac/dkq303
   Hadjipavlou AG, 2000, SPINE, V25, P1668, DOI 10.1097/00007632-200007010-00010
   Jain AK, 2002, CLIN ORTHOP RELAT R, P75
   Jaramillo-de la Tore JJ, 2006, NEUROSURG CLIN N AM, V17, P339, DOI 10.1016/j.nec.2006.05.003
   Jeong SJ, 2014, J KOREAN NEUROSURG S, V56, P21, DOI 10.3340/jkns.2014.56.1.21
   Kehrer M, 2014, J INFECTION, V68, P313, DOI 10.1016/j.jinf.2013.11.011
   Kim CJ, 2010, SPINE, V35, pE1096, DOI 10.1097/BRS.0b013e3181e04dd3
   Klockner C, 2003, SPINE, V28, P1036, DOI 10.1097/00007632-200305150-00016
   Korovessis P, 2006, SPINE, V31, P1014, DOI 10.1097/01.brs.0000215049.08622.9d
   Korovessis P, 2006, CLIN ORTHOP RELAT R, P51, DOI 10.1097/01.blo.0000203449.51769.7f
   Kuklo TR, 2006, J SPINAL DISORD TECH, V19, P376, DOI 10.1097/01.bsd.0000203945.03922.f6
   Kulowski J, 1936, J BONE JOINT SURG, V18, P343
   Kwon Ji-Woong, 2017, Korean J Spine, V14, P27, DOI 10.14245/kjs.2017.14.2.27
   LIEBERGALL M, 1991, CLIN ORTHOP RELAT R, P142
   Lora-Tamayo J, 2011, SEMIN ARTHRITIS RHEU, V41, P247, DOI 10.1016/j.semarthrit.2011.04.002
   McHenry MC, 2002, CLIN INFECT DIS, V34, P1342, DOI 10.1086/340102
   PATZAKIS MJ, 1991, CLIN ORTHOP RELAT R, P178
   Pee YH, 2008, J NEUROSURG-SPINE, V8, P405, DOI 10.3171/SPI/2008/8/5/405
   Przybylski GJ, 2001, J NEUROSURG, V94, P1, DOI 10.3171/spi.2001.94.1.0001
   Qiu Gui-xing, 2005, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V27, P249
   Rath SA, 1996, NEUROSURGERY, V38, P926, DOI 10.1097/00006123-199605000-00013
   Robertson PA, 2004, J SPINAL DISORD TECH, V17, P44, DOI 10.1097/00024720-200402000-00010
   Ruf M, 2007, SPINE, V32, pE275, DOI 10.1097/01.brs.0000261034.83395.7f
   Si M, 2013, ORTHOPEDICS, V36, P831, DOI 10.3928/01477447-20130523-33
   Sundararaj GD, 2007, J BONE JOINT SURG BR, V89B, P1201, DOI 10.1302/0301-620X.89B9
   Wang YX, 2017, INJURY, V48, P378, DOI 10.1016/j.injury.2016.12.025
   Wang YX, 2016, CHILD NERV SYST, V32, P1495, DOI 10.1007/s00381-016-3152-9
   Wang YX, 2016, INT ORTHOP, V40, P1117, DOI 10.1007/s00264-016-3161-z
   Wei FX, 2010, SPINE, V35, pE714, DOI 10.1097/BRS.0b013e3181d7ad1d
   Yang SC, 2017, WORLD J ORTHOP, V8, P710, DOI 10.5312/wjo.v8.i9.710
   Zhang HQ, 2011, CHILD NERV SYST, V27, P735, DOI 10.1007/s00381-010-1319-3
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.11.072
PG 10
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600016
PM 31756509
DA 2020-05-12
ER

PT J
AU Zhang, M
   Zhang, Y
   Zheng, E
   Gephart, MH
   Veeravagu, A
   Desai, A
   Ratliff, JK
   Li, G
AF Zhang, Michael
   Zhang, Yi
   Zheng, Eric
   Gephart, Melanie Hayden
   Veeravagu, Anand
   Desai, Atman
   Ratliff, John K.
   Li, Gordon
TI Outcomes and Costs Following Ommaya Placement with Thrombocytopenia
   Among US Patients with Cancer
SO WORLD NEUROSURGERY
LA English
DT Article
DE Intracranial hemorrhage; Leptomeningeal; Leukemia; Lymphoma; Ommaya;
   Thrombocytopenia
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; SAFETY; CHEMOTHERAPY; RESERVOIRS;
   CHILDREN; TUMORS
AB BACKGROUND: Placement of Ommaya reservoirs for the administration of intrathecal chemotherapy may be complicated by comorbid thrombocytopenia among patients with hematologic or leptomeningeal disease. Aggregated data on risks of Ommaya placement among thrombocytopenic patients are lacking. This study assesses complications, revision rates, and costs associated with Ommaya placement among patients with thrombocytopenia in a large population sample.
   METHODS: Using a national administrative database, this retrospective study identifies a cohort of adult patients with cancer who underwent Ommaya placement between 2007 and 2016. Preoperative thrombocytopenia was defined as diagnosis of secondary thrombocytopenia, bleeding event, procedure to control bleeding, or platelet transfusion, within 30 days before index admission. Univariate and multivariate analyses were performed to assess costs, 30-day complications, readmissions, and revisions among patients with and without preoperative thrombocytopenia.
   RESULTS: The analytic cohort included 1652 patients, of whom 29.3% met criteria for preoperative thrombocytopenia. In-hospital mortality rates were 7.7% among patients thrombocytopenia with versus 1.2% among patients without thrombocytopenia (P < 0.001). Preoperative thrombocytopenia was associated with 14.5 times greater hazard of intracranial hemorrhage within 30 days following Ommaya placement, occurring in 25.6% versus 2.0% of patients with and without thrombocytopenia, respectively (P < 0.014). Revision rates did not differ significantly between patients with and without thrombocytopenia. Thrombocytopenia was associated with longer length of stay (7.4 vs. 13.9 days, P < 0.001) and additional $10,000 per patient in costs of index hospitalization (P < 0.001) .
   CONCLUSIONS: This is the largest study to date documenting costs and complication rates of Ommaya placement in patients with and without thrombocytopenia.
C1 [Zhang, Michael; Zhang, Yi; Zheng, Eric; Gephart, Melanie Hayden; Veeravagu, Anand; Desai, Atman; Ratliff, John K.; Li, Gordon] Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA.
RP Zhang, Y (reprint author), Stanford Univ, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA.
EM yizhang9@stanford.edu
OI Ratliff, John/0000-0003-3452-1907; Zhang, Michael/0000-0002-7067-0689
CR Brown RS, 2019, GASTROHEP, V1, P236
   Dasenbrock HH, 2016, CANCER-AM CANCER SOC, V122, P1708, DOI 10.1002/cncr.29984
   Field P, 2001, J NEUROSURG, V94, P545, DOI 10.3171/jns.2001.94.4.0545
   Greenfield JP, 2005, CANC TREAT, V125, P107
   Higuchi T, 2005, LEUKEMIA LYMPHOMA, V46, P1169, DOI 10.1080/10428190500102662
   Howard SC, 2000, JAMA-J AM MED ASSOC, V284, P2222, DOI 10.1001/jama.284.17.2222
   Intusoma U, 2019, PEDIATR NEUROL, V99, P23, DOI 10.1016/j.pediatrneurol.2019.06.005
   Kramer K, 2014, PEDIATR BLOOD CANCER, V61, P1590, DOI 10.1002/pbc.25080
   Lau JC, 2018, ACTA NEUROCHIR, V160, P539, DOI 10.1007/s00701-017-3454-z
   Major K, 2019, CUREUS, V11, DOI 10.7759/cureus.5291
   Peyrl A, 2014, J NEURO-ONCOL, V120, P139, DOI 10.1007/s11060-014-1531-1
   Sandberg DI, 2000, NEUROSURGERY, V47, P49, DOI 10.1097/00006123-200007000-00011
   Wang A, 2019, WORLD NEUROSURG, V122, pE723, DOI 10.1016/j.wneu.2018.10.127
   Weycker D, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5354-5
   Wu Y, 2009, CLIN THER, V31, P2416, DOI 10.1016/j.clinthera.2009.11.020
NR 15
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.063
PG 14
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600065
PM 31866457
DA 2020-05-12
ER

PT J
AU Zheng, MM
   Zhang, JP
   Song, Y
   Zhao, W
   Sun, LL
   Zhang, J
   Yin, H
   Wang, W
   Han, J
AF Zheng, Meimei
   Zhang, Jinping
   Song, Yun
   Zhao, Wei
   Sun, Lili
   Zhang, Jun
   Yin, Hao
   Wang, Wei
   Han, Ju
TI Endovascular Recanalization of Nonacute Symptomatic Vertebral Ostial
   Occlusion Performed Using a Distal Embolic Protection Device
SO WORLD NEUROSURGERY
LA English
DT Article
DE Embolic protection device; Endovascular recanalization; Feasibility;
   Total occlusion; Vertebral artery
ID CEREBRAL HYPERPERFUSION SYNDROME; SELF-EXPANDING STENTS;
   ISCHEMIC-STROKE; ARTERY; STENOSIS; ANGIOPLASTY
AB OBJECTIVE: Endovascular recanalization of symptomatic vertebral ostial occlusion in the nonacute phase has not been well documented. Distal thromboembolic events negatively affect the success of endovascular treatment. We aimed to investigate the feasibility, safety, and out-comes of stenting performed with the use of a distal embolic protection device for patients with symptomatic vertebral ostial occlusion in the nonacute phase.
   METHODS: We retrospectively reviewed the data of 7 patients with symptomatic vertebral ostial occlusion despite medical management who underwent stenting performed using a distal embolic protection device between January 2015 and February 2019. The occlusive lesions were predilated with small balloons, followed by placement of distal embolic protection devices and stents sequentially. At last, the protection devices were retrieved. The rate of successful recanalization, perioperative complications, and clinical and angiographic outcomes were analyzed.
   RESULTS: The rate of successful recanalization was 100% with all distal embolic protection devices deployed and retrieved. Poststenting angiography showed no significant residual stenosis. There were no major acute thromboembolic events during and after the procedure. There were no recurrent ischemic symptoms after a mean clinical follow-up of 20.6 +/- 16.3 months. At 6-month imaging follow-up, repeat vascular images from 5 patients showed asymptomatic restenosis in 1 artery.
   CONCLUSIONS: Our single-center preliminary experience indicated that performing stent placement for vertebral ostial occlusion using a distal protection device may be feasible with a high rate of procedural success. However, this strategy should be confirmed in future prospective randomized studies with larger patient numbers.
C1 [Zheng, Meimei; Zhang, Jinping; Song, Yun; Zhao, Wei; Sun, Lili; Zhang, Jun; Yin, Hao; Wang, Wei; Han, Ju] Shandong First Med Univ, Dept Neurol, Affiliated Hosp 1, Jinan, Peoples R China.
   [Zheng, Meimei; Zhang, Jinping; Song, Yun; Zhao, Wei; Sun, Lili; Zhang, Jun; Yin, Hao; Wang, Wei; Han, Ju] Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Neurol, Jinan, Peoples R China.
RP Han, J (reprint author), Shandong First Med Univ, Dept Neurol, Affiliated Hosp 1, Jinan, Peoples R China.; Han, J (reprint author), Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Neurol, Jinan, Peoples R China.
EM hanjujack1@163.com
OI Zhang, Jun/0000-0002-5673-2193
FU Key Research and Development Program of Shandong Province
   [2019GSF108138]
FX The conduction of this research was partially supported by Key Research
   and Development Program of Shandong Province (2019GSF108138).
CR Al-Ali F, 2011, STROKE, V42, P2544, DOI 10.1161/STROKEAHA.110.610451
   Bando K, 2001, J NEUROSURG, V94, P826, DOI 10.3171/jns.2001.94.5.0826
   Blacker DJ, 2003, STROKE, V34, P2659, DOI 10.1161/01.STR.0000092120.03676.D6
   Caplan Lr, 2005, J Clin Neurol, V1, P14, DOI 10.3988/jcn.2005.1.1.14
   Chung SY, 2010, KOREAN J RADIOL, V11, P156, DOI 10.3348/kjr.2010.11.2.156
   Divani AA, 2008, J ENDOVASC THER, V15, P263, DOI 10.1583/07-2326.1
   Fu C, 2018, J NEUROINTERV SURG, V10, DOI 10.1136/neurintsurg-2017-013412.rep
   Geng XK, 2015, J ENDOVASC THER, V22, P436, DOI 10.1177/1526602815579406
   Glass TA, 2002, ARCH NEUROL-CHICAGO, V59, P369, DOI 10.1001/archneur.59.3.369
   Gupta R, 2011, J NEUROINTERV SURG, V3, P54, DOI 10.1136/jnis.2009.002139
   Higashida RT, 2003, STROKE, V34, pE109, DOI 10.1161/01.STR.0000082721.62796.09
   Iwata T, 2012, NEUROSURGERY, V70, P82, DOI 10.1227/NEU.0b013e31822e074c
   Iwata T, 2009, NEUROSURGERY, V65, P378, DOI 10.1227/01.NEU.0000348293.01482.0F
   Karameshev A, 2010, NEURORADIOLOGY, V52, P371, DOI 10.1007/s00234-010-0662-0
   Langwieser N, 2014, J ENDOVASC THER, V21, P683, DOI 10.1583/14-4713MR.1
   Lesley WS, 2010, J NEUROINTERV SURG, V2, P198, DOI 10.1136/jnis.2010.002311
   Meyers PM, 2000, NEUROSURGERY, V47, P335, DOI 10.1097/00006123-200008000-00013
   Mintz EP, 2004, CATHETER CARDIO INTE, V61, P12, DOI 10.1002/ccd.10710
   Musialek P, 2015, J ENDOVASC THER, V22, P445, DOI 10.1177/1526602815583490
   Park S, 2014, AM J NEURORADIOL, V35, P367, DOI 10.3174/ajnr.A3681
   Rezende MT, 2006, STROKE, V37, pE12, DOI 10.1161/01.STR.0000196959.77184.49
   Suzuki M, 2018, INTERNAL MED, V57, P733, DOI 10.2169/internalmedicine.9317-17
   van Mook WNKA, 2005, LANCET NEUROL, V4, P877, DOI 10.1016/S1474-4422(05)70251-9
   Vemmos KN, 2000, CEREBROVASC DIS, V10, P133, DOI 10.1159/000016042
   Vos A W Floris, 2004, Vascular, V12, P369
   Yoshie T, 2016, NEURORADIOLOGY, V58, P253, DOI 10.1007/s00234-015-1623-4
   Zhang F, 2009, MOD PHYS LETT B, V23, P681, DOI 10.1142/S0217984909018898
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1878-8750
EI 1878-8769
J9 WORLD NEUROSURG
JI World Neurosurg.
PD MAR
PY 2020
VL 135
DI 10.1016/j.wneu.2019.12.132
PG 8
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA KR7GS
UT WOS:000517784600156
PM 31899403
DA 2020-05-12
ER

PT J
AU Le, TN
   Da Silva, D
   Colas, C
   Darrouzet, E
   Baril, P
   Leseurre, L
   Maunit, B
AF Thao Nhi Le
   Da Silva, David
   Colas, Cyril
   Darrouzet, Eric
   Baril, Patrick
   Leseurre, Lucie
   Maunit, Benoit
TI Asian hornet Vespa velutina nigrithorax venom: Evaluation and
   identification of the bioactive compound responsible for human
   keratinocyte protection against oxidative stress
SO TOXICON
LA English
DT Article
DE Antioxidant activity; Keratinocyte; Mass spectrometry; Reactive oxygen
   species; Thin layer chromatography; Vespa velutina venom
ID WASP POLYBIA-PAULISTA; ANTIOXIDANT; SEROTONIN; PEPTIDES; PROPERTY;
   PROTEOME
AB The present study aimed to explore the potential antioxidant molecules of the Asian hornet venom (Vespa velutina nigrithorax) responsible for radical scavenging activity and human keratinocyte protection against oxidative stress. We developed a first technical platform that combined a DPPH radical scavenging chemical assay and cytotoxicity and ROS (reactive oxygen species) production in HaCaT keratinocyte cells exposed to UVB to evaluate the antioxidant property of V. velutina venom. We further employed Thin Layer Chromatography (TLC) combined with the DPPH assay as a targeted separation approach to isolate the antioxidant compounds responsible for the free radical scavenging property of V. velutina venom. In parallel, the latter was fractionated by a HPLC-DAD non-targeted separation approach. From this experiment, nine fractions were generated which were again evaluated separately for their antioxidant properties using DPPH assays. Results showed that only one fraction exhibited significant antioxidant activity in which serotonin was identified as the major compound by a UHPLC-ESI-QTOF HRMS/MS approach. We finally demonstrated, using purified serotonin molecule that this bioactive structure is mostly responsible for the free radical scavenging property of the crude venom as evidenced by DPPH and ROS assays in HaCaT cells exposed to UVB.
C1 [Thao Nhi Le; Da Silva, David; Colas, Cyril; Maunit, Benoit] Univ Orleans, ICOA, CNRS, UMR 7311, F-45067 Orleans, France.
   [Colas, Cyril; Baril, Patrick] Univ Orleans, CBM, CNRS, UPR 4301, F-45071 Orleans, France.
   [Darrouzet, Eric] Univ Tours, Fac Sci, IRBI, UMR CNRS 7261, Parc Grandmont, F-37200 Tours, France.
   [Leseurre, Lucie] CHIMEX Grp LOreal, 16 Rue Maurice Berteaux, F-95500 Le Thillay, France.
   [Maunit, Benoit] Univ Clermont Auvergne, IMost, INSERM, F-63000 Clermont Ferrand, France.
RP Da Silva, D (reprint author), Univ Orleans, ICOA, CNRS, UMR 7311, F-45067 Orleans, France.
EM thao-nhi.le@univ-orleans.fr; david.da-silva@univ-orleans.fr;
   cyril.colas@univ-orleans.fr; eric.darrouzet@univ-tours.fr;
   patrick.baril@cnrs.fr; lucie.leseurre@loreal.com; benoit.maunit@uca.fr
OI COLAS, Cyril/0000-0003-1651-6813
FU Region Centre-Val de LoireRegion Centre-Val de Loire; ARD 2020
   Cosmetosciences
FX We express our acknowledgement to Mr. Yoan LAURENT of the Centre de
   Biophysique Moleculaire (CBM, CNRS UPR4301) for the XTT cytotoxicity and
   ROS assay performed on HaCaT cells. This research was supported by ARD
   2020 Cosmetosciences, a global training and research program dedicated
   to the cosmetic industry. Located in the heart of the cosmetic valley,
   This program led by University of Orleans is funded by the Region
   Centre-Val de Loire.
CR Azouzi S, 2017, BIOPHYS J, V112, P1863, DOI 10.1016/j.bpj.2017.03.037
   Badarinath A. V., 2010, INT J PHARMATECH RES, V2, P1276
   Balamurugan E, 2010, MOL CELL BIOCHEM, V338, P69, DOI 10.1007/s11010-009-0339-3
   Bandoniene D, 2002, J AGR FOOD CHEM, V50, P2482, DOI 10.1021/jf011475s
   BHUSHAN R, 1989, BIOMED CHROMATOGR, V3, P95, DOI 10.1002/bmc.1130030302
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brieva A, 2008, SKIN PHARMACOL PHYS, V21, P15, DOI 10.1159/000109084
   Cheng YN, 2017, J EXP BIOL, V220, P645, DOI 10.1242/jeb.148783
   Choi JY, 2010, FITOTERAPIA, V81, P1134, DOI 10.1016/j.fitote.2010.07.015
   Colinet D, 2011, J BIOL CHEM, V286, P40110, DOI 10.1074/jbc.M111.288845
   Das T, 2011, TOXICON, V57, P1065, DOI 10.1016/j.toxicon.2011.04.012
   Dias NB, 2014, PEPTIDES, V51, P122, DOI 10.1016/j.peptides.2013.10.029
   Dongol Y, 2014, PHARMACOL THERAPEUT, P49, DOI [10.5772/57227, DOI 10.5772/57227]
   dos Santos LD, 2010, J PROTEOME RES, V9, P3867, DOI 10.1021/pr1000829
   Dunaway S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00392
   FRIEDMAN M, 1974, BIOORG CHEM, V3, P267, DOI 10.1016/0045-2068(74)90017-0
   Gulcin I, 2008, J ENZYM INHIB MED CH, V23, P871, DOI [10.1080/14756360701626223, 10.1080/14756360701626223 ]
   Hossain M.A., 2012, J BOT, V2012, P1, DOI [10.1155/2012/872875, DOI 10.1155/2012/217037]
   Kedare SB, 2011, J FOOD SCI TECH MYS, V48, P412, DOI 10.1007/s13197-011-0251-1
   Kusumawati I., 2013, STUDIES NATURAL PROD, V40, P485, DOI [10.1016/B978-0-444-59603-, DOI 10.1016/B978-0-444-59603-1.00015-1]
   Lam SC, 2016, J FOOD SCI, V81, pC2218, DOI 10.1111/1750-3841.13402
   Liu NY, 2018, ARCH INSECT BIOCHEM, V99, DOI 10.1002/arch.21503
   Liu ZR, 2015, SCI REP-UK, V5, DOI 10.1038/srep09454
   Lobayan RM, 2018, J MOL GRAPH MODEL, V80, P224, DOI 10.1016/j.jmgm.2018.01.006
   LU Y, 2014, PHARM PHARM, P39, DOI DOI 10.4236/PP.2014.54047
   Monceau K, 2014, J PEST SCI, V87, P1, DOI 10.1007/s10340-013-0537-3
   Peiren N, 2005, BBA-PROTEINS PROTEOM, V1752, P1, DOI 10.1016/j.bbapap.2005.07.017
   Piek T., 2013, VENOMS HYMENOPTERA B
   Sadiq A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041034
   Sansone Randy A, 2013, Innov Clin Neurosci, V10, P20
   Shi Wan-Jun, 2003, Acta Genetica Sinica, V30, P555
   Slominski A, 2002, FASEB J, V16, P896, DOI 10.1096/fj.01-0952fje
   Sobral F, 2016, FOOD CHEM TOXICOL, V94, P172, DOI 10.1016/j.fct.2016.06.008
   Somwongin S, 2018, TOXICON, V145, P32, DOI 10.1016/j.toxicon.2018.02.049
   Sookrung N, 2014, J PROTEOME RES, V13, P1336, DOI 10.1021/pr4009139
   Teng ZW, 2017, TOXINS, V9, DOI 10.3390/toxins9040135
   Vlazan P., 2012, ANAL CHEM, DOI [10.5772/51619, DOI 10.5772/51619]
   Want EJ, 2006, ANAL CHEM, V78, P743, DOI 10.1021/ac051312t
   Weisel-Eichler A, 2004, J COMP PHYSIOL A, V190, P683, DOI 10.1007/s00359-004-0526-3
   Yang MJ, 2011, PEPTIDES, V32, P2037, DOI 10.1016/j.peptides.2011.08.026
   Yang Y, 2017, J DIABETES RES, DOI 10.1155/2017/7680576
   Zhang Su-fang, 2003, Entomologia Sinica, V10, P21
   Zhang Y, 2015, J AGR FOOD CHEM, V63, P8819, DOI 10.1021/acs.jafc.5b03062
   Zhu CZ, 2013, J AGR FOOD CHEM, V61, P1265, DOI 10.1021/jf3044764
   강창근, 2015, [Journal of Agriculture & Life Science, 농업생명과학연구], V49, P125, DOI 10.14397/jals.2015.49.1.125
NR 45
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR
PY 2020
VL 176
BP 1
EP 9
DI 10.1016/j.toxicon.2020.01.001
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KT2UI
UT WOS:000518870700001
PM 31935389
DA 2020-05-12
ER

PT J
AU Murgai, AA
   Jog, M
AF Murgai, Aditya Ashok
   Jog, Mandar
TI Focal limb dystonia and tremor: Clinical update
SO TOXICON
LA English
DT Article
DE Dystonia; Tremor; Electrophysiology
ID PRIMARY WRITING TREMOR; BOTULINUM-TOXIN; WRITERS CRAMP; MUSCULORUM
   DEFORMANS; MOVEMENT-DISORDER; A INJECTIONS; ONSET; INHIBITION;
   PREVALENCE; PROFILE
AB The association between tremor and dystonia has been known for many decades. Dystonic tremor is seen in the body part affected with dystonia. Tremor and dystonia can also co-exist in different body parts. Subtle dystonic posturing can be missed in patients with upper limb tremor and these patients are often misdiagnosed as essential tremor. Careful clinical examination and electrophysiology may help in differentiating classical essential tremor from dystonic tremor. Writer's cramp, a common focal hand dystonia can mimic primary writing tremor when the dystonic posturing is subtle. Oral medications have limited therapeutic efficacy. Botulinum toxin is considered as first line therapy for focal limb dystonia and is also effective in the treatment of tremor. Surgical options are reserved for cases refractory to medical therapy. In this review, we summarize the current state of knowledge of focal limb dystonia and tremor with a focus on underlying neurophysiology in these conditions.
C1 [Murgai, Aditya Ashok; Jog, Mandar] Western Univ, Dept Clin Neurol Sci, London, ON, Canada.
RP Jog, M (reprint author), Univ Hosp, Clin Neurol Sci, 339 Windermere Rd, London, ON N6A 5A5, Canada.
EM Mandar.Jog@lhsc.on.ca
CR Albanese A, 2016, TREMOR OTHER HYPERK, V6, DOI 10.7916/D8X34XBM
   Altenmuller E, 2003, HAND CLIN, V19, P523, DOI 10.1016/S0749-0712(03)00043-X
   Asahi T, 2014, STEREOT FUNCT NEUROS, V92, P405, DOI 10.1159/000366004
   Bain PG, 1995, BRAIN, V118, P1461, DOI 10.1093/brain/118.6.1461
   CHEN RS, 1995, MOVEMENT DISORD, V10, P556, DOI 10.1002/mds.870100505
   Choudhury S, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00517
   Das CP, 2007, PARKINSONISM RELAT D, V13, P421, DOI 10.1016/j.parkreldis.2007.01.009
   Defazio G, 2015, NEUROLOGY, V84, P1053, DOI 10.1212/WNL.0000000000001341
   Deuschl G, 2003, REV NEUROL-FRANCE, V159, P900
   Deuschl G, 1998, MOVEMENT DISORD, V13, P2, DOI 10.1002/mds.870131303
   Doshi PK, 2017, ANN INDIAN ACAD NEUR, V20, P324, DOI 10.4103/aian.AIAN_15_17
   ELBLE RJ, 1990, MOVEMENT DISORD, V5, P118, DOI 10.1002/mds.870050205
   Elble RJ, 2013, CURR NEUROPHARMACOL, V11, P48, DOI 10.2174/157015913804999478
   FELDMAN AG, 1980, NEUROSCIENCE, V5, P81, DOI 10.1016/0306-4522(80)90073-1
   Goh EL, 2017, BURNS TRAUMA, V5, DOI 10.1186/s41038-016-0066-4
   Hedera P, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-66
   Jain S, 2006, ARCH NEUROL-CHICAGO, V63, P1100, DOI 10.1001/archneur.63.8.1100
   Jankovic J, 2013, MOVEMENT DISORD, V28, P1001, DOI 10.1002/mds.25552
   Jhunjhunwala K, 2015, EUR NEUROL, V73, P316, DOI 10.1159/000381949
   Kojovic M, 2011, MOVEMENT DISORD, V26, P1282, DOI 10.1002/mds.23681
   Konczak J, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00297
   Kruisdijk JJM, 2007, J NEUROL NEUROSUR PS, V78, P264, DOI 10.1136/jnnp.2005.083170
   Lobo PP, 2013, MOVEMENT DISORD, V28, P1306, DOI 10.1002/mds.25340
   LOU JS, 1991, NEUROLOGY, V41, P234, DOI 10.1212/WNL.41.2_Part_1.234
   Louis ED, 2013, PARKINSONISM RELAT D, V19, P359, DOI 10.1016/j.parkreldis.2012.09.015
   McKeon A, 2008, PARKINSONISM RELAT D, V14, P613, DOI 10.1016/j.parkreldis.2008.01.012
   Meng Y, 2018, CAN J NEUROL SCI, V45, P474, DOI 10.1017/cjn.2018.19
   Michalec M, 2014, PARKINSONISM RELAT D, V20, P541, DOI 10.1016/j.parkreldis.2014.01.021
   Modugno N, 2002, MOVEMENT DISORD, V17, P1336, DOI 10.1002/mds.10292
   Munchau A, 2001, BRAIN, V124, P1765, DOI 10.1093/brain/124.9.1765
   Niemann N, 2018, TOXINS, V10, DOI 10.3390/toxins10070299
   Nistico R, 2012, NEUROLOGY, V79, P1490, DOI 10.1212/WNL.0b013e31826d5f83
   Pandey S, 2016, PARKINSONISM RELAT D, V29, P3, DOI 10.1016/j.parkreldis.2016.03.024
   Papapetropoulos S, 2006, CLIN NEUROPHARMACOL, V29, P364, DOI 10.1097/01.WNF.0000236765.00785.9C
   RIDDING MC, 1995, J NEUROL NEUROSUR PS, V59, P493, DOI 10.1136/jnnp.59.5.493
   Romeo S, 1998, MUSCLE NERVE, V21, P1304, DOI 10.1002/(SICI)1097-4598(199810)21:10<1304::AID-MUS9>3.0.CO;2-F
   ROTHWELL JC, 1979, J NEUROL NEUROSUR PS, V42, P1106, DOI 10.1136/jnnp.42.12.1106
   Samotus O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178670
   Schmidt A, 2009, NEUROLOGY, V72, P1248, DOI 10.1212/01.wnl.0000345670.63363.d1
   SCHWARTZMAN RJ, 1990, NEUROLOGY, V40, P57, DOI 10.1212/WNL.40.1.57
   Singer C, 2005, MOVEMENT DISORD, V20, P1387, DOI 10.1002/mds.20590
   Singer C, 2005, J NEUROL NEUROSUR PS, V76, P1608, DOI 10.1136/jnnp.2004.062265
   Sussman Jon, 2015, Pract Neurol, V15, P317, DOI 10.1136/practneurol-2015-001148
   Tijssen MAJ, 2000, BRAIN, V123, P677, DOI 10.1093/brain/123.4.677
   van Hilten JJ, 2010, PAIN MED, V11, P1274, DOI 10.1111/j.1526-4637.2010.00916.x
   van Rijn MA, 2007, PAIN, V130, P287, DOI 10.1016/j.pain.2007.03.027
   Warner T, 2000, J NEUROL, V247, P787
   YANAGISAWA N, 1972, J NEUROL SCI, V16, P125, DOI 10.1016/0022-510X(72)90082-2
   ZEMAN W, 1960, NEUROLOGY, V10, P1068, DOI 10.1212/WNL.10.12.1068
NR 49
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR
PY 2020
VL 176
BP 10
EP 14
DI 10.1016/j.toxicon.2020.01.004
PG 5
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KT2UI
UT WOS:000518870700002
PM 31965968
OA Bronze
DA 2020-05-12
ER

PT J
AU Jiang, WJ
   Hu, LL
   Ren, YP
   Lu, X
   Luo, XQ
   Li, YH
   Xu, YN
AF Jiang, Wen-Jie
   Hu, Lin-Lin
   Ren, Yan-Ping
   Lu, Xiang
   Luo, Xiao-Qiong
   Li, Ying-Hua
   Xu, Yong-Nan
TI Podophyllotoxin affects porcine oocyte maturation by inducing oxidative
   stress-mediated early apoptosis
SO TOXICON
LA English
DT Article
DE Oocyte; Podophyllotoxin; Meiosis; ROS; Apoptosis
ID DAMAGE
AB Podophyllotoxin (PPT) is a lignan extracted from podophyllum genera and it shows potent antitumor activity since it could effectively inhibit the assembly of microtubule in tumor cells. However, the effects of podophyllotoxin exposure on porcine oocyte quality is still unclear. In present study we tried to examine whether podophyllotoxin exposure was toxic to porcine oocyte maturation. Our results showed that podophyllotoxin exposure inhibited porcine oocyte maturation, showing with the failure of polar body extrusion, and the inhibitory effects of podophyllotoxin on porcine oocytes was dose-depended. Moreover, the meiotic spindle formation was disturbed and the chromosomes were misaligned in the podophyllotoxin-treated porcine oocytes. However, there was no different expression for p-MAPK and ace-tubulin between the control and podophyllotoxin treatment group. In addition, after 0.01 mu M podophyllotoxin treatment, the intracellular reactive oxygen species (ROS) levels and the Annexin-V signal at MI stage significantly increased compared to the control group, indicating the occurrence of oxidative stress and early apoptosis. Taken together, our results suggested that the toxic effects of podophyllotoxin exposure on porcine oocyte maturation might be through its effects on spindle formation and the induction of oxidative stress-mediated early apoptosis.
C1 [Jiang, Wen-Jie; Li, Ying-Hua; Xu, Yong-Nan] Yanbian Univ, Coll Agr, Yanji, Peoples R China.
   [Hu, Lin-Lin; Luo, Xiao-Qiong] Youjiang Med Univ Nationalities, Affiliated Hosp, Baise, Peoples R China.
   [Ren, Yan-Ping; Lu, Xiang] Zunyi Med Univ, Coll Basic Med Sci, Zunyi, Guizhou, Peoples R China.
RP Li, YH; Xu, YN (reprint author), Yanbian Univ, Coll Agr, Yanji, Peoples R China.
EM lyh2015@ybu.edu.cn; ynxu0613@163.com
FU Jilin Province Education Department, Jilin Province, China
   [JJKH20191132KJ]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [31860329]; Yanbian University
   Research project, China [2018-09]; First Batch of High-level Talent
   Scientific Research Projects of the Affiliated Hospital of Youjiang
   Medical University [R20196317]
FX This work was supported by the project of the Jilin Province Education
   Department, Jilin Province, China (JJKH20191132KJ); National Natural
   Science Foundation of China (31860329); Yanbian University Research
   project (No. 2018-09), China; The First Batch of High-level Talent
   Scientific Research Projects of the Affiliated Hospital of Youjiang
   Medical University for Nationalities in 2019 (R20196317).
CR Agarwal A, 2005, REPROD BIOMED ONLINE, V11, P641, DOI 10.1016/S1472-6483(10)61174-1
   AHARI UZ, 2016, BIOMED PHARMACOL J, V9, P499, DOI DOI 10.13005/bpj/964
   Ardalani H, 2017, AVICENNA J PHYTOMEDI, V7, P285
   Chen JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062082
   Cohen T, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8100295
   Desbene Stephanie, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P71, DOI 10.2174/1568011023354353
   Dutta S, 2016, FOOD CHEM TOXICOL, V91, P141, DOI 10.1016/j.fct.2016.03.007
   Hu LL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28544-1
   JORDAN MA, 1992, J CELL SCI, V102, P401
   Lenart P, 2005, NATURE, V436, P812, DOI 10.1038/nature03810
   Sun SC, 2008, MOL REPROD DEV, V75, P1542, DOI 10.1002/mrd.20891
   Sun SC, 2013, MICROSC MICROANAL, V19, P883, DOI 10.1017/S1431927613001566
   Tamura H, 2008, J PINEAL RES, V44, P280, DOI 10.1111/j.1600-079X.2007.00524.X
   Tripathi A, 2009, FREE RADICAL RES, V43, P287, DOI 10.1080/10715760802695985
   Van Blerkom J, 2011, MITOCHONDRION, V11, P797, DOI 10.1016/j.mito.2010.09.012
   Wang F, 2015, CELL CYCLE, V14, P2835, DOI 10.1080/15384101.2015.1031438
   Xu H, 2009, CURR MED CHEM, V16, P327, DOI 10.2174/092986709787002682
   Xu ZJ, 2017, SCIENCE, V356, P328, DOI 10.1126/science.aai8764
   Yi K, 2011, NAT CELL BIOL, V13, P1252, DOI 10.1038/ncb2320
   Zhang HQ, 2012, MOL BIOL REP, V39, P5651, DOI 10.1007/s11033-011-1372-3
   Zhang X, 2018, BIOORGAN MED CHEM, V26, P340, DOI 10.1016/j.bmc.2017.11.026
   Zhu CC, 2016, ARCH TOXICOL, V90, P1495, DOI 10.1007/s00204-015-1560-3
NR 22
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR
PY 2020
VL 176
BP 15
EP 20
DI 10.1016/j.toxicon.2020.01.006
PG 6
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KT2UI
UT WOS:000518870700003
PM 31965969
DA 2020-05-12
ER

PT J
AU Lee, ST
   Welch, KD
   Stonecipher, CA
   Cook, D
   Gardner, DR
   Pfister, JA
AF Lee, Stephen T.
   Welch, Kevin D.
   Stonecipher, Clinton A.
   Cook, Daniel
   Gardner, Dale R.
   Pfister, James A.
TI Analysis of rumen contents and ocular fluid for toxic alkaloids from
   goats and cows dosed larkspur (Delphinium barbeyi), lupine (Lupinus
   leucophyllus), and death camas (Zigadenus paniculatus)
SO TOXICON
LA English
DT Article
DE Larkspur; Lupine; Death camas; Toxic alkaloids; Rumen; Ocular fluid
ID VITREOUS-HUMOR; NORDITERPENOID ALKALOIDS; DITERPENOID ALKALOIDS;
   ZYGADENUS-VENENOSUS; ZYGACINE; BLOOD; SPP.; MICE; METHYLLYCACONITINE;
   POSTMORTEM
AB Larkspurs, lupines, and death camas can be acutely toxic to livestock and are serious poisonous plant problems in western North America. The toxicity of these plants depends on the composition and concentrations of the toxic alkaloids in the plants. In this study, goats and cows were dosed sub-lethal doses of larkspur, lupine, and death camas. Rumen contents and ocular fluid samples were collected, and simple extraction, sample preparation, and analytical methods were developed for the detection of toxic alkaloids in the rumen contents and ocular fluid samples. Toxic alkaloids were detected in the rumen contents and ocular fluid samples from the goats and cows dosed larkspur, lupine, and death camas. In addition, results from a case report where rumen contents were analyzed from a steer that was suspected to have died due to larkspur are reported. This demonstrates the utility of the methods described for the diagnosis of acute plant poisonings.
C1 [Lee, Stephen T.; Welch, Kevin D.; Stonecipher, Clinton A.; Cook, Daniel; Gardner, Dale R.; Pfister, James A.] ARS, Poisonous Plant Res Lab, USDA, 1150 E 1400 N, Logan, UT 84341 USA.
RP Lee, ST (reprint author), ARS, Poisonous Plant Res Lab, USDA, 1150 E 1400 N, Logan, UT 84341 USA.
EM stephen.lee@ars.usda.gov
FU U.S. Department of Agriculture-Agricultural Research ServiceUnited
   States Department of Agriculture (USDA)
FX The authors thank Dr. Steve Ensley, Kansas State Veterinary Diagnostic
   Laboratory, for providing diagnostic samples and information regarding
   the larkspur poisoning case. The authors also thank Charles Hailes for
   technical assistance. This research was supported by U.S. Department of
   Agriculture-Agricultural Research Service.
CR Bevalot F, 2016, FORENSIC TOXICOL, V34, P12, DOI 10.1007/s11419-015-0294-5
   Burrows G.E., 2013, TOXIC PLANTS N AM
   Butler R., 2017, INT J POISONOUS PLAN, V4, P68
   Collett S, 1996, AGRI-PRACTICE, V17, P5
   Cook D, 2015, TOXICON, V99, P36, DOI 10.1016/j.toxicon.2015.03.005
   Cook D, 2011, AM J VET RES, V72, P706, DOI 10.2460/ajvr.72.5.706
   Crandall CS, 2006, J ANAL TOXICOL, V30, P651, DOI 10.1093/jat/30.9.651
   De Letter EA, 2000, INT J LEGAL MED, V114, P29, DOI 10.1007/s004140000135
   Gardner D. R., 1993, Journal of Natural Toxins, V2, P1
   Gardner DR, 2009, PHYTOCHEM ANALYSIS, V20, P104, DOI 10.1002/pca.1104
   Gardner DR, 2000, J NAT PROD, V63, P1127, DOI 10.1021/np0000116
   Gigler B.C., 2005, OCULAR PARAMETERS RE, V8, P265
   GILBERTSON TJ, 1973, PHYTOCHEMISTRY, V12, P2079, DOI 10.1016/S0031-9422(00)91555-3
   Gottas A, 2016, FORENSIC TOXICOL, V34, P277, DOI 10.1007/s11419-016-0315-z
   Green B. T., 2014, Rangelands, V36, P10, DOI 10.2111/RANGELANDS-D-13-00031.1
   Holechek JL, 2002, J RANGE MANAGE, V55, P270, DOI 10.2307/4003134
   Holstege DM, 1996, J AGR FOOD CHEM, V44, P2310, DOI 10.1021/jf950091x
   Keeler R. F, 1989, TOXICANTS PLANT ORIG, VI, p[133, 335]
   KINGSBURY JM, 1964, POISONOUS PLANTS US
   Knight AP, 2001, GUIDE PLANT POISONIN
   LAJIS NH, 1993, STEROIDS, V58, P387, DOI 10.1016/0039-128X(93)90043-M
   MAJAK W, 1992, PHYTOCHEMISTRY, V31, P3417, DOI 10.1016/0031-9422(92)83697-W
   Nicholson S.S., 2007, VET TOXICOLOGY BASIC, P878
   Panter KE, 2002, BIOCHEM SYST ECOL, V30, P113, DOI 10.1016/S0305-1978(01)00123-5
   Panter KE, 2001, VET HUM TOXICOL, V43, P279
   PANTER KE, 1987, VET HUM TOXICOL, V29, P45
   Pfister JA, 1999, J NAT TOXINS, V8, P81
   SMITH RA, 1991, VET HUM TOXICOL, V33, P615
   STEGELMEIER BL, 2009, RANGELANDS, V31, P5, DOI DOI 10.2111/1551-501X-31.1.5
   Stonecipher CA, 2019, TOXICON, V161, P33, DOI 10.1016/j.toxicon.2019.02.013
   Struble C., 2014, COMP OCULAR TISSUE W
   Teixeira HM, 2004, HUM EXP TOXICOL, V23, P571, DOI 10.1191/0960327104ht490oa
   Welch KD, 2008, J ANIM SCI, V86, P2761, DOI 10.2527/jas.2008-1025
   Welch KD, 2015, J ANIM SCI, V93, P4181, DOI 10.2527/jas.2015-9101
   Welch KD, 2013, TOXICON, V76, P50, DOI 10.1016/j.toxicon.2013.09.007
   Welch KD, 2012, J ANIM SCI, V90, P2394, DOI 10.2527/jas.2011-4560
   Welch KD, 2011, J ANIM SCI, V89, P1650, DOI 10.2527/jas.2010-3444
   Welch KD, 2010, AM J VET RES, V71, P487, DOI 10.2460/ajvr.71.4.487
NR 38
TC 1
Z9 1
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR
PY 2020
VL 176
BP 21
EP 29
DI 10.1016/j.toxicon.2020.01.003
PG 9
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KT2UI
UT WOS:000518870700004
PM 31965970
DA 2020-05-12
ER

PT J
AU Vlasenko, AE
   Kuznetsov, VG
   Petrova, IY
   Magarlamov, TY
AF Vlasenko, A. E.
   Kuznetsov, V. G.
   Petrova, I. Yu
   Magarlamov, T. Yu
TI Development of a polyclonal antibody-based indirect competitive ELISA
   for the determination of tetrodotoxins in marine ribbon worms (NEMERTEA)
   and its comparison with high performance liquid chromatography-tandem
   mass spectrometry
SO TOXICON
LA English
DT Article
DE Tetrodotoxin; Guanidinium toxins; Tetrodotoxin analogues; ELISA;
   Antibodies; HPLC-MS/MS
ID ANALOGS; TOXICITY; TTX
AB Tetrodotoxin (TTX) is a potent neurotoxin frequently occurring in marine organisms along with its numerous analogues. To determine the total TTX content, we developed an enzyme-linked immunosorbent assay (ELISA) technique utilizing polyclonal antibodies against TTX. The technique was tested using extracts of marine worms of the phylum Nemertea and confirmed by HPLC-MS/MS. It proved to be suitable for a preliminary assessment of the toxicity of marine organisms.
C1 [Vlasenko, A. E.; Kuznetsov, V. G.; Petrova, I. Yu; Magarlamov, T. Yu] Russian Acad Sci, Far Eastern Branch, AV Zhirmunsky Natl Sci Ctr Marine Biol, Vladivostok 690041, Russia.
   [Kuznetsov, V. G.] Far Eastern Fed Univ, Sch Nat Sci, Vladivostok 690092, Russia.
   [Magarlamov, T. Yu] Far Eastern Fed Univ, Sch Biomed, Vladivostok 690092, Russia.
RP Magarlamov, TY (reprint author), Far Eastern Fed Univ, Sch Biomed, Vladivostok 690092, Russia.
EM biotimur@yandex.ru
OI Magarlamov, Timur/0000-0003-4175-5007
FU Russian Foundation for Basic Research (RFBR)Russian Foundation for Basic
   Research (RFBR) [18-04-00808 A.]
FX The present study was supported by the Russian Foundation for Basic
   Research (RFBR). Grant no. 18-04-00808 A.
CR Abal P, 2017, TOXINS, V9, DOI 10.3390/toxins9030075
   Asakawa M, 2013, TOXINS, V5, P376, DOI 10.3390/toxins5020376
   Bane V, 2016, FOOD ADDIT CONTAM A, V33, P1468, DOI 10.1080/19440049.2016.1218070
   Bane V, 2014, TOXINS, V6, P693, DOI 10.3390/toxins6020693
   Chen XW, 2011, TOXICON, V57, P938, DOI 10.1016/j.toxicon.2011.03.011
   Dellafiora L, 2017, TOXICON, V138, P107, DOI 10.1016/j.toxicon.2017.08.008
   Eangoor P, 2017, J ANAL TOXICOL, V41, P755, DOI 10.1093/jat/bkx072
   Goransson U, 2019, TOXINS, V11, DOI 10.3390/toxins11020120
   KAUFMAN B, 1991, TOXICON, V29, P581, DOI 10.1016/0041-0101(91)90052-S
   Lago J, 2015, MAR DRUGS, V13, P6384, DOI 10.3390/md13106384
   Magarlamov TY, 2017, TOXINS, V9, DOI 10.3390/toxins9050166
   Noguchi T, 2001, J TOXICOL-TOXIN REV, V20, P1, DOI 10.1081/TXR-100103080
   Orosz F, 2002, J IMMUNOL METHODS, V270, P155, DOI 10.1016/S0022-1759(02)00295-8
   Puilingi CG, 2015, TOXINS, V7, P3436, DOI 10.3390/toxins7093436
   Shrivastava A., 2011, CHRON YOUNG SCI, V2, P21, DOI DOI 10.4103/2229-5186.79345
   Stokes AN, 2012, BIOL PROCED ONLINE, V14, DOI 10.1186/1480-9222-14-3
   Takati N, 2007, TOXICON, V50, P311, DOI 10.1016/j.toxicon.2007.04.016
   Turner AD, 2018, MAR DRUGS, V16, DOI 10.3390/md16110452
   Vlasenko AE, 2018, TOXICON, V156, P48, DOI 10.1016/j.toxicon.2018.11.006
   Wang RZ, 2014, TOXICON, V83, P22, DOI 10.1016/j.toxicon.2014.02.021
NR 20
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR
PY 2020
VL 176
BP 30
EP 33
DI 10.1016/j.toxicon.2020.01.009
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KT2UI
UT WOS:000518870700005
PM 31975690
DA 2020-05-12
ER

PT J
AU Wang, WJ
   Ji, Y
   Yang, WJ
   Zhang, CZ
   Angwa, L
   Jin, BM
   Liu, J
   Lv, M
   Ma, WJ
   Yang, J
   Wang, KW
AF Wang, Wenji
   Ji, Yi
   Yang, Wenjing
   Zhang, Chengzhi
   Angwa, Linet
   Jin, Baiming
   Liu, Juan
   Lv, Man
   Ma, Wenjing
   Yang, Jie
   Wang, Kewei
TI Inhibitors of apoptosis proteins (IAPs) are associated with T-2
   toxin-induced decreased collagen II in mouse chondrocytes in vitro
SO TOXICON
LA English
DT Article
DE T-2 toxin; Collagen II; IAPs; Chondrocytes; In vitro
ID XIAP
AB T-2 toxin is considered an unavoidable pollutant, which contaminates food crops and stockpiled cereals, impairing the health of humans and animals due to its multi-organ toxicity. Studies have shown that T-2 toxin can cause articular cartilage damage; however, the underlying molecular mechanism is still unclear. Here, we investigated the possible mechanism of the following inhibitors of apoptosis proteins (IAPs) family members: NAIP, cIAP1, cIAP2, XIAP, and Survivin, and their involvement in T-2 toxin-induced mouse chondrocyte damage. In this study, mouse articular chondrocytes were isolated and cultured in vitro, and the chondrocytes were then treated with 0, 5, 10, and 20 ng/mL T-2 toxin. Firstly, the toxic effect of T-2 toxin on chondrocytes was determined. CCK-8 assay results showed that T-2 toxin induced a dose-dependent inhibition of chondrocyte viability. Transmission electron microscopy demonstrated that T-2 toxin caused morphological changes in chondrocyte endoplasmic reticulum and an increase in mitochondrial swelling. In addition, Annexin-V-FITC/PI staining and caspase 3 protein expression showed that T-2 toxin induced an increase in the apoptotic rate of chondrocytes. Secondly, it was found that T-2 toxin cause decreased expression of cellular and secreted Collagen II. Finally, we examined the expression of NAIP, cIAP1, cIAP2, XIAP, and Survivin in chondrocytes in the presence of T-2 toxin and their relationship with decreased Collagen II. The decrease in Collagen II was negatively correlated with the expression of cIAP1, cIAP2 and positively correlated with NAIP and Survivin mRNA level. Survivin mRNA level had a positive correlation with Collagen H as shown by partial correlation analysis. This study revealed the new role of IAPs in chondrocyte injury and provides new insights and clues into the mechanism of T-2 toxin-induced chondrocyte damage.
C1 [Wang, Wenji; Ji, Yi; Yang, Wenjing; Zhang, Chengzhi; Angwa, Linet; Jin, Baiming; Lv, Man; Ma, Wenjing; Yang, Jie; Wang, Kewei] Harbin Med Univ, Ctr Endem Dis Control, Chinese Ctr Dis Control & Prevent, Key Lab Etiol & Epidemiol,Educ Bur Heilongiiang P, Harbin 150081, Peoples R China.
   [Wang, Wenji; Ji, Yi; Yang, Wenjing; Zhang, Chengzhi; Angwa, Linet; Jin, Baiming; Lv, Man; Ma, Wenjing; Yang, Jie; Wang, Kewei] Harbin Med Univ, Minist Hlth 23618504, Harbin 150081, Peoples R China.
   [Wang, Wenji; Ji, Yi; Yang, Wenjing; Jin, Baiming; Lv, Man; Ma, Wenjing; Yang, Jie; Wang, Kewei] Harbin Med Univ, China & Russia Med Res Ctr, Inst Cell Biotechnol, Harbin 150081, Peoples R China.
   [Wang, Kewei] Univ Illinois, Dept Surg, Coll Med, One Illini Dr, Peoria, IL 61605 USA.
   [Liu, Juan] Harbin Med Univ, Dept Biochem & Mol Biol, Harbin 150081, Peoples R China.
   [Jin, Baiming] Qiqihar Med Univ, Sch Publ Hlth, Qiqihar 161006, Heilongjiang, Peoples R China.
   [Angwa, Linet] Kabarak Univ, Dept Clin Med, Private Bag, Kabarak 20157, Kenya.
RP Wang, KW (reprint author), Harbin Med Univ, China & Russia Med Res Ctr, Inst Cell Biotechnol, Harbin 150081, Peoples R China.
EM keweiwang0718@163.com
FU State Administration of Foreign Experts Affairs [20172300014]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [81773367]
FX This study was supported by: (1) State Administration of Foreign Experts
   Affairs (20172300014); (2) National Natural Science Foundation of China
   (81773367).
CR Abdel-Magid Ahmed F, 2017, ACS Med Chem Lett, V8, P471, DOI 10.1021/acsmedchemlett.7b00148
   Anderton H, 2017, J INVEST DERMATOL, V137, P2371, DOI 10.1016/j.jid.2017.05.031
   Arcella D, 2017, EFSA J, V15, DOI 10.2903/j.efsa.2017.4972
   Caron MM, 2018, OSTEOARTHR CARTILAGE, V26, pS109
   Chen Jing-hong, 2006, Sichuan Da Xue Xue Bao Yi Xue Ban, V37, P583
   Chen JH, 2011, TOXICOL IN VITRO, V25, P492, DOI 10.1016/j.tiv.2010.12.001
   Conze DB, 2005, MOL CELL BIOL, V25, P3348, DOI 10.1128/MCB.25.8.3348-3356.2005
   Davoodi J, 2010, INT J BIOCHEM CELL B, V42, P958, DOI 10.1016/j.biocel.2010.02.008
   Deveraux QL, 2001, ADV CELL AGING GERON, V5, P297
   Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200
   Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795
   Fagone P, 2009, J LIPID RES, V50, pS311, DOI 10.1194/jlr.R800049-JLR200
   Gagarina V, 2008, J BIOL CHEM, V283, P648, DOI 10.1074/jbc.M704035200
   Goldring MB, 2000, ARTHRITIS RHEUM-US, V43, P1916, DOI 10.1002/1529-0131(200009)43:9<1916::AID-ANR2>3.0.CO;2-I
   Hu ZH, 2015, SCIENCE, V350, P399, DOI 10.1126/science.aac5489
   Hwang HS, 2015, INT J MOL SCI, V16, P26035, DOI 10.3390/ijms161125943
   Jia Qi, 2015, Chinese Journal of Endemiology, V34, P485
   Kim HA, 2001, J RHEUMATOL, V28, P2038
   Labbe K, 2011, IMMUNITY, V35, P897, DOI 10.1016/j.immuni.2011.10.016
   Lechler P, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471-2474-12-150
   Maier JKX, 2007, J HISTOCHEM CYTOCHEM, V55, P911, DOI 10.1369/jhc.6A7144.2007
   Makowska K, 2017, NEUROTOX RES, V31, P136, DOI 10.1007/s12640-016-9675-8
   Morcia C, 2016, TOXINS, V8, DOI 10.3390/toxins8080247
   Nagata S, 2018, ANNU REV IMMUNOL, V36, P489, DOI 10.1146/annurev-immunol-042617-053010
   Sikoparija B, 2017, AEROBIOLOGIA, V33, P191, DOI 10.1007/s10453-016-9461-3
   Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125
   Suetens C, 2001, INT ORTHOP, V25, P180, DOI 10.1007/s002640100247
   Wang KW, 2013, CELL SIGNAL, V25, P1970, DOI 10.1016/j.cellsig.2013.06.003
   Wang Y, 2013, FOOD ADDIT CONTAM B, V6, P116, DOI 10.1080/19393210.2013.764506
   Xu J, 2015, MANUF REV, V2, DOI 10.1051/mfreview/2015003
   Yang X, 2019, ENVIRON POLLUT, V251, P372, DOI 10.1016/j.envpol.2019.05.023
   Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874
   Zamli Z, 2011, INT J RHEUM DIS, V14, P159, DOI 10.1111/j.1756-185X.2011.01618.x
NR 33
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR
PY 2020
VL 176
BP 34
EP 43
DI 10.1016/j.toxicon.2020.01.002
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KT2UI
UT WOS:000518870700006
PM 32103793
DA 2020-05-12
ER

PT J
AU Tsui, JKC
AF Tsui, Joseph K. C.
TI Strategy for starting BoNT treatment (written consent, initial dose and
   subsequent doses, interval, follow-up)
SO TOXICON
LA English
DT Article
ID BOTULINUM TOXIN; INJECTION
AB Botulinum toxin (BoNT) has become a therapeutic agent for a large variety of medical conditions. It is a symptomatic treatment and in most cases requires repeat injections at regular intervals. The first session is crucial in establishing rapport between the physician and the patient to ensure a continuity of treatment on a long term basis. Since the clinical practice varies widely across different therapeutic indications and in different clinical settings around the world, a general set of strategic approach is difficult to be formulated. This article will focus on the important issues when starting BoNT treatment in patients with cervical dystonia (CD).
C1 [Tsui, Joseph K. C.] Univ British Columbia, UBC Movement Disorders Clin, Vancouver, BC, Canada.
RP Tsui, JKC (reprint author), Univ British Columbia, UBC Movement Disorders Clin, Vancouver, BC, Canada.
EM jtsui@mail.ubc.ca
CR Bellows S, 2019, TOXINS, V11, DOI 10.3390/toxins11090491
   BRIN MF, 1987, MOVEMENT DISORD, V2, P237, DOI 10.1002/mds.870020402
   Charles PD, 2016, PAIN PRACT, V16, P1073, DOI 10.1111/papr.12408
   JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437
   Marciniec M., 2019, REV NEUROSCI, V27
   SCOTT AB, 1985, ARCH OPHTHALMOL-CHIC, V103, P347
   SCOTT AB, 1980, J PEDIAT OPHTH STRAB, V17, P21, DOI 10.3928/0191-3913-19800101-06
   SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407
   Tinazzi M, 2012, J NEUROL, V259, P2060, DOI 10.1007/s00415-012-6454-1
   TSUI JKC, 1986, LANCET, V2, P245
NR 10
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR
PY 2020
VL 176
BP 44
EP 46
DI 10.1016/j.toxicon.2020.01.014
PG 3
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KT2UI
UT WOS:000518870700007
PM 32103794
OA Bronze
DA 2020-05-12
ER

PT J
AU Gao, YN
   Lu, J
   Orr, PT
   Chuang, A
   Franklin, HM
   Burford, MA
AF Gao, Yunni
   Lu, Jing
   Orr, Philip T.
   Chuang, Ann
   Franklin, Hannah M.
   Burford, Michele A.
TI Enhanced resistance of co-existing toxigenic and non-toxigenic
   Microcystis aeruginosa to pyrogallol compared with monostrains
SO TOXICON
LA English
DT Article
DE Co-existing strains; Microcystis aeruginosa; Pyrogallol; Direct
   co-culture; Dialysis co-culture
ID FRESH-WATER; CYANOBACTERIUM; GROWTH; RESPONSES; TOXICITY; ACID;
   COMPETITION; INHIBITION; STRAINS; BLOOMS
AB Cyanobacteria species are sensitive to many plant allelochemicals, such as pyrogallol. However, little attention has been paid to the relative effects of these xenobiotics on co-occurring toxigenic and non-toxigenic cyanobacterial strains, despite their co-existence in blooms. Hence, the responses of one toxigenic (TS2) and two nontoxigenic (NS1, NS2) Microcystis aeruginosa strains to pyrogallol were tested under three conditions: monoculture and co-cultured either directly or separately by dialysis membrane. The study showed that the inhibitory effects of pyrogallol on the growth and photosynthetic yield (Fv/Fm) of either toxigenic or non-toxigenic M. aeruginosa strains were lower in direct and dialysis co-culture conditions than those in mono-culture conditions. This result indicated that chemical-mediated reciprocal effects occur between the co-existing toxigenic and non-toxigenic strains. The toxigenic M. aeruginosa strain was more sensitive to pyrogallol than the non-toxigenic strains in both mono- and co-culture systems, though whether this outcome is due to the former's toxigenic status is unclear. Intracellular microcystin-LR (MC-LR) concentrations of the toxigenic strain decreased after pyrogallol addition in both mono- and co-culture systems, whereas extracellular MC-LR concentrations increased. This finding may reflect the cell damage of M. aeruginosa because of the pyrogallol. At the same initial number of cells, the extracellular MC-LR concentration released from the same amount of TS2 cells in mono-culture was slightly higher than that in dialysis co-culture conditions. Overall, this study shows that plant allelochemicals may have the potential to reduce bloom toxicity by reducing the proportion of toxigenic cyanobacterial strains, and the effects of co-existing strains must be considered when assessing the effects of plant allelochemicals on target strains.
C1 [Gao, Yunni] Henan Normal Univ, Coll Fisheries, Engn Technol Res Ctr Henan Prov Aquat Anim Cultiv, Engn Lab Henan Prov Aquat Anim Dis Control, Xinxiang 453007, Henan, Peoples R China.
   [Lu, Jing; Orr, Philip T.; Chuang, Ann; Franklin, Hannah M.; Burford, Michele A.] Griffith Univ, Australian Rivers Inst, 170 Kessels Rd, Nathan, Qld 4111, Australia.
RP Burford, MA (reprint author), Griffith Univ, Australian Rivers Inst, 170 Kessels Rd, Nathan, Qld 4111, Australia.; Gao, YN (reprint author), Henan Normal Univ, Coll Fisheries, 46 East Construct Rd, Xinxiang 453007, Henan, Peoples R China.
EM gaoyn@htu.cn; M.Burford@griffith.edu.au
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31700405]; Major Science and Technology Program in
   Henan Province [182102110196]; Breeding Project of Henan Normal
   University [HNU20180073]; Australian Rivers Institute at Griffith
   University; Australian Research CouncilAustralian Research Council
   [LP120100284]
FX This work was supported by National Natural Science Foundation of China
   (31700405), Major Science and Technology Program in Henan Province
   (182102110196), Breeding Project of Henan Normal University
   (HNU20180073), and the Australian Rivers Institute at Griffith
   University. Burford was supported by Australian Research Council grant
   LP120100284. We also appreciate the kind suggestions of Dr. Amanda
   Neilen and Dr. Man Xiao for experimental design and manuscript writing.
CR Alexova R, 2016, ENVIRON MICROBIOL, V18, P401, DOI 10.1111/1462-2920.12958
   Bates D., 2013, R PACKAGE VERSION 0
   Cheung MY, 2013, J MICROBIOL, V51, P1, DOI 10.1007/s12275-013-2549-3
   Davis TW, 2009, HARMFUL ALGAE, V8, P715, DOI 10.1016/j.hal.2009.02.004
   Dunker S, 2017, MICROB ECOL, V74, P22, DOI 10.1007/s00248-016-0927-1
   Dziga D., 2007, ENVIRON TOXICOL, V24, P296
   Gao YN, 2017, CHEMOSPHERE, V174, P732, DOI 10.1016/j.chemosphere.2017.01.102
   Harke MJ, 2016, HARMFUL ALGAE, V54, P4, DOI 10.1016/j.hal.2015.12.007
   JONES GJ, 1994, WATER RES, V28, P871, DOI 10.1016/0043-1354(94)90093-0
   Kardinaal WEA, 2007, APPL ENVIRON MICROB, V73, P2939, DOI 10.1128/AEM.02892-06
   Korner S, 2002, J PHYCOL, V38, P862, DOI 10.1046/j.1529-8817.2002.t01-1-02001.x
   Le Rouzic B, 2016, ECOL ENG, V97, P74, DOI 10.1016/j.ecoleng.2016.07.021
   Lei LM, 2015, ECOTOXICOLOGY, V24, P1411, DOI 10.1007/s10646-015-1456-2
   Liu BY, 2007, B ENVIRON CONTAM TOX, V78, P499, DOI 10.1007/s00128-007-9096-8
   Liu Y, 2016, ENVIRON POLLUT, V219, P399, DOI 10.1016/j.envpol.2016.05.021
   Lu ZY, 2017, ALGAL RES, V21, P148, DOI 10.1016/j.algal.2016.11.007
   Lu ZY, 2016, ECOTOX ENVIRON SAFE, V132, P413, DOI 10.1016/j.ecoenv.2016.06.039
   Nakai S, 2000, WATER RES, V34, P3026, DOI 10.1016/S0043-1354(00)00039-7
   Orr PT, 2018, J OCEANOL LIMNOL, V36, P1063, DOI 10.1007/s00343-019-7188-z
   Orr PT, 1998, LIMNOL OCEANOGR, V43, P1604, DOI 10.4319/lo.1998.43.7.1604
   Paerl HW, 2016, HARMFUL ALGAE, V54, P213, DOI 10.1016/j.hal.2015.09.009
   Qian HF, 2010, AQUAT TOXICOL, V99, P405, DOI 10.1016/j.aquatox.2010.05.018
   R Development Core Team R, 2011, R LANG ENV STAT COMP
   Shao JH, 2013, J ENVIRON MANAGE, V125, P149, DOI 10.1016/j.jenvman.2013.04.001
   Shao JH, 2009, CHEMOSPHERE, V75, P924, DOI 10.1016/j.chemosphere.2009.01.021
   Song H, 2017, ISME J, V11, P1865, DOI 10.1038/ismej.2017.45
   Suominen S, 2017, AQUAT ECOL, V51, P117, DOI 10.1007/s10452-016-9603-2
   Svanys A, 2016, FEMS MICROBIOL LETT, V363, DOI 10.1093/femsle/fnv227
   Techer D, 2016, SCI TOTAL ENVIRON, V547, P157, DOI 10.1016/j.scitotenv.2015.12.164
   THOMPSON AS, 1988, CULTURE COLLECTION A
   Van de Waal DB, 2011, ISME J, V5, P1438, DOI 10.1038/ismej.2011.28
   Wang J, 2013, ALLELOPATHY J, V31, P199
   Wang J, 2016, ECOTOX ENVIRON SAFE, V134, P273, DOI 10.1016/j.ecoenv.2016.09.010
   Wu ZX, 2013, ECOTOXICOLOGY, V22, P271, DOI 10.1007/s10646-012-1023-z
   Xiao M, 2018, BIOL REV, V93, P1399, DOI 10.1111/brv.12401
   Xiao M, 2017, HARMFUL ALGAE, V62, P84, DOI 10.1016/j.hal.2016.12.008
   Yu L, 2015, J ENVIRON SCI, V27, P251, DOI 10.1016/j.jes.2014.05.047
   Zohary T, 2016, INLAND WATERS, V6, P131, DOI 10.5268/IW-6.2.965
NR 38
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR
PY 2020
VL 176
BP 47
EP 54
DI 10.1016/j.toxicon.2020.01.013
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KT2UI
UT WOS:000518870700008
PM 32103795
DA 2020-05-12
ER

PT J
AU Welch, KD
   Stonecipher, CA
   Lee, ST
   Cook, D
AF Welch, K. D.
   Stonecipher, C. A.
   Lee, S. T.
   Cook, D.
TI The acute toxicity of water hemlock (Cicuta douglasii) in a goat model
SO TOXICON
LA English
DT Article
DE Water hemlock; Cicuta; Cicutoxin; Polyacetylene; Goat; Caprine
ID TOXICOSES; ALCOHOLS; CATTLE; TOXINS; CONIUM; SHEEP
AB Water hemlock (Cicuta douglasii) is one of the most toxic plants to livestock and humans. Little is known regarding the amount of plant required to cause death. The objective of this study was to determine a lethal dose of water hemlock in a goat model. Plants were dosed to goats via oral gavage of freeze-dried ground plant material. The results from this study suggest that 1-2 fresh tubers would be lethal to goats.
C1 [Welch, K. D.; Stonecipher, C. A.; Lee, S. T.; Cook, D.] ARS, USDA, Poisonous Plant Res Lab, 1150 East 1400 North, Logan, UT 84341 USA.
RP Welch, KD (reprint author), ARS, USDA, Poisonous Plant Res Lab, 1150 East 1400 North, Logan, UT 84341 USA.
EM Kevin.Welch@usda.gov
CR ANET EFLJ, 1953, J CHEM SOC, P309, DOI 10.1039/jr9530000309
   APPLEFELD JJ, 1979, JACEP-J AM COLL EMER, V8, P401, DOI 10.1016/S0361-1124(79)80404-9
   Berger M, 2018, CHEM COMMUN, V54, P2008, DOI 10.1039/c7cc09801d
   Burrows G.E., 2013, TOXIC PLANTS N AM
   Davis TZ, 2014, J AGR FOOD CHEM, V62, P7393, DOI 10.1021/jf500861p
   Fleming C.E., 1920, POISON PARSNIP WATER
   Frank BS, 1995, WESTERN J MED, V163, P573
   Gardner D., 1993, COMP BLOOD PLASMA AL
   GOEGER DE, 1982, AM J VET RES, V43, P252
   Green BT, 2015, TOXICON, V108, P11, DOI 10.1016/j.toxicon.2015.09.015
   GRUNDY HF, 1956, BRIT J PHARM CHEMOTH, V11, P225, DOI 10.1111/j.1476-5381.1956.tb01058.x
   Heath KB, 2001, VET HUM TOXICOL, V43, P35
   KINGSBURY JM, 1964, POISONOUS PLANTS US
   LANDERS D, 1985, WESTERN J MED, V142, P637
   Lee ST, 2020, TOXICON, V176, P21, DOI 10.1016/j.toxicon.2020.01.003
   Lee ST, 2019, J AGR FOOD CHEM, V67, P43, DOI 10.1021/acs.jafc.8b05673
   MITCHELL MI, 1978, CLIN TOXICOL, V12, P417, DOI 10.3109/15563657809150012
   MULLIGAN GA, 1980, CAN J BOT, V58, P1755, DOI 10.1139/b80-204
   NELSON RB, 1978, P W PHARMACOL SOC, V21, P137
   Ohta T, 1999, TETRAHEDRON, V55, P12087, DOI 10.1016/S0040-4020(99)00706-1
   PANTER KE, 1988, J ANIM SCI, V66, P2407
   Panter KE, 1996, J VET DIAGN INVEST, V8, P474, DOI 10.1177/104063879600800413
   Panter KE, 2011, TOXICON, V57, P157, DOI 10.1016/j.toxicon.2010.11.009
   Schep LJ, 2009, CLIN TOXICOL, V47, P270, DOI 10.1080/15563650902904332
   SMITH RA, 1987, VET HUM TOXICOL, V29, P240
   STARREVELD E, 1975, NEUROLOGY, V25, P730, DOI 10.1212/WNL.25.8.730
   Stonecipher CA, 2020, BIOCHEM SYST ECOL, V89, DOI 10.1016/j.bse.2020.104012
   Stonecipher CA, 2019, TOXICON, V161, P33, DOI 10.1016/j.toxicon.2019.02.013
   Uwai K, 1999, TETRAHEDRON, V55, P9469, DOI 10.1016/S0040-4020(99)00520-7
   Uwai K, 2000, J MED CHEM, V43, P4508, DOI 10.1021/jm000185k
   Uwai K, 2001, BRAIN RES, V889, P174, DOI 10.1016/S0006-8993(00)03130-9
   Welch KD, 2016, TOXICON, V119, P270, DOI 10.1016/j.toxicon.2016.06.020
   Welch KD, 2012, J ANIM SCI, V90, P2394, DOI 10.2527/jas.2011-4560
   WITTSTOCK U, 1995, PLANTA MED, V61, P439, DOI 10.1055/s-2006-958132
NR 34
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR
PY 2020
VL 176
BP 55
EP 58
DI 10.1016/j.toxicon.2020.02.010
PG 4
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KT2UI
UT WOS:000518870700009
PM 32103796
DA 2020-05-12
ER

PT J
AU Lagarto, A
   Bueno, V
   Perez, MR
   Rodriguez, CC
   Guevara, I
   Valdes, O
   Bellma, A
   Gabilondo, T
   Padron, AS
AF Lagarto, Alicia
   Bueno, Viviana
   Perez, Maria R.
   Rodriguez, Caridad C.
   Guevara, Irania
   Valdes, Odalys
   Bellma, Addis
   Gabilondo, Tatiana
   Padron, Alejandro S.
TI Safety evaluation of the venom from scorpion Rhopalurus junceus:
   Assessment of oral short term, subchronic toxicity and teratogenic
   effect
SO TOXICON
LA English
DT Article
DE Rhopalurus junceus; Scorpion venom; Oral toxicity; Teratogenic;
   Toxicological profile
ID NITRIC-OXIDE; INVOLVEMENT; DELIVERY
AB Rhopalurus junceus is the most common scorpion in Cuba and the venom is often used as a natural product for anti-cancer therapy. Despite this, no study has been published concerning its toxicological profile. The aim of the study was characterizing the short-term, subchronic toxicity and the teratogenic potential of Rhopalurus junceus scorpion venom by oral route in mice. Short-term oral toxicity was test in both sexes NMRI mice that received 100 mg/kg/day of scorpion venom extract for 28 days. For the subchronic study, mice were administered with three doses (0.1, 10, and 100 mg/kg) by oral route for 90 days. Teratogenic potential was tested in pregnant mice administered from day 6-15 post conception. Significant differences were observed in body weight and food intake of animal treated for short-term and subchronic assays. Variations in serum urea and cholesterol were observed after 90 days oral treatment. Spontaneous findings not related to the treatment were reveal in histology evaluation. Exposure in pregnant mice did not produce maternal toxicity. Signs of embryo-fetal toxicity were not observed. The current study provides evidence that exposure to low or moderate dose of Rhopalurus junceus scorpion venom by oral route did not affect health of animals and has low impact on reproductive physiology.
C1 [Lagarto, Alicia; Bueno, Viviana; Valdes, Odalys; Bellma, Addis; Gabilondo, Tatiana; Padron, Alejandro S.] CIDEM, Drug Res & Dev Ctr, Ave 26 N 1605 Entre Ave Boyeros & Calzada Puentes, Havana, Cuba.
   [Perez, Maria R.; Rodriguez, Caridad C.; Guevara, Irania] LABIOFAM, Labs Biopharmaceut & Chemistries Prod, Ave Independencia Km 16 1-2 Mulgoba, Havana, Cuba.
RP Lagarto, A (reprint author), Ave 26 N 1605 Entre Ave Boyeros & Calzada Puentes, Havana, Cuba.
EM alicialagarto@yahoo.com; alicialp@infomed.sld.cu
CR Aleman CL, 2000, LAB ANIM-UK, V34, P379, DOI 10.1258/002367700780387741
   Bucaretchi F, 1999, BRAZ J MED BIOL RES, V32, P431, DOI 10.1590/S0100-879X1999000400009
   Burdan Franciszek, 2005, Folia Morphol (Warsz), V64, P1
   CHOU CC, 1982, ANNU REV PHYSIOL, V44, P29, DOI 10.1146/annurev.ph.44.030182.000333
   Claudio L, 1999, AM J IND MED, V35, P554, DOI 10.1002/(SICI)1097-0274(199906)35:6<554::AID-AJIM2>3.3.CO;2-O
   Dorce ALC, 2009, REPROD TOXICOL, V28, P365, DOI 10.1016/j.reprotox.2009.04.008
   Cruttenden K, 2008, REPROD TOXICOL, V25, P497, DOI 10.1016/j.reprotox.2008.04.011
   Diaz-Garcia A, 2019, IRAN J BASIC MED SCI, V22, P759, DOI 10.22038/ijbms.2019.33308.7956
   Diaz-Garcia Alexis, 2019, Iranian Biomedical Journal, V23, P287, DOI 10.29252/.23.4.287
   Diaz-Garcia Alexis, 2017, J Venom Res, V8, P9
   Diaz-Garcia Alexis, 2015, J Venom Res, V6, P11
   Diaz-Garcia Alexis, 2013, J Venom Res, V4, P5
   Ding J, 2014, EXP BIOL MED, V239, P387, DOI 10.1177/1535370213513991
   Garcia-Gomez BI, 2011, TOXICON, V58, P18, DOI 10.1016/j.toxicon.2011.04.011
   Grupo Medico LifEscozul, 2018, ESC CON RES OBT TIP
   GWEE MCE, 1995, TOXICON, V33, P1141, DOI 10.1016/0041-0101(95)00064-S
   ICH, 2005, DET TOX REPR MED PRO, V55
   Kievit FM, 2010, ACS NANO, V4, P4587, DOI 10.1021/nn1008512
   Lagarto A, 2013, EXP TOXICOL PATHOL, V65, P49, DOI 10.1016/j.etp.2011.05.009
   MCDONNELL R, 2009, REV CUB INVEST BIOME, V28, DOI DOI 10.1145/1531326.1531361
   National Research Council (2011), 2011, GUIDE CARE USE LAB A
   OECD, 1998, TEST NO 408 REP DOS
   Organization for Economic Cooperation and Development, 2008, TEST NO 407 REP DOS
   Peckham J.C., 2002, HDB TOXICOLOGY, P668
   Poch Mulgado E., 1999, ANAL GUANTANAMO
   Barao AAS, 2008, BRAIN RES BULL, V76, P499, DOI 10.1016/j.brainresbull.2008.02.033
   Shah V, 2004, GASTROENTEROLOGY, V126, P903, DOI 10.1053/j.gastro.2003.11.046
   Sofer S, 1997, CRIT CARE MED, V25, P834, DOI 10.1097/00003246-199705000-00020
   Solecki Roland, 2003, Reproductive Toxicology, V17, P625, DOI 10.1016/S0890-6238(03)00092-3
   Song XF, 2012, EXP THER MED, V4, P146, DOI 10.3892/etm.2012.548
   Teixeira CE, 1998, BRIT J PHARMACOL, V123, P435, DOI 10.1038/sj.bjp.0701623
   Yglesias-Rivera A., 2018, ANN MICROBIOL IMMUNO, V1, P1007
   Yglesias-Rivera A, 2019, J PHARM PHARMACOGN R, V7, P67
NR 33
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR
PY 2020
VL 176
BP 59
EP 66
DI 10.1016/j.toxicon.2020.02.002
PG 8
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KT2UI
UT WOS:000518870700010
PM 32057833
DA 2020-05-12
ER

PT J
AU Webb, R
   Wright, PM
   Brown, JL
   Skerry, JC
   Guernieri, RL
   Smith, TJ
   Stawicki, C
   Smith, LA
AF Webb, Robert
   Wright, Patrick M.
   Brown, Jennifer L.
   Skerry, Janet C.
   Guernieri, Rebecca L.
   Smith, Theresa J.
   Stawicki, Christopher
   Smith, Leonard A.
TI Potency and stability of a trivalent, catalytically inactive vaccine
   against botulinum neurotoxin serotypes C, E and F (triCEF)
SO TOXICON
LA English
DT Article
DE Botulinum neurotoxins; BoNTs; Vaccine; Catalytically inactive botulinum
   neurotoxin; holoproteins (ciBoNT HPs); Polyvalent vaccine; Botulism
ID IMMUNE-RESPONSE; FRAGMENT; GENE; A1
AB Botulism is an acute neuroparalytic affliction of the motor and autonomic neurons caused by the toxins produced from Clostridium botulinum and related bacterial strains. The botulinum neurotoxins, or BoNTs, consist of a phylogenetically diverse group of highly potent protein toxins. Current medical interventions for confirmed cases of botulism are limited to immediate administration of antitoxins and respiratory support. There is currently no licensed vaccine against botulism in the United States. The most widely distributed botulism vaccine was a pentavalent BoNT toxoid (PBT) against serotypes A-E administered until 2011 under an investigational new drug license. A binary vaccine composed of the recombinant, non-toxic, receptor binding domains (RBD) of serotypes/Al and/B1 has completed a phase II clinical trial, but has yet to attain full licensure. We have previously published data demonstrating catalytically inactive, full length botulinum neurotoxin holoproteins (ciBoNT HPs) against serotypes/A1,/B1,/C1,/E1 and/F1 provide equivalent or superior potency against parental and dissimilar subtype toxins as compared the RBD vaccines. Here we describe the consistent potencies of the three independent lots each of ciBoNT/C1,/E1, and/F1 HPs against substantial monovalent challenges of the parental toxins. We also present data that a trivalent formulation of ciBoNT/C1,/E1 and/F1 (triCEF) maintains potency against both monovalent and polyvalent toxin challenges when stored as an adjuvanted vaccine at 4-8 degrees C for up to 2 years.
C1 [Webb, Robert; Stawicki, Christopher] US Army, Med Res Inst Infect Dis, Frederick, MD 21702 USA.
   [Wright, Patrick M.; Brown, Jennifer L.; Skerry, Janet C.] Cherokee Nat Assurances, Ft Detrick, MD USA.
   [Guernieri, Rebecca L.] USAMRIID, Keaki Technol LLC, Ft Detrick, MD USA.
   [Smith, Theresa J.] USAMRIID, Oak Ridge Inst Sci & Educ, Ft Detrick, MD USA.
   [Smith, Leonard A.] USAMRIID, Off Chief Scientist, Ft Detrick, MD USA.
RP Webb, R (reprint author), US Army, Med Res Inst Infect Dis, Frederick, MD 21702 USA.
EM robert.p.webb6.civ@mail.mil
FU Joint Science and Technology Office for Chemical-Biological Defense,
   Defense Threat Reduction AgencyUnited States Department of
   DefenseDefense Threat Reduction Agency [CB 2041]
FX The research described herein was sponsored by the Joint Science and
   Technology Office for Chemical-Biological Defense, Defense Threat
   Reduction Agency under project #CB 2041. Opinions, interpretations,
   conclusions, and recommendations are those of the author and are not
   necessarily endorsed by the U.S. Army.
CR Binz T, 2010, TOXINS, V2, P665, DOI 10.3390/toxins2040665
   Boles J, 2006, TOXICON, V47, P877, DOI 10.1016/j.toxicon.2006.02.013
   Brunt J, 2018, FEBS LETT, V592, P310, DOI 10.1002/1873-3468.12969
   CLAYTON MA, 1995, INFECT IMMUN, V63, P2738, DOI 10.1128/IAI.63.7.2738-2742.1995
   Contreras E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10732-w
   Hatheway C.L., 1994, THERAPY BOTULINUM TO, P93
   Johnson E.A., 2005, TOPLEY WILSONS MICRO, V8, P1035
   Kiyatkin N, 1997, INFECT IMMUN, V65, P4586, DOI 10.1128/IAI.65.11.4586-4591.1997
   Lam KH, 2015, PROG BIOPHYS MOL BIO, V117, P225, DOI 10.1016/j.pbiomolbio.2015.02.004
   Mansfield MJ, 2015, FEBS LETT, V589, P342, DOI 10.1016/j.febslet.2014.12.018
   MOREFIELD GL, 2008, J IMMUNE BASED THERA, V6, P1
   Peck KW., 2017, HIST PERSPECTIVES GU, V9, DOI [10.3390/to'dns9010038, DOI 10.3390/TO'DNS9010038]
   Pier CL, 2008, INFECT IMMUN, V76, P437, DOI 10.1128/IAI.00843-07
   Pirazzini M, 2018, TOXICON, V147, P32, DOI 10.1016/j.toxicon.2017.10.028
   Przedpelski A, 2018, VACCINE, V36, P827, DOI 10.1016/j.vaccine.2017.12.064
   Przedpelski A, 2013, INFECT IMMUN, V81, P2638, DOI 10.1128/IAI.00382-13
   Rummel A, 2015, TOXICON, V107, P9, DOI 10.1016/j.toxicon.2015.09.009
   Rummel A, 2009, J NEUROCHEM, V110, P1942, DOI 10.1111/j.1471-4159.2009.06298.x
   Rusnak JM, 2009, HUM VACCINES, V5, P794, DOI 10.4161/hv.9420
   Sanford DC, 2010, CLIN VACCINE IMMUNOL, V17, P1293, DOI 10.1128/CVI.00080-10
   Shearer JD, 2012, VACCINE, V30, P1917, DOI 10.1016/j.vaccine.2012.01.035
   Smith LA, 2009, VACCINE, V27, pD33, DOI 10.1016/j.vaccine.2009.08.059
   Webb RP, 2017, TOXINS, V9, DOI 10.3390/toxins9090269
   Webb RP, 2013, EXPERT REV VACCINES, V12, P481, DOI [10.1586/erv.13.37, 10.1586/ERV.13.37]
   Webb RP, 2009, VACCINE, V27, P4490, DOI 10.1016/j.vaccine.2009.05.030
   2011, MMWR MORBID MORTAL W, V60, P1454
NR 26
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0041-0101
J9 TOXICON
JI Toxicon
PD MAR
PY 2020
VL 176
BP 67
EP 76
DI 10.1016/j.toxicon.2020.02.001
PG 10
WC Pharmacology & Pharmacy; Toxicology
SC Pharmacology & Pharmacy; Toxicology
GA KT2UI
UT WOS:000518870700011
PM 32032587
OA Bronze
DA 2020-05-12
ER

PT J
AU Almeida, FA
   Albuquerque, ACA
   Bassetto, CC
   Starling, RZC
   Lins, JGG
   Amarante, AFT
AF Almeida, Fabiana A.
   Albuquerque, Ana Claudia A.
   Bassetto, Cesar C.
   Starling, Renan Z. C.
   Lins, Jose Gabriel G.
   Amarante, Alessandro F. T.
TI Long spelling periods are required for pasture to become free of
   contamination by infective larvae of Haemonchus contortus in a humid
   subtropical climate of Sao Paulo state, Brazil
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Environment; Gastrointestinal nematodes; Pasture decontamination; Sheep
ID FREE-LIVING STAGES; SHEEP INTESTINAL PARASITES; 3RD STAGE LARVAE;
   TRICHOSTRONGYLUS-COLUBRIFORMIS; MOISTURE REQUIREMENTS; NORTH-ISLAND;
   MIGRATION; DYNAMICS; SURVIVAL; EPIDEMIOLOGY
AB The objective of this trial was to evaluate the period of spelling necessary for a pasture to become free of contamination by infective larvae of gastrointestinal nematodes (GIN) of sheep, in different seasons of the year, as well as to determine when the greatest pasture contamination occurs and how long it lasts. An area was divided into four paddocks, one for each season (spring, summer, autumn, and winter). In order to contaminate the paddocks with free living stages of GIN, eight ewes, naturally infected, grazed on each paddock for 14 consecutive days, starting on the following dates: autumn, on April 4, 2017; winter, on July 4, 2017; spring, on September 26, 2017; summer, on January 2, 2019. At the beginning and end of the grazing period, faecal samples were taken directly from the rectums of the ewes to count eggs per gram of faeces (EPG) and for faecal cultures. Every 14 days pasture samples were collected to assess the number of infective larvae (L3) per kilogram of dry matter. At the end of the 14 day ewe grazing period, 21 stakes were placed where there were faeces on the paddock. Subsequently, every 14 days, the faeces located at three of the stakes were collected and the L3 were recovered. After the exit of the ewes, monthly, two tracer lambs, free of helminth infection, were allocated into the paddock for 14 days. M the end of this period they were housed in covered stalls for 28 days. Faeces from the lambs were collected for individual EPG counting and faecal culture at 21 and 28 days after grazing. Infective larvae recuperation was observed from faeces and pasture in all seasons. In the autumn, spring, and summer, high EPG counts were observed in the first tracer lambs (8521, 4800, and 8064 EPG, respectively), while in winter, high infection (14132 EPG) of the animals was observed only from the second pair of tracer lambs. For a pasture to become "clean", 322 days, 350 days, 294 days, and 182 days following contamination were necessary, respectively, in the autumn, winter, spring, and summer. In autumn, spring, and summer, massive contamination of the pasture with L3 occurred soon after an area had been grazed by infected sheep, while in winter this took a little longer. The contamination persisted, approximately, from a minimum of six months post contamination in summer to up to almost one year post contamination in winter.
C1 [Almeida, Fabiana A.; Bassetto, Cesar C.; Amarante, Alessandro F. T.] Univ Estadual Paulista, Inst Biociencias, UNESP, Botucatu, SP, Brazil.
   [Albuquerque, Ana Claudia A.; Starling, Renan Z. C.; Lins, Jose Gabriel G.] Univ Estadual Paulista, Fac Med Vet & Zootecnia, UNESP, Botucatu, SP, Brazil.
RP Almeida, FA (reprint author), Univ Estadual Paulista, Dept Bioestat Biol Vegetal Parasitol & Zool, Inst Biociencias, BR-18618000 Botucatu, SP, Brazil.
EM faalvesalmeida@yahoo.com.br
RI Lins, Jose/U-6773-2017
OI Lins, Jose/0000-0002-0810-1434
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2015/25718-7, 2015/00221-2]; National
   Council for Scientific and Technological Development (CNPq)National
   Council for Scientific and Technological Development (CNPq)
   [305187/2017-1]
FX The authors would like to thank Mr. Francisco Fernandes for their
   support in carrying out this research. Fabiana A. Almeida and Cesar C.
   Bassetto received a scholarship from Sao Paulo Research Foundation
   (FAPESP), grant #2015/25718-7 and grant #2015/00221-2, respectively; and
   Alessandro F. T. Amarante is in receipt of a fellowship from National
   Council for Scientific and Technological Development (CNPq) (grant
   #305187/2017-1).
CR de Albuquerque ACA, 2017, VET PARASITOL, V246, P112, DOI 10.1016/j.vetpar.2017.09.010
   Almeida FA, 2018, SMALL RUMINANT RES, V166, P66, DOI 10.1016/j.smallrumres.2018.07.009
   Alvares CA, 2013, METEOROL Z, V22, P711, DOI 10.1127/0941-2948/2013/0507
   Amarante AFT, 2007, PESQUISA VET BRASIL, V27, P43, DOI 10.1590/S0100-736X2007000100008
   Amarante AFT, 2014, SMALL RUMINANT RES, V118, P56, DOI 10.1016/j.smallrumres.2013.12.016
   Besier RB, 2016, ADV PARASIT, V93, P181, DOI 10.1016/bs.apar.2016.02.024
   Besier RB, 2016, ADV PARASIT, V93, P95, DOI 10.1016/bs.apar.2016.02.022
   Carneiro RD, 2008, ARQ BRAS MED VET ZOO, V60, P864, DOI 10.1590/S0102-09352008000400014
   Chaudary FR, 2008, TROP ANIM HEALTH PRO, V40, P85, DOI 10.1007/s11250-007-9037-x
   Colvin AF, 2008, VET PARASITOL, V153, P108, DOI 10.1016/j.vetpar.2008.01.014
   de Almeida FA, 2018, REV BRAS PARASITOL V, V27, P280, DOI [10.1590/S1984-296120180044, 10.1590/s1984-296120180044]
   Escobedo JF, 2011, RENEW ENERG, V36, P169, DOI 10.1016/j.renene.2010.06.018
   HSU CK, 1977, AM J VET RES, V38, P1115
   KRECEK RC, 1991, VET PARASITOL, V40, P87, DOI 10.1016/0304-4017(91)90085-A
   Leathwick DM, 2013, NEW ZEAL VET J, V61, P32, DOI 10.1080/00480169.2012.712092
   Lettini SE, 2006, J PARASITOL, V92, P1002, DOI 10.1645/GE-784R.1
   Molento MB, 2016, LIVEST SCI, V192, P48, DOI 10.1016/j.livsci.2016.08.013
   Niezen JH, 1998, VET PARASITOL, V78, P37, DOI 10.1016/S0304-4017(98)00119-8
   O'Connor LJ, 2007, VET PARASITOL, V150, P128, DOI 10.1016/j.vetpar.2007.07.021
   O'Connor LJ, 2007, VET PARASITOL, V146, P90, DOI 10.1016/j.vetpar.2007.02.002
   Reynecke DP, 2011, NEW ZEAL VET J, V59, P287, DOI 10.1080/00480169.2011.610280
   Piza MLSD, 2019, SEMIN-CIENC AGRAR, V40, P713, DOI 10.5433/1679-0359.2019v40n2p713
   Santos MC, 2012, VET PARASITOL, V188, P277, DOI 10.1016/j.vetpar.2012.03.056
   Silva BF, 2008, VET PARASITOL, V158, P85, DOI 10.1016/j.vetpar.2008.08.009
   TAYLOR E. L., 1939, PARASITOLOGY, V31, P473, DOI 10.1017/S0031182000013007
   Tontini JF, 2019, SMALL RUMINANT RES, V174, P62, DOI 10.1016/j.smallrumres.2019.03.013
   Ueno H., 1998, MANUAL DIAGNOSTICO H
   van Dijk J, 2011, PARASITOLOGY, V138, P780, DOI 10.1017/S0031182011000308
   Waghorn TS, 2011, NEW ZEAL VET J, V59, P279, DOI 10.1080/00480169.2011.610279
   Wang T, 2018, AGR ECOSYST ENVIRON, V265, P31, DOI 10.1016/j.agee.2018.05.029
   Wang T, 2014, VET PARASITOL, V204, P258, DOI 10.1016/j.vetpar.2014.05.014
   Wilmsen MO, 2014, REV BRAS PARASITOL V, V23, P348, DOI 10.1590/S1984-29612014058
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109060
DI 10.1016/j.vetpar.2020.109060
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400013
PM 32143013
DA 2020-05-12
ER

PT J
AU Ballent, M
   Canton, C
   Dominguez, P
   Bernat, G
   Lanusse, C
   Virkel, G
   Lifschitz, A
AF Ballent, M.
   Canton, C.
   Dominguez, P.
   Bernat, G.
   Lanusse, C.
   Virkel, G.
   Lifschitz, A.
TI Pharmacokinetic-pharmacodynamic assessment of the ivermectin and
   abamectin nematodicidal interaction in cattle
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Avermectins; Drug-Drug interactions; Anthelmintic combinations;
   Anthelmintic resistance
ID MACROCYCLIC LACTONE RESISTANCE; P-GLYCOPROTEIN; ANTHELMINTIC RESISTANCE;
   HAEMONCHUS-CONTORTUS; INTESTINAL SECRETION; DISPOSITION KINETICS;
   WORLD-ASSOCIATION; IN-VITRO; NEMATODES; SHEEP
AB In a context of nematodicidal resistance, anthelmintic combinations have emerged as a reliable pharmacological strategy to control gastrointestinal nematodes in grazing systems of livestock production. The current work evaluated the potential drug-drug interactions following the coadministration of two macrocyclic lactones (ML) ivermectin (IVM) and abamectin (ABM) to parasitized cattle using a pharmacokinetic/pharmacodynamic (PK/ PD) approach. The kinetic behavior of both compounds administered either separately or coadministered was assessed and the therapeutic response of the combination was evaluated under different resistance scenarios. In the pharmacological trial, calves received a single subcutaneous (s.c.) injection of IVM (100 mu g/Kg); a single s.c. injection of ABM (100 mu g/Kg) or IVM + ABM (50 mu g/Kg each) administered in different injection sites to reach a final ML dose of 100 mu g/Kg (Farm 1). Plasma samples were taken from those animals up to 20 days posttreatment. IVM and ABM plasma concentrations were quantified by HPLC. A parasitological trial was carried out in three farms with different status of nematodes resistance to IVM. Experimental animals received IVM (200 mu g/ Kg), ABM (200 mu g/Kg) or IVM + ABM (100 mu g/Kg each) in Farm 2, and IVM + ABM (200 mu g/Kg each) in Farms 3 and 4. The anthelmintic efficacy was determined by fecal egg count reduction test (FECRT). PK analysis showed similar trends for IVM kinetic behavior after coadministration with ABM. Conversely, the ABM elimination halflife was prolonged and the systemic exposure during the elimination phase was increased in the presence of IVM. Although IVM alone failed to control Cooperia spp., the combination IVM + ABM was the only treatment that achieved an efficacy higher than 95% against resistant Cooperia spp. in all farms. In fact, when Cooperia spp. was the main genus within the nematode population and Haemonchus spp. was susceptible or slightly resistant to ML (Farms 2 and 4), the total FECR for the combination IVM + ABM was higher than 90%. Instead, when the predominant nematode genus was a highly resistant Haemonchus spp. (Farm 3), the total FECR after the combined treatment was as low as the single treatments. Therefore, the rational use of these pharmacological tools should be mainly based on the knowledge of the epidemiology and the nematode susceptibility status in each cattle farm.
C1 [Ballent, M.; Canton, C.; Dominguez, P.; Lanusse, C.; Virkel, G.; Lifschitz, A.] Univ Nacl Ctr Prov Buenos Aires, Fac Ciencias Vet, CONICET, Lab Farmacol,Ctr Invest Vet Tandil CIVETAN,CICPBA, Campus Univ, RA-7000 Tandil, Argentina.
   [Bernat, G.] Univ Nacl Ctr Prov Buenos Aires, Fac Ciencias Vet, CONICET, Lab Parasitol,Ctr Invest Vet Tandil CIVETAN,CICPB, Campus Univ, RA-7000 Tandil, Argentina.
RP Ballent, M; Lifschitz, A (reprint author), Univ Nacl Ctr Prov Buenos Aires, Fac Ciencias Vet, CONICET, Lab Farmacol,Ctr Invest Vet Tandil CIVETAN,CICPBA, Campus Univ, RA-7000 Tandil, Argentina.
EM mballent@vet.unicen.edu.ar; adrianl@vet.unicen.edu.ar
OI Lifschitz, Adrian/0000-0001-7605-9744
FU CONICET-CICPBA; Agencia Nacional de Promocion Cientifica y Tecnica
   (ANPCyT), ArgentinaANPCyT [PICT 1140]
FX The research at the Laboratorio de Farmacologia, CIVETAN, Facultad de
   Cs. Veterinarias, UNCPBA is supported by CONICET-CICPBA (Proyecto
   PUE-CIVETAN) and Agencia Nacional de Promocion Cientifica y Tecnica
   (ANPCyT) (PICT 1140), Argentina. We wish to express our gratitude to
   Professor Cesar Fiel for his collaboration during the field activities
   and Professor Cecilia Stambuk for the revision of English style.
CR Alka, 2004, VET PARASITOL, V121, P277, DOI 10.1016/j.vetpar.2004.03.007
   ALVINERIE M, 1993, VET RES, V24, P417
   Alvinerie M, 2008, VET PARASITOL, V157, P117, DOI 10.1016/j.vetpar.2008.06.017
   ANDERSON N, 1988, AUST VET J, V65, P62, DOI 10.1111/j.1751-0813.1988.tb07355.x
   Ballent M, 2007, J VET PHARMACOL THER, V30, P242, DOI 10.1111/j.1365-2885.2007.00848.x
   Ballent M, 2006, DRUG METAB DISPOS, V34, P457, DOI 10.1124/dmd.105.007757
   Ballent M, 2019, J VET PHARMACOL THER, V42, P189, DOI 10.1111/jvp.12739
   Bartley DJ, 2012, VET PARASITOL, V187, P464, DOI 10.1016/j.vetpar.2012.02.011
   Bartram DJ, 2012, VET PARASITOL, V186, P151, DOI 10.1016/j.vetpar.2011.11.030
   Borges FA, 2008, VET PARASITOL, V155, P299, DOI 10.1016/j.vetpar.2008.04.019
   Borges FA, 2007, J VET PHARMACOL THER, V30, P62, DOI 10.1111/j.1365-2885.2007.00816.x
   Canton C, 2018, J VET PHARMACOL THER, V41, P83, DOI 10.1111/jvp.12438
   Canton C, 2017, VET PARASITOL, V234, P40, DOI 10.1016/j.vetpar.2016.12.021
   COLES GC, 1992, VET PARASITOL, V44, P35, DOI 10.1016/0304-4017(92)90141-U
   Cristel Silvina, 2017, Vet Parasitol Reg Stud Reports, V9, P25, DOI 10.1016/j.vprsr.2017.04.003
   Demeler J, 2013, MOL BIOCHEM PARASIT, V188, P10, DOI 10.1016/j.molbiopara.2013.01.004
   DEMONTIGNY P, 1990, J PHARMACEUT BIOMED, V8, P507, DOI 10.1016/0731-7085(90)80060-3
   Dupuy J, 2003, VET PARASITOL, V112, P337, DOI 10.1016/S0304-4017(03)00008-6
   Entrocasso C, 2008, VET PARASITOL, V155, P249, DOI 10.1016/j.vetpar.2008.04.015
   Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149
   Geary TG, 2012, VET PARASITOL, V190, P306, DOI 10.1016/j.vetpar.2012.09.004
   Geurden T, 2015, INT J PARASITOL-DRUG, V5, P163, DOI 10.1016/j.ijpddr.2015.08.001
   GIBALDI M, 1982, PHARMACOKINETICS
   Kaplan RM, 2012, VET PARASITOL, V186, P70, DOI 10.1016/j.vetpar.2011.11.048
   Kotze AC, 2014, VET PARASITOL, V203, P294, DOI 10.1016/j.vetpar.2014.04.005
   Laffont C, 2002, DRUG METAB DISPOS, V30, P626, DOI 10.1124/dmd.30.6.626
   Lanusse C, 2018, TRENDS PARASITOL, V34, P664, DOI 10.1016/j.pt.2018.05.005
   Lanusse C, 2015, VET PARASITOL, V212, P35, DOI 10.1016/j.vetpar.2015.07.015
   Leathwick DM, 2014, VET PARASITOL, V204, P44, DOI 10.1016/j.vetpar.2013.12.022
   Leathwick DM, 2000, NEW ZEAL VET J, V48, P151, DOI 10.1080/00480169.2000.36183
   Lespine A, 2007, EUR J PHARM SCI, V30, P84, DOI 10.1016/j.ejps.2006.10.004
   Lespine A, 2012, INT J PARASITOL-DRUG, V2, P58, DOI 10.1016/j.ijpddr.2011.10.001
   Lifschitz A, 2010, VET PARASITOL, V172, P291, DOI 10.1016/j.vetpar.2010.04.039
   Lifschitz A, 1999, VET PARASITOL, V86, P203, DOI 10.1016/S0304-4017(99)00142-9
   Lifschitz A, 2010, EXP PARASITOL, V125, P172, DOI 10.1016/j.exppara.2010.01.009
   Lloberas M, 2013, INT J PARASITOL-DRUG, V3, P20, DOI 10.1016/j.ijpddr.2012.11.001
   MAFF (Ministry of Agriculture Fisheries and Food), 1986, MAN VET PAR LAB TECH
   Mate L, 2018, VET PARASITOL, V264, P1, DOI 10.1016/j.vetpar.2018.10.011
   MCKENNA PB, 1990, NEW ZEAL VET J, V38, P142, DOI 10.1080/00480169.1990.35640
   Molento MB, 2004, PARASITOL RES, V92, P121, DOI 10.1007/s00436-003-1022-3
   Prichard RK, 2007, PARASITOLOGY, V134, P1123, DOI 10.1017/S0031182007000091
   ROBERTS FHS, 1950, AUST J AGR RES, V1, P99, DOI 10.1071/AR9500099
   Sangster NC, 1999, EXP PARASITOL, V91, P250, DOI 10.1006/expr.1998.4373
   Suarez G, 2014, VET PARASITOL, V201, P110, DOI 10.1016/j.vetpar.2013.12.015
   Vercruysse J., 2002, P185, DOI 10.1079/9780851996172.0185
   Virkel G, 2019, CURR MED CHEM, V26, P1251, DOI 10.2174/0929867325666180201094730
   Yeh P, 2006, NAT GENET, V38, P489, DOI 10.1038/ng1755
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109010
DI 10.1016/j.vetpar.2019.109010
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400001
PM 32035291
DA 2020-05-12
ER

PT J
AU Barone, CD
   Wit, J
   Hoberg, EP
   Gilleard, JS
   Zarlenga, DS
AF Barone, Carly D.
   Wit, Janneke
   Hoberg, Eric P.
   Gilleard, John S.
   Zarlenga, Dante S.
TI Wild ruminants as reservoirs of domestic livestock gastrointestinal
   nematodes
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Haemonchus; Ostertagia; Nematode; Anthelmintic resistance; Cattle;
   Nemabiome; Deep amplicon sequencing; Ruminant
ID WHITE-TAILED DEER; HAEMONCHUS-CONTORTUS; CLIMATE-CHANGE; CATTLE FARMS;
   EGG COUNTS; TRANSMISSION; DISEASES; PARATUBERCULOSIS; GENERALISTS;
   PARASITES
AB Gastrointestinal nematode (GIN) infections in cattle cause appetite suppression which leads to poor feed conversion, reduced weight gain and reduced milk production. Overuse and exclusive reliance on anthelmintic drugs has resulted in widespread resistance in many parasitic nematode species infecting livestock making control increasingly difficult. Wild ruminants are competent hosts of a number of nematode species that typically infect and are best adapted for cattle, sheep, and goats. Thus, the potential exists for wild ruminants to act as reservoirs in the translocation of domestic GIN, including those carrying anthelmintic resistance mutations as well as susceptible genotypes. The potential for parasite exchange is heightened by interfaces or ecotones between managed and wild rangelands, and by perturbations linked to climate warming that can increasingly alter the distributions of wild ungulates and their interactions with domestic and free-ranging ruminants. To investigate the extent to which wild ruminants harbour parasites capable of infecting domestic ruminants we first performed an epidemiological study of feces from wildlife hosts that spanned 16 states and included white-tailed deer (85 % of the samples), pronghorn, elk, mule deer, bighorn sheep, moose, cattle, and caribou across the United States. All samples were cultured to third stage larvae and nematode DNA was isolated and PCR amplified. Among the 548 wild ruminant samples received, 33 % (181 samples) were positive for nematode DNA, among which half (84 samples) contained DNA from GIN species commonly found in cattle. DNA from cattle GIN species was detected in 46 % of samples from the Northeast, 42 % from the Southeast, 10 % from the Midwest, 0 % from the Southwest and 11 % from the West. Deep amplicon sequencing of the ITS-2 rDNA indicated that Ostertagia and Trichostrongylus were present in 90 % and 69 % of the nematode DNA positive samples, respectively, whereas Haemonchus, Cooperia and Oesophagostomum were present in 26 %, 2 % and 10 % of the samples, respectively. These data clearly show that wild ruminants commonly harbour multiple parasite species whose primary hosts are domestic cattle, and suggest that further work is warranted to investigate their specific roles in the management of anthelmintic resistance.
C1 [Barone, Carly D.; Zarlenga, Dante S.] ARS, Anim Parasit Dis Lab, USDA, Bldg 1180, Beltsville, MD 20705 USA.
   [Wit, Janneke; Gilleard, John S.] Univ Calgary, Dept Comparat Biol & Expt Med, 3330 Hosp Dr, Calgary, AB T2N 4N1, Canada.
   [Hoberg, Eric P.] Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA.
RP Barone, CD (reprint author), ARS, Anim Parasit Dis Lab, USDA, Bldg 1180, Beltsville, MD 20705 USA.
EM carlydbarone@gmail.com
OI Gilleard, John/0000-0002-6787-4699; Barone, Carly/0000-0003-1008-6170
FU USDAUnited States Department of Agriculture (USDA) [8042-32000-105-00D];
   Oak Ridge Institute for Science and Education (ORISE); Alberta
   Agriculture and Forestry and Canada [2017R021R]; NSERC-CREATE Host
   Parasite Interactions (HPI) graduate training program
FX This work was supported by USDA Research Project 8042-32000-105-00D and
   Fellowship funding from the Oak Ridge Institute for Science and
   Education (ORISE), Alberta Agriculture and Forestry Grant number
   2017R021R and Canada, NSERC-CREATE Host Parasite Interactions (HPI)
   graduate training program.
CR Agosta SJ, 2010, ZOOLOGIA-CURITIBA, V27, P151, DOI 10.1590/S1984-46702010000200001
   Altizer S, 2013, SCIENCE, V341, P514, DOI 10.1126/science.1239401
   Araujo SBL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139225
   Avramenko RW, 2017, INT J PARASITOL, V47, P893, DOI 10.1016/j.ijpara.2017.06.006
   Avramenko RW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143559
   Bengis RG, 2002, REV SCI TECH OIE, V21, P53
   Berentsen AR, 2014, EUR J WILDLIFE RES, V60, P161, DOI 10.1007/s10344-013-0760-5
   Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160
   Brooks D.R., 2014, COMP PARASITOL, V81, P155
   Brooks D.R., 2019, STOCKHOLM PARADIGM C
   Chintoan-Uta C, 2014, P ROY SOC B-BIOL SCI, V281, DOI 10.1098/rspb.2013.2985
   Dobson A., 1992, Global warming and biological diversity., P201
   DOBSON RJ, 1992, INT J PARASITOL, V22, P1005, DOI 10.1016/0020-7519(92)90060-X
   Fredriksen B, 2004, VET REC, V154, P522, DOI 10.1136/vr.154.17.522
   Gasbarre LC, 2015, CAN J VET RES, V79, P296
   GASSER RB, 1993, NUCLEIC ACIDS RES, V21, P2525, DOI 10.1093/nar/21.10.2525
   Hoberg EP, 2008, REV SCI TECH OIE, V27, P511, DOI 10.20506/rst.27.2.1818
   Hoberg EP, 2016, ADV PARASIT, V93, P1, DOI 10.1016/bs.apar.2016.02.021
   Hoberg EP, 2010, REV SCI TECH OIE, V29, P255, DOI 10.20506/rst.29.2.1972
   Hoberg EP, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2013.0553
   Hoberg Eric P., 2001, P193, DOI 10.1002/9780470377000.ch8
   Hrabok JT, 2006, VET PARASITOL, V136, P297, DOI 10.1016/j.vetpar.2005.11.020
   Kaneene JB, 2002, J AM VET MED ASSOC, V221, P837, DOI 10.2460/javma.2002.221.837
   Matthee S, 2004, J PARASITOL, V90, P1263, DOI 10.1645/GE-3353
   MCGHEE MB, 1981, J WILDLIFE DIS, V17, P353, DOI 10.7589/0090-3558-17.3.353
   Miller RS, 2013, PREV VET MED, V110, P119, DOI 10.1016/j.prevetmed.2012.11.021
   Peters R.L., 1992, GLOBAL WARMING BIOL, P15
   Raizman EA, 2005, CAN J VET RES, V69, P32
   ROBERTS FHS, 1950, AUST J AGR RES, V1, P99, DOI 10.1071/AR9500099
   Roeber F, 2014, VET PARASITOL, V205, P619, DOI 10.1016/j.vetpar.2014.08.005
   Saunders D.A., 1988, ADIRONDACK MAMMALS, P216
   Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09
   Stromberg BE, 2015, CAN J VET RES, V79, P290
   Stromberg BE, 2012, VET PARASITOL, V183, P284, DOI 10.1016/j.vetpar.2011.07.030
   USDA National Agricultural Statistics Service, 2012, 2012 CENS AGR STAT D, P310
   Walker Josephine G., 2014, International Journal for Parasitology Parasites and Wildlife, V3, P242, DOI 10.1016/j.ijppaw.2014.08.001
   Winter J, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00030
   Zaffaroni E, 2000, VET PARASITOL, V90, P221, DOI 10.1016/S0304-4017(00)00240-5
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109041
DI 10.1016/j.vetpar.2020.109041
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400004
PM 32160579
DA 2020-05-12
ER

PT J
AU Bilska-Zajac, E
   Rozycki, M
   Gradziel-Krukowska, K
   Belcik, A
   Mizak, I
   Karamon, J
   Sroka, J
   Zdybel, J
   Cencek, T
AF Bilska-Zajac, Ewa
   Rozycki, Miroslaw
   Gradziel-Krukowska, Katarzyna
   Belcik, Aneta
   Mizak, Iwona
   Karamon, Jacek
   Sroka, Jacek
   Zdybel, Jolanta
   Cencek, Tomasz
TI Diversity of Trichinella species in relation to the host species and
   geographical location
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Trichinellaspp.; Pig; Wild boar; Rat; Red fox; Poland; Prevalence
ID FOXES VULPES-VULPES; RED FOXES; WILD BOARS; FREEZE-RESISTANCE; POTENTIAL
   SOURCE; DOMESTIC PIGS; POLAR BEARS; INFECTION; SPIRALIS; SPP.
AB Trichinella nematodes still circulate in various hosts in both domestic and sylvatic environments. Recently, in Europe, the transmission of Trichinella spp. to humans has been attributed more to wild animals than to domestic animals. However, domestic animals could still be a source of human infections in some regions. Therefore, our aim was to determine the species composition of Trichinella and the prevalence and intensity of infections in animal populations from the domestic cycle, namely pigs (Sus scrofa f. domestica); the synantropic cycle, in the form of rats (Rattus norvegicus); and the sylvatic cycle, namely wild boars (Sus scrofa) and red foxes (Vulpes vulpes), in Poland.
   The findings showed that the nematode prevalence in pigs (0.0002 %) and wild boars (0.3 %) was lower than it was in red foxes (4 %). A very high prevalence was found in rats (23.3 %), but it must be emphasized that the investigated rat samples were collected from farms where pigs were infected with Trichinella spp. The mean larval burden was found to be higher in wild boars and pigs (11.48 lpg and 10.19 lpg) than in red foxes and rats (4.09 and 2.30).
   Trichinella spiralis was the predominant species in pigs (98.6 %), wild boars (77.3 %) and rats (100 %), while in red foxes, this species occurred less frequently (15.5 %). The most frequently occurring species in red foxes was Trichinella britovi (73.2 %). Moreover, in wild boar and red fox coinfections, T. spiralis/T. britovi were detected (3.1 and 9.9 %, respectively). In addition, Trichinella pseudospiralis was detected in a few wild boars (0.5 %) and Trichinella nativa was found in one red fox and one wild boar. Furthermore, different T. spiralis and T. britovi prevalence ratios in various geographical regions were found. In the wild boar population, a higher frequency of T. spiralis (70-85 % of infected animals) was observed in the western and central parts of Poland, while in the eastern part, this dominance was not as evident (46-59 %). In the red fox population, T. britovi was abundant throughout the entire territory; however, its highest prevalence was in the east (90-100 %).
C1 [Bilska-Zajac, Ewa; Rozycki, Miroslaw; Gradziel-Krukowska, Katarzyna; Belcik, Aneta; Mizak, Iwona; Karamon, Jacek; Sroka, Jacek; Zdybel, Jolanta; Cencek, Tomasz] Natl Vet Res Inst Pulawy, Dept Parasitol & Invas Dis, Al Partyzantow 57, PL-24100 Pulawy, Poland.
RP Bilska-Zajac, E (reprint author), Natl Vet Res Inst Pulawy, Dept Parasitol & Invas Dis, Al Partyzantow 57, PL-24100 Pulawy, Poland.
EM ewa.bilska@piwet.pulawy.pl
RI ; Karamon, Jacek/H-1824-2011
OI Bilska-Zajac, Ewa/0000-0002-5952-7531; Karamon,
   Jacek/0000-0002-5830-167X; Rozycki, Miroslaw/0000-0002-8125-973X
CR Airas N, 2010, J PARASITOL, V96, P67, DOI 10.1645/GE-2202.1
   Bilska- Zajac E., 2019, THESIS
   Bilska-Zajac E, 2018, ANN AGR ENV MED, V25, P698, DOI 10.26444/aaem/99555
   Bilska-Zajac E, 2017, PARASITOL RES, V116, P1705, DOI 10.1007/s00436-017-5446-6
   Cabaj W, 2004, MED WETER, V60, P80
   Cabaj Wladyslaw, 2006, Wiadomosci Parazytologiczne, V52, P175
   Chmurzynska E, 2013, VET PARASITOL, V198, P254, DOI 10.1016/j.vetpar.2013.07.034
   COMMISION E., 2015, OFFICIAL J EUROPEAN
   Cybulska A, 2016, VECTOR-BORNE ZOONOT, V16, P717, DOI 10.1089/vbz.2016.1996
   Faber M, 2015, CLIN INFECT DIS, V60, pE98, DOI 10.1093/cid/civ199
   Franssen F., 2013, THESIS
   Gomez-Morales MA, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1437-1
   Hryszko K., 2018, P 42 INT AC C ROM
   Hurnikova Z, 2016, VET PARASITOL, V231, P106, DOI 10.1016/j.vetpar.2016.06.010
   Kapel CMO, 1998, PARASITOL RES, V84, P264, DOI 10.1007/s004360050393
   Karssin A, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2571-0
   KJOSHANSSEN B, 1983, ACTA VET SCAND, V24, P244
   KJOSHANSSEN B, 1984, NORD VET MED, V36, P57
   KOZAR ZBIGNIEW, 1965, WIAD PARAZYTOL, V11, P285
   KOZAR ZBIGNIEW, 1965, WIAD PARAZYTOL, V11, P245
   Lacour SA, 2013, VET PARASITOL, V194, P175, DOI 10.1016/j.vetpar.2013.01.049
   LEIBY DA, 1990, J PARASITOL, V76, P360, DOI 10.2307/3282667
   Liciardi M, 2009, VET PARASITOL, V161, P345, DOI 10.1016/j.vetpar.2009.01.013
   MADSEN H, 1961, Nord Med, V65, P342
   Malakauskas A, 2007, PARASITOL RES, V100, P687, DOI 10.1007/s00436-006-0320-y
   Malakauskas A, 2003, J PARASITOL, V89, P744, DOI 10.1645/GE-2969.1
   Mikkonen T, 2005, J PARASITOL, V91, P210, DOI 10.1645/GE-3230RN
   Moskwa B, 2015, ACTA PARASITOL, V60, P530, DOI 10.1515/ap-2015-0075
   Moskwa B, 2013, ACTA PARASITOL, V58, P149, DOI 10.2478/s11686-013-0121-2
   Moskwa B, 2012, ACTA PARASITOL, V57, P402, DOI 10.2478/s11686-012-0054-1
   Oivanen L, 2002, J PARASITOL, V88, P84, DOI 10.1645/0022-3395(2002)088[0084:ABTSAH]2.0.CO;2
   Pannwitz G, 2010, EMERG INFECT DIS, V16, P936, DOI 10.3201/eid1606.091629
   Pawlas-Opiela M., 2007, POLSKI ACTA SCI POL, V6, P29
   Pejsak Z, 2014, POL J VET SCI, V17, P665, DOI 10.2478/pjvs-2014-0097
   Pozio E, 2009, INT J PARASITOL, V39, P71, DOI 10.1016/j.ijpara.2008.06.006
   Pozio E, 2005, VET PARASITOL, V132, P3, DOI 10.1016/j.vetpar.2005.05.024
   Ramisz A, 1979, Wiad Parazytol, V25, P565
   Ramisz A, 2011, B VET I PULAWY, V55, P199
   Rozycki M, 2020, INT J PARASITOL-PAR, V11, P46, DOI 10.1016/j.ijppaw.2019.11.005
   Sattmann H, 2005, WIEN TIERARZTL MONAT, V92, P283
   Scheuring W, 1999, MED WETER, V55, P155
   Sofronic-Milosavljevic L, 2013, VET PARASITOL, V194, P145, DOI 10.1016/j.vetpar.2013.01.042
   Stojcevic D, 2004, J PARASITOL, V90, P666, DOI 10.1645/GE-158R
   Thi NV, 2014, VET PARASITOL, V200, P207, DOI 10.1016/j.vetpar.2013.11.011
   Webster P, 1999, ACTA VET SCAND, V40, P93
   Zarlenga DS, 1999, INT J PARASITOL, V29, P1859, DOI 10.1016/S0020-7519(99)00107-1
NR 46
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109052
DI 10.1016/j.vetpar.2020.109052
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400008
PM 32050131
DA 2020-05-12
ER

PT J
AU dos Santos, MC
   Amarante, MRV
   Amarante, AFT
AF dos Santos, Michelle C.
   Amarante, Monica R., V
   Amarante, Alessandro F. T.
TI Is there competition between Haemonchus contortus and Haemonchus placei
   in a pasture grazed by only sheep?
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cross-infection; Gastrointestinal nematodes; Specificity; Ovine; Grazing
ID SAO-PAULO STATE; NEMATODE INFECTIONS; HOST-SPECIFICITY; DOMESTIC
   RUMINANTS; CATTLE; HYBRIDIZATION; TRICHOSTRONGYLOIDEA; DIFFERENTIATION;
   MORPHOMETRICS; POPULATIONS
AB This study aimed to evaluate the dynamics of Haemonchus contortus and Haemonchus placei infections and hybridization between these species in grazing sheep without contact with cattle. On January 14, 2014, sixteen young sheep were infected with 4000 infective H. placei third-stage larvae L3; 11 days later, another group n = 16 was infected with 4000 H. conforms L3. The establishment rates of H. contortus and H. placei L3 were, on average, 61.6 % and 56.8 %, respectively, in the permanent sheep. After the establishment of patent infections, all permanent sheep were allocated together in the same clean pasture where they grazed for the next 12 months. Euthanasia of a sample of the permanent sheep was performed every three months: in May, August, November and February. Two weeks before the sheep were removed for euthanasia, 2 worm-free tracer sheep were introduced to the pasture to evaluate the larval population in the field. The tracer sheep grazed alongside the permanent sheep for 2 weeks. Then, they were housed indoors for 20 days; at the end of this period, they were euthanized. Parasites were recovered from the permanent and tracer sheep and identified using morphological and molecular techniques. A total of 432 worms (from permanent and tracer animals) were analyzed by PCR using species-specific primer pairs. Of these specimens, only two (0.46 %) male worms were identified as hybrids: one was recovered from a permanent animal euthanized in August and the other from a tracer sheep that grazed in May. The last detection of adult H. placei worms occurred in sheep euthanized in May (approximately 3.5 months after the beginning of the grazing period). The morphological evaluation of the L3 produced in fecal cultures showed that H. placei were progressively replaced by H. contortus populations starting in March. The last trace of H. placei L3 was found in August, when a small percentage (0.5 %) of infective larvae with H. placei morphology was identified in a fecal culture. In conclusion, hybridization between H. contortus and H. placei can occur in the field during coinfection. It was demonstrated that H. placei established successfully in artificially infected worm-free sheep; however, with concomitant natural reinfection with H. contortus, the H. placei population showed a rapid decrease and was eliminated within a few months in an environment without cattle.
C1 [dos Santos, Michelle C.; Amarante, Monica R., V; Amarante, Alessandro F. T.] Univ Estadual Paulista, Inst Biociencias, UNESP, Botucatu, SP, Brazil.
RP Amarante, AFT (reprint author), Univ Estadual Paulista, Inst Biociencias, UNESP, Botucatu, SP, Brazil.
EM alessandro.amarante@unesp.br
RI Amarante, Alessandro/C-8773-2012
OI Amarante, Alessandro/0000-0003-3995-5501
FU Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2012/23941-2, 2015/12900-1, 2014/02305-6];
   CNPqNational Council for Scientific and Technological Development (CNPq)
   [305187/2017-1]
FX The authors are grateful for the technical assistance provided by
   Adriana M. D. Anaya, Cesar C. Bassetto, Jose H. Neves, Gabriela F.
   Caetano, Maria Regina L. Silva, Nadino Carvalho and Natalia B. Pinto.
   Michelle C. Santos received financial support from the Sao Paulo
   Research Foundation (FAPESP, Grant Number 2012/23941-2 and
   2015/12900-1). Alessandro F. T. Amarante is the recipient of a
   fellowship from CNPq (305187/2017-1). This study was supported by the
   Sao Paulo Research Foundation (FAPESP - Grant Number 2014/02305-6).
CR Achi YL, 2003, VET PARASITOL, V116, P151, DOI 10.1016/S0304-4017(03)00258-9
   Agneessens J, 2000, VET PARASITOL, V90, P83, DOI 10.1016/S0304-4017(00)00232-6
   de Albuquerque ACA, 2017, VET PARASITOL, V246, P112, DOI 10.1016/j.vetpar.2017.09.010
   Alvares CA, 2013, METEOROL Z, V22, P711, DOI 10.1127/0941-2948/2013/0507
   Amarante AFT, 1997, VET PARASITOL, V73, P89, DOI 10.1016/S0304-4017(97)00036-8
   Amarante MRV, 2017, J HELMINTHOL, V91, P757, DOI 10.1017/S0022149X16000882
   Avramenko RW, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2880-y
   Avramenko RW, 2017, INT J PARASITOL, V47, P893, DOI 10.1016/j.ijpara.2017.06.006
   Bailey JN, 2009, VET PARASITOL, V161, P218, DOI 10.1016/j.vetpar.2009.01.016
   Bassetto CC, 2011, PARASITE IMMUNOL, V33, P377, DOI 10.1111/j.1365-3024.2011.01295.x
   Brasil BSAF, 2012, INT J PARASITOL, V42, P469, DOI 10.1016/j.ijpara.2012.03.003
   BREMNER K. C., 1955, AUSTRALIAN JOUR ZOOL, V3, P312, DOI 10.1071/ZO9550312
   Brito DL, 2013, REV BRAS PARASITOL V, V22, P485, DOI 10.1590/S1984-29612013000400007
   Cerutti MC, 2010, J HELMINTHOL, V84, P276, DOI 10.1017/S0022149X09990587
   Chaudhry U, 2015, INT J PARASITOL, V45, P149, DOI 10.1016/j.ijpara.2014.09.002
   d'Alexis S, 2014, J AGR SCI-CAMBRIDGE, V152, P655, DOI 10.1017/S0021859613000622
   d'Alexis S, 2012, VET PARASITOL, V184, P384, DOI 10.1016/j.vetpar.2011.08.030
   das Neves JH, 2014, VET PARASITOL, V206, P216, DOI 10.1016/j.vetpar.2014.10.015
   de Almeida FA, 2018, REV BRAS PARASITOL V, V27, P280, DOI [10.1590/S1984-296120180044, 10.1590/s1984-296120180044]
   dos Santos IB, 2019, VET PARASITOL, V271, P64, DOI 10.1016/j.vetpar.2019.06.012
   dos Santos MC, 2014, REV BRAS PARASITOL V, V23, P495, DOI 10.1590/S1984-29612014085
   Escobedo JF, 2011, RENEW ENERG, V36, P169, DOI 10.1016/j.renene.2010.06.018
   Favero FC, 2016, VET PARASITOL, V217, P25, DOI 10.1016/j.vetpar.2015.12.017
   Fernandes LH, 2004, ARQ BRAS MED VET ZOO, V56, P733, DOI 10.1590/S0102-09352004000600006
   Hogg R, 2010, VET REC, V166, P373, DOI 10.1136/vr.c1509
   Jabbar A, 2014, INFECT GENET EVOL, V21, P252, DOI 10.1016/j.meegid.2013.10.025
   Jacquiet P, 1998, INT J PARASITOL, V28, P253, DOI 10.1016/S0020-7519(97)00185-9
   LEJAMBRE LF, 1981, INT J PARASITOL, V11, P323, DOI 10.1016/0020-7519(81)90043-6
   LEJAMBRE LF, 1983, INT J PARASITOL, V13, P365, DOI 10.1016/S0020-7519(83)80042-3
   LEJAMBRE LF, 1979, INT J PARASITOL, V9, P455, DOI 10.1016/0020-7519(79)90049-3
   LICHTENFELS JR, 1994, J PARASITOL, V80, P107, DOI 10.2307/3283353
   Lindqvist A, 2001, ACTA VET SCAND, V42, P377, DOI 10.1186/1751-0147-42-377
   Mahieu M, 2009, TROP ANIM HEALTH PRO, V41, P229, DOI 10.1007/s11250-008-9180-z
   Reiniger RCP, 2017, RES VET SCI, V114, P136, DOI 10.1016/j.rvsc.2017.02.017
   Riggs NL, 2001, VET PARASITOL, V94, P191, DOI 10.1016/S0304-4017(00)00381-2
   Santos MC, 2019, J HELMINTHOL, V93, P697, DOI 10.1017/S0022149X18000743
   Santos MC, 2017, VET PARASITOL, V244, P71, DOI 10.1016/j.vetpar.2017.07.011
   Santos MC, 2014, VET PARASITOL, V203, P127, DOI 10.1016/j.vetpar.2014.02.048
   Sargison ND, 2019, INT J PARASITOL, V49, P531, DOI 10.1016/j.ijpara.2019.02.008
   Shen DD, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2377-0
   Silva MRL, 2015, J HELMINTHOL, V89, P302, DOI 10.1017/S0022149X14000078
   SMEAL MG, 1977, AUST VET J, V53, P566, DOI 10.1111/j.1751-0813.1977.tb15828.x
   Ueno H., 1998, MANUAL DIAGNOSTICO H
   van Wyk JA, 2004, VET PARASITOL, V119, P277, DOI 10.1016/j.vetpar.2003.11.012
   Waghorn TS, 2019, NEW ZEAL VET J, V67, P40, DOI 10.1080/00480169.2018.1532849
   Wilmsen MO, 2014, REV BRAS PARASITOL V, V23, P348, DOI 10.1590/S1984-29612014058
   Winter J, 2018, FRONT VET SCI, V5, DOI 10.3389/fvets.2018.00030
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109054
DI 10.1016/j.vetpar.2020.109054
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400010
PM 32065932
DA 2020-05-12
ER

PT J
AU Gu, XB
   Zhang, N
   Xie, Y
   Zheng, YL
   Chen, YH
   Zhou, X
   Li, XY
   Zhong, ZJ
   He, R
   Yang, GY
AF Gu, Xiaobin
   Zhang, Na
   Xie, Yue
   Zheng, Youle
   Chen, Yuhang
   Zhou, Xuan
   Li, Xiaoying
   Zhong, Zhijun
   He, Ran
   Yang, Guangyou
TI Metarhizium anisopliae CQMa128 regulates antioxidant/detoxification
   enzymes and exerts acaricidal activity against Psoroptes ovis var.
   cuniculi in rabbits: A preliminary study
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Metarhiziumanisopliae; Psoroptes ovis var. cuniculi; Rabbits; Biological
   control; Antioxidant enzymes; Detoxification enzymes
ID ENTOMOPATHOGENIC FUNGI; BEAUVERIA-BASSIANA; SCAB MITE;
   RHIPICEPHALUS-MICROPLUS; EFFICACY; INFECTION; SHEEP; FORMULATIONS;
   GERMINATION; VIRULENCE
AB The entomopathogenic fungi Metarhizium anisopliae is highly pathogenic toward arthropods. Here, we evaluated the efficacy of a commercial formulation of M. anisopliae against P. ovis var. cuniculi in vivo and in vitro and explored the acaricidal mechanism of M. anisopliae by determining the antioxidant/detoxification-related enzymes activities including glutathione S-transferase (GST), superoxide dismutase (SOD), peroxidase (POD) and catalase (CAT) in mites. The results showed that M. anisopliae had high acaricidal activity against P. ovis var. cuniculi in vitro, in a time- and dose-dependent manner, with 83.33 % mortality at day 9 and a median lethal time (LT50) of 6.10 days after applying 6.14 x 10(9) conidia/ml of M. anisopliae. In vivo experiments, M. anisopliae achieved 100 % therapeutic effect after 3 days, compared with only 62.21 % for ivermectin. Enzyme assays showed that M. anisopliae significantly upregulated activities of GST, SOD and CAT in Psoroptes mites. The results indicate that M. anisopliae may be an effective biological agent for control of P. ovis var. cuniculi infestations in rabbits and the acaricidal activity may be associated with the changes of enzyme activities of the detoxification and antioxidant system in Psoroptes mites.
C1 [Gu, Xiaobin; Zhang, Na; Xie, Yue; Zheng, Youle; Chen, Yuhang; Zhong, Zhijun; He, Ran; Yang, Guangyou] Sichuan Agr Univ, Coll Vet Med, Dept Parasitol, Chengdu 611130, Peoples R China.
   [Zhang, Na] Coll AKsu Vocat & Tech, Dept Biol Engn, Xingjiang 843000, Peoples R China.
   [Zhou, Xuan] Sichuan Agr Univ, Inst Anim Genet & Breeding, Coll Anim Sci & Technol, Chengdu 611130, Peoples R China.
   [Li, Xiaoying] Chongqing Univ Arts & Sci, Coll Landscape Architecture & Life Sci, Inst Special Plants, Chongqing 402160, Peoples R China.
RP Gu, XB (reprint author), Sichuan Agr Univ, Coll Vet Med, Dept Parasitol, Chengdu 611130, Peoples R China.
EM guxiaobin198225@126.com; zhangna2018@outlook.com; xyue1985@gmail.com;
   zhengyoule1@163.com; ChenYH1995@hotmail.com; zhouxuan198866@163.com;
   lxyi2@126.com; zhongzhijun488@126.com; ranhe1991@hotmail.com;
   guangyou1963@aliyun.com
FU Sichuan Science & Technology Program of Sichuan Province, China
   [2019YFN0155]
FX This work was supported by Sichuan Science & Technology Program of
   Sichuan Province, China (Grant No., 2019YFN0155).
CR Abolins S, 2007, VET PARASITOL, V148, P310, DOI 10.1016/j.vetpar.2007.06.008
   Abro NA, 2019, ENVIRON SCI POLLUT R, V26, P17797, DOI 10.1007/s11356-019-05158-2
   Adames M., 2011, J INSECT SCI, V11, P90
   Angel-Sahagun CA, 2010, VET PARASITOL, V170, P278, DOI 10.1016/j.vetpar.2010.02.037
   Apel K, 2004, ANNU REV PLANT BIOL, V55, P373, DOI 10.1146/annurev.arplant.55.031903.141701
   Bates PG, 1999, VET PARASITOL, V83, P201, DOI 10.1016/S0304-4017(99)00058-8
   Brooks A, 2005, BIOL CONTROL, V34, P58, DOI 10.1016/j.biocontrol.2005.03.016
   Brooks A.J., 2004, THESIS
   Brooks AJ, 2004, PEST MANAG SCI, V60, P1043, DOI 10.1002/ps.910
   Brooks AJ, 2001, EXP APPL ACAROL, V25, P869, DOI 10.1023/A:1020428514608
   Camargo MG, 2014, VET PARASITOL, V205, P271, DOI 10.1016/j.vetpar.2014.07.011
   Camargo MG, 2012, VET PARASITOL, V188, P140, DOI 10.1016/j.vetpar.2012.03.012
   DAOUST RA, 1982, J INVERTEBR PATHOL, V40, P107, DOI 10.1016/0022-2011(82)90042-8
   Doherty E, 2018, VET REC, V182, DOI 10.1136/vr.104657
   Dunstand-Guzman E, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0890-6
   Fichi G, 2007, EXP PARASITOL, V115, P168, DOI 10.1016/j.exppara.2006.07.005
   Finney J., 1971, PROBIT ANAL
   Jiang A, 2019, BIOL CONTROL, V131, P43, DOI 10.1016/j.biocontrol.2019.01.010
   Kaaya GP, 2011, EXP APPL ACAROL, V55, P273, DOI 10.1007/s10493-011-9471-3
   Lekimme M, 2006, VET PARASITOL, V139, P196, DOI 10.1016/j.vetpar.2006.02.041
   Lekimme M, 2008, EXP APPL ACAROL, V46, P95, DOI 10.1007/s10493-008-9171-9
   Li C, 2019, CERAM INT, V45, P15015, DOI 10.1016/j.ceramint.2019.04.238
   Ling SF, 2013, ECOTOX ENVIRON SAFE, V98, P187, DOI 10.1016/j.ecoenv.2013.08.023
   Losson BJ, 2012, VET PARASITOL, V189, P39, DOI 10.1016/j.vetpar.2012.03.030
   Meyling NV, 2007, BIOL CONTROL, V43, P145, DOI 10.1016/j.biocontrol.2007.07.007
   Milner RJ, 1997, J INVERTEBR PATHOL, V69, P64, DOI 10.1006/jipa.1996.4636
   Mounsey KE, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-43
   Nong X, 2013, VET PARASITOL, V192, P247, DOI 10.1016/j.vetpar.2012.10.005
   O'Brien DJ, 1999, VET PARASITOL, V83, P177, DOI 10.1016/S0304-4017(99)00056-4
   ROBERTS IH, 1971, ANN ENTOMOL SOC AM, V64, P105, DOI 10.1093/aesa/64.1.105
   Sanders A, 2000, MED VET ENTOMOL, V14, P131, DOI 10.1046/j.1365-2915.2000.00223.x
   Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001
   Smith KE, 2000, VET PARASITOL, V92, P97, DOI 10.1016/S0304-4017(00)00277-6
   SWEATMAN GORDON K., 1958, CANADIAN JOUR ZOOL, V36, P905, DOI 10.1139/z58-078
   Tabassam SM, 2008, J ETHNOPHARMACOL, V115, P284, DOI 10.1016/j.jep.2007.10.003
   Wall R, 1999, VET PARASITOL, V83, P253, DOI 10.1016/S0304-4017(99)00062-X
   Wang WB, 2009, PLANT PHYSIOL BIOCH, V47, P570, DOI 10.1016/j.plaphy.2009.02.009
   Wen HQ, 2010, PARASITOL RES, V106, P607, DOI 10.1007/s00436-009-1704-6
   Zimmermann G, 2007, BIOCONTROL SCI TECHN, V17, P879, DOI 10.1080/09583150701593963
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109059
DI 10.1016/j.vetpar.2020.109059
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400012
PM 32112975
DA 2020-05-12
ER

PT J
AU Haehling, MB
   Cruvinel, GG
   Toscano, JHB
   Giraldelo, LA
   Santos, IB
   Esteves, SN
   Benavides, MV
   Barioni, W
   Niciura, SCM
   Chagas, ACS
AF Haehling, Marei B.
   Cruvinel, Giovanna G.
   Toscano, Joao H. B.
   Giraldelo, Luciana A.
   Santos, Isabella B.
   Esteves, Sergio N.
   Benavides, Magda, V
   Barioni Junior, Waldomiro
   Niciura, Simone C. M.
   Chagas, Ana Carolina S.
TI Four single nucleotide polymorphisms (SNPs) are associated with
   resistance and resilience to Haemonchus contortus in Brazilian Morada
   Nova sheep
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Host resistance; Parasite challenge; Genetic markers; Morada Nova sheep
ID GASTROINTESTINAL NEMATODES; TRICHOSTRONGYLUS-COLUBRIFORMIS; MERINO
   SHEEP; SANTA-INES; RED MAASAI; INFECTIONS; SELECTION; GENE; PERFORMANCE;
   POPULATION
AB Gastrointestinal nematodes are a major constraint in sheep production. Breeding for resistance has proven to be an effective and feasible approach to address this problem. The use and investigation of genetic markers for resistance traits could accelerate genetic progress and lead to a better understanding of underlying molecular mechanisms. Thus, the aim of this study was to evaluate if five single nucleotide polymorphisms SNPs OAR2_14765360, OAR6_81718546, OAR11_62887032, OAR12_69606944 and OAR15_59871543 are associated with resistance and resilience traits in a flock of the Morada Nova sheep breed. Lambs were submitted to two consecutive parasite challenges by oral infection with 4000 infective larvae L-3) of Haemonchus contortus. Fecal egg counts (FEC), packed cell volume (PVC) and body weight were measured every one or two weeks for 42 days in each trial. DNA samples from 287 lambs, 131 ewes and 4 rams were amplified by ARMS-PCR or PCR-RFLP and genotypes were determined. Analysis of variance (ANOVA) was used for association analyses between genotypes and phenotypes. In case of significant association, the allele substitution effect was calculated based on a linear model. OAR2_14765360 and OAR12_69606944 were associated with FEC, and OAR12_69606944 also had significant effects on PCV and weight gain, showing favourable associations of the CC genotype with all evaluated traits. Both OAR6_81718546 and OAR11_62887032 were associated with weight gain, and OAR6_81718546 had an additional effect on PCV. OAR15_59871543 was not polymorphic in the population. OAR6_81718546 and OAR12_69606944 presented significant allele substitution effects of -1.06 +/- 0.52 kg for the T allele on final body weight and 0.74 +/- 0.32 for the C allele in PCV of the same sampling date, respectively. This is the first report of SNPs associated with gastrointestinal nematode resistance in this sheep breed. Our findings support the existence of quantitatice trait loci (QTL) for resistance and resilience in linkage disequilibrium with the polymorphic SNPs and suggest their future use for explorations of these traits in Morada Nova sheep.
C1 [Haehling, Marei B.; Toscano, Joao H. B.; Santos, Isabella B.] Univ Estadual Paulista, Fac Ciencias Agr & Vet, UNESP, Via Acesso Prof Paulo Donato Castellane S-N, BR-14884900 Jaboticabal, SP, Brazil.
   [Cruvinel, Giovanna G.; Giraldelo, Luciana A.] Ctr Univ Cent Paulista UNICEP, Rua Miguel Petroni 5111, BR-13563470 Sao Carlos, SP, Brazil.
   [Esteves, Sergio N.; Barioni Junior, Waldomiro; Niciura, Simone C. M.; Chagas, Ana Carolina S.] Embrapa Pecuaria Sudeste, Rod Washington Luiz,Km 234 Fazenda Canchim, BR-13560970 Sao Carlos, SP, Brazil.
   [Benavides, Magda, V] Embrapa Pecuaria Sul, BR 153 Km 633, Bage, RS, Brazil.
RP Haehling, MB (reprint author), Fazenda Santana Cp2, BR-13590000 Dourado, SP, Brazil.
EM marei.borsch@gmail.com
RI ; Benavides, M/F-6643-2015; Niciura, Simone/C-1150-2012; Chagas, Ana
   Carolina/H-7751-2013
OI Barbosa Toscano, Joao Henrique/0000-0002-5501-6099; Benavides,
   M/0000-0002-0219-3163; Niciura, Simone/0000-0003-0046-0050; Chagas, Ana
   Carolina/0000-0003-3939-0088
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2017/01626-1,
   2017/00373-2, 2017/24289-0]; Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq)National Council for Scientific and
   Technological Development (CNPq) [131537/2018-0]
FX We thank the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) - project no. 2017/01626-1 for financial support and
   scholarships (grants no. 2017/00373-2 and 2017/24289-0), and the
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) -
   grant no. 131537/2018-0 for the scholarship.
CR Akiyama H, 2008, MOD RHEUMATOL, V18, P213, DOI 10.1007/s10165-008-0048-x
   Ali AOA, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12626
   Amarante AFT, 2004, VET PARASITOL, V120, P91, DOI 10.1016/j.vetpar.2003.12.004
   Baker RL, 2004, ANIM SCI, V79, P343, DOI 10.1017/S1357729800090214
   Benavides MV, 2016, TRENDS PARASITOL, V32, P470, DOI 10.1016/j.pt.2016.03.007
   Benavides MV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122797
   Berton MP, 2017, J ANIM SCI BIOTECHNO, V8, DOI 10.1186/s40104-017-0190-4
   Bishop SC, 2007, SMALL RUMINANT RES, V70, P48, DOI 10.1016/j.smallrumres.2007.01.006
   Bishop SC, 2012, ANIMAL, V6, P741, DOI 10.1017/S1751731111000681
   Bishop SC, 2003, VET PARASITOL, V115, P147, DOI 10.1016/S0304-4017(03)00204-8
   Bishop Stephen C., 2012, Frontiers in Genetics, V3, P168, DOI 10.3389/fgene.2012.00168
   Lobo RNB, 2011, SMALL RUMINANT RES, V96, P93, DOI 10.1016/j.smallrumres.2011.01.009
   BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0
   Brown DJ, 2017, ANIM PROD SCI, V57, P209, DOI 10.1071/AN15469
   Chagas ACS, 2013, PARASITOL INT, V62, P1, DOI 10.1016/j.parint.2012.07.001
   Colditz IG, 1996, INT J PARASITOL, V26, P869, DOI 10.1016/S0020-7519(96)80058-0
   Coltman DW, 2001, PARASITOLOGY, V122, P571, DOI 10.1017/S0031182001007570
   Deniz E, 2017, FUNCT INTEGR GENOMIC, V17, P135, DOI 10.1007/s10142-016-0524-x
   Eady SJ, 2003, LIVEST PROD SCI, V81, P11, DOI 10.1016/S0301-6226(02)00197-5
   Faco O., 2008, RACA MORADA NOVA ORI, P43
   Ghaleb AM, 2017, GENE, V611, P27, DOI 10.1016/j.gene.2017.02.025
   Goldberg V, 2012, LIVEST SCI, V147, P181, DOI 10.1016/j.livsci.2012.05.003
   Gruner L, 2004, VET PARASITOL, V119, P51, DOI 10.1016/j.vetpar.2003.10.014
   Hunt Peter W, 2008, Trop Biomed, V25, P18
   Huttlin EL, 2017, NATURE, V545, P505, DOI 10.1038/nature22366
   Ingham A, 2008, INT J PARASITOL, V38, P431, DOI 10.1016/j.ijpara.2007.07.012
   Issakowicz J, 2016, SMALL RUMINANT RES, V136, P96, DOI 10.1016/j.smallrumres.2016.01.015
   Jackson F, 2009, SMALL RUMINANT RES, V86, P40, DOI 10.1016/j.smallrumres.2009.09.015
   Janssen MA, 2002, COMPLEXITY AND ECOSYSTEM MANAGEMENT, P1
   Kadarmideen HN, 2011, MOL BIOSYST, V7, P235, DOI 10.1039/c0mb00190b
   Kemper KE, 2011, GENET RES, V93, P203, DOI 10.1017/S0016672311000097
   Liu GE, 2011, MAMM GENOME, V22, P111, DOI 10.1007/s00335-010-9308-0
   Maizels RM, 2005, CURR OPIN IMMUNOL, V17, P656, DOI 10.1016/j.coi.2005.09.001
   Matika O, 2003, SMALL RUMINANT RES, V47, P95, DOI 10.1016/S0921-4488(02)00251-1
   Niciura SCM, 2018, MOL BIOL REP, V45, P651, DOI 10.1007/s11033-018-4206-8
   Morris CA, 1997, ANIM SCI, V64, P319, DOI 10.1017/S1357729800015897
   Mugambi JM, 2005, SMALL RUMINANT RES, V56, P239, DOI 10.1016/j.smallrumres.2004.06.003
   Papadopoulos E, 2012, VET PARASITOL, V189, P85, DOI 10.1016/j.vetpar.2012.03.036
   PERRY BD, 2002, INVESTING ANIMAL HLT
   Ruxton GD, 2008, BEHAV ECOL, V19, P690, DOI 10.1093/beheco/arn020
   Snyman MA, 2019, SMALL RUMINANT RES, V176, P76, DOI 10.1016/j.smallrumres.2019.01.004
   STEAR MJ, 1989, J ANIM SCI, V67, P641
   Toscano J.H.B., 2019, VET PARASITOL, V2, DOI [10.1016/j.vpoa.2019.100019, DOI 10.1016/J.VPOA.2019.100019]
   Woolaston RR, 1996, ANIM SCI, V62, P451, DOI 10.1017/S1357729800014995
   Woolaston RR, 2001, ANIM SCI, V73, P41, DOI 10.1017/S1357729800058033
   Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098
   Zvinorova PI, 2016, VET PARASITOL, V225, P19, DOI 10.1016/j.vetpar.2016.05.015
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109053
DI 10.1016/j.vetpar.2020.109053
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400009
PM 32109653
DA 2020-05-12
ER

PT J
AU Huercha
   Song, RQ
   Li, M
   Fan, XL
   Hu, ZX
   Wu, LJ
   Li, YC
   Zhang, W
   Zhang, Y
   Ma, YH
   Bayin, C
AF Huercha
   Song, Ruiqi
   Li, Min
   Fan, Xinli
   Hu, Zhengxiang
   Wu, Lijiang
   Li, Yongchang
   Zhang, Wei
   Zhang, Yang
   Ma, Yuhui
   Bayin, Chahan
TI Caracterization of glutathione S-transferase of Dermacantor marginatus
   and effect of the recombinant antigen as a potential anti-tick vaccine
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE GST; Dermacentor marginatus; Real-time PCR; Enzyme activity; Vaccine
   trail
ID RHIPICEPHALUS BOOPHILUS MICROPLUS; HAEMAPHYSALIS-LONGICORNIS;
   MOLECULAR-CLONING; SUPERGENE FAMILY; ACARI IXODIDAE; DOG TICK;
   EXPRESSION; GENE; APPENDICULATUS
AB Dermacentor marginatus is one of the main tick species in northwestern China, and is a vector of various tickborne pathogens. Tick control method largely depends on chemical agents, but the disadvantages of using such approach would cause environmental damage and the risk of developing tick resistance to acaricides. Vaccination of tick protective antigen is an eco-friendly approach which is an alternative and promising method to mitigate tick infestation in livestock. In the study, a mu-class glutathione S-transferase (GST) sequence of D. marginatus was cloned and the recombinant protein (rDmGST) was expressed. Transcriptional level of the GST was measured together with native GST activity of the tick. Finally, A vaccine trial on rabbits against D. marginatus was proceeded to evaluate the anti-tick effect of rDmGST. Results reveled that the CDs of the D. margiantus glutathione S-transferase mu 1 gene has 669 base pair nucleotide sequence encoding a 223 amino acid. The deduced GST protein sequence had over 95 % similarly with that of D. variabilis. The rDmGST was efficiently expressed soluble and purified by His trap affinity chromatography. Enzyme activity of native GST and transcriptional profiles of the GST showed up-regulation in different stages and organs of D. marginaus during blood feeding. Polyclonal antibody reacted with rDmGST in Western blotting. Tick challenge on rDmGST inoculated rabbits showed reductions in adult female engorgement rate, total egg mass and egg hatching rate with an overall vaccine efficacy of 43.69 %. The results of the experiment indicated the GST has potential value to be an effective protective antigen of D. marginatus.
C1 [Huercha; Song, Ruiqi] Xinjiang Agr Univ, Coll Anim Sci, Urumqi 830053, Xinjiang, Peoples R China.
   [Huercha; Song, Ruiqi; Li, Min; Fan, Xinli; Wu, Lijiang; Zhang, Wei; Zhang, Yang; Ma, Yuhui; Bayin, Chahan] Xinjiang Agr Univ, Coll Vet, Parasitol Lab, Urumqi 830053, Xinjiang, Peoples R China.
   [Li, Yongchang] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Obihiro, Hokkaido 0808555, Japan.
   [Hu, Zhengxiang] Bayingol Vocat & Tech Coll, Korla, Xinjiang 841000, Japan.
RP Bayin, C (reprint author), Xinjiang Agr Univ, Coll Vet Med, 311 Nongda Rd, Urumqi 830052, Peoples R China.
EM 2514062881@qq.com
FU Xinjiang Agricultural University as National Key R&D Program of China
   [2017FYD0500401]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [31660711]
FX This work was supported by Xinjiang Agricultural University as National
   Key R&D Program of China, project number 2017FYD0500401, and National
   Natural Science Foundation of China, project number 31660711. The
   funders had no role in the study design, data collection and analysis,
   decision to publish or preparation of the manuscript.
CR Adamson S, 2014, INSECT MOL BIOL, V23, P497, DOI 10.1111/imb.12098
   Aguilar G, 2018, FRONT BIOSCI-LANDMRK, V23, P65, DOI 10.2741/4582
   AGYEI AD, 1995, INT J PARASITOL, V25, P55, DOI 10.1016/0020-7519(94)00114-4
   Bonnet S, 2013, VECTOR-BORNE ZOONOT, V13, P226, DOI 10.1089/vbz.2011.0933
   Chisu V, 2019, ACTA TROP, V196, P60, DOI 10.1016/j.actatropica.2019.05.013
   Cicculli V, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8030138
   Contreras M, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00977
   Contreras M, 2016, METHODS MOL BIOL, V1404, P275, DOI 10.1007/978-1-4939-3389-1_19
   DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794
   de la Fuente J, 2013, VACCINE, V31, P5923, DOI 10.1016/j.vaccine.2013.10.049
   de Lima MFR, 2002, INSECT BIOCHEM MOLEC, V32, P747, DOI 10.1016/S0965-1748(01)00157-6
   Ding YC, 2003, BMC GENOMICS, V4, DOI 10.1186/1471-2164-4-35
   Dreher-Lesnick SM, 2006, INSECT MOL BIOL, V15, P445, DOI 10.1111/j.1365-2583.2006.00657.x
   Duscher GG, 2014, TICKS TICK-BORNE DIS, V5, P225, DOI 10.1016/j.ttbdis.2013.11.006
   Fomenko DE, 2011, P NATL ACAD SCI USA, V108, P2729, DOI 10.1073/pnas.1010721108
   Franta Z, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-119
   Galay RL, 2015, PARASITOL INT, V64, P182, DOI 10.1016/j.parint.2014.12.005
   HABIG WH, 1974, J BIOL CHEM, V249, P7130
   He HQ, 1999, INSECT BIOCHEM MOLEC, V29, P737, DOI 10.1016/S0965-1748(99)00056-9
   Hernandez EP, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2667-1
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Lewis B.C., 1986, BLOOD MEAL DIGESTION
   Liu Xiafei, 2020, Clin Infect Dis, V70, P2155, DOI 10.1093/cid/ciz602
   Lumjuan N, 2007, INSECT BIOCHEM MOLEC, V37, P1026, DOI 10.1016/j.ibmb.2007.05.018
   Ndawula C, 2019, VACCINE, V37, P1918, DOI 10.1016/j.vaccine.2019.02.039
   Oldiges DP, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005152
   Parizi LF, 2012, VACCINE, V30, P6912, DOI 10.1016/j.vaccine.2012.08.078
   Parizi LF, 2011, EXP PARASITOL, V127, P113, DOI 10.1016/j.exppara.2010.07.001
   Aguirre ADR, 2015, INT J PARASITOL, V45, P357, DOI 10.1016/j.ijpara.2015.02.003
   Reddy BPN, 2011, COMPUT BIOL CHEM, V35, P114, DOI 10.1016/j.compbiolchem.2011.03.004
   Reynolds CR, 2018, J MOL BIOL, V430, P2244, DOI 10.1016/j.jmb.2018.01.013
   Rubel F, 2016, TICKS TICK-BORNE DIS, V7, P224, DOI 10.1016/j.ttbdis.2015.10.015
   Rubel F, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0477-7
   Sabadin GA, 2017, VACCINE, V35, P6649, DOI 10.1016/j.vaccine.2017.10.026
   Shahein YE, 2008, VET PARASITOL, V152, P116, DOI 10.1016/j.vetpar.2007.12.014
   Sheng JL, 2019, TICKS TICK-BORNE DIS, V10, P665, DOI 10.1016/j.ttbdis.2019.02.011
   Song R, 2018, TRANSBOUND EMERG DIS, V65, P1537, DOI 10.1111/tbed.12894
   Song SN, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3233-6
   Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8
   Sun DL, 2019, CHEMOSPHERE, V226, P782, DOI 10.1016/j.chemosphere.2019.03.183
   Tirloni L, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0918-y
   Wang Q, 2018, TICKS TICK-BORNE DIS, V9, P1045, DOI 10.1016/j.ttbdis.2018.03.021
   WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187
   Wong PSY, 2001, ARCH BIOCHEM BIOPHYS, V394, P216, DOI 10.1006/abbi.2001.2532
   Xavier MA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23090-2
   Zhang Lin, 2014, Zhonghua Liu Xing Bing Xue Za Zhi, V35, P262
NR 47
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109043
DI 10.1016/j.vetpar.2020.109043
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400005
PM 32070900
DA 2020-05-12
ER

PT J
AU Rizk, MA
   El-Sayed, SAS
   Nassif, M
   Mosqueda, J
   Xuan, XN
   Igarashi, I
AF Rizk, Mohamed Abdo
   El-Sayed, Shimaa Abd El-Salam
   Nassif, Medhat
   Mosqueda, Juan
   Xuan, Xuenan
   Igarashi, Ikuo
TI Assay methods for in vitro and in vivo anti-Babesia drug efficacy
   testing: Current progress, outlook, and challenges
SO VETERINARY PARASITOLOGY
LA English
DT Review
DE Babesia; Theileria equi; Fluorescence assay; Drug testing; Review
ID NUCLEIC-ACID PRECURSORS; RICH PROTEIN-II; PLASMODIUM-FALCIPARUM;
   LACTATE-DEHYDROGENASE; THEILERIA-EQUI; STABLE EXPRESSION;
   CRYSTAL-STRUCTURE; BOVINE BABESIA; GREEN TEA; GROWTH
AB Absence of an effective high-throughput drug-screening system for Babesia parasites is considered one of the main causes for the presence of a wide gap in the treatment of animal babesiosis when compared with other hemoprotozoan diseases, such as malaria. Recently, a simple, accurate, and automatic fluorescence assay was established for large-scale anti-Babesia (B. bovis, B. bigemina, B. divergens, B. caballi and T. equi) drug screening. Such development will facilitate anti-Babesia drug discovery, especially in the post-genomic era, which will bring new chemotherapy targets with the completion of the Babesia genome sequencing project currently in progress. In this review, we present the current progress in the various assays for in vitro and in vivo anti-Babesia drug testing, as well as the challenges, highlighting new insights into the future of anti-Babesia drug screening.
C1 [Rizk, Mohamed Abdo; El-Sayed, Shimaa Abd El-Salam; Mosqueda, Juan; Xuan, Xuenan; Igarashi, Ikuo] Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Inada Cho, Obihiro, Hokkaido 0808555, Japan.
   [Rizk, Mohamed Abdo] Mansoura Univ, Fac Vet Med, Dept Internal Med & Infect Dis, Mansoura 35516, Egypt.
   [El-Sayed, Shimaa Abd El-Salam] Mansoura Univ, Fac Vet Med, Dept Biochem & Chem Nutr, Mansoura 35516, Egypt.
   [Nassif, Medhat] Kafrelsheikh Univ, Fac Vet Med, Dept Anim Med, Kafr Al Sheikh, Egypt.
   [Mosqueda, Juan] Univ Autonoma Queretaro, Fac Ciencias Nat, Ave Ciencias S-N, Juriquilla 76230, Queretaro, Mexico.
RP Igarashi, I (reprint author), Obihiro Univ Agr & Vet Med, Natl Res Ctr Protozoan Dis, Inada Cho, Obihiro, Hokkaido 0808555, Japan.
EM igarcpmi@obihiro.ac.jp
RI Rizk, Mohamed Abdo/J-7232-2019
OI Rizk, Mohamed Abdo/0000-0002-5250-6172; Mosqueda,
   Juan/0000-0001-8892-6390
FU Japan Society for the Promotion of Science (JSPS)Ministry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [P18091]
FX Mohamed Abdo Rizk is supported by a research grant fellowship for young
   scientists from the Japan Society for the Promotion of Science (JSPS)
   (ID No. P18091).
CR ABADZAPATERO C, 1987, J MOL BIOL, V198, P445, DOI 10.1016/0022-2836(87)90293-2
   AbouLaila M., 2011, Journal of Protozoology Research, V21, P30
   Aboulaila M, 2010, PARASITOLOGY, V137, P785, DOI 10.1017/S0031182009991594
   AbouLaila M, 2012, ANTIMICROB AGENTS CH, V56, P3196, DOI 10.1128/AAC.05488-11
   AbouLaila M, 2010, PARASITOL INT, V59, P278, DOI 10.1016/j.parint.2010.02.006
   AbouLaila M, 2010, VET PARASITOL, V167, P19, DOI 10.1016/j.vetpar.2009.09.049
   Akel T, 2017, ANN CLIN MICROB ANTI, V16, DOI 10.1186/s12941-017-0179-z
   Al-Anouti F, 2004, J BIOL CHEM, V279, P52300, DOI 10.1074/jbc.M409175200
   Ali Shuja, 1996, Journal of Equine Science, V7, P67, DOI 10.1294/jes.7.67
   Armstrong I, 1999, TLS-TIMES LIT SUPPL, P26
   Asada M, 2012, MOL BIOCHEM PARASIT, V181, P162, DOI 10.1016/j.molbiopara.2011.11.001
   Bacon DJ, 2007, ANTIMICROB AGENTS CH, V51, P1172, DOI 10.1128/AAC.01313-06
   Baniecki ML, 2007, ANTIMICROB AGENTS CH, V51, P716, DOI 10.1128/AAC.01144-06
   Basco L.K., 2007, FIELD APPL IN VITRO
   Bennett TN, 2004, ANTIMICROB AGENTS CH, V48, P1807, DOI 10.1128/AAC.48.5.1807-1810.2004
   Bock R, 2004, PARASITOLOGY, V129, pS247, DOI 10.1017/S0031182004005190
   Bork S, 2004, MOL BIOCHEM PARASIT, V136, P165, DOI 10.1016/j.molbiopara.2004.03.009
   Bork S, 2003, AM J TROP MED HYG, V68, P334, DOI 10.4269/ajtmh.2003.68.334
   Brasseur P, 1998, ANTIMICROB AGENTS CH, V42, P818, DOI 10.1128/AAC.42.4.818
   BROCKELMAN CR, 1991, J PARASITOL, V77, P994, DOI 10.2307/3282755
   Brown WM, 2004, BIOCHEMISTRY-US, V43, P6219, DOI 10.1021/bi049892w
   BZIK DJ, 1993, MOL BIOCHEM PARASIT, V59, P155, DOI 10.1016/0166-6851(93)90016-Q
   Chaturvedi S, 2017, IEEE INT SYMP DESIGN, P2, DOI 10.1109/DDECS.2017.7934566
   CHULAY JD, 1983, EXP PARASITOL, V55, P138, DOI 10.1016/0014-4894(83)90007-3
   Corbett Y, 2004, AM J TROP MED HYG, V70, P119, DOI 10.4269/ajtmh.2004.70.119
   Cui L, 2008, EXP PARASITOL, V120, P80, DOI 10.1016/j.exppara.2008.05.003
   Cui L, 2007, ANTIMICROB AGENTS CH, V51, P488, DOI 10.1128/AAC.01238-06
   Cursino-Santos JR, 2017, CYTOM PART A, V91A, P216, DOI 10.1002/cyto.a.23062
   Dalgliesh R. J., 1993, Immunology and molecular biology of parasitic infections., P352
   De Vos AJ, 2000, ANN NY ACAD SCI, V916, P540
   Dertinger SD, 2002, MUTAT RES-GEN TOX EN, V515, P3, DOI 10.1016/S1383-5718(02)00009-8
   Desakorn V, 1997, T ROY SOC TROP MED H, V91, P479, DOI 10.1016/S0035-9203(97)90292-3
   El-Sayed SA, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3296-z
   El-Sayed Shimaa Abd El-Salam, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P977, DOI 10.1016/j.apjtb.2015.09.001
   ELABBADI N, 1992, ANTIMICROB AGENTS CH, V36, P50, DOI 10.1128/AAC.36.1.50
   Elsify A, 2015, PARASITOL INT, V64, P79, DOI 10.1016/j.parint.2014.10.002
   Florin-Christensen M, 2014, PARASITOLOGY, V141, P1563, DOI 10.1017/S0031182014000961
   Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97
   GEARY TG, 1983, J PARASITOL, V69, P577, DOI 10.2307/3281373
   Gomes LI, 2012, EXP PARASITOL, V131, P175, DOI 10.1016/j.exppara.2012.03.021
   Gopalakrishnan A, 2016, VET PARASITOL, V217, P1, DOI 10.1016/j.vetpar.2015.12.024
   Guswanto A, 2018, INT J PARASITOL-DRUG, V8, P104, DOI 10.1016/j.ijpddr.2018.02.005
   Guswanto A, 2014, ANTIMICROB AGENTS CH, V58, P4713, DOI 10.1128/AAC.00022-14
   HABELA M, 1990, VET PARASITOL, V35, P1, DOI 10.1016/0304-4017(90)90111-N
   Hakimi H, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1439-z
   HASSAN HF, 1987, PARASITOL RES, V73, P121, DOI 10.1007/BF00536467
   Homer MJ, 2000, CLIN MICROBIOL REV, V13, P451, DOI 10.1128/CMR.13.3.451-469.2000
   HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269
   Hunfeld KP, 2008, INT J PARASITOL, V38, P1219, DOI 10.1016/j.ijpara.2008.03.001
   Hwang SJ, 2010, J VET MED SCI, V72, P765, DOI 10.1292/jvms.09-0535
   Igarashi I, 1998, EXP PARASITOL, V90, P290, DOI 10.1006/expr.1998.4331
   Inglese J, 2006, P NATL ACAD SCI USA, V103, P11473, DOI 10.1073/pnas.0604348103
   IRVIN AD, 1979, INT J PARASITOL, V9, P109, DOI 10.1016/0020-7519(79)90099-7
   IRVIN AD, 1978, INT J PARASITOL, V8, P19, DOI 10.1016/0020-7519(78)90046-2
   Jang J.W., 2014, TRANSFUS APHER SCI, V2014, P1
   Johnson JD, 2007, ANTIMICROB AGENTS CH, V51, P1926, DOI 10.1128/AAC.01607-06
   Kavanagh KL, 2004, BIOCHEMISTRY-US, V43, P879, DOI 10.1021/bi035108g
   Khan T, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-369
   Knapp M., 1998, P 4 ANN C EXH
   Kosaisavee V, 2006, EXP PARASITOL, V114, P34, DOI 10.1016/j.exppara.2006.02.006
   KUTTLER KL, 1986, VET PARASITOL, V21, P107, DOI 10.1016/0304-4017(86)90151-2
   LORBER M, 1958, BLOOD, V13, P972, DOI 10.1182/blood.V13.10.972.972
   Losos B.E., 1986, ANN RECH VET, V29, P501
   MAKLER MT, 1993, AM J TROP MED HYG, V48, P205, DOI 10.4269/ajtmh.1993.48.205
   MAKLER MT, 1993, AM J TROP MED HYG, V48, P739, DOI 10.4269/ajtmh.1993.48.739
   Mayr LM, 2008, J BIOMOL SCREEN, V13, P443, DOI 10.1177/1087057108319644
   McCosker P.J., 1981, GLOBAL IMPORTANCE BA, P1
   MOLTMANN UG, 1983, J PARASITOL, V69, P111, DOI 10.2307/3281285
   Mosqueda J, 2012, CURR MED CHEM, V19, P1504, DOI 10.2174/092986712799828355
   Munkhjargal T, 2012, AM J TROP MED HYG, V87, P681, DOI 10.4269/ajtmh.2012.12-0218
   Nagai A, 2003, ANTIMICROB AGENTS CH, V47, P800, DOI 10.1128/AAC.47.2.800-803.2003
   Noedl H, 2002, ANTIMICROB AGENTS CH, V46, P1658, DOI 10.1128/AAC.46.6.1658-1664.2002
   Noedl H, 2003, AM J TROP MED HYG, V68, P140, DOI 10.4269/ajtmh.2003.68.140
   NOTT SE, 1990, INT J PARASITOL, V20, P797, DOI 10.1016/0020-7519(90)90014-E
   Nugraha AB, 2019, INT J PARASITOL-DRUG, V10, P84, DOI 10.1016/j.ijpddr.2019.06.004
   Pandey AV, 1999, J BIOL CHEM, V274, P19383, DOI 10.1074/jbc.274.27.19383
   Pasini EM, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-190
   PAYNE D, 1988, B WORLD HEALTH ORGAN, V66, P621
   Quashie N.B., 2006, MALARIA J, V95, P1
   Rizk MA, 2019, VET PARASITOL, V274, DOI 10.1016/j.vetpar.2019.07.003
   Rizk MA, 2018, INFECT DRUG RESIST, V11, P1605, DOI 10.2147/IDR.S159519
   Rizk MA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13052-5
   Rizk MA, 2017, EXP PARASITOL, V179, P43, DOI 10.1016/j.exppara.2017.06.003
   Rizk MA, 2016, VET PARASITOL, V227, P93, DOI 10.1016/j.vetpar.2016.07.032
   Rizk MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125276
   Salama AA, 2014, PARASITOL RES, V113, P275, DOI 10.1007/s00436-013-3654-2
   Salama AA, 2013, VET PARASITOL, V191, P1, DOI 10.1016/j.vetpar.2012.08.022
   SASS C, 1989, J BIOL CHEM, V264, P4076
   SCHEIN E, 1981, TROPENMED PARASITOL, V32, P223
   Sherman Irwin W., 1998, P135
   SHERMAN IW, 1977, B WORLD HEALTH ORGAN, V55, P211
   SHERMAN IW, 1961, J EXP MED, V114, P1049, DOI 10.1084/jem.114.6.1049
   Silva MG, 2018, INT J PARASITOL-DRUG, V8, P265, DOI 10.1016/j.ijpddr.2018.04.004
   Silva MG, 2013, INT J PARASITOL-DRUG, V3, P59, DOI 10.1016/j.ijpddr.2013.01.003
   SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325
   Smilkstein M, 2004, ANTIMICROB AGENTS CH, V48, P1803, DOI 10.1128/AAC.48.5.1803-1806.2004
   Sriwilaijaroen Nongluk, 2004, Southeast Asian Journal of Tropical Medicine and Public Health, V35, P840
   Suarez CE, 2009, INT J PARASITOL, V39, P289, DOI 10.1016/j.ijpara.2008.08.006
   Tayebwa DS, 2018, TICKS TICK-BORNE DIS, V9, P1192, DOI 10.1016/j.ttbdis.2018.04.019
   Tekwani BL, 2005, COMB CHEM HIGH T SCR, V8, P63, DOI 10.2174/1386207053328101
   Telford Sam R. III, 1993, P1
   Tuvshintulga B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14304-0
   Uilenberg G, 2006, VET PARASITOL, V138, P3, DOI 10.1016/j.vetpar.2006.01.035
   Van Voorhis WC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005763
   VANVIANEN PH, 1990, AM J TROP MED HYG, V43, P602, DOI 10.4269/ajtmh.1990.43.602
   Vossen MG, 2010, AM J TROP MED HYG, V82, P398, DOI 10.4269/ajtmh.2010.09-0417
   WAKI S, 1986, T ROY SOC TROP MED H, V80, P47, DOI 10.1016/0035-9203(86)90192-6
   Wein S, 2010, J CLIN MICROBIOL, V48, P1651, DOI 10.1128/JCM.02250-09
   Weisman JL, 2006, CHEM BIOL DRUG DES, V67, P409, DOI 10.1111/j.1747-0285.2006.00391.x
   Winter VJ, 2003, MOL BIOCHEM PARASIT, V131, P1, DOI 10.1016/S0166-6851(03)00170-1
   Yamasaki M, 2017, EXP PARASITOL, V183, P92, DOI 10.1016/j.exppara.2017.10.016
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
NR 112
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109013
DI 10.1016/j.vetpar.2019.109013
PG 12
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400002
PM 32070899
DA 2020-05-12
ER

PT J
AU Tian, XW
   Lu, MM
   Jia, CW
   Bu, YQ
   Aimulajiang, K
   Zhang, Y
   Li, C
   Yan, RF
   Xu, LX
   Song, XK
   Li, XR
AF Tian, Xiaowei
   Lu, Mingmin
   Jia, Caiwen
   Bu, Yongqian
   Aimulajiang, Kalibixiati
   Zhang, Yang
   Li, Charles
   Yan, Ruofeng
   Xu, Lixin
   Song, Xiaokai
   Li, Xiangrui
TI Haemonchus contortus transthyretin domain - containing protein (HcTTR):
   A promising vaccine candidate against Haemonchus contortus infection
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Haemonchus contortus; HcTTR; Passive and active immunization; Vaccine
   development
ID GROWTH-FACTOR-BETA; ANTHELMINTIC RESISTANCE; EXCRETORY/SECRETORY
   PRODUCTS; PROTECTIVE IMMUNITY; SHEEP; PARASITE; RESPONSES; GOATS;
   INTERLEUKIN-4; PROGRESS
AB Haemonchus contortus transthyretin domain-containing protein (HcTTR) with 136 amino acids belongs to a transthyretin-like (TTL) family member. In our previous study, it was reported that HcTTR was a novel antagonist of the goat cytokine Interleukin 4 (IL-4), and was involved in the regulation of host immune responses, implying that it might be applied for therapeutic strategies or vaccine development against the infection of H. contortus. Thus, the protective capacities of HcTTR against H. contortus infections via active and passive immunization trials were examined. For the passive protection trials, H. contortus-infected goats were intravenously immunized twice with 5 mg of total IgG containing anti-rHcTTR goat polyclonal antibodies. The results showed that the significant rates of reduction in egg shedding and worm burden was 58.12% and 64.61%, respectively, as compared with the positive control group. For the active protection trials, local goats were vaccinated twice with 500 mu g of recombinant HcTTR to generate antigen-specific circulating antibodies, resulting in 63.7% reduction in eggs shedding and 66.4% reduction in worm burdens after H. contortus challenge. In both passive and active trials, the immunized goats displayed higher mucosal IgA levels and less anaemic compared to the challenged positive controls. Pen trials indicated that HcTTR generated partial immune protective effects against H. contortus challenge and it could be a promising vaccine candidate for development of effective strategy to control H. contortus.
C1 [Tian, Xiaowei; Lu, Mingmin; Jia, Caiwen; Bu, Yongqian; Aimulajiang, Kalibixiati; Zhang, Yang; Yan, Ruofeng; Xu, Lixin; Song, Xiaokai; Li, Xiangrui] Nanjing Agr Univ, Coll Vet Med, MOE Joint Int Res Lab Anim Hlth & Food Safety, Nanjing 210095, Peoples R China.
   [Li, Charles] ARS, Anim Biosci & Biotechnol Lab, Beltsville Agr Res Ctr, USDA, Beltsville, MD 20705 USA.
RP Li, XR (reprint author), Nanjing Agr Univ, Coll Vet Med, MOE Joint Int Res Lab Anim Hlth & Food Safety, Nanjing 210095, Peoples R China.
EM 2017207011@njau.edu.cn; mingmin.lu@hotmail.com; WayneJ5@126.com;
   2016207023@njau.edu.cn; 2017207022@njau.edu.cn; 2018207018@njau.edu.cn;
   charles.li@usda.gov; yanruofeng@njau.edu.cn; xulixin@njau.edu.cn;
   songxiaokai@njau.edu.cn; lixiangrui@njau.edu.cn
FU National Key Research and Development Program of China [2017YFD0501200];
   policy guidance project of Jiangsu Province for international scientific
   and technological cooperation [BZ2019013]
FX This work was funded by grants from the National Key Research and
   Development Program of China (Grant No.2017YFD0501200) and the policy
   guidance project of Jiangsu Province for international scientific and
   technological cooperation (Grant No. BZ2019013).
CR Amarante AFT, 2005, VET PARASITOL, V128, P99, DOI 10.1016/j.vetpar.2004.11.021
   Arunkumar Selvarayar, 2012, Vet Res Forum, V3, P239
   Bakker N, 2004, VACCINE, V22, P618, DOI 10.1016/j.vaccine.2003.08.025
   Ehsani M, 2017, PIPELINES 2017: CONSTRUCTION AND REHABILITATION, P10
   Falzon LC, 2013, VET PARASITOL, V193, P150, DOI 10.1016/j.vetpar.2012.11.014
   Fanyao K., 1997, LIVESTOCK PARASITOLO, P365
   Fawzi EM, 2014, INT J PARASITOL, V44, P429, DOI 10.1016/j.ijpara.2014.02.009
   Fleming SA, 2006, J VET INTERN MED, V20, P435, DOI 10.1892/0891-6640(2006)20[435:AROGPI]2.0.CO;2
   Gadahi JA, 2016, EXP PARASITOL, V171, P57, DOI 10.1016/j.exppara.2016.10.014
   Gill HS, 2000, IMMUNOLOGY, V99, P458, DOI 10.1046/j.1365-2567.2000.00974.x
   Gilleard JS, 2016, ADV PARASIT, V93, P31, DOI 10.1016/bs.apar.2016.02.009
   Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704
   Han KK, 2012, VET IMMUNOL IMMUNOP, V149, P177, DOI 10.1016/j.vetimm.2012.06.016
   Hewitson JR, 2008, MOL BIOCHEM PARASIT, V160, P8, DOI 10.1016/j.molbiopara.2008.02.007
   Hotez PJ, 2003, INT J PARASITOL, V33, P1245, DOI 10.1016/S0020-7519(03)00158-9
   Matos AFIM, 2017, SMALL RUMINANT RES, V151, P1, DOI 10.1016/j.smallrumres.2017.03.016
   Jacobs JR, 2015, VET PARASITOL, V211, P102, DOI 10.1016/j.vetpar.2015.04.024
   Knox DP, 2001, VET PARASITOL, V100, P21, DOI 10.1016/S0304-4017(01)00480-0
   Kotze AC, 2016, ADV PARASIT, V93, P397, DOI 10.1016/bs.apar.2016.02.012
   Lacroux C, 2006, VET RES, V37, P607, DOI 10.1051/vetres:2006022
   Lamb J, 2017, VET PARASITOL, V241, P48, DOI 10.1016/j.vetpar.2017.05.008
   Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737
   Lu M, 2017, IEEE ASME INT C ADV, P106, DOI 10.1109/AIM.2017.8014003
   Matsuzaki G, 2018, MICROBIOL IMMUNOL, V62, P1, DOI 10.1111/1348-0421.12560
   Matthews JB, 2016, PARASITE IMMUNOL, V38, P744, DOI 10.1111/pim.12391
   Nisbet AJ, 2016, ADV PARASIT, V93, P353, DOI 10.1016/bs.apar.2016.02.011
   RAHMAN WA, 1990, VET PARASITOL, V35, P189, DOI 10.1016/0304-4017(90)90053-E
   SCHALLIG HDFH, 1994, PARASITOLOGY, V108, P351, DOI 10.1017/S0031182000076198
   SCHALLIG HDFH, 1995, VET PARASITOL, V56, P149, DOI 10.1016/0304-4017(94)00675-3
   Schalling H.D.F.H., 1997, PARASITOLOGY 3, V114, P293
   Sonnhammer ELL, 1997, GENOMICS, V46, P200, DOI 10.1006/geno.1997.4989
   Stear MJ, 2004, PARASITOLOGY, V129, P363, DOI 10.1017/S0031182004005736
   Tian XW, 2019, VET RES, V50, DOI 10.1186/s13567-019-0661-z
   Torres-Acosta JFJ, 2012, VET PARASITOL, V189, P89, DOI 10.1016/j.vetpar.2012.03.037
   URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513
   Vercauteren I, 2003, MOL BIOCHEM PARASIT, V126, P201, DOI 10.1016/S0166-6851(02)00274-8
   Wang Q, 2019, CMC-COMPUT MATER CON, V59, P105, DOI 10.32604/cmc.2019.03739
   Wang YJ, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2368-1
   Wen YL, 2017, VET PARASITOL, V243, P100, DOI 10.1016/j.vetpar.2017.06.018
   Weybridge C.V.L., 1977, AUST VET J, V54, P310
   Yan R., 2009, ANIMAL HUSBANDRY VET, V41, P86
   Yanming S, 2007, PARASITE IMMUNOL, V29, P319, DOI 10.1111/j.1365-3024.2007.00949.x
   Yatsuda AP, 2003, J BIOL CHEM, V278, P16941, DOI 10.1074/jbc.M212453200
   Zhao GW, 2012, VET J, V191, P94, DOI 10.1016/j.tvjl.2010.12.023
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109045
DI 10.1016/j.vetpar.2020.109045
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400007
PM 32045836
DA 2020-05-12
ER

PT J
AU Tsoi, FMB
   Slapeta, J
   Reynolds, M
AF Tsoi, Fei Man Bernice
   Slapeta, Jan
   Reynolds, Michael
TI Ctenocephalides felis (cat flea) infestation in neonatal dairy calves
   managed with deltamethrin pour-on in Australia
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Siphonaptera; Holstein Friesian cattle; Deltamethrin; Flea management;
   Flea infestation
ID DOGS; COLLARS
AB Ctenocephalides fells infestations outbreak is documented as a welfare and production limiting disease in neonatal calves in eastern New South Wales, Australia. Due to the calves' discomfort, the first objective was to relieve the calves from the large burden of fleas. The affected neonatal 0-4 week old calves showed dull and quiet demeanour, with the geometric mean of body condition score (BCS) 2.67 (2-4) and geometric mean burden 41.51 (15-75) of fleas collected over 3 min. Deltamethrin pour-on (Arrest Easy-Dose, Virbac Animal Health, Australia) registered for treatment of lice and flies on cattle in Australia was evaluated for control effect of the cat flea (C. fells) on cattle. The fleas were identified morphologically as being C. fells which was confirmed by sequencing cytochrome c oxidase I gene (cox1). We report successful improvement of welfare and reduction of flea counts post application of pour-on deltamethrin on the property. In the absence of registered flea product for cattle in Australia, deltamethrin pour-on product is a suitable option, because of its registration for control of lice and flies on cattle.
C1 [Tsoi, Fei Man Bernice; Slapeta, Jan; Reynolds, Michael] Univ Sydney, Fac Sci, Sydney Sch Vet Sci, Sydney, NSW 2006, Australia.
RP Slapeta, J (reprint author), Univ Sydney, Fac Sci, Sydney Sch Vet Sci, Sydney, NSW 2006, Australia.
EM jan.slapeta@sydney.edu.au
OI Slapeta, Jan/0000-0003-1459-9117
FU Sydney School of Veterinary Science Research & Enquiry Unit of Study
   2018 fund
FX This work was completed in partial fulfilment for the requirements of
   the Doctor of Veterinary Medicine degree, The University of Sydney
   (FMBT). The work was funded by the Sydney School of Veterinary Science
   Research & Enquiry Unit of Study 2018 fund.
CR Araujo FR, 1998, VET PARASITOL, V80, P83, DOI 10.1016/S0304-4017(98)00181-2
   Clark NJ, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-017-2564-z
   Crkvencic N, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3399-6
   DRYDEN MW, 1993, J AM VET MED ASSOC, V203, P1448
   DRYDEN MW, 1994, VET PARASITOL, V52, P1, DOI 10.1016/0304-4017(94)90031-0
   Dunnet G., 1974, AUSTR J ZOOLOGY S, V22, P1, DOI DOI 10.1071/AJZS030
   Eads DA, 2018, J WILDLIFE DIS, V54, P745, DOI 10.7589/2017-10-250
   Franc M, 1998, AM J VET RES, V59, P59
   Franc M, 1999, VET PARASITOL, V81, P341, DOI 10.1016/S0304-4017(98)00257-X
   Halos L, 2014, TRENDS PARASITOL, V30, P228, DOI 10.1016/j.pt.2014.02.007
   Kaal JF, 2006, VET PARASITOL, V141, P313, DOI 10.1016/j.vetpar.2006.05.034
   KillickKendrick R, 1997, MED VET ENTOMOL, V11, P105, DOI 10.1111/j.1365-2915.1997.tb00298.x
   Lanyon SR, 2014, VET J, V199, P201, DOI 10.1016/j.tvjl.2013.07.024
   Lawrence AL, 2014, MED VET ENTOMOL, V28, P330, DOI 10.1111/mve.12051
   Lawrence AL, 2019, INT J PARASITOL, V49, P321, DOI 10.1016/j.ijpara.2019.01.001
   MESTRES R, 1992, REV ENVIRON CONTAM T, V124, P1
   Paulin S, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3094-z
   Reynolds M.W., 2014, P WORLD BUIATR C CAI
   Rust MK, 2017, INSECTS, V8, DOI 10.3390/insects8040118
   Slapeta J, 2011, VET PARASITOL, V180, P383, DOI 10.1016/j.vetpar.2011.03.035
   Weber T, 2016, CHEMMEDCHEM, V11, P270, DOI 10.1002/cmdc.201500516
   Webster MC, 2011, AUST VET J, V89, P439, DOI 10.1111/j.1751-0813.2011.00828.x
   YERUHAM I, 1989, VET PARASITOL, V30, P351, DOI 10.1016/0304-4017(89)90105-2
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109039
DI 10.1016/j.vetpar.2020.109039
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400003
PM 32044501
DA 2020-05-12
ER

PT J
AU Turner, JD
   Marriott, AE
   Hong, D
   O'Neill, P
   Ward, SA
   Taylor, MJ
AF Turner, Joseph D.
   Marriott, Amy E.
   Hong, David
   O'Neill, Paul
   Ward, Steve A.
   Taylor, Mark J.
TI Novel anti-Wolbachia drugs, a new approach in the treatment and
   prevention of veterinary filariasis?
SO VETERINARY PARASITOLOGY
LA English
DT Article; Proceedings Paper
CT Symposium of the American-Heartworm-Society
CY SEP 08-11, 2019
CL New Orleans, LA
SP Amer Heartworm Soc
DE Filariasis; Dirofilaria; Heartworm disease; Wolbachia; Doxycycline;
   Chemotherapy
ID MACROCYCLIC LACTONE RESISTANCE; DIROFILARIA-IMMITIS INFECTIONS;
   MACROFILARICIDAL ACTIVITY; BRUGIA-MALAYI; DOXYCYCLINE TREATMENT; CANINE
   HEARTWORM; DOUBLE-BLIND; LITOMOSOIDES-SIGMODONTIS; WUCHERERIA-BANCROFTI;
   ONCHOCERCA-VOLVULUS
AB Filarial nematodes are tissue-dwelling parasitic worms that can cause a range of disfiguring pathologies in humans and potentially lethal infections of companion animals. The bacterial endosymbiont, Wolbachia, is present within most human and veterinary filarial pathogens, including the causative agent of heartworm disease, Dirofilaria immitis. Doxycycline-mediated drug targeting of Wolbachia leads to sterility, clearance of microfilariae and gradual death of adult filariae. This mode of action is attractive in the treatment of filariasis because it avoids severe host inflammatory adverse reactions invoked by rapid-killing anthelmintic agents. However, doxycycline needs to be taken for four weeks to exert curative activity. In this review, we discuss the evidence that Wolbachia drug targeting is efficacious in blocking filarial larval development as well as in the treatment of chronic filarial disease. We present the current portfolio of next-generation anti-Wolbachia candidates discovered through phenotypic screening of chemical libraries and validated in a range of in vitro and in vivo filarial infection models. Several novel chemotypes have been identified with selected narrow-spectrum anti-Wolbachia specificity and superior time-to-kill kinetics compared with doxycycline. We discuss the opportunities of developing these novel anti-Wolbachia agents as either cures, adjunct therapies or new preventatives for the treatment of veterinary filariasis.
C1 [Turner, Joseph D.; Marriott, Amy E.; Ward, Steve A.; Taylor, Mark J.] Univ Liverpool Liverpool Sch Trop Med, Ctr Drugs & Diagnost, Dept Trop Dis Biol, Liverpool, Merseyside, England.
   [Hong, David; O'Neill, Paul] Univ Liverpool, Dept Chem, Liverpool, Merseyside, England.
RP Turner, JD (reprint author), Univ Liverpool Liverpool Sch Trop Med, Ctr Drugs & Diagnost, Dept Trop Dis Biol, Liverpool, Merseyside, England.
EM joseph.turner@lstmed.ac.uk
OI Marriott, Amy/0000-0002-4806-9539; Turner, Joseph/0000-0002-2185-5476
CR AHS, 2019, CURR CAN GUID PREV D
   AHS, 2016, HEARTW NUMB
   AHS, 2019, CURR FEL GUID PREV D
   Albers A, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-12
   Aljayyoussi G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00322-5
   Arumugam S, 2008, INT J PARASITOL, V38, P981, DOI 10.1016/j.ijpara.2007.12.006
   Bakowski MA, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav3523
   Ballesteros C, 2018, INT J PARASITOL-DRUG, V8, P596, DOI 10.1016/j.ijpddr.2018.06.006
   Bandi C, 1998, P ROY SOC B-BIOL SCI, V265, P2407, DOI 10.1098/rspb.1998.0591
   Bazzocchi C, 2008, INT J PARASITOL, V38, P1401, DOI 10.1016/j.ijpara.2008.03.002
   BOSSHARDT SC, 1993, J PARASITOL, V79, P775, DOI 10.2307/3283620
   Bourguinat C, 2015, VET PARASITOL, V210, P167, DOI 10.1016/j.vetpar.2015.04.002
   Bourguinat C, 2011, VET PARASITOL, V181, P388, DOI 10.1016/j.vetpar.2011.04.012
   Bourguinat C, 2011, VET PARASITOL, V176, P374, DOI 10.1016/j.vetpar.2011.01.024
   Bowman D, 2009, VET PARASITOL, V160, P138, DOI 10.1016/j.vetpar.2008.10.093
   Chandrashekar R, 2014, VET PARASITOL, V206, P93, DOI 10.1016/j.vetpar.2014.08.011
   Clare RH, 2019, SLAS DISCOV, V24, P537, DOI 10.1177/2472555219838341
   Clare RH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07826-2
   Clare RH, 2015, J BIOMOL SCREEN, V20, P64, DOI 10.1177/1087057114551518
   CLARK JN, 1992, AM J VET RES, V53, P517
   Debrah AY, 2007, TROP MED INT HEALTH, V12, P1433, DOI 10.1111/j.1365-3156.2007.01949.x
   Debrah AY, 2006, PLOS PATHOG, V2, P829, DOI 10.1371/journal.ppat.0020092
   Debrah AY, 2015, CLIN INFECT DIS, V61, P517, DOI 10.1093/cid/civ363
   Debrah Alexander Yaw, 2011, J Parasitol Res, V2011, P201617, DOI 10.1155/2011/201617
   Di Cesare A, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-347
   Foster J, 2005, PLOS BIOL, V3, P599, DOI 10.1371/journal.pbio.0030121
   Genchi C, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2434-8
   Genchi C, 2009, VET PARASITOL, V163, P286, DOI 10.1016/j.vetpar.2009.03.026
   Genchi M, 2019, VET PARASITOL, V273, P11, DOI 10.1016/j.vetpar.2019.07.011
   Giannelli A, 2013, VET PARASITOL, V197, P702, DOI 10.1016/j.vetpar.2013.05.012
   Grandi G, 2010, VET PARASITOL, V169, P347, DOI 10.1016/j.vetpar.2010.01.025
   Hise AG, 2007, J IMMUNOL, V178, P1068, DOI 10.4049/jimmunol.178.2.1068
   Hoerauf A, 1999, J CLIN INVEST, V103, P11, DOI 10.1172/JCI4768
   Hoerauf A, 2009, PARASITOL RES, V104, P437, DOI 10.1007/s00436-008-1217-8
   Hoerauf A, 2008, MED MICROBIOL IMMUN, V197, P335, DOI 10.1007/s00430-007-0072-z
   Hong WD, 2019, P NATL ACAD SCI USA, V116, P1414, DOI 10.1073/pnas.1816585116
   Hubner MP, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007636
   Jacobs RT, 2019, J MED CHEM, V62, P2521, DOI 10.1021/acs.jmedchem.8b01854
   Johnston KL, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao1551
   Johnston KL, 2014, INT J PARASITOL-DRUG, V4, P278, DOI 10.1016/j.ijpddr.2014.09.001
   Khowawisetsut L, 2017, VET PARASITOL, V245, P42, DOI 10.1016/j.vetpar.2017.08.009
   Klarmann-Schulz U, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005156
   KOZEK WJ, 1977, J PARASITOL, V63, P992, DOI 10.2307/3279832
   KOZEK WJ, 1977, AM J TROP MED HYG, V26, P663, DOI 10.4269/ajtmh.1977.26.663
   Kramer L, 2011, VET PARASITOL, V176, P357, DOI 10.1016/j.vetpar.2011.01.021
   Kryda K, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3702-6
   Landmann F, 2012, BIOL OPEN, V1, P536, DOI 10.1242/bio.2012737
   Langworthy NG, 2000, P ROY SOC B-BIOL SCI, V267, P1063, DOI 10.1098/rspb.2000.1110
   Lee ACY, 2010, TRENDS PARASITOL, V26, P168, DOI 10.1016/j.pt.2010.01.003
   Lefoulon E, 2016, PEERJ, V4, DOI 10.7717/peerj.1840
   Lespine A, 2012, INT J PARASITOL-DRUG, V2, P58, DOI 10.1016/j.ijpddr.2011.10.001
   Levy JK, 2007, JAVMA-J AM VET MED A, V231, P218, DOI 10.2460/javma.231.2.218
   Li ZM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041658
   Mallawarachchi CH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206633
   Mallawarachchi CH, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2649-3
   Mand S, 2009, AM J TROP MED HYG, V81, P702, DOI 10.4269/ajtmh.2009.09-0155
   McCall JW, 2014, VET PARASITOL, V206, P5, DOI 10.1016/j.vetpar.2014.09.023
   McCall JW, 2011, VET PARASITOL, V176, P361, DOI 10.1016/j.vetpar.2011.01.022
   McCall JW, 2008, ADV PARASIT, V66, P193, DOI 10.1016/S0065-308X(08)00204-2
   McCall JW, 1996, AM J VET RES, V57, P1189
   McGarry HF, 2004, MOL BIOCHEM PARASIT, V135, P57, DOI 10.1016/j.molbiopara.2004.01.006
   MCLAREN DJ, 1975, T ROY SOC TROP MED H, V69, P509, DOI 10.1016/0035-9203(75)90110-8
   McTier TL, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3632-3
   Morchon R, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00196
   Nochot H, 2019, EXP PARASITOL, V200, P73, DOI 10.1016/j.exppara.2019.03.016
   PAUL AJ, 1986, AM J VET RES, V47, P883
   Pollono F., 1998, Parassitologia (Rome), V40, P457
   Pomba C, 2017, J ANTIMICROB CHEMOTH, V72, P957, DOI 10.1093/jac/dkw481
   Prichard RK, 2019, INT J PARASITOL-DRUG, V10, P69, DOI 10.1016/j.ijpddr.2019.06.002
   Pulaski CN, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0494-6
   Savadelis MD, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3264-z
   Serbus LR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002922
   Simon F, 2012, CLIN MICROBIOL REV, V25, P507, DOI 10.1128/CMR.00012-12
   Sironi M, 1995, MOL BIOCHEM PARASIT, V74, P223, DOI 10.1016/0166-6851(95)02494-8
   Slatko BE, 2010, SYMBIOSIS, V51, P55, DOI 10.1007/s13199-010-0067-1
   Snyder DE, 2011, VET PARASITOL, V180, P262, DOI 10.1016/j.vetpar.2011.03.034
   Specht S, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006116
   Specht S, 2009, PARASITOL RES, V106, P23, DOI 10.1007/s00436-009-1624-5
   Taylor MJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau2086
   Taylor MJ, 2014, PARASITOLOGY, V141, P119, DOI 10.1017/S0031182013001108
   Taylor MJ, 2010, LANCET, V376, P1175, DOI 10.1016/S0140-6736(10)60586-7
   Taylor MJ, 2005, LANCET, V365, P2116, DOI 10.1016/S0140-6736(05)66591-9
   Turner JD, 2006, CLIN INFECT DIS, V42, P1081, DOI 10.1086/501351
   Turner JD, 2006, J IMMUNOL, V177, P1240, DOI 10.4049/jimmunol.177.2.1240
   Turner JD, 2017, P NATL ACAD SCI USA, V114, pE9712, DOI 10.1073/pnas.1710845114
   Turner JD, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000660
   Turner JD, 2009, J BIOL CHEM, V284, P22364, DOI 10.1074/jbc.M901528200
   von Geldern TW, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007159
   Voronin D, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008085
   Walker M, 2015, CLIN INFECT DIS, V60, P1199, DOI 10.1093/cid/ciu1152
   Wanji S, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-39
   Wolstenholme AJ, 2015, PARASITOLOGY, V142, P1249, DOI 10.1017/S003118201500061X
   Wu B, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000475
   Zueva T, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3570-0
NR 94
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109057
DI 10.1016/j.vetpar.2020.109057
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400011
PM 32126342
DA 2020-05-12
ER

PT J
AU Xu, ZM
   Yan, YJ
   Zhang, HS
   Cao, J
   Zhou, YZ
   Xu, QM
   Zhou, JL
AF Xu, Zhengmao
   Yan, Yijie
   Zhang, Houshuang
   Cao, Jie
   Zhou, Yongzhi
   Xu, Qianming
   Zhou, Jinlin
TI A serpin from the tick Rhipicephalus haemaphysaloides: Involvement in
   vitellogenesis
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Tick; Serpin; RNA interference; Vitellogenin
ID PROTEASE INHIBITORS SERPINS; IXODES-SCAPULARIS; RESISTANT CATTLE;
   MICROPLUS; EXPRESSION; ACARICIDES; APPENDICULATUS; THROMBIN; TARGETS;
   PROFILE
AB Tick serpins are involved in enzyme activity, food digestion, blood-feeding, immune response and anticoagulation. Little is known about the potential roles of serpins in tick reproduction. RHS8, a serpin from the tick Rhipicephalus haemaphysaloides, has an open reading frame 1212 bp long and encodes a protein that has 404 amino acids and a predicted molecular weight of 45 kDa. RHS8 exhibits 89.58 % amino acid identity with RmS15 in Rhipicephalus microplus. RHS8 was expressed primarily in larvae and nymphs. RHS8 mRNA expression in the ovaries, fat bodies and salivary glands were up-regulated from feeding to ovipositing ticks. RNAi results showed that RHS8 dsRNA-injected ticks had a lower body weight, longer feeding time, fewer eggs laid and lower egg hatchability. Tick reproduction, such as egg laying and hatching, was disrupted by RNAi. Compared with the control group, ovaries of the RHS8 interference group were light brown color, indicating a reduction in yolk granule accumulation. Western blot results showed that the expression of RHVg3 and RHVg4 proteins in ovaries was reduced in the RHS8 dsRNA-injected group. These results indicate that RHS8 is related to tick reproduction and its interference affects vitellogenesis.
C1 [Xu, Zhengmao; Yan, Yijie; Zhang, Houshuang; Cao, Jie; Zhou, Yongzhi; Zhou, Jinlin] Chinese Acad Agr Sci, Shanghai Vet Res Inst, Key Lab Anim Parasitol, Minist Agr, Shanghai, Peoples R China.
   [Yan, Yijie; Xu, Qianming] Anhui Agr Univ, Coll Anim Sci & Technol, Hefei, Peoples R China.
RP Zhou, JL (reprint author), Chinese Acad Agr Sci, Shanghai Vet Res Inst, Key Lab Anim Parasitol, Minist Agr, Shanghai, Peoples R China.
EM xzhengmao92@163.com; 1104471292@qq.com; zhanghoushuang@shvri.ac.cn;
   caojie@shvri.ac.cn; zhyzhi@shvri.ac.cn; xuqianming2006@163.com;
   jinlinzhou@shvri.ac.cn
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China [31572512]
FX This work was supported by a grant (No. 31572512) from the National
   Natural Science Foundation of China (NSFC).
CR Araman S.F., 1979, P385
   Bakshi M, 2018, TICKS TICK-BORNE DIS, V9, P506, DOI 10.1016/j.ttbdis.2018.01.001
   Benelli G, 2017, TICKS TICK-BORNE DIS, V8, P821, DOI 10.1016/j.ttbdis.2017.08.004
   BHAT HR, 1978, ACTA VIROL, V22, P241
   Chan SF, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.113.117200
   Chen T, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.115030
   Chen Z, 2010, EXP APPL ACAROL, V51, P393, DOI 10.1007/s10493-010-9335-2
   Chmelar J, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00216
   Chmelar J, 2011, BLOOD, V117, P736, DOI 10.1182/blood-2010-06-293241
   Dantas-Torres F, 2012, TRENDS PARASITOL, V28, P437, DOI 10.1016/j.pt.2012.07.003
   de la Fuente J, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00114
   De Meneghi D, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00239
   Diyes GCP, 2017, MED VET ENTOMOL, V31, P327, DOI 10.1111/mve.12238
   Domingos A, 2015, METHODS MOL BIOL, V1247, P475, DOI 10.1007/978-1-4939-2004-4_32
   Eatemadi A, 2017, BIOMED PHARMACOTHER, V86, P221, DOI 10.1016/j.biopha.2016.12.021
   Estrela AB, 2010, COMP BIOCHEM PHYS B, V157, P326, DOI 10.1016/j.cbpb.2010.08.002
   Fular A, 2018, TICKS TICK-BORNE DIS, V9, P1184, DOI 10.1016/j.ttbdis.2018.04.014
   Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+
   Ghosh S, 2015, TICKS TICK-BORNE DIS, V6, P668, DOI 10.1016/j.ttbdis.2015.05.013
   Gubb D, 2010, BIOCHIMIE, V92, P1749, DOI 10.1016/j.biochi.2010.09.004
   Guerrero FD, 2012, REV BRAS PARASITOL V, V21, P1, DOI 10.1590/S1984-29612012000100002
   HOPKINS PCR, 1995, BIOCHEMISTRY-US, V34, P15872, DOI 10.1021/bi00048a033
   HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008
   Huntington JA, 2011, J THROMB HAEMOST, V9, P26, DOI 10.1111/j.1538-7836.2011.04360.x
   Huo Y, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006909
   Ibelli AMG, 2014, INT J PARASITOL, V44, P369, DOI 10.1016/j.ijpara.2014.01.010
   Imamura S, 2006, VACCINE, V24, P2230, DOI 10.1016/j.vaccine.2005.10.055
   Jittapalapong S, 2010, TRANSBOUND EMERG DIS, V57, P103, DOI 10.1111/j.1865-1682.2010.01108.x
   Jongejan F, 2004, PARASITOLOGY, V129, pS3, DOI 10.1017/S0031182004005967
   Khalil SMS, 2011, J INSECT PHYSIOL, V57, P400, DOI 10.1016/j.jinsphys.2010.12.008
   Khan M.S., 2011, J AMINO ACIDS, V2011, P1, DOI DOI 10.4061/2011/606797
   Kim TK, 2015, INT J PARASITOL, V45, P613, DOI 10.1016/j.ijpara.2015.03.009
   Li L, 2017, FISH SHELLFISH IMMUN, V69, P6, DOI 10.1016/j.fsi.2017.08.002
   Lopez-Arias A, 2014, ENVIRON HEALTH INSIG, V8, P71, DOI [10.4137/EHI.S16006, 10.4137/EHi.s16006]
   Lu K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030269
   Luo X, 2015, PEPTIDES, V68, P58, DOI 10.1016/j.peptides.2014.11.002
   Maritz-Olivier C, 2007, TRENDS PARASITOL, V23, P397, DOI 10.1016/j.pt.2007.07.005
   Mulenga A, 2013, INSECT MOL BIOL, V22, P306, DOI 10.1111/imb.12024
   Mulenga A, 2003, INSECT BIOCHEM MOLEC, V33, P267, DOI 10.1016/S0965-1748(02)00240-0
   Mulenga A, 2007, J EXP BIOL, V210, P3188, DOI 10.1242/jeb.006494
   Mulenga A, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-217
   Park HG, 2018, DEV COMP IMMUNOL, V85, P51, DOI 10.1016/j.dci.2018.04.001
   Pavela R, 2016, RES VET SCI, V109, P1, DOI 10.1016/j.rvsc.2016.09.001
   Perner J, 2016, SCI REP-UK, V6, DOI 10.1038/srep36695
   Porter LM, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2080-1
   Radulovic ZM, 2017, INSECT BIOCHEM MOLEC, V80, P1, DOI 10.1016/j.ibmb.2016.11.002
   Rodriguez-Hidalgo R, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0174652, 10.1371]
   Rodriguez-Valle M, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-014-0605-4
   Rodriguez-Valle M, 2012, TICKS TICK-BORNE DIS, V3, P159, DOI 10.1016/j.ttbdis.2012.03.002
   Rodriguez-Vivas RI, 2018, PARASITOL RES, V117, P3, DOI 10.1007/s00436-017-5677-6
   Seixas A, 2018, TICKS TICK-BORNE DIS, V9, P72, DOI 10.1016/j.ttbdis.2017.10.006
   Smith AD, 2014, TICKS TICK-BORNE DIS, V5, P821, DOI 10.1016/j.ttbdis.2014.06.001
   Sugino M, 2003, VACCINE, V21, P2844, DOI 10.1016/S0264-410X(03)00167-1
   Tirloni L, 2016, INSECT BIOCHEM MOLEC, V71, P12, DOI 10.1016/j.ibmb.2016.01.004
   Tirloni L, 2014, EXP PARASITOL, V137, P25, DOI 10.1016/j.exppara.2013.12.001
   Tufail M, 2008, J INSECT PHYSIOL, V54, P1447, DOI 10.1016/j.jinsphys.2008.08.007
   Xavier MA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23090-2
   Xu T, 2016, TICKS TICK-BORNE DIS, V7, P180, DOI 10.1016/j.ttbdis.2015.09.007
   Yin H, 1997, TROP ANIM HEALTH PRO, V29, p11S, DOI 10.1007/BF02632908
   Yu XM, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2161-1
   Yu XM, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1213-7
   Yu YF, 2013, TICKS TICK-BORNE DIS, V4, P297, DOI 10.1016/j.ttbdis.2013.02.001
   Zhang Y, 2018, PARASITOL INT, V67, P415, DOI 10.1016/j.parint.2018.04.002
   Zhou JL, 2006, PARASITOL RES, V100, P77, DOI 10.1007/s00436-006-0243-7
NR 64
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109064
DI 10.1016/j.vetpar.2020.109064
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400016
PM 32143012
DA 2020-05-12
ER

PT J
AU Zeb, J
   Shams, S
   Din, IU
   Ayaz, S
   Khan, A
   Nasreen, N
   Khan, H
   Khan, MA
   Senbill, H
AF Zeb, Jehan
   Shams, Sumaira
   Din, Israr Ud
   Ayaz, Sultan
   Khan, Adil
   Nasreen, Nasreen
   Khan, Hamidullah
   Khan, Munsif Ali
   Senbill, Haytham
TI Molecular epidemiology and associated risk factors of Anaplasma
   marginale and Theileria annulata in cattle from North-western Pakistan
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Anaplasma marginale; Theileria annulata; Cattle; Pakistan; Epidemiology;
   Ticks & TBDs
ID BUFFALOS; IDENTIFICATION; RICKETTSIACEAE; PREVALENCE; BABESIOSIS
AB Ticks and tick-borne pathogens are one of the major threats to livestock production worldwide. The aim of present study is to specify the molecular epidemiology and its associated risk factors of two well-distributed tickborne pathogens Anaplasma marginale and Theileria annulata in cattle population from North-western Pakistan. Blood samples were Collected from 60 (32.6 %) local breed cattle, 101 (54.9 %) from crossbreed, and 24 (13.0 %) from exotic breed with total of 184 blood samples. Species-specific PCR assays were performed to detect the presence of A. marginale and T. annulata based on 16S rRNA and 18S rRNA genetic makers respectively. PCR results showed that A. marginale was 16.3 % prevalent and T. annulata was 29.9 % prevalent in the study area with a total prevalence rate of 46.2 % (85/184) of the tested blood samples. District wise analysis revealed that both pathogens were highly prevalent in district Dir Upper (13.6 %) and least prevalent in district Chitral (10.3 %). Univariable analysis of risk factors showed that only breed and acaricidal treatment were significant determinants (P < 0.05) for A. marginale infection, however, in case of T. annulata infection; breed, age, gender, grazing practice, and acaricidal treatment were potential determinants (P < 0.05). Multivariable analysis specified that breed and acaricidal treatment were considered as significant risk factors for A. marginale infection (P < 0.05) whereas acaricidal treatment was found to be a significant determinant for T. annulata infection (P < 0.05). Phylogenetic analysis indicated that A. marginale 16S rRNA and T. annulata 18S rRNA isolates showed similarities and shared phylogeny with same isolates reported from Asia. This is the first molecular report on the epidemiology and risk factors analysis of A. marginale and T. annulata infections in cattle population from NW Pakistan. Further large scale study is required to investigate molecular, epidemiological and genotypic aspects as well as potential risk factors analysis from the country to facilitate designing strategies to control tick-borne pathogen and reduce losses to cattle industry.
C1 [Zeb, Jehan; Shams, Sumaira; Khan, Adil; Nasreen, Nasreen; Khan, Munsif Ali] Abdul Wali Khan Univ, Dept Zool, Mardan 23200, Pakistan.
   [Din, Israr Ud] Univ Agr, Inst Biotechnol & Genet Engn, Peshawar 25130, Pakistan.
   [Ayaz, Sultan; Khan, Hamidullah] Abdul Wali Khan Univ, Coll Anim Husb & Vet Sci, Mardan 23200, Pakistan.
   [Senbill, Haytham] Assam Agr Univ, Fac Agr, Dept Entomol, Jorhat 785013, Assam, India.
   [Senbill, Haytham] Alexandria Univ, Fac Agr, Dept Appl Entomol & Zool, Alexandria 21545, Egypt.
RP Senbill, H (reprint author), Alexandria Univ, Fac Agr, Dept Appl Entomol & Zool, Alexandria 21545, Egypt.
EM zebjehan2012@gmail.com; sumairashams@awkum.edu.pk;
   israr.uddin@aup.edu.pk; sultanayaz64@awkum.edu.pk;
   zoologyawkum@gmail.com; nasreen@awkum.edu.pk; attitude.khan@gmail.com;
   munsifalikhan111@gmail.com; haytham.senbill@alexu.edu.eg
FU Higher Education Commission of PakistanHigher Education Commission of
   Pakistan
FX We acknowledge Higher Education Commission of Pakistan for funding
   support for the study. The funding agency had no role in study design,
   samples collection, data analysis and interpretation.
CR Akhter N, 2010, VET WORLD, V3, P272
   Ali A, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00793
   Aubry P, 2011, TRANSBOUND EMERG DIS, V58, P1, DOI 10.1111/j.1865-1682.2010.01173.x
   Bhutta M.S., 2014, PAKISTAN GLOB VET, V12, P146
   Bilgic HB, 2010, VET PARASITOL, V174, P341, DOI 10.1016/j.vetpar.2010.08.025
   Bishop Richard P., 2009, P191, DOI 10.1007/978-3-540-74042-1_6
   Brown C., 2008, FOREIGN ANIMAL DIS, P401
   Bursakov SA, 2019, TICKS TICK-BORNE DIS, V10, P709, DOI 10.1016/j.ttbdis.2019.03.004
   da Silveira JAG, 2011, VET PARASITOL, V177, P61, DOI 10.1016/j.vetpar.2010.10.044
   de la Fuente J, 2001, VET PARASITOL, V97, P65, DOI 10.1016/S0304-4017(01)00378-8
   Dumler JS, 2001, INT J SYST EVOL MICR, V51, P2145, DOI 10.1099/00207713-51-6-2145
   Durrani AZ, 2008, J ANIM PLANT SCI, V18, P57
   Farooqi SH, 2018, TROP ANIM HEALTH PRO, V50, P1591, DOI 10.1007/s11250-018-1599-2
   Hassan MA, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3035-x
   Jabbar A, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0894-2
   Jonsson NN, 2008, VET PARASITOL, V155, P1, DOI 10.1016/j.vetpar.2008.03.022
   Khan MK, 2013, INFECT GENET EVOL, V13, P124, DOI 10.1016/j.meegid.2012.09.007
   Khattak RM, 2012, PARASITE, V19, P91, DOI 10.1051/parasite/2012191091
   Kocan KM, 2008, TICKS: BIOLOGY, DISEASE AND CONTROL, P325, DOI 10.1017/CBO9780511551802.016
   Kocan KM, 2010, VET PARASITOL, V167, P95, DOI 10.1016/j.vetpar.2009.09.012
   Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msw054, 10.1093/molbev/msv279]
   Kundave VR, 2014, TROP BIOMED, V31, P728
   Lew-Tabor AE, 2016, TICKS TICK-BORNE DIS, V7, P573, DOI 10.1016/j.ttbdis.2015.12.012
   Liu ZJ, 2005, VET MICROBIOL, V107, P145, DOI 10.1016/j.vetmic.2005.01.007
   Merino O, 2011, VACCINE, V29, P8575, DOI 10.1016/j.vaccine.2011.09.023
   Moumouni PFA, 2018, TICKS TICK-BORNE DIS, V9, P450, DOI 10.1016/j.ttbdis.2017.12.015
   Ola-Fadunsin SD, 2018, PARASITOL INT, V67, P659, DOI 10.1016/j.parint.2018.06.013
   Rehman A, 2019, TRANSBOUND EMERG DIS, V66, P526, DOI 10.1111/tbed.13059
   Roberts T.J., 1997, MAMMALS PAKISTAN, P525
   Sajid M. S., 2014, Global Veterinaria, V12, P146
   Theiler A., 1908, REPORT GOVT VET BACT, P7
   UILENBERG G, 1995, VET PARASITOL, V57, P19, DOI 10.1016/0304-4017(94)03107-8
   Zeb J, 2019, EXP APPL ACAROL, V79, P233, DOI 10.1007/s10493-019-00418-9
   Zhou M, 2016, TICKS TICK-BORNE DIS, V7, P126, DOI 10.1016/j.ttbdis.2015.09.008
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109044
DI 10.1016/j.vetpar.2020.109044
PG 8
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400006
PM 32032840
DA 2020-05-12
ER

PT J
AU Zhao, NN
   Lv, JF
   Lu, YR
   Jiang, YY
   Li, HM
   Liu, YM
   Zhang, X
   Zhao, XM
AF Zhao, Ningning
   Lv, Junfeng
   Lu, Yaru
   Jiang, Yingying
   Li, Hongmei
   Liu, Yumin
   Zhang, Xiao
   Zhao, Xiaomin
TI Prolonging and enhancing the protective efficacy of the EtMIC3-C-MAR
   against eimeria tenella through delivered by attenuated salmonella
   typhimurium
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Attenuated S. typhimurium; Oral vaccine; E. tenella; MAR
ID ENTERICA SEROVAR TYPHIMURIUM; MEDIATED INHIBITION; IMMUNE-RESPONSES;
   SECRETORY IGA; IN-VITRO; VACCINE; ACERVULINA; CHICKENS; EXPRESSION;
   PROTEIN
AB The microneme adhesive repeats (MAR) of Eimeria tenella microneme protein 3 (EtMIC3) are associated with binding to and invasion of host cells. Adhesion and invasion-related proteins or domains are often strongly immunogenic, immune responses mounted against these factors that play a key role in blocking invasion. In the present study, an oral live vaccine consisting of attenuated Salmonella typhimurium X4550 carrying two MAR domains fragment (St-X4550-MAR) was constructed and its protective efficacies were evaluated. The results showed that St-X4550-MAR was more immunogenic and conferred a higher degree of protection than recombinant MAR polypeptide as reflected by increased body weight, decreased oocyst shedding and lesion scores, increased serum IgG and cecal sIgA antibody production, and increasing levels of interferon-y and interleukin10. Thus, MAR domains are highly immunogenic and St-X4550-MAR had moderate activity against E. tenella infection by stimulating humoral, mucosal and cellular immunity. Chickens immunized with our constructed live vaccine provided considerable protections as early as at 10 d post-immunization (ACI: 155.17), and maintained higher protection levels at 20 d post-immunization (ACI: 173.66), and at 30 d post-immunization (ACI: 162.4). While the protective efficacy of chickens immunized with the recombinant MAR peptides showed a decreased trend as the post immunization time prolonging. Thus, using live-attenuated S. typhimurium X4550 as a vaccine expression and delivery system can significantly improve the protective efficacy and duration of protective immunity of MAR of EtMIC3.
C1 [Zhao, Ningning; Lv, Junfeng; Lu, Yaru; Jiang, Yingying; Li, Hongmei; Zhang, Xiao; Zhao, Xiaomin] Shandong Agr Univ, Coll Vet Med, Dept Prevent Vet Med, Tai An, Shandong, Peoples R China.
   [Zhao, Xiaomin] Shandong Agr Univ, Shandong Prov Key Lab Anim Biotechnol & Dis Contr, 61 Daizong St, Tai An 271018, Shandong, Peoples R China.
   [Zhao, Xiaomin] Shandong Agr Univ, Shandong Prov Engn Technol Res Ctr Anim Dis Contr, 61 Daizong St, Tai An, Shandong, Peoples R China.
   [Liu, Yumin] Shandong Huamutianyuan Agr & Anim Husb Co Ltd, 1 Gangxing 3 Rd, Jinan 250101, Shandong, Peoples R China.
RP Zhang, X; Zhao, XM (reprint author), Shandong Agr Univ, Shandong Prov Key Lab Anim Biotechnol & Dis Contr, 61 Daizong St, Tai An 271018, Shandong, Peoples R China.
EM tzhangxiao@126.com; xmzhao66@163.com
FU National Key Research and Development Program of China [2017YFD0500400];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31572514]; Funds of Shandong "Double Tops" Program
   [SYL2017YSTD11]
FX This work was supported by grants from the National Key Research and
   Development Program of China (Grant No. 2017YFD0500400), National
   Natural Science Foundation of China (No. 31572514) and Funds of Shandong
   "Double Tops" Program (SYL2017YSTD11).
CR Blumenschein TMA, 2007, EMBO J, V26, P2808, DOI 10.1038/sj.emboj.7601704
   Cao HD, 2010, TUMORI J, V96, P296
   Carrero JC, 2007, PARASITE IMMUNOL, V29, P331, DOI 10.1111/j.1365-3024.2007.00955.x
   Chen PP, 2015, EXP PARASITOL, V155, P1, DOI 10.1016/j.exppara.2015.04.020
   Chen ZT, 2018, VACCINE, V36, P2435, DOI 10.1016/j.vaccine.2018.03.046
   Chin'ombe N, 2013, VIRUSES-BASEL, V5, P2062, DOI 10.3390/v5092062
   Cong H, 2005, PARASITE IMMUNOL, V27, P29, DOI 10.1111/j.1365-3024.2005.00738.x
   Cornelissen JBWJ, 2009, VET PARASITOL, V162, P58, DOI 10.1016/j.vetpar.2009.02.001
   Cowper B, 2012, MOL BIOCHEM PARASIT, V186, P1, DOI 10.1016/j.molbiopara.2012.08.007
   CURTISS R, 1994, DEV BIOL STAND, V82, P23
   DAVIS PJ, 1979, IMMUNOLOGY, V36, P471
   DAVIS PJ, 1978, IMMUNOLOGY, V34, P879
   del Cacho E, 2016, VET PARASITOL, V224, P1, DOI 10.1016/j.vetpar.2016.04.043
   Du AF, 2005, INT J PARASITOL, V35, P777, DOI 10.1016/j.ijpara.2005.03.005
   Fetterer RH, 2003, J PARASITOL, V89, P553, DOI 10.1645/GE-3159
   Friedrich N, 2010, J BIOL CHEM, V285, P2064, DOI 10.1074/jbc.M109.060988
   Geriletu, 2011, VET PARASITOL, V177, P6, DOI 10.1016/j.vetpar.2010.11.041
   Ghunaim H, 2014, VET MICROBIOL, V172, P13, DOI 10.1016/j.vetmic.2014.04.019
   Guillermo T., 2014, VET MED RES REP, V23
   Han Y, 2017, PATHOG DIS, V75, DOI 10.1093/femspd/ftx102
   Hong YH, 2006, VET IMMUNOL IMMUNOP, V114, P209, DOI 10.1016/j.vetimm.2006.07.007
   JOHNSON J, 1970, EXP PARASITOL, V28, P30, DOI 10.1016/0014-4894(70)90063-9
   Kang HY, 2002, INFECT IMMUN, V70, P1739, DOI 10.1128/IAI.70.4.1739-1749.2002
   Kardani K, 2016, VACCINE, V34, P413, DOI 10.1016/j.vaccine.2015.11.062
   Kim JH, 2018, VET RES, V49, DOI 10.1186/s13567-018-0509-y
   Konjufca V, 2008, INFECT IMMUN, V76, P5745, DOI 10.1128/IAI.00897-08
   Konjufca V, 2006, INFECT IMMUN, V74, P6785, DOI 10.1128/IAI.00851-06
   Kundu K, 2017, VET PARASITOL, V244, P44, DOI 10.1016/j.vetpar.2017.07.025
   Lawal JR, 2016, VET WORLD, V9, P653, DOI 10.14202/vetworld.2016.653-659
   Lillehoj HS, 1998, AVIAN DIS, V42, P307, DOI 10.2307/1592481
   Lillehoj HS, 2004, POULTRY SCI, V83, P611, DOI 10.1093/ps/83.4.611
   LILLEHOJ HS, 1987, AVIAN DIS, V31, P112, DOI 10.2307/1590782
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MCMANUS EC, 1968, J PARASITOL, V54, P1190, DOI 10.2307/3276989
   NAKAYAMA K, 1988, BIO-TECHNOL, V6, P693, DOI 10.1038/nbt0688-693
   Pastor-Fernandez I, 2018, INT J PARASITOL, V48, P505, DOI 10.1016/j.ijpara.2018.01.003
   Periz J, 2007, J BIOL CHEM, V282, P16891, DOI 10.1074/jbc.M702407200
   Qi NS, 2013, PARASITOL RES, V112, P2281, DOI 10.1007/s00436-013-3389-0
   Rothwell L, 2004, J IMMUNOL, V173, P2675, DOI 10.4049/jimmunol.173.4.2675
   Shirley MW, 2005, ADV PARASIT, V60, P285, DOI 10.1016/S0065-308X(05)60005-X
   Sirard JC, 1999, IMMUNOL REV, V171, P5, DOI 10.1111/j.1600-065X.1999.tb01340.x
   Song XK, 2017, RES VET SCI, V111, P31, DOI 10.1016/j.rvsc.2016.11.012
   Sun H, 2014, VACCINE, V32, P1869, DOI 10.1016/j.vaccine.2014.01.068
   Tomley FM, 2001, INT J PARASITOL, V31, P1303, DOI 10.1016/S0020-7519(01)00255-7
   Vermeulen A, 2001, VET PARASITOL, V100, P13, DOI 10.1016/S0304-4017(01)00479-4
   Williams RB, 1999, INT J PARASITOL, V29, P1209, DOI 10.1016/S0020-7519(99)00086-7
   Zhang B, 2019, AUTOPHAGY, DOI 10.1080/15548627.2019.1664705
   Zhao NN, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00596-19
   Zhou BH, 2015, KOREAN J PARASITOL, V53, P675, DOI 10.3347/kjp.2015.53.6.675
NR 49
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109061
DI 10.1016/j.vetpar.2020.109061
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400014
PM 32143014
DA 2020-05-12
ER

PT J
AU Zhou, CH
   Chen, JP
   Niu, HY
   Ouyang, S
   Wu, XP
AF Zhou, Chunhua
   Chen, Jinping
   Niu, Hongyan
   Ouyang, Shan
   Wu, Xiaoping
TI Study on the population evolution of Ascaris lumbricoides and Ascaris
   suum based on whole genome resequencing
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Genome resequencing; Ascaris lumbricoides; Ascaris suum; Population
   history
ID GLUTAMATE-RECEPTOR; HUMANS; EPIDEMIOLOGY; INFECTIONS; GENOTYPES; PIGS;
   NEMATODES; DYNAMICS; SEQUENCE
AB Ascaris lumbricoides and Ascaris suum are parasitic nematodes that mainly parasitize the small intestines of people and pigs, respectively. Ascariasis seriously endangers human health and causes huge economic losses in the pig industry. A. lumbricoides and A. suum have similar morphologies and genetic structures, and occasionally these organisms cross-infect the alternate host. Therefore, their taxonomies are controversial. In this study, the whole genomes of A. lumbricoides (n = 6) and A. suum (n = 6) were resequenced using a HiSeq X Ten sequencing platform. Phylogenetic, principal component, and population structure analyses showed clear genetic differentiation between the two Ascaris populations. Linkage disequilibrium analysis indicated that the A. lumbricoides population was more primitive than the A. suum population. In the selective elimination analysis, 160 and 139 candidate regions were screened in A. lumbricoides and A. suum, respectively, and the selected regions were analyzed by Gene Ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses. The A. lumbricoides population had no significant enrichment in GO terms, but two KEGG pathways, the RNA degradation and tyrosine metabolism pathways, were significantly enriched. Five GO entries and one KEGG pathway, the alanine, aspartate, and glutamate metabolism signaling pathway, were significantly enriched in the A. suum population. An analysis of the demographic histories of Ascaris populations revealed that A. lumbricoides and A. suum had similar trends in effective population size in different historical periods. Ascaris populations peaked about 1 million years ago and then began to decline. In the last glacial period, they dropped to a historical low and continued at this level until the last glacial maximum. This phenomenon may be associated with the cold climate at that time. This study provides new information on the genetic differentiation, evolutionary relationships, gene functional enrichment, and population dynamics of Ascaris populations, with implications for host differences, evolution, and classification of A. lumbricoides and A. suum.
C1 [Zhou, Chunhua; Chen, Jinping; Niu, Hongyan; Ouyang, Shan; Wu, Xiaoping] Nanchang Univ, Sch Life Sci, Nanchang 330031, Jiangxi, Peoples R China.
RP Zhou, CH; Wu, XP (reprint author), Nanchang Univ, Sch Life Sci, Nanchang 330031, Jiangxi, Peoples R China.
EM zhouchunhuajx@hotmail.com; xpwu@ncu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [81460318]
FX This work was funded by the National Natural Science Foundation of China
   (81460318). Thanks to Professor Weidong Peng at Nanchang University,
   China, for his help in data analysis. Thanks also to Dr. Tao Wang at the
   University of Melbourne, Australia, for kindly providing reference data.
CR Abad P, 2008, NAT BIOTECHNOL, V26, P909, DOI 10.1038/nbt.1482
   Anderson JD, 2003, J PARASITOL, V89, P1232, DOI 10.1645/GE-99R
   Anderson TJC, 1998, ADV PARASIT, V41, P219, DOI 10.1016/S0065-308X(08)60425-X
   Anderson TJC, 1997, PARASITOLOGY, V115, P325, DOI 10.1017/S0031182097001339
   ANDERSON TJC, 1995, PARASITOLOGY, V110, P215, DOI 10.1017/S0031182000063988
   ANDERSON TJC, 1993, PARASITOLOGY, V107, P319, DOI 10.1017/S0031182000079294
   Arizono N, 2010, JPN J INFECT DIS, V63, P447
   Betson M, 2014, J INFECT DIS, V210, P932, DOI 10.1093/infdis/jiu193
   Cleland TA, 1996, MOL NEUROBIOL, V13, P97, DOI 10.1007/BF02740637
   Criscione CD, 2007, P ROY SOC B-BIOL SCI, V274, P2669, DOI 10.1098/rspb.2007.0877
   Cully DF, 1996, J BIOL CHEM, V271, P20187, DOI 10.1074/jbc.271.33.20187
   Ehlers J, 2007, QUATERN INT, V164-65, P6, DOI 10.1016/j.quaint.2006.10.008
   Fosu-Nyarko J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147511
   GRATION KAF, 1979, BRAIN RES, V171, P360, DOI 10.1016/0006-8993(79)90343-3
   Greenberg RM, 2014, CURR CLIN MICROBIOL, V1, P51, DOI 10.1007/s40588-014-0007-6
   Guo Y, 2011, J INSECT SCI, V11, DOI 10.1673/031.011.15501
   Holland C, 2013, ASCARIS: THE NEGLECTED PARASITE, pXVII
   Kaminsky R, 2008, NATURE, V452, P176, DOI 10.1038/nature06722
   Leles D, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-42
   Li H, 2011, NATURE, V475, P493, DOI 10.1038/nature10231
   Liu GH, 2012, GENE, V492, P110, DOI 10.1016/j.gene.2011.10.043
   Loreille O, 2003, MEM I OSWALDO CRUZ, V98, P39, DOI 10.1590/S0074-02762003000900008
   Nadachowska-Brzyska K, 2015, CURR BIOL, V25, P1375, DOI 10.1016/j.cub.2015.03.047
   Nejsum P, 2009, PARASITOLOGY, V136, P193, DOI 10.1017/S0031182008005349
   Nejsum P, 2005, J CLIN MICROBIOL, V43, P1142, DOI 10.1128/JCM.43.3.1142-1148.2005
   Peng W, 2007, PARASITOLOGY, V134, P325, DOI 10.1017/S0031182006001521
   Peng W, 2006, PARASITOLOGY, V133, P651, DOI 10.1017/S0031182006000643
   Peng WD, 2005, ELECTROPHORESIS, V26, P4317, DOI 10.1002/elps.200500276
   Peng WD, 1998, PARASITOLOGY, V117, P355, DOI 10.1017/S0031182098003102
   Peng WD, 2003, ELECTROPHORESIS, V24, P2308, DOI 10.1002/elps.200305455
   Peng WD, 1998, ADV PARASIT, V41, P109, DOI 10.1016/S0065-308X(08)60423-6
   Peng W, 2012, INFECT GENET EVOL, V12, P227, DOI 10.1016/j.meegid.2012.01.012
   Shao CC, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-99
   SHOOP WL, 1995, VET PARASITOL, V59, P139, DOI 10.1016/0304-4017(94)00743-V
   Stratton M, 2008, NAT BIOTECHNOL, V26, P65, DOI 10.1038/nbt0108-65
   [王婧 WANG Jing], 2008, [中国病原生物学杂志, Journal of Pathogen Biology], V3, P209
   Wang XY, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r107
   Wit J, 2017, TRENDS PARASITOL, V33, P388, DOI 10.1016/j.pt.2017.01.009
   Xia JH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14168
   Yang D, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0138-6
   Yang Yang, 2017, Acta Veterinaria et Zootechnica Sinica, V48, P979
   Young ND, 2012, NAT GENET, V44, P221, DOI 10.1038/ng.1065
   Zhao SC, 2013, NAT GENET, V45, P67, DOI 10.1038/ng.2494
   Zheng HJ, 2013, NAT GENET, V45, P1168, DOI 10.1038/ng.2757
   Zhou CH, 2012, INFECT GENET EVOL, V12, P1172, DOI 10.1016/j.meegid.2012.04.016
   Zhou CH, 2011, PARASITOL RES, V109, P329, DOI 10.1007/s00436-011-2260-4
   Zhou Y, 2009, NATURE, V460, P345, DOI 10.1038/nature08140
   Zhu XQ, 1999, INT J PARASITOL, V29, P469, DOI 10.1016/S0020-7519(98)00226-4
NR 48
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAR
PY 2020
VL 279
AR UNSP 109062
DI 10.1016/j.vetpar.2020.109062
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LD0IS
UT WOS:000525717400015
PM 32126343
DA 2020-05-12
ER

PT J
AU Driscoll, AJ
   Arshad, SH
   Bont, L
   Brunwasser, SM
   Cherian, T
   Englund, JA
   Fell, DB
   Hammitt, LL
   Hartert, TV
   Innis, BL
   Karron, RA
   Langley, GE
   Mulholland, EK
   Munywoki, PK
   Nair, H
   Ortiz, JR
   Savitz, DA
   Scheltema, NM
   Simoes, EAF
   Smith, PG
   Were, F
   Zar, HJ
   Feikin, DR
AF Driscoll, Amanda J.
   Arshad, S. Hasan
   Bont, Louis
   Brunwasser, Steven M.
   Cherian, Thomas
   Englund, Janet A.
   Fell, Deshayne B.
   Hammitt, Laura L.
   Hartert, Tina V.
   Innis, Bruce L.
   Karron, Ruth A.
   Langley, Gayle E.
   Mulholland, E. Kim
   Munywoki, Patrick K.
   Nair, Harish
   Ortiz, Justin R.
   Savitz, David A.
   Scheltema, Nienke M.
   Simoes, Eric A. F.
   Smith, Peter G.
   Were, Fred
   Zar, Heather J.
   Feikin, Daniel R.
TI Does respiratory syncytial virus lower respiratory illness in early life
   cause recurrent wheeze of early childhood and asthma? Critical review of
   the evidence and guidance for future studies from a World Health
   Organization-sponsored meeting
SO VACCINE
LA English
DT Review
DE Respiratory syncytial virus; Wheeze; Asthma; Vaccine; Monoclonal
   antibody
ID IMPORTANT RISK-FACTOR; FOLLOW-UP; RSV BRONCHIOLITIS; PRETERM INFANTS;
   TRACT INFECTIONS; PALIVIZUMAB PROPHYLAXIS; ALLERGIC SENSITIZATION;
   SUBSEQUENT DEVELOPMENT; RHINOVIRUS INFECTION; VIRAL-INFECTIONS
AB Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection (LRTI) and hospitalization in infants and children globally. Many observational studies have found an association between RSV LRTI in early life and subsequent respiratory morbidity, including recurrent wheeze of early childhood (RWEC) and asthma. Conversely, two randomized placebo-controlled trials of efficacious anti-RSV monoclonal antibodies (mAbs) in heterogenous infant populations found no difference in physiciandiagnosed RWEC or asthma by treatment group. If a causal association exists and RSV vaccines and mAbs can prevent a substantial fraction of RWEC/asthma, the full public health value of these interventions would markedly increase. The primary alternative interpretation of the observational data is that RSV LRTI in early life is a marker of an underlying predisposition for the development of RWEC and asthma. If this is the case, RSV vaccines and mAbs would not necessarily be expected to impact these outcomes. To evaluate whether the available evidence supports a causal association between RSV LRTI and RWEC/asthma and to provide guidance for future studies, the World Health Organization convened a meeting of subject matter experts on February 12-13,2019 in Geneva, Switzerland. After discussing relevant background information and reviewing the current epidemiologic evidence, the group determined that: (i) the evidence is inconclusive in establishing a causal association between RSV LRTI and RWEC/ asthma, (ii) the evidence does not establish that RSV mAbs (and, by extension, future vaccines) will have a substantial effect on these outcomes and (iii) regardless of the association with long-term childhood respiratory morbidity, severe acute RSV disease in young children poses a substantial public health burden and should continue to be the primary consideration for policy-setting bodies deliberating on RSV vaccine and mAb recommendations. Nonetheless, the group recognized the public health importance of resolving this question and suggested good practice guidelines for future studies. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Driscoll, Amanda J.; Ortiz, Justin R.; Feikin, Daniel R.] Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, 685 W Baltimore St,Suite 480, Baltimore, MD 21201 USA.
   [Arshad, S. Hasan; Feikin, Daniel R.] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Wight, England.
   [Arshad, S. Hasan] Univ Southampton, Southampton Gen Hosp, Fac Med, Clin & Expt Sci, Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Bont, Louis; Nair, Harish] ReSViNET Fdn, Zeist, Netherlands.
   [Bont, Louis; Scheltema, Nienke M.] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Infect Dis, Lundlaan 6, Utrecht, Netherlands.
   [Bont, Louis] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Translat Immunol, Lundlaan 6, Utrecht, Netherlands.
   [Brunwasser, Steven M.; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Ctr Asthma Res Allergy Pulm & Crit Care Med, 2525 West End Ave,Suite 450, Nashville, TN 37203 USA.
   [Cherian, Thomas] MM Global Hlth Consulting, Chemin Maurice Ravel 11C, CH-1290 Versoix, Switzerland.
   [Englund, Janet A.] Seattle Childrens Hosp, 4800 Sand Point Way NE, Seattle, WA 98105 USA.
   [Englund, Janet A.] Univ Washington, Dept Pediat, 1959 NE Pacific St, Seattle, WA 98195 USA.
   [Fell, Deshayne B.] Univ Ottawa, Sch Epidemiol & Publ Hlth, CHEO, Res Inst,CPCR, 401 Smyth Rd,Room L-1154, Ottawa, ON K1H 8L1, Canada.
   [Hammitt, Laura L.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, 615 N Wolfe St, Baltimore, MD 21205 USA.
   [Innis, Bruce L.] PATH, Ctr Vaccine Innovat & Access, 455 Massachusetts Ave NW,Suite 1000, Washington, DC 20001 USA.
   [Karron, Ruth A.] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Immunizat Res, 624 N Broadway,Suite 217, Baltimore, MD 21205 USA.
   [Langley, Gayle E.] US Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, 1600 Clifton Rd, Atlanta, GA 30329 USA.
   [Mulholland, E. Kim] Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.
   [Mulholland, E. Kim] Univ Melbourne, Dept Paediat, Flemington Rd, Parkville, Vic 3052, Australia.
   [Mulholland, E. Kim] London Sch Hyg & Trop Med, Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
   [Munywoki, Patrick K.] US Ctr Dis Control & Prevent, Div Global Hlth Protect, POB 606-00621, Nairobi, Kenya.
   [Nair, Harish] Univ Edinburgh, Usher Inst, Ctr Global Hlth Res, Med Sch, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.
   [Savitz, David A.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02903 USA.
   [Simoes, Eric A. F.] Univ Colorado, Sch Med, Sect Infect Dis, Dept Pediat, 13123 E 16th Ave,B065, Aurora, CO 80045 USA.
   [Simoes, Eric A. F.] Childrens Hosp Colorado, 13123 E 16th Ave,B065, Aurora, CO 80045 USA.
   [Simoes, Eric A. F.] Colorado Sch Publ Hlth, Ctr Global Hlth, Dept Epidemiol, 13001 E 17th Pl B119, Aurora, CO 80045 USA.
   [Smith, Peter G.] London Sch Hyg & Trop Med, Trop Epidemiol Grp, Keppel St, London WC1E 7HT, England.
   [Were, Fred] Univ Nairobi, Dept Pediat & Child Hlth, POB 30197, Nairobi, Kenya.
   [Zar, Heather J.] Red Cross War Mem Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa.
   [Zar, Heather J.] Univ Cape Town, SA Med Res Council Unit Child & Adolescent Hlth, 5th Floor ICH Bldg,Klipfontein Rd, Cape Town, South Africa.
   [Feikin, Daniel R.] WHO, Dept Immunizat Vaccines & Biol, 20 Ave Appia, Geneva, Switzerland.
RP Feikin, DR (reprint author), Univ Maryland, Sch Med, Ctr Vaccine Dev & Global Hlth, 685 W Baltimore St,Suite 480, Baltimore, MD 21201 USA.; Feikin, DR (reprint author), St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Wight, England.
EM frednwere@gmail.com
RI Nair, Harish/E-7431-2010
OI Nair, Harish/0000-0002-9432-9100; Zar, Heather/0000-0002-9046-759X
FU Bill & Melinda Gates FoundationGates Foundation [OPP1114766]
FX This meeting was funded by a grant from the Bill & Melinda Gates
   Foundation (Global Health Grant OPP1114766) to the World Health
   Organization, which sponsored the meeting. Disclaimer: the views,
   findings, and conclusions in this report are those of the authors. They
   should not be construed to represent the positions or policies of the
   Bill & Melinda Gates Foundation or the World Health Organization, nor do
   they necessarily represent the official position of the US Centers for
   Disease Control and Prevention or the US Public Health Service.
CR Al-Shawwa Baha, 2006, Pediatric Asthma Allergy & Immunology, V19, P26, DOI 10.1089/pai.2006.19.26
   [Anonymous], 1987, CANCER RES, V47, P5782
   [Anonymous], 2014, REV WHO CLASS TREATM
   ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483
   Asthma Glf, 2019, GLOB STRAT ASTHM MAN
   Backman K, 2018, CLIN EXP ALLERGY, V48, P138, DOI 10.1111/cea.13062
   Bergroth E, 2016, PEDIATR INFECT DIS J, V35, P363, DOI 10.1097/INF.0000000000001017
   Blanken MO, 2016, PAEDIATR PERINAT EP, V30, P376, DOI 10.1111/ppe.12295
   Bloemers BLP, 2010, PEDIATR INFECT DIS J, V29, P39, DOI 10.1097/INF.0b013e3181b34e52
   Bonnelykke K, 2015, J ALLERGY CLIN IMMUN, V136, P81, DOI 10.1016/j.jaci.2015.02.024
   Borchers AT, 2013, CLIN REV ALLERG IMMU, V45, P331, DOI 10.1007/s12016-013-8368-9
   Bosis S, 2008, CLIN MICROBIOL INFEC, V14, P677, DOI 10.1111/j.1469-0691.2008.02016.x
   Brand PLP, 2013, NEW ENGL J MED, V369, P782, DOI 10.1056/NEJMc1307429
   Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592
   Carbonell-Estrany X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125422
   Carroll KN, 2017, J ALLERGY CLIN IMMUN, V139, P66, DOI 10.1016/j.jaci.2016.01.055
   Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021
   Cifuentes L, 2003, PEDIATR PULM, V36, P316, DOI 10.1002/ppul.10365
   Daley D, 2012, J ALLERGY CLIN IMMUN, V130, P1284, DOI 10.1016/j.jaci.2012.07.051
   del Rosal T, 2016, ALLERGOL IMMUNOPATH, V44, P410, DOI 10.1016/j.aller.2015.07.004
   Drysdale SB, 2012, ACTA PAEDIATR, V101, P1114, DOI 10.1111/j.1651-2227.2012.02825.x
   Eriksson M, 2000, PEDIAT ALLERG IMM-UK, V11, P193, DOI 10.1034/j.1399-3038.2000.00076.x
   Escobar GJ, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-97
   Fauroux B, 2014, EPIDEMIOL INFECT, V142, P1362, DOI 10.1017/S0950268813001738
   Fauroux B, 2017, INFECT DIS THER, V6, P173, DOI 10.1007/s40121-017-0151-4
   Fjaerli Hans-Olav, 2005, BMC Pediatr, V5, P31, DOI 10.1186/1471-2431-5-31
   Gao ZH, 2019, COMPEND PL GENOME, P9, DOI 10.1007/978-3-030-10797-0_3
   Garcia-Garcia ML, 2007, PEDIATR PULM, V42, P458, DOI 10.1002/ppul.20597
   Glezen WP, 1960, AM J DIS CHILD, V1986, P543
   Goksor E, 2006, ACTA PAEDIATR, V95, P471, DOI 10.1080/08035250500499440
   Gray D, 2017, THORAX, V72, P445, DOI 10.1136/thoraxjnl-2015-207401
   Haerskjold A, 2017, PEDIATR DRUGS, V19, P155, DOI 10.1007/s40272-017-0215-7
   Henderson J, 2005, PEDIATR ALLERGY IMMU, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x
   Homaira N, 2018, J INFECT DIS
   Homaira N, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017936
   Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC
   Jerschow E, 2017, AM J PREV MED, V52, P579, DOI 10.1016/j.amepre.2016.12.018
   Katz MA, 2019, VACCINE, V37, P392, DOI 10.1016/j.vaccine.2017.01.083
   Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770
   Koponen P, 2012, EUR RESPIR J, V39, P76, DOI 10.1183/09031936.00040211
   KORPPI M, 1993, AM J DIS CHILD, V147, P628, DOI 10.1001/archpedi.1993.02160300034017
   KORPPI M, 1994, ARCH PEDIAT ADOL MED, V148, P1079, DOI 10.1001/archpedi.1994.02170100077015
   Kotaniemi-Syrjanen A, 2002, PEDIAT ALLERG IMM-UK, V13, P418, DOI 10.1034/j.1399-3038.2002.02091.x
   Kramer U, 2010, CLIN EXP ALLERGY, V40, P289, DOI 10.1111/j.1365-2222.2009.03435.x
   Krishnamoorthy N, 2012, NAT MED, V18, P1525, DOI 10.1038/nm.2896
   KUIKKA L, 1994, ACTA PAEDIATR, V83, P744, DOI 10.1111/j.1651-2227.1994.tb13131.x
   Kusel MMH, 2012, EUR RESPIR J, V39, P876, DOI 10.1183/09031936.00193310
   Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669
   La Vincente SF, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6639-y
   Larkin EK, 2015, FUTURE VIROL, V10, P883, DOI 10.2217/FVL.15.55
   Lee KK, 2007, PEDIATR PULM, V42, P290, DOI 10.1002/ppul.20578
   Lehtinen P, 2007, J ALLERGY CLIN IMMUN, V119, P570, DOI 10.1016/j.jaci.2006.11.003
   Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024
   Lin Hong-Chieh, 2001, Journal of Microbiology Immunology and Infection, V34, P259
   Loss GJ, 2016, AM J RESP CRIT CARE, V193, P889, DOI 10.1164/rccm.201507-1493OC
   Lukkarinen M, 2017, J ALLERGY CLIN IMMUN, V140, P988, DOI 10.1016/j.jaci.2016.12.991
   Mallol J, 2013, ALLERGOL IMMUNOPATH, V41, P73, DOI 10.1016/j.aller.2012.03.001
   Mikalsen IB, 2013, PEDIATR PULM, V48, P538, DOI 10.1002/ppul.22675
   Mochizuki H, 2017, AM J RESP CRIT CARE, V196, P29, DOI [10.1164/rccm.201609-1812OC, 10.1164/rccm.201609-1812oc]
   Modjarrad K, 2016, VACCINE, V34, P190, DOI 10.1016/j.vaccine.2015.05.093
   MOK JYQ, 1982, BRIT MED J, V285, P333, DOI 10.1136/bmj.285.6338.333
   Munywoki PK, 2013, EMERG INFECT DIS, V19, P223, DOI 10.3201/eid1902.120940
   MURRAY M, 1992, ARCH DIS CHILD, V67, P482, DOI 10.1136/adc.67.4.482
   Narita A, 2011, JPN J INFECT DIS, V64, P433
   O'Brien KL, 2016, LANCET INFECT DIS, V16, P1329, DOI 10.1016/S1473-3099(16)30454-6
   O'Brien KL, 2015, LANCET INFECT DIS, V15, P1398, DOI 10.1016/S1473-3099(15)00247-9
   Openshaw PJ, 2013, CURR OPIN VIROL, V3, P468, DOI 10.1016/j.coviro.2013.05.005
   OSUNDWA VM, 1993, EUR J PEDIATR, V152, P1001, DOI 10.1007/BF01957225
   Oymar K, 2006, PEDIAT ALLERG IMM-UK, V17, P37, DOI 10.1111/j.1399-3038.2005.00345.x
   Oymar K, 2001, ACTA PAEDIATR, V90, P843, DOI 10.1080/08035250152509528
   Palmer L, 2011, CURR MED RES OPIN, V27, P403, DOI 10.1185/03007995.2010.542744
   Palmer L, 2010, PEDIATR PULM, V45, P772, DOI 10.1002/ppul.21244
   Patel SP, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-57
   PATH, 2019, RSV VACC MAB SNAPSH
   Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169
   Pearl J, 2010, INT J BIOSTAT, V6, DOI 10.2202/1557-4679.1203
   Perez-Yarza EG, 2007, PEDIATR INFECT DIS J, V26, P733, DOI 10.1097/INF.0b013e3180618c42
   Petrarca L, 2018, J MED VIROL, V90, P631, DOI 10.1002/jmv.24994
   Pickles RJ, 2015, J PATHOL, V235, P266, DOI 10.1002/path.4462
   Piippo-Savolainen E, 2007, PEDIATR INT, V49, P190, DOI 10.1111/j.1442-200X.2007.02340.x
   Poorisrisak P, 2010, CHEST, V138, P338, DOI 10.1378/chest.10-0365
   Prais D, 2016, CHEST, V149, P801, DOI 10.1378/chest.15-0328
   PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665
   Regnier SA, 2013, PEDIATR INFECT DIS J, V32, P820, DOI 10.1097/INF.0b013e31829061e8
   Reijonen TM, 2000, PEDIATRICS, V106, P1406, DOI 10.1542/peds.106.6.1406
   Riddell CA, 2018, VACCINE, V36, P8100, DOI 10.1016/j.vaccine.2018.10.041
   Rinawi F, 2017, WORLD J PEDIATR, V13, P41, DOI 10.1007/s12519-016-0056-4
   Rubner FJ, 2017, J ALLERGY CLIN IMMUN, V139, P501, DOI 10.1016/j.jaci.2016.03.049
   Ruotsalainen M, 2010, ALLERGY, V65, P503, DOI 10.1111/j.1398-9995.2009.02212.x
   Ruotsalainen M, 2013, PEDIATR PULM, V48, P633, DOI 10.1002/ppul.22692
   Ruotsalainen M, 2010, PEDIATR INFECT DIS J, V29, P872, DOI 10.1097/INF.0b013e3181dea5de
   Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902
   Scheltema NM, 2018, LANCET RESP MED, V6, P257, DOI 10.1016/S2213-2600(18)30055-9
   Shi T, 2017, LANCET, V390, P946, DOI [10.1016/s0140-6736(17)30938-8, 10.1016/S0140-6736(17)30938-8]
   Shi T, 2015, J GLOB HEALTH, V5, P203, DOI 10.7189/jogh.05.020416
   Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC
   SIGURS N, 1995, PEDIATRICS, V95, P500
   Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501, DOI 10.1164/ajrccm.161.5.9906076
   Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582
   Simoes EA, 2007, J PEDIAT, V151, pe1
   Simoes EAF, 2010, J ALLERGY CLIN IMMUN, V126, P256, DOI 10.1016/j.jaci.2010.05.026
   Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC
   SIMS DG, 1978, BRIT MED J, V1, P11, DOI 10.1136/bmj.1.6104.11
   Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP
   Singleton RJ, 2003, PEDIATRICS, V112, P285, DOI 10.1542/peds.112.2.285
   Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5
   Stensballe LG, 2009, J ALLERGY CLIN IMMUN, V123, pe1
   Swingler GH, 2000, ARCH PEDIAT ADOL MED, V154, P997, DOI 10.1001/archpedi.154.10.997
   Szabo SM, 2012, PAEDIATR RESPIR REV, V13, pS9
   Tahamtan A, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2026
   Tapia LI, 2013, INFECT GENET EVOL, V16, P54, DOI 10.1016/j.meegid.2012.12.030
   Teeratakulpisarn J, 2014, ASIAN PAC J ALLERGY, V32, P226, DOI [10.12932/AP0417.32.3.2014, 10.12932/ap0417.32.3.2014]
   Thomsen SF, 2009, AM J RESP CRIT CARE, V179, P1091, DOI 10.1164/rccm.200809-1471OC
   Thwaites RS, 2018, AM J RESP CRIT CARE, V198, P1074, DOI 10.1164/rccm.201712-2567OC
   Turi KN, 2018, AM J RESP CRIT CARE, V198, P1064, DOI 10.1164/rccm.201711-2348OC
   Valkonen H, 2009, ALLERGY, V64, P1359, DOI 10.1111/j.1398-9995.2009.02022.x
   Voraphani N, 2014, AM J RESP CRIT CARE, V190, P392, DOI 10.1164/rccm.201311-2095OC
   Weber MW, 1999, J PEDIATR-US, V135, P683, DOI 10.1016/S0022-3476(99)70085-5
   Welliver RC, 2010, CURR MED RES OPIN, V26, P2175, DOI 10.1185/03007995.2010.505126
   WENNERGREN G, 1992, ACTA PAEDIATR, V81, P40, DOI 10.1111/j.1651-2227.1992.tb12076.x
   Wenzel SE, 2002, AM J MED, V112, P627, DOI 10.1016/S0002-9343(02)01095-1
   WHO, 2018, GLOB ASTHM REP
   WITTIG HJ, 1959, J ALLERGY, V30, P19, DOI 10.1016/0021-8707(59)90054-1
   World Health Organization, 2016, MAL VACC WHO POS PAP
   Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC
   Yasuno T, 2008, PEDIATR INT, V50, P500, DOI 10.1111/j.1442-200X.2008.02702.x
   Yoshihara S, 2013, PEDIATRICS, V132, P811, DOI 10.1542/peds.2013-0982
   Zhang XB, 2014, WORLD J PEDIATR, V10, P360, DOI 10.1007/s12519-014-0513-x
   Zomer-Kooijker K, 2014, EUR RESPIR J, V44, P666, DOI 10.1183/09031936.00009314
NR 129
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2435
EP 2448
DI 10.1016/j.vaccine.2020.01.020
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200002
PM 31974017
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Jensen, SK
   Jensen, TM
   Birk, NM
   Stensballe, LG
   Benn, CS
   Jensen, KJ
   Pryds, O
   Jeppesen, DL
   Nissen, TN
AF Jensen, Signe Kjeldgaard
   Jensen, Trine Molbaek
   Birk, Nina Marie
   Stensballe, Lone Graff
   Benn, Christine Stabell
   Jensen, Kristoffer Jarlov
   Pryds, Ole
   Jeppesen, Dorthe Lisbeth
   Nissen, Thomas Norrelykke
TI Bacille Calmette-Guerin vaccination at birth and differential white
   blood cell count in infancy. A randomised clinical trial
SO VACCINE
LA English
DT Article
DE Bacillus Calmette-Guerin; Heterologous immunity; Infants; Non-specific
   effects; Trained innate immunity; Vaccination; White blood cell
   differential count
ID BCG VACCINATION; NEONATAL-MORTALITY; RESPONSES; PROTECTION; INFECTION;
   CHILDREN
AB Background: The Bacille Calmette-Guerin (BCG) vaccine against tuberculosis (TB) may have beneficial non-specific effects (NSEs) beyond the protection against TB. This may be related to modifications of the innate immune system. We investigated the effect of BCG at birth on differential white blood cell (WBC) count in healthy, Danish infants.
   Method: The Danish Calmette Study randomised newborns to BCG at birth (Danish strain 1331, Statens Serum Institut) or no intervention. A sub-group of infants had blood samples collected 4 days after randomisation (n = 161), and at age 3 months (n = 152) and 13 months (n = 300). We evaluated the effect of BCG on WBC differential count (total leucocytes, lymphocytes, monocytes, eosinophil, neutrophil and basophil granulocytes (10(9) cells/L)) measured in peripheral blood.
   Results: Overall, we found no effect of BCG on differential WBC counts at any time point.
   Conclusion: BCG at birth did not affect WBC count in our cohort of healthy, Danish infants. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Jensen, Signe Kjeldgaard; Jensen, Trine Molbaek; Birk, Nina Marie; Pryds, Ole; Jeppesen, Dorthe Lisbeth; Nissen, Thomas Norrelykke] Copenhagen Univ Hosp, Dept Pediat, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.
   [Stensballe, Lone Graff] Copenhagen Univ Hosp, Rigshosp, Juliane Marie Ctr, Dept Pediat & Adolescent Med, Hvidovre, Denmark.
   [Benn, Christine Stabell; Jensen, Kristoffer Jarlov] Statens Serum Inst, Res Ctr Vitamins & Vaccines CVIVA, Copenhagen, Denmark.
   [Jensen, Kristoffer Jarlov] Tech Univ Denmark, Dept Hlth Technol, Lyngby, Denmark.
   [Benn, Christine Stabell] Univ Southern Denmark, Dept Clin Res, Odense Univ Hosp, Odense Patient Data Explorat Network OPEN, DK-5000 Odense, Denmark.
RP Jensen, SK (reprint author), Copenhagen Univ Hosp, Dept Pediat, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.
EM signe.jensen@dbac.dk
OI Nissen, Thomas Norrelykke/0000-0001-8565-9629; Jensen, Kristoffer
   Jarlov/0000-0001-9687-5706
FU Copenhagen University Hospital, Hvidovre; Danish National Research
   FoundationDanmarks Grundforskningsfond [DNRF108]
FX The study was funded by Copenhagen University Hospital, Hvidovre, and
   the Danish National Research Foundation (DNRF108).
CR Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010
   Biering-Sorensen S, 2018, J INFECT DIS, V217, P759, DOI 10.1093/infdis/jix612
   Biering-Sorensen S, 2017, CLIN INFECT DIS, V65, P1183, DOI 10.1093/cid/cix525
   Birk NM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11601-6
   Blok BA, 2020, CLIN INFECT DIS, V70, P455, DOI 10.1093/cid/ciz246
   Freyne B, 2018, J INFECT DIS, V217, P1798, DOI 10.1093/infdis/jiy069
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI [10.1136/bn-0517Qi5170, DOI 10.1136/BN-0517QI5170]
   Jayaraman K, 2019, PEDIATR INFECT DIS J, V38, P198, DOI 10.1097/INF.0000000000002198
   Jensen KJ, 2015, J INFECT DIS, V211, P956, DOI 10.1093/infdis/jiu508
   de Castro MJ, 2015, CLIN INFECT DIS, V60, P1611, DOI 10.1093/cid/civ144
   Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031
   Kjaergaard J, 2016, PEDIATR RES, V80, P681, DOI 10.1038/pr.2016.142
   Kleinnijenhuis J, 2014, J INNATE IMMUN, V6, P152, DOI 10.1159/000355628
   Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109
   Nissen TN, 2018, EUR J CLIN MICROBIOL, V37, P29, DOI 10.1007/s10096-017-3097-2
   Nissen TN, 2017, VACCINE, V35, P2084, DOI 10.1016/j.vaccine.2017.02.048
   OMS, 2014, RELEV EPIDEMIOL HEBD, V2014, P221
   Prentice S, 2018, VACCINE, V36, P2870, DOI 10.1016/j.vaccine.2018.03.026
   Steenhuis TJ, 2008, CLIN EXP ALLERGY, V38, P79, DOI 10.1111/j.1365-2222.2007.02859.x
   Stensballe LG, 2017, ARCH DIS CHILD, V102, P224, DOI 10.1136/archdischild-2016-310760
   Thostesen LM, 2015, CONTEMP CLIN TRIALS, V42, P213, DOI 10.1016/j.cct.2015.04.006
   Thostesen LM, 2017, ALLERGY, DOI [10.1111/a11.13314, DOI 10.1111/A11.13314]
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2449
EP 2455
DI 10.1016/j.vaccine.2020.02.006
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200003
PM 32057570
DA 2020-05-12
ER

PT J
AU Beal, JL
   Kadakia, NN
   Reed, JB
   Plake, KSI
AF Beal, Jenny L.
   Kadakia, Nira N.
   Reed, Jason B.
   Plake, Kimberly S. Illingworth
TI Pharmacists' impact on older adults' access to vaccines in the United
   States
SO VACCINE
LA English
DT Review
ID PNEUMOCOCCAL VACCINATION RATES; INFLUENZA VACCINATION; ZOSTER
   VACCINATION; STANDING ORDERS; CARE; IMMUNIZATION; POPULATION;
   PHYSICIANS; COSTS
AB Objective: The purpose of this systematic review was to explore pharmacists' impact on older adults' access to vaccines in terms of realized accessibility, financial accessibility, and vaccine availability.
   Methods: Five databases were searched using a search strategy developed in PubMed and translated to other databases. Included studies were English-language, United States-based primary literature published between 1994 to present day. Studies were excluded if they were incomplete studies or did not focus on at least one of three dimensions of access to immunizations: realized accessibility, availability, and financial accessibility. The following data were gathered: title, authors, year published, subdimension of accessibility, health care setting, intervention or data source, pharmacist role, type of immunization, duration of study, sample size, and main outcome measures.
   Results: Twenty-five studies met the inclusion criteria. Of those, the majority evaluated realized accessibility (n = 22, 88%). Eleven studies evaluated vaccine availability, and one study addressed financial accessibility. Pharmacists had a variety of roles in the immunization process, including screener, educator, immunizer, or documenter, and often played more than one role (n = 10, 40%). Pharmacists participated in the vaccination process across multiple health care settings, including in community pharmacies (n = 8, 32%) and hospitals (n = 7, 28%). In the majority (n = 21, 84%) of studies, pharmacists positively impacted older adults' access to vaccines. The most common vaccinations studied were pneumococcal and influenza vaccinations (n = 20, 80%).
   Conclusion: Vaccinations are important in protecting and maintaining the health of older adults. Pharmacists improved access to vaccinations and served many roles in the vaccination process. Future research should explore how pharmacists impact access to vaccines beyond vaccination rates, especially regarding the financial impact on patients. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Beal, Jenny L.; Kadakia, Nira N.; Plake, Kimberly S. Illingworth] Purdue Univ, Coll Pharm, W Lafayette, IN 47907 USA.
   [Reed, Jason B.] Purdue Univ, Lib & Sch Informat Studies, W Lafayette, IN 47907 USA.
RP Plake, KSI (reprint author), 575 W Stadium Mall Ave, W Lafayette, IN 47907 USA.
EM kplake@purdue.edu
OI Reed, Jason B/0000-0001-6712-9413; Beal, Jenny/0000-0003-3997-8893
CR ANDERSON R, 2013, CHANGING US HLTH CAR, V1136, P33
   Aw D, 2007, IMMUNOLOGY, V120, P435, DOI 10.1111/j.1365-2567.2007.02555.x
   Bach AT, 2015, INTEGR PHARM RES PRA, V4, P67, DOI 10.2147/IPRP.S63822
   Baucom A, 2018, ANN PHARMACOTHER, P1
   Bramer WM, 2016, J MED LIBR ASSOC, V104, DOI [10.5195/JMLA.2016.24, DOI 10.5195/JMLA.2016.24]
   Brownfield E, 2012, AM J INFECT CONTROL, V40, P672, DOI 10.1016/j.ajic.2011.12.006
   Burson RC, 2016, HUM VACC IMMUNOTHER, V12, P3146, DOI 10.1080/21645515.2016.1215393
   CDC, REC VACC AG
   CDC, SURV STAT IMM INF SY
   CDC, AD VACC RES
   Coyle CM, 2004, INFECT CONT HOSP EP, V25, P904, DOI 10.1086/502317
   Drozd EM, 2017, CLIN THER, V39, P1563, DOI 10.1016/j.clinthera.2017.07.004
   Gai YW, 2017, J AM PHARM ASSOC, V57, P474, DOI 10.1016/j.japh.2017.03.011
   Goad JA, 2013, ANN FAM MED, V11, P429, DOI 10.1370/afm.1542
   Grabenstein JD, 2002, J CLIN EPIDEMIOL, V55, P279, DOI 10.1016/S0895-4356(01)00452-8
   Grabenstein JD, 2001, MED CARE, V39, P340, DOI 10.1097/00005650-200104000-00005
   Hess R, 2013, J AM PHARM ASSOC, V53, P182, DOI 10.1331/JAPhA.2013.12222
   Hogue MD, 2006, J AM PHARM ASSOC, V46, P168, DOI 10.1331/154434506776180621
   Hurley LP, 2017, VACCINE, V35, P647, DOI 10.1016/j.vaccine.2016.12.007
   Hurley LP, 2014, ANN INTERN MED, V160, P161, DOI 10.7326/M13-2332
   Inguva S, 2017, J AM PHARM ASSOC, V57, P654, DOI 10.1016/j.japh.2017.07.007
   Isenor JE, 2016, VACCINE, V34, P5708, DOI 10.1016/j.vaccine.2016.08.085
   Jacobson TA, 1999, JAMA-J AM MED ASSOC, V282, P646, DOI 10.1001/jama.282.7.646
   Johnson DR, 2008, AM J MED, V121, pS28, DOI 10.1016/j.amjmed.2008.05.005
   Lam AY, 2008, J AM PHARM ASSOC, V48, P758, DOI 10.1331/JAPhA.2008.07135
   Loughlin SM, 2007, PHARMACOTHERAPY, V27, P729, DOI 10.1592/phco.27.5.729
   McConeghy KW, 2016, VACCINE, V34, P3463, DOI 10.1016/j.vaccine.2016.04.076
   McLaughlin JM, 2015, J PRIM PREV, V36, P259, DOI 10.1007/s10935-015-0394-3
   Middleton DB, 2008, INFECT CONT HOSP EP, V29, P385, DOI 10.1086/587155
   Nilsen P, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-63
   Nowalk MP, 2004, VACCINE, V22, P3457, DOI 10.1016/j.vaccine.2004.02.022
   OTSUKA S, 2013, AM J MED, V126, P832, DOI DOI 10.1016/J.AMJMED.2013.02.018
   Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
   Patel AR, 2018, J AM PHARM ASSOC, V58, P505, DOI 10.1016/j.japh.2018.05.011
   Peters DH, 2008, ANN NY ACAD SCI, V1136, P161, DOI 10.1196/annals.1425.011
   Pizzi LT, 2018, ANN PHARMACOTHER, V52, P446, DOI 10.1177/1060028017745566
   Prosser LA, 2008, PHARMACOECONOMICS, V26, P163, DOI 10.2165/00019053-200826020-00006
   ROBKE JT, 2002, HOSP PHARM, V37, P1050
   Rosenblatt RA, 1998, JAMA-J AM MED ASSOC, V279, P1364, DOI 10.1001/jama.279.17.1364
   Shelton R, 2012, TLS-TIMES LIT SUPPL, P28
   Starfield B, 2009, J AMBUL CARE MANAG, V32, P216, DOI 10.1097/JAC.0b013e3181ac9ca2
   Steyer TE, 2004, VACCINE, V22, P1001, DOI 10.1016/j.vaccine.2003.08.045
   Taitel M, 2011, VACCINE, V29, P8073, DOI 10.1016/j.vaccine.2011.08.051
   Taitel MS, 2013, AM J MANAG CARE, V19
   Terrie YC, 2010, PHARM TIMES
   U.S. Department of Health and Human Services, 2013, ANN PHARM BAS INFL A, P1
   Van Amburgh JA, 2001, PHARMACOTHERAPY, V21, P1115, DOI 10.1592/phco.21.13.1115.34624
   VELTRI KT, 2009, HOSP PHARM, V44, P874
   WALKER JL, 1969, AM POLIT SCI REV, V63, P880, DOI 10.2307/1954434
   Wang JL, 2013, J AM PHARM ASSOC, V53, P46, DOI 10.1331/JAPhA.2013.12019
   Williams WW, 2016, MMWR-MORBID MORTAL W, V65, P2
   Winegarden W., 2018, PROMOTING ACCESS LOW
   Zimmerman RK, 2003, VACCINE, V21, P1486, DOI 10.1016/S0264-410X(02)00698-9
   Zorek JA, 2015, FAM MED, V47, P558
   2012, PUBLIC HEALTH REP S1, V127, P1
NR 55
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2456
EP 2465
DI 10.1016/j.vaccine.2020.01.061
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200004
PM 32046889
DA 2020-05-12
ER

PT J
AU De Schryver, A
   Lambaerts, T
   Lammertyn, N
   Francois, G
   Bulterys, S
   Godderis, L
AF De Schryver, Antoon
   Lambaerts, Tom
   Lammertyn, Nathalie
   Francois, Guido
   Bulterys, Simon
   Godderis, Lode
TI European survey of hepatitis B vaccination policies for healthcare
   workers: An updated overview
SO VACCINE
LA English
DT Article
DE Hepatitis B; Vaccination; Policy; Healthcare workers; Europe; EU;
   Survey; Occupational medicine
ID C VIRUS; COVERAGE; INFECTIONS; PREVENTION; GUIDELINES; FACILITIES;
   PERSONNEL; HBV
AB Background: The risk of transmission of bloodborne pathogens, including hepatitis B virus (HBV) to healthcare workers (HCWs) is well known. In 2005 we performed a survey on HBV prevention in HCWs in the European Union (EU). An update of the 2005 survey deemed necessary as an EU Council Directive (2010/32/EU) on sharps injuries was to be implemented into national legislation by 11 May 2013 and more countries were starting universal HBV vaccination.
   Methods: We performed an electronic survey in 2016, among national representatives from the Occupational Medicine section of the European Union of Medical Specialists (UEMS), to find out how policies have been put into practice in the European Union countries (plus Norway and Switzerland). The data were updated in 2019.
   Results: Answers were received from 21 countries (among them 19 EU Member States), representing 78% of the population and 60% of HCWs in the EU-28. HBV vaccination was mandatory for medical and nursing staff in 10 countries; for other paramedical staff, medical and nursing students in 9 countries; for paramedical students in 8 countries; for cleaning staff in 7 countries; and for technical staff in 5 countries; it was recommended in all but one of other countries. Serotesting before vaccination was done in 7 countries. The vaccination schedule most often used was 0, 1, 6 months (18countries), monovalent HBV vaccine was used in 14 countries, and combined (HAV + HBV) vaccine in 11 countries. Serotesting after vaccination was done in 18 countries and boosters were recommended in 14 countries. A non-responder policy was present in 18 countries. HBV vaccination coverage (5 countries) was 70-95%. Sharps injuries were reported in 13 countries, nationwide in 7 of them; European-wide reporting was not mentioned by respondents.
   Discussion: These results show the variation in the implementation of EU legislation in the participating countries. More consultation between actors at EU level, including enhancing medical surveillance in occupational medicine could help to optimise policies in European countries in order to further reduce HBV transmission to HCWs. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [De Schryver, Antoon; Francois, Guido] Univ Antwerp, Dept Epidemiol & Social Med, Univ Pl 1, BE-2610 Antwerp, Belgium.
   [De Schryver, Antoon; Lambaerts, Tom; Lammertyn, Nathalie; Bulterys, Simon; Godderis, Lode] IDEWE Occupat Serv, Interleuvenlaan 58, BE-3001 Leuven, Belgium.
   [Godderis, Lode] Katholieke Univ Leuven, Dept Publ Hlth & Primary Care, Kapucijnenvoer 35 Blok D,Bus 7001, BE-3000 Leuven, Belgium.
RP De Schryver, A (reprint author), Univ Antwerp, Dept Epidemiol & Social Med, Univ Pl 1, BE-2610 Antwerp, Belgium.
EM antoon.deschryver@uantwerpen.be
RI De Schryver, Antoon/B-6128-2017
OI De Schryver, Antoon/0000-0001-7048-1979
CR Banatvala J, 2000, LANCET, V355, P561
   Beskovnik L, 2013, ZDR VESTN, V82, P452
   Bruce MG, 2016, J INFECT DIS, V214, P16, DOI 10.1093/infdis/jiv748
   Byrd KK, 2013, PUBLIC HEALTH REP, V128, P498, DOI 10.1177/003335491312800609
   Cardell K, 2008, J INFECT DIS, V198, P299, DOI 10.1086/589722
   Cashman C, 2005, OCCUP MED-OXFORD, V55, P308, DOI 10.1093/occmed/kqi059
   Civljak R, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-520
   De Schryver A, 2014, J HOSP INFECT, V86, P147, DOI 10.1016/j.jhin.2013.11.005
   De Schryver A, 2011, EUR J PUBLIC HEALTH, V21, P338, DOI 10.1093/eurpub/ckq122
   European Centre for Disease Prevention and Control, 2018, ANN EP REP 2016
   European Centre for Disease Prevention and Control, 2016, SYST REV HEP B C PRE
   EUROSTAT, 2014, CENS HUB POP CENS 20
   EUROSTAT, PROD DAT REAL GDP PE
   Fitzsimons D, 2008, OCCUP ENVIRON MED, V65, P446, DOI 10.1136/oem.2006.032334
   FitzSimons D, 2014, VACCINE, V32, P4849, DOI 10.1016/j.vaccine.2014.06.072
   Galanakis E, 2014, EXPERT REV VACCINES, V13, P277, DOI 10.1586/14760584.2014.869174
   Ganczak M, 2010, VACCINE, V28, P3972, DOI 10.1016/j.vaccine.2010.03.042
   Ganczak M, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6628-1
   Genovese C, 2019, J Prev Med Hyg, V60, pE12, DOI 10.15167/2421-4248/jpmh2019.60.1.1097
   Gunson RN, 2003, J CLIN VIROL, V27, P213, DOI 10.1016/S1386-6532(03)00087-8
   Guthmann JP, 2012, VACCINE, V30, P4648, DOI 10.1016/j.vaccine.2012.04.098
   Jost M, 2011, VERHUTUNG BLUTUBERTR
   Koc OM, 2018, J VIRAL HEPATITIS, V25, P1048, DOI 10.1111/jvh.12909
   Lernout T, 2014, CLIN MICROBIOL INFEC, V20, P19, DOI 10.1111/1469-0691.12535
   Maltezou HC, 2019, VACCINE, V37, P7576, DOI 10.1016/j.vaccine.2019.09.061
   Maltezou HC, 2014, VACCINE, V32, P4876, DOI 10.1016/j.vaccine.2013.10.046
   Maltezou HC, 2013, AM J INFECT CONTROL, V41, P66, DOI 10.1016/j.ajic.2012.01.028
   Maltezou HC, 2011, VACCINE, V29, P9557, DOI 10.1016/j.vaccine.2011.09.076
   Nasjonalt folkehelseinstitutt, 2008, AN BRUK HEP B VAKS N
   Organization WH, 2016, GLOB HLTH SECT STRAT
   Poorolajal J, 2010, VACCINE, V28, P623, DOI 10.1016/j.vaccine.2009.10.068
   Schillie S, 2013, MMWR RECOMM REP, V62, P1
   UEMS Section of occupational medicine, 2018, STAT MON PREV COMP O
   Vandermeulen C, STUDIE VACCINATIEGRA
   Werner JM, 2013, GASTROENTEROLOGY, V145, P1026, DOI 10.1053/j.gastro.2013.07.044
   World Health Organization Geneva, 2018, WHO GLOB HLTH WORKF
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2466
EP 2472
DI 10.1016/j.vaccine.2020.02.003
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200005
PM 32057571
DA 2020-05-12
ER

PT J
AU Juan-Giner, A
   Alsalhani, A
   Panunzi, I
   Lambert, V
   Van Herp, M
   Gairola, S
AF Juan-Giner, Aitana
   Alsalhani, Alain
   Panunzi, Isabella
   Lambert, Vincent
   Van Herp, Michel
   Gairola, Sunil
TI Evaluation of the stability of measles vaccine out of the cold chain
   under extended controlled temperature conditions
SO VACCINE
LA English
DT Article
DE Controlled temperature chain; Extended controlled temperature
   conditions; Out of the cold chain; Outbreak response; Measles
AB Measles outbreaks occur periodically in remote and difficult to reach areas in countries such as the Democratic Republic of Congo. The possibility to keep measles vaccines at temperatures outside the cold chain for a limited period prior to administration would be an advantage for organizations such as Medecins Sans Frontieres, which repeatedly respond to measles outbreaks in difficult contexts.
   Using stability data at 37 degrees C and 40 degrees C provided by Serum Institute of India Private Limited we applied the product release model for Extended Controlled Temperature Conditions (ECTC) to evaluate the possibility of an out of the cold chain excursion.
   Measles vaccine in the lyophilized form remains above the minimum required potency at the end of the shelf-life for up to 6 days at 37 degrees C or for 2 days at 40 degrees C.
   This evaluation supports the use of a monodose presentation of measles vaccine in ECTC. This could be an advantage for outbreak response in isolated and difficult to reach areas. However the operational advantages of this approach need to be established. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Juan-Giner, Aitana] Epicentre, 14-34 Ave Jean Jaures, F-75019 Paris, France.
   [Alsalhani, Alain] Access Campaign, Med Sans Frontieres, Bordeaux, France.
   [Panunzi, Isabella; Lambert, Vincent; Van Herp, Michel] Med Sans Frontieres, Operat Ctr Brussels, Brussels, Belgium.
   [Gairola, Sunil] Serum Inst India Private Ltd, Pune, Maharashtra, India.
RP Juan-Giner, A (reprint author), Epicentre, 14-34 Ave Jean Jaures, F-75019 Paris, France.
EM aitana.juan@epicentre.mstorg
CR CLIMIE A, 1984, J TROP MED HYG, V87, P249
   HEYMANN DL, 1979, BRIT MED J, V2, P99, DOI 10.1136/bmj.2.6182.99
   OMS AFRO, EP ROUG REP DEM CONG
   Patel MK, 2019, WKLY EPIDEMIOL REC, V49, P581
   WHO, 2018, IMM VACC BIOL
   WHO, 2006, WHOIVB0610
   WHO, 2014, WHOIVB1407
   WHO, 2017, WHOIVB1720
   WHO, 1994, WHO TECHN REP SER, V840
   WHO Africa, 2020, DEATHS DEM REP CONG
   WHO Expert Committee on Biological Standardization, 2016, WHO TECHN REP SER, V999, P235
   WHO-UNICEF, 1999, WHOVB9918 UNICEF
   World Health Organisation, 2018, WHOIVB1811
   World Health Organization, 2016, MEASL
NR 14
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2473
EP 2477
DI 10.1016/j.vaccine.2020.02.005
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200006
PM 32046890
OA Other Gold
DA 2020-05-12
ER

PT J
AU Li, S
   Yang, YL
   Lin, X
   Li, ZJ
   Ma, GH
   Su, ZG
   Zhang, SP
AF Li, Shuai
   Yang, Yanli
   Lin, Xuan
   Li, Zhengjun
   Ma, Guanghui
   Su, Zhiguo
   Zhang, Songping
TI Biocompatible cationic solid lipid nanoparticles as adjuvants
   effectively improve humoral and T cell immune response of foot and mouth
   disease vaccines
SO VACCINE
LA English
DT Article
DE Cationic solid lipid nanoparticles; Foot and mouth disease virus;
   Cellular immunity; Adjuvant; Vaccine
ID B SURFACE-ANTIGEN; INACTIVATED VACCINE; 12S PARTICLES; VIRUS; DELIVERY;
   EMULSION; CARRIERS; OIL; MICROPARTICLES; DISSOCIATION
AB In this work, we explored the potential of cationic solid lipid nanoparticles (cSLN) as efficient adjuvants for inactivated foot and mouth disease virus (iFMDV) vaccine. The cSLN were prepared by O/W emulsion method with Compritol 888 ATO as lipid matrix, and were modified by cationic lipid Didodecyldimethylammonium bromide (DDAB). The content of cationic lipid was optimized to produce cSLN with appropriate particle size, surface morphology, zeta potential, and polydispersity. Loading iFMDV onto cSLN by electrostatic attraction did not destruct iFMDV particle structure as measured by high performance size exclusion chromatography (HPSEC). Differential scanning fluorimetry (DSF) showed the transition temperature, T-m, related to iFMDV dissociation increased for 1.2 degrees C after loading on cSLN, indicating an enhanced stability of this unstable antigen. The cSLN loaded iFMDV enhanced in vitro antigen uptake and activation of bone-marrow-derived dendritic cells (BMDCs) with augmented expression of CD86, CD40, and MHC 1. In animal trials, BALB/c mice were immunized with free iFMDV, antigen adjuvanted with the cSLN, and antigen adjuvanted with Montanide ISA 206 emulsion. Specific antibody titers showed cSLN could stimulate similar FMDV-specific IgG and IgG subclasses antibody level compared with the widely used ISA 206. In addition, cSLN significantly enhanced memory immune response including effector-memory T cells and central-memory T cells compared to free iFMDV antigen and antigen adjuvanted with ISA 206. Taken together the enhanced humoral and T cell immune responses and the antigen structure friendly properties, cSLN can be a potential adjuvant for iFMDV vaccines. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Li, Shuai; Yang, Yanli; Lin, Xuan; Li, Zhengjun; Ma, Guanghui; Su, Zhiguo; Zhang, Songping] Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China.
   [Li, Shuai; Lin, Xuan] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Su, ZG; Zhang, SP (reprint author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China.
EM zgsu@ipe.ac.cn; spzhang@ipe.ac.cn
FU National Natural Sciences Foundation of ChinaNational Natural Science
   Foundation of China [21808226, 21821005, 31970872]
FX No financial conflict of interest was reported by the authors of this
   paper. The authors are thankful for financial support from the National
   Natural Sciences Foundation of China (Nos. 21808226, 21821005,
   31970872).
CR Abubakar M, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1966
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Batista A, 2010, VACCINE, V28, P6361, DOI 10.1016/j.vaccine.2010.06.098
   Brehm KE, 2008, VACCINE, V26, P1681, DOI 10.1016/j.vaccine.2008.01.038
   BROWN F, 1995, SEMIN VIROL, V6, P243, DOI 10.1006/smvy.1995.0029
   Cao YM, 2016, EXPERT REV VACCINES, V15, P783, DOI 10.1586/14760584.2016.1140042
   Cao YM, 2014, EXPERT REV VACCINES, V13, P1377, DOI 10.1586/14760584.2014.963562
   Chen GH, 2014, RES VET SCI, V96, P62, DOI 10.1016/j.rvsc.2013.11.017
   Chen ZH, 2017, ARTIF CELL NANOMED B, V45, P897, DOI 10.1080/21691401.2016.1188396
   De Jesus MB, 2015, J CONTROL RELEASE, V201, P1, DOI 10.1016/j.jconrel.2015.01.010
   DOEL TR, 1982, ARCH VIROL, V73, P185, DOI 10.1007/BF01314726
   Doroud D, 2011, J CONTROL RELEASE, V153, P154, DOI 10.1016/j.jconrel.2011.04.011
   Erni C, 2002, BIOMATERIALS, V23, P4667, DOI 10.1016/S0142-9612(02)00216-8
   FENG HB, 2015, IMMUNOL INVESTIG, V4, P1
   Hansen B, 2009, VACCINE, V27, P888, DOI 10.1016/j.vaccine.2008.11.078
   Harmsen MM, 2015, VACCINE, V33, P2477, DOI 10.1016/j.vaccine.2015.03.066
   Hwang TL, 2015, CHEM-BIOL INTERACT, V235, P106, DOI 10.1016/j.cbi.2015.04.011
   Jin YG, 2015, COLLOID SURFACE B, V126, P257, DOI 10.1016/j.colsurfb.2014.12.032
   Kitching P, 2007, VACCINE, V25, P5660, DOI 10.1016/j.vaccine.2006.10.052
   Li H, 2015, PROTEIN EXPRES PURIF, V113, P23, DOI 10.1016/j.pep.2015.04.011
   Lin X, 2019, RSC ADV, V9, P13933, DOI 10.1039/c9ra02722j
   Mehnert W, 2001, ADV DRUG DELIVER REV, V47, P165, DOI 10.1016/S0169-409X(01)00105-3
   Mishra H, 2010, J PHARM PHARM SCI, V13, P495, DOI 10.18433/J3XK53
   Muller RH, 1996, INT J PHARM, V144, P115, DOI 10.1016/S0378-5173(96)04731-X
   Naseri N, 2015, ADV PHARM BULL, V5, P305, DOI 10.15171/apb.2015.043
   Norwitz ER, 2010, CRITICAL CARE OBSTETRICS, 5TH EDITION, P30
   Pan L, 2014, INT J NANOMED, V9, P5603, DOI 10.2147/IJN.S72318
   Quattrocchi V, 2014, VACCINE, V32, P2167, DOI 10.1016/j.vaccine.2014.02.061
   Ren JL, 2011, VACCINE, V29, P7960, DOI 10.1016/j.vaccine.2011.08.072
   Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702
   Schley D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030435
   Shahbazi M, 2015, VET PARASITOL, V212, P130, DOI 10.1016/j.vetpar.2015.07.005
   Song XM, 2009, VACCINE, V27, P51, DOI 10.1016/j.vaccine.2008.10.030
   Torres MP, 2011, ACTA BIOMATER, V7, P2857, DOI 10.1016/j.actbio.2011.03.023
   van Vlijmen HWT, 1998, J MOL BIOL, V275, P295, DOI 10.1006/jmbi.1997.1418
   Wang Y. H., 2016, FRONT MICROBIOL, V7, P12
   Xia YF, 2018, NAT MATER, V17, P187, DOI [10.1038/nmat5057, 10.1038/NMAT5057]
   Yang YT, 2017, VACCINE, V35, P6583, DOI 10.1016/j.vaccine.2017.10.031
   Yang YL, 2015, VACCINE, V33, P1143, DOI 10.1016/j.vaccine.2015.01.031
   Zhang CR, 2018, MICROBIOL IMMUNOL, V62, P187, DOI 10.1111/1348-0421.12567
   Zhou CX, 2014, BMC VET RES, V10, DOI 10.1186/1746-6148-10-2
NR 41
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2478
EP 2486
DI 10.1016/j.vaccine.2020.02.004
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200007
PM 32057580
DA 2020-05-12
ER

PT J
AU Steiniche, MM
   Thysen, SM
   Jensen, AKG
   Rodrigues, A
   Martins, C
   Meyrowitsch, DW
   Aaby, P
   Fisker, AB
AF Steiniche, Mette Moller
   Thysen, Sanne Marie
   Jensen, Aksel Karl Georg
   Rodrigues, Amabelia
   Martins, Cesario
   Meyrowitsch, Dan Wolf
   Aaby, Peter
   Fisker, Ane Baerent
TI The effect of early measles vaccination on morbidity and growth: A
   randomised trial from Guinea-Bissau
SO VACCINE
LA English
DT Article
DE Measies vaccine; Morbidity; Growth; Non-specific (heterologous) effects
   of vaccines; Childhood vaccination
AB Background: Measles vaccine (MV) has beneficial non-specific effects protecting against non-measles infections in some situations. Within a trial of the effect of MV on mortality, we assessed effects of early MV on the secondary outcomes consultations and growth, overall, and by sex and exposure to campaigns with oral polio vaccine (OPV).
   Materials and methods: Children were randomly assigned to MV at 4.5 + 9 months or MV at 9 months as recommended. At enrolment and 9 months children had their mid-upper-arm-circumference (MUAC) and weight measured. Consultations (out/inpatient) were registered at monthly home visits. Weight-for-age and MUAC-for-age Z-scores were obtained using the WHO growth reference and compared by group in linear regression models. Consultation rates between enrolment and 9 months were compared in Cox proportional hazards models, providing consultation Hazard Ratios (HRs) for early MV versus no early MV. We tested whether the effect of early MV was modified by OPV campaigns by splitting observation time at exposure to OPV campaigns.
   Results: Among 3548 children enrolled between 2012 and 2015, early MV had no effect on MUAC-for-age (mean difference comparing early MV vs. no MV -0.01, 95% CI -0.06-0.04), weight-for-age (mean difference -0.03, 95% CI -0.07-0.02) or rates of consultations (HR = 1.03, 95% CI 0.92-1.16). The rate of consultations for children enrolled was lower after exposure to OPV campaigns (HR - 0.81, 95% CI 0.71-0.92). The effect of MV differed before exposure to OPV campaigns (HR 1.12, 95% CI 0.98-1.29) and after OPV campaigns (HR = 0.83, 95% CI 0.67-1.03) (test for interaction: p = 0.03). Associations did not differ by sex.
   Conclusion: Early MV had no overall effect on consultation rates and growth between enrolment and 9 months of age. However, early MV tended to have beneficial effects for children subsequently exposed to OPV campaigns. As beneficial effects were observed in subgroups, the results should be interpreted with caution. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Steiniche, Mette Moller; Thysen, Sanne Marie; Rodrigues, Amabelia; Martins, Cesario; Aaby, Peter; Fisker, Ane Baerent] INDEPTH Network, Bandim Hlth Project, Bissau, Guinea Bissau.
   [Steiniche, Mette Moller; Thysen, Sanne Marie; Jensen, Aksel Karl Georg; Fisker, Ane Baerent] Statens Serum Inst, Res Ctr Vitamins & Vaccines CVIVA, Copenhagen S, Denmark.
   [Thysen, Sanne Marie] Aarhus Univ, Dept Publ Hlth, Ctr Global Hlth GloHAU, Aarhus C, Denmark.
   [Jensen, Aksel Karl Georg] Univ Copenhagen, Sect Biostat, Copenhagen K, Denmark.
   [Meyrowitsch, Dan Wolf] Univ Copenhagen, Dept Publ Hlth, Global Hlth Sect, Copenhagen K, Denmark.
   [Fisker, Ane Baerent] Univ Southern Denmark, Odense Univ Hosp, Inst Clin Res, OPEN, Odense C, Denmark.
RP Fisker, AB (reprint author), Univ Southern Denmark, Odense Univ Hosp, Inst Clin Res, OPEN,Bandim Hlth Project, Odense S, Denmark.
EM a.fisker@bandim.org
RI ; Fisker, Ane/E-9283-2019
OI Thysen, Sanne Marie/0000-0003-4541-3901; Aaby,
   Peter/0000-0001-8331-1389; Fisker, Ane/0000-0002-8521-0992
FU European UnionEuropean Union (EU) [Health-F3-2011-261375]; Danish
   Council for Independent ResearchDet Frie Forskningsrad (DFF)
   [DFF-6110-00043]; Danish National Research Foundation via CVIVA
   [DNRF108]; Fonden of 17-12-1981
FX The trial was funded by the European Union FP7 support for OPTIMUNISE
   [grant number Health-F3-2011-261375]. Grants from the Danish Council for
   Independent Research [grant number DFF-6110-00043], Fonden of 17-12-1981
   and The Danish National Research Foundation via CVIVA [grant number
   DNRF108] supported the work of some of the authors. The funding agencies
   had no role in the study design, data collection, data analysis, data
   interpretation or writing the paper.
CR Aaby P, 2004, INT J EPIDEMIOL, V33, P367, DOI 10.1093/ije/dyh004
   Aaby P, 2016, BMJ OPEN, V6
   Aaby P, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000707
   Aaby Peter, 2003, Semin Pediatr Infect Dis, V14, P220, DOI 10.1016/S1045-1870(03)00037-2
   Aaby P, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c6495
   [Anonymous], 2009, Wkly Epidemiol Rec, V84, P349
   Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004
   Brond M, 2017, J PEDIAT INFECT DIS
   de Bree LCJ, 2018, SEMIN IMMUNOL, V39, P35, DOI 10.1016/j.smim.2018.06.002
   Do VA, 2017, J INFECT DIS, V215, P1188, DOI 10.1093/infdis/jiw512
   Feikin DR, 2010, INT J EPIDEMIOL, V39, P450, DOI 10.1093/ije/dyp374
   Fisker AB, 2018, CLIN INFECT DIS, V66, P1573, DOI 10.1093/cid/cix1033
   Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170
   Martins CL, 2014, J INFECT DIS, V209, P1731, DOI 10.1093/infdis/jit804
   Rasmussen SM, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0738-z
   Schoeps A, 2018, VACCINE, V36, P1965, DOI 10.1016/j.vaccine.2018.02.104
NR 16
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2487
EP 2494
DI 10.1016/j.vaccine.2020.01.096
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200008
PM 32061387
OA Bronze
DA 2020-05-12
ER

PT J
AU Liu, CH
   Yeh, YC
   Huang, WT
   Chie, WC
   Chan, KA
AF Liu, Chia-Hung
   Yeh, Yi-Chun
   Huang, Wan-Ting
   Chie, Wei-Chu
   Chan, K. Arnold
TI Assessment of pre-specified adverse events following varicella vaccine:
   A population-based self-controlled risk interval study
SO VACCINE
LA English
DT Article
DE Variceila vaccine; Safety assessment; Self-controlled risk interval
   design
ID RUBELLA VACCINE; SAFETY PROFILE; CHILDREN; IMMUNOGENICITY; MEASLES;
   MUMPS; TAIWAN; TOLERABILITY; IMMUNIZATION; STROKE
AB Background: Clinical trials and spontaneous reporting systems have revealed rare but biologically plausible adverse events following varicella immunization. Few post-marketing controlled studies have been conducted to assess the relationship between the varicella vaccine and these outcomes.
   Objectives: To evaluate the risk of pneumonia, idiopathic thrombocytopenic purpura (ITP), meningitis, encephalitis and ischemic stroke following varicella immunization.
   Materials and methods: This nationwide observational study was based on Taiwan National Health Insurance data and National Immunization Information System from 2004 through 2014. Primary analysis included children aged 12-35 months who received the single varicella vaccine on the date of administration. The self-controlled risk interval design compared the incidence of pre-specified outcomes during a risk interval of 1-42 days post-vaccination and a control interval of 43-84 days. The outcomes of interest were defined as admitted pneumonia, ITP, meningitis, encephalitis, and ischemic stroke, as well as fracture as a negative control. Conditional Poisson regression was used to assess the incidence rate ratio (aIRR) with adjustments for age and seasonal effects.
   Results: Among 1,194,189 children, who receiving the varicella vaccine, there was no observed increase in the risk for ITP (aIRR 1.00; 95% CI, 0.76-1.33), meningitis (aIRR 1.21; 95% CI, 0.49-2.95), encephalitis (aIRR 1.00; 95% CI, 0.62-1.60), or ischemic stroke (aIRR 1.24; 95% CI, 0.31-4.95). A clustering feature with pneumonia occurred during days 36-42 post-vaccination (aIRR 1.10; 95% CI, 1.02-1.18). An increase in the risk for ITP was observed in children receiving the varicella and MMR vaccines concomitantly (aIRR 1.70; 95% CI, 1.19-2.43), but not among those receiving the varicella vaccine only.
   Conclusions: We detected a small risk of incidental pneumonia associated with varicella vaccine in the 6th week after immunization. There was no increase in the risk of other pre-specified adverse events. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Liu, Chia-Hung; Chie, Wei-Chu] Natl Taiwan Univ, Coll Publ Hlth, Grad Inst Epidemiol & Prevent Med, Taipei, Taiwan.
   [Liu, Chia-Hung] Taipei Med Univ, Shuang Ho Hosp, Dept Family Med, New Taipei, Taiwan.
   [Liu, Chia-Hung] Taipei Med Univ, Coll Med, Sch Med, Dept Family Med, Taipei, Taiwan.
   [Yeh, Yi-Chun] Natl Taiwan Univ Hosp, Dept Med Res, Taipei, Taiwan.
   [Huang, Wan-Ting] Minist Hlth & Welf, Taiwan Ctr Dis Control, Taipei, Taiwan.
   [Chan, K. Arnold] Natl Taiwan Univ, Hlth Data Res Ctr, Taipei, Taiwan.
RP Huang, WT (reprint author), Minist Hlth & Welf, Taiwan Ctr Dis Control, Taipei, Taiwan.
EM muagi@cdc.gov.tw
OI Huang, Wan-Ting/0000-0002-4344-9567; Chan, Kinwei/0000-0001-8161-1986
FU Taiwan Ministry of Science and Technology [MOST 105-2314-B002-055-MY2]
FX This research was supported by a grant (MOST 105-2314-B002-055-MY2) from
   the Taiwan Ministry of Science and Technology. The funding body was in
   no way involved in the study design, the analysis or the presentation of
   the data or writing the report.
CR Amir A, 2010, ACTA PAEDIATR, V99, P1385, DOI 10.1111/j.1651-2227.2010.01842.x
   [Anonymous], 2014, VAR HERP ZOST VACC W
   [Anonymous], 2019, 10 THREATS GLOB 2019
   Baker MA, 2015, AM J EPIDEMIOL, V181, P608, DOI 10.1093/aje/kwu322
   Black S, 1999, PEDIATR INFECT DIS J, V18, P1041, DOI 10.1097/00006454-199912000-00003
   Bozzola E, 2017, ITAL J PEDIATR, V43, DOI [10.1186/s13052-017-0366-8, 10.1186/s13052-017-0416-2]
   CDC, 2007, PREVENTION VARICELLA
   Chaves SS, 2008, J INFECT DIS, V197, pS170, DOI 10.1086/522161
   Cheng HY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35451-y
   Donahue JG, 2009, PEDIATRICS, V123, pE228, DOI 10.1542/peds.2008-2384
   Ferrera G, 2009, HUM VACCINES, V5, P455, DOI 10.4161/hv.8269
   France EK, 2008, PEDIATRICS, V121, pE687, DOI 10.1542/peds.2007-1578
   Galea SA, 2008, J INFECT DIS, V197, pS165, DOI 10.1086/522125
   Gatchalian S, 2004, AM J TROP MED HYG, V70, P273, DOI 10.4269/ajtmh.2004.70.273
   Glanz JM, 2006, J CLIN EPIDEMIOL, V59, P808, DOI 10.1016/j.jclinepi.2005.11.012
   Grahn A, 2015, J INFECTION, V71, P281, DOI 10.1016/j.jinf.2015.06.004
   GUESS HA, 1986, PEDIATRICS, V78, P723
   Gwini SM, 2011, VACCINE, V29, P1145, DOI 10.1016/j.vaccine.2010.12.017
   Hawken S, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0225-0
   Heininger U, 2006, LANCET, V368, P1365, DOI 10.1016/S0140-6736(06)69561-5
   Hsing AW, 2015, JAMA INTERN MED, V175, P1527, DOI 10.1001/jamainternmed.2015.3540
   Kulldorff M, 2003, BIOMETRICS, V59, P323, DOI 10.1111/1541-0420.00039
   Kulldorff M, 2017, 33 INT C PHARM ICPE
   Kulldorff M, 2013, PHARMACOEPIDEM DR S, V22, P517, DOI 10.1002/pds.3423
   Lau DT, 2012, BMJ-BRIT MED J, V26, P606, DOI DOI 10.1136/BMJ.I4515
   Lau YL, 2002, VACCINE, V20, P2942, DOI 10.1016/S0264-410X(02)00245-1
   Lin TC, 2009, DEMOGR RES, V20, P377, DOI 10.4054/DemRes.2009.20.16
   Liu DP, 2014, EUROSURVEILLANCE, V19, P27, DOI 10.2807/1560-7917.ES2014.19.50.20994
   MacDonald SE, 2018, VACCINE, V36, P2764, DOI 10.1016/j.vaccine.2018.04.012
   Mantadakis E, 2010, J PEDIATR-US, V156, P623, DOI 10.1016/j.jpeds.2009.10.015
   Marin M, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3741
   Paddy Farrington YG-W, SELF CONTROLLED CASE
   Parment PA, 2003, SCAND J INFECT DIS, V35, P736, DOI 10.1080/00365540310015719
   Ramkissoon A, 1995, S AFR MED J, V85, P1295
   Reis AF, 2014, ACTA PAEDIATR, V103, pE176, DOI 10.1111/apa.12535
   Remschmidt C, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1154-y
   Sharrar RG, 2000, VACCINE, V19, P916, DOI 10.1016/S0264-410X(00)00297-8
   Shinefield HR, 2002, PEDIATR INFECT DIS J, V21, P555, DOI 10.1097/00006454-200206000-00014
   WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201
   Wise RP, 2000, JAMA-J AM MED ASSOC, V284, P1271, DOI 10.1001/jama.284.10.1271
   Yang LY, 2015, INT J ENV RES PUB HE, V12, P14043, DOI 10.3390/ijerph121114043
   Yih WK, 2014, NEW ENGL J MED, V370, P503, DOI 10.1056/NEJMoa1303164
   Zhou Weigong, 2003, MMWR Surveill Summ, V52, P1
   Ziebold C, 2001, PEDIATRICS, V108
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2495
EP 2502
DI 10.1016/j.vaccine.2020.01.090
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200009
PM 32046891
DA 2020-05-12
ER

PT J
AU Fan, J
   Cong, S
   Wang, N
   Bao, HL
   Wang, BH
   Feng, YJ
   Lv, XL
   Zhang, Y
   Zha, ZQ
   Yu, LZ
   Yang, T
   Wang, LH
   Fang, LW
AF Fan, Jing
   Cong, Shu
   Wang, Ning
   Bao, Heling
   Wang, Baohua
   Feng, Yajing
   Lv, Xueli
   Zhang, Yang
   Zha, Zhenqiu
   Yu, Lianzheng
   Yang, Ting
   Wang, Linhong
   Fang, Liwen
TI Influenza vaccination rate and its association with chronic diseases in
   China: Results of a national cross-sectional study
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination; Rate; Chronic disease; China
ID SELF-REPORT; RISK; VACCINES; COVERAGE; ADULTS; IMPACT
AB Introduction: Influenza vaccination is the most effective way to prevent influenza. Few studies on its rate were reported throughout China and for populations with chronic diseases. An estimation of the rates in China was accomplished.
   Methods: All data were from a national cross-sectional survey of a sample representing the population aged 40 years or older in mainland China in 2014-15. A total of 74,484 individuals with complete self-reported influenza vaccination status were analyzed in 2018-19.
   Results: The overall influenza vaccination rate was 2.4% (95% CI 1.4-3.3) with 1.7% (95% CI 1.2-2.2) for the age group 40-59 years and 3.8% (95% CI 1.6-5.9) for the group >= 60 years. The rate was 4.0% (95% CI 2.0-5.9) among people with a chronic disease. People with asthma and people with emphysema had the highest rates (7.1%, 95% CI 3.2-11.0 and 6.6%, 95% CI 3.6-9.7) while people with chronic obstructive pulmonary disease (COPD) and people with chronic bronchitis had the lower rates (3.6%, 95% CI 2.0-5.2 and 4.8%, 95% CI 2.6-7.0). The rate was the highest among former smokers (3.3%, 95% CI 2.3-4.4) compared to current smokers (1.8%, 95% CI 0.9-2.7) and never smokers (2.5%, 95% CI 1.4-3.6). People living with finance-reimbursed vaccination policy, a positive factor for vaccination, had a higher vaccination rate (11.5%, 95% CI 10.8-12.2) (p < 0.05). People with older age, higher education level, occupation of professionals or technical personnel, living in rural areas or Northern China, former/never smoking were more likely to be vaccinated (p < 0.05).
   Conclusions: The influenza vaccination rate is low among adults aged >= 40 years, those >= 60 years and those with chronic diseases in China. Reimbursement policy targeting the elderly should be implemented widely and strategies towards patients with chronic diseases need urgent attention to increase the influenza vaccination coverage. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Fan, Jing; Cong, Shu; Wang, Ning; Bao, Heling; Wang, Baohua; Feng, Yajing; Lv, Xueli; Zhang, Yang; Wang, Linhong; Fang, Liwen] Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, 27 Nanwei Rd, Beijing 100050, Peoples R China.
   [Zha, Zhenqiu] Anhui Prov Ctr Dis Control & Prevent, 12560 Fanhua Rd, Hefei 230601, Anhui, Peoples R China.
   [Yu, Lianzheng] Liaoning Prov Ctr Dis Control & Prevent, 242 Shayang Rd, Shenyang 110005, Liaoning, Peoples R China.
   [Yang, Ting] China Japan Friendship Hosp, Ctr Resp Med, Yinghuayuan East Rd, Beijing 100029, Peoples R China.
RP Fang, LW (reprint author), Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, 27 Nanwei Rd, Beijing 100050, Peoples R China.
EM fangliwen@ncncd.chinacdc.cn
FU Ministry of Science and Technology of the People's Republic of
   ChinaMinistry of Science and Technology, China [2016YFC1303905,
   2016YFC1303900]; Chinese Central Government [2014814]
FX This work was supported by the Ministry of Science and Technology of the
   People's Republic of China [national key R&D programme of China,
   2016YFC1303905, 2016YFC1303900] and the Chinese Central Government [key
   project of public health programme, grant no 2014814]. We thank all
   research staff from local Centers for Disease Control and Prevention in
   China and local hospitals in China for collection of data.
CR (AECOPD) EGoDaToAEoCOPD, 2017, INT J RESP, V37, P1041
   Akturk UA, 2017, BALK MED J, V34, P206, DOI 10.4274/balkanmedj.2016.1028
   Annunziata K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050553
   [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107, DOI 10.1164/ajrccm.152.3.7663792
   Arabyat RM, 2018, RES SOC ADMIN PHARM, V14, P162, DOI 10.1016/j.sapharm.2017.02.010
   Asthma Committee Chinese Thoracic Society, 2009, CHINESE J TUBERCULOS, V32, P407
   Astray-Mochales J, 2016, VACCINE, V34, P4898, DOI 10.1016/j.vaccine.2016.08.065
   Bekkat-Berkani R, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0420-8
   Branch of Influenza vaccine Technical group on National Immunization Program Chinese Center for Disease Control and Prevention, TECHN GUID VACC INFL
   Chinese Diabetes Society, 2014, CHIN J ENDOCRINOL ME, V30, P893, DOI DOI 10.3760/CMA.J.ISSN.1000-6699.2014.10.020
   Chronic Obstructive Pulmonary Disease Committee Chinese Thoracic Society, 2013, CHINESE J TUBERCULOS, V36, P255
   Cromer D, 2014, J INFECTION, V68, P363, DOI 10.1016/j.jinf.2013.11.013
   Davis MM, 2006, J AM COLL CARDIOL, V48, P1498, DOI 10.1016/j.jacc.2006.09.004
   Fang LW, 2018, LANCET RESP MED, V6, P421, DOI 10.1016/S2213-2600(18)30103-6
   Feng Luzhao, 2014, Zhonghua Liu Xing Bing Xue Za Zhi, V35, P1295
   Feng LZ, 2012, B WORLD HEALTH ORGAN, V90, P279, DOI 10.2471/BLT.11.096958
   Garrastazu R, 2016, ARCH BRONCONEUMOL, V52, P88, DOI 10.1016/j.arbres.2015.09.001
   GOLD, 2018 REPORT
   Hsu DJ, 2016, CHRON OBSTR PULM DIS, V3, P620, DOI 10.15326/jcopdf.3.3.2015.0156
   Jimenez-Garcia R, 2005, VACCINE, V23, P3679, DOI 10.1016/j.vaccine.2005.02.007
   Lu PJ, 2009, AM J PREV MED, V37, P109, DOI 10.1016/j.amepre.2009.03.021
   Mac Donald R, 1999, AM J PREV MED, V16, P173, DOI 10.1016/S0749-3797(98)00159-7
   Michiels B, 2011, VACCINE, V29, P9159, DOI 10.1016/j.vaccine.2011.08.008
   Mowls DS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067600
   National Bureau of Statistics of China, 2014, ADM AR COD URB RUR C
   O'Halloran AC, 2016, AM J PREV MED, V50, pE15, DOI 10.1016/j.amepre.2015.06.008
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Peng ZB, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0884-1
   Santaularia J, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2884-5
   The Ministry of Health of the People's Republic of China, 2011, NAT STAND BAS PUBL H
   Vozoris NT, 2009, RESP MED, V103, P50, DOI 10.1016/j.rmed.2008.08.004
   Wagner AL, 2017, J PUBLIC HEALTH-UK, V39, P358, DOI 10.1093/pubmed/fdw041
   Wooten KG, 2012, VACCINE, V30, P6927, DOI 10.1016/j.vaccine.2012.08.036
   World Health Organization, INFL BURD DIS
   World Health Organization (WHO), 2020, INFL SEAS
   Wu SS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017459
   Yang J, 2016, VACCINE, V34, P5724, DOI 10.1016/j.vaccine.2016.10.013
   Yu HJ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001552
   Zhou L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073724
   Zimmerman RK, 2003, VACCINE, V21, P1486, DOI 10.1016/S0264-410X(02)00698-9
NR 40
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2503
EP 2511
DI 10.1016/j.vaccine.2020.01.093
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200010
PM 32046892
DA 2020-05-12
ER

PT J
AU Hopman, HA
   Crowcroft, NS
   Cesuroglu, T
   Langley, JM
AF Hopman, Hester A.
   Crowcroft, Natasha S.
   Cesuroglu, Tomris
   Langley, Joanne M.
TI Incorporation of health economic evaluation into immunization
   policy-making in Canada: Barriers and facilitators
SO VACCINE
LA English
DT Article
DE Immunization programs; Vaccines; Health care economics and
   organizations; Economics; Public policy
ID DECISION-MAKING; ADVISORY-COMMITTEE; VACCINES
AB Introduction: Despite the WHO recommendation that economic evidence be considered in national vaccine recommendations, this element of decision-making has been lacking or not done routinely in Canada. This study aimed to investigate barriers and facilitators to using economic evaluations in public health immunization programs decision-making across Canadian jurisdictions.
   Methods: This mixed methods study consisted of a cross-sectional survey and semi-structured interviews of national, provincial and territorial public health level key informants, and of members of the national immunization research network in Canada. Barriers were categorized according to accessibility (e.g. access to human resources to conduct the evaluation) and acceptability (e.g. political resistance to using the evaluation).
   Results: Of 63 survey participants, 12 were federal, provincial or territorial key informants (response rate 12/31, 39%) and 51 were members from the research network (response rate 51/214, 24%). Eleven stakeholders gave semi-structured interviews. All respondents support increased use of economic evaluation and of it becoming a routine part of immunization policy-making. However, 70% of the survey respondents identified limited resources (human and financial) to perform economic evaluations, and 39% reported lack of expertise to interpret economic evidence. Vaccine effectiveness and the burden of disease were seen as more important than cost-effectiveness by survey respondents and interviewees. Potential facilitators were for economic evaluations to either be conducted at the national level, or through a collaboration between provinces and territories with capacity to address shared needs so that evaluations occurred in a co-ordinated but distributed way.
   Recommendations:: Barriers to incorporation of economic evaluation in immunization policy-making in Canada include lacking human and financial resources to conduct them and understanding of economic evidence. National, provincial and territorial public health actors reported that facilitators to incorporating economic evidence include developing increased capacity to conduct and use economic evaluations and establishing inter-jurisdictional systems to share the work of conducting economic evaluation and/or by national leadership. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hopman, Hester A.; Crowcroft, Natasha S.] Univ Toronto, Lab Med & Pathobiol, ICES, Toronto, ON, Canada.
   [Hopman, Hester A.; Crowcroft, Natasha S.] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Hopman, Hester A.; Cesuroglu, Tomris] Vrije Univ Amsterdam, Fac Sci, Athena Inst, Amsterdam, Netherlands.
   [Langley, Joanne M.] Dalhousie Univ, IWK Hlth Ctr, Nova Scotia Hlth Author, Canadian Ctr Vaccinol, Halifax, NS, Canada.
RP Langley, JM (reprint author), IWK Hlth Ctr, 4th Floor,Goldbloom Bldg,5850 Univ Ave, Halifax, NS B3K 6R8, Canada.
EM Joanne.Langley@Dal.Ca
RI Cesuroglu, Tomris/AAL-9046-2020
OI Cesuroglu, Tomris/0000-0002-2500-7132
CR Barbieri M, 2001, Curr Oncol Rep, V3, P410, DOI 10.1007/s11912-001-0027-2
   Chit A, 2016, HUM VACC IMMUNOTHER, V12, P1257, DOI 10.1080/21645515.2015.1137405
   Dempsey AF, 2008, VACCINE, V26, P5389, DOI 10.1016/j.vaccine.2008.07.085
   Eddama O, 2008, HEALTH POLICY, V86, P129, DOI 10.1016/j.healthpol.2007.11.010
   Grey DE, 2015, DOING RES REAL WORLD
   Hall AJ, 2010, VACCINE, V28, pA54, DOI 10.1016/j.vaccine.2010.02.034
   Hoffmann C, 2000, HEALTH POLICY, V52, P179, DOI 10.1016/S0168-8510(00)00076-2
   Ismail SJ, 2010, VACCINE, V28, pA58, DOI 10.1016/j.vaccine.2010.02.035
   Kim JJ, 2011, NEW ENGL J MED, V365, P1760, DOI 10.1056/NEJMp1110539
   Krahn M, 2019, CAN MED ASSOC J, V191, pE733, DOI 10.1503/cmaj.181606
   Langley JM, 2014, EXPERT REV VACCINES, V13, P1291, DOI 10.1586/14760584.2014.939637
   Merlo G, 2015, APPL HEALTH ECON HEA, V13, P303, DOI 10.1007/s40258-014-0132-7
   Nolan TM, 2010, VACCINE, V28, pA76, DOI 10.1016/j.vaccine.2010.02.038
   Robbins MJ, 2015, EXPERT REV VACCINES, V14, P605, DOI 10.1586/14760584.2015.985662
   Scheifele D W, 2000, Paediatr Child Health, V5, P371
   Scheifele DW, 2014, VACCINE, V32, P766, DOI 10.1016/j.vaccine.2013.12.027
   Sibbald B, 2003, CAN MED ASSOC J, V168, P598
   Thompson C, 1999, QUAL HEALTH RES, V9, P815, DOI 10.1177/104973299129122306
   Williams I, 2008, HEALTH TECHNOL ASSES, V12, P1
   Williams I, 2007, HEALTH POLICY, V80, P135, DOI 10.1016/j.healthpol.2006.03.006
   World Health Organization, 2008, WHO GUID STAND EC EV, P116
   World Health Organization, 2014, PRINC CONS ADD VACC, P136
   World Health Organization, 2019, WHO GUID STAND EC EV, P158
NR 23
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2512
EP 2518
DI 10.1016/j.vaccine.2020.01.092
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200011
PM 32057578
DA 2020-05-12
ER

PT J
AU Moreira, C
   Ferreira, MRA
   Finger, PF
   Magalhaes, CG
   Cunha, CEP
   Rodrigues, RR
   Otaka, DY
   Galvao, CC
   Salvarani, FM
   Moreira, AN
   Conceicao, FR
AF Moreira, Clovis, Jr.
   Ferreira, Marcos R. A.
   Finger, Paula F.
   Magalhaes, Carolina G.
   Cunha, Carlos E. P.
   Rodrigues, Rafael R.
   Otaka, Denis Y.
   Galvao, Cleideanny C.
   Salvarani, Felipe M.
   Moreira, Angela N.
   Conceicao, Fabricio R.
TI Protective efficacy of recombinant bacterin vaccine against botulism in
   cattle
SO VACCINE
LA English
DT Article
DE Clostridium botulinum; Botulinum neurotoxins; Formaldehyde-inactivated
   recombinant vaccine; Recombinant E. coli bacterin
ID CLOSTRIDIUM-BOTULINUM; BOVINE BOTULISM; SEROTYPES C; CONTAMINATION;
   OUTBREAK; DAIRY
AB Botulism is a paralytic disease caused by the intoxication of neurotoxins produced by Clostridium botulinum. Among the seven immunologically distinct serotypes of neurotoxins (BoNTs A - G), serotypes C and D, or a chimeric fusion termed CID or INC, are responsible for animal botulism. The most effective way to prevent botulism in cattle is through vaccination; however, the commercially available vaccines produced by detoxification of native neurotoxins are time-consuming and hazardous. To overcome these drawbacks, a non-toxic recombinant vaccine was developed as an alternative. In this study, the recombinant protein vaccine was produced using an Escherichia coil cell-based system. The formaldehyde-inactivated E. coil is able to induce 7.45 +/- 1.77 and 6.6 +/- 1.28 neutralizing mean titers against BoNTs C and D in cattle, respectively, determined by mouse neutralization bioassay, and was deemed protective by the Brazilian legislation. Moreover, when the levels of anti-BoNT/C and D were compared with those achieved by the recombinant purified vaccines, no significant statistical difference was observed. Cattle vaccinated with the commercial vaccine developed 1.33 and 3.33 IU/mL neutralizing mean titers against BoNT serotypes C and D, respectively. To the best of our knowledge, this study is the first report on recombinant E. coil bacterin vaccine against botulism. The vaccine was safe and effective in generating protective antibodies and, thus, represents an industry-friendly alternative for the prevention of cattle botulism. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Moreira, Clovis, Jr.; Ferreira, Marcos R. A.; Finger, Paula F.; Magalhaes, Carolina G.; Cunha, Carlos E. P.; Rodrigues, Rafael R.; Moreira, Angela N.; Conceicao, Fabricio R.] Univ Fed Pelotas, Nucleo Biotecnol, Ctr Desenvolvimento Tecnol, BR-96160000 Pelotas, RS, Brazil.
   [Otaka, Denis Y.; Galvao, Cleideanny C.; Salvarani, Felipe M.] Univ Fed Para, Inst Med Vet, BR-68740970 Castanhal, Para, Brazil.
RP Conceicao, FR (reprint author), Univ Fed Pelotas, Nucleo Biotecnol, Ctr Desenvolvimento Tecnol, BR-96160000 Pelotas, RS, Brazil.
EM fabricio.rochedo@ufpel.edu.br
OI Alves Ferreira, Marcos Roberto/0000-0002-6658-7196; Moreira junior,
   clovis/0000-0003-1613-1569
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES
   [001]; CNPqNational Council for Scientific and Technological Development
   (CNPq); FAPERGSFoundation for Research Support of the State of Rio
   Grande do Sul (FAPERGS)
FX This study was financed in part by the Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES - Finance Code 001), CNPq and FAPERGS.
CR Baldwin MR, 2008, INFECT IMMUN, V76, P1314, DOI 10.1128/IAI.01025-07
   Connan C, 2013, TOXICON, V75, P90, DOI 10.1016/j.toxicon.2013.06.001
   Cunha CEP, 2014, VACCINE, V32, P214, DOI 10.1016/j.vaccine.2013.11.025
   da Costa GM, 2008, CIENC RURAL, V38, P2068, DOI 10.1590/S0103-84782008000700045
   Ferreira MRA, 2019, ANAEROBE, V59, P163, DOI 10.1016/j.anaerobe.2019.07.002
   Ferreira MRA, 2018, VACCINE, V36, P7589, DOI 10.1016/j.vaccine.2018.10.081
   Gil LAF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069692
   Guizelini CC, 2019, ANAEROBE, V55, P103, DOI 10.1016/j.anaerobe.2018.11.003
   IBGE, 2016, IND IBGE, P14
   Keller JE, 2008, CLIN VACCINE IMMUNOL, V15, P1374, DOI 10.1128/CVI.00117-08
   Mawhinney I, 2012, VET J, V192, P382, DOI 10.1016/j.tvjl.2011.08.024
   Moreira C, 2018, TOXINS, V10, DOI 10.3390/toxins10100381
   Moreira C, 2016, ANAEROBE, V40, P58, DOI 10.1016/j.anaerobe.2016.05.012
   Moreira GMSG, 2014, ANAEROBE, V28, P130, DOI 10.1016/j.anaerobe.2014.06.003
   Oliveira Junior CA, 2019, ANAEROBE, V59, P72, DOI [10 1016/j anaerobe. 2019. 05. 011, DOI 10.1016/J.ANAEROBE.2019.05.011]
   Otaka DY, 2017, TOXINS, V9, DOI 10.3390/toxins9100297
   Payne JH, 2011, VET REC, V168, DOI 10.1136/vr.d1846
   Relun A, 2017, EPIDEMIOL INFECT, V145, P3477, DOI 10.1017/S0950268817002382
   Moreira GMSG, 2016, SCI REP-UK, V6, DOI 10.1038/srep22816
   Silva ROS, 2018, ANAEROBE, V54, P19, DOI 10.1016/j.anaerobe.2018.07.014
   Silva ROS, 2016, CIENC RURAL, V46, P1411, DOI 10.1590/0103-8478cr20151486
   Smith LA, 2009, VACCINE, V27, pD33, DOI 10.1016/j.vaccine.2009.08.059
   Smith TJ, 2011, J BIOTERROR BIODEF, DOI [10.4172/2157-2526, 10.4172/2157-2526 S2-003, DOI 10.4172/2157-2526-S2-003]
   Souillard R, 2017, VET MICROBIOL, V208, P212, DOI 10.1016/j.vetmic.2017.07.022
   Stahl C, 2009, VACCINE, V27, P5661, DOI 10.1016/j.vaccine.2009.07.021
   Turton K, 2002, TRENDS BIOCHEM SCI, V27, P552, DOI 10.1016/S0968-0004(02)02177-1
   Woudstra C, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00757
   Yari K, 2012, BIOPROC BIOSYST ENG, V35, P407, DOI 10.1007/s00449-011-0579-y
NR 28
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2519
EP 2526
DI 10.1016/j.vaccine.2020.01.089
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200012
PM 32037222
DA 2020-05-12
ER

PT J
AU Sicca, F
   Martinuzzi, D
   Montomoli, E
   Huckriede, A
AF Sicca, Federica
   Martinuzzi, Donata
   Montomoli, Emanuele
   Huckriede, Anke
TI Comparison of influenza-specific neutralizing antibody titers determined
   using different assay readouts and hemagglutination inhibition titers:
   good correlation but poor agreement
SO VACCINE
LA English
DT Article
DE Microneutralization assay; Hemagglutination inhibition assay; Assays
   standardization; Correlation; Agreement; Bland-Altman
ID SEROLOGIC ASSAYS; VIRUS; PROTECTION; REPRODUCIBILITY
AB Determination of influenza-specific antibody titers is commonly done using the hemagglutination inhibition assay (HAl) and the viral microneutralization assay (MN). Both assays are characterized by high intra- and inter-laboratory variability. The HAl assay offers little opportunity for standardization. For the MN assay, variability might be due to the use of different assay protocols employing different readouts. We therefore aimed at investigating which of the MN assay readout methods currently in use would be the most suitable choice for a standardized MN assay that could serve as a substitute for the HAI assay. For this purpose, human serum samples were tested for the presence of influenza specific neutralizing antibodies against A/California/7/09 HI NI (49 sera) or A/Hong Kong/4801/2014 (50 sera) using four different infection readout methods for the MN assay (cytopathic effect, hemagglutination, ELISA, RT qPCR) and using the HAI assay. The results were compared by correlation analysis and by determining the level of agreement before and after normalization to a standard serum. Titers as measured by the 4 MN assay readouts showed good correlation, with high Person's r for most comparisons. However, agreement between nominal titers varied with readouts compared and virus strain used. In addition, Pearson's correlation of MN titers with HAl titers was high but agreement of nominal titers was moderate and the average difference between the readings of two assays (bias) was virus strain-dependent. Normalization to a standard serum did not result in better agreement of assay results. Our study demonstrates that different MN readouts result in nominally different antibody titers. Accordingly, the use of a common and standardized MN assay protocol will be crucial to minimize inter-laboratory variability. Based on reproducibility, cost effectiveness and unbiased assessment of results we elected the MN assay with ELISA readout as most suitable for a possible replacement of the HAI assay. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Sicca, Federica; Huckriede, Anke] Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol & Infect Prevent, POB 30001,HPC EB88, NL-9700 RB Groningen, Netherlands.
   [Martinuzzi, Donata; Montomoli, Emanuele] Univ Siena, Dept Life Sci, Siena, Italy.
   [Martinuzzi, Donata; Montomoli, Emanuele] Vismederi Srl, Siena, Italy.
RP Huckriede, A (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Microbiol & Infect Prevent, POB 30001,HPC EB88, NL-9700 RB Groningen, Netherlands.
EM a.l.w.huckriede@umcg.nl
FU EU Horizon 2020 Program under the Marie Skiodowska-Curie grant [713660]
FX F Sicca was supported by the EU Horizon 2020 Program under the Marie
   Skiodowska-Curie grant agreement 713660 (Pronkjewail). We would like to
   thank Prof. Franz J. Weissing (Groningen Institute for Evolutionary Life
   Sciences, University of Groningen, The Netherlands) for help with the
   statistical analysis in this work. We are also grateful to Ymkje
   Stienstra (University Medical Center Groningen, Department of Internal
   Medicine/Infectious Diseases, Groningen, The Netherlands) for helpful
   discussion and advise.
CR Allwinn R, 2010, MED MICROBIOL IMMUN, V199, P117, DOI 10.1007/s00430-010-0143-4
   Belongia EA, 2017, EXPERT REV VACCINES, V16, P723, DOI 10.1080/14760584.2017.1334554
   Benne CA, 1998, CLIN DIAGN LAB IMMUN, V5, P114, DOI 10.1128/CDLI.5.1.114-117.1998
   Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272
   Coudeville L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-18
   Cox RJ, 2013, HUM VACC IMMUNOTHER, V9, P405, DOI 10.4161/hv.22908
   de Jong J C, 2003, Dev Biol (Basel), V115, P63
   deStFazekas Groth Webster RG, 1966, J EXP MED, V124, P331, DOI [10.1084/jem 124 3331, DOI 10.1084/JEM.124.3.331]
   Horby PW, 2017, INFLUENZA OTHER RESP, V11, P2, DOI 10.1111/irv.12411
   Katz JM, 2011, EXPERT REV ANTI-INFE, V9, P669, DOI [10.1586/eri.11.51, 10.1586/ERI.11.51]
   Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6
   Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y
   Laurie KL, 2015, CLIN VACCINE IMMUNOL, V22, P957, DOI 10.1128/CVI.00278-15
   LAVER WG, 1984, VIROLOGY, V137, P314, DOI 10.1016/0042-6822(84)90223-X
   Lin YP, 2016, JOVE-J VIS EXP, DOI 10.3791/54897
   Nunes MC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0210124
   Poland GA, 2018, EXPERT REV VACCINES, V17, P495, DOI 10.1080/14760584.2018.1484284
   Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010
   Sicca F, 2018, EXPERT REV VACCINES, V17, P785, DOI 10.1080/14760584.2018.1516553
   Spearman C, 1908, BRIT J PSYCHOL, V2, P227, DOI 10.1111/j.2044-8295.1908.tb00176.x
   Stephenson I, 2007, VACCINE, V25, P4056, DOI 10.1016/j.vaccine.2007.02.039
   Stephenson I, 2009, EMERG INFECT DIS, V15, P1250, DOI 10.3201/eid1508.081754
   Teferedegne B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056023
   Trombetta C M, 2018, J Prev Med Hyg, V59, pE1, DOI 10.15167/2421-4248/jpmh2018.59.1.870
   Trombetta CM, 2018, INFLUENZA OTHER RESP, V12, P675, DOI 10.1111/irv.12591
   Truelove S, 2016, INFLUENZA OTHER RESP, V10, P518, DOI 10.1111/irv.12408
   van Baalen CA, 2014, J CLIN MICROBIOL, V52, P1672, DOI 10.1128/JCM.03575-13
   van Baalen CA, 2017, VACCINE, V35, P46, DOI 10.1016/j.vaccine.2016.11.060
   Verschoor CP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131531
   Ward BJ, 2018, HUM VACC IMMUNOTHER, V14, P647, DOI 10.1080/21645515.2017.1413518
   World Health Organization, 2011, WHO GLOB INFL SURV N, P153
   Zacour M, 2016, CLIN VACCINE IMMUNOL, V23, P236, DOI 10.1128/CVI.00613-15
   Zhang Wenqing, 2011, MANUAL LAB DIAGNOSIS, P63
   Zhao XH, 2016, EPIDEMIOLOGY, V27, P143, DOI 10.1097/EDE.0000000000000402
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2527
EP 2541
DI 10.1016/j.vaccine.2020.01.088
PG 15
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200013
PM 32044163
OA Other Gold
DA 2020-05-12
ER

PT J
AU Basu, R
   Zhai, L
   Rosso, B
   Tumban, E
AF Basu, Rupsa
   Zhai, Lukai
   Rosso, Brenna
   Tumban, Ebenezer
TI Bacteriophage Q beta virus-like particles displaying Chikungunya virus
   B-cell epitopes elicit high-titer E2 protein antibodies but fail to
   neutralize a Thailand strain of Chikungunya virus
SO VACCINE
LA English
DT Article
DE Chikungunya virus; Q beta virus-like particles (VLPs); 8-cell epitopes;
   Vaccine; Neutralization; FRNT
ID VACCINE; IMMUNOGENICITY; INTERFERENCE; IMMUNIZATION; CANDIDATE;
   ARTHRITIS; SAFETY; MICE
AB Chikungunya virus (CHIKV) is a mosquito-borne virus associated with arthritis and musculoskeletal pains. More than 2.9 million people worldwide have been infected with the virus within the last 1.5 decades; currently, there are no approved vaccines to protect against CHIKV infection. To assess the potential of using CHIKV peptides as vaccine antigens, we multivalently displayed CHIKV peptides representing B-cell epitopes (amino acids 2800-2818, 3025-3058, 3073-3081, 3121-3146, and 3177-3210), from E2 glycoprotein (Singapore strain), on the surface of a highly immunogenic bacteriophage Q beta virus-like particle (VLP). We assessed the immunogenicity of CHIKV E2 amino acid 3025-3058 (including the other epitopes) displayed on Q beta VLPs in comparison to the same peptide not displayed on VLPs. Mice immunized with the E2 peptides displayed on Q beta VLPs elicited high-titer antibodies compared with the group immunized just with the peptide. However, sera from immunized mice did not neutralize CHIKV AF15561 (isolated from Thailand). The data suggest that Q beta VLPs is an excellent approach to elicit high-titer CHIKV E2-protein antibodies at a lower dose of antigen and future studies should assess whether Q beta-CHIKV E2 aa 2800-2818 VLPs and Q beta-CHIKV E2 aa 3025-3058 VLPs can neutralize a Singapore Strain of CHIKV. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Basu, Rupsa; Zhai, Lukai; Rosso, Brenna; Tumban, Ebenezer] Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA.
   [Basu, Rupsa] TechnoVax Inc, Elmsford, NY 10523 USA.
   [Zhai, Lukai] Van Andel Res Inst, Grand Rapids, MI 49503 USA.
RP Tumban, E (reprint author), Michigan Technol Univ, Dept Biol Sci, Houghton, MI 49931 USA.
EM etumban@mtu.edu
FU Michigan Technological University; Songer Research Award
FX This study was supported in part by a start-up fund from Michigan
   Technological University and in part by Songer Research Award from Dr.
   Matthew Songer and Mrs. Laura Songer. The funding body had no role in
   the design of the study nor in collection, analysis, and interpretation
   of data. We would like to thank Dr. Kathryn Carpentier and Dr. Thomas
   Morrison at the University of Colorado School of Medicine, Aurora,
   Colorado for help with virus ELISA study and CHIKV FRNT.
CR Akahata W, 2012, J VIROL, V86, P8879, DOI 10.1128/JVI.00370-12
   Amaral JK, 2018, J RHEUMATOL, V45, P1491, DOI 10.3899/jrheum.171237
   de Brito CAA, 2017, REV SOC BRAS MED TRO, V50, P585, DOI 10.1590/0037-8682-0479-2016
   Ashbrook AW, 2014, J VIROL, V88, P12180, DOI 10.1128/JVI.01672-14
   Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868
   Basu R, 2018, VACCINE, V36, P1256, DOI 10.1016/j.vaccine.2018.01.056
   Brandler S, 2013, VACCINE, V31, P3718, DOI 10.1016/j.vaccine.2013.05.086
   Broeckel R, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005637
   Chackerian B, 2006, VACCINE, V24, P6321, DOI 10.1016/j.vaccine.2006.05.059
   Chang LJ, 2014, LANCET, V384, P2046, DOI 10.1016/S0140-6736(14)61185-5
   Chua CL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004960
   Edelman R, 2000, AM J TROP MED HYG, V62, P681, DOI 10.4269/ajtmh.2000.62.681
   Gardner CL, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002719
   Gorchakov R, 2012, J VIROL, V86, P6084, DOI 10.1128/JVI.06449-11
   Hawman DW, 2017, J VIROL, V91, DOI 10.1128/JVI.00816-17
   Jia B, 2016, OPEN BIOL, V6, DOI 10.1098/rsob.160196
   Kam YW, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003445
   Kam YW, 2012, EMBO MOL MED, V4, P330, DOI 10.1002/emmm.201200213
   Konongoi SL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205058
   Kose N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw6647
   Leung JYS, 2011, ADV VIROL, V2011, DOI 10.1155/2011/249640
   Li WD, 2014, VACCINES-BASEL, V2, P515, DOI 10.3390/vaccines2030515
   Lum FM, 2013, J IMMUNOL, V190, P6295, DOI 10.4049/jimmunol.1300304
   Macek B, 2019, NAT REV MICROBIOL, V17, P651, DOI 10.1038/s41579-019-0243-0
   McClain DJ, 1998, J INFECT DIS, V177, P634, DOI 10.1086/514240
   Morrison CR, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.EI10-0017-2016
   Morrison TE, 2014, J VIROL, V88, P11644, DOI 10.1128/JVI.01432-14
   Morrison TE, 2011, AM J PATHOL, V178, P32, DOI 10.1016/j.ajpath.2010.11.018
   Pal P, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003312
   Peters CMM, 2018, J VECTOR DIS, V55, P137, DOI 10.4103/0972-9062.242561
   Pittman PR, 2009, VACCINE, V27, P4879, DOI 10.1016/j.vaccine.2009.02.090
   Quiroz JA, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008061
   Ramsauer K, 2015, LANCET INFECT DIS, V15, P519, DOI 10.1016/S1473-3099(15)70043-5
   Roy CJ, 2014, J INFECT DIS, V209, P1891, DOI 10.1093/infdis/jiu014
   Silva LA, 2017, J CLIN INVEST, V127, P737, DOI 10.1172/JCI84417
   Slingluff CL, 2011, CANCER J, V17, P343, DOI 10.1097/PPO.0b013e318233e5b2
   Smith SA, 2015, CELL HOST MICROBE, V18, P86, DOI 10.1016/j.chom.2015.06.009
   Tumban E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023310
   Tyler M, 2014, VACCINE, V32, P4267, DOI 10.1016/j.vaccine.2014.06.054
   Wagner JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094401
   Wang E, 2008, VACCINE, V26, P5030, DOI 10.1016/j.vaccine.2008.07.054
   Weaver SC, 2012, EXPERT REV VACCINES, V11, P1087, DOI [10.1586/erv.12.84, 10.1586/ERV.12.84]
   Zhai LK, 2017, ANTIVIR RES, V147, P116, DOI 10.1016/j.antiviral.2017.09.012
NR 43
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2542
EP 2550
DI 10.1016/j.vaccine.2020.01.091
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200014
PM 32044164
DA 2020-05-12
ER

PT J
AU Pullagura, GR
   Violette, R
   Houle, SKD
   Waite, NM
AF Pullagura, Gokul Raj
   Violette, Richard
   Houle, Sherilyn K. D.
   Waite, Nancy M.
TI Shades of gray in vaccination decisions - Understanding community
   pharmacists' perspectives of, and experiences with, influenza vaccine
   hesitancy in Ontario, Canada
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Influenza vaccines; Community pharmacy; Pharmacists;
   Patient engagement
ID IMMUNIZATION; IMPACT; RATES; PREDICTORS; EDUCATION; COVERAGE
AB Background and objectives: Vaccine hesitancy (VH) has been increasingly recognized as a global threat to public health. Yet, limited research exists exploring healthcare providers' experience of this phenomenon. Our study aims to understand community pharmacists' attitudes towards, and experiences with, influenza VH, and explore factors impacting their engagement with patients on the influenza vaccine.
   Methods: A semi-structured interview guide was developed, and interviews were conducted to saturation with community pharmacists practicing in Ontario, Canada. Interview data was transcribed verbatim and analyzed using a thematic content analysis framework. The analysis yielded 110 unique codes, which were merged into five major themes and 15 sub-themes.
   Results: A total of 22 pharmacists were interviewed to achieve saturation. Most pharmacists were authorized to administer injections (n = 20, 90.9%) and practiced for >20 years (n = 16, 72.7%). Pharmacists' engagement with patients on the influenza vaccine was found to be modulated by a complex and mutually reinforcing constellation of attitudes and behaviours which include: a binary (pro-vaccine or antivaccine) perception of patient vaccination decisions; a conflation of those expressing hesitancy with those who are anti-vaccine; and a passive approach to patient engagement, wherein patients were found to be the primary initiators of vaccine conversations. Although pharmacists recognized the importance of educating patients and addressing their vaccine-related concerns, barriers such as limited time, inadequate staffing, and poor remuneration were found to restrict optimal patient engagement on influenza vaccinations.
   Conclusion: While pharmacists hold the potential to effectively address influenza VH within their communities, future interventions must aim to break the loop of passive patient engagement and enable proactive pharmacist-patient interactions on influenza vaccinations in this setting. Crown Copyright (C) 2020 Published by Elsevier Ltd. All rights reserved.
C1 [Pullagura, Gokul Raj; Violette, Richard; Houle, Sherilyn K. D.; Waite, Nancy M.] Univ Waterloo, Sch Pharm, 10A Victoria St South, Kitchener, ON N2G 1C5, Canada.
RP Waite, NM (reprint author), Sch Pharm, PHR 6009,10A Victoria St South, Kitchener, ON N2G 1C5, Canada.
EM gokul.pullagura@uwaterloo.ca; rviolette@uwaterloo.ca;
   sherilyn.houle@uwaterloo.ca; nmwaite@uwaterloo.ca
CR Alsabbagh MW, 2019, RES SOC ADMIN PHARM, V15, P202, DOI 10.1016/j.sapharm.2018.04.015
   Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   Andrew MK, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1180-5
   Bertoldo G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215978
   Bombard Y, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0784-z
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Brewer NT, 2017, PSYCHOL SCI PUBL INT, V18, P149, DOI 10.1177/1529100618760521
   Buchan SA, 2017, CAN MED ASSOC J, V189, pE146, DOI 10.1503/cmaj.151027
   Danis K, 2010, VACCINE, V28, P1861, DOI 10.1016/j.vaccine.2009.11.078
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Dube E, 2014, AM J INFECT CONTROL, V42, pE55, DOI 10.1016/j.ajic.2014.01.006
   Dube E, 2013, HUM VACC IMMUNOTHER, V9, P1763, DOI 10.4161/hv.24657
   Fereday J, 2006, INT J QUAL METH, V5, P1, DOI DOI 10.1177/160940690600500107
   Gargano LM, 2011, HUM VACCINES, V7, P89, DOI 10.4161/hv.7.1.13460
   Kunze U, 2019, CENT EUR J PUBL HEAL, V27, P127, DOI 10.21101/cejph.a5010
   Larson HJ, 2014, VACCINE, V32, P2150, DOI 10.1016/j.vaccine.2014.01.081
   Leung KC, 2017, HEALTH EDUC RES, V32, P455, DOI 10.1093/her/cyx053
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Meyer SB, 2019, VACCINE, V37, P1769, DOI 10.1016/j.vaccine.2019.02.028
   Meyer SB, 2017, J HEALTH COMMUN, V22, P506, DOI 10.1080/10810730.2017.1312720
   O'Reilly DJ, 2018, CLINICOECONOMIC OUTC, V10, P655, DOI 10.2147/CEOR.S167500
   Offeddu V, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7172-8
   Papastergiou John, 2014, Can Pharm J (Ott), V147, P359, DOI 10.1177/1715163514552557
   Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
   Polisena J, 2012, VACCINE, V30, P1981, DOI 10.1016/j.vaccine.2012.01.009
   Pullagura G, 2017, CAN PHARM J, V150, pS55
   Rosenthal SL, 2011, VACCINE, V29, P890, DOI 10.1016/j.vaccine.2009.12.063
   Schmid P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170550
   Seither R, 2017, MMWR-MORBID MORTAL W, V66, P1073, DOI 10.15585/mmwr.mm6640a3
   Smith PJ, 2006, PEDIATRICS, V118, pE1287, DOI 10.1542/peds.2006-0923
   Spier RE, 2001, VACCINE, V20, pS78, DOI 10.1016/S0264-410X(01)00306-1
   Streefland P, 1999, SOC SCI MED, V49, P1705, DOI 10.1016/S0277-9536(99)00239-7
   Usami T, 2009, YAKUGAKU ZASSHI, V129, P1063, DOI 10.1248/yakushi.129.1063
   Van Amburgh JA, 2001, PHARMACOTHERAPY, V21, P1115, DOI 10.1592/phco.21.13.1115.34624
   Vikram K, 2012, SOC SCI MED, V75, P331, DOI 10.1016/j.socscimed.2012.02.043
   Wade GH, 2014, MCN-AM J MATERN-CHIL, V39, P351, DOI 10.1097/NMC.0000000000000083
   Wiley KE, 2013, VACCINE, V31, P3972, DOI 10.1016/j.vaccine.2013.06.015
   Wu SS, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017459
NR 38
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2551
EP 2558
DI 10.1016/j.vaccine.2020.01.085
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200015
PM 32037223
DA 2020-05-12
ER

PT J
AU Camargos, P
   Nascimento-Carvalho, CM
   Teixeira, R
   Franca, E
AF Camargos, Paulo
   Nascimento-Carvalho, Cristiana M.
   Teixeira, Renato
   Franca, Elisabeth
TI Lower respiratory infections mortality among Brazilians under-five
   before and after national pneumococcal conjugate vaccine implementation
SO VACCINE
LA English
DT Article
DE Pneumococcal conjugate vaccine; PCV 10; Vaccine effectiveness;
   Mortality; Pneumonia
ID CHILDREN; MENINGITIS; PNEUMONIA; DISEASE; IMPACT
AB Background: Studies on the impact of pneumococcal conjugate vaccines (PCV) on mortality, especially among preschoolers are scarce. We aimed to assess time trend mortality from lower respiratory infections (LRI), taken as a proxy of pneumonia, from 1990 to 2017.
   Methods: This ecological study assessed the mortality rate among Brazilians under-five before and after the national PCV-10 implementation in 2010. Pneumococcal meningitis (PM) and diarrhea] diseases (DD) were included as a "positive and negative controls", respectively. Trend analysis was performed through Global Burden of Disease estimates. Joinpoint regression modeling was used to describe trends in mortality and to identify time points of its statistically significant decreases throughout the study period.
   Results: There was a sustainable reduction in mortality rates for these three diseases, with no relevant changes in the secular trends for LRI and PM after the PCV-10 implementation. For LRI, PM, and DD the higher and statistically significant (p < 0.05) annual percent change reduction occurred between 2000 and 2003, (-8.3%), 1997-2000 (-11.9%), and 1990-1994.
   (-13.8%), respectively, i.e., several years before the nationwide implementation of PCV-10. Moreover, for LRI the annual percent change (from -5.9 to -8.8) verified from 1990 to 2009, i.e., 20 years before countrywide vaccination, was comparable to that observed during the PCV era, that is, from minus 5.8 to minus 7.8, between 2010 and 2017.
   Conclusion: Mortality from LRI, PM, and DD decreased over time, irrespective of national PCV-10 implementation in Brazil. Other factors such as healthcare delivery, socioeconomic status improvement, and health interventions may have impacted this secular trend. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Camargos, Paulo; Teixeira, Renato; Franca, Elisabeth] Univ Fed Minas Gerais, Sch Med, Belo Horizonte, MG, Brazil.
   [Nascimento-Carvalho, Cristiana M.] Univ Fed Bahia, Sch Med, Salvador, BA, Brazil.
RP Camargos, P (reprint author), Univ Fed Minas Gerais, Med Sch, Dept Paediat, Ave Alfredo Balena 190,Room 267, BR-30130100 Belo Horizonte, MG, Brazil.
EM pcamargs@medicina.ufmg.br
FU Brazilian Ministry of Health (GBD 2017 Brasilia, Brazil, through the
   National Health Fund) [17217.9850001/17-018]
FX Brazilian Ministry of Health (GBD 2017 Brasilia, Brazil, through the
   National Health Fund, Grant number 17217.9850001/17-018). The Brazilian
   Ministry of Health had no influence in the design and conduct of the
   study; in the collection, management, analysis, and data interpretation;
   in the writing, review, or approval of the manuscript, and in the
   decision to submit the paper for publication.
CR [Anonymous], 2017, JOINP REGR VERS 4 5
   [Anonymous], 1989, REV SAUDE PUBLICA, V23, P388, DOI 10.1590/S0034- 89101989000500005
   Bahwere P, 2004, PEDIATR INFECT DIS J, V23, P739, DOI 10.1097/01.inf.0000135663.17018.51
   Brandileone MCC, 2018, VACCINE, V36, P2559, DOI 10.1016/j.vaccine.2018.04.010
   Brazilian Ministry of Health, NAT IMM PROGR INF SY
   Caierao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111129
   de Oliveira LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166736
   Diaz J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153141
   Domingues CMAS, 2014, LANCET RESP MED, V2, P464, DOI 10.1016/S2213-2600(14)70060-8
   Dowell SF, 2000, NEW ENGL J MED, V342, P1399, DOI 10.1056/NEJM200005113421904
   GBD 2017 causes of death collaborators, 2018, LANCET, V392, P736
   Grando IM, 2015, CAD SAUDE PUBLICA, V31, P276, DOI 10.1590/0102-311X00169913
   Hirose TE, 2015, J PEDIAT-BRAZIL, V91, P130, DOI 10.1016/j.jped.2014.07.002
   Kupek E, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00131414
   Madhi SA, 2013, PEDIATR INFECT DIS J, V32, pE119, DOI 10.1097/INF.0b013e3182784b26
   Minamisava R, 2014, PNEUMONIA, V3, P248
   Morais Rinaldo Macedo de, 2017, Saúde debate, V41, P101, DOI 10.1590/0103-11042017s09
   Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
   Nascimento-Carvalho CM, 2008, PEDIATR INFECT DIS J, V27, P939, DOI 10.1097/INF.0b013e3181723751
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Schuck-Paim C, 2019, LANCET GLOB HEALTH, V7, pE249, DOI 10.1016/S2214-109X(18)30455-8
   Suarez V, 2016, VACCINE, V34, P4738, DOI 10.1016/j.vaccine.2016.07.027
   Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4
   Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1
   von Mollendorf C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179905
   Wang HD, 2017, LANCET, V390, P1084, DOI 10.1016/S0140-6736(17)31833-0
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2559
EP 2565
DI 10.1016/j.vaccine.2020.01.084
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200016
PM 32033849
DA 2020-05-12
ER

PT J
AU Emerson, A
   Allison, M
   Kelly, PJ
   Ramaswamy, M
AF Emerson, Amanda
   Allison, Molly
   Kelly, Patricia J.
   Ramaswamy, Megha
TI Barriers and facilitators of implementing a collaborative HPV vaccine
   program in an incarcerated population: A case study
SO VACCINE
LA English
DT Article
DE HPV vaccine; Collaboration; County health departments; Jails;
   Implementation research
ID HUMAN-PAPILLOMAVIRUS VACCINATION; UNITED-STATES; CANCER; ADULTS; WOMEN
AB Background: Men and women in county jails make up a population that is difficult to reach with traditional preventive health interventions. Collaborations between local health departments and county jails represent an opportunity to enhance public health by reaching a vulnerable population with services like vaccinations. The objective of this study was to coordinate planning and implementation of a collaborative program between a local health department (HD) and a county jail to offer human papillomavirus (HPV) vaccinations to adolescents (ages 10-17) and young adults (ages 18-26) in the jail and to identify facilitators and barriers to inform future program development.
   Methods: A county-municipal jail and a local HD in Kansas participated. A case study method was employed based on data collected from a focus group, telephone interviews, and site observations, September 2016 to December 2017. Data were coded using codes roughly drawn from the consolidated framework for implementation research (CFIR). Codes were then consolidated into themes related to barriers and facilitators.
   Results: No adults were vaccinated; two juveniles were vaccinated. Barriers to a collaborative program to offer HPV vaccine to young adults arose in two areas: constrained resources and divergent organizational cultures and priorities. Barriers to offering HPV vaccinations to juveniles in the jail included parental consent and the unpredictable, often brief duration of juvenile detentions. A shared commitment to offering HPV vaccination services by leaders and staff in the two agencies was a key facilitator.
   Conclusion: Finding ways to leverage leadership and staff buy-in and address specific barriers of constrained resources and divergent culture and priorities merits close attention, since partnerships between jails and local HD have potential to increase HPV vaccination rates in an overlooked population and advance public health. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Emerson, Amanda; Kelly, Patricia J.] Univ Missouri, Sch Nursing & Hlth Studies, 2464 Charlotte St, Kansas City, MO 64108 USA.
   [Allison, Molly; Ramaswamy, Megha] Univ Kansas, Sch Med, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.
RP Emerson, A (reprint author), Univ Missouri, Sch Nursing & Hlth Studies, 2464 Charlotte St, Kansas City, MO 64108 USA.
EM emersonam@umkc.edu; mallison2@vet.k-state.edu; kellypj@umkc.edu;
   mramaswamy@kumc.edu
FU National Institutes of Health, National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R21 CA204767]
FX National Institutes of Health, National Cancer Institute, R21 CA204767
   (PI: Megha Ramaswamy).
CR Allison M, 2019, INCARCERATED ADOLESC, V6
   Allison M, 2018, AM J PUBLIC HEALTH, V108, P1000, DOI 10.2105/AJPH.2018.304499
   [Anonymous], 2019, AM HLTH RANK STAT FI
   Badger K, 2011, SOC WORK HEALTH CARE, V50, P577, DOI 10.1080/00981389.2011.592114
   Barr E, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.09.001
   Binswanger IA, 2011, J WOMENS HEALTH, V20, P1839, DOI 10.1089/jwh.2011.2864
   Brogly SB, 2014, SEX TRANSM DIS, V41, P511, DOI 10.1097/OLQ.0000000000000162
   Burger EA, 2016, CANCER-AM CANCER SOC, V122, P2057, DOI 10.1002/cncr.30007
   CFIR Research Team, CONSTR
   Chandra Anita, 2017, Rand Health Q, V6, P3
   Coll S., 2019, NEW YORKER, V95, P28
   Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50
   DeSalvo KB, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.170017
   Dunne EF, 2014, SEX TRANSM DIS, V41, P46, DOI 10.1097/OLQ.0000000000000071
   Franco M, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6566-y
   Gonzalez C, 2008, EPIDEMIOL INFECT, V136, P215, DOI 10.1017/S0950268807008382
   Kaiser Family Foundation, 2018, HPV VACC ACC US US
   Kelly PJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199220
   Kelly PJ, 2017, J COMMUN HEALTH, V42, P15, DOI 10.1007/s10900-016-0225-3
   Kouyoumdjian FG, 2017, PLOS ONE, V12
   Lang A, 2018, PUBLIC CRISIS PUBLIC
   Lewis RM, 2018, VACCINE, V36, P2567, DOI 10.1016/j.vaccine.2018.03.083
   Meites E, 2019, MMWR-MORBID MORTAL W, V68, P698, DOI 10.15585/mmwr.mm6832a3
   Moore A, 2019, J CORRECT HEALTH CAR, V25, P219, DOI 10.1177/1078345819853286
   National Association of County & City Health Officials, 2017, 2016 NAT PROF LOC HL
   National Center for Immunization and Respiratory Diseases, 2019, IMM SCHED TABL 2 CAT
   Pew Charitable Trusts Jails, 2018, JAILS IN HLTH CAR
   Potter RH, 2012, AM J CRIM JUSTICE, V37, P200, DOI 10.1007/s12103-011-9116-4
   Ramaswamy M, 2020, J PUBLIC HEALTH MAN, V26, P168, DOI 10.1097/PHH.0000000000001021
   U.S. Centers for Disease Control, 2017, GEN HPV INF FACT SHE
   U.S. Centers for Disease Control and Prevention, VACC CHILDR PROGR VF
   Udo T, 2019, HEALTH PSYCHOL, V38, P217, DOI 10.1037/hea0000720
   United States Census Bureau, ANN EST RES POP APR
   *US CENS BUR, SMALL AR INC POV EST
   Van Dyne EA, 2018, MMWR-MORBID MORTAL W, V67, P918, DOI 10.15585/mmwr.mm6733a2
   Walker TY, 2019, MMWR-MORBID MORTAL W, V68, P718, DOI 10.15585/mmwr.mm6833a2
   Wallace M, 2020, PUBLIC HEALTH REP, V135, P97, DOI 10.1177/0033354919890862
   Zeng Z., 2019, 251774 NCJ DEP JUST
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2566
EP 2571
DI 10.1016/j.vaccine.2020.01.086
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200017
PM 32046888
DA 2020-05-12
ER

PT J
AU Hendry, AJ
   Beard, FH
   Dey, A
   Quinn, H
   Hueston, L
   Dwyer, DE
   McIntyre, PB
AF Hendry, Alexandra J.
   Beard, Frank H.
   Dey, Aditi
   Quinn, Helen
   Hueston, Linda
   Dwyer, Dominic E.
   McIntyre, Peter B.
TI Lower immunity to poliomyelitis viruses in Australian young adults not
   eligible for inactivated polio vaccine
SO VACCINE
LA English
DT Article
DE Poliomyelitis; Polio; Inactivated polio vaccine; Serosurveillance;
   Serosurvey; Immunity; Australia
ID ERADICATION; WORLDWIDE; IMPACT
AB There are limited long-term data on seroprevalence of neutralising antibody (nAb) to the three poliovirus serotypes following the switch from oral polio vaccine (OPV) to inactivated polio vaccine (IPV). In Australia, combination vaccines containing IPV replaced OPV in late 2005. Using serum and plasma specimens collected during 2012 and 2013, we compared prevalence of nAb to poliovirus type 1 (PV1), type 2 (PV2) and type 3 (PV3) in birth cohorts with differing IPV and OPV eligibility from an Australian population-based sample. In the total sample of 1673 persons aged 12 months to 99 years, 85% had nAb against PV1, 83% PV2 and 67% PV3. In the cohort 12 to <18 years (eligible for 4 OPV doses, last dose 8-14 years prior), a significantly lower proportion had nAb than in the 7 to <12 year cohort (eligible for 3 OPV doses and an IPV booster, last dose 3-8 years prior) for all poliovirus types: [PV1: 87.1% vs. 95.9% (P = 0.01), PV2: 80.4% vs. 92.9% (P - 0.003) and PV3: 38.1% vs. 84.0% (P < 0.0001)]. These data suggest individual-level immunity may be better maintained when an OPV primary schedule is boosted by IPV, and support inclusion of an IPV booster in travel recommendations for young adults who previously received only OPV. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hendry, Alexandra J.; Beard, Frank H.; Dey, Aditi; Quinn, Helen; McIntyre, Peter B.] Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance, Sydney, NSW, Australia.
   [Beard, Frank H.; Dey, Aditi; Quinn, Helen] Univ Sydney, Sydney, NSW, Australia.
   [Hueston, Linda; Dwyer, Dominic E.] NSW Hlth Pathol, Inst Clin Pathol & Med Res, Sydney, NSW, Australia.
RP Hendry, AJ (reprint author), Childrens Hosp Westmead, Kids Res Inst, Natl Ctr Immunisat Res & Surveillance, Locked Bag 4001, Westmead, NSW 2145, Australia.
EM alexandra.hendry@health.nsw.gov.au
FU Australian Government Department of HealthAustralian
   GovernmentDepartment of Health & Ageing; Children's Hospital at
   Westmead; NSW Ministry of Health
FX The National Centre for Immunisation Research and Surveillance is
   supported by the Australian Government Department of Health, the NSW
   Ministry of Health and The Children's Hospital at Westmead. The opinions
   expressed in this report are those of the authors, and do not
   necessarily represent the views of these agencies.
CR Adamu US, 2019, WKLY EPIDEMIOL REC, V30, P329
   Africa Renewal United Nations, AFRICA RENEWAL
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P350
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P145
   [Anonymous], 2014, WKLY EPIDEMIOL REC, V89, P500
   Australian Technical Advisory Group on Immunisation (ATAGI), 2018, AUSTR IMM HDB
   Bandyopadhyay AS, 2015, FUTURE MICROBIOL, V10, P791, DOI [10.2217/FMB.15.19, 10.2217/fmb.15.19]
   CDC, 2002, MMWR-MORBID MORTAL W, V51, P572
   Centers for Disease Control and Prevention, 2015, EPIDEMIOLOGY PREVENT
   Centers for Disease Control & Prevention, 1994, MMWR-MORBID MORTAL W, V43, P720
   Centers for Disease Control & Prevention, 2001, MMWR-MORBID MORTAL W, V50, P1
   Conyn-van Spaendonck MAE, 2001, AM J EPIDEMIOL, V153, P207, DOI 10.1093/aje/153.3.207
   Durrheim DN, 2014, COMMUN DIS INTELL, V38, pE105
   Edirisuriya C, 2018, VACCINE, V36, P2794, DOI 10.1016/j.vaccine.2018.03.086
   Fine P, 2013, VACCINES
   Gidding HF, 2005, AUST NZ J PUBL HEAL, V29, P48, DOI 10.1111/j.1467-842X.2005.tb00748.x
   Gilbert GL, 2001, EPIDEMIOL INFECT, V127, P297, DOI 10.1017/S0950268801005830
   Global, OPV CESS
   Global Polio Eradication Initiative, 2019, 2 OUT 3 WILD POL STR
   Global Polio Eradication Initiative, 2012, GLOB ER WILD POL TYP
   Hall R., 1993, Communicable Disease Intelligence, V17, P226
   HANLON P, 1987, LANCET, V1, P800
   Hull B, 2017, ANN IMMUNISATION COV
   Hull B, 2009, COMMUN DIS INTELL, V33, P170
   Jorba J, 2018, MMWR-MORBID MORTAL W, V67, P1189, DOI 10.15585/mmwr.mm6742a5
   Kelly H, 2002, VACCINE, V20, P3130, DOI 10.1016/S0264-410X(02)00255-4
   Kew OM, 2014, MMWR-MORBID MORTAL W, V63, P1031
   Kim HJ, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0894-z
   Lister S, 1999, Commun Dis Intell, V23, P145
   Lupi S, 2018, HUM VACC IMMUNOTHER, V2018, DOI [10.1080/21645515, DOI 10.1080/2164551520181547608]
   Martin N, 2014, COMMUN DIS INTELL, V38, pE107
   Morales M, 2016, MMWR-MORBID MORTAL W, V65, P470, DOI 10.15585/mmwr.mm6518a4
   MORINIERE BJ, 1993, LANCET, V341, P1545, DOI 10.1016/0140-6736(93)90693-B
   National Centre for Immunisation Research and Surveillance, 2015, VACC HIST TABL SIGN
   Nijsten DRE, 2015, HUM VACC IMMUNOTHER, V11, P2123, DOI 10.1080/21645515.2015.1016673
   Parker EPK, 2015, EXPERT REV VACCINES, V14, P1113, DOI 10.1586/14760584.2015.1052800
   Paterson BJ, 2013, COMMUN DIS INTELL, V37, pE149
   Reinheimer C, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-24
   Roche Paul, 2002, Commun Dis Intell Q Rep, V26, P113
   Stewardson AJ, 2009, EMERG INFECT DIS, V15, P63, DOI 10.3201/eid1501.080791
   van der Maas NA, 2014, EUROSURVEILLANCE, V19, P21, DOI 10.2807/1560-7917.ES2014.19.7.20705
   Wallace GS, 2017, HUM VACC IMMUNOTHER, V13, P776, DOI 10.1080/21645515.2016.1255386
   Wallace GS, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3386-1
   World Health Organization, 2017, POL FACT SHEET
   World Health Organization, 2019, CIRC VACC DER POL TY
   World Health Organization, 2018, CIRC VACC DER POL PA
   World Health Organization, INT TRAV HLTH POL PO
   World Health Organization (WHO), 2013, POL ER ENDG STRAT PL
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2572
EP 2577
DI 10.1016/j.vaccine.2020.01.080
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200018
PM 32037225
DA 2020-05-12
ER

PT J
AU Zier, ER
   Bradford, WD
AF Zier, Emily R.
   Bradford, W. David
TI To attend or not to attend? The effect of school-immunization exemption
   policies on enrollment rates for prekindergarten, kindergarten and
   elementary aged youth
SO VACCINE
LA English
DT Article
DE Vaccines; Vaccine policy; Vaccine exemption; Education; School
   enrollment; Health policy
ID UNITED-STATES; VACCINE REFUSAL; PUBLIC-SCHOOLS; CHILDREN; PRIVATE;
   COMPETITION; POLITICS; HEALTH; RISKS
AB There is no national immunization policy in the United States, and the strictness of regulations allowing vaccine exemption for school attendance varies greatly by state. Despite substantial evidence on the safety and health benefits of immunization, there has been a recent upsurge in skepticism amongst parents regarding vaccine safety and efficacy for their children. To measure the effect of strictness of immunization policy on enrollment rates for school aged children, we utilize fixed effects regression. We construct a panel of data on county level enrollment rate and county characteristics from the American Community Survey, and utilize a recently validated measure of state vaccination policy effectiveness to identify level of strictness amongst states. Given the positive effects early education has for a child's future, paired with the importance of public health, understanding these outcomes may be of interest to policymakers. We find that as children exit the 3-and 4-year-old age cohort and enter the 5-to 9-year-old cohort, stricter vaccination policy has a positive effect on overall enrollment and, specifically, public school enrollment. We also find that female 3-and 4-year-olds' enrollment is more negatively affected by policy strictness than their male counterpart's. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Zier, Emily R.] Univ Georgia, Dept Publ Adm & Policy, 203B Baldwin Hall, Athens, GA 30602 USA.
   [Bradford, W. David] Univ Georgia, Dept Publ Adm & Policy, George D Busbee Chair Publ Policy, 201C Baldwin Hall, Athens, GA 30602 USA.
RP Zier, ER (reprint author), 355 S Jackson St,203B, Athens, GA 30602 USA.
EM emilyz@uga.edu; bradfowd@uga.edu
CR Bean SJ, 2013, QUAL HEALTH RES, V23, P1251, DOI 10.1177/1049732313501891
   Bean SJ, 2011, VACCINE, V29, P1874, DOI 10.1016/j.vaccine.2011.01.003
   Becker J, 2011, DEFENDING THE SOCIAL LICENCE OF FARMING: ISSUES, CHALLENGES AND NEW DIRECTIONS FOR AGRICULTURE, P93
   Biscontini T., 2018, HERD IMMUNITY, P1
   Blank NR, 2013, HEALTH AFFAIR, V32, P1282, DOI 10.1377/hlthaff.2013.0239
   Bradford WD, 2015, HEALTH AFFAIR, V34, P1383, DOI 10.1377/hlthaff.2014.1428
   Brewer T. Jameson, 2017, Pro-Posições, V28, P21, DOI 10.1590/1980-6248-2016-0040
   CDC, 2014, WOULD HAPP WE STOPP
   CDC, 2019, MEASL CAS OUTBR
   Colgrove J, 2016, HEALTH AFFAIR, V35, P348, DOI 10.1377/hlthaff.2015.1172
   Collom E, 2005, EDUC URBAN SOC, V37, P307, DOI 10.1177/0013124504274190
   Constable C, 2014, VACCINE, V32, P1793, DOI 10.1016/j.vaccine.2014.01.085
   Cooper BS, 2007, EDUC POLICY, V21, P110, DOI 10.1177/0895904806296856
   Deas J, 2018, HLTH PROMOTION PRACT, Patent No. 1524839918778830
   Doherty M, 2016, VACCINE, V34, P6707, DOI 10.1016/j.vaccine.2016.10.025
   Epple D, 1998, AM ECON REV, V88, P33
   Epple D, 2004, J PUBLIC ECON, V88, P1215, DOI 10.1016/S0047-2727(02)00187-1
   Epple D, 2002, INT ECON REV, V49, P1395
   Feikin DR, 2000, JAMA-J AM MED ASSOC, V284, P3145, DOI 10.1001/jama.284.24.3145
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Kennedy AM, 2005, J SCHOOL HEALTH, V75, P276, DOI 10.1111/j.1746-1561.2005.00037.x
   Lantos JD, 2010, CURR PROB PEDIATR AD, V40, P38, DOI 10.1016/j.cppeds.2010.01.003
   Mayer M, 1996, QUAL LIFE RES, V5, P568, DOI 10.1007/BF00439230
   Mitra T, 2016, 10 INT AAAI C WEB SO
   Moher D, 2010, INT J SURG, V8, P336, DOI 10.1016/j.ijsu.2010.02.007
   Noel A, 2013, 2013028 NCES
   Olpi ski M, 2012, PEDIAT POLSKA, V87, P381, DOI [10.1016/j.pepo.2012.05.003, DOI 10.1016/J.PEPO.2012.05.003]
   Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477
   Perrin A, 2015, AM INTERNET ACCESS 2, P26
   Poland GA, 2009, VACCINE, V27, P3240, DOI 10.1016/j.vaccine.2009.01.069
   Ray BD, 2015, RES FACTS HOMESCHOOL
   Rogers Catherine, 2014, R I Med J (2013), V97, P27
   Sadaf A, 2013, VACCINE, V31, P4293, DOI 10.1016/j.vaccine.2013.07.013
   Salmon DA, 2005, AM J PUBLIC HEALTH, V95, P778, DOI 10.2105/AJPH.2004.046193
   Salmon DA, 2005, ARCH PEDIAT ADOL MED, V159, P470, DOI 10.1001/archpedi.159.5.470
   Sandra JB, 2018, SAGE OPEN MED
   Seither R, 2014, MMWR-MORBID MORTAL W, V63, P913
   Shaw J, 2014, J PEDIATR-US, V165, P129, DOI 10.1016/j.jpeds.2014.03.039
   Streefland PH, 2001, HEALTH POLICY, V55, P159, DOI 10.1016/S0168-8510(00)00132-9
   Sugerman DE, 2010, PEDIATRICS
   Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0
   Zhou FJ, 2014, PEDIATRICS, V133, P577, DOI 10.1542/peds.2013-0698
NR 42
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2578
EP 2584
DI 10.1016/j.vaccine.2020.01.079
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200019
PM 32037224
DA 2020-05-12
ER

PT J
AU Champredon, D
   Shoukat, A
   Moghadas, SM
AF Champredon, David
   Shoukat, Affan
   Moghadas, Seyed M.
TI Effectiveness and cost-effectiveness of a Clostridium difficile vaccine
   candidate in a hospital setting
SO VACCINE
LA English
DT Article
DE C. difficile; Toxoid vaccine; Cost-effectiveness; Agent-based
   simulations; Hospital epidemiology
ID ENVIRONMENTAL CONTAMINATION; INFECTION; BURDEN; RISK; TRANSMISSION;
   PREVENTION; GUIDELINES; EPIDEMIC; CARRIERS; SPREAD
AB Toxoid vaccines against Clostridium difficile infections (CDI) appear promising in reducing the risk of developing toxin-mediated symptoms. We sought to evaluate the effectiveness and cost-effectiveness of a vaccine candidate in a hospital setting. We developed an agent-based simulation model of nosocomial CDI in a 300-bed hospital. Targeting high-risk patients for vaccination, we estimated the reduction of symptomatic CDI. Using the net reduction of CDI-associated isolation days, we evaluated the vaccine's cost-effectiveness from a healthcare provider perspective over a 2-year period with an average monthly incidence of 5 cases per 10,000 patient-days pre-vaccination.
   Assuming a vaccine efficacy in the range 60-90%, vaccinating 40% of high-risk patients pre-admission reduced symptomatic CDI by 16.6% (95% CI: 15.2, 17.9). When the vaccine coverage increased to 80%, the reduction of symptomatic CDI was 34.6% (95% CI: 33.7, 35.9). For a willingness to pay (WTP) of CDN$1000 (corresponding to the average costs of case isolation per day), vaccine was cost-effective for vaccination costs per individual (VCPI) up to CDN$111 in the scenario of 40% vaccine coverage. With the same WTP, vaccine was cost-effective for VCPI up to CDN$121 when the vaccine coverage increased to 80%. A significant portion (similar to 80%) of hospital colonization is caused by environmental transmission of C difficile, which markedly reduced the effectiveness of vaccine below its assumed efficacy. However, due to the number of CDI-associated isolation days averted, vaccination of high-risk patients can be cost-effective depending on the WTP and the VCPI. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Champredon, David] Univ Western Ontario, Dept Pathol & Lab Med, London, ON N6A 3K7, Canada.
   [Shoukat, Affan] Yale Univ, Ctr Infect Dis Modelling & Anal, New Haven, CT 06510 USA.
   [Champredon, David; Shoukat, Affan; Moghadas, Seyed M.] York Univ, Agent Based Modelling Lab, N York, ON M3J 1P3, Canada.
RP Moghadas, SM (reprint author), York Univ, Agent Based Modelling Lab, N York, ON M3J 1P3, Canada.
EM Moghadas@yorku.ca
FU Pfizer Inc.Pfizer; Mitacs matching funds; Natural Sciences and
   Engineering Research Council of CanadaNatural Sciences and Engineering
   Research Council of Canada
FX This work was supported by an unrestricted grant from Pfizer Inc., and
   by Mitacs matching funds. SMM also acknowledges the funding support of a
   Discovery Grant from the Natural Sciences and Engineering Research
   Council of Canada. The funders had no role in the study design,
   evaluation and analysis of the results, or writing the manuscript.
CR Barker AK, 2018, CLIN INFECT DIS, V66, P1192, DOI 10.1093/cid/cix962
   Bauer MP, 2011, LANCET, V377, P63, DOI 10.1016/S0140-6736(10)61266-4
   Bobulsky GS, 2008, CLIN INFECT DIS, V46, P447, DOI 10.1086/525267
   Briggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W
   Canadian Institute for Health Information, HOSP STAYS CAN
   Chalmers JD, 2016, J INFECTION, V73, P45, DOI 10.1016/j.jinf.2016.04.008
   Champredon D, 2019, AM J INFECT CONTROL
   Codella J, 2015, MED DECIS MAKING, V35, P211, DOI 10.1177/0272989X14545788
   Crobach MJT, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00021-17
   Dubberke ER, 2007, AM J INFECT CONTROL, V35, P315, DOI 10.1016/j.ajic.2006.12.006
   Dubberke ER, 2012, CLIN INFECT DIS, V55, pS88, DOI 10.1093/cid/cis335
   Durham DP, 2016, EMERG INFECT DIS, V22, P608, DOI 10.3201/eid2204.150455
   Eze P, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.010417
   Freedberg DE, 2016, JAMA INTERN MED, V176, P1801, DOI 10.1001/jamainternmed.2016.6193
   He M, 2013, NAT GENET, V45, P109, DOI 10.1038/ng.2478
   Henderson M, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5030025
   Holleck JL, 2017, AM J INFECT CONTROL, V45, P811, DOI 10.1016/j.ajic.2017.02.004
   Jansen KU, 2018, HUM VACC IMMUNOTHER, V14, P2142, DOI 10.1080/21645515.2018.1476814
   Johnson S, 2009, J INFECTION, V58, P403, DOI 10.1016/j.jinf.2009.03.010
   Kociolek LK, 2016, NAT REV GASTRO HEPAT, V13, P150, DOI 10.1038/nrgastro.2015.220
   Lapointe-Shaw L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149521
   Lee BY, 2010, VACCINE, V28, P5245, DOI 10.1016/j.vaccine.2010.05.062
   Lessa FC, 2015, NEW ENGL J MED, V372, P825, DOI [10.1056/NEJMoa1408913, 10.1056/NEJMc1505190]
   Levy AR, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv076
   Longtin Y, 2016, JAMA INTERN MED, V176, P796, DOI [10.1001/jama, 10.1001/jamainternmed.2016.0177]
   Loo VG, 2018, JAMMI, V3, P71, DOI DOI 10.3138/JAMMI.2018.02.13
   McDonald LC, 2018, CLIN INFECT DIS, V66, pE1, DOI [10.1093/cid/cix1085, 10.1093/cid/ciy149]
   McGlone SM, 2012, CLIN MICROBIOL INFEC, V18, P282, DOI 10.1111/j.1469-0691.2011.03571.x
   Najafi M, 2017, MED DECIS MAKING, V37, P871, DOI 10.1177/0272989X17708564
   Nelson RE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152248
   Nissle K, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0358-3
   Riggs MM, 2007, CLIN INFECT DIS, V45, P992, DOI 10.1086/521854
   Rubin MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080671
   Sethi AK, 2010, INFECT CONT HOSP EP, V31, P21, DOI 10.1086/649016
   Sheth PM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0207138
   Surawicz CM, 2013, AM J GASTROENTEROL, V108, P478, DOI 10.1038/ajg.2013.4
   Temime L, 2009, P NATL ACAD SCI USA, V106, P18420, DOI 10.1073/pnas.0900974106
   Tracy M, 2018, ANNU REV PUBL HEALTH, V39, P77, DOI 10.1146/annurev-publhealth-040617-014317
   van Kleef E, 2016, VACCINE, V34, P5562, DOI 10.1016/j.vaccine.2016.09.046
   Verity P, 2001, J HOSP INFECT, V49, P204, DOI 10.1053/jhin.2001.1078
   Walker AS, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001172
   Yakob L, 2016, LANCET INFECT DIS, V16, P1100, DOI 10.1016/S1473-3099(16)30324-3
   Zhang DM, 2018, CLIN INFECT DIS, V66, P1326, DOI 10.1093/cid/cix1021
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2585
EP 2591
DI 10.1016/j.vaccine.2020.01.073
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200020
PM 32014268
DA 2020-05-12
ER

PT J
AU Yufika, A
   Wagner, AL
   Nawawi, Y
   Wahyuniati, N
   Anwar, S
   Yusri, F
   Haryanti, N
   Wijayanti, NP
   Rizal, R
   Fitriani, D
   Maulida, NF
   Syahriza, M
   Ikram, I
   Fandoko, TP
   Syahadah, M
   Asrizal, FW
   Aletta, A
   Haryanto, S
   Jamil, KF
   Mudatsir, M
   Harapan, H
AF Yufika, Amanda
   Wagner, Abram Luther
   Nawawi, Yusuf
   Wahyuniati, Nur
   Anwar, Samsul
   Yusri, Fitria
   Haryanti, Novi
   Wijayanti, Nanda Putri
   Rizal, Rizal
   Fitriani, Devi
   Maulida, Nurul Fadhliati
   Syahriza, Muhammad
   Ikram, Ikram
   Fandoko, Try Purwo
   Syahadah, Muniati
   Asrizal, Febrivan Wahyu
   Aletta, Alma
   Haryanto, Sotianingsih
   Jamil, Kurnia Fitri
   Mudatsir, Mudatsir
   Harapan, Harapan
TI Parents' hesitancy towards vaccination in Indonesia: A cross-sectional
   study in Indonesia
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Vaccine coverage; Vaccine acceptance; Parents'
   hesitancy; Indonesia
ID ACCEPTANCE; CHILDREN; IMMUNIZATION; COUNTRIES; ATTITUDES; REFUSAL
AB Background: Hesitancy towards vaccination has been studied as a barrier to vaccination among children, as well as participation in vaccine trials. This study aimed to investigate hesitancy towards vaccination among parents in Indonesia, as a part of the Indonesia Zika Vaccine Study.
   Methods: A cross-sectional study was conducted in eleven regencies and municipalities in Aceh and West Sumatra province, Indonesia. Parents were recruited from families at outpatient clinics of community health centers or hospitals. The survey included various questions about sociodemographic factors and the Parent Attitudes about Childhood Vaccination (PACV) scale. Linear regression was employed to assess the association between explanatory variables and vaccine hesitancy.
   Results: A total of 956 parents were interviewed and 26.4% of participants had heard about Zika. Overall, 152 parents (15.9%) were vaccine hesitant, and this proportion was the highest in the safety and efficacy subdomain (61.6%). In the unadjusted analysis, having a diploma certificate, working in the health sector, and having heard about Zika were significantly associated with non-hesitancy towards children vaccination. Having heard about Zika was the only factor that was significantly associated with hesitancy towards vaccination in multivariate model (aOR: 0.43, 95% CI: 0.26-0.71). Mothers, younger parents (aged 20-29 years old), and those with only a primary school education were more concerned about vaccine safety and efficacy compared to fathers, older groups, and individuals with more education, respectively.
   Conclusions: Hesitancy towards pediatric vaccination is observed in 15% of respondents and most of the hesitancy was expressed in terms of vaccine safety and efficacy. Therefore, continuous dissemination of vaccine information needs to be carried out to earn parents' trust and increase vaccination coverage in Indonesia. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Yufika, Amanda; Wahyuniati, Nur; Ikram, Ikram; Jamil, Kurnia Fitri; Mudatsir, Mudatsir; Harapan, Harapan] Univ Syiah Kuala, Sch Med, Med Res Unit, Banda Aceh, Aceh, Indonesia.
   [Yufika, Amanda; Nawawi, Yusuf; Aletta, Alma] Univ Syiah Kuala, Sch Med, Dept Family Med, Banda Aceh, Aceh, Indonesia.
   [Wagner, Abram Luther] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Anwar, Samsul] Univ Syiah Kuala, Fac Math & Nat Sci, Dept Stat, Banda Aceh, Aceh, Indonesia.
   [Yusri, Fitria] Malikussaleh Univ, Sch Med, Lhokseumawe, Aceh, Indonesia.
   [Haryanti, Novi] Commun Hlth Ctr Meurah Mulia, North Aceh, Aceh, Indonesia.
   [Wijayanti, Nanda Putri] Community Hlth Ctr Tapaktuan, South Aceh, Aceh, Indonesia.
   [Rizal, Rizal] Bunda Hosp, Lhokseumawe, Aceh, Indonesia.
   [Fitriani, Devi] Community Hlth Ctr Teunom, Aceh Jaya, Aceh, Indonesia.
   [Maulida, Nurul Fadhliati] Meuraxa Hosp, Banda Aceh, Aceh, Indonesia.
   [Syahriza, Muhammad] Univ Syiah Kuala, Sch Med, Dept Publ Hlth & Community Med, Banda Aceh, Aceh, Indonesia.
   [Fandoko, Try Purwo] Community Hlth Ctr Gunung, Padang Panjang, West Sumatra, Indonesia.
   [Syahadah, Muniati] Community Hlth Ctr Lima Kaum, Tanah Datar, West Sumatra, Indonesia.
   [Asrizal, Febrivan Wahyu] Community Hlth Ctr Tanjung, Solok, West Sumatra, Indonesia.
   [Haryanto, Sotianingsih] Jambi Univ, Dept Clin Pathol, Fac Med & Hlth Sci, Jambi, Indonesia.
   [Jamil, Kurnia Fitri] Univ Syiah Kuala, Dept Internal Med, Sch Med, Banda Aceh, Aceh, Indonesia.
   [Mudatsir, Mudatsir; Harapan, Harapan] Univ Syiah Kuala, Sch Med, Trop Dis Ctr, Banda Aceh, Aceh, Indonesia.
   [Mudatsir, Mudatsir; Harapan, Harapan] Univ Syiah Kuala, Sch Med, Dept Microbiol, Banda Aceh, Aceh, Indonesia.
RP Harapan, H (reprint author), Univ Syiah Kuala, Sch Med, Med Res Unit, Darussalam 23111, Banda Aceh, Indonesia.
EM harapan@unsyiah.ac.id
RI ; Mudatsir, Mudatsir/Q-4999-2017
OI Nawawi, Yusuf/0000-0001-8726-0793; Mudatsir,
   Mudatsir/0000-0002-5643-9384
CR Azizi FSM, 2017, VACCINE, V35, P2955, DOI 10.1016/j.vaccine.2017.04.010
   Barbacariu CL, 2014, PROCD SOC BEHV, V149, P84, DOI 10.1016/j.sbspro.2014.08.165
   Berkley S, 2019, NATURE, V569, P309, DOI 10.1038/d41586-019-01493-z
   Bogoch II, 2016, LANCET INFECT DIS, V16, P1237, DOI 10.1016/S1473-3099(16)30270-5
   Bonett DG, 2000, PSYCHOMETRIKA, V65, P23, DOI 10.1007/BF02294183
   Corben P, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5389-6
   Dube E, 2015, EXPERT REV VACC, V14
   Dube E, 2014, VACCINE, V32, P6649, DOI 10.1016/j.vaccine.2014.09.039
   Esposito S, 2014, CLIN MICROBIOL INFEC, V20, P25, DOI 10.1111/1469-0691.12447
   Harapan H., 2017, Asian Pacific Journal of Tropical Disease, V7, P193, DOI 10.12980/apjtd.7.2017D6-386
   Harapan H, 2018, VIRUSES, V10, P14
   Harapan H, 2019, VACCINE, V37, P1398, DOI 10.1016/j.vaccine.2019.01.062
   Harapan H, 2016, VACCINE, V34, P3670, DOI 10.1016/j.vaccine.2016.05.026
   Hellyer JMH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029478
   Kemenkes RI, 2014, IMM TEACH BOOK BUK A
   Kesehatan B, BPJS KESEHATAN PRACT
   Larson HJ, 2019, HUM VACC IMMUNOTHER, DOI 10.1080/21645515.2019.1628510
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   Marti M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172310
   McKee Chephra, 2016, J Pediatr Pharmacol Ther, V21, P104, DOI 10.5863/1551-6776-21.2.104
   Munoz DC, 2015, INT J PUBLIC HEALTH, V60, P767, DOI 10.1007/s00038-015-0715-6
   Omer SB, 2009, NEW ENGL J MED, V360, P1981, DOI 10.1056/NEJMsa0806477
   Opel DJ, 2013, JAMA PEDIATR, V167, P1065, DOI 10.1001/jamapediatrics.2013.2483
   Opel DJ, 2011, VACCINE, V29, P6598, DOI 10.1016/j.vaccine.2011.06.115
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Rajamoorthy Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208402
   Ren J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209117
   Ri K., 2018, HASIL UTAMA RISKESDA
   Seale H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-99
   Smith LE, 2017, VACCINE, V35, P6059, DOI 10.1016/j.vaccine.2017.09.046
   Strelitz B, 2015, VACCINE, V33, P1802, DOI 10.1016/j.vaccine.2015.02.034
   Sun XD, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5734-9
   Wagner AL, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040155
   Wagner AL, 2017, VACCINE, V35, P4362, DOI 10.1016/j.vaccine.2017.06.077
   WHO, 2018, S E AS REG VACC ACT
   WHO, 2005, GLOB STAT IMM SAF RE
   WHO, 2018, WHO IMM COV FACT SHE
   World Health Organization, 10 THREATS GLOB HLTH
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 40
TC 1
Z9 1
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2592
EP 2599
DI 10.1016/j.vaccine.2020.01.072
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200021
PM 32019704
DA 2020-05-12
ER

PT J
AU Overton, ET
   Lawrence, SJ
   Stapleton, JT
   Weidenthaler, H
   Schmidt, D
   Koenen, B
   Silbernagl, G
   Nopora, K
   Chaplin, P
AF Overton, Edgar Turner
   Lawrence, Steven J.
   Stapleton, Jack T.
   Weidenthaler, Heinz
   Schmidt, Darja
   Koenen, Brigitte
   Silbernagl, Guenter
   Nopora, Katrin
   Chaplin, Paul
TI A randomized phase II trial to compare safety and immunogenicity of the
   MVA-BN smallpox vaccine at various doses in adults with a history of
   AIDS
SO VACCINE
LA English
DT Article
DE Vaccine; Smallpox; MVA; HIV; AIDS; Cardiac safety
ID ANKARA; MYOPERICARDITIS; COMPLICATIONS; EFFICACY
AB Traditional replicating smallpox vaccines are associated with serious safety concerns in the general population and are contraindicated in immunocompromised individuals. However, this very population remains at greatest risk for severe complications following viral infections, making vaccine prevention particularly relevant. MVA-BN was developed as a non-replicating smallpox vaccine that is potentially safer for people who are immunocompromised. In this phase II trial, 3 MVA-BN dosing regimens were evaluated for safety, tolerability, and immunogenicity in persons with HIV (PWH) who had a history of AIDS. Following randomization, 87 participants who were predominately male and African American received either 2 standard doses on weeks 0 and 4 in the standard dose (SD) group (N = 27), 2 double-standard doses on the same schedule in the double dose (DD) group (N = 29), or 3 standard doses on weeks 0, 4 and 12 in the booster dose (BD) group (N = 31). No safety concerns were identified, and injection site pain was the most commonly reported solicited adverse event (AE) in all groups (66.7%), with no meaningful differences between groups. The incidence of severe (Grade 3) AEs was low across groups and no serious AEs or AEs of special interest considered related to study vaccine were reported. Doubling the standard MVA-BN dose had no significant effect on induction of neutralizing antibodies, with 100% seroconversion and comparable GMTs at week 6 in the SD and DD groups (78.9 and 100.3, respectively). A booster dose significantly increased peak neutralizing titers in the BD group (GMT: 281.1), which remained elevated at 12 months (GMT: 45.3) compared to the SD (GMT: 6.2) and DD (GMT: 10.6) groups. However, based on the immune response previously reported for healthy participants, a third dose (booster) does not appear necessary, even for immunocompromised participants. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Overton, Edgar Turner] Univ Alabama Birmingham, Div Infect Dis, Birmingham, AL USA.
   [Lawrence, Steven J.] Washington Univ, Sch Med, Div Infect Dis, St Louis, MO 63110 USA.
   [Stapleton, Jack T.] Univ Iowa, Dept Internal Med, Carver Coll Med, Div Infect Dis, Iowa City, IA 52242 USA.
   [Stapleton, Jack T.] Univ Iowa, Dept Microbiol & Immunol, Carver Coll Med, Div Infect Dis, Iowa City, IA USA.
   [Stapleton, Jack T.] Iowa City Vet Adm Healthcare, Iowa City, IA USA.
   [Weidenthaler, Heinz; Schmidt, Darja; Koenen, Brigitte; Silbernagl, Guenter; Nopora, Katrin] Bavarian Nord GmbH, Fraunhoferstr 13, D-82152 Martinsried, Germany.
   [Chaplin, Paul] Bavarian Nord AS, Hejreskovvej 10A, DK-3490 Kvistgard, Denmark.
RP Weidenthaler, H (reprint author), Bavarian Nord GmbH, Fraunhoferstr 13, D-82152 Martinsried, Germany.
EM Heinz.Weidenthaler@bavarian-nordic.com
FU Bavarian Nordic
FX The investigators wish to thank all study participants. The study
   described herein was funded by Bavarian Nordic, with medical writing and
   editorial assistance provided by Jacqueline D. Powell, PhD, a company
   employee. Study investigators included Barbara Wade, Thomas Jefferson,
   Ian Frank, Richard Novak, Jennifer Bartczak, Douglas Ward, Jacob
   Lalezari, Javier Morales-Ramirez, and Grisell Ortiz-Lasanta in addition
   to those listed as authors.
CR Arness MK, 2004, AM J EPIDEMIOL, V160, P642, DOI 10.1093/aje/kwh269
   Bicknell WJ, 2002, NEW ENGL J MED, V346, P1323, DOI 10.1056/NEJMsb020357
   Cassimatis DC, 2004, J AM COLL CARDIOL, V43, P1503, DOI 10.1016/j.jacc.2003.11.053
   Committee VaRBPA, 2007, ACAM2000 SMALLP VACC, P1
   Damon IK, 2009, J GEN VIROL, V90, P1962, DOI 10.1099/vir.0.010553-0
   Eckart RE, 2004, J AM COLL CARDIOL, V44, P201, DOI 10.1016/j.jacc.2004.05.004
   Frey SE, 2007, VACCINE, V25, P8562, DOI 10.1016/j.vaccine.2007.10.017
   Frey SE, 2015, VACCINE, V33, P5225, DOI 10.1016/j.vaccine.2015.06.075
   Frey SE, 2014, VACCINE, V32, P2732, DOI 10.1016/j.vaccine.2014.02.043
   Frey SE, 2013, VACCINE, V31, P3025, DOI 10.1016/j.vaccine.2013.04.050
   Geretti AM, 2016, HIV MED, V17, pS2, DOI 10.1111/hiv.12424
   Greenberg RN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157335
   Greenberg RN, 2013, J INFECT DIS, V207, P749, DOI 10.1093/infdis/jis753
   Halsell JS, 2003, JAMA-J AM MED ASSOC, V289, P3283, DOI 10.1001/jama.289.24.3283
   Landrum M, 2008, INFECT DIS CLIN PRAC, V16, P85
   LANE JM, 1970, J INFECT DIS, V122, P303, DOI 10.1093/infdis/122.4.303
   LANE JM, 1969, NEW ENGL J MED, V281, P1201, DOI 10.1056/NEJM196911272812201
   MACK TM, 1972, AM J TROP MED HYG, V21, P214, DOI 10.4269/ajtmh.1972.21.214
   Overton ET, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195897
   Overton ET, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv040
   PERRONNE C, 1990, ARCH DERMATOL, V126, P1033, DOI 10.1001/archderm.126.8.1033
   Petersen BW, 2016, MMWR-MORBID MORTAL W, V65, P257, DOI 10.15585/mmwr.mm6510a2
   Petersen BW, 2015, MMWR RECOMM REP, V64, P1
   Pittman PR, 2019, NEW ENGL J MED, V381, P1897, DOI 10.1056/NEJMoa1817307
   Rotz L D, 2001, MMWR Recomm Rep, V50, P1
   Rubin LG, 2014, CLIN INFECT DIS, V58, pE44, DOI 10.1093/cid/cit684
   Suter M, 2009, VACCINE, V27, P7442, DOI 10.1016/j.vaccine.2009.05.095
   Vollmar J, 2006, VACCINE, V24, P2065, DOI 10.1016/j.vaccine.2005.11.022
   von Krempelhuber A, 2010, VACCINE, V28, P1209, DOI 10.1016/j.vaccine.2009.11.030
   Walsh SR, 2013, J INFECT DIS, V207, P1888, DOI 10.1093/infdis/jit105
   Wharton Melinda, 2003, MMWR Recomm Rep, V52, P1
   Zitzmann-Roth EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122653
NR 32
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2600
EP 2607
DI 10.1016/j.vaccine.2020.01.058
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200022
PM 32057574
DA 2020-05-12
ER

PT J
AU Samy, N
   Reichhardt, D
   Schmidt, D
   Chen, LM
   Silbernagl, G
   Vidojkovic, S
   Meyer, TPH
   Jordan, E
   Adams, T
   Weidenthaler, H
   Stroukova, D
   De Carli, S
   Chaplin, P
AF Samy, Nathaly
   Reichhardt, Daniela
   Schmidt, Darja
   Chen, Liddy M.
   Silbernagl, Guenter
   Vidojkovic, Sanja
   Meyer, Thomas P. H.
   Jordan, Elke
   Adams, Tatiana
   Weidenthaler, Heinz
   Stroukova, Dania
   De Carli, Sonja
   Chaplin, Paul
TI Safety and immunogenicity of novel modified vaccinia Ankara-vectored RSV
   vaccine: A randomized phase I clinical trial
SO VACCINE
LA English
DT Article
ID RESPIRATORY SYNCYTIAL VIRUS; SMALLPOX VACCINE; VIRAL LOAD; INFECTION;
   PROTEIN; INFLUENZA; CHILDREN; CLEARANCE; IMMUNITY; DISEASE
AB Respiratory disease caused by RSV infection is recognized as a severe public health issue in infants, young children and elderly with no specific treatment option. Vaccination may be the most effective strategy to combat this highly infectious virus although no vaccine has been approved. The novel vaccine candidate MVA-BN-RSV encodes RSV surface proteins F and G (subtypes A, B) as well as internal proteins N and M2 in the MVA-BN viral vector backbone to provide broad protection against RSV. This was a first in human study to investigate safety, reactogenicity and immunogenicity of MVA-BN-RSV. Sixty-three participants were allocated to 3 groups: adult (18-49 years) low (1 x 10(7) TCID50) or high (1 x 10(8) TCID50) dose and older adult (50-65 years) high dose. Participants in each group were randomized in a 6:1 ratio to receive 2 doses of MVA-BN-RSV or placebo 4 weeks apart and were monitored for 30 weeks. All participants completed the study, receiving both doses. No serious AEs or AEs of special interest were reported. The most common AEs were injection site pain (56% in the combined high dose groups, 17% in the low dose group). MVA-BN-RSV induced robust T cell responses covering all 5 inserts with fold increases ranging from 1.8 to 3.8. Higher and broader responses were observed in the high dose groups (83% responders to at least 3 peptide pools in the combined high dose groups compared to 63% in the low dose group). Moderate but consistent humoral responses were observed against A and B RSV subtypes (up to approximately 2-fold increases in the high dose groups). No differences were observed between the adult and the older adult groups in safety, reactogenicity or immunogenicity. The study demonstrated that the well tolerated MVA-BN-RSV vaccine candidate induces broad cellular and humoral immune responses, warranting further development. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Samy, Nathaly; Reichhardt, Daniela; Schmidt, Darja; Silbernagl, Guenter; Vidojkovic, Sanja; Meyer, Thomas P. H.; Jordan, Elke; Adams, Tatiana; Weidenthaler, Heinz; Stroukova, Dania; De Carli, Sonja] Bavarian Nord GmbH, Fraunhoferstr 13, D-82152 Martinsried, Germany.
   [Chen, Liddy M.] Bavarian Nord Inc, 3025 Carrington Mill Blvd, Morrisville, NC 27560 USA.
   [Chaplin, Paul] Bavarian Nord AS, Hejreskovvej 10A, DK-3990 Kvistgard, Denmark.
RP Weidenthaler, H (reprint author), Bavarian Nord GmbH, Fraunhoferstr 13, D-82152 Martinsried, Germany.
EM Heinz.Weidenthaler@bavarian-nordic.com
CR Anderson CA, 2016, RESP SYNCYTIAL VIRUS, P1
   Botosso VF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000254
   CANNON MJ, 1987, IMMUNOLOGY, V62, P133
   Castagne N, 2004, J GEN VIROL, V85, P1643, DOI 10.1099/vir.0.79830-0
   Castilow EM, 2007, IMMUNOL RES, V39, P225, DOI 10.1007/s12026-007-0071-6
   Cheminay C, NOVEL MULTIINS UNPUB
   Cheng X, 2005, J VIROL, V79, P13943, DOI 10.1128/JVI.79.22.13943-13952.2005
   Cherukuri A, 2013, CLIN VACCINE IMMUNOL, V20, P239, DOI 10.1128/CVI.00580-12
   Cherukuri A, 2012, IMMUN AGEING, V9, DOI 10.1186/1742-4933-9-21
   Darsow U, 2016, J EUR ACAD DERMATOL, V30, P1971, DOI 10.1111/jdv.13797
   DeVincenzo JP, 2010, AM J RESP CRIT CARE, V182, P1305, DOI 10.1164/rccm.201002-0221OC
   Falloon J, 2017, J INFECT DIS, V216, P1362, DOI 10.1093/infdis/jix503
   Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951
   FISHAUT M, 1980, J PEDIATR-US, V96, P179, DOI 10.1016/S0022-3476(80)80799-2
   Frey SE, 2015, VACCINE, V33, P5225, DOI 10.1016/j.vaccine.2015.06.075
   Frey SE, 2013, VACCINE, V31, P3025, DOI 10.1016/j.vaccine.2013.04.050
   Gilbert SC, 2012, IMMUNOLOGY, V135, P19, DOI 10.1111/j.1365-2567.2011.03517.x
   Glenn GM, 2016, J INFECT DIS, V213, P411, DOI 10.1093/infdis/jiv406
   Greenberg RN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157335
   Greenberg RN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138348
   Greenberg RN, 2013, J INFECT DIS, V207, P749, DOI 10.1093/infdis/jis753
   Grubeck-Loebenstein B, 2009, AGING CLIN EXP RES, V21, P201, DOI 10.1007/BF03324904
   Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877
   Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507
   HALL CB, 1986, NEW ENGL J MED, V315, P77, DOI 10.1056/NEJM198607103150201
   HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693
   Harrer E, 2005, ANTIVIR THER, V10, P285
   Kamphuis T, 2013, INFLUENZA OTHER RESP, V7, P1227, DOI 10.1111/irv.12112
   Kaye M, 2006, EPIDEMIOL INFECT, V134, P792, DOI 10.1017/S0950268805005364
   Kim JY, 2016, YONSEI MED J, V57, P809, DOI 10.3349/ymj.2016.57.4.809
   Lee MS, 2005, HUM VACCINES, V1, P6, DOI 10.4161/hv.1.1.1424
   Li CF, 2016, J IMMUNOL, V196, P1721, DOI 10.4049/jimmunol.1502103
   Mitra R, 2012, J VIROL, V86, P4432, DOI 10.1128/JVI.06744-11
   MUNOZ JL, 1991, J VIROL, V65, P4494
   Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1
   Overton ET, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv040
   Piedra PA, 2003, VACCINE, V21, P3479, DOI 10.1016/S0264-410X(03)00355-4
   Sancho MC, 2002, J VIROL, V76, P8318, DOI 10.1128/JVI.76.16.8318-8334.2002
   Saxena S, 2017, J MED VIROL, V89, P49, DOI 10.1002/jmv.24607
   Shinoff JJ, 2008, J INFECT DIS, V198, P1007, DOI 10.1086/591460
   Sikkel MB, 2008, PEDIATR INFECT DIS J, V27, pS63, DOI 10.1097/INF.0b013e3181684d67
   Suter M, 2009, VACCINE, V27, P7442, DOI 10.1016/j.vaccine.2009.05.095
   SUTTER G, 1992, P NATL ACAD SCI USA, V89, P10847, DOI 10.1073/pnas.89.22.10847
   Tayyari F, 2011, NAT MED, V17, P1132, DOI 10.1038/nm.2444
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Trombetta CM, 2018, HUM VACC IMMUNOTHER, V14, P657, DOI 10.1080/21645515.2017.1423153
   von Sonnenburg F, 2014, VACCINE, V32, P5696, DOI 10.1016/j.vaccine.2014.08.022
   Zitzmann-Roth EM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122653
NR 48
TC 0
Z9 0
U1 4
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2608
EP 2619
DI 10.1016/j.vaccine.2020.01.055
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200023
PM 32057576
DA 2020-05-12
ER

PT J
AU Buttenheim, AM
   Joyce, CM
   Ibarra, J
   Agas, J
   Feemster, K
   Handy, LK
   Amin, AB
   Omer, SB
AF Buttenheim, Alison M.
   Joyce, Caroline M.
   Ibarra, Jose
   Agas, Jessica
   Feemster, Kristen
   Handy, Lori K.
   Amin, Avnika B.
   Omer, Saad B.
TI Vaccine exemption requirements and parental vaccine attitudes: an online
   experiment
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Exemptions; Health policy
ID REFUSAL; INFECTION; STATES; RISK
AB Increases in vaccine hesitancy and vaccine-preventable disease outbreaks have focused attention on state laws governing school-entry vaccine mandates and the allowable exemptions (medical and nonmedical) from those mandates. There is substantial variation in the type of exemptions available in each state, and states with more rigorous or burdensome exemption requirements generally have lower exemption rates. States have little evidence, however, about how vaccine-hesitant parents respond to different requirements. Despite recent efforts to formulate "model legislation" templates for states to follow, policy evidence about optimal exemption regimes is limited to observational studies in states that have changed exemption laws. We conducted two online experiments to explore how parental attitudes and intentions responded to different school-entry vaccine mandate exemption requirements. We randomly assigned online participants to one of four hypothetical vaccine exemption application scenarios: parental signature only, a checklist of vaccines for which an exemption is requested, a lengthy (10-30+ min) video-based vaccine education module, and a requirement to write a statement justifying the exemption. Among parents with high vaccine hesitancy, a required vaccine education module led to significant decreases in vaccine hesitancy, while checklist and justification requirements increased vaccine hesitancy slightly. Among parents with low vaccine hesitancy, we observed a potential backfire effect when parents were required to write a justification statement. Our findings warrant replication in a larger, fully-powered trial to accelerate knowledge about how parents across the vaccine hesitancy spectrum respond to exemption regimes. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Buttenheim, Alison M.; Ibarra, Jose; Agas, Jessica] Univ Penn, Sch Nursing, Dept Family & Community Hlth, Philadelphia, PA 19104 USA.
   [Buttenheim, Alison M.] Univ Penn, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
   [Buttenheim, Alison M.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.
   [Joyce, Caroline M.] McGill Univ, Fac Med, Dept Epidemiol, Montreal, PQ, Canada.
   [Feemster, Kristen] Philadelphia Dept Publ Hlth, Immunizat Program & Acute Communicable Dis, Philadelphia, PA USA.
   [Feemster, Kristen] Childrens Hosp Philadelphia, Vaccine Educ Ctr, Philadelphia, PA 19104 USA.
   [Feemster, Kristen] Univ Penn, Perelman Sch Med, Div Infect Dis, Philadelphia, PA 19104 USA.
   [Handy, Lori K.] Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA.
   [Handy, Lori K.] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA.
   [Amin, Avnika B.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA.
   [Omer, Saad B.] Yale Univ, Yale Inst Global Hlth, New Haven, CT USA.
   [Omer, Saad B.] Yale Univ, Sch Med, Dept Med, Infect Dis, New Haven, CT 06510 USA.
   [Omer, Saad B.] Yale Univ, Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
RP Joyce, CM (reprint author), McGill Univ, Fac Med, Dept Epidemiol, Montreal, PQ, Canada.
EM caroline.joyce@mail.mcgill.ca
OI Amin, Avnika/0000-0003-2212-2546
FU Office of Nursing Research at the University of Pennsylvania School of
   Nursing
FX This research was funded by a grant from the Office of Nursing Research
   at the University of Pennsylvania School of Nursing.
CR Blank NR, 2013, HEALTH AFFAIR, V32, P1282, DOI 10.1377/hlthaff.2013.0239
   Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P241
   De Vaus D., 2013, SURVEYS SOCIAL RES
   Glanz JM, 2010, ARCH PEDIAT ADOL MED, V164, P66, DOI 10.1001/archpediatrics.2009.244
   Glanz JM, 2009, PEDIATRICS, V123, P1446, DOI 10.1542/peds.2008-2150
   Hinman AR, CHILDHOOD IMMUNIZATI, P10
   Horne Z, 2015, P NATL ACAD SCI USA, V112, P10321, DOI 10.1073/pnas.1504019112
   Kennedy A, 2011, HEALTH AFFAIR, V30, P1151, DOI 10.1377/hlthaff.2011.0396
   Mohanty S, 2018, PEDIATRICS, V142, P12
   Nyhan B, 2019, J ELECT PUBLIC OPIN, V29, P222, DOI 10.1080/17457289.2018.1465061
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Siddiqui M, 2013, HUM VACC IMMUNOTHER, V9, P2643, DOI 10.4161/hv.27243
   Smith PJ, 2011, PUBLIC HEALTH REP, V126, P135, DOI 10.1177/00333549111260S215
   Smith PJ, 2004, PEDIATRICS, V114, P187, DOI 10.1542/peds.114.1.187
   Wang E, 2014, AM J PUBLIC HEALTH, V104, pE62, DOI 10.2105/AJPH.2014.302190
NR 15
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2620
EP 2625
DI 10.1016/j.vaccine.2020.01.035
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200024
PM 32057577
DA 2020-05-12
ER

PT J
AU Gary, EN
   Kathuria, N
   Makurumidze, G
   Curatola, A
   Ramamurthi, A
   Bernui, ME
   Myles, D
   Yan, J
   Pankhong, P
   Muthumani, K
   Haddad, E
   Humeau, L
   Weiner, DB
   Kutzler, MA
AF Gary, E. N.
   Kathuria, N.
   Makurumidze, G.
   Curatola, A.
   Ramamurthi, A.
   Bernui, M. E.
   Myles, D.
   Yan, J.
   Pankhong, P.
   Muthumani, K.
   Haddad, E.
   Humeau, L.
   Weiner, D. B.
   Kutzler, M. A.
TI CCR10 expression is required for the adjuvant activity of the mucosal
   chemokine CCL28 when delivered in the context of an HIV-1 Env DNA
   vaccine
SO VACCINE
LA English
DT Article
DE CCL28/MEC; CCR10; DNA vaccine; Mucosal IgA antibody; In vivo
   electroporation
ID TRANSCUTANEOUS IMMUNIZATION; IMMUNE-RESPONSES; SYSTEMIC COMPARTMENTS;
   RHESUS MACAQUES; CHOLERA-TOXIN; PROTECTS MICE; CUTTING EDGE; IGA; CELLS;
   ANTIBODIES
AB An effective prophylactic vaccine targeting HIV must induce a robust humoral response and must direct the bulk of this response to the mucosa-the primary site of HIV transmission. The chemokine, CCL28, is secreted by epithelial cells at mucosa] surfaces and recruits' cells expressing its receptor CCR10. CCR10 is predominantly expressed by IgA + ASCs. We hypothesized that co-immunization with plasmid DNA encoding consensus envelope antigens with plasmid-encoded CCL28 would enhance anti-HIV IgA responses at mucosal surfaces. Indeed, animals receiving pCCL28 and pEnvA/C had significantly increased HIV-specific IgA in fecal extract. Surprisingly, CCL28 co-immunization induced a significant increase in anti-HIV IgG in the serum in mice compared to those receiving pEnvA/C alone. These robust antibody responses were not associated with changes in the frequency of germinal center B cells but depended upon the expression of CCR10, as these responses we abolished in CCR10-deficient animals. Finally, immunization with CCL28 led to increased frequencies in HIV-specific CCR10 + and CCR10 + IgA + B cells in the small intestine and Peyer's patches of vaccinated animals as compared to those receiving pEnvA/C alone. These data indicate that CCL28 administration can enhance antigen-specific humoral responses systemically and at mucosal surfaces. (C) 2020 Published by Elsevier Ltd.
C1 [Gary, E. N.; Kathuria, N.; Curatola, A.; Ramamurthi, A.; Bernui, M. E.; Kutzler, M. A.] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA.
   [Makurumidze, G.; Bernui, M. E.; Kutzler, M. A.] Drexel Univ, Coll Med, Dept Med, Philadelphia, PA 19104 USA.
   [Myles, D.; Pankhong, P.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
   [Yan, J.; Humeau, L.] Inovio Pharmaceut, Blue Bell, PA USA.
   [Muthumani, K.; Weiner, D. B.] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.
RP Kutzler, MA (reprint author), Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19104 USA.
EM mak98@drexel.edu
OI Gary, Ebony/0000-0002-2928-1120
FU National Institute of Health through NIAID [F32AI054152]; Pennsylvania
   Department of Health/CURE award; Philadelphia Health and Education
   Corporation grant; National Institutes of Health (National Institute of
   Mental Health)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Mental Health (NIMH) [T32-MH079785]; Drexel University; National
   Institute of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [N01A1154 NIAID-HVDDT,
   HIVRAD P01 Al071739]
FX This work is supported by grants funded through the National Institute
   of Health including an F32AI054152 through NIAID (to MAK), an N01A1154
   NIAID-HVDDT (to DBW), HIVRAD P01 Al071739 (to DBW), Pennsylvania
   Department of Health/CURE award (to MAK), Philadelphia Health and
   Education Corporation grant (to MAK). ENG is partially funded by Drexel
   University's Interdisciplinary and Transnational Research Training Grant
   in NeuroAIDS, funded by the National Institutes of Health (National
   Institute of Mental Health) grant T32-MH079785.
CR Azegami T, 2014, INT IMMUNOL, V26, P517, DOI 10.1093/intimm/dxu063
   Belec L, 2001, J INFECT DIS, V184, P1412, DOI 10.1086/324375
   Berry LJ, 2004, INFECT IMMUN, V72, P1019, DOI 10.1128/IAI.72.2.1019-1028.2004
   Castelletti E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000969
   Chang SY, 2008, J IMMUNOL, V180, P1609, DOI 10.4049/jimmunol.180.3.1609
   Cox E, 2006, VET RES, V37, P511, DOI 10.1051/vetres:2006014
   Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400
   Devito C, 2000, AIDS, V14, P1917, DOI 10.1097/00002030-200009080-00006
   Devito C, 2002, J ACQ IMMUN DEF SYND, V30, P413, DOI [10.1097/01.QAI.0000021664.20213.5A, 10.1097/00042560-200208010-00007]
   Dorrell L, 2000, AIDS, V14, P1117, DOI 10.1097/00002030-200006160-00008
   Dullaers M, 2009, IMMUNITY, V30, P120, DOI 10.1016/j.immuni.2008.11.008
   Duperret EK, 2019, CANCER IMMUNOL RES, V7, P174, DOI 10.1158/2326-6066.CIR-18-0283
   Gary EN, 2018, J IMMUNOL RES, DOI 10.1155/2018/3734207
   Girard MP, 2013, VACCINE, V31, P2984, DOI 10.1016/j.vaccine.2013.02.067
   Girard MP, 2013, VACCINE, V31, P2979, DOI 10.1016/j.vaccine.2013.02.068
   Glenn GM, 1998, J IMMUNOL, V161, P3211
   Godefroy S, 2003, VACCINE, V21, P1665, DOI 10.1016/S0264-410X(02)00733-8
   Haase AT, 2010, NATURE, V464, P217, DOI 10.1038/nature08757
   Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213
   Hu K, 2013, J IMMUNOL, V191, P1935, DOI 10.4049/jimmunol.1300120
   Hu SM, 2011, P NATL ACAD SCI USA, V108, pE1035, DOI 10.1073/pnas.1100156108
   Iwasaki A, 2016, ANNU REV IMMUNOL, V34, P575, DOI 10.1146/annurev-immunol-032414-112315
   Kaul R, 1999, AIDS, V13, P23, DOI 10.1097/00002030-199901140-00004
   Kaul R, 2001, AIDS, V15, P431, DOI 10.1097/00002030-200102160-00026
   Khoshnejad M, 2019, MOL THER, V27, P188, DOI 10.1016/j.ymthe.2018.10.016
   Kim JJ, 1999, J MED PRIMATOL, V28, P214, DOI 10.1111/j.1600-0684.1999.tb00272.x
   Kim JJ, 2000, J VIROL, V74, P3427, DOI 10.1128/JVI.74.7.3427-3429.2000
   Kunkel EJ, 2003, J CLIN INVEST, V111, P1001, DOI 10.1172/JCI200317244
   Kutzler MA, 2016, MUCOSAL IMMUNOL, V9, P13, DOI 10.1038/mi.2015.31
   Kutzler MA, 2010, GENE THER, V17, P72, DOI 10.1038/gt.2009.112
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Laddy DJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002517
   Laddy DJ, 2007, VACCINE, V25, P2984, DOI 10.1016/j.vaccine.2007.01.063
   Lauterslager TGM, 2003, VACCINE, V21, P1391, DOI 10.1016/S0264-410X(02)00687-4
   LAYTON GT, 1983, CLIN EXP IMMUNOL, V54, P305
   Lazarus NH, 2003, J IMMUNOL, V170, P3799, DOI 10.4049/jimmunol.170.7.3799
   Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994
   Mazzoli S, 1997, NAT MED, V3, P1250, DOI 10.1038/nm1197-1250
   Mestecky J, 2004, AIDS RES HUM RETROV, V20, P972, DOI 10.1089/aid.2004.20.972
   Mora JR, 2009, SEMIN IMMUNOL, V21, P28, DOI 10.1016/j.smim.2008.08.002
   Morteau O, 2008, J IMMUNOL, V181, P6309, DOI 10.4049/jimmunol.181.9.6309
   Nakayama T, 2003, J IMMUNOL, V170, P1136, DOI 10.4049/jimmunol.170.3.1136
   Ogawa H, 2004, AM J PHYSIOL-GASTR L, V287, pG1062, DOI 10.1152/ajpgi.00162.2004
   OGAWA T, 1989, J IMMUNOL, V142, P1150
   Plotkin SA, 2010, HUM VACCINES, V6, P159
   Rainone V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026979
   Ramirez JEV, 2017, ADV DRUG DELIV REV
   Rashidiani S, 2017, AM J CLIN EXP IMMUNO, V6, P60
   Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008
   Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522
   Vaccari M, 2010, EXPERT REV VACCINES, V9, P997, DOI [10.1586/erv.10.104, 10.1586/ERV.10.104]
   Wang W, 2000, J BIOL CHEM, V275, P22313, DOI 10.1074/jbc.M001461200
   Wilson E, 2004, J EXP MED, V200, P805, DOI 10.1084/jem.20041069
   Xu R, 2008, VACCINE, V26, P4819, DOI 10.1016/j.vaccine.2008.06.103
   Yu JM, 2002, INFECT IMMUN, V70, P1056, DOI 10.1128/IAI.70.3.1056-1068.2002
NR 55
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2626
EP 2635
DI 10.1016/j.vaccine.2020.01.023
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200025
PM 32057572
DA 2020-05-12
ER

PT J
AU Yang, H
   Fan, FM
   Liu, LN
   Liu, J
   Sun, Y
   Xie, AP
   Shi, XL
   Liu, L
   Yu, YX
   Li, YH
   Ge, YH
   Zeng, XW
   Yang, HG
AF Yang, Huan
   Fan, Fengming
   Liu, Lina
   Liu, Jie
   Sun, Yan
   Xie, Anping
   Shi, Xiaoling
   Liu, Li
   Yu, Yongxin
   Li, Yuhua
   Ge, Yonghong
   Zeng, Xianwu
   Yang, Huigiang
TI A novel amino acid site closely associated with the neurovirulence of
   live, attenuated Japanese encephalitis vaccine (SA14-14-2 strain)
SO VACCINE
LA English
DT Article
DE E244; Japanese encephalitis virus; SA14-14-2; Neurovirulence;
   Neuroinvasiveness; Safety
ID MOLECULAR-BASIS; VIRUS; MUTATION; REGION; DOMAIN
AB Japanese encephalitis (JE) poses a serious threat to the world's public health yet without a cure, the only way to prevent Japanese encephalitis virus (JEV) infection is vaccination. Live attenuated vaccine (SA1414-2 strain) is the most widely used JE vaccine, and clinical data have confirmed its safety and effectiveness. Eight sitesassociated with virulence in the Envelope (E) protein are often the focus of quality control of JE vaccine. However, sequences retrieved from NCBI, as well as our previous results showed that the wild strain SA14 may harbor two different amino acids at amino acid residue 244 of the E glycoprotein (E244), and it may be related to virulence. In this study, we introduced a single mutation at ntl 708 (G -> A) in the full-length cDNA clone of SA14-14-2, replacing a Gly with Glu at amino acid residue 244 of the E glycoprotein, and successfully constructed the mutant virus (JEV E244). JEV E244 exhibited a similar plaque morphology and growth characteristics to JEV SA14-14-2 in cell culture. However, it had lethal neurovirulence in mice and could enter the brain following intraperitoneal inoculation. Moreover, the virulence of JEV E244 in the context of vaccine in mice is significantly different from that of the JEV E244 alone. These results suggested that E244 site should be included in the assessment of the genetic stability of the attenuated JE vaccine. The detection of minor mutations in vaccine population and influence on the safety of vaccine is discussed. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Yang, Huan; Fan, Fengming; Liu, Lina; Liu, Jie; Sun, Yan; Xie, Anping; Shi, Xiaoling; Liu, Li; Ge, Yonghong; Zeng, Xianwu; Yang, Huigiang] Chengdu Inst Biol Prod Co Ltd, Dept Viral Vaccines, Chengdu 610023, Peoples R China.
   [Yu, Yongxin; Li, Yuhua] Natl Inst Food & Drug Control, Dept Arbovirus Vaccines, Beijing 100050, Peoples R China.
RP Yang, HG (reprint author), Chengdu Inst Biol Prod Co Ltd, Dept Viral Vaccines, Chengdu 610023, Peoples R China.; Li, YH (reprint author), Natl Inst Food & Drug Control, Dept Arbovirus Vaccines, Beijing 100050, Peoples R China.
EM liyuhua@nifdc.org.cn; yanghuiqiang@sinopharm.com
FU National key projects of "863" High Technology of P. R. China
   [2012AA02A401]
FX This study was supported by National key projects of "863" High
   Technology of P. R. China (No. 2012AA02A401).
CR AIHARA S, 1991, VIRUS GENES, V5, P95, DOI 10.1007/BF00571925
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P69
   Beck A, 2014, J INFECT DIS, V209, P334, DOI 10.1093/infdis/jit546
   Galler R, 1997, BRAZ J MED BIOL RES, V30, P157, DOI 10.1590/S0100-879X1997000200002
   Halstead SB, 2018, VACCINES, P511
   Kim JK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124318
   Li Jing, 2011, Chinese Journal of Viral Diseases, V1, P51
   Lin CW, 2003, J VIROL, V77, P2600, DOI 10.1128/JVI.77.4.2600-2606.2003
   Liu XY, 2018, VACCINE, V36, P4650, DOI 10.1016/j.vaccine.2018.06.040
   MASON PW, 1989, J GEN VIROL, V70, P2037, DOI 10.1099/0022-1317-70-8-2037
   Monath TP, 2002, J VIROL, V76, P1932, DOI 10.1128/JVI.76.4.1932-1943.2002
   National Pharmacopoeia Commission, 2015, PHARMACOPOEIA PEOPLE, P122
   NI HL, 1994, J GEN VIROL, V75, P1505, DOI 10.1099/0022-1317-75-6-1505
   NI HL, 1995, J GEN VIROL, V76, P409, DOI 10.1099/0022-1317-76-2-409
   Schioler KL, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004263.pub2
   Solomon T, 2000, J NEUROL NEUROSUR PS, V68, P405, DOI 10.1136/jnnp.68.4.405
   Wu YongLin, 2007, Chinese Journal of Biologicals, V20, P19
   Yang D, 2014, VACCINE, V32, P2675, DOI 10.1016/j.vaccine.2014.03.074
   Yang HQ, 2015, INT J BIOL, V6, P108
   Yang J, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9010020
   Yu YX, 2010, VACCINE, V28, P3635, DOI 10.1016/j.vaccine.2010.02.105
   Yun SI, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004465
   Zhao ZJ, 2005, J GEN VIROL, V86, P2209, DOI 10.1099/vir.0.80638-0
NR 23
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 4
PY 2020
VL 38
IS 11
BP 2636
EP 2642
DI 10.1016/j.vaccine.2020.01.005
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KX1PD
UT WOS:000521654200026
PM 32044162
DA 2020-05-12
ER

PT J
AU Davis, H
   Dow, T
   Isopi, L
   Blue, JT
AF Davis, Harrison
   Dow, Tylina
   Isopi, Lynne
   Blue, Jeffrey T.
TI Examination of the effect of agitation on the potency of the Ebola Zaire
   vaccine rVSV Delta G-ZEBOV-GP
SO VACCINE
LA English
DT Article
DE Vaccine degradation; Ebolavirus disease; Vaccine potency; Vaccine
   stability
ID VIRUS DISEASE; DOUBLE-BLIND; IMMUNOGENICITY; CANDIDATE; SAFETY
AB The Ebolavirus vaccine (rVSV Delta G-ZEBOV-GP) is stored at -80 to -60 degrees C and should be kept frozen for transport. Due to significant logistical challenges, frozen transport is not feasible for some remote locations. To determine if local distribution at 2-8 degrees C is a potential option for these locations, a study was conducted to evaluate the impact of agitation on the thawed vaccine. After up to 7 days of constant agitation, no impact on vaccine potency was evident for the agitated vaccine versus the corresponding vaccine kept stationary at 2-8 degrees C. In conclusion, in-country transport of the Ebolavirus vaccine, rVSV Delta G-ZEBOV-GP, at 2-8 degrees C appears to be a feasible option for those remote locations where significant logistical challenges prohibit transporting the vaccine at -80 to -60 degrees C. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Davis, Harrison; Dow, Tylina; Isopi, Lynne; Blue, Jeffrey T.] Merck & Co Inc, 2000 Galloping Hill Rd, Kenilworth, NJ 07033 USA.
RP Isopi, L (reprint author), Merck & Co Inc, POB 4,770 Sumneytown Pike, West Point, PA 19486 USA.
EM harrison_davis@merck.com; tylina_dow@merck.com; lynne_isopi@merck.com;
   jeff_blue@merck.com
FU Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.,
   Kenilworth, NJ, USA; Department of Health and Human Services; Biomedical
   Advanced Research and Development Authority [HHS010201600031C]; Office
   of the Assistant Secretary of Preparedness and Response
FX Funding was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck
   & Co., Inc., Kenilworth, NJ, USA. This project has been funded in part
   with federal funds from the Department of Health and Human Services;
   Office of the Assistant Secretary of Preparedness and Response;
   Biomedical Advanced Research and Development Authority, under Contract
   No. HHS010201600031C.
CR [Anonymous], 2019, WHAT IS EB VIR DIS
   Arnemo M, 2016, J INFECT DIS, V213, P930, DOI 10.1093/infdis/jiv532
   Baer A, 2014, JOVE-J VIS EXP, DOI 10.3791/52065
   Hasija M, 2013, VACCINE DEV THER, V3, P11, DOI DOI 10.2147/VDT.S41998
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Heppner DG, 2017, LANCET INFECT DIS, V17, P854, DOI 10.1016/S1473-3099(17)30313-4
   Huttner A, 2015, LANCET INFECT DIS, V15, P1156, DOI 10.1016/S1473-3099(15)00154-1
   Murray MJ, 2015, ANESTH ANALG, V121, P798, DOI 10.1213/ANE.0000000000000866
   Prevention CfDCa, 2015, PREV CFDCA EP PREV V
   Stein DR, 2019, EMERG INFECT DIS, V25, P1563, DOI 10.3201/eid2508.190281
   WHO, 2019, EB VIR DIS
   Wilson J., 2014, BORDERS CLOSING EBOL
NR 12
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2643
EP 2645
DI 10.1016/j.vaccine.2020.02.002
PG 3
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800001
PM 32081445
DA 2020-05-12
ER

PT J
AU Esteve, M
   Carreras, R
   Casas, I
   Pena, P
   Guixeras, A
   Torrecillas, S
   Bretau, F
   Subirats, P
   Alonso, A
   Soldevila, N
   Costa, J
   Dominguez, A
AF Esteve, M.
   Carreras, R.
   Casas, I
   Pena, P.
   Guixeras, A.
   Torrecillas, S.
   Bretau, F.
   Subirats, P.
   Alonso, A.
   Soldevila, N.
   Costa, J.
   Dominguez, A.
CA Xarxa Catalana Hosp Promotors Salu
TI The immune status against tetanus and diphtheria in healthcare workers
   in Catalonia
SO VACCINE
LA English
DT Article
DE Vaccination coverage; Heath care workers; Seroprevalence; Occupational
   health programme
ID UNITED-STATES; VACCINATION; PREVALENCE; ANTIBODIES; ADULTS
AB The objective was to investigate the immune status against tetanus and diphtheria of healthcare workers in Catalonia. A cross-sectional multicentre study was conducted in seven health centres. Blood samples were obtained, and demographic and clinical variables collected.
   509 health workers were included. The prevalence of protective antibodies against tetanus was 94.7% (95% CI: 92.3-96.4) overall and 85.1% (95% CI: 74.5-92.0) in workers aged >= 55 years. The prevalence of protective antibodies against diphtheria was 68.6% (95% CI: 64.3-72.5%) overall and 29.7% (95% Cl: 19.9-41.6) in workers aged >= 55 years.
   Protection against tetanus in healthcare workers is high, but should be improved in workers aged >= 55 years. Protection against diphtheria has improved in healthcare workers over the past decade (68.6% vs 46.5%) but should be improved in all ages, especially in workers aged >= 55 years. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Esteve, M.; Casas, I] Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Serv Med Prevent, Barcelona, Spain.
   [Carreras, R.] Inst Assistancia Sanitaria, Serv Prevencio, Salt, Girona, Spain.
   [Pena, P.] Hosp Parc Tauli, Serv Prevencio Riscos Laborals, Sabadell, Spain.
   [Guixeras, A.] Inst Catala Salut, Unitat Basica Prevencio, Girona, Spain.
   [Torrecillas, S.] Hosp San Rafael, Serv Prevencio Riscos Laborals, Barcelona, Spain.
   [Bretau, F.] Consorci Sanitari Garraf, Serv Prevencio, Barcelona, Spain.
   [Subirats, P.] Hosp Univ St Joan, Unitat Vigilancia Salut, Tarragona, Spain.
   [Alonso, A.; Costa, J.] Univ Barcelona, CDB Hosp Clin, Serv Microbiol, Barcelona, Spain.
   [Soldevila, N.; Dominguez, A.] Inst Salud Carlos III, CIBERESP, Madrid, Spain.
   [Soldevila, N.; Dominguez, A.] Univ Barcelona, Dept Med, Barcelona, Spain.
   [Costa, J.] Inst Salud Carlos Ill, CIBEREHD, Madrid, Spain.
RP Casas, I (reprint author), Hosp Badalona Germans Trias & Pujol, Dept Prevent Med, Ctra Canyet S-N, Badalona 08006, Spain.
EM icasas.germanstrias@gencat.cat
FU CIBER de Epidemiologia y Salud PCiblica (CIBERESP), Instituto de Salud
   Carlos III, Madrid, Spain; Catalan Agency for the Management of
   University Grants (AGAUR) [2017/SGR 1342]
FX This study was supported by CIBER de Epidemiologia y Salud PCiblica
   (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain and the Catalan
   Agency for the Management of University Grants (AGAUR Grant Number
   2017/SGR 1342).
CR Ang LW, 2016, J PUBLIC HEALTH-UK, V38, P99, DOI 10.1093/pubmed/fdv011
   [Anonymous], 2006, Wkly Epidemiol Rec, V81, P24
   [Anonymous], 2018, COB VAC DOS REC DTPA
   Brandon D, 2018, VACCINE, V36, P6325, DOI 10.1016/j.vaccine.2018.08.051
   Esteve M, 2012, AM J INFECT CONTROL, V40, P896, DOI 10.1016/j.ajic.2011.11.012
   Galazcka AM, DIPHTERIA IMMUNOLOGI, V12, P3
   Grupo de trabajo recomendaciones Td, 2017, PON PROGR REG VAC
   Grupo de trabajo vacunacifin en poblacion adulta y grupos de riesgo de la Ponencia de Programa y Registro de Vacunaciones, 2018, VAC GRUP RIESG VAC V
   Haviari S, 2015, HUM VACC IMMUNOTHER, V11, P2522, DOI 10.1080/21645515.2015.1082014
   Liang JL, 2018, MMWR RECOMM REP, V67, P1, DOI 10.15585/mmwr.rr6702a1
   Maltezou HC, 2019, VACCINE, V37, P7576, DOI 10.1016/j.vaccine.2019.09.061
   Maple PAC, 2000, VACCINE, V19, P167, DOI 10.1016/S0264-410X(00)00184-5
   Moskosky S. B., 2011, Morbidity and Mortality Weekly Report, V60, P1
   Naing L, 2006, ARCH OROFAC SCI, V1, P9
   O'Halloran AC, 2018, AM J PREV MED, V54, P119, DOI 10.1016/j.amepre.2017.09.017
   Ortega P, 1999, Enferm Infecc Microbiol Clin, V17, P135
   Stark K, 1999, VACCINE, V17, P844, DOI 10.1016/S0264-410X(98)00269-2
   Wagner KS, 2012, VACCINE, V30, P7111, DOI 10.1016/j.vaccine.2012.09.029
NR 18
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2646
EP 2650
DI 10.1016/j.vaccine.2020.01.076
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800002
PM 32063435
DA 2020-05-12
ER

PT J
AU Madhi, SA
   Izu, A
   Violari, A
   Cotton, MF
   Jean-Philippe, P
   Otwombe, K
   Adrian, PV
AF Madhi, Shabir A.
   Izu, Alane
   Violari, Avy
   Cotton, Mark F.
   Jean-Philippe, Patrick
   Otwombe, Kennedy
   Adrian, Peter, V
CA CIPRA 4 Team
TI Effect of HIV-exposure and timing of antiretroviral treatment initiation
   in children living with HIV on antibody persistence and memory responses
   to Haemophilus influenzae type b and pneumococcal polysaccharide-protein
   conjugate vaccines
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Pneumococcal conjugate vaccine; Haemophilus
   influenzae type b conjugate; vaccine; HIV exposure; HIV;
   Opsonophagocytic assay; Memory responses; Antibody persistence
ID TREATMENT STRATEGIES; UNINFECTED CHILDREN; INFECTED CHILDREN;
   IMMUNOGENICITY; THERAPY
AB Background: We investigated the effect of in utero HIV-exposure, timing of antiretroviral treatment (ART) initiation, and ART interruption on memory responses and persistence of immunity induced by pneumococcal (PCV) and Haemophilus influenzae type b (HibCV) polysaccharide-protein conjugate vaccines.
   Methods: Children were enrolled (6-12 weeks of age), and vaccinated with a three-dose primary series of 7-valent PCV (PCV7) and HibCV at 6, 10 and 14 weeks of age. Study groups included infants infected with HIV perinatally with CD4+ >= 25% initiating ART following immunological or clinical deterioration (ART-Def), or immediately upon enrolment followed by interruption at 40 (ART-Immed/40w) or 96 weeks (ART-Immed/96w); and HIV-uninfected infants with (HEU), and without HIV (HIV-unexpsoed) exposure in utero. Within each group, children were randomized to receive either a booster dose of PCV7 or HibCV at 15 months of age. PCV serotype-specific and polyribosyl ribitol phosphate (PRP) IgG were measured pre-boost, two-weeks post-boost and at two-years of age. Opsonophagocytic activity (OPA) to serotypes 9V, 19F and 23F was measured post-booster dose.
   Results: Persistence of IgG to PCV vaccine-serotypes and anti-PRP was similar in all groups of children living with HIV (CLWH) compared to HIV-unexposed children. Anamnestic responses to PCV and HibCV were also similar in all three groups of CLWH compared to HIV-unexposed children. CLWH, however, tended to have lower functional antibody (OPA) titers than HIV-unexposed children after the PCV booster dose for some serotypes. Immunity to PCV and HibCV was similar between the ART-Immed/40w and ART-Immed-96w groups. There were no differences in IgG kinetics between HEU and HIV-unexposed children.
   Conclusions: A three dose primary series, with or without PCV or HibCV booster doses in CLWH initiated on ART during infancy, would likely be similarly effective in preventing invasive bacterial disease as in HIV-unexposed children. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Madhi, Shabir A.; Izu, Alane; Adrian, Peter, V] Univ Witwatersrand, Fac Hlth Sci, MRC, Resp & Meningeal Pathogens Res Unit, Johannesburg, South Africa.
   [Madhi, Shabir A.; Izu, Alane; Adrian, Peter, V] Univ Witwatersrand, Dept Sci, Fac Hlth Sci, Natl Res Fdn Vaccine Preventable Dis, Johannesburg, South Africa.
   [Violari, Avy; Otwombe, Kennedy] Univ Witwatersrand, Fac Hlth Sci, Perinatal HIV Res Unit, Johannesburg, South Africa.
   [Cotton, Mark F.] Stellenbosch Univ, Fac Med Ubuntu, Family Ctr, Dept Paediat & ChildMed & Hlth Sci,Clin Res Unit, Cape Town, South Africa.
   [Jean-Philippe, Patrick] NIAID, Div AIDS, Bethesda, MD 20892 USA.
RP Madhi, SA (reprint author), Chris Hani Baragwanath Acad Hosp, Chris Hani Rd,RMPRU 11th Floor West Wing, ZA-2013 Bertsham, Gauteng, South Africa.
EM madhis@rmpru.co.za
OI Madhi, Shabir/0000-0002-7629-0636; Cotton, Mark/0000-0003-2559-6034
FU National Institute of Allergy and Infectious Diseases (NIAID) of the US;
   National Institutes for Health (NIH), through the Comprehensive
   International Program of Research on AIDS networkUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [U19 AI53217]; NIAID, NIH, Department of Health and Human
   ServicesUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Allergy &
   Infectious Diseases (NIAID) [HHSN272200800014C]
FX Financial support: National Institute of Allergy and Infectious Diseases
   (NIAID) of the US; National Institutes for Health (NIH), through the
   Comprehensive International Program of Research on AIDS network (grant
   U19 AI53217). Additional support for this work was provided with federal
   funds from NIAID, NIH, Department of Health and Human Services (contract
   HHSN272200800014C). Prevenar was donated by Wyeth Vaccines and
   Pediatrics.
CR [Anonymous], 2012, Wkly Epidemiol Rec, V87, P129
   Bamford A, 2014, AIDS, V28, P2033, DOI 10.1097/QAD.0000000000000385
   Cohen C, 2014, CLIN INFECT DIS, V59, P808, DOI 10.1093/cid/ciu431
   Cotton MF, 2013, LANCET, V382, P1555, DOI 10.1016/S0140-6736(13)61409-9
   Goetghebuer T, 2009, AIDS, V23, P597, DOI 10.1097/QAD.0b013e328326ca37
   IVAC, PNEUM CONJ VACC CURR
   Jallow S, 2017, EXPERT REV VACCINES, V16, P453, DOI 10.1080/14760584.2017.1307740
   Jodar L, 2003, VACCINE, V21, P3265, DOI 10.1016/S0264-410X(03)00230-5
   Jones SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072794
   KAYHTY H, 1994, BIOLOGICALS, V22, P397, DOI 10.1006/biol.1994.1062
   King JC, 1998, VACCINE, V16, P361, DOI 10.1016/S0264-410X(97)80914-0
   Kurikka SKH, 1995, INFECT DIS, V172, P5
   Madhi SA, 2005, VACCINE, V23, P5517, DOI 10.1016/j.vaccine.2005.07.038
   Madhi SA, 2005, PEDIATR INFECT DIS J, V24, P410, DOI 10.1097/01.inf.0000160942.84169.14
   Madhi SA, 2002, PEDIATR INFECT DIS J, V21, P315, DOI 10.1097/00006454-200204000-00011
   Madhi SA, 2007, VACCINE, V25, P2451, DOI 10.1016/j.vaccine.2006.09.019
   Madhi SA, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005881
   Madhi SA, 2010, J INFECT DIS, V202, P355, DOI 10.1086/653704
   Madhi SA, 2009, J INFECT DIS, V199, P1168, DOI 10.1086/597388
   Meiring S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149104
   Mutsaerts E, 2018, CLIN INFECT DIS
   Nunes MC, 2011, AIDS, V25, P453, DOI 10.1097/QAD.0b013e328341b7f1
   Simani OE, 2019, EXPERT REV VACCINES, V18, P95, DOI 10.1080/14760584.2019.1547195
   Simani OE, 2014, AIDS, V28, P531, DOI 10.1097/QAD.0000000000000127
   Simani OE, 2013, AIDS, V27, P1583, DOI 10.1097/QAD.0b013e32835fae26
   Spoulou VI, 2005, VACCINE, V23, P5289, DOI 10.1016/j.vaccine.2005.06.002
   Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971
NR 27
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2651
EP 2659
DI 10.1016/j.vaccine.2020.02.026
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800003
PM 32070681
DA 2020-05-12
ER

PT J
AU Hoschler, K
   Maharjan, S
   Whitaker, H
   Southern, J
   Okai, B
   Baldevarona, J
   Turner, PJ
   Andrews, NJ
   Miller, E
   Zambon, M
AF Hoschler, Katja
   Maharjan, Sunil
   Whitaker, Heather
   Southern, Jo
   Okai, Blessing
   Baldevarona, Janice
   Turner, Paul J.
   Andrews, Nick J.
   Miller, Elizabeth
   Zambon, Maria
TI Use of traditional serological methods and oral fluids to assess
   immunogenicity in children aged 2-16 years after successive annual
   vaccinations with LAIV
SO VACCINE
LA English
DT Article
DE Vaccine; Influenza; Immunogenicity; Oral fluid; Oil-in-water adjuvant
ID ATTENUATED INFLUENZA VACCINE; UNITED-KINGDOM; VIRUS; ANTIBODY;
   RESPONSES; END
AB Background: The UK introduced quadrivalent live attenuated influenza vaccine (qLAIV) for children in 2013/2014. The impact of annual vaccination on effectiveness and immunogenicity is being assessed.
   Method: A phase III/IV open-label study of the immunogenicity of annual vaccination with qLAIV (Fluene (TM)) was conducted over three consecutive years (2014/15-2016/17) in 254, 249 and 162 children respectively. Serum responses to vaccine components were measured by Haemagglutination Inhibition (HAI) and anti-A(H1N1)pdm09 Neuraminidase (NAI) assays, stratified according to previous receipt of AS03(B)-adjuvanted A(H1N1)pdm09 pandemic vaccine in 2009/10. Antibody levels to the A(H1N1) pdm09 and H3N2 vaccine components in oral fluids (OF) were explored using an ELISA.
   Findings: More paired pre- and post-vaccination oral fluids (96%) than paired sera (87%) were obtained. Geometric mean titre rises using HAI assays were limited, with maximum rises seen in year one for both influenza B strains when 39% and 43% of subjects seroconverted (95% confidence interval 33-46% and 3650%, respectively) and year two for influenza H3N2, when 40% (33-46%) individuals seroconverted. Prior pandemic vaccine receipt resulted in higher pre- and post-vaccination A(H1N1)pdm09 HAI titres and lower pre-and post-vaccination NAI (N1 neuraminidase) titres in all three years. OF results were congruent with HAI results; assay specificity compared to HAI was 88.1 and 71.6 percent, and sensitivity was 86.4 and 74.8 percent respectively for A(H1N1)pdm09 and H3N2.
   Conclusion: In all three study years, vaccination with qLAIV resulted in poor antibody responses. However, OFs are an alternative specimen type that allows self sampling, can easily be obtained from children, and their analysis leads to similar conclusions as classic serology by HAI. Their suitability for seroprevalence studies should be investigated. We demonstrated a sustained effect from prior receipt of the AS03(B)-adjuvanted A(H1N1)pdm09 vaccine, even after repeat vaccination with qLAIV indicating that early exposure to influenza antigens has a significant long lasting effect. Crown Copyright (C) 2020 Published by Elsevier Ltd.
C1 [Hoschler, Katja; Maharjan, Sunil; Okai, Blessing; Baldevarona, Janice; Zambon, Maria] Publ Hlth England Colindale, Virus Reference Dept, London, England.
   [Whitaker, Heather; Andrews, Nick J.] Publ Hlth England Colindale, Stat Modelling & Econ Dept, London, England.
   [Southern, Jo; Turner, Paul J.; Miller, Elizabeth] Publ Hlth England Colindale, Immunisat & Countermeasures, London, England.
   [Turner, Paul J.] Imperial Coll London, Natl Heart & Lung Inst, London, England.
RP Hoschler, K (reprint author), Publ Hlth England, Virus Reference Dept, Resp Virus Unit, Microbiol Serv Colindale, 61 Colindale Ave, London NW9 5HT, England.
EM katja.hoschler@phe.gov.uk
FU NIHR Policy Research Programme (National Vaccine Evaluation Consortium)
   [039/0031]; National Institute for Health Research Health Protection
   Research Unit (NIHR HPRU) in Respiratory Infections at Imperial College
   London; Public Health England (PHE)
FX This work was funded by the NIHR Policy Research Programme (National
   Vaccine Evaluation Consortium, Grant number 039/0031-grant holder EM)
   and by the National Institute for Health Research Health Protection
   Research Unit (NIHR HPRU) in Respiratory Infections at Imperial College
   London in partnership with Public Health England (PHE), collaborating
   with Ajit Lalvani. Sunil Maharjan and Blessing Okai were affiliated to
   the NIHR HPRU in Respiratory Infections and both based at the National
   Infection Service, Public Health England during this work. The views
   expressed in the publication are those of the authors and not
   necessarily those of the NHS, the NIHR, the Department of Health, arms'
   length bodies, other government departments.
CR Ambrose CS, 2012, VACCINE, V30, P6794, DOI 10.1016/j.vaccine.2012.09.018
   [Anonymous], ANN NAT FLU PROGR LE
   Block SL, 2008, VACCINE, V26, P4940, DOI 10.1016/j.vaccine.2008.07.013
   Cobey S, 2017, CURR OPIN VIROL, V22, P105, DOI 10.1016/j.coviro.2016.12.004
   Hakin B, FLU IMMUNISATION PRO
   Hoft DF, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00414-16, 10.1128/cvi.00414-16]
   Hoschler K, 2018, VACCINE, V36, P3034, DOI 10.1016/j.vaccine.2018.04.017
   Hoschler K, 2014, CLIN INFECT DIS, V58, P181, DOI 10.1093/cid/cit692
   Jackson D, 2019, CLIN INFECT DIS
   King JP, 2018, VACCINE, V36, P1214, DOI 10.1016/j.vaccine.2018.01.016
   Lewis KDC, 2018, CLIN INFECT DIS
   Lindsey BB, 2019, LANCET RESP MED
   McKie A, 2002, LANCET INFECT DIS, V2, P18, DOI 10.1016/S1473-3099(01)00169-4
   Mohn KGI, 2018, HUM VACC IMMUNOTHER, V14, P571, DOI 10.1080/21645515.2017.1377376
   MURPHY BR, 1981, J CLIN MICROBIOL, V13, P554, DOI 10.1128/JCM.13.3.554-560.1981
   NETO RSDA, 1995, T ROY SOC TROP MED H, V89, P115, DOI 10.1016/0035-9203(95)90680-0
   Nunez IA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185666
   Parry RP, 2012, VOX SANG, V103, P107, DOI 10.1111/j.1423-0410.2012.01599.x
   Pebody R, 2016, EUROSURVEILLANCE, V21, P41, DOI 10.2807/1560-7917.ES.2016.21.38.30348
   Pebody R, 2015, EUROSURVEILLANCE, V20, P2, DOI 10.2807/1560-7917.ES.2015.20.36.30013
   Pebody R, 2017, EUROSURVEILLANCE, V22, P10, DOI 10.2807/1560-7917.ES.2017.22.44.17-00306
   Pebody R, 2018, ARCH DIS CHILD, V103, P101, DOI 10.1136/archdischild-2016-312165
   Public Health England, GREEN BOOK IMM INF D
   Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999
   Stelzer-Braid S, 2008, J CLIN VIROL, V43, P241, DOI 10.1016/j.jcv.2008.06.012
   Trombetta CM, 2018, INFLUENZA OTHER RESP, V12, P675, DOI 10.1111/irv.12591
   Vyse AJ, 2001, PUBLIC HEALTH, V115, P201, DOI 10.1016/S0033-3506(01)00444-9
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2660
EP 2670
DI 10.1016/j.vaccine.2020.02.024
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800004
PM 32070679
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Xu, Q
   Cao, QF
   Yang, WQ
   Liu, XD
   Liu, HD
   Tian, XH
   Li, J
   Fang, XQ
   Jia, NN
   Zeng, G
   Xu, AA
AF Xu, Qing
   Cao, Qingfan
   Yang, Wanqi
   Liu, Xiaodong
   Liu, Haidong
   Tian, Xiaohui
   Li, Jing
   Fang, Xueqiang
   Jia, Ningning
   Zeng, Gang
   Xu, Aiqaing
TI Interchangeability of two Enterovirus 71 inactivated vaccines in Chinese
   children: A phase IV, open-label, and randomized controlled trial
SO VACCINE
LA English
DT Article
DE Interchangeability; EV71 vaccine; Immunogenicity; Safety
ID HEPATITIS-A VACCINES; DOUBLE-BLIND; B VACCINES; SAFETY; IMMUNOGENICITY;
   EFFICACY
AB Background: In China, three inactivated Enterovirus 71 (EV71) vaccines have been approved. Although the vaccines in an immunization series should be from a single manufacture, children sometimes have to receive EV71 vaccines from more than one manufacturers. The aim of this study was to evaluate the interchangeability and safety of vaccination with EV71 vaccines from two manufacturers among Chinese children.
   Methods: We conducted an open label and randomized controlled study among children aged 6-35 months from November 2018 to January 2019. The participants were randomly assigned (1:1:1:1) to receive EV71 vaccines in one of the four different schedules (two using a single vaccine for all doses from one manufacture, and two mixed schedules using vaccines from two manufactures). Blood samples were collected pre-vaccination (Day 0) and one month after the second dose (Day 60) for neutralizing antibody assay. Immunogenicity was assessed in the per-protocol cohort and safety was assessed in the total vaccinated cohort.
   Results: A total of 300 children were enrolled and randomized, of whom 89.0% (267/300) were included in the per-protocol cohort for immunogenicity analysis. The seroconversion rates of the EV71 neutralizing antibody in four groups ranged from 98.4% to 100.0%, and were not significantly different among the groups. Compared with other groups, geometric mean titer was higher in group D, in which the participants received Institute of Medical Biology Chinese Academy of Medical Sciences (CAMS) vaccine in the first dose and the Sinovac vaccine in the second dose. Safety profiles were similar among the four groups and no serious adverse events related to the vaccination were reported.
   Conclusions: Interchangeability of EV71 vaccines from two manufactures to complete an immunization series showed good immunogenicity and safety. The antibody response levels may vary by vaccination sequences of EV71 vaccines from the two manufacturers. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Xu, Qing; Liu, Xiaodong; Fang, Xueqiang; Xu, Aiqaing] Shandong Ctr Dis Control & Prevent, Shandong Prov Key Lab Infect Dis Control & Preven, 16992 Jingshi Rd, Jinan, Shandong, Peoples R China.
   [Xu, Qing; Xu, Aiqaing] Shandong Univ, Acad Prevent Med, Jinan, Peoples R China.
   [Cao, Qingfan; Liu, Haidong] Rushan City Ctr Dis Control & Prevent, Rushan, Shandong, Peoples R China.
   [Yang, Wanqi; Tian, Xiaohui; Li, Jing; Jia, Ningning; Zeng, Gang] Sinovac Biotech Co Ltd, 39 Shangdi Western Rd, Beijing, Peoples R China.
RP Xu, AA (reprint author), Shandong Ctr Dis Control & Prevent, Shandong Prov Key Lab Infect Dis Control & Preven, 16992 Jingshi Rd, Jinan, Shandong, Peoples R China.; Zeng, G (reprint author), Sinovac Biotech Co Ltd, 39 Shangdi Western Rd, Beijing, Peoples R China.
EM zengg@sinovac.com; aqxuepi@163.com
FU Sinovac Biotech Co., LTD; Taishan Scholar Project of Shandong Province
   [ts20151105]
FX This study was supported by Sinovac Biotech Co., LTD and the Taishan
   Scholar Project of Shandong Province (No. ts20151105).
CR Abarca K, 2008, INT J INFECT DIS, V12, P270, DOI 10.1016/j.ijid.2007.08.006
   ANDERSON EL, 1995, JAMA-J AM MED ASSOC, V273, P849, DOI 10.1001/jama.273.11.849
   Bewley KM, 1996, PEDIATRICS, V98, P898
   Bryan JP, 2000, VACCINE, V19, P743, DOI 10.1016/S0264-410X(00)00301-7
   Chinese Center for Disease Control and Prevention, 2019, INFECT DIS REPORT, V7, P17
   Chinese Center for Disease Control and Prevention, 2016, TECHN GUID US IN ENT
   Huang J, 2018, EMERG INFECT DIS, V24, P432, DOI 10.3201/eid2403.171303
   Li L, 2015, VACCINE, V33, P1107, DOI 10.1016/j.vaccine.2014.10.081
   Li RC, 2014, NEW ENGL J MED, V370, P829, DOI 10.1056/NEJMoa1303224
   Li YP, 2014, J INFECT DIS, V209, P46, DOI 10.1093/infdis/jit429
   Li YP, 2012, VACCINE, V30, P3295, DOI 10.1016/j.vaccine.2012.03.010
   Libster R, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-2603
   Ng QY, 2015, VIRUSES-BASEL, V7, P6441, DOI 10.3390/v7122949
   Solomon T, 2010, LANCET INFECT DIS, V10, P778, DOI 10.1016/S1473-3099(10)70194-8
   Tregnaghi M, 2004, REV PANAM SALUD PUBL, V15, P35, DOI 10.1590/S1020-49892004000100006
   Yi EJ, 2017, CLIN EXP VACCINE RES, V6, P4, DOI [10.7774/cevr.2017.6.1.4., 10.7774/cevr.2017.6.1.4]
   Zhang L, 2019, INFECT DIS-NOR, DOI 10.1080/23744235.2019.1671987
   Zhang ZL, 2012, VACCINE, V30, P4028, DOI 10.1016/j.vaccine.2012.04.038
   Zhu FC, 2013, LANCET, V381, P2024, DOI 10.1016/S0140-6736(13)61049-1
   Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2671
EP 2677
DI 10.1016/j.vaccine.2020.02.013
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800005
PM 32067817
DA 2020-05-12
ER

PT J
AU Di Lello, F
   Blejer, JL
   Alter, A
   Bartoli, S
   Vargas, F
   Ruiz, R
   Galli, C
   Blanco, S
   Gallego, S
   Fernandez, R
   Martinez, AP
   Flichman, D
AF Di Lello, Federico
   Blejer, Jorgelina L.
   Alter, Adriana
   Bartoli, Sonia
   Vargas, Fabiana
   Ruiz, Rosangela
   Galli, Claudio
   Blanco, Sebastian
   Gallego, Sandra
   Fernandez, Roberto
   Martinez, Alfredo P.
   Flichman, Diego
TI Hepatitis B surface antibodies seroprevalence among people born before
   and after implementation of universal HBV vaccination
SO VACCINE
LA English
DT Article
DE Hepatitis B virus; Vaccine; Anti-HBs titers
ID BOOSTER VACCINATION; VIRUS; IMMUNIZATION; PERSISTENCE
AB Universal vaccination is the most effective strategy to control hepatitis B virus (HBV) infection. In Argentina, vaccination against HBV was incorporated in year 2000 for newborns and in 2003 for 11 years old children. However, there is a paucity of data about protection levels against HBV infection.
   The aim of this work was to determine the prevalence of seroprotective anti-HBs antibodies (aHBs) in Argentina.
   Serum samples negative for HBsAg and anti-HBc from 132 children born after year 2000 and 762 blood donors, older than 18 years, from five centers across the country, were analyzed for aHBs.
   Titers >= 10 mILI/mL were observed in 74/132 children (56.1%) and 336/762 (44.1%) in blood donors. The median age for blood donors was 33.9 (23-43); from them, 210 (27.6%) were born after 1992 and, therefore, were catch-up by vaccine implementation at 11 years old age. Donors born in 1992 or before showed a significantly lower frequency of protection (32.2%) compared to donors born after 1992 (75.2%), p < 0.0001. In addition, significant differences were observed in the status of seroprotection between different participating centers (p = 0.024).
   Implementation of HBV vaccine in 2000 and 2003 implied an overall increase of the aHBs seroprotective rates, with a particularly adequate response in children vaccinated at 11 years old age. The observed results suggest that population born in 1992 or before is currently the most susceptible. Consequently, it would be advisable to become aware of the risk of transmission in this age group and to stress this population vaccination campaigns. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Di Lello, Federico] Univ Buenos Aires, Fac Farm & Bioquim, Inst Invest Bacteriol & Virol Mol IBaViM, Buenos Aires, DF, Argentina.
   [Di Lello, Federico; Flichman, Diego] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina.
   [Blejer, Jorgelina L.; Alter, Adriana; Fernandez, Roberto] Fdn Hemoctr, Buenos Aires, DF, Argentina.
   [Bartoli, Sonia] Ctr Reg Hemoterapia Jujuy, San Salvador De Jujuy, Jujuy, Argentina.
   [Vargas, Fabiana] Ctr Reg Hemoterapia Mendoza, Mendoza, Argentina.
   [Ruiz, Rosangela; Galli, Claudio] Hosp Reg Rio Grande, Rio Grande, Tierra Del Fueg, Argentina.
   [Blanco, Sebastian; Gallego, Sandra] Univ Nacl Cordoba, Fac Ciencias Med, Cordoba, Argentina.
   [Blanco, Sebastian; Gallego, Sandra] Fdn Banco Cent Sangre, Cordoba, Argentina.
   [Martinez, Alfredo P.] Ctr Educ Med & Invest Clin Norberto Quirno CEMIC, Secc Virol, Buenos Aires, DF, Argentina.
   [Flichman, Diego] Univ Buenos Aires, Inst Invest Biomed Retrovirus & Sindrome Inmunode, CONICET, Buenos Aires, DF, Argentina.
RP Di Lello, F (reprint author), Univ Buenos Aires, Fac Farm & Bioquim, Junin 956,4 Piso, RA-1113 Buenos Aires, DF, Argentina.; Flichman, D (reprint author), Inst Invest Biomed Retrovirus & Sindrome Inmunode, Buenos Aires, DF, Argentina.
EM fadilello@ffyb.uba.ar; dflichman@ffyb.uba.ar
FU Fundacion Alberto J. Roemmers
FX F.A.D. and D.M.F. are members of the Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET) Research Career Program. Grant from
   Fundacion Alberto J. Roemmers. We would like to thank to Mrs. Silvina
   Heisecke for providing language assistance.
CR Bianchi FP, 2019, J VIRAL HEPATITIS, V26, P136, DOI 10.1111/jvh.13001
   Blanco S, 2017, TRANSFUSION, V57, P816, DOI 10.1111/trf.13946
   Boxall EH, 2004, J INFECT DIS, V190, P1264, DOI 10.1086/423818
   Bruce MG, 2016, J INFECT DIS, V214, P16, DOI 10.1093/infdis/jiv748
   Cassidy A, 2011, EXPERT REV VACCINES, V10, P1709, DOI [10.1586/ERV.11.151, 10.1586/erv.11.151]
   Chiara F, 2013, VACCINE, V32, P62, DOI 10.1016/j.vaccine.2013.10.074
   Coppeta L, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16091515
   Coppola N, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0874-3
   Dini G, 2017, HUM VACC IMMUNOTHER, V13, P440, DOI 10.1080/21645515.2017.1264788
   Evdokimov K, 2017, CLIN MICROBIOL INFEC, V23, P197, DOI 10.1016/j.cmi.2016.10.007
   Fassio Eduardo, 2009, Acta Gastroenterol Latinoam, V39, P47
   Flichman DM, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-218
   Klinger G, 2018, VACCINE, V36, P2288, DOI 10.1016/j.vaccine.2018.03.028
   Leuridan E, 2011, CLIN INFECT DIS, V53, P68, DOI 10.1093/cid/cir270
   Marciano S, 2018, 25 C AS LAT EST HIG
   Mendizabal M, 2014, LIVER TRANSPLANT, V20, P483, DOI 10.1002/lt.23823
   Mendy M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058029
   Pollard AJ, 2009, NAT REV IMMUNOL, V9, P212, DOI 10.1038/nri2494
   Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X
   Simms KT, 2019, INT J INFECT DIS, V78, P128, DOI 10.1016/j.ijid.2018.11.007
   WHO, HEP B
   Williams IT, 2003, PEDIATR INFECT DIS J, V22, P157
   World Health Organization, GLOB HLTH SECT STRAT
   Wu ZK, 2018, HUM VACC IMMUNOTHER, V14, P1251, DOI 10.1080/21645515.2018.1426419
   Zhao YQ, 2019, BMC PLANT BIOL, V19, DOI [10.1186/s12870-019-1691-4, 10.1186/s12879-019-4073-5, 10.1186/s12879-019-4134-9]
NR 25
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2678
EP 2682
DI 10.1016/j.vaccine.2020.02.014
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800006
PM 32061386
DA 2020-05-12
ER

PT J
AU Becerra-Culqui, TA
   Sy, LS
   Ackerson, BK
   Chen, LH
   Fischetti, CA
   Solano, Z
   Schmidt, JE
   Malvisi, L
   Curina, C
   Pellegrini, M
   Tseng, HF
AF Becerra-Culqui, Tracy A.
   Sy, Lina S.
   Ackerson, Bradley K.
   Chen, Lie Hong
   Fischetti, Christine A.
   Solano, Zendi
   Schmidt, Johannes E.
   Malvisi, Lucio
   Curina, Carlo
   Pellegrini, Michele
   Tseng, Hung Fu
TI Safety of MenACWY-CRM vaccine exposure during pregnancy
SO VACCINE
LA English
DT Article
DE Safety; Meningococcal vaccine; Pregnancy registry; Observational study
ID URINARY-TRACT-INFECTIONS; UNITED-STATES; RISK-FACTORS; EPIDEMIOLOGY;
   MISCARRIAGE; WOMEN
AB Background: Although the meningococcal conjugate MenACWY-CRM vaccine is not approved for use in pregnant women, unintentional exposure during pregnancy can occur, especially during early pregnancy among women of child-bearing age. This study provides safety information about inadvertent MenACWY-CRM vaccination during pregnancy.
   Methods: The evaluated population consisted of pregnant female members of Kaiser Permanente Southern California who inadvertently received MenACWY-CRM at 11-21 years of age during 09/30/2011-06/30/2013 within 28 days prior to conception or during pregnancy. Chart abstraction was conducted to identify pregnancy and birth outcomes, including spontaneous and induced abortions, preterm births, low weight births, and major congenital malformations (MCMs).
   Results: There were 92 women who received MenACWY-CRM during the pregnancy exposure period, mainly during the first trimester (76.1%). Hispanics represented the largest race/ethnicity category (68.5%). Among the known pregnancy outcomes (n - 66; excluding induced abortions and unknown pregnancy outcomes), the prevalence of spontaneous abortions was 18.2% (n = 12). Among live born infants (n = 55; from 54 pregnancies), 14.5% (n = 8) were born preterm (<37 weeks gestation) and 9.1% (n = 5) had a low birthweight (<2500 g). The prevalence rate of MCMs among live born infants (n = 55) was 1.8% (n = 1).
   Conclusions: This study provides baseline prevalence estimates of spontaneous abortions, preterm births, low weight births, and MCMs among women inadvertently exposed to MenACWY-CRM during the pregnancy period. These estimates appear to be comparable with U.S. background prevalence estimates. (C) 2020 Published by Elsevier Ltd.
C1 [Becerra-Culqui, Tracy A.; Sy, Lina S.; Chen, Lie Hong; Fischetti, Christine A.; Solano, Zendi; Tseng, Hung Fu] Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Los Robles Ave,2 Floor, Pasadena, CA 91101 USA.
   [Ackerson, Bradley K.] Southern Calif Permanente Med Grp, Pediat & Pediat Infect Dis, 25965 S Normandie Ave, Harbor City, CA 90710 USA.
   [Schmidt, Johannes E.; Malvisi, Lucio; Curina, Carlo; Pellegrini, Michele] GSK, Clin Res & Dev Ctr, Via Fiorentina 1, I-53100 Siena, SI, Italy.
RP Tseng, HF (reprint author), Kaiser Permanente Southern Calif, Dept Res & Evaluat, 100 S Los Robles Ave,2 Floor, Pasadena, CA 91101 USA.
EM Hung-fu.x.tseng@kp.org
OI PELLEGRINI, MICHELE/0000-0001-8505-9260
FU GlaxoSmithKline SAGlaxoSmithKline; Kaiser Permanente Southern California
   internal research funds
FX This research was sponsored by GlaxoSmithKline SA and Kaiser Permanente
   Southern California internal research funds.
CR Ailes EC, 2018, MMWR-MORBID MORTAL W, V67, P18, DOI 10.15585/mmwr.mm6701a4
   [Anonymous], 2013, Obstet Gynecol, V121, P1394, DOI 10.1097/01.AOG.0000431056.79334.cc
   Arck PC, 2008, REPROD BIOMED ONLINE, V17, P101, DOI 10.1016/S1472-6483(10)60300-8
   Bookstaver PB, 2015, PHARMACOTHERAPY, V35, P1052, DOI 10.1002/phar.1649
   Choi Tae Yeong, 2014, Obstet Gynecol Sci, V57, P518, DOI 10.5468/ogs.2014.57.6.518
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   Correa Adolfo, 2007, Birth Defects Res A Clin Mol Teratol, V79, P65
   Dautt-Leyva JG, 2018, J OBSTET GYNAECOL RE, V44, P1384, DOI 10.1111/jog.13687
   Delzell JE, 2000, AM FAM PHYSICIAN, V61, P713
   Finer LB, 2011, CONTRACEPTION, V84, P478, DOI 10.1016/j.contraception.2011.07.013
   Garcia-Enguidanos A, 2002, EUR J OBSTET GYN R B, V102, P111, DOI 10.1016/S0301-2115(01)00613-3
   GlaxoSmithKline Biologicals S.A, MENVEO PACK INS HIGH
   Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4
   Goss MA, 2015, VACCINE, V33, P3422, DOI 10.1016/j.vaccine.2015.04.014
   Halperin SA, 2012, VACCINE, V30, pB26, DOI 10.1016/j.vaccine.2011.12.032
   Jatlaoui TC, 2018, MMWR SURVEILL SUMM, V67, P1, DOI [10.15585/mmwr.ss6713a1, 10.15585/mmwr.ss6625a1]
   Leftwich HK, 2017, PEDIATR CLIN N AM, V64, P381, DOI 10.1016/j.pcl.2016.11.007
   MacNeil JR, 2018, CLIN INFECT DIS, V66, P1276, DOI 10.1093/cid/cix993
   Martin Joyce A, 2013, Natl Vital Stat Rep, V62, P1
   Mollborn S, 2009, J HEALTH SOC BEHAV, V50, P310, DOI 10.1177/002214650905000305
   Muanda FT, 2017, CAN MED ASSOC J, V189, pE625, DOI 10.1503/cmaj.161020
   Myers TR, 2017, VACCINE, V35, P1758, DOI 10.1016/j.vaccine.2017.02.030
   National Center for Birth Defects and Developmental Disabilities Centers for Disease Control and Prevention, 2018, MENTR ATL CONG DEF P
   Office of Population Affairs, 2016, CAL AD REPR HLTH FAC
   Rossen LM, 2018, PAEDIATR PERINAT EP, V32, P19, DOI 10.1111/ppe.12417
   Sanofi Pasteur Inc, 2018, MEN PACK INS HIGHL P
   Vidal AC, 2005, INT J OBESIT, V2013, P907, DOI DOI 10.1038/IJO2013.47
   Wyatt PR, 2005, AM J OBSTET GYNECOL, V192, P240, DOI 10.1016/j.ajog.2004.06.099
   Zheteyeva Y, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.02.027
   Zinaman MJ, 1996, FERTIL STERIL, V65, P503, DOI 10.1016/S0015-0282(16)58144-8
   2014, OBSTET GYNECOL, V124, P863, DOI DOI 10.1097/Q1AOC,0000494CRI,15177BE
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2683
EP 2690
DI 10.1016/j.vaccine.2020.02.008
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800007
PM 32057568
DA 2020-05-12
ER

PT J
AU Sharon, AJ
   Yom-Tov, E
   Baram-Tsabari, A
AF Sharon, Aviv J.
   Yom-Tov, Elad
   Baram-Tsabari, Ayelet
TI Vaccine information seeking on social Q&A services
SO VACCINE
LA English
DT Article
DE Vaccine hesitancy; Information seeking; Trustworthiness; Online;
   Internet
ID WEB; ATTITUDES; CRITERIA; PARENTS; ANSWERS; TRUST
AB Experts are concerned about the spread and recalcitrance of vaccine misinformation and its contribution to vaccine hesitancy. Despite this risk, little research attention has been paid to understanding how individuals seek vaccine information online and evaluate its trustworthiness. Here, we hypothesized that when vaccine-hesitant parents seek information about vaccines, they prefer trustworthy sources based on their competence, integrity and benevolence. We explored this issue using 4910 questions and 2583 answers retrieved from two social question-and-answer (Q&A) platforms: "Yahool Answers" and the Facebook group "Talking about Vaccines." We examined what kinds of questions are asked about vaccines, to what extent they are explicitly directed at health professionals or parents, and what features of the answers predict perceived answer quality, based on the theory of epistemic trust. The findings indicate that on different platforms, vaccine-related questions focus on different topics; namely, questions on one platform focused on the risks and benefits of vaccination, whereas they dealt with vaccine schedules on the other. On both platforms, most questions did not specify that an answer should be based on professional expertise or parents' experience. Both pro-vaccine and anti-vaccine answers were proportionately represented among the "best answers". However, if an answer was written by a health professional, the askers and the community on "Yahoo! Answers" were twice as likely to choose it as the "best answer" to a vaccine-related question, irrespective of whether it encouraged or discouraged vaccination. By contrast, an online experiment revealed that both the identity of the respondent and the stance towards vaccination affected the perceived trustworthiness of the answers. These findings indicate that despite the proliferation of anti-vaccine messages, epistemic trust in mainstream science and medicine is robust. User responses to expert answers suggest that expert outreach in online environments may be an effective intervention to address vaccine hesitancy. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Sharon, Aviv J.; Baram-Tsabari, Ayelet] Technion Israel Inst Technol, Fac Educ Sci & Technol, IL-3200003 Haifa, Israel.
   [Yom-Tov, Elad] Microsoft Res Israel, 13 Shenkar St, IL-4672513 Herzliyya, Israel.
   [Yom-Tov, Elad] Technion Israel Inst Technol, Fac Ind Engn & Management, IL-3200003 Haifa, Israel.
RP Baram-Tsabari, A (reprint author), Technion Israel Inst Technol, Fac Educ Sci & Technol, IL-3200003 Haifa, Israel.
EM ayelet@technion.ac.il
OI Baram-Tsabari, Ayelet/0000-0002-8123-5519
FU I CORE Program of the Planning and Budgeting Committee; Israel Science
   FoundationIsrael Science Foundation [1599/15, 1716/12]
FX This research was supported by the I CORE Program of the Planning and
   Budgeting Committee and the Israel Science Foundation grant 1716/12 and
   Israel Science Foundation grant 1599/15.
CR Bickert M., 2019, COMBATTING VACCINE M
   Brossard D, 2013, SCIENCE, V339, P40, DOI 10.1126/science.1232329
   Buhrmester MD, 2018, PERSPECT PSYCHOL SCI, V13, P149, DOI 10.1177/1745691617706516
   Casiday R, 2006, VACCINE, V24, P177, DOI 10.1016/j.vaccine.2005.07.063
   Chou WYS, 2018, JAMA-J AM MED ASSOC, V320, P2417, DOI 10.1001/jama.2018.16865
   Dredze M, 2016, AM J PREV MED, V50, P550, DOI 10.1016/j.amepre.2015.10.002
   Freed GL, 2011, PEDIATRICS, V127, pS107, DOI 10.1542/peds.2010-1722P
   Fu HY, 2019, INFORM PROCESS MANAG, V56, P14, DOI 10.1016/j.ipm.2018.08.007
   Garcia-Basteiro AL, 2012, VACCINE, V30, P3798, DOI 10.1016/j.vaccine.2011.10.003
   Gust D, 2005, AM J HEALTH BEHAV, V29, P81, DOI 10.5993/AJHB.29.1.7
   Haase N, 2012, MED DECIS MAKING, V32, P645, DOI 10.1177/0272989X12445286
   Harmsen IA, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1219
   Hendriks F, 2016, PROGR IS, P143, DOI 10.1007/978-3-319-28059-2_8
   Hilton S, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-42
   Kim S, 2009, J AM SOC INF SCI TEC, V60, P716, DOI 10.1002/asi.21026
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Orr D, 2018, J MICROBIOL BIOL EDU, V19, DOI 10.1128/jmbe.v19i1.1500
   Orr D, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0093-4
   Peretti-Watel P, 2015, PLOS CURR, P1, DOI [10.1371/currentsoutbreaks.6844c80ff9f5b273114r91171b7fc289, DOI 10.1371/CURRENTS.OUTBREAKS.6844C80FF9F5B273F34C91F71B7FC289]
   Peretti-Watel P, 2019, SOCIOL HLTH ILLN, P1467, DOI [10.111111467-956612907, DOI 10.1111/1467-956612907]
   Rechavi A., 2012, 2012 45th Hawaii International Conference on System Sciences (HICSS), P781, DOI 10.1109/HICSS.2012.398
   Royal Society for Public Health, 2019, MOV NEEDL PROM VACC
   Rubin L, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4658
   Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040
   Shah C, 2009, LIBR INFORM SCI RES, V31, P205, DOI 10.1016/j.lisr.2009.07.006
   Sharon AJ, 2020, PUBLIC UNDERST SCI, V29, P252, DOI 10.1177/0963662519899884
   Sillence E, 2007, SOC SCI MED, V64, P1853, DOI 10.1016/j.socscimed.2007.01.012
   Smith N, 2019, INFORM COMMUN SOC, V22, P1310, DOI 10.1080/1369118X.2017.1418406
   Stahl JP, 2016, MED MALADIES INFECT, V46, P117, DOI 10.1016/j.medmal.2016.02.002
   van Dijk D, 2015, SIGIR 2015: PROCEEDINGS OF THE 38TH INTERNATIONAL ACM SIGIR CONFERENCE ON RESEARCH AND DEVELOPMENT IN INFORMATION RETRIEVAL, P995, DOI 10.1145/2766462.2767840
   WHO, 2019, 10 THREATS GLOB HLTH
   Witteman HO, 2012, VACCINE, V30, P3734, DOI 10.1016/j.vaccine.2011.12.039
   Yang J, 2014, 2014 INTERNATIONAL CONFERENCE ON ADVANCED EDUCATION AND MANAGEMENT (ICAEM), P263
   Yaqub O, 2014, SOC SCI MED, V112, P1, DOI 10.1016/j.socscimed.2014.04.018
NR 34
TC 0
Z9 0
U1 5
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2691
EP 2699
DI 10.1016/j.vaccine.2020.02.010
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800008
PM 32061384
DA 2020-05-12
ER

PT J
AU Langsam, D
   Anis, E
   Haas, EJ
   Gosinov, R
   Yechezkel, M
   Grotto, I
   Shmueli, E
   Dan, YM
AF Langsam, Dean
   Anis, Emilia
   Haas, Eric J.
   Gosinov, Ruslan
   Yechezkel, Matan
   Grotto, Itamar
   Shmueli, Erez
   Dan Yamin
TI Tdap vaccination during pregnancy interrupts a twenty-year increase in
   the incidence of pertussis
SO VACCINE
LA English
DT Article
DE Tdap; Pertussis vaccination; Periodicity; Epidemiology; Vaccination;
   Maternal immunity
ID BORDETELLA-PERTUSSIS; IMMUNIZATION; EPIDEMIOLOGY; DIPHTHERIA; CHILDREN;
   INFANTS; IMPACT
AB Pertussis incidence in developed countries, including Israel, has increased over the past two decades despite the addition of two booster doses in children. However, as pertussis is characterized by a multi-annual periodicity, and since clinical diagnosis can miss cases, determining disease trends at the population level is challenging. To bridge this gap, we developed a simple statistical model to capture the temporal patterns of pertussis incidence in Israel. Our model was calibrated and tested using laboratory-confirmed cases of pertussis for the Israeli population between 1998 and 2019. The model identifies a clear four-year periodicity of pertussis incidence over the past two decades that is identical to the one observed in the pre-vaccine era. Accounting for this periodicity, the model shows a 325% increase in pertussis incidence from 2002 to 2014. These multi-year trends were interrupted shortly after the introduction of routine immunization of Tdap vaccine in pregnancy in 2015, after which we found a 59.7% (95% CI: 57.7-61.6%) decline in pertussis incidence and a 49.5% (36.0-61.6%) decline in hospitalizations compared to the model's projection. While this sharp decline cannot be fully attributed to the newly introduced vaccination policy, sharper reductions of 71.2% (65.6-76.1%) in incidence and 58.4% (39.6-72.7%) in hospitalizations, have been observed in infants of age two months and below - young infants that have yet to become vaccinated and are more likely to be protected by maternal vaccination. Our work suggests that Tdap vaccination during pregnancy is a promising policy for controlling pertussis. Furthermore, due to the stable periodicity of pertussis, public health decision-makers should invest continuous efforts in the implementation of this strategy with additional reinforcement in expected peak years. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Langsam, Dean; Yechezkel, Matan; Shmueli, Erez; Dan Yamin] Tel Aviv Univ, Fac Engn, Dept Ind Engn, IL-69978 Tel Aviv, Israel.
   [Anis, Emilia; Haas, Eric J.; Gosinov, Ruslan; Grotto, Itamar] Minist Hlth, Div Epidemiol, Publ Hlth Serv, Jerusalem, Israel.
   [Anis, Emilia] Hebrew Univ & Hadassah, Braun Sch Publ Hlth, IL-91120 Jerusalem, Israel.
   [Haas, Eric J.; Grotto, Itamar] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel.
RP Dan, YM (reprint author), Tel Aviv Univ, Fac Engn, Dept Ind Engn, IL-69978 Tel Aviv, Israel.
EM dan.yamin@gmail.com
OI Shmueli, Erez/0000-0003-3193-5768
FU James B. Crystal/Lillian Yaros Philanthropic fund; Israeli National
   Institute for Health Policy Research (NIHP) [164-16]
FX The authors are profoundly thankful to Prof. Alison Galvani and Prof.
   Meagan Fitzpatrick for their helpful advice on several methodological
   aspects. This study was supported by the James B. Crystal/Lillian Yaros
   Philanthropic fund and the Israeli National Institute for Health Policy
   Research (NIHP) as part of project number 164-16. The funders had no
   role in study design, data collection, and analysis, decision to
   publish, or preparation of the manuscript.
CR Althouse BM, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0382-8
   Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   [Anonymous], INF DIS UN
   Atkins KE, 2016, AM J EPIDEMIOL, V183, P1159, DOI 10.1093/aje/kwv347
   Broutin H, 2005, AM J EPIDEMIOL, V161, P1159, DOI 10.1093/aje/kwi141
   Broutin H, 2010, P ROY SOC B-BIOL SCI, V277, P3239, DOI 10.1098/rspb.2010.0994
   Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821
   de Celles MD, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaj1748
   Jackson DW, 2014, EPIDEMIOL INFECT, V142, P672, DOI 10.1017/S0950268812003093
   Kaczmarek MC, 2013, MED J AUSTRALIA, V198, P624, DOI 10.5694/mja13.10044
   Mattoo S, 2005, CLIN MICROBIOL REV, V18, P326, DOI 10.1128/CMR.18.2.326-382.2005
   Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
   Okun BS, 2016, POP STUD-J DEMOG, V70, DOI 10.1080/00324728.2016.1195913
   Rendi-Wagner P, 2010, VACCINE, V28, P3285, DOI 10.1016/j.vaccine.2010.02.104
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   Skoff TH, 2018, CLIN INFECT DIS, DOI [10.1093/cid/cLy757, DOI 10.1093/CID/CLY757]
   Srugo I, 2000, EMERG INFECT DIS, V6, P526, DOI 10.3201/eid0605.000512
   Wearing HJ, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000647
   Yeung KHT, 2017, LANCET INFECT DIS, V17, P974, DOI 10.1016/S1473-3099(17)30390-0
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2700
EP 2706
DI 10.1016/j.vaccine.2020.01.095
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800009
PM 32070682
DA 2020-05-12
ER

PT J
AU Sigurdsson, S
   Eythorsson, E
   Erlendsdottir, H
   Hrafnkelsson, B
   Kristinsson, KG
   Haraldsson, A
AF Sigurdsson, Samuel
   Eythorsson, Elias
   Erlendsdottir, Helga
   Hrafnkelsson, Birgir
   Kristinsson, Karl G.
   Haraldsson, Asgeir
TI Impact of the 10-valent pneumococcal conjugate vaccine on hospital
   admissions in children under three years of age in Iceland
SO VACCINE
LA English
DT Article
DE PCV-10; Pneumonia; IPD; Pneumococcus; Cohort study; Sepsis
ID CHILDHOOD PNEUMONIA; OTITIS-MEDIA; DISEASE; POPULATION; INFECTIONS;
   INFLUENZA; ETIOLOGY; GENOTYPE; BURDEN; ON1
AB Introduction: Pneumococcus is an important respiratory pathogen. The 10-valent pneumococcal vaccine (PHiD-CV) was introduced into the Icelandic vaccination programme in 2011. The aim was to estimate the impact of PHiD-CV on paediatric hospitalisations for respiratory tract infections and invasive disease.
   Methods: The 2005-2015 birth-cohorts were followed until three years of age and hospitalisations were recorded for invasive pneumococcal disease (IPD), meningitis, sepsis, pneumonia and otitis media. Hospitalisations for upper- and lower respiratory tract infections (URTI, LRTI) were used as comparators. The 2005-2010 birth-cohorts were defined as vaccine non-eligible cohorts (VNEC) and 2011-2015 birthcohorts as vaccine eligible cohorts (VEC). Incidence rates (IR) were estimated for diagnoses, birth-cohorts and age groups, and incidence rate ratios (IRR) between VNEC and VEC were calculated assuming Poisson variance. Cox regression was used to estimate the hazard ratio (HR) of hospitalisation between VNEC and VEC.
   Results: 51,264 children were followed for 142,315 person-years, accumulating 1,703 hospitalisations for the respective study diagnoses. Hospitalisations for pneumonia decreased by 20% (HR 0.80, 95%CI:0.67-0.95) despite a 32% increase in admissions for LRTI (HR 1.32, 95%CI:1.14-1.53). Hospital admissions for culture-confirmed IPD decreased by 93% (HR 0.07, 95%CI:0.01-0.50) and no hospitalisations for IPD with vaccine-type pneumococci were observed in the VEC. Hospitalisations for meningitis and sepsis did not change. A decrease in hospital admissions for otitis media was observed, but did not coincide with PHiD-CV introduction.
   Conclusion: Following the introduction of PHiD-CV in Iceland, hospitalisations for pneumonia and culture confirmed IPD decreased. Admissions for other LRTIs and URTIs increased during this period. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Sigurdsson, Samuel; Eythorsson, Elias; Erlendsdottir, Helga; Kristinsson, Karl G.; Haraldsson, Asgeir] Univ Iceland, Fac Med, Reykjavik, Iceland.
   [Erlendsdottir, Helga; Kristinsson, Karl G.] Landspitali Univ Hosp, Dept Clin Microbiol, Reykjavik, Iceland.
   [Hrafnkelsson, Birgir] Univ Iceland, Dept Math, Reykjavik, Iceland.
   [Haraldsson, Asgeir] Landspitali Univ Hosp, Childrens Hosp Iceland, IS-101 Reykjavik, Iceland.
RP Haraldsson, A (reprint author), Landspitali Univ Hosp, Childrens Hosp Iceland, IS-101 Reykjavik, Iceland.; Haraldsson, A (reprint author), Univ Iceland, IS-101 Reykjavik, Iceland.
EM asgeir@lsh.is
OI Haraldsson, Asgeir/0000-0001-5364-7877
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline; Landspitali University
   Hospital Research Fund
FX An investigator-initiated study funded by GlaxoSmithKline Biologicals
   SA. Additionally, a grant was received from the Landspitali University
   Hospital Research Fund. GlaxoSmithKline Biologicals SA was provided the
   opportunity to review a draft version of this manuscript, but the
   authors are solely responsible for final content and interpretation. The
   authors received no financial support or other form of compensation
   related to the development of the manuscript.
CR Ampofo K, 2008, PEDIATRICS, V122, P229, DOI 10.1542/peds.2007-3192
   Andrade AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184204
   Berg AS, 2016, PEDIATR INFECT DIS J, V35, pE69, DOI 10.1097/INF.0000000000001009
   Berglund A, 2014, PLOS ONE, V9, DOI [10.1371/journalpone.0112211, DOI 10.1371/OURNALPONE0112211]
   de Oliveira LH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166736
   Department of Virology LUH, 2018, DIAGN RESP VIR OTH I
   DURANDO P, 2009, ITALY, V27, P3459, DOI DOI 10.10161/,VACCINE700901052
   Duvvuri VR, 2015, SCI REP-UK, V5, DOI 10.1038/srep14268
   Eriksson M, 2017, ACTA PAEDIATR, V106, P1825, DOI 10.1111/apa.13923
   Eykorsson E, 2017, HIGH UPTAKE PNEUMOCO
   Fitzwater SP, 2012, PEDIATR INFECT DIS J, V31, P501, DOI 10.1097/INF.0b013e31824de9f6
   Gisselsson-Solen M., 2017, PEDIAT INFECT DIS, V36, P1, DOI [10.1097/INF 0000000000001654, DOI 10.1097/INF0000000000001654]
   Griffin H, 2014, COMPANION TO REALITY TELEVISION, P155
   Grijalva CG, 2014, CLIN INFECT DIS, V58, P1369, DOI 10.1093/cid/ciu148
   Harboe ZB, 2014, CLIN INFECT DIS, V59, P1066, DOI 10.1093/cid/ciu524
   Heiskanen-Kosma T, 2003, APMIS, V111, P945, DOI 10.1034/j.1600-0463.2003.1111005.x
   Howie SRC, 2014, CLIN INFECT DIS, V59, P682, DOI 10.1093/cid/ciu384
   Jokinen J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120290
   Jonnalagadda S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171687
   Knol MJ, 2015, EMERG INFECT DIS, V21, P2040, DOI 10.3201/eid2111.140780
   Marom T, 2017, INT J PEDIATR OTORHI, V97, P251, DOI 10.1016/j.ijporl.2017.04.023
   Moore MR, 2015, LANCET INFECT DIS, V15, P301, DOI 10.1016/S1473-3099(14)71081-3
   Nair H, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1693-x
   O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6
   Otieno JR, 2017, EMERG INFECT DIS, V23, P264, DOI 10.3201/eid2302.161149
   Palmu AA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172690
   Peltola VT, 2004, PEDIATR INFECT DIS J, V23, pS87, DOI 10.1097/01.inf.0000108197.81270.35
   Pierangeli A, 2014, EUROSURVEILLANCE, V19, P11, DOI 10.2807/1560-7917.ES2014.19.26.20843
   Prasso JE, 2017, CLIN CHEST MED, V38, P127, DOI 10.1016/j.ccm.2016.11.006
   Sartori AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179222
   Savulescu C, 2017, LANCET RESP MED, V5, P648, DOI [10.1016/S2213-2600(17)30110-8, 10.1016/s2213-2600(17)30110-8]
   Sigurdsson S, 2018, CLIN INFECT DIS, V67, P1213, DOI 10.1093/cid/ciy233
   Sigurdsson S, 2015, PEDIATR INFECT DIS J, V34, P1385, DOI 10.1097/INF.0000000000000899
   Snaebjarnardottir K, 2013, SCAND J INFECT DIS, V45, P819, DOI 10.3109/00365548.2013.817680
   Tasher D, 2011, CLIN INFECT DIS, V53, P1199, DOI 10.1093/cid/cir726
   Tawfik KO, 2017, OTOLARYNG HEAD NECK, V156, P938, DOI 10.1177/0194599817699599
   Taylor S, 2012, CLIN INFECT DIS, V54, P1765, DOI 10.1093/cid/cis292
   Todberg T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111732
   Troeger C, 2017, LANCET INFECT DIS, V17, P1133, DOI 10.1016/S1473-3099(17)30396-1
   Waight PA, 2015, LANCET INFECT DIS, V15, P535, DOI 10.1016/S1473-3099(15)70044-7
   Walker CLF, 2013, LANCET, V381, P1405, DOI 10.1016/S0140-6736(13)60222-6
   Yoshihara K, 2016, SCI REP-UK, V6, DOI 10.1038/srep27856
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2707
EP 2714
DI 10.1016/j.vaccine.2020.01.094
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800010
PM 32063434
OA Other Gold
DA 2020-05-12
ER

PT J
AU Mouratidou, E
   Lambrou, A
   Andreopoulou, A
   Gioula, G
   Exindari, M
   Kossyvakis, A
   Pogka, V
   Mentis, A
   Georgakopoulou, T
   Lytras, T
AF Mouratidou, Elisavet
   Lambrou, Angeliki
   Andreopoulou, Anastasia
   Gioula, Georgia
   Exindari, Maria
   Kossyvakis, Athanasios
   Pogka, Vasiliki
   Mentis, Andreas
   Georgakopoulou, Theano
   Lytras, Theodore
TI Influenza vaccine effectiveness against hospitalization with
   laboratory-confirmed influenza in Greece: A pooled analysis across six
   seasons, 2013-2014 to 2018-2019
SO VACCINE
LA English
DT Article
DE Influenza surveillance; Vaccine effectiveness; Viral subtypes;
   Epidemiology
ID TEST-NEGATIVE DESIGN; UNITED-STATES; CIRCULATION; SURVEILLANCE;
   METAANALYSIS; CHALLENGES; VIRUSES; BURDEN; US
AB Background: Monitoring seasonal influenza Vaccine Effectiveness (VE) is key to inform vaccination strategies and sustain uptake. Pooling data across multiple seasons increases precision and allows for subgroup analyses, providing more conclusive evidence. Our aim was to assess VE against hospitalization with laboratory-confirmed influenza in Greece over six seasons, from 2013 to 2014 to 2018-2019, using routinely collected surveillance data.
   Methods: Swab samples from hospitalized patients across the country were tested for influenza by RT-PCR. We used the test-negative design, with patients testing positive for influenza serving as cases and those testing negative serving as controls. VE was calculated as one minus the Odds Ratio (OR) for influenza vaccination, estimated by mixed-effects logistic regression and adjusted for age, sex, hospitalization type (being in intensive care or not), time from symptom onset to swabbing, and calendar time. Stratified estimates by age and hospitalization type were obtained, and also subgroup estimates by influenza type/subtype and season. Antigenic and genetic characterization of a subset of circulating influenza strains was performed.
   Results: A total of 3,882 test-positive cases and 5,895 test-negative controls were analyzed. Across all seasons, adjusted VE was 45.5% (95% CI: 31.6-56.6) against all influenza, 62.8% against A(H1N1)pdm09 (95% CI: 40.7-76.7), 28.2% against A(H3N2) (95% CI: 12.0-41.3) and 45.5% against influenza B (95% CI: 29.1-58.1). VE was slightly lower for patients aged 60 years and over, and similar between patients hospitalized inside or outside intensive care. Circulating A(H1N1)pdm09 and B strains were antigenically similar to the vaccine strains, whereas A(H3N2) were not.
   Conclusion: Our results confirm the public health benefits from seasonal influenza vaccination, despite the suboptimal effectiveness against A(H3N2) strains. Continued monitoring of VE is essential, and routinely collected surveillance data can be valuable in this regard. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Mouratidou, Elisavet; Lambrou, Angeliki; Andreopoulou, Anastasia; Georgakopoulou, Theano; Lytras, Theodore] Natl Publ Hlth Org, Agrafon 3-5, Athens 15123, Greece.
   [Mouratidou, Elisavet] European Ctr Dis Prevent & Control ECDC, EPIET, Stockholm, Sweden.
   [Gioula, Georgia; Exindari, Maria] Aristotle Univ Thessaloniki, Natl Influenza Ctr Northern Greece, Med Sch, Thessaloniki, Greece.
   [Kossyvakis, Athanasios; Pogka, Vasiliki; Mentis, Andreas] Hellenic Pasteur Inst, Natl Influenza Ctr Southern Greece, Athens, Greece.
RP Mouratidou, E (reprint author), Natl Publ Hlth Org, Agrafon 3-5, Athens 15123, Greece.
EM e.mouratidou@keelpno.gr
OI Lytras, Theodore/0000-0002-4146-4122
CR Ainslie KEC, 2019, EXPERT REV VACCINES, V18, P615, DOI 10.1080/14760584.2019.1622419
   Andrew MK, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2905-8
   [Anonymous], 2012, Wkly Epidemiol Rec, V87, P461
   Backer JA, 2019, EPIDEMICS-NETH, V26, P77, DOI 10.1016/j.epidem.2018.10.001
   Bedford T, 2015, NATURE, V523, P217, DOI 10.1038/nature14460
   Belongia EA, 2019, CLIN INFECT DIS, V69, P1817, DOI 10.1093/cid/ciz411
   Beyer WEP, 2017, VACCINE, V35, P4167, DOI 10.1016/j.vaccine.2017.06.038
   Cassini A, 2018, EUROSURVEILLANCE, V23, P15, DOI 10.2807/1560-7917.ES.2018.23.16.17-00454
   Castilla J, 2016, VACCINE, V34, P1350, DOI 10.1016/j.vaccine.2016.01.054
   Darvishian M, 2017, LANCET RESP MED, V5, P200, DOI 10.1016/S2213-2600(17)30043-7
   El Omeiri N, 2018, VACCINE, V36, P3555, DOI 10.1016/j.vaccine.2017.06.036
   Foppa IM, 2016, INT J EPIDEMIOL, V45, P2052, DOI 10.1093/ije/dyw022
   Foppa IM, 2015, VACCINE, V33, P3003, DOI 10.1016/j.vaccine.2015.02.042
   Fry AM, 2014, CLIN INFECT DIS, V59, P406, DOI 10.1093/cid/ciu328
   Fukushima W, 2017, VACCINE, V35, P4796, DOI 10.1016/j.vaccine.2017.07.003
   Gravenstein S, 2017, LANCET RESP MED, V5, P738, DOI 10.1016/S2213-2600(17)30235-7
   Hellenic Ministry of Health, 2017, NAT IMM SCHED CHILDR
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Jackson ML, 2018, VACCINE, V36, P467, DOI 10.1016/j.vaccine.2017.12.014
   Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053
   Kossyvakis A, 2015, J CLIN MICROBIOL, V53, P1493, DOI 10.1128/JCM.03236-14
   Kostova D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066312
   Kwong JC, 2019, VACCINE, V37, P4392, DOI 10.1016/j.vaccine.2019.06.011
   Lewnard JA, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020028
   Lytras T, 2019, EUROSURVEILLANCE, V24, P11, DOI 10.2807/1560-7917.ES.2019.24.14.1800118
   Lytras T, 2016, J MED VIROL, V88, P1896, DOI 10.1002/jmv.24551
   Lytras T, 2015, VACCINE, V33, P367, DOI 10.1016/j.vaccine.2014.11.005
   Marta Valenciano, 2016, EUROSURVEILLANCE, V21, DOI [10.2807/1560-7917.ES.2016.713.30139, DOI 10.2807/1560-7917.ES.2016.713.30139]
   Nicoll A, 2013, LANCET INFECT DIS, V13, P7, DOI 10.1016/S1473-3099(12)70313-4
   Nilsson AC, 2010, SCAND J INFECT DIS, V42, P679, DOI 10.3109/00365548.2010.486001
   Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X
   Palekar R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219595
   Preaud E, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-813
   Puig-Barbera J, 2010, VACCINE, V28, P7460, DOI 10.1016/j.vaccine.2010.09.042
   R Core Team, 2012, LANG ENV STAT COMP
   Rolfes MA, 2018, INFLUENZA OTHER RESP, V12, P132, DOI 10.1111/irv.12486
   Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010
   Savulescu C, 2014, VACCINE, V32, P4404, DOI 10.1016/j.vaccine.2014.06.063
   Skowronski DM, 2017, J INFECT DIS, V216, P1487, DOI 10.1093/infdis/jix526
   Skowronski DM, 2012, CLIN INFECT DIS, V55, P332, DOI 10.1093/cid/cis431
   Sullivan SG, 2016, EPIDEMIOL INFECT, V144, P2317, DOI 10.1017/S0950268816000819
   Tam YH, 2018, VACCINE, V36, P6117, DOI 10.1016/j.vaccine.2018.08.075
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Thompson MG, 2018, VACCINE, V36, P5916, DOI 10.1016/j.vaccine.2018.07.028
   Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153
   Vandenbroucke JP, 2019, EPIDEMIOLOGY, V30, P838, DOI 10.1097/EDE.0000000000001088
   Vandenbroucke JP, 2012, INT J EPIDEMIOL, V41, P1480, DOI 10.1093/ije/dys147
   World Health Organization Global Influenza Surveillance Network, 2011, MAN LAB DIAGN VIR SU
NR 48
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2715
EP 2724
DI 10.1016/j.vaccine.2020.01.083
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800011
PM 32033848
DA 2020-05-12
ER

PT J
AU Sompagdee, N
   Anuwutnavin, S
   Phongsamart, W
   Senawong, S
   Umrod, P
   Robkhonburi, A
AF Sompagdee, Nalat
   Anuwutnavin, Sanitra
   Phongsamart, Wanatpreeya
   Senawong, Sansnee
   Umrod, Pinklow
   Robkhonburi, Amporn
TI Seroprevalence of Bordetella pertussis antibodies and anti-pertussis
   antibody response after a single dose of reduced-antigen combined
   diphtheria, tetanus, and acellular pertussis vaccine (Tdap) in pregnant
   Thai women
SO VACCINE
LA English
DT Article
DE Bordetella pertussis; Seroprevalence; Immunity; Pregnancy; Tdap;
   Vaccination
ID MATERNAL TETANUS; IMMUNIZATION; INFANTS; OUTBREAK; PROGRAM; ADOLESCENTS;
   PROTECTION; ENGLAND; ADULTS; CORD
AB Background: Maternal immunization with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) has recently been implemented to prevent infant pertussis. Tdap is still not routinely recommended in Thailand, and there are limited data to support or challenge this strategy.
   Objectives: The primary aim was to determine the seroprevalence of anti-pertussis toxin antibodies (anti-PT IgG) among pregnant Thai women. The secondary aims were to evaluate antibodies response after Tdap vaccination between seronegative and seropositive mothers and to compare the different antibody titers at delivery among seropositive mothers who received Tdap to those who received tetanus-diphtheria vaccine (Td).
   Methods: This randomized clinical trial was conducted during April 2018 to April 2019 at Siriraj Hospital, Bangkok, Thailand. A total of 129 pregnant women were included. Paired blood samples for anti-PT IgG levels were obtained during the first antenatal visit and at delivery. A baseline cut-off value of <5 IU/ml indicated seronegativity. There were 29 exclusions from the original 129 enrollment. All seronegative participants (n = 69) received Tdap, while the seropositive group were randomized 1:1 to receive either Tdap (n = 18) or Td (n = 13) during 27-36 weeks' gestation. The antibody levels from both sera were compared between groups.
   Results: The seroprevalence of maternal anti-PT IgG was 33.3% (43/129). There was no significant difference in the increment of antibody levels after Tdap vaccination between the seronegative and seropositive groups (30.2 vs. 42 IU/ml; p = 0.183). Among seropositive groups, all Tdap recipients had increased antibody titers at delivery, while all Td recipients showed waning of immunity throughout gestation. (42 IU/ml vs. -7.4 IU/ml; p < 0.001).
   Conclusion: Most pregnant Thai women have seronegative against pertussis. Most seropositive mothers had initial low antibody titers and their immunity significantly decreased before delivery. Our findings highlight the need for universal pertussis immunization in pregnancy regardless of individual baseline immunity. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Sompagdee, Nalat; Anuwutnavin, Sanitra; Robkhonburi, Amporn] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Obstet & Gynaecol, 2 Prannok Rd, Bangkok 10700, Thailand.
   [Phongsamart, Wanatpreeya] Mahidol Univ, Siriraj Hosp, Dept Pediat, Div Infect Dis,Fac Med, Bangkok, Thailand.
   [Senawong, Sansnee; Umrod, Pinklow] Mahidol Univ, Siriraj Hosp, Dept Immunol, Fac Med, Bangkok, Thailand.
RP Anuwutnavin, S (reprint author), Mahidol Univ, Siriraj Hosp, Fac Med, Dept Obstet & Gynaecol, 2 Prannok Rd, Bangkok 10700, Thailand.
EM asanitra@hotmail.com
FU Siriraj Research Development Fund [R016135032]
FX This study was supported by a grant from the Siriraj Research
   Development Fund (Managed by Routine to Research: R2R; grant no.
   R016135032).
CR Abu Raya B, 2014, VACCINE, V32, P5787, DOI 10.1016/j.vaccine.2014.08.038
   Amirthalingam G, 2016, CLIN INFECT DIS, V63, pS236, DOI 10.1093/cid/ciw559
   Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   Barkoff AM, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv050
   Beigi R, 2017, OBSTET GYNECOL, V130, pE153, DOI 10.1097/AOG.0000000000002301
   Bisgard KM, 2004, PEDIATR INFECT DIS J, V23, P985, DOI 10.1097/01.inf.0000145263.37198.2b
   Calvert A, 2017, CURR OPIN INFECT DIS, V30, P268, DOI 10.1097/QCO.0000000000000372
   Campbell H, 2018, J MED MICROBIOL, V67, P1426, DOI 10.1099/jmm.0.000829
   Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P73
   Chinthanate S, 2018, SE ASIAN J TROP MED, V49, P447
   Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821
   de Melker HE, 2000, EMERG INFECT DIS, V6, P348, DOI 10.3201/eid0604.000404
   Eberhardt CS, 2017, CLIN INFECT DIS, V64, P1129, DOI 10.1093/cid/cix046
   Eberhardt CS, 2016, CLIN INFECT DIS, V62, P829, DOI 10.1093/cid/ciw027
   Esposito S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01344
   Gonik Bernard, 2005, Infect Dis Obstet Gynecol, V13, P59, DOI 10.1080/10647440500068289
   Griffin JB, 2018, VACCINE, V36, P5173, DOI 10.1016/j.vaccine.2018.07.011
   Guiso N, 2011, EUR J CLIN MICROBIOL, V30, P307, DOI 10.1007/s10096-010-1104-y
   Guris D, 1999, CLIN INFECT DIS, V28, P1230, DOI 10.1086/514776
   Hoang HTT, 2016, VACCINE, V34, P151, DOI 10.1016/j.vaccine.2015.10.098
   Halperin SA, 1999, CLIN INFECT DIS, V28, P1238, DOI 10.1086/514792
   Halperin SA, 2018, CLIN INFECT DIS, V67, P1063, DOI 10.1093/cid/ciy244
   Hashemi SH, 2014, J RES HEALTH SCI, V14, P128
   Healy CM, 2018, JAMA-J AM MED ASSOC, V320, P1464, DOI 10.1001/jama.2018.14298
   Healy CM, 2013, CLIN INFECT DIS, V56, P539, DOI 10.1093/cid/cis923
   Healy CM, 2004, J INFECT DIS, V190, P335, DOI 10.1086/421033
   Izurieta HS, 1996, CLIN INFECT DIS, V22, P503, DOI 10.1093/clinids/22.3.503
   Kirkland KB, 2009, CLIN INFECT DIS, V49, P584, DOI 10.1086/603555
   Lindley MC, 2019, MMWR-MORBID MORTAL W, V68, P885, DOI 10.15585/mmwr.mm6840e1
   Mikelova LK, 2003, J PEDIATR-US, V143, P576, DOI 10.1067/S0022-3476(03)00365-2
   Munoz FM, 2014, JAMA-J AM MED ASSOC, V311, P1760, DOI 10.1001/jama.2014.3633
   Nooitgedagt JE, 2009, CLIN INFECT DIS, V49, P1086, DOI 10.1086/605575
   Pichichero ME, 2005, JAMA-J AM MED ASSOC, V293, P3003, DOI 10.1001/jama.293.24.3003
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   Siriyakorn N, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1357-x
   Skoff TH, 2017, CLIN INFECT DIS, V65, P1977, DOI 10.1093/cid/cix724
   Storsaeter J, 1998, VACCINE, V16, P1907, DOI 10.1016/S0264-410X(98)00227-8
   Van Rie Annelies, 2005, Pediatr Infect Dis J, V24, pS62, DOI 10.1097/01.inf.0000160915.93979.8f
   Wanlapakorn N, 2018, VACCINE, V36, P1453, DOI 10.1016/j.vaccine.2018.01.059
   Wanlapakorn N, 2017, PEERJ, V5, DOI 10.7717/peerj.4043
   Wanlapakorn N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148338
   Wanlapakorn N, 2014, SE ASIAN J TROP MED, V45, P1132
   Xing D, 2009, CLIN VACCINE IMMUNOL, V16, P303, DOI 10.1128/CVI.00372-08
   Zheteyeva YA, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.05.006
NR 44
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2725
EP 2733
DI 10.1016/j.vaccine.2020.01.074
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800012
PM 32070680
DA 2020-05-12
ER

PT J
AU Okenwa, UJ
   Dairo, MD
   Bamgboye, E
   Ajumobi, O
AF Okenwa, Uchechukwu Joel
   Dairo, Magbagbeola David
   Bamgboye, Eniola
   Ajumobi, Olufemi
TI Maternal knowledge and infant uptake of valid hepatitis B vaccine birth
   dose at routine immunization clinics in Enugu State - Nigeria
SO VACCINE
LA English
DT Article
DE Hepatitis B vaccine birth dose; Health facilities; Infant; Mothers;
   Routine immunization; Nigeria
ID TRANSMISSION; PREVENTION; COVERAGE; CHILDREN
AB Background: World Health Organization recommends hepatitis B vaccine birth dose for all infants within 24 hours of birth as the most cost-effective measure to prevent perinatal hepatitis B virus infection (HBV). We assessed and identified the predictors of maternal knowledge and infants' uptake of valid hepatitis B vaccine birth dose (HepB-BD).
   Methods: We conducted a hospital-based cross-sectional survey among 366 mother-infant attendees of routine immunization clinics selected by multi-stage sampling technique in Enugu State, Nigeria. We collected data on socio-demographic characteristics, delivery history, maternal knowledge and infant's receipt of valid HepB-BD with interviewer-administered questionnaire. Maternal knowledge was assessed using nine domain questions. Overall, good knowledge was defined as a score of >= 50%. Only infants who received first hepatitis B dose within 24 hours were considered to have received valid BD. We calculated frequencies, performed Chi square test and logistic regression.
   Results: One hundred and two (29.7%) mothers knew HBV can be transmitted from mother to child; 119 (34.6%) and 156 (45.3%) knew their infant should receive valid HepB-BD and four doses for full immunization of HepB respectively. Overall, 114 (31.1%) mothers had good knowledge of HBV and 88 (26.9%) of 327 who delivered at the health facilities had valid HepB-BD. Predictors of maternal knowledge were attainment of tertiary education (adjusted Odds Ratio (aOR): 2.1, 95%CI: 1.3-3.5) and living in rural areas (aOR: 0.5, 95%CI: 0.3-0.9). Predictors of valid HepB-BD uptake were maternal knowledge (aOR: 2.4, 95%CI: 1.4-4.0) and delivery at facilities offering routine immunization services (aOR: 5.4, 95%CI: 2.5-11.9).
   Conclusion: Knowledge and uptake of valid HepB-BD were low. Health education on benefits of valid HepB-BD was given to mothers after administration of questionnaires. We disseminated findings to the State Ministry of Health and recommended integration of child delivery and immunization services for birth dose vaccines especially valid HepB-BD. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Okenwa, Uchechukwu Joel; Ajumobi, Olufemi] Nigeria Field Epidemiol & Lab Training Program, Abuja, Nigeria.
   [Dairo, Magbagbeola David; Bamgboye, Eniola] Univ Ibadan, Fac Publ Hlth, Dept Epidemiol & Med Stat, Ibadan, Nigeria.
   [Ajumobi, Olufemi] Univ Nevada, Sch Community Hlth Sci, Reno, NV 89557 USA.
   [Ajumobi, Olufemi] Fed Minist Hlth, Abuja, Nigeria.
   [Okenwa, Uchechukwu Joel] Enugu State Minist Hlth, Enugu, Nigeria.
RP Okenwa, UJ (reprint author), Nigeria Field Epidemiol & Lab Training Program, Abuja, Nigeria.
EM okexta@yahoo.com
FU United States Centers for Disease Control and Prevention through African
   Field Epidemiology Network to the Nigeria Field Epidemiology and
   Laboratory Training Programme (NFELTP)United States Department of Health
   & Human ServicesCenters for Disease Control & Prevention - USA
   [NU2GGH001876]
FX This study was supported by the United States Centers for Disease
   Control and Prevention through African Field Epidemiology Network to the
   Nigeria Field Epidemiology and Laboratory Training Programme (NFELTP)
   [Cooperative Agreement Number NU2GGH001876]. Its contents are solely the
   responsibility of the authors and do not necessarily represent the
   official views of the United States Centres for Disease Control and
   Prevention or the Department of Health and Human Services.
CR ADEDIRE EB, 2016, BMC PUBLIC HEALTH, V16, P1, DOI DOI 10.1186/S12913-015-1014
   Adeyemi AB, 2013, J OBSTET GYNAECOL, V33, P155, DOI 10.3109/01443615.2012.711389
   Adeyemi AS, 2014, OPEN J OBSTET GYNECO, P621
   Al Awaidy ST, 2013, AM J TROP MED HYG, V89, P811, DOI 10.4269/ajtmh.13-0333
   Allison RD, 2017, VACCINE, V35, P4094, DOI 10.1016/j.vaccine.2017.06.051
   Andersson MI, 2015, LANCET GLOB HEALTH, V3, pE358, DOI 10.1016/S2214-109X(15)00056-X
   [Anonymous], 2009, Wkly Epidemiol Rec, V84, P405
   Breakwell Lucy, 2017, Pan Afr Med J, V27, P17, DOI 10.11604/pamj.supp.2017.27.3.11981
   Edomwonyi P, 2015, ARC J NURS HEALTHC, V1, P29
   Frambo AAB, 2014, PREVALENCE HBSAG KNO
   Franco E, 2012, WORLD J HEPATOL, V4, P74, DOI 10.4254/wjh.v4.i3.74
   Gidado S, 2010, DETERMINANTS ROUTINE, V18, P1, DOI [10.11694/pamjsupp.2014.18.1.4149., DOI 10.11694/PAMJSUPP.2014.18.1.4149]
   Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Miyahara R, 2016, VACCINE, V34, P3335, DOI 10.1016/j.vaccine.2016.05.017
   Nankabirwa V, 2010, MATERNAL ED IS ASS V
   National Primary Health Care Development Agency and National Bureau of Statistics, 2016, NIG NAT IMM COV SURV, V4, P1
   National Programme on Immunization (NPI), 2004, BAS GUID ROUT IMM SE
   Nd U, 2015, NIGERIAN J PAEDIAT, V42, P199
   NDHS, 2014, NATL POPUL COMM FED, P1
   Odusanya OO, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-381
   Okenwa UJ, 2019, VACCINE, V37, P6894, DOI 10.1016/j.vaccine.2019.09.056
   Okwaraji YB, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-476
   Sadoh AE, 2013, TANZAN J HLTH RES, DOI DOI 10.4314/THRHV15I4.6
   Sadoh AE, 2009, J HEALTH POPUL NUTR, V27, P391
   Wang WH, 2017, DIG J NANOMATER BIOS, V12, P1
   *WHO, 2006, PREV CHEM HUM HELM C, P1
   WHO Publication, 2010, Vaccine, V28, P589, DOI 10.1016/j.vaccine.2009.10.110
   World Health Organization, 2017, GLOB HEP REP 2017
   Xeuatvongsa A, 2013, MMWR-MORBID MORTAL W, V62, P587
   Zhang L, 2014, HUM VACC IMMUNOTHER, V10, P2755, DOI 10.4161/hv.29648
   Zhou YQ, 2009, AM J TROP MED HYG, V81, P869, DOI 10.4269/ajtmh.2009.09-0238
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2734
EP 2740
DI 10.1016/j.vaccine.2020.01.044
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800013
PM 32007294
DA 2020-05-12
ER

PT J
AU Esparza, J
AF Esparza, Jose
TI Three different paths to introduce the smallpox vaccine in early 19th
   century United States
SO VACCINE
LA English
DT Article
DE Inoculation; Jenner; Mexico; Peru; Smallpox; United States; Vaccination;
   Waterhouse
ID INOCULATION; EXPEDITION; JENNER
AB The ancient technique of variolation (inoculation of the smallpox) which was introduced in the United States in 1721 was replaced by vaccination (inoculation of the cowpox) soon after the procedure was published by Edward Jenner in 1798. Benjamin Waterhouse is recognized as the introducer of smallpox vaccination in the United States having conducted the first vaccination in Boston on 8 July 1800, although other American physicians also played an important role in extending vaccination in the East Coast of the United States. A different route of introduction brought the smallpox vaccine from Mexico to New Mexico (March 1805) and Texas (April 1806) which at that time where part of the Viceroyalty of New Spain. The vaccine was brought to California in 1817 by Russian merchants who obtained it in Peru, where the vaccine had arrived in 1806 with the Spanish Philanthropic Expedition of the Vaccine. It took almost 150 years of vaccination efforts before the last natural outbreak of smallpox occurred in the United States in 1949. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Esparza, Jose] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA.
RP Esparza, J (reprint author), 11990 Market St,212, Reston, VA 20190 USA.
EM Jose.esparza5@live.com
OI Esparza, Jose/0000-0002-2305-6264
CR [Anonymous], 1899, MARYLAND MED J, V42, P252
   Artenstein Andrew W, 2005, Mil Med, V170, P3
   Behbehani AM, 1988, SMALLPOX STORY
   Bell WJ, 1940, ANN MED HIST, V2, P500
   BLAKE JB, 1987, REV INFECT DIS, V9, P1044
   Blake JB, 1957, BENJAMIN WATERHOUSE
   Boylston A, 2008, J ROY SOC MED, V101, P476, DOI 10.1258/jrsm.2008.08k008
   Boylston Z., 1726, HIST ACCOUNT SMALLPO
   Brooke HC, 1935, B HIST MED, P83
   Carroll DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023086
   Cash P., 2006, LIFE MED PUBLIC HLTH
   Cook SF, 1939, B HIST MED, V6-7, P153
   Copland J, 1859, DICT PRACTICAL MED
   Coxe JR, 1802, PRACTICAL OBSERVATIO
   Cramaussel Chantal, 2008, Relac. Estud. hist. soc., V29, P101
   Currie DP, 1998, GREEN BAG, V1, P243
   Damaso CR, 2018, LANCET INFECT DIS, V18, pE55, DOI 10.1016/S1473-3099(17)30445-0
   DAVIES JW, 1970, CAN MED ASSOC J, V102, P957
   Dinc G, 2007, VACCINE, V25, P4261, DOI 10.1016/j.vaccine.2007.02.076
   Torrijos JLD, 2019, VACCINE, V37, P4651, DOI 10.1016/j.vaccine.2019.05.088
   Esparza J, 2020, VACCINE, V38, P1450, DOI 10.1016/j.vaccine.2019.11.077
   Esparza J, 2017, VACCINE, V35, P7222, DOI 10.1016/j.vaccine.2017.11.003
   Esparza JA, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007082
   FARMER L, 1958, Bull N Y Acad Med, V34, P599
   FENNER F, 1988, SMALLPOX ITS ERADICA
   Harris H., 1932, CALIFORNIA MED HIST
   HOPKINS DR, 1977, AM J TROP MED HYG, V26, P1060, DOI 10.4269/ajtmh.1977.26.1060
   Hosack D, 1814, AM MED PHILOS REGIES
   IRONS JV, 1953, AM J PUBLIC HEALTH, V43, P25, DOI 10.2105/AJPH.43.1.25
   Jenner E, 1798, INQUIRY CAUSES EFFEC
   Kass Amalie M. Kass, 2012, MASSACHUSETTS HIST R, V14, P151
   Lanzarotta T, 2018, AM J PUBLIC HEALTH, V108, P741, DOI 10.2105/AJPH.2018.304348
   Leavell B S, 1977, Trans Am Clin Climatol Assoc, V88, P119
   Mark C, 2009, B HIST MED, V83, P63, DOI 10.1353/bhm.0.0173
   Martin HA, 1878, ANIMAL VACCINATION
   Martin HA, 1881, N CAROLINA M J, V7, P1
   McIntyre JWR, 1999, CAN MED ASSOC J, V161, P1543
   Meyer MC, 1991, ESTUD HIST NOVOHISP, V1, P135
   MILES W D, 1956, Bull Hist Med, V30, P469
   Miller G, 1983, LETT E JENNER OTHER
   Moniz AB, 2018, EMPIRE HUMANITY AM R
   Nixon Pl, 1946, MED HIST EARLY TEXAS
   Ramirez Marin SM, 2002, SALUD IMPERIO REAL E
   Rhodes NH, 1803, PHILOS MAG, V16, P152
   Seaman V., 1816, DISCOURSE VACCINATIO
   Toner JM, 1865, T MED SOC STATE  JUN, P1
   Tuells J, 2015, GAC MED MEX, V151, P416
   VALLE RK, 1973, CALIF MED, V119, P73
   Waring JI, 1964, HIST MED S CAROLINA
   Waterhouse B., 1800, PROSPECT EXTERMINATI, P1800
   Waterhouse B., 1802, PROSPECT EXTERMINATI
   Weiss RA, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0378
   Winslow Ola Elizabeth, 1974, DESTROYING ANGEL CON
NR 53
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 10
PY 2020
VL 38
IS 12
BP 2741
EP 2745
DI 10.1016/j.vaccine.2020.01.077
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA KT2WH
UT WOS:000518875800014
PM 32057569
DA 2020-05-12
ER

PT J
AU Albrand, P
   Julcour, C
   Gerbaud, V
   Billet, AM
AF Albrand, Pierre
   Julcour, Carine
   Gerbaud, Vincent
   Billet, Anne-Marie
TI Accurate hydrogenated vegetable oil viscosity predictions for monolith
   reactor simulations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Edible oil; Viscosity; Monolith reactor; Three-phase catalytic reactor;
   Taylor flow; Hydrogenation
ID LIQUID MASS-TRANSFER; PHYSICAL-PROPERTIES; HEAT-TRANSFER; 2-PHASE FLOW;
   FATTY-ACIDS; EDIBLE OIL; AIR-WATER; TRIGLYCERIDES; PALM; COEFFICIENTS
AB The viscosity of edible oils was measured before and after hydrogenation to assess a new model for predicting the viscosity of partially hydrogenated oils with given saturation degree and temperature. This contribution group model is based on a semi-predictive approach, and can be used to estimate viscosity changes due to hydrogenation. It was experimentally validated using three different oils, and the results show an overall relative average deviation of 3.7%. The model was implemented in a transient CFD simulation of a three-phase monolith catalytic reactor for edible oil hydrogenation. Hydrogenation in Taylor flow was described with the unit cell approach. The influence of viscosity changes on the reaction yield and selectivity were investigated in relation with the coupling between hydrodynamics, mass transfer, and reaction kinetics. This effect proved to be significant in the former case; the reactor length was increased by a factor 1.5, yielding approximately 30% conversion. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Albrand, Pierre; Julcour, Carine; Gerbaud, Vincent; Billet, Anne-Marie] Univ Toulouse, CNRS, INPT, UPS,Lab Genie Chim, Toulouse, France.
RP Billet, AM (reprint author), Univ Toulouse, CNRS, INPT, UPS,Lab Genie Chim, Toulouse, France.
EM annemarie.billet@toulouse-inp.fr
RI GERBAUD, Vincent/Q-6864-2019
OI GERBAUD, Vincent/0000-0003-2738-7922
CR Abiev RS, 2011, THEOR FOUND CHEM EN+, V45, P156, DOI 10.1134/S0040579511020011
   ANDERSSON B, 1982, CHEM ENG J BIOCH ENG, V24, P201, DOI 10.1016/0300-9467(82)80035-X
   ANDERSSON K, 1974, J AM OIL CHEM SOC, V51, P171, DOI 10.1007/BF02639732
   Aussillous P, 2000, PHYS FLUIDS, V12, P2367, DOI 10.1063/1.1289396
   Azian MN, 2001, J AM OIL CHEM SOC, V78, P1001, DOI 10.1007/s11746-001-0378-9
   Belkacemi K, 2006, TOP CATAL, V37, P113, DOI 10.1007/s11244-006-0012-y
   Belkacemi K., 2006, INT J CHEM REACTOR E, V3
   Belkacemi K., 2007, INT J CHEM REACT ENG, V5, P1, DOI DOI 10.2202/1542-6580.1528
   Boger T, 2004, IND ENG CHEM RES, V43, P2337, DOI 10.1021/ie030809v
   BOYES AP, 1995, J CHEM TECHNOL BIOT, V64, P55, DOI 10.1002/jctb.280640110
   BRETHERTON FP, 1961, J FLUID MECH, V10, P166, DOI 10.1017/S0022112061000160
   Butler C, 2016, CHEM ENG RES DES, V115, P292, DOI 10.1016/j.cherd.2016.09.001
   Carlson KM, 2012, P NATL ACAD SCI USA, V109, P7559, DOI 10.1073/pnas.1200452109
   Ceriani R, 2004, FLUID PHASE EQUILIBR, V215, P227, DOI 10.1016/j.fluid.2003.08.011
   Ceriani R, 2007, J CHEM ENG DATA, V52, P965, DOI 10.1021/je600552b
   Coupland JN, 1997, J AM OIL CHEM SOC, V74, P1559, DOI 10.1007/s11746-997-0077-1
   Diaz-Tovar CA, 2011, FLUID PHASE EQUILIBR, V302, P284, DOI 10.1016/j.fluid.2010.09.011
   DUTT NVK, 1989, J AM OIL CHEM SOC, V66, P701, DOI 10.1007/BF02669956
   EITEMAN MA, 1994, J AM OIL CHEM SOC, V71, P1261, DOI 10.1007/BF02540548
   Fasina OO, 2006, J AM OIL CHEM SOC, V83, P899, DOI 10.1007/s11746-006-5044-8
   Fernandez MB, 2007, INT J CHEM REACT ENG, V5
   Fillion B, 2000, IND ENG CHEM RES, V39, P2157, DOI 10.1021/ie990882e
   Fillion B, 2002, IND ENG CHEM RES, V41, P697, DOI 10.1021/ie0104013
   Fisher CH, 1998, J AM OIL CHEM SOC, V75, P1229, DOI 10.1007/s11746-998-0167-8
   Fukagata K, 2007, INT J HEAT FLUID FL, V28, P72, DOI 10.1016/j.ijheatfluidflow.2006.04.010
   GANGULI KL, 1978, CHEM ENG J BIOCH ENG, V16, P193
   GUNSTONE FD, 2002, VEGETABLE OILS FOOD
   Gupta A, 2007, INDIAN J CHEM TECHN, V14, P642
   Gupta R., 2010, J COMPUT MULTIPHASE, V2, P1, DOI DOI 10.1260/1757-482X.2.1.1
   Gupta R, 2009, CHEM ENG SCI, V64, P2941, DOI 10.1016/j.ces.2009.03.018
   GUT G, 1979, CHEM ENG SCI, V34, P1051, DOI 10.1016/0009-2509(79)80005-6
   Haase S, 2016, CHEM ENG RES DES, V113, P304, DOI 10.1016/j.cherd.2016.06.017
   Hasenhuettl G.L., 2000, FATS AND FATTY OILS, DOI DOI 10.1002/0471238961.0601201908011905.A01.PUB2
   HATZIANTONIOU V, 1982, IND ENG CHEM FUND, V21, P451, DOI 10.1021/i100008a024
   Haynes WM, 2014, CRC HDB CHEM PHYS
   HOOPER L, 2015, COCHRANE DATABASE SY
   Joglekar R., 2013, J INDIAN I SCI, V13, P119
   Kim J, 2010, FOOD CHEM, V118, P398, DOI 10.1016/j.foodchem.2009.05.011
   Koh LP, 2008, CONSERV LETT, V1, P60, DOI 10.1111/j.1755-263X.2008.00011.x
   Martinez Francisco Martin, 2017, THESIS
   Martinez FLD, 2016, CATAL TODAY, V273, P121, DOI 10.1016/j.cattod.2016.04.009
   MILLER KS, 1994, J FOOD PROCESS PRES, V18, P461, DOI 10.1111/j.1745-4549.1994.tb00268.x
   Mishima K, 1996, INT J MULTIPHAS FLOW, V22, P703, DOI 10.1016/0301-9322(96)00010-9
   MORRISON WH, 1978, J AM OIL CHEM SOC, V55, P451, DOI 10.1007/BF02668480
   Mozaffarian D, 2009, EUR J CLIN NUTR, V63, pS5, DOI 10.1038/sj.ejcn.1602973
   NIELSEN K, 1960, J AM OIL CHEM SOC, V37, P271, DOI 10.1007/BF02631764
   Nirmal GM, 2019, SOFT MATTER, V15, P2746, DOI 10.1039/c8sm01144c
   NOUREDDINI H, 1992, J AM OIL CHEM SOC, V69, P1189, DOI 10.1007/BF02637678
   Rabelo J, 2000, J AM OIL CHEM SOC, V77, P1255, DOI 10.1007/s11746-000-0197-z
   RAY JD, 1985, J AM OIL CHEM SOC, V62, P1218, DOI 10.1007/BF02541831
   RHINES PB, 1983, J FLUID MECH, V133, P133, DOI 10.1017/S0022112083001822
   Savchenko V. I., 1999, PLATIN MET REV, V43, P74
   SCHMIDT HJ, 1970, J AM OIL CHEM SOC, V47, P134, DOI 10.1007/BF02640403
   Shao N, 2011, HEAT TRANSFER ENG, V32, P1117, DOI 10.1080/01457632.2011.562460
   Silva M. G. da, 1995, Journal of Food Processing and Preservation, V19, P259, DOI 10.1111/j.1745-4549.1995.tb00293.x
   SNYDER JM, 1978, J AM OIL CHEM SOC, V55, P383, DOI 10.1007/BF02911896
   Thomas A., 2000, FATS AND FATTY OILS
   TIMMS RE, 1985, J AM OIL CHEM SOC, V62, P241, DOI 10.1007/BF02541385
   Topallar H, 1995, J AM OIL CHEM SOC, V72, P1519, DOI 10.1007/BF02577846
   Valeri D, 1997, J AM OIL CHEM SOC, V74, P1221, DOI 10.1007/s11746-997-0048-6
   van Baten JM, 2004, CHEM ENG SCI, V59, P2535, DOI 10.1016/j.ces.2004.03.010
   Veldsink JW, 1997, CATAL REV, V39, P253, DOI 10.1080/01614949709353778
   Vibrans F.C., 1935, OIL SOAP, V12, P14
   WILKE CR, 1955, AICHE J, V1, P264, DOI 10.1002/aic.690010222
   Wolff J.P., 2003, OILS FATS MANUAL
   Yang CY, 2001, INT J MULTIPHAS FLOW, V27, P1163, DOI 10.1016/S0301-9322(00)00070-7
   Yang L, 2017, CHEM ENG SCI, V169, P106, DOI 10.1016/j.ces.2016.12.003
   YOUNG W, 1989, PHYS FLUIDS A-FLUID, V1, P462, DOI 10.1063/1.857415
NR 68
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115388
DI 10.1016/j.ces.2019.115388
PG 18
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100027
DA 2020-05-12
ER

PT J
AU Babakhani, SM
   Ho-Van, S
   Bouillot, B
   Douzet, J
   Herri, JM
AF Babakhani, Saheb Maghsoodloo
   Ho-Van, Son
   Bouillot, Baptiste
   Douzet, Jerome
   Herri, Jean-Michel
TI Phase equilibrium measurements and modelling of mixed cyclopentane and
   carbon dioxide hydrates in presence of salts
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Clathrate hydrates; Crystallization; Carbon capture; Desalination;
   Thermodynamics
ID GAS HYDRATE; CO2 HYDRATE; METHANE HYDRATE; POTENTIAL APPLICATION;
   DESALINATION; SEAWATER; WATER; CRYSTALLIZATION; DISSOCIATION;
   ELECTROLYTE
AB Interest of Clathrate hydrates for industrial applications is rising. While numerous studies can be found on carbon capture or desalination, this effort investigates thermodynamics of the combined process using cyclopentane (CP) as second guest molecule.
   This document provides numerous equilibrium data of mixed CP/CO2 hydrates in presence of salt (NaCl, KCl) under differents concentrations. Final dissociation points are collected, as well as intermediate dissociation points in presence of hydrates. While the first provide equilibrium data, the others are not at equilibrium. Indeed, Results show that, in presence of salts, several crystallization events occur in the system. Consequently, multiple hydrate structures could be formed in the bulk, such as pure CO2 hydrates and mixed CO2/CP hydrates.
   Finally, van der Waals and Platteeuw approach has been used and furnishes results within 0.4 K uncertainty compared to this work and within 0.5 K compared to literature. Besides, thermodynamic consistency of data has been evaluated. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Babakhani, Saheb Maghsoodloo; Ho-Van, Son; Bouillot, Baptiste; Douzet, Jerome; Herri, Jean-Michel] Univ Lyon, CNRS, UMR LGF 5307, Mines St Etienne,Ctr SPIN, F-42023 St Etienne, France.
   [Ho-Van, Son] Hanoi Univ Min & Geol, Oil Refinery & Petrochem Dept, Hanoi 100000, Vietnam.
RP Bouillot, B (reprint author), Univ Lyon, CNRS, UMR LGF 5307, Mines St Etienne,Ctr SPIN, F-42023 St Etienne, France.
EM bouillot@emse.fr
OI Van Son, HO/0000-0001-7276-0517
FU French National Research Agency (ANR)French National Research Agency
   (ANR) [ANR-18-CE05-0006]
FX The authors would like to thank French National Research Agency (ANR)
   for financial support. Especially, this work is part of INNOHYD French
   ANR-18-CE05-0006 project.; Also, the authors would like to heartily
   thank Fabien Chauvy for his technical help for all the experiments that
   are being conducted in the hydrate team at Mines Saint-Etienne.
CR Babakhani SM, 2015, J NAT GAS SCI ENG, V26, P1, DOI 10.1016/j.jngse.2015.05.026
   Babu P, 2014, CHEM ENG SCI, V117, P342, DOI 10.1016/j.ces.2014.06.044
   BARDUHN AJ, 1962, AICHE J, V8, P176, DOI 10.1002/aic.690080210
   Bradshaw R., 2008, DESALINATION UTILIZI
   Cai L., 2016, THESIS
   Cha JH, 2013, ACS SUSTAIN CHEM ENG, V1, P1218, DOI 10.1021/sc400160u
   COLTEN SL, 1972, DESALINATION, V11, P31, DOI 10.1016/S0011-9164(00)84047-3
   Corak D, 2011, DESALINATION, V278, P268, DOI 10.1016/j.desal.2011.05.035
   Deaton Jr W.M., 1946, GAS HYDRATES THEIR R
   DHOLABHAI PD, 1993, J CHEM ENG DATA, V38, P650, DOI 10.1021/je00012a045
   Duc NH, 2007, ENERG CONVERS MANAGE, V48, P1313, DOI 10.1016/j.enconman.2006.09.024
   Englezos P, 1994, DEV CHEM ENG MINERAL, V2, P3
   Fan SS, 2000, CHEM ENG J, V78, P173, DOI 10.1016/S1385-8947(00)00157-1
   Galfre A., 2014, THESIS
   Galfre A, 2014, J CHEM ENG DATA, V59, P592, DOI 10.1021/je4002587
   Ganji H, 2013, J PETROL SCI ENG, V112, P32, DOI 10.1016/j.petrol.2013.11.026
   Han S, 2017, DESALINATION, V404, P132, DOI 10.1016/j.desal.2016.11.016
   Han S, 2014, DESALINATION, V354, P17, DOI 10.1016/j.desal.2014.09.023
   Hashimoto H, 2017, ENERGY, V129, P292, DOI 10.1016/j.energy.2017.04.074
   He T., 2019, ENERGY TECHNOL-GER, DOI [10.1002/ente.201900212, DOI 10.1002/ENTE.201900212]
   He TB, 2018, APPL ENERG, V222, P13, DOI 10.1016/j.apenergy.2018.04.006
   Herri JM, 2011, FLUID PHASE EQUILIBR, V301, P171, DOI 10.1016/j.fluid.2010.09.041
   Herslund PJ, 2014, FLUID PHASE EQUILIBR, V381, P20, DOI 10.1016/j.fluid.2014.08.015
   Herslund PJ, 2013, INT J GREENH GAS CON, V17, P397, DOI 10.1016/j.ijggc.2013.05.022
   Ho-Van S, 2019, J ENVIRON CHEM ENG, V7, DOI 10.1016/j.jece.2019.103359
   Ho-Van S, 2018, AICHE J, V64, P2207, DOI 10.1002/aic.16067
   Ho-Van S, 2019, CHEM ENG TECHNOL, V42, P1481, DOI 10.1002/ceat.201800746
   Ho-Van S, 2018, IND ENG CHEM RES, V57, P14774, DOI 10.1021/acs.iecr.8b02796
   Hong S, 2019, CHEM ENG J, V363, P99, DOI 10.1016/j.cej.2019.01.108
   Karamoddin M, 2014, DESALIN WATER TREAT, V52, P2450, DOI 10.1080/19443994.2013.798840
   KUBOTA H, 1984, J CHEM ENG JPN, V17, P423, DOI 10.1252/jcej.17.423
   Kumar A, 2019, APPL ENERG, V235, P21, DOI 10.1016/j.apenergy.2018.10.085
   KVENVOLDEN KA, 1988, CHEM GEOL, V71, P41, DOI 10.1016/0009-2541(88)90104-0
   Kwaterski M, 2014, FLUID PHASE EQUILIBR, V371, P22, DOI 10.1016/j.fluid.2014.02.032
   Le Quang D, 2016, FLUID PHASE EQUILIBR, V413, P10, DOI 10.1016/j.fluid.2015.10.022
   Lee H, 2016, DESALIN WATER TREAT, V57, P9009, DOI 10.1080/19443994.2015.1049405
   Lee JW, 2002, KOREAN J CHEM ENG, V19, P673, DOI 10.1007/BF02699316
   Li F, 2018, DESALINATION, V445, P197, DOI 10.1016/j.desal.2018.08.011
   Ling Z, 2020, SEP PURIF TECHNOL, V231, DOI 10.1016/j.seppur.2019.115921
   Liu WG, 2015, J NAT GAS SCI ENG, V24, P357, DOI 10.1016/j.jngse.2015.03.030
   Lv YN, 2017, DESALINATION, V413, P217, DOI 10.1016/j.desal.2017.03.025
   Makogon YF, 2010, J NAT GAS SCI ENG, V2, P49, DOI 10.1016/j.jngse.2009.12.004
   Matsumoto Y, 2014, FLUID PHASE EQUILIBR, V362, P379, DOI 10.1016/j.fluid.2013.10.057
   Max M., 2006, Patent, Patent No. 6991722B2
   MCAULIFFE C, 1966, J PHYS CHEM-US, V70, P1267, DOI 10.1021/j100876a049
   McCormack R., 1995, CLATHRATE DESALINATI
   McCormack R.A., 1998, WATER TREAT TECHNOL
   Mottet B., 2017, METHOD TREATING AQUE
   Najibi H, 2015, J NAT GAS SCI ENG, V27, P1771, DOI 10.1016/j.jngse.2015.11.002
   OHGAKI K, 1993, J CHEM ENG JPN, V26, P558, DOI 10.1252/jcej.26.558
   Oya S, 2017, INT J GREENH GAS CON, V63, P386, DOI 10.1016/j.ijggc.2017.06.007
   PARRISH WR, 1972, IND ENG CHEM PROC DD, V11, P26, DOI 10.1021/i260041a006
   Prah B, 2018, APPL THERM ENG, V128, P653, DOI 10.1016/j.applthermaleng.2017.09.053
   Sa JH, 2018, FLUID PHASE EQUILIBR, V473, P294, DOI 10.1016/j.fluid.2018.06.012
   Sloan E.D., 2007, CLATHRATE HYDRATES N
   Sloan ED, 2011, NATURAL GAS HYDRATES IN FLOW ASSURANCE, P1
   Subramani A, 2015, WATER RES, V75, P164, DOI 10.1016/j.watres.2015.02.032
   Sugi J., 1967, DESALINATION, V3, P27, DOI [10.1016/s0011-9164(00)84021-7, DOI 10.1016/S0011-9164(00)84021-7, https://doi.org/10.1016/S0011-9164, (00)84021-7.]
   Sun SC, 2017, J CHEM THERMODYN, V107, P141, DOI 10.1016/j.jct.2016.12.026
   Takeuchi F, 2009, INT J THERMOPHYS, V30, P1838, DOI 10.1007/s10765-009-0661-8
   TEE LS, 1966, IND ENG CHEM FUND, V5, P363, DOI 10.1021/i160019a012
   Tomita S, 2015, APPL ENERG, V146, P104, DOI 10.1016/j.apenergy.2015.01.088
   VANDERWAALS JH, 1959, ADV CHEM PHYS, V2, P1
   Wang M, 2016, J CHEM ENG DATA, V61, P3250, DOI 10.1021/acs.jced.6b00333
   Xu HF, 2018, J CHEM ENG DATA, V63, P1081, DOI 10.1021/acs.jced.7b00815
   Zhang Y, 2017, J CHEM ENG DATA, V62, P2461, DOI 10.1021/acs.jced.7b00404
   Zheng JN, 2017, J CHEM THERMODYN, V104, P9, DOI 10.1016/j.jct.2016.09.006
NR 67
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115442
DI 10.1016/j.ces.2019.115442
PG 12
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100026
DA 2020-05-12
ER

PT J
AU Centineo, A
   Brandani, S
AF Centineo, Alessio
   Brandani, Stefano
TI Measurement of water vapor adsorption isotherms in mesoporous materials
   using the zero length column technique
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Water adsorption; Hysteresis loop; Scanning curves; Zero length column;
   Equilibrium
ID ZLC DESORPTION CURVES; SCANNING CURVES; CAPILLARY CONDENSATION;
   HYSTERESIS LOOP; 2 CAVITIES; EQUILIBRIUM; DYNAMICS; CARBONS; ARGON;
   DIFFUSION
AB Measurement of water adsorption isotherms is important for industrial applications and for the characterization of nanoporous materials. The zero-length column technique is used for the first time to measure the adsorption-desorption isotherm of water on a mesoporous adsorbent, SBA-15, up to 90% relative humidity at 298 K. The technique showed two key advantages; (a) The experimental flexibility for the measurement of continuous adsorption-desorption isotherms characterized by complex shapes and hysteresis loops; (b) The possibility to measure a complete set of adsorption-desorption isotherms and scanning curves in few days compared to several weeks needed with traditional gravimetric techniques. The adsorption isotherm measured was compared and validated against isotherms measured on a commercial gravimetric system designed for water vapor adsorption. For the system considered, the adsorption and desorption branches are very steep, and the zero-length column technique is shown to allow setting easily the starting point of the scanning curves. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Centineo, Alessio; Brandani, Stefano] Univ Edinburgh, Sch Engn, Inst Mat & Proc, Edinburgh EH9 3FB, Midlothian, Scotland.
RP Brandani, S (reprint author), Univ Edinburgh, Sch Engn, Inst Mat & Proc, Edinburgh EH9 3FB, Midlothian, Scotland.
EM s.brandani@ed.ac.uk
FU University of Edinburgh; PSE Ltd; Energy Technologies Partnership
FX One of the authors (A.C.) acknowledges the support received from The
   University of Edinburgh, PSE Ltd and the Energy Technologies Partnership
   who funded his PhD studentship.
CR Ahn H, 2004, CHEM ENG SCI, V59, P2727, DOI 10.1016/j.ces.2004.04.011
   Ahn H, 2003, AICHE J, V49, P1601, DOI 10.1002/aic.690490623
   ARIS R, 1991, CHEM ENG SCI, V46, P1535, DOI 10.1016/0009-2509(91)87003-U
   BAKER FS, 1976, J COLLOID INTERF SCI, V55, P605, DOI 10.1016/0021-9797(76)90071-0
   Brandani F, 2003, IND ENG CHEM RES, V42, P1451, DOI 10.1021/ie020572n
   Brandani F, 2003, IND ENG CHEM RES, V42, P1462, DOI 10.1021/ie020573f
   Brandani S, 2005, ADSORPTION, V11, P231, DOI 10.1007/s10450-005-5929-0
   Brandani S, 1996, ADSORPTION, V2, P133, DOI 10.1007/BF00127043
   Brandani S, 1996, CHEM ENG SCI, V51, P3283, DOI 10.1016/0009-2509(95)00399-1
   Brandani S, 1996, IND ENG CHEM RES, V35, P315, DOI 10.1021/ie950287m
   Brandani S, 1998, CHEM ENG SCI, V53, P2791, DOI 10.1016/S0009-2509(98)00075-X
   Brandani S, 2000, CHEM ENG SCI, V55, P1205, DOI 10.1016/S0009-2509(99)00411-X
   Brandani S, 2016, CHEM ENG TECHNOL, V39, P1194, DOI 10.1002/ceat.201500634
   Canivet J, 2014, CHEM SOC REV, V43, P5594, DOI 10.1039/c4cs00078a
   Centineo A, 2019, MICROPOR MESOPOR MAT, V282, P53, DOI 10.1016/j.micromeso.2019.03.018
   Chiang WS, 2016, J PHYS CHEM C, V120, P4354, DOI 10.1021/acs.jpcc.5b10688
   Chmelik C, 2016, MICROPOR MESOPOR MAT, V225, P128, DOI 10.1016/j.micromeso.2015.11.051
   Cordero S, 2002, APPL SURF SCI, V196, P224, DOI 10.1016/S0169-4332(02)00061-2
   Cychosz KA, 2017, CHEM SOC REV, V46, P389, DOI 10.1039/c6cs00391e
   Duncan WL, 2002, CHEM ENG SCI, V57, P2641, DOI 10.1016/S0009-2509(02)00161-6
   EIC M, 1988, ZEOLITES, V8, P40, DOI 10.1016/S0144-2449(88)80028-9
   Friedrich D, 2015, CHEM ENG SCI, V126, P616, DOI 10.1016/j.ces.2014.12.062
   Glover TG, 2008, LANGMUIR, V24, P13406, DOI 10.1021/la802222r
   Hefti M, 2015, IND ENG CHEM RES, V54, P12165, DOI 10.1021/acs.iecr.5b03445
   Karger J., 2012, DIFFUSION NANOPOROUS, DOI DOI 10.1002/9783527651276
   Klomkliang N, 2015, J PHYS CHEM C, V119, P9355, DOI 10.1021/acs.jpcc.5b01184
   Klomkliang N, 2014, LANGMUIR, V30, P12879, DOI 10.1021/la5035992
   Lin TF, 1996, J ENVIRON ENG-ASCE, V122, P169, DOI 10.1061/(ASCE)0733-9372(1996)122:3(169)
   Malek A, 1997, CHEM ENG SCI, V52, P443, DOI 10.1016/S0009-2509(96)00417-4
   Mangano E, 2013, CHEM-ING-TECH, V85, P1714, DOI 10.1002/cite.201300083
   Monson PA, 2012, MICROPOR MESOPOR MAT, V160, P47, DOI 10.1016/j.micromeso.2012.04.043
   Morishige K, 2017, J PHYS CHEM C, V121, P5099, DOI 10.1021/acs.jpcc.6b12566
   NAONO H, 1980, J COLLOID INTERF SCI, V76, P74, DOI 10.1016/0021-9797(80)90272-6
   Nguyen VT, 2014, CARBON, V67, P72, DOI 10.1016/j.carbon.2013.09.057
   Qiu LQ, 2019, FOOD RES INT, V116, P90, DOI 10.1016/j.foodres.2018.12.055
   Rajniak P., 1993, DESORPTION HYSTERESI, V39
   Ruthven D.M., 1984, PRINCIPLES ADSORPTIO
   Sarkisov L, 2017, CARBON, V118, P127, DOI 10.1016/j.carbon.2017.03.044
   Thommes M, 2011, ADSORPTION, V17, P653, DOI 10.1007/s10450-011-9360-4
   Thommes M, 2015, PURE APPL CHEM, V87, P1051, DOI 10.1515/pac-2014-1117
   Thommes M, 2013, LANGMUIR, V29, P14893, DOI 10.1021/la402832b
   Thommes M, 2012, NOVEL CARBON ADSORBENTS, P107, DOI 10.1016/B978-0-08-097744-7.00004-1
   Tompsett GA, 2005, LANGMUIR, V21, P8214, DOI 10.1021/la050068y
   Velasco LF, 2016, CARBON, V96, P753, DOI 10.1016/j.carbon.2015.10.017
   Wang HD, 2011, ADSORPTION, V17, P687, DOI 10.1007/s10450-011-9364-0
   Wang R, 2014, ADSORPTION REFRIGERATION TECHNOLOGY: THEORY AND APPLICATION, P1, DOI 10.1002/9781118197448
   Waterman KC, 2010, J PHARM SCI-US, V99, P4437, DOI 10.1002/jps.22161
   Young J. P., 2007, J APPL CHEM-USSR, V17, P241, DOI [10.1002/jctb.5010170901, DOI 10.1002/JCTB.5010170901]
   Zeng YH, 2016, COLLOID SURFACE A, V496, P52, DOI 10.1016/j.colsurfa.2015.08.023
NR 49
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115417
DI 10.1016/j.ces.2019.115417
PG 10
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100019
DA 2020-05-12
ER

PT J
AU Chen, MY
   Yu, CY
   Yao, MH
   Liu, XY
   Xu, SJ
   Tang, WW
   Dong, WB
   Gong, JB
AF Chen, Mingyang
   Yu, Changyou
   Yao, Menghui
   Liu, Xinyu
   Xu, Shijie
   Tang, Weiwei
   Dong, Weibing
   Gong, Junbo
TI The time and location dependent prediction of crystal caking by a
   modified crystal bridge growth model and DEM simulation considering
   particle size and shape
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Caking; Crystal; Non-homogeneous; Non-spherical crystals; Model; DEM
   simulation
ID TENSILE-STRENGTH; MECHANISM; HUMIDITY; CRYSTALLIZATION; SYSTEMS; FORCE
AB Unequal crystal size and anisotropic shape lead to non-homogeneous caking which fails to be investigated by conventional caking testers. The simulation method in this work considers crystal size and shape and achieves the prediction of non-homogeneous caking from single caking bridge at each contact point to the entire caking bridge network. It develops a modified model for predicting single bridge growth with higher precision by considering the mass transfer of bridge dissolution and recrystallization. The non-homogeneous bridge networks are then constructed based on DEM (Discrete Element Method) simulation with crystal shapes represented by the multiple spheres method. The outputs include the time and location dependent mechanical, morphological and statistical indices. Furthermore, a full-scale anticaking design system based on the simulation method is discussed. Parameters including particle size, particle shape, anti-caking agent, impurity, polymorph, temperature, humidity, packing, and breakage operation can be fully designed achieving anti-caking by the system. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Mingyang; Yu, Changyou; Yao, Menghui; Liu, Xinyu; Tang, Weiwei; Dong, Weibing; Gong, Junbo] Tianjin Univ, Sch Chem Engn & Technol, State Key Lab Chem Engn, Tianjin 300072, Peoples R China.
   [Xu, Shijie] Tianjin Univ Sci & Technol, Coll Chem Engn & Mat Sci, Tianjin Key Lab Marine Resources & Chem, Tianjin 300457, Peoples R China.
   [Dong, Weibing; Gong, Junbo] Qinghai Nationalities Univ, Sch Chem & Chem Engn, Xining 810007, Peoples R China.
   [Gong, Junbo] Tianjin Univ, Key Lab Modern Drug Delivery & High Efficiency, Tianjin 300072, Peoples R China.
RP Gong, JB (reprint author), Tianjin Univ, Sch Chem Engn & Technol, State Key Lab Chem Engn, Tianjin 300072, Peoples R China.; Gong, JB (reprint author), Qinghai Nationalities Univ, Sch Chem & Chem Engn, Xining 810007, Peoples R China.; Gong, JB (reprint author), Tianjin Univ, Key Lab Modern Drug Delivery & High Efficiency, Tianjin 300072, Peoples R China.
EM chenmingyang@tju.edu.cn; junbo_gong@tju.edu.cn
RI Tang, Weiwei/U-4080-2017
OI Tang, Weiwei/0000-0002-7998-4350; Xu, Shijie/0000-0002-1586-8457
FU Innovative Group Project [21621004]; Natural Science Foundation of
   Qinghai Province [2019-ZJ-901]; Demonstration Project on Innovative
   Development of Marine Economy [BHSF2017-17]; Science and Technology
   Projects of Qinghai Nationalities University, China [2019-XJZD01]
FX The authors are grateful to the financial support of Innovative Group
   Project 21621004, Natural Science Foundation of Qinghai Province, Grant
   No. 2019-ZJ-901, Demonstration Project on Innovative Development of
   Marine Economy, No. BHSF2017-17, and the Science and Technology Projects
   of Qinghai Nationalities University, China, Grant No. 2019-XJZD01.
CR Butt HJ, 2008, LANGMUIR, V24, P4715, DOI 10.1021/la703640f
   Butt HJ, 2009, ADV COLLOID INTERFAC, V146, P48, DOI 10.1016/j.cis.2008.10.002
   Chen MY, 2019, CHINESE J CHEM ENG, V27, P1429, DOI 10.1016/j.cjche.2019.02.004
   Chen MY, 2018, POWDER TECHNOL, V337, P51, DOI 10.1016/j.powtec.2017.04.052
   Chen MY, 2016, PARTICUOLOGY, V27, P115, DOI 10.1016/j.partic.2015.04.005
   Chen MY, 2015, POWDER TECHNOL, V272, P235, DOI 10.1016/j.powtec.2014.12.012
   Christaks N, 2006, ADV POWDER TECHNOL, V17, P543, DOI 10.1163/156855206778440480
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Dopfer D, 2013, POWDER TECHNOL, V238, P35, DOI 10.1016/j.powtec.2012.06.029
   Jin SS, 2018, POWDER TECHNOL, V329, P455, DOI 10.1016/j.powtec.2018.02.001
   Langlet M, 2013, CHEM ENG SCI, V86, P78, DOI 10.1016/j.ces.2012.05.014
   Leaper MC, 2003, P I MECH ENG E-J PRO, V217, P41, DOI 10.1243/09544080360562972
   Listiohadi Y, 2008, INT J PHARM, V359, P123, DOI 10.1016/j.ijpharm.2008.03.044
   Lowry T.M., 1919, T FARADAY SOC, V15, P1
   Lu G, 2015, CHEM ENG SCI, V127, P425, DOI 10.1016/j.ces.2014.11.050
   MEHROTRA VP, 1980, POWDER TECHNOL, V25, P203, DOI 10.1016/0032-5910(80)87031-8
   Petean PGC, 2015, POWDER TECHNOL, V274, P67, DOI 10.1016/j.powtec.2014.12.047
   Pierrat P, 1997, POWDER TECHNOL, V91, P83, DOI 10.1016/S0032-5910(96)03179-8
   PIRARD E, 1994, J MICROSC-OXFORD, V175, P214, DOI 10.1111/j.1365-2818.1994.tb03487.x
   Soifer YM, 2003, PHYS SOLID STATE+, V45, P1701, DOI 10.1134/1.1611237
   TANAKA T, 1978, IND ENG CHEM PROD RD, V17, P241, DOI 10.1021/i360067a013
   Thakur SC, 2014, PARTICUOLOGY, V12, P2, DOI 10.1016/j.partic.2013.06.009
   TUCKER WJ, 1955, J AGR FOOD CHEM, V3, P669, DOI 10.1021/jf60054a002
   Wahl M, 2008, POWDER TECHNOL, V188, P147, DOI 10.1016/j.powtec.2008.04.062
   Walker GM, 1999, IND ENG CHEM RES, V38, P4100, DOI 10.1021/ie990204s
   Weuster A, 2015, GRANUL MATTER, V17, P271, DOI 10.1007/s10035-015-0555-3
   Zafar U, 2017, POWDER TECHNOL, V313, P389, DOI 10.1016/j.powtec.2017.02.024
   Zhu HP, 2007, CHEM ENG SCI, V62, P3378, DOI 10.1016/j.ces.2006.12.089
NR 28
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115419
DI 10.1016/j.ces.2019.115419
PG 17
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100002
DA 2020-05-12
ER

PT J
AU Chen, Q
   Hu, JH
   Yang, HP
   Wang, DQ
   Liu, HH
   Wang, XH
   Chen, HP
AF Chen, Qi
   Hu, Junhao
   Yang, Haiping
   Wang, Daqian
   Liu, Huihui
   Wang, Xianhua
   Chen, Hanping
TI Experiment and simulation of the pneumatic classification and drying of
   coking coal in a fluidized bed dryer
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Coking coal; Wide size range; Fluidized bed; Drying; Classification;
   Simulation
ID REACTING FLOW; CPFD METHOD; LOOP SEAL; MODEL; GAS; EFFICIENCY; IMPACT;
   ENERGY
AB Coking coal pneumatic classification and drying behavior within a three-stage cross-flow fluidized bed dryer were investigated experimentally and numerically. Firstly, the influence of fluidization velocities on coal classification and drying was analyzed with a pilot-scale fluidized bed dryer. It was found that the coal was dried fast and the moisture content of the product particles was below 2%, and the optimum classification efficiency was 92 wt% at a fluidization velocity of 2.2 m/s. Then the fluid dynamics property inside the dryer was calculated with a computational particle fluid dynamics modeling approach, simultaneously the optimization of the classification parameters and dryer configuration was studied. The classification efficiency can be increased by increasing the fluidization velocity in the 3rd stage chamber connected to the overflow outlet or a decrease in the overflow outlet height. However, the latter was not as sensitive as the fluidization velocity in the 3rd stage chamber. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Chen, Qi; Hu, Junhao; Yang, Haiping; Wang, Daqian; Liu, Huihui; Wang, Xianhua; Chen, Hanping] Huazhong Univ Sci & Technol, State Key Lab Coal Combust, Wuhan 430074, Peoples R China.
RP Yang, HP (reprint author), Huazhong Univ Sci & Technol, State Key Lab Coal Combust, Wuhan 430074, Peoples R China.
EM yhping2002@163.com
OI Hu, Junhao/0000-0001-5179-5921
FU National key research and development plan [2017YFB060270102]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [51906082]
FX The authors wish to acknowledge the financial support by the National
   key research and development plan (2017YFB060270102) and the National
   Natural Science Foundation of China (no. 51906082). The authors express
   their gratitude to the Analytical and Testing Center, Huazhong
   University of Science and Technology, People's Republic of China.
CR Andrews MJ, 1996, INT J MULTIPHAS FLOW, V22, P379, DOI 10.1016/0301-9322(95)00072-0
   Bigda J, 2014, DRY TECHNOL, V32, P1277, DOI 10.1080/07373937.2014.929586
   Chen C, 2013, POWDER TECHNOL, V235, P238, DOI 10.1016/j.powtec.2012.10.014
   Chen LG, 2015, APPL THERM ENG, V86, P151, DOI 10.1016/j.applthermaleng.2015.04.026
   Chen XZ, 2014, POWDER TECHNOL, V254, P94, DOI 10.1016/j.powtec.2013.12.056
   Geng F, 2009, CHEM ENG J, V150, P581, DOI 10.1016/j.cej.2009.03.035
   Gong MH, 2017, ENERG CONVERS MANAGE, V133, P318, DOI 10.1016/j.enconman.2016.12.010
   Gu JR, 2018, CHEM ENG SCI, V192, P619, DOI 10.1016/j.ces.2018.08.008
   Hu SW, 2019, CHEM ENG SCI, V205, P14, DOI 10.1016/j.ces.2019.04.033
   Innocentini MDM, 2009, FOOD BIOPROD PROCESS, V87, P237, DOI 10.1016/j.fbp.2008.11.001
   Jayarathna CK, 2019, POWDER TECHNOL, V342, P621, DOI 10.1016/j.powtec.2018.10.026
   Jayarathna CK, 2018, POWDER TECHNOL, V336, P30, DOI 10.1016/j.powtec.2018.05.026
   Kato K., 2006, NIPPON STEEL TECHNIC, V94, P42
   Knuii D., 1991, FLUIDIZATION ENG
   Liu Z.E., 2010, P ECI C 13 INT C FLU
   Liu ZE, 2012, PARTICUOLOGY, V10, P600, DOI 10.1016/j.partic.2012.03.005
   Nakagawa T., 2006, 94 NIPP STEEL, P63
   Nakagawa T., 2012, NIPPON STEEL TECHNIC, V101, P79
   Nomura S, 2004, FUEL, V83, P1771, DOI 10.1016/j.fuel.2004.03.006
   Nomura S, 2017, FUEL PROCESS TECHNOL, V159, P1, DOI 10.1016/j.fuproc.2017.01.016
   Parker JM, 2014, POWDER TECHNOL, V265, P47, DOI 10.1016/j.powtec.2014.01.027
   Petit HA, 2018, COMPUT PART MECH, V5, P87, DOI 10.1007/s40571-017-0155-6
   Snider D, 2010, POWDER TECHNOL, V199, P100, DOI 10.1016/j.powtec.2009.04.023
   Snider DM, 2007, POWDER TECHNOL, V176, P36, DOI 10.1016/j.powtec.2007.01.032
   Snider DM, 2011, CHEM ENG SCI, V66, P1285, DOI 10.1016/j.ces.2010.12.042
   Snider DM, 2001, J COMPUT PHYS, V170, P523, DOI 10.1006/jcph.2001.6747
   T Makkawi Y, 2006, POWDER TECHNOL, V163, P69, DOI 10.1016/j.powtec.2006.01.020
   Tahmasebi A, 2012, FUEL PROCESS TECHNOL, V101, P85, DOI 10.1016/j.fuproc.2012.04.005
   WAKURI S, 1985, T IRON STEEL I JPN, V25, P1111
   Wang QG, 2014, POWDER TECHNOL, V253, P822, DOI 10.1016/j.powtec.2013.11.040
   Wang QG, 2014, POWDER TECHNOL, V253, P814, DOI 10.1016/j.powtec.2013.11.041
   Wang S, 2018, ENERG CONVERS MANAGE, V173, P296, DOI 10.1016/j.enconman.2018.07.043
   Welty R.J., 2001, FUNDAMENTALS MOMENTU
   Yang GH, 2002, MINER ENG, V15, P623, DOI 10.1016/S0892-6875(02)00057-2
   Zeneli M, 2017, FUEL PROCESS TECHNOL, V162, P105, DOI 10.1016/j.fuproc.2017.03.032
NR 35
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115364
DI 10.1016/j.ces.2019.115364
PG 14
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100007
DA 2020-05-12
ER

PT J
AU Dang, WL
   Friedrich, D
   Brandani, S
AF Dang, Wenli
   Friedrich, Daniel
   Brandani, Stefano
TI Dual-piston pressure swing adsorption system: Instrumentation and
   characterisation with pure gas experiments
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pressure swing adsorption; Fast cycle piston driven PSA; Material
   screening; Mathematical model; Kinetic and equilibrium properties
ID FREQUENCY-RESPONSE METHOD; FLUID DISPERSION COEFFICIENTS; HEAT-TRANSFER;
   PACKED-BEDS; NUMERICAL-SIMULATION; CO2 CAPTURE; DIFFUSION; ADSORBENTS;
   PARAMETERS; COLUMN
AB Dual Piston-Pressure Swing Adsorption systems offer the potential for rapid testing of novel adsorbent materials under a wide range of operating conditions. This characterisation of the properties of adsorbents is crucial for the development of efficient adsorption based separation processes. Here the instrumentation and characterisation of a semi-automated DP-PSA system as well as a mathematical model for the analysis of the experiments are presented. In this system each piston is independently controlled by a real-time computer which allows the autonomous running of a series of experiment with different cycle times, compression ratios and flow conditions. The real-time computer also handles the data acquisition from the pressure transducers (absolute and differential) and thermocouples which are placed inside the column. The entire system is enclosed in an oven to control the surrounding temperature and to enable experiments at different temperatures (20-200 degrees C). The small amount of solid material (5-10 g) together with the possibility of fast cycle times (down to 1 Hz) allow the rapid testing of the material under a large number of different conditions. The DP-PSA is demonstrated with two series of experiments: first, empty column experiments showed that the system has a low leak rate and negligible flow resistance between the pistons and column; second, experiments with the column packed with zeolite 13X pellets to validate the mathematical model and to demonstrate the experimental procedure for pure components. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Dang, Wenli; Friedrich, Daniel; Brandani, Stefano] Univ Edinburgh, Sch Engn, Edinburgh EH9 3JL, Midlothian, Scotland.
RP Brandani, S (reprint author), Univ Edinburgh, Sch Engn, Edinburgh EH9 3JL, Midlothian, Scotland.
EM s.brandani@ed.ac.uk
RI Friedrich, Daniel/A-9498-2015
OI Friedrich, Daniel/0000-0002-3951-2201
CR Abanades JC, 2015, INT J GREENH GAS CON, V40, P126, DOI 10.1016/j.ijggc.2015.04.018
   Arvind R, 2002, CHEM ENG SCI, V57, P419, DOI 10.1016/S0009-2509(01)00374-8
   BONIFACE HA, 1985, CHEM ENG SCI, V40, P2053, DOI 10.1016/0009-2509(85)87022-6
   Bourdin V, 1996, CHEM ENG SCI, V51, P269, DOI 10.1016/0009-2509(95)00280-4
   Brzic D, 2015, CHEM ENG SCI, V132, P9, DOI 10.1016/j.ces.2015.04.007
   Chan K. C., 2012, BIOMETRIKA, V10, P1
   D'Alessandro DM, 2010, ANGEW CHEM INT EDIT, V49, P6058, DOI 10.1002/anie.201000431
   Dang WL, 2013, ENRGY PROCED, V37, P57, DOI 10.1016/j.egypro.2013.05.085
   de Klerk A, 2003, AICHE J, V49, P2022, DOI 10.1002/aic.690490812
   DEC JE, 1992, INT J HEAT MASS TRAN, V35, P2311, DOI 10.1016/0017-9310(92)90074-3
   Farooq S, 1998, SEP PURIF TECHNOL, V13, P181, DOI 10.1016/S1383-5866(98)00042-2
   Friedrich D, 2015, CHEM ENG SCI, V126, P616, DOI 10.1016/j.ces.2014.12.062
   Friedrich D, 2013, IND ENG CHEM RES, V52, P8897, DOI 10.1021/ie3036349
   Hayashi S, 1996, GAS SEP PURIF, V10, P19, DOI 10.1016/0950-4214(95)00022-4
   Hindmarsh AC, 2005, ACM T MATH SOFTWARE, V31, P363, DOI 10.1145/1089014.1089020
   Hu XY, 2015, IND ENG CHEM RES, V54, P6772, DOI 10.1021/acs.iecr.5b00513
   Hu XY, 2014, ADSORPTION, V20, P121, DOI 10.1007/s10450-013-9554-z
   Keller G.E., 1982, United States Patent, Patent No. 4354859
   LI C, 1977, CHEM ENG SCI, V32, P1055, DOI 10.1016/0009-2509(77)80143-7
   Rees L.V.C., 1993, GAS SEP PURIF, V7, P83
   Ruthven D. M., 1994, PRESSURE SWING ADSOR
   Ruthven D.M., 1984, PRINCIPLES ADSORPTIO
   Sereno C., 1993, GAS SEP PURIF, V7, P167
   Sieder EN, 1936, IND ENG CHEM, V28, P1429, DOI 10.1021/ie50324a027
   Singh K, 1997, CHEM ENG SCI, V52, P3133, DOI 10.1016/S0009-2509(97)00123-1
   Sward BK, 2003, ADSORPTION, V9, P37, DOI 10.1023/A:1023863213893
   WAKAO N, 1978, CHEM ENG SCI, V33, P1375, DOI 10.1016/0009-2509(78)85120-3
   WAKAO N, 1979, CHEM ENG SCI, V34, P325, DOI 10.1016/0009-2509(79)85064-2
   Wang Y, 2007, IND ENG CHEM RES, V46, P2141, DOI 10.1021/ie061214d
   WHITAKER S, 1972, AICHE J, V18, P361, DOI 10.1002/aic.690180219
   Yang J, 1998, KOREAN J CHEM ENG, V15, P211, DOI 10.1007/BF02707074
   YASUDA Y, 1994, HETEROGEN CHEM REV, V1, P103
   YASUDA Y, 1976, J PHYS CHEM-US, V80, P1867, DOI 10.1021/j100558a010
   Zhang J, 2008, ENERG CONVERS MANAGE, V49, P346, DOI 10.1016/j.enconman.2007.06.007
NR 34
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115423
DI 10.1016/j.ces.2019.115423
PG 13
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100020
DA 2020-05-12
ER

PT J
AU Davis, D
   Troiano, M
   Chinnici, A
   Saw, WL
   Lau, T
   Solimene, R
   Salatino, P
   Nathan, GJ
AF Davis, Dominic
   Troiano, Maurizio
   Chinnici, Alfonso
   Saw, Woei L.
   Lau, Timothy
   Solimene, Roberto
   Salatino, Piero
   Nathan, Graham J.
TI Particle residence time distributions in a vortex-based solar particle
   receiver-reactor: An experimental, numerical and theoretical study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Particle; Residence time; RTD; Solar particle receiver; Solar vortex
   receiver; CST
ID HYDROGEN-PRODUCTION; CYCLONE REACTOR; HEAT-TRANSFER; FLOW-FIELD; GAS;
   DECONVOLUTION; TURBULENT; DESIGN; HOLDUP; SYSTEM
AB We report a joint experimental, numerical and theoretical study of particle residence times in a novel vortex-based vessel for thermal processing of suspended particles. The tracer pulse-response method, in which the particle phase itself is employed as the tracer, is used to measure the particle residence time distribution (RTD) within a laboratory-scale model of a class of Solar Expanding Vortex Receiver-Reactor (SEVR). The operating parameters of particle size, gas volumetric flow rate and inlet velocity were systematically varied to assess their influence on the particle RTD and to determine the mechanisms controlling the behaviour of the two-phase flow in the SEVR. The particle RTD behaviour is also described by a compartment model consisting of a small plug flow reactor followed by a series of two interconnected continuously-stirred tank reactors (CSTRs). (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Davis, Dominic; Chinnici, Alfonso; Saw, Woei L.; Lau, Timothy; Nathan, Graham J.] Univ Adelaide, Ctr Energy Technol, Adelaide, SA 5005, Australia.
   [Davis, Dominic; Chinnici, Alfonso; Lau, Timothy; Nathan, Graham J.] Univ Adelaide, Sch Mech Engn, Adelaide, SA 5005, Australia.
   [Saw, Woei L.] Univ Adelaide, Sch Chem Engn & Adv Mat, Adelaide, SA 5005, Australia.
   [Troiano, Maurizio; Salatino, Piero] Univ Napoli Federico II, Dipartimento Ingn Chim Mat & Prod Ind, Piazzale V Tecchio 80, I-80125 Naples, Italy.
   [Solimene, Roberto] CNR, Ist Ric Combust, Piazzale V Tecchio 80, I-80125 Naples, Italy.
RP Davis, D (reprint author), Univ Adelaide, Ctr Energy Technol, Adelaide, SA 5005, Australia.
EM dominic.davis@adelaide.edu.au
RI Chinnici, Alfonso/AAL-9759-2020
OI Chinnici, Alfonso/0000-0002-0743-3904; Lau, Timothy/0000-0003-1851-706X;
   Troiano, Maurizio/0000-0001-7417-7333
FU Australian Solar Thermal Research Initiative (ASTRI) - Australian
   Government, through the Australian Renewable Energy Agency
   (ARENA)Australian Renewable Energy Agency (ARENA); Dominic
FX We gratefully acknowledge the financial support of the Australian Solar
   Thermal Research Initiative (ASTRI), a project supported by the
   Australian Government, through the Australian Renewable Energy Agency
   (ARENA). Dominic is also grateful for additional assistance in the form
   of an Australian Government Research Training Program Scholarship.
CR Allal KM, 1998, CHEM ENG RES DES, V76, P643, DOI 10.1205/026387698525171
   Amaral SS, 2015, ATMOSPHERE-BASEL, V6, P1327, DOI 10.3390/atmos6091327
   Bellan S, 2019, CHEM ENG SCI, V203, P511, DOI 10.1016/j.ces.2018.09.012
   BUFFHAM BA, 1993, CHEM ENG SCI, V48, P3879, DOI 10.1016/0009-2509(93)80366-X
   Cai RR, 2014, POWDER TECHNOL, V254, P22, DOI 10.1016/j.powtec.2013.12.050
   Chinnici A, 2016, SOL ENERGY, V133, P451, DOI 10.1016/j.solener.2016.04.006
   Chinnici A, 2015, SOL ENERGY, V122, P58, DOI 10.1016/j.solener.2015.08.017
   Chirone R., 2013, 14 INT C FLUID FUND
   Cortes C, 2007, PROG ENERG COMBUST, V33, P409, DOI 10.1016/j.pecs.2007.02.001
   DANCKWERTS PV, 1953, CHEM ENG SCI, V2, P1, DOI 10.1016/0009-2509(53)80001-1
   Davis D, 2019, SOL ENERGY, V190, P126, DOI 10.1016/j.solener.2019.07.078
   Davis D, 2017, GREEN CHEM, V19, P2992, DOI 10.1039/c7gc00585g
   ELGHOBASHI S, 1994, APPL SCI RES, V52, P309, DOI 10.1007/BF00936835
   Essadki AH, 2011, CHEM ENG SCI, V66, P3125, DOI 10.1016/j.ces.2011.02.063
   Fogler HS, 2006, ELEMENTS CHEM REACTI
   Gao YJ, 2012, POWDER TECHNOL, V228, P416, DOI 10.1016/j.powtec.2012.05.060
   Gao YJ, 2011, CHEM ENG SCI, V66, P417, DOI 10.1016/j.ces.2010.10.045
   Guio-Perez DC, 2013, IND ENG CHEM RES, V52, P10732, DOI 10.1021/ie400211h
   Harris AT, 2003, CHEM ENG SCI, V58, P2181, DOI 10.1016/S0009-2509(03)00082-4
   Harris AT, 2002, CHEM ENG J, V89, P127, DOI 10.1016/S1385-8947(02)00004-9
   Hirsch D, 2004, INT J HYDROGEN ENERG, V29, P47, DOI 10.1016/S0360-3199(03)00048-X
   Ho CK, 2014, RENEW SUST ENERG REV, V29, P835, DOI 10.1016/j.rser.2013.08.099
   Hoffmann A.C., 2007, GAS CYCLONES SWIRL T
   KANG SK, 1989, POWDER TECHNOL, V58, P211, DOI 10.1016/0032-5910(89)80116-0
   Kehlenbeck R, 2002, IND ENG CHEM RES, V41, P2637, DOI 10.1021/ie010513u
   KIEVIET F, 1995, DRY TECHNOL, V13, P1241, DOI 10.1080/07373939508917019
   Kodama T, 2014, ENRGY PROCED, V49, P1990, DOI 10.1016/j.egypro.2014.03.211
   Lau TCW, 2016, J FLUID MECH, V809, P72, DOI 10.1017/jfm.2016.666
   LEDE J, 1987, CHEM ENG PROCESS, V22, P215, DOI 10.1016/0255-2701(87)85004-3
   LEVENSPIEL O, 1999, CHEM REACTION ENG
   Li SH, 2008, CHEM ENG TECHNOL, V31, P224, DOI 10.1002/ceat.200700264
   MILLS PL, 1989, COMPUT CHEM ENG, V13, P881, DOI 10.1016/0098-1354(89)85062-8
   Mitsutani K, 2005, CHEM ENG SCI, V60, P2703, DOI 10.1016/j.ces.2004.09.084
   Moumin G, 2019, SOL ENERGY, V182, P480, DOI 10.1016/j.solener.2019.01.093
   Nauman EB, 2008, IND ENG CHEM RES, V47, P3752, DOI 10.1021/ie071635a
   Shilapuram V, 2011, INT J HYDROGEN ENERG, V36, P13488, DOI 10.1016/j.ijhydene.2011.08.035
   STEINFELD A, 1992, J SOL ENERG-T ASME, V114, P171, DOI 10.1115/1.2930001
   Syred N, 2006, PROG ENERG COMBUST, V32, P93, DOI 10.1016/j.pecs.2005.10.002
   SZEKELY J, 1966, CHEM ENG SCI, V21, P1119, DOI 10.1016/0009-2509(66)85033-9
   Trachsel F, 2005, CHEM ENG SCI, V60, P5729, DOI 10.1016/j.ces.2005.04.039
   Tregambi C, 2016, SOL ENERGY, V129, P85, DOI 10.1016/j.solener.2016.01.057
   Valera-Medina A, 2009, COMBUST FLAME, V156, P1723, DOI 10.1016/j.combustflame.2009.06.014
   Viitanen P, 1997, APPL RADIAT ISOTOPES, V48, P893, DOI 10.1016/S0969-8043(97)00029-8
   Yogev A, 1998, INT J HYDROGEN ENERG, V23, P239, DOI 10.1016/S0360-3199(97)00059-1
   Z'Graggen A, 2006, INT J HYDROGEN ENERG, V31, P797, DOI 10.1016/j.ijhydene.2005.06.011
NR 45
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115421
DI 10.1016/j.ces.2019.115421
PG 14
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100004
DA 2020-05-12
ER

PT J
AU Fan, DD
   Tan, W
   Zhu, GR
AF Fan, Dongdong
   Tan, Wei
   Zhu, Guorui
TI A multiple-outlet adaptive boundary condition for Eulerian-Eulerian
   multiphase numerical simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multiphase flow; Adaptive boundary condition; Outflow; Flow split
ID GAS-SOLID FLOW; KINETIC-THEORY; CFD SIMULATION; GRANULAR FLOW;
   FLUIDIZATION; PARTICLES; MODEL
AB An adaptive algorithm was developed to handle some multiphase situations where outlet information is included in results or multiple inlets/outlets are implemented while only flow rates through inlets/outlets are known. This algorithm includes a first-order expanded Bernoulli equation and a mixed approximation algorithm. The expanded Bernoulli equation offers an initialization value for a concerned object for subsequent approximation processes. The mixed approximation algorithm completes final convergence via iteration and correction. The executed code was successfully compiled into a commercial computational fluid dynamics software. To test the algorithm, a series of corresponding experiments were performed. Three key parameters including the validity of the initialization condition from the expanded equation, convergence efficiency and reliability were evaluated and discussed. The results show that this boundary condition could accomplish the desired functions and maintain errors lower than 15% compared to experimental data, and in less rigorous applications, the error may be approximate to 5%. (C) 2019 Published by Elsevier Ltd.
C1 [Fan, Dongdong; Tan, Wei; Zhu, Guorui] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
RP Zhu, GR (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
EM dongdongfan@tju.edu.cn; wtan@tju.edu.cn; zhuguorui@tju.edu.cn
FU Tianjin key research and development program [17YFCZZC00290]; Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [21606164]
FX This work is supported by Tianjin key research and development program
   (17YFCZZC00290) the Natural Science Foundation of China (21606164).
CR ANSYS Incoporated, 2016, ANSYS FLUENT 17 0 US
   ANSYS Incoporated, 2016, ANSYS FLUENT 17 0 GU
   Asendrych D, 2013, CHEM PROCESS ENG-INZ, V34, P269, DOI 10.2478/cpe-2013-0022
   CAMPBELL CS, 1990, ANNU REV FLUID MECH, V22, P57, DOI 10.1146/annurev.fl.22.010190.000421
   Chen LQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124095
   DING J, 1990, AICHE J, V36, P523, DOI 10.1002/aic.690360404
   Fan L.-S., 2005, PRINCIPLES GAS SOLID
   Gao JS, 2008, CHEM ENG SCI, V63, P1827, DOI 10.1016/j.ces.2007.12.009
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Gidaspow D., 1991, HYDRODYNAMICS CIRCUL
   Huang S, 2005, CAN J CHEM ENG, V83, P829
   Huilin L, 2003, CHEM ENG J, V95, P1, DOI 10.1016/S1385-8947(03)00062-7
   Huilin L., 2003, J CHEM ENG SCI, V58, P1197, DOI DOI 10.1016/S0009-2509(02)00635-8
   Jiradilok V, 2006, CHEM ENG SCI, V61, P5544, DOI 10.1016/j.ces.2006.04.006
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   Lan XY, 2009, CHEM ENG SCI, V64, P3847, DOI 10.1016/j.ces.2009.05.019
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   Neri A, 2000, AICHE J, V46, P52, DOI 10.1002/aic.690460108
   Ogawa S., 1978, P US JAP SEM CONT ME, P208
   Pfleger D, 1999, CHEM ENG SCI, V54, P5091, DOI 10.1016/S0009-2509(99)00261-4
   Prosperetti A, 2009, COMPUTATIONAL METHOD
   Vorobieff P., 2015, COMPUTATIONAL METHOD
   WALTON OR, 1986, J RHEOL, V30, P949, DOI 10.1122/1.549893
   Wang XJ, 2017, J DISPER SCI TECHNOL, V38, P1509, DOI 10.1080/01932691.2016.1259072
   Yu L, 2007, FUEL, V86, P722, DOI 10.1016/j.fuel.2006.09.008
   Zhu GR, 2013, IND ENG CHEM RES, V52, P17249, DOI 10.1021/ie401902m
NR 26
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115447
DI 10.1016/j.ces.2019.115447
PG 11
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100034
DA 2020-05-12
ER

PT J
AU Guo, HB
   Liu, S
   Cheng, HY
   Sun, SX
   Ding, JK
   Guo, HQ
AF Guo, Hongbo
   Liu, Shi
   Cheng, Hongyan
   Sun, Shanxun
   Ding, Jiankang
   Guo, Hongqi
TI Iterative computational imaging method for flow pattern reconstruction
   based on electrical capacitance tomography
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Review
DE Flow pattern imaging; Image reconstruction; Split Bregman algorithm;
   Regularization method; Electrical capacitance tomography
ID TIKHONOV REGULARIZATION; FLUIDIZED-BED; ALGORITHM; HYDRODYNAMICS;
   2-PHASE
AB The electrical capacitance tomography (ECT) is a promising measurement technique, which tries to reconstruct the permittivity distribution in a measurement domain by solving an inverse problem. Low quality images narrow the applicability of the technique. To address the challenge, a new cost function, which considers model deviation and measurement noises, is devised to model the ECT reconstruction problem. The soft thresholding method and the fast-iterative shrinkage thresholding technique (FIST) are embedded into the iterative split Bregman (ISB) method to solve the devised objective functional. The numerical and experimental results indicate that the proposed ECT imaging technique not only mitigates the ill-posed nature, but also improves the reconstruction quality. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Guo, Hongbo; Cheng, Hongyan; Sun, Shanxun] North China Elect Power Univ, Sch Control & Comp Engn, Beijing 102206, Peoples R China.
   [Liu, Shi] North China Elect Power Univ, Sch Energy Power & Mech Engn, Beijing 102206, Peoples R China.
   [Ding, Jiankang] North China Power Engn Co Ltd, China Power Engn Consulting Grp, Engn Technol Ctr, Beijing 100120, Peoples R China.
   [Guo, Hongqi] Shanxi Yanbei Coal Ind Sch, Elect Dept, Datong 037005, Peoples R China.
RP Guo, HB (reprint author), North China Elect Power Univ, Sch Control & Comp Engn, Beijing 102206, Peoples R China.
EM mtmmbb@163.com
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [JB2019117, 2017MS012,
   2017MS073]; National Natural Science Foundation of ChinaNational Natural
   Science Foundation of China [61871181, 61571189]; National Key Research
   and Development Program of China [2017YFB0903601]; State Administration
   of Foreign Experts Affairs [B13009]
FX This work was supported by the Fundamental Research Funds for the
   Central Universities [grant numbers JB2019117, 2017MS012 and 2017MS073];
   the National Natural Science Foundation of China [grant numbers 61871181
   and 61571189,]; the National Key Research and Development Program of
   China [grant number 2017YFB0903601]; the State Administration of Foreign
   Experts Affairs for supporting the project 'Overseas Expertise
   Introduction Program for Disciplines Innovation in Universities' [grant
   number B13009].
CR Atta A, 2010, CHEM ENG SCI, V65, P1144, DOI 10.1016/j.ces.2009.09.069
   Beck A, 2009, SIAM J IMAGING SCI, V2, P183, DOI 10.1137/080716542
   Bell J.B., 1978, MATH COMPUT, V32, P1320, DOI [10.2307/2006360., DOI 10.2307/2006360]
   BERTERO M, 1988, P IEEE, V76, P869, DOI 10.1109/5.5962
   Bot RI, 2019, ADV COMPUT MATH, V45, P327, DOI 10.1007/s10444-018-9619-3
   Brezinski C, 2003, NUMER MATH, V94, P203, DOI 10.1007/s00211-002-0435-8
   Cai JF, 2009, MULTISCALE MODEL SIM, V8, P337, DOI 10.1137/090753504
   Chen JX, 2017, MEAS SCI TECHNOL, V28, DOI 10.1088/1361-6501/aa524e
   de Moura HL, 2017, IEEE SENS J, V17, P8157, DOI 10.1109/JSEN.2017.2719003
   DONOHO DL, 1995, IEEE T INFORM THEORY, V41, P613, DOI 10.1109/18.382009
   Elvetun OL, 2016, COMPUT OPTIM APPL, V64, P699, DOI 10.1007/s10589-016-9823-3
   Ghannadi B, 2019, NONLINEAR DYNAM, V95, P57, DOI 10.1007/s11071-018-4550-1
   Goldstein T, 2009, SIAM J IMAGING SCI, V2, P323, DOI 10.1137/080725891
   Guan NY, 2012, IEEE T NEUR NET LEAR, V23, P1087, DOI 10.1109/TNNLS.2012.2197827
   Haddadi MB, 2016, IEEE SENS J, V16, P1786, DOI 10.1109/JSEN.2015.2506409
   Hamidipour M, 2010, CHEM ENG SCI, V65, P504, DOI 10.1016/j.ces.2009.06.040
   Hu H., 2016, PEDIATR RADIOL, P1, DOI 10.1109/i2mtc.2016.7520484.
   Isaac Y, 2017, SIGNAL PROCESS, V130, P389, DOI 10.1016/j.sigpro.2016.07.013
   Jiao YL, 2016, SIAM J NUMER ANAL, V54, P2114, DOI 10.1137/15M1029308
   Lei J, 2017, MEAS SCI TECHNOL, V28, DOI 10.1088/1361-6501/aa58a3
   Lei J, 2011, COMPUT MATH APPL, V61, P2843, DOI 10.1016/j.camwa.2011.03.060
   Lei J, 2009, MEASUREMENT, V42, P368, DOI 10.1016/j.measurement.2008.07.003
   Li S, 2015, MAGN RESON MED, V73, P1643, DOI 10.1002/mrm.25265
   Li ZC, 2011, NUMER LINEAR ALGEBR, V18, P205, DOI 10.1002/nla.766
   Liu J, 2016, MEAS SCI REV, V16, P280, DOI 10.1515/msr-2016-0035
   Lysaker M, 2006, INT J COMPUT VISION, V66, P5, DOI 10.1007/s11263-005-3219-7
   Mei ILS, 2016, MEAS SCI TECHNOL, V27, DOI 10.1088/0957-0233/27/2/025403
   Neumayer M, 2012, IEEE IMTC P, P929
   Omar R, 2018, CHEM ENG SCI, V187, P377, DOI 10.1016/j.ces.2018.04.075
   Peng LH, 2000, PART PART SYST CHAR, V17, P96, DOI 10.1002/1521-4117(200010)17:3<96::AID-PPSC96>3.0.CO;2-8
   Peng LH, 2007, FLOW MEAS INSTRUM, V18, P277, DOI 10.1016/j.flowmeasinst.2007.06.005
   Qiu GZ, 2014, CHEM ENG SCI, V116, P195, DOI 10.1016/j.ces.2014.05.006
   Tran-Dinh Q, 2018, SIAM J OPTIMIZ, V28, P96, DOI 10.1137/16M1093094
   Ren SJ, 2015, FLOW MEAS INSTRUM, V46, P284, DOI 10.1016/j.flowmeasinst.2015.07.004
   Rimpilainen V, 2012, CHEM ENG SCI, V75, P220, DOI 10.1016/j.ces.2012.03.028
   Salahuddin S, 2002, ELECTRON LETT, V38, P1605, DOI 10.1049/el:20020990
   Su BL, 2000, CHEM ENG J, V77, P37
   Sun BY, 2015, MEAS SCI TECHNOL, V26, DOI 10.1088/0957-0233/26/12/125402
   Vauhkonen M, 1998, IEEE T MED IMAGING, V17, P285, DOI 10.1109/42.700740
   Voss A, 2016, CEMENT CONCRETE RES, V89, P158, DOI 10.1016/j.cemconres.2016.07.011
   Wang AN, 2014, CHEM ENG SCI, V119, P77, DOI 10.1016/j.ces.2014.08.011
   Warsito W, 2001, MEAS SCI TECHNOL, V12, P2198, DOI 10.1088/0957-0233/12/12/323
   Wen DB, 2010, GPS SOLUT, V14, P375, DOI 10.1007/s10291-010-0161-0
   Wu CL, 2010, SIAM J IMAGING SCI, V3, P300, DOI 10.1137/090767558
   XIE CG, 1989, IEE PROC-A, V136, P173, DOI 10.1049/ip-a-2.1989.0031
   Xu Y, 2013, J APPL MATH, DOI 10.1155/2013/238561
   Yan H, 2014, IET SCI MEAS TECHNOL, V8, P487, DOI 10.1049/iet-smt.2013.0124
   Yang WQ, 1999, MEAS SCI TECHNOL, V10, P1065, DOI 10.1088/0957-0233/10/11/315
   Yang WQ, 2003, MEAS SCI TECHNOL, V14, pR1, DOI 10.1088/0957-0233/14/1/201
   Yang X., 2010, INT C COMPUT APPL SY, V9, P2161, DOI [https://doi.org/10.1109/iccasm.2010.5619343., DOI 10.1109/ICCASM.2010.5619343]
   Yang YJ, 2013, IEEE SENS J, V13, P1582, DOI 10.1109/JSEN.2013.2237763
   Ye JM, 2017, IEEE T INSTRUM MEAS, V66, P1751, DOI 10.1109/TIM.2017.2664458
   Ye JM, 2016, IEEE SENS J, V16, P2466, DOI 10.1109/JSEN.2015.2513747
   YIN W., 2010, SIAM J IMAGING SCI, V1, P143
   Zhang L., 2011, Proceedings of the 2011 2nd International Conference on Intelligent Control and Information Processing (ICICIP), P277, DOI 10.1109/ICICIP.2011.6008248
   Zhang XQ, 2011, J SCI COMPUT, V46, P20, DOI 10.1007/s10915-010-9408-8
   Zhang Z, 2015, IEEE ACCESS, V3, P490, DOI 10.1109/ACCESS.2015.2430359
   Zhao B, 2007, MEAS SCI TECHNOL, V18, P3373, DOI 10.1088/0957-0233/18/11/017
   Zhao YW, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00272
   Zwaan IN, 2017, J SCI COMPUT, V70, P990, DOI 10.1007/s10915-016-0271-0
NR 60
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115432
DI 10.1016/j.ces.2019.115432
PG 19
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100010
DA 2020-05-12
ER

PT J
AU Hiraga, Y
   Sasagawa, T
   Yamamoto, S
   Komatsu, H
   Ota, M
   Tsukada, T
   Smith, RL
AF Hiraga, Yuya
   Sasagawa, Takuya
   Yamamoto, Shinichiro
   Komatsu, Hiroyuki
   Ota, Masaki
   Tsukada, Takao
   Smith, Richard L., Jr.
TI A precise deconvolution method to derive methane hydrate cage occupancy
   ratios using Raman spectroscopy
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Energy; Clathrate hydrate; Experimental technique; Raman spectra
   deconvolution
ID NUMERICAL-ANALYSIS; BEHAVIOR; REPLACEMENT; KINETICS; MODEL; FLOW
AB Raman spectroscopy was used to analyze cage occupancy of thin homogeneous methane hydrate (MH) films at (2.9 to 7.6) MPa and (273 to 276) K. The MH films were synthesized on the lower surface of a sapphire window of a high-pressure cell to eliminate noise associated with the C-H stretching vibration of bulk methane gas. Methane medium-size to small-size cage occupancy ratios of the MH films were determined for purposes of assessing the reliability of deconvolution functions used in data reduction. Gaussian, Lorentzian and Voigt functions were considered and the Voigt function was found to provide the most reliable function in terms of fitting precision. Methane occupancy ratios tend to decrease with increasing pressure which is important for practical scale simulations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hiraga, Yuya; Ota, Masaki; Smith, Richard L., Jr.] Tohoku Univ, Res Ctr Supercrit Fluid Technol, Aoba Ku, Aramaki Aza Aoba 6-6-11, Sendai, Miyagi 9808579, Japan.
   [Sasagawa, Takuya; Yamamoto, Shinichiro; Smith, Richard L., Jr.] Tohoku Univ, Grad Sch Environm Studies, Aoba Ku, Aramaki Aza Aoba 6-6-11, Sendai, Miyagi 9808579, Japan.
   [Ota, Masaki; Tsukada, Takao] Tohoku Univ, Grad Sch Engn, Aoba Ku, Aramaki Aza Aoba 6-6-11, Sendai, Miyagi 9808579, Japan.
   [Komatsu, Hiroyuki] Niigata Univ, Grad Sch Sci & Technol, Nishi Ku, 8050 Ikarashi 2 No Cho, Niigata 9502181, Japan.
RP Hiraga, Y; Smith, RL (reprint author), Tohoku Univ, Res Ctr Supercrit Fluid Technol, Aoba Ku, Aramaki Aza Aoba 6-6-11, Sendai, Miyagi 9808579, Japan.
EM yuya-h@scf.che.tohoku.ac.jp; smith@scf.che.tohoku.ac.jp
RI ; Smith, Richard/E-3495-2012
OI Komatsu, Hiroyuki/0000-0002-8836-1294; Smith,
   Richard/0000-0002-9174-7681
FU JST-CREST, JapanCore Research for Evolutional Science and Technology
   (CREST) [JPMJCR13C4]
FX This work was supported by JST-CREST (Program: Breakthrough on
   Multi-Scale Interfacial Transport Phenomena in Oceanic Methane Hydrate
   Reservoir and Application to Large-Scale Methane Production, Number:
   JPMJCR13C4), Japan.
CR Chari VD, 2014, SPECTROCHIM ACTA A, V120, P636, DOI 10.1016/j.saa.2013.10.080
   Chazallon B, 2007, CHEM GEOL, V244, P175, DOI 10.1016/j.chemgeo.2007.06.012
   Chen L, 2018, ENERGY, V143, P128, DOI 10.1016/j.energy.2017.10.108
   Chen L, 2017, CHEM ENG SCI, V163, P31, DOI 10.1016/j.ces.2017.01.032
   Chen L, 2016, CHEM ENG SCI, V153, P221, DOI 10.1016/j.ces.2016.07.035
   Chen LT, 2015, CHEM ENG SCI, V138, P706, DOI 10.1016/j.ces.2015.09.001
   Du ZF, 2018, J ASIAN EARTH SCI, V168, P197, DOI 10.1016/j.jseaes.2018.02.003
   Falenty A, 2016, J PHYS CHEM C, V120, P27159, DOI 10.1021/acs.jpcc.6b09460
   Feng YC, 2019, ENERGY, V166, P1106, DOI 10.1016/j.energy.2018.10.184
   Fuseya G, 2018, RSC ADV, V8, P3237, DOI 10.1039/c7ra12334e
   Huo ZX, 2003, AICHE J, V49, P1300, DOI 10.1002/aic.690490521
   Komatsu H, 2019, FLUID PHASE EQUILIBR, V489, P41, DOI 10.1016/j.fluid.2019.02.004
   Lee JM, 2015, ENERGY TECHNOL-GER, V3, P925, DOI 10.1002/ente.201500066
   Liu CL, 2012, MAR GEOL, V307, P22, DOI 10.1016/j.margeo.2012.03.004
   Liu CL, 2008, ENERG FUEL, V22, P3986, DOI 10.1021/ef800440s
   Moryama CT, 2015, J CHEM ENG DATA, V60, P3581, DOI 10.1021/acs.jced.5b00533
   Nakano S, 1999, J CHEM ENG DATA, V44, P254, DOI 10.1021/je980152y
   Nakano S, 2000, J CHEM ENG JPN, V33, P554, DOI 10.1252/jcej.33.554
   Nishikawa A, 2013, CHEM ENG SCI, V101, P1, DOI 10.1016/j.ces.2013.05.044
   Ota M, 2005, FLUID PHASE EQUILIBR, V228, P553, DOI 10.1016/j.fluid.2004.10.002
   Ota M, 2007, AICHE J, V53, P2715, DOI 10.1002/aic.11294
   Qin JF, 2015, J CHEM ENG DATA, V60, P369, DOI 10.1021/je500613y
   Qin JF, 2013, AICHE J, V59, P2155, DOI 10.1002/aic.13994
   Seo Y, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014226
   Stern LA, 2001, J PHYS CHEM B, V105, P1756, DOI 10.1021/jp003061s
   Subramanian S, 2000, CHEM ENG SCI, V55, P1981, DOI 10.1016/S0009-2509(99)00389-9
   Subramanian S, 1999, FLUID PHASE EQUILIBR, V158, P813, DOI 10.1016/S0378-3812(99)00134-X
   Sugahara K, 2004, J CHEM ENG DATA, V49, P326, DOI 10.1021/je0341716
   Sum AK, 1997, J PHYS CHEM B, V101, P7371, DOI 10.1021/jp970768e
   Susilo R, 2007, CHEM ENG SCI, V62, P3930, DOI 10.1016/j.ces.2007.03.045
   Uchida T, 1999, AICHE J, V45, P2641, DOI 10.1002/aic.690451220
   Wen L, 2019, RSC ADV, V9, P14727, DOI 10.1039/c9ra01611b
   Zhong JR, 2016, SCI REP-UK, V6, DOI 10.1038/srep38855
NR 33
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115361
DI 10.1016/j.ces.2019.115361
PG 5
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100022
DA 2020-05-12
ER

PT J
AU Hoffmann, C
   Weigert, J
   Esche, E
   Repke, JU
AF Hoffmann, Christian
   Weigert, Joris
   Esche, Erik
   Repke, Jens-Uwe
TI Towards demand-side management of the chlor-alkali electrolysis:
   Dynamic, pressure-driven modeling and model validation of the
   1,2-dichloroethane synthesis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dynamic pressure-driven modeling; Chloralkali electrolysis; Ethylene
   dichloride; Plant flexibilization
ID BUBBLE-COLUMN REACTOR; DIRECT CHLORINATION; ETHYLENE; SIEVE
AB A promising application of demand-side management is the chlor-alkali electrolysis. However, storing the produced chlorine for flexibility should be avoided whenever possible. If PVC is produced from chlorine, storing the intermediate 1,2-dichloroethane resulting from direct chlorination of ethene is a better alternative as it is less toxic than chlorine and can be easily stored. Currently, no dynamic process models to study the process behavior or to develop optimal trajectories for the 1,2-dichloroethane production under different demand response scenarios are available. Hence, we formulate and solve a dynamic, pressure-driven model of the synthesis of 1,2-dichloroethane and validate it with real process data in this contribution. As part of this dynamic model, differentiable formulations for weeping and the flow over a weir of a distillation tray are presented, which are also valid whenever certain trays run dry. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Hoffmann, Christian; Weigert, Joris; Esche, Erik; Repke, Jens-Uwe] Tech Univ Berlin, Proc Dynam & Operat Grp, Sekr KWT 9,Str 17 Juni 135, D-10623 Berlin, Germany.
RP Hoffmann, C (reprint author), Tech Univ Berlin, Proc Dynam & Operat Grp, Sekr KWT 9,Str 17 Juni 135, D-10623 Berlin, Germany.
EM c.hoffmann@tu-berlin.de; joris.weigert@tu-berlin.de;
   erik.esche@tu-berlin.de; j.repke@tu-berlin.de
OI Hoffmann, Christian/0000-0002-6709-9987; Esche, Erik/0000-0002-2223-1825
FU Federal Ministry of Economic Affairs and Energy of Germany [0350013A]
FX The authors acknowledge the financial support by the Federal Ministry of
   Economic Affairs and Energy of Germany in the project ChemEFlex (project
   number 0350013A).
CR Ausfelder F., 2018, FLEXIBILITATSOPTIONE
   Azapagic A., 2004, SUSTAINABLE DEV PRAC
   BALASUBRAMANIAN SN, 1966, IND ENG CHEM FUND, V5, P184, DOI 10.1021/i160018a006
   Baldea M., 2017, EMPLOYING CHEM PROCE, P247, DOI [https://doi.org/10.1007/978-3-319-42803-1_9., DOI 10.1007/978-3-319-42803-1_9]
   BENNETT DL, 1983, AICHE J, V29, P434, DOI 10.1002/aic.690290313
   Bigg D.C., 1964, J CHEM ENG DATA, V9, P17, DOI DOI 10.1021/JE60020A007
   Bree LC, 2019, AICHE J, V65, DOI 10.1002/aic.16352
   Budiarto T., 2017, Procedia Engineering, V170, P473, DOI 10.1016/j.proeng.2017.03.076
   Dreher E.-L., 2014, ULLMANNS ENCY IND CH, DOI [10.1002/J.246545., DOI 10.1002/J.246545]
   Esche E, 2017, CHEM-ING-TECH, V89, P620, DOI 10.1002/cite.201600114
   Fischer I., 2014, ULLMANNS ENCY IND CH, DOI [10.1002/14356007.o06_o01.pub2, DOI 10.1002/14356007.O06_O01.PUB2]
   Fourer R., 2002, AMPL MODELING LANGUA
   Gmehling J., 2012, CHEM THERMODYNAMICS
   Green D. W., 2007, PERRYS CHEM ENG HDB
   KISSELL FN, 1962, J CHEM ENG DATA, V7, P205
   Klaucke F, 2017, CHEM-ING-TECH, V89, P1133, DOI 10.1002/cite.201600073
   Kohler S., 2010, TECHNICAL REPORT
   Merchan VA, 2016, CHEM-ING-TECH, V88, P50, DOI 10.1002/cite.201500099
   Orejas JA, 1999, CHEM ENG SCI, V54, P5299, DOI 10.1016/S0009-2509(99)00254-7
   Orejas JA, 2001, CHEM ENG SCI, V56, P513, DOI 10.1016/S0009-2509(00)00255-4
   Otashu JI, 2019, COMPUT CHEM ENG, V121, P396, DOI 10.1016/j.compchemeng.2018.08.030
   PENG D, 1976, IND ENG CHEM FUND, V15, P59, DOI 10.1021/i160057a011
   REN21, 2018, REN 2018 GLOB STAT R
   Roetzel W., 2013, C3 TYPISCHE WERTE WA, P85, DOI [10.1007/978-3-642-19981-3_7., DOI 10.1007/978-3-642-19981-3_7]
   Sass S, 2019, COMPUT CHEM ENG, V124, P133, DOI 10.1016/j.compchemeng.2019.02.011
   SOAVE G, 1972, CHEM ENG SCI, V27, P1197, DOI 10.1016/0009-2509(72)80096-4
   Staak D., 2010, THESIS
   Stichlmair J., 2010, ULLMANNS ENCY IND CH, DOI [10.1002/14356007.o08_o01, DOI 10.1002/14356007.O08_O01.]
   Szepvolgyi J., 1978, HUNG J IND CHEM
   Verband der chemischen Industrie e.V, 2018, CHEM ZAHL 2018
   WACHI S, 1987, J CHEM ENG JPN, V20, P238, DOI 10.1252/jcej.20.238
   Wachter A, 2006, MATH PROGRAM, V106, P25, DOI 10.1007/s10107-004-0559-y
   Westhaus U, 1999, FLUID PHASE EQUILIBR, V158, P429, DOI 10.1016/S0378-3812(99)00139-9
   Wijn EF, 1998, CHEM ENG J, V70, P143, DOI 10.1016/S0923-0467(98)00089-X
   Zhang Q., 2016, PLANNING SCHEDULING, DOI [https://doi.org/10.1007/978-3-319-28752-2_14., DOI 10.1007/978-3-319-28752-2_14]
NR 35
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115358
DI 10.1016/j.ces.2019.115358
PG 16
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100011
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Jia, LY
   Qiao, Y
   Pedersen, CM
   Jia, SY
   Ma, H
   Zhang, ZZ
   Wang, YX
   Hou, XL
AF Jia, Lingyu
   Qiao, Yan
   Pedersen, Christian Marcus
   Jia, Shiyu
   Ma, Hui
   Zhang, Zhenzhou
   Wang, Yingxiong
   Hou, Xianglin
TI Mechanistic study on the conversion of D-fructose into
   deoxyfructosazine: Insights from NMR and DFT study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fructose; C-N bond construction; NMR techniques; DFT calculation;
   Reactive intermediate; Deoxyfructosazine
ID MOLECULAR-ORBITAL METHODS; IONIC LIQUID; LIGNOCELLULOSIC BIOMASS;
   BASIS-SETS; SPECTROSCOPY; GLUCOSAMINE; ACID; TRANSFORMATION; CATALYSTS;
   MAILLARD
AB In situ C-13 and H-1 NMR and selective 1D TOCSY spectra have been used for analyzing reactive intermediates in fructose conversion, where fructose with diammonium hydrogen phosphate [(NH4)(2)HPO4] is consumed via a glucosamine (GlcNH(2)) intermediate. Our data indicate that the nitrogen in (NH4)(2)HPO4 maps onto the intermediate GlcNH(2) and subsequent to the corresponding product deoxyfructosazine (DOF). Pathways leading to isomerization of fructose have furthermore been identified through DFT calculations. The inclusion of solvent effects results in substantial reduction of the fructose ring-opening free energy barrier (19.4 kcal/mol). Interestingly, lower free energy barrier (21.0 kcal/mol) indicating that the formation of intermediate GlcNH(2) is both thermodynamically and kinetically accessible in agreement with the experimental results. Yield of DOF reaches 46% under the optimized conditions. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jia, Lingyu; Qiao, Yan; Jia, Shiyu; Ma, Hui; Wang, Yingxiong; Hou, Xianglin] Chinese Acad Sci, Shanxi Engn Res Ctr Biorefinery, Inst Coal Chem, Taiyuan 030001, Peoples R China.
   [Zhang, Zhenzhou] Zhengzhou Univ, Sch Chem Engn & Energy, Zhengzhou 450001, Peoples R China.
   [Jia, Lingyu] Zhengzhou Univ, Sch Basic Med Sci, Zhengzhou 450001, Peoples R China.
   [Pedersen, Christian Marcus] Univ Copenhagen, Dept Chem, Univ Pk 5, DK-2100 Copenhagen, Denmark.
RP Wang, YX; Hou, XL (reprint author), Chinese Acad Sci, Shanxi Engn Res Ctr Biorefinery, Inst Coal Chem, Taiyuan 030001, Peoples R China.; Zhang, ZZ (reprint author), Zhengzhou Univ, Sch Chem Engn & Energy, Zhengzhou 450001, Peoples R China.
EM zhangzhenzhou@zzu.edu.cn; wangyx@sxicc.ac.cn; houxl@sxicc.ac.cn
OI wang, Yingxiong/0000-0002-1917-5180
FU China Postdoctoral Science foundationChina Postdoctoral Science
   Foundation [2018M642788]; Key Scientific Research Project of Colleges
   and Universities in Henan Province [19A530003]; CAS President's
   International Fellowship Initiative [2015VMB052]
FX The calculations were supplied by the Tianhe-2 in LvLiang Cloud
   Computing Center. This work was China Postdoctoral Science foundation
   (2018M642788), Key Scientific Research Project of Colleges and
   Universities in Henan Province (19A530003). Christian Marcus Pedersen
   acknowledges the CAS President's International Fellowship Initiative
   (2015VMB052).
CR Agyei-Aye K, 2002, CARBOHYD RES, V337, P2273, DOI 10.1016/S0008-6215(02)00221-5
   Akien GR, 2012, CHEM COMMUN, V48, P5850, DOI 10.1039/c2cc31689g
   Araujo JMM, 2013, J PHYS CHEM B, V117, P4109, DOI 10.1021/jp400749j
   Assary RS, 2012, PHYS CHEM CHEM PHYS, V14, P16603, DOI 10.1039/c2cp41842h
   Barclay T, 2012, CARBOHYD RES, V347, P136, DOI 10.1016/j.carres.2011.11.003
   BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913
   BECKE AD, 1988, PHYS REV A, V38, P3098, DOI 10.1103/PhysRevA.38.3098
   Binder JB, 2009, J AM CHEM SOC, V131, P1979, DOI 10.1021/ja808537j
   BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069
   Chen X, 2017, ACS SUSTAIN CHEM ENG, V5, P11096, DOI 10.1021/acssuschemeng.7b03048
   CLARK T, 1983, J COMPUT CHEM, V4, P294, DOI 10.1002/jcc.540040303
   Climent MJ, 2014, GREEN CHEM, V16, P516, DOI 10.1039/c3gc41492b
   DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052
   Deng TS, 2012, CHEM COMMUN, V48, P5494, DOI 10.1039/c2cc00122e
   Duus JO, 2000, CHEM REV, V100, P4589, DOI 10.1021/cr990302n
   Ferreira SB, 2012, EXPERT OPIN THER PAT, V22, P1033, DOI 10.1517/13543776.2012.714370
   Frisch M. J., 2013, GAUSSIAN 09 REVISION
   FRISCH MJ, 1984, J CHEM PHYS, V80, P3265, DOI 10.1063/1.447079
   FUKUI K, 1981, ACCOUNTS CHEM RES, V14, P363, DOI 10.1021/ar00072a001
   Ge WZ, 2016, ACS SUSTAIN CHEM ENG, V4, P1193, DOI 10.1021/acssuschemeng.5b01259
   Gheysen K, 2008, CHEM-EUR J, V14, P8869, DOI 10.1002/chem.200801081
   Goerigk L, 2011, PHYS CHEM CHEM PHYS, V13, P6670, DOI 10.1039/c0cp02984j
   Grimme S, 2011, J COMPUT CHEM, V32, P1456, DOI 10.1002/jcc.21759
   HEYNS K, 1953, CHEM BER-RECL, V86, P1453
   HEYNS K, 1952, Z NATURFORSCH B, V7, P486
   Hong PK, 2016, FOOD CHEM, V212, P234, DOI 10.1016/j.foodchem.2016.05.170
   Hratchian HP, 2005, J CHEM THEORY COMPUT, V1, P61, DOI 10.1021/ct0499783
   Hratchian HP, 2004, J CHEM PHYS, V120, P9918, DOI 10.1063/1.1724823
   Hratchian HP, 2005, THEORY AND APPLICATIONS OF COMPUTATIONAL CHEMISTRY: THE FIRST FORTY YEARS, P195, DOI 10.1016/B978-044451719-7/50053-6
   Hrynets Y, 2016, J AGR FOOD CHEM, V64, P3266, DOI 10.1021/acs.jafc.6b00761
   Hrynets Y, 2015, J AGR FOOD CHEM, V63, P6249, DOI 10.1021/acs.jafc.5b02664
   Hrynets Y, 2013, FOOD CHEM, V139, P1062, DOI 10.1016/j.foodchem.2013.02.026
   Hulsey MJ, 2018, ACS SUSTAIN CHEM ENG, V6, P5694, DOI 10.1021/acssuschemeng.8b00612
   Jia LY, 2017, IND ENG CHEM RES, V56, P2925, DOI 10.1021/acs.iecr.6b05057
   Jia LY, 2017, APPL CATAL B-ENVIRON, V202, P420, DOI 10.1016/j.apcatb.2016.09.058
   Jia LY, 2015, PHYS CHEM CHEM PHYS, V17, P23173, DOI 10.1039/c5cp02169c
   Jia LY, 2014, RSC ADV, V4, P44253, DOI 10.1039/c4ra06832g
   KESSLER H, 1988, ANGEW CHEM INT EDIT, V27, P490, DOI 10.1002/anie.198804901
   Kimura H, 2013, J PHYS CHEM A, V117, P2102, DOI 10.1021/jp312002h
   Kimura H, 2011, J PHYS CHEM A, V115, P14013, DOI 10.1021/jp206355e
   KRISHNAN R, 1980, J CHEM PHYS, V72, P650, DOI 10.1063/1.438955
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Lee YY, 2012, PHYS CHEM CHEM PHYS, V14, P13914, DOI 10.1039/c2cp42751f
   Lewis BE, 2006, J AM CHEM SOC, V128, P5049, DOI 10.1021/ja0573054
   McKay RT, 2011, CONCEPT MAGN RESON A, V38A, P197, DOI 10.1002/cmr.a.20223
   MCLEAN AD, 1980, J CHEM PHYS, V72, P5639, DOI 10.1063/1.438980
   MIERTUS S, 1981, CHEM PHYS, V55, P117, DOI 10.1016/0301-0104(81)85090-2
   MIERTUS S, 1982, CHEM PHYS, V65, P239, DOI 10.1016/0301-0104(82)85072-6
   Moulthrop JS, 2005, CHEM COMMUN, P1557, DOI 10.1039/b417745b
   Myers AG, 2000, J AM CHEM SOC, V122, P3236, DOI 10.1021/ja000136x
   Nair V, 2006, ACCOUNTS CHEM RES, V39, P520, DOI 10.1021/ar0502026
   Nashalian O, 2016, FOOD CHEM, V197, P489, DOI 10.1016/j.foodchem.2015.10.140
   Novoa-Carballal R, 2011, NAT PROD REP, V28, P78, DOI 10.1039/c005320c
   Ohmi Y, 2013, CHEMSUSCHEM, V6, P2259, DOI 10.1002/cssc.201300303
   PASCUALAHUIR JL, 1994, J COMPUT CHEM, V15, P1127, DOI 10.1002/jcc.540151009
   Qiao Y, 2014, ACS SUSTAIN CHEM ENG, V2, P2576, DOI 10.1021/sc5004693
   Qu YS, 2012, BIORESOURCE TECHNOL, V106, P170, DOI 10.1016/j.biortech.2011.11.069
   Shipar MA, 2011, J IRAN CHEM SOC, V8, P433, DOI 10.1007/BF03249077
   Silva AM, 2006, CARBOHYD RES, V341, P1029, DOI 10.1016/j.carres.2006.02.035
   Simpson AJ, 2005, J MAGN RESON, V175, P340, DOI 10.1016/j.jmr.2005.05.008
   STOTT K, 1995, J AM CHEM SOC, V117, P4199, DOI 10.1021/ja00119a048
   Tomasi J, 2005, CHEM REV, V105, P2999, DOI 10.1021/cr9904009
   Uslamin EA, 2019, CHEM ENG SCI, V198, P305, DOI 10.1016/j.ces.2018.09.023
   van Putten RJ, 2013, CHEM REV, V113, P1499, DOI 10.1021/cr300182k
   Wang H.-Y., 2015, RSC ADV, V5
   Wang M, 2018, ACS CATAL, V8, P2129, DOI 10.1021/acscatal.7b03790
   Wei YW, 2013, CHEM COMMUN, V49, P5408, DOI 10.1039/c3cc41661e
   Wolfe JP, 1998, ACCOUNTS CHEM RES, V31, P805, DOI 10.1021/ar9600650
   Wrodnigg TM, 1999, ANGEW CHEM INT EDIT, V38, P827, DOI 10.1002/(SICI)1521-3773(19990315)38:6<827::AID-ANIE827>3.0.CO;2-N
   Xu LJ, 2015, ACS SUSTAIN CHEM ENG, V3, P2890, DOI 10.1021/acssuschemeng.5b00841
   Yamabe S, 1999, J ORG CHEM, V64, P4519, DOI 10.1021/jo9815453
   Yan N, 2015, NATURE, V524, P155, DOI 10.1038/524155a
   Yang G, 2012, J CATAL, V295, P122, DOI 10.1016/j.jcat.2012.08.002
   Zhang J, 2012, ACS CATAL, V2, P1211, DOI 10.1021/cs300045r
   Zhang JM, 2010, PHYS CHEM CHEM PHYS, V12, P1941, DOI 10.1039/b920446f
   Zhang YC, 2016, GREEN CHEM, V18, P3139, DOI 10.1039/c6gc00038j
   Zhao HB, 2007, SCIENCE, V316, P1597, DOI 10.1126/science.1141199
NR 77
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115444
DI 10.1016/j.ces.2019.115444
PG 9
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100013
DA 2020-05-12
ER

PT J
AU Jin, B
   Zhao, YL
   Fan, YH
   Deng, ZK
   Liang, ZW
AF Jin, Bo
   Zhao, Yunlei
   Fan, Yihan
   Deng, Zhikai
   Liang, Zhiwu
TI Thermal management for chemical looping systems with chemical production
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Chemical looping; Process simulation; Heat integration; Thermodynamic
   evaluation; Exergy cost analysis
ID AIR SEPARATION; PURIFICATION UNIT; CO2 COMPRESSION; COMBUSTION PROCESS;
   EXERGY ANALYSIS; OXYGEN CARRIER; POWER; FUEL; CA; SIMULATION
AB Chemical looping technology is a promising pathway to realize a clean production of value-added chemicals with less energy penalty. Its core concept, utilizing heat storage in the cycled solid materials to maintain an efficient operation, needs further confirmation. Here, a combined thermal management method is firstly proposed to achieve an autothermal operation for chemical looping system. New dual fast fluidized bed reactors with optimal reaction temperatures are designed to match the redox reaction rates, while heat integration and exergy cost assessment are conducted to locate the source of thermodynamic irreversibility and interpret the cost formation process. The heat transfer between high temperature exhaust gases and low temperature inlet streams contributes to the main thermodynamic irreversibility and exergy cost. The external energy demand for system gets a maximum 62.37% decrement, the exergy efficiency shows a maximum 9.00% increment and the unit exergy cost for oxygen production gains a maximum 42.18% decrement. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Jin, Bo; Zhao, Yunlei; Fan, Yihan; Deng, Zhikai; Liang, Zhiwu] Hunan Univ, Coll Chem & Chem Engn, Joint Int Ctr CO2 Capture & Storage iCCS, Lushannan Rd 1, Changsha 410082, Hunan, Peoples R China.
RP Jin, B; Liang, ZW (reprint author), Hunan Univ, Coll Chem & Chem Engn, Joint Int Ctr CO2 Capture & Storage iCCS, Lushannan Rd 1, Changsha 410082, Hunan, Peoples R China.
EM kingjinbo1988@hnu.edu.cn; zwliang@hnu.edu.cn
OI Liang, Zhiwu/0000-0003-1935-0759
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21808050, 21978075, 21536003]; Natural Science
   Foundation of Hunan Province in ChinaNatural Science Foundation of Hunan
   Province [2018JJ3061]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [531107050907]
FX The authors gratefully acknowledge the financial supports of the
   National Natural Science Foundation of China (Grants 21808050, 21978075
   and 21536003), Natural Science Foundation of Hunan Province in China
   (Grant 2018JJ3061), and Fundamental Research Funds for the Central
   Universities (Grant 531107050907).
CR Abanades JC, 2010, ENVIRON SCI TECHNOL, V44, P6901, DOI 10.1021/es101707t
   Adanez J, 2018, PROG ENERG COMBUST, V65, P6, DOI 10.1016/j.pecs.2017.07.005
   Adanez J, 2012, PROG ENERG COMBUST, V38, P215, DOI 10.1016/j.pecs.2011.09.001
   Anheden M, 1998, ENERG CONVERS MANAGE, V39, P1967, DOI 10.1016/S0196-8904(98)00052-1
   Bejan A., 1996, THERMAL DESIGN OPTIM
   Chan MSC, 2018, J CATAL, V359, P1, DOI 10.1016/j.jcat.2017.12.030
   Chen SY, 2018, APPL THERM ENG, V132, P8, DOI 10.1016/j.applthermaleng.2017.12.070
   Deng ZK, 2018, ENERG CONVERS MANAGE, V160, P289, DOI 10.1016/j.enconman.2018.01.039
   Erlach B, 1999, ENERG CONVERS MANAGE, V40, P1627, DOI 10.1016/S0196-8904(99)00057-6
   Fan L.-S., 2017, CHEM LOOPING PARTIAL
   Fan LS, 2015, AICHE J, V61, P2, DOI 10.1002/aic.14695
   Farooqui A, 2019, ENERG CONVERS MANAGE, V186, P200, DOI 10.1016/j.enconman.2019.02.043
   Fleischer V, 2018, J CATAL, V360, P102, DOI 10.1016/j.jcat.2018.01.022
   Gaol WB, 2018, NAT ENERGY, V3, P1067, DOI 10.1038/s41560-018-0268-z
   Hu J, 2016, J CO2 UTIL, V16, P8, DOI 10.1016/j.jcou.2016.05.006
   Jin B, 2016, CHEM ENG SCI, V144, P336, DOI 10.1016/j.ces.2016.01.044
   Jin B, 2015, ENERG CONVERS MANAGE, V106, P53, DOI 10.1016/j.enconman.2015.09.014
   Jin B, 2015, ENERG CONVERS MANAGE, V99, P92, DOI 10.1016/j.enconman.2015.04.031
   Jin B, 2015, ENERGY, V83, P416, DOI 10.1016/j.energy.2015.02.039
   Jung JW, 2008, POWDER TECHNOL, V183, P401, DOI 10.1016/j.powtec.2008.01.019
   Kemp I.C., 2011, PINCH ANAL PROCESS I
   Kunii D., 1991, FLUIDIZATION ENG
   Liao JW, 2019, CHEM ENG J, V372, P1028, DOI 10.1016/j.cej.2019.04.212
   Lyngfelt A, 2001, CHEM ENG SCI, V56, P3101, DOI 10.1016/S0009-2509(01)00007-0
   Moghtaderi B, 2010, ENERG FUEL, V24, P190, DOI 10.1021/ef900553j
   Nurdiawati A, 2019, CHEM ENG RES DES, V146, P311, DOI 10.1016/j.cherd.2019.04.013
   Proll T, 2009, AICHE J, V55, P3255, DOI 10.1002/aic.11934
   Fernandez JR, 2019, CHEM ENG SCI, V193, P120, DOI 10.1016/j.ces.2018.09.001
   Scott SA, 2006, AICHE J, V52, P3325, DOI 10.1002/aic.10942
   Shi B, 2017, ENERGY, V134, P449, DOI 10.1016/j.energy.2017.05.080
   Song H., 2015, CHEM LOOPING AIR SEP
   Tasirin SM, 1998, POWDER TECHNOL, V95, P240, DOI 10.1016/S0032-5910(97)03343-3
   Tian SC, 2016, APPL ENERG, V170, P345, DOI 10.1016/j.apenergy.2016.02.120
   Tian X, 2018, CHEM ENG J, V334, P611, DOI 10.1016/j.cej.2017.10.084
   Wang K, 2016, J THERM ANAL CALORIM, V124, P1555, DOI 10.1007/s10973-016-5237-9
   Wang K, 2016, CHEM ENG J, V287, P292, DOI 10.1016/j.cej.2015.11.009
   Wang S, 2014, CHEM ENG J, V236, P121, DOI 10.1016/j.cej.2013.09.033
   Yusuf S, 2018, APPL CATAL B-ENVIRON, V232, P77, DOI 10.1016/j.apcatb.2018.03.037
   Zeng L, 2018, NAT REV CHEM, V2, P349, DOI 10.1038/s41570-018-0046-2
   Zhang YW, 2017, CHEM ENG J, V320, P271, DOI 10.1016/j.cej.2017.03.046
   Zhang ZW, 2018, INT J GREENH GAS CON, V71, P36, DOI 10.1016/j.ijggc.2018.02.004
   Zhao X, 2017, ENERG ENVIRON SCI, V10, P1885, DOI 10.1039/c6ee03718f
   Zhao YL, 2018, ENERG CONVERS MANAGE, V171, P1685, DOI 10.1016/j.enconman.2018.06.101
   Zhao ZL, 2014, FUEL, V121, P327, DOI 10.1016/j.fuel.2013.11.056
NR 44
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115431
DI 10.1016/j.ces.2019.115431
PG 12
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100009
DA 2020-05-12
ER

PT J
AU Li, DD
   Wang, YQ
   Wu, L
   Yang, FS
   Wu, Z
   Zheng, L
   Song, J
   Zang, XY
   Zhang, ZX
AF Li, Dandi
   Wang, Yuqi
   Wu, Le
   Yang, Fusheng
   Wu, Zhen
   Zheng, Lan
   Song, Jing
   Zang, Xiyu
   Zhang, Zaoxiao
TI Kinetics study on the nonlinear modified varying-size model of LaNi5
   during hydrogenation/dehydrogenation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Metal hydride; Kinetics; Varying-size model; Nonlinear modified;
   Hydrogenation/dehydrogenation
ID HYDROGEN ABSORPTION-DESORPTION; DEHYDRIDING KINETICS; HYDRIDING
   KINETICS; ALLOY; NI; BEHAVIOR; PHASE; CELL; AL
AB Due to the large kinetics model deviation caused by the actual expansion/shrinkage of LaNi5 particle during H-2 absorption/desorption process, the nonlinear modified varying-size model (M-VSM) was proposed based on varying-size model (VSM) to calibrate the kinetics equations precisely. The related hydriding and dehydriding kinetics experiments were conducted under various temperatures and pressures, and the model equations of LaNi5 were achieved based on M-VSM. Both experimental and simulation results confirmed the rate controlling step was internal diffusion. Moreover, the model accuracy of M-VSM was investigated and compared with other conventional models, and the results indicated that M-VSM owned the highest model precision than any other models including shrinking-core model, Johnson-MehlAvrami model and Jander diffusion model. Furthermore, the simplified hydriding/dehydriding equations were also derived, whose correlation coefficient R-2 could reach 0.98 and 0.99, respectively. Hence the M-VSM has favorable accuracy and convenience which will show its great potential application in the future. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Li, Dandi; Wang, Yuqi; Wu, Le; Zheng, Lan; Song, Jing; Zang, Xiyu] Northwest Univ, Sch Chem Engn, Xian 710069, Peoples R China.
   [Wang, Yuqi] Tsinghua Univ, Dept Chem Engn, State Key Lab Chem Engn, Beijing 100084, Peoples R China.
   [Yang, Fusheng; Wu, Zhen; Zhang, Zaoxiao] Xi An Jiao Tong Univ, Sch Chem Engn & Technol, Xian 710049, Peoples R China.
RP Wang, YQ (reprint author), Northwest Univ, Sch Chem Engn, Xian 710069, Peoples R China.
EM wangyuqi@nwu.edu.cn
RI Wang, Yuqi/J-1632-2017
OI Wang, Yuqi/0000-0001-6230-0330; Wu, Le/0000-0002-0346-8376
FU National Natural Science Foundation of China under ChinaNational Natural
   Science Foundation of China [21276209, 21808183]; Local Service Fund of
   Education Department of Shaanxi Province [18JC031]; State Key Laboratory
   of Chemical Engineering [SKL-ChE-18A02]
FX This project was supported by the National Natural Science Foundation of
   China under China (21276209 and 21808183), Local Service Fund of
   Education Department of Shaanxi Province (18JC031) and State Key
   Laboratory of Chemical Engineering (No. SKL-ChE-18A02).
CR AKIBA E, 1987, J LESS-COMMON MET, V129, P159, DOI 10.1016/0022-5088(87)90043-9
   Anikina ID, 2017, INT J HYDROGEN ENERG, V42, P636, DOI 10.1016/j.ijhydene.2016.04.256
   Ao BY, 2005, J ALLOY COMPD, V390, P122, DOI 10.1016/j.jallcom.2004.05.092
   Briki C., 2019, INT J HYDROGEN ENERG
   Briki C, 2017, INT J HYDROGEN ENERG, V42, P10081, DOI 10.1016/j.ijhydene.2017.02.065
   Charlas B, 2012, INT J HYDROGEN ENERG, V37, P16031, DOI 10.1016/j.ijhydene.2012.07.091
   Chou KC, 2005, INT J HYDROGEN ENERG, V30, P301, DOI 10.1016/j.ijhydene.2004.04.006
   Drozdov IV, 2015, INT J HYDROGEN ENERG, V40, P10111, DOI 10.1016/j.ijhydene.2015.05.119
   Eikani MH, 2019, RENEW ENERG, V131, P660, DOI 10.1016/j.renene.2018.07.091
   GOUDY AJ, 1983, J LESS-COMMON MET, V91, P149, DOI 10.1016/0022-5088(83)90103-0
   Homma S, 2005, CHEM ENG SCI, V60, P4971, DOI 10.1016/j.ces.2005.03.057
   Jander W, 1938, Z ANORG ALLG CHEM, V239, P418, DOI 10.1002/zaac.19382390408
   KOH JT, 1989, J LESS-COMMON MET, V153, P89, DOI 10.1016/0022-5088(89)90536-5
   Kumar S, 2018, J THERM ANAL CALORIM, V134, P889, DOI 10.1007/s10973-018-7403-8
   Kumar S, 2017, RENEW SUST ENERG REV, V72, P791, DOI 10.1016/j.rser.2017.01.063
   Li SL, 2009, J ALLOY COMPD, V485, P867, DOI 10.1016/j.jallcom.2009.06.111
   Liu W, 2016, INT J HYDROGEN ENERG, V41, P1679, DOI 10.1016/j.ijhydene.2015.10.128
   Lototskyy MV, 2014, INT J HYDROGEN ENERG, V39, P5818, DOI 10.1016/j.ijhydene.2014.01.158
   Lototskyy MV, 2017, PROG NAT SCI-MATER, V27, P3, DOI 10.1016/j.pnsc.2017.01.008
   Luo Q, 2010, INT J HYDROGEN ENERG, V35, P7842, DOI 10.1016/j.ijhydene.2010.05.073
   Mellouli S, 2016, INT J HYDROGEN ENERG, V41, P1711, DOI 10.1016/j.ijhydene.2015.10.058
   Mi T., 2018, INT J HYDROGEN ENERG
   MIYAMOTO M, 1983, J LESS-COMMON MET, V89, P111, DOI 10.1016/0022-5088(83)90254-0
   Nakamura Y, 1998, J ALLOY COMPD, V267, P205, DOI 10.1016/S0925-8388(97)00503-3
   Okumura M, 2012, INT J HYDROGEN ENERG, V37, P6686, DOI 10.1016/j.ijhydene.2012.01.097
   ONO S, 1985, J LESS-COMMON MET, V113, P113, DOI 10.1016/0022-5088(85)90153-5
   Ribeiro ES, 2015, INT J HYDROGEN ENERG, V40, P14900, DOI 10.1016/j.ijhydene.2015.08.063
   Shahgaldi S, 2012, J ALLOY COMPD, V541, P335, DOI 10.1016/j.jallcom.2012.06.124
   Sharma VK, 2017, INT J HYDROGEN ENERG, V42, P437, DOI 10.1016/j.ijhydene.2016.09.154
   SNIJDER ED, 1993, AICHE J, V39, P1444, DOI 10.1002/aic.690390904
   Song J, 2018, CHEM ENG SCI, V176, P580, DOI 10.1016/j.ces.2017.11.010
   SOUBEYROUX JL, 1987, J LESS-COMMON MET, V129, P181, DOI 10.1016/0022-5088(87)90046-4
   Stamatakis E., 2018, RENEW ENERG
   Tatsumi K, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.184105
   WALTERS RT, 1990, J LESS-COMMON MET, V157, P97, DOI 10.1016/0022-5088(90)90410-L
   Wang YQ, 2010, INT J HYDROGEN ENERG, V35, P321, DOI 10.1016/j.ijhydene.2009.10.085
   Wjihi S, 2016, FLUID PHASE EQUILIBR, V414, P170, DOI 10.1016/j.fluid.2016.01.029
   Xie LS, 2017, INT J HYDROGEN ENERG, V42, P21121, DOI 10.1016/j.ijhydene.2017.07.046
   Yang T, 2018, J POWER SOURCES, V378, P636, DOI 10.1016/j.jpowsour.2018.01.003
   Zhang CY, 2008, PHYSICA B, V403, P2372, DOI 10.1016/j.physb.2007.12.019
   ZHANG W, 1993, J ALLOY COMPD, V201, P175, DOI 10.1016/0925-8388(93)90880-V
   Zhevago N.K., 2016, COMPEND HYDROG ENERG, P189
NR 42
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115439
DI 10.1016/j.ces.2019.115439
PG 15
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100017
DA 2020-05-12
ER

PT J
AU Lian, WH
   Pan, XE
   Li, ZC
   Yang, JX
   Hao, XG
   Zhang, H
   Fushimi, C
   Tsutsumi, A
   Huang, W
   Guan, GQ
AF Lian, Wenhao
   Pan, Xueer
   Li, Zhengchen
   Yang, Jingxuan
   Hao, Xiaogang
   Zhang, Hui
   Fushimi, Chihiro
   Tsutsumi, Atsushi
   Huang, Wei
   Guan, Guoqing
TI A drag model considering the particle size distribution via
   multi-subgrid for the simulation of downer
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Flow behavior; Drag model; Particle size distribution; Downer; CFD;
   Sub-grid
ID GAS-SOLID FLOW; CIRCULATING FLUIDIZED-BED; COARSE GRID SIMULATION; CFD
   SIMULATION; BEHAVIORS; PYROLYSIS; BUBBLE; HYDRODYNAMICS; VALIDATION;
   VELOCITY
AB A new drag model, which is developed from the perspective of the particle size distribution (PSD), was proposed to improve the prediction accuracy for the simulation of flow behaviors in the downer. In this model, the actual control volume was divided into several sub-grids characterized by different characteristic particle sizes, and the total drag force was obtained by summing all the sub-grids drag forces. To obtain the slip velocity for each sub-grid separately, the widely-used Richardson-Zaki (R-Z) equation was introduced into each sub-grid. The simulation results showed that this model can more accurately predict the average solids holdup than other models, as well as the axial solids holdup distribution. Also, the axial pressure and pressure gradient distribution were given, and the unique flow pattern in the downer can be clearly captured. This model is expected to provide a new idea for the simulation of low solids holdup gas-solids system with a wide PSD. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lian, Wenhao; Pan, Xueer; Li, Zhengchen; Yang, Jingxuan; Hao, Xiaogang] Taiyuan Univ Technol, Sch Chem & Chem Engn, Taiyuan 030024, Peoples R China.
   [Zhang, Hui] Univ Western Ontario, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
   [Fushimi, Chihiro] Tokyo Univ Agr & Technol, Dept Chem Engn, 2-24-16 Naka Cho, Koganei, Tokyo 1848588, Japan.
   [Tsutsumi, Atsushi] Univ Tokyo, Grad Sch Art & Sci, Meguro Ku, Komaba Org Educ Excellence, 3-8-1 Komaba, Tokyo 1538902, Japan.
   [Huang, Wei] Taiyuan Univ Technol, Minist Educ & Shanxi Prov, Key Lab Coal Sci & Technol, Taiyuan 030024, Peoples R China.
   [Guan, Guoqing] Hirosaki Univ, IRI, Lab Energy Convers Engn, 2-1-3 Matsubara, Aomori, Osaka 0300813, Japan.
RP Hao, XG (reprint author), Taiyuan Univ Technol, Sch Chem & Chem Engn, Taiyuan 030024, Peoples R China.; Huang, W (reprint author), Taiyuan Univ Technol, Minist Educ & Shanxi Prov, Key Lab Coal Sci & Technol, Taiyuan 030024, Peoples R China.; Guan, GQ (reprint author), Hirosaki Univ, IRI, Lab Energy Convers Engn, 2-1-3 Matsubara, Aomori, Osaka 0300813, Japan.
EM xghao@tyut.edu.cn; huangwei@tyut.edu.cn; guan@hirosaki-u.ac.jp
RI Fushimi, Chihiro/B-9979-2013; Guan, Guoqing/K-6555-2013
OI Fushimi, Chihiro/0000-0003-2219-3117; Guan, Guoqing/0000-0002-5875-3596
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1710101]; Special Talents Project of Shanxi
   Province [201605D211005]; JSPS KAKENHIMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT)Japan Society for the
   Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)
   [17H03451]
FX This work was supported by the National Natural Science Foundation of
   China (No. U1710101), the Special Talents Project of Shanxi Province
   (No. 201605D211005), and the JSPS KAKENHI Grant-in-Aid for Scientific
   Research B (Kiban B, 17H03451), Japan.
CR Anantharaman A, 2015, CHEM ENG SCI, V130, P92, DOI 10.1016/j.ces.2015.03.022
   Andreux R, 2008, AICHE J, V54, P406, DOI 10.1002/aic.11390
   BAEYENS J, 1974, CHEM ENG SCI, V29, P255, DOI 10.1016/0009-2509(74)85051-7
   Chen HZ, 2018, POWDER TECHNOL, V323, P163, DOI 10.1016/j.powtec.2017.10.015
   Chen XZ, 2011, POWDER TECHNOL, V205, P276, DOI 10.1016/j.powtec.2010.09.039
   Chen XZ, 2013, CHEM ENG J, V234, P173, DOI 10.1016/j.cej.2013.08.108
   Cheng Y, 2008, POWDER TECHNOL, V183, P364, DOI 10.1016/j.powtec.2008.01.022
   FRYER C, 1976, AICHE J, V22, P38, DOI 10.1002/aic.690220104
   Fushimi C, 2014, ADV POWDER TECHNOL, V25, P379, DOI 10.1016/j.apt.2013.06.007
   Fushimi C, 2012, POWDER TECHNOL, V221, P70, DOI 10.1016/j.powtec.2011.12.017
   Gao JS, 2008, CHEM ENG SCI, V63, P1827, DOI 10.1016/j.ces.2007.12.009
   GARSIDE J, 1977, IND ENG CHEM PROC DD, V16, P206, DOI 10.1021/i260062a008
   Guan GQ, 2011, CHEM ENG SCI, V66, P4212, DOI 10.1016/j.ces.2011.06.006
   Guan GQ, 2010, PARTICUOLOGY, V8, P602, DOI 10.1016/j.partic.2010.07.013
   Hou BL, 2016, CHEM ENG J, V284, P1224, DOI 10.1016/j.cej.2015.09.073
   KHAN AR, 1989, CHEM ENG COMMUN, V78, P111, DOI 10.1080/00986448908940189
   Kwauk M., 1963, SCI SINICA, V6, P135
   Li J H, 2005, MULTISCALE SIMULATIO
   Li JH, 2003, CHEM ENG SCI, V58, P521, DOI 10.1016/S0009-2509(02)00577-8
   Lian WH, 2018, POWDER TECHNOL, V336, P573, DOI 10.1016/j.powtec.2018.06.029
   Lin CL, 2011, POWDER TECHNOL, V207, P290, DOI 10.1016/j.powtec.2010.11.010
   Liu W, 2001, POWDER TECHNOL, V115, P27, DOI 10.1016/S0032-5910(00)00276-X
   Liu WM, 2015, POWDER TECHNOL, V286, P516, DOI 10.1016/j.powtec.2015.08.049
   LOCKETT MJ, 1967, CHEM ENG SCI, V22, P1059, DOI 10.1016/0009-2509(67)80170-2
   Lv XL, 2014, CHEM ENG J, V236, P149, DOI 10.1016/j.cej.2013.09.067
   Ma JS, 2006, CHEM ENG SCI, V61, P7096, DOI 10.1016/j.ces.2006.07.042
   Maki T, 1997, ENERG FUEL, V11, P972, DOI 10.1021/ef960224w
   Qi XB, 2008, POWDER TECHNOL, V183, P417, DOI 10.1016/j.powtec.2008.01.018
   Qin ZY, 2019, CHEM ENG SCI, V207, P358, DOI 10.1016/j.ces.2019.06.037
   Shi XG, 2014, POWDER TECHNOL, V266, P135, DOI 10.1016/j.powtec.2014.06.025
   Shi ZS, 2011, CHEM ENG SCI, V66, P5541, DOI 10.1016/j.ces.2011.07.020
   van Wachem B, 2008, AICHE J, V54, P9, DOI 10.1002/aic.11335
   Wang JL, 2017, FUEL, V207, P126, DOI 10.1016/j.fuel.2017.06.078
   Wang JL, 2016, ENERG FUEL, V30, P9693, DOI 10.1021/acs.energyfuels.6b01599
   Wang SY, 2014, ADV POWDER TECHNOL, V25, P1103, DOI 10.1016/j.apt.2014.02.009
   Yang N, 2010, CHEM ENG SCI, V65, P517, DOI 10.1016/j.ces.2009.06.014
   Zhang H, 1999, CHEM ENG SCI, V54, P5461, DOI 10.1016/S0009-2509(99)00284-5
   Zhou Q, 2015, CHEM ENG SCI, V122, P637, DOI 10.1016/j.ces.2014.10.025
   Zhou RT, 2017, POWDER TECHNOL, V314, P466, DOI 10.1016/j.powtec.2016.09.083
   ZHU JX, 1995, CAN J CHEM ENG, V73, P662, DOI 10.1002/cjce.5450730510
   Zhu LT, 2019, CHEM ENG SCI, V204, P228, DOI 10.1016/j.ces.2019.04.026
   Zhu LT, 2019, CHEM ENG SCI, V196, P478, DOI 10.1016/j.ces.2018.11.026
   Zhu LT, 2018, CHEM ENG SCI, V192, P759, DOI 10.1016/j.ces.2018.08.026
NR 43
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115363
DI 10.1016/j.ces.2019.115363
PG 10
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100006
DA 2020-05-12
ER

PT J
AU Ma, CC
   Liu, JL
   Xie, SL
   Liu, YQ
AF Ma, Chicheng
   Liu, Jianlin
   Xie, Shilin
   Liu, Yongqi
TI Contact line instability of gravity driven thin films flowing down an
   inclined plane with wall slippage
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fingering instability; Slippery effect; Gravity driven films; Traveling
   wave; Three dimensional simulation
ID LIQUID-FILMS; FALLING FILM; FINGERING INSTABILITY; STABILITY; DYNAMICS;
   SURFACES; FLUID
AB Coating liquid films exist widely in nature and industrial processes, such as lava flows, falling-film evaporators, and microfabrication processes. In this paper, we aim to give a comprehensive study on contact line instability of thin film flows on a slippery substrate, which has different slippery lengths in the streamwise direction and the spanwise direction. It is reported here for thin film flows with contact lines, the streamwise slippery effect plays an opposite role compared with the spanwise slippery effect, different from the conclusion by Ding and Wong that the wall slippage always promoted the instability of the thin film flow [Ding and Wong, Int. J. Heat Mass Tran. 90, 2015]. The evolution equation of the thin film flow is derived by the lubrication theory, and traveling wave solutions are obtained, showing that with a larger streamwise slippery length, the traveling wave speed is promoted and a higher capillary ridge is induced. Linear stability analysis (LSA) and energy analysis are carried out to elucidate the mechanism of the flow instability. Results indicate that for thin film flows with dynamic contact lines, the slippery effect in the streamwise and spanwise direction plays different roles in the flow instability. The wall slippage in the streamwise direction suppresses the wave height of traveling waves and impedes the instability of the flow, while the wall slippage in the spanwise direction promotes the instability with a smaller cut off wavenumber. Besides, numerical simulations for thin film flows are performed, and the flow phenomenon agrees well with the prediction by the LSA. Our findings offer insight into the influence of the wall slippage on the dynamics of thin films coating on biomaterials and compliant substrates. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ma, Chicheng; Liu, Yongqi] Shandong Univ Technol, Sch Transportat & Vehicle Engn, Zibo 255000, Peoples R China.
   [Ma, Chicheng; Liu, Jianlin] China Univ Petr East China, Coll Pipeline & Civil Engn, Dept Engn Mech, Qingdao 266580, Peoples R China.
   [Xie, Shilin] Xi An Jiao Tong Univ, State Key Lab Strength & Vibrat Mech Struct, Xian 710049, Peoples R China.
RP Ma, CC (reprint author), Shandong Univ Technol, Sch Transportat & Vehicle Engn, Zibo 255000, Peoples R China.
EM machch@sdut.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [11702162, 11972375]; Natural Science Foundation of
   Shandong ProvinceNatural Science Foundation of Shandong Province
   [ZR2018LE014, ZR2018MEE006]
FX The authors acknowledge support from National Natural Science Foundation
   of China (Grant Nos. 11702162 and 11972375) and Natural Science
   Foundation of Shandong Province (Grant Nos. ZR2018LE014 and
   ZR2018MEE006).
CR Bertozzi AL, 1997, PHYS FLUIDS, V9, P530, DOI 10.1063/1.869217
   Chao YC, 2019, PHYS REV E, V99, DOI 10.1103/PhysRevE.99.043101
   Chao YC, 2018, CHEM ENG SCI, V175, P354, DOI 10.1016/j.ces.2017.10.013
   Craster RV, 2009, REV MOD PHYS, V81, P1131, DOI 10.1103/RevModPhys.81.1131
   Craster RV, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2180776
   Deblais A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12458
   Diez J.A., 2000, PHYS REV E, V63
   Diez JA, 2002, J COMPUT PHYS, V183, P274, DOI 10.1006/jcph.2002.7197
   Diez JA, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.3685802
   Ding ZJ, 2019, J FLUID MECH, V873, P835, DOI 10.1017/jfm.2019.450
   Ding ZJ, 2019, CHEM ENG SCI, V199, P342, DOI 10.1016/j.ces.2018.12.058
   Ding ZJ, 2015, INT J HEAT MASS TRAN, V90, P689, DOI 10.1016/j.ijheatmasstransfer.2015.07.003
   Ding ZJ, 2013, INT J HEAT MASS TRAN, V67, P627, DOI 10.1016/j.ijheatmasstransfer.2013.07.098
   Ding ZJ, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4808112
   Ding ZJ, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.046307
   Edmonstone BD, 2005, PHYSICA D, V209, P62, DOI 10.1016/j.physd.2005.06.014
   Edmonstone BD, 2005, J COLLOID INTERF SCI, V287, P261, DOI 10.1016/j.jcis.2005.01.105
   Edmonstone BD, 2004, J ENG MATH, V50, P141, DOI 10.1007/s10665-004-3689-6
   Gaskell PH, 2004, J FLUID MECH, V509, P253, DOI 10.1017/S0022112004009425
   Goddard JV, 2015, J FLUID MECH, V772, P535, DOI 10.1017/jfm.2015.212
   Golovin AA, 2001, LANGMUIR, V17, P3930, DOI 10.1021/la000859u
   GREENSPAN HP, 1978, J FLUID MECH, V84, P125, DOI 10.1017/S0022112078000075
   Hayes M, 2000, PHYS FLUIDS, V12, P2845, DOI 10.1063/1.1311970
   Hecht F., 2005, FREEFEM MANUAL
   Hu B, 2015, J NON-NEWTON FLUID, V225, P62, DOI 10.1016/j.jnnfm.2015.09.002
   HUPPERT HE, 1982, NATURE, V300, P427, DOI 10.1038/300427a0
   JERRETT JM, 1992, PHYS FLUIDS A-FLUID, V4, P234, DOI 10.1063/1.858351
   Liu JL, 2006, ACTA MECH SINICA-PRC, V22, P315, DOI 10.1007/s10409-006-0009-6
   Jiang JK, 2019, P NATL ACAD SCI USA, V116, P2482, DOI 10.1073/pnas.1817172116
   JOO SW, 1993, NUCL ENG DES, V141, P225, DOI 10.1016/0029-5493(93)90103-G
   Kalliadasis S, 2000, J FLUID MECH, V413, P355, DOI 10.1017/S0022112000008508
   Kim P, 2012, ACS NANO, V6, P6569, DOI 10.1021/nn302310q
   Kondic L, 2001, PHYS FLUIDS, V13, P3168, DOI 10.1063/1.1409965
   Kondic L, 2003, SIAM REV, V45, P95, DOI 10.1137/S003614450240135
   Leizerson I, 2004, LANGMUIR, V20, P291, DOI 10.1021/la034955h
   Lin C, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3314871
   Lin TS, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.3682001
   Liu JL, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/35/356002
   Liu JL, 2012, ACTA MECH SINICA-PRC, V28, P928, DOI 10.1007/s10409-012-0131-6
   Liu R, 2017, PHYS REV E, V95, DOI 10.1103/PhysRevE.95.053101
   Marshall JS, 2005, COMPUT FLUIDS, V34, P664, DOI 10.1016/j.compfluid.2004.06.002
   Matar OK, 2007, J ENG MATH, V57, P145, DOI 10.1007/s10665-006-9069-7
   Mayo LC, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.053018
   Munch A, 2005, PHYSICA D, V209, P178, DOI 10.1016/j.physd.2005.06.027
   Oron A, 1997, REV MOD PHYS, V69, P931, DOI 10.1103/RevModPhys.69.931
   Perazzo CA, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.016307
   Samanta A, 2013, J FLUID MECH, V716, P414, DOI 10.1017/jfm.2012.550
   Samanta A, 2011, J FLUID MECH, V684, P353, DOI 10.1017/jfm.2011.304
   SCHWARTZ LW, 1989, PHYS FLUIDS A-FLUID, V1, P443, DOI 10.1063/1.857466
   Spaid MA, 1996, PHYS FLUIDS, V8, P460, DOI 10.1063/1.868800
   Thiele U, 2003, PHYS FLUIDS, V15, P892, DOI 10.1063/1.1545443
   Tiwari N, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4871079
   Tiwari N, 2010, PHYS FLUIDS, V22, DOI 10.1063/1.3407645
   Tiwari N, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3241967
   Tiwari N, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3068757
   Tiwari N, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.056306
   Veremieiev S., 2011, GRAVITY DRIVEN CONTI
   Wong TS, 2011, NATURE, V477, P443, DOI 10.1038/nature10447
   Zhang XX, 2019, P NATL ACAD SCI USA, V116, P20863, DOI 10.1073/pnas.1912467116
NR 59
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115418
DI 10.1016/j.ces.2019.115418
PG 13
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100028
DA 2020-05-12
ER

PT J
AU Mansour, M
   Khot, P
   Thevenin, D
   Nigam, KDP
   Zahringer, K
AF Mansour, Michael
   Khot, Prafull
   Thevenin, Dominique
   Nigam, Krishna D. P.
   Zaehringer, Katharina
TI Optimal Reynolds number for liquid-liquid mixing in helical pipes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Liquid-liquid mixing; Optimal Reynolds number; Helical pipes;
   Computational fluid dynamics
ID COILED FLOW INVERTER; KENICS STATIC MIXER; HEAT-TRANSFER; LAMINAR
   DISPERSION; TURBULENT-FLOW; PRESSURE-DROP; ENHANCEMENT; PERFORMANCE;
   CURVATURE; TORSION
AB A computational study has been performed to determine the mixing behaviour of two miscible liquids in helical pipes with different geometrical dimensions. To evaluate the mixing efficiency between the two liquids, the scalar transport technique has been employed. The main objectives are to investigate the influence of the geometrical parameters on the mixing behaviour and to find the optimal values of Reynolds number (Re) corresponding to the highest possible mixing efficiencies, while keeping acceptable pressure drop. The Reynolds number has been varied broadly from Re = 5 to Re = 4000, corresponding to Dean numbers from De = 1 to De = 1500, covering a wide range of laminar flows relevant for practical applications. Three main geometrical parameters of the helical pipe have been considered; the coil pitch, the pipe diameter, and the coil diameter were varied in the ranges of 16-60 mm, 5-15 mm, and 70-150 mm, respectively. The results show that an increase in coil pitch results generally in lower mixing efficiencies, negligibly higher pressure drops, and lower values of optimal Reynolds numbers. Increasing the pipe diameter leads to lower mixing efficiencies but significantly lower pressure drops. Finally, as the coil diameter is increased, the mixing efficiency and the pressure drop are slightly reduced, while the optimal Reynolds number is moderately shifted to higher values. Furthermore, two optimal values of Reynolds number could be obtained for all configurations, leading systematically to high mixing performance, Re approximate to 40 and Re approximate to 750. The pressure drop for the lower value of the Reynolds number is considerably lower than that of the second optimal value, while mixing efficiency is comparable. Therefore, it is recommended to operate liquid-liquid mixing in helical reactors at Re approximate to 40. This value corresponds to the Dean number range of 7 <= De <= 15 for all the considered geometries. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Mansour, Michael; Khot, Prafull; Thevenin, Dominique; Zaehringer, Katharina] Univ Magdeburg Otto Von Guericke, Lab Fluid Dynam & Tech Flows, D-39106 Magdeburg, Germany.
   [Mansour, Michael] Helwan Univ, Fac Engn Mattaria, Mech Power Engn Dept, Cairo 11718, Egypt.
   [Nigam, Krishna D. P.] Indian Inst Technol Delhi, New Delhi 110016, India.
RP Mansour, M (reprint author), Univ Magdeburg Otto Von Guericke, Lab Fluid Dynam & Tech Flows, D-39106 Magdeburg, Germany.
EM michael.mansour@ovgu.de
OI Mansour, Michael/0000-0002-6404-9546
FU German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)German
   Research Foundation (DFG) [SFB/TR 63]; Egyptian government
FX This work is part of the Collaborative Research Center "Integrated
   Chemical Processes in Liquid Multiphase Systems" (Subpro-ject B1)
   coordinated by the Technische Universitt Berlin. Financial support by
   the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) is
   gratefully acknowledged (SFB/TR 63). The Ph.D. work of Mr. Mansour is
   partially supported by a scholarship from the Egyptian government.
CR Agrawal S, 2001, CHEM ENG J, V84, P437, DOI 10.1016/S1385-8947(00)00370-3
   Alam A, 2012, CHEM ENG J, V181, P708, DOI 10.1016/j.cej.2011.12.076
   Bessoth FG, 1999, ANAL COMMUN, V36, P213, DOI 10.1039/a902237f
   Branebjerg J, 1996, PROC IEEE MICR ELECT, P441, DOI 10.1109/MEMSYS.1996.494022
   Brodkey R., 2012, TURBULENCE MIXING OP
   Castelain C, 1997, EXP FLUIDS, V22, P359, DOI 10.1007/s003480050061
   Cioncolini A, 2006, EXP THERM FLUID SCI, V30, P367, DOI 10.1016/j.expthermflusci.2005.08.005
   Dean WR, 1928, PHILOS MAG, V5, P673
   Dean WR, 1927, PHILOS MAG, V4, P208
   Fsadni AM, 2016, APPL THERM ENG, V103, P616, DOI 10.1016/j.applthermaleng.2016.04.125
   Gelhausen MG, 2014, PROCEEDINGS OF THE ASME 12TH INTERNATIONAL CONFERENCE ON NANOCHANNELS, MICROCHANNELS, AND MINICHANNELS, 2014
   Hobbs DM, 1997, CHEM ENG J, V67, P153, DOI 10.1016/S1385-8947(97)00013-2
   Hohmann L, 2016, CHEM ENG TECHNOL, V39, P1268, DOI 10.1002/ceat.201600072
   Huttl TJ, 2001, COMPUT FLUIDS, V30, P591, DOI 10.1016/S0045-7930(01)00008-1
   Huttl TJ, 2000, INT J HEAT FLUID FL, V21, P345, DOI 10.1016/S0142-727X(00)00019-9
   Ito H., 1959, J BASIC ENGINEERIN D, V81, P123
   Jiang F, 2004, AICHE J, V50, P2297, DOI 10.1002/aic.10188
   Jokiel M, 2017, CHEM ENG SCI, V170, P410, DOI 10.1016/j.ces.2017.01.027
   Ju HM, 2001, J NUCL SCI TECHNOL, V38, P826, DOI 10.3327/jnst.38.826
   KOUTSKY JA, 1964, CAN J CHEM ENG, V42, P239, DOI 10.1002/cjce.5450420602
   Kumar V, 2008, CHEM ENG J, V139, P284, DOI 10.1016/j.cej.2007.07.101
   Kumar V, 2007, CHEM ENG SCI, V62, P2386, DOI 10.1016/j.ces.2007.01.032
   Kumar V, 2006, CHEM ENG SCI, V61, P5742, DOI 10.1016/j.ces.2006.04.040
   Kumar V, 2006, CHEM ENG SCI, V61, P4403, DOI 10.1016/j.ces.2006.01.039
   Kumar V, 2008, CHEM ENG PROCESS, V47, P2287, DOI 10.1016/j.cep.2008.01.001
   Kurt SK, 2017, IND ENG CHEM RES, V56, P11320, DOI 10.1021/acs.iecr.7b02240
   Kurt SK, 2016, CHEM ENG J, V284, P764, DOI 10.1016/j.cej.2015.08.099
   Lasbet Y, 2007, HEAT TRANSFER ENG, V28, P795, DOI 10.1080/01457630701328908
   LIOU TM, 1992, EXP FLUIDS, V13, P332
   Litster S, 2006, HEAT MASS TRANSFER, V42, P387, DOI 10.1007/s00231-005-0029-y
   Liu RH, 2000, J MICROELECTROMECH S, V9, P190, DOI 10.1109/84.846699
   Mandal MM, 2011, IND ENG CHEM RES, V50, P13230, DOI 10.1021/ie2002473
   Mandal MM, 2011, MICROFLUID NANOFLUID, V10, P415, DOI 10.1007/s10404-010-0679-z
   Mansour M, 2018, CHEM ENG SCI, V177, P369, DOI 10.1016/j.ces.2017.11.031
   Mansour M, 2017, CHEM ENG SCI, V172, P250, DOI 10.1016/j.ces.2017.06.015
   Mansur EA, 2008, CHINESE J CHEM ENG, V16, P503, DOI 10.1016/S1004-9541(08)60114-7
   MISHRA P, 1979, IND ENG CHEM PROC DD, V18, P130, DOI 10.1021/i260069a017
   Miyake R., 1993, Proceedings. IEEE. Micro Electro Mechanical Systems. An Investigation of Micro Structures, Sensors, Actuators, Machines and Systems (Cat. No.93CH3265-6), P248, DOI 10.1109/MEMSYS.1993.296914
   Mohammed HA, 2012, INT COMMUN HEAT MASS, V39, P1375, DOI 10.1016/j.icheatmasstransfer.2012.07.019
   Mrldha M, 2008, CHEM ENG SCI, V63, P1724, DOI 10.1016/j.ces.2007.10.028
   Nguyen NT, 2005, J MICROMECH MICROENG, V15, pR1, DOI 10.1088/0960-1317/15/2/R01
   Nigam K.D.P., 1986, ENCVCL FLUID MECH, V1, P675
   Ottino J. M., 1989, KINEMATICS MIXING ST, V3
   Plouffe P, 2012, PROCEEDINGS OF THE ASME 10TH INTERNATIONAL CONFERENCE ON NANOCHANNELS, MICROCHANNELS AND MINICHANNELS 2012, P611
   Rennie TJ, 2005, EXP THERM FLUID SCI, V29, P919, DOI 10.1016/j.expthermflusci.2005.02.001
   Salem MR, 2016, J THERM SCI ENG APPL, V8, DOI 10.1115/1.4030732
   SAXENA AK, 1983, CAN J CHEM ENG, V61, P53, DOI 10.1002/cjce.5450610109
   SAXENA AK, 1979, CHEM ENG SCI, V34, P425, DOI 10.1016/0009-2509(79)85079-4
   SAXENA AK, 1984, AICHE J, V30, P363, DOI 10.1002/aic.690300303
   SCHMIDT EF, 1967, CHEM-ING-TECH, V39, P781, DOI 10.1002/cite.330391302
   Sharma L, 2017, CHEM ENG SCI, V160, P227, DOI 10.1016/j.ces.2016.11.034
   SINGH D, 1981, J APPL POLYM SCI, V26, P785, DOI 10.1002/app.1981.070260304
   SREENIVASAN KR, 1983, EXP FLUIDS, V1, P31, DOI 10.1007/BF00282264
   Srinivasan P., 1968, CHEM ENG, V218, pCE113
   Tang LD, 2017, ADV MECH ENG, V9, DOI 10.1177/1687814017700059
   Tang LD, 2016, ADV MECH ENG, V8, DOI 10.1177/1687814016660242
   Thakur RK, 2003, CHEM ENG RES DES, V81, P787, DOI 10.1205/026387603322302968
   Tohidi A, 2015, APPL THERM ENG, V86, P91, DOI 10.1016/j.applthermaleng.2015.04.043
   Vanka SP, 2004, AICHE J, V50, P2359, DOI 10.1002/aic.10196
   Vashisth S, 2008, IND ENG CHEM RES, V47, P3291, DOI 10.1021/ie701760h
   WANG CY, 1981, J FLUID MECH, V108, P185, DOI 10.1017/S0022112081002073
   Wiggins S, 2004, PHILOS T ROY SOC A, V362, P937, DOI 10.1098/rsta.2003.1356
   Yamagishi A, 2007, INT J HEAT MASS TRAN, V50, P1238, DOI 10.1016/j.ijheatmasstransfer.2006.09.033
   YAMAMOTO K, 1994, FLUID DYN RES, V14, P259, DOI 10.1016/0169-5983(94)90035-3
   Yasuo M, 1965, INT J HEAT MASS TRAN, V8, P67, DOI [10.1016/0017-9310(65)90098-0, DOI 10.1016/0017-9310(65)90098-0]
NR 65
TC 5
Z9 5
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 114522
DI 10.1016/j.ces.2018.09.046
PG 16
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100036
DA 2020-05-12
ER

PT J
AU Mishra, I
   Liu, PY
   Shetty, A
   Hrenya, CM
AF Mishra, Ipsita
   Liu, Peiyuan
   Shetty, Abhishek
   Hrenya, Christine M.
TI On the use of a powder rheometer to probe defluidization of cohesive
   particles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
ID NANOSCALE ROUGH SURFACES; MICRO FLUIDIZED-BEDS; VAN-DER-WAALS; CFD-DEM;
   INTERPARTICLE FORCES; AERATED POWDERS; FLOW PROPERTIES; WALL FRICTION;
   SIMULATION; ADHESION
AB Inter-particle cohesion plays an important role in various industrial unit operations. Recently, particle defluidization was identified as a bulk measurement that can be used to extract inter-particle cohesion (Liu et al., 2018). This method requires direct-coupling of experimental, "standard" defluidization curves (pressure-drop vs. gas velocity) with discrete-element-method (DEM) simulations; "standard" refers to defluidization without channeling. Hence, the method is not readily applicable to highly-cohesive (Group C) particles that exhibit channeling. In this work, we obtain standard-defluidization-curves for Group C particles using a rheometer with a rotating impeller. Then, we confirm that the measurements from the rheometer are system-size-independent, thereby ensuring the feasibility of direct-coupling of the experiments with smaller DEM simulations. Furthermore, we show that the torque required to rotate the impeller may provide an alternative to the pressure-drop to characterize particle defluidization. Finally, we show that the extracted characteristic-velocities from these experiments may provide a relative-gauge for particle-level cohesion. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mishra, Ipsita; Liu, Peiyuan; Hrenya, Christine M.] Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80303 USA.
   [Shetty, Abhishek] Anton Paar USA Inc, Rheol Dept, 10215 Timber Ridge Dr, Ashland, VA 23005 USA.
RP Hrenya, CM (reprint author), Univ Colorado, Dept Chem & Biol Engn, Boulder, CO 80303 USA.
EM hrenya@colorado.edu
FU National Science FoundationNational Science Foundation (NSF)
   [CBET-1707046]
FX The authors are grateful for the financial support provided by the
   National Science Foundation (CBET-1707046). The authors would also like
   to gratefully acknowledge Anton Paar for providing the rheometer through
   their VIP academic research program. The authors thank Michael Molnar,
   Jing Huang, and Margaret Hwang of Dow for stimulating discussions.
CR Alobaid F, 2014, PARTICUOLOGY, V16, P41, DOI 10.1016/j.partic.2013.11.004
   Amritkar A, 2014, J COMPUT PHYS, V256, P501, DOI 10.1016/j.jcp.2013.09.007
   Bharadwaj R, 2010, CHEM ENG SCI, V65, P5747, DOI 10.1016/j.ces.2010.04.002
   Boyce CM, 2018, POWDER TECHNOL, V336, P12, DOI 10.1016/j.powtec.2018.05.027
   Bruni G, 2005, CHEM ENG RES DES, V83, P1311, DOI 10.1205/cherd.05092
   Bruni G, 2007, CHEM ENG SCI, V62, P397, DOI 10.1016/j.ces.2006.08.060
   Butt HJ, 2005, SURF SCI REP, V59, P1, DOI 10.1016/j.surfrep.2005.08.003
   Cappella B, 1999, SURF SCI REP, V34, P1, DOI 10.1016/S0167-5729(99)00003-5
   Carman P.C., 1937, T I CHEM ENG-LOND, V15, P17, DOI [10.1016/S0263-8762(97)80003-2, DOI 10.1016/S0263-8762(97)80003-2]
   Castellanos A, 1999, PHYS REV LETT, V82, P1156, DOI 10.1103/PhysRevLett.82.1156
   Castellanos A, 2005, ADV PHYS, V54, P263, DOI 10.1080/17461390500402657
   Chen YH, 2010, COLLOID SURFACE A, V361, P66, DOI 10.1016/j.colsurfa.2010.03.015
   Chew JW, 2010, AICHE J, V56, P3049, DOI 10.1002/aic.12219
   Chirone R., 2018, THESIS
   Claesson PM, 1996, ADV COLLOID INTERFAC, V67, P119, DOI 10.1016/0001-8686(96)00302-8
   Cocco R, 2017, CHEM ENG PROG, V113, P38
   Cooper K, 2001, J COLLOID INTERF SCI, V234, P284, DOI 10.1006/jcis.2000.7276
   Di Maio FP, 2004, CHEM ENG SCI, V59, P3461, DOI 10.1016/j.ces.2004.05.014
   Ducker W.A., 1991, NATURE COM, DOI [10.1111/j.1365- 2966.2009.15405.x, DOI 10.1111/J.1365-2966.2009.15405.X]
   Eichenlaub S, 2004, J COLLOID INTERF SCI, V280, P289, DOI 10.1016/j.jcis.2004.08.017
   Fernandez N, 2015, LANGMUIR, V31, P8809, DOI 10.1021/acs.langmuir.5b01086
   Forsyth AJ, 2002, POWDER TECHNOL, V126, P150, DOI 10.1016/S0032-5910(02)00046-3
   Freeman R, 2007, POWDER TECHNOL, V174, P25, DOI 10.1016/j.powtec.2006.10.016
   Freyssingeas E, 2011, PHYS REV E, V83, DOI 10.1103/PhysRevE.83.051307
   GELDART D, 1984, POWDER TECHNOL, V37, P25, DOI 10.1016/0032-5910(84)80003-0
   GELDART D, 1973, POWDER TECHNOL, V7, P285, DOI 10.1016/0032-5910(73)80037-3
   Herminghaus S, 2005, ADV PHYS, V54, P221, DOI 10.1080/00018730500167855
   Hou QF, 2012, CHEM ENG SCI, V84, P449, DOI 10.1016/j.ces.2012.08.051
   Jaiswal RP, 2009, LANGMUIR, V25, P10612, DOI 10.1021/la804275m
   Jones R, 2003, POWDER TECHNOL, V132, P196, DOI 10.1016/S0032-5910(03)00072-X
   Kunii D., 1991, FLUIDIZATION ENG
   LaMarche CQ, 2017, CHEM ENG J, V310, P259, DOI 10.1016/j.cej.2016.10.119
   LaMarche CQ, 2017, CHEM ENG SCI, V158, P140, DOI 10.1016/j.ces.2016.09.024
   LaMarche CQ, 2016, AICHE J, V62, P3585, DOI 10.1002/aic.15281
   LaMarche CQ, 2015, AICHE J, V61, P4051, DOI 10.1002/aic.15057
   LARSON I, 1993, J AM CHEM SOC, V115, P11885, DOI 10.1021/ja00078a029
   Leturia M, 2014, POWDER TECHNOL, V253, P406, DOI 10.1016/j.powtec.2013.11.045
   Li TW, 2012, PARTICUOLOGY, V10, P532, DOI 10.1016/j.partic.2012.02.006
   Liu PY, 2018, PHYS REV LETT, V121, DOI 10.1103/PhysRevLett.121.238001
   Liu PY, 2018, AICHE J, V64, P2329, DOI 10.1002/aic.16089
   Liu PY, 2016, AICHE J, V62, P3529, DOI 10.1002/aic.15383
   Liu PY, 2016, CHEM ENG SCI, V145, P266, DOI 10.1016/j.ces.2016.02.024
   Liu PY, 2014, POWDER TECHNOL, V264, P620, DOI 10.1016/j.powtec.2014.04.095
   Liu XH, 2008, CHEM ENG J, V137, P302, DOI 10.1016/j.cej.2007.04.035
   Loezos PN, 2002, CHEM ENG SCI, V57, P5123, DOI 10.1016/S0009-2509(02)00421-9
   Luding S, 2005, J PHYS-CONDENS MAT, V17, pS2623, DOI 10.1088/0953-8984/17/24/017
   McCarthy JJ, 2003, POWDER TECHNOL, V138, P63, DOI 10.1016/j.powtec.2003.08.042
   McMillan J, 2013, CHEM ENG SCI, V100, P39, DOI 10.1016/j.ces.2013.02.047
   Mikami T, 1998, CHEM ENG SCI, V53, P1927, DOI 10.1016/S0009-2509(97)00325-4
   Mitarai N, 2006, ADV PHYS, V55, P1, DOI 10.1080/00018730600626065
   MOLERUS O, 1982, POWDER TECHNOL, V33, P81, DOI 10.1016/0032-5910(82)85041-9
   Muller CR, 2008, POWDER TECHNOL, V184, P241, DOI 10.1016/j.powtec.2007.11.046
   Rabinovich YI, 2000, J COLLOID INTERF SCI, V232, P10, DOI 10.1006/jcis.2000.7167
   Rabinovich YI, 2000, J COLLOID INTERF SCI, V232, P17, DOI 10.1006/jcis.2000.7168
   Rhodes M. J., 2008, INTRO PARTICLE TECHN
   Rhodes MJ, 2001, CHEM ENG SCI, V56, P69, DOI 10.1016/S0009-2509(00)00427-9
   Rognon PG, 2006, EUROPHYS LETT, V74, P644, DOI 10.1209/epl/i2005-10578-y
   Rumpf H., 1990, PARTICLE TECHNOLOGY
   Salehi H, 2018, PARTICUL SCI TECHNOL, V36, P501, DOI 10.1080/02726351.2017.1409850
   Salehi H, 2017, AICHE J, V63, P4788, DOI 10.1002/aic.15934
   Salehi H, 2017, PARTICUOLOGY, V32, P10, DOI 10.1016/j.partic.2016.08.003
   Seville JPK, 2000, POWDER TECHNOL, V113, P261, DOI 10.1016/S0032-5910(00)00309-0
   Shabanian J, 2015, CHEM ENG J, V259, P135, DOI 10.1016/j.cej.2014.07.117
   Srivastava A, 2002, POWDER TECHNOL, V124, P45, DOI 10.1016/S0032-5910(01)00471-5
   Stevens AB, 2005, POWDER TECHNOL, V154, P99, DOI 10.1016/j.powtec.2005.04.033
   Tegzes P, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.094301
   Tomas J, 2004, CHEM ENG TECHNOL, V27, P605, DOI 10.1002/ceat.200406134
   TSINONTIDES SC, 1993, J FLUID MECH, V255, P237, DOI 10.1017/S0022112093002472
   Valverde JM, 2006, EUROPHYS LETT, V75, P985, DOI 10.1209/epl/i2006-10208-4
   Valverde JM, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.051305
   VISSER J, 1989, POWDER TECHNOL, V58, P1, DOI 10.1016/0032-5910(89)80001-4
   Wang ZL, 1998, CHEM ENG SCI, V53, P377, DOI 10.1016/S0009-2509(97)00280-7
   Xu YP, 2017, POWDER TECHNOL, V318, P321, DOI 10.1016/j.powtec.2017.06.020
   Yang RY, 2003, J APPL PHYS, V94, P3025, DOI 10.1063/1.1598638
NR 74
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115422
DI 10.1016/j.ces.2019.115422
PG 10
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100005
DA 2020-05-12
ER

PT J
AU Qian, ZY
   Guo, R
   Ma, YL
   Li, CJ
   Du, L
   Wang, Y
   Du, CY
   Huo, H
   Yin, GP
AF Qian, Zhengyi
   Guo, Rui
   Ma, Yulin
   Li, Changjin
   Du, Lei
   Wang, Yang
   Du, Chunyu
   Huo, Hua
   Yin, Geping
TI Se-doped carbon as highly stable cathode material for high energy
   nonaqueous Li-O-2 batteries
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Li-O-2 battery; Se-doped carbon; Discharge; Stability
ID PERFORMANCE; REDUCTION; NITROGEN; NANOTUBES; ELECTRODE; CATALYST
AB Hetero-doped carbon materials have been generally applied as the cathode materials for Li-O-2 batteries due to the improved catalytic activity. However, they commonly suffer from performance fading because of carbon corrosion under harsh oxidative environments in Li-O-2 batteries. Herein, an elegant cathode material for Li-O-2 batteries is developed through doping Se in carbon. The results show that the Se-doped carbon cathode reveals 53% higher discharge capacity, decreased overpotential and superior rate capability. Structure evolution analysis and density functional theory calculation reveal that the products mainly grow via solution driven mechanism, which can better sustain discharge. Se-doped carbon cathode also presents high stability due to its prominent antioxidant ability, efficiently suppressing the side reaction and cathode passivation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Qian, Zhengyi; Ma, Yulin; Li, Changjin; Du, Lei; Wang, Yang; Du, Chunyu; Huo, Hua; Yin, Geping] Harbin Inst Technol, Inst Adv Chem Power Sources, Sch Chem & Chem Engn, Harbin 150001, Peoples R China.
   [Guo, Rui] Shanghai Inst Space Power Sources, State Key Lab Space Power Sources Technol, Shanghai 200245, Peoples R China.
   [Qian, Zhengyi; Ma, Yulin; Li, Changjin; Du, Lei; Wang, Yang; Du, Chunyu; Huo, Hua; Yin, Geping] Harbin Inst Technol, MIIT Key Lab Crit Mat Technol New Energy Convers, Harbin 150001, Peoples R China.
RP Ma, YL (reprint author), Harbin Inst Technol, Inst Adv Chem Power Sources, Sch Chem & Chem Engn, Harbin 150001, Peoples R China.
EM mayulin@hit.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21773049, 21433003]; Shanghai Aerospace Science and
   Technology Innovation Fund [SAST2017-138]; Natural Science Foundation of
   Heilongjiang ProvinceNatural Science Foundation of Heilongjiang Province
   [LH2019B008]
FX This research work was supported by National Natural Science Foundation
   of China (21773049 and 21433003), Shanghai Aerospace Science and
   Technology Innovation Fund (SAST2017-138), and Natural Science
   Foundation of Heilongjiang Province (LH2019B008).
CR Andersson MP, 2005, J PHYS CHEM A, V109, P2937, DOI 10.1021/jp045733a
   Belova AI, 2017, J PHYS CHEM C, V121, P1569, DOI 10.1021/acs.jpcc.6b12221
   Cao XC, 2015, ACS CATAL, V5, P4890, DOI 10.1021/acscatal.5b00494
   Du L, 2016, NANO ENERGY, V29, P314, DOI 10.1016/j.nanoen.2016.03.016
   Feng NN, 2016, ADV ENERGY MATER, V6, DOI 10.1002/aenm.201502303
   Freunberger SA, 2011, J AM CHEM SOC, V133, P8040, DOI 10.1021/ja2021747
   Frisch MJ, 2009, GAUSSIAN 09 REVISION, V27, P34
   Grande L, 2015, ADV MATER, V27, P784, DOI 10.1002/adma.201403064
   Guo DH, 2016, SCIENCE, V351, P361, DOI 10.1126/science.aad0832
   Guo ZY, 2013, ADV MATER, V25, P5668, DOI 10.1002/adma.201302459
   Han J., 2016, ADV ENERGY MAT, V6
   Hua C, 2018, J ALLOY COMPD, V749, P378, DOI 10.1016/j.jallcom.2018.03.297
   Itkis DM, 2013, NANO LETT, V13, P4697, DOI 10.1021/nl4021649
   Jiang HR, 2016, J PHYS CHEM C, V120, P6612, DOI 10.1021/acs.jpcc.6b00136
   Jin ZP, 2012, NANOSCALE, V4, P6455, DOI 10.1039/c2nr31858j
   Johnson L, 2014, NAT CHEM, V6, P1091, DOI [10.1038/NCHEM.2101, 10.1038/nchem.2101]
   Kicinski W, 2018, MICROPOR MESOPOR MAT, V272, P260, DOI 10.1016/j.micromeso.2018.06.047
   LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785
   Li F, 2017, ANGEW CHEM INT EDIT, V129, P10042, DOI DOI 10.1002/ange.201705989
   Li YL, 2011, ELECTROCHEM COMMUN, V13, P668, DOI 10.1016/j.elecom.2011.04.004
   Ma L, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201800348
   Nakanishi S, 2012, CARBON, V50, P4794, DOI 10.1016/j.carbon.2012.06.003
   Peng ZQ, 2011, ANGEW CHEM INT EDIT, V50, P6351, DOI 10.1002/anie.201100879
   Shui JL, 2014, ACS NANO, V8, P3015, DOI 10.1021/nn500327p
   Thomas ML, 2015, CHEM COMMUN, V51, P3977, DOI 10.1039/c4cc08815h
   Thotiyl MMO, 2013, J AM CHEM SOC, V135, P494, DOI 10.1021/ja310258x
   Trahan MJ, 2014, J ELECTROCHEM SOC, V161, pA1706, DOI 10.1149/2.0981410jes
   Wong RA, 2018, ACS ENERGY LETT, V3, P592, DOI 10.1021/acsenergylett.8b00054
   Wu F, 2016, ACS APPL MATER INTER, V8, P23635, DOI 10.1021/acsami.6b05403
   Yang J, 2018, ELECTROCHIM ACTA, V264, P341, DOI 10.1016/j.electacta.2018.01.105
   Yang LJ, 2011, ANGEW CHEM INT EDIT, V50, P7132, DOI 10.1002/anie.201101287
   Yang WC, 2017, CARBON, V118, P139, DOI 10.1016/j.carbon.2017.03.037
   Yin W, 2017, J PHYS CHEM LETT, V8, P214, DOI 10.1021/acs.jpclett.6b02610
   Zimmerman MT, 2015, J INORG BIOCHEM, V145, P30, DOI 10.1016/j.jinorgbio.2014.12.020
NR 34
TC 1
Z9 1
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115413
DI 10.1016/j.ces.2019.115413
PG 7
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100001
DA 2020-05-12
ER

PT J
AU Quezada, GR
   Saavedra, JH
   Rozas, RE
   Toledo, PG
AF Quezada, Gonzalo R.
   Saavedra, Jorge H.
   Rozas, Roberto E.
   Toledo, Pedro G.
TI Molecular dynamics simulations of the conformation and diffusion of
   partially hydrolyzed polyacrylamide in highly saline solutions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
ID HYDROGEN-BOND LIFETIME; CHARGED POLYELECTROLYTES; ANIONIC
   POLYACRYLAMIDE; VISCOELASTIC BEHAVIOR; WATER; FLOCCULATION; IONS;
   CALCIUM; POLYMER; MODEL
AB The impact of salts on partially hydrolyzed polyacrylamide (HPAM) is of great interest in mineral processing, considering that the use of seawater seems to be the only sustainable solution in regions with severe aridity. Here the conformation and transport of an HPAM chain in several saline solutions are studied by means of molecular dynamics simulations. Results indicate that the electrostatic repulsion between anionic acrylate units causes the polymer to adopt diverse and complex expanded tertiary conformations, however in the presence of cations this repulsion is shielded causing the polymer to fold into balledup conformations. The structure assumed by the HPAM chain depends slightly on the type of cation and much on intramolecular crosslinking. Cations influence the ordering of water structure and orientation of water dipoles reducing the mobility of water, ions, and HPAM. These results are expected to contribute to a better understanding of particle flocculation for sustainable water management. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Quezada, Gonzalo R.; Toledo, Pedro G.] Univ Concepcion, Water Res Ctr Agr & Min CRHIAM, Concepcion, Chile.
   [Saavedra, Jorge H.] Univ Bio Bio, Dept Wood Engn, Av Collao 1202,POB 5-C, Concepcion, Chile.
   [Rozas, Roberto E.] Univ Bio Bio, Dept Phys, Av Collao 1202,POB 5-C, Concepcion, Chile.
   [Toledo, Pedro G.] Univ Concepcion, Dept Chem Engn, POB 160-C,Correo 3, Concepcion, Chile.
   [Toledo, Pedro G.] Univ Concepcion, Lab Surface Anal ASIF, POB 160-C,Correo 3, Concepcion, Chile.
RP Toledo, PG (reprint author), Univ Concepcion, Water Res Ctr Agr & Min CRHIAM, Concepcion, Chile.; Toledo, PG (reprint author), Univ Concepcion, Dept Chem Engn, POB 160-C,Correo 3, Concepcion, Chile.
EM gonzaloquezada@udec.cl; jsaavedra@ubiobio.cl; rrozas@ubiobio.cl;
   petoledo@udec.cl
OI Quezada, Gonzalo R./0000-0002-8670-6260
FU Centro CRHIAM Project [Conicyt/Fondap/15130015]; FONDEQUIP [EQM150134];
   Universidad de Concepcion; CONICYT-ChileComision Nacional de
   Investigacion Cientifica y Tecnologica (CONICYT)
FX We thank Centro CRHIAM Project Conicyt/Fondap/15130015 for financial
   support and the Southern GPU-cluster (SGPU-C) UDEC funded by FONDEQUIP
   EQM150134 for computational support. GRQ thanks Universidad de
   Concepcion and CONICYT-Chile for graduate student fellowships.
CR Abdel-Azeim S, 2018, ENERG FUEL, V32, P3335, DOI 10.1021/acs.energyfuels.8b00010
   Antipova ML, 2013, RUSS J PHYS CHEM A+, V87, P1170, DOI 10.1134/S0036024413070030
   Bakker HJ, 2009, NAT CHEM, V1, P24, DOI 10.1038/nchem.154
   Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2
   BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E
   BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   BERG JM, 1993, J COLLOID INTERF SCI, V161, P182, DOI 10.1006/jcis.1993.1457
   Carnal F, 2012, J PHYS CHEM A, V116, P6600, DOI 10.1021/jp3010019
   CASKEY JA, 1986, ENVIRON PROG, V5, P98, DOI 10.1002/ep.670050210
   Castro S, 2015, MINER ENG, V74, P13, DOI 10.1016/j.mineng.2014.12.027
   Chen PK, 2012, J MOL MODEL, V18, P3153, DOI 10.1007/s00894-011-1332-9
   CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   Dewan S, 2014, LANGMUIR, V30, P8056, DOI 10.1021/la5011055
   Friedman M, 2015, FOOD FUNCT, V6, P1752, DOI [10.1039/c5fo00320b, 10.1039/C5FO00320B]
   Goni C, 2015, COLLOID SURFACE A, V482, P500, DOI 10.1016/j.colsurfa.2015.06.036
   Greenwell HC, 2006, J MATER CHEM, V16, P708, DOI 10.1039/b506932g
   Gregory J, 2011, ADV COLLOID INTERFAC, V169, P1, DOI 10.1016/j.cis.2011.06.004
   Hsiao PY, 2008, J PHYS CHEM B, V112, P7347, DOI 10.1021/jp800331b
   Jeldres RI, 2015, ADV COLLOID INTERFAC, V224, P62, DOI 10.1016/j.cis.2015.07.009
   Jeldres RI, 2014, COLLOID SURFACE A, V461, P295, DOI 10.1016/j.colsurfa.2014.08.003
   Katiyar RS, 2017, POLYMER, V114, P266, DOI 10.1016/j.polymer.2017.03.007
   Kopecek J, 2009, J POLYM SCI POL CHEM, V47, P5929, DOI 10.1002/pola.23607
   Kurenkov VF, 2001, RUSS J APPL CHEM+, V74, P1600, DOI 10.1023/A:1013746311198
   Larentzos JP, 2008, J PHYS CHEM B, V112, P14243, DOI 10.1021/jp802771w
   Laskowski J.S., 2012, P 13 INT MIN PROC S, P219
   Lee SS, 2011, J SOIL WATER CONSERV, V66, P172, DOI 10.2489/jswc.66.3.172
   Li PF, 2015, J CHEM THEORY COMPUT, V11, P1645, DOI 10.1021/ct500918t
   Li PF, 2014, J CHEM THEORY COMPUT, V10, P289, DOI 10.1021/ct400751u
   MARCUS Y, 1988, CHEM REV, V88, P1475, DOI 10.1021/cr00090a003
   Marcus Y, 2009, CHEM REV, V109, P1346, DOI 10.1021/cr8003828
   MICHAELS AS, 1954, IND ENG CHEM, V46, P1485, DOI 10.1021/ie50535a049
   Nair RK, 2006, J DISPER SCI TECHNOL, V27, P1021, DOI 10.1080/01932690600767072
   Nasser MS, 2006, SEP PURIF TECHNOL, V52, P241, DOI 10.1016/j.seppur.2006.04.005
   OHTAKI H, 1993, CHEM REV, V93, P1157, DOI 10.1021/cr00019a014
   Patel KH, 2017, MOL SIMULAT, V43, P691, DOI 10.1080/08927022.2017.1295454
   PENG FF, 1994, J COLLOID INTERF SCI, V164, P229, DOI 10.1006/jcis.1994.1161
   Quezada G, 2017, MINER ENG, V110, P131, DOI 10.1016/j.mineng.2017.04.017
   Quezada GR, 2017, J PHYS CHEM C, V121, P25271, DOI 10.1021/acs.jpcc.7b08836
   Ramos O, 2013, MINER ENG, V53, P108, DOI 10.1016/j.mineng.2013.07.009
   Ran QP, 2015, COMP MATER SCI, V109, P90, DOI 10.1016/j.commatsci.2015.06.020
   Rath D, 2015, BIOCHIMIE, V117, P119, DOI 10.1016/j.biochi.2015.03.025
   Simmons CS, 2013, LAB CHIP, V13, P646, DOI 10.1039/c2lc41110e
   Singh V, 2009, J HAZARD MATER, V166, P327, DOI 10.1016/j.jhazmat.2008.11.026
   SMITHPALMER T, 1990, CAN J CHEM, V68, P26, DOI 10.1139/v90-006
   Sorin EJ, 2005, BIOPHYS J, V88, P2472, DOI 10.1529/biophysj.104.051938
   Stevens MJ, 2001, BIOPHYS J, V80, P130, DOI 10.1016/S0006-3495(01)76000-6
   Voloshin VP, 2009, J STRUCT CHEM+, V50, P78, DOI 10.1007/s10947-009-0010-6
   Wang H, 2012, J COLLOID INTERF SCI, V386, P205, DOI 10.1016/j.jcis.2012.07.026
   Wang YF, 2013, SCI JUSTICE, V53, P350, DOI 10.1016/j.scijus.2013.04.007
   Wong SS, 2006, J HAZARD MATER, V135, P378, DOI 10.1016/j.jhazmat.2005.11.076
   Yang T.-H., 2008, RECENT PAT MAT SCI, V1, P29, DOI DOI 10.2174/1874465610801010029
   Yethiraj A, 2017, J PHYS CHEM B, V121, P6294, DOI 10.1021/acs.jpcb.7b05957
   Yuan R, 2013, COLLOID SURFACE A, V434, P16, DOI 10.1016/j.colsurfa.2013.05.036
   Yuxin Pei, 2016, Petroleum, V2, P399, DOI 10.1016/j.petlm.2016.08.006
   Zhang WF, 2016, ACS APPL MATER INTER, V8, P21816, DOI 10.1021/acsami.6b07018
   Zheng HL, 2013, ASIAN J CHEM, V25, P7071, DOI 10.14233/ajchem.2013.15144
NR 58
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115366
DI 10.1016/j.ces.2019.115366
PG 11
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100021
DA 2020-05-12
ER

PT J
AU Rahmani, F
   Weathers, T
   Hosangadi, A
   Chiew, YC
AF Rahmani, Farzin
   Weathers, Timothy
   Hosangadi, Ashvin
   Chiew, Yee C.
TI A non-equilibrium molecular dynamics study of subcritical, supercritical
   and transcritical mixing of liquid-gas systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Non-equilibrium molecular dynamics simulation; Subcritical mixing;
   Transcritical mixing; Supercritical mixing; Liquid-vapor interface
ID STEADY-STATE HEAT; TRANSFER-COEFFICIENTS; MASS-TRANSPORT; CONDENSATION;
   SIMULATIONS; EVAPORATION; INTERFACE; FLUID; VAPORIZATION; SURFACE
AB A non-equilibrium molecular dynamics (NEMD) simulation method has been developed to simulate mixing of a liquid with a vapor and identify the characteristics of the liquid-vapor interface in the mixing process. Our results show that for the case of subcritical mixing, local phase equilibrium is established, and saturated liquid and saturated vapor are formed on either side of the interface at the prevailing saturation temperature that is fixed by the pressure of the system independent of the temperature difference across the interface. For transcritical mixing, significant clustering of molecules is found at the "transitional diffuse" interface. We found that the local density and local temperature of the transcritical interface can be directly mapped to the near critical region of the Ar/Ar and Kr/Ar vapor-liquid phase diagram. Finally, for the case of supercritical mixing, our simulations show a gradual change of density consistent with diffusion-controlled fluid mixing. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rahmani, Farzin; Chiew, Yee C.] Rutgers Univ New Brunswick, Dept Chem & Biochem Engn, Piscataway, NJ 08854 USA.
   [Weathers, Timothy; Hosangadi, Ashvin] Combust Res & Flow Technol Inc, Pipersville, PA 18947 USA.
RP Chiew, YC (reprint author), Rutgers Univ New Brunswick, Dept Chem & Biochem Engn, Piscataway, NJ 08854 USA.
EM ychiew@scarletmail.rutgers.edu
FU Air Force Phase II STTR contract [FA9550-17-C-0015]; AFOSR, United
   States
FX This work is being performed under Air Force Phase II STTR contract
   FA9550-17-C-0015 with Dr. Malissa Lightfoot as the technical monitor. We
   gratefully acknowledge support from AFOSR, United States, for this STTR
   program. We would also like to thank Drs. Chiping Li, Malissa Lightfoot,
   Jeff Mills, and Venke Sankaran for their technical feedback during the
   course of this work.
CR Bedeaux D, 2004, CHEM ENG SCI, V59, P109, DOI 10.1016/j.ces.2003.09.028
   Bedeaux D, 2018, ENTROPY-SWITZ, V20, DOI 10.3390/e20040250
   Bellan J, 2000, PROG ENERG COMBUST, V26, P329, DOI 10.1016/S0360-1285(00)00008-3
   Chehroudi B, 2012, INT J AEROSPACE ENG, DOI 10.1155/2012/121802
   Chen L, 2013, CHEM ENG SCI, V97, P67, DOI 10.1016/j.ces.2013.04.010
   Dahms RN, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4820346
   DEAVEN DM, 1995, PHYS REV LETT, V75, P288, DOI 10.1103/PhysRevLett.75.288
   Dunweg B, 1991, INT J MOD PHYS C, V2, P817, DOI 10.1142/S0129183191001037
   Givler SD, 1996, PROG ENERG COMBUST, V22, P1, DOI 10.1016/0360-1285(95)00013-5
   Huai XL, 2005, CHEM ENG SCI, V60, P3337, DOI 10.1016/j.ces.2005.02.039
   Inzoli I, 2011, CHEM ENG SCI, V66, P4533, DOI 10.1016/j.ces.2011.06.011
   Kjelstrup S, 1996, IND ENG CHEM RES, V35, P4203, DOI 10.1021/ie960199h
   Mayer WOH, 1998, J PROPUL POWER, V14, P835, DOI 10.2514/2.5348
   Meland R, 2004, PHYS FLUIDS, V16, P223, DOI 10.1063/1.1630797
   Meland R, 2003, PHYS FLUIDS, V15, P3244, DOI 10.1063/1.1604779
   Meland R, 2002, J CHEM PHYS, V117, P7254, DOI 10.1063/1.1502252
   Mo GY, 2017, COMBUST FLAME, V176, P60, DOI 10.1016/j.combustflame.2016.09.028
   Olivier ML, 2002, COLLOID SURFACE A, V210, P199, DOI 10.1016/S0927-7757(02)00378-3
   Oschwald M, 2006, COMBUST SCI TECHNOL, V178, P49, DOI 10.1080/00102200500292464
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Rosjorde A, 2001, J COLLOID INTERF SCI, V240, P355, DOI 10.1006/jcis.2001.7611
   Rosjorde A, 2000, J COLLOID INTERF SCI, V232, P178, DOI 10.1006/jcis.2000.7203
   Savin T., 2016, APS M
   SCHNEIDER T, 1978, PHYS REV B, V17, P1302, DOI 10.1103/PhysRevB.17.1302
   Schweizer M, 2016, PHYS REV E, V93, DOI 10.1103/PhysRevE.93.052803
   Segal C, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2912055
   Simon JM, 2006, J PHYS CHEM B, V110, P18528, DOI 10.1021/jp062047y
   Simon JM, 2004, J PHYS CHEM B, V108, P7186, DOI 10.1021/jp0375719
   Talu O, 2001, COLLOID SURFACE A, V187, P83, DOI 10.1016/S0927-7757(01)00628-8
   Tsuruta T, 2005, ENERGY, V30, P795, DOI 10.1016/j.energy.2004.04.011
   Wilhelmsen O, 2015, J PHYS CHEM C, V119, P8160, DOI 10.1021/acs.jpcc.5b00615
   Xu J, 2006, J COLLOID INTERF SCI, V299, P452, DOI 10.1016/j.jcis.2006.01.043
   Yang V, 2000, P COMBUST INST, V28, P925, DOI 10.1016/S0082-0784(00)80299-4
NR 33
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115424
DI 10.1016/j.ces.2019.115424
PG 12
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100029
DA 2020-05-12
ER

PT J
AU Saikali, E
   Rodio, MG
   Bois, G
   Bieder, U
   Leterrier, N
   Bertrand, M
   Dolias, Y
AF Saikali, E.
   Rodio, M. G.
   Bois, G.
   Bieder, U.
   Leterrier, N.
   Bertrand, M.
   Dolias, Y.
TI Validation of the hydrodynamics in a turbulent un-baffled stirred tank:
   A necessity for vortex-reactor precipitation studies
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Reactor with vortex effect (RVE); Large Eddy Simulation (LES);
   Wall-adapting local eddy-viscosity (WALE); Chemical reactors; TrioCFD;
   Mesh sensitivity
ID FLOW; LES; SIMULATIONS; VESSEL
AB This paper is devoted to large eddy simulations of a turbulent flow in an un-baffled stirred tank reactor with vortex effect. The work aims at providing reference solutions regarding the hydrodynamics and the different mixing regions. Such data serve in modelling the precipitation process that takes place in many chemical engineering applications. The numerical study is performed by the open source TrioCFD code that employs a discontinuous front-tracking algorithm to solve the free surface at the top of the reactor. A sufficiently converged mesh has been identified from a sensitivity analysis where a convergence at the same order of the employed numerical scheme has been recorded. The quality of the resolved fields confirm that the performed LES is good and that the mesh size is almost of the Taylor turbulent micro-scale order. The converged statistical fields have shown a good agreement with both the theoretical models and the experimental measurements. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Saikali, E.; Rodio, M. G.; Bois, G.; Bieder, U.; Leterrier, N.] Univ Paris Saclay, STMF, CEA, DEN, F-91191 Gif Sur Yvette, France.
   [Bertrand, M.] CEA, DEN Dept Rech Proc Mine & Recyclage Combustible D, F-30207 Bagnols Sur Ceze, France.
   [Dolias, Y.] CEA, DRT, DPI, F-38000 Grenoble, France.
RP Saikali, E (reprint author), Univ Paris Saclay, STMF, CEA, DEN, F-91191 Gif Sur Yvette, France.
EM elie.saikali@cea.fr
FU Cross-Disciplinary Program on Numerical Simulation of CEA; French
   Alternative Energies; Atomic Energy CommissionFrench Atomic Energy
   Commission
FX The authors would like to gratefully thank Christophe Bourcier for his
   help with the SALOME platform. This work was granted access to the HPC
   resources of CINES under the allocations A0052A07571 and A0062B07712
   made by GENCI, attributed bonus hours used. We acknowledge the financial
   support of the Cross-Disciplinary Program on Numerical Simulation of
   CEA, the French Alternative Energies and Atomic Energy Commission.
CR Altman DG, 2005, BRIT MED J, V331, P903, DOI 10.1136/bmj.331.7521.903
   Angeli P.E., 2015, OVERVIEW TRIO CFD CO
   Armenante PM, 1997, CHEM ENG SCI, V52, P3483, DOI 10.1016/S0009-2509(97)00150-4
   Auchapt P., 1981, BREVET FR
   Belliard M, 2016, COMPUT MATH APPL, V71, P1089, DOI 10.1016/j.camwa.2016.01.024
   Bertrand M, 2012, CHEM ENG SCI, V77, P95, DOI 10.1016/j.ces.2012.03.019
   Brucato A, 1998, CHEM ENG SCI, V53, P3653, DOI 10.1016/S0009-2509(98)00149-3
   Ciofalo M, 1996, CHEM ENG SCI, V51, P3557, DOI 10.1016/0009-2509(96)00004-8
   Delafosse A, 2008, CHEM ENG RES DES, V86, P1322, DOI 10.1016/j.cherd.2008.07.008
   du Cluzeau A, 2020, J FLUID MECH, V882, DOI 10.1017/jfm.2019.807
   du Cluzeau A, 2019, J FLUID MECH, V866, P132, DOI 10.1017/jfm.2019.100
   Fadlun EA, 2000, J COMPUT PHYS, V161, P35, DOI 10.1006/jcph.2000.6484
   Fortin T., 2006, THESIS
   Giaiotti D.B., 2006, RANKINE VORTEX MODEL
   Labourasse E, 2007, INT J MULTIPHAS FLOW, V33, P1, DOI 10.1016/j.ijmultiphaseflow.2006.05.010
   Lamarque N, 2010, CHEM ENG SCI, V65, P4307, DOI 10.1016/j.ces.2010.03.014
   Le Lan A., 1972, Chemical Engineering Science, V27, P1969, DOI 10.1016/0009-2509(72)87055-6
   McDonald John H., 2009, HDB BIOL STAT, V2
   Murthy BN, 2008, CHEM ENG SCI, V63, P5468, DOI 10.1016/j.ces.2008.06.019
   Nagata S., 1955, MEM FAC ENG KYOTO U, V17, P175
   Nicoud F, 1999, FLOW TURBUL COMBUST, V62, P183, DOI 10.1023/A:1009995426001
   Perry J.H., 1950, CHEM ENG HDB
   Saikali E, 2019, INT J HYDROGEN ENERG, V44, P8856, DOI 10.1016/j.ijhydene.2018.08.108
   Saikali E., 2018, THESIS
   Smagorinsky J., 1963, MON WEATHER REV, V91, P99, DOI [10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)091, 10.1175/1520-0493(1963)091<less than>0099:GCEWTP<greater than>2.3.CO;2]
   TIAO GC, 1990, J GEOPHYS RES-ATMOS, V95, P20507, DOI 10.1029/JD095iD12p20507
   Xuereb C., 2006, AGITATION MELANGE AS
   YIANNESKIS M, 1987, J FLUID MECH, V175, P537, DOI 10.1017/S002211208700051X
   Yoon HS, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3210776
NR 29
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115426
DI 10.1016/j.ces.2019.115426
PG 19
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100030
DA 2020-05-12
ER

PT J
AU Shi, ZN
   Liang, H
   Yang, WY
   Liu, J
   Liu, ZL
   Qiao, ZW
AF Shi, Zenan
   Liang, Hong
   Yang, Wenyuan
   Liu, Jie
   Liu, Zili
   Qiao, Zhiwei
TI Machine learning and in silico discovery of metal-organic frameworks:
   Methanol as a working fluid in adsorption-driven heat pumps and chillers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Metal-organic frameworks; Adsorption; Molecular simulation;
   Computational screening; Machine learning
ID STRUCTURE-PROPERTY RELATIONSHIP; COMPUTATION-READY; GAS-ADSORPTION; CO2
   CAPTURE; FORCE-FIELD; CARBON; SEPARATION; PREDICTION; CAPACITY; STORAGE
AB With the increasingly serious energy-consumption, the adsorption-driven heat pumps/chillers were paid more attention. To select the promising adsorbents and suitable working fluids in this technology, a high-throughput computational screening of 6013 computation-ready experimental metal organic frameworks (MOFs) is employed to identity the best candidates for methanol-MOF pairs in adsorption-driven heat pumps and chillers. The highest working capacity (Delta W) and coefficient of performance (COP) under operating condition of heat pump are 512.86 mg/g and 1.83, respectively. The structure-performance relationships are derived for Delta W and COP with 6 MOF descriptors, the saturated Delta W is, for the first time, defined for the improvement of heat pump efficiency, and 10 best MOFs are identified. Then four machine learning algorithms are applied to predict the relative importance of each MOF descriptor. The microscopic insights obtained from our bottom-up approach provide the guidelines for the design of new MOFs in adsorption-driven heat pumps and chillers. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shi, Zenan; Liang, Hong; Yang, Wenyuan; Liu, Zili; Qiao, Zhiwei] Guangzhou Univ, Sch Chem & Chem Engn, Guangzhou Key Lab New Energy & Green Catalysis, Guangzhou 510006, Peoples R China.
   [Liu, Jie] Wuhan Inst Technol, Sch Chem Engn & Pharm, Key Lab Green Chem Proc, Minist Educ, Wuhan 430073, Peoples R China.
RP Qiao, ZW (reprint author), Guangzhou Univ, Sch Chem & Chem Engn, Guangzhou Key Lab New Energy & Green Catalysis, Guangzhou 510006, Peoples R China.
EM zqiao@gzhu.edu.cn
OI Shi, Zenan/0000-0002-4966-8306
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676094, 21576058, 21676060, 21706197]
FX The authors are very grateful for the financial support from the
   National Natural Science Foundation of China (Nos. 21676094, 21576058,
   21676060, and 21706197).
CR Aghaji MZ, 2016, EUR J INORG CHEM, P4505, DOI 10.1002/ejic.201600365
   Altintas C, 2018, ACS APPL MATER INTER, V10, P17257, DOI 10.1021/acsami.8b04600
   Altintas C, 2018, ACS APPL MATER INTER, V10, P3668, DOI 10.1021/acsami.7b18037
   Budhathoki S, 2019, ENERG ENVIRON SCI, V12, P1255, DOI 10.1039/c8ee02582g
   Campana C, 2009, J CHEM THEORY COMPUT, V5, P2866, DOI 10.1021/ct9003405
   Chung YG, 2014, CHEM MATER, V26, P6185, DOI 10.1021/cm502594j
   Darunte LA, 2019, IND ENG CHEM RES, V58, P366, DOI 10.1021/acs.iecr.8b05042
   de Lange MF, 2015, CHEM REV, V115, P12205, DOI 10.1021/acs.chemrev.5b00059
   de Lange MF, 2015, LANGMUIR, V31, P12783, DOI 10.1021/acs.langmuir.5b03272
   Dubbeldam D, 2016, MOL SIMULAT, V42, P81, DOI 10.1080/08927022.2015.1010082
   Dureckova H, 2019, J PHYS CHEM C, V123, P4133, DOI 10.1021/acs.jpcc.8b10644
   Elsayed A, 2017, APPL ENERG, V186, P509, DOI 10.1016/j.apenergy.2016.03.113
   Erdos M, 2018, ACS APPL MATER INTER, V10, P27074, DOI 10.1021/acsami.8b09343
   Ewald PP, 1921, ANN PHYS-BERLIN, V64, P253
   Fan WD, 2018, CHINESE CHEM LETT, V29, P865, DOI 10.1016/j.cclet.2017.11.020
   Fernandez M, 2016, ACS COMB SCI, V18, P243, DOI 10.1021/acscombsci.5b00188
   Fernandez M, 2013, J PHYS CHEM C, V117, P7681, DOI 10.1021/jp4006422
   Furukawa H, 2014, J AM CHEM SOC, V136, P4369, DOI 10.1021/ja500330a
   Ge TS, 2018, RENEW ENERG, V126, P1126, DOI 10.1016/j.renene.2017.06.081
   Guan HY, 2018, COORDIN CHEM REV, V369, P76, DOI 10.1016/j.ccr.2018.05.001
   Guo A, 2018, J MEMBRANE SCI, V562, P76, DOI 10.1016/j.memsci.2018.05.032
   Henninger SK, 2012, INT J REFRIG, V35, P543, DOI 10.1016/j.ijrefrig.2011.10.004
   Henninger SK, 2012, EUR J INORG CHEM, P2625, DOI 10.1002/ejic.201101056
   Huang G, 2016, CHEM-EUR J, V22, P3470, DOI 10.1002/chem.201504867
   Jeremias F, 2014, NEW J CHEM, V38, P1846, DOI 10.1039/c3nj01556d
   Kabir KMA, 2018, INT J AIR-COND REFRI, V26, DOI 10.1142/S2010132518500165
   Kadantsev ES, 2013, J PHYS CHEM LETT, V4, P3056, DOI 10.1021/jz401479k
   Li S, 2016, LANGMUIR, V32, P10368, DOI 10.1021/acs.langmuir.6b02803
   Li W, 2019, J MATER CHEM A, V7, P7470, DOI 10.1039/c8ta07909a
   Martin MG, 1998, J PHYS CHEM B, V102, P2569, DOI 10.1021/jp972543+
   MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010
   Nandasiri MI, 2016, COORDIN CHEM REV, V311, P38, DOI 10.1016/j.ccr.2015.12.004
   Nguyen BT, 2016, CHEM MATER, V28, P6243, DOI 10.1021/acs.chemmater.6b02431
   Pan QW, 2017, ENERG CONVERS MANAGE, V154, P322, DOI 10.1016/j.enconman.2017.11.023
   Pardakhti M, 2017, ACS COMB SCI, V19, P640, DOI 10.1021/acscombsci.7b00056
   Qiao ZW, 2018, J MATER CHEM A, V6, P18898, DOI 10.1039/c8ta04939d
   Qiao ZW, 2018, J MEMBRANE SCI, V551, P47, DOI 10.1016/j.memsci.2018.01.020
   Qiao ZW, 2017, J PHYS CHEM C, V121, P22208, DOI 10.1021/acs.jpcc.7b07758
   Qiao ZW, 2016, J MATER CHEM A, V4, P2105, DOI 10.1039/c5ta08984k
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Rezk A, 2013, APPL ENERG, V112, P1025, DOI 10.1016/j.apenergy.2013.06.041
   Rogge SMJ, 2017, CHEM SOC REV, V46, P3134, DOI 10.1039/c7cs00033b
   Tang D, 2018, CHEMSUSCHEM, V11, P1567, DOI 10.1002/cssc.201702289
   Thakkar H, 2017, ACS APPL MATER INTER, V9, P35908, DOI 10.1021/acsami.7b11626
   Willems TF, 2012, MICROPOR MESOPOR MAT, V149, P134, DOI 10.1016/j.micromeso.2011.08.020
   Wilmer CE, 2012, ENERG ENVIRON SCI, V5, P9849, DOI 10.1039/c2ee23201d
   Wilmer CE, 2012, NAT CHEM, V4, P83, DOI [10.1038/NCHEM.1192, 10.1038/nchem.1192]
   Wu W, 2016, APPL ENERG, V176, P258, DOI 10.1016/j.apenergy.2016.04.115
   Wu XJ, 2018, PHYS CHEM CHEM PHYS, V20, P30150, DOI 10.1039/c8cp05724a
   Younes MM, 2017, APPL THERM ENG, V114, P394, DOI 10.1016/j.applthermaleng.2016.11.138
   Zhang H, 2017, J MATER SCI, V52, P11360, DOI 10.1007/s10853-017-1311-3
   Zhao SN, 2017, COORDIN CHEM REV, V337, P80, DOI 10.1016/j.ccr.2017.02.010
   Ziatdinov M, 2017, NPJ COMPUT MATER, V3, DOI 10.1038/s41524-017-0038-7
NR 53
TC 1
Z9 1
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115430
DI 10.1016/j.ces.2019.115430
PG 9
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100025
DA 2020-05-12
ER

PT J
AU Shih, C
   Park, J
   Sholl, DS
   Realff, MJ
   Yajima, T
   Kawajiri, Y
AF Shih, Chunkai
   Park, Jongwoo
   Sholl, David S.
   Realff, Matthew J.
   Yajima, Tomoyuki
   Kawajiri, Yoshiaki
TI Hierarchical Bayesian estimation for adsorption isotherm parameter
   determination
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Adsorption isotherm; Isotherm model parameters; Hierarchical Bayesian
   estimation; Probability distributions; Statistical analysis
ID METAL-ORGANIC FRAMEWORKS; CO2 ADSORPTION; SWING ADSORPTION; UIO-66;
   SEPARATION; GAS; QUANTIFICATION; TECHNOLOGIES; PREDICTION; REDUCTION
AB Estimation of isotherm model parameters from experimental data is necessary in adsorption process modeling. To facilitate isotherm modeling, databases that store experimental data exist. Nevertheless, data inconsistency among different researchers must be resolved to find a single set of isotherm parameters from multiple data sets. Herein, we propose a hierarchical Bayesian estimation method to quantify the discrepancy by a multiplicative factor while simultaneously obtaining the probability distributions of a single set of isotherm parameters. This approach also allows us to identify outliers, which are data sets that are not in agreement with other sets. The proposed approach is demonstrated for the case of CO2 adsorption in the metal-organic framework UiO-66. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shih, Chunkai; Yajima, Tomoyuki; Kawajiri, Yoshiaki] Nagoya Univ, Dept Mat Proc Engn, Chikusa Ku, Furo Cho 1, Nagoya, Aichi 4648603, Japan.
   [Park, Jongwoo; Sholl, David S.; Realff, Matthew J.; Kawajiri, Yoshiaki] Georgia Inst Technol, Sch Chem & Biomol Engn, 311 Ferst Dr, Atlanta, GA 30332 USA.
RP Kawajiri, Y (reprint author), Nagoya Univ, Dept Mat Proc Engn, Chikusa Ku, Furo Cho 1, Nagoya, Aichi 4648603, Japan.
EM kawajiri@nagoya-u.jp
OI Realff, Matthew/0000-0002-5423-5206
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP18H01776];
   U.S. Department of Energy (DOE)United States Department of Energy (DOE)
   [DE-FE0026433]
FX Chunkai Shih and Yoshiaki Kawajiri acknowledge funding from JSPS KAKENHI
   Grant Number JP18H01776. Jongwoo Park, David S. Sholl, and Matthew J.
   Realff were supported by the U.S. Department of Energy (DOE) through
   Grant DE-FE0026433. Any options, findings, conclusions or
   recommendations expressed herein are those of the authors and do not
   necessarily reflect the views of the DOE.
CR Aaron D, 2005, SEP SCI TECHNOL, V40, P321, DOI 10.1081/SS-200042244
   Abid HR, 2012, J COLLOID INTERF SCI, V366, P120, DOI 10.1016/j.jcis.2011.09.060
   Afilalo J, 2008, J AM COLL CARDIOL, V51, P37, DOI 10.1016/j.jacc.2007.06.063
   Andersen A, 2013, ENRGY PROCED, V37, P33, DOI 10.1016/j.egypro.2013.05.082
   Andrieu C, 2003, MACH LEARN, V50, P5, DOI 10.1023/A:1020281327116
   Arrhenius S., 1896, PHILOS MAG, V41, P237, DOI [10.1080/14786449608620846, DOI 10.1080/14786449608620846]
   BARD Y, 1974, NONLINEAR PARAMETER
   Brunetti A, 2010, J MEMBRANE SCI, V359, P115, DOI 10.1016/j.memsci.2009.11.040
   Burtch NC, 2014, CHEM REV, V114, P10575, DOI 10.1021/cr5002589
   Cavka JH, 2008, J AM CHEM SOC, V130, P13850, DOI 10.1021/ja8057953
   Choi S, 2009, CHEMSUSCHEM, V2, P796, DOI 10.1002/cssc.200900036
   Cmarik GE, 2012, LANGMUIR, V28, P15606, DOI 10.1021/la3035352
   Ferey G, 2005, ACCOUNTS CHEM RES, V38, P217, DOI 10.1021/ar040163i
   Gelman A., 2013, BAYESIAN DATA ANAL
   Ghosh P, 2014, CHEM COMMUN, V50, P11329, DOI 10.1039/c4cc04945d
   Grzenda W, 2015, INFORM SYST MANAGE, V4, P53
   Hoffman MD, 2014, J MACH LEARN RES, V15, P1593
   Huang YT, 2012, DALTON T, V41, P9283, DOI 10.1039/c2dt30950e
   Jasuja H, 2012, J PHYS CHEM C, V116, P23526, DOI 10.1021/jp308657x
   Kalyanaraman J, 2016, AICHE J, V62, P3352, DOI 10.1002/aic.15381
   Kalyanaraman J, 2015, COMPUT CHEM ENG, V81, P376, DOI 10.1016/j.compchemeng.2015.04.028
   Kalyanaraman J, 2014, COMPUT-AIDED CHEM EN, V34, P345
   Keskin S, 2010, CHEMSUSCHEM, V3, P879, DOI 10.1002/cssc.201000114
   Lau CH, 2013, CHEM COMMUN, V49, P3634, DOI 10.1039/c3cc40470f
   Li LJ, 2015, J MATER CHEM A, V3, P21849, DOI 10.1039/c5ta05997f
   Liu Y, 2008, ATMOS ENVIRON, V42, P8464, DOI 10.1016/j.atmosenv.2008.08.018
   Nguyen HGT, 2018, ADSORPTION, V24, P531, DOI 10.1007/s10450-018-9958-x
   Nik OG, 2012, J MEMBRANE SCI, V413, P48, DOI 10.1016/j.memsci.2012.04.003
   Olajire AA, 2010, ENERGY, V35, P2610, DOI 10.1016/j.energy.2010.02.030
   Omlin M, 1999, ECOL MODEL, V115, P45, DOI 10.1016/S0304-3800(98)00174-4
   Park J, 2017, CHEM MATER, V29, P10487, DOI 10.1021/acs.chemmater.7b04287
   Park J, 2017, J MATER CHEM A, V5, P12258, DOI 10.1039/c7ta02916k
   Sholl DS, 2016, NATURE, V532, P435, DOI 10.1038/532435a
   Sholl DS, 2015, J PHYS CHEM LETT, V6, P3437, DOI 10.1021/acs.jpclett.5b01135
   Siderius D. W., 2014, NIST ARPA E DATABASE, DOI [10.18434/T43882, DOI 10.18434/T43882]
   Sun DR, 2013, CHEM-EUR J, V19, P14279, DOI 10.1002/chem.201301728
   Thallapally PK, 2008, J AM CHEM SOC, V130, P16842, DOI 10.1021/ja806391k
   Wu H, 2013, J AM CHEM SOC, V135, P10525, DOI 10.1021/ja404514r
   Xu G, 2014, ENERGIES, V7, P3484, DOI 10.3390/en7053484
   Yang QY, 2011, J PHYS CHEM C, V115, P13768, DOI 10.1021/jp202633t
   Yang R. T., 1987, GAS SEPARATION ADSOR
NR 41
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115435
DI 10.1016/j.ces.2019.115435
PG 11
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100032
DA 2020-05-12
ER

PT J
AU Shu, SL
   Zhang, JC
   Yang, N
AF Shu, Shuli
   Zhang, Jingchang
   Yang, Ning
TI GPU-accelerated transient lattice Boltzmann simulation of bubble column
   reactors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Transient simulation; GPU acceleration; Multiphase flow; Lattice
   Boltzmann Method; Bubble column reactor
ID DIRECT NUMERICAL-SIMULATION; DYNAMIC FLOW BEHAVIOR; GAS-LIQUID FLOW; CFD
   SIMULATION; 2-PHASE FLOWS; MODEL; IMPLEMENTATION; COALESCENCE; FORCES;
   DRAG
AB Design parameters for Bubble Column Reactors such as backmixing and light/dark cycles of microalgae cells are pertinent to transient flow dynamics and mesoscale coherent structures. Transient simulation is therefore of practical significance. Traditional CFD solvers are generally implemented on multi-core CPU workstations, which is time-consuming and difficult to meet the requirement of industry applications. We developed a GPU-accelerated transient LBM simulation of gas-liquid flow, achieving 5000 times acceleration in comparison with the CFD simulation. A notable feature of this method, which allows a tunable and smaller dimensionless relaxation time, is the remarkable decrease of required mesh number in LBM simulation by several orders of magnitude. The solver is validated against experimental data, resolving two mechanisms of mesoscale structure, i.e., vortex rotation and radial migration, in the intensification of macromixing. The computation acceleration and resolution of mesoscale structures demonstrate the potential of this approach for fast simulation of industrial applications. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Ning] Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.
   Univ Chinese Acad Sci, Sch Chem Engn, Beijing 100049, Peoples R China.
RP Yang, N (reprint author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.
EM nyang@ipe.ac.cn
RI Yang, Ning/F-5888-2010
OI Yang, Ning/0000-0002-7446-8568
FU National Key Research and Development Program of China [2017YFB0602500];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91834303, 91634203, 21925805, 21808222]
FX Financial support from National Key Research and Development Program of
   China (2017YFB0602500) and National Natural Science Foundation of China
   (Grant Nos. 91834303, 91634203, 21925805, 21808222) are acknowledged.
CR Becker S, 1999, CHEM ENG SCI, V54, P4929, DOI 10.1016/S0009-2509(99)00214-6
   Buwa VV, 2003, CAN J CHEM ENG, V81, P402
   Buwa VV, 2002, CHEM ENG SCI, V57, P4715, DOI 10.1016/S0009-2509(02)00274-9
   Chen P, 2004, CHEM ENG SCI, V59, P5201, DOI 10.1016/j.ces.2004.07.037
   Chen P, 2005, AICHE J, V51, P696, DOI 10.1002/aic.10381
   Deen NG, 2013, CHEM ENG SCI, V102, P268, DOI 10.1016/j.ces.2013.08.025
   Delnoij E, 1997, CHEM ENG SCI, V52, P3759, DOI 10.1016/S0009-2509(97)00222-4
   Delnoij E, 1999, CHEM ENG SCI, V54, P5159, DOI 10.1016/S0009-2509(99)00233-X
   Dijkhuizen W, 2010, CHEM ENG SCI, V65, P1415, DOI 10.1016/j.ces.2009.10.021
   Holmen V., 2012, THESIS
   Icardi M, 2014, APPL MATH MODEL, V38, P4277, DOI 10.1016/j.apm.2014.04.052
   Inamuro T, 2004, J COMPUT PHYS, V198, P628, DOI 10.1016/j.jcp.2004.01.019
   Jiang GS, 1996, J COMPUT PHYS, V126, P202, DOI 10.1006/jcph.1996.0130
   Joshi JB, 2001, CHEM ENG SCI, V56, P5893, DOI 10.1016/S0009-2509(01)00273-1
   Kliphuis AMJ, 2010, BIOTECHNOL PROGR, V26, P687, DOI 10.1002/btpr.379
   Laborde-Boutet C, 2009, CHEM ENG SCI, V64, P4399, DOI 10.1016/j.ces.2009.07.009
   Li J., 2013, MULTISCALE MODELING
   Manninen M., 1996, MIXTURE MODEL MULTIP
   Masood RMA, 2015, CHEM ENG TECHNOL, V38, P777, DOI 10.1002/ceat.201400182
   McClure DD, 2014, IND ENG CHEM RES, V53, P14526, DOI 10.1021/ie501105m
   Pfleger D, 1999, CHEM ENG SCI, V54, P5091, DOI 10.1016/S0009-2509(99)00261-4
   Pfleger D, 2001, CHEM ENG SCI, V56, P1737, DOI 10.1016/S0009-2509(00)00403-6
   Roghair I, 2011, CHEM ENG SCI, V66, P3204, DOI 10.1016/j.ces.2011.02.030
   Sankaranarayanan K, 2002, J FLUID MECH, V452, P61, DOI 10.1017/S0022112001006619
   Sankaranarayanan K, 2008, IND ENG CHEM RES, V47, P9165, DOI 10.1021/ie800283b
   Sanyal J, 1999, CHEM ENG SCI, V54, P5071, DOI 10.1016/S0009-2509(99)00235-3
   Schielicke L, 2016, TELLUS A, V68, DOI 10.3402/tellusa.v68.29464
   Shu SL, 2019, RENEW ENERG, V141, P613, DOI 10.1016/j.renene.2019.04.020
   Shu SL, 2018, CHEM ENG SCI, V181, P132, DOI 10.1016/j.ces.2018.02.011
   Shu SL, 2018, CHINESE J CHEM ENG, V26, P31, DOI 10.1016/j.cjche.2017.05.013
   Shu SL, 2013, IND ENG CHEM RES, V52, P11391, DOI 10.1021/ie303486y
   Silva MK, 2014, IND ENG CHEM RES, V53, P3353, DOI 10.1021/ie4030159
   Sokolichin A, 1997, CHEM ENG SCI, V52, P611, DOI 10.1016/S0009-2509(96)00425-3
   Sokolichin A, 1999, CHEM ENG SCI, V54, P2273, DOI 10.1016/S0009-2509(98)00420-5
   Song FF, 2013, CHEM ENG SCI, V102, P442, DOI 10.1016/j.ces.2013.08.037
   Swiderski K, 2016, COMPUT CHEM ENG, V90, P151, DOI 10.1016/j.compchemeng.2016.04.023
   Tabib MV, 2008, CHEM ENG J, V139, P589, DOI 10.1016/j.cej.2007.09.015
   Wang TF, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.045301
   Witz C, 2016, CHEM ENG SCI, V152, P636, DOI 10.1016/j.ces.2016.06.053
   Xiao Q, 2013, CHEM ENG SCI, V100, P279, DOI 10.1016/j.ces.2013.02.027
   Xue J., 2017, INT J CHEM REACT ENG, V15
   Xue J, 2017, CHINESE J CHEM ENG, V25, P249, DOI 10.1016/j.cjche.2016.08.006
   Yang N, 2011, CHEM ENG SCI, V66, P3212, DOI 10.1016/j.ces.2011.02.029
   Yuan P, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2187070
NR 44
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115436
DI 10.1016/j.ces.2019.115436
PG 10
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100033
DA 2020-05-12
ER

PT J
AU Tada, EFR
   Buck, A
   Tsotsas, E
   Thomeo, JC
AF Tada, Erika Fernanda Rezendes
   Bueck, Andreas
   Tsotsas, Evangelos
   Thomeo, Joao Claudio
TI Mass transport in a partially filled horizontal drum: Modelling and
   experiments
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mass transfer; Horizontal drum; One-phase model; Sugar cane bagasse;
   Effective diffusivity
ID SOLID-STATE FERMENTATION; PACKED-BED BIOREACTORS; WATER ACTIVITY;
   ASPERGILLUS-NIGER; HEAT-TRANSFER; SCALE-UP; TEMPERATURE; SUBSTRATE;
   POROSITY; COEFFICIENTS
AB This work presents a one-phase two-dimensional model describing the mass transport in an isothermal horizontal drum partially filled with silica beads and sugar cane bagasse (SCB), with air flowing in parallel to the bed surface, aiming further applications to solid-state cultivation processes (SSC). The effective diffusivities (D-eff) of silica and SCB beds were experimentally determined, as well the equilibrium moisture content of the solids. Deff was of 1.67 10(-9)m(-2)/s for the silica bed and 29.2 10(-)(9) m(-2)/s for SCB. Classical correlations were applied to estimate the theoretical effective diffusivity in a bed of spherical (silica beads) and cylindrical (SCB) particles. Experiments were carried out in a still horizontal drum with filling degree 0.5 using low and high air flow rates and good agreement was noted between experimental and simulated results. The results obtained will be of help to model SSC processes in horizontal drums in a more realistic basis. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tada, Erika Fernanda Rezendes; Thomeo, Joao Claudio] Sao Paulo State Univ, UNESP, Inst Biosci Humanities & Exact Sci IBILCE, Food Engn & Technol Dept, Cristovao Colombo 2265, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil.
   [Bueck, Andreas] Friedrich Alexander Univ Erlangen Nuremberg, Inst Particle Technol LFG, Cauerstr 4, D-91058 Erlangen, Germany.
   [Tsotsas, Evangelos] Otto Von Guericke Univ, Thermal Proc Engn NaWiTec, Univ Pl 2, D-39106 Magdeburg, Germany.
RP Tada, EFR (reprint author), Sao Paulo State Univ, UNESP, Inst Biosci Humanities & Exact Sci IBILCE, Food Engn & Technol Dept, Cristovao Colombo 2265, BR-15054000 Sao Jose Do Rio Preto, SP, Brazil.
EM erikartada@gmail.com
RI Tada, Erika Fernanda Rezendes/AAB-5971-2020; Tsotsas,
   Evangelos/E-6610-2013
OI Tsotsas, Evangelos/0000-0001-9575-1138
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior -CAPESCAPES
   [88887.161386/2017-00, 33004153070P-2]; Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo FAPESPFundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2014/23453-3]
FX This work was supported by Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior -CAPES (Grant Number Process 88887.161386/2017-00 and
   Social Demand 33004153070P-2) and by Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo FAPESP (Process 2014/23453-3). The authors also
   would like to thank Professor Maria Aparecida Mauro (IBILCE/UNESP) for
   her kind attention and valuable discussion about the topic.
CR ACUNAARGUELLES M, 1994, BIOTECHNOL LETT, V16, P23, DOI 10.1007/BF01022618
   Alonso E, 2017, SOL ENERGY, V144, P90, DOI 10.1016/j.solener.2017.01.004
   Babitha S, 2007, BIORESOURCE TECHNOL, V98, P1554, DOI 10.1016/j.biortech.2006.06.005
   BEAVERS GS, 1973, J APPL MECH-T ASME, V40, P655, DOI 10.1115/1.3423067
   Casciatori F. P., 2015, THESIS
   Casciatori FP, 2016, CHEM ENG J, V287, P103, DOI 10.1016/j.cej.2015.10.108
   Casciatori FP, 2015, IND CROP PROD, V64, P114, DOI 10.1016/j.indcrop.2014.11.034
   Casciatori FP, 2014, CHEM ENG J, V255, P214, DOI 10.1016/j.cej.2014.06.040
   Castilho LR, 2000, BIORESOURCE TECHNOL, V71, P45, DOI 10.1016/S0960-8524(99)00058-9
   Corona A, 2005, PROCESS BIOCHEM, V40, P2655, DOI 10.1016/j.procbio.2004.11.008
   Couto SR, 2005, BIOCHEM ENG J, V22, P211, DOI 10.1016/j.bej.2004.09.013
   CRANK J., 1979, MATH DIFFUSION
   DEREU JC, 1993, APPL MICROBIOL BIOT, V40, P261, DOI 10.1007/BF00170377
   Dhillon GS, 2013, IND CROP PROD, V41, P78, DOI 10.1016/j.indcrop.2012.04.001
   Doriya K, 2018, BIOCHEM ENG J, V138, P188, DOI 10.1016/j.bej.2018.07.024
   Flodman HR, 2013, BIOCHEM ENG J, V81, P24, DOI 10.1016/j.bej.2013.09.011
   Frinkler A.T.J., 2017, BIOCH ENG J
   Gan J, 2008, BIORESOURCE TECHNOL, V99, P2571, DOI 10.1016/j.biortech.2007.04.041
   GERVAIS P, 1988, APPL MICROBIOL BIOT, V27, P389
   GERVAIS P, 1988, J FERMENT BIOENG, V66, P403, DOI 10.1016/0385-6380(88)90006-4
   GHILDYAL NP, 1994, ENZYME MICROB TECH, V16, P253, DOI 10.1016/0141-0229(94)90051-5
   Giese M, 1998, THESIS
   Gnielinski V, 1975, NASA STI RECON TEC A, V75, P8
   Gomes LD, 2018, REV VIRTUAL QUIM, V10, P1018, DOI 10.21577/1984-6835.20180072
   GOODLING JS, 1983, POWDER TECHNOL, V35, P23, DOI 10.1016/0032-5910(83)85022-0
   Grajales L.M., 2014, THESIS
   Gu CH, 2014, POWDER TECHNOL, V267, P234, DOI 10.1016/j.powtec.2014.06.059
   Inagaki S, 1996, J COLLOID INTERF SCI, V180, P623, DOI 10.1006/jcis.1996.0345
   Kalogeris E, 2003, BIORESOURCE TECHNOL, V86, P207, DOI 10.1016/S0960-8524(02)00175-X
   Kast W., 2010, HEAT TRANSFER FREE C
   KELLUM GE, 1967, ANAL CHEM, V39, P341, DOI 10.1021/ac60247a046
   Krischer O., 1956, FORSCH GEB INGENIEUR, V22, P1
   Lin YS, 2013, APPL ENERG, V105, P389, DOI 10.1016/j.apenergy.2012.12.020
   Lu WQ, 2003, ENZYME MICROB TECH, V32, P305, DOI 10.1016/S0141-0229(02)00292-2
   Mendes F.B., 2014, BLUCHER CHEM ENG P, V1, P6401
   Miranda M.N.N., 2007, THESIS
   Mitchell DA, 2003, BIOCHEM ENG J, V13, P137, DOI 10.1016/S1369-703X(02)00126-2
   Mitchell DA, 1999, PROCESS BIOCHEM, V35, P167, DOI 10.1016/S0032-9592(99)00048-5
   Mitchell DA, 2000, PROCESS BIOCHEM, V35, P1211, DOI 10.1016/S0032-9592(00)00157-6
   Mueller GE, 2010, POWDER TECHNOL, V203, P626, DOI 10.1016/j.powtec.2010.07.007
   Mueller R, 2003, LANGMUIR, V19, P160, DOI 10.1021/la025785w
   Nagel FJJI, 2001, BIOTECHNOL BIOENG, V72, P231, DOI 10.1002/1097-0290(20000120)72:2<231::AID-BIT11>3.0.CO;2-S
   ORIOL E, 1988, APPL MICROBIOL BIOT, V27, P498, DOI 10.1007/BF00451620
   PANDEY A, 1994, WORLD J MICROB BIOT, V10, P485, DOI 10.1007/BF00144481
   Pandey A, 2003, BIOCHEM ENG J, V13, P81, DOI 10.1016/S1369-703X(02)00121-3
   PELEG M, 1988, J FOOD SCI, V53, P1216, DOI 10.1111/j.1365-2621.1988.tb13565.x
   Peng L, 2009, COLLOID SURFACE A, V334, P112, DOI 10.1016/j.colsurfa.2008.10.028
   Perez CL, 2019, CHEM ENG J, V361, P1142, DOI 10.1016/j.cej.2018.12.169
   Tada EFR, 2017, CHEM ENG J, V316, P988, DOI 10.1016/j.cej.2017.01.120
   ROBLEE LHS, 1958, AICHE J, V4, P460, DOI 10.1002/aic.690040415
   Rodriguez-Jasso RM, 2013, FOOD BIOPROD PROCESS, V91, P587, DOI 10.1016/j.fbp.2013.02.004
   Ruijter GJG, 2004, MICROBIOL-SGM, V150, P1095, DOI 10.1099/mic.0.26723-0
   Saithi S, 2016, AGRIC AGRIC SCI PROC, V11, P25, DOI 10.1016/j.aaspro.2016.12.005
   Sangsurasak P, 1998, BIOTECHNOL BIOENG, V60, P739, DOI 10.1002/(SICI)1097-0290(19981220)60:6<739::AID-BIT10>3.0.CO;2-U
   SAUCEDOCASTANEDA G, 1990, BIOTECHNOL BIOENG, V35, P802, DOI 10.1002/bit.260350808
   SCHLUNDER EU, 1966, CHEM-ING-TECH, V38, P967, DOI 10.1002/cite.330380909
   Schutyser MAI, 2004, BIOTECHNOL BIOENG, V86, P405, DOI 10.1002/bit.20076
   Smits JP, 1999, BIOPROCESS ENG, V20, P391, DOI 10.1007/s004490050607
   Soares M, 2000, PROCESS BIOCHEM, V35, P857, DOI 10.1016/S0032-9592(99)00144-2
   Stuart D.M., 1996, THESIS
   Tada E.F.R., 2019, BRAZ J CHEM ENG
   Tarhan S, 2010, IND CROP PROD, V32, P420, DOI 10.1016/j.indcrop.2010.06.003
   Time B., 1998, THESIS
   von Meien OF, 2002, BIOTECHNOL BIOENG, V79, P416, DOI 10.1002/bit.10268
   Wang EQ, 2010, APPL ENERG, V87, P2839, DOI 10.1016/j.apenergy.2009.05.032
   Winterberg M, 2000, CHEM ENG SCI, V55, P967, DOI 10.1016/S0009-2509(99)00379-6
   Winterberg M, 2000, CHEM ENG SCI, V55, P5937, DOI 10.1016/S0009-2509(00)00198-6
   Zanelato AI, 2012, BRAZ J MICROBIOL, V43, P1536, DOI 10.1590/S1517-838220120004000038
   ZEHNER P, 1970, CHEM-ING-TECH, V42, P933, DOI 10.1002/cite.330421408
   Zhuravlev LT, 2000, COLLOID SURFACE A, V173, P1, DOI 10.1016/S0927-7757(00)00556-2
NR 70
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115448
DI 10.1016/j.ces.2019.115448
PG 18
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100035
DA 2020-05-12
ER

PT J
AU Tao, C
   Jia, QP
   Han, B
   Ma, ZL
AF Tao, Chang
   Jia, Qunpeng
   Han, Bing
   Ma, Zhiling
TI Tunable selectivity of radical generation over TiO2 for photocatalysis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Photocatalysis; Titanium dioxide; Advanced oxidation; Reactive radical;
   Solar energy
ID TITANIUM-DIOXIDE; ANATASE; OXYGEN; RUTILE; DECHLORINATION; DEGRADATION;
   TEMPERATURE; ABSORPTION; MECHANISM; ROLES
AB The realization of controllable radical generation through structural modification of photocatalyst is a challenging goal and is an important strategy for environmental remediation and noncomplete and selective photo-oxidation. Here, we control structural composition of TiO2 through crystalline modification and use photocatalytic dye degradation as a model system to investigate photocatalytic details. Importantly, modified TiO2 materials exhibit tunable mechanism pathway towards photocatalytic decomposing methylene blue (MB) monitored by radical trapping experiments. The anatase-rich TiO2 heterojunction shows preferential hole-mediated decomposition pathway in comparison with superoxide and hydroxyl radicals. In contrast, increasing ratio of rutile in TiO2 favors superoxide-facilitated MB decomposition over hole. The surface chemistry of specific surface atomic configuration is a key factor in tuning the capability of oxygen reduction and hole trapping, resulting in photocatalytic selectivity of radical generation towards photo-oxidation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tao, Chang; Jia, Qunpeng; Han, Bing; Ma, Zhiling] Hebei Univ, Coll Chem & Environm Sci, Baoding 071002, Peoples R China.
   [Han, Bing] Univ Melbourne, Fac Vet & Agr Sci, Parkville, Vic 3010, Australia.
RP Han, B (reprint author), Univ Melbourne, Fac Vet & Agr Sci, Parkville, Vic 3010, Australia.
EM bing.han@unimelb.edu.au
OI Han, Bing/0000-0002-9746-2855
FU Natural Science Foundation of Hebei provinceNatural Science Foundation
   of Hebei Province [B2019201064]; Advanced Talents Incubation Program of
   the Hebei University [1081/801260201284]
FX This work was supported by Natural Science Foundation of Hebei province
   (B2019201064) and Advanced Talents Incubation Program of the Hebei
   University (1081/801260201284).
CR Bedouhene S, 2017, AM J BLOOD RES, V7, P41
   Buchalska M, 2015, ACS CATAL, V5, P7424, DOI 10.1021/acscatal.5b01562
   CAREY JH, 1976, B ENVIRON CONTAM TOX, V16, P697, DOI 10.1007/BF01685575
   Chen CC, 2010, CHEM SOC REV, V39, P4206, DOI 10.1039/b921692h
   Chen XB, 2011, SCIENCE, V331, P746, DOI 10.1126/science.1200448
   Cheng HZ, 2009, PHYS REV B, V79, DOI 10.1103/PhysRevB.79.092101
   Cheng J, 2014, J PHYS CHEM C, V118, P5437, DOI 10.1021/jp500769q
   Duan ZY, 2015, ACS CATAL, V5, P1589, DOI 10.1021/cs501610a
   Fotiou T, 2016, WATER RES, V90, P52, DOI 10.1016/j.watres.2015.12.006
   Henrich V. E., 1993, SURFACE SCI METAL OX
   Jiang YM, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.099401
   Kafizas A, 2016, J PHYS CHEM A, V120, P715, DOI 10.1021/acs.jpca.5b11567
   Kakuma Y, 2015, PHYS CHEM CHEM PHYS, V17, P18691, DOI 10.1039/c5cp02004b
   Li YF, 2014, ACCOUNTS CHEM RES, V47, P3361, DOI 10.1021/ar400312t
   Li YF, 2013, J AM CHEM SOC, V135, P9195, DOI 10.1021/ja404044t
   Liu SW, 2010, J AM CHEM SOC, V132, P11914, DOI 10.1021/ja105283s
   Low JX, 2017, ADV MATER, V29, DOI 10.1002/adma.201601694
   Ndong LBB, 2015, CHEM ENG SCI, V123, P367, DOI 10.1016/j.ces.2014.11.034
   OHSAKA T, 1978, J RAMAN SPECTROSC, V7, P321, DOI 10.1002/jrs.1250070606
   Schneider J, 2014, CHEM REV, V114, P9919, DOI 10.1021/cr5001892
   SPURR RA, 1957, ANAL CHEM, V29, P760, DOI 10.1021/ac60125a006
   Tan SJ, 2011, J AM CHEM SOC, V133, P2002, DOI 10.1021/ja110375n
   Wang SB, 2015, J AM CHEM SOC, V137, P2975, DOI 10.1021/ja512047k
   Wang ZH, 2011, CHEM ENG J, V170, P353, DOI 10.1016/j.cej.2010.12.002
   Wang ZT, 2012, J PHYS CHEM LETT, V3, P102, DOI 10.1021/jz2014055
   Wenderich K, 2016, CHEM REV, V116, P14587, DOI 10.1021/acs.chemrev.6b00327
   Wijnhoven JEGJ, 1998, SCIENCE, V281, P802, DOI 10.1126/science.281.5378.802
   Xu HF, 2015, CATAL COMMUN, V62, P52, DOI 10.1016/j.catcom.2015.01.001
   Xu MC, 2012, ANGEW CHEM INT EDIT, V51, P4731, DOI 10.1002/anie.201200585
   Yan JQ, 2013, PHYS CHEM CHEM PHYS, V15, P10978, DOI 10.1039/c3cp50927c
   Ye LQ, 2012, ACS CATAL, V2, P1677, DOI 10.1021/cs300213m
   Yu JG, 2003, J PHYS CHEM B, V107, P13871, DOI 10.1021/jp036158y
NR 32
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115438
DI 10.1016/j.ces.2019.115438
PG 7
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100012
DA 2020-05-12
ER

PT J
AU Teng, SY
   How, BS
   Leong, WD
   Teoh, JH
   Lam, HL
AF Teng, Sin Yong
   How, Bing Shen
   Leong, Wei Dong
   Teoh, Jun Hao
   Lam, Hon Loong
TI Bottleneck Tree Analysis (BOTA) with green and lean index for process
   capacity debottlenecking in industrial refineries
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Capacity debottlenecking; Lean and green; Multiple criteria decision
   making; Expert system; Reversed onion model; Bottleneck Tree Analysis
   (BOTA)
ID ANALYTIC HIERARCHY PROCESS; RELATIONAL ANALYSIS; P-GRAPH; PERFORMANCE;
   FRAMEWORK; DESIGN; MANAGEMENT; OPTIMIZATION; INTEGRATION; QUALITY
AB This paper presents a novel Bottleneck Tree Analysis (BOTA) to cope with the increasing capacities within industrial refineries. BOTA is a clear and concise heuristic graphical debottlenecking method that can accurately pinpoint the process capacity bottlenecks. Coupled with BOTA, four multiple criteria decision-making methods are used for an ensemble with Spearman's correlation to assess the Green and Lean Index (GLI) of industrial processes. The decision-making tool is formulated to improve operational performance with the consideration for environmental conditions. Empirically, BOTA demonstrated a debottleneck stopping mechanism which can be theoretically explained with the reversed onion model. An additional advantage is that retrofit projects can be guided by BOTA with effective scheduling. From an industrial case study, BOTA improved normalized Global Warming Potential by 94.43 %, normalized energy consumption by 93.09 % and return on investment by 58.36 %. Project implementation by scheduling also reduced payback period from 85 to 66 months. (C) 2019 Published by Elsevier Ltd.
C1 [Teng, Sin Yong] Brno Univ Technol, Inst Proc Engn, Tech 2896-2, Brno 61669, Czech Republic.
   [Teng, Sin Yong] Brno Univ Technol, NETME Ctr, Tech 2896-2, Brno 61669, Czech Republic.
   [How, Bing Shen] Swinburne Univ Technol, Fac Engn Comp & Sci, Chem Engn Dept, Jalan Simpang Tiga, Sarawak 93350, Malaysia.
   [Leong, Wei Dong; Teoh, Jun Hao; Lam, Hon Loong] Univ Nottingham, Dept Chem & Environm Engn, Malaysia Campus,Jalan Broga, Semenyih 43500, Selangor, Malaysia.
RP Lam, HL (reprint author), Univ Nottingham, Dept Chem & Environm Engn, Malaysia Campus,Jalan Broga, Semenyih 43500, Selangor, Malaysia.
EM HonLoong.Lam@nottingham.edu.my
OI Teng, Sin Yong/0000-0002-2988-8053; How, Bing Shen/0000-0002-0969-9167
FU Ministry of Education, Youth and Sports of the Czech Republic under OP
   RDE [CZ.02.1.01/0.0/0.0/16_026/0008413]
FX Immense gratitude towards Pentas Flora Sdn. Bhd. for approving the case
   study to be carried out and performing lab test in their respected
   laboratory. Special thanks to Mr. Donny Goh and Ms. Tan Yuan Ni of
   Pentas Flora laboratory team. The research leading to these results has
   received funding from the Ministry of Education, Youth and Sports of the
   Czech Republic under OP RDE grant number
   CZ.02.1.01/0.0/0.0/16_026/0008413 ``Strategic Partnership for
   Environmental Technologies and Energy Production".
CR Ahmad A., 2010, P WORLD ACAD SCI ENG, V4, P97
   AHMAD S, 1991, COMPUT CHEM ENG, V15, P809, DOI 10.1016/0098-1354(91)80027-S
   Alshekhli O, 2011, FOOD BIOPROD PROCESS, V89, P528, DOI 10.1016/j.fbp.2010.09.013
   Andiappan V, 2017, ENERGY, V134, P1038, DOI 10.1016/j.energy.2017.06.054
   Bagajewicz M, 2002, AICHE J, V48, P2255, DOI 10.1002/aic.690481016
   Bey N, 2013, CIRP ANN-MANUF TECHN, V62, P43, DOI 10.1016/j.cirp.2013.03.001
   Carr D., 2007, NONLINEAR CONTROL DE
   Carvalho H., 2019, LEAN ENG GLOBAL DEV, P293
   Jabbour CJC, 2013, J CLEAN PROD, V47, P129, DOI 10.1016/j.jclepro.2012.07.010
   Chiarini A, 2014, J CLEAN PROD, V85, P226, DOI 10.1016/j.jclepro.2014.07.080
   Cucek L., 2017, CHEM ENG T, V61, P1687
   D'Errico F, 2009, JOM-US, V61, P14, DOI 10.1007/s11837-009-0045-3
   de Haan J, 2001, INT J PROD ECON, V71, P101, DOI 10.1016/S0925-5273(00)00110-9
   Deif AM, 2011, J CLEAN PROD, V19, P1553, DOI 10.1016/j.jclepro.2011.05.022
   DENG JL, 1982, SYST CONTROL LETT, V1, P288, DOI 10.1016/S0167-6911(82)80025-X
   Deng Julong, 1989, Journal of Grey Systems, V1, P1
   DIAZ S, 1995, COMPUT CHEM ENG, V19, pS175, DOI 10.1016/0098-1354(95)00171-W
   Dieste M, 2019, J CLEAN PROD, V224, P120, DOI 10.1016/j.jclepro.2019.03.243
   DOUGLAS JM, 1985, AICHE J, V31, P353, DOI 10.1002/aic.690310302
   Dues CM, 2013, J CLEAN PROD, V40, P93, DOI 10.1016/j.jclepro.2011.12.023
   Dunn RF, 2003, J CHEM TECHNOL BIOT, V78, P1011, DOI 10.1002/jctb.738
   Gai H., 2018, HUAXUE GONGCHENG, V35, P57
   Hasani H, 2012, J ENG FIBER FABR, V7, P81
   Hegedic M, 2018, INTERDISCIP DESCR CO, V16, P21, DOI 10.7906/indecs.16.1.2
   Heitmann M, 2017, CHEM ENG RES DES, V128, P85, DOI 10.1016/j.cherd.2017.09.028
   Hines P., 2009, SOURCE MAGAZINE HOME
   How B.S., 2018, PROCESS INTEGR OPTIM, DOI [https://doi.org/10.1007/s41660-018-0036-3., DOI 10.1007/S41660-018-0036-3, 10.1007/s41660-018-0036-3]
   How BS, 2018, J CLEAN PROD, V193, P720, DOI 10.1016/j.jclepro.2018.04.240
   Hsu HM, 2015, MATEC WEB CONF, V27, DOI 10.1051/matecconf/20152701006
   Hwang CL, 1981, MULTIPLE ATTRIBUTES
   Joint Research Centre-European Commission, 2008, HDB CONSTRUCTING COM
   Kasivisvanathan H, 2014, CHEM ENG RES DES, V92, P2071, DOI 10.1016/j.cherd.2014.02.024
   Kemp I.C., 2007, PINCH ANAL PROCESS I, V2
   King AA, 2001, PROD OPER MANAG, V10, P244, DOI 10.1111/j.1937-5956.2001.tb00373.x
   Koulouris A, 2000, COMPUT CHEM ENG, V24, P1387, DOI 10.1016/S0098-1354(00)00382-3
   Kuo MS, 2011, EXPERT SYST APPL, V38, P1304, DOI 10.1016/j.eswa.2010.07.003
   Kuo Y, 2008, COMPUT IND ENG, V55, P80, DOI 10.1016/j.cie.2007.12.002
   Lee J., 2008, SPE ANN TECHN C EXH
   Leong W.D., 2019, PROCESS INTEGR OPTIM, V3, P5, DOI DOI 10.1007/S41660-019-00082-X
   Leong WD, 2019, J CLEAN PROD, V235, P190, DOI 10.1016/j.jclepro.2019.06.143
   Lever J, 2017, NAT METHODS, V14, P641, DOI 10.1038/nmeth.4346
   Li XX, 2011, PROCEDIA ENGINEER, V26, DOI 10.1016/j.proeng.2011.11.2410
   Liang XQ, 2016, IND ENG CHEM RES, V55, P2574, DOI 10.1021/acs.iecr.5b04120
   Liliana L, 2016, IOP CONF SER-MAT SCI, V161, DOI 10.1088/1757-899X/161/1/012099
   Linnhoff B, 1982, USER GUIDE PROCESS I
   Litzen DB, 1999, CHEM ENG PROG, V95, P25
   Long NVD, 2010, CHEM ENG PROCESS, V49, P825, DOI 10.1016/j.cep.2010.06.008
   Mardani A, 2015, ECON RES-EKON ISTRAZ, V28, P516, DOI 10.1080/1331677X.2015.1075139
   Matsuda K, 2009, ENERGY, V34, P1687, DOI 10.1016/j.energy.2009.05.017
   McDonald S, 2014, ROUTL COMPANION BUS, P210
   Metternich J, 2013, PROC CIRP, V7, P592, DOI 10.1016/j.procir.2013.06.038
   MIZSEY P, 1990, COMPUT CHEM ENG, V14, P1213, DOI 10.1016/0098-1354(90)80003-T
   Nguyen VDL, 2011, ASIA-PAC J CHEM ENG, V6, P338, DOI 10.1002/apj.577
   Offord P., 2011, RPR PROBLEM DIAGNOSI
   Opricovic S., 1998, THESIS
   Opricovic S., 1990, PROGRAMSKI PAKET VIK
   Opricovic S, 2007, EUR J OPER RES, V178, P514, DOI 10.1016/j.ejor.2006.01.020
   Patel D, 2014, PROCESSES, V2, P311, DOI 10.3390/pr2010311
   Pearson K, 1901, PHILOS MAG, V2, P559, DOI 10.1080/14786440109462720
   Pechmann W., 1948, IND ENG CHEM, V40, p77A
   Ran R, 2015, J INTELL FUZZY SYST, V29, P1301, DOI 10.3233/IFS-141380
   Ray SC, 2015, EUR J OPER RES, V245, P602, DOI 10.1016/j.ejor.2015.03.024
   SAATY RW, 1987, MATH MODELLING, V9, P161, DOI 10.1016/0270-0255(87)90473-8
   Sawhney R., 2007, International Journal of Enterprise Network Management, V1, P238, DOI 10.1504/IJENM.2007.012757
   Seifert T, 2015, CHEM ENG RES DES, V93, P511, DOI 10.1016/j.cherd.2014.07.019
   SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x
   SMITH R, 1988, CHEM ENG RES DES, V66, P195
   Strasunskas D, 2006, ADVANCES IN INFORMATION SYSTEMS DEVELOPMENT, VOL 1 AND 2, P771, DOI 10.1007/978-0-387-36402-5_66
   Sufiyan M, 2019, SUSTAIN PROD CONSUMP, V20, P40, DOI 10.1016/j.spc.2019.03.004
   Sullivan WG, 2002, ROBOT CIM-INT MANUF, V18, P255, DOI 10.1016/S0736-5845(02)00016-9
   Sun J., 2017, B TECNICO, V55, P982
   Tan J., 2004, MAL SOC MOL BIOL BIO
   Tan J., 2006, PHARM ENG, V2006, P72
   Tan J, 2016, CLEAN TECHNOL ENVIR, V18, P2049, DOI 10.1007/s10098-016-1163-6
   Tan May May, 2018, MATEC Web of Conferences, V152, DOI 10.1051/matecconf/201815201012
   Tan RR, 2017, COMPUT CHEM ENG, V106, P872, DOI 10.1016/j.compchemeng.2017.01.047
   Teng SY, 2019, J CLEAN PROD, V225, P359, DOI 10.1016/j.jclepro.2019.03.272
   Vinogradova I, 2018, SYMMETRY-BASEL, V10, DOI 10.3390/sym10060205
   Walker WR, 2011, AM ECON REV, V101, P442, DOI 10.1257/aer.101.3.442
   Wang QB, 2010, MECHANICAL ENGINEERING AND GREEN MANUFACTURING, PTS 1 AND 2, P1931, DOI 10.4028/www.scientific.net/AMM.34-35.1931
   WAR GUI, 2011, WAST RED ALG CHEM PR
   Weng ZK, 1996, EUR J OPER RES, V89, P259, DOI 10.1016/0377-2217(95)00268-5
   Yang Shanliang, 2015, Journal of System Simulation, V27, P2169
   Yang Y., 2017, 2017 29 CHIN CONTR D
   Zhang J, 2001, IND ENG CHEM RES, V40, P1528, DOI 10.1021/ie990854w
   Zhang L.J., 2006, DISCOVERY SCI
   Zhi-Hong Z, 2006, J ENVIRON SCI-CHINA, V18, P1020, DOI 10.1016/S1001-0742(06)60032-6
NR 87
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115429
DI 10.1016/j.ces.2019.115429
PG 21
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100008
DA 2020-05-12
ER

PT J
AU Tesser, R
   Russo, V
   Turco, R
   Vitiello, R
   Di Serio, M
AF Tesser, Riccardo
   Russo, Vincenzo
   Turco, Rosa
   Vitiello, Rosa
   Di Serio, Martino
TI Bio-lubricants synthesis from the epoxidized oil promoted by clays:
   Kinetic modelling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bio-lubricants; Oxirane ring opening; Clays; Kinetics; Modelling
AB Bio-based lubricants are an attractive class of products, gaining more attention in the recent years. The production of bio-based lubricants starting from vegetable oils derivates (e.g. epoxidized) and alcohols is gaining relevance among the various synthetic routes. Broensted acids are normally used to promote the oxirane ring opening reaction, obtaining interesting products depending on the branching and chain length of the alcohol molecule. The use of homogeneous catalysts leads to evident drawbacks that could be overcome by replacing them with heterogeneous catalysts. Clays can be considered good candidates as they show reasonable acidity and are characterized by high availability and low price. In the present paper, the use of TONSIL EX 2166 was demonstrated to be a good candidate for the synthesis of bio-lubricant bases in the presence of 2-butanol. A kinetic model was proposed to describe the physical and chemical phenomena occurring in the reaction network. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Tesser, Riccardo; Russo, Vincenzo; Turco, Rosa; Vitiello, Rosa] Univ Naples Federico II, Dept Chem Sci, Via Cintia, I-80126 Naples, Italy.
   [Russo, Vincenzo] Abo Akad Univ, Lab Ind Chem & React Engn, Piispankatu, FI-20500 Turku, Finland.
   [Di Serio, Martino] Kumamoto Univ, IROAST, Kumamoto 8608555, Japan.
RP Tesser, R (reprint author), Univ Naples Federico II, Dept Chem Sci, Via Cintia, I-80126 Naples, Italy.
EM riccardo.tesser@unina.it
RI ; Di Serio, Martino/B-4166-2013
OI TESSER, Riccardo/0000-0001-7002-7194; Turco, Rosa/0000-0002-2681-4286;
   Russo, Vincenzo/0000-0002-1867-739X; Di Serio,
   Martino/0000-0003-4489-7115
FU Finanziamento della Ricerca di Ateneo [000023-ALTRI_DR_3450_2016_Ricerca
   di Ateneo-CA_BIO]; PRIN-2017 CARDIGAN
FX Thanks are due to the Finanziamento della Ricerca di Ateneo
   (000023-ALTRI_DR_3450_2016_Ricerca di Ateneo-CA_BIO) and to PRIN-2017
   CARDIGAN for financial support.
CR Adhvaryu A, 2005, IND CROP PROD, V21, P113, DOI 10.1016/j.indcrop.2004.02.001
   Allie-Ebrahim T, 2018, PHYS CHEM CHEM PHYS, V20, P18436, DOI 10.1039/c8cp03227k
   [Anonymous], 2018, LUBRICANTS MARKET AN
   Fogler H. S., 2016, ELEMENTS CHEM REACTI
   Lathi PS, 2007, APPL CATAL B-ENVIRON, V69, P207, DOI 10.1016/j.apcatb.2006.06.016
   McNutt J, 2016, J IND ENG CHEM, V36, P1, DOI 10.1016/j.jiec.2016.02.008
   Santacesaria E, 2011, CHEM ENG J, V173, P198, DOI 10.1016/j.cej.2011.05.018
   Sharma BK, 2006, J AM OIL CHEM SOC, V83, P129, DOI 10.1007/s11746-006-1185-z
   Sharma RV, 2013, APPL CATAL B-ENVIRON, V142, P604, DOI 10.1016/j.apcatb.2013.06.001
   Trifiro F., 2017, IND CHIMICA SPECIALI, V4
   Turco R, 2017, CATALYSTS, V7, DOI 10.3390/catal7100309
   Turco R, 2013, GREEN PROCESS SYNTH, V2, P427, DOI 10.1515/gps-2013-0045
   Zhou CH, 2011, APPL CLAY SCI, V53, P87, DOI 10.1016/j.clay.2011.04.016
NR 13
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115445
DI 10.1016/j.ces.2019.115445
PG 7
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100014
DA 2020-05-12
ER

PT J
AU Urmes, C
   Obeid, J
   Schweitzer, JM
   Cabiac, A
   Julcour, C
   Schuurman, Y
AF Urmes, Caroline
   Obeid, Joanne
   Schweitzer, Jean-Marc
   Cabiac, Amandine
   Julcour, Carine
   Schuurman, Yves
TI Periodic reactor operation for parameter estimation in catalytic
   heterogeneous kinetics. Case study for ethylene adsorption on Ni/Al2O3
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Transient kinetics; Periodic oscillations; Gain and phase shift;
   Frequency analysis
ID FREQUENCY-RESPONSE METHOD; CO; PERFORMANCE; DIFFUSION; GAS
AB Periodic operation of chemical reactors has usually been analyzed for a potential gain in performance. However, at the laboratory scale, periodic operation of a catalytic reactor can be used for kinetic studies with better parameter estimation, which is inherent to transient kinetic studies.
   Different mathematical methods are developed and compared in this study to simulate and model concentration cycling in a fixed bed catalytic reactor. Different cases including dissociative and molecular adsorption are considered with or without external and internal mass transfer limitations. The analysis of these cases gives information on the contribution of the different parameters on the phase lag and gain loss. This information can be used to better plan experimental kinetic studies.
   Ethylene adsorption over a Ni/Al2O3 catalyst has been studied experimentally in a dedicated set-up with a high-speed Infrared analyzer capable of analyzing the outlet gas mixture with a data acquisition frequency up to 30 Hz. The data are modeled with one of the analytical expressions developed in this work to estimate the equilibrium adsorption constant. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Urmes, Caroline; Obeid, Joanne; Schuurman, Yves] Univ Lyon, Univ Claude Bernard Lyon 1, CNRS, IRCELYON,UMR 5256, 2 Ave Albert Einstein, F-69626 Villeurbanne, France.
   [Julcour, Carine] Univ Toulouse, UPS, Lab Genie Chim, CNRS,INPT, Toulouse, France.
   [Urmes, Caroline; Schweitzer, Jean-Marc; Cabiac, Amandine] IFP Energies Nouvelles, Etab Lyon, Rond Point Echangeur Solaize BP3, F-69360 Solaize, France.
RP Schuurman, Y (reprint author), Univ Lyon, Univ Claude Bernard Lyon 1, CNRS, IRCELYON,UMR 5256, 2 Ave Albert Einstein, F-69626 Villeurbanne, France.
EM yves.schuurman@ircelyon.univ.lyon1.fr
CR Aida T, 1999, CHEM ENG SCI, V54, P4449, DOI 10.1016/S0009-2509(99)00039-1
   Alvarez J, 2012, CHEM ENG SCI, V74, P256, DOI 10.1016/j.ces.2012.02.048
   Berger RJ, 2008, APPL CATAL A-GEN, V342, P3, DOI 10.1016/j.apcata.2008.03.020
   Boudart M., 1967, IND CHIM BELG, V32, P281
   Brown WA, 1999, J MOL CATAL A-CHEM, V141, P21, DOI 10.1016/S1381-1169(98)00246-5
   Brzic D, 2012, CHEM ENG SCI, V82, P62, DOI 10.1016/j.ces.2012.07.013
   Garayhi AR, 2001, CHEM ENG J, V82, P329, DOI 10.1016/S1385-8947(00)00364-8
   Herz RK, 2015, IND ENG CHEM RES, V54, P4095, DOI 10.1021/ie503860w
   Hoebink JHBJ, 1999, CHEM ENG SCI, V54, P4459, DOI 10.1016/S0009-2509(99)00103-7
   Iijima Shun-ichiro, 1940, REV PHYS CHEM JAPAN, V14, P68
   Kalz KF, 2017, CHEMCATCHEM, V9, P17, DOI 10.1002/cctc.201600996
   Koci P, 2004, CATAL TODAY, V98, P345, DOI 10.1016/j.cattod.2004.08.002
   LI YE, 1989, AICHE J, V35, P423, DOI 10.1002/aic.690350310
   LIE ABK, 1993, CHEM ENG J BIOCH ENG, V53, P47, DOI 10.1016/0923-0467(93)80006-I
   MARCELIN G, 1986, J CATAL, V102, P240, DOI 10.1016/0021-9517(86)90158-2
   Markovic A, 2008, CHEM ENG RES DES, V86, P682, DOI 10.1016/j.cherd.2008.02.003
   Meyer D, 2017, CHEM ENG TECHNOL, V40, P2096, DOI 10.1002/ceat.201700122
   Nievergeld A., 1998, THESIS
   Park IS, 1998, CHEM ENG SCI, V53, P833, DOI 10.1016/S0009-2509(97)00372-2
   Petkovska M, 2018, ISR J CHEM, V58, P663, DOI 10.1002/ijch.201700132
   Poling B., 1988, PROPERTIES GASES LIQ
   Radhakrishnan K., 1993, NASA REFERENCE PUBLI
   Reyes SC, 2005, J PHYS CHEM B, V109, P2421, DOI 10.1021/jp048708d
   Reyes SC, 1994, CATALYSIS, V11, P51
   SILVESTON P, 1995, CATAL TODAY, V25, P91, DOI 10.1016/0920-5861(95)00101-K
   THULLIE J, 1993, CHEM ENG SCI, V48, P3921, DOI 10.1016/0009-2509(93)80370-6
   vanNeer FJR, 1996, CAN J CHEM ENG, V74, P664, DOI 10.1002/cjce.5450740517
   WATANABE N, 1981, CHEM ENG SCI, V36, P809, DOI 10.1016/0009-2509(81)85032-4
   YASUDA Y, 1991, J PHYS CHEM-US, V95, P2486, DOI 10.1021/j100159a070
   YOSHIDA F, 1962, AICHE J, V8, P5, DOI 10.1002/aic.690080106
NR 30
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 114544
DI 10.1016/j.ces.2018.10.012
PG 11
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100018
OA Green Accepted
DA 2020-05-12
ER

PT J
AU Wang, JJ
   Li, WH
   Zhou, ZH
   Gao, ZY
   Hu, YH
   Sun, W
AF Wang, Jianjun
   Li, Wenheng
   Zhou, Zihan
   Gao, Zhiyong
   Hu, Yuehua
   Sun, Wei
TI 1-Hydroxyethylidene-1,1-diphosphonic acid used as pH-dependent switch to
   depress and activate fluorite flotation I: Depressing behavior and
   mechanism
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluorite; Calcite; Flotation; 1-Hydroxyethylidene-1,1-diphosphonic acid;
   Sodium oleate; DFT
ID SELECTIVE FLOTATION; WATER GLASS; CALCITE; SCHEELITE; SEPARATION;
   ADSORPTION; INHIBITION; COLLECTOR; HEDP; BENEFICIATION
AB Fluorite is usually separated from calcite by froth flotation method using large amounts of sodium silicate depressant, which can cause trouble in the loss of fluorite and wastewater treatment. In this study, green and low-cost 1-hydroxyethylidene-1,1-diphosphonic acid (HEDP or H4L) was used as pH-dependent switch to initially depress fluorite for calcite pre-removal at pH 6.0, and then activate fluorite for further upgrading fluorite concentrate at pH 8.0. The depressing behavior and mechanism were reported in this work. H2L2 was the dominant form of HEDP, and a stronger chemical adsorption of H2L2 on fluorite hindered the subsequent adsorption of sodium oleate (NaOL), while that of the calcite showed the opposite result. Two active 0 atoms in H2L2 could well match in interatom distance with two Ca sites on fluorite to form Ca-H2L complexes. The pH-dependent switch reagent reported here may open a new avenue for more selective separation among mixed mineral systems. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Jianjun; Zhou, Zihan; Gao, Zhiyong; Hu, Yuehua; Sun, Wei] Cent South Univ, Sch Minerals Proc & Bioengn, Changsha 410083, Peoples R China.
   [Wang, Jianjun; Zhou, Zihan; Gao, Zhiyong; Hu, Yuehua; Sun, Wei] Cent South Univ, Key Lab Hunan Prov Clean & Efficient Utilizat Str, Changsha 410083, Peoples R China.
   [Li, Wenheng] Hunan Shizhuyuan Nonferrous Met Co Ltd, Chenzhou 423037, Peoples R China.
RP Gao, ZY; Sun, W (reprint author), Cent South Univ, Sch Minerals Proc & Bioengn, Changsha 410083, Peoples R China.
EM zhiyong.gao@csu.edu.cn; sunmenghu@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51774328, 51374247, 51404300]; National 111
   ProjectMinistry of Education, China - 111 Project [B14034]; Young Elite
   Scientists Sponsorship Program by CAST [2017QNRC001]; Young Elite
   Scientists Sponsorship Program by Hunan province of China [2018RS3011];
   Natural Science Foundation of Hunan Province of ChinaNatural Science
   Foundation of Hunan Province [2018JJ2520]; Collaborative Innovation
   Center for Clean and Efficient utilization of Strategic Metal Mineral
   Resources; National science and Technology Support Project of China
   [2015BAB14B02]; Fundamental Research Funds for the Central Universities
   of Central South University [2019zzts312]
FX This work was supported by the National Natural Science Foun-dation of
   China (51774328, 51374247 and 51404300), the National 111 Project (No.
   B14034), the Young Elite Scientists Sponsorship Program by CAST
   (2017QNRC001), the Young Elite Scientists Sponsorship Program by Hunan
   province of China (2018RS3011), the Natural Science Foundation of Hunan
   Province of China (2018JJ2520), the Collaborative Innovation Center for
   Clean and Efficient utilization of Strategic Metal Mineral Resources,
   the National science and Technology Support Project of China
   (2015BAB14B02), and the Fundamental Research Funds for the Central
   Universities of Central South University (No. 2019zzts312). The authors
   would like to thank professor Kirsten Corin from University of Cape Town
   for her help to improve the English of the manuscript.
CR Asadi M, 2018, J CLEAN PROD, V186, P782, DOI 10.1016/j.jclepro.2018.03.118
   Boddien A, 2011, SCIENCE, V333, P1733, DOI 10.1126/science.1206613
   Boulahlib-Bendaoud Y, 2012, ENRGY PROCED, V18, P1501, DOI 10.1016/j.egypro.2012.05.167
   BROWNING FH, 1995, LANGMUIR, V11, P4143, DOI 10.1021/la00010a082
   Browning FH, 1996, LANGMUIR, V12, P5231, DOI 10.1021/la9603277
   Bulatovic S.M., 2015, HDB FLOTATION REAGEN
   Chen C, 2019, MINER ENG, V133, P60, DOI 10.1016/j.mineng.2018.12.027
   Chen W, 2017, MINER ENG, V113, P1, DOI 10.1016/j.mineng.2017.07.016
   Choi WH, 2011, DESALIN WATER TREAT, V30, P247, DOI 10.5004/dwt.2011.2081
   Cruz VL, 2005, ORGANOMETALLICS, V24, P5095, DOI 10.1021/om050458f
   Demadis KD, 2005, BIOINORG CHEM APPL, V3, P119, DOI 10.1155/BCA.2005.119
   Deng LQ, 2016, J IND ENG CHEM, V33, P131, DOI 10.1016/j.jiec.2015.09.027
   Devyatov FV, 2013, RUSS J GEN CHEM+, V83, P1990, DOI 10.1134/S1070363213110042
   Dong LY, 2018, APPL SURF SCI, V444, P747, DOI 10.1016/j.apsusc.2018.03.097
   Earnshaw A., 1998, CHEM ELEMENTS
   Fa K., 2015, INT J MINER PROCESS, V81, P166
   Fa KQ, 2003, LANGMUIR, V19, P10523, DOI 10.1021/la035335j
   Filippova IV, 2014, MINER ENG, V66-68, P135, DOI 10.1016/j.mineng.2014.05.009
   FISCHER K, 1993, WATER RES, V27, P485, DOI 10.1016/0043-1354(93)90049-N
   Gao JD, 2019, CHEM ENG SCI, V193, P255, DOI 10.1016/j.ces.2018.09.017
   Gao YS, 2018, J COLLOID INTERF SCI, V512, P39, DOI 10.1016/j.jcis.2017.10.045
   Gao YS, 2016, INT J MINER PROCESS, V154, P10, DOI 10.1016/j.minpro.2016.06.010
   Gao ZY, 2019, MINER ENG, V130, P15, DOI 10.1016/j.mineng.2018.09.024
   Gao ZY, 2018, LANGMUIR, V34, P2511, DOI 10.1021/acs.langmuir.7b04165
   Gao ZY, 2016, MINERALS-BASEL, V6, DOI 10.3390/min6040114
   Gao ZY, 2016, LANGMUIR, V32, P6282, DOI 10.1021/acs.langmuir.6b01252
   Gao ZY, 2015, MINER ENG, V72, P23, DOI 10.1016/j.mineng.2014.12.025
   Geerlings P, 2003, CHEM REV, V103, P1793, DOI 10.1021/cr990029p
   GOLD V, 1988, J ORGANOMET CHEM, V356, pC76, DOI DOI 10.1016/0022-328X(88)83113-9
   Guan QJ, 2018, J COLLOID INTERF SCI, V530, P292, DOI 10.1016/j.jcis.2018.06.068
   Harichandran G, 2014, J MOL CATAL A-CHEM, V392, P31, DOI 10.1016/j.molcata.2014.04.035
   Huang ZJ, 2019, MINER ENG, V140, DOI 10.1016/j.mineng.2019.105890
   Jiang W, 2018, APPL SURF SCI, V435, P752, DOI 10.1016/j.apsusc.2017.11.093
   Jiao F, 2019, MINER ENG, V136, P120, DOI 10.1016/j.mineng.2019.03.019
   Khormali A, 2017, J PETROL SCI ENG, V153, P257, DOI 10.1016/j.petrol.2017.04.008
   Kwan YCG, 2015, THIN SOLID FILMS, V590, P40, DOI 10.1016/j.tsf.2015.07.051
   Li CW, 2018, MINER ENG, V128, P123, DOI 10.1016/j.mineng.2018.08.044
   Li CW, 2017, POWDER TECHNOL, V322, P386, DOI 10.1016/j.powtec.2017.08.066
   Li SC, 2010, SCIENCE, V328, P882, DOI 10.1126/science.1188328
   Liu GY, 2008, MINER ENG, V21, P1050, DOI 10.1016/j.mineng.2008.04.017
   Liu GY, 2012, COLLOID SURFACE A, V409, P1, DOI 10.1016/j.colsurfa.2012.04.036
   Lu JS, 2018, J CLEAN PROD, V172, P1978, DOI 10.1016/j.jclepro.2017.11.228
   LUO YR, 2007, COMPREHENSIVE HDB CH
   MOHAMMADI F, 1994, J POWER SOURCES, V52, P61, DOI 10.1016/0378-7753(94)01938-X
   MOROZOV VV, 1992, INT J MINER PROCESS, V35, P177, DOI 10.1016/0301-7516(92)90032-R
   Nagakane K, 2006, DENT MATER J, V25, P645, DOI 10.4012/dmj.25.645
   PENG HQ, 2017, MINERALS-BASEL, V7, DOI DOI 10.3390/MIN7070108
   Pina CM, 2004, SURF SCI, V553, P61, DOI 10.1016/j.susc.2004.01.022
   Pradip, 2002, J COLLOID INTERF SCI, V256, P106, DOI 10.1006/jcis.2001.7994
   Pradip, 2002, LANGMUIR, V18, P932, DOI 10.1021/la010625q
   Puziy AM, 2008, CARBON, V46, P2113, DOI 10.1016/j.carbon.2008.09.010
   Raju GB, 2000, MINER METALL PROC, V17, P167
   REN ZJ, 2017, MINERALS-BASEL, V7, DOI DOI 10.3390/MIN7020024
   SANDERSON RT, 1983, J AM CHEM SOC, V105, P2259, DOI 10.1021/ja00346a026
   Schaufuss AG, 1998, SURF SCI, V411, P321, DOI 10.1016/S0039-6028(98)00355-0
   SCHUBERT H, 1990, INT J MINER PROCESS, V30, P185, DOI 10.1016/0301-7516(90)90014-P
   Sergienko VS, 2000, CRYSTALLOGR REP+, V45, P64, DOI 10.1134/1.171138
   Sergienko VS, 2001, RUSS J COORD CHEM+, V27, P681, DOI 10.1023/A:1012334908835
   Sitepu H, 2005, J APPL CRYSTALLOGR, V38, P158, DOI 10.1107/S0021889804031231
   Spanos N, 2006, LANGMUIR, V22, P2074, DOI 10.1021/la052062e
   Speziale S, 2002, PHYS CHEM MINER, V29, P465, DOI 10.1007/s00269-002-0250-x
   Tian MJ, 2018, J COLLOID INTERF SCI, V529, P150, DOI 10.1016/j.jcis.2018.05.113
   Wang D., 1988, SOLUTION CHEM FLOTAT
   Wang JJ, 2018, MINERALS-BASEL, V8, DOI 10.3390/min8080313
   Wang JJ, 2016, MINER ENG, V98, P261, DOI 10.1016/j.mineng.2016.09.006
   Wei Z, 2018, MINER ENG, V120, P29, DOI 10.1016/j.mineng.2018.01.036
   Zhang CH, 2018, J COLLOID INTERF SCI, V512, P55, DOI 10.1016/j.jcis.2017.10.043
   Zhang Y, 2003, MINER ENG, V16, P597, DOI 10.1016/S0892-6875(03)00136-5
   Zhang Y, 2012, INT J MIN SCI TECHNO, V22, P285, DOI 10.1016/j.ijmst.2012.03.008
   Zhao G, 2013, MINER ENG, V49, P54, DOI 10.1016/j.mineng.2013.04.025
   Zhao YY, 2008, CHEMOSPHERE, V73, P86, DOI 10.1016/j.chemosphere.2008.05.018
   ZHOU Q, 1992, MINER ENG, V5, P435
   Zhou WB, 2013, MINER ENG, V45, P142, DOI 10.1016/j.mineng.2013.02.017
NR 73
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115369
DI 10.1016/j.ces.2019.115369
PG 12
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100024
DA 2020-05-12
ER

PT J
AU Wang, QL
   Liu, XW
   Wu, XW
   Yang, C
   Qiu, T
AF Wang, Qinglian
   Liu, Xuwei
   Wu, Xiaowei
   Yang, Chen
   Qiu, Ting
TI A multi-scale approach to optimize vapor-liquid mass transfer layer in
   structured catalytic packing
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Catalytic distillation process; Structured catalytic packings;
   Vapor-liquid mass transfer layer; Structure parameters; Mass transfer
   coefficient
ID LATTICE BOLTZMANN SIMULATION; REACTIVE DISTILLATION; PRESSURE-DROP;
   MULTIPHASE FLOW; SCALE-UP; CFD; HYDRODYNAMICS; DISPERSION; MODEL;
   EFFICIENCY
AB In order to implement the multi-scale model to optimize the structure of vapor-liquid mass transfer layer, vapor and liquid mass transfer coefficients that embrace the effects of structure parameters of mass transfer layer should be obtained in advance. In the study, the influences of four structure parameters on mass transfer performance were studied by the tracer method. Moreover, the corresponding mass transfer coefficients were correlated. By comparing with the experimental data of different types of structured catalytic packings, it has been found that the correlations exhibit good universality. Furthermore, the correlations were applied to the non-equilibrium model for the hydrolysis of methyl acetate (MA), so as to investigate the influences of four structure parameters on catalytic distillation process. The results indicated that wavy height and the area ratio of mass transfer layer to catalyst layer have more significant influences on the conversion of MA than inclined angle and base length. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Qinglian; Liu, Xuwei; Wu, Xiaowei; Yang, Chen; Qiu, Ting] Fuzhou Univ, Fujian Prov Univ, Coll Chem Engn, Engn Res Ctr React Distillat, Fuzhou 350116, Fujian, Peoples R China.
RP Yang, C; Qiu, T (reprint author), Fuzhou Univ, Fujian Prov Univ, Coll Chem Engn, Engn Res Ctr React Distillat, Fuzhou 350116, Fujian, Peoples R China.
EM cyang@fzu.edu.cn; tingqiu@fzu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21808037]
FX The authors wish to acknowledge the financial support by the National
   Natural Science Foundation of China (Project No. 21808037).
CR Behrens M., 2006, ICHEME S SERIES, V152, P991
   BRACKBILL JU, 1992, J COMPUT PHYS, V100, P335, DOI 10.1016/0021-9991(92)90240-Y
   Cao Z, 2001, J MEMBRANE SCI, V185, P157, DOI 10.1016/S0376-7388(00)00643-8
   Chen JB, 2009, CHINESE J CHEM ENG, V17, P381, DOI 10.1016/S1004-9541(08)60220-7
   Dai CN, 2013, CHEM ENG SCI, V100, P342, DOI 10.1016/j.ces.2013.02.066
   Dai CN, 2012, SEP PURIF TECHNOL, V98, P78, DOI 10.1016/j.seppur.2012.06.035
   Dong B, 2017, CHEM ENG RES DES, V124, P238, DOI 10.1016/j.cherd.2017.06.017
   Egorov Y, 2005, CHEM ENG PROCESS, V44, P631, DOI 10.1016/j.cep.2003.10.011
   Gotze L, 2001, CATAL TODAY, V69, P201, DOI 10.1016/S0920-5861(01)00370-4
   Harmsen GJ, 2007, CHEM ENG PROCESS, V46, P774, DOI 10.1016/j.cep.2007.06.005
   Hoffmann A, 2004, CHEM ENG PROCESS, V43, P383, DOI 10.1016/S0255-2701(03)00121-1
   Jaroszynski M, 2006, PRZEM CHEM, V85, P1113
   Kloker A, 2003, CATAL TODAY, V79, P479, DOI 10.1061/S0920-5861(03)00068-3
   Kolodziej A, 2004, CHEM ENG PROCESS, V43, P457, DOI 10.1016/S0255-2701(03)00134-X
   Kolodziej A, 2001, CATAL TODAY, V69, P75, DOI 10.1016/S0920-5861(01)00357-1
   Lei ZG, 2011, IND ENG CHEM RES, V50, P5942, DOI 10.1021/ie102206x
   Li JM, 2016, CAN J CHEM ENG, V94, P556, DOI 10.1002/cjce.22398
   Li QS, 2016, CHEM ENG SCI, V143, P23, DOI 10.1016/j.ces.2015.12.014
   Lin YX, 2019, INT J HEAT MASS TRAN, V138, P1014, DOI 10.1016/j.ijheatmasstransfer.2019.04.105
   Liu BT, 2016, IND ENG CHEM RES, V55, P7810, DOI 10.1021/acs.iecr.5b05003
   Liu JJ, 2013, CHEM ENG J, V225, P280, DOI 10.1016/j.cej.2013.03.046
   Luo JZ, 2016, CHEM ENG SCI, V155, P386, DOI 10.1016/j.ces.2016.08.010
   Manduca E, 2003, SEPAR SCI TECHNOL, V38, P3535, DOI 10.1081/SS-120023415
   MENTER FR, 1994, AIAA J, V32, P1598, DOI 10.2514/3.12149
   Onda K., 1968, J CHEM ENG JPN, V1, P56, DOI DOI 10.1252/JCEJ.1.56
   Petre CF, 2003, CHEM ENG SCI, V58, P163, DOI 10.1016/S0009-2509(02)00473-6
   Qi WZ, 2017, IND ENG CHEM RES, V56, P15184, DOI 10.1021/acs.iecr.7b04194
   Qiu T., 1999, J FUZHOU U NATL SCI, V27, P100
   Ratheesh S, 2004, CHEM ENG J, V104, P45, DOI 10.1016/j.cej.2004.08.004
   Raynal L, 2007, CHEM ENG SCI, V62, P7196, DOI 10.1016/j.ces.2007.08.010
   Ri PC, 2017, INT J HYDROGEN ENERG, V42, P9630, DOI 10.1016/j.ijhydene.2017.02.035
   Saleh AR, 2011, CHEM ENG TECHNOL, V34, P1402, DOI 10.1002/ceat.201000557
   Sebastia-Saez D, 2013, INT J GREENH GAS CON, V19, P492, DOI 10.1016/j.ijggc.2013.10.013
   Sharma M.M., 2002, REACTIVE DISTILLATIO, P3
   Shilkin A, 2006, AICHE J, V52, P3055, DOI 10.1002/aic.10937
   Singh RK, 2018, CHEM ENG J, V353, P949, DOI 10.1016/j.cej.2018.07.067
   Sotoodeh MM, 2018, CHEM ENG PROCESS, V129, P1, DOI 10.1016/j.cep.2018.04.034
   Sun B, 2013, AICHE J, V59, P3119, DOI 10.1002/aic.14082
   Sun ZM, 2007, CHEM ENG SCI, V62, P1839, DOI 10.1016/j.ces.2006.12.021
   Tomasic V, 2004, CHEM ENG PROCESS, V43, P765, DOI 10.1016/S0255-2701(03)00045-X
   van Baten JM, 2002, CHEM ENG SCI, V57, P1531, DOI 10.1016/S0009-2509(02)00026-X
   Wang QL, 2017, CHEM ENG SCI, V174, P472, DOI 10.1016/j.ces.2017.09.040
   Wu Y., 1999, STUDY CATALYTIC DIST
   Xiang WY, 2016, IND ENG CHEM RES, V55, P1768, DOI 10.1021/acs.iecr.5b02685
   Yang C, 2020, CHEM ENG RES DES, V153, P582, DOI 10.1016/j.cherd.2019.10.048
   Yang C, 2018, AICHE J, V64, P2770, DOI 10.1002/aic.16088
   Zhang H, 2013, CHEM ENG SCI, V101, P699, DOI 10.1016/j.ces.2013.07.030
   Zheng YK, 2019, CHEM ENG PROCESS, V139, P183, DOI 10.1016/j.cep.2019.03.016
   Zivdar M., 2017, JCHPE, V51, P27, DOI DOI 10.22059/JCHPE.2017.62163
NR 49
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115434
DI 10.1016/j.ces.2019.115434
PG 17
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100031
DA 2020-05-12
ER

PT J
AU Wehbe, M
   Abu Tarboush, BJ
   Shehadeh, M
   Ahmad, M
AF Wehbe, Malak
   Abu Tarboush, Belal J.
   Shehadeh, Mutasem
   Ahmad, Mohammad
TI Molecular dynamics simulations of the removal of lead(II) from water
   using the UiO-66 metal-organic framework
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Molecular dynamics; Water treatment; Adsorption; Metal-organic
   framework; Lead(II); UiO-66
ID SELECTIVE ADSORPTION; EFFICIENT REMOVAL; AQUEOUS SAMPLES;
   GAS-ADSORPTION; ION-EXCHANGE; FORCE-FIELD; ZR-MOFS; PB(II); ACID;
   FUNCTIONALIZATION
AB In this work, we use molecular dynamics simulations to investigate the viability of using the UiO-66 MOF for the removal of lead ions, Pb2+, from water. We study the concentration of Pb(II) in water in the presence of this MOF under varying conditions of number density of particles in the system (500, 300, 74 and 20 particles), metal cation concentration (1.5 M, 3.7 M, 6 M and 55.6 M) and presence of NO3 ions. Pb(II) ions are observed to adsorb onto the UiO-66 framework under favorable conditions, corresponding to: low number density of particles, high metal cation concentration and absence of NO3 ions in the vicinity of the MOF. According to the radial distribution functions, preferential adsorption sites for the Pb2+ in UiO-66 correspond to the oxygen atoms forming the Zr-O-Zr bridge. This study indicates that UiO-66 could be a successful candidate for the removal of Pb(II) from water. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wehbe, Malak; Abu Tarboush, Belal J.; Ahmad, Mohammad] Amer Univ Beirut, Bahaa & Walid Bassatne Dept Chem Engn & Adv Energ, Beirut, Lebanon.
   [Shehadeh, Mutasem] Amer Univ Beirut, Mech Engn Dept, Beirut, Lebanon.
   [Wehbe, Malak] Imperial Coll London, Ctr Proc Syst Engn, Dept Chem Engn, South Kensington Campus, London SW7 2AZ, England.
RP Shehadeh, M (reprint author), Amer Univ Beirut, Mech Engn Dept, Beirut, Lebanon.
EM ms144@aub.edu.lb
OI Shehadeh, Mutasem/0000-0002-8416-3303
FU Research Board at the American University of Beirut
FX Support from the Research Board at the American University of Beirut is
   greatly acknowledged. This research did not receive any specific grant
   from funding agencies in the public, commercial, or not-for-profit
   sectors.
CR Allen F. H., 1993, J MOL GRAPHICS, V8, P31
   [Anonymous], 2007, TOXICOLOGICAL PROFIL
   Barakat MA, 2011, ARAB J CHEM, V4, P361, DOI 10.1016/j.arabjc.2010.07.019
   Bradl H., 2005, HEAVY METALS ENV
   Burrows AD, 2008, DALTON T, P2465, DOI 10.1039/b718947h
   Cavka J.H., 2008, J AM CHEM SOC, V6, P1, DOI DOI 10.1021/JA8057953
   Custelcean R, 2007, CHEM COMMUN, P1541, DOI 10.1039/b616761f
   Cychosz KA, 2010, LANGMUIR, V26, P17198, DOI 10.1021/la103234u
   DeCoste JB, 2013, J MATER CHEM A, V1, P11922, DOI 10.1039/c3ta12497e
   Dietzel PDC, 2008, CHEM COMMUN, P5125, DOI 10.1039/b810574j
   Dinca M, 2008, ANGEW CHEM INT EDIT, V47, P6766, DOI 10.1002/anie.200801163
   Duffus JH, 2002, PURE APPL CHEM, V74, P793, DOI 10.1351/pac200274050793
   Environmental Protection Agency, 2019, BAS INF LEAD DRINK W
   Farrusseng D, 2009, ANGEW CHEM INT EDIT, V48, P7502, DOI 10.1002/anie.200806063
   Flora Gagan, 2012, Interdiscip Toxicol, V5, P47, DOI 10.2478/v10102-012-0009-2
   Fu FL, 2011, J ENVIRON MANAGE, V92, P407, DOI 10.1016/j.jenvman.2010.11.011
   Granato MA, 2014, MICROPOR MESOPOR MAT, V190, P165, DOI 10.1016/j.micromeso.2014.02.014
   Greathouse JA, 2006, J AM CHEM SOC, V128, P10678, DOI 10.1021/ja063506b
   Halder GJ, 2002, SCIENCE, V298, P1762, DOI 10.1126/science.1075948
   Harvey B., 2002, MANAGING ELEVATED BL
   Hasan Z, 2015, J HAZARD MATER, V283, P329, DOI 10.1016/j.jhazmat.2014.09.046
   Horcajada P, 2006, ANGEW CHEM INT EDIT, V45, P5974, DOI 10.1002/anie.200601878
   Howarth AJ, 2015, J AM CHEM SOC, V137, P7488, DOI 10.1021/jacs.5b03904
   Ihsanullah, 2016, SEP PURIF TECHNOL, V157, P141, DOI 10.1016/j.seppur.2015.11.039
   Jamali A, 2016, DALTON T, V45, P9193, DOI 10.1039/c6dt00782a
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Ke F, 2011, J HAZARD MATER, V196, P36, DOI 10.1016/j.jhazmat.2011.08.069
   Khan NA, 2015, J HAZARD MATER, V282, P194, DOI 10.1016/j.jhazmat.2014.03.047
   Kommu A, 2016, RSC ADV, V6, P63190, DOI 10.1039/c6ra06817k
   Lee J, 2009, CHEM SOC REV, V38, P1450, DOI 10.1039/b807080f
   Li CJ, 2008, CHEM COMMUN, P6348, DOI 10.1039/b815024a
   Li KH, 2008, CHEM COMMUN, P6123, DOI 10.1039/b814498b
   Lin KYA, 2016, J COLLOID INTERF SCI, V461, P79, DOI 10.1016/j.jcis.2015.08.061
   Liu XL, 2015, J AM CHEM SOC, V137, P6999, DOI 10.1021/jacs.5b02276
   Luo XB, 2015, J CHEM ENG DATA, V60, P1732, DOI 10.1021/je501115m
   MAYO SL, 1990, J PHYS CHEM-US, V94, P8897, DOI 10.1021/j100389a010
   Murray LJ, 2009, CHEM SOC REV, V38, P1294, DOI 10.1039/b802256a
   Nalaparaju A, 2012, J PHYS CHEM C, V116, P6925, DOI 10.1021/jp210082f
   Phang WJ, 2015, ANGEW CHEM INT EDIT, V54, P5142, DOI 10.1002/anie.201411703
   Plimpton S, 2007, SANDIA NATL LAB, V18, P43, DOI DOI 10.1002/ejoc.201200111
   Qin QD, 2011, CHEM ENG J, V172, P68, DOI 10.1016/j.cej.2011.05.066
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Seo YS, 2015, CHEM ENG J, V270, P22, DOI 10.1016/j.cej.2015.02.007
   Tahmasebi E, 2015, INORG CHEM, V54, P425, DOI 10.1021/ic5015384
   Tchounwou Paul B, 2012, Exp Suppl, V101, P133, DOI 10.1007/978-3-7643-8340-4_6
   US Department of Health and Human Services, 2016, 14 US DEP HLTH HUM S
   Vu TA, 2015, RSC ADV, V5, P5261, DOI 10.1039/c4ra12326c
   Wang C, 2015, SCI REP-UK, V5, DOI 10.1038/srep12735
   Wang K, 2017, IND ENG CHEM RES, V56, P1880, DOI 10.1021/acs.iecr.6b04997
   Wang L, 2017, ENVIRON SCI POLLUT R, V24, P14198, DOI 10.1007/s11356-017-9002-9
   WHO, 2008, INT HLTH REG
   Yang QY, 2011, CHEM-EUR J, V17, P8882, DOI 10.1002/chem.201003596
   Yee KK, 2013, J AM CHEM SOC, V135, P7795, DOI 10.1021/ja400212k
   Yin N, 2016, CHEM LETT, V45, P625, DOI 10.1246/cl.160148
   Zhang JM, 2016, J MOL LIQ, V221, P43, DOI 10.1016/j.molliq.2016.05.054
   Zhou HC, 2012, CHEM REV, V112, P673, DOI 10.1021/cr300014x
   Zou F, 2013, CHEMPHYSCHEM, V14, P2825, DOI 10.1002/cphc.201300215
NR 58
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115396
DI 10.1016/j.ces.2019.115396
PG 11
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100016
DA 2020-05-12
ER

PT J
AU Wu, GL
   Yin, YC
   Chen, WB
   Xin, F
   Lu, YT
   Qin, K
   Zhang, L
   Song, YX
   Li, MF
AF Wu, Guilian
   Yin, Yachen
   Chen, Wenbin
   Xin, Feng
   Lu, Yutao
   Qin, Kang
   Zhang, Le
   Song, Yuexiao
   Li, Mingfeng
TI Catalytic kinetics for ultra-deep hydrodesulfurization of diesel
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Ultra-deep hydrodesulfurization; Micro-packed trickle bed reactor;
   Kinetic model; Parameter estimation
ID 3-PHASE REACTOR MODEL; TRICKLE-BED REACTOR; PARAMETER ESTIMATION;
   COMO/AL2O3 CATALYST; REACTION NETWORK; SIMULATION; HYDRODENITROGENATION;
   HYDROGENATION; 4-METHYLDIBENZOTHIOPHENE; DIBENZOTHIOPHENE
AB A set of rate laws for hydrodesulfurization (HDS), hydrodenitrogenation (HDN) and aromatic hydrosaturation (AHS) of diesel was established to describe ultra-deep HDS in the sulfur concentration range from more than 10,000 ppm to below 10 ppm. High throughput experiments in micro-packed bed reactors with 2 mm inner diameter were conducted using NiMo/Al2O3 catalyst at temperatures from 300 degrees C to 360 degrees C, a pressure range of 4.4 MPa to 7.4 MPa, and liquid hourly space velocity (LHSV) between 0.75 h(-1) and 12 h(-1). To establish the rate laws, the sulfur content was divided into two regions, and the inhibition effects of H2S, nitrogen compounds, aromatics and the virtually refractory compounds were included. All kinetic parameters were estimated by combining genetic algorithm and least square regression to fit experimental data well. Finally, an appropriate operation interval of such reactor was obtained by using the developed model. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wu, Guilian; Yin, Yachen; Xin, Feng; Song, Yuexiao] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
   [Chen, Wenbin; Lu, Yutao; Qin, Kang; Zhang, Le; Li, Mingfeng] Sinopec Res Inst Petr Proc, Sinopec Grp, Beijing 100083, Peoples R China.
RP Xin, F (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.; Li, MF (reprint author), Sinopec Res Inst Petr Proc, Sinopec Grp, Beijing 100083, Peoples R China.
EM xinf@tju.edu.cn; limf.ripp@sinopec.com
OI Xin, Feng/0000-0003-0877-8434
FU China Petrochemical Corporation (Sinopec Group) [117006]
FX We thank for the finacal support of the China Petrochemical Corporation
   (Sinopec Group, 117006).
CR Albazzaz H, 2017, ENERG FUEL, V31, P831, DOI 10.1021/acs.energyfuels.6b02581
   Alvarez A, 2009, APPL CATAL A-GEN, V361, P1, DOI 10.1016/j.apcata.2009.03.008
   Alvarez A, 2008, APPL CATAL A-GEN, V351, P148, DOI 10.1016/j.apcata.2008.09.010
   Ancheyta J, 2013, CHEM IND-SER, P1, DOI 10.1201/b13879
   Beltramone AR, 2008, IND ENG CHEM RES, V47, P7161, DOI 10.1021/ie8004258
   Bhaskar M, 2004, IND ENG CHEM RES, V43, P6654, DOI 10.1021/ie049642b
   BRODERICK DH, 1981, AICHE J, V27, P663, DOI 10.1002/aic.690270419
   Chowdhury R, 2002, AICHE J, V48, P126, DOI 10.1002/aic.690480113
   Cooper BH, 1996, APPL CATAL A-GEN, V137, P203, DOI 10.1016/0926-860X(95)00258-8
   de Mello MD, 2018, FUEL PROCESS TECHNOL, V177, P66, DOI 10.1016/j.fuproc.2018.04.010
   Feng X, 2018, FUEL, V230, P113, DOI 10.1016/j.fuel.2018.05.023
   FROMENT GF, 1994, IND ENG CHEM RES, V33, P2975, DOI 10.1021/ie00036a012
   Gates BC, 1997, POLYHEDRON, V16, P3213, DOI 10.1016/S0277-5387(97)00074-0
   GIRGIS MJ, 1991, IND ENG CHEM RES, V30, P2021, DOI 10.1021/ie00057a001
   Ho TC, 2004, J CATAL, V222, P450, DOI 10.1016/j.jcat.2003.12.010
   Ho TC, 2003, J CATAL, V219, P442, DOI 10.1016/S0021-9517(03)00215-X
   HO TC, 1988, CATAL REV, V30, P117, DOI 10.1080/01614948808078617
   HO TC, 1987, AICHE J, V33, P1050, DOI 10.1002/aic.690330621
   Ho TC, 2018, AICHE J, V64, P595, DOI 10.1002/aic.15969
   Jarullah AT, 2011, FUEL, V90, P2165, DOI 10.1016/j.fuel.2011.01.025
   Knudsen KG, 1999, APPL CATAL A-GEN, V189, P205, DOI 10.1016/S0926-860X(99)00277-X
   Korsten H, 1996, AICHE J, V42, P1350, DOI 10.1002/aic.690420515
   Lylykangas MS, 2002, IND ENG CHEM RES, V41, P5632, DOI 10.1021/ie0202930
   Mederos FS, 2012, APPL CATAL A-GEN, V425, P13, DOI 10.1016/j.apcata.2012.02.034
   Morales-Valencia EM, 2018, ACS CATAL, V8, P3926, DOI 10.1021/acscatal.8b00629
   Nguyen TTH, 2017, ENERG FUEL, V31, P5673, DOI 10.1021/acs.energyfuels.7b00360
   Novaes LD, 2017, FUEL, V209, P184, DOI 10.1016/j.fuel.2017.07.092
   Plantenga FL, 2003, APPL CATAL A-GEN, V248, P1, DOI 10.1016/S0926-860X(03)00133-9
   Stanislaus A, 2010, CATAL TODAY, V153, P1, DOI 10.1016/j.cattod.2010.05.011
   Szymanska A, 2003, J CATAL, V218, P24, DOI 10.1016/S0021-9517(03)00072-1
   Toosi AF, 2014, ENERG FUEL, V28, P4828, DOI 10.1021/ef500701q
   Vanrysselberghe V, 1996, IND ENG CHEM RES, V35, P3311, DOI 10.1021/ie960099b
   Vanrysselberghe V, 1998, IND ENG CHEM RES, V37, P1235, DOI 10.1021/ie970533p
   VRINAT ML, 1983, APPL CATAL, V6, P137, DOI 10.1016/0166-9834(83)80260-7
   Whitehurst DD, 1998, CATAL TODAY, V45, P299, DOI 10.1016/S0920-5861(98)00234-X
   Yang H, 2005, CATAL TODAY, V109, P16, DOI 10.1016/j.cattod.2005.08.028
   Yang YQ, 2017, ENERG FUEL, V31, P5491, DOI 10.1021/acs.energyfuels.7b00496
NR 37
TC 0
Z9 0
U1 7
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115446
DI 10.1016/j.ces.2019.115446
PG 10
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100015
DA 2020-05-12
ER

PT J
AU Yang, LL
   Zhang, J
   Ma, Y
   Xu, JY
   Wang, J
AF Yang, Lele
   Zhang, Jan
   Ma, Yong
   Xu, Jingyu
   Wang, Jing
TI Experimental and numerical study of separation characteristics in
   gas-liquid cylindrical cyclone
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas-liquid cylinder cyclone; Droplets; Breakup; Coalescence; Migration
   model
ID DROPLET SIZE DISTRIBUTION; TURBULENT SWIRLING FLOW;
   VELOCITY-MEASUREMENTS; LASER DIFFRACTION; 2-PHASE FLOW; DESIGN;
   PRESSURE; OIL; HYDRODYNAMICS; HYDROCYCLONE
AB The separation characteristics of the gas-liquid cylindrical cyclone (GLCC) has been investigated by experiment and numerical analysis. The droplet size and phase distributions were measured using Malvern RTsizer and electrical resistivity tomography, respectively. The Discrete Phase Model was used to numerically analyze the swirling hydrodynamics. The results showed that the separator with strong swirl intensity would not necessarily get better separation performance, and the nozzle with Ne = 5.9 performed best. The small and medium droplets tended to initially coalesce and subsequently break up with increased gas superficial velocity, whereas they always tended to coalesce with increased liquid superficial velocity. ERT measurement results proved the existence of the flow reversal for the gas core. Finally, a droplet migration model was developed based on the force analysis of droplet and the swirling hydrodynamics, which accurately predicted the separation performance of GLCC. These results can be used in the design of the GLCC. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Lele; Ma, Yong; Wang, Jing] Sun Yat Sen Univ, Sch Marine Engn & Technol, Guangzhou 518000, Peoples R China.
   [Zhang, Jan; Xu, Jingyu] Chinese Acad Sci, Inst Mech, Beijing 100190, Peoples R China.
   [Yang, Lele; Ma, Yong] Southern Marine Sci & Engn Guangdong Lab Zhuhai, Zhuhai 519000, Peoples R China.
RP Ma, Y (reprint author), Sun Yat Sen Univ, Sch Marine Engn & Technol, Guangzhou 518000, Peoples R China.; Xu, JY (reprint author), Chinese Acad Sci, Inst Mech, Beijing 100190, Peoples R China.
EM mayong3@mail.sysu.edu.cn; xujingyu@imech.ac.cn
RI Xu, Jing-yu/J-4472-2012
OI Xu, Jing-yu/0000-0002-1058-2257
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2019M663242]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
   [19lgpy86]; Dedicated Fund for Promoting High-Quality Economic
   Development in Guangdong Province (Marine Economic Development Project)
   [GDOE2019A43]
FX This research was funded by the China Postdoctoral Science Foundation
   (No. 2019M663242), the Fundamental Research Funds for the Central
   Universities (No. 19lgpy86) and the Dedicated Fund for Promoting
   High-Quality Economic Development in Guangdong Province (Marine Economic
   Development Project) (NO. GDOE2019A43).
CR Arpandi I., 1996, SPE J, V1, P427
   Bergstrom J, 2007, SEP PURIF TECHNOL, V53, P8, DOI 10.1016/j.seppur.2006.09.019
   CHANG F, 1994, INT J HEAT FLUID FL, V15, P346, DOI 10.1016/0142-727X(94)90048-5
   Chirinos W., 1999, SPE ANN TECHN C EXH
   Ding JW, 2017, EXP THERM FLUID SCI, V82, P166, DOI 10.1016/j.expthermflusci.2016.11.014
   Erdal F.M., 1996, SPE J, V2, P436
   Erdal FM, 2004, J ENERG RESOUR-ASME, V126, P326, DOI 10.1115/1.1805539
   Eshel G, 2004, SOIL SCI SOC AM J, V68, P736, DOI 10.2136/sssaj2004.0736
   Gomez LE, 1999, J ENERG RESOUR-ASME, V121, P15, DOI 10.1115/1.2795054
   Gupta A, 2007, INT J HEAT FLUID FL, V28, P249, DOI 10.1016/j.ijheatfluidflow.2006.04.005
   Han Q, 2013, AIP CONF PROC, V1547, P350, DOI 10.1063/1.4816885
   HINZE JO, 1955, AICHE J, V1, P289, DOI 10.1002/aic.690010303
   Hreiz R, 2014, CHEM ENG RES DES, V92, P2231, DOI 10.1016/j.cherd.2014.02.029
   Hreiz R, 2011, CHEM ENG RES DES, V89, P2521, DOI 10.1016/j.cherd.2011.05.001
   Jia JB, 2015, FLOW MEAS INSTRUM, V41, P75, DOI 10.1016/j.flowmeasinst.2014.10.010
   KITOH O, 1991, J FLUID MECH, V225, P445, DOI 10.1017/S0022112091002124
   Kouba G., 1996, INT C PROD SEP SYST, P23
   KOUBA GE, 1995, BHR GR CONF SER PUBL, P307
   KUSTERS KA, 1991, APPL OPTICS, V30, P4839, DOI 10.1364/AO.30.004839
   Lan ZK, 2014, ANN NUCL ENERGY, V63, P215, DOI 10.1016/j.anucene.2013.07.048
   Liu S, 2018, CHEM ENG RES DES, V129, P35, DOI 10.1016/j.cherd.2017.10.033
   Mantilla I., 1998, BUBBLE TRAJECTORY AN
   Melendez-Ramirez A.J., 2004, P IMECE2004 2004 ASM
   Mohan RS, 1998, J ENERG RESOUR-ASME, V120, P49, DOI 10.1115/1.2795009
   MONREDON TC, 1992, INT J MINER PROCESS, V35, P65, DOI 10.1016/0301-7516(92)90005-H
   Movafaghian S, 2000, INT J MULTIPHAS FLOW, V26, P999, DOI 10.1016/S0301-9322(99)00076-2
   O'Rourke P.J., 1981, THESIS
   Patruno LE, 2010, CHEM ENG SCI, V65, P1407, DOI 10.1016/j.ces.2009.10.011
   Reitz R.D., 1987, ATOMISATION SPRAY TE, V3, P309
   Reyes-Gutierrez MA, 2006, J FLUID ENG-T ASME, V128, P832, DOI 10.1115/1.2201623
   Santolaya JL, 2013, INT J MULTIPHAS FLOW, V56, P160, DOI 10.1016/j.ijmultiphaseflow.2013.06.007
   Sardeshpande MV, 2017, CHEM ENG SCI, V170, P476, DOI 10.1016/j.ces.2017.04.025
   Simmons MJH, 2001, INT J MULTIPHAS FLOW, V27, P861, DOI 10.1016/S0301-9322(00)00053-7
   Singh BK, 2017, CHEM ENG SCI, V158, P124, DOI 10.1016/j.ces.2016.10.006
   Sommerfeld M, 1998, INT J HEAT FLUID FL, V19, P173, DOI 10.1016/S0142-727X(97)10022-4
   Steimes J, 2017, INT J MULTIPHAS FLOW, V93, P84, DOI 10.1016/j.ijmultiphaseflow.2017.03.013
   Wang M, 1999, CHEM ENG COMMUN, V175, P49, DOI 10.1080/00986449908912139
   Wang S., 1997, THESIS
   Wang SB, 2010, J ENERG RESOUR-ASME, V132, DOI 10.1115/1.4001900
   WILLIAMS RA, 1995, CHEM ENG J BIOCH ENG, V56, P135, DOI 10.1016/0923-0467(94)02908-3
   Yilmaz F, 2009, KOREA-AUST RHEOL J, V21, P161
   Yue T, 2019, CHEM ENG J, V358, P806, DOI 10.1016/j.cej.2018.10.018
   Zhang J, 2016, CAN J CHEM ENG, V94, P324, DOI 10.1002/cjce.22377
NR 43
TC 1
Z9 1
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115362
DI 10.1016/j.ces.2019.115362
PG 18
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100023
DA 2020-05-12
ER

PT J
AU Zhou, YDZ
   Zhu, J
AF Zhou, Yandaizi
   Zhu, Jesse
TI Group C+ particles: Extraordinary dense phase expansion during
   fluidization through nano-modulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Group C+ particle fluidization; Nanoparticle modulation; Dense phase
   expansion; Bubble holdup; Bed collapse test
ID 2-PHASE THEORY; PERFORMANCE ANALYSIS; FINE POWDERS; BED REACTOR; GAS;
   BEHAVIOR; SIZE; FLOW; VOIDAGE; BUBBLE
AB Group C particles, although deemed to be difficult to fluidize because of their cohesive nature, fluidize well with high bed expansion and therefore hold more gas in the bed after nano-modulation. Using the bed collapse test, the dense phase properties of those formed Group C+ and Group A particles were characterized. Group C+ particles exhibited much higher dense phase expansion and larger dense phase voidage than Group A particles, indicating more gas holdup in the dense phase available for intimate gas-olid contact. Therefore, Group C+ particles, with the extraordinary dense phase expansion and the large specific surface area, are significantly better for industrial processes, especially in gas-phase catalytic reactions. Maximum dense phase expansion (E-d,(max)) was defined as a factor for quantifying the expansion ability of the dense phase for different particles. Group C+ particles with greater E-d,(max) values signifies higher dense phase expansions, beneficial for gas-solid contact. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhou, Yandaizi; Zhu, Jesse] Univ Western Ontario, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
RP Zhu, J (reprint author), Univ Western Ontario, Dept Chem & Biochem Engn, London, ON N6A 5B9, Canada.
EM jzhu@uwo.ca
RI Zhu, Jesse/E-4048-2017
OI Zhu, Jesse/0000-0001-7749-8917
CR ABRAHAMSEN AR, 1980, POWDER TECHNOL, V26, P35, DOI 10.1016/0032-5910(80)85005-4
   ABRAHAMSEN AR, 1980, POWDER TECHNOL, V26, P47, DOI 10.1016/0032-5910(80)85006-6
   BARRETO GF, 1983, CHEM ENG SCI, V38, P345, DOI 10.1016/0009-2509(83)80152-3
   BARRETO GF, 1988, CHEM ENG SCI, V43, P3037, DOI 10.1016/0009-2509(88)80057-5
   BAUMGARTEN PK, 1960, AICHE J, V6, P115, DOI 10.1002/aic.690060122
   CHAVARIE C, 1975, IND ENG CHEM FUND, V14, P79, DOI 10.1021/i160054a002
   CHAVARIE C, 1975, IND ENG CHEM FUND, V14, P75, DOI 10.1021/i160054a001
   CHAVARIE C, 1975, IND ENG CHEM FUND, V14, P86, DOI 10.1021/i160054a003
   Chen YH, 2008, AICHE J, V54, P104, DOI 10.1002/aic.11368
   DAVIDSON JF, 1966, CHEM ENG SCI, V21, P731, DOI 10.1016/0009-2509(66)87001-X
   DRY RJ, 1983, POWDER TECHNOL, V34, P213, DOI 10.1016/0032-5910(83)87053-3
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Gao XH, 2010, J MOL CATAL A-CHEM, V325, P36, DOI 10.1016/j.molcata.2010.03.026
   GELDART D, 1984, POWDER TECHNOL, V37, P25, DOI 10.1016/0032-5910(84)80003-0
   GELDART D, 1973, POWDER TECHNOL, V7, P285, DOI 10.1016/0032-5910(73)80037-3
   GELDART D, 1985, CHEM ENG SCI, V40, P653, DOI 10.1016/0009-2509(85)80011-7
   Gelderbloom SJ, 2003, AICHE J, V49, P844, DOI 10.1002/aic.690490405
   GRACE JR, 1991, CAN J CHEM ENG, V69, P1126, DOI 10.1002/cjce.5450690512
   GRACE JR, 1974, CHEM ENG SCI, V29, P327, DOI 10.1016/0009-2509(74)80039-4
   Han M, 2019, J QUAL TECHNOL, DOI 10.1080/00224065.2019.1611358
   Huang Q, 2010, PARTICUOLOGY, V8, P19, DOI 10.1016/j.partic.2009.05.007
   Iwadate Y, 1998, POWDER TECHNOL, V100, P223, DOI 10.1016/S0032-5910(98)00143-0
   Lettieri P, 2002, POWDER TECHNOL, V123, P221, DOI 10.1016/S0032-5910(01)00463-6
   LOCKETT MJ, 1967, CHEM ENG SCI, V22, P1059, DOI 10.1016/0009-2509(67)80170-2
   Lorences MJ, 2003, POWDER TECHNOL, V131, P234, DOI 10.1016/S0032-5910(03)00004-4
   MOROOKA S, 1988, J CHEM ENG JPN, V21, P41, DOI 10.1252/jcej.21.41
   PYLE DL, 1967, CHEM ENG SCI, V22, P1199, DOI 10.1016/0009-2509(67)80186-6
   RIETEMA K, 1967, P INT S FLUIDIZATION, P154
   ROWE PN, 1978, CHEM ENG SCI, V33, P133, DOI 10.1016/0009-2509(78)85079-9
   TOOMEY RD, 1952, CHEM ENG PROG, V48, P220
   Wang Chao, 2013, THESIS
   XIE HY, 1995, POWDER TECHNOL, V82, P269, DOI 10.1016/0032-5910(94)02932-E
   Xu C., 2006, 5 WORLD C PART TECHN
   Xu CB, 2005, CHEM ENG SCI, V60, P6529, DOI 10.1016/j.ces.2005.05.062
   Yamamoto K, 2009, NAT CHEM, V1, P397, DOI [10.1038/NCHEM.288, 10.1038/nchem.288]
   YATES JG, 1986, CHEM ENG SCI, V41, P801, DOI 10.1016/0009-2509(86)87160-3
   Zhou T, 2006, ADV POWDER TECHNOL, V17, P159, DOI 10.1163/156855206775992382
   Zhou Y, 2019, CHEM ENG SCI, V207, P653, DOI 10.1016/j.ces.2019.06.056
   Zhu J, 2004, U.S. Patent, Patent No. [6,833,185, 6833185]
   Zhu J.-X., 2007, U.S. Patent, Patent No. 7240861
NR 40
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAR 16
PY 2020
VL 214
AR 115420
DI 10.1016/j.ces.2019.115420
PG 12
WC Engineering, Chemical
SC Engineering
GA KN1EQ
UT WOS:000514583100003
DA 2020-05-12
ER

PT J
AU Lane, MC
   Gordon, JL
   Jiang, C
   Leitner, WW
   Pickett, TE
   Stemmy, E
   Bozick, BA
   Deckhut-Augustine, A
   Embry, AC
   Post, DJ
AF Lane, M. Chelsea
   Gordon, Jennifer L.
   Jiang, Chao
   Leitner, Wolfgang W.
   Pickett, Thames E.
   Stemmy, Erik
   Bozick, Brooke A.
   Deckhut-Augustine, Alison
   Embry, Alan C.
   Post, Diane J.
TI Workshop report: Optimization of animal models to better predict
   influenza vaccine efficacy
SO VACCINE
LA English
DT Article
DE Animal models; Influenza virus; Universal influenza vaccine
ID A VIRUS; IMMUNE-SYSTEM; INFECTION; SWINE
AB Animal models that can recapitulate the human immune system are essential for the preclinical development of safe and efficacious vaccines. Development and optimization of representative animal models are key components of the NIAID strategic plan for the development of a universal influenza vaccine. To gain insight into the current landscape of animal model usage in influenza vaccine development, NIAID convened a workshop in Rockville, Maryland that brought together experts from academia, industry and government. Panelists discussed the benefits and limitations of the field's most widely-used animal models, identified currently available and critically needed resources and reagents, and suggested areas for improvement based on inadequacies of existing models. Although appropriately-selected animal models can be useful for evaluating safety, mechanism-of-action, and superiority over existing vaccines, workshop participants concluded that multiple animal models will likely be required to sufficiently test all aspects of a novel vaccine candidate. Refinements are necessary for all current model systems, for example, to better represent special human populations, and will be facilitated by the development and broader availability of new reagents. NIAID continues to support progress towards increasing the predictive value of animal models.
C1 [Lane, M. Chelsea; Gordon, Jennifer L.; Pickett, Thames E.; Stemmy, Erik; Bozick, Brooke A.; Embry, Alan C.; Post, Diane J.] NIAID, Div Microbiol & Infect Dis, 9000 Rockville Pike, Bethesda, MD 20892 USA.
   [Jiang, Chao; Leitner, Wolfgang W.; Deckhut-Augustine, Alison] NIAID, Div Allergy Immunol & Transplantat, 9000 Rockville Pike, Bethesda, MD 20892 USA.
RP Lane, MC (reprint author), 5601 Fishers Lane,Room 8A19, Bethesda, MD 20892 USA.
EM lanemc@niaid.nih.gov
CR Albrecht RA, 2018, BIOMED RES MODEL MBI, V9, DOI [10.1128/mBio.01113-18, DOI 10.1128/MBIO.01113-18]
   Beura LK, 2016, NATURE, V532, P512, DOI 10.1038/nature17655
   Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020
   Butler JE, 2017, ANNU REV ANIM BIOSCI, V5, P255, DOI 10.1146/annurev-animal-022516-022818
   Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133
   Cobey S, 2017, CURR OPIN VIROL, V22, P105, DOI 10.1016/j.coviro.2016.12.004
   Crank MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123969
   D'Alessio F, 2018, VACCINE, V36, P6895, DOI 10.1016/j.vaccine.2018.10.024
   Dawson HD, 2018, RES VET SCI, V118, P199, DOI 10.1016/j.rvsc.2018.02.007
   Dhakal S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00934
   Dhakal S, 2017, VACCINE, V35, P1124, DOI 10.1016/j.vaccine.2017.01.019
   Erbelding EJ, 2018, J INFECT DIS, V218, P347, DOI 10.1093/infdis/jiy103
   Fan ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109755
   Ferris MT, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003196
   Gerner W, 2015, MOL IMMUNOL, V66, P3, DOI 10.1016/j.molimm.2014.10.025
   Hiremath J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151922
   Holzer B, 2018, J IMMUNOL, V200, P4068, DOI 10.4049/jimmunol.1800142
   Iwatsuki-Horimoto K, 2017, J VIROL, V91, DOI [10.1128/JVI.01716-16, 10.1128/jvi.01716-16]
   IWATSUKIHORIMOTO K, 2017, J VIROL, V91, DOI DOI 10.1128/JVI.01693-17.JVI.01693-17
   Johnson MB, 2018, NATURE, V556, P370, DOI 10.1038/s41586-018-0035-0
   KIM HT, 2019, SCI REP, V9, DOI DOI 10.1038/S41598-018-37192-4
   Mair KH, 2014, DEV COMP IMMUNOL, V45, P321, DOI 10.1016/j.dci.2014.03.022
   Margine I, 2014, PATHOGENS, V3, P845, DOI 10.3390/pathogens3040845
   Masopust D, 2017, J IMMUNOL, V199, P383, DOI 10.4049/jimmunol.1700453
   Paules CI, 2017, IMMUNITY, V47, P599, DOI 10.1016/j.immuni.2017.09.007
   Powell TJ, 2012, J VIROL, V86, P13397, DOI 10.1128/JVI.01820-12
   Rajao DS, 2015, ILAR J, V56, P44, DOI 10.1093/ilar/ilv002
   Rajao DS, 2014, CURR TOP MICROBIOL, V385, P307, DOI 10.1007/82_2014_391
   Reese TA, 2016, CELL HOST MICROBE, V19, P713, DOI 10.1016/j.chom.2016.04.003
   Rosen BH, 2018, J CYST FIBROS, V17, pS28, DOI 10.1016/j.jcf.2017.09.001
   Rosshart SP, 2017, CELL, V171, P1015, DOI 10.1016/j.cell.2017.09.016
   Rothkotter HJ, 2009, DEV COMP IMMUNOL, V33, P267, DOI 10.1016/j.dci.2008.06.016
   Saalmuller A, 2016, ENCYCLOPEDIA OF IMMUNOBIOLOGY, VOL 1: DEVELOPMENT AND PHYLOGENY OF THE IMMUNE SYSTEM, P538, DOI 10.1016/B978-0-12-374279-7.12019-3
   Sandbulte MR, 2015, VACCINES-BASEL, V3, P22, DOI 10.3390/vaccines3010022
   Schwartz JC, 2018, HLA, V92, P40, DOI 10.1111/tan.13281
   Sun XS, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau7531
   Sun XS, 2010, J CLIN INVEST, V120, P3149, DOI 10.1172/JCI43052
   Tchitchek N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112617
   Tungatt K, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007017
   US-UK Collaborative, SWIN IMM TOOLK DEV B
   Wonderlich ER, 2017, J IMMUNOL, V198, P1616, DOI 10.4049/jimmunol.1601770
   Ying BL, 2015, VIROLOGY, V485, P305, DOI 10.1016/j.virol.2015.07.024
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2751
EP 2757
DI 10.1016/j.vaccine.2020.01.101
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200002
PM 32145879
DA 2020-05-12
ER

PT J
AU Choe, YJ
   Jee, Y
   Takashima, Y
   Lee, JK
AF Choe, Young June
   Jee, Youngmee
   Takashima, Yoshihiro
   Lee, Jong-koo
TI Japanese encephalitis in the Western Pacific Region: Implication from
   the Republic of Korea
SO VACCINE
LA English
DT Article
DE Japanese encephalitis; Vaccine; Korea
ID SOUTH-KOREA
AB Japanese encephalitis (JE) is endemic in the Western Pacific Region. We aim to describe the regional status of control of JE, based on the World Health Organization (WHO) surveillance data, and to share the experience from the Republic of Korea. Substantial progress has been made in the region to date; however, epidemiologic changes have not been delineated. The vaccination coverage should be addressed to close the immunity gap. The lessons learned from Korea may aid in establishing a high-quality surveillance system with a sustainable JE vaccination program in order to prepare for new challenges that this region will face. (C) 2020 Published by Elsevier Ltd.
C1 [Choe, Young June] Brown Univ, Div Pediat Infect Dis, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Choe, Young June] Hallym Univ, Dept Social & Prevent Med, Coll Med, Chunchon, South Korea.
   [Jee, Youngmee] Korea Ctr Dis Control & Prevent, Natl Inst Hlth, Cheongju, South Korea.
   [Takashima, Yoshihiro] WHO, Expanded Programme Immunizat Unit, Reg Off Western Pacific, Manila, Philippines.
   [Lee, Jong-koo] Seoul Natl Univ, Dept Family Med, Coll Med, 103 Daehak Ro, Seoul 03080, South Korea.
   [Lee, Jong-koo] Seoul Natl Univ, Ctr Hlth Soc & Educ, Coll Med, Seoul, South Korea.
RP Lee, JK (reprint author), Seoul Natl Univ, Dept Family Med, Coll Med, 103 Daehak Ro, Seoul 03080, South Korea.
EM docmohw@snu.ac.kr
FU World Health OrganizationWorld Health Organization [001]
CR Bae W, 2018, J KOREAN MED SCI, V33, DOI 10.3346/jkms.2018.33.e70
   Gao XY, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003015
   Kim H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116547
   Korea centers for disease control and prevention, 2017, NAT CHILDH VACC COV
   Lee DW, 2012, INT J INFECT DIS, V16, pE448, DOI 10.1016/j.ijid.2012.02.006
   Lopez AL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003630
   Mayxay M, 2013, LANCET GLOB HEALTH, V1, pE46, DOI 10.1016/S2214-109X(13)70008-1
   Nguyen TY, 2010, AM J TROP MED HYG, V83, P816, DOI 10.4269/ajtmh.2010.10-0262
   Sohn YM, 2000, EMERG INFECT DIS, V6, P17
   WHO, 2016, VACCINE, V34, P302, DOI 10.1016/j.vaccine.2015.07.057
   WHO (World Health Organization), GLOB HLTH OBS GHO DA
   World Health Organization, REG FRAM IMPL GLOB V
   World Health Organization, 2018, 27 M TECHN ADV GROUP
   Yang DK, 2011, J VET SCI, V12, P373, DOI 10.4142/jvs.2011.12.4.373
NR 14
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2760
EP 2763
DI 10.1016/j.vaccine.2020.02.061
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200005
PM 32111531
DA 2020-05-12
ER

PT J
AU Hu, D
   Martin, C
   Dredze, M
   Broniatowski, DA
AF Hu, Dian
   Martin, Christine
   Dredze, Mark
   Broniatowski, David A.
TI Chinese social media suggest decreased vaccine acceptance in China: An
   observational study on Weibo following the 2018 Changchun Changsheng
   vaccine incident
SO VACCINE
LA English
DT Article
DE Vaccine acceptance; Vaccine safety; Weibo; Social media; Changchun
   Changsheng; China vaccine incident
ID CONTROVERSY; REFUSAL
AB China is home to the world's largest population, with the potential for disease outbreaks to affect billions. However, knowledge of Chinese vaccine acceptance trends is limited. In this work we use Chinese social media to track responses to the recent Changchun Changsheng Biotechnology vaccine scandal, which led to extensive discussion regarding vaccine safety and regulation in China. We analyzed messages from the popular Chinese microblogging platform Sina Weibo in July 2018 (n = 11,085), and August 2019 (n = 500). Thus, we consider Chinese vaccine acceptance, before, during, immediately after, and one year after the scandal occurred. Results show that expressions of distrust in government pertaining to vaccines increased significantly during and immediately after the scandal. Self-reports of vaccination occurred both before, and one year after, the scandal; however, these self-reports changed from positive endorsements of vaccination to concerns about vaccine harms. Data suggest that expressed support for vaccine acceptance in China may be decreasing. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hu, Dian; Broniatowski, David A.] George Washington Univ, Dept Engn Management & Syst Engn, Washington, DC USA.
   [Martin, Christine] Johns Hopkins Univ, Paul H Nitze Sch Adv Int Studies, Washington, DC USA.
   [Dredze, Mark] Johns Hopkins Univ, Dept Comp Sci, Baltimore, MD 21218 USA.
   [Broniatowski, David A.] George Washington Univ, Inst Data Democracy & Polit, Washington, DC USA.
RP Hu, D (reprint author), Sch Engn & Appl Sci, Dept Engn Management & Syst Engn, 800 22nd St NW,Sci & Engn Hall,B1800, Washington, DC 20052 USA.
EM hudian@gwu.edu
OI Hu, Dian/0000-0003-1277-142X; Broniatowski, David/0000-0002-3302-9497
FU National Institute of General Medical Sciences, National Institutes of
   Health (NIH)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [5R01GM114771]; John S. and James L. Knight
   Foundation [ECNS21702N]
FX This research was supported in part by the National Institute of General
   Medical Sciences, National Institutes of Health (NIH; award
   5R01GM114771) and by the John S. and James L. Knight Foundation under
   award number ECNS21702N.
CR [Anonymous], 2016, CHIN SHAND ILL VACC
   Attwell K, 2018, VACCINE, V36, P7377, DOI 10.1016/j.vaccine.2018.10.019
   Betsch C, 2012, VACCINE, V30, P3727, DOI 10.1016/j.vaccine.2012.02.025
   Blei DM, 2003, J MACH LEARN RES, V3, P993, DOI 10.1162/jmlr.2003.3.4-5.993
   Broniatowski DA, 2018, AM J PUBLIC HEALTH, V108, P1378, DOI 10.2105/AJPH.2018.304567
   CAO H, 2012, CHIN J VACC IMMUN, V5, DOI DOI 10.1142/S1793524512600042
   China.org.cn, 2010, SHANX VACC SCAND
   Dixon G, 2013, HEALTH EDUC RES, V28, P352, DOI 10.1093/her/cys110
   Dredze M, 2016, AM J PREV MED, V50, P550, DOI 10.1016/j.amepre.2015.10.002
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   Fu KW, 2013, IEEE INTERNET COMPUT, V17, P42, DOI 10.1109/MIC.2013.28
   Gollust SE, 2010, HEALTH AFFAIR, V29, P2041, DOI 10.1377/hlthaff.2010.0174
   Hong J, 2018, BLOOMBERG
   Kennedy J, 2019, EUR J PUBLIC HEALTH, V29, P512, DOI 10.1093/eurpub/ckz004
   Lama P, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0233-z
   Orr D, 2016, ISR J HEALTH POLICY, V5, DOI 10.1186/s13584-016-0093-4
   Radcliffe D., 2017, UNDERSTANDING SOCIAL
   Tan R., 2018, VACCINE SCANDAL GRIP
   The Lancet, 2018, Lancet, V392, P360, DOI 10.1016/S0140-6736(18)31695-7
   Xu X, INT C PASS ACT NETW, P133
NR 20
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2764
EP 2770
DI 10.1016/j.vaccine.2020.02.027
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200006
PM 32093982
DA 2020-05-12
ER

PT J
AU Elkin, LE
   Pullon, SRH
   Stubbe, MH
AF Elkin, Lucy E.
   Pullon, Susan R. H.
   Stubbe, Maria H.
TI Should I vaccinate my child?' comparing the displayed stances of vaccine
   information retrieved from Google, Facebook and YouTube
SO VACCINE
LA English
DT Article
DE Vaccination; Health communication; Internet; Social media; Vaccine
   criticism; Public health
ID SOCIAL MEDIA; HEALTH-CARE; WEB; RESISTANCE; ACTIVISTS; HESITANCY;
   COVERAGE; IMPACT
AB Whether to vaccinate or not is currently a hot topic in social discourse. Despite the majority view that childhood vaccination is safe and effective, websites and social media content opposing such vaccination are common. In this study, we searched the internet platforms Google, Facebook and YouTube for childhood vaccine information. We made every attempt to minimise selection bias generated by internet algorithms. We compared the displayed stances of vaccine information retrieved. Most of the information had a clearly stated stance on vaccines or made some sort of recommendation on whether or not to vaccinate. Despite our careful attempt to search comprehensively and systematically for vaccine information with as little bias as possible, this search yielded a sizeable minority of vaccine negative information. This research shows that negative vaccine information persists and is readily accessible online despite algorithm and policy changes in recent years, even when searching in the least biased way possible. It is important that vaccine-promoting entities and agencies continue to make every effort to maximize their presence online so that parents searching the internet to answer the question 'should I vaccinate my child?' continue to receive vaccine positive information. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Elkin, Lucy E.; Pullon, Susan R. H.; Stubbe, Maria H.] Univ Otago, Dept Primary Hlth Care & Gen Practice, POB 7343,23A Mein St, Wellington, New Zealand.
RP Elkin, LE (reprint author), Univ Otago, Dept Primary Hlth Care & Gen Practice, POB 7343,23A Mein St, Wellington, New Zealand.
EM lucy.elkin@postgrad.otago.ac.nz
FU University of Otago Academic General Practitioner Registrar PhD
   Scholarship
FX The lead author would like to acknowledge funding by the University of
   Otago Academic General Practitioner Registrar PhD Scholarship.
CR Ache KA, 2008, AM J PREV MED, V35, P389, DOI 10.1016/j.amepre.2008.06.029
   Baker B, 2018, SEX REPROD HEALTHC, V17, P31, DOI 10.1016/j.srhc.2018.05.003
   Betsch C, 2010, J HEALTH PSYCHOL, V15, P446, DOI 10.1177/1359105309353647
   Briones R, 2012, HEALTH COMMUN, V27, P478, DOI 10.1080/10410236.2011.610258
   Buchanan R, 2014, HEALTH INFO LIBR J, V31, P227, DOI 10.1111/hir.12073
   Chitika, 2013, CHIT INS VAL GOOGL R
   Covolo L, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-83
   Davies P, 2002, ARCH DIS CHILD, V87, P22, DOI 10.1136/adc.87.1.22
   Dube E, 2015, EXPERT REV VACCINES, V14, P99, DOI 10.1586/14760584.2015.964212
   ELLERY PJ, 2008, J COMMUNICATION HEAL, V1, P441, DOI DOI 10.1179/175380608790912905
   Guidry JPD, 2015, VACCINE, V33, P5051, DOI 10.1016/j.vaccine.2015.08.064
   Hobson-West P, 2007, SOCIOL HEALTH ILL, V29, P198, DOI 10.1111/j.1467-9566.2007.00544.x
   Horling B., 2009, PERSONALIZED SEARCH
   Jacobs W, 2017, COGENT SOC SCI, V3, DOI 10.1080/23311886.2017.1302785
   Kata A, 2012, VACCINE, V30, P3778, DOI 10.1016/j.vaccine.2011.11.112
   Kata A, 2010, VACCINE, V28, P1709, DOI 10.1016/j.vaccine.2009.12.022
   Keelan J, 2007, JAMA-J AM MED ASSOC, V298, P2482, DOI 10.1001/jama.298.21.2482
   Keelan J, 2010, VACCINE, V28, P1535, DOI 10.1016/j.vaccine.2009.11.060
   Lai C, 2019, YOU CANT SEE WHAT YO
   Larson HJ, 2018, LANCET, V392, P2244, DOI 10.1016/S0140-6736(18)32608-4
   Larson HJ, 2016, EBIOMEDICINE, V12, P295, DOI 10.1016/j.ebiom.2016.08.042
   Larson HJ, 2011, LANCET, V378, P526, DOI 10.1016/S0140-6736(11)60678-8
   MacDonald NE, 2015, EBIOMEDICINE, V2, P792, DOI 10.1016/j.ebiom.2015.06.028
   Madden K, 2012, VACCINE, V30, P3741, DOI 10.1016/j.vaccine.2011.10.025
   McGee M., 2013, EDGERANK IS DEAD FAC
   Mnookin S, 2011, PANIC VIRUS FEAR MYT
   Moon RY, 2019, J MED INTERNET RES, V21, DOI 10.2196/14289
   Newman L. H., 2019, INCOGNITO GOOGLE MAP
   Nuti SV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109583
   Pariser E., 2011, FILTER BUBBLE WHAT I
   Paterson P, 2016, VACCINE, V34, P6700, DOI 10.1016/j.vaccine.2016.10.042
   Peters B., SCI SOCIAL MEDIA
   Peterson A, 1996, NEW PUBLIC HLTH HLTH
   Pew Research Center, 2019, SOC MED FACT SHEET
   Rozenblum R, 2013, BMJ QUAL SAF, V22, P183, DOI 10.1136/bmjqs-2012-001744
   Ruiz JB, 2014, VACCINE, V32, P5776, DOI 10.1016/j.vaccine.2014.08.042
   Ryzik M., 2016, NY TIMES
   Stahl JP, 2016, MED MALADIES INFECT, V46, P117, DOI 10.1016/j.medmal.2016.02.002
   Statista, 2017, WORLDW DESKT MARK SH
   Statista, 2017, GLOB ACT US PEN LEAD
   Statista, 2017, MOST FAM SOC NETW SI
   Wolfe RM, 2002, JAMA-J AM MED ASSOC, V287, P3245, DOI 10.1001/jama.287.24.3245
   Wong J. C., 2019, ANTIVAXX PROPAGANDA
   Wong J.C., 2019, FACEBOOK YOUTUBE HEL
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
NR 45
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2771
EP 2778
DI 10.1016/j.vaccine.2020.02.041
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200007
PM 32107061
DA 2020-05-12
ER

PT J
AU Blyth, CC
   Cheng, AC
   Crawford, NW
   Clark, JE
   Buttery, JP
   Marshall, HS
   Francis, JR
   McRae, J
   Kotsimbos, T
   Kelly, PM
   Macartney, KK
AF Blyth, Christopher C.
   Cheng, Allen C.
   Crawford, Nigel W.
   Clark, Julia E.
   Buttery, Jim P.
   Marshall, Helen S.
   Francis, Joshua R.
   McRae, Jocelynne
   Kotsimbos, Tom
   Kelly, Paul M.
   Macartney, Kristine K.
CA Paediat Active Enhanced Dis Survei
   Influenza Complications Alert Netw
TI The impact of new universal child influenza programs in Australia:
   Vaccine coverage, effectiveness and disease epidemiology in hospitalised
   children in 2018
SO VACCINE
LA English
DT Article
DE Influenza; Hospitalization; Vaccination; Children; Vaccine effectiveness
ID OSELTAMIVIR TREATMENT; PANDEMIC INFLUENZA; COMMON DISEASES;
   SURVEILLANCE; ASSUMPTION
AB Background: New jurisdictionally-based vaccination programs were established providing free quadrivalent influenza vaccine (QIV) for preschool Australian children in 2018. This was in addition to the National Immunisation Program (NIP) funded QIV for Indigenous children and children with comorbid medical conditions. We assessed the impact of this policy change on influenza disease burden and vaccine coverage, as well as report on 2018 vaccine effectiveness in a hospital-based surveillance system.
   Methods: Subjects were recruited prospectively from twelve PAEDS-FluCAN sentinel hospital sites (April until October 2018). Children aged <= 16 years hospitalised with an acute respiratory illness (ARI) and laboratory-confirmed influenza were considered cases. Hospitalised children with ARI who tested negative for influenza were considered controls. VE estimates were calculated from the adjusted odds ratio of vaccination in cases and controls.
   Results: A total of 458 children were hospitalised with influenza: 31.7% were <2 years, 5.0% were Indigenous, and 40.6% had medical comorbidities predisposing to severe influenza. Influenza A was detected in 90.6% of children (A/H1N1: 38.0%; A/H3N2: 3.1%; A/unsubtyped 48.6%). The median length of stay was 2 days (IQR: 1,3) and 8.1% were admitted to ICU. Oseltamivir use was infrequent (16.6%). Two in-hospital deaths occurred (0.45%). 12.0% of influenza cases were vaccinated compared with 36.0% of test-negative controls. Vaccine effectiveness of QIV for preventing influenza hospitalisation was estimated at 78.8% (95%CI: 66.9; 86.4).
   Conclusions: Compared with 2017 (n = 1268 cases), a significant reduction in severe influenza was observed in Australian children, possibly contributed to by improved vaccine coverage and high vaccine effectiveness. Despite introduction of jurisdictionally-funded preschool programs and NIP-funded vaccine for children with risk factors for severe disease, improved coverage is required to ensure adequate protection against paediatric influenza morbidity and mortality. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Blyth, Christopher C.] Univ Western Australia, Sch Med, Perth, WA, Australia.
   [Blyth, Christopher C.] Perth Childrens Hosp, Dept Infect Dis, Perth, WA, Australia.
   [Blyth, Christopher C.] QEII Med Ctr, Dept Microbiol, PathWest Lab Med WA, Perth, WA, Australia.
   [Blyth, Christopher C.] Univ Western Australia, Wesfarmers Ctr Vaccines & Infect Dis, Telethon Kids Inst, Perth, WA, Australia.
   [Cheng, Allen C.] Alfred Hlth, Infect Prevent & Healthcare Epidemiol Unit, Melbourne, Vic, Australia.
   [Cheng, Allen C.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.
   [Crawford, Nigel W.] Royal Childrens Hosp, Dept Gen Paediat, Melbourne, Vic, Australia.
   [Crawford, Nigel W.] Murdoch Childrens Res Inst, Infect & Immun, Melbourne, Vic, Australia.
   [Crawford, Nigel W.] Univ Melbourne, Melbourne, Vic, Australia.
   [Clark, Julia E.] Queensland Childrens Hosp, Infect Management & Prevent Serv, Brisbane, Qld, Australia.
   [Buttery, Jim P.] Monash Hlth, Dept Infect & Immun, Monash Childrens Hosp, Melbourne, Vic, Australia.
   [Buttery, Jim P.] Monash Univ, Monash Ctr Hlth Care Res & Implementat, Dept Paediat, Melbourne, Vic, Australia.
   [Marshall, Helen S.] Univ Adelaide, Robinson Res Inst, Womens & Childrens Hlth Network, Adelaide, SA, Australia.
   [Marshall, Helen S.] Univ Adelaide, Adelaide Med Sch, Adelaide, SA, Australia.
   [Francis, Joshua R.] Charles Darwin Univ, Royal Darwin Hosp, Darwin, NT, Australia.
   [Francis, Joshua R.] Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT, Australia.
   [McRae, Jocelynne; Macartney, Kristine K.] Univ Sydney, Natl Ctr Immunisat Res & Surveillance Vaccine Pre, Sydney, NSW, Australia.
   [McRae, Jocelynne; Macartney, Kristine K.] Univ Sydney, Sch Paediat & Child Hlth, Sydney, NSW, Australia.
   [Kotsimbos, Tom] Monash Univ, Dept Allergy Immunol & Resp Med, Alfred Hlth, Melbourne, Vic, Australia.
   [Kelly, Paul M.] Australian Natl Univ, ACT Govt Hlth Directorate, Med Sch, Canberra, ACT, Australia.
   [Macartney, Kristine K.] Childrens Hosp Westmead, Dept Infect Dis & Microbiol, Sydney, NSW, Australia.
RP Blyth, CC (reprint author), Univ Western Australia, Perth Childrens Hosp, Sch Med, Hosp Ave, Nedlands, WA 6008, Australia.
EM christopher.blyth@uwa.edu.au
RI Clark, Julia/A-8214-2012
OI Clark, Julia/0000-0001-7746-0599; CRAWFORD, NIGEL/0000-0003-1851-5080
FU Australian Government Department of HealthAustralian
   GovernmentDepartment of Health & Ageing; National Health and Medical
   Research Council (NHMRC Partnership Grant)National Health and Medical
   Research Council of Australia [APP1113851]; Australian Government
   Departments of Health; Departments of Health in NSW; NHMRC
   FellowshipsNational Health and Medical Research Council of Australia;
   Department of Health in Victoria; Department of Health in Queensland;
   Department of Health in South Australia; Department of Health in Western
   Australia; Department of Health in Northern Territory
FX FluCAN receives support from the Australian Government Department of
   Health. PAEDS receives support from the National Health and Medical
   Research Council (NHMRC Partnership Grant: APP1113851), Australian
   Government Departments of Health and Departments of Health in NSW,
   Victoria, Queensland, South Australia, Western Australia and the
   Northern Territory. A/Prof Blyth, Prof Marshall and Prof Cheng are
   supported by NHMRC Fellowships.
CR [Anonymous], 2018, DEP HLTH AUSTR INFL
   [Anonymous], 2017, DEP HLTH AUSTR INFL
   Antibiotic Expert Group, 2014, THER GUID ANT VERS 1
   Austarlian Technical Advisory Group on Immunisation, AUSTR IMM HDB AUSTR, P201
   Australian Technical Advisory Group on Immunisation, 2018, STAT ADM SEAS INFL V
   Beard FH, 2019, MED J AUSTRALIA, V210, P484, DOI 10.5694/mja2.50141
   Blyth CC, 2014, EUROSURVEILLANCE, V2016, P21, DOI DOI 10.2807/1560-7917
   Blyth CC, 2017, AUSTR SOC INF DIS C
   Blyth CC, 2019, CLIN INFECT DIS, V68, P940, DOI 10.1093/cid/ciy597
   Blyth CC, 2014, PEDIATRICS, V133, pE1218, DOI 10.1542/peds.2013-3707
   Cheng AC, 2016, COMMUN DIS INTELL, V40, pE521
   Cheng AC, 2013, COMMUN DIS INTELL, V37, pE246
   Cheng AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068760
   Chiu Clayton, 2010, Commun Dis Intell Q Rep, V34 Supp, pS1
   Dawood FS, 2012, LANCET INFECT DIS, V12, P687, DOI 10.1016/S1473-3099(12)70121-4
   Dixon GA, 2010, INFLUENZA OTHER RESP, V4, P231, DOI 10.1111/j.1750-2659.2010.00141.x
   Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1
   GREENLAND S, 1982, AM J EPIDEMIOL, V116, P547, DOI 10.1093/oxfordjournals.aje.a113439
   Hull BP, 2009, VACCINE, V27, P5054, DOI 10.1016/j.vaccine.2009.06.056
   Kelly H, 2011, PEDIATR INFECT DIS J, V30, P107, DOI 10.1097/INF.0b013e318201811c
   Kelly PM, 2011, MED J AUSTRALIA, V194, P169, DOI 10.5694/j.1326-5377.2011.tb03764.x
   Naidu L, 2013, COMMUN DIS INTELL, V37, pS1
   RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205
   Ruf BR, 2014, EUR J PEDIATR, V173, P265, DOI 10.1007/s00431-013-2023-6
   SMITH PG, 1984, INT J EPIDEMIOL, V13, P87, DOI 10.1093/ije/13.1.87
   Whitley RJ, 2001, PEDIATR INFECT DIS J, V20, P127, DOI 10.1097/00006454-200102000-00002
   Zurynski Y, 2013, J PAEDIATR CHILD H, V49, P588, DOI 10.1111/jpc.12282
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2779
EP 2787
DI 10.1016/j.vaccine.2020.02.031
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200008
PM 32107062
DA 2020-05-12
ER

PT J
AU Hvass, AMF
   Norredam, M
   Sodemann, M
   Thomsen, MK
   Christian, W
AF Hvass, Anne Mette Floe
   Norredam, Marie
   Sodemann, Morten
   Thomsen, Marianne Kragh
   Christian, Wejse
TI Are refugees arriving in Denmark an under-immunised group for measles? A
   cross-sectional serology study
SO VACCINE
LA English
DT Article
DE Measles; Vaccination; Immunisation; Refugee; Migrant Health
ID RUBELLA; VARICELLA; SEROPREVALENCE; GERMANY; MUMPS
AB Background: In 2018, Europe faced the highest number of Measles cases in a decade. In Denmark, the childhood vaccination programme has a coverage of approximately 90%. To eliminate the disease, vaccine coverage needs to be above the herd immunity threshold of 95%. This can be even more difficult to obtain, when vaccination programmes break down due to war, natural disasters etc. and concern has been raised, that unvaccinated refugees could facilitate spread of measles when migrating.
   Methods: In order to address this concern, we tested 513 newly arrived refugees and family reunified refugees aged between 0 and 70 years for measles IgG antibodies. The participants were tested as part of a general health assessment between May 2016 and October 2018. In the cohort, 50% were males and the majority came from Syria (55%).
   Results: We found that 85% of the total group of refugees had immunity against measles. The 15% lacking antibodies were evenly distributed between the various countries of origin. Moreover, we found immunity to increase with age, leaving young children most vulnerable to infection, 79.9% (<19 years) vs 89.1% (>= 19 years). Interview questions on previous vaccinations did not correlate to serology.
   Conclusion: Refugees have measles immunity slightly lower than the host population. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hvass, Anne Mette Floe; Christian, Wejse] Aarhus Univ Hosp, Dept Infect Dis, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark.
   [Hvass, Anne Mette Floe] Aarhus Municipal, Dept Social Med, Aarhus, Denmark.
   [Hvass, Anne Mette Floe; Christian, Wejse] Aarhus Univ, Dept Clin Med, Aarhus, Denmark.
   [Norredam, Marie] Univ Copenhagen, Danish Res Ctr Migrat Ethnic & Hlth, Inst Publ Hlth, Copenhagen, Denmark.
   [Norredam, Marie] Hvidovre Univ Hosp, Dept Infect Dis, Sect Immigrant Med, Hvidovre, Denmark.
   [Sodemann, Morten] Odense Univ Hosp, Dept Infect Dis, Migrant Hlth Clin, Odense, Denmark.
   [Thomsen, Marianne Kragh] Aarhus Univ Hosp, Dept Clin Microbiol, Aarhus, Denmark.
   [Christian, Wejse] Aarhus Univ, Ctr Global Hlth, Dept Publ Hlth, Aarhus, Denmark.
   [Norredam, Marie] Univ Copenhagen, Oster Farimagsgade 5, DK-1353 Copenhagen K, Denmark.
   [Sodemann, Morten] Odense Univ Hosp, Sdr Blvd 29, DK-5000 Odense, Denmark.
   [Thomsen, Marianne Kragh] Aarhus Univ Hosp, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark.
   [Christian, Wejse] Aarhus Univ, Bartolins Alle 4, DK-8000 Aarhus C, Denmark.
RP Hvass, AMF (reprint author), Aarhus Univ Hosp, Dept Infect Dis, Palle Juul Jensens Blvd 99, DK-8200 Aarhus N, Denmark.
EM anhvas@rm.dk; mano@sund.ku.dk; msodemann@health.sdu.dk; marthoms@rm.dk;
   wejse@ph.au.dk
OI Sodemann, Morten/0000-0001-8992-2500
FU Aarhus Municipality Department of Social Medicine, Aarhus University;
   Kerrn-Jespersen Foundation; "Folkesundhed I Midten"Foundation
FX This work was supported by the Aarhus Municipality Department of Social
   Medicine, Aarhus University Ph.D. grant, The Kerrn-Jespersen Foundation
   and The ``Folkesundhed I Midten"Foundation.
CR ECDC, 2018, PUBL HLTH GUID SCREE
   ECDC, 2019, EL, P1
   Freidl GS, 2018, VACCINE, V36, P1664, DOI 10.1016/j.vaccine.2018.01.079
   Hagstam P, 2019, INFECT DIS-NOR, V51, P122, DOI 10.1080/23744235.2018.1524583
   Hargreaves S, 2018, EUROSURVEILLANCE, V23, P21, DOI 10.2807/1560-7917.ES.2018.23.41.1700772
   Hubschen JM, 2018, VACCINE, V36, P899, DOI 10.1016/j.vaccine.2017.12.041
   Hui C, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15102065
   Hvass AMF, 2019, EXPERT REV VACCINES, V18, P1317, DOI 10.1080/14760584.2019.1698953
   Hvass AMF, 2017, ANN HUM BIOL, V44, P475, DOI 10.1080/03014460.2017.1330897
   Jablonka A, 2017, INFECT DIS THER, V6, P487, DOI 10.1007/s40121-017-0169-7
   Jablonka A, 2016, INFECTION, V44, P781, DOI 10.1007/s15010-016-0926-7
   Jakab Z., 2015, POPULATION MOVEMENT
   Jones G, 2016, MEASLES OUTBREAK REF, V2016, P1
   Mipatrini D, 2017, PATHOG GLOB HEALTH, V111, P59, DOI 10.1080/20477724.2017.1281374
   Moller SP, 2016, EUR J PEDIATR, V175, P539, DOI 10.1007/s00431-015-2663-9
   Nakken CS, 2018, TACTICS EMPLOYED HEA, V1, P1
   Plans-Rubio P, 2019, EUR J CLIN MICROBIOL, V38, P1719, DOI 10.1007/s10096-019-03604-0
   Roberts L, 2015, SCIENCE, V348, P962, DOI 10.1126/science.348.6238.962
   SSI, SSI VACC COV DENM 20
   Staehelin C, 2019, J TRAVEL MED, V26, DOI 10.1093/jtm/taz035
   The Danish Ministry of Immigration and Integration, 2018, INT MIGR DENM REP OE
   Thornton J., 2019, BMJ-BRIT MED J, V364, DOI [10.1136/bmj.l634l634, DOI 10.1136/BMJ.L634L634]
   Toikkanen SE, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13070650
   UNICEF/WHO, WHO GLOB IMM MON 201
   Valadez JJ, 1992, AM J PUBLIC HEAL, V82, P1991
   Wadman M, 2019, SCIENCE, V363, P677, DOI 10.1126/science.363.6428.677
   Werber D, 2017, EUROSURVEILLANCE, V22, P6, DOI 10.2807/1560-7917.ES.2017.22.34.30599
   WHO, WHO MEASL 2018
   WHO, 2019, MEASL GLOB SIT 2019
   WHO, WHO MEASL EUR 2019
   WHO Europe, 2015, EUR VACC ACT PLAN 20, P98
   World Health Organization (WHO), 2012, GLOB MEASL RUB STRAT
   World Health Organization (WHO), 2019, MEASL WHO 2019
   Xiong YZ, 2014, HUM VACC IMMUNOTHER, V10, P1097, DOI 10.4161/hv.27734
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2788
EP 2794
DI 10.1016/j.vaccine.2020.02.025
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200009
PM 32089459
DA 2020-05-12
ER

PT J
AU Gorman, DR
   Bielecki, K
   Larson, HJ
   Willocks, LJ
   Craig, J
   Pollock, KG
AF Gorman, D. R.
   Bielecki, K.
   Larson, H. J.
   Willocks, L. J.
   Craig, J.
   Pollock, K. G.
TI Comparing vaccination hesitancy in Polish migrant parents who accept or
   refuse nasal flu vaccination for their children
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine; Immunisation; Hesitancy; Polish; Migrants; Uptake
AB This study investigates the background to low uptake of nasal influenza vaccination in Polish pupils in Edinburgh, Scotland. In autumn 2018, one week after their child's nasal flu vaccination sessions, 365 Polish parents were sent a questionnaire exploring influences on their vaccination choices. The questionnaire included a series of 10 vaccine hesitancy questions recommended by the WHO SAGE Working Group on Vaccine Hesitancy.
   128 questionnaires were returned representing 43.4% of vaccinated, 41.9% of refusing and 23.8% of non-consent form returning parents. Responses highlighted concerns about side effects, new vaccines and the accuracy of professional advice and information sources. There was complacency expressed about vaccination against diseases that are not common any more. Vaccine refusers were consistently more negative about all aspects vaccination and more likely to answer 'don't know'. Almost half of refusers were uncertain about the quality of health information offered to them.
   Polish migrants in Scotland come with their beliefs about vaccination and modify these as they acculturate to the UK system. They also continue to be influenced by developments and opinions, norms and values from their home country, as well as diaspora media. We have highlighted issues of concern among Polish migrants as a group and gained additional insights by comparing responses of parents who have refused or accepted vaccination. These insights can inform and target messages and strategies to build confidence and encourage immunisation, which should lead to improved vaccine uptake among ethnic population groups. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Gorman, D. R.; Bielecki, K.; Willocks, L. J.] NHS Lothian, Directorate Publ Hlth & Hlth Policy, Edinburgh, Midlothian, Scotland.
   [Larson, H. J.] London Sch Hyg & Trop Med, London, England.
   [Craig, J.] NHS Hlth Scotland, Populat Hlth Dept, Edinburgh, Midlothian, Scotland.
   [Pollock, K. G.] Glasgow Caledonian Univ, Sch Hlth & Life Sci, Glasgow, Lanark, Scotland.
RP Gorman, DR (reprint author), NHS Lothian, 2-4 Waterloo Pl, Edinburgh EH1 3EG, Midlothian, Scotland.
EM Dermot.Gorman@nhslothian.scot.nhs.uk
FU Vaccination Transformation Programme
FX This project was commissioned by NHS Health Scotland and funded by the
   Vaccination Transformation Programme.
CR [Anonymous], 2018, INCR PROBL VACC HES
   Bell S, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-028228
   Bielecki K, 2019, VACCINE, V37, P693, DOI 10.1016/j.vaccine.2018.11.029
   Bielecki KCJ, 2019, VACCINE UNPUB
   Gorman DR, 2019, VACCINE, V37, P2741, DOI 10.1016/j.vaccine.2019.03.073
   Gorman DR, 2018, PUBLIC HEALTH, V158, P86, DOI 10.1016/j.puhe.2017.11.026
   Gunaratne K, 2019, VACCINE, V37, P4867, DOI 10.1016/j.vaccine.2019.06.086
   Larson H, 2018, STATE VACCINE CONFID
   Larson HJ, 2015, VACCINE, V33, P4165, DOI 10.1016/j.vaccine.2015.04.037
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   McKee M., 2018, Eurohealth, V24, P35
   McKee M, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l2144
   National Records of Scotland, 2018, POP COUNTR BIRTH NAT
   Nelson R, 2019, LANCET INFECT DIS, V19, P248, DOI 10.1016/S1473-3099(19)30074-X
   Nitsch-Osuch A, 2017, ADV EXP MED BIOL, V968, P19, DOI 10.1007/5584_2016_193
   Paniz-Mondolfi AE, 2019, EMERG INFECT DIS, V25, P625, DOI 10.3201/eid2504.181305
   Poland T., 2018, UNVACCINATED FOREIGN
   Pollock KG, 2019, VACCINE, V37, P690, DOI 10.1016/j.vaccine.2018.10.097
   Sim JA, 2011, PUBLIC HEALTH, V125, P505, DOI 10.1016/j.puhe.2011.05.005
   Tanne JH, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l312
   Trust Wellcome, 2019, WELLC GLOB MON 2019
   Walker S., 2019, GUARDIAN
   WHO, 2019, 10 THREATS GLOB HLTH
   Zarobkiewicz MK, 2017, HUM VACC IMMUNOTHER, V13, P2654, DOI 10.1080/21645515.2017.1365994
   Zaton W., 2018, IMPORTANCE HLTH LITE, V4, P73
NR 25
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2795
EP 2799
DI 10.1016/j.vaccine.2020.02.028
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200010
PM 32089460
DA 2020-05-12
ER

PT J
AU Coulborn, RM
   Nackers, F
   Bachy, C
   Porten, K
   Vochten, H
   Ndele, E
   Van Herp, M
   Bibala-Faray, E
   Cohuet, S
   Panunzi, I
AF Coulborn, R. M.
   Nackers, F.
   Bachy, C.
   Porten, K.
   Vochten, H.
   Ndele, E.
   Van Herp, M.
   Bibala-Faray, E.
   Cohuet, S.
   Panunzi, I
TI Field challenges to measles elimination in the Democratic Republic of
   the Congo
SO VACCINE
LA English
DT Article
DE Measles vaccination; Mass vaccination; Vaccination coverage; Vaccine
   effectiveness; Democratic Republic of the Congo
ID MALNUTRITION; CHILDREN; VACCINE; IMMUNIZATION
AB Background: During a measles epidemic, the Ministry of Public Health (MOH) of the Democratic Republic of the Congo conducted supplementary immunization activities (2016-SIA) from August 28-September 3, 2016 throughout Maniema Province. From October 29-November 4, 2016, Medecins Sans Frontieres and the MOH conducted a reactive measles vaccination campaign (2016-RVC) targeting children six months to 14 years old in seven health areas with heavy ongoing transmission despite inclusion in the 2016-SIA, and a post-vaccination survey. We report the measles vaccine coverage (VC) and effectiveness (VE) of the 2016-SIA and VC of the 2016-RVC.
   Methods: A cross-sectional VC cluster survey stratified by semi-urban/rural health area and age was conducted. A retrospective cohort analysis of measles reported by the parent/guardian allowed calculation of the cumulative measles incidence according to vaccination status after the 2016-SIA for an estimation of crude and adjusted VE.
   Results: In November 2016, 1145 children (6-59 months old) in the semi-urban and 1158 in the rural areas were surveyed. Post-2016-SIA VC (documentation/declaration) was 81.6% (95%CI: 76.5-85.7) in the semi-urban and 91.0% (95%CI: 84.9-94.7) in the rural areas. The reported measles incidence in October among children less than 5 years old was 5.0% for 2016-SIA-vaccinated and 11.2% for 2016-SIA-non-vaccinated in the semi-urban area, and 0.7% for 2016-SIA-vaccinated and 4.0% for 2016-SIA-non-vaccinated in the rural area. Post-2016-SIA VE (adjusted for age, sex) was 53.9% (95%CI: 2.9-78.8) in the semi-urban and 78.7% (95%CI: 0-97.1) in the rural areas. Post 2016-RVC VC (documentation/declaration) was 99.1% (95%CI: 98.2-99.6) in the semi-urban and 98.8% (95%CI: 96.5-99.6) in the rural areas.
   Conclusions: Although our VE estimates could be underestimated due to misclassification of measles status, the VC and VE point estimates of the 2016-SIA in the semi-urban area appear suboptimal, and in combination, could not limit the epidemic. Further research is needed on vaccination strategies adapted to urban contexts. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Coulborn, R. M.; Nackers, F.; Porten, K.; Cohuet, S.] Epicentre, 14-34 Ave Jean Jaures, F-75019 Paris, France.
   [Bachy, C.; Van Herp, M.; Panunzi, I] Medecins Sans Frontieres, Brussels, Belgium.
   [Vochten, H.; Ndele, E.] Medecins Sans Frontieres, Kinshasa, DEM REP CONGO.
   [Bibala-Faray, E.] Minist Publ Hlth, Maniema, DEM REP CONGO.
RP Coulborn, RM (reprint author), Epicentre, 14-34 Ave Jean Jaures, F-75019 Paris, France.
EM rebecca.coulborn@epicentre.msf.org
FU Medecins Sans FrontieresOperational Centre Brussels
FX This work was supported by Medecins Sans FrontieresOperational Centre
   Brussels.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205
   Bhaskaram P, 2002, NUTR REV, V60, pS40, DOI 10.1301/00296640260130722
   Bruneau J-C, 2009, ESPACE POLITIQUE, DOI [10.4000/espacepolitique.1296., DOI 10.4000/ESPACEPOLITIQUE.1296]
   Cutts FT, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001404
   CUTTS FT, 1990, AM J EPIDEMIOL, V131, P349, DOI 10.1093/oxfordjournals.aje.a115504
   Doshi RH, 2015, VACCINE, V33, P6786, DOI 10.1016/j.vaccine.2015.10.020
   Doshi RH, 2015, VACCINE, V33, P3407, DOI 10.1016/j.vaccine.2015.04.067
   Goodson JL, 2012, VACCINE, V30, P4709, DOI 10.1016/j.vaccine.2012.04.058
   GREENWOOD BM, 1972, LANCET, V1, P169
   Grout L, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-232
   HAFEZ M, 1977, J TROP MED HYG, V80, P36
   HALSEY NA, 1985, NEW ENGL J MED, V313, P544, DOI 10.1056/NEJM198508293130904
   Idris S, 1983, Ann Trop Paediatr, V3, P63
   Ijarotimi IT, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206086
   Kizito D, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-619
   Mancini S, 2014, CONFL HEALTH, DOI [10.1186/1752-1505-8-9., DOI 10.1186/1752-1505-8-9.]
   McMurray D N, 1979, Bull Pan Am Health Organ, V13, P52
   Minetti A, 2014, AM J EPIDEMIOL, V179, P245, DOI 10.1093/aje/kwt236
   Nair TN, 1994, INDIAN PEDIAT
   Portnoy A, 2018, VACCINE, V36, P170, DOI 10.1016/j.vaccine.2017.10.080
   Powell G M, 1982, Ann Trop Paediatr, V2, P143
   REDDY V, 1986, AM J CLIN NUTR, V44, P924
   Rytter MJH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105017
   Schoeps A, 2013, VACCINE, V32, P96, DOI 10.1016/j.vaccine.2013.10.063
   Shibeshi ME, 2014, VACCINE, V32, P1798, DOI 10.1016/j.vaccine.2014.01.089
   Tabatabaei SM, 2015, INT J INFECT, DOI [10.17795/iji28109., DOI 10.17795/IJI28109]
   Thompson KM, 2016, RISK ANAL, V36, P1383, DOI 10.1111/risa.12637
   Uzicanin A, 2011, J INFECT DIS, V204, pS133, DOI 10.1093/infdis/jir102
   Vijayaraghavan M, 2007, HEALTH POLICY, V83, P27, DOI 10.1016/j.healthpol.2006.11.008
   World Health Organization (WHO), 2012, GLOB MEASL RUB STRAT
   Zhang JE, 2012, P NATL ACAD SCI USA, V109, P11981, DOI 10.1073/pnas.1206210109
   Zhang XY, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0802-4
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2800
EP 2807
DI 10.1016/j.vaccine.2020.02.029
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200011
PM 32111528
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kabore, L
   Meda, CZ
   Sawadogo, F
   Bengue, MM
   Kabore, WMF
   Essoh, AT
   Gervaix, A
   Galetto-Lacour, A
   Medah, I
   Betsem, E
AF Kabore, Lassane
   Meda, Clement Z.
   Sawadogo, Francois
   Bengue, Michele M.
   Kabore, William M. F.
   Essoh, Alima T.
   Gervaix, Alain
   Galetto-Lacour, Annick
   Medah, Isaie
   Betsem, Edouard
TI Quality and reliability of vaccination documentation in the routine
   childhood immunization program in Burkina Faso: Results from a
   cross-sectional survey
SO VACCINE
LA English
DT Article
DE Immunization; Vaccination; Data recording; Home-based records; EPI;
   Burkina Faso
ID PARENTAL RECALL; COVERAGE; VALIDITY; CARDS; RECORDS
AB Introduction: Accurate and timely vaccination data are important to the Expanded Program on Immunization (EPI) to assess individual vaccination status and to monitor performance and vaccine coverage (VC). Since 2013, Burkina Faso introduced several new vaccines into the routine childhood immunization schedule. However, sustained efforts for a timely update and alignment of immunization home-based (HBRs) and health facility-based records (FBRs) with the evolving schedule were not implemented.
   Methods: In 2016-17, we conducted a 6-week cross-sectional survey in 30 health facilities (HFs) across 10 health districts (HDs), targeting children aged < 24 months and their caregivers. Data collected included sociodemographics, availability of vaccination recording fields in HBRs, and vaccination dates. We evaluated the characteristics, completion patterns, and concordance of HBRs and FBRs to determine their reliability as data sources in estimating VC. A standard HBR was defined as one that had recording fields for all recommended 17 vaccine doses of the schedule, and discordance between HBR and FBR as having different vaccination dates recorded, or vaccination information missing in one of the records. We computed proportions and concordance statistics, and used logistic regression to explore predictors of discordance.
   Results: We recruited 619 children, including 74% (n = 458) aged 0-11 months. Half (50.6%) of HBRs were non-standard. About two-thirds (64.6%) of children were concerned with discordant information. Compared to HBRs, FBRs were generally associated with low negative predictive values (median: 0.41; IQR: 0.16-0.70). Multivariate logistic regression model showed that standard HBR was protectively associated with discordant information (OR = 0.46, 95% CI: 0.26-0.81, p = 0.010).
   Conclusion: We documented a lack of standardization of HBRs and frequent information discordance with FBRs. There is a pressing need to update and standardize vaccination recording tools and ensure their continuous availability in HFs to improve data quality in Burkina Faso. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kabore, Lassane; Sawadogo, Francois; Bengue, Michele M.; Essoh, Alima T.; Betsem, Edouard] Agence Med Prevent, Villa 7,Ave Kwame Nkrumah,10POB 638, Ouagadougou, Burkina Faso.
   [Kabore, Lassane] Univ Geneva, Fac Med, Inst Global Hlth, 9 Chemin Mines, CH-1202 Geneva, Switzerland.
   [Meda, Clement Z.] Univ Nazi Boni, Bobo Dioulasso, Burkina Faso.
   [Kabore, William M. F.; Medah, Isaie] Minist Hlth, Ouagadougou, Burkina Faso.
   [Gervaix, Alain; Galetto-Lacour, Annick] Univ Hosp Geneva, Dept Pediat, Geneva, Switzerland.
   [Betsem, Edouard] Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon.
RP Betsem, E (reprint author), Univ Yaounde I, Fac Med & Biomed Sci, Yaounde, Cameroon.
EM tae@aamp.org; edouard.betsem@medcamer.org
FU Centers for Disease Control and Prevention as part of the Global Health
   Security Agenda, United States [1U2GGH001719-01]
FX This work was supported by the Centers for Disease Control and
   Prevention as part of the Global Health Security Agenda, United States
   [grant number: 1U2GGH001719-01].
CR Aiga H, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.29924
   Andre FE, 2008, B WORLD HEALTH ORGAN, V86, P140, DOI 10.2471/BLT.07.040089
   [Anonymous], GLOB VACC ACT PLAN 2
   [Anonymous], SURV DAT REF MAN
   [Anonymous], 2019, GLOBAL HLTH SECURITY
   Arsenault C, 2017, B WORLD HEALTH ORGAN, V95, P128, DOI 10.2471/BLT.16.178079
   Binyaruka P, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3270-z
   Bolton P, 1998, PUBLIC HEALTH REP, V113, P521
   Brown DW, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201538
   Brown DW, 2014, VACCINE, V32, P1775, DOI 10.1016/j.vaccine.2014.01.098
   Brown DW, 2017, WORLD J VACCINE, V7, P1, DOI [10.4236/wjv.2017.71001, DOI 10.4236/WJV.2017.71001]
   Cutts FT, 2016, VACCINE, V34, P4103, DOI 10.1016/j.vaccine.2016.06.053
   Cutts FT, 2013, PLOS MED, V10
   Danovaro-Holliday MC, 2018, VACCINE, V36, P5150, DOI 10.1016/j.vaccine.2018.07.019
   Dansereau Emily, 2019, Gates Open Res, V3, P923, DOI 10.12688/gatesopenres.12916.1
   Dolan SB, 2019, VACCINE, V37, P1859, DOI 10.1016/j.vaccine.2019.02.017
   Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433
   Haddad S, 2010, HEALTH POLICY PLANN, V25, P393, DOI 10.1093/heapol/czq007
   Hasman A, 2016, VACCINE, V34, P5697, DOI 10.1016/j.vaccine.2016.09.064
   Huhn GD, 2006, VACCINE, V24, P730, DOI 10.1016/j.vaccine.2005.08.077
   John Snow Inc, DAT TRIANG US HLTH F
   John Snow Inc, COND SIT AN ENG STAK
   Luman ET, 2009, VACCINE, V27, P2534, DOI 10.1016/j.vaccine.2008.10.002
   Mansour Z, 2019, VACCINE, V37, P4177, DOI 10.1016/j.vaccine.2019.05.032
   Miles M, 2013, VACCINE, V31, P1560, DOI 10.1016/j.vaccine.2012.10.089
   Ministere de la Sante Burkina Faso, 2009, REV APRR PEV RAPP FI
   Ministere de la Sante Burkina Faso, 2015, PLAN PLUR ANN COMPL
   Namageyo-Funa A, 2018, PAN AFR MED J, V29, P30
   Pan American Health Organization, INTR IMPL NEW VACC F
   Porth JM, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020048
   Seymour D, 2019, FRONT PUBLIC HEALTH, V7, DOI 10.3389/fpubh.2019.00218
   Sow C, 2018, VACCINE, V36, P3747, DOI 10.1016/j.vaccine.2018.05.062
   Vaccines for Africa Initiative (University of Cape Town), NAT IMM SCHED BURK F
   World Health Assembly, EXP PROGR IMM
   World Health Organization, 2018, WHO REC HOM BAS REC
   World Health Organization, REP SAGE WORK GROUP
   World Health Organization, IMM COV
   World Health Organization, WHO VACC COV CLUST S
   World Health Organization, 2015, PRACT GUID DES US PR
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2808
EP 2815
DI 10.1016/j.vaccine.2020.02.023
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200012
PM 32089461
DA 2020-05-12
ER

PT J
AU Vos, RA
   Pasmans, H
   Tymchenko, L
   Janga-Jansen, AVA
   Baboe-Kalpoe, S
   Hulshof, K
   de Melker, HE
   van der Klis, FRM
AF Vos, Regnerus A.
   Pasmans, Hella
   Tymchenko, Liza
   Janga-Jansen, Alcira V. A.
   Baboe-Kalpoe, Sharda
   Hulshof, Koen
   de Melker, Hester E.
   van der Klis, Fiona R. M.
TI High seroprevalence of multiple high-risk human papillomavirus types
   among the general population of Bonaire, St. Eustatius and Saba,
   Caribbean Netherlands
SO VACCINE
LA English
DT Article
DE Human papillomavirus; HPV; Seroepidemiology; Vaccination; Cervical
   cancer screening; Caribbean Netherlands
ID HPV TYPES; WOMEN; IMMUNOGENICITY; PREVALENCE; VACCINE; SAFETY;
   INFECTION; RESPONSES; EFFICACY; COHORT
AB Background: Incidence and mortality of human papillomavirus (HPV)-related cancers differs geographically, with high rates in Caribbean countries. Seroepidemiological data provide information on lifetime cumulative HPV exposure and contributing risk factors, but has not been available yet for Caribbean Netherlands (CN), comprising the islands Bonaire, St. Eustatius and Saba. Therefore, a cross-sectional population-based serosurveillance study was performed in this (recently girls-only HPV-vaccinated) population in 2017.
   Methods: Blood samples from participants (n = 1,823, 0-90 years) were tested for seven high-risk (hr)-HPV-specific IgG-antibodies using a VLP-based multiplex-immunoassay. Risk factors for HPV-seropositivity were analysed among persons unvaccinated aged >= 15 years who ever had sex (n = 1,080).
   Results: Among unvaccinated individuals aged >= 15 years, overall seropositivity was high (34%), with over half of them being seropositive for >= 2 hr-HPV types, and HPV16 and 52 being most prevalent (13%). Seroprevalence was substantial higher in unvaccinated women (51%) than men (18%), predominantly peaking in women aged 20-59 years, and was highest on St. Eustatius (38%). Besides age and sex, sexual risk factors were associated with HPV-seropositivity.
   Conclusions: In accordance with the Caribbean region, seroprevalence of multiple hr-HPV types was high in CN. These data corroborate the decision regarding introduction of a sex-neutral HPV-vaccination program and the relevance for considering a population-based cervical cancer screening program. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Vos, Regnerus A.; Pasmans, Hella; Tymchenko, Liza; de Melker, Hester E.; van der Klis, Fiona R. M.] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands.
   [Baboe-Kalpoe, Sharda] Publ Ent St Eustatius, Dept Publ Hlth, St Eustatius, Caribbean Nethe, Netherlands.
   [Hulshof, Koen] Publ Ent Saba, Dept Publ Hlth, Saba, Caribbean Nethe, Netherlands.
   [Janga-Jansen, Alcira V. A.] Publ Ent Bonaire, Dept Publ Hlth, Kaya Neerlandia 41, Bonaire, Caribbean Nethe, Netherlands.
RP Vos, RA (reprint author), Antonie von Leeuwenhoeklaan 9,POB 1,Postbak 41, NL-3720 MA Bilthoven, Netherlands.
EM eric.vos.02@rivm.nl
FU Dutch Ministry of Health, Welfare and Sport (VWS)
FX This work was supported by the Dutch Ministry of Health, Welfare and
   Sport (VWS) (grant nr.: NA). The funding source had no involvement in
   study design, collection, analysis and interpretation of data, in
   writing of the manuscript and in decision to submit the article for
   publication.
CR Allen CF, 2013, W INDIAN MED J, V62, P292, DOI 10.7727/WIMJ.2013.025
   Bedoya AM, 2012, INT J GYNECOL CANCER, V22, P303, DOI 10.1097/IGC.0b013e31823c2469
   Bickel P, 2001, MATH STAT BASIC IDEA, P101
   Carter JJ, 2000, J INFECT DIS, V181, P1911, DOI 10.1086/315498
   Castellsague X, 2011, BRIT J CANCER, V105, P28, DOI 10.1038/bjc.2011.185
   Castro FA, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-361
   Clinical and Laboratory Standards Institute (CLSI), 2013, BLOOD COLL FILT PAP
   Coseo S, 2010, SEX TRANSM DIS, V37, P706, DOI 10.1097/OLQ.0b013e3181e1a2c5
   Desai S, 2011, SEX TRANSM DIS, V38, P622, DOI 10.1097/OLQ.0b013e31820bc880
   Dunne EF, 2005, J INFECT DIS, V191, P1817, DOI 10.1086/430274
   Einstein MH, 2009, LANCET INFECT DIS, V9, P347, DOI 10.1016/S1473-3099(09)70108-2
   Frey A, 1998, J IMMUNOL METHODS, V221, P35, DOI 10.1016/S0022-1759(98)00170-7
   Grunberg MG, 2017, EPIDEMIOL INFECT, V145, P245, DOI 10.1017/S0950268816002132
   Health Council of the Netherlands, 2019, VACC HPV
   Hooi DJ, 2018, SEX TRANSM INFECT, V94, P262, DOI 10.1136/sextrans-2017-053109
   IARC, 2019, CANC FACT SHEETS
   Kim MA, 2010, OBSTET GYNECOL, V116, P932, DOI 10.1097/AOG.0b013e3181edbeba
   Loenenbacha AD, 2019, INT J INFECT DIS, V83, P3, DOI 10.1016/j.ijid.2019.03.022
   Mei JV, 2001, J NUTR, V131, p1631S
   Michael KM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000091
   Mindell JS, 2015, BMC MED RES METHODOL, V15, DOI 10.1186/s12874-015-0072-4
   Mollers M, 2013, J MED VIROL, V85, P1379, DOI 10.1002/jmv.23616
   Munoz N, 2004, INT J CANCER, V111, P278, DOI 10.1002/ijc.20244
   Naud PS, 2014, HUM VACC IMMUNOTHER, V10, P2147, DOI 10.4161/hv.29532
   Newall AT, 2008, CLIN INFECT DIS, V46, P1647, DOI 10.1086/587895
   Nygard M, 2015, CLIN VACCINE IMMUNOL, V22, P943
   Ortiz AP, 2018, PAPILLOMAVIRUS RES, V5, P109, DOI 10.1016/j.pvr.2018.03.006
   Ragin C, 2008, CANCER INVEST, V26, P936, DOI 10.1080/07357900801975280
   Ragin Camille C, 2009, Infect Agent Cancer, V4 Suppl 1, pS9, DOI 10.1186/1750-9378-4-S1-S9
   Sabeena S, 2017, J OBSTET GYNAECOL RE, V43, P429, DOI 10.1111/jog.13248
   Sadate-Ngatchou P, 2016, SEX TRANSM DIS, V43, P192, DOI 10.1097/OLQ.0000000000000409
   Scherpenisse M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048807
   Scherpenisse M, 2012, VACCINE, V30, P6686, DOI 10.1016/j.vaccine.2012.08.068
   Schiller JT, 2009, J INFECT DIS, V200, P166, DOI 10.1086/599988
   Slavinsky J, 2001, INT J STD AIDS, V12, P516, DOI 10.1258/0956462011923615
   Spence D, 2019, LANCET ONCOL, V20, pE503, DOI 10.1016/S1470-2045(19)30512-1
   Statistics Netherlands (CBS), 2017, POP CAR NETH
   Stone KM, 2002, J INFECT DIS, V186, P1396, DOI 10.1086/344354
   Strickler HD, 1999, INT J CANCER, V80, P339, DOI 10.1002/(SICI)1097-0215(19990129)80:3&lt;339::AID-IJC1&gt;3.0.CO;2-F
   The Netherlands Comprehensive Cancer Organisation (IKNL), 2019, CANC REGISTRY
   van Lier EA, 2019, VACCINATION COVERAGE
   Verberk JDM, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4019-y
   Wang SS, 2003, BRIT J CANCER, V89, P1248, DOI 10.1038/sj.bjc.6601272
   Wheeler CM, 2008, VACCINE, V26, P686, DOI 10.1016/j.vaccine.2007.11.043
   Wilson LE, 2013, INT J CANCER, V133, P2172, DOI 10.1002/ijc.28215
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2816
EP 2826
DI 10.1016/j.vaccine.2020.02.017
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200013
PM 32088019
OA Other Gold
DA 2020-05-12
ER

PT J
AU Dudley, MZ
   Limaye, RJ
   Omer, SB
   O'Leary, ST
   Ellingson, MK
   Spina, CI
   Brewer, SE
   Chamberlain, AT
   Bednarczyk, RA
   Malik, F
   Frew, PM
   Salmon, DA
AF Dudley, Matthew Z.
   Limaye, Rupali J.
   Omer, Saad B.
   O'Leary, Sean T.
   Ellingson, Mallory K.
   Spina, Christine, I
   Brewer, Sarah E.
   Chamberlain, Allison T.
   Bednarczyk, Robert A.
   Malik, Fauzia
   Frew, Paula M.
   Salmon, Daniel A.
TI Factors associated with referring close contacts to an app with
   individually-tailored vaccine information
SO VACCINE
LA English
DT Article
DE Vaccines; Cocooning; App; Referral; Education; Social Network
ID MATERNAL INFLUENZA IMMUNIZATION; PREGNANT-WOMEN; DECISION-MAKING;
   ADVISORY-COMMITTEE; SEASONAL INFLUENZA; UNITED-STATES; PERTUSSIS;
   PARENTS; RECOMMENDATIONS; DIPHTHERIA
AB Background: Infants too young to be fully vaccinated are vulnerable to potentially deadly influenza and pertussis infections. The cocooning strategy limits this risk by vaccinating those likely to interact with the infant and mother during this vulnerable time, such as close friends and family members. Distribution of accurate and accessible vaccine information through existing social networks could be an important tool in increasing vaccine confidence and coverage.
   Methods: We surveyed 1095 pregnant women from diverse prenatal care practices in Georgia and Colorado. These women were surveyed through a mobile app to assess vaccine intentions, attitudes, beliefs, norms, and levels of trust, and then presented brief individually-tailored educational videos about maternal and infant vaccines and the cocooning strategy. They were then given the opportunity to refer up to six contacts to enroll in the app and receive similar vaccine education.
   Results: Twenty-eight percent of these women referred at least one contact, with an average of 2.67 contacts per referring woman. Most referrals (93%) were partners, parents, siblings, relatives, or close friends. Attitudinal constructs significantly associated with increased likelihood of referring contacts included: intention to receive maternal influenza vaccine, perceived safety of maternal Tdap vaccine, perceived efficacy of maternal influenza vaccine, perceived susceptibility to and severity of influenza during pregnancy, and trust in vaccine information from the Centers for Disease Control and Prevention (CDC) and academic institutions. Uncertainty about infant vaccine intentions was associated with decreased likelihood of referring contacts.
   Conclusions: Pregnant women who valued vaccination and trusted vaccine information from academic institutions were more likely to refer an educational app about vaccines than those who did not. Further research is needed to determine the potential impact of this strategy on vaccine coverage when implemented on a large scale. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Dudley, Matthew Z.; Limaye, Rupali J.; Salmon, Daniel A.] Johns Hopkins Univ, Dept Int Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Limaye, Rupali J.; Salmon, Daniel A.] Johns Hopkins Univ, Dept Hlth Behav & Soc, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Limaye, Rupali J.] Johns Hopkins Univ, Dept Epidemiol, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Dudley, Matthew Z.; Limaye, Rupali J.; Salmon, Daniel A.] Johns Hopkins Univ, Inst Vaccine Safety, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
   [Bednarczyk, Robert A.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA.
   [O'Leary, Sean T.; Spina, Christine, I; Brewer, Sarah E.] Univ Colorado, Adult & Child Consortium Hlth Outcomes Res & Deli, Anschutz Med Campus, Aurora, CO USA.
   [O'Leary, Sean T.; Spina, Christine, I; Brewer, Sarah E.] Childrens Hosp Colorado, Aurora, CO USA.
   [O'Leary, Sean T.] Univ Colorado, Dept Pediat, Anschutz Med Campus, Aurora, CO USA.
   [Brewer, Sarah E.] Univ Colorado, Dept Family Med, Anschutz Med Campus, Aurora, CO USA.
   [Chamberlain, Allison T.; Bednarczyk, Robert A.] Emory Univ, Dept Epidemiol, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   [Bednarczyk, Robert A.] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA.
   [Frew, Paula M.] Univ Nevada, Sch Publ Hlth, Las Vegas, NV 89154 USA.
   [Frew, Paula M.] Univ Nevada, Sch Med, Las Vegas, NV 89154 USA.
   [Frew, Paula M.] Univ Nevada, Populat Hlth & Hlth Equ Initiat, Las Vegas, NV 89154 USA.
   [Omer, Saad B.; Ellingson, Mallory K.] Yale Univ, Yale Sch Publ Hlth, Epidemiol Microbial Dis, New Haven, CT USA.
   [Omer, Saad B.] Yale Inst Global Hlth, New Haven, CT USA.
   [Omer, Saad B.; Malik, Fauzia] Yale New Haven Med Ctr, Yale Sch Med, Infect Dis, 20 York St, New Haven, CT 06504 USA.
   [Malik, Fauzia] Yale Univ, Yale Sch Publ Hlth, Global Hlth Leadership Initiat, Hlth Policy & Management, New Haven, CT USA.
RP Dudley, MZ (reprint author), 615 N Wolfe St,W5041, Baltimore, MD 21205 USA.
EM mattdudley@jhu.edu
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01AI110482];
   Walgreens Corporation
FX This work was supported by the National Institutes of Health [grant
   number R01AI110482]. The funder had no role in the design and conduct of
   the study; collection, management, analysis, or interpretation of the
   data; or preparation, review or approval of the manuscript. This work
   was also supported by Walgreens Corporation. We would like to thank
   everyone who contributed to survey design and/or participant recruitment
   in this study.
CR [Anonymous], 2013, Obstet Gynecol, V121, P1411, DOI 10.1097/01.AOG.0000431054.33593.e3
   Anonymous, 2011, Morbidity and Mortality Weekly Report, V60, P1424
   BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191
   Brunson EK, 2013, PEDIATRICS, V131, pE1397, DOI 10.1542/peds.2012-2452
   Cassell JA, 2006, PUBLIC HEALTH, V120, P783, DOI 10.1016/j.puhe.2006.03.011
   Centers for Disease Control and Prevention, 2015, EPIDEMIOLOGY PREVENT
   Chung YM, 2017, MATERN CHILD HLTH J, V21, P2178, DOI 10.1007/s10995-017-2336-6
   Cialdini RB, 2003, CURR DIR PSYCHOL SCI, V12, P105, DOI 10.1111/1467-8721.01242
   Flynn M, 2004, BRIT J GEN PRACT, V54, P526
   Forsyth K, 2015, PEDIATRICS, V135, pE1475, DOI 10.1542/peds.2014-3925
   Fortner KB, 2012, OBSTET GYNECOL SURV, V67, P251, DOI 10.1097/OGX.0b013e3182524cee
   Frew PM, 2017, HUM VACC IMMUNOTHER, V13, P2503, DOI 10.1080/21645515.2017.1367069
   Frew PM, 2016, HUM VACC IMMUNOTHER, V12, P1989, DOI 10.1080/21645515.2016.1199309
   Frew PM, 2014, HUM VACC IMMUNOTHER, V10, P2576, DOI 10.4161/hv.32248
   Frew PM, 2014, CLIN INFECT DIS, V59, pS400, DOI 10.1093/cid/ciu726
   Frew PM, 2014, VACCINE, V32, P1736, DOI 10.1016/j.vaccine.2014.01.030
   Gorman JR, 2012, VACCINE, V31, P213, DOI 10.1016/j.vaccine.2012.10.064
   Grohskopf LA, 2017, MMWR RECOMM REP, V66, P3, DOI 10.15585/mmwr.rr6602a1
   Kahn KE, 2018, MMWR-MORBID MORTAL W, V67, P1055, DOI 10.15585/mmwr.mm6738a3
   Moriarty LF, 2014, HUM VACC IMMUNOTHER, V10, P2721, DOI 10.4161/hv.29669
   O'Leary ST, 2015, PEDIATR INFECT DIS J, V34, P1244, DOI 10.1097/INF.0000000000000873
   Opel DJ, 2011, HUM VACCINES, V7, P419, DOI 10.4161/hv.7.4.14120
   Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068
   Salmon DA, 2019, VACCINE, V37, P6478, DOI 10.1016/j.vaccine.2019.08.080
   Sawyer M, 2013, MMWR-MORBID MORTAL W, V62, P131
   Schmidt AL, 2018, VACCINE, V36, P3606, DOI 10.1016/j.vaccine.2018.05.040
   Singh M, 2006, CHEST, V130, P1547, DOI 10.1016/S0012-3692(15)37335-9
   Swamy GK, 2014, EXPERT REV VACCINES, V13, P1107, DOI 10.1586/14760584.2014.944509
   Wheeler M, 2013, HUM VACC IMMUNOTHER, V9, P1782, DOI 10.4161/hv.25959
   Wolla S, 2017, P SOC PHOTO-OPT INS, P1
   Zhang LJ, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001478.pub6
NR 31
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2827
EP 2832
DI 10.1016/j.vaccine.2020.02.019
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200014
PM 32098739
OA Green Published
DA 2020-05-12
ER

PT J
AU Vodicka, E
   Zimmermann, M
   Lopez, AL
   Silva, MW
   Gorgolon, L
   Kohei, T
   Mooney, J
   Muhib, F
   Pecenka, C
   Marfin, AA
AF Vodicka, Elisabeth
   Zimmermann, Marita
   Lopez, Anna Lena
   Silva, Maria Wilda
   Gorgolon, Leonita
   Kohei, Toda
   Mooney, Jessica
   Muhib, Farzana
   Pecenka, Clint
   Marfin, Anthony A.
TI Japanese encephalitis vaccination in the Philippines: A
   cost-effectiveness analysis comparing alternative delivery strategies
SO VACCINE
LA English
DT Article
DE Japanese encephalitis; Japanese encephalitis vaccine;
   Cost-effectiveness; Cost analysis; Philippines
ID IMMUNIZATION; THRESHOLDS
AB Introduction: Japanese encephalitis (JE) is a mosquito-borne viral infection of the brain that can cause permanent brain damage and death. In the Philippines, efforts are underway to deliver a live attenuated JE vaccine (CD-JEV) to children under five years of age (YOA), who are disproportionately infected. Multiple vaccination strategies are being considered.
   Methods: We conducted a cost-effectiveness analysis comparing three vaccination strategies to the current state of no vaccination from the societal and government perspectives: (1) national routine vaccination only, (2) sub-national campaign followed by national routine, and (3) national campaign followed by national routine. We developed a Markov model to estimate impact of vaccination or no vaccination over the child's lifetime horizon, assuming an annual incidence of 10.6 cases per 100,000. Costs of illness ($859/case), vaccine ($0.50/dose), routine vaccination ($0.95/dose), and campaign vaccination ($0.98/dose) were based on hospital financial records, expert opinion and literature. The societal perspective included transportation and opportunity costs of caregiver time, in addition to costs incurred by the health system.
   Results: JE vaccination via national campaign followed by national routine delivery was the most costeffective strategy modeled with a cost per disability adjusted life year (DALY) averted of $233 and $29 from the government and societal perspectives, respectively. Results were similar for other delivery strategies with cost/DALY ranging from $233 to $265 from the government perspective and $29-$57 from the societal perspective. JE vaccination was projected to prevent 27,856-37,277 cases, 55717455 deaths, and 173,233-230,704 DALYs among children under five over 20 consecutive birth cohorts. Total incremental costs of vaccination versus no vaccination over 20 birth cohorts were $6.6-$9.8 million from the societal perspective ($230 K-$440 K annually) and $45.9-$53.9 million ($2.2 M-$2.7 M annually) from the governmental perspective.
   Conclusion: Vaccination with CD-JEV in the Philippines is projected to be cost-effective, reducing long-term costs associated with JE illness and improving health outcomes compared to no vaccination. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Vodicka, Elisabeth; Mooney, Jessica; Muhib, Farzana; Pecenka, Clint; Marfin, Anthony A.] PATH, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA.
   [Zimmermann, Marita] Consultants Global Hlth LLC, 1523B NW 64th St, Seattle, WA 98107 USA.
   [Lopez, Anna Lena] Univ Philippines, Inst Child Hlth & Human Dev, Manila Natl Inst Hlth, 623 Pedro Gil St, Manila 1000, Philippines.
   [Silva, Maria Wilda; Gorgolon, Leonita] San Lazaro Compound, Dept Hlth, Rizal Ave, Manila, Philippines.
   [Kohei, Toda] WHO, Reg Off Western Pacific, POB 2932, Manila 1000, Philippines.
   [Zimmermann, Marita] Inst Dis Modeling, Seattle, WA USA.
RP Vodicka, E (reprint author), PATH, 2201 Westlake Ave,Suite 200, Seattle, WA 98121 USA.
EM evodicka@path.org
FU Bill & Melinda Gates Foundation, Seattle, WAGates Foundation
   [OPP1115522]
FX This work was supported by the Bill & Melinda Gates Foundation, Seattle,
   WA [grant number OPP1115522].
CR [Anonymous], 2015, INTERNAL REPORT
   [Anonymous], 2017, WORLD EC OUTL DAT
   Bertram MY, 2016, B WORLD HEALTH ORGAN, V94, P925, DOI 10.2471/BLT.15.164418
   Bilinski A, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002397
   Campbell GL, 2011, B WORLD HEALTH ORGAN, V89, P766, DOI 10.2471/BLT.10.085233
   Ding D, 2003, B WORLD HEALTH ORGAN, V81, P334
   Garrison LP, 2010, VALUE HEALTH, V13, P8, DOI 10.1111/j.1524-4733.2009.00660.x
   Haasis MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131156
   Heffelfinger JD, 2017, MMWR-MORBID MORTAL W, V66, P579, DOI 10.15585/mmwr.mm6622a3
   Hutubessy R, 2003, COST EFFECT RESOUR A, V1, P8, DOI DOI 10.1186/1478-7547-1-8
   Japanese Encephalitis Vaccines, 2016, VACCINE, V34, P302, DOI 10.1016/j.vaccine.2015.07.057
   Kim SY, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-253
   Leech AA, 2018, VALUE HEALTH, V21, P759, DOI 10.1016/j.jval.2017.12.016
   Lopez AL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003630
   Li X, 2014, HUM VACC IMMUNOTHER, V10, P3579, DOI 10.4161/21645515.2014.980197
   Liu W, 2008, VACCINE, V26, P4456, DOI 10.1016/j.vaccine.2008.06.050
   PATH, 2018, SAF CD JEV PROV TOOL
   Republic of the Philippines Department of Health, 2018, 12 REP PHIL DEP HLTH
   Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8
   Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195
   Solomon T, 2000, J NEUROL NEUROSUR PS, V68, P405, DOI 10.1136/jnnp.68.4.405
   The World Bank, BIRTH RAT CRUD PER 1
   Touch S, 2010, VACCINE, V28, P4593, DOI 10.1016/j.vaccine.2010.04.086
   Tsai Theodore F., 2000, Vaccine, V18, P1, DOI 10.1016/S0264-410X(00)00037-2
   WHO, 2016, INF SHEET OBS RAT VA
   *WORLD BANK, 1993, WORLD DEV REP 1993 I
   Yin ZD, 2012, VACCINE, V30, P5569, DOI 10.1016/j.vaccine.2012.05.068
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2833
EP 2840
DI 10.1016/j.vaccine.2020.02.018
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200015
PM 32085954
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Qiu, Y
   Zhao, Y
   Liu, F
   Ye, B
   Zhao, ZJ
   Thongpoon, S
   Roobsoong, W
   Sattabongkot, J
   Cui, LW
   Fan, Q
   Cao, YM
AF Qiu, Yue
   Zhao, Yan
   Liu, Fei
   Ye, Bo
   Zhao, Zhenjun
   Thongpoon, Sataporn
   Roobsoong, Wanlapa
   Sattabongkot, Jetsumon
   Cui, Liwang
   Fan, Qi
   Cao, Yaming
TI Evaluation of Plasmodium vivax HAP2 as a transmission-blocking vaccine
   candidate
SO VACCINE
LA English
DT Article
DE Transmission-blocking vaccine; HAP2; Baculovirus expression
ID MALARIA TRANSMISSION; ANTIBODIES; PROTEIN; CHLAMYDOMONAS; REPRODUCTION;
   IMMUNITY; BERGHEI; PFS25; GCS1
AB Transmission-blocking vaccine (TBV) is a promising strategy to interfere with the transmission of malaria. To date, only limited TBV candidate antigens have been identified for Plasmodium vivax. HAP2 is a gamete membrane fusion protein, with homology to the class II viral fusion proteins. Herein we reported the characterization of the PvHAP2 for its potential as a TBV candidate for P. vivax. The HAP2/GCS1 domain of PvHAP2 was expressed in the baculovirus expression system and the recombinant protein was used to raise antibodies in rabbits. Indirect immunofluorescence assays showed that anti-PvHAP2 antibodies reacted only with the male gametocytes on blood smears. Direct membrane feeding assays were conducted using four field P. vivax isolates in Anopheles dirus. At a mean infection intensity of 72.4, 70.7, 51.3, and 15.6 oocysts/midgut with the control antibodies, anti-PvHAP2 antibodies significantly reduced the midgut oocyst intensity by 40.3, 44.4, 61.9, and 89.7%. Whereas the anti-PvHAP2 antibodies were not effective in reducing the infection prevalence at higher parasite exposure (51.3-72.4 oocysts/midgut in the control group), the anti-PvHAP2 antibodies reduced infection prevalence by 50% at a low challenge (15.6 oocysts/midgut). Multiple sequence alignment showed 100% identity among these Thai P. vivax isolates, suggesting that polymorphism may not be an impediment for the utilization of PvHAP2 as a TBV antigen. In conclusion, our results suggest that PvHAP2 could serve as a TBV candidate for P. vivax, and further optimization and evaluation are warranted. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Qiu, Yue; Zhao, Yan; Liu, Fei; Cao, Yaming] China Med Univ, Coll Basic Med Sci, Dept Immunol, Shenyang 110122, Liaoning, Peoples R China.
   [Ye, Bo; Zhao, Zhenjun; Fan, Qi] Dalian Inst Biotechnol, Dalian, Liaoning, Peoples R China.
   [Thongpoon, Sataporn; Roobsoong, Wanlapa; Sattabongkot, Jetsumon] Mahidol Univ, Fac Trop Med, Mahidol Vivax Res Unit, Bangkok, Thailand.
   [Cui, Liwang] Univ S Florida, Morsani Coll Med, Dept Internal Med, 3720 Spectrum Blvd,Suite 304, Tampa, FL 33612 USA.
RP Cao, YM (reprint author), China Med Univ, Coll Basic Med Sci, Dept Immunol, Shenyang 110122, Liaoning, Peoples R China.
EM ymcao@cmu.edu.cn
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01AI099611,
   U19AI089672, D43TW006571]
FX This study was supported by the National Institutes of Health (grant
   numbers R01AI099611, U19AI089672 and D43TW006571).
CR Acquah FK, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00775-18
   Angrisano F, 2017, CELL REP, V21, P2868, DOI 10.1016/j.celrep.2017.11.024
   Anstey NM, 2009, TRENDS PARASITOL, V25, P220, DOI 10.1016/j.pt.2009.02.003
   Baird JK, 2013, CLIN MICROBIOL REV, V26, P36, DOI 10.1128/CMR.00074-12
   Baird JK, 2011, ANTIMICROB AGENTS CH, V55, P1827, DOI 10.1128/AAC.01296-10
   Baquero E, 2018, STRUCTURE
   Blagborough AM, 2009, VACCINE, V27, P5187, DOI 10.1016/j.vaccine.2009.06.069
   Bourgard C, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00034
   Chowdhury DR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006352
   Churcher TS, 2012, INT J PARASITOL, V42, P1037, DOI 10.1016/j.ijpara.2012.09.002
   Clark T, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.3000007
   Davidson EA, 2001, BIOCHIMIE, V83, P601, DOI 10.1016/S0300-9084(01)01316-5
   Delves MJ, 2018, TRENDS PARASITOL, V34, P735, DOI 10.1016/j.pt.2018.07.001
   Dinglasan RR, 2007, P NATL ACAD SCI USA, V104, P13461, DOI 10.1073/pnas.0702239104
   Duffy PE, 1997, INFECT IMMUN, V65, P1109, DOI 10.1128/IAI.65.3.1109-1113.1997
   Farrance CE, 2011, CLIN VACCINE IMMUNOL, V18, P1351, DOI 10.1128/CVI.05105-11
   Fedry J, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2006357
   Fedry J, 2017, CELL, V168, P904, DOI 10.1016/j.cell.2017.01.024
   Feng J, 2018, ELIFE, V7
   Hirai M, 2008, CURR BIOL, V18, P607, DOI 10.1016/j.cub.2008.03.045
   Hirai M, 2010, ACTA TROP, V114, P157, DOI 10.1016/j.actatropica.2009.08.005
   Hisaeda H, 2000, INFECT IMMUN, V68, P6618, DOI 10.1128/IAI.68.12.6618-6623.2000
   Howes RE, 2016, AM J TROP MED HYG, V95, P15, DOI 10.4269/ajtmh.16-0141
   Johnson MA, 2004, GENETICS, V168, P971, DOI 10.1534/genetics.104.029447
   KASLOW DC, 1994, INFECT IMMUN, V62, P5576, DOI 10.1128/IAI.62.12.5576-5580.1994
   Lee SM, 2019, PROTEIN EXPRES PURIF, V160, P56, DOI 10.1016/j.pep.2019.04.001
   Lee SM, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1464-6
   Liu YJ, 2008, GENE DEV, V22, P1051, DOI 10.1101/gad.1656508
   Malkin EM, 2005, VACCINE, V23, P3131, DOI 10.1016/j.vaccine.2004.12.019
   McCaffery JN, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00135
   MEDLEY GF, 1993, PARASITOLOGY, V106, P441, DOI 10.1017/S0031182000076721
   Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520
   Miura K, 2008, VACCINE, V26, P193, DOI 10.1016/j.vaccine.2007.10.064
   Miura K, 2013, INFECT IMMUN, V81, P4377, DOI 10.1128/IAI.01056-13
   Mizutani M, 2014, INFECT IMMUN, V82, P4348, DOI 10.1128/IAI.02040-14
   Mori T, 2006, NAT CELL BIOL, V8, P64, DOI 10.1038/ncb1345
   Mori T, 2015, MOL PLANT, V8, P1442, DOI 10.1016/j.molp.2015.06.008
   Mori T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015957
   Mueller I, 2015, VACCINE, V33, P7489, DOI 10.1016/j.vaccine.2015.09.060
   Mueller I, 2009, LANCET INFECT DIS, V9, P555, DOI 10.1016/S1473-3099(09)70177-X
   MUNESINGHE YD, 1986, PARASITE IMMUNOL, V8, P231, DOI 10.1111/j.1365-3024.1986.tb01035.x
   Nikolaeva D, 2015, EXPERT REV VACCINES, V14, P653, DOI 10.1586/14760584.2015.993383
   Ning J, 2013, GENE DEV, V27, P1198, DOI 10.1101/gad.212746.112
   Outchkourov NS, 2008, P NATL ACAD SCI USA, V105, P4301, DOI 10.1073/pnas.0800459105
   Palomares LA, 2018, ADV BIOCH ENG BIOTEC
   Pinello JF, 2017, CURR BIOL, V27, P651, DOI 10.1016/j.cub.2017.01.049
   Price RN, 2014, LANCET INFECT DIS, V14, P982, DOI 10.1016/S1473-3099(14)70855-2
   Rosenberg R, 2008, TRENDS PARASITOL, V24, P487, DOI 10.1016/j.pt.2008.07.009
   Sagara I, 2018, LANCET INFECT DIS, V18, P969, DOI 10.1016/S1473-3099(18)30344-X
   Sauerwein RW, 2015, VACCINE, V33, P7476, DOI 10.1016/j.vaccine.2015.08.073
   Steele RE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007680
   Tachibana M, 2015, VACCINE, V33, P1901, DOI 10.1016/j.vaccine.2015.03.008
   Tachibana M, 2012, VACCINE, V30, P1807, DOI 10.1016/j.vaccine.2012.01.003
   Tham WH, 2017, INT J PARASITOL, V47, P111, DOI 10.1016/j.ijpara.2016.09.006
   Valansi C, 2017, J CELL BIOL, V216, P571, DOI 10.1083/jcb.201610093
   von Besser K, 2006, DEVELOPMENT, V133, P4761, DOI 10.1242/dev.02683
   White NJ, 2012, ADV PARASIT, V80, P113, DOI 10.1016/B978-0-12-397900-1.00002-5
   Wong JL, 2010, TRENDS CELL BIOL, V20, P134, DOI 10.1016/j.tcb.2009.12.007
   Wu YM, 2015, ADV PARASIT, V89, P109, DOI 10.1016/bs.apar.2015.04.001
   Wu YM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002636
NR 60
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2841
EP 2848
DI 10.1016/j.vaccine.2020.02.011
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200016
PM 32093983
OA Other Gold
DA 2020-05-12
ER

PT J
AU Zhou, YG
   Lin, YF
   Meng, XJ
   Duan, QB
   Wang, ZY
   Yang, B
   Zheng, HP
   Li, PY
   Li, MJ
   Lu, Y
   Luo, ZZ
   Zou, HC
AF Zhou, Yiguo
   Lin, Yi-Fan
   Meng, Xiaojun
   Duan, Qibin
   Wang, Zhenyu
   Yang, Bin
   Zheng, Heping
   Li, Peiyang
   Li, Meijuan
   Lu, Yong
   Luo, Zhenzhou
   Zou, Huachun
TI Anal human papillomavirus among men who have sex with men in three
   metropolitan cities in southern China: implications for HPV vaccination
SO VACCINE
LA English
DT Article
DE Vaccination; Human papillomavirus; Human immunodeficiency virus; Men who
   have sex with men; Sexually transmitted infections
ID AGE-SPECIFIC PREVALENCE; HIV-INFECTED MEN; QUADRIVALENT VACCINE;
   RISK-FACTORS; LESIONS
AB Introduction: Men who have sex with men (MSM), especially those infected with human immunodeficiency virus (HIV), are at disproportionate risk for human papillomavirus (HPV) infection. Data about anal HPV prevalence among MSM in southern China are limited.
   Methods: MSM were recruited between January 1 and August 31, 2017 in three metropolitan cities: Guangzhou, Shenzhen and Wuxi. A self-completed tablet-based questionnaire was used to collect information about socio-demographic/sexual behavioral characteristics, history of sexually transmitted infections (STIs) and recreational drug use. An anal brush was used to collect exfoliated cells for HPV DNA testing and genotyping, and a blood sample was taken for HIV testing. Penile/anal warts were checked by a clinician.
   Results: A total of 536 MSM were enrolled, including 39 HIV-positive and 497 HIV-negative individuals. Compared with HIV-negative MSM, prevalence of any HPV genotype (79.5% vs 46.7%), any high-risk genotype (64.1% vs 36.6%) and any nonavalent vaccine-preventable genotype (53.9% vs 31.6%) was significantly higher in HIV-positive MSM, with all P < 0.01. HIV infection (adjusted odds ratio [AOR], 4.28; 95% confidence interval [CI], 1.87-9.80), using recreational drugs (AOR, 1.87; 95% CI, 1.22-2.87), having >= 3 years of sexual experience (AOR, 1.52; 95% CI, 1.01-2.28), having >= 6 lifetime male partners (AOR, 1.92; 95% CI, 1.29-2.86), and engaging receptive anal intercourse (AOR, 2.30; 95% CI, 1.48-3.57) were associated with higher anal HPV prevalence. Any HPV prevalence increased with age, from 24.5% at < 20 years to 55.8% at >= 40 years.
   Conclusions: Anal HPV prevalence was high among MSM in southern China, significantly associated with HIV status and sexual experience. HPV prevalence increased with age among MSM. A targeted HPV vaccination program for teenage MSM might be necessary. Our findings will inform targeted HPV modelling among MSM in China. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Zhou, Yiguo; Lin, Yi-Fan; Li, Meijuan; Zou, Huachun] Sun Yat Sen Univ, Sch Publ Hlth Shenzhen, Shenzhen, Peoples R China.
   [Lin, Yi-Fan] Univ Newcastle, Sch Math & Phys Sci Stat, Callaghan, NSW, Australia.
   [Meng, Xiaojun] Wuxi Municipal Ctr Dis Control & Prevent, Wuxi, Jiangsu, Peoples R China.
   [Duan, Qibin; Zou, Huachun] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Wang, Zhenyu; Li, Peiyang; Lu, Yong] Sun Yat Sen Univ, Sch Publ Hlth, Guangzhou, Peoples R China.
   [Yang, Bin; Zheng, Heping] Southern Med Univ, Dermatol Hosp, Guangzhou, Peoples R China.
   [Luo, Zhenzhou] Shenzhen Nanshan Ctr Chron Dis Control, Shenzhen, Peoples R China.
   [Zou, Huachun] Shanghai Jiao Tong Univ, Sch Publ Hlth, Sch Med, Shanghai, Peoples R China.
   [Lu, Yong] 74 Zhongshan 2nd Rd, Guangzhou 510085, Peoples R China.
   [Luo, Zhenzhou] 7 Huaming Rd, Shenzhen 518054, Peoples R China.
RP Lu, Y; Luo, ZZ; Zou, HC (reprint author), 74 Zhongshan 2nd Rd, Guangzhou 510085, Peoples R China.
EM luyong@mail2.sysu.edu.cn; paulluo9909@163.com;
   zouhuachun@mail.sysu.edu.cn
OI Duan, Qibin/0000-0003-0764-1380; Zhou, Yiguo/0000-0002-2172-4396
FU Natural Science Foundation of China Young Scientist Fund [81703278];
   Australian National Health and Medical Research Commission (NHMRC) Early
   Career FellowshipNational Health and Medical Research Council of
   Australia [APP1092621]; Precision Targeted Intervention Studies among
   High Risk Groups for HIV Prevention in China; National Science and
   Technology Major Project of China [2018ZX10721102]; Sanming Project of
   Medicine in Shenzhen [SZSM201811071]; Open Research Fund of State Key
   Laboratory of Molecular Vaccinology and Molecular Diagnosticsh
   [SKLVD2019KF001]
FX This study was supported by the Natural Science Foundation of China
   Young Scientist Fund (grant number 81703278), the Australian National
   Health and Medical Research Commission (NHMRC) Early Career Fellowship
   (grant number APP1092621), the Precision Targeted Intervention Studies
   among High Risk Groups for HIV Prevention in China, National Science and
   Technology Major Project of China (grant number 2018ZX10721102), the
   Sanming Project of Medicine in Shenzhen (grant number SZSM201811071) and
   the Open Research Fund of State Key Laboratory of Molecular Vaccinology
   and Molecular Diagnosticsh (grant number SKLVD2019KF001). All funding
   parties did not have any role in the design of the study or in the
   explanation of the data.
CR [Anonymous], 2017, Wkly Epidemiol Rec, V92, P241
   Brown DR, 1999, J CLIN MICROBIOL, V37, P3316, DOI 10.1128/JCM.37.10.3316-3322.1999
   Chin-Hong PV, 2004, J INFECT DIS, V190, P2070, DOI 10.1086/425906
   Combes JD, 2018, J INFECT DIS, V217, P1535, DOI 10.1093/infdis/jiy059
   de Martel C, 2017, INT J CANCER, V141, P664, DOI 10.1002/ijc.30716
   De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002/ijc.24116
   Dona MG, 2014, FUTURE MICROBIOL, V9, P837, DOI [10.2217/fmb.14.44, 10.2217/FMB.14.44]
   Garland SM, 2007, NEW ENGL J MED, V356, P1928, DOI 10.1056/NEJMoa061760
   Garland SM, 2009, J INFECT DIS, V199, P805, DOI 10.1086/597071
   Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537
   Goldstone S, 2011, J INFECT DIS, V203, P66, DOI 10.1093/infdis/jiq016
   Gonzalez C, 2013, INT J CANCER, V133, P1164, DOI 10.1002/ijc.28102
   HAN XX, 2017, BIOMED RES INT, V2017, DOI DOI 10.1155/2017/9405204
   Hu YF, 2013, JAIDS-J ACQ IMM DEF, V64, P103, DOI 10.1097/QAI.0b013e31829b6298
   Kim JJ, 2010, LANCET INFECT DIS, V10, P845, DOI 10.1016/S1473-3099(10)70219-X
   Koutsky Laura, 1997, American Journal of Medicine, V102, P3
   Li Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125120
   Lin A, 2017, CLIN INFECT DIS, V64, P580, DOI 10.1093/cid/ciw845
   Lin W, 2019, TROP MED INT HEALTH, V24, P1054, DOI 10.1111/tmi.13283
   Liu X, 2019, EPIDEMIOL INFECT, V147, DOI [10.1017/S0950268818003205, 10.1017/s0950268818003205]
   Ma XM, 2018, SEX TRANSM INFECT, V94, P434, DOI 10.1136/sextrans-2017-053412
   Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3
   Marra E, 2019, J INFECT DIS, V219, P590, DOI 10.1093/infdis/jiy556
   Nyitray AG, 2011, J INFECT DIS, V203, P49, DOI 10.1093/infdis/jiq021
   Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971
   Sakamoto J, 2019, INT J INFECT DIS, V78, P148, DOI 10.1016/j.ijid.2018.11.003
   Tian T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187928
   Torres M, 2013, J CLIN MICROBIOL, V51, P3512, DOI 10.1128/JCM.01405-13
   Vajdic CM, 2009, SEX TRANSM INFECT, V85, P330, DOI 10.1136/sti.2008.034744
   Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741
   Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F
   Welton Mark Lane, 2004, Surg Oncol Clin N Am, V13, P263, DOI 10.1016/j.soc.2003.12.005
   Wu XC, 2016, SCI REP-UK, V6, DOI 10.1038/srep19000
   [许娟 Xu Juan], 2010, [中华预防医学杂志, Chinese Journal of Preventive Medicine], V44, P975
   Zhang DZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100793
   Zhang L, 2017, VACCINE, V35, P4923, DOI 10.1016/j.vaccine.2017.07.078
   Zou HC, 2014, J INFECT DIS, V209, P642, DOI 10.1093/infdis/jit626
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2849
EP 2858
DI 10.1016/j.vaccine.2020.02.009
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200017
PM 32088017
DA 2020-05-12
ER

PT J
AU Lockyer, K
   Gao, F
   Francis, RJ
   Eastwood, D
   Khatri, B
   Stebbings, R
   Derrick, JP
   Bolgiano, B
AF Lockyer, Kay
   Gao, Fang
   Francis, Robert J.
   Eastwood, David
   Khatri, Bhagwati
   Stebbings, Richard
   Derrick, Jeremy P.
   Bolgiano, Barbara
TI Higher mass meningococcal group C-tetanus toxoid vaccines conjugated
   with carbodiimide correlate with greater immunogenicity
SO VACCINE
LA English
DT Article
DE Chromatography; Conjugate vaccine; Fluorescence quenching; Light
   scattering; Tetanus toxoid; Spectroscopy
ID INFLUENZAE TYPE-B; ADIPIC ACID DIHYDRAZIDE; THERMAL-STABILITY;
   CHAIN-LENGTH; POLYSACCHARIDE; CARRIER; SIZE; DISEASE; ENGLAND; ADULTS
AB To examine the link between meningococcal C (MenC) vaccine size and immunogenic response, a panel of MenC glycoconjugate vaccines were prepared differing in chain length, molar mass and hydrodynamic volume. The preparations consisted of different lengths of MenC polysaccharide (PS) covalently linked to monomeric purified tetanus toxoid (TT) carrier protein using the coupling reagent ethylcarbodiimide hydrochloride (EDC). Size exclusion chromatography with multi-angle light scattering (SEC-MALS) and viscometry analysis confirmed that the panel of MenC-TT conjugates spanned masses of 191,500 to 2,348,000 g/mol, and hydrodynamic radii ranging from 12.1 to 47.9 nm. The two largest conjugates were elliptical in shape, whereas the two smallest conjugates were more spherical. The larger conjugates appeared to fit a model described by multiple TTs with cross-linked PS, typical of lattice-like networks described previously for TT conjugates, while the smaller conjugates were found to fit a monomeric or dimeric TT configuration. The effect of vaccine conjugate size on immune responses was determined using a two-dose murine immunization. The two larger panel vaccine conjugates produced higher anti-MenC IgG1 and IgG2b titres after the second dose. Larger vaccine conjugate size also stimulated greater T-cell proliferative responses in an in vitro recall assay, although cytokines indicative of a T-helper response were not measurable. In conclusion, larger MenC-TT conjugates up to 2,348,000 g/mol produced by EDC chemistry correlate with greater humoral and cellular murine immune responses. These observations suggest that conjugate size can be an important modulator of immune response. Crown Copyright (C) 2020 Published by Elsevier Ltd.
C1 [Lockyer, Kay; Gao, Fang; Khatri, Bhagwati; Bolgiano, Barbara] NIBSC, Div Bacteriol, Blanche Lane, South Mimms EN6 3QG, Herts, England.
   [Francis, Robert J.] NIBSC, Div Analyt Biol Serv, Blanche Lane, South Mimms EN6 3QG, Herts, England.
   [Eastwood, David; Stebbings, Richard] NIBSC, Div Biotherapeut, Blanche Lane, Potters Bar EN6 3QG, Herts, England.
   [Derrick, Jeremy P.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat,Sch Biol Sc, Oxford Rd, Manchester, Lancs, England.
RP Lockyer, K (reprint author), NIBSC, Div Bacteriol, Blanche Lane, Potters Bar EN6 3QG, Herts, England.
EM Kay.Lockyer@nibsc.org
CR Abdelhameed AS, 2016, SCI REP-UK, V6, DOI 10.1038/srep35588
   Abdelhameed AS, 2012, CARBOHYD POLYM, V90, P1831, DOI 10.1016/j.carbpol.2012.07.032
   ANDERSON PW, 1989, J IMMUNOL, V142, P2464
   ANDERSON PW, 1986, J IMMUNOL, V137, P1181
   Arcuri M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189100
   Bastos RC, 2018, GLYCOCONJUGATE J, V35, P3, DOI 10.1007/s10719-017-9787-2
   Beresford NJ, 2017, VACCINE, V35, P3598, DOI 10.1016/j.vaccine.2017.03.066
   Berti F., 2018, CARBOHYDRATE BASED V, DOI [10.1021/bk-2018-1290.ch006, DOI 10.1021/BK-2018-1290.CH006]
   Carmenate T, 2004, FEMS IMMUNOL MED MIC, V40, P193, DOI 10.1016/S0928-8244(03)00346-8
   Costantino P, 1999, VACCINE, V17, P1251, DOI 10.1016/S0264-410X(98)00348-X
   COSTANTINO P, 1992, VACCINE, V10, P691, DOI 10.1016/0264-410X(92)90091-W
   Cuello M, 2007, VACCINE, V25, P1798, DOI 10.1016/j.vaccine.2006.11.029
   Daum RS, 1997, J INFECT DIS, V176, P445, DOI 10.1086/514063
   FATTOM A, 1992, INFECT IMMUN, V60, P584, DOI 10.1128/IAI.60.2.584-589.1992
   Gray SJ, 2006, J MED MICROBIOL, V55, P887, DOI 10.1099/jmm.0.46288-0
   Hennessey Jr J.P., 2018, ACS S SERIES
   Hitri K, 2019, VACCINE, V37, P3866, DOI 10.1016/j.vaccine.2019.05.050
   Ho MM, 2002, VACCINE, V20, P3509, DOI 10.1016/S0264-410X(02)00342-0
   HORAN PK, 1989, NATURE, V340, P167, DOI 10.1038/340167a0
   Jin ZG, 2003, INFECT IMMUN, V71, P5115, DOI 10.1128/IAI.71.9.5115-5120.2003
   Jumel K, 2002, BIOTECHNOL APPL BIOC, V36, P219, DOI 10.1042/BA20020066
   Kossaczka Z, 1997, INFECT IMMUN, V65, P2088, DOI 10.1128/IAI.65.6.2088-2093.1997
   Ladhani SN, 2012, VACCINE, V30, P3710, DOI 10.1016/j.vaccine.2012.03.011
   Laferriere CA, 1997, VACCINE, V15, P179, DOI 10.1016/S0264-410X(96)00148-X
   Laferriere C, 2011, GLYCOCONJUGATE J, V28, P463, DOI 10.1007/s10719-011-9344-3
   LaForce FM, 2007, VACCINE, V25, pA97, DOI 10.1016/j.vaccine.2007.04.049
   Lai ZZ, 2009, VACCINE, V27, P3137, DOI 10.1016/j.vaccine.2009.03.064
   Lockyer K, 2011, THESIS
   Lockyer K, 2015, VACCINE, V33, P1345, DOI 10.1016/j.vaccine.2015.01.046
   MANZI AE, 1994, J BIOL CHEM, V269, P23617
   Michon F, 2006, CLIN VACCINE IMMUNOL, V13, P936, DOI 10.1128/CVI.00122-06
   Micoli F, 2011, VACCINE, V29, P712, DOI 10.1016/j.vaccine.2010.11.022
   Oh DJ, 1999, CYTOMETRY, V36, P312, DOI 10.1002/(SICI)1097-0320(19990801)36:4<312::AID-CYTO5>3.0.CO;2-V
   Parish CR, 1999, IMMUNOL CELL BIOL, V77, P499, DOI 10.1046/j.1440-1711.1999.00877.x
   PEETERS CCAM, 1991, J IMMUNOL, V146, P4308
   Qazi O, 2007, J MOL BIOL, V365, P123, DOI 10.1016/j.jmb.2006.09.050
   Rana R, 2015, VACCINE, V33, P2646, DOI 10.1016/j.vaccine.2015.04.031
   Rappuoli R, 2019, P NATL ACAD SCI USA, V116, P14, DOI 10.1073/pnas.1819612116
   Saydam M, 2010, VACCINE, V28, P6228, DOI 10.1016/j.vaccine.2010.07.005
   Soininen A, 1999, VACCINE, V17, P1889, DOI 10.1016/S0264-410X(98)00475-7
   Sun XM, 2019, P NATL ACAD SCI USA, V116, P193, DOI 10.1073/pnas.1816401115
   Tiffay K, 2015, CLIN INFECT DIS, V61, pS396, DOI 10.1093/cid/civ594
   Tontini M., 2012, THESIS
   TSUNASHIMA Y, 1978, BIOPOLYMERS, V17, P251, DOI 10.1002/bip.1978.360170202
   Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520
   Vipond C, 2012, BIOLOGICALS, V40, P353, DOI 10.1016/j.biologicals.2012.03.003
   Wessels MR, 1998, INFECT IMMUN, V66, P2186, DOI 10.1128/IAI.66.5.2186-2192.1998
   World Health Organization, 2004, WHO TECHN REP SER, V924
   Zhang Y, 1997, ANAL BIOCHEM, V250, P245, DOI 10.1006/abio.1997.2225
NR 49
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2859
EP 2869
DI 10.1016/j.vaccine.2020.02.012
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200018
PM 32089463
OA Other Gold
DA 2020-05-12
ER

PT J
AU Church, JA
   Chasekwa, B
   Rukobo, S
   Govha, M
   Lee, B
   Carmolli, MP
   Ntozini, R
   Mutasa, K
   McNeal, MM
   Majo, FD
   Tavengwa, NV
   Kirkpatrick, BD
   Moulton, LH
   Humphrey, JH
   Prendergast, AJ
AF Church, James A.
   Chasekwa, Bernard
   Rukobo, Sandra
   Govha, Margaret
   Lee, Benjamin
   Carmolli, Marya P.
   Ntozini, Robert
   Mutasa, Kuda
   McNeal, Monica M.
   Majo, Florence D.
   Tavengwa, Naume, V
   Kirkpatrick, Beth D.
   Moulton, Lawrence H.
   Humphrey, Jean H.
   Prendergast, Andrew J.
TI Predictors of oral rotavirus vaccine immunogenicity in rural Zimbabwean
   infants
SO VACCINE
LA English
DT Article
DE Infants; Africa; Rotavirus; Oral vaccine; Immunogenicity
ID POLIOVIRUS VACCINE; IMPROVED WATER; EFFICACY; TRIAL; SANITATION;
   DIARRHEA; HYGIENE; IMPACT; SAFETY; RISK
AB Background: Oral rotavirus vaccines (RVV) have poor immunogenicity in low-income countries, for reasons that remain unclear. This study identified the determinants of RVV immunogenicity among infants in rural Zimbabwe.
   Methods: Anti-rotavirus IgA titres were measured among a sub-group of infants enrolled in the Sanitation Hygiene Infant Nutrition Efficacy (SHINE) trial (NCT01824940). SHINE was a cluster-randomized trial of improved infant and young child feeding, and improved water, sanitation and hygiene (WASH) in two rural Zimbabwean districts. Infants received RVV as part of the national immunisation programme. Among HIV-unexposed infants in the non-WASH trial arms, we evaluated associations between potential risk factors (vaccine schedule and dose, maternal and infant nutritional status, infant diarrhoea, and household environment) and RVV immunogenicity (seroconversion, seropositivity and geometric mean titres) using multivariable regression.
   Results: Among 219 infants with seroconversion data, 43 (20%) successfully seroconverted and 176 (80%) failed to seroconvert to RVV. Seroconversion was positively associated with a higher length-for-age Z-score (LAZ) around the time of vaccination (adjusted RR 1.27 (95% CI 1.04, 1.55), P = 0.021), and negatively associated with concurrent OPV and RVV administration (adjusted RR 0.36 (0.19, 0.71), P = 0.003). Among 472 infants with post-vaccination titres, a higher LAZ score was associated with increased seropositivity (aRR 1.21 (95% CI 1.06, 1.38), P = 0.004), and higher birthweight was associated with increased IgA titres (0.45 (95%CI 0.18, 1.09) U/mL greater per 100 g gain in birthweight; P = 0.001).
   Conclusions: Infant ponderal and linear growth were positively associated with RVV immunogenicity, while concurrent administration of OPV was negatively associated with RVV immunogenicity. Together, these findings suggest that improving foetal growth and separating RVV and OPV administration are plausible approaches to increasing RVV immunogenicity. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Church, James A.; Chasekwa, Bernard; Rukobo, Sandra; Govha, Margaret; Ntozini, Robert; Mutasa, Kuda; Majo, Florence D.; Tavengwa, Naume, V; Humphrey, Jean H.; Prendergast, Andrew J.] Zvitambo Inst Maternal & Child Hlth Res, Harare, Zimbabwe.
   [Church, James A.; Prendergast, Andrew J.] Queen Mary Univ London, Ctr Genom & Child Hlth, Blizard Inst, London, England.
   [Lee, Benjamin] Univ Vermont, Larner Coll Med, Vaccine Testing Ctr, Dept Pediat, Burlington, VT USA.
   [Carmolli, Marya P.; Kirkpatrick, Beth D.] Univ Vermont, Dept Microbiol & Mol Genet, Vaccine Testing Ctr, Lamer Coll Med, Burlington, VT 05405 USA.
   [McNeal, Monica M.] Univ Cincinnati, Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Coll Med,Div Infect Dis, Cincinnati, OH USA.
   [Moulton, Lawrence H.; Humphrey, Jean H.; Prendergast, Andrew J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
RP Church, JA; Prendergast, AJ (reprint author), Queen Mary Univ London, Ctr Genom & Child Hlth, 4 Newark St, London E1 2AT, England.
EM j.church@qmul.ac.uk; a.prendergast@qmul.ac.uk
OI Lee, Benjamin/0000-0001-7213-5631
FU Wellcome TrustWellcome Trust [203905/Z/16/Z, 093768/Z/10/Z,
   108065/Z/15/Z]; Bill and Melinda Gates FoundationGates Foundation
   [OPP1021542, OPP113707]; UK Department for International Development (UK
   Aid); Swiss Agency for Development and Cooperation; US National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [2R01HD060338-06]
FX This work was supported by the Wellcome Trust [203905/Z/16/Z to JAC and
   093768/Z/10/Z and 108065/Z/15/Z to AJP]. The SHINE trial was funded by
   the Bill and Melinda Gates Foundation [OPP1021542 and OPP113707]; UK
   Department for International Development (UK Aid); Swiss Agency for
   Development and Cooperation and US National Institutes of Health
   [2R01HD060338-06]. The study funders approved the trial design, but were
   not involved in data collection, analysis, interpretation, or manuscript
   preparation. The corresponding author had full access to the data and
   took the decision to submit for publication.
CR Adair LS, 2013, LANCET, V382, P525, DOI 10.1016/S0140-6736(13)60103-8
   Angel J, 2014, HUM VACC IMMUNOTHER, V10, P3659, DOI 10.4161/hv.34361
   Armah GE, 2019, J INFECT DIS, V219, P746, DOI 10.1093/infdis/jiy573
   Bernstein DI, 1998, VACCINE, V16, P381, DOI 10.1016/S0264-410X(97)00210-7
   Chasekwa B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199393
   Church JA, 2018, LANCET INFECT DIS
   Church JA, 2019, CLIN INFECT DIS
   Church JA, 2019, PEDIATR INFECT DIS J, V38, P1242, DOI 10.1097/INF.0000000000002485
   Church JA, 2018, FUTURE MICROBIOL, V13, P1055, DOI 10.2217/fmb-2018-0016
   Colgate ER, 2016, CLIN INFECT DIS, V63, P634, DOI 10.1093/cid/ciw346
   Fung CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146542
   Furman D, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.15
   GIAMMANCO G, 1988, EUR J EPIDEMIOL, V4, P121, DOI 10.1007/BF00152704
   Glass RI, 2006, LANCET, V368, P323, DOI 10.1016/S0140-6736(06)68815-6
   Gruber JF, 2017, PEDIATR INFECT DIS J, V36, P72, DOI 10.1097/INF.0000000000001362
   Haque R, 2014, VACCINE, V32, P478, DOI 10.1016/j.vaccine.2013.11.056
   Harris VC, 2017, J INFECT DIS, V215, P34, DOI 10.1093/infdis/jiw518
   Humphrey JH, 2019, LANCET GLOB HEALTH, V7, pE132, DOI 10.1016/S2214-109X(18)30374-7
   Humphrey JH, 2015, CLIN INFECT DIS, V61, pS685, DOI 10.1093/cid/civ844
   Humphrey JH, 2018, LANCET GLOB HLTH
   Iliff PJ, 2005, AIDS, V19, P699, DOI 10.1097/01.aids.0000166093.16446.c9
   Kazi AM, 2017, J INFECT DIS, V215, P786, DOI 10.1093/infdis/jix028
   Khagayi S, 2019, CLIN INFECT DIS
   Koyanagi A, 2009, AM J CLIN NUTR, V89, P1375, DOI 10.3945/ajcn.2008.26810
   Lee B, 2018, J INFECT DIS, V217, P1399, DOI 10.1093/infdis/jiy054
   Lopman BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041720
   Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797
   MIGASENA S, 1995, VACCINE, V13, P168, DOI 10.1016/0264-410X(95)93131-R
   Moulton LH, 1998, J INFECT DIS, V178, P1562, DOI 10.1086/314504
   Mujuru HA, 2017, PEDIATR INFECT DIS J, V36, P995, DOI [10.1097/INF.0000000000001648, 10.1097/inf.0000000000001648]
   Mwila K, 2017, CLIN VACCINE IMMUNOL, P24
   Naylor C, 2015, EBIOMEDICINE, V2, P1759, DOI 10.1016/j.ebiom.2015.09.036
   Okala SG, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002854
   Pan WK, 2019, VACCINE, V37, P352, DOI 10.1016/j.vaccine.2018.05.080
   Parker EP, 2017, FUTURE MICROBIOL
   Patel M, 2013, J INFECT DIS, V208, P284, DOI 10.1093/infdis/jit166
   Perez-Schael I, 2007, J INFECT DIS, V196, P537, DOI 10.1086/519687
   Platts-Mills JA, 2015, LANCET GLOB HEALTH, V3, pE564, DOI 10.1016/S2214-109X(15)00151-5
   Pollock L, 2018, CLIN INFECT DIS
   Prendergast AJ, 2015, CLIN INFECT DIS, V61, pS726, DOI 10.1093/cid/civ848
   Ruiz-Palacios GM, 2006, NEW ENGL J MED, V354, P11, DOI 10.1056/NEJMoa052434
   Rytter MJH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105017
   Saleem AF, 2015, VACCINE, V33, P2757, DOI 10.1016/j.vaccine.2015.04.055
   Steele AD, 2010, VACCINE, V28, P6542, DOI 10.1016/j.vaccine.2008.08.034
   Taniuchi M, 2016, VACCINE, V34, P3068, DOI 10.1016/j.vaccine.2016.04.080
   Dinh TH, 2018, CLIN INFECT DIS, V66, P576, DOI 10.1093/cid/cix820
   Troeger C, 2017, LANCET INFECT DIS, V17, P909, DOI 10.1016/S1473-3099(17)30276-1
   Tsang JS, 2014, CELL, V157, P499, DOI 10.1016/j.cell.2014.03.031
   Vesikari T, 2006, NEW ENGL J MED, V354, P23, DOI 10.1056/NEJMoa052664
   VODOPIJA I, 1986, VACCINE, V4, P233, DOI 10.1016/0264-410X(86)90135-0
   Wang HP, 2012, VIRUS RES, V167, P48, DOI 10.1016/j.virusres.2012.04.001
   WARD RL, 1989, J INFECT DIS, V159, P79, DOI 10.1093/infdis/159.1.79
   Watson-Jones D, 2007, B WORLD HEALTH ORGAN, V85, P9, DOI 10.2471/BLT.06.033258
   World Health Organization (WHO), 2013, POL ER ENDG STRAT PL
NR 54
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2870
EP 2878
DI 10.1016/j.vaccine.2020.01.097
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200019
PM 32088018
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Koivumagi, K
   Toompere, K
   Soeorg, H
   Kallas, E
   Jogeda, EL
   Huik, K
   Lutsar, I
AF Koivumagi, Kadri
   Toompere, Karolin
   Soeorg, Hiie
   Kallas, Eveli
   Jogeda, Ene-Ly
   Huik, Kristi
   Lutsar, Irja
CA Rotavirus Study Grp
TI Acute gastroenteritis hospitalizations after implementation of universal
   mass vaccination against rotavirus
SO VACCINE
LA English
DT Article
DE Acute gastroenteritis; Rotavirus vaccine; Immunization program;
   Hospitalization; Severity score; Estonia
ID IMMUNIZATION PROGRAM; NOROVIRUS; IMPACT; CHILDREN; FINLAND
AB Background: Estonia implemented rotavirus universal mass vaccination (RV UMV) in July 2014. We aimed to describe changes in acute gastroenteritis (AGE) hospitalization during RV seasons before (2007-2013) and after (2015-2018) RV UMV and compare patient profile of hospitalized AGE patients aged 0-18 years during first two consecutive RV seasons 2015 vs 2016.
   Methods: We described AGE hospitalization patterns pre-and post-vaccine era using Estonian Health Insurance Fund (HIF) database. During a two-year observational multicenter study in seven Estonian hospitals from 01st of February 2015 to 30th August 2016 we assessed patient profile of all patients who met pre-determined AGE criteria.
   Results: In post-vaccine era AGE hospitalization rate decreased from 10 to 8 per 1000 population (RR 0.81, 95% CI 0.79-0.83) compared to pre-vaccine era. Decreased RV seasonal activity, 81% (95% CI 77-84) and 55% (95% CI 52-58) reduction of rotavirus gastroenteritis (RVGE) hospitalization among age groups <1 and 1-4, respectively and upsurge of norovirus gastroenteritis (NoVGE) hospitalizations (RR = 1.8; 95% CI 1.6-1.9) was seen. In the multicenter observational study, among 2249 AGE patients hospitalized median age of RVGE patients increased from 2 to 3 years (p < 0.01) and duration of hospital stay decreased among RVGE, NoVGE and other GE patients during two consecutive RV seasons. According to Vesikari Clinical Severity Scoring System statistically significant change of severity score distribution in two RV seasons was seen (p < 0.001) with trend towards less severe AGE hospitalizations; 82.5% vs 70.5% severe cases in 2015 vs 2016, respectively.
   Conclusion: RV UMV lead to immediate and sustainable reduction of hospitalizations due to RVGE in children aged <4 years and reduction of overall AGE accompanied with the decrease in the severity of hospitalized children. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Koivumagi, Kadri; Toompere, Karolin; Soeorg, Hiie; Kallas, Eveli; Jogeda, Ene-Ly; Huik, Kristi; Lutsar, Irja; Rotavirus Study Grp] Univ Tartu, Tartu, Estonia.
RP Koivumagi, K (reprint author), Univ Tartu, Tartu, Estonia.
FU Estonian Ministry of Education and ResearchMinistry of Education and
   Research, Estonia [IUT-34-24]
FX The work presented here was funded by the Basic Financing and the Target
   Financing of Estonian Ministry of Education and Research (IUT-34-24).
CR Baker JM, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3816-7
   Burke RM, 2019, CURR OPIN INFECT DIS, V32, P435, DOI 10.1097/QCO.0000000000000572
   *CONT ECFDP, 2013, EFF ROT VACC GEN STU
   de Hoog MLA, 2018, HUM VACC IMMUNOTHER, V14, P1027, DOI 10.1080/21645515.2017.1412019
   Hanquet G, 2011, VACCINE, V29, P4698, DOI 10.1016/j.vaccine.2011.04.098
   Heinsbroek E, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027739
   Hemming M, 2013, INFECT GENET EVOL, V19, P51, DOI 10.1016/j.meegid.2013.06.026
   Hemming M, 2013, EUR J PEDIATR, V172, P739, DOI 10.1007/s00431-013-1945-3
   Hemming-Harlo M, 2016, PEDIATR INFECT DIS J, V35, P1304, DOI 10.1097/INF.0000000000001305
   Hungerford DI-GM, 2019, EUROROTANET ANN REPO
   Huppertz HI, 2014, VACCINE, V32, P4243, DOI 10.1016/j.vaccine.2014.05.029
   Leino T, 2017, VACCINE, V35, P5611, DOI 10.1016/j.vaccine.2017.08.052
   Leino T, 2012, VACCINE, V31, P176, DOI 10.1016/j.vaccine.2012.10.068
   Leshem E, 2015, JAMA-J AM MED ASSOC, V313, P2282, DOI 10.1001/jama.2015.5571
   Leshem E, 2014, LANCET INFECT DIS, V14, P847, DOI 10.1016/S1473-3099(14)70832-1
   Liiv KTE, 2014, ROTAVIIRUSINFEKTSIOO
   Lo Vecchio A, 2017, VACCINE, V35, P1637, DOI 10.1016/j.vaccine.2017.01.082
   Lopman B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006671
   Parez N, 2014, LANCET INFECT DIS, V14, P416, DOI 10.1016/S1473-3099(14)70035-0
   Payne DC, 2013, NEW ENGL J MED, V368, P1121, DOI 10.1056/NEJMsa1206589
   Soeorg H, 2012, HUM VACC IMMUNOTHER, V8, P465, DOI 10.4161/hv.19135
   Terviseamet, 2019, NAKK HAIG
   Terviseamet, 2017, NAKK JA MM EEST 2016
   Terviseamet, 2016, NAKK JA IMM EEST 201
   Vesikari KL, 2011, CLIN SEVERITY SCORIN
   Vesikari T, 2015, PEDIATR INFECT DIS J, V34, P635, DOI 10.1097/INF.0000000000000683
   Vesikari T, 2013, PEDIATR INFECT DIS J, V32, P1365, DOI 10.1097/INF.0000000000000086
   Wang PL, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0699-2
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 17
PY 2020
VL 38
IS 13
BP 2879
EP 2886
DI 10.1016/j.vaccine.2020.01.098
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TF
UT WOS:000525317200020
PM 32067818
DA 2020-05-12
ER

PT J
AU Stepanek, L
   Nakladalova, M
   Borikova, A
   Horakova, D
   Stepanek, L
AF Stepanek, Ladislav
   Nakladalova, Marie
   Borikova, Alena
   Horakova, Dagmar
   Stepanek, Lubomir
TI Measles immunity in a Czech tertiary care hospital
SO VACCINE
LA English
DT Article
DE Measles; Seroprevalence of measles immunity; Tertiary care hospital;
   Hospital employees; Vaccination
AB Background: Given the increasing incidence of measles, the aim was to assess the seroprevalence of measles immunity among employees of a Czech tertiary care hospital and to assess their willingness to revaccination.
   Methods: 3027 hospital employees (2421 females, 606 males) underwent a serological analysis of their measles antibody levels with an option of revaccination in case of an insufficient level.
   Results: The median age of participants was 42 years. Seropositivity was noted in 54% of the participants, with the antibody values higher in the oldest study participants and with a decrease around the birth year 1968. Logistic regression analysis confirmed a significant relationship of seropositivity with age (odds ratio 0.97, p < 0.005). Out of the seronegative, 80.9% individuals got revaccinated.
   Conclusions: 46% of the participants did not reach a sufficient antibody level set by the assay's manufacturer. Although the routine vaccination system is well established it may be ineffective. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Stepanek, Ladislav; Nakladalova, Marie; Borikova, Alena] Palacky Univ Olomouc, Univ Hosp Olomouc, Dept Occupat Med, IP Pavlova 185-6, Olomouc 77900, Czech Republic.
   [Stepanek, Ladislav; Nakladalova, Marie; Borikova, Alena] Palacky Univ Olomouc, Fac Med & Dent, IP Pavlova 185-6, Olomouc 77900, Czech Republic.
   [Horakova, Dagmar] Palacky Univ Olomouc, Fac Med & Dent, Dept Publ Hlth, Hnevotinska 976-3, Olomouc 77515, Czech Republic.
   [Stepanek, Lubomir] Charles Univ Prague, Fac Med 1, Inst Biophys & Informat, Salmovska 1, Prague 12000 2, Czech Republic.
RP Stepanek, L (reprint author), Palacky Univ Olomouc, Univ Hosp Olomouc, Dept Occupat Med, IP Pavlova 185-6, Olomouc 77900, Czech Republic.; Stepanek, L (reprint author), Palacky Univ Olomouc, Fac Med & Dent, IP Pavlova 185-6, Olomouc 77900, Czech Republic.
EM ladislav.stepanek@fnol.cz; marie.nakladalova@fnol.cz;
   alena.borikova@fnol.cz; dagmar.horakova@upol.cz;
   Lubomir.Stepanek@lf1.cuni.cz
FU University Hospital Olomouc Fund [RVO 00098892]; Palacky' University
   Fund [RVO 61989592]
FX The study was supported by the University Hospital Olomouc Fund (RVO
   00098892) and the Palacky ' University Fund (RVO 61989592).
CR Coppeta L, 2019, OCCUP MED-OXFORD, V69, P143, DOI 10.1093/occmed/kqy132
   Coppeta L, 2019, HUM VACC IMMUNOTHER, V15, P2847, DOI 10.1080/21645515.2019.1616505
   Georgakopoulou T, 2018, EPIDEMIOL INFECT, V146, P1692, DOI [10.1017/s0950268818002170, 10.1017/S0950268818002170]
   Giri P, 2013, OCCUP MED-OXFORD, V63, P422, DOI 10.1093/occmed/kqt086
   Griffin DE, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8100282
   Hughes SL, 2020, VACCINE, V38, P460, DOI 10.1016/j.vaccine.2019.10.090
   Jung J, 2019, INFECT CHEMOTHER, V51, P58, DOI 10.3947/ic.2019.51.1.58
   Liu CP, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4139-4
   Maltezou HC, 2020, VACCINE, V38, P1181, DOI 10.1016/j.vaccine.2019.11.021
   Smetana J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170257
   World Health Organization, 2019, NEW MEASL SURV DAT W
   Zibolenova J, 2017, CENT EUR J PUBL HEAL, V25, P46, DOI 10.21101/cejph.a4914
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2889
EP 2892
DI 10.1016/j.vaccine.2020.02.067
PG 4
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400001
PM 32127226
DA 2020-05-12
ER

PT J
AU Kalligeros, M
   Shehadeh, F
   Mylona, EK
   Dapaah-Afriyie, C
   van Aalst, R
   Chit, A
   Mylonakis, E
AF Kalligeros, Markos
   Shehadeh, Fadi
   Mylona, Evangelia K.
   Dapaah-Afriyie, Christine
   van Aalst, Robertus
   Chit, Ayman
   Mylonakis, Eleftherios
TI Influenza vaccine effectiveness against influenza-associated
   hospitalization in children: A systematic review and meta-analysis
SO VACCINE
LA English
DT Review
DE Influenza; Vaccine effectiveness; Pediatric hospitalization; Children;
   Systematic review; Meta-analysis
ID LABORATORY-CONFIRMED INFLUENZA; TEST-NEGATIVE DESIGN; HONG-KONG;
   PREVENTING HOSPITALIZATION; ILLNESS; SEASONS; ADULTS; AGE; PROTECTION
AB Vaccination remains the most effective way to prevent influenza infection, albeit vaccine effectiveness (VE) varies by year. Compared to other age groups, children and elderly adults have the highest risk of developing influenza-related complications and requiring hospitalization. During the last years, "test negative design" (TND) studies have been implemented in order to estimate influenza VE. The aim of this systematic review and meta-analysis was to summarize the findings of TND studies reporting influenza VE against laboratory-confirmed influenza-related hospitalization in children aged 6 months to 17 years. We searched the PubMed and Embase databases and identified 2615 non-duplicate studies that required detailed review. Among them, 28 met our inclusion criteria and we performed a random-effects meta-analysis using adjusted VE estimates. In our primary analysis, influenza vaccine offered significant protection against any type influenza-related hospitalization (57.48%; 95% CI 49.46-65.49). When we examined influenza VE per type and strain, VE was higher against H1N1 (74.07%; 95% CI: 54.85-93.30) and influenza B (50.87%; 95% CI: 41.75-59.98), and moderate against H3N2 (40.77%; 95% CI: 25.65-55.89). Notably, influenza vaccination offered higher protection in children who were fully vaccinated (61.79%; 95% CI: 54.45-69.13), compared to those who were partially vaccinated (33.91%; 95% CI: 21.12 - 46.69). Also, influenza VE was high in children less than 5 years old (61.71%; 95% CI: 49.29-74.12) as well as in children 6-17 years old (54.37%; 95% CI: 35.14-73.60). In conclusion, in the pediatric population, influenza vaccination offered significant protection against influenza-related hospitalization and complete annual vaccination should be encouraged. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kalligeros, Markos; Shehadeh, Fadi; Mylona, Evangelia K.; Dapaah-Afriyie, Christine; Mylonakis, Eleftherios] Brown Univ, Infect Dis Div, Warren Alpert Med Sch, Providence, RI 02903 USA.
   [van Aalst, Robertus; Chit, Ayman] Sanofi Pasteur, Vaccine Epidemiol & Modelling, Swiftwater, PA USA.
   [van Aalst, Robertus] Univ Groningen, Univ Med Ctr Groningen, Dept Hlth Sci, Groningen, Netherlands.
   [Chit, Ayman] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada.
RP Mylonakis, E (reprint author), Brown Univ, Warren Alpert Med Sch, Rhode Isl Hosp, Infect Dis, 593 Eddy St,3rd Floor,Suite 328-330, Providence, RI 02903 USA.; Mylonakis, E (reprint author), Brown Univ, Warren Alpert Med Sch, Rhode Isl Hosp, Infect Dis Div, 593 Eddy St,3rd Floor,Suite 328-330, Providence, RI 02903 USA.
EM emylonakis@lifespan.org
RI van Aalst, Robertus/F-8207-2016
OI van Aalst, Robertus/0000-0003-3025-7811
CR Arriola C, 2017, CLIN INFECT DIS, V65, P1289, DOI 10.1093/cid/cix468
   Baselga-Moreno V, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6713-5
   Belongia EA, 2019, CLIN INFECT DIS, V69, P1817, DOI 10.1093/cid/ciz411
   Belongia EA, 2016, LANCET INFECT DIS, V16, P942, DOI 10.1016/S1473-3099(16)00129-8
   Belongia EA, 2015, VACCINE, V33, P246, DOI 10.1016/j.vaccine.2014.06.052
   Blyth CC, 2014, EUROSURVEILLANCE, V2016, P21, DOI DOI 10.2807/1560-7917
   Blyth CC, 2019, CLIN INFECT DIS, V68, P940, DOI 10.1093/cid/ciy597
   Blyth CC, 2016, PEDIATR INFECT DIS J, V35, P309, DOI 10.1097/INF.0000000000000999
   Blyth CC, 2015, VACCINE, V33, P7239, DOI 10.1016/j.vaccine.2015.10.122
   Boddington NL, 2019, EPIDEMIOL INFECT, V147, DOI [10.1017/S0950268819000876, 10.1017/s0950268819000876]
   Buchan SA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187834
   Chi CY, 2008, PEDIATR INFECT DIS J, V27, P640, DOI 10.1097/INF.0b013e31816be008
   Chiu SS, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.5.1900056
   Chiu SS, 2018, J INFECT DIS, V217, P1365, DOI 10.1093/infdis/jiy027
   Chiu SS, 2018, EUROSURVEILLANCE, V23, P2, DOI 10.2807/1560-7917.ES.2018.23.8.18
   Chiu SS, 2016, VACCINE, V34, P2164, DOI 10.1016/j.vaccine.2016.03.032
   Chiu SS, 2009, CLIN INFECT DIS, V49, P1016, DOI 10.1086/605570
   Chua HY, 2019, J INFECT DIS, V220, P1568, DOI 10.1093/infdis/jiz361
   Chung JR, 2019, PEDIATRICS, V143, DOI 10.1542/peds.2018-2094
   Cowling BJ, 2017, INFLUENZA OTHER RESP, V11, P61, DOI 10.1111/irv.12399
   Cowling BJ, 2014, VACCINE, V32, P5278, DOI 10.1016/j.vaccine.2014.07.084
   Tran D, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-4643
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Eisenberg KW, 2008, PEDIATRICS, V122, P911, DOI 10.1542/peds.2007-3304
   Feng S, 2016, VACCINE, V34, P1672, DOI 10.1016/j.vaccine.2016.02.039
   Foppa IM, 2016, INT J EPIDEMIOL, V45, P2052, DOI 10.1093/ije/dyw022
   Gavigan P, 2019, CURR OPIN PEDIATR, V31, P112, DOI 10.1097/MOP.0000000000000712
   Grohskopf LA, 2019, MMWR RECOMM REP, V68, P1, DOI 10.15585/mmwr.rr6803a1
   Harvala H, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.37.20903
   Higgins JP, 2011, COCHRANE COLLABORATI, DOI DOI 10.1002/9780470712184
   Jackson ML, 2013, VACCINE, V31, P2165, DOI 10.1016/j.vaccine.2013.02.053
   Lee BY, 2012, EXPERT REV ANTI-INFE, V10, P1139, DOI [10.1586/ERI.12.106, 10.1586/eri.12.106]
   Menniti-Ippolito F, 2014, VACCINE, V32, P4466, DOI 10.1016/j.vaccine.2014.06.048
   Norio Sugaya, 2016, EURO SURVEILL, V21
   Nyaga VN, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-39
   Pebody RG, 2020, VACCINE, V38, P158, DOI 10.1016/j.vaccine.2019.10.035
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Petrie JG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075339
   Pierse N, 2016, VACCINE, V34, P503, DOI 10.1016/j.vaccine.2015.11.073
   Poehling KA, 2010, PEDIATRICS, V126, P665, DOI 10.1542/peds.2009-2620
   Puig-Barbera J, 2017, VACCINE, V35, P5799, DOI 10.1016/j.vaccine.2017.09.035
   Qin Y, 2016, VACCINE, V34, P2329, DOI 10.1016/j.vaccine.2016.03.068
   Ritzwoller DP, 2005, PEDIATRICS, V116, P153, DOI 10.1542/peds.2005-0049
   Rondy M, 2017, J INFECTION, V75, P381, DOI 10.1016/j.jinf.2017.09.010
   Segaloff HE, 2019, CLIN INFECT DIS, V69, P2153, DOI 10.1093/cid/ciz125
   Shinjoh M, 2018, VACCINE, V36, P5510, DOI 10.1016/j.vaccine.2018.07.065
   Shinjoh M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136539
   Shuler CM, 2007, PEDIATRICS, V119, pE587, DOI 10.1542/peds.2006-1878
   Skowronski D. M., 2005, Canada Communicable Disease Report, V31, P181
   Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153
   Sofia Arriola C, 2019, VACCINE, V3
   Staat MA, 2011, VACCINE, V29, P9005, DOI 10.1016/j.vaccine.2011.09.037
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Sugaya N, 2018, VACCINE, V36, P1063, DOI 10.1016/j.vaccine.2018.01.024
   Sullivan SG, 2016, AM J EPIDEMIOL, V184, P345, DOI 10.1093/aje/kww064
   Sullivan SG, 2014, EXPERT REV VACCINES, V13, P1571, DOI 10.1586/14760584.2014.966695
   Tricco AC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-153
   Turner N, 2014, EUROSURVEILLANCE, V19, P19, DOI 10.2807/1560-7917.ES2014.19.42.20934
   Uyeki TM, 2014, NEW ENGL J MED, V370, P789, DOI 10.1056/NEJMp1400034
   Vesikari T, 2019, INT J INFECT DIS IJI
   Wells GA, NEWCASTLE OTTAWA SCA
   Westreich D, 2016, AM J EPIDEMIOL, V184, P354, DOI 10.1093/aje/kww063
   XU XY, 1994, J INFECT DIS, V170, P1432, DOI 10.1093/infdis/170.6.1432
   Yeung KHT, 2018, VACCINE, V36, P3477, DOI 10.1016/j.vaccine.2018.04.081
   Zhai YS, 2017, AM J PREV MED, V52, pE103, DOI 10.1016/j.amepre.2016.10.040
   Zhang Y, 2017, VACCINE, V35, P3129, DOI 10.1016/j.vaccine.2017.03.084
   Zhao B, 2015, CLIN MICROBIOL INFEC, V21, P694, DOI 10.1016/j.cmi.2015.03.009
NR 67
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2893
EP 2903
DI 10.1016/j.vaccine.2020.02.049
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400002
PM 32113808
DA 2020-05-12
ER

PT J
AU Song, YM
   Yang, YL
   Lin, X
   Li, XN
   Zhang, X
   Ma, GH
   Su, ZG
   Zhang, SP
AF Song, Yanmin
   Yang, Yanli
   Lin, Xuan
   Li, Xiunan
   Zhang, Xuan
   Ma, Guanghui
   Su, Zhiguo
   Zhang, Songping
TI In-situ and sensitive stability study of emulsion and aluminum
   adjuvanted inactivated foot-and-mouth disease virus vaccine by
   differential scanning fluorimetry analysis
SO VACCINE
LA English
DT Article
DE DSF; In-situ; Adjuvant; iFMDV; Stability; High throughput
ID SIZE-EXCLUSION HPLC; B SURFACE-ANTIGEN; QUALITY-CONTROL; ADSORPTION;
   IMMUNOGENICITY; FORMULATION; PARTICLES; THERMOSTABILITY; STABILIZATION;
   DENATURATION
AB Adjuvants are important to enhance the antigens immunogenicity, but may also alter the structures of antigens. Currently off-line methods for adjuvants induced antigen alteration suffer from incomplete release and possible structural alteration of antigens. Here we investigated the differential scanning fluorimetry (DSF) as an in-situ and high-throughput strategy to analyze the stability of inactivated foot-and- mouth disease virus (iFMDV), known as 146S, in three representative adjuvants including aluminum hydroxide (AH), oil-in-water (O/W) emulsion, and water-in-oil (W/O) emulsion. Under optimized DSF conditions, the T-m referring to 146S dissociation can be detected in all three adjuvants. Using SYBR Green II as fluorescent dye enables detection of iFMDV as low as 5 mu g/mL. By comparing the T-m in different pH, three adjuvants showed different effects on 146S. Screening for excipients was successfully conducted using DSF. Sugars and glycerol increased the T-m of iFMDV in all three adjuvants, but to different degree. The stabilization by 20% (w/v) sucrose and glycerol was further verified by differential scanning calorimetry (DSC) and high performance size exclusion chromatography (HPSEC). DSF is proved also applicative for low-purity iFMDV and pre-adjuvanted iFMDV vaccines. In summary, the DSF can be a powerful tool in formulation study and vaccine quality control for inactivated virus vaccines. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Song, Yanmin; Yang, Yanli; Lin, Xuan; Li, Xiunan; Zhang, Xuan; Ma, Guanghui; Su, Zhiguo; Zhang, Songping] Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China.
   [Song, Yanmin; Lin, Xuan] Univ Chinese Acad Sci, Sch Chem Engn, Beijing 100049, Peoples R China.
RP Su, ZG; Zhang, SP (reprint author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Biochem Engn, Beijing 100190, Peoples R China.
EM zgsu@ipe.ac.cn; spzhang@ipe.ac.cn
FU National Natural Sciences Foundation of ChinaNational Natural Science
   Foundation of China [21808226, 21821005, 31970872]
FX Financial supports from the National Natural Sciences Foundation of
   China (Nos., 21808226, 21821005, 31970872) are acknowledged.
CR Ablinger E, 2013, INT J PHARMACEUT, V441, P255, DOI 10.1016/j.ijpharm.2012.11.035
   Ausar SF, 2011, J PHARM SCI-US, V100, P431, DOI 10.1002/jps.22282
   Bonam SR, 2017, TRENDS PHARMACOL SCI, V38, P771, DOI 10.1016/j.tips.2017.06.002
   Brito LA, 2013, SEMIN IMMUNOL, V25, P130, DOI 10.1016/j.smim.2013.05.007
   Brown F, 2003, VIRUS RES, V91, P3, DOI 10.1016/S0168-1702(02)00268-X
   Chang CB, 2008, ACS NANO, V2, P281, DOI 10.1021/nn700385z
   Correia-Pinto JF, 2013, INT J PHARMACEUT, V440, P27, DOI 10.1016/j.ijpharm.2012.04.047
   Egan PM, 2009, VACCINE, V27, P3175, DOI 10.1016/j.vaccine.2009.03.054
   Fox Christopher B, 2013, Ther Adv Vaccines, V1, P7, DOI 10.1177/2051013613480144
   Greiner VJ, 2012, VACCINE, V30, P5240, DOI 10.1016/j.vaccine.2012.05.082
   Hansen B, 2009, VACCINE, V27, P888, DOI 10.1016/j.vaccine.2008.11.078
   Harmsen MM, 2015, VACCINE, V33, P2477, DOI 10.1016/j.vaccine.2015.03.066
   He F, 2010, J PHARM SCI-US, V99, P1707, DOI 10.1002/jps.21955
   Hosseini P, 2016, VACCINE RES, V3, P44, DOI [10.18869/acadpub.vacres.3.7.6, DOI 10.18869/ACADPUB.VACRES.3.7.6]
   Huang YJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08092-y
   Jain NK, 2015, ADV DRUG DELIVER REV, V93, P42, DOI 10.1016/j.addr.2014.10.023
   Jones LS, 2005, J BIOL CHEM, V280, P13406, DOI 10.1074/jbc.M500687200
   Kotecha A, 2015, NAT STRUCT MOL BIOL, V22, P788, DOI 10.1038/nsmb.3096
   Liang SQ, 2017, BIOCHEM ENG J, V124, P99, DOI 10.1016/j.bej.2017.05.004
   Liu FG, 2016, FOOD CHEM, V196, P338, DOI 10.1016/j.foodchem.2015.09.047
   McKee AS, 2017, CURR OPIN IMMUNOL, V47, P44, DOI 10.1016/j.coi.2017.06.005
   Miles AP, 2005, VACCINE, V23, P2530, DOI 10.1016/j.vaccine.2004.08.049
   Niesen FH, 2007, NAT PROTOC, V2, P2212, DOI 10.1038/nprot.2007.321
   Nkolola JP, 2014, VACCINE, V32, P2109, DOI 10.1016/j.vaccine.2014.02.001
   Peek LJ, 2007, J PHARM SCI-US, V96, P547, DOI 10.1002/jps.20762
   Regnier M, 2012, VACCINE, V30, P6783, DOI 10.1016/j.vaccine.2012.09.020
   Samra HS, 2012, MOL PHARMACEUT, V9, P696, DOI 10.1021/mp200404c
   Santos LER, 2009, J COLLOID INTERF SCI, V340, P112, DOI 10.1016/j.jcis.2009.08.025
   Tleugabulova D, 1998, J CHROMATOGR B, V720, P153, DOI 10.1016/S0378-4347(98)00425-3
   Wei YJ, 2018, J PHARM SCI-US, V107, P2325, DOI 10.1016/j.xphs.2018.05.019
   Yang YL, 2017, VACCINE, V35, P2413, DOI 10.1016/j.vaccine.2017.03.037
   Yang YL, 2015, J CHROMATOGR A, V1408, P161, DOI 10.1016/j.chroma.2015.07.019
   Yang YL, 2015, VACCINE, V33, P1143, DOI 10.1016/j.vaccine.2015.01.031
   Yu C, 2017, BIOLOGICALS, V46, P114, DOI 10.1016/j.biologicals.2017.02.001
   Zhai JL, 2011, LANGMUIR, V27, P9227, DOI 10.1021/la201483y
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2904
EP 2912
DI 10.1016/j.vaccine.2020.02.068
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400003
PM 32127228
DA 2020-05-12
ER

PT J
AU Shu, JY
   Shen, W
   Liu, HT
   Zhou, YQ
   Li, JH
   Zhuang, Y
   Huang, ZH
   Yin, SG
   Jiang, LB
   Sun, YT
   Jin, X
   Xu, JQ
AF Shu, Jiayi
   Shen, Wei
   Liu, Haitao
   Zhou, Yiqing
   Li, Jianhui
   Zhuang, Yan
   Huang, Zhenghui
   Yin, Shigang
   Jiang, Lubin
   Sun, Yongtao
   Jin, Xia
   Xu, Jianqing
TI The immunologic dominance of an epitope within a rationally designed
   poly-epitope vaccine is influenced by multiple factors
SO VACCINE
LA English
DT Article
DE CD4(+) T cell; HIV; Epitope-based vaccine; Immunodominance
ID BROADLY NEUTRALIZING ANTIBODIES; MHC CLASS-II; HIV-1 VACCINE; ELISPOT
   ASSAY; DOUBLE-BLIND; PEPTIDE VACCINE; CLINICAL-TRIAL; EFFICACY;
   IMMUNITY; INFECTION
AB Introduction: CD4(+) T cells are essential for inducing optimal CD8(+) T cell and antibody-producing B cell responses and maintaining their long-term immunological memory. Therefore, CD4(+) T cells are a critical component in HIV vaccine development. Due to enormous viral gene variation and significant human host genetic diversity, HIV vaccines may need to be custom-made for different countries.
   Methods: Previously, we designed a CD4(+) T cell vaccine based on Chinese HIV isolates and HLA-DR alleles using bioinformatics tools and predicted that 20 epitopes could cover 98.1% of the Chinese population. In vivo testing of the poly-epitope antigen in mice only activated specific T cells for some epitopes. To elucidate the mechanism of the observed differential immunogenicity, we examined poly-epitope antigen processing and presentation using in vitro and in vivo analytical methods.
   Results: Enzymatic digestion indicated that all 20 epitopes comprising the poly-epitope antigen could be liberated, but MHC II binding assays showed that neither binding affinity nor dissociation rate was associated with the magnitude of T cell immune responses elicited by each peptide epitope in vaccinated mice. Mass spectrometry analysis of MHC II-bound peptides suggested that the abundance of endogenously processed peptides bound to MHC II molecules was significantly associated with the relative immunodominance of these epitopes.
   Conclusion: These results provide a new rationale for improving the design and testing of poly-epitope vaccines for HIV and other diseases. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Shu, Jiayi; Jin, Xia; Xu, Jianqing] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.
   [Shu, Jiayi; Shen, Wei; Liu, Haitao; Jin, Xia] Chinese Acad Sci, Inst Pasteur Shanghai, Viral Dis & Vaccine Translat Res Unit, B507 Life Sci Res Bldg,320 Yueyang Rd, Shanghai 200031, Peoples R China.
   [Zhou, Yiqing] Changshu Inst Technol, Sch Biotechnol & Food Engn, Changshu 215500, Jiangsu, Peoples R China.
   [Li, Jianhui; Zhuang, Yan; Sun, Yongtao] Air Force Med Univ PLA, Tangdu Hosp, Dept Infect Dis, 1 Xinsi Rd, Xian 710038, Shanxi, Peoples R China.
   [Huang, Zhenghui; Yin, Shigang; Jiang, Lubin] Univ Chinese Acad Sci, Chinese Acad Sci, Inst Pasteur Shanghai, Key Lab Mol Virol & Immunol,Unit Human Parasite M, Shanghai 200031, Peoples R China.
   [Shen, Wei] Ark Biosci Inc, 218 Xinghu St,B2-706,Suzhou Ind Pk, Suzhou 215123, Jiangsu, Peoples R China.
   [Liu, Haitao] Shanghai Zerun Biotech Co Ltd, Bldg 9,1690 Zhangheng Rd, Shanghai 201203, Peoples R China.
RP Jin, X; Xu, JQ (reprint author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Shanghai 201508, Peoples R China.; Jin, X (reprint author), Chinese Acad Sci, Inst Pasteur Shanghai, Viral Dis & Vaccine Translat Res Unit, B507 Life Sci Res Bldg,320 Yueyang Rd, Shanghai 200031, Peoples R China.
EM jinxia@shphc.org.cn; xujianqing@shphc.org.cn
FU National Major Program Project Grant Against Infections Diseases
   [2013ZX10001002002002]
FX This work was supported in part by the National Major Program Project
   Grant Against Infections Diseases (Grant No. 2013ZX10001002002002, XJ
   and JQX). The founders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.; We
   thank YQZ, ZHH, SHY and LBJ for the assistance with LC-MS/MS
   methodology, and JHL, YZ and YTS for clinical sample collection and
   analysis of memory human T cell responses.
CR Bar KJ, 2016, NEW ENGL J MED, V375, P2037, DOI 10.1056/NEJMoa1608243
   Bricault CA, 2019, CELL HOST MICROBE, V25, P59, DOI 10.1016/j.chom.2018.12.001
   Buchbinder SP, 2008, LANCET, V372, P1881, DOI 10.1016/S0140-6736(08)61591-3
   Fauci AS, 2016, JAMA-J AM MED ASSOC, V316, P143, DOI 10.1001/jama.2016.7538
   Flynn MN, 2005, J INFECT DIS, V191, P654
   Gray GE, 2011, LANCET INFECT DIS, V11, P507, DOI 10.1016/S1473-3099(11)70098-6
   Haynes BF, 2017, SCIENCE, V355, P1129, DOI 10.1126/science.aan0662
   He W, 2017, CAN J MICROBIOL, V63, P493, DOI 10.1139/cjm-2016-0528
   Hudgens MG, 2004, J IMMUNOL METHODS, V288, P19, DOI 10.1016/j.jim.2004.01.018
   Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991
   Jin X, 2009, VACCINE, V27, P7080, DOI 10.1016/j.vaccine.2009.09.060
   Karlsson I, 2013, CLIN IMMUNOL, V146, P120, DOI 10.1016/j.clim.2012.12.005
   Krebs SJ, 2019, IMMUNITY, V50, P677, DOI 10.1016/j.immuni.2019.02.008
   Larsson M, 1999, AIDS, V13, P767, DOI 10.1097/00002030-199905070-00005
   Lazarski CA, 2005, IMMUNITY, V23, P29, DOI 10.1016/j.immuni.2005.05.009
   Lilleby W, 2017, CANCER IMMUNOL IMMUN, V66, P891, DOI 10.1007/s00262-017-1994-y
   Liu H., 2017, IEEE T POWER SYSTEMS, VPP, P1, DOI DOI 10.1109/TCSVT.2016.2637798
   Lu CL, 2016, SCIENCE, V352, P1001, DOI 10.1126/science.aaf1279
   Maslak PG, 2018, BLOOD ADV, V2, P224, DOI 10.1182/bloodadvances.2017014175
   McElrath MJ, 2008, LANCET, V372, P1894, DOI 10.1016/S0140-6736(08)61592-5
   Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2
   Miller MA, 2015, NAT MED, V21, P1216, DOI 10.1038/nm.3958
   Miyazawa M, 2017, INT J CANCER, V140, P973, DOI 10.1002/ijc.30510
   Moodie Z, 2010, CANCER IMMUNOL IMMUN, V59, P1489, DOI 10.1007/s00262-010-0875-4
   Moodie Z, 2006, J IMMUNOL METHODS, V315, P121, DOI 10.1016/j.jim.2006.07.015
   Pitisuttithum P, 2006, J INFECT DIS, V194, P1661, DOI 10.1086/508748
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Roman VRG, 2013, AIDS RES HUM RETROV, V29, P1504, DOI 10.1089/AID.2013.0076
   Rountree W, 2016, J IMMUNOL METHODS, V433, P69, DOI 10.1016/j.jim.2016.03.004
   Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857
   Shiver JW, 2002, NATURE, V415, P331, DOI 10.1038/415331a
   Shu JY, 2014, BIOMED RES INT, DOI 10.1155/2014/272950
   Sok D, 2017, NATURE, V548, P108, DOI 10.1038/nature23301
   Tewari MK, 2005, NAT IMMUNOL, V6, P287, DOI 10.1038/ni1171
   Tomaras GD, 2013, P NATL ACAD SCI USA, V110, P9019, DOI 10.1073/pnas.1301456110
   Wada S, 2005, CANCER RES, V65, P4939, DOI 10.1158/0008-5472.CAN-04-3759
   WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288
   Walsh SR, 2016, J INFECT DIS, V213, P541, DOI 10.1093/infdis/jiv496
   Wang CY, 2019, NEW ENGL J MED, V380, P1535, DOI 10.1056/NEJMoa1802264
   West AP, 2014, CELL, V156, P633, DOI 10.1016/j.cell.2014.01.052
   Xu L, 2017, SCIENCE, V358, P85, DOI 10.1126/science.aan8630
   Yewdell JW, 2006, IMMUNITY, V25, P533, DOI 10.1016/j.immuni.2006.09.005
   Zhou TQ, 2015, CELL, V161, P1280, DOI 10.1016/j.cell.2015.05.007
NR 43
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2913
EP 2924
DI 10.1016/j.vaccine.2020.02.069
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400004
PM 32127225
DA 2020-05-12
ER

PT J
AU Hoang, HH
   Wang, PC
   Chen, SC
AF Hoang, Huy Hoa
   Wang, Pei-Chi
   Chen, Shih-Chu
TI The protective efficacy of recombinant hypoxic response protein 1 of
   Nocardia seriolae in largemouth bass (Micropterus salmoides)
SO VACCINE
LA English
DT Article
DE Nocardiosis; Nocardiaseriolae; Hypoxic response protein 1; Vaccine;
   Immune response
ID MUCOSAL HOST-DEFENSE; MYCOBACTERIUM-TUBERCULOSIS; T-CELLS; NEUTROPHIL
   RECRUITMENT; SUBUNIT VACCINES; IL-17 PRODUCTION; LATENCY ANTIGEN;
   IMMUNE-RESPONSE; INFECTION; EXPRESSION
AB Nocardia seriolae has become one of the major pathogens affecting the aquaculture industry and causes Nocardiosis, a highly devastating disease of marine and freshwater fish that leads to severe economic losses. Therefore, research efforts towards developing efficacious vaccines to control this disease are of high importance. In this study, the hypoxic response protein 1 (HRP1) cloned into pET32a vector was expressed, and produced in Escherichia coli strain BL21 (DE3). The antigenicity of purified recombinant TRX-tagged HRP (rHRP1) was analysed by western blotting using largemouth bass anti-N. seriolae sera. The results showed that largemouth bass anti-N. seriolae sera could specifically detect a 33 kDa rHRP1 protein. Further, the vaccine efficacy of rHRP1 was evaluated in a largemouth bass fish model by calculating the relative percent survival (RPS). rHRP1 incurred an RPS of 73.33% as compared to the control group. Immunological analysis showed that rHRP1 could produce significantly higher serum concentrations of anti-N. seriolae antibodies and serum lysozyme activity as compared to the control groups. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis showed that rHRP1 significantly enhanced the expression of immune-related genes, such as IL-12p40, IL-8, IL-1 beta, TNF alpha, IFN gamma, NKEF, MHCI alpha, MHCII alpha, CD4-1, CD8 alpha, IgM, NF-kappa beta, STAT3, IRF4, ROR alpha, and CCL20. These results indicate that rHRP1 may be a promising vaccine candidate against nocardiosis. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hoang, Huy Hoa; Wang, Pei-Chi; Chen, Shih-Chu] Natl Pingtung Univ Sci & Technol, Coll Vet Med, Dept Vet Med, 1 Shuefu Rd, Pingtung 91201, Taiwan.
   [Wang, Pei-Chi; Chen, Shih-Chu] Natl Pingtung Univ Sci & Technol, Southern Taiwan Fish Dis Ctr, 1 Shuefu Rd, Pingtung 91201, Taiwan.
   [Chen, Shih-Chu] Natl Pingtung Univ Sci & Technol, Int Coll, Int Degree Program Ornamental Fish Sci & Technol, 1 Shuefu Rd, Pingtung 91201, Taiwan.
   [Chen, Shih-Chu] Natl Pingtung Univ Sci & Technol, Res Ctr Anim Biol, Pingtung, Taiwan.
RP Wang, PC; Chen, SC (reprint author), Natl Pingtung Univ Sci & Technol, Dept Vet Med, 1 Shuefu Rd, Pingtung 91201, Taiwan.
EM hoanghuyhoa2003@yahoo.com; pc921003@gmail.com; scchen@mail.npust.edu.tw
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [MOST 107-2313-B-020-012MY3]
FX This work was supported by the Ministry of Science and Technology,
   Taiwan under Grant number MOST 107-2313-B-020-012MY3.
CR Abdallah AM, 2007, NAT REV MICROBIOL, P883
   Ashraf Sajjad, 2014, J Immunoassay Immunochem, V35, P120, DOI 10.1080/15321819.2013.824897
   Aujla SJ, 2008, NAT MED, V14, P275, DOI 10.1038/nm1710
   Bai H, 2009, J IMMUNOL, V183, P5886, DOI 10.4049/jimmunol.0901584
   Bashir N, 2010, IMMUNOLOGY, V130, P34, DOI 10.1111/j.1365-2567.2009.03196.x
   Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749
   Boon C, 2001, J BACTERIOL, V183, P2672, DOI 10.1128/JB.183.8.2672-2676.2001
   Brustle A, 2007, NAT IMMUNOL, V8, P958, DOI 10.1038/ni1500
   Burggraaf MJ, 2019, MICROB CELL FACT, V18, DOI 10.1186/s12934-019-1093-1
   Byadgi O, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081315
   Cai YQ, 2018, ONCOL LETT, V16, P4372, DOI 10.3892/ol.2018.9216
   Chen JL, 2019, FISH SHELLFISH IMMUN, V95, P128, DOI 10.1016/j.fsi.2019.10.024
   Chen SC, 2000, J FISH DIS, V23, P299, DOI 10.1046/j.1365-2761.2000.00217.x
   Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463
   Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491
   Ellis A.E., 1990, Fish Immunology Technical Communications, P101
   Flynn JL, 2001, ANNU REV IMMUNOL, V19, P93, DOI 10.1146/annurev.immunol.19.1.93
   Fujiie S, 2001, INT IMMUNOL, V13, P1255, DOI 10.1093/intimm/13.10.1255
   Nguyen HT, 2017, FISH SHELLFISH IMMUN, V65, P118, DOI 10.1016/j.fsi.2017.04.008
   Han HJ, 2019, MICROBIOLOGYOPEN, V8, DOI 10.1002/mbo3.656
   Herbst S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019105
   Hess J, 2000, ADV IMMUNOL, V75, P1, DOI 10.1016/S0065-2776(00)75001-2
   Ho PY, 2018, FISH SHELLFISH IMMUN, V78, P35, DOI 10.1016/j.fsi.2018.04.024
   Ho PY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101670
   Huang Shih-Ling, 2004, Journal of Taiwan Fisheries Research, V12, P61
   Ignoul S, 2005, AM J PHYSIOL-CELL PH, V289, pC1369, DOI 10.1152/ajpcell.00282.2005
   Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009
   Ismail TF, 2011, FISHERIES SCI, V77, P113, DOI 10.1007/s12562-010-0302-y
   Jaafar RM, 2015, FISH SHELLFISH IMMUN, V47, P797, DOI 10.1016/j.fsi.2015.10.023
   Jiang Yiyi, 2012, Acta Scientiarum Naturalium Universitatis Sunyatseni, V51, P76
   Kariya T, 1968, FISH PATHOL, V3, P16
   Kaufmann SHE, 2003, FUNDAMENTAL IMMUNOLO, P1229
   Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449
   Lee AYS, 2019, IMMUNOBIOLOGY, V224, P449, DOI 10.1016/j.imbio.2019.01.005
   Li F, 2017, SCAND J IMMUNOL, V85, P425, DOI 10.1111/sji.12556
   Lin YY, 2009, IMMUNITY, V31, P799, DOI 10.1016/j.immuni.2009.08.025
   Liu X, 2016, HUM VACC IMMUNOTHER, V12, P1670, DOI 10.1080/21645515.2016.1141159
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loo GH, 2012, FISH SHELLFISH IMMUN, V32, P1074, DOI 10.1016/j.fsi.2012.03.002
   Ma JL, 2016, ONCOTARGET, V7, P63804, DOI 10.18632/oncotarget.11542
   Magnadottir B, 2006, FISH SHELLFISH IMMUN, V20, P137, DOI 10.1016/j.fsi.2004.09.006
   Martyniuk CJ, 2016, COMP BIOCHEM PHYS D, V19, P140, DOI 10.1016/j.cbd.2016.06.003
   Matsumoto M, 2018, DEV COMP IMMUNOL, V85, P142, DOI 10.1016/j.dci.2018.04.012
   Matsumoto M, 2017, FISH SHELLFISH IMMUN, V67, P263, DOI 10.1016/j.fsi.2017.06.025
   Miyoshi Y, 2003, FISH PATHOL, V38, P93, DOI 10.3147/jsfp.38.93
   MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145
   Moyle PM, 2017, BIOTECHNOL ADV, V35, P375, DOI 10.1016/j.biotechadv.2017.03.005
   Moyle PM, 2013, CHEMMEDCHEM, V8, P360, DOI 10.1002/cmdc.201200487
   Munang'andu HM, 2018, MICROORGANISMS, V6, DOI 10.3390/microorganisms6020033
   Nguyen TTT, 2017, FISH SHELLFISH IMMUN, V67, P159, DOI 10.1016/j.fsi.2017.06.014
   Nordmo R, 1997, DEV BIOLOGICALS, V90, P303
   Orgun NN, 2008, J IMMUNOL, V180, P4109, DOI 10.4049/jimmunol.180.6.4109
   Paidipally P, 2009, J IMMUNOL, V183, P1940, DOI 10.4049/jimmunol.0803578
   Patel K, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2018.11.47
   Pitta MGR, 2009, J CLIN INVEST, V119, P2379, DOI 10.1172/JCI38813
   Prados-Rosales R, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006250
   Raffatellu M, 2008, NAT MED, V14, P421, DOI 10.1038/nm1743
   Rawool DB, 2008, J IMMUNOL, V180, P5548, DOI 10.4049/jimmunol.180.8.5548
   Robinson K, 2017, GLOBAL PERSPECTIVE OF SOCIAL JUSTICE LEADERSHIP FOR SCHOOL PRINCIPALS, P21
   Roupie V, 2007, INFECT IMMUN, V75, P941, DOI 10.1128/IAI.01137-06
   Schulz SM, 2008, INT IMMUNOL, V20, P1129, DOI 10.1093/intimm/dxn069
   Scott AE, 2014, INFECT IMMUN, V82, P3206, DOI 10.1128/IAI.01847-14
   Scriba TJ, 2008, J IMMUNOL, V180, P1962, DOI 10.4049/jimmunol.180.3.1962
   Sharpe ML, 2008, J MOL BIOL, V383, P822, DOI 10.1016/j.jmb.2008.07.001
   Shimahara Y, 2005, B EUR ASSOC FISH PAT, V25, P270
   Shimahara Y, 2010, FISHERIES SCI, V76, P489, DOI 10.1007/s12562-010-0239-1
   Singh AK, 2014, VACCINE, V32, P1233, DOI 10.1016/j.vaccine.2014.01.044
   Singh S, 2019, COMP IMMUNOL MICROB, V62, P46, DOI 10.1016/j.cimid.2018.11.016
   Stadhouders R, 2018, J AUTOIMMUN, V87, P1, DOI 10.1016/j.jaut.2017.12.007
   Tang XQ, 2018, VACCINE, V36, P2337, DOI 10.1016/j.vaccine.2018.03.022
   The Brennan MJ, 2017, INFECT IMMUN, V85
   Umemura M, 2007, J IMMUNOL, V178, P3786, DOI 10.4049/jimmunol.178.6.3786
   Wozniak TM, 2006, J IMMUNOL, V177, P8684, DOI 10.4049/jimmunol.177.12.8684
   Wu Q, 2007, MICROBES INFECT, V9, P78, DOI 10.1016/j.micinf.2006.10.012
   Xu WT, 2019, FISH SHELLFISH IMMUN, V84, P56, DOI 10.1016/j.fsi.2018.09.024
   Yang XXO, 2008, IMMUNITY, V28, P29, DOI 10.1016/j.immuni.2007.11.016
   Yasuike M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173198
   Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519
   Ylikoski E, 2005, EUR J IMMUNOL, V35, P3297, DOI 10.1002/eji.200526101
   Zhao LF, 2014, MICROBES INFECT, V16, P864, DOI 10.1016/j.micinf.2014.08.005
NR 80
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2925
EP 2936
DI 10.1016/j.vaccine.2020.02.062
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400005
PM 32115295
DA 2020-05-12
ER

PT J
AU Moran, EB
   Wagner, AL
   Asiedu-Bekoe, F
   Abdul-Karim, A
   Schroeder, LF
   Boulton, ML
AF Moran, Elizabeth B.
   Wagner, Abram L.
   Asiedu-Bekoe, Franklin
   Abdul-Karim, Abass
   Schroeder, Lee F.
   Boulton, Matthew L.
TI Socioeconomic characteristics associated with the introduction of new
   vaccines and full childhood vaccination in Ghana, 2014
SO VACCINE
LA English
DT Article
DE Rotavirus vaccines; Yellow fever vaccine; BCG vaccine; Health surveys;
   Socioeconomic factors
ID IMMUNIZATION; COVERAGE; IMPACT
AB Background: Childhood vaccination in Ghana has historically been high, but the impact of recently introduced vaccines on coverage is unknown. We calculate vaccine coverage of Ghanaian children- contrasting newly introduced vaccines and those long available - and describe associations between sociodemographic indicators and full vaccination.
   Methods: Data from the 2014 Ghana Demographic and Health Survey was used to calculate full vaccination, defined as receipt of one dose bacillus Calmette-Guerin (BCG); two doses of rotavirus vaccine; 3 doses of pentavalent vaccine, oral polio vaccine (OPV), and pneumococcal conjugate vaccine (PCV); and one dose of measles-rubella vaccine and yellow fever vaccine, among children age 12-24 months. Logistic regression with survey procedures was used to estimate odds ratios for socioeconomic factors' association with full vaccination.
   Results: The sample comprised a total of 1107 children 12-24 months. Full vaccination coverage was 70.8%. Vaccination coverage was higher for vaccines administered at younger ages (e.g., birth dose of BCG was 97.0%) than at older ages (e.g., yellow fever at 9 months was 88.2%). Newly introduced vaccines had lower coverage: at 10 weeks, pentavalent 2 was 95.4%, versus 91.2% for PCV 2 and 88.8% for rotavirus 2. Living outside of Greater Accra, home delivery, younger maternal age, urban residence, and more than one child under five in the home were all associated with decreased odds of full vaccination in the adjusted analysis whereas sex of the child, wealth, religion, and maternal education were not associated with full vaccination status.
   Conclusion: Ghana has high overall vaccination rates although disparities in full vaccination by sociodemographic status exist. As vaccine recommendations are revised, it will be important to insure equitable access to vaccination for all children regardless of demographic and socioeconomic background. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Moran, Elizabeth B.; Wagner, Abram L.; Boulton, Matthew L.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Asiedu-Bekoe, Franklin] Ghana Hlth Serv, Accra, Ghana.
   [Abdul-Karim, Abass] Zonal Publ Hlth Lab, Tamale, Ghana.
   [Schroeder, Lee F.] Michigan Med, Dept Pathol, Ann Arbor, MI USA.
   [Boulton, Matthew L.] Michigan Med, Div Infect Dis, Dept Internal Med, Ann Arbor, MI USA.
RP Wagner, AL (reprint author), 1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM ebmoran@umich.edu; awag@umich.edu; kofi2711@gmail.com;
   abass.komei@yahoo.com; leeschro@med.umich.edu; mboulton@umich.edu
OI Wagner, Abram/0000-0003-4691-7802
CR Abdulraheem I. S., 2011, Journal of Public Health and Epidemiology, V3, P194
   Adamu AA, 2019, EXPERT REV VACCINES, V18, P547, DOI 10.1080/14760584.2019.1588728
   Adetifa IMO, 2018, VACCINE, V36, P7965, DOI 10.1016/j.vaccine.2018.11.005
   Antai D, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-181
   Arevshatian L, 2007, B WORLD HEALTH ORGAN, V85, P421
   Asuman D, 2018, HEALTH ECON REV, V8, DOI 10.1186/s13561-018-0193-7
   Baguune B, 2017, ARCH PUBLIC HEALTH, V75, DOI 10.1186/s13690-017-0186-8
   Bawah AA, 2010, SCAND J PUBLIC HEALT, V38, P95, DOI 10.1177/1403494809352532
   Bonu S, 2003, SOC SCI MED, V57, P1807, DOI 10.1016/S0277-9536(03)00056-X
   Canavan ME, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0095709e95709, DOI 10.1371/JOURNAL.PONE.0095709E95709]
   Deogaonkar R, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-878
   Fu LY, 2015, J PEDIATR-US, V166, P412, DOI 10.1016/j.jpeds.2014.10.066
   Government of Ghana, 2014, COMPR MULT PLAN IMM
   Gram L, 2014, TROP MED INT HEALTH, V19, P802, DOI 10.1111/tmi.12324
   GSS, 2015, GHAN DEM HLTH SURV 2, DOI 10.15171/ijhpm.2016.42
   Kagone M, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1399749
   Kazungu Jacob S, 2017, Wellcome Open Res, V2, P12, DOI 10.12688/wellcomeopenres.10690.1
   Masters NB, 2019, HUM VACC IMMUNOTHER, V15, P2790, DOI 10.1080/21645515.2019.1616503
   McGavin ZA, 2018, VACCINE, V36, P7294, DOI 10.1016/j.vaccine.2018.10.043
   Mesenburg MA, 2018, LANCET GLOB HEALTH, V6, pE902, DOI [10.1016/S2214-109X(18)30300-0, 10.1016/s2214-109x(18)30300-0]
   Sally ET, 2017, PAN AFR MED J, V28, DOI 10.11604/pamj.2017.28.238.11538
   Tefera YA, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020022
   The Strategic Advisory Group of Experts (SAGE), 2018, 2018 ASS REP GLOB VA
   Wagner AL, 2019, HUM VACC IMMUNOTHER, V15, P2844, DOI 10.1080/21645515.2019.1625647
   Wagner AL, 2017, VACCINE, V35, P4362, DOI 10.1016/j.vaccine.2017.06.077
   Weinberg M, 2017, VACCINE, V35, P1018, DOI 10.1016/j.vaccine.2017.01.013
   World Bank Group, RIS CIT GHAN TIM ACT
   World Health Organization, IMM COV 2018
   World Health Organization, 2011, GLOB VACC ACT PLAN 2
   World Health Organization (WHO), WHO VACC PREV DIS MO
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2937
EP 2942
DI 10.1016/j.vaccine.2020.02.065
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400006
PM 32139314
DA 2020-05-12
ER

PT J
AU Mueller, S
   Stauft, CB
   Kalkeri, R
   Koidei, F
   Kushnir, A
   Tasker, S
   Coleman, JR
AF Mueller, Steffen
   Stauft, Charles B.
   Kalkeri, Raj
   Koidei, Fusataka
   Kushnir, Anna
   Tasker, Sybil
   Coleman, J. Robert
TI A codon-pair deoptimized live-attenuated vaccine against respiratory
   syncytial virus is immunogenic and efficacious in non-human primates
SO VACCINE
LA English
DT Article
DE Vaccine; Respiratory syncytial virus; Non-human primates; Respiratory
   illness; Live-attenuated virus; Codon-pair-bias; Codon usage; African
   green monkeys
ID CANDIDATE; INFLUENZA; INFANTS; MUTATIONS; STABILITY
AB Despite a critical need for a respiratory syncytial virus (RSV) vaccine and decades of development efforts, a vaccine to protect infants, elderly, and other at-risk populations from RSV infection remains elusive. We have previously generated a new, live-attenuated vaccine candidate against RSV using rational, computer-aided gene design and chemical synthesis through a process termed viral gene "deoptimization." In this study, we assessed the attenuation, immunogenicity, and efficacy of this synthetic, live-attenuated RSV vaccine candidate, RSV-MinL4.0, in African Green Monkeys. RSV-MinL4.0 was produced under good-manufacturing-practice (GMP) in Vero cells. Vaccination with RSV-MinL4.0 resulted in minimal virus shedding after vaccination, generation of robust humoral and cellular immune responses (despite the presence of baseline RSV neutralizing antibodies in one animal) that were comparable to a wildtype infection, and protection from virus shedding post-challenge with wildtype RSV. These findings demonstrate the promise of RSV-MinL4.0 as a live-attenuated vaccine which will undergo clinical trials to test its ability to safely and effectively protect pediatric and elderly populations from infection with RSV. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Mueller, Steffen; Stauft, Charles B.; Kushnir, Anna; Tasker, Sybil; Coleman, J. Robert] Codagenix Inc, Farmingdale, NY USA.
   [Kalkeri, Raj; Koidei, Fusataka] Southern Res Inc, Frederick, MD USA.
   [Mueller, Steffen; Stauft, Charles B.; Kushnir, Anna; Tasker, Sybil; Coleman, J. Robert] 3 Biosci Pk Dr, Farmingdale, NY 11735 USA.
RP Coleman, JR (reprint author), 3 Biosci Pk Dr, Farmingdale, NY 11735 USA.
EM mueller@codagenix.com; stauft@codagenix.com;
   rkalkeri@southernresearch.org; fkoide@southernresearch.org;
   anna@codagenix.com; tasker@codagenix.com; coleman@codagenix.com
FU National Institute for Allergy and Infectious Diseases at the National
   Institutes of Health [1 R44 AI131756-01]
FX This work was supported by the National Institute for Allergy and
   Infectious Diseases at the National Institutes of Health grant number 1
   R44 AI131756-01 to SM.
CR Bourgeois FT, 2009, PEDIATRICS, V124, pE1072, DOI 10.1542/peds.2008-3074
   Buchholz UJ, 2018, J INFECT DIS, V217, P1338, DOI 10.1093/infdis/jiy066
   Coffin JM, 2008, NEW ENGL J MED, V359, P2283, DOI 10.1056/NEJMcibr0805820
   Coleman JR, 2008, SCIENCE, V320, P1784, DOI 10.1126/science.1155761
   CONNORS M, 1995, VIROLOGY, V208, P478, DOI 10.1006/viro.1995.1178
   Durbin AP, 2003, CLIN INFECT DIS, V37, P1668, DOI 10.1086/379775
   FRIEDEWALD WT, 1968, J AMER MED ASSOC, V204, P690, DOI 10.1001/jama.1968.03140210044011
   Ispas G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126959
   Kaplan BS, 2018, VACCINE, V36, P1101, DOI 10.1016/j.vaccine.2018.01.027
   Karron RA, 2005, J INFECT DIS, V191, P1093, DOI 10.1086/427813
   KIM HW, 1971, PEDIATRICS, V48, P745
   KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955
   Le Nouen C, 2017, P NATL ACAD SCI USA, V114, pE386, DOI 10.1073/pnas.1619242114
   Le Nouen C, 2014, P NATL ACAD SCI USA, V111, P13169, DOI 10.1073/pnas.1411290111
   Luongo C, 2013, J VIROL, V87, P1985, DOI 10.1128/JVI.02769-12
   Luongo C, 2012, J VIROL, V86, P10792, DOI 10.1128/JVI.01227-12
   Mueller S, 2010, NAT BIOTECHNOL, V28, P723, DOI 10.1038/nbt.1636
   Ogra Pearay L, 2004, Paediatr Respir Rev, V5 Suppl A, pS119, DOI 10.1016/S1526-0542(04)90023-1
   Openshaw PJ, 2013, CURR OPIN VIROL, V3, P468, DOI 10.1016/j.coviro.2013.05.005
   Stauft CB, 2019, VIROLOGY, V537, P237, DOI 10.1016/j.virol.2019.09.003
   Tang YW, 2011, MANUAL CLIN MICROBIO, P1357
   Tregoning JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009381
   Tregoning JS, 2010, CLIN MICROBIOL REV, V23, P74, DOI 10.1128/CMR.00032-09
   Wright PF, 2000, J INFECT DIS, V182, P1331, DOI 10.1086/315859
   Yang C, 2013, P NATL ACAD SCI USA, V110, P9481, DOI 10.1073/pnas.1307473110
NR 25
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2943
EP 2948
DI 10.1016/j.vaccine.2020.02.056
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400007
PM 32107060
DA 2020-05-12
ER

PT J
AU Johnson, DM
   Jokinen, JD
   Wang, M
   Pfeffer, T
   Tretyakova, I
   Carrion, R
   Griffiths, A
   Pushko, P
   Lukashevich, IS
AF Johnson, Dylan M.
   Jokinen, Jenny D.
   Wang, Min
   Pfeffer, Tia
   Tretyakova, Irina
   Carrion, Ricardo
   Griffiths, Anthony
   Pushko, Peter
   Lukashevich, Igor S.
TI Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA
   replicon vector
SO VACCINE
LA English
DT Article
DE South American Hemorrhagic Fevers; Junin and Machupo arenaviruses;
   Bivalent vaccine; Alphavirus RNA replicons
ID ARGENTINE HEMORRHAGIC-FEVER; PROTECT GUINEA-PIGS; NEUTRALIZING
   ANTIBODIES; CANDID NUMBER-1; VIRUS; GLYCOPROTEIN; ATTENUATION; LASSA;
   PATHOGENESIS; IMMUNOGENICITY
AB Junin (JUNV) and Machupo (MACV), two mammalian arenaviruses placed on the 2018 WHO watch list, are prevalent in South America causing Argentine and Bolivian hemorrhagic fevers (AHF and BHF), respectively. The live attenuated JUNV vaccine, Candid #1, significantly reduced the incidence of AHF. Vaccination induces neutralizing antibody (nAb) responses which effectively target GP1 (the viral attachment glycoprotein) pocket which accepts the tyrosine residue of the cellular receptor, human transferrin receptor 1 (TfR1). In spite of close genetic relationships between JUNV and MACV, variability in the GP1 receptor binding site (e.g., MACV GP1 loop 10) results in poor MACV neutralization by Candid #1-induced nAbs. Candid #1 is not recommended for vaccination of children younger than 15 years old (a growing "at risk" group), pregnant women, or other immunocompromised individuals. Candid #1's primary reliance on limited missense mutations for attenuation, genetic heterogeneity, and potential stability concerns complicate approval of this vaccine in the US. To address these issues, we applied alphavirus RNA replicon vector technology based on the human Venezuelan equine encephalitis vaccine (VEEV) TC-83 to generate replication restricted virus-like-particles vectors (VLPVs) simultaneously expressing cellular glycoprotein precursors (GPC) of both viruses, JUNV and MACV. Resulting JV&MV VLPVs were found safe and immunogenic in guinea pigs. Immunization with VLPVs induced humoral responses which correlated with complete protection against lethal disease after challenge with pathogenic strains of JUNV (Romero) and MACV (Carvallo). (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Johnson, Dylan M.] Univ Louisville, Dept Microbiol & Immunol, Sch Med, Ctr Predict Med Biodef & Emerging Infect Dis,NIH, Louisville, KY 40292 USA.
   [Jokinen, Jenny D.; Wang, Min; Pfeffer, Tia; Lukashevich, Igor S.] Univ Louisville, Dept Pharmacol & Toxicol, Sch Med, Ctr Predict Med Biodef & Emerging Infect Dis,NIH, Louisville, KY 40292 USA.
   [Tretyakova, Irina; Pushko, Peter] Medigen Inc, Frederick, MD USA.
   [Carrion, Ricardo; Griffiths, Anthony] TBRI, San Antonio, TX USA.
   [Griffiths, Anthony] Boston Univ, Sch Med, NEIDL, Boston, MA 02118 USA.
RP Lukashevich, IS (reprint author), Univ Louisville, Dept Pharmacol & Toxicol, Sch Med, Ctr Predict Med Biodef & Emerging Infect Dis,NIH, Louisville, KY 40292 USA.
EM igor.lukashevich@louisville.edu
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [R01 AI093450]
FX The authors sincerely thank Dr. Slobodan Paessler (University of Texas
   Medical Branch, Galveston, TX) for providing Candid #1 and challenge
   stock of Machupo (Carvallo) virus. These studies were supported by the
   National Institute of Allergy and Infectious Diseases of the National
   Institutes of Health under award number R01 AI093450. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the National Institutes of Health. The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Abraham J, 2010, NAT STRUCT MOL BIOL, V17, P438, DOI 10.1038/nsmb.1772
   Abreu-Mota T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06741-w
   Aguilar PV, 2009, EMERG INFECT DIS, V15, P1526, DOI 10.3201/eid1509.090017
   Albarino CG, 2011, J VIROL, V85, P10404, DOI 10.1128/JVI.00856-11
   Albarino CG, 1997, J GEN VIROL, V78, P1605, DOI 10.1099/0022-1317-78-7-1605
   Alfson KJ, 2015, J INFECT DIS, V212, pS295, DOI 10.1093/infdis/jiv216
   Amanat F, 2019, J VIROL, DOI [10.1128/jvi.01741-19.JVI.01741-19, DOI 10.1128/JVI.01741-19.JVI.01741-19]
   Ambrosio A, 2011, HUM VACCINES, V7, P694, DOI 10.4161/hv.7.6.15198
   Bell TM, 2016, VET PATHOL, V53, P190, DOI 10.1177/0300985815588609
   Bowden TA, 2009, J VIROL, V83, P8259, DOI 10.1128/JVI.00761-09
   Brouillette RB, 2017, J VIROL, V91, DOI [10.1128/JVI.01454-16, 10.1128/jvi.01454-16]
   Carrion R, 2012, J VACCINES VACCIN, V3, DOI DOI 10.4172/2157-7560.1000160
   Clark LE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04271-z
   EDDY GA, 1975, B WORLD HEALTH ORGAN, V52, P723
   Goni SE, 2010, VIRUS GENES, V40, P320, DOI 10.1007/s11262-010-0450-2
   Emonet SF, 2011, J VIROL, V85, P1473, DOI 10.1128/JVI.02102-10
   ENRIA DA, 1984, LANCET, V2, P255, DOI 10.1016/S0140-6736(84)90299-X
   Enria DA, 2002, CURR TOP MICROBIOL, V263, P239
   Friedrich MJ, 2018, JAMA-J AM MED ASSOC, V319, P1973, DOI 10.1001/jama.2018.5712
   Goicochea MA, 2012, VACCINE, V30, P1445, DOI 10.1016/j.vaccine.2011.12.134
   Golden JW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04889-x
   Golden JW, 2016, J VIROL, V90, P3515, DOI 10.1128/JVI.02969-15
   Golden JW, 2015, BIOMED RES INT, DOI 10.1155/2015/793257
   Johnson DM, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8010009
   JOHNSON KM, 1966, AM J TROP MED HYG, V15, P103, DOI 10.4269/ajtmh.1966.15.103
   Koma T, 2016, J VIROL, V90, P1290, DOI 10.1128/JVI.02615-15
   Kotturi MF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000695
   Leske A, 2019, ANTIVIR RES, V163, P106, DOI 10.1016/j.antiviral.2019.01.006
   MACKENZIE RB, 1964, AM J TROP MED HYG, V13, P620, DOI 10.4269/ajtmh.1964.13.620
   Mahmutovic S, 2015, CELL HOST MICROBE, V18, P705, DOI 10.1016/j.chom.2015.11.005
   MAIZTEGUI JI, 1979, LANCET, V2, P1216
   Manning JT, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00020
   McKee KT, 2009, VACCINES FOR BIODEFENSE AND EMERGING AND NEGLECTED DISEASES, P537
   MCKEE KT, 1993, AM J TROP MED HYG, V48, P403, DOI 10.4269/ajtmh.1993.48.403
   McNamara A, 2011, FASEB J, V25
   Montemiglio LC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09098-w
   Patterson M, 2014, J VIROL, V88, P10995, DOI 10.1128/JVI.01007-14
   Patterson M, 2014, CURR OPIN VIROL, V5, P82, DOI 10.1016/j.coviro.2014.02.007
   PETERS CJ, 1987, CURR TOP MICROBIOL, V134, P5
   Pittman PR, 1996, VACCINE, V14, P337, DOI 10.1016/0264-410X(95)00168-Z
   Pushko P, 2001, J VIROL, V75, P11677, DOI 10.1128/JVI.75.23.11677-11685.2001
   Pushko P, 2014, NOVEL TECHNOLOGIES V, P61
   Radoshitzky SR, 2007, NATURE, V446, P92, DOI 10.1038/nature05539
   Radoshitzky SR, 2014, VIRAL HEMORRHAGIC FEVERS, P339
   Radoshitzky SR, 2015, ARCH VIROL, V160, P1851, DOI 10.1007/s00705-015-2418-y
   Radoshitzky SR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021398
   Radoshitzky SR, 2018, MED ASPECTS BIOL WAR, P517
   Romanowski V, 2014, VIRAL HEMORRHAGIC FEVERS, P317
   Salvato MS, HEMORRHAGIC FEVER VI
   SANCHEZ A, 1989, J GEN VIROL, V70, P1125, DOI 10.1099/0022-1317-70-5-1125
   Seregin AV, 2015, J VIROL, V89, P5949, DOI 10.1128/JVI.00104-15
   Seregin AV, 2010, VACCINE, V28, P4713, DOI 10.1016/j.vaccine.2010.04.077
   Sinchi A, 2018, INT J INFECT DIS, V73, P53, DOI 10.1016/j.ijid.2018.04.3544
   Snoy PJ, 2010, VET PATHOL, V47, P774, DOI 10.1177/0300985810372506
   Syromyatnikova S. I., 2009, Voprosy Virusologii, V54, P37
   Teferedegne B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056023
   Varada JC, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-195
   Wang M, 2018, VACCINE, V36, P683, DOI 10.1016/j.vaccine.2017.12.046
   Yun NE, 2008, AM J TROP MED HYG, V79, P275, DOI 10.4269/ajtmh.2008.79.275
   Zaza AD, 2018, VIROL J, V15, DOI 10.1186/s12985-018-1009-4
   Zeitlin L, 2016, P NATL ACAD SCI USA, V113, P4458, DOI 10.1073/pnas.1600996113
   Zeltina A, 2017, P NATL ACAD SCI USA, V114, P7031, DOI 10.1073/pnas.1702127114
NR 62
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2949
EP 2959
DI 10.1016/j.vaccine.2020.02.053
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400008
PM 32111526
OA Other Gold
DA 2020-05-12
ER

PT J
AU Whitby, PW
   Morton, DJ
   Mussa, HJ
   Mirea, L
   Stull, TL
AF Whitby, Paul W.
   Morton, Daniel J.
   Mussa, Huda J.
   Mirea, Lucia
   Stull, Terrence L.
TI A bacterial vaccine polypeptide protective against nontypable
   Haemophilus influenzae
SO VACCINE
LA English
DT Article
DE Nontypable Haemophilus influenzae (NTHi); Haemophilus influenzae
   vaccine; Structural Vaccinology; Bacterial vaccine polypeptide; Otitis
   media
ID OUTER-MEMBRANE PROTEIN; 1ST 2 YEARS; OTITIS-MEDIA; NASOPHARYNGEAL
   COLONIZATION; CHINCHILLA MODEL; STREPTOCOCCUS-PNEUMONIAE;
   HEME-UTILIZATION; IMMUNOGENICITY; IDENTIFICATION; ADHESIN
AB Nontypeable strains of Haemophilus influenzae (NTHi) are one of the most common cause of otitis media and the most frequent infection associated with exacerbations of chronic obstructive pulmonary disease; there is currently no vaccine in the U.S. to prevent NTHi. Using bioinformatics and structural vaccinology, we previously identified several NTHi species-conserved and sequence-conserved peptides that mediate passive protection in the rat model of infection. Using these, and similar peptides, we designed Hi Poly 1, a Bacterial Vaccine Polypeptide, comprising 9 unique peptides from 6 different surface proteins. Recombinant Hi Poly 1 was purified by affinity chromatography. Forty chinchillas were immunized three times with 200 mu g of Hi Poly 1 with alum adjuvant; similarly, 41 controls were immunized with adjuvant alone. The average Log(2) IgG titer among immunized animals was 17.04, and IgG antibodies against each component peptide were detected. In the infant rat model, antisera from immunized chinchillas provided significant passive protection compared to PBS (p = 0.01) and pre-immune sera (p = 0.03). In the established chinchilla model of NTHi otitis media, the vaccinated group cleared infection faster than the control group as indicated by significantly decreased positive findings on video-otoscopy (p < 0.0001) and tympanometry (p = 0.0002) on day 7, and for middle ear fluid obtained by aspiration (p = 0.0001) on day 10 post-infection. Using 12 representative NTHi strains in a Live-Cell ELISA, greater antibody binding to each strain was detected with post Hi Poly 1 than the pre-immune chinchilla antisera. The data from this proof-of-principle study demonstrate the effectiveness of Hi Poly 1 against the NTHi in two relevant preclinical models of bacteremia and otitis media as well as surface antibody binding across the species. The Bacterial Vaccine Polypeptide approach to a vaccine against NTHi also serves as a paradigm for development of similar vaccines to protect against other bacteria. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Whitby, Paul W.; Morton, Daniel J.; Mussa, Huda J.; Mirea, Lucia; Stull, Terrence L.] Univ Arizona, Dept Child Hlth, Coll Med Phoenix, BSPB E519,475 N 5th St, Phoenix, AZ 85004 USA.
   [Whitby, Paul W.; Morton, Daniel J.; Mussa, Huda J.; Mirea, Lucia; Stull, Terrence L.] Phoenix Childrens Hosp, Phoenix, AZ USA.
RP Whitby, PW (reprint author), Univ Arizona, Dept Child Hlth, Coll Med Phoenix, BSPB E519,475 N 5th St, Phoenix, AZ 85004 USA.
EM Pwhitby@email.arizona.edu
FU University of Arizona College of Medicine-Phoenix; Phoenix Children's
   Hospital
FX The research was funded by the University of Arizona College of
   Medicine-Phoenix and Phoenix Children's Hospital.
CR Agiro A, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.512
   Bakaletz LO, 2009, EXPERT REV VACCINES, V8, P1063, DOI 10.1586/ERV.09.63
   Bakaletz LO, 1999, INFECT IMMUN, V67, P2746, DOI 10.1128/IAI.67.6.2746-2762.1999
   Barbieri E, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0696-9
   Carbonetti NH, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv073
   CDC, 2019, PINK BOOK HAEM INFL
   Chng SS, 2010, BIOCHEMISTRY-US, V49, P4565, DOI 10.1021/bi100493e
   Cope LD, 2001, INFECT IMMUN, V69, P2353, DOI 10.1128/IAI.69.4.2353-2363.2001
   Cutter D, 2002, J INFECT DIS, V186, P1115, DOI 10.1086/344233
   Dale JB, 2017, VACCINE, V35, P19, DOI 10.1016/j.vaccine.2016.11.065
   Dale JB, 1999, VACCINE, V17, P193, DOI 10.1016/S0264-410X(98)00150-9
   Esposito S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01344
   Faden H, 1996, ACTA OTO-LARYNGOL, P128
   FADEN H, 1995, J INFECT DIS, V172, P132, DOI 10.1093/infdis/172.1.132
   Fedele G, 2011, J IMMUNOL, V186, P5388, DOI 10.4049/jimmunol.1003765
   Fedele G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008734
   Forbes ML, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001969
   Francis MJ, 2018, VET CLIN N AM-SMALL, V48, P231, DOI 10.1016/j.cvsm.2017.10.002
   Giufre M, 2018, VACCINE, V36, P6615, DOI 10.1016/j.vaccine.2018.09.060
   Giufre M, 2017, CLIN INFECT DIS, V64, P1626, DOI 10.1093/cid/cix234
   Gu XX, 1998, INFECT IMMUN, V66, P1891, DOI 10.1128/IAI.66.5.1891-1897.1998
   Hempel RJ, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-134
   Hu MC, 2002, INFECT IMMUN, V70, P2171, DOI 10.1128/IAI.70.4.2171-2177.2002
   Jalalvand F, 2018, EXPERT REV VACCINES, V17, P503, DOI 10.1080/14760584.2018.1484286
   Jett BD, 1997, BIOTECHNIQUES, V23, P648, DOI 10.2144/97234bm22
   Kapil P, 2019, CURR OPIN IMMUNOL, V59, P72, DOI 10.1016/j.coi.2019.03.006
   KARASIC RB, 1989, PEDIATR INFECT DIS J, V8, pS62
   Kaur R, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-0181
   Kawai K, 2018, J PEDIATR-US, V201, P122, DOI 10.1016/j.jpeds.2018.05.047
   Kennedy BJ, 2000, INFECT IMMUN, V68, P2756, DOI 10.1128/IAI.68.5.2756-2765.2000
   Klugman KP, 2018, P NATL ACAD SCI USA, V115, P12896, DOI 10.1073/pnas.1721095115
   Koelman DLH, 2019, CLIN MICROBIOL INFEC
   Lal H, 2015, NEW ENGL J MED, V373, P1576, DOI 10.1056/NEJMc1508392
   Lieberthal AS, 2013, PEDIATRICS, V131, pE964, DOI 10.1542/peds.2012-3488
   Mak WS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10005
   Mak WS, 2014, CURR OPIN STRUC BIOL, V27, P87, DOI 10.1016/j.sbi.2014.05.010
   Morton DJ, 2007, MICROBES INFECT, V9, P932, DOI 10.1016/j.micinf.2007.03.013
   Morton DJ, 2007, MICROBIOL-SGM, V153, P215, DOI 10.1099/mic.0.2006/000190-0
   Morton Daniel J, 2012, BMC Res Notes, V5, P327, DOI 10.1186/1756-0500-5-327
   Morton DJ, 2009, INT J MED MICROBIOL, V299, P479, DOI 10.1016/j.ijmm.2009.03.004
   Morton DJ, 2004, MICROBIOL-SGM, V150, P3923, DOI 10.1099/mic.0.27238-0
   Morton DJ, 2004, MICROB PATHOGENESIS, V36, P25, DOI 10.1016/j.micpath.2003.08.007
   MURPHY TF, 1986, J CLIN INVEST, V78, P1020, DOI 10.1172/JCI112656
   Murphy TF, 2003, CURR OPIN INFECT DIS, V16, P129, DOI 10.1097/00001432-200304000-00009
   Murphy TF, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00130-17
   MUSSER JM, 1986, INFECT IMMUN, V52, P183, DOI 10.1128/IAI.52.1.183-191.1986
   Nasso M, 2009, J IMMUNOL, V183, P1892, DOI 10.4049/jimmunol.0901071
   Nizet V, 1996, J INFECT DIS, V173, P180, DOI 10.1093/infdis/173.1.180
   Novotny LA, 2000, INFECT IMMUN, V68, P2119, DOI 10.1128/IAI.68.4.2119-2128.2000
   Pichichero M, 2018, LANCET CHILD ADOLESC, V2, P561, DOI 10.1016/S2352-4642(18)30168-8
   Plotkin SA, 2005, NAT MED, V11, pS5, DOI 10.1038/nm1209
   Prymula R, 2006, LANCET, V367, P740, DOI 10.1016/S0140-6736(06)68304-9
   Roberts KE, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002477
   SAMUELSON A, 1995, SCAND J INFECT DIS, V27, P303, DOI 10.3109/00365549509032722
   Scarselli M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002234
   SCHNEERSON R, 1980, J EXP MED, V152, P361, DOI 10.1084/jem.152.2.361
   Seeberger PH, 2017, ANGEW CHEM INT EDIT, V56, P13973, DOI 10.1002/anie.201700964
   SIRAKOVA T, 1994, INFECT IMMUN, V62, P2002, DOI 10.1128/IAI.62.5.2002-2020.1994
   Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h
   Smith-Vaughan HC, 2014, CLIN VACCINE IMMUNOL, V21, P250, DOI 10.1128/CVI.00632-13
   Soeters HM, 2018, CLIN INFECT DIS, V67, P881, DOI 10.1093/cid/ciy187
   St Geme JW, 2000, VACCINE, V19, pS41, DOI 10.1016/S0264-410X(00)00277-2
   SUZUKI K, 1994, INFECT IMMUN, V62, P1710, DOI 10.1128/IAI.62.5.1710-1718.1994
   TURK DC, 1984, J MED MICROBIOL, V18, P1, DOI 10.1099/00222615-18-1-1
   Usmani SS, 2018, ADV PROTEIN CHEM STR, V112, P221, DOI 10.1016/bs.apcsb.2018.01.006
   Voulhoux R, 2003, SCIENCE, V299, P262, DOI 10.1126/science.1078973
   Whitby PW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136867
   Whitby PW, 2012, J MICROBIOL METH, V91, P336, DOI 10.1016/j.mimet.2012.10.005
   Winter LE, 2003, INFECT IMMUN, V71, P6884, DOI 10.1128/IAI.71.12.6884-6891.2003
   Yarian F, 2018, J MED MICROBIOL, V67, P820, DOI 10.1099/jmm.0.000744
   Zagursky RJ, 2000, INFECT IMMUN, V68, P2525, DOI 10.1128/IAI.68.5.2525-2534.2000
   Zhou XF, 2019, INT J PEDIATR OTORHI, V119, P96, DOI 10.1016/j.ijporl.2019.01.023
NR 72
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2960
EP 2970
DI 10.1016/j.vaccine.2020.02.054
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400009
PM 32111525
OA Other Gold
DA 2020-05-12
ER

PT J
AU Selvey, LA
   Roux, F
   Burns, S
AF Selvey, Linda A.
   Roux, Felicity
   Burns, Sharyn
TI Potential process improvements to increase coverage of human
   papillomavirus vaccine in schools - A focus on schools with low vaccine
   uptake
SO VACCINE
LA English
DT Article
DE Human papillomavirus vaccine; Vaccine coverage; School based
   immunisation
ID HPV VACCINE; ADOLESCENT GIRLS; INFORMATION; PARENTS; PROGRAM
AB Introduction: Human papillomavirus (HPV) vaccination is offered in Australia through school-based programs. While HPV vaccination coverage is high, coverage of the full course of vaccination is suboptimal in Australia and there is a drop in coverage between the first and third doses. This study aimed to describe the drivers of low HPV vaccination coverage in Western Australian (WA) schools and barriers and enablers to improving vaccine coverage. This paper focusses on process and system-level factors.
   Materials and methods: This was a mixed methods study. We analysed WA vaccination coverage data by school, undertook an online survey targeting the individuals responsible for the HPV vaccination program in their schools and school nurses, and compared survey findings and HPV vaccine dose three coverage in schools with 50 or more students in the eligible cohort. We also conducted focus groups with students and interviews with parents in schools with low HPV vaccine coverage.
   Results: Schools with low HPV vaccine coverage had low coverage for the first dose of HPV vaccine as well as a higher drop off between first and third doses compared to schools with higher HPV vaccine coverage. Respondents from low and middle HPV vaccine coverage schools reported more issues with return of consent forms, low parental literacy, language barriers, absenteeism and difficulty contacting parents compared to schools with high coverage. Parents and students raised a number of challenges in relation to HPV vaccination including student absenteeism, language barriers, and issues with the return of consent forms.
   Conclusions: A multifaceted approach to improving HPV vaccination coverage should be targeted at schools with low coverage. Based on our findings, these actions should include a range of approaches to obtaining parental consent and intensive follow up with students who are absent on vaccination days. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Selvey, Linda A.] Univ Queensland, Sch Publ Hlth, 288 Herston Rd, Herston, Qld 4006, Australia.
   [Roux, Felicity; Burns, Sharyn] Curtin Univ, Sch Publ Hlth, Collaborat Evidence Res & Impact, Publ Hlth, Kent St, Bentley, WA 6102, Australia.
RP Selvey, LA (reprint author), Univ Queensland, Sch Publ Hlth, 288 Herston Rd, Herston, Qld 4006, Australia.
EM L.selvey@uq.edu.au
RI Selvey, Linda/B-8473-2017
OI Selvey, Linda/0000-0001-8493-0974
FU Communicable Disease Control Branch within the Western Australian
   Department of Health, Western Australia, Australia
FX This work was funded by the Communicable Disease Control Branch within
   the Western Australian Department of Health, Western Australia,
   Australia.
CR Brotherton JML, 2013, MED J AUSTRALIA, V199, P614, DOI 10.5694/mja13.10272
   Bryman A, 2016, SOCIAL RES METHODS
   Choi KB, 2013, J SPEC PEDIATR NURS, V18, P297, DOI 10.1111/jspn.12041
   Davies C, 2017, SEX EDUC-SEX SOC LEA, V17, P256, DOI 10.1080/14681811.2017.1300770
   Dempsey AF, 2010, VACCINE, V28, P7179, DOI 10.1016/j.vaccine.2010.08.066
   Forster AS, 2017, BRIT J CANCER, V117, P1121, DOI 10.1038/bjc.2017.284
   Fujiwara H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084126
   Gallagher KE, 2016, BMC PUBLIC HEALTH, V16
   Gottvall M, 2011, VACCINE, V29, P4576, DOI 10.1016/j.vaccine.2011.04.054
   Gowda C, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-509
   Grandahl M, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-540
   Kang HS, 2018, J PEDIATR NURS, V39, P7, DOI 10.1016/j.pedn.2017.12.003
   Kent H, 2010, SEX HEALTH, V7, P391, DOI 10.1071/SH09148
   Kessels SJM, 2012, VACCINE, V30, P3546, DOI 10.1016/j.vaccine.2012.03.063
   Lorick SA, 2015, J PUBLIC HEALTH MAN, V21, P186, DOI 10.1097/PHH.0000000000000156
   Mak DB, 2013, J PAEDIATR CHILD H, V49, P895, DOI 10.1111/jpc.12030
   Mak DB, 2011, AUST NZ J PUBL HEAL, V35, P89, DOI 10.1111/j.1753-6405.2010.00669.x
   National HPV vaccination program register, 2018, HPV VACC COV DAT
   Paul P, 2014, VACCINE, V32, P320, DOI 10.1016/j.vaccine.2013.11.070
   Perman S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4168-0
   Poole T, 2012, VACCINE, V31, P84, DOI 10.1016/j.vaccine.2012.10.099
   Rambout L, 2014, PREV MED, V58, P22, DOI 10.1016/j.ypmed.2013.10.009
   Robbins SCC, 2010, HEALTH PSYCHOL, V29, P618, DOI 10.1037/a0021449
   Robbins SCC, 2010, SEX HEALTH, V7, P271, DOI 10.1071/SH09140
   Robbins SCC, 2010, VACCINE, V28, P3398, DOI 10.1016/j.vaccine.2010.02.078
   Rockliffe L, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5278-z
   Rose SB, 2011, J SCHOOL HEALTH, V81, P680, DOI 10.1111/j.1746-1561.2011.00644.x
   Skinner SR, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2168-5
   Smith LM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-645
   Tarney C, 2016, OBSTET GYNECOL S1, V127, p4S
   Trucchi C, 2019, BIOMED RES INT, DOI 10.1155/2019/6764154
   Whelan NW, 2014, VACCINE, V32, P4665, DOI 10.1016/j.vaccine.2014.06.026
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2971
EP 2977
DI 10.1016/j.vaccine.2020.02.047
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400010
PM 32115296
DA 2020-05-12
ER

PT J
AU Liu, FJ
   Shi, DY
   Mao, YY
   Xiong, XH
   Lu, JS
   Pang, XB
   Dong, XJ
   Yang, ZX
   Yu, YZ
AF Liu, Fu-Jia
   Shi, Dan-Yang
   Mao, Yun-Yun
   Xiong, Xiang-Hua
   Lu, Jian-Sheng
   Pang, Xiao-Bin
   Dong, Xiao-Jie
   Yang, Zhi-Xin
   Yu, Yun-Zhou
TI Immunological characterisation and immunoprotective efficacy of
   functional domain antigens of botulinum neurotoxin serotype A
SO VACCINE
LA English
DT Article
DE Botulinum neurotoxin; Functional domain; Subunit vaccine;
   Immunogenicity; Protective effect
ID VACCINE; ANTIBODIES; VOLUNTEERS; SUBUNIT
AB Botulinum neurotoxins (BoNTs) are highly toxic proteins that mediate their effects by binding to neuronal receptors and block the neutralizing ability of therapeutic antibodies. Vaccination is currently the most effective strategy to prevent botulism. In this study, a series of recombinant functional domain antigens of BoNT/A were prepared and identified, and their immunoprotective efficacies were explored and compared. Our results showed that all antigens produced strong humoral immune responses, although their protective effects against the toxin were different. Only the Hc and HN-L antigens produced strong protective effects and afforded complete immunoprotection. In addition, the combined vaccine groups showed that there was no synergistic effect on immune responses after antigen combination, suggesting that the integrity of the toxin antigen or domain is crucial to the immune effects. Studies of the dose-dependent immunoprotective effects further confirmed that the Hc domain antigen afforded more effective protective potency than the HN-L antigen, equivalent to the immune effect of the fulll-ength toxin (Hc + HN-L combination group). Overall, our results demonstrated that the Hc domain elicited a strong protective immune response and also provided basic data and theoretical support for the development of Hc-based BoNT/A subunit vaccine. Therefore, the receptor binding domain Hc is implicated as a promising target antigen of the BoNT/A recombinant subunit vaccine as an alternative to the toxoid vaccine. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Liu, Fu-Jia; Shi, Dan-Yang; Mao, Yun-Yun; Xiong, Xiang-Hua; Lu, Jian-Sheng; Dong, Xiao-Jie; Yang, Zhi-Xin; Yu, Yun-Zhou] Beijing Inst Biotechnol, 20 Dongdajie St, Beijing 100071, Peoples R China.
   [Liu, Fu-Jia; Pang, Xiao-Bin] Henan Univ, Pharmaceut Coll, Kaifeng 475001, Peoples R China.
RP Dong, XJ; Yu, YZ (reprint author), Beijing Inst Biotechnol, 20 Dongdajie St, Beijing 100071, Peoples R China.
EM pxb0411@163.com; ammsbiotechbase@163.com; yunzhouyu@163.com
FU Special Key Project of Biosafety Technologies [2017YFC1200902]; National
   Major Research and Development Program of China
FX This work was supported by grants from the Special Key Project of
   Biosafety Technologies (2017YFC1200902) for the National Major Research
   and Development Program of China. The funders had no role in the study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Atassi MZ, 2004, MOVEMENT DISORD, V19, pS68, DOI 10.1002/mds.20020
   Avril A, 2017, ADV EXP MED BIOL, V1053, P173, DOI 10.1007/978-3-319-72077-7_9
   Cheng LW, 2009, INFECT IMMUN, V77, P4305, DOI 10.1128/IAI.00405-09
   Connan C, 2017, CURR TOP MICROBIOL, V406, P39, DOI 10.1007/82_2017_50
   Garcia-Rodriguez C, 2011, PROTEIN ENG DES SEL, V24, P321, DOI 10.1093/protein/gzq111
   Karalewitz APA, 2012, CURR OPIN MICROBIOL, V15, P317, DOI 10.1016/j.mib.2012.05.009
   Khouri JM, 2018, VACCINE, V36, P2041, DOI 10.1016/j.vaccine.2018.02.042
   Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338
   Levy R, 2007, J MOL BIOL, V365, P196, DOI 10.1016/j.jmb.2006.09.084
   Lou JL, 2018, TOXINS, V10, DOI 10.3390/toxins10020084
   Montecucco C, 1995, Q REV BIOPHYS, V28, P423, DOI 10.1017/S0033583500003292
   Moreira GMSG, 2014, ANAEROBE, V28, P130, DOI 10.1016/j.anaerobe.2014.06.003
   Peck MW, 2017, TOXINS, V9, DOI 10.3390/toxins9010038
   Pirazzini M, 2017, PHARMACOL REV, V69, P200, DOI 10.1124/pr.116.012658
   Przedpelski A, 2018, VACCINE, V36, P827, DOI 10.1016/j.vaccine.2017.12.064
   Ravichandran E, 2016, PHARM RES-DORDR, V33, P639, DOI 10.1007/s11095-015-1816-x
   Rossetto O, 2013, TOXICON, V67, P31, DOI 10.1016/j.toxicon.2013.01.017
   Sahay B, 2018, VACCINE, V36, P155, DOI 10.1016/j.vaccine.2017.11.008
   Shearer JD, 2010, VACCINE, V28, P7313, DOI 10.1016/j.vaccine.2010.08.076
   Shi DY, 2019, HUM VACC IMMUNOTHER, V15, P755, DOI 10.1080/21645515.2018.1547613
   Smith TJ, 2015, RES MICROBIOL, V166, P290, DOI 10.1016/j.resmic.2014.09.007
   Sundeen G, 2017, TOXINS, V9, DOI 10.3390/toxins9090268
   Swaminathan S, 2011, FEBS J, V278, P4467, DOI 10.1111/j.1742-4658.2011.08183.x
   Webb RP, 2017, TOXINS, V9, DOI 10.3390/toxins9090269
   Webb RP, 2013, EXPERT REV VACCINES, V12, P481, DOI [10.1586/erv.13.37, 10.1586/ERV.13.37]
   Yu CH, 2018, HUM VACC IMMUNOTHER, V14, P329, DOI 10.1080/21645515.2017.1405201
   Yu YZ, 2009, VACCINE, V27, P2816, DOI 10.1016/j.vaccine.2009.02.091
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2978
EP 2983
DI 10.1016/j.vaccine.2020.02.060
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400011
PM 32113807
DA 2020-05-12
ER

PT J
AU Aris, E
   Montourcy, M
   Esterberg, E
   Kurosky, SK
   Poston, S
   Hogea, C
AF Aris, Emmanuel
   Montourcy, Marion
   Esterberg, Elizabeth
   Kurosky, Samantha K.
   Poston, Sara
   Hogea, Cosmina
TI The adult vaccination landscape in the United States during the
   Affordable Care Act era: Results from a large retrospective database
   analysis
SO VACCINE
LA English
DT Article
DE Adult; Influenza; Herpes zoster; Pneumococcal; Tdap; Vaccine
ID MISSED OPPORTUNITIES; HEALTH
AB Background: Early provisions of the Affordable Care Act (ACA) reduced financial barriers to preventive care, including routinely recommended vaccines; however, vaccination coverage remains suboptimal. This study examined characteristics of routine adult vaccinations and potential missed opportunities for vaccinations through the lens of healthcare resource utilization among adults in the ACA era.
   Methods: This was a retrospective analysis of healthcare claims from the Truven Health MarketScan Commercial Claims and Encounters (CCAE), Medicare Supplemental (MS), and Multi-State Medicaid databases among adults aged 19 years or older. Influenza, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis), herpes zoster (HZ), and pneumococcal vaccinations were identified between 2011 and 2016. Potential missed opportunities were defined as well-visits at which individuals were age-eligible for vaccination but did not receive it, assessed during recommended windows for each vaccine. Missed encounters were defined as having no well-visits. Multivariable logistic regression was used to identify factors associated with vaccination and potential missed opportunities.
   Results: Family/internal medicine and unknown/other providers administered most influenza, Tdap, and pneumococcal vaccinations, for the CCAE/MS and Medicaid cohorts, respectively. HZ vaccinations were primarily administered through pharmacies. The proportion of vaccination events increased in the pharmacy setting between 2011 and 2016. Having preventive care visits, non-well-visits, and receiving most care from a family/internal medicine practitioner were associated with increased odds of vaccination. Missed encounters were common in Medicaid enrollees. Potential missed opportunities were more prevalent in the CCAE/MS cohort than among Medicaid enrollees. Having non-well-visits was associated with a reduced likelihood of having a missed opportunity.
   Conclusion: Since the ACA implementation, preventive care among adults was sporadic. Many adults had limited opportunities for vaccination. The large prevalence of missed opportunities suggests vaccination uptake could be improved. Better support for vaccination or referrals for providers who may not traditionally vaccinate could improve vaccine uptake. (C) 2020 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.
C1 [Aris, Emmanuel; Montourcy, Marion] GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
   [Esterberg, Elizabeth; Kurosky, Samantha K.; Poston, Sara] RTI Hlth Solut, 3040 E Cornwallis Rd, Res Triangle Pk, NC USA.
   [Hogea, Cosmina] GSK, 5 Crescent Dr, Philadelphia, PA 19112 USA.
RP Aris, E (reprint author), GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
EM emmanuel.x.aris@gsk.com; marion.montourcy@sciensano.be;
   eesterberg@rti.org; skkurosky@gmail.com; sara.a.poston@gsk.com;
   cosmina.s.hogea@gsk.com
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX GlaxoSmithKline Biologicals SA was the funding source (GSK study
   identifier: HO-17-18478) and was involved in all stages of the study
   conduct and analysis. GlaxoSmithKline Biologicals SA also funded all
   costs associated with the development and the publishing of the present
   manuscript. All authors had full access to the data and agreed with the
   submission of the publication.
CR Andrew MK, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-36
   [Anonymous], 2014, REPORT SAGE WORKING
   Burnham KP, 2011, BEHAV ECOL SOCIOBIOL, V65, P23, DOI 10.1007/s00265-010-1029-6
   Burnham KP, 2012, MODEL SELECTION MULT
   Centers for Disease Control and Prevention, 2019, REC AD IMM SCHED AG
   Espinosa CM, 2017, J PEDIAT INF DIS SOC, V6, P360, DOI 10.1093/jpids/pix067
   Hung MC, 2016, VACCINATION COVERAGE
   Irving SA, 2018, ACAD PEDIATR, V18, pS85, DOI 10.1016/j.acap.2017.09.002
   Johnson DR, 2008, AM J MED, V121, pS28, DOI 10.1016/j.amjmed.2008.05.005
   Matanock A, 2019, MMWR-MORBID MORTAL W, V68, P1069, DOI 10.15585/mmwr.mm6846a5
   Singhal PK, 2014, J MANAG CARE SPEC PH, V20, P930, DOI 10.18553/jmcp.2014.20.9.930
   Westrick SC, 2018, VACCINE, V36, P5657, DOI 10.1016/j.vaccine.2018.07.027
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2984
EP 2994
DI 10.1016/j.vaccine.2020.02.057
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400012
PM 32115298
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ferreira, VM
   Ferreira, IE
   Chang, HY
   Nunes, AMPB
   Topaz, N
   Pimentel, ER
   Moura, ARSS
   Ribeiro, GS
   Feitosa, CA
   Reis, MG
   Wang, X
   Campos, LC
AF Ferreira, Viviane Matos
   Ferreira, Italo Eustaquio
   Chang, How-Yi
   Pithon Borges Nunes, Amelia Maria
   Topaz, Nadav
   Pimentel, Ellen Reis
   Silva Simoes Moura, Ana Rafaela
   Ribeiro, Guilherme Sousa
   Feitosa, Caroline Alves
   Reis, Mitermayer Galvao
   Wang, Xin
   Campos, Leila Carvalho
TI Meningococcal carriage in young adults six years after meningococcal C
   conjugate (MCC) vaccine catch-up campaign in Salvador, Brazil
SO VACCINE
LA English
DT Article
DE Neisseria meningitidis; Oropharyngeal colonization; Vaccine;
   Meningococcal disease
ID NEISSERIA-MENINGITIDIS; SEROGROUP-B; DISEASE; ADOLESCENTS; IMPACT;
   CAPSULE; EPIDEMIOLOGY; IMMUNIZATION; POPULATION; DIVERSITY
AB Meningococcal carriage studies are important to improve the knowledge of disease epidemiology as well as to support appropriate vaccination strategies. We conducted a cross-sectional study to determine the prevalence and genotypic characteristics of meningococci collected from young adults in Salvador, Brazil six years after a meningococcal C conjugate vaccine catch-up campaign. From August through November 2016, oropharyngeal swabs were collected from 407 students aged 1824 years attending a private college in Salvador, Brazil. Neisseria meningitidis was identified by standard microbiology methods and real time PCR. Genetic characteristics of meningococci were assessed by rt-PCR and/or whole genome sequencing. We also investigated potential factors associated with carriage. N. meningitidis was detectable in 50 students, 39 by both culture and rt-PCR, 7 by culture alone and 4 by rt-PCR alone, resulting in an overall meningococcal carriage prevalence of 12.3% (50/407). Carriage was independently associated with male sex (adjusted PR: 1.97; 95% CI: 1.12-3.46; p = 0.018) and attending bars or parties at least once per month (aPR: 3.31; 95% CI: 1.49-7.38; p = 0.003). Molecular tests identified 92% (46/50) N. meningitidis as non-groupable, of which 63% (29/46) had the capsule null genotype; 14 NG isolates contained disrupted capsule backbones and belonged to the following genogroups: 7 B, 3 Z, 3 E and 1 W. One isolate belonged to genogroup C tested only by PCR; 3 isolates contained a complete B capsule backbones, 2 of which were determined to be NG by slide agglutination serogrouping. While most meningococcal carriage isolates were non-groupable, there was a high degree of genetic diversity present in the collection, as evidenced by 25 unique STs being detected. The carriage prevalence of meningococcal serogroup C was low among young adults. Continuous vaccination is important to maintain reduced meningococcal carriage and transmission, inducing herd protection. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ferreira, Viviane Matos; Ferreira, Italo Eustaquio; Pithon Borges Nunes, Amelia Maria; Pimentel, Ellen Reis; Silva Simoes Moura, Ana Rafaela; Ribeiro, Guilherme Sousa; Reis, Mitermayer Galvao; Campos, Leila Carvalho] Fundacao Oswaldo Cruz, Inst Goncalo Moniz, Salvador, BA, Brazil.
   [Ferreira, Viviane Matos; Feitosa, Caroline Alves] Escola Bahiana Med & Saude Publ, Salvador, BA, Brazil.
   [Chang, How-Yi; Topaz, Nadav; Wang, Xin] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Ribeiro, Guilherme Sousa; Reis, Mitermayer Galvao] Univ Fed Bahia, Fac Med, Salvador, BA, Brazil.
   [Reis, Mitermayer Galvao] Yale Sch Publ Hlth, Dept Epidemiol Microbial Dis, New Haven, CT USA.
RP Campos, LC (reprint author), FIOCRUZ Bahia, Inst Goncalo Moniz, Lab Patol & Biol Mol, Rua Waldemar Falcao 121, BR-40296710 Salvador, BA, Brazil.
EM leila.campos@fiocruz.br
RI Ribeiro, Guilherme/B-6624-2008
OI Ribeiro, Guilherme/0000-0002-6798-2059
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq)National Council for Scientific and Technological Development
   (CNPq) [407558/2016-0]
FX This study was supported by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) [grant number 407558/2016-0].
CR Acevedo R, 2019, EXPERT REV VACCINES, V18, P15, DOI 10.1080/14760584.2019.1557520
   Andrade AL, 2017, VACCINE, V35, P2025, DOI 10.1016/j.vaccine.2017.03.010
   Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021
   Borrow R, 2017, EXPERT REV VACCINES, V16, P313, DOI 10.1080/14760584.2017.1258308
   Breakwell L, 2018, VACCINE, V36, P29, DOI 10.1016/j.vaccine.2017.11.040
   Burman C, 2019, HUM VACC IMMUNOTHER, V15, P459, DOI 10.1080/21645515.2018.1528831
   Cardoso CW, 2012, VACCINE, V30, P5541, DOI 10.1016/j.vaccine.2012.06.044
   Caugant DA, 2008, INFECT GENET EVOL, V8, P558, DOI 10.1016/j.meegid.2008.04.002
   Caugant DA, 2007, FEMS MICROBIOL REV, V31, P52, DOI 10.1111/j.1574-6976.2006.00052.x
   Christensen H, 2010, LANCET INFECT DIS, V10, P853, DOI 10.1016/S1473-3099(10)70251-6
   Claus H, 2002, MICROBIOL-SGM, V148, P1813, DOI 10.1099/00221287-148-6-1813
   Comanducci M, 2004, INFECT IMMUN, V72, P4217, DOI 10.1128/IAI.72.7.4217-4223.2004
   de Moraes JC, 2015, PEDIATR INFECT DIS J, V34, P1197, DOI 10.1097/INF.0000000000000853
   Departamento de Informatica do SUS-DATASUS BR, 2019, MEN CAS CONF NOT SIS
   do Macedo LE, 2018, HUM VACC IMMUNOTHER, V14, P1131, DOI 10.1080/21645515.2017.1415682
   Gardner SN, 2015, BIOINFORMATICS, V31, P2877, DOI 10.1093/bioinformatics/btv271
   Gasparini R, 2014, J CLIN MICROBIOL, V52, P1901, DOI 10.1128/JCM.03584-13
   Gianchecchi E, 2017, EXPERT REV ANTI-INFE, V15, P689, DOI 10.1080/14787210.2017.1333422
   HAMMERSCHMIDT S, 1994, MOL MICROBIOL, V11, P885, DOI 10.1111/j.1365-2958.1994.tb00367.x
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Harrison LH, 2015, J INFECT DIS, V211, P1761, DOI 10.1093/infdis/jiu679
   Instituto Brasileiro de Geografia e Estatistica-IBGE, 2018, POP EST SALV BAH
   Jolley KA, 2007, FEMS MICROBIOL REV, V31, P89, DOI 10.1111/j.1574-6976.2006.00057.x
   Jolley KA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-595
   Letunic I, 2016, NUCLEIC ACIDS RES, V44, pW242, DOI 10.1093/nar/gkw290
   Lucidarme J, 2010, CLIN VACCINE IMMUNOL, V17, P919, DOI 10.1128/CVI.00027-10
   MacLennan J, 2006, EMERG INFECT DIS, V12, P950
   Marshall HS, 2020, NEW ENGL J MED, V382, P318, DOI 10.1056/NEJMoa1900236
   Masignani V, 2003, J EXP MED, V197, P789, DOI 10.1084/jem.20021911
   Ministerio da Saude BR. Departamento de Vigilancia Epidemiologica Coordenacao Geral do Programa Nacional de Imunizacoes, 2010, INTR VAC MEN C CONJ
   Moreno J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135497
   Moreno J, 2015, BIOMEDICA, V35, P138, DOI [10.7705/biomedica.v35i1.2414, 10.1590/S0120-41572015000100017]
   Nunes AMPB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166475
   Pollard AJ, 2013, ARCH DIS CHILD, V98, P248, DOI 10.1136/archdischild-2012-303103
   Rodrigues CMC, 2019, WELLCOME OPEN RES, V3, P151, DOI [10.12688/wellcomeopenres.14859.2, DOI 10.12688/WELLCOMEOPENRES.14859.2]
   Rouphael NG, 2012, METHODS MOL BIOL, V799, P1, DOI 10.1007/978-1-61779-346-2_1
   Schneider MC, 2006, J IMMUNOL, V176, P7566, DOI 10.4049/jimmunol.176.12.7566
   Serruto D, 2012, VACCINE, V30, pB87, DOI 10.1016/j.vaccine.2012.01.033
   Shirley M, 2018, DRUGS, V78, P257, DOI 10.1007/s40265-018-0869-7
   Moura ARSS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185038
   Snape MD, 2008, BRIT MED J, V336, P1487, DOI 10.1136/bmj.39563.545255.AE
   Sociedade Brasileira de Imunizacoes (BR), NOT TECN CONJ SBIM S
   Soeters HM, 2017, CLIN INFECT DIS, V64, P1115, DOI 10.1093/cid/cix091
   Thomas JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019361
   Tzeng YL, 2016, CRIT REV MICROBIOL, V42, P759, DOI 10.3109/1040841X.2015.1022507
   van de Beek D, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.74
   Vetter V, 2016, EXPERT REV VACCINES, V15, P641, DOI 10.1586/14760584.2016.1130628
   Weckx LY, 2017, BRAZ J INFECT DIS, V21, P587, DOI 10.1016/j.bjid.2017.06.005
NR 48
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 2995
EP 3002
DI 10.1016/j.vaccine.2020.02.050
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400013
PM 32115294
DA 2020-05-12
ER

PT J
AU Kasereka, MC
   Ericson, AD
   Conroy, AL
   Tumba, L
   Mwesha, OD
   Hawkes, MT
AF Kasereka, Masumbuko Claude
   Ericson, Austin D.
   Conroy, Andrea L.
   Tumba, Lukaba
   Mwesha, Ombeni Didier
   Hawkes, Michael T.
TI Prior vaccination with recombinant Vesicular Stomatitis Virus - Zaire
   Ebolavirus vaccine is associated with improved survival among patients
   with Ebolavirus infection
SO VACCINE
LA English
DT Article
DE Ebolavirus; rVSV-ZEBOV; Organ impairment; Survival benefit
ID GLOMERULAR-FILTRATION-RATE; EQUATION
AB The second largest Ebolavirus disease (EVD) outbreak ever recorded is currently ongoing in Eastern Democratic Republic of the Congo (DRC). This is the first outbreak for which the recombinant Vesicular Stomatitis Virus - Zaire Ebolavirus (rVSV-ZEBOV) candidate vaccine has been widely administered, using a ring vaccination strategy. We examined whether prior vaccination with rVSV-ZEBOV impacts viral load, organ impairment, and survival among patients with EVD admitted to Ebola Treatment Units (ETUs) in the DRC. We conducted a retrospective observational study of patients admitted to the ETUs in Butembo and Katwa, Eastern DRC, between 30 March and 10 August 2019. We included 257 patients, of whom 44 had been vaccinated prior to admission and 213 were unvaccinated. Vaccinated patients were admitted to hospital sooner than unvaccinated patients (median 2 days (IQR 1.8-4) versus 4 days (IQR 3-6), p < 0.001). Vaccinated patients had a lower viral load at admission compared to those who were unvaccinated: 6.0 log(10) cp/mL (IQR 5.0-7.1) versus 6.9 log(10) cp/mL (IQR 5.4-7.6), p = 0.017. In a longitudinal analysis of daily viral load measurements, vaccinated patients had an overall viremia 1.32 log(10) cp/mL (95% CI 0.58-2.1) lower than unvaccinated patients over the course of their infection. Acute kidney injury at admission was less common in vaccinated patients: OR 0.44 (95% CI 0.20-0.94), p = 0.027. Mortality in vaccinated patients was 10/44 (23%) compared to 117/213 (55%) unvaccinated patients (OR 0.24, 95% CI 0.11-0.51, p < 0.001). In conclusion, prior rVSV-ZEBOV vaccination was associated with reduced severity of infection and improved survival among patients with confirmed EVD treated at ETUs in Eastern DRC. These findings support the efficacy of the rVSV-ZEBOV vaccine in modulating EVD severity. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kasereka, Masumbuko Claude] Univ Catholique Graben, Dept Med, Butembo, DEM REP CONGO.
   [Ericson, Austin D.] Univ Alberta, Edmonton, AB, Canada.
   [Conroy, Andrea L.] Indiana Univ Sch Med, Ryan White Ctr Pediat Infect Dis & Global Hlth, Indianapolis, IN 46202 USA.
   [Tumba, Lukaba] WHO, Coordinat Prise Charge Malad Virus Ebola, Kinshasa, DEM REP CONGO.
   [Mwesha, Ombeni Didier] WHO, Ebola Virus Dis Infect Prevent & Control, Kinshasa, DEM REP CONGO.
   [Hawkes, Michael T.] Univ Alberta, Dept Pediat, Edmonton, AB, Canada.
   [Hawkes, Michael T.] Univ Alberta, Dept Med Microbiol & Immunol, Edmonton, AB, Canada.
   [Hawkes, Michael T.] Univ Alberta, Sch Publ Hlth, Edmonton, AB, Canada.
   [Hawkes, Michael T.] Univ Alberta, Stollery Sci Lab, Edmonton, AB, Canada.
   [Hawkes, Michael T.] Univ Alberta, Women & Childrens Res Inst, Edmonton, AB, Canada.
RP Hawkes, MT (reprint author), 3-593 Edmonton Clin Hlth Acad 11405 87, Edmonton, AB T5G 1C9, Canada.
EM mthawkes@ualberta.ca
OI Kasereka, Masumbuko/0000-0003-1367-3426
FU Association for Health Innovation in Africa (AFHIA) [2018-03]; Women and
   Children's Health Research Institute
FX This study was supported by Association for Health Innovation in Africa
   (AFHIA, Grant Number 2018-03 [KMC]). The funder had no role in study
   design, data collection, data analysis, data interpretation, writing of
   the report, or decision to submit the article for publication.; Author
   MH is supported by the Women and Children's Health Research Institute
   and is a Distinguished Researcher, Stollery Science Lab.
CR [Anonymous], 2019, Nature, V572, P288, DOI 10.1038/d41586-019-02416-8
   [Anonymous], 2019, PREL RES EFF RVSV ZE
   Branswell H., 2019, EBOLA VACCINE WILL B
   Claude KM, 2018, LANCET, V392, P1399, DOI 10.1016/S0140-6736(18)32419-X
   Gaudinski MR, 2019, LANCET, V393, P889, DOI 10.1016/S0140-6736(19)30036-4
   Group P.I.W., 2013, NEW ENGL J MED, V75, P1448
   Hartley MA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005265
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Hoste L, 2014, NEPHROL DIAL TRANSPL, V29, P1082, DOI 10.1093/ndt/gft277
   Hunt L, 2015, LANCET INFECT DIS, V15, P1292, DOI 10.1016/S1473-3099(15)00144-9
   Kasereka MC, 2019, VACCINE, V37, P2174, DOI 10.1016/j.vaccine.2019.03.004
   Khwaja A, 2012, NEPHRON CLIN PRACT, V120, pC179, DOI 10.1159/000339789
   Lanini S, 2015, J CLIN INVEST, V125, P4692, DOI 10.1172/JCI83111
   Maxmen A, 2019, NATURE, V567, P153, DOI 10.1038/d41586-019-00805-7
   McMullan LK, 2019, LANCET INFECT DIS, V19, P1023, DOI 10.1016/S1473-3099(19)30291-9
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Pinsky BA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142216
   Pottel H, 2016, NEPHROL DIAL TRANSPL, V31, P798, DOI 10.1093/ndt/gfv454
   R Core Team, 2018, R LANG ENV STAT COMP
   SAGE, 2019, SAGE INT REC VACC EB
   Sivapalasingam S, 2018, LANCET INFECT DIS, V18, P884, DOI 10.1016/S1473-3099(18)30397-9
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   WHO, 2019, EB SIT REP DEM REP C
   WHO, 2019, STRAT RESP PLAN EB V
   World Health Organization, 2019, EB OUTBR DEM REP CON
NR 25
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 3003
EP 3007
DI 10.1016/j.vaccine.2020.02.044
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400014
PM 32093984
DA 2020-05-12
ER

PT J
AU Leidner, AJ
   Fisun, H
   Trimble, S
   Lucas, P
   Noblit, C
   Stevenson, JM
AF Leidner, Andrew J.
   Fisun, Helen
   Trimble, Sean
   Lucas, Paul
   Noblit, Cameron
   Stevenson, John M.
TI Evaluation of temperature stability among different types and grades of
   vaccine storage units: Data from continuous temperature monitoring
   devices
SO VACCINE
LA English
DT Article
DE Vaccines; Storage units; Cold-chain; Continuous temperature monitoring;
   Digital data logger
ID COLD CHAIN; IMMUNIZATION; MEASLES; STATES
AB Objective: To evaluate the ability of different types of vaccine storage units to maintain appropriate temperatures for the storage of vaccines and to characterize deviations from recommended temperatures.
   Data sources: Continuous temperature monitoring devices, or digital data loggers, from vaccine providers who participated in a continuous temperature monitoring pilot project.
   Study design: We computed descriptive statistics on the percentage of runtime with an out-of-range temperature, or excursion, for different storage unit types (freezers and refrigerators) and for different storage unit grades (household-grade combination, household-grade stand alone, and purpose-built or pharmaceutical grade). We developed frequency histograms for the percentage of storage unit runtime outside of the normal range. We plotted the duration and temperature extrema for identified excursions. Analyses were stratified by storage unit type and grade.
   Results: Household-grade combination units underperformed relative to household-grade stand-alone and purpose-built units. Among refrigerators, household-grade combination units operated in the normal temperature range an average of 98.9% of their observed runtime, which was lower than 99.4% (p value = 0.038) for household-grade stand-alone and 99.9% (p value < 0.001) for purpose-built units. Among freezers, household-grade combination units operated in the normal temperature range an average of 95.0% of their observed runtime, which was lower than 99.3% (p value < 0.001) for household-grade stand-alone units and 99.7% (p value < 0.001) for purpose-built units.
   Conclusion: These findings, in particular the underperformance of household-grade combination units relative to household-grade stand-alone and purpose-built units, support current CDC recommendations to avoid the use of household-grade combination storage units when possible. Published by Elsevier Ltd.
C1 [Leidner, Andrew J.; Trimble, Sean; Lucas, Paul; Noblit, Cameron; Stevenson, John M.] CDC, Immunizat Serv Div, Atlanta, GA USA.
   [Fisun, Helen] Assoc Sch & Programs Publ Hlth, Washington, DC USA.
RP Leidner, AJ (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,MS A-19, Atlanta, GA 30333 USA.
EM aleidner@cdc.gov
CR Boros CA, 2001, VACCINE, V19, P3537, DOI 10.1016/S0264-410X(01)00063-9
   Centers for Disease Control and Prevention, 2018, VACC STOR HANDL TOOL
   Chojnacky M., 2009, THERMAL ANAL REFRIGE
   Chojnacky M, 2012, DATA LOGGER THERMOME
   Chojnacky MJ, 2010, THERMAL ANAL REFRIGE
   Dabestani NM, 2019, PREV MED, V126, DOI 10.1016/j.ypmed.2019.05.022
   East AR, 2008, VACCINE, V26, P1322, DOI 10.1016/j.vaccine.2007.12.055
   Fisun H., 2016, NAT IMM C ATL GEOGR
   Galazka A, 1998, THERMOSTABILITY VACC
   Gazmararian JA, 2002, AM J PREV MED, V23, P246, DOI 10.1016/S0749-3797(02)00512-3
   Glista K., 2014, HARTFORD HEALTHCARE
   Karp CL, 2015, VACCINE, V33, P3471, DOI 10.1016/j.vaccine.2015.05.071
   Kartoglu U, 2010, VACCINE, V28, P4065, DOI 10.1016/j.vaccine.2010.03.076
   Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3
   Leidner AJ, 2020, J PUBLIC HEALTH-HEID, DOI 10.1007/s10389-020-01207-0
   Leidner AJ, 2019, VACCINE, V37, P226, DOI 10.1016/j.vaccine.2018.11.056
   Levinson DR, 2012, VACCINES CHILDREN PR
   Lloyd J, 2015, VACCINE, V33, P902, DOI 10.1016/j.vaccine.2014.10.080
   MCALEER WJ, 1980, J BIOL STAND, V8, P281, DOI 10.1016/S0092-1157(80)80005-9
   McColloster P, 2011, AM J PUBLIC HEALTH, V101, P46, DOI 10.2105/AJPH.2009.179853
   Milstien JB, 2006, TEMPERATURE SENSITIV, P1
   Muegge S, 2012, AM J NURS, V112, P61, DOI 10.1097/01.NAJ.0000422257.03331.bd
   Mukherjee A, 2004, J HEALTH POPUL NUTR, V22, P13
   Schlehuber LD, 2011, VACCINE, V29, P5031, DOI 10.1016/j.vaccine.2011.04.079
   Setia S, 2002, VACCINE, V20, P1148, DOI 10.1016/S0264-410X(01)00433-9
   Stevenson J, 2016, SUMMARY PROGR RECIPE
   Whitney CG, 2014, MMWR-MORBID MORTAL W, V63, P352
   Zhou FJ, 2005, ARCH PEDIAT ADOL MED, V159, P1136, DOI 10.1001/archpedi.159.12.1136
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 3008
EP 3014
DI 10.1016/j.vaccine.2020.02.043
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400015
PM 32111527
DA 2020-05-12
ER

PT J
AU Lin, YL
   Lin, Z
   He, F
   Chen, HL
   Lin, X
   Zimet, GD
   Alias, H
   He, SQ
   Hu, ZJ
   Wong, L
AF Lin, Yulan
   Lin, Zheng
   He, Fei
   Chen, Huilin
   Lin, Xi
   Zimet, Gregory D.
   Alias, Haridah
   He, Shuqiong
   Hu, Zhijian
   Wong, Li Ping
TI HPV vaccination intent and willingness to pay for 2-,4-, and 9-valent
   HPV vaccines: A study of adult women aged 27-45 years in China
SO VACCINE
LA English
DT Article
DE HPV vaccination intention; Adult women; China; 2-, 4-and 9-valent HPV
   vaccines
ID CERVICAL-CANCER; PAPILLOMAVIRUS; IMMUNOGENICITY; ACCEPTABILITY;
   INFECTIONS; EFFICACY; SAFETY; OLDER
AB Objective: This study aims to investigate acceptance and willingness to pay for HPV vaccination among adult women in China.
   Methods: An online survey was sent to mothers aged 27-45 years of primary school pupils in the Fujian province, China. Participants completed questions about HPV related knowledge and health beliefs, intention to take the HPV vaccine and the willingness to pay for bivalent vaccine (2vHPV), quadrivalent vaccine (4vHPV), and 9-valent HPV vaccine (9vHPV).
   Results: Of a total of 2339 complete responses, 58.3% reported intent to obtain HPV vaccine. Mothers who were younger in age, residing in urban, working in managerial or professional occupations, who knew someone with cervical cancer and who were able to make independent decisions about the HPV vaccine (vs. joint decision with spouse) were more likely to express intent to have HPV vaccination. Perceived barriers, cues to action and self-efficacy were three of the constructs in the health belief model that significantly influenced HPV vaccination intent. A higher proportion of participants expressed willingness to pay for 2vHPV (81.2%) and 4vHPV (75.9%), as compared to 9vHPV (67.7%).
   Conclusion: Adults women expressed moderate intention to receive the HPV vaccine. Intervention to address barriers to uptake of the HPV vaccine among adult women in China is warranted. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Lin, Yulan; Lin, Zheng; He, Fei; Hu, Zhijian] Fujian Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Fujian Prov Key Lab Environm Factors & Canc, Fuzhou 350122, Fujian, Peoples R China.
   [Lin, Yulan; Lin, Zheng; He, Fei; Hu, Zhijian] Fujian Med Univ, Minist Educ Gastrointestinal Canc, Key Lab, Fuzhou 350122, Fujian, Peoples R China.
   [Chen, Huilin] Anxi Cty Hosp, Dept Radiat Oncol, Quanzhou 352400, Fujian, Peoples R China.
   [Lin, Xi] Fujian Med Univ, Zhangzhou Affiliated Hosp, Zhangzhou 363000, Fujian, Peoples R China.
   [Zimet, Gregory D.] Indiana Univ, Sch Med, Dept Pediat, 410 W,10th St,HS 1001, Indianapolis, IN 46202 USA.
   [Alias, Haridah; Wong, Li Ping] Univ Malaya, Fac Med, Ctr Epidemiol & Evidence Based Practice, Dept Social & Prevent Med, Kuala Lumpur 50603, Malaysia.
   [He, Shuqiong] Fujian Med Univ, Prenatal Diag Ctr, Fujian Prov Matern & Childrens Hosp, Fuzhou 350001, Fujian, Peoples R China.
RP Hu, ZJ (reprint author), Fujian Med Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Fujian Prov Key Lab Environm Factors & Canc, Fuzhou 350122, Fujian, Peoples R China.; Hu, ZJ (reprint author), Fujian Med Univ, Minist Educ Gastrointestinal Canc, Key Lab, Fuzhou 350122, Fujian, Peoples R China.; Wong, L (reprint author), Univ Malaya, Fac Med, Ctr Epidemiol & Evidence Based Practice, Dept Social & Prevent Med, Kuala Lumpur 50603, Malaysia.
EM huzhijian@fjmu.edu.cn; wonglp@ummc.edu.my
RI Wong, Li Ping/C-1049-2010
OI Wong, Li Ping/0000-0002-0107-0532; Lin, Yulan/0000-0002-4208-9408
FU Natural Science Foundation of Fujian Province, China - Science and
   Technology Department of Fujian Province, China [2018J01825];
   Cultivation Program for Distinguished Young Scholar in Fujian Province
   University - Education Department of Fujian Province, China [2017B020];
   Fujian Medical University's Research Foundation for Talented Scholars -
   Fujian Medical University, China [XRCZX2017012]; National Key R&D
   Program of China - Ministry of Education of the People's Republic of
   China [2017YFC0907100]
FX This work was supported by the following grants: (1) Natural Science
   Foundation of Fujian Province, China [Grant No. 2018J01825], funded by
   Science and Technology Department of Fujian Province, China; (2)
   Cultivation Program for Distinguished Young Scholar in Fujian Province
   University [Grant No. 2017B020], funded by The Education Department of
   Fujian Province, China; (3) Fujian Medical University's Research
   Foundation for Talented Scholars [Grant No. XRCZX2017012], funded by
   Fujian Medical University, China; and (4) National Key R&D Program of
   China [Grant No. 2017YFC0907100], funded by Ministry of Education of the
   People's Republic of China. All funding sources were not involved in
   study design, data collection, data analysis, report writing, nor the
   publication.
CR [Anonymous], 2018, FDA APPR EXP US GARD
   Tran BX, 2018, PATIENT PREFER ADHER, V12, P1717, DOI 10.2147/PPA.S171362
   Becker M.H., 1974, HLTH ED MONOGRAPHS, V2, P324, DOI DOI 10.1177/109019817400200401
   Black LL, 2009, VACCINE, V27, P1668, DOI 10.1016/j.vaccine.2009.01.035
   Brotherton JML, 2009, MED J AUSTRALIA, V191, P188, DOI 10.5694/j.1326-5377.2009.tb02738.x
   Buang SN, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4602
   Burger EA, 2017, CLIN INFECT DIS, V65, P893, DOI 10.1093/cid/cix475
   Castellsague X, 2011, BRIT J CANCER, V105, P28, DOI 10.1038/bjc.2011.185
   Champion V L, 1984, ANS Adv Nurs Sci, V6, P73
   Chen LH, 2018, CANCER CONTROL, V25, DOI 10.1177/1073274818775356
   Dempsey AF, 2015, VACCINE, V33, P1556, DOI 10.1016/j.vaccine.2015.02.018
   Glanz JM, 2017, PEDIATRICS, V140, DOI 10.1542/peds.2017-1117
   He JY, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0619-8
   Hosmer D.W., 2013, APPL LOGISTIC REGRES
   ICO/IARC information centre on HPV and cancer, 2017, CHIN HUM PAP REL CAN
   Jiang LB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210311
   Liau A, 2012, PREV MED, V54, P277, DOI 10.1016/j.ypmed.2012.02.002
   ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P328, DOI 10.1177/109019817400200403
   Skinner SR, 2014, LANCET, V384, P2213, DOI 10.1016/S0140-6736(14)60920-X
   Song BB, 2017, CHINESE J CANCER RES, V29, P471, DOI 10.21147/j.issn.1000-9604.2017.06.01
   Wang T, 2015, CHINESE MED J-PEKING, V128, P3298, DOI 10.4103/0366-6999.171420
   Weisberg E, 2009, AUST FAM PHYSICIAN, V38, P72
   Weiss Thomas W, 2011, ISRN Obstet Gynecol, V2011, P670318, DOI 10.5402/2011/670318
   Winer RL, 2012, SEX TRANSM DIS, V39, P848, DOI 10.1097/OLQ.0b013e3182641f1c
   Wong LP, 2010, INT J PUBLIC HEALTH, V55, P35, DOI 10.1007/s00038-009-0072-4
   Yin Y, 2017, LANCET, V390, P1735, DOI 10.1016/S0140-6736(17)32606-5
   Yu YRA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150606
   Zhang Y, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-2045-8
   Zhao FH, 2019, LANCET, V393, P969, DOI 10.1016/S0140-6736(18)32849-6
   Zhao XL, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e30
   Zhou HL, 2018, J INFECTION, V76, P522, DOI 10.1016/j.jinf.2018.02.008
   Zhou M, 2019, HUM VACC IMMUNOTHER, V15, P1688, DOI 10.1080/21645515.2018.1547605
   Zhu FC, 2014, HUM VACC IMMUNOTHER, V10, P1795, DOI 10.4161/hv.28702
NR 33
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 3015
EP 3024
DI 10.1016/j.vaccine.2020.02.042
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400016
PM 32127227
DA 2020-05-12
ER

PT J
AU Gold, MS
   MacDonald, NE
   McMurtry, CM
   Balakrishnan, MR
   Heininger, U
   Menning, L
   Benes, O
   Pless, R
   Zuber, PLF
AF Gold, Michael S.
   MacDonald, Noni E.
   McMurtry, C. Meghan
   Balakrishnan, Madhava Ram
   Heininger, Ulrich
   Menning, Lisa
   Benes, Oleg
   Pless, Robert
   Zuber, Patrick L. F.
TI Immunization stress-related response - Redefining immunization
   anxiety-related reaction as an adverse event following immunization
SO VACCINE
LA English
DT Article
DE Immunization; Anxiety; Stress; AEFI; Clusters; Immunization
   stress-related responses; Immunization anxiety responses
ID CONVERSION DISORDER; VACCINATION; SEIZURES; SYNCOPE; MODEL
AB The Council for the International Organizations of Medical Sciences (CIOMS) and WHO working group on pharmacovigilance defines five cause specific AEFI which includes an immunization anxiety-related reaction. Historically this term has been used to describe a range of symptoms and signs that may arise after immunization that are related to "anxiety" about the immunization. However, the term "anxiety" does not adequately capture all the elements of this cause specific AEFI. In 2015, the Global Advisory Committee for Vaccine Safety convened an expert working group with the purpose of redefining, preventing and managing this particular AEFI. The term "Immunization Stress-Related Response" is proposed to replace the former terminology. We present a manual that redefines this AEFI and present a framework for prevention, diagnosis and management in both an individual and also when such events occur as clusters and affect multiple individuals. Since such mass events can result in cessation of immunization programmes and/or a loss of public confidence, a communication response is essential. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Gold, Michael S.] Univ Adelaide, Sch Med, Discipline Paediat, 77 King William Rd, Adelaide, SA 5000, Australia.
   [MacDonald, Noni E.] Dalhousie Univ, IWK Hlth Ctr, Dept Paediat, Halifax, NS, Canada.
   [McMurtry, C. Meghan] Univ Guelph, Dept Psychol, Guelph, ON, Canada.
   [McMurtry, C. Meghan] McMaster Childrens Hosp, Pediat Chron Pain Program, Hamilton, ON, Canada.
   [Balakrishnan, Madhava Ram; Zuber, Patrick L. F.] WHO, Dept Essential Med & Hlth Prod EMP, Geneva, Switzerland.
   [Heininger, Ulrich] Univ Basel, Div Pediat Infect Dis & Vaccinol, Childrens Hosp, Basel, Switzerland.
   [Menning, Lisa] WHO, Expanded Programme Immunizat, Geneva, Switzerland.
   [Benes, Oleg] WHO, Reg Off Europe, Copenhagen, Denmark.
   [Pless, Robert] Hlth Canada, Clin Evaluat Div, Vaccines Blood Biol & Genet Therapies Directorate, Ottawa, ON, Canada.
RP Gold, MS (reprint author), Univ Adelaide, Sch Med, Discipline Paediat, 77 King William Rd, Adelaide, SA 5000, Australia.
EM michael.gold@adelaide.edu.au
FU World Health OrganizationWorld Health Organization [001]
CR [Anonymous], CAUS ASS ADV EV FOLL
   Belda X, 2015, STRESS, V18, P269, DOI 10.3109/10253890.2015.1067678
   Bodde NMG, 2009, SEIZURE-EUR J EPILEP, V18, P543, DOI 10.1016/j.seizure.2009.06.006
   Borrell-Carrio F, 2004, ANN FAM MED, V2, P576, DOI 10.1370/afm.245
   Braun MM, 1997, ARCH PEDIAT ADOL MED, V151, P255, DOI 10.1001/archpedi.1997.02170400041007
   Brinth LS, 2015, VACCINE, V33, P2602, DOI 10.1016/j.vaccine.2015.03.098
   ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460
   European Medicines Agency, HPV VACC EMA CONF EV
   Fedorowski A, 2019, J INTERN MED, V285, P352, DOI 10.1111/joim.12852
   Feiring B, 2017, VACCINE, V35, P4203, DOI 10.1016/j.vaccine.2017.06.031
   Freedman T, 2019, PAED CHILD HEALT-CAN, V24, pS42, DOI 10.1093/pch/pxz020
   Huygen F, 2015, EBIOMEDICINE, V2, P1114, DOI 10.1016/j.ebiom.2015.07.003
   Kozlowska K, 2007, J AM ACAD CHILD PSY, V46, P68, DOI 10.1097/01.chi.0000242235.83140.1f
   LaFrance WC, 2013, EPILEPSIA, V54, P2005, DOI 10.1111/epi.12356
   Larson HJ, 2014, HUM VACC IMMUNOTHER, V10, P2543, DOI 10.4161/21645515.2014.969618
   Loharikar A, 2018, VACCINE, V36, P299, DOI 10.1016/j.vaccine.2017.11.017
   MacDonald NE, 2015, VACCINE, V33, P4161, DOI 10.1016/j.vaccine.2015.04.036
   McEwen BS, 2007, PHYSIOL REV, V87, P873, DOI 10.1152/physrev.00041.2006
   McMurtry C Meghan, 2015, Clin J Pain, V31, pS3, DOI 10.1097/AJP.0000000000000272
   Mink JW, 2013, ANN NY ACAD SCI, V1304, P40, DOI 10.1111/nyas.12298
   OST LG, 1984, BEHAV RES THER, V22, P109, DOI 10.1016/0005-7967(84)90099-8
   Schwartzstein RM, 2019, HYPERVENTILATION SYN
   SELYE H, 1976, CAN MED ASSOC J, V115, P53
   Sigurdardottir KR, 1998, EPILEPSIA, V39, P749, DOI 10.1111/j.1528-1157.1998.tb01161.x
   Simas C, 2019, HUM VACC IMMUNOTHER, V15, P163, DOI 10.1080/21645515.2018.1511667
   Sutherland A., 2008, Morbidity and Mortality Weekly Report, V57, P457
   Taddio A, 2015, CMAJ
   VANLIESHOUT JJ, 1991, CLIN SCI, V81, P575, DOI 10.1042/cs0810575
   WARD D, 2017, EURO SURVEILL, V27
   World Health Organization, 2019, NEW MEASL SURV DAT W
   World Health Organization, 2018, INT STAT CLASS DIS R
   World Health Organization, 2015, WER, V90, P505
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 3025
EP 3030
DI 10.1016/j.vaccine.2020.02.046
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400017
PM 32131975
DA 2020-05-12
ER

PT J
AU Liu, MY
   Zhong, YX
   Chen, J
   Liu, Y
   Tang, CF
   Wang, XW
   Zhang, YB
   Wang, P
   Logan, SM
   Chen, WX
   Wei, B
AF Liu, Meiying
   Zhong, Youxiu
   Chen, Jing
   Liu, Yu
   Tang, Chongfa
   Wang, Xuewei
   Zhang, Yanbin
   Wang, Ping
   Logan, Susan M.
   Chen, Wangxue
   Wei, Bo
TI Oral immunization of mice with a multivalent therapeutic subunit vaccine
   protects against Helicobacter pylori infection
SO VACCINE
LA English
DT Article
DE Helicobacter pylori; Therapeutic vaccines; Mucosal adjuvant; Immune
   responses; Th17 immune response; Mice
ID HEAT-LABILE TOXIN; ESCHERICHIA-COLI; IMMUNE-RESPONSES; GASTRIC-CANCER;
   DOUBLE-BLIND; SAFETY; IMMUNOGENICITY; ERADICATION; ANTIBODIES; ADJUVANT
AB Helicobacter pylori is a human class I carcinogen and no effective prophylactic or therapeutic H. pylori vaccine has yet been marketed. H. pylori can escape the host immune response, but the precise immune protection mechanisms in humans remain unknown. In this study, we developed a multivalent, subunit H. pylori vaccine candidate by formulating three commonly used H. pylori antigens, neutrophil-activating protein (NAP), urease subunit A (UreA) and subunit B (UreB) with the mucosal adjuvant, a double-mutant heat-labile toxin (dmLT) from Escherichia coli, and evaluated its immunogenicity and therapeutic efficacy in a mouse model of H. pylori infection. We found that oral immunization of H. pylori-infected mice significantly reduced gastric bacterial colonization at both 2 and 8 weeks after immunization. The reduction in bacterial burdens was accompanied with significantly increased serum antigen-specific IgG responses and mucosal IgA responses. Moreover, oral immunization also induced Th1/Th17 immune responses, which may play a synergistic role with the specific antibodies in the elimination of H. pylori. Thus, our vaccine candidate appears able to overcome the immune evasion mechanism of H. pylori, restore the suppression of Th2 immune responses with the induction of a strong humoral immune response. These results lay the foundation for the development of an optimized oral therapeutic H. pylori vaccine with increased immunogenicity of UreA and UreB, as well as providing long-term immunity. Crown Copyright (C) 2020 Published by Elsevier Ltd. All rights reserved.
C1 [Liu, Meiying; Zhong, Youxiu; Chen, Jing; Liu, Yu; Tang, Chongfa; Wang, Xuewei; Zhang, Yanbin; Wang, Ping; Wei, Bo] NVSI, Beijing Econ & Technol Dev Zone, 38 Jinghai 2nd Rd, Beijing, Peoples R China.
   [Logan, Susan M.; Chen, Wangxue] Natl Res Council Canada, Human Hlth Therapeut HHT Res Ctr, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.
   [Wei, Bo] 2600 Hilltop Dr, Richmond, CA 94806 USA.
RP Wei, B (reprint author), NVSI, Beijing Econ & Technol Dev Zone, 38 Jinghai 2nd Rd, Beijing, Peoples R China.; Chen, WX (reprint author), Natl Res Council Canada, Human Hlth Therapeut HHT Res Ctr, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.; Wei, B (reprint author), 2600 Hilltop Dr, Richmond, CA 94806 USA.
EM wangxue.chen@nrc.gc.ca; bwei@JoinnUSA.com
FU CNBG-NRC Vaccine RD Collaboration
FX We would like to thank Annie Aubry, Greg Harris and Hongyan Zhou for
   their technical supports to part of this study, and Rhonda KuoLee for
   project management and technical advice. The dmLT adjuvant used for this
   study were kindly provided by PATH. This study was partially supported
   under the CNBG-NRC Vaccine R&D Collaboration.
CR Abadi ATB, 2016, WORLD J GASTROENTERO, V22, P3150, DOI 10.3748/wjg.v22.i11.3150
   Abbasi J, 2017, JAMA-J AM MED ASSOC, V317, P1400, DOI 10.1001/jama.2017.2629
   Akhiani AA, 2004, J IMMUNOL, V172, P5024, DOI 10.4049/jimmunol.172.8.5024
   [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P177
   Bhuiyan TR, 2010, J INFECT DIS, V202, P1676, DOI 10.1086/657085
   Blanchard TG, 2017, PEDIATR RES, V81, P170, DOI 10.1038/pr.2016.199
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen W, 1999, SCAND J GASTROENTERO, V34, P987
   Chen WX, 2001, J GASTROEN HEPATOL, V16, P377, DOI 10.1046/j.1440-1746.2001.02459.x
   Chen WX, 2000, J GASTROEN HEPATOL, V15, P1000, DOI 10.1046/j.1440-1746.2000.02286.x
   Corral JE, 2017, WORLD J GASTRO ONCOL, V9, P184, DOI 10.4251/wjgo.v9.i4.184
   D'Elios MM, 2014, HELICOBACTER, V19, P19, DOI 10.1111/hel.12156
   Daugule Ilva, 2015, World J Methodol, V5, P203, DOI 10.5662/wjm.v5.i4.203
   De Koster E, 1994, Eur J Cancer Prev, V3, P247
   El-Kamary SS, 2013, CLIN VACCINE IMMUNOL, V20, P1764, DOI 10.1128/CVI.00464-13
   Ermak TH, 1998, J EXP MED, V188, P2277, DOI 10.1084/jem.188.12.2277
   Flach CF, 2011, INFECT IMMUN, V79, P879, DOI 10.1128/IAI.00756-10
   Ford AC, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3174
   Ford AC, 2008, WORLD J GASTROENTERO, V14, P7361, DOI 10.3748/wjg.14.7361
   Fu HW, 2014, WORLD J GASTROENTERO, V20, P5294, DOI 10.3748/wjg.v20.i18.5294
   Guo L, 2012, APPL MICROBIOL BIOT, V93, P1937, DOI 10.1007/s00253-011-3726-0
   Hooi JKY, 2017, GASTROENTEROLOGY, V153, P420, DOI 10.1053/j.gastro.2017.04.022
   HU LT, 1990, INFECT IMMUN, V58, P992, DOI 10.1128/IAI.58.4.992-998.1990
   Imrie C, 2001, PEDIATRICS, V107, P373, DOI 10.1542/peds.107.2.373
   Kandulski A, 2014, CURR OPIN GASTROEN, V30, P402, DOI 10.1097/MOG.0000000000000085
   KUIPERS EJ, 1995, AM J GASTROENTEROL, V90, P1401
   Lender N, 2014, ALIMENT PHARM THER, V40, P24, DOI 10.1111/apt.12790
   Lina TT, 2014, WORLD J GASTROENTERO, V20, P12753, DOI 10.3748/wjg.v20.i36.12753
   Lundgren A, 2014, VACCINE, V32, P7077, DOI 10.1016/j.vaccine.2014.10.069
   Makola D, 2007, J CLIN GASTROENTEROL, V41, P548, DOI 10.1097/MCG.0b013e318030e3c3
   Malfertheiner P, 2017, GUT, V66, P6, DOI 10.1136/gutjnl-2016-312288
   Malfertheiner P, 2018, LANCET GASTROENTEROL, V3, P698, DOI 10.1016/S2468-1253(18)30125-0
   Mirzaei N, 2017, CRIT REV MICROBIOL, V43, P631, DOI 10.1080/1040841X.2017.1291578
   Novartis, 2017, EFF SAF H PYL VACC H
   O'Connor A, 2017, HELICOBACTER, V22, DOI 10.1111/hel.12410
   Ottsjo LS, 2017, IMMUNOLOGY, V150, P172, DOI 10.1111/imm.12676
   Ottsjo LS, 2013, INFECT IMMUN, V81, P1532, DOI 10.1128/IAI.01407-12
   PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603
   Raghavan S, 2003, CLIN EXP IMMUNOL, V132, P393, DOI 10.1046/j.1365-2249.2003.02177.x
   Savoldi A, 2018, GASTROENTEROLOGY, V155, P1372, DOI 10.1053/j.gastro.2018.07.007
   Sougioultzis S, 2002, VACCINE, V21, P194, DOI 10.1016/S0264-410X(02)00467-X
   Sutton P., 2016, VACCINE DEV HELICOBA
   Sutton P, 2019, VACCINE, V37, P7295, DOI 10.1016/j.vaccine.2018.01.001
   Sutton P, 2015, LANCET, V386, P1424, DOI 10.1016/S0140-6736(15)60579-7
   Sutton P, 2013, EXPERT REV VACCINES, V12, P433, DOI [10.1586/erv.13.20, 10.1586/ERV.13.20]
   Talebi Bezmin Abadi Amin, 2016, World J Gastrointest Pharmacol Ther, V7, P412, DOI 10.4292/wjgpt.v7.i3.412
   Tegtmeyer N, 2017, CELL HOST MICROBE, V22, P552, DOI 10.1016/j.chom.2017.09.005
   Velin D, 2016, HELICOBACTER, V21, P26, DOI 10.1111/hel.12336
   Welch M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007002
   Wong BCY, 2004, JAMA-J AM MED ASSOC, V291, P187, DOI 10.1001/jama.291.2.187
   Zamani M, 2018, ALIMENT PHARM THER, V47, P868, DOI 10.1111/apt.14561
   Zeng M, 2015, LANCET, V386, P1457, DOI 10.1016/S0140-6736(15)60310-5
NR 52
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 3031
EP 3041
DI 10.1016/j.vaccine.2020.02.036
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400018
PM 32139315
DA 2020-05-12
ER

PT J
AU McDonald, SL
   Weldon, WC
   Wei, L
   Chen, Q
   Shaw, J
   Zhao, K
   Jorba, J
   Kew, OM
   Pallansch, MA
   Burns, CC
   Oberste, MS
AF McDonald, Sharla L.
   Weldon, William C.
   Wei, Ling
   Chen, Qi
   Shaw, Jing
   Zhao, Kun
   Jorba, Jaume
   Kew, Olen M.
   Pallansch, Mark A.
   Burns, Cara C.
   Oberste, M. Steven
TI Neutralization capacity of highly divergent type 2 vaccine-derived
   polioviruses from immunodeficient patients
SO VACCINE
LA English
DT Article
DE Polio; Vaccine-derived; iVDPV; Neutralization
ID PARALYTIC POLIOMYELITIS; EVOLUTION; EXCRETION; INFECTION; SEWAGE; WILD;
   WORLDWIDE; OUTBREAK; FEATURES; DISEASE
AB The use of the oral poliovirus vaccine (OPV) in developing countries has reduced the incidence of poliomyelitis by >99% since 1988 and is the primary tool for global polio eradication. Spontaneous reversions of the vaccine virus to a neurovirulent form can impede this effort. In persons with primary B-cell immunodeficiencies, exposure to OPV can result in chronic infection, mutation, and excretion of immunodeficiency-associated vaccine-derived polioviruses, (iVDPVs). These iVDPVs may have the potential for transmission in a susceptible population and cause paralysis. The extent to which sera from OPV recipients are able to neutralize iVDPVs with varying degrees of antigenic site substitutions is investigated here. We tested sera from a population immunized with a combination vaccine schedule (both OPV and inactivated polio vaccine) against a panel of iVDPVs and found that increases in amino acid substitution in the P1 capsid protein resulted in a decrease in the neutralizing capacity of the sera. This study underscores the importance of maintaining high vaccine coverage in areas of OPV use as well as active surveillance of those known to be immunocompromised. Published by Elsevier Ltd.
C1 [McDonald, Sharla L.; Wei, Ling] IHRC Inc, Contract Polio & Picornavirus Lab Branch, Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Weldon, William C.; Chen, Qi; Shaw, Jing; Zhao, Kun; Jorba, Jaume; Kew, Olen M.; Pallansch, Mark A.; Burns, Cara C.; Oberste, M. Steven] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
RP Oberste, MS (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA.
EM mbo2@cdc.gov
FU Federal appropriations to the Centers for Disease Control and
   PreventionUnited States Department of Health & Human ServicesCenters for
   Disease Control & Prevention - USA
FX This work was supported by Federal appropriations to the Centers for
   Disease Control and Prevention. We greatly appreciate the contributions
   of Jackie Quay, Jane Iber and Renee Park in sequence analysis, and
   Shohreh Shahmahmoodi and Dioselina Pelaez for laboratory testing of
   isolates from Iran and Colombia, respectively.
CR Agol VI, 2006, BIOLOGICALS, V34, P103, DOI 10.1016/j.biologicals.2006.02.007
   Alexander JP, 2009, J INFECT DIS, V199, P391, DOI 10.1086/596052
   [Anonymous], 2002, Wkly Epidemiol Rec, V77, P133
   Bellmunt A, 1999, VIROLOGY, V265, P178, DOI 10.1006/viro.1999.0003
   Blomqvist S, 2004, J VIROL, V78, P4876, DOI 10.1128/JVI.78.9.4876-4883.2004
   Blomqvist S, 2003, J GEN VIROL, V84, P573, DOI 10.1099/vir.0.18708-0
   BROWN GC, 1955, J IMMUNOL, V74, P71
   Burns CC, 2014, J INFECT DIS, V210, pS283, DOI 10.1093/infdis/jiu295
   Burns CC, 2013, J VIROL, V87, P4907, DOI 10.1128/JVI.02954-12
   Chen ZC, 2011, J VIROL, V85, P4354, DOI 10.1128/JVI.02553-10
   Cherkasova EA, 2005, J VIROL, V79, P1062, DOI 10.1128/JVI.79.2.1062-1070.2005
   Collett MS, 2017, J INFECT DIS, V215, P335, DOI 10.1093/infdis/jiw542
   de Silva R, 2012, VACCINE, V30, P7561, DOI 10.1016/j.vaccine.2012.10.035
   DeVries AS, 2011, NEW ENGL J MED, V364, P2316, DOI 10.1056/NEJMoa1008677
   Driss N, 2012, CLIN VACCINE IMMUNOL, V19, P1684, DOI 10.1128/CVI.00293-12
   Dunn G, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005114
   Halliday E, 2003, J INFECTION, V46, P1, DOI 10.1053/jinf.2002.1066
   HENDERSON DA, 1964, JAMA-J AM MED ASSOC, V190, P41
   HOGLE JM, 1989, PHILOS T ROY SOC B, V323, P467, DOI 10.1098/rstb.1989.0024
   Horie H, 2002, J MED VIROL, V68, P445, DOI 10.1002/jmv.10224
   JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275
   Jorba J, 2016, MMWR-MORBID MORTAL W, V65, P763, DOI 10.15585/mmwr.mm6530a3
   Karber G, 1931, N-S ARCH EX PATH PH, V162, P480, DOI 10.1007/BF01863914
   Kew O, 2002, SCIENCE, V296, P356, DOI 10.1126/science.1068284
   LAMONICA N, 1987, VIROLOGY, V161, P429, DOI 10.1016/0042-6822(87)90136-X
   Maarschalk-Ellerbroek LJ, 2011, INT J ANTIMICROB AG, V37, P396, DOI 10.1016/j.ijantimicag.2010.11.027
   Martin J, 2004, J VIROL, V78, P13839, DOI 10.1128/JVI.78.24.13839-13847.2004
   Moturi EK, 2014, MMWR-MORBID MORTAL W, V63, P468
   Mulders MN, 1999, J GEN VIROL, V80, P907, DOI 10.1099/0022-1317-80-4-907
   Parvaneh N, 2007, J CLIN VIROL, V39, P145, DOI 10.1016/j.jcv.2007.04.002
   PATEL V, 1993, VIROLOGY, V192, P361, DOI 10.1006/viro.1993.1044
   Pliaka V, 2010, VACCINE, V29, P26, DOI 10.1016/j.vaccine.2010.10.028
   Prevots DR, 2004, PEDIATR INFECT DIS J, V23, P1130, DOI 10.1097/01.inf.0000143641.27336.2e
   Rezapkin G, 2005, BIOLOGICALS, V33, P29, DOI 10.1016/j.biologicals.2004.11.001
   Roivainen M, 2010, EUROSURVEILLANCE, V15, P8
   Shaw J, 2018, J VIROL, V92, DOI 10.1128/JVI.01949-17
   Shimizu H, 2004, J VIROL, V78, P13512, DOI 10.1128/JVI.78.24.13512-13521.2004
   Shulman LM, 2000, J CLIN MICROBIOL, V38, P3729, DOI 10.1128/JCM.38.10.3729-3734.2000
   STIRK HJ, 1994, PROTEIN ENG, V7, P47, DOI 10.1093/protein/7.1.47
   STREBEL PM, 1994, AM J EPIDEMIOL, V140, P1111, DOI 10.1093/oxfordjournals.aje.a117211
   Sun MB, 2017, CLIN INFECT DIS, V64, P1317, DOI 10.1093/cid/cix110
   Sutter RW, 2013, VACCINES, P598
   Weldon WC, 2016, METHODS MOL BIOL, V1387, P145, DOI 10.1007/978-1-4939-3292-4_8
   World Health Organization (WHO), 2013, POL ER ENDG STRAT PL
   Yakovenko ML, 2006, J VIROL, V80, P2641, DOI 10.1128/JVI.80.6.2641-2653.2006
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 3042
EP 3049
DI 10.1016/j.vaccine.2020.02.035
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400019
PM 32089462
DA 2020-05-12
ER

PT J
AU Chase-Topping, M
   Xie, JX
   Pooley, C
   Trus, I
   Bonckaert, C
   Rediger, K
   Bailey, RI
   Brown, H
   Bitsouni, V
   Barrio, MB
   Gueguen, S
   Nauwynck, H
   Doeschl-Wilson, A
AF Chase-Topping, Margo
   Xie, Jiexiong
   Pooley, Christopher
   Trus, Ivan
   Bonckaert, Caroline
   Rediger, Kelly
   Bailey, Richard, I
   Brown, Helen
   Bitsouni, Vasiliki
   Barrio, Maria Belen
   Gueguen, Sylvie
   Nauwynck, Hans
   Doeschl-Wilson, Andrea
TI New insights about vaccine effectiveness: Impact of attenuated
   PRRS-strain vaccination on heterologous strain transmission
SO VACCINE
LA English
DT Article
DE Vaccination; Transmission; Bayesian; Porcine reproductive and
   respiratory syndrome; R-0
ID RESPIRATORY-SYNDROME VIRUS; MODIFIED-LIVE VACCINE; EFFICACY; PIGS;
   INFECTION
AB Vaccination is the main tool for controlling infectious diseases in livestock. Yet current vaccines only provide partial protection raising concerns about vaccine effectiveness in the field.
   Two successive transmission trials were performed involving 52 pigs to evaluate the effectiveness of a Porcine Reproductive and Respiratory Syndrome (PRRS) vaccinal strain candidate against horizontal transmission of a virulent heterologous strain. PRRS virus, above the specified limit of detection, was observed in serum and nasal secretions for all but one pig (the exception only tested positive for serum), indicating that vaccination did not protect pigs from becoming infected and shedding the heterologous strain. However, vaccination delayed the onset of viraemia, reduced the duration of shedding and significantly decreased viral load throughout infection. Serum antibody profiles indicated that 4 out of 13 (31%) vaccinates in one trial had no serological response (NSR).
   A Bayesian epidemiological model was fitted to the data to assess the impact of vaccination and presence of NSRs on PRRS virus transmission dynamics. Despite little evidence for reduction in the transmission rate, vaccinated animals were on average slower to become infectious, experienced a shorter infectious period and recovered faster. The overall PRRSV transmission potential, represented by the reproductive ratio R-0 was lower for the vaccinated animals, although there was substantial overlap in the credibility intervals for both groups. Model selection suggests that transmission parameters of vaccinated pigs with NSR were more similar to those of unvaccinated animals. The presence of NSRs in a population, however, seemed to only marginally affect the transmission dynamics.
   The results suggest that even when vaccination can't prevent infection, it can still have beneficial impacts on the transmission dynamics and contribute to reducing a herd's R-0. However, biosecurity and other measures need to be considered to decrease contact rates and lower R-0 below 1. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Chase-Topping, Margo; Pooley, Christopher; Bailey, Richard, I; Brown, Helen; Bitsouni, Vasiliki; Doeschl-Wilson, Andrea] Roslin Inst, Easter Bush EH25 9RG, Midlothian, Scotland.
   [Chase-Topping, Margo] Univ Edinburgh, Usher Inst, Edinburgh EH8 9AG, Midlothian, Scotland.
   [Xie, Jiexiong; Trus, Ivan; Bonckaert, Caroline; Rediger, Kelly; Nauwynck, Hans] Univ Ghent, Fac Vet Med, B-9820 Merelbeke, Belgium.
   [Pooley, Christopher] Biomath & Stat Scotland BIOSS, Kings Bldg, Edinburgh EH9 3FD, Midlothian, Scotland.
   [Barrio, Maria Belen] INRAE, Dept Sante Anim, UAR 0564, ISP, Bat 213, F-37380 Nouzilly, France.
   [Gueguen, Sylvie] VIRBAC, LID, Biol Dev Dept, 13Eme Rue,BP27, F-06511 Carros, France.
RP Chase-Topping, M (reprint author), Roslin Inst, Easter Bush EH25 9RG, Midlothian, Scotland.
EM margo.chase@ed.ac.uk
OI Bitsouni, Vasiliki/0000-0002-0684-0583; Trus, Ivan/0000-0003-2849-5140
FU EUEuropean Union (EU) [633184]; Institute Strategic Programme Grant ISPG
   2, Theme 2 [BBS/E/D/20002173]; Strategic Research programme of the
   Scottish Government (RESAS)
FX Financial support for this research was provided by the EU Horizon 2020
   project.; SAPHIR (https://www.h2020-saphir.eu), Project No. 633184 (ALL
   Co-authors, except for CP and RB), by the
   (https://bbsrc.ukri.org/research/institutes/strategically-funded-institu
   tes/); Institute Strategic Programme Grant ISPG 2, Theme 2 (no.
   BBS/E/D/20002173) (ADW & RB), and by the Strategic Research programme of
   the Scottish Government (RESAS) (CP).
CR Amadori M, 2014, FRONT VET SCI, V1, P1, DOI [10.3389/fvets.2014.-00002, DOI 10.3389/FVETS.2014.-00002]
   Bailey Richard I, 2020, PLoS Biol, V18, pe3000619, DOI 10.1371/journal.pbio.3000619
   Balka G, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26036-w
   Bitsouni V, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220738
   Bos MEH, 2008, VACCINE, V26, P6322, DOI 10.1016/j.vaccine.2008.09.022
   Brar MS, 2015, J GEN VIROL, V96, P1570, DOI 10.1099/vir.0.000104
   Butler JE, 2014, IMMUNOL RES, V59, P81, DOI 10.1007/s12026-014-8549-5
   Cador C, 2016, VET RES, V47, DOI 10.1186/s13567-016-0365-6
   Chen NH, 2016, INFECT GENET EVOL, V40, P167, DOI 10.1016/j.meegid.2016.03.002
   de Rueda CB, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-58
   Dong JG, 2018, J VET SCI, V19, P89, DOI 10.4142/jvs.2018.19.1.89
   Eclercy J, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030296
   Fenner, 2017, ART RON FENN VET VIR, DOI [10.1016/B978-0-12-800946-8.00025-8, DOI 10.1016/B978-0-12-800946-8.00025-8]
   Gibson GJ, 1998, IMA J MATH APPL MED, V15, P19
   Haiwick G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209784
   Halbur PG, 1996, J VET DIAGN INVEST, V8, P11, DOI 10.1177/104063879600800103
   HALLORAN ME, 1992, AM J EPIDEMIOL, V136, P328, DOI 10.1093/oxfordjournals.aje.a116498
   Huong VTL, 2016, EPIDEMIOL INFECT, V144, P35, DOI 10.1017/S0950268815000990
   Islam ZU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083567
   Jeong J, 2018, VET REC, V182, P485, DOI 10.1136/vr.104397
   Kappes MA, 2015, VIROLOGY, V479, P475, DOI 10.1016/j.virol.2015.02.012
   KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572
   Kimman TG, 2009, VACCINE, V27, P3704, DOI 10.1016/j.vaccine.2009.04.022
   Knight-Jones TJD, 2014, VACCINE, V32, P1848, DOI 10.1016/j.vaccine.2014.01.071
   Kristensen CS, 2018, VACCINE, V36, P227, DOI 10.1016/j.vaccine.2017.11.059
   Kwon T, 2019, VIRUS RES, V260, P12, DOI 10.1016/j.virusres.2018.11.004
   Meeusen ENT, 2007, CLIN MICROBIOL REV, V20, P489, DOI 10.1128/CMR.00005-07
   Nan YC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01635
   O'Neill PD, 1999, J ROY STAT SOC A STA, V162, P121, DOI 10.1111/1467-985X.00125
   Phoo-ngurn P, 2019, ADV DIFFER EQU-NY, V2019, DOI 10.1186/s13662-019-2351-6
   Pileri E, 2017, VET MICROBIOL, V201, P18, DOI 10.1016/j.vetmic.2016.12.012
   Pileri E, 2016, VET RES, V47, DOI 10.1186/s13567-016-0391-4
   Pileri E, 2015, VET MICROBIOL, V175, P7, DOI 10.1016/j.vetmic.2014.11.007
   Pooley CM, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.171519
   Read AF, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002198
   Rose N, 2015, VACCINE, V33, P2493, DOI 10.1016/j.vaccine.2015.03.040
   Roth JA, 2011, PROCEDIA VACCINOL, V5, P127, DOI 10.1016/j.provac.2011.10.009
   Salines M, 2019, INT J FOOD MICROBIOL, V292, P144, DOI 10.1016/j.ijfoodmicro.2018.12.023
   Tait-Burkard C, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1583-1
   Trus I, 2016, VET RES, V47, DOI 10.1186/s13567-015-0292-y
   Trus I, 2014, VACCINE, V32, P2995, DOI 10.1016/j.vaccine.2014.03.077
   Van Aarle P, 2010, VACCINE EFFICACY IMM
   Wang X, 2015, VIRUS RES, V210, P34, DOI 10.1016/j.virusres.2015.07.004
   Xie JX, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010036
NR 44
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 3050
EP 3061
DI 10.1016/j.vaccine.2020.02.015
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400020
PM 32122719
DA 2020-05-12
ER

PT J
AU Utazi, CE
   Wagai, J
   Pannell, O
   Cutts, FT
   Rhoda, DA
   Ferrari, MJ
   Dieng, B
   Oteri, J
   Danovaro-Holliday, MC
   Adeniran, A
   Tatem, AJ
AF Utazi, C. Edson
   Wagai, John
   Pannell, Oliver
   Cutts, Felicity T.
   Rhoda, Dale A.
   Ferrari, Matthew J.
   Dieng, Boubacar
   Oteri, Joseph
   Danovaro-Holliday, M. Carolina
   Adeniran, Adeyemi
   Tatem, Andrew J.
TI Geospatial variation in measles vaccine coverage through routine and
   campaign strategies in Nigeria: Analysis of recent household surveys
SO VACCINE
LA English
DT Article
DE Measles vaccine; Supplementary immunization activities; Routine
   immunization; Geospatial analysis; Post-campaign coverage survey
ID HEALTH SYSTEMS FINDINGS; IMMUNIZATION; IMPACT; MODEL
AB Measles vaccination campaigns are conducted regularly in many low- and middle-income countries to boost measles control efforts and accelerate progress towards elimination. National and sometimes first-level administrative division campaign coverage may be estimated through post-campaign coverage surveys (PCCS). However, these large-area estimates mask significant geographic inequities in coverage at more granular levels. Here, we undertake a geospatial analysis of the Nigeria 2017-18 PCCS data to produce coverage estimates at 1 x 1 km resolution and the district level using binomial spatial regression models built on a suite of geospatial covariates and implemented in a Bayesian framework via the INLA-SPDE approach. We investigate the individual and combined performance of the campaign and routine immunization (RI) by mapping various indicators of coverage for children aged 9-59 months. Additionally, we compare estimated coverage before the campaign at 1 x 1 km and the district level with predicted coverage maps produced using other surveys conducted in 2013 and 2016-17. Coverage during the campaign was generally higher and more homogeneous than RI coverage but geospatial differences in the campaign's reach of previously unvaccinated children are shown. Persistent areas of low coverage highlight the need for improved RI performance. The results can help to guide the conduct of future campaigns, improve vaccination monitoring and measles elimination efforts. Moreover, the approaches used here can be readily extended to other countries. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Utazi, C. Edson; Pannell, Oliver; Tatem, Andrew J.] Univ Southampton, Sch Geog & Environm Sci, WorldPop, Southampton SO17 1BJ, Hants, England.
   [Utazi, C. Edson] Univ Southampton, Southampton Stat Sci Res Inst, Southampton SO17 1BJ, Hants, England.
   [Wagai, John] World Hlth Org Consultant, Abuja, Nigeria.
   [Cutts, Felicity T.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England.
   [Rhoda, Dale A.] Biostat Global Consulting, Worthington, OH USA.
   [Ferrari, Matthew J.] Penn State Univ, Ctr Infect Dis Dynam, State Coll, PA 16802 USA.
   [Dieng, Boubacar] GAVI Alliance, Abuja, Nigeria.
   [Oteri, Joseph] Natl Primary Hlth Care Dev Agcy, Abuja, Nigeria.
   [Danovaro-Holliday, M. Carolina] WHO, Geneva, Switzerland.
   [Adeniran, Adeyemi] Natl Bur Stat, Abuja, Nigeria.
RP Utazi, CE (reprint author), Univ Southampton, Sch Geog & Environm Sci, WorldPop, Southampton SO17 1BJ, Hants, England.
EM c.e.utazi@soton.ac.uk
FU Bill & Melinda Gates Foundation (BMGF)Gates Foundation; BMGF; DFID;
   Clinton Health Access Initiative; Wellcome TrustWellcome Trust
FX This work was partly supported by funding from the Bill & Melinda Gates
   Foundation (BMGF). AJT is supported by funding from the BMGF, DFID, the
   Clinton Health Access Initiative, and the Wellcome Trust. The authors
   are grateful to the GRID3 program (www.grid3.org) for providing the
   settlement data and technical assistance during the work. Also, the
   authors would like to thank two anonymous referees for their
   constructive comments which greatly improved the manuscript.
CR Andrus JK, 2011, VACCINE, V29, pD91, DOI 10.1016/j.vaccine.2011.04.059
   [Anonymous], 2017, Wkly Epidemiol Rec, V92, P205
   Banerjee S., 2014, HIERARCHICAL MODELIN
   Cutts FT, 2016, VACCINE, V34, P4103, DOI 10.1016/j.vaccine.2016.06.053
   Danovaro-Holliday MC, 2018, VACCINE, V36, P5150, DOI 10.1016/j.vaccine.2018.07.019
   Dansereau Emily, 2019, Gates Open Res, V3, P923, DOI 10.12688/gatesopenres.12916.1
   Diggle PJ, 1998, J R STAT SOC C-APPL, V47, P299, DOI 10.1111/1467-9876.00113
   Doshi RH, 2015, VACCINE, V33, P6786, DOI 10.1016/j.vaccine.2015.10.020
   eHealth Africa Oak Ridge National Laboratory Proxy Logics, 2019, PROX LOG GEO REF INF
   Goodson JL, 2011, J INFECT DIS, V204, pS205, DOI 10.1093/infdis/jir129
   Gunnala R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167835
   Hanvoravongchai P, 2011, J INFECT DIS, V204, pS82, DOI 10.1093/infdis/jir091
   Lindgren F, 2015, J STAT SOFTW, V63, P1, DOI 10.18637/jss.v063.i19
   Lindgren F, 2011, J R STAT SOC B, V73, P423, DOI 10.1111/j.1467-9868.2011.00777.x
   Masresha B, 2018, J IMMUNOL SCI S
   Matern B, 1960, SPATIAL VARIATION
   Mayala BK, 2019, DHS SPATIAL ANAL REP, V17
   Mosser JF, 2019, LANCET, V393, P1843, DOI 10.1016/S0140-6736(19)30226-0
   National Bureau of Statistics (NBS) and United Nations Children's Fund (UNICEF), 2017, 2017 MULT IND CLUST
   National Population Commission (NPC) and ICF International, 2014, NIG DEM HLTH SURV 20
   National Primary Healthcare Development Agency and National Bureau of Statistics, 2017, NIG NAT IMM COV SURV
   Nigeria Centre for Disease Control, WEEKL EP REP
   Portnoy A, 2018, VACCINE, V36, P170, DOI 10.1016/j.vaccine.2017.10.080
   R Core Team, 2017, R LANG ENV STAT COMP
   Rue H, 2009, J R STAT SOC B, V71, P319, DOI 10.1111/j.1467-9868.2008.00700.x
   Saki Takahashi, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15585
   Subaiya S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199786
   Tatem AJ, 2017, SCI DATA, V4
   Tatem AJ, 2017, SCI DATA, V4, DOI 10.1038/sdata.2017.4
   Utazi CE, 2019, STAT METHODS MED RES, V28, P3226, DOI 10.1177/0962280218797362
   Utazi CE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09611-1
   Utazi CE, 2018, VACCINE, V36, P1583, DOI 10.1016/j.vaccine.2018.02.020
   Verguet S, 2013, J EPIDEMIOL COMMUN H, V67, P947, DOI 10.1136/jech-2012-202216
   Weber EM, 2018, REMOTE SENS ENVIRON, V204, P786, DOI 10.1016/j.rse.2017.09.024
   WHO Regional Committee for Africa, 2011, MEASL EL 2020 STRAT
   World Health Organization, SUMM MEASL RUB SUPPL
   World Health Organization, 2016, PLANN IMPL HIGH QUAL
   World Health Organization, 2018, VACC COV CLUST SURV
   World Health Organization, 2019, MEASL RUB SURV DAT
   World Health Organization, 2013, GLOB VACC ACT PLAN 2
   World Health Organization, RED STRAT
   World Health Organization, 2019, WHO UNICEF EST NAT I
   World Health Organization (WHO), 2012, GLOB MEASL RUB STRAT
   Zimmermann M, 2019, VACCINE, V37, P6039, DOI 10.1016/j.vaccine.2019.08.050
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 23
PY 2020
VL 38
IS 14
BP 3062
EP 3071
DI 10.1016/j.vaccine.2020.02.070
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TG
UT WOS:000525317400021
PM 32122718
OA Green Published, Other Gold, Green Accepted
DA 2020-05-12
ER

PT J
AU McClymont, E
   Ogilvie, G
   Albert, A
   Johnston, A
   Raboud, J
   Walmsley, S
   Lipsky, N
   Loutfy, M
   Trottier, S
   Smaill, F
   Yudin, MH
   Klein, MB
   Harris, M
   Wobeser, W
   Bitnun, A
   Kakkar, F
   Samson, L
   Brophy, J
   Karatzios, C
   Money, D
AF McClymont, Elisabeth
   Ogilvie, Gina
   Albert, Arianne
   Johnston, Angela
   Raboud, Janet
   Walmsley, Sharon
   Lipsky, Nancy
   Loutfy, Mona
   Trottier, Sylvie
   Smaill, Fiona
   Yudin, Mark H.
   Klein, Marina B.
   Harris, Marianne
   Wobeser, Wendy
   Bitnun, Ari
   Kakkar, Fatima
   Samson, Lindy
   Brophy, Jason
   Karatzios, Christos
   Money, Deborah
CA CTN 236 HPV HIV Study Team
TI Impact of quadrivalent HPV vaccine dose spacing on immunologic response
   in women living with HIV
SO VACCINE
LA English
DT Article
DE HPV vaccine; HIV; HPV; Women
ID HUMAN-PAPILLOMAVIRUS; ANTIBODY-RESPONSES; IMMUNOGENICITY;
   HUMAN-PAPILLOMAVIRUS-16; INFECTION; EFFICACY
AB HPV vaccination schedules have changed as evidence has supported reduced dosing and extended intervals. Women living with HIV (WLWH) represent an important population with no data on alternative dosing.
   Girls and WLWH received quadrivalent HPV (qHPV) vaccine in a pan-Canadian study of immunogenicity and efficacy. Serology was performed at months 0/2/7/12/18/24. Medical and sexual history was collected throughout. Linear regression was used to determine if spacing of doses was associated with peak antibody titer.
   Multivariable analyses demonstrated significant relationships between peak antibody titer and time to blood draw post last vaccine dose, naivety to the relevant HPV type, and HIV viral load for all qHPV types. There was a significant relationship between peak HPV16/18 antibody titer and age.
   Taking age, time to serology, CD4 cell count, CD4 nadir, HIV viral load, and HPV naivety into account, spacing of the three qHPV vaccine doses did not significantly impact peak antibody titers. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [McClymont, Elisabeth; Money, Deborah] Univ British Columbia, Dept Obstet & Gynecol, Vancouver, BC, Canada.
   [Ogilvie, Gina] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.
   [Ogilvie, Gina; Albert, Arianne; Lipsky, Nancy] Womens Hlth Res Inst, Vancouver, BC, Canada.
   [Johnston, Angela] Univ British Columbia, Fac Med, Vancouver, BC, Canada.
   [Raboud, Janet; Walmsley, Sharon] Univ Hlth Network, Univ Toronto, Toronto Gen Hosp Res Inst, Toronto, ON, Canada.
   [Raboud, Janet; Walmsley, Sharon] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada.
   [Loutfy, Mona; Yudin, Mark H.] Univ Toronto, Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada.
   [Trottier, Sylvie] Univ Laval, Infect Dis Res Ctr, Quebec City, PQ, Canada.
   [Smaill, Fiona] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
   [Yudin, Mark H.] Univ Toronto, St Michaels Hosp, Dept Obstet & Gynecol, Toronto, ON, Canada.
   [Klein, Marina B.] McGill Univ, Hlth Ctr, Montreal, PQ, Canada.
   [Harris, Marianne] British Columbia Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
   [Wobeser, Wendy] Queens Univ, Dept Publ Hlth, Kingston, ON, Canada.
   [Wobeser, Wendy] Queens Univ, Dept Biomed & Mol Sci, Kingston, ON, Canada.
   [Bitnun, Ari] Univ Toronto, Hosp Sick Children, Dept Paediat, Toronto, ON, Canada.
   [Kakkar, Fatima] Univ Montreal, Fac Med, Dept Pediat, Montreal, PQ, Canada.
   [Kakkar, Fatima] CHU St Justine, Ctr Maternel & Infantile SIDA, Montreal, PQ, Canada.
   [Samson, Lindy] Univ Ottawa, Dept Paediat, Ottawa, ON, Canada.
   [Brophy, Jason] Univ Ottawa, Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON, Canada.
   [Karatzios, Christos] Univ Montreal, Ctr Hosp Univ St Justine, Dept Paediat, Montreal, PQ, Canada.
   [Karatzios, Christos] McGill Univ, Montreal Childrens Hosp, Dept Pediat, Hlth Ctr, Montreal, PQ, Canada.
RP Money, D (reprint author), Univ British Columbia, 317-2194 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.
EM deborah.money@ubc.ca
FU Canadian Institutes for Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR) [MOP 136784]; CIHR Canadian HIV Trials
   NetworkCanadian Institutes of Health Research (CIHR) [CTN 236]; Chair in
   Clinical Management and Aging from the Ontario HIV Treatment Network
FX This work was supported by the Canadian Institutes for Health Research
   (CIHR) [funding reference number: MOP 136784]; CIHR Canadian HIV Trials
   Network (CTN 236); Chair in Clinical Management and Aging from the
   Ontario HIV Treatment Network to SW; and in-kind contribution from Merck
   Canada Inc. The opinions expressed in this paper are those of the
   authors and do not necessarily represent those of Merck Canada Inc.
CR Arbyn M, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009069.pub3
   Castellsague X, 2011, BRIT J CANCER, V105, P28, DOI 10.1038/bjc.2011.185
   Denslow SA, 2014, INCIDENCE PROGR CERV, P163
   Dias D, 2005, CLIN DIAGN LAB IMMUN, V12, P959, DOI 10.1128/CDLI.12.8.959-969.2005
   Dobson SRM, 2013, JAMA-J AM MED ASSOC, V309, P1793, DOI 10.1001/jama.2013.1625
   Fiore Anthony E., 2007, Morbidity and Mortality Weekly Report, V56, P1
   Gilca V, 2015, HUM VACC IMMUNOTHER, V11, P732, DOI 10.1080/21645515.2015.1011570
   Joura EA, 2008, VACCINE, V26, P6844, DOI 10.1016/j.vaccine.2008.09.073
   LaMontagne DS, 2013, J INFECT DIS, V208, P1325, DOI 10.1093/infdis/jit363
   Lazcano-Ponce E, 2019, J INFECT DIS, V219, P41, DOI 10.1093/infdis/jiy465
   Lord JM, 2013, HUM VACC IMMUNOTHER, V9, P1364, DOI 10.4161/hv.24696
   Lowy DR, 2015, LANCET ONCOL, V16, pE226, DOI 10.1016/S1470-2045(15)70075-6
   Massad LS, 2014, AIDS, V28, P2601, DOI 10.1097/QAD.0000000000000455
   McClymont E, 2018, CLIN INFECT DIS
   Money DM, 2016, VACCINE, V34, P4799, DOI 10.1016/j.vaccine.2016.08.016
   Poland GA, 2005, MAYO CLIN PROC, V80, P601, DOI 10.4065/80.5.601
   Russell K, 2015, VACCINE, V33, P1953, DOI 10.1016/j.vaccine.2015.02.058
   Sankaranarayanan R, 2018, VACCINE, V36, P4783, DOI 10.1016/j.vaccine.2018.02.087
   Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903
   Villa LL, 2006, VACCINE, V24, P5571, DOI 10.1016/j.vaccine.2006.04.068
   WHO, 2019, DRAFT GLOB STRAT EL
   World Health Organization, 2019, GLOB HLTH OBS DAT
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3073
EP 3078
DI 10.1016/j.vaccine.2020.02.075
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500001
PM 32147300
DA 2020-05-12
ER

PT J
AU Mounier-Jack, S
   Bell, S
   Chantler, T
   Edwards, A
   Yarwood, J
   Gilbert, D
   Paterson, P
AF Mounier-Jack, Sandra
   Bell, Sadie
   Chantler, Tracey
   Edwards, Angela
   Yarwood, Jo
   Gilbert, Douglas
   Paterson, Pauline
TI Organisational factors affecting performance in delivering influenza
   vaccination to staff in NHS Acute Hospital Trusts in England: A
   qualitative study
SO VACCINE
LA English
DT Article
DE Health workers; Health personal; Healthcare; Influenza; Vaccine;
   Vaccination rates; Public health; Health policy; Operational research
ID HEALTH-CARE WORKERS; CHALLENGES; ATTITUDES; BEHAVIOR
AB Health care workers are a priority group for seasonal influenza vaccination, which is recommended by the World Health Organisation. There is a wide variation in uptake between and within countries. England has achieved 69.5% of health care workers vaccinated overall in 2017/18 across NHS acute and community health care settings, but it varies between Trusts from 50% to over 92.3%. While attitudinal factors have been well researched, there is limited evidence on organisational factors associated with high uptake. In England, most NHS Trusts are now implementing a similar range of interventions as part of their flu programme, and it remains unclear why performance remains so variable. This qualitative study is the first to explore reasons for this variation and provide recommendations for lower performing Trusts on how to improve. Fifty-seven interviews of managers and vaccinators were conducted in nine hospitals with flu vaccination uptake ranging from just over 55% to above 90%. Our study found that while Trusts deployed a wide range of both demand generating and supply interventions to increase uptake, there were marked differences in the organisational and delivery models utilised. Our study suggests that organisational culture was possibly the most important ingredient when trying to differentiate between high and low performing Trusts. We found that a positive culture aimed at fostering continuous improvement and favouring non-coercion on balance yielded more adherence from staff. Where influenza vaccination was embedded in the organisation wellbeing strategy, rather than executed as a siloed seasonal programme, this tended to foster good performance. Improving performance of influenza vaccination in health care workers will involve not only deploying the right interventions, and following "best practices". It will require the adaptation of flu progamme delivery strategies to the organisation context, and embedding vaccination into the organisational culture, thus supporting the normalisation of yearly vaccination. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Mounier-Jack, Sandra; Bell, Sadie; Chantler, Tracey] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, Dept Global Hlth & Dev, London WC1H 9SH, England.
   [Edwards, Angela; Yarwood, Jo] Publ Hlth England, Dept Immunisat & Countermeasures, London, England.
   [Gilbert, Douglas] NHS England & NHS Improvement, London, England.
   [Paterson, Pauline] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Dept Infect Dis Epidemiol, London WC1E 7HT, England.
RP Mounier-Jack, S (reprint author), London Sch Hyg & Trop Med, 15-17 Tavistock Pl, London WC1H 9SH, England.
EM sandra.mounier-jack@lshtm.ac.uk
OI Chantler, Tracey/0000-0001-7776-7339; Bell, Sadie/0000-0003-4381-0030
FU National Institute for Health Research Health Protection Research Unit
   (NIHR HPRU) in Immunisation at the London School of Hygiene & Tropical
   Medicine; Public Health England (PHE) [HPRU-2012-10096]
FX This work was funded by the National Institute for Health Research
   Health Protection Research Unit (NIHR HPRU) in Immunisation at the
   London School of Hygiene & Tropical Medicine in partnership with Public
   Health England (PHE) [Award letter refs: HPRU-2012-10096 dated 11th Dec
   2013].
CR Anikeeva O, 2009, AM J PUBLIC HEALTH, V99, P24, DOI 10.2105/AJPH.2008.136440
   Beguin C, 1998, Am J Med Qual, V13, P223, DOI 10.1177/106286069801300408
   Boey L, 2018, VACCINE, V36, P3351, DOI 10.1016/j.vaccine.2018.04.044
   Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI DOI 10.1191/1478088706QP0630A
   Burls A, 2006, VACCINE, V24, P4212, DOI 10.1016/j.vaccine.2005.12.043
   Chen SC, 2012, VACCINE, V30, P493, DOI 10.1016/j.vaccine.2011.04.032
   Cherian T, 2019, VACCINE, V37, P6255, DOI 10.1016/j.vaccine.2019.07.079
   Edelstein M, 2014, EPIDEMIOL INFECT, V142, P438, DOI 10.1017/S095026881300112X
   Falomir-Pichastor JM, 2009, APPL PSYCHOL-INT REV, V58, P42, DOI 10.1111/j.1464-0597.2008.00381.x
   FitzSimons D, 2014, VACCINE, V32, P4849, DOI 10.1016/j.vaccine.2014.06.072
   GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008
   Hollmeyer H, 2013, INFLUENZA OTHER RESP, V7, P604, DOI 10.1111/irv.12002
   Hollmeyer HG, 2009, VACCINE, V27, P3935, DOI 10.1016/j.vaccine.2009.03.056
   Hopman CE, 2011, J HOSP INFECT, V77, P327, DOI 10.1016/j.jhin.2010.10.009
   Imai C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198685
   Jenkin Dawn C, 2019, Vaccine X, V2, P100036, DOI 10.1016/j.jvacx.2019.100036
   Khodyakov D, 2014, VACCINE, V32, P3082, DOI 10.1016/j.vaccine.2013.06.077
   Knowler P, 2018, INFECT DIS HEALTH, V23, P156, DOI 10.1016/j.idh.2018.03.003
   Lam PP, 2010, CAN MED ASSOC J, V182, pE542, DOI 10.1503/cmaj.091304
   Lewthwaite P, 2014, OCCUP MED-OXFORD, V64, P348, DOI 10.1093/occmed/kqu048
   Manuel DG, 2002, INFECT CONT HOSP EP, V23, P609, DOI 10.1086/501980
   Marteau TM, 2012, SCIENCE, V337, P1492, DOI 10.1126/science.1226918
   Nagata JM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-388
   Ng TWY, 2020, VACCINE, V38, P690, DOI 10.1016/j.vaccine.2019.10.041
   Public Health England, SEAS INFL VACC UPT H
   Quach S, 2013, AM J INFECT CONTROL, V41, P1017, DOI 10.1016/j.ajic.2013.05.016
   Salgado CD, 2004, INFECT CONT HOSP EP, V25, P923, DOI 10.1086/502321
   Seale H, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-325
   Seale H, 2010, INFLUENZA OTHER RESP, V4, P41, DOI 10.1111/j.1750-2659.2009.00112.x
   Shrikrishna D, 2015, BMJ OPEN RESP RES, V2, P1
   Stead M, 2019, INFECT DIS HEALTH, V24, P3, DOI 10.1016/j.idh.2018.09.082
   To KW, 2016, J HOSP INFECT, V94, P133, DOI 10.1016/j.jhin.2016.07.003
   Weinstock DM, 2000, INFECT CONT HOSP EP, V21, P730, DOI 10.1086/501726
   World Health Organization, 2012, WHO GLOB MAL PROGR W, V87, P461
   World Health Organization, 2019, IMPL SEAS INFL VACC
   Yassi A, 2010, CAN J PUBLIC HEALTH, V101, pS41, DOI 10.1007/BF03403845
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3079
EP 3085
DI 10.1016/j.vaccine.2020.02.077
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500002
PM 32147294
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Hoeve, CE
   Gadroen, K
   Kwa, MSG
   van Haren, A
   Sturkenboom, MCJM
   Straus, SMJM
AF Hoeve, Christina E.
   Gadroen, Kartini
   Kwa, Marcel S. G.
   van Haren, Anja
   Sturkenboom, Miriam C. J. M.
   Straus, Sabine M. J. M.
TI Fatal outcomes following immunization errors as reported to the
   EudraVigilance: A case series
SO VACCINE
LA English
DT Article
DE Immunization errors; Causality assessment; Spontaneous reporting;
   Fatalities; Pharmacovigilance
ID ATTENUATED INFLUENZA VACCINE; POST-LICENSURE SURVEILLANCE;
   INFANT-DEATH-SYNDROME; ADVERSE EVENTS; UNITED-STATES; SYSTEM VAERS;
   RABIES; RISK; VARICELLA; CHILDREN
AB Background: Serious adverse reactions after immunization are rare but do occur. In very rare instances, cases with fatal outcome have been reported. These reports can have a huge impact and even more so when due to an immunization error. The aim of this study is to systematically review immunization errors with fatal outcomes in EudraVigilance.
   Methods: This was a case-series analysis of Individual Case Safety Reports (ICSRs) reporting immunization errors and a fatal outcome. To determine the level of certainty of a causal association between the immunization errors and fatal outcomes two independent reviewers assessed all ICSRs using the WHO tool "Causality assessment of an Adverse Event Following Immunization (AEFI)". In accordance with the tool, the ICSRs were classified as consistent, indeterminate, inconsistent/coincidental, or unclassifiable. In addition, we estimated the contribution of reported errors to the fatal outcomes as large, moderate, small, none, or unclassifiable using a classification developed for this study.
   Results: A total of 154 ICSRs met the inclusion criteria. Vaccines reported most frequently were pneumococcal (33), rabies (27) and influenza vaccines (24). Most frequently reported errors were noncompliance with recommended schedules of immunization (63). The most frequently reported vaccine-error combination was rabies vaccines and non-compliance with a recommended schedule of immunization (23). Twelve cases were classified as consistent with causal association and had a large error contribution. These cases concerned a cluster of six cases reporting incorrect handling of multidose vials containing measles vaccine and six cases reporting administration of live-attenuated vaccines to immunocompromised patients.
   Discussion: In this study, we showed that fatal outcomes following immunization errors are very rare. Four key issues were the importance of: (1) quality control of multi-dose vaccines, (2) screening patients for immunocompromising factors, (3) education on the importance of adherence, and (4) measures to improve distinction between vaccines and medicines. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hoeve, Christina E.; Kwa, Marcel S. G.; van Haren, Anja; Straus, Sabine M. J. M.] Med Evaluat Board, Utrecht, Netherlands.
   [Hoeve, Christina E.; Gadroen, Kartini; Straus, Sabine M. J. M.] Erasmus MC, Dept Med Informat, Rotterdam, Netherlands.
   [Gadroen, Kartini] Med Sans Frontieres, Amsterdam, Netherlands.
   [Sturkenboom, Miriam C. J. M.] Univ Utrecht, Julius Global Hlth, Med Ctr, Utrecht, Netherlands.
RP Hoeve, CE (reprint author), Erasmus MC, Dept Med Informat, Rotterdam, Netherlands.
EM c.hoeve@erasmusmc.nl
CR Alexander KE, 2018, VACCINE, V36, P3890, DOI 10.1016/j.vaccine.2018.05.078
   Amdekar YK, 2008, INDIAN PEDIATR, V45, P479
   [Anonymous], 2016, IMPL GUID EL TRANSM
   Bhalla P, 2015, CLIN INFECT DIS, V60, P1068, DOI 10.1093/cid/ciu970
   Centers for Disease Control and Prevention, 2018, VACC SUDD INF DEATH
   Centers for Disease Control and Prevention (CDC), 1994, MMWR-MORBID MORTAL W, V43, P720
   Cooper E, 2012, US ARMY MED DEP J, V4
   Corwin M., 2019, SUDDEN INFANT DEATH
   Costa E, 2016, BMJ CASE REP
   Council for International Organization of Medical Sciences (CIOMS), 2016, DEV RAT US STAND MED
   CURPHEY TJ, 1947, JAMA-J AM MED ASSOC, V133, P1062, DOI 10.1001/jama.1947.62880150001007
   Depani SJ, 2012, MALAWI MED J, V24, P61
   Egyptian Drug Authority, 2013, EGYPT PHARM VIGILANC, V4, P1
   European Medicines Agency, 2017, GUID GOOD PHARM PRAC
   Ferraz-Filho Jose Roberto Lopes, 2010, Pediatr Radiol, V40 Suppl 1, pS138, DOI 10.1007/s00247-010-1650-6
   Gadroen K, 2016, VACCINE, V34, P4892, DOI 10.1016/j.vaccine.2016.08.062
   Haber P, 2015, J PEDIAT INF DIS SOC, V4, P205, DOI 10.1093/jpids/piu034
   Haber P, 2015, VACCINE, V33, P1987, DOI 10.1016/j.vaccine.2015.01.080
   Haber P, 2014, VACCINE, V32, P6499, DOI 10.1016/j.vaccine.2014.09.018
   Hadjipanayis A, 2018, VACCINE, V36, P5685, DOI 10.1016/j.vaccine.2018.08.021
   Hibbs BF, 2018, VACCINE, V36, P553, DOI 10.1016/j.vaccine.2017.11.083
   Hibbs BF, 2015, VACCINE, V33, P3171, DOI 10.1016/j.vaccine.2015.05.006
   Hoeve CE, 2018, VACCINE, V36, P7956, DOI 10.1016/j.vaccine.2018.11.003
   Huang WT, 2017, PHARMACOEPIDEM DR S, V26, P17, DOI 10.1002/pds.4141
   Institute of Medicine (US) Immunization Safety Review Committee, 2003, IMM SAF REV VACC SUD
   John TJ, 2008, INDIAN PEDIATR, V45, P477
   Klinkenberg D, 2015, PEDIATR INFECT DIS J, V34, P114, DOI 10.1097/INF.0000000000000507
   Kuhnert R, 2012, VACCINE, V30, P2349, DOI 10.1016/j.vaccine.2012.01.043
   Lei JY, 2018, VACCINE, V36, P1577, DOI 10.1016/j.vaccine.2018.02.012
   Leung J, 2014, HUM VACC IMMUNOTHER, V10, P146, DOI 10.4161/hv.26200
   McNeil MM, 2010, CLIN INFECT DIS PUBL, V2010, P7
   Mohite A, 2007, INDIAN PEDIATR, V44, P702
   Morfopoulou S, 2017, ACTA NEUROPATHOL, V133, P139, DOI 10.1007/s00401-016-1629-y
   Muhammad RD, 2011, PEDIATR INFECT DIS J, V30, pE1, DOI 10.1097/INF.0b013e3181ff9795
   O'Conghaile S, 2014, ANAESTH INTENS CARE, V42, P423
   Ogola E, 2012, ATYPICAL RABIES CASE
   Parthasarathy A, 2008, INDIAN PEDIATR, V45, P606
   Pellegrino P, 2014, AUTOIMMUN REV, V13, P736, DOI 10.1016/j.autrev.2014.01.054
   Pharmacovigilance Risk Assessment Committee, 2015, EMA7625632014 PHARM
   Plotkin S, 2018, PLOTKINS VACCINES, P1
   Public Health England, 2014, GREEN BOOK 2014
   Pue H. L., 2009, Morbidity and Mortality Weekly Report, V58, P1207
   Puliyel J, 2018, F1000RESEARCH, P243
   Quiambao BP, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000243
   Radjou AN, 2011, INDIAN J MED MICROBI, V29, P178, DOI [10.4103/0255-0857.81786, 10.4103/0255-0857.81790]
   Riaz A, 2018, VACCINE, V36, P5288, DOI 10.1016/j.vaccine.2018.07.024
   Salahuddin N, 2013, ANAESTH PAIN INTENSI, V17, P210
   Silvers LE, 2001, PHARMACOEPIDEM DR S, V10, P279, DOI 10.1002/pds.619
   Simonsen L, 2005, J INFECT DIS, V192, pS36, DOI 10.1086/431512
   Soldevilla HF, 2012, LUPUS, V21, P158, DOI 10.1177/0961203311429556
   The World Bank, 2019, WORLD BANK LIST EC 2
   Tozzi AE, 2013, VACCINE, V31, P5041, DOI 10.1016/j.vaccine.2013.08.087
   Ulloa-Gutierrez R, 2007, LANCET, V369, P1860, DOI 10.1016/S0140-6736(07)60848-4
   Varricchio F, 2002, VACCINE, V20, P3049, DOI 10.1016/S0264-410X(02)00252-9
   Vennemann MMT, 2007, VACCINE, V25, P4875, DOI 10.1016/j.vaccine.2007.02.077
   Vennemann MMT, 2007, VACCINE, V25, P336, DOI 10.1016/j.vaccine.2006.07.027
   WHO, 2009, STAT WORLDS VACC IMM
   WILDE H, 1989, VACCINE, V7, P49, DOI 10.1016/0264-410X(89)90010-8
   Wilde H, 2007, INFECT DIS J, V16, P65
   Wilson K, 2011, VACCINE, V29, P3746, DOI 10.1016/j.vaccine.2011.03.044
   Woo EJ, 2016, PEDIATR INFECT DIS J, V35, pE253, DOI 10.1097/INF.0000000000001201
   Woo EJ, 2015, HUM VACC IMMUNOTHER, V11, P679, DOI 10.1080/21645515.2014.1004034
   World Health Organization, 2019, VACC DIS 2019
   World Health Organization, 2012, GLOB VACC SAF BLUEPR
   World Health Organization, 2018, CAUSALITY ASSESSMENT
   World Health Organization, 2015, IMM PRACT MOD 2 VACC
   World health Organization, 2019, GLOB VACC SAF BLUEPR
   World Health Organization, 2018, VACC SAF BAS EL COUR
   Yang YT, 2018, VACCINE, V36, P595, DOI 10.1016/j.vaccine.2017.12.065
   Young EJ, 2016, MAYO CLIN PROC, V91, P971, DOI 10.1016/j.mayocp.2016.04.010
NR 70
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3086
EP 3095
DI 10.1016/j.vaccine.2020.02.074
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500003
PM 32147297
DA 2020-05-12
ER

PT J
AU Ahmed, N
   Giorgakoudi, K
   Usuf, E
   Okomo, U
   Clarke, E
   Kampmann, B
   Le Doare, K
   Trotter, C
AF Ahmed, N.
   Giorgakoudi, K.
   Usuf, E.
   Okomo, U.
   Clarke, E.
   Kampmann, B.
   Le Doare, K.
   Trotter, C.
TI Potential cost-effectiveness of a maternal Group B streptococcal vaccine
   in The Gambia
SO VACCINE
LA English
DT Article
DE Cost-effectiveness; Vaccine; Group B streptococcus; Streptococcus
   agalactiae; Neonatal infection
ID PREGNANT-WOMEN; DISEASE; BURDEN
AB Objective: To estimate neonatal health benefits and healthcare provider costs of a theoretical Group B streptococcal (GBS) hexavalent maternal vaccination programme in The Gambia, a low-income setting in West Africa.
   Methods: A static decision analytic cost-effectiveness model was developed from the healthcare provider perspective. Demographic data and acute care costs were available from studies in The Gambia undertaken in 2012-2015. Further model parameters were taken from United Nations and World Health Organisation sources, supplemented by data from a global systematic review of GBS and literature searches. As vaccine efficacy is not known, we simulated vaccine efficacy estimates of 50-90%. Costs are reported in US dollars. Cost-effectiveness thresholds of one (US$473, very cost effective) and three (US$1420, cost effective) times Gambian GDP were used.
   Results: Vaccination with a hexavalent vaccine would avert 24 GBS disease cases (55%) and 768 disability adjusted life years compared to current standard of care (no interventions to prevent GBS disease). At vaccine efficacy of 70%, the programme is cost-effective at a maximum vaccine price per dose of 12 US $ (2016 US$), and very cost-effective at a maximum of $3/dose. The total costs of vaccination at $12 is $1,056,962 for one annual cohort of Gambian pregnant women. One-way sensitivity analysis showed that GBS incidence was the most influential parameter on the cost effectiveness ratio.
   Conclusion: The introduction of a hexavalent vaccine would considerably reduce the current burden of GBS disease in The Gambia but to be cost-effective, the vaccine price per dose would need to be $12/dose or less. (C) 2020 Published by Elsevier Ltd.
C1 [Ahmed, N.] Imperial Coll London, London, England.
   [Giorgakoudi, K.] City Univ London, Sch Hlth Sci, London, England.
   [Giorgakoudi, K.] Royal Marsden NHS Fdn Trust, NIHR Biomed Res Ctr, Inst Canc Res, London, England.
   [Usuf, E.; Okomo, U.; Clarke, E.; Kampmann, B.; Le Doare, K.] Gambia MRCG LSHTM, Med Res Council Unit, Fajara, Gambia.
   [Trotter, C.] Univ Cambridge, Cambridge, England.
   [Le Doare, K.] St Georges Univ London, London, England.
   [Le Doare, K.] West African Global Hlth Alliance, Dakar, Senegal.
RP Trotter, C (reprint author), Univ Cambridge, Dept Vet Med, Dis Dynam Unit, Madingley Rd, Cambridge CB3 0ES, England.
EM clt56@cam.ac.uk
FU Wellcome Trust Clinical Research FellowshipWellcome Trust [WT104482MA];
   Thrasher Research Fund [BK: 12250]; UK MRCMedical Research Council UK
   (MRC) [MC_UP_A900/1122, MC_UP_A900/115]; UK Medical Research Council
   (MRC) under the MRC/DFID Concordat arrangement; Department for
   International Development (DFID) under the MRC/DFID Concordat
   arrangement
FX This work was supported by a Wellcome Trust Clinical Research Fellowship
   to KLD (WT104482MA) and the Thrasher Research Fund (BK: 12250). BK is
   also supported by grants from the UK MRC (MC_UP_A900/1122,
   MC_UP_A900/115) and the UK Medical Research Council (MRC) and the
   Department for International Development (DFID) under the MRC/DFID
   Concordat arrangement.
CR [Anonymous], 2013, 12 JUNE 2013 JOINT C
   [Anonymous], 2007, PREVENTION EARLY ONS
   [Anonymous], WORLD POPULATION REV
   Chou D, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4255
   Christie D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175024
   Country meters, 2018, LIV GAMB POP 2018 CU
   Duke T, 2005, ARCH DIS CHILD-FETAL, V90, P211, DOI 10.1136/adc.2003.048108
   GBDx, GLOB BURD DIS STUD 2
   Giorgakoudi K, 2018, VACCINE, V36, P7033, DOI 10.1016/j.vaccine.2018.09.058
   Global Burden of Disease Collaborative Netowrk, DIS WEIGHTS GHDX
   Griffiths UK, 2012, PEDIATR INFECT DIS J, V31, pE189, DOI 10.1097/INF.0b013e3182615297
   Husereau D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1049
   Kallenberg J., GAVIS VACCINE INVEST
   Kim SY, 2017, VACCINE, V35, P6238, DOI 10.1016/j.vaccine.2017.08.085
   Kim SY, 2014, VACCINE, V32, P1954, DOI 10.1016/j.vaccine.2014.01.062
   Kim SY, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-260
   Kobayashi M, 2019, VACCINE, V37, P7307, DOI 10.1016/j.vaccine.2016.12.029
   Kohli-Lynch M, 2017, CLIN INFECT DIS, V65, pS190, DOI 10.1093/cid/cix663
   Kuznik A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188595
   Le Doare K, 2016, J INFECTION, V72, P283, DOI 10.1016/j.jinf.2015.12.014
   Le Doare K, 2019, LANCET INFECT DIS, V19, pE162, DOI 10.1016/S1473-3099(18)30659-5
   Li C, 2018, 2018 CHINESE AUTOMATION CONGRESS (CAC), P278, DOI 10.1109/CAC.2018.8623803
   Liu L, 2015, LANCET, V385, P430, DOI 10.1016/S0140-6736(14)61698-6
   Marseille E, 2015, B WORLD HEALTH ORGAN, V93, P118, DOI 10.2471/BLT.14.138206
   Minimum-Wage.org, 2019, GAMB MIN WAG WORLD M
   Nuccitelli Annalisa, 2015, Ther Adv Vaccines, V3, P76, DOI 10.1177/2051013615579869
   Okomo UA, 2015, PAEDIATR INT CHILD H, V35, P252, DOI 10.1179/2046905515Y.0000000036
   Ranjeva SL, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000347
   Roca A, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.03.005
   Russell LB, 2017, VACCINE, V35, P6905, DOI 10.1016/j.vaccine.2017.07.108
   Seale AC, 2017, CLIN INFECT DIS, V65, pS200, DOI 10.1093/cid/cix664
   Sinha A, 2016, PEDIATR INFECT DIS J, V35, P933, DOI 10.1097/INF.0000000000001233
   Tan-Torres Edejer T, 2003, WHO GUIDE COST EFFEC
   Tann CJ, 2017, CLIN INFECT DIS, V65, pS173, DOI 10.1093/cid/cix662
   UNICEF, AD HLTH UNICEF DAT
   UNICEF, STATISTICS
   Usuf E, 2014, VACCINE, V32, P1975, DOI 10.1016/j.vaccine.2014.01.045
   Usuf E, 2016, COST EFFECT RESOUR A, V14, DOI 10.1186/s12962-016-0053-4
   WHO, 2013, GUID MAN COMM ILLN, P125, DOI [10.1016/j.cardfail.2011.02.010, DOI 10.1016/J.CARDFAIL.2011.02.010]
   WHO, 2017, WHO GBS VACC RES DEV
NR 40
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3096
EP 3104
DI 10.1016/j.vaccine.2020.02.071
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500004
PM 32147298
DA 2020-05-12
ER

PT J
AU Zahn, T
   Akhras, S
   Spengler, C
   Murra, RO
   Holzhauser, T
   Hildt, E
AF Zahn, Tobias
   Akhras, Sami
   Spengler, Catrina
   Murra, Robin Oliver
   Holzhauser, Thomas
   Hildt, Eberhard
TI A new approach for therapeutic vaccination against chronic HBV
   infections
SO VACCINE
LA English
DT Article
DE Virus-like particles; Vaccine platform; Transdermal vaccination; chronic
   HBV infection; Therapeutic vaccination; Neutralizing antibodies; CTL
   response; TLM-peptide; HBcAg capsid; Oral vaccination
ID HEPATITIS-B-VIRUS; MALARIA VACCINE; DENDRITIC CELLS; CORE ANTIGEN;
   PARTICLES; SURFACE; ANTIBODY; EPITOPES; HBSAG; IMMUNOTHERAPY
AB There are currently about 257 million people suffering from chronic HBV infection worldwide. In many cases, an insufficient T cell response is causative for establishment of a chronic infection. To ensure a robust cellular immune response and induction of neutralizing antibodies a novel vaccine platform based on modified cell-permeable HBV capsids was utilized. Cell permeability was achieved by fusion of the membrane-permeable TLM-peptide to HBV core monomers, assembling the capsids. Insertion of a Strep-tagIII into the spike tip domain that protrudes from the capsid surface enables flexible loading with antigens that are fused to streptavidin. In this study, HBV surface antigen-derived PreS1PreS2 domain, fused to monomeric streptavidin, served as cargo antigen. Binding between antigen and capsids was characterized by surface plasmon resonance spectroscopy, electron microscopy and density gradient centrifugation. Confocal immunofluorescence microscopy and in vivo imaging of immunized mice demonstrated membrane permeability of cargo-loaded carriers and spread of antigen over the whole organism. Immunization experiments of mice revealed a robust induction of a specific cellular immune response, leading to destruction of HBV-positive cells and induction of HBV-specific neutralizing antibodies. Membrane permeability of these carriers allows needle-free application of antigen-loaded capsids as evidenced by induction of an HBV-specific CTL response and HBV-specific B cell response after oral or transdermal vaccination.
   These data indicate that cell-permeable antigen carriers, based on HBV capsids and loaded with HBV antigen, have the capacity to induce a cellular and a neutralizing humoral immune response. In addition, cell permeability of the vaccine platform enables antigen transfer across several cell layers, that could allow oral or transdermal immunization. (C) 2020 Published by Elsevier Ltd.
C1 [Zahn, Tobias; Akhras, Sami; Spengler, Catrina; Murra, Robin Oliver; Hildt, Eberhard] Paul Ehrlich Inst, Div Virol, D-63325 Langen, Germany.
   [Zahn, Tobias; Hildt, Eberhard] German Ctr Infect Res DZIF, Langen, Germany.
   [Holzhauser, Thomas] Paul Ehrlich Inst, Div Allergol, D-63325 Langen, Germany.
RP Hildt, E (reprint author), Paul Ehrlich Inst, Div Virol, D-63325 Langen, Germany.
EM eberhard.hildt@pei.de
FU DZIF (Deutsches Zentrum fur Infektionsforschung)
FX This work was supported by a grant from DZIF (Deutsches Zentrum fur
   Infektionsforschung) to EH.
CR Akhras S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08787-0
   Almeida AJ, 1996, J DRUG TARGET, V3, P455, DOI 10.3109/10611869609015965
   Arora U, 2013, VACCINE, V31, P873, DOI 10.1016/j.vaccine.2012.12.016
   BARNABA V, 1989, J IMMUNOL, V143, P2650
   Beckebaum S, 2003, IMMUNOLOGY, V109, P487, DOI 10.1046/j.1365-2567.2003.01699.x
   Bertoletti A, 2016, J HEPATOL, V64, pS71, DOI 10.1016/j.jhep.2016.01.026
   Betsch C, 2019, BUNDESGESUNDHEITSBLA, V62, P400, DOI 10.1007/s00103-019-02900-6
   Birkett A, 2002, INFECT IMMUN, V70, P6860, DOI 10.1128/IAI.70.12.6860-6870.2002
   Bleifuss E, 2006, CELL MOL LIFE SCI, V63, P627, DOI 10.1007/s00018-005-5548-7
   Blokhina EA, 2013, VIROLOGY, V435, P293, DOI 10.1016/j.virol.2012.09.014
   Boni C, 2007, J VIROL, V81, P4215, DOI 10.1128/JVI.02844-06
   Boni C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112754
   Boonstra A, 2008, BEST PRACT RES CL GA, V22, P1049, DOI 10.1016/j.bpg.2008.11.015
   Boyaka PN, 2003, J IMMUNOL, V170, P5636, DOI 10.4049/jimmunol.170.11.5636
   Brandenburg B, 2005, HEPATOLOGY, V42, P1300, DOI 10.1002/hep.20950
   Cavenaugh JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014626
   Conway JF, 2003, J VIROL, V77, P6466, DOI 10.1128/JVI.77.11.6466-6473.2003
   Corti D, 2018, CURR OPIN VIROL, V30, P48, DOI 10.1016/j.coviro.2018.04.002
   Das M, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008575
   Engelke M, 2006, HEPATOLOGY, V43, P750, DOI 10.1002/hep.21112
   Flacher V, 2006, J IMMUNOL, V177, P7959, DOI 10.4049/jimmunol.177.11.7959
   Gao Y, 2017, HUM VACC IMMUNOTHER, V13, P1768, DOI 10.1080/21645515.2017.1319021
   Glebe D, 2005, GASTROENTEROLOGY, V129, P234, DOI 10.1053/j.gastro.2005.03.090
   Godon O, 2014, MOL THER, V22, P675, DOI 10.1038/mt.2013.274
   Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699
   HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984
   Isaguliants MG, 1996, IMMUNOL LETT, V52, P37, DOI 10.1016/0165-2478(96)02579-5
   JIN Y, 1988, J EXP MED, V168, P293, DOI 10.1084/jem.168.1.293
   Kalchiem-Dekel O, 2015, J GASTROEN HEPATOL, V30, P1782, DOI 10.1111/jgh.13022
   Kusumoto S, 2011, J GASTROENTEROL, V46, P9, DOI 10.1007/s00535-010-0331-4
   Lee WM, 1997, NEW ENGL J MED, V337, P1733, DOI 10.1056/NEJM199712113372406
   LENZ A, 1993, J CLIN INVEST, V92, P2587, DOI 10.1172/JCI116873
   Lobaina Y, 2006, VACCINE, V24, pS58, DOI 10.1016/j.vaccine.2005.01.122
   Lumley SF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01561
   Mihailova M, 2006, VACCINE, V24, P4369, DOI 10.1016/j.vaccine.2006.02.051
   NAGAFUCHI S, 1991, JAMA-J AM MED ASSOC, V265, P2679, DOI 10.1001/jama.265.20.2679
   Nardin EH, 2004, INFECT IMMUN, V72, P6519, DOI 10.1128/IAI.72.11.6519-6527.2004
   Nebbia G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047648
   Neirynck S, 1999, NAT MED, V5, P1157
   Nicolas JF, 2008, EXPERT REV VACCINES, V7, P1201, DOI 10.1586/14760584.7.8.1201
   Oess S, 2000, GENE THER, V7, P750, DOI 10.1038/sj.gt.3301154
   Ott JJ, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-131
   Paul S, 2017, HEPATOLOGY, V66, P379, DOI 10.1002/hep.29082
   Peyret H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120751
   Plummer EM, 2011, WIRES NANOMED NANOBI, V3, P174, DOI 10.1002/wnan.119
   Pol S, 2001, J HEPATOL, V34, P917, DOI 10.1016/S0168-8278(01)00028-9
   Pyrski M, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040211
   Sambrook J., 1989, MOL CLONING
   Schurich A, 2011, HEPATOLOGY, V53, P1494, DOI 10.1002/hep.24249
   Spellberg B, 2000, LIFE SCI, V67, P477, DOI 10.1016/S0024-3205(00)00653-6
   Suffner S, 2018, J VIROL, V92, DOI 10.1128/JVI.02232-17
   van den Berg LM, 2015, J IMMUNOL, V195, P1763, DOI 10.4049/jimmunol.1402356
   Vandepapeliere P, 2007, VACCINE, V25, P8585, DOI 10.1016/j.vaccine.2007.09.072
   Voss S, 1997, PROTEIN ENG, V10, P975, DOI 10.1093/protein/10.8.975
   Werle-Lapostolle B, 2004, GASTROENTEROLOGY, V126, P1750, DOI 10.1053/j.gastro.2004.03.018
   World Health Organization, 2017, GLOB HEP REP 2017
   Xu DZ, 2013, J HEPATOL, V59, P450, DOI 10.1016/j.jhep.2013.05.003
   Xu Y, 2009, MOL IMMUNOL, V46, P2640, DOI 10.1016/j.molimm.2009.04.031
   Zhang XN, 2016, J CLIN INVEST, V126, P1079, DOI 10.1172/JCI83339
   Zheng BJ, 2004, J VIRAL HEPATITIS, V11, P217, DOI 10.1111/j.1365-2893.2004.00497.x
NR 60
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3105
EP 3120
DI 10.1016/j.vaccine.2020.02.063
PG 16
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500005
PM 32113806
DA 2020-05-12
ER

PT J
AU Belongia, EA
   Levine, MZ
   Olaiya, O
   Gross, FL
   King, JP
   Flannery, B
   McLean, HQ
AF Belongia, Edward A.
   Levine, Min Z.
   Olaiya, Oluwatosin
   Gross, F. Liaini
   King, Jennifer P.
   Flannery, Brendan
   McLean, Huong Q.
TI Clinical trial to assess immunogenicity of high-dose, adjuvanted, and
   recombinant influenza vaccines against cell-grown A(H3N2) viruses in
   adults 65 to 74 years, 2017-2018
SO VACCINE
LA English
DT Article
DE Influenza; Vaccine; Immunogenicity; Adjuvant; High-dose; Recombinant
ID EFFICACY
AB Background: Licensed inactivated influenza vaccines (IIV) are recommended for persons aged >65 years, including trivalent high-dose IIV (HD-IIV3) and adjuvanted IIV (aIIV3); both are manufactured in eggs. Quadrivalent recombinant vaccine (RIV4) is produced without eggs. We conducted an exploratory study to compare immunogenicity of HD-IIV3, allV3 and RIV4 against cell-grown vaccine and circulating A (H3N2) viruses in 2017-18.
   Methods: Eighty-nine adults aged 65-74 years participating in a 2-year, open-label immunogenicity trial (ClinicalTrails.gov: NCT02872311) were randomized 1:1:1 to receive HD-IIV3, aIIV3, or RIV4 after receipt of standard dose IIV3 in 2016-17. Serum was obtained at baseline and day 28 post vaccination. Microneutralization titers were determined using four cell-propagated A(H3N2) viruses: 2017-18 vaccine strain (Glade 3C.2a), circulating viruses from clades 3C.2a1 and 3C.2a2, and 'antigenically advanced' Glade 3C.3a (2019-20 vaccine strain). Active surveillance was conducted to identify influenza illnesses.
   Results: Post vaccination geometric mean titer (GMT) against the vaccine strain was <1:60 in each group and <15% seroconverted. RIV4 generated a greater fold-rise (2.0, 95% CI 1.7-2.5) compared to HD-IIV3 (1.6, 95% CI 1.3-1.8). RIV4 generated higher post vaccination titers against 3C.2a1 and 3C.2a2 viruses, and the mean fold-rise after RIV4 was twice as high (3.3 and 3.5, respectively) relative to HD-IIV3 (1.4 and 1.6) and allV3 (1.7 and 1.6). Against the antigenically advanced 3C.3a virus, RIV4 generated a greater mean fold-rise (2.9, 95% CI 2.0-4.3) vs HD-IIV3 (1.3, 95% CI 1.1-1.6) and allV3 (1.7, 95% CI 1.3-2.1). Postvaccination titers against 3C.2a2 were >= 1:40 in 5 of 7 participants with PCR-confirmed A(H3N2) infection during the ensuing influenza season.
   Conclusion: High-dose, adjuvanted, and recombinant vaccines generated suboptimal neutralizing antibody responses to the cell-grown vaccine strain, but RIV4 generated a greater cross-protective response against circulating and antigenically advanced viruses. Recombinant technology may contribute to more broadly protective influenza vaccines, and comparative effectiveness studies are needed. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Belongia, Edward A.; Olaiya, Oluwatosin; King, Jennifer P.; McLean, Huong Q.] Marshfield Clin Res Inst, Ctr Clin Epidemiol & Populat Hlth, 1000 North Oak Ave ML2, Marshfield, WI 54449 USA.
   [Levine, Min Z.; Gross, F. Liaini; Flannery, Brendan] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA.
RP Belongia, EA (reprint author), Marshfield Clin Res Inst, Ctr Clin Epidemiol & Populat Hlth, 1000 North Oak Ave ML2, Marshfield, WI 54449 USA.
EM belongia.edward@marshfieldclinic.org
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [5U01IP001038]
FX This work was supported by a cooperative agreement (5U01IP001038) from
   the Centers for Disease Control and Prevention to the Marshfield Clinic
   Research Institute.
CR Allen JD, 2018, HUM VACC IMMUNOTHER, V14, P1840, DOI 10.1080/21645515.2018.1462639
   Belongia EA, 2019, CLIN INFECT DIS, V69, P1817, DOI 10.1093/cid/ciz411
   Buckland B, 2014, VACCINE, V32, P5496, DOI 10.1016/j.vaccine.2014.07.074
   Center for Biologics Evaluation and Research, 2007, GUID IND CLIN DAT NE
   DiazGranados CA, 2014, NEW ENGL J MED, V371, P635, DOI 10.1056/NEJMoa1315727
   Dunkle LM, 2017, J INFECT DIS, V216, P1219, DOI 10.1093/infdis/jix478
   Dunkle LM, 2017, NEW ENGL J MED, V376, P2427, DOI [10.1056/NEJMoa1608862, 10.1056/nejmoa1608862]
   Dunkle LM, 2016, EXPERT REV VACCINES, V15, P957, DOI 10.1080/14760584.2016.1203261
   Dunning AJ, 2016, CLIN VACCINE IMMUNOL, V23, P228, DOI 10.1128/CVI.00604-15
   Flannery B, 2019, CLIN INFECT DIS, V68, P1798, DOI 10.1093/cid/ciy775
   Flannery B, 2016, J INFECT DIS, V214, P1010, DOI 10.1093/infdis/jiw181
   Garten R, 2018, MMWR-MORBID MORTAL W, V67, P634, DOI 10.15585/mmwr.mm6722a4
   Gouma S, 2019, CLIN INFECT DIS
   Gross FL, 2017, JOVE-J VIS EXP, V22, P129
   Levine MZ, 2019, J INFECT DIS, V219, P1904, DOI 10.1093/infdis/jiz049
   Nachbagauer R, 2016, MBIO, V7, DOI 10.1128/mBio.01996-15
   Orsi A, 2013, HUM VACC IMMUNOTHER, V9, P582, DOI 10.4161/hv.23239
   Reber AJ, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv052
   Skowronski DM, 2016, CLIN INFECT DIS, V63, P21, DOI 10.1093/cid/ciw176
   Skowronski DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092153
   Sun BJ, 2018, CAN J INFECT DIS MED, DOI 10.1155/2018/2751457
   Valenciano M, 2016, EUROSURVEILLANCE, V21, P15, DOI 10.2807/1560-7917.ES.2016.21.7.30139
   Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114
   Zost SJ, 2017, P NATL ACAD SCI US
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3121
EP 3128
DI 10.1016/j.vaccine.2020.02.055
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500006
PM 32145994
OA Other Gold
DA 2020-05-12
ER

PT J
AU Tachibana, M
   Baba, M
   Takashima, E
   Tsuboi, T
   Torii, M
   Ishino, T
AF Tachibana, Mayumi
   Baba, Minami
   Takashima, Eizo
   Tsuboi, Takafumi
   Torii, Motomi
   Ishino, Tomoko
TI The C-terminal region of the Plasmodium yoelii microgamete surface
   antigen PyMiGS induces potent anti-malarial transmission-blocking
   immunity in mice
SO VACCINE
LA English
DT Article
DE Microgamete; Plasmodium yoelii; PyMiGS; Transmission-blocking
ID MALARIA TRANSMISSION; VACCINE CANDIDATES; FALCIPARUM; PROTEINS; BERGHEI;
   HAP2; ANTIBODIES; PFS230; TRIAL
AB Malaria transmission-blocking vaccines (TBVs) aim to inhibit parasite fertilization or further development within the mosquito midgut. Because TBV-immunized individuals reduce the transmission of malaria parasites to mosquito vectors, TBVs could serve as a promising strategy to eliminate malaria. We previously reported that a male specific protein, PyMiGS (Plasmodium yoelii microgamete surface protein), is localized to the surface of microgametes and anti-PyMiGS antibodies have strong transmissionblocking activity. In this study we determine a region of PyMiGS that contains epitopes inducing potent transmission-blocking antibodies. PyMiGS excluding the N-terminal signal sequence and C-terminal hydrophobic region (PyMiGS-full) was divided into five overlapping regions, named I through V, and corresponding truncated recombinant proteins were produced. Anti-region V antibody, affinity-purified from anti-PyMiGS-full rabbit antiserum, significantly reduced the number of oocysts in a mosquito membrane-feeding assay. Antibodies from mice immunized with PyMiGS-V recognized the microgamete surface and showed higher transmission-blocking efficacy than antibodies obtained by PyMiGS-full immunization. These results indicate that the major epitopes for transmission-blocking antibodies are within region V at the C-terminal region of PyMiGS. Therefore, region V of MiGS could be a promising pre-fertilization TBV candidate antigen. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Tachibana, Mayumi; Baba, Minami; Torii, Motomi; Ishino, Tomoko] Ehime Univ, Proteo Sci Ctr, Div Mol Parasitol, Toon, Ehime 7910295, Japan.
   [Takashima, Eizo; Tsuboi, Takafumi; Torii, Motomi] Ehime Univ, Proteo Sci Ctr, Div Malaria Res, Matsuyama, Ehime 7908577, Japan.
RP Ishino, T (reprint author), Ehime Univ, Proteo Sci Ctr, Div Mol Parasitol, Toon, Ehime 7910295, Japan.
EM tishino@m.ehime-u.ac.jp
OI Ishino, Tomoko/0000-0003-2466-711X
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP 24590506, JP
   15K08443]; Global Health Innovative Technology Fund [GHIT G2014-110]
FX This work was partially supported by JSPS KAKENHI Grant (grant numbers
   JP 24590506, JP 15K08443) and Global Health Innovative Technology Fund
   (grant number GHIT G2014-110).
CR Abdulla S, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0621-7
   Angrisano F, 2017, CELL REP, V21, P2868, DOI 10.1016/j.celrep.2017.11.024
   Bhatt S, 2015, NATURE, V526, P207, DOI 10.1038/nature15535
   Blagborough AM, 2009, VACCINE, V27, P5187, DOI 10.1016/j.vaccine.2009.06.069
   Boddey JA, 2010, NATURE, V463, P627, DOI 10.1038/nature08728
   Canepa GE, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0065-5
   Chanda E, 2017, TRENDS PARASITOL, V33, P30, DOI 10.1016/j.pt.2016.09.006
   Eksi S, 2006, MOL MICROBIOL, V61, P991, DOI 10.1111/j.1365-2958.2006.05284.x
   Fedry J, 2017, CELL, V168, P904, DOI 10.1016/j.cell.2017.01.024
   Hemingway J, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002380
   Hodder AN, 2015, NAT STRUCT MOL BIOL, V22, P590, DOI 10.1038/nsmb.3061
   Jacobs-Lorena VY, 2010, MOL BIOCHEM PARASIT, V171, P40, DOI 10.1016/j.molbiopara.2009.12.009
   KASLOW DC, 1994, INFECT IMMUN, V62, P5576, DOI 10.1128/IAI.62.12.5576-5580.1994
   Kaslow DC, 2002, CHEM IMMUNOL, V80, P287
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Lin JT, 2014, TRENDS PARASITOL, V30, P183, DOI 10.1016/j.pt.2014.02.004
   Long CA, 2016, CURR OPIN MICROBIOL, V32, P96, DOI 10.1016/j.mib.2016.04.006
   Malkin EM, 2005, VACCINE, V23, P3131, DOI 10.1016/j.vaccine.2004.12.019
   Mitchell AL, 2019, NUCLEIC ACIDS RES, V47, pD351, DOI 10.1093/nar/gky1100
   Miura K, 2013, INFECT IMMUN, V81, P4377, DOI 10.1128/IAI.01056-13
   Mori T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015957
   Nikolaeva D, 2015, EXPERT REV VACCINES, V14, P653, DOI 10.1586/14760584.2015.993383
   Outchkourov NS, 2008, P NATL ACAD SCI USA, V105, P4301, DOI 10.1073/pnas.0800459105
   RENER J, 1983, J EXP MED, V158, P976, DOI 10.1084/jem.158.3.976
   Sagara I, 2018, LANCET INFECT DIS, V18, P969, DOI 10.1016/S1473-3099(18)30344-X
   Sala KA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18831-8
   Schneider P, 2007, AM J TROP MED HYG, V76, P470, DOI 10.4269/ajtmh.2007.76.470
   Sowunmi A, 2011, CHEMOTHERAPY, V57, P497, DOI 10.1159/000334126
   Stone WJR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02646-2
   Tachibana M, 2018, CELL MICROBIOL, V20, DOI 10.1111/cmi.12821
   Tachibana M, 2019, VACCINE, V37, P1799, DOI 10.1016/j.vaccine.2019.02.021
   Tachibana M, 2018, VACCINE, V36, P7463, DOI 10.1016/j.vaccine.2018.10.067
   Tachibana M, 2015, VACCINE, V33, P1901, DOI 10.1016/j.vaccine.2015.03.008
   Tsuboi T, 1997, INFECT IMMUN, V65, P2260, DOI 10.1128/IAI.65.6.2260-2264.1997
   Tsuboi T, 2008, INFECT IMMUN, V76, P1702, DOI 10.1128/IAI.01539-07
   Tsuboi T, 2010, METHODS MOL BIOL, V607, P73, DOI 10.1007/978-1-60327-331-2_8
   Ukegbu CV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05917-6
   van Dijk MR, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000853
   van Dijk MR, 2001, CELL, V104, P153, DOI 10.1016/S0092-8674(01)00199-4
   van Schaijk BCL, 2006, MOL BIOCHEM PARASIT, V149, P216, DOI 10.1016/j.molbiopara.2006.05.015
   WHO, 2018, WORLD MAL REP 2018
   Williamson KC, 1995, MOL BIOCHEM PARASIT, V75, P33, DOI 10.1016/0166-6851(95)02507-3
   WINGER LA, 1988, PARASITE IMMUNOL, V10, P193, DOI 10.1111/j.1365-3024.1988.tb00214.x
   Wu YM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002636
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3129
EP 3136
DI 10.1016/j.vaccine.2020.02.058
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500007
PM 32147299
DA 2020-05-12
ER

PT J
AU Menzies, R
   Heron, L
   Lampard, J
   McMillan, M
   Joseph, T
   Chan, J
   Storken, A
   Marshall, H
AF Menzies, R.
   Heron, L.
   Lampard, J.
   McMillan, M.
   Joseph, T.
   Chan, J.
   Storken, A.
   Marshall, H.
TI A randomised controlled trial of SMS messaging and calendar reminders to
   improve vaccination timeliness in infants
SO VACCINE
LA English
DT Article
DE Text messaging; Immunization programs; Reminder systems
ID IMMUNIZATION
AB Background: The effectiveness of SMS reminders in improving vaccination coverage has been assessed previously, with effectiveness varying between settings. However, there are very few studies on their effect on the timeliness of vaccination.
   Design: Unblinded, randomised controlled trial with blocked sampling.
   Methods: 1594 Australian infants and young children were recruited to assess the impact of (1) SMS reminders only, (2) a personalised calendar, (3) SMS reminder and personalised calendar and (4) no intervention, on receipt of vaccine within 30 days of the due date. Outcomes were measured for receipt of vaccines due at 2, 4, 6,12 and 18 months of age. A post-hoc assessment was also conducted of the impact of a new national "No jab No Pay" policy introduced during the trial, which removed philosophical objections as an exemption for financial penalties for non-vaccination.
   Results: There was a statistically significant improvement in on-time vaccination only at the 12 month schedule point amongst infants who received SMS reminders alone (RR 1.09, 95% CI 1.01-1.18) or in com-bination with a personalised calendar (1.11, CI 1.03-1.20) compared to controls. This impact was limited to participants who had received one or more previous doses late. No statistically significant impacts of calendar interventions alone were seen. There was a high rate of on-time compliance amongst control participants - 95%, 86%, 80%, 74% at the 4, 6, 12 and 18 month schedule points respectively, which increased more than 10 percentage points after implementation of the "No Jab, No Pay" policy.
   Conclusions: SMS reminders are more effective in improving timeliness where pre-existing compliance is lower, but the 18 month schedule point appeared to be less amenable to intervention. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Menzies, R.; Joseph, T.] Univ New South Wales, Kirby Inst, Kensington, NSW, Australia.
   [Heron, L.; Chan, J.] Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance, Westmead, NSW, Australia.
   [Heron, L.; Lampard, J.] Childrens Hosp Westmead, Kids Res Inst, Westmead, NSW, Australia.
   [McMillan, M.; Marshall, H.] Univ Adelaide, Womens & Childrens Hosp, Vaccinol & Immunol Res Trials Unit, Adelaide, SA, Australia.
   [McMillan, M.; Marshall, H.] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia.
   [Chan, J.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia.
   [Storken, A.] Dept Hlth, Adelaide, SA, Australia.
RP Menzies, R (reprint author), Univ New South Wales, Kirby Inst, Kensington, NSW, Australia.
EM r.menzies@unsw.edu.au
OI McMillan, Mark/0000-0002-6490-7707; Menzies, Rob/0000-0003-3833-5765
FU NHMRCNational Health and Medical Research Council of Australia [CDF
   APP1084951]; GSKGlaxoSmithKline; Novavax; PfizerPfizer; Sanofi; Seqirus;
   MerckMerck & Company
FX The authors declare the following financial interests/personal
   relationships which may be considered as potential competing interests:
   HM is supported by a NHMRC CDF APP1084951 and is a member of the
   Australian Technical Advisory Group on Immunisation, Australian
   Government. HM is an investigator on vaccine trials sponsored by
   Industry (GSK, Novavax, Pfizer, Sanofi, Seqirus, and Merck). HM's and
   MM's institution receives funding for investigator led studies from
   Industry. HM and MM receive no personal payments from Industry. RM
   serves on the Pneumococcal Advisory Board (Seqirus) and Healthy Aging
   Advisory Board (GSK).
CR Abbott P, 2013, BMC PUBLIC HEALTH, V13, P1
   ADAM H, 2014, BMC PUBLIC HEALTH, V13, DOI DOI 10.1186/S12889-016-2823-5
   Bangure D, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1470-6
   Beard F, 2016, MED J AUSTRALIA, V204, P1
   Beard F, 2017, MED J AUSTRALIA, V206, P3
   Chai S, 2013, AM J PREV MED, V45, P7
   Community Preventive Services Task Force, 2008, INCR APPR VACC CLIEN
   Ghadieh A, 2015, VACCINE, V33, P5
   Hofstetter AM, 2015, VACCINE, V33, P5741, DOI 10.1016/j.vaccine.2015.09.042
   Hull B, 2014, COMMUN DIS INTELL, V38, P22
   Hull B, 2018, ANN IMMUNISATION COV
   Hull BP, 2006, VACCINE, V24, P4403, DOI 10.1016/j.vaccine.2006.02.049
   Hull BP, 2013, COMMUN DIS INTELL, V37, pE291
   Kharbanda EO, 2011, VACCINE, V29, P2537, DOI 10.1016/j.vaccine.2011.01.065
   Kreuter M, 2004, AM J PUBLIC HLTH NAT, V94, P6
   Leask J, 2017, J PAEDIATR CHILD H, V53, P5
   McIver R, 2015, J AM MED INFORM ASSN, V23, P5
   Moniz MH, 2013, OBSTET GYNECOL, V121, P734, DOI 10.1097/AOG.0b013e31828642b1
   Niederhauser V, 2015, VACCINE, V33, P2984, DOI 10.1016/j.vaccine.2015.04.069
   O'Leary S, 2015, PEDIATRICS, V136
   Patel A, 2014, VACCINE, V32, P2428, DOI 10.1016/j.vaccine.2014.02.095
   Plotkin SA, 2008, VACCINES
   Regan A, 2017, ANN FAMILY MED, V15, P8
   Stockwell M, 2015, PEDIATRICS, V135, P9
   Stockwell M, 2012, JAMA-J AM MED ASSOC, V307, P7
   Stockwell M, 2012, AM J PUBLIC HLTH NAT, V102, P7
   Vilella A, 2004, PREV MED, V38, P503, DOI 10.1016/j.ypmed.2003.12.005
   Ward J, 2012, AUST NZ J PUBL HEAL, V36, P91, DOI 10.1111/j.1753-6405.2012.00835.x
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3137
EP 3142
DI 10.1016/j.vaccine.2020.02.045
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500008
PM 32147296
DA 2020-05-12
ER

PT J
AU Thompson, EL
   Wheldon, CW
   Rosen, BL
   Maness, SB
   Kasting, ML
   Massey, PM
AF Thompson, Erika L.
   Wheldon, Christopher W.
   Rosen, Brittany L.
   Maness, Sarah B.
   Kasting, Monica L.
   Massey, Philip M.
TI Awareness and knowledge of HPV and HPV vaccination among adults ages
   27-45 years
SO VACCINE
LA English
DT Article
DE HPV; Vaccine; Adults; Knowledge; Awareness
ID HUMAN-PAPILLOMAVIRUS; ADVISORY-COMMITTEE; UNITED-STATES; RECOMMENDATIONS
AB Objective: Recent guidelines indicate adults 27-45 years old can receive the human papillomavirus (HPV) vaccine based on a shared-decision with their healthcare provider. With this expansion in recommendations, there is a need to examine the awareness and knowledge of HPV and HPV vaccination among this age group for cancer prevention.
   Methods: HINTS-5 Cycle-2 is a national survey of US adults, and was restricted to a complete case analysis of adults ages 27-45 years (N = 725). Sociodemographic, healthcare, and health information correlates were assessed for the outcomes of HPV awareness, HPV vaccine awareness, knowledge of HPV and cervical cancer, and knowledge of HPV and non-cervical cancers. Survey-weighted logistic regression models were conducted.
   Results: Most respondents were aware of HPV (72.9%) and HPV vaccination (67.1%). Respondents were more likely to be aware of HPV and HPV vaccination if they were female, had a higher level of education, and had previous cancer information seeking behaviors. Although there was widespread knowledge of HPV as a cause of cervical cancer (79.6%), knowledge of HPV as a cause of non-cervical cancers was reported by a minority of respondents (36.1%). College education was positively associated with cervical cancer knowledge (aOR = 4.62; 95%CI: 1.81-11.78); however, no significant correlates were identified for non-cervical HPV associated cancer knowledge.
   Conclusion: While more than half of adults ages 27-45 years are aware of HPV and HPV vaccination, there are opportunities to improve awareness and knowledge, particularly related to non-cervical cancers, as these are critical first steps toward shared decision-making for HPV vaccination in mid-adulthood. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Thompson, Erika L.] Univ North Texas, Sch Publ Hlth, Dept Hlth Behav & Hlth Syst, Hlth Sci Ctr, Ft Worth, TX USA.
   [Wheldon, Christopher W.] Temple Univ, Dept Social & Behav Sci, Coll Publ Hlth, Philadelphia, PA 19122 USA.
   [Rosen, Brittany L.] Cincinnati Childrens Hosp, Dept Pediat, Cincinnati, OH USA.
   [Maness, Sarah B.] Univ Oklahoma, Dept Hlth & Exercise Sci, Coll Arts & Sci, Norman, OK 73019 USA.
   [Kasting, Monica L.] Purdue Univ, Coll Hlth & Human Sci, Dept Publ Hlth, W Lafayette, IN 47907 USA.
   [Massey, Philip M.] Drexel Univ, Dept Community Hlth & Prevent, Dornsife Sch Publ Hlth, Philadelphia, PA 19104 USA.
RP Thompson, EL (reprint author), 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA.
EM Erika.thompson@unthsc.edu; chris.wheldon@temple.edu;
   brittany.rosen@cchmc.org; smaness@ou.edu; mlkastin@purdue.edu;
   pmm85@drexel.edu
OI Massey, Philip/0000-0002-0577-8618
CR Andridge RR, 2010, INT STAT REV, V78, P40, DOI 10.1111/j.1751-5823.2010.00103.x
   Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P630
   Betsch C, 2012, VACCINE, V30, P3723, DOI 10.1016/j.vaccine.2012.03.078
   Blake KD, 2015, AM J PREV MED, V48, P402, DOI 10.1016/j.amepre.2014.10.024
   Boakye EA, 2017, HUM VACC IMMUNOTHER, V13, P2713, DOI 10.1080/21645515.2017.1363133
   Cates JR, 2011, SOC MARK Q, V17, P4, DOI 10.1080/15245004.2010.546943
   Chesson HW, 2014, SEX TRANSM DIS, V41, P660, DOI 10.1097/OLQ.0000000000000193
   Fiore Anthony E., 2007, Morbidity and Mortality Weekly Report, V56, P1
   Fu LY, 2014, VACCINE, V32, P1901, DOI 10.1016/j.vaccine.2014.01.091
   Kasting M., 2019, BASELINE HUMAN PAPIL
   Kasymova S, 2019, INFECT DIS AUCKL, V12
   Kolff CA, 2018, HUM VACC IMMUNOTHER, V14, P1636, DOI 10.1080/21645515.2018.1477458
   Maness SB, 2016, AM J HEALTH BEHAV, V40, P771, DOI 10.5993/AJHB.40.6.9
   McBride KR, 2018, HEALTH EDUC BEHAV, V45, P68, DOI 10.1177/1090198117709318
   Meites E, 2019, MMWR-MORBID MORTAL W, V68, P698, DOI 10.15585/mmwr.mm6832a3
   Nyhan B, 2015, VACCINE, V33, P459, DOI 10.1016/j.vaccine.2014.11.017
   Nyhan B, 2014, PEDIATRICS, V133, pE835, DOI 10.1542/peds.2013-2365
   Osazuwa-Peters N, 2017, PREV MED, V99, P299, DOI 10.1016/j.ypmed.2017.03.014
   Rust K F, 1996, Stat Methods Med Res, V5, P283, DOI 10.1177/096228029600500305
   Senkomago V, 2019, MMWR-MORBID MORTAL W, V68, P724, DOI 10.15585/mmwr.mm6833a3
   Suk R, 2019, JAMA PEDIATR, V173, P1099, DOI 10.1001/jamapediatrics.2019.3105
   Thompson EL, 2019, J COMMUN HEALTH, V44, P149, DOI 10.1007/s10900-018-0565-2
   Walker TY, 2019, MMWR-MORBID MORTAL W, V68, P718, DOI 10.15585/mmwr.mm6833a2
   Watkins KL, 2015, AM J HEALTH BEHAV, V39, P204, DOI 10.5993/AJHB.39.2.7
   Westat, 2018, HLTH INF NAT TRENDS
   Wheldon CW, 2019, AM J PREV MED, V56, pE117, DOI 10.1016/j.amepre.2018.11.005
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3143
EP 3148
DI 10.1016/j.vaccine.2020.01.053
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500009
PM 32029321
DA 2020-05-12
ER

PT J
AU Tiley, K
   Tessier, E
   White, JM
   Andrews, N
   Saliba, V
   Ramsay, M
   Edelstein, M
AF Tiley, K.
   Tessier, E.
   White, J. M.
   Andrews, N.
   Saliba, V
   Ramsay, M.
   Edelstein, M.
TI School-based vaccination programmes: An evaluation of school
   immunisation delivery models in England in 2015/16
SO VACCINE
LA English
DT Article
DE Vaccines; Immunisation; Vaccine-preventable diseases; Human
   papillomavirus- HPV; Meningococcal disease; Vaccine delivery model
ID COVERAGE
AB Schools are increasingly being used to deliver vaccines. In 2015/16 three school-based vaccination programmes were delivered to adolescents in England: human papillomavirus (HPV), meningococcal groups A, C, W and Y disease (MenACWY) and tetanus, diphtheria and polio (Td/IPV). We assessed how school delivery models impact vaccine coverage and how a delivery model for one programme may impact another. Routinely collected national data were analysed to ascertain the school grade achieving highest coverage within each one-dose programme and to compare two-dose delivery models (within year vs across years) for the HPV vaccine. We also assessed whether the HPV delivery model was associated with coverage in other programmes.
   MenACWY and Td/IPV coverage was highest in younger school grades. Overall similar HPV coverage was achieved with both models (86.7% two doses within one year, 85.8% two doses across two years, p = 0.20). High two-dose HPV coverage in 2015/16 was reported in areas that achieved high HPV coverage in 2013/14 when three doses were required. Areas with high three-dose coverage in 2013/14 achieved higher coverage with a within-one-year approach (92.0% vs 85.2%, p < 0.001), whilst areas reporting low coverage in 2013/14 achieved lower but similar coverage in 2015/16 with both models (79.2% vs 80.9% p = 0.29). MenACWY and Td/IPV coverage were higher in areas with high HPV coverage in 2013/14. Among high HPV coverage areas, MenACWY coverage was higher when HPV doses were delivered within year.
   School-based programmes should be offered as early as feasible and acceptable to optimise coverage. The choice of delivery model for HPV should take into account local performance and provider experience. Single providers may delivery multiple vaccines and the delivery for one programme may affect the performance of other programmes. Providers should consider local circumstances including past and current vaccine coverage and factors influencing coverage when deciding what delivery model to adopt. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Tiley, K.; Tessier, E.; White, J. M.; Saliba, V; Ramsay, M.; Edelstein, M.] Publ Hlth England, Immunisat & Countermeasures Div, Natl Infect Serv, London, England.
   [Andrews, N.] Publ Hlth England, Natl Infect Serv, Stat Modelling & Econ Dept, London, England.
RP Tessier, E (reprint author), Publ Hlth England, Immunisat & Countermeasures Div, Natl Infect Serv, London, England.
EM Elise.Tessier@phe.gov.uk
CR Audrey S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021321
   Brotherton JML, 2013, MED J AUSTRALIA, V199, P614, DOI 10.5694/mja13.10272
   CAMPBELL H, 2015, EUROSURVEILLANCE, V2015, P20, DOI DOI 10.2807/1560-7917.ES2015.20.28.21188
   Campbell H, 2017, VACCINE, V35, P2979, DOI 10.1016/j.vaccine.2017.03.089
   Centers for Disease Control and Prevention, 2018, NATL REGIONAL STATE
   Christensen H, 2019, J PUBL HLTH OXFORD E
   Crocker J, 2012, J PUBLIC HEALTH-UK, V34, P498, DOI 10.1093/pubmed/fds047
   Doare K, 2016, J INFECTION
   England PH, 2018, NHS PUBL HLTH FUNCT
   Fletcher R, 2019, PUBLIC HEALTH, V171, P24, DOI 10.1016/j.puhe.2019.03.018
   Gillilck V., 1985, W NORFOLK WISBECH AR
   Gordon J., 2013, BRIT J SCH NURSING, V8, P20
   Joint Committee on Vaccination and Immunisation, 2012, JCVI SUBC AD VACC M
   National HPV Vaccinatin Program Register Australia, 2017, NAT AUSTR HPV 3 DOS
   Paterson P, 2019, J PUBL HLTH
   Perman S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4168-0
   Public Health England, 2015, MENACWY VACC INTR
   Public Health England, 2016, PREL VACC COV SCH BA
   Public Health England, 2015, HUM PAP HPV VACC COV
   Public Health England, 2018, SEAS INFL VACC UPT C
   Public Health England, 2016, HLTH PROTECTION REPO, P10
   Public Health England, 2018, COMPL ROUT IMM SCHED
   Public Health England Department of Health NHS England, 2014, HPV VACC PROGR CHANG
   Reagan-Steiner S, 2016, MMWR-MORBID MORTAL W, V65, P850, DOI 10.15585/mmwr.mm6533a4
   Rehn M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149857
   Tiley K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029087
   WHITE JM, 1992, BRIT MED J, V304, P682, DOI 10.1136/bmj.304.6828.682
NR 27
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3149
EP 3156
DI 10.1016/j.vaccine.2020.01.031
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500010
PM 31980192
OA Other Gold
DA 2020-05-12
ER

PT J
AU Jiang, Y
   Cheng, X
   Zhao, XM
   Yu, Y
   Gao, MY
   Zhou, S
AF Jiang, Yi
   Cheng, Xu
   Zhao, Xiumei
   Yu, Yan
   Gao, Mingyan
   Zhou, Sheng
TI Recombinant infectious bronchitis coronavirus H120 with the spike
   protein S1 gene of the nephropathogenic IBYZ strain remains attenuated
   but induces protective immunity
SO VACCINE
LA English
DT Article
DE Infectious bronchitis virus; Attenuation; Spike; Vaccine; QX-like
ID CYTOTOXIC T-LYMPHOCYTES; REVERSE GENETICS; VIRUS-STRAIN; MOLECULAR
   CHARACTERIZATION; AMINO-ACIDS; N-PROTEIN; EFFICACY; VACCINE; LIVE; CHINA
AB Infectious bronchitis (IB) is a highly infectious viral disease responsible for major economic losses in the poultry industry. A reverse genetic vaccine is a safe, rapid, and effective method of achieving IB prevention and control. In this study, we constructed the recombinant strain, rH120-S1/YZ, using a reverse genetic system, based on the backbone of the H120 vaccine strain, with the S1 gene replaced with that of the QX-like nephropathogenic strain, ck/CH/IBYZ/2011, isolated in China. The results of dwarf chicken embryos, growth kinetics, and viral titration in the embryos demonstrated that the biological characteristics of the recombinant virus remained unchanged. Like the rH120-infected group and in contrast to the rIBYZ-infected group, no mortality, clinical signs, or lesions were observed in the lungs or kidneys of young chickens inoculated with rH120-S1/YZ. The viral loads in various tissues, cloacal, and oral swabs was lower in most types of samples, indicating that the rH120-S1/YZ strain was highly safe in chicks. Compared to rH120 vaccination group, when the efficacy of this strain was evaluated against the QX-like IBV strain, better protection, with 100% survival rate and no disease symptom or gross lesion was observed in the chickens vaccinated with rH120-S1/YZ. Increased levels of IBV-specific antibodies were detected in the serum of the rH120-S1/YZ-vaccinated animals 14 days post-vaccination. Collectively, our results suggest that the recombinant strain, rH120-S1/YZ, may represent a promising vaccine candidate against QX-like IBVs. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Jiang, Yi; Cheng, Xu; Zhao, Xiumei; Yu, Yan; Gao, Mingyan; Zhou, Sheng] Chinese Acad Agr Sci, Poultry Inst, 58 Cangjie Rd, Yangzhou 225125, Jiangsu, Peoples R China.
RP Zhou, S (reprint author), Chinese Acad Agr Sci, Poultry Inst, 58 Cangjie Rd, Yangzhou 225125, Jiangsu, Peoples R China.
EM yixuanjiang@126.com
FU National Natural Science Foundations of ChinaNational Natural Science
   Foundation of China [31602091, 31101832, 31572524]; National Key
   Research and Development Program, China [2017YFD0500703]; Jiangsu
   Province Agricultural Science & Technology Support Program [BE2012369]
FX This work was supported by the National Natural Science Foundations of
   China (31602091, 31101832, 31572524), the National Key Research and
   Development Program, China (2017YFD0500703), and Jiangsu Province
   Agricultural Science & Technology Support Program (BE2012369).
CR ALEXANDER DJ, 1978, RES VET SCI, V24, P228, DOI 10.1016/S0034-5288(18)33077-7
   Armesto M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007384
   Bande F, 2015, J IMMUNOL RES, DOI 10.1155/2015/424860
   Bentley K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067875
   Bickerton E, 2018, J GEN VIROL, V99, P1681, DOI 10.1099/jgv.0.001167
   BOX PG, 1980, VET REC, V106, P264, DOI 10.1136/vr.106.12.264
   Britton P, 2012, BIOENGINEERED, V3, P114, DOI 10.4161/bbug.18983
   Casais R, 2003, J VIROL, V77, P9084, DOI 10.1128/JVI.77.16.9084-9089.2003
   Casais R, 2001, J VIROL, V75, P12359, DOI 10.1128/JVI.75.24.12359-12369.2001
   CAVANAGH D, 1986, VIRUS RES, V4, P133, DOI 10.1016/0168-1702(86)90037-7
   Cavanagh D, 2005, AVIAN PATHOL, V34, P439, DOI 10.1080/03079450500367682
   Cavanagh D, 1997, AVIAN PATHOL, V26, P63, DOI 10.1080/03079459708419194
   CAVANAGH D, 1986, VIRUS RES, V4, P145, DOI 10.1016/0168-1702(86)90038-9
   Cavanagh D, 2003, AVIAN PATHOL, V32, P567, DOI 10.1080/03079450310001621198
   CAVANAGH D, 1988, VIRUS RES, V11, P141, DOI 10.1016/0168-1702(88)90039-1
   Cavanagh D, 2007, VET RES, V38, P281, DOI 10.1051/vetres:2006055
   Chen LF, 2015, VET MICROBIOL, V181, P241, DOI 10.1016/j.vetmic.2015.10.003
   Collisson EW, 2000, DEV COMP IMMUNOL, V24, P187, DOI 10.1016/S0145-305X(99)00072-5
   Cook JKA, 2012, AVIAN PATHOL, V41, P239, DOI 10.1080/03079457.2012.680432
   Eldemery F, 2017, VACCINE, V35, P5864, DOI 10.1016/j.vaccine.2017.09.013
   Ellis S, 2018, J VIROL, V92, DOI 10.1128/JVI.01473-18
   Feng KY, 2015, VACCINE, V33, P1113, DOI 10.1016/j.vaccine.2015.01.036
   Feng KY, 2014, VIRUS GENES, V49, P292, DOI 10.1007/s11262-014-1097-1
   Geerligs HJ, 2011, AVIAN PATHOL, V40, P93, DOI 10.1080/03079457.2010.542742
   Gelb J, 2005, AVIAN PATHOL, V34, P194, DOI 10.1080/03079450500096539
   Han ZX, 2011, INFECT GENET EVOL, V11, P190, DOI 10.1016/j.meegid.2010.09.002
   Hodgson T, 2004, J VIROL, V78, P13804, DOI 10.1128/JVI.78.24.13804-13811.2004
   Ignjatovic J, 2005, ARCH VIROL, V150, P1813, DOI 10.1007/s00705-005-0541-x
   IGNJATOVIC J, 1994, ARCH VIROL, V138, P117, DOI 10.1007/BF01310043
   Jackwood MW, 2012, AVIAN DIS, V56, P634, DOI 10.1637/10227-043012-Review.1
   Jackwood MW, 2005, AVIAN DIS, V49, P614, DOI 10.1637/7389-052905R.1
   KANT A, 1992, J GEN VIROL, V73, P591, DOI 10.1099/0022-1317-73-3-591
   Kotani T, 2000, J VET MED SCI, V62, P397, DOI 10.1292/jvms.62.397
   KUSTERS JG, 1990, VACCINE, V8, P605, DOI 10.1016/0264-410X(90)90018-H
   KUSTERS JG, 1989, J IMMUNOL, V143, P2692
   Laconi A, 2018, J GEN VIROL
   Lee HJ, 2010, VACCINE, V28, P2887, DOI 10.1016/j.vaccine.2010.01.062
   Lee SW, 2012, SCIENCE, V337, P188, DOI 10.1126/science.1217134
   Lin SY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102030
   Liu SW, 2006, AVIAN PATHOL, V35, P394, DOI 10.1080/03079450600920984
   Liu SW, 2009, INTERVIROLOGY, V52, P223, DOI 10.1159/000227134
   Liu SW, 2004, AVIAN PATHOL, V33, P321, DOI 10.1080/0307945042000220697
   Ma HJ, 2012, AVIAN DIS, V56, P15, DOI 10.1637/9804-052011-Reg.1
   MARTINS NRD, 1991, AVIAN DIS, V35, P470
   Masters PS, 2005, CURR TOP MICROBIOL, V287, P133, DOI 10.1007/3-540-26765-4_5
   MCDOUGALL JS, 1969, VET REC, V85, P378, DOI 10.1136/vr.85.14.378
   McKinley ET, 2008, VACCINE, V26, P1274, DOI 10.1016/j.vaccine.2008.01.006
   Meeusen ENT, 2007, CLIN MICROBIOL REV, V20, P489, DOI 10.1128/CMR.00005-07
   Moore KM, 1997, ARCH VIROL, V142, P2249, DOI 10.1007/s007050050239
   Promkuntod N, 2013, VIRUS RES, V177, P127, DOI 10.1016/j.virusres.2013.09.006
   Raj GD, 1996, VET MICROBIOL, V53, P239, DOI 10.1016/S0378-1135(96)01258-8
   REED L. J., 1938, AMER JOUR HYG, V27, P493
   Ruch TR, 2011, J VIROL, V85, P675, DOI 10.1128/JVI.01570-10
   Seo SH, 1997, J VIROL, V71, P5173, DOI 10.1128/JVI.71.7.5173-5177.1997
   Shahwan K, 2013, VIRUSES-BASEL, V5, P1924, DOI 10.3390/v5081924
   Shan D, 2018, VIRUS RES, V250, P104, DOI 10.1016/j.virusres.2018.04.013
   Shang J, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007009
   Tarpey I, 2006, VACCINE, V24, P6830, DOI 10.1016/j.vaccine.2006.06.040
   Thompson G, 1997, AVIAN DIS, V41, P519, DOI 10.2307/1592140
   van Beurden SJ, 2018, VACCINE, V36, P1085, DOI 10.1016/j.vaccine.2018.01.017
   Wakenell PS, 1995, AVIAN DIS, V39, P752, DOI 10.2307/1592412
   Wei Yan-quan, 2014, Bing Du Xue Bao, V30, P668
   Wickramasinghe INA, 2014, VIRUS RES, V194, P37, DOI 10.1016/j.virusres.2014.10.009
   Wickramasinghe INA, 2011, J VIROL, V85, P8903, DOI 10.1128/JVI.05112-11
   Xia J, 2018, VACCINE, V36, P4087, DOI 10.1016/j.vaccine.2018.05.094
   Xia J, 2016, INFECT GENET EVOL, V45, P11, DOI 10.1016/j.meegid.2016.08.011
   Yan SH, 2018, VACCINE, V36, P1880, DOI 10.1016/j.vaccine.2018.02.053
   Zhang Y, 2018, VACCINE, V36, P4245, DOI 10.1016/j.vaccine.2018.05.123
   Zhao Y, 2015, VET MICROBIOL, V180, P49, DOI 10.1016/j.vetmic.2015.07.036
   Zhao Y, 2014, ARCH VIROL, V159, P3457, DOI 10.1007/s00705-014-2213-1
   Zhou SDY, 2010, CHINA POLUTRY, V32, P22
   Zhou Sheng, 2011, Bing Du Xue Bao, V27, P11
   Zhou YS, 2013, VET MICROBIOL, V162, P53, DOI 10.1016/j.vetmic.2012.08.013
   Zou NL, 2010, VIRUS GENES, V41, P202, DOI 10.1007/s11262-010-0500-9
NR 74
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3157
EP 3168
DI 10.1016/j.vaccine.2020.01.001
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500011
PM 32057575
OA Bronze, Green Published
DA 2020-05-12
ER

PT J
AU Silcock, R
   Crawford, NW
   Selvaraj, G
   McMinn, A
   Danchin, M
   Lazzaro, T
   Perrett, KP
AF Silcock, Rowena
   Crawford, Nigel W.
   Selvaraj, Gowri
   McMinn, Alissa
   Danchin, Margie
   Lazzaro, Teresa
   Perrett, Kirsten P.
TI Subcutaneous nodules following immunization in children; in Victoria,
   Australia from 2007 to 2016
SO VACCINE
LA English
DT Article
DE Vaccine; Immunization; Adverse event following (AEFI); Nodule
ID PERSISTENT ITCHING NODULES; EVENTS FOLLOWING IMMUNIZATION; CONTACT
   ALLERGY; ADVERSE EVENTS; INJECTION-SITE; DELAYED-HYPERSENSITIVITY;
   ADSORBED VACCINES; ALUMINUM; VACCINATION; SURVEILLANCE
AB Background: Subcutaneous nodules are a rare adverse event following immunization (AEFI). We aimed to describe nodules at the injection site reported to SAEFVIC (Surveillance of Adverse Events Following Vaccination in the Community) using the Brighton Collaboration Case Definition (BCCD), management and recurrence following subsequent immunizations.
   Method: We assessed 58 cases (<18 years of age) of 'nodule at injection site' reported to SAEFVIC, Melbourne, Australia, between May 2007 and June 2016. Case details were analyzed from records and phone interview follow-up. The Australian Immunization Registry was reviewed for immunization status.
   Results: 71% (41/58 reported cases) were consistent with the BCCD for subcutaneous nodule, 14% (8 cases) were 'possible subcutaneous nodules', 10% (6 cases) were nodules associated with BCG immuniza-tion and 5% (3 cases) were attributable to an alternative diagnosis. The median age at immunization was 12 months, (range 1 month-12 years); 54% male (22/41 cases). 17% (7 cases) had multiple nodules. Nodules were associated with immunizations containing aluminum (74%, 36/49 nodules), no aluminum (8%, 4 nodules) and unknown (18%, 9 nodules). Most cases developed symptoms within 3 days post-immunization (59%, 24 cases) and in the thigh (59%, 29 nodules). Pruritus was associated in 41% (17 cases). Around 1/3 (34%) of nodules resolved 6 months post immunization, 2/3 (68%) by 12 months, how-ever 1/4 (24%) remained persistent for >24 months. 5 cases had prior nodules and 1 case had recurrence with subsequent immunization. 83% (34 cases) were fully immunized for age at follow-up.
   Conclusion: Subcutaneous nodules at the injection site may occur following a wide range of vaccines, including vaccines without aluminum. All cases require careful review and where possible, specialist management and to support subsequent immunizations. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Silcock, Rowena; Crawford, Nigel W.; Danchin, Margie; Lazzaro, Teresa] Royal Childrens Hosp, Dept Gen Med, Melbourne, Vic, Australia.
   [Silcock, Rowena; Crawford, Nigel W.; Selvaraj, Gowri; McMinn, Alissa] Murdoch Childrens Res Inst, SAEFVIC Surveillance Adverse Events Following Vac, Melbourne, Vic, Australia.
   [Danchin, Margie] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia.
   [Perrett, Kirsten P.] Murdoch Childrens Res Inst, Populat Allergy Res Grp, Melbourne, Vic, Australia.
   [Perrett, Kirsten P.] Murdoch Childrens Res Inst, Melbourne Childrens Trial Ctr, Melbourne, Vic, Australia.
   [Perrett, Kirsten P.] Royal Childrens Hosp, Dept Allergy & Immunol & Gen Med, Melbourne, Vic, Australia.
   [Danchin, Margie; Perrett, Kirsten P.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [Danchin, Margie] Murdoch Childrens Res Inst, Vaccine & Immunisat Res Grp, Melbourne, Vic, Australia.
RP Silcock, R (reprint author), Royal Childrens Hosp, Dept Gen Med, Melbourne, Vic, Australia.
EM rowena.silcock@rch.org.au; nigel.crawford@mcri.edu.au;
   gowri.selvaraj@mcri.edu.au; alissa.mcminn@mcri.edu.au;
   margie.danchin@rch.org.au; teresa.lazzarro@rch.org.au;
   kirsten.perrett@rch.org.au
CR Baylor NW, 2002, VACCINE, V20, pS18, DOI 10.1016/S0264-410X(02)00166-4
   Ben-Zvi G, 2013, J AM ACAD DERMATOL, V68, pAB67
   Bergfors E, 2005, EUR J PEDIATR, V164, P691, DOI 10.1007/s00431-005-1704-1
   Bergfors E, 2003, VACCINE, V22, P64, DOI 10.1016/S0264-410X(03)00531-0
   Bergfors Elisabet, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr-2012-007779
   Bergfors E, 2014, EUR J PEDIATR, V173, P1297, DOI 10.1007/s00431-014-2318-2
   Bergfors E, 2013, EUR J PEDIATR, V172, P171, DOI 10.1007/s00431-012-1841-2
   BOHLERSOMMEREGGER K, 1986, CONTACT DERMATITIS, V15, P278, DOI 10.1111/j.1600-0536.1986.tb01368.x
   Chong H, 2006, HISTOPATHOLOGY, V48, P182, DOI 10.1111/j.1365-2559.2005.02312.x
   Clothier HJ, 2017, DRUG SAFETY, V40, P483, DOI 10.1007/s40264-017-0520-7
   Clothier HJ, 2011, COMMUN DIS INTELL, V35, P294
   COX NH, 1988, CONTACT DERMATITIS, V18, P143, DOI 10.1111/j.1600-0536.1988.tb04500.x
   Diggle L, 2006, BMJ-BRIT MED J, V333, P571, DOI 10.1136/bmj.38906.704549.7C
   ERDOHAZI M, 1971, BRIT MED J, V3, P621, DOI 10.1136/bmj.3.5775.621
   Exley C, 2004, LANCET INFECT DIS, V4, P324, DOI 10.1016/S1473-3099(04)01039-4
   FAWCETT HA, 1984, ARCH DERMATOL, V120, P1318, DOI 10.1001/archderm.120.10.1318
   Forbes TA, 2015, HUM VACC IMMUNOTHER, V11, P2895, DOI 10.1080/21645515.2015.1070997
   Jefferson T, 2004, LANCET INFECT DIS, V4, P84, DOI 10.1016/S1473-3099(04)00927-2
   Jenner Nicole, 2004, Australas J Dermatol, V45, P16, DOI 10.1111/j.1440-0960.2004.00046.x
   Kohl KS, 2008, VACCINE, V26, P6349, DOI 10.1016/j.vaccine.2008.09.002
   Lam M, 2014, CLIN EXP DERMATOL, V39, P844, DOI 10.1111/ced.12399
   Lauren CT, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2014-1690
   Leventhal JS, 2012, DERMATITIS, V23, P102, DOI 10.1097/DER.0b013e31825228cf
   Lidholm AG, 2013, CONTACT DERMATITIS, V68, P286, DOI 10.1111/cod.12053
   MILIAUSKAS JR, 1993, AM J SURG PATHOL, V17, P516, DOI 10.1097/00000478-199305000-00012
   Netterlid E, 2004, VACCINE, V22, P3698, DOI 10.1016/j.vaccine.2004.03.036
   Ortqvist A, 2010, Acta Paediatr, V99, P1, DOI 10.1111/j.1651-2227.2010.01823.x
   Rothstein E, 2004, VACCINE, V22, P575, DOI 10.1016/j.vaccine.2003.09.005
   Schijns VEJC, 2011, EXPERT REV VACCINES, V10, P539, DOI [10.1586/ERV.11.21, 10.1586/erv.11.21]
   Silcock R, 2019, EXPERT REV VACCINES, V18, P405, DOI 10.1080/14760584.2019.1586540
   Skowron E, 1998, CONTACT DERMATITIS, V39, P135, DOI 10.1111/j.1600-0536.1998.tb05865.x
   Thierry-Carstensen B, 2004, VACCINE, V22, P1845, DOI 10.1016/j.vaccine.2003.11.048
   WHO, 2012, INF SHEET OBS RAT VA
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD MAR 30
PY 2020
VL 38
IS 15
BP 3169
EP 3177
DI 10.1016/j.vaccine.2019.12.066
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TH
UT WOS:000525317500012
PM 32147295
DA 2020-05-12
ER

PT J
AU Benfodil, K
   Buscher, P
   Abdelli, A
   Van Reet, N
   Mohamed-herif, A
   Ansel, S
   Fettata, S
   Dehou, S
   Bebronne, N
   Geerts, M
   Balharbi, F
   Ait-Oudhia, K
AF Benfodil, Karima
   Buescher, Philippe
   Abdelli, Amine
   Van Reet, Nick
   Mohamed-herif, Abdellah
   Ansel, Samir
   Fettata, Said
   Dehou, Sara
   Bebronne, Nicolas
   Geerts, Manon
   Balharbi, Fatima
   Ait-Oudhia, Khatima
TI Comparison of serological and molecular tests for detection of
   Trypanosoma evansi in domestic animals from Ghardaia district, South
   Algeria
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Trypanosoma evansi; PCR; qPCR; ELISA; CATT; Immune trypanolysis;
   Diagnostic accuracy
ID FOLLOW-UP; INFECTION; CAMELS; PREVALENCE; DIAGNOSIS; PCR; HORSES;
   SEROPREVALENCE; IDENTIFICATION; AGREEMENT
AB Trypanosoma evansi (T. evansi) is a hemoflagellate parasite that affects a broad range of mammalian hosts and that causes a disease called surra. Diagnosis of surra based on clinical symptoms alone is inaccurate. Therefore, a variety of serological and molecular diagnostic tests are used to assist in the detection of T. evansi infections.
   The aim of this study was to compare the diagnostic performance of four serological tests (CATT/T.evansi, immune trypanolysis, ELISA with purified variant surface glycoprotein RoTat 1.2 and with whole cell lysate) and two molecular PCR tests targeting sequences within the ribosomal genes locus (ITS1 TD PCR and 18S qPCR). Tests were carried out on blood samples from 161 dromedary camels, 93 horses, 129 goats, 168 sheep, 127 bovines and 76 dogs. Latent class analysis was carried out to calculate the sensitivity and specificity of each diagnostic test. Cohen's Kappa test was used to assess the concordance between the different diagnostic tests.
   Overall positivity rates observed with the serological tests were as follows: 3.1 % with CATT/T.evansi, 4.9 % with ELISA/RoTat 1.2, 3.4 % with ELISA/whole lysate and 2.0 % with immune trypanolysis (TL). Among the 754 samples tested with the molecular tests, 1.7 % were positive with 18S qPCR and 1.3 % with ITS1 TD PCR. Cohen's Kappa test showed agreement ranging from fair to substantial (k= 0.2-0.8) between serological diagnostic tests. However, it showed a perfect agreement (k= 0.868) between molecular diagnostic tests. Latent class analysis showed that all serological tests were 100 % sensitive, in contrast to the molecular tests with 47 % sensitivity. All tests, though, were highly specific (>= 97 %).
   Given the persistence of circulating antibodies after cure, detectable by serological tests, it is recommend combining a serological and a molecular diagnostic test for accurate diagnosis of infection with T. evansi in domestic animals.
C1 [Benfodil, Karima; Mohamed-herif, Abdellah; Ansel, Samir; Ait-Oudhia, Khatima] High Natl Vet Sch Algiers, Issad St, Oued Smar, Bab Ezzouar, Algeria.
   [Benfodil, Karima; Abdelli, Amine] Akli Mohand Oulhadj Univ, Dept Agr Sci, Drissi Yahia St, Bouira, Algeria.
   [Buescher, Philippe; Van Reet, Nick; Dehou, Sara; Bebronne, Nicolas; Geerts, Manon; Balharbi, Fatima] Inst Trop Med, Dept Biomed Sci, Natl Str 155, B-2000 Antwerp, Belgium.
   [Fettata, Said] Vet Practice, Thnia St, Ghardaia, Algeria.
RP Benfodil, K (reprint author), High Natl Vet Sch Algiers, Issad St, Oued Smar, Bab Ezzouar, Algeria.; Benfodil, K (reprint author), Akli Mohand Oulhadj Univ, Dept Agr Sci, Drissi Yahia St, Bouira, Algeria.
EM karimaensv@gmail.com
RI ; Buscher, Philippe/B-9956-2012
OI BENFODIL, Karima/0000-0001-7767-6437; Buscher,
   Philippe/0000-0002-1926-7472
FU High National Veterinary School of Algiers, Algeria
FX We thank the OIE Reference Laboratory for Surra for allowing us to carry
   out the diagnostic tests at the Institute of Tropical Medicine in
   Antwerp and the High National Veterinary School of Algiers, Algeria for
   funding the stay of Karima Benfodil in Belgium.
CR Abo-Shehada MN, 1999, PREV VET MED, V38, P289, DOI 10.1016/S0167-5877(98)00138-X
   Alanazi AD, 2018, J VET DIAGN INVEST, V30, P942, DOI 10.1177/1040638718798688
   Aregawi WG, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3311-4
   Atarhouch T, 2003, VET PARASITOL, V111, P277, DOI 10.1016/S0304-4017(02)00382-5
   Beath KJ, 2017, J STAT SOFTW, V81, P1, DOI 10.18637/jss.v081.i13
   Benfodil K, 2019, J HELL VET MED SOC, V70, P1631
   Bennoune Omar, 2013, Vet Res Forum, V4, P273
   Birhanu H, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004556
   Birhanu H, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0818-1
   Boushaki D, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02086
   Brun R, 1998, VET PARASITOL, V79, P95, DOI 10.1016/S0304-4017(98)00146-0
   Chiweshe SM, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007189
   Clausen PH, 1999, PARASITOL RES, V85, P206, DOI 10.1007/s004360050536
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Deborggraeve S, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000972
   Desquesnes M, 2002, VET PARASITOL, V109, P213, DOI 10.1016/S0304-4017(02)00270-4
   Desquesnes M, 2001, INT J PARASITOL, V31, P610, DOI 10.1016/S0020-7519(01)00161-8
   DESQUESNES M, 1995, ACTA TROP, V60, P133, DOI 10.1016/0001-706X(95)00117-W
   Desquesnes M, 2013, BIOMED RES INT, DOI 10.1155/2013/194176
   Desquesnes M, 2009, VET PARASITOL, V162, P214, DOI 10.1016/j.vetpar.2009.03.033
   Dia ML, 1997, VET PARASITOL, V72, P111, DOI 10.1016/S0304-4017(97)00054-X
   Echeverria JT, 2019, REV BRAS PARASITOL V, V28, P320, DOI [10.1590/s1984-29612019018, 10.1590/S1984-29612019018]
   Elhaig MM, 2018, MICROB PATHOGENESIS, V123, P201, DOI 10.1016/j.micpath.2018.07.017
   Elshafie EI, 2013, RES VET SCI, V94, P285, DOI 10.1016/j.rvsc.2012.09.004
   Fikru R, 2015, VET PARASITOL, V211, P175, DOI 10.1016/j.vetpar.2015.04.008
   Gamer M., 2012, IRR VARIOUS COEFFICI
   Gari FR, 2010, TROP ANIM HEALTH PRO, V42, P1649, DOI 10.1007/s11250-010-9615-1
   Gutierrez C, 2006, ANN NY ACAD SCI, V1081, P300, DOI 10.1196/annals.1373.040
   Herrera HM, 2004, VET PARASITOL, V125, P263, DOI 10.1016/j.vetpar.2004.07.013
   Hoare C.A., 1972, TRYPANOSOMES MAMMALS
   Holland WG, 2002, ACTA TROP, V81, P159, DOI 10.1016/S0001-706X(01)00211-X
   Jaimes-Duenez J, 2017, PREV VET MED, V139, P82, DOI 10.1016/j.prevetmed.2017.02.007
   Laha R, 2008, TROP ANIM HEALTH PRO, V40, P357, DOI 10.1007/s11250-007-9107-0
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7
   Lejon V, 2005, INT J PARASITOL, V35, P455, DOI 10.1016/j.ijpara.2004.12.015
   LUCKINS AG, 1988, PARASITOL TODAY, V4, P137, DOI 10.1016/0169-4758(88)90188-3
   MASIGA DK, 1992, INT J PARASITOL, V22, P909, DOI 10.1016/0020-7519(92)90047-O
   Njiru ZK, 2006, INFECT GENET EVOL, V6, P292, DOI 10.1016/j.meegid.2005.08.002
   Njiru ZK, 2004, VET PARASITOL, V124, P187, DOI 10.1016/j.vetpar.2004.06.029
   OIE (World Organisation for Animal Health), 2008, MANUAL DIAGNOSTIC TE
   OIE (World Organisation for Animal Health), 2018, TRYP EV INF SURR MAN
   OIE (World Organisation for Animal Health), 2017, REC PROT STAND TECHN
   Parsani HR, 2008, VET WORLD, V1, P317
   Ramirez-Iglesias J.R., 2017, Journal of Parasitic Diseases, V41, P450, DOI 10.1007/s12639-016-0826-x
   Ramirez-Iglesias JR, 2011, EXP PARASITOL, V128, P91, DOI 10.1016/j.exppara.2011.02.010
   Rodrigues A, 2009, VET PATHOL, V46, P251, DOI 10.1354/vp.46-2-251
   Tamarit A, 2010, VET PARASITOL, V167, P74, DOI 10.1016/j.vetpar.2009.09.050
   Tehseen S, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-1002-3
   Tran T, 2014, VET PARASITOL, V202, P164, DOI 10.1016/j.vetpar.2014.03.005
   Ul Hasan M, 2006, ANN NY ACAD SCI, V1081, P322, DOI 10.1196/annals.1373.043
   VanMeirvenne N, 1995, ACTA TROP, V60, P189, DOI 10.1016/0001-706X(95)00127-Z
   Verloo D, 2000, VET PARASITOL, V92, P87, DOI 10.1016/S0304-4017(00)00284-3
   Wagemans G., 2011, THESIS
   Yadav SC, 2019, J EQUINE VET SCI, V79, P63, DOI 10.1016/j.jevs.2019.05.019
   Zayed A. A., 2010, American-Eurasian Journal of Agricultural and Environmental Science, V8, P633
NR 56
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109089
DI 10.1016/j.vetpar.2020.109089
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300005
PM 32222595
DA 2020-05-12
ER

PT J
AU Cardoso, AD
   Santos, EGG
   Lima, AD
   Temeyer, KB
   de Leon, AAP
   Costa, LM
   Soares, AMD
AF Cardoso, Alana dos Santos
   Guimaraes Santos, Everton Gomes
   Lima, Aldilene da Silva
   Temeyer, Kevin B.
   de Leon, Adalberto A. Perez
   Costa Junior, Livio Martins
   dos Santos Soares, Alexandra Martins
TI Terpenes on Rhipicephalus (Boophilus) microplus: Acaricidal activity and
   acetylcholinesterase inhibition
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Tick; Natural compound; Terpenes
ID GRACILIS ESSENTIAL OIL; MAJOR CONSTITUENTS; TICK; RESISTANCE; CARVACROL;
   THYMOL; ORGANOPHOSPHATE; DERIVATIVES; NOOTKATONE; EFFICACY
AB The Rhipicephalus (Boophilus) microplus tick is the main ectoparasite of cattle in tropical and subtropical regions worldwide. Resistance to chemical acaricides has become widespread affirming the need for new drugs to tick control. Terpenes have become a promising alternative for cattle tick control, however the mechanism of action of these compounds is still controversial. Inhibition of acetylcholinesterase (AChE) is a well established mechanism of action of organophosphate and carbamate acaricides, but the possible action of terpenes on tick AChEs has seldom been studied in resistant and sensitive strains of R. (B.) microplus. The aim of the present study was to evaluate terpene inhibition of AChE from resistant and sensitive strains of R. (B.) microplus in correlation with their acaricidal activity. Among the terpenes used in the present study, p-cymene, thymol, carvacrol, and citral displayed acaricidal activity with LC50 of 1.75, 1.54, 1.41, and 0.38 mg.mL(-1) for the susceptible strain, and LC50 of 1.40, 1.81, 1.10, and 1.13 mg.mL(-1) for the resistant strain. Thymol and carvacrol inhibited the AChE of the susceptible strain larvae with IC50 of 0.93 and 0.04 mg.mL(-1), respectively. The IC50 exhibited by eucalyptol, carvacrol and thymol for AChE of the resistant strain larvae were 0.36, 0.28, and 0.13 mg.mL(-1), respectively. This was the first study to investigate the action of terpenes on AChE from susceptible and resistant R. (B.) microplus. As not all terpenes with acaridical activity showed AChE inhibition, the participation of AChE in the acaricidal activity of terpenes needs further investigation.
C1 [Cardoso, Alana dos Santos; Guimaraes Santos, Everton Gomes; dos Santos Soares, Alexandra Martins] Univ Fed Maranhao, Lab Plant Biochem, Sao Luis, MA, Brazil.
   [Lima, Aldilene da Silva; Costa Junior, Livio Martins] Univ Fed Maranhao, Lab Parasite Control, Sao Luis, MA, Brazil.
   [Temeyer, Kevin B.; de Leon, Adalberto A. Perez] Knipling Bushland US Livestock Insects Res Lab, Kerrville, TX USA.
RP Soares, AMD (reprint author), Univ Fed Maranhao, Lab Plant Biochem, Sao Luis, MA, Brazil.; Costa, LM (reprint author), Univ Fed Maranhao, Lab Parasite Control, Sao Luis, MA, Brazil.
EM livioslz@yahoo.com; alexandra.ufma@gmail.com
RI Costa-Junior, Livio/H-7530-2012
OI Costa-Junior, Livio/0000-0002-1475-049X; Perez de Leon,
   Adalberto/0000-0002-4115-7747
FU FAPEMA (Maranhao State Research Foundation) [UNIVERSAL-00739/17];
   FINEPCiencia Tecnologia e Inovacao (FINEP); FAPEMA; CAPES (Higher
   Education Personnel Improvement Coordination)CAPES; CNPq (Brazilian
   National Council for Scientific and Technological Development)National
   Council for Scientific and Technological Development (CNPq)
FX We thank the FAPEMA (Maranhao State Research Foundation) for financial
   support under process UNIVERSAL-00739/17 and for awarding a fellowship
   to E.G.G Santos. We thank the FINEP (Funding Authority for Studies and
   Projects) and FAPEMA for supporting the IECT (Science and Technology
   Institute of Maranhao) Biotechnology. We thank the CAPES (Higher
   Education Personnel Improvement Coordination) for awarding a fellowship
   to A.S Cardoso and CNPq (Brazilian National Council for Scientific and
   Technological Development) for awarding a fellowship to L.M.
   Costa-Junior. We also thank Dr. Jose Tadeu A. Oliveira (Federal
   University of Ceara) and Dr. Paul Michels (The University of Edinburgh)
   for his valuable suggestions, assistance and critical review of this
   manuscript.
CR Aazza S, 2011, MOLECULES, V16, P7672, DOI 10.3390/molecules16097672
   Abdelgaleil SAM, 2009, J CHEM ECOL, V35, P518, DOI 10.1007/s10886-009-9635-3
   Anderson JA, 2012, PESTIC BIOCHEM PHYS, V102, P124, DOI 10.1016/j.pestbp.2011.12.002
   Bandara KMUJ, 2017, PESTIC BIOCHEM PHYS, V139, P68, DOI 10.1016/j.pestbp.2017.05.002
   Baxter GD, 1999, EXP APPL ACAROL, V23, P907, DOI 10.1023/A:1006364816302
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Carroll JF, 2017, NAT PROD RES, V31, P2192, DOI 10.1080/14786419.2017.1280485
   Chagas A.C.S., 2002, BRAZ J VET RES ANIM, V39, P247, DOI DOI 10.1590/S1413-95962002000500006
   Conceicao RS, 2017, TICKS TICK-BORNE DIS, V8, P275, DOI 10.1016/j.ttbdis.2016.11.013
   Costa-Junior LM, 2016, VET PARASITOL, V228, P60, DOI 10.1016/j.vetpar.2016.05.028
   Dandlen SA, 2011, J ESSENT OIL BEAR PL, V14, P140, DOI 10.1080/0972060X.2011.10643914
   Castro KND, 2018, REV BRAS PARASITOL V, V27, P203, DOI [10.1590/S1984-296120180015, 10.1590/s1984-296120180015]
   Cruz EMD, 2013, VET PARASITOL, V195, P198, DOI 10.1016/j.vetpar.2012.12.046
   Monteiro CMD, 2010, PARASITOL RES, V106, P615, DOI 10.1007/s00436-009-1709-1
   Dohi S, 2009, J AGR FOOD CHEM, V57, P4313, DOI 10.1021/jf804013j
   Dolan MC, 2009, J ECON ENTOMOL, V102, P2316, DOI 10.1603/029.102.0638
   ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9
   Foil LD, 2004, VET PARASITOL, V125, P163, DOI 10.1016/j.vetpar.2004.05.012
   Furlani RPZ, 2015, FOOD CONTROL, V48, P43, DOI 10.1016/j.foodcont.2014.04.004
   Games E, 2016, MOLECULES, V21, DOI 10.3390/molecules21101390
   Gomes A, 2011, CIENC RURAL, V41, P1447, DOI 10.1590/S0103-84782011005000105
   Gross AD, 2017, CHEM-BIOL INTERACT, V263, P1, DOI 10.1016/j.cbi.2016.12.009
   Guo DH, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1741-6
   Hue T, 2015, PARASITOL RES, V114, P91, DOI 10.1007/s00436-014-4164-6
   Jukic M, 2007, PHYTOTHER RES, V21, P259, DOI 10.1002/ptr.2063
   Klafke GM, 2006, VET PARASITOL, V142, P386, DOI 10.1016/j.vetpar.2006.07.001
   Lee SH, 2015, PESTIC BIOCHEM PHYS, V120, P118, DOI 10.1016/j.pestbp.2014.11.004
   Lewis K.A., 2013, EFSA SUPPORTING PUBL, P182
   Li AY, 2005, PESTIC BIOCHEM PHYS, V81, P145, DOI 10.1016/j.pestbp.2004.12.002
   Lima AD, 2017, IND CROP PROD, V108, P190, DOI 10.1016/j.indcrop.2017.06.037
   Lima AS, 2018, PARASITOL RES, V117, P59, DOI 10.1007/s00436-017-5662-0
   Lopes A.J.O., 2015, THESIS
   Peixoto MG, 2015, VET PARASITOL, V210, P118, DOI 10.1016/j.vetpar.2015.03.010
   Prado-Ochoa MG, 2014, VET PARASITOL, V199, P215, DOI 10.1016/j.vetpar.2013.10.028
   Reck J, 2014, VET PARASITOL, V201, P128, DOI 10.1016/j.vetpar.2014.01.012
   Rodriguez A, 2007, PROG ORG COAT, V60, P33, DOI 10.1016/j.porgcoat.2007.06.006
   Rodriguez-Vivas RI, 2018, PARASITOL RES, V117, P3, DOI 10.1007/s00436-017-5677-6
   Russell RJ, 2004, PESTIC BIOCHEM PHYS, V79, P84, DOI 10.1016/j.pestbp.2004.03.002
   Sharifi M, 2017, PESTIC BIOCHEM PHYS, V136, P12, DOI 10.1016/j.pestbp.2016.08.010
   Silberman J., 2019, CARBAMATE TOXICITY
   Tabari MA, 2017, VET PARASITOL, V245, P86, DOI 10.1016/j.vetpar.2017.08.012
   Temeyer KB, 2018, FRONT BIOSCI-LANDMRK, V23, P1320, DOI 10.2741/4646
   Temeyer KB, 2013, CHEM-BIOL INTERACT, V203, P319, DOI 10.1016/j.cbi.2012.09.010
   Temeyer KB, 2010, VET PARASITOL, V172, P114, DOI 10.1016/j.vetpar.2010.04.016
   Hieu TT, 2012, J MED ENTOMOL, V49, P1084, DOI 10.1603/ME12047
   Valente PP, 2017, PARASITOL RES, V116, P929, DOI 10.1007/s00436-016-5366-x
   Yeom HJ, 2012, J AGR FOOD CHEM, V60, P7194, DOI 10.1021/jf302009w
NR 47
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109090
DI 10.1016/j.vetpar.2020.109090
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300012
PM 32208306
DA 2020-05-12
ER

PT J
AU Dade, MM
   Daniele, MR
   Silvestrini, MP
   Bozzolo, F
   Francini, F
   Mestorino, N
AF Dade, Martin M.
   Daniele, Martin R.
   Silvestrini, Maria P.
   Bozzolo, Facundo
   Francini, Flavio
   Mestorino, Nora
TI A study of the effects of imidacloprid under laboratory and field
   conditions on nymphs of Triatoma infestans (Hemiptera: Reduviidae)
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Dogs; Imidacloprid; Triatoma infestans; Xenointoxication
ID PYRETHROID INSECTICIDES; ABDOMINAL CUTICLE; PLASTICIZATION;
   FORMULATIONS; RESISTANCE; RECOVERY; EFFICACY; VECTOR; DOGS
AB The aim of this study was to determine imidacloprid's lethal activity against fifth-instar nymphs of Triatoma infestans. In the first stage of this work, it was assayed the topical application of this insecticide on non-fed and repletion-fed nymphs. Results showed a DL50 three times greater in non-fed bugs than in those fully engorged. The presence of food determined less time for the insecticide's maximum lethal effect: 24 h post topical application in fed nymphs and 72 h in non-fed nymphs. In the study's second stage, we assayed a xenointoxication assay on dogs. The commercial products, Advantage (R), Bayer (imidacloprid 10 % p/v) and Power Ultra (R), Brouwer (imidacloprid 5.15 %, permethrin 40 % and piperonyl butoxide [PBO] 3%) were evaluated. Following administration of the insecticide, nymphs were fed on dogs 24, 72, 168, 240 and 336 h. Blood intake was similar in nymphs exposed to treated dogs versus controls. Although both commercial products showed low triatomicidal activity, a higher efficacy of the product combining imidacloprid with the synergist piperonyl butoxide and permethrin versus the product with imidacloprid as the only active ingredient was observed, causing in nymphs a mortality rate of 36.3 % and 20.7 %, respectively. Our results suggest that imidacloprid, alone or in combination with permethrin and PBO, is not an alternative for control of T. infestans.
C1 [Dade, Martin M.; Daniele, Martin R.; Bozzolo, Facundo; Mestorino, Nora] Univ Nacl La Plata, LEFyT, Fac Ciencias Vet, 60 & 118S-N,CC 296, RA-1900 La Plata, Argentina.
   [Dade, Martin M.] Univ Nacl La Plata, Catedra Farmacol Basica, Fac Ciencias Med, 60 & 120S-N, RA-1900 La Plata, Argentina.
   [Silvestrini, Maria P.] Univ Nacl Ctr Prov Buenos Aires, Fac Ciencias Salud, Inst Invest Ciencias Salud, Av Pringles 4375, RA-7400 Olavarria, Argentina.
   [Francini, Flavio] Univ Nacl La Plata, Ctr Endocrinol Expt & Aplicada CENEXA UNLP CONICE, CEAS CICPBA, Fac Ciencias Med, 60 & 120 S-N, RA-1900 La Plata, Argentina.
RP Dade, MM (reprint author), Univ Nacl La Plata, Catedra Farmacol Basica, Fac Ciencias Med, 60 & 120S-N, RA-1900 La Plata, Argentina.
EM mdade@fcv.unlp.edu.ar; mdaniele@fcv.unlp.edu.ar;
   pia.silvestrini@salud.unicen.edu.ar; bozzolo@hotmail.com;
   f_francini@yahoo.com; noram@fcv.unlp.edu.ar
CR Abbott WS, 1925, J ECON ENTOMOL, V18, P265, DOI 10.1093/jee/18.2.265a
   Alzogaray RA, 1997, MEM I OSWALDO CRUZ, V92, P431, DOI 10.1590/S0074-02761997000300023
   Amelotti I, 2012, MEM I OSWALDO CRUZ, V107, P1011, DOI 10.1590/S0074-02762012000800008
   Amelotti I, 2012, PARASITOL RES, V111, P1457, DOI 10.1007/s00436-012-2979-6
   Amelotti I, 2009, MEM I OSWALDO CRUZ, V104, P481, DOI 10.1590/S0074-02762009000300014
   Bingham G, 2011, TROP MED INT HEALTH, V16, P492, DOI 10.1111/j.1365-3156.2010.02717.x
   Busvine R.J., 1971, CRITICAL REV TECHNIQ, P263
   Carvajal G, 2014, MEM I OSWALDO CRUZ, V109, P761, DOI 10.1590/0074-0276140100
   Carvajal G, 2012, MEM I OSWALDO CRUZ, V107, P675, DOI 10.1590/S0074-02762012000500015
   Cecere M C, 1997, Rev Panam Salud Publica, V1, P273, DOI 10.1590/S1020-49891997000400003
   Chopade H, 2010, VET THER, V11
   Dade M.M., 2014, J PHARM PHARMACOL, V2, P353
   Dade M, 2017, BIOMEDICA, V37, P324, DOI [10.7705/biomedica.v37i3.3316, 10.7705/biomedica.v34i2.3316]
   FONTAN A, 1992, COMP BIOCHEM PHYS C, V101, P589, DOI 10.1016/0742-8413(92)90091-K
   GUERENSTEIN PG, 1994, J INSECT PHYSIOL, V40, P747, DOI 10.1016/0022-1910(94)90002-7
   Gurtler RE, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000447
   Juan LW, 2013, PARASITOL RES, V112, P155, DOI 10.1007/s00436-012-3119-z
   Laino MA, 2019, VET PARASITOL, V268, P98, DOI 10.1016/j.vetpar.2019.03.005
   Lent Herman, 1944, REV BRASIL BIOL, V4, P329
   LeOra Software, 1987, POL PC US GUID PROB
   Loza A, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2278-2
   Lussenhop J, 2012, J VET PHARMACOL THER, V35, P206, DOI 10.1111/j.1365-2885.2011.01324.x
   Melcon ML, 2005, J INSECT PHYSIOL, V51, P989, DOI 10.1016/j.jinsphys.2005.04.013
   Mougabure-Cueto G, 2015, ACTA TROP, V149, P70, DOI 10.1016/j.actatropica.2015.05.014
   NUNEZ JA, 1963, NATURE, V199, P621, DOI 10.1038/199621a0
   NUNEZ JA, 1990, J APPL ENTOMOL, V109, P87, DOI 10.1111/j.1439-0418.1990.tb00023.x
   Pfister K, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1719-7
   Picollo MI, 2005, J MED ENTOMOL, V42, P637, DOI 10.1603/0022-2585(2005)042[0637:HRTPIA]2.0.CO;2
   REYNOLDS SE, 1975, J EXP BIOL, V62, P81
   REYNOLDS SE, 1974, J INSECT PHYSIOL, V20, P1957, DOI 10.1016/0022-1910(74)90103-6
   Robertson J. L., 2007, BIOASSAYS ARTHROPODS
   World Health Organization (WHO), 1994, ACTA TOXICOL ARGENT, V2, P29
NR 32
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109092
DI 10.1016/j.vetpar.2020.109092
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300003
PM 32278223
DA 2020-05-12
ER

PT J
AU de Mendonca, IL
   Batista, JF
   Lopes, KSPD
   Neto, FDRM
   Alcantara, DS
   Merigueti, YFFB
   Costa, CHN
AF de Mendonca, Ivete Lopes
   Batista, Joilson Ferreira
   Pimentel do Prado Lopes, Kayo Sandro
   Ribeiro Magalhaes Neto, Francisco das Chagas
   Alcantara, Diana Sousa
   Fitz Balo Merigueti, Yslla Fernanda
   Nery Costa, Carlos Henrique
TI Infection of Lutzomyia longipalpis in cats infected with Leishmania
   infantum
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cat; Infection; Leishmaniasis; Phlebotomine sand fly; Xenodiagnosis
AB The clinical manifestations most frequently observed in cats with leishmaniasis caused by Leishmania infantum are cutaneous alterations, which suggest a high parasitic load in the skin and the possibility of infecting a vector. This study evaluated the infectiousness of to phlebotomine sand flies cats infected with L. infantum. A total of 12 cats with infection by L. infantum from the city of Teresina, Piaui, Brazil, were included in the study. Cats were diagnosed by direct visualization of the parasite. Laboratory-bred insects, free from infection by Leishmania spp. were offered a blood meal for 60 min on cats infected with L. infantum. On the fifth and sixth day after the blood meal, flies were dissected to assess promastigote forms of the parasite in the digestive system. Eight cats (67 %) were able to infect the vectors. The frequency of infected insects per cat ranged 0.0-94.4%. The mean frequency of insects feeding on cats was 95.2 %. Large numbers of the parasite were observed per insect, but were not quantified. The result confirm that cats are able to infect L. longipalpis, indicating that cats are part of the epidemiological chain of VL, acting as reservoir of the disease.
C1 [de Mendonca, Ivete Lopes] Univ Fed Piaui, Dept Clin & Vet Surg, BR-65049550 Teresina, PI, Brazil.
   [Batista, Joilson Ferreira; Ribeiro Magalhaes Neto, Francisco das Chagas; Alcantara, Diana Sousa] Univ Fed Piaui, Grad Program Anim Sci, Teresina, PI, Brazil.
   [Pimentel do Prado Lopes, Kayo Sandro] Univ Fed Piaui, Anim Hlth Lab, Teresina, PI, Brazil.
   [Fitz Balo Merigueti, Yslla Fernanda] Univ Western Paulista UNOESTE, Vet Teaching Hosp, Vet Parasitol Lab, Sao Paulo, Brazil.
   [Nery Costa, Carlos Henrique] Univ Fed Piaui, Dept Community Med, Teresina, PI, Brazil.
RP de Mendonca, IL (reprint author), Univ Fed Piaui, Dept Clin & Vet Surg, BR-65049550 Teresina, PI, Brazil.
EM etemendonca54@gmail.com
RI Merigueti, Yslla Fernanda Fitz Balo/D-9788-2019
OI Merigueti, Yslla Fernanda Fitz Balo/0000-0001-9287-5477
FU Ministry of HealthMinistry of Health - Turkey; Foundation for Research
   Support of the State of Piaui (FAPEPI), through the Research Program of
   the Unified Health System - PPSUS-2016
FX This study received financial aid from the Ministry of Health, in
   partnership with the Foundation for Research Support of the State of
   Piaui (FAPEPI), through the Research Program of the Unified Health
   System - PPSUS-2016. The funding source was not involved in the design,
   collection, analysis or interpretation of data, in the drafting of the
   report, or the decision to submit the article for publication.
CR Soares MRA, 2011, ACTA TROP, V117, P6, DOI 10.1016/j.actatropica.2010.08.015
   da Silva SM, 2010, VET PARASITOL, V174, P150, DOI 10.1016/j.vetpar.2010.08.005
   de Mendonca IL, 2017, REV SOC BRAS MED TRO, V50, P483, DOI 10.1590/0037-8682-0014-2017
   Coelho WMD, 2011, VET PARASITOL, V176, P281, DOI 10.1016/j.vetpar.2010.10.052
   Maia C, 2011, TRENDS PARASITOL, V27, P341, DOI 10.1016/j.pt.2011.03.008
   Maroli M, 2007, VET PARASITOL, V145, P357, DOI 10.1016/j.vetpar.2006.11.009
   Mendonca I. L. de, 2017, Parasitology Open, V3, pe1, DOI 10.1017/pao.2017.1
   Pennisi MG, 2018, VET PARASITOL, V251, P131, DOI 10.1016/j.vetpar.2018.01.012
   Pennisi MG, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0909-z
   Savani ESMM, 2004, VET PARASITOL, V120, P229, DOI 10.1016/j.vetpar.2004.01.008
   Silva JC, 2016, MEM I OSWALDO CRUZ, V111, P517, DOI 10.1590/0074-02760160185
   Vides JP, 2011, VET PARASITOL, V178, P22, DOI 10.1016/j.vetpar.2010.12.042
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109058
DI 10.1016/j.vetpar.2020.109058
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300006
PM 32200198
DA 2020-05-12
ER

PT J
AU de Oliveira, CS
   Savadelis, MD
   McLean, NJ
   Verocai, GG
AF de Oliveira, Caroline Sobotyk
   Savadelis, Molly D.
   McLean, Nancy Johnstone
   Verocai, Guilherme G.
TI Assessing the potential cross-reactivity using a commercial heartworm
   ELISA kits of serum from dogs naturally infected with Onchocerca lupi
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Antigen ELISA; Canine heartworm disease; Canine ocular onchocercosis;
   Filarial co-infection; Serological diagnosis
ID CANINE OCULAR ONCHOCERCIASIS; DIROFILARIA-IMMITIS; UNITED-STATES;
   NEMATODES; ANTIGEN; SAMPLES
AB Onchocerca lupi is an emerging zoonotic parasite of dogs, endemic to the southwestern USA and areas of the Old World. Currently, there are no specific serological diagnostic tests able to detect O. lupi infection. Recent literature has demonstrated that commercially available heartworm antigen tests, despite being highly sensitive, may cross-react with infections by other filarid nematodes. There is no information on potential cross-reactivity of such tests in serum of dogs infected with O. lupi. Our objective was to assess serum samples of dogs naturallyinfected with O. lupi for potential cross-reactivity before and after heat-treatment using a commercial heartworm ELISA kit. We obtained serum from 23 dogs naturally-infected with O. lupi. These dogs presented with ocular disease, and were consulted to schedule either surgical removal of ocular nodules due to infection or enucleation. Samples were tested in triplicate using the DiroCHEK (R) Heartworm Antigen Test kit (Synbiotics Corporation, Zoetis, Kalamazoo, MI, USA) following the manufacturers' protocol pre- and post-heat-treatment. Samples were heat-treated using a dry heat block at 103 degrees C for 10 min and then centrifuged at 1818xg for 20 min. Out of a total of 23 dogs, 19 (82.6 %) had no antigen detected regardless of heat-treatment, three dogs tested positive before and after heat-treatment, and a single dog turned positive after heat-treatment. These three dogs that were positive before and after heat-treatment were confirmedly co-infected with Dirofilaria immitis by the veterinarians responsible for these cases, and we were unable to get the history or follow up with the dog that turned positive post-heat-treatment only. Our data suggest that O. lupi infections should not result in falsepositives when using the DiroCHEK (R) in dog serum, before or after heat-treatment. Dogs with clinical ocular onchocercosis that test antigen-positive in DiroCHEK (R) are likely co-infected with D. immitis, and should be further tested, including evaluation of microfilariae in blood and diagnostic imaging. If heartworm infection is confirmed, the animals should be enrolled in the recommended treatment protocol in accordance to the guidelines of the American Heartworm Society or other local organizations.
C1 [de Oliveira, Caroline Sobotyk; Verocai, Guilherme G.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA.
   [Savadelis, Molly D.; Verocai, Guilherme G.] Univ Georgia, Coll Vet Med, Dept Infect Dis, Athens, GA 30602 USA.
   [Savadelis, Molly D.] Zoetis Vet Med Res & Dev, Kalamazoo, MI 49007 USA.
   [McLean, Nancy Johnstone] VCA Vet Care Anim Hosp & Referral Ctr, Ophthalmol, Albuquerque, NM 87111 USA.
RP Verocai, GG (reprint author), Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Pathobiol, College Stn, TX 77843 USA.
EM gverocai@cvm.tamu.edu
OI Verocai, Guilherme/0000-0002-4543-7105
CR Angelou A, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3543-3
   Aroch I, 2015, VET PARASITOL, V211, P303, DOI 10.1016/j.vetpar.2015.06.010
   Beall MJ, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2442-8
   Campbell B, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1783-z
   Cantey PT, 2016, CLIN INFECT DIS, V62, P778, DOI 10.1093/cid/civ983
   Carmichael J, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2445-5
   Ciuca L, 2016, VET PARASITOL, V225, P81, DOI 10.1016/j.vetpar.2016.05.032
   Companion Animal Parasite Council, 2019, HEARTW CAN
   Coura-Vital W, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001291
   DiGangi BA, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2443-7
   Giannelli A, 2014, PARASITOL RES, V113, P1989, DOI 10.1007/s00436-014-3844-6
   Gruntmeir J.M., 2016, J FELINE MED SURG
   Hassan HK, 2015, EMERG INFECT DIS, V21, P789, DOI 10.3201/eid2105.142011
   Ilhan HD, 2013, ACTA PARASITOL, V58, P384, DOI 10.2478/s11686-013-0152-8
   Labelle AL, 2011, VET OPHTHALMOL, V14, P105, DOI 10.1111/j.1463-5224.2011.00911.x
   Latrofa MS, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006402
   Little S, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2736-5
   Little SE, 2014, VET PARASITOL, V203, P250, DOI 10.1016/j.vetpar.2014.01.007
   McLean NJ, 2017, VET OPHTHALMOL, V20, P349, DOI 10.1111/vop.12433
   Mowlavi G, 2014, J HELMINTHOL, V88, P250, DOI 10.1017/S0022149X13000060
   Nelson C.T., 2018, CURRENT CANINE GUIDE
   Otranto D, 2015, EMERG INFECT DIS, V21, P868, DOI 10.3201/eid2105.141812
   Otranto D, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0699-3
   Otranto D, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002585
   Otranto D, 2013, EMERG INFECT DIS, V19, P2000, DOI 10.3201/eid1912.130264
   Pampiglione S, 2009, HISTOPATHOLOGY, V54, P192, DOI [10.1111/j.1365-2559.2008.03197_a.x, 10.1111/j.1365-2559.2008.03197.x]
   Quintana JF, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12395
   Quintana JF, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0656-1
   Savadelis M.D., 2018, PARASITE VECTOR, V11
   Schnyder M, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-258
   Tritten L, 2014, MOL BIOCHEM PARASIT, V198, P14, DOI 10.1016/j.molbiopara.2014.11.001
   Tritten L, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002971
   Velasquez L, 2014, VET PARASITOL, V206, P67, DOI 10.1016/j.vetpar.2014.03.021
   Venco L, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2444-6
   Verocai GG, 2016, EMERG INFECT DIS, V22, P1477, DOI 10.3201/eid2208.151918
   Zarfoss MK, 2005, VET OPHTHALMOL, V8, P51, DOI 10.1111/j.1463-5224.2005.00348.x
NR 36
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109070
DI 10.1016/j.vetpar.2020.109070
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300002
PM 32247934
DA 2020-05-12
ER

PT J
AU dos Santos, LB
   Favero, FC
   Conde, MH
   Freitas, MG
   Santos-Zanuncio, VS
   Carollo, CA
   Borges, FD
AF dos Santos, Larissa Bezerra
   Favero, Flavia Carolina
   Conde, Mario Henrique
   Freitas, Mariana Green
   Santos-Zanuncio, Vanessa Samudio
   Carollo, Carlos Alexandre
   Borges, Fernando de Almeida
TI Clinical safety of lauric acid for cattle and its in vitro and in vivo
   efficacy against Rhipicephalus microplus
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Lauric acid; Carboxylic acid; Rhipicephalus microplus; Green chemistry
ID BOOPHILUS-MICROPLUS; FATTY-ACID; RESISTANCE; TICK
AB The aim of the present study was to test the in vitro acaricidal activity of saturated fatty acids (hexanoic, octanoic, decanoic, lauric, myristic, palmitic, octadecanoic, eicosanoic, docosanoic and tetracosanoic) against Rhipicephalus microplus and select a candidate compound for the subsequent determination of its clinical safety for mice and bovines as well as its in vivo efficacy (ethical clearance number 507/2013). None of the compounds exhibited in vitro larvicidal effectiveness, but acaricidal effectiveness was greater than 95 % in the adult immersion test at 40 mg/ml (hexanoic, octanoic, decanoic, lauric, myristic, palmitic and eicosanoic acids). After a second AIT evaluation of serial concentrations of the fatty acids, lauric and myristic acids were selected for the safety and in vivo efficacy assays. No adverse effect was found in the local lymph node assay in mice treated with lauric or myristic acid. Moreover, no clinical signs of systemic poisoning or dermatological, hematological or biochemical abnormalities were found in cattle after the topical application of 1 % lauric acid. In the dose determination test, the 1% solution of this compound exhibited 86% efficacy in cattle naturally infested by a field population of Rhipicephalus microplus susceptible to all chemical groups, except synthetic pyrethroids. The efficacy of 1 % lauric acid was 53.4 % in the dose confirmation test performed on another herd with a field R. microplus population resistant to all chemical groups of acaricides. In conclusion, fatty acids are potential bioactive compounds for the control of R. microplus. Topically applied lauric acid (C12) exhibits in vivo acaricide activity against adults, nymphs and larvae of R. (B) microplus and is safe for cattle.
C1 [dos Santos, Larissa Bezerra; Favero, Flavia Carolina; Conde, Mario Henrique; Freitas, Mariana Green; Borges, Fernando de Almeida] Univ Fed Mato Grosso do Sul, Sch Vet Med & Anim Sci, Campo Grande, MS, Brazil.
   [Santos-Zanuncio, Vanessa Samudio; Carollo, Carlos Alexandre] Fed Univ Mato Grosso do Sul UFMS, Sch Pharmaceut Food & Nutr Sci FACFAN, Lab Nat Prod & Mass Spectrometry LaPNEM, Campo Grande, MS, Brazil.
RP Borges, FD (reprint author), Univ Fed Mato Grosso do Sul, Grad Program Anim Sci, Ave Senador Filinto Muller 2443,Caixa Postal 549, BR-79074460 Campo Grande, MS, Brazil.
EM fernando.borges@ufms.br
OI Borges, Fernando/0000-0002-8888-6269; Carollo, Carlos
   Alexandre/0000-0003-1231-9441
FU FundectFundect [23/200, 720/2013]; CNPqNational Council for Scientific
   and Technological Development (CNPq) [47936/2013-6]; INAU (Instituto
   Nacional de Areas Umidas)
FX The authors are grateful for the funding of this work by Fundect
   (23/200,720/2013) and CNPq (47936/2013-6) in the form of a doctoral
   grant. We also thank INAU (Instituto Nacional de Areas Umidas) for their
   support in carrying out the study.
CR Arceo-Medina GN, 2016, VET PARASITOL, V228, P121, DOI 10.1016/j.vetpar.2016.08.023
   Chantadee T., 2019, THAI B PHARM SCI, V14, P1
   Dayrit Fabian M, 2014, PHILIPP J SCI, V143, P157
   dos Santos LB, 2013, REV BRAS PARASITOL V, V22, P532, DOI 10.1590/S1984-29612013000400013
   DRUMMOND RO, 1973, J ECON ENTOMOL, V66, P130, DOI 10.1093/jee/66.1.130
   GUTNIKOV G, 1995, J CHROMATOGR B, V671, P71, DOI 10.1016/0378-4347(95)00116-Z
   Hierholzer John C, 1982, J Food Saf, V4, P1, DOI 10.1111/j.1745-4565.1982.tb00429.x
   Holdsworth PA, 2006, VET PARASITOL, V136, P29, DOI 10.1016/j.vetpar.2005.11.011
   KABARA JJ, 1984, J AM OIL CHEM SOC, V61, P397, DOI 10.1007/BF02678802
   MALONE MH, 1962, LLOYD, V25, P320
   Pazinato R, 2016, J ADV RES, V7, P1029, DOI 10.1016/j.jare.2016.05.003
   Prajapati H. N., 2011, J EXCIPIENTS FOOD CH, V2, P73
   Quispe N.B.P., 2020, BRAZ J DEV, V6, P1510
   Santos FO, 2018, VET PARASITOL, V255, P102, DOI 10.1016/j.vetpar.2018.04.003
   Santos L.B., 2017, THESIS
   Schwantes U, 2008, PARASITE VECTOR, V1, DOI 10.1186/1756-3305-1-8
   Seleem D, 2016, PEERJ, V4, DOI 10.7717/peerj.2148
   SHAW RD, 1966, B ENTOMOL RES, V56, P389, DOI 10.1017/S0007485300056480
   Silva EL, 2015, J NANOSCI NANOTECHNO, V15, P792, DOI 10.1166/jnn.2015.9184
   WEST CC, 1992, ENVIRON SCI TECHNOL, V26, P2324, DOI 10.1021/es00036a002
   WHARTON RH, 1970, AUST J AGR RES, V21, P163, DOI 10.1071/AR9700163
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109095
DI 10.1016/j.vetpar.2020.109095
PG 7
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300004
PM 32251919
DA 2020-05-12
ER

PT J
AU Garcia-Sanchez, M
   Moreno-Gonzalo, J
   Gonzalez-Warleta, M
   Mezo, M
   Ortega-Mora, LM
   Regidor-Cerrillo, J
AF Garcia-Sanchez, Marta
   Moreno-Gonzalo, Javier
   Gonzalez-Warleta, Marta
   Mezo, Mercedes
   Miguel Ortega-Mora, Luis
   Regidor-Cerrillo, Javier
TI Isolation and genetic characterization of Neospora caninum from
   naturally infected sheep
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Neospora caninum; Isolation; Congenitally infected lambs; Genetic
   characterization; Multilocus microsatellite genotyping
ID OVINE
AB Neospora caninum is considered one of the main causes of abortion in cattle but can also cause abortion in sheep. There is limited knowledge of the N. caninum population infecting sheep, and only one N. caninum isolate from a pregnant sheep from Japan has been reported. This study describes the in vitro isolation and genetic characterization of two new sheep isolates of N. caninum implicated in ovine reproductive failure. We used IFN-.knockout mice inoculated with PCR-positive brain homogenates from two clinically healthy but congenitally infected lambs at 4.5 months of age for parasite isolation. The lambs were born to dams from a sheep farm that had experienced pregnancy failure caused by N. caninum in successive generations. Tachyzoites were microscopically visualized in peritoneal flushes from all inoculated mice and were also observed in MARC-145 cell cultures within one week after inoculation with peritoneal flushes. Two N. caninum isolates, Nc-Spain11 and NcSpain12, were obtained from each lamb. The genotyping of the Nc-Spain11 and Nc-Spain12 isolates based on 9 microsatellite markers showed identical multilocus genotype (MLG). Comparison between a previous N. caninum genotype dataset including 80 MLGs from Argentinean, Spanish, Mexican, German and Scottish bovine isolates and the Japanese sheep isolate showed that the Nc-Spain11 and Nc-Spain12 MLG was unique and differed from the other MLGs. eBURST analyses showed that the Nc-Spain11 and Nc-Spain12 MLG was genetically clustered with other bovine MLGs and one ovine MLG, and the nearest genetic relationship was with an MLG from a bovine abortion collected in the same geographical area of Galicia.
C1 [Garcia-Sanchez, Marta; Moreno-Gonzalo, Javier; Miguel Ortega-Mora, Luis; Regidor-Cerrillo, Javier] Univ Complutense Madrid, Fac Vet Sci, Anim Hlth Dept, SALUVET, Ciudad Univ S-N, Madrid 28040, Spain.
   [Gonzalez-Warleta, Marta; Mezo, Mercedes] AGACAL, Ctr Invest Agr Mabegondo, Lab Parasitol, Abegondo 15318, A Coruna, Spain.
RP Regidor-Cerrillo, J (reprint author), Univ Complutense Madrid, Fac Vet Sci, Anim Hlth Dept, SALUVET, Ciudad Univ S-N, Madrid 28040, Spain.
EM martag17@ucm.es; jmorenog@pdi.ucm.es; marta.gonzalez.warleta@xunta.es;
   mercedes.mezo.menendez@xunta.es; luis.ortega@ucm.es; jregidor@vet.ucm.es
RI Garcia-Sanchez, Marta/AAJ-1637-2020
OI Garcia-Sanchez, Marta/0000-0001-5034-3384
FU Ministerio de Ciencia, Innovacion y Universidades of Spain
   [RTA2014-00013]; European Social FundEuropean Social Fund (ESF);
   European Regional Development FundEuropean Union (EU) [PLATESA2-CM
   P2018/BAA-4370]
FX The present study was co-financed by the Ministerio de Ciencia,
   Innovacion y Universidades of Spain (INIA project RTA2014-00013), the
   European Social Fund and the European Regional Development Fund
   (PLATESA2-CM P2018/BAA-4370). We would like to thank Natividad Moya
   Extremera for her assistance with the graphical abstract design.
CR Almeria S, 2010, VET PARASITOL, V169, P304, DOI 10.1016/j.vetpar.2009.12.044
   Arranz-Solis D, 2015, VET RES, V46, DOI 10.1186/s13567-014-0139-y
   Bien J, 2010, VET PARASITOL, V173, P200, DOI 10.1016/j.vetpar.2010.06.038
   Costa RC, 2019, EXP PARASITOL, V205, DOI 10.1016/j.exppara.2019.107736
   Dubey JP, 2007, CLIN MICROBIOL REV, V20, P323, DOI 10.1128/CMR.00031-06
   Dubey JP, 2011, VET PARASITOL, V180, P90, DOI 10.1016/j.vetpar.2011.05.031
   Dubey JP, 2009, VET PARASITOL, V163, P1, DOI 10.1016/j.vetpar.2009.02.026
   Feil EJ, 2004, J BACTERIOL, V186, P1518, DOI 10.1128/JB.186.5.1518-1530.2004
   Gonzalez-Warleta M, 2018, VET RES, V49, DOI 10.1186/s13567-018-0601-3
   Gonzalez-Warleta M, 2014, VET RES, V45, DOI 10.1186/s13567-014-0088-5
   Khan A, 2019, P NATL ACAD SCI USA, V116, P22764, DOI 10.1073/pnas.1913531116
   Koyama T, 2001, J PARASITOL, V87, P1486, DOI 10.1645/0022-3395(2001)087[1486:IONCFT]2.0.CO;2
   Medina-Esparza L, 2016, VET PARASITOL, V228, P183, DOI 10.1016/j.vetpar.2016.09.009
   Moreno B, 2012, VET PARASITOL, V187, P312, DOI 10.1016/j.vetpar.2011.12.034
   Pena HFJ, 2007, VET PARASITOL, V147, P61, DOI 10.1016/j.vetpar.2007.03.002
   Regidor-Cerrillo J, 2008, PARASITOLOGY, V135, P1651, DOI 10.1017/S003118200800509X
   Regidor-Cerrillo J, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-10
   Regidor-Cerrillo J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072678
   Regidor-Cerrillo J, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-41
   Vazquez P, 2019, VET RES, V50, DOI 10.1186/s13567-019-0686-3
NR 20
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109091
DI 10.1016/j.vetpar.2020.109091
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300007
PM 32208305
OA Bronze
DA 2020-05-12
ER

PT J
AU Genchi, C
   Kramer, LH
AF Genchi, Claudio
   Kramer, Laura Helen
TI The prevalence of Dirofilaria immitis and D. repens in the Old World
SO VETERINARY PARASITOLOGY
LA English
DT Review
DE Dirofilaria immitis; Dirofilaria repens; prevalence; Old World
ID BURGDORFERI SENSU-LATO; DOMESTIC DOGS; ANAPLASMA-PHAGOCYTOPHILUM;
   MOLECULAR-DETECTION; HEARTWORM DISEASE; CANINE HEARTWORM;
   EHRLICHIA-CANIS; INFECTIONS; CATS; SEROPREVALENCE
AB Dirofilaria immitis and D. repens are endemic throughout Europe and southern eastern regions of Asia and reported with increasing frequency in Africa. Nevertheless, the increased awareness of veterinary practitioners, even in countries where the prevalence is low, has led to a decrease D. immitis prevalence in dogs, especially in previously endemic/hyper-endemic areas. Prevalence has significantly increased, however, in areas where heartworm has apparently spread more recently, such as Central and North Eastern Europe. Furthermore, autochthonous cases have been observed in Siberia. Low seroprevalence has been reported in Croatia, while in Romania it has reached 14%. In Greece, the prevalence ranges between 0.7% and 25% whilst in Turkey is 0-18%. Data for canine dirofilariosis in Africa is scarce, and most are case reports. Overall, the dominant species is Achanthocheilonema dracunculoides, although both D. immitis and D. repens have been reported from some countries. In the Far East, the prevalence ranges from 2% to 15% in northeastern of China. In Hong Kong a novel species has been found in dogs and humans (Candidatus Dirofilaria hongkongensis). In India, the prevalence ranges from 4.7%-29.5% in Northeastern states.
   The main factors that have influenced the spreading of Dirofilaria infections are the climate changes and the introduction of new, invasive, competent mosquito species such as Aedes albopictus and Ae. koreicus. Other factors include relocation and insufficient prevention in dogs, manly in the new areas of colonization.
   Feline heartworm infection has been diagnosed in every European country when diagnosed either by the Knott test or by serology for circulating antibodies and antigens of the parasite. However, prevalence is much lower than in dogs.
   In spite of the continuing spreading of heartworm infection, D. repens is the main concern in Europe, mostly for physicians, while the infection is nearly always asymptomatic in dogs. The infection is spreading from Portugal to the Southeastern regions of Finland and Siberia, and in some areas its prevalence overlaps that of D. immitis. Many reasons make more difficult the control of D. repens than D. immitis: the frequent lack of clinical symptoms of suspicion, the specific diagnosis being possible only by blood examination and the inefficacy of some macrocyclic lactones.
C1 [Genchi, Claudio] Univ Milan, Dept Vet Med, Milan, Italy.
   [Kramer, Laura Helen] Dept Vet Med Sci, Parma, Italy.
RP Genchi, C (reprint author), Univ Milan, Dept Vet Med, Milan, Italy.
EM claudio.genchi@unimi.it
CR Montoya-Alonso JA, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2299-x
   Montoya-Alonso JA, 2015, VET PARASITOL, V212, P456, DOI 10.1016/j.vetpar.2015.06.025
   Albrechtova K, 2011, VET PARASITOL, V182, P230, DOI 10.1016/j.vetpar.2011.05.042
   Alho AM, 2018, VET PARASITOL, V252, P120, DOI 10.1016/j.vetpar.2018.01.008
   Angelou A, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3543-3
   Bacsadi A, 2016, VET PARASITOL, V220, P83, DOI 10.1016/j.vetpar.2016.03.001
   Bamorovat M, 2017, IRAN J PARASITOL, V12, P260
   Boonyapakorn Chaovalit, 2008, Southeast Asian Journal of Tropical Medicine and Public Health, V39, P33
   Borthakur Sonjoy Kumar, 2015, ScientificWorldJournal, V2015, P265385, DOI 10.1155/2015/265385
   Bowman DD, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1804-y
   Capelli G, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3205-x
   Ciuca L, 2016, GEOSPATIAL HEALTH, V11, P318, DOI 10.4081/gh.2016.499
   Demiaszkiewicz AW, 2014, POL J VET SCI, V17, P515, DOI 10.2478/pjvs-2014-0075
   Diakou A, 2019, PARASITOL RES, V118, P677, DOI 10.1007/s00436-018-6135-9
   Diosdado A, 2018, J HELMINTHOL, V92, P520, DOI 10.1017/S0022149X17000591
   Fuehrer HP, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004547
   Genchi C, 2005, VET PARASITOL, V133, P137, DOI 10.1016/j.vetpar.2005.04.009
   Genchi C, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2434-8
   Genchi C, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-206
   Genchi C, 2009, VET PARASITOL, V163, P286, DOI 10.1016/j.vetpar.2009.03.026
   Genchi M, 2019, VET PARASITOL, V267, P26, DOI 10.1016/j.vetpar.2019.01.014
   Guerrero J, 1989, P HEARTW S 89, V89, P13
   Heidari Z, 2015, J VECTOR DIS, V52, P329
   Hou HL, 2017, KOREAN J PARASITOL, V55, P673, DOI 10.3347/kjp.2017.55.6.673
   ILIEV P, 2017, BULG J VET MED S1, V20, P389
   Ionica AM, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1524-3
   Jokelainen P, 2016, VECTOR-BORNE ZOONOT, V16, P136, DOI 10.1089/vbz.2015.1833
   Jurkovic D, 2019, PARASITOL RES, V118, P347, DOI 10.1007/s00436-018-6129-7
   Kartashev Vladimir, 2011, Vet Med Int, V2011, P685713, DOI 10.4061/2011/685713
   Khedri J, 2014, IRAN J PARASITOL, V9, P560
   Kose M, 2012, BERL MUNCH TIERARZTL, V125, P503, DOI 10.2376/0005-9366-125-503
   Kramer F, 2014, PARASITOL RES, V113, P3229, DOI 10.1007/s00436-014-3985-7
   Kravchenko Victor, 2016, Vet Parasitol Reg Stud Reports, V6, P35, DOI 10.1016/j.vprsr.2016.08.004
   Liu CW, 2013, KOREAN J PARASITOL, V51, P375, DOI 10.3347/kjp.2013.51.3.375
   Mallawarachchi CH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206633
   McCall JW, 2008, ADV PARASIT, V66, P193, DOI 10.1016/S0065-308X(08)00204-2
   Metlarova H., 2018, PARASIT VECTORS P S1, V11, P623, DOI [10.1186/s13071-018-3183-z., DOI 10.1186/S13071-018-3183-Z]
   Mircean V, 2012, VECTOR-BORNE ZOONOT, V12, P595, DOI 10.1089/vbz.2011.0915
   Miterpakova M, 2018, PARASITOL RES, V117, P2347, DOI 10.1007/s00436-018-5912-9
   Montarsi F, 2015, PARASITE VECTOR, V8, DOI 10.1186/s13071-015-0800-y
   Montoya-Alonso JA, 2010, VET PARASITOL, V173, P165, DOI 10.1016/j.vetpar.2010.06.008
   Moskvina TV, 2018, RUSS OPEN MED J, V7, DOI 10.15275/rusomj.2018.0102
   Mukendi JPK, 2016, VET PARASITOL, V220, P1, DOI 10.1016/j.vetpar.2016.02.005
   Nazar N, 2017, INDIAN J MED RES, V146, P528, DOI 10.4103/ijmr.IJMR_1425_15
   Oi M., 2014, PARASITE, V2014, DOI [10.1051/parasite/2014008.21-10., DOI 10.1051/PARASITE/2014008.21-10]
   Otranto D, 2019, ACTA TROP, V197, DOI 10.1016/j.actatropica.2019.105058
   Otranto D, 2015, VET PARASITOL, V213, P24, DOI 10.1016/j.vetpar.2015.04.020
   Pantchev N, 2009, PARASITOL RES, V105, pS101, DOI 10.1007/s00436-009-1501-2
   Petry G, 2015, PARASITOL RES, V114, pS131, DOI 10.1007/s00436-015-4519-7
   Pietikainen R, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2499-4
   Radev V., 2016, Bulgarian Journal of Veterinary Medicine, V19, P57
   Rjeibi MR, 2017, TRANSBOUND EMERG DIS, V64, P1505, DOI 10.1111/tbed.12541
   Rossi A, 2015, ACTA TROP, V142, P1, DOI 10.1016/j.actatropica.2014.10.021
   Salamatin RV, 2013, ACTA PARASITOL, V58, P592, DOI 10.2478/s11686-013-0187-x
   Schwan EV, 2002, J S AFR VET ASSOC, V73, P124
   Simon F, 2012, CLIN MICROBIOL REV, V25, P507, DOI 10.1128/CMR.00012-12
   Siwila J, 2015, VET PARASITOL, V210, P250, DOI 10.1016/j.vetpar.2015.04.009
   Suh GH, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2076-x
   Sukhumavasi W, 2012, VET PARASITOL, V188, P25, DOI 10.1016/j.vetpar.2012.02.021
   Tahir D, 2017, COMP IMMUNOL MICROB, V51, P66, DOI 10.1016/j.cimid.2017.04.001
   Tasic-Otasevic SA, 2015, VET PARASITOL, V209, P151, DOI 10.1016/j.vetpar.2015.02.016
   To KKW, 2012, J CLIN MICROBIOL, V50, P3534, DOI 10.1128/JCM.01590-12
   Trotz-Williams LA, 2003, VET REC, V152, P97, DOI 10.1136/vr.152.4.97
   Tumolskaya NI, 2016, PARASITE, V23, DOI 10.1051/parasite/2016037
   Venco L, 2008, VET PARASITOL, V158, P232, DOI 10.1016/j.vetpar.2008.09.011
   Venco L, 2011, VET PARASITOL, V176, P300, DOI 10.1016/j.vetpar.2011.01.013
   Vrhovec MG, 2017, PARASITOL RES, V116, pS131, DOI 10.1007/s00436-017-5499-6
   Yilmaz E, 2019, TRANSBOUND EMERG DIS, V66, P389, DOI 10.1111/tbed.13033
   Zohdy S, 2019, INT J PARASITOL-PAR, V9, P119, DOI 10.1016/j.ijppaw.2019.04.005
NR 69
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 108995
DI 10.1016/j.vetpar.2019.108995
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300013
PM 32155518
DA 2020-05-12
ER

PT J
AU Mahieu, M
   Arquet, R
   Fleury, J
   Bonneau, M
   Mandonnet, N
AF Mahieu, Maurice
   Arquet, Remy
   Fleury, Jerome
   Bonneau, Mathieu
   Mandonnet, Nathalie
TI Mixed grazing of adult goats and cattle: Lessons from long-term
   monitoring
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Leader-follower grazing; Rotational grazing; Simultaneous grazing;
   Gastrointestinal parasitism
ID SHEEP; PASTURE; INFECTION; STOCKING; PERFORMANCE; RESISTANCES;
   ALTERNATE; HEIFERS; RATES
AB Mixed grazing of breeding goats and cattle (goats to cattle ratio: about 50 %, based on metabolic weight) was monitored for 2 years on a rotational pasture with the two species grazing together, then for 5 years with cattle grazing immediately after goats. For both modalities, the level of goat parasite infection was not significantly different from that of the control groups. Nevertheless, the association allowed a slight improvement in kid growth and goat productivity, probably in relation to a better food quality. The response of adult goats to mixed grazing is therefore very different from that previously obtained with kids post-weaning. The question of the relationship between heterogeneity of pastures, knowledge of their environment, grazing behaviour of adult goats and risk of infection with gastrointestinal nematodes requires further investigation.
C1 [Mahieu, Maurice; Bonneau, Mathieu; Mandonnet, Nathalie] INRAE, URZ Rech Zootech, F-97170 Petit Bourg, Guadeloupe, France.
   [Arquet, Remy; Fleury, Jerome] INRAE, UEPTEA Plateforme Trop Expt Anim, F-97170 Petit Bourg, Guadeloupe, France.
RP Mahieu, M (reprint author), INRAE, URZ Rech Zootech, F-97170 Petit Bourg, Guadeloupe, France.
EM maurice.mahieu@inrae.fr
RI MAHIEU, Maurice/J-2199-2019
OI MAHIEU, Maurice/0000-0001-6429-7841
FU Region Guadeloupe; European Union Fund (FEDER)European Union (EU)
FX The study was supported by Region Guadeloupe and the European Union Fund
   (FEDER) in the framework of the AgroEcoDiv project.
CR Anderson DM, 2012, ANIMAL, V6, P1339, DOI 10.1017/S175173111200016X
   ARUNDEL JH, 1975, AUST VET J, V51, P436, DOI 10.1111/j.1751-0813.1975.tb15794.x
   Aumont G., 1997, INRA PROD ANIM, V10, P79
   Aumont G., 1991, REV ELEV MED VET PAY, V44, P123
   Bath G.F., 1996, 7 ANN C LIV HLTH PRO
   Bath GF, 2001, TCPSAF8821A FAO
   Blaes JL, 2010, ADV ANIM BIOSCI, V1, P413
   Brito DL, 2013, REV BRAS PARASITOL V, V22, P485, DOI 10.1590/S1984-29612013000400007
   Celaya R, 2007, SMALL RUMINANT RES, V72, P165, DOI 10.1016/j.smallrumres.2006.10.005
   Cruz P., 1989, 16TH P C INT HERB NI, P499
   Hilario MC, 2017, APPL ANIM BEHAV SCI, V191, P17, DOI 10.1016/j.applanim.2017.02.009
   d'Alexis S, 2014, J AGR SCI-CAMBRIDGE, V152, P655, DOI 10.1017/S0021859613000622
   d'Alexis S, 2012, VET PARASITOL, V184, P384, DOI 10.1016/j.vetpar.2011.08.030
   Fernandes LH, 2004, ARQ BRAS MED VET ZOO, V56, P733, DOI 10.1590/S0102-09352004000600006
   Fraser MD, 2007, LIVEST SCI, V110, P251, DOI 10.1016/j.livsci.2006.11.006
   Fraser MD, 2018, REV SCI TECH OIE, V37, P247, DOI 10.20506/rst.37.1.2755
   Fraser M.D., 2014, PLOS ONE, V9
   Gebrelul S, 2016, J ANIM SCI, V94, P49, DOI 10.2527/ssasas2015-100
   HAMILTON D, 1970, Australian Journal of Experimental Agriculture and Animal Husbandry, V10, P19, DOI 10.1071/EA9700019
   Houdijk JGM, 2001, P NUTR SOC, V60, P515, DOI 10.1079/PNS2001114
   Lenth R., 2019, EMMEANS ESTIMATED MA
   Liu J, 2015, J APPL ECOL, V52, P1053, DOI 10.1111/1365-2664.12456
   Mahieu M, 1997, PROD ANIM, V10, P55
   Mahieu M, 2009, TROP ANIM HEALTH PRO, V41, P229, DOI 10.1007/s11250-008-9180-z
   Mahieu M, 2007, VET PARASITOL, V146, P135, DOI 10.1016/j.vetpar.2007.02.003
   Mahieu M, 2014, VET PARASITOL, V205, P379, DOI 10.1016/j.vetpar.2014.07.029
   Mahieu M, 2013, VET PARASITOL, V198, P136, DOI 10.1016/j.vetpar.2013.08.029
   Marley CL, 2006, VET PARASITOL, V142, P134, DOI 10.1016/j.vetpar.2006.06.030
   Marshall R., 2012, American Journal of Animal and Veterinary Sciences, V7, P61
   NOLAN T, 1989, ANIM PROD, V48, P519, DOI 10.1017/S0003356100004049
   Osoro K, 2017, ANIM PROD SCI, V57, P102, DOI 10.1071/AN15153
   Pinheiro J., 2019, R PACKAGE VERSION, V3, P1, DOI DOI 10.HTTP://DX.D0L0RG/10.3390/F10090810
   R Core Team, 2019, R LANG ENV STAT COMP
   SALL C, 1993, ANN ZOOTECH, V42, P196, DOI 10.1051/animres:19930260
   Sehested J, 2004, LIVEST PROD SCI, V88, P223, DOI 10.1016/j.livprodsci.2003.11.008
   Sharpe P, 2019, HORSE PASTURE MANAGEMENT, P157, DOI 10.1016/B978-0-12-812919-7.00010-X
   Wright IA, 2006, ANIM SCI, V82, P271, DOI 10.1079/ASC200517
NR 37
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109087
DI 10.1016/j.vetpar.2020.109087
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300008
PM 32220696
DA 2020-05-12
ER

PT J
AU Pena-Espinoza, M
   Valente, AH
   Bornancin, L
   Simonsen, HT
   Thamsborg, SM
   Williams, AR
   Lopez-Munoz, R
AF Pena-Espinoza, Miguel
   Valente, Angela H.
   Bornancin, Louis
   Simonsen, Henrik T.
   Thamsborg, Stig M.
   Williams, Andrew R.
   Lopez-Munoz, Rodrigo
TI Anthelmintic and metabolomic analyses of chicory (Cichorium intybus)
   identify an industrial by-product with potent in vitro antinematodal
   activity
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Cichorium intybus; Anthelmintic; Pig; In vitro assays; Metabolomics;
   Caenorhabditis elegans; Ascaris suum; Sesquiterpene lactones
ID SESQUITERPENE LACTONES; NATURAL-PRODUCTS; BIOSYNTHESIS; PARASITES;
   EXTRACTS; ELEGANS; QUALITY; ROOTS; MODEL
AB Chicory (Cichorium intybus) is a bioactive forage rich in sesquiterpene lactones (SLs) with reported in vitro and in vivo anthelmintic activity in livestock. However, the on-farm adoption of chicory as an anthelmintic crop is limited and may be facilitated by using standardised industrial chicory material. Chicory root pulp is a byproduct obtained from industrial chicory roots after inulin extraction and can potentially retain SLs. However, SL content and associated anthelmintic activity of chicory root pulp have not been investigated. Here, we evaluated the anthelmintic activity of SL-enriched extracts from chicory root pulp and forage chicory, and used untargeted metabolomics and molecular networking to identify potential anthelmintic molecules. Six different sources of chicory material were used: fresh chicory root pulp (from industrial chicory roots C. intybus var. sativum; "Root Pulp"), fresh leaves from chicory cv. Spadona (sampled on four occasions) and fresh leaves from chicory cv. Choice. The resulting extracts were tested for anthelmintic activity against the free-living nematode Caenorhabditis elegans and the pig nematode Ascaris suum. The cytotoxicity of the chicory extracts was evaluated on mammalian (Vero) cells. In the C. elegans assays, the Root Pulp was the most potent extract and induced paralysis in> 95% of worms exposed to> 250 mu g extract/mL (EC50= 64.2 mu g/mL). In the A. suum assays, the Root Pulp was also the most potent chicory extract to inhibit worm motility (EC50 = 87.6 mu g/mL), followed closely by two of the Spadona leaf extracts (EC50= 89.8 mu g/mL and 112.2 mu g/mL) The Root Pulp extract had the lowest cytotoxicity of all tested extracts towards mammalian cells, with a selectivity index of 5.37. Untargeted metabolomics revealed that chicory Root Pulp had a markedly different chemical profile in comparison with forage chicory extracts. Molecular networking confirmed several SLs and SL-derivatives mainly present in chicory root pulp, that may be responsible of its potent anti-parasitic activity. Bioactivity-based molecular networking of chicory root pulp and the most potent forage chicory extracts revealed a high predicted anthelmintic score for the guaianolide SL 11,13-dihydro-lactucopicrin. In conclusion, chicory root pulp showed potent and selective in vitro anthelmintic activity against C. elegans and A. suum, with low cytotoxicity in mammalian cells. The promising anthelmintic activity of chicory root pulp should be confirmed in vivo to further explore the potential of this agro-industrial by-product as a nutraceutical anthelmintic for livestock and as novel source of anti-parasitic compounds.
C1 [Pena-Espinoza, Miguel; Lopez-Munoz, Rodrigo] Univ Austral Chile, Fac Ciencias Vet, Inst Farmacol & Morfofisiol, Campus Isla Teja, Valdivia 5090000, Chile.
   [Valente, Angela H.; Thamsborg, Stig M.; Williams, Andrew R.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Vet & Anim Sci, Dyrlaegevej 100, DK-1870 Frederiksberg C, Denmark.
   [Bornancin, Louis; Simonsen, Henrik T.] Tech Univ Denmark, Dept Biotechnol & Biomed, Soltofts Plads, DK-2800 Lyngby, Denmark.
RP Pena-Espinoza, M; Lopez-Munoz, R (reprint author), Univ Austral Chile, Fac Ciencias Vet, Inst Farmacol & Morfofisiol, Campus Isla Teja, Valdivia 5090000, Chile.
EM miguel.pena@uach.cl; rodrigo.lopez@uach.cl
RI Simonsen, Henrik Toft/I-4263-2016; Lopez-Munoz, Rodrigo/I-1097-2013;
   Pena-Espinoza, Miguel/A-4306-2018
OI Simonsen, Henrik Toft/0000-0003-3070-807X; Valente, Angela
   Hordum/0000-0002-6721-6231; Bornancin, Louis/0000-0003-3456-2952;
   Williams, Andrew/0000-0002-8231-282X; Lopez-Munoz,
   Rodrigo/0000-0003-1825-8563; Pena-Espinoza, Miguel/0000-0001-5992-8995
FU NIH Office of Research Infrastructure ProgramsUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA [P40
   OD010440]; CONICYT Chile (FONDECYT Postdoctorado) [3170875]; Danish
   Council for Independent ResearchDet Frie Forskningsrad (DFF)
   [6111-00394]; Green Development and Demonstration Programme
   [34009-17-1220]
FX Dra. Andrea Calixto (Universidad Mayor, Chile) is gratefully
   acknowledged for helping in the establishment of C. elegans cultures.
   Dr. Daniel Alomar and Dra. Romina Rodriguez (Universidad Austral de
   Chile) are acknowledged for contributing with chicory cv. Choice
   material, and Claudia Cordova (Beneo-Orafti Chile) is thanked for
   providing chicory root pulp material. Dr. Javier Parada and Sandy
   Gonzalez (Universidad Austral de Chile) are gratefully thanked for
   collaborating with freeze-drying of chicory material. Some C. elegans
   strains were provided by the CGC, which is funded by NIH Office of
   Research Infrastructure Programs (P40 OD010440). This work was supported
   by CONICYT Chile (FONDECYT Postdoctorado #3170875), the Danish Council
   for Independent Research (6111-00394) and the Green Development and
   Demonstration Programme (34009-17-1220, The Danish Ministry of
   Environment and Food).
CR Aluwe M, 2013, MEAT SCI, V94, P402, DOI 10.1016/j.meatsci.2013.02.015
   Awad WA, 2011, J ANIM PHYSIOL AN N, V95, P65, DOI 10.1111/j.1439-0396.2010.00999.x
   Bais HP, 2001, J SCI FOOD AGR, V81, P467, DOI 10.1002/jsfa.817
   Bischoff TA, 2004, J ETHNOPHARMACOL, V95, P455, DOI 10.1016/j.jep.2004.06.031
   Bogdanovic M, 2019, IND CROP PROD, V129, P253, DOI 10.1016/j.indcrop.2018.12.011
   Burns A.R., 2012, PARASITIC HELMINTHS, P201, DOI [10.1002/9783527652969.ch12, DOI 10.1002/9783527652969.CH12]
   Burns AR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8485
   Charlier J, 2018, TRANSBOUND EMERG DIS, V65, P217, DOI 10.1111/tbed.12707
   de Kraker JW, 2002, PLANT PHYSIOL, V129, P257, DOI 10.1104/pp.010957
   de Kraker JW, 2001, PLANT PHYSIOL, V125, P1930, DOI 10.1104/pp.125.4.1930
   Drew DP, 2009, PHYTOCHEM REV, V8, P581, DOI 10.1007/s11101-009-9130-z
   Ferioli F, 2012, FOOD CHEM, V135, P243, DOI 10.1016/j.foodchem.2012.04.079
   Foster JG, 2011, GRASS FORAGE SCI, V66, P424, DOI 10.1111/j.1365-2494.2011.00801.x
   Foster JG, 2011, VET PARASITOL, V180, P298, DOI 10.1016/j.vetpar.2011.03.013
   Gupta J, 2012, EXP PARASITOL, V130, P449, DOI 10.1016/j.exppara.2012.01.009
   Hoste H, 2015, VET PARASITOL, V212, P5, DOI 10.1016/j.vetpar.2015.06.026
   Hoste H., 2014, Organic farming, prototype for sustainable agricultures, P149
   Hours MA, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0899-x
   Katiki LM, 2011, VET PARASITOL, V182, P264, DOI 10.1016/j.vetpar.2011.05.020
   Kayser O, 2003, PARASITOL RES, V90, pS55, DOI 10.1007/s00436-002-0768-3
   Kisiel W, 2001, PHYTOCHEMISTRY, V57, P523, DOI 10.1016/S0031-9422(01)00072-3
   Lumaret JP, 2012, CURR PHARM BIOTECHNO, V13, P1004, DOI 10.2174/138920112800399257
   Maertens L, 2014, WORLD RABBIT SCI, V22, P97, DOI 10.4995/wrs.2014.1540
   Nass R., 2007, CURRENT PROTOCOLS TO
   Nothias LF, 2018, J NAT PROD, V81, P758, DOI 10.1021/acs.jnatprod.7b00737
   Olivon F, 2017, ACS CHEM BIOL, V12, P2644, DOI 10.1021/acschembio.7b00413
   Park HeeJuhn, 2000, Natural Product Sciences, V6, P86
   Parkinson J, 2004, NAT GENET, V36, P1259, DOI 10.1038/ng1472
   Partridge FA, 2008, DEV BIOL, V317, P549, DOI 10.1016/j.ydbio.2008.02.060
   Pena-Espinoza M, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-3012-4
   Pena-Espinoza M, 2017, VET PARASITOL, V243, P204, DOI 10.1016/j.vetpar.2017.07.008
   Pena-Espinoza M, 2016, PARASITOLOGY, V143, P1279, DOI 10.1017/S0031182016000706
   Pena-Espinoza M, 2015, INT J PARASITOL-DRUG, V5, P191, DOI 10.1016/j.ijpddr.2015.10.002
   Perry BD, 1999, VET PARASITOL, V84, P145, DOI 10.1016/S0304-4017(99)00040-0
   Pluskal T, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-395
   Ramasamy US, 2013, J AGR FOOD CHEM, V61, P6077, DOI 10.1021/jf401621h
   Rist CL, 2015, TRENDS PARASITOL, V31, P527, DOI 10.1016/j.pt.2015.09.005
   Robert C, 2008, FOOD CHEM, V108, P1008, DOI 10.1016/j.foodchem.2007.12.013
   Rodriguez R, 2019, SMALL RUMINANT RES, V170, P91, DOI 10.1016/j.smallrumres.2018.11.022
   Rumball W, 2003, NEW ZEAL J AGR RES, V46, P49, DOI 10.1080/00288233.2003.9513528
   Rush I., 1999, NEBRASKA BEEF CATTLE
   Salinas G, 2018, PARASITOLOGY, V145, P979, DOI 10.1017/S0031182017002165
   Sangster NC, 2018, TRENDS PARASITOL, V34, P553, DOI 10.1016/j.pt.2018.05.001
   Schmidt BM, 2007, FOOD CHEM TOXICOL, V45, P1131, DOI 10.1016/j.fct.2006.12.019
   SETO M, 1988, CHEM PHARM BULL, V36, P2423, DOI 10.1248/cpb.36.2423
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Simonsen H.T., 2013, NATURAL PRODUCTS, V5, P3069
   Spiegler V, 2015, MOLECULES, V20, P14810, DOI 10.3390/molecules200814810
   Stepek G, 2004, TRENDS PARASITOL, V20, P322, DOI 10.1016/j.pt.2004.05.003
   Stiernagle T., 1999, WORMBOOK, DOI [10.1895/wormbook.1.101.1, DOI 10.1895/WORMBOOK.1.101.1]
   Street RA, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/579319
   VANBEEK TA, 1990, J AGR FOOD CHEM, V38, P1035, DOI 10.1021/jf00094a026
   Waller PJ, 2004, TRENDS PARASITOL, V20, P493, DOI 10.1016/j.pt.2004.07.012
   Wang MX, 2016, NAT BIOTECHNOL, V34, P828, DOI 10.1038/nbt.3597
   Weeks JC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18457-w
   Williams AR, 2016, PARASITE, V23, DOI 10.1051/parasite/2016024
   Williams AR, 2016, PARASITOLOGY, V143, P770, DOI 10.1017/S0031182016000287
   Wink M, 2012, MOLECULES, V17, P12771, DOI 10.3390/molecules171112771
   Woodgate R.G., 2017, ANTIMICROBIAL DRUG R, P1305, DOI DOI 10.1007/978-3-319-47266-930
NR 59
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109088
DI 10.1016/j.vetpar.2020.109088
PG 11
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300001
PM 32278938
DA 2020-05-12
ER

PT J
AU Soman, SP
   Singh, SK
   Kumari, P
   Choudhury, S
   Singh, A
   Kanwal, S
   Khushboo, R
   Garg, SK
AF Soman, Sandeep P.
   Singh, Shanker K.
   Kumari, Priyambada
   Choudhury, Soumen
   Singh, Alok
   Kanwal, Sarita
   Khushboo, Richa
   Garg, Satish K.
TI Quantification of immuno-regulatory cytokine and toll-like receptors
   gene expression in dogs with generalized demodicosis
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Demodex; Interleukin-10; Interferon-gamma; Transforming growth
   factor-beta; Toll-like receptor
ID BLOOD MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; DEMODEX-CANIS; HEALTHY DOGS;
   TIME
AB The proliferation of Demodex mites is mainly controlled by host immunity; however, the precised mechanism of host-mite interplay and host immune response in the cutaneous microenvironment of dogs with generalized demodicosis (GD) are not yet established. In the present study, we envisaged the alterations in the expression of toll-like receptors (TLRs) and immuno-regulatory cytokine gene in the skin lesions and peripheral blood mononuclear cells (PBMCs) of dogs with GD. The expression of TLR2, TLR6, IFN-gamma, TGF-beta and IL-10 genes in the skin lesions and PBMCs of 15 dogs with GD was quantified by qRT-PCR. Compared to healthy dogs, significantly elevated expression of TLR2 (P = 0.048), TGF-beta (P = 0.04) and IL-10 (P = 0.012) were found in the PBMCs of dogs with GD. Conversely, there was significantly reduced expression of TLR6 gene (P = 0.021) in the PBMCs of these dogs. The infested dogs also revealed significantly elevated expression of TLR2 gene (P = 0.034) in the skin lesions, while, the expression of the TLR6 gene was found to be significantly (P = 0.004) reduced. Interestingly, significant alterations in TGF-beta (P = 0.105) and IL-10 (P = 0.162) genes expression were not observed in the skin lesions of diseased dogs. Our findings suggest that Demodex mites contribute to a different systemic and cutaneous immune response in dogs for their proliferation, and consequently the development of GD. Therefore, Demodex mites might be inducing the immunosuppression through activating the systemic overexpression of immunosuppressive cytokines; however, in the cutaneous lesions, the expression of immunosuppressive cytokines remained unaltered. Both systemic and local over-expression of TLR2 and reduced expression of TLR6 genes might be responsible for the inflammatory signs of canine demodicosis and helping to the mite to escape the host immunity.
C1 [Soman, Sandeep P.; Singh, Shanker K.; Singh, Alok; Kanwal, Sarita; Khushboo, Richa] UP Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vig, Dept Vet Med, Coll Vet Sci & Anim Husb, Mathura 281001, UP, India.
   [Kumari, Priyambada] UP Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vig, Coll Biotechnol, Mathura 281001, UP, India.
   [Choudhury, Soumen; Garg, Satish K.] UP Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vig, Dept Vet Pharmacol & Toxicol, Coll Vet Sci & Anim Husb, Mathura 281001, UP, India.
RP Singh, SK (reprint author), UP Pandit Deen Dayal Upadhyaya Pashu Chikitsa Vig, Dept Vet Med, Coll Vet Sci & Anim Husb, Mathura 281001, UP, India.
EM pshankervet@gmail.com
OI Singh, Shanker/0000-0002-0326-4226
FU Indian Council of Agricultural Research, New Delhi, IndiaIndian Council
   of Agricultural Research (ICAR); ICAR under outreach programme on
   Ethnoveterinary Medicine [1-72/(EVM-Outreach Programme)/2009/Med]
FX The financial assistance provided from the Indian Council of
   Agricultural Research, New Delhi, India under "Development Grant" to the
   University is thankfully acknowledged. The partial financial assistance
   from ICAR under outreach programme on Ethnoveterinary Medicine (Grant
   No. 1-72/(EVM-Outreach Programme)/2009/Med; Dated 05-02-2010) is also
   thankfully acknowledged.
CR Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
   Babu S, 2005, J IMMUNOL, V175, P1170, DOI 10.4049/jimmunol.175.2.1170
   Bardagi M, 2013, VET DERMATOL, V24, P377
   Caswell JL, 1997, VET PATHOL, V34, P279, DOI 10.1177/030098589703400403
   Cen-Cen C. J., 2018, Revista Ciencia y Agricultura, V15, P61
   Felix AOC, 2013, VET PARASITOL, V193, P312, DOI 10.1016/j.vetpar.2012.11.012
   Ferrer L, 2014, VET DERMATOL, V25, P427, DOI 10.1111/vde.12136
   Figueiredo MM, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-22
   Gasparetto ND, 2018, VET PARASITOL, V257, P1, DOI 10.1016/j.vetpar.2018.05.003
   Gazi U, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12673
   Hancock REW, 2012, NAT REV MICROBIOL, V10, P243, DOI 10.1038/nrmicro2745
   Hosein S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140325
   Koller B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016594
   Kumari P, 2018, PARASITE IMMUNOL, V40, DOI 10.1111/pim.12509
   Kumari P, 2017, PARASITOLOGY, V144, P1412, DOI 10.1017/S0031182017000774
   Lacey N, 2012, J INVEST DERMATOL, V132, pS116
   Larsson C.E., 2016, TRATADO MED EXTERNA, P853
   Miller LS, 2007, J INVEST DERMATOL, V127, P262, DOI 10.1038/sj.jid.5700559
   Miller W.H., 2013, MULLER KIRKS SMALL A, P284
   Montserrat-Sangra S, 2016, VET PARASITOL, V228, P172, DOI 10.1016/j.vetpar.2016.09.005
   Paterson TE, 2009, VET DERMATOL, V20, P447, DOI 10.1111/j.1365-3164.2009.00803.x
   Ravera I, 2015, RES VET SCI, V101, P161, DOI 10.1016/j.rvsc.2015.06.011
   Ravera I, 2013, VET DERMATOL, V24, P168, DOI 10.1111/j.1365-3164.2012.01099.x
   Richter KR, 2018, VET PATHOL, V55, P53, DOI 10.1177/0300985817725388
   Sanchez-Robert E, 2008, VET RES, V39, DOI 10.1051/vetres:2008013
   Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142
   Schmid-Hempel P, 2009, PHILOS T R SOC B, V364, P85, DOI 10.1098/rstb.2008.0157
   Scott D.W., 2001, SMALL ANIMAL DERMATO, P457
   Singh A, 2019, VET PARASITOL, V275, DOI 10.1016/j.vetpar.2019.108954
   Singh SK, 2010, PARASITOLOGY, V137, P1921, DOI 10.1017/S0031182010000879
   Singh SK, 2019, EXP APPL ACAROL, V79, P387, DOI 10.1007/s10493-019-00444-7
   Singh SK, 2014, VET PARASITOL, V206, P253, DOI 10.1016/j.vetpar.2014.10.024
   Singh SK, 2014, VET PARASITOL, V203, P1, DOI 10.1016/j.vetpar.2014.03.008
   Singh SK, 2011, VET IMMUNOL IMMUNOP, V144, P487, DOI 10.1016/j.vetimm.2011.08.008
   Souza CP, 2018, VET DERMATOL, V29, P482, DOI 10.1111/vde.12681
   Takeda Kiyoshi, 2015, Curr Protoc Immunol, V109, DOI 10.1002/0471142735.im1412s109
   Tani K, 2002, J VET MED SCI, V64, P513, DOI 10.1292/jvms.64.513
   Testro AG, 2009, J GASTROEN HEPATOL, V24, P943, DOI 10.1111/j.1440-1746.2009.05854.x
   Turchetti AP, 2015, VET IMMUNOL IMMUNOP, V163, P67, DOI 10.1016/j.vetimm.2014.11.010
   Yamasaki K, 2011, J INVEST DERMATOL, V131, P688, DOI 10.1038/jid.2010.351
   Yarim GF, 2013, REV MED VET-TOULOUSE, V164, P13
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109063
DI 10.1016/j.vetpar.2020.109063
PG 5
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300010
PM 32151890
DA 2020-05-12
ER

PT J
AU Szell, Z
   Bacsadi, A
   Szeredi, L
   Nemes, C
   Fezer, B
   Bakcsa, E
   Kalla, H
   Tolnai, Z
   Sreter, T
AF Szell, Zoltan
   Bacsadi, Arpad
   Szeredi, Levente
   Nemes, Csaba
   Fezer, Brigitta
   Bakcsa, Erika
   Kalla, Hedi
   Tolnai, Zoltan
   Sreter, Tamas
TI Rapid spread and emergence of heartworm resulting from climate and
   climate-driven ecological changes in Hungary
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Heartworm; Dirofilaria immitis; Dog; Golden jackal; Spread; Emergence;
   Climate change; Global warming; Hungary
ID GOLDEN JACKALS; CANIS AUREUS; DIROFILARIA; DISEASE
AB In Europe, Dirofilaria immitis persists mainly in the southern countries with a Mediterranean climate. Because spreading of heartworms from these countries towards the northern ones could be observed in the past decades, necropsy records of 4076 Hungarian dogs were reviewed for heartworm infections. The first autochthonous canine D. immitis case was detected on the Great Hungarian Plain in 2007. Until 2011, the number of heartworm infection cases was low, and these cases were restricted to a small part of the Great Hungarian Plain. Since 2012, the number of cases has increased considerably, and the rapid expansion of the parasites geographic range could also be observed. Our retrospective study has revealed that most of the Hungarian territory became a heartworm endemic region, and the prevalence of infection greatly multiplied over the past 12 years. The establishment, rapid spread, and emergence of D. immitis may be mainly explained by the warming climate in Hungary. However, the partly climate-driven spread of the most important reservoir host in wildlife, the golden jackal (Canis aureus) from the Mediterranean Balkan Peninsula might have also played a significant role. This study is an example of the rapid spread and emergence of pathogens resulting from climate and climate-driven ecological changes. Because a continuous increase in the temperature and further dispersal of golden jackals in Europe are projected, further spread and emergence of heartworm can be expected. Similar spread and emergence of D. immitis could be observed in North America. It cannot be excluded that similar reasons (global warming and rapid dispersal and population growth of the most important wild canine reservoir host) are in the background on both continents.
C1 [Szell, Zoltan; Tolnai, Zoltan; Sreter, Tamas] Natl Food Chain Safety Off, Natl Reference Lab Parasites Fish & Bee Dis, Directorate Food Chain Safety Labs, Mester Utca 81, H-1095 Budapest, Hungary.
   [Bacsadi, Arpad; Szeredi, Levente; Nemes, Csaba; Fezer, Brigitta; Bakcsa, Erika; Kalla, Hedi] Natl Food Chain Safety Off, Directorate Vet Diagnost, Cent & Reg Labs Pathol, Tabornok Utca 2, H-1143 Budapest, Hungary.
RP Sreter, T (reprint author), Natl Food Chain Safety Off, Natl Reference Lab Parasites Fish & Bee Dis, Directorate Food Chain Safety Labs, Mester Utca 81, H-1095 Budapest, Hungary.
EM sretert@nebih.gov.hu
CR [Anonymous], 2019, NATL GAME MANAGEMENT
   Kiss Bela, 2015, Magy Seb, V68, P209, DOI 10.1556/1046.68.2015.5.4
   Drake J, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2631-0
   Genchi C., 2007, DIROFILARIA IMMITIS
   Genchi C., 2020, VET PARASITOL
   Genchi C, 2011, VET PARASITOL, V176, P295, DOI 10.1016/j.vetpar.2011.01.012
   Genchi C, 2009, VET PARASITOL, V163, P286, DOI 10.1016/j.vetpar.2009.03.026
   Gherman CM, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2329-8
   Hody JW, 2018, ZOOKEYS, P81, DOI 10.3897/zookeys.759.15149
   Hungarian Meteorological Service, 2019, CLIM HUNG
   Ionica AM, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1524-3
   McCall JW, 2008, ADV PARASIT, V66, P193, DOI 10.1016/S0065-308X(08)00204-2
   Miller DL, 2009, J WILDLIFE DIS, V45, P863, DOI 10.7589/0090-3558-45.3.863
   Miterpakova M, 2018, PARASITOL RES, V117, P2347, DOI 10.1007/s00436-018-5912-9
   Morchon R, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00196
   Otranto D, 2013, PARASITE VECTOR, V6, DOI 10.1186/1756-3305-6-16
   QGIS Development Team, 2015, QGIS GEOGR INF SYST
   Sergenat E.S.G., 2019, EPITOOLS EPIDEMIOLOG
   Simon F, 2012, CLIN MICROBIOL REV, V25, P507, DOI 10.1128/CMR.00012-12
   Szabo L, 2009, MAMMALIA, V73, P307, DOI 10.1515/MAMM.2009.048
   Szell Z, 2013, VET PARASITOL, V197, P393, DOI 10.1016/j.vetpar.2013.04.032
   Tolnai Z, 2014, VET PARASITOL, V203, P339, DOI 10.1016/j.vetpar.2014.04.004
   Toth T, 2009, NORTH-WEST J ZOOL, V5, P386
   US Global Change Research Program, 2019, US SURF TEMP
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109067
DI 10.1016/j.vetpar.2020.109067
PG 4
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300011
PM 32145530
DA 2020-05-12
ER

PT J
AU Wang, D
   Gong, QL
   Huang, HB
   Yang, WT
   Shi, CW
   Jiang, YL
   Wang, JZ
   Kang, YH
   Zhao, Q
   Yang, GL
   Wang, CF
AF Wang, Dan
   Gong, Qing-Long
   Huang, Hai-Bin
   Yang, Wen-Tao
   Shi, Chun-Wei
   Jiang, Yan-Long
   Wang, Jian-Zhong
   Kang, Yuan-Huan
   Zhao, Quan
   Yang, Gui-Lian
   Wang, Chun-Feng
TI Protection against Trichinella spiralis in BALB/c mice via oral
   administration of recombinant Lactobacillus plantarum expressing murine
   interleukin-4
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Recombinant Lactobacillus plantarum; Trichinella spiralis; Interleukin-4
ID AVIAN INFLUENZA-VIRUS; RESPONSES; IL-4; INFECTION; IDENTIFICATION;
   MICROBIOTA; CHALLENGE; BACTERIA; IMMUNITY; ANTIGEN
AB Interleukin-4 (IL-4), an immunomodulatory cytokine derived from activated T lymphocytes were shown to regulate Th2-type immune responses. It plays an important role in anti-parasitic infections. In this study, a recombinant plasmid was designed using murine IL-4 co-expressed with pgsA anchor system of Lactobacillus plantarum NC8 and was delivered by live Lactobacillus plantarum NC8, which exhibited an enhanced immunogenicity in protection of BALB/c mice from infection with Trichinella spiralis. The results showed that the levels of serum IgG1 and mucosal secretory IgA (sIgA) were both increased significantly in mice orally inoculated with NC8-pSIP409-pgsA-mIL-4, and the Th2 phenotype immune response was up-regulated. A 29.9 % reduction in adult worm burden at 7 days post-infection (dpi) and 83.3 % reduction in muscle larvae burden at 28 dpi were observed in immune-stimulated mice with NC8-pSIP409-pgsA-mIL-4. Moreover, weight loss and pathological changes were also improved in mice of NC8-pSIP409-pgsA-mIL-4 group. Taken together, it suggests that NC8pSIP409-pgsA-mIL-4 could improve the intestinal mucosal immunity and promoted the elimination of the adult worm in Trichinella-infected mice. This study laid the foundation for the development of a novel vaccines against Trichinellosis.
C1 [Wang, Dan; Gong, Qing-Long; Huang, Hai-Bin; Yang, Wen-Tao; Shi, Chun-Wei; Jiang, Yan-Long; Wang, Jian-Zhong; Kang, Yuan-Huan; Zhao, Quan; Yang, Gui-Lian; Wang, Chun-Feng] Jilin Agr Univ, Coll Anim Sci & Technol, Jilin Prov Engn Res Ctr Anim Probiot, Key Lab Anim Prod & Prod Qual Safety,Minist Educ, 2888 Xincheng St, Changchun 130118, Jilin, Peoples R China.
RP Yang, GL; Wang, CF (reprint author), Jilin Agr Univ, Coll Anim Sci & Technol, Jilin Prov Engn Res Ctr Anim Probiot, Key Lab Anim Prod & Prod Qual Safety,Minist Educ, 2888 Xincheng St, Changchun 130118, Jilin, Peoples R China.
EM yangguilian@jlau.edu.cn; wangchunfeng@jlau.edu.cn
FU National Key Research and Development Program of China [2017YFD0501200,
   2017YFD0500400, 2017YFD0501000]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China [31672528, 31602092];
   Science and Technology Development Program of Jilin Province
   [20180201040NY, 20190301042NY]
FX This work was supported by the National Key Research and Development
   Program of China (2017YFD0501200, 2017YFD0500400, 2017YFD0501000), the
   National Natural Science Foundation of China (31672528, 31602092) and
   Science and Technology Development Program of Jilin Province
   (20180201040NY, 20190301042NY).
CR AndradeBecerra J.I., 2017, VACCINATION TRICHINE, P219
   Cai RP, 2016, J MICROBIOL BIOTECHN, V26, P421, DOI 10.4014/jmb.1509.09030
   CHALLACOMBE SJ, 1992, IMMUNOLOGY, V76, P164
   Cvetkovic J, 2016, INT J PARASITOL, V46, P833, DOI 10.1016/j.ijpara.2016.07.008
   Duerkop BA, 2009, IMMUNITY, V31, P368, DOI 10.1016/j.immuni.2009.08.009
   Dvoroznakova E, 2016, VET PARASITOL, V231, P69, DOI 10.1016/j.vetpar.2016.07.004
   El Temsahy MM, 2015, VET PARASITOL, V214, P303, DOI 10.1016/j.vetpar.2015.08.029
   Gao XW, 2019, VIRULENCE, V10, P166, DOI 10.1080/21505594.2019.1582975
   Gareau MG, 2010, NAT REV GASTRO HEPAT, V7, P503, DOI 10.1038/nrgastro.2010.117
   Gu Y, 2014, BIOMED RES INT, DOI 10.1155/2014/326860
   Ilic N, 2012, IMMUNOL RES, V52, P111, DOI 10.1007/s12026-012-8287-5
   Inaba T, 2003, J VET MED SCI, V65, P1227, DOI 10.1292/jvms.65.1227
   Kechaou N, 2013, APPL ENVIRON MICROB, V79, P1491, DOI 10.1128/AEM.03075-12
   KING IL, 2009, CYTOKINE, V206, P1001, DOI DOI 10.1084/JEM.20090313
   Kolandaswamy A, 2009, CURR MICROBIOL, V58, P117, DOI 10.1007/s00284-008-9286-6
   Li ZJ, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0380-7
   Long SR, 2014, PARASITE VECTOR, V7, DOI 10.1186/s13071-014-0600-9
   Ma Y, 2013, HUM VACC IMMUNOTHER, V9, P242, DOI 10.4161/hv.22888
   Macpherson AJ, 2007, CURR OPIN GASTROEN, V23, P673, DOI 10.1097/MOG.0b013e3282f0d012
   Martinez-Gomez F, 2011, PARASITOL RES, V109, P1609, DOI 10.1007/s00436-011-2432-2
   Melief C.J.M., 1988, B LYMPHOCYTE ACTIVAT
   Min B, 2004, J EXP MED, V200, P507, DOI 10.1084/jem.20040590
   Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013
   Organization A., 2014, MULT BAS RANK RISK M
   Qi Xin, 2018, VET RES, V49, P2
   Randazzo V., 2010, REV IBERO LATINOAMER
   Randazzo Viviano, 2005, Revista de Patologia Tropical, V34, P129
   Romaris F, 2002, MOL BIOCHEM PARASIT, V122, P149, DOI 10.1016/S0166-6851(02)00094-4
   Rostami A, 2017, FOOD MICROBIOL, V64, P65, DOI 10.1016/j.fm.2016.12.012
   Scales HE, 2007, PARASITE IMMUNOL, V29, P81, DOI 10.1111/j.1365-3024.2006.00920.x
   Sharma N, 2015, VET WORLD, V8, P590, DOI 10.14202/vetworld.2015.590-598
   Shi SH, 2016, VIRUS RES, V211, P46, DOI 10.1016/j.virusres.2015.09.005
   Soliman Gamal A., 2011, Turkiye Parazitoloji Dergisi, V35, P86, DOI 10.5152/tpd.2011.22
   Stager S, 2003, INFECT IMMUN, V71, P4804, DOI 10.1128/IAI.71.8.4804-4807.2003
   Thi NV, 2010, VET PARASITOL, V168, P136, DOI 10.1016/j.vetpar.2009.10.024
   Travers Marie-Agnes, 2011, J Parasitol Res, V2011, P610769, DOI 10.1155/2011/610769
   Vinusha K Sri, 2018, Biochem Biophys Rep, V14, P140, DOI 10.1016/j.bbrep.2018.04.009
   Voehringer D., 2016, TH2 TYPE IMMUNE RESP, P1
   Wang ZQ, 2006, VACCINE, V24, P1205, DOI 10.1016/j.vaccine.2005.08.104
   Wyszynska A, 2015, APPL MICROBIOL BIOT, V99, P2967, DOI [10.1007/s00253-015-6498-0, 10.1007/s00253-015-6569-2]
   Yang WT, 2017, APPL MICROBIOL BIOT, V101, P8475, DOI 10.1007/s00253-017-8600-2
   Yang WT, 2017, APPL MICROBIOL BIOT, V101, P4593, DOI 10.1007/s00253-017-8230-8
   Zhu JF, 2002, IMMUNITY, V16, P733, DOI 10.1016/S1074-7613(02)00317-5
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109068
DI 10.1016/j.vetpar.2020.109068
PG 9
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300009
PM 32278937
DA 2020-05-12
ER

PT J
AU Jaramillo, EY
   Nunez, CR
   Zavala, MDA
   Lopez, EC
   Diaz, JR
   Contreras, LM
   Franco, EG
   Cardenas, RH
AF Yarto Jaramillo, Enrique
   Romero Nunez, Camilo
   Alvarez Zavala, Maria de los A.
   Cruz Lopez, Eduardo
   Rangel Diaz, Josue
   Miranda Contreras, Laura
   Galicia Franco, Evelyn
   Heredia Cardenas, Rafael
TI Use of afoxolaner for the treatment of lice (Goniodes pavonis) in
   different genera (Chrysolophus spp, Lophura spp, Phasianus spp, and
   Syrmaticus spp) and species of pheasants and West Mexican Chachalacas
   (Ortalis poliocephala)
SO VETERINARY PARASITOLOGY
LA English
DT Article
DE Isoxazoline; zoo birds; ectoparasites; infestation
ID POULTRY
AB Lice are ectoparasites capable of affecting birds, and can result in direct and indirect damage to their host. Afoxolaner is an isoxazoline that has been shown to be effective against these ectoparasites without known adverse effects. The objective of this research was to evaluate the effect of afoxolaner on lice in pheasants and plain chachalacas. A total of 29 pheasants of different genera and species (Chrysolophus pictus, C. amherstiae, Lophura swinghoii, L. nycthemera, Phasianus colchicus, and Syrmaticus reevesii) and 18 West Mexican Chachalacas (Ortalis poliocephala) naturally infested with Goniodes pavonis were used. The birds were allocated to one of two groups: group 1 treated with 2.50 mg/kg of afoxolaner, and group 2 given no treatment. Ectoparasites were collected using the adhesive tape technique and identified. Afoxolaner was administered later as a single dose to group 1, and the clinical assessment to detect ectoparasites was repeated 28 days post-treatment. On day 28 post-treatment, group 1 was found to be negative for the presence of lice. The body weights were compared at the beginning and end of the clinical assessment in both groups and a significant difference in weight of treated birds was found. The mean body weight decreased by 0.017 g in control group, whereas it increased by 0.016 g in treated group. Oral administration of afoxolaner is an effective option for the treatment of Goniodes pavonis infestations in zoo birds.
C1 [Yarto Jaramillo, Enrique] Ctr Vet Mexico, Calle Cincinnati 22, Ciudad De Mexico 03710, Mexico.
   [Romero Nunez, Camilo; Miranda Contreras, Laura; Galicia Franco, Evelyn; Heredia Cardenas, Rafael] Hosp Vet Espacio Anim, Mz 187,Lt 33, Ciudad De Mexico, Mexico.
   [Alvarez Zavala, Maria de los A.; Cruz Lopez, Eduardo; Rangel Diaz, Josue] Parque Zool Benito Juarez Morelia, Morelia 58070, Michoacan, Mexico.
RP Nunez, CR (reprint author), Hosp Vet Espacio Anim, Mz 187,Lt 33, Ciudad De Mexico, Mexico.
EM mvzcamilo@yahoo.com.mx
OI Heredia, Rafael/0000-0002-6127-3825
CR Ashraf S, 2015, J ANIM PLANT SCI, V25, P359
   Barretto M.L.M., 2017, MED VET UFRPE, V11, P185
   Brauneis MD, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2534-5
   Goldova Maria, 2006, Veterinarski Arhiv, V76, pS83
   Gonzalez-Acuna D, 2009, ARCH MED VET, V41, P181, DOI 10.4067/S0301-732X2009000200013
   Hendrix C.M., 2017, DIAGNOSTIC PARASITOL
   Hinkle NC, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2678-y
   Kohler-Aanesen H, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2344-9
   Marangi M, 2009, EXP APPL ACAROL, V48, P11, DOI 10.1007/s10493-008-9224-0
   Millan Javier, 2004, Parasitol Res, V93, P79, DOI 10.1007/s00436-004-1113-9
   Rushton J, 1998, WORLD ANIM REV, P43
   Salifou S, 2013, REV BRAS PARASITOL V, V22, P119, DOI 10.1590/S1984-29612013000100022
   Sanchez-Montes S, 2018, ZOOTAXA, V4372, P1, DOI 10.11646/zootaxa.4372.1.1
   Sojka PA, 2018, J EXOT PET MED, V27, P118, DOI 10.1053/j.jepm.2018.02.038
   Tantalean M., 2010, MANUAL DIAGNOSTICO P
   Taylor M.A., 2016, VET PARASITOL, P207
   Wall R., 2001, VET ECTOPARASITES BI, P123
   Jaramillo EY, 2019, VET DERMATOL, V30, P167, DOI 10.1111/vde.12713
   Zweifel RG, 2003, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2003)415<0001:SOMFGO>2.0.CO;2
NR 19
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD APR
PY 2020
VL 280
AR UNSP 109065
DI 10.1016/j.vetpar.2020.109065
PG 3
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA LF0GD
UT WOS:000527104300014
PM 32203695
DA 2020-05-12
ER

PT J
AU Ruscio, B
   Bolster, A
   Bresee, J
   Abelin, A
   Boutet, P
   Christiansen, H
   Etholm, P
   Desai, S
   Gellin, B
   Golding, J
   Jit, M
   Kerr, L
   McKinlay, M
   Kluglein, S
   Lobos, F
   Mathewson, S
   Mazur, M
   Pagliusi, S
   Penttinen, P
   Richardson, D
   Alvarez, AMR
   Scovitch, JR
   Seedorff, JE
   Shaxson, L
   Tam, JS
   Taylor, B
   Wairagkar, N
   Watson, J
   Xeuatvongsa, A
AF Ruscio, Bruce
   Bolster, Amanda
   Bresee, Joseph
   Abelin, Atika
   Boutet, Philippe
   Christiansen, Hans
   Etholm, Per
   Desai, Samir
   Gellin, Bruce
   Golding, Josephine
   Jit, Mark
   Kerr, Lawrence
   McKinlay, Mark
   Kluglein, Samantha
   Lobos, Fernando
   Mathewson, Sophie
   Mazur, Marie
   Pagliusi, Sonia
   Penttinen, Pasi
   Richardson, Dominique
   Alvarez, Alba Maria Ropero
   Scovitch, Joseph R.
   Seedorff, Jennifer E.
   Shaxson, Louise
   Tam, John S.
   Taylor, Beverly
   Wairagkar, Niteen
   Watson, John
   Xeuatvongsa, Anonh
CA London Shaping Meeting Participant
TI Shaping meeting to explore the value of a coordinated work plan for
   epidemic and pandemic influenza vaccine preparedness
SO VACCINE
LA English
DT Article
DE Immunization; Influenza vaccine; Pandemic influenza; Seasonal influenza;
   Health security; Pandemic preparedness; Policy
ID DOSE DISTRIBUTION; MORTALITY; PROGRESS
AB In March 2019, a group of global health leaders with expertise in influenza, vaccinology and pandemic preparedness was convened for a meeting titled "Shaping Meeting to explore the value of a coordinated work plan for epidemic and pandemic influenza vaccine preparedness." Influenza epidemics occur annually in every country in the world, resulting in significant global burden of illness and deaths. While every country is effected, most deaths and severe disease occur in low- and lower middle-income countries (LIC and LMIC). Influenza immunization programs that limit the burden of disease, deaths, and reduce economic impact are a fundamental public health intervention for seasonal epidemics. In addition, they provide the experience, systems and infrastructure for the timely and efficient use of vaccines and other medical countermeasures critical for effective pandemic responses. Pandemic influenza response activities, including vaccination efforts, will be most effective if used and practiced regularly. Consequently, countries with seasonal influenza prevention and control programs should be better prepared for, and have more effective pandemic responses than countries without such programs. A decade after the 2009 pandemic, despite ongoing prevention efforts, most LICs and LMICs still lack access to robust seasonal influenza immunization programs. Given this current state, meeting participants concluded that there is critical need to advance the expansion and strengthening of seasonal influenza immunization programs in LICs and LMICs not only to reduce the economic and public health effects of annual influenza epidemics, but also to increase preparedness to mitigate the threat of future pandemics and improve global heath security. Many government and private sectors, in a whole of government approach, need to be working together to support and advance countries' epidemic and pandemic influenza capacities preparedness objectives. Accomplishment of these objectives can be achieved with a coordinated work plan developed and guided by an alliance of international stakeholders, to include, among others, government, and nongovernment organization representation, civil society representatives, vaccine manufacturers, international organizations, and health security and influenza experts.
C1 [Ruscio, Bruce] Publ Hlth Consultant, Charlotte, NC 28105 USA.
   [Bolster, Amanda; McKinlay, Mark; Kluglein, Samantha; Richardson, Dominique] Task Force Global Hlth Inc, Decatur, GA USA.
   [Bresee, Joseph] Ctr Dis Control & Prevent, Atlanta, GA USA.
   [Abelin, Atika] Sanofi Pasteur, Lyon, France.
   [Boutet, Philippe] GSK, Wavre, Belgium.
   [Christiansen, Hans] UNICEF, Copenhagen, Denmark.
   [Etholm, Per] Coalit Epidem Preparedness Innovat, Oslo, Norway.
   [Desai, Samir] Cadila Healthcare Ltd Zydus Cadila, BU Biol, Ahmadabad, Gujarat, India.
   [Gellin, Bruce] Sabin Vaccine Inst, Washington, DC USA.
   [Golding, Josephine] Wellcome, London, England.
   [Jit, Mark] London Sch Hyg & Trop Med, London, England.
   [Jit, Mark; Watson, John] Publ Hlth England, London, England.
   [Jit, Mark] Univ Hong Kong, Hong Kong, Peoples R China.
   [Kerr, Lawrence] Hlth & Human Serv, Washington, DC USA.
   [Lobos, Fernando] Sinergium Biotech SA, Garin, Argentina.
   [Mathewson, Sophie] Gavi, Geneva, Switzerland.
   [Mazur, Marie] Seqirus, Summit, NJ USA.
   [Pagliusi, Sonia] Developing Countries Vaccine Manufacturers Networ, Nyon, Switzerland.
   [Penttinen, Pasi] European Ctr Dis Prevent & Control ECDC, London, England.
   [Alvarez, Alba Maria Ropero] WHO, Pan Amer Hlth Org, Geneva, Switzerland.
   [Scovitch, Joseph R.; Seedorff, Jennifer E.] US Dept State, Washington, DC 20520 USA.
   [Shaxson, Louise] ODI, London, England.
   [Tam, John S.] Hong Kong Polytech Univ, Hong Kong, Peoples R China.
   [Taylor, Beverly] Seqirus Vaccines, Liverpool, Merseyside, England.
   [Wairagkar, Niteen] Vaccines All, Pune, Maharashtra, India.
   [Xeuatvongsa, Anonh] Minist Hlth, Natl Immunizat Program, Viangchan, Laos.
RP Ruscio, B (reprint author), Publ Hlth Consultant, Charlotte, NC 28105 USA.
EM brucearuscio@gmail.com
OI ruscio, bruce/0000-0003-4074-762X
FU World Health OrganizationWorld Health Organization [001]
CR 56th World Health Assembly, 2003, PREV CONTR INFL PAND
   Black S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001738
   Bresee J, 2018, EMERG INFECT DIS, V24, P1173, DOI 10.3201/eid2407.171270
   Burgess DC, 2006, VACCINE, V24, P3921, DOI 10.1016/j.vaccine.2006.02.033
   Centers for Disease Control and Prevention, 2004, ACIP JUN 20 2018
   Cooper LZ, 2008, PEDIATRICS, V122, P149, DOI 10.1542/peds.2008-0987
   de Francisco N, 2015, VACCINE, V33, P6537, DOI 10.1016/j.vaccine.2015.10.066
   Fan VY, 2016, 22137 NAT BUR EC RES
   Gates B, 2018, NEW ENGL J MED, V378, P2057, DOI 10.1056/NEJMp1806283
   Hirve S, 2016, INFLUENZA OTHER RESP
   Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2
   Lafond KE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001977
   McLean KA, 2016, VACCINE, V34, P5410, DOI 10.1016/j.vaccine.2016.08.019
   Murray CJL, 2006, LANCET, V368, P2211, DOI 10.1016/S0140-6736(06)69895-4
   Ortiz JR, 2016, VACCINE, V34, P5400, DOI 10.1016/j.vaccine.2016.07.045
   Palache A, 2015, VACCINE, V33, P5598, DOI 10.1016/j.vaccine.2015.08.082
   Palache A, 2014, VACCINE, V32, P6369, DOI 10.1016/j.vaccine.2014.07.012
   Peasah SK, 2013, VACCINE, V31, P5339, DOI 10.1016/j.vaccine.2013.09.013
   Richard Mihigo, 2009, J INFECT DIS S1, V206, pS22, DOI [10.1093/infdis/jis535, DOI 10.1093/INFDIS/JIS535]
   Rolfes M, ESTIMATED INFLUENZA
   Ropero-Alvarez AM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-361
   Taubenberger JK, 2006, EMERG INFECT DIS, V12, P15, DOI 10.3201/eid1209.05-0979
   WHO, 2017, EV INFL VACC EFF GUI
   WHO, 2016, WORLD MALARIA REPORT, P1, DOI DOI 10.1017/CBO9781107415324.004
   WHO, 2019, GLOB INFL STRAT 2019
   World Bank, 2017, PAN NEGL INV HLTH SE
   World Health, 2012, WKLY EPIDEMIOL REC, V87, P201
   World Health Organization, 2016, WHO GUID EC EV INFL
   World Health Organization, 2006, GLOB VACC ACT PLAN I
   World Health Organization, 2011, PAND INFL PREP FRAM
   World Health Organization, 2005, RESP AV INFL PAND TH
   World Health Organization, 2016, REP 3 WHO CONS GLOB
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3179
EP 3183
DI 10.1016/j.vaccine.2020.02.038
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600001
PM 32171576
DA 2020-05-12
ER

PT J
AU Cho, HK
   Kang, YM
   Kim, HM
   Lee, CH
   Kim, DY
   Choi, SH
   Lee, MH
   Kang, HM
AF Cho, Hyun-Kyu
   Kang, Yong-Myung
   Kim, Hyun-Mi
   Lee, Chi-Ho
   Kim, Do-Young
   Choi, Sang-Hyun
   Lee, Myoung-Heon
   Kang, Hyun-Mi
TI Sales and immunogenicity of commercial vaccines to H9N2 low pathogenic
   avian influenza virus in Korea from 2007 to 2017
SO VACCINE
LA English
DT Article
DE Vaccine; Avian influenza; H9N2; Korea; Chicken
ID EVOLUTION
AB The present study was conducted to monitor sales activity and immunogenicity of commercial H9N2 vaccines produced in Korea from 2007 to 2017. Recorded sales of H9N2 vaccine were around 671 million doses, with 10 million doses sold in 2007, rising to a peak of 93 million doses in 2016, with a slight fall in 2017. Multivalent combined vaccines made up around 90% of all vaccine sales, and around 30% of all vaccines were distributed by regional governments for free. The regional vaccination rate was the highest in Gyeonggi and Chungnam, respectively with proportional to the population of layer and breeder chickens. There have been no cases of field infection since 2009. The mean antibody titer was 5.82 log2 across the study period. Our results suggest that continuous genetic monitoring of H9N2 viruses circulating in the field and updating the vaccine seed strain periodically are necessary in order to control H9N2 outbreaks. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Cho, Hyun-Kyu; Kang, Yong-Myung; Kim, Hyun-Mi; Lee, Chi-Ho; Kim, Do-Young; Choi, Sang-Hyun; Lee, Myoung-Heon; Kang, Hyun-Mi] Anim & Plant Quarantine Agcy, Avian Influenza Res & Diagnost Div, 177 Hyeoksin 8 Ro, Gimcheon Si 39660, Gyeongsangbuk D, South Korea.
   [Cho, Hyun-Kyu] Seoul Natl Univ, Coll Vet Med, 1 Gwanak Ro, Seoul 08826, South Korea.
RP Kang, HM (reprint author), Anim & Plant Quarantine Agcy, Avian Influenza Res & Diagnost Div, 177 Hyeoksin 8 Ro, Gimcheon Si 39660, Gyeongsangbuk D, South Korea.
EM greenkang@korea.kr
FU Ministry of Agriculture, Food and Rural Affairs, Republic of Korea
   [M-1543418-2019-20-01]
FX This work was supported by a grant from (APQA), [No.
   M-1543418-2019-20-01]; Ministry of Agriculture, Food and Rural Affairs,
   Republic of Korea.
CR ADA GL, 1986, CURR TOP MICROBIOL, V128, P1
   Alexander DJ, 2007, VACCINE, V25, P5637, DOI 10.1016/j.vaccine.2006.10.051
   Bouma A, 2008, REV SCI TECH OIE, V27, P633, DOI 10.20506/rst.27.3.1823
   Choi JG, 2008, J VET SCI, V9, P67, DOI 10.4142/jvs.2008.9.1.67
   Choi YK, 2005, VIROLOGY, V332, P529, DOI 10.1016/j.virol.2004.12.002
   COUCH RB, 1983, ANNU REV MICROBIOL, V37, P529, DOI 10.1146/annurev.mi.37.100183.002525
   Ducatez MF, 2008, VACCINE, V26, pD67, DOI 10.1016/j.vaccine.2008.07.064
   Ge FF, 2016, ARCH VIROL, V161, P1437, DOI 10.1007/s00705-016-2767-1
   Gharaibeh S, 2015, AVIAN DIS, V59, P508, DOI 10.1637/11123-050615-Reg
   Kim HR, 2010, J GEN VIROL, V91, P1978, DOI 10.1099/vir.0.021238-0
   Korean Statistical Information Service, 2019, NUMB CHICK CHICK FAR
   Lee DH, 2016, VIROLOGY, V488, P225, DOI 10.1016/j.virol.2015.11.023
   Lee DH, 2013, CLIN EXP VACCINE RES, V2, P26, DOI 10.7774/cevr.2013.2.1.26
   Park KJ, 2011, J GEN VIROL, V92, P36, DOI 10.1099/vir.0.024992-0
   Song JM, 2008, VET MICROBIOL, V130, P268, DOI 10.1016/j.vetmic.2008.02.005
   World Organisation for Animal Health, 2019, MANUAL DIAGNOSTIC TE
   Zhang PH, 2008, J GEN VIROL, V89, P3102, DOI 10.1099/vir.0.2008/005652-0
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3191
EP 3195
DI 10.1016/j.vaccine.2020.02.083
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600004
PM 32169392
DA 2020-05-12
ER

PT J
AU Jogi, P
   Soeorg, H
   Oona, M
   Kaart, T
   Toompere, K
   Maskina, T
   Koort, I
   Ratsep, A
   Lutsar, I
AF Jogi, Piia
   Soeorg, Hiie
   Oona, Marje
   Kaart, Tanel
   Toompere, Karolin
   Maskina, Tereza
   Koort, Iris
   Ratsep, Anneli
   Lutsar, Irja
CA Pertussis Study Grp Estonia
TI Dynamics of pertussis toxin IgG after symptomatic pertussis in children
   and adults
SO VACCINE
LA English
DT Article
DE Pertussis toxin; PT-IgG; Biexponential model; Power function decay model
ID INFECTION; ANTIBODIES; AGE
AB Background and aim: The knowledge of dynamics of pertussis toxin (PT)-IgG after pertussis and the appropriate diagnostic cut-off value is limited. We aimed to describe the dynamics of PT-IgG in children and adults up to three years after symptomatic pertussis.
   Methods: Patients with persistent cough of unknown aetiology were prospectively enrolled 2012-2014. Pertussis was confirmed by culture, PCR and/or serology. The follow-up samples were taken 4-6 weeks, 1, 2 and 3 years after enrolment. PT-IgG kinetics was described by biexponential model.
   Results: Pertussis was diagnosed in 22 patients [median (IQR) age 17.7 (8.4-38.6) years]. Adults compared with children had higher peak of the PT-IgG 397 (IQR 374-518) vs 292 (200-363), p = 0.007, longer time to reach peak PT-IgG 16.4 (IQR 15.6-16.8) days vs 13.3 (13.2-13.4) days, p=<0.001 and shorter PT-IgG half-life 24 days (IQR 20-40) and 364 days (IQR 359-486) p < 0.001.
   Conclusion: After symptomatic pertussis, adults and children have different dynamics of PT-IgG. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Jogi, Piia] Tartu Univ Hosp, Childrens Clin, Lunini 6, EE-50406 Tartu, Estonia.
   [Jogi, Piia] Univ Tartu, Dept Pediat, Tartu, Estonia.
   [Soeorg, Hiie; Lutsar, Irja] Univ Tartu, Dept Microbiol, Tartu, Estonia.
   [Oona, Marje; Ratsep, Anneli] Univ Tartu, Dept Family Med, Tartu, Estonia.
   [Kaart, Tanel] Estonian Univ Life Sci, Inst Vet Med & Anim Sci, Tartu, Estonia.
   [Toompere, Karolin] Univ Tartu, Dept Publ Hlth, Tartu, Estonia.
   [Maskina, Tereza] Family Doctor Ctr Tereza Maskina FIE, Paide, Estonia.
   [Koort, Iris] Merekivi Family Doctor Ctr, Tallinn, Estonia.
RP Jogi, P (reprint author), Tartu Univ Hosp, Childrens Clin, Lunini 6, EE-50406 Tartu, Estonia.
EM Piia.Jogi@kliinikum.ee
FU Estonian Science Foundation [9259]
FX This work was supported by the Estonian Science Foundation under Grant
   [number 9259].
CR Barkoff AM, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv050
   de Graaf WF, 2014, EPIDEMICS-NETH, V9, P1, DOI 10.1016/j.epidem.2014.08.002
   Guiso N, 2011, EUR J CLIN MICROBIOL, V30, P307, DOI 10.1007/s10096-010-1104-y
   Health Board of Estonia, 2019, IMMUNISATION SCHEDUL
   Heininger U, 2004, CLIN INFECT DIS, V38, P591, DOI 10.1086/381439
   Jogi P, 2018, INFECTION, V46, P83, DOI 10.1007/s15010-017-1095-z
   Riffelmann M, 2010, J CLIN MICROBIOL, V48, P4459, DOI 10.1128/JCM.01371-10
   Tennis PFM, 2016, EPIDEMICS-NETH, V16, P33, DOI 10.1016/j.epidem.2016.04.001
   van Twillert I, 2017, SCI REP-UK, V7, DOI 10.1038/srep40328
   van Twillert I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085227
   Versteegh FGA, 2005, EPIDEMIOL INFECT, V133, P737, DOI 10.1017/S0950268805003833
   WHO, 2003, WHO REC STAND SURV S
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3196
EP 3200
DI 10.1016/j.vaccine.2020.02.080
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600005
PM 32171577
DA 2020-05-12
ER

PT J
AU Aston-Deaville, S
   Carlsson, E
   Saleem, M
   Thistlethwaite, A
   Chan, H
   Maharjan, S
   Facchetti, A
   Feavers, IM
   Siebert, CA
   Collins, RF
   Roseman, A
   Derrick, JP
AF Aston-Deaville, Sebastian
   Carlsson, Emil
   Saleem, Muhammad
   Thistlethwaite, Angela
   Chan, Hannah
   Maharjan, Sunil
   Facchetti, Alessandra
   Feavers, Ian M.
   Siebert, C. Alistair
   Collins, Richard F.
   Roseman, Alan
   Derrick, Jeremy P.
TI An assessment of the use of Hepatitis B Virus core protein virus-like
   particles to display heterologous antigens from Neisseria meningitidis
SO VACCINE
LA English
DT Article
DE Neisseria meningitidis; Virus-like particle; Electron microscopy;
   Structural vaccinology
ID MENINGOCOCCAL SEROGROUP-B; H-BINDING-PROTEIN; VACCINE CANDIDATE; CAPSID
   PARTICLES; IMMUNE-RESPONSE; EPITOPE; SURFACE; DOMAIN; NADA;
   IMMUNOGENICITY
AB Neisseria meningitidis is the causative agent of meningococcal meningitis and sepsis and remains a significant public health problem in many countries. Efforts to develop a comprehensive vaccine against serogroup B meningococci have focused on the use of surface-exposed outer membrane proteins. Here we report the use of virus-like particles derived from the core protein of Hepatitis B Virus, HBc, to incorporate antigen domains derived from Factor H binding protein (FHbp) and the adhesin NadA. The extracellular domain of NadA was inserted into the major immunodominant region of HBc, and the C-terminal domain of FHbp at the C-terminus (CFHbp), creating a single polypeptide chain 3.7-fold larger than native HBc. Remarkably, cryoelectron microscopy revealed that the construct formed assemblies that were able to incorporate both antigens with minimal structural changes to native HBc. Electron density was weak for NadA and absent for CFHbp, partly attributable to domain flexibility. Following immunization of mice, three HBc fusions (CFHbp or NadA alone, NadA + CFHbp) were able to induce production of IgG1, IgG2a and IgG2b antibodies reactive against their respective antigens at dilutions in excess of 1:18,000. However, only HBc fusions containing NadA elicited the production of antibodies with serum bactericidal activity. It is hypothesized that this improved immune response is attributable to the adoption of a more native-like folding of crucial conformational epitopes of NadA within the chimeric VLP. This work demonstrates that HBc can incorporate insertions of large antigen domains but that maintenance of their threedimensional structure is likely to be critical in obtaining a protective response. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Aston-Deaville, Sebastian; Carlsson, Emil; Saleem, Muhammad; Thistlethwaite, Angela; Collins, Richard F.; Roseman, Alan; Derrick, Jeremy P.] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Sch Biol Sci, Fac Biol Med & Hlth,Manchester Acad Hlth Sci Ctr, Manchester M13 9PL, Lancs, England.
   [Chan, Hannah; Maharjan, Sunil; Facchetti, Alessandra; Feavers, Ian M.] Natl Inst Biol Stand & Controls, Blanche Lane, South Mimms EN6 3QG, Herts, England.
   [Siebert, C. Alistair] Harwell Sci & Innovat Campus, Electron Bioimaging Ctr, Diamond Light Source, Didcot, Oxon, England.
RP Derrick, JP (reprint author), Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Sch Biol Sci, Fac Biol Med & Hlth,Manchester Acad Hlth Sci Ctr, Manchester M13 9PL, Lancs, England.
EM Jeremy.Derrick@manchester.ac.uk
FU Biotechnology and Biological Sciences Research Council (BBSRC) as part
   of the Bioprocessing Research Industry Club (BRIC)
   initiativeBiotechnology and Biological Sciences Research Council
   (BBSRC); eBIC Block Allocation Grouping [EM16619]
FX Financial support for this work was provided by the Biotechnology and
   Biological Sciences Research Council (BBSRC) as part of the
   Bioprocessing Research Industry Club (BRIC) initiative. We thank the
   University of Manchester FBMH electron microscopy facility for
   assistance in sample preparation/refinement and cryoscreening. We also
   thank the generous support of eBIC Block Allocation Grouping EM16619,
   the support of Senior EM specialists and staff of the Biological
   Services Division, NIBSC.
CR Afonine PV, 2018, ACTA CRYSTALLOGR D, V74, P531, DOI 10.1107/S2059798318006551
   BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784
   Betancourt AA, 2007, INT J INFECT DIS, V11, P394, DOI 10.1016/j.ijid.2006.09.010
   Borrow R, 2005, CLIN DIAGN LAB IMMUN, V12, P970, DOI 10.1128/CDLI.12.8.970-976.2005
   Brehony C, 2016, VACCINE, V34, P4690, DOI 10.1016/j.vaccine.2016.08.015
   Bruun TUJ, 2018, ACS NANO, V12, P8855, DOI 10.1021/acsnano.8b02805
   Burnley T, 2017, ACTA CRYSTALLOGR D, V73, P469, DOI 10.1107/S2059798317007859
   Caugant DA, 2009, VACCINE, V27, pB64, DOI 10.1016/j.vaccine.2009.04.061
   Cendron L, 2011, ACTA CRYSTALLOGR F, V67, P531, DOI 10.1107/S1744309111006154
   Cielens I, 2014, MOL BIOTECHNOL, V56, P459, DOI 10.1007/s12033-014-9743-3
   Comanducci M, 2004, INFECT IMMUN, V72, P4217, DOI 10.1128/IAI.72.7.4217-4223.2004
   Comanducci M, 2002, J EXP MED, V195, P1445, DOI 10.1084/jem.20020407
   Dishlers A, 2015, MOL BIOTECHNOL, V57, P1038, DOI 10.1007/s12033-015-9895-9
   Esposito V, 2011, J BIOL CHEM, V286, P41767, DOI 10.1074/jbc.M111.289314
   Fehr T, 1998, P NATL ACAD SCI USA, V95, P9477, DOI 10.1073/pnas.95.16.9477
   Fletcher LD, 2004, INFECT IMMUN, V72, P2088, DOI 10.1128/IAI.72.4.2088-2100.2004
   Frasch CE, 2009, VACCINE, V27, pB112, DOI 10.1016/j.vaccine.2009.04.065
   FREDRIKSEN J H, 1991, NIPH (National Institute of Public Health) Annals (Oslo), V14, P67
   GALLINA A, 1989, J VIROL, V63, P4645, DOI 10.1128/JVI.63.11.4645-4652.1989
   Giuliani MM, 2006, P NATL ACAD SCI USA, V103, P10834, DOI 10.1073/pnas.0603940103
   Gregson AL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001556
   Harrison LH, 2010, J INFECT DIS, V201, P1208, DOI 10.1086/651505
   HAYRINEN J, 1995, J INFECT DIS, V171, P1481, DOI 10.1093/infdis/171.6.1481
   Huang XF, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0006-8
   Kean J, 2008, MOL MEMBR BIOL, V25, P653, DOI 10.1080/09687680802541169
   Kelly DF, 2005, ADV EXP MED BIOL, V568, P217
   Koho T, 2015, EUR J PHARM BIOPHARM, V96, P22, DOI 10.1016/j.ejpb.2015.07.002
   Liguori A, 2018, MBIO, V9, DOI 10.1128/mBio.01914-18
   Lobley A, 2002, BIOINFORMATICS, V18, P211, DOI 10.1093/bioinformatics/18.1.211
   Lua LHL, 2014, BIOTECHNOL BIOENG, V111, P425, DOI 10.1002/bit.25159
   Malito E, 2014, P NATL ACAD SCI USA, V111, P17128, DOI 10.1073/pnas.1419686111
   Malito E, 2013, P NATL ACAD SCI USA, V110, P3304, DOI 10.1073/pnas.1222845110
   Martin DR, 2006, CLIN VACCINE IMMUNOL, V13, P486, DOI 10.1128/CVI.13.4.486-491.2006
   Masignani V, 2003, J EXP MED, V197, P789, DOI 10.1084/jem.20021911
   MILICH DR, 1986, SCIENCE, V234, P1398, DOI 10.1126/science.3491425
   NATH N, 1992, J CLIN MICROBIOL, V30, P1617, DOI 10.1128/JCM.30.6.1617-1619.1992
   Ostergaard L, 2016, VACCINE, V34, P1465, DOI 10.1016/j.vaccine.2016.01.044
   Peyret H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120751
   Pizza M, 2000, SCIENCE, V287, P1816, DOI 10.1126/science.287.5459.1816
   RAJNAVOLGYI E, 1978, IMMUNOCHEMISTRY, V15, P887, DOI 10.1016/0161-5890(78)90123-2
   Ratanji KD, 2016, TOXICOL SCI, V153, P258, DOI 10.1093/toxsci/kfw121
   Roseman AM, 2012, J MOL BIOL, V423, P63, DOI 10.1016/j.jmb.2012.06.032
   Roseman AM, 2005, P NATL ACAD SCI USA, V102, P15821, DOI 10.1073/pnas.0504874102
   Schneider MC, 2009, NATURE, V458, P890, DOI 10.1038/nature07769
   Serruto D, 2012, VACCINE, V30, pB87, DOI 10.1016/j.vaccine.2012.01.033
   Sexton Kerry, 2004, N Z Med J, V117, pU1015
   Sheldon EA, 2012, HUM VACC IMMUNOTHER, V8, P888, DOI 10.4161/hv.19983
   Sominskaya I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075938
   Tyler M, 2014, BIOTECHNOL BIOENG, V111, P2398, DOI 10.1002/bit.25311
   Viner RM, 2012, LANCET NEUROL, V11, P774, DOI 10.1016/S1474-4422(12)70180-1
   Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9
   Wheeler CM, 2008, VACCINE, V26, P686, DOI 10.1016/j.vaccine.2007.11.043
   Wynne SA, 1999, MOL CELL, V3, P771, DOI 10.1016/S1097-2765(01)80009-5
   ZHOU S, 1992, P NATL ACAD SCI USA, V89, P10046, DOI 10.1073/pnas.89.21.10046
NR 54
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3201
EP 3209
DI 10.1016/j.vaccine.2020.03.001
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600006
PM 32178907
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Ma, C
   Hao, LX
   Rodewald, L
   An, Q
   Wannemuehler, KA
   Su, QR
   An, ZJ
   Quick, LD
   Liu, YB
   Yan, R
   Liu, XD
   Zhang, YY
   Yu, W
   Zhang, XS
   Wang, HQ
   Cairns, L
   Luo, HM
   Gregory, CJ
AF Ma, Chao
   Hao, Lixin
   Rodewald, Lance
   An, Qian
   Wannemuehler, Kathleen A.
   Su, Qiru
   An, Zhijie
   Quick, Linda
   Liu, Yuanbao
   Yan, Rui
   Liu, Xiaodong
   Zhang, Yanyang
   Yu, Wen
   Zhang, Xiaoshu
   Wang, Huaqing
   Cairns, Lisa
   Luo, Huiming
   Gregory, Christopher J.
TI Risk factors for measles virus infection and susceptibility in persons
   aged 15 years and older in China: A multi-site case-control study,
   2012-2013
SO VACCINE
LA English
DT Article
DE Measles elimination; China; Nosocomial transmission; Adults
ID ELIMINATION; CHILDREN; TRANSMISSION; VACCINATION; CAMPAIGN; OUTBREAK;
   PROGRESS
AB Introduction: Endemic measles persists in China, despite >95% reported coverage of two measlescontaining vaccine doses and nationwide campaign that vaccinated >100 million children in 2010. An increasing proportion of infections now occur among adults and there is concern that persistent susceptibility in adults is an obstacle to measles elimination in China. We performed a case-control study in six Chinese provinces between January 2012 to June 2013 to identify risk factors for measles virus infection and susceptibility among adults.
   Methods: Persons >= 15 years old with laboratory-confirmed measles were age and neighborhood matched with three controls. Controls had blood specimens collected to determine their measles IgG serostatus. We interviewed case-patients and controls about potential risk factors for measles virus infection and susceptibility. Unadjusted and adjusted matched odds ratios and 95% confidence intervals (CIs) were calculated via conditional logistic regression. We calculated attributable fractions for infection for risk factors that could be interpreted as causal.
   Results: 899 cases and 2498 controls were enrolled. Among controls, 165 (6.6%) were seronegative for measles IgG indicating persistent susceptibility to infection. In multivariable analysis, hospital visit and travel outside the prefecture in the prior 1-3 weeks were significant risk factors for measles virus infection. Occupation and reluctance to accept measles vaccination were significant risk factors for measles susceptibility. The calculated attributable fraction of measles cases from hospital visitation was 28.6% (95% CI: 20.6-38.8%).
   Conclusions: Exposure to a healthcare facility was the largest risk factor for measles virus infection in adults in China. Improved adherence to hospital infection control practices could reduce risk of ongoing measles virus transmission and increase the likelihood of achieving and sustaining measles elimination in China. The use of control groups stratified by serological status identified distinct risk factors for measles virus infection and susceptibility among adults. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ma, Chao; Hao, Lixin; Su, Qiru; An, Zhijie; Wang, Huaqing; Luo, Huiming] Chinese Ctr Dis Control & Prevent, Natl Immunizat Program, Beijing, Peoples R China.
   [Rodewald, Lance] World Hlth Org Off China, Expanded Program Immunizat, Beijing, Peoples R China.
   [An, Qian; Wannemuehler, Kathleen A.; Quick, Linda; Cairns, Lisa; Gregory, Christopher J.] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA.
   [Liu, Yuanbao] Jiangsu Prov CDC, Div Expanded Program Immunizat, Nanjing, Peoples R China.
   [Yan, Rui] Zhejiang Prov CDC, Div Expanded Program Immunizat, Hangzhou, Peoples R China.
   [Liu, Xiaodong] Shandong Prov CDC, Div Expanded Program Immunizat, Jinan, Peoples R China.
   [Zhang, Yanyang] Henan Prov CDC, Div Expanded Program Immunizat, Zhengzhou, Peoples R China.
   [Yu, Wen] Yunnan Prov CDC, Div Expanded Program Immunizat, Kunming, Yunnan, Peoples R China.
   [Zhang, Xiaoshu] Gansu Prov CDC, Div Expanded Program Immunizat, Lanzhou, Peoples R China.
RP Hao, LX (reprint author), Chinese Ctr Dis Control & Prevent, Natl Immunizat Program, Beijing, Peoples R China.
EM Haolx@chinacdc.cn
FU Chinese Center for Disease Control and Prevention; Global Immunization
   Division, US Centers for Disease Control and Prevention through World
   Health Organization Representative Office of China [CHN-12-EPI-004401,
   2012/280062-0]
FX Funding to support the activities described in this article came from
   Chinese Center for Disease Control and Prevention and the Global
   Immunization Division, US Centers for Disease Control and Prevention
   through World Health Organization Representative Office of China
   (Contract number: CHN-12-EPI-004401, WHO Reference: 2012/280062-0).
CR [Anonymous], 2014, Wkly Epidemiol Rec, V89, P45
   [Anonymous], 2017, CHUNYUN 3 BILLION PA
   [Anonymous], 2018, CHINA STAT YB 2017
   [Anonymous], 2016, JOINT S CLOS IMM GAP
   Botelho-Nevers E, 2012, VACCINE, V30, P3996, DOI 10.1016/j.vaccine.2012.04.023
   Castillo-Solorzano CC, 2011, J INFECT DIS, V204, pS270, DOI 10.1093/infdis/jir166
   Chao M, 2011, CHINESE J VACCINES I, V17, P242
   Chao M, 2010, CHIN J VACCIN IMMUN, V16, P297
   Fiebelkorn AP, 2015, CLIN INFECT DIS, V61, P615, DOI 10.1093/cid/civ387
   Fiebelkorn AP, 2014, VACCINE, V32, P4823, DOI 10.1016/j.vaccine.2013.11.005
   Hagan Jose E, 2018, MMWR Morb Mortal Wkly Rep, V67, P491, DOI 10.15585/mmwr.mm6717a3
   Hao L, 2019, INT J EPIDEMIOL
   Hao LX, 2016, VACCINE, V34, P6545, DOI 10.1016/j.vaccine.2016.02.005
   Jia HM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-2950-y
   Lebo EJ, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv006
   Llorca J, 2000, STAT MED, V19, P1089, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1089::AID-SIM411>3.0.CO;2-0
   Ma C, 2016, VACCINE, V34, P6553, DOI 10.1016/j.vaccine.2016.02.002
   Ma C, 2016, VACCINE, V34, P6539, DOI 10.1016/j.vaccine.2016.02.051
   Ma Chao, 2015, Disease Surveillance, V30, P818
   Ma C, 2014, B WORLD HEALTH ORGAN, V92, P340, DOI 10.2471/BLT.13.130195
   Ma C, 2011, J INFECT DIS, V204, pS447, DOI 10.1093/infdis/jir103
   MOH, 2006, NAT PLAN MEASL EL CH
   Monitoring WHO, 2010, WKLY EPIDEMIOL REC, V85, P490
   Progress WHO, 2013, WKLY EPIDEMIOL REC, V88, P233
   Qiru S, 2018, CHIN J VACC IMMUNI, V24, P146
   State The. Council of the people's Republic of China, 1986, 7 5 YEAR PLAN
   Wagner AL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185465
   Zhang DL, 2015, VACCINE, V33, P4100, DOI 10.1016/j.vaccine.2015.06.066
   Zhang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034401
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3210
EP 3217
DI 10.1016/j.vaccine.2020.03.006
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600007
PM 32173094
DA 2020-05-12
ER

PT J
AU Bartholomeus, E
   De Neuter, N
   Suls, A
   Elias, G
   van der Heijden, S
   Keersmaekers, N
   Jansens, H
   Van Tendeloo, V
   Beutels, P
   Laukens, K
   Ogunjimi, B
   Mortier, G
   Meysman, P
   Van Damme, P
AF Bartholomeus, Esther
   De Neuter, Nicolas
   Suls, Arvid
   Elias, George
   van der Heijden, Sanne
   Keersmaekers, Nina
   Jansens, Hilde
   Van Tendeloo, Viggo
   Beutels, Philippe
   Laukens, Kris
   Ogunjimi, Benson
   Mortier, Geert
   Meysman, Pieter
   Van Damme, Pierre
TI Transcriptomic profiling of different responder types in adults after a
   Priorix (R) vaccination
SO VACCINE
LA English
DT Article
DE Priorix; Measles-mumps-rubella vaccination; RNA-sequencing; Gene
   expression profiling
ID IMMUNE-RESPONSES; MEASLES-VACCINE; HEPATITIS-A; MUMPS; RUBELLA;
   PERSISTENCE; ANTIBODIES; IMMUNIZATION; INDIVIDUALS
AB Thanks to the recommendation of a combined Measles/Mumps/Rubella (MMR) vaccine, like Priorix (R), these childhood diseases are less common now. This is beneficial to limit the spread of these diseases and work towards their elimination. However, the measles, mumps and rubella antibody titers show a large variability in short- and long-term immunity. The recent outbreaks worldwide of measles and mumps and previous studies, which mostly focused on only one of the three virus responses, illustrate that there is a clear need for better understanding the immune responses after vaccination. Our healthy cohort was already primed with the MMR antigens in their childhood. In this study, the adult volunteers received one Priorix (R) vaccine dose at day 0. First, we defined 4 different groups of responders, based on their antibody titers' evolution over 4 time points (Day 0, 21, 150 and 365). This showed a high variability within and between individuals. Second, we determined transcriptome profiles using 30mRNA sequencing at day 0, 3 and 7. Using two analytical approaches, "one response group per time point" and "a time comparison per response group", we correlated the short-term gene expression profiles to the different response groups. In general, the list of differentially expressed genes is limited, however, most of them are clearly immune-related and upregulated at day 3 and 7, compared to the baseline day 0. Depending on the specific response group there are overlapping signatures for two of the three viruses. Antibody titers and transcriptomics data showed that an additional Priorix vaccination does not facilitate an equal immune response against the 3 viruses or among different vaccine recipients. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Bartholomeus, Esther; Suls, Arvid; Mortier, Geert] Univ Antwerp, Dept Med Genet, Antwerp Univ Hosp, Edegem, Belgium.
   [Bartholomeus, Esther; De Neuter, Nicolas; Suls, Arvid; Elias, George; Keersmaekers, Nina; Van Tendeloo, Viggo; Beutels, Philippe; Laukens, Kris; Ogunjimi, Benson; Mortier, Geert; Meysman, Pieter; Van Damme, Pierre] Univ Antwerp, Antwerp Unit Data Anal & Computat Immunol & Seque, AUDACIS, Antwerp, Belgium.
   [De Neuter, Nicolas; Laukens, Kris; Meysman, Pieter] Univ Antwerp, Dept Math & Comp Sci, Adrem Data Lab, Antwerp, Belgium.
   [De Neuter, Nicolas; Laukens, Kris; Meysman, Pieter] Univ Antwerp, Biomed Informat Res Network Antwerp Biomina, Antwerp, Belgium.
   [Elias, George; van der Heijden, Sanne; Van Tendeloo, Viggo; Ogunjimi, Benson] Univ Antwerp, Vaccine & Infect Dis Inst VAXINFECTIO, LEH, Antwerp, Belgium.
   [Keersmaekers, Nina; Beutels, Philippe; Ogunjimi, Benson] Univ Antwerp, CHERMID, Vaccine & Infect Dis Inst VAXINFECTIO, Antwerp, Belgium.
   [Jansens, Hilde] Antwerp Univ Hosp, Dept Lab Med, Edegem, Belgium.
   [Ogunjimi, Benson] Antwerp Univ Hosp, Dept Paediat, Edegem, Belgium.
   [Van Damme, Pierre] Univ Antwerp, CEV, Vaccine & Infect Dis Inst VAXINFECTIO, Antwerp, Belgium.
RP Bartholomeus, E (reprint author), Univ Antwerp, Med Genet, Prins Boudewijnlaan 43, B-2650 Edegem, Belgium.
EM esther.bartholomeus@uantwerpen.be; benson.ogunjimi@uantwerpen.be
RI Meysman, Pieter/I-1891-2019
OI Meysman, Pieter/0000-0001-5903-633X
FU University of Antwerp [BOF Concerted Research Action] [30730]; Hercules
   Foundation -Belgium; Research Foundation Flanders (FWO)FWO [151316,
   1861219N]; Antwerp Study Centre for Infectious Diseases (ASCID) at the
   University of Antwerp
FX This research was funded by the University of Antwerp [BOF Concerted
   Research Action (PS ID 30730), Methusalem funding], the Hercules
   Foundation -Belgium and the Research Foundation Flanders (FWO) [Personal
   PhD grant to NDN (151316) and 1861219N to BO]. The authors (NK, GE, HJ,
   VVT, PB, PVD, BO) also acknowledge support of the Antwerp Study Centre
   for Infectious Diseases (ASCID) at the University of Antwerp.
CR Bartholomeus E, 2018, VACCINE, V36, P6282, DOI 10.1016/j.vaccine.2018.09.001
   Center for Disease Control and prevention, 2009, MON VACC ATTENUVAX M
   Center for Disease Control and prevention, 2019, MEASL MUMPS RUB MMR
   Civas A, 2002, BIOCHIMIE, V84, P643, DOI 10.1016/S0300-9084(02)01431-1
   Czajka H, 2019, ADV EXP MED BIOL, V1153, P101, DOI 10.1007/5584_2019_344
   Duval B, 2005, VACCINE, V23, P4082, DOI 10.1016/j.vaccine.2004.07.022
   European centre for disease prevention and control, 2019, VACC SCHED
   Genin P, 2009, CYTOKINE GROWTH F R, V20, P283, DOI 10.1016/j.cytogfr.2009.07.005
   Haralambieva IH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188149
   Haralambieva IH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160970
   Haralambieva IH, 2015, VIRUSES-BASEL, V7, P1113, DOI 10.3390/v7031113
   Haralambieva IH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062149
   Haralambieva IH, 2013, EXPERT REV VACCINES, V12, P57, DOI [10.1586/erv.12.134, 10.1586/ERV.12.134]
   Haralambieva IH, 2011, VACCINE, V29, P4485, DOI 10.1016/j.vaccine.2011.04.037
   Kallinowski B, 2000, VACCINE, V19, P16, DOI 10.1016/S0264-410X(00)00166-3
   Klopfenstein DV, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28948-z
   LeBaron CW, 2007, ARCH PEDIAT ADOL MED, V161, P294, DOI 10.1001/archpedi.161.3.294
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   McLean HQ, 2018, VACCINE, V36, P5732, DOI 10.1016/j.vaccine.2018.08.010
   Mesplede T, 2003, AUTOIMMUNITY, V36, P447, DOI 10.1080/08916930310001602119
   Mi K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172156
   Overbosch D, 2005, J TRAVEL MED, V12, P319, DOI 10.2310/7060.2005.12604
   Ovsyannikova IG, 2005, IMMUNOGENETICS, V56, P798, DOI 10.1007/s00251-004-0756-0
   Ovsyannikova IG, 2007, VACCINE, V25, P3090, DOI 10.1016/j.vaccine.2007.01.020
   Ovsyannikova IG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171261
   Perelygina L, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008080
   Rager-Zisman B, 2003, VACCINE, V21, P2580, DOI 10.1016/S0264-410X(03)00053-7
   Seagle EE, 2018, VACCINE, V36, P818, DOI 10.1016/j.vaccine.2017.12.075
   Sharma S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7881
   Thornton J., 2019, BMJ-BRIT MED J, V364, DOI [10.1136/bmj.l634l634, DOI 10.1136/BMJ.L634L634]
   Umlauf BJ, 2012, VIRAL IMMUNOL, V25, P29, DOI 10.1089/vim.2011.0051
   Vandermeulen C, 2004, VACCINE, V22, P2713, DOI 10.1016/j.vaccine.2004.02.001
   Vandermeulen C, 2007, VACCINE, V25, P6672, DOI 10.1016/j.vaccine.2007.07.008
   Vandermeulen C, 2010, IMMUNOLOGY, V131, P33, DOI 10.1111/j.1365-2567.2010.03263.x
   Vandermeulen C, 2009, HUM VACCINES, V5, P494, DOI 10.4161/hv.7943
   Vandermeulen C, 2009, J INFECT DIS, V199, P1457, DOI 10.1086/598482
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3218
EP 3226
DI 10.1016/j.vaccine.2020.03.004
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600008
PM 32165045
DA 2020-05-12
ER

PT J
AU Beran, J
   Leroux-Roels, G
   Van Damme, P
   de Hoon, J
   Vandermeulen, C
   Al-Ibrahim, M
   Johnson, C
   Peterson, J
   Baker, S
   Seidl, C
   Dreisbach, A
   Karsten, A
   Corsaro, B
   Henry, O
   Lattanzi, M
   Bebia, Z
AF Beran, Jiri
   Leroux-Roels, Geert
   Van Damme, Pierre
   de Hoon, Jan
   Vandermeulen, Corinne
   Al-Ibrahim, Mohamed
   Johnson, Casey
   Peterson, James
   Baker, Sherryl
   Seidl, Claudia
   Dreisbach, Annette
   Karsten, Annette
   Corsaro, Bartholomew
   Henry, Ouzama
   Lattanzi, Maria
   Bebia, Zourab
TI Safety and immunogenicity of fully liquid and lyophilized formulations
   of an investigational trivalent group B streptococcus vaccine in healthy
   non-pregnant women: Results from a randomized comparative phase II trial
SO VACCINE
LA English
DT Article
DE Group B streptococcus; Maternal immunization; Safety; Immunogenicity;
   Lyophilized; Liquid
ID DISEASE WORLDWIDE; PREGNANT-WOMEN; IMMUNIZATION; STILLBIRTHS;
   PREVENTION; INFANTS
AB Background: We evaluated the safety and immunogenicity of liquid and lyophilized formulations of an investigational trivalent group B streptococcus (GBS) vaccine in non-pregnant women and assessed the formulations' equivalence in terms of serotype-specific immune response.
   Methods: This phase II, randomized, comparative, observer-blind trial enrolled healthy non-pregnant women 18-40 years of age. Women received a single dose of fully liquid (n = 529) or lyophilized (n = 521) trivalent GBS vaccine on day 1. Safety assessments were performed up to day 181 (study termination). Serotype Ia/Ib/III-specific immunoglobulin G (IgG) antibodies were measured in sera from women on day 1 (pre-vaccination) and day 31. Equivalence between the two formulations was demonstrated if the two-sided 95% confidence interval (CI) for the ratio (liquid/lyophilized) of the geometric mean concentrations (GMCs) on day 31 was contained in a (0.5, 2.0) interval for each serotype.
   Results: Solicited and unsolicited adverse events were reported at similar rates for both formulations. Serious adverse events were reported for six (1.1%) liquid GBS and nine (1.7%) lyophilized GBS vaccinated women, none of which were considered related to vaccination or fatal. On day 31, serotype-specific IgG concentrations were 8-16-fold higher than on day 1 in both groups. Equivalence of the liquid to the lyophilized formulation 30 days post-vaccination was demonstrated as the 95% CIs of the GMC ratios were within the pre-specified interval for the three serotypes: GMC ratios were 1.02 (95% CI: 0.79, 1.32) for serotype Ia, 0.93 (0.71, 1.21) for serotype Ib and 0.99 (0.76, 1.30) for serotype III.
   Conclusions: Both formulations of the investigational trivalent GBS vaccine had favorable safety profiles and induced similar GBS serotype-specific antibody concentrations. This study demonstrated that the fully liquid formulation was equivalent to the lyophilized formulation in healthy non-pregnant women in terms of immunogenicity for all three serotypes. (C) 2020 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Beran, Jiri] Vaccinat & Travel Med Ctr, Tylovo Nabrezi 418-6, Hradec Kralove 50002, Czech Republic.
   [Leroux-Roels, Geert] Univ Ghent, Ctr Vaccinol, Ghent, Belgium.
   [Leroux-Roels, Geert] Ghent Univ Hosp, Ghent, Belgium.
   [Van Damme, Pierre] Univ Antwerp, Ctr Evaluat Vaccinat, Antwerp, Belgium.
   [de Hoon, Jan; Vandermeulen, Corinne] UZ Leuven, Ctr Clin Pharmacol, Leuven, Belgium.
   [Al-Ibrahim, Mohamed] SNBL Clin Pharmacol Ctr, Baltimore, MD USA.
   [Johnson, Casey] Johnson Cty Clin Trials, Lenexa, KS USA.
   [Peterson, James] Foothill Family Clin, Salt Lake City, UT USA.
   [Baker, Sherryl] GSK, Cambridge, MA USA.
   [Seidl, Claudia; Lattanzi, Maria] GSK, Siena, Italy.
   [Dreisbach, Annette; Karsten, Annette] GSK, Marburg, Germany.
   [Corsaro, Bartholomew; Henry, Ouzama; Bebia, Zourab] GSK, Rockville, MD USA.
RP Beran, J (reprint author), Vaccinat & Travel Med Ctr, Tylovo Nabrezi 418-6, Hradec Kralove 50002, Czech Republic.
EM jiri.beran@vakcinace.cz; geert.lerouxroels@ugent.be;
   pierre.vandamme@uantwerpen.be; jan.dehoon@u-zleuven.be;
   corinne.vandermeulen@kuleuven.be; mohamed.al-ibrahim@pharmaron-us.com;
   cjohnson@jcct.com; jpeterson@foothillfamilyclinic.com;
   sb@rscstatconsulting.com; claudia.x.seidl@gsk.com;
   annette.x.dreisbach@gsk.com; annette.x.karsten@gsk.com;
   bart.x.corsaro@gsk.com; ouzama.n.henry@gsk.com;
   maria.x.lattanzi@gsk.com; zourab.x.bebia@gsk.com
FU Novartis Vaccines Division; GlaxoSmithKline Biologicals
   SAGlaxoSmithKline
FX This work was supported by Novartis Vaccines Division and
   GlaxoSmithKline Biologicals SA; on 2 March 2015, Novartis' noninfluenza
   vaccines business was acquired by the GSK group of companies.
   GlaxoSmithKline Biologicals SA paid for all costs associated with the
   development and publishing of this manuscript.
CR Beran J, 2018, J INFECT DIS, V217, P1616, DOI 10.1093/infdis/jiy065
   D'Heilly C, 2019, INFECT DIS THER, V8, P543, DOI 10.1007/s40121-019-00265-6
   Donders GGG, 2016, OBSTET GYNECOL, V127, P213, DOI 10.1097/AOG.0000000000001190
   Dzanibe S, 2018, EXPERT REV VACCINES, V17, P635, DOI 10.1080/14760584.2018.1496021
   Fortner KB, 2018, VACCINE, V36, P6354, DOI 10.1016/j.vaccine.2018.07.012
   Furuta M, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1559-2
   Heaton A, 2017, VACCINE, V35, P2272, DOI 10.1016/j.vaccine.2016.11.066
   Heyderman RS, 2016, LANCET INFECT DIS, V16, P546, DOI 10.1016/S1473-3099(15)00484-3
   Kobayashi Miwako, 2016, F1000Res, V5, P2355
   Kristensen DD, 2016, VACCINE, V34, P899, DOI 10.1016/j.vaccine.2016.01.001
   Lawn JE, 2017, CLIN INFECT DIS, V65, pS89, DOI 10.1093/cid/cix653
   Le Doare K, 2019, LANCET INFECT DIS, V19, pE162, DOI 10.1016/S1473-3099(18)30659-5
   Le Doare K, 2017, CLIN INFECT DIS, V65, pS143, DOI 10.1093/cid/cix654
   Leroux-Roels Geert, 2019, Clin Infect Dis, DOI 10.1093/cid/ciz737
   Leroux-Roels G, 2016, VACCINE, V34, P1786, DOI 10.1016/j.vaccine.2016.02.044
   Madhi SA, 2017, CLIN INFECT DIS, V65, P1897, DOI 10.1093/cid/cix666
   Madhi SA, 2016, LANCET INFECT DIS, V16, P923, DOI 10.1016/S1473-3099(16)00152-3
   Madrid L, 2017, CLIN INFECT DIS, V65, pS160, DOI 10.1093/cid/cix656
   Paoletti LC, 2001, INFECT IMMUN, V69, P6696, DOI 10.1128/IAI.69.11.6696-6701.2001
   Russell NJ, 2017, CLIN INFECT DIS, V65, pS100, DOI 10.1093/cid/cix658
   Schrag SJ, 2013, VACCINE, V31, pD20, DOI 10.1016/j.vaccine.2012.11.056
   Seale AC, 2017, CLIN INFECT DIS, V65, pS125, DOI 10.1093/cid/cix585
   Seale AC, 2017, CLIN INFECT DIS, V65, pS200, DOI 10.1093/cid/cix664
   Slotved HC, 2007, J CLIN MICROBIOL, V45, P2929, DOI 10.1128/JCM.00117-07
   Wallace AS, 2017, VACCINE, V35, P6751, DOI 10.1016/j.vaccine.2017.09.082
   WHO, VACC PRES PNEUM CONJ
   WHO, PROP HANDL REC VACC
   Wiedenmayer KA, 2009, VACCINE, V27, P655, DOI 10.1016/j.vaccine.2008.11.045
NR 28
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3227
EP 3234
DI 10.1016/j.vaccine.2020.02.085
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600009
PM 32169390
OA Other Gold
DA 2020-05-12
ER

PT J
AU Danchin, MH
   Bines, JE
   Watts, E
   Cowley, D
   Pavlic, D
   Lee, KJ
   Huque, H
   Kirkwood, C
   Nirwati, H
   At Thobari, J
   Satria, CD
   Soenarto, Y
   Oktaria, V
AF Danchin, Margie H.
   Bines, Julie E.
   Watts, Emma
   Cowley, Daniel
   Pavlic, Daniel
   Lee, Katherine J.
   Huque, Hamidul
   Kirkwood, Carl
   Nirwati, Hera
   At Thobari, Jarir
   Satria, Cahya Dewi
   Soenarto, Yati
   Oktaria, Vicka
TI Rotavirus specific maternal antibodies and immune response to RV3-BB
   rotavirus vaccine in central java and yogyakarta, Indonesia
SO VACCINE
LA English
DT Article
DE Maternal antibodies; Rotavirus vaccines; Efficacy; Developing countries
ID MALAWIAN CHILDREN; LESS-THAN-5 YEARS; DOUBLE-BLIND; LIVE; INFANTS;
   IMMUNOGENICITY; IMPACT; IGG; MORTALITY; EFFICACY
AB Background: Placental or breast milk maternal antibodies can potentially reduce oral rotavirus vaccine efficacy in developing countries. We aimed to examine the relationship between the level of rotavirus specific immunoglobulin A (IgA) and neutralising antibodies (NA) in colostrum and breast milk and cord IgG, with cumulative vaccine take following one and three doses of oral RV3-BB rotavirus vaccine within a Phase IIb trial in Indonesia.
   Methods: 196 infants received three doses of RV3-BB in a randomized, double-blinded trial, using a neonatal schedule (first dose at 0-5 days of age, n = 61), an infant schedule (first dose at similar to 8 weeks of age, n = 67) or placebo (n = 68). Rotavirus specific IgA and NA in colostrum and breast milk, rotavirus specific cord IgG, Serum IgA and stool excretion were measured.
   Results: There was little evidence of an association between IgA in colostrum or breast milk and cumulative vaccine take after three doses in the neonatal or infant groups. In the neonatal group, there was a negative association between IgG titre in cord blood and cumulative vaccine take (odds ratio [OR] 0.96; 95% confidence interval [CI] 0.92-1.00; p = 0.03) and serum IgA response (OR 0.94; 95%CI 0.89-0.99; p = 0.02) after one dose of vaccine, which were not evident after three doses in the neonatal or infant groups.
   Conclusions: Amongst Indonesian infants we did not find an association between IgA in colostrum or breast milk and vaccine take after 3 doses of RV3-BB vaccine. Maternal rotavirus antibodies in breast milk appear to have minimal impact on RV3-BB vaccine take when administered with a short delay in breastfeeding in settings with a high rotavirus disease burden. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Danchin, Margie H.; Bines, Julie E.; Watts, Emma; Cowley, Daniel; Pavlic, Daniel; Lee, Katherine J.; Huque, Hamidul] Murdoch Childrens Res Inst, Rotavirus Vaccine Program RV3, Parkville, Vic, Australia.
   [Nirwati, Hera; At Thobari, Jarir; Satria, Cahya Dewi; Soenarto, Yati; Oktaria, Vicka] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Child Hlth Dept, Paediat Res Off, Yogyakarta, Indonesia.
   [Danchin, Margie H.; Bines, Julie E.; Lee, Katherine J.; Huque, Hamidul; Oktaria, Vicka] Univ Melbourne, Dept Paediat, Parkville, Vic, Australia.
   [Danchin, Margie H.; Bines, Julie E.] Royal Childrens Hosp, Parkville, Vic, Australia.
   [Kirkwood, Carl] Bill & Melinda Gates Fdn, Seattle, WA USA.
   [Nirwati, Hera] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Microbiol, Yogyakarta, Indonesia.
   [At Thobari, Jarir] Univ Gadjah Mada, Fac Med Publ Hlth & Nursing, Dept Pharmacol & Therapy, Yogyakarta, Indonesia.
RP Danchin, MH (reprint author), Murdoch Childrens Res Inst, Rotavirus Res Grp, Flemington Rd, Parkville, Vic 3052, Australia.
EM margie.danchin@rch.org.au
RI Huque, Md Hamidul/E-4778-2018
OI Huque, Md Hamidul/0000-0002-5605-3801
FU Murdoch Childrens Research Institute; Maurice and Phyllis Paykel Trust;
   Shepard Foundation
FX This work was supported by grants from the Murdoch Childrens Research
   Institute, the Maurice and Phyllis Paykel Trust and the Shepard
   Foundation.
CR Ali A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127622
   Appaiahgari MB, 2014, VACCINE, V32, P651, DOI 10.1016/j.vaccine.2013.12.017
   Armah G, 2016, J INFECT DIS, V213, P1678, DOI 10.1093/infdis/jiw023
   Armah GE, 2010, LANCET, V376, P606, DOI 10.1016/S0140-6736(10)60889-6
   Bar-Zeev N, 2018, LANCET GLOB HEALTH, V6, pE1036, DOI 10.1016/S2214-109X(18)30314-0
   Bar-Zeev N, 2016, CLIN INFECT DIS, V62, pS213, DOI 10.1093/cid/civ1183
   Becker-Dreps S, 2015, PEDIATR INFECT DIS J, V34, P115, DOI 10.1097/INF.0000000000000481
   Bennett A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0190256
   Bines JE, 2018, NEW ENGL J MED, V378, P719, DOI 10.1056/NEJMoa1706804
   Bines JE, 2015, LANCET INFECT DIS, V15, P1389, DOI 10.1016/S1473-3099(15)00227-3
   Chen MY, 2017, HUMAN VACC IMMUNOTHE, P1
   Chilengi R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150100
   Cunliffe NA, 2012, VACCINE, V30, pA36, DOI 10.1016/j.vaccine.2011.09.120
   Fouda Genevieve G, 2018, Immunohorizons, V2, P14, DOI 10.4049/immunohorizons.1700057
   Gastanaduy PA, 2016, CLIN INFECT DIS, V62, pS161, DOI 10.1093/cid/civ1207
   Graham KL, 2003, J VIROL, V77, P9969, DOI 10.1128/JVI.77.18.9969-9978.2003
   Groome MJ, 2014, B WORLD HEALTH ORGAN, V92, P238, DOI 10.2471/BLT.13.128066
   Gruber JF, 2017, PEDIATR INFECT DIS J, V36, P72, DOI 10.1097/INF.0000000000001362
   Madhi SA, 2016, MALAWI MED J, V28, P108, DOI 10.1056/NEJMoa0904797
   Moon SS, 2016, CLIN INFECT DIS, V62, P157, DOI 10.1093/cid/civ828
   Morrow AL, 2005, J NUTR, V135, P1304
   Mpabalwani EM, 2016, CLIN INFECT DIS, V62, pS183, DOI 10.1093/cid/civ1027
   Nelson EAS, 2008, VACCINE, V26, P3192, DOI 10.1016/j.vaccine.2008.03.073
   Nicoara C, 1999, CLIN DIAGN LAB IMMUN, V6, P868, DOI 10.1128/CDLI.6.6.868-871.1999
   Niewiesk S, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00446
   Oktaria V, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0966-x
   Praharaj I, 2015, PHILOS T R SOC LON B, V370
   Rongsen-Chandola T, 2014, VACCINE, V32, pA134, DOI 10.1016/j.vaccine.2014.04.078
   Sindhu KNC, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016577
   Tate JE, 2016, CLIN INFECT DIS, V62, pS96, DOI 10.1093/cid/civ1013
   Tate JE, 2014, CLIN INFECT DIS, V59, P1291, DOI 10.1093/cid/ciu564
   Van Den Driessche M, 1999, J PEDIATR GASTR NUTR, V29, P46, DOI 10.1097/00005176-199907000-00013
   VANSAVAGE J, 1990, J INFECT DIS, V161, P487, DOI 10.1093/infdis/161.3.487
   Velasquez DE, 2018, EXPERT REV VACCINES, V17, P145, DOI 10.1080/14760584.2018.1418665
   Voysey M, 2017, JAMA PEDIATR, V171, P637, DOI 10.1001/jamapediatrics.2017.0638
   Zaman K, 2016, J INFECT DIS, V213, P1686, DOI 10.1093/infdis/jiw024
   Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6
NR 37
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3235
EP 3242
DI 10.1016/j.vaccine.2020.02.087
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600010
PM 32160948
DA 2020-05-12
ER

PT J
AU Braeye, T
   Emborg, HD
   Llorente-Garcia, A
   Huerta, C
   Martin-Merino, E
   Duarte-Salles, T
   Danieli, G
   Tramontan, L
   Weibel, D
   McGee, C
   Villa, M
   Gini, R
   Lehtinen, M
   Titievsky, L
   Sturkenboom, M
AF Braeye, Toon
   Emborg, Hanne-Dorthe
   Llorente-Garcia, Ana
   Huerta, Consuelo
   Martin-Merino, Elisa
   Duarte-Salles, Talita
   Danieli, Giorgia
   Tramontan, Lara
   Weibel, Daniel
   McGee, Chris
   Villa, Marco
   Gini, Rosa
   Lehtinen, Matti
   Titievsky, Lina
   Sturkenboom, Miriam
TI Age-specific vaccination coverage estimates for influenza, human
   papillomavirus and measles containing vaccines from seven
   population-based healthcare databases from four EU countries - The
   ADVANCE project
SO VACCINE
LA English
DT Article
DE Vaccination coverage; Influenza vaccines; Papillomavirus vaccines;
   Measles vaccines; Probability
ID IMMUNIZATION COVERAGE; LEFT TRUNCATION; ACCURACY; VALIDITY; REGISTRY;
   EUROPE; BIAS
AB Background: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk monitoring of vaccines using existing healthcare databases in Europe. We estimated vaccine coverage from electronic healthcare databases as part of a fit-for-purpose assessment for vaccine benefit-risk studies.
   Methods: A retrospective dynamic cohort study was conducted through a distributed network approach. Coverage with measles-vaccine for birth year 2006, human papillomavirus (HPV)-vaccine for birth years 1990-2000 and influenza-vaccine for birth years 1920-1950 was estimated using period-prevalence and inverse probability weighting methods. Seven databases from four countries participated: Italy (Pedianet, Val Padana), Spain (BIFAP, SIDIAP), UK (RCGP-RSC, THIN), Denmark (SSI/AUH). Database access providers extracted the data, transformed it into a common structure and ran an R-script locally. The created output tables were shared and pooled at a central server.
   Results: The total study population comprised 274,616 persons for measles-vaccine, 2,011,666 persons for HPV-vaccine and 14,904,033 persons for influenza-vaccine. Measles-vaccine coverage varied from 84.3% (Denmark) to 96.5% (Italy, Val Padana) for the first dose and from 82.8% (Italy, Val Padana) to 90.9% (UK) for the second dose at the age of 7 years. The HPV-vaccine coverage, aggregated over birth years 1997-2000, ranged from 60% (UK) to 88.3% (Denmark) at the age of 15 years. The influenza-vaccine coverage for the influenza seasons from 2009 to 2015 for persons aged 65 years and more was roughly stable around 43% in Denmark and around 68% in the UK while a decrease from 58 to 50% was observed in Catalonia (Spain).
   Conclusions: We obtained detailed, age-specific coverage estimates though a common procedure. We discussed between database comparability and comparability to published national estimates. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Braeye, Toon] Sciensano, Rue Juliette Wytsman 14, B-1050 Brussels, Belgium.
   [Braeye, Toon] Univ Hasselt, Hasselt, Belgium.
   [Emborg, Hanne-Dorthe] Statens Serum Inst, Copenhagen, Denmark.
   [Llorente-Garcia, Ana; Huerta, Consuelo; Martin-Merino, Elisa] Spanish Agcy Med & Med Devices, BIFAP Database, Madrid, Spain.
   [Duarte-Salles, Talita] Fundacio Inst Univ Recerca Atencio Primaria Salut, Barcelona, Spain.
   [Danieli, Giorgia; Tramontan, Lara] Consorzio Arsenal IT, Treviso, Veneto Region, Italy.
   [Danieli, Giorgia; Tramontan, Lara] Italian Network Family Paediatricians PEDIANET, Epidemiol Informat Clin Res, Padua, Italy.
   [Weibel, Daniel] Erasmus MC, Rotterdam, Netherlands.
   [McGee, Chris] Univ Surrey, Surrey, England.
   [Villa, Marco] ATS Val Padana, Cremona, Italy.
   [Gini, Rosa] Agenzia Regionale Sanita Toscana, Florence, Italy.
   [Lehtinen, Matti] Univ Tampere, Tampere, Finland.
   [Titievsky, Lina] Pfizer, Epidemiol, New York, NY USA.
   [Sturkenboom, Miriam] P95, Heverlee, Belgium.
   [Sturkenboom, Miriam] VACCINE GRID, Basel, Switzerland.
   [Sturkenboom, Miriam] Univ Med Ctr Utrecht, Julius Global Hlth, Utrecht, Netherlands.
RP Braeye, T (reprint author), Sciensano, Rue Juliette Wytsman 14, B-1050 Brussels, Belgium.
EM toon.braeye@sciensano.be
FU Innovative Medicines Initiative Joint Undertaking under ADVANCE grant
   from the European Union's Seventh Framework Programme (FP7/2007-2013)
   [115557]
FX The Innovative Medicines Initiative Joint Undertaking funded this
   project under ADVANCE grant agreement no 115557, resources of which were
   composed of a financial contribution from the European Union's Seventh
   Framework Programme (FP7/2007-2013) and in kind contributions from EFPIA
   member companies.
CR [Anonymous], SEAS FLU VACC UPT GP
   Baker MA, 2013, VACCINE, V31, pK98, DOI 10.1016/j.vaccine.2013.04.088
   Blank PR, 2009, J INFECTION, V58, P446, DOI 10.1016/j.jinf.2009.04.001
   Blank PR, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-272
   Braeye Toon, 2019, PLoS One, V14, pe0222296, DOI 10.1371/journal.pone.0222296
   Bruni L, 2016, LANCET GLOB HEALTH, V4, pE453, DOI 10.1016/S2214-109X(16)30099-7
   Cain KC, 2011, AM J EPIDEMIOL, V173, P1078, DOI 10.1093/aje/kwq481
   Datta SS, 2018, VACCINE, V36, P5408, DOI 10.1016/j.vaccine.2017.06.042
   Greenberg M, 2016, HUM VACC IMMUNOTHER, V12, P176, DOI 10.1080/21645515.2015.1075679
   Haverkate M, 2011, EXPERT REV VACCINES, V10, P1195, DOI [10.1586/ERV.11.87, 10.1586/erv.11.87]
   Hazelbag CM, 2015, ANN EPIDEMIOL, V25, P590, DOI 10.1016/j.annepidem.2015.03.019
   Irving SA, 2009, VACCINE, V27, P6546, DOI 10.1016/j.vaccine.2009.08.050
   Jimenez-Garcia R, 2014, VACCINE, V32, P4386, DOI 10.1016/j.vaccine.2014.06.074
   Jimenez-Garcia R, 2014, HUM VACC IMMUNOTHER, V10, P449, DOI 10.4161/hv.27152
   Khare M, 2006, ARCH PEDIAT ADOL MED, V160, P838, DOI 10.1001/archpedi.160.8.838
   Laubereau B, 2002, EPIDEMIOL INFECT, V128, P185, DOI 10.1017/S0950268801006550
   Lehtinen M, 2019, EXPERT REV VACCINES, V18, P153, DOI 10.1080/14760584.2019.1568876
   Limia A, 2011, EUROSURVEILLANCE, V16, P12
   Lopalco PL, 2014, CLIN MICROBIOL INFEC, V20, P7, DOI 10.1111/1469-0691.12453
   MacDonald SE, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-1
   Martin-Merino E, 2019, PHARM MED, V33, P135, DOI 10.1007/s40290-019-00268-1
   Martin-Merino E, 2019, PHARMACOEPIDEM DR S, V28, P201, DOI 10.1002/pds.4674
   Mereckiene J, 2014, EUROSURVEILLANCE, V19, P29, DOI 10.2807/1560-7917.ES2014.19.16.20780
   Miles M, 2013, VACCINE, V31, P1560, DOI 10.1016/j.vaccine.2012.10.089
   Ministerio de Sanidad, CONS BIEN SOC PROF V
   Murray CJL, 2003, LANCET, V362, P1022, DOI 10.1016/S0140-6736(03)14411-X
   Regan AK, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2234-z
   Samuels RC, 2002, AMBUL PEDIATR, V2, P187, DOI 10.1367/1539-4409(2002)002<0187:IAIACI>2.0.CO;2
   Skorstengaard M, 2017, VACCINE, V35, P5939, DOI 10.1016/j.vaccine.2017.08.062
   Sturkenboom Miriam, 2020, Vaccine, DOI 10.1016/j.vaccine.2020.01.100
   Sturkenboom M, 2018, VACCINE, V36, P194, DOI 10.1016/j.vaccine.2017.08.043
   Suppli CH, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6268-x
   Sy LS, 2010, VACCINE, V28, P5254, DOI 10.1016/j.vaccine.2010.05.061
   Torner N, 2007, WKLY RELEASES, V12, P3144, DOI [10.2807/esw.12.08.03144-en, DOI 10.2807/ESW.12.08.03144-EN]
   Trinh L, 2017, VACCINE, V35, P1524, DOI 10.1016/j.vaccine.2017.01.063
   Walton S, 2017, VACCINE, V35, P7166, DOI 10.1016/j.vaccine.2017.10.085
   WHO World Health Organization, 2018, GLOB SUMM REF TIM SE
   Wilson SE, 2017, HUM VACC IMMUNOTHER, V13, P1928, DOI 10.1080/21645515.2017.1319022
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3243
EP 3254
DI 10.1016/j.vaccine.2020.02.082
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600011
PM 32171573
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Li, H
   Cameron, B
   Douglas, D
   Stapleton, S
   Cheguelman, G
   Butler, T
   Luciani, F
   Lloyd, AR
AF Li, Hui
   Cameron, Barbara
   Douglas, Dominic
   Stapleton, Sam
   Cheguelman, Grigori
   Butler, Tony
   Luciani, Fabio
   Lloyd, Andrew R.
TI Incident hepatitis B virus infection and immunisation uptake in
   Australian prison inmates
SO VACCINE
LA English
DT Article
DE Viral hepatitis; HBV; Prison; Immunisation; Transmission
ID INJECTING DRUG-USERS; VACCINATION SCHEDULE; RISK BEHAVIORS; PEOPLE;
   PREVALENCE; IMMUNOGENICITY; TRANSMISSION; POPULATION; IMMUNITY; ENGLAND
AB Introduction: Despite an effective vaccine, hepatitis B virus (HBV) infection continues to impose a large burden of disease globally. Until childhood immunisation achieves high adult population coverage, people who inject drugs (PWID), including prison inmates remain at risk. PWID have a higher prevalence of HBV than the wider population, and lower rates of vaccine-conferred immunity. This study sought to identify the incidence and predictors of HBV transmission and uptake of immunisation in PWID prisoners in Australia.
   Methods: Longitudinally collected, stored sera from subjects previously enrolled in a prospective study of hepatitis C in recently incarcerated PWID prisoners (n = 590) were serologically tested for HBV. Interviews recording demographic and behavioural risks were analysed. Multivariate statistical analyses were applied to identify associations of incident infection or immunisation.
   Results: Upon imprisonment there were n = 373 (63%) individuals who were HBV susceptible, of whom 140 remained susceptible at the subsequent enrolment into the cohort, and had one or more follow-up visits (a total of 406.73 person years [p.y.]), and so were included in this analysis. There were 7 incident cases of HBV infection (1.7 per 100 p.y.) in this group, with transmission being associated with injecting drug use daily or more often. There were 48 individuals who were successfully immunised (11.8 per 100 p.y.) with younger age and continuous imprisonment predicting this outcome.
   Conclusions: The Australian prison environment poses a high risk for HBV infection, and also provides an opportunity for immunisation for PWID. Further efforts are required to improve coverage and prevent ongoing transmissions. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Li, Hui; Cameron, Barbara; Butler, Tony; Luciani, Fabio; Lloyd, Andrew R.] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Douglas, Dominic; Stapleton, Sam; Luciani, Fabio; Lloyd, Andrew R.] Univ New South Wales, Sch Med Sci, Sydney, NSW, Australia.
   [Cheguelman, Grigori] Justice Hlth & Forens Mental Hlth Network, Populat Hlth, Sydney, NSW, Australia.
RP Cameron, B (reprint author), Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
EM b.cameron@unsw.edu.au
FU National Health and Medical Research Council (NHMRC) of
   AustraliaNational Health and Medical Research Council of Australia
   [510448]; NHMRC Practitioner FellowshipNational Health and Medical
   Research Council of Australia [1137587]
FX This project was supported by a Program Grant from National Health and
   Medical Research Council (NHMRC) of Australia (No. 510448). ARL was
   supported by a NHMRC Practitioner Fellowship (No. 1137587). The funding
   body had no involvement in planning, research or publication.
CR Baral S, 2007, LANCET INFECT DIS, V7, P667, DOI 10.1016/S1473-3099(07)70237-2
   Beck CR, 2012, VACCINE, V30, P1965, DOI 10.1016/j.vaccine.2012.01.020
   Blome MA, 2017, VACCINE, V35, P84, DOI 10.1016/j.vaccine.2016.11.041
   Butler T., 2017, NATL PRISON ENTRANTS
   Campbell JV, 2007, DRUG ALCOHOL DEPEN, V91, pS64, DOI 10.1016/j.drugalcdep.2006.09.022
   Cunningham EB, 2017, J VIRAL HEPATITIS, V24, P733, DOI 10.1111/jvh.12701
   Cunningham EB, 2018, INT J DRUG POLICY, V54, P18, DOI 10.1016/j.drugpo.2017.12.013
   Day CA, 2016, J CLIN VIROL, V74, P66, DOI 10.1016/j.jcv.2015.11.031
   de Viggiani N, 2007, SOCIOL HEALTH ILL, V29, P115, DOI 10.1111/j.1467-9566.2007.00474.x
   Dolan K, 2016, LANCET, V388, P1089, DOI 10.1016/S0140-6736(16)30466-4
   Geue C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145022
   Gidding HF, 2015, EPIDEMIOL INFECT, V143, P2813, DOI 10.1017/S0950268814003914
   Gough E, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-777
   Hahne S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067866
   Hochstatter Karli R, 2017, Health Justice, V5, P10, DOI 10.1186/s40352-017-0055-0
   Hwang LY, 2010, J INFECT DIS, V202, P1500, DOI 10.1086/656776
   Imam MH, 2017, J NEPHROL, V30, P803, DOI 10.1007/s40620-017-0443-5
   Indig D, 2010, 2009 NSW INMATE HLTH
   Jin H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133464
   Kamath GR, 2014, VACCINE, V32, P2265, DOI 10.1016/j.vaccine.2014.02.072
   Kirby Institute, 2018, HIV VIR HEP SEX TRAN
   Korthuis PT, 2017, ANN INTERN MED, V166, P268, DOI 10.7326/M16-2149
   Leuridan E, 2011, CLIN INFECT DIS, V53, P68, DOI 10.1093/cid/cir270
   Lu Xinting, 2018, INFECT DISORD DRUG T, V18, P1
   Lugoboni F, 2004, SCAND J INFECT DIS, V36, P131, DOI 10.1080/00365540310018833
   MacLachlan J, 2018, AUST NZ J PUBL HEAL, V42, P62, DOI 10.1111/1753-6405.12693
   Maher L, 2004, J GASTROEN HEPATOL, V19, P1114, DOI 10.1111/j.1440-1746.2004.03438.x
   Niveau G, 2006, PUBLIC HEALTH, V120, P33, DOI 10.1016/j.puhe.2005.03.017
   Organization WH, 2016, GLOB HLTH SECT STRAT
   Palmateer NE, 2018, ADDICTION, V113, P80, DOI 10.1111/add.13944
   Plein LM, 2018, BRIT J PHARMACOL, V175, P2717, DOI 10.1111/bph.13750
   Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6
   Saltoglu Nese, 2003, Ann Clin Microbiol Antimicrob, V2, P10, DOI 10.1186/1476-0711-2-10
   Shah DP, 2015, AM J PUBLIC HEALTH, V105, pE36, DOI 10.2105/AJPH.2014.302487
   Shi J, 2017, VACCINE, V35, P2443, DOI 10.1016/j.vaccine.2017.03.034
   Sutton AJ, 2006, VACCINE, V24, P2377, DOI 10.1016/j.vaccine.2005.11.055
   Tavoschi L, 2018, EPIDEMIOL REV, V40, P105, DOI 10.1093/epirev/mxy001
   Vermeulen M, 2017, EMERG INFECT DIS, V23, P1560, DOI 10.3201/eid2309.161594
   White B, 2012, AUST NZ J PUBL HEAL, V36, P351, DOI 10.1111/j.1753-6405.2012.00881.x
   Wirtz AL, 2018, EPIDEMIOL REV, V40, P12, DOI 10.1093/epirev/mxy003
   World Health Organisation, 2018, HBV OV
NR 41
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3255
EP 3260
DI 10.1016/j.vaccine.2020.02.076
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600012
PM 32151462
DA 2020-05-12
ER

PT J
AU Bartsch, SM
   Stokes-Cawley, OJ
   Buekens, P
   Asti, L
   Bottazzi, ME
   Strych, U
   Wedlock, PT
   Mitgang, EA
   Meymandi, S
   Falcon-Lezama, JA
   Hotez, PJ
   Lee, BY
AF Bartsch, Sarah M.
   Stokes-Cawley, Owen J.
   Buekens, Pierre
   Asti, Lindsey
   Bottazzi, Maria Elena
   Strych, Ulrich
   Wedlock, Patrick T.
   Mitgang, Elizabeth A.
   Meymandi, Sheba
   Abelardo Falcon-Lezama, Jorge
   Hotez, Peter J.
   Lee, Bruce Y.
TI The potential economic value of a therapeutic Chagas disease vaccine for
   pregnant women to prevent congenital transmission
SO VACCINE
LA English
DT Article
DE Chagas disease; Vaccine; Pregnancy; Economics; Congenital transmission
ID TRYPANOSOMA-CRUZI INFECTION; ADVERSE EVENTS; RISK-FACTORS; MALARIA
   VACCINE; EARLY-DIAGNOSIS; PREVALENCE; CHILDREN; NEWBORNS; EFFICACY;
   BIRTH
AB Background: Currently, there are no solutions to prevent congenital transmission of Chagas disease during pregnancy, which affects 1-40% of pregnant women in Latin America and is associated with a 5% transmission risk. With therapeutic vaccines under development, now is the right time to determine the economic value of such a vaccine to prevent congenital transmission.
   Methods: We developed a computational decision model that represented the clinical outcomes and diagnostic testing strategies for an infant born to a Chagas-positive woman in Mexico and evaluated the impact of vaccination.
   Results: Compared to no vaccination, a 25% efficacious vaccine averted 125 [95% uncertainty interval (UI): 122-128] congenital cases, 1.9 (95% UI: 1.6-2.2) infant deaths, and 78 (95% UI: 66-91) DALYs per 10,000 infected pregnant women; a 50% efficacious vaccine averted 251 (95% UI: 248-254) cases, 3.8 (95% UI: 3.6-4.2) deaths, and 160 (95% UI: 148-171) DALYs; and a 75% efficacious vaccine averted 376 (95% UI: 374-378) cases, 5.8 (95% UI: 5.5-6.1) deaths, and 238 (95% UI: 227-249) DALYs. A 25% efficacious vaccine was cost-effective (incremental cost-effectiveness ratio <3x Mexico's gross domestic product per capita, <$29,698/DALY averted) when the vaccine cost <=$240 and <=$310 and cost-saving when <=$10 and <=$80 from the third-party payer and societal perspectives, respectively. A 50% efficacious vaccine was cost-effective when costing <=$490 and <=$615 and cost-saving when <=$25 and <=$160, from the third-party payer and societal perspectives, respectively. A 75% efficacious vaccine was cost-effective when <=$720 and <=$930 and cost-saving when <=$40 and <=$250 from the third-party payer and societal perspectives, respectively. Additionally, 13-42 fewer infants progressed to chronic disease, saving $0.41-$1.21 million to society.
   Conclusion: We delineated the thresholds at which therapeutic vaccination of Chagas-positive pregnant women would be cost-effective and cost-saving, providing economic guidance for decision-makers to consider when developing and bringing such a vaccine to market. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Bartsch, Sarah M.; Stokes-Cawley, Owen J.; Asti, Lindsey; Wedlock, Patrick T.; Mitgang, Elizabeth A.; Lee, Bruce Y.] CUNY, PHICOR, 55 W 125th St, New York, NY 10027 USA.
   [Buekens, Pierre] Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA USA.
   [Bottazzi, Maria Elena; Strych, Ulrich; Hotez, Peter J.] Baylor Coll Med, Natl Sch Trop Med, One Baylor Plaza,BCM113, Houston, TX 77030 USA.
   [Bottazzi, Maria Elena; Strych, Ulrich; Hotez, Peter J.] Baylor Coll Med, Dept Pediat, One Baylor Plaza,BCM113, Houston, TX 77030 USA.
   [Bottazzi, Maria Elena; Strych, Ulrich; Hotez, Peter J.] Baylor Coll Med, Dept Mol Virol & Microbiol, One Baylor Plaza,BCM113, Houston, TX 77030 USA.
   [Meymandi, Sheba] Olive View UCLA Med Ctr, Ctr Excellence Chagas Dis, 14445 Olive View Dr, Sylmar, CA 91342 USA.
   [Abelardo Falcon-Lezama, Jorge] Carlos Slim Fdn, Lago Zurich 245,Piso 20 Ampliacion Granada, Ciudad De Mexico 11529, Mexico.
RP Lee, BY (reprint author), CUNY, Grad Sch Publ Hlth & Hlth Policy, 55 W 125th St, New York, NY 10027 USA.
EM bruceleemdmba@gmail.com
FU Carlos Slim Foundation; Agency for Healthcare Research and Quality
   (AHRQ)United States Department of Health & Human ServicesAgency for
   Healthcare Research & Quality [R01HS023317]; Eunice Kennedy Shriver
   National Institute of Child Health and Human Development (NICHD)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child
   Health & Human Development (NICHD) [U01HD086861, R01HD086013];
   NICHDUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National
   Institute of Child Health & Human Development (NICHD); Office of
   Behavioral and Social Sciences Research (OBSSR)United States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USA
   [U54HD070725]; United States Agency for International Development
   (USAID)United States Agency for International Development (USAID)
   [AID-OAA-A-150064]
FX This work was supported by the Carlos Slim Foundation, the Agency for
   Healthcare Research and Quality (AHRQ) via grant R01HS023317, the Eunice
   Kennedy Shriver National Institute of Child Health and Human Development
   (NICHD) via grant U01HD086861 and R01HD086013, the NICHD and Office of
   Behavioral and Social Sciences Research (OBSSR) under award number
   U54HD070725, and the United States Agency for International Development
   (USAID) under agreement number AID-OAA-A-150064. The funders had no role
   in the design and conduct of the study; collection, management,
   analysis, and interpretation of the data; and preparation, review or
   approval of the manuscript.
CR Minsoko PA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001685
   Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1
   Alonso-Vega C, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002304
   Altcheh J, 2011, PEDIATRICS, V127, pE212, DOI 10.1542/peds.2010-1172
   Alvarez MG, 2017, ACTA TROP, V174, P149, DOI 10.1016/j.actatropica.2017.07.004
   Ancel PY, 2015, JAMA PEDIATR, V169, P230, DOI 10.1001/jamapediatrics.2014.3351
   [Anonymous], 2015, Wkly Epidemiol Rec, V90, P33
   Arnal A, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0006859
   Barreto Mauricio L., 2006, J. Pediatr. (Rio J.), V82, ps45, DOI 10.1590/S0021-75572006000400006
   Bartsch SM, 2019, VACCINE, V37, P3704, DOI 10.1016/j.vaccine.2019.05.028
   Beaumier CM, 2016, VACCINE, V34, P2996, DOI 10.1016/j.vaccine.2016.03.074
   Bern C, 2009, CLIN INFECT DIS, V49, P1667, DOI 10.1086/648070
   Bestetti RB, 2015, NEW ENGL J MED, V373, P1881, DOI [10.1056/NEJMra1410150, 10.1056/NEJMc1510996]
   Blanco SB, 2000, TROP MED INT HEALTH, V5, P293, DOI 10.1046/j.1365-3156.2000.00548.x
   Botton J, 2008, AM J CLIN NUTR, V87, P1760
   Carlier Y, 2015, ACTA TROP, V151, P103, DOI 10.1016/j.actatropica.2015.07.016
   Carlier Y, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001250
   Carlier Y, 2010, ELSEV INSIGHT, P539, DOI 10.1016/B978-0-12-384876-5.00022-8
   Center for Disease Control and Prevention, GUID VACC PREGN WOM
   Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases, CDC SEAS FLU VACC EF
   Chippaux JP, 2010, TROP MED INT HEALTH, V15, P87, DOI 10.1111/j.1365-3156.2009.02431.x
   Clavijo NAS, 2012, ACTA TROP, V124, P87, DOI 10.1016/j.actatropica.2012.06.012
   Cucunuba ZM, 2012, AM J TROP MED HYG, V87, P837, DOI 10.4269/ajtmh.2012.12-0086
   Diez-Domingo J, 2015, VACCINE, V33, P789, DOI 10.1016/j.vaccine.2014.12.024
   Dumonteil E, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0006985
   Edwards T, 2018, ARTECH HSE MICROW LI, P75
   Fabbro DL, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003312
   FREILIJ H, 1995, CLIN INFECT DIS, V21, P551, DOI 10.1093/clinids/21.3.551
   Global Burden of Disease Collaborative Network, 2018, GLOB BURD DIS STUD 2
   Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4
   Gonzalez F, 2018, APPL ECON, V50, P1156, DOI 10.1080/00036846.2017.1355540
   Hotez PJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004744
   Howard EJ, 2014, BJOG-INT J OBSTET GY, V121, P22, DOI 10.1111/1471-0528.12396
   Instituto Nacional de Estadistica y Geografia, 2016, ENC NAC INGR GAST HO
   Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3
   Lee BY, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005457
   Lee BY, 2017, VACCINE, V35, pA36, DOI 10.1016/j.vaccine.2016.11.033
   Lee BY, 2015, ADV PARASIT, V87, P329, DOI 10.1016/bs.apar.2015.01.002
   Lee BY, 2013, LANCET INFECT DIS, V13, P342, DOI 10.1016/S1473-3099(13)70002-1
   Lee BY, 2012, HUM VACC IMMUNOTHER, V8, P1293, DOI 10.4161/hv.20966
   Lee BY, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000916
   Lee BY, 2010, VACCINE, V28, P2806, DOI 10.1016/j.vaccine.2009.09.047
   Management Sciences for Health, 2016, INT MED PROD PRIC GU
   Cevallos AM, 2014, BIOMED RES INT, DOI 10.1155/2014/401864
   De Rissio AM, 2010, AM J TROP MED HYG, V82, P838, DOI 10.4269/ajtmh.2010.08-0383
   Markets Bloomberg, 2018, USDMXN SPOT EXCH RAT
   Martinez-Valverde S, 2014, SALUD PUBLICA MEXICO, V56, P612
   Montes-Rincon LM, 2016, ACTA TROP, V164, P100, DOI 10.1016/j.actatropica.2016.08.029
   Messenger LA, 2018, CURR OPIN INFECT DIS, V31, P415, DOI [10.1097/QCO.0000000000000478, 10.1097/qco.0000000000000478]
   Messenger LA, 2017, CLIN INFECT DIS, V65, P268, DOI 10.1093/cid/cix277
   Mian-McCarthy S, 2012, NEW ENGL J MED, V367, P2284, DOI 10.1056/NEJMoa1208394
   Mora MC, 2005, J PARASITOL, V91, P1468, DOI 10.1645/GE-549R.1
   Moscatelli G, 2015, MEM I OSWALDO CRUZ, V110, P507, DOI 10.1590/0074-02760140347
   Munoz FM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00436
   Murcia L, 2017, J INFECT DIS, V215, P1452, DOI 10.1093/infdis/jix087
   Murcia L, 2013, CLIN INFECT DIS, V56, P496, DOI 10.1093/cid/cis910
   Negrette OS, 2005, PEDIATRICS, V115, pE668, DOI 10.1542/peds.2004-1732
   Olotu A, 2016, NEW ENGL J MED, V374, P2519, DOI 10.1056/NEJMoa1515257
   Perez-Molina JA, 2018, LANCET, V391, P82, DOI 10.1016/S0140-6736(17)31612-4
   Pinheiro E, 2017, REV SOC BRAS MED TRO, V50, P296, DOI 10.1590/0037-8682-0433-2016
   Profit J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000379
   Rendell VR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119527
   Roy A, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4643
   Russomando G, 1998, AM J TROP MED HYG, V59, P487, DOI 10.4269/ajtmh.1998.59.487
   Salas NA, 2007, TROP MED INT HEALTH, V12, P1498, DOI 10.1111/j.1365-3156.2007.01958.x
   Sari T, 2014, TRAVEL MED INFECT DI, V12, P659, DOI 10.1016/j.tmaid.2014.03.004
   Schijman AG, 2003, J ANTIMICROB CHEMOTH, V52, P441, DOI 10.1093/jac/dkg338
   Secretaria de Hacienda y Credito Publico Unidad de Politicas de Ingresos No Tributarios, 2018, AN 1 APR AUT I DDIAG
   Spencer JP, 2017, AM FAM PHYSICIAN, V95, P786
   The World Bank, 2019, WORLD DEV IND 1960 2
   Ticona CAM, 2005, REV PANAM SALUD PUBL, V17, P147, DOI 10.1590/S1020-49892005000300001
   Torrico F, 2004, AM J TROP MED HYG, V70, P201, DOI 10.4269/ajtmh.2004.70.201
   World Health Organization, 2013, GLOB HLTH OBS COUNTR
NR 73
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3261
EP 3270
DI 10.1016/j.vaccine.2020.02.078
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600013
PM 32171575
DA 2020-05-12
ER

PT J
AU Colrain, P
   Blanc, DC
   Grundy, J
   Kone, S
AF Colrain, Paul
   Blanc, Diana Chang
   Grundy, John
   Kone, Solo
TI The binomial nature of immunization session size distributions and the
   implications for vaccine wastage
SO VACCINE
LA English
DT Article
DE Vaccine wastage; Vaccine wastage monitoring; Vaccine forecasting;
   Program management; Policy; Immunization session; Immunization planning
AB In this paper we demonstrate that immunization session size distributions are governed by binomial statistics and determined by just two readily available programmatic parameters, the birth cohort of the catchment area and the session frequency. Given this new knowledge, the unavoidable component of an immunization facility's opened vial wastage rate can be determined algebraically for each vial size and discard time. This has significant positive programmatic implications for immunization session planning, vaccine needs forecasting, vaccine wastage monitoring, and vaccine product specification and choice. Further operational research is required to field test the different applications of the model and to inform the development of tools and guidance. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Colrain, Paul; Blanc, Diana Chang; Kone, Solo] WHO, Ave Appia 20, CH-1202 Geneva, Switzerland.
   [Grundy, John] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, Australia.
RP Colrain, P (reprint author), Flat 1-1,2 Old Castle Rd, Glasgow G44 4SS, Lanark, Scotland.
EM pcolrain@yahoo.com
FU World Health OrganizationWorld Health Organization [001]
CR [Anonymous], 2012, SESS SIZ DAT ON COUN
   Blanc Diana Chang, 2004, PATH STUDY VAC UNPUB
   Dorelien A., 2013, 13785 U MICH POP STU
   Guichard S, 2010, VACCINE, V28, P858, DOI 10.1016/j.vaccine.2009.08.035
   Jaillard Philippe, 2009, AGENCE MED PRE UNPUB
   John Snow Inc, 2019, DOS PER CONT PARTN I
   Kone Solo, 2011, MOJT HAGH AFGH EVM A
   National Rural Health Mission Ministry of Health and Family Welfare UNICEF India, 2010, VACC WAST ASS FIELD
   Parmar D, 2010, HUM VACCINES, V21, P10397
   Samia Abdul Samad Ministry of Health of Brazil Brasilia Distrito Federal Brazil Antonia Maria Teixeira Brendan Flannery Ricardo Goncalves Consuelo Freiria, 2011, DEV INF SYST EV VACC
   Shreyash Mehta, 2013, NATL J COMMUNITY MED, V4
   Suarez-Castaneda E, 2015, VACCINE, V33, P6865, DOI 10.1016/j.vaccine.2015.07.092
   WHO, 2005, WHOVB0318REV1, P6
   Williams BA, 2016, HEALTH POLICY PLANN, V31, P563, DOI 10.1093/heapol/czv103
   World Health Organisation, 2018, WHOIVB1811
   World Health Organisation and Bill and Melinda Gates Foundation, 2004, HIST AN COMPR MULT P
   World Health Organisation and UNICEF, 2009, EFF VACC MAN GLOB DA
   Yawson AE, 2017, ARCH PUBLIC HEALTH, V75, DOI 10.1186/s13690-017-0179-7
NR 18
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3271
EP 3279
DI 10.1016/j.vaccine.2020.02.064
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600014
PM 32171578
DA 2020-05-12
ER

PT J
AU Yu, H
   Karunakaran, KP
   Jiang, XZ
   Chan, Q
   Rose, C
   Foster, LJ
   Johnson, RM
   Brunham, RC
AF Yu, Hong
   Karunakaran, Karuna P.
   Jiang, Xiaozhou
   Chan, Queenie
   Rose, Caren
   Foster, Leonard J.
   Johnson, Raymond M.
   Brunham, Robert C.
TI Comparison of Chlamydia outer membrane complex to recombinant outer
   membrane proteins as vaccine
SO VACCINE
LA English
DT Article
DE Vaccine; Chlamydia; COMC; Outer membrane proteins; CMI; Neutralizing
   antibody
ID T-CELL ANTIGENS; GENITAL-TRACT INFECTION; INDUCE PROTECTIVE IMMUNITY;
   TRACHOMATIS INFECTION; MONOCLONAL-ANTIBODIES; SERUM ANTIBODY; MURINE
   MODEL; WILD-TYPE; MURIDARUM; IMMUNIZATION
AB The Chlamydial outer membrane complex (COMC) from the elementary body (EB) is a protein rich insoluble outer membrane shell from which cytosolic proteins have been extracted with detergent. In this study we conducted mass spectrometry experiments to detect proteins in the COMC prepared from C. muridarum EB. Proteomic analysis showed that the COMC contained 75 proteins that included 10 outer membrane proteins (OMPs) such as the major outer membrane protein (MOMP) and polymorphic membrane proteins (Pmps) that were previously identified as CD4 T cell vaccine candidates. We tested the vaccine efficacy of COMC in comparison to individual or combination of recombinant OMPs formulated with Th1 polarizing adjuvant DDA/MPL in two murine genital tract models (C. muridarum and C. trachomatis) by measuring organismal shedding, tubal pathology and immune responses including neutralizing antibodies. In the C. muridarum model, the COMC vaccine generated broadly reactive immune responses against multiple outer membrane proteins, high levels of EB binding and neutralizing antibody and exhibited superior protection against genital infection and pathology when compared to the recombinant PmpG vaccine. Denaturing the COMC by boiling significantly reduced protection. In the C. trachomatis model, the COMC vaccine also conferred greater protection compared to individual or multiple recombinant outer membrane proteins. Immunization with multiple COMCs from C. trachomatis serovars D, F and J generated neutralizing antibodies against multiple C. trachomatis serovars. We conclude that broader immunogenicity and generation of neutralizing antibody may explain the superior efficacy of COMC vaccine. The study suggests that conformationally intact proteins will be necessary for a successful recombinant OMP vaccine. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Yu, Hong; Karunakaran, Karuna P.; Jiang, Xiaozhou; Brunham, Robert C.] Univ British Columbia, Ctr Dis Control, Vaccine Res Lab, Vancouver, BC, Canada.
   [Chan, Queenie; Foster, Leonard J.] Univ British Columbia, Ctr High Throughput Biol, Dept Biochem & Mol Biol, Vancouver, BC, Canada.
   [Rose, Caren] Univ British Columbia, Fac Med, Sch Populat & Publ Hlth, Vancouver, BC, Canada.
   [Johnson, Raymond M.] Yale Univ, Sch Med, Sect Infect Dis, New Haven, CT USA.
RP Brunham, RC (reprint author), 655 West 12th Ave, Vancouver, BC V5Z 4R4, Canada.
EM robert.brunham@bccdc.ca
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [R01AI076483]; Genome
   BC "Proof of Concept" Program; Canada Foundation for InnovationCanada
   Foundation for Innovation; British Columbia Knowledge Development Fund;
   BC Proteomics Network
FX This work was supported by a National Institutes of Health Grant
   R01AI076483 and a Genome BC "Proof of Concept" Program. Mass
   spectrometry infrastructure used here was supported by the Canada
   Foundation for Innovation, the British Columbia Knowledge Development
   Fund and the BC Proteomics Network.
CR Abraham S, 2019, LANCET INFECT DIS
   Anttila T, 2001, JAMA-J AM MED ASSOC, V285, P47, DOI 10.1001/jama.285.1.47
   Bakshi RK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01981
   BATTEIGER BE, 1993, J GEN MICROBIOL, V139, P2965, DOI 10.1099/00221287-139-12-2965
   Bilenki L, 2005, J IMMUNOL, V175, P3197, DOI 10.4049/jimmunol.175.5.3197
   Brunham RC, 2005, J INFECT DIS, V192, P1836, DOI 10.1086/497341
   Brunham RC, 2005, NAT REV IMMUNOL, V5, P149, DOI 10.1038/nri1551
   Brunham RC, 2013, VACCINE, V31, P1892, DOI 10.1016/j.vaccine.2013.01.024
   CAMPOS M, 1995, INVEST OPHTH VIS SCI, V36, P1477
   Chan PHW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07999-8
   Chen D, 2010, J BACTERIOL, V192, P6017, DOI 10.1128/JB.00847-10
   COTTER TW, 1995, INFECT IMMUN, V63, P4704, DOI 10.1128/IAI.63.12.4704-4714.1995
   Darville T, 2019, AM J REPROD IMMUNOL, V81, DOI 10.1111/aji.13103
   Farris CM, 2011, INFECT IMMUN, V79, P986, DOI 10.1128/IAI.00881-10
   Finco O, 2011, P NATL ACAD SCI USA, V108, P9969, DOI 10.1073/pnas.1101756108
   Gondek DC, 2012, J IMMUNOL, V189, P2441, DOI 10.4049/jimmunol.1103032
   GRAYSTON JT, 1978, SEX TRANSM DIS, V5, P73, DOI 10.1097/00007435-197804000-00011
   He W, 2017, J BIOL CHEM, V292, P15121, DOI 10.1074/jbc.M117.784561
   Ioannou XP, 2002, J VIROL, V76, P9002, DOI 10.1128/JVI.76.18.9002-9010.2002
   Ishihama Y, 2006, J PROTEOME RES, V5, P988, DOI 10.1021/pr050385q
   Kari L, 2011, J EXP MED, V208, P2217, DOI 10.1084/jem.20111266
   Kari L, 2009, J IMMUNOL, V182, P8063, DOI 10.4049/jimmunol.0804375
   Karunakaran KP, 2008, J IMMUNOL, V180, P2459, DOI 10.4049/jimmunol.180.4.2459
   Karunakaran KP, 2015, VACCINE, V33, P2159, DOI 10.1016/j.vaccine.2015.02.055
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Liu XY, 2010, J BACTERIOL, V192, P2852, DOI 10.1128/JB.01628-09
   Liu Y, 2014, INFECT IMMUN, V82, P5327, DOI 10.1128/IAI.02576-14
   Longbottom D, 2003, J MED MICROBIOL, V52, P537, DOI 10.1099/jmm.0.05093-0
   Mabey DCW, 2014, VACCINE, V32, P1572, DOI 10.1016/j.vaccine.2013.10.016
   Miguel RDV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058565
   Moore T, 2002, IMMUNOLOGY, V105, P213, DOI 10.1046/j.0019-2805.2001.01354.x
   Morrison SG, 2005, J IMMUNOL, V175, P7536, DOI 10.4049/jimmunol.175.11.7536
   Ness RB, 2008, SEX TRANSM DIS, V35, P129, DOI 10.1097/OLQ.0b013e3181557c25
   Newman L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143304
   Notti RQ, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.VMBF-0004-2015
   O'Connell CM, 2007, J IMMUNOL, V179, P4027, DOI 10.4049/jimmunol.179.6.4027
   Olsen AK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011349
   Paavonen J, 2003, AM J OBSTET GYNECOL, V189, P1287, DOI 10.1067/S0002-9378(03)00755-5
   Pal S, 1997, INFECT IMMUN, V65, P3361, DOI 10.1128/IAI.65.8.3361-3369.1997
   Pal S, 2001, INFECT IMMUN, V69, P6240, DOI 10.1128/IAI.69.10.6240-6247.2001
   Pal S, 2008, INFECT IMMUN, V76, P5581, DOI 10.1128/IAI.00574-08
   PEELING RW, 1991, INFECT IMMUN, V59, P2624, DOI 10.1128/IAI.59.8.2624-2630.1991
   PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233
   Qu YY, 2015, INFECT IMMUN, V83, P4056, DOI 10.1128/IAI.00841-15
   RANK RG, 1989, INFECT IMMUN, V57, P299, DOI 10.1128/IAI.57.1.299-301.1989
   ROCK KL, 1984, J EXP MED, V160, P1102, DOI 10.1084/jem.160.4.1102
   Sanchez-Campillo M, 1999, ELECTROPHORESIS, V20, P2269, DOI 10.1002/(SICI)1522-2683(19990801)20:11<2269::AID-ELPS2269>3.0.CO;2-D
   SU H, 1995, VACCINE, V13, P1023, DOI 10.1016/0264-410X(95)00017-U
   TAN TW, 1990, INFECT IMMUN, V58, P3101, DOI 10.1128/IAI.58.9.3101-3108.1990
   Wang J, 2010, J IMMUNOL, V185, P1670, DOI 10.4049/jimmunol.1001240
   WANG SP, 1967, AM J OPHTHALMOL, V63, P1615, DOI 10.1016/0002-9394(67)94155-4
   Wen ZY, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0787-3
   Yu H, 2014, VACCINE, V32, P4672, DOI 10.1016/j.vaccine.2014.06.002
   Yu H, 2012, INFECT IMMUN, V80, P1510, DOI 10.1128/IAI.06338-11
   Yu H, 2011, J IMMUNOL, V186, P3615, DOI 10.4049/jimmunol.1002952
   Yu H, 2010, INFECT IMMUN, V78, P2272, DOI 10.1128/IAI.01374-09
   Yu H, 2009, J IMMUNOL, V182, P1602, DOI 10.4049/jimmunol.182.3.1602
NR 57
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3280
EP 3291
DI 10.1016/j.vaccine.2020.02.059
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600015
PM 32151463
DA 2020-05-12
ER

PT J
AU Kuter, BJ
   Offit, P
AF Kuter, Barbara J.
   Offit, Paul
TI Celebrating the Centennial of the Birth of the World's Greatest
   Vaccinologist, Maurice R. Hilleman, 1919-2005
SO VACCINE
LA English
DT Article
C1 [Kuter, Barbara J.; Offit, Paul] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
RP Kuter, BJ (reprint author), Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
EM vacinfo@email.chop.edu
CR Collins H., 1999, INQUIRER MAGAZI 0829
   Hamborsky J, 2015, EPIDEMIOLOGY PREVENT
NR 2
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 3
PY 2020
VL 38
IS 16
BP 3292
EP 3293
DI 10.1016/j.vaccine.2020.02.072
PG 2
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TI
UT WOS:000525317600016
PM 32171574
DA 2020-05-12
ER

PT J
AU Abunahman, SS
   dos Santos, LC
   Tavares, FW
   Kontogeorgis, GM
AF Abunahman, Samir S.
   dos Santos, Leticia C.
   Tavares, Frederico W.
   Kontogeorgis, Georgios M.
TI A computational tool for parameter estimation in EoS: New methodologies
   and natural gas phase equilibria calculations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Equations of state; Parameter estimation; Computational tool; Natural
   gas production
ID EQUATION-OF-STATE; DIRECTIONAL ATTRACTIVE FORCES; DEW-POINT GAS;
   WATER-CONTENT; CPA EQUATION; MUTUAL SOLUBILITIES; HYDROCARBON SYSTEMS;
   HYDROGEN-SULFIDE; FLOW ASSURANCE; MIXTURES
AB Brazilian pre-salt reservoirs represent the discovery of large amounts of light oil, but at high pressures and containing high concentration of CO2. Proper parameter estimation procedures are essential to perform more accurate predictions of their thermodynamic properties. Therefore, two new methodologies for such calculations have been implemented here: by applying simultaneously VLE and LLE to the metric; and by handling water content in dew point conditions. Utilizing the Cubic-Plus-Association (CPA) EoS, they were employed to obtain new parameters for water. Also, new parameters were obtained for H2O + CO2 mixtures, whose average absolute deviation in water content at high pressures fell from 24% to 3% compared to previous publications. The same procedure was performed for other aqueous mixtures containing H2S and light hydrocarbons. Finally, this study has been applied into a natural gas compressing simulation with CO2, studying streams properties comparing the parameters obtained in this work with the literature. (C) 2019 Published by Elsevier Ltd.
C1 [Abunahman, Samir S.; dos Santos, Leticia C.] Petrobras Ctr Empresarial Senado, Av Henrique Valadares 28, BR-20231030 Rio De Janeiro, Brazil.
   [Tavares, Frederico W.] Univ Fed Rio de Janeiro, Escola Quim, Av Horacio Macedo 2030, BR-21945970 Rio De Janeiro, RJ, Brazil.
   [Kontogeorgis, Georgios M.] Tech Univ Denmark, Dept Chem & Biochem Engn, CERE, DK-2800 Lyngby, Denmark.
RP Abunahman, SS (reprint author), Petrobras Ctr Empresarial Senado, Av Henrique Valadares 28, BR-20231030 Rio De Janeiro, Brazil.
EM sabunahman@petrobras.com.br
FU CNPqNational Council for Scientific and Technological Development
   (CNPq); CAPESCAPES; FAPERJCarlos Chagas Filho Foundation for Research
   Support of the State of Rio de Janeiro (FAPERJ); PETROBRAS; ANP
FX The authors thank CNPq, CAPES, ANP, FAPERJ and PETROBRAS for financial
   support.
CR Abunahman S.S., 2018, THESIS
   ANTHONY RG, 1967, J CHEM ENG DATA, V12, P21, DOI 10.1021/je60032a007
   Beltrao R.L.C., 2009, OFFSH TECHN C HOUST
   CHAPMAN WG, 1988, MOL PHYS, V65, P1057, DOI 10.1080/00268978800101601
   Chapoy A, 2005, J CHEM ENG DATA, V50, P1157, DOI 10.1021/je049615s
   Das S., 2006, IEEE C EV COMP
   de Hemptinne J.-C., 2012, EDITIONS TECHNIP
   Derawi SO, 2003, FLUID PHASE EQUILIBR, V209, P163, DOI 10.1016/S0378-3812(03)00056-6
   dos Santos LC, 2015, IND ENG CHEM RES, V54, P743, DOI 10.1021/ie504224x
   dos Santos LC, 2015, IND ENG CHEM RES, V54, P6812, DOI 10.1021/acs.iecr.5b01410
   Folas GK, 2007, FLUID PHASE EQUILIBR, V252, P162, DOI 10.1016/j.fluid.2006.12.018
   Folas GK, 2006, IND ENG CHEM RES, V45, P1527, DOI 10.1021/ie050976q
   GPSA, 1998, GPSA ENG DAT
   Haghighi H, 2009, FLUID PHASE EQUILIBR, V276, P24, DOI 10.1016/j.fluid.2008.10.006
   HUANG SH, 1990, IND ENG CHEM RES, V29, P2284, DOI 10.1021/ie00107a014
   HUANG SSS, 1985, FLUID PHASE EQUILIBR, V19, P21, DOI 10.1016/0378-3812(85)85033-0
   Kennedy J, 1995, 1995 IEEE INTERNATIONAL CONFERENCE ON NEURAL NETWORKS PROCEEDINGS, VOLS 1-6, P1942, DOI 10.1109/ICNN.1995.488968
   Kobayashi R., 1953, IND ENG CHEM, V45, P441
   KOH CA, 1993, FLUID PHASE EQUILIBR, V83, P51, DOI 10.1016/0378-3812(93)87006-M
   Kontogeorgis G. M., 2010, THERMODYNAMIC MODELS
   Kontogeorgis GM, 2006, IND ENG CHEM RES, V45, P4855, DOI 10.1021/ie051305v
   Kontogeorgis GM, 2006, IND ENG CHEM RES, V45, P4869, DOI 10.1021/ie051306n
   Kontogeorgis GM, 1999, FLUID PHASE EQUILIBR, V158, P201, DOI 10.1016/S0378-3812(99)00060-6
   Kontogeorgis GM, 1996, IND ENG CHEM RES, V35, P4310, DOI 10.1021/ie9600203
   Li ZD, 2009, AICHE J, V55, P1803, DOI 10.1002/aic.11784
   Lundstrom C., 2005, THESIS
   Maddox R.N., 1988, LAUR REID GAS COND C
   Maribo-Mogensen B., 2014, THESIS
   Michelsen ML, 2006, IND ENG CHEM RES, V45, P8449, DOI 10.1021/ie060029x
   Mohammadi AH, 2004, IND ENG CHEM RES, V43, P7148, DOI 10.1021/ie049843f
   Moraes AOS, 2015, APPL MATH MODEL, V39, P4223, DOI 10.1016/j.apm.2014.12.034
   NELDER JA, 1965, COMPUT J, V7, P308, DOI 10.1093/comjnl/7.4.308
   Ng H.J., 2001, RR174 GPA RES
   Niederberger J, 2009, COMPUT-AIDED CHEM EN, V27, P675
   Olds RH, 1942, IND ENG CHEM, V34, P1223, DOI 10.1021/ie50394a018
   Oliveira MB, 2007, FLUID PHASE EQUILIBR, V258, P58, DOI 10.1016/j.fluid.2007.05.023
   PENG D, 1976, IND ENG CHEM FUND, V15, P59, DOI 10.1021/i160057a011
   Prausnitz JM, 1998, MOL THERMODYNAMICS F
   Reamer HH, 1943, IND ENG CHEM, V35, P790, DOI 10.1021/ie50403a012
   Reamer HH, 1944, IND ENG CHEM, V36, P381, DOI 10.1021/ie50412a024
   Santos L.C., 2015, THESIS
   SANTOS LC, 2015, FLUID PHASE EQUILIBR, V400, P76
   Schwaab M., 2007, E PAPERS
   Schwaab M, 2008, CHEM ENG SCI, V63, P1542, DOI 10.1016/j.ces.2007.11.024
   SELLECK FT, 1952, IND ENG CHEM, V44, P2219, DOI 10.1021/ie50513a064
   Shi Y., 1998, P IEEE INT C EV COMP
   Shiguematsu F.M., 2014, THESIS
   Smith J. M., 2005, INTRO CHEM ENG THERM
   SOAVE G, 1972, CHEM ENG SCI, V27, P1197, DOI 10.1016/0009-2509(72)80096-4
   SONG KY, 1994, FLUID PHASE EQUILIBR, V95, P281, DOI 10.1016/0378-3812(94)80074-X
   Tsivintzelis I., 2012, CUBIC PLUS ASS EOS P
   Tsivintzelis I, 2010, AICHE J, V56, P2965, DOI 10.1002/aic.12207
   TSONOPOULOS C, 1983, AICHE J, V29, P990, DOI 10.1002/aic.690290618
   Wei YS, 2000, AICHE J, V46, P169, DOI 10.1002/aic.690460119
   WERTHEIM MS, 1986, J STAT PHYS, V42, P477, DOI 10.1007/BF01127722
   WERTHEIM MS, 1984, J STAT PHYS, V35, P35, DOI 10.1007/BF01017363
   WERTHEIM MS, 1986, J STAT PHYS, V42, P459, DOI 10.1007/BF01127721
   WERTHEIM MS, 1984, J STAT PHYS, V35, P19, DOI 10.1007/BF01017362
   Wiebe R., 1941, Journal of the American Chemical Society, V63, P475, DOI 10.1021/ja01847a030
   Yakoumis IV, 1997, FLUID PHASE EQUILIBR, V130, P31, DOI 10.1016/S0378-3812(96)03200-1
   Zirrahi M, 2010, FLUID PHASE EQUILIBR, V299, P171, DOI 10.1016/j.fluid.2010.10.012
NR 61
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115437
DI 10.1016/j.ces.2019.115437
PG 13
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300002
DA 2020-05-12
ER

PT J
AU Bagkeris, I
   Michael, V
   Prosser, R
   Kowalski, A
AF Bagkeris, Ioannis
   Michael, Vipin
   Prosser, Robert
   Kowalski, Adam
TI Large-eddy simulation in a Sonolator high-pressure homogeniser
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Large-eddy simulation; Elliptic jet; High-pressure homogeniser; Liquid
   whistle; Turbulence
ID ENERGY DISSIPATION RATE; INFLOW CONDITIONS; FLOW-FIELD; TURBULENCE;
   SPECTRUM; CAVITATION; BREAKUP; MODELS; REACTORS; SQUARE
AB This paper examines the fluid dynamics of a pilot-scale high-pressure homogeniser using large-eddy simulation. The mixer consists of a non-planar elliptic jet released into a confined cylindrical chamber. The simulated results are validated by comparing mean quantities with published experimental data. The evolution of the shear layers in the jet near-field shows a localised region of high turbulent energy dissipation rate in the major plane, whereas in the minor plane the dissipation rate is of smaller magnitude and spreads over a wider region. The validity of the turbulence isotropy assumption, typically made in dispersed-phase modelling, is examined. Energy spectra exhibit an amplification close to the nozzle at frequencies associated with vortex shedding. Kolmogorovs classical 2/3 scaling in the second-order structure functions is found to be overshadowed by vortex shedding, resulting in steeper slopes in the jet near-field, where the rate of energy dissipation assumes the largest value in the mixer. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Bagkeris, Ioannis; Michael, Vipin; Prosser, Robert] Univ Manchester, Sch Mech Aerosp & Civil Engn, Manchester M13 9PL, Lancs, England.
   [Kowalski, Adam] Unilever R&D, Port Sunlight Lab, Quarry Rd East, Wirral CH63 3JW, Merseyside, England.
RP Bagkeris, I (reprint author), Univ Manchester, Sch Mech Aerosp & Civil Engn, Manchester M13 9PL, Lancs, England.
EM ioannis.bagkeris@manchester.ac.uk
OI Bagkeris, Ioannis/0000-0002-3923-8142
FU Engineering and Physical Sciences Research CouncilEngineering & Physical
   Sciences Research Council (EPSRC); Unilever [EP/N509280/1]; Center in
   Advanced Fluid Engineering for Digital Manufacturing (CAFE4DM)
FX Financial support by the Engineering and Physical Sciences Research
   Council and by Unilever (Grant No. EP/N509280/1) and the Center in
   Advanced Fluid Engineering for Digital Manufacturing (CAFE4DM) project
   is gratefully acknowledged. We thank the anonymous reviewers whose
   comments helped improve and clarify this manuscript. We also acknowledge
   Dr. Umair Ahmed (Newcastle University) for assistance in developing the
   computational grids and preliminary LES analysis, Prof. Mark Simmons
   (University of Birmingham) for kindly providing the Sonolator nozzles
   and for discussions regarding the PIV data, Dr. Marc Schimdt (University
   of Manchester) for the laser microscope measurements and the
   computational resources provided by Hartree Centre, ARCHER HPC and the
   University of Manchester HPC Pool.
CR Afgan I, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3596267
   Ahmed U, 2017, RENEW ENERG, V112, P235, DOI 10.1016/j.renene.2017.05.048
   Ahmed U, 2018, CHEM ENG RES DES, V133, P398, DOI 10.1016/j.cherd.2018.02.019
   Aleyasin SS, 2017, FLOW TURBUL COMBUST, V99, P329, DOI 10.1007/s10494-017-9820-3
   Alopaeus V, 2002, CHEM ENG SCI, V57, P1815, DOI 10.1016/S0009-2509(02)00067-2
   Archambeau F, 2004, INT J FINITE, V1, P1
   Bagkeris I, 2019, CHEM ENG TECHNOL, V42, P1555, DOI 10.1002/ceat.201800717
   Baldi S, 2004, CHEM ENG SCI, V59, P2659, DOI 10.1016/j.ces.2004.03.021
   Benhamadouche S, 2020, FLOW TURBUL COMBUST, V104, P19, DOI 10.1007/s10494-019-00046-8
   Chand R, 2007, BIOCHEM ENG J, V35, P357, DOI 10.1016/j.bej.2007.01.032
   Deen NG, 2001, CHEM ENG SCI, V56, P6341, DOI 10.1016/S0009-2509(01)00249-4
   Dhotre MT, 2009, CHEM ENG SCI, V64, P2692, DOI 10.1016/j.ces.2009.02.040
   Fiedler H. E., 1988, Progress in Aerospace Sciences, V25, P231, DOI 10.1016/0376-0421(88)90001-2
   GERMANO M, 1991, PHYS FLUIDS A-FLUID, V3, P1760, DOI 10.1063/1.857955
   Gogate PR, 2000, AICHE J, V46, P372, DOI 10.1002/aic.690460215
   Gogate PR, 2001, REV CHEM ENG, V17, P1
   Gogate PR, 2000, AICHE J, V46, P1641, DOI 10.1002/aic.690460815
   Gomes-Fernandes R, 2015, J FLUID MECH, V771, DOI 10.1017/jfm.2015.201
   Gothsch T, 2016, CHEM ENG SCI, V144, P239, DOI 10.1016/j.ces.2016.01.034
   Hakansson A, 2017, CHEM ENG SCI, V171, P625, DOI 10.1016/j.ces.2017.06.042
   Hakansson A, 2011, CHEM ENG SCI, V66, P1790, DOI 10.1016/j.ces.2011.01.026
   Han LC, 2014, CHEM ENG SCI, V117, P55, DOI 10.1016/j.ces.2014.06.018
   Hanjalic K., 2011, MODELLING TURBULENCE
   HUSSAIN AKMF, 1977, PHYS FLUIDS, V20, P1416, DOI 10.1063/1.862037
   HUSSAIN F, 1989, J FLUID MECH, V208, P257, DOI 10.1017/S0022112089002843
   Innings F, 2007, EXP THERM FLUID SCI, V32, P345, DOI 10.1016/j.expthermflusci.2007.04.007
   Jarrin N, 2006, INT J HEAT FLUID FL, V27, P585, DOI 10.1016/j.ijheatfluidflow.2006.02.006
   JEONG J, 1995, J FLUID MECH, V285, P69, DOI 10.1017/S0022112095000462
   John T.P., 2019, IND ENG CHEM RES, V211, DOI [10.1016/0255-2701(94)04005-2, DOI 10.1016/0255-2701(94)04005-2]
   KARBSTEIN H, 1995, CHEM ENG PROCESS, V34, P205, DOI 10.1016/0255-2701(94)04005-2
   Karimi M, 2018, CHEM ENG SCI, V192, P850, DOI 10.1016/j.ces.2018.08.016
   Khadem B, 2019, IND ENG CHEM RES, V58, P8220, DOI 10.1021/acs.iecr.9b00556
   Kim J, 2009, J FLUID MECH, V620, P383, DOI 10.1017/S0022112008004722
   Kolmogoroff A, 1941, CR ACAD SCI URSS, V30, P301
   Liao YX, 2009, CHEM ENG SCI, V64, P3389, DOI 10.1016/j.ces.2009.04.026
   LILLY DK, 1992, PHYS FLUIDS A-FLUID, V4, P633, DOI 10.1063/1.858280
   LILLY DK, 1967, P IBM SCI COMP S ENV, P195, DOI DOI 10.5065/D62R3PMM
   Manceau R, 2002, PHYS FLUIDS, V14, P744, DOI 10.1063/1.1432693
   MENTER FR, 1994, AIAA J, V32, P1598, DOI 10.2514/3.12149
   Meyers J., 2008, QUALITY RELIABILITY, P319, DOI [10.1007/978-1-4020-8578-9_13, DOI 10.1007/978-1-4020-8578-9_13]
   Mi J, 2010, FLOW TURBUL COMBUST, V84, P583, DOI 10.1007/s10494-009-9240-0
   Michael V., 2018, 12 INT ERCOFTAC S EN
   Michael V, 2017, CHEM ENG RES DES, V125, P494, DOI 10.1016/j.cherd.2017.08.002
   Mortensen HH, 2011, CAN J CHEM ENG, V89, P1076, DOI 10.1002/cjce.20587
   New TH, 2013, EXP THERM FLUID SCI, V49, P51, DOI 10.1016/j.expthermflusci.2013.03.009
   Nicoud F, 1999, FLOW TURBUL COMBUST, V62, P183, DOI 10.1023/A:1009995426001
   PANCHAPAKESAN NR, 1993, J FLUID MECH, V246, P225, DOI 10.1017/S0022112093000102
   Pope S. B., 2000, TURBULENT FLOWS
   Portela FA, 2017, J FLUID MECH, V825, P315, DOI 10.1017/jfm.2017.390
   POWELL A, 1961, J ACOUST SOC AM, V33, P395, DOI 10.1121/1.1908677
   ROCKWELL D, 1979, ANNU REV FLUID MECH, V11, P67, DOI 10.1146/annurev.fl.11.010179.000435
   Ryan D. J., 2015, THESIS
   Ryan DJ, 2017, CHEM ENG SCI, V163, P123, DOI 10.1016/j.ces.2017.01.035
   Saarenrinne P, 2000, EXP FLUIDS, V29, pS300, DOI 10.1007/s003480070032
   Saffman PG, 1992, VORTEX DYNAMICS
   Shah Y. T., 1999, CAVITATION REACTION
   Sheng J, 2000, CHEM ENG SCI, V55, P4423, DOI 10.1016/S0009-2509(00)00039-7
   Sivakumar M, 2014, ULTRASON SONOCHEM, V21, P2069, DOI 10.1016/j.ultsonch.2014.03.025
   Solsvik J, 2017, EUR J MECH B-FLUID, V61, P170, DOI 10.1016/j.euromechflu.2016.10.011
   Solsvik J, 2016, IND ENG CHEM RES, V55, P1449, DOI 10.1021/acs.iecr.5b04077
   Solsvik J, 2013, REV CHEM ENG, V29, P241, DOI 10.1515/revce-2013-0009
   SPEZIALE CG, 1991, J FLUID MECH, V227, P245, DOI 10.1017/S0022112091000101
   Tanaka T, 2007, EXP FLUIDS, V42, P893, DOI 10.1007/s00348-007-0298-y
   Taylor GI, 1938, PROC R SOC LON SER-A, V164, P0476, DOI 10.1098/rspa.1938.0032
   Tennekes H., 1972, 1 COURSE TURBULENCE
   WALSTRA P, 1983, ENCY EMULSION TECHNO, V1, P57
   Wu XG, 2011, HARMFUL ALGAE, V10, P738, DOI 10.1016/j.hal.2011.06.005
   Xu G, 2002, EXP FLUIDS, V33, P677, DOI 10.1007/s00348-002-0523-7
   Xu MY, 2014, CHINESE PHYS B, V23, DOI 10.1088/1674-1056/23/12/124703
   Yeoh SL, 2005, CHEM ENG SCI, V60, P2293, DOI 10.1016/j.ces.2004.10.048
   Yeung PK, 1997, PHYS REV E, V56, P1746, DOI 10.1103/PhysRevE.56.1746
NR 71
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115441
DI 10.1016/j.ces.2019.115441
PG 26
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300022
DA 2020-05-12
ER

PT J
AU Bao, LL
   Li, XJ
   Qi, YM
   Wang, ZW
   Li, J
AF Bao, Lele
   Li, Xiangjun
   Qi, Yingmeng
   Wang, Zhenwei
   Li, Jun
TI PEG/SBA-15-containing acrylic bone cement with enhanced drug release
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE SBA-15; PEG; Synergism; PMMA bone cement; Drug release
ID MESOPOROUS SILICA NANOPARTICLES; MECHANICAL-PROPERTIES; GENTAMICIN;
   CHITOSAN; HYDROXYAPATITE; ANTIBACTERIAL; PROSTHESIS; POROSITY; SBA-15
AB PMMA-based bone cements Formulated with PEG/SBA-15 were synthesized to achieve efficient and sustainable release of drugs. The presence of PEG/SBA-15 has a beneficial effect on the release of gentamicin (GTMC) in 70 days. The release of GTMC was improved markedly when the mass ratio of PEG/SBA-15 was up to 30% without notable change in mechanical properties. As a comparison, limited improvement of the GTMC release was found in the bone cement formulated with SBA-15 or PEG alone, while high content of single SBA-15 shown detrimental effect on the mechanical properties although the release of GTMC could be increased, disclosing the synergism of PEG and SBA-15. A normalized drug release model was adopted to describe the drug-release kinetics in the materials, and the diffusion coefficients were obtained. The excellent antimicrobial properties and low cytotoxicity of the materials have also been confirmed, demonstrating the potential applicability of the material in orthopedic surgery. (C) 2019 Published by Elsevier Ltd.
C1 [Bao, Lele; Qi, Yingmeng; Wang, Zhenwei; Li, Jun] Shanghai Inst Technol, Sch Chem & Environm Engn, Shanghai 201418, Peoples R China.
   [Li, Xiangjun] Shanghai Harmony Biotech Co Ltd, Shanghai 201300, Peoples R China.
RP Li, J (reprint author), Shanghai Inst Technol, Sch Chem & Environm Engn, Shanghai 201418, Peoples R China.
EM junliecust0967@sina.com
RI Wang, Zhenwei/AAL-3225-2020
OI Wang, Zhenwei/0000-0001-8955-1164
FU Consortium Plan Project of Shanghai, China [LM201638]; SIT, China
   [26220U190011-A06 (CHJJ-5), 1021ZK19100600149-A21]
FX The authors gratefully acknowledge Shanghai Harmony Biotech Co, Ltd,
   China for the help in cytotoxic experiment. We also acknowledge the
   financial support of Consortium Plan Project of Shanghai (LM201638),
   China, and the development funds of SIT, China (26220U190011-A06
   (CHJJ-5), 1021ZK19100600149-A21).
CR Anagnostakos K, 2009, J BIOMED MATER RES B, V90B, P467, DOI 10.1002/jbm.b.31281
   CHARNLEY J, 1960, J BONE JOINT SURG BR, V42, P28
   Chen F, 2012, MICROPOR MESOPOR MAT, V150, P83, DOI 10.1016/j.micromeso.2011.07.023
   Dalby MJ, 2002, BIOMATERIALS, V23, P569, DOI 10.1016/S0142-9612(01)00139-9
   Doadrio AL, 2004, J CONTROL RELEASE, V97, P125, DOI 10.1016/j.jconrel.2004.03.005
   Ewald A, 2011, ACTA BIOMATER, V7, P4064, DOI 10.1016/j.actbio.2011.06.049
   FU JC, 1976, J BIOMED MATER RES, V10, P743, DOI 10.1002/jbm.820100507
   Hanssen AD, 2004, J ARTHROPLASTY, V19, P73, DOI 10.1016/j.arth.2004.04.006
   Hendriks JGE, 2004, BIOMATERIALS, V25, P545, DOI 10.1016/S0142-9612(03)00554-4
   Hu SG, 2003, BIOMATERIALS, V24, P2685, DOI 10.1016/S0142-9612(03)00079-6
   Jayasree R, 2018, CERAM INT, V44, P9227, DOI 10.1016/j.ceramint.2018.02.133
   John A., 2015, J SURG RES, V194, P161
   Kang T, 2016, COMPOS SCI TECHNOL, V123, P232, DOI 10.1016/j.compscitech.2016.01.002
   Krasko MY, 2007, J CONTROL RELEASE, V117, P90, DOI 10.1016/j.jconrel.2006.10.010
   Letchmanan K, 2017, J MECH BEHAV BIOMED, V72, P163, DOI 10.1016/j.jmbbm.2017.05.003
   Lewis G, 2009, J BIOMED MATER RES B, V89B, P558, DOI 10.1002/jbm.b.31220
   Miola M, 2014, MAT SCI ENG C-MATER, V43, P65, DOI 10.1016/j.msec.2014.06.026
   Nandi SK, 2009, MAT SCI ENG C-MATER, V29, P2478, DOI 10.1016/j.msec.2009.07.014
   Ormsby R, 2010, J MECH BEHAV BIOMED, V3, P136, DOI 10.1016/j.jmbbm.2009.10.002
   Ormsby RW, 2014, J BIOMATER APPL, V29, P209, DOI 10.1177/0885328214521252
   Padilla S, 2002, J CONTROL RELEASE, V83, P343, DOI 10.1016/S0168-3659(02)00168-2
   Rasyid HN, 2009, ACTA ORTHOP, V80, P508, DOI 10.3109/17453670903389782
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Shanthini GM, 2015, APPL SURF SCI, V329, P116, DOI 10.1016/j.apsusc.2014.12.129
   Shen SC, 2016, MAT SCI ENG C-MATER, V58, P233, DOI 10.1016/j.msec.2015.08.011
   Shen SC, 2011, J MATER SCI-MATER M, V22, P2283, DOI 10.1007/s10856-011-4397-1
   Shi ZL, 2006, BIOMATERIALS, V27, P2440, DOI 10.1016/j.biomaterials.2005.11.036
   SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603
   Slane J, 2014, J MECH BEHAV BIOMED, V37, P141, DOI 10.1016/j.jmbbm.2014.05.015
   Szegedi A, 2011, J SOLID STATE CHEM, V184, P1201, DOI 10.1016/j.jssc.2011.03.005
   van de Belt H, 2000, BIOMATERIALS, V21, P1981, DOI 10.1016/S0142-9612(00)00082-X
   Wang M, 2018, MAT SCI ENG C-MATER, V90, P264, DOI 10.1016/j.msec.2018.04.075
   Wu P, 2006, BIOMATERIALS, V27, P2450, DOI 10.1016/j.biomaterials.2005.11.031
   Xu ZG, 2010, APPL SURF SCI, V256, P3160, DOI 10.1016/j.apsusc.2009.11.091
   Yu H, 2009, MICROPOR MESOPOR MAT, V123, P298, DOI 10.1016/j.micromeso.2009.04.013
   Yuan L, 2011, J PHYS CHEM C, V115, P9926, DOI 10.1021/jp201053d
   ZHANG XC, 1994, J PHARM PHARMACOL, V46, P718, DOI 10.1111/j.2042-7158.1994.tb03890.x
   ZHAO DY, 1998, J SCI, V279, P548
NR 38
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115379
DI 10.1016/j.ces.2019.115379
PG 9
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300029
DA 2020-05-12
ER

PT J
AU Besagni, G
   Deen, NG
AF Besagni, Giorgio
   Deen, Niels G.
TI Aspect ratio of bubbles in different liquid media: A novel correlation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble column; Correlation; Bubble size; Bubble shape
ID SINGLE BUBBLES; SHAPES; BEHAVIOR; COLUMNS; MOTION; DROPS; RISE; DRAG
AB The bubble shape is a required parameter in the modeling and design of multiphase reactors. This communication contributes to the broader discussion and closes the knowledge gap by providing a practical correlation for the bubble shape. The correlation is based on a very large experimental dataset, encompassing a wide range of Morton numbers (Log(10)(Mo) in the range of -10.8 and 2.3), flow conditions (single bubbles and dense bubbly flows) and considering both gravity-driven flows and flows with an extraexternal pressure gradient (counter-current flows). The experimental data were post-processed to derive a simple and physics-based correlation, relating the bubble aspect ratio to the bubble Reynolds and Eotyos numbers. This correlation provides a more accurate description and covers a wider range of applicability compared with literature correlations. As such, it can be helpful in the estimation of the interfacial area and velocity of a dispersed phase rising in a continuous phase. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Besagni, Giorgio] Politecn Milan, Dept Energy, Via Lambruschini 4a, I-20156 Milan, Italy.
   [Besagni, Giorgio; Deen, Niels G.] Eindhoven Univ Technol, Dept Mech Engn, Power & Flow Grp, POB 513, NL-5600 MB Eindhoven, Netherlands.
RP Besagni, G (reprint author), Politecn Milan, Dept Energy, Via Lambruschini 4a, I-20156 Milan, Italy.
EM giorgio.besagni@polimi.it
RI Deen, Niels G./C-2568-2009
OI Deen, Niels G./0000-0003-4159-3909
CR Aoyama S, 2016, INT J MULTIPHAS FLOW, V79, P23, DOI 10.1016/j.ijmultiphaseflow.2015.10.003
   Aoyama S, 2018, EXP THERM FLUID SCI, V96, P460, DOI 10.1016/j.expthermflusci.2018.03.015
   Besagni Giorgio, 2018, ChemEngineering, V2, DOI 10.3390/chemengineering2020013
   Besagni G, 2019, FLOW MEAS INSTRUM, V67, P55, DOI 10.1016/j.flowmeasinst.2019.04.008
   Besagni G, 2017, CHEM ENG RES DES, V118, P170, DOI 10.1016/j.cherd.2016.12.012
   Besagni G, 2017, CHEM ENG SCI, V158, P516, DOI 10.1016/j.ces.2016.11.003
   Besagni G, 2016, EXP THERM FLUID SCI, V74, P27, DOI 10.1016/j.expthermflusci.2015.11.020
   Cai ZQ, 2010, CHINESE J CHEM ENG, V18, P923, DOI 10.1016/S1004-9541(09)60149-X
   Celata GP, 2006, EXP THERM FLUID SCI, V31, P37, DOI 10.1016/j.expthermflusci.2005.08.006
   FAN LS, 1990, BUBBLE WAKE DYNAMICS
   GRACE JR, 1976, T I CHEM ENG-LOND, V54, P167
   Huang CR, 2018, EXP THERM FLUID SCI, V98, P170, DOI 10.1016/j.expthermflusci.2018.05.009
   Liang-Shih F., 2013, BUBBLE WAKE DYNAMICS
   Liu L, 2015, EXP THERM FLUID SCI, V62, P109, DOI 10.1016/j.expthermflusci.2014.11.018
   Loth E, 2008, INT J MULTIPHAS FLOW, V34, P523, DOI 10.1016/j.ijmultiphaseflow.2007.08.010
   Montoya G, 2016, CHEM ENG SCI, V141, P86, DOI 10.1016/j.ces.2015.09.011
   MOORE DW, 1965, J FLUID MECH, V23, P749, DOI 10.1017/S0022112065001660
   Mudde RF, 2005, ANNU REV FLUID MECH, V37, P393, DOI 10.1146/annurev.fluid.37.061903.175803
   MYINT W, 2007, J FLUID SCI TECHNOL, V2, P184, DOI DOI 10.1299/JFST.2.184
   Okawa T, 2003, INT J HEAT MASS TRAN, V46, P903, DOI 10.1016/S0017-9310(02)00345-9
   Risso F, 2018, ANNU REV FLUID MECH, V50, P25, DOI 10.1146/annurev-fluid-122316-045003
   Roghair I., 2012, DIRECT NUMERICAL SIM
   Sanada T, 2008, FLUID DYN RES, V40, P534, DOI 10.1016/j.fluiddyn.2007.12.005
   Seo H, 2018, ENERGY, V162, P892, DOI 10.1016/j.energy.2018.08.049
   Shi WB, 2018, CHEM ENG SCI, V187, P391, DOI 10.1016/j.ces.2018.05.013
   Sugihara K, 2007, KAGAKU KOGAKU RONBUN, V33, P402, DOI 10.1252/kakoronbunshu.33.402
   Tadaki T., 1961, KAGAKU KOGAKU, V25, P254
   Tomiyama A, 2002, CHEM ENG SCI, V57, P1849, DOI 10.1016/S0009-2509(02)00085-4
   Tomiyama A., 2004, 3 INT S 2 PHAS FLOW
   Vakrushev I. A., 1970, CHEM TECHNOLOGY FUEL, V5, P376
   WELLEK RM, 1966, AICHE J, V12, P854, DOI 10.1002/aic.690120506
   Zhen T, 2019, EXP THERM FLUID SCI, V102, P528, DOI 10.1016/j.expthermflusci.2018.12.018
   Ziegenhein T, 2017, EXP THERM FLUID SCI, V85, P248, DOI 10.1016/j.expthermflusci.2017.03.009
NR 33
TC 2
Z9 2
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115383
DI 10.1016/j.ces.2019.115383
PG 9
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300005
DA 2020-05-12
ER

PT J
AU Blanco-Aguilera, R
   Lara, JL
   Barajas, G
   Tejero, I
   Diez-Montero, R
AF Blanco-Aguilera, R.
   Lara, J. L.
   Barajas, G.
   Tejero, I
   Diez-Montero, R.
TI CFD simulation of a novel anaerobic-anoxic reactor for biological
   nutrient removal: Model construction, validation and hydrodynamic
   analysis based on OpenFOAM (R)
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Computational fluid dynamics; Multi-environment; Turbulent flow; RTD
   analysis; Tracer tests; Biological nutrient removal
ID RESIDENCE TIME DISTRIBUTION; FULL-SCALE; HYDRAULIC CHARACTERISTICS;
   BAFFLED REACTOR; PERFORMANCE EVALUATION; AXIAL-DISPERSION; WATER; FLOW;
   BIOREACTOR; OPTIMIZATION
AB AnoxAn is a novel multi-environment reactor for biological nutrient removal (BNR) from wastewater. Although its biological efficacy has been demonstrated on a pilot scale, hydrodynamics is observed to significantly affect the performance of AnoxAn. To study its complex hydraulic behaviour, a model based on Computational Fluid Dynamics 3D (CFD) is constructed using the OpenFOAM (R) open source toolbox and validated by experimental tests of Residence Time Distribution (RTD). Reactor elements represent a key factor in the modelling process. In this sense, the impeller of the anoxic zone is modelled as a flat disk, and the baffle after the anoxic zone as a porous media. According to CFD model simulations, stagnant, short-circuit zones and mixing quality are established and quantified. Finally, the influence on the hydrodynamics of reactor elements is also evaluated. The results of this detailed hydrodynamic analysis will form the basis for the design and optimization of scalable AnoxAn configurations. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Blanco-Aguilera, R.; Tejero, I; Diez-Montero, R.] Univ Cantabria, Dept Water & Environm Sci & Technol, Grp Environm Engn, Ave Castros S-N, E-39005 Santander, Spain.
   [Lara, J. L.; Barajas, G.] Univ Cantabria, Environm Hydraul Inst IHCantabria, Isabel Torres 15, Santander 39011, Spain.
   [Diez-Montero, R.] Univ Politecn Cataluna, Dept Civil & Environm Engn, Grp Environm Engn & Microbiol, C Jordi Girona 1-3,Bldg D1, E-08034 Barcelona, Spain.
RP Blanco-Aguilera, R (reprint author), Univ Cantabria, Dept Water & Environm Sci & Technol, Grp Environm Engn, Ave Castros S-N, E-39005 Santander, Spain.
EM blancoagr@unican.es
RI Lara, Javier/H-4703-2013
OI Lara, Javier/0000-0003-0968-1909
FU MEC (Ministerio de Educacion, Cultura y Deporte, Spain)German Research
   Foundation (DFG) [FPU16-05036]; Spanish Ministry of Industry and Economy
   [FJCI-2016-30997]; University of Cantabria; SODERCAN; FEDER programme
   (Proyecto integrado sostenible para la eliminacion biologica de
   nutrients: hacia la EDAR con balance de energia positiva)
FX R. Blanco-Aguilera is indebted to the MEC (Ministerio de Educacion,
   Cultura y Deporte, Spain) for the funding provided in the FPU (Formacion
   del Profesorado Universitario) Grant Program (FPU16-05036).; R.
   Diez-Montero would like to thank the Spanish Ministry of Industry and
   Economy for his research grant (FJCI-2016-30997). We acknowledge
   Santander Supercomputacion support group at the University of Cantabria
   who provided access to the supercomputer Altamira Supercomputer at the
   Institute of Physics of Cantabria (IFCA-CSIC), member of the Spanish
   Supercomputing Network, for performing simulations.; This work is part
   of a project funded by University of Cantabria, SODERCAN and YFEDER
   programme (Proyecto integrado sostenible para la eliminacion biologica
   de nutrients: hacia la EDAR con balance de energia positiva).
CR Al-Sammarraee M, 2009, CHEM ENG J, V152, P315, DOI 10.1016/j.cej.2009.01.052
   Angeloudis A, 2016, ENVIRON MODEL ASSESS, V21, P563, DOI 10.1007/s10666-016-9502-x
   Arnaldos M, 2018, WATER SCI TECHNOL, V77, P576, DOI 10.2166/wst.2017.550
   Bai H, 2008, CHEM ENG RES DES, V86, P1462, DOI 10.1016/j.cherd.2008.08.012
   Behzadian F, 2013, BIOPROC BIOSYST ENG, V36, P1043, DOI 10.1007/s00449-012-0857-3
   Brannock M, 2010, WATER RES, V44, P3181, DOI 10.1016/j.watres.2010.02.029
   Brannock M, 2010, DESALINATION, V250, P815, DOI 10.1016/j.desal.2008.11.048
   Brannock M., 2003, THESIS
   Bridgeman J, 2012, ADV ENG SOFTW, V44, P54, DOI 10.1016/j.advengsoft.2011.05.037
   BURCHARTH HF, 1995, COAST ENG, V24, P233, DOI 10.1016/0378-3839(94)00025-S
   Calder RSD, 2013, J ENVIRON ENG, V139, P849, DOI 10.1061/(ASCE)EE.1943-7870.0000678
   Celik IB, 2008, J FLUID ENG-T ASME, V130, DOI 10.1115/1.2960953
   Choi BS, 2004, IND ENG CHEM RES, V43, P6548, DOI 10.1021/ie0308240
   Climent J, 2019, CHEM ENG J, V374, P760, DOI 10.1016/j.cej.2019.05.195
   Climent J, 2018, CHEM ENG J, V348, P1, DOI 10.1016/j.cej.2018.04.058
   Couper JR, 2010, CHEMICAL PROCESS EQUIPMENT: SELECTION AND DESIGN, P1
   Dapelo D, 2018, BIORESOURCE TECHNOL, V265, P480, DOI 10.1016/j.biortech.2018.06.036
   De Clercq B., 2003, THESIS
   Diez-Montero R., 2015, THESIS
   Diez-Montero R, 2019, SCI TOTAL ENVIRON, V661, P187, DOI 10.1016/j.scitotenv.2019.01.136
   Diez-Montero R, 2016, BIORESOURCE TECHNOL, V209, P195, DOI 10.1016/j.biortech.2016.02.084
   Diez-Montero R, 2015, BIOPROC BIOSYST ENG, V38, P93, DOI 10.1007/s00449-014-1247-9
   Fang F, 2011, CHEM ENG J, V174, P635, DOI 10.1016/j.cej.2011.09.079
   Fernandez J.M., 2012, TECNICAS NUMERICAS I
   Gomez C., 2010, THESIS
   Hu BB, 2012, APPL MICROBIOL BIOT, V94, P817, DOI 10.1007/s00253-011-3659-7
   Jasak H, 2019, INT J NAV ARCH OCEAN, V11, P33, DOI 10.1016/j.ijnaoe.2017.12.004
   Ji JY, 2012, BIORESOURCE TECHNOL, V116, P47, DOI 10.1016/j.biortech.2012.04.026
   Klusener PAA, 2007, CHEM ENG SCI, V62, P5495, DOI 10.1016/j.ces.2007.03.044
   Kwon JC, 2005, WATER SCI TECHNOL, V52, P443
   Launder B, 1972, LECT MATH MODELS TUR
   Le Moullec Y, 2008, CHEM ENG SCI, V63, P2436, DOI 10.1016/j.ces.2008.01.029
   Levenspiel O., 1999, CHEM REACTION ENG, P54
   Liu MM, 2018, BIORESOURCE TECHNOL, V269, P300, DOI 10.1016/j.biortech.2018.08.089
   Lopez I, 2010, ENVIRON TECHNOL, V31, P591, DOI 10.1080/09593331003646638
   Losada IJ, 2016, J WATERW PORT COAST, V142, DOI 10.1061/(ASCE)WW.1943-5460.0000361
   Makinia J, 2006, J ENVIRON ENG-ASCE, V132, P476, DOI 10.1061/(ASCE)0733-9372(2006)132:4(476)
   Martin KJ, 2012, BIORESOURCE TECHNOL, V122, P83, DOI 10.1016/j.biortech.2012.02.110
   Martin-Dominguez A, 2005, J WATER SUPPLY RES T, V54, P435
   Michalopoulos I, 2018, COMPUT CHEM ENG, V111, P278, DOI 10.1016/j.compchemeng.2018.01.014
   Mihovilovic B., 2010, OPTIMIZACION PROCESO
   Nemade PD, 2010, J CHEM TECHNOL BIOT, V85, P77, DOI 10.1002/jctb.2269
   Olivet D, 2005, J CHEM TECHNOL BIOT, V80, P425, DOI 10.1002/jctb.1201
   Pereira J., 2011, ACTIVATED SLUDGE MOD
   Plascencia-Jatomea R, 2015, CHEM ENG SCI, V138, P324, DOI 10.1016/j.ces.2015.08.004
   Qi WK, 2013, CHEM ENG SCI, V104, P460, DOI 10.1016/j.ces.2013.09.035
   Qi WK, 2013, BIORESOURCE TECHNOL, V136, P94, DOI 10.1016/j.biortech.2013.02.033
   Rehman U., 2016, THESIS
   Renade V.V., 2002, COMPUTATIONAL FLOW M
   Sarathai Y, 2010, J ENVIRON SCI-CHINA, V22, P1319, DOI 10.1016/S1001-0742(09)60257-6
   Seb B., 2017, THESIS
   Tang DH, 2004, CHEM ENG TECHNOL, V27, P866, DOI 10.1002/ceat.200402076
   Tejero I., 2010, Spanish Patent, Patent No. [ES2338979B2, 2338979B2]
   Tejero I., 1991, Spanish Patent, Patent No. [ES2038556, 2038556]
   Terashima M, 2009, BIORESOURCE TECHNOL, V100, P2228, DOI 10.1016/j.biortech.2008.07.069
   Trad Z, 2015, CHEM ENG J, V282, P77, DOI 10.1016/j.cej.2015.04.119
   Wei P, 2019, WATER RES, V149, P86, DOI 10.1016/j.watres.2018.10.077
   Weller HG, 1998, COMPUT PHYS, V12, P620, DOI 10.1063/1.168744
   Wicklein E, 2016, WATER SCI TECHNOL, V73, P969, DOI 10.2166/wst.2015.565
   Wu B, 2009, T ASABE, V52, P1371, DOI 10.13031/2013.27786
   Yan XX, 2015, BIORESOURCE TECHNOL, V175, P633, DOI 10.1016/j.biortech.2014.10.133
   Yerushalmi L, 2011, WATER SCI TECHNOL, V64, P1967, DOI 10.2166/wst.2011.776
   Yerushalmi L, 2013, BIOPROC BIOSYST ENG, V36, P1339, DOI 10.1007/s00449-012-0836-8
   Zeng Y, 2005, BIOCHEM ENG J, V25, P113, DOI 10.1016/j.bej.2005.04.024
   Zhang J, 2016, J AM WATER WORKS ASS, V108, pE50, DOI 10.5942/jawwa.2016.108.0005
NR 65
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115390
DI 10.1016/j.ces.2019.115390
PG 19
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300008
DA 2020-05-12
ER

PT J
AU Cheng, J
   Lai, X
   Ye, Q
   Guo, WB
   Zhou, JH
AF Cheng, Jun
   Lai, Xin
   Ye, Qing
   Guo, Wangbiao
   Zhou, Junhu
TI Numerical simulation on optimizing flow field and flashing-light effect
   in jet-aerated tangential swirling-flow plate photobioreactor to improve
   microalgal growth
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CFD; Flashing-light effect; Microalgae; Plate photobioreactor;
   Swirling-flow
ID CULTIVATION; BIOREACTOR; ENHANCEMENT; PERFORMANCE; VELOCITY; KINETICS;
   BAFFLES; DARK
AB To reduce the dead zone in photobioreactors, strengthen the flashing-light effect and promote microalgal growth, computational fluid dynamics (CFD) simulation was employed to optimize the turbulent kinetic energy (TKE) and light/dark circle frequency in jet-aerated tangential swirling-flow plate (JTSP) photobioreactor. The tangential jets created a large clockwise vertical vortex and several secondary vortices in the JTSP photobioreactor, which significantly reduced the proportion of the dead zone and increased the light/dark circle frequency. Compared with the traditional airlift plate photobioreactor, the dead zone of the JTSP photobioreactor was reduced by 56.9%, whereas TKE increased by 35.5% to 18.2 cm(2)/s(2). Meanwhile, the light/dark circle frequency increased by 11.4-fold to 0.13 Hz, and the light time ratio increased by 17.1-fold to 33.4%. This led to a 46.5% increase in the biomass dry weight and 54.8% increase in the CO2 fixation rate in the JTSP photobioreactor. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cheng, Jun; Lai, Xin; Ye, Qing; Guo, Wangbiao; Zhou, Junhu] Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Peoples R China.
RP Cheng, J (reprint author), Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Peoples R China.
EM juncheng@zju.edu.cn
FU National Key Research and Development Program-China [2016YFB0601002]
FX This study was supported by the National Key Research and Development
   Program-China (2016YFB0601002).
CR Abu-Ghosh S, 2015, EUR J PHYCOL, V50, P469, DOI 10.1080/09670262.2015.1069404
   Alias CB, 2004, BIOTECHNOL BIOENG, V87, P723, DOI 10.1002/bit.20179
   Bannari R, 2011, CHEM ENG SCI, V66, P2057, DOI 10.1016/j.ces.2011.01.038
   Bitog JP, 2011, COMPUT ELECTRON AGR, V76, P131, DOI 10.1016/j.compag.2011.01.015
   Borowitzka M.A, 2005, ALGAL CULTURING TECH, P205
   Cheng J, 2019, BIORESOURCE TECHNOL, V288, DOI 10.1016/j.biortech.2019.121531
   Cheng J, 2018, BIORESOURCE TECHNOL, V270, P352, DOI 10.1016/j.biortech.2018.09.067
   Cheng J, 2018, BIORESOURCE TECHNOL, V261, P151, DOI 10.1016/j.biortech.2018.04.022
   Cheng J, 2013, BIORESOURCE TECHNOL, V136, P496, DOI 10.1016/j.biortech.2013.03.072
   Decostere B, 2013, CHEM ENG J, V222, P85, DOI 10.1016/j.cej.2013.01.103
   Gris B, 2014, APPL BIOCHEM BIOTECH, V172, P2377, DOI 10.1007/s12010-013-0679-z
   Huang JK, 2015, J APPL PHYCOL, V27, P49, DOI 10.1007/s10811-014-0281-y
   Huang JK, 2014, BIORESOURCE TECHNOL, V159, P8, DOI 10.1016/j.biortech.2014.01.134
   Jaouen P, 1999, BIORESOURCE TECHNOL, V68, P149, DOI 10.1016/S0960-8524(98)00144-8
   Liao Q, 2017, BIORESOURCE TECHNOL, V243, P528, DOI 10.1016/j.biortech.2017.06.091
   Luo HP, 2004, BIOTECHNOL BIOENG, V85, P382, DOI 10.1002/bit.10831
   Meng C, 2015, BIOPROC BIOSYST ENG, V38, P1347, DOI 10.1007/s00449-015-1376-9
   Pirasaci T, 2017, ALGAL RES, V28, P57, DOI 10.1016/j.algal.2017.10.009
   Saeid A, 2015, CHEM ENG RES DES, V93, P377, DOI 10.1016/j.cherd.2014.06.008
   Sun YH, 2016, BIORESOURCE TECHNOL, V220, P215, DOI 10.1016/j.biortech.2016.08.063
   Valdes FJ, 2012, BIORESOURCE TECHNOL, V119, P1, DOI 10.1016/j.biortech.2012.05.120
   Wang L, 2013, CHEM BIOCHEM ENG Q, V27, P211
   Wang LL, 2014, BIORESOURCE TECHNOL, V164, P20, DOI 10.1016/j.biortech.2014.04.100
   Xu L, 2012, BIORESOURCE TECHNOL, V119, P300, DOI 10.1016/j.biortech.2012.05.123
   Yang ZF, 2014, J APPL PHYCOL, V26, P2097, DOI 10.1007/s10811-014-0239-0
   Yang ZB, 2016, BIORESOURCE TECHNOL, V211, P519, DOI 10.1016/j.biortech.2016.03.145
   Ye Q, 2019, ACS SUSTAIN CHEM ENG, V7, P384, DOI 10.1021/acssuschemeng.8b03718
   Ye Q, 2018, BIORESOURCE TECHNOL, V266, P89, DOI 10.1016/j.biortech.2018.06.055
   Ye Q, 2018, RSC ADV, V8, P18828, DOI 10.1039/c8ra02863j
   Yu G, 2009, J APPL PHYCOL, V21, P719, DOI 10.1007/s10811-009-9407-z
   Zeng XH, 2012, CHEM ENG J, V183, P192, DOI 10.1016/j.cej.2011.12.062
   Zhang QH, 2013, BIOTECHNOL PROGR, V29, P127, DOI 10.1002/btpr.1641
NR 32
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115371
DI 10.1016/j.ces.2019.115371
PG 10
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300026
DA 2020-05-12
ER

PT J
AU Cho, JIS
   Marquis, J
   Trogadas, P
   Neville, TP
   Brett, DJL
   Coppens, MO
AF Cho, J. I. S.
   Marquis, J.
   Trogadas, P.
   Neville, T. P.
   Brett, D. J. L.
   Coppens, M-O
TI Optimizing the architecture of lung-inspired fuel cells
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Lung-inspired; Fractal; Flow-field; Gas diffusion layer; Pt utilization
ID CATHODE CATALYST LAYER; GAS-DIFFUSION-LAYER; FLOW-FIELD DESIGNS; WATER
   MANAGEMENT; LIQUID WATER; OXYGEN-TRANSPORT; MULTIVARIABLE OPTIMIZATION;
   NUMERICAL-SIMULATION; NONISOTHERMAL MODEL; MOLECULAR-DYNAMICS
AB A finite-element model of a polymer electrolyte membrane fuel cell (PEMFC) with fractal branching, lung-inspired flow-field is presented. The effect of the number of branching generations N on the thickness of the gas diffusion layer (GDL) and fuel cell performance is determined. Introduction of a fractal flow-field to homogenize reactant concentration at the flow-field vertical bar GDL interface allows for the use of thinner GDLs. The model is coupled with an optimized cathode catalyst layer microstructure with respect to platinum utilization and power density, revealing that the 2020 DoE target of similar to 8 kW/g(pt) is met at N = 4 generations, and a platinum utilization of similar to 36 kW/g(pt) is achieved at N = 6 generations. In terms of the overall fuel cell stack architecture, our results indicate that either the platinum loading or the number of cells in the stack can be reduced by similar to 75%, the latter option of which, when combined with a 100 mu m GDL, can lead to >80% increase in the volumetric power density of the fuel cell stack. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Cho, J. I. S.; Trogadas, P.; Coppens, M-O] UCL, EPSRC Frontier Engn Ctr Nat Inspired Engn, London WC1E 7JE, England.
   [Cho, J. I. S.; Trogadas, P.; Coppens, M-O] UCL, Dept Chem Engn, London WC1E 7JE, England.
   [Cho, J. I. S.; Trogadas, P.; Neville, T. P.; Brett, D. J. L.] UCL, Dept Chem Engn, Electrochem Innovat Lab, London WC1E 7JE, England.
   [Marquis, J.] Rensselaer Polytech Inst, Dept Chem & Biol Engn, Troy, NY 12180 USA.
   [Marquis, J.] Moment Performance Mat, Waterford, NY 12188 USA.
RP Coppens, MO (reprint author), UCL, EPSRC Frontier Engn Ctr Nat Inspired Engn, London WC1E 7JE, England.; Coppens, MO (reprint author), UCL, Dept Chem Engn, London WC1E 7JE, England.
EM m.coppens@ucl.ac.uk
OI Coppens, Marc-Olivier/0000-0002-1810-2537; Brett,
   Dan/0000-0002-8545-3126
FU US National Science Foundation Fuel Cell IGERT at Rensselaer
   [DGE-0504361]; EPSRC ``Frontier Engineering"AwardEngineering & Physical
   Sciences Research Council (EPSRC) [EP/K038656/1]; UCL Faculty of
   Engineering Sciences Dean's Scholarship
FX The authors wish to thank the US National Science Foundation Fuel Cell
   IGERT at Rensselaer (grant number DGE-0504361) for supporting the start
   of this work. Continued research at UCL was made possible thanks to
   financial support from an EPSRC ``Frontier Engineering"Award (grant
   number EP/K038656/1) and a UCL Faculty of Engineering Sciences Dean's
   Scholarship.
CR Adilet Z., 2017, ADV SCI, V4
   Andersson M, 2016, APPL ENERG, V180, P757, DOI 10.1016/j.apenergy.2016.08.010
   Arvay A, 2013, INT J HYDROGEN ENERG, V38, P3717, DOI 10.1016/j.ijhydene.2012.12.149
   Barbir F., 2013, PEM FUEL CELLS THEOR
   BERNARDI DM, 1992, J ELECTROCHEM SOC, V139, P2477, DOI 10.1149/1.2221251
   Berning T, 2011, J POWER SOURCES, V196, P6305, DOI 10.1016/j.jpowsour.2011.03.068
   Berning T, 2003, J POWER SOURCES, V124, P440, DOI 10.1016/S0378-7753(03)00816-4
   Bevers D, 1997, J APPL ELECTROCHEM, V27, P1254, DOI 10.1023/A:1018488021355
   Bourell DL, 2016, ANNU REV MATER RES, V46, P1, DOI 10.1146/annurev-matsci-070115-031606
   Cao TF, 2015, INT J HEAT MASS TRAN, V87, P544, DOI 10.1016/j.ijheatmasstransfer.2015.04.010
   Cetinbas FC, 2017, J ELECTROCHEM SOC, V164, pF1596, DOI 10.1149/2.1111714jes
   Chen L, 2019, ELECTROCHIM ACTA, V306, P454, DOI 10.1016/j.electacta.2019.03.158
   Chen L, 2018, J POWER SOURCES, V400, P114, DOI 10.1016/j.jpowsour.2018.07.099
   Chiang MS, 2006, J POWER SOURCES, V160, P340, DOI 10.1016/j.jpowsour.2006.01.086
   Cho JIS, 2019, ENERGY, V170, P14, DOI 10.1016/j.energy.2018.12.143
   Cho JIS, 2018, INT J HYDROGEN ENERG, V43, P21949, DOI 10.1016/j.ijhydene.2018.10.030
   Cindrella L, 2009, J POWER SOURCES, V194, P146, DOI 10.1016/j.jpowsour.2009.04.005
   Coppens MO, 2012, CURR OPIN CHEM ENG, V1, P281, DOI 10.1016/j.coche.2012.03.002
   Cussler E. L., 2009, DIFFUSION MASS TRANS
   Dobson P, 2012, J ELECTROCHEM SOC, V159, pB514, DOI 10.1149/2.041205jes
   Du CY, 2006, J POWER SOURCES, V160, P224, DOI 10.1016/j.jpowsour.2006.01.041
   Ebrahimi S, 2016, INT J HYDROGEN ENERG, V41, P22260, DOI 10.1016/j.ijhydene.2016.07.247
   Eikerling M, 1998, J ELECTROANAL CHEM, V453, P89, DOI 10.1016/S0022-0728(98)00214-9
   Gandomi YA, 2016, J ELECTROCHEM SOC, V163, pF933, DOI 10.1149/2.1331608jes
   Gheorghiu S, 2005, MATH BIOSCI INTERACT, P31, DOI 10.1007/3-7643-7412-8_3
   Greszler TA, 2012, J ELECTROCHEM SOC, V159, pF831, DOI 10.1149/2.061212jes
   Guo NN, 2014, INT J HYDROGEN ENERG, V39, P21185, DOI 10.1016/j.ijhydene.2014.10.069
   Guo NN, 2013, INT J HYDROGEN ENERG, V38, P6750, DOI 10.1016/j.ijhydene.2013.03.066
   Guvelioglu GH, 2005, J POWER SOURCES, V147, P95, DOI 10.1016/j.jpowsour.2005.01.011
   Hamilton PJ, 2010, FUEL CELLS, V10, P489, DOI 10.1002/fuce.201000033
   Hashemi F, 2012, MATH COMPUT MODEL, V55, P1540, DOI 10.1016/j.mcm.2011.10.047
   Hirt L, 2017, ADV MATER, V29, DOI 10.1002/adma.201604211
   Hu GL, 2014, J ENERGY INST, V87, P163, DOI 10.1016/j.joei.2014.03.004
   Jang JH, 2006, J POWER SOURCES, V161, P323, DOI 10.1016/j.jpowsour.2006.03.089
   Jang JH, 2006, J POWER SOURCES, V156, P244, DOI 10.1016/j.jpowsour.2005.06.029
   Jeng KT, 2004, J POWER SOURCES, V138, P41, DOI 10.1016/j.jpowsour.2004.06.019
   Jinnouchi R, 2016, ELECTROCHIM ACTA, V188, P767, DOI 10.1016/j.electacta.2015.12.031
   Khajeh-Hosseini-Dalasm N, 2010, INT J HYDROGEN ENERG, V35, P2417, DOI 10.1016/j.ijhydene.2009.12.111
   Kjelstrup S, 2010, ENERG FUEL, V24, P5097, DOI 10.1021/ef100610w
   Kozakai M, 2016, INT J HYDROGEN ENERG, V41, P13180, DOI 10.1016/j.ijhydene.2016.05.131
   Kulkarni N, 2019, J POWER SOURCES, V439, DOI 10.1016/j.jpowsour.2019.227074
   Kurihara Y, 2019, J POWER SOURCES, V414, P263, DOI 10.1016/j.jpowsour.2019.01.011
   Lee J, 2017, ELECTROCHIM ACTA, V236, P161, DOI 10.1016/j.electacta.2017.03.162
   Ligon SC, 2017, CHEM REV, V117, P10212, DOI 10.1021/acs.chemrev.7b00074
   Lim BH, 2016, IONICS, V22, P301, DOI 10.1007/s11581-016-1644-y
   Limjeerajarus N, 2015, INT J HYDROGEN ENERG, V40, P7144, DOI 10.1016/j.ijhydene.2015.04.007
   Litster S, 2013, FUEL CELLS, V13, P935, DOI 10.1002/fuce.201300008
   Lum KW, 2005, J POWER SOURCES, V143, P103, DOI 10.1016/j.jpowsour.2004.11.032
   Mandelbrot B. B., 1983, FRACTAL GEOMETRY NAT
   Mandelbrot Benoit, 2004, FRACTALS CHAOS MANDE
   Marquis J, 2013, CHEM ENG SCI, V102, P151, DOI 10.1016/j.ces.2013.08.003
   Marquis J., 2013, CHEM BIOL ENG, P202
   Marr C, 1999, J POWER SOURCES, V77, P17, DOI 10.1016/S0378-7753(98)00161-X
   Mauroy B, 2004, NATURE, V427, P633, DOI 10.1038/nature02287
   Mittal VO, 2007, J ELECTROCHEM SOC, V154, pB652, DOI 10.1149/1.2734869
   Moein-Jahromi M, 2012, INT J HYDROGEN ENERG, V37, P17954, DOI 10.1016/j.ijhydene.2012.09.120
   Molaeimanesh GR, 2018, INT J HYDROGEN ENERG, V43, P20959, DOI 10.1016/j.ijhydene.2018.09.076
   Mortazavi M., 2013, ASME 2013 11 INT C F
   Murray CD, 1926, P NATL ACAD SCI USA, V12, P207, DOI 10.1073/pnas.12.3.207
   Myles TD, 2015, J ELECTROCHEM SOC, V162, pF645, DOI 10.1149/2.0131507jes
   Nalbant Y, 2018, INT J HYDROGEN ENERG, V43, P5939, DOI 10.1016/j.ijhydene.2017.10.148
   Narimani M, 2016, INT J HYDROGEN ENERG, V41, P4843, DOI 10.1016/j.ijhydene.2016.01.057
   Natarajan D, 2003, J POWER SOURCES, V115, P66, DOI 10.1016/S0378-7753(02)00624-9
   Owejan JP, 2010, J ELECTROCHEM SOC, V157, pB1456, DOI 10.1149/1.3468615
   Ozden A, 2017, INT J HYDROGEN ENERG, V42, P21546, DOI 10.1016/j.ijhydene.2017.01.007
   Park S, 2012, INT J HYDROGEN ENERG, V37, P5850, DOI 10.1016/j.ijhydene.2011.12.148
   Pasaogullari U, 2005, J ELECTROCHEM SOC, V152, pA380, DOI 10.1149/1.1850339
   Pollet BG, 2019, CURR OPIN ELECTROCHE, V16, P90, DOI 10.1016/j.coelec.2019.04.021
   Qu SG, 2008, J POWER SOURCES, V185, P302, DOI 10.1016/j.jpowsour.2008.06.080
   Randrianarizafy B, 2018, INT J HYDROGEN ENERG, V43, P8907, DOI 10.1016/j.ijhydene.2018.03.036
   RIDGE SJ, 1989, J ELECTROCHEM SOC, V136, P1902, DOI 10.1149/1.2097078
   Rizvandi OB, 2019, ELECTROCHIM ACTA, V302, P180, DOI 10.1016/j.electacta.2019.02.018
   Sander R, 1999, COMPILATION HENRYS L
   Sapoval B, 2002, P NATL ACAD SCI USA, V99, P10411, DOI 10.1073/pnas.122352499
   Schmittinger W, 2008, J POWER SOURCES, V180, P1, DOI 10.1016/j.jpowsour.2008.01.070
   Secanell M, 2007, ELECTROCHIM ACTA, V52, P6318, DOI 10.1016/j.electacta.2007.04.028
   Secanell M, 2010, STRUCT MULTIDISCIP O, V40, P563, DOI 10.1007/s00158-009-0387-z
   Shah AA, 2007, J POWER SOURCES, V163, P793, DOI 10.1016/j.jpowsour.2006.09.022
   Smith J. M., 2005, INTRO CHEM ENG THERM
   Sohn YJ, 2017, INT J HYDROGEN ENERG, V42, P13226, DOI 10.1016/j.ijhydene.2017.04.036
   SPRINGER TE, 1991, J ELECTROCHEM SOC, V138, P2334, DOI 10.1149/1.2085971
   Sun W, 2005, J POWER SOURCES, V144, P42, DOI 10.1016/j.jpowsour.2004.11.035
   Sun W, 2005, ELECTROCHIM ACTA, V50, P3359, DOI 10.1016/j.electacta.2004.12.009
   Suzuki T, 2013, J POWER SOURCES, V222, P379, DOI 10.1016/j.jpowsour.2012.08.068
   Taniguchi A, 2004, J POWER SOURCES, V130, P42, DOI 10.1016/j.jpowsour.2003.12.035
   Thomas A, 2014, INT J HYDROGEN ENERG, V39, P2649, DOI 10.1016/j.ijhydene.2013.11.105
   TIEDEMANN W, 1975, J ELECTROCHEM SOC, V122, P1482, DOI 10.1149/1.2134046
   Trogadas P, 2018, ENERG ENVIRON SCI, V11, P136, DOI 10.1039/c7ee02161e
   Trogadas P, 2008, ELECTROCHEM SOLID ST, V11, pB113, DOI 10.1149/1.2916443
   Trogadas P, 2016, ANGEW CHEM INT EDIT, V55, P122, DOI 10.1002/anie.201506394
   Trogadas P, 2014, CARBON, V75, P5, DOI 10.1016/j.carbon.2014.04.005
   Trogadas P, 2012, ACS APPL MATER INTER, V4, P5098, DOI 10.1021/am3016069
   Vicsek T., 1989, FRACTAL GROWTH PHENO
   Vyatskikh A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03071-9
   Wang C, 2017, INT J HYDROGEN ENERG, V42, P23107, DOI 10.1016/j.ijhydene.2017.07.136
   Wang C, 2017, SCI REP-UK, V7, DOI 10.1038/srep43447
   Wang GQ, 2007, ELECTROCHIM ACTA, V52, P6367, DOI 10.1016/j.electacta.2007.04.073
   Wang XH, 2008, J ELECTROCHEM SOC, V155, pB1085, DOI 10.1149/1.2965512
   Wang YL, 2017, INT J HEAT MASS TRAN, V105, P18, DOI 10.1016/j.ijheatmasstransfer.2016.09.030
   Wang Y, 2008, J ELECTROCHEM SOC, V155, pB1289, DOI 10.1149/1.2988763
   Wawdee P, 2015, INT J HYDROGEN ENERG, V40, P3739, DOI 10.1016/j.ijhydene.2015.01.037
   Weber AZ, 2008, ELECTROCHIM ACTA, V53, P7668, DOI 10.1016/j.electacta.2008.05.018
   Weber AZ, 2007, J ELECTROCHEM SOC, V154, pB405, DOI 10.1149/1.2437062
   Weber AZ, 2004, J ELECTROCHEM SOC, V151, pA1715, DOI 10.1149/1.1792891
   Whiteley M, 2019, J POWER SOURCES, V442, DOI 10.1016/j.jpowsour.2019.227218
   Wong KH, 2019, J ELECTROCHEM SOC, V166, pF128, DOI 10.1149/2.0771902jes
   Wu HW, 2016, APPL ENERG, V165, P81, DOI 10.1016/j.apenergy.2015.12.075
   Wu Y, 2018, J POWER SOURCES, V399, P254, DOI 10.1016/j.jpowsour.2018.07.085
   Xing L, 2014, INT J HYDROGEN ENERG, V39, P9087, DOI 10.1016/j.ijhydene.2014.03.225
   Xing L, 2013, INT J HYDROGEN ENERG, V38, P14295, DOI 10.1016/j.ijhydene.2013.08.104
   Ye GH, 2019, AICHE J, V65, P140, DOI 10.1002/aic.16410
   Ye GH, 2017, CHEM ENG J, V329, P56, DOI 10.1016/j.cej.2017.02.036
   Ye Q, 2007, J ELECTROCHEM SOC, V154, pB1242, DOI 10.1149/1.2783775
   You LX, 2001, INT J HYDROGEN ENERG, V26, P991, DOI 10.1016/S0360-3199(01)00035-0
   Zamel N, 2010, INT J ENERG RES, V34, P568, DOI 10.1002/er.1572
   Zhan NH, 2019, ELECTROCHIM ACTA, V306, P264, DOI 10.1016/j.electacta.2019.03.115
   Zhang ZQ, 2019, INT J HYDROGEN ENERG, V44, P379, DOI 10.1016/j.ijhydene.2018.05.149
   Zhou B, 2006, J POWER SOURCES, V155, P190, DOI 10.1016/j.jpowsour.2005.04.027
NR 118
TC 0
Z9 0
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115375
DI 10.1016/j.ces.2019.115375
PG 14
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300028
DA 2020-05-12
ER

PT J
AU Farizhandi, AAK
   Zhao, H
   Chen, T
   Lau, R
AF Farizhandi, Amir Abbas Kazemzadeh
   Zhao, Han
   Chen, Theodore
   Lau, Raymond
TI Evaluation of material properties using planetary ball milling for
   modeling the change of particle size distribution in a gas-solid
   fluidized bed using a hybrid artificial neural network-genetic algorithm
   approach
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Particle size distribution; Rosin-Rammler distribution; Particle
   attrition; Planetary ball milling; Gas-solid fluidized bed; Artificial
   neural network
ID COAL ASH PARTICLES; ATTRITION PHENOMENA; ROSIN-RAMMLER; PREDICTION;
   PARAMETERS; COMBUSTION; CATALYST
AB This study aims to use planetary ball-milling as an evaluation tool of material properties and the result is subsequently used to develop a model for the change in particle size distribution (PSD) during fluidization for a range of materials using artificial neural network (ANN) method. It is believed that material properties such as hardness, density, brittleness, structure, etc play a crucial role in the particle attrition behavior. Unfortunately, little information on material properties is available, considering the wide variety of materials present. As a result, planetary ball-milling is proposed as a fast assessment technique to identify the properties of different materials. Planetary ball milling devices are readily available in most laboratories and the reduction in PSD can resemble the particle attrition process during fluidization. A Rosin-Rammler (RR) distribution was used to describe the PSD for both fluidization and ball milling processes. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Farizhandi, Amir Abbas Kazemzadeh; Zhao, Han; Chen, Theodore; Lau, Raymond] Nanyang Technol Univ, Sch Chem & Biomed Engn, 62 Nanyang Dr, Singapore 637459, Singapore.
   [Farizhandi, Amir Abbas Kazemzadeh] Rowan Univ, Dept Chem Engn, 201 Mull Hill Rd, Glassboro, NJ 08028 USA.
RP Lau, R (reprint author), Nanyang Technol Univ, Sch Chem & Biomed Engn, 62 Nanyang Dr, Singapore 637459, Singapore.
EM wmlau@ntu.edu.sg
RI Lau, Raymond/E-6843-2010
OI Lau, Raymond/0000-0001-5967-530X
FU National Environmental Agency (NEA), Singapore ETRP [1102 108]
FX This work is funded by National Environmental Agency (NEA), Singapore
   ETRP Grant No. 1102 108.
CR Alderliesten M, 2013, PART PART SYST CHAR, V30, P244, DOI 10.1002/ppsc.201200021
   Alexander DLJ, 2015, J CHEM INF MODEL, V55, P1316, DOI 10.1021/acs.jcim.5b00206
   ARENA U, 1984, COMBUST FLAME, V57, P123, DOI 10.1016/0010-2180(84)90142-1
   Behrisch M., 2011, SIMUL 2011, P55
   BEMROSE CR, 1987, POWDER TECHNOL, V49, P97, DOI 10.1016/0032-5910(87)80054-2
   BLINICHEV VN, 1968, INT CHEM ENG, V8, P615
   Clift R, 1996, POWDER TECHNOL, V88, P335, DOI 10.1016/S0032-5910(96)03138-5
   El-Kareh B., 2012, FUNDAMENTALS SEMICON
   Farizhandi AAK, 2016, CHEM ENG SCI, V155, P210, DOI 10.1016/j.ces.2016.08.015
   Fonseca DJ, 2002, ADV ENG INFORM, V16, P241, DOI 10.1016/S1474-0346(03)00005-3
   Gangolli S., 2007, DICT SUBSTANCES THEI
   Holland J.H., 1992, ADAPTATION NATURAL A
   Klett C, 2007, AICHE J, V53, P769, DOI 10.1002/aic.11130
   Krajzewicz D., 2012, INT J ADV SYST MEAS, V5, P128
   KRAJZEWICZ D, 2002, P 4 MIDDL E S SIM MO, P183
   Li YF, 2010, APPL SOFT COMPUT, V10, P1257, DOI 10.1016/j.asoc.2009.11.034
   Lin CL, 2005, KOREAN J CHEM ENG, V22, P154, DOI 10.1007/BF02701478
   Macias-Garcia A, 2004, MATER CHARACT, V52, P159, DOI 10.1016/j.matchar.2004.04.007
   Merrick D., 1974, PARTICLE SIZE REDUCT, P367
   Metta N, 2018, INT J PHARMACEUT, V549, P271, DOI 10.1016/j.ijpharm.2018.07.056
   PATIENCE GS, 1994, STUD SURF SCI CATAL, V82, P1
   Pell M., 1990, HDB POWDER TECHNOLOG, P97
   Perry R., 2008, CHEM ENG HDB, P56
   PIS JJ, 1991, POWDER TECHNOL, V66, P41, DOI 10.1016/0032-5910(91)80079-X
   RAY YC, 1987, POWDER TECHNOL, V49, P193, DOI 10.1016/0032-5910(87)80128-6
   Reppenhagen J, 2000, POWDER TECHNOL, V113, P55, DOI 10.1016/S0032-5910(99)00290-9
   RODRIGUEZREINOS.F, 2002, HDB POROUS SOLIDS, V3, P1766, DOI DOI 10.1002/9783527618286.CH24A
   Scala F, 2013, WOODHEAD PUBL SER EN, P254, DOI 10.1533/9780857098801.1.254
   Searson DP, 2015, HDB GENETIC PROGRAMM, P551, DOI DOI 10.1007/978-3-319-20883-1_22
   SHAMLOU PA, 1990, CHEM ENG SCI, V45, P809
   Tasdemir A, 2009, PART PART SYST CHAR, V26, P69, DOI 10.1002/ppsc.200800035
   Tomeczek J, 2007, AICHE J, V53, P1159, DOI 10.1002/aic.11140
   Werther J, 2004, IND ENG CHEM RES, V43, P5593, DOI 10.1021/ie030760t
   Werther J., 2003, HDB FLUIDIZATION FLU
   Wu SY, 1999, CAN J CHEM ENG, V77, P738, DOI 10.1002/cjce.5450770415
   Yao QJ, 2014, CHEM ENG SCI, V118, P214, DOI 10.1016/j.ces.2014.07.013
   Yu HM, 2015, IND ENG CHEM RES, V54, P10825, DOI 10.1021/acs.iecr.5b02679
NR 37
TC 1
Z9 1
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115469
DI 10.1016/j.ces.2020.115469
PG 10
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300018
DA 2020-05-12
ER

PT J
AU Guzman-Meza, M
   Laurindo, JB
   Jarpa-Parra, M
   Segura-Ponce, L
AF Guzman-Meza, Marco
   Laurindo, Joao Borges
   Jarpa-Parra, Marcela
   Segura-Ponce, Luis
TI Isothermal drying of plant-based food material: An approach using 2D
   polydimethylsiloxane (PDMS) micromodels
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Porous media; Micromodels; PDMS; Plant-based food material; Drying
   mechanisms
ID OIL ABSORPTION PROFILES; MODEL POROUS-MEDIUM; PORE-NETWORK; WATER
   TRANSPORT; MOISTURE LOSS; MEDIA; MICROSTRUCTURE; ULTRASTRUCTURE;
   EVAPORATION; SIMULATION
AB The aims of this study were to build PDMS micromodels that simulated plant-based food material, and use them to investigate the drying mechanisms at pore-scale, the drying front morphologies and the drying curves during the isothermal drying process. Micromodels were built using a modified photolithographic technique. Three normal pore size distribution functions were developed to simulate the plasmodesma, intercellular space, and cell wall. Micromodels were impregnated with a pyranine aqueous solution and placed on a balance illuminated with ultraviolet light. Isothermal drying was developed by natural convection (20 degrees C). Drying front morphologies displayed a hierarchical behavior in which pores with the largest diameter dried first. Drainage and surface evaporation sequences and internal evaporation controlled the drying of PDMS micromodels. The micromodels were useful to simulate plant-based food material and study isothermal drying of such porous media. The results led to the proposal of some drying mechanisms that were involved. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Guzman-Meza, Marco; Segura-Ponce, Luis] Univ Bio Bio, Food Engn Dept, POB 447, Chillan, Chile.
   [Laurindo, Joao Borges] Univ Fed Santa Catarina, Dept Chem & Food Engn, BR-88040900 Florianopolis, SC, Brazil.
   [Jarpa-Parra, Marcela] Univ Adventista Chile, Box 7-D, Chillan, Chile.
RP Segura-Ponce, L (reprint author), Univ Bio Bio, Food Engn Dept, POB 447, Chillan, Chile.
EM lsegura@ubiobio.cl
FU Universidad del Bio-Bio; INNOVA BIOBIO [16IP65192]; Fondef IdeaComision
   Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT
   FONDEF [ID16I10206]
FX This work was supported by the Universidad del Bio-Bio [Scholarship fund
   for postgraduate research], the INNOVA BIOBIO [16IP65192 project], and
   the Fondef Idea [project No ID16I10206].
CR Aguilera JM, 2005, J FOOD ENG, V67, P1, DOI 10.1016/j.jfoodeng.2004.09.001
   Badillo GM, 2011, INT J MULTIPHAS FLOW, V37, P1219, DOI 10.1016/j.ijmultiphaseflow.2011.06.002
   Bai Y, 2002, J AGR FOOD CHEM, V50, P3179, DOI 10.1021/jf011354s
   Barbosa-Canovas G.V., 1996, DEHYDRATION FOODS, DOI [10.1007/978-1-4757-2456-1, DOI 10.1007/978-1-4757-2456-1]
   BONNET J, 1977, REV I FR PETROL, V32, P477, DOI 10.2516/ogst:1977026
   Cen HY, 2013, POSTHARVEST BIOL TEC, V85, P30, DOI 10.1016/j.postharvbio.2013.04.014
   Cortes P, 2016, AICHE J, V62, P629, DOI 10.1002/aic.15088
   Cortes P, 2015, FOOD BIOPROD PROCESS, V95, P133, DOI 10.1016/j.fbp.2015.05.001
   Cortes P, 2014, J FOOD ENG, V140, P19, DOI 10.1016/j.jfoodeng.2014.04.005
   DAIAN JF, 1991, INT J HEAT MASS TRAN, V34, P2081, DOI 10.1016/0017-9310(91)90219-5
   Defraeye T, 2016, DRY TECHNOL, V34, P1904, DOI 10.1080/07373937.2016.1144062
   Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z
   Eloukabi H, 2011, CHEM ENG TECHNOL, V34, P1085, DOI 10.1002/ceat.201100064
   Diaz RE, 2011, CIENCIA TECNOL ALIME, V31, P960, DOI 10.1590/S0101-20612011000400022
   Fanta SW, 2014, J FOOD ENG, V124, P86, DOI 10.1016/j.jfoodeng.2013.10.007
   Gonzalez-Fesler M, 2008, J FOOD ENG, V87, P323, DOI 10.1016/j.jfoodeng.2007.12.007
   Haider A, 2011, AICHE J, V57, P2574, DOI 10.1002/aic.12465
   HALLETT IC, 1992, INT J PLANT SCI, V153, P49, DOI 10.1086/297006
   Herremans E, 2015, BMC PLANT BIOL, V15, DOI 10.1186/s12870-015-0650-y
   Huang XL, 2012, DRY TECHNOL, V30, P1742, DOI 10.1080/07373937.2012.718306
   Jeffery J, 2012, J SCI FOOD AGR, V92, P2594, DOI 10.1002/jsfa.5767
   Joardder MUH, 2015, INT J FOOD PROP, V18, P2327, DOI 10.1080/10942912.2014.980945
   Khan MIH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33159-7
   Khan MIH, 2018, FOOD RES INT, V105, P772, DOI 10.1016/j.foodres.2017.12.010
   Khan MIH, 2017, INT J THERM SCI, V117, P266, DOI 10.1016/j.ijthermalsci.2017.04.006
   Khan MIH, 2016, INNOV FOOD SCI EMERG, V38, P252, DOI 10.1016/j.ifset.2016.10.015
   Laurindo JB, 1996, CHEM ENG SCI, V51, P5171, DOI 10.1016/S0009-2509(96)00341-7
   Laurindo JB, 1998, CHEM ENG SCI, V53, P2257, DOI 10.1016/S0009-2509(97)00348-5
   Lewicki PP, 2006, TRENDS FOOD SCI TECH, V17, P153, DOI 10.1016/j.tifs.2005.10.012
   Metzger T, 2007, AICHE J, V53, P3029, DOI 10.1002/aic.11307
   Mujumdar A.S., 2006, HDB IND DRYING, DOI [10.1201/9781420017618, DOI 10.1201/9781420017618]
   NOWICKI SC, 1992, DRY TECHNOL, V10, P925, DOI 10.1080/07373939208916488
   Oyarzun CA, 2009, DRY TECHNOL, V27, P14, DOI 10.1080/07373930802565731
   Pieczywek PM, 2012, COMPUT ELECTRON AGR, V81, P72, DOI 10.1016/j.compag.2011.11.006
   PRAT M, 1993, INT J MULTIPHAS FLOW, V19, P691, DOI 10.1016/0301-9322(93)90096-D
   Rahman MM, 2018, CHEM ENG SCI, V187, P1, DOI 10.1016/j.ces.2018.04.060
   Rahman MM, 2018, BIOSYST ENG, V169, P126, DOI 10.1016/j.biosystemseng.2018.02.007
   Ramirez C, 2011, J FOOD ENG, V106, P253, DOI 10.1016/j.jfoodeng.2011.05.020
   Roy S, 1997, PLANT PHYSIOL, V114, P539, DOI 10.1104/pp.114.2.539
   SanMartin FA, 2011, DRY TECHNOL, V29, P873, DOI 10.1080/07373937.2010.547968
   Segura LA, 2012, INT J REFRIG, V35, P2102, DOI 10.1016/j.ijrefrig.2012.08.014
   Segura L.A., 2013, P 6 NORD DRYING C ND
   Segura LA, 2005, CHEM ENG J, V111, P237, DOI 10.1016/j.cej.2005.02.004
   SEGURA LA, 2015, BLUCHER CHEM ENG P, V1, P2942
   Segura LA, 2007, DRY TECHNOL, V25, P1677, DOI 10.1080/07373930701590889
   Sghaier N, 2009, TRANSPORT POROUS MED, V80, P441, DOI 10.1007/s11242-009-9373-6
   Shaw T.M., 1986, MATER RES SOC S P, V73, DOI 10.1557/PROC-73-215
   SHAW TM, 1987, PHYS REV LETT, V59, P1671, DOI 10.1103/PhysRevLett.59.1671
   Sutherland P, 1999, INT J PLANT SCI, V160, P1099, DOI 10.1086/314196
   Varela P, 2007, J FOOD ENG, V78, P622, DOI 10.1016/j.jfoodeng.2005.10.034
   Vicent V, 2017, J FOOD ENG, V212, P154, DOI 10.1016/j.jfoodeng.2017.05.028
   Vorhauer N, 2013, DRY TECHNOL, V31, P920, DOI 10.1080/07373937.2012.724750
   Xiao B, 2014, DRY TECHNOL, V32, P1071, DOI 10.1080/07373937.2014.883629
NR 53
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115385
DI 10.1016/j.ces.2019.115385
PG 12
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300020
DA 2020-05-12
ER

PT J
AU Han, S
   Maruthamuthu, MK
   Lee, W
   Hong, SH
   Kang, SP
AF Han, Songlee
   Maruthamuthu, Murali Kannan
   Lee, Wonhee
   Hong, Soon Ho
   Kang, Seong-Pil
TI Efficacy of antifreeze proteins from Clupea harangues and Anarhichas
   minor on gas hydrate inhibition via cell surface display
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas hydrate; Antifreeze protein; Kinetic hydrate inhibitor; Cell surface
   display
ID WINTER FLOUNDER; CRYSTAL-GROWTH; ADSORPTION; DECOMPOSITION; PERFORMANCE;
   NUCLEATION; DYNAMICS; SYSTEM; MEMORY; SALINE
AB The expression of anti-freeze proteins (AFPs) on the Escherichia coli using the cell surface display (CSD) strategy was investigated to determine the feasibility of the method as a potential application of kinetic hydrate inhibitors. Monomers to hexamers of type II and III AFPs were displayed on the surfaces of bacterial cells. The kinetic inhibition performance of the AFPs on the synthetic natural gas hydrate formation was tested. The displayed AFPs exhibited higher KHI effectiveness with the increase in the number of peptides attached to the cells. In addition, best KHI performance of the AFPs could be achieved with higher dosages of the cultures when the concentration of the inducer is optimized, regardless of AFP type. Only a small portion of AFPs in the cell cultures exhibited considerable KHI performance, which implies that the CSD could be an effective strategy, reducing the cost for the production and purification of the AFPs. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Han, Songlee; Lee, Wonhee; Kang, Seong-Pil] Korea Inst Energy Res, Climate Change Res Div, 152 Gajeong Ro, Daejeon 34129, South Korea.
   [Maruthamuthu, Murali Kannan; Hong, Soon Ho] Univ Ulsan, Sch Chem Engn, 93 Daehak Ro, Ulsan 44610, South Korea.
RP Kang, SP (reprint author), Korea Inst Energy Res, Climate Change Res Div, 152 Gajeong Ro, Daejeon 34129, South Korea.; Hong, SH (reprint author), Univ Ulsan, Sch Chem Engn, 93 Daehak Ro, Ulsan 44610, South Korea.
EM shhong@ulsan.ac.kr; spkang@kier.re.kr
OI Kang, Seong-Pil/0000-0003-4191-9796
FU Korea Institute of Energy Technology Evaluation and Planning (KETEP);
   Ministry of Trade, Industry & Energy (MOTIE) of the Republic of Korea
   [20182010600430]
FX This work was conducted under the framework of the Research and
   Development Program of the Korea Institute of Energy Research (KIER,
   B9-2441), and also supported by the Korea Institute of Energy Technology
   Evaluation and Planning (KETEP) and the Ministry of Trade, Industry &
   Energy (MOTIE) of the Republic of Korea (20182010600430).
CR Bagherzadeh SA, 2015, PHYS CHEM CHEM PHYS, V17, P9984, DOI 10.1039/c4cp05003g
   Berg JM, 2012, BIOCHEMISTRY
   Cha M, 2013, J PHYS CHEM A, V117, P13988, DOI 10.1021/jp408346z
   Daraboina N, 2015, CAN J CHEM, V93, P1025, DOI 10.1139/cjc-2014-0543
   Daraboina N, 2013, FUEL, V105, P630, DOI 10.1016/j.fuel.2012.10.007
   Daraboina N, 2011, ENERG FUEL, V25, P4392, DOI 10.1021/ef200812m
   Daraboina N, 2011, ENERG FUEL, V25, P4384, DOI 10.1021/ef200813v
   Daraboina N, 2011, ENERG FUEL, V25, P4398, DOI 10.1021/ef200814z
   Desjardins M, 2012, FEBS J, V279, P2215, DOI 10.1111/j.1742-4658.2012.08605.x
   Drew D, 2006, NAT METHODS, V3, P303, DOI 10.1038/nmeth0406-303
   DUMAN JG, 1974, NATURE, V247, P237, DOI 10.1038/247237a0
   DUMAN JG, 1976, COMP BIOCHEM PHYS B, V54, P375, DOI 10.1016/0305-0491(76)90260-1
   Evans RP, 2005, FEBS J, V272, P5327, DOI 10.1111/j.1742-4658.2005.04929.x
   Feeney RE, 1998, TRENDS FOOD SCI TECH, V9, P102, DOI 10.1016/S0924-2244(98)00025-9
   Gordienko R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008953
   Graham LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081285
   Jensen L, 2011, ENERG FUEL, V25, P17, DOI 10.1021/ef100833n
   Jensen L, 2010, IND ENG CHEM RES, V49, P1486, DOI 10.1021/ie901321p
   Jimenez-Angeles F, 2018, ACS CENTRAL SCI, V4, P820, DOI 10.1021/acscentsci.8b00076
   Karig SP, 2014, CHEM ENG SCI, V116, P817, DOI 10.1016/j.ces.2014.04.035
   Ke W, 2016, ENERG FUEL, V30, P10015, DOI 10.1021/acs.energyfuels.6b02739
   Kelland M.A., 2012, ADV MAT SCI RES
   Kelland MA, 2006, ENERG FUEL, V20, P825, DOI 10.1021/ef050427x
   Kelland MA, 2018, ENERG FUEL, V32, P12001, DOI 10.1021/acs.energyfuels.8b03363
   Kelland MA, 2018, ENERG FUEL, V32, P9349, DOI 10.1021/acs.energyfuels.8b02239
   Kim H., 2017, MAR DRUGS, V15, P1
   Lee W, 2018, ENERG FUEL, V32, P4932, DOI 10.1021/acs.energyfuels.8b00294
   Li PS, 2015, CRIT REV MICROBIOL, V41, P140, DOI 10.3109/1040841X.2013.813898
   Magnusson C, 2018, ENERG FUEL, V32, P5772, DOI 10.1021/acs.energyfuels.8b00367
   Maruthamuthu MK, 2017, BIOCHEM ENG J, V122, P31, DOI 10.1016/j.bej.2017.02.009
   Maruthamuthu MK, 2015, BIOPROC BIOSYST ENG, V38, P2077, DOI 10.1007/s00449-015-1447-y
   Meister K, 2013, P NATL ACAD SCI USA, V110, P1617, DOI 10.1073/pnas.1214911110
   Neidhardt F.C., 1999, ESCHERICHIA COLI SAL
   Ohno H, 2010, CHEM-EUR J, V16, P10409, DOI 10.1002/chem.200903201
   Olijve LLC, 2016, P NATL ACAD SCI USA, V113, P3740, DOI 10.1073/pnas.1524109113
   Perfeldt CM, 2014, ENERG FUEL, V28, P3666, DOI 10.1021/ef500349w
   Ravikumar S, 2011, APPL BIOCHEM BIOTECH, V165, P1674, DOI 10.1007/s12010-011-9386-9
   Reshes G, 2008, BIOPHYS J, V94, P251, DOI 10.1529/biophysj.107.104398
   Salem M, 2008, BIOTECHNOL ADV, V26, P151, DOI 10.1016/j.biotechadv.2007.10.002
   Sharifi H, 2015, J CHEM ENG DATA, V60, P336, DOI 10.1021/je500591q
   Sharifi H, 2014, ENERG FUEL, V28, P3712, DOI 10.1021/ef500524m
   Sharifi H, 2014, CRYST GROWTH DES, V14, P2923, DOI 10.1021/cg500218q
   Sharp K.A., 2014, WATER TREATMENT TECH, V31
   Sloan ED, 2008, CHEM IND-SER, V119, pXIX
   Sun MW, 2013, J COLLOID INTERF SCI, V402, P312, DOI 10.1016/j.jcis.2013.02.053
   Sun TJ, 2015, BIOPHYS J, V109, P1698, DOI 10.1016/j.bpj.2015.08.041
   Sun TJ, 2015, J PHYS CHEM B, V119, P12808, DOI 10.1021/acs.jpcb.5b06474
   Sundramoorthy JD, 2015, CRYST GROWTH DES, V15, P1233, DOI 10.1021/cg501626h
   Townson I, 2012, ENERG FUEL, V26, P7170, DOI 10.1021/ef301077m
   Udegbunam LU, 2018, J CHEM THERMODYN, V117, P155, DOI 10.1016/j.jct.2017.08.015
   Ustun NS, 2015, J FOOD PROCESS PRES, V39, P3189, DOI 10.1111/jfpp.12476
   Walker V.K., 2005, US Patent, Patent No. [2005/0161631 A1, 20050161631]
   Walker VK, 2015, CAN J CHEM, V93, P839, DOI 10.1139/cjc-2014-0538
   Zeng H, 2006, J AM CHEM SOC, V128, P2844, DOI 10.1021/ja0548182
   Zeng H, 2003, CAN J PHYS, V81, P17, DOI 10.1139/P03-001
   Zeng H, 2006, AICHE J, V52, P3304, DOI 10.1002/aic.10929
   Zeng H, 2007, ANGEW CHEM INT EDIT, V46, P5402, DOI 10.1002/anie.200605027
   Zhou HX, 2017, CHEM ENG SCI, V167, P42, DOI 10.1016/j.ces.2017.03.060
NR 58
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115470
DI 10.1016/j.ces.2020.115470
PG 12
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300015
DA 2020-05-12
ER

PT J
AU He, J
   Ju, Y
   Lammers, L
   Kulasinski, K
   Zheng, LG
AF He, Jian
   Ju, Yang
   Lammers, Laura
   Kulasinski, Karol
   Zheng, Liange
TI Tortuosity of kerogen pore structure to gas diffusion at molecular- and
   nano-scales: A molecular dynamics simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Tortuosity; Molecular-scale pores; Shale kerogen; Gas diffusion; Gas
   adsorption ability; Molecular dynamics
ID CARBON-DIOXIDE; ELECTRICAL-CONDUCTIVITY; MODEL-KEROGEN; ORGANIC TYPE;
   ADSORPTION; SHALE; TRANSPORT; MECHANISM; MIXTURES; RECOVERY
AB The tortuosity of kerogen pore structures is a vital parameter in the quantification of the gas diffusion ability and production of shale reservoirs. In this study, we perform a molecular dynamics simulation on the gas diffusion in the molecular- and nano-scale pores of shale kerogen to evaluate the tortuosity of the kerogen pore structure to gas diffusion. A novel diffusion model is proposed to evaluate the tortuosity by considering gas adsorption affinity, transportation regime, and probe gas atomic size. The results indicate that the tortuosity of the kerogen pore structure to gas diffusion is not a constant; instead, it highly depends on the probe gas atomic size and gas adsorption ability. The diffusive tortuosity is overestimated when the effect of gas adsorption ability is ignored. We find that the electrical tortuosity is lower than the diffusive tortuosity. This confirms that the tortuosity is underestimated when considering a purely geometric effect. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [He, Jian] China Univ Min & Technol, State Key Lab Geomech & Deep Underground Engn, 1 Univ Ave, Xuzhou 221116, Jiangsu, Peoples R China.
   [Ju, Yang] China Univ Min & Technol Beijing, State Key Lab Coal Resources & Safe Min, D11 Xueyuan Rd, Beijing 100083, Peoples R China.
   [Lammers, Laura] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA.
   [Kulasinski, Karol] Natl Ctr Nucl Res, Dept Mat Phys, A Soltana 7, PL-05400 Otwock, Poland.
   [Zheng, Liange] Lawrence Berkeley Natl Lab, Energy Geosci Div, Berkeley, CA 94720 USA.
RP Ju, Y (reprint author), China Univ Min & Technol Beijing, State Key Lab Coal Resources & Safe Min, D11 Xueyuan Rd, Beijing 100083, Peoples R China.
EM juy@cumtb.edu.cn
RI zheng, liange/B-9748-2011
OI zheng, liange/0000-0002-9376-2535
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51727807, 51674251, 51374213]; State Key Research
   Development Program of ChinaState Key Development Program for Basic
   Research of China [2016YFC0600705]; National Major Project for Science
   and Technology [2017ZX05049003-006]; Innovation Teams of the
   Ten-Thousand Talents Program - Ministry of Science and Technology of
   China [2016RA4067]; China Scholarship Council (CSC)China Scholarship
   Council
FX The authors gratefully appreciate the constructive comments and valuable
   suggestions from the associate editor and anonymous reviewers to help
   improve this manuscript. The authors sincerely acknowledge the financial
   support provided by the National Natural Science Foundation of China
   (Grant Nos. 51727807, 51674251 and 51374213), the State Key Research
   Development Program of China (Grant No. 2016YFC0600705), the National
   Major Project for Science and Technology (Grant No. 2017ZX05049003-006),
   the Innovation Teams of the Ten-Thousand Talents Program sponsored by
   the Ministry of Science and Technology of China (Grant No. 2016RA4067).
   In addition, Jian He gratefully acknowledges the China Scholarship
   Council (CSC) for funding his study at the Lawrence Berkeley National
   Laboratory and University of California Berkeley. The authors would like
   to thank Jennifer Mills for the valuable suggestions and for revising
   the language of this paper.
CR Bisoi S, 2017, J MEMBRANE SCI, V522, P77, DOI 10.1016/j.memsci.2016.09.007
   Bondarenko T, 2017, J PETROL SCI ENG, V150, P288, DOI 10.1016/j.petrol.2016.12.011
   Bousige C, 2016, NAT MATER, V15, P576, DOI [10.1038/nmat4541, 10.1038/NMAT4541]
   Bui K, 2017, SPE J, V22, P854, DOI 10.2118/185162-PA
   Cai JC, 2017, EARTH-SCI REV, V171, P419, DOI 10.1016/j.earscirev.2017.06.013
   Castez MF, 2017, J PHYS CHEM C, V121, P28527, DOI 10.1021/acs.jpcc.7b09811
   Chen C, 2013, GEOCHEM GEOPHY GEOSY, V14, P4066, DOI 10.1002/ggge.20254
   Chen L, 2015, SCI REP-UK, V5, DOI 10.1038/srep08089
   Elgmati M.M., 2013, N AM UNC GAS C EXH J, DOI [10.2118/144267-MS, DOI 10.2118/144267-MS]
   Elwinger F, 2017, J PHYS CHEM C, V121, P13757, DOI 10.1021/acs.jpcc.7b03885
   Fathi E, 2009, TRANSPORT POROUS MED, V80, P281, DOI 10.1007/s11242-009-9359-4
   Fleury M, 2016, J PETROL SCI ENG, V137, P55, DOI 10.1016/j.petrol.2015.11.006
   Hu HX, 2017, FUEL, V187, P220, DOI 10.1016/j.fuel.2016.09.056
   Huang L, 2018, APPL ENERG, V210, P28, DOI 10.1016/j.apenergy.2017.10.122
   Huang L, 2018, FUEL, V211, P159, DOI 10.1016/j.fuel.2017.09.060
   Javadpour F, 2007, J CAN PETROL TECHNOL, V46, P55, DOI 10.2118/07-10-06
   Jia ZJ, 2018, MICROPOR MESOPOR MAT, V269, P12, DOI 10.1016/j.micromeso.2017.11.049
   Jiang JY, 2017, PHYS CHEM CHEM PHYS, V19, P27974, DOI 10.1039/c7cp05437h
   Kang SM, 2011, SPE J, V16, P842, DOI 10.2118/134583-PA
   Katsube T.J., 2010, GEOLOGICAL SURVEY CA
   Kazemi M., 2016, SPE E REG M
   Kazemi M, 2016, J NAT GAS SCI ENG, V33, P1087, DOI 10.1016/j.jngse.2016.05.068
   Kulasinski K, 2016, J PHYS CHEM C, V120, P28144, DOI 10.1021/acs.jpcc.6b10777
   Kulasinski K, 2015, LANGMUIR, V31, P10843, DOI 10.1021/acs.langmuir.5b03122
   Lavenson DM, 2012, CELLULOSE, V19, P1085, DOI 10.1007/s10570-012-9732-2
   Michalec L, 2017, MOL PHYS, V115, P1086, DOI 10.1080/00268976.2016.1243739
   Mueller R, 2015, PHYS CHEM CHEM PHYS, V17, P27481, DOI 10.1039/c5cp04609b
   Pang Y, 2017, FUEL, V199, P272, DOI 10.1016/j.fuel.2017.02.072
   Parkes MV, 2014, MICROPOR MESOPOR MAT, V194, P190, DOI 10.1016/j.micromeso.2014.03.027
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Psarras P, 2017, ACCOUNTS CHEM RES, V50, P1818, DOI 10.1021/acs.accounts.7b00003
   Saomoto H, 2015, THEOR APPL MECH LETT, V5, P177, DOI 10.1016/j.taml.2015.07.001
   Sevostianov I, 2017, INT J ENG SCI, V121, P108, DOI 10.1016/j.ijengsci.2017.08.013
   Sha HY, 2016, COMP MATER SCI, V114, P160, DOI 10.1016/j.commatsci.2015.12.031
   Shen L, 2007, CHEM ENG SCI, V62, P3748, DOI 10.1016/j.ces.2007.03.041
   Suleimenova A, 2014, FUEL, V135, P492, DOI 10.1016/j.fuel.2014.07.005
   Sun HY, 2017, J PHYS CHEM C, V121, P10233, DOI 10.1021/acs.jpcc.7b02618
   Tjaden B, 2018, INT MATER REV, V63, P47, DOI 10.1080/09506608.2016.1249995
   Tozzi EJ, 2012, AICHE J, V58, P59, DOI 10.1002/aic.12578
   Ho TA, 2016, SCI REP-UK, V6, DOI 10.1038/srep28053
   Ungerer P, 2015, ENERG FUEL, V29, P91, DOI 10.1021/ef502154k
   Wang S, 2016, FUEL, V171, P74, DOI 10.1016/j.fuel.2015.12.071
   Wang XH, 2019, GLOB CHALL, V3, DOI 10.1002/gch2.201900006
   Xiang JH, 2014, SCI CHINA EARTH SCI, V57, P1749, DOI 10.1007/s11430-014-4849-9
   Yiannourakou M, 2013, OIL GAS SCI TECHNOL, V68, P977, DOI 10.2516/ogst/2013134
   Zalc JM, 2004, CHEM ENG SCI, V59, P2947, DOI 10.1016/j.ces.2004.04.028
   Zhang PW, 2015, SCI REP-UK, V5, DOI 10.1038/srep13501
   Zhang XL, 2014, SCI REP-UK, V4, DOI 10.1038/srep04843
   Ziarani AS, 2012, J APPL GEOPHYS, V83, P65, DOI 10.1016/j.jappgeo.2012.05.008
NR 49
TC 0
Z9 0
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115460
DI 10.1016/j.ces.2019.115460
PG 11
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300034
DA 2020-05-12
ER

PT J
AU Li, QJ
   Prigiobbe, V
AF Li, Qingjian
   Prigiobbe, Valentina
TI Studying the generation of foam in the presence of nanoparticles using a
   microfluidic system
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Artificial intelligence; Bubbles; Foam; Foam generation; Microfluidics;
   Porous media; Nanoparticles
ID ENHANCED OIL-RECOVERY; IN-WATER FOAMS; POROUS-MEDIA; SOLID PARTICLES;
   STABILIZED FOAM; AQUEOUS FOAMS; WIDE-RANGE; SURFACTANT; FLOW; LIQUID
AB In this paper, a study on the generation of foam in the presence of nanoparticles in porous media using microfluidics is reported. Drainage and co-injection tests were carried out and monitored with a high-speed camera. Convolutional neural network model was applied to quantify foam texture over time, efficiently. Microscopy images show a generation process characterized by early snap-off, followed by lamella-division, and finally leave-behind. In the presence of nanoparticles, the latter stage is delayed due to resistance to drainage imparted by capillary forces within the liquid films. Moreover, a general relationship between the generation rate and the pressure gradient, which resembles the classical constitutive equation for foam generation, i.e., r(g) proportional to del P-alpha, could be formulated. This indicates that the generation of a foam in the presence of partially hydrophobic nanoparticles and anionic surfactant, used for strong foam formation, follows the same mechanism of a foam stabilized only with surfactant. (C)2019 Elsevier Ltd. All rights reserved.
C1 [Li, Qingjian; Prigiobbe, Valentina] Stevens Inst Technol, Dept Civil Environm & Ocean Engn, Hoboken, NJ 07030 USA.
   [Prigiobbe, Valentina] Stevens Inst Technol, Dept Chem Engn & Mat Sci, Hoboken, NJ 07030 USA.
RP Prigiobbe, V (reprint author), Dept Civil Environm & Ocean Engn, Hoboken, NJ 07030 USA.
EM valentina.prigiobbe@stevens.edu
FU American Chemical Society Petroleum Research Fund (ACS-PRF)American
   Chemical Society [57739-DNI9]; Innovation & Entrepreneurial Fellowship
   Program at Stevens Institute of Technology
FX The authors would like to thank the American Chemical Society Petroleum
   Research Fund (ACS-PRF) under the Grant No. PRF# 57739-DNI9 and the
   Innovation & Entrepreneurial Fellowship Program at Stevens Institute of
   Technology for financial support.
CR Almajid MM, 2016, ADV COLLOID INTERFAC, V233, P65, DOI 10.1016/j.cis.2015.10.008
   Alvarez JM, 2001, SPE J, V6, P325, DOI 10.2118/74141-PA
   ARONSON AS, 1994, COLLOID SURFACE A, V83, P109, DOI 10.1016/0927-7757(94)80094-4
   Ashoori E, 2011, COLLOID SURFACE A, V377, P228, DOI 10.1016/j.colsurfa.2010.12.042
   Aveyard R, 2000, COLLOID POLYM SCI, V278, P155, DOI 10.1007/s003960050026
   Azmin M, 2012, MAT SCI ENG C-MATER, V32, P2654, DOI 10.1016/j.msec.2012.06.019
   Binks BP, 2008, SOFT MATTER, V4, P2373, DOI 10.1039/b811291f
   Binks BP, 2002, LANGMUIR, V18, P1270, DOI 10.1021/la011420k
   Binks BP, 2002, CURR OPIN COLLOID IN, V7, P21, DOI 10.1016/S1359-0294(02)00008-0
   Carn F, 2009, LANGMUIR, V25, P7847, DOI 10.1021/la900414q
   Chen HS, 2014, LANGMUIR, V30, P4262, DOI 10.1021/la5004929
   Chen YF, 2010, INT J MOL SCI, V11, P4417, DOI 10.3390/ijms11114417
   Conn CA, 2014, LAB CHIP, V14, P3968, DOI 10.1039/c4lc00620h
   Dicksen T., 2012, SOC PETROL ENG J
   Du ZP, 2003, LANGMUIR, V19, P3106, DOI 10.1021/la034042n
   Duan XG, 2014, J PETROL SCI ENG, V122, P428, DOI 10.1016/j.petrol.2014.07.042
   Elhag AS, 2018, J COLLOID INTERF SCI, V522, P151, DOI 10.1016/j.jcis.2018.03.037
   Espinoza D.A., 2010, SPE IMPR OIL REC S S
   Falls A.H., 1989, SPE RESERVOIR ENG, P155, DOI DOI 10.2118/16048-PA
   Ganan-Calvo AM, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.274501
   Garstecki P, 2006, LAB CHIP, V6, P693
   Gauglitz PA, 2002, CHEM ENG SCI, V57, P4037
   Goodfellow I., 2016, DEEP LEARNING
   Guignot S, 2010, CHEM ENG SCI, V65, P2579, DOI 10.1016/j.ces.2009.12.039
   Hirasaki G., 2000, AATDF MONOGRAPH SE 1, P3
   HIRASAKI GJ, 1985, SOC PETROL ENG J, V25, P176, DOI 10.2118/12129-PA
   Horozov TS, 2008, CURR OPIN COLLOID IN, V13, P134, DOI 10.1016/j.cocis.2007.11.009
   Huerre A, 2014, SOFT MATTER, V10, P6888, DOI 10.1039/c4sm00595c
   Jimenez A.I., 1989, DYNAMIC STABILITY FO, P460
   Kam SI, 2007, SPE J, V12, P35, DOI 10.2118/90938-PA
   Kam SI, 2008, COLLOID SURFACE A, V318, P62, DOI 10.1016/j.colsurfa.2007.12.017
   Kam SI, 2003, SPE J, V8, P417, DOI 10.2118/87334-PA
   Kaptay G, 2006, COLLOID SURFACE A, V282, P387, DOI 10.1016/j.colsurfa.2005.12.021
   Kaptay G, 2003, COLLOID SURFACE A, V230, P67, DOI 10.1016/j.colsurfa.2003.09.016
   Khatib Z., 1998, SPE RESERVOIR ENG, P919
   Khodaparast S, 2017, ENVIRON SCI TECHNOL, V51, P1340, DOI 10.1021/acs.est.6b04369
   Kim I, 2016, J NANOPART RES, V18, DOI 10.1007/s11051-016-3395-0
   Kovscek A., 1994, FUNDAMENTALS FOAM TR
   KOVSCEK AR, 1995, CHEM ENG SCI, V50, P3783, DOI 10.1016/0009-2509(95)00199-F
   Lake L.W., 2014, SOC PETROL ENG
   Lake LW, 1989, ENHANCED OIL RECOVER
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Liu SH, 2010, SPE J, V15, P282, DOI 10.2118/113936-PA
   Lotfollahi M, 2017, TRANSPORT POROUS MED, V116, P687, DOI 10.1007/s11242-016-0796-6
   Ma K, 2012, SOFT MATTER, V8, P10669, DOI 10.1039/c2sm25833a
   Martinez AC, 2008, SOFT MATTER, V4, P1531, DOI 10.1039/b804177f
   Mulligan CN, 2006, ENG GEOL, V85, P75, DOI 10.1016/j.enggeo.2005.09.029
   Osei-Bonsu K, 2017, J COLLOID INTERF SCI, V490, P850, DOI 10.1016/j.jcis.2016.12.015
   Park JI, 2010, ACS NANO, V4, P6579, DOI 10.1021/nn102248g
   Portois C, 2018, TRANSPORT POROUS MED, V124, P787, DOI 10.1007/s11242-018-1097-z
   Prigiobbe V, 2016, TRANSPORT POROUS MED, V111, P265, DOI 10.1007/s11242-015-0593-7
   Pugh RJ, 2016, BUBBLE FOAM CHEM
   Ransohoff T.C., 1988, SPE RESERVOIR ENG, V3, P573, DOI DOI 10.2118/15441-PA
   Redmon J., 2014, ABS14123128 CORR
   Redmon J, 2016, PROC CVPR IEEE, P779, DOI 10.1109/CVPR.2016.91
   Rossen W. R., 1996, FOAMS THEORY MEASURE, P413, DOI DOI 10.1002/FOOD.19970410116
   Shojaei MJ, 2019, IND ENG CHEM RES, V58, P1068, DOI 10.1021/acs.iecr.8b05265
   Singh R, 2017, FUEL, V197, P58, DOI 10.1016/j.fuel.2017.02.019
   Singh R, 2015, ENERG FUEL, V29, P467, DOI 10.1021/ef5015007
   Subramaniam AB, 2006, LANGMUIR, V22, P5986, DOI 10.1021/la060388x
   Sun Q, 2014, ENERG FUEL, V28, P2384, DOI 10.1021/ef402453b
   Vecchiolla D, 2018, SOFT MATTER, V14, DOI 10.1039/c8sm01285g
   Worthen AJ, 2013, AICHE J, V59, P3490, DOI 10.1002/aic.14124
   Worthen AJ, 2013, J COLLOID INTERF SCI, V391, P142, DOI 10.1016/j.jcis.2012.09.043
   Yang QW, 2011, J HAZARD MATER, V192, P1900, DOI 10.1016/j.jhazmat.2011.07.018
   Yekeen N, 2018, J PETROL SCI ENG, V164, P43, DOI 10.1016/j.petrol.2018.01.035
   Yekeen N, 2017, CHINESE J CHEM ENG, V25, P347, DOI 10.1016/j.cjche.2016.08.012
   Yekeen N, 2017, J DISPER SCI TECHNOL, V38, P416, DOI 10.1080/01932691.2016.1172969
   Yu JJ, 2014, FUEL, V126, P104, DOI 10.1016/j.fuel.2014.02.053
   Zhao MW, 2019, CHEM ENG SCI, V206, P203, DOI 10.1016/j.ces.2019.05.033
NR 70
TC 2
Z9 2
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115427
DI 10.1016/j.ces.2019.115427
PG 12
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300032
DA 2020-05-12
ER

PT J
AU Li, XC
   Huang, YY
   Chen, XQ
   Wu, Z
AF Li, Xingchen
   Huang, Yiyong
   Chen, Xiaoqian
   Wu, Zan
TI Breakup dynamics of low-density gas and liquid interface during Taylor
   bubble formation in a microchannel flow-focusing device
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Microfluidics; Multiphase flow; Nonlinear dynamics; Low-density gas;
   Confinement; Pinch-off
ID MICROFLUIDIC DEVICES; VISCOUS-LIQUIDS; MECHANISM; MEMS
AB This work aims to investigate the breakup dynamics of the low-density gas and liquid interface during bubble formation in a microchannel flow-focusing device. A high-contrast interface tracking method is developed. After the neck motion analysis in radial and axial directions, the time domain criterion between the liquid squeezing stage and the free pinch-off stage is proved to be two orders of magnitude less than the capillary time and is close to the viscous time of the liquid. Comparing to Nitrogen bubbles, the pinch-off point of Helium bubbles deflects downstream in viscous liquids and upstream in low surface tension liquids. Helium bubbles generate faster in viscous liquids and slower in low surface tension liquids. The power law exponents of thread diameter to the pinch-off remaining time in Helium experiments, which are larger than those in Nitrogen experiments, agree with previous studies in both ranges (1/3-1/2) and tendency. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Li, Xingchen] Natl Univ Def Technol, Coll Aeronaut & Astronaut, Changsha, Peoples R China.
   [Li, Xingchen; Wu, Zan] Lund Univ, Dept Energy Sci, Box 118, Lund, Sweden.
   [Huang, Yiyong; Chen, Xiaoqian] Chinese Acad Mil Sci, Natl Innovat Inst Def Technol, Beijing, Peoples R China.
RP Wu, Z (reprint author), Lund Univ, Dept Energy Sci, Box 118, Lund, Sweden.; Chen, XQ (reprint author), Chinese Acad Mil Sci, Natl Innovat Inst Def Technol, Beijing, Peoples R China.
EM chenxiaoqian@nudt.edu.cn; zan.wu@energy.lth.se
FU Swedish Research CouncilSwedish Research Council; Crafoord Foundation;
   AForsk Foundation; National Science Foundation for Young Scientists of
   China [11702320]; China Scholarship CouncilChina Scholarship Council
FX The financial supports for this project are from the Swedish Research
   Council, the Crafoord Foundation, the AForsk Foundation and the National
   Science Foundation for Young Scientists of China (Grant No. 11702320).
   X.C. Li appreciates the financial aid from China Scholarship Council.
   The authors would also like to thank Qi Liu at Xi'an Satellite Control
   Center for his help during the course of this work.
CR Bolanos-Jimenez R, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3173195
   Bolanos-Jimenez R, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.3009298
   BRETHERTON FP, 1961, J FLUID MECH, V10, P166, DOI 10.1017/S0022112061000160
   Castro-Hernandez E, 2011, LAB CHIP, V11, P2023, DOI 10.1039/c0lc00731e
   Chou H.-P., 2000, INTEGRATED ELASTOMER
   Cohen I, 1999, PHYS REV LETT, V83, P1147, DOI 10.1103/PhysRevLett.83.1147
   Eggers J, 1997, REV MOD PHYS, V69, P865, DOI 10.1103/RevModPhys.69.865
   Fu TT, 2015, CHEM ENG SCI, V135, P343, DOI 10.1016/j.ces.2015.02.016
   Fu TT, 2010, MICROFLUID NANOFLUID, V8, P467, DOI 10.1007/s10404-009-0471-0
   Fu TT, 2009, CHEM ENG SCI, V64, P2392, DOI 10.1016/j.ces.2009.02.022
   Garstecki P, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.164501
   Gekle S, 2009, PHYS REV E, V80, DOI 10.1103/PhysRevE.80.036305
   Gordillo JM, 2006, J FLUID MECH, V562, P303, DOI 10.1017/S0022112006001388
   Gordillo JM, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.3009297
   Gordillo JM, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2747996
   Gordillo JM, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.194501
   Hilgenfeldt S, 1998, J FLUID MECH, V365, P171, DOI 10.1017/S0022112098001207
   Ho CM, 1998, ANNU REV FLUID MECH, V30, P579, DOI 10.1146/annurev.fluid.30.1.579
   Joseph DD, 2006, INT J MULTIPHAS FLOW, V32, P285, DOI 10.1016/j.ijmultiphaseflow.2005.09.004
   Li XC, 2018, MICROSYST TECHNOL, V24, P2409, DOI 10.1007/s00542-017-3649-5
   Lister JR, 1998, PHYS FLUIDS, V10, P2758, DOI 10.1063/1.869799
   Lu YT, 2016, CHEM ENG SCI, V152, P516, DOI 10.1016/j.ces.2016.06.048
   Lu YT, 2014, MICROFLUID NANOFLUID, V16, P1047, DOI 10.1007/s10404-013-1274-x
   Lu YT, 2014, CHEM ENG SCI, V105, P213, DOI 10.1016/j.ces.2013.11.017
   McKinley G. H., 2005, SOC RHEOL B, V2005, P6
   McKinley G.H., 2005, SOC RHEOL B
   Puccetti G, 2015, EXP THERM FLUID SCI, V67, P62, DOI 10.1016/j.expthermflusci.2015.01.010
   Rayleigh L., 1879, P LOND MATH SOC, V10, P4, DOI DOI 10.1112/PLMS/S1-10.1.4
   Stone HA, 2004, ANNU REV FLUID MECH, V36, P381, DOI 10.1146/annurev.fluid.36.050802.122124
   Tan J, 2009, CHEM ENG J, V146, P428, DOI 10.1016/j.cej.2008.10.024
   Thoroddsen ST, 2008, ANNU REV FLUID MECH, V40, P257, DOI 10.1146/annurev.fluid.40.111406.102215
   Thoroddsen ST, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2710269
   van Hoeve W, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3631323
   Wang K, 2016, LANGMUIR, V32, P3174, DOI 10.1021/acs.langmuir.6b00271
   Wang K, 2013, CHEM ENG SCI, V100, P486, DOI 10.1016/j.ces.2013.02.021
   Wu Z, 2017, CHEM ENG SCI, V174, P56, DOI 10.1016/j.ces.2017.08.032
   Xiong RQ, 2009, EXP THERM FLUID SCI, V33, P1156, DOI 10.1016/j.expthermflusci.2009.07.005
   Xu JL, 1999, INT J MULTIPHAS FLOW, V25, P411, DOI 10.1016/S0301-9322(98)00057-3
   Yamamoto T, 2011, PHYS CHEM CHEM PHYS, V13, P16142, DOI 10.1039/c1cp22018g
   Zhang C, 2017, CHEM ENG SCI, V172, P278, DOI 10.1016/j.ces.2017.06.026
   Zhang FH, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2835664
NR 41
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115473
DI 10.1016/j.ces.2020.115473
PG 14
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300007
DA 2020-05-12
ER

PT J
AU Liu, K
   Biegler, LT
   Zhang, BJ
   Chen, QL
AF Liu, Kai
   Biegler, Lorenz T.
   Zhang, Bingjian
   Chen, Qinglin
TI Dynamic optimization of natural gas pipeline networks with demand and
   composition uncertainty
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dynamic optimization; Uncertainty; Pipeline network; Back-off
   constraints; Monte Carlo simulation
ID STATE ESTIMATION; MODEL; SIMULATION; OPERATION; SYSTEMS; FLOW
AB Pipelines are one of the most efficient methods to transport large quantities of natural gas from gas reserves to main markets. However, because of the unsteady nature of gas flow, the operation of pipelines is always dynamic. Furthermore, the uncertainties in demand and the fluctuation of gas composition also make the efficient operation of these dynamic processes challenging. This study addresses the problem of determining the optimal operation to minimize compression costs, while considering demand and gas composition uncertainties. A dynamic pipeline network model is developed with rigorous thermodynamic equations, allowing accurate calculation of gas compressibility factor at any temporal and spatial point. The supply gas composition and demand nodes flow rates are assumed to be uncertain. To deal with these uncertainties, a robust optimization algorithm is applied using back-off constraints calculated from Monte Carlo simulation. Through successive iterations, the algorithm terminates at a solution that is robust to a specified level of process variability with minimal cost. We show from the case studies that the formulated model and the algorithm can successfully address the problem with acceptable computational cost. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Kai; Zhang, Bingjian; Chen, Qinglin] Sun Yat Sen Univ, Guangdong Engn Ctr Petrochem Energy Conservat, Sch Mat Sci & Engn, Key Lab Low Carbon Chem & Energy Conservat Guangd, Guangzhou 510275, Peoples R China.
   [Biegler, Lorenz T.] Carnegie Mellon Univ, Dept Chem Engn, Pittsburgh, PA 15213 USA.
RP Zhang, BJ (reprint author), Sun Yat Sen Univ, Guangdong Engn Ctr Petrochem Energy Conservat, Sch Mat Sci & Engn, Key Lab Low Carbon Chem & Energy Conservat Guangd, Guangzhou 510275, Peoples R China.; Biegler, LT (reprint author), Carnegie Mellon Univ, Dept Chem Engn, Pittsburgh, PA 15213 USA.
EM liukai26@mail2.sysu.edu.cn; biegler@cmu.edu; zhbingj@mail.sysu.edu.cn;
   chqlin@mail.sysu.edu.cn
FU China Scholarship CouncilChina Scholarship Council; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   [21776323]; Center for Advanced Process Decision-making at Carnegie
   Mellon University
FX The authors gratefully acknowledge financial support from China
   Scholarship Council, the National Natural Science Foundation of China
   (No. 21776323), as well as the support from Center for Advanced Process
   Decision-making at Carnegie Mellon University.
CR Alves FD, 2016, COMPUT CHEM ENG, V93, P212, DOI 10.1016/j.compchemeng.2016.06.006
   Baumrucker BT, 2010, COMPUT CHEM ENG, V34, P900, DOI 10.1016/j.compchemeng.2009.07.012
   Behrooz HA, 2017, ENERGY, V134, P968, DOI 10.1016/j.energy.2017.06.087
   Behrooz HA, 2016, J NAT GAS SCI ENG, V34, P100, DOI 10.1016/j.jngse.2016.06.051
   Behrooz HA, 2015, J NAT GAS SCI ENG, V22, P551, DOI 10.1016/j.jngse.2015.01.002
   Chiang NY, 2016, APPL ENERG, V168, P226, DOI 10.1016/j.apenergy.2016.01.017
   Demissie A, 2017, COMPUT CHEM ENG, V100, P94, DOI 10.1016/j.compchemeng.2017.02.017
   Diehl M, 2006, MATH PROGRAM, V107, P213, DOI 10.1007/s10107-005-0685-1
   Geissler B, 2018, INFORMS J COMPUT, V30, P309, DOI 10.1287/ijoc.2017.0780
   Gopalakrishnan A, 2013, COMPUT CHEM ENG, V52, P90, DOI 10.1016/j.compchemeng.2012.11.011
   Grossmann IE, 2016, COMPUT CHEM ENG, V91, P3, DOI 10.1016/j.compchemeng.2016.03.002
   Guandalini G, 2017, APPL ENERG, V185, P1712, DOI 10.1016/j.apenergy.2016.03.006
   Gugat M, 2018, COMPUT OPTIM APPL, V70, P267, DOI 10.1007/s10589-017-9970-1
   Hahn M., 2017, TECH REP
   Hart W. E., 2017, PYOMO OPTIMIZATION M, V67
   Hart WE, 2011, MATH PROGRAM COMPUT, V3, P219, DOI 10.1007/s12532-011-0026-8
   Herran-Gonzalez A, 2009, APPL MATH MODEL, V33, P1584, DOI 10.1016/j.apm.2008.02.012
   HSL, 2016, COLL FORTR COD LARG
   Kamath RS, 2010, COMPUT CHEM ENG, V34, P2085, DOI 10.1016/j.compchemeng.2010.07.028
   Koch T., 2015, EVALUATING GAS NETWO
   Koller RW, 2018, AICHE J, V64, P2379, DOI 10.1002/aic.16092
   Lurie M.V., 2008, MODELING OIL PRODUCT
   Maussner J, 2018, CHEM ENG SCI, V192, P306, DOI 10.1016/j.ces.2018.06.079
   Middleton RS, 2017, APPL ENERG, V199, P88, DOI 10.1016/j.apenergy.2017.04.034
   Mikolajkova M, 2018, ENERGY, V146, P156, DOI 10.1016/j.energy.2017.05.185
   Mokhatab S, 2012, HANDBOOK OF NATURAL GAS TRANSMISSION AND PROCESSING, 2ND EDITION, P1
   Nicholson B, 2018, MATH PROGRAM COMPUT, V10, P187, DOI 10.1007/s12532-017-0127-0
   Osiadacz A, 1987, SIMULATION ANAL GAS
   Osiadacz AJ, 2001, CHEM ENG J, V81, P41, DOI 10.1016/S1385-8947(00)00194-7
   PENG D, 1976, IND ENG CHEM FUND, V15, P59, DOI 10.1021/i160057a011
   Puranik Y, 2016, AICHE J, V62, P3215, DOI 10.1002/aic.15344
   Raoni R, 2017, COMPUT CHEM ENG, V96, P169, DOI 10.1016/j.compchemeng.2016.10.001
   Reddy HP, 2006, IND ENG CHEM RES, V45, P3853, DOI 10.1021/ie050755k
   REDLICH O, 1949, CHEM REV, V44, P233, DOI 10.1021/cr60137a013
   Rios-Mercado RZ, 2015, APPL ENERG, V147, P536, DOI 10.1016/j.apenergy.2015.03.017
   Rose D, 2016, MATH METHOD OPER RES, V83, P409, DOI 10.1007/s00186-016-0533-5
   Schmidt M, 2015, OPTIM ENG, V16, P131, DOI 10.1007/s11081-014-9246-x
   Shi J, 2016, COMPUT CHEM ENG, V95, P260, DOI 10.1016/j.compchemeng.2016.08.002
   Song R, 2017, ENERGY, V124, P19, DOI 10.1016/j.energy.2017.02.073
   Srinivasan B, 2003, COMPUT CHEM ENG, V27, P27, DOI 10.1016/S0098-1354(02)00117-5
   Steinbach MC, 2007, J COMPUT APPL MATH, V203, P345, DOI 10.1016/j.cam.2006.04.018
   Uster H, 2014, APPL ENERG, V133, P56, DOI 10.1016/j.apenergy.2014.06.042
   Union I., 2011, PETR B GUID GAS INT
   Vallerio M, 2016, CHEM ENG SCI, V140, P201, DOI 10.1016/j.ces.2015.09.012
   Wachter A, 2006, MATH PROGRAM, V106, P25, DOI 10.1007/s10107-004-0559-y
   Zavala VM, 2014, COMPUT CHEM ENG, V64, P103, DOI 10.1016/j.compchemeng.2014.02.002
NR 46
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115449
DI 10.1016/j.ces.2019.115449
PG 18
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300012
DA 2020-05-12
ER

PT J
AU Liu, X
   Fan, CY
   Do, DD
   Pareek, V
   Yang, PY
AF Liu, Xiu
   Fan, Chunyan
   Do, D. D.
   Pareek, Vishnu
   Yang, Peiyu
TI A temperature-dependent potential model for mercury in the description
   of vapour-liquid equilibrium & adsorption in activated carbon
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mercury; Liquid-vapor equilibrium; Potential model; Adsorption; Monte
   Carlo Simulation
ID MONTE-CARLO-SIMULATION; FLUE-GAS; THERMODYNAMICS; COEXISTENCE; BINDING;
   SIZE; HG
AB A practical potential equation for mercury was developed, by incorporating the long-ranged interaction and multi-body effects into the temperature-dependent dispersion parameters, to describe the thermodynamic properties of the liquid-vapour equilibrium and adsorption in carbonaceous materials. The collision diameter (sigma) decreases and the well depth of interaction energy (epsilon) increases with temperature, with the product sigma(6)epsilon (a measure of attraction) decreasing with temperature. The critical temperature derived from this model, 1745 K, agrees well with the experimental value of 1751 K, and the wetting temperature of mercury on graphite was found to be 1600 K, supporting the fact that mercury does not wet carbon under ambient conditions. Furthermore, it was illustrated with mercury can fill ultrafine graphitic slit pores, whose widths less than 0.7 nm, under ambient temperatures, because of the enhancement of the solid-fluid potential and the strong intermolecular interactions, and the simulation results qualitatively agree well with experimental data. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Liu, Xiu; Fan, Chunyan; Pareek, Vishnu] Curtin Univ, WA Sch Mines Minerals Energy & Chem Engn, Discipline Chem Engn, Bentley, WA 6102, Australia.
   [Do, D. D.] Univ Queensland, Sch Chem Engn, St Lucia, Qld 4072, Australia.
   [Yang, Peiyu] East China Univ Sci & Technol, Shanghai Key Lab Multiphase Mat Chem Engn, Shanghai 200237, Peoples R China.
RP Fan, CY (reprint author), Curtin Univ, WA Sch Mines Minerals Energy & Chem Engn, Discipline Chem Engn, Bentley, WA 6102, Australia.
EM chunyan.fan@curtin.edu.au
OI Pareek, Vishnu/0000-0002-0848-3671
FU Australian GovernmentAustralian Government; Government of Western
   Australia; DECRA [DE160100959]; ARCAustralian Research Council
FX This work was supported by resources provided by the Pawsey
   Supercomputing Centre with funding from the Australian Government and
   the Government of Western Australia. The author C. Fan acknowledges the
   financial support from ARC with DECRA (DE160100959)
CR Biscay F, 2009, J CHEM PHYS, V130, DOI 10.1063/1.3132708
   BOJAN MJ, 1988, SURF SCI, V199, pL395, DOI 10.1016/0039-6028(88)90904-1
   BOJAN MJ, 1993, LANGMUIR, V9, P2569, DOI 10.1021/la00034a015
   Bomont JM, 2008, J PHYS CONF SER, V98, pU389, DOI 10.1088/1742-6596/98/4/042018
   Bomont JM, 2007, J NON-CRYST SOLIDS, V353, P3454, DOI 10.1016/j.jnoncrysol.2007.05.165
   Bomont JM, 2006, J CHEM PHYS, V124, DOI 10.1063/1.2166384
   Bonechi A, 1998, J CHEM PHYS, V109, P5880, DOI 10.1063/1.477210
   Calderin L, 2011, J PHYS-CONDENS MAT, V23, DOI 10.1088/0953-8984/23/37/375105
   Calvo F, 2012, J CHEM THEORY COMPUT, V8, P639, DOI 10.1021/ct200846a
   Chen JY, 2005, SCIENCE, V310, P1480, DOI 10.1126/science.1120385
   Czuchaj E., 1997, CHEM PHYS
   Desgranges C, 2014, J PHYS CHEM B, V118, P3175, DOI 10.1021/jp500577t
   Do DD, 2008, J COLLOID INTERF SCI, V324, P15, DOI 10.1016/j.jcis.2008.05.028
   Do DD, 2006, J PHYS CHEM B, V110, P9520, DOI 10.1021/jp057230q
   Dolg M, 1997, MOL PHYS, V91, P815, DOI 10.1080/002689797170923
   Fan C., 2013, COLLOIDS SURF
   Fan C, 2012, FLUID PHASE EQUILIBR, V325, P53, DOI 10.1016/j.fluid.2012.04.006
   Galashev AE, 2015, COLLOID J+, V77, P582, DOI 10.1134/S1061933X15040080
   Gregg S.J., 1982, ADSORPTION SURFACE A
   HABERLAND H, 1993, Z PHYS D ATOM MOL CL, V26, P8, DOI 10.1007/BF01429096
   Hsi HC, 2012, FUEL, V98, P229, DOI 10.1016/j.fuel.2012.04.011
   HUBBARD SR, 1983, J PHYS C SOLID STATE, V16, P6921, DOI 10.1088/0022-3719/16/36/007
   Huber ML, 2006, IND ENG CHEM RES, V45, P7351, DOI 10.1021/ie060560s
   Inui M, 2016, J PHYS SOC JPN, V85, DOI 10.7566/JPSJ.85.035001
   Kernaghan M, 1931, PHYS REV, V37, P990, DOI 10.1103/PhysRev.37.990
   [况敏 KUANG Min], 2008, [燃料化学学报, Journal of Fuel Chemistry and Technology], V36, P468, DOI 10.1016/S1872-5813(08)60030-4
   LIESSMANN G, 1995, DATA COMPILATION SAE
   Maria I.Y, 2010, RELATIVISTIC METHODS, V10
   Munro LJ, 2001, J CHEM PHYS, V114, P5545, DOI 10.1063/1.1351877
   Nguyen VT, 2014, MOL SIMULAT, V40, P713, DOI 10.1080/08927022.2013.829229
   Nguyen VT, 2013, CHEM ENG SCI, V102, P220, DOI 10.1016/j.ces.2013.07.041
   Nguyen VT, 2011, J PHYS CHEM B, V115, P7862, DOI 10.1021/jp202073r
   Padak B, 2009, CARBON, V47, P2855, DOI 10.1016/j.carbon.2009.06.029
   Pahl E, 2010, J CHEM PHYS, V132, DOI 10.1063/1.3354976
   Podak B, 2006, ENVIRON PROG, V25, P319, DOI 10.1002/ep.10165
   Prasetyo L., 2018, MICROPOR MESOPOR MAT
   Prasetyo L, 2018, COLLOID SURFACE A, V554, P169, DOI 10.1016/j.colsurfa.2018.06.037
   Raabe G, 2003, J CHEM PHYS, V119, P6691, DOI 10.1063/1.1605381
   Schautz F, 1998, THEOR CHEM ACC, V99, P231, DOI 10.1007/s002140050331
   Schwerdtfeger P, 2001, J CHEM PHYS, V115, P7401, DOI 10.1063/1.1402163
   Tang HJ, 2019, J PHYS CHEM C, V123, P5972, DOI 10.1021/acs.jpcc.8b11268
   Tomonari Sumi E.M., 1999, PHYS REV B
   Trokhymchuk A, 1999, J CHEM PHYS, V111, P8510, DOI 10.1063/1.480192
   Zeng HC, 2004, FUEL, V83, P143, DOI 10.1016/S0016-2361(03)00235-7
NR 44
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115453
DI 10.1016/j.ces.2019.115453
PG 13
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300006
DA 2020-05-12
ER

PT J
AU Ma, C
   Skoglund, N
   Carlborg, M
   Brostrom, M
AF Ma, Charlie
   Skoglund, Nils
   Carlborg, Markus
   Brostrom, Markus
TI Viscosity of molten CaO-K2O-SiO2 woody biomass ash slags in relation to
   structural characteristics from molecular dynamics simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Viscosity; Biomass ash; Slag; Molecular dynamics; Silicate melt
ID ENTRAINED-FLOW GASIFICATION; SILICATE-GLASSES; COKE ASH; SODIUM; COAL;
   COMBUSTION; MELTS; BEHAVIOR; SYSTEM
AB Molten compositions in the CaO-K2O-SiO2 system relevant to woody biomass ash slags were simulated with molecular dynamics to extract structural characteristics. Multivariate analysis elucidated correlations of these structural characteristics with viscosity measurements. The simulations show SiO4/silicate tetrahedral units (STUB) diffusing slowly and forming flexible networks via oxygen bridges. The degree of STU polymerization varies linearly with the (K2O + CaO)/SiO2 ratio. Ca depolymerises stronger than K, but K diffuses quicker. Depolymerization and diffusion cause network disruptions and agitations that promote collective atomic mobility of the system. This imposes structural characteristics in the slag that correlate with viscosity. The inter-STU Si-O-Si angle narrows with decreasing viscosity, while the Si-O bond length of these bridges increases. Attributes related to atomic mobility, such as the variations in the Si-O-Si angle and the distance of nearest Si-Si pairs, also correlate with viscosity. The discussion provides insight into the connection between structural characteristics and viscosity. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ma, Charlie; Skoglund, Nils; Carlborg, Markus; Brostrom, Markus] Umea Univ, Dept Appl Phys & Elect, TEC Lab, S-90187 Umea, Sweden.
RP Ma, C (reprint author), Umea Univ, Dept Appl Phys & Elect, TEC Lab, S-90187 Umea, Sweden.
EM charlie.ma@umu.se
RI Skoglund, Nils/D-3493-2011
OI Skoglund, Nils/0000-0002-5777-9241
FU Swedish strategic research program Bio4Energy; Swedish Energy Agency
   through the Swedish Gasification CenterSwedish Energy Agency; Swedish
   Research CouncilSwedish Research Council [2017-05331]
FX We gratefully acknowledge the financial supports from the Swedish
   strategic research program Bio4Energy, the Swedish Energy Agency through
   the Swedish Gasification Center, and the Swedish Research Council under
   Grant No. 2017-05331. We thank Prof. Dan Bostrom for his helpful
   insights, and Leif Johansson and Robert Sjoblom for organising computing
   resources.
CR Bostrom D, 2012, ENERG FUEL, V26, P85, DOI 10.1021/ef201205b
   Carlborg M, 2018, J EUR CERAM SOC, V38, P777, DOI 10.1016/j.jeurceramsoc.2017.09.016
   Chen M, 2016, FUEL, V180, P638, DOI 10.1016/j.fuel.2016.04.099
   Chen XD, 2017, APPL ENERG, V206, P1241, DOI 10.1016/j.apenergy.2017.10.020
   Cormack AN, 2001, GLASS PHYS CHEM+, V27, P28, DOI 10.1023/A:1009555719885
   Dai X, 2019, FUEL, V237, P163, DOI 10.1016/j.fuel.2018.09.127
   DOMINE F, 1983, J NON-CRYST SOLIDS, V55, P125, DOI 10.1016/0022-3093(83)90012-1
   Du J, 2004, J NON-CRYST SOLIDS, V349, P66, DOI 10.1016/j.jnoncrysol.2004.08.264
   Eriksson L, 2006, MULTI MEGAVARIATE 1
   Fan GZ, 2015, MATER TRANS, V56, P655, DOI 10.2320/matertrans.M2014363
   Jiang CH, 2019, METALL MATER TRANS B, V50, P367, DOI 10.1007/s11663-018-1450-1
   Kleinhans U, 2018, PROG ENERG COMBUST, V68, P65, DOI 10.1016/j.pecs.2018.02.001
   Lange RA, 1997, CONTRIB MINERAL PETR, V130, P1, DOI 10.1007/s004100050345
   Li KJ, 2017, ENERG FUEL, V31, P13466, DOI 10.1021/acs.energyfuels.7b02795
   Li KJ, 2017, CHEM ENG J, V313, P1184, DOI 10.1016/j.cej.2016.11.011
   Ma C, 2016, ENERG FUEL, V30, P10543, DOI 10.1021/acs.energyfuels.6b02222
   Ma C, 2013, ENERG FUEL, V27, P6801, DOI 10.1021/ef401591a
   Miyake A., 1998, MINERAL J, V20, P189
   MYSEN BO, 1982, REV GEOPHYS, V20, P353, DOI 10.1029/RG020i003p00353
   NAVROTSKY A, 1985, PHYS CHEM MINER, V11, P284, DOI 10.1007/BF00307406
   Nazelius IL, 2015, ENERG FUEL, V29, P894, DOI 10.1021/ef502531m
   Noritake F., 2015, J COMP CHEM JAPAN, V14, P124
   Noritake F, 2012, J NON-CRYST SOLIDS, V358, P3109, DOI 10.1016/j.jnoncrysol.2012.08.027
   OGAWA H, 1990, J NON-CRYST SOLIDS, V119, P151, DOI 10.1016/0022-3093(90)90838-D
   PANT AK, 1968, ACTA CRYSTALL B-STRU, VB 24, P13, DOI 10.1107/S0567740868001640
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Van Ginhoven RM, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.024208
   Vargas S, 2001, PROG ENERG COMBUST, V27, P237, DOI 10.1016/S0360-1285(00)00023-X
   Vassilev SV, 2010, FUEL, V89, P913, DOI 10.1016/j.fuel.2009.10.022
   WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9
   Wu T, 2016, J NON-CRYST SOLIDS, V450, P23, DOI 10.1016/j.jnoncrysol.2016.07.024
   Wu T, 2016, J NON-CRYST SOLIDS, V435, P17, DOI 10.1016/j.jnoncrysol.2015.12.025
   Xuan WW, 2019, FUEL, V242, P362, DOI 10.1016/j.fuel.2019.01.049
   Yuan XL, 2003, J NON-CRYST SOLIDS, V319, P31, DOI 10.1016/S0022-3093(02)01960-9
   Zhang GH, 2012, METALL MATER TRANS B, V43, P841, DOI 10.1007/s11663-012-9668-9
   Zheng K, 2012, ISIJ INT, V52, P342, DOI 10.2355/isijinternational.52.342
NR 36
TC 0
Z9 0
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115464
DI 10.1016/j.ces.2019.115464
PG 12
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300037
DA 2020-05-12
ER

PT J
AU Nikoo, AH
   Malayeri, MR
AF Nikoo, Amir Hossein
   Malayeri, Mohammad Reza
TI Incorporation of surface energy properties into general crystallization
   fouling model for heat transfer surfaces
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Heat exchanger fouling; Surface energy; Surface modification; Shear
   strength of deposit; Removal rate
ID EXCHANGER; ADHESION; MITIGATION; DEPOSITION; CRYSTALS; TENSION; GYPSUM;
   FORCES; GROWTH; VAN
AB Crystallization fouling models for heat transfer surfaces are indispensable to provide reliable prediction of fouling behavior that would, in turn, facilitate the optimal design and operation of heat exchangers. Nonetheless, most previous models exclude surface properties in terms of surface energy and its components despite many studies confirmed otherwise. In this study, a general fouling model is developed which includes surface energy and its components. Primarily, the surface properties are incorporated into the work of adhesion. Thereafter, these properties, via a force balance, are corresponded to the shear strength of deposit in terms of removal rate. The model predicts that the shear strength of CaSO4 deposit and its adhesion on various coatings would be decreased up to 66% and 91% compared to the untreated surface, respectively. Finally, the validity of the proposed model is examined against the experimental results of CaSO4 crystallization fouling which resulted in good agreement. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Nikoo, Amir Hossein; Malayeri, Mohammad Reza] Shiraz Univ, Sch Chem & Petr Eng, Shiraz, Iran.
   [Malayeri, Mohammad Reza] Tech Univ Dresden, Inst Verfahrenstech & Umwelttech IVU, D-01062 Dresden, Germany.
RP Malayeri, MR (reprint author), Shiraz Univ, Sch Chem & Petr Engn, Sch Engn 3, Molla Sadra Ave, Shiraz 7134851154, Iran.
EM malayeri@shirazu.ac.ir
CR Al-Janabi A, 2015, CHEM ENG RES DES, V100, P212, DOI 10.1016/j.cherd.2015.05.033
   Al-Janabi A, 2013, DESALINATION, V324, P21, DOI 10.1016/j.desal.2013.05.020
   Al-Janabi A, 2011, HEAT TRANSFER ENG, V32, P291, DOI 10.1080/01457632.2010.495628
   Al-Janabi A, 2010, INT J THERM SCI, V49, P1063, DOI 10.1016/j.ijthermalsci.2009.05.009
   AMJAD Z, 1988, J COLLOID INTERF SCI, V123, P523, DOI 10.1016/0021-9797(88)90274-3
   Augustin W., 2005, P 5 INT C ENH COMP U
   Bansal B., 2005, INT J TRANSPORT PHEN, V7, P1
   Bansal B, 2008, CHEM ENG PROCESS, V47, P1201, DOI 10.1016/j.cep.2007.03.016
   Bargir S, 2009, APPL SURF SCI, V255, P4873, DOI 10.1016/j.apsusc.2008.12.017
   Bott T. R., 1995, FOULING HEAT EXCHANG
   Cai YW, 2014, IND ENG CHEM RES, V53, P3509, DOI 10.1021/ie402308m
   Choo KH, 2000, J COLLOID INTERF SCI, V226, P367, DOI 10.1006/jcis.2000.6845
   DERJAGUIN B, 1993, PROG SURF SCI, V43, P30, DOI 10.1016/0079-6816(93)90013-L
   Elimelech M., 1998, PARTICLE DEPOSITION
   Forster M, 2000, INT J THERM SCI, V39, P697, DOI 10.1016/S1290-0729(00)00229-5
   Forster M, 1999, CHEM ENG PROCESS, V38, P449, DOI 10.1016/S0255-2701(99)00042-2
   Forster M., 2001, VERMINDERUNG KRISTAL
   FOWKES FM, 1964, IND ENG CHEM, V56, P40, DOI 10.1021/ie50660a008
   GILL JS, 1980, J CRYST GROWTH, V48, P34, DOI 10.1016/0022-0248(80)90190-6
   Hirsch H, 1996, CHEM-ING-TECH, V68, P691, DOI 10.1002/cite.330680609
   Israelachvili J., 1991, INTERMOLECULAR SURFA
   Jalalirad M.R., 2014, UTILIZATION VARIOUS, DOI [10.18419/opus-8789, DOI 10.18419/OPUS-8789]
   Kazi SN, 2012, DESALINATION, V288, P126, DOI 10.1016/j.desal.2011.12.022
   Kern DQ, 1959, BRIT CHEM ENGNG, V4, P258
   KONAK AR, 1974, CHEM ENG SCI, V29, P1537, DOI 10.1016/0009-2509(74)87004-1
   Kukulka DJ, 2007, APPL THERM ENG, V27, P2732, DOI 10.1016/j.applthermaleng.2007.03.024
   Kwok DY, 1996, CAN J CHEM ENG, V74, P551, DOI 10.1002/cjce.5450740417
   Malayeri MR, 2009, INT J ENERG RES, V33, P1101, DOI 10.1002/er.1599
   Matjie R, 2016, FUEL, V181, P573, DOI 10.1016/j.fuel.2016.04.105
   MCGUIRE J, 1989, J FOOD PROCESS PRES, V13, P145, DOI 10.1111/j.1745-4549.1989.tb00097.x
   Mohammadi K, 2015, HEAT TRANSFER ENG, V36, P706, DOI 10.1080/01457632.2015.954949
   Muller-Steinhagen H, 2011, HEAT TRANSFER ENG, V32, P189, DOI 10.1080/01457632.2010.503108
   Muller-Steinhagen H, 2011, HEAT TRANSFER ENG, V32, P1, DOI 10.1080/01457632.2010.505127
   NEUMANN AW, 1974, J COLLOID INTERF SCI, V49, P291, DOI 10.1016/0021-9797(74)90365-8
   Nikoo AH, 2019, HEAT TRANSFER ENG, DOI 10.1080/01457632.2019.1589982
   Oliveira R, 1997, EXP THERM FLUID SCI, V14, P316, DOI 10.1016/S0894-1777(96)00134-3
   OWENS DK, 1969, J APPL POLYM SCI, V13, P1741, DOI 10.1002/app.1969.070130815
   Perry R.H., 2008, PERRYS CHEM ENG HDB
   Rahmanian I, 2009, ACTA POLYTECH, V49, P16
   Sharma PK, 2002, ADV COLLOID INTERFAC, V98, P341, DOI 10.1016/S0001-8686(02)00004-0
   Treybal R.E., 1980, MASS TRANSFER OPERAT
   Tsibouklis J, 2000, INT J ADHES ADHES, V20, P91, DOI 10.1016/S0143-7496(99)00034-2
   VANOSS CJ, 1986, J COLLOID INTERF SCI, V111, P378, DOI 10.1016/0021-9797(86)90041-X
   VANOSS CJ, 1987, SEPAR SCI TECHNOL, V22, P1
   VANOSS CJ, 1988, LANGMUIR, V4, P884, DOI 10.1021/la00082a018
   VANOSS CJ, 1994, INTERFACIAL FORCES A
   Verwey E.J.W., 1948, THEORY STABILITY LYO
   WU S, 1973, J ADHESION, V5, P39, DOI 10.1080/00218467308078437
   WU S, 1971, J POLYM SCI POL SYM, P19
   Wu S., 1982, POLYM INTERFACE ADHE
   Yao J, 2016, MATH PROBL ENG, V2016, DOI 10.1155/2016/8430745
   Zhao Q, 2005, DESALINATION, V180, P133, DOI 10.1016/j.desal.2005.01.002
   Zhao Q., 2002, HEAT EXCHANGER FOULI, P41
   ZISMAN WA, 1964, ADV CHEM SER, V43, P1, DOI DOI 10.1021/BA-1964-0043.CH001
NR 54
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115461
DI 10.1016/j.ces.2019.115461
PG 12
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300019
DA 2020-05-12
ER

PT J
AU Qi, RH
   Dong, CS
   Zhang, LZ
   Guo, MM
   Lu, L
AF Qi, Ronghui
   Dong, Chuanshuai
   Zhang, Li-Zhi
   Guo, Mingming
   Lu, Lin
TI Modelling on space-domain surface waves of vertical low-Re falling film
   and the enhancement on mass transfer in halide-solution/air absorption
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Liquid/air absorption; Low-Re falling film; Surface wave along the flow
   direction; Theoretical modelling; Mass transfer
ID LIQUID DESICCANT DEHUMIDIFICATION; FLOW; LIBR-H2O; SIMULATION
AB Vertical falling film with low Reynolds number (Re) is widely used, but the influence of surface waves on mass transfer is still unclear. This paper theoretically described the wave structure along the flow direction, and evaluating the enhancement on mass transfer during halide-solution/air absorption. The effects of flow viscosity, surface tension gradient, liquid/air convective heat transfer, film thickness and flow distance are considered. Model validation were performed by comparing with the data from literatures and our experiments. For practical use, empirical correlations of wavelength and amplitude are provided, using Re, Marangoni and Nusselt numbers as variables. Wavelength increases proportionally with liquid Re, and amplitude mainly increases with the flow distance. When Re increases from 20 to 60, wave amplitude and wavelength increase by 10% and 40%. The enhancement effect is determined by the wavelength and frequency, and is more obvious under conditions of large liquid concentration or small liquid Re. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Qi, Ronghui; Dong, Chuanshuai; Zhang, Li-Zhi; Guo, Mingming] South China Univ Technol, Sch Chem & Chem Engn, Key Lab Enhanced Heat Transfer & Energy Conservat, Educ Minist, Guangzhou, Peoples R China.
   [Zhang, Li-Zhi] South China Univ Technol, State Key Lab Subtrop Bldg Sci, Guangzhou, Peoples R China.
   [Lu, Lin] Hong Kong Polytech Univ, RERG, Dept Bldg Serv Engn, Hong Kong, Peoples R China.
RP Qi, RH (reprint author), South China Univ Technol, Sch Chem & Chem Engn, Key Lab Enhanced Heat Transfer & Energy Conservat, Educ Minist, Guangzhou, Peoples R China.
EM qirh@scut.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51876067]; Natural Science Foundation of Guangdong
   Province: Distinguished Young Scholars [2018B030306014]; Science and
   Technology Planning Project of Guangdong Province: Guangdong-Hong Kong
   Technology Cooperation Funding Scheme (TCFS) [2017B050506005]; National
   Science Fund for Distinguished Young ScholarsNational Natural Science
   Foundation of ChinaNational Science Fund for Distinguished Young
   Scholars [51425601]; high-level Talent Project of Guangdong Province
FX The project is supported by the National Natural Science Foundation of
   China (51876067), Natural Science Foundation of Guangdong Province:
   Distinguished Young Scholars (2018B030306014). It is also supported by
   the Science and Technology Planning Project of Guangdong Province:
   Guangdong-Hong Kong Technology Cooperation Funding Scheme (TCFS), No.
   2017B050506005, the National Science Fund for Distinguished Young
   Scholars (No. 51425601), and the high-level Talent Project of Guangdong
   Province.
CR Aktershev SP, 2013, PROC IUTAM, V8, P3, DOI 10.1016/j.piutam.2013.04.002
   Al-Sibai F., 2005, THESIS
   Budakli M, 2019, INT J THERM SCI, V146, DOI 10.1016/j.ijthermalsci.2019.106077
   CLOOT A, 1984, J FLUID MECH, V145, P447, DOI 10.1017/S0022112084003013
   Daiguji H, 1997, INT J HEAT MASS TRAN, V40, P1743, DOI 10.1016/S0017-9310(96)00290-6
   DANCKWERTS PV, 1951, IND ENG CHEM, V43, P1460, DOI 10.1021/ie50498a055
   Fernandez-Seara J, 2014, APPL THERM ENG, V64, P155, DOI 10.1016/j.applthermaleng.2013.11.023
   FRISK DP, 1972, INT J HEAT MASS TRAN, V15, P1537, DOI 10.1016/0017-9310(72)90009-9
   Gao D, 2003, J COMPUT PHYS, V192, P624, DOI 10.1016/j.jcp.2003.07.013
   Grossman G., 1984, HDB HEAT MASS TRANSF
   [谷芳 Gu Fang], 2005, [高校化学工程学报, Journal of Chemical Engineering of Chinese Universities], V19, P438
   Haidl J, 2016, CHEM ENG SCI, V144, P126, DOI 10.1016/j.ces.2015.12.027
   Hofmann E, 2012, INT J HEAT MASS TRAN, V55, P7686, DOI 10.1016/j.ijheatmasstransfer.2012.07.074
   Kabova YO, 2012, INT J HEAT MASS TRAN, V55, P1271, DOI 10.1016/j.ijheatmasstransfer.2011.09.020
   Kapitza P.L., 1948, Journal of Experimental and Theoretical Physics, V18, P3
   Karami S, 2011, HEAT MASS TRANSFER, V47, P259, DOI 10.1007/s00231-010-0715-2
   Karami S, 2009, HEAT MASS TRANSFER, V46, P197, DOI 10.1007/s00231-009-0557-y
   KHESHGI HS, 1987, PHYS FLUIDS, V30, P990, DOI 10.1063/1.866286
   Kil SH, 2001, INT J REFRIG, V24, P500, DOI 10.1016/S0140-7007(00)00072-4
   LEVICH VG, 1962, PHYSICOCHEMICAL HYDR
   Lu H, 2016, ENERGY, V101, P229, DOI 10.1016/j.energy.2016.02.023
   [马学虎 MA Xue-hu], 2010, [高校化学工程学报, Journal of Chemical Engineering of Chinese Universities], V24, P10
   Mendez MA, 2017, CHEM ENG SCI, V170, P122, DOI 10.1016/j.ces.2016.12.050
   Narvaez-Romo B, 2017, APPL THERM ENG, V123, P1079, DOI 10.1016/j.applthermaleng.2017.05.092
   Patnaik V, 1996, INT J HEAT FLUID FL, V17, P63, DOI 10.1016/0142-727X(95)00075-2
   Qi RH, 2019, INT J HEAT MASS TRAN, V141, P491, DOI 10.1016/j.ijheatmasstransfer.2019.06.099
   Qi RH, 2019, INT J HEAT MASS TRAN, V132, P96, DOI 10.1016/j.ijheatmasstransfer.2018.11.150
   Rouhollahi R, 2018, EXP THERM FLUID SCI, V98, P497, DOI 10.1016/j.expthermflusci.2018.06.024
   Sepehri A, 2020, J CLEAN PROD, V247, DOI 10.1016/j.jclepro.2019.119164
   Sepehri A, 2018, CHEM ENG PROCESS, V128, P10, DOI 10.1016/j.cep.2018.04.006
   Shi YQ, 2019, INT J HEAT MASS TRAN, V128, P991, DOI 10.1016/j.ijheatmasstransfer.2018.09.036
   TRIFONOV YY, 1991, J FLUID MECH, V229, P531, DOI 10.1017/S0022112091003154
   Wang B, 2019, ANN NUCL ENERGY, V132, P741, DOI 10.1016/j.anucene.2019.06.060
   Wang LS, 2016, INT J REFRIG, V70, P289, DOI 10.1016/j.ijrefrig.2016.06.005
   Wen T, 2019, APPL ENERG, V239, P757, DOI 10.1016/j.apenergy.2019.01.245
   Xu ZF, 2008, CHEM ENG SCI, V63, P2559, DOI 10.1016/j.ces.2008.02.014
   Ye Xue-min, 2002, Journal of North China Electric Power University, V29, P43
   Yin YG, 2008, INT J REFRIG, V31, P857, DOI 10.1016/j.ijrefrig.2007.10.004
   Yu LM, 2006, IND ENG CHEM RES, V45, P1201, DOI 10.1021/ie050855q
   Zhang F, 2008, INT J THERM SCI, V47, P1454, DOI 10.1016/j.ijthermalsci.2007.10.021
   Zhang F, 2008, INT J MULTIPHAS FLOW, V34, P13, DOI 10.1016/j.ijmultiphaseflow.2007.08.003
   Zhang F, 2009, EXP THERM FLUID SCI, V33, P424, DOI 10.1016/j.expthermflusci.2008.10.010
   Zhang H, 2019, APPL THERM ENG, V146, P752, DOI 10.1016/j.applthermaleng.2018.10.046
   Zhang H, 2019, APPL THERM ENG, V146, P203, DOI 10.1016/j.applthermaleng.2018.09.127
   Zhang JT, 2000, INT J HEAT MASS TRAN, V43, P3847, DOI 10.1016/S0017-9310(99)00371-3
NR 45
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115459
DI 10.1016/j.ces.2019.115459
PG 11
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300025
DA 2020-05-12
ER

PT J
AU Rezaeianjouybari, B
   Sheikholeslami, M
   Shafee, A
   Babazadeh, H
AF Rezaeianjouybari, Behnoush
   Sheikholeslami, M.
   Shafee, Ahmad
   Babazadeh, Houman
TI A novel Bayesian optimization for flow condensation enhancement using
   nanorefrigerant: A combined analytical and experimental study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Two Stage-Bayesian optimization (TS-BO); Refrigerant; Condensation; Heat
   transfer; Nanoparticle
ID BOILING HEAT-TRANSFER; REFRIGERANT-BASED NANOFLUID;
   THERMAL-CONDUCTIVITY; NANO-REFRIGERANT; PRESSURE-DROP; SUPERHEATED
   STEAM; GAS-RESERVOIRS; NANOPARTICLES; GENERATION; TRANSPORT
AB According to the recent researches, adding nanomaterial within the pure refrigerant can substantially enhance the heat transfer rate in phase change (boiling/condensing) flows. Therefore, for a given operating conditions, it is unclear whether the heat transfer is optimized at a certain mass fraction of nanoparticles. In the present study, an integrated analytical, and experimental approach was scrutinized to find the heat transfer optimization of flow condensation using nanorefrigerant. For the experiment, CuO nanoparticles were disperesed with varying mass fractions (0.5-3.5%) in the baseline refrigerant/oil (R600a/POE) to produce Nanorefrigerants (R600a/POE/CuO). The optimum nanomaterial concentration for maximum perfromance has been desiganted by a novel optimization method called two stageBayesian optimization (TS-BO), which replaces the expensive experimental process by a cheap surrogate model constructed by Kriging. It was proved that the optimum nanoparticle fraction is significantly depend on the mass velocity and vapor quality while at a fixed vapor quality, the optimum nanoparticle concentration increased with decreasing mass flux. The highest heat transfer enhancement was achieved by nanparticle concentrations of 1.5-2.2%. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Rezaeianjouybari, Behnoush] Univ Missouri, Dept Mech & Aerosp Engn, Columbia, MO 65211 USA.
   [Sheikholeslami, M.] Babol Noshirvani Univ Technol, Dept Mech Engn, Babol Sar, Iran.
   [Sheikholeslami, M.] Babol Noshirvani Univ Technol, Renewable Energy Syst & Nanofluid Applicat Heat T, Babol Sar, Iran.
   [Shafee, Ahmad] Duy Tan Univ, Inst Res & Dev, Da Nang 550000, Vietnam.
   [Babazadeh, Houman] Ton Duc Thang Univ, Dept Management Sci & Technol Dev, Ho Chi Minh City, Vietnam.
   [Babazadeh, Houman] Ton Duc Thang Univ, Fac Environm & Labour Safety, Ho Chi Minh City, Vietnam.
RP Babazadeh, H (reprint author), Ton Duc Thang Univ, Dept Management Sci & Technol Dev, Ho Chi Minh City, Vietnam.
EM houman.babazadeh@tdtu.edu.vn
RI Sheikholeslami, Mohsen/G-9034-2015; Babazadeh, Houman/AAF-3613-2020
OI Sheikholeslami, Mohsen/0000-0002-8839-0458; rezaeianjouybari,
   behnoush/0000-0002-8702-1351
CR Akhavan-Behabadi MA, 2015, EXP THERM FLUID SCI, V66, P46, DOI 10.1016/j.expthermflusci.2015.02.027
   Brochu E., 2010, ARXIV10095419
   Calm JM, 2008, INT J REFRIG, V31, P1123, DOI 10.1016/j.ijrefrig.2008.01.013
   Choi S., 1995, ASME FED, V231, P99, DOI DOI 10.1115/1.1532008
   Couckuyt I, 2014, J MACH LEARN RES, V15, P3183
   Das SK, 2003, J HEAT TRANS-T ASME, V125, P567, DOI 10.1115/1.1571080
   Ding GL, 2009, INT J REFRIG, V32, P114, DOI 10.1016/j.ijrefrig.2008.08.007
   Hwang Y, 2007, THERMOCHIM ACTA, V455, P70, DOI 10.1016/j.tca.2006.11.036
   Jiang WT, 2009, INT J THERM SCI, V48, P1108, DOI 10.1016/j.ijthermalsci.2008.11.012
   Jones DR, 1998, J GLOBAL OPTIM, V13, P455, DOI 10.1023/A:1008306431147
   Kim J, 2018, CHEM ENG SCI, V175, P168, DOI 10.1016/j.ces.2017.09.052
   KURYLO MJ, 1990, INT J REFRIG, V13, P62, DOI 10.1016/0140-7007(90)90003-F
   Kushner H.J., 1964, Transactions of the ASME. Series D, Journal of Basic Engineering, V86, P97
   Li C., 2017, SCI REPORTS, V7
   MOCKUS J, 1994, J GLOBAL OPTIM, V4, P347, DOI 10.1007/BF01099263
   MOLINA MJ, 1974, NATURE, V249, P810, DOI 10.1038/249810a0
   Park KJ, 2007, INT J HEAT MASS TRAN, V50, P4499, DOI 10.1016/j.ijheatmasstransfer.2007.03.012
   Park KJ, 2007, ENERG BUILDINGS, V39, P1061, DOI 10.1016/j.enbuild.2006.12.001
   Peng H, 2009, INT J REFRIG, V32, P1259, DOI 10.1016/j.ijrefrig.2009.01.025
   Peng Q, 2018, APPL THERM ENG, V129, P812, DOI 10.1016/j.applthermaleng.2017.10.108
   Qin YH, 2019, CONSTR BUILD MATER, V215, P114, DOI 10.1016/j.conbuildmat.2019.04.164
   Qin YH, 2018, J CLEAN PROD, V199, P948, DOI 10.1016/j.jclepro.2018.07.250
   Qin YH, 2015, COLD REG SCI TECHNOL, V120, P30, DOI 10.1016/j.coldregions.2015.09.005
   Sadoughi MK, 2018, STRUCT MULTIDISCIP O, V57, P235, DOI 10.1007/s00158-017-1748-7
   Sadoughi Mohammad Kazem, 2017, P 18 AIAA ISSMO MULT, P4432
   Schultz R., 1979, AICHE S SER
   Shah MM, 2009, HVAC&R RES, V15, P889, DOI 10.1080/10789669.2009.10390871
   Sheikholeslami M, 2019, INT J HEAT MASS TRAN, V141, P974, DOI 10.1016/j.ijheatmasstransfer.2019.07.043
   Sheikholeslami M, 2018, INT J HEAT MASS TRAN, V125, P1087, DOI 10.1016/j.ijheatmasstransfer.2018.04.155
   Sheikholeslami M, 2018, INT J HEAT MASS TRAN, V122, P643, DOI 10.1016/j.ijheatmasstransfer.2018.02.015
   Sun B, 2014, INT J REFRIG, V38, P206, DOI 10.1016/j.ijrefrig.2013.08.020
   Sun FR, 2018, J PETROL SCI ENG, V163, P199, DOI 10.1016/j.petrol.2017.12.085
   Sun FR, 2018, ENERGY, V143, P995, DOI 10.1016/j.energy.2017.11.028
   Sun Z, 2018, INT J HEAT MASS TRAN, V126, P1007, DOI 10.1016/j.ijheatmasstransfer.2018.05.078
   Sun Z, 2017, INT J HEAT MASS TRAN, V115, P1008, DOI 10.1016/j.ijheatmasstransfer.2017.07.123
   Sunstein CR, 2007, HARVARD ENVIRON LAW, V31, P1
   Tang X, 2014, EXP THERM FLUID SCI, V52, P88, DOI 10.1016/j.expthermflusci.2013.08.025
   Trisaksri V, 2009, INT J HEAT MASS TRAN, V52, P1582, DOI 10.1016/j.ijheatmasstransfer.2008.07.041
   Vazquez-Pufleau M, 2020, CHEM ENG SCI, V211, DOI 10.1016/j.ces.2019.115230
   Wang K.-J., 2006, P 4 S REFR AIR COND
   Wang RX, 2003, PROCEEDINGS OF THE 4TH INTERNATIONAL SYMPOSIUM ON HEATING, VENTILATING AND AIR CONDITIONING, VOLS 1 AND 2, P888
   Wang S, 2014, INT J REFRIG, V41, P200, DOI 10.1016/j.ijrefrig.2013.03.019
   Wang Z., 2013, P 23 INT JOINT C ART, P1778
   Wen MY, 2014, APPL THERM ENG, V64, P348, DOI 10.1016/j.applthermaleng.2013.12.074
   Wigley Paul B., 2016, SCI, P6
   Yang L, 2020, J THERM ANAL CALORIM, V140, P2033, DOI 10.1007/s10973-019-08987-y
   Yang L, 2019, POWDER TECHNOL, V356, P335, DOI 10.1016/j.powtec.2019.08.031
   YESILYURT S, 1995, COMPUT METHOD APPL M, V121, P231, DOI 10.1016/0045-7825(94)00684-F
   Zhang XW, 2018, CHEM ENG SCI, V180, P95, DOI 10.1016/j.ces.2017.11.044
NR 49
TC 14
Z9 14
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115465
DI 10.1016/j.ces.2019.115465
PG 9
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300004
DA 2020-05-12
ER

PT J
AU Sakalak, H
   YIlmaz, K
   Gursoy, M
   Karaman, M
AF Sakalak, Huseyin
   YIlmaz, KurtuluS
   Gursoy, Mehmet
   Karaman, Mustafa
TI Roll-to roll initiated chemical vapor deposition of super hydrophobic
   thin films on large-scale flexible substrates
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE iCVD; Superhydrophobic; Roll-to-roll; Polymer; Thin film
ID EXPANDED PERLITE PARTICLES; FABRICATION; SURFACE; PAPER; STABILITY;
   POLYMERS; SMOOTH; PECVD
AB In this study, a large-scale roll-to-roll initiated chemical vapor deposition (iCVD) system was developed to allow for coating superhydrophobic thin films on flexible substrates. Poly(hexafluorobutyl acrylate), which possesses a short fluorinated side-chain, was chosen as the hydrophobic finish material, while a commercial porous bamboo fabric was used as the flexible substrate. After iCVD coating, bamboo surface, which is superhydrophilic by its nature, transformed into a superhydrophobic with a water contact angle of 156 degrees without changing its porous and flexible structure. Similar hydrophobic properties were observed against various daily liquids. Complete coverage of as-deposited films on both sides of bamboo surfaces was observed at very high roll speeds up to 225 mm/min, which allow coatings on 20 m(2) flexible substrates in a single run. Large scale contact angle and chemical uniformity of coatings on fabric surfaces were evaluated using contact angle and XPS analyses. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Sakalak, Huseyin] Selcuk Univ, Adv Mat & Nanotechnol Dept, TR-42075 Konya, Turkey.
   [YIlmaz, KurtuluS; Gursoy, Mehmet; Karaman, Mustafa] Konya Tech Univ, Chem Engn Dept, TR-42030 Konya, Turkey.
RP Gursoy, M; Karaman, M (reprint author), Konya Tech Univ, Dept Chem Engn, TR-42030 Konya, Turkey.
EM mgursoy@ktun.edu.tr; mkaraman@ktun.edu.tr
FU Scientific and Technological Research Council of Turkey (TUBITAK)Turkiye
   Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK) [TEYDEB-1507, 7160940]
FX This work was supported in part by the Scientific and Technological
   Research Council of Turkey (TUBITAK) under the grant program TEYDEB-1507
   with project number 7160940.
CR Asatekin A, 2011, NANO LETT, V11, P677, DOI 10.1021/nl103799d
   Balu B, 2008, LANGMUIR, V24, P4785, DOI 10.1021/la703766c
   Baxamusa SH, 2009, PHYS CHEM CHEM PHYS, V11, P5227, DOI 10.1039/b900455f
   Chen B, 2013, ACS APPL MATER INTER, V5, P12701, DOI 10.1021/am404049x
   Cheng C, 2018, IND ENG CHEM RES, V57, P11675, DOI 10.1021/acs.iecr.8b03030
   Danglad-Flores J, 2018, CHEM ENG SCI, V179, P257, DOI 10.1016/j.ces.2018.01.012
   Dubal DP, 2018, CHEM SOC REV, V47, P2065, DOI 10.1039/c7cs00505a
   Elam FM, 2017, PLASMA PROCESS POLYM, V14, DOI 10.1002/ppap.201600143
   FRANCISCO JS, 1984, SPECTROCHIM ACTA A, V40, P923, DOI 10.1016/0584-8539(84)80151-8
   Gao Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11586
   Grandjean P, 2012, JAMA-J AM MED ASSOC, V307, P391, DOI 10.1001/jama.2011.2034
   Guerrero MP, 2011, CHEM ENG SCI, V66, P5313, DOI 10.1016/j.ces.2011.07.026
   Gupta M, 2006, THIN SOLID FILMS, V515, P1579, DOI 10.1016/j.tsf.2006.05.021
   Gursoy M, 2017, COLLOID SURFACE A, V529, P959, DOI 10.1016/j.colsurfa.2017.06.065
   Gursoy M, 2017, COLLOID SURFACE A, V529, P195, DOI 10.1016/j.colsurfa.2017.05.071
   Gursoy M, 2019, J APPL POLYM SCI, V136, DOI 10.1002/app.47768
   Gursoy M, 2018, PROG ORG COAT, V120, P190, DOI 10.1016/j.porgcoat.2018.03.021
   Gursoy M, 2016, PLASMA PROCESS POLYM, V13, P438, DOI 10.1002/ppap.201500091
   Gursoy M, 2016, CHEM ENG J, V284, P343, DOI 10.1016/j.cej.2015.09.007
   Hamadi F, 2009, MAT SCI ENG C-BIO S, V29, P1302, DOI 10.1016/j.msec.2008.10.023
   Jiang JX, 2016, ACS APPL MATER INTER, V8, P10513, DOI 10.1021/acsami.6b01102
   Karaman M, 2017, SURFACE TREATMENTS FOR BIOLOGICAL, CHEMICAL, AND PHYSICAL APPLICATIONS, P23
   Karaman M, 2017, PLASMA SCI TECHNOL, V19, DOI 10.1088/2058-6272/aa6fec
   Karaman M, 2012, APPL SURF SCI, V259, P542, DOI 10.1016/j.apsusc.2012.07.079
   Kovacik P, 2015, MATER HORIZ, V2, P221, DOI 10.1039/c4mh00222a
   Kuba AG, 2016, CHEM ENG SCI, V154, P136, DOI 10.1016/j.ces.2016.05.007
   Kumar V, 2010, PLASMA PROCESS POLYM, V7, P926, DOI 10.1002/ppap.201000038
   Lee JW, 2012, J IND ENG CHEM, V18, P1647, DOI 10.1016/j.jiec.2012.03.005
   Lei ZY, 2019, MATER HORIZ, V6, P538, DOI 10.1039/c8mh01157e
   Liu JX, 2013, ENVIRON INT, V61, P98, DOI 10.1016/j.envint.2013.08.022
   Maydannik PS, 2011, CHEM ENG J, V171, P345, DOI 10.1016/j.cej.2011.03.097
   Men XH, 2016, CHEM ENG J, V296, P458, DOI 10.1016/j.cej.2016.03.129
   MILLER FA, 1967, SPECTROCHIM ACTA A-M, VA 23, P1609, DOI 10.1016/0584-8539(67)80043-6
   Olsen GW, 2009, TOXICOLOGY, V256, P65, DOI 10.1016/j.tox.2008.11.008
   Pan GM, 2019, SURF COAT TECH, V360, P318, DOI 10.1016/j.surfcoat.2018.12.094
   Politakos Nikolaos, 2018, Nano-Structures & Nano-Objects, V16, P412, DOI 10.1016/j.nanoso.2017.09.006
   Premkumar PA, 2010, PLASMA PROCESS POLYM, V7, P635, DOI 10.1002/ppap.200900179
   Schlaich C, 2018, ADV MATER INTERFACES, V5, DOI 10.1002/admi.201701254
   Shen YZ, 2017, CHEM ENG J, V313, P47, DOI 10.1016/j.cej.2016.12.063
   Singh N, 2018, LANGMUIR, V34, P11405, DOI 10.1021/acs.langmuir.8b02430
   Wedershoven HMJM, 2018, CHEM ENG SCI, V181, P92, DOI 10.1016/j.ces.2018.02.006
   Yang Y, 2019, CHEM ENG J, V369, P813, DOI 10.1016/j.cej.2019.03.134
   Yang YR, 2019, CHEM SOC REV, V48, P1465, DOI 10.1039/c7cs00730b
   Zhang Y, 2013, COLLOID SURFACE A, V436, P563, DOI 10.1016/j.colsurfa.2013.07.020
NR 44
TC 1
Z9 1
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115466
DI 10.1016/j.ces.2019.115466
PG 8
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300031
DA 2020-05-12
ER

PT J
AU Salaeva, AA
   Salaev, MA
   Mamontov, GV
AF Salaeva, A. A.
   Salaev, M. A.
   Mamontov, G., V
TI Effect of Cu modifier on the performance of CrOx/Al2O3 catalysts for
   isobutane dehydrogenation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CrOx/Al2O3 catalyst; Isobutane dehydrogenation; Isobutylene; Cu
   modifier; Chromium species
ID CHROMIUM-OXIDE CATALYSTS; IN-SITU XRD; OXIDATIVE DEHYDROGENATION;
   RAMAN-SPECTROSCOPY; NO REDUCTION; ACTIVE-SITES; ALUMINA; PROPANE; AL2O3;
   ZRO2
AB The peculiarities of active surface formation and the effect of Cu modifier on the performance of CrOx/Al2O3 catalysts in a fixed-bed isobutane dehydrogenation into isobutylene are considered using a series of model Cu-modified alumina supports (0.7-6.5% wt Cu) and CrOx catalysts on the basis thereof. The samples are characterized using a complex of physical-chemical methods, including low-temperature N-2 adsorption, STA, XRF, XRD, UV-vis DR, Raman spectroscopy and H-2-TPR. The modification of the alumina-chromia catalysts by a proper amount of copper is shown to enhance the catalyst activity. The catalyst with 2.6% wt Cu shows high conversion and selectivity towards isobutylene. The role of Cu modifier is connected with stabilizing of the active component mostly as monomeric and dimeric Cr(VI) species that can be reduced into the most active mononuclear and dimeric Cr (3+) sites. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Salaeva, A. A.; Salaev, M. A.; Mamontov, G., V] Tomsk State Univ, 36 Lenin Ave, Tomsk 634050, Russia.
RP Mamontov, GV (reprint author), Tomsk State Univ, 36 Lenin Ave, Tomsk 634050, Russia.
EM grigoriymamontov@mail.ru
OI Mamontov, Grigory/0000-0001-7007-8389
FU Tomsk State University Competitiveness Improvement Program [8.2.03.2018]
FX This work was supported by "The Tomsk State University Competitiveness
   Improvement Program"(8.2.03.2018). The authors thank Dr. V.A.
   Svetlichnyi for Raman studies and Dr. I.N. Lapin for elemental analysis
   studies.
CR [Anonymous], 2017, Pat. US, Patent No. [9725380B2, 9725380]
   [Anonymous], 2009, Pat. RU, Patent No. 2350594
   [Anonymous], 2018, Pat, Patent No. [WO2018144188A1, 2018144188]
   [Anonymous], 2004, Pat. US, Patent No. [2004/0092391 A1, 20040092391]
   [Anonymous], 2005, Pat. US, Patent No. [2005/0075243 A1, 20050075243]
   [Anonymous], 2009, Pat. RU, Patent No. 2349378
   [Anonymous], 2013, Pat. US, Patent No. [20130072739 A1, 20130072739]
   [Anonymous], 2006, Pat. RU, Patent No. [2287366 C1, 2287366]
   Bahmani M, 2016, APPL CATAL A-GEN, V520, P178, DOI 10.1016/j.apcata.2016.04.018
   Beccari M., 2006, ENCY HYDROCARBONS, V2, P687
   Bekmukhamedov GE, 2016, CATALYSTS, V6, DOI 10.3390/catal6100162
   Bugrova TA, 2018, KINET CATAL+, V59, P143, DOI 10.1134/S0023158418020027
   Bugrova TA, 2015, KINET CATAL+, V56, P758, DOI 10.1134/S0023158415060014
   Bugrova TA, 2019, CATAL TODAY, V333, P71, DOI 10.1016/j.cattod.2018.04.047
   Cabrera F, 2008, CATAL TODAY, V133, P800, DOI 10.1016/j.cattod.2007.12.039
   Cavani F, 1996, J CATAL, V158, P236, DOI 10.1006/jcat.1996.0023
   Cheng M, 2019, CATAL LETT, V149, P1326, DOI 10.1007/s10562-019-02686-x
   Cutrufello MG, 2005, THERMOCHIM ACTA, V434, P62, DOI 10.1016/j.tca.2005.01.017
   Dines TJ, 2003, PHYS CHEM CHEM PHYS, V5, P1320, DOI 10.1039/b211857b
   Dong AH, 2017, FUEL PROCESS TECHNOL, V158, P218, DOI 10.1016/j.fuproc.2017.01.004
   Fridman VZ, 2010, APPL CATAL A-GEN, V382, P139, DOI 10.1016/j.apcata.2010.04.026
   Fridman VZ, 2017, IND ENG CHEM RES, V56, P7937, DOI 10.1021/acs.iecr.7b01638
   Fridman VZ, 2017, APPL CATAL A-GEN, V530, P154, DOI 10.1016/j.apcata.2016.11.024
   Fridman VZ, 2016, APPL CATAL A-GEN, V523, P39, DOI 10.1016/j.apcata.2016.05.008
   Fridman VZ, 2004, J CATAL, V222, P545, DOI 10.1016/j.jcat.2003.12.016
   Geilen F.M.A., 2014, ULLMANNS ENCY IND CH
   HARDCASTLE FD, 1988, J MOL CATAL, V46, P173, DOI 10.1016/0304-5102(88)85092-2
   He M, 2006, J RARE EARTH, V24, P188, DOI 10.1016/S1002-0721(06)60091-4
   Hosseini ZS, 2014, SENSOR ACTUAT A-PHYS, V212, P80, DOI 10.1016/j.sna.2014.03.007
   Kharlamova T, 2016, CATAL TODAY, V278, P174, DOI 10.1016/j.cattod.2016.05.006
   Kim TW, 2001, APPL CATAL A-GEN, V210, P35, DOI 10.1016/S0926-860X(00)00801-2
   Lamberov AA, 2017, CATAL IND, V9, P17, DOI 10.1134/S2070050417010093
   Lindstrom B, 2002, APPL CATAL A-GEN, V234, P111, DOI 10.1016/S0926-860X(02)00202-8
   Liu JF, 2018, IND ENG CHEM RES, V57, P11265, DOI 10.1021/acs.iecr.8b01728
   Liu Y, 2018, CATAL SCI TECHNOL, V8, P4916, DOI 10.1039/c8cy01420e
   Luo MF, 2005, J MOL CATAL A-CHEM, V239, P243, DOI 10.1016/j.molcata.2005.06.029
   Ma RH, 2011, CATAL TODAY, V175, P598, DOI 10.1016/j.cattod.2011.04.025
   Martino GA, 2018, J CATAL, V357, P206, DOI 10.1016/j.jcat.2017.11.007
   Matveyeva AN, 2019, CHEM ENG J, V372, P1194, DOI 10.1016/j.cej.2019.04.181
   Merk AA, 2018, KINET CATAL+, V59, P211, DOI 10.1134/S0023158418020118
   Mindru I, 2016, CERAM INT, V42, P154, DOI 10.1016/j.ceramint.2015.08.058
   Mukhamed'yarova A.N., 2019, INFLUENCE OBTAINING, DOI [10.3390/coatings9010041, DOI 10.3390/COATINGS9010041]
   Nawaz Z, 2015, REV CHEM ENG, V31, P413, DOI 10.1515/revce-2015-0012
   Neri G, 2004, APPL CATAL A-GEN, V260, P75, DOI 10.1016/j.apcata.2003.10.002
   OSKAM A, 1990, J MOL STRUCT, V217, P325, DOI 10.1016/0022-2860(90)80371-P
   Otroshchenko TP, 2017, J CATAL, V356, P197, DOI 10.1016/j.jcat.2017.10.012
   Redaoui D, 2017, ACTA PHYS POL A, V131, P562, DOI 10.12693/APhysPolA.131.562
   Rodemerck U, 2017, J CATAL, V352, P256, DOI 10.1016/j.jcat.2017.05.022
   Rodemerck U, 2016, CHEM COMMUN, V52, P12222, DOI 10.1039/c6cc06442f
   Rombi E, 2003, APPL CATAL A-GEN, V251, P255, DOI 10.1016/S0926-860X(03)00308-9
   Salaeva AA, 2019, APPL CATAL A-GEN, V581, P82, DOI 10.1016/j.apcata.2019.05.018
   Sanfilippo D, 2006, CATAL TODAY, V111, P133, DOI 10.1016/j.cattod.2005.10.012
   Sattler JJHB, 2014, CHEM REV, V114, P10613, DOI 10.1021/cr5002436
   Shee D, 2010, APPL CATAL A-GEN, V389, P155, DOI 10.1016/j.apcata.2010.09.013
   Tasbihi M, 2007, FUEL PROCESS TECHNOL, V88, P883, DOI 10.1016/j.fuproc.2007.04.007
   Tian YP, 2016, FUEL PROCESS TECHNOL, V151, P31, DOI 10.1016/j.fuproc.2016.05.024
   VUURMAN MA, 1993, J MOL CATAL, V84, P193, DOI 10.1016/0304-5102(93)85052-U
   VUURMAN MA, 1992, J PHYS CHEM-US, V96, P5008, DOI 10.1021/j100191a051
   Wang GJ, 2018, CHEM PAP, V72, P921, DOI 10.1007/s11696-017-0335-0
   Wang GW, 2016, CHEMCATCHEM, V8, P3137, DOI 10.1002/cctc.201600685
   Wang GW, 2016, CATAL SCI TECHNOL, V6, P3128, DOI 10.1039/c5cy01950h
   Wang XS, 2018, APPL CATAL A-GEN, V555, P171, DOI 10.1016/j.apcata.2018.02.021
   Weckhuysen BM, 1997, J CATAL, V166, P160, DOI 10.1006/jcat.1997.1518
   Yamamoto T, 2002, PHYS CHEM CHEM PHYS, V4, P2449, DOI 10.1039/b201120b
   Yashnik SA, 2015, KINET CATAL+, V56, P466, DOI 10.1134/S0023158415040205
   Yim SD, 2004, J CATAL, V221, P601, DOI 10.1016/j.jcat.2003.09.026
   Zhang Yan, 2018, Food and Nutrition Sciences, V9, P1, DOI 10.4236/fns.2018.91001
   Zhang YW, 2012, FUEL PROCESS TECHNOL, V96, P220, DOI 10.1016/j.fuproc.2011.12.040
   Zykova A., 2016, AIP C P, V1772
NR 69
TC 0
Z9 0
U1 12
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115462
DI 10.1016/j.ces.2019.115462
PG 10
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300014
DA 2020-05-12
ER

PT J
AU Salmi, T
   Eranen, K
   Tolvanen, P
   Mikkola, JP
   Russo, V
AF Salmi, Tapio
   Eranen, Kari
   Tolvanen, Pasi
   Mikkola, J-P
   Russo, Vincenzo
TI Determination of kinetics and equilibria of heterogeneously catalyzed
   gas-phase reactions in gradientless autoclave reactors by using the
   total pressure method: Methanol synthesis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Kinetics; Total pressure method; Modelling; Methanol synthesis; Solid
   catalyst; Gradientless reactor
ID DIFFUSION; MODEL
AB Rapid methods are very valuable in the determination of the kinetic and mass transfer effects for heterogeneously catalyzed reactions. The total pressure method is a classical tool in the measurement of the kinetics of gas-phase reactions, but it can be successfully applied to the kinetic measurements of gasphase processes enhanced by solid catalysts. A general theory for the analysis of heterogeneously catalyzed gas-phase kinetics in gradientless batch reactors was presented for the case of intrinsic kinetic control and combined kinetic-diffusion control in porous catalysts. The concept was applied to gasphase synthesis of methanol from carbon monoxide and hydrogen on a commercial copper-based catalyst (CuO/ZnO/Al2O3 R3-12 BASF). The reaction temperature was 180-210 degrees C and the initial total pressure was varied between 11 and 21 bar in a laboratory-scale autoclave reactor equipped with a rotating basket for the catalyst particles. The initial molar ratios CO-to-H-2 were approximately 1:2, 1:3 and 1:4. The experimental data from methanol synthesis were compared with numerical simulations and a good agreement between the experiments and model simulations was achieved. The predicted equilibrium agrees with previously reported values. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Salmi, Tapio; Eranen, Kari; Tolvanen, Pasi; Mikkola, J-P; Russo, Vincenzo] Abo Akad Univ, Johan Gadolin Proc Chem Ctr PCC, Lab Ind Chem & React Engn, FI-20500 Turku, Finland.
   [Mikkola, J-P] Umea Univ, Chem Chem Biol Ctr, Tech Chem Dept, SE-90187 Umea, Sweden.
   [Russo, Vincenzo] Univ Napoli Federico II, Chem Sci Dept, IT-80126 Naples, Italy.
RP Salmi, T (reprint author), Abo Akad Univ, Johan Gadolin Proc Chem Ctr PCC, Lab Ind Chem & React Engn, FI-20500 Turku, Finland.
EM tapio.salmi@abo.fi
OI Russo, Vincenzo/0000-0002-1867-739X
FU Academy of FinlandAcademy of Finland [319002, 320115]
FX This work is part of the activities financed by Academy of Finland, the
   Academy Professor grants 319002 (T. Salmi) and 320115 (P. Tolvanen).
   SpinChemTM AB is gratefully acknowledged for providing the rotating
   basket equipment. The authors are grateful to several undergraduate
   students who contributed to the experimental performance.
CR Aris R., 1975, MATH THEORY DIFFUSIO
   ASKGAARD TS, 1995, J CATAL, V156, P229, DOI 10.1006/jcat.1995.1250
   Aumo J, 2006, CHEM ENG SCI, V61, P814, DOI 10.1016/j.ces.2005.07.036
   COTERON A, 1994, CHEM ENG SCI, V49, P209, DOI 10.1016/0009-2509(94)80039-1
   Fott P., 1984, RECENT ANAL CHEM REA
   gPROMS, 2018, PROC SYST ENT
   Graaf GH, 2016, IND ENG CHEM RES, V55, P5854, DOI 10.1021/acs.iecr.6b00815
   Graaf GH, 1996, CHEM ENG PROCESS, V35, P413, DOI 10.1016/S0255-2701(96)04147-5
   GRAAF GH, 1990, CHEM ENG SCI, V45, P773, DOI 10.1016/0009-2509(90)85001-T
   Grabow LC, 2011, ACS CATAL, V1, P365, DOI 10.1021/cs200055d
   Hill C.G., 2014, INTRO CHEM ENG KINET
   Leonov VE, 1973, KINET KATAL, V14, P848
   LEVENSPIEL O, 1999, CHEM REACTION ENG
   MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030
   Mayra O., 2018, METHANOL, P475
   Ovesen CV, 1997, J CATAL, V168, P133, DOI 10.1006/jcat.1997.1629
   Reid RC, 1988, PROPERTIES GASES LIQ
   SALMI T, 1991, COMPUT CHEM ENG, V15, P715, DOI 10.1016/0098-1354(91)85017-O
   Salmi T., 2019, CHEM REACTION ENG RE
   SATTERFIELD CN, 1970, MASS TRANSFER HETERO
   SKRZYPEK J, 1991, CHEM ENG SCI, V46, P2809, DOI 10.1016/0009-2509(91)85150-V
   Temkin M.I., 1984, COMM DEP CHEM BULG A, V50, P50
   THOMAS WJ, 1958, IND ENG CHEM, V50, P967, DOI 10.1021/ie50582a048
   Thomopoulos N., 2016, GLOBAL MARKETS RENEW
   VandenBussche KM, 1996, J CATAL, V161, P1
NR 25
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115393
DI 10.1016/j.ces.2019.115393
PG 9
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300010
DA 2020-05-12
ER

PT J
AU Schack, D
   Liesche, G
   Sundmacher, K
AF Schack, Dominik
   Liesche, Georg
   Sundmacher, Kai
TI The FluxMax approach: Simultaneous flux optimization and heat
   integration by discretization of thermodynamic state space illustrated
   on methanol synthesis process
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Integrated process design; Process optimization; Energy efficiency;
   Methanol synthesis; Heat integration
ID TECHNOECONOMIC OPTIMIZATION; EXCHANGER NETWORKS; PROCESS
   INTENSIFICATION; CHEMICAL-STORAGE; IDEAS APPROACH; DESIGN; ENERGY; CO2;
   METHODOLOGY; RECOVERY
AB Resource efficiency is a key driver in the chemical industry for both economic and ecological reasons. However, often the design of chemical processes or units and the corresponding heat integration, is divided into two design phases: a flow optimization to identify an optimal design and the subsequent evaluation of the heat integration potential. This procedure cannot guarantee the identification of the global resource optimum, which increases the need for a method that can do both simultaneously. This is the aim of the FluxMax approach that discretizes the thermodynamic state space. The introduction of nodes corresponding to mixtures, elementary processes and utilities allows the representation of any chemical process as a directed graph, which decouples effectively process-based nonlinearities from the optimization problem. Heat integration is considered by additional constraints. Using the methanol synthesis process as example, energy-optimal process configurations are identified that outperform configurations identified in a sequential procedure. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Schack, Dominik; Liesche, Georg; Sundmacher, Kai] Max Planck Inst Dynam Complex Tech Syst, Dept Proc Syst Engn, Sandtorstr 1, D-39106 Magdeburg, Germany.
   [Sundmacher, Kai] Otto von Guericke Univ, Dept Proc Syst Engn, Univ Pl 2, D-39106 Magdeburg, Germany.
RP Schack, D (reprint author), Max Planck Inst Dynam Complex Tech Syst, Dept Proc Syst Engn, Sandtorstr 1, D-39106 Magdeburg, Germany.
EM schack@mpi-magdeburg.mpg.de; liesche@mpi-magdeburg.mpg.de;
   sundmacher@mpi-magdeburg.mpg.de
OI Schack, Dominik/0000-0003-1304-5200; Liesche, Georg/0000-0002-1677-6087
CR Bertau M., 2014, METHANOL BASIC CHEM
   Cabezas H, 2018, ENVIRON PROG SUSTAIN, V37, P624, DOI 10.1002/ep.12887
   COLBERG RD, 1990, COMPUT CHEM ENG, V14, P1, DOI 10.1016/0098-1354(90)87002-7
   da Cruz FE, 2017, COMPUT CHEM ENG, V105, P39, DOI 10.1016/j.compchemeng.2016.12.006
   Dimian A.C., 2008, CHEM PROCESS DESIGN
   Dimian AC, 2018, CHEM ENG RES DES, V131, P41, DOI 10.1016/j.cherd.2017.11.009
   Dowling AW, 2015, COMPUT CHEM ENG, V72, P3, DOI 10.1016/j.compchemeng.2014.05.013
   DURAN MA, 1986, AICHE J, V32, P123, DOI 10.1002/aic.690320114
   Elsido C, 2017, ENRGY PROCED, V129, P26, DOI 10.1016/j.egypro.2017.09.171
   Freund H, 2008, CHEM ENG PROCESS, V47, P2051, DOI 10.1016/j.cep.2008.07.011
   FRIEDLER F, 1992, CHEM ENG SCI, V47, P1973, DOI 10.1016/0009-2509(92)80315-4
   Gencer E, 2018, RESOUR CONSERV RECY, V133, P331, DOI 10.1016/j.resconrec.2018.01.030
   Hartono B, 2012, IND ENG CHEM RES, V51, P14428, DOI 10.1021/ie301232t
   Hentschel B, 2014, CHEM ENG SCI, V115, P69, DOI 10.1016/j.ces.2013.09.046
   Holiastos K, 2002, COMPUT CHEM ENG, V26, P3, DOI 10.1016/S0098-1354(01)00726-8
   Holiastos K, 2004, IND ENG CHEM RES, V43, P7826, DOI 10.1021/ie010434i
   Huang B, 2018, COMPUT CHEM ENG, V117, P117, DOI 10.1016/j.compchemeng.2018.02.008
   International Energy Agency, 2018, EN EFF 2018 AN OUTL
   Jogwar SS, 2015, IFAC PAPERSONLINE, V48, P1192, DOI 10.1016/j.ifacol.2015.09.130
   Kaiser NM, 2017, IND ENG CHEM RES, V56, P11507, DOI 10.1021/acs.iecr.7b01939
   Kermani M, 2018, APPL ENERG, V212, P1203, DOI 10.1016/j.apenergy.2017.12.094
   Kessler T, 2019, CHEM ENG SCI, V197, P235, DOI 10.1016/j.ces.2018.12.002
   Kim J, 2013, ENERG ENVIRON SCI, V6, P1093, DOI 10.1039/c3ee24243a
   Konig A, 2019, ENERG FUEL, V33, P1659, DOI 10.1021/acs.energyfuels.8b03790
   Kokossis AC, 2015, COMPUT CHEM ENG, V81, P40, DOI 10.1016/j.compchemeng.2015.05.021
   Liesche G, 2019, AICHE J, V65, DOI 10.1002/aic.16554
   Liesche G, 2018, COMPUT-AIDED CHEM EN, V43, P881, DOI 10.1016/B978-0-444-64235-6.50154-6
   LINNHOFF B, 1978, AICHE J, V24, P633, DOI 10.1002/aic.690240411
   Maussner J., 2019, J ADV MANUF PROCESS, V1, DOI [10.1002/amp2.10024, DOI 10.1002/AMP2.10024]
   Moioli E, 2019, RENEW SUST ENERG REV, V107, P497, DOI 10.1016/j.rser.2019.03.022
   Nagy AB, 2001, APPL THERM ENG, V21, P1407, DOI 10.1016/S1359-4311(01)00033-3
   Ott J., 2000, METHANOL, DOI [10.1002/14356007.a16_465.pub3, DOI 10.1002/14356007.A16_465.PUB3]
   Otto A, 2015, ENERG ENVIRON SCI, V8, P3283, DOI 10.1039/c5ee02591e
   Ouda M., 2019, POWER TO METHANOL TE, P380, DOI [10.1007/978-3-662-58006-6_17, DOI 10.1007/978-3-662-58006-6_17]
   PAPOULIAS SA, 1983, COMPUT CHEM ENG, V7, P707, DOI 10.1016/0098-1354(83)85023-6
   PAPOULIAS SA, 1983, COMPUT CHEM ENG, V7, P723, DOI 10.1016/0098-1354(83)85024-8
   Peschel A, 2010, IND ENG CHEM RES, V49, P10535, DOI 10.1021/ie100476q
   Pichardo P, 2017, CHEM ENG RES DES, V120, P372, DOI 10.1016/j.cherd.2017.01.026
   Rihko-Struckmann LK, 2010, IND ENG CHEM RES, V49, P11073, DOI 10.1021/ie100508w
   Ryu J, 2019, IND ENG CHEM RES, V58, P6002, DOI 10.1021/acs.iecr.8b04083
   Schack D., 2019, CHEM ENG T, V76, P337, DOI [10.3303/CET1976057, DOI 10.3303/CET1976057]
   Schack D, 2018, IND ENG CHEM RES, V57, P9889, DOI 10.1021/acs.iecr.7b05305
   Schack D, 2017, COMPUT-AIDED CHEM EN, V40B, P1975, DOI 10.1016/B978-0-444-63965-3.50331-7
   Schack D, 2018, CHEM-ING-TECH, V90, P256, DOI 10.1002/cite.201700163
   Schack D, 2016, COMPUT-AIDED CHEM EN, V38B, P1551
   Short M, 2018, CHEM ENG SCI, V178, P118, DOI 10.1016/j.ces.2017.12.019
   Surya Prakash G.K., 2011, ECS T, V35, P31, DOI [10.1149/1.3645178, DOI 10.1149/1.3645178]
   Uebbing J, 2019, APPL ENERG, V233, P271, DOI 10.1016/j.apenergy.2018.10.014
   Ulonska K, 2016, AICHE J, V62, P3096, DOI 10.1002/aic.15305
   Voll A, 2012, AICHE J, V58, P1788, DOI 10.1002/aic.12704
   Wilson S, 2000, AICHE J, V46, P2408, DOI 10.1002/aic.690461209
   YEE TF, 1990, COMPUT CHEM ENG, V14, P1185, DOI 10.1016/0098-1354(90)80001-R
   Yu HS, 2017, ENERGY, V119, P322, DOI 10.1016/j.energy.2016.12.061
   Zondervan E, 2011, COMPUT CHEM ENG, V35, P1752, DOI 10.1016/j.compchemeng.2011.01.042
NR 54
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115382
DI 10.1016/j.ces.2019.115382
PG 17
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300033
DA 2020-05-12
ER

PT J
AU Shi, T
   Chun, W
   Yang, A
   Su, Y
   Jin, SM
   Ren, JZ
   Shen, WF
AF Shi, Tao
   Chun, Wei
   Yang, Ao
   Su, Yang
   Jin, Saimeng
   Ren, Jingzheng
   Shen, Weifeng
TI Optimization and control of energy saving side-stream extractive
   distillation with heat integration for separating ethyl acetate-ethanol
   azeotrope
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Side-stream extractive distillation; Conceptual design; Optimization;
   Dynamic control
ID PRESSURE-SWING DISTILLATION; REACTIVE DIVIDING WALL; MULTIOBJECTIVE
   OPTIMIZATION; THERMODYNAMIC INSIGHTS; VAPOR RECOMPRESSION; TEMPERATURE
   CONTROL; ENTRAINER RECYCLE; PROCESS DESIGN; COLUMN; WATER
AB Currently, limited efforts have focused on the multi-objective optimization and effective control of the side-stream extractive distillation processes (EDS). Herein, the EDS and a heat-integration scheme (EDSH) are proposed for separating the minimum-boiling azeotropic mixture ethyl acetate (EtAC)-ethanol (EtOH). Firstly, the conceptual design by residue curve maps is demonstrated for the EDS. Following which, the genetic algorithm (GA) optimization is carried out to minimize the total capital investment cost (CAP) and the annual energy cost (ENR). Optimal scheme under the product purity constraints is then obtained from the Pareto front. And the EDSH scheme is shown with less TAC and CO2 emission. Therefore, an improved control structure CS3 combining the composition-(RR1/SIDE) cascade and feedforward strategy is developed to achieve decent dynamic responses for the EDSH. The antidisturbance capability of different control structures in terms of the transient deviation and offsets are compared with the assistance of the integral absolute error. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Shi, Tao; Yang, Ao; Su, Yang; Jin, Saimeng; Shen, Weifeng] Chongqing Univ, Sch Chem & Chem Engn, Chongqing 400044, Peoples R China.
   [Shi, Tao; Yang, Ao; Su, Yang; Jin, Saimeng; Shen, Weifeng] Chongqing Univ, Natl Municipal Joint Engn Lab Chem Proc Intensifi, Chongqing 400044, Peoples R China.
   [Chun, Wei] Chongqing Univ, Sch Econ & Business Adm, Chongqing 400044, Peoples R China.
   [Ren, Jingzheng] Hong Kong Polytech Univ, Dept Ind & Syst Engn, Hong Kong, Peoples R China.
RP Shen, WF (reprint author), Chongqing Univ, Sch Chem & Chem Engn, Chongqing 400044, Peoples R China.
EM 201718021063@cqu.edu.cn; chunwei@cqu.edu.cn; yang-ao@cqu.edu.cn;
   yang2019@cqu.edu.cn; sj708@cqu.edu.cn; jzhren@polyu.edu.hk;
   shenweifeng@cqu.edu.cn
OI Yang, Ao/0000-0001-8867-1375; shen, weifeng/0000-0002-0418-6848
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21606026, 21878028]; Fundamental Research Funds for
   the Central UniversitiesFundamental Research Funds for the Central
   Universities [2019CDQYHG021, 2019CDXYHG0013]
FX We acknowledge the financial support provided by the National Natural
   Science Foundation of China (Nos. 21606026, 21878028); the Fundamental
   Research Funds for the Central Universities (No. 2019CDQYHG021,
   2019CDXYHG0013).
CR Alcocer-Garcia H, 2019, CHEM ENG PROCESS, V136, P123, DOI 10.1016/j.cep.2019.01.008
   An Y, 2015, CHEM ENG SCI, V135, P166, DOI 10.1016/j.ces.2015.05.003
   Vazquez-Castillo JA, 2009, COMPUT CHEM ENG, V33, P1841, DOI 10.1016/j.compchemeng.2009.04.011
   Bortz M, 2014, COMPUT CHEM ENG, V60, P354, DOI 10.1016/j.compchemeng.2013.09.015
   Bravo-Bravo C, 2010, IND ENG CHEM RES, V49, P3672, DOI 10.1021/ie9006936
   Chien IL, 2004, IND ENG CHEM RES, V43, P2160, DOI 10.1021/ie030406v
   Chua WJ, 2017, CHEM ENG PROCESS, V118, P108, DOI 10.1016/j.cep.2017.04.021
   Contreras-Zarazua G, 2019, IND ENG CHEM RES, V58, P6105, DOI 10.1021/acs.iecr.8b03646
   Cui CT, 2019, CHEM ENG RES DES, V145, P48, DOI 10.1016/j.cherd.2019.03.001
   Dai Y, 2019, IND ENG CHEM RES, V58, P2379, DOI 10.1021/acs.iecr.8b04983
   Douglas J. M., 1988, CONCEPTUAL DESIGN CH
   Gadalla MA, 2005, ENVIRON SCI TECHNOL, V39, P6860, DOI 10.1021/es049795q
   Gerbaud V, 2019, CHEM ENG RES DES, V141, P229, DOI 10.1016/j.cherd.2018.09.020
   Ghuge PD, 2017, COMPUT CHEM ENG, V103, P188, DOI 10.1016/j.compchemeng.2017.03.019
   Gomez A, 2010, ENERG CONVERS MANAGE, V51, P859, DOI 10.1016/j.enconman.2009.11.022
   Gu JL, 2018, CHEM ENG RES DES, V133, P303, DOI 10.1016/j.cherd.2018.03.015
   Gutierrez-Antonio C, 2009, COMPUT CHEM ENG, V33, P454, DOI 10.1016/j.compchemeng.2008.11.004
   Han ZW, 2019, IND ENG CHEM RES, V58, P5252, DOI 10.1021/acs.iecr.8b06044
   Hegely L, 2018, FRONT CHEM SCI ENG, V12, P643, DOI 10.1007/s11705-018-1760-5
   Hu YJ, 2019, SEP PURIF TECHNOL, V211, P723, DOI 10.1016/j.seppur.2018.10.030
   Kiva VN, 2003, CHEM ENG SCI, V58, P1903, DOI 10.1016/S0009-2509(03)00018-6
   Lai IK, 2007, CHEM ENG SCI, V62, P878, DOI 10.1016/j.ces.2006.10.019
   LANG YD, 1987, COMPUT CHEM ENG, V11, P143, DOI 10.1016/0098-1354(87)80014-5
   Liang SS, 2017, CHEM ENG RES DES, V117, P318, DOI 10.1016/j.cherd.2016.10.040
   Luo H, 2015, IND ENG CHEM RES, V54, P2208, DOI 10.1021/ie504459c
   Luyben WL, 2008, IND ENG CHEM RES, V47, P2696, DOI 10.1021/ie701695u
   Luyben WL, 2017, SEP PURIF TECHNOL, V174, P232, DOI 10.1016/j.seppur.2016.10.020
   Luyben WL, 2013, COMPUT CHEM ENG, V50, P1, DOI 10.1016/j.compchemeng.2012.10.014
   Luyben WL, 2006, J PROCESS CONTR, V16, P115, DOI 10.1016/j.jprocont.2005.05.004
   Luyben WL, 2013, DISTILLATION DESIGN AND CONTROL USING ASPEN(TM) SIMULATION, 2ND EDITION, P1, DOI 10.1002/9781118510193
   Ma K, 2019, SEP PURIF TECHNOL, V210, P195, DOI 10.1016/j.seppur.2018.08.004
   Ma ST, 2019, SEP PURIF TECHNOL, V209, P833, DOI 10.1016/j.seppur.2018.09.021
   Mitra K, 2004, CHEM ENG SCI, V59, P385, DOI 10.1016/j.ces.2003.09.036
   Olujic Z, 2006, ENERGY, V31, P3083, DOI 10.1016/j.energy.2006.03.030
   Pan H, 2019, CHEM ENG SCI, V203, P321, DOI 10.1016/j.ces.2019.03.061
   Qian X, 2019, IND ENG CHEM RES, V58, P4546, DOI 10.1021/acs.iecr.8b06179
   Rezende MCAF, 2008, CHEM ENG SCI, V63, P330, DOI 10.1016/j.ces.2007.09.001
   Shen WF, 2015, AICHE J, V61, P3898, DOI 10.1002/aic.14908
   Shen WF, 2013, IND ENG CHEM RES, V52, P4606, DOI 10.1021/ie3011148
   Shen WF, 2013, IND ENG CHEM RES, V52, P4623, DOI 10.1021/ie302693c
   Shi T, 2019, SEP PURIF TECHNOL, V225, P1, DOI 10.1016/j.seppur.2019.05.061
   Su Y, 2020, COMPUT CHEM ENG, V132, DOI 10.1016/j.compchemeng.2019.106618
   Tututi-Avila S, 2017, COMPUT CHEM ENG, V102, P17, DOI 10.1016/j.compchemeng.2016.12.001
   Wang C, 2018, CHEM ENG RES DES, V136, P513, DOI 10.1016/j.cherd.2018.06.017
   Wang C, 2018, IND ENG CHEM RES, V57, P10551, DOI 10.1021/acs.iecr.8b01875
   Wang ZH, 2019, GREEN CHEM, V21, P4555, DOI 10.1039/c9gc01968e
   Yang A, 2019, SEP PURIF TECHNOL, V225, P41, DOI 10.1016/j.seppur.2019.05.063
   Yang A, 2019, IND ENG CHEM RES, V58, P7265, DOI 10.1021/acs.iecr.9b00466
   Yang A, 2019, ENERGY, V172, P320, DOI 10.1016/j.energy.2019.01.126
   Yang A, 2019, AICHE J, V65, P1281, DOI 10.1002/aic.16526
   Yang A, 2018, IND ENG CHEM RES, V57, P8036, DOI 10.1021/acs.iecr.8b00668
   Yang A, 2017, IND ENG CHEM RES, V56, P14565, DOI 10.1021/acs.iecr.7b03459
   Yi CC, 2018, SEP PURIF TECHNOL, V207, P489, DOI 10.1016/j.seppur.2018.07.003
   You XQ, 2018, CHEM ENG SCI, V177, P354, DOI 10.1016/j.ces.2017.11.035
   Zhang QJ, 2019, COMPUT CHEM ENG, V120, P30, DOI 10.1016/j.compchemeng.2018.09.014
   Zhang QJ, 2018, CHEM ENG RES DES, V136, P57, DOI 10.1016/j.cherd.2018.04.043
   Zhao YT, 2018, ENERGY, V148, P296, DOI 10.1016/j.energy.2018.01.161
   Zhu ZY, 2019, PROCESS SAF ENVIRON, V125, P16, DOI 10.1016/j.psep.2019.03.009
   Zhu ZY, 2016, SEP PURIF TECHNOL, V169, P66, DOI 10.1016/j.seppur.2016.06.009
NR 59
TC 2
Z9 2
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115373
DI 10.1016/j.ces.2019.115373
PG 18
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300027
DA 2020-05-12
ER

PT J
AU Su, HP
   Lian, C
   Gallegos, A
   Deng, SW
   Shang, YZ
   Liu, HL
   Wu, JZ
AF Su, Haiping
   Lian, Cheng
   Gallegos, Alejandro
   Deng, Shengwei
   Shang, Yazhuo
   Liu, Honglai
   Wu, Jianzhong
TI Microscopic insights into the Faradaic reaction effects on the electric
   double layers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Molecular model; Electric double layer; Faradaic capacitance; Classical
   density functional theory; Pseudocapacitor
ID REDUCED GRAPHENE OXIDE; FUNCTIONAL-GROUPS; ENERGY-STORAGE; IONIC
   LIQUIDS; CAPACITANCE; DENSITY; ELECTROLYTE; PERFORMANCE; REDUCTION;
   ALKALINE
AB Oxygen-containing functional groups have strong effect on the electrochemical capacitive behavior of carbon electrodes and have been subjected to many experimental investigations. However, there are relatively few theoretical reports on the relation between the oxygen-containing functional groups and the capacitance of carbon supercapacitors. In this study, we present a simple molecular model to describe electric double layer (EDL) in the presence of Faradaic reactions. We find that electrodes modified with oxygen functional groups increase the Faradaic capacitance but have relatively little influence on the EDL capacitance. The theoretical predictions agree quantitatively with experimental observations. We hope that this joint model by combining quantum DFT and classical DFT could provide a theoretical routine to study pseudocapacitors. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Su, Haiping; Lian, Cheng; Shang, Yazhuo; Liu, Honglai] East China Univ Sci & Technol, State Key Lab Chem Engn, Sch Chem Engn, Shanghai Engn Res Ctr Hierarch Nanomat, Shanghai 200237, Peoples R China.
   [Su, Haiping; Lian, Cheng; Shang, Yazhuo; Liu, Honglai] East China Univ Sci & Technol, Sch Chem & Mol Engn, Shanghai 200237, Peoples R China.
   [Gallegos, Alejandro; Wu, Jianzhong] Univ Calif Riverside, Dept Chem & Environm Engn, Riverside, CA 92521 USA.
   [Deng, Shengwei] Zhejiang Univ Technol, Coll Chem Engn, Hangzhou 310014, Peoples R China.
RP Lian, C; Liu, HL (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, Sch Chem Engn, Shanghai Engn Res Ctr Hierarch Nanomat, Shanghai 200237, Peoples R China.; Lian, C; Liu, HL (reprint author), East China Univ Sci & Technol, Sch Chem & Mol Engn, Shanghai 200237, Peoples R China.; Wu, JZ (reprint author), Univ Calif Riverside, Dept Chem & Environm Engn, Riverside, CA 92521 USA.
EM liancheng@ecust.edu.cn; hlliu@ecust.edu.cn; jwu@engr.ucr.edu
OI Lian, Cheng/0000-0002-9016-832X; Wu, Jianzhong/0000-0002-4582-5941
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [91834301, 21808055, 21908053]; National Natural
   Science Foundation of China for Innovative Research GroupsNational
   Natural Science Foundation of China [51621002]; Shanghai Sailing Program
   [19YF1411700]; China Postdoctoral Science FoundationChina Postdoctoral
   Science Foundation [2019 M651416]; Fluid Interface Reactions, Structures
   and Transport (FIRST) Center, an Energy Frontier Research Center - U.S.
   Department of Energy, Office of Science, Office of Basic Energy
   SciencesUnited States Department of Energy (DOE)
FX This work was sponsored by the National Natural Science Foundation of
   China (No. 91834301, 21808055 and 21908053), National Natural Science
   Foundation of China for Innovative Research Groups (No. 51621002),
   Shanghai Sailing Program (19YF1411700), China Postdoctoral Science
   Foundation (2019 M651416). This research was also sponsored by the Fluid
   Interface Reactions, Structures and Transport (FIRST) Center, an Energy
   Frontier Research Center funded by the U.S. Department of Energy, Office
   of Science, Office of Basic Energy Sciences. We also thank Dr. Cheng
   Zhan for the helpful discussion.
CR Abdelkader AM, 2015, J MATER CHEM A, V3, P8519, DOI 10.1039/c5ta00545k
   Andreas HA, 2006, ELECTROCHIM ACTA, V51, P6510, DOI 10.1016/j.electacta.2006.04.045
   Bazant MZ, 2013, ACCOUNTS CHEM RES, V46, P1144, DOI 10.1021/ar300145c
   Bo Z, 2018, NANO-MICRO LETT, V10, DOI 10.1007/s40820-018-0188-2
   Chmiola J, 2006, SCIENCE, V313, P1760, DOI [10.1126/science.1132195, 10.1126/science/1132195]
   Dou QY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02152-5
   Fang BZ, 2006, J POWER SOURCES, V163, P616, DOI 10.1016/j.jpowsour.2006.09.014
   Fedorov MV, 2014, CHEM REV, V114, P2978, DOI 10.1021/cr400374x
   Frackowiak E, 2014, FARADAY DISCUSS, V172, P179, DOI 10.1039/c4fd00052h
   Gao W, 2009, NAT CHEM, V1, P403, DOI [10.1038/NCHEM.281, 10.1038/nchem.281]
   Gao X, 2015, ENERG ENVIRON SCI, V8, P897, DOI 10.1039/c4ee03172e
   Garrity KF, 2014, COMP MATER SCI, V81, P446, DOI 10.1016/j.commatsci.2013.08.053
   Girotto M, 2017, J PHYS CHEM B, V121, P6408, DOI 10.1021/acs.jpcb.7b02258
   Goodwin ZAH, 2017, ELECTROCHIM ACTA, V225, P190, DOI 10.1016/j.electacta.2016.12.092
   Grimme S, 2006, J COMPUT CHEM, V27, P1787, DOI 10.1002/jcc.20495
   Hatzell MC, 2014, ENVIRON SCI TECHNOL, V48, P14041, DOI 10.1021/es5043782
   Hayes R, 2015, CHEM REV, V115, P6357, DOI 10.1021/cr500411q
   Islam MM, 2016, J PHYS CHEM C, V120, P27128, DOI 10.1021/acs.jpcc.6b08688
   Islam MM, 2016, J CHEM THEORY COMPUT, V12, P3463, DOI 10.1021/acs.jctc.6b00432
   Jiang DE, 2014, NANOSCALE, V6, P5545, DOI 10.1039/c4nr00046c
   Jiang DE, 2011, NANO LETT, V11, P5373, DOI 10.1021/nl202952d
   Jiang DE, 2011, CHEM PHYS LETT, V504, P153, DOI 10.1016/j.cplett.2011.01.072
   Jiang J, 2014, J PHYS-CONDENS MAT, V26, DOI 10.1088/0953-8984/26/28/284102
   Kar T, 2014, RSC ADV, V4, P57781, DOI 10.1039/c4ra10794b
   Karatrantos A., 2018, EFFECT DIFFERENT ORG
   Kondrat S, 2011, PHYS CHEM CHEM PHYS, V13, P11359, DOI 10.1039/c1cp20798a
   Kondrat S, 2011, J PHYS-CONDENS MAT, V23, DOI 10.1088/0953-8984/23/2/022201
   Letchworth-Weaver K, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.075140
   Lian C, 2016, ACS ENERGY LETT, V1, P21, DOI 10.1021/acsenergylett.6b00010
   Lian C., 2019, ARXIV191109924
   Lian C, 2019, ACS NANO, V13, P8185, DOI 10.1021/acsnano.9b03303
   Lian C, 2019, AICHE J, V65, P804, DOI 10.1002/aic.16467
   Lian C, 2017, J PHYS CHEM C, V121, P14066, DOI 10.1021/acs.jpcc.7b04869
   Lian C, 2016, J CHEM PHYS, V145, DOI 10.1063/1.4968037
   Liu XJ, 2014, RSC ADV, V4, P13673, DOI 10.1039/c3ra46992a
   Nisancioglu K, 2012, J ELECTROCHEM SOC, V159, pE59, DOI 10.1149/2.009204jes
   Oda H, 2006, J POWER SOURCES, V158, P1510, DOI 10.1016/j.jpowsour.2005.10.061
   Oh YJ, 2014, ELECTROCHIM ACTA, V116, P118, DOI 10.1016/j.electacta.2013.11.040
   Pak AJ, 2016, CHEMELECTROCHEM, V3, P741, DOI 10.1002/celc.201600064
   Paz-Garcia JM, 2014, ELECTROCHIM ACTA, V150, P263, DOI 10.1016/j.electacta.2014.10.056
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Pope MA, 2015, J PHYS CHEM C, V119, P20369, DOI 10.1021/acs.jpcc.5b07521
   Seredych M, 2008, CARBON, V46, P1475, DOI 10.1016/j.carbon.2008.06.027
   Simon P, 2008, NAT MATER, V7, P845, DOI 10.1038/nmat2297
   Sun Y., 2019, ACS APPL MAT INTERFA
   Sundararaman R, 2015, J CHEM PHYS, V142, DOI 10.1063/1.4907731
   Tojo T, 2014, RSC ADV, V4, P62678, DOI 10.1039/c4ra10439k
   Wu JZ, 2007, ANNU REV PHYS CHEM, V58, P85, DOI 10.1146/annurev.physchem.58.032806.104650
   Wu JZ, 2011, SOFT MATTER, V7, P11222, DOI 10.1039/c1sm06089a
   Xu K, 2015, ELECTROCHIM ACTA, V166, P142, DOI 10.1016/j.electacta.2015.03.101
   Yu YX, 2002, J CHEM PHYS, V117, P10156, DOI 10.1063/1.1520530
   Zhong C, 2015, CHEM SOC REV, V44, P7484, DOI 10.1039/c5cs00303b
NR 52
TC 0
Z9 0
U1 9
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115452
DI 10.1016/j.ces.2019.115452
PG 7
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300023
DA 2020-05-12
ER

PT J
AU Tang, YL
   Chen, MC
   Cheng, ZM
   Yang, T
   Chen, B
   Ge, HL
   Fang, XC
AF Tang, Yanling
   Chen, Meichen
   Cheng, Zhenmin
   Yang, Tao
   Chen, Bo
   Ge, Hailong
   Fang, Xiangchen
TI Effectiveness factors for a partially wetted catalyst based on the
   rivulet flow model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Partially wetted catalyst; Film flow; Rivulet flow; Effectiveness factor
ID TRICKLE-BED REACTORS; WETTING EFFICIENCY; STEADY-STATE; OXIDATION
AB Partial wetting is a common phenomenon in a trickle bed reactor, which causes nonuniform mass transfer flux at the external surface of the catalyst. Previous work on effectiveness factor for a partially wetted catalyst are mainly based on the assumption that the spherical catalyst is wetted by a liquid film. In fact, it is only true when the liquid-solid contact angle is very small. In most situations, rivulet flow prevails. The purpose of the article is to calculate effectiveness factors for both gas-limited and liquid-limited reactions under the two wetting modes by using finite element method (FEM). The effects of wetting efficiency, Biot number, and Thiele modulus on effectiveness factors are investigated. On the basis of the FEM results, the intrinsic reason for the variation of effectiveness factors with respect to wetting efficiency is revealed, and good agreements are observed between this work and the conventional models. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Tang, Yanling; Chen, Meichen; Cheng, Zhenmin] East China Univ Sci & Technol, Sch Chem Engn, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
   [Yang, Tao; Chen, Bo; Ge, Hailong; Fang, Xiangchen] SINOPEC, Dalian Res Inst Petr & Petrochem, Dalian 116045, Peoples R China.
RP Cheng, ZM (reprint author), East China Univ Sci & Technol, Sch Chem Engn, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.; Fang, XC (reprint author), SINOPEC, Dalian Res Inst Petr & Petrochem, Dalian 116045, Peoples R China.
EM zmcheng@ecust.edu.cn; fangxiangchen.fshy@sinopec.com
OI Cheng, zhenmin/0000-0001-8315-8580
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21676085]; SINOPEC
FX The authors are grateful to the financial supports from the National
   Natural Science Foundation of China (21676085) and the Key Research
   Project "Packaged Technology Development in Residue Oil Hydroprocessing
   and Industrial Applications" supported by the SINOPEC.
CR ALDAHHAN MH, 1995, CHEM ENG SCI, V50, P2377, DOI 10.1016/0009-2509(95)00092-J
   ARIS R, 1957, CHEM ENG SCI, V6, P262, DOI 10.1016/0009-2509(57)85028-3
   Augier F, 2010, CHEM ENG SCI, V65, P255, DOI 10.1016/j.ces.2009.06.027
   Baussaron L., 2005, THESIS
   Baussaron L, 2007, AICHE J, V53, P1850, DOI 10.1002/aic.11189
   Bazer-Bachi F, 2011, CHEM ENG SCI, V66, P1953, DOI 10.1016/j.ces.2011.01.052
   BEAUDRY EG, 1987, AICHE J, V33, P1435, DOI 10.1002/aic.690330904
   Dudukovic MP, 1999, CHEM ENG SCI, V54, P1975, DOI 10.1016/S0009-2509(98)00367-4
   DUDUKOVIC MP, 1977, AICHE J, V23, P940, DOI 10.1002/aic.690230624
   Extrand CW, 2008, LANGMUIR, V24, P9470, DOI 10.1021/la801091n
   FUNK GA, 1991, AICHE J, V37, P202, DOI 10.1002/aic.690370206
   Hartley D.E., 1964, INT J HEAT MASS TRAN, V7, P1003, DOI DOI 10.1016/0017-9310(64)90042-0
   HERSKOWITZ M, 1981, CHEM ENG SCI, V36, P1665, DOI 10.1016/0009-2509(81)80011-5
   Horowitz GI, 1999, CHEM ENG SCI, V54, P4811, DOI 10.1016/S0009-2509(99)00198-0
   Houwelingen A.J.V., 2010, AICHE J, V52, P3532
   Iliuta I, 1999, CHEM ENG SCI, V54, P5633, DOI 10.1016/S0009-2509(99)00129-3
   Kumar R., 2017, APPL RAD ISOT
   Ling D, 2017, AICHE J, V63, P226, DOI 10.1002/aic.15543
   Maiti R, 2006, IND ENG CHEM RES, V45, pCP5, DOI 10.1021/ie060238h
   Massa P, 2009, CATAL COMMUN, V10, P1706, DOI 10.1016/j.catcom.2009.05.014
   Mederos FS, 2009, CATAL REV, V51, P485, DOI 10.1080/01614940903048612
   MILLS PL, 1979, IND ENG CHEM FUND, V18, P139, DOI 10.1021/i160070a009
   Palmisano E, 2003, COMPUT CHEM ENG, V27, P1431, DOI 10.1016/S0098-1354(03)00033-4
   Rajashekharam MV, 1998, CHEM ENG SCI, V53, P787, DOI 10.1016/S0009-2509(97)00366-7
   RAMACHANDRAN PA, 1979, AICHE J, V25, P538, DOI 10.1002/aic.690250321
   Ravindra PV, 1997, IND ENG CHEM RES, V36, P5125, DOI 10.1021/ie9703402
   RING ZE, 1989, AICHE J, V35, P1821, DOI 10.1002/aic.690351108
   SAKORNWIMON W, 1982, IND ENG CHEM PROC DD, V21, P16, DOI 10.1021/i200016a004
   Satterfield C.N., 1963, ROLE DIFFUSION CATAL
   Valerius G, 1996, CHEM ENG PROCESS, V35, P1, DOI 10.1016/0255-2701(95)04100-1
   Wang YN, 2013, CAN J CHEM ENG, V91, P136, DOI 10.1002/cjce.20702
   ZIMMERMAN SP, 1986, CHEM ENG SCI, V41, P861, DOI 10.1016/0009-2509(86)87168-8
NR 32
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115515
DI 10.1016/j.ces.2020.115515
PG 11
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300013
DA 2020-05-12
ER

PT J
AU Thomas, I
   Wunderlich, B
   Grohmann, S
AF Thomas, Ingo
   Wunderlich, Bernd
   Grohmann, Steffen
TI Pressure-driven dynamic process simulation using a new generic stream
   object
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dynamic simulation; Pressure-driven flow; Flow reversal; Start-up;
   Shut-down
ID MODEL
AB This paper discusses a new approach in dynamic process simulation, where the process flow sheet is interpreted as a one-dimensional pressure-driven flow network. The underlying pressure-flow dynamics is implemented analogously to CFD flux functions and hence physically accurate. Coupling with traditional unit models is feasible.
   The approach includes a new stream object that enables the accurate simulation of interactions between process components, the simulation of boundary cases such as start-up and shut-down, as well as machine tripping or other kind of equipment failure. A numerically stable way for the initialization and switchover from steady-state to dynamic simulation is presented. Moreover, the systematic regularization of discontinuities is discussed, which leads to a considerable improvement in numerical robustness and efficiency. (C) 2019 Published by Elsevier Ltd.
C1 [Thomas, Ingo; Wunderlich, Bernd] Linde AG, Engn Div, Dr Carl von Linde Str 6-14, D-82049 Pullach, Germany.
   [Grohmann, Steffen] Karlsruhe Inst Technol, Inst Tech Thermodynam & Refrigerat, Engler Bunte Ring 21, D-76131 Karlsruhe, Germany.
RP Thomas, I (reprint author), Linde AG, Engn Div, Dr Carl von Linde Str 6-14, D-82049 Pullach, Germany.
EM ingo.thomas@linde.com
RI Grohmann, Steffen/M-8671-2016
OI Grohmann, Steffen/0000-0003-1298-5110
CR aspentech, 2003, ASP DYN 12 1 US GUID
   Cao Y., 2011, P 2011 AM CONTR C
   Cao YA, 2011, P AMER CONTR CONF, P2683
   DURAN MA, 1986, AICHE J, V32, P123, DOI 10.1002/aic.690320114
   Eich-Soellner E., 1997, Surveys on Mathematics for Industry, V7, P1
   Forner F, 2007, CHEM-ING-TECH, V79, P367, DOI 10.1002/cite.200600145
   Gopal V, 1999, AICHE J, V45, P1535, DOI 10.1002/aic.690450715
   IFC, 1967, INT C PROP STEAM I S
   Kender R., 2018, CHEM ENG T, V69, P271
   Michelsen M, 2007, THERMODYNAMIC MODELS
   Mohajer M, 2008, CHEM PROD PROCESS MO, V3, DOI 10.2202/1934-2659.1119
   Process Systems Enterprise Limited, 2016, GPROMS PROCESSBUILDE
   Sahlodin AM, 2016, AICHE J, V62, P3334, DOI 10.1002/aic.15378
   Scattolini R, 2009, J PROCESS CONTR, V19, P723, DOI 10.1016/j.jprocont.2009.02.003
   SHACHAM M, 1982, COMPUT CHEM ENG, V6, P79, DOI 10.1016/0098-1354(82)87001-4
   Sigloch H., 2005, TECHNISCHE FLUIDMECH
   Skogestad S, 1997, MODEL IDENT CONTROL, V18, P177, DOI 10.4173/mic.1997.3.1
   SOAVE G, 1972, CHEM ENG SCI, V27, P1197, DOI 10.1016/0009-2509(72)80096-4
   UniSim, 2018, UNISIM DES DYN MOD R
   Wunderlich B., 2018, THESIS
NR 20
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115171
DI 10.1016/j.ces.2019.115171
PG 10
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300030
DA 2020-05-12
ER

PT J
AU Valeije, A
   Sastre, F
   Martin, E
   Velazquez, A
AF Valeije, A.
   Sastre, F.
   Martin, E.
   Velazquez, A.
TI Energy-efficient mixing generated by prescribed crosswise oscillations
   of a square prism in highly confined flows
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mixing efficiency; Moving square cylinder; Frequency effect; Highly
   confined laminar flow; 3D numerical simulation
ID LOW-REYNOLDS-NUMBER; NUMERICAL-SIMULATION; MICROCHANNEL; MICROMIXERS;
   MIXERS; CFD
AB Mixing downstream of a moving square cylinder placed inside a square section channel was analyzed experimentally and numerically at blockage ratio 2/5 and Reynolds 200. Three frequencies were considered for the prescribed sinusoidal, constant amplitude, cylinder motion: 0.5f(0), 1f(0) and 2f(0), where f(0) stands for the frequency of the first instability of the wake in the unmoving cylinder case. Mixing was quantified by computing the downstream standard deviation of the distribution of virtual particles seeded behind the cylinder. Experimental PIV frames were used to evaluate mixing at the channel symmetry plane. Numerical streak-lines were used to compute mixing at the full section of the channel. The power required to move the cylinder was computed as well. It was found that maximum mixing efficiency combined with minimum motion power occurred for the frequency 1f(0), proving that optimum mixing does not necessarily require high frequencies and/or high input power. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Valeije, A.; Martin, E.] Univ Vigo, Fluid Mech Area, Dept Mech Engn Heat Engines & Fluids, Sch Ind Engn, Campus Lagoas Marcosende, Vigo 36310, Spain.
   [Sastre, F.; Velazquez, A.] Univ Politecn Madrid, Fluid Mech & Aerosp Prop Dept, Plaza Cardenal Cisneros 3, Madrid 28040, Spain.
RP Martin, E (reprint author), Univ Vigo, Fluid Mech Area, Dept Mech Engn Heat Engines & Fluids, Sch Ind Engn, Campus Lagoas Marcosende, Vigo 36310, Spain.
EM emortega@uvigo.es
FU Spanish Ministry of Economy and Competitiveness (Ministerio de Economia
   y Competitividad, MINECO) [DPI2016-75296-P]
FX A. Velazquez has been funded by the Spanish Ministry of Economy and
   Competitiveness (Ministerio de Economia y Competitividad, MINECO) under
   research contract DPI2016-75296-P.
CR An SJ, 2006, J KOREAN PHYS SOC, V49, P651
   Capretto L, 2011, TOP CURR CHEM, V304, P27, DOI 10.1007/128_2011_150
   Celik B, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3177001
   Clemente R, 2019, EXP THERM FLUID SCI, V109, DOI 10.1016/j.expthermflusci.2019.109846
   DANCKWERTS PV, 1952, APPL SCI RES, V3, P279, DOI 10.1007/BF03184936
   De AK, 2006, INT J NUMER METH FL, V52, P801, DOI 10.1002/fld.1210
   Ferziger JH., 1999, COMPUTATIONAL METHOD, pxiv 389
   Finn MD, 2004, J ENG MATH, V48, P129, DOI 10.1023/B:ENGI.0000011930.55539.69
   Ghanem A, 2014, CHEM ENG RES DES, V92, P205, DOI 10.1016/j.cherd.2013.07.013
   Gouillart E, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3506817
   Hessel V, 2005, CHEM ENG SCI, V60, P2479, DOI 10.1016/j.ces.2004.11.033
   Hsiao KY, 2014, CHEM ENG J, V235, P27, DOI 10.1016/j.cej.2013.09.010
   Issa R., 1986, J COMPUT PHYS, V62
   JEONG J, 1995, J FLUID MECH, V285, P69, DOI 10.1017/S0022112095000462
   Khozeymeh-Nezhad H, 2018, INT J HEAT MASS TRAN, V122, P913, DOI 10.1016/j.ijheatmasstransfer.2018.02.033
   Kukukova A, 2009, CHEM ENG RES DES, V87, P633, DOI 10.1016/j.cherd.2009.01.001
   Kumar S, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4967729
   Kumar V, 2011, CHEM ENG SCI, V66, P1329, DOI 10.1016/j.ces.2010.08.016
   Lacey P.M.C., 1943, T I CHEM ENG-LOND, V21, P53
   Lee CY, 2016, CHEM ENG J, V288, P146, DOI 10.1016/j.cej.2015.10.122
   Lee SB, 2017, INT J NAV ARCH OCEAN, V9, P429, DOI 10.1016/j.ijnaoe.2016.11.007
   MENEGHINI JR, 1995, J FLUID STRUCT, V9, P435, DOI 10.1006/jfls.1995.1025
   Nguyen NT, 2005, J MICROMECH MICROENG, V15, pR1, DOI 10.1088/0960-1317/15/2/R01
   Ortega-Casanova J, 2018, COMPUT FLUIDS, V168, P318, DOI 10.1016/j.compfluid.2018.03.068
   Ortega-Casanova J, 2017, COMPUT FLUIDS, V145, P141, DOI 10.1016/j.compfluid.2016.12.022
   Ortega-Casanova J, 2016, J FLUID STRUCT, V65, P1, DOI 10.1016/j.jfluidstructs.2016.05.002
   Phelps JH, 2006, CHEM ENG SCI, V61, P6826, DOI 10.1016/j.ces.2006.07.008
   Raisee M, 2012, J PHYS CONF SER, V362, DOI 10.1088/1742-6596/362/1/012041
   Roache P., 1998, VERIFICATION VALIDAT
   Saad Y., 2003, ITERATIVE METHODS SP
   Shamsoddini R, 2016, J MECH SCI TECHNOL, V30, P307, DOI 10.1007/s12206-015-1234-3
   SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x
   Singh AP, 2009, INT J NUMER METH FL, V61, P658, DOI 10.1002/fld.1979
NR 33
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115456
DI 10.1016/j.ces.2019.115456
PG 16
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300017
DA 2020-05-12
ER

PT J
AU Vlasov, VA
AF Vlasov, Valeriy A.
TI Diffusion model of gas hydrate dissociation into ice and gas that takes
   into account the ice microstructure
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas hydrate; Growth model; Diffusion; Ice microstructure;
   Self-preservation effect
ID SELF-PRESERVATION; METHANE HYDRATE; NATURAL-GAS; ANOMALOUS PRESERVATION;
   CH4 HYDRATE; CRUDE OILS; TEMPERATURE; DECOMPOSITION; DEPENDENCE; STORAGE
AB A diffusion model of gas hydrate dissociation into ice and gas is presented, which allows us to simulate the self-preservation effect of gas hydrates. This model takes into account that the forming ice layer has a porous structure that changes during the process of gas hydrate dissociation. Three problems of gas hydrate dissociation into ice and gas were considered separately: the dissociation of a spherical gas hydrate particle, the dissociation of a cylindrical gas hydrate, and the dissociation of a flat gas hydrate layer. For each problem, a solution in the framework of a quasi-stationary approximation is obtained. From the comparison of the calculated data with the available experimental data on the kinetics of dissociation of a powdery methane hydrate into ice and methane, the molecular diffusion coefficient of methane in ice and the diffusion coefficient of methane through the system of pores in the forming ice layer were estimated. Based on this estimation, an explanation of the anomalous preservation thermal regime of methane hydrate is provided. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Vlasov, Valeriy A.] Russian Acad Sci, Tyumen Sci Ctr, Inst Earth Cryosphere, Siberian Branch, POB 1230, Tyumen 625000, Russia.
RP Vlasov, VA (reprint author), Russian Acad Sci, Tyumen Sci Ctr, Inst Earth Cryosphere, Siberian Branch, POB 1230, Tyumen 625000, Russia.
EM vlasov.ikz@gmail.com
FU Basic Research Program of the Russian Academy of SciencesRussian Academy
   of Sciences [IX.135.2.3]
FX This work was supported by the Basic Research Program of the Russian
   Academy of Sciences (project No. IX.135.2.3).
CR Bai DS, 2015, SCI REP-UK, V5, DOI 10.1038/srep14599
   Everett SM, 2013, J PHYS CHEM A, V117, P3593, DOI 10.1021/jp4020178
   Falenty A, 2014, ENERG FUEL, V28, P6275, DOI 10.1021/ef501409g
   Falenty A, 2009, J PHYS CHEM B, V113, P15975, DOI 10.1021/jp906859a
   Giavarini C, 2004, IND ENG CHEM RES, V43, P6616, DOI 10.1021/ie040038a
   Hachikubo A, 2011, PHYS CHEM CHEM PHYS, V13, P17449, DOI 10.1039/c1cp22353d
   HANDA YP, 1986, J CHEM THERMODYN, V18, P891, DOI 10.1016/0021-9614(86)90124-2
   Heidaryan E, 2019, J LOW TEMP PHYS, V194, P27, DOI 10.1007/s10909-018-2049-2
   Hori A, 2003, CAN J PHYS, V81, P251, DOI 10.1139/P02-142
   Kida M, 2017, JPN J APPL PHYS, V56, DOI 10.7567/JJAP.56.095601
   Komai T, 2004, J PHYS CHEM B, V108, P8062, DOI 10.1021/jp0310955
   Kuhs WF, 2004, PHYS CHEM CHEM PHYS, V6, P4917, DOI 10.1039/b412866d
   Lv YN, 2015, ENERG FUEL, V29, P5563, DOI 10.1021/acs.energyfuels.5b00837
   Mel'nikov VP, 2016, DOKL CHEM, V466, P53, DOI 10.1134/S0012500816020038
   Mimachi H, 2016, FLUID PHASE EQUILIBR, V413, P22, DOI 10.1016/j.fluid.2015.10.029
   Mimachi H, 2015, ENERG FUEL, V29, P4827, DOI 10.1021/acs.energyfuels.5b00832
   Mimachi H, 2014, CHEM ENG SCI, V118, P208, DOI 10.1016/j.ces.2014.07.050
   Misyura SY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30324
   Misyura SY, 2016, CHEM ENG SCI, V148, P65, DOI 10.1016/j.ces.2016.03.021
   Mousis O, 2015, ASTROBIOLOGY, V15, P308, DOI 10.1089/ast.2014.1189
   Mousis O, 2013, SPACE SCI REV, V174, P213, DOI 10.1007/s11214-012-9942-9
   Nakoryakov VE, 2013, CHEM ENG SCI, V104, P1, DOI 10.1016/j.ces.2013.08.049
   Ogienko AG, 2006, J PHYS CHEM B, V110, P2840, DOI 10.1021/jp053915e
   Ohno H, 2011, CHEMPHYSCHEM, V12, P1661, DOI 10.1002/cphc.201100079
   Ohno H, 2011, J PHYS CHEM LETT, V2, P201, DOI 10.1021/jz101595t
   Prasad PSR, 2015, J NAT GAS SCI ENG, V25, P10, DOI 10.1016/j.jngse.2015.04.030
   Rehder G, 2012, ENERGIES, V5, P2499, DOI 10.3390/en5072499
   Sato H, 2013, CHEM ENG SCI, V91, P86, DOI 10.1016/j.ces.2013.01.014
   Shagapov VS, 2013, THEOR FOUND CHEM EN+, V47, P388, DOI 10.1134/S0040579513030111
   Shimada W, 2005, J PHYS CHEM B, V109, P5802, DOI 10.1021/jp044624t
   Sloan ED, 2008, CHEM IND-SER, V119, pXIX
   Stern LA, 2003, CAN J PHYS, V81, P271, DOI 10.1139/P03-018
   Stern LA, 2001, J PHYS CHEM B, V105, P1756, DOI 10.1021/jp003061s
   Stern LA, 2001, ENERG FUEL, V15, P499, DOI 10.1021/ef000277k
   Stoporev AS, 2018, ENERG FUEL, V32, P11279, DOI 10.1021/acs.energyfuels.8b02599
   Stoporev AS, 2016, ENERG FUEL, V30, P9014, DOI 10.1021/acs.energyfuels.6b01531
   Stoporev AS, 2014, ENERG FUEL, V28, P794, DOI 10.1021/ef401779d
   Sun CY, 2006, FLUID PHASE EQUILIBR, V242, P123, DOI 10.1016/j.fluid.2006.01.025
   Sun D, 2011, IND ENG CHEM RES, V50, P13854, DOI 10.1021/ie2017724
   Takeya S, 2005, CHEM ENG SCI, V60, P1383, DOI 10.1016/j.ces.2004.10.011
   Takeya S, 2002, J CRYST GROWTH, V237, P379, DOI 10.1016/S0022-0248(01)01946-7
   Takeya S, 2001, J PHYS CHEM A, V105, P9756, DOI 10.1021/jp011435r
   Takeya S, 2008, ANGEW CHEM INT EDIT, V47, P1276, DOI 10.1002/anie.200703718
   Takeya S, 2018, APPL ENERG, V230, P86, DOI 10.1016/j.apenergy.2018.08.015
   Takeya S, 2016, FLUID PHASE EQUILIBR, V413, P137, DOI 10.1016/j.fluid.2015.10.036
   Takeya S, 2012, J PHYS CHEM C, V116, P13842, DOI 10.1021/jp302269v
   Takeya S, 2010, CHEMPHYSCHEM, V11, P70, DOI 10.1002/cphc.200900731
   Veluswamy HP, 2018, APPL ENERG, V216, P262, DOI 10.1016/j.apenergy.2018.02.059
   Vlasov VA, 2016, INT J HEAT MASS TRAN, V102, P631, DOI 10.1016/j.ijheatmasstransfer.2016.06.057
   Vlasov VA, 2013, REACT KINET MECH CAT, V110, P5, DOI 10.1007/s11144-013-0578-x
   Wu QB, 2012, J NAT GAS CHEM, V21, P91, DOI 10.1016/S1003-9953(11)60338-1
   Yakushev VS, 2018, COLD REG SCI TECHNOL, V149, P46, DOI 10.1016/j.coldregions.2018.02.007
   Yakushev V.S., 1992, PHYS CHEM ICE, P136
NR 53
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115443
DI 10.1016/j.ces.2019.115443
PG 9
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300011
DA 2020-05-12
ER

PT J
AU Wang, JW
AF Wang, Junwu
TI Continuum theory for dense gas-solid flow: A state-of-the-art review
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Review
DE Heterogeneous structure; Drag force; Kinetic theory; Mesoscale
   structure; Filtered method; EMMS method
ID CIRCULATING FLUIDIZED-BED; DIRECT NUMERICAL-SIMULATION;
   LARGE-EDDY-SIMULATION; STRUCTURE-DEPENDENT DRAG; LATTICE-BOLTZMANN
   SIMULATIONS; DISCRETE PARTICLE SIMULATION; AVERAGED 2-FLUID MODEL;
   COARSE-GRID SIMULATION; MASS-TRANSFER MODEL; WALL-BOUNDARY-CONDITIONS
AB Gas-solid fluidization technology has been commercialized in many industrial applications since its implementation in the fluid catalytic cracking process in the early 1940s, however, the understanding of the complex hydrodynamics of gas-solid flow inside fluidized beds is still far from satisfactory due to its dynamic and multiscale nature, especially, the critical role played by mesoscale structures. In recent decades, computational fluid dynamics (CFD) has become an important toolkit in understanding the physics of complex gas-solid flow and then for the scale-up, optimization and design of gas-solid fluidized bed reactors. This article presented a pedagogical and comprehensive review to the Navier-Stokes order continuum theory for CFD simulation of the hydrodynamics of gas-solid fluidization, without taking the effects of heat and mass transfer as well as chemical reactions into consideration. A concise introduction to the methods for multiscale CFD simulation of gas-solid fluidization was firstly provided, which include direct numerical simulation, (coarse-grained) discrete particle method, kinetic method, continuum method and mesoscale-structure-based multiscale method. The underlying postulates of homogeneous continuum theory that assume the structure inside each computational cell is (nearly) homogeneous were then examined, followed by an overview of the constitutive relationships available in literature, including the particle phase stress models, the interphase drag models and the models for particle-wall interactions. The importance of mesoscale structures that take the form of gas bubbles and/or particle clusters and streamers in the quantification of the hydrodynamics of gas-solid flows was then addressed, and the explicit resolution (or highly resolved) method and implicit modeling method for quantifying the effects of mesoscale structures in continuum modeling of gas-solid fluidization were highlighted. Coarse grid simulation of large scale fluidized beds with proper mesoscale, sub-grid scale or turbulent models for constitutive relationships were then reviewed, focusing on the filtered method, turbulence modelling and heterogeneity-based method where the energy-minimization multi-scale (EMMS) based method is a representative. Finally, the scope for the further research areas is described. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wang, Junwu] Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.
   [Wang, Junwu] Univ Chinese Acad Sci, Sch Chem Engn, Beijing 100049, Peoples R China.
   [Wang, Junwu] Chinese Acad Sci, Innovat Acad Green Manufacture, Beijing 100190, Peoples R China.
RP Wang, JW (reprint author), Chinese Acad Sci, Inst Proc Engn, State Key Lab Multiphase Complex Syst, POB 353, Beijing 100190, Peoples R China.; Wang, JW (reprint author), Univ Chinese Acad Sci, Sch Chem Engn, Beijing 100049, Peoples R China.; Wang, JW (reprint author), Chinese Acad Sci, Innovat Acad Green Manufacture, Beijing 100190, Peoples R China.
EM jwwang@ipe.ac.cn
RI Wang, Junwu/P-5040-2019; Wang, Junwu/C-6591-2009
OI Wang, Junwu/0000-0003-3988-1477; Wang, Junwu/0000-0003-3988-1477
FU Innovation Academy for Green Manufacture, Chinese Academy of Sciences
   [IAGM-2019-A13]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [21978295, 11988102, 91834303]; Key
   Research Program of Frontier Science, Chinese Academy of Sciences
   [QYZDJ-SSW-JSC029]; "Transformational Technologies for Clean Energy and
   Demonstration", Strategic Priority Research Program of the Chinese
   Academy of Sciences [XDA21030700]
FX We thank Dr. Bidan Zhao for many helps in the use of Latex. This study
   is financially supported by AcademInnovationy for Green Manufacture,
   Chinese Academy of Sciences (IAGM-2019-A13), National Natural Science
   Foundation of China (21978295,11988102,91834303), Key Research Program
   of Frontier Science, Chinese Academy of Sciences (QYZDJ-SSW-JSC029), the
   "Transformational Technologies for Clean Energy and Demonstration",
   Strategic Priority Research Program of the Chinese Academy of Sciences
   (XDA21030700).
CR Abate AR, 2008, PHYS REV LETT, V101, DOI 10.1103/PhysRevLett.101.245701
   Abdulle A, 2012, ACTA NUMER, V21, P1, DOI 10.1017/S0962492912000025
   ABRAHAMSEN AR, 1980, POWDER TECHNOL, V26, P35, DOI 10.1016/0032-5910(80)85005-4
   ABRAHAMSON J, 1975, CHEM ENG SCI, V30, P1371, DOI 10.1016/0009-2509(75)85067-6
   AbuZaid S, 1996, POWDER TECHNOL, V89, P45, DOI 10.1016/S0032-5910(96)03152-X
   ABUZAID S, 1995, INT J NONLINEAR MECH, V30, P509, DOI 10.1016/0020-7462(95)00015-G
   Acosta-Iborra A, 2013, J FLUID MECH, V732, P245, DOI 10.1017/jfm.2013.401
   Acosta-Iborra A, 2011, CHEM ENG SCI, V66, P3499, DOI 10.1016/j.ces.2011.04.009
   Agrawal K, 2001, J FLUID MECH, V445, P151, DOI 10.1017/S0022112001005663
   Agrawal K, 2013, CHEM ENG SCI, V95, P291, DOI 10.1016/j.ces.2013.03.017
   Ahmad N, 2019, CHEM ENG SCI, V200, P257, DOI 10.1016/j.ces.2019.02.016
   Ahmad N, 2019, CHINESE J CHEM ENG, V27, P54, DOI 10.1016/j.cjche.2018.04.011
   AHMADI G, 1990, INT J MULTIPHAS FLOW, V16, P323, DOI 10.1016/0301-9322(90)90062-N
   Ahmadi G, 2006, INT J ENG SCI, V44, P699, DOI 10.1016/j.ijengsci.2006.06.001
   ALDER BJ, 1984, PHYS TODAY, V37, P56, DOI 10.1063/1.2916048
   Alipchenkov VM, 2008, FLUID DYNAM+, V43, P731, DOI 10.1134/S0015462808050074
   Almuttahar A, 2008, POWDER TECHNOL, V185, P11, DOI 10.1016/j.powtec.2007.09.010
   Almuttahar A, 2008, CHEM ENG SCI, V63, P1696, DOI 10.1016/j.ces.2007.11.020
   Amarouchene Y, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2185689
   ANDERSON TB, 1967, IND ENG CHEM FUND, V6, P527, DOI 10.1021/i160024a007
   Andreotti B., 2013, GRANULAR MEDIA FLUID
   Andrews AT, 2005, IND ENG CHEM RES, V44, P6022, DOI 10.1021/ie0492193
   Andrews MJ, 1996, INT J MULTIPHAS FLOW, V22, P379, DOI 10.1016/0301-9322(95)00072-0
   Annaland MV, 2009, CHEM ENG SCI, V64, P4237, DOI 10.1016/j.ces.2009.06.043
   Annaland MV, 2009, CHEM ENG SCI, V64, P4222, DOI 10.1016/j.ces.2009.06.044
   Ansumali S, 2004, PHYSICA A, V338, P379, DOI 10.1016/j.physa.2004.02.013
   Aranson IS, 2008, SCIENCE, V320, P612, DOI 10.1126/science.1153456
   Aranson IS, 2006, REV MOD PHYS, V78, P641, DOI 10.1103/RevModPhys.78.641
   Aranson IS, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.061303
   ARASTOOPOUR H, 1979, POWDER TECHNOL, V22, P77, DOI 10.1016/0032-5910(79)85009-3
   Arnarson BO, 1998, PHYS FLUIDS, V10, P1324, DOI 10.1063/1.869658
   Askarishahi M, 2018, COMPUT PART MECH, V5, P607, DOI 10.1007/s40571-018-0193-8
   Atsonios K, 2011, CHEM ENG SCI, V66, P3979, DOI 10.1016/j.ces.2011.05.024
   Ayeni OO, 2016, CHEM ENG J, V302, P395, DOI 10.1016/j.cej.2016.05.056
   Azizi S, 2010, CHEM ENG TECHNOL, V33, P421, DOI 10.1002/ceat.200900407
   BABIC M, 1993, J FLUID MECH, V254, P127, DOI 10.1017/S002211209300206X
   Babic M, 1997, INT J ENG SCI, V35, P523, DOI 10.1016/S0020-7225(96)00094-8
   Bahramian A, 2013, IND ENG CHEM RES, V52, P7569, DOI 10.1021/ie4005089
   Bakshi A, 2018, POWDER TECHNOL, V332, P114, DOI 10.1016/j.powtec.2018.03.048
   Bakshi A, 2016, POWDER TECHNOL, V299, P185, DOI 10.1016/j.powtec.2016.05.029
   Bakshi A, 2015, POWDER TECHNOL, V277, P47, DOI 10.1016/j.powtec.2015.02.056
   Balachandar S, 2010, ANNU REV FLUID MECH, V42, P111, DOI 10.1146/annurev.fluid.010908.165243
   Balachandar S, 2009, INT J MULTIPHAS FLOW, V35, P801, DOI 10.1016/j.ijmultiphaseflow.2009.02.013
   Balzer G., 1995, FLUIDIZATION, VVIII, P409
   Barrat A, 2002, GRANUL MATTER, V4, P57, DOI 10.1007/s10035-002-0108-4
   Baskakov A., 1964, INT CHEM ENG, V4, P320
   Basu P, 1996, CHEM ENG SCI, V51, P1, DOI 10.1016/0009-2509(95)00124-7
   Batchelor G. K., 2000, INTRO FLUID DYNAMICS
   BATCHELOR GK, 1988, J FLUID MECH, V193, P75, DOI 10.1017/S002211208800206X
   BATCHELOR GK, 1982, J FLUID MECH, V124, P495, DOI 10.1017/S0022112082002602
   BATCHELOR GK, 1982, J FLUID MECH, V119, P379, DOI 10.1017/S0022112082001402
   BAYLE J, 2001, FLUIDIZATION, V10, P125
   Beetstra R, 2007, AICHE J, V53, P489, DOI 10.1002/aic.11065
   Beetstra R, 2006, COMPUT FLUIDS, V35, P966, DOI 10.1016/j.compfluid.2005.03.009
   Behzadi A, 2004, CHEM ENG SCI, V59, P759, DOI 10.1016/j.ces.2003.11.018
   Benavides A, 2008, POWDER TECHNOL, V182, P294, DOI 10.1016/j.powtec.2007.06.028
   Benavides A, 2009, INT J HEAT FLUID FL, V30, P452, DOI 10.1016/j.ijheatfluidflow.2009.02.012
   Benyahia S, 2006, POWDER TECHNOL, V162, P166, DOI 10.1016/j.powtec.2005.12.014
   Benyahia S, 2005, POWDER TECHNOL, V156, P62, DOI 10.1016/j.powtec.2005.04.002
   Benyahia S, 2008, CHEM ENG SCI, V63, P2536, DOI 10.1016/j.ces.2008.02.012
   Benyahia S, 2007, AICHE J, V53, P2549, DOI 10.1002/aic.11276
   Benyahia S, 2012, AICHE J, V58, P3589, DOI 10.1002/aic.13826
   Benyahia S, 2012, POWDER TECHNOL, V220, P2, DOI 10.1016/j.powtec.2011.10.052
   Benyahia S, 2010, IND ENG CHEM RES, V49, P10588, DOI 10.1021/ie100662z
   Benyahia S, 2010, IND ENG CHEM RES, V49, P5122, DOI 10.1021/ie900658k
   Berselli L. C., 2005, MATH LARGE EDDY SIMU
   Berzi D, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4914920
   BESNARD DC, 1988, INT J MULTIPHAS FLOW, V14, P679, DOI 10.1016/0301-9322(88)90068-7
   Bi HT, 1996, CHEM ENG SCI, V51, P663, DOI 10.1016/0009-2509(95)00263-4
   Bian W, 2019, CHEM ENG SCI, V210, DOI 10.1016/j.ces.2019.115233
   Biggs MJ, 2008, GRANUL MATTER, V10, P63, DOI 10.1007/s10035-007-0077-8
   Bird G. A., 1994, MOL GAS DYNAMICS DIR
   Bird R. B., 2002, TRANSPORT PHENOMENA
   Bizon C, 1999, PHYS REV E, V60, P4340, DOI 10.1103/PhysRevE.60.4340
   Boelle A., 1995, GAS PARTICLE FLOWS A, V228, P9
   Boemer A., 1994, 29 IEA FBC M PAR FRA, P24
   Bogner S, 2015, INT J MULTIPHAS FLOW, V68, P71, DOI 10.1016/j.ijmultiphaseflow.2014.10.001
   Bokkers GA, 2006, CHEM ENG SCI, V61, P5590, DOI 10.1016/j.ces.2006.04.009
   Bokkers GA, 2004, POWDER TECHNOL, V140, P176, DOI 10.1016/j.powtec.2004.01.018
   BOLIO EJ, 1995, INT J MULTIPHAS FLOW, V21, P985, DOI 10.1016/0301-9322(95)00004-H
   BOLIO EJ, 1995, AICHE J, V41, P1375, DOI 10.1002/aic.690410604
   Boltzmann L., 1964, LECT GAS THEORY
   Bonniol F, 2009, POWDER TECHNOL, V189, P14, DOI 10.1016/j.powtec.2008.05.011
   Boon JP, 1991, MOL HYDRODYNAMICS
   Bougie J, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.051301
   BOUILLARD JX, 1989, AICHE J, V35, P908, DOI 10.1002/aic.690350604
   Boyce CM, 2013, IND ENG CHEM RES, V52, P18085, DOI 10.1021/ie401896x
   Breault RW, 2008, POWDER TECHNOL, V182, P137, DOI 10.1016/j.powtec.2007.08.018
   Breault RW, 2013, POWDER TECHNOL, V242, P108, DOI 10.1016/j.powtec.2013.01.010
   Breault RW, 2010, POWDER TECHNOL, V203, P33, DOI 10.1016/j.powtec.2010.03.024
   Breuer M, 2017, INT J MULTIPHAS FLOW, V89, P23, DOI 10.1016/j.ijmultiphaseflow.2016.10.007
   Brey JJ, 2012, AIP CONF PROC, V1501, P961, DOI 10.1063/1.4769646
   Brilliantov N, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.134301
   Brilliantov N.V., 2004, KINETIC THEORY GRANU
   Brilliantov NV, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02803-7
   Brown E, 2014, REP PROG PHYS, V77, DOI 10.1088/0034-4885/77/4/046602
   Buettner KE, 2020, POWDER TECHNOL, V365, P83, DOI 10.1016/j.powtec.2019.01.068
   Buettner KE, 2017, AICHE J, V63, P5384, DOI 10.1002/aic.15933
   Burnett D, 1935, P LOND MATH SOC, V39, P385
   Burns A. D., 2004, EULERIAN MULTIPHASE, V4, P1
   Bussing W, 2001, CHEM ENG SCI, V56, P3803, DOI 10.1016/S0009-2509(01)00099-9
   BUYEVICH YA, 1971, CHEM ENG SCI, V26, P1195, DOI 10.1016/0009-2509(71)87006-9
   Buyevich YA, 1999, IND ENG CHEM RES, V38, P731, DOI 10.1021/ie980370k
   Buyevich Yu. A., 1999, International Journal of Fluid Mechanics Research, V26, P72
   Cabezas-Gomez L, 2003, POWDER TECHNOL, V132, P216, DOI 10.1016/S0032-5910(03)00071-8
   Cahyadi A, 2017, CHEM ENG SCI, V158, P70, DOI 10.1016/j.ces.2016.10.002
   CALLEN HB, 1985, THERMODYNAMICS INTRO
   CAMMARATA L, 2003, INT J CHEM REACT ENG, V1
   Campbell CS, 2006, POWDER TECHNOL, V162, P208, DOI 10.1016/j.powtec.2005.12.008
   CAMPBELL CS, 1989, J FLUID MECH, V203, P449, DOI 10.1017/S0022112089001540
   CAMPBELL CS, 1986, J FLUID MECH, V164, P107, DOI 10.1017/S0022112086002495
   CAMPBELL CS, 1985, J FLUID MECH, V151, P167, DOI 10.1017/S002211208500091X
   CAMPBELL CS, 1991, J FLUID MECH, V227, P495, DOI 10.1017/S0022112091000216
   CAMPBELL CS, 1990, ANNU REV FLUID MECH, V22, P57, DOI 10.1146/annurev.fl.22.010190.000421
   Candela D, 2007, AM J PHYS, V75, P754, DOI 10.1119/1.2737470
   Capecelatro J, 2018, J FLUID MECH, V845, P499, DOI 10.1017/jfm.2018.259
   Capecelatro J, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4943234
   Capecelatro J, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4943231
   Capecelatro J, 2015, J FLUID MECH, V780, P578, DOI 10.1017/jfm.2015.459
   Capecelatro J, 2014, J FLUID MECH, V747, DOI 10.1017/jfm.2014.194
   Capecelatro J, 2014, CHEM ENG J, V245, P295, DOI 10.1016/j.cej.2014.02.040
   Cardoso J, 2019, RENEW ENERG, V131, P713, DOI 10.1016/j.renene.2018.07.080
   Carrica PM, 1999, INT J MULTIPHAS FLOW, V25, P257, DOI 10.1016/S0301-9322(98)00047-0
   Carrillo JA, 2008, J FLUID MECH, V597, P119, DOI 10.1017/S0022112007009792
   Cello F, 2010, CHEM ENG SCI, V65, P3128, DOI 10.1016/j.ces.2010.02.006
   CELMINS A, 1988, INT J MULTIPHAS FLOW, V14, P81
   Chalermsinsuwan B, 2013, POWDER TECHNOL, V245, P80, DOI 10.1016/j.powtec.2013.04.026
   Chalermsinsuwan B, 2011, CHEM ENG J, V171, P301, DOI 10.1016/j.cej.2011.04.007
   Chang J, 2016, POWDER TECHNOL, V304, P134, DOI 10.1016/j.powtec.2016.04.048
   Chang J, 2012, POWDER TECHNOL, V217, P50, DOI 10.1016/j.powtec.2011.10.008
   Chao ZX, 2012, POWDER TECHNOL, V224, P311, DOI 10.1016/j.powtec.2012.03.013
   Chao ZX, 2011, CHEM ENG SCI, V66, P3605, DOI 10.1016/j.ces.2011.04.027
   Chapman S., 1990, MATH THEORY NONUNIFO
   Chassaing P, 2001, FLOW TURBUL COMBUST, V66, P293, DOI 10.1023/A:1013533322651
   CHASSAING P, 2002, VARIABLE DENSITY FLU
   Chen C, 2016, CHEM ENG SCI, V141, P8, DOI 10.1016/j.ces.2015.10.025
   [陈飞国 Chen Feiguo], 2019, [过程工程学报, The Chinese Journal of Process Engineering], V19, P651
   Chen HD, 2004, J FLUID MECH, V519, P301, DOI 10.1017/s0022112004001211
   Chen HD, 2003, SCIENCE, V301, P633, DOI 10.1126/science.1085048
   Chen HD, 1999, PHYS REV E, V59, pR2527, DOI 10.1103/PhysRevE.59.R2527
   Chen HZ, 2018, POWDER TECHNOL, V323, P163, DOI 10.1016/j.powtec.2017.10.015
   Chen HU, 2013, PHYS SCRIPTA, VT155, DOI 10.1088/0031-8949/2013/T155/014040
   Chen JC, 1999, CHEM ENG SCI, V54, P5529, DOI 10.1016/S0009-2509(99)00300-0
   Chen JH, 2019, CHEM ENG J, V357, P508, DOI 10.1016/j.cej.2018.09.171
   Chen J, 2015, POWDER TECHNOL, V274, P112, DOI 10.1016/j.powtec.2015.01.010
   Chen JH, 2017, PARTICUOLOGY, V34, P70, DOI 10.1016/j.partic.2016.12.003
   Chen JH, 2012, AICHE J, V58, P3653, DOI 10.1002/aic.13754
   Chen X., 2018, ARXIV181100714
   Chen X., 2018, ARXIV180804489
   Chen XZ, 2018, CHEM ENG SCI, V192, P864, DOI 10.1016/j.ces.2018.08.019
   [陈锡忠 Chen Xizhong], 2017, [中国粉体技术, China Powder Science and Technology], V23, P62
   Chen XZ, 2017, AICHE J, V63, P3681, DOI 10.1002/aic.15723
   Chen XZ, 2016, POWDER TECHNOL, V304, P177, DOI 10.1016/j.powtec.2016.08.017
   Chen XZ, 2015, PROCEDIA ENGINEER, V102, P661, DOI 10.1016/j.proeng.2015.01.160
   Chen XZ, 2014, POWDER TECHNOL, V254, P94, DOI 10.1016/j.powtec.2013.12.056
   Chen XZ, 2013, CHEM ENG J, V234, P173, DOI 10.1016/j.cej.2013.08.108
   Chen YP, 2017, PHYSICA A, V469, P293, DOI 10.1016/j.physa.2016.11.104
   Chen YM, 2006, POWDER TECHNOL, V163, P2, DOI 10.1016/j.powtec.2006.01.001
   CHEN YM, 1991, CHEM ENG SCI, V46, P2253, DOI 10.1016/0009-2509(91)85124-G
   Cheng Y, 1999, CHEM ENG SCI, V54, P2019, DOI 10.1016/S0009-2509(98)00293-0
   Chevrier S., 2017, THESIS
   Chevrier S., 2016, 9 INT C MULT FLOW MA
   Chhabra RP, 1999, POWDER TECHNOL, V101, P288, DOI 10.1016/S0032-5910(98)00178-8
   Chialvo S, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4812804
   Chialvo S, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.021305
   Chiesa M, 2005, COMPUT CHEM ENG, V29, P291, DOI 10.1016/j.compchemeng.2004.09.002
   CHOU PY, 1945, Q APPL MATH, V3, P38, DOI 10.1090/qam/11999
   Chu KW, 2016, MINER ENG, V90, P43, DOI 10.1016/j.mineng.2016.01.020
   CLARK RA, 1979, J FLUID MECH, V91, P1, DOI 10.1017/S002211207900001X
   Clift R., 1985, FLUIDIZATION
   Clift R., 1978, BUBBLES DROPS PARTIC
   Cloete JH, 2018, CHEM ENG SCI, V192, P930, DOI 10.1016/j.ces.2018.06.041
   Cloete JH, 2018, CHEM ENG SCI, V192, P906, DOI 10.1016/j.ces.2018.06.040
   Cloete JH, 2017, POWDER TECHNOL, V316, P265, DOI 10.1016/j.powtec.2016.11.064
   Cloete JH, 2016, POWDER TECHNOL, V303, P156, DOI 10.1016/j.powtec.2016.07.009
   Cloete S, 2018, CHEM ENG SCI, V182, P93, DOI 10.1016/j.ces.2018.02.032
   Cloete S, 2016, POWDER TECHNOL, V289, P65, DOI 10.1016/j.powtec.2015.11.011
   Cloete S, 2015, POWDER TECHNOL, V269, P153, DOI 10.1016/j.powtec.2014.08.055
   Cloete S, 2013, POWDER TECHNOL, V239, P21, DOI 10.1016/j.powtec.2013.01.036
   Cloete S, 2013, POWDER TECHNOL, V235, P735, DOI 10.1016/j.powtec.2012.11.041
   Cloete S, 2013, POWDER TECHNOL, V235, P91, DOI 10.1016/j.powtec.2012.09.027
   Cloete S, 2011, POWDER TECHNOL, V210, P6, DOI 10.1016/j.powtec.2011.02.003
   Cocco R, 2010, POWDER TECHNOL, V203, P3, DOI 10.1016/j.powtec.2010.03.023
   Cody GD, 1996, POWDER TECHNOL, V87, P211, DOI 10.1016/0032-5910(96)03087-2
   Cody GD, 2008, POWDER TECHNOL, V182, P146, DOI 10.1016/j.powtec.2007.06.013
   COHEN EGD, 1993, AM J PHYS, V61, P524, DOI 10.1119/1.17204
   COHEN EGD, 1993, PHYSICA A, V194, P229, DOI 10.1016/0378-4371(93)90357-A
   Cokljat D, 2006, PROG COMPUT FLUID DY, V6, P168, DOI 10.1504/PCFD.2006.009494
   COLEMAN BD, 1961, REV MOD PHYS, V33, P239, DOI 10.1103/RevModPhys.33.239
   CONDIFF DW, 1969, PHYS FLUIDS, V12, P539, DOI 10.1063/1.1692517
   Cooper S, 2005, POWDER TECHNOL, V151, P27, DOI 10.1016/j.powtec.2004.11.041
   Crowe CT, 1996, ANNU REV FLUID MECH, V28, P11, DOI 10.1146/annurev.fl.28.010196.000303
   Cruz E, 2006, POWDER TECHNOL, V169, P115, DOI 10.1016/j.powtec.2006.08.005
   CURTISS CF, 1956, J CHEM PHYS, V24, P225, DOI 10.1063/1.1742459
   Dahl SR, 2005, CHEM ENG SCI, V60, P6658, DOI 10.1016/j.ces.2005.05.057
   Dai Q., 2017, THESIS
   Dai QT, 2016, POWDER TECHNOL, V288, P87, DOI 10.1016/j.powtec.2015.10.031
   Dai QT, 2015, POWDER TECHNOL, V283, P120, DOI 10.1016/j.powtec.2015.05.030
   Daitche A, 2015, J FLUID MECH, V782, P567, DOI 10.1017/jfm.2015.551
   Dan S, 2009, CHEM ENG SCI, V64, P5013, DOI 10.1016/j.ces.2009.08.005
   Dartevelle S., 2003, THESIS
   Das Sharma S, 2006, AICHE J, V52, P2391, DOI 10.1002/aic.10858
   DASGUPTA S, 1994, AICHE J, V40, P215, DOI 10.1002/aic.690400204
   Davidson J.F., 1963, FLUIDIZED PARTICLES
   Davidson J. F., 1985, FLUIDIZATION
   de Bertodano MAL, 1998, NUCL ENG DES, V179, P65, DOI 10.1016/S0029-5493(97)00244-6
   de Groot SR, 1962, NONEQUILIBRIUM THERM
   de Jong JF, 2012, POWDER TECHNOL, V230, P93, DOI 10.1016/j.powtec.2012.06.059
   Braun MPD, 2010, MATH COMPUT MODEL, V52, P1390, DOI 10.1016/j.mcm.2010.05.017
   De Wilde J, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2131925
   De Wilde J, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2732441
   De Zarate J.M.O., 2006, HYDRODYNAMIC FLUCTUA
   DEARDORFF JW, 1970, J FLUID MECH, V41, P453, DOI 10.1017/S0022112070000691
   Deen NG, 2007, CHEM ENG SCI, V62, P28, DOI 10.1016/j.ces.2006.08.014
   Deen NG, 2014, CURR OPIN CHEM ENG, V5, P84, DOI 10.1016/j.coche.2014.05.005
   Deen NG, 2014, CHEM ENG SCI, V116, P710, DOI 10.1016/j.ces.2014.05.039
   Derksen JJ, 2007, J FLUID MECH, V587, P303, DOI 10.1017/S0022112007007094
   Desjardins O, 2008, J COMPUT PHYS, V227, P2514, DOI 10.1016/j.jcp.2007.10.026
   DEUTSCH E, 1991, TURBULENCE MODIFICAT, V110, P35
   Dhotre MT, 2007, CHEM ENG SCI, V62, P7140, DOI 10.1016/j.ces.2007.08.016
   DIFELICE R, 1995, CHEM ENG SCI, V50, P1213, DOI 10.1016/0009-2509(95)98838-6
   DIFELICE R, 1994, INT J MULTIPHAS FLOW, V20, P153, DOI 10.1016/0301-9322(94)90011-6
   DING J, 1990, AICHE J, V36, P523, DOI 10.1002/aic.690360404
   Dingrong B., 1991, J CHEM IND ENG, V42, P548
   Dingrong B., 1991, J CHEM IND ENG, V42, P697
   Doisneau F., 2015, TECH REP
   Domaradzki JA, 2002, J TURBUL, V3
   Dong WG, 2008, CHEM ENG SCI, V63, P2798, DOI 10.1016/j.ces.2008.01.038
   Dong WG, 2008, CHEM ENG SCI, V63, P2811, DOI 10.1016/j.ces.2008.01.039
   Dorfman J., 2015, ARXIV151202679
   DREW DA, 1983, ANNU REV FLUID MECH, V15, P261, DOI 10.1146/annurev.fl.15.010183.001401
   Drew DA, 2001, J ENG MATH, V41, P259, DOI 10.1023/A:1011901711594
   Du M., 2018, THESIS
   Du SH, 2019, CHEM ENG J, V368, P687, DOI 10.1016/j.cej.2019.03.009
   Du W, 2006, CHEM ENG SCI, V61, P1401, DOI 10.1016/j.ces.2005.08.013
   Duan YF, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4979632
   Dufty JW, 2011, MATH MODEL NAT PHENO, V6, P19, DOI 10.1051/mmnp/20116402
   Dufty JW, 2007, J PHYS CHEM C, V111, P15605, DOI 10.1021/jp0736490
   Duraisamy K, 2019, ANNU REV FLUID MECH, V51, P357, DOI 10.1146/annurev-fluid-010518-040547
   Duru P, 2002, J FLUID MECH, V470, P359, DOI 10.1017/S0022112002002100
   Dutta A, 2004, J HEAT TRANS-T ASME, V126, P1040, DOI 10.1115/1.1833360
   Edwards SF, 2002, ADV PHYS, V51, P1669, DOI 10.1080/0001873021000030780
   ELGHOBASHI S, 1994, APPL SCI RES, V52, P309, DOI 10.1007/BF00936835
   ELGHOBASHI S, 2004, FLUID MEC A, V81, P3, DOI DOI 10.1007/1-4020-4977-3_1
   Elghobashi S, 2019, ANNU REV FLUID MECH, V51, P217, DOI 10.1146/annurev-fluid-010518-040401
   ELGHOBASHI SE, 1983, PHYS FLUIDS, V26, P931, DOI 10.1063/1.864243
   Ellis N, 2011, IND ENG CHEM RES, V50, P4697, DOI 10.1021/ie101141f
   Enskog D., 1922, ALMQVIST WIKSELLS BO
   Enwald H, 1996, INT J MULTIPHAS FLOW, V22, P21, DOI 10.1016/S0301-9322(96)90004-X
   Enwald H, 1999, CHEM ENG SCI, V54, P311, DOI 10.1016/S0009-2509(98)00186-9
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Eringen A.C., 2002, NONLOCAL CONTINUUM F
   ERLEBACHER G, 1992, J FLUID MECH, V238, P155, DOI 10.1017/S0022112092001678
   Ernst M.H., 1997, CONDMAT9707146 ARXIV
   Esmaili E, 2011, ADV ENG SOFTW, V42, P375, DOI 10.1016/j.advengsoft.2011.03.005
   Essadki M, 2018, SIAM J APPL MATH, V78, P2003, DOI 10.1137/16M1108364
   Estejab B, 2016, J FLUID ENG-T ASME, V138, DOI 10.1115/1.4031490
   ETTEHADIEH B, 1984, AICHE J, V30, P529, DOI 10.1002/aic.690300402
   Evans D.J., 2008, STAT MECH NONEQUILIB
   FAN LS, 1998, PRINCIPLES GAS SOLID
   Fan R, 2008, CHEM ENG SCI, V63, P272, DOI 10.1016/j.ces.2007.09.038
   FAVRE A, 1965, J MECANIQUE, V4, P391
   Favre A., 1969, PROBLEMS HYDRODYNAMI, P231
   Favre A.J., 1992, STUDIES TURBULENCE, P324
   Feitosa K, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.198301
   Feng H. S.-H, 2016, THESIS
   Feng YQ, 2004, AICHE J, V50, P1713, DOI 10.1002/aic.10169
   Feng ZG, 2014, POWDER TECHNOL, V265, P88, DOI 10.1016/j.powtec.2014.01.020
   Ferschneider G, 1996, REV I FR PETROL, V51, P301, DOI 10.2516/ogst:1996026
   Ferziger J. H., 1972, MATH THEORY TRANSPOR
   Fevrier P, 2005, J FLUID MECH, V533, P1, DOI 10.1017/S0022112005004088
   Fiedler O, 1997, POWDER TECHNOL, V94, P51, DOI 10.1016/S0032-5910(97)03287-7
   Forster D., 2018, HYDRODYNAMIC FLUCTUA
   Forterre Y, 2008, ANNU REV FLUID MECH, V40, P1, DOI 10.1146/annurev.fluid.40.111406.102142
   FOSCOLO PU, 1987, CHEM ENG SCI, V42, P1489, DOI 10.1016/0009-2509(87)85021-2
   FOSCOLO PU, 1984, CHEM ENG SCI, V39, P1667, DOI 10.1016/0009-2509(84)80100-1
   Fox RO, 2008, J COMPUT PHYS, V227, P6313, DOI 10.1016/j.jcp.2008.03.014
   Fox R.O., 2018, ADV CHEM ENG, V52, P1
   Fox R.O., 2017, TURBULENCE MULTIPHAS, P1
   Fox RO, 2014, J FLUID MECH, V742, P368, DOI 10.1017/jfm.2014.21
   Fox RO, 2012, ANNU REV FLUID MECH, V44, P47, DOI 10.1146/annurev-fluid-120710-101118
   Frohlich J, 2008, PROG AEROSP SCI, V44, P349, DOI 10.1016/j.paerosci.2008.05.001
   Fullmer WD, 2018, CHEM ENG SCI, V186, P84, DOI 10.1016/j.ces.2018.04.035
   Fullmer WD, 2017, J FLUID MECH, V823, P433, DOI 10.1017/jfm.2017.295
   Fullmer WD, 2017, ANNU REV FLUID MECH, V49, P485, DOI 10.1146/annurev-fluid-010816-060028
   Fullmer WD, 2016, AICHE J, V62, P11, DOI 10.1002/aic.15052
   Gage D., 1966, NONEQUILIBRIUM THERM, P283
   Galvin J.E., 2007, THESIS
   GANSER GH, 1993, POWDER TECHNOL, V77, P143, DOI 10.1016/0032-5910(93)80051-B
   Gao JS, 2008, PARTICUOLOGY, V6, P59, DOI 10.1016/j.partic.2007.11.003
   Gao JS, 2008, CHEM ENG SCI, V63, P1827, DOI 10.1016/j.ces.2007.12.009
   Gao JS, 2008, AICHE J, V54, P1164, DOI 10.1002/aic.11444
   Gao JS, 2009, AICHE J, V55, P1680, DOI 10.1002/aic.11824
   Gao JS, 1999, AICHE J, V45, P1095, DOI 10.1002/aic.690450517
   Gao X, 2018, AICHE J, V64, P3565, DOI 10.1002/aic.16341
   Gao X, 2018, CHEM ENG SCI, V184, P33, DOI 10.1016/j.ces.2018.03.038
   Gao X, 2013, IND ENG CHEM RES, V52, P10835, DOI 10.1021/ie4002298
   Gao X, 2012, POWDER TECHNOL, V228, P1, DOI 10.1016/j.powtec.2012.04.025
   Gao X, 2012, CHEM ENG SCI, V78, P98, DOI 10.1016/j.ces.2012.03.030
   Garcia-Colin LS, 2008, PHYS REP, V465, P149, DOI 10.1016/j.physrep.2008.04.010
   Garnier E., 2009, LARGE EDDY SIMULATIO
   GARSIDE J, 1977, IND ENG CHEM PROC DD, V16, P206, DOI 10.1021/i260062a008
   Garzo V, 2012, J FLUID MECH, V712, P129, DOI 10.1017/jfm.2012.404
   Garzo V, 1999, PHYS REV E, V59, P5895, DOI 10.1103/PhysRevE.59.5895
   Garzo V., 2003, KINETIC THEORY GASES
   Garzo V, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.031303
   Garzo V, 2010, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2010/07/P07024
   Garzo V, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.031304
   Garzo V, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.041303
   Gatski T.B., 2013, COMPRESSIBILITY TURB
   Gauthier T, 2000, OIL GAS SCI TECHNOL, V55, P187, DOI 10.2516/ogst:2000012
   Ge W, 2003, CHEM ENG SCI, V58, P1565, DOI 10.1016/S0009-2509(02)00673-5
   Ge W, 2002, CHEM ENG SCI, V57, P3993, DOI 10.1016/S0009-2509(02)00234-8
   Ge W, 2007, CHEM ENG SCI, V62, P3346, DOI 10.1016/j.ces.2007.02.049
   Ge W, 2019, COMPUT CHEM ENG, V126, P68, DOI 10.1016/j.compchemeng.2019.03.042
   Ge W, 2019, CHEM ENG SCI, V198, P198, DOI 10.1016/j.ces.2018.12.037
   Ge W, 2017, REV CHEM ENG, V33, P551, DOI 10.1515/revce-2015-0079
   Ge W, 2017, ENGINEERING-PRC, V3, P152, DOI 10.1016/J.ENG.2017.02.010
   Ge W, 2015, CHEM ENG TECHNOL, V38, P575, DOI 10.1002/ceat.201400746
   Ge W, 2011, CHEM ENG SCI, V66, P4426, DOI 10.1016/j.ces.2011.05.029
   GELDART D, 1973, POWDER TECHNOL, V7, P285, DOI 10.1016/0032-5910(73)80037-3
   Geldart D, 1986, GAS FLUIDIZATION TEC
   Geng CM, 2015, POWDER TECHNOL, V276, P144, DOI 10.1016/j.powtec.2015.01.077
   Gera D, 2004, INT J MULTIPHAS FLOW, V30, P419, DOI 10.1016/j.ijmultiphaseflow.2004.01.003
   GERMANO M, 1991, PHYS FLUIDS A-FLUID, V3, P1760, DOI 10.1063/1.857955
   GERMANO M, 1986, PHYS FLUIDS, V29, P2323, DOI 10.1063/1.865568
   Geurts BJ, 1997, PHYS FLUIDS, V9, P3585, DOI 10.1063/1.869495
   Ghadirian E, 2016, POWDER TECHNOL, V288, P35, DOI 10.1016/j.powtec.2015.10.034
   GHOSAL S, 1995, J COMPUT PHYS, V118, P24, DOI 10.1006/jcph.1995.1077
   GIBILARO LG, 1985, CHEM ENG SCI, V40, P1817, DOI 10.1016/0009-2509(85)80116-0
   Gibou F, 2019, J COMPUT PHYS, V380, P442, DOI 10.1016/j.jcp.2018.05.031
   GIDASPOW D, 1989, AICHE J, V35, P714, DOI 10.1002/aic.690350503
   Gidaspow D, 1998, AICHE J, V44, P279, DOI 10.1002/aic.690440207
   Gidaspow D, 2004, POWDER TECHNOL, V148, P123, DOI 10.1016/j.powtec.2004.09.025
   Gidaspow D, 2009, ENERG SCI ENG TECH, P1
   GIDASPOW D, 1983, IND ENG CHEM FUND, V22, P193, DOI 10.1021/i100010a008
   Gidaspow D, 1996, AICHE J, V42, P2503, DOI 10.1002/aic.690420910
   Gidaspow D., 1986, APPL MECH REV, V39, P1, DOI DOI 10.1115/1.3143702
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Girardi M, 2016, CHEM ENG SCI, V144, P224, DOI 10.1016/j.ces.2016.01.017
   Girimaji SS, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.034501
   Glansdorff P., 1971, THERMODYNAMIC THEORY, V306
   Glasser BJ, 2001, PHYS FLUIDS, V13, P407, DOI 10.1063/1.1338543
   Glasser BJ, 1998, PHYS REV LETT, V81, P1849, DOI 10.1103/PhysRevLett.81.1849
   Glasser BJ, 1997, J FLUID MECH, V334, P157, DOI 10.1017/S0022112096004351
   Glasser BJ, 1996, J FLUID MECH, V306, P183, DOI 10.1017/S0022112096001280
   Glicksman L.R., 2003, FLUIDIZED BED SCALE
   Gobin A, 2003, INT J NUMER METH FL, V43, P1199, DOI 10.1002/fld.542
   Goldenberg C, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.168001
   Goldhirsch I, 1999, CHAOS, V9, P659, DOI 10.1063/1.166440
   Goldhirsch I, 2003, ANNU REV FLUID MECH, V35, P267, DOI 10.1146/annurev.fluid.35.101101.161114
   GOLDHIRSCH I, 1993, PHYS REV LETT, V70, P1619, DOI 10.1103/PhysRevLett.70.1619
   GOLDMAN E, 1967, PHYS FLUIDS, V10, P1928, DOI 10.1063/1.1762389
   Goldschmidt MJV, 2004, POWDER TECHNOL, V142, P23, DOI 10.1016/j.powtec.2004.02.020
   Goldschmidt MJV, 2002, CHEM ENG SCI, V57, P2059, DOI 10.1016/S0009-2509(02)00082-9
   Goldschmidt MJV, 2001, CHEM ENG SCI, V56, P571, DOI 10.1016/S0009-2509(00)00262-1
   Goldshtein A, 1996, J FLUID MECH, V316, P29, DOI 10.1017/S0022112096000432
   GOLDSHTEIN A, 1995, J FLUID MECH, V282, P75, DOI 10.1017/S0022112095000048
   Gomez LC, 2005, POWDER TECHNOL, V149, P78, DOI 10.1016/j.powtec.2004.11.010
   Gonzalez-Ondina JM, 2018, J FLUID MECH, V839, P198, DOI 10.1017/jfm.2017.920
   Goodfellow I., 2016, DEEP LEARNING
   GOSMAN AD, 1992, AICHE J, V38, P1946, DOI 10.1002/aic.690381210
   Grace J. R., 1997, CIRCULATING FLUIDIZE
   Grace JR, 2004, POWDER TECHNOL, V139, P99, DOI 10.1016/j.powtec.2003.10.006
   GRAD H, 1949, COMMUN PUR APPL MATH, V2, P331, DOI 10.1002/cpa.3160020403
   Grad H, 1958, HANDB PHYSIK, VXII, P205, DOI DOI 10.1007/978-3-642-45892-7_3
   GRAHAM AL, 1984, IND ENG CHEM FUND, V23, P406, DOI 10.1021/i100016a005
   Grinstein FF, 2007, IMPLICIT LARGE EDDY SIMULATION: COMPUTING TURBULENT FLUID DYNAMICS, P1, DOI 10.1017/CBO9780511618604
   Gu WK, 1999, AICHE SYM S, V95, P42
   Gu WK, 1998, FLUIDIZATION IX, P501
   Gu YL, 2019, J FLUID MECH, V860, P318, DOI 10.1017/jfm.2018.856
   Guazzelli E, 2011, ANNU REV FLUID MECH, V43, P97, DOI 10.1146/annurev-fluid-122109-160736
   Guenther C, 2001, POWDER TECHNOL, V116, P142, DOI 10.1016/S0032-5910(00)00386-7
   Gunn D., 1967, P INT S FLUIDIZATION, P52
   Guo Q, 2019, AICHE J, V65, DOI 10.1002/aic.16583
   Haghgoo MR, 2018, PARTICUOLOGY, V38, P31, DOI 10.1016/j.partic.2017.04.010
   Haghgoo MR, 2018, INT J MULTIPHAS FLOW, V99, P500, DOI 10.1016/j.ijmultiphaseflow.2017.11.017
   HAIDER A, 1989, POWDER TECHNOL, V58, P63, DOI 10.1016/0032-5910(89)80008-7
   HANJALIC K, 1972, J FLUID MECH, V52, P609, DOI 10.1017/S002211207200268X
   Happel J, 1983, LOW REYNOLDS NUMBER
   Harris AT, 2002, POWDER TECHNOL, V127, P128, DOI 10.1016/S0032-5910(02)00114-6
   HARRIS SE, 1994, J FLUID MECH, V266, P243, DOI 10.1017/S0022112094000996
   Hartge E.-U., 1988, CIRCULATING FLUIDIZE, VII, P165
   Hashemi Z, 2017, IJST-T MECH ENG, V41, P71, DOI 10.1007/s40997-016-0035-3
   He J., 1993, ASME FED, V166, P253
   He L, 2019, POWDER TECHNOL, V345, P379, DOI 10.1016/j.powtec.2019.01.013
   Helland E, 2007, CHEM ENG SCI, V62, P148, DOI 10.1016/j.ces.2006.08.012
   Helland E, 2005, CHEM ENG SCI, V60, P27, DOI 10.1016/j.ces.2004.06.048
   HENLINE WD, 1970, J CHEM PHYS, V52, P5027, DOI 10.1063/1.1672741
   HERCZYNSKI R, 1975, NATURE, V255, P540, DOI 10.1038/255540a0
   HESS W, 1983, ADV PHYS, V32, P173, DOI 10.1080/00018738300101551
   Heynderickx GJ, 2004, IND ENG CHEM RES, V43, P4635, DOI 10.1021/ie034122m
   Hill RJ, 2001, J FLUID MECH, V448, P213, DOI 10.1017/S0022112001005948
   Hill SA, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.061302
   Holzer A, 2009, COMPUT FLUIDS, V38, P572, DOI 10.1016/j.compfluid.2008.06.001
   Holland DJ, 2008, POWDER TECHNOL, V182, P171, DOI 10.1016/j.powtec.2007.06.030
   Holloway W, 2012, J FLUID MECH, V713, P27, DOI 10.1017/jfm.2012.425
   Holloway W, 2014, CHEM ENG SCI, V108, P67, DOI 10.1016/j.ces.2013.12.037
   Holloway W, 2012, CHEM ENG SCI, V82, P132, DOI 10.1016/j.ces.2012.07.019
   Holloway W, 2011, CHEM ENG SCI, V66, P4403, DOI 10.1016/j.ces.2011.05.037
   Holloway W, 2010, AICHE J, V56, P1995, DOI 10.1002/aic.12127
   Hong K, 2016, POWDER TECHNOL, V296, P2, DOI 10.1016/j.powtec.2015.07.003
   Hong K, 2014, POWDER TECHNOL, V266, P424, DOI 10.1016/j.powtec.2014.06.064
   Hong K, 2013, CHEM ENG SCI, V99, P191, DOI 10.1016/j.ces.2013.05.050
   Hong K, 2012, CHEM ENG SCI, V75, P376, DOI 10.1016/j.ces.2012.03.022
   Hoomans BPB, 1996, CHEM ENG SCI, V51, P99, DOI 10.1016/0009-2509(95)00271-5
   Hoomans BPB, 1998, CHEM ENG SCI, V53, P2645
   HOPKINS MA, 1991, PHYS FLUIDS A-FLUID, V3, P47, DOI 10.1063/1.857863
   HORIO M, 1994, CHEM ENG SCI, V49, P2413, DOI 10.1016/0009-2509(94)E0071-W
   Hosseini SH, 2009, KOREAN J CHEM ENG, V26, P1405, DOI 10.1007/s11814-009-0220-9
   Hou BL, 2017, POWDER TECHNOL, V321, P13, DOI 10.1016/j.powtec.2017.07.081
   Hou BL, 2016, CHEM ENG J, V284, P1224, DOI 10.1016/j.cej.2015.09.073
   Hou BL, 2013, CHEM ENG SCI, V102, P354, DOI 10.1016/j.ces.2013.06.050
   Hou BL, 2010, CHEM ENG J, V163, P108, DOI 10.1016/j.cej.2010.07.028
   Hou BL, 2010, CHEM ENG J, V157, P509, DOI 10.1016/j.cej.2009.12.047
   Hou QF, 2019, AICHE J, V65, DOI 10.1002/aic.16690
   Hrenya CM, 2008, J FLUID MECH, V598, P429, DOI 10.1017/S0022112007000079
   Hrenya C.M., 1996, THESIS
   Hrenya CM, 2011, COMPUTATIONAL GAS-SOLIDS FLOWS AND REACTING SYSTEMS: THEORY, METHODS AND PRACTICE, P102, DOI 10.4018/978-1-61520-651-3.ch003
   Hrenya CM, 1997, AICHE J, V43, P853, DOI 10.1002/aic.690430402
   Hsiau SS, 1996, ACTA MECH, V114, P121, DOI 10.1007/BF01170399
   Hsu TJ, 2004, P ROY SOC A-MATH PHY, V460, P2223, DOI 10.1098/rspa.2003.1273
   Hu HH, 1996, INT J MULTIPHAS FLOW, V22, P335, DOI 10.1016/0301-9322(95)00068-2
   Hu SW, 2020, CHEM ENG J, V383, DOI 10.1016/j.cej.2019.123122
   Hu SW, 2019, CHEM ENG SCI, V205, P14, DOI 10.1016/j.ces.2019.04.033
   Hu SW, 2017, CHEM ENG J, V307, P326, DOI 10.1016/j.cej.2016.08.084
   Hu SW, 2013, CHEM ENG SCI, V96, P165, DOI 10.1016/j.ces.2013.04.004
   Hua LN, 2015, POWDER TECHNOL, V284, P299, DOI 10.1016/j.powtec.2015.06.057
   Huang WL, 2018, NATL SCI REV, V5, P321, DOI 10.1093/nsr/nwx083
   Huang XY, 2013, POWDER TECHNOL, V239, P458, DOI 10.1016/j.powtec.2013.02.038
   Huang ZQ, 2017, POWDER TECHNOL, V321, P435, DOI 10.1016/j.powtec.2017.08.035
   HUI K, 1984, J FLUID MECH, V145, P223, DOI 10.1017/S0022112084002883
   Huilin L., 2003, J CHEM ENG SCI, V58, P1197, DOI DOI 10.1016/S0009-2509(02)00635-8
   Hulme I, 2005, IND ENG CHEM RES, V44, P4254, DOI 10.1021/ie049837j
   Hummel M, 2016, EPL-EUROPHYS LETT, V114, DOI 10.1209/0295-5075/114/10002
   Hunt ML, 1997, INT J HEAT MASS TRAN, V40, P3059, DOI 10.1016/S0017-9310(96)00350-X
   Ibsen CH, 2004, POWDER TECHNOL, V149, P29, DOI 10.1016/j.powtec.2004.09.042
   ICHIKI K, 1995, PHYS REV E, V52, P658, DOI 10.1103/PhysRevE.52.658
   Iddir H, 2005, AICHE J, V51, P1620, DOI 10.1002/aic.10429
   Igci Y, 2008, AICHE J, V54, P1431, DOI 10.1002/aic.11481
   Igci Y, 2012, IND ENG CHEM RES, V51, P2094, DOI 10.1021/ie2007278
   Igci Y, 2011, IND ENG CHEM RES, V50, P13190, DOI 10.1021/ie200190q
   Igci Y, 2011, AICHE J, V57, P2691, DOI 10.1002/aic.12486
   Ishihara T, 2009, ANNU REV FLUID MECH, V41, P165, DOI 10.1146/annurev.fluid.010908.165203
   ISHII M, 1984, NUCL ENG DES, V82, P107, DOI 10.1016/0029-5493(84)90207-3
   Ishii M., 1975, THERMOFLUID DYNAMIC
   Ishii M, 2011, THERMO-FLUID DYNAMICS OF TWO-PHASE FLOW, SECOND EDITION, P1, DOI 10.1007/978-1-4419-7985-8
   Issangya A.S., 1998, THESIS
   Issangya AS, 2000, POWDER TECHNOL, V111, P104, DOI 10.1016/S0032-5910(00)00246-1
   Jackson R., 1963, T I CHEM ENG-LOND, V41, P13
   Jackson R., 2000, DYNAMICS FLUIDIZED P
   Jalalinejad F, 2016, POWDER TECHNOL, V290, P27, DOI 10.1016/j.powtec.2015.12.014
   Jayawickrama TR, 2019, INT J MULTIPHAS FLOW, V117, P130, DOI 10.1016/j.ijmultiphaseflow.2019.04.022
   Jenkins JT, 2010, GRANUL MATTER, V12, P151, DOI 10.1007/s10035-010-0169-8
   Jenkins JT, 1997, PHYS FLUIDS, V9, P2835, DOI 10.1063/1.869396
   Jenkins JT, 2002, PHYS FLUIDS, V14, P1228, DOI 10.1063/1.1449466
   JENKINS JT, 1989, PHYS FLUIDS A-FLUID, V1, P2050, DOI 10.1063/1.857479
   JENKINS JT, 1992, J APPL MECH-T ASME, V59, P120, DOI 10.1115/1.2899416
   JENKINS JT, 1987, J APPL MECH-T ASME, V54, P27, DOI 10.1115/1.3172990
   JENKINS JT, 1986, J FLUID MECH, V171, P53, DOI 10.1017/S0022112086001362
   Jiang Y, 2019, MATER TECHNOL, DOI 10.1080/10667857.2019.1664096
   Jiang Y, 2014, CHEM ENG SCI, V109, P85, DOI 10.1016/j.ces.2014.01.029
   Jiang YD, 2019, POWDER TECHNOL, V346, P403, DOI 10.1016/j.powtec.2018.11.092
   Jin GD, 2010, INT J MULTIPHAS FLOW, V36, P432, DOI 10.1016/j.ijmultiphaseflow.2009.12.005
   Jiradilok V, 2008, CHEM ENG SCI, V63, P2135, DOI 10.1016/j.ces.2008.01.019
   Jiradilok V, 2007, CHEM ENG SCI, V62, P3397, DOI 10.1016/j.ces.2007.01.084
   Jiradilok V, 2006, CHEM ENG SCI, V61, P5544, DOI 10.1016/j.ces.2006.04.006
   Johansson K., 2001, 4 INT C MULT FLOWS N
   JOHNSON PC, 1990, J FLUID MECH, V210, P501, DOI 10.1017/S0022112090001380
   JOHNSON PC, 1987, J FLUID MECH, V176, P67, DOI 10.1017/S0022112087000570
   Jop P, 2006, NATURE, V441, P727, DOI 10.1038/nature04801
   Jou D, 2010, EXTENDED IRREVERSIBLE THERMODYNAMICS, FOURTH EDITION, P1, DOI 10.1007/978-90-481-3074-0
   Jung J, 2005, IND ENG CHEM RES, V44, P1329, DOI 10.1021/ie0496838
   Jung JW, 2006, CHEM ENG COMMUN, V193, P946, DOI 10.1080/00986440500351982
   Kadanoff LP, 1999, REV MOD PHYS, V71, P435, DOI 10.1103/RevModPhys.71.435
   Kajishima T, 2004, INT J HEAT FLUID FL, V25, P721, DOI 10.1016/j.ijheatfluidflow.2004.05.007
   Kallio S, 2015, POWDER TECHNOL, V274, P227, DOI 10.1016/j.powtec.2015.01.029
   Kallio S, 2014, POWDER TECHNOL, V261, P257, DOI 10.1016/j.powtec.2014.04.045
   Kallio S, 2014, POWDER TECHNOL, V257, P20, DOI 10.1016/j.powtec.2014.02.022
   Kandhai D, 2003, AICHE J, V49, P1060, DOI 10.1002/aic.690490423
   Kanholy SK, 2012, J FLUID ENG-T ASME, V134, DOI 10.1115/1.4007803
   Karniadakis G., 2006, MICROFLOWS NANOFLOWS, V29
   Kashiwa B.A., 2001, LAUR014531 LOS AL NA
   Kashiwa B.B., 1995, LALP95206 LOS AL NAT
   Kashyap M, 2011, PARTICUOLOGY, V9, P572, DOI 10.1016/j.partic.2011.06.007
   Kashyap M, 2011, IND ENG CHEM RES, V50, P7549, DOI 10.1021/ie1012079
   Kashyap M, 2010, POWDER TECHNOL, V203, P40, DOI 10.1016/j.powtec.2010.03.025
   KAZARI M, 1995, P 2 INT C MULT FLOW
   Kellogg KM, 2019, CHEM ENG SCI, V199, P249, DOI 10.1016/j.ces.2019.01.012
   Kellogg KM, 2017, J FLUID MECH, V832, P345, DOI 10.1017/jfm.2017.642
   Ketterhagen WR, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.061307
   Khan MJH, 2014, J IND ENG CHEM, V20, P3919, DOI 10.1016/j.jiec.2014.01.044
   Kharel P, 2017, PHYS REV LETT, V119, DOI 10.1103/PhysRevLett.119.178001
   Kim H, 2002, POWDER TECHNOL, V122, P83, DOI 10.1016/S0032-5910(01)00395-3
   Kim S., 2005, MICROHYDRODYNAMICS P
   Lopez de Bertodano M., 1992, THESIS
   Lu HL, 2005, CHEM ENG SCI, V60, P6757, DOI 10.1016/j.ces.2005.05.063
   Lu HL, 2010, CHEM ENG SCI, V65, P1462, DOI 10.1016/j.ces.2009.10.019
   SEUKIM H, 1995, CAN J CHEM ENG, V73, P603, DOI 10.1002/cjce.5450730503
   VANBEIJEREN H, 1973, PHYSICA, V70, P225, DOI 10.1016/0031-8914(73)90247-4
   Bin Rashid TA, 2020, POWDER TECHNOL, V359, P126, DOI 10.1016/j.powtec.2019.09.060
   Knowlton TM, 2005, POWDER TECHNOL, V150, P72, DOI 10.1016/j.powtec.2004.11.036
   Koch DL, 1999, J FLUID MECH, V400, P229, DOI 10.1017/S0022112099006485
   KOCH DL, 1990, PHYS FLUIDS A-FLUID, V2, P1711, DOI 10.1063/1.857698
   Koch DL, 2001, ANNU REV FLUID MECH, V33, P619, DOI 10.1146/annurev.fluid.33.1.619
   Kolehmainen J, 2018, J FLUID MECH, V848, P340, DOI 10.1017/jfm.2018.361
   KOLMOGOROV AN, 1962, J FLUID MECH, V13, P82, DOI 10.1017/S0022112062000518
   Kolmogorov AN, 1954, IZV AN SSSR FIZ, V6, P56
   Kong B, 2017, AICHE J, V63, P2630, DOI 10.1002/aic.15686
   Kong B, 2017, J COMPUT PHYS, V344, P575, DOI 10.1016/j.jcp.2017.05.013
   Kong L, 2014, PARTICUOLOGY, V13, P114, DOI 10.1016/j.partic.2013.04.007
   Kravets B, 2019, POWDER TECHNOL, V345, P438, DOI 10.1016/j.powtec.2019.01.028
   Kriebitzsch SHL, 2013, AICHE J, V59, P316, DOI 10.1002/aic.13804
   Kriebitzsch SHL, 2013, CHEM ENG SCI, V91, P1, DOI 10.1016/j.ces.2012.12.038
   Krishna R, 2001, CHEM ENG J, V82, P247, DOI 10.1016/S1385-8947(00)00369-7
   Kryuchkov YN, 2001, REFRACT IND CERAM+, V42, P390, DOI 10.1023/A:1015071103237
   Kuerten JGM, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2176589
   KUIPERS JAM, 1992, CHEM ENG SCI, V47, P1913, DOI 10.1016/0009-2509(92)80309-Z
   Kumaran V, 2006, J FLUID MECH, V561, P1, DOI 10.1017/S0022112006000279
   Kumaran V, 2010, PROG THEOR PHYS SUPP, P88
   Kunii D., 1991, FLUIDIZATION ENG
   Kutz JN, 2017, J FLUID MECH, V814, P1, DOI 10.1017/jfm.2016.803
   Kuwagi K, 2004, INT C FLUID ENG 11 I, V160, P243
   Ladd AJC, 1996, PHYS REV LETT, V76, P1392, DOI 10.1103/PhysRevLett.76.1392
   Ladd AJC, 2001, J STAT PHYS, V104, P1191, DOI 10.1023/A:1010414013942
   LAHEY RT, 1993, NUCL ENG DES, V141, P177, DOI 10.1016/0029-5493(93)90101-E
   Lan XY, 2012, CHEM ENG SCI, V69, P419, DOI 10.1016/j.ces.2011.10.064
   Landau L., 1980, COURSE THEORETICAL P
   Landau L.D., 1959, COURSE THEORETICAL P, V6
   Lane WA, 2018, CHEM ENG SCI, V176, P409, DOI 10.1016/j.ces.2017.11.018
   Lane WA, 2016, CHEM ENG SCI, V151, P7, DOI 10.1016/j.ces.2016.05.005
   Lasinski M.E., 2004, THESIS
   Lasinski ME, 2004, PHYS FLUIDS, V16, P265, DOI 10.1063/1.1633264
   Lathouwers D, 2000, P COMBUST INST, V28, P2297, DOI 10.1016/S0082-0784(00)80640-2
   LAUNDER BE, 1975, J FLUID MECH, V68, P537, DOI 10.1017/S0022112075001814
   Layton WJ, 2012, LECT NOTES MATH, V2042, P1, DOI 10.1007/978-3-642-24409-4
   Leboreiro J, 2008, POWDER TECHNOL, V183, P385, DOI 10.1016/j.powtec.2008.01.008
   Leckner B, 2011, FUEL, V90, P2951, DOI 10.1016/j.fuel.2011.04.038
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lee JH, 2018, COMPUT CHEM ENG, V114, P111, DOI 10.1016/j.compchemeng.2017.10.008
   Leonard A., 1975, ADV GEOPHYSICS     A, P237, DOI [DOI 10.1016/S0065-2687(08)60464-1, 10.1016/S0065-2687(08)60464-1]
   Leszczynski JS, 2002, POWDER TECHNOL, V128, P22, DOI 10.1016/S0032-5910(02)00150-X
   Levenspiel O, 2008, IND ENG CHEM RES, V47, P273, DOI 10.1021/ie071355v
   Li D, 2018, POWDER TECHNOL, V325, P381, DOI 10.1016/j.powtec.2017.10.057
   [李飞 Li Fei], 2011, [工程热物理学报, Journal of Engineering Thermophysics], V32, P75
   LI HZ, 1991, POWDER TECHNOL, V66, P231, DOI 10.1016/0032-5910(91)80035-H
   Li J, 2003, CHEM ENG SCI, V58, P711, DOI 10.1016/S0009-2509(02)00599-7
   Li J., 1991, P CHIN JAP CHEM ENG, P754
   Li J., 2018, COMP AIDED CHEM ENG, V44, P11
   Li J., 1994, PARTICLE FLUID 2 PHA
   Li J, 2014, MESOSCIENCE PRINCIPL
   Li J., 1988, CIRCULATING FLUIDIZE, P89
   Li J., 2013, MULTISCALE MODELING
   Li J., 1993, P 4 INT C CIRC FLUID, P49
   Li J., 2007, P 12 INT C FLUID ECI, P15
   Li J H, 2005, MULTISCALE SIMULATIO
   Li J.P., 2003, THESIS, P1
   Li JH, 1999, CHEM ENG SCI, V54, P5409, DOI 10.1016/S0009-2509(99)00274-2
   Li JH, 1998, CHEM ENG SCI, V53, P3367, DOI 10.1016/S0009-2509(98)00130-4
   Li JH, 2004, CHEM ENG SCI, V59, P1687, DOI 10.1016/j.ces.2004.01.025
   Li JH, 2003, CHEM ENG SCI, V58, P521, DOI 10.1016/S0009-2509(02)00577-8
   Li JH, 2001, IND ENG CHEM RES, V40, P4227, DOI 10.1021/ie0011021
   Li JH, 1996, CHEM ENG SCI, V51, P667
   Li JH, 2018, ANNU REV CHEM BIOMOL, V9, P41, DOI 10.1146/annurev-chembioeng-060817-084249
   Li JH, 2018, CHEM ENG J, V333, P327, DOI 10.1016/j.cej.2017.09.162
   Li JH, 2016, CURR OPIN CHEM ENG, V13, P10, DOI 10.1016/j.coche.2016.07.008
   Li JH, 2015, CHEM ENG J, V278, P541, DOI 10.1016/j.cej.2014.10.005
   [李静海 Li Jinghai], 2014, [中国科学. 化学, Scientia Sinica Chimica], V44, P277
   Li P, 2009, PARTICUOLOGY, V7, P269, DOI 10.1016/j.partic.2009.03.010
   Li TW, 2008, POWDER TECHNOL, V184, P89, DOI 10.1016/j.powtec.2007.08.007
   Li TW, 2017, CHEM ENG SCI, V169, P259, DOI 10.1016/j.ces.2016.07.043
   Li TW, 2017, AICHE J, V63, P1203, DOI 10.1002/aic.15507
   Li TW, 2016, POWDER TECHNOL, V301, P1130, DOI 10.1016/j.powtec.2016.07.056
   Li TW, 2014, CHEM ENG SCI, V120, P10, DOI 10.1016/j.ces.2014.08.041
   Li TW, 2012, AICHE J, V58, P2058, DOI 10.1002/aic.12728
   Li TW, 2012, CHEM ENG SCI, V84, P746, DOI 10.1016/j.ces.2012.09.024
   Li TW, 2010, IND ENG CHEM RES, V49, P10767, DOI 10.1021/ie100519s
   Li TW, 2010, POWDER TECHNOL, V203, P447, DOI 10.1016/j.powtec.2010.06.005
   Li TW, 2014, POWDER TECHNOL, V265, P2, DOI 10.1016/j.powtec.2014.04.008
   Li Y., 1982, 1 CHIN JAP S FLUID H, P124
   Li ZG, 2003, PHYS REV E, V68, DOI 10.1103/PhysRevE.68.061206
   LILLY DK, 1992, PHYS FLUIDS A-FLUID, V4, P633, DOI 10.1063/1.858280
   Lin Q, 2001, CHEM ENG SCI, V56, P2179, DOI 10.1016/S0009-2509(00)00499-1
   Lindborg H, 2007, CHEM ENG SCI, V62, P5854, DOI 10.1016/j.ces.2007.06.011
   Lindborg H, 2009, IND ENG CHEM RES, V48, P1332, DOI 10.1021/ie800522p
   Link JM, 2009, POWDER TECHNOL, V189, P202, DOI 10.1016/j.powtec.2008.04.017
   Liss ED, 2001, POWDER TECHNOL, V116, P116, DOI 10.1016/S0032-5910(00)00392-2
   Liu CF, 2019, PARTICUOLOGY, V43, P1, DOI 10.1016/j.partic.2018.04.004
   Liu CF, 2015, CHEM ENG SCI, V122, P114, DOI 10.1016/j.ces.2014.09.002
   Liu D., 1993, FLUID DYNAMICS 2 PHA
   Liu D., 1987, CHIN J THEOR APPL ME, V19, P213
   Liu MX, 2014, IND ENG CHEM RES, V53, P13475, DOI 10.1021/ie501474t
   Liu WM, 2017, POWDER TECHNOL, V314, P367, DOI 10.1016/j.powtec.2016.09.087
   Liu WM, 2016, POWDER TECHNOL, V295, P122, DOI 10.1016/j.powtec.2016.03.042
   Liu WM, 2015, POWDER TECHNOL, V286, P516, DOI 10.1016/j.powtec.2015.08.049
   Liu XJ, 2006, J UNIV SCI TECHNOL B, V13, P301, DOI 10.1016/S1005-8850(06)60063-7
   Liu XJ, 2009, POWDER TECHNOL, V195, P235, DOI 10.1016/j.powtec.2009.06.007
   Liu XW, 2017, AICHE J, V63, P3, DOI 10.1002/aic.15489
   Liu XX, 2015, PARTICUOLOGY, V21, P118, DOI 10.1016/j.partic.2014.05.012
   Liu XH, 2015, CHEM ENG J, V278, P492, DOI 10.1016/j.cej.2014.11.093
   Liu XH, 2014, IND ENG CHEM RES, V53, P2800, DOI 10.1021/ie4029335
   Liu XH, 2012, CHEM ENG PROG, V108, P28
   Liu X, 2018, POWDER TECHNOL, V338, P79, DOI 10.1016/j.powtec.2018.06.039
   Liu YN, 2011, POWDER TECHNOL, V212, P289, DOI 10.1016/j.powtec.2011.04.035
   Liu Z., 2013, 14 INT C FLUID
   Ljus C., 2000, THESIS
   Loezos PN, 2002, CHEM ENG SCI, V57, P5123, DOI 10.1016/S0009-2509(02)00421-9
   Loha C, 2013, PARTICUOLOGY, V11, P673, DOI 10.1016/j.partic.2012.08.007
   Loha C, 2012, CHEM ENG SCI, V75, P400, DOI 10.1016/j.ces.2012.03.044
   Loth E, 2004, POWDER TECHNOL, V142, P209, DOI 10.1016/j.powtec.2004.04.033
   LOUGE MY, 1991, J FLUID MECH, V231, P345, DOI 10.1017/S0022112091003427
   LOUGE MY, 1994, PHYS FLUIDS, V6, P2253, DOI 10.1063/1.868178
   Lu BN, 2019, REV CHEM ENG, V35, P879, DOI 10.1515/revce-2017-0023
   Lu BN, 2017, CHEM ENG SCI, V171, P244, DOI 10.1016/j.ces.2017.05.007
   [鲁波娜 Lu Bona], 2013, [化工学报, Journal of Chemical Industry and Engineering (China)], V64, P1983
   Lu BN, 2013, AICHE J, V59, P1108, DOI 10.1002/aic.13917
   Lu BN, 2012, PARTICUOLOGY, V10, P663, DOI 10.1016/j.partic.2012.06.003
   Lu BN, 2011, CHEM ENG SCI, V66, P4624, DOI 10.1016/j.ces.2011.06.026
   Lu BN, 2009, CHEM ENG SCI, V64, P3437, DOI 10.1016/j.ces.2009.04.024
   Lu H., 2017, KINETIC THEORY DENSE
   Lu HL, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.061301
   Lu HL, 2003, POWDER TECHNOL, V134, P86, DOI 10.1016/S0032-5910(03)00126-8
   Lu HL, 2003, CHEM ENG SCI, V58, P3777, DOI 10.1016/S0009-2509(03)00238-0
   Lu HL, 2003, IND ENG CHEM RES, V42, P2390, DOI 10.1021/ie020521q
   Lu HL, 2008, POWDER TECHNOL, V182, P282, DOI 10.1016/j.powtec.2007.09.003
   Lu HL, 2007, CHEM ENG SCI, V62, P301, DOI 10.1016/j.ces.2006.08.031
   Lu LQ, 2019, POWDER TECHNOL, V349, P109, DOI 10.1016/j.powtec.2018.10.055
   Lu LQ, 2018, ADV CHEM ENG, V53, P53, DOI 10.1016/bs.ache.2017.12.001
   Lu LQ, 2017, POWDER TECHNOL, V321, P301, DOI 10.1016/j.powtec.2017.08.034
   Lu LQ, 2017, AICHE J, V63, P5320, DOI 10.1002/aic.15832
   Lu LQ, 2016, CHEM ENG SCI, V155, P314, DOI 10.1016/j.ces.2016.08.013
   Lu LQ, 2014, CHEM ENG SCI, V120, P67, DOI 10.1016/j.ces.2014.08.004
   Lu X, 2016, POWDER TECHNOL, V304, P41, DOI 10.1016/j.powtec.2016.07.063
   Lucas D, 2007, CHEM ENG SCI, V62, P4146, DOI 10.1016/j.ces.2007.04.035
   Luding S, 2001, COMPUT METHOD APPL M, V191, P21, DOI 10.1016/S0045-7825(01)00242-0
   Luding S., 2017, SOFT HARD PARTICLE S
   Luding S., 2008, EUROPEAN J ENV CIVIL, V12, P785, DOI DOI 10.1080/19648189.2008.9693050
   Luding S, 2009, NONLINEARITY, V22, pR101, DOI 10.1088/0951-7715/22/12/R01
   LUN CKK, 1984, J FLUID MECH, V140, P223, DOI 10.1017/S0022112084000586
   Lun CKK, 2003, LECT NOTES PHYS, V624, P267
   LUN CKK, 1987, J APPL MECH-T ASME, V54, P47, DOI 10.1115/1.3172993
   Luo CB, 2017, CAN J CHEM ENG, V95, P1999, DOI 10.1002/cjce.22816
   Luo H, 2017, CHEM ENG J, V326, P47, DOI 10.1016/j.cej.2017.04.145
   Luo J., 2004, LOCAL EQUILIBRIUM TH
   Luo K, 2016, AICHE J, V62, P1917, DOI 10.1002/aic.15186
   Lv XL, 2016, POWDER TECHNOL, V292, P323, DOI 10.1016/j.powtec.2016.02.001
   Lv XL, 2014, CHEM ENG J, V236, P149, DOI 10.1016/j.cej.2013.09.067
   MA D, 1988, POWDER TECHNOL, V56, P191, DOI 10.1016/0032-5910(88)80030-5
   MA D, 1990, INT J MULTIPHAS FLOW, V16, P341, DOI 10.1016/0301-9322(90)90063-O
   Ma JS, 2006, CHEM ENG SCI, V61, P7096, DOI 10.1016/j.ces.2006.07.042
   MACAULAY M, 2019, J FLUID MECH, V858, DOI DOI 10.1017/JFM.2018.861
   Mahajan V.V., 2019, CHEM ENG SCI, VX
   Majmudar TS, 2005, NATURE, V435, P1079, DOI 10.1038/nature03805
   Marchioli C, 2017, ACTA MECH, V228, P741, DOI 10.1007/s00707-017-1803-x
   Marchioro M, 2001, INT J MULTIPHAS FLOW, V27, P237, DOI 10.1016/S0301-9322(00)00021-5
   Marchioro M, 2000, INT J MULTIPHAS FLOW, V26, P783, DOI 10.1016/S0301-9322(99)00068-3
   Marchisio DL, 2013, CAM CHEM ENGN, P1, DOI 10.1017/CBO9781139016599
   MASSOUDI M, 1992, AICHE J, V38, P471, DOI 10.1002/aic.690380317
   Mathiesen V, 1999, AICHE J, V45, P2503, DOI 10.1002/aic.690451206
   Mathiesen V, 2000, INT J MULTIPHAS FLOW, V26, P387, DOI 10.1016/S0301-9322(99)00027-0
   Mathiesen V, 2000, POWDER TECHNOL, V112, P34, DOI 10.1016/S0032-5910(99)00303-4
   MATSEN JM, 1982, POWDER TECHNOL, V32, P21, DOI 10.1016/0032-5910(82)85003-1
   Maugin GA, 2015, MECH RES COMMUN, V69, P79, DOI 10.1016/j.mechrescom.2015.06.009
   Maxey M, 2017, ANNU REV FLUID MECH, V49, P171, DOI 10.1146/annurev-fluid-122414-034408
   Maxwell JC, 1878, PHILOS T R SOC LONDO, V27, P304, DOI DOI 10.1098/RSTL.1879.0067
   Mazzei L, 2007, CHEM ENG SCI, V62, P6129, DOI 10.1016/j.ces.2007.06.028
   McKeen T, 2003, POWDER TECHNOL, V129, P139, DOI 10.1016/S0032-5910(02)00294-2
   Mckeen T., 2003, INT J CHEM REACT ENG, V1, P10907
   Mehrabadi M, 2015, J FLUID MECH, V770, P210, DOI 10.1017/jfm.2015.146
   Mehrabadi M, 2016, INT J MULTIPHAS FLOW, V86, P99, DOI 10.1016/j.ijmultiphaseflow.2016.07.006
   Mehrabadi M, 2016, CHEM ENG SCI, V152, P199, DOI 10.1016/j.ces.2016.06.006
   Meneveau C., 2010, SCHOLARPEDIA, V5, p[9489, 9489], DOI DOI 10.4249/scholarpedia.9489
   Meng FX, 2012, POWDER TECHNOL, V224, P404, DOI 10.1016/j.powtec.2012.03.037
   Menon N, 1997, PHYS REV LETT, V79, P3407, DOI 10.1103/PhysRevLett.79.3407
   Mewis J, 2012, COLLOIDAL SUSPENSION
   Michaelides E. E., 2013, HEAT MASS TRANSFER P
   Michaelides EE, 2006, PARTICLES, BUBBLES AND DROPS: THEIR MOTION, HEAT AND MASS TRANSFER, P1, DOI 10.1142/9789812774316
   Michalek W., 2013, PHYS FLUIDS, V25, P12
   Michalski RS, 2013, MACHINE LEARNING ART
   MICKLEY HS, 1955, AICHE J, V1, P374, DOI 10.1002/aic.690010317
   Milioli CC, 2013, AICHE J, V59, P3265, DOI 10.1002/aic.14130
   MILLER A, 1992, AICHE J, V38, P1801, DOI 10.1002/aic.690381111
   Mitrano PP, 2014, J FLUID MECH, V738, DOI 10.1017/jfm.2013.602
   Mitrano PP, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.041303
   Mitrano PP, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3633012
   Mo Y, 2020, PARTICUOLOGY, V48, P109, DOI 10.1016/j.partic.2018.09.004
   Moin P, 1998, ANNU REV FLUID MECH, V30, P539, DOI 10.1146/annurev.fluid.30.1.539
   Mokhtar MA, 2012, AICHE J, V58, P87, DOI 10.1002/aic.12568
   Moon SJ, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2338597
   Moraga FJ, 2003, INT J MULTIPHAS FLOW, V29, P655, DOI 10.1016/S0301-9322(03)00018-1
   Moran JC, 2003, CHEM ENG SCI, V58, P1879, DOI 10.1016/S0009-2509(02)00684-X
   Moreau M, 2010, FLOW TURBUL COMBUST, V84, P295, DOI 10.1007/s10494-009-9233-z
   Morrison F.A., 2001, UNDERSTANDING RHEOLO
   Motlagh AHA, 2014, CHEM ENG SCI, V120, P22, DOI 10.1016/j.ces.2014.08.042
   Mouallem J, 2019, CHEM ENG SCI, V195, P553, DOI 10.1016/j.ces.2018.09.054
   Mouallem J, 2018, CHEM ENG SCI, V182, P200, DOI 10.1016/j.ces.2018.02.039
   Movahedirad S, 2012, AICHE J, V58, P3306, DOI 10.1002/aic.13729
   Muller CR, 2008, POWDER TECHNOL, V184, P241, DOI 10.1016/j.powtec.2007.11.046
   Muller I, 2012, EUR PHYS J H, V37, P139, DOI 10.1140/epjh/e2012-20029-1
   Muller I, 1998, RATIONAL EXTENDED TH
   Municchi F, 2018, INT J HEAT MASS TRAN, V120, P1146, DOI 10.1016/j.ijheatmasstransfer.2017.12.105
   Municchi F, 2017, INT J HEAT MASS TRAN, V111, P171, DOI 10.1016/j.ijheatmasstransfer.2017.03.122
   Municchi F, 2016, COMPUT PHYS COMMUN, V207, P400, DOI 10.1016/j.cpc.2016.05.026
   Murray JA, 2012, POWDER TECHNOL, V220, P24, DOI 10.1016/j.powtec.2011.09.030
   Narayan V, 2007, SCIENCE, V317, P105, DOI 10.1126/science.1140414
   Naren PR, 2007, CHEM ENG RES DES, V85, P1188, DOI 10.1205/cherd06077
   Nelson MJ, 2017, ENGINEERING, V3, P330, DOI 10.1016/J.ENG.2017.03.021
   Nicolis G., 1977, SELF ORG NONEQUILIBR
   NICOLIS G, 1989, EXPLORING COMPLEXITY
   Nicolis G., 2012, FDN COMPLEX SYSTEMS
   Nikolopoulos A, 2013, CHEM ENG SCI, V90, P137, DOI 10.1016/j.ces.2012.12.007
   Nikolopoulos A, 2010, CHEM ENG SCI, V65, P4089, DOI 10.1016/j.ces.2010.03.053
   Nikolopoulos A, 2010, CHEM ENG SCI, V65, P4080, DOI 10.1016/j.ces.2010.03.054
   Niu L, 2019, IND ENG CHEM RES, V58, P8456, DOI 10.1021/acs.iecr.9b01077
   NOTT PR, 1994, J FLUID MECH, V275, P157, DOI 10.1017/S0022112094002326
   Nott PR, 2011, J FLUID MECH, V678, P179, DOI 10.1017/jfm.2011.105
   O'Brien T.J., 1993, CIRCUL FLUID BED TEC, VIV, P367
   O'Brien TJ, 2014, POWDER TECHNOL, V265, P83, DOI 10.1016/j.powtec.2014.01.030
   O'Rourke PJ, 2014, POWDER TECHNOL, V256, P39, DOI 10.1016/j.powtec.2014.01.084
   OCONE R, 1993, AICHE J, V39, P1261, DOI 10.1002/aic.690390802
   OGAWA S, 1980, Z ANGEW MATH PHYS, V31, P483, DOI 10.1007/BF01590859
   Ojha RP, 2004, NATURE, V427, P521, DOI 10.1038/nature02294
   Olivieri S, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4871480
   ORSZAG SA, 1972, PHYS REV LETT, V28, P76, DOI 10.1103/PhysRevLett.28.76
   Ostoja-Starzewski M, 2007, MICROSTRUCTURAL RAND
   Owoyemi O, 2008, IND ENG CHEM RES, V47, P6316, DOI 10.1021/ie800138n
   Owoyemi O, 2007, AICHE J, V53, P1924, DOI 10.1002/aic.11227
   Ozarkar SS, 2015, POWDER TECHNOL, V284, P159, DOI 10.1016/j.powtec.2015.06.028
   Ozel A, 2013, INT J MULTIPHAS FLOW, V55, P43, DOI 10.1016/j.ijmultiphaseflow.2013.04.002
   Ozel A., 2010, 7 INT C MULT FLOW IC
   Ozel A., 2013, 8 INT C MULT FLOW MA
   Ozel A, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.5000516
   Ozel A, 2016, CHEM ENG SCI, V155, P258, DOI 10.1016/j.ces.2016.08.014
   Pai S.-I., 1977, 2 PHASE FLOWS
   Paillusson F, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.208001
   Pandya RVR, 2002, INT J HEAT MASS TRAN, V45, P4753, DOI 10.1016/S0017-9310(02)00191-6
   Park GI, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.044301
   Parmentier J.-F., 2008, CIRCULATING FLUIDIZE, VIX
   Parmentier JF, 2012, AICHE J, V58, P1084, DOI 10.1002/aic.12647
   Passalacqua A, 2010, CHEM ENG SCI, V65, P2267, DOI 10.1016/j.ces.2009.09.002
   Passalacqua A, 2009, CHEM ENG SCI, V64, P2795, DOI 10.1016/j.ces.2009.03.005
   Passalacqua A, 2013, IND ENG CHEM RES, V52, P187, DOI 10.1021/ie300424m
   Patel RG, 2017, AICHE J, V63, P5396, DOI 10.1002/aic.15949
   Patil DJ, 2005, CHEM ENG SCI, V60, P57, DOI 10.1016/j.ces.2004.07.059
   Patil DJ, 2005, CHEM ENG SCI, V60, P73, DOI 10.1016/j.ces.2004.07.058
   Peirano E, 2001, CHEM ENG SCI, V56, P4787, DOI 10.1016/S0009-2509(01)00141-5
   Peirano E, 1998, PROG ENERG COMBUST, V24, P259, DOI 10.1016/S0360-1285(98)00002-1
   Peng C, 2018, POWDER TECHNOL, V326, P443, DOI 10.1016/j.powtec.2017.11.011
   Peng ZB, 2014, AICHE J, V60, P2000, DOI 10.1002/aic.14421
   Pinheiro CIC, 2012, IND ENG CHEM RES, V51, P1, DOI 10.1021/ie200743c
   PITA JA, 1991, AICHE J, V37, P1009, DOI 10.1002/aic.690370706
   PITA JA, 1993, AICHE J, V39, P541, DOI 10.1002/aic.690390402
   Polashenski W, 1997, POWDER TECHNOL, V90, P13, DOI 10.1016/S0032-5910(96)03191-9
   Polashenski W, 1999, IND ENG CHEM RES, V38, P705, DOI 10.1021/ie980354n
   Pope S. B., 2000, TURBULENT FLOWS
   Popoff B., 2007, INT C MULT FLOW LEIP
   Pozorski J, 2009, INT J MULTIPHAS FLOW, V35, P118, DOI 10.1016/j.ijmultiphaseflow.2008.10.005
   Prandtl L, 1925, Z ANGEW MATH MECH, V5, P136, DOI 10.1002/zamm.19250050212
   PRIGOGINE I, 1949, PHYSICA, V15, P272, DOI 10.1016/0031-8914(49)90056-7
   PRIGOGINE I, 1977, SELF ORG NONEQUILIBR
   PRIGOGINE I, 1967, INTRO THERMODYNAMICS
   Prosperetti A., 2006, MULTIPHASE SCI TECHN, V18, P135
   Prosperetti A., 1998, ENSEMBLE AVERAGING T, P99
   Qi H., 1997, THESIS
   Qi H., 2000, 7 CHIN JAP FLUID S, P231
   Qi HY, 2007, CHEM ENG SCI, V62, P1670, DOI 10.1016/j.ces.2005.07.002
   [漆小波 Qi Xiaobo], 2005, [四川大学学报. 工程科学版, Journal of Sichuan University. Engineering Science Edition], V37, P46
   Qin ZY, 2019, CHEM ENG SCI, V207, P358, DOI 10.1016/j.ces.2019.06.037
   Qin ZY, 2019, CAN J CHEM ENG, V97, P793, DOI 10.1002/cjce.23160
   Queteschiner D, 2018, POWDER TECHNOL, V338, P614, DOI 10.1016/j.powtec.2018.07.033
   Queteschiner D, 2018, PARTICUL SCI TECHNOL, V36, P517, DOI 10.1080/02726351.2017.1402836
   Radl S., 2012, EUR C COMP METH APPL
   Radl S, 2014, CHEM ENG SCI, V117, P416, DOI 10.1016/j.ces.2014.07.011
   Rahaman MF, 2003, POWDER TECHNOL, V138, P82, DOI 10.1016/j.powtec.2003.08.050
   Rahman K, 2002, J FLUID MECH, V455, P103, DOI 10.1017/S002211200100725X
   Rahmani M, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5010989
   Rao A, 2012, AICHE J, V58, P1381, DOI 10.1002/aic.12673
   Rao K., 2008, INTRO GRANULAR FLOW
   Ray B, 2011, J FLUID MECH, V680, P488, DOI 10.1017/jfm.2011.174
   Reddy BV, 2003, INT J ENERG RES, V27, P813, DOI 10.1002/er.911
   Reeks M.W., 2016, MULTIPHASE FLOW HDB, V144
   REEKS MW, 1991, PHYS FLUIDS A-FLUID, V3, P446, DOI 10.1063/1.858101
   REEKS MW, 1977, J FLUID MECH, V83, P529, DOI 10.1017/S0022112077001323
   Rericha EC, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.014302
   Reuge N, 2008, CHEM ENG SCI, V63, P5540, DOI 10.1016/j.ces.2008.07.028
   Riber E, 2009, J COMPUT PHYS, V228, P539, DOI 10.1016/j.jcp.2008.10.001
   Riber E, 2006, PROCEEDINGS OF THE ASME FLUIDS ENGINEERING DIVISION SUMMER CONFERENCE, VOL 1, PTS A AND B, P1663
   RICHARDSON JF, 1954, T I CHEM ENG-LOND, V32, P35, DOI DOI 10.1016/S0263-8762(97)80006-8
   RICHMAN MW, 1988, ACTA MECH, V75, P227, DOI 10.1007/BF01174637
   Riella M, 2018, INT J MULTIPHAS FLOW, V106, P95, DOI 10.1016/j.ijmultiphaseflow.2018.04.014
   ROGALLO RS, 1981, 81315 NASA
   Luna CMR, 2017, PARTICUOLOGY, V33, P129, DOI 10.1016/j.partic.2016.08.008
   Rong LW, 2014, CHEM ENG SCI, V116, P508, DOI 10.1016/j.ces.2014.05.025
   Rong LW, 2013, CHEM ENG SCI, V99, P44, DOI 10.1016/j.ces.2013.05.036
   Rowe PN, 1997, CHEM ENG RES DES, V75, pS116, DOI 10.1016/S0263-8762(97)80009-3
   Rubinstein GJ, 2017, J FLUID MECH, V833, P599, DOI 10.1017/jfm.2017.705
   Rubinstein GJ, 2016, J FLUID MECH, V788, P576, DOI 10.1017/jfm.2015.679
   Rudisuli M, 2012, POWDER TECHNOL, V217, P21, DOI 10.1016/j.powtec.2011.10.004
   Russell S. J., 2016, ARTIFICIAL INTELLIGE
   Rycroft CH, 2009, J MECH PHYS SOLIDS, V57, P828, DOI 10.1016/j.jmps.2009.01.009
   Sabat M, 2019, INT J MULTIPHAS FLOW, V112, P243, DOI 10.1016/j.ijmultiphaseflow.2018.10.004
   Sagaut P., 2006, LARGE EDDY SIMULATIO
   Sakai M, 2014, CHEM ENG J, V244, P33, DOI 10.1016/j.cej.2014.01.029
   Sakai M, 2012, CHEM ENG J, V200, P663, DOI 10.1016/j.cej.2012.06.080
   Sakai M, 2012, ADV POWDER TECHNOL, V23, P673, DOI 10.1016/j.apt.2011.08.006
   Sakai M, 2010, INT J NUMER METH FL, V64, P1319, DOI 10.1002/fld.2364
   Sakano M., 2000, JPN J MULTIPHASE FLO, V14, P66
   San O, 2018, J SCI COMPUT, V75, P1187, DOI 10.1007/s10915-017-0583-8
   Sande PC, 2014, POWDER TECHNOL, V264, P43, DOI 10.1016/j.powtec.2014.05.019
   Sande PC, 2016, IND ENG CHEM RES, V55, P2623, DOI 10.1021/acs.iecr.5b03565
   Sangani AS, 1996, J FLUID MECH, V313, P309, DOI 10.1017/S0022112096002224
   Sarkar A, 2016, CHEM ENG SCI, V152, P443, DOI 10.1016/j.ces.2016.06.023
   Sarkar A, 2014, CHEM ENG SCI, V114, P144, DOI 10.1016/j.ces.2014.04.018
   Sarkar A, 2013, CHEM ENG SCI, V104, P399, DOI 10.1016/j.ces.2013.08.050
   Sarkar S, 2009, PARTICUOLOGY, V7, P233, DOI 10.1016/j.partic.2009.02.002
   Sarkar S, 2009, CHEM ENG SCI, V64, P2683, DOI 10.1016/j.ces.2009.02.045
   Savage S.B., 1983, APPL MECH, V7, P261
   Savage SB, 1998, J FLUID MECH, V377, P1, DOI 10.1017/S0022112098002936
   SCHAEFFER DG, 1987, J DIFFER EQUATIONS, V66, P19, DOI 10.1016/0022-0396(87)90038-6
   Schneiderbauer S., 2014, J COMPUT MULTIPHASE, V6, P29, DOI DOI 10.1260/1757-482X.6.1.29
   Schneiderbauer S., 2012, P 9 INT C CFD MIN PR
   Schneiderbauer S., 2016, 9 INT C MULT FLOW FI
   Schneiderbauer S, 2019, INT J MULTIPHAS FLOW, V114, P287, DOI 10.1016/j.ijmultiphaseflow.2019.03.017
   Schneiderbauer S, 2018, AICHE J, V64, P1606, DOI 10.1002/aic.16141
   Schneiderbauer S, 2018, AICHE J, V64, P1591, DOI 10.1002/aic.16142
   Schneiderbauer S, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5017004
   Schneiderbauer S, 2017, AICHE J, V63, P3544, DOI 10.1002/aic.15684
   Schneiderbauer S, 2015, CHEM ENG J, V264, P99, DOI 10.1016/j.cej.2014.11.058
   Schneiderbauer S, 2014, AICHE J, V60, P839, DOI 10.1002/aic.14321
   Schneiderbauer S, 2013, AICHE J, V59, P4077, DOI 10.1002/aic.14155
   Schneiderbauer S, 2012, CHEM ENG SCI, V80, P279, DOI 10.1016/j.ces.2012.06.041
   Schneiderbauer S, 2012, INT J MULTIPHAS FLOW, V43, P149, DOI 10.1016/j.ijmultiphaseflow.2012.03.006
   Segre PN, 1997, PHYS REV LETT, V79, P2574, DOI 10.1103/PhysRevLett.79.2574
   Sela N, 1998, J FLUID MECH, V361, P41, DOI 10.1017/S0022112098008660
   Serero D, 2006, J FLUID MECH, V554, P237, DOI 10.1017/S0022112006009281
   Shaffer F, 2013, POWDER TECHNOL, V242, P86, DOI 10.1016/j.powtec.2013.01.012
   Shah K., 1995, ANN RES BRIEFS, P73
   Shah MT, 2016, CHEM ENG RES DES, V111, P403, DOI 10.1016/j.cherd.2016.04.017
   Shah MT, 2013, CHEM ENG SCI, V102, P365, DOI 10.1016/j.ces.2013.08.010
   Shah MT, 2011, CHEM ENG SCI, V66, P3291, DOI 10.1016/j.ces.2011.01.056
   Shah S, 2013, CHEM ENG SCI, V89, P206, DOI 10.1016/j.ces.2012.11.020
   Shah S, 2012, POWDER TECHNOL, V218, P131, DOI 10.1016/j.powtec.2011.11.053
   Shahnam M., 2016, J VERIF VALID UNCERT, V1
   Shaw RA, 2003, ANNU REV FLUID MECH, V35, P183, DOI 10.1146/annurev.fluid.35.101101.161125
   Sheikh B, 2018, COMPUT FLUIDS, V171, P15, DOI 10.1016/j.compfluid.2018.05.029
   Shi DM, 1998, CHEM ENG PROCESS, V37, P287, DOI 10.1016/S0255-2701(98)00039-7
   Shi ZS, 2011, CHEM ENG SCI, V66, P5541, DOI 10.1016/j.ces.2011.07.020
   SHIH YT, 1987, POWDER TECHNOL, V50, P201, DOI 10.1016/0032-5910(87)80065-7
   Shotorban B, 2007, INT J HEAT MASS TRAN, V50, P3728, DOI 10.1016/j.ijheatmasstransfer.2007.02.033
   Shotorban B, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2001691
   Shu Z, 2016, IND ENG CHEM RES, V55, P2634, DOI 10.1021/acs.iecr.5b04150
   Shu Z, 2015, POWDER TECHNOL, V281, P34, DOI 10.1016/j.powtec.2015.04.055
   Shu Z, 2014, IND ENG CHEM RES, V53, P9915, DOI 10.1021/ie500568d
   Shu Z, 2014, IND ENG CHEM RES, V53, P3378, DOI 10.1021/ie403496a
   Shuai W., 2014, POWDER TECHNOL, V254, P214, DOI DOI 10.1016/J.P0WTEC2013.12.036
   Shuyan W, 2009, POWDER TECHNOL, V196, P184, DOI 10.1016/j.powtec.2009.07.020
   SIMONIN O, 1993, APPL SCI RES, V51, P275, DOI 10.1007/BF01082549
   Simonin O., 1990, P 5 WORKSH 2 PHAS FL, P156
   Simonin O., 1996, COMBUSTION TURBULENC, V2, P1
   Simonin O., 1991, ASME FED, V121, P197
   Sinclair J., 1998, P ASME FLUIDS ENG DI, P21
   SINCLAIR JL, 1989, AICHE J, V35, P1473, DOI 10.1002/aic.690350908
   Smagorinsky J., 1963, MON WEATHER REV, V91, P99, DOI [10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)091, 10.1175/1520-0493(1963)091<less than>0099:GCEWTP<greater than>2.3.CO;2]
   SMITH TN, 1968, J FLUID MECH, V32, P203, DOI 10.1017/S0022112068000662
   Snider DM, 2001, J COMPUT PHYS, V170, P523, DOI 10.1006/jcph.2001.6747
   Soleimani A, 2015, PROCEDIA ENGINEER, V102, P1026, DOI 10.1016/j.proeng.2015.01.225
   Soleimani A, 2015, POWDER TECHNOL, V281, P28, DOI 10.1016/j.powtec.2015.04.067
   Soleimani A, 2015, INT J MULTIPHAS FLOW, V71, P94, DOI 10.1016/j.ijmultiphaseflow.2014.12.008
   Sommerfeld M, 1999, INT J MULTIPHAS FLOW, V25, P1457, DOI 10.1016/S0301-9322(99)00047-6
   SOMMERFELD M, 1992, INT J MULTIPHAS FLOW, V18, P905, DOI 10.1016/0301-9322(92)90067-Q
   Sommerfeld M., 2018, POW TECHNOL
   Song FF, 2014, CHEM ENG SCI, V120, P112, DOI 10.1016/j.ces.2014.08.057
   Songprawat S., 2009, THESIS
   Songprawat S, 2010, CHEM ENG SCI, V65, P1134, DOI 10.1016/j.ces.2009.09.068
   Soto R, 1999, PHYS REV LETT, V83, P5003, DOI 10.1103/PhysRevLett.83.5003
   SPEZIALE CG, 1985, J FLUID MECH, V156, P55, DOI 10.1017/S0022112085001987
   Srivastava A, 2003, POWDER TECHNOL, V129, P72, DOI 10.1016/S0032-5910(02)00132-8
   Srivastava A, 2002, POWDER TECHNOL, V124, P45, DOI 10.1016/S0032-5910(01)00471-5
   Stanly R, 2018, CHEM ENG SCI, V188, P132, DOI 10.1016/j.ces.2018.05.030
   STEWART HB, 1984, J COMPUT PHYS, V56, P363
   Stolz S, 1999, PHYS FLUIDS, V11, P1699, DOI 10.1063/1.869867
   Stolz S, 2001, PHYS FLUIDS, V13, P997, DOI 10.1063/1.1350896
   Stromgren T, 2012, POWDER TECHNOL, V224, P36, DOI 10.1016/j.powtec.2012.02.017
   Struchtrup H, 2005, INTER MEC M
   Su MZ, 2017, AICHE J, V63, P2588, DOI 10.1002/aic.15573
   SUBBARAO D, 1986, INT J HEAT MASS TRAN, V29, P487, DOI 10.1016/0017-9310(86)90217-6
   Subbarao D, 2010, POWDER TECHNOL, V199, P48, DOI 10.1016/j.powtec.2009.04.015
   Subramaniam S, 2013, PROG ENERG COMBUST, V39, P215, DOI 10.1016/j.pecs.2012.10.003
   Sun B, 1999, IND ENG CHEM RES, V38, P787, DOI 10.1021/ie9803669
   Sun Qiao-Qun, 2007, Journal of the Harbin Institute of Technology, V39, P114
   Sun QQ, 2005, FUEL, V84, P1739, DOI 10.1016/j.fuel.2004.09.026
   Sundaresan S, 2000, AICHE J, V46, P1102, DOI 10.1002/aic.690460602
   Sundaresan S, 2003, ANNU REV FLUID MECH, V35, P63, DOI 10.1146/annurev.fluid.35.101101.161151
   Sundaresan S., 2013, 14 INT C FLUID
   Sundaresan S, 2018, ANNU REV CHEM BIOMOL, V9, P61, DOI 10.1146/annurev-chembioeng-060817-084025
   Sutkar VS, 2013, CHEM ENG SCI, V104, P790, DOI 10.1016/j.ces.2013.10.005
   Syamlal M, 2003, AICHE J, V49, P2793, DOI 10.1002/aic.690491112
   Syamlal M, 2009, J PHYS CONF SER, V180, DOI 10.1088/1742-6596/180/1/012034
   Syamlal M., 1987, DERIVATION DRAG COEF
   Syamlal M., 2011, IGI GLOBAL
   Syamlal M., 1993, DOEMETC941004
   Syamlal M., 1989, AICHE S SER, V85, P22
   Syamlal M, 2011, CHEM ENG PROG, V107, P23
   T Makkawi Y, 2006, POWDER TECHNOL, V163, P69, DOI 10.1016/j.powtec.2006.01.020
   Tabib MV, 2011, CHEM ENG SCI, V66, P3071, DOI 10.1016/j.ces.2011.03.058
   Taghipour F, 2005, CHEM ENG SCI, V60, P6857, DOI 10.1016/j.ces.2005.05.044
   Takada S, 2018, PHYS REV E, V97, DOI 10.1103/PhysRevE.97.042902
   Takada S, 2016, PHYS REV E, V94, DOI 10.1103/PhysRevE.94.012906
   Takagi S, 2003, J COMPUT PHYS, V187, P371, DOI 10.1016/S0021-9991(03)00077-9
   Tambun R, 2012, J CHEM ENG JPN, V45, P279, DOI 10.1252/jcej.11we243
   Tan ML, 1998, PHYS REV LETT, V81, P3022, DOI 10.1103/PhysRevLett.81.3022
   Tanaka T, 1996, JSME INT J B-FLUID T, V39, P239, DOI 10.1299/jsmeb.39.239
   Tanaka T., 1995, ASME FED, V228, P297
   Tang GW, 2017, POWDER TECHNOL, V305, P662, DOI 10.1016/j.powtec.2016.09.082
   Tang GW, 2015, J THERM SCI ENG APPL, V7, DOI 10.1115/1.4029209
   Tang Y, 2015, AICHE J, V61, P688, DOI 10.1002/aic.14645
   Tang YL, 2016, AICHE J, V62, P1958, DOI 10.1002/aic.15197
   Tartan M, 2004, AICHE J, V50, P1760, DOI 10.1002/aic.10192
   Tavanashad V, 2019, ACTA MECH, V230, P469, DOI 10.1007/s00707-018-2267-3
   TAXMAN N, 1958, PHYS REV, V110, P1235, DOI 10.1103/PhysRev.110.1235
   TenCate A, 2006, INT J MULTIPHAS FLOW, V32, P106, DOI 10.1016/j.ijmultiphaseflow.2005.08.001
   Tennekes H., 1972, 1 COURSE TURBULENCE
   Tenneti S, 2011, INT J MULTIPHAS FLOW, V37, P1072, DOI 10.1016/j.ijmultiphaseflow.2011.05.010
   Tenneti S, 2010, POWDER TECHNOL, V203, P57, DOI 10.1016/j.powtec.2010.03.042
   Tenneti S, 2016, J FLUID MECH, V788, P695, DOI 10.1017/jfm.2015.693
   Tenneti S, 2014, ANNU REV FLUID MECH, V46, P199, DOI 10.1146/annurev-fluid-010313-141344
   Third JR, 2016, COMPUT PART MECH, V3, P373, DOI 10.1007/s40571-015-0086-z
   Tian P, 2015, ACS CATAL, V5, P1922, DOI 10.1021/acscatal.5b00007
   Tian YJ, 2017, CHEM ENG SCI, V171, P271, DOI 10.1016/j.ces.2017.05.037
   TOOMEY RD, 1952, CHEM ENG PROG, V48, P220
   Torrilhon M, 2016, ANNU REV FLUID MECH, V48, P429, DOI 10.1146/annurev-fluid-122414-034259
   Tran-Cong S, 2004, POWDER TECHNOL, V139, P21, DOI 10.1016/j.powtec.2003.10.002
   Truesdell C., 2012, RATIONAL THERMODYNAM
   TSINONTIDES SC, 1993, J FLUID MECH, V255, P237, DOI 10.1017/S0022112093002472
   Tsuji Y, 1998, POWDER TECHNOL, V95, P254, DOI 10.1016/S0032-5910(97)03349-4
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   TSUO YP, 1990, AICHE J, V36, P885, DOI 10.1002/aic.690360610
   Tu QY, 2018, POWDER TECHNOL, V323, P534, DOI 10.1016/j.powtec.2017.09.045
   Uddin MH, 2017, PARTICUOLOGY, V34, P61, DOI 10.1016/j.partic.2016.12.002
   Uhlmann M, 2005, J COMPUT PHYS, V209, P448, DOI 10.1016/j.jcp.2005.03.017
   Ullah A, 2015, POWDER TECHNOL, V281, P129, DOI 10.1016/j.powtec.2015.03.016
   Vaidheeswaran A, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.112301
   Valverde JM, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.051305
   Valverde JM, 2001, PHYS REV LETT, V86, P3020, DOI 10.1103/PhysRevLett.86.3020
   van Cittert PH, 1931, Z PHYS, V69, P298, DOI 10.1007/BF01391351
   Van den Akker H.E., 2015, ADV CHEM ENG, V46, P281, DOI DOI 10.1016/BS.ACHE.2015.10.010
   van der Hoef MA, 2008, ANNU REV FLUID MECH, V40, P47, DOI 10.1146/annurev.fluid.40.111406.102130
   van der Hoef M.A., 2006, ADV CHEM ENG, P65, DOI DOI 10.1016/S0065-2377(06)31002-2
   Van der Hoef MA, 2005, J FLUID MECH, V528, P233, DOI 10.1017/S0022112004003295
   van der Hoef MA, 2004, CHEM ENG SCI, V59, P5157, DOI 10.1016/j.ces.2004.07.013
   van Noije TPC, 1998, PHYSICA A, V251, P266, DOI 10.1016/S0378-4371(97)00610-9
   van Wachem B, 2008, AICHE J, V54, P9, DOI 10.1002/aic.11335
   van Wachem BGM, 2001, AICHE J, V47, P1292, DOI 10.1002/aic.690470607
   van Wachem BGM, 2001, AICHE J, V47, P1035, DOI 10.1002/aic.690470510
   Vejahati F, 2009, CAN J CHEM ENG, V87, P19, DOI 10.1002/cjce.20139
   Venier CM, 2018, CHEM ENG COMMUN, V205, P456, DOI 10.1080/00986445.2017.1403907
   Venier CM, 2016, COMPUT FLUIDS, V133, P151, DOI 10.1016/j.compfluid.2016.05.003
   Venkatasubramanian V, 2019, AICHE J, V65, P466, DOI 10.1002/aic.16489
   Vepsalainen A, 2014, CHEM ENG SCI, V106, P30, DOI 10.1016/j.ces.2013.11.042
   Verma V, 2017, POWDER TECHNOL, V316, P225, DOI 10.1016/j.powtec.2016.12.044
   Verma V, 2013, CHEM ENG SCI, V102, P227, DOI 10.1016/j.ces.2013.08.002
   Vescovi D, 2014, PHYS FLUIDS, V26, DOI 10.1063/1.4879267
   Vescovi D, 2016, SOFT MATTER, V12, P8616, DOI 10.1039/c6sm01444e
   Vie A, 2015, COMMUN COMPUT PHYS, V17, P1, DOI 10.4208/cicp.021213.140514a
   Wagner NJ, 2009, PHYS TODAY, V62, P27, DOI 10.1063/1.3248476
   Wang CX, 2020, PARTICUOLOGY, V48, P144, DOI 10.1016/j.partic.2018.12.003
   Wang HF, 2018, AICHE J, V64, P2364, DOI 10.1002/aic.16163
   Wang J., 2010, PARTICUOLOGY, V8, P96
   Wang JW, 2010, AIP CONF PROC, V1207, P766, DOI 10.1063/1.3366461
   Wang J, 2019, J FLUID MECH, V866, P776, DOI 10.1017/jfm.2019.156
   Wang JW, 2008, CHEM ENG SCI, V63, P3341, DOI 10.1016/j.ces.2008.03.041
   Wang JW, 2008, CHEM ENG SCI, V63, P2294, DOI 10.1016/j.ces.2008.01.021
   Wang JW, 2008, CHEM ENG SCI, V63, P1553, DOI 10.1016/j.ces.2007.11.023
   Wang JW, 2017, CHEM ENG SCI, V168, P11, DOI 10.1016/j.ces.2017.04.031
   Wang JW, 2016, AICHE J, V62, P2649, DOI 10.1002/aic.15244
   Wang JW, 2013, CHEM ENG SCI, V97, P264, DOI 10.1016/j.ces.2013.04.028
   Wang JW, 2013, CHEM-ING-TECH, V85, P290, DOI 10.1002/cite.201200101
   Wang JW, 2012, CHEM ENG SCI, V75, P349, DOI 10.1016/j.ces.2012.03.021
   Wang JW, 2011, CHEM ENG SCI, V66, P4229, DOI 10.1016/j.ces.2011.06.004
   Wang JW, 2010, CHEM ENG SCI, V65, P3772, DOI 10.1016/j.ces.2010.03.023
   Wang JW, 2010, IND ENG CHEM RES, V49, P5279, DOI 10.1021/ie901555p
   Wang JW, 2010, CHEM ENG SCI, V65, P2125, DOI 10.1016/j.ces.2009.12.004
   Wang JW, 2010, POWDER TECHNOL, V197, P241, DOI 10.1016/j.powtec.2009.09.022
   Wang JW, 2009, IND ENG CHEM RES, V48, P5567, DOI 10.1021/ie900247t
   Wang JW, 2009, CHEM ENG SCI, V64, P622, DOI 10.1016/j.ces.2008.09.028
   Wang JW, 2006, CHEM ENG SCI, V61, P2736, DOI 10.1016/j.ces.2005.11.050
   Wang LN, 2005, CHEM ENG COMMUN, V192, P1636, DOI 10.1080/009864490896223
   Wang M, 2019, CHEM ENG TECHNOL, V42, P932, DOI 10.1002/ceat.201800542
   Wang SA, 2015, FUEL, V139, P646, DOI 10.1016/j.fuel.2014.09.027
   Wang S, 2014, CHEM ENG SCI, V116, P773, DOI 10.1016/j.ces.2014.05.046
   Wang S, 2013, APPL MATH MODEL, V37, P8179, DOI 10.1016/j.apm.2013.02.033
   Wang S, 2012, POWDER TECHNOL, V225, P176, DOI 10.1016/j.powtec.2012.04.006
   Wang SA, 2011, POWDER TECHNOL, V208, P98, DOI 10.1016/j.powtec.2010.12.007
   Wang SA, 2011, CHEM ENG SCI, V66, P593, DOI 10.1016/j.ces.2010.10.039
   Wang SY, 2008, CHEM ENG SCI, V63, P4116, DOI 10.1016/j.ces.2008.05.021
   Wang SY, 2010, POWDER TECHNOL, V199, P238, DOI 10.1016/j.powtec.2010.01.012
   Wang SY, 2005, CHEM ENG J, V106, P197, DOI [10.1016/j.cej.2004.21.036, 10.1016/j.cej.2004.12.036]
   Wang YC, 2014, PARTICUOLOGY, V15, P151, DOI 10.1016/j.partic.2013.07.003
   Yin LJ, 2010, CHEM ENG SCI, V65, P2664, DOI 10.1016/j.ces.2009.12.043
   Zhou LX, 2004, ACTA MECH SINICA, V20, P447
   An XD, 2007, CHINA PART, V5, P305, DOI 10.1016/j.cpart.2007.07.001
   E W, 2007, COMMUN COMPUT PHYS, V2, P367
   Jiang XX, 2020, INT J MULTIPHAS FLOW, V122, DOI 10.1016/j.ijmultiphaseflow.2019.103126
   Wang SY, 2007, FOOD BIOPROD PROCESS, V85, P231, DOI 10.1205/fbp07003
   Wang S, 2018, POWDER TECHNOL, V338, P280, DOI 10.1016/j.powtec.2018.06.031
   Wang S, 2016, ADV POWDER TECHNOL, V27, P57, DOI 10.1016/j.apt.2015.10.015
   Wang S, 2016, POWDER TECHNOL, V289, P44, DOI 10.1016/j.powtec.2015.11.024
   Wang S, 2014, IND ENG CHEM RES, V53, P15776, DOI 10.1021/ie502412g
   Wang S, 2014, IND ENG CHEM RES, V53, P4182, DOI 10.1021/ie402787v
   Wang SY, 2017, PARTICUOLOGY, V31, P95, DOI 10.1016/j.partic.2016.05.013
   Wang SY, 2015, POWDER TECHNOL, V276, P1, DOI 10.1016/j.powtec.2015.02.009
   Wang W, 2004, CHINESE J CHEM ENG, V12, P335
   Wang W., 2015, ADV CHEM ENG, V47, P193
   Wang W, 2007, CHEM ENG SCI, V62, P208, DOI 10.1016/j.ces.2006.08.017
   Wang W, 2011, ADV CHEM ENG, V40, P1, DOI 10.1016/B978-0-12-387036-0.00005-0
   Wang W, 2010, INT J MULTIPHAS FLOW, V36, P109, DOI 10.1016/j.ijmultiphaseflow.2009.01.008
   Wang XY, 2010, POWDER TECHNOL, V199, P203, DOI 10.1016/j.powtec.2009.12.016
   Wang X, 2011, PARTICUOLOGY, V9, P288, DOI 10.1016/j.partic.2010.02.002
   Wang X, 2011, POWDER TECHNOL, V209, P112, DOI 10.1016/j.powtec.2011.02.018
   Wang XF, 2010, ENERG FUEL, V24, P1242, DOI 10.1021/ef901104g
   Wang XJ, 2013, ENERG FUEL, V27, P2173, DOI 10.1021/ef302075n
   [王晓赞 Wang Xiaozan], 2018, [过程工程学报, The Chinese Journal of Process Engineering], V18, P1187
   Watanabe T, 2015, J COMPUT PHYS, V294, P127, DOI 10.1016/j.jcp.2015.03.038
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   Werther J, 1994, AICHE S SER, V301, P31
   Wilcox D. C., 2006, TURBULENCE MODELING
   Wildman RD, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.064301
   WILHELM RH, 1948, CHEM ENG PROG, V44, P201
   Wiratni W, 2005, CAN J CHEM ENG, V83, P418
   WU RL, 1990, CHEM ENG SCI, V45, P3389, DOI 10.1016/0009-2509(90)87144-H
   Wylie JJ, 2003, J FLUID MECH, V480, P95, DOI 10.1017/S0022112002003531
   Wylie JJ, 2000, PHYS FLUIDS, V12, P964, DOI 10.1063/1.870351
   [肖海涛 Xiao Haitao], 2003, [化工学报, Journal of Chemical Industry and Engineering (China)], V54, P311
   Xie L, 2006, EUROPHYS LETT, V74, P268, DOI 10.1209/epl/i2005-10526-y
   Xie N, 2008, POWDER TECHNOL, V182, P1, DOI 10.1016/j.powtec.2007.07.005
   Xie N, 2008, POWDER TECHNOL, V182, P14, DOI 10.1016/j.powtec.2007.09.014
   Xing EP, 2016, ENGINEERING-PRC, V2, P179, DOI 10.1016/J.ENG.2016.02.008
   Xiong QG, 2012, CHEM ENG SCI, V71, P422, DOI 10.1016/j.ces.2011.10.059
   Xu BH, 1998, CHEM ENG SCI, V53, P2646
   Xu GW, 1998, CHEM ENG SCI, V53, P3335, DOI 10.1016/S0009-2509(98)00129-8
   Xu GW, 1998, J CHEM ENG JPN, V31, P236, DOI 10.1252/jcej.31.236
   Xu J., 2019, J ADV MANUF PROCESS, V1
   Xu M, 2007, CHEM ENG SCI, V62, P2302, DOI 10.1016/j.ces.2006.12.008
   Xu Y, 2006, PHYS FLUIDS, V18, DOI 10.1063/1.2180289
   Xu Y, 2010, FLOW TURBUL COMBUST, V85, P735, DOI 10.1007/s10494-010-9298-8
   Xu Y, 2007, PHYS FLUIDS, V19, DOI 10.1063/1.2756579
   Yan CY, 2010, CHEM ENG SCI, V65, P2707, DOI 10.1016/j.ces.2010.01.005
   Yan D, 2019, CHEM ENG SCI, V210, DOI 10.1016/j.ces.2019.115235
   Yan D, 2018, PARTICUOLOGY, V39, P40, DOI 10.1016/j.partic.2017.09.003
   Yang L, 2016, CHEM ENG SCI, V152, P767, DOI 10.1016/j.ces.2016.05.031
   Yang L, 2016, CHEM ENG SCI, V152, P783, DOI 10.1016/j.ces.2016.06.015
   Yang L, 2017, CHEM ENG SCI, V174, P238, DOI 10.1016/j.ces.2017.09.014
   Yang L, 2017, AICHE J, V63, P1853, DOI 10.1002/aic.15534
   Yang N, 2004, IND ENG CHEM RES, V43, P5548, DOI 10.1021/ie049773c
   Yang N, 2003, CHEM ENG J, V96, P71, DOI 10.1016/j.cej.2003.08.006
   Yang S, 2016, POWDER TECHNOL, V296, P37, DOI 10.1016/j.powtec.2015.09.026
   Yang S, 2015, CHEM ENG J, V259, P338, DOI 10.1016/j.cej.2014.07.055
   Yang TY, 2009, AICHE J, V55, P612, DOI 10.1002/aic.11758
   Yao XY, 2015, AICHE J, V61, P68, DOI 10.1002/aic.14635
   Yates J.G., 2016, FLUIDIZED BED REACTO
   Ye M, 2008, PARTICUOLOGY, V6, P540, DOI 10.1016/j.partic.2008.07.005
   Yerushalmi J., 1976, AICHE S SER, V74, P1
   Yin XL, 2009, AICHE J, V55, P1352, DOI 10.1002/aic.11800
   Yin XL, 2009, IND ENG CHEM RES, V48, P227, DOI 10.1021/ie800171p
   Yong Y, 2005, ACTA MECH SINICA-PRC, V21, P228, DOI 10.1007/s10409-005-0037-7
   Yu Z.Q., 2001, FLUIDIZATION ENG PRI
   Yuan C, 2011, J COMPUT PHYS, V230, P8216, DOI 10.1016/j.jcp.2011.07.020
   Yue YH, 2018, ACM T GRAPHIC, V37, DOI 10.1145/3272127.3275095
   Zaichik L. I., 2008, PARTICLES TURBULENT
   Zaidi AA, 2018, CHEM ENG RES DES, V132, P714, DOI 10.1016/j.cherd.2018.02.013
   Zaidi AA, 2014, ADV POWDER TECHNOL, V25, P1860, DOI 10.1016/j.apt.2014.07.019
   ZAMANKHAN P, 1995, PHYS REV E, V52, P4877, DOI 10.1103/PhysRevE.52.4877
   Zeneli M, 2015, CHEM ENG SCI, V138, P482, DOI 10.1016/j.ces.2015.08.008
   Zeng ZX, 2007, ACTA MECH SINICA-PRC, V23, P621, DOI 10.1007/s10409-007-0119-9
   Zeng ZX, 2012, APPL MECH MATER, V204-208, P4327, DOI 10.4028/www.scientific.net/AMM.204-208.4327
   Zeng ZX, 2006, POWDER TECHNOL, V162, P27, DOI 10.1016/j.powtec.2005.10.011
   Zhang DZ, 2002, INT J MULTIPHAS FLOW, V28, P805, DOI 10.1016/S0301-9322(02)00005-8
   Zhang DZ, 1997, INT J MULTIPHAS FLOW, V23, P425, DOI 10.1016/S0301-9322(96)00080-8
   Zhang DZ, 2001, POWDER TECHNOL, V116, P133, DOI 10.1016/S0032-5910(00)00387-9
   Zhang J, 2010, PROG THEOR PHYS SUPP, P16
   Zhang JY, 2005, CHEM ENG SCI, V60, P3091, DOI 10.1016/j.ces.2004.11.057
   Zhang N, 2010, CHEM ENG J, V162, P821, DOI 10.1016/j.cej.2010.06.033
   Zhang N, 2008, PARTICUOLOGY, V6, P529, DOI 10.1016/j.partic.2008.07.013
   Zhang Y., 2007, APT 2007 3 AS PART T, P392
   Zhang Y., 2013, INT J CHEM REACT ENG, V11, P1
   Zhang YF, 1996, AICHE J, V42, P1590, DOI 10.1002/aic.690420610
   Zhang YH, 2003, CHEM ENG SCI, V58, P1641, DOI 10.1016/S0009-2509(02)00659-0
   Zhang YH, 2001, INT J MULTIPHAS FLOW, V27, P1945, DOI 10.1016/S0301-9322(01)00039-8
   Zhang Y, 2019, RENEW ENERG, V136, P193, DOI 10.1016/j.renene.2018.12.121
   Zhang Y, 2017, CHEM ENG SCI, V160, P106, DOI 10.1016/j.ces.2016.11.028
   Zhang Y, 2011, PARTICUOLOGY, V9, P365, DOI 10.1016/j.partic.2011.03.004
   Zhang ZX, 2018, IEEE J SEL TOP QUANT, V24, DOI 10.1109/JSTQE.2017.2761126
   Zhao B., 2018, THESIS
   Zhao BD, 2019, CHEM ENG SCI, V197, P69, DOI 10.1016/j.ces.2018.11.054
   Zhao BD, 2018, CHEM ENG SCI, V177, P333, DOI 10.1016/j.ces.2017.11.047
   Zhao BD, 2017, CHEM ENG SCI, V172, P297, DOI 10.1016/j.ces.2017.06.039
   Zhao BD, 2016, CHEM ENG SCI, V156, P44, DOI 10.1016/j.ces.2016.09.012
   Zhao BD, 2015, CHEM ENG SCI, V134, P477, DOI 10.1016/j.ces.2015.05.032
   Zhao YH, 2016, IND ENG CHEM RES, V55, P1439, DOI 10.1021/acs.iecr.5b03792
   Zhao YH, 2014, AICHE J, V60, P4065, DOI 10.1002/aic.14596
   Zheng Y, 2001, CHEM ENG SCI, V56, P6813, DOI 10.1016/S0009-2509(01)00319-0
   Zhong WQ, 2016, CHEM ENG SCI, V140, P16, DOI 10.1016/j.ces.2015.09.035
   Zhou GF, 2014, CHEM ENG SCI, V116, P9, DOI 10.1016/j.ces.2014.04.025
   Zhou L.X., 2018, THEORY MODELING DISP
   Zhou LX, 2017, POWDER TECHNOL, V314, P253, DOI 10.1016/j.powtec.2016.07.021
   Zhou LX, 2014, PARTICUOLOGY, V16, P100, DOI 10.1016/j.partic.2013.06.007
   Zhou LX, 2011, SCI CHINA PHYS MECH, V54, P1296, DOI 10.1007/s11433-011-4322-0
   Zhou LX, 2011, SCI CHINA PHYS MECH, V54, P1098, DOI 10.1007/s11433-011-4323-z
   ZHOU LX, 1990, SCI CHINA SER A, V33, P52
   ZHOU LX, 2002, DYNAMICS MULTIPHASE
   Zhou Q., 2012, 9 INT C COMP FLUID D
   Zhou Q, 2015, THESIS
   Zhou Q, 2015, PHYS FLUIDS, V27, DOI 10.1063/1.4927552
   Zhou Q, 2016, INT J MINER PROCESS, V151, P40, DOI 10.1016/j.minpro.2016.04.005
   Zhou Q, 2015, CHEM ENG SCI, V122, P637, DOI 10.1016/j.ces.2014.10.025
   Zhou Q, 2014, POWDER TECHNOL, V253, P486, DOI 10.1016/j.powtec.2013.12.022
   Zhou Q, 2014, CHEM ENG SCI, V107, P206, DOI 10.1016/j.ces.2013.12.020
   Zhou T, 1999, POWDER TECHNOL, V101, P57, DOI 10.1016/S0032-5910(98)00148-X
   Zhou XY, 2013, PARTICUOLOGY, V11, P556, DOI 10.1016/j.partic.2012.08.006
   Zhou ZY, 2010, J FLUID MECH, V661, P482, DOI 10.1017/S002211201000306X
   Zhou ZD, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5049731
   Zhu HP, 2007, CHEM ENG SCI, V62, P3378, DOI 10.1016/j.ces.2006.12.089
   Zhu HP, 2008, CHEM ENG SCI, V63, P5728, DOI 10.1016/j.ces.2008.08.006
   Zhu HP, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.021302
   Zhu L.-T., 2019, CHEM ENG J
   Zhu LT, 2019, CHEM ENG SCI, V204, P228, DOI 10.1016/j.ces.2019.04.026
   Zhu LT, 2019, CHEM ENG SCI, V196, P478, DOI 10.1016/j.ces.2018.11.026
   Zhu LT, 2018, CHEM ENG SCI, V192, P759, DOI 10.1016/j.ces.2018.08.026
   Zhu LT, 2017, IND ENG CHEM RES, V56, P1090, DOI 10.1021/acs.iecr.6b04026
   Zhu LT, 2016, IND ENG CHEM RES, V55, P11887, DOI 10.1021/acs.iecr.6b02819
   Zhu LT, 2016, CHEM ENG SCI, V143, P369, DOI 10.1016/j.ces.2016.01.006
   Zimmermann S, 2005, IND ENG CHEM RES, V44, P9818, DOI 10.1021/ie050490+
   ZOU B, 1994, POWDER TECHNOL, V78, P173, DOI 10.1016/0032-5910(93)02786-A
   Zou Z, 2019, CHEM ENG SCI, V202, P157, DOI 10.1016/j.ces.2019.03.034
   Zou Z, 2013, IND ENG CHEM RES, V52, P11302, DOI 10.1021/ie303105v
NR 1135
TC 1
Z9 1
U1 10
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115428
DI 10.1016/j.ces.2019.115428
PG 92
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300009
DA 2020-05-12
ER

PT J
AU Wei, ZY
   Wang, YF
   Wu, ZW
   Peng, X
   Yu, GS
AF Wei, Zongyao
   Wang, Yifei
   Wu, Ziwei
   Peng, Xin
   Yu, Guangsuo
TI Wave characteristics of the falling liquid film in the development
   region at high Reynolds numbers
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Liquid falling film; Film thickness; Statistical property; Breakup
ID STATISTICAL CHARACTERISTICS; FLOW CHARACTERISTICS; MOMENTUM TRANSPORT;
   HEAT-TRANSFER; THIN; VELOCITY; HYDRODYNAMICS; SIMULATION; CONDENSATION;
   DYNAMICS
AB The wave characteristics of the turbulent falling liquid film in the development region along the vertical Perspex plate were studied by using an Ultrasonic Doppler Velocimetry (a non-intrusive technique). The instantaneous thickness of the falling film at the center of the plate with axial distance ranges from 50 mm to 1300 mm was measured and the Re! (the liquid film Reynolds number) ranges from 2.28 x 10(3) to 1.43 x 10(4). The results show that the mean thickness, wave frequency and amplitude increase while the growth rate decreases with the increase of Rel. The Probability Density Function of the liquid film instantaneous thickness tends to an approximately normal distribution with increasing Rel. Furthermore, the Plateau-Rayleigh instability can cause the breakup of the liquid film surface and resist the increase of the liquid film thickness, which results in the fluctuation range of the liquid film approximate to a fixed value when the Re-1 > 1.20 x 10(4). (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Wei, Zongyao; Wang, Yifei; Wu, Ziwei; Peng, Xin; Yu, Guangsuo] East China Univ Sci & Technol, Shanghai Engn Res Ctr Coal Gasificat, Inst Clean Coal Technol, Shanghai 200237, Peoples R China.
RP Wang, YF (reprint author), East China Univ Sci & Technol, Shanghai Engn Res Ctr Coal Gasificat, Inst Clean Coal Technol, Shanghai 200237, Peoples R China.
EM wangyf@ecust.edu.cn
FU National Key R&D Program of China [2017YFB0602601]; Shanghai Engineering
   Research Center of Coal Gasification [18DZ2283900]
FX This work was supported by the National Key R&D Program of China
   (2017YFB0602601), the Shanghai Engineering Research Center of Coal
   Gasification (18DZ2283900).
CR Adomeit P, 2000, INT J MULTIPHAS FLOW, V26, P1183, DOI 10.1016/S0301-9322(99)00079-8
   Aktershev SP, 2013, PROC IUTAM, V8, P3, DOI 10.1016/j.piutam.2013.04.002
   Aktershev SP, 2005, INT J HEAT MASS TRAN, V48, P1039, DOI 10.1016/j.ijheatmasstransfer.2004.09.045
   Alekseenko SV, 2007, EXP FLUIDS, V43, P197, DOI 10.1007/s00348-007-0322-2
   Ambrosini W, 2002, INT J MULTIPHAS FLOW, V28, P1521, DOI 10.1016/S0301-9322(02)00039-3
   CHU KJ, 1975, AICHE J, V21, P583, DOI 10.1002/aic.690210323
   Commenge JM, 2017, CHEM ENG PROCESS, V122, P44, DOI 10.1016/j.cep.2017.09.015
   Dai G.C., 2005, FLUID MECH CHEM ENG
   de Azevedo MB, 2017, INT J MULTIPHAS FLOW, V88, P133, DOI 10.1016/j.ijmultiphaseflow.2016.09.021
   Doro EO, 2013, J FLUID MECH, V726, P261, DOI 10.1017/jfm.2013.172
   Du WF, 2018, PROG NUCL ENERG, V105, P1, DOI 10.1016/j.pnucene.2017.12.007
   Eggers J, 1997, REV MOD PHYS, V69, P865, DOI 10.1103/RevModPhys.69.865
   Fischer S, 2008, FLOW MEAS INSTRUM, V19, P197, DOI 10.1016/j.flowmeasinst.2007.06.008
   Fu Q., 2015, ADV FLUID MECH
   Guzanov VV, 2018, INT J MULTIPHAS FLOW, V99, P474, DOI 10.1016/j.ijmultiphaseflow.2017.11.013
   Helbig K, 2005, FLOW TURBUL COMBUST, V75, P85, DOI 10.1007/s10494-005-8582-5
   Jaafar W, 2009, MEASUREMENT, V42, P175, DOI 10.1016/j.measurement.2008.05.004
   Jayakumar A, 2019, EXP THERM FLUID SCI, V109, DOI 10.1016/j.expthermflusci.2019.109906
   Jayanti S, 1997, INT J HEAT MASS TRAN, V40, P2445, DOI 10.1016/S0017-9310(96)00288-8
   Kalliadasis S, 2003, J FLUID MECH, V492, P303, DOI 10.1017/S0022112003005809
   KARAPANTSIOS TD, 1995, INT J MULTIPHAS FLOW, V21, P119, DOI 10.1016/0301-9322(94)00048-O
   Kostoglou M, 2010, AICHE J, V56, P11, DOI 10.1002/aic.11992
   Landel JR, 2015, FOOD BIOPROD PROCESS, V93, P310, DOI 10.1016/j.fbp.2014.09.009
   Li FC, 2004, FUSION ENG DES, V70, P185, DOI 10.1016/j.fusengdes.2003.11.004
   Li XS, 2019, P COMBUST INST, V37, P3287, DOI 10.1016/j.proci.2018.07.101
   Lin S, 2018, INT J HEAT MASS TRAN, V117, P465, DOI 10.1016/j.ijheatmasstransfer.2017.10.005
   Lu C., 2016, SCI TECHNOL NUCL INS, V2016, P1
   Mascarenhas N, 2013, INT J HEAT MASS TRAN, V64, P647, DOI 10.1016/j.ijheatmasstransfer.2013.04.061
   Mead-Hunter R, 2012, LANGMUIR, V28, P6731, DOI 10.1021/la300622h
   MUDAWAR I, 1993, INT J HEAT MASS TRAN, V36, P4151, DOI 10.1016/0017-9310(93)90077-J
   MUDAWAR I, 1993, INT J HEAT MASS TRAN, V36, P3437, DOI 10.1016/0017-9310(93)90162-Y
   Nusselt W, 1916, Z VER DTSCH ING, V60, P541
   Patnaik V, 1996, INT J HEAT FLUID FL, V17, P63, DOI 10.1016/0142-727X(95)00075-2
   Peng ZB, 2010, INT J MULTIPHAS FLOW, V36, P119, DOI 10.1016/j.ijmultiphaseflow.2009.03.013
   Plateau J., 1873, EXPT THEORETICAL STA, V1
   PORTALSKI S, 1972, CHEM ENG SCI, V27, P1257, DOI 10.1016/0009-2509(72)80102-7
   Rayleigh L., 1878, P LONDON MATH SOC
   Rob M., 1995, FLUID MECH, V301, P175
   SHEINTUCH M, 1989, AICHE J, V35, P177, DOI 10.1002/aic.690350202
   [宋建 Song Jian], 2012, [原子能科学技术, Atomic Energy Science and Technology], V46, P804
   Szulczewska B, 2003, CHEM ENG TECHNOL, V26, P580, DOI 10.1002/ceat.200390089
   TAKAHAMA H, 1980, INT J MULTIPHAS FLOW, V6, P203, DOI 10.1016/0301-9322(80)90011-7
   TELLES AS, 1970, IND ENG CHEM FUND, V9, P412, DOI 10.1021/i160035a018
   Trifonov Y, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4984005
   Valluri P, 2005, CHEM ENG SCI, V60, P1965, DOI 10.1016/j.ces.2004.12.008
   Yan LC, 2017, CHEM ENG RES DES, V117, P627, DOI 10.1016/j.cherd.2016.11.010
   Yu YQ, 2014, INT J HEAT MASS TRAN, V79, P561, DOI 10.1016/j.ijheatmasstransfer.2014.08.035
   Zhang YC, 2018, J FOOD ENG, V225, P26, DOI 10.1016/j.jfoodeng.2018.01.016
NR 48
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115454
DI 10.1016/j.ces.2019.115454
PG 14
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300038
DA 2020-05-12
ER

PT J
AU Yang, MM
   Lu, YY
   Ge, ZL
   Zhou, Z
   Chai, CJ
   Wang, HM
   Zhang, L
   Bo, T
AF Yang, Mengmeng
   Lu, Yiyu
   Ge, Zhaolong
   Zhou, Zhe
   Chai, Chengjuan
   Wang, Haoming
   Zhang, Liang
   Bo, Tao
TI Viscoelastic surfactant fracturing fluids for use in coal seams: Effects
   of surfactant composition and formulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fracturing fluid; Surfactant; Coal; Viscosity; Micelles
ID ADSORPTION; TEMPERATURE; MECHANISM
AB Recently, viscoelastic surfactant (VES) fracturing fluids have attracted wide attention because they are highly viscoelastic and environmentally benign. To optimize fracturing fluid formulations for coal reservoir conditions, 135 groups of VES fracturing fluids were prepared. The influence of the cationic surfactant's hydrocarbon chain lengths on water loss, wettability, viscosity, and temperature resistance were analyzed. To further improve the surfactant's aggregation capabilities, zwitterionic surfactants were added to fracturing fluids prepared with stearyl trimethyl ammonium chloride (STAC). We found that STAC can reduce water loss more effectively during fracturing than the cationic surfactant hexadecyl trimethyl ammonium chloride (CTAC). Appropriate amounts of cocoamidopropyl betaine (CAB) increased the viscosity and temperature resistance of the fracturing fluid. It is important to note that as the concentration of sodium salicylate (NaSal) increases, the maximum viscosity of VES fracturing fluid with CAB added is twice that of a fracturing fluid without CAB. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Mengmeng; Lu, Yiyu; Ge, Zhaolong; Zhou, Zhe; Chai, Chengjuan; Wang, Haoming; Zhang, Liang] Chongqing Univ, State Key Lab Coal Mine Disaster Dynam & Control, Chongqing 400044, Peoples R China.
   [Yang, Mengmeng; Lu, Yiyu; Ge, Zhaolong; Chai, Chengjuan; Wang, Haoming; Zhang, Liang] Chongqing Univ, Sch Resources & Safety Engn, Chongqing 400044, Peoples R China.
   [Zhou, Zhe] Chongqing Univ, Postdoctoral Stn Safety Sci & Engn, Chongqing 400044, Peoples R China.
   [Bo, Tao] South China Univ Technol, Sch Mech & Automot Engn, Guangzhou 510000, Peoples R China.
RP Zhou, Z (reprint author), Chongqing Univ, State Key Lab Coal Mine Disaster Dynam & Control, Chongqing 400044, Peoples R China.
EM yangmengmeng@cqu.edu.cn; luyiyu@cqu.edu.cn; zhouzhe@cqu.edu.cn
RI Zhang, Liang/AAJ-7537-2020
OI Zhang, Liang/0000-0002-4777-3970; Zhou, Zhe/0000-0002-7992-9722
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China [51774055, 51625401]; Graduate Research and
   Innovation Foundation of Chongqing, China [CYB18030]; Fundamental
   Research Funds for the Central UniversitiesFundamental Research Funds
   for the Central Universities [2018CDQYZH0030]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China
   [51804050]; State Key Laboratory Postdoctoral Science Foundation
   [2011DA105287-BH201908]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2019T120810]
FX This work was supported by National Natural Science Foundation of China
   (NSFC) [No. 51774055, 51625401]; Graduate Research and Innovation
   Foundation of Chongqing, China[Grant No. CYB18030]; Project No.
   2018CDQYZH0030 supported by the Fundamental Research Funds for the
   Central Universities; the National Natural Science Foundation of China
   [51804050]; the State Key Laboratory Postdoctoral Science Foundation
   [2011DA105287-BH201908] and the China Postdoctoral Science Foundation
   [2019T120810].
CR Ahmed HM, 2019, FUEL, V251, P187, DOI 10.1016/j.fuel.2019.04.038
   Ahn CH, 2014, J UNCONV OIL GAS RES, V8, P25, DOI 10.1016/j.juogr.2014.06.003
   Atkin R, 2003, ADV COLLOID INTERFAC, V103, P219, DOI 10.1016/S0001-8686(03)00002-2
   Barati R, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.40735
   Baruah A, 2016, J PETROL SCI ENG, V146, P340, DOI 10.1016/j.petrol.2016.05.001
   CATES ME, 1990, J PHYS-CONDENS MAT, V2, P6869, DOI 10.1088/0953-8984/2/33/001
   Chen ZR, 2012, J PETROL SCI ENG, V88-89, P136, DOI 10.1016/j.petrol.2011.12.021
   Danov KD, 2019, J COLLOID INTERF SCI, V547, P245, DOI 10.1016/j.jcis.2019.03.105
   GEERTSMA J, 1969, J PETROL TECHNOL, V21, P1571, DOI 10.2118/2458-PA
   Geng XF, 2014, COLLOID POLYM SCI, V292, P915, DOI 10.1007/s00396-013-3137-0
   Huang QM, 2019, FUEL, V251, P30, DOI 10.1016/j.fuel.2019.04.031
   Kahrilas GA, 2015, ENVIRON SCI TECHNOL, V49, P16, DOI 10.1021/es503724k
   Khair EMM, 2011, J PETROL SCI ENG, V78, P131, DOI 10.1016/j.petrol.2011.05.011
   KHATORY A, 1993, LANGMUIR, V9, P1456, DOI 10.1021/la00030a005
   Liu YL, 2019, FUEL, V239, P471, DOI 10.1016/j.fuel.2018.10.150
   Lu YY, 2019, J TAIWAN INST CHEM E, V97, P207, DOI 10.1016/j.jtice.2019.01.024
   Lu YY, 2017, FUEL, V194, P1, DOI 10.1016/j.fuel.2016.12.078
   Lu YY, 2015, J NAT GAS SCI ENG, V27, P1649, DOI 10.1016/j.jngse.2015.10.031
   Makhanov K, 2014, J UNCONV OIL GAS RES, V7, P22, DOI 10.1016/j.juogr.2014.04.001
   Mao JC, 2019, J TAIWAN INST CHEM E, V95, P424, DOI 10.1016/j.jtice.2018.08.016
   Mao JC, 2016, RSC ADV, V6, P88426, DOI 10.1039/c6ra17823e
   National Development and Reform Commision, 2005, REC PARCT MEAS PROP
   Ni GH, 2019, ADV POWDER TECHNOL, V30, P940, DOI 10.1016/j.apt.2019.02.008
   Ni GH, 2018, POWDER TECHNOL, V323, P60, DOI 10.1016/j.powtec.2017.09.044
   NORDGREN RP, 1972, SOC PETROL ENG J, V12, P306, DOI 10.2118/3009-PA
   Perkins TK, 1961, J PET TECHNOL, V13, P937, DOI DOI 10.2118/89-PA
   Sehgal P, 2008, J DISPER SCI TECHNOL, V29, P327, DOI 10.1080/01932690701716028
   Shao HB, 2015, GEOTHERMICS, V58, P22, DOI 10.1016/j.geothermics.2015.07.010
   Smilek J., 2019, POLYMERS, V11, P1
   Tang SF, 2018, ENERGIES, V11, DOI 10.3390/en11113182
   Wang J, 2017, J MOL LIQ, V241, P563, DOI 10.1016/j.molliq.2017.06.050
   Wei JJ, 2012, CAN J CHEM ENG, V90, P1304, DOI 10.1002/cjce.20622
   Yang XJ, 2019, ENERG SOURCE PART A, V41, P1446, DOI 10.1080/15567036.2018.1548520
   Yekeen N, 2018, J IND ENG CHEM, V66, P45, DOI 10.1016/j.jiec.2018.05.039
   Young T., 1956, PHILOS T R SOC LOND, V95, P65
   Zhao MW, 2019, CHEM ENG SCI, V206, P203, DOI 10.1016/j.ces.2019.05.033
NR 36
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115370
DI 10.1016/j.ces.2019.115370
PG 9
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300036
DA 2020-05-12
ER

PT J
AU Yang, SY
   Bao, SX
   Liu, C
   Yuan, DC
   Huang, W
AF Yang, Siyuan
   Bao, Shenxu
   Liu, Cheng
   Yuan, Dachao
   Huang, Wei
TI An analytical model of the growth of invisible bubbles on solid surfaces
   in a supersaturated solution
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Air bubble growth; Diffusion theory; Molecular-kinetic; Supersaturation
ID NANOBUBBLES; DYNAMICS; NUCLEATION; FLOTATION; WATER
AB Heterogeneous nucleation of gas bubbles is central to many engineering fields, from boiling and heat transfer to cavitation and particle separation. In this paper, models accounting for the origin and growth of gas bubbles on solid surfaces in a supersaturated solution are proposed by applying the diffusion theory and the molecular-kinetic model. Both are validated by the available experimental results during the specific period. The theory provides an explanation for the bubbles' growth from the pre-existing invisible nanobubbles on the submerged surface. The non-linear evolution of the bubble is attributed to the progression from the pinning stage to the floating stage, transition stage and expansion stage. In the pinning stage, when the base radius of the optically invisible surface bubbles is smaller than the critical value, they are speculated to be stable with the constant base radius because of the equilibrium between the driving force of diffusion and the Laplace pressure. Otherwise, the contact line of the surface bubble will start to move, is no longer pinned, and continues to grow with a constant bubble radius, which is called the floating stage. This is followed by the transition stage in which both the bubble radius and contact angle change with time. The final expansion stage is characterised by the bubble growth with the constant contact angle. Unlike the classical Epstein-Plesset model for bubble growth in the bulk, the diffusion theory can satisfactorily predict the growth of surface bubbles while the molecular-kinetic model can only fit the floating and expansion stages. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yang, Siyuan; Bao, Shenxu; Liu, Cheng; Yuan, Dachao] Wuhan Univ Technol, Sch Resources & Environm Engn, Wuhan 430070, Peoples R China.
   [Yang, Siyuan] State Key Lab Mineral Proc, Beijing 100160, Peoples R China.
   [Yang, Siyuan; Huang, Wei] Univ Queensland, Sch Chem Engn, Brisbane, Qld 4072, Australia.
   [Yang, Siyuan; Bao, Shenxu; Liu, Cheng] Wuhan Univ Technol, Hubei Key Lab Mineral Resources Proc & Environm, Luoshi Rd 122, Wuhan 430070, Hubei, Peoples R China.
RP Yuan, DC (reprint author), Wuhan Univ Technol, Sch Resources & Environm Engn, Wuhan 430070, Peoples R China.; Huang, W (reprint author), Univ Queensland, Sch Chem Engn, Brisbane, Qld 4072, Australia.
EM yuandachao@whut.edu.cn; w.huang@uq.edu.au
OI Huang, Wei/0000-0001-8482-1962; Yang, Siyuan/0000-0002-0481-9721
FU China Scholarship Council (CSC) of the Chinese Government; Open
   Foundation of State Key Laboratory of Mineral Processing
   [BGRIMM-KJSKL-2019-02]; University of Queensland (UQ)University of
   Queensland
FX The authors gratefully acknowledge the China Scholarship Council (CSC)
   of the Chinese Government and the University of Queensland (UQ) for the
   CSC-UQ scholarships for the first author (SY). This work is funded by
   the Open Foundation of State Key Laboratory of Mineral Processing (No.
   BGRIMM-KJSKL-2019-02).
CR An HJ, 2015, ACS NANO, V9, P7596, DOI 10.1021/acsnano.5b02915
   BLAKE TD, 1994, AICHE J, V40, P229, DOI 10.1002/aic.690400205
   Borkent BM, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.204502
   Borkent BM, 2009, PHYS FLUIDS, V21, DOI 10.1063/1.3249602
   BORUVKA L, 1977, J CHEM PHYS, V66, P5464, DOI 10.1063/1.433866
   Brennen CE, 2014, CAVITATION AND BUBBLE DYNAMICS, P1
   Brotchie A, 2011, SOFT MATTER, V7, P265, DOI 10.1039/c0sm00731e
   Cadogan SP, 2014, J CHEM ENG DATA, V59, P519, DOI 10.1021/je401008s
   Craig VSJ, 2011, SOFT MATTER, V7, P40, DOI 10.1039/c0sm00558d
   De Gennes P.-G., 2013, CAPILLARITY WETTING
   Deegan RD, 2000, PHYS REV E, V62, P756, DOI 10.1103/PhysRevE.62.756
   Ducker WA, 2009, LANGMUIR, V25, P8907, DOI 10.1021/la902011v
   EPSTEIN PS, 1950, J CHEM PHYS, V18, P1505, DOI 10.1063/1.1747520
   Frenkel I.A.I.I., 1955, KINETIC THEORY LIQUI
   German SR, 2014, ACS NANO, V8, P6193, DOI 10.1021/nn5016049
   Gong S, 2013, INT J HEAT MASS TRAN, V64, P122, DOI 10.1016/j.ijheatmasstransfer.2013.03.058
   Hain N, 2016, LANGMUIR, V32, P11155, DOI 10.1021/acs.langmuir.6b01662
   Huang ZQ, 2019, MINER ENG, V132, P22, DOI 10.1016/j.mineng.2018.11.055
   Ishida N, 2000, LANGMUIR, V16, P6377, DOI 10.1021/la000219r
   Jones SF, 1999, ADV COLLOID INTERFAC, V80, P27, DOI 10.1016/S0001-8686(98)00074-8
   Kuchma AE, 2009, COLLOID J+, V71, P520, DOI 10.1134/S1061933X09040140
   Li DQ, 1996, COLLOID SURFACE A, V116, P1, DOI 10.1016/0927-7757(96)03582-0
   Li J, 2014, LANGMUIR, V30, P4223, DOI 10.1021/la404658h
   Liu C, 2019, MINER ENG, V131, P385, DOI 10.1016/j.mineng.2018.11.045
   Lohse D, 2015, REV MOD PHYS, V87, P981, DOI 10.1103/RevModPhys.87.981
   Lohse D, 2015, PHYS REV E, V91, DOI 10.1103/PhysRevE.91.031003
   Lou ST, 2000, J VAC SCI TECHNOL B, V18, P2573, DOI 10.1116/1.1289925
   Masoud H, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.016301
   Nguyen TAH, 2012, CHEM ENG SCI, V69, P522, DOI 10.1016/j.ces.2011.11.009
   Petrov JG, 1999, LANGMUIR, V15, P3365, DOI 10.1021/la971012+
   PLESSET MS, 1977, ANNU REV FLUID MECH, V9, P145, DOI 10.1146/annurev.fl.09.010177.001045
   Popov YO, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.036313
   Scatena LF, 2001, SCIENCE, V292, P908, DOI 10.1126/science.1059514
   SCRIVEN LE, 1959, CHEM ENG SCI, V10, P1, DOI 10.1016/0009-2509(59)80019-1
   Sedev R, 2015, ADV COLLOID INTERFAC, V222, P661, DOI 10.1016/j.cis.2014.09.008
   Seo H, 2007, LANGMUIR, V23, P1623, DOI 10.1021/la062763r
   Weijs JH, 2013, PHYS REV LETT, V110, DOI 10.1103/PhysRevLett.110.054501
   Wu JY, 2015, SOFT MATTER, V11, P587, DOI 10.1039/c4sm02380c
   Xiao QX, 2017, LANGMUIR, V33, P8090, DOI 10.1021/acs.langmuir.7b01231
   Yang SJ, 2009, LANGMUIR, V25, P1466, DOI 10.1021/la8027513
   Yang SY, 2019, MINER ENG, V138, P31, DOI 10.1016/j.mineng.2019.04.027
   Zhang XH, 2007, PHYS REV LETT, V98, DOI 10.1103/PhysRevLett.98.136101
   Zhang XH, 2008, LANGMUIR, V24, P4756, DOI 10.1021/la703475q
   Zhang XH, 2013, LANGMUIR, V29, P1017, DOI 10.1021/la303837c
   Zhao BY, 2013, SOFT MATTER, V9, P8837, DOI 10.1039/c3sm50942g
   Zhou ZA, 2009, MINER ENG, V22, P419, DOI 10.1016/j.mineng.2008.12.010
NR 46
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 114968
DI 10.1016/j.ces.2019.05.004
PG 9
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300003
DA 2020-05-12
ER

PT J
AU Yu, HP
   Song, XY
   Luo, JH
   Zhao, GL
   Bao, B
   Peng, BL
   Zhao, SL
AF Yu, Hongping
   Song, Xianyu
   Luo, Jianhui
   Zhao, Guolin
   Bao, Bo
   Peng, Baoliang
   Zhao, Shuangliang
TI Microscopic insights into the intensification effect of shear fields on
   molecular transport across interfaces
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Solute transport; Interface; Shear field; Surfactant; Dissipative
   Particle Dynamics
ID DISSIPATIVE PARTICLE DYNAMICS; MASS-TRANSFER; SINGLE-DROP; WATER/HEXANE
   INTERFACE; PHOSPHOLIPID-BILAYERS; SURFACTANT MIXTURES;
   PHYSICAL-PROPERTIES; DMSO TRANSPORT; SIMULATION; HYDRODYNAMICS
AB Shear field is widely applied to intensify interfacial molecular transport in many chemical engineering processes, and the intensification effect is generally ascribed to the significant increase of contact area between two immiscible liquid phases. Herein, by investigating molecular transport across waterbenzene interfaces under different shear fields as a representative study, we show that the interfacial molecular transport per unit area of the interface can be also enhanced by shear field when surfactants are introduced. The microscopic mechanism towards the latter effect is extensively explored by means of Dissipative Particle Dynamics simulation at various shear rates (0-0.3 ps(-1)) and surfactant volume fractions (0-7.1%), and we find that shear flows inhibit the accumulation of surfactants at the interface, and align the remained surfactants along the direction of mass transport, thus enhancing the molecular transfer across the interface. This work provides a microscopic insight into the regulation of interfacial transport with shear flow. (C) 2019 Published by Elsevier Ltd.
C1 [Yu, Hongping; Song, Xianyu; Luo, Jianhui; Zhao, Guolin; Bao, Bo; Zhao, Shuangliang] East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.
   [Yu, Hongping; Song, Xianyu; Luo, Jianhui; Zhao, Guolin; Bao, Bo; Zhao, Shuangliang] East China Univ Sci & Technol, Sch Chem Engn, Shanghai 200237, Peoples R China.
   [Luo, Jianhui; Peng, Baoliang] PetroChina, RIPED, Beijing 100083, Peoples R China.
   [Luo, Jianhui; Peng, Baoliang] CNPC, KLNC, Beijing 100083, Peoples R China.
RP Bao, B; Peng, BL (reprint author), East China Univ Sci & Technol, State Key Lab Chem Engn, Shanghai 200237, Peoples R China.; Bao, B; Peng, BL (reprint author), East China Univ Sci & Technol, Sch Chem Engn, Shanghai 200237, Peoples R China.
EM bbao@ecust.edu.cn; pengbl@petrochina.com.cn
RI Peng, Baoliang/AAL-6277-2020; Zhao, Shuangliang/B-6139-2017
OI Song, Xianyu/0000-0002-5572-9152; Zhao, Shuangliang/0000-0002-9547-4860
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21808056, 21878078]; Shanghai Science and
   Technology Innovation Action Plan [18160743700]; PetroChina Scientific
   Research and Technology Development Project [2018A-0907]
FX This work is supported by National Natural Science Foundation of China
   (Nos. 21808056, 21878078), by the Shanghai Science and Technology
   Innovation Action Plan (18160743700), and by PetroChina Scientific
   Research and Technology Development Project (2018A-0907).
CR [Anonymous], 2001, MAT STUD ACC
   Ashrafizadeh SN, 2008, IND ENG CHEM RES, V47, P7242, DOI 10.1021/ie0715557
   Baier G, 2000, AICHE J, V46, P2395, DOI 10.1002/aic.690461208
   Chakravorty A, 2018, CHEM ENG PROCESS, V133, P90, DOI 10.1016/j.cep.2018.09.017
   Chen LH, 2000, AICHE J, V46, P160, DOI 10.1002/aic.690460118
   Chen S, 2004, J NON-NEWTON FLUID, V118, P65, DOI 10.1016/j.jnnfm.2004.02.005
   Commenge JM, 2014, CHEM ENG PROCESS, V84, P109, DOI 10.1016/j.cep.2014.03.001
   Cussler E. L., 2009, DIFFUSION MASS TRANS
   D'Aubeterre A, 2005, INT COMMUN HEAT MASS, V32, P677, DOI 10.1016/j.icheatmasstransfer.2004.06.012
   Dashliborun AM, 2017, AICHE J, V63, P283, DOI 10.1002/aic.15549
   Dungan SR, 2003, COLLOID SURFACE A, V216, P149, DOI 10.1016/S0927-7757(02)00549-6
   Ertl G, 2008, ANGEW CHEM INT EDIT, V47, P3524, DOI 10.1002/anie.200800480
   ESPANOL P, 1995, EUROPHYS LETT, V30, P191, DOI 10.1209/0295-5075/30/4/001
   Espanol P, 2017, J CHEM PHYS, V146, DOI 10.1063/1.4979514
   Ginzburg VV, 2011, J PHYS CHEM B, V115, P4654, DOI 10.1021/jp109234u
   Gong XC, 2008, CHINESE J CHEM ENG, V16, P876, DOI 10.1016/S1004-9541(09)60009-4
   Groot RD, 1997, J CHEM PHYS, V107, P4423, DOI 10.1063/1.474784
   Gupta A, 2008, J CHEM PHYS, V128, DOI 10.1063/1.2939123
   Hickey RJ, 2016, SOFT MATTER, V12, P53, DOI 10.1039/c5sm02009c
   HOOGERBRUGGE PJ, 1992, EUROPHYS LETT, V19, P155, DOI 10.1209/0295-5075/19/3/001
   Hu YX, 2017, AICHE J, V63, P2464, DOI 10.1002/aic.15636
   Hu YX, 2010, LANGMUIR, V26, P10693, DOI 10.1021/la101025h
   Hu YF, 2015, CHEM ENG SCI, V134, P813, DOI 10.1016/j.ces.2015.05.068
   Hu YF, 2013, IND ENG CHEM RES, V52, P6550, DOI 10.1021/ie303006d
   Ji T, 2016, J MATER CHEM A, V4, P6290, DOI 10.1039/c6ta01247g
   Jia XW, 2015, CHINESE J CHEM ENG, V23, P476, DOI 10.1016/j.cjche.2014.11.027
   KARR AE, 1959, AICHE J, V5, P446, DOI 10.1002/aic.690050410
   Knopf FC, 2006, AICHE J, V52, P1103, DOI 10.1002/aic.10698
   LARSON RG, 1992, J CHEM PHYS, V96, P7904, DOI 10.1063/1.462343
   Lewis WK, 1924, IND ENG CHEM, V16, P1215, DOI 10.1021/ie50180a002
   Li GL, 2018, CHEM ENG SCI, V192, P665, DOI 10.1016/j.ces.2018.08.025
   Li H, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8080589
   Li SW, 2012, IND ENG CHEM RES, V51, P11245, DOI 10.1021/ie300821t
   Luo JH, 2018, ANGEW CHEM INT EDIT, V57, P11752, DOI 10.1002/anie.201807372
   Luo M, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/37/375109
   Orhan R, 2016, CHEM ENG RES DES, V109, P477, DOI 10.1016/j.cherd.2016.02.030
   Paul N, 2015, AICHE J, V61, P1092, DOI 10.1002/aic.14699
   Paula S, 1996, BIOPHYS J, V70, P339, DOI 10.1016/S0006-3495(96)79575-9
   Paula S, 1998, BIOPHYS J, V74, P319, DOI 10.1016/S0006-3495(98)77789-6
   Peng BL, 2017, RSC ADV, V7, P32246, DOI 10.1039/c7ra05592g
   Piemonte V, 2013, SUSTAINABLE DEVELOPMENT IN CHEMICAL ENGINEERING: INNOVATIVE TECHNOLOGIES, P1, DOI 10.1002/9781118629703
   Ramezani M, 2017, CHEM ENG J, V319, P288, DOI 10.1016/j.cej.2017.03.005
   Rekvig L, 2003, LANGMUIR, V19, P8195, DOI 10.1021/la0346346
   Ruiz-Morales Y, 2015, ENERG FUEL, V29, P1597, DOI 10.1021/ef502766v
   Saien J, 2006, IND ENG CHEM RES, V45, P1434, DOI 10.1021/ie0508379
   Saien J, 2011, IND ENG CHEM RES, V50, P6925, DOI 10.1021/ie1022783
   Scott K, 2018, RENEW SUST ENERG REV, V81, P1406, DOI 10.1016/j.rser.2017.05.189
   Seader J.D., 2011, SEPARATION PROCESS P
   Sepehri A, 2019, APPL WATER SCI, V9, DOI 10.1007/s13201-019-1017-6
   Sepehri A, 2018, CHEM ENG PROCESS, V128, P10, DOI 10.1016/j.cep.2018.04.006
   Shevchenko EA, 2019, CHEM ENG SCI, V195, P301, DOI 10.1016/j.ces.2018.09.018
   Shi KH, 2015, CHEM ENG SCI, V122, P185, DOI 10.1016/j.ces.2014.09.030
   Song XY, 2018, CHEM ENG SCI, V189, P75, DOI 10.1016/j.ces.2018.05.023
   Song XY, 2016, IND ENG CHEM RES, V55, P9077, DOI 10.1021/acs.iecr.6b02400
   Tang WQ, 2018, J POWER SOURCES, V384, P249, DOI 10.1016/j.jpowsour.2018.02.088
   Tang YH, 2015, J MEMBRANE SCI, V474, P196, DOI 10.1016/j.memsci.2014.09.034
   van Delden ML, 2004, J CHEM ENG DATA, V49, P1760, DOI 10.1021/je049797q
   Van Gerven T, 2009, IND ENG CHEM RES, V48, P2465, DOI 10.1021/ie801501y
   Wardle KE, 2011, SEP SCI TECHNOL, V46, P2409, DOI 10.1080/01496395.2011.600748
   Wardle KE, 2009, SEPAR SCI TECHNOL, V44, P517, DOI 10.1080/01496390802634398
   Wegener M, 2007, CHEM ENG SCI, V62, P2967, DOI 10.1016/j.ces.2007.03.003
   Wegener M, 2009, INT J HEAT MASS TRAN, V52, P2673, DOI 10.1016/j.ijheatmasstransfer.2009.01.005
   Wyatt NB, 2013, AICHE J, V59, P2219, DOI 10.1002/aic.14109
   Xu Y, 2013, APPL MECH MATER, V321-324, P799, DOI 10.4028/www.scientific.net/AMM.321-324.799
   Yong NA, 2011, LANGMUIR, V27, P2420, DOI 10.1021/la103550v
   Zhao GL, 2019, J PHYS CHEM C, V123, P12818, DOI 10.1021/acs.jpcc.9b01876
   Zhao GL, 2018, LANGMUIR, V34, P15587, DOI 10.1021/acs.langmuir.8b02892
   Zhao SL, 2016, LANGMUIR, V32, P12975, DOI 10.1021/acs.langmuir.6b03046
   Zheng HD, 2014, CHEM ENG SCI, V111, P278, DOI 10.1016/j.ces.2014.02.015
   Zheng WZ, 2018, AICHE J, V64, P950, DOI 10.1002/aic.15984
   Zhou WJ, 2014, J AM CHEM SOC, V136, P4869, DOI 10.1021/ja501019n
NR 71
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115381
DI 10.1016/j.ces.2019.115381
PG 9
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300024
DA 2020-05-12
ER

PT J
AU Yue, XJ
   Li, WY
   Li, ZD
   Qiu, FX
   Pan, JM
   Zhang, T
AF Yue, Xuejie
   Li, Woyuan
   Li, Zhangdi
   Qiu, Fengxian
   Pan, Jianming
   Zhang, Tao
TI Laminated superwetting aerogel/membrane composite with large pore sizes
   for efficient separation of surfactant-stabilized water-in-oil emulsions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Aerogel; Membrane; Water-in-oil emulsions; Superwetting; Cellulose
ID WASTE PAPER; AEROGELS; ABSORPTION; MEMBRANES; LAYER
AB Although superwetting filtration membranes have been widely used, they suffer from the disadvantages of low flux and membrane fouling caused by the nanoscale pore size. Herein, a laminated cellulose aerogel/membrane composite with large pore size is fabricated via combining facile freeze-drying and hydrophobic modification using cellulose fibers as building blocks. An ultrathin silanization coating layer on cellulose fibers surface is constructed via directly coupling alkoxysilane and endows the composite with excellent superhydrophobicity (161 degrees) and superoleophilicity (0 degrees). Upon contact with a water-in-oil emulsion, the aerogel layer causes the micrometer-sized water droplets to coalesce. The coalesced water droplets are then repelled by the membrane layer with large pore size, achieving ultrafast gravity-driven separation with high separation efficiency (99.5%) and separation flux (12890 L m(-2) h(-1)). Moreover, the composite exhibits ease to cycle and good usability. The outstanding performance of composite highlights its potential applications in the field of oil related industry. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Yue, Xuejie; Li, Woyuan; Li, Zhangdi; Qiu, Fengxian; Pan, Jianming; Zhang, Tao] Jiangsu Univ, Sch Chem & Chem Engn, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Pan, Jianming; Zhang, Tao] Jiangsu Univ, Sch Chem & Chem Engn, Inst Green Chem & Chem Technol, Zhenjiang 212013, Jiangsu, Peoples R China.
RP Zhang, T (reprint author), Jiangsu Univ, Sch Chem & Chem Engn, Zhenjiang 212013, Jiangsu, Peoples R China.
EM zhangtaochem@163.com
OI Zhang, Tao/0000-0001-9255-9802
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21706100, 21878132, 21822807]; Key Laboratory of
   Pollution Control and Resource Reuse Foundation [PCRRF18003]; Natural
   Science Foundation of Hebei ProvinceNatural Science Foundation of Hebei
   Province [B2019108017]; Society Development Fund of Zhenjiang
   [SH2018009]
FX This work was financially supported by the National Natural Science
   Foundation of China (21706100, 21878132 and 21822807), Key Laboratory of
   Pollution Control and Resource Reuse Foundation (NO. PCRRF18003),
   Natural Science Foundation of Hebei Province (B2019108017), and Society
   Development Fund of Zhenjiang (SH2018009).
CR Agarwal S, 2013, IND ENG CHEM RES, V52, P13164, DOI 10.1021/ie4018995
   Cai YH, 2016, J MATER CHEM A, V4, P18815, DOI 10.1039/c6ta08168a
   Chakrabarty B, 2008, J MEMBRANE SCI, V325, P427, DOI 10.1016/j.memsci.2008.08.007
   Che HL, 2015, ANGEW CHEM INT EDIT, V54, P8934, DOI 10.1002/anie.201501034
   Chen CL, 2019, ACS APPL MATER INTER, V11, P11006, DOI 10.1021/acsami.9b01293
   Guo HS, 2019, ACS APPL MATER INTER, V11, P13704, DOI 10.1021/acsami.9b01108
   Li LX, 2017, J MATER CHEM A, V5, P14858, DOI 10.1039/c7ta03511j
   Li ZD, 2020, J CLEAN PROD, V251, DOI 10.1016/j.jclepro.2019.119609
   Li ZD, 2020, SCI TOTAL ENVIRON, V703, DOI 10.1016/j.scitotenv.2019.135032
   Qiu ZW, 2020, WATER RES, V168, DOI 10.1016/j.watres.2019.115147
   Shi Z, 2013, ADV MATER, V25, P2422, DOI 10.1002/adma.201204873
   Si Y, 2015, ACS NANO, V9, P3791, DOI 10.1021/nn506633b
   Wang Z., 2017, ANGEW CHEM INT EDIT, V129, P13072
   Wang ZD, 2017, J MATER CHEM A, V5, P5895, DOI 10.1039/c6ta10248d
   Wang ZJ, 2016, ANGEW CHEM INT EDIT, V55, P14610, DOI 10.1002/anie.201607581
   Wang ZJ, 2016, ANGEW CHEM INT EDIT, V55, P1291, DOI 10.1002/anie.201507451
   Yue XJ, 2019, J CLEAN PROD, V230, P966, DOI 10.1016/j.jclepro.2019.05.141
   Yue XJ, 2019, CHEM ENG SCI, V203, P237, DOI 10.1016/j.ces.2019.03.081
   Yue XJ, 2018, J CLEAN PROD, V199, P411, DOI 10.1016/j.jclepro.2018.07.181
   Zeng XJ, 2017, ACS NANO, V11, P760, DOI 10.1021/acsnano.6b07182
   Zhang F, 2013, ADV MATER, V25, P4192, DOI 10.1002/adma.201301480
   Zhang T, 2019, FOOD BIOPROD PROCESS, V114, P154, DOI 10.1016/j.fbp.2018.12.007
   Zhang T, 2017, CHEM ENG J, V309, P7, DOI 10.1016/j.cej.2016.08.085
   Zhang YG, 2018, ACS APPL MATER INTER, V10, P13019, DOI 10.1021/acsami.8b02081
NR 24
TC 0
Z9 0
U1 12
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115450
DI 10.1016/j.ces.2019.115450
PG 9
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300021
DA 2020-05-12
ER

PT J
AU Zhang, W
   Wang, JF
   Li, B
   Liu, HL
   Mulbah, C
   Wang, DB
   Yongphet, P
AF Zhang, Wei
   Wang, Junfeng
   Li, Bin
   Liu, Hailong
   Mulbah, Christian
   Wang, Dongbao
   Yongphet, Piyaphong
TI EHD effects on periodic bubble formation and coalescence in ethanol
   under non-uniform electric field
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Electrohydrodynamics (EHD); Bubble formation; Electrical Bond number
   (Bo(E)); Weber number (We); Bubble coalescence
ID HEAT-TRANSFER; GROWTH; DETACHMENT; BEHAVIOR; GAS; ORIFICE; FLOW;
   VISUALIZATION; PERFORMANCE; CONVECTION
AB This paper focus on the effects of electrohydrodynamic (EHD) on bubble dynamic characteristics generated on a submerged capillary in ethanol under non-uniform electric field, using high-speed photography and with a particular interest in the effect of electrical Bond number (Bo(E)) on the bubble behaviors. The obtained results ranges of Bo(E) from zero to 5.52 and Weber number (We) from 0.0006 to 0.1365 show that the bubble formation process associated with three stages at the low electric field strengths, including the nucleation, stable growth and necking stages, while the stable growth stage is absent for the high field strengths. With the increase of both We and Bo(E), the bubble period and waiting times are shortened rapidly, while the frequency is accelerated remarkably. The bubble dynamic behavior, which is characterized by the bubble volume and curvature radius, depends primarily on the Bo(E), and the increase in the We slightly raises the bubble volume and curvature radius at the departure time. Furthermore, it is found that with the increasing of Bo(E), bubbles coalescence evidenced at high We is weakened and eventually disappeared. Nevertheless, this phenomenon has the tendency to subsequently reappear at the higher We and Bo(E). (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhang, Wei; Wang, Junfeng; Li, Bin; Liu, Hailong; Mulbah, Christian; Wang, Dongbao; Yongphet, Piyaphong] Jiangsu Univ, Sch Energy & Power Engn, Zhenjiang 212013, Peoples R China.
RP Wang, JF (reprint author), Jiangsu Univ, Sch Energy & Power Engn, Zhenjiang 212013, Peoples R China.
EM wangjunfeng@ujs.edu.cn
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [51761145011, 51876086]; Postgraduate Research & Practice
   Innovation Program of Jiangsu Province [KYCX19_1599]
FX The authors are grateful for the financial support from the Natural
   Science Foundation of China under Grant No. 51761145011 and No.
   51876086, and Postgraduate Research & Practice Innovation Program of
   Jiangsu Province under Grant No. KYCX19_1599.
CR Cattide A., 2007, 25 NAT C UIT HEAT TR
   Chen F, 2007, EXP THERM FLUID SCI, V32, P174, DOI 10.1016/j.expthermflusci.2007.03.006
   Cho HJ, 1996, INT J MULTIPHAS FLOW, V22, P909, DOI 10.1016/0301-9322(96)00024-9
   Cui HP, 2001, POWDER TECHNOL, V120, P12, DOI 10.1016/S0032-5910(01)00341-2
   Di Bari S, 2013, INT J HEAT MASS TRAN, V64, P468, DOI 10.1016/j.ijheatmasstransfer.2013.04.002
   Di Bari S, 2013, EXP THERM FLUID SCI, V44, P114, DOI 10.1016/j.expthermflusci.2012.06.004
   Di Marco P, 2003, INT J MULTIPHAS FLOW, V29, P559, DOI 10.1016/S0301-9322(03)00030-2
   Di Marco P, 2002, INT J THERM SCI, V41, P567, DOI 10.1016/S1290-0729(02)01351-0
   Di Marco P, 2009, HEAT MASS TRANSFER, V45, P959, DOI 10.1007/s00231-007-0328-6
   Di Marco P, 2013, EXP THERM FLUID SCI, V49, P160, DOI 10.1016/j.expthermflusci.2013.04.015
   Di Marco P, 2012, MICROGRAVITY SCI TEC, V24, P215, DOI 10.1007/s12217-012-9312-y
   Diao YH, 2014, INT J HEAT MASS TRAN, V78, P371, DOI 10.1016/j.ijheatmasstransfer.2014.07.004
   Dong W, 2006, EXP THERM FLUID SCI, V30, P579, DOI 10.1016/j.expthermflusci.2005.12.003
   Elcock D, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3662436
   Feng JJ, 2016, CHEM ENG SCI, V141, P261, DOI 10.1016/j.ces.2015.11.014
   Gao M, 2013, INT J HEAT MASS TRAN, V67, P984, DOI 10.1016/j.ijheatmasstransfer.2013.08.098
   Garstecki P, 2004, APPL PHYS LETT, V85, P2649, DOI 10.1063/1.1796526
   Georgoulas A, 2015, INT J MULTIPHAS FLOW, V74, P59, DOI 10.1016/j.ijmultiphaseflow.2015.04.008
   Hassen W, 2017, NUMER HEAT TR A-APPL, V71, P789, DOI 10.1080/10407782.2017.1308725
   Hepworth NJ, 2003, CHEM ENG SCI, V58, P4071, DOI 10.1016/S0009-2509(03)00266-5
   Herman C, 2002, EXP FLUIDS, V32, P396, DOI [10.1007/s003480100366, 10.1007/S003480100366]
   Hijano AJ, 2015, PHYS REV E, V91, DOI 10.1103/PhysRevE.91.013011
   Iacona E, 2006, EXP THERM FLUID SCI, V31, P121, DOI 10.1016/j.expthermflusci.2006.03.029
   Kweon YC, 1998, INT J MULTIPHAS FLOW, V24, P145, DOI 10.1016/S0301-9322(97)00044-X
   Kweon YC, 2000, INT J MULTIPHAS FLOW, V26, P1351, DOI 10.1016/S0301-9322(99)00090-7
   Landau B.L.D., 1984, ELECTRODYNAMICS CONT, V8
   Liao C, 2016, COLLOID SURFACE A, V507, P124, DOI 10.1016/j.colsurfa.2016.07.093
   Liu Z, 2006, EXP THERM FLUID SCI, V31, P151, DOI 10.1016/j.expthermflusci.2006.03.025
   Maatki C, 2013, INT COMMUN HEAT MASS, V49, P86, DOI 10.1016/j.icheatmasstransfer.2013.08.019
   MARRUCCI G, 1969, CHEM ENG SCI, V24, P975, DOI 10.1016/0009-2509(69)87006-5
   Mauro A., 1978, CAMBRIDGE MONOGRAPHS, V55
   OOLMAN TO, 1986, CHEM ENG COMMUN, V43, P237, DOI 10.1080/00986448608911334
   Pan G, 2016, LANGMUIR, V32, P11133, DOI 10.1021/acs.langmuir.6b01483
   Poullikkas A, 2003, PROG NUCL ENERG, V42, P3, DOI 10.1016/S0149-1970(03)80002-1
   Quan XJ, 2011, INT J HEAT MASS TRAN, V54, P2110, DOI 10.1016/j.ijheatmasstransfer.2010.12.017
   RAMAKRIS.S, 1969, CHEM ENG SCI, V24, P731, DOI 10.1016/0009-2509(69)80065-5
   Sanada T, 2005, CHEM ENG SCI, V60, P5372, DOI 10.1016/j.ces.2005.04.077
   Selimefendigil F, 2018, INT J MECH SCI, V136, P264, DOI 10.1016/j.ijmecsci.2017.12.035
   Siedel S, 2011, EXP THERM FLUID SCI, V35, P762, DOI 10.1016/j.expthermflusci.2010.06.006
   TSUGE H, 1992, CHEM ENG SCI, V47, P3273, DOI 10.1016/0009-2509(92)85035-A
   Wang T, 2016, MICROGRAVITY SCI TEC, V28, P133, DOI 10.1007/s12217-016-9490-0
   Xie J, 2012, INT J HEAT MASS TRAN, V55, P3205, DOI 10.1016/j.ijheatmasstransfer.2012.02.053
   Xu X, 2015, SEP PURIF TECHNOL, V152, P80, DOI 10.1016/j.seppur.2015.07.058
   Zhang J, 2017, CHEM ENG SCI, V168, P1, DOI 10.1016/j.ces.2017.04.012
NR 44
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115451
DI 10.1016/j.ces.2019.115451
PG 11
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300016
DA 2020-05-12
ER

PT J
AU Zhu, Y
   Li, WP
   Cai, LL
   Zhu, XF
   Yang, WS
AF Zhu, Yue
   Li, Wenping
   Cai, Lili
   Zhu, Xuefeng
   Yang, Weishen
TI Universally applicable kinetic model for mixed ionic-electronic
   conducting membranes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE MIEC membranes; Oxygen permeation; Kinetic model; Oxygen vacancy;
   Perovskite
ID OXYGEN PERMEATION PROPERTIES; SURFACE EXCHANGE KINETICS;
   SRCO0.8FE0.2O3-DELTA MEMBRANES; TRANSPORT MEMBRANES; PEROVSKITE;
   REACTOR; CO2; SEPARATION; METHANE; DESIGN
AB Kinetic model is significant for disclosing the oxygen permeation process through mixed ionic-electronic conducting (MIEC) membranes. However, current kinetic models are only applicable for certain materials. As a result, it is difficult to select a proper model to compare kinetic parameters of different membranes. In this paper, based on the dependence of oxygen vacancy concentration on oxygen partial pressure in the bulk of MIEC membrane, an extending of Zhu's model was established for extensive MIEC membranes by revising one assumption in the original model. La0.6Sr0.4Co0.2Fe0.8O3-delta (LSCF) membranes with different thickness and coated/uncoated LSCF catalyst layers and La(0.7)Sr(0.3)Coo(3)(-delta) (LSC) membrane were chosen to verify the correctness of the extended model. The fitting results of LSCF and LSC are reasonable and exclusive compared to the original model and Xu-Thomson's model. In a word, the extended model can be applied to various MIEC materials. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Zhu, Yue; Li, Wenping; Cai, Lili; Zhu, Xuefeng; Yang, Weishen] Chinese Acad Sci, Dalian Inst Chem Phys, State Key Lab Catalysis, 457 Zhongshan Rd, Dalian 116023, Peoples R China.
   [Zhu, Yue; Li, Wenping; Cai, Lili] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
RP Zhu, XF (reprint author), Chinese Acad Sci, Dalian Inst Chem Phys, State Key Lab Catalysis, 457 Zhongshan Rd, Dalian 116023, Peoples R China.
EM zhuxf@dicp.ac.cn
RI Zhu, Xuefeng/G-8809-2013
OI Zhu, Xuefeng/0000-0001-5932-7620
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21776267]; Strategic Priority Research Program of
   the Chinese Academy of Sciences (CAS) [XDB17000000]; Dalian National
   Laboratory for Clean Energy (DNL), CAS [DNL180203]; Youth Innovation
   Promotion Association of the CAS
FX We thank the financial support from National Natural Science Foundation
   of China (21776267), the Strategic Priority Research Program of the
   Chinese Academy of Sciences (CAS) (Grant No. XDB17000000) and Youth
   Innovation Promotion Association of the CAS, Dalian National Laboratory
   for Clean Energy (DNL), CAS (DNL180203).
CR Ahmed P, 2014, ENERGY, V77, P932, DOI 10.1016/j.energy.2014.10.003
   Behrouzifar A, 2012, CERAM INT, V38, P4797, DOI 10.1016/j.ceramint.2012.02.068
   Ben Mansour R, 2013, ENERGY, V54, P322, DOI 10.1016/j.energy.2013.03.027
   Bermudez JM, 2018, J MEMBRANE SCI, V562, P26, DOI 10.1016/j.memsci.2018.05.012
   BOUWMEESTER HJM, 1994, SOLID STATE IONICS, V72, P185, DOI 10.1016/0167-2738(94)90145-7
   Cai LL, 2019, AICHE J, V65, P1088, DOI 10.1002/aic.16491
   Dong XL, 2011, CHEM COMMUN, V47, P10886, DOI 10.1039/c1cc13001c
   Fan WW, 2016, RSC ADV, V6, P34564, DOI 10.1039/c6ra02251k
   Gao L, 2017, J POWER SOURCES, V371, P86, DOI 10.1016/j.jpowsour.2017.10.036
   Geffroy PM, 2017, CHEM ENG SCI, V162, P245, DOI 10.1016/j.ces.2017.01.006
   Geffroy PM, 2019, J EUR CERAM SOC, V39, P59, DOI 10.1016/j.jeurceramsoc.2018.03.034
   Hamel C, 2006, AICHE J, V52, P3118, DOI 10.1002/aic.10934
   Hunt A, 2014, J MEMBRANE SCI, V468, P62, DOI 10.1016/j.memsci.2014.05.043
   Lee TH, 1997, SOLID STATE IONICS, V100, P77, DOI 10.1016/S0167-2738(97)00257-9
   Lee TH, 1997, SOLID STATE IONICS, V100, P87, DOI 10.1016/S0167-2738(97)00258-0
   Li WP, 2017, AICHE J, V63, P1278, DOI 10.1002/aic.15502
   Li WP, 2016, ANGEW CHEM INT EDIT, V55, P8566, DOI 10.1002/anie.201602207
   Liang FY, 2012, CATAL TODAY, V193, P95, DOI 10.1016/j.cattod.2011.12.016
   LIN YS, 1994, AICHE J, V40, P786, DOI 10.1002/aic.690400506
   Liu Y, 2015, CURR MICROWAV CHEM, V2, P8, DOI 10.2174/221333560201150212101808
   Liu Y, 2016, AICHE J, V62, P2803, DOI 10.1002/aic.15239
   Lu Y, 2017, J MATER CHEM A, V5, P7999, DOI 10.1039/c7ta00907k
   Lu Y, 2016, J MATER CHEM A, V4, P10454, DOI 10.1039/c6ta01749e
   Qiu ZH, 2018, CHEM ENG SCI, V177, P18, DOI 10.1016/j.ces.2017.11.006
   Salles C, 2017, J MEMBRANE SCI, V527, P191, DOI 10.1016/j.memsci.2016.11.083
   Smart S, 2010, ENERG ENVIRON SCI, V3, P268, DOI 10.1039/b924327e
   Tan XY, 2009, AICHE J, V55, P2675, DOI 10.1002/aic.11873
   Vincent A, 2010, J POWER SOURCES, V195, P769, DOI 10.1016/j.jpowsour.2009.08.018
   Wang L, 2010, J ELECTROCHEM SOC, V157, pB1802, DOI 10.1149/1.3494224
   Wei YY, 2011, AICHE J, V57, P975, DOI 10.1002/aic.12321
   Xu SJ, 1999, CHEM ENG SCI, V54, P3839, DOI 10.1016/S0009-2509(99)00015-9
   Yang W, 2019, CHEM ENG SCI, V199, P210, DOI 10.1016/j.ces.2019.01.023
   Yang ZH, 2002, IND ENG CHEM RES, V41, P2775, DOI 10.1021/ie010736k
   Zeng Y, 1998, SOLID STATE IONICS, V110, P209, DOI 10.1016/S0167-2738(98)00136-2
   Zhang LX, 2019, ACS SUSTAIN CHEM ENG, V7, P9629, DOI 10.1021/acssuschemeng.9b01183
   Zhang YQ, 2016, ACS APPL MATER INTER, V8, P6457, DOI 10.1021/acsami.5b11979
   Zhu XF, 2012, AICHE J, V58, P1744, DOI 10.1002/aic.12710
   Zhu Y, 2017, AICHE J, V63, P4043, DOI 10.1002/aic.15718
NR 38
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 6
PY 2020
VL 215
AR 115455
DI 10.1016/j.ces.2019.115455
PG 10
WC Engineering, Chemical
SC Engineering
GA KU9FF
UT WOS:000520029300035
DA 2020-05-12
ER

PT J
AU Murakami, K
   Fujii, Y
   Someya, Y
AF Murakami, Kosuke
   Fujii, Yoshiki
   Someya, Yuichi
TI Effects of the thermal denaturation of Sabin-derived inactivated polio
   vaccines on the D-antigenicity and the immunogenicity in rats
SO VACCINE
LA English
DT Article
DE Inactivated polio vaccine; Sabin IPV; D-antigen; Neutralizing antibody;
   ELISA
ID STRAINS
AB The efficacy of a Sabin-derived inactivated polio vaccine (sIPV) can be evaluated by measuring the immunogenicity and the contents of D-antigens, which induce the neutralizing antibodies. The immunogenic potency test in rats was done as a national assay in Japan. The two manufacturers of sIPV in Japan have performed both assays since development, and there is no clear discrepancy between the results obtained in the two assays. To further know the relationship between the two assays, we analyzed the effects of the heat treatment of sIPV on the D-antigenicity and the immunogenicity. We observed that the marginal D-antigen that remained after the thermal treatment was capable of inducing relatively high neutralizing antibodies in rats. This indicates that the measurement of the D-antigen contents as part of the quality control of sIPV is more sensitive and appropriate to detect denatured vaccines. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Murakami, Kosuke; Fujii, Yoshiki; Someya, Yuichi] Natl Inst Infect Dis, Dept Virol 2, 4-7-1 Gakuen, Tokyo 2080011, Japan.
RP Someya, Y (reprint author), Natl Inst Infect Dis, Dept Virol 2, 4-7-1 Gakuen, Tokyo 2080011, Japan.
EM someya@niid.go.jp
FU Research Program on Emerging and Re-emerging Infectious Diseases from
   the Japan Agency for Medical Research and Development (AMED)Japan Agency
   for Medical Research and Development (AMED) [18fk0108004k0403,
   19fk0108084j0401]; Ministry of Health, Labour and Welfare, JapanMinistry
   of Health, Labour and Welfare, Japan [H30-Iyaku-Ippann-002]
FX This work was supported in part by the Research Program on Emerging and
   Re-emerging Infectious Diseases from the Japan Agency for Medical
   Research and Development (AMED) [grant numbers 18fk0108004k0403 and
   19fk0108084j0401 to YS], and a Grant-in-Aid from the Ministry of Health,
   Labour and Welfare, Japan [grant number H30-Iyaku-Ippann-002 to YS].
CR [Anonymous], 2015, WHO GLOB ACT PLAN MI
   Crawt L, 2020, J INFECT DIS, V221, P544, DOI 10.1093/infdis/jiz076
   Global Polio Eradication Initiative, 2015, GLOB ER WILD POL TYP
   Okada K, 2013, J INFECT DIS, V208, P275, DOI 10.1093/infdis/jit155
   Okayasu H, 2016, BIOLOGICALS, V44, P581, DOI 10.1016/j.biologicals.2016.08.005
   SCHWERDT CE, 1957, VIROLOGY, V4, P41, DOI 10.1016/0042-6822(57)90042-9
   Shimizu H, 2016, VACCINE, V34, P1975, DOI 10.1016/j.vaccine.2014.11.015
   Shirato H, 2014, VACCINE, V32, P5163, DOI 10.1016/j.vaccine.2014.07.065
   Someya Y, 2018, BIOLOGICALS, V52, P12, DOI 10.1016/j.biologicals.2018.02.001
   VANDERWERF S, 1983, P NATL ACAD SCI-BIOL, V80, P5080, DOI 10.1073/pnas.80.16.5080
   World Health Organization, 2014, WHO TECHN REP SER, V3
   World Health Organization, 2019, WHO TECHN REP SER, V4
   World Health Organization, 2018, REP WHO COLL STUD ES
   World Health Organization, 2002, WHO TECHN REP SER, V910
   World Health Organization, 2015, PREP WITHDR ALL OR P
   World Health Organization, 2017, GAPIII CONT CERT SCH
   World Hlth Org, 2017, VACCINE, V35, P1197, DOI 10.1016/j.vaccine.2016.11.017
NR 17
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3295
EP 3299
DI 10.1016/j.vaccine.2020.03.027
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800001
PM 32197923
DA 2020-05-12
ER

PT J
AU Feyssaguet, M
   Berthold, V
   Helle, L
   Povey, M
   Ravault, S
   Carryn, S
   Gillard, P
   Di Paolo, E
AF Feyssaguet, Muriel
   Berthold, Valerie
   Helle, Laurent
   Povey, Michael
   Ravault, Stephanie
   Carryn, Stephane
   Gillard, Paul
   Di Paolo, Emmanuel
TI Comparison of a glycoprotein E-based ELISA with a varicella-zoster
   whole-virus ELISA for the quantification of varicella vaccine immune
   responses in young children
SO VACCINE
LA English
DT Article
DE Varicella-zoster virus; Antibody assay; ELISA; Glycoprotein E; Varicella
   vaccination; Children
ID LINKED-IMMUNOSORBENT-ASSAY; IMMUNOGENICITY; REACTOGENICITY; ANTIBODY
AB Antibody response against varicella-zoster virus (VZV) is frequently assessed by whole-virus- (anti-VZV) or glycoprotein-based ELISAs. This study compared antibody concentrations measured by an assay quantifying anti-VZV glycoprotein E (anti-gE) and anti-VZV ELISA in 12-23-month-olds, receiving two varicella vaccine doses in a phase III trial (NCT02570126). Samples (pre- and 42 days post-each vaccination) initially tested with anti-VZV ELISA were re-tested with anti-gE ELISA. Of 1138 samples from 397 children, 757 were positive by anti-VZV (antibody concentration >= 25 mIU/mL) and 758 by anti-gE ELISA (>= 97 mIU/mL). There were 375 double-negative and only 11 discrepant samples. The overall agreement was 99.03% (95% confidence interval: 98.28-99.52; McNemar p-value = 1). The ratio between antibody geometric mean concentrations (anti-gE/anti-VZV) for the 752 double-positive samples was 3.78 overall, 4.75 post-first, and 3.01 post-second vaccination. The anti-gE ELISA is a valid alternative for trials assessing antibody response to new varicella vaccines versus established ones, used as control. (C) 2020 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Feyssaguet, Muriel; Berthold, Valerie; Helle, Laurent; Ravault, Stephanie; Carryn, Stephane; Di Paolo, Emmanuel] GSK, Rue Inst 89, B-1330 Rixensart, Belgium.
   [Povey, Michael; Gillard, Paul] GSK, Av Fleming 20, B-1300 Wavre, Belgium.
RP Feyssaguet, M (reprint author), GSK, Rue Inst 89, B-1330 Rixensart, Belgium.
EM muriel.m.feyssaguet@gsk.com; valerie.berthold@gsk.com;
   laurent.x.helle@gsk.com; michael.x.povey@gsk.com;
   stephanie.p.ravault@gsk.com; stephane.x.carryn@gsk.com;
   paul.gillard@gsk.com; emmanuel.di-paolo@gsk.com
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX This study was funded by the GlaxoSmithKline Biologicals SA.
   GlaxoSmithKline Biologicals SA covered all costs associated with the
   development and publishing of this manuscript.
CR ARVIN AM, 1992, J INFECT DIS, V166, pS35, DOI 10.1093/infdis/166.Supplement_1.S35
   Arvin AM, 2008, J INFECT DIS, V197, pS58, DOI 10.1086/522123
   Cohen J.I., 2007, FIELDS VIROLOGY, V2, P2773
   Cunningham AL, 2018, J INFECT DIS, V217, P1750, DOI 10.1093/infdis/jiy095
   de Ory F, 2006, J CLIN VIROL, V36, P111, DOI 10.1016/j.jcv.2006.01.017
   Faust SN, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1425-7
   Gershon AA, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.16
   Grose C., 2002, STRUCTURE FUNCTION R, P195
   Hadinegoro SRH, 2009, SE ASIAN J TROP MED, V40, P991
   Lal H, 2018, VACCINE, V36, P148, DOI 10.1016/j.vaccine.2017.11.019
   Liu J, 2016, APPL MICROBIOL BIOT, V100, P9321, DOI 10.1007/s00253-016-7821-0
   Prymula R, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0546-5
   Sauerbrei A, 2006, J CLIN MICROBIOL, V44, P3094, DOI 10.1128/JCM.00719-06
   Sauerbrei A, 2012, CLIN VACCINE IMMUNOL, V19, P1261, DOI 10.1128/CVI.00183-12
   Schwarz TF, 2018, HUM VACC IMMUNOTHER, V14, P1370, DOI 10.1080/21645515.2018.1442162
   SHARP M, 1992, J INFECT DIS, V165, P852, DOI 10.1093/infdis/165.5.852
   Shingrix, SUMMARY PRODUCT CHAR
   Varilrix, SUMMARY PRODUCT CHAR
   WASMUTH EH, 1990, J MED VIROL, V32, P189, DOI 10.1002/jmv.1890320310
NR 19
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3300
EP 3304
DI 10.1016/j.vaccine.2020.03.009
PG 5
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800002
PM 32184033
OA Other Gold
DA 2020-05-12
ER

PT J
AU Hirsch, J
   Faber, BW
   Crowe, JE
   Verstrepen, B
   Cornelissen, G
AF Hirsch, Janet
   Faber, Bart W.
   Crowe, James E., Jr.
   Verstrepen, Babs
   Cornelissen, Gesine
TI E. coli production process yields stable dengue 1 virus-sized particles
   (VSPs)
SO VACCINE
LA English
DT Article
DE Virus-sized particle; Virus-like particle; Dengue; E. coli; Stability;
   Dynamic light scattering
ID ENVELOPE PROTEIN; NEUTRALIZING ANTIBODIES; BACULOVIRUS; STRATEGIES;
   EPITOPES; ARGININE; VACCINE
AB Dengue fever is one of the most wide-spread vector-borne diseases in the world. Although dengue-associated mortality is low, morbidity and economic impact are high. Current licensed vaccines are limited and mediate only partial protection, thus a cost-effective vaccine with improved efficacy is strongly needed.
   In this work, recombinant dengue serotype 1 E protein was produced in E. coli, inclusion bodies were isolated and the E protein solubilized in urea and purified using an immobilized metal chelate affinity column. The protein was refolded by dialysis in order to obtain virus-like particles (VLPs).
   Particle assembly was confirmed using size-exclusion chromatography, dynamic light scattering (DLS), transmission electron microscopy (TEM), atomic force microscopy and stimulated emission depletion fluorescence (STED) microscopy. Particle diameter was strongly dependent on temperature, pH, buffer salt composition, and addition of L-arginine. Particles were stable in carbonate buffer at pH 9.5 and higher at 4 degrees C and did not aggregate during short-term temperature increase up to 55 degrees C. However, on basis of the above analyses, especially the results of DLS, TEM and STED, it was concluded that the particles obtained did not have an optimal virus-like structure and were therefore designated "virus-sized particles" (VSPs) rather than VLPs.
   Immunization of rabbits with the particles did not induce neutralizing antibodies, despite the recognition of the native virus by rabbit antibodies. As the titers against the immunogen were much higher than against the (heat-inactivated) virus, it is assumed that the conformation of the particles at the time of immunization was not optimal. Studies are currently underway to improve the quality of the E protein virus-sized particles towards true virus-like particles in order to optimize its potential as a dengue vaccine candidate. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hirsch, Janet; Cornelissen, Gesine] Hamburg Univ Appl Sci, Ulmenliet 20, D-21033 Hamburg, Germany.
   [Faber, Bart W.] Biomed Primate Res Ctr, Dept Parasitol, Lange Kleiweg 161, NL-2288 GJ Rijswijk, Netherlands.
   [Crowe, James E., Jr.] Vanderbilt Univ, Dept Pediat & Pathol, Med Ctr, 2213 Garland Ave, Nashville, TN 37232 USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Dept Microbiol, Med Ctr, 2213 Garland Ave, Nashville, TN 37232 USA.
   [Crowe, James E., Jr.] Vanderbilt Univ, Dept Immunol, Med Ctr, 2213 Garland Ave, Nashville, TN 37232 USA.
   [Verstrepen, Babs] Biomed Primate Res Ctr, Dept Virol, Lange Kleiweg 161, NL-2288 GJ Rijswijk, Netherlands.
RP Hirsch, J (reprint author), Hamburg Univ Appl Sci, Ulmenliet 20, D-21033 Hamburg, Germany.
EM janet.hirsch@haw-hamburg.de; faber@bprc.nl; james.crowe@vumc.org;
   verstrepen@bprc.nl; gesine.cornelissen@haw-hamburg.de
CR Akahata W, 2010, NAT MED, V16, P334, DOI 10.1038/nm.2105
   Allison SL, 2001, J VIROL, V75, P4268, DOI 10.1128/JVI.75.9.4268-4275.2001
   Martinez CA, 2010, BIOTECHNOL LETT, V32, P867, DOI 10.1007/s10529-010-0236-6
   [Anonymous], 2012, GLOB STRAT DENG PREV
   Arakawa T, 2007, BIOPHYS CHEM, V127, P1, DOI 10.1016/j.bpc.2006.12.007
   ASAKURA S, 1958, J POLYM SCI, V33, P183, DOI 10.1002/pol.1958.1203312618
   Baynes BM, 2005, BIOCHEMISTRY-US, V44, P4919, DOI 10.1021/bi047528r
   Boigard H, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005608
   Brady OJ, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001760
   Das U, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001176
   de Alwis R, 2012, P NATL ACAD SCI USA, V109, P7439, DOI 10.1073/pnas.1200566109
   De Carlo S, 2011, MICRON, V42, P117, DOI 10.1016/j.micron.2010.06.003
   Dejnirattisai W, 2015, NAT IMMUNOL, V16, P170, DOI 10.1038/ni.3058
   Effio CL, 2016, J BIOTECHNOL, V219, P7, DOI 10.1016/j.jbiotec.2015.12.018
   Esposito DLA, 2015, J GEN VIROL, V96, P1702, DOI 10.1099/vir.0.000113
   Ferlenghi I, 2001, MOL CELL, V7, P593, DOI 10.1016/S1097-2765(01)00206-4
   Fibriansah G, 2015, SCIENCE, V349, P88, DOI 10.1126/science.aaa8651
   Fibriansah G, 2014, EMBO MOL MED, V6, P358, DOI 10.1002/emmm.201303404
   Grodeland G, 2013, J IMMUNOL, V191, P3221, DOI 10.4049/jimmunol.1300504
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Halstead SB, 2003, ADV VIRUS RES, V60, P421, DOI 10.1016/S0065-3527(03)60011-4
   Kelly EP, 2000, VACCINE, V18, P2549, DOI 10.1016/S0264-410X(00)00032-3
   Khetarpal N, 2017, AM J TROP MED HYG, V96, P126, DOI 10.4269/ajtmh.16-0503
   Kusi KA, 2018, EXPERT REV VACCINES, V17, P13, DOI 10.1080/14760584.2018.1411198
   Liu N, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-123
   Liu WQ, 2010, VIRUS GENES, V40, P53, DOI 10.1007/s11262-009-0418-2
   Ludwig C, 2007, CURR OPIN BIOTECH, V18, P537, DOI 10.1016/j.copbio.2007.10.013
   Luz PM, 2011, LANCET, V377, P1673, DOI 10.1016/S0140-6736(11)60246-8
   Mani S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064595
   Matsui K, 2009, VIROLOGY, V384, P16, DOI 10.1016/j.virol.2008.11.013
   Metz SW, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002124
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Poddar A, 2016, BMC BIOTECHNOL, V16, DOI 10.1186/s12896-016-0280-y
   Rajpoot RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26904-5
   Rito-Palomares M, 2002, J CHEM TECHNOL BIOT, V77, P1025, DOI 10.1002/jctb.673
   Roehrig JT, ADV VIRUS RES, P141
   Roessl U, 2014, J PHARM SCI-US, V103, P417, DOI 10.1002/jps.23814
   Tatem AJ, 2006, P NATL ACAD SCI USA, V103, P6242, DOI 10.1073/pnas.0508391103
   Tripathi L, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01005
   Urakami A, 2017, J VIROL, V91, DOI [10.1128/JVI.01181-17, 10.1128/jvi.01181-17]
   World Health Organization Special Programme for Research Training in Tropical Diseases World Health Organization. Department of Control of Neglected Tropical Diseases World Health Organization, 2009, DENG GUID DIAGN TREA
   Yamaji H, 2012, J BIOSCI BIOENG, V114, P657, DOI 10.1016/j.jbiosc.2012.06.012
   Zhang W, 1998, VIROLOGY, V243, P423, DOI 10.1006/viro.1998.9050
NR 43
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3305
EP 3312
DI 10.1016/j.vaccine.2020.03.003
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800003
PM 32197924
DA 2020-05-12
ER

PT J
AU Sundaram, AK
   Ewing, D
   Blevins, M
   Liang, ZD
   Sink, S
   Lassan, J
   Raviprakash, K
   Defang, G
   Williams, M
   Porter, KR
   Sanders, JW
AF Sundaram, Appavu K.
   Ewing, Daniel
   Blevins, Maria
   Liang, Zhaodong
   Sink, Sandy
   Lassan, Josef
   Raviprakash, Kanakatte
   Defang, Gabriel
   Williams, Maya
   Porter, Kevin R.
   Sanders, John W.
TI Comparison of purified psoralen-inactivated and formalin-inactivated
   dengue vaccines in mice and nonhuman primates
SO VACCINE
LA English
DT Article
DE Dengue virus; Formalin-inactivation; Psoralen-inactivation; Tetravalent
   dengue vaccines; DENV neutralizing antibodies; Conformational epitopes;
   4 '-Aminomethyl-4, 5 ', 8-trimethylpsoralen (AMT)
ID PHOTOCHEMICAL INACTIVATION; IMMUNOGENICITY; FORMALDEHYDE; PROTECTION;
   PROTOTYPE; CANDIDATE; VIRUSES; FUTURE; SAFETY
AB Dengue fever, caused by dengue viruses (DENV 1-4) is a leading cause of illness and death in the tropics and subtropics. Therefore, an effective vaccine is urgently needed. Currently, the only available licensed dengue vaccine is a chimeric live attenuated vaccine that shows varying efficacy depending on serotype, age and baseline DENV serostatus. Accordingly, a dengue vaccine that is effective in seronegative adults, children of all ages and in immunocompromised individuals is still needed. We are currently researching the use of psoralen to develop an inactivated tetravalent dengue vaccine. Unlike traditional formalin inactivation, psoralen inactivates pathogens at the nucleic acid level, potentially preserving envelope protein epitopes important for protective anti-dengue immune responses. We prepared highly purified monovalent vaccine lots of formalin- and psoralen-inactivated DENV 1-4, using Capto DeVirS and Capto Core 700 resin based column chromatography. Tetravalent psoralen-inactivated vaccines (PsIV) and formalin-inactivated vaccines (FIV) were prepared by combining the four monovalent vaccines. Mice were immunized with either a low or high dose of PsIV or FIV to evaluate the immunogenicity of monovalent as well as tetravalent formulations of each inactivation method. In general, the monovalent and tetravalent PsIVs elicited equivalent or higher titers of neutralizing antibodies to DENV than the FIV dengue vaccines and this response was dose dependent. The immunogenicity of tetravalent dengue PsIVs and FIVs were also evaluated in nonhuman primates (NHPs). Consistent with what was observed in mice, significantly higher neutralizing antibody titers for each dengue serotype were observed in the NHPs vaccinated with the tetravalent dengue PsIV compared to those vaccinated with the tetravalent dengue FIV, indicative of the importance of envelope protein epitope preservation during psoralen inactivation of DENV. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Sundaram, Appavu K.; Ewing, Daniel; Liang, Zhaodong; Raviprakash, Kanakatte; Defang, Gabriel] Naval Med Res Ctr, Viral & Rickettsial Dis Dept, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
   [Sundaram, Appavu K.; Liang, Zhaodong] Henry M Jackson Fdn Adv Mil Med, 6720A Rockledge Dr, Bethesda, MD 20817 USA.
   [Blevins, Maria; Sink, Sandy; Lassan, Josef; Sanders, John W.] Wake Forest Sch Med, Sect Infect Dis, Winston Salem, NC 27157 USA.
   [Williams, Maya; Porter, Kevin R.] Naval Med Res Ctr, Infect Dis Directorate, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
RP Sundaram, AK (reprint author), Naval Med Res Ctr, Viral & Rickettsial Dis Dept, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.
EM Apavu.k.sundaram.ctr@mail.mil
FU Peer Reviewed Medical Research Program (PRMRP) [PR130236]; 
   [6000.RAD1.L.A1436]
FX This work was funded by Peer Reviewed Medical Research Program (PRMRP)
   research grant#PR130236 and supported by Work Unit Number
   6000.RAD1.L.A1436.
CR [Anonymous], 2018, WHO ADVISES DENGVAXI
   Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060
   Boigard H, 2018, VACCINE, V36, P7728, DOI 10.1016/j.vaccine.2018.10.072
   Borges MB, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007721
   de Silva AM, 2018, COLD SPRING HARB PER, V10
   Diaz C, 2018, AM J TROP MED HYG, V98, P1435, DOI 10.4269/ajtmh.17-0627
   Fernandez S, 2015, AM J TROP MED HYG, V92, P698, DOI 10.4269/ajtmh.14-0268
   FRAENKELCONRAT H, 1949, J BIOL CHEM, V177, P477
   GARD S, 1957, Bull World Health Organ, V17, P979
   Godoi IP, 2017, J COMP EFFECT RES, V6, P165, DOI 10.2217/cer-2016-0045
   HANSON CV, 1978, J GEN VIROL, V40, P345, DOI 10.1099/0022-1317-40-2-345
   HANSON CV, 1992, BLOOD CELLS, V18, P7
   Kanlaya R, 2016, J VIROL METHODS, V234, P174, DOI 10.1016/j.jviromet.2016.04.023
   Martinez LJ, 2015, AM J TROP MED HYG, V93, P454, DOI 10.4269/ajtmh.14-0819
   Maves RC, 2011, VACCINE, V29, P2691, DOI 10.1016/j.vaccine.2011.01.077
   Maves RC, 2010, CLIN VACCINE IMMUNOL, V17, P304, DOI 10.1128/CVI.00353-09
   Murray Natasha Evelyn Anne, 2013, Clin Epidemiol, V5, P299, DOI 10.2147/CLEP.S34440
   Ndaya-Oloo P, 2018, J CLIN PHARMACOL, V58, pS123, DOI 10.1002/jcph.1140
   Putnak R, 1996, J INFECT DIS, V174, P1176, DOI 10.1093/infdis/174.6.1176
   Putnak R, 1996, AM J TROP MED HYG, V55, P504
   Raviprakash K, 2008, J VIROL, V82, P6927, DOI 10.1128/JVI.02724-07
   Raviprakash K, 2013, HUM VACC IMMUNOTHER, V9, P2336, DOI 10.4161/hv.25602
   Recker M, 2016, VACCINE, V34, P4461, DOI 10.1016/j.vaccine.2016.06.082
   Schmidt AC, 2017, AM J TROP MED HYG, V96, P1325, DOI 10.4269/ajtmh.16-0634
   Schwartz LM, 2015, VACCINE, V33, P3293, DOI 10.1016/j.vaccine.2015.05.010
   Williams C, 1999, AM J PATHOL, V155, P1467, DOI 10.1016/S0002-9440(10)65461-2
   Williams M, 2019, VACCINE, V37, P4444, DOI 10.1016/j.vaccine.2019.06.083
   Wilton T, 2014, J VIROL, V88, P11955, DOI 10.1128/JVI.01809-14
   Wollowitz S, 2001, SEMIN HEMATOL, V38, P4, DOI 10.1053/shem.2001.29495
NR 29
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3313
EP 3320
DI 10.1016/j.vaccine.2020.03.008
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800004
PM 32184032
OA Other Gold
DA 2020-05-12
ER

PT J
AU Woestenberg, PJ
   van Benthem, BHB
   Bogaards, JA
   King, AJ
   van der Klis, FRM
   Pasmans, H
   Leussink, S
   van der Sande, MAB
   Hoebe, CJPA
AF Woestenberg, Petra J.
   van Benthem, Birgit H. B.
   Bogaards, Johannes A.
   King, Audrey J.
   van der Klis, Fiona R. M.
   Pasmans, Hella
   Leussink, Suzan
   van der Sande, Marianne A. B.
   Hoebe, Christian J. P. A.
CA Med Microbiological Labs
   Public Hlth Serv
TI HPV infections among young MSM visiting sexual health centers in the
   Netherlands: Opportunities for targeted HPV vaccination
SO VACCINE
LA English
DT Article
DE Human papillomavirus (HPV); Vaccination; Herd protection; Men who have
   sex with men (MSM); Targeted vaccination
ID HUMAN-PAPILLOMAVIRUS VACCINATION; ANAL HUMAN-PAPILLOMAVIRUS; GENITAL
   WARTS; MEN; PREVALENCE; EFFICACY; WOMEN; CANCER; GAY
AB Introduction: In 2009, girls-only HPV16/18 vaccination was introduced in the Netherlands which has achieved 46-61% uptake. Heterosexual men have benefitted from herd protection, but it is unknown whether men who have sex with men (MSM) also benefit from herd effects of the girls-only HPV16/18 vaccination program. Because MSM bear a high HPV-related disease burden, countries might consider targeted vaccination for MSM. To study possible herd effects and prior HPV exposure at a potential moment of vaccination, we assessed trends in the HPV prevalence and proportions (sero)negative for the various vaccine types among young MSM visiting sexual health centers (SHCs).
   Methods: We used data from MSM included in PASSYON study years 2009-2017. In this biennial cross-sectional study among visitors of SHCs aged 16-24 years, MSM provided a penile and anal swab for HPV DNA testing (including vaccine types HPV6/11/16/18/31/33/45/52/58) and blood for HPV antibody testing (HPV16/18/31/33/45/52/58).
   Results: In total 575 MSM were included, with a median of 22 years of age and 15 lifetime sex partners and 3.5% HIV positive. Trends in penile or anal HPV prevalence during 2009-2017 were statistically non-significant for all vaccine types. Of the 455 MSM with a penile and anal swab, 360 (79%), 283 (62%) and 242 (53%) were HPV DNA negative at both anatomical sites for HPV16/18, HPV6/11/16/18 and HPV6/11/16/18/31/33/45/52/58 respectively. Among MSM who were HPV16/18 and HPV16/18/31/33/45/52/58 DNA negative and were tested for serology (n = 335 and 279 respectively), 82% and 71% were also seronegative for the respective types.
   Discussion: There were no significant declines in the HPV prevalence among MSM up to eight years after introduction of girls-only HPV16/18 vaccination, indicating that MSM are unlikely to benefit largely from herd effects from girls-only vaccination. Most MSM were vaccine-type DNA negative and seronegative, suggesting that vaccination of young MSM visiting SHCs could still be beneficial. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Woestenberg, Petra J.; van Benthem, Birgit H. B.; Bogaards, Johannes A.; King, Audrey J.; van der Klis, Fiona R. M.; Pasmans, Hella; Leussink, Suzan] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands.
   [Woestenberg, Petra J.; Hoebe, Christian J. P. A.] Maastricht Univ, CAPHRI, Med Ctr, NL-6200 MD Maastricht, Netherlands.
   [Bogaards, Johannes A.] Vrije Univ Amsterdam, Dept Epidemiol & Biostat, Amsterdam UMC, Locat VUmc, NL-1007 MB Amsterdam, Netherlands.
   [Pasmans, Hella] Leiden Univ, Dept Med Oncol, Med Ctr, NL-2333 ZA Leiden, Netherlands.
   [van der Sande, Marianne A. B.] Inst Trop Med, Dept Publ Hlth, B-2000 Antwerp, Belgium.
   [van der Sande, Marianne A. B.] Univ Med Ctr Utrecht, Julius Ctr, NL-3508 GA Utrecht, Netherlands.
   [Hoebe, Christian J. P. A.] South Limburg Publ Hlth Serv, Dept Sexual Hlth Infect Dis & Environm, NL-6411 TE Heerlen, Netherlands.
RP Woestenberg, PJ (reprint author), RIVM, Internal Postbox 75 Petra Woestenberg,Postbox 1, NL-3720 BA Bilthoven, Netherlands.
EM petra.woestenberg@rivm.nl
OI Woestenberg, Petra/0000-0003-1010-7373
FU Ministry of Health, Welfare and Sport, the Netherlands
FX This work was supported by the Ministry of Health, Welfare and Sport,
   the Netherlands. The funders had no role in study design, data
   collection and analysis, interpretation
CR Bogaards JA, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002756
   Cameron RL, 2020, SEX TRANSM INFECT, V96, P55, DOI 10.1136/sextrans-2018-053668
   Castellsague X, 2011, BRIT J CANCER, V105, P28, DOI 10.1038/bjc.2011.185
   Chaturvedi AK, 2010, J ADOLESCENT HEALTH, V46, pS20, DOI 10.1016/j.jadohealth.2010.01.016
   Checchi M, 2019, SEX TRANSM INFECT, V95, P608, DOI 10.1136/sextrans-2018-053923
   Chow EPF, 2017, LANCET INFECT DIS, V17, P68, DOI 10.1016/S1473-3099(16)30116-5
   Chow EPF, 2015, SEX TRANSM INFECT, V91, P214, DOI 10.1136/sextrans-2014-051813
   Daling JR, 2004, CANCER, V101, P270, DOI 10.1002/cncr.20365
   Drolet M, 2019, LANCET, V394, P497, DOI 10.1016/S0140-6736(19)30298-3
   European Medicines Agency, GARD EPAR PROD INF
   European Medicines Agency, CERV EPAR PROD INF
   European Medicines Agency, GARD 9 EPAR PROD INF
   Frisch M, 2003, AM J EPIDEMIOL, V157, P966, DOI 10.1093/aje/kwg067
   Garland SM, 2009, J INFECT DIS, V199, P805, DOI 10.1086/597071
   Gheit T, 2011, CANCER EPIDEM BIOMAR, V20, P1315, DOI 10.1158/1055-9965.EPI-10-1187
   Giuliano AR, 2011, NEW ENGL J MED, V364, P401, DOI 10.1056/NEJMoa0909537
   King EM, 2015, BRIT J CANCER, V112, P1585, DOI 10.1038/bjc.2015.90
   Lin A, 2017, CLIN INFECT DIS, V64, P580, DOI 10.1093/cid/ciw845
   Machalek DA, 2012, LANCET ONCOL, V13, P487, DOI 10.1016/S1470-2045(12)70080-3
   Meites E, 2016, J INFECT DIS, V214, P689, DOI 10.1093/infdis/jiw232
   Mooij SH, 2014, CANCER EPIDEM BIOMAR, V23, P2455, DOI 10.1158/1055-9965.EPI-14-0199
   Mooij SH, 2014, J INFECTION, V69, P375, DOI 10.1016/j.jinf.2014.06.003
   Palefsky JM, 2011, NEW ENGL J MED, V365, P1576, DOI 10.1056/NEJMoa1010971
   Poynten IM, 2017, PAPILLOMAVIRUS RES, V3, P80, DOI 10.1016/j.pvr.2017.02.003
   Poynten IM, 2016, SEX TRANSM INFECT, V92, P228, DOI 10.1136/sextrans-2015-052032
   Qendri V, 2018, EXPERT REV VACCINES, V17, P1093, DOI 10.1080/14760584.2018.1547196
   Ranjeva SL, 2017, P NATL ACAD SCI USA, V114, P13573, DOI 10.1073/pnas.1714712114
   Ryser MD, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004113
   Scherpenisse M, 2012, VACCINE, V30, P6686, DOI 10.1016/j.vaccine.2012.08.068
   Swedish KA, 2012, CLIN INFECT DIS, V54, P891, DOI 10.1093/cid/cir1036
   Szarewski A, 2012, INT J CANCER, V131, P106, DOI 10.1002/ijc.26362
   Twisk DE, 2018, J INFECT DIS, V218, P1018, DOI 10.1093/infdis/jiy276
   Villa LL, 2007, J INFECT DIS, V196, P1438, DOI 10.1086/522864
   Visser M, 2017, SEXUALLY TRANSMITTED
   Vriend HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060696
   Vriend HJ, 2012, SEX TRANSM DIS, V39, P72, DOI 10.1097/OLQ.0b013e318235b3b0
   WHO SAGE, UPD HPV VACC INTR PR
   Wilkin TJ, 2018, CLIN INFECT DIS, V67, P1339, DOI 10.1093/cid/ciy274
   Woestenberg PJ, 2019, INT J CANCER, V144, P2718, DOI 10.1002/ijc.31989
   Woestenberg Petra J, 2018, J Infect Dis, V217, P213, DOI 10.1093/infdis/jix582
   World Health Organization, GLOB MARK STUD HPV V
   Xiridou M, 2013, SEX TRANSM INFECT, V89, P666, DOI 10.1136/sextrans-2012-050900
   Zhang L, 2017, VACCINE, V35, P4923, DOI 10.1016/j.vaccine.2017.07.078
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3321
EP 3329
DI 10.1016/j.vaccine.2020.03.002
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800005
PM 32201140
OA Other Gold
DA 2020-05-12
ER

PT J
AU Takahashi, K
   Orito, N
   Yanagisawa, D
   Yano, A
   Mori, Y
   Inoue, N
AF Takahashi, Keita
   Orito, Nozomi
   Yanagisawa, Daiki
   Yano, Ayumu
   Mori, Yusuke
   Inoue, Naoki
TI Eosinophils are the main cellular targets for oral gene delivery using
   Lactic acid bacteria
SO VACCINE
LA English
DT Article
DE DNA vaccine; Mucosal vaccine; Lactococcus lactis; Eosinophil
ID BINDING PROTEIN-A; LACTOCOCCUS-LACTIS; DNA VACCINE; DENDRITIC CELLS;
   SAFETY; INTERNALIN; SUBSETS; PLASMID; SURFACE
AB Lactic acid bacteria have been studied as a vehicle for the delivery of plasmid DNA to the gastrointestinal tract. However, low levels of gene expression in vivo limit their practical use. Furthermore, it is still unclear how the orally administrated bacteria transfer their harbored plasmid DNA to host intestinal cells. To more easily track the delivery of plasmid DNA for eukaryotic expression in the intestine, we constructed an L. lactis-E. coli shuttle plasmid (pLEC) that allowed significantly elevated expression of the target protein of interest in eukaryotic cells. We first demonstrated its usefulness for delivery from L. lactis to Caco-2 cells in vitro. We then investigated the cellular target for the L. lactis DNA delivery system in vivo. Mice were orally administrated with LL/pLEC:EGFP, an L. lactis strain carrying pLEC for EGFP expression, and immunofluorescent analyses of frozen sections prepared from their small intestines identified a number of EGFP-expressing cells in the lamina propria and some in the sub-epithelial dome of the Peyer's patches. Flow cytometric analysis revealed that these EGFP-expressing cells were both CD11c- and F4/80-positive but CX(3)CR1-negative, suggesting that they are eosinophils. Immunostaining of the sections with an antibody against Siglec-F, a marker protein of eosinophils, confirmed the flow cytometric findings. Thus, the target cells of DNA delivery from L. lactis in the intestines are mainly eosinophils in the lamina propria and Peyer's patches. This finding may open a new approach to the development of DNA vaccines for oral administration. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Takahashi, Keita; Orito, Nozomi; Yanagisawa, Daiki; Yano, Ayumu; Mori, Yusuke; Inoue, Naoki] Gifu Pharmaceut Univ, Dept Microbiol & Immunol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
   [Yano, Ayumu] Denka Seiken Co Ltd, Niigata 9591695, Japan.
   [Mori, Yusuke] Shion Pharma Co Ltd, Osaka 5410045, Japan.
RP Takahashi, K (reprint author), Gifu Pharmaceut Univ, Dept Microbiol & Immunol, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.
EM takahashi@gifu-pu.ac.jp
OI Takahashi, Keita/0000-0002-0859-6449; Inoue, Naoki/0000-0002-9245-4979
FU Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [JP 19K16649]; Lactic Acid Bacteria Foundation
FX This study was supported by a Grant-in-Aid for Young Scientists B (JP
   19K16649) from the Japan Society for the Promotion of Science to KT and
   by a scholarship fund from the Lactic Acid Bacteria Foundation to NI.
CR Almeida JF, 2014, BMC MICROBIOL, V14, DOI 10.1186/s12866-014-0248-9
   Chatel JM, 2008, GENE THER, V15, P1184, DOI 10.1038/gt.2008.59
   Chu VT, 2014, IMMUNITY, V40, P582, DOI 10.1016/j.immuni.2014.02.014
   Collins MH, 2018, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00261
   de Azevedo M, 2015, VACCINE, V33, P4807, DOI 10.1016/j.vaccine.2015.07.077
   de Azevedo M, 2012, BMC MICROBIOL, V12, DOI 10.1186/1471-2180-12-299
   Felber BK, 2014, VACCINES-BASEL, V2, P354, DOI 10.3390/vaccines2020354
   Ferraro B, 2011, CLIN INFECT DIS, V53, P296, DOI 10.1093/cid/cir334
   Gicheva N, 2016, BIOCHEM BIOPH RES CO, V479, P1, DOI 10.1016/j.bbrc.2016.08.055
   GUIMARAES EMB, 2009, GENET VACCINES THER, V7, DOI DOI 10.1186/1479-0556-7-4
   Guimaraes VD, 2005, MICROBES INFECT, V7, P836, DOI 10.1016/j.micinf.2005.02.012
   Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365
   Innocentin S, 2009, APPL ENVIRON MICROB, V75, P4870, DOI 10.1128/AEM.00825-09
   Jang MH, 2004, P NATL ACAD SCI USA, V101, P6110, DOI 10.1073/pnas.0400969101
   Jung Y, 2014, J IMMUNOL, V193, P999, DOI 10.4049/jimmunol.1400413
   Kraemer LS, 2017, J MICROBIOL METH, V137, P19, DOI 10.1016/j.mimet.2017.03.015
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Le TP, 2000, VACCINE, V18, P1893, DOI 10.1016/S0264-410X(99)00407-7
   MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613
   Mancha-Agresti P, 2017, MOL THER-METH CLIN D, V4, P83, DOI 10.1016/j.omtm.2016.12.005
   Morikawa M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163607
   Ohno H, 2016, J BIOCHEM, V159, P151, DOI 10.1093/jb/mvv121
   Pabst O, 2010, EUR J IMMUNOL, V40, P2107, DOI 10.1002/eji.201040557
   Persson EK, 2013, EUR J IMMUNOL, V43, P3098, DOI 10.1002/eji.201343740
   Pontes D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084509
   Pontes D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044892
   Schuijs MJ, 2019, TRENDS IMMUNOL, V40, P22, DOI 10.1016/j.it.2018.11.001
   Song AAL, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0669-x
   Tacket CO, 1999, VACCINE, V17, P2826, DOI 10.1016/S0264-410X(99)00094-8
   Tao L, 2011, PLASMID, V65, P8, DOI 10.1016/j.plasmid.2010.09.001
   Williams JA, 2014, CURR GENE THER, V14, P170, DOI 10.2174/156652321403140819122538
   Williams JA, 2013, VACCINES, V1, P225, DOI 10.3390/vaccines1030225
   Wyszynska A, 2015, APPL MICROBIOL BIOT, V99, P2967, DOI [10.1007/s00253-015-6498-0, 10.1007/s00253-015-6569-2]
   Xenakis JJ, 2018, IMMUNOLOGY, V154, P298, DOI 10.1111/imm.12885
   Yano A, 2018, BIOL PHARM BULL, V41, P190, DOI 10.1248/bpb.b17-00657
   Yurina Valentina, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6020027
NR 36
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3330
EP 3338
DI 10.1016/j.vaccine.2020.02.084
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800006
PM 32197922
DA 2020-05-12
ER

PT J
AU Oesterreich, S
   Lindemann, M
   Goldblatt, D
   Horn, PA
   Wilde, B
   Witzke, O
AF Oesterreich, Simon
   Lindemann, Monika
   Goldblatt, David
   Horn, Peter A.
   Wilde, Benjamin
   Witzke, Oliver
TI Humoral response to a 13-valent pneumococcal conjugate vaccine in kidney
   transplant recipients
SO VACCINE
LA English
DT Article
DE Pneumococcal conjugate vaccine; Opsonophagocytic assay; Kidney
   transplant recipients; Serotype specific; Pneumococcal antibody global
   serum assays; Pneumococcal vaccination in immunocompromised individuals
ID STREPTOCOCCUS-PNEUMONIAE; CAPSULAR POLYSACCHARIDES;
   HAEMOPHILUS-INFLUENZAE; HEALTHY-CHILDREN; DOUBLE-BLIND; ANTIBODIES;
   ADULTS; IMMUNOGENICITY; IMMUNITY; SEROTYPE
AB Background: Vaccination against S. pneumoniae is recommended by national guidelines. Moderate immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) has been reported in adult kidney transplant recipients (KTR). This study further defines the immunogenicity of PCV13 in this cohort.
   Methods: 49 KTR were immunized with PCV13. A validated opsonophagocytic killing assay (OPA), a global anti-pneumococcal capsular polysaccharide (anti-PCP) IgG, IgG2, IgM and IgA ELISA, and - for selected patients - a serotype specific anti-PCP WHO reference ELISA were performed pre-vaccination and at month 1 and 12 post-vaccination.
   Results: Geometric mean OPA titers increased significantly for 13/13 serotypes at month 1 and for 10/13 serotypes at month 12 post-vaccination. Vaccine response defined as an OPA titer >= 1:8 was reached in 9/13 serotypes (median). 53% reached the vaccine response criteria at month 1 and 45% at month 12. At month 1 after vaccination, the median OPA titer in an age-group matched healthy reference population was 5- to 10-fold higher than in KTR. OPA titers correlated strongly with results to the global and serotype specific anti-PCP IgG ELISA. Lower OPA titers significantly (p < 0.05) correlated with albuminuria, an interval between vaccination and transplantation <12 months, age and treatment with mycophenolate mofetil. Global IgG, IgG2, IgM and IgA, as well as serotype specific anti-PCP antibody concentrations (12/13 serotypes) increased significantly at month 1 and 12 post-vaccination.
   Conclusions: Kidney transplant recipients show a significant humoral response after vaccination with PCV13. Functional antibody response exists, but is not as vigorous as in healthy adults. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Oesterreich, Simon; Witzke, Oliver] Univ Duisburg Essen, Univ Hosp Essen, Dept Infect Dis, Essen, Germany.
   [Oesterreich, Simon; Wilde, Benjamin] Univ Duisburg Essen, Univ Hosp Essen, Dept Nephrol, Essen, Germany.
   [Oesterreich, Simon; Lindemann, Monika; Horn, Peter A.] Univ Duisburg Essen, Univ Hosp Essen, Inst Transfus Med, Essen, Germany.
   [Goldblatt, David] UCL, Inst Child Hlth, London, England.
   [Goldblatt, David] WHO, Pneumococcal Serol Reference Lab, London, England.
RP Lindemann, M (reprint author), Univ Hosp Essen, Inst Transfus Med, Virchowstr 179, D-45147 Essen, Germany.
EM monika.lindemann@uk-essen.de
RI ; Goldblatt, David/C-5972-2008
OI Lindemann, Monika/0000-0001-6708-4390; Goldblatt,
   David/0000-0002-0769-5242
FU University Hospital Essen, University Duisburg-Essen, Essen, Germany
FX This study was funded by the University Hospital Essen, University
   Duisburg-Essen, Essen, Germany.
CR Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9
   [Anonymous], PNEUM DIS GLOB PNEUM
   [Anonymous], PNEUM SENT PNEUMOWEB
   [Anonymous], 2012, PNEUMOCOCCAL VACCINE
   Arason VA, 2006, MICROB DRUG RESIST, V12, P169, DOI 10.1089/mdr.2006.12.169
   Bennett Nancy M., 2012, Morbidity and Mortality Weekly Report, V61, P816
   Bonatti H, 2009, TRANSPL P, V41, P371, DOI 10.1016/j.transproceed.2008.10.045
   Bryant KA, 2015, VACCINE, V33, P5854, DOI 10.1016/j.vaccine.2015.08.080
   Cavaliere FM, 2013, J CLIN IMMUNOL, V33, P838, DOI 10.1007/s10875-012-9856-z
   Cooper D, 2011, VACCINE, V29, P7207, DOI 10.1016/j.vaccine.2011.06.056
   Crowther RR, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00255
   Daly TM, 2015, CLIN VACCINE IMMUNOL, V22, P148, DOI 10.1128/CVI.00735-14
   Dendle C, 2018, VACCINE, V36, P6253, DOI 10.1016/j.vaccine.2018.08.069
   Dendle C, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12866
   Fishman JA, 2017, TRANSPLANT INT OFF J
   Hu BT, 2005, CLIN DIAGN LAB IMMUN, V12, P287, DOI 10.1128/CDLI.12.2.287-295.2005
   Jackson LA, 2013, VACCINE, V31, P3577, DOI 10.1016/j.vaccine.2013.04.085
   Karlsson J, 2016, CLIN VACCINE IMMUNOL, V23, P379, DOI 10.1128/CVI.00654-15
   Kumar D, 2007, AM J TRANSPLANT, V7, P633, DOI 10.1111/j.1600-6143.2007.01668.x
   Kumar D, 2003, J INFECT DIS, V187, P1639, DOI 10.1086/374784
   Legris T, 2013, ANN TRANSPL, V18, P622, DOI 10.12659/AOT.889536
   Lindemann M, 2013, SCAND J IMMUNOL, V78, P554, DOI 10.1111/sji.12111
   Lindemann M, 2013, HUM IMMUNOL, V74, P1267, DOI 10.1016/j.humimm.2013.07.010
   Lindemann M, 2012, TRANSPLANTATION, V94, P50, DOI 10.1097/TP.0b013e318250fc8c
   Lindemann M, 2010, TRANSPLANTATION, V90, P1463, DOI 10.1097/TP.0b013e3181f5d878
   Meerveld-Eggink A, 2009, BIOL BLOOD MARROW TR, V15, P1523, DOI 10.1016/j.bbmt.2009.07.020
   Miller E, 2011, LANCET INFECT DIS, V11, P760, DOI 10.1016/S1473-3099(11)70090-1
   Musher DM, 2017, CLIN INFECT DIS, V65, P1736, DOI 10.1093/cid/cix549
   Orange JS, 2012, J ALLERGY CLIN IMMUN, V130, pS1, DOI 10.1016/j.jaci.2012.07.002
   Orsi A, 2016, INT J MOL SCI, V17
   Papadatou I, 2016, CLIN VACCINE IMMUNOL, V23, P388, DOI 10.1128/CVI.00721-15
   Parker Antony R, 2016, Pract Lab Med, V5, P1, DOI 10.1016/j.plabm.2016.02.004
   Pichichero ME, 2016, HUM VACC IMMUNOTHER, V12, P194, DOI 10.1080/21645515.2015.1052198
   Prymula R, 2006, LANCET, V367, P740, DOI 10.1016/S0140-6736(06)68304-9
   Romero-Steiner S, 2006, CLIN VACCINE IMMUNOL, V13, P165, DOI 10.1128/CVI.13.2.165-169.2006
   Rose MA, 2013, MED MICROBIOL IMMUN, V202, P285, DOI 10.1007/s00430-013-0292-3
   Rubin RH, 2008, TRANSPL INFECT DIS, V10, P1, DOI 10.1111/j.1399-3062.2008.00297.x
   Schauer U, 2003, CLIN DIAGN LAB IMMUN, V10, P202, DOI 10.1128/CDLI.10.2.202-207.2003
   Shigayeva A, 2016, CLIN INFECT DIS, V62, P139, DOI 10.1093/cid/civ803
   Soininen A, 1999, VACCINE, V17, P1889, DOI 10.1016/S0264-410X(98)00475-7
   Song JY, 2013, J INFECT CHEMOTHER, V19, P412, DOI 10.1007/s10156-013-0601-1
   Tarrago D, 2007, CLIN MICROBIOL INFEC, V13, P369, DOI 10.1111/j.1469-0691.2006.01677.x
   Tobudic S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046133
   Turk T, 2010, NEPHROLOGE, V5, P94
   Vandecasteele SJ, 2015, CLIN KIDNEY J, V8, P318, DOI 10.1093/ckj/sfv030
   Wernette CM, 2003, CLIN DIAGN LAB IMMUN, V10, P514, DOI 10.1128/CDLI.10.4.514-519.2003
   Westerink MAJ, 2012, AGING DIS, V3, P51
   Wilson R, 2015, MUCOSAL IMMUNOL, V8, P627, DOI 10.1038/mi.2014.95
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3339
EP 3350
DI 10.1016/j.vaccine.2020.02.088
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800007
PM 32178906
DA 2020-05-12
ER

PT J
AU Carias, C
   Hills, SL
   Kahn, EB
   Adhikari, BB
   Fischer, M
   Meltzer, MI
AF Carias, Cristina
   Hills, Susan L.
   Kahn, Emily B.
   Adhikari, Bishwa B.
   Fischer, Marc
   Meltzer, Martin, I
TI Comparative economic analysis of strategies for Japanese encephalitis
   vaccination of US travelers
SO VACCINE
LA English
DT Article
DE Japanese encephalitis; Japanese encephalitis vaccine; Numbers needed to
   treat; Cost-effectiveness; Travel
ID ADVISORY-COMMITTEE; COST-EFFECTIVENESS; RECOMMENDATIONS; IMMUNIZATION
AB Background: Japanese encephalitis (JE) virus is the leading vaccine-preventable cause of encephalitis in Asia. For most travelers, JE risk is very low but varies based on several factors, including travel duration, location, and activities. To aid public health officials, health care providers, and travelers evaluate the worth of administering/receiving pre-travel JE vaccinations, we estimated the numbers-needed-to-treat to prevent a case and the cost-effectiveness ratios of JE vaccination for U.S. travelers in different risk categories.
   Methods: We used a decision tree model to estimate cost per case averted from a societal and traveler perspective for hypothetical cohorts of vaccinated and unvaccinated travelers. Risk Category I included travelers planning to spend >= 1 month in JE-endemic areas, Risk Category II were shorter-term (<1 month) travelers spending >= 20% of their time doing outdoor activities in rural areas, and Risk Category III were all remaining travelers. We performed sensitivity analyses including examining changes in cost-effectiveness with 10- and 100-fold increases in incidence and medical treatment costs.
   Results: The numbers-needed-to-treat to prevent a case and cost per case averted were approximately 0.7 million and $0.6 billion for Risk Category I, 1.6 million and $1.2 billion for Risk Category II, and 9.8 million and $7.6 billion for Risk Category III. Increases of 10-fold and 100-fold in disease incidence proportionately decreased cost-effectiveness ratios. Similar levels of increases in medical treatment costs resulted in negligible changes in cost-effectiveness ratios.
   Conclusion: Numbers-needed-to-treat and cost-effectiveness ratios associated with preventing JE cases in U.S. travelers by vaccination varied greatly by risk category and disease incidence. While cost effectiveness ratios are not the sole rationale for decision-making regarding JE vaccination, the results presented here can aid in making such decisions under very different risk and cost scenarios. Published by Elsevier Ltd.
C1 [Carias, Cristina; Kahn, Emily B.; Adhikari, Bishwa B.; Meltzer, Martin, I] Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Emergency Preparedness & Response Branch, 1600 Clifton Rd MS H24-11, Atlanta, GA 30329 USA.
   [Hills, Susan L.; Fischer, Marc] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arboviral Dis Branch, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
RP Hills, SL (reprint author), Ctr Dis Control & Prevent, 3156 Rampart Rd, Ft Collins, CO 80521 USA.
EM shills@cdc.gov
CR [Anonymous], 1982, HIST CONS PRIC IND A
   BEHRENS RH, 1994, BRIT MED J, V309, P918, DOI 10.1136/bmj.309.6959.918
   Campbell GL, 2011, B WORLD HEALTH ORGAN, V89, P766, DOI 10.2471/BLT.10.085233
   Coleman MS, 2005, VACCINE, V23, P915, DOI 10.1016/j.vaccine.2004.07.028
   Deshpande BR, 2014, AM J TROP MED HYG, V91, P694, DOI 10.4269/ajtmh.14-0062
   Duffy MR, 2013, J TRAVEL MED, V20, P165, DOI 10.1111/jtm.12020
   Grosse SD, 2016, J MED ECON, V2018, P1
   Hills SL, 2017, CDC YELLOW BOOK 2018, P214
   Hills SL, 2019, MMWR RECOMM REP, V68, P1
   Hills SL, 2010, AM J TROP MED HYG, V82, P930, DOI 10.4269/ajtmh.2010.09-0676
   IBM Micromedex, IBM MICR RED BOOK ON
   Lee G, 2018, MMWR-MORBID MORTAL W, V67, P1271, DOI 10.15585/mmwr.mm6745a4
   Lopez-Gigosos R, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-65
   Lundkvist J, 2009, J TRAVEL MED, V16, P28, DOI 10.1111/j.1708-8305.2008.00270.x
   Paulke-Korinek M, 2015, VACCINE, V33, P3600, DOI 10.1016/j.vaccine.2015.05.037
   Rabe IB, 2015, VACCINE, V33, P708, DOI 10.1016/j.vaccine.2014.11.046
   Rogers WH, 2019, J OCCUP ENVIRON MED, V61, P16, DOI 10.1097/JOM.0000000000001474
   Schuller E, 2008, VACCINE, V26, P6151, DOI 10.1016/j.vaccine.2008.08.056
   Shankar MB, 2017, VACCINE, V35, P3143, DOI 10.1016/j.vaccine.2016.11.078
   Siraprapasiri T, 1997, Southeast Asian J Trop Med Public Health, V28, P143
   Solomon T, 2000, J NEUROL NEUROSUR PS, V68, P405, DOI 10.1136/jnnp.68.4.405
   Staples JE, 2014, AM J TROP MED HYG, V90, P402, DOI 10.4269/ajtmh.13-0206
   Taucher C, 2019, VACCINE, V37, P2529, DOI 10.1016/j.vaccine.2019.03.030
   Touch S, 2010, VACCINE, V28, P4593, DOI 10.1016/j.vaccine.2010.04.086
   Walker WL, 2018, VACCINE, V36, P4369, DOI 10.1016/j.vaccine.2018.04.038
   Yin ZD, 2012, VACCINE, V30, P5569, DOI 10.1016/j.vaccine.2012.05.068
NR 26
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3351
EP 3357
DI 10.1016/j.vaccine.2020.02.032
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800008
PM 32169391
DA 2020-05-12
ER

PT J
AU Mohammed, H
   Roberts, CT
   Grzeskowiak, LE
   Giles, L
   Leemaqz, S
   Dalton, J
   Dekker, G
   Marshall, HS
AF Mohammed, Hassen
   Roberts, Claire T.
   Grzeskowiak, Luke E.
   Giles, Lynne
   Leemaqz, Shalem
   Dalton, Julia
   Dekker, Gustaaf
   Marshall, Helen S.
TI Psychosocial determinants of pertussis and influenza vaccine uptake in
   pregnant women: A prospective study
SO VACCINE
LA English
DT Article
DE Maternal immunization; Pertussis; Influenza; Psychosocial factors;
   Provider recommendation
ID UNITED-STATES; ATTITUDES; COVERAGE; PREDICTORS; DIPHTHERIA; BEHAVIORS;
   KNOWLEDGE; BELIEFS; TETANUS; INFANTS
AB Objective: To identify the psychosocial factors influencing women's uptake and willingness to receive pertussis and influenza vaccine during pregnancy.
   Methods: The study population comprised 1364 healthy nulliparous pregnant women who participated in a prospective cohort study at two obstetric hospitals in South Australia between 2015 and 2017. Information on women's vaccination status, sociodemographic, lifestyle and psychological state were collected at 9-16 weeks' gestation and medical case notes were checked post-delivery to verify the reported vaccination status. Poisson regression models were used to estimate the crude and adjusted prevalence ratios (aPRs) to identify psychosocial factors influencing uptake of vaccination during pregnancy.
   Results: Willingness to receive the recommended maternal vaccines was high (90%). Overall, 79% and 48% received maternal pertussis and influenza vaccines respectively. There was no evidence to support the influence of psychosocial factors on women's willingness to receive immunization during pregnancy. High levels of anxiety (aPR 0.98, 95% CI: 0.87-1.09) was not associated with uptake of maternal pertussis vaccine. However, elevated depressive symptoms (aPR 1.14, 95% CI: 1.00-1.30) and very high-perceived stress during pregnancy were significantly associated with receipt of pertussis vaccination (aPR 0.87; 95% CI 0.76-0.99). Women with mild depressive symptoms (aPR 1.21, 95% CI 1.00-1.44) and mild anxiety symptoms (aPR 1.21, 95% CI: 0.99-1.48) were more likely to receive influenza vaccine during pregnancy. A history of major depressive disorder was independently associated with receipt of pertussis (aPR 1.16, 95% CI 1.06-1.26) and influenza vaccination during pregnancy (aPR 1.32; 95% CI 1.14-1.58).
   Conclusion: Regardless of psychosocial factors, most women reported a positive willingness to receive the recommended vaccinations during pregnancy. However, psychosocial factors influenced the uptake of pertussis and influenza vaccines during pregnancy. Psychosocial factors should be taken into consideration in designing interventions and implementation of maternal pertussis and influenza immunization programs. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Mohammed, Hassen; Marshall, Helen S.] Womens & Childrens Hosp, Vaccinol & Immunol Res Trials Unit, 72 King William Rd, Adelaide, SA 5006, Australia.
   [Mohammed, Hassen; Roberts, Claire T.; Grzeskowiak, Luke E.; Giles, Lynne; Leemaqz, Shalem; Dalton, Julia; Marshall, Helen S.] Univ Adelaide, Robinson Res Inst, Adelaide, SA, Australia.
   [Dekker, Gustaaf] Univ Adelaide, Lyell McEwin Hosp, Northern Campus Womens & Childrens Div, Elizabeth Vale, SA, Australia.
RP Marshall, HS (reprint author), Womens & Childrens Hosp, Vaccinol & Immunol Res Trials Unit, 72 King William Rd, Adelaide, SA 5006, Australia.
EM hassen.mohammed@adelaide.edu.au; claire.roberts@adelaide.edu.au;
   luke.grzeskowiak@adelaide.edu.au; lynne.giles@adelaide.edu.au;
   shalem.leemaqz@adelaide.edu.au; julia.dalton@adelaide.edu.au;
   gustaaf.dekker@adelaide.edu.au; helen.marshall@adelaide.edu.au
FU University of Adelaide
FX The Screening Tests to predict poor Outcomes of Pregnancy (STOP) study
   was funded by the University of Adelaide. The authors would like to
   thank all of the women who participated in the STOP study, Samantha Pahl
   and Suzette Coat for their assistance with recruitment and data
   collection.
CR Amirthalingam G, 2014, LANCET, V384, P1521, DOI 10.1016/S0140-6736(14)60686-3
   [Anonymous], 2020, HLTH PEOPL 2020, V2019
   Austin Marie-Paule, 2003, Aust Fam Physician, V32, P119
   Austin MP, 2013, WOMEN BIRTH, V26, P17, DOI 10.1016/j.wombi.2011.06.002
   Australian Goverment Department of Health, 2019, INFL FLU
   Barber A, 2017, MMWR-MORBID MORTAL W, V66, P56, DOI 10.15585/mmwr.mm6602a4
   Barrett G, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0672-3
   Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21
   Benowitz I, 2010, CLIN INFECT DIS, V51, P1355, DOI 10.1086/657309
   Blanchard-Rohner G, 2011, VACCINE, V29, P7542, DOI 10.1016/j.vaccine.2011.08.013
   Buist A, 2014, AUST FAM PHYSICIAN, V43, P182
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782
   Dabrera G, 2015, CLIN INFECT DIS, V60, P333, DOI 10.1093/cid/ciu821
   Department for Health and Ageing, 2017, S AUSTR PER PRACT GU
   Haslam C, 2003, FAM PRACT, V20, P528, DOI 10.1093/fampra/cmg506
   Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152
   Kahn KE, 2018, MMWR-MORBID MORTAL W, V67, P1055, DOI 10.15585/mmwr.mm6738a3
   Koepke R, 2015, MMWR-MORBID MORTAL W, V64, P746
   Laenen J, 2015, VACCINE, V33, P2125, DOI 10.1016/j.vaccine.2015.03.020
   MacDougall DM, 2016, HUM VACC IMMUNOTHER, V12, P879, DOI 10.1080/21645515.2015.1130193
   Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480
   MARTEAU TM, 1992, BRIT J CLIN PSYCHOL, V31, P301, DOI 10.1111/j.2044-8260.1992.tb00997.x
   McMillan M, 2015, VACCINE, V33, P2108, DOI 10.1016/j.vaccine.2015.02.068
   McMillan M, 2017, OBSTET GYNECOL, V129, P560, DOI 10.1097/AOG.0000000000001888
   McNeil SA, 2011, AM J OBSTET GYNECOL, V204, pS54, DOI 10.1016/j.ajog.2011.04.031
   Mohammed H, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214538
   Mohammed H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197867
   Moniz MH, 2014, HUM VACC IMMUNOTHER, V10, P2562, DOI 10.4161/21645515.2014.970901
   Munoz Flor M, 2006, Semin Pediatr Infect Dis, V17, P14, DOI 10.1053/j.spid.2005.11.005
   Myers KL, 2016, VACCINE, V34, P3942, DOI 10.1016/j.vaccine.2016.06.042
   Omidvar S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191723
   Public Health England, 2018, PERT VACC PROGR PREG
   Quinn HE, 2007, COMMUN DIS INTELL, V31, P205
   Rasmussen SA, 2012, AM J OBSTET GYNECOL, V207, pS3, DOI 10.1016/j.ajog.2012.06.068
   REUMAN PD, 1987, PEDIATR INFECT DIS J, V6, P398, DOI 10.1097/00006454-198704000-00011
   Rowe SL, 2019, MED J AUSTRALIA, V210, P454, DOI 10.5694/mja2.50125
   Shishehgar S, 2013, IRAN RED CRESCENT ME, V15, P560, DOI 10.5812/ircmj.12174
   Silverman NS, 2001, J REPROD MED, V46, P989
   Taksdal SE, 2013, AUST FAM PHYSICIAN, V42, P582
   Tong A, 2008, J OBSTET GYNAECOL CA, V30, P404, DOI 10.1016/S1701-2163(16)32825-0
   Weinstein ND, 2007, HEALTH PSYCHOL, V26, P146, DOI 10.1037/0278-6133.26.2.146
   Wilcox CR, 2018, PEDIAT INFECT DIS J
   Wiley KE, 2015, QUAL HEALTH RES, V25, P360, DOI 10.1177/1049732314551061
   Williams L, 2012, MATERN CHILD HLTH J, V16, P1854, DOI 10.1007/s10995-011-0932-4
   Wilson RJ, 2015, VACCINE, V33, P6420, DOI 10.1016/j.vaccine.2015.08.046
   Yudin MH, 2014, IN J WOMENS HEALTH, V6, P681, DOI 10.2147/IJWH.S47235
   Yuen CYS, 2014, VACCINE, V32, P4602, DOI 10.1016/j.vaccine.2014.06.067
NR 48
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3358
EP 3368
DI 10.1016/j.vaccine.2020.02.020
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800009
PM 32070678
DA 2020-05-12
ER

PT J
AU Albershardt, TC
   Parsons, AJ
   Reeves, RS
   Flynn, PA
   Campbell, DJ
   Ter Meulen, J
   Berglund, P
AF Albershardt, Tina Chang
   Parsons, Andrea Jean
   Reeves, Rebecca Susan
   Flynn, Patrick Alexander
   Campbell, David James
   Ter Meulen, Jan
   Berglund, Peter
TI Therapeutic efficacy of PD1/PDL1 blockade in B16 melanoma is greatly
   enhanced by immunization with dendritic cell-targeting lentiviral vector
   and protein vaccine
SO VACCINE
LA English
DT Article
DE Lentiviral vector; TLR4 agonist; Immune checkpoint inhibitors
ID SYNTHETIC TLR4 AGONIST; IMMUNE-RESPONSES; SYNOVIAL SARCOMA; PD-1
   PATHWAY; T-CELLS; CTLA-4; 1ST-IN-HUMAN; PHASE; GLA; EXPRESSION
AB While immune checkpoint inhibition is rapidly becoming standard of care in many solid tumors, immune checkpoint inhibitors (ICIs) fail to induce clinical responses in many patients, presumably due to insufficient numbers of tumor-specific T cells in the tumor milieu. To this end, immunization protocols using viral vectors expressing tumor-associated antigens are being explored to induce T cell responses that synergize with ICIs. However, the optimal combination of vaccine and immune checkpoint regimen remains undefined. Here, a dendritic cell-targeting lentiviral vector (ZVex (R)) expressing the endogenous murine tyrosinase-related protein 1 (mTRP1), or the human tumor antigen NY-ESO-1, was explored as monotherapy or heterologous prime-boost (HPB) vaccine regimen together with recombinant tumor antigen in the murine B16 melanoma model. PD1/PDL1 blockade significantly enhanced ZVex/mTRP1, but not ZVex/NY-ESO-1, induced immune responses in mice, whereas the opposite effect was observed with anti-CTLA4 antibody. Anti-tumor efficacy of anti-PD1, but not anti-PDL1 or anti-CTLA4, was significantly enhanced by ZVex/mTRP1 and HPB vaccination. These results suggest mechanistic differences in the effect of checkpoint blockade on vaccine-induced immune and anti-tumor responses against self versus non-self tumor antigens, possibly due to tolerance and state of exhaustion of anti-tumor T cells. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Albershardt, Tina Chang; Parsons, Andrea Jean; Reeves, Rebecca Susan; Flynn, Patrick Alexander; Campbell, David James; Ter Meulen, Jan; Berglund, Peter] Immune Design, Kenilworth, NJ USA.
RP Albershardt, TC (reprint author), 1616 Eastlake Ave E,Suite 310, Seattle, WA 98102 USA.
EM tina.immunedesign@gmail.com
OI Flynn, Patrick/0000-0003-4174-5562
CR Albershardt TC, 2016, Mol Ther-Oncolytics, V3, DOI 10.1038/mto.2016.10
   Azijli K, 2014, ANTICANCER RES, V34, P1493
   Bevan MJ, 2004, NAT REV IMMUNOL, V4, P595, DOI 10.1038/nri1413
   Blank C, 2004, CANCER RES, V64, P1140, DOI 10.1158/0008-5472.CAN-03-3259
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   Buchbinder EI, 2016, AM J CLIN ONCOL-CANC, V39, P98, DOI 10.1097/COC.0000000000000239
   Coler RN, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0057-5
   Coler RN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016333
   Erickson JJ, 2012, J CLIN INVEST, V122, P2967, DOI 10.1172/JCI62860
   Falloon J, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/cvi.00157-17, 10.1128/CVI.00157-17]
   Falloon J, 2016, VACCINE, V34, P2847, DOI 10.1016/j.vaccine.2016.04.002
   Freeman GJ, 2006, J EXP MED, V203, P2223, DOI 10.1084/jem.20061800
   Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5
   He Y, 2007, CURR OPIN MOL THER, V9, P439
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Jenkins RW, 2018, BRIT J CANCER, V118, P9, DOI 10.1038/bjc.2017.434
   Jin HT, 2011, CURR TOP MICROBIOL, V350, P17, DOI 10.1007/82_2010_116
   Kamphorst AO, 2013, CURR OPIN IMMUNOL, V25, P381, DOI 10.1016/j.coi.2013.03.003
   Keir ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776
   LaFleur MW, 2018, J IMMUNOL, V200, P375, DOI 10.4049/jimmunol.1701044
   Lambert SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119509
   Lee Junghwa, 2015, For Immunopathol Dis Therap, V6, P7, DOI 10.1615/ForumImmunDisTher.2015014188
   Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016
   Mahipal A, 2019, CANCER IMMUNOL IMMUN, V68, P1211, DOI 10.1007/s00262-019-02331-x
   Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8
   Odegard JM, 2016, VACCINE, V34, P101, DOI 10.1016/j.vaccine.2015.10.137
   Odegard JM, 2015, J IMMUNOTHER, V38, P41, DOI 10.1097/CJI.0000000000000067
   Okazaki T, 2007, INT IMMUNOL, V19, P813, DOI 10.1093/intimm/dxm057
   Orr MT, 2013, EUR J IMMUNOL, V43, P2398, DOI 10.1002/eji.201243124
   Pantel A, 2012, EUR J IMMUNOL, V42, P101, DOI 10.1002/eji.201141855
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Peggs KS, 2009, J EXP MED, V206, P1717, DOI 10.1084/jem.20082492
   Peggs KS, 2006, CURR OPIN IMMUNOL, V18, P206, DOI 10.1016/j.coi.2006.01.011
   Pollack SM, 2018, EXPERT REV VACCINES, V17, P107, DOI 10.1080/14760584.2018.1419068
   Pollack SM, 2017, J IMMUNOTHER, V40, P302, DOI 10.1097/CJI.0000000000000183
   Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358
   Reed SG, 2016, CURR OPIN IMMUNOL, V41, P85, DOI 10.1016/j.coi.2016.06.007
   Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060
   Rudd CE, 2009, IMMUNOL REV, V229, P12, DOI 10.1111/j.1600-065X.2009.00770.x
   Seya T, 2016, IMMUNOTHER CANC, P235
   Seydoux E, 2018, J IMMUNOL, V201, P98, DOI 10.4049/jimmunol.1701604
   Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172
   Somaiah N, 2019, CLIN CANC RES
   Tareen SU, 2014, MOL THER, V22, P575, DOI 10.1038/mt.2013.278
   Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001
   Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035
   Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062
   Woodland DL, 2004, TRENDS IMMUNOL, V25, P98, DOI 10.1016/j.it.2003.11.009
   Yang HG, 2011, CANCER GENE THER, V18, P370, DOI 10.1038/cgt.2011.13
   Yao S, 2009, BLOOD, V113, P5811, DOI 10.1182/blood-2009-02-203141
   Zinkemagel RM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00030
NR 51
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3369
EP 3377
DI 10.1016/j.vaccine.2020.02.034
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800010
PM 32088020
DA 2020-05-12
ER

PT J
AU Tretyakova, I
   Plante, KS
   Rossi, SL
   Lawrence, WS
   Peel, JE
   Gudjohnsen, S
   Wang, E
   Mirchandani, D
   Tibbens, A
   Lamichhane, TN
   Lukashevich, IS
   Comer, JE
   Weaver, SC
   Pushko, P
AF Tretyakova, Irina
   Plante, Kenneth S.
   Rossi, Shannan L.
   Lawrence, William S.
   Peel, Jennifer E.
   Gudjohnsen, Sif
   Wang, Eryu
   Mirchandani, Divya
   Tibbens, Alexander
   Lamichhane, Tek N.
   Lukashevich, Igor S.
   Comer, Jason E.
   Weaver, Scott C.
   Pushko, Peter
TI Venezuelan equine encephalitis vaccine with rearranged genome resists
   reversion and protects non-human primates from viremia after aerosol
   challenge
SO VACCINE
LA English
DT Article
DE DNA vaccine; Live-attenuated vaccine; iDNA; Infectious clone; Venezuelan
   equine encephalitis virus; VEEV; VEE; TC83; TC-83; V4020
ID LIVE-ATTENUATED VACCINES; NEUTRALIZING ANTIBODIES; IMMUNE-RESPONSE; DNA
   VACCINE; IN-VITRO; INITIATES REPLICATION; INJECTION-SITE; NEEDLE LENGTH;
   VIRUS; ENCEPHALOMYELITIS
AB Live-attenuated V4020 vaccine for Venezuelan equine encephalitis virus (VEEV) containing attenuating rearrangement of the virus structural genes was evaluated in a non-human primate model for immunogenicity and protective efficacy against aerosol challenge with wild-type VEEV. The genomic RNA of V4020 vaccine virus was encoded in the pMG4020 plasmid under control of the CMV promoter and contained the capsid gene downstream from the glycoprotein genes. It also included attenuating mutations from the VEE TC83 vaccine, with E2-120Arg substitution genetically engineered to prevent reversion mutations. The population of V4020 vaccine virus derived from pMG4020-transfected Vero cells was characterized by next generation sequencing (NGS) and indicated no detectable genetic reversions. Cynomolgus macaques were vaccinated with V4020 vaccine virus. After one or two vaccinations including by intramuscular route, high levels of virus-neutralizing antibodies were confirmed with no viremia or apparent adverse reactions to vaccinations. The protective effect of vaccination was evaluated using an aerosol challenge with VEEV. After challenge, macaques had no detectable viremia, demonstrating a protective effect of vaccination with live V4020 VEEV vaccine. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Tretyakova, Irina; Tibbens, Alexander; Lamichhane, Tek N.; Pushko, Peter] Medigen Inc, 8420 Gas House Pike,Suite S, Frederick, MD 21701 USA.
   [Plante, Kenneth S.; Rossi, Shannan L.; Lawrence, William S.; Peel, Jennifer E.; Gudjohnsen, Sif; Wang, Eryu; Mirchandani, Divya; Comer, Jason E.; Weaver, Scott C.] Univ Texas Med Branch, Inst Human Infect & Immun, Galveston, TX 77555 USA.
   [Plante, Kenneth S.; Rossi, Shannan L.; Lawrence, William S.; Peel, Jennifer E.; Gudjohnsen, Sif; Wang, Eryu; Mirchandani, Divya; Comer, Jason E.; Weaver, Scott C.] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA.
   [Plante, Kenneth S.; Gudjohnsen, Sif; Mirchandani, Divya; Comer, Jason E.; Weaver, Scott C.] Univ Texas Med Branch, World Reference Ctr Emerging Viruses & Arboviruse, Galveston, TX 77555 USA.
   [Lukashevich, Igor S.] Univ Louisville, Dept Pharmacol & Toxicol, 505 S Hancock St, Louisville, KY 40202 USA.
RP Tretyakova, I; Pushko, P (reprint author), Medigen Inc, 8420 Gas House Pike,Suite S, Frederick, MD 21701 USA.
EM itretyakova@medigen-usa.com; ppushko@medigen-usa.com
FU National Institute of Allergy and Infectious Diseases of the National
   Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [AI094863]
FX We sincerely thank Rachel Sklutuis and Pavel Skums for their
   contributions. The authors declare that they have no known conflicts of
   interest. IT and PP are Medigen shareholders. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the funding agency. Research reported in this
   publication was supported by the National Institute of Allergy and
   Infectious Diseases of the National Institutes of Health under Award
   Number AI094863.
CR BERGE TO, 1961, J IMMUNOL, V87, P509
   BERGE TO, 1961, AM J HYG, V73, P209, DOI 10.1093/oxfordjournals.aje.a120178
   Brault AC, 2004, P NATL ACAD SCI USA, V101, P11344, DOI 10.1073/pnas.0402905101
   Bull JJ, 2015, VIRUS EVOL, V1, DOI 10.1093/ve/vev005
   Coffey LL, 2011, P NATL ACAD SCI USA, V108, P16038, DOI 10.1073/pnas.1111650108
   Cozzi E, 2000, TRANSPLANTATION, V70, P15
   DAVIS NL, 1995, VIROLOGY, V212, P102, DOI 10.1006/viro.1995.1458
   DAVIS NL, 1989, VIROLOGY, V171, P189, DOI 10.1016/0042-6822(89)90526-6
   Dupuy LC, 2011, CLIN VACCINE IMMUNOL, V18, P707, DOI 10.1128/CVI.00030-11
   Dupuy LC, 2010, VACCINE, V28, P7345, DOI 10.1016/j.vaccine.2010.09.005
   Dye JM, 2012, P NATL ACAD SCI USA, V109, P5034, DOI 10.1073/pnas.1200409109
   Erasmus JH, 2018, J VIROL, V92, DOI 10.1128/JVI.01274-17
   Fine DL, 2007, VACCINE, V25, P1868, DOI 10.1016/j.vaccine.2006.10.030
   Fine DL, 2010, J VIROL METHODS, V163, P424, DOI 10.1016/j.jviromet.2009.11.006
   Flanagan EB, 2003, J VIROL, V77, P5740, DOI 10.1128/JVI.77.10.5740-5748.2003
   Glass PJ, 2007, CHIKUNGUNYA VIRUS ST
   Go YY, 2014, CLIN EXP VACCINE RES, V3, P58, DOI 10.7774/cevr.2014.3.1.58
   Gorchakov R, 2012, J VIROL, V86, P6084, DOI 10.1128/JVI.06449-11
   Gorguner M, 2010, EURASIAN J MED, V42, P28, DOI 10.5152/eajm.2010.09
   Grabenstein JD, 2006, EPIDEMIOL REV, V28, P3, DOI 10.1093/epirev/mxj003
   GREENBLATT DJ, 1978, JAMA-J AM MED ASSOC, V240, P542, DOI 10.1001/jama.240.6.542
   Grossegesse M, 2017, VIRUSES, V9
   Groswasser J, 1997, PEDIATRICS, V100, P400, DOI 10.1542/peds.100.3.400
   Haramati N, 1994, Arch Fam Med, V3, P146, DOI 10.1001/archfami.3.2.146
   Hodgson LA, 1999, VACCINE, V17, P1151, DOI 10.1016/S0264-410X(98)00335-1
   Hoke Charles H Jr, 2005, Mil Med, V170, P92
   Kendra JA, 2017, J VIROL, V91, DOI 10.1128/JVI.01766-16
   Kenney JL, 2011, VACCINE, V29, P2230, DOI 10.1016/j.vaccine.2011.01.055
   Kim DY, 2011, J VIROL, V85, P8022, DOI 10.1128/JVI.00644-11
   KINNEY RM, 1993, J VIROL, V67, P1269, DOI 10.1128/JVI.67.3.1269-1277.1993
   Kitchen LW, 2007, VACCINE, V25, P7017, DOI 10.1016/j.vaccine.2007.07.030
   Ko SY, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav3113
   Koscielniak D, 2018, MICROB CELL FACT, V17, DOI 10.1186/s12934-018-1034-4
   Ly HJ, 2017, VACCINE, V35, P6634, DOI 10.1016/j.vaccine.2017.10.036
   Ma H, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040240
   Martin SS, 2010, VACCINE, V28, P3143, DOI 10.1016/j.vaccine.2010.02.056
   Martin SS, 2010, VACCINE, V28, P1031, DOI 10.1016/j.vaccine.2009.10.126
   MICHAELS L, 1970, CAN MED ASSOC J, V102, P626
   Nickols B, 2017, VIROLOGY, V512, P66, DOI 10.1016/j.virol.2017.09.005
   Olspert A, 2015, EMBO REP, V16, P995, DOI 10.15252/embr.201540509
   Paessler S, 2006, J VIROL, V80, P2784, DOI 10.1128/JVI.80.6.2784-2796.2006
   Paessler S, 2003, J VIROL, V77, P9278, DOI 10.1128/JVI.77.17.9278-9286.2003
   Paessler S, 2009, VACCINE, V27, pD80, DOI 10.1016/j.vaccine.2009.07.095
   Phillpotts RJ, 1999, VACCINE, V17, P982, DOI 10.1016/S0264-410X(98)00315-6
   Pittman PR, 1996, VACCINE, V14, P337, DOI 10.1016/0264-410X(95)00168-Z
   Poirier EZ, 2016, J VIROL, V90, P2446, DOI 10.1128/JVI.02921-15
   Poland GA, 1997, JAMA-J AM MED ASSOC, V277, P1709, DOI 10.1001/jama.277.21.1709
   Pratt WD, 2003, VACCINE, V21, P3854, DOI 10.1016/S0264-410X(03)00328-1
   Preiss S, 2016, VACCINE, V34, P6665, DOI 10.1016/j.vaccine.2016.10.079
   Pushko P, 2001, U.S. Patent, Patent No. 6296854
   Pushko P, 2016, EXPERT REV VACCINES, V15, P1223, DOI 10.1080/14760584.2016.1175943
   Reed DS, 2005, VACCINE, V23, P3139, DOI 10.1016/j.vaccine.2004.12.023
   Reed DS, 2004, J INFECT DIS, V189, P1013, DOI 10.1086/382281
   ROMANOS J, 1994, EUR J SURG, V160, P643
   Rossi SL, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003797
   Rouxel RN, 2016, J VIROL, V90, P10857, DOI 10.1128/JVI.01024-16
   SCHERER WF, 1987, AM J TROP MED HYG, V36, P194, DOI 10.4269/ajtmh.1987.36.194
   Sharma A, 2011, VACCINE, V29, P953, DOI 10.1016/j.vaccine.2010.11.033
   SHAW FE, 1989, VACCINE, V7, P425, DOI 10.1016/0264-410X(89)90157-6
   SMART D L, 1975, Journal of Wildlife Diseases, V11, P195
   Srichana T, 2016, BIOL PHARM BULL, V39, P1815, DOI 10.1248/bpb.b16-00354
   Steele KE, 1998, VET PATHOL, V35, P386, DOI 10.1177/030098589803500508
   STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994
   Tretyakova I, 2019, VACCINE, V37, P3317, DOI 10.1016/j.vaccine.2019.04.072
   Tretyakova I, 2014, VIROLOGY, V468, P28, DOI 10.1016/j.virol.2014.07.050
   Tretyakova I, 2014, J INFECT DIS, V209, P1882, DOI 10.1093/infdis/jiu114
   Tretyakova I, 2013, VACCINE, V31, P1019, DOI 10.1016/j.vaccine.2012.12.050
   Vaughn JA, 2011, AM FAM PHYSICIAN, V84, P1015
   Warfield KL, 2007, J INFECT DIS, V196, pS430, DOI 10.1086/520583
   Weaver SC, 2004, ANNU REV ENTOMOL, V49, P141, DOI 10.1146/annurev.ento.49.061802.123422
   Weaver SC, 1999, AM J TROP MED HYG, V60, P441, DOI 10.4269/ajtmh.1999.60.441
   WEAVER SC, 1993, VIROLOGY, V195, P700, DOI 10.1006/viro.1993.1421
   Wilder-Smith A, 2017, LANCET INFECT DIS, V17, pe101, DOI DOI 10.1016/S1473-3099(16)30518-7
   Zuckerman JN, 2000, BRIT MED J, V321, P1237, DOI 10.1136/bmj.321.7271.1237
NR 74
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3378
EP 3386
DI 10.1016/j.vaccine.2020.02.007
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800011
PM 32085953
DA 2020-05-12
ER

PT J
AU Naber, SK
   Bruijning-Verhagen, PCJL
   de Hoog, MLA
   van Giessen, A
AF Naber, Steffie K.
   Bruijning-Verhagen, Patricia C. J. L.
   de Hoog, Marieke L. A.
   van Giessen, Anoukh
TI Cost-effectiveness of inactivated influenza vaccination in children with
   medical risk conditions in the Netherlands
SO VACCINE
LA English
DT Article
DE Influenza vaccination; High-risk medical condition; Cost-effectiveness
ID RESPIRATORY SYNCYTIAL-VIRUS; ECONOMIC-EVALUATION; SEASONAL INFLUENZA;
   TRACT INFECTIONS; DOUBLE-BLIND; MORTALITY; ADULTS; HOSPITALIZATION;
   REDUCTION; SEVERITY
AB Background: In many countries, annual immunization with inactivated influenza vaccine (IIV) is recommended for children with medical risk conditions. Prior cost-effectiveness analyses found such immunization to be cost saving, but assumed effectiveness against non-severe influenza outcomes and a higher effectiveness against severe influenza outcomes than recent studies would suggest. However, recent vaccine studies do not indicate any reduction in community or outpatient disease episodes in IIV immunized individuals. We therefore evaluated cost-effectiveness of IIV immunization in children with medical risk conditions in the Netherlands, assuming that IIV reduces influenza-related hospitalization and death, but has no meaningful impact on non-severe health outcomes.
   Methods: A health economic decision tree model was developed to evaluate health effects and costs of annual IIV immunization versus no immunization. Model inputs were based on our study on influenza-related primary care visits and other literature. Immunization was considered cost effective if associated costs were less than (sic)20,000 per quality-adjusted life year (QALY) gained. Probabilistic sensitivity analyses were performed to assess robustness of results, and one-way sensitivity analyses and scenario analyses were done to assess the influence of individual parameters.
   Results: Annual IIV prevents an average of 1.59 influenza-related hospitalizations and 0.02 deaths per 1,000 children with medical risk conditions. This results in an expected QALY gain of 0.43 at incremental costs of (sic)21,564 per 1,000 children, corresponding to an incremental cost-effectiveness ratio (ICER) of (sic)50,297/QALY compared to no immunization. Under base case assumptions, immunization had a 5% probability of being cost effective. Results were most influenced by vaccine efficacy against fatal influenza, QALY loss due to death, and mortality rate.
   Conclusions: If IIV only reduces severe disease outcomes, as current evidence suggests, annual immunization of medical risk children is unlikely to be cost effective. Results should however be interpreted with caution as cost-effectiveness is largely dependent on incidence and QALY losses for fatal influenza, for which evidence is scarce. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Naber, Steffie K.; Bruijning-Verhagen, Patricia C. J. L.; de Hoog, Marieke L. A.; van Giessen, Anoukh] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, STR 6-131,POB 85500, NL-3508 GA Utrecht, Netherlands.
   [Naber, Steffie K.] Univ Med Ctr Rotterdam, Dept Publ Hlth, Erasmus MC, Rotterdam, Netherlands.
   [van Giessen, Anoukh] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.
RP Bruijning-Verhagen, PCJL (reprint author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, STR 6-131,POB 85500, NL-3508 GA Utrecht, Netherlands.
EM p.bruijning@umcutrecht.nl
FU Netherlands Organization for Health Research and Development
   (ZonMw)Netherlands Organization for Health Research and Development;
   Hague, the NetherlandsNetherlands Government [50-53000-98-162]
FX This work was supported by the Netherlands Organization for Health
   Research and Development (ZonMw), the Hague, the Netherlands [grant
   number 50-53000-98-162].
CR Abadoglu O, 2004, J ASTHMA, V41, P279, DOI 10.1081/JAS-120026084
   Achten NB, 2017, J INFECT DIS, V215, P1102, DOI 10.1093/infdis/jix031
   Ampofo K, 2006, PEDIATRICS, V118, P2409, DOI 10.1542/peds.2006-1475
   [Anonymous], POP GEND AG MAR STAT
   [Anonymous], CONTR WAG WORK DUR I
   Arriola C, 2017, CLIN INFECT DIS, V65, P1289, DOI 10.1093/cid/cix468
   Baguelin M, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001527
   Baguelin M, 2010, VACCINE, V28, P2370, DOI 10.1016/j.vaccine.2010.01.002
   Bhat N, 2005, NEW ENGL J MED, V353, P2559, DOI 10.1056/NEJMoa051721
   Blyth CC, 2016, PEDIATR INFECT DIS J, V35, P309, DOI 10.1097/INF.0000000000000999
   Briggs AH, 2012, MED DECIS MAKING, V32, P722, DOI 10.1177/0272989X12458348
   Brisson M, 2003, MED DECIS MAKING, V23, P76, DOI 10.1177/0272989X02239651
   Bruijning-Verhagen P, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-112
   Bueving HJ, 2004, AM J RESP CRIT CARE, V169, P488, DOI 10.1164/rccm.200309-1251OC
   Cowling BJ, 2012, CLIN INFECT DIS, V54, P1778, DOI 10.1093/cid/cis307
   Danier J, 2019, PEDIATR INFECT DIS J, V38, P866, DOI 10.1097/INF.0000000000002387
   Dayan GH, 2001, VACCINE, V19, P4204, DOI 10.1016/S0264-410X(01)00160-8
   de Hoog MLA, 2020, VACCINE
   Deiss RG, 2015, VACCINE, V33, P7160, DOI 10.1016/j.vaccine.2015.11.004
   Flannery B, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-4244
   Fleming DM, 2005, J EPIDEMIOL COMMUN H, V59, P586, DOI 10.1136/jech.2004.026450
   Friesema IHM, 2012, EUR J CLIN MICROBIOL, V31, P1895, DOI 10.1007/s10096-011-1518-1
   Hakkaart-van Roijen L, 2016, BIJLAGE 1 KOSTENHAND
   Iwane MK, 2004, PEDIATRICS, V113, P1758, DOI 10.1542/peds.113.6.1758
   Jain VK, 2013, NEW ENGL J MED, V369, P2481, DOI 10.1056/NEJMoa1215817
   Jansen AGSC, 2007, EUR RESPIR J, V30, P1158, DOI 10.1183/09031936.00034407
   Jansen AGSC, 2008, J PEDIATR-US, V153, P764, DOI 10.1016/j.jpeds.2008.05.060
   Jules A, 2015, PEDIATRICS, V135, pE66, DOI 10.1542/peds.2014-1168
   Meltzer MI, 2005, VACCINE, V23, P1004, DOI 10.1016/j.vaccine.2004.07.040
   Merekiene J., 2016, SEASONAL INFLUENZA V
   Michiels B, 2011, VACCINE, V29, P9159, DOI 10.1016/j.vaccine.2011.08.008
   Miller EK, 2008, PEDIATRICS, V121, P1, DOI 10.1542/peds.2007-1053
   Nair H, 2011, LANCET, V378, P1917, DOI 10.1016/S0140-6736(11)61051-9
   National Health Care Institute, 2017, INFL VACC PRIC DISP
   National Influenza Prevention Program, 2017, REIMB 2017
   O'Brien MA, 2004, PEDIATRICS, V113, P585, DOI 10.1542/peds.113.3.585
   Portegijs W, 2016, EMANCIPATION MONITOR
   Prosser LA, 2008, PHARMACOECONOMICS, V26, P163, DOI 10.2165/00019053-200826020-00006
   Prosser LA, 2006, EMERG INFECT DIS, V12, P1548, DOI 10.3201/eid1210.051015
   Restivo V, 2018, HUM VACC IMMUNOTHER, V14, P724, DOI 10.1080/21645515.2017.1321722
   Schechter NL, 2007, PEDIATRICS, V119, pE1184, DOI 10.1542/peds.2006-1107
   Shang M, 2018, PEDIATRICS, V141, DOI 10.1542/peds.2017-2918
   Smits AJ, 2002, EPIDEMIOL INFECT, V128, P205, DOI 10.1017/S0950268801006574
   Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179
   Uijen JHJM, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-76
   Ungar WJ, 2011, PHARMACOECONOMICS, V29, P641, DOI 10.2165/11591570-000000000-00000
   Valenciano M, 2013, EUROSURVEILLANCE, V18, P12
   van Beek J, 2017, J INFECT DIS, V216, P415, DOI 10.1093/infdis/jix268
   van den Berg M, 2008, 4 REPORT COST EFFECT
   van den Wijngaard CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031197
   Versteegh MM, 2016, VALUE HEALTH, V19, P343, DOI 10.1016/j.jval.2016.01.003
   Vrieze HA, 2016, NHG SNPG GUIDELINE I
NR 52
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3387
EP 3396
DI 10.1016/j.vaccine.2020.01.057
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800012
PM 32115297
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU de Hoog, MLA
   Venekamp, RP
   Meijer, A
   Sanders, EAM
   Bruijning-Verhagen, PCJL
AF de Hoog, Marieke L. A.
   Venekamp, Roderick P.
   Meijer, Adam
   Sanders, Elisabeth A. M.
   Bruijning-Verhagen, Patricia C. J. L.
TI Inactivated influenza vaccine does not reduce all cause respiratory
   illness in children with pre-existing medical conditions
SO VACCINE
LA English
DT Article
DE Influenza; Immunization; Pre-existing medical conditions; Children;
   Paediatrics; Respiratory infections
ID VIRAL-INFECTIONS; TRACT INFECTIONS; SYNCYTIAL VIRUS; DOUBLE-BLIND;
   ASTHMA; RISK; COMMUNITY; MILD; LIFE
AB respiratory illness (RI) in children with pre-existing medical conditions has not been fully established and varies from season to season. This study aims to quantify the overall impact of IIV immunization on primary care attended RI episodes in children with pre-existing medical conditions, using robust observational data spanning twelve influenza seasons.
   Methods: Electronic records of IIV eligible children aged 6 months to 18 years were extracted from primary care databases over the years 2004-2015. IIV eligibility criteria according to Dutch guidelines included (chronic) respiratory and cardiovascular disease and diabetes mellitus. For each year, information on IIV immunization status, primary care attended RI episodes (including influenza, acute respiratory tract infections and asthma exacerbations) and potential confounders were collected. Generalized estimating equations were used to model the association between IIV status and occurrence of at least one RI episode during the influenza epidemic period with "current year immunized" as reference group. Robustness of findings were assessed by performing various sensitivity analyzes in which (i) seasons with a mismatch between the dominant circulating influenza virus and vaccine strain were excluded, (ii) influenza periods were further restricted to weeks with at least 30% influenza virus positive specimens in sentinel surveillance (instead of 5%), (iii) propensity scores were used to adjust for confounding.
   Results: In total, 11,797 children (follow-up duration: 38,701 child-years) were eligible for IIV for >= one season with 29% immunized at least once. The adjusted odds for primary care attended RI episodes during the influenza epidemic period did not differ between current season immunized versus not immunized children (adjusted OR:1.01; 95%CI:0.90-1.13). The various sensitivity analysis showed comparable results.
   Conclusions: IIV immunization in children with pre-existing medical conditions does not reduce all cause RI episodes encountered in primary care during the influenza season. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [de Hoog, Marieke L. A.; Venekamp, Roderick P.; Bruijning-Verhagen, Patricia C. J. L.] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Meijer, Adam; Sanders, Elisabeth A. M.; Bruijning-Verhagen, Patricia C. J. L.] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.
   [Sanders, Elisabeth A. M.] Univ Utrecht, Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Paediat Immunol, Utrecht, Netherlands.
RP Bruijning-Verhagen, PCJL (reprint author), Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, STR 6-131,POB 85500, NL-3508 GA Utrecht, Netherlands.
EM p.bruijning@umcutrecht.nl
FU Netherlands Organization for Health Research and Development
   (ZonMw)Netherlands Organization for Health Research and Development;
   Hague, the NetherlandsNetherlands Government [50-53000-98-162]
FX This work was supported by the Netherlands Organization for Health
   Research and Development (ZonMw), the Hague, the Netherlands [grant
   number 50-53000-98-162].
CR Abadoglu O, 2004, J ASTHMA, V41, P279, DOI 10.1081/JAS-120026084
   Akkerman A, 2008, HUISARTS WET, V51, P90
   [Anonymous], 2014, INFL ILLN ART DUTCH
   Blanken MO, 2013, NEW ENGL J MED, V368, P1791, DOI 10.1056/NEJMoa1211917
   Blyth CC, 2016, PEDIATR INFECT DIS J, V35, P309, DOI 10.1097/INF.0000000000000999
   Bueving HJ, 2004, AM J RESP CRIT CARE, V169, P488, DOI 10.1164/rccm.200309-1251OC
   Bueving HJ, 2004, EUR RESPIR J, V24, P925, DOI 10.1183/09031936.04.00060504
   Bueving HJ, 2008, HUISARTS WETENSCHAP, V51, P4
   Casalegno JS, 2010, EURO SURVEILLANCE B, V15
   Castilla J, 2013, CLIN INFECT DIS, V57, P167, DOI 10.1093/cid/cit194
   Cowling BJ, 2012, CLIN INFECT DIS, V54, P1778, DOI 10.1093/cid/cis307
   Danier J, 2019, PEDIATR INFECT DIS J, V38, P866, DOI 10.1097/INF.0000000000002387
   Darvishian M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169528
   de Hoog MLA, 2019, ANN FAM MED, V17, P7, DOI 10.1370/afm.2340
   De Wit R, 2019, NHG SNPG GUIDELINE I
   Donker GA, 2016, NIVEL PRIMARY CARE D
   Esposito S, 2014, NEW ENGL J MED, V370, P1167, DOI 10.1056/NEJMc1400874
   Gezondheidsraad, 2007, 20079 GEZ
   Heins M, 2016, VACCINE COVERAGE DUT
   Heins M, 2015, MONITOR VACCINATIEGR
   Hoberman A, 2003, JAMA-J AM MED ASSOC, V290, P1608, DOI 10.1001/jama.290.12.1608
   Jackson DJ, 2010, CURR OPIN ALLERGY CL, V10, P133, DOI 10.1097/ACI.0b013e3283352f7c
   Jain VK, 2013, NEW ENGL J MED, V369, P2481, DOI 10.1056/NEJMoa1215817
   Jaiwong C, 2015, ASIAN PAC J ALLERGY, V33, P3, DOI 10.12932/AP0511.33.2.2015
   Jansen AGSC, 2008, J PEDIATR-US, V153, P764, DOI 10.1016/j.jpeds.2008.05.060
   JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225
   Kelly H, 2010, EURO SURVEILLANCE B, V15
   Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y
   Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669
   Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024
   Merekiene J., 2016, SEASONAL INFLUENZA V
   Michiels B, 2011, VACCINE, V29, P9159, DOI 10.1016/j.vaccine.2011.08.008
   Perez-Romero P, 2012, CLIN MICROBIOL INFEC, V18, pE533, DOI 10.1111/1469-0691.12044
   Ridenhour BJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076318
   Ruohola A, 2009, EMERG INFECT DIS, V15, P344, DOI 10.3201/eid1502.081468
   Smeets HM, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3528-5
   Smits AJ, 2002, EPIDEMIOL INFECT, V128, P205, DOI 10.1017/S0950268801006574
   Teirlinck AC, 2016, 20160071 CTR INF DIS
   Truyers C, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-24
   Valenciano M, 2013, EUROSURVEILLANCE, V18, P12
   van Beek J, 2017, J INFECT DIS, V216, P415, DOI 10.1093/infdis/jix268
   Vasileiou E, 2017, CLIN INFECT DIS, V65, P1388, DOI 10.1093/cid/cix524
   Zambon MC, 2001, LANCET, V358, P1410, DOI 10.1016/S0140-6736(01)06528-X
NR 43
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 9
PY 2020
VL 38
IS 17
BP 3397
EP 3403
DI 10.1016/j.vaccine.2019.11.086
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TK
UT WOS:000525317800013
PM 31859200
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Mallory, RM
   Bandell, A
   Ambrose, CS
   Yu, J
AF Mallory, Raburn M.
   Bandell, Allyn
   Ambrose, Christopher S.
   Yu, Jing
TI A systematic review and meta-analysis of the effectiveness of LAIV4 and
   IIV in children aged 6 months to 17 years during the 2016-2017 season
SO VACCINE
LA English
DT Review
DE Influenza; Vaccine effectiveness; 2016; Live attenuated; Inactivated
   influenza vaccine
ID INFLUENZA VACCINE EFFECTIVENESS; UNITED-STATES; IMMUNIZATION PRACTICES;
   ADVISORY-COMMITTEE; RECOMMENDATIONS; PREVENTION; BINDING
AB As the real-world effectiveness of quadrivalent live attenuated influenza vaccine (LAIV4) and inactivated influenza vaccine (IIV) has varied in recent seasons, a systematic review and meta-analysis was conducted to more precisely estimate effectiveness in the 2016-2017 season. Relevant studies were identified from a systematic review of published literature and personal communication with study investigators. Five studies conducted in Canada, Finland, Germany, the United Kingdom, and the United States were identified for inclusion. Data were analyzed using a random effects model, with heterogeneity testing and a sensitivity analysis restricted to test-negative case-control studies. Consolidated vaccine effectiveness estimates against all strains were 69% (95% CI: 46 to 82) for LAIV4 and 47% (95% CI: 29 to 61) for IIV. Heterogeneity testing was not statistically significant, indicating consistency of individual study results. In conclusion, LAIV4 and IIV showed moderate and comparable effectiveness against influenza in children during the 2016-2017 influenza season. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mallory, Raburn M.; Yu, Jing] MedImmune, 1 MedImmune Way, Gaithersburg, MD 20878 USA.
   [Bandell, Allyn; Ambrose, Christopher S.] AstraZeneca, Gaithersburg, MD USA.
   [Yu, Jing] GlaxoSmithKline, Rockville, MD USA.
RP Mallory, RM (reprint author), MedImmune, 1 MedImmune Way, Gaithersburg, MD 20878 USA.
EM malloryr@MedImmune.com
FU AstraZenecaAstraZeneca
FX The systematic review literature search and screening was undertaken by
   Mahalia Gilmartin, PhD, and Talya Underwood, MPhil, of Core Medica,
   London, UK. Medical writing support was provided by Talya Underwood,
   MPhil, and editorial support was provided by Bethany King, of Core
   Medica, London, UK, supported by AstraZeneca according to Good
   Publication Practice guidelines (Link). The Sponsor was involved in the
   study design, collection, analysis, and interpretation of data, as well
   as data checking of information provided in the manuscript. However,
   ultimate responsibility for opinions, conclusions, and data
   interpretation lies with the authors.
CR [Anonymous], 2017, VIRAL FINDINGS RESP
   Appiah GD, 2015, MMWR-MORBID MORTAL W, V64, P583
   Baum U, 2017, ESPID 2017
   Centers for Disease Control and Prevention, 2018, SEAS INFL VACC EFF 2
   Centers for Disease Control and Prevention, 2018, VACC EFF WELL DO FLU
   Cullen KA, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6502a1
   European Centre for Disease Prevention and Control, 2015, SUMM INFL 2014 2015
   European Centre for Disease Prevention and Control, 2017, SUMM INFL 2016 2017
   Flannery B, 2019, CLIN INFECT DIS, V68, P1798, DOI 10.1093/cid/ciy775
   Flannery B, 2017, MMWR-MORBID MORTAL W, V66, P167, DOI 10.15585/mmwr.mm6606a3
   Garten R, 2018, MMWR-MORBID MORTAL W, V67, P634, DOI 10.15585/mmwr.mm6722a4
   Gaspard N, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx111
   Gemmill I, 2016, Can Commun Dis Rep, V42, P188
   Grohskopf LA, 2018, MMWR RECOMM REP, V67, DOI 10.15585/mmwr.rr6703a1
   Melidou A, 2017, VACCINE, V35, P4828, DOI 10.1016/j.vaccine.2017.07.057
   Murphy Trudy V., 2008, Morbidity and Mortality Weekly Report, V57, P1
   National Advisory Committee on Immunization, 2018, NACI SUMM INFL 2018
   Pebody R, 2017, EUROSURVEILLANCE, V22, P10, DOI 10.2807/1560-7917.ES.2017.22.44.17-00306
   Public Health England, 2018, INFL VACC EFF VE AD
   Skowronski DM, 2017, COMMUNICATION
   Skowronski DM, 2017, EURO SURVEILL, V22
   WHO, 2018, FACT SHEET INFL SEAS
   Yang H, 2015, VIROLOGY, V477, P18, DOI 10.1016/j.virol.2014.12.024
   Zost SJ, 2017, P NATL ACAD SCI USA, V114, P12578, DOI 10.1073/pnas.1712377114
NR 24
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3405
EP 3410
DI 10.1016/j.vaccine.2019.12.015
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000001
PM 31917037
DA 2020-05-12
ER

PT J
AU Asante, KP
   Ansong, D
   Kaali, S
   Adjei, S
   Lievens, M
   Badu, LN
   Darko, PA
   Buabeng, PBY
   Boahen, O
   Rettig, TM
   Agutu, C
   Harrison, SBE
   Ntiamoah, Y
   Anim, JA
   Adeniji, E
   Dornudo, AA
   Gvozdenovic, E
   Dosoo, D
   Sambian, D
   Owusu-Boateng, H
   Wilson, EA
   Prempeh, F
   Vandoolaeghe, P
   Schuerman, L
   Owusu-Agyei, S
   Agbenyega, T
   Ofori-Anyinam, O
AF Asante, Kwaku Poku
   Ansong, Daniel
   Kaali, Seyram
   Adjei, Samuel
   Lievens, Marc
   Badu, Lydia Nana
   Darko, Prince Agyapong
   Buabeng, Patrick Boakye Yiadom
   Boahen, Owusu
   Rettig, Theresa Maria
   Agutu, Clara
   Harrison, Samuel Benard Ekow
   Ntiamoah, Yaw
   Anim, Japhet Adomako
   Adeniji, Elisha
   Dornudo, Albert Agordo
   Gvozdenovic, Emilia
   Dosoo, David
   Sambian, David
   Owusu-Boateng, Harry
   Wilson, Elvis Ato
   Prempeh, Frank
   Vandoolaeghe, Pascale
   Schuerman, Lode
   Owusu-Agyei, Seth
   Agbenyega, Tsiri
   Ofori-Anyinam, Opokua
TI Immunogenicity and safety of the RTS,S/AS01 malaria vaccine
   co-administered with measles, rubella and yellow fever vaccines in
   Ghanaian children: A phase IIIb, multi-center, non-inferiority,
   randomized, open, controlled trial
SO VACCINE
LA English
DT Article
DE Non-inferiority; RTS; S/AS01; Co-administration; Yellow fever; Measles;
   Rubella
ID EXPANDED-PROGRAM; CONFIDENCE; EFFICACY; INFANTS
AB Background: To optimize vaccine implementation visits for young children, it could be efficient to administer the first RTS,S/AS01 malaria vaccine dose during the Expanded Programme on Immunization (EPI) visit at 6 months of age together with Vitamin A supplementation and the third RTS,S/AS01 dose on the same day as yellow fever (YF), measles and rubella vaccines at 9 months of age. We evaluated the safety and immunogenicity of RTS,S/AS01 when co-administered with YF and combined measles-rubella (MR) vaccines.
   Methods: In this phase 3b, open-label, controlled study (NCT02699099), 709 Ghanaian children were randomized (1:1:1) to receive RTS,S/AS01 at 6, 7.5 and 9 months of age, and YF and MR vaccines at 9 or 10.5 months of age (RTS,S coad and RTS,S alone groups, respectively). The third group received YF and MR vaccines at 9 months of age and will receive RTS,S/AS01 at 10.5, 11.5 and 12.5 months of age (Control group). All children received Vitamin A at 6 months of age. Non-inferiority of immune responses to the vaccine antigens was evaluated 1 month following co-administration versus RTS,S/AS01 or EPI vaccines (YF and MR vaccines) alone using pre-defined non-inferiority criteria. Safety was assessed until Study month 4.5.
   Results: Non-inferiority of antibody responses to the anti-circumsporozoite and anti-hepatitis B virus surface antigens when RTS,S/AS01 was co-administered with YF and MR vaccines versus RTS,S/AS01 alone was demonstrated. Non-inferiority of antibody responses to the measles, rubella, and YF antigens when RTS,S/AS01 was co-administered with YF and MR vaccines versus YF and MR vaccines alone was demonstrated. The safety profile of all vaccines was clinically acceptable in all groups.
   Conclusions: RTS,S/AS01 can be co-administered with Vitamin A at 6 months and with YF and MR vaccines at 9 months of age during EPI visits, without immune response impairment to any vaccine antigen or negative safety effect. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Asante, Kwaku Poku; Kaali, Seyram; Darko, Prince Agyapong; Boahen, Owusu; Harrison, Samuel Benard Ekow; Anim, Japhet Adomako; Adeniji, Elisha; Dosoo, David; Wilson, Elvis Ato; Owusu-Agyei, Seth] Ghana Hlth Serv, Kintampo Hlth Res Ctr, POB 200, Kintampo, Ghana.
   [Ansong, Daniel; Adjei, Samuel; Badu, Lydia Nana; Buabeng, Patrick Boakye Yiadom; Rettig, Theresa Maria; Ntiamoah, Yaw; Dornudo, Albert Agordo; Sambian, David; Owusu-Boateng, Harry; Prempeh, Frank; Agbenyega, Tsiri] Kwame Nkrumah Univ Sci & Technol, Agogo Presbyterian Hosp, POB 27, Agogo, Asante Akyem, Ghana.
   [Lievens, Marc; Agutu, Clara; Gvozdenovic, Emilia; Vandoolaeghe, Pascale; Schuerman, Lode; Ofori-Anyinam, Opokua] GSK Vaccines, Ave Fleming 20, B-1300 Wavre, Belgium.
   [Owusu-Agyei, Seth] London Sch Hyg & Trop Med, London, England.
   [Owusu-Agyei, Seth] Univ Hlth & Allied Sci, Ho, Ghana.
   [Agutu, Clara] Kemri Wellcome Trust Res Programme, Kilifi, Kenya.
   [Gvozdenovic, Emilia] Galapagos NV, Generaal Wittelaan L11A3, B-2800 Mechelen, Belgium.
RP Ofori-Anyinam, O (reprint author), GSK Vaccines, Ave Fleming 20, B-1300 Wavre, Belgium.
EM kwakupoku.asante@kintampo-hrc.org; kaali.seyram@kintampo-hrc.org;
   marc.lievens@gsk.com; agyapong.darko@kintampo-hrc.org;
   owusu.boahen@kintampo-hrc.org; CAgutu@kemri-wellcome.org;
   samuel.harrison@kintampo-hrc.org; japhet.anim@kintampo-hrc.org;
   elisha.adeniji@kintampo-hrc.org; david.dosoo@kintampo-hrc.org;
   elvis.wilson@kintampo-hrc.org; pascale.vandoolaeghe@gsk.com;
   Lode.Schuerman@gsk.com; sowusuagyei@uhas.edu.gh; tsiri@ghana.com;
   opokua.ofori-anyinam@gsk.com
OI Kaali, Seyram/0000-0001-6949-4203
FU GlaxoSmithKline Biologicals S.A.GlaxoSmithKline
FX This study and related publication were sponsored by GlaxoSmithKline
   Biologicals S.A. GlaxoSmithKline Biologicals SA was involved in all
   stages of the study conduct and analysis. GlaxoSmithKline Biologicals SA
   also took responsibility for all costs associated with the development
   and publishing of the present manuscript.
CR Abdulla S, 2008, NEW ENGL J MED, V359, P2533, DOI 10.1056/NEJMoa0807773
   Agnandji ST, 2010, J INFECT DIS, V202, P1076, DOI 10.1086/656190
   Minsoko PA, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001685
   Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287
   [Anonymous], 2016, Wkly Epidemiol Rec, V91, P33
   [Anonymous], 2011, Wkly Epidemiol Rec, V86, P301
   Asante KP, 2011, LANCET INFECT DIS, V11, P741, DOI 10.1016/S1473-3099(11)70100-1
   Chowdhury PR, 2015, CLIN INFECT DIS, V61, pS586, DOI 10.1093/cid/civ603
   CICERO TJ, 2019, HUM VACC IMMUNOTHER, P1, DOI DOI 10.1080/21645515.2019.1586040
   Clarke E, 2016, LANCET GLOB HEALTH, V4, pE534, DOI 10.1016/S2214-109X(16)30075-4
   Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.1093/biomet/26.4.404
   Cohen J, 2010, HUM VACCINES, V6, P90, DOI 10.4161/hv.6.1.9677
   Dolan S, 2015, SAGE YELLOW BOOK, P222
   European Medicines Agency, 2015, COMM MED PROD HUM US
   Ministry of Health/Ghana Health Service, 2011, IMM PROGR COMPR MULT
   NURMINEN M, 1990, BIOMETRICS, V46, P269
   Ota MOC, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002461
   Shinefield H, 2005, PEDIATR INFECT DIS J, V24, P665, DOI 10.1097/01.inf.0000172902.25009.a1
   Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8
   Valea I, 2018, HUM VACC IMMUNOTHER, V14, P1489, DOI 10.1080/21645515.2018.1442996
   WHO, 2018, WORLD MALARIA REPORT
   WHO, 2013, LARV SOURC MAN SUPPL
   WHO, 2011, GUID VIT A SUPPL INF
   World Health Organization, 2018, MAL CHILDR 5
NR 24
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3411
EP 3421
DI 10.1016/j.vaccine.2020.03.014
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000002
PM 32192811
DA 2020-05-12
ER

PT J
AU Huang, K
   Tao, S
   Zhou, XF
   Mo, JP
   Zhu, BW
   Shen, P
   Lin, HB
   Arena, PJ
   He, N
AF Huang, Kui
   Tao, Sha
   Zhou, Xiaofeng
   Mo, Jingping
   Zhu, Bowen
   Shen, Peng
   Lin, Hongbo
   Arena, Patrick J.
   He, Na
TI Incidence rates of health outcomes of interest among Chinese children
   exposed to selected vaccines in Yinzhou Electronic Health Records: A
   population-based retrospective cohort study
SO VACCINE
LA English
DT Article
DE Population-based electronic health records; Incidence; Vaccine; China
ID GUILLAIN-BARRE-SYNDROME; ACELLULAR PERTUSSIS; FEBRILE SEIZURES; SAFETY;
   VACCINATION; RISK; EPIDEMIOLOGY; ASTHMA
AB Introduction: Oral poliovirus vaccine (OPV) and diphtheria-tetanus-acellular pertussis vaccine (DTaP) are widely used in China while Haemophilus influenzae type b vaccines (Hib) and a DTaP, inactivated poliovirus (IPV) and Hib polysaccharide conjugated to tetanus protein (PRP similar to T) combined vaccine (DTaP-IP V//PRP similar to T) have lower coverage. There are limited safety data on these vaccines in Chinese pediatric populations. Methods: To estimate incidence rates (IRs) of health outcomes of interest (HOIs) among children exposed to OPV, DTaP, Hib, and DTaP-IPV//PRP similar to T, we conducted a retrospective cohort study using a population-based electronic health record (EHR) database in Yinzhou district, Ningbo City. Children 0-2 years of age receiving at least one dose of these vaccines between January 1, 2012 and March 31, 2017 were included in the study. Yinzhou EHR database consisted of immunization records and healthcare data of children from hospitals and community health centers in the district. Eight HOIs (i.e., anaphylaxis, febrile seizures, all seizures, asthma, apnea, Kawasaki disease [KD], urticaria/angioedema, Guillain-Barre syndrome [GBS]) were identified using ICD-10 codes. Results: A total of 220,422 eligible children was identified. No cases of apnea, KD, and GBS were observed within 7 days post-vaccination. During 0-7 days post-vaccination for OPV, DTaP, Hib, and DTaP-IPV//PRP similar to T, the IRs of anaphylaxis, febrile seizures, all seizures, urticaria/angioedema and asthma ranged from 0.0 to 50.0, 0.0 to 99.9, 29.1 to 249.8, 297.8 to 949.1, and 992.7 to 2298.2 per 100,000 person-years, respectively, and 0.0 to 0.9, 0.0 to 1.9, 0.6 to 4.6, 5.6 to 17.5, and 18.7 to 42.3 per 100,000 doses, respectively. Conclusion: IRs of some HOIs in our study were comparable with those in the literature while IRs of other HOIs were not due to differences in study design, post-vaccination risk periods assessed, and vaccine types. Future studies should consider medical chart review for validating HOIs obtained in the EHR. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Huang, Kui; Zhou, Xiaofeng; Mo, Jingping; Arena, Patrick J.] Pfizer Inc, 235 East 42nd St, New York, NY 10017 USA.
   [Tao, Sha; Zhu, Bowen; He, Na] Fudan Univ, Sch Publ Hlth, 138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.
   [Shen, Peng; Lin, Hongbo] Yinzhou Ctr Dis Control & Prevent, 221 Xueshi Rd, Ningbo 315100, Zhejiang, Peoples R China.
RP He, N (reprint author), Fudan Univ, Sch Publ Hlth, 138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.
EM nhe@shmu.edu.cn
RI Arena, Patrick/E-1444-2017
OI Arena, Patrick/0000-0003-3024-771X
FU Pfizer Inc.Pfizer
FX This work was funded by Pfizer Inc.
CR Bohlke K, 2003, PEDIATRICS, V112, P815, DOI 10.1542/peds.112.4.815
   Chen JJ, 2016, PEDIATR INFECT DIS J, V35, P7, DOI 10.1097/INF.0000000000000914
   Chen Y, 2014, EUR J NEUROL, V21, P124, DOI 10.1111/ene.12265
   Chung B, 2006, PEDIATR NEUROL, V34, P121, DOI 10.1016/j.pediatrneurol.2005.08.007
   Destefano F, 2002, PEDIATR INFECT DIS J, V21, P498, DOI 10.1097/00006454-200206000-00004
   Duffy J, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-0320
   Global Vaccine Safety Essential Medicine & Health Products World Health Organization, 2014, INF SHEET OBS RAT VA
   Gold M, 2010, VACCINE, V28, P4308, DOI 10.1016/j.vaccine.2010.04.021
   Hu JY, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1485-3
   Huang WC, 2015, NEUROEPIDEMIOLOGY, V44, P249, DOI 10.1159/000430917
   Kerdpanich A, 2008, INT J INFECT DIS, V12, P88, DOI 10.1016/j.ijid.2007.06.002
   Kuwabara S, 2004, DRUGS, V64, P597, DOI 10.2165/00003495-200464060-00003
   Liu FC, 2017, SHOCK, V48, P525, DOI 10.1097/SHK.0000000000000899
   McNeil MM, 2018, J ALLERGY CLIN IMMUN, V141, P463, DOI 10.1016/j.jaci.2017.12.971
   Nishi J, 2013, JPN J INFECT DIS, V66, P235, DOI 10.7883/yoken.66.235
   Norback D, 2018, ENVIRON INT, V115, P1, DOI 10.1016/j.envint.2018.02.023
   Rosenthal S, 1996, ARCH PEDIAT ADOL MED, V150, P457, DOI 10.1001/archpedi.1996.02170300011001
   Shu M, 2011, VACCINE, V29, P3507, DOI 10.1016/j.vaccine.2009.10.106
   Silfverdal SA, 2017, EXPERT REV VACCINES, V16, P109, DOI 10.1586/14760584.2016.1164044
   Spycher BD, 2009, PEDIATRICS, V123, P944, DOI 10.1542/peds.2008-0115
   Sun YL, 2017, CLIN EPIDEMIOL, V9, P167, DOI 10.2147/CLEP.S106258
   Sun YL, 2012, JAMA-J AM MED ASSOC, V307, P823, DOI 10.1001/jama.2012.165
   Tsakok T, 2014, IMMUNOL ALLERGY CLIN, V34, P117, DOI 10.1016/j.iac.2013.09.008
   Wang YX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071818
   World Health Organization, VACC PREV DIS MON S
   Yang Y, 2018, DRUG SAFETY, V41, P125, DOI 10.1007/s40264-017-0589-z
   Zhang XM, 2012, PEDIATR CARDIOL, V33, P272, DOI 10.1007/s00246-011-0121-7
   Zheng YM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3422-0
   Zhou XJ, 2018, PEDIATR DRUGS, V20, P105, DOI 10.1007/s40272-017-0276-7
NR 29
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3422
EP 3428
DI 10.1016/j.vaccine.2020.03.013
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000003
PM 32178909
DA 2020-05-12
ER

PT J
AU Benzaken, CL
   Miller, JD
   Onono, M
   Young, SL
AF Benzaken, Casey L.
   Miller, Joshua D.
   Onono, Maricianah
   Young, Sera L.
TI Development of a cumulative metric of vaccination adherence behavior and
   its application among a cohort of 12-month-olds in western Kenya
SO VACCINE
LA English
DT Article
DE Vaccination coverage; Vaccination adherence; Vaccination maintenance;
   Vaccination timeliness; Kenya; sub-Saharan Africa
ID CHILDHOOD VACCINATIONS; AGE-APPROPRIATE; IMMUNIZATION; TIMELINESS;
   COVERAGE; DETERMINANTS; IMMUNITY; DELAY
AB Objectives: The timely receipt of the recommended vaccination regimen, i.e. vaccination maintenance, is an underexplored, but important, indicator of public health. There is currently no standardized method for quantifying cumulative vaccination maintenance, however, and no simple way to explore predictors of adherence to vaccination schedules. We therefore sought to (1) develop a Vaccination Maintenance Score (VMS) and (2) apply this score to determine the predictors of vaccination behavior among infants in western Kenya (n = 245).
   Methods: Women in western Kenya were enrolled during pregnancy and surveyed repeatedly through one year postpartum. Data were collected on a range of sociodemographic and health indicators and vaccinations. For each infant, we analyzed receipt of 11 vaccines recommended by the Kenyan Ministry of Health. We operationalized VMS as the total number of vaccines received on schedule. Vaccines that were not received or received off schedule were scored 0. VMS was modeled using multivariable tobit regression models.
   Results: We found that 85.7% of infants were fully immunized, but only 42.4% had optimal VMS, i.e. scored 11. The median (IQR) VMS was 10 (3). In multivariable regression, each one-point increase in maternal quality of life score (range: 0-32) was associated with a 0.22-point increase in VMS; each additional child in the household was associated with a 0.34-point increase in VMS; and initiating breastfeeding at birth was associated a 2.01-point increase in VMS.
   Conclusions: Coverage of the recommended vaccinations (85.7%) was nearly twice as high as cumulative timely receipt (42.4%). The VMS satisfies a need for a location-specific but easily adaptable metric of vaccination adherence behavior. It can be used to complement traditional methods of vaccination coverage and timeliness to better understand underlying behaviors that influence vaccination events, and thereby inform interventions to improve vaccination rates and decrease the burden of vaccine-preventable disease. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Benzaken, Casey L.] Northwestern Univ, Dept Global Hlth Studies, Evanston, IL 60201 USA.
   [Miller, Joshua D.; Young, Sera L.] Northwestern Univ, Dept Anthropol, Evanston, IL 60201 USA.
   [Onono, Maricianah] Kenya Govt Med Res Ctr, Nairobi, Kenya.
RP Young, SL (reprint author), 1819 Hinman Ave, Evanston, IL 60201 USA.
EM sera.young@northwestern.edu
RI Miller, Joshua/H-4835-2018
OI Miller, Joshua/0000-0002-2171-856X; Young, Sera/0000-0002-1763-1218
FU National Institute of Mental HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Mental Health (NIMH) [K01 MH098902, R21 MH108444]
FX This work was supported by the National Institute of Mental Health (K01
   MH098902 and R21 MH108444). The views and conclusions contained herein
   are those of the authors and should not be interpreted as those of the
   National Institute of Mental Health or the National Institutes of
   Health.
CR Adetifa IMO, 2018, VACCINE, V36, P7965, DOI 10.1016/j.vaccine.2018.11.005
   Akmatov MK, 2008, VACCINE, V26, P3805, DOI 10.1016/j.vaccine.2008.05.031
   [Anonymous], 2018, FACT SHEET WHO IMM C
   [Anonymous], 2013, NATL POLICY GUIDELIN
   [Anonymous], 2014, FIN REP
   [Anonymous], 2019, TABL 2 SUMM WHO POS
   Babirye JN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035432
   Boateng GO, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00149
   Briesacher BA, 2008, PHARMACOTHERAPY, V28, P437, DOI 10.1592/phco.28.4.437
   Burton DC, 2011, J HEALTH POPUL NUTR, V29, P61, DOI 10.3329/jhpn.v29i1.7567
   Clark A, 2009, LANCET, V373, P1543, DOI 10.1016/S0140-6736(09)60317-2
   Coates J, 2007, HOUSEHOLD FOOD INSEC, DOI [10.1037/e576842013-001., DOI 10.1037/E576842013-001]
   COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404
   Dayan GH, 2006, AM J EPIDEMIOL, V163, P561, DOI 10.1093/aje/kwj074
   De Jong MCM, 2001, VACCINE, V19, P2722, DOI 10.1016/S0264-410X(00)00509-0
   Gans H, 2003, VACCINE, V21, P3398, DOI 10.1016/S0264-410X(03)00341-4
   Gibson DG, 2015, VACCINE, V33, P6778, DOI 10.1016/j.vaccine.2015.10.021
   Gierisch JM, 2010, AM J HEALTH BEHAV, V34, P669
   Hoest C, 2017, VACCINE, V35, P443, DOI 10.1016/j.vaccine.2016.11.075
   Hoshi T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148636
   Hughes MM, 2016, VACCINE, V34, P933, DOI 10.1016/j.vaccine.2015.12.061
   Jones CE, 2011, JAMA-J AM MED ASSOC, V305, P576, DOI 10.1001/jama.2011.100
   Kusuma YS, 2010, TROP MED INT HEALTH, V15, P1326, DOI 10.1111/j.1365-3156.2010.02628.x
   Laubereau B, 2002, EPIDEMIOL INFECT, V128, P185, DOI 10.1017/S0950268801006550
   Limo FJ, 2018, FACTORS ASS EXCLUSIV
   Luman ET, 2005, JAMA-J AM MED ASSOC, V293, P1204, DOI 10.1001/jama.293.10.1204
   Matare CR, 2015, CLIN INFECT DIS, V61, pS745, DOI 10.1093/cid/civ851
   Natamba BK, 2015, PUBLIC HEALTH NUTR, V18, P2895, DOI 10.1017/S1368980014001669
   Odutola A, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1015-9
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Smith PG, 2010, PROCEDIA VACCINOL, V2, P134, DOI 10.1016/j.provac.2010.07.005
   Statistics KNB of Health/Kenya M of Council/Kenya NAC Institute KMR Development/Kenya NC for P and, 2015, DEV KEN NC P KEN DEM
   Stein-Zamir C, 2017, HUM VACC IMMUNOTHER, V13, P2102, DOI 10.1080/21645515.2017.1341028
   Stirratt MJ, 2015, TRANSL BEHAV MED, V5, P470, DOI 10.1007/s13142-015-0315-2
   Stokley S, 2004, AM J PREV MED, V26, P34, DOI 10.1016/j.amepre.2003.09.002
   Tariku A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179056
   Tauil MD, 2016, VACCINE, V34, P2635, DOI 10.1016/j.vaccine.2016.04.016
   Tozzi AE, 2014, VACCINE, V32, P793, DOI 10.1016/j.vaccine.2013.12.044
   Turner Cathy, 2003, Int J Nurs Pract, V9, P120, DOI 10.1046/j.1322-7114.2003.00410.x
   Vermandere H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109353
   Ware J, 2008, SCORE INTERPRET SING
   WILSON CB, 1986, J PEDIATR-US, V108, P1, DOI 10.1016/S0022-3476(86)80761-2
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3429
EP 3435
DI 10.1016/j.vaccine.2020.03.011
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000004
PM 32184035
DA 2020-05-12
ER

PT J
AU Lai, JI
   Eszterhas, SK
   Brooks, SA
   Guo, CZ
   Zolla-Pazner, S
   Seaman, MS
   Bailey-Kellogg, C
   Griswold, KE
   Ackerman, ME
AF Lai, Jennifer, I
   Eszterhas, Susan K.
   Brooks, Seth A.
   Guo, Chengzi
   Zolla-Pazner, Susan
   Seaman, Michael S.
   Bailey-Kellogg, Chris
   Griswold, Karl E.
   Ackerman, Margaret E.
TI Induction of cross-reactive HIV-1 specific antibody responses by
   engineered V1V2 immunogens with reduced conformational plasticity
SO VACCINE
LA English
DT Article
DE Structure-based immunogen design; HIV-1 vaccines; V1V2 loops;
   Immunogenicity
ID VACCINE EFFICACY; RECOGNITION; EPITOPES; V2
AB Antibodies against the HIV-1 V1V2 loops were the only correlate of reduced infection risk in the RV144 vaccine trial, highlighting the V1V2 loops as promising targets for vaccine design. The V1V2 loops are structurally plastic, exhibiting either an alpha-helix-coil or beta-strand conformation. V1V2-specific antibodies may thus recognize distinct conformations, and an antibody's conformational specificity can be an important determinant of breadth and function. Restricting V1V2 conformational plasticity in an immunogen may thus provide control over the conformational specificity and quality of a vaccine-elicited antibody response.
   Previously, we identified a V1V2 sequence variant (K155M) that results in enhanced recognition by cross-reactive antibodies recognizing the beta-strand conformation. Here, we relate V1V2 antigenicity to immunogenicity by comparing the immunogenicity profiles of wildtype and K155M immunogens in two mouse models. In one model, immunization with gp70 V1V2 K155M but not wildtype elicited antibody responses that were cross-reactive to a panel of heterologous gp120 and gp140 antigens. In a second model, we compared the effect of K155M on immunogenicity in the context of gp70 V1V2, gD V1V2 and gp120, examining the effects of scaffold, epitope-focusing and immunization regimen. K155M variants, especially in the context of a gp120 immunogen, resulted in more robust, durable and cross-reactive antibody responses than wildtype immunogens. Restriction of the beta-stranded V1V2 conformation in K155M immunogens may thus be associated with the induction of cross-reactive antibody responses thought to be required of a protective HIV-1 vaccine. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Lai, Jennifer, I; Eszterhas, Susan K.; Brooks, Seth A.; Guo, Chengzi; Griswold, Karl E.; Ackerman, Margaret E.] Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Hanover, NH 03755 USA.
   [Zolla-Pazner, Susan] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA.
   [Seaman, Michael S.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02115 USA.
   [Bailey-Kellogg, Chris] Dartmouth Coll, Dept Comp Sci, Hanover, NH 03755 USA.
   [Ackerman, Margaret E.] Dartmouth Coll, Dept Microbiol & Immunol, Geisel Sch Med, Hanover, NH 03755 USA.
RP Ackerman, ME (reprint author), Dartmouth Coll, Thayer Sch Engn, 14 Engn Dr, Hanover, NH 03755 USA.
EM Margaret.E.Ackerman@dartmouth.edu
OI Ackerman, Margaret/0000-0002-4253-3476
FU National Institutes of Health National Institute of Allergy and
   Infectious DiseaseUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Allergy & Infectious Diseases (NIAID) [1R01AI102691, 1F31AI45106];
   Bill and Melinda Gates FoundationGates Foundation [OPP1146996];
   Collaboration for AIDS Vaccine Discovery (CAVD) Antigen Reagent Program
   (ARP); National Institute of General Medical SciencesUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [R01GM098977, P20GM113132]
FX This work was supported by the National Institutes of Health National
   Institute of Allergy and Infectious Disease [1R01AI102691 and
   1F31AI45106], The Bill and Melinda Gates Foundation [OPP1146996],
   Collaboration for AIDS Vaccine Discovery (CAVD) Antigen Reagent Program
   (ARP), the National Institute of General Medical Sciences [R01GM098977
   and P20GM113132].
CR AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U
   Behrens AJ, 2016, CELL REP, V14, P2695, DOI 10.1016/j.celrep.2016.02.058
   Bhiman JN, 2015, NAT MED, V21, P1332, DOI 10.1038/nm.3963
   Bonsignori M, 2012, J VIROL, V86, P11521, DOI 10.1128/JVI.01023-12
   Brown EP, 2012, J IMMUNOL METHODS, V386, P117, DOI 10.1016/j.jim.2012.09.007
   Burton DR, 2012, CELL HOST MICROBE, V12, P396, DOI 10.1016/j.chom.2012.09.008
   de Taeye SW, 2019, J BIOL CHEM, V294, P5616, DOI 10.1074/jbc.RA118.005396
   Fouts TR, 2002, J VIROL, DOI [10.1128/jvi.74.24.11427-11436.2000., DOI 10.1128/JVI.74.24.11427-11436.2000.]
   Georgiev IS, 2013, CURR OPIN HIV AIDS, V8, P382, DOI 10.1097/COH.0b013e328363a90e
   Gohain Trinh, 2019, CELLS, DOI [10.3390/cells8040365, DOI 10.3390/CELLS8040365.]
   Gorny MK, 2012, VIROLOGY, V427, P198, DOI 10.1016/j.virol.2012.02.003
   Gorny MK, 1994, J VIROL
   Grundner C, 2004, VIROLOGY, V330, P233, DOI 10.1016/j.virol.2004.08.037
   Halper-Stromberg A, 2014, CELL, V158, P989, DOI 10.1016/j.cell.2014.07.043
   Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425
   Hessell AJ, 2018, J VIROL, V92, DOI 10.1128/JVI.02198-17
   Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905
   Ito K, 1996, J EXP MED, V183, P2635, DOI 10.1084/jem.183.6.2635
   Julien JP, 2013, SCIENCE, V342, P1477, DOI 10.1126/science.1245625
   Kaushansky N, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-29
   Klein F, 2013, SCIENCE, V341, P1199, DOI 10.1126/science.1241144
   Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188
   Lai JI, 2018, PROTEIN ENG DES SEL, DOI [10.1093/protein/gzy010., DOI 10.1093/PROTEIN/GZY010.]
   Liao HX, 2013, IMMUNITY, V38, P176, DOI 10.1016/j.immuni.2012.11.011
   Liu L, 2019, VIROLOGY, V529, P57, DOI 10.1016/j.virol.2019.01.011
   Lynch RM, 2012, J VIROL, DOI [10.1128/JVI.00734-12, DOI 10.1128/JVI.00734-12.]
   Mayr LM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12883-6
   Mayr LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070859
   McLellan JS, 2011, NATURE, DOI [10.1038/nature10696, DOI 10.1038/NATURE10696.]
   Moldt B, 2012, P NATL ACAD SCI USA, V109, P18921, DOI 10.1073/pnas.1214785109
   Montefiori DC, 2012, J INFECT DIS, V206, P431, DOI 10.1093/infdis/jis367
   Moore PL, 2006, J VIROL, V80, P2515, DOI 10.1128/JVI.80.5.2515-2528.2006
   Morales JF, 2016, MOL IMMUNOL, V77, P14, DOI 10.1016/j.molimm.2016.07.003
   Munro JB, 2015, J VIROL, V89, P5752, DOI 10.1128/JVI.03187-14
   Pan RM, 2015, J VIROL, V89, P8003, DOI 10.1128/JVI.00754-15
   Pancera M, 2013, NAT STRUCT MOL BIOL, V20, P804, DOI 10.1038/nsmb.2600
   Perez LG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180720
   Politou M, 2016, IEEE INT INTERC TECH, P200, DOI 10.1109/IITC-AMC.2016.7507731
   Pollara J, 2014, J VIROL, DOI [10.1128/jvi.00156-14., DOI 10.1128/JVI.00156-14.]
   Rappuoli R, 2016, J EXP MED, V213, P469, DOI 10.1084/jem.20151960
   Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492
   Rolland M, 2012, NATURE, V490, P417, DOI 10.1038/nature11519
   Sanders RW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003618
   Schief WR, 2009, CURR OPIN HIV AIDS, DOI [10.1097/COH.0b013e32832e6184., DOI 10.1097/COH.0B013E32832E6184.]
   Spurrier B, 2014, J VIROL, V88, P4100, DOI 10.1128/JVI.03153-13
   Upadhyay C, 2014, J VIROL, V88, P12853, DOI 10.1128/JVI.02125-14
   van Eeden C, 2018, CELL REP, V25, P3123, DOI 10.1016/j.celrep.2018.11.058
   Yates NL, 2018, J VIROL, V92, DOI 10.1128/JVI.01843-17
   Yuan M, 2019, CELL HOST MICROBE, V25, P873, DOI 10.1016/j.chom.2019.04.011
NR 49
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3436
EP 3446
DI 10.1016/j.vaccine.2020.03.010
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000005
PM 32192810
OA Green Published, Other Gold
DA 2020-05-12
ER

PT J
AU Ikilezi, G
   Augusto, OJ
   Sbarra, A
   Sherr, K
   Dieleman, JL
   Lim, SS
AF Ikilezi, Gloria
   Augusto, Orvalho J.
   Sbarra, Alyssa
   Sherr, Kenneth
   Dieleman, Joseph L.
   Lim, Stephen S.
TI Determinants of geographical inequalities for DTP3 vaccine coverage in
   sub-Saharan Africa
SO VACCINE
LA English
DT Article
DE DTP3; Sub-Saharan Africa; Inequality; Development assistance for health;
   Universal vaccine coverage
ID MIDDLE-INCOME COUNTRIES; REACHING EVERY DISTRICT; IMMUNIZATION COVERAGE;
   SYSTEMATIC ANALYSIS; HEALTH; DIPHTHERIA; GOVERNANCE; TETANUS; EQUITY;
   IMPACT
AB Childhood immunization is one of the most effective health interventions, making it a key indicator of progress towards universal health coverage. In the last decade, improvements in coverage have been made globally, however, slow progress has been documented in sub-Saharan Africa with considerable subnational variations. We explore potential drivers of equitable immunization services based on subnational DTP3 coverage estimates.
   Using vaccine coverage at the 5 by 5 km area from 2000 to 2016, we quantify inequality using three measures. We assess the shortfall inequality which is the average deviation across subnational units from that with the highest coverage for each country. Secondly we estimate the threshold index, the proportion of children below a globally set subnational coverage target, and lastly, a Gini coefficient representing the within-country distribution of coverage. We use time series analyses to quantify associations with immunization expenditures controlling for country socio-economic and population characteristics.
   Development assistance, maternal education and governance were associated with reductions in inequality. Furthermore, high quality governance was associated with a stronger relationship between development assistance and reductions in inequality. Results from this analysis also indicate that countries with the lowest coverage suffer the highest inequalities. We highlight growing inequalities among countries which have met national coverage targets such as South Africa and Kenya. In 2016, values for the shortfall inequality ranged from 1% to 43%, the threshold index from 0% to 100% and Gini coefficient from 0.01 to 0.37. Burundi, Comoros, Eswatini, Lesotho, Namibia, Rwanda, and Sao Tome and Principe had the least shortfall inequality (<5%) while Angola, Ethiopia and Nigeria had values greater than 40%. A similar picture was noted for the other dimensions of inequality among these particular countries.
   Immunization program investments offer promise in addressing inequality, however, domestic mechanisms for resource implementation and accountability should be strengthened to maximize gains in coverage. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Ikilezi, Gloria; Sbarra, Alyssa; Dieleman, Joseph L.; Lim, Stephen S.] Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA.
   [Augusto, Orvalho J.; Sherr, Kenneth] Univ Washington, Dept Global Hlth, Harris Hydraul Lab, Box 357965, Seattle, WA 98195 USA.
RP Ikilezi, G (reprint author), Univ Washington, Inst Hlth Metr & Evaluat, 2301 5th Ave,Suite 600, Seattle, WA 98121 USA.
EM gri@uw.edu
CR Agier I, 2016, SOC SCI MED, V151, P157, DOI 10.1016/j.socscimed.2016.01.017
   [Anonymous], IHME VIZ HUB
   [Anonymous], GLOB VACC ACT PLAN 2
   [Anonymous], DEV ASS HLTH DAT 199
   [Anonymous], 2019, CDC GLOBAL HLTH IMMU
   [Anonymous], 2018, FIN GLOB HLTH 2017 F
   Arsenault C, 2017, VACCINE, V35, P951, DOI 10.1016/j.vaccine.2016.12.041
   Bado AR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159186
   Cassell JA, 2006, HEALTH POLICY PLANN, V21, P373, DOI 10.1093/heapol/czl020
   Ciccone DK, 2014, SOC SCI MED, V117, P86, DOI 10.1016/j.socscimed.2014.07.010
   Clark TS, 2015, POLIT SCI RES METH, V3, P399, DOI 10.1017/psrm.2014.32
   CLELAND JG, 1988, SOC SCI MED, V27, P1357, DOI 10.1016/0277-9536(88)90201-8
   De Maio FG, 2007, J EPIDEMIOL COMMUN H, V61, DOI 10.1136/jech.2006.052969
   Delamonica E, 2005, B WORLD HEALTH ORGAN, V83, P384
   Dieleman JL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110257
   Fullman N, 2017, LANCET, V390, P1423, DOI 10.1016/S0140-6736(17)32336-X
   GVAP secretariat, 2017, GLOB VACC ACT PLAN S
   Haakenstad A, 2016, HEALTH AFFAIR, V35, P242, DOI 10.1377/hlthaff.2015.1080
   Haddad S, 2010, HEALTH POLICY PLANN, V25, P393, DOI 10.1093/heapol/czq007
   Hosseinpoor AR, 2016, LANCET GLOB HEALTH, V4, pE617, DOI 10.1016/S2214-109X(16)30141-3
   Hosseinpoor AR, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0307-y
   Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1
   Jonathan H, 2009, HDB POVERTY INEQUALI
   Kaufmann D, 2011, HAGUE J RULE LAW, V3, P220, DOI 10.1017/S1876404511200046
   Khan J, 2018, PLOS ONE, V13
   Kirigia Joses Muthuri, 2011, Int Arch Med, V4, P11, DOI 10.1186/1755-7682-4-11
   Leiderer S, 2015, J INT DEV, V27, P1422, DOI 10.1002/jid.3184
   Lim SS, 2008, LANCET, V372, P2031, DOI 10.1016/S0140-6736(08)61869-3
   Lu CL, 2006, LANCET, V368, P1088, DOI 10.1016/S0140-6736(06)69337-9
   Mooketsane KS, 2015, GLOB SOC POLICY, V15, P345, DOI 10.1177/1468018115600123d
   Mosser JF, 2019, LANCET, V393, P1843, DOI 10.1016/S0140-6736(19)30226-0
   Ojewola RW, 2017, PAN AFR MED J, V27, DOI 10.11604/pamj.2017.27.151.10605
   Raza O, 2018, INT J EQUITY HEALTH, V17, DOI 10.1186/s12939-018-0837-6
   Ryman T, 2010, J PUBLIC HEALTH-UK, V32, P18, DOI 10.1093/pubmed/fdp048
   Shawky S., 2018, GLOB ADV HLTH MED, V7
   Soeung SC, 2013, HEALTH POLICY PLANN, V28, P526, DOI 10.1093/heapol/czs096
   Wang SA, 2013, VACCINE, V31, pB122, DOI 10.1016/j.vaccine.2012.10.116
   WHO, REACH EV DISTR RED A
   World Bank, 1997, WORLD DEV IND
   World Health Organization, 2010, CONC FRAM ACT SOC DE
   World Health Organization, 2009, REACH EV DISTR RED A
   Yourkavitch J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201870
NR 42
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3447
EP 3454
DI 10.1016/j.vaccine.2020.03.005
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000006
PM 32204938
OA Other Gold
DA 2020-05-12
ER

PT J
AU Diamos, AG
   Pardhe, MD
   Sun, HY
   Hunter, JGL
   Mor, T
   Meador, L
   Kilbourne, J
   Chen, Q
   Mason, HS
AF Diamos, Andrew G.
   Pardhe, Mary D.
   Sun, Haiyan
   Hunter, Joseph G. L.
   Mor, Tsafrir
   Meador, Lydia
   Kilbourne, Jacquelyn
   Chen, Qiang
   Mason, Hugh S.
TI Codelivery of improved immune complex and virus-like particle vaccines
   containing Zika virus envelope domain III synergistically enhances
   immunogenicity
SO VACCINE
LA English
DT Article
DE Zika virus; Envelope protein; Recombinant immune complex; Virus-like
   particle; Plant-made vaccine
ID ANTIBODY-DEPENDENT ENHANCEMENT; ANTIGEN; INFECTION; IMMUNIZATION;
   VACCINATION; RESPONSES; PLANTS
AB Zika virus (ZIKV) reemergence poses a significant health threat especially due to its risks to fetal development, necessitating safe and effective vaccines that can protect pregnant women. Zika envelope domain III (ZE3) has been identified as a safe and effective vaccine candidate, however it is poorly immunogenic. We previously showed that plant-made recombinant immune complex (RIC) vaccines are a robust platform to improve the immunogenicity of weak antigens. In this study, we altered the antigen fusion site on the RIC platform to accommodate N-terminal fusion to the IgG heavy chain (N-RIC), and thus a wider range of antigens, with a resulting 40% improvement in RIC expression over the normal C-terminal fusion (C-RIC). Both types of RICs containing ZE3 were efficiently assembled in plants and purified to >95% homogeneity with a simple one-step purification. Both ZE3 RICs strongly bound complement receptor C1q and elicited strong ZE3-specific antibody titers that correlated with ZIKV neutralization. When either N-RIC or C-RIC was codelivered with plant-produced hepatitis B core (HBc) virus-like particles (VLP) displaying ZE3, the combination elicited 5-fold greater antibody titers (>1,000,000) and more strongly neutralized ZIKV than either RICs or VLPs alone, after only two doses without adjuvant. These findings demonstrate that antigens that require a free N-terminus for optimal antigen display can now be used with the RIC system, and that plant-made RICs and VLPs are highly effective vaccines targeting ZE3. Thus, the RIC platform can be more generally applied to a wider variety of antigens. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Mason, Hugh S.] Arizona State Univ, Ctr Immunotherapy Vaccines & Virotherapy, Biodesign Inst, Tempe, AZ 85287 USA.
   Arizona State Univ, Tempe, AZ 85287 USA.
RP Mason, HS (reprint author), Arizona State Univ, Ctr Immunotherapy Vaccines & Virotherapy, Biodesign Inst, Tempe, AZ 85287 USA.
EM hugh.mason@asu.edu
OI chen, qiang/0000-0003-1498-7013; Mason, Hugh/0000-0002-0192-6716
FU National Institute of Allergy and Infectious Diseases (NIAID)United
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Allergy & Infectious
   Diseases (NIAID) [R33AI101329]
FX This work was supported in part by a grant from National Institute of
   Allergy and Infectious Diseases (NIAID) #R33AI101329 to QC.
CR Alam A, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00102
   Barzon L, 2017, EXPERT OPIN BIOL TH, V17, P1185, DOI 10.1080/14712598.2017.1346081
   Belmusto-Worn VE, 2005, RANDOMIZED DOUBLE BL
   Boigard H, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005608
   Brinkmann U, 2017, MABS-AUSTIN, V9, P182, DOI 10.1080/19420862.2016.1268307
   Castilho A, 2012, BIOTECHNOL J, V7, DOI 10.1002/biot.201200032
   Chargelegue D, 2005, INFECT IMMUN, V73, P5915, DOI 10.1128/IAI.73.9.5915-5922.2005
   Chen Qiang, 2016, F1000Res, V5, DOI 10.12688/f1000research.8010.1
   Chen Q, 2013, HUM VACC IMMUNOTHER, V9, P26, DOI 10.4161/hv.22218
   Chun J, 2019, J MICROBIOL BIOTECHN, V29, P813, DOI 10.4014/jmb.1903.03043
   Dai LP, 2016, CELL HOST MICROBE, V19, P696, DOI 10.1016/j.chom.2016.04.013
   Dent M, 2016, J GEN VIROL, V97, P3280, DOI 10.1099/jgv.0.000635
   Diamos AG, 2019, FRONT PLANT SCI, V9, DOI 10.3389/fpls.2018.01974
   Diamos AG, 2019, VACCINE, V37, P137, DOI 10.1016/j.vaccine.2018.11.021
   Diamos AG, 2018, PROTEIN EXPRES PURIF, V151, P86, DOI 10.1016/j.pep.2018.06.011
   Diamos AG, 2018, PLANT BIOTECHNOL J, V16, P1971, DOI 10.1111/pbi.12931
   Diamos AG, 2016, FRONT PLANT SCI, V7, DOI 10.3389/fpls.2016.00200
   Diebolder CA, 2014, SCIENCE, V343, P1260, DOI 10.1126/science.1248943
   Durbin A, 2017, EXPERT REV VACCINES, V16, P781, DOI 10.1080/14760584.2017.1345309
   Fletcher EAK, 2018, J IMMUNOL, V201, P87, DOI 10.4049/jimmunol.1700911
   Freivalds J, 2011, PROTEIN EXPRES PURIF, V75, P218, DOI 10.1016/j.pep.2010.09.010
   Haiyan Zhao A, 2016, CELL, V166, DOI [10.1016/j.cell.2016.07.020, DOI 10.1016/J.CELL.2016.07.020.]
   Heinz FX, 2007, VACCINE, V25, P7559, DOI 10.1016/j.vaccine.2007.08.024
   Hioe CE, 2009, VACCINE, V28, P352, DOI 10.1016/j.vaccine.2009.10.040
   Ho NI, 2017, J IMMUNOL, V198, P4235, DOI 10.4049/jimmunol.1602169
   Huang Z, 2004, PLANT BIOTECHNOL J, V2, P241, DOI 10.1111/j.1467-7652.2004.00068.x
   Jones LS, 2005, J BIOL CHEM, V280, P13406, DOI 10.1074/jbc.M500687200
   Kallolimath Somanath, 2014, Human Antibodies, V23, P45, DOI 10.3233/HAB-150283
   Kim MY, 2015, VACCINE, V33, P1830, DOI 10.1016/j.vaccine.2015.02.036
   Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984
   Marusic C, 2018, BIOTECHNOL BIOENG, V115, P565, DOI 10.1002/bit.26503
   Mason HS, 2016, HUM VACC IMMUNOTHER, V12, P988, DOI 10.1080/21645515.2015.1116655
   Mastrangeli R, 2019, GLYCOBIOLOGY, V29, P199, DOI 10.1093/glycob/cwy092
   McCluskie MJ, 1998, VIRAL IMMUNOL, V11, P245, DOI 10.1089/vim.1998.11.245
   MORRISON SL, 1966, J IMMUNOL, V96, P901
   Oliveira ERA, 2017, VIRUS RES, V227, P115, DOI 10.1016/j.virusres.2016.10.005
   Peyret H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120751
   Phoolcharoen W, 2011, PLANT BIOTECHNOL J, V9, P807, DOI 10.1111/j.1467-7652.2011.00593.x
   Rabaan AA, 2017, J INFECT PUBLIC HEAL, V10, P141, DOI 10.1016/j.jiph.2016.05.007
   Santi L, 2008, VACCINE, V26, P1846, DOI 10.1016/j.vaccine.2008.01.053
   Schmidt JA, 2019, NAT PLANTS, V5, P715, DOI 10.1038/s41477-019-0467-z
   Simon D, 2018, VIRUSES, V10, DOI [10.3390/v10120698, DOI 10.3390/V10120698.]
   Simon D, 2017, BIOCHEM BIOPH RES CO, V492, P572, DOI 10.1016/j.bbrc.2017.06.088
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Taylor A, 2015, IMMUNOL REV, V268, P340, DOI 10.1111/imr.12367
   Tuse D, 2014, BIOMED RES INT, DOI 10.1155/2014/256135
   Wang G, 2016, MOL CELL, V63, P135, DOI 10.1016/j.molcel.2016.05.016
   Wang XY, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-018-0095-z
   Wen YM, 2016, EMBO MOL MED, V8, P1120, DOI 10.15252/emmm.201606593
   Whitacre DC, 2009, EXPERT REV VACCINES, V8, P1565, DOI [10.1586/erv.09.121, 10.1586/ERV.09.121]
   Wilder-Smith A, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1067-x
   Yang M, 2018, PLANT BIOTECHNOL J, V16, P572, DOI 10.1111/pbi.12796
   Yang M, 2017, VACCINE, V35, P4287, DOI 10.1016/j.vaccine.2017.04.052
   Zeitlin L, 2011, P NATL ACAD SCI USA, V108, P20690, DOI 10.1073/pnas.1108360108
   Zhang XC, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9110338
NR 55
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3455
EP 3463
DI 10.1016/j.vaccine.2020.02.089
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000007
PM 32173095
OA Green Published, Bronze
DA 2020-05-12
ER

PT J
AU Wilson-Welder, JH
   Boggiatto, P
   Nally, JE
   Wafa, EI
   Alt, DP
   Hornsby, RL
   Frank, A
   Jones, DE
   Olsen, SC
   Bowden, NB
   Salem, AK
AF Wilson-Welder, Jennifer H.
   Boggiatto, Paola
   Nally, Jarlath E.
   Wafa, Emad, I
   Alt, David P.
   Hornsby, Richard L.
   Frank, Ami
   Jones, Douglas E.
   Olsen, Steven C.
   Bowden, Ned B.
   Salem, Aliasger K.
TI Bovine immune response to leptospira antigen in different novel
   adjuvants and vaccine delivery platforms
SO VACCINE
LA English
DT Article
DE Cattle; Vaccine; Leptospira; Adjuvant; Biodegradable polymer
ID BORGPETERSENII SEROVAR HARDJO; WC1(+) GAMMA-DELTA; INTERROGANS;
   EFFICACY; MICROPARTICLES; INFECTION; CATTLE; TYPE-1; IMMUNIZATION;
   PREVALENCE
AB Leptospirosis is a global zoonosis causing significant economic losses for cattle production. Current cattle vaccines against leptospirosis need improvement to provide efficacy against multiple serovars, reduce shedding in urine, and to induce earlier and more robust immune responses. In this study, Leptospira borgpetersenii serovar Hardjo strain 203 antigen was combined with novel adjuvants (a biodegradable polyanhydride compressed rod implant (VPEAR), poly(diaminosulfide) microparticles, a water-oil-water emulsion adjuvant, and aluminum hydroxide) to develop novel vaccines. Cattle were immunized twice, at a 4 week interval, with inoculums containing adjuvants alone or leptospira antigens and immune responses were compared to responses of cattle receiving a commercial monovalent leptospirosis vaccine (Spirovac). All animals were inoculated with a single dose of Spirovac at 20 weeks to assess antigen recall responses. Serum antibody responses were increased (P > 0.05) at 8 and 20 weeks after vaccination in cattle receiving inoculums containing leptospira antigens combined with water-oil-emulsion, poly(diaminosulfide) microparticles (PNSN-MP), or aluminum hydroxide and in cattle vaccinated with Spirovac. Humoral responses were predominantly IgG1 isotypes. Antigen-specific proliferative responses were detected after initial vaccination in cattle vaccinated with Spirovac, PNSN-MP and water-oil-water treatments. Most proliferative responses occurring within CD4+ and gamma delta T cell populations expressing CD45RO and CD25 markers, a response consistent with an effector memory phenotype. Antigen-specific immune responses were not detected in cattle vaccinated with VPEAR after initial inoculation, but were detected in the antigen recall responses. PBMCs from cattle vaccinated with Spirovac, oil-water-oil, or PNSN-MP treatments had increased (P < 0.05) IL-17A release after in vitro stimulation with leptospirosis antigens, whereas all groups produced IFN-gamma and IL-17A after in vitro stimulation during the antigen recall response. Our data demonstrates that combining leptospirosis antigens with these adjuvants enhances immunogenicity in cattle.
   Interpretative Summary: Vaccination of livestock is a key mechanism for minimizing transmission of leptospirosis, a zoonotic disease. Leptospirosis vaccines for cattle need to be improved to provide greater levels of protection from kidney colonization, better immune responses, and protection against multiple serovars. This could be accomplished using new vaccine adjuvants. In this study, several novel adjuvants were evaluated for their ability to induce effective immune responses in cattle to leptospira antigens as compared to currently available vaccines. Data suggested that vaccines containing biodegradable polymer microparticles and oil-emulsion adjuvants induced similar or greater immune responses as compared to a commercial vaccine. Our data suggest these new vaccine formulations warrant further investigation as new vaccine formulations for cattle and other livestock. Published by Elsevier Ltd.
C1 [Wilson-Welder, Jennifer H.; Boggiatto, Paola; Nally, Jarlath E.; Alt, David P.; Hornsby, Richard L.; Frank, Ami; Olsen, Steven C.] USDA Agr Res Serv, Infect Bacterial Dis Res Unit, Natl Anim Dis Ctr, Ames, IA 50010 USA.
   [Wafa, Emad, I; Salem, Aliasger K.] Univ Iowa, Coll Pharm, Div Pharmaceut & Translat Therapeut, Iowa City, IA 52242 USA.
   [Jones, Douglas E.] Iowa State Univ, Coll Vet Med, Vet Pathol, Ames, IA 50011 USA.
   [Bowden, Ned B.] Univ Iowa, Coll Liberal Arts & Sci, Dept Chem, Iowa City, IA 52242 USA.
RP Wilson-Welder, JH (reprint author), ARS, Infect Bacterial Dis Res Unit, NADC, 1920 Dayton Ave, Ames, IA 50010 USA.
EM jennifer.wilson-welder@ars.usda.gov
OI Wafa, Emad/0000-0002-9854-502X
CR Adler B, 2015, CURR TOP MICROBIOL, V387, P251, DOI 10.1007/978-3-662-45059-8_10
   Balakrishnan G, 2014, VET IMMUNOL IMMUNOP, V159, P11, DOI 10.1016/j.vetimm.2014.03.002
   Blumerman SL, 2007, EUR J IMMUNOL, V37, P1204, DOI 10.1002/eji.200636216
   Boggiatto PM, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02370
   Bolin C, 2000, 21 WORLD BUIATRICS C
   BOLIN CA, 1991, AM J VET RES, V52, P1639
   BOLIN CA, 1989, AM J VET RES, V50, P161
   Bolin CA, 2001, AM J VET RES, V62, P995, DOI 10.2460/ajvr.2001.62.995
   Brown RA, 2003, VACCINE, V21, P4448, DOI 10.1016/S0264-410X(03)00439-0
   COLE JR, 1973, APPL MICROBIOL, V25, P976, DOI 10.1128/AEM.25.6.976-980.1973
   Cortese VS, 2014, AM J VET RES, V75, P507, DOI 10.2460/ajvr.75.5.507
   D'Mello SR, 2014, J MICROENCAPSUL, V31, P137, DOI 10.3109/02652048.2013.814728
   Dar P, 2013, VACCINE, V31, P3327, DOI 10.1016/j.vaccine.2013.05.078
   Dorneles EMS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136696
   Ellis W, 2000, IMMUNITY BOVINE LEPT
   ELLIS WA, 1985, RES VET SCI, V39, P292, DOI 10.1016/S0034-5288(18)31716-8
   Ellis WA, 2015, CURR TOP MICROBIOL, V387, P99, DOI 10.1007/978-3-662-45059-8_6
   Estes DM, 2002, VET IMMUNOL IMMUNOP, V90, P1, DOI 10.1016/S0165-2427(02)00201-5
   Favero JF, 2017, MICROB PATHOGENESIS, V107, P149, DOI 10.1016/j.micpath.2017.03.032
   Geary SM, 2015, J CONTROL RELEASE, V220, P682, DOI 10.1016/j.jconrel.2015.09.002
   Ghazali-Bina M, 2019, IRAN J MICROBIOL, V11, P39, DOI 10.18502/ijm.v11i1.703
   Hickey AJ, 2011, DRUG FUTURE, V36, P589, DOI 10.1358/dof.2011.36.8.1665559
   Huntimer L, 2013, J BIOMED MATER RES B, V101B, P91, DOI 10.1002/jbm.b.32820
   Ibrahim EES, 2015, VET WORLD, V8, P1189, DOI 10.14202/vetworld.2015.1189-1198
   Jones GJ, 2013, VACCINE, V31, P5250, DOI 10.1016/j.vaccine.2013.08.051
   Kipper MJ, 2006, J BIOMED MATER RES A, V76A, P798, DOI 10.1002/jbm.a.30545
   Krejci J, 2013, RES VET SCI, V94, P73, DOI 10.1016/j.rvsc.2012.07.021
   Krueger LA, 2016, J DAIRY SCI, V99, P9040, DOI 10.3168/jds.2016-11144
   Lilenbaum W, 1996, VET REC, V138, P570, DOI 10.1136/vr.138.23.570
   LITTLE TV, 1992, VET CLIN N AM-EQUINE, V8, P1
   Martins G, 2017, RES VET SCI, V112, P156, DOI 10.1016/j.rvsc.2017.03.021
   Martins G, 2010, VET REC, V167, P629, DOI 10.1136/vr.c5695
   Mughini-Gras L, 2014, EPIDEMIOL INFECT, V142, P1172, DOI 10.1017/S0950268813001817
   Naiman BM, 2002, INFECT IMMUN, V70, P6147, DOI 10.1128/IAI.70.11.6147-6157.2002
   Naiman BM, 2001, INFECT IMMUN, V69, P7550, DOI 10.1128/IAI.69.12.7550-7558.2001
   Nally JE, 2018, VET MICROBIOL, V218, P25, DOI 10.1016/j.vetmic.2018.03.023
   Pashine A, 2005, NAT MED, V11, pS63, DOI 10.1038/nm1210
   Petermann J, 2017, EXP APPL ACAROL, V72, P303, DOI 10.1007/s10493-017-0156-4
   Ptak CP, 2019, BIOTECHNOL BIOENG, V116, P260, DOI 10.1002/bit.26864
   Ramli SR, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007131
   Rinehart CL, 2012, AM J VET RES, V73, P735, DOI 10.2460/ajvr.73.5.735
   Rusk RA, 2017, VET IMMUNOL IMMUNOP, V193, P38, DOI 10.1016/j.vetimm.2017.10.004
   Sanhueza JM, 2018, PREV VET MED, V153, P71, DOI 10.1016/j.prevetmed.2018.02.015
   Schaut RG, 2018, VACCINE, V36, P1024, DOI 10.1016/j.vaccine.2017.11.067
   Schaut RG, 2018, VACCINE, V36, P1016, DOI 10.1016/j.vaccine.2017.12.050
   Sonada RB, 2018, BRAZ J MICROBIOL, V49, P347, DOI 10.1016/j.bjm.2017.06.008
   Torres MP, 2011, ACTA BIOMATER, V7, P2857, DOI 10.1016/j.actbio.2011.03.023
   Wafa EI, 2020, BIOMACROMOLECULES, DOI [10.1021/acs.biomac.9b01257, DOI 10.1021/ACS.BI0MAC.9B01257]
   Wafa EI, 2019, J PHARMACOL EXP THER, V370, P855, DOI 10.1124/jpet.118.252809
   Wafa EI, 2017, ACTA BIOMATER, V50, P417, DOI 10.1016/j.actbio.2017.01.005
   Wilson-Welder JH, 2009, J PHARM SCI-US, V98, P1278, DOI 10.1002/jps.21523
   Yoo J, 2012, MACROMOLECULES, V45, P2292, DOI 10.1021/ma300190b
   Yoo J, 2012, MACROMOLECULES, V45, P688, DOI 10.1021/ma2023167
   Yupiana Y, 2019, ZOONOSES PUBLIC HLTH, V66, P470, DOI 10.1111/zph.12578
   Zuerner RL, 2011, CLIN VACCINE IMMUNOL, V18, P684, DOI 10.1128/CVI.00288-10
NR 55
TC 0
Z9 0
U1 3
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3464
EP 3473
DI 10.1016/j.vaccine.2020.02.086
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000008
PM 32204939
DA 2020-05-12
ER

PT J
AU O'Leary, ST
   Cataldi, JR
   Lindley, MC
   Hurley, LP
   Riley, LE
   Brtnikova, M
   Crane, LA
   Beaty, B
   Stokley, S
   Fisher, A
   Kempe, A
AF O'Leary, Sean T.
   Cataldi, Jessica R.
   Lindley, Megan C.
   Hurley, Laura P.
   Riley, Laura E.
   Brtnikova, Michaela
   Crane, Lori A.
   Beaty, Brenda
   Stokley, Shannon
   Fisher, Allison
   Kempe, Allison
TI Impact of media reports regarding influenza vaccine on obstetricians'
   vaccination practices
SO VACCINE
LA English
DT Article
DE Influenza; Vaccination; Pregnancy; Media
ID PREGNANT-WOMEN; UNITED-STATES; MEASLES OUTBREAK; IMMUNIZATION; COVERAGE;
   CONTROVERSY; OUTCOMES; SAFETY
AB Background: In 2017, three media stories regarding influenza vaccine may have impacted obstetricians' (OB) influenza vaccination practices: reports of reduced influenza vaccine effectiveness, a severe influenza season, and a possible increased risk of miscarriage among pregnant women receiving 2009 H1N1 vaccine in the 1st trimester who had received H1N1 vaccine the previous season (later disproven).
   Objective: Describe OB's: (1) awareness of; (2) attitudes and experiences related to; and (3) reported alterations in practice as a result of these reports.
   Methods: A survey among a nationally representative sample of OBs April to June 2018.
   Results: Response rate was 65% (302/468). 88% of OBs were ''very aware" of the severe season, 74% of lower effectiveness, and 25% of the miscarriage study (47% ''completely unaware" of miscarriage study). Among those aware, 58%, 57%, and 16% reported >= 10% of pregnant patients initiated discussions about the severe season, lower effectiveness, and miscarriage study, respectively. Most (83%) agreed reports about increased severity increased their enthusiasm for recommending influenza vaccine; fewer agreed reports about the miscarriage study (18%) and lower vaccine effectiveness (12%) decreased their enthusiasm for recommending influenza vaccine. Providers were more likely to initiate discussion with patients about increased severity of the season than the other reports. However, 35% agreed the miscarriage study reports increased their concerns about influenza vaccine safety; 18% (n = 48) reported changing the way they recommended influenza vaccine. Of those, 17 (6% of all respondents) reported not recommending influenza vaccine to women during the 1st trimester and 26 (10% of all respondents) recommended it but were willing to delay until the 2nd trimester.
   Conclusions: During a season in which media stories could have influenced OB influenza vaccination behaviors in different directions, reports underscoring importance of influenza vaccine may have had more impact on OBs' recommendations than reports questioning vaccine safety or effectiveness. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [O'Leary, Sean T.; Cataldi, Jessica R.; Hurley, Laura P.; Brtnikova, Michaela; Crane, Lori A.; Beaty, Brenda; Kempe, Allison] Univ Colorado, Adult & Child Consortium Hlth Outcomes Res & Deli, Aurora, CO USA.
   [O'Leary, Sean T.; Cataldi, Jessica R.; Hurley, Laura P.; Brtnikova, Michaela; Crane, Lori A.; Beaty, Brenda; Kempe, Allison] Childrens Hosp Colorado, Anschutz Med Campus, Aurora, CO USA.
   [O'Leary, Sean T.; Cataldi, Jessica R.; Brtnikova, Michaela; Kempe, Allison] Univ Colorado, Dept Pediat, Anschutz Med Campus, Aurora, CO USA.
   [Lindley, Megan C.; Stokley, Shannon; Fisher, Allison] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA.
   [Hurley, Laura P.] Denver Hlth, Div Gen Internal Med, Denver, CO USA.
   [Riley, Laura E.] Amer Coll Obstetricians & Gynecologists, 409 12th St SW, Washington, DC 20024 USA.
   [Crane, Lori A.] Univ Colorado, Dept Community & Behav Hlth, Anschutz Med Campus, Aurora, CO USA.
RP O'Leary, ST (reprint author), Univ Colorado, Dept Pediat, Mail Stop F443,13199 E Montview Blvd,Suite 300, Aurora, CO 80045 USA.
EM sean.oleary@ucdenver.edu
RI Cataldi, Jessica/Y-6544-2019
OI Cataldi, Jessica/0000-0002-4480-0304
FU Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [5U01IP001072-02]
FX The authors would like to thank leaders of the ACOG for collaborating in
   the establishment of the sentinel network in obstetricians and
   gynecologists. We would also like to thank all obstetricians and
   gynecologists in the network for participating and responding to this
   survey. This work was funded by the Centers for Disease Control and
   Prevention, Grant Number 5U01IP001072-02.
CR Belluz J., 2018, VOX
   Brtnikova M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202755
   Cacciatore MA, 2016, HEALTH AFFAIR, V35, P334, DOI 10.1377/hlthaff.2015.1093
   Caplan AL, 2010, LANCET, V375, P444, DOI 10.1016/S0140-6736(10)60175-4
   Cataldi JR, 2016, VACCINE, V34, P6375, DOI 10.1016/j.vaccine.2016.10.048
   Crane LA, 2008, EVAL HEALTH PROF, V31, P43, DOI 10.1177/0163278707311872
   Deer B, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c5258
   Dillman DA, 2009, INTERNET MAIL MIXED
   Ding H, 2017, MMWR-MORBID MORTAL W, V66, P1016, DOI 10.15585/mmwr.mm6638a2
   Ding HL, 2015, MMWR-MORBID MORTAL W, V64, P1000, DOI 10.3201/mmwr.mm6436a2
   Dobson Roger, 2003, BMJ, V326, P1107
   Donahue J., 2019, 2019 ADV COMM IMM PR
   Donahue JG, 2017, VACCINE, V35, P5314, DOI 10.1016/j.vaccine.2017.06.069
   Fox M., 2017, NBC NEWS
   Goodman NW, 2007, BRIT MED J, V335, P222, DOI 10.1136/bmj.39289.666157.BE
   Hanley SJB, 2015, LANCET, V385, P2571, DOI 10.1016/S0140-6736(15)61152-7
   Harper Scott A., 2004, Morbidity and Mortality Weekly Report, V53, P1
   Hartert TV, 2003, AM J OBSTET GYNECOL, V189, P1705, DOI 10.1016/S0002-9378(03)00857-3
   Holton A, 2012, HEALTH COMMUN, V27, P690, DOI 10.1080/10410236.2011.633158
   Howard J., 2018, CNN
   Kahn KE, 2018, MMWR-MORBID MORTAL W, V67, P1055, DOI 10.15585/mmwr.mm6738a3
   Leslie TF, 2018, VACCINE, V36, P1808, DOI 10.1016/j.vaccine.2018.02.086
   Maggie F., 2018, NBC NEWS
   McMahon SR, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e299
   Mertz D, 2017, VACCINE, V35, P521, DOI 10.1016/j.vaccine.2016.12.012
   Munoz FM, 2005, AM J OBSTET GYNECOL, V192, P1098, DOI 10.1016/j.ajog.2004.12.019
   Nordin JD, 2013, OBSTET GYNECOL, V121, P519, DOI 10.1097/AOG.0b013e3182831b83
   O'Leary ST, 2019, OBSTET GYNECOL, V133, P40, DOI 10.1097/AOG.0000000000003005
   O'Leary ST, 2018, AM J PREV MED, V54, P205, DOI 10.1016/j.amepre.2017.10.016
   O'Leary ST, 2015, PEDIATR INFECT DIS J, V34, P1244, DOI 10.1097/INF.0000000000000873
   Owens SR, 2002, EMBO REP, V3, P406, DOI 10.1093/embo-reports/kvf106
   Paules CI, 2018, NEW ENGL J MED, V378, P7, DOI 10.1056/NEJMp1714916
   Poehling KA, 2006, NEW ENGL J MED, V355, P31, DOI 10.1056/NEJMoa054869
   Poehling KA, 2011, AM J OBSTET GYNECOL, V204, pS141, DOI 10.1016/j.ajog.2011.02.042
   Power ML, 2009, AM J PREV MED, V37, P231, DOI 10.1016/j.amepre.2009.05.019
   Rossman S., 2017, US TODAY
   Scutti S., 2018, CDC REPORTS
   Simas C, 2019, HUM VACC IMMUNOTHER, V15, P163, DOI 10.1080/21645515.2018.1511667
   Smith MJ, 2008, PEDIATRICS, V121, pE836, DOI 10.1542/peds.2007-1760
   Speers Tammy, 2004, Commun Med, V1, P171
   Steenhuysen J., 2018, REUTERS
   Welch A., 2017, CBS NEWS
   Woods B., 2018, CNBC
   Zaman K, 2008, NEW ENGL J MED, V359, P1555, DOI 10.1056/NEJMoa0708630
NR 44
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3474
EP 3479
DI 10.1016/j.vaccine.2020.02.051
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000009
PM 32204941
DA 2020-05-12
ER

PT J
AU van den Boogaard, J
   Rots, NY
   van der Klis, F
   de Melker, HE
   Knol, MJ
AF van den Boogaard, J.
   Rots, Nynke Y.
   van der Klis, Fiona
   de Melker, Hester E.
   Knol, Mirjam J.
TI Is there an association between socioeconomic status and immune response
   to infant and childhood vaccination in the Netherlands?
SO VACCINE
LA English
DT Article
DE Immune response; Vaccine preventable diseases; Vaccination;
   Socioeconomic status; Netherlands; Immunoglobulin G
ID NATIONAL IMMUNIZATION PROGRAM; MULTIPLEX IMMUNOASSAY; SOCIAL
   DETERMINANTS; SERUM ANTIBODIES; RUBELLA; HEALTH; SEROPREVALENCE;
   DIPHTHERIA; TETANUS; MEASLES
AB Introduction: Socioeconomic status (SES) is a well-known determinant of health, but its relation with vaccine-induced immunity is less documented. We explored the association between SES and immunoglobulin G (IgG) levels against vaccine-preventable diseases in vaccinated children in the Dutch National Immunization Programme.
   Methods: Data from a population-wide cross-sectional serosurvey in the Netherlands (2006-2007) were used. We compared geometric mean IgG concentrations/titers (GMC/T ratios) against measles, mumps, rubella, Haemophilus influenzae type b (Hib), Neisseria meningococcus type C, diphtheria, tetanus, poliovirus types 1,2,3 and pertussis in children of high versus low SES by linear regression analysis. We included 894 children (0-12 years) at one of two timeframes: 1 month to 1 year, or 1-3 years after vaccination. Mother's educational level and net household income served as binary indicators of SES.
   Results: Of 58 possible associations of vaccine-induced antibody responses with educational level and 58 with income, 10 (9%) were statistically significant: 2 favouring (that is, with higher IgG levels at) high educational level (for Hib 1 m-1y after vaccination (GMC/T ratio: 2.99, 95%CI: 1.42-6.30) and polio 2 1 m-1y after the 9-year booster dose (1.14, 1.01-1.27)) and 8 favouring low income (polio 1, 2 and 3 1 m-1y after the 11-month booster (0.74, 0.58-0.94; 0.79, 0.64-0.97; 0.72, 0.55-0.95), polio 3 and pertussis 1-3y after the 11-month booster (0.70, 0.56-0.88; pertussis-prn: 0.60, 0.37-0.98; pertussis-ptx: 0.66, 0.47-0.95), mumps and rubella 1-3y after first vaccination (0.73, 0.55-0.97; 0.70, 0.55-0.90), and rubella 1 m-1y after second vaccination (0.83, 0.55-0.90)). After adjustment for multiple testing, none of the differences remained significant. There was no association between SES and proportion of children with protective IgG levels.
   Conclusion: In this explorative study, we found no consistent association between SES and immune response to vaccination in the Netherlands and no association with protective IgG levels. Additional studies in other settings should confirm this finding. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [van den Boogaard, J.; Rots, Nynke Y.; van der Klis, Fiona; de Melker, Hester E.; Knol, Mirjam J.] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.
   [van den Boogaard, J.] European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden.
RP van den Boogaard, J (reprint author), RIVM, Antonie van Leeuwenhoeklaan 9, NL-3720 BA Bilthoven, Netherlands.
EM jossy.van.den.boogaard@rivm.nl
FU Dutch Ministry of Health
FX This study was funded by the Dutch Ministry of Health.
CR Adler NE, 2002, HEALTH AFFAIR, V21, P60, DOI 10.1377/hlthaff.21.2.60
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   de Gier Brechje, 2020, Eur J Public Health, V30, P270, DOI 10.1093/eurpub/ckz230
   de Greeff SC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014183
   De Melker HE, 1998, EPIDEMIOL INFECT, V121, P637, DOI 10.1017/S0950268898001587
   de Melker HE, 2003, VACCINE, V21, P716, DOI 10.1016/S0264-410X(02)00587-X
   de Voer RM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012144
   de Voer RM, 2009, CLIN VACCINE IMMUNOL, V16, P433, DOI 10.1128/CVI.00364-08
   Dowd JB, 2009, EPIDEMIOLOGY, V20, P902, DOI 10.1097/EDE.0b013e3181bb5302
   Hoes J, 2019, VACCINE, V37, P4504, DOI 10.1016/j.vaccine.2019.06.055
   Hoes J, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00209
   Jain A, 2017, VACCINE, V35, P2315, DOI 10.1016/j.vaccine.2017.03.013
   Kriz P, 2000, ARCH DIS CHILD, V83, P117, DOI 10.1136/adc.83.2.117
   Lockwood KG, 2018, PHYSIOL BEHAV, V188, P212, DOI 10.1016/j.physbeh.2018.02.016
   Loeb MB, 2004, CLIN INFECT DIS, V38, P1293, DOI 10.1086/383469
   Mackenbach J, 2018, HLTH INEQUALITIES IN
   Marmot M, 2012, LANCET, V380, P1011, DOI 10.1016/S0140-6736(12)61228-8
   McVernon J, 2008, ARCH DIS CHILD, V93, P670, DOI 10.1136/adc.2006.097501
   Mollema L, 2014, EPIDEMIOL INFECT, V142, P1100, DOI 10.1017/S0950268813001532
   Smits G, 2014, VACCINE, V32, P1890, DOI 10.1016/j.vaccine.2014.01.066
   Smits G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058234
   Smits GP, 2012, CLIN VACCINE IMMUNOL, V19, P396, DOI 10.1128/CVI.05537-11
   Sommer I, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2227-y
   Steens A, 2010, VACCINE, V28, P7803, DOI 10.1016/j.vaccine.2010.09.036
   Swart EM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148605
   Tauil MD, 2016, VACCINE, V34, P2635, DOI 10.1016/j.vaccine.2016.04.016
   van der Klis FRM, 2009, NETH J MED, V67, P301
   Van der Maas N, 2014, EDITORIAL TEAM EDITO, V2006, P43
   van Gageldonk PGM, 2008, J IMMUNOL METHODS, V335, P79, DOI 10.1016/j.jim.2008.02.018
   Van Lier EA, 2008, 210021007 RIVM
   Van Loveren H, 2001, ENVIRON HEALTH PERSP, V109, P757, DOI 10.2307/3454816
   Whelan J, 2012, HUM VACC IMMUNOTHER, V8, P743, DOI 10.4161/hv.19642
   Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3480
EP 3488
DI 10.1016/j.vaccine.2020.01.071
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000010
PM 32063433
DA 2020-05-12
ER

PT J
AU Tavares-Da-Silva, F
   Co, MM
   Dessart, C
   Herve, C
   Lopez-Fauqued, M
   Mahaux, O
   Van Holle, L
   Stegmann, JU
AF Tavares-Da-Silva, Fernanda
   Co, Maribel Miranda
   Dessart, Christophe
   Herve, Caroline
   Lopez-Fauqued, Marta
   Mahaux, Olivia
   Van Holle, Lionel
   Stegmann, Jens-Ulrich
TI Review of the initial post-marketing safety surveillance for the
   recombinant zoster vaccine
SO VACCINE
LA English
DT Review
DE Herpes zoster; Recombinant zoster vaccine; AS01; Post-marketing safety
ID GUILLAIN-BARRE-SYNDROME; BACKGROUND INCIDENCE RATES; UNITED-STATES;
   DATA-COLLECTION; CASE-DEFINITION; SUBUNIT VACCINE; IMMUNIZATION;
   GUIDELINES; EPIDEMIOLOGY; OPHTHALMICUS
AB Background: The adjuvanted recombinant zoster vaccine (RZV) received its first marketing authorization in October 2017, for prevention of herpes zoster in individuals aged >= 50 years.
   Methods: We summarized safety information, following RZV administration, received by GSK via spontaneous adverse event (AE) reports submitted by healthcare providers, vaccine recipients and other reporters. Observed-to-expected (O/E) analyses were performed for selected outcomes: reports of death, Guillain-Barre syndrome and Bell's palsy. Standard case definitions were used to assess individual case reports. Data mining, using proportional reporting ratio and time-to-onset signal detection methods, was employed to identify RZV-AE pairs with disproportionate reporting or unexpected time-to-onset distribution.
   Results: Between October 13, 2017 and February 10, 2019, an estimated 9.3 million doses were distributed and GSK received 15,638 spontaneous AE reports involving RZV. Most reports were classified as non-serious (95.3%) and originated from the United States (81.7%), where the majority of doses were distributed. Among reports with age or sex reported, individuals were mainly 50-69-year-olds (62.1%) and female (66.7%). Of all reports, 3,579 (22.9%) described vaccination errors, of which 82.7% were without associated symptoms. Of all vaccination error reports, most described errors of vaccine preparation and reconstitution (29.7%), inappropriate schedule or incomplete course of administration (26.7%), incorrect route of administration (16.4%), and storage errors (12.9%). The most commonly reported symptoms were consistent with the known RZV reactogenicity profile observed in clinical trials, including injection site reactions, pyrexia, chills, fatigue, headache. O/E analyses for selected outcomes and data mining analyses for all reported AEs did not identify any unexpected patterns.
   Conclusions: Review of the initial data from the post-marketing safety surveillance showed that the safety profile of RZV is consistent with that previously observed in pre-licensure clinical trials. Other studies are ongoing and planned, to continue generating real-world safety data and further characterize RZV. (C) 2019 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.
C1 [Tavares-Da-Silva, Fernanda; Co, Maribel Miranda; Dessart, Christophe; Herve, Caroline; Lopez-Fauqued, Marta; Mahaux, Olivia; Van Holle, Lionel; Stegmann, Jens-Ulrich] GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
RP Tavares-Da-Silva, F (reprint author), GSK, Ave Fleming 20, B-1300 Wavre, Belgium.
EM fernanda.tavares@gsk.com; maribel.x.co@gsk.com;
   christophe.d.dessart@gsk.com; caroline.c.herve@gsk.com;
   marta.x.lopez-fauqued@gsk.com; olivia.x.malhaux@gsk.com;
   lionel.vanholle@gmail.com; jens-ulrich.x.stegmann@gsk.com
FU GlaxoSmithKline Biologicals SAGlaxoSmithKline
FX This work was supported by GlaxoSmithKline Biologicals SA, including all
   costs associated with the development and publishing of the manuscript.
CR [Anonymous], 2010, PRACT ASP SIGN DET P
   Baker MA, 2013, VACCINE, V31, pK98, DOI 10.1016/j.vaccine.2013.04.088
   Benedetti MD, 2015, NEUROEPIDEMIOLOGY, V45, P90, DOI 10.1159/000438752
   Black S, 2009, LANCET, V374, P2115, DOI 10.1016/S0140-6736(09)61877-8
   Centers for Disease Control and Prevention, NEW SHINGL VACC FACT
   Centers for Disease Control and Prevention National Center for Health Statistics, UND CAUS DEATH 1999
   Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800
   Da Silva FT, 2013, VACCINE, V31, P1870, DOI 10.1016/j.vaccine.2013.01.042
   Delannoy A, 2017, J PERIPHER NERV SYST, V22, P51, DOI 10.1111/jns.12202
   Didierlaurent AM, 2014, J IMMUNOL, V193, P1920, DOI 10.4049/jimmunol.1400948
   Dooling KL, 2018, MMWR-MORBID MORTAL W, V67, P103, DOI 10.15585/mmwr.mm6703a5
   Frenzen PD, 2007, NEUROEPIDEMIOLOGY, V29, P83, DOI 10.1159/000109501
   Gnann JW, 2002, NEW ENGL J MED, V347, P340, DOI 10.1056/NEJMcp1302674
   Goldman SA, 1998, CLIN THER, V20, pC40, DOI 10.1016/S0149-2918(98)80007-6
   Halsey Neal A, 2002, Semin Pediatr Infect Dis, V13, P205, DOI 10.1053/spid.2002.125864
   Hauck LJ, 2008, J NEUROL NEUROSUR PS, V79, P318, DOI 10.1136/jnnp.2007.118810
   Hense S, 2014, NEUROEPIDEMIOLOGY, V43, P244, DOI 10.1159/000369344
   Hersh AO, 2016, VACCINE, V34, P6572, DOI 10.1016/j.vaccine.2016.09.031
   Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6
   Hesse EM, 2019, MMWR-MORBID MORTAL W, V68, P91, DOI 10.15585/mmwr.mm6804a4
   Hibbs BF, 2015, VACCINE, V33, P3171, DOI 10.1016/j.vaccine.2015.05.006
   Johnson RW, 2014, NEW ENGL J MED, V371, P1526, DOI 10.1056/NEJMcp1403062
   Johnson RW, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-37
   Kawai K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004833
   Kohl KS, 2005, ADV PATIENT SAFETY R, V2
   Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184
   LANGMUIR AD, 1979, J ROY SOC MED, V72, P660, DOI 10.1177/014107687907200908
   Liesegang TJ, 2008, OPHTHALMOLOGY, V115, pS3, DOI 10.1016/j.ophtha.2007.10.009
   Lopez-Fauqued M, 2019, VACCINE, V37, P2482, DOI 10.1016/j.vaccine.2019.03.043
   Mahaux O, 2016, PHARMACOEPIDEM DR S, V25, P215, DOI 10.1002/pds.3918
   Rath B, 2017, VACCINE, V35, P1972, DOI 10.1016/j.vaccine.2016.05.023
   Ruggeberg JU, 2007, VACCINE, V25, P5675, DOI 10.1016/j.vaccine.2007.02.064
   Schmader KE, 2019, J GERONTOL A-BIOL, V74, P1217, DOI 10.1093/gerona/gly218
   SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P105, DOI 10.1093/oxfordjournals.aje.a112795
   Sejvar JJ, 2007, VACCINE, V25, P5771, DOI 10.1016/j.vaccine.2007.04.060
   Sejvar JJ, 2011, VACCINE, V29, P599, DOI 10.1016/j.vaccine.2010.06.003
   Shimabukuro T., 2019, UPDATE POSTLICENSURE
   Shimabukuro T., 2019, FEBRUARY 2019 ADVISO
   Shimabukuro TT, 2018, MMWR-MORBID MORTAL W, V67, P585, DOI 10.15585/mmwr.mm6720a4
   Shingrix (zoster vaccine recombinant ajuvanted), HIGHL PRESCR INF
   Skufca J, 2017, PAPILLOMAVIRUS RES, V3, P91, DOI 10.1016/j.pvr.2017.03.001
   Su JR, 2016, MMWR-MORBID MORTAL W, V65, P161, DOI 10.15585/mmwr.mm6506a4
   The Federal Health Monitoring System, 1998, DEATHS CAS 100000 IN
   Tran KD, 2016, OPHTHALMOLOGY, V123, P1469, DOI 10.1016/j.ophtha.2016.03.005
   van der Maas NAT, 2011, J PERIPHER NERV SYST, V16, P243, DOI 10.1111/j.1529-8027.2011.00356.x
   Van Holle L, 2014, DRUG SAFETY, V37, P1047, DOI 10.1007/s40264-014-0237-9
   Van Holle L, 2012, PHARMACOEPIDEM DR S, V21, P603, DOI 10.1002/pds.3226
   Woerner A, 2017, VACCINE, V35, P1559, DOI 10.1016/j.vaccine.2016.09.024
   Yawn, 2008, MAYO CLIN PROC, V83, P255
   Yawn BP, 2013, NEUROLOGY, V81, P928, DOI 10.1212/WNL.0b013e3182a3516e
   Yawn BP, 2013, MAYO CLIN PROC, V88, P562, DOI 10.1016/j.mayocp.2013.03.014
   Zanoni G, 2016, VACCINE, V34, P6561, DOI 10.1016/j.vaccine.2016.09.032
NR 52
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3489
EP 3500
DI 10.1016/j.vaccine.2019.11.058
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000011
PM 31818534
OA Other Gold
DA 2020-05-12
ER

PT J
AU Mirinaviciute, G
   Quist-Paulsen, E
   Brantsaeter, AB
   Flem, E
AF Mirinaviciute, Grazina
   Quist-Paulsen, Else
   Brantsaeter, Arne Broch
   Flem, Elmira
TI The burden of herpes zoster disease in Norway
SO VACCINE
LA English
DT Article
DE Herpes zoster; Shingles; Postherpetic neuralgia; Burden; Registries;
   Norway; Primary healthcare; Hospitalizations; Deaths
ID POSTHERPETIC NEURALGIA; VARICELLA; VIRUS; EPIDEMIOLOGY; IMPACT;
   VACCINATION; OLDER; RISK
AB Background: No national vaccination program against herpes zoster (HZ) is currently in place in Norway. We aimed to quantify the burden of medically attended HZ to assess the need for a vaccination program.
   Methods: We linked data from several health registries to identify medically attended HZ cases during 2008-2014 and HZ-associated deaths during 1996-2012 in the entire population of Norway. We calculated HZ incidences for primary and hospital care by age, sex, type of health encounter, vaccination status, and co-morbidities among hospital patients. We also estimated HZ-associated mortality and case-fatality.
   Results: The study included 82,064 HZ patients, of whom none were reported as vaccinated against HZ. The crude annual incidence of HZ was 227.1 cases per 100,000 in primary healthcare and 24.8 cases per 100,000 in hospitals. Incidence rates were higher in adults aged >= 50 years (461 per 100,000 in primary care and 57 per 100,000 in hospitals), and women than in men both in primary healthcare (267 vs 188 per 100,000), and hospitals (28 vs 22 per 100,000). Among hospital patients, 47% had complicated zoster and 25% had comorbidities, according to the Charlson comorbidity index. The duration of hospital stay (median 4 days) increased with the severity of comorbidities. The estimated mortality rate was 0.18 per 100,000; and in-hospital case-fatality rate was 1.04%.
   Conclusions: Medically attended HZ poses a substantial burden in the Norwegian healthcare sector. The majority of the zoster cases occurred among adults aged >= 50 years - the group eligible for zoster vaccination - and increased use of zoster vaccination may be warranted, especially among persons with comorbidities. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Mirinaviciute, Grazina; Flem, Elmira] Norwegian Inst Publ Hlth, Dept Infect Dis Epidemiol & Modeling, Infect Control & Environm Hlth, POB 222, N-0213 Oslo, Norway.
   [Quist-Paulsen, Else] Univ Oslo, Oslo Univ Hosp, Dept Infect Dis, Oslo, Norway.
   [Quist-Paulsen, Else] Univ Oslo, Inst Clin Med, Oslo, Norway.
   [Brantsaeter, Arne Broch] Oslo Univ Hosp, Dept Infect Dis, POB 4956, N-0424 Oslo, Norway.
   [Brantsaeter, Arne Broch] Oslo Univ Hosp, Dept Acute Med, POB 4956, N-0424 Oslo, Norway.
   [Flem, Elmira] MSD Norway, Med Affairs Vaccines, Drammen, Norway.
RP Mirinaviciute, G (reprint author), Norwegian Inst Publ Hlth, Oslo, Norway.
EM grazina.mirinaviciute@gmail.com; el-pa1@ous-hf.no; uxarbr@ous-hf.no;
   elmira.flem@merck.com
OI Mirinaviciute, Grazina/0000-0002-2512-3328
FU Norwegian Institute of Public Health
FX The Norwegian Institute of Public Health provided the funds to conduct
   this study.
CR Ahmad OB, 2001, AGE STANDARTIZATION, V31
   Amlie-Lefond C, 2016, J STROKE CEREBROVASC, V25, P1561, DOI 10.1016/j.jstrokecerebrovasdis.2016.03.052
   Ansaldi F, 2016, ADV THER, V33, P1094, DOI 10.1007/s12325-016-0355-0
   Bakken Inger Johanne, 2014, Tidsskr Nor Laegeforen, V134, P12, DOI 10.4045/tidsskr.13.1417
   Bricout H, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1753-y
   Carville KS, 2010, VACCINE, V28, P2532, DOI 10.1016/j.vaccine.2010.01.036
   Chiappe SG, 2010, VACCINE, V28, P7933, DOI 10.1016/j.vaccine.2010.09.074
   Cunningham AL, 2016, NEW ENGL J MED, V375, P1019, DOI 10.1056/NEJMoa1603800
   de Melker H, 2006, VACCINE, V24, P3946, DOI 10.1016/j.vaccine.2006.02.017
   Di Legami V, 2007, VACCINE, V25, P7598, DOI 10.1016/j.vaccine.2007.07.049
   Fleming DM, 2004, EPIDEMIOL INFECT, V132, P1, DOI 10.1017/S0950268803001523
   Gater A, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1514-y
   Gilden D, 2015, NEUROLOGY, V84, P1948, DOI 10.1212/WNL.0000000000001409
   Grahn A, 2015, J INFECTION, V71, P281, DOI 10.1016/j.jinf.2015.06.004
   Hobbelen PHF, 2016, J INFECTION, V73, P241, DOI 10.1016/j.jinf.2016.05.008
   HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106
   Insinga RP, 2005, J GEN INTERN MED, V20, P748, DOI 10.1111/j.1525-1497.2005.0150.x
   John AR, 2017, INFECT DIS CLIN N AM, V31, P811, DOI 10.1016/j.idc.2017.07.016
   Johnson RW, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-37
   JUNKER AK, 1991, PEDIATR INFECT DIS J, V10, P569, DOI 10.1097/00006454-199108000-00004
   Kang JH, 2011, J INFECT DIS, V204, P188, DOI 10.1093/infdis/jir239
   Kawai K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004833
   Laing KJ, 2018, J INFECT DIS, V218, pS68, DOI 10.1093/infdis/jiy403
   Lal H, 2015, NEW ENGL J MED, DOI [10.1056/NEJMoa1501184., DOI 10.1056/NEJMOA1501184.]
   Marchetti S, 2018, VACCINE, V36, P1116, DOI 10.1016/j.vaccine.2018.01.038
   Mirinaviciute G, 2017, PEDIATR INFECT DIS J, V36, P1032, DOI [10.1097/INF.0000000000001656, 10.1097/inf.0000000000001656]
   Opstelten W, 2002, FAM PRACT, V19, P471, DOI 10.1093/fampra/19.5.471
   Oxman MN, 2009, J AM OSTEOPATH ASSOC, V109, pS13
   Pedersen AG, 2015, TIDSSKR NORSKE LAEGE, V135, P768, DOI 10.4045/tidsskr.14.1065
   Pinchinat S, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-170
   Rimseliene G, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1581-4
   Schmidt SAJ, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1369-6
   Sporaland Geir Lindquist, 2019, Tidsskr Nor Laegeforen, V139, DOI 10.4045/tidsskr.18.0440
   Studahl M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-586
   Takao Y, 2015, J EPIDEMIOL, V25, P617, DOI 10.2188/jea.JE20140210
   Trogstad L, 2012, EUROSURVEILLANCE, V17, P11
   United Nations DESA, 2015, WORLD POP PROSP 2015
   Watson PN, 2010, CLIN EVID
   Weinmann S, 2019, PEDIATRICS, V144, DOI 10.1542/peds.2018-2917
   Wen SY, 2015, PEDIATRICS, V135, pE565, DOI 10.1542/peds.2013-4037
NR 40
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3501
EP 3507
DI 10.1016/j.vaccine.2019.11.054
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000012
PM 31843267
OA Green Published
DA 2020-05-12
ER

PT J
AU Lee, WN
   Stuck, D
   Konty, K
   Rivers, C
   Brown, CR
   Zbikowski, SM
   Foschini, L
AF Lee, Wei-Nchih
   Stuck, David
   Konty, Kevin
   Rivers, Caitlin
   Brown, Courtney R.
   Zbikowski, Susan M.
   Foschini, Luca
TI Large-scale influenza vaccination promotion on a mobile app platform: A
   randomized controlled trial
SO VACCINE
LA English
DT Article
ID UNITED-STATES; ADULT-POPULATIONS; IMMUNIZATION; MESSAGES; PROMPTS
AB While health-care providers have used incentives in an attempt to motivate patients to obtain vaccinations, their effect on vaccination rates has not been systematically evaluated on a large scale. In this study, we examined whether mobile applications may improve population vaccination rates through enhanced communication and incentives education. Our study is the first randomized controlled trial assessing the effect of large-scale messaging combined with individualized incentives on influenza-vaccination rates. In this trial, we delivered messages regarding influenza vaccinations to 50,286 adults, aged 18 through 65, then compared the subsequent vaccination rate, the effectiveness of the message content and the timing. Multiple rounds of messaging occurred over a seven-week period during the 2016 flu season, after which vaccination rates were observed for one week. Participants were randomly assigned to one of three messaging approaches: conspicuous (highlighting the amount of rewards to be received for obtaining a flu shot); generic (promoting vaccinations with no mention of rewards); or no-message. Evidence of vaccination obtainment was indicated by medical and pharmacy claims, augmented by patients self-reporting through the mobile wellness app during the study period. Of the people assigned to receive messaging, 23.2% obtained influenza vaccination, compared to 22.0% of people who obtained vaccination in the no-messaging control arm. This difference was statistically significant (p < 0.01). The research revealed that messaging effectiveness decreased after each successive batch sent, suggesting that most participants responsive to messaging would become activated immediately after receiving one alert. Interestingly, in this large-scale study, there were no significant differences between conspicuous incentives and generic messaging, suggesting an important area for future research. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Lee, Wei-Nchih; Stuck, David] Evidat Hlth, 167 2nd Ave, San Mateo, CA 94401 USA.
   [Konty, Kevin; Foschini, Luca] Evidat Hlth, 15 Figueroa St, Santa Barbara, CA 93101 USA.
   [Rivers, Caitlin] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, 621 E Pratt St,Suite 210, Baltimore, MD 21230 USA.
   [Brown, Courtney R.] Humana, 500 W Main St, Louisville, KY 40202 USA.
   [Zbikowski, Susan M.] 834 NE 95th St, Seattle, WA 98115 USA.
   [Zbikowski, Susan M.] InZights Consulting, Seattle, WA USA.
RP Lee, WN (reprint author), Evidat Hlth, 167 2nd Ave, San Mateo, CA 94401 USA.
EM wlee@evidation.com; dstuck@evidation.com; kkonty@evidation.com;
   crivers6@jhu.edu; cbrown37@humana.com; lfoschini@evidation.com
FU  [DARPA-BAA-15-35];  [W911NF-16-C-0055]
FX LF thanks Prof. Katherine Milkman for fruitful input, and Glenn Morell
   for help in the campaign implementation. All authors attest they meet
   the ICMJE criteria for authorship. This research was funded by
   DARPA-BAA-15-35, Award Number W911NF-16-C-0055.
CR Adams J, 2014, HEALTH PSYCHOL REV, V8, P286, DOI 10.1080/17437199.2013.848410
   Bridges CB, 2000, JAMA-J AM MED ASSOC, V284, P1655, DOI 10.1001/jama.284.13.1655
   Center for Disease Control and Prevention, 2020, HLTH PEOPL 2020
   Centers for Disease Control, 2016, VACC WHO SHOULD DO I
   Centers for Disease Control, FLU VACC COV US 2015
   Dale LP, 2019, VACCINE, V37, P4594, DOI 10.1016/j.vaccine.2018.04.018
   Grubb MD, 2015, REV ECON STUD, V82, P219, DOI 10.1093/restud/rdu024
   Harris KM, 2009, J GEN INTERN MED, V24, P1311, DOI 10.1007/s11606-009-1126-2
   Herrett E, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004633
   Hirvensalo M, 2011, SCAND J PUBLIC HEALT, V39, P669, DOI 10.1177/1403494811420324
   HOSMER DW, 1992, EPIDEMIOLOGY, V3, P452, DOI 10.1097/00001648-199209000-00012
   John LK, 2017, MANAGE SCI
   Lam PP, 2010, CAN MED ASSOC J, V182, pE542, DOI 10.1503/cmaj.091304
   Lu PJ, 2014, VACCINE, V32, P3198, DOI 10.1016/j.vaccine.2014.04.003
   Lu PJ, 2013, AM J EPIDEMIOL, V178, P1478, DOI 10.1093/aje/kwt158
   Mast Eric E., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Milkman KL, 2011, P NATL ACAD SCI USA, V108, P10415, DOI 10.1073/pnas.1103170108
   Miller Rupert G, 1966, SIMULTANEOUS STAT IN
   Peterson ED, 2018, JAMA-J AM MED ASSOC, V320, P137, DOI 10.1001/jama.2018.8512
   Prati G, 2012, HEALTH COMMUN, V27, P413, DOI 10.1080/10410236.2011.606523
   Regan AK, 2017, ANN FAM MED, V15, P507, DOI 10.1370/afm.2120
   Rolfes MA, 2016, ESTIMATED INFLUENZA
   Silva VD, 2017, INT J MARKETING STUD, V9, P160
   Stockwell MS, 2012, JAMA-J AM MED ASSOC, V307, P1702, DOI 10.1001/jama.2012.502
   Szilagyi PG, 2015, ACAD PEDIATR, V15, P149, DOI 10.1016/j.acap.2014.10.006
   Thomson A, 2016, VACCINE, V34, P1018, DOI 10.1016/j.vaccine.2015.11.065
   Treanor JJ, 2016, NEW ENGL J MED, V375, P1261, DOI 10.1056/NEJMcp1512870
   Yudin MH, 2017, VACCINE, V35, P842, DOI 10.1016/j.vaccine.2016.12.002
NR 28
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 16
PY 2020
VL 38
IS 18
BP 3508
EP 3514
DI 10.1016/j.vaccine.2019.11.053
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TM
UT WOS:000525318000013
PM 31787410
DA 2020-05-12
ER

PT J
AU Qamar, FN
   Yousafzai, MT
   Khaliq, A
   Karim, S
   Memon, H
   Junejo, A
   Baig, I
   Rahman, N
   Bhurgry, S
   Afroz, H
   Sami, U
AF Qamar, Farah Naz
   Yousafzai, Mohammad Tahir
   Khaliq, Asif
   Karim, Sultan
   Memon, Hina
   Junejo, Amber
   Baig, Inayat
   Rahman, Najeeb
   Bhurgry, Shafqat
   Afroz, Hina
   Sami, Uzma
TI Adverse events following immunization with typhoid conjugate vaccine in
   an outbreak setting in Hyderabad, Pakistan
SO VACCINE
LA English
DT Article
DE Adverse events; AEFI; Typbar-TCV; Salmonella Typhi; Campaign;
   Vaccination
ID SALMONELLA-TYPHI; EFFICACY; IMMUNOGENICITY; CHILDREN; SAFETY
AB Pakistan is facing the world's largest outbreak of extensively drug-resistant (XDR) Typhoid. Vaccination campaign for children aged 6 months to 10 years old with Typhoid Conjugate Vaccine (Typbar-TCV (R)) was conducted in high-risk areas of Hyderabad during 2018. About 207,000 children were vaccinated. Here we report the adverse events following immunization (AEFI) during the campaign. The campaign was carried out using outreach and fixed centre strategy. Community mobilizers visited each household to perform line listing and mobilize parents with age-eligible children. Children were observed for 30 min post-vaccination. Two-pronged strategy was used for ascertainment of AEFI. A 24/7 hotline number was provided to all parents/caretakers (n = 199,861) to report AEFI during 14 days following immunization. An age-stratified (n = 7139 children) were actively followed at days 7 and 14 for the ascertainment of AEFI. All AEFI were examined by three trained medical officers. A structured questionnaire using Brighton collaboration criteria with level 3 diagnostic certainty was used for the recording of AEFI. Data were analysed using Microsoft Excel Office 365. Overall, 499 AEFI (433 in the subset actively followed and 66 self-reported through hotline) were observed. The rate of AEFI was significantly higher among very young children (age group 6 to 12 months) as compared to 2 to 3 years old children (0.54% vs. 0.33% respectively; p-value < 0.001). Fever was the most common AEFI self-reported through the hotline (38/199,861 = 0.02%) and among the subset followed actively for 14 days (206/7139 = 2.89%). Fever was followed by local reactogenicity 10/199,861(0.01%), and 134/7139 (1.88%) through self-reported hotline and active follow-up, respectively. No serious AEFI was observed. Administration of a single dose of Typbar-TCV among children aged 6 months to 10 years old during an outbreak setting of Hyderabad Pakistan was safe. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Qamar, Farah Naz; Yousafzai, Mohammad Tahir; Khaliq, Asif; Karim, Sultan; Memon, Hina; Junejo, Amber; Baig, Inayat; Rahman, Najeeb] Aga Khan Univ Karachi, Dept Pediat & Child Hlth, Karachi, Pakistan.
   [Yousafzai, Mohammad Tahir] Univ New South Wales, Kirby Inst, Sydney, NSW, Australia.
   [Bhurgry, Shafqat] Taluka Hosp Qasimabad, Dept Pediat, Qasimabad, Pakistan.
   [Afroz, Hina; Sami, Uzma] Shah Bhitai Hosp, Latifabad, Pakistan.
RP Yousafzai, MT (reprint author), Aga Khan Univ Karachi, Dept Pediat & Child Hlth, Karachi, Pakistan.
EM m.tahir.yousafzai@gmail.com
FU Bill & Melinda Gates FoundationGates Foundation
FX This work is funded by Bill & Melinda Gates Foundation through emergency
   response fund. We are thankful to all local stakeholders such as DG
   Health Sindh, DHO Hyderabad, DC Hyderabad, and Lady Health Workers
   Program for providing support during the vaccination campaign.
CR Andrews JR, 2018, NEW ENGL J MED, V379, P1493, DOI 10.1056/NEJMp1803926
   Browne AJ, 2020, BMC MED, V18, DOI 10.1186/s12916-019-1443-1
   Capeding MR, 2019, VACCINE
   Dewan AM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0001998
   Jin C, 2017, LANCET, V390, P2472, DOI 10.1016/S0140-6736(17)32149-9
   Kim JH, 2019, CLIN INFECT DIS, V69, pS492, DOI 10.1093/cid/ciz525
   Klemm EJ, 2018, MBIO, V9, DOI 10.1128/mBio.00105-18
   Kohl KS, 2005, BRIGHTON COLLABORATI, V2
   Liu DW, 2015, VACCINE, V33, P4041, DOI 10.1016/j.vaccine.2015.04.060
   Mitra M, 2016, HUM VACC IMMUNOTHER, V12, P939, DOI 10.1080/21645515.2015.1117715
   Mohan VK, 2015, CLIN INFECT DIS, V61, P393, DOI 10.1093/cid/civ295
   National Institute of Population Studies, 2018, PAK DEM HLTH SURV 20
   Pakistan Bureau of Statistics, 2017, 6 POP HOUS CES 2017
   Qamar FN, 2018, LANCET INFECT DIS, V18, P1368, DOI 10.1016/S1473-3099(18)30483-3
   Qamar FN, 2018, J INFECT DIS, V218, pS201, DOI 10.1093/infdis/jiy205
   Capeding MR, 2018, VACCINE, V36, P3794, DOI 10.1016/j.vaccine.2018.05.038
   Shakya M, 2019, NEW ENGL J MED, V381, P2209, DOI 10.1056/NEJMoa1905047
   Stanaway JD, 2019, LANCET INFECT DIS, V19, P369, DOI 10.1016/S1473-3099(18)30685-6
   World Health Organization, 2018, TYPB TCV BHAR BIOT W
   World Health Organization [WHO], 2014, ANT RES GLOB REP SUR
   World Hlth Org, 2019, VACCINE, V37, P214, DOI 10.1016/j.vaccine.2018.04.022
   Yousafzai MT, 2019, CLIN INFECT DIS, V68, pS16, DOI 10.1093/cid/ciy877
NR 22
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3518
EP 3523
DI 10.1016/j.vaccine.2020.03.028
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100003
PM 32201138
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Moreno, J
   Duarte, C
   Cassiolato, AP
   Chacon, GC
   Alarcon, P
   Sanchez, J
   San Martin, YN
   Valenzuela, C
   Castillo, W
   Gabarrot, GG
AF Moreno, Jaime
   Duarte, Carolina
   Paula Cassiolato, Ana
   Chanto Chacon, Grettel
   Alarcon, Pedro
   Sanchez, Jacqueline
   Narvaez San Martin, Yolanda
   Valenzuela, Claudia
   Castillo, Wendy
   Garcia Gabarrot, Gabriela
CA SIREVA II Grp
TI Molecular characterization of Latin American invasive Streptococcus
   pneumoniae serotype 19A isolates
SO VACCINE
LA English
DT Article
DE Streptococcus pneumoniae; Invasive pneumococcal disease; Latin America;
   Serotype 19A; Laboratory surveillance
ID PNEUMOCOCCAL DISEASE; POPULATION-STRUCTURE; OTITIS-MEDIA; CLONES;
   CHILDREN; EVOLUTION; CARRIAGE; FEATURES; ST320; PCV7
AB Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide, especially among children and the elderly. S. pneumoniae serotype 19A has emerged as a major cause of invasive disease in many countries, regardless of whether pneumococcal conjugate vaccines are used. The aim of this study was molecular characterization of invasive S. pneumoniae serotype 19A isolates recovered between 2000 and 2015 from 13 National Laboratories through the laboratory-based surveillance of invasive S. pneumoniae program SIREVA II in Latin American countries. The isolates were submitted with antimicrobial susceptibility tests and were genotyped by a combination of pulsed field gel electrophoresis (PFGE) and multilocus sequence typing (MLST). Of the 185 isolates assayed, notable rates of resistance to penicillin (MIC >= 0.125 mu g/mL; 68.6%), tetracycline (63.7%), trimethoprim-sulfamethoxazole (63.2%), and erythromycin (43.2%) were observed, while 44.3% of isolates were multidrug resistant. The most frequently observed sequence types (ST) were ST320 (32.4%), ST199 (14.1%), ST172 (10.8%) and ST5204 (7.1%). The distribution of STs indicated regional differences in the epidemiology of the clonal groups. The present study showed a diverse genetic background of the pneumococcal population in Latin American countries. Continuous surveillance of the pneumococcal serotype 19A population in the region will be necessary to obtain information about geographical differences and changes in the spread and the establishment of particular clones. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Moreno, Jaime; Duarte, Carolina] Inst Nacl Salud, Bogota, Colombia.
   [Paula Cassiolato, Ana] Inst Adolfo Lutz Sao Paulo, Sao Paulo, Brazil.
   [Chanto Chacon, Grettel] INCIENSA, Ctr Nacl Referencia Bacteriol, San Jose, Costa Rica.
   [Alarcon, Pedro] Inst Salud Publ Chile ISP, Santiago, Chile.
   [Sanchez, Jacqueline] Hosp Infantil Doctor Robert Reid Cabral, Santo Domingo, Dominican Rep.
   [Narvaez San Martin, Yolanda] Inst Nacl Higiene & Med Trop, Guayaquil, Ecuador.
   [Valenzuela, Claudia] Minist Salud Publ & Asistencia Social, Guatemala City, Guatemala.
   [Castillo, Wendy] Inst Conmemorat Gorgas Estudios Salud, Panama City, Panama.
   [Garcia Gabarrot, Gabriela] Minist Salud Publ, Dept Labs, Montevideo, Uruguay.
RP Moreno, J (reprint author), Inst Nacl Salud, Grp Microbiol, Ave Calle 26 51-20, Bogota, Colombia.
EM jmoreno@ins.gov.co
FU Instituto Nacional de Salud, Colombia and Panamerican Health
   Organization/World Health Organization (PAHO/WHO)
FX Instituto Nacional de Salud, Colombia and Panamerican Health
   Organization/World Health Organization (PAHO/WHO).
CR Perez-Maya AA, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.00195-16
   [Anonymous], 2014, REGIONAL REPORT SIRE
   Balsells E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177113
   Beall BW, 2011, J INFECT DIS, V203, P1360, DOI 10.1093/infdis/jir052
   Caierao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111129
   Castaneda E, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-124
   Ciapponi A, 2014, PEDIATR INFECT DIS J, V33, P971, DOI 10.1097/INF.0000000000000363
   Clinical and Laboratory Standards Institute (CLSI), 2016, M100S24 CLSI S
   Cohen R, 2010, VACCINE, V28, P6114, DOI 10.1016/j.vaccine.2009.05.037
   Croucher NJ, 2014, GENOME BIOL EVOL, V6, P1589, DOI 10.1093/gbe/evu120
   dos Santos MS, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1049-y
   Enright MC, 1998, MICROBIOL-UK, V144, P3049, DOI 10.1099/00221287-144-11-3049
   Frazao N, 2016, MICROB DRUG RESIST, V22, P97, DOI 10.1089/mdr.2015.0109
   Gagetti P, 2017, VACCINE, V35, P4548, DOI 10.1016/j.vaccine.2017.07.030
   Galanis I, 2016, EUR RESPIR J, V47, P1208, DOI 10.1183/13993003.01451-2015
   Golden AR, 2015, J ANTIMICROB CHEMOTH, V70, P2199, DOI 10.1093/jac/dkv107
   Habib M, 2014, JOVE-J VIS EXP, DOI 10.3791/51208
   Hawkins P, 2017, INT J MED MICROBIOL, V307, P415, DOI 10.1016/j.ijmm.2017.07.008
   Henriques-Normark B, 2008, NAT REV MICROBIOL, V6, P827, DOI 10.1038/nrmicro2011
   Hsieh YC, 2013, J INFECT DIS, V208, P203, DOI 10.1093/infdis/jit145
   Agudelo CI, 2018, VACCINE, V36, P4861, DOI 10.1016/j.vaccine.2018.06.068
   Isturiz R, 2017, EXPERT REV VACCINES, V16, P1007, DOI 10.1080/14760584.2017.1362339
   Kim L, 2016, CLIN MICROBIOL REV, V29, P525, DOI 10.1128/CMR.00058-15
   Makarewicz O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169370
   Metcalf BJ, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2015.08.027
   Miernyk KM, 2016, DIAGN MICR INFEC DIS, V86, P224, DOI 10.1016/j.diagmicrobio.2016.07.004
   Ramos V, 2014, VACCINE, V32, P755, DOI 10.1016/j.vaccine.2013.12.024
   Reinert RR, 2010, VACCINE, V28, P4249, DOI 10.1016/j.vaccine.2010.04.020
   Setchanova LP, 2015, MICROB DRUG RESIST, V21, P35, DOI 10.1089/mdr.2014.0076
   Shin J, 2011, J ANTIMICROB CHEMOTH, V66, P1001, DOI 10.1093/jac/dkr048
   Sinha A, 2008, REV PANAM SALUD PUBL, V24, P304, DOI 10.1590/S1020-49892008001100002
   Song JH, 2012, VACCINE, V30, P2728, DOI 10.1016/j.vaccine.2012.01.091
   Tarrago D, 2011, ANTIMICROB AGENTS CH, V55, P2297, DOI 10.1128/AAC.01494-10
   Valenzuela MT, 2009, REV PANAM SALUD PUBL, V25, P270, DOI 10.1590/S1020-49892009000300011
   Tyrrell GJ, 2011, J INFECT DIS, V203, P1345, DOI 10.1093/infdis/jir056
   Vela MC, 2001, MICROB DRUG RESIST, V7, P153, DOI 10.1089/10766290152045020
   Zhou HJ, 2017, INFECT GENET EVOL, V55, P104, DOI 10.1016/j.meegid.2017.08.034
NR 37
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3524
EP 3530
DI 10.1016/j.vaccine.2020.03.030
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100004
PM 32204942
DA 2020-05-12
ER

PT J
AU Dayan, GH
   Langevin, E
   Gilbert, PB
   Wu, YK
   Moodie, Z
   Forrat, R
   Price, B
   Frago, C
   Bouckenooghe, A
   Cortes, M
   Noriega, F
   DiazGranados, CA
AF Dayan, Gustavo H.
   Langevin, Edith
   Gilbert, Peter B.
   Wu, Yukun
   Moodie, Zoe
   Forrat, Remi
   Price, Brenda
   Frago, Carina
   Bouckenooghe, Alain
   Cortes, Margarita
   Noriega, Fernando
   DiazGranados, Carlos A.
TI Assessment of the long-term efficacy of a dengue vaccine against
   symptomatic, virologically-confirmed dengue disease by baseline dengue
   serostatus
SO VACCINE
LA English
DT Article; Proceedings Paper
CT Annual Conference on Vaccinology Research
CY APR 03-05, 2019
CL Baltimore, MD
DE CYD-TDV; Vaccine efficacy; Serostatus; Asia-Pacific; Latin America
ID ZIKA VIRUS; COHORT
AB CYD-TDV is a live, attenuated, tetravalent dengue vaccine licensed in 21 countries. We undertook a posthoc analysis of the long-term efficacy of CYD-TDV during the surveillance expansion phase (SEP) of two Phase III studies (CYD14 in the Asia-Pacific region; CYD15 in Latin America). The SEP included approximately Year 5 and the entire Year 6 of follow-up after the first study injection. Vaccine efficacy against symptomatic virologically-confirmed dengue (VCD) was assessed by participant age (any age, >= 9, <9, 2-5, and 6-8 years at the time of the first injection) and baseline dengue serostatus using a casecohort framework. Baseline dengue serostatus was estimated by several methods including logistic regression-based multiple imputation (MI) to predict PRNT50 with key predictor being Month 13 (M13) anti-non-structural protein (NS1) titers; superlearner-based imputation by targeted minimum loss based estimation (TMLE); and M13 anti-NS1 titer threshold 9 EU/mL (NS1 M13). There were 436 symptomatic VCD cases (CYD14: n = 360; CYD15: n = 76) during the SEP. Vaccine efficacy in seropositive participants aged >= 9 years was assessed by MI (47.9% [95% CI 19.4; 66.3]), TMLE (53.0% [95% CI 23; 71]), and NS1 M13 (52.4% [95% CI 30.8; 67.3]). Vaccine efficacy estimates were lower in seropositive individuals aged <9 years compared with individuals >= 9 years. Among seropositive individuals aged 2-5 and 6-8 years, vaccine efficacy across the different approaches for assessing serostatus ranged from between -25.7 to 36.9% and 44.4 to 64.7% during the SEP, respectively. In the pooled CYD14/15 data of seronegatives, vaccine efficacy was null to modest. In conclusion, CYD-TDV was shown to maintain efficacy against symptomatic VCD in seropositive participants aged >= 9 years up to six years after the first dose. Persistence of efficacy was also observed in seropositive participants aged 6-8 years. (C) 2020 Sanofi Pasteur. Published by Elsevier Ltd.
C1 [Dayan, Gustavo H.; Wu, Yukun; Noriega, Fernando] Sanofi Pasteur, Discovery Dr, Swiftwater, PA 18370 USA.
   [Langevin, Edith; Forrat, Remi; DiazGranados, Carlos A.] Sanofi Pasteur, 1541 Ave Marcel Merieux, F-69280 Marcy Letoile, France.
   [Gilbert, Peter B.; Moodie, Zoe; Price, Brenda] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, 1124 Columbia St, Seattle, WA 98104 USA.
   [Frago, Carina; Bouckenooghe, Alain] Sanofi Pasteur, 38 Beach Rd 18-11,South Beach Tower, Singapore 189767, Singapore.
   [Cortes, Margarita] Sanofi Pasteur, Bogota, Colombia.
RP Dayan, GH (reprint author), Sanofi Pasteur, Discovery Dr, Swiftwater, PA 18370 USA.
EM Gustavo.Dayan@sanofi.com; Edith.Langevin@sanofi.com;
   pgilbert@fredhutch.org; Yukun.Wu@sanofi.com; zoe@fredhutch.org;
   Remi.Forrat@sanofi.com; blp7@uw.edu; Carina.Frago@sanofi.com;
   Margarita.Cortes@sanofi.com; Carlos.DiazGranados@sanofi.com
FU Sanofi Pasteur
FX This work was supported by Sanofi Pasteur.
CR Anders KL, 2011, AM J TROP MED HYG, V84, P127, DOI 10.4269/ajtmh.2011.10-0476
   Barba-Spaeth G, 2016, NATURE, V539, DOI 10.1038/nature19780
   BARLOW WE, 1994, BIOMETRICS, V50, P1064, DOI 10.2307/2533444
   Capeding MR, 2014, LANCET, V384, P1358, DOI 10.1016/S0140-6736(14)61060-6
   Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297
   Gordon A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002726
   Hadinegoro SR, 2015, NEW ENGL J MED, V373, P1195, DOI 10.1056/NEJMoa1506223
   Halstead SB, 2016, VACCINE, V34, P1643, DOI 10.1016/j.vaccine.2016.02.004
   Nascimento EJM, 2018, J VIROL METHODS, V257, P48, DOI 10.1016/j.jviromet.2018.03.007
   PRENTICE RL, 1986, BIOMETRIKA, V73, P1
   Priyamvada L, 2017, J INFECT DIS, V216, pS906, DOI 10.1093/infdis/jix513
   Rodriguez-Barraquer I, 2019, SCIENCE, V363, P607, DOI 10.1126/science.aav6618
   Roehrig JT, 2008, VIRAL IMMUNOL, V21, P123, DOI 10.1089/vim.2008.0007
   Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085
   Sridhar S, 2018, NEW ENGL J MED, V379, P327, DOI 10.1056/NEJMoa1800820
   Trung DT, 2010, CURR TOP MICROBIOL, V338, P57, DOI 10.1007/978-3-642-02215-9_5
   Vannice KS, 2018, VACCINE, V36, P3411, DOI 10.1016/j.vaccine.2018.02.062
   Villar L, 2015, NEW ENGL J MED, V372, P113, DOI 10.1056/NEJMoa1411037
   Wills BA, 2004, J INFECT DIS, V190, P810, DOI 10.1086/422754
   World Health Organization, 2007, GUID PLAQ RED NEUTR
   World Health Organization, 2008, GUID CLIN EV DENG VA
NR 21
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3531
EP 3536
DI 10.1016/j.vaccine.2020.03.029
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100005
PM 32204943
OA Other Gold
DA 2020-05-12
ER

PT J
AU Wang, SH
   Chen, J
   Smith, D
   Cao, ZY
   Acosta, H
   Fan, YY
   Ciotti, S
   Fattom, A
   Baker, J
AF Wang, Su He
   Chen, Jesse
   Smith, Douglas
   Cao, Zhengyi
   Acosta, Hugo
   Fan, Yongyi
   Ciotti, Susan
   Fattom, Ali
   Baker, James
TI A novel combination of intramuscular vaccine adjuvants, nanoemulsion and
   CpG produces an effective immune response against influenza A virus
SO VACCINE
LA English
DT Article
DE Intramuscular adjuvant; Nanoemulsion; CpG; Influenza A virus; Ferret
ID IMMUNOGENICITY; INTRANASAL; DNA
AB Background: Vaccination is the most effective approach to prevent infection with highly pathogenic avian influenza (HPAI). Adjuvants are often used to induce effective immune responses and overcome the immunological weakness of recombinant HPAI antigens. Given the logistical challenges of immunization to HPAI during pandemic situations, vaccines administered via the intramuscular (I.M.) route would be of value.
   Methods: A new formulation of nanoemulsion adjuvant (NE02) suitable for I.M. vaccination was developed. This NE02 was evaluated alone and in combination with CpG to develop H5 immune responses in mouse and ferret models. Measures of recombinant H5 (rH5) specific immunity evaluated included serum IgG and IgG subclasses, bronchoalveolar lavage fluid IgA, and cytokines. The activation of NF-kB was also analyzed. The efficacy of the vaccine was assessed by performing hemagglutination inhibition (HAI), virus neutralization (VN) assays, and viral challenges in ferrets.
   Results: I.M. vaccination with rH5-NE02 significantly increased rH5-specific IgG and protected ferrets in the viral challenge model providing complete protection and sterile immunity in all animals tested. Combining NE02 and CpG produced accelerated antibody responses and this was accompanied by an elevation of IFN-gamma and IL-17 responses and the downregulation of IL-5. The combination also caused a synergistic effect on NF-kB activation. In immunized ferrets after viral challenge, the rH5-NE02 + CpG vaccine via I.M. achieved at least 75% and 88% seroconversion of HAI and VN antibody responses, respectively, and improved body temperature stabilization and weight loss over NE02 alone.
   Conclusions: The I.M. injection of NE02 adjuvanted rH5 elicits strong and broad immune responses against H5 antigens and effectively protects animals from lethal H5 challenge. Combining this adjuvant with CpG enhanced immune responses and provided improvements in outcomes to viral challenge in ferrets. The results suggest that combinations of adjuvants may be useful to enhance H5 immune responses and improve protection against influenza infection. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Wang, Su He; Chen, Jesse; Cao, Zhengyi; Fan, Yongyi; Baker, James] Univ Michigan, Michigan Nanotechnol Inst Med & Biol Sci, Michigan Med, Ann Arbor, MI 48109 USA.
   [Smith, Douglas; Acosta, Hugo; Ciotti, Susan; Fattom, Ali] BlueWillow Biol, Ann Arbor, MI USA.
RP Wang, SH (reprint author), Univ Michigan, Michigan Nanotechnol Inst Med & Biol Sci, Michigan Med, Ann Arbor, MI 48109 USA.
FU NIH NIAID Adjuvant Development Program [HHSN272201300028C]; Michigan
   Nanotechnology Institute for Medicine and Biological Sciences
FX This project was funded from the NIH NIAID Adjuvant Development Program
   Contract #HHSN272201300028C and from Michigan Nanotechnology Institute
   for Medicine and Biological Sciences.
CR Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]
   Boudreau CM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00440
   Chichester JA, 2012, VIRUSES-BASEL, V4, P3227, DOI 10.3390/v4113227
   Clemens EB, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6020018
   Luna ACD, 2016, INT J NANOMED, V11, P1577, DOI 10.2147/IJN.S90850
   Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320
   Egli A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004556
   Fotouhi F, 2017, ARCH VIROL, V162, P1251, DOI 10.1007/s00705-017-3230-7
   Fraternale A, 2010, VACCINE, V28, P7676, DOI 10.1016/j.vaccine.2010.09.033
   Garcon N, 2017, HUM VACC IMMUNOTHER, V13, P19, DOI 10.1080/21645515.2016.1225635
   Han XJ, 2019, EUR J IMMUNOL, V49, P476, DOI 10.1002/eji.201847822
   Hellens RP, 2000, PLANT MOL BIOL, V42, P819, DOI 10.1023/A:1006496308160
   Hodgins B, 2017, CLIN VACCINE IMMUNOL, V24, DOI 10.1128/CVI.00273-17
   Krammer F, 2019, NAT REV IMMUNOL, V19, P383, DOI 10.1038/s41577-019-0143-6
   Lim HX, 2018, J IMMUNOL, V201, P2832, DOI 10.4049/jimmunol.1800386
   Muszkat M, 2003, VACCINE, V21, P1180, DOI 10.1016/S0264-410X(02)00481-4
   Nakada EM, 2014, RESP RES, V15, DOI 10.1186/s12931-014-0090-5
   Pedersen JC, 2014, METHODS MOL BIOL, V1161, P11, DOI 10.1007/978-1-4939-0758-8_2
   Reber AJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24394-z
   Riese P, 2013, CURR TOP MED CHEM, V13, P2562, DOI 10.2174/15680266113136660183
   Scurlock AM, 2011, INFECT IMMUN, V79, P1349, DOI 10.1128/IAI.00984-10
   Shoji Y, 2009, VACCINE, V27, P1087, DOI 10.1016/j.vaccine.2008.11.108
   Shoji Y, 2008, VACCINE, V26, P2930, DOI 10.1016/j.vaccine.2008.03.045
   Smith D, 2019, VACCINE, V37, P6162, DOI 10.1016/j.vaccine.2019.08.071
   Stein T, 2018, FEBS J, V285, P3097, DOI 10.1111/febs.14600
   WALDMAN RH, 1987, J CLIN IMMUNOL, V7, P327, DOI 10.1007/BF00915555
   Wang SH, 2019, VACCINE, V37, P1591, DOI 10.1016/j.vaccine.2019.02.002
   Wong PT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126120
   Wong PT, 2014, MOL PHARMACEUT, V11, P531, DOI 10.1021/mp4005029
   Wong SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep44727
NR 30
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3537
EP 3544
DI 10.1016/j.vaccine.2020.03.026
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100006
PM 32245642
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ceyhan, M
   Ozsurekci, Y
   Lucidarme, J
   Borrow, R
   Gurler, N
   Emiroglu, MK
   Oz, FN
   Kurugol, Z
   Celik, U
   Parlakay, AO
   Dinleyici, EC
   Karbuz, A
   Celebi, S
   Devrim, I
   Gulfidan, G
   Gundeslioglu, O
   Yucel, M
   Ulusoy, E
   Cengiz, AB
   Belet, N
AF Ceyhan, Mehmet
   Ozsurekci, Yasemin
   Lucidarme, Jay
   Borrow, Ray
   Gurler, Nezahat
   Emiroglu, Melike Keser
   Oz, Fatma Nur
   Kurugol, Zafer
   Celik, Umit
   Parlakay, Ashnur Ozkaya
   Dinleyici, Ener Cagri
   Karbuz, Adem
   Celebi, Solmaz
   Devrim, Ilker
   Gulfidan, Gamze
   Gundeslioglu, Ozlem
   Yucel, Mihriban
   Ulusoy, Emel
   Cengiz, Ali Bulent
   Belet, Nursen
CA Meningitis Surveillance Grp
TI Characterization of invasive Neisseria meningitidis isolates recovered
   from children in Turkey during a period of increased serogroup B
   disease, 2013-2017
SO VACCINE
LA English
DT Article
DE Neisseria meningitidis; Invasive meningococcal disease (IMD);
   Genotyping; Molecular epidemiology; Turkey
ID W135 MENINGOCOCCAL DISEASE; STREPTOCOCCUS-PNEUMONIAE;
   HAEMOPHILUS-INFLUENZAE; STRAIN COVERAGE; EPIDEMIOLOGY; EMERGENCE;
   MORTALITY; OUTBREAK; COMPLEX; 4CMENB
AB Diverse Neisseria meningitidis strains belonging to various serogroups and clonal complexes cause epidemic and endemic life-threatening disease worldwide. This study aimed to investigate the genetic diversity of recent invasive meningococci in Turkey with respect to multilocus sequence type (MLST) and also meningococcal serogroup B (MenB) vaccine antigens to enable assessment of potential MenB strain coverage using the genetic Meningococcal Antigen Typing System (gMATS). Fifty-four isolates, representing 37.5% of all pediatric (ages 0-18 years) invasive meningococcal disease cases in Turkey from January 2013 to December 2017, underwent genome sequence analysis. Thirty-six (66.7%) isolates were MenB, 10 (18.5%) were serogroup W (MenW), 4 (7.4%) were serogroup A (MenA), 3 (5.6%) were serogroup Y (MenY) and 1 (1.8%) was serogroup X (MenX). The MenB isolates were diverse with cc35 (19.4%), cc41/44 (19.4%) and cc32 (13.8%) as the most prevalent clonal complexes. The MenW isolates (n = 10) comprised cc11 (n = 5), ST-2754 (cc-unassigned; n = 4) and cc22 (n = 1). gMATS was indicative of high 4CMenB coverage (72.2-79.1%) of Turkish invasive MenB strains from pediatric patients. Strain coverage of several clonal complexes differed from that seen elsewhere in Europe highlighting the importance of performing local assessments and also the use of phenotypic methods, i.e. MATS, where possible. All of the isolates possessed in-frame fhbp alleles and so were potentially covered by MenB-fHbp. Continued surveillance is essential to guide recommendations for current and future vaccines as well as understanding changes in epidemiology. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ceyhan, Mehmet; Ozsurekci, Yasemin; Cengiz, Ali Bulent] Hacettepe Univ, Fac Med, Dept Pediat Infect Dis, Ankara, Turkey.
   [Lucidarme, Jay; Borrow, Ray] Meningococcal Reference Unit, Publ Hlth England, Manchester, Lancs, England.
   [Gurler, Nezahat] Istanbul Univ, Dept Microbiol, Fac Med, Istanbul, Turkey.
   [Emiroglu, Melike Keser] Selcuk Univ, Dept Pediat Infect Dis, Fac Med, Konya, Turkey.
   [Oz, Fatma Nur] Dr Sami Ulus Matern & Childrens Training & Res Ho, Dept Pediat Infect Dis, Ankara, Turkey.
   [Kurugol, Zafer] Ege Univ, Dept Pediat Infect Dis, Fac Med, Izmir, Turkey.
   [Celik, Umit] Adana Numune Training & Res Hosp, Dept Pediat Infect Dis, Adana, Turkey.
   [Parlakay, Ashnur Ozkaya] Diskapi Training & Res Hosp, Dept Pediat Infect Dis, Ankara, Turkey.
   [Dinleyici, Ener Cagri] Osmangazi Univ, Dept Pediat Infect Dis, Fac Med, Eskisehir, Turkey.
   [Karbuz, Adem] Okmeydani Training & Res Hosp, Dept Pediat Infect Dis, Istanbul, Turkey.
   [Belet, Nursen] Dokuz Eylul Univ, Dept Pediat Infect Dis, Fac Med, Izmir, Turkey.
   [Celebi, Solmaz] Uludag Univ, Dept Pediat Infect Dis, Fac Med, Bursa, Turkey.
   [Devrim, Ilker; Gulfidan, Gamze] Behcet Uz Training & Res Hosp, Dept Pediat Infect Dis, Izmir, Turkey.
   [Gundeslioglu, Ozlem] Cukurova Univ, Dept Pediat Infect Dis, Fac Med, Adana, Turkey.
   [Yucel, Mihriban] Ankara Numune Training & Res Hosp, Ankara, Turkey.
   [Ulusoy, Emel] Dokuz Eylul Univ, Emergency Dept, Fac Med, Izmir, Turkey.
RP Ozsurekci, Y (reprint author), Hacettepe Univ, Fac Med, Dept Pediat Infect Dis, Ankara, Turkey.
EM yas.oguz99@yahoo.com
RI Ulusoy, Emel/AAB-8205-2020
OI Emiroglu, Melike/0000-0003-1307-0246
FU Wellcome TrustWellcome Trust; European UnionEuropean Union (EU)
FX This publication made use of the Neisseria Multi Locus Sequence Typing
   website (https://pubmlst.org/neisseria/) sited at the University of
   Oxford [version 1; referees: 2 approved]) [45]. The development of this
   site has been funded by the Wellcome Trust and European Union.
CR Bai X, 2019, J INFECT
   Bilukha Oleg O., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Brik A, 2020, INT J INFECT DIS, V91, P73, DOI 10.1016/j.ijid.2019.11.013
   Caugant DA, 1998, APMIS, V106, P505, DOI 10.1111/j.1699-0463.1998.tb01379.x
   Ceyhan M, 2013, CLIN VACCINE IMMUNOL, V20, P66, DOI 10.1128/CVI.00314-12
   Ceyhan M, 2016, HUM VACC IMMUNOTHER, V12, P2940, DOI 10.1080/21645515.2016.1209278
   Ceyhan M, 2014, HUM VACC IMMUNOTHER, V10, P2706, DOI 10.4161/hv.29678
   Diallo K, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3789-0
   Donnelly J, 2010, P NATL ACAD SCI USA, V107, P19490, DOI 10.1073/pnas.1013758107
   du Chatelet IP, 2017, J INFECTION, V74, P564, DOI 10.1016/j.jinf.2017.02.011
   European Center for Diseases Prevention and Control (ECDC), 2015, SURV INV BACT DIS EU
   Greenwood B, 1999, T ROY SOC TROP MED H, V93, P341, DOI 10.1016/S0035-9203(99)90106-2
   Harrison LH, 2009, VACCINE, V27, pB51, DOI 10.1016/j.vaccine.2009.04.063
   Harrison OB, 2013, EMERG INFECT DIS, V19, P566, DOI 10.3201/eid1904.111799
   Harrison OB, 2011, MICROBIOL-SGM, V157, P2181, DOI 10.1099/mic.0.050518-0
   John TJ, 2013, VACCINE, V31, P2731, DOI 10.1016/j.vaccine.2013.04.003
   Jolley KA, 2007, FEMS MICROBIOL REV, V31, P1147
   Jolley Keith A, 2018, Wellcome Open Res, V3, P124, DOI 10.12688/wellcomeopenres.14826.1
   Krone M, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.14.1800245
   Li JH, 2018, J INFECTION, V76, P429, DOI 10.1016/j.jinf.2018.01.007
   Lucidarme J, 2015, J INFECTION, V71, P544, DOI 10.1016/j.jinf.2015.07.007
   MacNeil JR, 2018, CLIN INFECT DIS, V66, P1276, DOI 10.1093/cid/cix993
   Martin NV, 2016, COMMUN DIS INTELL, V40, pE454
   Mayer LW, 2002, J INFECT DIS, V185, P1596, DOI 10.1086/340414
   McNeil LK, 2018, MBIO, V9, DOI 10.1128/mBio.00036-18
   Medini D, 2015, VACCINE, V33, P2629, DOI 10.1016/j.vaccine.2015.04.015
   Moodley C, 2012, J CLIN MICROBIOL, P3678
   Muzzi A, 2019, VACCINE, V37, P991, DOI 10.1016/j.vaccine.2018.12.061
   Parikh SR, 2017, LANCET INFECT DIS, V17, P754, DOI 10.1016/S1473-3099(17)30170-6
   Pathan N, 2003, ARCH DIS CHILD, V88, P601, DOI 10.1136/adc.88.7.601
   Rosenstein NE, 2001, NEW ENGL J MED, V344, P1378, DOI 10.1056/NEJM200105033441807
   Sharip A, 2006, PEDIATR INFECT DIS J, V25, P191, DOI 10.1097/01.inf.0000202065.03366.0c
   Sorhouet-Pereira C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058065
   Sridhar S, 2015, LANCET INFECT DIS, V15, P1334, DOI 10.1016/S1473-3099(15)00217-0
   Taha MK, 2000, J CLIN MICROBIOL, V38, P855, DOI 10.1128/JCM.38.2.855-857.2000
   Tanir G, 2018, HUM VACC IMMUNOTHER, V14, P209, DOI 10.1080/21645515.2017.1377380
   Tsang RSW, 2018, INT J INFECT DIS, V69, P55, DOI 10.1016/j.ijid.2018.01.019
   Tsolia MN, 2003, FEMS IMMUNOL MED MIC, V36, P87, DOI 10.1016/S0928-8244(03)00083-X
   Vieusseux M., 1805, J MED CHIR PHARMACOL, V11, P163
   Virji M, 2009, NAT REV MICROBIOL, V7, P274, DOI 10.1038/nrmicro2097
   Vogel U, 2013, LANCET INFECT DIS, V13, P416, DOI 10.1016/S1473-3099(13)70006-9
   von Gottberg A, 2008, CLIN INFECT DIS, V46, P377, DOI 10.1086/525260
   Watkins ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045349
   Whittaker R, 2017, VACCINE, V35, P2034, DOI 10.1016/j.vaccine.2017.03.007
   Zerbino DR, 2008, GENOME RES, V18, P821, DOI 10.1101/gr.074492.107
NR 45
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3545
EP 3552
DI 10.1016/j.vaccine.2020.03.024
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100007
PM 32199701
DA 2020-05-12
ER

PT J
AU Leong, RNF
   Wood, JG
   Liu, B
   McIntyre, PB
   Newall, AT
AF Leong, Robert Neil F.
   Wood, James G.
   Liu, Bette
   McIntyre, Peter B.
   Newall, Anthony T.
TI High healthcare resource utilisation due to pertussis in Australian
   adults aged 65 years and over
SO VACCINE
LA English
DT Article
DE Pertussis; Whooping cough; Older adults; Healthcare utilisation
ID DISEASE; ADOLESCENTS; MORBIDITY
AB Background: In the context of co-morbid illness and increasing age, data on excess morbidity from pertussis in older adults is crucial for immunisation policy but has been largely limited to case-series.
   Methods: We designed a matched case-control study nested within a population-based cohort of 267,153 adults aged >= 45 years in New South Wales, Australia (The 45 and Up Study cohort). Excess hospital bed days, emergency department (ED) admissions, general practitioner (GP) visits, and prescriptions were estimated using negative binomial regression models. An additional self-controlled analysis was also conducted to validate the main models, and to evaluate results for those with either asthma or a body mass index (BMI)>= 30 compared to those without these risk factors.
   Results: Based on 524 pairs of PCR-confirmed pertussis cases and matched controls, we estimated an excess healthcare utilisation per case of 2.5 prescriptions (95% CI: 0.2-4.7), of which 1.1 (95% CI: 0.5-2.2) were antibiotics, 2.3 GP visits (95% CI: 2.0-2.6), and 0.1 ED admissions (95% CI: 0.1-0.2). Compared to those 45-64 years, cases >65 years had a significantly greater excess for all prescriptions (1.1 vs 4.7/case), antibiotic prescriptions (0.1 vs 2.2/case), and ED admissions (0.1 vs 0.2/case), but no significant excess of respiratory-related hospital bed days. An additional self-controlled analysis confirmed that cases with either asthma or BMI >= 30 had higher overall healthcare utilisation but this was not associated with pertussis infection.
   Conclusion: We found a substantial excess outpatient healthcare burden among adults aged 65 years and over with PCR-confirmed pertussis, supporting further evaluation of preventive measures. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Leong, Robert Neil F.; Wood, James G.; Liu, Bette; Newall, Anthony T.] Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia.
   [McIntyre, Peter B.] Childrens Hosp Westmead, Natl Ctr Immunisat Res & Surveillance Vaccine Pre, Kids Res Inst, Westmead, NSW, Australia.
RP Leong, RNF (reprint author), Univ New South Wales, Sch Publ Hlth & Community Med, UNSW Sydney, Sydney, NSW 2052, Australia.
EM robertneil.leong@unsw.edu.au
OI Wood, James/0000-0002-0122-4482; Liu, Bette/0000-0002-0787-5825;
   McIntyre, Peter/0000-0001-5808-7450
FU University International Postgraduate Award (UIPA); Australian National
   Health and Medical Research Council (NHMRC) fellowshipNational Health
   and Medical Research Council of Australia; Australian National Health
   and Medical Research CouncilNational Health and Medical Research Council
   of Australia [1107008]
FX RN Leong is supported by the University International Postgraduate Award
   (UIPA) for study toward a PhD in the Faculty of Medicine, School of
   Public Health and Community Medicine, University of New South Wales,
   Australia. B Liu is supported by an Australian National Health and
   Medical Research Council (NHMRC) fellowship. Access and use of the 45
   and Up Study was funded by the Australian National Health and Medical
   Research Council Grant #1107008.
CR Australian Government Department of Health, 2015, AUSTR IMM HDB, P312
   Australian Government Department of Health, 2014, PERT CAS DEF
   Banks E, 2008, INT J EPIDEMIOL, V37, P941, DOI 10.1093/ije/dym184
   Buck P, 2017, EPIDEMIOL INFECT, P1
   Center for Health Record Linkage (CheReL), QUALITY ASSURANCE
   De Serres G, 2000, J INFECT DIS, V182, P174, DOI 10.1086/315648
   Guiso N, 2010, GLOB PERT IN M 4 REG
   Fernandez-Cano MI, 2014, EUR J PEDIATR, V173, P721, DOI 10.1007/s00431-013-2228-8
   Kaczmarek MC, 2013, MED J AUSTRALIA, V198, P624, DOI 10.5694/mja13.10044
   Kandeil W, 2019, EXPERT REV VACCINES, V18, P439, DOI 10.1080/14760584.2019.1588727
   Karki S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160446
   Kilgore PE, 2016, CLIN MICROBIOL REV, V29, P449, DOI 10.1128/CMR.00083-15
   Lasserre A, 2011, EUROSURVEILLANCE, V16, P16
   Leong RNF, 2019, EPIDEMIOL INFECT, V147, DOI [10.1017/S0950268818003680, 10.1017/s0950268818003680]
   Leuven E., 2018, PSMATCH2 STATA MODUL
   Liu B, 2019, CLIN INFECT DIS
   Liu B, 2012, CHIN INT CONF ELECTR
   Long Scott, 2006, REGRESSION MODELS CA
   Marchant J, 2009, AUST PRESCR, V32, P36
   McGuiness CB, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-32
   Mclntyre P, 2009, CURR OPIN INFECT DIS, V22, P215, DOI 10.1097/QCO.0b013e32832b3540
   Mellish Leigh, 2015, BMC Res Notes, V8, P634, DOI 10.1186/s13104-015-1616-8
   Michel JP, 2010, EXPERT REV VACCINES, V9, P7, DOI 10.1586/ERV.10.27
   Moineddin R, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-160
   Muller-Pebody B, 2006, EPIDEMIOL INFECT, V134, P1150, DOI 10.1017/S0950268806006376
   O'Brien JA, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-57
   Pillsbury A, 2014, COMMUN DIS INTELL, V38, pE179
   Ridda I, 2012, VACCINE, V30, P6745, DOI 10.1016/j.vaccine.2012.08.079
   Rothstein Edward, 2005, Pediatr Infect Dis J, V24, pS44, DOI 10.1097/01.inf.0000160912.58660.87
   Sax Institute, 45 BAS DAT DICT
   Thomas PF, 2000, MED J AUSTRALIA, V173, P74, DOI 10.5694/j.1326-5377.2000.tb139246.x
   Wang K, 2014, COCHRANE DB SYST REV, V9
   Wu JY, 2018, J INT MED RES, V46, P1326, DOI 10.1177/0300060517740813
   2011, MMWR MORBID MORTAL W, V60, P13
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3553
EP 3559
DI 10.1016/j.vaccine.2020.03.021
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100008
PM 32220516
DA 2020-05-12
ER

PT J
AU Chang, LJ
   Hedrick, J
   Christensen, S
   Pan, J
   Jordanov, E
   Dhingra, MS
AF Chang, Lee-Jah
   Hedrick, James
   Christensen, Shane
   Pan, Judy
   Jordanov, Emilia
   Dhingra, Mandeep S.
TI A Phase II, randomized, immunogenicity and safety study of a
   quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy
   adolescents in the United States
SO VACCINE
LA English
DT Article
DE MenACYW-TT; Invasive meningococcal disease; Meningococcal vaccine naive
   adolescents; Conjugate vaccine; HPV4; Tdap; Concomitant vaccine
ID INFECTION; INFANTS; DISEASE; RISK
AB Background: MenACYW-TT is an investigational quadrivalent meningococcal conjugate vaccine intended for use in individuals >= 6 weeks of age. We evaluated the safety and immunogenicity of MenACYW-TT when compared to a licensed quadrivalent conjugate meningococcal vaccine (Menveo (R); MCV4-CRM; GlaxoSmithKline, Italy), and when co-administered with tetanus, diphtheria, acellular pertussis (Tdap) and human papilloma virus (HPV4) vaccines in healthy meningococcal vaccine-naive adolescents (10-17 years old) in the United States of America.
   Methods: In this pivotal Phase II, open-label, multicenter study, 1715 participants were randomized to receive MenACYW-TT, MCV4-CRM, MenACYW-TT co-administered with Tdap and HPV4, or Tdap and HPV4 vaccines alone (NCT02199691).
   The primary objective was to evaluate whether antibody responses to MenACYW-TT antigens were non-inferior to antibody responses after MCV4-CRM administration. Meningococcal antibody titers were determined using human complement serum bactericidal assay (hSBA) with titers measured at baseline, and 30 days post vaccination (D30). A vaccine seroresponse was defined as baseline titers <1:8 with postvaccination titers >= 1:8 or baseline titers >= 1:8 with a >= 4-fold increase at post-vaccination. Safety data were collected up to six months post-vaccination.
   Results: Non-inferiority was demonstrated for MenACYW-TT vs MCV4-CRM (primary endpoint), and for MenACYW-TT co-administered with Tdap and HPV4 vs MenACYW-TT alone (secondary endpoint). The vaccine seroresponse rate was higher with MenACYW-TT than with MCV4-CRM, for each serogroup: A: 75.6% vs 66.4%; C: 97.2% vs 72.6%; W: 86.2% vs 66.6%; Y: 97.0% vs 80.8%. The safety profiles of MenACYW-TT, MCV4-CRM, and Tdap and HPV4 vaccines, administered with or without MenACYW-TT, were comparable. There were no vaccine-related serious adverse events.
   Conclusions: The MenACYW-TT vaccine was well tolerated and generated an immune response that was non-inferior to the licensed MCV4-CRM vaccine. Immunogenicity and safety profiles were comparable when MenACYW-TT was administered with or without Tdap and HPV4 vaccines in meningococcal vaccine-naive adolescents. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Chang, Lee-Jah; Pan, Judy; Jordanov, Emilia; Dhingra, Mandeep S.] Sanofi Pasteur, 1 Discovery Dr, Swiftwater, PA 18370 USA.
   [Hedrick, James] Kentucky Pediat Adult Res, Bardstown, KY USA.
   [Christensen, Shane] J Lewis Res Inc, Salt Lake City, UT USA.
RP Dhingra, MS (reprint author), Sanofi Pasteur, 1 Discovery Dr, Swiftwater, PA 18370 USA.
EM lee-jah.chang@sanofi.com; jhedrick@bardstowncable.net;
   schristensen@jlewisresearch.com; judy.pan@sanofi.com;
   emilia.jordanov@sanofi.com; MandeepSingh.Dhingra@sanofi.com
OI Chang, Lee-Jah/0000-0003-1766-3153
FU Sanofi Pasteur
FX This study was funded by Sanofi Pasteur.
CR [Anonymous], 2017, ANN EP REP 2017
   Arguedas A, 2010, VACCINE, V28, P3171, DOI 10.1016/j.vaccine.2010.02.045
   Beresford NJ, 2017, VACCINE, V35, P3598, DOI 10.1016/j.vaccine.2017.03.066
   Bilukha Oleg O., 2005, Morbidity and Mortality Weekly Report, V54, P1
   Borrow R, 2017, EXPERT REV VACCINES, V16, P313, DOI 10.1080/14760584.2017.1258308
   Bruce MG, 2001, JAMA-J AM MED ASSOC, V286, P688, DOI 10.1001/jama.286.6.688
   Burman C, 2019, HUM VACC IMMUNOTHER, V15, P459, DOI 10.1080/21645515.2018.1528831
   Centers for Disease Control and Prevention, 2017, MEN DIS
   Centers for Disease Control and Prevention, MEN DIS OTH COUNTR
   Centers for Disease Control and Prevention, 2019, REC IMM SCHED CHILDR
   Cohn AC, 2013, MMWR RECOMM REP, V62, P1
   Decker MD, 2019, VACCINE, V37, P5003, DOI 10.1016/j.vaccine.2019.07.015
   European Medicines Agency, ASS REP MENV
   Findlow H, 2009, CLIN VACCINE IMMUNOL, V16, P969, DOI 10.1128/CVI.00068-09
   Findlow H, 2012, PEDIATR INFECT DIS J, V31, P616, DOI 10.1097/INF.0b013e31824f34e6
   Findlow J, 2019, HUM VACC IMMUNOTHER, V15, P2491, DOI 10.1080/21645515.2019.1593082
   Halperin SA, 2014, J PEDIAT INF DIS SOC, V3, P33, DOI 10.1093/jpids/pit058
   Harrison LH, 1999, JAMA-J AM MED ASSOC, V281, P1906, DOI 10.1001/jama.281.20.1906
   Inc. P, PREVN 13 PNEUM 13 VA
   Kapasi A, 2012, CLIN VACCINE IMMUNOL, V19, P64, DOI 10.1128/CVI.05460-11
   Knuf M, 2013, EUR J PEDIATR, V172, P601, DOI 10.1007/s00431-012-1924-0
   Krone M, 2019, EUROSURVEILLANCE, V24, P2, DOI 10.2807/1560-7917.ES.2019.24.14.1800245
   Leonardi M, 2015, VACCINE, V33, P924, DOI 10.1016/j.vaccine.2014.09.064
   MacNeil JR, 2018, CLIN INFECT DIS, V66, P1276, DOI 10.1093/cid/cix993
   Marshall GS, 2014, CLIN VACCINE IMMUNOL, V21, P1560, DOI 10.1128/CVI.00474-14
   McIntosh EDG, 2015, VACCINE, V33, P4414, DOI 10.1016/j.vaccine.2015.07.019
   Nimenrix, 2019, SUMMARY PRODUCT CHAR
   Opalka D, 2003, CLIN DIAGN LAB IMMUN, V10, P108, DOI 10.1128/CDLI.10.1.108-115.2003
   Pina LM, 2012, PEDIATR INFECT DIS J, V31, P1173, DOI 10.1097/INF.0b013e318268dfe4
   Practices ACoI, 2019, REC CHILD AD IMM SCH
   Presa JV, 2019, INT J INFECT DIS, V85, P37, DOI 10.1016/j.ijid.2019.05.006
   Rivera L, 2018, VACCINE, V36, P4750, DOI 10.1016/j.vaccine.2018.04.034
   Rouphael NG, 2012, METHODS MOL BIOL, V799, P1, DOI 10.1007/978-1-61779-346-2_1
NR 33
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3560
EP 3569
DI 10.1016/j.vaccine.2020.03.017
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100009
PM 32209248
OA Other Gold
DA 2020-05-12
ER

PT J
AU Ruansit, W
   Charerntantanakul, W
AF Ruansit, Wilawan
   Charerntantanakul, Wasin
TI Oral supplementation of quercetin in PRRSV-1 modified-live virus
   vaccinated pigs in response to HP-PRRSV-2 challenge
SO VACCINE
LA English
DT Article
DE Porcine reproductive and respiratory syndrome virus; Quercetin;
   Modified-live virus vaccine; Interferon; Cross protection
ID RESPIRATORY SYNDROME VIRUS; HEPATITIS-C VIRUS; IMMUNE-RESPONSES; INNATE
AB This study evaluated the immunomodulatory effect of quercetin on improving cross protection of porcine reproductive and respiratory syndrome virus-1 (PRRSV-1) modified-live virus (MLV) vaccine against highly pathogenic (HP)-PRRSV-2 challenge. Ex vivo experiments demonstrated that quercetin significantly enhanced type I interferon-regulated genes (IRGs) and type I and II interferon (IFN), and significantly decreased pro- and anti-inflammatory cytokine expressions in HP-PRRSV-inoculated monocytederived macrophages. In vivo experiments divided pigs (4-week-old; n = 24) into four groups of six pigs. Group 1 and group 2 were immunized with PRRSV-1 MLV vaccine at 0 dpv (day post vaccination). Group 2 also received oral administration of quercetin at 0-49 dpv. Group 3 was injected with PRRSV-1 MLV vaccine solvent at 0 dpv. Group 4 served as strict control. Group 1-3 were challenged intranasally with HP-PRRSV at 28 dpv and immune and clinical parameters were monitored weekly until 49 dpv. Group 1 demonstrated significantly reduced HP-PRRSV viremia, rectal temperature and clinical scores, and significantly improved average daily weight gain (ADWG), compared to group 3. Group 2 demonstrated significantly increased IFN regulatory factor 3, stimulator of IFN genes, IFN alpha, and significantly decreased transforming growth factor beta (TGF beta) mRNA expressions, compared to group 1. The animals demonstrated significantly reduced HP-PRRSV viremia, but did not demonstrate any further improved PRRSVspecific antibody responses, rectal temperature, clinical scores, and ADWG as compared to group 1. Our findings suggest that quercetin up-regulates IRGs, IFN alpha, and down-regulates TGFb mRNA expressions which may contribute to further reducing number of viremic pigs and HP-PRRSV viremia which were conferred by PRRSV-1 MLV vaccine. Our findings also suggest that quercetin may serve as an effective oral immunomodulator for improving cell-mediated immune defense to HP-PRRSV. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ruansit, Wilawan; Charerntantanakul, Wasin] Maejo Univ, Fac Sci, Program Biotechnol, Chiang Mai 50290, Thailand.
RP Charerntantanakul, W (reprint author), Maejo Univ, Fac Sci, Program Biotechnol, Chiang Mai 50290, Thailand.
EM wasin@mju.ac.th
FU Royal Golden Jubilee Ph.D. programThailand Research Fund (TRF)
   [PHD/0132/2556]; Thailand Research FundThailand Research Fund (TRF)
   [RSA5880053]
FX This work is supported by the Royal Golden Jubilee Ph.D. program
   (grant#PHD/0132/2556) and the Thailand Research Fund (grant#RSA5880053).
   The Thai HP-PRRSV isolate 10PL01 was a kind gift from the Veterinary
   Diagnostic Laboratory, Chulalongkorn University, Thailand. The authors
   thank Dr.Krisana Lanumteang for statistical advice. The authors also
   thank Dr.Varaporn Sangtong, Dr. Jiraporn Rojtinnakorn, Dante Fabros Jr.,
   and Ruankaew Phraphruet for excellent technical supports.
CR Bachmetov L, 2012, J VIRAL HEPATITIS, V19, pE81, DOI 10.1111/j.1365-2893.2011.01507.x
   Beura LK, 2010, J VIROL, V84, P1574, DOI 10.1128/JVI.01326-09
   Bieger J, 2008, J NUTR, V138, P1417
   Binjawadagi B, 2014, INT J NANOMED, V9, P679, DOI 10.2147/IJN.S56127
   Cermak R, 2009, EUR J PHARM SCI, V38, P519, DOI 10.1016/j.ejps.2009.09.018
   Charerntantanakul W, 2006, VIRAL IMMUNOL, V19, P646, DOI 10.1089/vim.2006.19.646
   Charerntantanakul W, 2018, VET IMMUNOL IMMUNOP, V205, P24, DOI 10.1016/j.vetimm.2018.10.005
   Charerntantanakul W, 2018, VET IMMUNOL IMMUNOP, V195, P76, DOI 10.1016/j.vetimm.2017.11.009
   Charerntantanakul Wasin, 2012, World J Virol, V1, P23, DOI 10.5501/wjv.v1.i1.23
   Charerntantanakul W, 2012, VET IMMUNOL IMMUNOP, V146, P159, DOI 10.1016/j.vetimm.2012.02.014
   Charerntantanakul W, 2010, VIRAL IMMUNOL, V23, P425, DOI 10.1089/vim.2009.0066
   Charerntantanakul W, 2009, VET IMMUNOL IMMUNOP, V129, P1, DOI 10.1016/j.vetimm.2008.12.018
   Charerntantankul W, 2006, VET IMMUNOL IMMUNOP, V109, P99, DOI 10.1016/j.vetimm.2005.07.026
   Gao JT, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-64
   Gomez-Laguna J, 2012, VET MICROBIOL
   Gonzalez O, 2009, HEPATOLOGY, V50, P1756, DOI 10.1002/hep.23232
   Granato M, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090482
   Hamalainen M, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/45673
   Han J, 2017, VET MICROBIOL, V209, P30, DOI 10.1016/j.vetmic.2017.02.020
   Han Z, 2015, TRANSBOUND EMERG DIS, V62, pE1, DOI 10.1111/tbed.12190
   Hou J, 2012, VIRUS RES, V167, P106, DOI 10.1016/j.virusres.2012.03.017
   Huang C, 2016, SCI REP-UK, V6, DOI 10.1038/srep28497
   Kappes MA, 2015, VIROLOGY, V479, P475, DOI 10.1016/j.virol.2015.02.012
   Kim O, 2010, VIROLOGY, V402, P315, DOI 10.1016/j.virol.2010.03.039
   Kim T, 2015, CLIN VACCINE IMMUNOL, V22, P631, DOI 10.1128/CVI.00001-15
   Ko SS, 2016, VET IMMUNOL IMMUNOP, V172, P43, DOI 10.1016/j.vetimm.2016.02.016
   Kuhn JH, 2016, ARCH VIROL, V161, P755, DOI 10.1007/s00705-015-2672-z
   Lee S, 2017, ARCH PHARM RES, V40, P623, DOI 10.1007/s12272-017-0898-x
   Li XD, 2013, VACCINE, V31, P4508, DOI 10.1016/j.vaccine.2013.07.080
   Li Y, 2016, NUTRIENTS, V8, P167, DOI DOI 10.3390/nu8030167
   Li ZG, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0854-x
   Loving CL, 2015, VET IMMUNOL IMMUNOP, V167, P1, DOI 10.1016/j.vetimm.2015.07.003
   Manjeet R, 1999, INT J IMMUNOPHARMACO, V21, P435
   Nair MPN, 2002, BBA-MOL CELL RES, V1593, P29, DOI 10.1016/S0167-4889(02)00328-2
   Nan YC, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01635
   Nedumpun T, 2017, J GEN VIROL, V98, P77, DOI 10.1099/jgv.0.000665
   Nilubol D, 2012, EMERG INFECT DIS, V18, P2039, DOI 10.3201/eid1812.111105
   Roca M, 2012, VET J, V193, P92, DOI 10.1016/j.tvjl.2011.11.019
   Sagong M, 2011, ARCH VIROL, V156, P2187, DOI 10.1007/s00705-011-1116-7
   Silva-Campa E, 2012, VIROLOGY, V430, P73, DOI 10.1016/j.virol.2012.04.009
   Sirisereewan C, 2018, TROP ANIM HEALTH PRO, V50, P1509, DOI 10.1007/s11250-018-1589-4
   Sun Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168314
   Sun Z, 2010, J VIROL, V84, P7832, DOI 10.1128/JVI.00217-10
   Tabynov K, 2016, VET MICROBIOL, V192, P81, DOI 10.1016/j.vetmic.2016.06.014
   Vergauwen H, 2016, ANTIOXIDANTS-BASEL, V5, DOI 10.3390/antiox5040041
   Wang D, 2015, MOL IMMUNOL, V68, P357, DOI 10.1016/j.molimm.2015.08.011
   Weng JR, 2018, J MICROBIOL IMMUNOL, V51, P456, DOI 10.1016/j.jmii.2017.01.005
   Wu W, 2015, VIRUSES, V8, P1
   Xiong ZX, 2015, RES VET SCI, V101, P175, DOI 10.1016/j.rvsc.2015.05.007
   Yang J, 2017, MATER CHEM FRONT, V1, P91, DOI 10.1039/c6qm00014b
NR 50
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3570
EP 3581
DI 10.1016/j.vaccine.2020.03.019
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100010
PM 32184034
DA 2020-05-12
ER

PT J
AU Ahmed, MA
   Naus, M
   Singer, J
   Valiquette, L
   Coleman, BL
   De Serres, G
   Vanderkooi, OG
   Top, KA
   Isenor, JE
   Kellner, JD
   McCarthy, AE
   Bettinger, JA
AF Ahmed, May A.
   Naus, Monika
   Singer, Joel
   Valiquette, Louis
   Coleman, Brenda L.
   De Serres, Gaston
   Vanderkooi, Otto G.
   Top, Karina A.
   Isenor, Jennifer E.
   Kellner, James D.
   McCarthy, Anne E.
   Bettinger, Julie A.
CA Canadian Immunization Res Network
TI Investigating the association of receipt of seasonal influenza vaccine
   with occurrence of anesthesia/paresthesia and severe headaches, Canada
   2012/13-2016/17, the Canadian Vaccine Safety Network
SO VACCINE
LA English
DT Article
DE Neurological events; Adverse event following immunization; Vaccine
   safety; Surveillance
ID QUALITY-OF-LIFE; ADVERSE EVENTS; PHASE-III; IMMUNOGENICITY; ADULTS;
   PAIN; IMMUNIZATION; CHILDREN
AB Background: Concern about adverse events following immunization is frequently cited by both those who receive or decline vaccines. Neurological adverse events are especially concerning. Objectives: Our aim was to detect associations between seasonal influenza vaccination and the occurrence of severe anesthesia/paresthesia or severe headaches.
   Methods: Data were analyzed from the Canadian National Vaccine Safety network. Events occuring on days 0-7 were self-reported and prevented daily activity, led to school or work absenteeism, or required medical attention. Controls were the previous year's vaccinees; events in controls were collected prior to the start of the influenza vaccination program of each year (2012/13 through 2016/17). Multivariable logistic regression was used to determine the association between seasonal influenza vaccination and the occurrence of anesthesia/paresthesia or severe headaches.
   Results: The total sample was 107,565 for investigating anesthesia/paresthesia and 97,420 for investigating severe headaches. Anesthesia/paresthesia was reported by 104/107,565 (0.10%) participants; 63/69,129 (0.09%) vaccinees and 41/38,436 (0.11%) controls (adjusted odds ratio (aOR) = 0.89; 95% CI = 0.60, 1.32). Severe headaches were reported by 1361/97,420 (1.40%) participants; 907/61,463 (1.48%) vaccinees and 454/35,957 (1.26%) controls (aOR = 1.21; 95% CI = 1.08, 1.36). No specific vaccine product was associated with severe headaches.
   Conclusions: Our study found no association between severe anesthesia/paresthesia and seasonal influenza vaccination. While there was an association with severe headaches as an adverse event following influenza vaccination, the rates of these events are similar to rates reported from clinical trials and are not a cause for additional concern. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Ahmed, May A.; Bettinger, Julie A.] Univ British Columbia, BC Childrens Hosp, Vaccine Evaluat Ctr, Vancouver, BC, Canada.
   [Naus, Monika; Singer, Joel] Univ British Columbia, Fac Med, Sch Publ & Populat Hlth, Vancouver, BC, Canada.
   [Valiquette, Louis] Univ Sherbrooke, Fac Med & Hlth Sci, Dept Microbiol & Infect Dis, Sherbrooke, PQ, Canada.
   [Coleman, Brenda L.] Sinai Hlth Syst, Toronto, ON, Canada.
   [Coleman, Brenda L.] Univ Toronto, Toronto, ON, Canada.
   [De Serres, Gaston] Univ Laval, CHU Quebec, Quebec City, PQ, Canada.
   [Vanderkooi, Otto G.] Univ Calgary, Alberta Childrens Hosp, Calgary, AB, Canada.
   [Top, Karina A.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada.
   [Top, Karina A.] Canadian Ctr Vaccinol, IWK Hlth Ctr, Halifax, NS, Canada.
   [Isenor, Jennifer E.] Coll Pharm, Halifax, NS, Canada.
   [Isenor, Jennifer E.] Canadian Ctr Vaccinol, Halifax, NS, Canada.
   [Kellner, James D.] Univ Calgary, Dept Pediat, Calgary, AB, Canada.
   [Kellner, James D.] Alberta Childrens Prov Gen Hosp, Alberta Hlth Serv, Res Inst, Calgary, AB, Canada.
   [McCarthy, Anne E.] Univ Ottawa, Ottawa Hosp, Dept Med, Ottawa, ON, Canada.
   [McCarthy, Anne E.] Ottawa Hlth Res Inst, Ottawa, ON, Canada.
RP Bettinger, JA (reprint author), BC Childrens Hosp, A5-950 West 28th St, Vancouver, BC V5Z 4H4, Canada.
EM jbettinger@cfri.ca
RI ; Kellner, James/D-6358-2011
OI Top, Karina/0000-0002-9981-368X; Isenor, Jennifer/0000-0003-1648-7362;
   Kellner, James/0000-0002-9083-2980
FU Canadian Institutes of Health ResearchCanadian Institutes of Health
   Research (CIHR); Public Health Agency of Canada [124309, 137470, 151944]
FX The Canadian National Vaccine Safety Network as part of the Canadian
   Immunization Research Network is funded by a research grant from the
   Canadian Institutes of Health Research and the Public Health Agency of
   Canada grants: #124309 (1 June 2012 - 31 May 2014), #137470 (1 June 2014
   - 31 May 2017), and #151944 (1 June 2017 - 31 December 2022).
CR AstraZeneca Canada Inc, FLUM QUADR INFL VACC
   Bardage C, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d5956
   Bettinger JA, 2016, SUCCESSFUL METHODOLO
   Bettinger JA, 2014, PEDIATR INFECT DIS J, V33, P1060, DOI 10.1097/INF.0000000000000373
   Bingefors K, 2004, EUR J PAIN, V8, P435, DOI 10.1016/j.ejpain.2004.01.005
   Budh CN, 2005, SPINAL CORD, V43, P85, DOI 10.1038/sj.sc.3101680
   Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17
   Cadorna-Carlos JB, 2015, VACCINE, V33, P2485, DOI 10.1016/j.vaccine.2015.03.065
   Cerpa-Cruz SS, 2013, IMMUNOL RES, V56, P299, DOI 10.1007/s12026-013-8400-4
   Chevat C, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-21
   Cocito D, 2006, NEUROL SCI, V27, P155, DOI 10.1007/s10072-006-0660-5
   De Serres G, 2015, VACCINE, V33, P4464, DOI 10.1016/j.vaccine.2015.07.028
   Demicheli V, 2018, COCHRANE DATABASE SY, DOI 10.1002/14651858.CD001269.pub66
   Goadsby PJ, 2017, PHYSIOL REV, V97, P553, DOI 10.1152/physrev.00034.2015
   Gorse GJ, 2015, VACCINE, V33, P1151, DOI 10.1016/j.vaccine.2015.01.025
   Government of Canada HC, 1995, CLIN SAF DAT MAN DEF
   Greenberg DP, 2013, VACCINE, V31, P770, DOI 10.1016/j.vaccine.2012.11.074
   Gust DA, 2006, AM J PREV MED, V31, P32, DOI 10.1016/j.amepre.2006.03.017
   Hartnell NR, 2004, PHARMACOTHERAPY, V24, P743, DOI 10.1592/phco.24.8.743.36068
   Hosmer D.W., 2013, APPL LOGISTIC REGRES
   Hosmer DW, 2013, WILEY SER PROBAB ST, P35
   Lakemedelsverket Medical Product Agency, 2010, FIN SUMM ADV DRUG RE
   MARGOLIS KL, 1990, JAMA-J AM MED ASSOC, V264, P1139, DOI 10.1001/jama.264.9.1139
   Montastruc JL, 2011, B ACAD NAT MED PARIS, V195, P1309, DOI 10.1016/S0001-4079(19)31991-0
   Morel S, 2011, VACCINE, V29, P2461, DOI 10.1016/j.vaccine.2011.01.011
   Ohmit SE, 2008, J INFECT DIS, V198, P312, DOI 10.1086/589885
   Pasteur Sanofi, FLUZ HIGH DOS INFL V
   Pepin S, 2013, VACCINE, V31, P5572, DOI 10.1016/j.vaccine.2013.08.069
   Persson I, 2014, J INTERN MED, V275, P172, DOI 10.1111/joim.12150
   Sanofi Pasteur, 2013, VAX IN INFL VACC TRI
   Sanofi Pasteur, FLUZ QUADR INFL VIR
   Sanofi Pasteur, INT CAN PROD MON INF
   Tihanyi BT, 2018, CONSCIOUS COGN, V58, P97, DOI 10.1016/j.concog.2017.10.015
   Tinoco JC, 2014, VACCINE, V32, P1480, DOI 10.1016/j.vaccine.2014.01.022
   Treanor JT, 2017, VACCINE, V35, P1856, DOI 10.1016/j.vaccine.2017.02.066
   Unruh AM, 1996, PAIN, V65, P123, DOI 10.1016/0304-3959(95)00214-6
   World Health Organization, 2012, INFL VACC INF SHEET
   Zhou W, 1991, MMWR SURVEILLANCE SU
NR 38
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3582
EP 3590
DI 10.1016/j.vaccine.2020.03.018
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100011
PM 32229052
OA Other Gold
DA 2020-05-12
ER

PT J
AU Kasher, M
   Roizin, H
   Cohen, A
   Jaber, H
   Mikhailov, S
   Rubin, C
   Doron, D
   Rahav, G
   Regev-Yochay, G
AF Kasher, Melody
   Roizin, Hector
   Cohen, Adi
   Jaber, Hanaa
   Mikhailov, Sharon
   Rubin, Carmit
   Doron, Daphna
   Rahav, Galia
   Regev-Yochay, Gili
TI The impact of PCV7/13 on the distribution of carried pneumococcal
   serotypes and on pilus prevalence; 14 years of repeated cross-sectional
   surveillance
SO VACCINE
LA English
DT Article
DE S. pneumoniae; Carriage; Pilus-1; Serotype replacement; Pneumococcal
   conjugate vaccines
ID STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; SEQUENTIAL INTRODUCTION;
   HAEMOPHILUS-INFLUENZAE; STAPHYLOCOCCUS-AUREUS; CAPSULAR SEROTYPES;
   DISEASE; CHILDREN; MASSACHUSETTS; COLONIZATION
AB Background: S. pneumoniae carriage by children is a major source of pneumococcal transmission, and the initial step prior to infection. Pilus type 1, reported in similar to 30% of pneumococcal strains in the pre-vaccine era, contributes to pneumococcal colonization and virulence. In this study, we report the impact of the pneumococcal conjugate vaccine (PCV), PCV7/PCV13 sequential implementation on serotype distribution, and on the prevalence of piliated strains among carried pneumococci during the pre- and post-vaccine eras.
   Methods: During 2002-2016, 12 repeated cross-sectional surveillances of nasopharyngeal S. pneumoniae carriage were conducted among 8,473 children <5.5 years old visiting primary care physicians in Central Israel. Seven biannual surveillances in the pre-PCV period, 2 surveillances after PCV7 was licensed but before implementation in the National Immunization Plan, and 3 additional surveillances in the post-PCV period. S. pneumoniae serotype distribution and prevalence of piliated strains were assessed.
   Results: Carriage of S. pneumoniae was relatively stable (45.4%). The prevalence of serotypes included in PCV13 was 65.7%, in the pre-vaccine period and the pilus was present in 26.4% of isolates. The distribution of serotypes and the pilus prevalence in the pre-PCV period was relatively stable except for a decrease in prevalence of piliated 19F, observed following the first study year. Following PCV7/PCV13 implementation, vaccine type 13 (VT13) strains were nearly eliminated to 3.3% by 2016. Piliated strains, which were primarily of VT13 serotypes, initially followed a similar trend and were nearly eliminated by 2014 (1.7%). Yet, two years later, pilus prevalence re-emerged among non-VT strains to 12.8% of all pneumococci.
   Conclusions: Following PCV implementation, a dramatic and rapid decrease in VT strains prevalence was observed with a concomitant increase in non-VT strains. Piliated strains were nearly eliminated, yet re-emerged 7 years following PCV7/PCV13 implementation in various non-VT strains. This suggests that the pilus confers an advantage in colonization. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kasher, Melody; Jaber, Hanaa; Mikhailov, Sharon; Rubin, Carmit; Regev-Yochay, Gili] Sheba Med Ctr, Infect Prevent & Control Unit, Bitan 16, Ramat Gan, Israel.
   [Kasher, Melody; Rahav, Galia; Regev-Yochay, Gili] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
   [Roizin, Hector; Cohen, Adi; Doron, Daphna] Maccabi Healthcare Serv, Jerusalem Shfela Dist, Jerusalem, Israel.
   [Rahav, Galia] Sheba Med Ctr, Infect Dis Unit, Ramat Gan, Israel.
RP Regev-Yochay, G (reprint author), Sheba Med Ctr, Infect Prevent & Control Unit, Bitan 16, Ramat Gan, Israel.
EM gili.regev@sheba.health.gov.il
OI Kasher, Melody/0000-0003-3741-4787
CR Aguiar SI, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-41
   Andrews NJ, 2014, LANCET INFECT DIS, V14, P839, DOI 10.1016/S1473-3099(14)70822-9
   [Anonymous], 2018, VACCINE, V36, P15, DOI [10.1016/j.vaccine.2017.11.052., DOI 10.1016/J.VACCINE.2017.11.052]
   Bagnoli F, 2008, J BACTERIOL, V190, P5480, DOI 10.1128/JB.00384-08
   Balsells E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177113
   Barocchi MA, 2006, P NATL ACAD SCI USA, V103, P2857, DOI 10.1073/pnas.0511017103
   Basset A, 2007, J CLIN MICROBIOL, V45, P1684, DOI 10.1128/JCM.00265-07
   Basset A, 2011, INFECT IMMUN, V79, P2974, DOI 10.1128/IAI.05117-11
   Beall B, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02670
   Ben-Shimol S, 2012, VACCINE, V30, P6600, DOI 10.1016/j.vaccine.2012.08.012
   Ben-Shimol S, 2014, CLIN INFECT DIS, V59, P1724, DOI 10.1093/cid/ciu683
   Ben-Shimol S, 2014, VACCINE, V32, P3452, DOI 10.1016/j.vaccine.2014.03.065
   Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7
   Bogaert D, 2004, VACCINE, V22, P2209, DOI 10.1016/j.vaccine.2003.11.038
   Bridy-Pappas AE, 2005, PHARMACOTHERAPY, V25, P1193, DOI 10.1592/phco.2005.25.9.1193
   Cho YC, 2017, PEDIATR INFECT DIS J, V36, pE334, DOI [10.1097/INF.0000000000001664, 10.1097/inf.0000000000001664]
   Daniels Calvin C, 2016, J Pediatr Pharmacol Ther, V21, P27, DOI 10.5863/1551-6776-21.1.27
   Danne C, 2012, RES MICROBIOL, V163, P645, DOI 10.1016/j.resmic.2012.10.012
   Dowell SF, 2003, EMERG INFECT DIS, V9, P573, DOI 10.3201/eid0905.020556
   Entwisle C, 2017, VACCINE, V35, P7181, DOI 10.1016/j.vaccine.2017.10.076
   Galanis I, 2016, EUR RESPIR J, V47, P1208, DOI 10.1183/13993003.01451-2015
   Gianfaldoni C, 2007, INFECT IMMUN, V75, P1059, DOI 10.1128/IAI.01400-06
   Gladstone RA, 2015, VACCINE, V33, P2015, DOI 10.1016/j.vaccine.2015.03.012
   Hill S, 2018, VACCINE, V36, P4255, DOI 10.1016/j.vaccine.2018.05.122
   Hjalmarsdottir MA, 2015, J ANTIMICROB CHEMOTH, V70, P2203, DOI 10.1093/jac/dkv096
   Huang SS, 2005, PEDIATRICS, V116, pE408, DOI 10.1542/peds.2004-2338
   Kais M, 2006, DIAGN MICR INFEC DIS, V55, P169, DOI 10.1016/j.diagmicrobio.2006.01.007
   Ladhani SN, 2018, LANCET INFECT DIS, V18, P441, DOI 10.1016/S1473-3099(18)30052-5
   LeMieux J, 2006, INFECT IMMUN, V74, P2453, DOI 10.1128/IAI.74.4.2453-2456.2006
   Lewnard JA, 2016, J INFECT DIS, V213, P1596, DOI 10.1093/infdis/jiv761
   Lock RA, 1996, MICROB PATHOGENESIS, V21, P71, DOI 10.1006/mpat.1996.0044
   Moschioni M, 2010, CLIN MICROBIOL INFEC, V16, P1501, DOI [10.1111/j.1469-0691.2010.03105.x, 10.1111/j.1469-0691.2009.03105.x]
   Moschioni M, 2008, J INFECT DIS, V197, P888, DOI 10.1086/528375
   Moschioni M, 2012, VACCINE, V30, P1349, DOI 10.1016/j.vaccine.2011.12.080
   Nelson AL, 2007, MOL MICROBIOL, V66, P329, DOI 10.1111/j.1365-2958.2007.05908.x
   Pai R, 2006, J CLIN MICROBIOL, V44, P124, DOI 10.1128/JCM.44.1.124-131.2006
   Papadatou I, 2016, CLIN VACCINE IMMUNOL, V23, P388, DOI 10.1128/CVI.00721-15
   Regev-Yochay G, 2004, CLIN INFECT DIS, V38, P632, DOI 10.1086/381547
   Regev-Yochay G, 2010, VACCINE, V28, P4842, DOI 10.1016/j.vaccine.2010.04.042
   Regev-Yochay G, 2009, CLIN INFECT DIS, V48, P760, DOI 10.1086/597040
   Slotved HC, 2004, J CLIN MICROBIOL, V42, P2518, DOI 10.1128/JCM.42.6.2518-2522.2004
   Steens A, 2013, VACCINE, V31, P6232, DOI 10.1016/j.vaccine.2013.10.032
   Turner P, 2012, CLIN MICROBIOL INFEC, V18, P970, DOI 10.1111/j.1469-0691.2011.03711.x
   Usuf E, 2019, CLIN INFECT DIS, V68, P1512, DOI 10.1093/cid/ciy726
   van der Linden M, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0941-9
   Vissers M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194823
   Weinberger DM, 2019, CLIN INFECT DIS, V69, P100, DOI 10.1093/cid/ciy875
   Weinberger DM, 2011, LANCET, V378, P1962, DOI 10.1016/S0140-6736(10)62225-8
   Weinberger DM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000476
   Zahner D, 2010, EMERG INFECT DIS, V16, P955, DOI 10.3201/eid1606.091820
   Zemlickova H, 2018, J MED MICROBIOL, V67, P1003, DOI 10.1099/jmm.0.000765
   Zhou H, 2012, EMERG INFECT DIS, V18, P294, DOI 10.3201/eid1802.102025
NR 52
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3591
EP 3599
DI 10.1016/j.vaccine.2020.03.016
PG 9
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100012
PM 32224005
DA 2020-05-12
ER

PT J
AU Colaprico, A
   Senesi, S
   Ferlicca, F
   Brunelli, B
   Ugozzoli, M
   Pallaoro, M
   O'Hagan, DT
AF Colaprico, Annalisa
   Senesi, Silvia
   Ferlicca, Francesca
   Brunelli, Brunella
   Ugozzoli, Mildred
   Pallaoro, Michele
   O'Hagan, Derek T.
TI Adsorption onto aluminum hydroxide adjuvant protects antigens from
   degradation
SO VACCINE
LA English
DT Article
DE Aluminum hydroxide; Antigen adsorption; Vaccine; Calorimetry; capture
   ELISA; Neisseria meningitidis type B
ID NEISSERIA-MENINGITIDIS; VACCINE CANDIDATE; STABILITY; FORMULATION;
   PROTEINS; IMMUNITY; NADA
AB Aluminum based adjuvants are widely used in commercial vaccines, since they are known to be safe and effective with a variety of antigens. The effect of antigen adsorption onto Aluminum Hydroxide is a complex area, since several mechanisms are involved simultaneously, whose impact is both antigen and formulation conditions dependent. Moreover, the mode of action of Aluminum Hydroxide is itself complex, with many mechanisms operating simultaneously. Within the literature there are contrasting theories regarding the effect of adsorption on antigen integrity and stability, with reports of antigen being stabilized by adsorption onto Aluminum Hydroxide, but also with contrary reports of antigen being destabilized. With the aim to understand the impact of adsorption on three recombinant proteins which, following in vivo immunization, are able to induce functional bactericidal antibodies against Neisseria meningitidis type B, we used a range of physico-chemical tools, such as DSC and UPLC, along with in vitro binding of antibodies that recognize structural elements of the proteins, and supported the in vitro data with in vivo evaluation in mice studies. We showed that, following exposure to accelerated degradation conditions involving heat, the recombinant proteins, although robust, were stabilized by adsorption onto Aluminum Hydroxide and retain their structural integrity unlike the not adsorbed proteins. The measure of the Melting Temperature was a useful tool to compare the behavior of proteins adsorbed and not adsorbed on Aluminum Hydroxide and to predict protein stability. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Colaprico, Annalisa; Senesi, Silvia; Ferlicca, Francesca; Brunelli, Brunella; O'Hagan, Derek T.] GSK, Siena, Italy.
   [Ugozzoli, Mildred; Pallaoro, Michele] Novartis Vaccines & Diagnost Srl, Siena, Italy.
RP Colaprico, A (reprint author), GSK, Siena, Italy.
EM annalisa.x.colaprico@gsk.com
CR Agopian A, 2007, BBA-PROTEINS PROTEOM, V1774, P351, DOI 10.1016/j.bbapap.2006.12.007
   [Anonymous], 2009, BIOLOGICALS, V37, P424, DOI 10.1016/j.biologicals.2009.08.017
   Ausar SF, 2011, J PHARM SCI-US, V100, P431, DOI 10.1002/jps.22282
   Borrow R, 2006, VACCINE, V24, P5093, DOI 10.1016/j.vaccine.2006.03.091
   Braun LJ, 2012, J PHARM SCI-US, V101, P1391, DOI 10.1002/jps.23039
   Capecchi B, 2005, MOL MICROBIOL, V55, P687, DOI 10.1111/j.1365-2958.2004.04423.x
   Comanducci M, 2002, J EXP MED, V195, P1445, DOI 10.1084/jem.20020407
   Deschuyteneer M, 2010, HUM VACCINES, V6, P407, DOI 10.4161/hv.6.5.11023
   Dong AC, 2006, ANAL BIOCHEM, V351, P282, DOI 10.1016/j.ab.2006.01.008
   Donnelly J, 2010, P NATL ACAD SCI USA, V107, P19490, DOI 10.1073/pnas.1013758107
   Frasch CE, 2009, VACCINE, V27, pB112, DOI 10.1016/j.vaccine.2009.04.065
   Giuliani MM, 2006, P NATL ACAD SCI USA, V103, P10834, DOI 10.1073/pnas.0603940103
   Giuliani MM, 2010, VACCINE, V28, P5023, DOI 10.1016/j.vaccine.2010.05.014
   Giuliani MM, 2005, INFECT IMMUN, V73, P1151, DOI 10.1128/IAI.73.2.1151-1160.2005
   GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327
   Hem SL, 2007, EXPERT REV VACCINES, V6, P685, DOI 10.1586/14760584.6.5.685
   Hem SL, 2010, VACCINE, V28, P4868, DOI 10.1016/j.vaccine.2010.05.007
   Iyer V, 2012, J PHARM SCI-US, V101, P3078, DOI 10.1002/jps.23175
   Jones LS, 2005, J BIOL CHEM, V280, P13406, DOI 10.1074/jbc.M500687200
   Ljutic B, 2012, VACCINE, V30, P2981, DOI 10.1016/j.vaccine.2012.02.038
   Madico G, 2006, J IMMUNOL, V177, P501, DOI 10.4049/jimmunol.177.1.501
   MANNHALTER JW, 1985, CLIN EXP IMMUNOL, V61, P143
   Masignani V, 2003, J EXP MED, V197, P789, DOI 10.1084/jem.20021911
   Morefield GL, 2005, VACCINE, V23, P1588, DOI 10.1016/j.vaccine.2004.07.050
   NORDE W, 1986, ADV COLLOID INTERFAC, V25, P267, DOI 10.1016/0001-8686(86)80012-4
   Peek LJ, 2007, J PHARM SCI-US, V96, P547, DOI 10.1002/jps.20762
   Privalov P L, 1986, Methods Enzymol, V131, P4
   Rabe M, 2011, ADV COLLOID INTERFAC, V162, P87, DOI 10.1016/j.cis.2010.12.007
   Regnier M, 2012, VACCINE, V30, P6783, DOI 10.1016/j.vaccine.2012.09.020
   Serruto D, 2010, P NATL ACAD SCI USA, V107, P3770, DOI 10.1073/pnas.0915162107
   van Alphen L, 2008, HUM VACCINES, V4, P158, DOI 10.4161/hv.4.2.4871
   Vessely C, 2009, J PHARM SCI-US, V98, P2970, DOI 10.1002/jps.21498
   Welsch JA, 2003, J INFECT DIS, V188, P1730, DOI 10.1086/379375
   Xing D, 2001, VACCINE, V20, P342, DOI 10.1016/S0264-410X(01)00372-3
   Zheng YW, 2007, SPECTROSC-INT J, V21, P257, DOI 10.1155/2007/354959
NR 35
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3600
EP 3609
DI 10.1016/j.vaccine.2020.02.001
PG 10
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100013
PM 32063436
DA 2020-05-12
ER

PT J
AU Burkhard, J
   Ciurea, A
   Gabay, C
   Hasler, P
   Muller, R
   Niedrig, M
   Fehr, J
   Villiger, P
   Visser, LG
   de Visser, AW
   Walker, UA
   Hatz, C
   Buhler, S
AF Burkhard, J.
   Ciurea, A.
   Gabay, C.
   Hasler, P.
   Mueller, R.
   Niedrig, M.
   Fehr, J.
   Villiger, P.
   Visser, L. G.
   de Visser, A. W.
   Walker, U. A.
   Hatz, C.
   Buehler, S.
TI Long-term immunogenicity after yellow fever vaccination in
   immunosuppressed and healthy individuals
SO VACCINE
LA English
DT Article
DE Yellow fever vaccination; Immunosuppression; Long-term immune response;
   Neutralising antibodies; Travel medicine
ID LIVED PLASMA-CELLS; PROTECTIVE IMMUNITY; MEMORY B; IMMUNOLOGICAL MEMORY;
   BONE-MARROW; 17D; IMMUNIZATION; METHOTREXATE; PERSISTENCE; ANTIBODIES
AB Background: The live-attenuated yellow fever vaccine (YFV) is generally contraindicated in immunosuppressed patients. Our aim was to investigate if immunosuppressive therapy impairs the long-term protection against yellow fever virus in patients who had received YFV prior to the start of their immunosuppressive therapy.
   Methods: Our study examined 35 healthy individuals and 40 immunosuppressed patients with autoimmune diseases or organ transplants. All individuals had received YFV prior to the onset of their immunosuppression. We analysed the long-term influence of the immunosuppressive therapy on the YFV protective immunity by measuring neutralising antibodies (NA) with the Plaque Reduction Neutralisation Test (PRNT). We assessed risk factors for a negative PRNT result (titre below 1: 10) and their influence on the magnitude of the NA.
   Results: A median time interval of 21.1 years (interquartile range 14.4-31.3 years) after the YFV in all patients, a total of 35 immunosuppressed patients (88%) were seropositive (PRNT >= 1:10) compared to 31 patients (89%) in the control group. The geometric mean titres of NA did not differ between the groups. The duration of an underlying rheumatic disease was the only risk factor found for a lower magnitude of NA. An insufficient level of NA was found in nine subjects (12%) who had received a single dose of YFV (in one subject, the number of YFV doses was unknown).
   Conclusion: The use of an immunosuppressive drug started after the administration of the YFV did not affect long-term persistence of NA. A second dose of YFV may be necessary to secure long-term immunity. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Burkhard, J.; Fehr, J.; Hatz, C.; Buehler, S.] Univ Zurich, Dept Publ Hlth, Div Infect Dis, Epidemiol Biostat & Prevent Inst, Hirschengraben 84, CH-8001 Zurich, Switzerland.
   [Ciurea, A.] Univ Hosp Zurich, Dept Rheumatol, Zurich, Switzerland.
   [Gabay, C.] Univ Hosp Geneva, Div Rheumatol, Geneva, Switzerland.
   [Hasler, P.] Cantonal Hosp Aarau, Dept Rheumatol, Aarau, Switzerland.
   [Mueller, R.] Cantonal Hosp St Gallen, Dept Internal Med, Div Rheumatol, St Gallen, Switzerland.
   [Mueller, R.] Ludwig Maximilians Univ Munchen, Div Rheumatol & Clin Immunol, Dept Internal Med, Munich, Germany.
   [Niedrig, M.] RKI, Berlin, Germany.
   [Villiger, P.] Univ Hosp Bern, Dept Rheumatol & Clin Immunol Allergol, Bern, Switzerland.
   [Visser, L. G.; de Visser, A. W.] Leiden Univ, Dept Infect Dis, Med Ctr, Leiden, Netherlands.
   [Walker, U. A.] Univ Hosp Basel, Dept Rheumatol, Basel, Switzerland.
   [Hatz, C.] Swiss Trop & Publ Hlth Inst, Dept Med & Diagnost, Basel, Switzerland.
   [Buehler, S.] Univ Med Ctr Hamburg Eppen, Dept Trop Med, Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.
   [Buehler, S.] Univ Med Ctr Hamburg Eppen, Dept Med 1, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.
   [Hatz, C.] Univ Basel, Basel, Switzerland.
   [Hatz, C.] Kantonsspital St Gallen, Div Infect Dis & Hosp Epidemiol, St Gallen, Switzerland.
RP Buhler, S (reprint author), Univ Zurich, Dept Publ Hlth, Div Infect Dis, Epidemiol Biostat & Prevent Inst, Hirschengraben 84, CH-8001 Zurich, Switzerland.; Buhler, S (reprint author), Univ Med Ctr Hamburg Eppen, Dept Trop Med, Bernhard Nocht Inst Trop Med, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.; Buhler, S (reprint author), Univ Med Ctr Hamburg Eppen, Dept Med 1, Bernhard Nocht Str 74, D-20359 Hamburg, Germany.
EM silja.buehler@bnitm.de
FU Swiss National Science FoundationSwiss National Science Foundation
   (SNSF) [320030_143480]; Hugo und Elsa Isler-Fonds; Theodor und Ida
   Herzog-Egli-Stiftung
FX The larger "tetanus study", of which this study was a part, was funded
   by the Swiss National Science Foundation (SNF Project Number:
   320030_143480), the Hugo und Elsa Isler-Fonds and the Theodor und Ida
   Herzog-Egli-Stiftung.
CR Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54
   Bassi MR, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004464
   Bassi MR, 2015, J IMMUNOL, V194, P1141, DOI 10.4049/jimmunol.1402605
   Buhler S, 2019, RHEUMATOLOGY, V58, P1585, DOI 10.1093/rheumatology/kez045
   Caldas IR, 2014, VACCINE, V32, P4977, DOI 10.1016/j.vaccine.2014.07.021
   Campi-Azevedo AC, 2016, HUM VACC IMMUNOTHER, V12, P491, DOI 10.1080/21645515.2015.1082693
   Cohen BJ, 2006, J VIROL METHODS, V131, P209, DOI 10.1016/j.jviromet.2005.08.001
   De Madrid AT, 1969, B WHO
   DiLillo DJ, 2008, J IMMUNOL, V180, P361, DOI 10.4049/jimmunol.180.1.361
   Dorner T, 2007, IMMUNITY, V27, P384, DOI 10.1016/j.immuni.2007.09.002
   Eperon G, 2018, REV MED SUISSE
   Ferreira CD, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1854-6
   Georgiou KR, 2012, INT J EXP PATHOL, V93, P104, DOI 10.1111/j.1365-2613.2011.00800.x
   Gotuzzo E, 2013, AM J TROP MED HYG, V89, P434, DOI 10.4269/ajtmh.13-0264
   Grobusch MP, 2013, CLIN MICROBIOL INFEC, V19, P885, DOI 10.1111/1469-0691.12332
   Hiepe F, 2011, NAT REV RHEUMATOL, V7, P170, DOI 10.1038/nrrheum.2011.1
   Hoyer BF, 2008, ANN RHEUM DIS, V67, P87, DOI 10.1136/ard.2008.098418
   Hoyer BF, 2004, J EXP MED, V199, P1577, DOI 10.1084/jem.20040168
   Hoyer BF, 2017, IMMUNOL LETT, V189, P10, DOI 10.1016/j.imlet.2017.04.014
   Ingelman-Sundberg HM, 2016, VACCINE, V34, P1304, DOI 10.1016/j.vaccine.2016.01.027
   Jaeger VK, 2015, J TRAVEL MED, V22, P161, DOI 10.1111/jtm.12184
   Julander JG, 2011, VACCINE, V29, P6008, DOI 10.1016/j.vaccine.2011.06.034
   Karnell JL, 2011, J IMMUNOL, V187, P3603, DOI 10.4049/jimmunol.1003319
   Kohler S, 2012, EUR J IMMUNOL, V42, P2363, DOI 10.1002/eji.201142306
   Kometani K, 2015, CURR OPIN IMMUNOL, V33, P64, DOI 10.1016/j.coi.2015.01.017
   Lindsey NP, 2018, J TRAVEL MED, V25, DOI 10.1093/jtm/tay108
   Maruyama M, 2000, NATURE, V407, P636, DOI 10.1038/35036600
   Miyaji KT, 2017, REV INST MED TROP SP, V59, DOI [10.1590/s1678-9946201759002, 10.1590/S1678-9946201759002]
   Miyaji K, 2017, 2017 IEEE INTERNATIONAL SYMPOSIUM ON RADIO-FREQUENCY INTEGRATION TECHNOLOGY (RFIT), P1, DOI 10.1109/RFIT.2017.8048270
   Monath TP, 2013, VACCINES, P870, DOI 10.1016/B978-1-4557-0090-5.00043-4.
   Mumtaz IM, 2012, J AUTOIMMUN, V39, P180, DOI 10.1016/j.jaut.2012.05.010
   Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795
   POLAND JD, 1981, B WORLD HEALTH ORGAN, V59, P895
   Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886
   Reinhardt B, 1998, J MED VIROL, V56, P159, DOI 10.1002/(SICI)1096-9071(199810)56:2&lt;159::AID-JMV10&gt;3.0.CO;2-B
   Seligman SJ, 2014, VACCINE, V32, P5769, DOI 10.1016/j.vaccine.2014.08.051
   Staples JE, 2011, TROPICAL INFECT DIS, P492, DOI 10.1016/B978-0-7020-3935-5.00074-4
   Veit O, 2009, CLIN INFECT DIS, V48, P659, DOI 10.1086/597006
   Veit O, 2018, CLIN INFECT DIS, V66, P1099, DOI 10.1093/cid/cix960
   WALDMANN TA, 1969, NEW ENGL J MED, V281, P1170, DOI 10.1056/NEJM196911202812107
   Wieten RW, 2016, J INFECTION, V72, P713, DOI 10.1016/j.jinf.2016.02.017
   Wieten RW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149871
   Wieten RW, 2016, VACCINE, V34, P1247, DOI 10.1016/j.vaccine.2016.01.037
   Zinkernagel RM, 2018, IMMUNOL REV, V283, P238, DOI 10.1111/imr.12648
   Zinkernagel RM, 2012, CELL MOL LIFE SCI, V69, P1635, DOI 10.1007/s00018-012-0972-y
NR 45
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3610
EP 3617
DI 10.1016/j.vaccine.2019.12.042
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100014
PM 31911033
DA 2020-05-12
ER

PT J
AU Ortega-Sanchez, R
   Camacho-Nuez, M
   Castaneda-Ortiz, EJ
   Martinez-Benitez, MB
   Hernandez-Silva, DJ
   Aguilar-Tipacamu, G
   Mosqueda, J
AF Ortega-Sanchez, Reyna
   Camacho-Nuez, Minerva
   Jacqueline Castaneda-Ortiz, Elizabeth
   Berto Martinez-Benitez, Maximo
   Josimar Hernandez-Silva, Diego
   Aguilar-Tipacamu, Gabriela
   Mosqueda, Juan
TI Vaccine efficacy of recombinant BmVDAC on Rhipicephalus microplus fed on
   Babesia bigemina-infected and uninfected cattle
SO VACCINE
LA English
DT Article
DE R. microplus; B. bigemina; VDAC; Immunization
ID DEPENDENT ANION CHANNEL; BOOPHILUS-MICROPLUS; TICK INFESTATIONS; PORIN;
   VDAC; ANTIGEN; BM86; PURIFICATION; EXPRESSION; INHIBITOR
AB Rhipicephalus microplus is the most widely distributed tick worldwide and causes significant economic losses in the livestock industry. It directly affects hosts (especially in large infestations) by feeding on blood and piercing the skin and indirectly affects hosts as a vector of pathogens that cause infectious diseases, such as bovine babesiosis. Current research on the control of ticks is focused on integrated tick control programmes, including vaccination treatment with acaricides and completely blocking pathogen transmission. Our previous studies showed that R. microplus VDAC (BmVDAC) expression is modulated by Babesia bigemina infection. VDAC is a mitochondrial protein with multiple functions in addition to its primary role as a central component of the apoptotic machinery. In this paper, we evaluated BmVDAC as an anti-tick vaccine and its capacity to block the infection of Babesia bigemina in ticks. Our results demonstrate that rBmVDAC is immunogenic and that antibodies specifically recognize the native protein from midguts of R. microplus. Immunization with rBmVDAC afforded an 82% efficacy against R. microplus infestation in the group of vaccinated cattle compared with the control group. In contrast, rBmVDAC showed a lower efficacy of 34% against tick infestation in cattle vaccinated with rBmVDAC, infested with R. microplus and infected with B. bigemina. The main effect on ticks fed in vaccinated and infected cattle was a 34% reduction in egg fertility (DF) compared to ticks fed on the control group. There was no reduction in the B. bigemina parasite levels of ticks fed on rBmVDAC-vaccinated cattle. These results suggest that the rBmVDAC protein could be tested as a vaccine for the control of tick infestation. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Ortega-Sanchez, Reyna; Josimar Hernandez-Silva, Diego; Mosqueda, Juan] Univ Autonoma Queretaro, CA Fac Ciencias Nat, Immunol & Vaccines Lab, Carretera Chichimequillas, Ejido Bolanos 76140, Queretaro Quere, Mexico.
   [Ortega-Sanchez, Reyna] Univ Autonoma Queretaro, Fac Ciencias Nat, Maestria Salud & Prod Anim Sustentable, Queretaro, Qro, Mexico.
   [Camacho-Nuez, Minerva; Jacqueline Castaneda-Ortiz, Elizabeth; Berto Martinez-Benitez, Maximo] Univ Autonoma Ciudad Mexico, Posgrad Ciencias Genom, San Lorenzo Num 290, Mexico City 03100, DF, Mexico.
   [Aguilar-Tipacamu, Gabriela; Mosqueda, Juan] Univ Autonoma Queretaro, Fac Ciencias Nat, Av Ciencias S-N, Queretaro 76230, Mexico.
RP Mosqueda, J (reprint author), Univ Autonoma Queretaro, CA Fac Ciencias Nat, Immunol & Vaccines Lab, Carretera Chichimequillas, Ejido Bolanos 76140, Queretaro Quere, Mexico.; Camacho-Nuez, M (reprint author), Univ Autonoma Ciudad Mexico, Posgrad Ciencias Genom, San Lorenzo Num 290, Mexico City 03100, DF, Mexico.; Mosqueda, J (reprint author), Univ Autonoma Queretaro, Fac Ciencias Nat, Av Ciencias S-N, Queretaro 76230, Mexico.
EM mcamachonuez@yahoo.com.mx; joel.mosqueda@uaq.mx
OI Mosqueda, Juan/0000-0001-8892-6390
FU CONACYT MexicoConsejo Nacional de Ciencia y Tecnologia (CONACyT)
   [283344, 451047]
FX This work was supported by a grant from CONACYT (283344) Mexico. R.O-H.
   was supported by a scholarship from CONACYT (451047) Mexico. We also
   thank Universidad Autonoma de la Ciudad de Mexico and Universidad
   Autonoma de Queretaro for all the facilities they provided. We are
   grateful to Alfredo Padilla Barberi for the artwork, to Jose Rodrigo
   Morales-Garcia and Gilberto Reyes-De Luna for their technical assistance
   and to Mariana Sanchez Calistro and Karen Becerril Puente for their help
   with the purification of rBmVDAC.
CR Ali A, 2015, VET PARASITOL, V207, P107, DOI 10.1016/j.vetpar.2014.11.007
   Almazan C, 2012, VACCINE, V30, P265, DOI 10.1016/j.vaccine.2011.10.102
   Andreotti R, 2012, VACCINE, V30, P6678, DOI 10.1016/j.vaccine.2012.08.066
   BATHORI G, 1993, BIOCHIM BIOPHYS ACTA, V1145, P168, DOI 10.1016/0005-2736(93)90394-F
   Bock R, 2004, PARASITOLOGY, V129, pS247, DOI 10.1017/S0031182004005190
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Camacho-Nuez M, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2510-0
   Canales M, 1997, VACCINE, V15, P414, DOI 10.1016/S0264-410X(96)00192-2
   COLOMBINI M, 1989, J MEMBRANE BIOL, V111, P103, DOI 10.1007/BF01871775
   Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d
   COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0
   Cunha RC, 2013, REV BRAS PARASITOL V, V22, P571, DOI 10.1590/S1984-29612013000400019
   de la Fuente J, 2016, PARASITE IMMUNOL, V38, P754, DOI 10.1111/pim.12339
   de la Fuente Jose, 2007, Animal Health Research Reviews, V8, P23
   de la Fuente J, 2008, FRONT BIOSCI-LANDMRK, V13, P6938, DOI 10.2741/3200
   de la Fuente J, 2015, EXPERT REV VACCINES, V14, P1367, DOI 10.1586/14760584.2015.1076339
   De Pinto V, 2010, BBA-BIOENERGETICS, V1797, P1268, DOI 10.1016/j.bbabio.2010.01.031
   Freeman JM, 2010, PARASITE VECTOR, V3, DOI 10.1186/1756-3305-3-101
   Garcia-Garcia JC, 2000, VACCINE, V18, P2275, DOI 10.1016/S0264-410X(99)00548-4
   Godbole A, 2003, BBA-MOL CELL RES, V1642, P87, DOI 10.1016/S0167-4889(03)00102-2
   Gonzalez-Gronow M, 2013, J BIOL CHEM, V288, P498, DOI 10.1074/jbc.M112.412502
   Guerrero FD, 2012, INT J PARASITOL, V42, P421, DOI 10.1016/j.ijpara.2012.04.003
   Guerrero FD, 2012, REV BRAS PARASITOL V, V21, P1, DOI 10.1590/S1984-29612012000100002
   Rodriguez-Vivas RI, 2017, REV MEX CIENC PECU, V8, P61, DOI 10.22319/rmcp.v8i1.4305
   Jitobaom K, 2016, SCI REP-UK, V6, DOI 10.1038/srep35753
   Jongejan F, 2004, PARASITOLOGY, V129, pS3, DOI 10.1017/S0031182004005967
   Kaewmongkol S, 2015, EXP APPL ACAROL, V66, P247, DOI 10.1007/s10493-015-9897-0
   Ke GM, 2006, J VIROL METHODS, V133, P6, DOI 10.1016/j.jviromet.2005.09.011
   KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x
   KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441
   Martinez-Arzate SG, 2019, BMC GENET, V20, DOI 10.1186/s12863-019-0754-8
   McCosker PJ, 1981, GLOBAL IMPORTANCE BA
   Merino O, 2013, VACCINE, V31, P5889, DOI 10.1016/j.vaccine.2013.09.037
   Mertins B, 2014, BIOL CHEM, V395, P1435, DOI 10.1515/hsz-2014-0203
   MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x
   Moon JI, 1999, NEUROREPORT, V10, P443, DOI 10.1097/00001756-199902250-00001
   Mtshali PS, 2014, J VET MED SCI, V76, P145, DOI 10.1292/jvms.13-0197
   OUHELLI H, 1987, VET PARASITOL, V23, P147, DOI 10.1016/0304-4017(87)90033-1
   Parola P, 2001, ANN BIOL CLIN-PARIS, V59, P177
   Peter RJ, 2005, VET PARASITOL, V132, P205, DOI 10.1016/j.vetpar.2005.07.004
   RIDING GA, 1994, J IMMUNOL, V153, P5158
   Riek RF, 1968, INFECT BLOOD DIS MAN
   Rodriguez-Hernandez E, 2015, VET PARASITOL, V212, P368, DOI 10.1016/j.vetpar.2015.06.016
   Rodriguez-Hernandez E, 2012, VET PARASITOL, V187, P538, DOI 10.1016/j.vetpar.2012.01.028
   Rodriquez RI, 1996, VET PARASITOL, V62, P35, DOI 10.1016/0304-4017(95)00850-0
   SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662
   Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321
   Shoshan-Barmatz V, 2010, MOL ASPECTS MED, V31, P227, DOI 10.1016/j.mam.2010.03.002
   Suarez CE, 2011, VET PARASITOL, V180, P109, DOI 10.1016/j.vetpar.2011.05.032
   THINNES FP, 1989, BIOL CHEM H-S, V370, P1253
   Willadsen P, 1996, PARASITE IMMUNOL, V18, P241, DOI 10.1046/j.1365-3024.1996.d01-90.x
   Willadsen P, 2004, PARASITOLOGY, V129, pS367, DOI 10.1017/S0031182003004657
   WILLADSEN P, 1995, PARASITOLOGY, V110, pS43, DOI 10.1017/S0031182000001487
   WRIGHT IG, 1973, RES VET SCI, V14, P29, DOI 10.1016/S0034-5288(18)33934-1
   Zintl A, 2003, CLIN MICROBIOL REV, V16, P622, DOI 10.1128/CMR.16.4.622-636.2003
NR 55
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 23
PY 2020
VL 38
IS 19
BP 3618
EP 3625
DI 10.1016/j.vaccine.2019.12.040
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TN
UT WOS:000525318100015
PM 31928853
DA 2020-05-12
ER

PT J
AU Bansal, R
   Srivastava, P
   Rathore, AS
   Chokshi, P
AF Bansal, Rohit
   Srivastava, Pulkit
   Rathore, Anurag S.
   Chokshi, Paresh
TI Population balance modelling of aggregation of monoclonal antibody based
   therapeutic proteins
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Monoclonal antibodies; Protein aggregation; Size exclusion
   chromatography; Dynamic light scattering; Population balance modelling;
   Aggregation kinetics
ID KINETICS; IMMUNOGENICITY; CHALLENGES; STABILITY; MECHANISM; PATHWAYS;
   IGG1
AB Monoclonal antibodies (mAbs) are one of the most important class of therapeutic proteins. Their proteinaceous nature makes them labile towards aggregation, considered a critical quality attribute (CQA) as it affects safety and efficacy of a biotherapeutic product. Present study examines early stage aggregation behaviour of monoclonal antibodies experimentally. The process is also described using hybrid reaction and population balance model. Size exclusion chromatography and dynamic light scattering have been used to obtain kinetic parameters featuring in the mechanistic model. The aggregation process of two different mAbs in the presence of either acetate or citrate buffer is analysed at two temperatures. The rate of aggregation is found to be significantly influenced by the type of buffer medium (faster in citrate compared to acetate buffer). The enhanced aggregation in citrate buffer is attributed to the reduction in the net energy barrier for protein-protein interaction resulting in loss of stability of mAb species. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Bansal, Rohit; Srivastava, Pulkit; Rathore, Anurag S.; Chokshi, Paresh] Indian Inst Technol Delhi, Dept Chem Engn, New Delhi 110016, India.
RP Chokshi, P (reprint author), Indian Inst Technol Delhi, Dept Chem Engn, New Delhi 110016, India.
EM paresh@chemical.iitd.ac.in
OI Rathore, Anurag/0000-0002-5913-4244
FU Centre of Excellence for Biopharmaceutical Technology grant from
   Department of Biotechnology, Ministry of Science and Technology
   [BT/COE/34/SP15097/2015]
FX This work was funded by the Centre of Excellence for Biopharmaceutical
   Technology grant from Department of Biotechnology, Ministry of Science
   and Technology (number BT/COE/34/SP15097/2015). The authors declare that
   there is no financial or commercial conflict of interest.
CR Andrews JM, 2007, J PHYS CHEM B, V111, P7897, DOI 10.1021/jp070212j
   Arosio P, 2012, J PHYS CHEM B, V116, P7066, DOI 10.1021/jp301091n
   Arosio P, 2011, PHARM RES-DORDR, V28, P1884, DOI 10.1007/s11095-011-0416-7
   Bansal R, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-019-2690-8
   Bansal R, 2017, BIOCONJUGATE CHEM, V28, P2549, DOI 10.1021/acs.bioconjchem.7b00389
   Bukofzer Stan, 2015, PDA J Pharm Sci Technol, V69, P123, DOI 10.5731/pdajpst.2015.01037
   Chi EY, 2003, PHARM RES-DORDR, V20, P1325, DOI 10.1023/A:1025771421906
   Cromwell MEM, 2006, AAPS J, V8, pE572, DOI 10.1208/aapsj080366
   Giri R, 2012, P NATL ACAD SCI USA, V109, P17772, DOI 10.1073/pnas.1201794109
   Goswami S, 2013, ANTIBODIES, V2, P452, DOI 10.3390/antib2030452
   Guttman A, 2012, LC GC N AM, V30, P412
   Hari SB, 2010, BIOCHEMISTRY-US, V49, P9328, DOI 10.1021/bi100841u
   Huang CT, 2009, J PHARM SCI-US, V98, P3058, DOI 10.1002/jps.21575
   Joshi V, 2014, ANAL CHEM, V86, P11606, DOI 10.1021/ac503140j
   Joshi V, 2014, BIOTECHNOL J, V9, P1195, DOI 10.1002/biot.201400052
   Kendrick BS, 1998, J PHARM SCI, V87, P1069, DOI 10.1021/js9801384
   Lin FB, 2016, COMMUN NONLINEAR SCI, V36, P378, DOI 10.1016/j.cnsns.2015.12.010
   Mahler HC, 2009, J PHARM SCI-US, V98, P2909, DOI 10.1002/jps.21566
   Mendhe R, 2012, LC GC N AM, V30, P52
   Narhi LO, 2012, J PHARM SCI-US, V101, P493, DOI 10.1002/jps.22790
   Nicolaides NC, 2006, DRUG DEVELOP RES, V67, P781, DOI 10.1002/ddr.20149
   Ratanji KD, 2014, J IMMUNOTOXICOL, V11, P99, DOI 10.3109/1547691X.2013.821564
   Rathore AS, 2013, BIOPHARM INT, V26, P40
   Roberts CJ, 2007, BIOTECHNOL BIOENG, V98, P927, DOI 10.1002/bit.21627
   Roberts CJ, 2013, J PHARM SCI-US, V102, P3556, DOI 10.1002/jps.23668
   Roberts D, 2015, MOL PHARMACEUT, V12, P179, DOI 10.1021/mp500533c
   RUBINSTEIN M, 2003, POLYM PHYS
   Singh R., 2017, BIOPHYS J, V112
   Singla A, 2016, AAPS J, V18, P689, DOI 10.1208/s12248-016-9887-0
   Tovey MG, 2011, THER ADV DRUG SAF, V2, P113, DOI 10.1177/2042098611406318
   Wang W, 2010, AGGREGATION THERAPEU
   Wang W, 2010, INT J PHARMACEUT, V390, P89, DOI 10.1016/j.ijpharm.2010.02.025
   Weiss WF, 2009, J PHARM SCI-US, V98, P1246, DOI 10.1002/jps.21521
   Wynn EJW, 1997, CHEM ENG SCI, V52, P733, DOI 10.1016/S0009-2509(96)00448-4
   Zbacnik T.J., 2017, J PHARM SCI
NR 35
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115479
DI 10.1016/j.ces.2020.115479
PG 9
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300011
DA 2020-05-12
ER

PT J
AU Blondeau, J
   Coppieters, T
   Mercier, FAG
AF Blondeau, J.
   Coppieters, T.
   Mercier, F. A. G.
TI A semi-empirical method to quantify the impact of mass transfer on
   lab-scale SCR deNOx catalyst activity testing
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Catalyst; deNOx; Activity; Mass transfer
ID TRANSFER CONTROLLED REGIME; TRANSFER COEFFICIENTS; TURBULENT PIPE; HEAT;
   OXIDATION
AB Industrial denitrification catalyst monoliths are regularly tested in controlled lab-scale conditions to quantify their activity. As mass transfer phenomena occurring inside the channels of the monoliths have an important impact on the global denitrification kinetics, activity measurements must be conducted in well-known conditions in terms of sample geometry and gaseous flow regimes, among others. The lack of accurate mass transfer correlations for the complex flows at stake however prevents any accurate generalisation of the test results. In this paper, we propose a semi-empirical method for the quantification of contribution of mass transfer to the global denitrification kinetics for any given test bench. It is based on the experimental adjustment of mass transfer correlations presenting a suitable form. Mass transfer can therefore be decoupled from the intrinsic kinetics and large ranges of conditions can be covered by conducting a limited number of measurements. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Blondeau, J.; Coppieters, T.] Vrije Univ Brussel, Fac Engn, Thermo & Fluid Dynam FLOW, Pl Laan 2, B-1050 Brussels, Belgium.
   [Blondeau, J.; Coppieters, T.] Vrije Univ Brussel, Combust & Robust Optimizat BURN, Brussels, Belgium.
   [Blondeau, J.; Coppieters, T.] Univ Libre Bruxelles, Brussels, Belgium.
   [Mercier, F. A. G.] Engie Laborelec, Rodestr 125, B-1630 Linkebeek, Belgium.
RP Blondeau, J (reprint author), Vrije Univ Brussel, Fac Engn, Thermo & Fluid Dynam FLOW, Pl Laan 2, B-1050 Brussels, Belgium.; Blondeau, J (reprint author), Univ Libre Bruxelles, Brussels, Belgium.
EM julien.blondeau@vub.be
CR Argyle MD, 2015, CATALYSTS, V5, P145, DOI 10.3390/catal5010145
   Balakotaiah V, 2002, CHEM ENG SCI, V57, P1269, DOI 10.1016/S0009-2509(02)00059-3
   Fogler H., 2006, ELEMENT CHEM REACTIO
   Gbadebo SA, 1999, HEAT MASS TRANSFER, V35, P377, DOI 10.1007/s002310050339
   GNIELINSKI V, 1976, INT CHEM ENG, V16, P359
   Gu T, 2016, CHEM ENG J, V284, P513, DOI 10.1016/j.cej.2015.09.005
   Gundlapally SR, 2011, CHEM ENG SCI, V66, P1879, DOI 10.1016/j.ces.2011.01.045
   Gupta N, 2001, CHEM ENG SCI, V56, P4771, DOI 10.1016/S0009-2509(01)00134-8
   Hawthorn R. D., 1974, AICHE S SERIES 137, V70, P428
   Henry X., 2018, 73 INDONESIA NATL EL
   Holmgren A, 1998, CHEM ENG SCI, V53, P2285, DOI 10.1016/S0009-2509(98)00080-3
   Lecompte T., 2017, TECH REP
   Muzio L., 2007, TECH REP
   Schwammle T, 2013, CHEM ENG J, V222, P274, DOI 10.1016/j.cej.2013.02.057
   Shah RK, 1978, LAMINAR FLOW FORCED
   Strom H, 2012, CHEM ENG SCI, V83, P128, DOI 10.1016/j.ces.2011.10.070
   Strom H, 2011, IND ENG CHEM RES, V50, P3194, DOI 10.1021/ie102291t
   Tang MJ, 2014, ATMOS CHEM PHYS, V14, P9233, DOI 10.5194/acp-14-9233-2014
   Tanno K, 2013, ADV POWDER TECHNOL, V24, P879, DOI 10.1016/j.apt.2013.05.003
   Tanno K, 2010, FUEL, V89, P855, DOI 10.1016/j.fuel.2009.03.028
   TRONCONI E, 1992, CHEM ENG SCI, V47, P2401, DOI 10.1016/0009-2509(92)87067-Z
   Tronconi E, 1999, CATAL TODAY, V52, P249, DOI 10.1016/S0920-5861(99)00079-6
   Uberoi M, 1996, IND ENG CHEM RES, V35, P113, DOI 10.1021/ie9501790
   und Chemieingenieurwesen V.-G. V., 2010, VDI HEAT ATLAS
   VGB, 1998, TECH REP
   West DH, 2003, CATAL TODAY, V88, P3, DOI 10.1016/j.cattod.2003.08.002
NR 26
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115457
DI 10.1016/j.ces.2019.115457
PG 10
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300003
DA 2020-05-12
ER

PT J
AU Chen, Y
   Muller, CR
AF Chen, Y.
   Mueller, C. R.
TI Gas-solid heat transfer in assemblies of cubes for Re-V <= 100
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Thermal lattice Boltzmann method; Heat transfer; Super-quadric cubes;
   Nusselt number
ID DIRECT NUMERICAL-SIMULATION; DRAG FORCE CORRELATION; PARTICULATE
   SUSPENSIONS; ELLIPSOIDAL PARTICLES; TRANSFER COEFFICIENTS; BIDISPERSE
   ARRAYS; CUBIC PARTICLES; VOLUME FRACTION; PACKED-BEDS; FLOW
AB The thermal lattice Boltzmann method using an immersed moving boundary condition was employed to calculate the particle-to-fluid heat transfer in an assembly of super-quadric cubes. The simulations were performed for Reynolds numbers 1-100 (based on the volume equivalent diameter) and solid volume fractions phi = 0.1-0.45. The simulation results show that the Nusselt numbers for assemblies of superquadric cubes are larger than those for assemblies of spheres, in particular for high solid volume fractions. A relationship between the average Nusselt number and the drag force (Chen & Muller, 2018) for assemblies of cubes was developed. It was found that the average drag force acting on cubes increases faster with increasing solid volume fraction than the average Nusselt number. Defining the Reynolds number and the Nusselt number using the hydraulic diameter of the packing system (Re-h) and the Sauter diameter of the cube, respectively, the Nusselt number correlation of Chen & Muller (2019), that was proposed for assemblies of spheres, can be applied for assemblies of non-spherical particles. We also demonstrate that the proposed Nusselt number correlation predicts well the heat transfer between a gas and ellipsoidal or cylindrical particles. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Chen, Y.; Mueller, C. R.] Swiss Fed Inst Technol, Lab Energy Sci & Engn, Dept Mech & Proc Engn, Leonhardstr 21, CH-8092 Zurich, Switzerland.
RP Muller, CR (reprint author), Swiss Fed Inst Technol, Lab Energy Sci & Engn, Dept Mech & Proc Engn, Leonhardstr 21, CH-8092 Zurich, Switzerland.
EM muelchri@ethz.ch
FU China Scholarship CouncilChina Scholarship Council; Swiss National
   Science FoundationSwiss National Science Foundation (SNSF) [182692]
FX The authors are grateful to the China Scholarship Council (Yong Chen)
   and the Swiss National Science Foundation (182692) for the partial
   financial support of this work.
CR Aidun CK, 1998, J FLUID MECH, V373, P287, DOI 10.1017/S0022112098002493
   Balachandar S, 2001, PHYS FLUIDS, V13, P3714, DOI 10.1063/1.1416886
   Beetstra R, 2007, AICHE J, V53, P489, DOI 10.1002/aic.11065
   Bird R.B., 1960, TRANSPORT PHENOMENA
   Chen Y, 2020, INT J MULTIPHAS FLOW, V123, DOI 10.1016/j.ijmultiphaseflow.2019.103184
   Chen Y, 2019, CHEM ENG J, V361, P1392, DOI 10.1016/j.cej.2018.10.182
   Chen Y, 2018, CHEM ENG SCI, V192, P1157, DOI 10.1016/j.ces.2018.08.027
   Chen Y, 2015, CHEM ENG SCI, V123, P146, DOI 10.1016/j.ces.2014.10.002
   Dan C, 2010, INT J HEAT FLUID FL, V31, P1050, DOI 10.1016/j.ijheatfluidflow.2010.07.007
   Das S, 2018, CHEM ENG SCI, V183, P260, DOI 10.1016/j.ces.2018.03.022
   Deen NG, 2012, CHEM ENG SCI, V81, P329, DOI 10.1016/j.ces.2012.06.055
   FRENKEL D, 1996, UNDERSTANDING MOL SI
   Guardo A, 2006, CHEM ENG SCI, V61, P4341, DOI 10.1016/j.ces.2006.02.011
   GUNN DJ, 1978, INT J HEAT MASS TRAN, V21, P467, DOI 10.1016/0017-9310(78)90080-7
   He L, 2017, INT J HEAT MASS TRAN, V114, P324, DOI 10.1016/j.ijheatmasstransfer.2017.06.068
   INCROPERA F, 1990, INTRO HEAT TRANSFER
   Kravets B, 2019, POWDER TECHNOL, V345, P438, DOI 10.1016/j.powtec.2019.01.028
   LADD AJC, 1994, J FLUID MECH, V271, P311, DOI 10.1017/S0022112094001783
   Municchi F, 2017, INT J HEAT MASS TRAN, V111, P171, DOI 10.1016/j.ijheatmasstransfer.2017.03.122
   Nsofor EC, 2001, EXP THERM FLUID SCI, V24, P1, DOI 10.1016/S0894-1777(00)00047-9
   Richter A, 2012, INT J HEAT MASS TRAN, V55, P1343, DOI 10.1016/j.ijheatmasstransfer.2011.09.005
   Singhal A, 2017, CHEM ENG SCI, V172, P1, DOI 10.1016/j.ces.2017.06.003
   Sun B, 2015, INT J HEAT MASS TRAN, V86, P898, DOI 10.1016/j.ijheatmasstransfer.2015.03.046
   Tavassoli H, 2015, CHEM ENG SCI, V129, P42, DOI 10.1016/j.ces.2015.02.024
   Tavassoli H, 2013, INT J MULTIPHAS FLOW, V57, P29, DOI 10.1016/j.ijmultiphaseflow.2013.06.009
   Tavassoli H., 2014, THESIS
   Tenneti S, 2013, INT J HEAT MASS TRAN, V58, P471, DOI 10.1016/j.ijheatmasstransfer.2012.11.006
   Van der Hoef MA, 2005, J FLUID MECH, V528, P233, DOI 10.1017/S0022112004003295
   WAKAO N, 1979, CHEM ENG SCI, V34, P325, DOI 10.1016/0009-2509(79)85064-2
   Yang J, 2012, CHEM ENG SCI, V71, P126, DOI 10.1016/j.ces.2011.12.005
   Yang J, 2010, CHEM ENG SCI, V65, P726, DOI 10.1016/j.ces.2009.09.026
   Zhu LT, 2019, CHEM ENG J, V374, P531, DOI 10.1016/j.cej.2019.05.194
NR 32
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115478
DI 10.1016/j.ces.2020.115478
PG 9
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300010
DA 2020-05-12
ER

PT J
AU Cui, JF
   Wu, KL
AF Cui, Jiangfeng
   Wu, Keliu
TI Equivalent permeability of shale rocks: Simple and accurate empirical
   coupling of organic and inorganic matter
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Equivalent permeability; Shale; Organic; Inorganic; Couple
ID TRIASSIC YANCHANG FORMATION; APPARENT PERMEABILITY; GAS-TRANSPORT;
   LIQUID PERMEABILITY; OIL TRANSPORT; MODEL; RESERVOIRS; NANOPORES;
   POROSITY; MECHANISMS
AB Coupling the organic/inorganic permeabilities in shale is fundamental. Simple treatments, including the arithmetic/geometric average methods, are problematic and can lead to large errors. More complicated methods can generate reasonable results but are much more expensive. In this work, a simple and accurate empirical model for the equivalent permeability of shale considering permeability contrast between organic and inorganic matter and TOC is established. Geometric explanation of the parameters in the model is also provided. Afterwards, model validation against numerical data demonstrates the accuracy of the model in all realistic scenarios. Moreover, model comparison with arithmetic/geometric average methods shows the superiority of the model in accurate calculation while keeping the form simple. Finally, the model is applied to liquid flow in shale, and the results are analyzed. The model is highly recommended for theoretical studies in shale gas/oil that need coupling of the organic and inorganic permeabilities, including single-phase and multi-phase flows. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Cui, Jiangfeng; Wu, Keliu] China Univ Petr, State Key Lab Petr Resources & Prospecting, Beijing 102249, Peoples R China.
RP Cui, JF (reprint author), China Univ Petr, State Key Lab Petr Resources & Prospecting, Beijing 102249, Peoples R China.
EM cuijiangfeng_pascal@126.com
RI ; Wu, Keliu/F-8287-2016
OI Cui, Jiangfeng/0000-0002-7397-2041; Wu, Keliu/0000-0002-0021-5007
FU Beijing Natural Science Foundation of ChinaBeijing Natural Science
   Foundation [2204093]
FX The authors would like to acknowledge the financial support of Beijing
   Natural Science Foundation of China (No. 2204093).
CR Akkutlu IY, 2012, SPE J, V17, P1002, DOI 10.2118/146422-PA
   Alfi M, 2015, J NAT GAS SCI ENG, V26, P1495, DOI 10.1016/j.jngse.2015.08.002
   Chen C, 2013, GEOCHEM GEOPHY GEOSY, V14, P4066, DOI 10.1002/ggge.20254
   Chen L, 2015, FUEL, V160, P346, DOI 10.1016/j.fuel.2015.07.070
   Cui JF, 2019, J PETROL SCI ENG, V183, DOI 10.1016/j.petrol.2019.106393
   Cui JF, 2019, J PETROL SCI ENG, V178, P640, DOI 10.1016/j.petrol.2019.03.088
   Cui JF, 2018, COMPUTAT GEOSCI, V22, P1083, DOI 10.1007/s10596-018-9739-3
   Cui JF, 2017, FUEL, V202, P426, DOI 10.1016/j.fuel.2017.04.057
   Geng LD, 2016, J NAT GAS SCI ENG, V35, P593, DOI 10.1016/j.jngse.2016.08.033
   Javadpour F, 2015, FUEL, V160, P549, DOI 10.1016/j.fuel.2015.08.017
   Ko-Chiu Wu, 2017, 2017 Pacific Neighborhood Consortium Annual Conference and Joint Meetings (PNC). Proceedings, P1, DOI 10.23919/PNC.2017.8203526
   Naraghi ME, 2015, INT J COAL GEOL, V140, P111, DOI 10.1016/j.coal.2015.02.004
   NEALE GH, 1973, SOC PETROL ENG J, V13, P69, DOI 10.2118/3812-PA
   Ross DJK, 2009, MAR PETROL GEOL, V26, P916, DOI 10.1016/j.marpetgeo.2008.06.004
   Sang GJ, 2016, J NAT GAS SCI ENG, V32, P423, DOI 10.1016/j.jngse.2016.04.044
   Sheng GL, 2018, INT J HEAT MASS TRAN, V120, P56, DOI 10.1016/j.ijheatmasstransfer.2017.12.014
   Sheng GL, 2015, J NAT GAS SCI ENG, V27, P1562, DOI 10.1016/j.jngse.2015.10.026
   Singh H, 2019, TRANSPORT POROUS MED, V126, P527, DOI 10.1007/s11242-018-1073-7
   Song WH, 2016, FUEL, V181, P973, DOI 10.1016/j.fuel.2016.05.011
   Sun Z, 2019, CHEM ENG SCI, V199, P199, DOI 10.1016/j.ces.2019.01.013
   Sun Z, 2018, INT J HEAT MASS TRAN, V126, P1007, DOI 10.1016/j.ijheatmasstransfer.2018.05.078
   Sun Z, 2017, INT J HEAT MASS TRAN, V115, P1008, DOI 10.1016/j.ijheatmasstransfer.2017.07.123
   Wang H, 2019, J PETROL SCI ENG, V176, P1041, DOI 10.1016/j.petrol.2019.02.027
   Wang JJ, 2016, FUEL, V181, P478, DOI 10.1016/j.fuel.2016.05.032
   Wang Q, 2019, CHEM ENG SCI, V198, P62, DOI 10.1016/j.ces.2018.12.042
   Wang S, 2016, FUEL, V171, P74, DOI 10.1016/j.fuel.2015.12.071
   Wang S, 2018, J NAT GAS SCI ENG, V55, P508, DOI 10.1016/j.jngse.2018.05.026
   Wang SH, 2017, J NAT GAS SCI ENG, V48, P13, DOI 10.1016/j.jngse.2017.06.009
   Yan BC, 2018, J PETROL SCI ENG, V160, P498, DOI 10.1016/j.petrol.2017.10.081
   Yan BC, 2016, COMPUTAT GEOSCI, V20, P69, DOI 10.1007/s10596-015-9548-x
   Yang H, 2016, PETROL EXPLOR DEV+, V43, P560, DOI 10.1016/S1876-3804(16)30066-0
   Yang YF, 2019, FUEL, V251, P683, DOI 10.1016/j.fuel.2019.03.083
   Yao JL, 2013, PETROL EXPLOR DEV+, V40, P161, DOI 10.1016/S1876-3804(13)60019-1
   Zhang M, 2015, J NAT GAS SCI ENG, V24, P252, DOI 10.1016/j.jngse.2015.03.032
   Zhang Q, 2018, INT J HEAT MASS TRAN, V125, P845, DOI 10.1016/j.ijheatmasstransfer.2018.04.129
   Zhang Q, 2017, INT J HEAT MASS TRAN, V115, P224, DOI 10.1016/j.ijheatmasstransfer.2017.08.024
   Zhang T, 2018, CHEM ENG SCI, V187, P280, DOI 10.1016/j.ces.2018.05.016
   Zou CN, 2013, PETROL EXPLOR DEV+, V40, P15, DOI 10.1016/S1876-3804(13)60002-6
NR 38
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115491
DI 10.1016/j.ces.2020.115491
PG 9
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300014
DA 2020-05-12
ER

PT J
AU Gu, YW
   Li, YY
   Zhang, JX
   Zhang, HY
   Wu, CH
   Lin, J
   Zhou, JY
   Fan, YH
   Murugadoss, V
   Guo, ZH
AF Gu, Yongwan
   Li, Yunyan
   Zhang, Jiaoxia
   Zhang, Huiying
   Wu, Chunhua
   Lin, Jing
   Zhou, Juying
   Fan, Yuhang
   Murugadoss, Vignesh
   Guo, Zhanhu
TI Effects of pretreated carbon supports in Pd/C catalysts on rosin
   disproportionation catalytic performance
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Rosin; Disproportionation; Pd/C; Activated carbon support; Drying
   process
ID SURFACE-CHEMISTRY; ACTIVATED CARBON; THERMAL-DECOMPOSITION; COMPOSITES;
   ADSORPTION; HYDROGEN; ACID
AB Pd/C catalysts were prepared by an incipient-wetness impregnation and their catalytic performance in disproportionation of rosin was investigated. The texture structure, groups on the activated carbon surfaces, and acidity were characterized by N-2 physisorption-desorption, Fourier transform infrared spectroscopy (FTIR), and temperature-programmed desorption (TPD). The Pd/AC3 (treated at 443 K) had the highest Pd dispersion (23.60%) with the highest specific surface area of activated carbon (1057 m(2)/g). Nevertheless, the Pd/AC0 (original carbon black) had the lowest Pd dispersion (13.07%) with a lower specific surface area of original activated carbon (994 m(2)/g). Pd/AC3 presented a considerable catalytic activity in the rosin disproportionation reaction, with 64.15% dehydroabietic acid and without abietic acid in product. However, Pd/AC0 (Pd supported on the original carbon) showed a much lower catalytic activity in the rosin disproportionation reaction, with 42.64% dehydroabietic acid and 3.59% abietic acid in product. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Gu, Yongwan; Li, Yunyan] Kunming Inst Precious Met, Kunming 650106, Yunnan, Peoples R China.
   [Zhang, Jiaoxia] Jiangsu Univ Sci & Technol, Sch Mat Sci & Engn, Zhenjiang 212003, Peoples R China.
   [Lin, Jing] Guangzhou Univ, Sch Chem & Chem Engn, Guangzhou 510006, Peoples R China.
   [Zhang, Huiying] Yunnan Agr Univ, Water Conservancy Coll, Kunming 650201, Yunnan, Peoples R China.
   [Wu, Chunhua; Fan, Yuhang] Southwest Forestry Univ, Sch Chem Engn, Kunming 650224, Yunnan, Peoples R China.
   [Zhou, Juying] Guangxi Univ Nationalities, Guangxi Key Lab Chem & Engn Forest Prod, Nanning 53006, Peoples R China.
   [Murugadoss, Vignesh] Zhengzhou Univ, Key Lab Mat Proc & Mold, Natl Engn Res Ctr Adv Polymer Proc Technol, Minist Educ, Zhengzhou, Peoples R China.
   [Zhang, Jiaoxia; Murugadoss, Vignesh; Guo, Zhanhu] Univ Tennessee, Dept Chem & Biomol Engn, Integrated Composites Lab, Knoxville, TN 37996 USA.
RP Lin, J (reprint author), Guangzhou Univ, Sch Chem & Chem Engn, Guangzhou 510006, Peoples R China.; Zhang, HY (reprint author), Yunnan Agr Univ, Water Conservancy Coll, Kunming 650201, Yunnan, Peoples R China.; Wu, CH (reprint author), Southwest Forestry Univ, Sch Chem Engn, Kunming 650224, Yunnan, Peoples R China.; Guo, ZH (reprint author), Univ Tennessee, Dept Chem & Biomol Engn, Integrated Composites Lab, Knoxville, TN 37996 USA.
EM 360662697@qq.com; kmwuchunhua@163.com; linjing@gzhu.edu.cn;
   zguo10@utk.edu
RI Murugadoss, Vignesh/O-7754-2018; Guo, Zhanhu/L-2164-2015
OI Murugadoss, Vignesh/0000-0001-7817-4113; Guo, Zhanhu/0000-0003-0134-0210
FU 13th Five-Year Plan of National Key R&D Projects of China
   [2018YFD0600401]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China [51964032, 31060099]; Specific
   research project of Guangxi for research bases and talents [AD18126005]
FX This work was financially supported by the 13th Five-Year Plan of
   National Key R&D Projects of China (No. 2018YFD0600401), National
   Natural Science Foundation of China (No. 51964032, No. 31060099),
   Specific research project of Guangxi for research bases and talents
   (AD18126005).
CR Aksoylu AE, 2001, CARBON, V39, P175, DOI 10.1016/S0008-6223(00)00102-0
   Auer E, 1998, APPL CATAL A-GEN, V173, P259, DOI 10.1016/S0926-860X(98)00184-7
   Auer E., 2010, APPL CATAL A, V30
   Biniak S, 1999, LANGMUIR, V15, P6117, DOI 10.1021/la9815704
   BOEHM HP, 1994, CARBON, V32, P759, DOI 10.1016/0008-6223(94)90031-0
   Cabiac A, 2007, CARBON, V45, P3, DOI 10.1016/j.carbon.2006.08.016
   Calo JM, 1997, CARBON, V35, P543, DOI 10.1016/S0008-6223(96)00173-X
   Calvo L, 2006, APPL CATAL B-ENVIRON, V67, P68, DOI 10.1016/j.apcatb.2006.04.016
   Souto JC, 2011, BIORESOURCE TECHNOL, V102, P3504, DOI 10.1016/j.biortech.2010.11.022
   Chingombe P, 2005, CARBON, V43, P3132, DOI 10.1016/j.carbon.2005.06.021
   Cordero T, 2002, IND ENG CHEM RES, V41, P6042, DOI 10.1021/ie020210f
   Domingo-Garcia M, 2002, J COLLOID INTERF SCI, V248, P116, DOI 10.1006/jcis.2001.8207
   Dong MY, 2018, POLYMER, V158, P381, DOI 10.1016/j.polymer.2018.11.003
   Enos Jr H.I., 1968, KIRK OTHMER ENCY CHE, V17, P475
   Figueiredo JL, 1999, CARBON, V37, P1379, DOI 10.1016/S0008-6223(98)00333-9
   Fonseca T, 2004, BIOORGAN MED CHEM, V12, P103, DOI 10.1016/j.bmc.2003.10.013
   Guo Y., 2019, ADV COMPOS HYBRID MA, V2, P681
   He YX, 2020, APPL SURF SCI, V506, DOI 10.1016/j.apsusc.2019.144946
   He YX, 2019, MACROMOL MATER ENG, V304, DOI 10.1002/mame.201900166
   He YX, 2018, COMPOS PART A-APPL S, V108, P12, DOI 10.1016/j.compositesa.2018.02.014
   Li JY, 2005, IND ENG CHEM RES, V44, P5478, DOI 10.1021/ie0488896
   Li YC, 2020, POLYMER, V190, DOI 10.1016/j.polymer.2020.122198
   Lou CQ, 2020, INT J BIOL MACROMOL, V149, P1130, DOI 10.1016/j.ijbiomac.2020.01.248
   Lou CQ, 2019, J MATER RES, V34, P2964, DOI 10.1557/jmr.2019.248
   Ma LN, 2019, 2019 INTERNATIONAL CONFERENCE ON ARTS, MANAGEMENT, EDUCATION AND INNOVATION (ICAMEI 2019), P176, DOI 10.23977/icamei.2019.033
   Moreno-Castilla C, 1997, CARBON, V35, P1619, DOI 10.1016/S0008-6223(97)00121-8
   Rodriguez-Reinoso F, 1998, CARBON, V36, P159, DOI 10.1016/S0008-6223(97)00173-5
   ROMANMARTINEZ MC, 1995, CARBON, V33, P3, DOI 10.1016/0008-6223(94)00096-I
   Szymanski GS, 2002, CARBON, V40, P2627, DOI 10.1016/S0008-6223(02)00188-4
   Wei HG, 2020, J ALLOY COMPD, V820, DOI 10.1016/j.jallcom.2019.153111
   Wu NN, 2019, CARBON, V145, P433, DOI 10.1016/j.carbon.2019.01.028
   Yuvaraj S, 2003, J PHYS CHEM B, V107, P1044, DOI 10.1021/jp026961c
   Zhang C., 2019, ENG SCI, V8, P39, DOI [10.30919/es8d516, DOI 10.30919/ES8D516]
   ZHANG HP, 1990, CARBON, V28, P657, DOI 10.1016/0008-6223(90)90066-8
   Zhang YD, 2019, J MATER CHEM A, V7, P19668, DOI 10.1039/c9ta06734e
   Zheng YW, 2020, POLYMERS-BASEL, V12, DOI 10.3390/polym12010045
   Zheng YW, 2020, POLYM ADVAN TECHNOL, V31, P527, DOI 10.1002/pat.4793
NR 37
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115588
DI 10.1016/j.ces.2020.115588
PG 8
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300026
DA 2020-05-12
ER

PT J
AU Guo, WB
   Cheng, J
   Song, YM
   Kumar, S
   Ali, KA
   Wang, YG
   Li, X
   Yang, WJ
AF Guo, Wangbiao
   Cheng, Jun
   Song, Yanmei
   Kumar, Santosh
   Ali, Kubar Ameer
   Wang, Yangang
   Li, Xi
   Yang, Weijuan
TI Improving flashing light frequency and CO2 fixation rate with vortex
   movement of algal cells in raceway pond with conic baffles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Algal cell; CO2 fixation; Flashing light frequency; Particle movement;
   Turbulent intensity
ID CARBON-DIOXIDE; MICROALGAE CULTIVATION; BIOMASS PRODUCTION; GROWTH;
   PHOTOBIOREACTOR; PRODUCTIVITY; ENERGY; CYCLE; CYANOBACTERIA; TEMPERATURE
AB The inefficiency of the flashing light effect is one of the major obstacles to CO2 fixation by microalgae. To improve the flashing light frequency of Chlorella vulgaris in a raceway pond with alternatively permutated conic baffles (RWP-APCB), the detailed vortex structures of algal cell movement were clarified and optimised. Numerical simulation results showed that the peak vortex intensity occurred in the centre of the APCB, whereas the peak solution velocity occurred in the middle of the baffle spacing. The vortex diameter was mainly affected by the relative spacing of the conic baffles, whereas the vortex centre was mainly affected by their relative height. Optimisation of the relative height and spacing of the RWP-APCB doubled the flashing light frequency of algal cells and increased the light fraction during the light/dark cycle by a factor of 3.1. The CO2 fixation rate of the algal biomass in the RWP-APCB increased by 18.1-3.8 g/L/d. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Guo, Wangbiao; Cheng, Jun; Song, Yanmei; Kumar, Santosh; Ali, Kubar Ameer; Yang, Weijuan] Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Peoples R China.
   [Wang, Yangang; Li, Xi] Jiaxing Univ, Coll Biol Chem Sci & Engn, Jiaxing 314001, Peoples R China.
RP Cheng, J (reprint author), Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Peoples R China.
EM juncheng@zju.edu.cn
OI Yang, Weijuan/0000-0003-4820-7302
FU National Key Research and Development Program of China [2017YFE0122800];
   2018 Zhejiang University Academic Award for Outstanding Doctoral
   Candidates
FX This study was supported by the National Key Research and Development
   Program of China (2017YFE0122800) and the 2018 Zhejiang University
   Academic Award for Outstanding Doctoral Candidates.
CR Abu-Ghosh S, 2016, BIORESOURCE TECHNOL, V203, P357, DOI 10.1016/j.biortech.2015.12.057
   Abu-Ghosh S, 2015, EUR J PHYCOL, V50, P469, DOI 10.1080/09670262.2015.1069404
   Aktas TS, 2012, DESALIN WATER TREAT, V48, P294, DOI 10.1080/19443994.2012.698828
   Baroukh C, 2015, CURR OPIN BIOTECH, V33, P198, DOI 10.1016/j.copbio.2015.03.002
   Bechet Q, 2013, BIOTECHNOL ADV, V31, P1648, DOI 10.1016/j.biotechadv.2013.08.014
   Cheah WY, 2016, APPL ENERG, V179, P609, DOI 10.1016/j.apenergy.2016.07.015
   Chen ZJ, 2016, BIORESOURCE TECHNOL, V219, P387, DOI 10.1016/j.biortech.2016.07.108
   Cheng J, 2018, BIORESOURCE TECHNOL, V261, P76, DOI 10.1016/j.biortech.2018.04.017
   Cheng J, 2018, BIORESOURCE TECHNOL, V249, P212, DOI 10.1016/j.biortech.2017.10.031
   Cheng J, 2015, BIORESOURCE TECHNOL, V190, P29, DOI 10.1016/j.biortech.2015.04.050
   Cheng J, 2013, BIORESOURCE TECHNOL, V136, P496, DOI 10.1016/j.biortech.2013.03.072
   Chiaramonti D, 2013, APPL ENERG, V102, P101, DOI 10.1016/j.apenergy.2012.07.040
   Chisti Yusuf, 2013, Green, V3, P195, DOI 10.1515/green-2013-0018
   Couvert O, 2017, FOOD MICROBIOL, V68, P89, DOI 10.1016/j.fm.2017.07.003
   Falkowski P.G., 2013, AQUATIC PHOTOSYNTHES
   Gibbs M., 1974, P WORKSH BIOS CONV H
   Henning S, 2005, ATMOS CHEM PHYS, V5, P575, DOI 10.5194/acp-5-575-2005
   Huang JK, 2015, ALGAL RES, V10, P64, DOI 10.1016/j.algal.2015.04.012
   Iluz D., 2012, ENHANCEMENT PHOTOSYN
   Jacob A, 2015, APPL ENERG, V148, P396, DOI 10.1016/j.apenergy.2015.03.077
   Jacob-Lopes E, 2009, CHEM ENG PROCESS, V48, P306, DOI 10.1016/j.cep.2008.04.007
   Ji CL, 2017, BIOPROC BIOSYST ENG, V40, P1079, DOI 10.1007/s00449-017-1770-6
   Kopetz H, 2013, NATURE, V494, P29, DOI 10.1038/494029a
   Kwak DH, 2015, WATER SCI TECHNOL, V72, P762, DOI 10.2166/wst.2015.265
   Liu TZ, 2013, BIORESOURCE TECHNOL, V127, P216, DOI 10.1016/j.biortech.2012.09.100
   Mackinder LCM, 2017, CELL, V171, P133, DOI 10.1016/j.cell.2017.08.044
   Ozkan A, 2013, COLLOID SURFACE B, V112, P287, DOI 10.1016/j.colsurfb.2013.08.001
   Perez-Lopez P, 2017, APPL ENERG, V205, P1151, DOI 10.1016/j.apenergy.2017.08.102
   Rosenzweig ESF, 2017, CELL, V171, P148, DOI 10.1016/j.cell.2017.08.008
   Sato T, 2010, ENERG CONVERS MANAGE, V51, P1196, DOI 10.1016/j.enconman.2009.12.030
   Shariff S, 2017, APPL ENERG, V185, P973, DOI 10.1016/j.apenergy.2015.12.033
   Sierra E, 2008, CHEM ENG J, V138, P136, DOI 10.1016/j.cej.2007.06.004
   Slegers PM, 2013, APPL ENERG, V105, P395, DOI 10.1016/j.apenergy.2012.12.068
   Soman A, 2015, APPL ENERG, V140, P246, DOI 10.1016/j.apenergy.2014.11.072
   Wu Xiaonan, 1992, Chinese Journal of Oceanology and Limnology, V10, P135
   Yan C, 2016, APPL ENERG, V178, P9, DOI 10.1016/j.apenergy.2016.06.012
   Yang B, 2017, BIOTECHNOL BIOFUELS, V10, DOI 10.1186/s13068-017-0916-8
   Yang ZB, 2016, BIORESOURCE TECHNOL, V220, P352, DOI 10.1016/j.biortech.2016.08.094
   Yarnold J, 2016, ALGAL RES, V13, P182, DOI 10.1016/j.algal.2015.11.001
   Zhang QH, 2015, BIORESOURCE TECHNOL, V198, P150, DOI 10.1016/j.biortech.2015.08.144
NR 40
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115536
DI 10.1016/j.ces.2020.115536
PG 13
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300021
DA 2020-05-12
ER

PT J
AU Haas, T
   Schubert, C
   Eickhoff, M
   Pfeifer, H
AF Haas, Tim
   Schubert, Christian
   Eickhoff, Moritz
   Pfeifer, Herbert
TI BubCNN: Bubble detection using Faster RCNN and shape regression network
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble detection; Machine learning; Convolutional neural networks; Image
   processing
AB Detailed knowledge about gas-liquid multiphase flows is important to optimize industrial systems. Imaging with image processing is the most commonly used measurement technique. However, the workflow and parameters strongly depend on the experimental conditions and no generally applicable process has been developed yet. Here, a workflow based on convolutional neural networks (CNN) is proposed that can be used with a wider range of experimental conditions. The method, named BubCNN, employs a Faster region-based CNN (RCNN) detector to locate bubbles and a shape regression CNN to predict bubble shape parameters. Hyperparameters and network architectures for both modules were systematically analyzed. BubCNN achieved accurate results for different experimental conditions. A pretrained program was made publicly available on GitHub. Since the whole variety of bubble images was not yet captured in the training data set, an additional semi-automatic transfer learning module is provided that allows to customize BubCNN for different images. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Haas, Tim; Schubert, Christian; Eickhoff, Moritz; Pfeifer, Herbert] Rhein Westfal TH Aachen, Dept Ind Furnaces & Heat Engn, Kopernikusstr 10, D-52074 Aachen, Germany.
RP Haas, T (reprint author), Rhein Westfal TH Aachen, Dept Ind Furnaces & Heat Engn, Kopernikusstr 10, D-52074 Aachen, Germany.
EM haas@iob.rwth-aachen.de
FU German Research Foundation (Deutsche Forschungsgemeinschaft (DFG))German
   Research Foundation (DFG) [RU 2050/2-1]; RWTH Aachen University
   [nova0032]
FX The authors gratefully acknowledge the support from the German Research
   Foundation (Deutsche Forschungsgemeinschaft (DFG)) within the project RU
   2050/2-1. Simulations were performed with computing resources granted by
   RWTH Aachen University under project nova0032. In addition, the authors
   are grateful to Thomas Hay and Ville-Valtteri Visuri for their valuable
   comments on this manuscript.
CR Broder D., 2007, MEASUREMENT SCI TECH, V18, P8
   Clift R., 2005, BUBBLES DROPS PARTIC
   Ferreira A., 2012, CHEM ENG J, P180
   Fu Y., 2016, INT J MULTIPHASE FLO, P84
   Fu YC, 2019, CHEM ENG SCI, V204, P35, DOI 10.1016/j.ces.2019.04.004
   Haas T., 2019, INT C MOD SIM MET PR
   Hukkanen J., 2010, 2010 18 EUR SIGN PRO
   Ilonen J., 2018, PATTERN RECOGN, P204
   Karn A, 2015, CHEM ENG SCI, V122, P240, DOI 10.1016/j.ces.2014.09.036
   Kaur S., 2017, INT J ADV RES COMPUT, V8, P5
   Lau YM, 2013, CHEM ENG SCI, V98, P203, DOI 10.1016/j.ces.2013.05.024
   Poletaev I., 2016, J PHYS C SERIES
   Ren Shaoqing, 2015, ADV NEURAL INFORM PR
   Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y
   Talbot H., 2002, P ISMM2002
   Zafari S., 2016, AS C COMP VIS
   Zafari S, 2015, IEEE T IMAGE PROCESS, V24, P5942, DOI 10.1109/TIP.2015.2492828
NR 17
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115467
DI 10.1016/j.ces.2019.115467
PG 13
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300005
DA 2020-05-12
ER

PT J
AU Halakoo, E
   Feng, XS
AF Halakoo, Elnaz
   Feng, Xianshe
TI Layer-by-layer assembled membranes from graphene oxide and
   polyethyleneimine for ethanol and isopropanol dehydration
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Pervaporation; Graphene oxide; Layer-by-layer assembly; Crosslinking;
   Membrane resistance
ID POLYELECTROLYTE MULTILAYER MEMBRANES; PERVAPORATION SEPARATION;
   COMPOSITE MEMBRANES; ETHYLENE-GLYCOL; NANOFILTRATION MEMBRANE; OSMOSIS
   MEMBRANES; COMPLEX MEMBRANES; HIGH-FLUX; PERFORMANCE; POLYAMIDE
AB Novel thin film composite membranes based on layer-by-layer (LbL) self-assembly of polyethyleneimine (PEI) and graphene oxide (GO) on chlorine-treated polyamide membranes were prepared for pervaporation dehydration of alcohols. To improve the membrane perfoarmance, the self-assembled bilayers were crosslinked with glutaraldehyde. A two-level factorial design was used to determine the effects of the main factors involved in the membrane preparation and their interactions on the permeation flux and separation factor. The impacts of the number of bilayers on the membrane performance were considered to gain an insight into the mass transfer resistance contributed by the bilayers. At 60 degrees C, the crosslinked (PEI/GO) 7 LbL membrane showed a flux of 1770 and 1494 g/m(2) h for ethanol/water and isopropanol/water mixtures, respectively, at 2 wt% water in feed, with a corresponding separation factor of 77 and 197. The long-term stability test showed the feasibility of the crosslinked membranes for alcohol dehydration. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Halakoo, Elnaz; Feng, Xianshe] Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada.
RP Feng, XS (reprint author), Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada.
EM xfeng@uwaterloo.ca
FU Natural Sciences and Engineering Research Council (NSERC) of
   CanadaNatural Sciences and Engineering Research Council of Canada
FX Research support from the Natural Sciences and Engineering Research
   Council (NSERC) of Canada is gratefully acknowledged.
CR Ali MEA, 2016, J MATER CHEM A, V4, P6620, DOI 10.1039/c6ta01460g
   Ang MBMY, 2019, J MEMBRANE SCI, V587, DOI 10.1016/j.memsci.2019.117188
   Bolto B, 2011, CHEM ENG PROCESS, V50, P227, DOI 10.1016/j.cep.2011.01.003
   Chapman PD, 2008, J MEMBRANE SCI, V318, P5, DOI 10.1016/j.memsci.2008.02.061
   Chen Q, 2015, J MEMBRANE SCI, V492, P312, DOI 10.1016/j.memsci.2015.05.068
   Choi W, 2013, ACS APPL MATER INTER, V5, P12510, DOI 10.1021/am403790s
   Decher G, 1997, SCIENCE, V277, P1232, DOI 10.1126/science.277.5330.1232
   DECHER G, 1991, BER BUNSEN PHYS CHEM, V95, P1430, DOI 10.1002/bbpc.19910951122
   Feng XS, 1997, IND ENG CHEM RES, V36, P1048, DOI 10.1021/ie960189g
   Feng XS, 1996, J MEMBRANE SCI, V109, P165, DOI 10.1016/0376-7388(95)00198-0
   Feng XS, 1996, J MEMBRANE SCI, V118, P127
   Halakoo E, 2020, SEP PURIF TECHNOL, V234, DOI 10.1016/j.seppur.2019.116077
   Hu M, 2014, J MEMBRANE SCI, V469, P80, DOI 10.1016/j.memsci.2014.06.036
   Hu M, 2013, ENVIRON SCI TECHNOL, V47, P3715, DOI 10.1021/es400571g
   Hua D, 2017, CHEM ENG SCI, V161, P341, DOI 10.1016/j.ces.2016.12.061
   Huang K, 2017, CURR OPIN CHEM ENG, V16, P56, DOI 10.1016/j.coche.2017.04.009
   HUANG RYM, 1993, SEPAR SCI TECHNOL, V28, P2035, DOI 10.1080/01496399308016732
   HUANG RYM, 1991, J MEMBRANE SCI, V58, P33, DOI 10.1016/S0376-7388(00)80635-3
   Huang RYM, 1998, J APPL POLYM SCI, V70, P317, DOI 10.1002/(SICI)1097-4628(19981010)70:2<317::AID-APP12>3.0.CO;2-0
   Huang RYM, 1999, J MEMBRANE SCI, V160, P17, DOI 10.1016/S0376-7388(99)00074-5
   HUMMERS WS, 1958, J AM CHEM SOC, V80, P1339, DOI 10.1021/ja01539a017
   Hyder MN, 2009, J MEMBRANE SCI, V326, P363, DOI 10.1016/j.memsci.2008.10.017
   ILER RK, 1966, J COLLOID INTERF SCI, V21, P569, DOI 10.1016/0095-8522(66)90018-3
   Kim BS, 2005, MACROMOLECULES, V38, P5214, DOI 10.1021/ma050493y
   Krasemann L, 1998, J MEMBRANE SCI, V150, P23, DOI 10.1016/S0376-7388(98)00212-9
   Krasemann L, 2001, J MEMBRANE SCI, V181, P221, DOI 10.1016/S0376-7388(00)00535-4
   Kusumocahyo SP, 2002, J MEMBRANE SCI, V208, P223, DOI 10.1016/S0376-7388(02)00264-8
   Lai GS, 2016, DESALINATION, V387, P14, DOI 10.1016/j.desal.2016.03.007
   Li D, 2008, NAT NANOTECHNOL, V3, P101, DOI 10.1038/nnano.2007.451
   Liu GP, 2015, CHEM SOC REV, V44, P5016, DOI 10.1039/c4cs00423j
   Liu YX, 2011, J MEMBRANE SCI, V385, P132, DOI 10.1016/j.memsci.2011.09.033
   Mangindaan DW, 2014, J MEMBRANE SCI, V458, P76, DOI 10.1016/j.memsci.2014.01.030
   Marcano DC, 2010, ACS NANO, V4, P4806, DOI 10.1021/nn1006368
   Meier-Haack J, 2001, J MEMBRANE SCI, V184, P233, DOI 10.1016/S0376-7388(00)00618-9
   Moon GY, 1999, J MEMBRANE SCI, V156, P17
   Nunes SP, 2001, MEMBRANE TECHNOLOGY
   Ong YK, 2016, PROG POLYM SCI, V57, P1, DOI 10.1016/j.progpolymsci.2016.02.003
   Onsekizoglu P, 2010, J MEMBRANE SCI, V349, P225, DOI 10.1016/j.memsci.2009.11.049
   Poptoshev E, 2004, LANGMUIR, V20, P829, DOI 10.1021/la035485u
   Qi SR, 2012, J MEMBRANE SCI, V405, P20, DOI 10.1016/j.memsci.2012.02.032
   Qiao XY, 2005, J MEMBRANE SCI, V252, P37, DOI 10.1016/j.memsci.2004.11.014
   Qiu CQ, 2011, J MEMBRANE SCI, V381, P74, DOI 10.1016/j.memsci.2011.07.013
   Semenova SI, 1997, DESALINATION, V110, P251, DOI 10.1016/S0011-9164(97)00103-3
   Shao P, 2007, J MEMBRANE SCI, V287, P162, DOI 10.1016/j.memsci.2006.10.043
   Soice NP, 2004, J MEMBRANE SCI, V243, P345, DOI 10.1016/j.memsci.2004.06.039
   Tian Y, 2013, ADV MATER, V25, P2980, DOI 10.1002/adma.201300118
   Tzeng P, 2015, LANGMUIR, V31, P5919, DOI 10.1021/acs.langmuir.5b00717
   van Ackern F, 1998, THIN SOLID FILMS, V327, P762, DOI 10.1016/S0040-6090(98)00782-2
   Villaluenga JPG, 2005, SEP PURIF TECHNOL, V47, P80, DOI 10.1016/j.seppur.2005.06.006
   Vorayos N, 2006, RENEW ENERG, V31, P2543, DOI 10.1016/j.renene.2006.01.016
   Wang L, 2016, SEP PURIF TECHNOL, V160, P123, DOI 10.1016/j.seppur.2016.01.024
   Wang NX, 2012, CHEM ENG J, V213, P318, DOI 10.1016/j.cej.2012.09.080
   Wu DH, 2015, J MEMBRANE SCI, V493, P622, DOI 10.1016/j.memsci.2015.07.016
   Wu JK, 2019, J MEMBRANE SCI, V577, P104, DOI 10.1016/j.memsci.2019.02.004
   Xia B, 2011, THIN SOLID FILMS, V520, P1120, DOI 10.1016/j.tsf.2011.09.056
   Xu J, 2011, J MEMBRANE SCI, V370, P116, DOI 10.1016/j.memsci.2011.01.001
   Xu YM, 2017, J MEMBRANE SCI, V531, P16, DOI 10.1016/j.memsci.2017.02.041
   Yin J, 2016, DESALINATION, V379, P93, DOI 10.1016/j.desal.2015.11.001
   Zhang GJ, 2007, J MEMBRANE SCI, V292, P1, DOI 10.1016/j.memsci.2006.11.023
   Zhang GJ, 2006, J MEMBRANE SCI, V280, P727, DOI 10.1016/j.memsci.2006.02.031
   Zhang Y, 2013, J MEMBRANE SCI, V444, P22, DOI 10.1016/j.memsci.2013.05.011
   Zhao D, 2018, J MEMBRANE SCI, V567, P311, DOI 10.1016/j.memsci.2018.09.026
   Zhao Q, 2011, J MEMBRANE SCI, V379, P19, DOI 10.1016/j.memsci.2011.06.016
   Zhu ZQ, 2006, MAT SCI ENG C-BIO S, V26, P1, DOI 10.1016/j.msec.2005.03.008
NR 64
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115488
DI 10.1016/j.ces.2020.115488
PG 16
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300012
DA 2020-05-12
ER

PT J
AU Huang, JJ
   Zhong, CR
   Yang, Y
AF Huang, Jingjing
   Zhong, Chuanrong
   Yang, Yan
TI Aggregating thermodynamic behavior of amphiphilic modified Xanthan gum
   in aqueous solution and oil-flooding properties for enhanced oil
   recovery
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Xanthan gum; Micellization; Thermodynamics; Displacement; Nuclear
   magnetic resonance imaging
ID COPOLYMER; POLYMER; POLYACRYLAMIDE
AB Novel chloride-substituted octylphenoxy polyoxyethylene (COP20, polymerization degree: 20) was synthesized. Xanthan gum (XG) was then modified by using COP20 to produce XGP20. XGP20 could be expected to be applied in polymer flooding. Compared with XG, the XGP20 solutions exhibited lower interfacial tensions in additional to higher apparent viscosities and salt-thickening effect. Its critical micelle concentrations (CMC) were 0.3 g/L in water and 5 g/L NaCl at 30 degrees C, and the interface tension was 0.46 mN/m in the saline solution. Large associating structures formed in the XGP20 saline solution. The thermodynamic data of micellization revealed that the micelle formations were spontaneous from 30 to 50 degrees C. Both standard enthalpy and entropy increased clearly with temperature. Compared with XG, the resistance and residual resistance factors were evidently higher in 5.177 g/L salt for XGP20. Nuclear magnetic resonance images showed that the sweep efficiency of water was enhanced significantly after XGP20 polymer flooding. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Zhong, Chuanrong] Chengdu Univ Technol, State Key Lab Oil & Gas Reservoir Geol & Exploita, Chengdu 610059, Sichuan, Peoples R China.
   Chengdu Univ Technol, Coll Energy, Chengdu 610059, Sichuan, Peoples R China.
RP Zhong, CR (reprint author), Chengdu Univ Technol, State Key Lab Oil & Gas Reservoir Geol & Exploita, Chengdu 610059, Sichuan, Peoples R China.
EM zhchrong2006@aliyun.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51674045]; Applied Basic Research Program of
   Sichuan [2019YJ0406]
FX We acknowledge the financial supports of National Natural Science
   Foundation of China (Contract Grant No.: 51674045) and Applied Basic
   Research Program of Sichuan (Contract Grant No.: 2019YJ0406).
CR Ahmadi MA, 2015, FUEL, V159, P15, DOI 10.1016/j.fuel.2015.06.035
   Bao CL, 2009, J POLYM RES, V16, P279, DOI 10.1007/s10965-008-9227-x
   Carrot G, 1997, POLYMER, V38, P6401, DOI 10.1016/S0032-3861(97)00203-6
   Choi J, 2015, MACROMOL RES, V23, P518, DOI 10.1007/s13233-015-3076-3
   Evertsson H, 1999, CARBOHYD POLYM, V40, P293, DOI 10.1016/S0144-8617(99)00065-X
   Ge Z, 2009, J APPL POLYM SCI, V114, P1457, DOI 10.1002/app.30577
   Hong P, 2007, CARBOHYD POLYM, V69, P625, DOI 10.1016/j.carbpol.2007.01.021
   Ji J, 2008, J POLYM SCI POL CHEM, V46, P3098, DOI 10.1002/pola.22659
   Lai NJ, 2014, J APPL POLYM SCI, V131, DOI 10.1002/app.39984
   Li CS, 2011, MICRORNAS IN CANCER TRANSLATIONAL RESEARCH, P309, DOI 10.1007/978-94-007-0298-1_14
   Ma JT, 2002, EUR POLYM J, V38, P1627, DOI 10.1016/S0014-3057(02)00034-4
   Mady MF, 2014, ENERG FUEL, V28, P5714, DOI 10.1021/ef501391g
   Mothe CG, 2006, J THERM ANAL CALORIM, V85, P31, DOI 10.1007/s10973-005-7339-7
   Raffa P, 2016, J PETROL SCI ENG, V145, P723, DOI 10.1016/j.petrol.2016.07.007
   Rashidi M, 2011, J APPL POLYM SCI, V119, P3623, DOI 10.1002/app.33056
   Riahinezhad M, 2017, FUEL, V203, P269, DOI 10.1016/j.fuel.2017.04.122
   Rieger J, 2006, LANGMUIR, V22, P7471, DOI 10.1021/la0602261
   Rosen O, 1998, LANGMUIR, V14, P5795, DOI 10.1021/la971168+
   Sofia GB, 2016, J MACROMOL SCI B, V55, P793, DOI 10.1080/00222348.2016.1207544
   Wang D.R., 1990, CHEMISTRY, V3, P1
   Wang XJ, 2016, COLLOID POLYM SCI, V294, P1333, DOI 10.1007/s00396-016-3898-3
   Xu L, 2013, CARBOHYD POLYM, V92, P516, DOI 10.1016/j.carbpol.2012.09.082
   Yang J, 2001, COLLOID POLYM SCI, V279, P279, DOI 10.1007/s003960000439
   Ye L, 2004, J APPL POLYM SCI, V93, P1175, DOI 10.1002/app.20551
   Zheng Z., 1995, PHYS CHEM PRINCIPLES, P74
   Zhong C., 2018, Patent No. [CN108117868A, 108117868A]
NR 26
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115476
DI 10.1016/j.ces.2020.115476
PG 9
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300008
DA 2020-05-12
ER

PT J
AU Jiang, N
   Yu, XY
   Sheng, YJ
   Zong, RW
   Li, CH
   Lu, SX
AF Jiang, Ning
   Yu, Xiaoyang
   Sheng, Youjie
   Zong, Ruowen
   Li, Changhai
   Lu, Shouxiang
TI Role of salts in performance of foam stabilized with sodium dodecyl
   sulfate
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Foam; Salt effect; Crystal; SDS; Stabilization
ID NONIONIC SURFACTANTS; INTERFACIAL BEHAVIOR; FLUOROCARBON; DRAINAGE;
   SYSTEMS
AB Surface activity, foaming ability, and foam stability of SDS and salts mixtures are experimentally studied. It is shown that adding KCl or CaCl2 can increase the surface activity but decrease the foaming ability of SDS solution. The capacity to stabilize SDS foam decreases as KCl>CaCl2>NaCl. The SDS foam ageing is delayed due to the crystals blocked in the plateau borders and adsorbed on the surface of bubble films. When the SDS concentration is too high, the foam stability rises only if there are enough crystals in the plateau borders. The influence of crystal structure on foam stability has been investigated by using FESEM. The KDS crystals with lower random close-packing density stabilize SDS foam more efficiently than Ca(DS)(2) crystals with higher random close-packing density. The understanding of this study is of great importance for the application of SDS foams in fire extinguishing and upstream petroleum industry. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Jiang, Ning; Yu, Xiaoyang; Zong, Ruowen; Li, Changhai; Lu, Shouxiang] Univ Sci & Technol China, State Key Lab Fire Sci, Hefei 230026, Peoples R China.
   [Sheng, Youjie] Xian Univ Sci & Technol, Coll Safety Sci & Engn, Xian 710054, Peoples R China.
RP Lu, SX (reprint author), Univ Sci & Technol China, State Key Lab Fire Sci, Hefei 230026, Peoples R China.
EM sxlu@ustc.edu.cn
FU Anhui Key Research and Development Plan Project [1804a0802202]; Opening
   Fund of State Key Laboratory of Fire Science [HZ2019KF03]
FX This work was financially supported by the Anhui Key Research and
   Development Plan Project (No. 1804a0802202) and the Opening Fund of
   State Key Laboratory of Fire Science (No. HZ2019KF03). The authors
   sincerely appreciate the support.
CR Bera A, 2017, PETROL SCI, V14, P362, DOI 10.1007/s12182-017-0156-3
   Bera A, 2013, J SURFACTANTS DETERG, V16, P621, DOI 10.1007/s11743-012-1422-4
   Caps H, 2014, COLLOID SURFACE A, V457, P392, DOI 10.1016/j.colsurfa.2014.05.063
   Denkov ND, 2004, LANGMUIR, V20, P9463, DOI 10.1021/la049676o
   Exerowa D, 1998, FOAM FOAM FILMS THEO
   Fameau AL, 2014, CR PHYS, V15, P748, DOI 10.1016/j.crhy.2014.09.009
   Gaillard T, 2015, COLLOID SURFACE A, V473, P68, DOI 10.1016/j.colsurfa.2015.01.089
   Hales TC, 2005, ANN MATH, V162, P1065, DOI 10.4007/annals.2005.162.1065
   Israelachvili JN, 2011, Q REV BIOL, V2, P59, DOI [10.1016/b978-0-12-375182-9.10025-9, DOI 10.1016/B978-0-12-375182-9.10025-9]
   Ivanov IB, 1997, COLLOID SURFACE A, V128, P155, DOI 10.1016/S0927-7757(96)03903-9
   Jiang N, 2018, J MOL LIQ, V268, P249, DOI 10.1016/j.molliq.2018.07.055
   Kumar S, 2017, APPL SURF SCI, V420, P9, DOI 10.1016/j.apsusc.2017.05.126
   Kumar S, 2016, APPL SURF SCI, V372, P42, DOI 10.1016/j.apsusc.2016.03.024
   Louvet N, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.041405
   Malhotra A.K., 1988, THIN LIQUID FILMS
   Martin AH, 2002, J COLLOID INTERF SCI, V254, P175, DOI 10.1006/jcis.2002.8592
   Masaki T, 2002, ECOL STU AN, V158, P53
   MCRAE O, 2017, INT J MULTIPHAS FLOW, V96
   Mitrinova Z, 2016, COLLOID SURFACE A, V489, P378, DOI 10.1016/j.colsurfa.2015.10.034
   Pal N, 2018, CHEM ENG SCI, V187, P200, DOI 10.1016/j.ces.2018.04.062
   Pandey S, 2003, J COLLOID INTERF SCI, V267, P160, DOI 10.1016/j.jcis.2003.06.001
   Pugh RJ, 1996, ADV COLLOID INTERFAC, V64, P67, DOI 10.1016/0001-8686(95)00280-4
   Rad MD, 2018, LANGMUIR, V34, P14274, DOI 10.1021/acs.langmuir.8b01966
   Rio E, 2014, ADV COLLOID INTERFAC, V205, P74, DOI 10.1016/j.cis.2013.10.023
   Safouane M, 2007, LANGMUIR, V23, P11546, DOI 10.1021/la700800a
   Saint-Jalmes A, 2006, SOFT MATTER, V2, P836, DOI 10.1039/b606780h
   Sett S, 2015, ADV COLLOID INTERFAC, V225, P98, DOI 10.1016/j.cis.2015.08.007
   Sheng Y., 2015, J DISPERSION SCI TEC, V37, P1664
   Sheng YJ, 2018, J DISPER SCI TECHNOL, V39, P1266, DOI 10.1080/01932691.2017.1393432
   Sheng YJ, 2016, J SURFACTANTS DETERG, V19, P823, DOI 10.1007/s11743-016-1822-y
   Souilem I, 2012, CHEM ENG TECHNOL, V35, P1692, DOI 10.1002/ceat.201100676
   Speight J.G., 2005, LANGES HDB CHEM
   Stocco A, 2011, SOFT MATTER, V7, P631, DOI 10.1039/c0sm00166j
   Studart AR, 2006, J AM CERAM SOC, V89, P1771, DOI 10.1111/j.1551-2916.2006.01044.x
   Tcholakova S, 2003, LANGMUIR, V19, P5640, DOI 10.1021/la034411f
   Wang GY, 2017, J MOL LIQ, V234, P142, DOI 10.1016/j.molliq.2017.03.059
   Weissenborn PK, 1996, J COLLOID INTERF SCI, V184, P550, DOI 10.1006/jcis.1996.0651
   Zhang H, 2004, J COLLOID INTERF SCI, V279, P539, DOI 10.1016/j.jcis.2004.06.103
   Zhang H, 2003, J COLLOID INTERF SCI, V263, P633, DOI 10.1016/S0021-9797(03)00367-9
   Zhang L., 2017, LANGMUIR, V33
   Zhang L, 2015, ANGEW CHEM INT EDIT, V54, P9533, DOI 10.1002/anie.201503236
NR 41
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115474
DI 10.1016/j.ces.2020.115474
PG 10
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300007
DA 2020-05-12
ER

PT J
AU Kim, D
   Choi, B
   Park, G
   Lee, K
   Lee, DW
   Jung, S
AF Kim, Daesuk
   Choi, Byungchul
   Park, Gyeongho
   Lee, Kyungseok
   Lee, Dong-Weon
   Jung, Seunghun
TI Effect of gamma-Al2O3 characteristics on hydrogen production of
   Cu/gamma-Al2O3 catalyst for steam reforming of dimethyl ether
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrogen; Steam reforming catalyst; Copper; Alumina; Dimethyl ether
ID COMPOSITE CATALYSTS; DME; FUEL; CU; CUO-ZNO-AL2O3; BEHAVIOR; ALUMINA;
   NMR; NI; DEACTIVATION
AB The objective of this study is to investigate the effect of the characteristics of gamma-Al2O3 on hydrogen production and the stability of the Cu/gamma-Al2O3 dimethyl ether steam reforming (SR) catalyst. Cu/gamma-Al2O3 catalysts with various amounts of Cu were prepared by impregnation into gamma-Al2O3 having different surface characteristics. The results demonstrate that the characteristics of the gamma-Al2O3 support greatly affect the hydrogen production performance of the Cu-based/gamma-Al2O3 DME SR catalysts, and that carbon deposition increased with the amount of CO and CH4 that come from oxygenates (DME/MeOH) as coke precursors formed by DME hydrolysis reaction. The concentration of H-2 produced with Cu10/gamma-Al2O3(200) was up to 72%, and it was higher than that of the other catalysts. The BET of Al2O3 affects different coke resistance and durability, in which the lowest BET shows severely deactivation and weak coke resistance compared to BET 140 and 200. Cu10/gamma-Al2O3(200) and (140) catalysts were more durable and stable than Cu10/gamma-Al2O3(70) due to lower carbon deposition on the catalyst surface. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kim, Daesuk; Park, Gyeongho] Chonnam Natl Univ, Dept Mech Engn, 77 Yongbong Ro, Gwangiu 61186, South Korea.
   [Choi, Byungchul; Lee, Dong-Weon; Jung, Seunghun] Chonnam Natl Univ, Sch Mech Engn, 77 Yongbong Ro, Gwangiu 61186, South Korea.
   [Lee, Kyungseok] Chonnam Natl Univ, Automot Res Ctr, 77 Yongbong Ro, Gwangiu 61186, South Korea.
RP Choi, B (reprint author), Chonnam Natl Univ, Sch Mech Engn, 77 Yongbong Ro, Gwangiu 61186, South Korea.
EM bcchoi@jnu.ac.kr
RI Lee, Kyungseok/AAK-1089-2020
OI Lee, Kyungseok/0000-0002-4138-6259
FU Basic Science Research Program through the National Research Foundation
   of South Korea (NRF) - Korea Ministry of Science, ICT & Future Planning
   (MSIP) [NRF-2015R1A4A1041746]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of South Korea (NRF) grant
   funded by the Korea Ministry of Science, ICT & Future Planning (MSIP)
   (Grant NRF-2015R1A4A1041746).
CR Chen XJ, 2017, APPL ENERG, V185, P687, DOI 10.1016/j.apenergy.2016.10.114
   Deng H, 2015, J PHYS CHEM C, V119, P3132, DOI 10.1021/jp5114416
   Deng XQ, 2019, INT J HYDROGEN ENERG, V44, P2417, DOI 10.1016/j.ijhydene.2018.11.072
   Durbin DJ, 2013, INT J HYDROGEN ENERG, V38, P14595, DOI 10.1016/j.ijhydene.2013.07.058
   Elewuwa FA, 2015, INT J HYDROGEN ENERG, V40, P15865, DOI 10.1016/j.ijhydene.2015.10.050
   Erena J, 2013, APPL CATAL B-ENVIRON, V142, P315, DOI 10.1016/j.apcatb.2013.05.034
   Fan FY, 2016, FUEL, V186, P11, DOI 10.1016/j.fuel.2016.08.036
   Faungnawakij K, 2008, J CATAL, V256, P37, DOI 10.1016/j.jcat.2008.02.022
   Fedotov AS, 2018, INT J HYDROGEN ENERG, V43, P7046, DOI 10.1016/j.ijhydene.2018.02.060
   Fukunaga T, 2008, APPL CATAL A-GEN, V348, P193, DOI 10.1016/j.apcata.2008.06.031
   Gayubo AG, 2014, APPL CATAL A-GEN, V483, P76, DOI 10.1016/j.apcata.2014.06.031
   Gonzalez-Gil R, 2016, INT J HYDROGEN ENERG, V41, P19781, DOI 10.1016/j.ijhydene.2016.05.074
   Hwang HT, 2014, CURR OPIN CHEM ENG, V5, P42, DOI 10.1016/j.coche.2014.04.004
   Inagaki R, 2018, INT J HYDROGEN ENERG, V43, P14310, DOI 10.1016/j.ijhydene.2018.05.164
   Jiao Y, 2016, INT J HYDROGEN ENERG, V41, P10473, DOI 10.1016/j.ijhydene.2015.09.151
   Kawabata T, 2006, APPL CATAL A-GEN, V308, P82, DOI 10.1016/j.apcata.2006.04.032
   Kim D, 2017, INT J HYDROGEN ENERG, V42, P29210, DOI 10.1016/j.ijhydene.2017.10.020
   Kwak JH, 2007, J CATAL, V251, P189, DOI 10.1016/j.jcat.2007.06.029
   Ledesma C, 2013, FUEL, V104, P711, DOI 10.1016/j.fuel.2012.06.116
   Ledesma C, 2011, APPL CATAL B-ENVIRON, V101, P690, DOI 10.1016/j.apcatb.2010.11.011
   Lei YQ, 2018, CATAL TODAY, V307, P162, DOI 10.1016/j.cattod.2017.05.072
   Mansouri A, 2014, J HAZARD MATER, V271, P120, DOI 10.1016/j.jhazmat.2014.02.006
   Manzoli M, 2005, APPL CATAL B-ENVIRON, V61, P192, DOI 10.1016/j.apcatb.2005.05.005
   Melkozerova MA, 2018, MENDELEEV COMMUN, V28, P668, DOI 10.1016/j.mencom.2018.11.038
   O'Dell LA, 2007, SOLID STATE NUCL MAG, V31, P169, DOI 10.1016/j.ssnmr.2007.05.002
   Oar-Arteta L, 2016, CHEM ENG J, V306, P401, DOI 10.1016/j.cej.2016.07.075
   Oar-Arteta L, 2016, J IND ENG CHEM, V36, P169, DOI 10.1016/j.jiec.2016.01.030
   Oar-Arteta L, 2014, FUEL PROCESS TECHNOL, V126, P145, DOI 10.1016/j.fuproc.2014.04.028
   Park S, 2012, APPL CATAL A-GEN, V437, P173, DOI 10.1016/j.apcata.2012.06.029
   Park S, 2011, INT J HYDROGEN ENERG, V36, P6422, DOI 10.1016/j.ijhydene.2011.02.124
   Park S, 2011, CATAL TODAY, V164, P240, DOI 10.1016/j.cattod.2010.10.079
   Pu YC, 2019, FUEL, V241, P607, DOI 10.1016/j.fuel.2018.12.067
   Qin Fa-jie, 2017, Journal of Fuel Chemistry and Technology, V45, P1481, DOI 10.1016/S1872-5813(17)30065-8
   Samain L, 2014, J SOLID STATE CHEM, V217, P1, DOI 10.1016/j.jssc.2014.05.004
   Semelsberger TA, 2006, APPL CATAL A-GEN, V309, P210, DOI 10.1016/j.apcata.2006.05.009
   Takeishi K, 2004, APPL CATAL A-GEN, V260, P111, DOI 10.1016/j.apcata.2003.10.006
   Takeishi K, 2016, APPL CATAL A-GEN, V510, P20, DOI 10.1016/j.apcata.2015.09.027
   Tanaka Y, 2005, APPL CATAL B-ENVIRON, V57, P211, DOI 10.1016/j.apcatb.2004.11.007
   Thyssen VV, 2015, J BRAZIL CHEM SOC, V26, P22, DOI 10.5935/0103-5053.20140209
   Turco M, 2007, APPL CATAL B-ENVIRON, V77, P46, DOI 10.1016/j.apcatb.2007.07.006
   Vicente J, 2014, IND ENG CHEM RES, V53, P3462, DOI 10.1021/ie402509c
   Vicente J, 2013, APPL CATAL B-ENVIRON, V130, P73, DOI 10.1016/j.apcatb.2012.10.019
   Vizcaino AJ, 2007, INT J HYDROGEN ENERG, V32, P1450, DOI 10.1016/j.ijhydene.2006.10.024
   ZHANG L, 1995, NANOSTRUCT MATER, V5, P299, DOI 10.1016/0965-9773(95)00245-A
   Zhang QC, 2018, 2018 24TH IEEE INTERNATIONAL CONFERENCE ON AUTOMATION AND COMPUTING (ICAC' 18), P2
   Zhang T, 2018, INT J HYDROGEN ENERG, V43, P13521, DOI 10.1016/j.ijhydene.2018.05.098
   Zhang ZM, 2018, FUEL, V217, P389, DOI 10.1016/j.fuel.2017.12.114
NR 47
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115535
DI 10.1016/j.ces.2020.115535
PG 10
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300020
DA 2020-05-12
ER

PT J
AU Liu, CH
   Ma, XT
   Du, PX
   Rao, ZH
AF Liu, Changhui
   Ma, Xiaotian
   Du, Peixing
   Rao, Zhonghao
TI Fabrication of highly efficient thermal energy storage composite from
   waste polystyrenes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Thermal energy storage; Waste polystyrene; Value-added utilization;
   Hyper-crosslinked; Phase change materials
ID PHASE-CHANGE MATERIAL; EXPANDED POLYSTYRENE; FOAM; PERFORMANCE;
   CONVERSION; POLYMERS; PLASTICS
AB To high value-added utilization of waste polystyrene (PS) foam, an in-situ phase change material (PCM) encapsulation protocol was realized by using waste PS foam as a holding material for thermal energy storage with a shape-stabilization methodology. Mechanistic study suggested that the robust Lewis acid catalysed Friedel-Crafts reaction involved was the key to the success of this method owing to a simultaneous process of porous structure formation and PCM impregnation, by which the PCM encapsulation rate can attain to 68.7% without leakage. Lewis acid catalysts used in the process were able to be converted to their corresponding metal oxides via a simple alkali treatment, which not only diminished the tedious metal species isolation step but also made an external thermal conductivity enhancement that an utmost 61.0% thermal conductivity enhancement can be achieved compared with that of pristine paraffin wax. Additionally, the PCM composite preparation process can be facilely scaled up which strongly demonstrated its real application feasibility. Moreover, besides waste PS foam, other waste PS based materials were proven to be feasible towards PCM holding materials with the same approach. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Rao, Zhonghao] China Univ Min & Technol, Jiangsu Prov Engn Lab High Efficient Energy Stora, Xuzhou 221116, Peoples R China.
   China Univ Min & Technol, Sch Elect & Power Engn, Lab Energy Storage & Heat Transfer, Xuzhou 221116, Peoples R China.
RP Rao, ZH (reprint author), China Univ Min & Technol, Jiangsu Prov Engn Lab High Efficient Energy Stora, Xuzhou 221116, Peoples R China.
EM raozhonghao@cumt.edu.cn
RI Rao, Zhonghao/B-6689-2012
OI Rao, Zhonghao/0000-0003-3350-6270
FU Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [2019XKQYMS69]
FX The authors thanks for the Fundamental Research Funds for the Central
   Universities (No. 2019XKQYMS69).
CR Ager JW, 2018, SCIENCE, V360, P707, DOI 10.1126/science.aat7918
   Alassali A, 2019, J HAZARD MATER, V380, DOI 10.1016/j.jhazmat.2019.120874
   Chaukura N, 2016, RESOUR CONSERV RECY, V107, P157, DOI 10.1016/j.resconrec.2015.10.031
   Chen JC, 2007, FUEL, V86, P2824, DOI 10.1016/j.fuel.2007.03.008
   de Assis GC, 2018, ACS APPL MATER INTER, V10, P8077, DOI 10.1021/acsami.7b19834
   de Paula FGF, 2018, MICROPOR MESOPOR MAT, V267, P181, DOI 10.1016/j.micromeso.2018.03.027
   Eskander SB, 2011, POLYM COMPOSITE, V32, P1430, DOI 10.1002/pc.21171
   Fang GY, 2014, RENEW SUST ENERG REV, V40, P237, DOI 10.1016/j.rser.2014.07.179
   Fonseca WS, 2015, ACS SUSTAIN CHEM ENG, V3, P2153, DOI 10.1021/acssuschemeng.5b00403
   Fu ZY, 2017, CHEM ENG J, V323, P557, DOI 10.1016/j.cej.2017.04.090
   Hahladakis JN, 2019, J HAZARD MATER, V380, DOI 10.1016/j.jhazmat.2019.120887
   Jia JZ, 2019, CHEM ENG RES DES, V142, P346, DOI 10.1016/j.cherd.2018.12.025
   Kenisarin MM, 2012, RENEW SUST ENERG REV, V16, P1999, DOI 10.1016/j.rser.2012.01.015
   Kumar A, 2018, ACS SUSTAIN CHEM ENG, V6, P8034, DOI 10.1021/acssuschemeng.8b01531
   Li BY, 2012, ADV MATER, V24, P3390, DOI 10.1002/adma.201200804
   Liu CH, 2019, J MATER CHEM A, V7, P8194, DOI 10.1039/c9ta01496a
   Liu CZ, 2017, SCI BULL, V62, P231, DOI 10.1016/j.scib.2017.01.019
   Liu CZ, 2017, RSC ADV, V7, P7238, DOI 10.1039/c6ra28056k
   Liu CZ, 2015, NANO ENERGY, V13, P814, DOI 10.1016/j.nanoen.2015.02.016
   Lv PZ, 2019, RENEW ENERG, V131, P911, DOI 10.1016/j.renene.2018.07.102
   Maleki M, 2019, CHEM ENG J, V362, P469, DOI 10.1016/j.cej.2019.01.032
   Mangalara SCH, 2016, ACS SUSTAIN CHEM ENG, V4, P6095, DOI 10.1021/acssuschemeng.6b01493
   Olabi AG, 2017, ENERGY, V136, P1, DOI 10.1016/j.energy.2017.07.054
   Qi GQ, 2015, CARBON, V88, P196, DOI 10.1016/j.carbon.2015.03.009
   Rajaeifar MA, 2017, RENEW SUST ENERG REV, V74, P278, DOI 10.1016/j.rser.2017.02.032
   Ramanan V, 2018, ACS SUSTAIN CHEM ENG, V6, P1627, DOI 10.1021/acssuschemeng.7b02852
   Shadangi KP, 2015, FUEL, V153, P492, DOI 10.1016/j.fuel.2015.03.017
   Shao YF, 2018, MICRO NANO LETT, V13, P998, DOI 10.1049/mnl.2017.0868
   Sun H, 2010, ENVIRON PROG SUSTAIN, V29, P494, DOI 10.1002/ep.10430
   Tan LX, 2017, CHEM SOC REV, V46, P3322, DOI 10.1039/c6cs00851h
   Tang J, 2017, APPL ENERG, V187, P514, DOI 10.1016/j.apenergy.2016.11.043
   Vilela F., 2012, ENERG ENVIRON SCI, P5
   Wu WX, 2019, APPL ENERG, V236, P10, DOI 10.1016/j.apenergy.2018.11.071
   Wu ZJ, 2015, ACS SUSTAIN CHEM ENG, V3, P552, DOI 10.1021/sc500840b
   Yan J, 2019, APPL ENERG, V240, pA1, DOI 10.1016/j.apenergy.2018.03.001
   Yang J., 2018, J MATER SCI, V54, P1197
   Yang J, 2017, NANOSCALE, V9, P17704, DOI 10.1039/c7nr05449a
   Yang SQ, 2018, ACS SUSTAIN CHEM ENG, V6, P4282, DOI 10.1021/acssuschemeng.7b04733
   Yang YW, 2016, J MATER CHEM A, V4, P15072, DOI 10.1039/c6ta05226f
   You CH, 2014, J MATER CHEM A, V2, P12240, DOI 10.1039/c4ta02225d
   Zhang YX, 2018, J MATER SCI, V53, P12115, DOI 10.1007/s10853-018-2513-z
   Zhao XY, 2019, ACS SUSTAIN CHEM ENG, V7, P1464, DOI 10.1021/acssuschemeng.8b05147
   Zhuang GL, 2016, CHEM ENG RES DES, V111, P204, DOI 10.1016/j.cherd.2016.03.033
NR 43
TC 0
Z9 0
U1 8
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115477
DI 10.1016/j.ces.2020.115477
PG 11
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300009
DA 2020-05-12
ER

PT J
AU Liu, Q
   Proust, C
   Gomez, F
   Luart, D
   Len, C
AF Liu, Qi
   Proust, Christophe
   Gomez, Francois
   Luart, Denis
   Len, Christophe
TI The prediction multi-phase, multi reactant equilibria by minimizing the
   Gibbs energy of the system: Review of available techniques and proposal
   of a new method based on a Monte Carlo technique
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Review
DE Global optimization; Gibbs free energy minimization; Monte-Carlo method;
   Thermodynamic equilibrium calculations
ID ISOTHERMAL FLASH PROBLEM; CHEMICAL-EQUILIBRIUM; PHASE-EQUILIBRIUM;
   MOLECULAR DESIGN; BINARY-SYSTEMS; MODEL; OPTIMIZATION; COMPUTATION;
   SIMULATION; ALGORITHM
AB Since already a few decades, researchers developed tools to predict chemical reactions in the context of the chemical industry. Numerical tools are now available to predict final chemical equilibriums using the principle of minimizing the Gibbs free energy of the reactions. In this paper, after recalling some basis on thermochemical equilibria, a brief review of the most renown techniques available to find the minimum of the Gibbs energy is presented. From this, limitations are discussed. Mathematically, the equations are always strongly non-linear, and the standard step by step resolution techniques may fail to find the global minimum. When non-mixed phases are present (solids, for instance), the calculations often fail. An example is given with biphenyl-CO2 mixtures. Especially when many phases are postulated. An alternative resolution method is proposed based on a Monte Carlo method which does not require nor a linearization of the Gibbs equation neither a step by step resolution. The method can solve any multi-phase and any multi-reactant equilibrium but is much more computer resource demanding than the traditional methods. It was implemented in a home-made code (CIRCE) briefly described in Appendix A. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Liu, Qi; Proust, Christophe; Gomez, Francois; Len, Christophe] Univ Technol Compiegne, Sorbonne Univ, Ctr Rech Royallieu, CS60319, F-60203 Compiegne, France.
   [Proust, Christophe] INERIS, Dept DRA, Parc Technol Alata,POB 2, F-60550 Verneuil En Halatte, France.
   [Luart, Denis] Ecole Super Chim Organ & Minerale, 1 Rue Reseau Jean Marie Buckmaster, F-60200 Compiegne, France.
   [Len, Christophe] PSL Univ, Inst Rech Chim, UMR 8247, CNRS,Chim ParisTech, 11 Rue Pierre & Marie Curie, F-75005 Paris, France.
RP Proust, C (reprint author), Univ Technol Compiegne, Sorbonne Univ, Ctr Rech Royallieu, CS60319, F-60203 Compiegne, France.
EM christophe.proust@ineris.fr
CR Bertsekas D. P., 2014, CONSTRAINED OPTIMIZA
   Bonilla-Petriciolet A, 2011, FLUID PHASE EQUILIBR, V300, P120, DOI 10.1016/j.fluid.2010.10.024
   BOUKOUVALAS C, 1994, FLUID PHASE EQUILIBR, V92, P75, DOI 10.1016/0378-3812(94)80043-X
   Brignole EA, 2003, COMP AID CH, V12, P23
   Burgos-Solorzano GI, 2004, FLUID PHASE EQUILIBR, V219, P245, DOI 10.1016/j.fluid.2003.12.013
   Canas-Marin WA, 2006, AICHE J, V52, P2887, DOI 10.1002/aic.10876
   CHEONG PL, 1986, FLUID PHASE EQUILIBR, V29, P555, DOI 10.1016/0378-3812(86)85054-3
   DANTZIG G, 1958, MANAGE SCI, V5, P38, DOI 10.1287/mnsc.5.1.38
   Dantzig GB, 1990, HIST SCI COMPUTING, P141, DOI DOI 10.1145/87252.88081
   Economou IG, 2002, IND ENG CHEM RES, V41, P953, DOI 10.1021/ie0102201
   Edgar T.F., 1999, PROCESS ENG 21 CENTU
   Fermeglia M, 2003, CHEM BIOCHEM ENG Q, V17, P19
   FREDENSLUND A, 1975, AICHE J, V21, P1086, DOI 10.1002/aic.690210607
   GAUTAM R, 1979, AICHE J, V25, P991, DOI 10.1002/aic.690250610
   GAUTAM R, 1979, AICHE J, V25, P999, DOI 10.1002/aic.690250611
   GORDON SR, 1994, PROG HISTOCHEM CYTOC, V28, P1
   Gurkan B, 2010, J PHYS CHEM LETT, V1, P3494, DOI 10.1021/jz101533k
   Hong JD, 2009, IND ENG CHEM RES, V48, P4579, DOI 10.1021/ie801179a
   Jalali F, 1999, COMPUT CHEM ENG, V23, P1319, DOI 10.1016/S0098-1354(99)00294-X
   Kattner UR, 1997, JOM-J MIN MET MAT S, V49, P14, DOI 10.1007/s11837-997-0024-5
   Levy A. V, 1985, NUMERICAL OPTIMIZATI, V1981, P213
   Liang XD, 2014, IND ENG CHEM RES, V53, P14493, DOI 10.1021/ie501993y
   Lim SP, 2013, LECT NOTES COMPUT SC, V7802, P255, DOI 10.1007/978-3-642-36546-1_27
   Masel R. I., 2001, CHEM KINETICS CATALY
   MCHUGH M, 1980, J CHEM ENG DATA, V25, P326, DOI 10.1021/je60087a018
   METROPOLIS N, 1949, J AM STAT ASSOC, V44, P335, DOI 10.2307/2280232
   Meyer C.A., 1996, CALCULATION CHEM PHA
   MICHELSEN ML, 1982, FLUID PHASE EQUILIBR, V9, P1, DOI 10.1016/0378-3812(82)85001-2
   MICHELSEN ML, 1982, FLUID PHASE EQUILIBR, V9, P21, DOI 10.1016/0378-3812(82)85002-4
   MOEBS W D C, 1974, Mathematical Biosciences, V22, P113, DOI 10.1016/0025-5564(74)90087-X
   Moodley K, 2015, COMPUT CHEM ENG, V74, P75, DOI 10.1016/j.compchemeng.2014.12.008
   Morley C., 2005, GASEQ CHEM EQUILIBRI
   National Research Council, 1999, IMP ADV COMP COMM TE
   Oliveira MB, 2011, IND ENG CHEM RES, V50, P2348, DOI 10.1021/ie1013585
   ONGIRO AO, 1995, HEAT RECOV SYST CHP, V15, P105, DOI 10.1016/0890-4332(95)90018-7
   Paz-Garcia JM, 2013, COMPUT CHEM ENG, V58, P135, DOI 10.1016/j.compchemeng.2013.06.013
   PEKNY JF, 1990, COMPUT CHEM ENG, V14, P1009, DOI 10.1016/0098-1354(90)87057-V
   Pereda S, 2010, APPLIED THERMODYNAMICS OF FLUIDS, P433, DOI 10.1039/9781849730983-00433
   Pertsinidis A, 1998, COMPUT CHEM ENG, V22, pS205, DOI 10.1016/S0098-1354(98)00056-8
   Plus A., 2009, VERSION 11
   Rangaiah GP, 2001, FLUID PHASE EQUILIBR, V187, P83, DOI 10.1016/S0378-3812(01)00528-3
   REYNOLDS G, 1986, MYTHLORE, P3
   Rossi CCRS, 2009, FLUID PHASE EQUILIBR, V278, P117, DOI 10.1016/j.fluid.2009.01.007
   Shih JS, 1998, EUR J OPER RES, V106, P1, DOI 10.1016/S0377-2217(97)00359-7
   Yoshida H, 2008, FUEL, V87, P2186, DOI 10.1016/j.fuel.2008.01.009
   Zainal ZA, 2001, ENERG CONVERS MANAGE, V42, P1499, DOI 10.1016/S0196-8904(00)00078-9
   Zirrahi M, 2019, CHEM PHYS, V517, P6, DOI 10.1016/j.chemphys.2018.09.030
NR 47
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115433
DI 10.1016/j.ces.2019.115433
PG 16
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300001
DA 2020-05-12
ER

PT J
AU Lu, LQ
   Gao, X
   Shahnam, M
   Rogers, WA
AF Lu, Liqiang
   Gao, Xi
   Shahnam, Mehrdad
   Rogers, William A.
TI Bridging particle and reactor scales in the simulation of biomass fast
   pyrolysis by coupling particle resolved simulation and coarse grained
   CFD-DEM
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Biomass; Pyrolysis; CFD-DEM; Coarse grained CFD-DEM; Particle Resolved
   Simulation; Fluidized Bed
ID FLUIDIZED-BED; HEAT-TRANSFER; STEAM GASIFICATION; SPOUTED BED; MODEL;
   VALIDATION; FLOW; HYDRODYNAMICS; VERIFICATION; PARAMETERS
AB Efficient utilization of biomass is challenging due to the complexity of the feedstock at molecular, particle, and reactor scales. Direct coupling of particle scale model and reactor scale simulation is computationally infeasible. In this research, the results from a particle resolved simulation were used to calibrate the heat transfer and reaction kinetics of particles. A hybrid drag model was used to consider the different fluidization properties of sands and biomass particles. The computation cost was reduced using a coarse-grained Discrete Element Method (DEM). The simulated conversion rate, char yield, tar yield, and pyrolysis gas yield compare well with experiment. The residence time and axial distributions of biomass were also analyzed. This novel multi-scale method provides an efficient and accurate tool for the modeling of biomass pyrolysis reactors. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Lu, Liqiang; Gao, Xi; Shahnam, Mehrdad; Rogers, William A.] Natl Energy Technol Lab, Morgantown, WV 26507 USA.
   [Lu, Liqiang] West Virginia Univ, Res Corp, Morgantown, WV 26506 USA.
   [Gao, Xi] Leidos Res Support Team, Morgantown, WV 26507 USA.
RP Lu, LQ (reprint author), Natl Energy Technol Lab, Morgantown, WV 26507 USA.
EM Liqiang.Lu@netl.doe.gov
FU U.S. Department of Energy (DOE) Bioenergy Technologies Office
   (BETO)United States Department of Energy (DOE)
FX This research was conducted as part of the Feedstock-Conversion
   Interface Consortium (FCIC) funded by the U.S. Department of Energy
   (DOE) Bioenergy Technologies Office (BETO).
CR Amutio M, 2012, RESOUR CONSERV RECY, V59, P23, DOI 10.1016/j.resconrec.2011.04.002
   Aramideh S, 2015, FUEL, V156, P234, DOI 10.1016/j.fuel.2015.04.038
   Carpenter D, 2014, GREEN CHEM, V16, P384, DOI 10.1039/c3gc41631c
   Chu KW, 2016, MINER ENG, V90, P43, DOI 10.1016/j.mineng.2016.01.020
   Ciesielski P., 2017, SIMULATING BIOMASS F
   Cui HP, 2007, CHEM ENG SCI, V62, P45, DOI 10.1016/j.ces.2006.08.006
   Fahmi R, 2008, FUEL, V87, P1230, DOI 10.1016/j.fuel.2007.07.026
   Gao X, 2018, CHEM ENG SCI, V184, P33, DOI 10.1016/j.ces.2018.03.038
   Hou QF, 2012, IND ENG CHEM RES, V51, P11572, DOI 10.1021/ie3015999
   Hu CS, 2019, POWDER TECHNOL, V353, P132, DOI 10.1016/j.powtec.2019.05.020
   Hu CS, 2019, IND ENG CHEM RES, V58, P1404, DOI 10.1021/acs.iecr.8b05279
   Hu CS, 2019, CHEM ENG SCI, V195, P693, DOI 10.1016/j.ces.2018.10.015
   Kaneko Y, 1999, CHEM ENG SCI, V54, P5809, DOI 10.1016/S0009-2509(99)00153-0
   Kraft S, 2017, APPL ENERG, V190, P408, DOI 10.1016/j.apenergy.2016.12.113
   LELA P, 2010, INT J ENG SCI TECHNO, V2, P5
   Liu H, 2015, APPL ENERG, V160, P489, DOI 10.1016/j.apenergy.2015.09.065
   Lu L., 2018, BRIDGING SCALES MODE
   Lu LQ, 2018, CHEM ENG SCI, V179, P53, DOI 10.1016/j.ces.2018.01.003
   Lu LQ, 2017, IND ENG CHEM RES, V56, P13642, DOI 10.1021/acs.iecr.7b03773
   Lu LQ, 2017, INT J HEAT MASS TRAN, V111, P723, DOI 10.1016/j.ijheatmasstransfer.2017.04.040
   Lu LQ, 2016, IND ENG CHEM RES, V55, P10477, DOI 10.1021/acs.iecr.6b02688
   Lu LQ, 2014, CHEM ENG SCI, V120, P67, DOI 10.1016/j.ces.2014.08.004
   Ma CY, 2018, APPL ENERG, V229, P1269, DOI 10.1016/j.apenergy.2017.03.059
   Morris AB, 2016, AICHE J, V62, P4526, DOI 10.1002/aic.15331
   Park HC, 2019, RENEW ENERG, V143, P1268, DOI 10.1016/j.renene.2019.05.072
   Pecha MB, 2018, ENERG FUEL, V32, P10683, DOI 10.1021/acs.energyfuels.8b02309
   Qi T, 2019, INT J HYDROGEN ENERG, V44, P6448, DOI 10.1016/j.ijhydene.2019.01.146
   RANZ WE, 1952, CHEM ENG PROG, V48, P141
   Safar M, 2019, APPL ENERG, V235, P346, DOI 10.1016/j.apenergy.2018.10.065
   Sakai M, 2014, CHEM ENG J, V244, P33, DOI 10.1016/j.cej.2014.01.029
   Syamlal M., 1987, DERIVATION DRAG COEF
   Trendewicz A, 2015, BIOMASS BIOENERG, V74, P15, DOI 10.1016/j.biombioe.2015.01.001
   Ullah A, 2019, RENEW ENERG, V141, P1054, DOI 10.1016/j.renene.2019.04.074
   Wang S, 2019, CHEM ENG SCI, V197, P280, DOI 10.1016/j.ces.2018.12.031
   Williams CL, 2016, BIOENERG RES, V9, P1, DOI 10.1007/s12155-015-9694-y
   Xiong QG, 2017, ACS SUSTAIN CHEM ENG, V5, P2783, DOI 10.1021/acssuschemeng.6b02634
   Xiong QG, 2014, POWDER TECHNOL, V262, P96, DOI 10.1016/j.powtec.2014.04.062
   Xu YP, 2019, CHEM ENG SCI, V195, P356, DOI 10.1016/j.ces.2018.09.034
   Yin WJ, 2020, CHEM ENG SCI, V211, DOI 10.1016/j.ces.2019.115293
   Zhang Y, 2019, RENEW ENERG, V136, P193, DOI 10.1016/j.renene.2018.12.121
   Zhong HB, 2018, CHEM ENG PROCESS, V128, P36, DOI 10.1016/j.cep.2018.03.030
   Zhong HB, 2016, ENERG FUEL, V30, P6440, DOI 10.1021/acs.energyfuels.6b00914
NR 42
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115471
DI 10.1016/j.ces.2020.115471
PG 11
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300006
DA 2020-05-12
ER

PT J
AU Ma, J
   Bian, RZ
   Ma, GQ
   Li, XG
   Sui, H
   He, L
AF Ma, Jun
   Bian, Renzhou
   Ma, Guoqiang
   Li, Xingang
   Sui, Hong
   He, Lin
TI Separation of asphalt from carbonate ore surfaces by reactive
   extraction: Kinetics and modelling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Asphalt; Carbonate ore; Reactive extraction; Kinetics; Modeling
ID NONAQUEOUS EXTRACTION; SOLVENT-EXTRACTION; OIL-SAND; BITUMEN; RECOVERY;
   WATER; PYROLYSIS; PETROLEUM; MIXTURES; MINERALS
AB Separation of asphalt from carbonate unconventional ores is a challenge due to the strong interactions between carbonate mineral surfaces and asphalt. Our previous results show that the reactive extraction process performs well in recovering both extra-heavy oil and minerals from carbonate oil ores (RSC Adv. 2019, 9: 14372-14381). Herein, further tests have been conducted to understand the kinetics of the reactive extraction. It is found that the reaction kinetics of carbonate minerals in asphalt rocks is beyond the description of traditional reaction shrinking-core model. This is mainly ascribed to the coating of asphalt on the carbonate mineral surface. To mathematically describe the reaction kinetics, a modified reaction shrinking-core model has been proposed considering the unreacted oil on the mineral surface by adding a coverage coefficient theta in the kinetic model. Results show that this modified shrinking-core kinetic model works well in describing the real reaction (R-2 > 0.96) under different conditions. In addition, the thermodynamic properties, including the apparent active energy, enthalpy change, entropy change, Gibbs free energy change, and pre-exponential factor of this reactive extraction process are also determined for this kind of ores. This work would provide a primary insight into predicting the reactive extraction with different kinds of reactive carbonate minerals or other similar oil ores with dissolved minerals. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ma, Jun; Bian, Renzhou; Ma, Guoqiang; Li, Xingang; Sui, Hong; He, Lin] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
   [Ma, Jun; Bian, Renzhou; Ma, Guoqiang; Li, Xingang; Sui, Hong; He, Lin] Natl Engn Res Ctr Distillat Technol, Tianjin 300072, Peoples R China.
   [Li, Xingang; Sui, Hong] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
RP He, L (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300072, Peoples R China.
EM linhe@tju.edu.cn
OI He, Lin/0000-0002-0125-7401
FU Municipal Natural Science Foundation of Tianjin [18JCQNJC06500]
FX The authors gratefully acknowledge the financial support of Municipal
   Natural Science Foundation of Tianjin [Grant 18JCQNJC06500].
CR BERNER RA, 1974, AM J SCI, V274, P108, DOI 10.2475/ajs.274.2.108
   Chen LM, 2017, ENERG FUEL, V31, P1993, DOI 10.1021/acs.energyfuels.6b03036
   Dean EW, 1920, J IND ENG CHEM-US, V12, P486, DOI 10.1021/ie50125a025
   Devianto I.M., 2013, CHEM MAT ENG, V1, P35
   Ding MS, 2014, AICHE J, V60, P2985, DOI 10.1002/aic.14483
   He L, 2015, CHEM SOC REV, V44, P5446, DOI 10.1039/c5cs00102a
   Hooshiar A, 2012, FUEL PROCESS TECHNOL, V94, P80, DOI 10.1016/j.fuproc.2011.10.008
   Jia CX, 2015, J ANAL APPL PYROL, V114, P250, DOI 10.1016/j.jaap.2015.06.003
   Kalfayan L., 2008, PRODUCTION ENHANCEME
   Li XG, 2019, RSC ADV, V9, P14372, DOI 10.1039/c9ra02025j
   Li XG, 2018, FUEL, V221, P303, DOI 10.1016/j.fuel.2018.02.081
   Li XG, 2011, ENERG FUEL, V25, P5224, DOI 10.1021/ef2010942
   MEADUS FW, 1982, FUEL PROCESS TECHNOL, V6, P289, DOI 10.1016/0378-3820(82)90008-X
   Mohammed HS, 2019, J RADIOANAL NUCL CH, V319, P245, DOI 10.1007/s10967-018-6289-z
   Natarajan A, 2011, J PHYS CHEM C, V115, P16043, DOI 10.1021/jp2039674
   Nikakhtari H, 2013, CAN J CHEM ENG, V91, P1153, DOI 10.1002/cjce.21751
   Pakdel H, 2003, ENERG FUEL, V17, P1145, DOI 10.1021/ef0300242
   Pal K, 2015, ENERG FUEL, V29, P2261, DOI 10.1021/ef502882c
   Sui H, 2016, ENERG FUEL, V30, P9242, DOI 10.1021/acs.energyfuels.6b01963
   Tiwari P, 2012, AICHE J, V58, P505, DOI 10.1002/aic.12589
   Wang Q, 2014, J THERM ANAL CALORIM, V116, P499, DOI 10.1007/s10973-013-3505-5
   Wang T, 2014, ENERG FUEL, V28, P2297, DOI 10.1021/ef402101s
   Wang ZJ, 2016, J THERM ANAL CALORIM, V123, P1707, DOI 10.1007/s10973-015-5012-3
   Yang HQ, 2012, IND ENG CHEM RES, V51, P3032, DOI 10.1021/ie202757k
   Zhang ZS, 2019, J CHEM ENG DATA, V64, P2475, DOI 10.1021/acs.jced.9b00009
   Zhang ZS, 2018, CHEM ENG SCI, V181, P264, DOI 10.1016/j.ces.2018.02.023
NR 26
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115533
DI 10.1016/j.ces.2020.115533
PG 10
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300019
DA 2020-05-12
ER

PT J
AU Paglianti, A
   Montante, G
AF Paglianti, A.
   Montante, G.
TI Simultaneous measurements of liquid velocity and tracer concentration in
   a continuous flow stirred tank
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mixing; Passive scalar transport; Particle image velocimetry; Planar
   laser induced fluorescence; Gradient diffusion hypothesis; Turbulent
   Schmidt number
ID SCALAR; FIELD; DISSIPATION; VESSELS
AB This work concerns the simultaneous measurements of the velocity of a liquid and of the concentration of a passive scalar in a standard geometry stirred tank provided with a continuous feed stream. The data are collected close to the tracer inlet on a vertical plane portion located in the vessel top region by a combined Particle Image Velocimetry and Planar Laser Induced Fluorescence system. The mean and fluctuating velocity and concentration components in the axial and radial directions obtained under stirred and unstirred conditions are presented. Following the definitions provided in the realm of the gradient diffusion hypothesis for the turbulent scalar transport, the measured variables are further exploited for the calculation of the turbulent viscosity, the turbulent diffusivity and their ratio, that is the turbulent Schmidt number. For the investigated conditions, the turbulent Schmidt number values are in the range 0.7-1.0, although significant local variations are observed. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Paglianti, A.] Univ Bologna, Alma Mater Studiorum, Dipartimento Ingn Civile Chim Ambientale & Mat, Via Terracini 34, I-40131 Bologna, Italy.
   [Montante, G.] Univ Bologna, Dipartimento Chim Ind Toso Montanari, Alma Mater Studiorum, Via Terracini 34, I-40131 Bologna, Italy.
RP Montante, G (reprint author), Univ Bologna, Dipartimento Chim Ind Toso Montanari, Alma Mater Studiorum, Via Terracini 34, I-40131 Bologna, Italy.
EM giuseppina.montante@unibo.it
FU Italian Government through the Grant "Excellent Departments" [2018-2022]
FX A. Paglianti acknowledges the support of the Italian Government through
   the Grant "Excellent Departments" 2018-2022.
CR Baldi S, 2004, CHEM ENG TECHNOL, V27, P275, DOI 10.1002/ceat.200401979
   Baldi S, 2003, IND ENG CHEM RES, V42, P7006, DOI 10.1021/ie0208265
   Busciglio A, 2015, CHEM ENG RES DES, V102, P42, DOI 10.1016/j.cherd.2015.06.017
   Combest DP, 2011, IND ENG CHEM RES, V50, P8817, DOI 10.1021/ie200055s
   Coroneo M, 2011, COMPUT CHEM ENG, V35, P1959, DOI 10.1016/j.compchemeng.2010.12.007
   Delafosse A, 2014, CHEM ENG SCI, V106, P76, DOI 10.1016/j.ces.2013.11.033
   Doulgerakis Z, 2009, CHEM ENG RES DES, V87, P412, DOI 10.1016/j.cherd.2008.12.019
   Escudie R, 2003, AICHE J, V49, P585, DOI 10.1002/aic.690490306
   Feng H, 2005, AICHE J, V51, P2649, DOI 10.1002/aic.10527
   Feng H, 2007, EXP FLUIDS, V42, P847, DOI 10.1007/s00348-007-0265-7
   Feng H, 2010, CHEM ENG SCI, V65, P3372, DOI 10.1016/j.ces.2010.02.038
   Gualtieri C, 2017, FLUIDS, V2, DOI 10.3390/fluids2020017
   Haringa C, 2018, CHEM ENG RES DES, V136, P870, DOI 10.1016/j.cherd.2018.06.005
   Hartmann H, 2006, AICHE J, V52, P3696, DOI 10.1002/aic.10997
   Hitimana E, 2019, EXP FLUIDS, V60, DOI 10.1007/s00348-018-2669-y
   Houcine I, 1996, EXP FLUIDS, V22, P95, DOI 10.1007/s003480050026
   Li GH, 2018, CHEM ENG SCI, V191, P288, DOI 10.1016/j.ces.2018.06.073
   Liu MY, 2012, CHEM ENG SCI, V69, P382, DOI 10.1016/j.ces.2011.10.062
   Liu Y, 2006, CHEM ENG SCI, V61, P6946, DOI 10.1016/j.ces.2006.07.011
   Montante G, 2012, CHEM ENG RES DES, V90, P1448, DOI 10.1016/j.cherd.2012.01.009
   Papadopoulos G., 2004, EXPT METHODS B, P202
   Stamatopoulos K, 2016, CHEM ENG SCI, V145, P1, DOI 10.1016/j.ces.2016.01.032
   Su LK, 2004, J FLUID MECH, V513, P1, DOI 10.1017/S0022112004009401
   YIANNESKIS M, 1993, CHEM ENG RES DES, V71, P543
NR 24
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115495
DI 10.1016/j.ces.2020.115495
PG 12
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300017
DA 2020-05-12
ER

PT J
AU Pan, DW
   Chen, Q
   Chen, SF
   Li, B
AF Pan, Dawei
   Chen, Qiang
   Chen, Shufan
   Li, Bo
TI Experimental study on millimeter-scale W1/O/W2 compound droplets
   formation in a co-flowing device with two-step structure
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE W1/O/W2 compound droplets; Co-flowing microfluidic device; Two-step
   structure; Flow mechanisms
ID MONODISPERSE DOUBLE EMULSIONS; MULTIPLE EMULSIONS; BREAKUP
AB W1/O/W2 compound droplets generation in a co-flowing microfluidic device with two-step structure was observed through experiments, and the formation process is quantitatively studied. Further the effects of the flow rates of all phases as well as the viscosity of W2 phase on the geometric size are extensively investigated. The results indicate that the outer diameter of compound droplets mainly depends on the flow rate and viscosity of external phase. The core water droplet diameter can be controlled by adjusting the flow rates of both inner and middle phases, and it is more sensitive to inner phase. Generally, the inner diameter of compound droplets is not only relative to the core droplet diameter, but also influenced by the encapsulated core water droplet number. Finally, a prediction correlation for dimensionless outer diameter with several dimensionless numbers is obtained. The results could provide an experimental basis for controllably preparing millimeter-scale monodisperse compound droplets. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Pan, Dawei; Chen, Qiang; Chen, Shufan; Li, Bo] China Acad Engn Phys, Res Ctr Laser Fus, Mianyang 621900, Sichuan, Peoples R China.
RP Li, B (reprint author), China Acad Engn Phys, Res Ctr Laser Fus, Mianyang 621900, Sichuan, Peoples R China.
EM lb67_11@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1530260]
FX We are gratefully to acknowledge the funding from National Natural
   Science Foundation of China (U1530260).
CR Abate AR, 2009, SMALL, V5, P2030, DOI 10.1002/smll.200900569
   Abate AR, 2011, LAB CHIP, V11, P253, DOI [10.1039/c0lc00236d, 10.1039/c01c00236d]
   Abate AR, 2010, LAB CHIP, V10, P1774, DOI 10.1039/c004124f
   Arriaga LR, 2015, LAB CHIP, V15, P3335, DOI 10.1039/c5lc00631g
   Bhandarkar S, 2016, FUSION SCI TECHNOL, V70, P127, DOI 10.13182/FST15-245
   Che ZZ, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5008908
   Chen HS, 2011, LAB CHIP, V11, P2312, DOI 10.1039/c1lc20265k
   Chu LY, 2007, ANGEW CHEM INT EDIT, V46, P8970, DOI 10.1002/anie.200701358
   Deng CJ, 2017, COLLOID SURFACE A, V533, P1, DOI 10.1016/j.colsurfa.2017.05.041
   Fu YH, 2016, CHEM ENG SCI, V146, P126, DOI 10.1016/j.ces.2016.02.036
   Hou LK, 2017, MICROFLUID NANOFLUID, V21, DOI 10.1007/s10404-017-1897-4
   Hua JS, 2007, AICHE J, V53, P2534, DOI 10.1002/aic.11287
   Lee D, 2008, ADV MATER, V20, P3498, DOI 10.1002/adma.200800918
   Liu MF, 2014, CHEM ENG J, V241, P466, DOI 10.1016/j.cej.2013.08.120
   Liu XD, 2017, COLLOID SURFACE A, V533, P87, DOI 10.1016/j.colsurfa.2017.08.026
   Liu ZM, 2018, CHINESE J ANAL CHEM, V46, P324, DOI 10.11895/j.issn.0253-3820.171187
   Lorenceau E, 2005, LANGMUIR, V21, P9183, DOI 10.1021/la050797d
   Nurumbetov G, 2012, POLYM CHEM-UK, V3, P1043, DOI 10.1039/c2py00605g
   Okushima S, 2004, LANGMUIR, V20, P9905, DOI 10.1021/la0480336
   Perro A, 2011, LANGMUIR, V27, P9034, DOI 10.1021/la1037102
   Romanowsky MB, 2012, LAB CHIP, V12, P802, DOI 10.1039/c2lc21033a
   Shao T, 2013, CHEM ENG SCI, V104, P55, DOI 10.1016/j.ces.2013.09.001
   Song H, 2006, ANGEW CHEM INT EDIT, V45, P7336, DOI 10.1002/anie.200601554
   Utada AS, 2005, SCIENCE, V308, P537, DOI 10.1126/science.1109164
   Vu TV, 2013, INT J MULTIPHAS FLOW, V49, P58, DOI 10.1016/j.ijmultiphaseflow.2012.10.004
   Wang W, 2011, LAB CHIP, V11, P1587, DOI 10.1039/c1lc20065h
   Wu LY, 2017, CHEM ENG SCI, V163, P56, DOI 10.1016/j.ces.2017.01.022
   Zhao CX, 2016, CHEMPHYSCHEM, V17, P1553, DOI 10.1002/cphc.201600142
NR 28
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115493
DI 10.1016/j.ces.2020.115493
PG 10
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300015
DA 2020-05-12
ER

PT J
AU Panicker, N
   Passalacqua, A
   Fox, RO
AF Panicker, N.
   Passalacqua, A.
   Fox, R. O.
TI Computational study of buoyancy driven turbulence in statistically
   homogeneous bubbly flows
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Two-fluid model; Reynolds stress model; Buoyancy driven turbulence;
   Turbulence characteristics
ID GAS-LIQUID FLOW; LARGE-EDDY SIMULATION; NUMERICAL-SIMULATION; CFD
   SIMULATION; 2-FLUID MODEL; TRANSVERSE MIGRATION; KINETIC-ENERGY; COLUMN
   FLOWS; LIFT FORCE; DYNAMICS
AB Buoyancy driven turbulence due to heterogeneous bubble swarms are typically encountered in bubble columns operating in the dense heterogeneous regime. The integral scales of such turbulence are much larger than single bubble produced pseudo-turbulence. Accurate computational fluid dynamics predictions in this regime require correctly formulated anisotropic turbulence models with closures accounting for buoyancy driven turbulence effects. In the current study, a Reynolds-stress transport equation is formulated for bubbly flows from a hyperbolic two-fluid model by Reynolds averaging. The unclosed terms generated due to Reynolds averaging are quantified using high grid resolution, two-fluid simulations for bubbly flows in a periodic domain. The relative importance of the unclosed terms are discussed from a modeling stand point. The turbulence statistics, length and time scales, energy spectra, mean momentum budget and the Reynolds stress budget are analyzed for different bubble void fractions. The results show that the unclosed terms generated due to the averaging of Drag is significant in the liquid phase Reynolds Stress budget. Moreover, the unclosed terms generated due to the averaging of Drag, Virtual mass and Buoyancy are significant in the gas phase Reynolds Stress budget. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Panicker, N.; Passalacqua, A.] Iowa State Univ, Dept Mech Engn, Black Engn Bldg, Ames, IA 50011 USA.
   [Fox, R. O.] Iowa State Univ, Dept Chem & Biol Engn, 618 Bissell Rd, Ames, IA 50011 USA.
   [Panicker, N.; Passalacqua, A.; Fox, R. O.] Iowa State Univ, Ctr Multiphase Flow Res & Educ CoMFRE, Ames, IA 50011 USA.
RP Panicker, N (reprint author), Iowa State Univ, Dept Mech Engn, Black Engn Bldg, Ames, IA 50011 USA.
EM panickns@iastate.edu
OI Fox, Rodney/0000-0003-1944-1861
FU U.S. National Science FoundationNational Science Foundation (NSF)
   [CBET-1438143]; American Chemical Society Petroleum Research Fund
   through the award PRF [53924-DNI9]
FX The authors gratefully acknowledge support from the U.S. National
   Science Foundation through grant CBET-1438143. A. P. and N. S. P. also
   wish to express their gratitude for the support from the American
   Chemical Society Petroleum Research Fund through the award
   PRF#53924-DNI9.
CR Almeras E, 2015, J FLUID MECH, V776, P458, DOI 10.1017/jfm.2015.338
   Beetstra R, 2007, AICHE J, V53, P489, DOI 10.1002/aic.11065
   Bois G, 2017, PROCEEDINGS OF THE ASME FLUIDS ENGINEERING DIVISION SUMMER MEETING, 2017, VOL 1C
   Buwa VV, 2002, CHEM ENG SCI, V57, P4715, DOI 10.1016/S0009-2509(02)00274-9
   Capecelatro J, 2016, PHYS FLUIDS, V28, DOI 10.1063/1.4943234
   Capecelatro J, 2015, J FLUID ENG-T ASME, V137, DOI 10.1115/1.4030644
   Capecelatro J, 2015, J FLUID MECH, V780, P578, DOI 10.1017/jfm.2015.459
   Capecelatro J, 2014, J FLUID MECH, V747, DOI 10.1017/jfm.2014.194
   Chahed J, 2003, INT J MULTIPHAS FLOW, V29, P23, DOI 10.1016/S0301-9322(02)00123-4
   Chen P, 2005, AICHE J, V51, P696, DOI 10.1002/aic.10381
   Climent E, 1999, PHYS REV LETT, V82, P4827, DOI 10.1103/PhysRevLett.82.4827
   COOK TL, 1984, INT J MULTIPHAS FLOW, V10, P691, DOI 10.1016/0301-9322(84)90005-3
   Cui Z, 2004, CHEM ENG SCI, V59, P1755, DOI 10.1016/j.ces.2004.01.031
   Deen NG, 2001, CHEM ENG SCI, V56, P6341, DOI 10.1016/S0009-2509(01)00249-4
   Degaleesan S, 2001, AICHE J, V47, P1913, DOI 10.1002/aic.690470904
   Delnoij E, 1997, CHEM ENG SCI, V52, P1429, DOI 10.1016/S0009-2509(96)00515-5
   Dhotre MT, 2008, CHEM ENG J, V136, P337, DOI 10.1016/j.cej.2007.04.016
   DREW DA, 1983, ANNU REV FLUID MECH, V15, P261, DOI 10.1146/annurev.fl.15.010183.001401
   Druzhinin OA, 1998, PHYS FLUIDS, V10, P685, DOI 10.1063/1.869594
   du Cluzeau A, 2019, J FLUID MECH, V866, P132, DOI 10.1017/jfm.2019.100
   Ekambara K, 2008, IND ENG CHEM RES, V47, P8505, DOI 10.1021/ie071393e
   Ellingsen K, 2001, J FLUID MECH, V440, P235, DOI 10.1017/S0022112001004761
   Fleau S., 2015, ICHMT DIGITAL LIB ON
   Fox RO, 2014, J FLUID MECH, V742, P368, DOI 10.1017/jfm.2014.21
   Fujiwara A, 2004, INT J HEAT FLUID FL, V25, P481, DOI 10.1016/j.ijheatfluidflow.2004.02.018
   GRIENBERGER J, 1992, CHEM ENG SCI, V47, P2215, DOI 10.1016/0009-2509(92)87037-Q
   Happel J., 2012, LOW REYNOLDS NUMBER, V1
   HILLMER G, 1994, CHEM ENG SCI, V49, P837, DOI 10.1016/0009-2509(94)80020-0
   HJERTAGER BH, 1995, MODEL IDENT CONTROL, V16, P177, DOI 10.4173/mic.1995.4.1
   Ilic M, 2004, J NUCL SCI TECHNOL, V41, P331, DOI 10.3327/jnst.41.331
   Joshi J.B., 1998, P INDIAN NATL SCI A, V64, P441
   Joshi JB, 2001, CHEM ENG SCI, V56, P5893, DOI 10.1016/S0009-2509(01)00273-1
   KATAOKA I, 1989, INT J MULTIPHAS FLOW, V15, P843, DOI 10.1016/0301-9322(89)90045-1
   Kong B, 2017, AICHE J, V63, P2630, DOI 10.1002/aic.15686
   Krepper E, 2007, NUCL ENG DES, V237, P399, DOI 10.1016/j.nucengdes.2006.07.009
   Krishna R, 1999, INT COMMUN HEAT MASS, V26, P781, DOI 10.1016/S0735-1933(99)00066-4
   KRISHNA R, 1991, CHEM ENG SCI, V46, P2491, DOI 10.1016/0009-2509(91)80042-W
   KUMBARO A, 2011, J COMPUT MULTIPHASE, V3, P177, DOI DOI 10.1260/1757-482X.3.3.177
   Laborde-Boutet C, 2009, CHEM ENG SCI, V64, P4399, DOI 10.1016/j.ces.2009.07.009
   LAHEY RT, 1990, NUCL ENG DES, V122, P17, DOI 10.1016/0029-5493(90)90194-3
   Lakkaraju R, 2011, PHYS REV E, V84, DOI 10.1103/PhysRevE.84.036312
   LANCE M, 1991, J FLUID MECH, V222, P95, DOI 10.1017/S0022112091001015
   LAPIN A, 1994, CHEM ENG SCI, V49, P3661, DOI 10.1016/0009-2509(94)E0121-6
   LEVICH VG, 1962, PHYSICOCHEMICAL HYDR
   Lia G, 2009, CHEM ENG SCI, V64, P5104, DOI 10.1016/j.ces.2009.08.016
   Liu NS, 2011, J HYDRODYN, V23, P282, DOI 10.1016/S1001-6058(10)60114-X
   Lu JC, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2911034
   Lucas D, 2005, CHEM ENG SCI, V60, P3609, DOI 10.1016/j.ces.2005.02.032
   Lucas D, 2011, INT J MULTIPHAS FLOW, V37, P1178, DOI 10.1016/j.ijmultiphaseflow.2011.05.009
   Ma T, 2015, INT J HEAT FLUID FL, V56, P51, DOI 10.1016/j.ijheatfluidflow.2015.06.009
   Ma T, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.034301
   MAXEY MR, 1983, PHYS FLUIDS, V26, P883, DOI 10.1063/1.864230
   Mazzitelli IM, 2009, PHYS REV E, V79, DOI 10.1103/PhysRevE.79.066317
   Milne-Thompson L.M., 1968, THEORETICAL HYDRODYN, P1
   Mimouni S, 2017, NUCL ENG DES, V321, P118, DOI 10.1016/j.nucengdes.2016.12.009
   Monahan SM, 2007, CHEM ENG SCI, V62, P3159, DOI 10.1016/j.ces.2007.03.021
   Monahan SM, 2005, AICHE J, V51, P1897, DOI 10.1002/aic.10425
   Montoya G, 2016, CHEM ENG SCI, V141, P86, DOI 10.1016/j.ces.2015.09.011
   Morel C., 2015, MATH MODELING DISPER
   Mudde RF, 2005, ANNU REV FLUID MECH, V37, P393, DOI 10.1146/annurev.fluid.37.061903.175803
   Mudde RF, 1997, CHEM ENG SCI, V52, P4217, DOI 10.1016/S0009-2509(97)88935-X
   Murai Y, 2000, JSME INT J B-FLUID T, V43, P197, DOI 10.1299/jsmeb.43.197
   Nierhaus T, 2007, INT J HEAT FLUID FL, V28, P542, DOI 10.1016/j.ijheatfluidflow.2007.03.005
   Ojima S, 2014, INT J MULTIPHAS FLOW, V67, P111, DOI 10.1016/j.ijmultiphaseflow.2014.05.008
   OpenFOAM, 2016, OPENFOAM USER GUIDE
   Pakhomov MA, 2016, INT J HEAT MASS TRAN, V101, P1251, DOI 10.1016/j.ijheatmasstransfer.2016.05.054
   Pang MJ, 2013, ADV MECH ENG, DOI 10.1155/2013/379839
   Panicker N, 2018, APPL MATH MODEL, V57, P432, DOI 10.1016/j.apm.2018.01.011
   Pope S. B., 2000, TURBULENT FLOWS
   Prosperetti A, 2009, COMPUTATIONAL METHOD
   Raimundo PM, 2019, CHEM ENG SCI, V198, P52, DOI 10.1016/j.ces.2018.12.043
   Raimundo PM, 2016, CHEM ENG SCI, V155, P504, DOI 10.1016/j.ces.2016.08.041
   RANADE VV, 1992, CHEM ENG SCI, V47, P1857, DOI 10.1016/0009-2509(92)80304-U
   Rensen J, 2005, J FLUID MECH, V538, P153, DOI 10.1017/S0022112005005276
   Riboux G, 2013, J FLUID MECH, V719, P362, DOI 10.1017/jfm.2013.12
   Risso F, 2018, ANNU REV FLUID MECH, V50, P25, DOI 10.1146/annurev-fluid-122316-045003
   Roghair I, 2011, CHEM ENG SCI, V66, P3204, DOI 10.1016/j.ces.2011.02.030
   Roghair I, 2011, INT J MULTIPHAS FLOW, V37, P1093, DOI 10.1016/j.ijmultiphaseflow.2011.07.004
   Ruzicka MC, 2001, CHEM ENG SCI, V56, P4609, DOI 10.1016/S0009-2509(01)00116-6
   Santarelli C, 2016, CHEM ENG SCI, V141, P46, DOI 10.1016/j.ces.2015.10.013
   Sato Y., 1975, International Journal of Multiphase Flow, V2, P79, DOI 10.1016/0301-9322(75)90030-0
   Schiller L., 1935, VDI ZEITUNG, V77, P51
   Shaikh A, 2007, INT J CHEM REACT ENG, V5, DOI 10.2202/1542-6580.1368
   Sokolichin A, 1994, CHEM ENG SCI, V49, P5735, DOI 10.1016/0009-2509(94)00289-4
   Sommerfeld M, 2003, CAN J CHEM ENG, V81, P508, DOI 10.1002/cjce.5450810324
   SVENDSEN HF, 1992, CHEM ENG SCI, V47, P3297, DOI 10.1016/0009-2509(92)85038-D
   Tabib MV, 2008, CHEM ENG J, V139, P589, DOI 10.1016/j.cej.2007.09.015
   Tavanashad V., 2018, ACTA MECH, P1
   Tomiyama A, 2002, CHEM ENG SCI, V57, P1849, DOI 10.1016/S0009-2509(02)00085-4
   Tomiyama A, 1998, MULTIPHASE SCIENCE AND TECHNOLOGY, VOL 10 ISSUE 4 1998, P369
   TORVIK R, 1990, CHEM ENG SCI, V45, P2325, DOI 10.1016/0009-2509(90)80112-R
   Tryggvason G, 2001, J COMPUT PHYS, V169, P708, DOI 10.1006/jcph.2000.6726
   Tryggvason G., 2011, DIRECT NUMERICAL SIM
   Uchiyama T., 2013, ADV CHEM ENG SCI, V2013
   Yang N, 2011, CHEM ENG SCI, V66, P3212, DOI 10.1016/j.ces.2011.02.029
   Yang X, 2002, CHEM ENG SCI, V57, P555, DOI 10.1016/S0009-2509(01)00416-X
   YANG YB, 1993, EXP FLUIDS, V16, P1, DOI 10.1007/BF00188499
   Yeoh GH, 2006, APPL MATH MODEL, V30, P1370, DOI 10.1016/j.apm.2006.03.010
   Zhang D, 2006, CHEM ENG SCI, V61, P7593, DOI 10.1016/j.ces.2006.08.053
   ZUN I, 1980, INT J MULTIPHAS FLOW, V6, P583, DOI 10.1016/0301-9322(80)90053-1
NR 100
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115546
DI 10.1016/j.ces.2020.115546
PG 17
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300023
DA 2020-05-12
ER

PT J
AU Rahmatpour, A
   Meymandi, MG
AF Rahmatpour, Ali
   Meymandi, Mehdi Ghasemi
TI Techno-economic evaluation of titanium catalyst production cycle from
   ilmenite purer (a case study at Kahnooj mine in Iran)
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sour gas; Techno-economic evaluation; Hydrogen sulfide; Claus process;
   Titanium catalyst
ID SAND ILMENITE; TIO2; DIOXIDE; KINETICS; SPRAY
AB This study evaluates the construction of a production line for titanium catalyst based on three scenarios, one based on the chloride method with sol-gel synthesis (CP-SG) (case A), second case based on the sulfate process with hydrothermal synthesis (SP-H) (case B) and the chloride process with spray-pyrolysis synthesis (CP-SP) as third case (case C). Technical feasibility was tested through utilization of ilmenite feedstock in cycle's production using three mentioned scenarios. The economic indicators such as net present value (NPV) and internal rate of return (IRR) were used to evaluate the economic performance. The results show that at 50,000 Ton/y production capacity, NPV at 15% discounting rate is 409 M$ for case A, and 424.7 M$, 422.7 M$ for cases B and C, respectively. The sensitivity analysis shows that the production cost and titanium catalyst selling price were the most sensitive input parameters. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Rahmatpour, Ali] Shahid Beheshti Univ, Fac Chem & Petr Sci, Polymer Sci Grp, POB 1983969411, Tehran, Iran.
   [Meymandi, Mehdi Ghasemi] Shahid Beheshti Univ, Fac Econ & Polit Sci, Energy Econ Grp, Tehran, Iran.
RP Rahmatpour, A (reprint author), Shahid Beheshti Univ, Fac Chem & Petr Sci, Polymer Sci Grp, POB 1983969411, Tehran, Iran.
EM a_rahmatpour@sbu.ac.ir
FU Research & Technology Directorate of National Iranian Gas Company
   (NIGC); Research Institute of Petroleum Industry (RIPI)
FX The authors wish to thanks from the Research & Technology Directorate of
   National Iranian Gas Company (NIGC) for funding and Research Institute
   of Petroleum Industry (RIPI) and Behafarin Co. for evaluated data set of
   this research. The authors also thanks from Mrs Zohal Safaei for
   providing SEM images.
CR Abou-Helal MO, 2002, APPL SURF SCI, V195, P53, DOI 10.1016/S0169-4332(02)00533-0
   Aghighi A, 2015, J ENVIRON CHEM ENG, V3, P1622, DOI 10.1016/j.jece.2015.05.019
   [Anonymous], GLOBAL CATALYSTS IND
   Baasel W.D., 1989, PRELIMINARY CHEM ENG
   Barksdale J., 1966, TITANIUM ITS OCCURRE
   Bedinger G.M., 2013, TITANIUM TITANIUM DI
   Cao TP, 2011, LANGMUIR, V27, P2946, DOI 10.1021/la104195v
   Catalyst Market, 2018, CAT MARK 2018 GLOB A
   Chen C, 2010, J HAZARD MATER, V178, P560, DOI 10.1016/j.jhazmat.2010.01.121
   Chen X, 2007, CHEM REV, V107, P2891, DOI 10.1021/cr0500535
   Chernet T, 1999, MINER ENG, V12, P485, DOI 10.1016/S0892-6875(99)00035-7
   Eslamian M, 2009, RECENT PAT NANOTECH, V3, P99, DOI 10.2174/187221009788490068
   Gambogi J., 2010, USGS MINERAL COMMODI, P172
   Gratzel M, 2001, NATURE, V414, P338, DOI 10.1038/35104607
   Juhasz L, 2011, ECON SOCIOL, V4, P46, DOI 10.14254/2071-789X.2011/4-1/5
   Kang X., 2019, TITANIUM DIOXIDE ENG, V9, P1
   Khan H, 2017, REACT KINET MECH CAT, V121, P811, DOI 10.1007/s11144-017-1195-x
   Kolen'ko YV, 2003, MATER LETT, V57, P1124, DOI 10.1016/S0167-577X(02)00943-6
   Kuznesof P.M., 2006, TITANIUM DIOXIDE CHE, V1, P1
   Li ZJ, 2008, J HAZARD MATER, V155, P590, DOI 10.1016/j.jhazmat.2007.11.095
   Liao YL, 2012, J MATER CHEM, V22, P7937, DOI 10.1039/c2jm16628c
   Liu X, 2012, NATURAL GAS TECHNOLO, V6, P55
   MATSUDA S, 1983, APPL CATAL, V8, P149, DOI 10.1016/0166-9834(83)80076-1
   Perego C, 1997, CATAL TODAY, V34, P281, DOI 10.1016/S0920-5861(96)00055-7
   Pulisova P, 2011, CATAL TODAY, V161, P84, DOI 10.1016/j.cattod.2010.12.032
   Rad VN, 2018, INT J ENVIRON SCI TE, V15, P631, DOI 10.1007/s13762-017-1407-y
   Rezaee M., 2016, SCI IRANICA T C, V23
   Sahu KK, 2006, WASTE MANAGE RES, V24, P74, DOI 10.1177/0734242X06061016
   Salikin MS, 2009, 2009 34TH INTERNATIONAL CONFERENCE ON INFRARED, MILLIMETER, AND TERAHERTZ WAVES, VOLS 1 AND 2, P836
   Sasikumar C, 2004, HYDROMETALLURGY, V75, P189, DOI 10.1016/j.hydromet.2004.08.001
   Sassi Mohamed, 2008, American Journal of Environmental Sciences, V4, P502
   Sermyagina E, 2016, APPL ENERG, V183, P88, DOI 10.1016/j.apenergy.2016.08.151
   Shen GX, 2005, THIN SOLID FILMS, V489, P130, DOI 10.1016/j.tsf.2005.05.016
   Sprong Michael, 2014, PRIC BOOKL ED NR 30
   Sugimoto T, 2003, J COLLOID INTERF SCI, V259, P43, DOI 10.1016/S0021-9797(03)00036-5
   Tasdemir HM, 2015, INT J HYDROGEN ENERG, V40, P9989, DOI 10.1016/j.ijhydene.2015.06.056
   Turton R., 2008, ANAL SYNTHESIS DESIG
   Wang Y, 2014, J ENVIRON SCI, V26, pCOVER1, DOI 10.1016/j.jes.2014.09.023
   West R.H., 2009, THESIS
   WILLIAMS PC, 1973, J SCI FOOD AGR, V24, P343, DOI 10.1002/jsfa.2740240311
   Winkler J., 2003, TITANIUM DIOXIDE EUR
   Xue TY, 2009, HYDROMETALLURGY, V95, P22, DOI 10.1016/j.hydromet.2008.04.004
   Yang HG, 2009, J AM CHEM SOC, V131, P4078, DOI 10.1021/ja808790p
   Yang WE, 2009, J ALLOY COMPD, V479, P642, DOI 10.1016/j.jallcom.2009.01.021
   Yi QH, 2016, NANOSCALE RES LETT, V11, DOI 10.1186/s11671-016-1674-4
   Yu H, 2011, J MATER CHEM, V21, P11347, DOI 10.1039/c1jm11385b
   Zarogiannis Panos, 2017, ANAL SOCIOECONOMIC I
   Zhou WJ, 2011, J MATER CHEM, V21, P7937, DOI 10.1039/c1jm10588d
NR 48
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115489
DI 10.1016/j.ces.2020.115489
PG 13
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300013
DA 2020-05-12
ER

PT J
AU Shao, YJ
   Li, ZZ
   Zhong, WQ
   Bian, ZF
   Yu, AB
AF Shao, Yingjuan
   Li, Zhaozhi
   Zhong, Wenqi
   Bian, Zhoufeng
   Yu, Aibing
TI Minimum fluidization velocity of particles with different size
   distributions at elevated pressures and temperatures
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Minimum fluidization velocity; Pressurized fluidized bed; Particle size
   distribution; Pressure; Temperature
ID SPOUT-FLUID BED; INTERPARTICLE FORCES; COAL COMBUSTION; OPERATING
   TEMPERATURE; FLOW; GASIFICATION; SIMULATION; BEHAVIORS; EXPANSION;
   VOIDAGE
AB This paper presents a detailed investigation into the effect of pressure, temperature and particle size distribution (PSD) on the minimum fluidization velocity (U-mf). A series of measurement of U-mf were carried out under the pressure from 0.1 MPa to 0.5 MPa and the temperature from 300 degrees C to 850 degrees C on a lab-scale pressurized fluidized bed reactor for three narrow PSD and three wide PSD (binary, uniform, and Gaussian-type) silica sand particles. The results showed that the U-mf for narrow and wide PSDs both decreased with increasing temperature and decreased slightly with rising pressure. Besides, the Gaussian-type mixtures had almost the same U-mf as the reference narrow PSD particle, while the U-mf of binary and uniform PSD mixtures was larger than these two. Based on the experimental data, a new simple relationship for predicting U-mf of the different PSD particles at elevated pressures and temperatures was developed. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Shao, Yingjuan; Li, Zhaozhi; Zhong, Wenqi; Bian, Zhoufeng] Southeast Univ, Sch Energy & Environm, Key Lab Energy Thermal Convers & Control, Minist Educ, Nanjing 210096, Peoples R China.
   [Shao, Yingjuan; Li, Zhaozhi; Zhong, Wenqi; Bian, Zhoufeng; Yu, Aibing] Southeast Univ Monash Univ Joint Res Inst, Ctr Simulat & Modelling Particulate Syst, Suzhou, Peoples R China.
   [Yu, Aibing] Monash Univ, Dept Chem Engn, ARC Res Hub Computat Particle Technol, Clayton, Vic 3800, Australia.
RP Zhong, WQ (reprint author), Sipailou 2, Nanjing 210096, Jiangsu, Peoples R China.
EM wqzhong@seu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51736002, 51876037]
FX This work was supported by the National Natural Science Foundation of
   China [project number: 51736002 and 51876037].
CR Agu CE, 2019, POWDER TECHNOL, V349, P99, DOI 10.1016/j.powtec.2019.03.027
   Anantharaman A, 2018, POWDER TECHNOL, V323, P454, DOI 10.1016/j.powtec.2017.10.016
   BOTTERILL JSM, 1982, POWDER TECHNOL, V31, P101, DOI 10.1016/0032-5910(82)80009-0
   Chen Zhen-dong, 2010, Proceedings of the CSEE, V30, P21
   CHIBA S, 1979, POWDER TECHNOL, V22, P255, DOI 10.1016/0032-5910(79)80031-5
   Cui H., 2004, CHINA PART, V2, P113
   de Jong WB, 1999, RENEW ENERG, V16, P1110, DOI 10.1016/S0960-1481(98)00432-7
   Feng RT, 2017, POWDER TECHNOL, V320, P27, DOI 10.1016/j.powtec.2017.07.024
   Formisani B, 1998, CHEM ENG SCI, V53, P951, DOI 10.1016/S0009-2509(97)00370-9
   Forsyth AJ, 2002, POWDER TECHNOL, V126, P150, DOI 10.1016/S0032-5910(02)00046-3
   Fu ZJ, 2019, CHEM ENG J, V359, P1372, DOI 10.1016/j.cej.2018.11.041
   Gauthier D, 1999, CHEM ENG J, V74, P181, DOI 10.1016/S1385-8947(99)00075-3
   GELDART D, 1973, POWDER TECHNOL, V7, P285, DOI 10.1016/0032-5910(73)80037-3
   Girimonte R, 2009, POWDER TECHNOL, V189, P74, DOI 10.1016/j.powtec.2008.06.006
   Gong Z, 2019, CHINESE J CHEM ENG, V27, P1177, DOI 10.1016/j.cjche.2018.07.020
   Goo J.H., 2010, P 20 INT C FLUID BED, P305
   Gul S, 2018, APPL THERM ENG, V130, P203, DOI 10.1016/j.applthermaleng.2017.11.021
   HOFFMANN AC, 1986, CHEM ENG COMMUN, V41, P133, DOI 10.1080/00986448608911716
   Kang SH, 2004, J IND ENG CHEM, V10, P330
   KRUPP H, 1967, ADV COLLOID INTERFAC, V1, P111, DOI DOI 10.1016/0001-8686(67)80004-6
   Lasek JA, 2013, ENERGY, V62, P105, DOI 10.1016/j.energy.2013.04.079
   Lasek JA, 2012, ENERG FUEL, V26, P6492, DOI 10.1021/ef201677f
   Lettieri P, 2000, POWDER TECHNOL, V110, P117, DOI 10.1016/S0032-5910(99)00274-0
   Li L, 2018, INT J MULTIPHAS FLOW, V108, P1, DOI 10.1016/j.ijmultiphaseflow.2018.06.020
   Li QJ, 2009, CAN J CHEM ENG, V87, P169, DOI 10.1002/cjce.20151
   Lin CL, 2002, POWDER TECHNOL, V126, P297, DOI 10.1016/S0032-5910(02)00074-8
   Ma JL, 2013, POWDER TECHNOL, V235, P271, DOI 10.1016/j.powtec.2012.10.016
   OLOWSON PA, 1991, CHEM ENG SCI, V46, P637, DOI 10.1016/0009-2509(91)80023-R
   Pang L., 1983, J ENG THERMOPHYSICS, V4, P405
   Pang L, 2019, ENERG FUEL, V33, P1694, DOI 10.1021/acs.energyfuels.8b02654
   Pang L, 2018, ENERGY, V165, P1119, DOI 10.1016/j.energy.2018.09.198
   PATTIPATI RR, 1981, IND ENG CHEM PROC DD, V20, P705, DOI 10.1021/i200015a022
   Rasteh M, 2018, POWDER TECHNOL, V338, P563, DOI 10.1016/j.powtec.2018.07.077
   Seville JPK, 2000, POWDER TECHNOL, V113, P261, DOI 10.1016/S0032-5910(00)00309-0
   Shabanian J, 2017, CHEM ENG J, V313, P580, DOI 10.1016/j.cej.2016.12.061
   Shao YJ, 2019, POWDER TECHNOL, V350, P81, DOI 10.1016/j.powtec.2019.03.039
   Shao YJ, 2016, POWDER TECHNOL, V304, P73, DOI 10.1016/j.powtec.2016.06.054
   Shao YJ, 2014, CAN J CHEM ENG, V92, P742, DOI 10.1002/cjce.21888
   Shao YJ, 2013, POWDER TECHNOL, V234, P67, DOI 10.1016/j.powtec.2012.09.019
   Sidorenko I, 2004, POWDER TECHNOL, V141, P137, DOI 10.1016/j.powtec.2004.02.019
   Subramani HJ, 2007, EXP THERM FLUID SCI, V32, P166, DOI 10.1016/j.expthermflusci.2007.03.003
   Wang XJ, 2011, ENERG FUEL, V25, P3815, DOI 10.1021/ef200403w
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
   WU SY, 1991, POWDER TECHNOL, V67, P217, DOI 10.1016/0032-5910(91)80158-F
   YAMAZAKI R, 1995, POWDER TECHNOL, V84, P15, DOI 10.1016/0032-5910(95)02973-6
   ZHENG ZX, 1985, KAGAKU KOGAKU RONBUN, V11, P115
   Zhong WQ, 2008, CHEM ENG J, V139, P42, DOI 10.1016/j.cej.2007.07.075
   Zhong WQ, 2007, POWDER TECHNOL, V175, P90, DOI 10.1016/j.powtec.2007.01.034
   Zhong WQ, 2008, ENERG FUEL, V22, P4170, DOI 10.1021/ef800495u
   Zhou GW, 2018, FUEL, V234, P965, DOI 10.1016/j.fuel.2018.07.142
   Zhu ZP, 2007, J THERM SCI, V16, P264, DOI 10.1007/s11630-007-0264-2
NR 51
TC 0
Z9 0
U1 4
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115555
DI 10.1016/j.ces.2020.115555
PG 12
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300024
DA 2020-05-12
ER

PT J
AU Strasser, W
AF Strasser, Wayne
TI The war on liquids: Disintegration and reaction by enhanced pulsed
   blasting
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Acoustics; Turbulence; CFD
ID ATOMIZATION; SLURRY; FLOWS; LAYER
AB Under certain conditions in preferred three-stream geometries, a non-Newtonian airblast atomization flowfield violently pulses (axially and radially) by self-generating and self-sustaining interfacial instability mechanisms. The pulsing is severe enough to send acoustic waves throughout feed piping networks. The most recent work on this system instructed that exothermic chemical reactions enhance this moderate Mach number atomization. Explored herein is the potential to further enhance reaction-assisted disintegration by independently superimposing both sinusoidal and randomized mass flow fluctuations of +/- 50% of the mean onto otherwise constant gas feed streams using surrogate models. Two nozzle geometries (low versus high prefilming distance) and multiple superimposed feed frequencies (ranging from below to above the naturally dominant tone) are considered for each gas stream, making twenty-one total long-running unsteady PLIC-VOF CFD models. Droplet size, plus nine other temporal measures, were considered for assessing atomizer performance in our energy production process. Results indicate that superimposed frequencies have potential to enhance chaotic atomization in a statistically significant manner. Depending on the geometry, the largest effect was about a 10% reduction in droplet size; however, some combinations experienced a droplet size increase. Only marginal differences were seen in the nine other measures, such as injector face heat exposure. In addition to the immediate industrial benefit from modulation, dramatic changes in acoustics were produced by imposed feed perturbations at frequencies lower than the natural tone. A detailed study of start-up flow reveals new mechanisms which explain performance differences. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Strasser, Wayne] Eastman Chem Co, POB 511, Kingsport, TN 37660 USA.
RP Strasser, W (reprint author), Eastman Chem Co, POB 511, Kingsport, TN 37660 USA.
EM wstrasser@liberty.edu
CR Ahmed M, 2014, CHEM ENG SCI, V107, P149, DOI 10.1016/j.ces.2013.12.004
   Bazdidi-Tehrani F, 2018, CHEM ENG SCI, V189, P233, DOI 10.1016/j.ces.2018.05.046
   Bukov M, 2015, ADV PHYS, V64, P139, DOI 10.1080/00018732.2015.1055918
   Dombrowski N., 1963, CHEM ENG SCI, V158, P227
   GREENSPAN HP, 1963, J FLUID MECH, V15, P133, DOI 10.1017/S0022112063000112
   LING Y, 2019, J FLUID MECH, V859, P268, DOI DOI 10.1017/JFM.2018.825
   Mantripragada V.T., 2017, CHEM ENG SCI, V18, P203
   Rajabi A, 2017, CHEM ENG SCI, V165, P89, DOI 10.1016/j.ces.2017.02.024
   Shaikh J, 2018, CHEM ENG SCI, V176, P77, DOI 10.1016/j.ces.2017.10.022
   Strasser W, 2018, ATOMIZATION SPRAY, V28, P643, DOI 10.1615/AtomizSpr.2018026380
   Strasser W., 2018, CHEM ENG SCI, P214
   Strasser W., 2016, ASME J FLUIDS ENG, V138
   Strasser W., 2015, P P INT MECH ENG C E
   Strasser W, 2018, J FLUID ENG-T ASME, V140, DOI 10.1115/1.4039234
   Strasser W, 2017, ATOMIZATION SPRAY, V27, P929, DOI 10.1615/AtomizSpr.2017020111
   Strasser W, 2017, CHEM ENG J, V309, P532, DOI 10.1016/j.cej.2016.10.046
   Strasser W, 2016, J FLUID ENG-T ASME, V138, DOI 10.1115/1.4033422
   Strasser W, 2014, PROG COMPUT FLUID DY, V14, P386, DOI 10.1504/PCFD.2014.065467
   Strasser W, 2011, INT J MULTIPHAS FLOW, V37, P831, DOI 10.1016/j.ijmultiphaseflow.2011.01.011
   Strasser W, 2008, J FLUID ENG-T ASME, V130, DOI 10.1115/1.2816008
   Tian XW, 2018, CHEM ENG SCI, V183, P13, DOI 10.1016/j.ces.2018.02.040
   von Keyserlingk CW, 2016, PHYS REV B, V94, DOI 10.1103/PhysRevB.94.085112
   Xie ZH, 2017, CHEM ENG SCI, V166, P303, DOI 10.1016/j.ces.2017.04.015
   Xue ZC, 2018, CHEM ENG SCI, V190, P248, DOI 10.1016/j.ces.2018.06.039
   Zhang Q, 2017, CHEM ENG SCI, V162, P104, DOI 10.1016/j.ces.2016.12.072
NR 25
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115458
DI 10.1016/j.ces.2019.115458
PG 12
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300004
DA 2020-05-12
ER

PT J
AU Teklu, H
   Gautam, DK
   Subbiah, S
AF Teklu, Habtom
   Gautam, Dinesh Kumar
   Subbiah, Senthilmurugan
TI Axial flow hollow fiber forward osmosis module analysis for optimum
   design and operating conditions in desalination applications
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Forward osmosis; Axial flow; Hollow fiber; Modeling; Multi-objective
   optimization
ID PRESSURE-RETARDED OSMOSIS; INTERNAL CONCENTRATION POLARIZATION; SPIRAL
   WOUND MODULE; MEMBRANE PROCESSES; POWER-GENERATION; MODEL PARAMETERS;
   FLUX BEHAVIOR; WATER; DIFFUSION
AB In this article, a mathematical model is developed for axial flow hollow fiber (HF) forward osmosis (FO) module and validated with unsteady-state FO experimental data of NaCl-H2O system. A maximum of 0.7 and 12% deviation in draw solution (DS) and feed solution (FS) concentration shows a good agreement between experimental results and model outputs. Simulations were carried out at various module length and operating conditions to analyze their effects on permeate flow rate and power consumption. Based on the simulation results, a multi-objective optimization (MOO) was formulated to get optimal Pareto between FO water flux and power supplied to the pump by considering the module length, DS and FS pressure and flow rate as decision variables. The optimization analysis revealed the exponential behavior of power consumption with respect to the permeate flow rate. Finally, a procedure to optimize the FO plant performance using MOO optimal Pareto is presented. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Teklu, Habtom; Gautam, Dinesh Kumar; Subbiah, Senthilmurugan] Indian Inst Technol Guwahati, Dept Chem Engn, Gauhati 781039, Assam, India.
RP Subbiah, S (reprint author), Indian Inst Technol Guwahati, Dept Chem Engn, Gauhati 781039, Assam, India.
EM exohabt@gmail.com; gdineshkb@iitg.ac.in; senthilmurugan@iitg.ac.in
FU Department of Science and Technology, Government of IndiaDepartment of
   Science & Technology (India) [DST/TMI/WTI/2K16173 (G)]
FX This work is carried as part of the on-going technology development
   project in title "Membrane-based efficient energy storage, clean energy
   generation, and wastewater treatment system". This project is supported
   by the Department of Science and Technology, Government of India,
   Project Number DST/TMI/WTI/2K16173 (G).
CR Achilli A, 2009, J MEMBRANE SCI, V343, P42, DOI 10.1016/j.memsci.2009.07.006
   Achilli A, 2009, DESALINATION, V239, P10, DOI 10.1016/j.desal.2008.02.022
   Ali SM, 2018, WATER RES, V145, P429, DOI 10.1016/j.watres.2018.08.050
   [Anonymous], 2014, FORWARDOSMOSISTECH
   Attarde D, 2016, SEP PURIF TECHNOL, V164, P182, DOI 10.1016/j.seppur.2016.03.039
   Attarde D, 2015, DESALINATION, V361, P81, DOI 10.1016/j.desal.2015.01.025
   Baker R W, 2012, MEMBRANE TECHNOLOGY
   Bhattacharjee C, 2017, INNOV FOOD SCI EMERG, V43, P136, DOI 10.1016/j.ifset.2017.08.002
   Blandin G, 2015, DESALINATION, V363, P26, DOI 10.1016/j.desal.2014.12.011
   Boo C, 2012, J MEMBRANE SCI, V390, P277, DOI 10.1016/j.memsci.2011.12.001
   Bui NN, 2015, J MEMBRANE SCI, V492, P289, DOI 10.1016/j.memsci.2015.02.001
   Cath TY, 2005, J MEMBRANE SCI, V257, P85, DOI 10.1016/j.memsci.2004.08.039
   Cath TY, 2006, J MEMBRANE SCI, V281, P70, DOI 10.1016/j.memsci.2006.05.048
   Chatterjee A, 2004, J MEMBRANE SCI, V236, P1, DOI 10.1016/j.memsci.2004.01.006
   Cohen D., 2004, CHEM PROCESS, V67, P29
   COSTELLO MJ, 1993, J MEMBRANE SCI, V80, P1, DOI 10.1016/0376-7388(93)85127-I
   Garcia-Castello EM, 2009, J MEMBRANE SCI, V338, P61, DOI 10.1016/j.memsci.2009.04.011
   Gu B, 2011, J MEMBRANE SCI, V379, P403, DOI 10.1016/j.memsci.2011.06.012
   Han G, 2015, PROG POLYM SCI, V51, P1, DOI 10.1016/j.progpolymsci.2015.04.005
   Holloway RW, 2007, WATER RES, V41, P4005, DOI 10.1016/j.watres.2007.05.054
   Jiao B, 2004, J FOOD ENG, V63, P303, DOI 10.1016/j.jfoodeng.2003.08.003
   Kim JE, 2018, WATER RES, V128, P183, DOI 10.1016/j.watres.2017.10.042
   KRAVATH RE, 1975, DESALINATION, V16, P151, DOI 10.1016/S0011-9164(00)82089-5
   Lee KP, 2011, J MEMBRANE SCI, V370, P1, DOI 10.1016/j.memsci.2010.12.036
   Linares RV, 2016, WATER RES, V88, P225, DOI 10.1016/j.watres.2015.10.017
   Madhani SP, 2016, ASAIO J, V62, P329, DOI 10.1097/MAT.0000000000000348
   McCutcheon JR, 2006, J MEMBRANE SCI, V284, P237, DOI 10.1016/j.memsci.2006.07.049
   McGovern RK, 2014, J MEMBRANE SCI, V469, P245, DOI 10.1016/j.memsci.2014.05.061
   MEHTA GD, 1978, J MEMBRANE SCI, V4, P261, DOI 10.1016/S0376-7388(00)83301-3
   Penate B, 2012, DESALINATION, V284, P1, DOI 10.1016/j.desal.2011.09.010
   SABRY R, 2015, INT J CHEMTECH RES, V8, P102
   Sekino M, 1995, DESALINATION, V100, P85, DOI 10.1016/0011-9164(96)00010-0
   SEKINO M, 1993, J MEMBRANE SCI, V85, P241, DOI 10.1016/0376-7388(93)85278-5
   Senthilmurugan S, 2006, J MEMBRANE SCI, V279, P466, DOI 10.1016/j.memsci.2005.12.041
   Setiawan L, 2011, J MEMBRANE SCI, V369, P196, DOI 10.1016/j.memsci.2010.11.067
   Shenvi SS, 2015, DESALINATION, V368, P10, DOI 10.1016/j.desal.2014.12.042
   Shibuya M, 2016, J MEMBRANE SCI, V504, P10, DOI 10.1016/j.memsci.2015.12.040
   Su JC, 2010, J MEMBRANE SCI, V355, P36, DOI 10.1016/j.memsci.2010.03.003
   Tanaka Y, 2018, DESALINATION, V447, P133, DOI 10.1016/j.desal.2018.09.015
   Tang CYY, 2010, J MEMBRANE SCI, V354, P123, DOI 10.1016/j.memsci.2010.02.059
   Tiraferri A, 2013, J MEMBRANE SCI, V444, P523, DOI 10.1016/j.memsci.2013.05.023
   Touati K, 2016, DESALINATION, V389, P171, DOI 10.1016/j.desal.2016.02.014
   VITAGLIANO V, 1956, J AM CHEM SOC, V78, P1549, DOI 10.1021/ja01589a011
   Wang KY, 2007, J MEMBRANE SCI, V300, P6, DOI 10.1016/j.memsci.2007.05.035
   Wang R, 2010, J MEMBRANE SCI, V355, P158, DOI 10.1016/j.memsci.2010.03.017
   Xia LL, 2017, IND ENG CHEM RES, V56, P11919, DOI 10.1021/acs.iecr.7b02368
   Xiao DZ, 2012, J MEMBRANE SCI, V392, P76, DOI 10.1016/j.memsci.2011.12.006
   Yip NY, 2011, ENVIRON SCI TECHNOL, V45, P4360, DOI 10.1021/es104325z
   Yip NY, 2010, ENVIRON SCI TECHNOL, V44, P3812, DOI 10.1021/es1002555
NR 49
TC 0
Z9 0
U1 3
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115494
DI 10.1016/j.ces.2020.115494
PG 18
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300016
DA 2020-05-12
ER

PT J
AU Wen, LY
   Xu, JC
   Yang, Q
   Zhang, FS
   Li, FB
   Zhang, LJ
AF Wen, Liyang
   Xu, Jianchang
   Yang, Qian
   Zhang, Fusheng
   Li, Fangbai
   Zhang, Lijuan
TI Gelation process of nanosilica sol and its mechanism: Molecular dynamics
   simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Nanosilica sol; Gelation process; Molecular dynamics simulation;
   Polycondensation reaction
ID MONTE-CARLO SIMULATIONS; SILICA POLYMERIZATION; CADMIUM ACCUMULATION;
   FOLIAR APPLICATION; CHEMISTRY; GEL; SURFACES; FORCES; CELLS; MODEL
AB The spontaneous gelation tendency of nanosilica sol (NSS) greatly affects its application as a raw material in chemical production. Therefore, disclosing the gelation process and mechanism of NSS plays a vital role in effectively regulating the gelation process. Herein, we bring deep insight into the gelation process of NSS which mainly includes four stages: Short silicon oxide chains (Si-O chains) are formed on the surface of nanosilica particles. Si-O chains gradually grow into the solution. Si-O chains are intertwined and connected to the surface of the nanosilica particles. The 3D network gel structure is formed by using Si-O chains as a skeleton. The effect of silanol ionization on the gelation process and its mechanism was further explored. According to our results, appropriately increasing the ionization degree of silanol groups on silica surface or decreasing the ionization degree of silicic acids will greatly decrease the gelation process of NSS. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Wen, Liyang; Xu, Jianchang; Yang, Qian; Zhang, Fusheng; Zhang, Lijuan] South China Univ Technol, Sch Chem & Chem Engn, Guangdong Prov Key Lab Green Chem Prod Technol, Guangzhou 510640, Peoples R China.
   [Li, Fangbai] Guangdong Inst Ecoenvironm & Soil Sci, Guangdong Publ Lab Environm Sci & Technol, Guangzhou 510650, Peoples R China.
RP Zhang, LJ (reprint author), South China Univ Technol, Sch Chem & Chem Engn, Guangdong Prov Key Lab Green Chem Prod Technol, Guangzhou 510640, Peoples R China.
EM celjzh@scut.edu.cn
FU Key Research and Development Program of Guangdong Province, China
   [2019B110207002, 2019B110207001]; Fundamental Research Funds for the
   Central Universities of China, China [2019PY29]; National Natural
   Science Foundation of China, ChinaNational Natural Science Foundation of
   China [21776101, 21978105]
FX This work was financially supported by Key Research and Development
   Program of Guangdong Province, China (2019B110207002, 2019B110207001)
   the Fundamental Research Funds for the Central Universities of China,
   China (No. 2019PY29) and the National Natural Science Foundation of
   China, China (No. 21776101, No. 21978105).
CR BADLEY RD, 1990, LANGMUIR, V6, P792, DOI 10.1021/la00094a013
   Belton DJ, 2012, FEBS J, V279, P1710, DOI 10.1111/j.1742-4658.2012.08531.x
   BRINKER CJ, 1985, J NON-CRYST SOLIDS, V70, P301, DOI 10.1016/0022-3093(85)90103-6
   Cui JH, 2017, ENVIRON POLLUT, V228, P363, DOI 10.1016/j.envpol.2017.05.014
   Ding XD, 2013, PROCEDIA ENVIRON SCI, V18, P58, DOI 10.1016/j.proenv.2013.04.009
   Emami FS, 2014, CHEM MATER, V26, P2647, DOI 10.1021/cm500365c
   Feng JD, 2016, COLLOID SURFACE A, V506, P298, DOI 10.1016/j.colsurfa.2016.06.052
   Greger M, 2016, ENVIRON POLLUT, V211, P90, DOI 10.1016/j.envpol.2015.12.027
   Gurav JL, 2010, J NANOMATER, DOI 10.1155/2010/409310
   HENCH LL, 1990, CHEM REV, V90, P33, DOI 10.1021/cr00099a003
   Khan MN, 2014, J PHYS CHEM B, V118, P10989, DOI 10.1021/jp504961q
   Kobayashi M, 2005, LANGMUIR, V21, P5761, DOI 10.1021/la046829z
   Liu CP, 2014, RSC ADV, V4, P57227, DOI 10.1039/c4ra08496a
   Liu CP, 2009, J HAZARD MATER, V161, P1466, DOI 10.1016/j.jhazmat.2008.04.116
   Malani A, 2011, J PHYS CHEM C, V115, P15988, DOI 10.1021/jp202209g
   Moqadam M, 2017, PHYS CHEM CHEM PHYS, V19, P13361, DOI 10.1039/c7cp01268c
   Morris CA, 1999, SCIENCE, V284, P622, DOI 10.1126/science.284.5414.622
   Ninham BW, 1999, ADV COLLOID INTERFAC, V83, P1, DOI 10.1016/S0001-8686(99)00008-1
   Owens GJ, 2016, PROG MATER SCI, V77, P1, DOI 10.1016/j.pmatsci.2015.12.001
   PASHLEY RM, 1981, J COLLOID INTERF SCI, V83, P531, DOI 10.1016/0021-9797(81)90348-9
   Patwardhan SV, 2012, J AM CHEM SOC, V134, P6244, DOI 10.1021/ja211307u
   Pereira JCG, 1998, CHEM COMMUN, P1387, DOI 10.1039/a801816b
   Rimola A, 2016, J PHYS CHEM C, V120, P24817, DOI 10.1021/acs.jpcc.6b07945
   Rimola A, 2013, CHEM REV, V113, P4216, DOI 10.1021/cr3003054
   Saiev S, 2017, POLYM CHEM-UK, V8, P5988, DOI 10.1039/c7py00995j
   Sarwar N, 2010, J SCI FOOD AGR, V90, P925, DOI 10.1002/jsfa.3916
   Scholze H., 2012, GLASS NATURE STRUCTU
   Schroder HC, 2012, SILICON-NETH, V4, P33, DOI 10.1007/s12633-010-9057-4
   Trinh TT, 2006, J PHYS CHEM B, V110, P23099, DOI 10.1021/jp063670l
   Trinh TT, 2009, J PHYS CHEM C, V113, P2647, DOI 10.1021/jp076372c
   Varshney V, 2008, MACROMOLECULES, V41, P6837, DOI 10.1021/ma801153e
   Xuan MJ, 2016, J AM CHEM SOC, V138, P6492, DOI 10.1021/jacs.6b00902
   Yang H, 2015, SOFT MATTER, V11, P6305, DOI 10.1039/c5sm00942a
   Yang WF, 2017, LANGMUIR, V33, P1037, DOI 10.1021/acs.langmuir.6b04060
   Zargartalebi M, 2015, FUEL, V143, P21, DOI 10.1016/j.fuel.2014.11.040
   Zhang XQ, 2011, J AM CHEM SOC, V133, P6613, DOI 10.1021/ja110357k
   Zheng XR, 2018, SMART MATER STRUCT, V27, DOI 10.1088/1361-665X/aad7a1
NR 37
TC 0
Z9 0
U1 2
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115538
DI 10.1016/j.ces.2020.115538
PG 11
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300022
DA 2020-05-12
ER

PT J
AU Windows-Yule, CRK
   Moore, A
   Wellard, C
   Werner, D
   Parker, DJ
   Seville, JPK
AF Windows-Yule, C. R. K.
   Moore, A.
   Wellard, C.
   Werner, D.
   Parker, D. J.
   Seville, J. P. K.
TI Particle distributions in binary gas-fluidised beds: Shape matters - But
   not much
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Plastic recycling; Positron emission particle tracking; Fluidised bed;
   Segregation; Mixing; Shape
ID FLOW; SEGREGATION; PYROLYSIS; REACTOR; SIZE
AB While the influence of particle size and geometry on the dynamics of binary fluidised beds have been widely studied, the role of particle shape remains poorly understood. Using 3D-printed PLA particles with geometries chosen to allow significant alterations in geometry while maintaining a constant volume and density, we are able to isolate and hence systematically study the influence of particles' shape on their spatial distribution throughout the system. Using Positron Emission Particle Tracking, we track the motion of particles throughout the full, three-dimensional volume of the system, thereby characterising the distribution of PLA particles within the bed. Despite varying the aspect ratio of particles by more than two orders of magnitude, only minimal changes in particle distribution are observed. Our results also give potentially valuable new insight into the internal behaviours of sand-plastic systems representative of those used in the pyrolytic recycling of plastic waste. (C) 2019 Elsevier Ltd. All rights reserved.
C1 [Windows-Yule, C. R. K.; Moore, A.; Wellard, C.; Werner, D.; Seville, J. P. K.] Univ Birmingham, Sch Chem Engn, Birmingham B15 2TT, W Midlands, England.
   [Parker, D. J.] Univ Birmingham, Sch Phys & Astron, Birmingham B15 2TT, W Midlands, England.
RP Windows-Yule, CRK (reprint author), Univ Birmingham, Sch Chem Engn, Birmingham B15 2TT, W Midlands, England.
EM c.r.windows-yule@bham.ac.uk
OI Windows-yule, Christopher/0000-0003-1305-537X
CR Chladek J, 2018, CHEM ENG SCI, V177, P151, DOI 10.1016/j.ces.2017.11.042
   Ciesielski PN, 2015, ENERG FUEL, V29, P242, DOI 10.1021/ef502204v
   Cleary PW, 2008, POWDER TECHNOL, V179, P144, DOI 10.1016/j.powtec.2007.06.018
   Clift R., 2012, GAS CLEANING HIGH TE
   Cocco R, 2014, CHEM ENG PROG, V110, P21
   Formisani B, 2011, AICHE J, V57, P2325, DOI 10.1002/aic.12450
   Formisani B., 2003, KONA POWDER PART J, V21, P66, DOI DOI 10.14356/KONA.2003010
   GELDART D, 1973, POWDER TECHNOL, V7, P285, DOI 10.1016/0032-5910(73)80037-3
   Girimonte R, 2018, CHEM ENG J, V335, P63, DOI 10.1016/j.cej.2017.10.135
   Hameed S, 2019, POWDER TECHNOL, V353, P202, DOI 10.1016/j.powtec.2019.04.064
   He YR, 2004, POWDER TECHNOL, V145, P88, DOI 10.1016/j.powtec.2004.04.047
   Kaminsky W, 2000, ANGEW CHEM INT EDIT, V39, P331, DOI 10.1002/(SICI)1521-3773(20000117)39:2<331::AID-ANIE331>3.0.CO;2-H
   Kaminsky W., 1996, RECYCLING RECOVERY P
   King DM, 2007, SURF COAT TECH, V201, P9163, DOI 10.1016/j.surfcoat.2007.05.002
   Li YN, 2014, CHEM ENG SCI, V117, P455, DOI 10.1016/j.ces.2014.07.012
   Mastellone ML, 2004, POLYM DEGRAD STABIL, V85, P1051, DOI 10.1016/j.polymdegradstab.2003.04.002
   Mastral FJ, 2002, J ANAL APPL PYROL, V63, P1, DOI 10.1016/S0165-2370(01)00137-1
   Parker DJ, 2017, REV SCI INSTRUM, V88, DOI 10.1063/1.4983046
   Parker DJ, 2002, NUCL INSTRUM METH A, V477, P540, DOI 10.1016/S0168-9002(01)01919-2
   SHIBATA K, 1991, ISIJ INT, V31, P434, DOI 10.2355/isijinternational.31.434
   Teunou E, 2002, J FOOD ENG, V53, P325, DOI 10.1016/S0260-8774(01)00173-X
   Wildman R., 2000, PHYS REV E, V62
   Windows-Yule C., 2016, NEW J PHYS, V18
   Windows-Yule CRK, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.098001
NR 24
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115440
DI 10.1016/j.ces.2019.115440
PG 4
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300002
DA 2020-05-12
ER

PT J
AU Ye, CM
   Wu, XY
   Wu, H
   Yang, LX
   Ren, YX
   Wu, YZ
   Liu, YT
   Guo, ZY
   Zhao, R
   Jiang, ZY
AF Ye, Chumei
   Wu, Xingyu
   Wu, Hong
   Yang, Leixin
   Ren, Yanxiong
   Wu, Yingzhen
   Liu, Yutao
   Guo, Zheyuan
   Zhao, Rui
   Jiang, Zhongyi
TI Incorporating nano-sized ZIF-67 to enhance selectivity of polymers of
   intrinsic microporosity membranes for biogas upgrading
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Polymers of intrinsic microporosity; Nano-sized ZIFs; Mixed matrix
   membrane; Biogas upgrading; Modified Maxwell model
ID MIXED MATRIX MEMBRANES; GAS PERMEATION PARAMETERS; PARTIAL PORE
   BLOCKAGE; CHAIN RIGIDIFICATION; ORGANIC FRAMEWORK; PARTICLE-SIZE;
   SEPARATION; PERFORMANCE; PERMEABILITY; SPHERES
AB Membrane-based separations are of energy-efficient and environmentally benign attributes for biogas energy developments. Membranes from polymers of intrinsic microporosity (PIMs) often suffer from low selectivity. In this study, remarkable enhancements in CO2/CH4 selectivity of PIM-1 membranes are achieved by incorporating nano-sized ZIF-67 (ZIF-S) filler with a larger specific surface area and a better compatibility, thereby fortifying the interactions with PIM-1 matrix and effectively alleviating nonselective interfacial voids. For the resulting PIM-1/ZIF-S membranes, a maximum CO2/CH4 selectivity of 21.1 was acquired with 15 wt% loading of ZIF-S, an increase of 69.40% compared with the pristine PIM-1 membrane, along with an associated CO2 permeability above 2800 Barrer. To elucidate gas transport behaviors within membranes, a modified Maxwell model is developed and the calculation results match well with the experimental data. The strategy of incorporating framework nanofillers into membranes may find promising applications in enhancing the selectivity of highly permeable polymer membranes. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ye, Chumei; Wu, Xingyu; Wu, Hong; Yang, Leixin; Ren, Yanxiong; Wu, Yingzhen; Liu, Yutao; Guo, Zheyuan; Zhao, Rui; Jiang, Zhongyi] Tianjin Univ, Sch Chem Engn & Technol, Key Lab Green Chem Technol, Minist Educ, Tianjin 300072, Peoples R China.
   [Ye, Chumei; Wu, Xingyu; Wu, Hong; Yang, Leixin; Ren, Yanxiong; Wu, Yingzhen; Liu, Yutao; Guo, Zheyuan; Zhao, Rui; Jiang, Zhongyi] Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin 300072, Peoples R China.
   [Jiang, Zhongyi] Joint Sch Natl Univ Singapore & Tianjin Univ, Int Campus Tianjin Univ, Fuzhou 350207, Peoples R China.
RP Jiang, ZY (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Key Lab Green Chem Technol, Minist Educ, Tianjin 300072, Peoples R China.
EM hyjiang@tju.edu.cn
FU National Key Research and Development Program of China [2017YFB0603400];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21838008, 21621004]; State Key Laboratory of
   Separation Membranes and Membrane Processes and Tianjin Polytechnic
   University [M1-201501]; National Key Laboratory of United Laboratory for
   Chemical Engineering [SKL-ChE-17B01]
FX The authors gratefully acknowledge the financial support from the
   National Key Research and Development Program of China (2017YFB0603400),
   National Natural Science Foundation of China (Nos. 21838008 and
   21621004), State Key Laboratory of Separation Membranes and Membrane
   Processes and Tianjin Polytechnic University (No. M1-201501), National
   Key Laboratory of United Laboratory for Chemical Engineering
   (SKL-ChE-17B01).
CR Adatoz E, 2015, SEP PURIF TECHNOL, V152, P207, DOI 10.1016/j.seppur.2015.08.020
   Bae TH, 2010, ANGEW CHEM INT EDIT, V49, P9863, DOI 10.1002/anie.201006141
   Banerjee R, 2008, SCIENCE, V319, P939, DOI 10.1126/science.1152516
   Benzaqui M, 2016, ACS APPL MATER INTER, V8, P27311, DOI 10.1021/acsami.6b08954
   Bouma RHB, 1997, J MEMBRANE SCI, V128, P141, DOI 10.1016/S0376-7388(96)00303-1
   Budd PM, 2010, POLYM CHEM-UK, V1, P63, DOI 10.1039/b9py00319c
   Budd PM, 2008, J MEMBRANE SCI, V325, P851, DOI 10.1016/j.memsci.2008.09.010
   Budd PM, 2004, CHEM COMMUN, P230, DOI 10.1039/b311764b
   Bunz UHF, 1999, CHEM MATER, V11, P1416, DOI 10.1021/cm990036u
   Bushell AF, 2013, J MEMBRANE SCI, V427, P48, DOI 10.1016/j.memsci.2012.09.035
   Chen XY, 2015, RSC ADV, V5, P24399, DOI 10.1039/c5ra00666j
   Chung TS, 2007, PROG POLYM SCI, V32, P483, DOI 10.1016/j.progpolymsci.2007.01.008
   Cullity BD, 2001, ELEMENTS XRAY DIFFRA
   Dechnik J, 2017, CRYST GROWTH DES, V17, P4467, DOI 10.1021/acs.cgd.7b00595
   Deng LY, 2010, INT J GREENH GAS CON, V4, P638, DOI 10.1016/j.ijggc.2009.12.013
   Ding XL, 2018, CHINESE J CHEM ENG, V26, P501, DOI 10.1016/j.cjche.2017.07.017
   Du NY, 2008, MACROMOLECULES, V41, P9656, DOI 10.1021/ma801858d
   Fang MQ, 2015, J MEMBRANE SCI, V474, P103, DOI 10.1016/j.memsci.2014.09.040
   Galizia M, 2017, MACROMOLECULES, V50, P7809, DOI 10.1021/acs.macromol.7b01718
   Ge L, 2013, J MATER CHEM A, V1, P6350, DOI 10.1039/c3ta11131h
   Ghalei B, 2017, NAT ENERGY, V2, DOI 10.1038/nenergy.2017.86
   Hou QQ, 2019, ANGEW CHEM INT EDIT, V58, P327, DOI 10.1002/anie.201811638
   Japip S, 2016, IND ENG CHEM RES, V55, P9507, DOI 10.1021/acs.iecr.6b02811
   Japip S, 2014, J MEMBRANE SCI, V467, P162, DOI 10.1016/j.memsci.2014.05.025
   Khan MM, 2013, J MEMBRANE SCI, V436, P109, DOI 10.1016/j.memsci.2013.02.032
   Lau CH, 2015, ANGEW CHEM INT EDIT, V54, P2669, DOI 10.1002/anie.201410684
   Lau CH, 2014, ANGEW CHEM INT EDIT, V53, P5322, DOI 10.1002/anie.201402234
   Li Y, 2006, J MEMBRANE SCI, V275, P17, DOI 10.1016/j.memsci.2005.08.015
   Li Y, 2005, J MEMBRANE SCI, V260, P45, DOI 10.1016/j.memsci.2005.03.019
   Li Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24091666
   Low ZX, 2018, CHEM REV, V118, P5871, DOI 10.1021/acs.chemrev.7b00629
   Mahajan R, 2002, POLYM ENG SCI, V42, P1420, DOI 10.1002/pen.11041
   Moore TT, 2005, J MOL STRUCT, V739, P87, DOI 10.1016/j.molstruc.2004.05.043
   Nguyen TB, 2016, J MEMBRANE SCI, V520, P941, DOI 10.1016/j.memsci.2016.08.045
   Petersson A, 2009, IEA BIOENERGY, V20, P1
   Ren YX, 2019, CHEM ENG SCI, V195, P230, DOI 10.1016/j.ces.2018.11.055
   Rezakazemi M, 2014, PROG POLYM SCI, V39, P817, DOI 10.1016/j.progpolymsci.2014.01.003
   Robeson LM, 2008, J MEMBRANE SCI, V320, P390, DOI 10.1016/j.memsci.2008.04.030
   ROBESON LM, 1991, J MEMBRANE SCI, V62, P165, DOI 10.1016/0376-7388(91)80060-J
   Rodenas T, 2015, NAT MATER, V14, P48, DOI [10.1038/NMAT4113, 10.1038/nmat4113]
   Sabetghadam A, 2016, ADV FUNCT MATER, V26, P3154, DOI 10.1002/adfm.201505352
   Semino R, 2016, ACS APPL MATER INTER, V8, P809, DOI 10.1021/acsami.5b10150
   Song QL, 2016, J MATER CHEM A, V4, P270, DOI 10.1039/c5ta09060a
   Song QL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5813
   Sorribas S, 2014, J MEMBRANE SCI, V452, P184, DOI 10.1016/j.memsci.2013.10.043
   Swaidan R, 2014, J MEMBRANE SCI, V457, P95, DOI 10.1016/j.memsci.2014.01.055
   Tan YC, 2016, CHEM COMMUN, V52, P11591, DOI 10.1039/c6cc05699g
   Thornton AW, 2012, ENERG ENVIRON SCI, V5, P7637, DOI 10.1039/c2ee21743k
   Tian ZZ, 2016, J MEMBRANE SCI, V514, P15, DOI 10.1016/j.memsci.2016.04.019
   Wang R, 2002, CHEM ENG SCI, V57, P967
   Wu XY, 2018, J MEMBRANE SCI, V548, P309, DOI 10.1016/j.memsci.2017.11.038
   Wu XY, 2017, J MEMBRANE SCI, V528, P273, DOI 10.1016/j.memsci.2017.01.042
   Yang LX, 2017, J MEMBRANE SCI, V543, P69, DOI 10.1016/j.memsci.2017.08.050
   Yin HD, 2017, IND ENG CHEM RES, V56, P9167, DOI 10.1021/acs.iecr.7b01833
   Yu GL, 2019, ADV MATER, V31, DOI 10.1002/adma.201806853
   Zornoza B, 2011, CHEMPHYSCHEM, V12, P2781, DOI 10.1002/cphc.201100583
   Zornoza B, 2011, J MEMBRANE SCI, V368, P100, DOI 10.1016/j.memsci.2010.11.027
   Zou XQ, 2018, ADV MATER, V30, DOI 10.1002/adma.201700750
NR 58
TC 0
Z9 0
U1 11
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115497
DI 10.1016/j.ces.2020.115497
PG 11
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300018
DA 2020-05-12
ER

PT J
AU Yu, X
   Cui, ZX
   Xue, YQ
   Zhang, JH
   Li, HX
   Song, XR
AF Yu, Xing
   Cui, Zixiang
   Xue, Yongqiang
   Zhang, Jianhua
   Li, Hongxing
   Song, Xinru
TI Curvature-dependent melting models and melting thermodynamics of
   nanotubes in theory and experiment
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Curvature effects; Melting models; Melting temperature; Melting
   thermodynamic properties; Nanotubes
ID SIZE DEPENDENCE; TEMPERATURE; BEHAVIOR; CRYSTALLIZATION; EVOLUTION;
   NANOWIRE
AB Currently, the melting thermodynamic properties of nanotubes are still unclear. In this paper, the generalized relation of chemical potential of nano-condensed phases was first derived, and two types of curvature surfaces with different phase transition activities were found on nanotubes. On this basis, two melting models of nanotubes were proposed, the relations between the melting temperature, the melting thermodynamic properties, respectively, and the curvature (reciprocal of the radius) of nanotubes were derived. And the correctness of the theory was verified by the melting of selenium nanotube. The results showed that the initial melting temperature, melting enthalpy and melting entropy decrease with increasing the curvature, and present good linear relationships with curvature, respectively. This theory can provide theoretical guidance and new clues for the design, preparation, research and applications of nanomaterials with negative curvature surface. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Yu, Xing; Cui, Zixiang; Xue, Yongqiang; Zhang, Jianhua; Li, Hongxing; Song, Xinru] Taiyuan Univ Technol, Dept Chem, Taiyuan 030024, Peoples R China.
RP Cui, ZX (reprint author), Taiyuan Univ Technol, Dept Chem, Taiyuan 030024, Peoples R China.
EM czxlw2018@163.com; xyqlw@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21573157, 21373147]
FX The authors are very grateful for the financial support from the
   National Natural Science Foundation of China (Nos. 21573157 and
   21373147).
CR Adamson A.W., 1997, PHYS CHEM SURFACES, P259
   Bao JC, 2001, ADV MATER, V13, P1631, DOI 10.1002/1521-4095(200111)13:21<1631::AID-ADMA1631>3.0.CO;2-R
   Barone PW, 2005, NAT MATER, V4, P86, DOI 10.1038/nmat1276
   Cao SK, 2018, LANGMUIR, V34, P13888, DOI 10.1021/acs.langmuir.8b03408
   COUCHMAN PR, 1977, NATURE, V269, P481, DOI 10.1038/269481a0
   Cui ZX, 2011, J PHYS CHEM C, V115, P22796, DOI 10.1021/jp2067364
   Cui ZX, 2017, J PHYS CHEM C, V121, P24831, DOI 10.1021/acs.jpcc.7b07193
   Delogu F, 2007, PHYS REV B, V75, DOI 10.1103/PhysRevB.75.235421
   Dick K, 2002, J AM CHEM SOC, V124, P2312, DOI 10.1021/ja017281a
   Engels S, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957-4484/24/3/035204
   FELDMAN Y, 1995, SCIENCE, V267, P222, DOI 10.1126/science.267.5195.222
   Firlej L, 2006, STUD SURF SCI CATAL, V160, P487
   Fu QS, 2018, J PHYS CHEM C, V122, P15713, DOI 10.1021/acs.jpcc.8b03085
   Hu WY, 2005, EUR PHYS J B, V45, P547, DOI 10.1140/epjb/e2005-00210-8
   IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0
   Jiang HJ, 2006, CHEM PHYS LETT, V429, P492, DOI 10.1016/j.cplett.2006.08.027
   Kijima T, 2004, ANGEW CHEM INT EDIT, V43, P228, DOI 10.1002/anie.200352630
   Kowaki Y, 2007, J PHYS-CONDENS MAT, V19, DOI 10.1088/0953-8984/19/43/436224
   Li P, 2010, SMALL, V6, P1096, DOI 10.1002/smll.201000226
   Li YD, 2001, J AM CHEM SOC, V123, P9904, DOI 10.1021/ja016435j
   Martin CR, 2001, J PHYS CHEM B, V105, P1925, DOI 10.1021/jp003486e
   Miao JJ, 2005, SMALL, V1, P802, DOI 10.1002/smll.200500072
   Morgan D, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.134404
   Oner IH, 2018, ANGEW CHEM INT EDIT, V57, P7225, DOI 10.1002/anie.201802597
   Ouyang G, 2012, NANOSCALE, V4, P2748, DOI 10.1039/c2nr30095h
   Pan LS, 2008, EUR PHYS J D, V50, P27, DOI 10.1140/epjd/e2008-00183-2
   Paterson BM, 2017, ANGEW CHEM INT EDIT, V56, P8370, DOI 10.1002/anie.201701596
   Sankarasubramanian R, 2010, COMP MATER SCI, V49, P386, DOI 10.1016/j.commatsci.2010.05.026
   Sar DK, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/20/205701
   Shen HJ, 2007, J MATER SCI, V42, P6382, DOI 10.1007/s10853-006-1205-2
   Shi LA, 2011, LANGMUIR, V27, P3977, DOI 10.1021/la104529h
   Shin HS, 2007, APPL PHYS LETT, V91, DOI 10.1063/1.2801520
   Tanaka T, 2001, Z METALLKD, V92, P1236
   TENNE R, 1992, NATURE, V360, P444, DOI 10.1038/360444a0
   Wang D., 2013, SMALL, V9, P1120
   Wang HF, 2018, CHEM ENG SCI, V177, P399, DOI 10.1016/j.ces.2017.11.023
   Wang H, 2010, CHINESE PHYS LETT, V27, DOI 10.1088/0256-307X/27/2/026101
   Wang LL, 2017, NAT CHEM, V9, P219, DOI [10.1038/NCHEM.2729, 10.1038/nchem.2729]
   Wang XW, 2006, APPL PHYS LETT, V88, DOI 10.1063/1.2199469
   Wang ZG, 2006, J APPL PHYS, V100, DOI 10.1063/1.2345616
   WUNDERLICH B, 1980, J CRYST GROWTH, V48, P227, DOI 10.1016/0022-0248(80)90212-2
   Xiang L, 2018, NANOSCALE, V10, P21857, DOI 10.1039/c8nr08259f
   Yaws C.L., 1999, CHEM PROPERTIES HDB, P207
   Yaws C.L., 1999, CHEM PROPERTIES HDB, P154
   Yaws C.L., 1999, CHEM PROPERTIES HDB, P155
   Yaws C.L., 1999, CHEM PROPERTIES HDB, P212
   Yu T, 2005, NANOTECHNOLOGY, V16, P1238, DOI 10.1088/0957-4484/16/8/043
   Zhang JC, 2018, COMP MATER SCI, V143, P248, DOI 10.1016/j.commatsci.2017.11.011
   Zhang JH, 2017, J ELECTROCHEM SOC, V164, pII828, DOI 10.1149/2.1741712jes
   Zhang KL, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957-4484/18/27/275607
   Zhang WX, 2010, J PHYS CHEM C, V114, P8717, DOI 10.1021/jp910246t
   Zhao J, 2011, J PHYS CHEM C, V115, P22347, DOI 10.1021/jp205381b
   Zhou GB, 2015, CHINESE J CHEM PHYS, V28, P623, DOI 10.1063/1674-0068/28/cjcp1502011
NR 53
TC 0
Z9 0
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD APR 28
PY 2020
VL 216
AR 115558
DI 10.1016/j.ces.2020.115558
PG 12
WC Engineering, Chemical
SC Engineering
GA KZ5QR
UT WOS:000523317300025
DA 2020-05-12
ER

PT J
AU Geweniger, A
   Abbas, KM
AF Geweniger, Anne
   Abbas, Kaja M.
TI Childhood vaccination coverage and equity impact in Ethiopia by
   socioeconomic, geographic, maternal, and child characteristics
SO VACCINE
LA English
DT Article
DE Immunisation coverage; Vaccine equity; Ethiopia; Demographic and health
   survey
ID MIDDLE-INCOME COUNTRIES; IMMUNIZATION COVERAGE; HEALTH
AB Background: Ethiopia is a priority country of Gavi, the Vaccine Alliance to improve vaccination coverage and equitable uptake. The Ethiopian National Expanded Programme on Immunisation (EPI) and the Global Vaccine Action Plan set coverage goals of 90% at national level and 80% at district level by 2020. This study analyses full vaccination coverage among children in Ethiopia and estimates the equity impact by socioeconomic, geographic, maternal and child characteristics based on the 2016 Ethiopia Demographic and Health Survey dataset.
   Methods: Full vaccination coverage (1-dose BCG, 3-dose DTP3-HepB-Hib, 3-dose polio, 1-dose measles (MCV1), 3-dose pneumococcal (PCV3), and 2-dose rotavirus vaccines) of 2,004 children aged 12-23 months was analysed. Mean coverage was disaggregated by socioeconomic (household wealth, religion, ethnicity), geographic (area of residence, region), maternal (maternal age at birth, maternal education, maternal marital status, sex of household head), and child (sex of child, birth order) characteristics. Concentration indices estimated wealth and education-related inequities, and multiple logistic regression assessed associations between full vaccination coverage and socioeconomic, geographic, maternal, and child characteristics.
   Results: Full vaccination coverage was 33.3% [29.4-37.2] in 2016. Single vaccination coverage ranged from 49.1% [45.1-53.1] for PCV3 to 69.2% [65.5-72.8] for BCG. Wealth and maternal education related inequities were pronounced with concentration indices of 0.30 and 0.23 respectively. Children in Addis Ababa and Dire Dawa were seven times more likely to have full vaccination compared to children living in the Afar region. Children in female-headed households were 49% less likely to have full vaccination.
   Conclusion: Vaccination coverage in Ethiopia has a pro-advantaged regressive distribution with respect to both household wealth and maternal education. Children from poorer households, rural regions of Afar and Somali, no maternal education, and female-headed households had lower full vaccination coverage. Targeted programmes to reach under-immunised children in these subpopulations will improve vaccination coverage and equity outcomes in Ethiopia. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Geweniger, Anne] Univ Freiburg, Univ Med Ctr, Fac Med, Ctr Paediat & Adolescent Med, Freiburg, Germany.
   [Geweniger, Anne] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London, England.
   [Abbas, Kaja M.] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.
RP Geweniger, A (reprint author), Univ Med Ctr, Ctr Paediat & Adolescent Med, Heiliggeiststr 1, D-79106 Freiburg, Germany.
EM anne.geweniger1@alumni.lshtm.ac.uk; kaja.abbas@lshtm.ac.uk
OI Abbas, Kaja/0000-0003-0563-1576
FU NIH/NIGMSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [R01GM109718]; Vaccine Impact Modelling
   Consortium [OPP1157270]
FX We had presented the study results to the Ethiopia Interest Group at the
   London School of Hygiene and Tropical Medicine and we thank them for
   their valuable feedback. We thank Schadrac Agbla, Ana Maria Buller, Lars
   Ake Persson, Billy Quilty, and Anne Schlotheuber for helpful
   discussions. KMA is supported by NIH/NIGMS R01GM109718 and the Vaccine
   Impact Modelling Consortium (OPP1157270). We thank the reviewers for
   their valuable feedback on previous versions of the manuscript.
CR Abadura SA, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2315-z
   Ambel AA, 2017, INT J EQUITY HEALTH, V16, DOI 10.1186/s12939-017-0648-1
   [Anonymous], 2015, STAT STAT SOFTW REL
   Arsenault C, 2017, VACCINE, V35, P951, DOI 10.1016/j.vaccine.2016.12.041
   Brearley L, 2013, VACCINE, V31, pB103, DOI 10.1016/j.vaccine.2012.11.088
   Brown DW, 2015, VACCINE, V33, P2584, DOI 10.1016/j.vaccine.2015.03.101
   Burton A, 2009, B WORLD HEALTH ORGAN, V87, P535, DOI 10.2471/BLT.08.053819
   Central Statistical Agency Ethiopia, 2016, DHS PROGR ETH STAND
   Croft T. N., 2018, GUIDE DHS STAT
   Cutts FT, 2016, VACCINE, V34, P4103, DOI 10.1016/j.vaccine.2016.06.053
   Delamonica E, 2016, LANCET GLOB HEALTH, V4, pE582, DOI 10.1016/S2214-109X(16)30189-9
   Ethiopia Federal Ministry of Health Addis Ababa, 2015, ETH NAT EXP PROGR IM
   Ethiopia Public Health Institute Federal Ministry of Health World Health Organisation, 2017, ETH SERV AV READ ASS
   Ethiopian Public Health Institute Federal Ministry of Health Ethiopia The DHS Program ICF, 2019, MIN DEM HLTH SURV 20
   Federal Ministry of Health Addis Ababa, 2010, ETH NAT EXP PROGR IM
   Forshaw J, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2890-y
   Gavi, 2019, VACC GOAL IND GAV VA
   Gavi, GAV COUNTR FACTSH
   Gavi, 2019, EV TECHN ASS PARTN E
   Gavi, 2019, NEW 2021 2025 HIGH L
   Gavi The Vaccine Alliance, 2019, VACC ALL LEARN IMM K
   Geremew TT, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7529-z
   Hosseinpoor AR, 2016, LANCET GLOB HEALTH, V4, pE617, DOI 10.1016/S2214-109X(16)30141-3
   ICF, 1984, DHS PROGR QUAL INF P
   Kassebaum N, 2017, JAMA PEDIATR, V171, P573, DOI 10.1001/jamapediatrics.2017.0250
   Kinfe Y, 2019, PLOS ONE, V14, DOI [10.1371/journal.pone.0225639e0225639, DOI 10.1371/JOURNAL.PONE.0225639E0225639]
   Lakew Y, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2078-6
   Li AJ, 2019, VACCINE, V37, P4281, DOI 10.1016/j.vaccine.2019.06.041
   Marefiaw TA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218470
   Mosser JF, 2019, LANCET, V393, P1843, DOI 10.1016/S0140-6736(19)30226-0
   Norheim OF, 2014, COST EFFECT RESOUR A, V12, DOI 10.1186/1478-7547-12-18
   O'Donnell O, 2016, STATA J, V16, P112, DOI 10.1177/1536867X1601600112
   ODonnell O, 2007, ANAL HLTH EQUITY USI, DOI [10.1596/978-0-8213-6933-3, DOI 10.1596/978-0-8213-6933-3]
   Peck M, 2019, MMWR-MORBID MORTAL W, V68, P937, DOI 10.15585/mmwr.mm6842a1
   Porth JM, 2019, VACCINE, V37, P2106, DOI 10.1016/j.vaccine.2019.02.045
   Rainey JJ, 2011, VACCINE, V29, P8215, DOI 10.1016/j.vaccine.2011.08.096
   Restrepo-Mendez MC, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.30963
   Sodha SV, 2015, BRIT MED BULL, V113, P5, DOI 10.1093/bmb/ldv001
   Tamirat KS, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7356-2
   Tauil MD, 2016, VACCINE, V34, P2635, DOI 10.1016/j.vaccine.2016.04.016
   Thorpe S, 2016, MATERN CHILD HLTH J, V20, P172, DOI 10.1007/s10995-015-1817-8
   United Nations, 2019, 2019 WORLD POP PROSP
   United Nations, 2015, TRANSF OUR WORLD 203
   Wagstaff A, 2011, HEALTH ECON, V20, P1155, DOI 10.1002/hec.1752
   WHO, 2012, GLOB VACC ACT PLAN 2
   WHO, 2016, PLANN IMPL HIGH QU S
   WHO, 2018, EXPL IN CHILDH IMM
   WHO Ethiopia, 2018, EXP PROGR IMM EPI 20
   WHO/UNICEF, 2019, WHO UNICEF EST IMM C
   Wiysonge CS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037905
   World Health Organization, 2019, IMM COV
   World Health Organization, 2016, ANN GVAP SECR ANN RE
NR 52
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 29
PY 2020
VL 38
IS 20
BP 3627
EP 3638
DI 10.1016/j.vaccine.2020.03.040
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TO
UT WOS:000525318200001
PM 32253099
OA Other Gold, Green Published
DA 2020-05-12
ER

PT J
AU Berrie, DM
   Waters, RC
   Montoya, C
   Chatel, A
   Vela, EM
AF Berrie, Dalton M.
   Waters, Robin C.
   Montoya, Christopher
   Chatel, Alex
   Vela, Eric M.
TI Development of a high-yield live-virus vaccine production platform using
   a novel fixed-bed bioreactor
SO VACCINE
LA English
DT Article
DE Vesicular stomatitis virus; Fixed-bed bioreactor; Vaccine development;
   scale-X carbo
AB The increasing importance of viral vaccine manufacturing has driven the need for high cell density process optimization that allows for higher production levels. Vero cells are one of the more popular adherent cell lines used for viral vaccine production. However, production is limited due to the logistical limitations surrounding adherent cell line processes, such as large equipment footprints, time and labor-intensive processes, and larger costs per dose. We have addressed this limitation with the establishment of a viral vaccine production system utilizing the novel single use scale-X (TM) carbo bioreactor. The unit is compact and is scalable and one of the novel features of the system is the continuous in-line downstream purification and concentration processes associated with the bioreactor vessel. We present the results from a campaign featuring a proprietary Vero cell line for production of a live recombinant Vesicular stomatitis virus vaccine that features the Lassa Fever virus glycoproteins. Metabolite analyses and viral yield comparison between traditional flasks, cell factories, and the scale-X carbo bioreactor were performed, and on average, the single use bioreactor produced 2-4 logs higher titers per surface area, approximately 5 x 10(10) pfu/cm(2), compared to classical flatstock, 2.67 x 10(6) pfu/cm(2), and cell factories production, 5.77 x 10(8) pfu/cm(2). Overall, we describe a novel bioreactor platform that allows for a cost-efficient and scalable process for viral vaccine production. (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Berrie, Dalton M.; Waters, Robin C.; Montoya, Christopher; Vela, Eric M.] Proc Dev, Ology Bioserv, 13200 NW Nano Ct, Alachua, FL 32615 USA.
   [Chatel, Alex] Univercells, Rue Maitise 11, B-1400 Nivelles, Belgium.
RP Vela, EM (reprint author), Proc Dev, Ology Bioserv, 13200 NW Nano Ct, Alachua, FL 32615 USA.
EM eric.vela@ologybio.com
FU Ology Bioservices Inc.
FX Funding for this study was provided by Ology Bioservices Inc.
CR Cureton DK, 2010, PLOS PATHOG, V6
   Fine SM, 2015, VESICULAR STOMATITIS, V2, P1981
   Geisbert T, 2005, PLOS MED
   Henao-Restrepo AM, 2017, LANCET, V389, P505, DOI 10.1016/S0140-6736(16)32621-6
   Legmann R., PALL LIFE SCI
   Lennaertz A, 2013, BMC P
   Lichty BD, 2004, TRENDS MOL MED, V10, P210, DOI 10.1016/j.molmed.2004.03.003
   Merten OW, 2001, BIOTECHNOL PROGR, V17, P326, DOI 10.1021/bp000162z
   Meuwly F, 2007, BIOTECHNOL ADV, V25, P45, DOI 10.1016/j.biotechadv.2006.08.004
   Monath T, 2019, RVSVDG ZEBOV GP ALSO, V1
   Moroni L, 2014, TISSUE ENG INTRO
   Muik A, 2012, J MOL MED, V90, P959, DOI 10.1007/s00109-012-0863-6
   Rajendran R, 2014, AMB EXPRESS, V4, DOI 10.1186/s13568-014-0025-z
   Strauss JH, 2008, VIRUSES HUMAN DIS, P137
   Tapia F, 2016, APPL MICROBIOL BIOT, V100, P2121, DOI 10.1007/s00253-015-7267-9
   Velazquez-Salinas L, 2017, HUM GENE THER CL DEV, V28, P108, DOI 10.1089/humc.2017.015
NR 16
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 29
PY 2020
VL 38
IS 20
BP 3639
EP 3645
DI 10.1016/j.vaccine.2020.03.041
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TO
UT WOS:000525318200002
PM 32247568
OA Other Gold
DA 2020-05-12
ER

PT J
AU Lin, JL
   Wood, JG
   Bernardo, C
   Stocks, NP
   Liu, B
AF Lin, Jialing
   Wood, James G.
   Bernardo, Carla
   Stocks, Nigel P.
   Liu, Bette
TI Herpes zoster vaccine coverage in Australia before and after
   introduction of a national vaccination program
SO VACCINE
LA English
DT Article
DE Herpes zoster; Vaccine; Coverage; Primary health care; Australia
ID UNITED-STATES; INFLUENZA VACCINATION; ADULT-POPULATIONS; SURVEILLANCE;
   ENGLAND
AB Background: In Australia, a herpes zoster (HZ) vaccination program targeting adults aged 70 years old with catch-up for those 71-79 years began in November 2016 but there is limited information on vaccine uptake and coverage achieved since commencement.
   Methods: We used a national de-identified electronic primary care dataset, MedicineInsight, and extracted records from patients turning 50-90 years old during 2016-2018. Among patients considered regular attenders, with at least one visit per year in the two years prior, we estimated the crude and adjusted average monthly HZ vaccine uptake in the target population (70-79 years old) for each year since program implementation as well as cumulative vaccine coverage until December 2018. Multivariate logistic regression was used to analyse characteristics associated with higher coverage.
   Results: Among 52,229, 55,034, and 57,316 regular attenders turning 70-79 years old in 2016, 2017 and 2018 respectively, the average monthly vaccine uptake rate was 5.5%, 3.3%, and 1.6% respectively. Up to 31st December 2018, the estimated cumulative vaccine coverage in regularly attending adults was 46.9% (25,791/55,034). It was substantially lower at 41.6% (27,040/65,010) using an alternate definition of a regular attender. Vaccine coverage differed by sex (women: 48.5% versus men: 45.1%, adjusted OR = 1.1, 95% CI: 1.1-1.2); by jurisdiction (compared to New South Wales: 43.7%, South Australia: 55.6%, aOR = 1.6, 95% CI (1.5-1.8); Northern Territory: 27.6%, aOR = 0.6, (0.5-0.7)); by remoteness status (compared to major cities: 47.6%, remote/very remote areas: 38.2%, aOR = 0.7, (0.6-0.8)); and by socioeconomic disadvantage (compared to most disadvantaged: 41.8%, most advantaged: 48.6%, aOR = 1.6 (1.2-2.1)).
   Conclusions: Our estimates of HZ vaccine coverage are substantially higher than the only other reports based on the Australian Immunisation Register however they still suggest that uptake is suboptimal. The use of electronic medical records can complement other data for estimating vaccine coverage in Australian adults. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Lin, Jialing; Wood, James G.; Liu, Bette] Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia.
   [Bernardo, Carla; Stocks, Nigel P.] Univ Adelaide, Adelaide Med Sch, Discipline Gen Practice, Adelaide, SA, Australia.
RP Lin, JL (reprint author), Univ New South Wales, Sch Publ Hlth & Community Med, Sydney, NSW 2052, Australia.
EM jialing.lin@student.unsw.edu.au
RI Bernardo, Carla/F-2909-2015
OI Bernardo, Carla/0000-0001-6998-6419; Wood, James/0000-0002-0122-4482;
   Liu, Bette/0000-0002-0787-5825
FU University International Postgraduate Awards under a UNSW Tuition Fee
   Scholarship; School of Public Health and Community Medicine Stipend
   Scholarship; NHMRC FellowshipNational Health and Medical Research
   Council of Australia
FX We thank the NPS MedicineWise MedicineInsight for providing the data for
   this study. J. Lin is supported by the University International
   Postgraduate Awards under a UNSW Tuition Fee Scholarship and a School of
   Public Health and Community Medicine Stipend Scholarship. B. Liu is
   supported by an NHMRC Fellowship.
CR Amirthalingam G, 2018, LANCET PUBLIC HEALTH, V3, pE82, DOI 10.1016/S2468-2667(17)30234-7
   Australian Bureau of Statistics, 2018, SOC IND AR SEIFA 201
   Australian Bureau of Statistics, 2018, AUSTR STAT GEOGR STA
   Australian Bureau of Statistics, 2018, PAT EXP AUSTR SUMM F
   Australian Government Australian Digital Health Agency, 2016, AUSTR IMM REG
   Australian Government Department of Health, 2014, HLTH ASS PEOPL AG 75
   Australian Institute of Health and Welfare 2011, 2011, 2009 AD VACC SURV SU
   Bernardo CD, 2019, VACCINE, V37, P4268, DOI 10.1016/j.vaccine.2019.06.057
   Busingye D, 2019, INT J EPIDEMIOL, V48, P1741, DOI 10.1093/ije/dyz147
   Chiyaka ET, 2019, PHARMACOECONOMICS, V37, P169, DOI 10.1007/s40273-018-0735-1
   Cunningham AL, 2017, EXPERT REV VACCINES, V16, P661, DOI 10.1080/14760584.2017.1329012
   Department of Health, 2014, NEWSP OMN SURV SUMM
   Dyda A, 2015, VACCINE, V33, P3299, DOI 10.1016/j.vaccine.2015.05.046
   Fogelberg S, 2018, PHARMACOEPIDEM DR S, V27, P1159, DOI 10.1002/pds.4653
   Frank O, 2020, HUM VACC IMMUNOTHER, V16, P965, DOI 10.1080/21645515.2019.1682844
   Hales Craig M, 2014, MMWR Morb Mortal Wkly Rep, V63, P729
   Hull BP, 2009, VACCINE, V27, P5054, DOI 10.1016/j.vaccine.2009.06.056
   James SF, 2018, ANN PHARMACOTHER, V52, P673, DOI 10.1177/1060028018758431
   Kost RG, 1996, NEW ENGL J MED, V335, P32, DOI 10.1056/NEJM199607043350107
   MacIntyre R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125025
   National Centre for Immunisation Research and Surveillance, 2019, EV NAT SHINGL VACC P
   National Centre for Immunisation Research and Surveillance, 2019, EXPL AN 1 2 YEARS AD
   Norris Tina, 2017, NCHS Data Brief, P1
   NPS MedicineWise, 2019, MEDICINEINSIGHT DAT
   NPS MedicineWise, 2019, MEDICINEINSIGHT GEN
   The Royal Australian College of General Practitioners, 2015, STAND GEN PRACT
   Ward C, 2017, VACCINE, V35, P2372, DOI 10.1016/j.vaccine.2017.03.042
   Williams WW, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6611a1
   Williams WW, 2016, MMWR SURVEILL SUMM, V65, P1, DOI 10.15585/mmwr.ss6501a1
   Williams WW, 2015, MMWR-MORBID MORTAL W, V64, P95
NR 30
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 29
PY 2020
VL 38
IS 20
BP 3646
EP 3652
DI 10.1016/j.vaccine.2020.03.036
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TO
UT WOS:000525318200003
PM 32245643
DA 2020-05-12
ER

PT J
AU Amaral, MP
   Apostolico, JD
   Tomita, N
   Coirada, FC
   Lunardelli, VAS
   Fernandes, ER
   Souza, HFS
   Astray, RM
   Boscardin, SB
   Rosa, DS
AF Amaral, Marcelo Pires
   Apostolico, Juliana de Souza
   Tomita, Nadia
   Coirada, Fernanda Caroline
   Santos Lunardelli, Victoria Alves
   Fernandes, Edgar Ruz
   Santos Souza, Higo Fernando
   Astray, Renato Mancini
   Boscardin, Silvia Beatriz
   Rosa, Daniela Santoro
TI Homologous prime-boost with Zika virus envelope protein and poly (I:C)
   induces robust specific humoral and cellular immune responses
SO VACCINE
LA English
DT Article
DE Subunit vaccine; DNA vaccine; Prime-boost; Adjuvant; Envelope; Zika
   virus
ID DNA VACCINE; INFECTION; ANTIBODIES; CELLS
AB The recent outbreaks of Zika virus (ZIKV) infection and the potential association with Guillain-Barre syndrome in adults and with congenital abnormalities have highlighted the urgency for an effective vaccine. The ZIKV Envelope glycoprotein (E-ZIKV) is the most abundant protein on the virus surface, and has been evaluated together with the pre-membrane protein (prM) of the viral coat as a vaccine candidate in clinical trials. In this study, we performed a head-to-head comparison of the immune response induced by different E-ZIKV-based vaccine candidates in mice. We compared different platforms (DNA, recombinant protein), adjuvants (poly (I:C), CpG ODN 1826) and immunization strategies (homologous, heterologous).
   The hierarchy of adjuvant potency showed that poly (I:C) was a superior adjuvant than CpG ODN. While poly (I:C) assisted immunization reached a plateau in antibody titers after two doses, the CpG ODN group required an extra immunization dose. Besides, the administration of poly (I:C) induced higher E-ZIKV-specific cellular immune responses than CpG ODN. We also show that immunization with homologous prime-boost EZIKV protein + poly (I:C) regimen induced a more robust humoral response than homologous DNA (pVAX-E-ZIKV) or heterologous regimens (DNA/protein or protein/DNA). A detailed analysis of cellular immune responses revealed that homologous (E-ZIKV + poly (I:C)) and heterologous (pVAX-E-ZIKV/E-ZIKV + poly (I:C)) prime-boost regimens induced the highest magnitude of IFN-gamma secreting cells and cytokine-producing CD4(+) T cells.
   Overall, our data demonstrate that homologous E-ZIKV + poly (I:C) prime-boost immunization is sufficient to induce more robust specific-E-ZIKV humoral and cellular immune responses than the other strategies that contemplate homologous DNA (pVAX-E-ZIKV) or heterologous (pVAX-E-ZIKV/E-ZIKV + poly (I:C), and vice-versa) immunizations. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Amaral, Marcelo Pires; Apostolico, Juliana de Souza; Tomita, Nadia; Coirada, Fernanda Caroline; Santos Lunardelli, Victoria Alves; Fernandes, Edgar Ruz; Rosa, Daniela Santoro] Fed Univ Sao Paulo UNIFESP EPM, Dept Microbiol Immunol & Parasitol, Sao Paulo, Brazil.
   [Apostolico, Juliana de Souza; Santos Lunardelli, Victoria Alves; Boscardin, Silvia Beatriz; Rosa, Daniela Santoro] INCT, Inst Invest Immunol 3, Sao Paulo, Brazil.
   [Santos Souza, Higo Fernando; Boscardin, Silvia Beatriz] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil.
   [Astray, Renato Mancini] Butantan Inst, Viral Immunol Lab, Sao Paulo, Brazil.
RP Rosa, DS (reprint author), Rua Botucatu,862-4 Andar, BR-04023062 Sao Paulo, SP, Brazil.
EM dsantororosa@gmail.com
RI Lunardelli, Victoria/AAB-5424-2020; Fernandes, Edgar Ruz/T-6160-2019;
   Apostolico, Juliana/W-8804-2018; Amaral, Marcelo Pires/AAB-5077-2020;
   Boscardin, Silvia Beatriz/C-3397-2012; rosa, daniela/D-2190-2012
OI Apostolico, Juliana/0000-0002-3507-3117; Amaral, Marcelo
   Pires/0000-0002-5335-6196; Boscardin, Silvia
   Beatriz/0000-0002-7845-7110; Fernandes, Edgar Ruz/0000-0001-5981-5149;
   rosa, daniela/0000-0003-4536-891X
FU Sao Paulo Research Foundation [FAPESP]Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2017/17471-7]; Brazilian National Research
   Council (CNPq)/Institute for Investigation in Immunology [CNPq]
   [465434/2014-2]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior [CAPES]CAPES [001]; CNPq/FAPESPNational Council for Scientific
   and Technological Development (CNPq)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP); CAPESCAPES
FX This research was supported by Sao Paulo Research Foundation [FAPESP,
   grant number 2017/17471-7], the Brazilian National Research Council
   (CNPq)/Institute for Investigation in Immunology [CNPq, grant number
   465434/2014-2] and the Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior [CAPES, Finance Code 001]. JSA, VASL, FCC, ERF, NT, SBB
   and DSR received fellowships from CNPq/FAPESP. MPA and HFSS received
   fellowships from CAPES.
CR Abbink P, 2016, SCIENCE
   Abbink P, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aao4163
   Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   Ammi R, 2015, PHARMACOL THERAPEUT, V146, P120, DOI 10.1016/j.pharmthera.2014.09.010
   Apostolico JD, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00101
   Apostolico JD, 2016, J IMMUNOL RES, DOI 10.1155/2016/1459394
   de Araujo TVB, 2018, LANCET INFECT DIS, V18, P328, DOI 10.1016/S1473-3099(17)30727-2
   Baud D, 2017, LANCET, V390, P2099, DOI [10.1016/S0140-6736(17)31450-2, 10.1016/s0140-6736(17)31450-2]
   Britto C, 2018, EXPERT OPIN BIOL TH, V18, P1171, DOI 10.1080/14712598.2018.1526277
   Cao-Lormeau VM, 2016, LANCET, V387, P1531, DOI 10.1016/S0140-6736(16)00562-6
   Chang GJJ, 2003, VIROLOGY, V306, P170, DOI 10.1016/S0042-6822(02)00028-4
   Collins MH, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124588
   Dai LP, 2016, CELL HOST MICROBE, V19, P696, DOI 10.1016/j.chom.2016.04.013
   DICK GWA, 1952, T ROY SOC TROP MED H, V46, P509, DOI 10.1016/0035-9203(52)90042-4
   Dowd KA, 2016, SCIENCE, V354, P237, DOI 10.1126/science.aai9137
   Dudley DM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12204
   Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292
   Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7
   Griffin BD, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15743
   Han JF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10595-5
   Heinz FX, 2017, MICROBIOL MOL BIOL R, V81, DOI [10.1128/MMBR.00055-16, 10.1128/mmbr.00055-16]
   Hemmi H, 2003, J IMMUNOL, V170, P3059, DOI 10.4049/jimmunol.170.6.3059
   Hessert M, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007237
   Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432
   Kwissa M, 2012, BLOOD, V119, P2044, DOI 10.1182/blood-2011-10-388579
   Larocca RA, 2016, NATURE
   Li C, 2018, CELL REP, V23, P1424, DOI 10.1016/j.celrep.2018.04.005
   Li XF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02975-w
   Liang HB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194860
   Lucas CGO, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05519-4
   Martins KA, 2015, EXPERT REV VACCINES, V14, P447, DOI 10.1586/14760584.2015.966085
   Ngono AE, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007474
   Ngono AE, 2017, CELL HOST MICROBE, V21, P35, DOI 10.1016/j.chom.2016.12.010
   Pardi N, 2017, NATURE, V543, P248, DOI 10.1038/nature21428
   Poland GA, 2018, LANCET INFECT DIS, V18, pE211, DOI 10.1016/S1473-3099(18)30063-X
   Regla-Nava JA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05458-0
   Report S, 2017, ZIK VIR MICR GUILL B
   Robbiani DF, 2017, CELL, V169, P597, DOI 10.1016/j.cell.2017.04.024
   Roos AK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007226
   Rosa DS, 2015, J VACC VACC, V6
   Sant AJ, 2012, J EXP MED, V209, P1391, DOI 10.1084/jem.20121517
   Sapparapu G, 2016, NATURE, V540, P443, DOI 10.1038/nature20564
   Scott JM, 2018, J VIROL, V92, DOI 10.1128/JVI.00038-18
   Shan C, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00737-8
   Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322
   Shirota H, 2017, IMMUNOPOTENTIATORS IN MODERN VACCINES, 2ND EDITION, P163, DOI 10.1016/B978-0-12-804019-5.00009-8
   SIMPSON D. I. H., 1964, TRANS ROY SOC TROP MED HYG, V58, P335, DOI 10.1016/0035-9203(64)90201-9
   Sirohi D, 2016, SCIENCE, V352, P467, DOI 10.1126/science.aaf5316
   Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505
   Styczynski AR, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005869
   Tebas P, 2017, N ENGL J MED
   Touret F, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0161-7
   Turtle L, 2016, J EXP MED, V213, P1331, DOI 10.1084/jem.20151517
   van der Eijk AA, 2016, NEW ENGL J MED, V375, P1002, DOI 10.1056/NEJMc1605898
   Wang QH, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aai8336
   Wen J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01669-z
   Wikan N, 2017, LANCET INFECT DIS, V17, P15, DOI 10.1016/S1473-3099(16)30525-4
   Yang M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08247-9
   Yang M, 2017, VACCINE, V35, P4287, DOI 10.1016/j.vaccine.2017.04.052
   Yi GH, 2017, EBIOMEDICINE, V25, P87, DOI 10.1016/j.ebiom.2017.10.006
   Zhao HY, 2016, CELL, V166, P1016, DOI 10.1016/j.cell.2016.07.020
NR 61
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 29
PY 2020
VL 38
IS 20
BP 3653
EP 3664
DI 10.1016/j.vaccine.2020.03.037
PG 12
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TO
UT WOS:000525318200004
PM 32247567
DA 2020-05-12
ER

PT J
AU Zhang, X
   Liu, CR
   Wang, ZZ
   Ren, ZF
   Feng, XX
   Ma, W
   Gao, XH
   Zhang, R
   Brown, MD
   Qiao, YL
   Geng, Q
   Li, J
AF Zhang, Xi
   Liu, Chun-rong
   Wang, Zeng-zhen
   Ren, Ze-fang
   Feng, Xiang-xian
   Ma, Wei
   Gao, Xiao-hong
   Zhang, Rong
   Brown, Matthew D.
   Qiao, You-Lin
   Geng, Qian
   Li, Jing
TI Effect of a school-based educational intervention on HPV and HPV vaccine
   knowledge and willingness to be vaccinated among Chinese adolescents : a
   multi-center intervention follow-up study
SO VACCINE
LA English
DT Article
DE HPV awareness; HPV vaccine; Educational intervention; Chinese
   adolescents
ID HUMAN-PAPILLOMAVIRUS VACCINE; YOUNG ADOLESCENTS; ACCEPTABILITY;
   ATTITUDES; AWARENESS; PARENTS; COMMUNICATION; PERCEPTIONS; SEX
AB Background: Middle school students are recommended as the primary target population for human papillomavirus (HPV) vaccination. This study aimed to assess HPV and HPV vaccine knowledge, and to evaluate the effect of a school-based educational intervention, immediately and one year later, on HPV knowledge and vaccine acceptability among adolescents in mainland China.
   Methods: A school-based interventional follow-up study was conducted in seven representative cities in mainland China from May 2015 to May 2017. "Train-the-trainer" strategy was employed to educate school teachers in this study. Students aged 13 to 14 years old were assigned to intervention classes and control classes. All students were required to complete the baseline questionnaire. Students in the intervention classes were given a 45-minute lecture regarding HPV and HPV vaccine knowledge and were then asked to complete a post-education questionnaire. One year later, all students were asked to complete the post-education questionnaire again.
   Results: Baseline HPV knowledge was low among Chinese adolescents, with only 12.6% and 15.7% of students having heard of HPV and HPV vaccines, respectively. After the intervention, the level of HPV-related knowledge increased immediately, and students with higher knowledge levels of HPV and HPV vaccines were more willing to get vaccinated. One year after the intervention, the knowledge of HPV and HPV vaccines was dramatically diminished. However, knowledge was significantly higher in intervention classes compared to control classes.
   Conclusions: Knowledge and awareness of HPV and vaccination are generally deficient among Chinese adolescents. School-based health education was very effective in improving awareness and positive attitudes about HPV and HPV vaccines within a short time. Integrating health education on HPV into the existing school-based sexual health curriculum could be an effective way to increase HPV vaccination coverage and help to eliminate preventable HPV-associated cancers in China. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Zhang, Xi] Peking Univ, Key Lab Carcinogenesis & Translat Res, Beijing Off Canc Prevent & Control, Minist Educ Beijing,Canc Hosp & Inst, Beijing 100142, Peoples R China.
   [Liu, Chun-rong] Sichuan Univ, West China Hosp, Chinese Evidence Based Med Ctr, Chengdu 610041, Peoples R China.
   [Wang, Zeng-zhen] Huazhong Univ Sci & Technol, Sch Publ Hlth, Dept Epidemiol & Biostat, Tongji Med Coll, Wuhan 430030, Peoples R China.
   [Ren, Ze-fang] Sun Yat Sen Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Guangzhou 510080, Peoples R China.
   [Feng, Xiang-xian] Changzhi Med Coll, Dept Publ Hlth & Prevent Med, Changzhi 046000, Peoples R China.
   [Ma, Wei] Shandong Univ, Sch Publ Hlth, Dept Epidemiol, Jinan 250012, Peoples R China.
   [Gao, Xiao-hong] Dalian Med Univ, Sch Publ Hlth, Dept Epidemiol, Dalian 116044, Peoples R China.
   [Zhang, Rong] Xinjiang Uygur Autonomous Reg Ctr Dis Control & P, Postdoctoral Res Stn, Urumqi 830002, Peoples R China.
   [Brown, Matthew D.] NCI, Ctr Global Hlth, NIH, Bethesda, MD 20892 USA.
   [Qiao, You-Lin] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Epidemiol, Canc Hosp, Beijing 100021, Peoples R China.
   [Geng, Qian] Project HOPE, Global Hlth, Millwood, VA USA.
   [Geng, Qian] Campaign Tobacco Free Kids, 1400 I Eye St NW,Suite 1200, Washington, DC USA.
   [Li, Jing] Sichuan Univ, West China Sch Publ Hlth, Dept Occupat & Environm Hlth, Chengdu 610041, Peoples R China.
   [Li, Jing] Sichuan Univ, West China Fourth Hosp, Chengdu 610041, Peoples R China.
   [Li, Jing] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England.
RP Li, J (reprint author), Sichuan Univ, West China Sch Publ Hlth, Dept Occupat & Environm Hlth, Chengdu 610041, Peoples R China.; Li, J (reprint author), Sichuan Univ, West China Fourth Hosp, Chengdu 610041, Peoples R China.; Li, J (reprint author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England.
EM lijingwcph@scu.edu.cn
FU (Virginia, USA)
FX We thank Project HOPE (Millwood, Virginia, USA) for funding this project
   and we also thank the middle schools involved in this study and students
   who helped to complete the questionnaires. Thanks to Zeenat Williams
   from London School of Hygiene and Tropical Medicine for proofreading
   this paper.
CR Ali H, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2032
   Beavis AL, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00019
   Bellia-Weiss Tania, 2013, NASN Sch Nurse, V28, P86
   Brotherton JML, 2013, MED J AUSTRALIA, V199, P614, DOI 10.5694/mja13.10272
   Chang IJ, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-916
   Chen WQ, 2018, CHINESE J CANCER RES, V30, P1, DOI 10.21147/j.issn.1000-9604.2018.01.01
   Chiang VCL, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13050486
   Colombara DV, 2013, VACCINE, V31, P4057, DOI 10.1016/j.vaccine.2013.06.031
   Dodd RH, 2014, SEX TRANSM INFECT, V90, P201, DOI 10.1136/sextrans-2013-051402
   Feng SW, 2012, ASIA-PAC J PUBLIC HE, V24, P522, DOI 10.1177/1010539511415838
   Gao XH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044881
   Grigore M, 2018, J CANCER EDUC, V33, P154, DOI 10.1007/s13187-016-1130-2
   Hawkins NA, 2013, PREV MED, V57, P641, DOI 10.1016/j.ypmed.2013.08.021
   Kang HY, 2011, WOMEN HEALTH, V51, P759, DOI 10.1080/03630242.2011.627091
   Kasymova S, 2019, INFECT DIS RES TREAT, V12
   Kwan TTC, 2011, PATIENT EDUC COUNS, V84, P118, DOI 10.1016/j.pec.2010.06.018
   Leiber E, 2009, AIDS EDUC PREV, V21, P415, DOI 10.1521/aeap.2009.21.5.415
   Li C, 2017, REPROD HLTH, V14
   Li JM, 2015, BMC PLANT BIOL, V15, DOI 10.1186/s12870-015-0699-7
   Patel H, 2016, SEX TRANSM INFECT, V92, P474, DOI 10.1136/sextrans-2015-052341
   Ratanasiripong NT, 2012, J AM COLL HEALTH, V60, P461, DOI 10.1080/07448481.2012.684365
   Shapiro GK, 2017, VACCINE, V35, P5700, DOI 10.1016/j.vaccine.2017.07.079
   The Lancet, 2018, Lancet, V392, P360, DOI 10.1016/S0140-6736(18)31695-7
   Turhan E, 2019, J CANCER EDUC, V34, P234, DOI 10.1007/s13187-017-1292-6
   Wang SM, 2014, ASIAN PAC J CANCER P, V15, P3239, DOI 10.7314/APJCP.2014.15.7.3239
   Wang W, 2015, VACCINE, V33, P2570, DOI 10.1016/j.vaccine.2015.04.010
   World Hlth Org, 2017, VACCINE, V35, P5753, DOI 10.1016/j.vaccine.2017.05.069
   Zhang LY, 2007, EUR J CONTRACEP REPR, V12, P138, DOI 10.1080/13625180701300293
   Zhang SK, 2015, ANN EPIDEMIOL, V25, P231, DOI 10.1016/j.annepidem.2014.12.009
   Zhang SK, 2013, VACCINE, V31, P3244, DOI 10.1016/j.vaccine.2013.05.046
   Zhang XJ, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3627-3
   Zhao J, 2019, EURASIP J INF SECUR, DOI 10.1186/s13635-019-0084-4
NR 32
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 29
PY 2020
VL 38
IS 20
BP 3665
EP 3670
DI 10.1016/j.vaccine.2020.03.032
PG 6
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TO
UT WOS:000525318200005
PM 32245644
OA Other Gold
DA 2020-05-12
ER

PT J
AU Deng, HX
   Yu, S
   Guo, YZ
   Gu, LM
   Wang, GF
   Ren, ZH
   Li, YL
   Li, KS
   Li, R
AF Deng, Huixiong
   Yu, Shun
   Guo, Yingzhu
   Gu, Liming
   Wang, Gefei
   Ren, Zhihui
   Li, Yanlei
   Li, Kangsheng
   Li, Rui
TI Development of a multivalent enterovirus subunit vaccine based on
   immunoinformatic design principles for the prevention of HFMD
SO VACCINE
LA English
DT Article
DE HFMD; Enterovirus; Multivalent; Epitopes; In silico; Neutralization
ID PROTEIN-STRUCTURE; B-CELL; PREDICTION; EPITOPES; HAND; FOOT; EFFICACY;
   BINDING; SAFETY
AB Hand, foot and mouth disease (HFMD) is mainly caused by EV-A71 and CV-A16. An increasing number of cases have been found to be caused by CV-A10, CV-A6, CV-B3 and the outbreaks are becoming increasingly more complex, often accompanied by the prevalence of a variety of enteroviruses. Based on the principle of synthetic peptide vaccines, we applied immune-informatics to design a highly efficient and safe multivalent epitope-based vaccine against EV-A71, CV-A16, CV-A10, CV-A6 and CV-B3. By screening B-cells, HTL and CTL cell antigen epitopes with high conservativity and immunogenicity that have no toxic effect on the host, further analysis confirmed that the vaccine built was IFN-gamma inductive and IL-4 non-inductive HTL cell epitopes and had population coverage corresponding to MHC molecular alleles associated with T-cell phenotype. The multivalent enterovirus vaccine was constructed to connect the 50 s ribosomal protein L7/L12 adjuvant and candidate epitopes sequentially through appropriate linkers. Then, the antigenic, allergen and physical properties of the vaccine were evaluated, followed by a secondary structure analysis and tertiary structure modeling, disulfide engineering, refinement and validation. Moreover, the conformational B cell epitope of the vaccine was analyzed. The stability of the TLR4/MD2/Vaccine complex and details at atomic level were investigated by docking and molecular dynamics simulation. Finally, in silico immune simulation and in vivo immune experiments were done. This study provides a high cost-effective method of designing a multivalent enterovirus vaccine protect against a wide range of enterovirus pathogens. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Deng, Huixiong; Yu, Shun; Guo, Yingzhu; Gu, Liming; Wang, Gefei; Ren, Zhihui; Li, Yanlei; Li, Kangsheng; Li, Rui] Shantou Univ, Ctr Pathogen Biol & Immunol, Dept Microbiol & Immunol, Med Coll, Shantou 505041, Guangdong, Peoples R China.
   [Deng, Huixiong; Yu, Shun; Guo, Yingzhu; Gu, Liming; Wang, Gefei; Li, Yanlei; Li, Kangsheng; Li, Rui] Shantou Univ, Guangdong Prov Key Lab Infect Dis & Mol Immunopat, Med Coll, Shantou 505041, Guangdong, Peoples R China.
   [Ren, Zhihui] Cent South Univ, Dept Anesthesiol, Xiangya Hosp 2, Changsha 410011, Peoples R China.
RP Wang, GF; Li, R (reprint author), Shantou Univ, Ctr Pathogen Biol & Immunol, Dept Microbiol & Immunol, Med Coll, Shantou 505041, Guangdong, Peoples R China.
EM gefeiwang@stu.edu.cn; 07rli1@stu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [31300761, 31170852]; Natural Science Foundation of
   Guangdong ProvinceNational Natural Science Foundation of Guangdong
   Province [2018A030313548]; Department of Education of Guangdong
   ProvinceNational Natural Science Foundation of Guangdong Province
   [2020KZDZX1083]; Shantou Science and Technology Bureau
FX This work was supported by the grants from National Natural Science
   Foundation of China (31300761 and 31170852), Natural Science Foundation
   of Guangdong Province (2018A030313548), Department of Education of
   Guangdong Province (2020KZDZX1083), and Shantou Science and Technology
   Bureau.
CR An LL, 1997, J VIROL, V71, P2292, DOI 10.1128/JVI.71.3.2292-2302.1997
   Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639
   Aswathyraj S, 2016, MED MICROBIOL IMMUN, V205, P397, DOI 10.1007/s00430-016-0465-y
   Azoitei ML, 2011, SCIENCE, V334, P373, DOI 10.1126/science.1209368
   Baggen J, 2018, NAT REV MICROBIOL, V16, P368, DOI 10.1038/s41579-018-0005-4
   Bhasin M, 2004, VACCINE, V22, P3195, DOI 10.1016/j.vaccine.2004.02.005
   Buchan DWA, 2013, NUCLEIC ACIDS RES, V41, pW349, DOI 10.1093/nar/gkt381
   Bui HH, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-361
   Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266
   Cheng J, 2005, NUCLEIC ACIDS RES, V33, pW72, DOI 10.1093/nar/gki396
   Chong P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049973
   Craig DB, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-346
   Dhanda SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/263952
   Dhanda SK, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-30
   Dimitrov I, 2014, J MOL MODEL, V20, DOI 10.1007/s00894-014-2278-5
   Dimitrov I, 2010, BIOINFORMATICS, V26, P2066, DOI 10.1093/bioinformatics/btq324
   Doytchinova IA, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-4
   Fang CY, 2018, EXPERT REV VACCINES, V17, P819, DOI 10.1080/14760584.2018.1510326
   Fu XM, 2019, INT J INFECT DIS, V87, P1, DOI 10.1016/j.ijid.2019.07.012
   Greenbaum J, 2011, IMMUNOGENETICS, V63, P325, DOI 10.1007/s00251-011-0513-0
   Gupta S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073957
   Heo L, 2013, NUCLEIC ACIDS RES, V41, pW384, DOI 10.1093/nar/gkt458
   Klein M, 2015, HUM VACC IMMUNOTHER, V11, P2688, DOI 10.1080/21645515.2015.1049780
   Kringelum JV, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002829
   Larsen MV, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-424
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lee SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104351
   Li RC, 2014, NEW ENGL J MED, V370, P829, DOI 10.1056/NEJMoa1303224
   Liu CC, 2014, VACCINE, V32, P6177, DOI 10.1016/j.vaccine.2014.08.064
   Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286
   Lugo D, 2016, CURR OPIN PEDIATR, V28, P107, DOI 10.1097/MOP.0000000000000303
   Magnan CN, 2009, BIOINFORMATICS, V25, P2200, DOI 10.1093/bioinformatics/btp386
   Mao QY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079599
   Negahdaripour M, 2018, INFECT GENET EVOL, V58, P96, DOI 10.1016/j.meegid.2017.12.008
   Peters B, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-132
   Puenpa J, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0573-2
   Rapin N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009862
   Reche PA, 2004, IMMUNOGENETICS, V56, P405, DOI 10.1007/s00251-004-0709-7
   Roy A, 2011, JOVE-J VIS EXP, DOI 10.3791/3259
   Saha S, 2006, PROTEINS, V65, P40, DOI 10.1002/prot.21078
   Vajda S, 2017, PROTEINS, V85, P435, DOI 10.1002/prot.25219
   Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048
   Weiskopf D, 2013, P NATL ACAD SCI USA, V110, pE2046, DOI 10.1073/pnas.1305227110
   Wiederstein M, 2007, NUCLEIC ACIDS RES, V35, pW407, DOI 10.1093/nar/gkm290
   Wilkins MR, 1999, METH MOL B, V112, P531
   World Health Organization, 2011, WORLD HEAL ORGAN, V18
   Zhang ZJ, 2017, J VIROL, V91, DOI 10.1128/JVI.00333-17
   Zhu FC, 2013, LANCET, V381, P2024, DOI 10.1016/S0140-6736(13)61049-1
   Zhu FC, 2014, NEW ENGL J MED, V370, P818, DOI 10.1056/NEJMoa1304923
NR 49
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 29
PY 2020
VL 38
IS 20
BP 3671
EP 3681
DI 10.1016/j.vaccine.2020.03.023
PG 11
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TO
UT WOS:000525318200006
PM 32247566
DA 2020-05-12
ER

PT J
AU Nguyen, VH
   Vizzotti, C
   Uruena, A
   Giglio, N
   Magneres, C
   Richmond, H
AF Van Hung Nguyen
   Vizzotti, Carla
   Uruena, Analia
   Giglio, Norberto
   Magneres, Cecilia
   Richmond, Heather
TI Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza
   vaccine for older adults in Argentina
SO VACCINE
LA English
DT Article
DE Influenza vaccine; Cost-effectiveness; Argentina; Adjuvant; Older adult;
   Elderly
ID SEASONAL INFLUENZA; RISK; COMPLICATIONS; DISEASE; SAFETY; IMPACT
AB Introduction: Influenza surveillance in Argentina reported influenza-like illness at a rate of 3500/100,000, a hospitalization rate of 15.5/100,000, and a death rate of 0.32/100,000 annually in adults aged over 65 years. The high burden of disease may be due to a combination of immunosenescence and the suboptimal clinical effectiveness of conventional, non-adjuvanted influenza vaccines in this age group. There is a clinical need for more effective influenza vaccines in this population. This study evaluated the cost-effectiveness of an MF59 (R)-adjuvanted trivalent influenza vaccine (aTIV) in adults aged over 65 years in Argentina compared with the non-adjuvanted trivalent influenza vaccine (TIV) used under the current national vaccination policy.
   Methods: A decision tree cost-effectiveness model was developed to estimate the cost-effectiveness of switching from TIV to aTIV in Argentinian older adults. The model compared cost and health benefits of vaccination in one influenza season from the payer perspective. The main predictions included survival, quality-adjusted survival, and costs. Model inputs were sourced from Argentina or internationally where local data was considered inaccurate. Vaccine efficacy assumptions were extracted from recently published, peer-reviewed scientific literature.
   Results: Switching from TIV to aTIV would result in 170 deaths averted and 1310 incremental quality-adjusted life years (QALYs) gained. The incremental cost-effectiveness ratio per QALY was US $2660.59 from the payer perspective. In all sensitivity analyses, aTIV remained highly cost-effective. The probabilistic sensitivity analyses showed a 95% CI per QALY of US $113.74-7721.67.
   Conclusion: Introducing an adjuvanted influenza vaccine in Argentina is potentially beneficial and cost-effective relative to the currently-used TIV through the reduction of disease burden and utilization of healthcare resources. (C) 2020 The Authors. Published by Elsevier Ltd.
C1 [Van Hung Nguyen] VHN Consulting Inc, Montreal, PQ, Canada.
   [Vizzotti, Carla; Uruena, Analia] Univ Isalud, Buenos Aires, DF, Argentina.
   [Giglio, Norberto] Ricardo Gutierrez Childrens Hosp, Buenos Aires, DF, Argentina.
   [Magneres, Cecilia] Seqirus SA, Buenos Aires, DF, Argentina.
   [Richmond, Heather] Seqirus USA Inc, 25 Deforest Ave, Summit, NJ 07901 USA.
RP Richmond, H (reprint author), Seqirus USA Inc, 25 Deforest Ave, Summit, NJ 07901 USA.
EM heather.richmond@seqirus.com
FU Seqirus USA Inc.
FX This study was funded by Seqirus USA Inc.
CR Barbieri M, 2017, J Prev Med Hyg, V58, pE279, DOI 10.15167/2421-4248/jpmh2017.58.4.867
   Baxter D, 2016, HUM VACC IMMUNOTHER, V12, P2712, DOI 10.1080/21645515.2015.1091130
   Black S, 2015, VACCINE, V33, pB3, DOI 10.1016/j.vaccine.2014.11.062
   Bonvehi P, 11 C SOC ARG INF
   Cassini A, 2009, EUROSURVEILLANCE, V2018, P23
   Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001
   Del Giudice G, 2017, NPJ AGING MECH DIS, V4, DOI 10.1038/s41514-017-0020-0
   Direccion de Estadisticas e Informacion en Salud, IND BAS ARG 2018
   Domnich A, 2017, VACCINE, V35, P513, DOI 10.1016/j.vaccine.2016.12.011
   Dyer MTD, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-13
   European Union. European Centre for Disease Prevention and Control, FACTSH SEAS INFL
   Fisman DN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027420
   Frey SE, 2014, VACCINE, V32, P5027, DOI 10.1016/j.vaccine.2014.07.013
   Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105
   Goronzy JJ, 2013, NAT IMMUNOL, V14, P428, DOI 10.1038/ni.2588
   Government of Argentina. Ministry of Health and Social Development, 3 NAT SURV RISK FACT
   Hak E, 2002, CLIN INFECT DIS, V35, P370, DOI 10.1086/341403
   Jefferson T, 2005, LANCET, V366, P1165, DOI 10.1016/S0140-6736(05)67339-4
   Kaiser L, 2003, ARCH INTERN MED, V163, P1667, DOI 10.1001/archinte.163.14.1667
   Lee Grace M, 2005, Health Qual Life Outcomes, V3, P17, DOI 10.1186/1477-7525-3-17
   Linder JA, 2009, J GEN INTERN MED, V24, P504, DOI 10.1007/s11606-009-0933-9
   Mannino S, 2012, AM J EPIDEMIOL, V176, P527, DOI 10.1093/aje/kws313
   Matias G, 2014, INFLUENZA OTHER RESP, V8, P507, DOI 10.1111/irv.12258
   McElhaney JE, 2005, VACCINE, V23, pS10, DOI 10.1016/j.vaccine.2005.04.019
   Meier CR, 2000, EUR J CLIN MICROBIOL, V19, P834, DOI 10.1007/s100960000376
   Ministerio de Salud y Desarrollo Social, 2017, B INT VIG AN 2013 20
   Molinari NAM, 2007, VACCINE, V25, P5086, DOI 10.1016/j.vaccine.2007.03.046
   Moscoso N, 2010, DOCUMENTS CONTRIBUTI, V10, P29
   Mullikin M, 2015, INFECT DIS THER, V4, P459, DOI 10.1007/s40121-015-0076-8
   National Foundation for Infectious Diseases, 2016, CALL ACT REINV INFL
   O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/erv.12.140, 10.1586/ERV.12.140]
   Pellegrini M, 2009, VACCINE, V27, P6959, DOI 10.1016/j.vaccine.2009.08.101
   Pichon-Riviere A, 6 C INT SOC PHARM OU
   Puig-Barbera J, 2007, VACCINE, V25, P7313, DOI 10.1016/j.vaccine.2007.08.039
   Putri WCWS, 2018, VACCINE, V36, P3960, DOI 10.1016/j.vaccine.2018.05.057
   ROTA PA, 1990, VIROLOGY, V175, P59, DOI 10.1016/0042-6822(90)90186-U
   Ruiz -Aragon J, 2015, VACUNAS, V16, P6, DOI DOI 10.1016/j.vacun.2015.02.002
   Schaffner W, 2018, INT J CLIN PRACT, V72, DOI 10.1111/ijcp.13249
   Sindoni D, 2009, J Prev Med Hyg, V50, P121
   Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747
   TURNER D, 2003, HEALTH TECHNOL ASSES, V7, P1, DOI DOI 10.3310/HTA7350
   UK Government. Joint Committee on Vaccination and Immunisation (JCVI), 2017, JCVI M 4 OCT WELL HO
   US Government. Centers for Disease Control and Prevention, WEEKL US INFL SURV R
   Van Buynder PG, 2013, VACCINE, V31, P6122, DOI 10.1016/j.vaccine.2013.07.059
   Vizzotti C, 2018, MEDICINA-BUENOS AIRE, V78, P76
   Wat D, 2004, BMJ-BRIT MED J, V15, P79, DOI DOI 10.1136/bmj.i6258
   Weinberger B, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-017-0107-2
   Wilkins AL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01760
   World Health Organization, INFL REC COMP INFL V
   World Health Organization, FACT SHEET SEAS INFL
   World Health Organization, INFL SURV MON
NR 51
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 29
PY 2020
VL 38
IS 20
BP 3682
EP 3689
DI 10.1016/j.vaccine.2020.02.081
PG 8
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TO
UT WOS:000525318200007
PM 32249017
OA Other Gold
DA 2020-05-12
ER

PT J
AU Suo, LD
   Lu, L
   Zhao, D
   Pang, XH
AF Suo, Luodan
   Lu, Li
   Zhao, Dan
   Pang, Xinghuo
TI Impact of a 2-dose voluntary vaccination strategy on varicella
   epidemiology in Beijing, 2011-2017
SO VACCINE
LA English
DT Article
DE Varicella; Outbreak; Breakthrough; Vaccine effectiveness; Chickenpox
ID UNITED-STATES; OUTBREAK; PROGRAM; PREVENTION; INFECTION; SCHOOL
AB Background: One-dose voluntary varicella vaccination for children was introduced in Beijing since 1998. In Oct 2012, a second dose varicella vaccine (VarV) was recommended to further decrease varicella disease and the outbreaks. We describe the impact of the 2-dose voluntary vaccination strategy on varicella epidemiology in Beijing, China.
   Methods: Varicella incidence rates and outbreak characteristics in 2011-2017 was examined using surveillance data. Varicella vaccination coverage among children born in 2007-2012 was estimated through Beijing children immunization registry system. Vaccine effectiveness (VE) for VarV(2) was estimated by screening method.
   Results: Overall varicella incidence decreased by 37.8% from 103.2 per 100,000 population in 2011 to 64.2 per 100,000 population in 2017. Incidence declines in children aged <15 years with most significantly decrease by 82.3% in children aged 5-9 years, while no significant change happened in adolescent and adults. A total of 251 outbreaks with 3239 outbreak-related cases were reported in 2011-2017, the number of outbreaks decreased significantly by 50.7% from 69 in 2011 to 34 in 2017. The VarV(1) coverage ranged from 85.4% to 92.6% among children 4 year of age and the VarV(2) coverage ranged from 40.1% to 72.9% among children 6 year of age in the 2007-2012 birth cohort. Overall VE estimates against all varicella disease was 94.4% (95% CI: 89.9-98.9%) for VarV(2).
   Conclusions: Moderate VarV(2) coverage has been achieved in Beijing resulting in remarkable declining of the incidence in children. Varicella outbreaks has not been eliminated suggested that measures such as including a 2-dose varicella vaccination in routine immunization program should be taken in the future. (C) 2020 Published by Elsevier Ltd.
C1 [Suo, Luodan; Lu, Li; Zhao, Dan; Pang, Xinghuo] Beijing Ctr Dis Control & Prevent, Beijing Ctr Dis Prevent Med Res, EPI Dept, He Ping Li Zhong Jie 16, Beijing 100013, Peoples R China.
RP Lu, L (reprint author), Beijing Ctr Dis Control & Prevent, Beijing Ctr Dis Prevent Med Res, EPI Dept, He Ping Li Zhong Jie 16, Beijing 100013, Peoples R China.
EM lulibj@sina.com
CR [Anonymous], BEIJ STAT YB
   Arvin AM, 1996, CLIN MICROBIOL REV, V9, P361, DOI 10.1128/CMR.9.3.361
   Beijing Center for Disease Control and Prevention, 2013, CHIN J PREV MED, V47, P67
   Bialek SR, 2013, PEDIATRICS, V132, pE1134, DOI 10.1542/peds.2013-0863
   Brisson M, 2001, EPIDEMIOL INFECT, V127, P305, DOI 10.1017/S0950268801005921
   Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P884
   Chang LY, 2011, BMC INFECT DIS, V11, DOI 10.1186/1471-2334-11-352
   Choi JK, 2019, HUM VACC IMMUNOTHER, V15, P2554, DOI 10.1080/21645515.2019.1603985
   Cohen C, 2007, EMERG INFECT DIS, V13, P12
   Cui W, 2017, CHINESE J VACCINES I, V23, P58
   FARRINGTON CP, 1993, INT J EPIDEMIOL, V22, P742, DOI 10.1093/ije/22.4.742
   Gabutti G, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-372
   Hu Y, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13060560
   Kelly HA, 2014, EUROSURVEILLANCE, V19, DOI [10.2807/1560-7917.es2014.19.41.20926.pii:20926, DOI 10.2807/1560-7917.ES2014.19.41.20926]
   Liu YW, 2018, CELL REP, V24, P453, DOI 10.1016/j.celrep.2018.06.021
   Lopez AS, 2016, MMWR-MORBID MORTAL W, V65, P902, DOI 10.15585/mmwr.mm6534a4
   Lu L, 2014, ZHONGGUO YI MIAO HE, V20, P146
   Lu L, 2013, PEDIATR INFECT DIS J, V32, pE314, DOI 10.1097/INF.0b013e31828d948b
   Lu L, 2012, VACCINE, V30, P5094, DOI 10.1016/j.vaccine.2012.05.072
   Marin M, 2008, PEDIATRICS, V122, pE744, DOI 10.1542/peds.2008-0567
   Marin Mona, 2007, Morbidity and Mortality Weekly Report, V56, P1
   Marin M, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3741
   ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023
   Pan XQ, 2018, VACCINE, V36, P5665, DOI 10.1016/j.vaccine.2018.05.025
   Pinot de Moira A, 2005, EUROSURVEILLANCE, V10, P3, DOI 10.2807/esm.10.01.00511-en.
   Suo LD, 2017, VACCINE, V35, P4368, DOI 10.1016/j.vaccine.2017.06.065
   Wang X, 2017, INT J VIROL, V24, P318, DOI [10.3760/cma.j.issn.1673-4092.2017.05.007.in, DOI 10.3760/CMA.J.ISSN.1673-4092.2017.05.007]
   Ward K, 2013, VACCINE, V31, P1413, DOI 10.1016/j.vaccine.2012.12.052
   Wu J, 2017, NINGBO PRACT PREVENT, V24, P712
   Xu AQ, 2012, HUM VACC IMMUNOTHER, V8, P1213, DOI 10.4161/hv.20722
   Zhu YF, 2017, EPIDEMIOL INFECT, V145, P2129, DOI 10.1017/S0950268817000772
NR 31
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0264-410X
EI 1873-2518
J9 VACCINE
JI Vaccine
PD APR 29
PY 2020
VL 38
IS 20
BP 3690
EP 3696
DI 10.1016/j.vaccine.2020.01.087
PG 7
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA LC4TO
UT WOS:000525318200008
PM 32204940
DA 2020-05-12
ER

PT J
AU Bhoi, S
   Sarkar, D
AF Bhoi, Stutee
   Sarkar, Debasis
TI Hybrid finite volume and Monte Carlo method for solving
   multi-dimensional population balance equations in crystallization
   processes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Monte Carlo method; Population balance equation; Crystallization; High
   resolution finite volume method; Ultrasound
ID BATCH COOLING CRYSTALLIZATION; PARTICLE BREAKAGE PROCESS;
   MOMENT-CONSERVING METHOD; QUADRATURE METHOD; NUMERICAL-SOLUTION; SIZE
   DISTRIBUTION; CRYSTAL SIZE; SIMULATION; GROWTH; AGGREGATION
AB A novel hybrid framework that combines our recently proposed event driven constant number Monte Carlo (MC) method and a finite volume discretization scheme is developed to solve population balance equation (PBE) involving nucleation, growth, and breakage events for a batch crystallization process. At each time step, the nucleation and growth terms of the PBE are solved using high resolution finite volume method (HRFV), and then the breakage term is solved using the MC approach. This integrated approach is especially advantageous for solving multi-dimensional PBE involving nucleation, growth, and breakage events. The efficiency of the proposed approach is demonstrated by solving both onedimensional (1D) and two-dimensional (2D) PBE from published literature. Also, a set of seeded batch cooling crystallization of plate-like pyrazinamide crystals were performed in presence of ultrasound (US) and the proposed hybrid solution scheme was used successfully to model and simulate this system characterised by 2D PBE. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Bhoi, Stutee; Sarkar, Debasis] Indian Inst Technol Kharagpur, Dept Chem Engn, Kharagpur 721302, W Bengal, India.
RP Sarkar, D (reprint author), Indian Inst Technol Kharagpur, Dept Chem Engn, Kharagpur 721302, W Bengal, India.
EM dsarkar@che.iitkgp.ac.in
FU Science and Engineering Research Board (SERB), Government of India, New
   Delhi [EMR/2015/002266]
FX The financial assistance received from the Science and Engineering
   Research Board (SERB), Government of India, New Delhi (Project File
   Number: EMR/2015/002266) is gratefully acknowledged.
CR Aamir E, 2009, IND ENG CHEM RES, V48, P8575, DOI 10.1021/ie900430t
   Alexopoulos AH, 2007, CHEM ENG SCI, V62, P5048, DOI 10.1016/j.ces.2007.01.039
   Alopaeus V, 2007, CHEM ENG SCI, V62, P2277, DOI 10.1016/j.ces.2006.12.070
   Attarakih MM, 2009, CHEM ENG SCI, V64, P742, DOI 10.1016/j.ces.2008.05.006
   Bennett AK, 2001, CHEM ENG SCI, V56, P6623
   Bhoi S, 2019, CHEM ENG SCI, V203, P12, DOI 10.1016/j.ces.2019.03.070
   Bhoi S, 2018, ULTRASON SONOCHEM, V42, P162, DOI 10.1016/j.ultsonch.2017.11.017
   Bhoi S, 2016, CRYSTENGCOMM, V18, P4863, DOI 10.1039/c6ce00937a
   Briesen H, 2006, CHEM ENG SCI, V61, P104, DOI 10.1016/j.ces.2004.11.062
   Buffo A, 2016, COMPUT CHEM ENG, V87, P111, DOI 10.1016/j.compchemeng.2015.12.013
   Dorao CA, 2006, J COMPUT APPL MATH, V196, P619, DOI 10.1016/j.cam.2005.10.015
   Durr R, 2018, IFAC PAPERSONLINE, V51, P290, DOI 10.1016/j.ifacol.2018.03.050
   Falola A, 2013, COMPUT CHEM ENG, V56, P1, DOI 10.1016/j.compchemeng.2013.04.017
   Fevotte F, 2010, CHEM ENG SCI, V65, P3191, DOI 10.1016/j.ces.2010.02.009
   Gooch JRV, 1996, AICHE J, V42, P1864
   Hu Q, 2005, AICHE J, V51, P3000, DOI 10.1002/aic.10585
   HULBURT HM, 1964, CHEM ENG SCI, V19, P555, DOI 10.1016/0009-2509(64)85047-8
   Hussain M, 2013, CHEM ENG SCI, V101, P35, DOI 10.1016/j.ces.2013.06.004
   John V, 2014, CHEM ENG SCI, V106, P39, DOI 10.1016/j.ces.2013.11.029
   Khalili S, 2010, AICHE J, V56, P3137, DOI 10.1002/aic.12233
   KUBOTA N, 1995, J CRYST GROWTH, V152, P203, DOI 10.1016/0022-0248(95)00128-X
   Kumar J, 2008, COMPUT CHEM ENG, V32, P1810, DOI 10.1016/j.compchemeng.2007.10.001
   Kumar S, 1996, CHEM ENG SCI, V51, P1311, DOI 10.1016/0009-2509(96)88489-2
   Kumar S, 1996, CHEM ENG SCI, V51, P1333, DOI 10.1016/0009-2509(95)00355-X
   Lee KF, 2015, J COMPUT PHYS, V303, P1, DOI 10.1016/j.jcp.2015.09.031
   Lenka M, 2018, POWDER TECHNOL, V334, P106, DOI 10.1016/j.powtec.2018.04.038
   Lenka M, 2016, FLUID PHASE EQUILIBR, V412, P168, DOI 10.1016/j.fluid.2015.12.040
   Lenka M, 2014, J CRYST GROWTH, V408, P85, DOI 10.1016/j.jcrysgro.2014.09.027
   Lim YI, 2002, CHEM ENG SCI, V57, P3715, DOI 10.1016/S0009-2509(02)00236-1
   Lin YL, 2002, CHEM ENG SCI, V57, P2241, DOI 10.1016/S0009-2509(02)00114-8
   Lu SW, 2016, POWDER TECHNOL, V301, P186, DOI 10.1016/j.powtec.2016.05.059
   Ma CY, 2007, ADV POWDER TECHNOL, V18, P707, DOI 10.1163/156855207782514932
   Ma DL, 2002, IND ENG CHEM RES, V41, P6217, DOI 10.1021/ie010680u
   Ma DL, 2002, COMPUT CHEM ENG, V26, P1103, DOI 10.1016/S0098-1354(02)00033-9
   Maharana A, 2019, FLUID PHASE EQUILIBR, V497, P33, DOI 10.1016/j.fluid.2019.06.004
   Majumder A, 2012, CHEM ENG SCI, V69, P316, DOI 10.1016/j.ces.2011.10.051
   MARCHAL P, 1988, CHEM ENG SCI, V43, P59, DOI 10.1016/0009-2509(88)87126-4
   Marchisio DL, 2003, AICHE J, V49, P1266, DOI 10.1002/aic.690490517
   Marchisio DL, 2005, J AEROSOL SCI, V36, P43, DOI 10.1016/j.jaerosci.2004.07.009
   Mishra BK, 2000, POWDER TECHNOL, V110, P246, DOI 10.1016/S0032-5910(99)00281-8
   Nayhouse M, 2015, CHEM ENG SCI, V134, P414, DOI 10.1016/j.ces.2015.05.033
   Nicmanis M, 1998, AICHE J, V44, P2258, DOI 10.1002/aic.690441015
   Patterson RIA, 2011, J COMPUT PHYS, V230, P7456, DOI 10.1016/j.jcp.2011.06.011
   Puel F, 2003, CHEM ENG SCI, V58, P3715, DOI 10.1016/S0009-2509(03)00254-9
   Qamar S, 2006, COMPUT CHEM ENG, V30, P1119, DOI 10.1016/j.compchemeng.2006.02.012
   Qamar S, 2007, COMPUT CHEM ENG, V31, P1576, DOI 10.1016/j.compchemeng.2007.01.006
   Qamar S, 2011, COMPUT CHEM ENG, V35, P412, DOI 10.1016/j.compchemeng.2010.03.016
   Qamar S, 2009, CHEM ENG SCI, V64, P2088, DOI 10.1016/j.ces.2009.01.040
   Reinhold A, 2015, CHEM ENG SCI, V127, P220, DOI 10.1016/j.ces.2015.01.035
   Smith M, 1998, CHEM ENG SCI, V53, P1777, DOI 10.1016/S0009-2509(98)00045-1
   Szilagyi B, 2017, COMPUT CHEM ENG, V98, P180, DOI 10.1016/j.compchemeng.2016.11.028
   Terrazas-Velarde K, 2011, CHEM ENG SCI, V66, P1866, DOI 10.1016/j.ces.2011.01.037
   Terrazas-Velarde K, 2011, AICHE J, V57, P3012, DOI 10.1002/aic.12506
   Terrazas-Velarde K, 2009, CHEM ENG SCI, V64, P2631, DOI 10.1016/j.ces.2009.02.041
   Vreugdenhil C.B., 1993, NUMERICAL METHODS AD
   Wohlgemuth K, 2013, COMPUT CHEM ENG, V52, P216, DOI 10.1016/j.compchemeng.2012.12.001
   Yuan C, 2012, J AEROSOL SCI, V51, P1, DOI 10.1016/j.jaerosci.2012.04.003
   Zhao H, 2007, POWDER TECHNOL, V173, P38, DOI 10.1016/j.powtec.2006.12.010
NR 58
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115511
DI 10.1016/j.ces.2020.115511
PG 15
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600018
DA 2020-05-12
ER

PT J
AU Boiocchi, R
   Behera, CR
   Sherratt, A
   DeGroot, CT
   Gernaey, KV
   Sin, G
   Santoro, D
AF Boiocchi, Riccardo
   Behera, Chitta Ranjan
   Sherratt, Anthony
   DeGroot, Christopher T.
   Gernaey, Krist, V
   Sin, Gurkan
   Santoro, Domenico
TI Dynamic model validation and advanced polymer control for rotating belt
   filtration as primary treatment of domestic wastewaters
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Wastewater; Rotating belt filters; Primary treatment; Plant-wide
   assessment; Benchmark; Model validation
ID WASTE-WATER; CELLULOSE; RECOVERY; SOLIDS; FILTER
AB Rotating belt filters are a primary treatment technology currently used in municipal wastewater treatment plants as a high-rate alternative to primary clarifiers. Such systems are reported to efficiently remove particulates in the form of total suspended solids, achieving the highest removal efficiencies (>60%) when polymer is added as pre-treatment step. In this paper, a new dynamic model describing the RBF performance is presented. The model includes the dynamic effects of influent flow rate and TSS concentration and can also describe the effects of polymer dosing on RBF performance. The validated model was used to perform a plant-wide impact assessment using the Benchmark Simulation Model n.2. For a TSS removal efficiency that is identical to primary clarifiers (50%), rotating belt filters were found to only slightly decrease the aeration energy demand in the activated sludge unit (-0.5%), while increasing methane production and slightly increasing effluent TN concentrations (+1.5% and +1.9%, respectively). Furthermore, considerable savings in polymer costs could be attained using an advanced control strategy for polymer dosing, successfully tested in this work. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Boiocchi, Riccardo] Univ Alberta, Dept Civil & Environm Engn, Edmonton, AB T6G 2E1, Canada.
   [Behera, Chitta Ranjan; Gernaey, Krist, V; Sin, Gurkan] Tech Univ Denmark, Proc & Syst Engn Ctr PROSYS, Dept Chem & Biochem Engn, DK-2800 Lyngby, Denmark.
   [Sherratt, Anthony; DeGroot, Christopher T.] Western Univ, Dept Mech & Mat Engn, London, ON N6A 5B9, Canada.
   [Santoro, Domenico] Trojan Technol, London, ON N5V 4T7, Canada.
RP Santoro, D (reprint author), Trojan Technol, London, ON N5V 4T7, Canada.
EM dsantoro@trojanuv.com
RI Gernaey, Krist/J-1759-2018
OI Gernaey, Krist/0000-0002-0364-1773
FU Water Joint Programming Initiative, water challenge for a changing world
   waterworks 2014 co fund call; Natural Sciences and Engineering Research
   Council of Canada (NSERC)Natural Sciences and Engineering Research
   Council of Canada [RGPIN-2017-04078, CRDPJ-488704-15]
FX This work is part of the PIONEER STP project which is funded by Water
   Joint Programming Initiative, water challenge for a changing world
   waterworks 2014 co fund call. Dr. Christopher DeGroot acknowledges the
   funding provided by the Natural Sciences and Engineering Research
   Council of Canada (NSERC) [RGPIN-2017-04078 and CRDPJ-488704-15]. The
   contribution of Drs. Francesca Giaccherini and Furqan Khan is greatly
   appreciated. Dr. Ulf Jeppsson is greatly acknowledged for having
   provided the codes of the original Benchmark Simulation Model no2.
CR Behera CR, 2018, CHEM ENG J, V334, P1965, DOI 10.1016/j.cej.2017.11.091
   Boiocchi R, 2017, WATER RES, V123, P479, DOI 10.1016/j.watres.2017.06.074
   Chen R, 2017, BIORESOURCE TECHNOL, V228, P69, DOI 10.1016/j.biortech.2016.12.089
   Comas J, 2008, ENVIRON MODELL SOFTW, V23, P1250, DOI 10.1016/j.envsoft.2008.02.013
   Daynouri-Pancino F., 2018, P EC WAST TREATM 4 I
   DeGroot C.T., 2016, P WAT ENV FED, V2016, P1158, DOI 10.2175/193864716819712791
   DeGroot C. T., 2015, P WAT ENV FED, V2015, P1249, DOI DOI 10.2175/193864715819556273
   Domingo-Felez C., 2017, ESTABLISHMENT CALIBR
   Ebeling JM, 2006, AQUACULT ENG, V35, P61, DOI 10.1016/j.aquaeng.2005.08.006
   Franchi A, 2015, WATER PRACT TECHNOL, V10, P319, DOI 10.2166/wpt.2015.038
   Gernaey KV, 2014, SCI TECH REP SER, P1
   Guo LS, 2014, BIOPROC BIOSYST ENG, V37, P151, DOI 10.1007/s00449-013-0978-3
   Gupta M., 2018, MUNICIPAL WASTEWATER
   Hager WH, 2010, WASTEWATER HYDRAULICS: THEORY AND PRACTICE, SECOND EDITION, P289, DOI 10.1007/978-3-642-11383-3_10
   Jeppsson U, 2007, WATER SCI TECHNOL, V56, P67, DOI 10.2166/wst.2007.604
   Ni BJ, 2013, ENVIRON SCI TECHNOL, V47, P7795, DOI 10.1021/es4005398
   Otterpohl R., 1994, P IAWQ 17 BIENN INT
   Paulsrud B, 2014, WATER SCI TECHNOL, V69, P560, DOI 10.2166/wst.2013.737
   RIVERA DE, 1986, IND ENG CHEM PROC DD, V25, P252, DOI 10.1021/i200032a041
   Ruiken CJ, 2013, WATER RES, V47, P43, DOI 10.1016/j.watres.2012.08.023
   Sherratt A., 2018, CAN SOC MECH ENG T
   Sherratt A, 2019, CHEM ENG SCI, V195, P881, DOI 10.1016/j.ces.2018.10.033
   Sin G, 2008, BIOTECHNOL BIOENG, V100, P516, DOI 10.1002/bit.21769
   Sutton P.M., 2008, SESS 24 WEFTEC 2008, P1671, DOI 10.2175/193864708788733945
NR 24
TC 2
Z9 2
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115510
DI 10.1016/j.ces.2020.115510
PG 16
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600017
DA 2020-05-12
ER

PT J
AU Chen, L
   Lian, C
   Jiang, H
   Chen, LX
   Yan, J
   Liu, HL
   Li, CZ
AF Chen, Ling
   Lian, Cheng
   Jiang, Hao
   Chen, Lingxue
   Yan, Jian
   Liu, Honglai
   Li, Chunzhong
TI Dual-conductive N,S co-doped carbon nanoflowers for high-loading
   quasi-solid-state supercapacitor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE High mass loading; Nitrogen and sulfur co-doping; Carbon nanoflowers;
   Quasi-solid-state supercapacitor
ID POROUS CARBON; PERFORMANCE; ELECTRODE; NITROGEN; NANOSHEETS; SULFUR;
   FOAM
AB To cope the challenges including the low areal energy density and interface engineering between electrode and electrolyte of quasi-solid-state supercapacitors. We herein demonstrate the rational design and synthesis of ion/electron dual-conductive carbon nanoflowers assembled by N,S co-doped two-dimension mesoporous nanosheets. Electronic density functional theory calculations suggest that the S doping could lead to an extra quantum capacitance and suppress the side reactions. The structure characterization suggests that the bigger S atoms could enlarge interlayer distance of carbon from 0.347 nm to 0.378 nm, accelerating ions diffusion kinetics. Consequently, the N,S-C nanoflowers deliver excellent electrochemical performances even the loading mass of N,S-C reaches 6.38 mg cm(-2) owing to the good electrical conductivity and low charge transfer resistance. Furthermore, the a symmetrical quasi-solid-state supercapacitor is assembled and delivers a high specific capacitance of 52.5 F g(-1) even at 13.5 mg cm(-2) and a capacitance retention of 97.2% after 10,000 cycles. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Chen, Ling; Lian, Cheng; Jiang, Hao; Liu, Honglai; Li, Chunzhong] East China Univ Sci & Technol, Sch Chem Engn, Key Lab Ultrafine Mat, Minist Educ, Shanghai 200237, Peoples R China.
   [Jiang, Hao; Li, Chunzhong] East China Univ Sci & Technol, Shanghai Engn Res Ctr Hierarch Nanomat, Sch Mat Sci & Engn, Shanghai 200237, Peoples R China.
   [Chen, Lingxue; Yan, Jian] Hefei Univ Technol, Sch Mat Sci & Engn, Inst Ind & Equipment Technol, Hefei 230009, Peoples R China.
RP Jiang, H (reprint author), East China Univ Sci & Technol, Sch Chem Engn, Key Lab Ultrafine Mat, Minist Educ, Shanghai 200237, Peoples R China.; Jiang, H (reprint author), East China Univ Sci & Technol, Shanghai Engn Res Ctr Hierarch Nanomat, Sch Mat Sci & Engn, Shanghai 200237, Peoples R China.
EM jianghao@ecust.edu.cn; yanjian@hfut.edu.cn; czli@ecust.edu.cn
OI Lian, Cheng/0000-0002-9016-832X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51672082, 91534202, 91834301]; Basic Research
   Program of Shanghai [17JC1402300]; Shanghai Scientific and Technological
   Innovation Project [18JC1410500]; National Program for Support of
   Top-Notch Young Professionals; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [222201718002]
FX This work was supported by the National Natural Science Foundation of
   China (51672082, 91534202 and 91834301), the Basic Research Program of
   Shanghai (17JC1402300), the Shanghai Scientific and Technological
   Innovation Project (18JC1410500), the National Program for Support of
   Top-Notch Young Professionals, and the Fundamental Research Funds for
   the Central Universities (222201718002).
CR Boota M, 2016, ENERG ENVIRON SCI, V9, P2586, DOI 10.1039/c6ee00793g
   Chen JZ, 2016, NANO ENERGY, V25, P193, DOI 10.1016/j.nanoen.2016.04.037
   Chen T, 2014, SCI REP-UK, V4, DOI 10.1038/srep03612
   Fan XM, 2015, ADV ENERGY MATER, V5, DOI 10.1002/aenm.201401761
   Huang CF, 2019, CHEM ENG SCI, V206, P518, DOI 10.1016/j.ces.2019.06.002
   Huang XX, 2018, ACS ENERGY LETT, V3, P2914, DOI 10.1021/acsenergylett.8b01717
   Kale VS, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201803786
   Kumar KS, 2018, ACS ENERGY LETT, V3, P482, DOI 10.1021/acsenergylett.7b01169
   Li B, 2016, ENERG ENVIRON SCI, V9, P102, DOI 10.1039/c5ee03149d
   Li YJ, 2016, NANO ENERGY, V19, P165, DOI 10.1016/j.nanoen.2015.10.038
   Lian C, 2016, ACS ENERGY LETT, V1, P21, DOI 10.1021/acsenergylett.6b00010
   Lin TQ, 2015, SCIENCE, V350, P1508, DOI 10.1126/science.aab3798
   Ling Z, 2016, ADV FUNCT MATER, V26, P111, DOI 10.1002/adfm.201504004
   Liu F, 2019, NANO ENERGY, V61, P18, DOI 10.1016/j.nanoen.2019.04.003
   Liu YZ, 2016, ENERGY STORAGE MATER, V2, P69, DOI 10.1016/j.ensm.2015.09.006
   Lota G, 2005, CHEM PHYS LETT, V404, P53, DOI 10.1016/j.cplett.2005.01.074
   Lv T, 2018, ADV MATER, V30, DOI 10.1002/adma.201705489
   Ma S, 2019, CHEM ENG SCI, V205, P181, DOI 10.1016/j.ces.2019.05.001
   Na W, 2017, J MATER CHEM A, V5, P17379, DOI 10.1039/c7ta04406b
   Nie YF, 2016, J POWER SOURCES, V320, P140, DOI 10.1016/j.jpowsour.2016.04.093
   Pan ZH, 2019, ADV ENERGY MATER, V9, DOI 10.1002/aenm.201802753
   Peng ZY, 2019, ADV ENERGY MATER, V9, DOI 10.1002/aenm.201802928
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Qie L, 2015, ADV SCI, V2, DOI 10.1002/advs.201500195
   Qu QT, 2015, ADV MATER INTERFACES, V2, DOI 10.1002/admi.201500048
   Rathod D, 2009, J APPL ELECTROCHEM, V39, P1097, DOI 10.1007/s10800-008-9764-3
   Song L, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201700474
   Tang C, 2015, CHEMELECTROCHEM, V2, P1903, DOI 10.1002/celc.201500285
   Tang X, 2019, ACS CENTRAL SCI, V5, P365, DOI 10.1021/acscentsci.8b00921
   Wang T, 2019, ADV MATER, V31, DOI 10.1002/adma.201807876
   Wang YM, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201806207
   Wang Y, 2015, J MATER CHEM A, V3, P21314, DOI 10.1039/c5ta05345e
   Wei TY, 2016, J POWER SOURCES, V331, P373, DOI 10.1016/j.jpowsour.2016.09.053
   Xia L, 2019, SMALL METHODS, V3, DOI 10.1002/smtd.201800251
   Xia L, 2019, CHEM COMMUN, V55, P3371, DOI 10.1039/c9cc00602h
   Xu B, 2018, ENERGY STORAGE MATER, V12, P128, DOI 10.1016/j.ensm.2017.12.006
   Xu CX, 2016, RSC ADV, V6, P19826, DOI 10.1039/c5ra26848f
   Xu YX, 2013, ACS NANO, V7, P4042, DOI 10.1021/nn4000836
   Yan LJ, 2018, ACS SUSTAIN CHEM ENG, V6, P5265, DOI 10.1021/acssuschemeng.7b04922
   Yang JQ, 2017, ADV MATER, V29, DOI 10.1002/adma.201604108
   Yu LY, 2018, ACS ENERGY LETT, V3, P1597, DOI 10.1021/acsenergylett.8b00718
   Yu WH, 2016, J MATER CHEM A, V4, P5973, DOI 10.1039/c6ta01821a
   Yu X, 2016, CARBON, V101, P49, DOI 10.1016/j.carbon.2016.01.073
   Zhang LC, 2016, ACS NANO, V10, P1273, DOI 10.1021/acsnano.5b06648
   Zhang Q, 2018, NANOSCALE, V10, P2427, DOI 10.1039/c7nr07158b
   Zhou WD, 2017, ACS CENTRAL SCI, V3, P52, DOI 10.1021/acscentsci.6b00321
   Zhu ZJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep15936
NR 47
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115496
DI 10.1016/j.ces.2020.115496
PG 9
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600005
DA 2020-05-12
ER

PT J
AU Chew, JW
   Cocco, RA
AF Chew, Jia Wei
   Cocco, Ray A.
TI Application of machine learning methods to understand and predict
   circulating fluidized bed riser flow characteristics
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Machine learning; Mass flux; Species segregation; Voidage; Cluster;
   Circulating fluidized bed
ID GROUP-B PARTICLES; CLUSTER CHARACTERISTICS; MODEL
AB Machine learning methods were applied to circulating fluidized bed (CFB) riser data. The goals were to (i) provide insights on various fluidization phenomena through determining the relative dominance of the process variables, and (ii) develop a model to provide predictive capability in the absence of firstprinciples understanding that remains elusive. The Random Forest results indicate radial position had the most dominant influence on local mass flux and species segregation, overall mass flux was the most dominant for local particle concentration, while no variable was particularly dominant or negligible for the local clustering characteristics. Furthermore, the Neural Network can be trained to provide good predictive capability, without any mechanistic understanding needed, if a sufficiently large dataset is used for training and if the input variables fully account for all the effects at play. This study underscores the value of machine learning methods in fluidization to advance understanding and provide adequate predictions. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Chew, Jia Wei] Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore 637459, Singapore.
   [Chew, Jia Wei] Nanyang Technol Univ, Singapore Membrane Technol Ctr, Nanyang Environm & Water Res Inst, Singapore 637141, Singapore.
   [Cocco, Ray A.] Particulate Solid Res Inc, Chicago, IL 60632 USA.
RP Chew, JW (reprint author), Nanyang Technol Univ, Sch Chem & Biomed Engn, Singapore 637459, Singapore.
EM JChew@ntu.edu.sg
RI Chew, Jia Wei/A-7395-2018
OI Chew, Jia Wei/0000-0002-6603-1649
FU Singapore National Research FoundationSingapore National Research
   Foundation [NRF2017-ITS002-013]; Singapore Ministry of EducationMinistry
   of Education, Singapore [2019-T1-002-065]
FX The authors thank the financial support from the Singapore National
   Research Foundation 2nd Intra-CREATE Seed Collaboration Grant
   (NRF2017-ITS002-013) and the Singapore Ministry of Education Tier 1
   Grant (2019-T1-002-065).
CR Abbasi Mohammad R., 2019, REV CHEM ENG, V311
   Agrawal K, 2001, J FLUID MECH, V445, P151, DOI 10.1017/S0022112001005663
   Auret L, 2012, MINER ENG, V35, P27, DOI 10.1016/j.mineng.2012.05.008
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Cahyadi A, 2017, CHEM ENG SCI, V158, P70, DOI 10.1016/j.ces.2016.10.002
   Cahyadi A, 2015, POWDER TECHNOL, V275, P220, DOI 10.1016/j.powtec.2015.02.010
   Chew JW, 2015, CHEM ENG J, V260, P152, DOI 10.1016/j.cej.2014.08.086
   Chew JW, 2012, POWDER TECHNOL, V221, P1, DOI 10.1016/j.powtec.2011.12.019
   Chew JW, 2012, CHEM ENG SCI, V68, P82, DOI 10.1016/j.ces.2011.09.011
   Chew JW, 2012, CHEM ENG SCI, V68, P72, DOI 10.1016/j.ces.2011.09.012
   Chew JW, 2011, POWDER TECHNOL, V214, P89, DOI 10.1016/j.powtec.2011.07.040
   Chew JW, 2011, CHEM ENG SCI, V66, P4595, DOI 10.1016/j.ces.2011.06.031
   de Martin L, 2011, POWDER TECHNOL, V207, P104, DOI 10.1016/j.powtec.2010.10.015
   Dehghanian N, 2016, DESALIN WATER TREAT, V57, P9272, DOI 10.1080/19443994.2015.1027964
   Du B, 2006, IND ENG CHEM RES, V45, P5384, DOI 10.1021/ie051401w
   Dubrawski K, 2013, POWDER TECHNOL, V235, P203, DOI 10.1016/j.powtec.2012.10.031
   Fan LS, 2012, ENERG ENVIRON SCI, V5, P7254, DOI 10.1039/c2ee03198a
   Han T, 2018, T I MEAS CONTROL, V40, P2681, DOI 10.1177/0142331217708242
   Kunii D., 1991, FLUIDIZATION ENG, P1
   Li J, 2005, CHEM ENG SCI, V60, P1251, DOI 10.1016/j.ces.2004.09.083
   Otto S.A., 2019, NORMALIZE RMSE
   Park Y, 2017, DESALIN WATER TREAT, V77, P69, DOI 10.5004/dwt.2017.20661
   Patil-Shinde V, 2014, IND ENG CHEM RES, V53, P18678, DOI 10.1021/ie500593j
   Petrovic J, 2011, EUR J PHARM SCI, V44, P227, DOI 10.1016/j.ejps.2011.07.013
   Reichstein M, 2019, NATURE, V566, P195, DOI 10.1038/s41586-019-0912-1
   Schmitt F, 2018, BIOCHEM ENG J, V133, P47, DOI 10.1016/j.bej.2018.02.001
   Sun Q, 2019, CRIT REV FOOD SCI, V59, P2258, DOI 10.1080/10408398.2018.1446900
   Uzun H, 2017, BIORESOURCE TECHNOL, V234, P122, DOI 10.1016/j.biortech.2017.03.015
   Yang W., 2003, HDB FLUIDIZATION FLU
   Yang W.-C., 1998, FLUIDIZATION SOLIDS
   Zhao ZT, 2019, BIORESOURCE TECHNOL, V282, P262, DOI 10.1016/j.biortech.2019.03.044
   Zhu XZ, 2019, J HAZARD MATER, V378, DOI 10.1016/j.jhazmat.2019.06.004
NR 32
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115503
DI 10.1016/j.ces.2020.115503
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600011
DA 2020-05-12
ER

PT J
AU Cong, WT
   Li, ZS
   Cao, K
   Feng, G
   Chen, R
AF Cong, Wentao
   Li, Zoushuang
   Cao, Kun
   Feng, Guang
   Chen, Rong
TI Transient analysis and process optimization of the spatial atomic layer
   deposition using the dynamic mesh method
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Spatial ALD; Computational fluid dynamics; Chemical kinetics; Process
   optimization; Dynamic mesh method
ID HIGH-THROUGHPUT; FLUID-DYNAMICS; OXIDE; PRESSURE; ALUMINA; KINETICS;
   AL2O3; TMA; ALD
AB Spatial atomic layer deposition (ALD) is acknowledged as a high-throughput thin film preparation technique. Since the films are obtained at a high relative velocity of the substrate, the dynamic flow field distribution is more intricate compared to the traditional ALD. In this paper, by adopting the dynamic mesh method, a mathematical model combing fluid dynamics with chemical kinetics is established. Quantitative analysis is carried out to evaluate how different parameters influence precursor intermixing through this dynamic model. The viscous dragging effect caused by the relative movement of the substrate is also investigated. The good agreement between the mathematical results and the experimental data demonstrates the effectiveness of the dynamic model. To obtain a uniform thin film with a relatively high deposition rate and precursor usage, the motion speed of the substrate is also optimized. This numerical model has momentous guidance to the further process optimization and the spatial ALD system design. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Cong, Wentao; Li, Zoushuang; Cao, Kun; Chen, Rong] Huazhong Univ Sci & Technol, Sch Mech Sci & Engn, State Key Lab Digital Mfg Equipment & Technol, 1037 Luoyu Rd, Wuhan 430074, Hubei, Peoples R China.
   [Feng, Guang] Huazhong Univ Sci & Technol, Sch Energy & Power Engn, State Key Lab Coal Combust, Wuhan 430074, Hubei, Peoples R China.
RP Chen, R (reprint author), Huazhong Univ Sci & Technol, Sch Mech Sci & Engn, State Key Lab Digital Mfg Equipment & Technol, 1037 Luoyu Rd, Wuhan 430074, Hubei, Peoples R China.
EM rongchen@mail.hust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51575217, 51835005, 51911540476, 51702106];
   Flexible Electronics Research Center of HUST; Analytic Testing Center of
   HUST
FX This work was supported by the National Natural Science Foundation of
   China (51575217, 51835005, 51911540476 and 51702106). The authors would
   like to acknowledge the help of Yili Huang, Yun Li, and Xiaolei Wang,
   and the technology support by the Flexible Electronics Research Center
   of HUST & Analytic Testing Center of HUST.
CR Chen R, 2016, J VAC SCI TECHNOL A, V34, DOI 10.1116/1.4955289
   Comstock MJ, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2901877
   de la Huerta CM, 2019, COATINGS, V9, DOI 10.3390/coatings9010005
   DENG Z, 2016, J VAC SCI TECHNOL A, V34, DOI DOI 10.1116/1.4932564
   Ellinger CR, 2014, CHEM MATER, V26, P1514, DOI 10.1021/cm402464z
   Elliott SD, 2012, SEMICOND SCI TECH, V27, DOI 10.1088/0268-1242/27/7/074008
   Fitzpatrick PR, 2012, J VAC SCI TECHNOL A, V30, DOI 10.1116/1.3664765
   Gakis GP, 2018, CHEM ENG RES DES, V132, P795, DOI 10.1016/j.cherd.2018.02.031
   Gakis GP, 2019, CHEM ENG SCI, V195, P399, DOI 10.1016/j.ces.2018.09.037
   George SM, 2010, CHEM REV, V110, P111, DOI 10.1021/cr900056b
   Granneman E, 2007, SURF COAT TECH, V201, P8899, DOI 10.1016/j.surfcoat.2007.05.009
   Halls MD, 2004, J PHYS CHEM B, V108, P4058, DOI 10.1021/jp0378079
   HAUKKA S, 1993, J PHYS CHEM-US, V97, P5085, DOI 10.1021/j100121a040
   He WJ, 2015, IEEE T NANOTECHNOL, V14, P1094, DOI 10.1109/TNANO.2015.2471298
   Hoffmann L, 2018, ACS APPL MATER INTER, V10, P6006, DOI 10.1021/acsami.7b17701
   Holmqvist A, 2014, CHEM ENG SCI, V111, P15, DOI 10.1016/j.ces.2014.02.005
   Illiberi A., 2015, ECS Transactions, V69, P31, DOI 10.1149/06907.0031ecst
   Levy DH, 2009, J DISP TECHNOL, V5, P484, DOI 10.1109/JDT.2009.2022770
   Maydannik PS, 2011, CHEM ENG J, V171, P345, DOI 10.1016/j.cej.2011.03.097
   Maydannik PS, 2012, J VAC SCI TECHNOL A, V30, DOI 10.1116/1.3662861
   Miikkulainen V, 2013, J APPL PHYS, V113, DOI 10.1063/1.4757907
   Mousa MBM, 2018, J VAC SCI TECHNOL A, V36, DOI 10.1116/1.5022077
   Mousa MBM, 2012, J VAC SCI TECHNOL A, V30, DOI 10.1116/1.3670961
   Munoz-Rojas D, 2019, MATER TODAY CHEM, V12, P96, DOI 10.1016/j.mtchem.2018.11.013
   Musselman KP, 2016, CHEM MATER, V28, P8443, DOI 10.1021/acs.chemmater.6b03077
   Oviroh PO, 2019, SCI TECHNOL ADV MAT, V20, P465, DOI 10.1080/14686996.2019.1599694
   Pan DQ, 2019, INT J HEAT MASS TRAN, V144, DOI 10.1016/j.ijheatmasstransfer.2019.118642
   Pan DQ, 2016, INT J HEAT MASS TRAN, V96, P189, DOI 10.1016/j.ijheatmasstransfer.2016.01.034
   Pan DQ, 2015, J VAC SCI TECHNOL A, V33, DOI 10.1116/1.4905726
   Poodt P, 2013, J VAC SCI TECHNOL A, V31, DOI 10.1116/1.4756692
   Poodt P, 2012, J VAC SCI TECHNOL A, V30, DOI 10.1116/1.3670745
   Poodt P, 2012, J VAC SCI TECHNOL A, V30, DOI 10.1116/1.3667113
   Poodt P, 2010, ADV MATER, V22, P3564, DOI 10.1002/adma.201000766
   Puurunen RL, 2005, J APPL PHYS, V97, DOI 10.1063/1.1940727
   Remmers EM, 2015, CHEM ENG SCI, V127, P374, DOI 10.1016/j.ces.2015.01.051
   Shaeri MR, 2014, INT J HEAT MASS TRAN, V78, P1243, DOI 10.1016/j.ijheatmasstransfer.2014.07.079
   TILLMARK N, 1992, J FLUID MECH, V235, P89, DOI 10.1017/S0022112092001046
   Vandalon V, 2016, APPL PHYS LETT, V108, DOI 10.1063/1.4939654
   Wang XL, 2017, REV SCI INSTRUM, V88, DOI 10.1063/1.4991048
   Widjaja Y, 2002, APPL PHYS LETT, V80, P3304, DOI 10.1063/1.1473237
   Xie YY, 2015, CHEM ENG J, V259, P213, DOI 10.1016/j.cej.2014.07.105
   Yang YQ, 2014, J PHYS CHEM C, V118, P18783, DOI 10.1021/jp505974j
NR 42
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115513
DI 10.1016/j.ces.2020.115513
PG 12
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600020
DA 2020-05-12
ER

PT J
AU Deng, SG
   Wen, Z
   Lou, GF
   Zhang, DY
   Su, FY
   Liu, XL
   Dou, RF
AF Deng, Shengan
   Wen, Zhi
   Lou, Guofeng
   Zhang, Dengyu
   Su, Fuyong
   Liu, Xunliang
   Dou, Ruifeng
TI Process of particles flow across staggered tubes in moving bed
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Granular flow; Flow across tubes; Moving bed; Discrete element method;
   Residence time
ID HEAT-TRANSFER; MODEL; SIMULATION; EXCHANGERS; RECOVERY; PATTERN; SOLIDS
AB Moving beds with staggered tubes are widely used in industrial applications to heat or cool solid particles. The heat transfer process is complicated and involves heat transfer amongst particles and between particles and tubes. Furthermore, the heat transfer mechanism is directly determined by the flow characteristics of particles across the outer surfaces of tubes because particles are the main heat carriers of particle flow. However, the particle flow across tubes is a kind of non-continuum flow, which is substantially different from Newtonian fluids, and the continuum theory is inappropriate for predicting particle flow in moving bed. In addition, little attention has been focused on this process. Thus, it is necessary to study the flow patterns of particles across tubes before studying the corresponding heat transfer mechanism. To describe this process, this work establishes a quasi-funnel flow (QFF) model, which can be used to calculate parameters, such as velocity field and residence time, by analyzing particle flow characteristics. The discrete element method (DEM) is used for a numerical simulation of three-dimensional particle flow across staggered tubes. The flow patterns, velocity field, typical particle trajectories and particle flow of local areas are obtained. Meanwhile, a moving bed experimental system is constructed, and the obtained results are used to verify the DEM numerical simulation results. Lastly, the results of the QFF model and that of the validated DEM numerical simulation are compared and found to be consistent. The ranges of the parameters required to describe the particle flow across tubes and the applicable range of the QFF model are also determined. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Deng, Shengan; Wen, Zhi; Lou, Guofeng; Zhang, Dengyu; Su, Fuyong; Liu, Xunliang; Dou, Ruifeng] Univ Sci & Technol Beijing, Sch Energy & Environm Engn, Beijing 100083, Peoples R China.
   [Wen, Zhi; Lou, Guofeng; Su, Fuyong; Liu, Xunliang; Dou, Ruifeng] Univ Sci & Technol Beijing, Beijing Key Lab Energy Saving & Emiss Reduct Met, Beijing 100083, Peoples R China.
RP Wen, Z (reprint author), Mech & Informat Bldg,914 Room,30,Xueyuan Rd, Beijing, Peoples R China.
EM wenzhi@me.ustb.edu.cn; lgf@ustb.edu.cn
FU National Key R&D Program of China [2016YFC0401201]
FX This work was supposed by the National Key R&D Program of China [grant
   number 2016YFC0401201].
CR Bartsch P, 2016, ENRGY PROCED, V99, P72, DOI 10.1016/j.egypro.2016.10.099
   Baumann T, 2012, J PHYS CONF SER, V395, DOI 10.1088/1742-6596/395/1/012055
   Baumann T, 2014, HEAT TRANSFER ENG, V35, P224, DOI 10.1080/01457632.2013.825154
   Bellan S, 2018, ENERGY, V160, P245, DOI 10.1016/j.energy.2018.06.212
   Cleary PW, 2009, ENG COMPUTATION, V26, P698, DOI 10.1108/02644400910975487
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Gan JQ, 2016, CHEM ENG SCI, V156, P64, DOI 10.1016/j.ces.2016.09.017
   Hartl J, 2008, CHEM ENG RES DES, V86, P370, DOI 10.1016/j.cherd.2007.07.001
   JAEGER HM, 1992, SCIENCE, V255, P1523, DOI 10.1126/science.255.5051.1523
   Kurochkin Y.P., 1966, J ENG PHYS, V10, P447, DOI [10.1007/BF00831071, DOI 10.1007/BF00831071]
   Liu JX, 2015, INT COMMUN HEAT MASS, V69, P23, DOI 10.1016/j.icheatmasstransfer.2015.10.013
   Ma HQ, 2017, CHEM ENG SCI, V172, P636, DOI 10.1016/j.ces.2017.07.017
   Mahjoub M., 2014, International Journal of Biosciences (IJB), V5, P117
   Morris AB, 2016, AICHE J, V62, P4526, DOI 10.1002/aic.15331
   NIEGSCH J, 1994, CHEM ENG PROCESS, V33, P73, DOI 10.1016/0255-2701(94)85006-2
   OSTOJA-STARZEWSKI M, 1993, MECH MATER, V16, P55, DOI 10.1016/0167-6636(93)90027-O
   Pan G, 2015, IRONMAK STEELMAK, V42, P489, DOI 10.1179/1743281214Y.0000000253
   POLDERMAN HG, 1987, CHEM ENG SCI, V42, P737, DOI 10.1016/0009-2509(87)80033-7
   SCHAEFFER DG, 1992, P ROY SOC LOND A MAT, V436, P217, DOI 10.1098/rspa.1992.0016
   Takeuchi H, 1996, AICHE J, V42, P1621, DOI 10.1002/aic.690420613
   Tang TQ, 2017, CHEM ENG SCI, V172, P79, DOI 10.1016/j.ces.2017.06.025
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   Wu JT, 2008, POWDER TECHNOL, V181, P74, DOI 10.1016/j.powtec.2007.06.014
   Wu JT, 2009, ADV POWDER TECHNOL, V20, P62, DOI 10.1016/j.apt.2008.02.003
   Yang SC, 2001, POWDER TECHNOL, V120, P244, DOI 10.1016/S0032-5910(01)00277-7
   Yang SL, 2017, CHEM ENG SCI, V172, P652, DOI 10.1016/j.ces.2017.07.019
   Yang WJ, 2015, CHEM ENG J, V278, P339, DOI 10.1016/j.cej.2014.11.144
   Zhang RQ, 2013, POWDER TECHNOL, V249, P186, DOI 10.1016/j.powtec.2013.08.017
   Zhang S, 2014, GRANUL MATTER, V16, P857, DOI 10.1007/s10035-014-0533-1
NR 29
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115507
DI 10.1016/j.ces.2020.115507
PG 17
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600014
DA 2020-05-12
ER

PT J
AU Duan, ZY
   Wilms, T
   Neubauer, P
   Kravaris, C
   Bournazou, MNC
AF Duan, Zhaoyang
   Wilms, Terrance
   Neubauer, Peter
   Kravaris, Costas
   Bournazou, Mariano Nicolas Cruz
TI Model reduction of aerobic bioprocess models for efficient simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Model reduction; Dissolved oxygen tension; Aerobic; Nonlinear dynamics;
   Observer
ID NONLINEAR OBSERVER DESIGN; SINGULAR PERTURBATIONS; INVARIANT-MANIFOLDS;
   STATE ESTIMATION
AB Owing to the increasing demand for large scale and high efficiency in manufacturing processes, computer aided tools for process operation and control are rapidly gaining popularity. An important state variable in aerobic processes is the dissolved oxygen, which can be easily measured online and is an important indicator of the metabolic activity. However, due to the fast kinetics of the oxygen transfer, dynamical models describing aerobic bioprocesses tend to be highly stiff. This can lead to significant numerical problems hampering its use for fixed step discretization methods and computationally costly applications such as computer fluid dynamics. In this work we use the slow-motion invariant manifold and the quasi steady state assumption methods to eliminate the differential equation describing the dissolved oxygen (the fast mode). By doing this, the tractability of the model is significantly increased with a neglectable loss in description power. The reduced model is also useful for simplifying the observer design problems, which is demonstrated by a state and parameter estimation example at the end of the work. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Duan, Zhaoyang; Kravaris, Costas] Texas A&M Univ, Artie McFerrin Dept Chem Engn, College Stn, TX 77843 USA.
   [Wilms, Terrance] Tech Univ Berlin, Dept Proc Engn, Chair Measurement & Control, D-10623 Berlin, Germany.
   [Neubauer, Peter] Tech Univ Berlin, Inst Biotechnol, Dept Bioproc Engn, D-13355 Berlin, Germany.
   [Bournazou, Mariano Nicolas Cruz] DataHow AG, Zurich, Switzerland.
RP Kravaris, C (reprint author), Texas A&M Univ, Artie McFerrin Dept Chem Engn, College Stn, TX 77843 USA.
EM zy.duan@tamu.edu; terrance.wilms@tu-berlin.de;
   peter.neubauer@tu-berlin.de; kravaris@tamu.edu;
   nicolas.cruz@tu-berlin.de
FU National Science FoundationNational Science Foundation (NSF)
   [CBET-1706201]
FX Zhaoyang Duan and Costas Kravaris acknowledge financial support from the
   National Science Foundation through grant CBET-1706201.
CR Anane E, 2019, BIOTECHNOL BIOENG, V116, P2906, DOI 10.1002/bit.27116
   Anane E, 2017, BIOCHEM ENG J, V125, P23, DOI 10.1016/j.bej.2017.05.013
   Berlec A, 2013, J IND MICROBIOL BIOT, V40, P257, DOI 10.1007/s10295-013-1235-0
   Bournazou MNC, 2012, J CHEM TECHNOL BIOT, V87, P887, DOI 10.1002/jctb.3694
   Chen Ling, 2017, 2017 IEEE 56th Annual Conference on Decision and Control (CDC), P3664, DOI 10.1109/CDC.2017.8264198
   Chiavazzo E, 2007, COMMUN COMPUT PHYS, V2, P964
   Dochain D, 2003, J PROCESS CONTR, V13, P801, DOI 10.1016/S0959-1524(03)00026-X
   Dochain D., 2013, AUTOMATIC CONTROL BI
   Duan ZY, 2018, AICHE J, V64, P1295, DOI 10.1002/aic.16033
   Duan ZY, 2017, CHEM ENG J, V327, P1102, DOI 10.1016/j.cej.2017.06.110
   Enfors S.-O., 2000, BIOPROCESS TECHNOLOG
   Floudas CA, 2009, J GLOBAL OPTIM, V45, P3, DOI 10.1007/s10898-008-9332-8
   Gavrilescu M, 2005, BIOTECHNOL ADV, V23, P471, DOI 10.1016/j.biotechadv.2005.03.004
   Gorban AN, 2018, CURR OPIN CHEM ENG, V21, P48, DOI 10.1016/j.coche.2018.02.009
   Gorban A.N., 2005, LECT NOTES PHYS, V660
   Gorban AN, 2003, CHEM ENG SCI, V58, P4751, DOI 10.1016/j.ces.2002.12.001
   Haby B., 2018, BIOSPEKTRUM, V24, P39, DOI [10.1007/s12268-018-0889-6, DOI 10.1007/S12268-018-0889-6]
   Kalman R. E., 1960, J BASIC ENG, V82, P35, DOI DOI 10.1115/1.3662552
   Kazantzis N, 1998, SYST CONTROL LETT, V34, P241, DOI 10.1016/S0167-6911(98)00017-6
   Kazantzis N, 2010, NONLINEAR DYNAM, V59, P183, DOI 10.1007/s11071-009-9531-y
   KOKOTOVIC PV, 1976, AUTOMATICA, V12, P123, DOI 10.1016/0005-1098(76)90076-5
   Koutinas M, 2012, COMPUT STRUCT BIOTEC, V3, DOI 10.5936/csbj.201210022
   Kramer D, 2019, J PROCESS CONTR, V82, P91, DOI 10.1016/j.jprocont.2017.11.008
   Kravaris C, 2004, P AMER CONTR CONF, P2931
   Kravaris C, 2013, COMPUT CHEM ENG, V51, P111, DOI 10.1016/j.compchemeng.2012.06.001
   Kumar A, 1998, CHEM ENG SCI, V53, P1491, DOI 10.1016/S0009-2509(98)00006-2
   Ling C, 2017, AICHE J, V63, P3384, DOI 10.1002/aic.15707
   Liu AD, 2015, IEEE DECIS CONTR P, P6850, DOI 10.1109/CDC.2015.7403298
   LUENBERGER DG, 1964, IEEE T MIL ELECTRON, VMIL8, P74, DOI 10.1109/TME.1964.4323124
   Mears L, 2017, TRENDS BIOTECHNOL, V35, P914, DOI 10.1016/j.tibtech.2017.07.002
   Moller J., 2019, BIOPROC BIOSYST ENG, P1
   Neubauer P, 2013, ENG LIFE SCI, V13, P224, DOI 10.1002/elsc.201200021
   Okino MS, 1998, CHEM REV, V98, P391, DOI 10.1021/cr950223l
   Psaltis A, 2013, COMPUT CHEM ENG, V52, P240, DOI 10.1016/j.compchemeng.2013.01.005
   RABITZ H, 1983, ANNU REV PHYS CHEM, V34, P419, DOI 10.1146/annurev.pc.34.100183.002223
   Roussel MR, 2001, CHAOS, V11, P196, DOI 10.1063/1.1349891
   SEGEL LA, 1989, SIAM REV, V31, P446, DOI 10.1137/1031091
   Stamatelatou K, 2009, CHEM ENG J, V150, P462, DOI 10.1016/j.cej.2009.01.033
   Tatiraju S, 1999, AICHE J, V45, P769, DOI 10.1002/aic.690450412
   Wang RF, 2016, BIOTECHNOL BIOFUELS, V9, DOI 10.1186/s13068-016-0500-7
   Wang RF, 2014, BIORESOURCE TECHNOL, V172, P303, DOI 10.1016/j.biortech.2014.09.028
   Welch G., INTRO KALMAN FILTER
   Westman JO, 2015, BIOTECHNOL J, V10, P1185, DOI 10.1002/biot.201400581
   Zhaoyang Duan, 2017, 2017 IEEE 56th Annual Conference on Decision and Control (CDC), P2083, DOI 10.1109/CDC.2017.8263954
NR 44
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115512
DI 10.1016/j.ces.2020.115512
PG 12
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600019
DA 2020-05-12
ER

PT J
AU Gast, S
   Tuttlies, US
   Nieken, U
AF Gast, Sebastian
   Tuttlies, Ute S.
   Nieken, Ulrich
TI Kinetic study of the toluene oxidation in homogeneous liquid phase
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas-liquid reaction; Toluene oxidation; Homogeneous liquid phase;
   Reaction kinetics
ID AUTOXIDATION; CONSEQUENCES; BENZALDEHYDE; ACETATE; COBALT; ACID
AB To better understand the interplay of fluid dynamics, mass transport, and chemical reactions in multi-phase reactors, each of these effects needs to be studied separately. In particular, reactions are hard to study separately from mass transport. In this work, using a new reactor concept a macroscopic reaction kinetics of the oxidation of toluene is determined in homogeneous liquid-phase. By operating at elevated pressure, mass transport limitations are avoided. The reactor concept requires the measurement of the oxygen concentration within the organic liquid phase, which further allows to setup an atomic oxygen balance. Running experiments at different oxygen flow rates, a kinetic model was parameterized, which describes the experimental results for oxygen flow rates in an industrially relevant range. Since the developed model has no mass transport limitations, it can be used in processes where independent modelling of mass transport and chemical reactions are combined, such as with computational fluid dynamics. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Gast, Sebastian; Tuttlies, Ute S.; Nieken, Ulrich] Univ Stuttgart, Inst Chem Proc Engn, Boblinger Str 78, D-70199 Stuttgart, Germany.
RP Nieken, U (reprint author), Univ Stuttgart, Inst Chem Proc Engn, Boblinger Str 78, D-70199 Stuttgart, Germany.
EM ulrich.nieken@icvt.uni-stuttgart.de
FU  [SPP1740]
FX The authors gratefully acknowledge Holger Aschenbrenner and Dorthe
   Schiewe for their contribution to the reactor implementation and the
   financial support from the german research foundation priority program
   SPP1740, which deals with the "influence of local transport processes in
   chemical reactions in bubble flows"
CR BLACK JF, 1978, J AM CHEM SOC, V100, P527, DOI 10.1021/ja00470a028
   BORGAONKAR HV, 1984, IND ENG CHEM PROD RD, V23, P455, DOI 10.1021/i300015a026
   Bothe M, 2013, CHEM-ING-TECH, V85, P1023, DOI 10.1002/cite.201300051
   Bruhne F., 2011, ULLMANNS ENCY IND CH
   Bruhne F., 2000, ULLMANNS ENCY IND CH
   Bukharkina TV, 2004, ORG PROCESS RES DEV, V8, P320, DOI 10.1021/op030012f
   Fabri J., 2011, ULLMANNS ENCY IND CH, P109
   Gast S, 2017, CHEM ENG TECHNOL, V40, P1445, DOI 10.1002/ceat.201700045
   Guo CC, 2005, APPL CATAL A-GEN, V282, P55, DOI 10.1016/j.apcata.2004.11.045
   HENDRIKS CF, 1978, IND ENG CHEM PROD RD, V17, P256, DOI 10.1021/i360067a016
   Hermans I, 2006, J MOL CATAL A-CHEM, V251, P221, DOI 10.1016/j.molcata.2006.02.005
   Hermans I, 2007, CHEMPHYSCHEM, V8, P2678, DOI 10.1002/cphc.200700563
   Hoorn J.A.A., 2005, INT J CHEM REACT ENG, V3
   Hoorn JAA, 2005, CHEM ENG RES DES, V83, P187, DOI 10.1205/cherd.04161
   LEVENSPIEL O, 1999, CHEM REACTION ENG
   Mills PL, 1999, CATAL TODAY, V48, P17, DOI 10.1016/S0920-5861(98)00354-X
   MORIMOTO T, 1967, J CHEM SOC B, P62, DOI 10.1039/j29670000062
   MORIMOTO T, 1967, J CHEM SOC B, P1353, DOI 10.1039/j29670001353
   SAKOTA K, 1968, B CHEM SOC JPN, V41, P641, DOI 10.1246/bcsj.41.641
   Sandhiya L, 2015, CHEM-EUR J, V21, P14060, DOI 10.1002/chem.201502384
   Tan PH, 2010, CHEM ENG COMMUN, V197, P953, DOI 10.1080/00986440903359343
   Tang SW, 2007, IND ENG CHEM RES, V46, P6442, DOI 10.1021/ie070040c
   VASVARI G, 1993, BER BUNSEN PHYS CHEM, V97, P22, DOI 10.1002/bbpc.19930970105
NR 23
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115500
DI 10.1016/j.ces.2020.115500
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600008
DA 2020-05-12
ER

PT J
AU Ge, RH
   Ghadiri, M
   Bonakdar, T
   Zheng, QJ
   Zhou, ZY
   Larson, I
   Hapgood, K
AF Ge, Ruihuan
   Ghadiri, Mojtaba
   Bonakdar, Tina
   Zheng, Qijun
   Zhou, Zongyan
   Larson, Ian
   Hapgood, Karen
TI Deformation of 3D printed agglomerates: Multiscale experimental tests
   and DEM simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE 3D printing; Discrete Element Method (DEM); Agglomerates; Deformation
ID IMPACT BREAKAGE; NUMERICAL-SIMULATION; MODEL; CONTACT; ENERGY
AB Agglomerates are widely used in industry, and their mechanical properties are of great interest. In this work, we propose a new concept of using a coordinated multiscale approach to match the physical and digital agglomerate structures and properties. By using a multi-material 3D printing technology, the inter-particle bond properties and agglomerate structures could be precisely controlled and replicated. Quasi-static compression tests have been carried out for the 3D printed samples at different scales. A Timoshenko Beam Bond Model (TBBM) with bond properties matching those of the 3D printed agglomerates is used to describe bond deformations. Discrete Element Method (DEM) is then employed to simulate the agglomerate crushing process. The results show that for both agglomerate structures, the DEM simulation and experimental results show good agreement at the initial elastic deformation stage. This work opens up the chance for significant advances in agglomerate deformation and breakage modelling in future. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ge, Ruihuan; Hapgood, Karen] Monash Univ, Dept Chem Engn, Clayton, Vic, Australia.
   [Ghadiri, Mojtaba; Bonakdar, Tina] Univ Leeds, Sch Chem & Proc Engn, Leeds, W Yorkshire, England.
   [Zheng, Qijun; Zhou, Zongyan] Monash Univ, Dept Chem Engn, Lab Simulat & Modelling Particulate Syst, Clayton, Vic, Australia.
   [Larson, Ian] Monash Univ, Monash Inst Pharmaceut Sci, Drug Delivery Disposit & Dynam, Clayton, Vic, Australia.
   [Hapgood, Karen] Deakin Univ, Sch Engn, Geelong, Vic, Australia.
RP Hapgood, K (reprint author), Monash Univ, Dept Chem Engn, Clayton, Vic, Australia.; Hapgood, K (reprint author), Deakin Univ, Sch Engn, Geelong, Vic, Australia.
EM karen.hapgood@deakin.edu.au
OI Ghadiri, Mojtaba/0000-0003-0479-2845
FU International Fine Particle Research Institute (IFPRI); ARC Discovery
   grantAustralian Research Council [DP150100119]; China Scholarship
   Council (CSC)China Scholarship Council
FX This research project was supported by International Fine Particle
   Research Institute (IFPRI) and an ARC Discovery grant (DP150100119).
   Ruihuan Ge's PhD scholarship was supported by the China Scholarship
   Council (CSC). The authors would also like to acknowledge Dr Wenguang
   Nan at the University of Leeds for discussing the DEM simulations. The
   support of DEM Solutions for providing EDEM licences for the purpose of
   this work is greatly acknowledged.
CR ASTM D., 2008, C143715 ASTM INT, P1, DOI DOI 10.1520/C1437-15
   Brown N.J., 2013, THESIS
   Brown NJ, 2014, GRANUL MATTER, V16, P299, DOI 10.1007/s10035-014-0494-4
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   Dadkhah M, 2014, POWDER TECHNOL, V264, P256, DOI 10.1016/j.powtec.2014.05.037
   Dale S, 2014, POWDER TECHNOL, V264, P550, DOI 10.1016/j.powtec.2014.06.009
   DERJAGUIN BV, 1975, J COLLOID INTERF SCI, V53, P314, DOI 10.1016/0021-9797(75)90018-1
   Dosta M, 2016, POWDER TECHNOL, V299, P87, DOI 10.1016/j.powtec.2016.05.005
   Eckhard S, 2017, ADV POWDER TECHNOL, V28, P185, DOI 10.1016/j.apt.2016.09.008
   Ergenzinger C, 2011, GRANUL MATTER, V13, P341, DOI 10.1007/s10035-010-0230-7
   Farber L, 2003, CHEM ENG SCI, V58, P4515, DOI 10.1016/j.ces.2003.07.003
   Ge RH, 2019, POWDER TECHNOL, V356, P1045, DOI 10.1016/j.powtec.2019.08.113
   Ge RH, 2018, POWDER TECHNOL, V340, P299, DOI 10.1016/j.powtec.2018.09.029
   Ge RH, 2017, POWDER TECHNOL, V306, P103, DOI 10.1016/j.powtec.2016.10.070
   Golchert DJ, 2004, ADV POWDER TECHNOL, V15, P447, DOI 10.1163/1568552041270554
   Instron Corporation, 2005, INSTR SER 5500 LOAD
   JOHNSON KL, 1971, PROC R SOC LON SER-A, V324, P301, DOI 10.1098/rspa.1971.0141
   KAFUI KD, 1993, POWDERS & GRAINS 93, P401
   Liu L, 2010, POWDER TECHNOL, V199, P189, DOI 10.1016/j.powtec.2010.01.007
   Matuttis HG, 2001, INT J MOD PHYS C, V12, P1011, DOI 10.1142/S0129183101002723
   Mishra BK, 2001, INT J MINER PROCESS, V61, P225, DOI 10.1016/S0301-7516(00)00065-X
   Moreno-Atanasio R, 2006, CHEM ENG SCI, V61, P2476, DOI 10.1016/j.ces.2005.11.019
   Ning Z, 1997, ADV POWDER TECHNOL, V8, P15, DOI 10.1016/S0921-8831(08)60477-X
   Potyondy DO, 2004, INT J ROCK MECH MIN, V41, P1329, DOI 10.1016/j.ijrmms.2004.09.011
   Przemieniecki JS, 1985, THEORY MATRIX STRUCT
   Reynolds GK, 2005, CHEM ENG SCI, V60, P3969, DOI 10.1016/j.ces.2005.02.029
   Shen ZF, 2016, COMPUT GEOTECH, V75, P192, DOI 10.1016/j.compgeo.2016.02.007
   Subero J, 1999, POWDER TECHNOL, V105, P66, DOI 10.1016/S0032-5910(99)00119-9
   Subero J, 2000, CHEM ENG RES DES, V78, P55, DOI 10.1205/026387600527077
   Takezawa A, 2015, APL MATER, V3, DOI 10.1063/1.4926759
   Thornton C, 2004, POWDER TECHNOL, V143, P110, DOI 10.1016/j.powtec.2004.04.035
   Thornton C, 2004, POWDER TECHNOL, V140, P258, DOI 10.1016/j.powtec.2004.01.022
   Thornton C, 1996, J PHYS D APPL PHYS, V29, P424, DOI 10.1088/0022-3727/29/2/021
   Wang LF, 2011, ADV MATER, V23, P1524, DOI 10.1002/adma.201003956
NR 34
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115526
DI 10.1016/j.ces.2020.115526
PG 15
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600031
DA 2020-05-12
ER

PT J
AU Harun, NH
   Abdul-Aziz, A
   Rahman, RA
   Yaakub, H
   Aziz, R
   Ware, I
AF Harun, Noor Hafiza
   Abdul-Aziz, Azila
   Rahman, Roshanida A.
   Yaakub, Harisun
   Aziz, Ramlan
   Ware, Ismail
TI Dimensional-analysis and similitude for scale-up of solid-liquid
   extraction of Eurycoma longifolia roots
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dimensionless; Similitude; Extraction; Eurycoma longifolia; ShSc(-1)
   number
ID PHENOLIC-COMPOUNDS; OPTIMIZATION; PLANT; PILOT; OIL
AB A dimensionless model was proposed to scale-up the solid-liquid extraction of Eurycoma longifolia roots. ShSc(-1) dimensionless number was found to be the best fit of all proposed models. At optimum conditions of the extraction process, which were duration of extraction of 53 min, solvent to raw material ratio of 12.5:1 and roots particle size of 0.5 to 1.0 mm, the extract yield of 8.76% at lab-scale produced ShSc(-1) no. of 0.0312. Employing the scale up rule of P/V idem and scale-up factor of 7.65, the extract yield of 8.65% with 1.37% error was obtained at pilot-scale at ShSc(-1) no. of 0.0376. The outcome of this study provided useful scale-up knowledge in ensuring smooth transition from lab-scale to pilot-scale. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Harun, Noor Hafiza; Yaakub, Harisun; Aziz, Ramlan; Ware, Ismail] Univ Teknol Malaysia, Inst Bioprod Dev, Skudai 81310, Johor, Malaysia.
   [Harun, Noor Hafiza; Abdul-Aziz, Azila; Rahman, Roshanida A.; Yaakub, Harisun; Aziz, Ramlan] Univ Teknol Malaysia, Fac Engn, Sch Chem & Energy Engn, Skudai 81310, Johor, Malaysia.
   [Abdul-Aziz, Azila] Univ Teknol Malaysia, Inst Bioprod Dev, Jalan Sultan Yahya Petra, Kuala Lumpur 54100, Malaysia.
RP Abdul-Aziz, A (reprint author), Univ Teknol Malaysia, Fac Engn, Sch Chem & Energy Engn, Skudai 81310, Johor, Malaysia.; Abdul-Aziz, A (reprint author), Univ Teknol Malaysia, Inst Bioprod Dev, Jalan Sultan Yahya Petra, Kuala Lumpur 54100, Malaysia.
EM r-azila@utm.my
FU Ministry of Agricultural and Agro-based Industry, Malaysia under NKEA
   Herbal Research Grant Scheme [4H011, 4H022]; Ministry of Education
   Malaysia under MyBrain15 (MyPhD scholarship); Universiti Teknologi
   Malaysia (UTM), Skudai, Johor, Malaysia
FX The authors gratefully appreciate the support from the Ministry of
   Agricultural and Agro-based Industry, Malaysia under NKEA Herbal
   Research Grant Scheme (Vote no.: 4H011 and 4H022), Ministry of Education
   Malaysia under MyBrain15 (MyPhD scholarship) and Universiti Teknologi
   Malaysia (UTM), Skudai, Johor, Malaysia. We are also indebted to
   Institute of Bioproduct Development (IBD), UTM Skudai in providing the
   facilities and infrastructures that permit us to run all experimental
   works at both laboratory and pilot scales.
CR Athimulam A, 2006, FOOD BIOPROD PROCESS, V84, P139, DOI 10.1205/fbp.06004
   Bhat R, 2010, FITOTERAPIA, V81, P669, DOI 10.1016/j.fitote.2010.04.006
   Choi Y., 1986, FOOD ENG PROCESS APP, P93
   Couper J.R., 2012, CHEM PROCESS EQUIPME, P273
   Dickey D.S., 2009, FOOD MIXING PRINCIPL, P90
   Euzen J.P., 1993, SCALE UP METHODOLOGY, P9
   Filly A, 2014, FOOD CHEM, V150, P193, DOI 10.1016/j.foodchem.2013.10.139
   Fiori L, 2010, CHEM ENG PROCESS, V49, P866, DOI 10.1016/j.cep.2010.06.001
   Geankoplis C.J., 2003, TRANSPORT PROCESSES
   GEISLER RK, 1993, CHEM ENG J BIOCH ENG, V51, P29, DOI 10.1016/0300-9467(93)80005-9
   Hallstrom B., 1988, HEAT TRANSFER FOOD P
   Harun N.H., 2016, P 6 INT C BIOT WELLN, P154
   Heywood H., 1937, J SOC CHEM IND LOND, V56, P149
   Kresta S.M., 2004, HDB IND MIXING SCI P, P19
   Kumaresan S., 2008, THESIS
   Maloney J.O., 2008, PERRYS CHEM ENG HDB
   Mohamad M., 2010, Journal of Applied Sciences, V10, P2572
   Mohamed AN, 2015, J APPL SCI, V15, P831, DOI DOI 10.3923/jas.2015.831.844
   Mohtar M.A., 2007, J APPL SCI, V7, P2168
   Prado JM, 2011, J SUPERCRIT FLUID, V56, P231, DOI 10.1016/j.supflu.2010.10.036
   RICHARDSON JF, 1954, T I CHEM ENG-LOND, V32, P35, DOI DOI 10.1016/S0263-8762(97)80006-8
   Santos DT, 2012, J FOOD ENG, V108, P444, DOI 10.1016/j.jfoodeng.2011.08.022
   Sim C.C, 2004, THESIS
   SPIRO M, 1982, J CHEM SOC FARAD T 1, V78, P295, DOI 10.1039/f19827800295
   Fernandez-Ponce MT, 2016, CHEM ENG J, V299, P420, DOI 10.1016/j.cej.2016.04.046
   Thu HE, 2017, CHIN J NAT MEDICINES, V15, P71, DOI 10.1016/S1875-5364(17)30010-9
   Van Geem KM, 2007, CHEM ENG J, V134, P3, DOI 10.1016/j.cej.2007.03.065
   Zamri W.M.W., 2014, THESIS
   Zlakornik M., 2006, SCALE UP CHEM ENG
   Zlakornik M., 2001, STIRRING THEORY PRAC
   ZWIETERING TN, 1958, CHEM ENG SCI, V8, P244, DOI 10.1016/0009-2509(58)85031-9
NR 31
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115490
DI 10.1016/j.ces.2020.115490
PG 12
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600003
DA 2020-05-12
ER

PT J
AU Isner, AB
   Umbanhowar, PB
   Ottino, JM
   Lueptow, RM
AF Isner, Austin B.
   Umbanhowar, Paul B.
   Ottino, Julio M.
   Lueptow, Richard M.
TI Axisymmetric granular flow on a bounded conical heap: Kinematics and
   size segregation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Granular materials; Discrete element method; Conical heap; Segregation;
   Kinematics
ID DISCRETE ELEMENT; HOPPERS; PARTICLES; DYNAMICS; MODEL; SIMULATIONS;
   MECHANISM
AB Free surface flows of granular materials in bounded axisymmetric geometries such as a cylindrical silo are poorly understood. In particular, a detailed description of the local three-dimensional velocity field and predictive models for segregation are lacking. Here, the details of the kinematics of flow in a rising conical heap formed by a centrally fed mixture of spherical particles are investigated using Discrete Element Method (DEM) simulations in a wedge-shaped geometry with periodic azimuthal boundaries. The dependence of the streamwise and surface normal velocity components on the inlet flow rate and silo radius for size-bidisperse and monodisperse mixtures of glass spheres is characterized. Compared to a wedge with frictional sidewalls, the flowing layer is much thicker on average in the axisymmetric case. Using the scalings for kinematics obtained from the DEM simulations, a modified continuum advection-diffusionsegregation model accurately predicts steady-state segregation for axisymmetric conical heap flows of size-bidisperse mixtures. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Isner, Austin B.; Ottino, Julio M.; Lueptow, Richard M.] Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL 60208 USA.
   [Umbanhowar, Paul B.; Ottino, Julio M.; Lueptow, Richard M.] Northwestern Univ, Dept Mech Engn, Evanston, IL 60208 USA.
   [Ottino, Julio M.; Lueptow, Richard M.] Northwestern Univ, Northwestern Inst Complex Syst NICO, Evanston, IL 60208 USA.
   [Isner, Austin B.] Los Alamos Natl Lab, Los Alamos, NM 87544 USA.
RP Lueptow, RM (reprint author), Northwestern Univ, Dept Mech Engn, Evanston, IL 60208 USA.
EM r-lueptow@northwestern.edu
FU Dow Chemical Company
FX The authors thank Yi Fan and Karl Jacob of The Dow Chemical Company for
   many helpful discussions. This research was funded by The Dow Chemical
   Company.
CR Anand A, 2008, CHEM ENG SCI, V63, P5821, DOI 10.1016/j.ces.2008.08.015
   ARTEAGA P, 1990, CHEM ENG SCI, V45, P205, DOI 10.1016/0009-2509(90)87093-8
   Bi WT, 2005, J PHYS-CONDENS MAT, V17, pS2457, DOI 10.1088/0953-8984/17/24/006
   BRIDGWATER J, 1985, POWDER TECHNOL, V41, P147, DOI 10.1016/0032-5910(85)87033-9
   Cui L, 2007, GEOTECHNIQUE, V57, P831, DOI 10.1680/geot.2007.57.10.831
   Cui L., 2005, POWDERS GRAINS 2005, P301
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   de Silva S.R., 2000, IUTAM S SEGR GRAN FL, P11, DOI DOI 10.1007/978-94-015-9498-1_2
   Dolgunin VN, 1998, POWDER TECHNOL, V96, P211, DOI 10.1016/S0032-5910(97)03376-7
   DOLGUNIN VN, 1995, POWDER TECHNOL, V83, P95, DOI 10.1016/0032-5910(94)02954-M
   Fan Y., 2011, THESIS
   Fan Y, 2017, POWDER TECHNOL, V312, P67, DOI 10.1016/j.powtec.2017.02.026
   Fan Y, 2013, P ROY SOC A-MATH PHY, V469, DOI 10.1098/rspa.2013.0235
   Fan Y, 2014, J FLUID MECH, V741, P252, DOI 10.1017/jfm.2013.680
   Fan Y, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.051305
   Gajjar P, 2016, J FLUID MECH, V794, P460, DOI 10.1017/jfm.2016.170
   Goyal RK, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.051301
   Grasselli Y, 1997, PHYSICA A, V246, P301, DOI 10.1016/S0378-4371(97)00326-9
   Grasselli Y., 1998, GRANUL MATTER, V1, P43, DOI DOI 10.1007/PL00010909)
   Gray JMNT, 2006, J FLUID MECH, V569, P365, DOI 10.1017/S0022112006002977
   Gray JMNT, 2009, J FLUID MECH, V629, P387, DOI 10.1017/S0022112009006466
   Gray JMNT, 2005, P ROY SOC A-MATH PHY, V461, P1447, DOI 10.1098/rspa.2004.1420
   Gray JMNT, 1997, CONTINUUM MECH THERM, V9, P341, DOI 10.1007/s001610050075
   Gray JMNT, 2018, ANNU REV FLUID MECH, V50, P407, DOI [10.1146/annurev-fluid-122316045201, 10.1146/annurev-fluid-122316-045201]
   Isner AB, 2020, AICHE J, V66, DOI 10.1002/aic.16912
   Jones RP, 2018, PHYS REV FLUIDS, V3, DOI 10.1103/PhysRevFluids.3.094304
   Jop P, 2006, NATURE, V441, P727, DOI 10.1038/nature04801
   Jop P, 2005, J FLUID MECH, V541, P167, DOI 10.1017/S0022112005005987
   Ketterhagen WR, 2008, POWDER TECHNOL, V179, P126, DOI 10.1016/j.powtec.2007.06.023
   Ketterhagen WR, 2007, CHEM ENG SCI, V62, P6423, DOI 10.1016/j.ces.2007.07.052
   Ketterhagen WR, 2009, POWDER TECHNOL, V195, P1, DOI 10.1016/j.powtec.2009.05.002
   Lee J., 1992, J PHYS A, V26, P373
   Li YJ, 2005, POWDER TECHNOL, V160, P219, DOI 10.1016/j.powtec.2005.09.002
   Makse HA, 1997, NATURE, V386, P379, DOI 10.1038/386379a0
   Maneval JE, 2005, GRANUL MATTER, V7, P199, DOI 10.1007/s10035-005-0211-4
   Marks B, 2012, J FLUID MECH, V690, P499, DOI 10.1017/jfm.2011.454
   Meier SW, 2007, ADV PHYS, V56, P757, DOI 10.1080/00018730701611677
   MiDi GDR, 2004, EUR PHYS J E, V14, P341, DOI 10.1140/epje/i2003-10153-0
   MOSBY J, 1996, KONA POWDER PART J, V14, P31, DOI DOI 10.14356/K0NA
   Mosby J., 1996, THESIS
   NAKAGAWA M, 1993, EXP FLUIDS, V16, P54, DOI 10.1007/BF00188507
   NVIDIA, 2014, CUDA C PROGRAMMING G
   Parker DJ, 1997, CHEM ENG SCI, V52, P2011, DOI 10.1016/S0009-2509(97)00030-4
   Pignatel F, 2012, PHYS REV E, V86, DOI 10.1103/PhysRevE.86.011304
   Rahman M, 2011, CHEM ENG SCI, V66, P6089, DOI 10.1016/j.ces.2011.08.024
   Rapaport DC, 2002, PHYS REV E, V65, DOI 10.1103/PhysRevE.65.061306
   Ristow GH, 2000, SPRINGER TRAC MOD PH, V164, P1
   Salter G., 1998, THESIS
   Samadani A, 1999, PHYS REV E, V60, P7203, DOI 10.1103/PhysRevE.60.7203
   SAVAGE SB, 1988, J FLUID MECH, V189, P311, DOI 10.1017/S002211208800103X
   Schafer J, 1996, J PHYS I, V6, P5, DOI 10.1051/jp1:1996129
   Schlick C.P., 2014, THESIS
   Schlick CP, 2015, AICHE J, V61, P1524, DOI 10.1002/aic.14780
   Schlick CP, 2015, J FLUID MECH, V765, P632, DOI 10.1017/jfm.2015.4
   SHINOHARA K, 1972, IND ENG CHEM PROC DD, V11, P369, DOI 10.1021/i260043a008
   Silbert LE, 2001, PHYS REV E, V64, DOI 10.1103/PhysRevE.64.051302
   Silbert LE, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.068002
   Smith L, 2004, CHEM ENG SCI, V59, P3223, DOI 10.1016/j.ces.2004.03.026
   Smith L, 2001, J ENG MECH-ASCE, V127, P1000, DOI 10.1061/(ASCE)0733-9399(2001)127:10(1000)
   STANDISH N, 1985, POWDER TECHNOL, V45, P43, DOI 10.1016/0032-5910(85)85059-2
   Thomas N, 2000, PHYS REV E, V62, P961, DOI 10.1103/PhysRevE.62.961
   TRAIN D, 1958, J PHARM PHARMACOL, V10, pT127, DOI 10.1111/j.2042-7158.1958.tb10391.x
   Umbanhowar PB, 2019, ANNU REV CHEM BIOMOL, V10, P129, DOI 10.1146/annurev-chembioeng-060718-030122
   Wiederseiner S, 2011, PHYS FLUIDS, V23, DOI 10.1063/1.3536658
   Xiao H, 2019, CHEM ENG SCI, V193, P188, DOI 10.1016/j.ces.2018.08.039
   Xiao HY, 2016, P ROY SOC A-MATH PHY, V472, DOI 10.1098/rspa.2015.0856
   Zheng QJ, 2017, POWDER TECHNOL, V307, P63, DOI 10.1016/j.powtec.2016.11.037
   Zhou YC, 2002, POWDER TECHNOL, V125, P45, DOI 10.1016/S0032-5910(01)00520-4
NR 68
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115505
DI 10.1016/j.ces.2020.115505
PG 12
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600013
DA 2020-05-12
ER

PT J
AU Javan, H
   Asghari, E
   Ashassi-Sorkhabi, H
   Moradi-Haghighi, M
AF Javan, Hakimeh
   Asghari, Elnaz
   Ashassi-Sorkhabi, Habib
   Moradi-Haghighi, Masoumeh
TI Nickel nanoparticles decorated on carbon quantum dots as a novel
   non-platinum catalyst for methanol oxidation; a green, low-cost,
   electrochemically-synthesized electrocatalyst
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Electrodeposition; Methanol oxidation; Electrochemical impedance
   spectroscopy; High active surface area; Carbon quantum dots;
   Non-platinum catalyst
ID REDUCED GRAPHENE OXIDE; NONENZYMATIC GLUCOSE; ORGANIC-COMPOUNDS;
   FUEL-CELLS; ELECTRODE; PERFORMANCE; NI; ANODE; ELECTROOXIDATION;
   FABRICATION
AB The methanol oxidation reaction (MOR) is catalyzed by non- platinum catalysts of nickel nanoparticles (Ni-NPs) that deposited on a modified glassy carbon electrode by reduced carbon quantum dots (RCQD). The cyclic voltammetry (CV), and chronoamperometry (CA) techniques are used for the electrodeposition process. Then the morphology and structure of electrodeposited materials are characterized by X-ray diffraction (XRD), energy dispersive X-ray analysis (EDX) and scanning electron microscopy (SEM). Results showed that Ni-NPs are homogeneously electrodeposited on the surface of CQDs. Also, the catalysis of MOR on electrodes is investigated by different electrochemical techniques like CV and CA, and electrochemical impedance spectroscopy (EIS). The electrochemical behavior of electrodes for MOR has been informed with several parameters. For example, for Ni-NPs/RCQDs/GCE, the peak current density at E = 0.56 V, vs. Ag/AgCl was 32 mA.cm(-2) that is higher than of Ni-NPs/GCE. Also, the this catalyst shows excellent stability and high current at constant voltage. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Javan, Hakimeh; Asghari, Elnaz; Ashassi-Sorkhabi, Habib] Univ Tabriz, Fac Chem, Phys Chem Dept, Electrochem Res Lab, Tabriz, Iran.
   [Moradi-Haghighi, Masoumeh] Northeastern Univ, Shenyang Natl Lab Mat Sci, Shenyang 110819, Peoples R China.
RP Asghari, E (reprint author), Univ Tabriz, Fac Chem, Phys Chem Dept, Electrochem Res Lab, Tabriz, Iran.
EM e.asghari@tabrizu.ac.ir
FU Research Office of the University of Tabriz
FX This project was carried out in "Electrochemistry Research Laboratory"of
   "University of Tabriz''. Authors are grateful for financial supports
   from Research Office of the University of Tabriz.
CR Adzic RR, 2007, TOP CATAL, V46, P249, DOI 10.1007/s11244-007-9003-x
   Antolini E, 2012, APPL CATAL B-ENVIRON, V123, P52, DOI 10.1016/j.apcatb.2012.04.022
   Asgari M, 2011, J ELECTROCHEM SOC, V158, pK225, DOI 10.1149/2.055112jes
   Asghari E, 2017, SYNTHETIC MET, V229, P57, DOI 10.1016/j.synthmet.2017.05.009
   Ashassi-Sorkhabi H., 2018, J COLLOID INTERFACE
   Barbosa AFB, 2015, J ELECTROANAL CHEM, V746, P31, DOI 10.1016/j.jelechem.2015.03.024
   Bard A. J., 2001, ELECTROCHEM METHODS, V2, P482
   Bunazawa H, 2009, J POWER SOURCES, V190, P210, DOI 10.1016/j.jpowsour.2009.01.077
   Cao DX, 2010, INT J HYDROGEN ENERG, V35, P807, DOI 10.1016/j.ijhydene.2009.11.026
   Cao L, 2007, J AM CHEM SOC, V129, P11318, DOI 10.1021/ja073527l
   Cao L, 2012, THERANOSTICS, V2, P295, DOI 10.7150/thno.3912
   Chen Y, 2020, J COLLOID INTERF SCI, V559, P206, DOI 10.1016/j.jcis.2019.10.024
   Danaee I, 2008, INT J HYDROGEN ENERG, V33, P4367, DOI 10.1016/j.ijhydene.2008.05.075
   Ensafi AA, 2015, TALANTA, V134, P745, DOI 10.1016/j.talanta.2014.12.028
   Ferdowsi GS, 2015, J NANOSTRUCTURE CHEM, V5, P17, DOI 10.1007/s40097-014-0124-z
   Fernando KAS, 2015, ACS APPL MATER INTER, V7, P8363, DOI 10.1021/acsami.5b00448
   FLEISCHM.M, 1972, J CHEM SOC PERK T 2, P1396, DOI 10.1039/p29720001396
   FLEISCHMANN M, 1971, J ELECTROANAL CHEM, V31, P39, DOI 10.1016/S0022-0728(71)80040-2
   Ghasemi M, 2013, INT J HYDROGEN ENERG, V38, P9533, DOI 10.1016/j.ijhydene.2013.01.177
   Gong J, 2008, J ALLOY COMPD, V457, P6, DOI 10.1016/j.jallcom.2007.02.124
   Govindasamy M, 2019, ELECTROCHIM ACTA, V293, P328, DOI 10.1016/j.electacta.2018.10.051
   Govindasamy M, 2016, INT J ELECTROCHEM SC, V11, P10806, DOI 10.20964/2016.12.98
   Hameed RMA, 2015, APPL CATAL B-ENVIRON, V162, P217, DOI 10.1016/j.apcatb.2014.06.057
   Hosseini MG, 2018, ENERGY, V161, P1074, DOI 10.1016/j.energy.2018.07.148
   Hsin YL, 2007, J AM CHEM SOC, V129, P9999, DOI 10.1021/ja072367a
   Jahan M, 2013, ADV FUNCT MATER, V23, P5363, DOI 10.1002/adfm.201300510
   Jahanbakhshi M, 2016, BIOSENS BIOELECTRON, V81, P143, DOI 10.1016/j.bios.2016.02.064
   Javan H, 2019, SYNTHETIC MET, V254, P153, DOI 10.1016/j.synthmet.2019.06.006
   Kakaei K, 2016, INT J HYDROGEN ENERG, V41, P14684, DOI 10.1016/j.ijhydene.2016.06.093
   Kakaei K, 2016, J CHIN CHEM SOC-TAIP, V63, P432, DOI 10.1002/jccs.201500534
   Kong B, 2012, ADV MATER, V24, P5844, DOI 10.1002/adma.201202599
   Lee K, 2006, J APPL ELECTROCHEM, V36, P507, DOI 10.1007/s10800-006-9120-4
   Lee SA, 2002, J ELECTROCHEM SOC, V149, pA1299, DOI 10.1149/1.1502685
   Li HT, 2010, ANGEW CHEM INT EDIT, V49, P4430, DOI 10.1002/anie.200906154
   Li YC, 2015, SENSOR ACTUAT B-CHEM, V206, P735, DOI 10.1016/j.snb.2014.09.016
   Li YJ, 2010, CARBON, V48, P1124, DOI 10.1016/j.carbon.2009.11.034
   Lim SY, 2015, CHEM SOC REV, V44, P362, DOI 10.1039/c4cs00269e
   Liu ZL, 2004, J PHYS CHEM B, V108, P8234, DOI 10.1021/jp049422b
   Lugovskoy A., 2010, DEFECT DIFFUS FORUM, P1481
   Luo PJG, 2013, J MATER CHEM B, V1, P2116, DOI 10.1039/c3tb00018d
   MARITAN A, 1990, ELECTROCHIM ACTA, V35, P141, DOI 10.1016/0013-4686(90)85051-N
   Medway SL, 2006, J ELECTROANAL CHEM, V587, P172, DOI 10.1016/j.jelechem.2005.11.013
   Metin O, 2010, J AM CHEM SOC, V132, P1468, DOI 10.1021/ja909243z
   Ming H, 2012, DALTON T, V41, P9526, DOI 10.1039/c2dt30985h
   Monk P.M., 2008, FUNDAMENTALS ELECTRO
   Niu H.-J., 2019, J COLLOID INTERFACE
   Niu WJ, 2015, SENSOR ACTUAT B-CHEM, V218, P229, DOI 10.1016/j.snb.2015.05.006
   Pan D, 2018, APPL SURF SCI, V427, P715, DOI 10.1016/j.apsusc.2017.09.060
   Rashidi R, 2009, J POWER SOURCES, V187, P509, DOI 10.1016/j.jpowsour.2008.11.044
   Sakthivel K., 2018, J ELECTROANAL CHEM, V820, P161
   Scott K, 1999, J POWER SOURCES, V83, P204, DOI 10.1016/S0378-7753(99)00303-1
   Shao YY, 2007, J POWER SOURCES, V171, P558, DOI 10.1016/j.jpowsour.2007.07.004
   Steigerwalt ES, 2001, J PHYS CHEM B, V105, P8097, DOI 10.1021/jp011633i
   Tang D, 2014, ACS APPL MATER INTER, V6, P7918, DOI 10.1021/am501256x
   TARASZEWSKA J, 1994, J ELECTROANAL CHEM, V364, P209, DOI 10.1016/0022-0728(93)02919-9
   Tehrani RMA, 2009, FUEL CELLS, V9, P579, DOI 10.1002/fuce.200800122
   VERTES G, 1974, J ELECTROANAL CHEM, V52, P47, DOI 10.1016/S0022-0728(74)80100-2
   Vusa CSR, 2016, RSC ADV, V6, P33409, DOI 10.1039/c5ra27862g
   Wang B, 2005, J POWER SOURCES, V152, P1, DOI 10.1016/j.jpowsour.2005.05.098
   Wang J, 2016, J COLLOID INTERF SCI, V481, P229, DOI 10.1016/j.jcis.2016.07.061
   Wang QL, 2013, CARBON, V59, P192, DOI 10.1016/j.carbon.2013.03.009
   Wang ZG, 2012, SENSORS-BASEL, V12, P4860, DOI 10.3390/s120404860
   WEININGER JL, 1963, J ELECTROCHEM SOC, V110, P484, DOI 10.1149/1.2425798
   Wildgoose GG, 2006, SMALL, V2, P182, DOI 10.1002/smll.200500324
   Xu C, 2008, J PHYS CHEM C, V112, P19841, DOI 10.1021/jp807989b
   Zhang HC, 2012, J MATER CHEM, V22, P10501, DOI 10.1039/c2jm30703k
   Zhang LR, 2012, NEW J CHEM, V36, P1108, DOI 10.1039/c2nj20690k
   Zhang WM, 2010, ENERG ENVIRON SCI, V3, P1286, DOI 10.1039/c0ee00139b
   Zhang YL, 2013, RSC ADV, V3, P3733, DOI 10.1039/c3ra23410j
NR 69
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115534
DI 10.1016/j.ces.2020.115534
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600035
DA 2020-05-12
ER

PT J
AU Ji, YN
   Geng, WJ
   Ma, CY
   Tan, J
   Deng, WS
   Liu, B
   Su, YF
AF Ji, Ya-Ni
   Geng, Wen-Jie
   Ma, Chun-Yang
   Tan, Jing
   Deng, Wen-Sheng
   Liu, Bin
   Su, Yue-Feng
TI Preparation of microdispersed droplets by phase inversion in
   gas/liquid/liquid microdispersion system
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Emulsion preparation; Microdisperion; Gas/liquid/liquid system; Phase
   inversion; Flow regime transition; Modeling and correlation
ID PROCESS INTENSIFICATION; EXTRACTION; FLOW; MICROFLUIDICS; EMULSIONS;
   DEVICES; EMULSIFICATION; GENERATION; AGITATION; BREAKUP
AB A simple and effective method was conducted for preparing microdispersed droplets with decreased size and increased uniformity, in which phase inversion in high-phase-ratio liquid/liquid system was combined with addition of microbubbles. Five typical flow patterns were observed, including W/O, O/W/O, transition regime, O/W and G/W/O regimes. Flow regime transition was observed, according to which physical properties of systems and operating conditions for preparing single-oil-droplet-in-water emulsion were determined in different liquid/liquid and gas/liquid/liquid modes. Effects of liquid viscosities as well as interfacial tension on droplet size (D-O) and its standard deviation (SD) were studied systematically and the most effective gas/liquid/liquid mode was recommended. Mathematical models were established for correlating D-O in five different modes, which show relatively good agreement with experimental results. D-O decreases by 42% via introducing phase inversion and further reduces to 25% by addition of microbubbles, both under the same operating conditions. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ji, Ya-Ni; Geng, Wen-Jie; Ma, Chun-Yang; Tan, Jing; Deng, Wen-Sheng] Beijing Inst Technol, Sch Chem & Chem Engn, Beijing 100081, Peoples R China.
   [Liu, Bin] TSC Laser Technol Dev Beijing Co Ltd, Beijing 102200, Peoples R China.
   [Su, Yue-Feng] Beijing Inst Technol, Sch Mat Sci & Engn, Beijing Key Lab Environm Sci & Engn, Beijing 100081, Peoples R China.
RP Tan, J (reprint author), Beijing Inst Technol, Sch Chem & Chem Engn, Beijing 100081, Peoples R China.
EM tanjing@bit.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21878019]; Beijing Natural Science
   FoundationBeijing Natural Science Foundation [2182063]
FX The authors gratefully acknowledge the support of National Natural
   Science Foundation of China (21878019) and Beijing Natural Science
   Foundation (2182063). We also acknowledge the instrument support from
   the Analysis & Testing Center of Beijing Institute of Technology.
CR Anna SL, 2003, APPL PHYS LETT, V82, P364, DOI 10.1063/1.1537519
   Behrend O, 2000, ULTRASON SONOCHEM, V7, P77, DOI 10.1016/S1350-4177(99)00029-2
   Chen Z, 2017, SEP PURIF TECHNOL, V174, P352, DOI 10.1016/j.seppur.2016.10.059
   Dittrich PS, 2006, NAT REV DRUG DISCOV, V5, P210, DOI 10.1038/nrd1985
   Dreyfus R, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.144505
   Feng TF, 2018, CHEM ENG SCI, V177, P270, DOI 10.1016/j.ces.2017.11.029
   Fu TT, 2012, CHEM ENG SCI, V84, P207, DOI 10.1016/j.ces.2012.08.039
   Gallassi M, 2019, CHEM ENG SCI, V204, P270, DOI 10.1016/j.ces.2019.04.011
   Ge XH, 2016, CHINESE J CHEM ENG, V24, P677, DOI 10.1016/j.cjche.2016.02.009
   Guo MT, 2012, LAB CHIP, V12, P2146, DOI 10.1039/c2lc21147e
   Hennequin Y, 2009, LANGMUIR, V25, P7857, DOI 10.1021/la9004449
   Joanicot M, 2005, SCIENCE, V309, P887, DOI 10.1126/science.1112615
   Kralj JG, 2005, LAB CHIP, V5, P531, DOI 10.1039/b418815b
   Li LT, 2018, IND ENG CHEM RES, V57, P3523, DOI 10.1021/acs.iecr.8b00040
   Lin C-C, 2013, J ENG, V2013, P1, DOI DOI 10.1080/09640568
   Link DR, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.054503
   Mashaghi S, 2016, TRAC-TREND ANAL CHEM, V82, P118, DOI 10.1016/j.trac.2016.05.019
   Mulligan MK, 2012, MICROFLUID NANOFLUID, V13, P65, DOI 10.1007/s10404-012-0941-7
   Piao YX, 2015, BIOSENS BIOELECTRON, V65, P220, DOI 10.1016/j.bios.2014.10.032
   Ran R, 2017, CHEM ENG SCI, V169, P78, DOI 10.1016/j.ces.2017.01.008
   Riaud A, 2018, LANGMUIR, V34, P4980, DOI 10.1021/acs.langmuir.8b00123
   SAWISTOWSKI H, 1973, CHEM-ING-TECH, V45, P1093, DOI 10.1002/cite.330451802
   Schroen K, 2015, CURR OPIN FOOD SCI, V3, P33, DOI 10.1016/j.cofs.2014.11.009
   Shah RK, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369-7021(08)70053-1
   Shakeel F, 2013, CURR NANOSCI, V9, P248, DOI 10.2174/1573413711309020014
   Song H, 2010, ANGEW CHEM INT EDIT, V45, P7336
   Tan J, 2011, SEP PURIF TECHNOL, V80, P225, DOI 10.1016/j.seppur.2011.04.030
   Xu JH, 2008, CHEM ENG J, V141, P242, DOI 10.1016/j.cej.2007.12.030
   Xu QY, 2008, INNOV FOOD SCI EMERG, V9, P489, DOI 10.1016/j.ifset.2008.03.003
   Yang Y, 2015, J MATER SCI, V50, P3638, DOI 10.1007/s10853-015-8926-z
   Zhao CX, 2011, CHEM ENG SCI, V66, P1463, DOI 10.1016/j.ces.2010.08.039
   Zhu PA, 2017, LAB CHIP, V17, P34, DOI 10.1039/c6lc01018k
NR 32
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115498
DI 10.1016/j.ces.2020.115498
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600006
DA 2020-05-12
ER

PT J
AU Lan, Z
   Chen, FY
   Qiang, WL
   Xue, Q
   Ma, X
AF Lan, Zhong
   Chen, Fangying
   Qiang, Weili
   Xue, Quan
   Ma, Xuehu
TI Direct observation of water clusters for surface design
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Water cluster; Vapor condensation; Attenuated total reflection IR;
   Surface structure
ID CONDENSATION; COLLECTION; CAPTURE
AB Engineered surfaces for water collection have been intensively investigated. However, microscopic mechanism of condensation on structural surfaces is rarely explored and it's always a challenge to observe the dynamic behavior of clusters in nanometer size. Here, a measurement is developed to observe cluster along cooling surface. Experimental results show that clusters has been formed before reaching the surface, and condense would be formed by those clusters. Cluster size n gradually increases with closer to the cooling surface, ranging from tens to a few hundreds. Based on the spatial distribution of clusters, the effect of surface microstructures on condensation is analyzed by classical nucleation theory. Surface microstructures can increase the radius of curvature of clusters to exceed the critical size. This key distance is consistent with height of water-trapping villi of some organism. It will help us better understand the scale characteristics of water-trapping structures on some organisms. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Lan, Zhong; Chen, Fangying; Qiang, Weili; Xue, Quan; Ma, Xuehu] Dalian Univ Technol, Inst Chem Engn, Liaoning Key Lab Clean Utilizat Chem Resources, Dalian 116024, Peoples R China.
RP Lan, Z (reprint author), Dalian Univ Technol, Inst Chem Engn, Liaoning Key Lab Clean Utilizat Chem Resources, Dalian 116024, Peoples R China.
EM lanzhong@dlut.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51476018]
FX We thank Haiou Liu and Yansong Chen for helpful and insightful
   suggestions for the manuscript. We greatly appreciate the financial
   support from the National Natural Science Foundation of China (No.
   51476018).
CR Bai H, 2014, ADV MATER, V26, P5025, DOI 10.1002/adma.201400262
   Becker R, 1935, ANN PHYS-BERLIN, V24, P719
   Bourgalais J, 2016, PHYS REV LETT, V116, DOI 10.1103/PhysRevLett.116.113401
   Buch V, 2004, INT REV PHYS CHEM, V23, P375, DOI 10.1080/01442350412331316124
   BUCK U, 1994, J PHYS CHEM-US, V98, P5190, DOI 10.1021/j100071a005
   Buck U, 2000, CHEM REV, V100, P3863, DOI 10.1021/cr990054v
   Buck U, 2014, PHYS CHEM CHEM PHYS, V16, P6859, DOI 10.1039/c3cp55185g
   FAHRENFORT J, 1961, SPECTROCHIM ACTA, V17, P698, DOI 10.1016/0371-1951(61)80136-7
   Farkas L, 1927, Z PHYS CHEM-STOCH VE, V125, P236
   Fujii A, 2013, INT REV PHYS CHEM, V32, P266, DOI 10.1080/0144235X.2012.760836
   Hamashima T, 2011, J PHYS CHEM A, V115, P620, DOI 10.1021/jp111586p
   HARRICK NJ, 1967, INTERNAL REFLECTION
   Ju J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2253
   Jung S, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1630
   Laksmono H, 2011, PHYS CHEM CHEM PHYS, V13, P5855, DOI 10.1039/c0cp02485f
   Lan Z., 2009, J ENHANC HEAT TRANSF, V16, DOI [10.1615/JEnhHeatTransf.v16.i3.10, DOI 10.1615/JENHHEATTRANSF.V16.I3.10]
   Lan Z, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01190-9
   Lan Z, 2013, INT J THERM SCI, V68, P1, DOI 10.1016/j.ijthermalsci.2013.01.011
   Lippe M, 2018, J CHEM PHYS, V149, DOI 10.1063/1.5052482
   Ma XH, 2008, INT J HEAT MASS TRAN, V51, P1728, DOI 10.1016/j.ijheatmasstransfer.2007.07.021
   Ma XH, 2010, INT J THERM SCI, V49, P1517, DOI 10.1016/j.ijthermalsci.2010.05.011
   Mishchenko L, 2010, ACS NANO, V4, P7699, DOI 10.1021/nn102557p
   Parker AR, 2001, NATURE, V414, P33, DOI 10.1038/35102108
   Pradzynski CC, 2012, SCIENCE, V337, P1529, DOI 10.1126/science.1225468
   ROSE JW, 1981, INT J HEAT MASS TRAN, V24, P191, DOI 10.1016/0017-9310(81)90026-0
   Song TY, 2009, INT J THERM SCI, V48, P2228, DOI 10.1016/j.ijthermalsci.2009.05.004
   Tammann G., 1935, ANN PHYS, V414, P77, DOI 10.1002/andp.19354140108
   Thickett SC, 2011, ADV MATER, V23, P3718, DOI 10.1002/adma.201100290
   W T.G.B, 1935, ANN PHYS, V5, P3, DOI [10.1002/andp.19354140108, DOI 10.1002/ANDP.19354140108]
   Wyslouzil BE, 2016, J CHEM PHYS, V145, DOI 10.1063/1.4962283
   Xu W, 2015, J CHEM PHYS, V142, DOI 10.1063/1.4906877
   Zheng YM, 2010, NATURE, V463, P640, DOI 10.1038/nature08729
   Zurheide F, 2015, J PHYS CHEM A, V119, P2709, DOI 10.1021/jp509883m
NR 33
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115475
DI 10.1016/j.ces.2020.115475
PG 9
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600002
DA 2020-05-12
ER

PT J
AU Li, S
   Jiang, H
   Zhang, J
   Zhang, AS
   Zhao, YD
   Zhao, X
   Zhao, ZP
AF Li, Shuo
   Jiang, Han
   Zhang, Jun
   Zhang, Ao-Shuai
   Zhao, Yong-dong
   Zhao, Xin
   Zhao, Zhi-Ping
TI Fabrication of porous polysulfone microsphere covalently grafted with
   ionic liquid as catalyst and its catalytic hydrolysis kinetics of inulin
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Polysulfone; Loaded ionic liquids; Porous microsphere; Catalyst; Inulin
   hydrolysis
ID BIOMASS; WATER; ACID; CONVERSION; CELLULOSE; SILICA; PERFORMANCE;
   PYROLYSIS
AB Polysulfone (PSF) material loaded with ionic liquids (ILs), PSF-ILs, was prepared by grafting imidazolyl acid ILs onto PSF by chemical bonding. A porous PSF-ILs microsphere catalyst was prepared via non-solvent induced phase separation (NIPS) method in order to catalyze the biomass inulin hydrolysis. The influences of degree of chloromethylation of PSF, hydrolysis temperature, catalyst dosage, PSF-ILs microsphere morphology, coagulation bath of NIPS and inulin concentration on hydrolysis performance were studied respectively. Under this optimal reaction conditions, 95.65% conversion of inulin into reducing sugar was achieved. The results suggested that the catalytic inulin hydrolysis performance of PSF-ILs microsphere was attractive due to high-density spatial distribution of the active sites on the surface and inner pore wall of microsphere after ILs immobilized. The hydrolysis kinetics was also investigated. The kinetic models of inulin hydrolysis catalyzed by PSF-ILs microsphere were employed to predict the hydrolysis in a wider range of experimental conditions. Furthermore, the stability tests showed that PSF-ILs microsphere catalyst could be effectively separated and recovered from hydrolysates, and has good regeneration ability. The morphology of PSF-ILs microspheres remained intact after eight trials of catalytic hydrolysis, avoiding the crushing phenomenon like a powder polymer material. More importantly, the PSF-ILs microsphere can effectively avoid the potential harm of ILs to the ecological environment, and is a potential green catalyst. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Li, Shuo; Jiang, Han; Zhang, Jun; Zhang, Ao-Shuai; Zhao, Yong-dong; Zhao, Xin; Zhao, Zhi-Ping] Beijing Inst Technol, Sch Chem & Chem Engn, Beijing 102488, Peoples R China.
RP Zhao, ZP (reprint author), Beijing Inst Technol, Sch Chem & Chem Engn, Beijing 102488, Peoples R China.
EM zhaozp@bit.edu.cn
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China [21576024]; Doctoral Fund of the Ministry of
   EducationMinistry of Education, China [20131101130005]; Beijing Nature
   Science FoundationBeijing Natural Science Foundation [2162038]
FX The authors would like to thank the support of the National Nature
   Science Foundation of China (No. 21576024), Doctoral Fund of the
   Ministry of Education (No. 20131101130005) and Beijing Nature Science
   Foundation (No. 2162038).
CR Amarasekara AS, 2010, CATAL COMMUN, V11, P1072, DOI 10.1016/j.catcom.2010.05.012
   Barclay T, 2012, CARBOHYD RES, V352, P117, DOI 10.1016/j.carres.2012.03.001
   Cara PD, 2013, CATAL SCI TECHNOL, V3, P2057, DOI 10.1039/c3cy20838a
   Chinnappan A, 2017, CHEM ENG J, V316, P928, DOI 10.1016/j.cej.2017.02.015
   Czernik S, 2004, ENERG FUEL, V18, P590, DOI 10.1021/ef034067u
   Dhepe PL, 2008, CHEMSUSCHEM, V1, P969, DOI 10.1002/cssc.200800129
   Ettouney HM, 1996, ENVIRON POLLUT, V91, P187, DOI 10.1016/0269-7491(95)00050-X
   Gong JL, 2019, CHEM SOC REV, V48, P1862, DOI 10.1039/c9cs90020a
   Guillen GR, 2011, IND ENG CHEM RES, V50, P3798, DOI 10.1021/ie101928r
   Komiyama H, 2001, FUEL, V80, P707, DOI 10.1016/S0016-2361(00)00132-0
   Li JJ, 2015, CHEMPHYSCHEM, V16, P3044, DOI 10.1002/cphc.201500424
   Lu P, 2017, MOL CATAL, V435, P24, DOI 10.1016/j.mcat.2017.03.011
   Lu ZX, 2015, BIOMASS BIOENERG, V81, P154, DOI 10.1016/j.biombioe.2015.06.022
   Mamman A, 2010, BIOFUEL BIOPROD BIOR, V2, P438
   MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030
   Qi WY, 2006, GREEN CHEM, V8, P183, DOI 10.1039/B510602H
   Qi XH, 2019, BIORESOURCE TECHNOL, V273, P687, DOI 10.1016/j.biortech.2018.11.011
   Qiu YB, 2018, BIOTECHNOL BIOFUELS, V11, DOI 10.1186/s13068-018-1152-6
   Ricca E, 2007, CRIT REV BIOTECHNOL, V27, P129, DOI 10.1080/07388550701503477
   Romero I, 2010, CHEM ENG RES DES, V88, P633, DOI 10.1016/j.cherd.2009.10.007
   Schneider MJ, 2014, J CATAL, V309, P71, DOI 10.1016/j.jcat.2013.08.029
   Shen F, 2017, ACS SUSTAIN CHEM ENG, V5, P2421, DOI 10.1021/acssuschemeng.6b02765
   Shoaib M, 2016, CARBOHYD POLYM, V147, P444, DOI 10.1016/j.carbpol.2016.04.020
   Su Y, 2016, AICHE J, V62, P4403, DOI 10.1002/aic.15356
   Sun J, 2009, CATAL TODAY, V148, P361, DOI 10.1016/j.cattod.2009.07.070
   Szambelan K, 2004, BIOTECHNOL LETT, V26, P845, DOI 10.1023/B:BILE.0000025889.25364.4b
   Walton DG, 1996, PHYS REV E, V54, P2811, DOI 10.1103/PhysRevE.54.2811
   Wang B, 2015, CHEM ENG J, V260, P172, DOI 10.1016/j.cej.2014.08.076
   Xu HM, 2015, J MOL CATAL A-CHEM, V410, P235, DOI 10.1016/j.molcata.2015.09.020
   Xu ZJ, 2010, J MOL CATAL A-CHEM, V332, P152, DOI 10.1016/j.molcata.2010.09.011
   Yan Q, 2018, ACS SUSTAIN CHEM ENG, V6, P9640, DOI 10.1021/acssuschemeng.7b04743
   Yang JS, 2015, J MEMBRANE SCI, V493, P80, DOI 10.1016/j.memsci.2015.06.010
   Yang Q, 2016, ACS SUSTAIN CHEM ENG, V4, P4824, DOI 10.1021/acssuschemeng.6b01102
   Yuan XL, 2016, KOREAN J CHEM ENG, V33, P2134, DOI 10.1007/s11814-016-0044-3
   Zhang QA, 2010, GREEN CHEM, V12, P2246, DOI 10.1039/c0gc00472c
   Zhao W, 2008, J MEMBRANE SCI, V318, P405, DOI 10.1016/j.memsci.2008.03.013
   Zhao XT, 2014, J MEMBRANE SCI, V450, P111, DOI 10.1016/j.memsci.2013.08.044
   Zhao ZP, 2016, CHEM ENG SCI, V151, P16, DOI 10.1016/j.ces.2016.05.017
   Zhen B, 2012, APPL CATAL A-GEN, V445, P239, DOI 10.1016/j.apcata.2012.08.023
NR 39
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115544
DI 10.1016/j.ces.2020.115544
PG 12
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600039
DA 2020-05-12
ER

PT J
AU Lim, BH
   Majlan, EH
   Daud, WRW
   Rosli, MI
   Husaini, T
AF Lim, B. H.
   Majlan, E. H.
   Daud, W. R. W.
   Rosli, M., I
   Husaini, T.
TI Numerical investigation of the effect of three-dimensional modified
   parallel flow field designs on proton exchange membrane fuel cell
   performance
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fuel cell; Modified parallel flow field; CFD modeling; Three-dimensional
   model; PEMFCs
ID PEMFC; WATER; DISTRIBUTORS; MANAGEMENT; SIMULATION
AB Uneven flow resistance can cause a cell to have uneven distributions of temperature and current density. In this study, a three-dimensional (3-D) model with modified parallel flow field patterns is constructed, and simulation is performed to study the reactant distribution and cell performance. Two different modified parallel flow fields are applied to the cathode and anode. The flow characteristics and current density, temperature, and water distributions are analyzed with computational fluid dynamics (CFD). The results indicate that the hydrogen and air reactants are uniformly distributed in a gas diffusion layer (GDL) and gradually decrease from the inlet to the outlet for all channels. The numerical results show that modified parallel flow fields provide evenly distributed current density generation, where the reactant is uniformly distributed in the flow field. This property reduced the likelihood of forming hot spots and consequently enhanced the PEMFC performance. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Lim, B. H.; Majlan, E. H.; Daud, W. R. W.; Rosli, M., I; Husaini, T.] Univ Kebangsaan Malaysia, Fuel Cell Inst, Ukm Bangi 43600, Selangor Darul, Malaysia.
   [Daud, W. R. W.; Rosli, M., I] Univ Kebangsaan Malaysia, Dept Chem & Proc Engn, Ukm Bangi 43600, Selangor Darul, Malaysia.
   [Lim, B. H.] Mahsa Univ, Fac Engn & Built Environm, Jenjarom 42610, Selangor Darul, Malaysia.
RP Majlan, EH (reprint author), Univ Kebangsaan Malaysia, Fuel Cell Inst, Ukm Bangi 43600, Selangor Darul, Malaysia.
EM edy@eng.ukm.my
FU Universiti Kebangsaan Malaysia [GUP-2016-044]; Ministry of Higher
   EducationScience and Technology Development Fund (STDF)Ministry of
   Higher Education & Scientific Research (MHESR) [LRGS/2013/UKM-UKM/TP-01]
FX The authors acknowledge the financial support provided by the Universiti
   Kebangsaan Malaysia research university grant GUP-2016-044 and the
   Ministry of Higher Education research grant LRGS/2013/UKM-UKM/TP-01.
CR Ahmed DH, 2006, J POWER SOURCES, V162, P327, DOI 10.1016/j.jpowsour.2006.06.083
   Alizadeh E, 2016, INT J HYDROGEN ENERG, V41, P8525, DOI 10.1016/j.ijhydene.2016.03.187
   [Anonymous], 2001, FUEL CELLS B, V4, P15, DOI [10.1016/s1464-2859(01)80686-6, DOI 10.1016/S1464-2859(01)80686-6]
   Arvay A, 2013, INT J HYDROGEN ENERG, V38, P3717, DOI 10.1016/j.ijhydene.2012.12.149
   Bachman J, 2012, INT J HYDROGEN ENERG, V37, P17172, DOI 10.1016/j.ijhydene.2012.08.023
   Bi HT, 2010, PARTICUOLOGY, V8, P582, DOI 10.1016/j.partic.2010.07.011
   Elmer T, 2015, RENEW SUST ENERG REV, V42, P913, DOI 10.1016/j.rser.2014.10.080
   Falcucci G, 2012, J FUEL CELL SCI TECH, V9, DOI 10.1115/1.4005628
   Jeon DH, 2008, INT J HYDROGEN ENERG, V33, P1052, DOI 10.1016/j.ijhydene.2007.11.015
   Jiao K, 2011, PROG ENERG COMBUST, V37, P221, DOI 10.1016/j.pecs.2010.06.002
   Kandlikar SG, 2009, J POWER SOURCES, V194, P328, DOI 10.1016/j.jpowsour.2009.05.019
   Kim KN, 2012, INT J HYDROGEN ENERG, V37, P9212, DOI 10.1016/j.ijhydene.2012.03.039
   Lim BH, 2017, INT J HYDROGEN ENERG, V42, P9210, DOI 10.1016/j.ijhydene.2016.03.189
   Lim BH, 2016, IONICS, V22, P301, DOI 10.1007/s11581-016-1644-y
   Liu H, 2010, INT J HYDROGEN ENERG, V35, P9186, DOI 10.1016/j.ijhydene.2010.06.043
   Liu SH, 2019, INT J HYDROGEN ENERG, V44, P29618, DOI 10.1016/j.ijhydene.2019.06.046
   Manso AP, 2012, INT J HYDROGEN ENERG, V37, P15256, DOI 10.1016/j.ijhydene.2012.07.076
   Imbrioscia GM, 2014, INT J HYDROGEN ENERG, V39, P8861, DOI 10.1016/j.ijhydene.2013.11.079
   Pei PC, 2014, APPL ENERG, V125, P60, DOI 10.1016/j.apenergy.2014.03.048
   Ramos-Alvarado B, 2012, INT J HYDROGEN ENERG, V37, P436, DOI 10.1016/j.ijhydene.2011.09.080
   Roshandel R, 2012, RENEW ENERG, V41, P86, DOI 10.1016/j.renene.2011.10.008
   Santarelli MG, 2007, INT J HYDROGEN ENERG, V32, P710, DOI 10.1016/j.ijhydene.2006.08.008
   Wang J, 2012, FUEL CELLS, V12, P989, DOI 10.1002/fuce.201200074
   Wang JY, 2011, CHEM ENG J, V168, P1331, DOI 10.1016/j.cej.2011.02.050
   Yang ZR, 2019, ENERGY, V183, P462, DOI 10.1016/j.energy.2019.06.148
NR 25
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115499
DI 10.1016/j.ces.2020.115499
PG 14
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600007
DA 2020-05-12
ER

PT J
AU Liu, CW
   Wang, ZY
   Tian, JL
   Yan, C
   Li, MZ
AF Liu Chenwei
   Wang Zhiyuan
   Tian Jinlin
   Yan Ci
   Li Mingzhong
TI Fundamental investigation of the adhesion strength between cyclopentane
   hydrate deposition and solid surface materials
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Hydrate deposition; Adhesion strength; Multi-spray method; Subcooling;
   Roughness; Critical velocity
ID GAS-DOMINATED SYSTEMS; CLATHRATE HYDRATE; MICROMECHANICAL INTERACTIONS;
   WATER DROPLETS; PARTICLES; FORCE; MODEL; LIQUID; OIL; COHESION
AB Hydrate agglomerations and hydrate depositions are two main processes that form hydrate plugging in deep-water oil and gas pipelines. Hydrate that directly grows and sinters on the pipe wall is an important hydrate-deposition case, which has been rarely studied. Understanding the adhesion strength of the sintered hydrate depositions is crucial in advancing the management of hydrate formation to avoid plugging in pipelines. In this work, a multi-spray method was first applied to form a hydrate-deposition layer on a solid surface. Further, the adhesion strength was measured using a self-built adhesion-strength measurement apparatus. The effects of subcooling, formation time, surface roughness, and material types on the hydrate-adhesion strength were investigated. The water content in the deposition was found to decrease with the increase in the subcooling and formation time, which led to higher adhesion strength. The adhesion strength was also significantly influenced by the surface roughness and material types, and surfaces with low roughness and strong hydrophobicity (i.e., high contact angle) resulted in lower adhesion strength. After obtaining the adhesion force, a model was developed to evaluate the feasibility of sintered hydrate deposition on the pipe wall in gas and oil systems. The simulation results revealed that the critical velocity required to remove the deposition would increase and decrease with the length and thickness of the deposition, respectively. Compared with the settling-down hydrate particle on the pipe wall, the required critical removal velocity for sintered hydrate deposition was much higher, which was beyond most of the pipeline operating conditions. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Liu Chenwei; Wang Zhiyuan; Li Mingzhong] China Univ Petr East China, Key Lab Unconvent Oil & Gas Dev, Minist Educ, Qingdao 266580, Peoples R China.
   [Liu Chenwei; Wang Zhiyuan; Tian Jinlin; Yan Ci; Li Mingzhong] China Univ Petr East China, Sch Petr Engn, Qingdao 266580, Peoples R China.
RP Liu, CW; Wang, ZY (reprint author), China Univ Petr East China, Key Lab Unconvent Oil & Gas Dev, Minist Educ, Qingdao 266580, Peoples R China.
EM liuchenwei_upc@hotmail.com; Wangzy1209@126.com
FU National Natural Science Foundation of China, ChinaNational Natural
   Science Foundation of China [51704316, 5197040671]; National Natural
   Science Foundation-Outstanding Youth Foundation, China [51622405];
   Shandong Provincial Natural Science Foundation, ChinaNatural Science
   Foundation of Shandong Province [ZR2016EEB04]; Fundamental Research
   Funds for the Central Universities, ChinaFundamental Research Funds for
   the Central Universities [18CX02030A]
FX The work was supported by the National Natural Science Foundation of
   China, China (Grant 51704316 and 5197040671), the National Natural
   Science Foundation-Outstanding Youth Foundation, China (Grant No.
   51622405), the Shandong Provincial Natural Science Foundation, China
   (Grant No. ZR2016EEB04), the Fundamental Research Funds for the Central
   Universities, China (Grants 18CX02030A).
CR Aman ZM, 2016, J NAT GAS SCI ENG, V35, P1490, DOI 10.1016/j.jngse.2016.05.015
   Aman ZM, 2012, ENERG FUEL, V26, P5102, DOI 10.1021/ef300707u
   Aman ZM, 2011, PHYS CHEM CHEM PHYS, V13, P19796, DOI 10.1039/c1cp21907c
   Aman ZM, 2010, ENERG FUEL, V24, P5441, DOI 10.1021/ef100762r
   Aspenes G, 2010, J COLLOID INTERF SCI, V343, P529, DOI 10.1016/j.jcis.2009.11.071
   Camargo R., 2002, P 4 INT C GAS HYDR Y
   Cha MJ, 2013, LANGMUIR, V29, P5793, DOI 10.1021/la4005664
   Di Lorenzo M, 2014, ENERG FUEL, V28, P7274, DOI 10.1021/ef501609m
   Di Lorenzo M, 2014, ENERG FUEL, V28, P3043, DOI 10.1021/ef500361r
   Dieker LE, 2009, ENERG FUEL, V23, P5966, DOI 10.1021/ef9006615
   Dong HS, 2019, ACS SUSTAIN CHEM ENG, V7, P7932, DOI 10.1021/acssuschemeng.9b00651
   Du J, 2011, ENERG FUEL, V25, P3204, DOI 10.1021/ef200131y
   Estanga D., 2014, P 8 INT C GAS HYDR B
   Fidel-Dufour A, 2006, CHEM ENG SCI, V61, P505, DOI 10.1016/j.ces.2005.07.001
   GOOD RJ, 1992, J ADHES SCI TECHNOL, V6, P1269, DOI 10.1163/156856192X00629
   Grasso G. A., 2014, P 8 INT C GAS HYDR B
   Grasso G.A., 2015, THESIS
   Hu SJ, 2017, LANGMUIR, V33, P11299, DOI 10.1021/acs.langmuir.7b02676
   Lachance JW, 2012, ENERG FUEL, V26, P4059, DOI 10.1021/ef3002197
   Lee BR, 2015, LANGMUIR, V31, P3884, DOI 10.1021/acs.langmuir.5b00361
   Lingelem M.N., 1994, P INT C NAT GAS HYDR
   Liu CW, 2017, ENERG FUEL, V31, P4981, DOI 10.1021/acs.energyfuels.7b00364
   Liu CW, 2017, CHEM ENG SCI, V163, P44, DOI 10.1016/j.ces.2017.01.031
   Liu CW, 2016, ENERG FUEL, V30, P6240, DOI 10.1021/acs.energyfuels.6b00668
   Liu CW, 2015, PHYS CHEM CHEM PHYS, V17, P20021, DOI 10.1039/c5cp02247a
   Liu J.B., 2016, MACH DES MANUF, V5, P83
   Matsumoto K, 2017, INT J REFRIG, V78, P121, DOI 10.1016/j.ijrefrig.2017.03.005
   Nicholas JW, 2009, AICHE J, V55, P1882, DOI 10.1002/aic.11874
   Nicholas JW, 2009, J COLLOID INTERF SCI, V331, P322, DOI 10.1016/j.jcis.2008.11.070
   Pang HB, 2013, J ADHES SCI TECHNOL, V27, P46, DOI 10.1080/01694243.2012.701503
   Rao I, 2013, IND ENG CHEM RES, V52, P6262, DOI 10.1021/ie400493a
   Sloan E.D., 2007, CLATHRATE HYDRATES N
   Sloan ED, 2003, NATURE, V426, P353, DOI 10.1038/nature02135
   Smith JD, 2012, PHYS CHEM CHEM PHYS, V14, P6013, DOI 10.1039/c2cp40581d
   Sojoudi H, 2015, LANGMUIR, V31, P6186, DOI 10.1021/acs.langmuir.5b00413
   Sojoudi H, 2015, ADV MATER INTERFACES, V2, DOI 10.1002/admi.201500003
   Song GC, 2017, CHEM ENG SCI, V158, P487, DOI 10.1016/j.ces.2016.10.045
   Song JH, 2010, LANGMUIR, V26, P18119, DOI 10.1021/la103193m
   Song JH, 2010, LANGMUIR, V26, P9187, DOI 10.1021/la101309j
   Taylor CJ, 2007, CHEM ENG SCI, V62, P6524, DOI 10.1016/j.ces.2007.07.038
   Taylor CJ, 2007, J COLLOID INTERF SCI, V306, P255, DOI 10.1016/j.jcis.2006.10.078
   Turner D.J., 2005, THESIS
   Turner DJ, 2009, CHEM ENG SCI, V64, P3996, DOI 10.1016/j.ces.2009.05.051
   Varanasi  K., 2010, APPL PHYS LETT, V97, P1
   Vijayamoham P., 2014, P 8 INT C GAS HYDR B
   Wang ZY, 2019, FUEL, V236, P870, DOI 10.1016/j.fuel.2018.09.066
   Wang ZY, 2017, CHEM ENG SCI, V163, P145, DOI 10.1016/j.ces.2017.01.030
   Wang ZY, 2016, ENERG FUEL, V30, P4653, DOI 10.1021/acs.energyfuels.6b00521
   Xia Q, 2010, SO POWER SYSTEM TECH, V4, P156
   Yang SO, 2004, J COLLOID INTERF SCI, V277, P335, DOI 10.1016/j.jcis.2004.04.049
   Zhang LX, 2020, CHEM ENG J, V379, DOI 10.1016/j.cej.2019.122357
   Zhang LX, 2017, CHEM ENG J, V308, P40, DOI 10.1016/j.cej.2016.09.047
   Zhao JF, 2019, CHEM ENG J, V361, P12, DOI 10.1016/j.cej.2018.12.051
   Zhao JF, 2017, AICHE J, V63, P4136, DOI 10.1002/aic.15722
   Zhao JF, 2015, APPL ENERG, V142, P125, DOI 10.1016/j.apenergy.2014.12.071
   Zou M, 2011, APPL SURF SCI, V257, P3786, DOI 10.1016/j.apsusc.2010.11.149
NR 56
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115524
DI 10.1016/j.ces.2020.115524
PG 9
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600029
DA 2020-05-12
ER

PT J
AU Liu, YS
   Qian, XM
   Zhang, H
   Wang, L
   Zou, C
   Cui, YW
AF Liu, Yongsheng
   Qian, Xiaoming
   Zhang, Heng
   Wang, Liang
   Zou, Chi
   Cui, Yuanwen
TI Preparing micro/nano-fibrous filters for effective PM 2.5 under low
   filtration resistance
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Micro/nano-fibrous filter; Low air resistance; High efficiency;
   Particulate matter
ID LONG-TERM EXPOSURE; HIGH-EFFICIENCY; AIR FILTRATION; NANOFIBROUS
   MEMBRANES; COMPOSITE MEMBRANES; AEROSOL FILTRATION; PRESSURE-DROP;
   PERFORMANCE; MORTALITY; POLLUTION
AB An enhanced micro/nano-fibrous filter composed of microfibers and nanofiber was successfully prepared for effectively capturing particulate matter (PM). Electrospun polyacrylonitrile (PAN) nanofiber with an average diameter of 850 nm was received on PAN micro-fibrous supporting scaffold and then dispersed in PAN micro-fibrous assembly after the needle-punching process. The filtration property and structure of the PAN composite filters was controlled by adjusting the spinning time. The removal efficiency of the fabricated filters could reach to 99.99% for PM 1-2.5 with a low pressure drop below 35 Pa. In addition, the filtration mechanism of the prepared micro/nano-fibrous filter was distinctly explained by simulating the intercepted distributions and motion paths of particles using GeoDict software. These results indicated that the successful fabrication of the micro/nano-fibrous filters with a high efficiency and low air resistance was very attractive to reduce air pollution and save energy in air filtration applications. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Liu, Yongsheng; Qian, Xiaoming; Wang, Liang; Zou, Chi] Sch Text Sci & Engn, Tianjin 300387, Peoples R China.
   [Liu, Yongsheng; Cui, Yuanwen] Jiangsu Lantian Huanbao Co Ltd, Funing 224400, Jiangsu, Peoples R China.
   [Zhang, Heng] Zhongyuan Univ Technol, Sch Text, Zhengzhou 450007, Henan, Peoples R China.
   [Liu, Yongsheng; Qian, Xiaoming; Wang, Liang; Zou, Chi] 399 Binshui West Rd, Tianjin 300387, Peoples R China.
   [Liu, Yongsheng; Cui, Yuanwen] 18 Filter Ind Pk, Funing 224400, Jiangsu, Peoples R China.
   [Zhang, Heng] 41 Zhongyuan Rd M, Zhengzhou 450007, Henan, Peoples R China.
RP Qian, XM (reprint author), Tiangong Univ, Sch Text Sci & Engn, 399 Binshui West Rd, Tianjin 300387, Peoples R China.
EM qxmtjpu@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [U1607117, 2017YFB0309300]; Application Foundation
   and Advanced Technology Research Plan of Tianjin [16JCZDJC36400];
   Science and Technology Plans of Tianjin [17PTSYJC00150]
FX This work was supported by the National Natural Science Foundation of
   China (Grant: No. U1607117),(Project: No. 2017YFB0309300),the
   Application Foundation and Advanced Technology Research Plan of Tianjin
   (Project:No. 16JCZDJC36400) and Science and Technology Plans of Tianjin
   (Project: No. 17PTSYJC00150)
CR Ardkapan SR, 2014, J AEROSOL SCI, V72, P14, DOI 10.1016/j.jaerosci.2014.02.002
   Balazy A, 2007, J COLLOID INTERF SCI, V311, P323, DOI 10.1016/j.jcis.2007.03.008
   Bao L, 2016, SEP PURIF TECHNOL, V159, P100, DOI 10.1016/j.seppur.2015.12.045
   Brown R.C., 1995, PERGAMON, V26, P171
   Burnett RT, 2014, ENVIRON HEALTH PERSP, V122, P397, DOI 10.1289/ehp.1307049
   Cesaroni G., 2014, BMJ-BRIT MED J, V348, P1, DOI DOI 10.1136/BMJ17412
   Cheng ZQ, 2018, MATER LETT, V221, P157, DOI 10.1016/j.matlet.2018.03.110
   DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401
   Gao H.C., 2013, ENV SCI NANO
   Joubert A, 2011, CHEM ENG J, V166, P616, DOI 10.1016/j.cej.2010.11.033
   Kilic A, 2013, J ELECTROSTAT, V71, P41, DOI 10.1016/j.elstat.2012.11.005
   Kim KH, 2015, ENVIRON INT, V74, P136, DOI 10.1016/j.envint.2014.10.005
   Kim KH, 2013, ENVIRON INT, V59, P41, DOI 10.1016/j.envint.2013.05.007
   LEE KW, 1982, AEROSOL SCI TECH, V1, P147, DOI 10.1080/02786828208958584
   Leung WWF, 2018, SEP PURIF TECHNOL, V206, P26, DOI 10.1016/j.seppur.2018.05.033
   Leung WWF, 2010, SEP PURIF TECHNOL, V71, P30, DOI 10.1016/j.seppur.2009.10.017
   Li J, 2018, J MEMBRANE SCI, V551, P85, DOI 10.1016/j.memsci.2018.01.025
   Li P, 2014, SMALL, V10, P4543, DOI 10.1002/smll.201401553
   Li P, 2013, NANOSCALE, V5, P3367, DOI 10.1039/c3nr34325a
   Li XQ, 2015, J COLLOID INTERF SCI, V439, P12, DOI 10.1016/j.jcis.2014.10.014
   Li YP, 2010, J CONTROL RELEASE, V144, P314, DOI 10.1016/j.jconrel.2010.02.027
   Liu BW, 2015, J COLLOID INTERF SCI, V457, P203, DOI 10.1016/j.jcis.2015.07.019
   Liu C., 2015, NAT COMMUN
   LIU Y, 2019, J IND TEXT, DOI DOI 10.1177/1528083719838067
   Liu YS, 2020, POWDER TECHNOL, V360, P1192, DOI 10.1016/j.powtec.2019.11.012
   Ma HY, 2011, POLYMER, V52, P2594, DOI 10.1016/j.polymer.2011.03.051
   Ma ZW, 2006, J MEMBRANE SCI, V272, P179, DOI 10.1016/j.memsci.2005.07.038
   Maji KJ, 2018, ENVIRON INT, V121, P392, DOI 10.1016/j.envint.2018.09.024
   Mei Y, 2013, J APPL POLYM SCI, V128, P1089, DOI [10.1002/app.38296, 10.1002/APP.38296]
   Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F
   Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132
   Su JF, 2017, J COLLOID INTERF SCI, V507, P386, DOI 10.1016/j.jcis.2017.07.104
   Thompson JE, 2018, J OCCUP ENVIRON MED, V60, P392, DOI [10.1097/JOM.0000000000001277, 10.1097/jom.0000000000001277]
   Wan HG, 2014, J COLLOID INTERF SCI, V417, P18, DOI 10.1016/j.jcis.2013.11.009
   Wang CS, 2013, IND ENG CHEM RES, V52, P5, DOI 10.1021/ie300574m
   Wang D, 2007, MACROMOL MATER ENG, V292, P407, DOI 10.1002/mame.200600460
   Wang N, 2014, SEP PURIF TECHNOL, V126, P44, DOI 10.1016/j.seppur.2014.02.017
   Wang QN, 2016, POWDER TECHNOL, V292, P54, DOI 10.1016/j.powtec.2016.01.008
   Wang Z, 2015, APPL SURF SCI, V356, P1168, DOI 10.1016/j.apsusc.2015.08.211
   Xu ZW, 2017, J MEMBRANE SCI, V535, P94, DOI 10.1016/j.memsci.2017.04.029
   Yang CF, 2012, CHINESE J CHEM ENG, V20, P1, DOI 10.1016/S1004-9541(12)60356-5
   Yang YJ, 2015, SEP PURIF TECHNOL, V152, P14, DOI 10.1016/j.seppur.2015.08.005
   Zhang Q, 2010, J AEROSOL SCI, V41, P230, DOI 10.1016/j.jaerosci.2009.10.001
   Zhao J, 2003, BUILD ENVIRON, V38, P645, DOI 10.1016/S0360-1323(02)00212-3
   Zhao X., 2016, SCI REP, V6
   Zuo F.L., 2017, SMALL, V13
NR 46
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115523
DI 10.1016/j.ces.2020.115523
PG 11
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600028
DA 2020-05-12
ER

PT J
AU Ma, YL
   Zhu, XQ
   Wang, BY
   Liu, SY
   Meng, TT
   Chen, H
   Peng, B
   Deng, ZW
AF Ma, Yanling
   Zhu, Xinqiang
   Wang, Biyun
   Liu, Songyu
   Meng, Tingting
   Chen, Hao
   Peng, Bo
   Deng, Ziwei
TI Sacrificial template synthesis of hierarchical nickel hydroxidenitrate
   hollow colloidal particles for electrochemical energy storage
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Nickel hydroxidenitrate; Melamine-formaldehyde; Hollow colloidal
   particles; Sacrificial template method; Electrochemical energy storage
ID BIOMASS CARBONS; NI FOAM; PERFORMANCE; SPHERES; FABRICATION; HYBRID;
   NANOSHEETS; SUPERCAPACITORS; NI-3(NO3)(2)(OH)(4); MICROSPHERES
AB Synthesis of hollow colloidal particles with a well-defined structure in a single step is challenging and highly desired for numerous applications. We propose a simple and productive approach to synthesize hierarchical nickel hydroxidenitrate hollow colloidal particles (NiHNHCP) with tunable structure and property via a one-pot manner for the application in supercapacitor. In this approach, the formation of the NiHN shells and the dissolution of the melamine-formaldehyde (MF) template particles occur simultaneously and successively under a solvothermal condition with time. It is found that the nickel precursors can protonate the solvent, declining the pH and further causing the dissolution of the MF particles. Meanwhile, the nickel precursors transform into NiHN nanosheets that self-assemble into hierarchical shells exclusively at the surface of the MF particles. With the reactions proceeding, the NiHNHCP are yielded ultimately. These NiHNHCP are characterized with superior electrochemical performance, making them practically useful in the application of supercapacitor. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Ma, Yanling; Wang, Biyun; Liu, Songyu; Meng, Tingting; Deng, Ziwei] Shaanxi Normal Univ, Sch Mat Sci & Engn, Key Lab Appl Surface & Colloid Chem,Shaanxi Engn, Shaanxi Key Lab Adv Energy Devices,Natl Minist Ed, Xian 710119, Peoples R China.
   [Zhu, Xinqiang; Chen, Hao] Zhejiang A&F Univ, Sch Engn, Hangzhou 311300, Peoples R China.
   [Peng, Bo] Aalto Univ, Dept Appl Phys, FI-00076 Espoo, Finland.
RP Deng, ZW (reprint author), Shaanxi Normal Univ, Sch Mat Sci & Engn, Key Lab Appl Surface & Colloid Chem,Shaanxi Engn, Shaanxi Key Lab Adv Energy Devices,Natl Minist Ed, Xian 710119, Peoples R China.; Chen, H (reprint author), Zhejiang A&F Univ, Sch Engn, Hangzhou 311300, Peoples R China.; Peng, B (reprint author), Aalto Univ, Dept Appl Phys, FI-00076 Espoo, Finland.
EM haochen@zafu.edu.cn; pengbo006@gmail.com; zwdeng@snnu.edu.cn
RI Deng, Ziwei/A-7818-2013
OI Deng, Ziwei/0000-0001-9206-6178
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51473089]; Natural Science Basic Research Plan in
   Shaanxi Province of China [2018JM5093]; Program for Science & Technology
   Innovation Team of Shaanxi Province [2018TD-030]; Fundamental Research
   Funds for the Central UniversitiesFundamental Research Funds for the
   Central Universities [GK201702009, GK201901002]; Zhejiang Provincial
   Natural Science Foundation of ChinaNatural Science Foundation of
   Zhejiang Province [LY20E020004]; Zhejiang Provincial Key Research and
   Development Project [2019C02037]; 151 Talent Project of Zhejiang
   Province; Youth Top-Notch Talent Development and Training Program
   Foundation of Zhejiang AF University; Academy of FinlandAcademy of
   Finland [321443, 328942]
FX The financial support are from the National Natural Science Foundation
   of China (No. 51473089), the Natural Science Basic Research Plan in
   Shaanxi Province of China (No. 2018JM5093), the Program for Science &
   Technology Innovation Team of Shaanxi Province (No. 2018TD-030), the
   Fundamental Research Funds for the Central Universities (No.
   GK201702009, GK201901002), Zhejiang Provincial Natural Science
   Foundation of China (LY20E020004), Zhejiang Provincial Key Research and
   Development Project (2019C02037), 151 Talent Project of Zhejiang
   Province, and Youth Top-Notch Talent Development and Training Program
   Foundation of Zhejiang A&F University. Bo Peng thanks the financial
   support from the Academy of Finland (No. 321443 and No. 328942).
CR Caruso F, 1998, SCIENCE, V282, P1111, DOI 10.1126/science.282.5391.1111
   Chen H, 2015, ELECTROCHIM ACTA, V180, P241, DOI 10.1016/j.electacta.2015.08.133
   Chen H, 2014, ACS APPL MATER INTER, V6, P8621, DOI 10.1021/am5014375
   Chen H, 2014, ADV FUNCT MATER, V24, P934, DOI 10.1002/adfm.201301747
   Chen H, 2013, ADV ENERGY MATER, V3, P1636, DOI 10.1002/aenm.201300580
   Chen M, 2006, ADV MATER, V18, P801, DOI 10.1002/adma.200501528
   Deng ZW, 2008, J PHYS CHEM B, V112, P16, DOI 10.1021/jp077662w
   Deng ZW, 2006, LANGMUIR, V22, P6403, DOI 10.1021/la060944n
   Elbers NA, 2015, CHEM MATER, V27, P1709, DOI 10.1021/cm504504t
   Feng LD, 2014, J POWER SOURCES, V267, P430, DOI 10.1016/j.jpowsour.2014.05.092
   Hu J, 2011, CHEM SOC REV, V40, P5472, DOI 10.1039/c1cs15103g
   Imhof A, 2001, LANGMUIR, V17, P3579, DOI 10.1021/la001604j
   Jiang J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9622
   Kong LB, 2012, MATER RES BULL, V47, P1641, DOI 10.1016/j.materresbull.2012.03.051
   Li B, 2016, INORG CHEM FRONT, V3, P175, DOI 10.1039/c5qi00187k
   Li M, 2019, ELECTROCHIM ACTA, V302, P1, DOI 10.1016/j.electacta.2019.01.187
   Li XD, 2018, ELECTROCHIM ACTA, V265, P455, DOI 10.1016/j.electacta.2018.01.194
   Li ZC, 2017, ELECTROCHIM ACTA, V231, P617, DOI 10.1016/j.electacta.2017.02.087
   Liu JP, 2011, CHEM COMMUN, V47, P3436, DOI 10.1039/c0cc04906a
   Liu PF, 2017, DALTON T, V46, P7388, DOI 10.1039/c7dt00932a
   Lou XW, 2008, ADV MATER, V20, P3987, DOI 10.1002/adma.200800854
   Peng B, 2008, J COLLOID INTERF SCI, V321, P67, DOI 10.1016/j.jcis.2007.12.044
   Peng H, 2019, ELECTROCHIM ACTA, V300, P290, DOI 10.1016/j.electacta.2019.01.135
   Peng SJ, 2014, ADV FUNCT MATER, V24, P2155, DOI 10.1002/adfm.201303273
   Sahoo S, 2018, J IND ENG CHEM, V63, P181, DOI 10.1016/j.jiec.2018.02.014
   Shi MJ, 2018, APPL SURF SCI, V427, P678, DOI 10.1016/j.apsusc.2017.09.012
   Song XX, 2018, J MATER CHEM A, V6, P16205, DOI 10.1039/c8ta05037f
   Sun SY, 2019, J ELECTROCHEM SOC, V166, pA1799, DOI 10.1149/2.0291910jes
   Sun YG, 2004, J AM CHEM SOC, V126, P3892, DOI 10.1021/ja039734c
   Wang N, 2018, CHEM ENG J, V345, P31, DOI 10.1016/j.cej.2018.03.147
   Wang WC, 2018, CHEM ENG J, V338, P55, DOI 10.1016/j.cej.2018.01.024
   Wang XJ, 2016, CHEM REV, V116, P10983, DOI 10.1021/acs.chemrev.5b00731
   Wang YB, 2018, J COLLOID INTERF SCI, V513, P43, DOI 10.1016/j.jcis.2017.10.102
   Wang YB, 2018, CHEM COMMUN, V54, P559, DOI 10.1039/c7cc08879e
   Wen PH, 2018, J COLLOID INTERF SCI, V531, P544, DOI 10.1016/j.jcis.2018.07.014
   Wu YS, 2013, J MATER CHEM B, V1, P204, DOI 10.1039/c2tb00043a
   Xiong XH, 2015, NANO ENERGY, V11, P154, DOI 10.1016/j.nanoen.2014.10.029
   Yang HB, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9030345
   Yang ZX, 2011, CRYSTENGCOMM, V13, P1831, DOI 10.1039/c0ce00462f
   Yang ZZ, 2003, ANGEW CHEM INT EDIT, V42, P1943, DOI 10.1002/anie.200250443
   Yin YD, 2004, SCIENCE, V304, P711, DOI 10.1126/science.1096566
   Yu M, 2017, APPL SURF SCI, V396, P1816, DOI 10.1016/j.apsusc.2016.11.203
   Yu S, 2018, MATER DESIGN, V149, P184, DOI 10.1016/j.matdes.2018.04.023
   Yu S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23642-6
   Zhang Q, 2008, NANO LETT, V8, P2867, DOI 10.1021/nl8016187
   Zhang TR, 2008, ANGEW CHEM INT EDIT, V47, P5806, DOI 10.1002/anie.200800927
   Zhang YY, 2017, CERAM INT, V43, P2057, DOI 10.1016/j.ceramint.2016.10.179
   Zhao CY, 2019, ELECTROCHIM ACTA, V320, DOI 10.1016/j.electacta.2019.134591
   Zhu XQ, 2018, CHEM ENG SCI, V181, P36, DOI 10.1016/j.ces.2018.02.004
   Zoldesi CI, 2005, ADV MATER, V17, P924, DOI 10.1002/adma.200401183
NR 50
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115548
DI 10.1016/j.ces.2020.115548
PG 8
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600041
DA 2020-05-12
ER

PT J
AU Mahale, RS
   Parikh, PA
AF Mahale, Rohit S.
   Parikh, Parimal A.
TI Aromatization of n-hexane: Synergism afforded by C-1-C-3 alcohols
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Alkane aromatization; Alcohol aromatization; Synergetic aromatization;
   Zeolites
ID CATALYTIC PERFORMANCE; ZEOLITE CATALYSTS; ZSM-5 ZEOLITES; ETHANOL;
   CONVERSION; H-ZSM-5; ALKANES; ZN; GALLOALUMINOSILICATE; HYDROCARBONS
AB Relatively inexpensive straight chain alkane (hexane), methanol manufactured from abundantly available natural gas, and biorenewably obtainable ethanol have been converted into value-added aromatics. For comparison purposes, propanol too was studied. Catalysts employed include parent ZSM-5, GaZn-ZSM-5 and dealuminated GaZn-ZSM-5; 5 wt.% each of Ga and Zn. Reactions were carried at 3 MPa pressure, 500 degrees C and with nitrogen as carrier gas. Zeolite dealumination helped increase liquid yields. Liquid products contained only aromatics in addition to unconverted reactants. Presence of an alcohol in general brought more carbon atoms from hexane into aromatics. Propanol showed highest efficiency to aromatize hexane. Dealuminated GaZn-ZSM-5 afforded 100% alcohol conversion even at 28 h time-on-stream, whereas hexane conversion dropped to 80% during this period. Catalyst deactivated due to coke deposition arising from hexane cracking. Soft coke contained oxygenated hydrocarbons with carbon number from C-6 to C-27. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Mahale, Rohit S.; Parikh, Parimal A.] SV Natl Inst Technol, Chem Engn Dept, Surat 395007, India.
RP Parikh, PA (reprint author), SV Natl Inst Technol, Chem Engn Dept, Surat 395007, India.
EM Parimal.svr@gmail.com
CR Azzam KG, 2010, J CATAL, V270, P242, DOI 10.1016/j.jcat.2010.01.002
   Biscardi JA, 1996, CATAL TODAY, V31, P207, DOI 10.1016/S0920-5861(96)00028-4
   Caeiro G, 2006, J MOL CATAL A-CHEM, V255, P131, DOI 10.1016/j.molcata.2006.03.068
   Chen S, 2004, CATAL LETT, V96, P195, DOI 10.1023/B:CATL.0000030120.29538.5d
   Choudhary VR, 2003, MICROPOR MESOPOR MAT, V57, P317, DOI 10.1016/S1387-1811(02)00606-6
   Choudhary VR, 2002, APPL CATAL A-GEN, V231, P243, DOI 10.1016/S0926-860X(02)00061-3
   Chowdhury AD, 2019, ANGEW CHEM INT EDIT, V58, P3908, DOI 10.1002/anie.201814268
   Dai WL, 2018, ACS CATAL, V8, P1352, DOI 10.1021/acscatal.7b03457
   Du Z., 2019, ENERG FUEL, DOI [10.1021/ACS.ENEGYFUELS.9B02454., DOI 10.1021/ACS.ENEGYFUELS.9B02454]
   Eagan NM, 2019, NAT REV CHEM, V3, P223, DOI 10.1038/s41570-019-0084-4
   Gabrienko AA, 2010, CHEM PHYS LETT, V496, P148, DOI 10.1016/j.cplett.2010.07.063
   Galadima A, 2015, J IND ENG CHEM, V31, P1, DOI 10.1016/j.jiec.2015.07.015
   GUISNET M, 1992, APPL CATAL A-GEN, V89, P1, DOI 10.1016/0926-860X(92)80075-N
   Gujar AC, 2009, APPL CATAL A-GEN, V363, P115, DOI 10.1016/j.apcata.2009.05.004
   Hodala JL, 2016, CHEMISTRYSELECT, V1, P2515, DOI 10.1002/slct.201600412
   Hulea V, 2018, ACS CATAL, V8, P3263, DOI 10.1021/acscatal.7b04294
   Iwamoto M, 2015, CATALYSTS, V5, P2122, DOI 10.3390/catal5042122
   Jang HS, 2014, FUEL, V134, P439, DOI 10.1016/j.fuel.2014.05.086
   Jarvis J, 2018, FUEL, V223, P211, DOI 10.1016/j.fuel.2018.03.045
   KANAI J, 1989, APPL CATAL, V55, P115, DOI 10.1016/S0166-9834(00)82322-2
   KANAI J, 1988, J CATAL, V114, P284, DOI 10.1016/0021-9517(88)90032-2
   KATSUNO H, 1993, STUD SURF SCI CATAL, V75, P2419
   Lee K, 2017, J CATAL, V347, P222, DOI 10.1016/j.jcat.2017.01.018
   Li JH, 2019, CHEMCATCHEM, DOI [10.1002/cctc.201901226, 10.1002/cdc.20190122610.1002/cdc.201901226]
   Li QY, 2018, FUEL, V219, P331, DOI 10.1016/j.fuel.2018.01.104
   Li ZL, 2017, GREEN CHEM, V19, P4344, DOI 10.1039/c7gc01188a
   Madeira FF, 2012, APPL CATAL A-GEN, V443, P171, DOI 10.1016/j.apcata.2012.07.037
   Martinez A, 2017, RSC CATAL SER, V28, P351
   Meriaudeau P, 1997, CATAL REV, V39, P5, DOI 10.1080/01614949708006467
   Mochizuki H, 2012, APPL CATAL A-GEN, V449, P188, DOI 10.1016/j.apcata.2012.10.003
   Prestianni A, 2013, REACT KINET MECH CAT, V108, P565, DOI 10.1007/s11144-012-0522-5
   Rojasova E, 1999, STUD SURF SCI CATAL, V125, P441
   Rojasova E, 1999, COLLECT CZECH CHEM C, V64, P168, DOI 10.1135/cccc19990168
   Sikarin T., 2016, APPL CATAL A-GEN, V525, P190
   Sims S., METHAFORMING NOVEL P
   Song C, 2016, APPL CATAL A-GEN, V519, P48, DOI 10.1016/j.apcata.2016.03.023
   Su C, 2016, CATAL TODAY, V264, P63, DOI 10.1016/j.cattod.2015.09.022
   Sun J, 2014, ACS CATAL, V4, P1078, DOI 10.1021/cs4011343
   Thivasasith A, 2019, PHYS CHEM CHEM PHYS, V21, P5359, DOI 10.1039/c8cp05864d
   Tret'yakov VF, 2010, CATAL IND, V2, P402, DOI 10.1134/S2070050410040161
   Tshabalala TE, 2015, CATAL COMMUN, V72, P49, DOI 10.1016/j.catcom.2015.06.022
   Viswanadham N, 2004, J MOL CATAL A-CHEM, V223, P269, DOI 10.1016/j.molcata.2003.11.045
   Viswanadham N, 2012, FUEL, V95, P298, DOI 10.1016/j.fuel.2011.08.058
   Wang AG, 2016, APPL CATAL B-ENVIRON, V198, P480, DOI 10.1016/j.apcatb.2016.06.013
   Xu D, 2018, J CATAL, V365, P163, DOI 10.1016/j.jcat.2018.07.001
NR 45
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115519
DI 10.1016/j.ces.2020.115519
PG 7
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600024
DA 2020-05-12
ER

PT J
AU Valdes, JP
   Pico, P
   Pereyra, E
   Ratkovich, N
AF Pablo Valdes, Juan
   Pico, Paula
   Pereyra, Eduardo
   Ratkovich, Nicolas
TI Evaluation of drift-velocity closure relationships for highly viscous
   liquid-air slug flow in horizontal pipes through 3D CFD modelling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Drift velocity; CFD; Closure relationships; Slug flow; Two-phase;
   High-Viscous Liquid
ID 2-PHASE FLOW; ELONGATED BUBBLES; LONG BUBBLES; MOTION; DYNAMICS
AB In the past 50 years, several correlations have been developed in order to predict the drift velocity of a liquid-air slug-flow system inside horizontal pipelines. However, a great portion of these correlations is based on either very limited experimental data in terms of fluid properties and operating conditions or on often invalid assumptions. Considering this, the present study assesses the accuracy and validity of seven of the most common non-complex drift velocity correlations through the development of a 3D-Computational Fluid Dynamics (CFD) model using the commercial software Star-CCM+. For this assessment, 13 experimental measurements from the literature were used to validate the CFD model, and 11 case-studies were proposed in order to expand the range of analysis to high-viscosity fluids (mu > 0.3 Pa.s) often found in industrial settings. The two-phase system was modelled with an EulerianEulerian approach, coupled with the Volume of Fluid (VOF) method. Three VOF parameters were calibrated in order to obtain the best configurations for different viscosity ranges. The results indicated that the CFD model offers an excellent prediction of the drift velocity given than the average absolute relative error obtained was 6%, even considering highly viscous fluids (mu similar to 6.86 Pa.s). The model allowed to confirm that the slug units and gas bubbles do not behave symmetrically in the axial direction and therefore, a 3-D approach substantially improves the accuracy of the model when compared with some 2-D models developed previously. The correlations that showed the highest predicting capabilities were Jeyachandra's 2012 correlation and Livinus' 2018 correlation. These two studies considered the combined effect of the Viscosity and Eotvos Numbers, indicating that both parameters significantly influence the drift velocity. In addition, a new correlation was developed by the fitting of the CFD results for all the case-studies proposed. This new correlation slightly improves the prediction achieved by other authors as the overall average error obtained (18%) is 4% lower than the one found for the correlations of Livinus (2018) and Jeyachandra (2012) and around 11% and 6% lower for the high-viscosity range (N-vis > 0.1) when compared to those two correlations, respectively. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Pablo Valdes, Juan; Pico, Paula; Ratkovich, Nicolas] Univ Los Andes, Dept Chem Engn, Carrera 1 18a-12, Bogota, Colombia.
   [Pereyra, Eduardo] Univ Tulsa, McDougall Sch Petr Engn, Tulsa, OK 74104 USA.
RP Pico, P (reprint author), Univ Los Andes, Dept Chem Engn, Carrera 1 18a-12, Bogota, Colombia.
EM pd.pico10@uniandes.edu.co
OI Valdes Ujueta, Juan Pablo/0000-0003-3249-5194
CR ALVES IN, 1993, CHEM ENG SCI, V48, P3063, DOI 10.1016/0009-2509(93)80172-M
   Andreussi P., 2009, 14 INT C MULT PROD T, P309
   BENDIKSEN KH, 1984, INT J MULTIPHAS FLOW, V10, P467, DOI 10.1016/0301-9322(84)90057-0
   BENJAMIN TB, 1968, J FLUID MECH, V31, P209, DOI 10.1017/S0022112068000133
   DAVIES RM, 1950, PROC R SOC LON SER-A, V200, P375, DOI 10.1098/rspa.1950.0023
   DUKLER AE, 1975, IND ENG CHEM FUND, V14, P337, DOI 10.1021/i160056a011
   Dumitrescu DT, 1943, Z ANGEW MATH MECH, V23, P139, DOI 10.1002/zamm.19430230303
   GARDNER GC, 1970, J FLUID MECH, V43, P247, DOI 10.1017/S0022112070002343
   Gockal B., 2008, SOC PET ENG PROJ FAC, P1
   Gopala V.R., 2008, CHEM ENG J
   HEYWOOD NI, 1979, CHEM ENG SCI, V34, P17, DOI 10.1016/0009-2509(79)85174-X
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Jeon S., 2009, WORLD ACAD SCI ENG T, V3, P209
   Jeyachandra BC, 2012, SPE J, V17, P593, DOI 10.2118/151616-PA
   KHAN MAB, 1984, J CAN PETROL TECHNOL, V23, P47, DOI 10.2118/84-03-05
   Kroes R.F., 2014, P 9 AM C MULT TECHN, V2014, P283
   Livinus A., 2018, J PET SCI ENG
   Livinus A., 2018, STUDY SINGLE ELONGAT
   Lu M, 2015, INT CONF GEOINFORM
   Martins N.M.C., 2014, COMPUT FLUIDS
   Martins N.M.C., 2016, COMPUT FLUIDS
   Moreiras J, 2014, J PETROL SCI ENG, V124, P359, DOI 10.1016/j.petrol.2014.09.006
   Muzaferija S., 2013, STAR JAP C 2013
   Pico P.D., 2018, J FLUID FLOW HEAT MA, V5, P53
   Pineda H., 2016, CFD MODELLING HIGH V
   Pineda H, 2016, J PETROL SCI ENG, V139, P49, DOI 10.1016/j.petrol.2015.12.013
   Pineda-Perez H., 2018, CHEM ENG RES DES
   Ramdin M, 2012, J FLUID ENG-T ASME, V134, DOI 10.1115/1.4006405
   Ramdin M., 2011, OFFSHORE ARCTIC ENG, P1
   Reyes-Gutierrez MA, 2006, J FLUID ENG-T ASME, V128, P832, DOI 10.1115/1.2201623
   Sanderse B, 2015, J DISPER SCI TECHNOL, V36, P1407, DOI 10.1080/01932691.2014.989571
   Spiegel M., 2011, COMPUT METH BIOMECH
   Taha T, 2006, CHEM ENG SCI, V61, P676, DOI 10.1016/j.ces.2005.07.022
   Tanabe Y., 2015, ASSESSMENT VOLUME FL
   Tshuva M, 1999, INT J MULTIPHAS FLOW, V25, P1491, DOI 10.1016/S0301-9322(99)00048-8
   WALLIS GB, 1969, ONE DIMENSIONAL 2 PH
   WEBER ME, 1981, CAN J CHEM ENG, V59, P398, DOI 10.1002/cjce.5450590322
   WEBER ME, 1986, CHEM ENG SCI, V41, P2235, DOI 10.1016/0009-2509(86)85073-4
   WILKINSON DL, 1982, J FLUID MECH, V118, P109, DOI 10.1017/S0022112082000986
   YANG H, 2014, P 24 INT OC POL ENG, V3, P610
   ZUKOSKI EE, 1966, J FLUID MECH, V25, P821, DOI 10.1017/S0022112066000442
NR 41
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115537
DI 10.1016/j.ces.2020.115537
PG 20
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600036
DA 2020-05-12
ER

PT J
AU Roy, K
   Agarkoti, C
   Malani, RS
   Thokchom, B
   Moholkar, VS
AF Roy, Kuldeep
   Agarkoti, Chandrodai
   Malani, Ritesh S.
   Thokchom, Binota
   Moholkar, Vijayanand S.
TI Mechanistic study of sulfadiazine degradation by ultrasound-assisted
   Fenton-persulfate system using yolk-shell Fe3O4@hollow@mSiO(2)
   nanoparticles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sulfadiazine; Fenton; Persulfate; Kinetic model; Ultrasound; Yolk-shell
   nanoparticles
ID ADVANCED OXIDATION; HYDROXYL RADICALS; WATER-TREATMENT; RATE CONSTANTS;
   SULFATE; KINETICS; NITRATE; DECOMPOSITION; MICROSPHERES; ENHANCEMENT
AB This study has addressed ultrasound-assisted sulfadiazine (SDZ) degradation in heterogeneous Fentonpersulfate system and has also attempted to reveal mechanistic features. The Fenton reagent (Fe2+) was added in the form of yolk-shell nanoparticles Fe3O4@hollow@mSiO(2). A kinetic model for SDZ degradation was formulated using reactions of Fenton-persulfate system. Concurrent analysis of experiments and simulations revealed faster leaching of Fe2+/Fe3+ ions from the metal core of Fe3O4@hollow@mSiO(2) particles due to micro-convection generated by sonication, which enhanced SDZ degradation 4x. Inhibitio effect of inorganic anions (Cl-, NO3-, CO3-2,SO42-) on SDZ degradation was also studied with experiments and an extended kinetic model. CO32- and SO42- had the strongest inhibition effect due to both metal ion complexation and radical scavenging. Significant discrepancy between experimental and simulations results in the presence of anions were explained in terms of enhanced metal ion complexation and radical scavenging in the hollow core of yolk-shell particles. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Roy, Kuldeep; Agarkoti, Chandrodai; Thokchom, Binota; Moholkar, Vijayanand S.] Indian Inst Technol Guwahati, Dept Chem Engn, Gauhati 781039, Assam, India.
   [Malani, Ritesh S.; Moholkar, Vijayanand S.] Indian Inst Technol Guwahati, Ctr Energy, Gauhati 781039, Assam, India.
RP Moholkar, VS (reprint author), Indian Inst Technol Guwahati, Dept Chem Engn, Gauhati 781039, Assam, India.
EM vmoholkar@iitg.ac.in
RI Malani, Ritesh/AAM-9706-2020
CR Armstrong DA, 2015, PURE APPL CHEM, V87, P1139, DOI 10.1515/pac-2014-0502
   Aschmann SM, 2011, ENVIRON SCI TECHNOL, V45, P6896, DOI 10.1021/es201475g
   Augusto O., 2011, PRINCIPLES FREE RADI
   Balaji C, 2011, IND ENG CHEM RES, V50, P11485, DOI 10.1021/ie201127v
   Beltran FJ, 1998, WATER AIR SOIL POLL, V105, P685, DOI 10.1023/A:1005048206991
   Boczkaj G, 2017, CHEM ENG J, V320, P608, DOI 10.1016/j.cej.2017.03.084
   Bokare AD, 2014, J HAZARD MATER, V275, P121, DOI 10.1016/j.jhazmat.2014.04.054
   BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805
   Chakma S, 2017, ULTRASON SONOCHEM, V38, P652, DOI 10.1016/j.ultsonch.2016.08.015
   Chakma S, 2013, AICHE J, V59, P4303, DOI 10.1002/aic.14150
   De Laat J, 2004, CHEMOSPHERE, V55, P715, DOI 10.1016/j.chemosphere.2003.11.021
   Deng Y, 2008, J AM CHEM SOC, V130, P28, DOI 10.1021/ja0777584
   Devi LG, 2011, J TAIWAN INST CHEM E, V42, P341, DOI 10.1016/j.jtice.2010.05.010
   Evgenidou E, 2007, WATER RES, V41, P2015, DOI 10.1016/j.watres.2007.01.027
   Feng Y, 2016, SEP PURIF TECHNOL, V167, P136, DOI 10.1016/j.seppur.2016.04.051
   Garaix G, 2016, J PHYS CHEM B, V120, P5008, DOI 10.1021/acs.jpcb.6b02915
   Ghauch A, 2013, CHEM ENG J, V228, P1168, DOI 10.1016/j.cej.2013.05.045
   Grcic I, 2012, WATER RES, V46, P5683, DOI 10.1016/j.watres.2012.07.058
   Kusic H, 2011, CHEM ENG J, V172, P109, DOI 10.1016/j.cej.2011.05.076
   LI T, 2019, CHEM ENG J, DOI DOI 10.1016/J.CEJ.2019.03.170
   Liu N, 2016, SEP PURIF TECHNOL, V169, P230, DOI 10.1016/j.seppur.2016.05.039
   Luo CW, 2015, WATER RES, V80, P99, DOI 10.1016/j.watres.2015.05.019
   Lutze HV, 2015, WATER RES, V72, P349, DOI 10.1016/j.watres.2014.10.006
   Machulek A, 2009, PHOTOCH PHOTOBIO SCI, V8, P985, DOI 10.1039/b900553f
   Mack J, 1999, J PHOTOCH PHOTOBIO A, V128, P1, DOI 10.1016/S1010-6030(99)00155-0
   Merouani S, 2010, J HAZARD MATER, V175, P593, DOI 10.1016/j.jhazmat.2009.10.046
   Moholkar VS, 2000, AICHE J, V46, P684, DOI 10.1002/aic.690460404
   NETA P, 1988, J PHYS CHEM REF DATA, V17, P1027, DOI 10.1063/1.555808
   Poskrebyshev GA, 2001, J GEOPHYS RES-ATMOS, V106, P4995, DOI 10.1029/2000JD900702
   PRESS WH, 1992, NUMERICAL RECIPES
   Purbia R, 2015, NANOSCALE, V7, P19789, DOI 10.1039/c5nr04729c
   Qiu P, 2015, RSC ADV, V5, P96201, DOI 10.1039/c5ra15693a
   Shah Y.T., 2012, CAVITATION REACTION
   Sivasankar T, 2007, AICHE J, V53, P1132, DOI 10.1002/aic.11170
   Subramanian G, 2016, WATER RES, V104, P168, DOI 10.1016/j.watres.2016.07.070
   Wang YP, 2015, ADV POWDER TECHNOL, V26, P1537, DOI 10.1016/j.apt.2015.08.014
   Wang ZY, 2018, SEP PURIF TECHNOL, V195, P92, DOI 10.1016/j.seppur.2017.11.072
   Wu XL, 2015, SEP PURIF TECHNOL, V147, P186, DOI 10.1016/j.seppur.2015.04.031
   Wu YY, 2010, J HAZARD MATER, V179, P533, DOI 10.1016/j.jhazmat.2010.03.036
   Xie PC, 2015, WATER RES, V69, P223, DOI 10.1016/j.watres.2014.11.029
   Xu XR, 2010, SEP PURIF TECHNOL, V72, P105, DOI 10.1016/j.seppur.2010.01.012
   Zhou T, 2016, APPL CATAL B-ENVIRON, V185, P31, DOI 10.1016/j.apcatb.2015.12.004
   Zou XL, 2014, CHEM ENG J, V257, P36, DOI 10.1016/j.cej.2014.07.048
NR 43
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115522
DI 10.1016/j.ces.2020.115522
PG 16
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600027
DA 2020-05-12
ER

PT J
AU Shao, YL
   Agarwal, RK
   Wang, XD
   Jin, BS
AF Shao, Yali
   Agarwal, Ramesh K.
   Wang, Xudong
   Jin, Baosheng
TI Numerical simulation of a 3D full loop iG-CLC system including a
   two-stage counter-flow moving bed air reactor
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Cold flow simulation; Chemical looping; Two-stage air reactor; Moving
   bed reactor; Uniformity index; Gas leakage
ID SOLID FUELS; COMBUSTION PROCESS; OXYGEN-CARRIER; CFD SIMULATION;
   FLUIDIZED-BED; COAL; OPERATION; HYDRODYNAMICS; OPTIMIZATION; DESIGN
AB A three-dimensional two-fluid model is established for an in-situ gasification chemical looping combustion system to predict its dynamic characteristics and non-uniformity in gas-solid distribution. In the experiment, the fuel reactor (FR) and air reactor (AR) were designed as a high-velocity riser and a novel low-velocity moving bed, respectively. Simulations results show that the predicted pressure distributions agree reasonably well with the experimental data. AR operation did not show any obvious influence on oscillations in the full-loop particle circulation. Each stage of the moving bed AR is found to operate better at relatively lower gas fluidizing number, and the maximum allowable fluidizing number is estimated to be around 0.7. With increase in fluidizing number in AR, gas concentration, gas velocity and solid velocity uniformity index increase, while solid concentration uniformity index decreases. Compared to the parallel arrangement of gas distributors and exhausts, gas concentration and velocity uniformity indices are smaller except for the near-exhaust section under the vertical arrangement of gas distributors and exhausts. Increase in first-stage or second-stage AR outlet pressure has an opposite influence on gas leakage in both the first-stage AR and second-stage AR. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Shao, Yali; Wang, Xudong; Jin, Baosheng] Southeast Univ, Sch Energy & Environm, Key Lab Energy Thermal Convers & Control, Minist Educ, Nanjing 210096, Peoples R China.
   [Shao, Yali; Agarwal, Ramesh K.] Washington Univ, Dept Mech Engn & Mat Sci, 1 Brookings Dr, St Louis, MO 63130 USA.
RP Jin, BS (reprint author), Southeast Univ, Sch Energy & Environm, Key Lab Energy Thermal Convers & Control, Minist Educ, Nanjing 210096, Peoples R China.; Agarwal, RK (reprint author), Washington Univ, Dept Mech Engn & Mat Sci, 1 Brookings Dr, St Louis, MO 63130 USA.
EM rka@wustl.edu; bsjin@seu.edu.cn
OI Wang, Xudong/0000-0002-9201-1692
FU Natural Science Foundation of ChinaNational Natural Science Foundation
   of China [51676038]; National Key R&D Program of China [2018YFC1901200];
   Natural Science Foundation of Jiangsu ProvinceJiangsu Planned Projects
   for Postdoctoral Research FundsNatural Science Foundation of Jiangsu
   Province [BK20170669]; China Scholarship Council (SCS)China Scholarship
   Council [201806090034]
FX This work was supported by the Natural Science Foundation of China
   (51676038), National Key R&D Program of China (2018YFC1901200), Natural
   Science Foundation of Jiangsu Province (BK20170669) and China
   Scholarship Council (SCS) (No. 201806090034).
CR Abad A, 2013, CHEM ENG SCI, V87, P277, DOI 10.1016/j.ces.2012.10.006
   Adanez J, 2014, ENRGY PROCED, V63, P63, DOI 10.1016/j.egypro.2014.11.007
   Bayham SC, 2013, ENERG FUEL, V27, P1347, DOI 10.1021/ef400010s
   Berguerand N, 2008, FUEL, V87, P2713, DOI 10.1016/j.fuel.2008.03.008
   Bougamra A, 2014, ENERG FUEL, V28, P3420, DOI 10.1021/ef500114z
   Chen J, 2018, CHEM ENG J, V351, P1038, DOI 10.1016/j.cej.2018.06.176
   Cuadrat A, 2011, INT J GREENH GAS CON, V5, P1630, DOI 10.1016/j.ijggc.2011.09.010
   Cuadrat A, 2012, FUEL, V97, P536, DOI 10.1016/j.fuel.2012.01.071
   Deng ZY, 2009, INT J GREENH GAS CON, V3, P368, DOI 10.1016/j.ijggc.2008.11.004
   Garcia-Labiano F, 2013, CHEM ENG SCI, V87, P173, DOI 10.1016/j.ces.2012.10.007
   Guan YJ, 2014, POWDER TECHNOL, V268, P316, DOI 10.1016/j.powtec.2014.08.046
   He F, 2009, ENERG FUEL, V23, P2095, DOI 10.1021/ef800922m
   Jung JW, 2008, POWDER TECHNOL, V183, P401, DOI 10.1016/j.powtec.2008.01.019
   Kruggel-Emden H, 2010, CHEM ENG SCI, V65, P4732, DOI 10.1016/j.ces.2010.05.022
   Kun Z, 2019, ENERGY, V166, P807, DOI 10.1016/j.energy.2018.10.027
   Mahalatkar K, 2011, CHEM ENG SCI, V66, P469, DOI 10.1016/j.ces.2010.11.003
   Markstrom P, 2012, POWDER TECHNOL, V222, P182, DOI 10.1016/j.powtec.2012.02.041
   Nguyen TDB, 2012, COMPUT CHEM ENG, V36, P48, DOI 10.1016/j.compchemeng.2011.07.005
   Seo MW, 2011, CHEM ENG J, V168, P803, DOI 10.1016/j.cej.2011.01.041
   Shao YL, 2019, CHEM ENG RES DES, V143, P100, DOI 10.1016/j.cherd.2019.01.004
   Shao YL, 2017, ENERG FUEL, V31, P13859, DOI 10.1021/acs.energyfuels.7b02119
   Shen LH, 2010, COMBUST FLAME, V157, P934, DOI 10.1016/j.combustflame.2009.10.009
   Shen LH, 2009, COMBUST FLAME, V156, P1377, DOI 10.1016/j.combustflame.2009.02.005
   Wang S, 2018, ENERG CONVERS MANAGE, V173, P296, DOI 10.1016/j.enconman.2018.07.043
   Wang XJ, 2015, IND ENG CHEM RES, V54, P5749, DOI 10.1021/acs.iecr.5b00471
   Xiao R, 2012, INT J GREENH GAS CON, V10, P363, DOI 10.1016/j.ijggc.2012.07.008
NR 26
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115502
DI 10.1016/j.ces.2020.115502
PG 13
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600010
DA 2020-05-12
ER

PT J
AU Shen, ZF
   Cai, Q
   Yin, CC
   Xia, QN
   Cheng, J
   Li, X
   Wang, YG
AF Shen, Zhangfeng
   Cai, Qing
   Yin, Chaochuang
   Xia, Qineng
   Cheng, Jun
   Li, Xi
   Wang, Yangang
TI Facile synthesis of silica nanosheets with hierarchical pore structure
   and their amine-functionalized composite for enhanced CO2 capture
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Silica nanosheets; Hierarchical pore structure; Mesopores; Melamine; CO2
   capture
ID MESOPOROUS MOLECULAR-SIEVE; CARBON-DIOXIDE CAPTURE; ISOSTERIC HEAT;
   SURFACE-AREA; LOW-COST; GRAPHENE; POLYETHYLENEIMINE; ADSORPTION;
   ADSORBENTS; EFFICIENCY
AB The CO2 capture performance of amine-functionalized solid adsorbents highly relies on the structure of the porous supports. Here, we present a facile melamine based approach for the synthesis of hierarchical architecture composed of ultrathin mesoporous silica nanosheets. The synthesized silica nanosheets possess a surface area of 463.5 cm(2) g(-1) and pore volume of 1.3 cm(3) g(-1) with capability for loading large amount of amines. After impregnated with 50 wt% polyethyleneimine, the nanosheets based composite showed higher CO2 capture ability (176.5 mg g(-1) at 75 degrees C and 1 bar) than other mesoporous silica-supported amine sorbents, and provided a durable adsorption performance. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Shen, Zhangfeng; Cai, Qing; Yin, Chaochuang; Xia, Qineng; Li, Xi; Wang, Yangang] Jiaxing Univ, Coll Biol Chem Sci & Engn, Jiaxing 314001, Peoples R China.
   [Cheng, Jun] Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Peoples R China.
RP Wang, YG (reprint author), Jiaxing Univ, Coll Biol Chem Sci & Engn, Jiaxing 314001, Peoples R China.
EM ygwang8136@mail.zjxu.edu.cn
FU National Key Research and Development Program of China [2018YFB1502900];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21103024]; Zhejiang Provincial Natural Science
   Foundation of ChinaNatural Science Foundation of Zhejiang Province
   [LY19B060006]; Technology Development Project of Jiaxing University
FX This work received financial support from National Key Research and
   Development Program of China (Grant No. 2018YFB1502900), National
   Natural Science Foundation of China (Grant No. 21103024), Zhejiang
   Provincial Natural Science Foundation of China (Grant No. LY19B060006),
   and Technology Development Project of Jiaxing University.
CR Anderson TR, 2016, ENDEAVOUR, V40, P178, DOI 10.1016/j.endeavour.2016.07.002
   Bae TH, 2013, ENERG ENVIRON SCI, V6, P128, DOI 10.1039/c2ee23337a
   Boot-Handford ME, 2014, ENERG ENVIRON SCI, V7, P130, DOI 10.1039/c3ee42350f
   Chen C, 2017, J ENERGY CHEM, V26, P868, DOI 10.1016/j.jechem.2017.07.001
   Chen C, 2010, CHEM ENG J, V161, P46, DOI 10.1016/j.cej.2010.04.019
   Chen C, 2009, CHEM COMMUN, P3627, DOI 10.1039/b905589d
   Chowdhury S, 2015, CHEM ENG J, V263, P374, DOI 10.1016/j.cej.2014.11.037
   Creamer AE, 2016, ENVIRON SCI TECHNOL, V50, P7276, DOI 10.1021/acs.est.6b00627
   El Hadri N, 2017, APPL ENERG, V185, P1433, DOI 10.1016/j.apenergy.2016.03.043
   Gadipelli S, 2017, J MATER CHEM A, V5, P17833, DOI 10.1039/c7ta05789j
   Gibson JAA, 2015, MICROPOR MESOPOR MAT, V208, P129, DOI 10.1016/j.micromeso.2015.01.044
   Han Y, 2015, CHEM ENG J, V259, P653, DOI 10.1016/j.cej.2014.08.043
   Heydari-Gorji A, 2011, ENERG FUEL, V25, P4206, DOI 10.1021/ef200765f
   Jafari V, 2014, ADV POWDER TECHNOL, V25, P1571, DOI 10.1016/j.apt.2014.05.011
   Krungleviciute V, 2012, J PHYS CHEM C, V116, P306, DOI 10.1021/jp208766u
   Leung DYC, 2014, RENEW SUST ENERG REV, V39, P426, DOI 10.1016/j.rser.2014.07.093
   Li KM, 2015, J MATER CHEM A, V3, P2166, DOI 10.1039/c4ta04275a
   Li KK, 2016, APPL ENERG, V165, P648, DOI 10.1016/j.apenergy.2015.12.109
   Liu FQ, 2015, J MATER CHEM A, V3, P12252, DOI 10.1039/c5ta01536g
   Lutz H, 2015, ADV MATER INTERFACES, V2, DOI 10.1002/admi.201500282
   Ma XL, 2009, J AM CHEM SOC, V131, P5777, DOI 10.1021/ja8074105
   Nakanishi K, 2015, J ASIAN CERAM SOC, V3, P70, DOI 10.1016/j.jascer.2014.10.011
   Park JE, 2012, CATAL TODAY, V190, P15, DOI 10.1016/j.cattod.2011.09.032
   Qi GG, 2011, ENERG ENVIRON SCI, V4, P444, DOI 10.1039/c0ee00213e
   Rodriguez N, 2011, CHEM ENG RES DES, V89, P1763, DOI 10.1016/j.cherd.2010.11.009
   Sanz R, 2010, APPL SURF SCI, V256, P5323, DOI 10.1016/j.apsusc.2009.12.070
   Shen YH, 2018, J CO2 UTIL, V27, P259, DOI 10.1016/j.jcou.2018.08.001
   Shen ZF, 2019, CARBON, V145, P751, DOI 10.1016/j.carbon.2019.01.093
   Sing KSW, 2004, ADSORPT SCI TECHNOL, V22, P773, DOI 10.1260/0263617053499032
   Singh B, 2019, NANOSCALE, V11, P5365, DOI 10.1039/c8nr10119a
   Sircar S, 1999, J PHYS CHEM B, V103, P6539, DOI 10.1021/jp9903817
   Son WJ, 2008, MICROPOR MESOPOR MAT, V113, P31, DOI 10.1016/j.micromeso.2007.10.049
   Srinivas G, 2014, ENERG ENVIRON SCI, V7, P335, DOI 10.1039/c3ee42918k
   Toro Molina C, 2015, J CLEAN PROD, V103, P463, DOI 10.1016/j.jclepro.2014.03.024
   Wang K, 2012, J NAT GAS CHEM, V21, P319, DOI 10.1016/S1003-9953(11)60371-X
   Wang XX, 2012, CATAL TODAY, V194, P44, DOI 10.1016/j.cattod.2012.08.008
   Wang YG, 2018, APPL CATAL B-ENVIRON, V239, P196, DOI 10.1016/j.apcatb.2018.08.018
   Weinberger C, 2014, ACS SYM SER, V1183, P3
   Wilfong WC, 2014, ACS APPL MATER INTER, V6, P13617, DOI 10.1021/am5031006
   Xu XC, 2003, MICROPOR MESOPOR MAT, V62, P29, DOI 10.1016/S1387-1811(03)00388-3
   Xu XC, 2002, ENERG FUEL, V16, P1463, DOI 10.1021/ef020058u
   Xue Y, 2016, CHEM COMMUN, V52, P575, DOI 10.1039/c5cc06941f
   Yang QY, 2013, ANGEW CHEM INT EDIT, V52, P10316, DOI 10.1002/anie.201302682
   Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548
   Zhao JQ, 2012, RSC ADV, V2, P6509, DOI 10.1039/c2ra20149f
NR 45
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115528
DI 10.1016/j.ces.2020.115528
PG 6
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600033
DA 2020-05-12
ER

PT J
AU Su, Y
   Chen, SQ
   Yang, QS
   Wang, Y
AF Su, Yun
   Chen, Shuangqiang
   Yang, Qinsi
   Wang, Yong
TI Self-assembled 3D Fe-2(MoO4)(3) microspheres with amorphous shell as
   anode of lithium-ion batteries with superior electrochemical performance
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fe-2(MoO4)(3); Hierarchical 3D structure; Amorphous shell; Reduced grain
   boundaries; Lithium ion batteries
ID ENERGY-STORAGE; LONG-LIFE; GROWTH-MECHANISM; HIGH-CAPACITY; GRAPHENE;
   NANOWIRES; NANOSTRUCTURES; ARCHITECTURES; COMPOSITES; NANOSHEETS
AB Metal molybdates are regarding as promising electrode materials for next-generation lithium-ion batteries (LIBs). However, the poor electronic conductivity and sluggish ion diffusion are the two main obstacles that limit their electrochemical performances. In this work, self-assembled hierarchical Fe-2(MoO4)(3) microspheres with a thin amorphous shell (FMO-A) were prepared via a morphology-tunable and template-free hydrothermal method as an example of metal molybdates for LIBs. The morphologies were easily tunable by changing experimental parameters, such as the pH value, and reaction time. When applied as anode of LIBs, FMO-A delivered a high reversible capacity of 1138.2 mAh g(-1) after 250 cycles at 100 mA g(-1) and displayed remarkable rate performances. This is mainly ascribed to the unique hierarchical structure and high surface area of Fe-2(MoO4)(3) and the thin amorphous shell on providing low Gibbs free energy on redox reactions, reduced grain boundaries, isotropic nature, and buffering volume variations during cycles. (C) 2020 Published by Elsevier Ltd.
C1 [Su, Yun; Chen, Shuangqiang; Yang, Qinsi; Wang, Yong] Shanghai Univ, Sch Environm & Chem Engn, Dept Chem Engn, Shangda Rd 99, Shanghai 200444, Peoples R China.
   [Su, Yun] Xinxiang Univ, Phys & Elect Engn Dept, Jinsui Rd 181, Xinxiang 453003, Henan, Peoples R China.
RP Chen, SQ; Wang, Y (reprint author), Shanghai Univ, Sch Environm & Chem Engn, Dept Chem Engn, Shangda Rd 99, Shanghai 200444, Peoples R China.
EM chensq@shu.edu.cn; yongwang@shu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51603119, 21406136, 21975154]; Shanghai Science and
   Technology CommitteeShanghai Science & Technology Committee
   [15520720600, 17010500300]; Innovative research team of high-level local
   universities in Shanghai; Program for Professor of Special Appointment
   (Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai
   Key Laboratory of Materials Protection and Advanced Materials in
   Electric Power;  [IRT13078]
FX The authors gratefully acknowledge the National Natural Science
   Foundation of China (51603119, 21406136, 21975154), Shanghai Science and
   Technology Committee (15520720600, 17010500300), Innovative Research
   Team (IRT13078), and Innovative research team of high-level local
   universities in Shanghai for financial support. Research is also
   supported by The Program for Professor of Special Appointment (Eastern
   Scholar) at Shanghai Institutions of Higher Learning and Shanghai Key
   Laboratory of Materials Protection and Advanced Materials in Electric
   Power. The authors thank Laboratory for Microstructures, Instrumental
   Analysis, and Research Center of Shanghai University for offering access
   to materials characterization.
CR Ahn JH, 2015, ELECTROCHIM ACTA, V174, P102, DOI 10.1016/j.electacta.2015.05.149
   Chen P, 2013, ACS APPL MATER INTER, V5, P12073, DOI 10.1021/am403905x
   CONG H, 2013, ENERG ENVIRON SCI, V6, DOI DOI 10.1186/1756-3305-6-63
   Dasgupta NP, 2014, ADV MATER, V26, P2137, DOI 10.1002/adma.201305929
   Ding Y, 2007, CHEM-EUR J, V13, P746, DOI 10.1002/chem.200601426
   Gao XM, 2015, RSC ADV, V5, P37703, DOI 10.1039/c5ra03876f
   Ghosh D, 2013, NANOSCALE, V5, P10428, DOI 10.1039/c3nr02444j
   Guan BQ, 2016, ELECTROCHIM ACTA, V190, P354, DOI 10.1016/j.electacta.2016.01.008
   Guo D, 2013, J MATER CHEM A, V1, P7247, DOI 10.1039/c3ta10909g
   Haetge J, 2013, SMALL, V9, P2541, DOI 10.1002/smll.201202585
   Hu XL, 2015, CHEM SOC REV, V44, P2376, DOI 10.1039/c4cs00350k
   Jiang YZ, 2014, NANO ENERGY, V4, P23, DOI 10.1016/j.nanoen.2013.12.001
   Ju ZC, 2015, SMALL, V11, P4753, DOI 10.1002/smll.201501294
   Larcher D, 2015, NAT CHEM, V7, P19, DOI [10.1038/NCHEM.2085, 10.1038/nchem.2085]
   Li WJ, 2014, ADV MATER, V26, P4037, DOI 10.1002/adma.201400794
   Liu J, 2015, ANGEW CHEM INT EDIT, V54, P9632, DOI 10.1002/anie.201503150
   Mai LQ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1387
   Mai LQ, 2010, NANO LETT, V10, P4750, DOI 10.1021/nl103343w
   Ong WJ, 2014, NANOSCALE, V6, P1946, DOI 10.1039/c3nr04655a
   Pan J, 2015, 2015 NINTH INTERNATIONAL CONFERENCE ON FRONTIER OF COMPUTER SCIENCE AND TECHNOLOGY FCST 2015, P1, DOI 10.1109/FCST.2015.29
   Pramanik A, 2017, CHEM ENG J, V307, P239, DOI 10.1016/j.cej.2016.08.082
   Song YP, 2015, RSC ADV, V5, P16386, DOI 10.1039/c4ra15655b
   Sun YM, 2011, J MATER CHEM, V21, P17229, DOI 10.1039/c1jm12458g
   Thackeray MM, 2012, ENERG ENVIRON SCI, V5, P7854, DOI 10.1039/c2ee21892e
   Wang B, 2015, J MATER CHEM A, V3, P13691, DOI 10.1039/c5ta02795k
   Wang DJ, 2013, J MATER CHEM C, V1, P4153, DOI 10.1039/c3tc30189c
   Wang SQ, 2011, J MATER CHEM, V21, P6365, DOI 10.1039/c0jm04398b
   Wang W, 2016, ACS NANO, V10, P10106, DOI 10.1021/acsnano.6b05150
   Wu J, 2015, ANGEW CHEM, V127, P7462, DOI [10.1002/ange.201503072, DOI 10.1002/ANGE.201503072]
   Xu WW, 2016, J MATER CHEM A, V4, P19011, DOI 10.1039/c6ta08217c
   Xue RN, 2016, ELECTROCHIM ACTA, V222, P838, DOI 10.1016/j.electacta.2016.11.045
   Yan XD, 2016, J MATER CHEM A, V4, P3683, DOI 10.1039/c6ta00744a
   Yao JY, 2014, ACS APPL MATER INTER, V6, P20414, DOI 10.1021/am505983m
   Yao YJ, 2014, J HAZARD MATER, V270, P61, DOI 10.1016/j.jhazmat.2014.01.027
   Zhang C, 2005, CHEM MATER, V17, P3537, DOI 10.1021/cm0501517
   Zhang L, 2010, NEW J CHEM, V34, P2027, DOI 10.1039/c0nj00048e
   Zhang QF, 2013, CHEM SOC REV, V42, P3127, DOI 10.1039/c3cs00009e
   Zhang ZY, 2015, J MATER CHEM A, V3, P20527, DOI 10.1039/c5ta05723j
   Zheng H, 2015, J NANOPART RES, V17, DOI 10.1007/s11051-015-3254-4
   Zhou SL, 2016, CHEM MATER, V28, P4492, DOI 10.1021/acs.chemmater.6b01806
   Zhu LP, 2012, DALTON T, V41, P2959, DOI 10.1039/c2dt11822j
NR 41
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115517
DI 10.1016/j.ces.2020.115517
PG 9
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600022
DA 2020-05-12
ER

PT J
AU Wang, CP
   Gong, J
   Cui, WW
   Wang, FY
   Bai, HC
   Hu, XD
   Guo, QJ
AF Wang, Cuiping
   Gong, Jian
   Cui, Weiwei
   Wang, Fengyin
   Bai, Hongcun
   Hu, Xiude
   Guo, Qingjie
TI Study on multi-cycle reaction performance of Fe/Al compound oxygen
   carriers in chemical-looping pyrolysis of coal tar
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fe/Al oxygen carrier; CaO-modified; Chemical-looping pyrolysis; Reaction
   performance; Multi-cycle reaction
ID COMBUSTION; REDUCTION; GASIFICATION; GENERATION; SEPARATION; METHANE;
   OXIDE; NIO; CE
AB Two Fe/Al compound oxygen carriers were prepared by the impregnation method, in which one is CaO-modified, and they were applied in multi-cycle experiments of preparing carbon black (CB) by chemical-looping pyrolysis of coal tar in a small fluidized bed reactor in laboratory. X-ray diffraction, N-2 adsorption analysis, and scanning electron microscopy were employed to analyze the variation of composition, the pore distribution, and the surface morphology of the OCs during the cyclic reaction. XRD results show that the oxygen-carrying capacity of both two-compound OCs decreases with the increase of the number of cycles, but the CaO-modified OC performs better for carbonation of CaO and then thermal decomposition of CaCO3 during the cycle reaction. BET and SEM results show that the Fe/Al compound OC can maintain a good porous structure during the first 15 cycles. As the cycle numbers continuously increase, the sintering accumulation appears on the OC surface, resulting in an increase in the tar volatiles' diffusion resistance on the surface of the particles. The CaO-modified compound OC maintained a good porous structure during 20 cycles. The decrease of the oxygen-carrying capacity and the surface sintering of the OC are the main reasons for the decrease of the reaction activity. The CaO carbonation-decomposition can maintain the porous structure of the compound OC during the multi-cycle reaction and delay the surface sintering effectively, thus improving the reaction performance of the OC. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Wang, Cuiping; Cui, Weiwei] Shandong Univ Sci & Technol, Coll Civil Engn & Architecture, Qingdao 266590, Peoples R China.
   [Wang, Cuiping; Gong, Jian; Wang, Fengyin] Qingdao Univ, Coll Mech & Elect Engn, Qingdao 266071, Peoples R China.
   [Bai, Hongcun; Hu, Xiude; Guo, Qingjie] Ningxia Univ, State Key Lab High Efficiency Utilizat Coal & Gre, Yinchuan 750021, Ningxia, Peoples R China.
RP Wang, CP (reprint author), Shandong Univ Sci & Technol, Coll Civil Engn & Architecture, Qingdao 266590, Peoples R China.
EM wangcuiping@tsinghua.org.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51676102]; Key Technology Research and Development
   Project of Shandong Province [2019GGX103001]; Foundation of State Key
   Laboratory of Coal Clean Utilization and Ecological Chemical Engineering
   [2018-K03]; Taishan Scholar Program of Shandong Province [201511029]
FX This work was supported by the National Natural Science Foundation of
   China (51676102) and Key Technology Research and Development Project of
   Shandong Province (2019GGX103001). The authors greatly acknowledge the
   support from the Foundation of State Key Laboratory of Coal Clean
   Utilization and Ecological Chemical Engineering (2018-K03) and Taishan
   Scholar Program of Shandong Province (201511029).
CR Adanez J, 2004, ENERG FUEL, V18, P371, DOI 10.1021/ef0301452
   Adanez J, 2012, PROG ENERG COMBUST, V38, P215, DOI 10.1016/j.pecs.2011.09.001
   Baek JI, 2015, FUEL, V144, P317, DOI 10.1016/j.fuel.2014.11.035
   Bao JH, 2013, IND ENG CHEM RES, V52, P6119, DOI 10.1021/ie400237p
   Chen C., 2017, ENERGY TECHNOL
   Cho WC, 2015, IND ENG CHEM RES, V54, P3091, DOI 10.1021/ie504468a
   de Diego LF, 2008, CHEM ENG J, V144, P289, DOI 10.1016/j.cej.2008.06.004
   Dennis JS, 2010, FUEL, V89, P1623, DOI 10.1016/j.fuel.2009.08.019
   Dharanipragada NVRA, 2016, IND ENG CHEM RES, V55, P5911, DOI 10.1021/acs.iecr.6b00963
   Garcia-Labiano F, 2004, IND ENG CHEM RES, V43, P8168, DOI 10.1021/ie0493311
   Gong J, 2018, ENERG FUEL, V32, P10024, DOI 10.1021/acs.energyfuels.8b01542
   Gong MX, 2019, ENERG FUEL, V33, P595, DOI 10.1021/acs.energyfuels.8b03527
   Hossain MM, 2008, CHEM ENG SCI, V63, P4433, DOI 10.1016/j.ces.2008.05.028
   Hu JJ, 2018, BIORESOURCE TECHNOL, V263, P273, DOI 10.1016/j.biortech.2018.02.064
   Leion H, 2009, CHEM ENG RES DES, V87, P1543, DOI 10.1016/j.cherd.2009.04.003
   Li B, 2014, ENERGY, V68, P248, DOI 10.1016/j.energy.2014.02.088
   Li FX, 2010, AICHE J, V56, P2186, DOI 10.1002/aic.12093
   Li YP, 2017, ENERG FUEL, V31, P6501, DOI 10.1021/acs.energyfuels.7b00599
   Linderholm C, 2012, FUEL, V102, P808, DOI 10.1016/j.fuel.2012.05.010
   Lyngfelt A, 2001, CHEM ENG SCI, V56, P3101, DOI 10.1016/S0009-2509(01)00007-0
   Ma SW, 2018, INT J HYDROGEN ENERG, V43, P3154, DOI 10.1016/j.ijhydene.2017.12.111
   Mattisson T, 2001, FUEL, V80, P1953, DOI 10.1016/S0016-2361(01)00051-5
   Moldenhauer P, 2014, ENERG FUEL, V28, P5978, DOI 10.1021/ef5014677
   Pour NM, 2014, AICHE J, V60, P645, DOI 10.1002/aic.14273
   [蒲舸 Pu Ge], 2013, [中国电机工程学报, Proceedings of the Chinese Society of Electrical Engineering], V33, P67
   Ridha FN, 2015, FUEL, V153, P202, DOI 10.1016/j.fuel.2015.02.069
   Ryden M, 2010, AICHE J, V56, P2211, DOI 10.1002/aic.12143
   Saucedo MA, 2014, FUEL, V127, P186, DOI 10.1016/j.fuel.2013.07.045
   Shen LH, 2009, COMBUST FLAME, V156, P1377, DOI 10.1016/j.combustflame.2009.02.005
   Sun P, 2007, AICHE J, V53, P2432, DOI 10.1002/aic.11251
   Sun S., 2015, ENERG FUEL, V29, P15101
   Sun XY, 2010, J THERM SCI, V19, P266, DOI 10.1007/s11630-010-0266-3
   Yang ZH, 2009, IND ENG CHEM RES, V48, P10765, DOI 10.1021/ie901137s
   Zhang S, 2013, INT J GREENH GAS CON, V17, P1, DOI 10.1016/j.ijggc.2013.04.010
   Zhou ZM, 2012, CHEM ENG SCI, V74, P172, DOI 10.1016/j.ces.2012.02.042
   Zhu M, 2017, CHEM ENG J, V325, P322, DOI 10.1016/j.cej.2017.05.027
   Zhu X, 2013, INT J HYDROGEN ENERG, V38, P4492, DOI 10.1016/j.ijhydene.2013.01.115
NR 37
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115530
DI 10.1016/j.ces.2020.115530
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600034
DA 2020-05-12
ER

PT J
AU Wang, S
   Luo, K
   Fan, JR
AF Wang, Shuai
   Luo, Kun
   Fan, Jianren
TI CFD-DEM coupled with thermochemical sub-models for biomass gasification:
   Validation and sensitivity analysis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE MFIX-DEM; Open-source software; Biomass gasification; Model validation;
   Sensitivity analysis
ID BUBBLING FLUIDIZED-BED; FULL-LOOP SIMULATION; HEAT-TRANSFER;
   NUMERICAL-SIMULATION; PART II; PNEUMATIC TRANSPORT; STEAM GASIFICATION;
   COAL-GASIFICATION; SPOUT DEFLECTION; RANDOM ARRAYS
AB A user-defined solver towards the high-fidelity CFD-DEM method with thermochemical sub-models integrating is developed based on the open-source MFIX-DEM software for simulating biomass gasification in a fluidized bed reactor. In this method, the fluid phase is solved under Eulerian framework while the solid motion is solved under Lagrangian framework. The inter-particle and inter-phase interactions, heat and mass transfer, gas turbulence, radiation, particle conversion, drying, pyrolysis, and homogeneous reactions are synthetically considered. The method is validated with experimental data and simulation results, and the sensitivity analysis is conducted for assessing the influence of contact and drag models on the CFD-DEM simulation of biomass gasification. Results show that the magnitude of total calculation time for the non-linear Hertzian contact model is 6.8 times of that for the linear LSD contact model. The drag models significantly affect the gas-solid flow dynamics while having a slight influence on the thermochemical results obtained at the reactor exit. As a result, the present work delivers a promising perspective for modeling thermochemical processes (e.g., fast pyrolysis, coal combustion, iron smelting, and tablet coating) in dense reactive particulate systems by using the open-source MFIX-DEM software. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Wang, Shuai; Luo, Kun; Fan, Jianren] Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Peoples R China.
RP Luo, K (reprint author), Zhejiang Univ, State Key Lab Clean Energy Utilizat, Hangzhou 310027, Peoples R China.
EM zjulk@zju.edu.cn
RI Luo, Kun/A-8039-2012
OI Luo, Kun/0000-0003-3644-9400
FU National Key Research and Development Program of China [2017YFB0601805];
   National Key Research and Development Plan of China [2017YFE0112500];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51390493, 51621005]
FX Financial supports from the National Key Research and Development
   Program of China (2017YFB0601805), the National Key Research and
   Development Plan of China (2017YFE0112500), and the National Natural
   Science Foundation of China (Nos. 51390493, 51621005) are sincerely
   acknowledged.
CR Abani N, 2013, FUEL, V104, P664, DOI 10.1016/j.fuel.2012.06.006
   Abdelmotalib HM, 2016, APPL THERM ENG, V99, P928, DOI 10.1016/j.applthermaleng.2016.01.054
   Alobaid F, 2015, CHEM ENG SCI, V138, P173, DOI 10.1016/j.ces.2015.08.010
   BADZIOCH S, 1970, IND ENG CHEM PROC DD, V9, P521, DOI 10.1021/i260036a005
   BATCHELOR GK, 1977, P ROY SOC LOND A MAT, V355, P313, DOI 10.1098/rspa.1977.0100
   Bates RB, 2017, AICHE J, V63, P1543, DOI 10.1002/aic.15666
   BAUM MM, 1971, COMBUST SCI TECHNOL, V3, P231, DOI 10.1080/00102207108952290
   Beetstra R, 2007, CHEM ENG SCI, V62, P246, DOI 10.1016/j.ces.2006.08.054
   Bruchmuller J, 2013, P COMBUST INST, V34, P2373, DOI 10.1016/j.proci.2012.06.054
   Chen SH, 2017, POWDER TECHNOL, V317, P117, DOI 10.1016/j.powtec.2017.04.055
   Cheng GJ, 1999, CHEM ENG SCI, V54, P4199, DOI 10.1016/S0009-2509(99)00125-6
   Clarke DA, 2018, IND ENG CHEM RES, V57, P3002, DOI 10.1021/acs.iecr.7b04638
   CUNDALL PA, 1979, GEOTECHNIQUE, V29, P47, DOI 10.1680/geot.1979.29.1.47
   DELVOSALLE C, 1985, CHEM ENG SCI, V40, P769, DOI 10.1016/0009-2509(85)85030-2
   DWIVEDI PN, 1977, IND ENG CHEM PROC DD, V16, P157, DOI 10.1021/i260062a001
   Fan L.-S., 2005, PRINCIPLES GAS SOLID
   Gao X, 2018, CHEM ENG SCI, V184, P33, DOI 10.1016/j.ces.2018.03.038
   Garg R, 2012, POWDER TECHNOL, V220, P122, DOI 10.1016/j.powtec.2011.09.019
   Garzo V, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.031303
   Geng YM, 2011, CHEM ENG SCI, V66, P207, DOI 10.1016/j.ces.2010.10.011
   Gidaspow D., 1994, MULTIPHASE FLOW FLUI
   Gomez-Barea A, 2010, PROG ENERG COMBUST, V36, P444, DOI 10.1016/j.pecs.2009.12.002
   Grace JR, 2010, PARTICUOLOGY, V8, P498, DOI 10.1016/j.partic.2010.09.003
   GUNN DJ, 1978, INT J HEAT MASS TRAN, V21, P467, DOI 10.1016/0017-9310(78)90080-7
   Hannula I, 2010, BIORESOURCE TECHNOL, V101, P4608, DOI 10.1016/j.biortech.2010.01.072
   Hill RJ, 2001, J FLUID MECH, V448, P213, DOI 10.1017/S0022112001005948
   Holloway W, 2010, AICHE J, V56, P1995, DOI 10.1002/aic.12127
   Hong J, 2000, P COMBUST INST, V28, P2215, DOI 10.1016/S0082-0784(00)80631-1
   Hu CS, 2019, POWDER TECHNOL, V353, P132, DOI 10.1016/j.powtec.2019.05.020
   Jajcevic D, 2013, CHEM ENG SCI, V98, P298, DOI 10.1016/j.ces.2013.05.014
   Jiang ZC, 2018, CHEM ENG SCI, V179, P115, DOI 10.1016/j.ces.2018.01.013
   JONES WP, 1988, COMBUST FLAME, V73, P233, DOI 10.1016/0010-2180(88)90021-1
   Karl J, 2018, RENEW SUST ENERG REV, V98, P64, DOI 10.1016/j.rser.2018.09.010
   Ku XK, 2015, CHEM ENG SCI, V122, P270, DOI 10.1016/j.ces.2014.08.045
   Li J, 2000, POWDER TECHNOL, V112, P273, DOI 10.1016/S0032-5910(00)00302-8
   Li TW, 2014, POWDER TECHNOL, V265, P13, DOI 10.1016/j.powtec.2014.04.007
   Liu GS, 2004, PROG ENERG COMBUST, V30, P679, DOI 10.1016/j.pecs.2004.08.001
   Liu H, 2015, APPL ENERG, V160, P489, DOI 10.1016/j.apenergy.2015.09.065
   LOUGE M, 1993, INT J HEAT MASS TRAN, V36, P265, DOI 10.1016/0017-9310(93)80002-C
   Lu BN, 2013, AICHE J, V59, P1108, DOI 10.1002/aic.13917
   Lu LQ, 2018, CHEM ENG SCI, V179, P53, DOI 10.1016/j.ces.2018.01.003
   Lu LQ, 2017, CHEM ENG J, V326, P627, DOI 10.1016/j.cej.2017.06.002
   Lu LQ, 2017, AICHE J, V63, P5320, DOI 10.1002/aic.15832
   Lu LQ, 2017, INT J HEAT MASS TRAN, V111, P723, DOI 10.1016/j.ijheatmasstransfer.2017.04.040
   Lu LQ, 2016, IND ENG CHEM RES, V55, P10477, DOI 10.1021/acs.iecr.6b02688
   Luo K, 2016, AICHE J, V62, P1917, DOI 10.1002/aic.15186
   Luo K, 2015, CHEM ENG SCI, V123, P22, DOI 10.1016/j.ces.2014.10.039
   Mahmoudi AH, 2016, COMBUST FLAME, V163, P358, DOI 10.1016/j.combustflame.2015.10.010
   Musser J.M., 2011, MODELING HEAT TRANSF
   Nikolopoulos A, 2013, CHEM ENG SCI, V90, P137, DOI 10.1016/j.ces.2012.12.007
   Norouzi HR, 2017, POWDER TECHNOL, V316, P233, DOI 10.1016/j.powtec.2016.11.061
   Ostermeier P, 2019, FUEL, V255, DOI 10.1016/j.fuel.2019.115790
   Peng ZB, 2014, AICHE J, V60, P2000, DOI 10.1002/aic.14421
   Prakash N, 2008, J APPL SCI RES, V4, P1627, DOI DOI 10.1016/S0165-2370(96)00971-0
   Qi T, 2019, INT J HYDROGEN ENERG, V44, P6448, DOI 10.1016/j.ijhydene.2019.01.146
   Qin K, 2012, FUEL, V93, P589, DOI 10.1016/j.fuel.2011.10.063
   Radmanesh R, 2006, AICHE J, V52, P4258, DOI 10.1002/aic.11020
   RANZ WE, 1952, CHEM ENG PROG, V48, P141
   Rong D., 1999, 2 INT C CFD MIN PROC, P65
   Rong LW, 2014, CHEM ENG SCI, V116, P508, DOI 10.1016/j.ces.2014.05.025
   Song T, 2012, BIOMASS BIOENERG, V36, P258, DOI 10.1016/j.biombioe.2011.10.021
   SUN J, 1988, INT J HEAT MASS TRAN, V31, P969, DOI 10.1016/0017-9310(88)90085-3
   Syamlal M., 1987, DERIVATION DRAG COEF
   Tang Y, 2016, CHEM ENG SCI, V143, P166, DOI 10.1016/j.ces.2015.12.026
   TSUJI Y, 1993, POWDER TECHNOL, V77, P79, DOI 10.1016/0032-5910(93)85010-7
   Verma V, 2013, CHEM ENG SCI, V102, P227, DOI 10.1016/j.ces.2013.08.002
   WAKAO N, 1979, CHEM ENG SCI, V34, P325, DOI 10.1016/0009-2509(79)85064-2
   Wang S, 2019, CHEM ENG SCI, V197, P280, DOI 10.1016/j.ces.2018.12.031
   Wang S, 2018, POWDER TECHNOL, V333, P304, DOI 10.1016/j.powtec.2018.04.027
   Wang S, 2017, CHEM ENG SCI, V172, P199, DOI 10.1016/j.ces.2017.05.052
   Wang S, 2017, APPL THERM ENG, V111, P1523, DOI 10.1016/j.applthermaleng.2016.07.161
   Wen C.Y., 1967, P INT S FLUIDIZATION, P491
   Wen X, 2018, INT J MULTIPHAS FLOW, V108, P211, DOI 10.1016/j.ijmultiphaseflow.2018.06.017
   Xavier A.M., 1978, HEAT TRANSFER SURFAC, P333
   Xie N, 2008, POWDER TECHNOL, V182, P1, DOI 10.1016/j.powtec.2007.07.005
   Xie N, 2008, POWDER TECHNOL, V182, P14, DOI 10.1016/j.powtec.2007.09.014
   Xiong QG, 2018, CHEM ENG PROCESS, V127, P206, DOI 10.1016/j.cep.2018.04.005
   Xiong QG, 2014, POWDER TECHNOL, V262, P96, DOI 10.1016/j.powtec.2014.04.062
   Xu J, 2012, ENERG FUEL, V26, P5759, DOI 10.1021/ef3008745
   Xu YP, 2018, IND ENG CHEM RES, V57, P740, DOI 10.1021/acs.iecr.7b03817
   Yin XL, 2009, AICHE J, V55, P1352, DOI 10.1002/aic.11800
   Yue YH, 2019, IND ENG CHEM RES, V58, P23445, DOI 10.1021/acs.iecr.9b05225
   Yue YH, 2019, CHEM ENG SCI, V205, P121, DOI 10.1016/j.ces.2019.04.031
   Zhang W, 2016, CHEM ENG J, V303, P145, DOI 10.1016/j.cej.2016.05.139
   Zhang Y, 2008, FUEL, V87, P475, DOI 10.1016/j.fuel.2007.04.026
   Zhong WQ, 2016, CHEM ENG SCI, V140, P16, DOI 10.1016/j.ces.2015.09.035
NR 86
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115550
DI 10.1016/j.ces.2020.115550
PG 16
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600042
DA 2020-05-12
ER

PT J
AU Wei, T
   Li, XC
   Wang, DX
AF Wei, Tao
   Li, Xiaochuan
   Wang, Dongxue
TI Identification of gas-liquid two-phase flow patterns in dust scrubber
   based on wavelet energy entropy and recurrence analysis characteristics
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Wet dust scrubber; Gas-liquid two-phase flow; Flow pattern
   identification; WEE; RP; RQA
ID TIME-FREQUENCY ENTROPY; DYNAMIC CHARACTERISTICS; MULTISCALE ENTROPY;
   QUANTIFICATION
AB For a wet dust scrubber, dust collection efficiency is tightly connected with the gas-liquid two-phase flow pattern. Using the characteristic parameters selected by current flow pattern identification methods, regions of significant coincidence exist among different patterns, thereby leading to a decline in the identification efficiency. In this study, a new method for processing the wavelet decomposition signal of the dust collector pressure was proposed to obtain the characteristic parameters that distinguish the flow pattern. Firstly, detailed information regarding the different frequency bands of the pressure signal was extracted via wavelet analysis. Then, in combination with the information entropy theory, wavelet energy entropy (WEE) was proposed to evaluate the uniformity of energy distribution in different frequency bands. The results show that WEE is sensitive to the change in gas-liquid two-phase flow patterns, and the corresponding distinguishing efficiency of flow patterns is 92.5%. There was only a small amount of crossover between the shear liquid curtain and entrainment air bubble pattern. For this, using the recursive analysis method (RAM), the characteristic recurrence plots (RP) and recurrence quantification analysis (RQA) of the original pressure signals and the wavelet decomposition signal with different frequency bands were obtained. Results show that the RP characteristics can intuitively reflect the gasliquid flow state of different flow patterns. Although RQA characteristics are not sensitive to the change in low-level gas/liquid resonance flow pattern in the dust scrubber, it exhibits strong distinction to the evolution of other flow patterns. It effectively compensates for the crossover at the flow pattern distinguish between the shear liquid curtain and entrainment of air bubble using the parameters of the wavelet energy entropy. It is the highlight of this article that the combination of WEE and recurrence characteristics can effectively address the problems of high coincidence of flow pattern features in the dust scrubber. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Wei, Tao; Li, Xiaochuan] Minist Educ, Key Lab Coal Proc & Efficient Utilizat, Xuzhou 221116, Jiangsu, Peoples R China.
   [Wei, Tao; Li, Xiaochuan; Wang, Dongxue] China Univ Min & Technol, Sch Chem Engn & Technol, Daxue Rd 1, Xuzhou 221116, Jiangsu, Peoples R China.
RP Li, XC (reprint author), China Univ Min & Technol, Sch Chem Engn & Technol, Daxue Rd 1, Xuzhou 221116, Jiangsu, Peoples R China.
EM 5372@cumt.edu.cn
FU Key Research and Development Program of Xuzhou (Social Development)
   [KC18221]
FX This work is supported by Key Research and Development Program of Xuzhou
   (Social Development) KC18221.
CR [陈露阳 Chen Luyang], 2017, [仪器仪表学报, Chinese Journal of Scientific Instrument], V38, P2536
   Ding H, 2007, FLOW MEAS INSTRUM, V18, P37, DOI 10.1016/j.flowmeasinst.2006.12.004
   Dong F, 2008, ACTA PHYS SIN-CH ED, V57, P6145
   Du M, 2012, CHEM ENG SCI, V82, P144, DOI 10.1016/j.ces.2012.07.028
   ECKMANN JP, 1987, EUROPHYS LETT, V4, P973, DOI 10.1209/0295-5075/4/9/004
   Fan Chun-Ling, 2014, Journal of East China University of Science and Technology, V40, P81
   Gao ZK, 2010, PHYS LETT A, V374, P4014, DOI 10.1016/j.physleta.2010.08.005
   Huang SS, 2018, J CENT SOUTH UNIV, V25, P1690, DOI 10.1007/s11771-018-3860-2
   Jin ND, 2007, ACTA PHYS SIN-CH ED, V56, P720
   Lehner M, 2001, PROCESS SAF ENVIRON, V79, P109, DOI 10.1205/09575820151095193
   Li XC, 2019, CHEM ENG TECHNOL, V42, P2302, DOI 10.1002/ceat.201800685
   Li XC, 2019, J AIR WASTE MANAGE, V69, P764, DOI 10.1080/10962247.2019.1586012
   Li XC, 2018, J AIR WASTE MANAGE, V68, P73, DOI 10.1080/10962247.2017.1370037
   Li XC, 2016, CHEM ENG SCI, V151, P79, DOI 10.1016/j.ces.2016.05.010
   [李小川 Li Xiaochuan], 2015, [煤炭学报, Journal of China Coal Society], V40, P3001
   Lian EY, 2016, Z NATURFORSCH A, V71, P1031, DOI 10.1515/zna-2016-0235
   Liu S.Y., 1998, J CHIN U MIN TECHNO, V27, P49
   [龙军 Long Jun], 2011, [高校化学工程学报, Journal of Chemical Engineering of Chinese Universities], V25, P759
   [马晓旭 Ma Xiaoxu], 2018, [化工学报, CIESC Journal], V69, P1972
   MALLAT SG, 1989, IEEE T PATTERN ANAL, V11, P674, DOI 10.1109/34.192463
   Peddu A, 2018, INT J MULTIPHAS FLOW, V100, P1, DOI 10.1016/j.ijmultiphaseflow.2017.11.016
   SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x
   [孙斌 Sun Bin], 2014, [实验流体力学, Journal of Experiments in Fluid Mechanics], V28, P47
   Sun ZQ, 2013, MEAS SCI REV, V13, P83, DOI 10.2478/msr-2013-0016
   Takens F, 1980, LECT NOTES MATH, P366, DOI [DOI 10.1007/BFB0091924, 10.1007/bfb0091924]
   Tan C, 2015, ISA T, V55, P241, DOI 10.1016/j.isatra.2014.09.010
   Wang Dayang, 2019, CHEM ENG J, DOI [10.1016/j.cej.2019.03.113., DOI 10.1016/J.CEJ.2019.03.113]
   Wang Dongxue, 2017, Industry and Mine Automation, V43, P7, DOI 10.13272/j.issn.1671-251x.2017.10.002
   Wang YT, 2018, INT J HYDROGEN ENERG, V43, P2514, DOI 10.1016/j.ijhydene.2017.12.065
   Wei Tao, 2017, Journal of Mechanical Engineering, V53, P143, DOI 10.3901/JME.2017.02.143
   ZBILUT JP, 1992, PHYS LETT A, V171, P199, DOI 10.1016/0375-9601(92)90426-M
   Zheng GB, 2009, ACTA PHYS SIN-CH ED, V58, P4485
   Zhou Y.L., 2009, CHIN J NUCL SCI ENG, V67, P3625
   [周云龙 Zhou Yunlong], 2016, [化工学报, CIESC Journal], V67, P3625
   Zhou YL, 2013, FLOW MEAS INSTRUM, V30, P18, DOI 10.1016/j.flowmeasinst.2012.09.003
NR 35
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115504
DI 10.1016/j.ces.2020.115504
PG 15
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600012
DA 2020-05-12
ER

PT J
AU Wu, SL
   Chen, CM
   Kuo, JH
   Wey, MY
AF Wu, Shan-Luo
   Chen, Chun-Ming
   Kuo, Jia-Hong
   Wey, Ming-Yen
TI Synthesis of carbon nanotubes with controllable diameter by chemical
   vapor deposition of methane using Fe@Al2O3 core-shell nanocomposites
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Carbon nanotube; Core-shell; Nanocomposite; Mesoporous material
ID COX-FREE HYDROGEN; SUPPORTED IRON-OXIDE; CATALYTIC CARBONIZATION; AIR
   GASIFICATION; ACTIVATED CARBON; MIXED PLASTICS; MASS-TRANSFER; PART II;
   DECOMPOSITION; PERFORMANCE
AB A novel and simple synthetic approach toward core-shell Fe@Al2O3 nanocomposites were developed in this study. The as-synthesized catalyst was applied to convert the methane into carbon nanotubes. Moreover, due to the properties of the core-shell structure, the amount of surfactant can be adjusted to control the pore size of the shell and further control the diameter of the carbon nanotubes. In this study, the conversion of CH4 was up to 97% and the carbon production was 135 mg(C)/g(cat).*h, which is much higher than traditional supported catalysts under similar reaction conditions. In addition, the carbon product quality (IG/ID) was up to 1.96. The enhanced CH4 catalytic activity for the core-shell Fe@Al2O3 catalyst originated from the combined acidic sites on the surface of the Al2O3 shell and the high carbon diffusion rate of the Fe core, which led to the high efficiency of CH4 conversion and longer lifetime of the catalyst. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Wu, Shan-Luo; Chen, Chun-Ming; Wey, Ming-Yen] Natl Chung Hsing Univ, Dept Environm Engn, Taichung 402, Taiwan.
   [Kuo, Jia-Hong] Natl United Univ, Dept Safety Hlth & Environm Engn, Miaoli 360, Taiwan.
RP Wey, MY (reprint author), Natl Chung Hsing Univ, Dept Environm Engn, Taichung 402, Taiwan.
EM mywey@dragon.nchu.edu.tw
FU Ministry of Science and Technology (MOST), Taiwan, ROC [MOST
   106-2221-E-005-010-MY3]
FX The authors would like to thank the Ministry of Science and Technology
   (MOST), Taiwan, ROC for the financial support under Grant No. MOST
   106-2221-E-005-010-MY3.
CR Acomb JC, 2016, APPL CATAL B-ENVIRON, V180, P497, DOI 10.1016/j.apcatb.2015.06.054
   Acomb JC, 2015, J ANAL APPL PYROL, V113, P231, DOI 10.1016/j.jaap.2015.01.012
   Ago H, 2006, CARBON, V44, P2912, DOI 10.1016/j.carbon.2006.05.049
   Al-Fatesh AS, 2018, J SAUDI CHEM SOC, V22, P239, DOI 10.1016/j.jscs.2016.05.001
   Alipour Z, 2014, FUEL, V129, P197, DOI 10.1016/j.fuel.2014.03.045
   Awadallah AE, 2016, INT J HYDROGEN ENERG, V41, P16890, DOI 10.1016/j.ijhydene.2016.07.081
   Bayat N, 2017, FUEL, V195, P88, DOI 10.1016/j.fuel.2017.01.039
   Bayat N, 2016, INT J HYDROGEN ENERG, V41, P1574, DOI 10.1016/j.ijhydene.2015.10.053
   Cabrera S, 1999, ADV MATER, V11, P379, DOI 10.1002/(SICI)1521-4095(199903)11:5<379::AID-ADMA379>3.0.CO;2-6
   Cao CT, 2012, MATER LETT, V88, P61, DOI 10.1016/j.matlet.2012.08.041
   Chai SP, 2006, CHEM PHYS LETT, V426, P345, DOI 10.1016/j.cplett.2006.05.026
   Cho MH, 2015, ENERGY, V87, P586, DOI 10.1016/j.energy.2015.05.026
   Colomer JF, 2001, CHEM PHYS LETT, V345, P11, DOI 10.1016/S0009-2614(01)00841-7
   Daneyko A, 2015, J CHROMATOGR A, V1407, P139, DOI 10.1016/j.chroma.2015.06.047
   Das S, 2018, APPL CATAL B-ENVIRON, V230, P220, DOI 10.1016/j.apcatb.2018.02.041
   DiLeo RA, 2007, J APPL PHYS, V101, DOI 10.1063/1.2712152
   Dong MY, 2019, MACROMOL MATER ENG, V304, DOI 10.1002/mame.201900010
   Dong MY, 2018, POLYMER, V158, P381, DOI 10.1016/j.polymer.2018.11.003
   Du W, 2019, ELECTROCHIM ACTA, V296, P907, DOI 10.1016/j.electacta.2018.11.074
   Fakeeha AH, 2018, ARAB J CHEM, V11, P405, DOI 10.1016/j.arabjc.2016.06.012
   GAO XT, 1993, J CHEM SOC FARADAY T, V89, P1079, DOI 10.1039/ft9938901079
   Gong J, 2014, J MATER CHEM A, V2, P7461, DOI 10.1039/c4ta00173g
   Gong J, 2014, APPL CATAL B-ENVIRON, V152, P289, DOI 10.1016/j.apcatb.2014.01.051
   Gong J, 2012, APPL CATAL A-GEN, V449, P112, DOI 10.1016/j.apcata.2012.09.028
   Gong J, 2012, APPL CATAL B-ENVIRON, V117, P185, DOI 10.1016/j.apcatb.2012.01.015
   Gong XY, 2019, POLYMER, V168, P131, DOI 10.1016/j.polymer.2019.02.021
   Griboval-Constant A, 2014, APPL CATAL A-GEN, V481, P116, DOI 10.1016/j.apcata.2014.04.047
   Hornyak GL, 2002, J PHYS CHEM B, V106, P2821, DOI 10.1021/jp015554i
   Hou CX, 2019, J MATER CHEM A, V7, P13460, DOI 10.1039/c9ta03551f
   Hu Q, 2019, ACS SUSTAIN CHEM ENG, V7, P5912, DOI 10.1021/acssuschemeng.8b05847
   Ibrahim AA, 2015, J CHIN CHEM SOC-TAIP, V62, P592, DOI 10.1002/jccs.201500052
   Idrees M, 2019, ELECTROCHIM ACTA, V296, P925, DOI 10.1016/j.electacta.2018.11.088
   Jiang DW, 2019, MACROMOL MATER ENG, V304, DOI 10.1002/mame.201900074
   Jourdain V, 2013, CARBON, V58, P2, DOI 10.1016/j.carbon.2013.02.046
   Kaczmarski K, 2007, ANAL CHEM, V79, P4648, DOI 10.1021/ac070209w
   Kang KM, 2011, FUEL PROCESS TECHNOL, V92, P1236, DOI 10.1016/j.fuproc.2011.02.007
   Kim SM, 2017, J AM CHEM SOC, V139, P1937, DOI 10.1021/jacs.6b11487
   Kumar S, 2014, NANOSCALE, V6, P4830, DOI 10.1039/c3nr05271k
   Kunwar B, 2016, RENEW SUST ENERG REV, V54, P421, DOI 10.1016/j.rser.2015.10.015
   Kutteri DA, 2018, CATAL SCI TECHNOL, V8, P858, DOI 10.1039/c7cy01927k
   Le K, 2019, DALTON T, V48, P5193, DOI 10.1039/c9dt00615j
   Leofanti G, 1998, CATAL TODAY, V41, P207, DOI 10.1016/S0920-5861(98)00050-9
   Li QM, 2019, ACS APPL MATER INTER, V11, P21904, DOI 10.1021/acsami.9b03421
   Li SW, 2019, J MATER CHEM A, V7, P16902, DOI 10.1039/c9ta04562g
   Li ZW, 2016, APPL CATAL B-ENVIRON, V188, P324, DOI 10.1016/j.apcatb.2016.01.067
   Liang TX, 2019, COMPOS PART B-ENG, V166, P428, DOI 10.1016/j.compositesb.2019.02.024
   Liu H, 2018, J MATER CHEM C, V6, P12121, DOI 10.1039/c8tc04079f
   Liu MK, 2017, CHEM COMMUN, V53, P9097, DOI 10.1039/c7cc04523a
   Liu SJ, 2018, APPL SURF SCI, V455, P75, DOI 10.1016/j.apsusc.2018.05.188
   Liu XT, 2017, J ANAL APPL PYROL, V125, P32, DOI 10.1016/j.jaap.2017.05.001
   Luna AEC, 2008, APPL CATAL A-GEN, V343, P10, DOI 10.1016/j.apcata.2007.11.041
   Ma LC, 2019, COMPOS PART B-ENG, V176, DOI 10.1016/j.compositesb.2019.107078
   Ma LC, 2018, APPL SURF SCI, V433, P560, DOI 10.1016/j.apsusc.2017.10.036
   Ma Y, 2019, ELECTROCHIM ACTA, V315, P114, DOI 10.1016/j.electacta.2019.05.073
   Medvedeva NI, 2014, J ALLOY COMPD, V582, P475, DOI 10.1016/j.jallcom.2013.08.089
   Nunes-Pereira J, 2018, COMPOS PART B-ENG, V142, P1, DOI 10.1016/j.compositesb.2017.12.047
   Park JY, 2010, J MOL CATAL A-CHEM, V323, P84, DOI 10.1016/j.molcata.2010.03.025
   Plastics Europe, 2016, PLAST THE FACTS 2015
   Pradhan AC, 2017, J CHEM SCI, V129, P381, DOI 10.1007/s12039-017-1230-5
   Pudukudy M, 2015, APPL SURF SCI, V330, P418, DOI 10.1016/j.apsusc.2015.01.032
   Pudukudy M, 2015, CHEM ENG J, V262, P1009, DOI 10.1016/j.cej.2014.10.077
   Qi HJ, 2019, J COLLOID INTERF SCI, V539, P332, DOI 10.1016/j.jcis.2018.12.047
   Qian YX, 2018, J MATER CHEM A, V6, P24676, DOI 10.1039/c8ta09486a
   Enakonda L, 2016, CHEMSUSCHEM, V9, P1911, DOI 10.1002/cssc.201600500
   Reshetenko TV, 2004, APPL CATAL A-GEN, V270, P87, DOI 10.1016/j.apcata.2004.04.026
   ROSATO V, 1989, ACTA METALL MATER, V37, P2759, DOI 10.1016/0001-6160(89)90310-6
   Sanchez-Contador MS, 2018, FUEL PROCESS TECHNOL, V179, P258, DOI 10.1016/j.fuproc.2018.07.009
   Shamskar FR, 2017, ULTRASON SONOCHEM, V34, P436, DOI 10.1016/j.ultsonch.2016.06.021
   Shi ZJ, 2019, INT J BIOL MACROMOL, V133, P964, DOI 10.1016/j.ijbiomac.2019.04.128
   Tan SM, 2009, J ALLOY COMPD, V477, P785, DOI 10.1016/j.jallcom.2008.10.114
   Thostenson ET, 2001, COMPOS SCI TECHNOL, V61, P1899, DOI 10.1016/S0266-3538(01)00094-X
   Tiwari VK, 2017, J MATER CHEM A, V5, P12131, DOI 10.1039/c7ta01114h
   Toledo JM, 2011, IND ENG CHEM RES, V50, P11815, DOI 10.1021/ie200145p
   VOORHEES PW, 1985, J STAT PHYS, V38, P231, DOI 10.1007/BF01017860
   Wang C, 2018, CARBON, V140, P696, DOI 10.1016/j.carbon.2018.09.006
   Wang DA, 2013, ANGEW CHEM INT EDIT, V52, P11252, DOI 10.1002/anie.201303693
   Williams D.B., 1996, TRANSMISSION ELECT M, P3, DOI DOI 10.1007/978-1-4757-2519-3_1
   Xie PT, 2018, J MATER CHEM C, V6, P8812, DOI 10.1039/c8tc02127a
   Xie PT, 2018, J MATER CHEM C, V6, P5239, DOI 10.1039/c7tc05911f
   Zhang JX, 2019, J COLLOID INTERF SCI, V542, P159, DOI 10.1016/j.jcis.2019.01.135
   Zhang M, 2019, J MATER RES, V34, P3050, DOI 10.1557/jmr.2019.198
   Zhao ZY, 2019, J ALLOY COMPD, V792, P203, DOI 10.1016/j.jallcom.2019.04.007
   Zhu Q., 2004, J NAT GAS CHEM, V13, P191
NR 83
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115541
DI 10.1016/j.ces.2020.115541
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600038
DA 2020-05-12
ER

PT J
AU Xing, LW
   Gao, HY
   Chen, X
   Jia, DD
   Huang, XB
   Yang, M
   Dong, WJ
   Wang, G
AF Xing, Liwen
   Gao, Hongyi
   Chen, Xiao
   Jia, Dandan
   Huang, Xiubing
   Yang, Mu
   Dong, Wenjun
   Wang, Ge
TI Hierarchical nitrogen-doped porous carbon incorporating cobalt
   nanocrystal sites for nitrophenol reduction
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE N-doped porous carbon; Co species; Active sites; Flow catalysis
ID HIGHLY EFFICIENT CATALYSIS; METAL-ORGANIC FRAMEWORK; HIGH-SURFACE-AREA;
   OXYGEN REDUCTION; HYDROGENATION; NANOPARTICLES; ELECTROCATALYST;
   NANOTUBES; COMPOSITES; PYROLYSIS
AB The direct pyrolysis of metal organic frameworks (MOFs) has recently provided an effective method to prepare various metal-incorporated composite carbon materials. In this work, hierarchical Co-embedded N-doped porous carbon microspheres were synthesized by controlled pyrolysis of bimetallic Zn-Co Prussian blue analogues (PBAs), in which the metallic Zn component served as thermally removable template and ligand [Co(CN)(6)](3-) served as both Co and N sources. When devoted to catalyzing the reduction of 4-nitrophenol (4-NPh) into 4-aminophenol (4-APh), the optimized catalyst exhibited a large apparent rate constant of 1.35 min(-1) and high turnover frequency (TOF) of 0.0204 s(-1), which was superior to the majority of noble-metal-based catalysts. Besides, a home-made continuous flow catalysis system was readily constructed. Control experiments confirmed that both partially uncovered and totally inbuilt active metallic Co species acted as catalytically active sites. This work might provide a further understanding of the identification of active sites within metal-incorporated carbon-based catalysts. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Xing, Liwen; Gao, Hongyi; Huang, Xiubing; Yang, Mu; Dong, Wenjun; Wang, Ge] Univ Sci & Technol Beijing, Beijing Adv Innovat Ctr Mat Genome Engn, Sch Mat Sci & Engn, Beijing Key Lab Funct Mat Mol & Struct Construct, 30 Xueyuan Rd, Beijing 100083, Peoples R China.
   [Chen, Xiao] Beijing Normal Univ, Inst Adv Mat, Beijing 100875, Peoples R China.
   [Jia, Dandan] SINOPEC, Res Inst Petr Proc, Beijing 100083, Peoples R China.
RP Gao, HY; Wang, G (reprint author), Univ Sci & Technol Beijing, Beijing Adv Innovat Ctr Mat Genome Engn, Sch Mat Sci & Engn, Beijing Key Lab Funct Mat Mol & Struct Construct, 30 Xueyuan Rd, Beijing 100083, Peoples R China.
EM hygao2009@163.com; gewang@mater.ustb.edu.cn
RI Xing, Liwen/AAE-1177-2020; Chen, Xiao/AAE-5020-2020
OI Xing, Liwen/0000-0001-6748-4191; Chen, Xiao/0000-0001-6062-5596; chen,
   xiao/0000-0002-4421-6271
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51972024, 51702013, 51902025]; 111 ProjectMinistry
   of Education, China - 111 Project [B17003]; Fundamental Research Funds
   for the Central UniversitiesFundamental Research Funds for the Central
   Universities [FRF-BD-19-009A, 2019NTST29]
FX This work was supported by the National Natural Science Foundation of
   China (51972024, 51702013 and 51902025), 111 Project (B17003) and
   Fundamental Research Funds for the Central Universities (FRF-BD-19-009A
   and 2019NTST29).
CR Berry V, 2013, CARBON, V62, P1, DOI 10.1016/j.carbon.2013.05.052
   Cao YL, 2017, ACS CATAL, V7, P8090, DOI 10.1021/acscatal.7b02335
   Chen YZ, 2015, ADV MATER, V27, P5010, DOI 10.1002/adma.201502315
   Dai XP, 2016, ACS APPL MATER INTER, V8, P6439, DOI 10.1021/acsami.5b11717
   Deng J, 2017, ADV MATER, V29, DOI 10.1002/adma.201606967
   Deng J, 2015, ANGEW CHEM INT EDIT, V54, P2100, DOI 10.1002/anie.201409524
   Deng J, 2013, J MATER CHEM A, V1, P14868, DOI 10.1039/c3ta13759g
   Dong WJ, 2016, APPL CATAL B-ENVIRON, V180, P13, DOI 10.1016/j.apcatb.2015.05.061
   Du DJ, 2009, LANGMUIR, V25, P7057, DOI 10.1021/la900004v
   Fan S, 2017, ACS CATAL, V7, P243, DOI 10.1021/acscatal.6b02614
   Ferrari AC, 2006, PHYS REV LETT, V97, DOI 10.1103/PhysRevLett.97.187401
   Gao HY, 2015, ACS APPL MATER INTER, V7, P4667, DOI 10.1021/am508079j
   He L, 2016, ANGEW CHEM INT EDIT, V55, P12582, DOI 10.1002/anie.201603198
   Huang G, 2016, CHEM-EUR J, V22, P3470, DOI 10.1002/chem.201504867
   Huang RL, 2016, ENVIRON SCI TECHNOL, V50, P11263, DOI 10.1021/acs.est.6b03431
   Huang XB, 2017, J MATER CHEM A, V5, P24631, DOI 10.1039/c7ta08734a
   Huang XB, 2017, GREEN CHEM, V19, P769, DOI 10.1039/c6gc02065h
   Iablokov V, 2012, NANO LETT, V12, P3091, DOI 10.1021/nl300973b
   Jagadeesh RV, 2017, SCIENCE, V358, P326, DOI 10.1126/science.aan6245
   Jia DD, 2017, ACS APPL MATER INTER, V9, P20476, DOI 10.1021/acsami.7b02100
   Jiang H, 2016, ACS NANO, V10, P1648, DOI 10.1021/acsnano.5b07367
   Jiang LS, 2016, APPL CATAL B-ENVIRON, V180, P344, DOI 10.1016/j.apcatb.2015.06.033
   Li J, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957-4484/26/9/095601
   Li JL, 2017, J CATAL, V355, P53, DOI 10.1016/j.jcat.2017.09.007
   Li XY, 2016, J MATER CHEM A, V4, P7476, DOI 10.1039/c6ta01054g
   Liu SH, 2017, ADV MATER, V29, DOI 10.1002/adma.201700874
   Liu YB, 2017, IND ENG CHEM RES, V56, P2999, DOI 10.1021/acs.iecr.7b00357
   Lu AH, 2006, CHEM MATER, V18, P2086, DOI 10.1021/cm060135p
   Mo QJ, 2017, ACS APPL MATER INTER, V9, P37721, DOI 10.1021/acsami.7b10853
   Niu WH, 2015, J AM CHEM SOC, V137, P5555, DOI 10.1021/jacs.5b02027
   Sivanantham A, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201702838
   Su YH, 2014, NANOSCALE, V6, P15080, DOI 10.1039/c4nr04357j
   Tan PH, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevLett.87.214301
   Tang J, 2016, RSC ADV, V6, P40106, DOI 10.1039/c6ra04059d
   Wang HB, 2011, J MATER CHEM, V21, P5430, DOI 10.1039/c1jm00049g
   Wang P, 2018, J MATER CHEM A, V6, P14178, DOI 10.1039/c8ta04214d
   Wang SG, 2016, NANO RES, V9, P2270, DOI 10.1007/s12274-016-1114-x
   Wei ZZ, 2016, ACS CATAL, V6, P5816, DOI 10.1021/acscatal.6b01240
   Wei ZZ, 2015, ACS CATAL, V5, P4783, DOI 10.1021/acscatal.5b00737
   Westerhaus FA, 2013, NAT CHEM, V5, P537, DOI [10.1038/NCHEM.1645, 10.1038/nchem.1645]
   Wickramaratne NP, 2013, CHEM MATER, V25, P2803, DOI 10.1021/cm401124d
   Wu LH, 2015, J AM CHEM SOC, V137, P7071, DOI 10.1021/jacs.5b04142
   Yin PQ, 2016, ANGEW CHEM INT EDIT, V55, P10800, DOI 10.1002/anie.201604802
   Yusran Y, 2017, MICROPOR MESOPOR MAT, V241, P346, DOI 10.1016/j.micromeso.2016.12.029
   Zeng M, 2016, ADV FUNCT MATER, V26, P4397, DOI 10.1002/adfm.201600636
   Zhang MD, 2018, ADV MATER, V30, DOI 10.1002/adma.201705431
   Zhao HY, 2018, DALTON T, V47, P3321, DOI 10.1039/c7dt04272h
   Zhong W, 2015, ACS CATAL, V5, P1850, DOI 10.1021/cs502101c
NR 48
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115525
DI 10.1016/j.ces.2020.115525
PG 8
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600030
DA 2020-05-12
ER

PT J
AU Xu, YP
   Li, TW
   Lu, LQ
   Gao, X
   Tebianian, S
   Grace, JR
   Chaouki, J
   Leadbeater, TW
   Jafari, R
   Parker, DJ
   Seville, J
   Ellis, N
AF Xu, Yupeng
   Li, Tingwen
   Lu, Liqiang
   Gao, Xi
   Tebianian, Sina
   Grace, John R.
   Chaouki, Jamal
   Leadbeater, Thomas W.
   Jafari, Rouzbeh
   Parker, David J.
   Seville, Jonathan
   Ellis, Naoko
TI Development and confirmation of a simple procedure to measure solids
   distribution in fluidized beds using tracer particles
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Coarse grained method; Traveling fluidized bed; Tracer particles; Solids
   volume fraction; Particle tracking; Computational fluid dynamics
ID NUMERICAL-SIMULATION; DISCRETE PARTICLE; GELDART; FLOW; VELOCITY; MODEL;
   DEM; VALIDATION; COLUMN
AB The spatial distribution of solid particles is a key factor affecting the performance of fluidized bed reactors. Non-invasive techniques including radioactive particle tracking (RPT) and positron emission particle tracking (PEPT) are deployed to measure the solids distribution. Different methods to calibrate the particle tracking measurements have been developed to quantify mean solids concentration. In this paper, gas-solid flows in a traveling fluidized bed are simulated with CFD-DEM and the behavior of different particles, including bulk sand particles and tracer particles are investigated. The simulated hydrodynamics are compared with experimental measurements. Analyses are carried out to derive the mean solids concentration from the tracer particle data. Different calibration approaches are examined, and the simple calibration method is verified. It is shown that the mean solids concentration can be measured reliably using representative tracer particles. The experimental RPT data are then revisited with the new calibration method which yields more realistic results. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Xu, Yupeng; Lu, Liqiang; Gao, Xi] US DOE, Natl Energy Technol Lab, Morgantown, WV USA.
   [Li, Tingwen] SABIC Corp Res & Dev, Sugar Land, TX 77478 USA.
   [Tebianian, Sina] IFP Energies Nouvelles, Proc Design & Modeling Div, Lyon, France.
   [Chaouki, Jamal; Jafari, Rouzbeh] Ecole Polytech, Dept Genie Chim, Montreal, PQ H3T 1J4, Canada.
   [Parker, David J.; Seville, Jonathan] Univ Birmingham, Positron Imaging Ctr, Birmingham B15 2TT, W Midlands, England.
   [Grace, John R.; Ellis, Naoko] Univ British Columbia, Dept Chem & Biol Engn, Vancouver, BC V6T 1Z3, Canada.
   [Leadbeater, Thomas W.] Univ Cape Town, Dept Phys, Rondebosch, South Africa.
   [Xu, Yupeng; Gao, Xi] Res Support Team, 3610 Collins Ferry Rd, Morgantown, WV 26507 USA.
   [Lu, Liqiang] West Virginia Univ, Res Corp, Morgantown, WV 26506 USA.
RP Li, TW (reprint author), SABIC Corp Res & Dev, Sugar Land, TX 77478 USA.
EM litingwen@gmail.com
FU US Department of Energy's Fossil Energy Crosscutting Technology Research
   ProgramUnited States Department of Energy (DOE); NETL Research and
   Innovation Center's Advanced Reaction Systems FWP [89243318CFE000003]
FX This work was performed in support of the US Department of Energy's
   Fossil Energy Crosscutting Technology Research Program. The Research was
   executed through the NETL Research and Innovation Center's Advanced
   Reaction Systems FWP. Research performed by Leidos Research Support Team
   staff was conducted under RSS contract 89243318CFE000003.
CR Bellan S, 2019, CHEM ENG J, V360, P1287, DOI 10.1016/j.cej.2018.10.111
   Dietiker J.F., 2015, MULTIPHASE FLOW INTE
   Dubrawski K, 2013, POWDER TECHNOL, V235, P203, DOI 10.1016/j.powtec.2012.10.031
   Gao X, 2018, AICHE J, V64, P3565, DOI 10.1002/aic.16341
   Gao X, 2018, CHEM ENG SCI, V184, P33, DOI 10.1016/j.ces.2018.03.038
   Garg R, 2012, POWDER TECHNOL, V220, P122, DOI 10.1016/j.powtec.2011.09.019
   Grace J.R., 1982, HDB MULTIPHASE SYSTE
   Kirkpatrick MP, 2003, J COMPUT PHYS, V184, P1, DOI 10.1016/S0021-9991(02)00013-X
   Li TW, 2017, ADV POWDER TECHNOL, V28, P2961, DOI 10.1016/j.apt.2017.09.003
   Lu JT, 2018, IND ENG CHEM RES, V57, P15565, DOI 10.1021/acs.iecr.8b03158
   Lu LQ, 2018, CHEM ENG SCI, V179, P53, DOI 10.1016/j.ces.2018.01.003
   Lu LQ, 2016, CHEM ENG SCI, V155, P314, DOI 10.1016/j.ces.2016.08.013
   Sakai M, 2014, CHEM ENG J, V244, P33, DOI 10.1016/j.cej.2014.01.029
   Seville JPK, 2009, ADV CHEM ENG, V37, P149, DOI 10.1016/S0065-2377(09)03704-1
   Stein M., 1997, NONINVASIVE MONITORI, P309
   Tebianian S, 2016, CHEM ENG J, V306, P306, DOI 10.1016/j.cej.2016.07.058
   Tebianian S, 2016, POWDER TECHNOL, V296, P45, DOI 10.1016/j.powtec.2015.08.040
   Tebianian S, 2015, CHEM ENG SCI, V127, P310, DOI 10.1016/j.ces.2015.01.049
   Vashisth S, 2015, CHEM ENG SCI, V134, P269, DOI 10.1016/j.ces.2015.05.001
   Verma V, 2017, POWDER TECHNOL, V318, P282, DOI 10.1016/j.powtec.2017.05.037
   Verma V, 2016, CHEM ENG J, V287, P727, DOI 10.1016/j.cej.2015.11.049
   Xu Y, 2014, PHYS REV E, V90, DOI 10.1103/PhysRevE.90.062203
   Xu Y, 2013, CHEM ENG SCI, V104, P201, DOI 10.1016/j.ces.2013.09.023
   Xu Y., 2019, COMPUT MATH APPL
   Xu YP, 2019, CHEM ENG SCI, V195, P356, DOI 10.1016/j.ces.2018.09.034
   Xu YP, 2018, IND ENG CHEM RES, V57, P740, DOI 10.1021/acs.iecr.7b03817
   Xu YP, 2017, POWDER TECHNOL, V320, P304, DOI 10.1016/j.powtec.2017.07.047
   Xu YP, 2017, POWDER TECHNOL, V318, P321, DOI 10.1016/j.powtec.2017.06.020
NR 28
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115501
DI 10.1016/j.ces.2020.115501
PG 11
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600009
DA 2020-05-12
ER

PT J
AU Yamaguchi, D
   Tang, LG
   Scarlett, N
   Chiang, K
AF Yamaguchi, Doki
   Tang, Liangguang
   Scarlett, Nicola
   Chiang, Ken
TI The activation and conversion of carbon dioxide on the surface of
   zirconia-promoted ceria oxides
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CO2 conversion; Ceria-zirconia oxide; Oxygen carrier; Structural and
   redox property
ID CEO2-ZRO2 SOLID-SOLUTIONS; OXYGEN STORAGE CAPACITY; THERMAL-STABILITY;
   REDOX BEHAVIOR; CO2 ACTIVATION; PARTIAL OXIDATION; SYNTHESIS GAS; MIXED
   OXIDES; REDUCTION; METHANE
AB This study reports the conversion of carbon dioxide (CO2) by ceria (CeO2)-zirconia (ZrO2) composites with various ZrO2 contents (0, 20, 50, 80 and 100 %). The modification introduced by ZrO2 altered the structural properties of the ceria samples, affecting their reducibility and subsequent activity to convert CO2. The characterisation results showed a clear relationship between the structural properties of the materials and the activity for CO2 conversion. The addition of ZrO2 was effective to improve a close interaction between CeO2 and ZrO2 and induced the formation of structural defects that further promoted oxygen transport and facilitated the creation of oxygen vacancies that were critical for CO2 conversion. All samples investigated were found to be effective in converting CO2 into carbon monoxide (CO) at 450 degrees C, and the addition of ZrO2 was also found to be effective in improving the thermal resistance and stabilising the crystalline structure of the samples especially when the ZrO2 content was > 50 %. When the content of ZrO2 controlled between 50 % and 80 %, the onset temperature for CO2 conversion was found to be 285 degrees C, which was about 80 degrees C lower than that required for the sample without ZrO2 modification. Thus, modifying CeO2 by ZrO2 was effective to prevent both the textural and structural alteration of the samples under a high temperature environment as well as cyclic redox operations, resulting in a constant and high degree of CO2 conversion into CO. Crown Copyright (C) 2020 Published by Elsevier Ltd. All rights reserved.
C1 [Yamaguchi, Doki; Tang, Liangguang; Chiang, Ken] CSIRO Energy, Private Bag 10, Clayton, Vic 3168, Australia.
   [Scarlett, Nicola] CSIRO Mineral Resources, Private Bag 10, Clayton, Vic 3168, Australia.
RP Chiang, K (reprint author), RMIT Univ, Sch Engn, Melbourne, Vic 3000, Australia.
EM Ken.Chiang@rmit.edu.au
RI Chiang, Ken/A-5531-2011
OI Chiang, Ken/0000-0002-0241-0543
FU CSIRO EnergyCommonwealth Scientific & Industrial Research Organisation
   (CSIRO)
FX The authors gratefully acknowledge supports from CSIRO Energy. The
   authors also thank Mrs Lisa Wong for material characterisation works.
CR Albo J, 2010, IND ENG CHEM RES, V49, P11045, DOI 10.1021/ie1014266
   Aresta M, 2013, J CO2 UTIL, V3-4, P65, DOI 10.1016/j.jcou.2013.08.001
   BALDUCCI G, 1995, CATAL LETT, V33, P193, DOI 10.1007/BF00817058
   Boaro M, 2000, J CATAL, V193, P338, DOI 10.1006/jcat.2000.2887
   Bozo C, 2000, CATAL TODAY, V59, P33, DOI 10.1016/S0920-5861(00)00270-4
   Buelens LC, 2019, J CO2 UTIL, V29, P36, DOI 10.1016/j.jcou.2018.11.008
   Chueh WC, 2010, SCIENCE, V330, P1797, DOI 10.1126/science.1197834
   Chueh WC, 2010, PHILOS T R SOC A, V368, P3269, DOI 10.1098/rsta.2010.0114
   deLeitenburg C, 1997, J CATAL, V166, P98, DOI 10.1006/jcat.1997.1498
   Demoulin O, 2007, APPL CATAL B-ENVIRON, V70, P284, DOI 10.1016/j.apcatb.2005.12.024
   Di Monte R, 2000, APPL CATAL B-ENVIRON, V24, P157, DOI 10.1016/S0926-3373(99)00102-2
   Fornasiero P, 1996, J CATAL, V164, P173, DOI 10.1006/jcat.1996.0373
   FORNASIERO P, 1995, J CATAL, V151, P168, DOI 10.1006/jcat.1995.1019
   Ganduglia-Pirovano MV, 2007, SURF SCI REP, V62, P219, DOI 10.1016/j.surfrep.2007.03.002
   Haribal VP, 2019, ADV ENERGY MATER, V9, DOI 10.1002/aenm.201901963
   Hori CE, 1998, APPL CATAL B-ENVIRON, V16, P105, DOI 10.1016/S0926-3373(97)00060-X
   Kaspar J, 1999, CATAL TODAY, V50, P285, DOI 10.1016/S0920-5861(98)00510-0
   Kozlov AI, 2002, J CATAL, V209, P417, DOI 10.1006/jcat.2002.3644
   Li MS, 2018, APPL CATAL B-ENVIRON, V239, P27, DOI 10.1016/j.apcatb.2018.07.074
   Liotta LF, 2003, APPL CATAL A-GEN, V240, P295, DOI 10.1016/S0926-860X(02)00460-X
   Madier Y, 1999, J PHYS CHEM B, V103, P10999, DOI 10.1021/jp991270a
   Melchionna M, 2014, MATER TODAY, V17, P349, DOI 10.1016/j.mattod.2014.05.005
   Ocampo F, 2011, APPL CATAL A-GEN, V392, P36, DOI 10.1016/j.apcata.2010.10.025
   Ozkara-Aydinoglu S, 2009, INT J HYDROGEN ENERG, V34, P9711, DOI 10.1016/j.ijhydene.2009.09.005
   Otsuka K, 1998, J CATAL, V175, P152, DOI 10.1006/jcat.1998.1985
   Otsuka-Yao-Matsuo S, 1998, J SOLID STATE CHEM, V138, P47, DOI 10.1006/jssc.1998.7753
   Passos FB, 2005, CATAL TODAY, V101, P23, DOI 10.1016/j.cattod.2004.12.006
   PIJOLAT M, 1995, J CHEM SOC FARADAY T, V91, P3941, DOI 10.1039/ft9959103941
   Sharma S, 2000, J CATAL, V190, P199, DOI 10.1006/jcat.1999.2746
   Shi H, 2019, ENERGY TECHNOL-GER, V7, DOI 10.1002/ente.201800890
   Staudt T, 2010, J CATAL, V275, P181, DOI 10.1016/j.jcat.2010.07.032
   Stying P., 2011, CARBON CAPTURE UTILI
   Terribile D, 1998, CATAL TODAY, V43, P79, DOI 10.1016/S0920-5861(98)00136-9
   The Global CCS Institute, LARG SCAL CCS PROJ
   Traynor AJ, 2002, IND ENG CHEM RES, V41, P1935, DOI 10.1021/ie010871x
   TROVARELLI A, 1995, J CATAL, V151, P111, DOI 10.1006/jcat.1995.1014
   Trovarelli A, 1996, CATAL REV, V38, P439, DOI 10.1080/01614949608006464
   Vidal H, 2001, APPL CATAL B-ENVIRON, V30, P75, DOI 10.1016/S0926-3373(00)00221-6
   Von Dreele RB, 2008, POWDER DIFFRACTION: THEORY AND PRACTICE, P266, DOI 10.1039/9781847558237-00266
   Wang RG, 2012, J MATER CHEM, V22, P1770, DOI 10.1039/c2jm15348c
   Wang XQ, 2005, J PHYS CHEM B, V109, P19595, DOI 10.1021/jp051970h
   Yang Y, 2019, J PHYS CHEM C, V123, P17092, DOI 10.1021/acs.jpcc.9b02878
   Yentekakis IV, 2019, APPL CATAL B-ENVIRON, V243, P490, DOI 10.1016/j.apcatb.2018.10.048
   Zhao YT, 2019, ACS CATAL, V9, P3187, DOI 10.1021/acscatal.9b00291
NR 44
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115520
DI 10.1016/j.ces.2020.115520
PG 11
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600025
DA 2020-05-12
ER

PT J
AU Yan, FY
   Shi, YJ
   Wang, Y
   Jia, QZ
   Wang, Q
   Xia, SQ
AF Yan, Fangyou
   Shi, Yajuan
   Wang, Ying
   Jia, Qingzhu
   Wang, Qiang
   Xia, Shuqian
TI QSPR models for the properties of ionic liquids at variable temperatures
   based on norm descriptors
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Norm descriptor; Surface tension; Heat capacity; Ionic liquids (ILs);
   Temperature-dependent; QSPR model
ID SURFACE-TENSION; EXTENSIVE DATABASES; HEAT-CAPACITIES; QSAR MODELS;
   VALIDATION; PREDICTION; SEPARATION; CONVERSION; METRICS
AB Surface tension and heat capacity are fundamental and crucial properties for ionic liquids (ILs). Most often, separate descriptors based on the cations and anions are used to develop QSPR model, while the effect of ILs is neglected. Thus, in this work, ionic liquids are optimized as a whole; the contributions of not only cations and anions alone but also those of ILs overall are reflected in this treatment. Furthermore, norm descriptors are introduced into the temperature term to correct for temperature effects. Two QSPR models are proposed to predict the surface tension (gamma) for the temperature range of 262.89-533.2 K and the heat capacity (C-p) for the temperature range of 188.06-550.00 K. External validation and application domain analysis indicate the predictability and reliability of the models, which demonstrate that these models are thus applicable to calculate gamma and C-p for multiple structures in a wide temperature range. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Yan, Fangyou; Shi, Yajuan; Wang, Ying; Wang, Qiang] Tianjin Univ Sci & Technol, Sch Chem Engn & Mat Sci, TEDA, 13st 29, Tianjin 300457, Peoples R China.
   [Jia, Qingzhu] Tianjin Univ Sci & Technol, Sch Marine & Environm Sci, TEDA, 13st 29, Tianjin 300457, Peoples R China.
   [Xia, Shuqian] Tianjin Univ, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Sch Chem Engn & Technol, Key Lab Green Chem Technol,State Educ Minist, Tianjin 300072, Peoples R China.
RP Wang, Q (reprint author), Tianjin Univ Sci & Technol, Sch Chem Engn & Mat Sci, TEDA, 13st 29, Tianjin 300457, Peoples R China.; Xia, SQ (reprint author), Tianjin Univ, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Sch Chem Engn & Technol, Key Lab Green Chem Technol,State Educ Minist, Tianjin 300072, Peoples R China.
EM wang_q@tust.edu.cn; shuqianxia@tju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21808167, 21676203]
FX This work was financially supported by the National Natural Science
   Foundation of China [NO: 21808167 and 21676203].
CR Ahmadi A, 2015, FLUID PHASE EQUILIBR, V403, P95, DOI 10.1016/j.fluid.2015.06.009
   Albert J, 2014, IND ENG CHEM RES, V53, P17522, DOI 10.1021/ie503366p
   Almeida HFD, 2014, LANGMUIR, V30, P6408, DOI 10.1021/la501308q
   Arjmand F, 2019, J MOL LIQ, V277, P80, DOI 10.1016/j.molliq.2018.12.062
   Barati-Harooni A, 2017, J MOL LIQ, V227, P324, DOI 10.1016/j.molliq.2016.11.119
   Ben Ghanem O, 2015, J CHEM ENG DATA, V60, P1756, DOI 10.1021/je501162f
   Chen YQ, 2019, CHEM ENG SCI, V203, P402, DOI 10.1016/j.ces.2019.04.005
   Chen YQ, 2019, IND ENG CHEM RES, V58, P4277, DOI 10.1021/acs.iecr.8b05040
   DEY R, 2015, UNDERSTANDING BASICS, P230
   Gardas RL, 2009, AICHE J, V55, P1274, DOI 10.1002/aic.11737
   Gramatica P, 2007, QSAR COMB SCI, V26, P694, DOI 10.1002/qsar.200610151
   Gramatica P, 2016, J CHEM INF MODEL, V56, P1127, DOI 10.1021/acs.jcim.6b00088
   He WS, 2019, FLUID PHASE EQUILIBR, V500, DOI 10.1016/j.fluid.2019.112260
   John C.D., 2017, ONCOLOGY BREAKTHROUG, P67
   Lazzus JA, 2017, IND ENG CHEM RES, V56, P6869, DOI 10.1021/acs.iecr.7b01233
   Lazzus JA, 2012, FLUID PHASE EQUILIBR, V313, P1, DOI 10.1016/j.fluid.2011.09.018
   Le T, 2012, CHEM REV, V112, P2889, DOI 10.1021/cr200066h
   Lin HZ, 2017, AICHE J, V63, P257, DOI 10.1002/aic.15550
   Mirkhani SA, 2013, J MOL LIQ, V179, P78, DOI 10.1016/j.molliq.2012.11.018
   Moosavi M, 2017, J CHEM THERMODYN, V107, P1, DOI 10.1016/j.jct.2016.12.009
   Nancarrow P, 2015, CHEM ENG TECHNOL, V38, P632, DOI 10.1002/ceat.201400667
   Paduszynski K, 2019, IND ENG CHEM RES, V58, P17049, DOI 10.1021/acs.iecr.9b03150
   Paduszynski K, 2019, IND ENG CHEM RES, V58, P5322, DOI 10.1021/acs.iecr.9b00130
   Paduszynski K, 2012, IND ENG CHEM RES, V51, P591, DOI 10.1021/ie202134z
   Plechkova NV, 2008, CHEM SOC REV, V37, P123, DOI 10.1039/b006677j
   Rogers RD, 2003, SCIENCE, V302, P792, DOI 10.1126/science.1090313
   Roy K., 2015, UNDERSTANDING BASICS
   Roy K, 2007, EXPERT OPIN DRUG DIS, V2, P1567, DOI 10.1517/17460441.2.12.1567
   Roy K, 2016, CHEMOMETR INTELL LAB, V152, P18, DOI 10.1016/j.chemolab.2016.01.008
   Roy K, 2012, J CHEM INF MODEL, V52, P396, DOI 10.1021/ci200520g
   Sattari M, 2014, J THERM ANAL CALORIM, V115, P1863, DOI 10.1007/s10973-013-3474-8
   Sattari M, 2013, IND ENG CHEM RES, V52, P13217, DOI 10.1021/ie401782n
   Shahsavari S, 2018, J MOL LIQ, V265, P292, DOI 10.1016/j.molliq.2018.06.004
   Shang QY, 2013, CHEM ENG SCI, V101, P266, DOI 10.1016/j.ces.2013.05.053
   Sheldon R, 2001, CHEM COMMUN, P2399, DOI 10.1039/b107270f
   Shojaeian A, 2019, THERMOCHIM ACTA, V673, P119, DOI 10.1016/j.tca.2019.01.018
   Singh MP, 2014, J CHEM ENG DATA, V59, P2349, DOI 10.1021/je5000617
   Tariq M, 2012, CHEM SOC REV, V41, P829, DOI 10.1039/c1cs15146k
   Venkatraman V, 2018, J MOL LIQ, V264, P318, DOI 10.1016/j.molliq.2018.03.090
   Welton T, 1999, CHEM REV, V99, P2071, DOI 10.1021/cr980032t
   Yalcin D, 2019, J PHYS CHEM B, V123, P4085, DOI 10.1021/acs.jpcb.9b02072
   Yan FY, 2019, CHEMOSPHERE, V234, P116, DOI 10.1016/j.chemosphere.2019.06.064
   Yan FS, 2018, CHEM ENG SCI, V184, P134, DOI 10.1016/j.ces.2018.03.044
   Zhang YL, 2017, AICHE J, V63, P4920, DOI 10.1002/aic.15841
   Zhao YS, 2018, CHEM ENG SCI, V189, P43, DOI 10.1016/j.ces.2018.05.044
   Zhao YS, 2015, IND ENG CHEM RES, V54, P12987, DOI 10.1021/acs.iecr.5b03576
   Zheng WZ, 2019, CHEM ENG SCI, V205, P287, DOI 10.1016/j.ces.2019.05.008
NR 47
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115540
DI 10.1016/j.ces.2020.115540
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600037
DA 2020-05-12
ER

PT J
AU Yasuda, K
   Sato, T
   Asakura, Y
AF Yasuda, Keiji
   Sato, Tomofumi
   Asakura, Yoshiyuki
TI Size-controlled synthesis of gold nanoparticles by ultrafine bubbles and
   pulsed ultrasound
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gold nanoparticles; Ultrafine bubbles; Pulse wave; Ultrasound; Size
   control; Colloidal stabilization
ID SONOCHEMICAL SYNTHESIS; WATER; NANOBUBBLES; GENERATION; REDUCTION
AB Size-controlled gold nanoparticles (AuNPs) were synthesized by ultrasonic irradiation of HAuCl4 aqueous solutions with the aid of ultrafine bubbles (UFBs) in the absence of any capping and reducing agents. Upon addition of air-UFBs, the mean diameter of the spherical AuNPs decreased. This result was attributed to the sonochemical reduction of gold ions in aqueous solution being accelerated by the UFBs. Moreover, the AuNPs were stable in a solution containing UFBs because AuNPs electrostatically adsorbed onto UFBs, whose lifetime in water was very long. Compared with the mean diameter of AuNPs synthesized with argon-, nitrogen- and oxygen-UFBs, that of AuNPs synthesized with air-UFBs was smaller. Pulsed ultrasound delivered with the same time-averaged power as continuous-wave irradiation further decreased the mean diameter of the AuNPs. Size-controlled synthesis of AuNPs without the use of a capping or reducing agent was successful through optimization of the number air-UFBs and the pulsed ultrasound conditions. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Yasuda, Keiji; Sato, Tomofumi] Nagoya Univ, Grad Sch Engn, Dept Chem Syst Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.
   [Asakura, Yoshiyuki] Honda Elect Co Ltd, 20 Oyamazuka,Oiwa Cho, Toyohashi, Aichi 4413193, Japan.
RP Yasuda, K (reprint author), Nagoya Univ, Grad Sch Engn, Dept Chem Syst Engn, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan.
EM yasuda.keiji@material.nagoya-u.ac.jp
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [JP19H02505]
FX This work was supported by JSPS KAKENHI Grant Number JP19H02505.
CR Alheshibri M, 2016, LANGMUIR, V32, P11086, DOI 10.1021/acs.langmuir.6b02489
   BUFFAT P, 1976, PHYS REV A, V13, P2287, DOI 10.1103/PhysRevA.13.2287
   Caruso RA, 2002, LANGMUIR, V18, P7831, DOI 10.1021/la020276f
   Casadonte DJ, 2005, ULTRASON SONOCHEM, V12, P147, DOI 10.1016/j.ultsonch.2003.12.004
   Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+
   Ebina K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065339
   Koda S, 2003, ULTRASON SONOCHEM, V10, P149, DOI 10.1016/S1350-4177(03)00084-1
   Koltypin Y, 1997, J MATER CHEM, V7, P2453, DOI 10.1039/a704008c
   Link S, 1999, J PHYS CHEM B, V103, P8410, DOI 10.1021/jp9917648
   Liu S, 2016, LANGMUIR, V32, P11295, DOI 10.1021/acs.langmuir.6b01621
   Louisnard O, 2003, PHYS REV E, V67, DOI 10.1103/PhysRevE.67.036610
   Matsuno H, 2014, LANGMUIR, V30, P15238, DOI 10.1021/la5035883
   Minamikawa K, 2015, ENVIRON RES LETT, V10, DOI 10.1088/1748-9326/10/8/084012
   NEPPIRAS EA, 1980, PHYS REP, V61, P159, DOI 10.1016/0370-1573(80)90115-5
   Oh SH, 2017, LANGMUIR, V33, P3818, DOI 10.1021/acs.langmuir.7b00510
   Okitsu K, 2005, J PHYS CHEM B, V109, P20673, DOI 10.1021/jp0549374
   Okitsu K, 2009, LANGMUIR, V25, P7786, DOI 10.1021/la9017739
   Park JE, 2006, ULTRASON SONOCHEM, V13, P237, DOI 10.1016/j.ultsonch.2005.04.003
   Safonov VL, 2013, COLLOID SURFACE A, V436, P333, DOI 10.1016/j.colsurfa.2013.06.043
   Sakai T, 2014, ULTRASON SONOCHEM, V21, P946, DOI 10.1016/j.ultsonch.2013.12.010
   Sakai T, 2009, COLLOID SURFACE A, V347, P18, DOI 10.1016/j.colsurfa.2008.10.037
   Saliman MA, 2016, JPN J APPL PHYS, V55, DOI 10.7567/JJAP.55.07KE05
   Sari TK, 2018, ANAL SCI, V34, P155, DOI 10.2116/analsci.34.155
   Takahashi F, 2018, TALANTA, V188, P651, DOI 10.1016/j.talanta.2018.06.042
   Takahashi M, 2005, J PHYS CHEM B, V109, P21858, DOI 10.1021/jp0445270
   Temesgen T, 2017, ADV COLLOID INTERFAC, V246, P40, DOI 10.1016/j.cis.2017.06.011
   van Bokhoven JA, 2009, CHIMIA, V63, P257, DOI 10.2533/chimia.2009.257
   WEISER HB, 1933, INORGANIC COLLOID CH
   Xu Z, 2011, JPN J APPL PHYS, V50, DOI 10.1143/JJAP.50.07HE07
   Yasuda K, 2019, CHEM ENG SCI, V195, P455, DOI 10.1016/j.ces.2018.09.044
   Yasui K, 2016, LANGMUIR, V32, P11101, DOI 10.1021/acs.langmuir.5b04703
   Zhu J, 2016, LANGMUIR, V32, P11203, DOI 10.1021/acs.langmuir.6b01004
NR 32
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115527
DI 10.1016/j.ces.2020.115527
PG 7
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600032
DA 2020-05-12
ER

PT J
AU Yooprasertchuti, K
   Dechadilok, P
AF Yooprasertchuti, Kittipitch
   Dechadilok, Panadda
TI Effect of molecular shape of suspended colloids on an osmotic flow
   across a fibrous membrane
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Endothelial glycocalyx layer; Osmosis; Serum albumins; Fibrous membrane;
   Partition coefficient
ID ENDOTHELIAL GLYCOCALYX STRUCTURE; SERUM-ALBUMIN; REFLECTION
   COEFFICIENTS; CAPILLARY-PERMEABILITY; SIEVE PLUGS; IN-VIVO;
   MACROMOLECULES; CHARGE; CELLS; MECHANISM
AB Effects of colloid molecular shape on osmotic reflection coefficients (sigma(v)) in a liquid-filled hexagonal array of cylinders are investigated by employing lubrication theory. Results demonstrate that, for spheroids with equal Stokes-Einstein radius (alpha(SE)), an increase in the deviation from unity of the axial ratio (gamma) corresponds to an increased sigma(v). If the fiber matrix geometry is that of the quasiperiodic substructure of the glycocalyx layer adjacent to endothelial surfaces, believed to be the primary barrier for serum albumins, sigma(v) of a spheroid with alpha(SE) close to that of serum albumins is larger than sigma(v) of a sphere, and close to experimentally obtained sigma(v) of serum albumins even when the electrostatic interaction is not included, suggesting that serum albumin molecular shape contributes to its ability to prevent intravascular fluid extravasation, and, given the close correspondence between osmotic and filtration reflection coefficients, helps minimize albumin loss from microcirculation. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Yooprasertchuti, Kittipitch; Dechadilok, Panadda] Chulalongkorn Univ, Fac Sci, Dept Phys, 254 Payathai Rd, Bangkok 10330, Thailand.
   [Yooprasertchuti, Kittipitch] Natl Univ Singapore, Fac Sci, Dept Phys, 2 Sci Dr 3,Blk S13,02-04, Singapore 117551, Singapore.
RP Dechadilok, P (reprint author), Chulalongkorn Univ, Fac Sci, Dept Phys, 254 Payathai Rd, Bangkok 10330, Thailand.
EM kittipitchy@u.nus.edu; panadda.D@chula.ac.th
FU Development and Promotion of Science and Technology Talents Project, The
   Institute for the Promotion of Teaching Science and Technology,
   Thailand; Faculty of Science, Chulalongkorn UniversityChulalongkorn
   University
FX K. Y. was supported by the Development and Promotion of Science and
   Technology Talents Project, The Institute for the Promotion of Teaching
   Science and Technology, Thailand. A financial support from Faculty of
   Science, Chulalongkorn University, is gratefully acknowledged. We would
   like to thank the editor and the reviewers for their time and advice,
   and would like to thank K. Krusong and R. Roongtamskul for their
   suggestions during the manuscript revision.
CR ADAMSON RH, 1988, AM J PHYSIOL, V254, pH304
   Akinaga T, 2008, J PHYS SOC JPN, V77, DOI 10.1143/JPSJ.77.053401
   Ali MM, 2019, AM J PHYSIOL-HEART C, V316, pH647, DOI 10.1152/ajpheart.00090.2018
   Amiri M, 2010, J PHARMACEUT BIOMED, V51, P1097, DOI 10.1016/j.jpba.2009.11.011
   ANDERSON JL, 1974, BIOPHYS J, V14, P957, DOI 10.1016/S0006-3495(74)85962-X
   ANDERSON JL, 1981, J THEOR BIOL, V90, P405, DOI 10.1016/0022-5193(81)90321-0
   Arkill KP, 2011, BIOPHYS J, V101, P1046, DOI 10.1016/j.bpj.2011.07.036
   Arques S, 2018, EUR J INTERN MED, V52, P8, DOI 10.1016/j.ejim.2018.04.014
   Arques S, 2011, J CARD FAIL, V17, P451, DOI 10.1016/j.cardfail.2011.02.010
   Bai K, 2012, J R SOC INTERFACE, V9, P2290, DOI 10.1098/rsif.2011.0901
   Becker BF, 2010, CARDIOVASC RES, V87, P300, DOI 10.1093/cvr/cvq137
   Betteridge KB, 2017, J PHYSIOL-LONDON, V595, P5015, DOI 10.1113/JP274167
   Bhalla G., 2007, J COLLOID INTERF SCI, V333, P363, DOI DOI 10.1016/J.BPJ.2009.06.038
   Bhalla G, 2007, J MEMBRANE SCI, V306, P116, DOI 10.1016/j.memsci.2007.08.025
   Bhalla G, 2009, BIOPHYS J, V97, P1595, DOI 10.1016/j.bpj.2009.06.038
   BRANNON JH, 1982, J POLYM SCI POL PHYS, V20, P857, DOI 10.1002/pol.1982.180200508
   Brenner H., 1974, International Journal of Multiphase Flow, V1, P195, DOI 10.1016/0301-9322(74)90018-4
   Broekhuizen LN, 2010, DIABETOLOGIA, V53, P2646, DOI 10.1007/s00125-010-1910-x
   Curry FE, 2012, ANN BIOMED ENG, V40, P828, DOI 10.1007/s10439-011-0429-8
   CURRY FE, 1976, J PHYSIOL-LONDON, V261, P319, DOI 10.1113/jphysiol.1976.sp011561
   CURRY FE, 1989, AM J PHYSIOL, V257, pH1354
   Curry FE, 2019, BIORHEOLOGY, V56, P113, DOI 10.3233/BIR-180198
   Damiano ER, 2002, BIOPHYS J, V82, P1153, DOI 10.1016/S0006-3495(02)75474-X
   Davies HS, 2018, PHYS REV LETT, V120, DOI 10.1103/PhysRevLett.120.198001
   Dechadilok P, 2006, IND ENG CHEM RES, V45, P6953, DOI 10.1021/ie051387n
   DEEN WM, 1987, AICHE J, V33, P1409, DOI 10.1002/aic.690330902
   Ebong EE, 2011, ARTERIOSCL THROM VAS, V31, P1908, DOI 10.1161/ATVBAHA.111.225268
   Feng J, 2000, J FLUID MECH, V422, P281, DOI 10.1017/S0022112000001725
   Ferrer ML, 2001, BIOPHYS J, V80, P2422, DOI 10.1016/S0006-3495(01)76211-X
   Fu BMM, 2003, AM J PHYSIOL-HEART C, V284, pH1240, DOI 10.1152/ajpheart.00467.2002
   Geislinger TM, 2014, ADV COLLOID INTERFAC, V208, P161, DOI 10.1016/j.cis.2014.03.002
   Graetz TJ, 2017, NAT REV NEPHROL, V13, P5, DOI 10.1038/nrneph.2016.171
   Guell D.C., 1991, THESIS
   HARALDSSON B, 1984, ACTA PHYSIOL SCAND, V122, P93, DOI 10.1111/j.1748-1716.1984.tb07486.x
   HUXLEY VH, 1987, AM J PHYSIOL, V252, pH188
   HUXLEY VH, 1993, AM J PHYSIOL, V264, pH1428
   Iba T, 2019, J THROMB HAEMOST, V17, P283, DOI 10.1111/jth.14371
   Janczyk P, 2010, J ELECTRON MICROSC, V59, P291, DOI 10.1093/jmicro/dfq007
   Lazzara MJ, 2000, J COLLOID INTERF SCI, V226, P112, DOI 10.1006/jcis.2000.6800
   LAZZARA MJ, 2001, AM J PHYSIOL-RENAL, V281, pF86
   Losserand S, 2019, MICROVASC RES, V124, P30, DOI 10.1016/j.mvr.2019.02.003
   MICHEL CC, 1980, J PHYSIOL-LONDON, V309, P341, DOI 10.1113/jphysiol.1980.sp013512
   Michel CC, 1999, PHYSIOL REV, V79, P703
   Michel CC, 1997, EXP PHYSIOL, V82, P1
   MICHEL CC, 1988, J PHYSIOL-LONDON, V404, P1
   MICHEL CC, 1981, J PHYSL, V316, pP5
   MITCHELL BD, 1986, J COLLOID INTERF SCI, V113, P132, DOI 10.1016/0021-9797(86)90213-4
   Nieuwdorp M, 2006, DIABETES, V55, P1127, DOI 10.2337/diabetes.55.04.06.db05-1619
   OPONG WS, 1992, J MEMBRANE SCI, V72, P277, DOI 10.1016/0376-7388(92)85055-N
   Potter DR, 2008, CIRC RES, V102, P770, DOI 10.1161/CIRCRESAHA.107.160226
   RAY PM, 1960, PLANT PHYSIOL, V35, P783, DOI 10.1104/pp.35.6.783
   Reed C.C., 1978, THESIS
   REED RK, 1988, ACTA PHYSIOL SCAND, V134, P375, DOI 10.1111/j.1748-1716.1988.tb08504.x
   Reitsma S, 2011, J VASC RES, V48, P297, DOI 10.1159/000322176
   RENKIN EM, 1988, AM J PHYSIOL, V255, pH458
   RIPPE B, 1979, ACTA PHYSIOL SCAND, V105, P171, DOI 10.1111/j.1748-1716.1979.tb06329.x
   Rostgaard J, 1997, MICROVASC RES, V53, P1, DOI 10.1006/mvre.1996.1987
   Rostgaard J, 2002, CELLS TISSUES ORGANS, V170, P132, DOI 10.1159/000046186
   Satchell S, 2013, NAT REV NEPHROL, V9, P717, DOI 10.1038/nrneph.2013.197
   Squire JM, 2001, J STRUCT BIOL, V136, P239, DOI 10.1006/jsbi.2002.4441
   SQUIRE PG, 1968, BIOCHEMISTRY-US, V7, P4261, DOI 10.1021/bi00852a018
   STAVERMAN AJ, 1951, RECL TRAV CHIM PAY B, V70, P344
   Stevens AP, 2007, AM J PHYSIOL-LUNG C, V293, pL328, DOI 10.1152/ajplung.00390.2006
   Sugihara-Seki M, 2006, J FLUID MECH, V551, P309, DOI 10.1017/S0022l12005008359
   Sugihara-Seki M, 2010, J FLUID MECH, V664, P174, DOI 10.1017/S0022112010003708
   Tarbell JM, 2014, ANNU REV BIOMED ENG, V16, P505, DOI 10.1146/annurev-bioeng-071813-104908
   Tse D, 2010, SEMIN THROMB HEMOST, V36, P236, DOI 10.1055/s-0030-1253447
   Ueda A, 2004, AM J PHYSIOL-HEART C, V287, pH2287, DOI 10.1152/ajpheart.00808.2003
   van den Berg BM, 2009, PFLUG ARCH EUR J PHY, V457, P1199, DOI 10.1007/s00424-008-0590-6
   Vink H, 1996, CIRC RES, V79, P581, DOI 10.1161/01.RES.79.3.581
   Weinbaum S, 2003, P NATL ACAD SCI USA, V100, P7988, DOI 10.1073/pnas.1332808100
   Weinbaum S, 1998, ANN BIOMED ENG, V26, P627, DOI 10.1114/1.134
   Weisman A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058783
   Zhang WJ, 2019, CHEM SCI, V10, P7779, DOI 10.1039/c9sc02039j
   Zhang XB, 2006, AM J PHYSIOL-HEART C, V290, pH844
NR 75
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115521
DI 10.1016/j.ces.2020.115521
PG 14
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600026
DA 2020-05-12
ER

PT J
AU Yu, WC
   Fede, P
   Yazdanpanah, M
   Amblard, B
   Euzenat, F
   Simonin, O
AF Yu, Wenchao
   Fede, Pascal
   Yazdanpanah, Mahdi
   Amblard, Benjamin
   Euzenat, Florian
   Simonin, Olivier
TI Gas-solid fluidized bed simulations using the filtered approach:
   Validation against pilot-scale experiments
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fluidized bed; Subgrid scale drag; Euler-Euler approach; CFD
ID NUMERICAL-SIMULATION; PARTICLE FLOWS; EULERIAN SIMULATION; CONSTITUTIVE
   MODELS; 2-FLUID MODELS; VERIFICATION; CLOSURES; DRAG
AB Numerical simulations of large-scale fluidized beds still remain challenging due to the computational limitation and experimental validation. In the present work, a CFD study of a large-scale fluidized bed is investigated using the NEPTUNE_CFD code based on an Eulerian n-fluid modeling approach. A SubGrid Scale (SGS) drag model based on the filtered approach is used to take into account the effect of very small solid structures unresolved with the coarse mesh. The numerical results are compared with the experimental data carried out in a pilot-scale cold-flow fluidized bed unit and provided by Particulate Solid Research Inc (PSRI). By applying the SGS drag model without any specific or empirical tuning, reasonably good grid-independence is achieved. The flow regimes inside the fluidized bed are well predicted for all the superficial gas velocities studied here. The bed density profiles and the solid entrainment fluxes are also in good agreement with the experimental measurement. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Yu, Wenchao; Fede, Pascal; Simonin, Olivier] Univ Toulouse, IMFT, CNRS, FR-31400 Toulouse, France.
   [Yazdanpanah, Mahdi; Euzenat, Florian] TRTG, F-76700 Harfleur, France.
   [Amblard, Benjamin] IFP Energies Nouvelles, BP3, F-69360 Solaize, France.
RP Fede, P (reprint author), Univ Toulouse, IMFT, CNRS, FR-31400 Toulouse, France.
EM pascal.fede@imft.fr
FU CALMIPRegion Occitanie [2018 -p0111]; CINES Occigen [A0022B06012,
   A0042B06012]
FX This work was performed using HPC resources from CALMIP (Grant 2018
   -p0111) and from CINES Occigen under the allocation no A0022B06012 and
   no A0042B06012. The authors are grateful to S. Sundaram, A. Issangya, B.
   Freireich, R. Cocco and S.B. Reddy Karri from Particulate Solid Research
   Inc. for sharing their experimental data in the 0.9 m diameter fluidized
   bed.
CR Agrawal K, 2001, J FLUID MECH, V445, P151, DOI 10.1017/S0022112001005663
   Amblard B, 2017, CHEM ENG SCI, V170, P731, DOI 10.1016/j.ces.2016.12.055
   Andrews AT, 2005, IND ENG CHEM RES, V44, P6022, DOI 10.1021/ie0492193
   Bennani L, 2017, CHEM ENG RES DES, V120, P333, DOI 10.1016/j.cherd.2017.01.028
   Cloete JH, 2018, CHEM ENG SCI, V192, P930, DOI 10.1016/j.ces.2018.06.041
   Cloete JH, 2018, CHEM ENG SCI, V192, P906, DOI 10.1016/j.ces.2018.06.040
   ERGUN S, 1952, CHEM ENG PROG, V48, P89
   Fede P, 2016, CHEM ENG SCI, V142, P215, DOI 10.1016/j.ces.2015.11.016
   Fullmer WD, 2017, ANNU REV FLUID MECH, V49, P485, DOI 10.1146/annurev-fluid-010816-060028
   GERMANO M, 1991, PHYS FLUIDS A-FLUID, V3, P1760, DOI 10.1063/1.857955
   Gobin A, 2003, INT J NUMER METH FL, V43, P1199, DOI 10.1002/fld.542
   Hamidouche Z., 2018, NUMERICAL SIMULATI 1, V52, P55
   Igci Y, 2008, AICHE J, V54, P1431, DOI 10.1002/aic.11481
   Igci Y, 2011, IND ENG CHEM RES, V50, P13190, DOI 10.1021/ie200190q
   Igci Y, 2011, AICHE J, V57, P2691, DOI 10.1002/aic.12486
   Li J., 1994, PARTICLE FLUID 2 PHA
   Li J., 2007, 12 INT C FLUID NEW H
   Li JH, 2003, CHEM ENG SCI, V58, P521, DOI 10.1016/S0009-2509(02)00577-8
   LILLY DK, 1992, PHYS FLUIDS A-FLUID, V4, P633, DOI 10.1063/1.858280
   Milioli CC, 2013, AICHE J, V59, P3265, DOI 10.1002/aic.14130
   Ozel A, 2013, INT J MULTIPHAS FLOW, V55, P43, DOI 10.1016/j.ijmultiphaseflow.2013.04.002
   Parmentier JF, 2012, AICHE J, V58, P1084, DOI 10.1002/aic.12647
   Sarkar A, 2016, CHEM ENG SCI, V152, P443, DOI 10.1016/j.ces.2016.06.023
   Schneiderbauer S, 2017, AICHE J, V63, P3544, DOI 10.1002/aic.15684
   Schneiderbauer S, 2014, AICHE J, V60, P839, DOI 10.1002/aic.14321
   Schneiderbauer S, 2013, AICHE J, V59, P4077, DOI 10.1002/aic.14155
   Simonin O, 2002, J TURBUL, V3
   Simonin O., 2000, LECT SERIES, V6
   Srivastava A, 2003, POWDER TECHNOL, V129, P72, DOI 10.1016/S0032-5910(02)00132-8
   Sundaresan S, 2018, ANNU REV CHEM BIOMOL, V9, P61, DOI 10.1146/annurev-chembioeng-060817-084025
   van der Hoef MA, 2008, ANNU REV FLUID MECH, V40, P47, DOI 10.1146/annurev.fluid.40.111406.102130
   Wang JW, 2008, CHEM ENG SCI, V63, P1553, DOI 10.1016/j.ces.2007.11.023
   Wang JW, 2009, IND ENG CHEM RES, V48, P5567, DOI 10.1021/ie900247t
   Wen C.Y., 1966, CHEM ENG PROGR S SER, V62, P100, DOI DOI 10.1016/S0032-0633(98)00014-2
NR 34
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115472
DI 10.1016/j.ces.2020.115472
PG 13
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600001
DA 2020-05-12
ER

PT J
AU Yuan, XF
   Ou, C
   Wang, YL
   Yang, CH
   Gui, WH
AF Yuan, Xiaofeng
   Ou, Chen
   Wang, Yalin
   Yang, Chunhua
   Gui, Weihua
TI A novel semi-supervised pre-training strategy for deep networks and its
   application for quality variable prediction in industrial processes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Quality prediction; Soft sensor; Deep learning; Stacked autoencoder
   (SAE); Semi-supervised SAE (SS-SAE)
ID SOFT-SENSOR; REGRESSION-MODEL; ALGORITHM; AUTOENCODER; FRAMEWORK;
   MACHINE
AB Deep learning-based soft sensor has been a hot topic for quality variable prediction in modern industrial processes. Feature representation with deep learning is the key step to build an accurate and reliable soft sensor model from massive process data. To deal with the limited labeled data and abundant unlabeled data, a semi-supervised pre-training strategy is proposed for deep learning network in this paper, which is based on semi-supervised stacked autoencoder (SS-SAE). For traditional deep networks like SAE, the pre-training procedure is unsupervised and may discard important information in the labeled data. Different from them, SS-SAE automatically adjusts the training strategy according to the given data type. For unlabeled data, it learns the shape of the input distribution layer by layer. While for labeled data, it additionally learns quality-related features with the guidance of quality information. The proposed method is validated on two refining industries of a debutanizer column and a hydrocracking process. The results show that SS-SAE can utilize both labeled and unlabeled data to extract quality-relevant features for soft sensor modeling, which is superior to multi-layer neural network, traditional SAE and DBN. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Yuan, Xiaofeng; Ou, Chen; Wang, Yalin; Yang, Chunhua; Gui, Weihua] Cent South Univ, Sch Automat, Changsha 410083, Hunan, Peoples R China.
RP Ou, C; Wang, YL (reprint author), Cent South Univ, Sch Automat, Changsha 410083, Hunan, Peoples R China.
EM 657943838@qq.com; ylwang@csu.edu.cn
FU National Key Research and Development Program of China [2018YFB1701100];
   National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China [U1911401, 61703440, 61590921];
   Innovationdriven plan in Central South University [2018CX011];
   Fundamental Research Funds for the Central Universities of Central South
   University [2019zzts568]; Hunan Postgraduate Research Innovation Project
   [2019zzts148]
FX This paper is supported in part by National Key Research and Development
   Program of China (2018YFB1701100), and in part by National Natural
   Science Foundation of China (NSFC) (U1911401, 61703440, 61590921), and
   in part by Innovationdriven plan in Central South University
   (2018CX011), and in part by the Fundamental Research Funds for the
   Central Universities of Central South University (2019zzts568), and in
   part by the Hunan Postgraduate Research Innovation Project
   (2019zzts148).
CR Alain G, 2014, J MACH LEARN RES, V15, P3563
   Becker PJ, 2017, COMPUT CHEM ENG, V98, P70, DOI 10.1016/j.compchemeng.2016.11.035
   Bengio Y., 2007, P ADV NEUR INF PROC, P153
   Bengio Y., 2015, LECT NOTES COMPUT SC, V7700, P437
   Bosca S, 2011, CHEM ENG SCI, V66, P5127, DOI 10.1016/j.ces.2011.07.008
   Chen GY, 2017, CHIN CONTR CONF, P4488, DOI 10.23919/ChiCC.2017.8028065
   Chen N, 2018, IEEE T INSTRUM MEAS, V67, P2001, DOI 10.1109/TIM.2018.2810678
   Dai J., 2019, ISA T, DOI [10.1016/j.isatra.2019.1008.1023., DOI 10.1016/J.ISATRA.2019.1008.1023]
   Erhan D, 2010, J MACH LEARN RES, V11, P625
   Farizhandi AAK, 2016, CHEM ENG SCI, V155, P210, DOI 10.1016/j.ces.2016.08.015
   Fortuna L, 2005, CONTROL ENG PRACT, V13, P499, DOI 10.1016/j.conengprac.2004.04.013
   Gao SH, 2015, IEEE T INF FOREN SEC, V10, P2108, DOI 10.1109/TIFS.2015.2446438
   Ge ZQ, 2013, IND ENG CHEM RES, V52, P3543, DOI 10.1021/ie302069q
   Gupta S, 2009, COMPUT CHEM ENG, V33, P1202, DOI 10.1016/j.compchemeng.2008.12.009
   Hinton GE, 2006, NEURAL COMPUT, V18, P1527, DOI 10.1162/neco.2006.18.7.1527
   Huang B., 2013, DYNAMIC MODELLING PR
   Jana AK, 2009, COMPUT CHEM ENG, V33, P1484, DOI 10.1016/j.compchemeng.2009.03.005
   Kadlec P, 2009, COMPUT CHEM ENG, V33, P795, DOI 10.1016/j.compchemeng.2008.12.012
   Kaneko H, 2014, AICHE J, V60, P600, DOI 10.1002/aic.14299
   Kano M, 2008, COMPUT CHEM ENG, V32, P12, DOI 10.1016/j.compchemeng.2007.07.005
   Kim S, 2013, IND ENG CHEM RES, V52, P12346, DOI 10.1021/ie303488m
   Liu Y, 2013, CHEM ENG SCI, V102, P602, DOI 10.1016/j.ces.2013.07.002
   Ma JS, 2015, J CHEM INF MODEL, V55, P263, DOI 10.1021/ci500747n
   Ma M, 2015, AICHE J, V61, P518, DOI 10.1002/aic.14663
   Maiti SB, 2018, CHEM ENG SCI, V176, P233, DOI 10.1016/j.ces.2017.10.050
   Na J, 2018, CHEM ENG SCI, V181, P68, DOI 10.1016/j.ces.2018.02.008
   Qin Y, 2019, CHEM ENG SCI, V199, P28, DOI 10.1016/j.ces.2019.01.011
   Shang C, 2014, J PROCESS CONTR, V24, P223, DOI 10.1016/j.jprocont.2014.01.012
   Shao WM, 2019, CHEM ENG SCI, V193, P394, DOI 10.1016/j.ces.2018.09.031
   Shao WM, 2015, CHEM ENG RES DES, V95, P113, DOI 10.1016/j.cherd.2015.01.006
   Shardt YAW, 2015, IEEE T IND ELECTRON, V62, P3843, DOI 10.1109/TIE.2014.2364561
   Sharmin R, 2006, CHEM ENG SCI, V61, P6372, DOI 10.1016/j.ces.2006.05.046
   Su HP, 2019, CHEM ENG SCI, V202, P186, DOI 10.1016/j.ces.2019.03.037
   Sun KN, 2017, CHIN CONTR CONF, P4476, DOI 10.23919/ChiCC.2017.8028063
   Vincent P, 2010, J MACH LEARN RES, V11, P3371
   Wang Y., 2019, ISA T, DOI [10.1016/j.isatra.2019.1007.1001., DOI 10.1016/J.ISATRA.2019.1007.1001]
   Wang YL, 2019, J CHEMOMETR, V33, DOI 10.1002/cem.3185
   Wang YL, 2018, IEEE ACCESS, V6, P20995, DOI 10.1109/ACCESS.2018.2825451
   Yao L, 2018, IEEE T IND ELECTRON, V65, P1490, DOI 10.1109/TIE.2017.2733448
   Yoshua B., 2009, LEARNING DEEP ARCHIT
   Yu J, 2018, IEEE T IND ELECTRON, V65, P5060, DOI 10.1109/TIE.2017.2739691
   Yuan X., 2019, NEUROCOMPUTING, DOI [10.1016/j.neucom.2018.1011.1107, DOI 10.1016/J.NEUCOM.2018.1011.1107]
   Yuan Xiaofeng, 2019, IEEE Trans Neural Netw Learn Syst, DOI 10.1109/TNNLS.2019.2957366
   Yuan XF, 2019, CAN J CHEM ENG, DOI 10.1002/cjce.23665
   Yuan XF, 2020, IEEE T IND INFORM, V16, P3721, DOI 10.1109/TII.2019.2938890
   Yuan XF, 2020, IEEE T IND INFORM, V16, P3168, DOI 10.1109/TII.2019.2902129
   Yuan XF, 2018, PROCEEDINGS OF 2018 IEEE 7TH DATA DRIVEN CONTROL AND LEARNING SYSTEMS CONFERENCE (DDCLS), P1064, DOI 10.1109/DDCLS.2018.8516025
   Yuan XF, 2018, IEEE T IND INFORM, V14, P3235, DOI 10.1109/TII.2018.2809730
   Yuan XF, 2018, IEEE T IND ELECTRON, V65, P1508, DOI 10.1109/TIE.2017.2733443
   Yuan XF, 2017, IEEE T IND INFORM, V13, P532, DOI 10.1109/TII.2016.2610839
   Yuan XF, 2017, IEEE T CONTR SYST T, V25, P1124, DOI 10.1109/TCST.2016.2579609
   Yuan XF, 2014, IND ENG CHEM RES, V53, P13736, DOI 10.1021/ie4041252
   Zhou L, 2014, CHEM ENG SCI, V116, P296, DOI 10.1016/j.ces.2014.04.045
   Zhu JL, 2015, CHEM ENG SCI, V122, P573, DOI 10.1016/j.ces.2014.10.029
NR 54
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115509
DI 10.1016/j.ces.2020.115509
PG 12
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600016
DA 2020-05-12
ER

PT J
AU Zhan, YY
   Shi, J
   Su, MJ
   Luo, Y
   Chu, GW
   Zou, HK
   Chen, JF
AF Zhan, Yuan-Yuan
   Shi, Jie
   Su, Meng-Jun
   Luo, Yong
   Chu, Guang-Wen
   Zou, Hai-Kui
   Chen, Jian-Feng
TI Kinetics of catalytic oxidation of sodium ethyl mercaptide
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Kinetics; Catalytic oxidation; Ultraviolet visual spectra; Density
   functional theory; Statistical test
ID GAS-LIQUID SYSTEMS; TRANSITION-METAL; MIXED THIOLS; PHTHALOCYANINE;
   MECHANISM; COBALT; SULFIDE; OXYGEN; COOXIDATION; EXTRACTION
AB Catalytic oxidation of mercaptide is a significant way to eliminate waste emission of spent caustic and recycle the resource of caustic. However, the kinetics of mercaptide oxidation for spent caustic regeneration is still unclear, which hinders the reactor design. In this work, mechanism analyses and kinetics experiments were conducted to investigate the kinetics of homogeneous catalytic oxidation of sodium ethyl mercaptide. Ultraviolet visual spectra show that mercaptide ion is superior to oxygen molecule adsorbed on the catalyst, which is in accord with the simulations. Reaction mechanism of two-layer adsorption structure was proposed by density functional theory calculations. By applying the method of decoupling macroscopic kinetics and making pseudo-first-order fast reaction hypothesis, the rate expression of the intrinsic kinetics for the oxidation reaction of sodium ethyl mercaptide was proposed as - dC(A)/dt = 6.84 x 10(10) exp (-29584/RT) CACB. A statistical test was carried out to verify the intrinsic kinetics data, showing that the kinetics data were overall reasonable. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Zhan, Yuan-Yuan; Shi, Jie; Su, Meng-Jun; Luo, Yong; Chu, Guang-Wen; Zou, Hai-Kui; Chen, Jian-Feng] Beijing Univ Chem Technol, Res Ctr, Minist Educ High Grav Engn & Technol, Beijing 100029, Peoples R China.
   [Zhan, Yuan-Yuan; Shi, Jie; Su, Meng-Jun; Luo, Yong; Chu, Guang-Wen; Zou, Hai-Kui; Chen, Jian-Feng] Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
RP Luo, Y (reprint author), Beijing Univ Chem Technol, Res Ctr, Minist Educ High Grav Engn & Technol, Beijing 100029, Peoples R China.
EM luoyong@mail.buct.edu.cn
RI Luo, Yong/E-7522-2016
OI Luo, Yong/0000-0001-8300-5277
FU National Key Research and Development Program of China [2017YFB0306504]
FX This work was supported by the National Key Research and Development
   Program of China (No. 2017YFB0306504). We are grateful to the
   ``CHEMCLOUDCOMPUTING"of BUCT for computational support.
CR Afshar AS, 2013, PETROL SCI TECHNOL, V31, P2364, DOI 10.1080/10916466.2011.559508
   Assadi MHN, 2013, RSC ADV, V3, P1442, DOI 10.1039/c2ra22514j
   BASU B, 1993, CATAL REV, V35, P571, DOI 10.1080/01614949308013917
   Billeci F, 2018, GREEN CHEM, V20, P4260, DOI 10.1039/c8gc01615a
   Bricker JC, 2012, TOP CATAL, V55, P1315, DOI 10.1007/s11244-012-9913-0
   CULLIS CF, 1968, J APPL CHEM, V18, P335
   Dance I, 2006, INORG CHEM, V45, P5084, DOI 10.1021/ic060438l
   Danckwerts P.V., 1970, GAS LIQUID REACTIONS, DOI [10.1149/1.2407312., DOI 10.1149/1.2407312]
   Delley B, 2006, J PHYS CHEM A, V110, P13632, DOI 10.1021/jp0653611
   FOMIN VA, 1978, PETROL CHEM+, V18, P62, DOI 10.1016/0031-6458(78)90041-2
   Gao LD, 2009, AICHE J, V55, P3214, DOI 10.1002/aic.11928
   Garcia-Ochoa F, 2004, CHEM ENG SCI, V59, P2489, DOI 10.1016/j.ces.2004.02.009
   Gemoets HPL, 2016, CHEM SOC REV, V45, P83, DOI 10.1039/c5cs00447k
   Hoang H Y, 2018, Environ Technol, P1, DOI 10.1080/09593330.2018.1554003
   HOFFMANN MR, 1979, ENVIRON SCI TECHNOL, V13, P1406, DOI 10.1021/es60159a014
   HOFFMANN MR, 1987, SCI TOTAL ENVIRON, V64, P99, DOI 10.1016/0048-9697(87)90125-2
   LEITAO A, 1989, CHEM ENG SCI, V44, P1245, DOI 10.1016/0009-2509(89)87023-X
   LUCAS WR, 1959, IND ENG CHEM, V51, pA84
   Ma YY, 2019, CHEM ENG SCI, V203, P228, DOI 10.1016/j.ces.2019.03.068
   MACKAY D, 1981, J PHYS CHEM REF DATA, V10, P1175, DOI 10.1063/1.555654
   Mi GJ, 2010, CHINESE J CATAL, V31, P547, DOI 10.1016/S1872-2067(09)60070-X
   NARITA E, 1983, HYDROMETALLURGY, V10, P21, DOI 10.1016/0304-386X(83)90074-9
   Tran NH, 2018, WATER RES, V133, P182, DOI 10.1016/j.watres.2017.12.029
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Poling B. E., 2001, PROPERTIES GASES LIQ
   Sheu SH, 2001, WATER RES, V35, P2017, DOI 10.1016/S0043-1354(00)00466-8
   Sun ZY, 2012, GREEN CHEM, V14, P1909, DOI 10.1039/c2gc16462k
   SWAN CJ, 1968, J APPL CHEM, V18, P340
   Tang SW, 2007, IND ENG CHEM RES, V46, P6442, DOI 10.1021/ie070040c
   Vaiopoulou E, 2016, WATER RES, V92, P38, DOI 10.1016/j.watres.2016.01.039
   VANDEVUSSE JG, 1958, CHEM ENG SCI, V8, P72
   VANHERK AM, 1988, J MOL CATAL, V44, P269, DOI 10.1016/0304-5102(88)80037-3
   Vetere A., 2017, ANGEW CHEM, V129, P11073
   WALLACE TJ, 1964, IND ENG CHEM PROC DD, V3, P237, DOI 10.1021/i260011a010
   Wang HM, 2014, BULL CHEM REACT ENG, V9, P87, DOI 10.9767/bcrec.9.2.5113.87-92
   Wang ZY, 2018, AICHE J, V64, P1330, DOI 10.1002/aic.16016
   Wohrle D., 1991, J INORG ORGANOMET P, V1, P115
   Xan J., 1941, J AM CHEM SOC, V63, P1139, DOI [10.1021/ja01849a073., DOI 10.1021/JA01849A073]
   XIA DH, 1995, IND ENG CHEM RES, V34, P2001, DOI 10.1021/ie00045a009
   Xia DH, 1999, IND ENG CHEM RES, V38, P1291, DOI 10.1021/ie980541l
   Yabroff DL, 1940, IND ENG CHEM, V32, P257, DOI 10.1021/ie50362a022
   Ying JR, 2013, IND ENG CHEM RES, V52, P2548, DOI 10.1021/ie303450u
   Zhan YY, 2019, IND ENG CHEM RES, V58, P14588, DOI 10.1021/acs.iecr.9b02664
   Zhang RG, 2010, APPL SURF SCI, V256, P6717, DOI 10.1016/j.apsusc.2010.04.079
NR 44
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115516
DI 10.1016/j.ces.2020.115516
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600021
DA 2020-05-12
ER

PT J
AU Zhang, X
   Zhang, L
   Fung, KY
   Bakshi, BR
   Ng, KM
AF Zhang, Xiang
   Zhang, Lei
   Fung, Ka Yip
   Bakshi, Bhavik R.
   Ng, Ka Ming
TI Sustainable product design: A life-cycle approach
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sustainable product design; Product recycle; Life cycle sustainability
   assessment; Composite bumper beam; Lithium ion battery
ID ELECTRONIC WASTE; POLYACRYLIC-ACID; CHEMICAL-PRODUCT; RECOVERY;
   PERFORMANCE; TOOL; OPTIMIZATION; GENERATION; CATHODE; LITHIUM
AB A systematic framework is proposed for sustainable chemical product design. The product technical requirements are first identified as design constraints. Then, a base-case product is generated as a reference on top of which a more sustainable product is designed. To do so, the life cycle of base-case product (in particular, whether and how it should be recycled) is decided by using life cycle sustainability assessment (LCSA) or rule-based methods depending on the availability of life cycle inventory data. In addition, the hotspots (i.e., life cycle stages with major impact) are identified. Afterwards, to reduce the impact on hotspots, product design targets and design alternatives are generated using knowledge-base and heuristics. Lastly, LCSA or rule-based methods is applied to decide the most sustainable product from the generated product design alternatives. Two case studies - composite bumper beam and lithium ion battery - are provided to illustrate the framework. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Zhang, Xiang; Zhang, Lei; Fung, Ka Yip; Ng, Ka Ming] Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Clear Water Bay, Hong Kong, Peoples R China.
   [Zhang, Lei] Dalian Univ Technol, Sch Chem Engn, Inst Proc Syst Engn, Dalian 116012, Peoples R China.
   [Bakshi, Bhavik R.] Ohio State Univ, William G Lowrie Dept Chem & Biomol Engn, Columbus, OH 43210 USA.
RP Ng, KM (reprint author), Hong Kong Univ Sci & Technol, Dept Chem & Biol Engn, Clear Water Bay, Hong Kong, Peoples R China.
EM kekmng@ust.hk
RI Zhang, Lei/E-6294-2019; Zhang, Lei/W-4446-2019
OI Zhang, Lei/0000-0002-7519-2858; Zhang, Lei/0000-0002-7519-2858; Bakshi,
   Bhavik/0000-0002-6604-8408
CR Ahmad S, 2018, RESOUR CONSERV RECY, V132, P49, DOI 10.1016/j.resconrec.2018.01.020
   Andrews E.S., 2010, GUID SOC LIF CYCL AS
   Azapagic A, 2014, AICHE J, V60, P3998, DOI 10.1002/aic.14650
   Babi DK, 2015, COMPUT CHEM ENG, V81, P218, DOI 10.1016/j.compchemeng.2015.04.030
   Badurdeen F, 2018, J CLEAN PROD, V200, P756, DOI 10.1016/j.jclepro.2018.07.317
   Bakshi BR, 2019, ANNU REV CHEM BIOMOL, V10, P265, DOI 10.1146/annurev-chembioeng-060718-030332
   Bakshi BR, 2018, ACS SUSTAIN CHEM ENG, V6, P3632, DOI 10.1021/acssuschemeng.7b03953
   Bakshi BR, 2003, AICHE J, V49, P1350, DOI 10.1002/aic.690490602
   Bocken NMP, 2016, J IND PROD ENG, V33, P308, DOI 10.1080/21681015.2016.1172124
   Cai GQ, 2014, IND ENG CHEM RES, V53, P18245, DOI 10.1021/ie5025326
   Cai ZP, 2009, J POWER SOURCES, V189, P547, DOI 10.1016/j.jpowsour.2008.10.040
   Carvalho A, 2013, COMPUT CHEM ENG, V50, P8, DOI 10.1016/j.compchemeng.2012.11.007
   Chan YC, 2018, AICHE J, V64, P2462, DOI 10.1002/aic.16153
   Charter M., 2017, SUSTAINABLE SOLUTION, P167
   Cheng YS, 2009, COMPUT CHEM ENG, V33, P1097, DOI 10.1016/j.compchemeng.2008.10.010
   Chiu MC, 2012, INT J PRECIS ENG MAN, V13, P1259, DOI 10.1007/s12541-012-0169-1
   Chong J, 2011, J POWER SOURCES, V196, P7707, DOI 10.1016/j.jpowsour.2011.04.043
   Chou SL, 2014, PHYS CHEM CHEM PHYS, V16, P20347, DOI 10.1039/c4cp02475c
   Ciroth A., 2011, LIVE CYCLE SUSTAINAB
   Cui JR, 2008, J HAZARD MATER, V158, P228, DOI 10.1016/j.jhazmat.2008.02.001
   Cui JR, 2003, J HAZARD MATER, V99, P243, DOI 10.1016/S0304-3894(03)00061-X
   Cussler E.L., 2011, CHEM PRODUCT DESIGN
   Daoutidis P, 2016, J PROCESS CONTR, V44, P184, DOI 10.1016/j.jprocont.2016.06.002
   Fernandes PT, 2017, CLEAN TECHNOL ENVIR, V19, P775, DOI 10.1007/s10098-016-1265-1
   Fung KY, 2016, COMPUT CHEM ENG, V91, P15, DOI 10.1016/j.compchemeng.2016.03.009
   Ge SQ, 2018, AICHE J, V64, P3614, DOI 10.1002/aic.16329
   Go TF, 2015, J CLEAN PROD, V95, P16, DOI 10.1016/j.jclepro.2015.02.065
   Grigore M. E., 2017, RECYCLING, V2, P1
   Guillen-Cuevas K, 2018, ACS SUSTAIN CHEM ENG, V6, P1411, DOI 10.1021/acssuschemeng.7b03802
   Halim I, 2011, COMPUT CHEM ENG, V35, P1343, DOI 10.1016/j.compchemeng.2011.03.015
   Hanes RJ, 2015, AICHE J, V61, P3320, DOI 10.1002/aic.14918
   Heintz J, 2014, COMPUT CHEM ENG, V71, P362, DOI 10.1016/j.compchemeng.2014.09.009
   Huijbregts M., 2016, RECIPE 2016 LIFE CYC
   Huijbregts M., 1998, INT J LIFE CYCLE ASS, V3, P273, DOI DOI 10.1007/BF02979835
   ISO, 1997, 14040 ISO
   Jaafar I.H., 2007, ENV CONSCIOUS MECH D, V5, P25, DOI DOI 10.1002/9780470168202.CH2
   Kalakul S, 2018, COMPUT CHEM ENG, V116, P37, DOI 10.1016/j.compchemeng.2018.03.029
   Kaya M, 2016, WASTE MANAGE, V57, P64, DOI 10.1016/j.wasman.2016.08.004
   Kim DH, 2015, COMPOS STRUCT, V131, P742, DOI 10.1016/j.compstruct.2015.06.028
   Kloepffer W, 2008, INT J LIFE CYCLE ASS, V13, P89, DOI 10.1065/lca2008.02.376
   Laboratory A.N., 2015, BATPAC VERS 3 0
   Li J, 2007, AICHE J, V53, P2841, DOI 10.1002/aic.11311
   Li Q, 2019, IND ENG CHEM RES, V58, P3118, DOI 10.1021/acs.iecr.8b04899
   Li X, 2016, J CLEAN PROD, V127, P451, DOI 10.1016/j.jclepro.2016.03.139
   Liu Z, 2016, COMPOS STRUCT, V140, P630, DOI 10.1016/j.compstruct.2015.12.031
   Ljungberg LY, 2007, MATER DESIGN, V28, P466, DOI 10.1016/j.matdes.2005.09.006
   MALLICK P.K., 2007, FIBER REINFORCED COM
   Martinez-Guido SI, 2014, ACS SUSTAIN CHEM ENG, V2, P2380, DOI 10.1021/sc500409g
   Neidel T.L., 2013, REPORT INITIAL ASSES
   Nelson P.A., 2011, MODELING PERFORMANCE
   Pappa G, 2001, RESOUR CONSERV RECY, V34, P33, DOI 10.1016/S0921-3449(01)00092-1
   PASTORE CM, 1994, J COMPOS TECH RES, V16, P32
   Ramani K, 2010, J MECH DESIGN, V132, DOI 10.1115/1.4002308
   Rangaiah G.P., 2016, MULTIOBJECTIVE OPTIM
   Ren JZ, 2018, AICHE J, V64, P2103, DOI 10.1002/aic.16149
   Schoggl JP, 2017, J CLEAN PROD, V140, P1602, DOI 10.1016/j.jclepro.2016.09.195
   Schrijvers DL, 2016, INT J LIFE CYCLE ASS, V21, P976, DOI 10.1007/s11367-016-1063-3
   Seay JR, 2015, COMPUT CHEM ENG, V81, P147, DOI 10.1016/j.compchemeng.2015.03.010
   Seider W.D., 2017, PRODUCT PROCESS DESI
   Stouffer DB, 2008, AICHE J, V54, P3040, DOI 10.1002/aic.11720
   Tam SK, 2016, AICHE J, V62, P2740, DOI 10.1002/aic.15271
   Teixeira MA, 2012, AICHE J, V58, P1939, DOI 10.1002/aic.12715
   Tula AK, 2017, COMPUT CHEM ENG, V105, P74, DOI 10.1016/j.compchemeng.2017.01.001
   Tuncuk A, 2012, MINER ENG, V25, P28, DOI 10.1016/j.mineng.2011.09.019
   Van Boeijen A., 2014, DESIGN METHOD DESI 2
   Veit Hugo Marcelo, 2014, Rem: Rev. Esc. Minas, V67, P73, DOI 10.1590/S0370-44672014000100011
   Wang XN, 2018, ENVIRON SCI TECHNOL, V52, P3257, DOI 10.1021/acs.est.7b04659
   WEI J, 2007, PRODUCT ENG MOL STRU
   WESSELINGH JA, 2007, DESIGN DEV BIOL CHEM
   Witik RA, 2013, COMPOS PART A-APPL S, V49, P89, DOI 10.1016/j.compositesa.2013.02.009
   Xue MQ, 2012, ENVIRON SCI TECHNOL, V46, P10556, DOI 10.1021/es301830v
   Zampori L., 2016, GUIDE INTERPRETING L
   Zhang L, 2016, ANNU REV CHEM BIOMOL, V7, P557, DOI 10.1146/annurev-chembioeng-080615-034439
   Zhang X, 2018, COMPUT CHEM ENG, V118, P118, DOI 10.1016/j.compchemeng.2018.06.026
NR 74
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115508
DI 10.1016/j.ces.2020.115508
PG 15
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600015
DA 2020-05-12
ER

PT J
AU Zhu, HW
   Yu, HF
   Jiang, HB
   Hu, YJ
   Jiang, H
   Li, CZ
AF Zhu, Huawei
   Yu, Haifeng
   Jiang, Haibo
   Hu, Yanjie
   Jiang, Hao
   Li, Chunzhong
TI High-efficiency Mo doping stabilized LiNi0.9Co0.1O2 cathode materials
   for rapid charging and long-life Li-ion batteries
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE LiNi0.9Co0.1O2; Mo doping; Rapid charging; Phase transformation; Li-ion
   batteries
ID RICH OXIDE CATHODE; NI-RICH; PERFORMANCE; VOLTAGE; SURFACE; TRANSITION;
   TI
AB Exploring the high-efficiency doping technique is the pivotal to strengthening the lattice of the Ni-rich cathode materials with rapid ions transfer for Li-ion batteries (LIBs). Herein, we have proposed a precursor doping insight with subsequent annealing to synthesize the LiNi0.9-xCo0.1MoxO2 cathode materials without the enrichment of extra components on the surface. The high MoAO bond energy (560.2 KJ/mol) greatly ehnaces the reversibility of H2-H3 phase transformation. Meantime, the Li/Ni disorder and lattice oxygen loss are also impeded due to the Ni substitution by Mo with an accelerated Li+ diffusion kinetic. The optimized LiNi0.89Co0.1Mo0.01O2 gives a quite high reversible capacity of 202.4 mAh g(-1) at 0.2 C and 139.5 mAh g(-1) at 5 C. About 94.4% capacity can still be achieved after 200 cycles, much higher than the corresponding LiNi0.9Co0.1O2 (only 68.3%). This work gives an efficient doping method of the Ni-rich cathode materials for long driving range LIBs. (C) 2020 Published by Elsevier Ltd.
C1 [Zhu, Huawei; Jiang, Hao; Li, Chunzhong] East China Univ Sci & Technol, Sch Chem Engn, Minist Educ, Key Lab Ultrafine Mat, Shanghai 200237, Peoples R China.
   [Zhu, Huawei; Yu, Haifeng; Jiang, Haibo; Hu, Yanjie; Jiang, Hao; Li, Chunzhong] East China Univ Sci & Technol, Shanghai Engn Res Ctr Hierarch Nanomat, Sch Mat Sci & Engn, Shanghai 200237, Peoples R China.
RP Jiang, H; Li, CZ (reprint author), East China Univ Sci & Technol, Sch Chem Engn, Minist Educ, Key Lab Ultrafine Mat, Shanghai 200237, Peoples R China.
EM jianghao@ecust.edu.cn; czli@ecust.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21975074, 91534202, 91834301]; Basic Research
   Program of Shanghai [17JC1402300]; Shanghai Scientific and Technological
   Innovation Project [18JC1410500]; National Program for Support of
   Top-Notch Young Professionals; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [222201718002]
FX This work was supported by the National Natural Science Foundation of
   China (21975074, 91534202, and 91834301), the Basic Research Program of
   Shanghai (17JC1402300), the Shanghai Scientific and Technological
   Innovation Project (18JC1410500), the National Program for Support of
   Top-Notch Young Professionals, and the Fundamental Research Funds for
   the Central Universities (222201718002).
CR Chen ZH, 2010, J MATER CHEM, V20, P7606, DOI 10.1039/c0jm00154f
   Deng ZN, 2017, ADV MATER, V29, DOI 10.1002/adma.201603020
   Du K, 2016, ACS APPL MATER INTER, V8, P17713, DOI 10.1021/acsami.6b05629
   Hou PY, 2019, CHEM ENG J, V378, DOI 10.1016/j.cej.2019.122057
   Kang SH, 2002, J POWER SOURCES, V112, P41, DOI 10.1016/S0378-7753(02)00360-9
   Kim H, 2016, ADV MATER, V28, P4705, DOI [10.1002/adma.201670161, 10.1002/adma.201506256]
   Li JY, 2018, CHEM MATER, V30, P3101, DOI 10.1021/acs.chemmater.8b01077
   Li YC, 2017, ADV ENERGY MATER, V7, DOI 10.1002/aenm.201601397
   Liu D, 2019, ACS SUSTAIN CHEM ENG, V7, P10661, DOI 10.1021/acssuschemeng.9b01312
   Liu W, 2018, NANO ENERGY, V44, P111, DOI 10.1016/j.nanoen.2017.11.010
   Manthiram A., 2016, ADV ENERGY MATER, V6, DOI DOI 10.1002/AENM.201501010
   Myung ST, 2017, ACS ENERGY LETT, V2, P196, DOI 10.1021/acsenergylett.6b00594
   Noh HJ, 2013, J POWER SOURCES, V233, P121, DOI 10.1016/j.jpowsour.2013.01.063
   Park KJ, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201801202
   Park KJ, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201703612
   Ryu HH, 2018, CHEM MATER, V30, P1155, DOI 10.1021/acs.chemmater.7b05269
   Schipper F, 2018, ADV ENERGY MATER, V8, DOI 10.1002/aenm.201701682
   Susai FA, 2019, ACS APPL ENERG MATER, V2, P4521, DOI 10.1021/acsaem.9b00767
   Weigel T, 2019, ACS ENERGY LETT, V4, P508, DOI 10.1021/acsenergylett.8b02302
   Wu F, 2019, NANO ENERGY, V59, P50, DOI 10.1016/j.nanoen.2019.02.027
   Wu F, 2019, CHEMSUSCHEM, V12, P935, DOI 10.1002/cssc.201802304
   Xiao X, 2017, SMALL, V13, DOI 10.1002/smll.201602190
   Xie HB, 2015, J MATER CHEM A, V3, P20236, DOI 10.1039/c5ta05266a
   Xie Q, 2019, CHEM MATER, V31, P938, DOI 10.1021/acs.chemmater.8b03900
   Xu CL, 2019, ACS APPL MATER INTER, V11, P16629, DOI 10.1021/acsami.9b03403
   Xu MQ, 2016, ENERG ENVIRON SCI, V9, P1308, DOI 10.1039/c5ee03360h
   YAMADA S, 1995, J POWER SOURCES, V54, P209, DOI 10.1016/0378-7753(94)02068-E
   Yang J, 2016, ACS APPL MATER INTER, V8, P1297, DOI 10.1021/acsami.5b09938
   You Y, 2018, ANGEW CHEM INT EDIT, V57, P6480, DOI 10.1002/anie.201801533
   Yu HF, 2019, IND ENG CHEM RES, V58, P4108, DOI 10.1021/acs.iecr.8b06162
   Zhan C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3437
   Zhang Y, 2017, J POWER SOURCES, V358, P1, DOI 10.1016/j.jpowsour.2017.05.013
   Zhang YD, 2019, J MATER CHEM A, V7, P20958, DOI 10.1039/c9ta02803j
   Zou LF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11299-2
NR 34
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115518
DI 10.1016/j.ces.2020.115518
PG 8
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600023
DA 2020-05-12
ER

PT J
AU Zhu, SJ
   Ooi, A
   Manasseh, R
   Skvortsov, A
AF Zhu, S. J.
   Ooi, A.
   Manasseh, R.
   Skvortsov, A.
TI Prediction of gas holdup in partially aerated bubble columns using an
   EE-LES coupled model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bubble column; Gas holdup; Large eddy simulation; Eulerian-Eulerian
   model; Interfacial closures
ID LARGE-EDDY-SIMULATION; DYNAMIC FLOW BEHAVIOR; LIQUID FLOW; INTERPHASE
   FORCES; TURBULENCE MODEL
AB Transient gas-liquid flow dynamics in partially aerated square cross-sectioned bubble columns were studied using an Eulerian-Eulerian based large eddy simulation approach. The numerical model was validated with the interfacial closures evaluated for drag, lift and virtual mass forces. The simulation data showed good agreement with both numerical predictions and experimental measurements in the literature. The current model was also shown to be able to predict the global gas holdup in the bubble column up to a very high value. Further simulations were performed to study the influences of initial liquid phase height to width ratio and inlet area to column cross-sectional area ratio on the global gas holdup in the bubble column. The numerical results indicated that the global gas holdup increases linearly with the superficial gas velocity. Thus, an empirical multivariate regression model was proposed to predict the global gas holdup with an adjusted R-square value of 0.99. Crown Copyright (C) 2020 Published by Elsevier Ltd. All rights reserved.
C1 [Zhu, S. J.; Manasseh, R.] Swinburne Univ Technol, Dept Mech Engn & Prod Design Engn, Hawthorn, Vic 3122, Australia.
   [Zhu, S. J.; Ooi, A.] Univ Melbourne, Dept Mech Engn, Melbourne, Vic 3010, Australia.
   [Skvortsov, A.] Def Sci & Technol, Maritime Div, Fishermans Bend 3207, Australia.
RP Zhu, SJ (reprint author), Swinburne Univ Technol, Dept Mech Engn & Prod Design Engn, Hawthorn, Vic 3122, Australia.; Zhu, SJ (reprint author), Univ Melbourne, Dept Mech Engn, Melbourne, Vic 3010, Australia.
EM sjzhu@swin.edu.au
FU Defence Science and Technology
FX This research project was sponsored by Defence Science and Technology.
   The authors acknowledge Paul Dylejko for his helpful discussions and
   comments.
CR Bai W, 2012, IND ENG CHEM RES, V51, P1949, DOI 10.1021/ie102557h
   Becker S, 1994, CHEM ENG SCI, V49, P5747, DOI 10.1016/0009-2509(94)00290-8
   Burns A.D., 2004, P 5 INT C MULT FLOW
   Buwa VV, 2002, CHEM ENG SCI, V57, P4715, DOI 10.1016/S0009-2509(02)00274-9
   Darmana D, 2006, J COMPUT PHYS, V220, P216, DOI 10.1016/j.jcp.2006.05.011
   Deen NG, 2001, CHEM ENG SCI, V56, P6341, DOI 10.1016/S0009-2509(01)00249-4
   Dhotre MT, 2008, CHEM ENG J, V136, P337, DOI 10.1016/j.cej.2007.04.016
   Dhotre MT, 2013, INT J CHEM ENG, DOI 10.1155/2013/343276
   Dhotre MT, 2009, CHEM ENG SCI, V64, P2692, DOI 10.1016/j.ces.2009.02.040
   Fox RO, 2012, ANNU REV FLUID MECH, V44, P47, DOI 10.1146/annurev-fluid-120710-101118
   GRACE JR, 1976, T I CHEM ENG-LOND, V54, P167
   ISHII M, 1979, AICHE J, V25, P843, DOI 10.1002/aic.690250513
   Jakobsen HA, 1997, IND ENG CHEM RES, V36, P4052, DOI 10.1021/ie970276o
   Liu ZQ, 2018, CHEM ENG J, V338, P465, DOI 10.1016/j.cej.2018.01.051
   Lopez de Bertodano M., 1992, THESIS
   Loth E., 2005, MULTIPHASE FLOW HDB, P13
   Ma T, 2016, NUCL ENG DES, V299, P146, DOI 10.1016/j.nucengdes.2015.08.010
   Masood RMA, 2014, CHEM ENG SCI, V108, P154, DOI 10.1016/j.ces.2014.01.004
   Milelli M., 2001, DIRECT LARGE EDDY SI, VIV, P461
   Mohammadi MH, 2019, CHEM ENG SCI, V208, DOI 10.1016/j.ces.2019.115156
   Niceno B, 2008, CHEM ENG SCI, V63, P3923, DOI 10.1016/j.ces.2008.04.050
   Niceno B, 2009, SCI TECHNOL NUCL INS, V2009, DOI 10.1155/2009/410272
   Pfleger D, 1999, CHEM ENG SCI, V54, P5091, DOI 10.1016/S0009-2509(99)00261-4
   Pfleger D, 2001, CHEM ENG SCI, V56, P1737, DOI 10.1016/S0009-2509(00)00403-6
   Sato Y., 1975, International Journal of Multiphase Flow, V2, P79, DOI 10.1016/0301-9322(75)90030-0
   Schiller L, 1933, Z VER DTSCH ING, V77, P318
   Smagorinsky J., 1963, MON WEATHER REV, V91, P99, DOI [10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, DOI 10.1175/1520-0493(1963)091<0099:GCEWTP>2.3.CO;2, 10.1175/1520-0493(1963)091, 10.1175/1520-0493(1963)091<less than>0099:GCEWTP<greater than>2.3.CO;2]
   Sokolichin A, 1999, CHEM ENG SCI, V54, P2273, DOI 10.1016/S0009-2509(98)00420-5
   Sungkorn R, 2011, CHEM ENG SCI, V66, P2745, DOI 10.1016/j.ces.2011.03.032
   Tabib MV, 2008, CHEM ENG J, V139, P589, DOI 10.1016/j.cej.2007.09.015
   Tabib MV, 2011, CHEM ENG SCI, V66, P3071, DOI 10.1016/j.ces.2011.03.058
   Tomiyama A, 2002, CHEM ENG SCI, V57, P1849, DOI 10.1016/S0009-2509(02)00085-4
   Troshko AA, 2001, INT J MULTIPHAS FLOW, V27, P1965, DOI 10.1016/S0301-9322(01)00043-X
   Zhang D, 2006, CHEM ENG SCI, V61, P7593, DOI 10.1016/j.ces.2006.08.053
   Zhu SJ, 2017, PHYS REV FLUIDS, V2, DOI 10.1103/PhysRevFluids.2.064801
   Zhu S.J., 2019, EUR HEART J
   Zhu SJ, 2015, J BIOMECH ENG-T ASME, V137, DOI 10.1115/1.4028965
NR 37
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD MAY 18
PY 2020
VL 217
AR 115492
DI 10.1016/j.ces.2020.115492
PG 8
WC Engineering, Chemical
SC Engineering
GA LF3QZ
UT WOS:000527336600004
DA 2020-05-12
ER

PT J
AU Babu, P
   Nambiar, A
   Chong, ZR
   Daraboina, N
   Albeirutty, M
   Bamaga, OA
   Linga, P
AF Babu, Ponnivalavan
   Nambiar, Abhishek
   Chong, Zheng Rong
   Daraboina, Nagu
   Albeirutty, Mohammad
   Bamaga, Omar A.
   Linga, Praveen
TI Hydrate-based desalination (HyDesal) process employing a novel prototype
   design
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Gas hydrates; Desalination; Clathrate process; Seawater; Water-energy
   nexus
ID PRE-COMBUSTION CAPTURE; SEPARATION HBGS PROCESS; CARBON-DIOXIDE;
   SEAWATER DESALINATION; WATER; NEXUS; LNG; TEMPERATURE; PRESSURE;
   KINETICS
AB Water and energy are intricately interlinked and therefore it is imperative to develop sustainable technologies to strengthen water-energy nexus. One such industry where the energy - water nexus can be addressed is at Liquefied natural gas (LNG) regasification terminals. At the LNG regasification terminals, LNG is converted back to natural gas by heating using seawater which gets cooled during the process. This cooled seawater is dumped back to the sea leading to wastage of cold energy. One potential technology that can harvest and utilize this waste cold energy is the hydrate-based desalination (HyDesal) process. HyDesal process is based on a liquid to solid phase change by employing a suitable hydrate former for the phase change. While the HyDesal process was proposed almost 70 years ago, it was never commercialized primarily due to slow hydrate formation, inefficient hydrate crystal separation from brine and refrigeration. To address the above challenges, we proposed an innovative HyDesal process utilizing LNG cold energy with enhanced water recovery based on the unusual behavior of propane. In this study, we present the design and demonstration of a prototype for the HyDesal process. With our innovative prototype design, we carried out water recovery experiments and salt rejection studies. Water recovery of 34.85 (+/- 0.35)% and salt rejection of 87.5 (+/- 1.84)% was achieved with 3 wt% NaCl solution. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Babu, Ponnivalavan; Nambiar, Abhishek; Chong, Zheng Rong; Linga, Praveen] Natl Univ Singapore, Dept Chem & Biomol Engn, Engn Dr 4, Singapore 117585, Singapore.
   [Daraboina, Nagu] Univ Tulsa, Russell Sch Chem Engn, Tulsa, OK 74104 USA.
   [Albeirutty, Mohammad; Bamaga, Omar A.] King Abdulaziz Univ, Dept Mech Engn, POB 80204, Jeddah 21589, Saudi Arabia.
   [Albeirutty, Mohammad] King Abdulaziz Univ, Ctr Excellence Desalinat Technol, Jeddah 21589, Saudi Arabia.
RP Babu, P; Linga, P (reprint author), Natl Univ Singapore, Dept Chem & Biomol Engn, Engn Dr 4, Singapore 117585, Singapore.
EM valavan@u.nus.edu; praveen.linga@nus.edu.sg
OI Linga, Praveen/0000-0002-1466-038X; Daraboina, Nagu/0000-0002-6910-5295
FU Energy Innovation Research Programme (EIRP) [NRF2014EWTEIRP003-006];
   National Research Foundation, Singapore (NRF)Singapore National Research
   Foundation; Shell Energy Singapore; NSTIP strategic technologies program
   in the Kingdom of Saudi Arabia [11-WAT2007-03]; Science and Technology
   Unit at King AbdulAziz University, Saudi Arabia
FX The work was funded in part under the Energy Innovation Research
   Programme (EIRP, Award No. NRF2014EWTEIRP003-006), administrated by the
   Energy Market Authority (EMA). The EIRP is a competitive grant call
   initiative driven by the Energy Innovation Programme Office, and funded
   by the National Research Foundation, Singapore (NRF). The authors would
   like to acknowledge funding support from our industry collaborator,
   Shell Energy Singapore. MAand OAB would like to acknowledge the support
   by NSTIP strategic technologies program in the Kingdom of Saudi Arabia
   Project No (11-WAT2007-03) and Science and Technology Unit at King
   AbdulAziz University, Saudi Arabia.
CR Babu P, 2018, ACS SUSTAIN CHEM ENG, V6, P8093, DOI 10.1021/acssuschemeng.8b01616
   Babu P, 2016, ENERGY, V94, P431, DOI 10.1016/j.energy.2015.11.009
   Babu P, 2015, ENERGY, V85, P261, DOI 10.1016/j.energy.2015.03.103
   Babu P, 2014, ENERGY, V78, P458, DOI 10.1016/j.energy.2014.10.033
   Babu P, 2014, CHEM ENG SCI, V117, P342, DOI 10.1016/j.ces.2014.06.044
   Babu P, 2013, INT J GREENH GAS CON, V17, P206, DOI 10.1016/j.ijggc.2013.05.010
   Babu P, 2013, ENERGY, V50, P364, DOI 10.1016/j.energy.2012.10.046
   BARDUHN AJ, 1962, AICHE J, V8, P176, DOI 10.1002/aic.690080210
   Cai LC, 2014, CHEM ENG SCI, V119, P147, DOI 10.1016/j.ces.2014.08.025
   Chen SQ, 2016, APPL ENERG, V184, P905, DOI 10.1016/j.apenergy.2016.03.042
   Chong ZR, 2016, APPL ENERG, V162, P1633, DOI 10.1016/j.apenergy.2014.12.061
   Corak D, 2011, DESALINATION, V278, P268, DOI 10.1016/j.desal.2011.05.035
   Dai JY, 2018, APPL ENERG, V210, P393, DOI 10.1016/j.apenergy.2017.08.243
   ENGLEZOS P, 1993, IND ENG CHEM RES, V32, P1251, DOI 10.1021/ie00019a001
   Eslamimanesh A, 2012, J CHEM THERMODYN, V46, P62, DOI 10.1016/j.jct.2011.10.006
   Fakharian H, 2017, J TAIWAN INST CHEM E, V72, P157, DOI 10.1016/j.jtice.2017.01.025
   He TB, 2019, ENERGY, V170, P557, DOI 10.1016/j.energy.2018.12.170
   He TB, 2018, APPL ENERG, V222, P13, DOI 10.1016/j.apenergy.2018.04.006
   Hightower M, 2008, NATURE, V452, P285, DOI 10.1038/452285a
   Kang KC, 2017, J NANOSCI NANOTECHNO, V17, P4059, DOI 10.1166/jnn.2017.13383
   Kang KC, 2014, DESALINATION, V353, P84, DOI 10.1016/j.desal.2014.09.007
   Kumar S, 2011, APPL ENERG, V88, P4264, DOI 10.1016/j.apenergy.2011.06.035
   Linga P., 2018, CLATHRATE HYDRATE DE
   Liu JG, 2018, APPL ENERG, V210, P377, DOI 10.1016/j.apenergy.2017.10.064
   Mekala P, 2014, ENERG FUEL, V28, P2708, DOI 10.1021/ef402445k
   Nambiar Abhishek, 2019, ChemEngineering, V3, DOI 10.3390/chemengineering3010031
   Ogawa T, 2006, APPL THERM ENG, V26, P2157, DOI 10.1016/j.applthermaleng.2006.04.003
   Park KN, 2011, DESALINATION, V274, P91, DOI 10.1016/j.desal.2011.01.084
   Parker A, 1942, NATURE, V149, P184, DOI 10.1038/149184a0
   Raluy RG, 2005, DESALINATION, V183, P81, DOI 10.1016/j.desal.2005.04.023
   Simmons B.A., 2009, COMPLEX ADMIXTURES C
   Sloan Jr E.D., 2007, CLATHRATE HYDRATES N
   Subramani A, 2015, WATER RES, V75, P164, DOI 10.1016/j.watres.2015.02.032
   Sum AK, 2009, IND ENG CHEM RES, V48, P7457, DOI 10.1021/ie900679m
   Veluswamy HP, 2018, APPL ENERG, V216, P262, DOI 10.1016/j.apenergy.2018.02.059
   Yang SHB, 2016, APPL ENERG, V162, P1131, DOI 10.1016/j.apenergy.2014.11.052
   Zheng JJ, 2016, J NAT GAS SCI ENG, V35, P1499, DOI 10.1016/j.jngse.2016.03.100
   Zhou SD, 2018, J CHEM ENG DATA, V63, P389, DOI 10.1021/acs.jced.7b00785
NR 38
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115563
DI 10.1016/j.ces.2020.115563
PG 9
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600016
DA 2020-05-12
ER

PT J
AU Barbera, E
   Sforza, E
   Grandi, A
   Bertucco, A
AF Barbera, Elena
   Sforza, Eleonora
   Grandi, Alessia
   Bertucco, Alberto
TI Uncoupling solid and hydraulic retention time in photobioreactors for
   microalgae mass production: A model-based analysis
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Bioprocess engineering; Photosynthetic microorganism; Productivity
   optimization; Light utilization
ID CHLAMYDOMONAS-REINHARDTII; BIOMASS PRODUCTION; LIGHT; GROWTH;
   TEMPERATURE; REMOVAL; SEWAGE; TOOL
AB In conventional continuous bioreactor operations, it is a common practice to decouple the hydraulic retention time (HRT) from the solid retention time (SRT). When dealing with photosynthetic microorganisms, light intensity plays a major role in the growth kinetics; thus, the effect of HRT and SRT on biomass productivity may differ from that in chemotrophic bioreactors. In this study, we assessed the role of uncoupled SRT and HRT on biomass productivity in continuous photobioreactors (PBRs) based on simple mass balances, light transfer, and kinetic models to highlight the specific features of PBRs. Under a non-limiting nutrient supply, SRT is the fundamental variable used to maximize productivity and control the biomass concentration and light penetration in a PBR. Operating at SRT > HRT does not enhance the productivity. If the goal is biomass production, it is instead convenient to operate at SRT < HRT, thereby significantly reducing the water and nutrient consumption. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Barbera, Elena] Interdept Ctr Giorgio Levi Cases, Via Marzolo 9, I-35131 Padua, Italy.
   [Barbera, Elena; Sforza, Eleonora; Grandi, Alessia; Bertucco, Alberto] Univ Padua, Dept Ind Engn DII, Via Marzolo 9, I-35131 Padua, Italy.
   [Bertucco, Alberto] Univ Padua, CRIBI Biotechnol Ctr, I-35121 Padua, Italy.
RP Barbera, E (reprint author), Interdept Ctr Giorgio Levi Cases, Via Marzolo 9, I-35131 Padua, Italy.
EM elena.barbera@unipd.it
CR Barbera E, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00274
   Barbera E, 2015, BIOPROC BIOSYST ENG, V38, P2177, DOI 10.1007/s00449-015-1457-9
   Bechet Q, 2013, BIOTECHNOL ADV, V31, P1648, DOI 10.1016/j.biotechadv.2013.08.014
   Begum H, 2016, CRIT REV FOOD SCI, V56, P2209, DOI 10.1080/10408398.2013.764841
   Bernard O, 2012, BIORESOURCE TECHNOL, V123, P520, DOI 10.1016/j.biortech.2012.07.022
   Bertucco A, 2014, BIOPROC BIOSYST ENG, V37, P1535, DOI 10.1007/s00449-014-1125-5
   Camacho F, 2019, MAR DRUGS, V17, DOI 10.3390/md17060312
   Chisti Y, 2007, BIOTECHNOL ADV, V25, P294, DOI 10.1016/j.biotechadv.2007.02.001
   Concas A, 2012, CHEM ENG J, V213, P203, DOI 10.1016/j.cej.2012.09.119
   CORNET JF, 1995, CHEM ENG SCI, V50, P1489, DOI 10.1016/0009-2509(95)00022-W
   Cuaresma M, 2011, BIORESOURCE TECHNOL, V102, P7871, DOI 10.1016/j.biortech.2011.05.076
   Gonzalez-Camejo J, 2019, J ENVIRON MANAGE, V245, P76, DOI 10.1016/j.jenvman.2019.05.010
   GRIMA EM, 1994, J CHEM TECHNOL BIOT, V61, P167, DOI 10.1002/jctb.280610212
   Honda Ryo, 2017, Journal of Water and Environment Technology, V15, P1, DOI 10.2965/jwet.15-085
   Knutson CM, 2018, ALGAL RES, V35, P301, DOI 10.1016/j.algal.2018.08.020
   Li K, 2019, BIORESOURCE TECHNOL, V291, DOI 10.1016/j.biortech.2019.121934
   Li XM, 2013, CHEM ENG SCI, V88, P16, DOI 10.1016/j.ces.2012.11.015
   MONOD J, 1949, ANNU REV MICROBIOL, V3, P371, DOI 10.1146/annurev.mi.03.100149.002103
   Pottier L, 2005, BIOTECHNOL BIOENG, V91, P569, DOI 10.1002/bit.20475
   Rada-Ariza AM, 2019, ALGAL RES, V39, DOI 10.1016/j.algal.2019.101468
   Redfield A. C., 1934, P176
   Ronga D., 2019, AGRONOMY, V9, P1
   Sforza E, 2019, BIOPROC BIOSYST ENG, V42, P839, DOI 10.1007/s00449-019-02087-9
   Sforza E, 2015, J APPL PHYCOL, V27, P1453, DOI 10.1007/s10811-014-0460-x
   Sforza E, 2014, CHEM ENG RES DES, V92, P1153, DOI 10.1016/j.cherd.2013.08.017
   Smith BT, 2013, CHEM ENG SCI, V91, P79, DOI 10.1016/j.ces.2013.01.007
   Solmaz A, 2019, BIOENERG RES, V12, P197, DOI 10.1007/s12155-019-9961-4
   Takache H, 2012, BIOTECHNOL PROGR, V28, P681, DOI 10.1002/btpr.1545
   Takache H, 2010, BIOTECHNOL PROGR, V26, P431, DOI 10.1002/btpr.356
   Tchobanoglous G., 2014, WASTEWATER ENG TREAT
   Undurraga D., 2016, CURR BIOTECHNOL, V5, P227
   Yun YS, 2003, BIOTECHNOL BIOENG, V83, P303, DOI 10.1002/bit.10669
   Zeng XH, 2016, GREEN ENERGY TECHNOL, P77, DOI 10.1007/978-3-319-12334-9_5
NR 33
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115578
DI 10.1016/j.ces.2020.115578
PG 9
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600023
DA 2020-05-12
ER

PT J
AU Brezina, J
   Pecinka, R
   Boutikos, P
   Koci, P
AF Brezina, Jan
   Pecinka, Rudolf
   Boutikos, Panagiotis
   Koci, Petr
TI Comparison of dual CO light-off effect on Pt/CeO2/gamma-Al2O3,
   Pd/CeO2/gamma-Al2O3, Pt/c-Al2O3 and Pd/gamma-Al2O3 in the presence of
   C3H6
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Exhaust gas aftertreatment; CO oxidation; Hydrocarbon oxidation;
   Inhibition; Catalyst
ID CARBON-MONOXIDE; OXIDATION; CATALYSTS; PLATINUM; HYDROCARBONS;
   COOXIDATION; CONVERTERS; REDUCTION; PROPYLENE; PALLADIUM
AB Dual CO light-off may occur during simultaneous oxidation of CO and hydrocarbon on three-way catalysts (TWC) and diesel oxidation catalysts (DOC). A plateau, shoulder or secondary peak may occur on the CO light-off curve after a cold start. In this paper we present a comparative experimental study of this effect on Pt/CeO2/gamma-Al2O3, Pd/CeO2/gamma-Al2O3, Pt/gamma-Al2O3 and Pd/gamma-Al2O3 catalysts, focusing particularly on the role of CeO2 in the catalyst formulation. Two mechanisms for dual CO light-off are identified: (i) blocking of active sites by the hydrocarbon oxidation intermediates, and (ii) CO by-production during the hydrocarbon oxidation. The presence of CeO2 does not suppress the accumulation of C3H6 oxidation intermediates on the catalyst surface. Longer transients and more complex patterns are observed on Pt/CeO2/gamma-Al2O3, Pd/CeO2/gamma-Al2O3 when compared to the corresponding ceria-free catalyst formulations. On the other hand, the presence of CeO2 decreases the light-off temperature and minimizes CO formation during C3H6 oxidation. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Brezina, Jan; Pecinka, Rudolf; Boutikos, Panagiotis; Koci, Petr] Univ Chem & Technol Prague, Dept Chem Engn, Tech 5, Prague 16628, Czech Republic.
RP Koci, P (reprint author), Univ Chem & Technol Prague, Dept Chem Engn, Tech 5, Prague 16628, Czech Republic.
EM petr.koci@vscht.cz
FU Czech Science FoundationGrant Agency of the Czech Republic [GA
   17-26018S]; specific university research (MSMT)Ministry of Education,
   Youth & Sports - Czech Republic [21-SVV/2019]
FX The work was financially supported by the Czech Science Foundation (GA
   17-26018S) and specific university research (MSMT No 21-SVV/2019).
CR Arvajova AB, 2018, APPL CATAL B-ENVIRON, V233, P167, DOI 10.1016/j.apcatb.2018.03.081
   Brezina J, 2019, TOP CATAL, V62, P252, DOI 10.1007/s11244-018-1129-5
   Choi JS, 2016, CATALYSTS, V6, DOI 10.3390/catal6100155
   Daneshvar K, 2017, CHEM ENG J, V323, P347, DOI 10.1016/j.cej.2017.04.078
   GonzalezVelasco JR, 1997, APPL CATAL B-ENVIRON, V12, P61, DOI 10.1016/S0926-3373(96)00058-6
   Hauff K, 2010, APPL CATAL B-ENVIRON, V100, P10, DOI 10.1016/j.apcatb.2010.07.036
   Hazlett MJ, 2017, APPL CATAL B-ENVIRON, V202, P404, DOI 10.1016/j.apcatb.2016.09.034
   Hazlett MJ, 2016, CATAL TODAY, V267, P157, DOI 10.1016/j.cattod.2015.11.033
   Herrmann M, 2018, APPL CATAL B-ENVIRON, V220, P446, DOI 10.1016/j.apCatb.2017.08.026
   Kaneeda M, 2009, APPL CATAL B-ENVIRON, V90, P564, DOI 10.1016/j.apcatb.2009.04.011
   KAPICKA J, 1989, J CATAL, V119, P508, DOI 10.1016/0021-9517(89)90178-4
   Kaspar J, 1999, CATAL TODAY, V50, P285, DOI 10.1016/S0920-5861(98)00510-0
   Koci P, 2004, CHEM ENG SCI, V59, P5597, DOI 10.1016/j.ces.2004.07.115
   Koci P, 2004, IND ENG CHEM RES, V43, P4503, DOI 10.1021/ie034137k
   Koci P, 2019, CATAL TODAY, V320, P165, DOI 10.1016/j.cattod.2017.12.025
   Koop J, 2009, APPL CATAL B-ENVIRON, V91, P47, DOI 10.1016/j.apcatb.2009.05.006
   Lang W, 2017, APPL CATAL B-ENVIRON, V218, P430, DOI 10.1016/j.apcatb.2017.06.064
   Naseri M, 2011, SAE INT J ENGINES, V4, P1798, DOI 10.4271/2011-01-1312
   Patterson MJ, 2000, APPL CATAL B-ENVIRON, V26, P47, DOI 10.1016/S0926-3373(00)00110-7
   Pliangos C, 1997, APPL CATAL B-ENVIRON, V14, P161, DOI 10.1016/S0926-3373(97)00020-9
   Raj R, 2015, CHEM ENG J, V281, P322, DOI 10.1016/j.cej.2015.06.057
   Sa J, 2010, ANALYST, V135, P2260, DOI 10.1039/c0an00303d
   Scheuer A, 2012, APPL CATAL B-ENVIRON, V111, P445, DOI 10.1016/j.apcatb.2011.10.032
   SUMMERS JC, 1978, J CATAL, V51, P185, DOI 10.1016/0021-9517(78)90292-0
   Swanson JJ, 2013, ENVIRON SCI TECHNOL, V47, P4521, DOI 10.1021/es304971h
   Vaclavik M, 2017, CHEM ENG J, V329, P128, DOI 10.1016/j.cej.2017.05.129
   VOLTZ SE, 1973, IND ENG CHEM PROD RD, V12, P294, DOI 10.1021/i360048a006
   Zheng QH, 2015, CATALYSTS, V5, P1770, DOI 10.3390/catal5041770
   Zheng Y, 2014, APPL CATAL B-ENVIRON, V148, P311, DOI 10.1016/j.apcatb.2013.11.007
NR 29
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115542
DI 10.1016/j.ces.2020.115542
PG 9
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600006
DA 2020-05-12
ER

PT J
AU Du, PB
   Zhao, CT
   Peng, P
   Gao, T
   Huang, T
AF Du, Pengbin
   Zhao, Chuntian
   Peng, Peng
   Gao, Tao
   Huang, Ting
TI Fractal characterization of permeability prediction model in
   hydrate-bearing porous media
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Permeability; Fractal; Natural gas hydrates; Porous media; Tortuosity
ID NATURAL-GAS HYDRATE; METHANE-HYDRATE; RELATIVE PERMEABILITY;
   THERMAL-STIMULATION; WATER PERMEABILITY; DISSOCIATION; SATURATION;
   DEPRESSURIZATION; SEDIMENTS; SAND
AB Studies have shown that the permeability plays an extremely important role in NGHs decomposition flow and production analysis. However, several existing permeability calculation models are very divergent and usually contain some empirical parameters with unclear physical meaning. The accurate determination of these empirical parameters is often very difficult and needs to be improved urgently. In this work, a novel fractal permeability prediction model for water flowing through hydrate-bearing porous media is established based on the fractal theory. The fractal permeability model is expressed as a function of the pore area fractal dimension, tortuous dimension, porosity, hydrate saturation, and maximum pore diameter. In this expression, each parameters has specific physical meaning. The reliability of the deduced model is validated by comparing predictive results of the model with the available open experimental data. A good agreement is found between them and the accuracy of model prediction is always within +/- 10% error range. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Du, Pengbin; Zhao, Chuntian] Blue Ocean Inst Gas Hydrate Explorat & Prod, Weihai 264400, Shandong, Peoples R China.
   [Peng, Peng] Xinjiang Tarim Oilfield Co, Korla 841000, Xinjiang, Peoples R China.
   [Gao, Tao] Yanchang Petr Explorat & Dev Res Inst, Xian 710075, Shanxi, Peoples R China.
   [Huang, Ting] Yangtze Univ, Hubei Cooperat Innovat Ctr Unconvent Oil & Gas, Wuhan 430100, Peoples R China.
RP Du, PB (reprint author), Blue Ocean Inst Gas Hydrate Explorat & Prod, Weihai 264400, Shandong, Peoples R China.
EM du_pengbin@foxmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51704032]; China National Science and Technology
   Major Project [2017ZX05049005-010]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 51704032) and China National Science and Technology
   Major Project (Grant No. 2017ZX05049005-010).
CR Cai JC, 2017, EARTH-SCI REV, V171, P419, DOI 10.1016/j.earscirev.2017.06.013
   Chen BB, 2018, INT J HEAT MASS TRAN, V118, P1316, DOI 10.1016/j.ijheatmasstransfer.2017.11.085
   Chong ZR, 2016, APPL ENERG, V162, P1633, DOI 10.1016/j.apenergy.2014.12.061
   Cook AE, 2018, J GEOPHYS RES-SOL EA, V123, P2069, DOI 10.1002/2017JB015138
   Dai S, 2014, GEOPHYS RES LETT, V41, P4176, DOI 10.1002/2014GL060535
   Daigle H, 2016, J PETROL SCI ENG, V146, P526, DOI 10.1016/j.petrol.2016.07.011
   Delli ML, 2014, J PETROL SCI ENG, V120, P1, DOI 10.1016/j.petrol.2014.05.011
   Demirbas A, 2010, ENERG CONVERS MANAGE, V51, P1547, DOI 10.1016/j.enconman.2010.02.013
   Demirbas A, 2010, ENERG CONVERS MANAGE, V51, P1562, DOI 10.1016/j.enconman.2010.02.014
   Dong HM, 2019, J APPL GEOPHYS, V164, P153, DOI 10.1016/j.jappgeo.2019.03.005
   Dong HM, 2019, FUEL, V248, P27, DOI 10.1016/j.fuel.2019.03.038
   Fukumoto A, 2018, J NAT GAS SCI ENG, V50, P269, DOI 10.1016/j.jngse.2017.12.016
   Gambelli AM, 2019, ENERGY, V172, P423, DOI 10.1016/j.energy.2019.01.141
   Johnson A, 2011, MAR PETROL GEOL, V28, P419, DOI 10.1016/j.marpetgeo.2009.10.013
   Kang DH, 2016, GEOPHYS RES LETT, V43, P9018, DOI 10.1002/2016GL070511
   Kleinberg RL, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2003JB002389
   Kneafsey TJ, 2011, SPE J, V16, P78, DOI 10.2118/139525-PA
   Koh CA, 2012, J NAT GAS SCI ENG, V8, P132, DOI 10.1016/j.jngse.2012.01.005
   Koh DY, 2016, APPL ENERG, V162, P114, DOI 10.1016/j.apenergy.2015.10.082
   Konno Y, 2015, MAR PETROL GEOL, V66, P487, DOI 10.1016/j.marpetgeo.2015.02.020
   Konno Y, 2010, ENERG FUEL, V24, P6353, DOI 10.1021/ef1008727
   Kossel E, 2018, J GEOPHYS RES-SOL EA, V123, P1235, DOI 10.1002/2017JB014630
   Kumar A, 2010, J PETROL SCI ENG, V70, P109, DOI 10.1016/j.petrol.2009.10.005
   Lee, 2008, 20085219 US GEOL SUR
   Li G, 2019, CHEM ENG SCI, V193, P1, DOI 10.1016/j.ces.2018.08.055
   Li G, 2007, ENERG FUEL, V21, P3388, DOI 10.1021/ef060644d
   Li G, 2017, APPL ENERG, V202, P282, DOI 10.1016/j.apenergy.2017.05.147
   Li N, 2018, FUEL, V216, P612, DOI 10.1016/j.fuel.2017.11.112
   Li XS, 2016, APPL ENERG, V172, P286, DOI 10.1016/j.apenergy.2016.03.101
   Liang H, 2011, PETROL SCI TECHNOL, V29, P79, DOI 10.1080/10916460903096871
   Mahabadi N, 2019, J PETROL SCI ENG, V174, P696, DOI 10.1016/j.petrol.2018.11.084
   Mahabadi N, 2016, GEOCHEM GEOPHY GEOSY, V17, P3099, DOI 10.1002/2016GC006372
   Mahabadi N, 2014, GEOCHEM GEOPHY GEOSY, V15, P2346, DOI 10.1002/2014GC005331
   Malinverno A, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2008JB005702
   Mandelbort B.B., 1977, FRACTAL GEOMETRY NAT
   Masuda Y.S., 1999, 3 INT C GAS HYDR SAL
   Ordonez C., 2009, 62 CAN GEOT C CAN GE
   Sakamoto S, 2010, BEYOND WORLD-CLASS PRODUCTIVITY: INDUSTRIAL ENGINEERING PRACTICE AND THEORY, P1, DOI 10.1007/978-1-84996-269-8
   Santamarina JC, 2010, GEOPHYS DEV SER, P373, DOI 10.1190/1.9781560802197.ch26
   Song YC, 2015, APPL ENERG, V145, P265, DOI 10.1016/j.apenergy.2015.02.040
   Spangenberg E, 2001, J GEOPHYS RES-SOL EA, V106, P6535, DOI 10.1029/2000JB900434
   Wan QC, 2018, INT J HEAT MASS TRAN, V127, P206, DOI 10.1016/j.ijheatmasstransfer.2018.07.016
   Wang B, 2018, APPL ENERG, V229, P858, DOI 10.1016/j.apenergy.2018.08.056
   Wang JQ, 2015, FUEL, V145, P170, DOI 10.1016/j.fuel.2014.12.079
   Wang JQ, 2018, J NAT GAS SCI ENG, V51, P141, DOI 10.1016/j.jngse.2017.12.029
   Wang JQ, 2016, FUEL, V163, P34, DOI 10.1016/j.fuel.2015.09.044
   Wei W, 2015, GEOPHYS RES LETT, V42, P4833, DOI 10.1002/2015GL064460
   Wei W, 2015, FRACTALS, V23, DOI 10.1142/S0218348X15400125
   Xu P, 2008, ADV WATER RESOUR, V31, P74, DOI 10.1016/j.advwatres.2007.06.003
   Yang L, 2018, ENERGY, V163, P27, DOI 10.1016/j.energy.2018.08.100
   Yin ZY, 2018, CHEM ENG J, V342, P9, DOI 10.1016/j.cej.2018.01.120
   Yousif M.H., 2013, SPE RESERVOIR ENG, V6, P69, DOI [10.2118/18320-PA., DOI 10.2118/18320-PA]
   Yu BM, 2004, AICHE J, V50, P46, DOI 10.1002/aic.10004
   Yu BM, 2002, INT J HEAT MASS TRAN, V45, P2983, DOI 10.1016/S0017-9310(02)00014-5
   Yu BM, 2008, APPL MECH REV, V61, DOI 10.1115/1.2955849
   Zhan L, 2018, FUEL, V230, P37, DOI 10.1016/j.fuel.2018.05.008
   Zhang HT, 2018, J NAT GAS SCI ENG, V60, P144, DOI 10.1016/j.jngse.2018.10.015
   Zhao JF, 2016, INT J HEAT MASS TRAN, V103, P265, DOI 10.1016/j.ijheatmasstransfer.2016.05.111
   Zhao JF, 2015, APPL ENERG, V142, P125, DOI 10.1016/j.apenergy.2014.12.071
NR 59
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115576
DI 10.1016/j.ces.2020.115576
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600021
DA 2020-05-12
ER

PT J
AU Gulden, SJ
   Riedele, C
   Kopf, MH
   Nirschl, H
AF Gulden, S. J.
   Riedele, C.
   Kopf, M-H
   Nirschl, H.
TI Potential of flotation as alternative separation process in
   biotechnology with focus on cost and energy efficiency
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Flotation; Yeast; Economical comparison; Bubble size; Flotation rate;
   Energy efficiency
ID BUBBLE-SIZE; SACCHAROMYCES-CEREVISIAE; HANSENULA-POLYMORPHA; AIR
   FLOTATION; CELL RECOVERY; FLOW RATE; CULTIVATION; REMOVAL; YEAST;
   MICROORGANISMS
AB Flotation is a density separation process which is influenced by physico-chemical interaction between a particle and a bubble. In biotechnology, it finds application in the solid-liquid separation of biomass. The process mechanism depends on the formation of stable microorganism-bubble-complexes by collision and adsorption. The difference in density of these complexes and the surrounding liquid medium causes them to rise to the liquid surface, where a foam develops. This microorganism enriched foam can then be removed. An economical comparison of the separation technologies centrifugation, cross-flow-filtration and flotation showed, that flotation is a financially and energetically interesting alternative process step for the harvest of microorganisms. In this work separation results with a model microorganism S. cerevisiae are presented. Experiments were conducted batch-wise in a 6L-laboratory dissolved air flotation setup, where bubble generation classically results from expanding air from supersaturated medium. Goal was the optimization of the flotation rate and the energy efficiency of the flotation process by adaptation of operational parameters, such as gas- and recycle flow rate and saturation pressure. Flotation models show proportional dependency between the flotation rate and the bubble size and bubble surface area flow rate. Therefore, the effect of operational parameters, such as saturation pressure, recycle and gas flow rate, on the bubble size and surface area flow rate was analyzed. The positive effect of an increasing bubble surface area was possible with increasing gas flow rate, recycle flow rate and saturation pressure. Decreasing bubble sizes were measured for increasing recycle flow rate and saturation pressure, meanwhile the contrary was the case with an increasing gas flow rate. Evaluation of the flotation rate and flotation energy efficiency showed, increasing the recycle flow rate and the saturation pressure both improved the flotation rate, but had low effect on the energy efficiency. Increasing the gas flow rate improved both flotation rate and energy efficiency. It is the most interesting operational parameter for enhancing the process efficacy. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Gulden, S. J.; Riedele, C.; Kopf, M-H] BASF SE, Proc Res Ind Biotechnol, Ludwigshafen, Germany.
   [Gulden, S. J.; Nirschl, H.] Karlsruhe Inst Technol, Inst Mech Proc Engn & Mech, Karlsruhe, Germany.
RP Gulden, SJ (reprint author), BASF SE, Proc Res Ind Biotechnol, Ludwigshafen, Germany.; Gulden, SJ (reprint author), Karlsruhe Inst Technol, Inst Mech Proc Engn & Mech, Karlsruhe, Germany.
EM susanne.gulden@kit.edu
FU BASF SE
FX The authors thank Patrick Graefen for the development of the LabVIEW
   bubble size analysis application. This study was funded by BASF SE.
CR AHMED N, 1985, INT J MINER PROCESS, V14, P195, DOI 10.1016/0301-7516(85)90003-1
   Aulenbach DB, 2010, HANDB ENVIRON ENG, V12, P363, DOI 10.1007/978-1-60327-133-2_11
   Axelsson H., 2002, CELL SEPARATION CENT, DOI [10.1002/0471250589.ebt042., DOI 10.1002/0471250589.EBT042]
   BAHR KH, 1991, ENZYME MICROB TECH, V13, P747, DOI 10.1016/0141-0229(91)90054-E
   BAHR KH, 1992, CHEM ENG SCI, V47, P11, DOI 10.1016/0009-2509(92)80195-I
   Bicalho IC, 2013, SEP SCI TECHNOL, V48, P915, DOI 10.1080/01496395.2012.712597
   Bilad MR, 2013, BIORESOURCE TECHNOL, V138, P329, DOI 10.1016/j.biortech.2013.03.175
   BOYLES WA, 1958, APPL MICROBIOL, V6, P327, DOI 10.1128/AEM.6.5.327-334.1958
   Chmiel H., 2011, BIOPROZESSTECHNIK
   Coward T, 2013, ALGAL RES, V2, P135, DOI 10.1016/j.algal.2012.12.001
   Dai ZF, 2000, ADV COLLOID INTERFAC, V85, P231, DOI 10.1016/S0001-8686(99)00030-5
   Derjaguin B.V., 1961, T I MIN METALL, V70, P221
   Derjaguin B.V., 1979, P 13 INT MIN PROC C
   DEY A, 1989, INT J MINER PROCESS, V26, P73, DOI 10.1016/0301-7516(89)90044-6
   Edzwald JK, 2010, WATER RES, V44, P2077, DOI 10.1016/j.watres.2009.12.040
   EDZWALD JK, 1993, WATER SCI TECHNOL, V27, P67
   Elcik H, 2016, J MEMBRANE SCI, V499, P116, DOI 10.1016/j.memsci.2015.10.043
   Engelhardt H., 1986, PRACTICE HIGH PERFOR, DOI [10.1007/978-3-642-69225-3., DOI 10.1007/978-3-642-69225-3]
   Gao SS, 2010, J HAZARD MATER, V177, P336, DOI 10.1016/j.jhazmat.2009.12.037
   Gaudin A.M., 1957, FLOTATION
   GAUDIN AM, 1960, APPL MICROBIOL, V8, P91, DOI 10.1128/AEM.8.2.91-97.1960
   GAUDIN AM, 1962, BIOTECHNOL BIOENG, V4, P211, DOI 10.1002/bit.260040211
   GEERTSEMADOORNBUSCH GI, 1993, J MICROBIOL METH, V18, P61, DOI 10.1016/0167-7012(93)90072-P
   GEHLE R, 1991, J BIOTECHNOL, V17, P147, DOI 10.1016/0168-1656(91)90005-G
   Gorain BK, 1998, MINER ENG, V11, P627, DOI 10.1016/S0892-6875(98)00047-8
   Gulden SJ, 2018, CHEM ENG SCI, V185, P168, DOI 10.1016/j.ces.2018.04.009
   Guldena SJ, 2019, CHEM ENG SCI, V207, P1353, DOI 10.1016/j.ces.2019.07.027
   Guria C, 2005, INT J MINER PROCESS, V77, P165, DOI 10.1016/j.minpro.2005.06.003
   Habibian A, 2008, CHEM ENG J, V138, P30, DOI 10.1016/j.cej.2007.05.025
   Henry W., 1803, PHILOS T R SOC LOND, V1, P21
   ISRAELACHVILI J, 1982, NATURE, V300, P341, DOI 10.1038/300341a0
   Jameson GJ, 2010, MINER ENG, V23, P835, DOI 10.1016/j.mineng.2010.04.001
   Krichel S., 2012, EXERGIEFLUSSDIAGRAMM
   Lang H.J., 1948, CHEM ENG, V55, P112
   LAPLANTE AR, 1983, INT J MINER PROCESS, V11, P203, DOI 10.1016/0301-7516(83)90026-1
   Leppinen DM, 2004, J WATER SUPPLY RES T, V53, P531
   MEHROTRA SP, 1974, SEPAR SCI, V9, P167, DOI 10.1080/00372367408057055
   Nguyen AV, 1998, INT J MINER PROCESS, V53, P225, DOI 10.1016/S0301-7516(97)00073-2
   Qu X, 2013, MINER ENG, V41, P25, DOI 10.1016/j.mineng.2012.10.013
   REAY D, 1973, CAN J CHEM ENG, V51, P178, DOI 10.1002/cjce.5450510207
   RUBIN AJ, 1966, BIOTECHNOL BIOENG, V8, P135, DOI 10.1002/bit.260080112
   Savassi ON, 1998, MINER ENG, V11, P243, DOI 10.1016/S0892-6875(98)00003-X
   SCHUBERT H, 1978, INT J MINER PROCESS, V5, P131, DOI 10.1016/0301-7516(78)90010-8
   Schugerl K, 2000, ADV BIOCHEM ENG BIOT, V68, P191
   Smith P. G., 1989, MINER PROCESS EXTR M, V5, P123, DOI DOI 10.1080/08827508908952647
   STAUFFER CE, 1965, J PHYS CHEM-US, V69, P1933, DOI 10.1021/j100890a024
   Stephan K., 1986, THERMODYNAMIK GRUNDL, DOI [10.1007/3-540-29262-4., DOI 10.1007/3-540-29262-4]
   SUTHERLAND KL, 1948, J PHYS COLLOID CHEM, V52, P394, DOI 10.1021/j150458a013
   Szepessy S., 2016, CHEM-ING-TECH, V88, P1401, DOI [10.1002/cite.201650397., DOI 10.1002/CITE.201650397]
   TAKAHASHI T, 1979, J CHEM ENG JPN, V12, P275, DOI 10.1252/jcej.12.275
   TYBUSSEK R, 1994, APPL MICROBIOL BIOT, V41, P13, DOI 10.1007/s002530050100
   Vega-Garcia D, 2018, CHEM ENG J, V350, P653, DOI 10.1016/j.cej.2018.06.016
   VIEHWEG H, 1983, EUR J APPL MICROBIOL, V17, P96, DOI 10.1007/BF00499858
   Wang LK, 2005, HANDB ENVIRON ENG, V3, P431
   Yoon R.H., 1989, MINER PROCESS EXTR M, V5, P101, DOI DOI 10.1080/
   YOON RH, 1993, MINER ENG, V6, P619, DOI 10.1016/0892-6875(93)90116-5
   Yoon RH, 2000, INT J MINER PROCESS, V58, P129, DOI 10.1016/S0301-7516(99)00071-X
   Zhang XZ, 2010, BIORESOURCE TECHNOL, V101, P5297, DOI 10.1016/j.biortech.2010.02.007
NR 58
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115117
DI 10.1016/j.ces.2019.07.035
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600001
DA 2020-05-12
ER

PT J
AU Hissanaga, AM
   Padoin, N
   Paladino, EE
AF Hissanaga, A. M.
   Padoin, N.
   Paladino, E. E.
TI Mass transfer modeling and simulation of a transient homogeneous bubbly
   flow in a bubble column
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Two-phase; Bubbly; Bubble column; Mass transfer; Absorption; Transient
ID VELOCITY; LIQUID; PIPES
AB Bubble columns have wide applicability in the industry as contactors such as absorbers, strippers, and multiphase reactors. Despite their simple construction and operation, the success in the design of bubble columns requires deep knowledge of transport phenomena applied to multiphase flow. Modeling and simulating the fluid dynamics through numerical methods may circumvent the high cost of empirical methods when analyzing key parameters for the design and scale-up of bubble columns. The main objective of this work is to model and simulate the interfacial mass transfer in a bubble column, for both steady-state and transient analysis. The equations of mass, momentum, and species conservation are described in a Euler-Euler framework using a one-dimensional Two-Fluid Model (TFM), taking adequate closure relations for modeling interfacial transport phenomena. The equations are integrated by the Finite Volume Method (FVM) in an algorithm developed by the authors and the numerical results obtained are compared with experimental data found in the literature. The simulations are predictive and run with no need for matching experimental data, which is the main contribution of this work. The results obtained showed good agreement when compared with experimental data. Additionally, a high-order in space (TVD) and time (Crank-Nicolson) is developed to capture the gradients of gas fraction and composition, providing a remarkable tool for transient analysis. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hissanaga, A. M.; Paladino, E. E.] Fed Univ Santa Catarina UFSC, Dept Mech Engn, SINMEC Computat Fluid Dynam Lab, BR-88040900 Florianopolis, SC, Brazil.
   [Padoin, N.] Fed Univ Santa Catarina UFSC, Dept Chem & Food Engn, LABMAC Lab Mat & Sci Comp, BR-88040900 Florianopolis, SC, Brazil.
RP Paladino, EE (reprint author), Fed Univ Santa Catarina UFSC, Dept Mech Engn, SINMEC Computat Fluid Dynam Lab, BR-88040900 Florianopolis, SC, Brazil.
EM adrianohissanaga@gmail.com; natan.padoin@ufsc.br;
   paladino@sinmec.ufsc.br
RI Padoin, Natan/B-9363-2018
OI Padoin, Natan/0000-0002-7247-2934
CR Azizi S, 2017, CHEM ENG SCI, V170, P320, DOI 10.1016/j.ces.2017.02.015
   Bendiksen KH, 1991, SPE PROD ENG, V6, P171, DOI DOI 10.2118/19451-PA
   Besagni Giorgio, 2019, Petroleum, V5, P141, DOI 10.1016/j.petlm.2017.12.004
   Bonizzi M., 2003, THESIS
   Boussinesq J., 1905, J MATH PURE APPL, V1, P285
   CHAO BT, 1962, PHYS FLUIDS, V5, P69, DOI 10.1063/1.1706493
   Chen P, 2005, AICHE J, V51, P696, DOI 10.1002/aic.10381
   DECKWER WD, 1978, CAN J CHEM ENG, V56, P43, DOI 10.1002/cjce.5450560107
   Ekambara K, 2005, CHEM ENG SCI, V60, P6733, DOI 10.1016/j.ces.2005.05.047
   Ekambara K, 2010, NUCL ENG DES, V240, P963, DOI 10.1016/j.nucengdes.2010.01.016
   Gourma M., 2015, Journal of Computational Multiphase Flows, V7, P57
   Holmas H, 2010, CHEM ENG SCI, V65, P1811, DOI 10.1016/j.ces.2009.11.031
   IAPWS, 1997, TECH REP
   ISHII M, 1979, AICHE J, V25, P843, DOI 10.1002/aic.690250513
   Ishii M., 2011, THERMOFLUID DYNAMICS, DOI [DOI 10.1007/978-1-4419-7985-8, 10.1007/978-1-4419-7985-8]
   Issa RI, 2003, INT J MULTIPHAS FLOW, V29, P69, DOI 10.1016/S0301-9322(02)00127-1
   Kantarci N, 2005, PROCESS BIOCHEM, V40, P2263, DOI 10.1016/j.procbio.2004.10.004
   Lewis WK, 1924, IND ENG CHEM, V16, P1215, DOI 10.1021/ie50180a002
   Lima P., 1998, SPE ANN TECHN C EXH
   Lima P., 1999, SPE ANN TECHN C EXH
   LOCHIEL AC, 1964, CHEM ENG SCI, V19, P471, DOI 10.1016/0009-2509(64)85074-0
   Maliska C.R., 1983, P 3 INT C NUM METH L, P656
   Rzehak R, 2017, CHEM ENG SCI, V157, P147, DOI 10.1016/j.ces.2016.04.056
   Rzehak R, 2016, CHEM ENG SCI, V155, P459, DOI 10.1016/j.ces.2016.08.036
   SHAH YT, 1982, AICHE J, V28, P353, DOI 10.1002/aic.690280302
   Tomiyama A, 2002, INT J MULTIPHAS FLOW, V28, P1497, DOI 10.1016/S0301-9322(02)00032-0
   VERSTEEG GF, 1988, J CHEM ENG DATA, V33, P29, DOI 10.1021/je00051a011
   Zhang YJ, 2012, CHEM ENG SCI, V73, P55, DOI 10.1016/j.ces.2012.01.012
   Zhibaedov VD, 2016, FLUID DYNAM+, V51, P56, DOI 10.1134/S0015462816010075
   Zhou YF, 2020, CHEM ENG SCI, V211, DOI 10.1016/j.ces.2019.115295
NR 30
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115531
DI 10.1016/j.ces.2020.115531
PG 20
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600004
DA 2020-05-12
ER

PT J
AU Hunter, TN
   Peakall, J
   Egarr, D
   Cowell, DMJ
   Freear, S
   Tonge, AS
   Horton, L
   Rice, HP
   Smith, I
   Malone, K
   Burt, D
   Barnes, M
   Randall, G
   Biggs, S
   Fairweather, M
AF Hunter, Timothy N.
   Peakall, Jeff
   Egarr, Darrell
   Cowell, David M. J.
   Freear, Steven
   Tonge, Alastair S.
   Horton, Lucy
   Rice, Hugh P.
   Smith, Iain
   Malone, Kevin
   Burt, David
   Barnes, Martyn
   Randall, Geoff
   Biggs, Simon
   Fairweather, Michael
TI Concentration profiling of a horizontal sedimentation tank utilising a
   bespoke acoustic backscatter array and CFD simulations
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Acoustic backscatter systems; Ultrasonics; CFD; Horizontal
   sedimentation; Clarifier; Flocculation
ID IN-SITU CHARACTERIZATION; POTABLE WATER-TREATMENT; POLYMER FLOCCULATION;
   SETTLING VELOCITY; AGGREGATE DENSIFICATION; PARTICLE CONCENTRATION;
   NUMERICAL-SIMULATION; FLOC SIZE; MODEL; SUSPENSIONS
AB The performance of a pilot-scale horizontal sedimentation tank was characterised utilising computational fluid dynamics (CFD) and a bespoke ultrasonic backscatter array, for both spherical glass and flocculated calcite separation. The CFD simulation was developed in OpenFOAM, using algebraic slip and hindered settling models, in order to solve the transport of multiple particle size classes, enabled through a population balance approach. Simulations of concentration compared closely to samples for the glass dispersions, but under-predicted concentration with flocculated calcite (likely due to complexities from modelling floc break-up in the mixer). In comparison, the acoustic array measured the calcite concentration with a high degree of resolution, where in particular, evidence suspension mobilisation near the outlet was observed, due to recirculation. Overall, we demonstrate the performance and current limitations of large-scale CFD for complex floc systems, as well as the use of ultrasonics to significantly aid process understanding, through online monitoring of solid-liquid separations. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Hunter, Timothy N.; Tonge, Alastair S.; Rice, Hugh P.; Smith, Iain; Fairweather, Michael] Univ Leeds, Sch Chem & Proc Engn, Leeds LS2 9JT, W Yorkshire, England.
   [Peakall, Jeff] Univ Leeds, Sch Earth & Environm, Leeds LS2 9JT, W Yorkshire, England.
   [Egarr, Darrell; Horton, Lucy; Malone, Kevin] MMI Engn Ltd, Unit 2,Corum Off Pk,Crown Way, Bristol BS30 8FJ, Avon, England.
   [Cowell, David M. J.; Freear, Steven] Univ Leeds, Sch Elect & Elect Engn, Leeds LS2 9JT, W Yorkshire, England.
   [Burt, David] Univ Bristol, Dept Mech Engn, Bristol BS8 1TR, Avon, England.
   [Barnes, Martyn; Randall, Geoff] Sellafield Ltd, Hinton House,Birchwood Pk Ave, Warrington WA3 6GR, Cheshire, England.
   [Biggs, Simon] Univ Western Australia, Perth, WA 6009, Australia.
   [Egarr, Darrell; Horton, Lucy] Dyson Ltd, Tetbury Hill SN16 0RP, Wilts, England.
   [Malone, Kevin] Urenco Nucl Stewardship Ltd, Capenhurst Ln, Chester CH1 6ER, Cheshire, England.
RP Hunter, TN (reprint author), Univ Leeds, Sch Chem & Proc Engn, Leeds LS2 9JT, W Yorkshire, England.
EM t.n.hunter@leeds.ac.uk
FU Innovate UK; Sellafield Ltd., as part of the Developing the civil
   nuclear power supply chain programme [101433]; Nuclear Decommissioning
   Authority (NDA); UK's Engineering and Physical Sciences Research Council
   (EPSRC)Engineering & Physical Sciences Research Council (EPSRC); EPSRC,
   as part of the DISTINCTIVE nuclear consortiumEngineering & Physical
   Sciences Research Council (EPSRC) [EP/L014041/1]
FX The authors gratefully acknowledge the funding of this work from
   Innovate UK and Sellafield Ltd., as part of the Developing the civil
   nuclear power supply chain programme (Grant No: 101433) which contained
   additional funding from the Nuclear Decommissioning Authority (NDA) and
   the UK's Engineering and Physical Sciences Research Council (EPSRC). The
   EPSRC are also thanked for additional funding, as part of the
   DISTINCTIVE nuclear consortium (EP/L014041/1). Great thanks are given to
   NSG Environmental Ltd, especially Thomas Hurst and Fraser Hardy, for
   help in conduction of the large-scale clarifier trials. We also thank
   Luke Hissitt for research support with the batch sedimentation tests. We
   would lastly thank the anonymous reviewers for their constructive
   feedback, which helped improve the paper.
CR Antonopoulou E, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5010735
   Asgharzadeh H, 2011, SCI IRAN, V18, P938, DOI 10.1016/j.scient.2011.07.005
   Benn FA, 2018, CHEM ENG SCI, V184, P111, DOI 10.1016/j.ces.2018.03.037
   Biggs CA, 2002, POWDER TECHNOL, V124, P201, DOI 10.1016/S0032-5910(02)00017-7
   Bokil S.D., 1973, ADV WATER POLLUTION, P421
   Bridgeman J, 2010, ADV ENG SOFTW, V41, P99, DOI 10.1016/j.advengsoft.2008.12.007
   Brown PP, 2003, J ENVIRON ENG-ASCE, V129, P222, DOI 10.1061/(ASCE)0733-9372(2003)129:3(222)
   Burt D.J., 2010, THESIS
   Bux J, 2019, APPL ACOUST, V146, P9, DOI 10.1016/j.apacoust.2018.10.022
   Bux J, 2017, AICHE J, V63, P2618, DOI 10.1002/aic.15683
   Bux J, 2015, POWDER TECHNOL, V284, P530, DOI 10.1016/j.powtec.2015.07.028
   Concha F, 2017, POWDER TECHNOL, V314, P680, DOI 10.1016/j.powtec.2017.03.040
   Costine A, 2018, CHEM ENG SCI, V176, P127, DOI 10.1016/j.ces.2017.10.031
   Cowell D.M.J., 2015, ULTR S IUS 2015 IEEE, P1
   Cowell DMJ, 2013, IEEE T ULTRASON FERR, V60, P1084, DOI 10.1109/TUFFC.2013.2672
   Crittenden J. C., 2012, MWHS WATER TREATMENT
   Das S, 2016, ENG APPL COMP FLUID, V10, P130, DOI 10.1080/19942060.2015.1121518
   De Clercq B, 2004, J CHEM TECHNOL BIOT, V79, P610, DOI 10.1002/jctb.1028
   De Clercq J, 2005, WATER RES, V39, P2125, DOI 10.1016/j.watres.2005.03.023
   Derlon N, 2017, WATER RES, V114, P327, DOI 10.1016/j.watres.2017.01.049
   DOWNING A, 1995, J ACOUST SOC AM, V97, P1614, DOI 10.1121/1.412100
   Egarr D.A., 2016, 10 EUR WAST WAT MAN
   Fan L, 2007, J CHIN INST CHEM ENG, V38, P425, DOI 10.1016/j.jcice.2007.06.006
   Farrow JB, 2000, CHEM ENG J, V80, P149, DOI 10.1016/S1383-5866(00)00084-8
   Gladman BR, 2010, CHEM ENG SCI, V65, P4293, DOI 10.1016/j.ces.2010.04.010
   GORE RA, 1989, INT J MULTIPHAS FLOW, V15, P279, DOI 10.1016/0301-9322(89)90076-1
   Goula AM, 2008, WATER RES, V42, P3405, DOI 10.1016/j.watres.2008.05.002
   Guerrero M, 2016, WATER-SUI, V8, DOI 10.3390/w8010013
   Guo H, 2017, CHEM ENG SCI, V158, P21, DOI 10.1016/j.ces.2016.09.022
   Guyonvarch E, 2015, WATER RES, V83, P396, DOI 10.1016/j.watres.2015.06.012
   Harbottle D, 2011, CHEM ENG SCI, V66, P2309, DOI 10.1016/j.ces.2011.02.012
   Heath AR, 2006, AICHE J, V52, P1641, DOI 10.1002/aic.10749
   Heath AR, 2006, AICHE J, V52, P1284, DOI 10.1002/aic.10729
   Hunter TN, 2015, PROCEDIA ENGINEER, V102, P858, DOI 10.1016/j.proeng.2015.01.206
   Hunter TN, 2013, CHEM ENG RES DES, V91, P722, DOI 10.1016/j.cherd.2013.02.002
   Hunter TN, 2012, CHEM ENG SCI, V80, P409, DOI 10.1016/j.ces.2012.06.038
   Hunter TN, 2012, MINER ENG, V27, P20, DOI 10.1016/j.mineng.2011.12.003
   Jaworski AJ, 2009, J PETROL SCI ENG, V68, P47, DOI 10.1016/j.petrol.2009.06.007
   Jeldres RI, 2018, POWDER TECHNOL, V326, P190, DOI 10.1016/j.powtec.2017.12.033
   Johnson M, 2016, IND ENG CHEM RES, V55, P9983, DOI 10.1021/acs.iecr.6b02383
   JONES WP, 1972, INT J HEAT MASS TRAN, V15, P301, DOI 10.1016/0017-9310(72)90076-2
   Karpinska AM, 2016, WATER RES, V88, P861, DOI 10.1016/j.watres.2015.11.008
   Kim J, 2006, CHEM ENG SCI, V61, P45, DOI 10.1016/j.ces.2005.01.044
   Li T, 2006, POWDER TECHNOL, V168, P104, DOI 10.1016/j.powtec.2006.07.003
   Maggi F, 2007, J HYDROL, V343, P43, DOI 10.1016/j.jhydrol.2007.05.035
   MICHAELS AS, 1962, IND ENG CHEM FUND, V1, P24, DOI 10.1021/i160001a004
   Mohanarangam K, 2013, CHEM ENG SCI, V104, P925, DOI 10.1016/j.ces.2013.10.015
   Pena R, 2017, CHEM ENG SCI, V167, P66, DOI 10.1016/j.ces.2017.03.055
   Ramin E, 2014, WATER RES, V66, P447, DOI 10.1016/j.watres.2014.08.034
   Razmi AM, 2013, CAN J CIVIL ENG, V40, P140, DOI 10.1139/cjce-2012-0176
   Rice HP, 2015, CHEM ENG SCI, V126, P745, DOI 10.1016/j.ces.2014.11.063
   Rice HP, 2014, J ACOUST SOC AM, V136, P156, DOI 10.1121/1.4883376
   Salem AI, 2011, WATER RES, V45, P3541, DOI 10.1016/j.watres.2011.04.019
   Schewerda J, 2014, WATER SCI TECHNOL, V69, P775, DOI 10.2166/wst.2013.775
   Shahrokhi M, 2012, APPL MATH MODEL, V36, P3725, DOI 10.1016/j.apm.2011.11.001
   Simmons SM, 2017, APPL ACOUST, V126, P81, DOI 10.1016/j.apacoust.2017.05.004
   Smith PR, 2012, IEEE T ULTRASON FERR, V59, P40, DOI 10.1109/TUFFC.2012.2154
   Spehar R, 2015, CHEM ENG SCI, V122, P585, DOI 10.1016/j.ces.2014.10.018
   STAMOU AI, 1989, J HYDRAUL RES, V27, P665, DOI 10.1080/00221688909499117
   Stener JF, 2016, FLOW MEAS INSTRUM, V50, P135, DOI 10.1016/j.flowmeasinst.2016.06.022
   Tarpagkou R, 2014, POWDER TECHNOL, V268, P139, DOI 10.1016/j.powtec.2014.08.030
   Tarud F, 2010, WATER ENVIRON RES, V82, P675, DOI 10.2175/106143009X425889
   Thorne PD, 2004, J ACOUST SOC AM, V116, P2876, DOI 10.1121/1.1808458
   Thorne PD, 2002, CONT SHELF RES, V22, P603, DOI 10.1016/S0278-4343(01)00101-7
   Thorne PD, 2014, CONT SHELF RES, V73, P97, DOI 10.1016/j.csr.2013.10.017
   Torfs E, 2017, WATER RES, V110, P38, DOI 10.1016/j.watres.2016.11.067
   Vajihinejad V, 2018, CHEM ENG J, V346, P447, DOI 10.1016/j.cej.2018.04.039
   van Deventer BBG, 2011, CHEM ENG J, V171, P141, DOI 10.1016/j.cej.2011.03.075
   Vanrolleghem PA, 2006, WATER SCI TECHNOL, V53, P419, DOI 10.2166/wst.2006.148
   Vanrolleghem PA, 2003, WATER SCI TECHNOL, V47, P1
   Wilson GW, 2015, CONT SHELF RES, V106, P130, DOI 10.1016/j.csr.2015.07.005
   Xu GH, 2017, WATER RES, V127, P118, DOI 10.1016/j.watres.2017.10.013
   Zhang PF, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9051028
   Zhang Y, 2015, CHEM ENG SCI, V134, P297, DOI 10.1016/j.ces.2015.05.016
   Zhang Y, 2015, CHEM ENG SCI, V128, P54, DOI 10.1016/j.ces.2015.01.066
NR 75
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115560
DI 10.1016/j.ces.2020.115560
PG 12
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600015
DA 2020-05-12
ER

PT J
AU Jafarian, M
   Chisti, Y
   Nathan, GJ
AF Jafarian, Mehdi
   Chisti, Yusuf
   Nathan, Graham J.
TI Gas-lift circulation of a liquid between two inter-connected bubble
   columns
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Airlift reactor; Bubble column; Chemical looping; Two-phase flow; Gas
   holdup
ID CHEMICAL LOOPING GASIFICATION; FLOW REGIME TRANSITION; SIZE
   DISTRIBUTIONS; HOLDUP; PERFORMANCE; OXIDE; COMBUSTION; REACTORS; DESIGN
AB A pneumatically-mixed novel configuration of two inter-connected bubble column reactors is reported using air-water to demonstrate the device, enabling circulation of a liquid between the columns solely by a gas-lift mechanism. The new reactor may be used for circulating a high temperature/corrosive liquid between the columns, enabling the cyclical processing of a liquid medium with two different gaseous reactants. The effects of superficial gas velocity, unaerated liquid height in the columns and the diameter of aeration nozzles are discussed with reference to the gas holdup in, and rate of liquid circulation between, the two columns, together with the energetics of circulation. The height of the gas-free liquid in the reactor was found to influence the liquid circulation velocity positively, but the effect of aeration nozzles diameter was marginal. The lowest and highest measured flow rates of circulating water between the columns were 0.7 dm(3) min(-1) and 4.2 dm(3) min(-1), respectively. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Jafarian, Mehdi; Nathan, Graham J.] Univ Adelaide, Ctr Energy Technol, Sch Mech Engn, Adelaide, SA 5005, Australia.
   [Chisti, Yusuf] Massey Univ, Sch Engn, Private Bag 11 222, Palmerston North, New Zealand.
RP Jafarian, M (reprint author), Univ Adelaide, Sch Mech Engn, Adelaide, SA 5005, Australia.
EM mehdi.jafarian@adelaide.edu.au
FU Australian Government, through the Australian Renewable Energy Agency
   (ARENA)Australian Renewable Energy Agency (ARENA) [ARENA 1-SRI002];
   Australian Research Council (ARC)Australian Research Council
   [DP180102045]
FX This research was performed as part of the Australian Solar Thermal
   Research Institute (ASTRI), a project supported by the Australian
   Government, through the Australian Renewable Energy Agency (ARENA),
   ARENA 1-SRI002. This program was also supported by the Australian
   Research Council (ARC) through grant DP180102045. The views expressed
   herein are not necessarily the views of the Australian Government, and
   the Australian Government does not accept responsibility for any
   information or advice contained here. The valuable feedback on the
   original draft by the anonymous reviewers is gratefully acknowledged.
CR Besagni G, 2017, CHEM ENG SCI, V170, P270, DOI 10.1016/j.ces.2017.03.043
   Besagni G, 2016, CHEM ENG SCI, V146, P259, DOI 10.1016/j.ces.2016.02.043
   Besagni G, 2016, J FLUID ENG-T ASME, V138, DOI 10.1115/1.4031002
   CHISTI MY, 1987, CHEM ENG COMMUN, V60, P195, DOI 10.1080/00986448708912017
   CHISTI MY, 1988, CHEM ENG SCI, V43, P451, DOI 10.1016/0009-2509(88)87005-2
   CHISTI MY, 1988, CHEM ENG J BIOCH ENG, V38, P149, DOI 10.1016/0300-9467(88)80073-X
   CHISTI MY, 1989, AIRLIFT BIOREACTORS
   CHISTI Y, 1993, CHEM ENG PROG, V89, P38
   Chisti Y, 1998, APPL MECH REV, V51, P33, DOI DOI 10.1115/1.3098989
   DECKWER WD, 1992, BUBBLE COLUMN REACTO
   HIKITA H, 1980, CHEM ENG J BIOCH ENG, V20, P59, DOI 10.1016/0300-9467(80)85006-4
   Hikita H., 1973, B U OSAKA PERFECT A, V22, P151
   Jafarian M., 2017, International Patent Application, Patent No. [PCT/AU2018/050034, 2018132875]
   Jafarian M, 2019, SOL ENERGY, V182, P264, DOI 10.1016/j.solener.2019.02.027
   Jafarian M, 2017, CHEM ENG RES DES, V120, P69, DOI 10.1016/j.cherd.2017.02.005
   LEE YK, 1995, J APPL PHYCOL, V7, P47, DOI 10.1007/BF00003549
   Merchuk JC, 2003, CAN J CHEM ENG, V81, P324
   MERCHUK JC, 1988, J CHEM TECHNOL BIOT, V41, P105
   Moo-Young M, 1981, ADV BIOCHEM ENG, V19, P1, DOI DOI 10.1007/3-540-10464-X_16
   Rubio FC, 2004, CHEM ENG SCI, V59, P4369, DOI 10.1016/j.ces.2004.06.037
   Sarafraz MM, 2019, FUEL PROCESS TECHNOL, V188, P110, DOI 10.1016/j.fuproc.2019.02.015
   Sarafraz MM, 2019, INT J HYDROGEN ENERG, V44, P8038, DOI 10.1016/j.ijhydene.2019.02.081
   Sarafraz MM, 2018, INT J HYDROGEN ENERG, V43, P4195, DOI 10.1016/j.ijhydene.2018.01.035
   Sarafraz MM, 2017, INT J HYDROGEN ENERG, V42, P16396, DOI 10.1016/j.ijhydene.2017.05.116
   Sarafraz MM, 2017, APPL ENERG, V195, P702, DOI 10.1016/j.apenergy.2017.03.106
   Sasaki S, 2017, EXP THERM FLUID SCI, V82, P359, DOI 10.1016/j.expthermflusci.2016.11.032
   Upham DC, 2017, CHEM ENG SCI, V160, P245, DOI 10.1016/j.ces.2016.11.036
   Zhang T, 2017, REV CHEM ENG, V33, P163, DOI 10.1515/revce-2016-0005
   Zhang TW, 2005, CHEM ENG PROCESS, V44, P1221, DOI 10.1016/j.cep.2005.05.001
NR 29
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115574
DI 10.1016/j.ces.2020.115574
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600020
DA 2020-05-12
ER

PT J
AU Jin, XQ
   Chao, C
   Wu, KJ
   Xia, CY
   Fan, XF
AF Jin, Xiaoqiang
   Chao, Cong
   Wu, Kejian
   Xia, Changyou
   Fan, Xianfeng
TI The effect of CO2 phase on drainage process by analysis of transient
   differential pressure
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CO2 phase; CO2 breakthrough time; Capillary displacement pressure;
   Relative permeability; Water recovery
ID ENHANCED OIL-RECOVERY; RELATIVE PERMEABILITY; CONTACT-ANGLE;
   INTERFACIAL-TENSION; NUMERICAL-SIMULATION; SUPERCRITICAL CO2;
   POROUS-MEDIA; STORAGE; WATER; DISPLACEMENTS
AB CO2 sequestrated in deep geological formations can be in gaseous, supercritical or liquid state, depending on subsurface pressure and temperature. In this work, CO2 core flooding experiments were carried out to investigate the effect of CO2 phase on drainage process, especially parameters, such as capillary displacement pressure, relative permeability and displacement efficiency. The results indicated that CO2 phase significantly affected its breakthrough. The breakthrough took place with the least volume of injected liquid CO2 (LCO2) and with the largest volume of injected gas CO2 (gCO(2)). The capillary displacement pressure was measured based on the jump in the pressure profile and it showed the largest jump in gCO(2) drainage. The relative permeability was the largest in LCO2-water displacement and the smallest in gCO(2)-water displacement. The displacement efficiency can be improved by increasing capillary number when it was smaller than a critical value around 2 x 10(-8). (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Jin, Xiaoqiang; Chao, Cong; Fan, Xianfeng] Univ Edinburgh, Sch Engn, Inst Mat & Proc, Edinburgh EH9 3JL, Midlothian, Scotland.
   [Wu, Kejian] Univ Aberdeen, Sch Engn, Aberdeen AB24 3UE, Scotland.
   [Xia, Changyou] Harbin Inst Technol Shenzhen, Sch Econ & Management, Shenzhen Res Ctr Climate Change, Shenzhen 518055, Peoples R China.
RP Fan, XF (reprint author), Univ Edinburgh, Sch Engn, Inst Mat & Proc, Edinburgh EH9 3JL, Midlothian, Scotland.
EM x.fan@ed.ac.uk
FU China Scholarship Council (CSC)China Scholarship Council; UK India
   Education & Research Initiative (UKIERI)
FX Authors gratefully acknowledge the financial supports from China
   Scholarship Council (CSC) and UK India Education & Research Initiative
   (UKIERI).
CR Al-Zaidi E, 2018, INT J GREENH GAS CON, V71, P227, DOI 10.1016/j.ijggc.2018.01.018
   Bachu S, 2009, J CHEM ENG DATA, V54, P765, DOI 10.1021/je800529x
   Berg S, 2013, P NATL ACAD SCI USA, V110, P3755, DOI 10.1073/pnas.1221373110
   Bikkina PK, 2011, INT J GREENH GAS CON, V5, P1259, DOI 10.1016/j.ijggc.2011.07.001
   Buckley SE, 1942, T AM I MIN MET ENG, V146, P107, DOI 10.2118/942107-G
   Cao J., 2014, DETERMINATION 2 PHAS
   Chalbaud C.A., 2007, SPE EAGE RES CHAR SI
   Chase J. M. W., 1998, J PHYS CHEM REF DATA, V9, P1
   Chen A., 2001, P INT S SOC COR AN E, P17
   Chen XY, 2016, WATER RESOUR RES, V52, P8374, DOI 10.1002/2016WR019204
   Cheng CX, 2020, RENEW SUST ENERG REV, V117, DOI 10.1016/j.rser.2019.109492
   CHI SM, 1988, ENERG FUEL, V2, P141, DOI 10.1021/ef00008a007
   CIEPLAK M, 1988, PHYS REV LETT, V60, P2042, DOI 10.1103/PhysRevLett.60.2042
   Duan XG, 2016, J ENERGY INST, V89, P12, DOI 10.1016/j.joei.2015.01.014
   Egermann P., 2006, SPE ANN TECHN C EXH
   Espinoza DN, 2010, WATER RESOUR RES, V46, DOI 10.1029/2009WR008634
   Gozalpour F, 2005, OIL GAS SCI TECHNOL, V60, P537, DOI 10.2516/ogst:2005036
   Hildenbrand A, 2002, GEOFLUIDS, V2, P3, DOI 10.1046/j.1468-8123.2002.00031.x
   Huang JH, 2016, FRONT MICROBIOL, V7, DOI [10.3389/fmicb.2016.00055, 10.3389/fmicb.2016.00060]
   Iglauer S, 2012, J COLLOID INTERF SCI, V386, P405, DOI 10.1016/j.jcis.2012.06.052
   Jessen K, 2005, ENERG CONVERS MANAGE, V46, P293, DOI 10.1016/j.enconman.2004.02.019
   JOHNSON EF, 1959, T AM I MIN MET ENG, V216, P370
   Jung JW, 2012, ENERG FUEL, V26, P6053, DOI 10.1021/ef300913t
   Kozeny J., 1927, Sitzungsberichte der Akademie der Wissenschaften in Wien, Mathematisch-Naturwissenschaftliche Klasse, V136, P271
   Krevor SCM, 2012, WATER RESOUR RES, V48, DOI 10.1029/2011WR010859
   Kyte J., 1956, MECH WATER FLOODING
   LENORMAND R, 1988, J FLUID MECH, V189, P165, DOI 10.1017/S0022112088000953
   Leung DYC, 2014, RENEW SUST ENERG REV, V39, P426, DOI 10.1016/j.rser.2014.07.093
   Li S, 2005, GEOFLUIDS, V5, P326, DOI 10.1111/j.1468-8123.2005.00125.x
   Li XX, 2015, INT J GREENH GAS CON, V36, P106, DOI 10.1016/j.ijggc.2015.02.017
   Li XS, 2012, J CHEM ENG DATA, V57, P1078, DOI 10.1021/je201062r
   Liu R., 2010, INT OIL GAS C EXH CH
   Najafabadi AT, 2013, INT J ENERG RES, V37, P485, DOI 10.1002/er.3021
   Narayanan N, 2018, SPR TRANS CIV ENV EN, pVII
   Nobakht M, 2007, ENERG FUEL, V21, P3469, DOI 10.1021/ef700388a
   Parvazdavani Mohammad, 2017, Egyptian Journal of Petroleum, V26, P171, DOI 10.1016/j.ejpe.2016.01.002
   Perrin JC, 2009, ENRGY PROCED, V1, P3515, DOI 10.1016/j.egypro.2009.02.144
   Perrin JC, 2010, TRANSPORT POROUS MED, V82, P93, DOI 10.1007/s11242-009-9426-x
   Primkulov B.K., 2019, ARXIV190602364
   Ramakrishnan TS, 2013, CHEM ENG SCI, V95, P73, DOI 10.1016/j.ces.2013.03.009
   RAPOPORT LA, 1953, T AM I MIN MET ENG, V198, P139
   Riazi M, 2011, CHEM ENG RES DES, V89, P1827, DOI 10.1016/j.cherd.2011.03.009
   Safi R, 2016, CHEM ENG SCI, V144, P30, DOI 10.1016/j.ces.2016.01.021
   Saraji S, 2014, INT J GREENH GAS CON, V28, P147, DOI 10.1016/j.ijggc.2014.06.024
   Sarmadivaleh M, 2015, J COLLOID INTERF SCI, V441, P59, DOI 10.1016/j.jcis.2014.11.010
   Shi JQ, 2011, INT J GREENH GAS CON, V5, P75, DOI 10.1016/j.ijggc.2010.07.003
   Shi JQ, 2005, OIL GAS SCI TECHNOL, V60, P547, DOI 10.2516/ogst:2005037
   Shiraki R, 2000, APPL GEOCHEM, V15, P265, DOI 10.1016/S0883-2927(99)00048-7
   Tokunaga TK, 2013, WATER RESOUR RES, V49, P4566, DOI 10.1002/wrcr.20316
   Toth J, 2002, J PETROL SCI ENG, V36, P33, DOI 10.1016/S0920-4105(02)00249-8
   Toth J., 2001, SPE PROD OP S SOC PE
   Wang X, 2016, FUEL, V180, P228, DOI 10.1016/j.fuel.2016.04.039
   Xu RN, 2011, ENRGY PROCED, V4, P4418, DOI 10.1016/j.egypro.2011.02.395
NR 53
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115581
DI 10.1016/j.ces.2020.115581
PG 13
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600024
DA 2020-05-12
ER

PT J
AU Kingston, D
   Wilhelmsen, O
   Kjelstrup, S
AF Kingston, Diego
   Wilhelmsen, Oivind
   Kjelstrup, Signe
TI Minimum entropy production in a distillation column for air separation
   described by a continuous non-equilibrium model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Diabatic distillation; Entropy production; Non-equilibrium
   thermodynamics; Air separation
ID DESIGN; EQUIPARTITION; STATE; OPTIMIZATION; PERFORMANCE; REACTORS; PART
AB In this work, we apply the rate-based model of Taylor and Krishna to describe the separation of air in a low-pressure, packed distillation column. By use of numerical optimization, we identify the temperature profile for heat exchange with the column and its surroundings that minimizes the total entropy production. Optimal operation of the column reduces the entropy production by nearly 50%, and the total heating- and cooling duties by 30% and 50%, respectively. We find that the local entropy production is more uniform for the optimal solution than in the adiabatic column, a property that may be helpful for new designs. Using the equilibrium stage model, the state of minimum entropy production has higher cooling/heating duties than in the rate-based model case. This shows that more sophisticated models can be beneficial for the development of reliable strategies to improve the energy efficiency of distillation columns. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Kingston, Diego] Univ Buenos Aires, Fac Ingn, Dept Quim, Paseo Colon 850,C1063ACV, Buenos Aires, DF, Argentina.
   [Wilhelmsen, Oivind] Norwegian Univ Sci & Technol, Dept Energy & Proc Engn, NO-7491 Trondheim, Norway.
   [Wilhelmsen, Oivind] SINTEF Energy Res, NO-7465 Trondheim, Norway.
   [Kingston, Diego; Kjelstrup, Signe] Norwegian Univ Sci & Technol, Dept Chem, PoreLab, NO-7491 Trondheim, Norway.
RP Kingston, D (reprint author), Univ Buenos Aires, Fac Ingn, Dept Quim, Paseo Colon 850,C1063ACV, Buenos Aires, DF, Argentina.
EM dkingston@fi.uba.ar
FU Universidad de Buenos AiresUniversity of Buenos Aires [Res. C.S.
   1561/18]; HighEFF - Centre for an Energy Efficient and Competitive
   Industry for the Future, an 8 year Research Center under the FMEscheme
   (Centre for Environment-friendly Energy Research) [257632]; Research
   Council of Norway for PoreLab Center of ExcellenceResearch Council of
   Norway [262644]
FX Diego Kingston would like to thank Universidad de Buenos Aires for the
   travel grant to visit the Center of Excellence PoreLab, given by Res.
   C.S. 1561/18. This publication has been partly funded by HighEFF -
   Centre for an Energy Efficient and Competitive Industry for the Future,
   an 8 year Research Center under the FMEscheme (Centre for
   Environment-friendly Energy Research, 257632). The authors are grateful
   to the Research Council of Norway for PoreLab Center of Excellence,
   project no. 262644. The authors are grateful to Eivind Johannessen for
   valuable comments at the start of this work and making available his
   code for entropy production minimization to understand programming
   issues.
CR Agrawal R, 1991, GAS SEP PURIF, V5, P139
   Chang L, 2014, SEP PURIF TECHNOL, V134, P73, DOI 10.1016/j.seppur.2014.07.013
   de Koeijer G, 2003, CHEM ENG SCI, V58, P1587, DOI 10.1016/S0009-2509(02)00627-9
   de Koeijer G, 2004, ENERGY, V29, P2425, DOI 10.1016/j.energy.2004.03.034
   de Koeijer GM, 2002, IND ENG CHEM RES, V41, P5826, DOI 10.1021/ie010872p
   Fu C, 2012, ENERGY, V44, P60, DOI 10.1016/j.energy.2012.01.065
   Hande R, 2019, INT J HYDROGEN ENERG, V44, P15045, DOI 10.1016/j.ijhydene.2019.03.229
   Johannessen E, 2005, CHEM ENG SCI, V60, P3347, DOI 10.1016/j.ces.2005.01.026
   Johannessen E, 2004, ENERGY, V29, P2403, DOI 10.1016/j.energy.2004.03.033
   Johannessen E., 2004, THESIS
   Johannessen E, 2007, ENERGY, V32, P467, DOI 10.1016/j.energy.2006.06.009
   Kiss AA, 2014, CHEM ENG PROCESS, V86, P125, DOI 10.1016/j.cep.2014.10.017
   Kjelstrup S., 2017, NONEQUILIBRIUM THERM
   KRISHNAMURTHY R, 1985, AICHE J, V31, P456, DOI 10.1002/aic.690310313
   Magnanelli E, 2018, COMPUT CHEM ENG, V117, P105, DOI 10.1016/j.compchemeng.2018.06.002
   Nakaiwa M, 2003, CHEM ENG RES DES, V81, P162, DOI 10.1205/026387603321158320
   Perry R.H., 2008, PERRYS CHEM ENG HDB
   RATKJE SK, 1995, IND ENG CHEM RES, V34, P3001, DOI 10.1021/ie00048a011
   Rivero R., 1993, ENERGY EFFICIENCY PR, P1254
   Rizk J, 2012, ENERGY, V37, P417, DOI 10.1016/j.energy.2011.11.012
   Rosjorde A, 2005, CHEM ENG SCI, V60, P1199, DOI 10.1016/j.ces.2004.09.059
   Rosjorde A., 2004, THESIS
   Sauar E, 1997, ENERG CONVERS MANAGE, V38, P1777, DOI 10.1016/S0196-8904(96)00201-4
   Sauar E, 2001, J PHYS CHEM A, V105, P2312, DOI 10.1021/jp003555p
   Schaller M, 2002, J NON-EQUIL THERMODY, V27, P257, DOI 10.1515/JNETDY.2002.015
   Schaller M, 2001, COMPUT CHEM ENG, V25, P1537, DOI 10.1016/S0098-1354(01)00717-7
   Seader J.D., 2011, SEPARATION PROCESS P
   TAKAMATSU T, 1988, J CHEM ENG JPN, V21, P595, DOI 10.1252/jcej.21.595
   Taylor R., 1992, MULTICOMPONENT MASS
   TONDEUR D, 1987, IND ENG CHEM RES, V26, P50, DOI 10.1021/ie00061a010
   van der Ham LV, 2012, ENERG CONVERS MANAGE, V61, P31, DOI 10.1016/j.enconman.2012.03.004
   van der Ham LV, 2010, CHEM ENG SCI, V65, P2236, DOI 10.1016/j.ces.2009.12.021
   van der Ham L.V., 2011, THESIS
   Wakabayashi T, 2019, CHEM ENG RES DES, V142, P1, DOI 10.1016/j.cherd.2018.11.031
   Wilhelmsen O, 2018, INT J HYDROGEN ENERG, V43, P5033, DOI 10.1016/j.ijhydene.2018.01.094
   Wilhelmsen O, 2010, INT J HYDROGEN ENERG, V35, P13219, DOI 10.1016/j.ijhydene.2010.08.118
   Zhou H, 2012, IND ENG CHEM RES, V51, P15431, DOI 10.1021/ie3022225
NR 37
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115539
DI 10.1016/j.ces.2020.115539
PG 13
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600005
DA 2020-05-12
ER

PT J
AU Lawson, S
   Adebayo, B
   Robinson, C
   Al-Naddaf, Q
   Rownaghi, AA
   Rezaei, F
AF Lawson, Shane
   Adebayo, Busuyi
   Robinson, Chad
   Al-Naddaf, Qasim
   Rownaghi, Ali A.
   Rezaei, Fateme
TI The effects of cell density and intrinsic porosity on structural
   properties and adsorption kinetics in 3D-printed zeolite monoliths
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE 3D printing; Zeolite monolith; Intrinsic porosity; Adsorption kinetics;
   CO2 capture
ID FIXED-BED ADSORPTION; CARBON-DIOXIDE; 13X ZEOLITE; FLUE-GAS; COMPOSITE
   MONOLITHS; CO2; SEPARATION; PRESSURE; CAPTURE; ADSORBENTS
AB Herein, we report the evaluation of dynamic performance of 3D-printed zeolite monoliths for CO2/N-2 separation at 5 bar 25 degrees C. Monoliths with various cell densities (200, 400, 600 cpsi) and porosities (0.23-0.46) were printed and the effects of cell density, wall porosity, and inlet gas velocity on their separation performance were investigated. Dynamic breakthrough tests with 10% CO2/N-2 revealed that increasing cell density gives rise to gas throttling, inadequate time for molecular mass transfer, and broad wavefronts. For 200 cpsi monoliths, upon increasing wall porosity from 0.23 to 0.46, the mass transfer zone (MTZ) length decreased from 0.40 cm to 0.07 cm at the feed velocity of 1.8 cm/s. The mass transfer coefficients estimated from modeling the breakthrough profiles were found to decrease steadily with both velocity and monolith cell density. In the macroporous samples, the best mass transfer coefficient was found to be 0.049 s(-1) for the 200 cpsi monolith with kaolin binder substitution. Both increasing the plasticizer concentration and substituting a macroporous binder promoted mass transfer rate, however, the former method increased the number of zeolite-bentonite bonds around large surface defects during burnout and reduced the CO2 adsorption capacity by 27% from the other formulations. On the basis of adsorption capacity and kinetics, utilization of a macroporous binder was found to be the best method of developing 3D-printed zeolite monoliths because it could reduce intraparticle resistance without compromising adsorption capacity or mechanical integrity. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Lawson, Shane; Adebayo, Busuyi; Robinson, Chad; Al-Naddaf, Qasim; Rownaghi, Ali A.; Rezaei, Fateme] Missouri Univ Sci & Technol, Dept Chem & Biochem Engn, Rolla, MO 65409 USA.
RP Rezaei, F (reprint author), Missouri Univ Sci & Technol, Dept Chem & Biochem Engn, Rolla, MO 65409 USA.
EM rezaeif@mst.edu
OI Rezaei, Fateme/0000-0002-4214-4235
CR Agueda VI, 2015, CHEM ENG SCI, V124, P159, DOI 10.1016/j.ces.2014.08.039
   Al-Mamoori A, 2017, ENERGY TECHNOL-GER, V5, P834, DOI 10.1002/ente.201600747
   Barrande M, 2007, ANAL CHEM, V79, P9115, DOI 10.1021/ac071377r
   Benitez J., 2009, PRINCIPLE MODERN APP
   Byrne RS, 2002, INT J PHARM, V246, P61, DOI 10.1016/S0378-5173(02)00357-5
   Chahbani MH, 2000, SEP PURIF TECHNOL, V20, P185, DOI 10.1016/S1383-5866(00)00108-8
   Chandrasekhar S, 2002, APPL CLAY SCI, V21, P133, DOI 10.1016/S0169-1317(01)00083-7
   Chen JW, 2008, APPL CATAL A-GEN, V345, P1, DOI 10.1016/j.apcata.2008.04.010
   Couck S, 2018, MICROPOR MESOPOR MAT, V255, P185, DOI 10.1016/j.micromeso.2017.07.014
   Couck S, 2017, CHEM ENG J, V308, P719, DOI 10.1016/j.cej.2016.09.046
   Cychosz KA, 2017, CHEM SOC REV, V46, P389, DOI 10.1039/c6cs00391e
   Da Silva FA, 1999, IND ENG CHEM RES, V38, P2051, DOI 10.1021/ie980640z
   Dantas TLP, 2011, CHEM ENG J, V172, P698, DOI 10.1016/j.cej.2011.06.037
   DIAMOND S, 1970, CLAY CLAY MINER, V18, P7, DOI 10.1346/CCMN.1970.0180103
   Farooq S, 2002, IND ENG CHEM RES, V41, P1098, DOI 10.1021/ie0104621
   Girimonte R, 2017, POWDER TECHNOL, V311, P9, DOI 10.1016/j.powtec.2017.01.033
   Halevi O, 2018, ADV SUSTAIN SYST, V2, DOI 10.1002/adsu.201700150
   Hasegawa G, 2013, CHEM MATER, V25, P3504, DOI 10.1021/cm401933a
   Hossain MI, 2019, IND ENG CHEM RES, V58, P21679, DOI 10.1021/acs.iecr.9b04756
   Hu XY, 2014, ADSORPTION, V20, P121, DOI 10.1007/s10450-013-9554-z
   Joos L, 2013, LANGMUIR, V29, P15936, DOI 10.1021/la403824g
   Kaufhold S, 2013, J POROUS MAT, V20, P191, DOI 10.1007/s10934-012-9589-7
   Kooti M, 2018, J NAT GAS SCI ENG, V57, P331, DOI 10.1016/j.jngse.2018.07.015
   Lawson S, 2019, ENERG FUEL, V33, P2399, DOI 10.1021/acs.energyfuels.8b04508
   Lawson S, 2018, ACS APPL MATER INTER, V10, P19076, DOI 10.1021/acsami.8b05192
   Lawson S, 2017, SEP PURIF TECHNOL, V183, P173, DOI 10.1016/j.seppur.2017.03.072
   Li G, 2008, ADSORPTION, V14, P415, DOI 10.1007/s10450-007-9100-y
   Lodewyckx P., 2004, ADSORP J INT ADSORP
   Lodge KB, 2010, POWDER TECHNOL, V204, P167, DOI 10.1016/j.powtec.2010.07.028
   Malbrunot P, 1997, LANGMUIR, V13, P539, DOI 10.1021/la950969e
   Mosca A, 2010, MICROPOR MESOPOR MAT, V130, P38, DOI 10.1016/j.micromeso.2009.10.010
   Mulgundmath VP, 2012, SEP PURIF TECHNOL, V85, P17, DOI 10.1016/j.seppur.2011.07.038
   Myers S., 2010, SAE TECHNICAL PAPER, V1, DOI DOI 10.4271/2001-01-3663
   Pullumbi P, 2019, CURR OPIN CHEM ENG, V24, P131, DOI 10.1016/j.coche.2019.04.008
   Rajagopalan AK, 2016, INT J GREENH GAS CON, V46, P76, DOI 10.1016/j.ijggc.2015.12.033
   Regufe MJ, 2018, ADSORPTION, V24, P249, DOI 10.1007/s10450-018-9938-1
   Rezaei F, 2011, SEP PURIF TECHNOL, V81, P191, DOI 10.1016/j.seppur.2011.07.027
   Rezaei F, 2010, SEP PURIF TECHNOL, V70, P243, DOI 10.1016/j.seppur.2009.10.004
   Rezaei F, 2015, MICROPOR MESOPOR MAT, V204, P34, DOI 10.1016/j.micromeso.2014.10.047
   Rezaei F, 2012, CHEM ENG SCI, V69, P270, DOI 10.1016/j.ces.2011.10.039
   Rezaei F, 2009, CHEM ENG SCI, V64, P5182, DOI 10.1016/j.ces.2009.08.029
   Ruthven D.M., 1984, PRINCIPALS ADSORPTIO
   Sadeghi F, 2017, CHEM ENG RES DES, V118, P21, DOI 10.1016/j.cherd.2016.12.003
   Sarker AI, 2017, ENRGY PROCED, V114, P2450, DOI 10.1016/j.egypro.2017.03.1394
   Sivakumar SV, 2011, IND ENG CHEM RES, V50, P3426, DOI 10.1021/ie101177x
   Susarla N, 2015, CHEM ENG RES DES, V102, P354, DOI 10.1016/j.cherd.2015.06.033
   Thakkar H, 2018, CHEM ENG J, V348, P109, DOI 10.1016/j.cej.2018.04.178
   Thakkar H, 2017, ACS APPL MATER INTER, V9, P35908, DOI 10.1021/acsami.7b11626
   Thakkar H, 2016, ACS APPL MATER INTER, V8, P27753, DOI 10.1021/acsami.6b09647
   Thommes M, 2015, PURE APPL CHEM, V87, P1051, DOI 10.1515/pac-2014-1117
   Wang YX, 2019, SMALL, V15, DOI 10.1002/smll.201900058
   Wang ZY, 2014, SCI REP-UK, V4, DOI 10.1038/srep05939
   Webley PA, 2014, ADSORPTION, V20, P225, DOI 10.1007/s10450-014-9603-2
   Won W, 2012, SEP PURIF TECHNOL, V85, P120, DOI 10.1016/j.seppur.2011.09.056
   Xiao P, 2008, ADSORPTION, V14, P575, DOI 10.1007/s10450-008-9128-7
   Youn HK, 2011, MATER LETT, V65, P1772, DOI 10.1016/j.matlet.2011.03.039
NR 56
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115564
DI 10.1016/j.ces.2020.115564
PG 13
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600017
DA 2020-05-12
ER

PT J
AU Li, DS
   Wu, YF
   Wei, PP
   Gao, X
   Li, M
   Zhang, CB
   Zhou, ZJ
   Lu, WY
AF Li, Dashuai
   Wu, Yufen
   Wei, Panpan
   Gao, Xiao
   Li, Man
   Zhang, Chuanbo
   Zhou, Zhijiang
   Lu, Wenyu
TI Metabolic engineering of Yarrowia lipolytica for heterologous oleanolic
   acid production
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Yarrowia lipolytica; Oleanolic acid; Cytochrome P450 monooxygenase;
   Metabolic engineering
ID URSOLIC ACID; ESCHERICHIA-COLI; BIOSYNTHESIS; PATHWAY; OPTIMIZATION;
   INTEGRATION; EXPRESSION; CLONING; GENES
AB Oleanolic acid (OA) is a pentacyclic triterpenoid known for its biological properties such as antioxidation activity. Herein, we developed an efficient biosynthetic pathway for OA production in Yarrowia lipolytica. The engineered strain, YL-OA0, produced 16.3 mg/L of OA, and the production efficiency was further increased by 5.65-fold to 92.1 mg/L following overexpression of the key genes involved in the mevalonate (MVA) pathway. Transcriptomic and metabolomic analyses demonstrated the increase in the percentage of unsaturated fatty acids. The electron transfer of the strain YL-OA7 was restricted. Therefore, we fused the gene encoding cytochrome P450 (CYP716A12) to that encoding NADPH-P450 reductase; this resulted in an increase in the OA yield to 129.9 mg/L in the strain YL-fuOA1. The strain YL-fuOA1 could produce 540.7 mg/L OA in fed-batch fermentation in a 5 L fermenter. This study shows the feasibility of the production of high value triterpenoid compounds using Y. lipolytica as a platform. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Li, Dashuai; Wu, Yufen; Wei, Panpan; Gao, Xiao; Li, Man; Zhang, Chuanbo; Zhou, Zhijiang; Lu, Wenyu] Tianjin Univ, Sch Chem Engn & Technol, Tianjin, Peoples R China.
   [Lu, Wenyu] Tianjin Univ, Key Lab Syst Bioengn, Minist Educ, Tianjin, Peoples R China.
   [Lu, Wenyu] SynBio Res Platform, Collaborat Innovat Ctr Chem Sci & Engn Tianjin, Tianjin, Peoples R China.
RP Lu, WY (reprint author), Tianjin Univ, Sch Chem Engn & Technol, Tianjin, Peoples R China.
EM wenyulu@tju.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21878220]; Major Research Plan of Tianjin
   [16YFXTSF00460]
FX This work was financially supported by the National Natural Science
   Foundation of China (No. 21878220) and the Major Research Plan of
   Tianjin [No. 16YFXTSF00460].
CR Abad S, 2010, BIOTECHNOL J, V5, P413, DOI 10.1002/biot.200900233
   Ajikumar PK, 2010, SCIENCE, V330, P70, DOI 10.1126/science.1191652
   Baricevic D, 2001, J ETHNOPHARMACOL, V75, P125, DOI 10.1016/S0378-8741(00)00396-2
   Cao X, 2016, BIOTECHNOL BIOFUELS, V9, DOI 10.1186/s13068-016-0626-7
   Cheng Y., 2010, ACTA PHARM SIN, V26, P143
   Chubukov V, 2016, NPJ SYST BIOL APPL, V2, DOI 10.1038/npjsba.2016.9
   Codru A.S., 2014, MOLECULES, V19, P4924
   Dai ZB, 2014, SCI REP-UK, V4, DOI 10.1038/srep03698
   Dai ZB, 2013, METAB ENG, V20, P146, DOI 10.1016/j.ymben.2013.10.004
   Dejong J.H.M., 2010, BIOTECHNOL BIOENG, V93, P212
   Fei S., 2006, J BIOSCI BIOENG, V101
   Fickers P, 2011, BIOTECHNOL ADV, V29, P632, DOI 10.1016/j.biotechadv.2011.04.005
   Fukushima EO, 2011, PLANT CELL PHYSIOL, V52, P2050, DOI 10.1093/pcp/pcr146
   Gao SL, 2017, METAB ENG, V41, P192, DOI 10.1016/j.ymben.2017.04.004
   Gao SL, 2014, BIOTECHNOL LETT, V36, P2523, DOI 10.1007/s10529-014-1634-y
   Guo XY, 2018, BIOCHEM ENG J, V137, P125, DOI 10.1016/j.bej.2018.05.023
   Haralampidis K, 2001, P NATL ACAD SCI USA, V98, P13431, DOI 10.1073/pnas.231324698
   Hayashi H, 2001, BIOL PHARM BULL, V24, P912, DOI 10.1248/bpb.24.912
   Hemmerlin A, 2013, PLANT SCI, V203, P41, DOI 10.1016/j.plantsci.2012.12.008
   Husson F, 2006, J MOL CATAL B-ENZYM, V39, P179, DOI 10.1016/j.molcatb.2006.01.021
   Jiang M, 2012, APPL ENVIRON MICROB, V78, P2497, DOI 10.1128/AEM.07391-11
   Jin H, 2016, APPL MICROBIOL BIOT, V100, P6643, DOI 10.1007/s00253-016-7360-8
   Kim Y.S., 1998, INT J BIOCH CELL BIO, V30
   Kim YH, 2008, BIOSCI BIOTECH BIOCH, V72, P303, DOI 10.1271/bbb.70268
   Kurek A, 2014, POL J MICROBIOL, V63, P21
   Li DS, 2019, J AGR FOOD CHEM, V67, P2581, DOI 10.1021/acs.jafc.9b00009
   Liu HH, 2017, BIOCHEM ENG J, V119, P52, DOI 10.1016/j.bej.2016.12.004
   Liu J, 1995, J ETHNOPHARMACOL, V49, P57, DOI 10.1016/0378-8741(95)90032-2
   Lu CZ, 2018, AICHE J, V64, P3794, DOI 10.1002/aic.16370
   Morita M, 2000, EUR J BIOCHEM, V267, P3453, DOI 10.1046/j.1432-1327.2000.01357.x
   Nicaud JM, 2002, FEMS YEAST RES, V2, P371, DOI 10.1016/S1567-1356(02)00082-X
   Papanikolaou S, 2002, J APPL MICROBIOL, V92, P737, DOI 10.1046/j.1365-2672.2002.01577.x
   Phillips DR, 2006, CURR OPIN PLANT BIOL, V9, P305, DOI 10.1016/j.pbi.2006.03.004
   Rashid S, 2013, EUR J MED CHEM, V66, P238, DOI 10.1016/j.ejmech.2013.05.029
   Sabra W, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0690-0
   Sang-Hyun L., 2015, BIOTECHNOL BIOENG, V111, P2528
   Saravanan R, 2006, LIFE SCI, V78, P713, DOI 10.1016/j.lfs.2005.05.060
   Smith JJ, 1997, MOL CELL BIOL, V17, P2511, DOI 10.1128/MCB.17.5.2511
   Sun J, 2019, CHEM ENG SCI, V196, P82, DOI 10.1016/j.ces.2018.10.052
   Ullevig SL, 2011, ATHEROSCLEROSIS, V219, P409, DOI 10.1016/j.atherosclerosis.2011.06.013
   Xia ML, 2013, BIOTECHNOL BIOENG, V110, P2717, DOI 10.1002/bit.24941
   Xiang LP, 2015, ONCOTARGET, V6, P9295, DOI 10.18632/oncotarget.3261
   Yang X, 2016, BIORESOURCE TECHNOL, V216, P1040, DOI 10.1016/j.biortech.2016.06.028
   Yin H, 2015, BIOTECHNOL LETT, V37, P1249, DOI 10.1007/s10529-015-1784-6
   Yu ZJ, 2016, MOL PHARMACEUT, V13, P1699, DOI 10.1021/acs.molpharmaceut.6b00129
   Zhang XM, 2014, MICROB CELL FACT, V13, DOI 10.1186/s12934-014-0098-z
   Zhao FL, 2016, BIOTECHNOL BIOENG, V113, P1787, DOI 10.1002/bit.25934
   Zhao YJ, 2018, BIORESOURCE TECHNOL, V257, P339, DOI 10.1016/j.biortech.2018.02.096
   ZHENG X, 2015, J APPL BIOPHARM PHAR, V3, P27, DOI DOI 10.14205/2309-4435.2015.03.01.4
NR 49
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115529
DI 10.1016/j.ces.2020.115529
PG 7
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600003
DA 2020-05-12
ER

PT J
AU Li, Q
   Gao, HX
   Liu, S
   Lv, J
   Liang, ZW
AF Li, Qiang
   Gao, Hongxia
   Liu, Sen
   Lv, Juan
   Liang, Zhiwu
TI Novel thermodynamic model for vapor-liquid equilibrium of CO2 in aqueous
   solution of 4-(ethyl-methyl-amino)-2-butanol with designed structures
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE EMAB; Thermodynamic model; CO2 capture; Equilibrium solubility;
   Absorption heat
ID CARBON-DIOXIDE ABSORPTION; N-METHYLDIETHANOLAMINE; ALKANOLAMINE
   SOLUTIONS; DISSOCIATION-CONSTANT; CHEMICAL-STRUCTURE; TERTIARY-AMINES;
   SOLUBILITY; KINETICS; CAPTURE; HEAT
AB The aim of this project was to develop a thermodynamic model for the vapour-liquid equilibrium of an amine-water-carbon dioxide system and to evaluate the CO2 capture performance of aqueous EMAB solution. The structurally modified tertiary amine 4-(ethyl-methyl-amino)-2-butanol (EMAB) was chosen because of its molecular structure-activity relationship. Measurements were made of its equilibrium CO2 solubility, viscosity, dissociation constant, and second-order reaction rate constant, and the heat of absorption was then calculated. Additionally, the novel semi empirical model (Extended C-f model) and the novel rigorous thermodynamic model (fugacity-activity model) which take into consideration the association of the partial molar property and the equation of state were developed to predict the equilibrium CO2 solubility. The models can provide reasonable prediction results with AARDs of 2.3% and 3.68%, respectively. Furthermore, the thermodynamic and dynamic properties of EMAB were analyzed and evaluated by a comprehensive method and compared with some new tertiary amines and traditional commercial amines. The study concludes that EMAB has good CO2 capture performance and is expected to be one of the most promising alternative amines for post combustion CO2 capture technology. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Li, Qiang; Gao, Hongxia; Liu, Sen; Lv, Juan; Liang, Zhiwu] Hunan Univ, Coll Chem & Chem Engn, Joint Int Ctr CO2 Capture & Storage iCCS, Prov Hunan Key Lab Cost Effect Utilizat Fossil Fu, Changsha 410082, Hunan, Peoples R China.
RP Gao, HX; Liang, ZW (reprint author), Hunan Univ, Coll Chem & Chem Engn, Joint Int Ctr CO2 Capture & Storage iCCS, Prov Hunan Key Lab Cost Effect Utilizat Fossil Fu, Changsha 410082, Hunan, Peoples R China.
EM hxgao@hnu.edu.cn; zwliang@hnu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21536003, 21706057, 21978075, 51521006]; Natural
   Science Foundation of Hunan Province in ChinaNatural Science Foundation
   of Hunan Province [2018JJ3033]; China Outstanding Engineer Training Plan
   for Students of Chemical Engineering & Technology in Hunan University
   [2011-40]
FX The financial support from the National Natural Science Foundation of
   China (NSFC-Nos. 21536003, 21706057, 21978075 and 51521006), the Natural
   Science Foundation of Hunan Province in China (No. 2018JJ3033), and the
   China Outstanding Engineer Training Plan for Students of Chemical
   Engineering & Technology in Hunan University (MOE-No. 2011-40).
   Furthermore, the authors would like to state their great appreciation to
   Mr. Wilfired Olson for his assistance with a thorough upgrade of the
   English of the manuscript.
CR Albert A., 2012, DETERMINATION IONIZA
   ALVAREZFUSTER C, 1981, CHEM ENG SCI, V36, P1513, DOI 10.1016/0009-2509(81)85112-3
   Aronu UE, 2011, CHEM ENG SCI, V66, P6393, DOI 10.1016/j.ces.2011.08.042
   Bottinger W, 2008, FLUID PHASE EQUILIBR, V263, P131, DOI 10.1016/j.fluid.2007.09.017
   Bronsted JN, 1927, J AM CHEM SOC, V49, P2554, DOI 10.1021/ja01409a031
   CHAKRABORTY AK, 1988, J AM CHEM SOC, V110, P6947, DOI 10.1021/ja00229a003
   DESHMUKH RD, 1981, CHEM ENG SCI, V36, P355, DOI 10.1016/0009-2509(81)85015-4
   Diab F, 2013, FLUID PHASE EQUILIBR, V353, P22, DOI 10.1016/j.fluid.2013.05.029
   DONALDSON TL, 1980, IND ENG CHEM FUND, V19, P260, DOI 10.1021/i160075a005
   Dreimanis A., 1962, J SEDIMENT PETROL, V32, P520, DOI [10.1306/74D70D08-2B21-11D7-8648000102C1865D, DOI 10.1306/74D70D08-2B21-11D7-8648000102C1865D]
   Dymond J.H., 2003, VIRIAL COEFFICIENTS
   EDWARDS TJ, 1978, AICHE J, V24, P966, DOI 10.1002/aic.690240605
   Gao HX, 2020, INT J GREENH GAS CON, V94, DOI 10.1016/j.ijggc.2019.102948
   Haji-Sulaiman MZ, 1998, CHEM ENG RES DES, V76, P961, DOI 10.1205/026387698525603
   HU W, 1990, CHEM ENG COMMUN, V94, P53, DOI 10.1080/00986449008911455
   Jamal A, 2006, CHEM ENG SCI, V61, P6571, DOI 10.1016/j.ces.2006.04.046
   Kamps APS, 1996, J CHEM ENG DATA, V41, P1505
   KENT RL, 1976, HYDROCARB PROCESS, V55, P87
   Kim I, 2007, IND ENG CHEM RES, V46, P5803, DOI 10.1021/ie0616489
   Kim YE, 2013, B KOREAN CHEM SOC, V34, P783, DOI 10.5012/bkcs.2013.34.3.783
   Kundu M, 2003, J CHEM ENG DATA, V48, P789, DOI 10.1021/je0201626
   Liang ZW, 2015, INT J GREENH GAS CON, V40, P26, DOI 10.1016/j.ijggc.2015.06.017
   LITTEL RJ, 1992, CHEM ENG SCI, V47, P2027, DOI 10.1016/0009-2509(92)80319-8
   Liu HL, 2017, CHEM ENG SCI, V170, P3, DOI 10.1016/j.ces.2017.02.032
   Liu HR, 2017, DESTECH TRANS ENVIR, P1
   Liu JZ, 2012, INT J GREENH GAS CON, V9, P148, DOI 10.1016/j.ijggc.2012.03.013
   Liu S, 2019, AICHE J, V65, P652, DOI 10.1002/aic.16469
   Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859
   Najafloo A, 2015, J CHEM THERMODYN, V82, P143, DOI 10.1016/j.jct.2014.11.006
   Puxty G, 2009, ENVIRON SCI TECHNOL, V43, P6427, DOI 10.1021/es901376a
   Rayer AV, 2012, CARBON MANAG, V3, P467, DOI 10.4155/CMT.12.47
   Rho SW, 1997, J CHEM ENG DATA, V42, P1161, DOI 10.1021/je970097d
   Sema T, 2019, INT J GREENH GAS CON, V90, DOI 10.1016/j.ijggc.2019.102796
   Sema T, 2011, IND ENG CHEM RES, V50, P14008, DOI 10.1021/ie2008345
   Shokouhi M, 2015, FLUID PHASE EQUILIBR, V404, P96, DOI 10.1016/j.fluid.2015.06.034
   Singh P, 2007, INT J GREENH GAS CON, V1, P5, DOI 10.1016/S1750-5836(07)00015-1
   Singh P, 2009, CHEM ENG RES DES, V87, P135, DOI 10.1016/j.cherd.2008.07.014
   Singto S, 2017, ENRGY PROCED, V114, P852, DOI 10.1016/j.egypro.2017.03.1227
   Singto S, 2016, SEP PURIF TECHNOL, V167, P97, DOI 10.1016/j.seppur.2016.05.002
   Tagiuri A, 2016, J CHEM ENG DATA, V61, P247, DOI 10.1021/acs.jced.5b00517
   TEE LS, 1966, IND ENG CHEM FUND, V5, P363, DOI 10.1021/i160019a012
   Tellez-Arredondo P, 2013, FLUID PHASE EQUILIBR, V344, P45, DOI 10.1016/j.fluid.2013.01.005
   Tokarska KB, 2018, NAT CLIM CHANGE, V8, P296, DOI 10.1038/s41558-018-0118-9
   TONTIWACHWUTHIKUL P, 1991, J CHEM ENG DATA, V36, P130, DOI 10.1021/je00001a038
   Tontiwachwuthikul P., 2011, US Patent Application, Patent No. [US 2011/007910078 B2, 2011007910078]
   Xiao M, 2019, AICHE J, V65, DOI 10.1002/aic.16605
   Xiao M, 2017, AICHE J, V63, P3395, DOI 10.1002/aic.15709
   Xiao M, 2016, APPL ENERG, V184, P219, DOI 10.1016/j.apenergy.2016.10.006
   Zhang R, 2020, IND ENG CHEM RES, V59, P3261, DOI 10.1021/acs.iecr.9b05247
   Zhang Y, 2011, FLUID PHASE EQUILIBR, V311, P67, DOI 10.1016/j.fluid.2011.08.025
   Zhou WJ, 2016, ENERGY, V106, P464, DOI 10.1016/j.energy.2016.03.090
NR 51
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115557
DI 10.1016/j.ces.2020.115557
PG 14
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600014
DA 2020-05-12
ER

PT J
AU Li, S
   Wheeler, VM
   Kumar, A
   Lipinski, W
AF Li, Sha
   Wheeler, Vincent M.
   Kumar, Apurv
   Lipinski, Wojciech
TI Numerical modelling of ceria undergoing reduction in a particle-gas
   counter-flow: Effects of chemical kinetics under isothermal conditions
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Particle-gas reactive counter-flow; Euler-Lagrange approach; Ceria
   reduction; Reaction kinetics; Thermodynamics
ID RADIATIVE HEAT-TRANSFER; OXIDE DISSOCIATION KINETICS;
   CONCENTRATED-SOLAR; THERMAL REDUCTION; THERMODYNAMIC ANALYSES;
   STEAM-GASIFICATION; AEROSOL REACTOR; FUEL PRODUCTION; SUSPENSION; CO2
AB A numerical model is employed to simulate a single tube reactor featuring a downward particle flow counter to an upward inert gas flow for ceria reduction in the dilute flow regime. The coupled phenomena of mass and momentum transfer as well as chemical kinetics are simulated assuming isothermal operation for the reactor. The model predicts the reduction extent under varying reaction kinetics as well as design and operational choices. The reduction extent is found to increase with the reaction rate constant until achieving the thermodynamic upper limit at a certain critical value. This critical rate constant signifies a transition from a chemical kinetics limited conversion to a gas advection limited conversion. The effect of the reactor length and the particle size on reaction extent is studied for a range of realistic cases. An empirical correlation is developed to quantify the effects of particle and gas flow rates on reduction extent at both slow and fast kinetics. The present work offers insights to help guide reactor design and operation towards achieving the maximum reduction extent. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Li, Sha; Kumar, Apurv; Lipinski, Wojciech] Australian Natl Univ, Res Sch Elect Energy & Mat Engn, Canberra, ACT 2601, Australia.
   [Wheeler, Vincent M.] Univ Wisconsin Stout, Dept Engn & Technol, Menomonie, WI 54751 USA.
   [Kumar, Apurv] Federat Univ, Sch Sci Engn & Informat Technol, Ballarat, Vic, Australia.
RP Lipinski, W (reprint author), Australian Natl Univ, Res Sch Elect Energy & Mat Engn, Canberra, ACT 2601, Australia.
EM wojciech.lipinski@anu.edu.au
OI Wheeler, Vincent/0000-0002-2331-4905
FU China Scholarship CouncilChina Scholarship Council [[2015]3022,
   201506020092]; Australian Research CouncilAustralian Research Council
   [FT140101213]
FX The financial support of the China Scholarship Council (Sha Li, grant
   no. [2015]3022, 201506020092) and the Australian Research Council
   (Wojciech Lipin ' ski, Future Fellowship, award no. FT140101213) is
   gratefully acknowledged. We thank Dr Peter Kreider for the fruitful
   discussions of chemical kinetics models.
CR Abanades S, 2007, CHEM ENG SCI, V62, P6323, DOI 10.1016/j.ces.2007.07.042
   Ackermann S, 2014, J PHYS CHEM C, V118, P5216, DOI 10.1021/jp500755t
   ANSYS Inc., ANSYS FLUENT THEOR G
   Bader R, 2019, J THERMOPHYS HEAT TR, V33, P63, DOI 10.2514/1.T5314
   Bader R, 2013, ENERG FUEL, V27, P5533, DOI 10.1021/ef400132d
   Belloni A., 2008, IND GASES PROCESSING
   Bird R.B., 2015, INTRO TRANSPORT PHEN
   Brendelberger S, 2015, SOL ENERGY, V122, P1011, DOI 10.1016/j.solener.2015.10.036
   Bulfin B, 2016, PHYS CHEM CHEM PHYS, V18, P23147, DOI 10.1039/c6cp03158g
   Bulfin B, 2013, J PHYS CHEM C, V117, P24129, DOI 10.1021/jp406578z
   Chueh, 2010, PHILOS T ROYAL SOC M, V368, P1923
   Chueh WC, 2010, SCIENCE, V330, P1797, DOI 10.1126/science.1197834
   Clift R., 1970, P CHEMECA 70, V1, P14
   Crowe CT, 2012, MULTIPHASE FLOWS WITH DROPLETS AND PARTICLES, 2ND EDITION, P1
   Davidson T.A., 1993, SIMPLE ACCURATE METH, P1
   Francis TM, 2010, CHEM ENG SCI, V65, P4397, DOI 10.1016/j.ces.2010.03.048
   Francis TM, 2010, CHEM ENG SCI, V65, P3709, DOI 10.1016/j.ces.2010.03.002
   Graham T., 1846, PHILOS T ROY SOC LON, V136, P573
   Groehn AJ, 2016, SOL ENERGY, V140, P130, DOI 10.1016/j.solener.2016.11.003
   Haussener S, 2009, J SOL ENERG-T ASME, V131, DOI 10.1115/1.3097280
   Hernandez-Perez V, 2011, J COMPUT MULTIPHASE, V3, P13, DOI DOI 10.1260/1757-482X.3.1.13
   Keene DJ, 2014, CHEM ENG SCI, V111, P231, DOI 10.1016/j.ces.2014.01.010
   Keene DJ, 2013, J HEAT TRANS-T ASME, V135, DOI 10.1115/1.4023494
   Kundu P., 2015, FLUID MECH
   Lain S, 2008, POWDER TECHNOL, V184, P76, DOI 10.1016/j.powtec.2007.08.013
   Lain S, 2013, POWDER TECHNOL, V235, P764, DOI 10.1016/j.powtec.2012.11.029
   Lapp J, 2012, ENERGY, V37, P591, DOI 10.1016/j.energy.2011.10.045
   Lapp J, 2014, J SOL ENERG-T ASME, V136, DOI 10.1115/1.4026465
   Li S, 2019, J SOL ENERG-T ASME, V141, DOI 10.1115/1.4042228
   Li S, 2018, ENERG FUEL, V32, P10838, DOI 10.1021/acs.energyfuels.8b02081
   Li S, 2018, ENERG FUEL, V32, P10848, DOI 10.1021/acs.energyfuels.8b02082
   Lipinski W, 2006, CHEM ENG SCI, V61, P7029, DOI 10.1016/j.ces.2006.07.037
   Lipinski W, 2005, HEAT MASS TRANSFER, V41, P1021, DOI 10.1007/s00231-005-0654-5
   Lipinski W, 2013, J THERM SCI ENG APPL, V5, DOI 10.1115/1.4024088
   Loutzenhiser PG, 2010, CHEM ENG SCI, V65, P1855, DOI 10.1016/j.ces.2009.11.025
   Maag G, 2009, INT J HEAT MASS TRAN, V52, P4997, DOI 10.1016/j.ijheatmasstransfer.2009.02.049
   Martinek J, 2012, CHEM ENG SCI, V81, P285, DOI 10.1016/j.ces.2012.06.065
   Marxer D, 2017, ENERG ENVIRON SCI, V10, P1142, DOI 10.1039/c6ee03776c
   MORSI SA, 1972, J FLUID MECH, V55, P193, DOI 10.1017/S0022112072001806
   Oles AS, 2015, SOL ENERGY, V122, P126, DOI 10.1016/j.solener.2015.08.009
   PANLENER RJ, 1975, J PHYS CHEM SOLIDS, V36, P1213, DOI 10.1016/0022-3697(75)90192-4
   Patankar S, 2018, NUMERICAL HEAT TRANS
   Perkins C, 2007, J SOL ENERG-T ASME, V129, P391, DOI 10.1115/1.2769700
   PUTNAM A, 1961, ARSJ-AM ROCKET SOC J, V31, P1467
   Scheffe JR, 2014, IND ENG CHEM RES, V53, P2175, DOI 10.1021/ie402620k
   Schiller L, 1933, Z VER DTSCH ING, V77, P318
   Tou M, 2017, JOULE, V1, P146, DOI 10.1016/j.joule.2017.07.015
   Welte M, 2016, IND ENG CHEM RES, V55, P10618, DOI 10.1021/acs.iecr.6b02853
   Wheeler VM, 2017, SOL ENERGY, V156, P149, DOI 10.1016/j.solener.2017.07.069
   Whitaker S., 2013, METHOD VOLUME AVERAG
   Yaws C.L., 2014, TRANSPORT PROPERTIES
   Z'Graggen A, 2009, INT J HEAT MASS TRAN, V52, P385, DOI 10.1016/j.ijheatmasstransfer.2008.05.023
NR 52
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115553
DI 10.1016/j.ces.2020.115553
PG 14
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600011
DA 2020-05-12
ER

PT J
AU Liu, ZJ
   Cheng, Q
   Wang, YZ
   Li, Y
   Zhang, JL
AF Liu, ZhengJian
   Cheng, Qiang
   Wang, Yaozu
   Li, Yang
   Zhang, Jianliang
TI Sintering neck growth mechanism of Fe nanoparticles: A molecular
   dynamics simulation
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fe nanoparticles; Sintering neck; Surface atom recognition; Crystal
   structure evolution
ID EMBEDDED-ATOM METHOD; ZERO-VALENT IRON; TIO2 NANOPARTICLES; CARBON
   NANOTUBES; METAL; IDENTIFICATION; BEHAVIOR; POWDERS
AB In this paper, the sintering neck growth mechanism of Fe nanoparticles is studied by molecular dynamics method. The accuracy of the EAM potential function is verified. The relationship between the sintering temperature of the nanoparticles and the particle size has been investigated. The sintering temperature of the particles is linearly positively correlated with the size. The whole sintering process can be divided into three stages: the initial sintering, the stable growth and the sudden increase. The atoms are divided into surface atoms and internal atoms depending on the recognition method. By calculating the mean square displacement of the particles and observing the vector displacement of the atoms, the growth mechanisms of the sintering neck at different stages have been analyzed. Similarly, the evolution of crystal structure during sintering is captured by structure analysis. These simulation results firstly reveal the rule of atomic migration and the growth mechanism of the sintering neck. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Liu, ZhengJian; Cheng, Qiang; Wang, Yaozu; Li, Yang; Zhang, Jianliang] Univ Sci & Technol Beijing, Sch Met & Ecol Engn, 30th Xueyuan Rd, Beijing 100083, Peoples R China.
   [Zhang, Jianliang] Univ Queensland, Sch Chem Engn, St Lucia, Qld 4072, Australia.
RP Cheng, Q; Wang, YZ (reprint author), Univ Sci & Technol Beijing, Sch Met & Ecol Engn, 30th Xueyuan Rd, Beijing 100083, Peoples R China.
EM cq19950625@163.com; wgyozu@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [51874025]; Fundamental Research Funds for the
   Central UniversitiesFundamental Research Funds for the Central
   Universities [FRF-NP-19-004]; National Key R&D Program of China
   [2017YFB0304302-01]
FX The authors acknowledge the National Natural Science Foundation of China
   (51874025), Fundamental Research Funds for the Central Universities
   (FRF-NP-19-004) and Supported by National Key R&D Program of China
   (2017YFB0304302-01).
CR Arcidiacono S, 2004, INT J MULTIPHAS FLOW, V30, P979, DOI 10.1016/j.ijmultiphaseflow.2004.03.006
   Ausanio G, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1798-8
   Bacon DJ, 2000, J NUCL MATER, V276, P1, DOI 10.1016/S0022-3115(99)00165-8
   CALDER AF, 1993, J NUCL MATER, V207, P25, DOI 10.1016/0022-3115(93)90245-T
   Chen W, 2008, J AM CHEM SOC, V130, P9414, DOI 10.1021/ja8008192
   Ci LJ, 2002, CHEM PHYS LETT, V359, P63, DOI 10.1016/S0009-2614(02)00600-0
   DAW MS, 1984, PHYS REV B, V29, P6443, DOI 10.1103/PhysRevB.29.6443
   DAW MS, 1993, MATER SCI REP, V9, P251, DOI 10.1016/0920-2307(93)90001-U
   Erlebach A, 2015, NANOSCALE, V7, P2960, DOI 10.1039/c4nr06989g
   FIXMAN M, 1962, J CHEM PHYS, V36, P306, DOI 10.1063/1.1732501
   Francesco D., 2005, PHYS REV B, V72
   GIVORD D, 1988, IEEE T MAGN, V24, P1921, DOI 10.1109/20.11646
   Gong NJ, 2019, NEUROIMAGE, V191, P176, DOI 10.1016/j.neuroimage.2019.02.019
   Gu DD, 2009, MATER DESIGN, V30, P2903, DOI 10.1016/j.matdes.2009.01.013
   Jung H., 1992, J CATAL, V654, P134, DOI DOI 10.1016/0021-9517(92)90350-Q
   Koparde VN, 2005, J PHYS CHEM B, V109, P24280, DOI 10.1021/jp054667p
   Lahoz R, 2020, J IND ENG CHEM, V81, P340, DOI 10.1016/j.jiec.2019.09.024
   Liu XY, 1996, MODEL SIMUL MATER SC, V4, P293, DOI 10.1088/0965-0393/4/3/004
   Manfredi D, 2013, MATERIALS, V6, P856, DOI 10.3390/ma6030856
   Mao Z, 2016, ACTA PHYS-CHIM SIN, V32, P2113, DOI 10.3866/PKU.WHXB201604262
   Miao Z, 2016, ACTA PHYS-CHIM SIN, V32, P2119, DOI 10.3866/PKU.WHXB201604263
   Michalet X, 2010, PHYS REV E, V82, DOI 10.1103/PhysRevE.82.041914
   Pankhurst QA, 2003, J PHYS D APPL PHYS, V36, pR167, DOI 10.1088/0022-3727/36/13/201
   PLIMPTON S, 1995, J COMPUT PHYS, V117, P1, DOI 10.1006/jcph.1995.1039
   Qi L, 2004, INTERMETALLICS, V12, P1191, DOI 10.1016/j.intermet.2004.04.003
   Racka K, 2005, J MAGN MAGN MATER, V290, P127, DOI 10.1016/j.jmmm.2004.11.163
   Raty JY, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.096103
   Sankaranarayanan SKRS, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.195415
   Shi JM, 2019, J ENVIRON SCI, V81, P28, DOI 10.1016/j.jes.2019.02.010
   Simchi A, 2006, MAT SCI ENG A-STRUCT, V428, P148, DOI 10.1016/j.msea.2006.04.117
   Song PX, 2010, J NANOPART RES, V12, P823, DOI 10.1007/s11051-009-9718-7
   Stukowski A, 2009, MODEL SIMUL MATER SC, V17, DOI 10.1088/0965-0393/17/7/075005
   Tian XY, 2009, J EUR CERAM SOC, V29, P1903, DOI 10.1016/j.jeurceramsoc.2008.12.002
   Vilardi G., 2019, POWDER TECHNOL
   Wan S, 2014, ADV MATER RES-SWITZ, V827, P34, DOI 10.4028/www.scientific.net/AMR.827.34
   WANKE SE, 1975, CATAL REV, V12, P92
   Williams PL, 2006, MODEL SIMUL MATER SC, V14, P817, DOI 10.1088/0965-0393/14/5/002
   [吴茂 Wu Mao], 2014, [北京科技大学学报, Journal of University Science and Technology Beijing], V36, P345
   Yang LQ, 2012, APPL PHYS A-MATER, V106, P725, DOI 10.1007/s00339-011-6680-x
   Yang Z, 2008, J PHYS CHEM C, V112, P4937, DOI 10.1021/jp711702y
   Yi LY, 2013, POWDER TECHNOL, V235, P1001, DOI 10.1016/j.powtec.2012.11.043
   Yin WZ, 2019, MINER ENG, V139, DOI 10.1016/j.mineng.2019.105873
   Zhu HL, 1996, PHIL MAG LETT, V73, P27, DOI 10.1080/095008396181073
NR 43
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115583
DI 10.1016/j.ces.2020.115583
PG 9
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600026
DA 2020-05-12
ER

PT J
AU Mola, IA
   Fawell, PD
   Small, M
AF Mola, Ismael A.
   Fawell, Phillip D.
   Small, Michael
TI Particle-resolved direct numerical simulation of drag force on
   permeable, non-spherical aggregates
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Fractal aggregates; Drag coefficient; Non-spherical; Direct numerical
   simulation; Settling velocity
ID SETTLING VELOCITY; FRACTAL DIMENSION; CREEPING FLOW; COEFFICIENT;
   DENSITY; HYDRODYNAMICS; MODEL; PREDICTION; NUMBER; SIZE
AB Aggregation within particle suspensions is often sought to enhance settling. Aggregate settling velocity and density predictions are directly related to the drag coefficient. Despite extensive studies on aggregate drag forces, there remains a lack of explicit correlations suitable across a range of properties and flow conditions; most employ implicit approaches assuming non-spherical, porous aggregates are rigid spheres.
   Particle-resolved Direct Numerical Simulation (DNS) was used to directly study drag on aggregates with various properties (void fraction, shape, orientation, fractal dimension) for Reynolds numbers between 0.13 and 2256. Testing previous implicit models against DNS results, the smallest error achieved was similar to 21%. From simple modifications accounting for aggregate shape and orientation, three new implicit models are proposed that substantially improve drag prediction, reducing error to similar to 11%. Using DNS, a new explicit correlation is proposed to calculate drag coefficients for porous aggregates of arbitrary shape spanning a range of properties with only similar to 6% error. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Mola, Ismael A.; Fawell, Phillip D.] CSIRO Mineral Resources, 7 Conlon St, Waterford, WA 6152, Australia.
   [Mola, Ismael A.; Small, Michael] Complex Syst Grp, Dept Math & Stat, 35 Stirling Hwy, Crawley, WA 6009, Australia.
   [Small, Michael] CSIRO Mineral Resources, 26 Dick Perry Ave, Kensington, WA 6151, Australia.
RP Mola, IA (reprint author), CSIRO Mineral Resources, 7 Conlon St, Waterford, WA 6152, Australia.
EM Ismael.mola@csiro.au
RI Fawell, Phillip D/D-9323-2018; Mola, Ismael/AAM-5566-2020
OI Fawell, Phillip D/0000-0001-8483-3015; Mola, Ismael/0000-0002-3554-250X
FU Australian GovernmentAustralian Government; CSIRO Research-Plus
   Fellowship
FX Y The authors acknowledge assistance from CSIRO's High Performance
   Computational resources and the Pawsey Supercomputing Centre, which are
   both supported by the Australian Government. We also would like to thank
   Dr. Brendan J. Florio for his help on the aggregate generations. The
   first author (I.A. Mola) also wished to recognise financial support from
   a CSIRO Research-Plus Fellowship.
CR ADLER PM, 1987, FARADAY DISCUSS, V83, P145, DOI 10.1039/dc9878300145
   Benn FA, 2018, CHEM ENG SCI, V184, P111, DOI 10.1016/j.ces.2018.03.037
   Binder C, 2006, J COLLOID INTERF SCI, V301, P155, DOI 10.1016/j.jcis.2006.04.045
   Binder C, 2009, J COLLOID INTERF SCI, V331, P243, DOI 10.1016/j.jcis.2008.11.021
   Bushell GC, 2002, ADV COLLOID INTERFAC, V95, P1, DOI 10.1016/S0001-8686(00)00078-6
   CARSON B, 1988, MAR GEOL, V82, P83, DOI 10.1016/0025-3227(88)90008-4
   CLARK MM, 1991, J COLLOID INTERF SCI, V147, P407, DOI 10.1016/0021-9797(91)90174-7
   Clift R., 2005, BUBBLES DROPS PARTIC
   DAMMEL EE, 1991, WATER RES, V25, P841, DOI 10.1016/0043-1354(91)90165-M
   Dobias B., 1993, COAGULATION FLOCCULA
   Florio BJ, 2019, POWDER TECHNOL, V343, P551, DOI 10.1016/j.powtec.2018.11.030
   GIBBS RJ, 1985, J GEOPHYS RES-OCEANS, V90, P3249, DOI 10.1029/JC090iC02p03249
   Gmachowski L, 2007, COLLOID SURFACE A, V295, P34, DOI 10.1016/j.colsurfa.2006.08.026
   Gorczyca B, 2001, WATER QUAL RES J CAN, V36, P687
   GREGORY J, 1989, CRIT REV ENV CONTR, V19, P185, DOI 10.1080/10643388909388365
   Gruy F, 2004, J COLLOID INTERF SCI, V272, P465, DOI 10.1016/j.jcis.2003.11.026
   HAIDER A, 1989, POWDER TECHNOL, V58, P63, DOI 10.1016/0032-5910(89)80008-7
   HAWLEY N, 1982, J GEOPHYS RES-OCEANS, V87, P9489, DOI 10.1029/JC087iC12p09489
   Hilton JE, 2010, CHEM ENG SCI, V65, P1584, DOI 10.1016/j.ces.2009.10.028
   Holzer A, 2008, POWDER TECHNOL, V184, P361, DOI 10.1016/j.powtec.2007.08.021
   Hsu JP, 2005, J COLLOID INTERF SCI, V284, P332, DOI 10.1016/j.jcis.2004.09.070
   HUANG HN, 1993, CLAY CLAY MINER, V41, P373, DOI 10.1346/CCMN.1993.0410314
   Jeldres RI, 2018, POWDER TECHNOL, V326, P190, DOI 10.1016/j.powtec.2017.12.033
   Johnson CP, 1996, ENVIRON SCI TECHNOL, V30, P1911, DOI 10.1021/es950604g
   Johnson TA, 1999, J FLUID MECH, V378, P19, DOI 10.1017/S0022112098003206
   Khelifa A, 2006, J HYDRAUL RES, V44, P390, DOI 10.1080/00221686.2006.9521690
   Kim AS, 2005, J COLLOID INTERF SCI, V285, P627, DOI 10.1016/j.jcis.2004.12.009
   Kim YC, 2012, INT J NUMER METH FL, V69, P1567, DOI 10.1002/fld.2649
   KNOCKE WR, 1993, WATER ENVIRON RES, V65, P735, DOI 10.2175/WER.65.6.5
   Lagarias JC, 1998, SIAM J OPTIMIZ, V9, P112, DOI 10.1137/S1052623496303470
   Lee DJ, 1996, WATER RES, V30, P541, DOI 10.1016/0043-1354(95)00229-4
   LEITH D, 1987, AEROSOL SCI TECH, V6, P153, DOI 10.1080/02786828708959128
   LI DH, 1989, ENVIRON SCI TECHNOL, V23, P1385, DOI 10.1021/es00069a009
   LI DH, 1992, WATER ENVIRON RES, V64, P236, DOI 10.2175/WER.64.3.7
   Li XY, 2001, WATER RES, V35, P3373, DOI 10.1016/S0043-1354(01)00061-6
   Logan B.E., 1999, ENV TRANSPORT PROCES
   MATSUMOTO K, 1977, CHEM ENG SCI, V32, P445, DOI 10.1016/0009-2509(77)85009-4
   MEAKIN P, 1991, REV GEOPHYS, V29, P317, DOI 10.1029/91RG00688
   MILITZER J, 1989, POWDER TECHNOL, V57, P193, DOI 10.1016/0032-5910(89)80075-0
   Mitani T., 1983, JPN WATER RES, V6, P69
   Molaei EA, 2018, POWDER TECHNOL, V338, P677, DOI 10.1016/j.powtec.2018.07.063
   Moudgil B.M., 1988, P ENG FDN C PALM COA, P167
   Mroczka J, 2012, METROL MEAS SYST, V19, P459, DOI 10.2478/v10178-012-0039-2
   Mu Y, 2008, ENVIRON SCI TECHNOL, V42, P1718, DOI 10.1021/es702708p
   NEALE G, 1973, CHEM ENG SCI, V28, P1865, DOI 10.1016/0009-2509(73)85070-5
   PATANKAR SV, 1972, INT J HEAT MASS TRAN, V15, P1787, DOI 10.1016/0017-9310(72)90054-3
   ROGAK SN, 1990, J COLLOID INTERF SCI, V134, P206, DOI 10.1016/0021-9797(90)90268-S
   Rong LW, 2013, CHEM ENG SCI, V99, P44, DOI 10.1016/j.ces.2013.05.036
   ROSNER DE, 1994, AICHE J, V40, P1167, DOI 10.1002/aic.690400708
   SARKAR N, 1994, IEEE T SYST MAN CYB, V24, P115, DOI 10.1109/21.259692
   Schlichting H., 2000, BOUNDARY LAYER THEOR, P29
   Sommerfeld M, 2017, POWDER TECHNOL, V319, P34, DOI 10.1016/j.powtec.2017.06.016
   TAMBO N, 1979, WATER RES, V13, P409, DOI 10.1016/0043-1354(79)90033-2
   Tenneti S, 2014, ANNU REV FLUID MECH, V46, P199, DOI 10.1146/annurev-fluid-010313-141344
   Vahedi A, 2011, WATER RES, V45, P545, DOI 10.1016/j.watres.2010.09.014
   Valle J.M.D., 1948, MICROMERITICS TECHNO
   Vanni M, 2000, CHEM ENG SCI, V55, P685, DOI 10.1016/S0009-2509(99)00316-4
   Veerapaneni S, 1996, J COLLOID INTERF SCI, V177, P45, DOI 10.1006/jcis.1996.0005
   Winterwerp JC, 1998, J HYDRAUL RES, V36, P309, DOI 10.1080/00221689809498621
   WITTEN TA, 1981, PHYS REV LETT, V47, P1400, DOI 10.1103/PhysRevLett.47.1400
   Wittig K, 2017, INT J HEAT MASS TRAN, V112, P1005, DOI 10.1016/j.ijheatmasstransfer.2017.05.035
   Zhou ZY, 2011, CHEM ENG SCI, V66, P6128, DOI 10.1016/j.ces.2011.08.041
   ZHU C, 1994, INT J MULTIPHAS FLOW, V20, P117, DOI 10.1016/0301-9322(94)90009-4
NR 63
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115582
DI 10.1016/j.ces.2020.115582
PG 19
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600025
DA 2020-05-12
ER

PT J
AU Parikh, T
   Mansour, M
   Thevenin, D
AF Parikh, Trupen
   Mansour, Michael
   Thevenin, Dominique
TI Investigations on the effect of tip clearance gap and inducer on the
   transport of air-water two-phase flow by centrifugal pumps
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Centrifugal pumps; Pump inducer; Gas-liquid two-phase flow patterns;
   Computational Fluid Dynamics (CFD); Volume of Fluid model (VOF)
ID PERFORMANCE; IMPELLER; PATTERNS; MODELS; ESP; SIMULATION; FLUID;
   VISUALIZATION; VALIDATION; DYNAMICS
AB This study presents numerical and experimental investigations on air-water flows in a centrifugal pump. The objectives are to examine the accuracy of common numerical models, and to explain the influence of installing an inducer or increasing the tip clearance gap on the performance. 3D transient simulations were performed using the Volume of Fluid (VOF) method for two-phase modeling, and the k - omega SST model for turbulence modeling. The simulations agrees well with the experiments. However, the sudden head drop occurring at 5% gas content could not be predicted. Overall, the averaged relative errors between the simulations and the experiments for part-load, optimal, and overload conditions amount to 4%, 10% and 45%, respectively. The use of the inducer or increasing the gap leads to improvements in performance and phase mixing. Finally, bubble size distributions were analyzed using shadowgraphy, confirming that the inducer and the increased gap provide finer bubbles with narrower distributions. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Parikh, Trupen; Mansour, Michael; Thevenin, Dominique] Univ Magdeburg Otto von Guericke, Lab Fluid Dynam & Tech Flows, D-39106 Magdeburg, Germany.
   [Mansour, Michael] Helwan Univ, Fac Engn Mattaria, Mech Power Engn Dept, Cairo 11718, Egypt.
RP Mansour, M (reprint author), Univ Magdeburg Otto von Guericke, Lab Fluid Dynam & Tech Flows, D-39106 Magdeburg, Germany.
EM michael.mansour@ovgu.de
FU Verband Deutscher Maschinen-und Anlagenbau e.V. (VDMA); Egyptian
   government; Ruhr University in Bochum
FX The authors gratefully acknowledge the financial support of this project
   by the Verband Deutscher Maschinen-und Anlagenbau e.V. (VDMA), as part
   of a collaboration with Professor R. Skoda from Ruhr University in
   Bochum. The Ph.D. work of Mr. Mansour was partially supported by a
   scholarship from the Egyptian government.
CR Amoresano A., 2014, ADV MECH ENG, V6, P1
   Barrios L., 2011, J ENERGY RESOUR TECH, V133, P557
   Barrios L, 2011, J ENERG RESOUR-ASME, V133, DOI 10.1115/1.4004967
   Biazussi J.L., 2013, 22 INT C MECH ENG CO
   Cappellino C.A., 1992, P 9 INT PUMP US S TU, P262
   Caridad J, 2004, J ENERG RESOUR-ASME, V126, P99, DOI 10.1115/1.1725156
   Caridad J, 2008, J PETROL SCI ENG, V63, P18, DOI 10.1016/j.petrol.2008.06.005
   Chan AMC, 1999, NUCL ENG DES, V193, P159, DOI 10.1016/S0029-5493(99)00150-8
   Frank T, 2008, NUCL ENG DES, V238, P647, DOI 10.1016/j.nucengdes.2007.02.056
   Furukawa A, 1996, JSME INT J B-FLUID T, V39, P575, DOI 10.1299/jsmeb.39.575
   Golcu M, 2006, ENERG CONVERS MANAGE, V47, P638, DOI 10.1016/j.enconman.2005.05.001
   Gulich J.F., 2008, CENTRIFUGAL PUMPS
   HIRT CW, 1981, J COMPUT PHYS, V39, P201, DOI 10.1016/0021-9991(81)90145-5
   Huang QS, 2010, CHEM ENG SCI, V65, P5527, DOI 10.1016/j.ces.2010.07.021
   Huang S, 2014, ENERG CONVERS MANAGE, V85, P694, DOI 10.1016/j.enconman.2014.03.023
   Hundshagen M., 2019, P 13 EUR TURB C TURB
   ISHII M, 1984, NUCL ENG DES, V82, P107, DOI 10.1016/0029-5493(84)90207-3
   ISHII M, 1975, AICHE J, V21, P308, DOI 10.1002/aic.690210212
   Jafarzadeh B, 2011, APPL MATH MODEL, V35, P242, DOI 10.1016/j.apm.2010.05.021
   Jain SV, 2015, ENERG CONVERS MANAGE, V89, P808, DOI 10.1016/j.enconman.2014.10.036
   Jiang QF, 2019, ENERGIES, V12, DOI 10.3390/en12061078
   Li X., 2013, J APPL MATH, V2013, P12
   Mansour M, 2017, CHEM ENG SCI, V172, P250, DOI 10.1016/j.ces.2017.06.015
   Mansour M., 2019, 48 TURB 35 PUMP S
   Mansour M, 2020, J FLUID ENG-T ASME, V142, DOI 10.1115/1.4044651
   Mansour M, 2020, IND ENG CHEM RES, V59, P3873, DOI 10.1021/acs.iecr.9b05268
   Mansour M, 2020, CHEM ENG SCI, V214, DOI 10.1016/j.ces.2018.09.046
   Mansour M, 2018, PROCEEDINGS OF THE ASME TURBO EXPO: TURBOMACHINERY TECHNICAL CONFERENCE AND EXPOSITION, 2018, VOL 9
   Mansour M, 2018, EXP THERM FLUID SCI, V99, P487, DOI 10.1016/j.expthermflusci.2018.08.018
   Mansour M, 2018, EXP THERM FLUID SCI, V93, P210, DOI 10.1016/j.expthermflusci.2017.12.033
   MENTER FR, 1994, AIAA J, V32, P1598, DOI 10.2514/3.12149
   Morrison G.L., 2014, OFFSH TECHN C
   Muller T, 2015, 11TH EUROPEAN CONFERENCE ON TURBOMACHINERY: FLUID DYNAMICS AND THERMODYNAMICS
   Muller T., 2016, P INT S TRANSP PHEN
   MURAKAMI M, 1974, B JSME, V17, P1286
   MURAKAMI M, 1976, B JSME, V19, P1141
   Neumann M, 2016, J FLUID ENG-T ASME, V138, DOI 10.1115/1.4033029
   Nica EM, 2017, NPJ QUANTUM MATER, V2, DOI 10.1038/s41535-017-0027-6
   Paternost GM, 2015, SPE PROD OPER, V30, P146, DOI 10.2118/165028-PA
   Pineda H, 2016, J PETROL SCI ENG, V139, P49, DOI 10.1016/j.petrol.2015.12.013
   Pirouzpanah S, 2017, J PETROL SCI ENG, V148, P82, DOI 10.1016/j.petrol.2016.09.051
   Poullikkas A, 2003, PROG NUCL ENERG, V42, P3, DOI 10.1016/S0149-1970(03)80002-1
   Sato S, 1996, JSME INT J B-FLUID T, V39, P223, DOI 10.1299/jsmeb.39.223
   Sauer M., 2003, THESIS
   Schafer T, 2017, NUCL ENG DES, V316, P1, DOI 10.1016/j.nucengdes.2017.02.035
   Serena A., 2016, THESIS
   Shao CL, 2018, INT J HEAT FLUID FL, V71, P460, DOI 10.1016/j.ijheatfluidflow.2018.05.011
   Si QR, 2018, ENERGIES, V11, DOI 10.3390/en11113048
   Siemens PLM Software Inc, 2018, STAR CCM VERS 13 02
   Stephan P., 2010, VDI HEAT ATLAS
   Verde WM, 2017, EXP THERM FLUID SCI, V85, P37, DOI 10.1016/j.expthermflusci.2017.02.019
   Wang QG, 2016, INT J HEAT MASS TRAN, V98, P799, DOI 10.1016/j.ijheatmasstransfer.2016.03.064
   Yamoah S, 2015, CHEM ENG RES DES, V98, P17, DOI 10.1016/j.cherd.2015.04.007
   Zhang JY, 2016, EXP THERM FLUID SCI, V70, P125, DOI 10.1016/j.expthermflusci.2015.08.013
   Zhang JY, 2011, ENERG CONVERS MANAGE, V52, P538, DOI 10.1016/j.enconman.2010.07.029
   Zhang WW, 2017, ENERGIES, V10, DOI 10.3390/en10050634
   Zhu J., 2017, ASME 2017 INT MECH E
   Zhu JJ, 2019, J PETROL SCI ENG, V173, P339, DOI 10.1016/j.petrol.2018.10.038
   Zhu JJ, 2017, J NAT GAS SCI ENG, V45, P625, DOI 10.1016/j.jngse.2017.06.027
   Zhu JJ, 2016, J PETROL SCI ENG, V146, P735, DOI 10.1016/j.petrol.2016.07.033
   Zhu ZC, 2008, CHINESE J CHEM ENG, V16, P528, DOI 10.1016/S1004-9541(08)60116-0
NR 61
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115554
DI 10.1016/j.ces.2020.115554
PG 21
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600012
DA 2020-05-12
ER

PT J
AU Pati, AR
   Tayal, A
   Mohapatra, SS
AF Pati, A. R.
   Tayal, A.
   Mohapatra, S. S.
TI The role of exothermic reaction in the enhancement of high mass flux
   spray cooling
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Sodium carbonate; Exothermic reaction; Vapor layer; Additives
ID HIGH-ALCOHOL SURFACTANT; AIR ATOMIZED SPRAY; HEAT-TRANSFER RATE; BOILING
   REGIMES; REMOVAL RATE; METHODOLOGY; ADDITIVES; CORROSION; STEEL; ALLOY
AB Considerable reduction of vapour layer on the hot substrate is the main requirement during the process of ultrafast cooling of metals and this cannot be achieved by implementing the conventional cooling methodologies. Therefore, in the current work, an attempt has been made to reduce the vapour layer effect by using Na2CO3 as the additive in case of high mass flux spray cooling. The heat transfer analysis depicts augmentation and the maximum heat flux of 1.72 MW/m(2) is achieved in case of water spray with 50 g Na2CO3. The increment in latent heat extraction period due to the exothermic reaction between sodium carbonate and water, alteration in vapour bubble coalescence rate by the released CO2 after reaction and shifting of thermo-physical properties in the positive direction of heat transfer are the key reasons behind the heat transfer enhancement. In addition to the above, the dropwise evaporative cooling experiments were conducted to reveal and support the heat transfer mechanism more clearly. The variation in Nu, Pr and B-g clearly ensures the augmentation in heat transfer rate. Finally, the effect of Na2CO3 on the surface morphology of the steel plate and the corrosive nature are identified by conducting SEM analysis and corrosion test, respectively. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Pati, A. R.; Tayal, A.; Mohapatra, S. S.] Natl Inst Technol Rourkela, Dept Chem Engn, Rourkela 769008, India.
RP Mohapatra, SS (reprint author), NIT, Dept Chem Engn, Spray Boiling Heat Transfer Lab, Rourkela 769008, India.
EM mohapatras@nitrkl.ac.in
CR Abdalrahman KHM, 2014, INT J HEAT MASS TRAN, V78, P76, DOI 10.1016/j.ijheatmasstransfer.2014.06.070
   Alam Umair, 2008, Journal of ASTM International, V5, DOI 10.1520/JAI101805
   Bernardin JD, 1996, INT J HEAT MASS TRAN, V39, P2023, DOI 10.1016/0017-9310(95)00304-5
   Bhatt NH, 2017, EXP HEAT TRANSFER, V30, P369, DOI 10.1080/08916152.2016.1269138
   Bhatt NH, 2017, APPL THERM ENG, V120, P537, DOI 10.1016/j.applthermaleng.2017.03.137
   BROMLEY LA, 1950, CHEM ENG PROG, V46, P221
   BUSBY HR, 1985, INT J NUMER METH ENG, V21, P349, DOI 10.1002/nme.1620210211
   Chakraborty Samarshi, 2019, Thermal Science and Engineering Progress, V10, P217, DOI 10.1016/j.tsep.2019.02.003
   CHANDRA S, 1991, P R SOC-MATH PHYS SC, V432, P13, DOI 10.1098/rspa.1991.0002
   Cheng J, 2017, TRIBOL INT, V115, P483, DOI 10.1016/j.triboint.2017.06.027
   Cheng WL, 2013, EXP THERM FLUID SCI, V45, P198, DOI 10.1016/j.expthermflusci.2012.11.005
   Cui W, 2003, J HEAT TRANS-T ASME, V125, P326, DOI 10.1115/1.1532010
   Dasgupta A, 2015, J HEAT TRANS-T ASME, V137, DOI 10.1115/1.4030909
   DEB S, 1989, INT J HEAT MASS TRAN, V32, P2099, DOI 10.1016/0017-9310(89)90117-8
   Galindo-Luna YR, 2018, INT J ELECTROCHEM SC, V13, P631, DOI 10.20964/2018.01.64
   Guo RC, 2016, APPL THERM ENG, V107, P1065, DOI 10.1016/j.applthermaleng.2016.07.072
   Hammad J, 2004, INT J THERM SCI, V43, P743, DOI 10.1016/j.ijthermalsci.2004.02.014
   Liang GT, 2017, INT J HEAT MASS TRAN, V115, P1174, DOI 10.1016/j.ijheatmasstransfer.2017.06.029
   Liang G, 2017, INT J HEAT MASS TRAN, V115, P1206, DOI 10.1016/j.ijheatmasstransfer.2017.06.022
   Mahmoud MM, 2013, INT J HEAT MASS TRAN, V66, P553, DOI 10.1016/j.ijheatmasstransfer.2013.07.042
   Mohapatra S. S., 2019, Thermal Science and Engineering Progress, V9, P200, DOI 10.1016/j.tsep.2018.11.007
   Mohapatra SS, 2014, HEAT MASS TRANSFER, V50, P587, DOI 10.1007/s00231-013-1260-6
   Orzechowski T, 2013, ENERG CONVERS MANAGE, V76, P918, DOI 10.1016/j.enconman.2013.08.057
   Panda A, 2018, INT J HEAT MASS TRAN, V120, P1287, DOI 10.1016/j.ijheatmasstransfer.2017.12.051
   Pati AR, 2019, INVERSE PROBL SCI EN, V27, P808, DOI 10.1080/17415977.2018.1501369
   Pati AR, 2019, EXP HEAT TRANSFER, V32, P116, DOI 10.1080/08916152.2018.1485784
   Pati AR, 2018, HEAT MASS TRANSFER, V54, P1669, DOI 10.1007/s00231-017-2258-2
   Pati AR, 2018, INT J THERM SCI, V127, P335, DOI 10.1016/j.ijthermalsci.2018.01.028
   Pati AR, 2017, EXP THERM FLUID SCI, V89, P19, DOI 10.1016/j.expthermflusci.2017.07.012
   Puschmann F, 2004, STEEL RES INT, V75, P283, DOI 10.1002/srin.200405956
   Trujillo D.M., 1997, PRACTICAL INVERSE AN
   Trujillo D.M., 2003, INTEMP INVERSE HEAT, P1
   Zhang WW, 2018, INT J HEAT MASS TRAN, V126, P363, DOI 10.1016/j.ijheatmasstransfer.2018.05.130
   Zhao X, 2020, INT J HEAT MASS TRAN, V146, DOI 10.1016/j.ijheatmasstransfer.2019.118819
NR 34
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115556
DI 10.1016/j.ces.2020.115556
PG 11
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600013
DA 2020-05-12
ER

PT J
AU Saqib, S
   Rafiq, S
   Muhammad, N
   Khan, AL
   Mukhtar, A
   Mellon, NB
   Man, Z
   Ullah, S
   Al-Sehemi, AG
   Jamil, F
AF Saqib, Sidra
   Rafiq, Sikander
   Muhammad, Nawshad
   Khan, Asim Laeeq
   Mukhtar, Ahmad
   Mellon, Nurhayati Binti
   Man, Zakaria
   Ullah, Sami
   Al-Sehemi, Abdullah G.
   Jamil, Farrukh
TI Influence of interfacial layer parameters on gas transport properties
   through modeling approach in MWCNTs based mixed matrix composite
   membranes
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Mixed matrix composite membranes; Interfacial layer; Multi-walled carbon
   nanotubes; Permeability; Modeling; And gas separation
ID CO2 SEPARATION PERFORMANCE; WALLED CARBON NANOTUBES; GRAPHENE-OXIDE;
   HALLOYSITE NANOTUBES; THERMAL-CONDUCTIVITY; POLYMERIC MEMBRANES;
   PERMEATION BEHAVIOR; CO2/N-2; FUNCTIONALIZATION; NANOCOMPOSITES
AB Precise prediction of the gas permeability behavior through the mixed matrix Composite membranes (MMMs) composed of the tubular fillers using existing theoretical approaches are infrequent. This is normally due to the neglecting the interfacial characteristics of the tubular filler particles i.e. multi-walled structured carbon nanotubes (MWCNTs) and a matrix composed of polymeric material in the existing theoretical models, especially, the Kang-Jones-Nair (KJN) model and Hamilton-Crosser model (HC) which were developed for the prediction of gas permeability behavior through the mixed matrix membranes (MMMs) composed of the tubular fillers. In this work, raw- and functionalized MWCNTs filler based MMMs in polysulfone (PSF) matrix were synthesized successfully, followed by morphological analysis on matrix interfacial layers parameters. KJN model was modified by introducing pseudo-dispersed phase fillers that influenced the interfacial layer and consequently overall gas permeabilities, which was ignored in existing models. The new proposed theoretical model is able to predict the gas permeability behavior with significantly reduced average absolute relative error (%AARE) of 1.26% compared to 52.43% and 42.71% for unmodified KJN and HC models, respectively. Furthermore, the mKJN model revealed that the interfacial layer thickness is a unique characteristic and is autonomous of the penetrant molecules of gas which may be influenced by the heterogeneity in the experimental conditions. The cross-sectional morphology and mKJN model revealed that the filler functionalization may lead to the improvement in filler-polymer interaction which thus reduced interfacial layer thickness. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Saqib, Sidra; Khan, Asim Laeeq; Jamil, Farrukh] COMSATS Univ Islamabad, Dept Chem Engn, Lahore Campus,Def Rd, Lahore 54000, Punjab, India.
   [Rafiq, Sikander] Univ Engn & Technol, Dept Chem Polymer & Composite Mat Engn, New Campus, Lahore, Pakistan.
   [Muhammad, Nawshad] COMSATS Univ Islamabad, IRCBM, Lahore Campus,Def Rd, Lahore 54000, Punjab, Pakistan.
   [Saqib, Sidra; Mukhtar, Ahmad; Mellon, Nurhayati Binti; Man, Zakaria] UTP, Dept Chem Engn, Seri Iskandar 32610, Perak, Malaysia.
   [Ullah, Sami; Al-Sehemi, Abdullah G.] King Khalid Univ, Coll Sci, Dept Chem, Abha 61413, Saudi Arabia.
RP Rafiq, S (reprint author), Univ Engn & Technol, Dept Chem Polymer & Composite Mat Engn, New Campus, Lahore, Pakistan.
EM sikander@uet.edu.pk
RI Al-Sehemi, Abdullah/AAK-5902-2020; Al-Sehemi, Abdullah/J-9967-2012;
   al-sehemi, Abdullah/AAM-4039-2020; Muhammad, Nawshad/J-7760-2017; Ullah,
   Sami/P-5578-2016
OI Al-Sehemi, Abdullah/0000-0002-6793-3038; Muhammad,
   Nawshad/0000-0001-6453-0658; Ullah, Sami/0000-0002-9669-5737
FU COMSATS University Islamabad, Lahore Campus, Higher Education Commission
   (HEC) under NRPU Project [3957, 998]; Yayasan-UTP research grant,
   Department of Chemical Engineering at Universiti Teknologi PETRONAS
   (UTP), Malaysia [YUTP-0153AA-H01, R.G.P.2/59/40]; King Khalid
   University, Saudi Arabia (Deanship of Scientific Research)
   [R.G.P.2/59/40]
FX The authors are thankful to COMSATS University Islamabad, Lahore Campus,
   Higher Education Commission (HEC) financial support under NRPU Project
   #3957 and NRPU Project #998. The authors would like to acknowledge the
   Yayasan-UTP (YUTP-0153AA-H01) research grant, Department of Chemical
   Engineering at Universiti Teknologi PETRONAS (UTP), Malaysia, King
   Khalid University, Saudi Arabia (Deanship of Scientific Research) for
   financial support through the Research Groups Project under the grant
   number (R.G.P.2/59/40).
CR Ahmad AL, 2014, J MEMBRANE SCI, V451, P55, DOI 10.1016/j.memsci.2013.09.043
   Ahmad NNR, 2017, MICROPOR MESOPOR MAT, V244, P21, DOI 10.1016/j.micromeso.2016.10.001
   Anastasiou S, 2018, MATER CHEM PHYS, V212, P513, DOI 10.1016/j.matchemphys.2018.03.064
   Babar M., 2019, CRYOGENICS
   Babar M, 2020, CRYOGENICS, V105, DOI 10.1016/j.cryogenics.2019.103010
   Baker RW, 2014, MACROMOLECULES, V47, P6999, DOI 10.1021/ma501488s
   Bernardo P, 2009, IND ENG CHEM RES, V48, P4638, DOI 10.1021/ie8019032
   Bird RB, 2007, TRANSPORT PHENOMENA
   Bruggeman DAG, 1935, ANN PHYS-BERLIN, V24, P636, DOI 10.1002/andp.19354160705
   Chawla M, 2020, CHEM ENG TECHNOL, V43, P184, DOI 10.1002/ceat.201900375
   Chehrazi E, 2019, J MEMBRANE SCI, V570, P168, DOI 10.1016/j.memsci.2018.10.038
   Chehrazi E, 2017, ACS APPL MATER INTER, V9, P37321, DOI 10.1021/acsami.7b11545
   Chuah CY, 2018, CHEM REV, V118, P8655, DOI 10.1021/acs.chemrev.8b00091
   Cong HL, 2007, J MEMBRANE SCI, V294, P178, DOI 10.1016/j.memsci.2007.02.035
   Dorosti F, 2011, CHEM ENG J, V171, P1469, DOI 10.1016/j.cej.2011.05.081
   Fatemi S, 2011, CHEM ENG RES DES, V89, P1669, DOI 10.1016/j.cherd.2010.10.002
   Feng YN, 2017, J MEMBRANE SCI, V531, P27, DOI 10.1016/j.memsci.2017.02.040
   Freeman BD, 1999, MACROMOLECULES, V32, P375, DOI 10.1021/ma9814548
   Galizia M, 2017, MACROMOLECULES, V50, P7809, DOI 10.1021/acs.macromol.7b01718
   Ge L, 2017, SEP PURIF TECHNOL, V173, P63, DOI 10.1016/j.seppur.2016.09.015
   Ge L, 2011, J PHYS CHEM C, V115, P6661, DOI 10.1021/jp1120965
   HAMILTON RL, 1962, IND ENG CHEM FUND, V1, P187, DOI 10.1021/i160003a005
   Hashemifard SA, 2010, J MEMBRANE SCI, V347, P53, DOI 10.1016/j.memsci.2009.10.005
   Haul R., 1992, DIFFUSION ZEOLITES O, V97, P146
   HIGUCHI WI, 1960, J AM PHARM ASSOC, V49, P598, DOI 10.1002/jps.3030490910
   Vinh-Thang H, 2014, J MEMBRANE SCI, V452, P271, DOI 10.1016/j.memsci.2013.10.020
   Hoang VT, 2013, CHEM REV, V113, P4980, DOI 10.1021/cr3003888
   Jawad ZA, 2015, CURR NANOSCI, V11, P69
   Jawad ZA, 2015, J MEMBRANE SCI, V476, P590, DOI 10.1016/j.memsci.2014.11.008
   Junaidi MUM, 2013, FUEL PROCESS TECHNOL, V112, P1, DOI 10.1016/j.fuproc.2013.02.014
   Jusoh N, 2016, PROCEDIA ENGINEER, V148, P1259, DOI 10.1016/j.proeng.2016.06.499
   Kang DY, 2011, J MEMBRANE SCI, V381, P50, DOI 10.1016/j.memsci.2011.07.015
   Koolivand H, 2016, POLYM SCI SER A+, V58, P801, DOI 10.1134/S0965545X16050084
   Kumar R, 2013, CHEM COMMUN, V49, P4947, DOI 10.1039/c3cc00136a
   Lee JG, 2017, J MEMBRANE SCI, V526, P395, DOI 10.1016/j.memsci.2016.12.045
   LEVIN ML, 1981, USP FIZ NAUK+, V135, P425, DOI 10.3367/UFNr.0135.198111d.0425
   LEWIS TB, 1970, J APPL POLYM SCI, V14, P1449, DOI 10.1002/app.1970.070140604
   Li XQ, 2015, J MEMBRANE SCI, V479, P1, DOI 10.1016/j.memsci.2015.01.014
   Liew KM, 2016, COMPOS PART A-APPL S, V91, P301, DOI 10.1016/j.compositesa.2016.10.020
   Liu Y, 2016, ACS APPL MATER INTER, V8, P34151, DOI 10.1021/acsami.6b12915
   Mahajan R, 2002, POLYM ENG SCI, V42, P1420, DOI 10.1002/pen.11041
   Mohammadi T, 2008, IND ENG CHEM RES, V47, P7361, DOI 10.1021/ie071493k
   Molyanyan E, 2016, INT J ENVIRON SCI TE, V13, P2001, DOI 10.1007/s13762-016-0989-0
   Mukhtar A., 2019, MICROPOROUS MESOPORO
   Murali RS, 2014, SEP PURIF TECHNOL, V132, P187, DOI 10.1016/j.seppur.2014.05.020
   Niu L, 2007, SENSOR ACTUAT B-CHEM, V126, P361, DOI 10.1016/j.snb.2007.03.018
   Pal R, 2008, J COLLOID INTERF SCI, V317, P191, DOI 10.1016/j.jcis.2007.09.032
   Pal R, 2007, J REINF PLAST COMP, V26, P643, DOI 10.1177/0731684407075569
   Pandey P, 2001, PROG POLYM SCI, V26, P853, DOI 10.1016/S0079-6700(01)00009-0
   Park SH, 2010, IEEE T NANOTECHNOL, V9, P464, DOI 10.1109/TNANO.2009.2032656
   Robeson LM, 2008, J MEMBRANE SCI, V320, P390, DOI 10.1016/j.memsci.2008.04.030
   ROBESON LM, 1991, J MEMBRANE SCI, V62, P165, DOI 10.1016/0376-7388(91)80060-J
   Saqib S, 2020, J NAT GAS SCI ENG, V73, DOI 10.1016/j.jngse.2019.103072
   Saqib S, 2019, CHEM ENG TECHNOL, V42, P30, DOI 10.1002/ceat.201700653
   Sarfraz M, 2016, J TAIWAN INST CHEM E, V65, P427, DOI 10.1016/j.jtice.2016.04.033
   Shan MX, 2018, J MEMBRANE SCI, V549, P377, DOI 10.1016/j.memsci.2017.12.008
   Soleimani M., 2013, ISRN NANOTECHNOL, V2013
   Sridhar S, 2007, SEP PURIF REV, V36, P113, DOI 10.1080/15422110601165967
   STANNETT V, 1978, J MEMBRANE SCI, V3, P97, DOI 10.1016/S0376-7388(00)83016-1
   Sukitpaneenit P, 2012, ENVIRON SCI TECHNOL, V46, P7358, DOI 10.1021/es301559z
   Sun HX, 2017, SEP PURIF TECHNOL, V177, P327, DOI 10.1016/j.seppur.2017.01.015
   Trenberth KE, 2014, NAT CLIM CHANGE, V4, P17, DOI 10.1038/NCLIMATE2067
   Ullah S., 2019, MICROPOROUS MESOPORO
   Ullah S., 2020, MICROPOROUS MESOPORO
   Ullah S., 2019, GREENHOUSE GASES SCI
   Ullah S, 2019, J NAT GAS SCI ENG, V72, DOI 10.1016/j.jngse.2019.103014
   Vu DQ, 2003, J MEMBRANE SCI, V211, P335, DOI 10.1016/S0376-7388(02)00425-8
   Waheed N, 2016, SEP PURIF TECHNOL, V170, P122, DOI 10.1016/j.seppur.2016.06.035
   Wang M, 2015, J MEMBRANE SCI, V495, P252, DOI 10.1016/j.memsci.2015.08.019
   Wang SF, 2016, ENERG ENVIRON SCI, V9, P1863, DOI 10.1039/c6ee00811a
   Wong KC, 2015, INT BIODETER BIODEGR, V102, P339, DOI 10.1016/j.ibiod.2015.02.007
   Wu Y, 2017, ACS APPL MATER INTER, V9, P4998, DOI 10.1021/acsami.6b14895
   Xiao YC, 2009, PROG POLYM SCI, V34, P561, DOI 10.1016/j.progpolymsci.2008.12.004
   Xin QP, 2015, ACS APPL MATER INTER, V7, P1065, DOI 10.1021/am504742q
   Yang LX, 2019, J MEMBRANE SCI, V573, P301, DOI 10.1016/j.memsci.2018.12.018
   Yavari M, 2018, MACROMOLECULES, V51, P2489, DOI 10.1021/acs.macromol.8b00273
   Zhao D, 2017, J MEMBRANE SCI, V521, P104, DOI 10.1016/j.memsci.2016.08.061
   Zhao D, 2014, J MEMBRANE SCI, V467, P41, DOI 10.1016/j.memsci.2014.05.009
   Zhao XF, 2019, APPL SURF SCI, V478, P266, DOI 10.1016/j.apsusc.2019.01.209
   Zhu HT, 2016, ACS APPL MATER INTER, V8, P22696, DOI 10.1021/acsami.6b07686
NR 80
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115543
DI 10.1016/j.ces.2020.115543
PG 17
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600007
DA 2020-05-12
ER

PT J
AU Sathyanath, R
   Aarthi, A
   Kalpathy, SK
AF Sathyanath, Rahul
   Aarthi, A.
   Kalpathy, Sreeram K.
TI Liquid film entrainment during dip coating on a saturated porous
   substrate
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Dip coating; Landau-Levich problem; Thin liquid films; Darcy's law;
   No-slip condition
ID PERMEABILITY; SURFACES; FLOW
AB The present work examines the effect of substrate surface porosity on the coating thickness and meniscus profile during dip coating under saturated porous media conditions. The classical Landau-Levich formulation is modified by encoding the influence of porosity in an effective Navier slip boundary condition at the porous substrate surface. It is shown that simplified Navier slip-based model works well for creeping flow through the porous medium. The film height profile equation is derived as a function of a rescaled capillary number ((Ca) over bar) and a substrate permeability factor, with inertial effects neglected. Numerical solutions show that the classical 2/3rd power dependence of film thickness on capillary number is recovered only at sufficiently high (Ca) over bar values. As (Ca) over bar is decreased, a marked deviation is seen. The shrinking of the entrainment meniscus and the change in meniscus curvature are analyzed in detail. The theoretical results are also validated with a suitable experimental system. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Sathyanath, Rahul; Aarthi, A.; Kalpathy, Sreeram K.] Indian Inst Technol Madras, Dept Met & Mat Engn, Chennai 600036, Tamil Nadu, India.
RP Kalpathy, SK (reprint author), Indian Inst Technol Madras, Dept Met & Mat Engn, Chennai 600036, Tamil Nadu, India.
EM sreeram@iitm.ac.in
FU Science and Engineering Research Board (SERB), New Delhi, India
   [EMR/2016/001479]
FX This work was funded by the Science and Engineering Research Board
   (SERB), New Delhi, India, through the project Grant No. EMR/2016/001479
   to Sreeram K. Kalpathy.
CR Ajaev V., 2012, INTERFACIAL FLUID ME
   Alleborn N, 2004, CHEM ENG SCI, V59, P2071, DOI 10.1016/j.ces.2004.02.006
   BEAVERS GS, 1967, J FLUID MECH, V30, P197, DOI 10.1017/S0022112067001375
   BURDINE NT, 1953, T AM I MIN MET ENG, V198, P71
   CHRISTOPHER RH, 1965, IND ENG CHEM FUND, V4, P422, DOI 10.1021/i160016a011
   Craster RV, 2009, REV MOD PHYS, V81, P1131, DOI 10.1103/RevModPhys.81.1131
   Darhuber AA, 2000, J APPL PHYS, V88, P5119, DOI 10.1063/1.1317238
   Davis JM, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.1850751
   de Gennes PG, 2002, LANGMUIR, V18, P3413, DOI 10.1021/la0116342
   Eggers J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.094502
   Jing G, 2010, LANGMUIR, V26, P2288, DOI 10.1021/la9027223
   Koponen A, 1997, PHYS REV E, V56, P3319, DOI 10.1103/PhysRevE.56.3319
   Krechetnikov R, 2005, PHYS FLUIDS, V17, DOI 10.1063/1.2112647
   Kuznetsov AV, 2002, INT COMMUN HEAT MASS, V29, P35, DOI 10.1016/S0735-1933(01)00322-0
   Lauga E., 2007, SPRINGER HDB EXPT FL, P1219, DOI DOI 10.1007/978-3-540-30299-5_19
   Leal G., 2007, ADV TRANSPORT PHENOM, V7
   LEE CY, 1974, AICHE J, V20, P1079, DOI 10.1002/aic.690200604
   Lettieri M, 2014, APPL SURF SCI, V288, P466, DOI 10.1016/j.apsusc.2013.10.056
   LEVICH VG, 1962, PHYSICOCHEMICAL HYDR
   Li ZR, 2010, APPL PHYS LETT, V97, DOI 10.1063/1.3527076
   Liu XY, 2011, LAB CHIP, V11, P2189, DOI [10.1039/c1lc20161a, 10.1039/c11c20161a]
   Lopez-Alemany A, 2002, J BIOMED MATER RES, V63, P319, DOI 10.1002/jbm.10186
   MARSHALL TJ, 1958, J SOIL SCI, V9, P1, DOI 10.1111/j.1365-2389.1958.tb01892.x
   MILLINGTON R, 1961, T FARADAY SOC, V57, P1200, DOI 10.1039/tf9615701200
   Rio E, 2017, ADV COLLOID INTERFAC, V247, P100, DOI 10.1016/j.cis.2017.01.006
   Sadiq IMR, 2010, CHEM ENG SCI, V65, P4443, DOI 10.1016/j.ces.2010.04.005
   Sadiq IMR, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2841363
   Schmidhalter I, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4794972
   Schunk P., 1997, LIQUID FILM COATING, P673
   SCHUNK PR, 1994, INT J NUMER METH FL, V18, P821, DOI 10.1002/fld.1650180903
   Scriven L., 1988, MRS ONLINE P LIBR AR, V121
   Seiwert J, 2011, EPL-EUROPHYS LETT, V94, DOI 10.1209/0295-5075/94/16002
   Seiwert J, 2011, J FLUID MECH, V669, P55, DOI 10.1017/S0022112010005951
   SPIERS RP, 1974, CHEM ENG SCI, V29, P389, DOI 10.1016/0009-2509(74)80048-5
   Thomas LP, 2004, J FLUID MECH, V503, P299, DOI 10.1017/S0022112004007918
   Tiwari N, 2008, PHYS FLUIDS, V20, DOI 10.1063/1.2842378
   Tobjork D, 2011, ADV MATER, V23, P1935, DOI 10.1002/adma.201004692
   Vannozzi C, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.3680872
   Wenzel RN, 1936, IND ENG CHEM, V28, P988, DOI 10.1021/ie50320a024
   WILSON SDR, 1982, J ENG MATH, V16, P209, DOI 10.1007/BF00042717
   Yimsiri P, 2006, CHEM ENG SCI, V61, P3496, DOI 10.1016/j.ces.2005.12.018
NR 41
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115552
DI 10.1016/j.ces.2020.115552
PG 9
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600010
DA 2020-05-12
ER

PT J
AU Seshasai, PC
   Kurle, MM
   Verma, N
   Pushpavanam, S
AF Seshasai, P. C.
   Kurle, Mayuri M.
   Verma, Nitu
   Pushpavanam, S.
TI Multiplicity, travelling waves and spatial patterns in coupled
   autocatalytic reaction systems
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Autocatalytic reactions; Travelling waves; Turing patterns;
   Reaction-diffusion; Heteroclinic orbit; Bifurcation theory
ID ISOTHERMAL CHEMICAL-SYSTEM; CUBIC AUTOCATALYSIS; QUADRATIC
   AUTOCATALYSIS; OSCILLATIONS; FRONTS
AB In an autocatalytic reaction, one of the products catalyzes its own formation. In this work, we analyze a system of two species, each participating in two autocatalytic reactions. Each species participates in the autocatalysis of the other. We first analyze how the kinetics of the reactions determines the non-linear characteristics of the lumped system, such as multiple steady-states. Two cases are considered depending on the kinetics of the two reactions. In the first case, both reactions are quadratic in nature, while in the second, reactions are cubic. Singularity theory and bifurcation theory are employed to comprehensively understand the multiplicity features of the steady states and to classify the bifurcation behavior of the lumped system. The analysis here forms the basis to determine operating conditions under which a pure enantiomer can be produced. The occurrence of spontaneous spatio-temporal features like travelling waves and Turing patterns under specific conditions has been established. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Seshasai, P. C.; Kurle, Mayuri M.; Verma, Nitu; Pushpavanam, S.] Indian Inst Technol Madras, Dept Chem Engn, Chennai 600036, Tamil Nadu, India.
RP Pushpavanam, S (reprint author), Indian Inst Technol Madras, Dept Chem Engn, Chennai 600036, Tamil Nadu, India.
EM spush@iitm.ac.in
CR Beutel KM, 2006, J CHEM PHYS, V125, DOI 10.1063/1.2209228
   BILLINGHAM J, 1991, PHILOS T ROY SOC A, V334, P1, DOI 10.1098/rsta.1991.0001
   Billingham J., 1990, Q APPL MATH, V430, P509
   CASTETS V, 1990, PHYS REV LETT, V64, P2953, DOI 10.1103/PhysRevLett.64.2953
   Duim H, 2017, BEILSTEIN J ORG CHEM, V13, P1189, DOI 10.3762/bjoc.13.118
   DUNBAR SR, 1983, J MATH BIOL, V17, P11
   Epstein I.R., 1998, INTRO NONLINEAR CHEM
   Fisher R.A., 1954, WAVE ADV ADVANTAGEOU
   FRANK FC, 1953, BIOCHIM BIOPHYS ACTA, V11, P459, DOI 10.1016/0006-3002(53)90082-1
   Gatti RC, 2017, ECOL MODEL, V346, P70, DOI 10.1016/j.ecolmodel.2016.12.003
   GIERER A, 1972, KYBERNETIK, V12, P30, DOI 10.1007/BF00289234
   GRAY P, 1990, P R SOC-MATH PHYS SC, V430, P509, DOI 10.1098/rspa.1990.0104
   GRAY P, 1984, CHEM ENG SCI, V39, P1087, DOI 10.1016/0009-2509(84)87017-7
   Hanaor DAH, 2011, J MATER SCI, V46, P855, DOI 10.1007/s10853-010-5113-0
   Hordijk W, 2013, BIOSCIENCE, V63, P877, DOI 10.1525/bio.2013.63.11.6
   Hosono Y, 1998, B MATH BIOL, V60, P435, DOI 10.1006/bulm.1997.0008
   Kapral R., 1995, CHEM WAVES PATTERNS
   KAY SR, 1988, P ROY SOC LOND A MAT, V418, P345, DOI 10.1098/rspa.1988.0088
   Khot A, 2017, CHEM ENG SCI, V160, P254, DOI 10.1016/j.ces.2016.11.010
   LEVENSPIEL O, 1999, CHEM REACTION ENG
   Liehr A.W., 2013, SPRINGER SERIES SYNE
   Liu Y, 2018, J BIOL CHEM, V293, P18854, DOI 10.1074/jbc.RA118.003795
   Maini PK, 1997, J CHEM SOC FARADAY T, V93, P3601, DOI 10.1039/a702602a
   MERKIN JH, 1990, P ROY SOC LOND A MAT, V430, P315, DOI 10.1098/rspa.1990.0093
   MERKIN JH, 1991, P ROY SOC LOND A MAT, V434, P531, DOI 10.1098/rspa.1991.0112
   MERKIN JH, 1989, P ROY SOC LOND A MAT, V424, P187, DOI 10.1098/rspa.1989.0075
   MERKIN JH, 1989, J ENG MATH, V23, P343, DOI 10.1007/BF00128907
   Merkin JH, 1998, J ENG MATH, V33, P157, DOI 10.1023/A:1004292023428
   MERKIN JH, 1987, J ENG MATH, V21, P115, DOI 10.1007/BF00127669
   Murray J.D., 2001, MATH BIOL
   Murray J.D., 2003, MATH BIOL
   MURRAY JD, 1976, J THEOR BIOL, V56, P329, DOI 10.1016/S0022-5193(76)80078-1
   NEEDHAM DJ, 1992, NONLINEARITY, V5, P413, DOI 10.1088/0951-7715/5/2/006
   OKUBO A, 1989, PROC R SOC SER B-BIO, V238, P113, DOI 10.1098/rspb.1989.0070
   Page KM, 2005, PHYSICA D, V202, P95, DOI 10.1016/j.physd.2005.01.022
   PEARSON JE, 1993, SCIENCE, V261, P189, DOI 10.1126/science.261.5118.189
   PETROV V, 1994, PHILOS T R SOC A, V347, P631, DOI 10.1098/rsta.1994.0071
   Plasson R., 2013, ARTIF LIFE, V17, P119
   SCHNAKENBERG J, 1979, J THEOR BIOL, V81, P389, DOI 10.1016/0022-5193(79)90042-0
   SELKOV EE, 1968, EUR J BIOCHEM, V4, P79, DOI 10.1111/j.1432-1033.1968.tb00175.x
   Shibata T, 1996, J AM CHEM SOC, V118, P471, DOI 10.1021/ja953066g
   Taylor P., 1992, DYNAM STABIL SYST, V7, P37
   TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012
   Volpert V, 2009, PHYS LIFE REV, V6, P267, DOI 10.1016/j.plrev.2009.10.002
NR 44
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115565
DI 10.1016/j.ces.2020.115565
PG 14
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600018
DA 2020-05-12
ER

PT J
AU Suo, S
   Liu, MC
   Gan, YX
AF Suo, Si
   Liu, Mingchao
   Gan, Yixiang
TI An LBM-PNM framework for immiscible flow: With applications to droplet
   spreading on porous surfaces
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Multiphase flow; Multiscale modelling; Lattice Boltzmann method;
   Pore-network method; Droplet behaviour
ID LATTICE BOLTZMANN MODEL; 2-PHASE FLOW; MEDIA; ABSORPTION; IMBIBITION;
   ROUGH; THIN; INFILTRATION; SIMULATIONS; TRANSPORT
AB The behaviour of droplets on porous media, combining the spreading above and imbibition into the medium, is of foundational interests for a series of applications. In this work, we combine the lattice Boltzmann method (LBM) and pore-network method (PNM) to develop an efficient and robust numerical framework in which the coarse-scale multiphase transport in porous media are modelled by the PNM while the fluid dynamics containing multiple components are resolved by the LBM. An effective transport mechanism has been implemented to ensure mass conservation and pressure continuity across the interface. This method is ideally adapted to flow domains, with two distinguishable characteristic length-scales. The numerical framework is validated by comparison with experimental observations of droplets on flat porous surfaces. Moreover, the behaviour of droplets on non-flat porous surfaces has been also investigated, demonstrating the influence of surface curvature on the competing mechanisms of droplet spreading and imbibition. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Suo, Si; Gan, Yixiang] Univ Sydney, Sch Civil Engn, Sydney, NSW 2006, Australia.
   [Liu, Mingchao] Univ Oxford, Math Inst, Oxford OX2 6GG, England.
   [Liu, Mingchao] Tsinghua Univ, Dept Engn Mech CNMM & AML, Beijing 100084, Peoples R China.
RP Gan, YX (reprint author), Univ Sydney, Sch Civil Engn, Sydney, NSW 2006, Australia.
EM yixiang.gan@sydney.edu.au
RI Gan, Yixiang/B-1551-2008
OI Gan, Yixiang/0000-0002-9621-0277
FU Australian Research CouncilAustralian Research Council [DP170102886];
   University of Sydney SOAR Fellowship; Newton International Fellowship
FX This work was financially supported by Australian Research Council
   (Projects DP170102886) and The University of Sydney SOAR Fellowship.
   M.L. acknowledges the support from the Newton International Fellowship
   founded by the Royal Society. This research was undertaken with the
   assistance of resources and services from the HPC service at The
   University of Sydney. The authors would like to thank Professor Dominic
   Vella, from the Mathematical Institute at the University of Oxford, for
   his comments and feedbacks on this work.
CR Arshadi M., 2018, PORE SCALE EXPT INVE
   Ba Y, 2016, PHYS REV E, V94, DOI 10.1103/PhysRevE.94.023310
   Bakhta A, 2019, COMPUT PHYS COMMUN, V239, P1, DOI 10.1016/j.cpc.2019.02.001
   Bauer D, 2012, TRANSPORT POROUS MED, V94, P505, DOI 10.1007/s11242-012-9941-z
   Blunt MJ, 2013, ADV WATER RESOUR, V51, P197, DOI 10.1016/j.advwatres.2012.03.003
   Blunt MJ, 2001, CURR OPIN COLLOID IN, V6, P197, DOI 10.1016/S1359-0294(01)00084-X
   Camuffo D., 2013, MICROCLIMATE CULTURA
   Christodoulou C, 2018, CHEM ENG SCI, V175, P40, DOI 10.1016/j.ces.2017.09.021
   Clarke A, 2002, LANGMUIR, V18, P2980, DOI 10.1021/la0117810
   Daniel RC, 2006, ADV COLLOID INTERFAC, V123, P439, DOI 10.1016/j.cis.2006.05.012
   Das S, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5010716
   DENESUK M, 1994, J COLLOID INTERF SCI, V168, P142, DOI 10.1006/jcis.1994.1403
   Espin L, 2015, J FLUID MECH, V784, P465, DOI 10.1017/jfm.2015.603
   Frank X, 2012, PHYS FLUIDS, V24, DOI 10.1063/1.3701996
   Fu F., 2019, LANGMUIR
   Ginzburg I, 2008, COMMUN COMPUT PHYS, V3, P427
   GUNSTENSEN AK, 1991, PHYS REV A, V43, P4320, DOI 10.1103/PhysRevA.43.4320
   HSU CT, 1990, INT J HEAT MASS TRAN, V33, P1587, DOI 10.1016/0017-9310(90)90015-M
   Huang HB, 2014, COMPUT FLUIDS, V93, P164, DOI 10.1016/j.compfluid.2014.01.025
   Huang HB, 2011, COMPUT MATH APPL, V61, P3606, DOI 10.1016/j.camwa.2010.06.034
   Joekar-Niasar V, 2013, WATER RESOUR RES, V49, P4244, DOI 10.1002/wrcr.20313
   Joekar-Niasar V, 2010, J FLUID MECH, V655, P38, DOI 10.1017/S0022112010000704
   Keiser L, 2019, PHYS REV LETT, V122, DOI 10.1103/PhysRevLett.122.074501
   Ladd AJC, 2001, J STAT PHYS, V104, P1191, DOI 10.1023/A:1010414013942
   Latva-Kokko M, 2005, PHYS REV E, V72, DOI 10.1103/PhysRevE.72.046701
   Leang M., 2019, SOFT MATTER
   Leclaire S, 2013, J COMPUT PHYS, V246, P318, DOI 10.1016/j.jcp.2013.03.039
   LEVY T, 1975, INT J ENG SCI, V13, P923, DOI 10.1016/0020-7225(75)90054-3
   Liu HH, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.046309
   Markicevic B, 2010, TRANSPORT POROUS MED, V85, P953, DOI 10.1007/s11242-010-9603-y
   Markicevic B, 2009, J COLLOID INTERF SCI, V336, P698, DOI 10.1016/j.jcis.2009.04.085
   Marston JO, 2010, POWDER TECHNOL, V203, P223, DOI 10.1016/j.powtec.2010.05.012
   Meng S, 2014, INT J HEAT MASS TRAN, V77, P828, DOI 10.1016/j.ijheatmasstransfer.2014.05.056
   NEOGI P, 1983, J COLLOID INTERF SCI, V92, P338, DOI 10.1016/0021-9797(83)90156-X
   Oko A, 2014, MICROFLUID NANOFLUID, V17, P413, DOI 10.1007/s10404-013-1313-7
   Perazzo A, 2018, ADV COLLOID INTERFAC, V256, P305, DOI 10.1016/j.cis.2018.03.002
   Pham QN, 2018, LANGMUIR, V34, P14439, DOI 10.1021/acs.langmuir.8b02765
   Qin CZ, 2019, CHEM ENG SCI, V202, P194, DOI 10.1016/j.ces.2019.03.038
   Reis T, 2007, J PHYS A-MATH THEOR, V40, P4033, DOI 10.1088/1751-8113/40/14/018
   ROTHMAN DH, 1988, J STAT PHYS, V52, P1119, DOI 10.1007/BF01019743
   SHAN XW, 1993, PHYS REV E, V47, P1815, DOI 10.1103/PhysRevE.47.1815
   Sharma N, 2018, EUR J PHARM SCI, V111, P46, DOI 10.1016/j.ejps.2017.09.031
   Starov VM, 2003, ADV COLLOID INTERFAC, V104, P123, DOI 10.1016/S0001-8686(03)00039-3
   Swift MR, 1996, PHYS REV E, V54, P5041, DOI 10.1103/PhysRevE.54.5041
   Tan H, 2017, AICHE J, V63, P1690, DOI 10.1002/aic.15525
   Thompson KE, 2002, AICHE J, V48, P1369, DOI 10.1002/aic.690480703
   Valvatne PH, 2004, WATER RESOUR RES, V40, DOI 10.1029/2003WR002627
   Wang M, 2016, ADV WATER RESOUR, V96, P373, DOI 10.1016/j.advwatres.2016.08.006
   Wang ZF, 2016, CHEM ENG SCI, V146, P104, DOI 10.1016/j.ces.2016.02.006
   Wijshoff H, 2018, CURR OPIN COLLOID IN, V36, P20, DOI 10.1016/j.cocis.2017.11.004
   Yin X, 2018, TRANSPORT POROUS MED, V125, P239, DOI 10.1007/s11242-018-1116-0
   Yinghao S., 2018, IMPACT FRACTURING LI
   Zhou HH, 2017, LANGMUIR, V33, P130, DOI 10.1021/acs.langmuir.6b03820
NR 53
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115577
DI 10.1016/j.ces.2020.115577
PG 10
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600022
DA 2020-05-12
ER

PT J
AU Tang, KL
   Ouyang, Y
   Agarwal, RK
   Chen, JM
   Xiang, Y
   Chen, JF
AF Tang, Kai-Liang
   Ouyang, Yi
   Agarwal, Ramesh K.
   Chen, Jian-Ming
   Xiang, Yang
   Chen, Jian-Feng
TI Computation of gas-liquid flow in a square bubble column with
   Wray-Agarwal one-equation turbulence model
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Wray-Agarwal turbulence model; Gas-liquid flow; Bubble column
ID LARGE-EDDY SIMULATION; MASS-TRANSFER; NUMERICAL-SIMULATION; DETAILED
   EXPERIMENTS; INTERFACIAL AREA; PART II; REACTORS; BEHAVIOR; CO2
AB The newly proposed one-equation Wray-Agarwal (WA) turbulence model coupled with Euler-Euler (E-E) approach was used to simulate the gas-liquid flow in a square bubble column, which further validated the accuracy and expanded the application of the WA model comparing to a preliminary study (Ouyang et al., 2019). All simulation results of the WA model were compared with two widely used turbulence models of standard k-epsilon and SST k-omega and literature data. The numerical results of the time-averaged axial liquid and gas velocity were validated with experimental data, and it was found that the WA model showed overall the best agreement. Profiles of turbulent kinetic energy, turbulent dissipation rate, turbulent viscosity and gas holdup were investigated at three different heights. Results for the first time validate the WA model based on the turbulent characteristic values of gas-liquid flow in the bubble column, which shows its promising prospective in multiphase flow simulation. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Tang, Kai-Liang; Ouyang, Yi; Xiang, Yang; Chen, Jian-Feng] Beijing Univ Chem Technol, State Key Lab Organ Inorgan Composites, Beijing 100029, Peoples R China.
   [Tang, Kai-Liang; Ouyang, Yi; Chen, Jian-Ming; Xiang, Yang; Chen, Jian-Feng] Beijing Univ Chem Technol, Res Ctr Minist Educ High Grav Engn & Technol, Beijing 100029, Peoples R China.
   [Agarwal, Ramesh K.] Washington Univ, Dept Mech Engn & Mat Sci, 1 Brookings Dr, St Louis, MO 63128 USA.
RP Ouyang, Y; Xiang, Y (reprint author), Beijing Univ Chem Technol, 15 Beisanhuan East Rd, Beijing 100029, Peoples R China.
EM ouyy@mail.buct.edu.cn; xiangy@mail.buct.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21620102007]
FX This work was supported by the National Natural Science Foundation of
   China (No. 21620102007).
CR Acquaye F., 2016, AIAA FLUID DYN C
   Becker S, 1994, CHEM ENG SCI, V49, P5747, DOI 10.1016/0009-2509(94)00290-8
   Borchers O, 1999, CHEM ENG SCI, V54, P5927, DOI 10.1016/S0009-2509(99)00181-5
   Bouaifi M, 2001, CHEM ENG PROCESS, V40, P97, DOI 10.1016/S0255-2701(00)00129-X
   Chakraborty D, 2009, IND ENG CHEM RES, V48, P11225, DOI 10.1021/ie901322e
   de Bertodano MAL, 1998, NUCL ENG DES, V179, P65, DOI 10.1016/S0029-5493(97)00244-6
   deBillerbeck GM, 1996, BIOTECHNOL TECH, V10, P755, DOI 10.1007/BF00222561
   Deen N. G., 2000, P 14 INT C CHEM PROC
   Deen NG, 2001, CHEM ENG SCI, V56, P6341, DOI 10.1016/S0009-2509(01)00249-4
   DEEN NG, 2000, 10 INT S APPL LAS TE
   Degaleesan S, 2001, AICHE J, V47, P1913, DOI 10.1002/aic.690470904
   Dhotre MT, 2008, CHEM ENG J, V136, P337, DOI 10.1016/j.cej.2007.04.016
   Ekambara K, 2010, NUCL ENG DES, V240, P963, DOI 10.1016/j.nucengdes.2010.01.016
   Feng W, 2006, AICHE J, V52, P2864, DOI 10.1002/aic.10899
   Han X., 2018, 2018 AIAA AER SCI M
   Han X., 2016, 54 AIAA AER SCI M
   Hosokawa S., 2002, ASME 2002 JOINT US E
   Khan Z, 2017, CHEM ENG SCI, V164, P34, DOI 10.1016/j.ces.2017.01.023
   Lemoine R, 2008, FUEL PROCESS TECHNOL, V89, P322, DOI 10.1016/j.fuproc.2007.11.016
   Ma T, 2015, CHEM ENG SCI, V131, P101, DOI 10.1016/j.ces.2015.03.047
   Maceiras R, 2011, CHEM ENG J, V172, P335, DOI 10.1016/j.cej.2011.06.014
   Magnaudet J, 1998, APPL SCI RES, V58, P441
   Masood RMA, 2014, CHEM ENG TECHNOL, V37, P1697, DOI 10.1002/ceat.201400173
   Masterov MV, 2018, INT J MULTIPHAS FLOW, V107, P275, DOI 10.1016/j.ijmultiphaseflow.2018.06.006
   Mok KH, 2017, HIGH EDUC ASIA, P47, DOI 10.1007/978-981-10-1736-0_3
   Nedeltchev S, 2015, CHEM ENG TECHNOL, V38, P1940, DOI 10.1002/ceat.201400728
   Niceno B, 2008, CHEM ENG SCI, V63, P3923, DOI 10.1016/j.ces.2008.04.050
   Ouyang Y, 2019, COMPUT FLUIDS, V194, DOI 10.1016/j.compfluid.2019.104296
   Pfleger D, 2001, CHEM ENG SCI, V56, P1737, DOI 10.1016/S0009-2509(00)00403-6
   Pourtousi M, 2014, CHEM ENG PROCESS, V75, P38, DOI 10.1016/j.cep.2013.11.001
   Prakash A, 2001, BIOCHEM ENG J, V9, P155, DOI 10.1016/S1369-703X(01)00137-1
   Roghair I., 2012, THESIS
   Sahu JN, 2009, J HAZARD MATER, V161, P317, DOI 10.1016/j.jhazmat.2008.03.094
   Sato Y., 1975, International Journal of Multiphase Flow, V2, P79, DOI 10.1016/0301-9322(75)90030-0
   Schiller L., 1935, Z VER DTSCH ING, V77, P318
   SHAH YT, 1982, AICHE J, V28, P353, DOI 10.1002/aic.690280302
   Troshko AA, 2001, INT J MULTIPHAS FLOW, V27, P1965, DOI 10.1016/S0301-9322(01)00043-X
   Wang TF, 2006, AICHE J, V52, P125, DOI 10.1002/aic.10611
   Wray T.J., 2016, THESIS
   Wray TJ, 2014, AIAA J, V52, P1325, DOI 10.2514/1.J052832
   Zhang C, 2018, CHEM ENG SCI, V184, P161, DOI 10.1016/j.ces.2018.03.031
   Zhang D, 2006, CHEM ENG SCI, V61, P7593, DOI 10.1016/j.ces.2006.08.053
   Zhang DS, 2009, IND ENG CHEM RES, V48, P47, DOI 10.1021/ie800233y
   Zhang L, 2019, COMPLEXITY, DOI 10.1155/2019/1671340
NR 44
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115551
DI 10.1016/j.ces.2020.115551
PG 12
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600009
DA 2020-05-12
ER

PT J
AU Wang, Y
   Wang, BJ
   Ling, LX
   Zhang, RG
   Fan, MH
AF Wang, Ying
   Wang, Baojun
   Ling, Lixia
   Zhang, Riguang
   Fan, Maohong
TI Probe into the effects of surface composition and ensemble effect of
   active sites on the catalytic performance of C2H2 semi-hydrogenation
   over the Pd-Ag bimetallic catalysts
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Acetylene; Semi-hydrogenation; Pd-Ag bimetallic catalysts; Surface
   composition; Ensemble effect
ID ACETYLENE SELECTIVE HYDROGENATION; SYNCHRONOUS-TRANSIT METHOD;
   ETHENE-RICH STREAMS; PD-AG/AL2O3 CATALYSTS; PALLADIUM CATALYSTS;
   ETHYLENE HYDROGENATION; CU/AL2O3 CATALYSTS; SUBSURFACE CARBON; EFFICIENT
   REMOVAL; CU
AB Aiming at identifying the effects of surface composition and ensemble effect for the Pd-Ag bimetallic catalysts on the catalytic performance of C2H2 semi-hydrogenation, the selectivity and activity of C2H4 formation over the Ag-doped Pd, Pd-doped Ag catalysts and PdAg intermetallic compounds with different surface composition and ensemble effect are examined utilizing density functional theory calculations. The results indicated that the Pd-Ag bimetallic catalysts without Pd atoms, with isolated Pd atom or Pd dimer on the surface show poor C2H4 selectivity; while those with surface Pd trimer exhibit better C2H4 selectivity, especially, the Pd-doped Ag catalysts present better catalytic performance and low cost. This study not only helps scientists understand reaction theories associated with the experiment of C2H2 semi-hydrogenation over the Pd-Ag bimetallic catalysts, but also helps them advance the design of high-performance, cost-effective and structure-tunable Pd-Ag bimetallic catalysts for C2H2 removal from C2H4, which has broad impact on catalyst development. (C) 2020 Published by Elsevier Ltd.
C1 [Wang, Ying; Wang, Baojun; Ling, Lixia; Zhang, Riguang] Taiyuan Univ Technol, Key Lab Coal Sci & Technol, Minist Educ & Shanxi Prov, Taiyuan 030024, Shanxi, Peoples R China.
   [Zhang, Riguang; Fan, Maohong] Univ Wyoming, Dept Chem Engn, Laramie, WY 82071 USA.
   [Zhang, Riguang; Fan, Maohong] Univ Wyoming, Dept Petr Engn, Laramie, WY 82071 USA.
   [Fan, Maohong] Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA.
RP Zhang, RG; Fan, MH (reprint author), Univ Wyoming, Dept Chem Engn, Laramie, WY 82071 USA.; Zhang, RG; Fan, MH (reprint author), Univ Wyoming, Dept Petr Engn, Laramie, WY 82071 USA.
EM zhangriguang@tyut.edu.cn; mfan@uwyo.edu
OI Rony, Asif Hasan/0000-0001-5929-4072
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China [21776193, 21736007]; Top Young Innovative Talents
   of Shanxi
FX This work is financially supported by the National Natural Science
   Foundation of China (Nos. 21776193 and 21736007) and the Top Young
   Innovative Talents of Shanxi, and U.S. NSF-sponsored NCAR-Wyoming
   Supercomputing Center (NWSC).
CR [Anonymous], 2011, THESIS
   AZIZ RA, 1979, MOL PHYS, V38, P177, DOI 10.1080/00268977900101591
   BERGNER A, 1993, MOL PHYS, V80, P1431, DOI 10.1080/00268979300103121
   Borodzinki A, 2006, CATAL REV, V48, P91, DOI 10.1080/01614940500364909
   Borodzinski A, 2008, CATAL REV, V50, P379, DOI 10.1080/01614940802142102
   Chen YJ, 2016, APPL SURF SCI, V387, P16, DOI 10.1016/j.apsusc.2016.06.067
   Choi BS, 2019, ACS CATAL, V9, P819, DOI 10.1021/acscatal.8b04414
   DELLEY B, 1990, J CHEM PHYS, V92, P508, DOI 10.1063/1.458452
   Delley B, 2000, J CHEM PHYS, V113, P7756, DOI 10.1063/1.1316015
   Dickerson R.E., 1979, CHEM PRINCIPLES
   DOLG M, 1987, J CHEM PHYS, V86, P866, DOI 10.1063/1.452288
   Duan T, 2016, J PHYS CHEM C, V120, P2234, DOI 10.1021/acs.jpcc.5b10831
   Engstfeld AK, 2012, PHYS CHEM CHEM PHYS, V14, P10754, DOI 10.1039/c2cp41104k
   Filoti DI, 2010, J VAC SCI TECHNOL A, V28, P838, DOI 10.1116/1.3319349
   Govind N, 2003, COMP MATER SCI, V28, P250, DOI 10.1016/S0927-0256(03)00111-3
   HALGREN TA, 1977, CHEM PHYS LETT, V49, P225, DOI 10.1016/0009-2614(77)80574-5
   Hammer B, 1999, PHYS REV B, V59, P7413, DOI 10.1103/PhysRevB.59.7413
   He YF, 2015, J CATAL, V330, P61, DOI 10.1016/j.jcat.2015.06.017
   HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRev.136.B864
   Jin YM, 2001, J CATAL, V203, P292, DOI 10.1006/jcat.2001.3347
   Khan NA, 2006, CATAL LETT, V108, P159, DOI 10.1007/s10562-006-0041-y
   Kim SK, 2013, J CATAL, V306, P146, DOI 10.1016/j.jcat.2013.06.018
   Kim WJ, 2012, CATAL TODAY, V185, P2, DOI 10.1016/j.cattod.2011.09.037
   Lee JH, 2011, CATAL COMMUN, V12, P1251, DOI 10.1016/j.catcom.2011.04.015
   Li Q, 2018, NEW J CHEM, V42, P19827, DOI 10.1039/c8nj03274b
   Li Q, 2014, APPL SURF SCI, V288, P69, DOI 10.1016/j.apsusc.2013.09.116
   Li Q, 2013, PHYS CHEM CHEM PHYS, V15, P20345, DOI 10.1039/c3cp52504j
   Liu YN, 2017, J CATAL, V348, P135, DOI 10.1016/j.jcat.2017.02.020
   Lopez N, 2012, CHEM COMMUN, V48, P1379, DOI 10.1039/c1cc14922a
   Mancera LA, 2013, PHYS CHEM CHEM PHYS, V15, P1497, DOI 10.1039/c2cp42914d
   Mattson B, 2013, J CHEM EDUC, V90, P613, DOI 10.1021/ed300437k
   McCue AJ, 2015, CATAL SCI TECHNOL, V5, P2880, DOI 10.1039/c5cy00253b
   McCue AJ, 2014, J CATAL, V319, P127, DOI 10.1016/j.jcat.2014.08.016
   Mei DH, 2009, J CATAL, V268, P181, DOI 10.1016/j.jcat.2009.09.004
   Meng LD, 2014, PHYS CHEM CHEM PHYS, V16, P17541, DOI 10.1039/c4cp01818d
   Mitsudome T, 2016, ACS CATAL, V6, P666, DOI 10.1021/acscatal.5b02518
   NAIDU SVN, 2016, ASM ALLOY PHASE DIAG
   Ngamsom B, 2004, CATAL COMMUN, V5, P243, DOI 10.1016/j.catcom.2004.02.007
   Pachulski A, 2011, APPL CATAL A-GEN, V400, P14, DOI 10.1016/j.apcata.2011.03.019
   Pallassana V, 2000, J CATAL, V191, P301, DOI 10.1006/jcat.1999.2724
   Pei GX, 2015, ACS CATAL, V5, P3717, DOI 10.1021/acscatal.5b00700
   Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865
   Riyapan S, 2016, CATAL SCI TECHNOL, V6, P5608, DOI 10.1039/c6cy00121a
   SCHNEIDER U, 1994, J VAC SCI TECHNOL A, V12, P2069, DOI 10.1116/1.579138
   Sheth PA, 2005, J PHYS CHEM B, V109, P12449, DOI 10.1021/jp050194a
   Studt F, 2008, SCIENCE, V320, P1320, DOI 10.1126/science.1156660
   Studt F, 2008, ANGEW CHEM INT EDIT, V47, P9299, DOI 10.1002/anie.200802844
   Sun JY, 2018, APPL SURF SCI, V428, P703, DOI 10.1016/j.apsusc.2017.09.168
   Teschner D, 2008, SCIENCE, V320, P86, DOI 10.1126/science.1155200
   Wang WH, 2016, ACS APPL MATER INTER, V8, P20839, DOI 10.1021/acsami.6b08091
   Xu L, 2018, J CATAL, V362, P18, DOI 10.1016/j.jcat.2018.03.019
   Xu ZN, 2013, ACS CATAL, V3, P118, DOI 10.1021/cs300759h
   Yang B, 2014, J PHYS CHEM C, V118, P1560, DOI 10.1021/jp408807c
   Yang B, 2013, J CATAL, V305, P264, DOI 10.1016/j.jcat.2013.05.027
   Yang B, 2012, ACS CATAL, V2, P1027, DOI 10.1021/cs2006789
   Zhang QW, 2000, APPL CATAL A-GEN, V197, P221, DOI 10.1016/S0926-860X(99)00463-9
   Zhang RG, 2019, J PHYS CHEM C, V123, P16107, DOI 10.1021/acs.jpcc.9b01757
   Zhang RG, 2019, APPL SURF SCI, V481, P421, DOI 10.1016/j.apsusc.2019.03.006
   Zhang RG, 2018, CHEM ENG J, V351, P732, DOI 10.1016/j.cej.2018.06.083
   Zhang RG, 2018, CHEMCATCHEM, V10, P2424, DOI 10.1002/cctc.201701899
   Zhang RG, 2018, PHYS CHEM CHEM PHYS, V20, P17487, DOI 10.1039/c8cp02523a
   Zhang RG, 2017, J PHYS CHEM C, V121, P27936, DOI 10.1021/acs.jpcc.7b08125
   Zhao B, 2017, APPL CATAL A-GEN, V546, P111, DOI 10.1016/j.apcata.2017.08.001
NR 63
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115549
DI 10.1016/j.ces.2020.115549
PG 13
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600008
DA 2020-05-12
ER

PT J
AU Wattananusorn, S
AF Wattananusorn, S.
TI Non-decay of complex scalar field fluctuations in isotropic turbulence
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE Turbulence; Fluctuations; Isotropic
AB In this paper two things are done. (1) It is shown that the concept of a direct energy cascade is possible to be violated under specific circumstances as a consequence of dissipation process which initially takes place at Taylor microscales of the inertial subrange. (2) This work predicts, for the first time, the existence of isotropic turbulence at length scales smaller than that of Kolmogorov scales and that it never decays with time as long as the fluid is in motion. It should be remarked that no comparison with experiments searching for the proposed length scales can be made at present. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Wattananusorn, S.] King Mongkuts Inst Technol Ladkrabang, Fac Engn, Dept Chem Engn, Bangkok, Thailand.
RP Wattananusorn, S (reprint author), King Mongkuts Inst Technol Ladkrabang, Fac Engn, Dept Chem Engn, Bangkok, Thailand.
EM santi_wattananusorn@hotmail.com
CR Arpaci V.S., 1997, MICROSCALES TURBULEN
   Bonn D., 1993, PHYS REV E, V47, P28
   du Cluzeau A, 2019, J FLUID MECH, V866, P132, DOI 10.1017/jfm.2019.100
   Durbin PA, 2018, ANNU REV FLUID MECH, V50, P77, DOI 10.1146/annurev-fluid-122316-045020
   Fermi E., 1956, THERMODYNAMICS
   FISCHER AE, 1974, B AM MATH SOC, V80, P92, DOI 10.1090/S0002-9904-1974-13368-9
   Jimenez J, 2018, J FLUID MECH, V842, DOI 10.1017/jfm.2018.144
   Keylock CJ, 2018, J FLUID MECH, V848, P876, DOI 10.1017/jfm.2018.344
   Kolmogoroff A, 1941, CR ACAD SCI URSS, V30, P301
   KRAICHNAN RH, 1966, PHYS FLUIDS, V9, P1728, DOI 10.1063/1.1761928
   Lai CCK, 2018, J FLUID MECH, V843, P382, DOI 10.1017/jfm.2018.125
   LEE J, 1965, PHYS FLUIDS, V8, P1647, DOI 10.1063/1.1761477
   Leslie D.C., 1983, DEV THEORY TURBULENC
   LORD EA, 1972, J MATH ANAL APPL, V40, P509, DOI 10.1016/0022-247X(72)90066-2
   Mathieu J, 2000, INTRO TURBULENT FLOW
   Meneveau C, 2019, J TURBUL, V20, P2, DOI 10.1080/14685248.2019.1584664
   Pearson B, 2018, PHYS REV LETT, V120, DOI 10.1103/PhysRevLett.120.094501
   Poje AC, 2017, PHYS FLUIDS, V29, DOI 10.1063/1.4974331
   Reynolds O., 1894, P ROY SOC LONDON, V56, P40
   Reynolds O., 1883, PHILOS T ROY SOC LON, V174, P935, DOI DOI 10.1098/RSTL.1883.0029
   Ricca RL, 2008, P ROY SOC A-MATH PHY, V464, P293, DOI 10.1098/rspa.2007.0174
   Richardson L. F., 1922, WEATHER PREDICTION N
   Rodionov E.D., 2002, COMMENT MATH U CAROL, V43, P271
   SHE ZS, 1991, P R SOC-MATH PHYS SC, V434, P101, DOI 10.1098/rspa.1991.0083
   Stokes G. G., 1845, T CAMBRIDGE PHILOS S, V8, P287
   Taylor GI, 1922, P LOND MATH SOC, V20, P196
   Taylor GI, 1935, PROC R SOC LON SER-A, V151, P0421, DOI 10.1098/rspa.1935.0158
   Thorpe SA, 2012, J FLUID MECH, V708, P1, DOI 10.1017/jfm.2012.383
   Ustinov MV, 2014, FLUID DYNAM+, V49, P468, DOI 10.1134/S0015462814040073
   Zhu XJ, 2018, NAT PHYS, V14, P417, DOI 10.1038/s41567-017-0026-3
NR 30
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115463
DI 10.1016/j.ces.2019.115463
PG 8
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600002
DA 2020-05-12
ER

PT J
AU Xiang, H
   Carter, JH
   Tang, CC
   Murray, CA
   Yang, SH
   Fan, XL
   Siperstein, FR
AF Xiang, Huan
   Carter, Joseph H.
   Tang, Chiu C.
   Murray, Claire A.
   Yang, Sihai
   Fan, Xiaolei
   Siperstein, Flor R.
TI C2H4 and C2H6 adsorption-induced structural variation of pillared-layer
   CPL-2 MOF: A combined experimental and Monte Carlo simulation study
SO CHEMICAL ENGINEERING SCIENCE
LA English
DT Article
DE CPL-2 MOF; C2H4; C2H6; Adsorption; Linker rotation; Pore expansion
ID METAL-ORGANIC FRAMEWORKS; POROUS COORDINATION POLYMER; CO2 ADSORPTION;
   HYSTERETIC ADSORPTION; SELECTIVE ADSORPTION; FORCE-FIELD; TEMPERATURE;
   SEPARATION; ACTIVATION; TRANSITION
AB Coordination pillared-layer metal-organic frameworks (CPL-MOFs), such as CPL-2, are interesting versatile and porous materials with the potential for gas adsorption and separation. CPL-2 shows the unusual and gradual linker rotation upon the adsorption of ethylene (C2H4) and ethane (C2H6), leading to a fully reversible adsorption isotherm specifically under the conditions studied. Grand canonical Monte Carlo (GCMC) simulations showed that it is impossible to accommodate the experimentally observed loadings of C2H4 and C2H6 in CPL-2 using the crystallographic structure reported in the literature. According to the simulation findings, the pore expansion might be initiated by the clockwise 4,4'-bipyridine (bpy) pillar linker rotation. The pillar rotation leads to the enlarged pore volume, rendering additional adsorption sites, which are not present in the pristine structure. In situ synchrotron PXRD experiments for C2H4 and C2H6 adsorption on CPL-2 confirmed the occurrence of pore expansion in CPL-2 MOF. The combined experimental and simulation study shows for the first time that the linker rotation in CPL-2 can result in a adsorption isotherm without hysteresis. This work developed a real insight into the nature of pillared-layer MOFs, and the revealed structural changes could be potentially exploited to enhance alkene and alkane working capacities of such microporous materials. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Xiang, Huan; Fan, Xiaolei; Siperstein, Flor R.] Univ Manchester, Sch Engn, Dept Chem Engn & Analyt Sci, Manchester M13 9PL, Lancs, England.
   [Carter, Joseph H.; Yang, Sihai] Univ Manchester, Sch Nat Sci, Dept Chem, Manchester M13 9PL, Lancs, England.
   [Carter, Joseph H.; Tang, Chiu C.; Murray, Claire A.] Diamond Light Source Ltd, Harwell Sci & Innovat Campus, Didcot OX11 0DE, DE, England.
RP Fan, XL; Siperstein, FR (reprint author), Univ Manchester, Sch Engn, Dept Chem Engn & Analyt Sci, Manchester M13 9PL, Lancs, England.
EM xiaolei.fan@mancheste.ac.uk; Flor.Siperstein@manchester.ac.uk
OI FAN, Xiaolei/0000-0002-9039-6736; Siperstein, Flor/0000-0003-3464-2100
FU University of Manchester President's Doctoral Scholar Award; China
   Scholarship CouncilChina Scholarship Council [201606150068]
FX HX gratefully acknowledges The University of Manchester President's
   Doctoral Scholar Award and the China Scholarship Council (file no.
   201606150068) for supporting her PhD research. We thank the use of the
   Computational Shared Facility at The University of Manchester. We are
   especially grateful to Diamond Light Source for the access to Beamline
   I11.
CR Bureekaew S, 2008, SCI TECHNOL ADV MAT, V9, DOI 10.1088/1468-6996/9/1/014108
   Campbell C, 2017, J PHYS CHEM C, V121, P441, DOI 10.1021/acs.jpcc.6b10751
   Chen HH, 2016, CHEM ENG J, V283, P806, DOI 10.1016/j.cej.2015.08.017
   Chen YW, 2017, CHEM ENG J, V328, P360, DOI 10.1016/j.cej.2017.07.044
   Coudert FX, 2009, J AM CHEM SOC, V131, P11329, DOI 10.1021/ja904123f
   Do DD, 2004, LANGMUIR, V20, P10889, DOI 10.1021/la0486483
   Fairen-Jimenez D, 2011, J AM CHEM SOC, V133, P8900, DOI 10.1021/ja202154j
   Fischer M, 2012, LANGMUIR, V28, P8537, DOI 10.1021/la301215y
   Garcia-Ricard OJ, 2010, J PHYS CHEM C, V114, P1827, DOI 10.1021/jp9103068
   Horike S, 2006, ANGEW CHEM INT EDIT, V45, P7226, DOI 10.1002/anie.200603196
   Jorge M, 2014, IND ENG CHEM RES, V53, P15475, DOI 10.1021/ie500310c
   Jorgensen WL, 1996, J AM CHEM SOC, V118, P11225, DOI 10.1021/ja9621760
   Kishida K, 2014, EUR J INORG CHEM, V2014, P2747, DOI 10.1002/ejic.201402085
   Kitagawa S, 2004, ANGEW CHEM INT EDIT, V43, P2334, DOI 10.1002/anie.200300610
   Li D, 2000, J PHYS CHEM B, V104, P8940, DOI 10.1021/jp000660q
   Li HP, 2018, DALTON T, V47, P9310, DOI 10.1039/c8dt01592a
   Li JR, 2009, CHEM SOC REV, V38, P1477, DOI 10.1039/b802426j
   Liang WW, 2016, CHEM ENG SCI, V148, P275, DOI 10.1016/j.ces.2016.04.016
   Martin MG, 2013, MOL SIMULAT, V39, P1184, DOI 10.1080/08927022.2013.828208
   Matsuda R, 2004, J AM CHEM SOC, V126, P14063, DOI 10.1021/ja046925m
   Matsuda R, 2010, CHEM SCI, V1, P315, DOI 10.1039/c0sc00272k
   Matsuda R, 2010, MICROPOR MESOPOR MAT, V129, P296, DOI 10.1016/j.micromeso.2009.06.023
   Mcgrath MJ, 2007, MOL PHYS, V105, P1411, DOI 10.1080/00268970701364938
   Meza-Morales PJ, 2016, DALTON T, V45, P17168, DOI 10.1039/c6dt02994a
   Peng L, 2016, RSC ADV, V6, P72433, DOI 10.1039/c6ra12799a
   Perez-Pellitero J, 2010, CHEM-EUR J, V16, P1560, DOI 10.1002/chem.200902144
   Phan NTS, 2014, CATAL SCI TECHNOL, V4, P369, DOI 10.1039/c3cy00503h
   Phan NTS, 2013, CHEMCATCHEM, V5, P2374, DOI 10.1002/cctc.201300032
   Qi Y, 2018, CHEM MATER, V30, P5478, DOI 10.1021/acs.chemmater.8b02511
   Ramsahye NA, 2007, CHEM COMMUN, P3261, DOI 10.1039/b702986a
   RAPPE AK, 1992, J AM CHEM SOC, V114, P10024, DOI 10.1021/ja00051a040
   Riascos-Rodriguez K, 2014, DALTON T, V43, P10877, DOI 10.1039/c4dt00878b
   Sakamoto H, 2012, DALTON T, V41, P3956, DOI 10.1039/c2dt12012g
   Sakamoto H, 2010, CHEM LETT, V39, P218, DOI 10.1246/cl.2010.218
   Schneemann A, 2018, CHEM MATER, V30, P1667, DOI 10.1021/acs.chemmater.7b05052
   Sholl DS, 2016, NATURE, V532, P435, DOI 10.1038/532435a
   Sugiyama H, 2012, LANGMUIR, V28, P5093, DOI 10.1021/la205063f
   Tanaka H, 2014, J PHYS CHEM C, V118, P8445, DOI 10.1021/jp500931g
   Wang SY, 2007, ENERG FUEL, V21, P953, DOI 10.1021/ef060578f
   Wick CD, 2000, J PHYS CHEM B, V104, P8008, DOI 10.1021/jp001044x
   Xiang H, 2020, MICROPOR MESOPOR MAT, V293, DOI 10.1016/j.micromeso.2019.109784
   Xiang H, 2020, MICROPOR MESOPOR MAT, V292, DOI 10.1016/j.micromeso.2019.109724
   Xiang H, 2018, MOL SYST DES ENG, V3, P636, DOI 10.1039/c8me00024g
   Yang WB, 2012, CHEM SCI, V3, P2993, DOI 10.1039/c2sc20443f
NR 44
TC 0
Z9 0
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-2509
EI 1873-4405
J9 CHEM ENG SCI
JI Chem. Eng. Sci.
PD JUN 8
PY 2020
VL 218
AR 115566
DI 10.1016/j.ces.2020.115566
PG 11
WC Engineering, Chemical
SC Engineering
GA LF3TH
UT WOS:000527342600019
DA 2020-05-12
ER

EF